drug_name drug_type drug_MeSHID drug_status target_name gene_name target_type target_action interaction_score source zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational alpha-1b-glycoprotein A1BG NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b-glycoprotein A1BG NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational alpha-1b-glycoprotein A1BG NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational alpha-2-macroglobulin A2M NA ligand NA drugbank ocriplasmin biotech Tissue Adhesions[MeSHID:D000267],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2-macroglobulin A2M NA ligand NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational alpha-2-macroglobulin A2M NA unknown NA drugbank bacitracin small molecule Secondary Infections[MeSHID:D060085],Dermatologic disorders[MeSHID:D012871],Streptococcal pneumonia[MeSHID:D011018],Skin Diseases, Infectious[MeSHID:D012874],Empyema[MeSHID:D004653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-2-macroglobulin A2M NA inhibitor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational alpha-2-macroglobulin A2M NA unknown NA drugbank cisplatin small molecule ovarian neoplasm[MeSHID:D010051],Testicular Neoplasms[MeSHID:D013736],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Osteosarcoma[MeSHID:D012516] approved alpha-2-macroglobulin A2M NA unknown NA drugbank becaplermin biotech Diabetes Mellitus[MeSHID:D003920],Skin Ulcer[MeSHID:D012883],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational alpha-2-macroglobulin A2M NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental alpha-2-macroglobulin A2M NA ligand NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational alpha-2-macroglobulin A2M NA binder NA drugbank gibberellin a4 small molecule NA experimental arylacetamide deacetylase-like 2 AADACL2 NA unknown NA drugbank gibberellic acid small molecule NA experimental arylacetamide deacetylase-like 2 AADACL2 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical kynurenine/alpha-aminoadipate aminotransferase, mitochondrial AADAT NA cofactor NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical kynurenine/alpha-aminoadipate aminotransferase, mitochondrial AADAT NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ap2-associated protein kinase 1 AAK1 NA inhibitor NA drugbank lx9211 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 adaptor-associated kinase 1 AAK1 Clinical trial target unknown NA TTD , DGIDB coa-s-acetyl 5-bromotryptamine small molecule NA experimental serotonin n-acetyltransferase AANAT NA unknown NA drugbank medical cannabis biotech NA experimental,investigational arylalkylamine n-acetyltransferase AANAT NA inhibitor NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational arylalkylamine n-acetyltransferase AANAT NA inhibitor NA drugbank coa-s-acetyl tryptamine small molecule NA experimental serotonin n-acetyltransferase AANAT NA unknown NA drugbank coa-s-trimethylene-acetyl-tryptamine small molecule NA experimental serotonin n-acetyltransferase AANAT NA unknown NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational arylalkylamine n-acetyltransferase AANAT NA inhibitor NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical alanine--trna ligase, cytoplasmic AARS NA unknown NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical alanine--trna ligase, mitochondrial AARS2 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical alpha-aminoadipic semialdehyde synthase, mitochondrial AASS NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical alpha-aminoadipic semialdehyde synthase, mitochondrial AASS NA unknown NA drugbank nadph small molecule NA experimental alpha-aminoadipic semialdehyde synthase, mitochondrial AASS NA unknown NA drugbank l-saccharopine small molecule NA experimental alpha-aminoadipic semialdehyde synthase, mitochondrial AASS NA unknown NA drugbank 4-hydroxybenzaldehyde NA NA patented gaba transaminase ABAT Successful target unknown 4.55 TTD , DGIDB cpp-115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Gilles de la Tourette syndrome[MeSHID:D005879],Substance Use Disorders[MeSHID:D019966] phase 2 gaba transaminase ABAT Successful target unknown 18.19 TTD , DGIDB (4e)-4-aminohex-4-enoic acid NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD acetate ion NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD vigabatrin small molecule Visual Impairment[MeSHID:D014786],West Syndrome[MeSHID:D013036],Low Vision[MeSHID:D015354],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved 4-aminobutyrate aminotransferase, mitochondrial ABAT NA inhibitor 33.34 drugbank , DGIDB pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical 4-aminobutyrate aminotransferase, mitochondrial ABAT NA inhibitor NA drugbank , DGIDB alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical 4-aminobutyrate aminotransferase, mitochondrial ABAT NA inhibitor NA drugbank sodium valproate NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD 4-hydroxy-3-nitrobenzaldehyde NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical 4-aminobutyrate aminotransferase, mitochondrial ABAT NA inhibitor NA drugbank , DGIDB cpp-115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Gilles de la Tourette syndrome[MeSHID:D005879],Substance Use Disorders[MeSHID:D019966] phase 2 gaba transaminase ABAT Successful target inhibitor 18.19 TTD , DGIDB vigabatrin NA Visual Impairment[MeSHID:D014786],West Syndrome[MeSHID:D013036],Low Vision[MeSHID:D015354],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba transaminase ABAT Successful target inhibitor 33.34 TTD , DGIDB 4-amino hexanoic acid NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD k-828-ab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gaba transaminase ABAT Successful target unknown NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical 4-aminobutyrate aminotransferase, mitochondrial ABAT NA unknown NA drugbank t83193 NA NA patented gaba transaminase ABAT Successful target unknown NA TTD , DGIDB cpp -15 NA Choroid Plexus Papilloma[MeSHID:D020288],West Syndrome[MeSHID:D013036],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 gaba transaminase ABAT Successful target unknown NA TTD , DGIDB gamma-acetylenic gaba NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 4-aminobutyrate aminotransferase, mitochondrial ABAT NA inhibitor NA drugbank 4-hydroxybenzylamine NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD vigabatrin NA Visual Impairment[MeSHID:D014786],West Syndrome[MeSHID:D013036],Low Vision[MeSHID:D015354],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba transaminase ABAT Successful target unknown 33.34 TTD , DGIDB l-alanine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] approved gaba transaminase ABAT Successful target unknown 13.64 TTD , DGIDB (4e)-4-aminohex-4-enoic acid small molecule NA experimental 4-aminobutyrate aminotransferase, mitochondrial ABAT NA unknown NA drugbank oxamate NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD pyruvic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved gaba transaminase ABAT Successful target unknown NA TTD , DGIDB 1-(4-hydroxyphenyl)prop-2-en-1-one NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD 3-chloro-1-(4-hydroxyphenyl)propan-1-one NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD 4-amino hexanoic acid small molecule NA experimental 4-aminobutyrate aminotransferase, mitochondrial ABAT NA unknown NA drugbank nipecotic acid NA NA investigative gaba transaminase ABAT Successful target unknown NA TTD divalproex sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba transaminase ABAT Successful target unknown NA TTD , DGIDB pyridoxal phosphate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved gaba transaminase ABAT Successful target unknown NA TTD , DGIDB rg7232 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] investigative atp-binding cassette transporter a1 ABCA1 Successful target unknown NA TTD rg-7273 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] discontinued in phase 1 atp-binding cassette transporter a1 ABCA1 Successful target unknown NA TTD probucol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] approved,investigational atp-binding cassette sub-family a member 1 ABCA1 NA inhibitor 47.74 drugbank , DGIDB glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved atp-binding cassette sub-family a member 1 ABCA1 NA inhibitor NA drugbank atp small molecule NA investigational,nutraceutical atp-binding cassette sub-family a member 1 ABCA1 NA unknown NA drugbank probucol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] approved atp-binding cassette transporter a1 ABCA1 Successful target inhibitor 47.74 TTD , DGIDB probucol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] approved atp-binding cassette transporter a1 ABCA1 Successful target unknown 47.74 TTD , DGIDB stargen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinitis Pigmentosa[MeSHID:D012174] phase 1/2 atp-binding cassette transporter a4 ABCA4 Clinical trial target unknown NA TTD , DGIDB dexverapamil small molecule NA experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank xr-9544 NA NA investigative multidrug resistance protein 1 ABCB1 Successful target unknown 0.27 TTD , DGIDB fm-vp4 small molecule Neoplasms[MeSHID:D009369],Hypercholesterolemia[MeSHID:D006937],Hyperlipidemia[MeSHID:D006949],Set (Psychology)[MeSHID:D012718],Drug Interactions[MeSHID:D004347],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational p-glycoprotein 1 ABCB1 NA unknown NA drugbank tocofersolan small molecule Vitamin E Deficiency[MeSHID:D014811],Malabsorption Syndrome[MeSHID:D008286],Digestion[MeSHID:D004063],Cholestasis[MeSHID:D002779],Birth[MeSHID:D036801],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved p-glycoprotein 1 ABCB1 NA antagonist NA drugbank hm-30181 small molecule NA experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank dofequidar small molecule NA experimental,investigational p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank lomerizine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank w-198 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD , DGIDB atp small molecule NA investigational,nutraceutical p-glycoprotein 1 ABCB1 NA unknown NA drugbank edp-322 NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD , DGIDB trismethoxyresveratrol NA NA investigative multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD ly335979 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] discontinued in phase 3 multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD tariquidar NA Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] discontinued in phase 2 multidrug resistance protein 1 ABCB1 Successful target inhibitor 0.66 TTD , DGIDB elacridar small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational p-glycoprotein 1 ABCB1 NA unknown 0.27 drugbank , DGIDB fentanyl small molecule Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350] approved,illicit,investigational,vet_approved p-glycoprotein 1 ABCB1 NA unknown 0.08 drugbank , DGIDB tesmilifene small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational p-glycoprotein 1 ABCB1 NA inducer 0.11 drugbank , DGIDB voacamine small molecule Multi-Drug Resistance[MeSHID:D018432],Malignant Neoplasms[MeSHID:D009369],Malaria[MeSHID:D008288],Cells[MeSHID:D002477] experimental p-glycoprotein 1 ABCB1 NA inhibitor 1.06 drugbank , DGIDB tariquidar NA Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] discontinued in phase 2 multidrug resistance protein 1 ABCB1 Successful target unknown 0.66 TTD , DGIDB biricodar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] discontinued in phase 2 multidrug resistance protein 1 ABCB1 Successful target unknown 0.53 TTD , DGIDB miltefosine small molecule Leishmaniasis, Visceral[MeSHID:D007898],Disease susceptibility[MeSHID:D004198],Amebiasis[MeSHID:D000562],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leishmaniasis[MeSHID:D007896] approved,investigational p-glycoprotein 1 ABCB1 NA unknown 0.11 drugbank , DGIDB desmethylsertraline small molecule NA experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank [1,1':2',1'']-terphenyl-4,3'',5''-triol NA NA investigative multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD emopamil small molecule Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank elacridar NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 multidrug resistance protein 1 ABCB1 Successful target unknown 0.27 TTD , DGIDB 6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol NA NA investigative multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD tariquidar small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] investigational p-glycoprotein 1 ABCB1 NA unknown 0.66 drugbank , DGIDB tariquidar small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] investigational p-glycoprotein 1 ABCB1 NA inhibitor 0.66 drugbank , DGIDB dexniguldipine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank roxithromycin small molecule Respiratory tract structure[MeSHID:D012137],Soft Tissue Infections[MeSHID:D018461],Urinary tract[MeSHID:D014551],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn p-glycoprotein 1 ABCB1 NA unknown NA drugbank hycanthone small molecule NA experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank cbt-1 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Color Blindness, Blue[MeSHID:D003117] phase 3 multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD , DGIDB ont-093 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD concanamycin a small molecule NA experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank xr-9456 NA NA investigative multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD xr-9504 NA NA investigative multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD xr-9577 NA NA investigative multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank tetrandrine small molecule Colorectal Cancer[MeSHID:D015179],Sarcoma[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank ont-093 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank reversin 121 small molecule NA experimental p-glycoprotein 1 ABCB1 NA inhibitor NA drugbank zosuquidar small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938] investigational p-glycoprotein 1 ABCB1 NA inhibitor 0.8 drugbank , DGIDB 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl NA NA investigative multidrug resistance protein 1 ABCB1 Successful target unknown NA TTD atp small molecule NA investigational,nutraceutical bile salt export pump ABCB11 NA unknown NA drugbank glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved bile salt export pump ABCB11 NA inhibitor NA drugbank dofequidar fumarate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 3 multidrug resistance protein 3 ABCB4 Clinical trial target unknown NA TTD dexniguldipine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 multidrug resistance protein 3 ABCB4 Clinical trial target unknown NA TTD encequidar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943] phase 2 multidrug resistance protein 3 ABCB4 Clinical trial target unknown NA TTD laniquidar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 multidrug resistance protein 3 ABCB4 Clinical trial target unknown NA TTD ly335979 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] discontinued in phase 3 multidrug resistance protein 3 ABCB4 Clinical trial target unknown NA TTD biricodar small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] investigational atp-binding cassette sub-family b member 5 ABCB5 NA unknown NA drugbank dofequidar small molecule NA experimental,investigational atp-binding cassette sub-family b member 5 ABCB5 NA inhibitor NA drugbank atp small molecule NA investigational,nutraceutical multidrug resistance-associated protein 1 ABCC1 NA unknown NA drugbank biricodar small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] investigational multidrug resistance-associated protein 1 ABCC1 NA unknown NA drugbank xr-9504 NA NA investigative multidrug resistance-associated protein 1 ABCC1 Successful target unknown NA TTD sulfinpyrazone small molecule Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved multidrug resistance-associated protein 1 ABCC1 Successful target inhibitor 0.95 TTD , drugbank , DGIDB romidepsin small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Continuance of life[MeSHID:D013534],Peripheral T-Cell Lymphoma[MeSHID:D016411],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational multidrug resistance-associated protein 1 ABCC1 NA unknown NA drugbank xr-9456 NA NA investigative multidrug resistance-associated protein 1 ABCC1 Successful target unknown NA TTD xr-9544 NA NA investigative multidrug resistance-associated protein 1 ABCC1 Successful target unknown NA TTD benzbromarone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] approved multidrug resistance-associated protein 1 ABCC1 Successful target unknown 0.08 TTD , DGIDB leukotriene c4 small molecule NA experimental,investigational multidrug resistance-associated protein 1 ABCC1 NA unknown NA drugbank xr-9577 NA NA investigative multidrug resistance-associated protein 1 ABCC1 Successful target unknown NA TTD pyrrolopyrimidine NA NA investigative multidrug resistance-associated protein 1 ABCC1 Successful target unknown NA TTD atp small molecule NA investigational,nutraceutical canalicular multispecific organic anion transporter 1 ABCC2 NA unknown NA drugbank sulfinpyrazone small molecule Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved canalicular multispecific organic anion transporter 1 ABCC2 NA inhibitor 0.8 drugbank , DGIDB atp small molecule NA investigational,nutraceutical multidrug resistance-associated protein 4 ABCC4 NA unknown NA drugbank curcumin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational multidrug resistance-associated protein 5 ABCC5 NA inhibitor NA drugbank curcumin sulfate small molecule NA experimental multidrug resistance-associated protein 5 ABCC5 NA unknown NA drugbank atp small molecule NA investigational,nutraceutical multidrug resistance-associated protein 6 ABCC6 NA unknown NA drugbank repaglinide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor 2.5 drugbank , DGIDB nateglinide small molecule Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor 3 drugbank , DGIDB mitiglinide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor 4.99 drugbank , DGIDB glipizide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor,blocker 3.21 drugbank , DGIDB tolbutamide NA Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atp-binding cassette transporter c8 ABCC8 Successful target blocker 1.4 TTD , DGIDB repaglinide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target unknown 2.5 TTD , DGIDB gliclazide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette sub-family c member 8 ABCC8 NA binder 3.74 drugbank , DGIDB ns-11757 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative atp-binding cassette transporter c8 ABCC8 Successful target unknown NA TTD glimepiride NA Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hyperglycemia[MeSHID:D006943],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target blocker 2.81 TTD , DGIDB glimepiride small molecule Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hyperglycemia[MeSHID:D006943],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette sub-family c member 8 ABCC8 NA inducer 2.81 drugbank , DGIDB glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved sulfonylurea receptor 1, kir6.2 ABCC8 NA blocker 2.08 drugbank , DGIDB repaglinide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target blocker 2.5 TTD , DGIDB repaglinide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor,blocker 2.5 drugbank , DGIDB nn-414 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 1 atp-binding cassette transporter c8 ABCC8 Successful target unknown NA TTD , DGIDB tolazamide small molecule Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational sulfonylurea receptor 1, kir6.2 ABCC8 NA blocker 1.6 drugbank , DGIDB tolbutamide NA Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atp-binding cassette transporter c8 ABCC8 Successful target unknown 1.4 TTD , DGIDB glymidine small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inducer NA drugbank chlorpropamide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor,blocker 1.02 drugbank , DGIDB glimepiride NA Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hyperglycemia[MeSHID:D006943],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target unknown 2.81 TTD , DGIDB gliclazide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target unknown 3.74 TTD , DGIDB nateglinide small molecule Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor,blocker 3 drugbank , DGIDB chlorpropamide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor 1.02 drugbank , DGIDB glibenclamide NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target unknown 2.08 TTD , DGIDB gliquidone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor 3.74 drugbank , DGIDB repaglinide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target inhibitor 2.5 TTD , DGIDB hbr-985 NA NA investigative atp-binding cassette transporter c8 ABCC8 Successful target unknown NA TTD acetohexamide NA Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target blocker 2.5 TTD , DGIDB tolbutamide small molecule Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor,blocker 1.4 drugbank , DGIDB glimepiride small molecule Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hyperglycemia[MeSHID:D006943],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette sub-family c member 8 ABCC8 NA inducer,blocker 2.81 drugbank , DGIDB tolbutamide small molecule Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atp-binding cassette sub-family c member 8 ABCC8 NA inhibitor 1.4 drugbank , DGIDB acetohexamide NA Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c8 ABCC8 Successful target unknown 2.5 TTD , DGIDB atp small molecule NA investigational,nutraceutical atp-binding cassette sub-family c member 8 ABCC8 NA unknown NA drugbank nicorandil NA Risk Reduction[MeSHID:D040242],Stable angina[MeSHID:D060050],Acute Coronary Syndrome[MeSHID:D054058],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved atp-binding cassette transporter c9 ABCC9 Successful target unknown 2.83 TTD , DGIDB bts-67582 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 atp-binding cassette transporter c9 ABCC9 Successful target unknown NA TTD bms-191095 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 1 atp-binding cassette transporter c9 ABCC9 Successful target unknown NA TTD krn-2391 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 2 atp-binding cassette transporter c9 ABCC9 Successful target unknown NA TTD repaglinide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c9 ABCC9 Successful target unknown 0.47 TTD , DGIDB atp small molecule NA investigational,nutraceutical atp-binding cassette sub-family c member 9 ABCC9 NA unknown NA drugbank glimepiride NA Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hyperglycemia[MeSHID:D006943],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-binding cassette transporter c9 ABCC9 Successful target unknown 0.88 TTD , DGIDB nicorandil small molecule Risk Reduction[MeSHID:D040242],Stable angina[MeSHID:D060050],Acute Coronary Syndrome[MeSHID:D054058],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved,investigational atp-binding cassette sub-family c member 9 ABCC9 NA activator 2.83 drugbank , DGIDB ccx915 NA Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 atp-binding cassette transporter c9 ABCC9 Successful target unknown NA TTD tolbutamide NA Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atp-binding cassette transporter c9 ABCC9 Successful target unknown 0.88 TTD , DGIDB glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved atp-binding cassette sub-family c member 9 ABCC9 NA modulator NA drugbank atp small molecule NA investigational,nutraceutical atp-binding cassette sub-family g member 1 ABCG1 NA unknown NA drugbank biricodar small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] investigational atp-binding cassette sub-family g member 2 ABCG2 NA unknown NA drugbank sulfasalazine NA Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atp-binding cassette transporter g2 ABCG2 Successful target unknown 0.26 TTD , DGIDB avatrombopag small molecule Liver[MeSHID:D008099],Chronic disease[MeSHID:D002908],Thrombocytopenia[MeSHID:D013921] approved,investigational atp-binding cassette sub-family g member 2 ABCG2 NA inhibitor NA drugbank pmid29053063-compound-11c NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB piperazine carbamic compound 4 NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB pmid29053063-compound-11d NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB piperazine carbamic compound 1 NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB pyrazole derivative 81 NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB piperazine carbamic compound 2 NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB pyrazole derivative 82 NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB piperazine carbamic compound 5 NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB pyrazole derivative 80 NA NA patented monoacylglycerol lipase abhd6 ABHD6 Patented-recorded target unknown NA TTD , DGIDB radotinib small molecule Malignant Neoplasms[MeSHID:D009369],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tyrosine-protein kinase abl1 ABL1 NA antagonist NA drugbank bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved tyrosine-protein kinase abl1 ABL1 Successful target inhibitor 1.68 TTD , drugbank , DGIDB indol-5-ol derivative 1 NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB 6,6-fused nitrogenous heterocyclic compound 1 NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase abl1 ABL1 NA multitarget,inhibitor 0.59 drugbank , DGIDB tg-100435 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD 6,6-fused nitrogenous heterocyclic compound 2 NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB dcc-2036 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Myeloid Leukemia, Chronic[MeSHID:D015464],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 tyrosine-protein kinase abl1 ABL1 Successful target unknown 0.58 TTD , DGIDB atp small molecule NA investigational,nutraceutical tyrosine-protein kinase abl1 ABL1 NA inhibitor NA drugbank pmid25656651-compound-34c NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase abl1 ABL1 NA multitarget 0.59 drugbank , DGIDB bas-09534324 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD pmid25656651-compound-42 NA NA patented abl t315i mutant ABL1 Patented-recorded target unknown NA TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved tyrosine-protein kinase abl1 ABL1 NA inhibitor 0.51 drugbank , DGIDB indazole derivative 5 NA NA patented abl t315i mutant ABL1 Patented-recorded target unknown NA TTD pmid25656651-compound-33a NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational tyrosine-protein kinase abl1 ABL1 NA inhibitor NA drugbank azaindole derivative 1 NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB ap-24226 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD bas-00387328 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD bas-00672722 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD adenosine triphosphate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bradycardia[MeSHID:D001919],Malnutrition[MeSHID:D044342],Heart Diseases[MeSHID:D006331] approved tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB saracatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Osteosarcoma[MeSHID:D012516],Hematologic Neoplasms[MeSHID:D019337] phase 2 tyrosine-protein kinase abl1 ABL1 Successful target inhibitor 0.22 TTD , DGIDB bis-(5-hydroxy-1h-indol-2-yl)-methanone NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD 2-amino-5-[3-(1-ethyl-1h-pyrazol-5-yl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-n,n-dimethylbenzamide small molecule NA experimental tyrosine-protein kinase abl1 ABL1 NA unknown NA drugbank pmid23441572c24 NA NA investigative abl messenger rna ABL1 Discontinued target unknown NA TTD xl228 small molecule leukemia[MeSHID:D007938],Lymph[MeSHID:D008196] investigational tyrosine-protein kinase abl1 ABL1 NA inhibitor 0.18 drugbank , DGIDB xl228 small molecule leukemia[MeSHID:D007938],Lymph[MeSHID:D008196] investigational tyrosine-protein kinase abl1 ABL1 NA unknown 0.18 drugbank , DGIDB n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-pyridinecarboxamide small molecule NA experimental tyrosine-protein kinase abl1 ABL1 NA unknown NA drugbank azaindole derivative 2 NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB gnf-5 NA NA investigative abl messenger rna ABL1 Discontinued target inhibitor NA TTD , DGIDB bas-00387347 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD [1,1':2',1'']-terphenyl-4,3'',5''-triol NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD pp121 NA NA investigative abl messenger rna ABL1 Discontinued target inhibitor NA TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase abl1 ABL1 NA multitarget,inhibitor 0.59 drugbank , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved tyrosine-protein kinase abl1 ABL1 NA inhibitor 0.51 drugbank , DGIDB asciminib small molecule Mutation[MeSHID:D009154],Leukemia, Myeloid, Chronic-Phase[MeSHID:D015466],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase abl1 ABL1 NA inhibitor,allosteric modulator 2.89 drugbank , DGIDB isis-crp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Inflammation[MeSHID:D007249] phase 1 tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB pmid25656651-compound-28a NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB pd-0173956 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD mc-2001 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB g-1128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia, Chronic[MeSHID:D015464] discontinued in phase 2 abl messenger rna ABL1 Discontinued target unknown NA TTD trismethoxyresveratrol NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase abl1 ABL1 NA multitarget 0.59 drugbank , DGIDB bas-01373578 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase abl1 ABL1 Successful target inhibitor 1.86 TTD , drugbank , DGIDB pmid25656651-compound-46 NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB jnj-10198409 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD flumatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia, Chronic[MeSHID:D015464] phase 2 tyrosine-protein kinase abl1 ABL1 Successful target inhibitor 0.96 TTD , DGIDB bas-0338872 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD pmid25656651-compound-34a NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB pmid21561767c8h NA NA investigative abl messenger rna ABL1 Discontinued target unknown NA TTD pmid24900538c2c NA NA investigative abl messenger rna ABL1 Discontinued target unknown NA TTD regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase abl1 ABL1 NA inhibitor 0.03 drugbank , DGIDB pmid27774824-compound-figure9example2down NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure9example2up NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB umbralisib small molecule Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved,investigational tyrosine-protein kinase abl1 ABL1 NA inhibitor NA drugbank pmid25656651-compound-42 NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB bas-0338876 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD pmid25656651-compound-34b NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB kw-2449 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 tyrosine-protein kinase abl1 ABL1 Successful target unknown 0.58 TTD , DGIDB pmid25656651-compound-28b NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB adenosine triphosphate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bradycardia[MeSHID:D001919],Malnutrition[MeSHID:D044342],Heart Diseases[MeSHID:D006331] approved tyrosine-protein kinase abl1 ABL1 Successful target unknown 0.28 TTD , DGIDB pmid25656651-compound-33b NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB nilotinib small molecule leukemia[MeSHID:D007938],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase abl1 ABL1 NA inhibitor 2.73 drugbank , DGIDB 6,6-fused nitrogenous heterocyclic compound 3 NA NA patented tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , DGIDB 5-[3-(2-methoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-n,n-dimethylpyridine-3-carboxamide small molecule NA experimental tyrosine-protein kinase abl1 ABL1 NA unknown NA drugbank 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD kw-2449 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 tyrosine-protein kinase abl1 ABL1 Successful target inhibitor 0.58 TTD , DGIDB flumatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia, Chronic[MeSHID:D015464] phase 2 tyrosine-protein kinase abl1 ABL1 Successful target unknown 0.96 TTD , DGIDB 1-[4-(pyridin-4-yloxy)phenyl]-3-[3-(trifluoromethyl)phenyl]urea small molecule NA experimental tyrosine-protein kinase abl1 ABL1 NA unknown NA drugbank ski-758 NA Ischemia[MeSHID:D007511],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase abl1 ABL1 Successful target unknown 0.32 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase abl1 ABL1 NA inhibitor NA drugbank pd-0166326 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD myristic acid small molecule NA experimental,investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD , drugbank bas-00387275 NA NA investigative tyrosine-protein kinase abl1 ABL1 Successful target unknown NA TTD 2-{[(6-oxo-1,6-dihydropyridin-3-yl)methyl]amino}-n-[4-propyl-3-(trifluoromethyl)phenyl]benzamide small molecule NA experimental tyrosine-protein kinase abl1 ABL1 NA unknown NA drugbank saracatinib NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 2 tyrosine-protein kinase abl1 ABL1 Successful target inhibitor 0.22 TTD , DGIDB pd-166326 small molecule NA experimental tyrosine-protein kinase abl1 ABL1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational abelson tyrosine-protein kinase 2 ABL2 NA inhibitor NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational abelson tyrosine-protein kinase 2 ABL2 NA multitarget 1.24 drugbank , DGIDB k-00546 small molecule NA experimental abelson tyrosine-protein kinase 2 ABL2 NA unknown NA drugbank atp small molecule NA investigational,nutraceutical abelson tyrosine-protein kinase 2 ABL2 NA inhibitor NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational abelson tyrosine-protein kinase 2 ABL2 NA multitarget 1.24 drugbank , DGIDB xl228 small molecule leukemia[MeSHID:D007938],Lymph[MeSHID:D008196] investigational abelson tyrosine-protein kinase 2 ABL2 NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank 4-amino-2-octyloxy-6-hydroxymethyl-tetrahydro-pyran-3,5-diol small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank 4-amino-2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,5-diol small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,5-diol small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank galactose grease small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank h type ii trisaccharide small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank uridine-diphosphate-n-acetylgalactosamine small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank octyl 3-deoxy-2-o-(6-deoxy-alpha-l-galactopyranosyl)-beta-d-xylo-hexopyranoside small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank beta-methyllactoside small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank uridine-5'-diphosphate small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank human blood group h type 1 trisaccharide small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank galactose-uridine-5'-diphosphate small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank octyl 3-amino-3-deoxy-2-o-(2,6-dideoxy-alpha-l-lyxo-hexopyranosyl)-beta-d-galactopyranoside small molecule NA experimental histo-blood group abo system transferase ABO NA unknown NA drugbank trimetazidine small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved,investigational 3-ketoacyl-coa thiolase, mitochondrial ACAA2 NA inhibitor NA drugbank biotin small molecule NA approved,investigational,nutraceutical acetyl-coa carboxylase 1 ACACA NA cofactor NA drugbank metformin NA Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetyl-coa carboxylase 2 ACACB Successful target unknown 0.56 TTD , DGIDB cp-640186 NA NA investigative acetyl-coa carboxylase 2 ACACB Successful target unknown NA TTD adenine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical acetyl-coa carboxylase 2 ACACB NA unknown NA drugbank haloxyfop-p small molecule NA experimental acetyl-coa carboxylase 2 ACACB NA unknown NA drugbank a-80040 NA NA investigative acetyl-coa carboxylase 2 ACACB Successful target unknown NA TTD metformin NA Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved acetyl-coa carboxylase 2 ACACB Successful target unknown 0.56 TTD , DGIDB axokine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 3 acetyl-coa carboxylase 2 ACACB Successful target unknown NA TTD ac-8632 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigative acetyl-coa carboxylase 2 ACACB Successful target unknown NA TTD qlt-091382 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sebaceous Gland Diseases[MeSHID:D012625] investigative acetyl-coa carboxylase 2 ACACB Successful target unknown NA TTD biotin small molecule NA approved,investigational,nutraceutical acetyl-coa carboxylase 2 ACACB NA cofactor NA drugbank 2-[4-(2,4-dichlorophenoxy)phenoxy]propanoic acid small molecule NA experimental,investigative acetyl-coa carboxylase 2 ACACB Successful target unknown NA TTD , drugbank pf-05175157 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 acetyl-coa carboxylase 2 ACACB Successful target unknown 21.22 TTD , DGIDB soraphen a small molecule NA experimental,investigative acetyl-coa carboxylase 2 ACACB Successful target unknown NA TTD , drugbank methacrylyl-coenzyme a small molecule NA experimental isobutyryl-coa dehydrogenase, mitochondrial ACAD8 NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved isobutyryl-coa dehydrogenase, mitochondrial ACAD8 NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved medium-chain specific acyl-coa dehydrogenase, mitochondrial ACADM NA unknown NA drugbank 3-thiaoctanoyl-coa small molecule NA experimental medium-chain specific acyl-coa dehydrogenase, mitochondrial ACADM NA unknown NA drugbank octanoyl-coenzyme a small molecule NA experimental medium-chain specific acyl-coa dehydrogenase, mitochondrial ACADM NA unknown NA drugbank acetoacetyl-coa small molecule NA experimental short-chain specific acyl-coa dehydrogenase, mitochondrial ACADS NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved short-chain specific acyl-coa dehydrogenase, mitochondrial ACADS NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical short-chain specific acyl-coa dehydrogenase, mitochondrial ACADS NA unknown NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational short/branched chain specific acyl-coa dehydrogenase, mitochondrial ACADSB NA inhibitor NA drugbank , DGIDB isoleucine small molecule Dyskinetic syndrome[MeSHID:D020820] investigational,nutraceutical short/branched chain specific acyl-coa dehydrogenase, mitochondrial ACADSB NA unknown NA drugbank ilomastat small molecule NA experimental aggrecan core protein ACAN NA unknown NA drugbank pmid16242323c15b NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD pmid16242323c22c NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD (z)-2,6-diisopropyl-n-phenyloctadec-9-enamide NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD pmid16242323c15a NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD pmid25470667-compound-k-604 NA NA patented acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD , DGIDB pmid16242323c18b NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD pmid16242323c26b NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational acetyl-coa acetyltransferase, mitochondrial ACAT1 NA inhibitor NA drugbank benoxaprofen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] withdrawn from market acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetyl-coa acetyltransferase, mitochondrial ACAT1 NA inhibitor 13.26 drugbank , DGIDB pmid16242323c22d NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD pmid16242323c18a NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD atr-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] phase 1 acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD , DGIDB pmid16242323c16 NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD nonanoic acid biphenyl-2-ylamide NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational acetyl-coa acetyltransferase, mitochondrial ACAT1 NA inhibitor NA drugbank pmid16242323c26a NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD medical cannabis biotech NA experimental,investigational acetyl-coa acetyltransferase, mitochondrial ACAT1 NA inhibitor NA drugbank pmid16242323c26c NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD octanoic acid biphenyl-2-ylamide NA NA investigative acetoacetyl-coa thiolase ACAT1 Clinical trial target unknown NA TTD coenzyme a small molecule NA investigational,nutraceutical acetyl-coa acetyltransferase, cytosolic ACAT2 NA unknown NA drugbank s-hydroxycysteine small molecule NA experimental acetyl-coa acetyltransferase, cytosolic ACAT2 NA unknown NA drugbank vinylglycine small molecule NA experimental 1-aminocyclopropane-1-carboxylate synthase-like protein 1 ACCS NA unknown NA drugbank benazepril small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational angiotensin-converting enzyme ACE NA inhibitor 2.62 drugbank , DGIDB lisinopril small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational angiotensin-converting enzyme ACE NA inhibitor 3.17 drugbank , DGIDB trandolapril small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Congestive heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Kidney[MeSHID:D007668],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme ACE NA inhibitor 2.57 drugbank , DGIDB captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved angiotensin-converting enzyme ACE NA inhibitor 2.45 drugbank , DGIDB cilazapril small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved angiotensin-converting enzyme ACE NA inhibitor 22.18 drugbank , DGIDB epicaptopril small molecule NA experimental angiotensin-converting enzyme ACE NA unknown NA drugbank ramipril small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Cerebrovascular accident[MeSHID:D020521],Kidney[MeSHID:D007668],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved angiotensin-converting enzyme ACE NA inhibitor 2.41 drugbank , DGIDB temocapril small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Forecast of outcome[MeSHID:D011379],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Myocardial Infarction[MeSHID:D009203] experimental,investigational angiotensin-converting enzyme ACE NA inhibitor NA drugbank enalapril small molecule Disease Management[MeSHID:D019468],Hospitalization[MeSHID:D006760],Heart failure[MeSHID:D006333],heart rate[MeSHID:D006339],Ventricular Dysfunction, Left[MeSHID:D018487],Hypertension, Renovascular[MeSHID:D006978],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,vet_approved angiotensin-converting enzyme ACE NA inhibitor 0.68 drugbank , DGIDB spirapril small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme ACE NA inhibitor 8.68 drugbank , DGIDB candoxatril small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] experimental angiotensin-converting enzyme ACE NA inhibitor 1.93 drugbank , DGIDB ramipril small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Cerebrovascular accident[MeSHID:D020521],Kidney[MeSHID:D007668],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme ACE NA inhibitor 2.41 drugbank , DGIDB moexipril small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme ACE NA inhibitor 7.72 drugbank , DGIDB fosinopril small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Congestive heart failure[MeSHID:D006333],Kidney[MeSHID:D007668],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme ACE NA inhibitor 7.72 drugbank , DGIDB cilazaprilat small molecule NA experimental angiotensin-converting enzyme ACE NA unknown NA drugbank enalaprilat small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme ACE NA inhibitor 1.93 drugbank , DGIDB perindopril small molecule Coronary Artery Disease[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Coronary heart disease[MeSHID:D003327],Congestive heart failure[MeSHID:D006333],Essential Hypertension[MeSHID:D000075222],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme ACE NA inhibitor 2.65 drugbank , DGIDB lisinopril small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational angiotensin-converting enzyme ACE NA inhibitor 3.17 drugbank , DGIDB captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin-converting enzyme ACE NA inhibitor 2.45 drugbank , DGIDB omapatrilat small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational angiotensin-converting enzyme ACE NA unknown NA drugbank zofenopril small molecule NA approved angiotensin-converting enzyme ACE NA inhibitor 1.93 drugbank , DGIDB n-acetyl-alpha-d-glucosamine small molecule NA experimental angiotensin-converting enzyme ACE NA unknown NA drugbank rescinnamine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme ACE NA inhibitor 1.35 drugbank , DGIDB quinapril small molecule treatment failure[MeSHID:D017211],Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational angiotensin-converting enzyme ACE NA inhibitor 2.89 drugbank , DGIDB hydroxychloroquine small molecule Rheumatoid Arthritis[MeSHID:D001172],Lupus Erythematosus, Discoid[MeSHID:D008179],Malaria[MeSHID:D008288], Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme 2 ACE2 NA modulator NA drugbank pmid18324760c28 NA NA investigative angiotensin-converting enzyme 2 ACE2 Clinical trial target unknown NA TTD chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved,investigational,vet_approved angiotensin-converting enzyme 2 ACE2 NA modulator NA drugbank bromhexine small molecule Disease[MeSHID:D004194],Viscosity[MeSHID:D014783],Influenza[MeSHID:D007251],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Mucous body substance[MeSHID:D009093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859] approved angiotensin-converting enzyme 2 ACE2 NA binder NA drugbank ore-1001 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1/2 angiotensin-converting enzyme 2 ACE2 Clinical trial target unknown 47.74 TTD , DGIDB gsk2586881 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] phase 2 angiotensin-converting enzyme 2 ACE2 Clinical trial target unknown 31.83 TTD , DGIDB n-(2-aminoethyl)-1-aziridineethanamine small molecule Cardiovascular Diseases[MeSHID:D002318],Severe Acute Respiratory Syndrome[MeSHID:D045169] experimental angiotensin-converting enzyme 2 ACE2 NA inhibitor NA drugbank xnt NA NA investigative angiotensin-converting enzyme 2 ACE2 Clinical trial target unknown NA TTD hydroxychloroquine small molecule Rheumatoid Arthritis[MeSHID:D001172],Lupus Erythematosus, Discoid[MeSHID:D008179],Malaria[MeSHID:D008288], Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved angiotensin-converting enzyme 2 ACE2 NA modulator NA drugbank spp1148 small molecule Hypertensive disease[MeSHID:D006973] investigational angiotensin-converting enzyme 2 ACE2 NA unknown NA drugbank chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Malaria[MeSHID:D008288],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved angiotensin-converting enzyme 2 ACE2 NA modulator NA drugbank but-3-enyl-trimethyl-ammonium bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-hydrazino-1,2,3,4-tetrahydroacridine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD echothiophate iodide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved acetylcholinesterase ACHE Successful target inhibitor 1.55 TTD , DGIDB 6-methoxy-1,2-dimethyl-9h-beta-carbolin-2-ium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD haloxysterol a NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD trimethyl-(4-oxo-pentyl)-ammonium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pralidoxime small molecule Poisoning[MeSHID:D011041],Myasthenia Gravis[MeSHID:D009157] approved,vet_approved acetylcholinesterase ACHE NA activator,inhibitor 12.42 drugbank , DGIDB pmid27967267-compound-49 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB turbinatine NA NA investigative acetylcholinesterase ACHE Successful target unknown 3.1 TTD , DGIDB 3-(2-n-piperidyl-propionamino)-rutaecarpine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tacrine-caffeic acid hybrid derivative 2 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tacrine-indole hybrid derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 3-[3-(benzylmethylamino)propoxy]xanthen-9-one NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD methyl phosphinic acid NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pralidoxime chloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Poisoning[MeSHID:D011041] approved acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB chlorphrifos oxon NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-amino-7h-dibenzo[de,h]quinolin-7-one NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD choline small molecule NA approved,nutraceutical acetylcholinesterase ACHE NA product of NA drugbank isosorbide-di-(ethylcarbamate) NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD cpc-212 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Choroid Plexus Carcinoma[MeSHID:C562943] phase 1 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 9-o-[2-(phenylol-1-yloxy)hexyl]berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD demecarium small molecule Glaucoma, Open-Angle[MeSHID:D005902] approved acetylcholinesterase ACHE NA inhibitor NA drugbank pmid27967267-compound-51 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB (3-bromo-propyl)-trimethyl-ammonium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD eptastigmine NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 acetylcholinesterase ACHE Successful target unknown 0.78 TTD , DGIDB pmid27967267-compound-47 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB bis(18)-huperzine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD infractopicrin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-methyl-1'h-phenothiazine-1'-carboxamide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-43 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 6-hydroxy-2-methyl-9h-beta-carbolin-2-ium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD isosorbide-di-(benzylcarbamate) NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD isosorbide-2-benzylcarbamate-5-tosylate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 2-hex-5-enyl-5-non-8-enyl-3,4-dihydro-2h-pyrrole NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tacrine-caffeic acid hybrid derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB icopezil maleate NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD clebopride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD bis(8)-huperzine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD physostigmine small molecule Glaucoma[MeSHID:D005901],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Xerostomia[MeSHID:D014987] approved,investigational,discontinued in phase 2 acetylcholinesterase ACHE Successful target inhibitor 3.49 TTD , drugbank , DGIDB neostigmine small molecule Myasthenia Gravis[MeSHID:D009157],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved acetylcholinesterase ACHE Successful target inhibitor 17.08 TTD , drugbank , DGIDB n-benzyl-2-morpholinopyrimidin-4-amine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD bis(14)-huperzine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-13 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB paraoxon NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD carinatumins b (2) NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD ladostigil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 acetylcholinesterase ACHE Successful target unknown 0.52 TTD , DGIDB obidoxime NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD fluorinated donepezil derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetylcholinesterase ACHE Successful target inhibitor 3.33 TTD , drugbank , DGIDB 9-o-[3-(4-bromo-phenoxyl)butyl]-berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD haloxysterol c NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-o-[3-(4-nitro-phenoxyl)butyl]-berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-o-[3-(phenylamino)propyl]-berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD cis-2,6-dimethyl-1-methyl sulfonyl piperidine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB n-n-pentyl-7-methoxytacrine hydrochloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-12 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB decamethonium small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved acetylcholinesterase ACHE NA inhibitor NA drugbank 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pseudocolumbamine trifluoroacetate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD propidium small molecule NA experimental,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank hexyl-trimethyl-ammonium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-methyl-4-(4-o-tolylpiperazin-1-yl)coumarin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD chlorpyrifos NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-ethyl-2-methyl-beta-carboline-2-ium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD hydroxy(oxo)(2-{(1s)-2,2,2-trifluoro-1-[2-(trimethylarsonio)ethoxy]ethyl}phenyl)ammonium small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank decyle nelycorine dibromo salt derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB methanesulfonyl fluoride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB fluorinated donepezil derivative 2 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB pmid27967267-compound-3 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB demecarium bromide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma, Open-Angle[MeSHID:D005902] approved acetylcholinesterase ACHE Successful target inhibitor 1.55 TTD , DGIDB pmid27967267-compound-39 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 9-o-[2-(phenylol-1-yloxy)ethyl]berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-(4-o-tolylpiperazine-1-carbonyl)coumarin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (2-chloro-ethyl)-trimethyl-ammonium chloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pyridostigmine small molecule Myasthenia Gravis[MeSHID:D009157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational acetylcholinesterase ACHE Successful target inhibitor 2.22 TTD , drugbank , DGIDB 1,2-naphthoquinone NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD allyl-trimethyl-ammonium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-chloro-9-ethyl-6,7,8,9,10,11-hexahydro-7,11-methanocycloocta[b]quinolin-12-amine small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank lipocrine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (24s)-ethylcholesta-7,9(11),22(e)-triene-3b-ol NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD monoisopropylphosphorylserine small molecule NA experimental,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank 3-(2,5-dioxo-pyrrolidin-1-yl)-benzoic acid NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-propylnorlitebamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD methylphosphinate small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank 4alpha-(hydroxymethyl)-4alpha-demethylterritrem b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-o-[3-(2-pyridinoxyl)butyl]-berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD m-(n,n,n-trimethylammonio)-2,2,2-trifluoro-1,1-dihydroxyethylbenzene small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank 1-deoxy-1-thio-heptaethylene glycol small molecule NA experimental,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank 2-(n-morpholino)-ethanesulfonic acid NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (2-mercapto-ethyl)-trimethyl-ammonium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-(14-methylallyl)norgalanthamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid29757691-compound-8c NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB beta-l-fucose small molecule NA experimental,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank s-9977 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD n-acetyl-alpha-d-glucosamine small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank np-61 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 acetylcholinesterase ACHE Successful target unknown NA TTD bis(9)-huperzine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD ethyl octylfluorophosphonate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD isochroman-4-ketone derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB huprine y NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD phenserine small molecule NA investigational acetylcholinesterase ACHE NA unknown 1.16 drugbank , DGIDB nsc-23180 NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (-)-huperzine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tacrine-dihydropyridine hybrid derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB di-substituted piperidine derivative 2 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB pmid27967267-compound-28 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB chf-2819 NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD isopropyl dodecylfluorophosphonate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD egonol compound 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 2-propyl-beta-carboline-2-ium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD r-phenserine NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB desoxypeganine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 1 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB pralidoxime chloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Poisoning[MeSHID:D011041] approved acetylcholinesterase ACHE Successful target activator 1.55 TTD , DGIDB itopride small molecule Gastrointestinal Diseases[MeSHID:D005767],Disease[MeSHID:D004194] investigational acetylcholinesterase ACHE NA inhibitor 1.03 drugbank , DGIDB trimethyl-(3-nitro-phenyl)-ammonium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3,6,9,12,15-pentaoxaheptadecane small molecule NA experimental,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank lycorine dimer salt derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB diethylene glycol diethyl ether small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank tacrine small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn acetylcholinesterase ACHE Successful target inhibitor 4.66 TTD , drugbank , DGIDB 6-methoxy-2-methyl-9h-beta-carbolin-2-ium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank 4-pam derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB tacrine heterodimer derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 5-hex-5-enyl-2-nonyl-3,4-dihydro-2h-pyrrole NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD suronacrine maleate NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB caproctamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD sph-1285 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],SPHEROCYTOSIS, TYPE 1 (disorder)[MeSHID:C567159] preclinical acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 1,9-bis(pyridinium)-nonane dibromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-14 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 1-[3-({[(4-amino-5-fluoro-2-methylquinolin-3-yl)methyl]thio}methyl)phenyl]-2,2,2-trifluoroethane-1,1-diol small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank n,n'-(1',10'-decylene)-bis-(-)-nor-mep NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD isosorbide-di-(4-nitrophenyl carbamate) NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tetraethylene glycol NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-(2-diethylamino-acetamino)-rutaecarpine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-(dimethylamino)phenyl phenylcarbamate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD malathion NA Scalp structure[MeSHID:D012535],Ovum[MeSHID:D010063],Hair[MeSHID:D006197],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parasitic Diseases[MeSHID:D010272] approved acetylcholinesterase ACHE Successful target unknown 0.31 TTD , DGIDB ganstigmine small molecule NA investigational,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank pyridostigmine small molecule Myasthenia Gravis[MeSHID:D009157],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational acetylcholinesterase ACHE Successful target inhibitor 2.22 TTD , drugbank , DGIDB (rs)-tacrine(10)-hupyridone NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD zifrosilone NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD n,n'-(1',5'-pentylene)-bis-(-)-nor-mep NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tak-802 NA Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD n,n'-(1',8'-octylene)-bis-(-)-nor-mep NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 4-formylphenyl-o-beta-dglucopyranoside NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-[2-(1-benzyl-piperidin-4-yl)-ethyl]-1h-indazole NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-27 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 24-ethylcholest-6-ene-3,5-diol NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD isosorbide-di-phenylcarbamate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD edrophonium small molecule Myasthenia Gravis[MeSHID:D009157],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetylcholinesterase ACHE Successful target inhibitor 17.08 TTD , drugbank , DGIDB pseudopalmatine trifluoroacetate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD bis(12)-huperzine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tacrine-indole hybrid derivative 2 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 1,2-di(berberine-9-o-yl)ethane dibromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD galantamine analog 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB mf268 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] experimental,terminated acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank galantamine small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetylcholinesterase ACHE Successful target inhibitor 6.21 TTD , drugbank , DGIDB (r)-tacrine(10)-hupyridone small molecule NA experimental,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank isosorbide-2-(methylcarbamate)-5-benzoate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-o-[3-(phenylol-1-yloxy)propyl]berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD haloxysterol b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-chlorotacrine hydrochloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n,n'-(1',7'-heptylene)-bis-(-)-nor-mep NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD amidine oxime derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB dimetacrine small molecule NA experimental,withdrawn acetylcholinesterase ACHE NA antagonist NA drugbank (4as,6r,8as)-11-[8-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4ah-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank n-n-hexyl-7-methoxytacrine hydrochloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-o-[4-(phenylol-1-yloxy)butyl]berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (2-ethoxy-ethyl)-trimethyl-ammonium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (3,4,8b-trimethyl-3-oxido-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-3-ium-7-yl) n-(2-ethylphenyl)carbamate small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank dimethyl-pent-4-enyl-ammonium bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (s)-tacrine(10)-hupyridone small molecule NA experimental,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank lysicamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (3r)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD echothiophate iodide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB tetra-hydro-isoquinoline derivative 3 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB taspine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 1,3-di(berberine-9-o-yl)ethane dibromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-n-nonyl-7-methoxytacrine hydrochloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-o-[5-(phenylol-1-yloxy)pentyl]berberine bromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (3-hydroxy-2-methyl-phenyl)-trimethyl-ammonium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD amocarzine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Helminthiasis[MeSHID:D006373] phase 3 acetylcholinesterase ACHE Successful target unknown 1.55 TTD , DGIDB n,n'-(1',9'-nonylene)-bis-(-)-nor-mep NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD voacangine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD nap-226-90 small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank inm-176 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 2-hex-5-enyl-5-nonyl-pyrrolidine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-hydroxy-1,2,9-trimethyl-9h-beta-carbolin-2-ium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid29757691-compound-8a NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 10-hydroxy-infractopicrin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid29757691-compound-4 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 1,3-bis-(3-imidazolidin-2-yl-phenyl)-urea NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid29757691-compound-2a-i NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB pmid27967267-compound-neotuberostemonine NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB methylphosphinic acid small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank isosorbide-2-benzylcarbamate-5-cyclopentanoate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-allylnorlitebamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (-)-tolserine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD kw-5092 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB bis-7-tacrine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-hydroxy-n,n,n-trimethylbenzenaminium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD thioctic acid NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (2-butyryloxy-ethyl)-trimethyl-ammonium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD choline salicylate small molecule Exanthema[MeSHID:D005076],Teething syndrome[MeSHID:D014078],Oral Ulcer[MeSHID:D019226],Pain[MeSHID:D010146],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,nutraceutical acetylcholinesterase ACHE NA product of NA drugbank pmid27967267-compound-15 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB pralidoxime small molecule Poisoning[MeSHID:D011041],Myasthenia Gravis[MeSHID:D009157] approved,vet_approved acetylcholinesterase ACHE NA activator 12.42 drugbank , DGIDB quinazoline alkaloid derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB indoline derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB tacrine(8)-4-aminoquinoline small molecule NA experimental,investigative acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank n,n'-(1',12'-dodecydene)-bis-(-)-nor-mep NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-methoxy-2,9-dimethyl-9h-beta-carbolin-2-ium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 24-ethyl-cholest-7-ene-3,5,6-triol NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD choline iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-amino-1,2,3,4-tetrahydro-acridine-1,7-diol NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD gtp-004 NA Myasthenia Gravis[MeSHID:D009157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 3-(4-benzoylpiperazine-1-carbonyl)coumarin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-hydroxy-1,2-dimethyl-9h-beta-carbolin-2-ium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD xanthostigmine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1h)-imine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tacrine-indole hybrid derivative 3 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 2-morpholino-n-phenethylpyrimidin-4-amine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-hydroxy-2,9-dimethyl-9h-beta-carbolin-2-ium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD dipivefrin small molecule Glaucoma, Open-Angle[MeSHID:D005902],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetylcholinesterase ACHE NA inhibitor NA drugbank 3-(2-n-piperidyl-acetamino)-rutaecarpine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-butylnorlitebamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-benzylnorlitebamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-methoxy-1,9-dimethyl-9h-pyrido[3,4-b]indole NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (5-bromo-pentyl)-trimethyl-ammonium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 1,10-bis(pyridinium)-decane dibromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tacrine-phenothiazine hybrid derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB mesuagenin d NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD methylthioninium small molecule NA experimental,investigational acetylcholinesterase ACHE NA unknown NA drugbank n-n-dodecyl-7-methoxytacrine hydrochloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD phenserine tartrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] preclinical acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 6,8-dichloro-1,2,3,4-tetrahydro-acridin-9-ylamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 4-[4-(benzhydryloxy)piperidino]butyl benzoate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-stenine NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB acetylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Lens, Crystalline[MeSHID:D007908],Miosis disorder[MeSHID:D015877],Iris (Eye)[MeSHID:D007498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cataract[MeSHID:D002386] approved,investigational acetylcholinesterase ACHE NA unknown NA drugbank minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetylcholinesterase ACHE NA inhibitor NA drugbank trimedoxime NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 4 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB zanapezil small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 acetylcholinesterase ACHE Successful target unknown NA TTD , drugbank 2-pam derivative 1 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB decidium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 2 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 1-(3-bromomethyl-phenyl)-2,2,2-trifluoro-ethanone NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (9s)-9-[(8-ammoniooctyl)amino]-1,2,3,4,9,10-hexahydroacridinium small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank 3-(2-n-pyrrolyl-propionamino)-rutaecarpine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 2-(acetylamino)-2-deoxy-a-d-glucopyranose NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (s,s)-(-)-bis(10)-hupyridone NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-(2-n-pyrrolyl-acetamino)-rutaecarpine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-[4-(benzylmethylamino)butoxy]xanthen-9-one NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-n-heptyl-7-methoxytacrine hydrochloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 5,6-dinitroacenaphthoquinone NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-n-octyl-7-methoxytacrine hydrochloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD galanthamine derivative NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-[(1s)-1-(dimethylamino)ethyl]phenol NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD ap-2243 NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD chloranil NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD benzoquinone NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 1,11-bis(pyridinium)-undecane dibromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD huprine-tacrine heterodimer NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-allylnorgalanthamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (-)-phenserine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB velnacrine NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 acetylcholinesterase ACHE Successful target unknown NA TTD 3,8-diamino-6-phenyl-5-[6-[1-[2-[(1,2,3,4-tetrahydro-9-acridinyl)amino]ethyl]-1h-1,2,3-triazol-5-yl]hexyl]-phenanthridinium small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank pmid29757691-compound-8b NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 1,4-di(berberine-9-o-yl)ethane dibromide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD t-82 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB coronaridine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-(3-carboxy-propionylamino)-benzoic acid NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD demecarium bromide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma, Open-Angle[MeSHID:D005902] approved acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB pmid27967267-compound-48 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 1-benzene sulfonyl-cis-2,6-dimethyl piperidine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD haloxysterol d NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD ap-2238 NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3,8-diamino-6-phenyl-5-[6-[1-[2-[(1,2,3,4-tetrahydro-9-acridinyl)amino]ethyl]-1h-1,2,3-triazol-4-yl]hexyl]-phenanthridinium small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank cpc-250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Choroid Plexus Carcinoma[MeSHID:C562943] phase 1 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 1-ethoxy-2-(2-ethoxyethoxy)ethane NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD ranitidine small molecule Mastocytosis, Systemic[MeSHID:D034721],Esophagitis[MeSHID:D004941],Zollinger-Ellison syndrome[MeSHID:D015043],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Gastric Acid[MeSHID:D005744],Diagnosis[MeSHID:D003933],Stomach[MeSHID:D013270],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] approved,withdrawn acetylcholinesterase ACHE NA inhibitor NA drugbank 2-[4-(dimethylamino)phenyl]-6-hydroxy-3-methyl-1,3-benzothiazol-3-ium small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank pmid29757691-compound-8d NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB pmid29757691-compound-7 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB n-benzyl-2-thiomorpholinopyrimidin-4-amine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-52 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB bzyx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-n-propyl-7-methoxytacrine hydrochloride NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD bis(20)-huperzine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine small molecule NA experimental acetylcholinesterase ACHE NA unknown NA drugbank zt-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB pmid29757691-compound-10 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB 8-chloro-1,2,3,4-tetrahydro-acridin-9-ylamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD geneserine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-methyl-4-(4-benzoylpiperazin-1-yl)coumarin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 9-ethyl-beta-carboline NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 5-chloro-1,2,3,4-tetrahydro-acridin-9-ylamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3,7-bis(dimethylamino)phenothiazin-5-ium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tyrothricin small molecule NA approved acetylcholinesterase ACHE NA inhibitor NA drugbank 4-formylphenyl-o-beta-d-ribopyranoside NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid29757691-compound-2a NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB tolserine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-7 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB isoflurophate small molecule Glaucoma[MeSHID:D005901],Esotropia[MeSHID:D004948],Disorder of eye[MeSHID:D005128],Eye[MeSHID:D005123],Visual Accommodation[MeSHID:D000065],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] approved,investigational,withdrawn acetylcholinesterase ACHE Successful target inhibitor 6.21 TTD , drugbank , DGIDB mesuagenin b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 2-hex-5-enyl-5-non-8-enyl-pyrrolidine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-(2-diethylamino-propionamino)-rutaecarpine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 6-methyl-4-(4-phenylpiperazin-1-yl)coumarin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-neostenine NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB (4-bromo-butyl)-trimethyl-ammonium NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD petrosamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-42 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB (s,s)-(-)-bis(12)-hupyridone NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD ambenonium small molecule Myopathy[MeSHID:D009135],Myasthenia Gravis[MeSHID:D009157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetylcholinesterase ACHE Successful target inhibitor 15.52 TTD , drugbank , DGIDB ym443 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415] approved acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB cp-126998 NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3,4,5,6-tetrachloro-[1,2]benzoquinone NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD memoquin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD sm-10888 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD n-isopropylnorlitebamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD cryptadine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n,n'-(1',6-hexylene)-bis-(-)-nor-mep NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD hp-290 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD 4-isopropylphenserine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD lawsaritol NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD mmb-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative acetylcholinesterase ACHE Successful target unknown NA TTD 7-oxo-7h-dibenzo[de,g]quinoline NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD nprx-30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-isobutylnorlitebamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD bis(16)-huperzine b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 7-chloro-1,2,3,4-tetrahydro-acridin-9-ylamine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n-isopropylnorlitebaminen-methoiodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD tubocurarine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved acetylcholinesterase ACHE NA inhibitor NA drugbank 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD rivastigmine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational acetylcholinesterase ACHE Successful target inhibitor 7.37 TTD , drugbank , DGIDB huprine x NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-(4-phenylpiperazin-1-carbonyl)coumarin NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD ethylphenserine NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD territrem b NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD huperzine a small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental acetylcholinesterase ACHE Successful target inhibitor NA TTD , drugbank , DGIDB isosorbide-2-benzylcarbamate-5-cyclopropanoate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD (4-iodo-butyl)-trimethyl-ammonium iodide NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD n,n'-(1',11'-undecydene)-bis-(-)-nor-mep NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD bw284c51 NA NA investigative acetylcholinesterase ACHE Successful target inhibitor NA TTD , DGIDB (1r)-1,2,2-trimethylpropyl (s)-methylphosphinate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD isosorbide-2-(methylcarbamate)-5-mononitrate NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD prx-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB gallamine triethiodide small molecule Disease Management[MeSHID:D019468],Skeletal muscle structure[MeSHID:D018482],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acetylcholinesterase ACHE NA inhibitor NA drugbank fucose NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD huperzine b small molecule NA investigational acetylcholinesterase ACHE NA unknown NA drugbank iso-ompa NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD caracemide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 acetylcholinesterase ACHE Successful target unknown NA TTD mesuagenin a NA NA investigative acetylcholinesterase ACHE Successful target unknown NA TTD pmid27967267-compound-36 NA NA patented acetylcholinesterase ACHE Successful target unknown NA TTD , DGIDB chloroquine NA Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Malaria[MeSHID:D008288],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved duffy antigen chemokine receptor ACKR1 Successful target unknown 2.65 TTD , DGIDB aq-13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] phase 2 duffy antigen chemokine receptor ACKR1 Successful target unknown 31.83 TTD , DGIDB chloroquine NA Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved duffy antigen chemokine receptor ACKR1 Successful target unknown 2.65 TTD , DGIDB gw-766994 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 c-x-c chemokine receptor type 7 ACKR3 Preclinical target unknown NA TTD ccx-662 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative c-x-c chemokine receptor type 7 ACKR3 Preclinical target unknown NA TTD jt07 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical c-x-c chemokine receptor type 7 ACKR3 Preclinical target unknown NA TTD sb-201076 NA NA investigative atp-citrate synthase ACLY Successful target unknown NA TTD (-)-hydroxycitrate NA NA investigative atp-citrate synthase ACLY Successful target unknown NA TTD bempedoic acid small molecule Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Diet therapy[MeSHID:D004035],Hypercholesterolemia, Familial[MeSHID:D006938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,investigational atp-citrate synthase ACLY Successful target inhibitor NA TTD , drugbank alpha-methylisocitric acid small molecule NA experimental aconitate hydratase, mitochondrial ACO2 NA unknown NA drugbank 4-hydroxy-aconitate ion small molecule NA experimental aconitate hydratase, mitochondrial ACO2 NA unknown NA drugbank isocitric acid small molecule NA experimental aconitate hydratase, mitochondrial ACO2 NA unknown NA drugbank aconitate ion small molecule NA experimental aconitate hydratase, mitochondrial ACO2 NA unknown NA drugbank tricarballylic acid small molecule NA experimental aconitate hydratase, mitochondrial ACO2 NA unknown NA drugbank 2-undecanone small molecule NA experimental acyl-coenzyme a thioesterase 13 ACOT13 NA unknown NA drugbank (3r)-3-hydroxydodecanoic acid small molecule NA experimental peroxisomal acyl-coenzyme a oxidase 1 ACOX1 NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved peroxisomal acyl-coenzyme a oxidase 1 ACOX1 NA unknown NA drugbank adenine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical low molecular weight phosphotyrosine protein phosphatase ACP1 NA unknown NA drugbank 4-nitrophenyl phosphate small molecule NA experimental low molecular weight phosphotyrosine protein phosphatase ACP1 NA unknown NA drugbank mvi-816 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 prostatic acid phosphatase ACPP Clinical trial target unknown NA TTD sipuleucel-t biotech Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Cells[MeSHID:D002477],Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational prostatic acid phosphatase ACPP NA other NA drugbank alpha-benzyl-aminobenzyl-phosphonic acid small molecule NA experimental prostatic acid phosphatase ACPP NA unknown NA drugbank (2r,3r)-2,3-dihydroxy-4-oxo-4-(propylamino)butanoic acid small molecule NA experimental prostatic acid phosphatase ACPP NA unknown NA drugbank 2-(6-hydroxy-1,3-benzothiazol-2-yl)-1,3-thiazol-4(5h)-one small molecule NA experimental long-chain-fatty-acid--coa ligase acsbg1 ACSBG1 NA unknown NA drugbank atp small molecule NA investigational,nutraceutical long-chain-fatty-acid--coa ligase 1 ACSL1 NA unknown NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical long-chain-fatty-acid--coa ligase 1 ACSL1 NA product of NA drugbank icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical long-chain-fatty-acid--coa ligase 4 ACSL4 NA inducer NA drugbank rosiglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational long-chain-fatty-acid--coa ligase 4 ACSL4 NA inhibitor NA drugbank troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn long-chain-fatty-acid--coa ligase 4 ACSL4 NA inhibitor NA drugbank atp small molecule NA investigational,nutraceutical acetyl-coenzyme a synthetase 2-like, mitochondrial ACSS1 NA unknown NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical acetyl-coenzyme a synthetase, cytoplasmic ACSS2 NA product of NA drugbank atp small molecule NA investigational,nutraceutical acetyl-coenzyme a synthetase, cytoplasmic ACSS2 NA unknown NA drugbank reidispongiolide c small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank aplyronine a small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank sphinxolide b small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank latrunculin a small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA inhibitor NA drugbank sucrose small molecule NA approved,experimental,investigational actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank kabiramide c small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank 1-methylhistidine small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank reidispongiolide a small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank ulapualide a small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank latrunculin b small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank jaspisamide a small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank tmr small molecule NA experimental actin, alpha skeletal muscle ACTA1 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational actin, aortic smooth muscle ACTA2 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational actin, cytoplasmic 1 ACTB NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational actin, cytoplasmic 1 ACTB NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational actin, cytoplasmic 2 ACTG1 NA ligand NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational actin, cytoplasmic 2 ACTG1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-actinin-1 ACTN1 NA unknown NA drugbank human calcitonin biotech Metabolic Bone Disorder[MeSHID:D001851],Catabolism[MeSHID:D008660],Bone remodeling[MeSHID:D016723],Congenital Abnormality[MeSHID:D000013],Serum[MeSHID:D044967],Pathological fracture[MeSHID:D005598],Osteitis Deformans[MeSHID:D010001],Osteogenesis[MeSHID:D010012],Deafness[MeSHID:D003638],Urinary tract[MeSHID:D014551],Bone Tissue[MeSHID:D001842],Pain[MeSHID:D010146] approved,investigational alpha-actinin-1 ACTN1 NA incorporation into and destabilization NA drugbank (2s)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one small molecule NA experimental actin-related protein 2 ACTR2 NA unknown NA drugbank n-[2-(2-methyl-1h-indol-3-yl)ethyl]thiophene-2-carboxamide small molecule NA experimental actin-related protein 2 ACTR2 NA unknown NA drugbank (2s)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one small molecule NA experimental actin-related protein 3 ACTR3 NA unknown NA drugbank n-[2-(2-methyl-1h-indol-3-yl)ethyl]thiophene-2-carboxamide small molecule NA experimental actin-related protein 3 ACTR3 NA unknown NA drugbank ml347 NA NA investigative activin receptor-like kinase 2 ACVR1 Clinical trial target inhibitor NA TTD , DGIDB pmid27774822-compound-figure10compound4 NA NA patented activin receptor-like kinase 2 ACVR1 Clinical trial target unknown NA TTD pmid23639540c13r NA NA investigative activin receptor-like kinase 2 ACVR1 Clinical trial target unknown NA TTD ldn-214117 NA NA investigative activin receptor-like kinase 2 ACVR1 Clinical trial target inhibitor NA TTD , DGIDB dorsomorphin small molecule NA experimental activin receptor type-1 ACVR1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational activin receptor type-1 ACVR1 NA inhibitor NA drugbank pmid23639540c13a NA NA investigative activin receptor-like kinase 2 ACVR1 Clinical trial target unknown NA TTD incb00928 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Anemia[MeSHID:D000740],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] phase 2 activin receptor-like kinase 2 ACVR1 Clinical trial target unknown NA TTD pmid23639540c13d NA NA investigative activin receptor-like kinase 2 ACVR1 Clinical trial target unknown NA TTD atp small molecule NA investigational,nutraceutical activin receptor type-1 ACVR1 NA unknown NA drugbank tp-0184 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 activin receptor-like kinase 2 ACVR1 Clinical trial target unknown NA TTD pmid27774822-compound-figure10compound12 NA NA patented activin receptor-like kinase 2 ACVR1 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational activin receptor type-1b ACVR1B NA inhibitor NA drugbank atp small molecule NA investigational,nutraceutical activin receptor type-1b ACVR1B NA unknown NA drugbank sotatercept biotech MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational activin receptor type-2a ACVR2A NA unknown NA drugbank bym338 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inclusion Body Myositis (disorder)[MeSHID:D018979],Leukemia, Myelocytic, Acute[MeSHID:D015470],Muscular Atrophy[MeSHID:D009133] phase 3 activin receptor type iia ACVR2A Clinical trial target unknown 31.83 TTD , DGIDB acvr2b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Atrophy[MeSHID:D009133] investigative activin receptor type iib ACVR2B Literature-reported target unknown NA TTD ldn-214117 NA NA investigative activin receptor-like kinase-1 ACVRL1 Clinical trial target inhibitor NA TTD , DGIDB atp small molecule NA investigational,nutraceutical serine/threonine-protein kinase receptor r3 ACVRL1 NA unknown NA drugbank pf-03446962 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 activin receptor-like kinase-1 ACVRL1 Clinical trial target inhibitor 47.74 TTD , DGIDB pf-03446962 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 activin receptor-like kinase-1 ACVRL1 Clinical trial target unknown 47.74 TTD , DGIDB pmid23639540c13a NA NA investigative activin receptor-like kinase-1 ACVRL1 Clinical trial target unknown NA TTD pmid23639540c13d NA NA investigative activin receptor-like kinase-1 ACVRL1 Clinical trial target unknown NA TTD ml347 NA NA investigative activin receptor-like kinase-1 ACVRL1 Clinical trial target inhibitor NA TTD , DGIDB pmid23639540c13r NA NA investigative activin receptor-like kinase-1 ACVRL1 Clinical trial target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aminoacylase-1 ACY1 NA unknown NA drugbank acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational aminoacylase-1 ACY1 NA substrate NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical aminoacylase-1 ACY1 NA unknown NA drugbank formic acid small molecule NA experimental,investigational acylphosphatase-2 ACYP2 NA unknown NA drugbank 1-((1r)-1-(hydroxymethyl)-3-{6-[(3-phenylpropanoyl)amino]-1h-indol-1-yl}propyl)-1h-imidazole-4-carboxamide small molecule NA experimental adenosine deaminase ADA NA unknown NA drugbank fr117016 small molecule NA experimental,investigative adenosine deaminase ADA Successful target unknown NA TTD , drugbank 3-(6-amino-purin-9-yl)-non-5-yn-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD 3-(6-amino-purin-9-yl)-4-p-tolyl-butan-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD purine riboside NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD gsk2696273 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immunologic Deficiency Syndromes[MeSHID:D007153],Chronic pain[MeSHID:D059350] preregistration adenosine deaminase ADA Successful target unknown NA TTD , DGIDB fr236913 small molecule NA experimental,investigative adenosine deaminase ADA Successful target unknown NA TTD , drugbank 6-hydroxy-1,6-dihydro purine nucleoside small molecule NA experimental,investigative adenosine deaminase ADA Successful target unknown NA TTD , drugbank pentostatin small molecule Hairy Cell Leukemia[MeSHID:D007943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine deaminase ADA Successful target inhibitor 23.87 TTD , drugbank , DGIDB ehna NA NA investigative adenosine deaminase ADA Successful target inhibitor 1.06 TTD , DGIDB cladribine NA Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved adenosine deaminase ADA Successful target unknown 0.35 TTD , DGIDB 1-((1r,2s)-1-{2-[2-(4-chlorophenyl)-1,3-benzoxazol-7-yl]ethyl}-2-hydroxypropyl)-1h-imidazole-4-carboxamide small molecule NA experimental adenosine deaminase ADA NA unknown NA drugbank otl-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Combined Immunodeficiency[MeSHID:D016511] phase 3 adenosine deaminase ADA Successful target unknown NA TTD fr221647 small molecule NA experimental,investigative adenosine deaminase ADA Successful target unknown NA TTD , drugbank fr233623 NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD 3-(6-amino-purin-9-yl)-4-butoxy-butan-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD 3-(6-amino-purin-9-yl)-5-m-tolyl-pentan-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD 1-{(1r,2s)-2-hydroxy-1-[2-(2-naphthyloxy)ethyl]propyl}-1h-imidazone-4-carboxamide small molecule NA experimental adenosine deaminase ADA NA unknown NA drugbank ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy NA Hematopoietic stem cells[MeSHID:D006412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immunologic Deficiency Syndromes[MeSHID:D007153] phase 1/2 adenosine deaminase ADA Successful target unknown NA TTD , DGIDB nebularine small molecule NA experimental adenosine deaminase ADA NA unknown NA drugbank 3-(6-amino-purin-9-yl)-8-phenyl-octan-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD (2s,3r)-3-(6-amino-9h-purin-9-yl)nonan-2-ol small molecule NA experimental,investigative adenosine deaminase ADA Successful target unknown NA TTD , drugbank 6-hydroxy-7,8-dihydro purine nucleoside NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD 3-(6-amino-purin-9-yl)-4-phenethyloxy-butan-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD 3-(6-amino-purin-9-yl)-7-phenyl-heptan-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD 7,8-dihydroinosine small molecule NA experimental adenosine deaminase ADA NA unknown NA drugbank fludarabine NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved adenosine deaminase ADA Successful target unknown 0.27 TTD , DGIDB fr239087 small molecule NA experimental,investigative adenosine deaminase ADA Successful target unknown NA TTD , drugbank 3-(6-amino-purin-9-yl)-6-phenyl-hexan-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD 3-(6-amino-purin-9-yl)-non-5-en-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD fr-234938 small molecule NA experimental adenosine deaminase ADA NA unknown NA drugbank elapegademase NA Severe Combined Immunodeficiency[MeSHID:D016511],Disease[MeSHID:D004194],Severe combined immunodeficiency due to adenosine deaminase deficiency[MeSHID:C531816],Leukocytes[MeSHID:D007962],Hereditary Diseases[MeSHID:D030342],Mental Suffering[MeSHID:D013315],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immunologic Deficiency Syndromes[MeSHID:D007153] approved adenosine deaminase ADA Successful target unknown 5.3 TTD , DGIDB fr230513 small molecule NA experimental,investigative adenosine deaminase ADA Successful target unknown NA TTD , drugbank dipyridamole small molecule Heart Valves[MeSHID:D006351],Angina Pectoris[MeSHID:D000787],Postoperative Complications[MeSHID:D011183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved adenosine deaminase ADA NA inhibitor 0.31 drugbank , DGIDB 1-deaza-adenosine small molecule NA experimental,investigative adenosine deaminase ADA Successful target unknown NA TTD , drugbank 3-(6-amino-purin-9-yl)-6-o-tolyl-hexan-2-ol NA NA investigative adenosine deaminase ADA Successful target unknown NA TTD isis 100749 NA NA investigative adam10 messenger rna ADAM10 Literature-reported target unknown NA TTD isis 100748 NA NA investigative adam10 messenger rna ADAM10 Literature-reported target unknown NA TTD pmid18068976c25 NA NA investigative adam10 messenger rna ADAM10 Literature-reported target unknown NA TTD aderbasib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 mammalian disintegrin-metalloprotease ADAM10 Clinical trial target unknown 10.61 TTD , DGIDB xl784 small molecule Diabetes Mellitus[MeSHID:D003920],Proteinuria[MeSHID:D011507],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational disintegrin and metalloproteinase domain-containing protein 10 ADAM10 NA unknown NA drugbank isis 100743 NA NA investigative adam10 messenger rna ADAM10 Literature-reported target unknown NA TTD iai-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative mammalian disintegrin-metalloprotease ADAM10 Clinical trial target unknown NA TTD isis 100742 NA NA investigative adam10 messenger rna ADAM10 Literature-reported target unknown NA TTD isis 100750 NA NA investigative adam10 messenger rna ADAM10 Literature-reported target unknown NA TTD apratastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tnf alpha converting enzyme ADAM17 Clinical trial target unknown 7.07 TTD , DGIDB sr-973 NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD ch4474 NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD aderbasib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 tnf alpha converting enzyme ADAM17 Clinical trial target unknown 5.3 TTD , DGIDB 2-(biphenyl-4-ylsulfonamido)-n-hydroxyacetamide NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD n-hydroxy-3-(2-oxo-2h-chromen-3-yl)propanamide NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD sl422 NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD n-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD 2-(4-bromophenylsulfonamido)-n-hydroxyacetamide NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD (3s)-4-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-n-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 17 ADAM17 NA unknown NA drugbank pkf-242-484 NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD 4-({4-[(4-aminobut-2-ynyl)oxy]phenyl}sulfonyl)-n-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 17 ADAM17 NA unknown NA drugbank 3-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiol small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 17 ADAM17 NA unknown NA drugbank n-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-d-tryptophan small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 17 ADAM17 NA unknown NA drugbank n-hydroxy-3-(6-methoxy-2-oxo-2h-chromen-3-yl) NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD methyl (1r,2s)-2-(hydroxycarbamoyl)-1-{4-[(2-methylquinolin-4-yl)methoxy]benzyl}cyclopropanecarboxylate small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 17 ADAM17 NA unknown NA drugbank im-491 NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD gw-3333 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] preclinical tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD , DGIDB (3s)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 17 ADAM17 NA unknown NA drugbank pkf-241-466 NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD batimistat NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target unknown NA TTD apratastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tnf alpha converting enzyme ADAM17 Clinical trial target inhibitor 7.07 TTD , DGIDB (1s,3r,6s)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 17 ADAM17 NA unknown NA drugbank (2r)-n-hydroxy-2-[(3s)-3-methyl-3-{4-[(2-methylquinolin-4-yl)methoxy]phenyl}-2-oxopyrrolidin-1-yl]propanamide small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 17 ADAM17 NA unknown NA drugbank ik-862 NA NA investigative tnf alpha converting enzyme ADAM17 Clinical trial target inhibitor NA TTD , DGIDB 2-(thiomethylene)-4-methylpentanoic acid small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 28 ADAM28 NA unknown NA drugbank furoyl-leucine small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 28 ADAM28 NA unknown NA drugbank (2r,3r)-n^1^-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-n^4^-hydroxy-2-(2-methylpropyl)-3-{[(1,3-thiazol-2-ylcarbonyl)amino]methyl}butanediamide small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 28 ADAM28 NA unknown NA drugbank batimastat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] experimental disintegrin and metalloproteinase domain-containing protein 28 ADAM28 NA unknown NA drugbank ilomastat small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 28 ADAM28 NA unknown NA drugbank n-[(furan-2-yl)carbonyl]-(s)-leucyl-(r)-[1-amino-2(1h-indol-3-yl)ethyl]-phosphonic acid small molecule NA experimental disintegrin and metalloproteinase domain-containing protein 28 ADAM28 NA unknown NA drugbank pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational disintegrin and metalloproteinase domain-containing protein 28 ADAM28 NA unknown NA drugbank imgc936 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cellular disintegrin-related protein ADAM9 Clinical trial target unknown NA TTD incb7839 small molecule Malignant neoplasm of breast[MeSHID:D001943] investigational disintegrin and metalloproteinase domain-containing protein 9 ADAM9 NA unknown NA drugbank mmi270 NA NA investigative aggrecanase-1 ADAMTS4 Patented-recorded target unknown NA TTD 1607004-34-1 NA NA patented aggrecanase-1 ADAMTS4 Patented-recorded target unknown NA TTD , DGIDB us9206139, 5 NA NA patented aggrecanase-1 ADAMTS4 Patented-recorded target unknown NA TTD , DGIDB (r)-2-(biphenyl-4-sulfonylamino)-propionic acid NA NA investigative aggrecanase-1 ADAMTS4 Patented-recorded target unknown NA TTD us9206139, 4 NA NA patented aggrecanase-1 ADAMTS4 Patented-recorded target unknown NA TTD , DGIDB pmid21536437c15c NA NA investigative aggrecanase ADAMTS5 Clinical trial target unknown NA TTD cr-5259 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative aggrecanase ADAMTS5 Clinical trial target unknown NA TTD agg-523 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 aggrecanase ADAMTS5 Clinical trial target unknown 63.65 TTD , DGIDB (2r)-n~4~-hydroxy-2-(3-hydroxybenzyl)-n~1~-[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]butanediamide small molecule NA experimental a disintegrin and metalloproteinase with thrombospondin motifs 5 ADAMTS5 NA unknown NA drugbank n-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2h-pyran-4-carboxamide small molecule NA experimental a disintegrin and metalloproteinase with thrombospondin motifs 5 ADAMTS5 NA unknown NA drugbank batimastat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] experimental a disintegrin and metalloproteinase with thrombospondin motifs 5 ADAMTS5 NA unknown NA drugbank aurothioglucose small molecule Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved,withdrawn adenylate cyclase type 1 ADCY1 NA unknown NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical adenylate cyclase type 1 ADCY1 NA product of NA drugbank atp small molecule NA investigational,nutraceutical adenylate cyclase type 1 ADCY1 NA unknown NA drugbank hyoscyamine small molecule Renal Colic[MeSHID:D056844],Bodily secretions[MeSHID:D012634],Pancreas[MeSHID:D010179],Respiratory tract structure[MeSHID:D012137],Bile fluid[MeSHID:D001646],Stomach[MeSHID:D013270],Irritable Bowel Syndrome[MeSHID:D043183],Heart Block[MeSHID:D006327],cell motility[MeSHID:D002465],Acute Coryza[MeSHID:D003139],Kidney[MeSHID:D007668],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved adenylate cyclase type 1 ADCY1 NA inhibitor NA drugbank adenosine monophosphate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved adenylate cyclase type 1 ADCY1 Successful target unknown NA TTD , DGIDB 2',5'-dideoxy-adenosine 3'-monophosphate small molecule NA experimental adenylate cyclase type 2 ADCY2 NA unknown NA drugbank colforsin small molecule NA experimental,investigational adenylate cyclase type 2 ADCY2 NA unknown NA drugbank aurothioglucose small molecule Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved,withdrawn adenylate cyclase type 2 ADCY2 NA unknown NA drugbank aurothioglucose small molecule Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved,withdrawn adenylate cyclase type 5 ADCY5 NA unknown NA drugbank colforsin small molecule NA experimental,investigational adenylate cyclase type 5 ADCY5 NA unknown NA drugbank 2',5'-dideoxy-adenosine 3'-monophosphate small molecule NA experimental adenylate cyclase type 5 ADCY5 NA unknown NA drugbank pacap38 NA Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] phase 1 pituitary adenylate cyclase-activating 38 ADCYAP1 Clinical trial target unknown NA TTD 2,6-diamino-hexanoic acid amide small molecule NA experimental pituitary adenylate cyclase-activating polypeptide ADCYAP1 NA unknown NA drugbank amg 301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Hyperprolactinemia[MeSHID:D006966] phase 2 pacap type i receptor ADCYAP1R1 Clinical trial target unknown NA TTD , DGIDB pacap-27 NA NA investigative pacap type i receptor ADCYAP1R1 Clinical trial target agonist NA TTD , DGIDB onapristone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational probable g-protein coupled receptor 133 ADGRD1 NA unknown NA drugbank n-cyclopentyl-n-cyclobutylformamide small molecule NA experimental alcohol dehydrogenase 1a ADH1A NA unknown NA drugbank 4-iodopyrazole small molecule NA experimental alcohol dehydrogenase 1a ADH1A NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical alcohol dehydrogenase 1a ADH1A NA unknown NA drugbank fomepizole small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alcohol dehydrogenase 1a ADH1A Successful target inhibitor 39.78 TTD , drugbank , DGIDB n-heptylformamide small molecule NA experimental alcohol dehydrogenase 1b ADH1B NA unknown NA drugbank fomepizole small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alcohol dehydrogenase 1b ADH1B NA inhibitor 35.8 drugbank , DGIDB 4-iodopyrazole small molecule NA experimental alcohol dehydrogenase 1b ADH1B NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical alcohol dehydrogenase 1b ADH1B NA unknown NA drugbank cyclohexanol small molecule NA experimental alcohol dehydrogenase 1b ADH1B NA unknown NA drugbank n-benzylformamide small molecule NA experimental alcohol dehydrogenase 1b ADH1B NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental alcohol dehydrogenase 1b ADH1B NA unknown NA drugbank glycerin small molecule NA approved,investigational alcohol dehydrogenase 1b ADH1B NA unknown NA drugbank pyrazole small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank trifluoroethanol small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank fomepizole small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alcohol dehydrogenase 1c ADH1C NA inhibitor 22.28 drugbank , DGIDB para-bromobenzyl alcohol small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank 2,4-difluorobenzyl alcohol 2,4-difluoro-1-(hydroxymethyl)benzene small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank 2-ethoxyethanol small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank 5-beta-d-ribofuranosylnicotinamide adenine dinucleotide small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank cpad small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank n-formylpiperidine small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank (r)-n-(1-methyl-hexyl)-formamide small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank n-1-methylheptylformamide small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank 3-butylthiolane 1-oxide small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank cyclohexylformamide small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank 2,3-difluorobenzyl alcohol small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank 4-iodopyrazole small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank 2,3,4,5,6-pentafluorobenzyl alcohol small molecule NA experimental alcohol dehydrogenase 1c ADH1C NA unknown NA drugbank cyclohexylformamide small molecule NA experimental alcohol dehydrogenase 4 ADH4 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical alcohol dehydrogenase 4 ADH4 NA unknown NA drugbank 12-hydroxydodecanoic acid small molecule NA experimental alcohol dehydrogenase class-3 ADH5 NA unknown NA drugbank s-hydroxymethyl glutathione small molecule NA experimental alcohol dehydrogenase class-3 ADH5 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical alcohol dehydrogenase class-3 ADH5 NA unknown NA drugbank lauric acid small molecule NA approved,experimental alcohol dehydrogenase class-3 ADH5 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical alcohol dehydrogenase class 4 mu/sigma chain ADH7 NA unknown NA drugbank 7-(5-deoxy-beta-d-ribofuranosyl)-5-iodo-7h-pyrrolo[2,3-d]pyrimidin-4-amine small molecule NA experimental adenosine kinase ADK NA unknown NA drugbank 5-[4-(dimethylamino)phenyl]-6-[(6-morpholin-4-ylpyridin-3-yl)ethynyl]pyrimidin-4-amine small molecule NA experimental adenosine kinase ADK NA unknown NA drugbank gp-3269 NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 adenosine kinase ADK Clinical trial target unknown NA TTD , DGIDB iodotubercidin NA NA investigative adenosine kinase ADK Clinical trial target unknown NA TTD mb-03966 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] investigative adenosine kinase ADK Clinical trial target unknown NA TTD 5-iodo,5'-deoxytubercidin NA NA investigative adenosine kinase ADK Clinical trial target unknown NA TTD gp515 NA NA investigative adenosine kinase ADK Clinical trial target unknown NA TTD 6-benzylthioinosine NA NA investigative adenosine kinase ADK Clinical trial target unknown NA TTD adenosine phosphate small molecule NA approved,investigational,nutraceutical adenosine kinase ADK NA product of NA drugbank 5'-iodotubercidin NA NA investigative adenosine kinase ADK Clinical trial target unknown NA TTD a-987306 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD [3h]ccpa NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB cpfpx NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB cyclopentyl-(9-methyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD istradefylline small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] approved,investigational adenosine receptor a1 ADORA1 NA antagonist 0.65 drugbank , DGIDB luf-5980 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-bromo-n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD bay 1067197 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 adenosine a1 receptor ADORA1 Successful target unknown NA TTD , DGIDB psb-11 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB n-(2,6-diphenylpyrimidin-4-yl)butyramide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-diphenyl-9h-purine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD isobutylmethylxanthine NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist 0.43 TTD , DGIDB luf5831 NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB 9-(3-nitrobenzyl)-6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-(2,3-dihydroxypropyl)-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs1084 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-p-tolyl-2h-pyrazolo[3,4-c]quinolin-4-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-chloroadenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist 0.12 TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational adenosine receptor a1 ADORA1 NA activator NA drugbank luf-5981 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD peneca NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB 4-chloro-n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD [3h]neca NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-chloro-7-methyl-2-phenyl-[1,8]naphthyridine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 3,4-dichloro-n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-allyl-8-bromo-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD dti-0009 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 adenosine a1 receptor ADORA1 Successful target unknown NA TTD kf26777 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 3-(3-chloro-1h-pyrazol-5-yl)quinoxalin-2(1h)-one NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-cyclohexyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 3-benzyl-7-methyl-[1,8]naphthyridine-4-thiol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-isopropyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD st-1535 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist 0.32 TTD , DGIDB 2-(3''-pyrrolylethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(4-methyl-1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD vuf-8507 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs1065 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-phenyl-1-propyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-(3-aminobenzyl)-6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-4,6-diphenyl-pyrimidin-5-carbonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(5-benzoyl-4-phenylthiazol-2-yl)benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD atl802 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 5,7-dibromo-9h-pyrido[3,4-b]indol-6-ol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(4-chlorophenyl)-6-phenyl-9h-purine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD sdz-wag-994 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 adenosine a1 receptor ADORA1 Successful target unknown NA TTD 6-guanidino-2-(3''-indolylethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD (2-chloro-9-methyl-9h-purin-6-yl)-phenyl-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD neladenoson bialanate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adora1 messenger rna ADORA1 Clinical trial target unknown NA TTD l-97-1 intravenous NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD theobromine small molecule Disease Management[MeSHID:D019468],Hypotension, Orthostatic[MeSHID:D007024],Fatigue[MeSHID:D005221],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational adenosine receptor a1 ADORA1 NA antagonist NA drugbank 8-phenyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6,8-triphenyl-9h-purine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tcpa NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB as99 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 2-(1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-cyclopentyl-1h-imidazo[4,5-c]quinolin-4-ylamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mre 3008f20 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 2-(3''-indolylethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-propyl-2,6-diphenyl-9h-purine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD kf-17837 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 adenosine a1 receptor ADORA1 Successful target unknown 0.43 TTD , DGIDB mrs1132 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-p-tolyl-2h-pyrazolo[3,4-c]quinolin-4(5h)-one NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(4-chloro-1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 1-propyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mre 2029f20 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 1,3-dipropyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5978 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD gnf-pf-2224 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD fr194921 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 2-(hex-1-ynyl)-n6-methoxyadenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-m-tolyl-2h-pyrazolo[3,4-c]quinolin-4(5h)-one NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-(2-hydroxypropyl)-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD psb603 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 8-bromo-9-cyclobutyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-4-furan-2-yl-6-phenyl-nicotinonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 1-methylxanthine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-methoxy-n-(3-phenyl-isoquinolin-1-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD pd-115199 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-4,6-diphenyl-nicotinonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD capadenoson NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 adenosine a1 receptor ADORA1 Successful target partial agonist 2.6 TTD , DGIDB defibrotide biotech Lung[MeSHID:D008168],Hepatic Veno-Occlusive Disease[MeSHID:D006504],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational adenosine receptor a1 ADORA1 NA unknown NA drugbank 9-benzyl-6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved adenosine receptor a1 ADORA1 NA antagonist 0.48 drugbank , DGIDB selodenoson NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] phase 2 adenosine a1 receptor ADORA1 Successful target unknown 2.6 TTD , DGIDB fk-838 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 adenosine a1 receptor ADORA1 Successful target unknown NA TTD sch-63390 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-propyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD fk-453 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney Failure[MeSHID:D051437] discontinued in phase 2 adenosine a1 receptor ADORA1 Successful target antagonist 0.65 TTD , DGIDB pentoxifylline small molecule Blood Vessel[MeSHID:D001808],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Intermittent Claudication[MeSHID:D007383],Arterial Occlusive Diseases[MeSHID:D001157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a1 ADORA1 NA unknown 0.08 drugbank , DGIDB phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 7-dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD pmid27387065-compound-6 NA NA patented adenosine a1 receptor ADORA1 Successful target unknown NA TTD , DGIDB pentanoic acid (4,6-diphenylpyrimidin-2-yl)amide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD cvt-124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] discontinued in phase 3 adenosine a1 receptor ADORA1 Successful target unknown NA TTD pd-81723 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown 0.65 TTD , DGIDB 2,5'-dichloro-5'-deoxy-n6-cyclopentyladenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD cyclopentyl-(9-ethyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-ethynyl-n6-methoxyadenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-methoxy-2-phenylethynyladenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD (1-phenyl-propyl)-(9-phenyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs1062 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 1h-imidazo[4,5-c]quinolin-4-ylamine hcl NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)acetamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-cyclopentyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD enprofylline small molecule Disease Management[MeSHID:D019468],Anemia, Sickle Cell[MeSHID:D000755],Peripheral Vascular Diseases[MeSHID:D016491],Asthma[MeSHID:D001249],Cerebrovascular Insufficiency[MeSHID:D002561],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental adenosine receptor a1 ADORA1 NA inhibitor NA drugbank tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a1 ADORA1 NA agonist NA drugbank n-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD rolofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 3 adenosine a1 receptor ADORA1 Successful target unknown 1.3 TTD , DGIDB theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved adenosine receptor a1 ADORA1 NA antagonist 0.32 drugbank , DGIDB 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD ino-8875 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 1/2 adenosine a1 receptor ADORA1 Successful target unknown 3.9 TTD , DGIDB 4-(furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD (s)-pia NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB 8-phenyl theophylline NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-dimethyl-8-ethyl-1-deazapurine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-(3-hydroxypropyl)-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD phenyl-(9-phenyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD epi-2010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 adora1 messenger rna ADORA1 Clinical trial target unknown NA TTD dyphylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adenosine receptor a1 ADORA1 NA antagonist NA drugbank l-249313 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD naxifylline small molecule Congestive heart failure[MeSHID:D006333] investigational adenosine receptor a1 ADORA1 NA antagonist 1.3 drugbank , DGIDB psb-10 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 3-noradamantyl-1,3-dipropylxanthine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD oxtriphylline small molecule Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved adenosine receptor a1 ADORA1 NA antagonist 0.39 drugbank , DGIDB 2-(6-amino-8-bromo-9h-purin-9-yl)ethanol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5767 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-ethyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD caffeine NA Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved adenosine a1 receptor ADORA1 Successful target antagonist 0.48 TTD , DGIDB adenosine small molecule Sinus Tachycardia[MeSHID:D013616],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved,investigational adenosine receptor a1 ADORA1 NA agonist 0.94 drugbank , DGIDB 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-tert-butyl-n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-4,6-di-furan-2-yl-nicotinonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD wrc-0571 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB cyclohexyl-(9-methyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tonapofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adenosine a1 receptor ADORA1 Successful target unknown 1.95 TTD , DGIDB 4-methyl-n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD psb36 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs5151 NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB luf-5957 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-4,6-diphenyl-pyrimidine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-cyclopentyladenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 1-methyl-8-phenyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-[(4-nitro)-phenyl]-9-benzyl-2-phenyladenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-propyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 7-chloro-2-phenyl-[1,8]naphthyridin-4-ol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD depx NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD (9-methyl-9h-purin-6-yl)-phenyl-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD psb-1115 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD slv320 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 adenosine a1 receptor ADORA1 Successful target unknown NA TTD , DGIDB n6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)isobutyramide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD gnf-pf-2700 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-phenyl-9h-purin-6-ylamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(4-methoxyphenyl)-6-phenyl-9h-purine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n*6*-cyclooctyl-n*2*-phenyl-9h-purine-2,6-diamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-n-benzyl-6-phenyl-9h-purine-9-carboxamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(4,6-diphenylpyrimidin-2-yl)propionamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tecadenoson small molecule Cardiac Arrhythmia[MeSHID:D001145],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational adenosine receptor a1 ADORA1 NA unknown 2.17 drugbank , DGIDB n*6*-cyclohexyl-n*2*-ethyl-9h-purine-2,6-diamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(2-furyl)-6-(1h-pyrazol-1-yl)pyrimidin-4-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-methyl-8-[1,2,3]triazol-2-yl-9h-purin-6-ylamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-[(4-amino)-phenyl]-9-benzyl-2-phenyladenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD defibrotide biotech Lung[MeSHID:D008168],Hepatic Veno-Occlusive Disease[MeSHID:D006504],Kidney[MeSHID:D007668],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a1 ADORA1 NA unknown NA drugbank 2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD cyclohexyl-(9-ethyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-isobutyl-9h-purin-6-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(5-cyano-1-pent-1-ynyl)-n6-methoxyadenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-phenyl-1h-imidazo[4,5-c]quinolin-4-ylamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-bis(4-tolyl)-9h-purine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-cyclopentyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-diphenyl-8-tbutyl-1-deazapurine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-dphenyl-8-propyl-1-deazapurine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD xanthine amine congener NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB aminophylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adenosine receptor a1 ADORA1 NA antagonist 0.39 drugbank , DGIDB 2-(2''-indolylethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2'-me-tecadenoson NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 3-benzyl-7-methyl-[1,8]naphthyridin-4-ol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5962 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown 2.6 TTD , DGIDB 9-ethyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5433 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5417 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational adenosine receptor a1 ADORA1 NA agonist NA drugbank 2-amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD gr-79236 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 1 adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-[(4-acetylphenyl)ethynyl]-n6-methoxyadenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-(4-nitrobenzyl)-6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 5,7-diphenyl-3h-imidazo[4,5-b]pyridin-2-ol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-cyclohexyl-6-(4-tolyl)-2-phenyl-9h-purine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-nitro-n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-((+/-)-endo-norborn-2-yl)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-tolyl-6-phenyl-9h-purine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD anthoptilide c NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-phenyl-2h-pyrazolo[3,4-c]quinolin-4-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(4-hydroxypent-1-yl)-n6-methoxyadenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tecadenoson NA Cardiac Arrhythmia[MeSHID:D001145],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 adenosine a1 receptor ADORA1 Successful target agonist 2.17 TTD , DGIDB psb-601 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD isoguanosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5737 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs928 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD [3h]osip339391 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD brl-61063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] discontinued in phase 2 adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD (r,s)-phpneca NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB 1,3-diisobutyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 1-butyl-8-phenyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-m-tolyl-2h-pyrazolo[3,4-c]quinolin-4-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD [3h]hemado NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(4,6-diphenylpyrimidin-2-yl)benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD flavone NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-diphenyl-1-deazapurine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-ethyl-8-phenylethynyl-9h-purin-6-ylamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-methyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-(sec-butyl)-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tecadenoson NA Cardiac Arrhythmia[MeSHID:D001145],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 adenosine a1 receptor ADORA1 Successful target unknown 2.17 TTD , DGIDB cirsimarin NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-benzyl-8-bromo-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-cyclopentyltheophylline NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist 0.32 TTD , DGIDB sch-442416 NA NA phase 1 adenosine a1 receptor ADORA1 Successful target unknown 0.43 TTD , DGIDB sakuranetin NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD as70 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB capadenoson NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 adenosine a1 receptor ADORA1 Successful target unknown 2.6 TTD , DGIDB 2-(6-cyclopentylamino-purin-9-yl)-ethanol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-diphenyl-8-ethyl-1-deazapurine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD caffeine NA Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved adenosine a1 receptor ADORA1 Successful target unknown 0.48 TTD , DGIDB 1,3-diethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tonapofylline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] investigational adenosine receptor a1 ADORA1 NA antagonist 1.95 drugbank , DGIDB 2-amino-6-furan-2-yl-4-phenyl-nicotinonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD gs 9667 NA Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 adenosine a1 receptor ADORA1 Successful target unknown NA TTD , DGIDB luf-5764 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD amp-579 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 adenosine a1 receptor ADORA1 Successful target unknown 1.3 TTD , DGIDB [3h]dpcpx NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB p-iodoamphetamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tecadenoson small molecule Cardiac Arrhythmia[MeSHID:D001145],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational adenosine receptor a1 ADORA1 NA agonist 2.17 drugbank , DGIDB 2-azido-n6-methyl-9-(beta-d-ribofuranosyl)adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD kuanoniamine d NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-phenylethyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5956 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 7-bromo-2-phenyl-[1,8]naphthyridin-4-ol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-methyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD rolofylline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] investigational adenosine receptor a1 ADORA1 NA antagonist 1.3 drugbank , DGIDB mrs1191 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD rolofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 3 adenosine a1 receptor ADORA1 Successful target antagonist 1.3 TTD , DGIDB 8-bromo-9-(2-butyl)-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 9-cyclobutyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD cp608,039 NA NA investigative adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB apaxifylline NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 adenosine a1 receptor ADORA1 Successful target unknown 1.3 TTD , DGIDB 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD vcp-28 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-diphenyl-8-methyl-1-deazapurine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-6-phenyl-4-p-tolylnicotinonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD psb-0788 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD r-n6-(phenylisopropyl)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD paeoniflorin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5816 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-6258 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD vuf5574 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n*6*-cyclohexyl-n*2*-phenyl-9h-purine-2,6-diamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD fk-352 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-chloro-2'-c-methyl-tecadenoson NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs1041 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 3-chloro-n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD sb-298 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD rolofylline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] investigational adenosine receptor a1 ADORA1 NA unknown 1.3 drugbank , DGIDB luf-5853 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)propionamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tonapofylline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] investigational adenosine receptor a1 ADORA1 NA unknown 1.95 drugbank , DGIDB n-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 8-bromo-9-isopropyl-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs1086 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD fr-166124 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD cyclohexyl-(2-phenylsulfanyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 7-methyl-2-propyl-[1,8]naphthyridin-4-ol NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-phenyl-2h-pyrazolo[3,4-c]quinolin-4(5h)-one NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-[(4-fluorophenyl)ethynyl]-n6-methoxyadenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD luf-5735 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD selodenoson NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] phase 2 adenosine a1 receptor ADORA1 Successful target agonist 2.6 TTD , DGIDB mrs1523 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB cyclopentyl-(9-cyclopentyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-(4,5-diphenylpyrimidin-2-yl)acetamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,6-diphenyl-pyrimidin-4-ylamine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n-0861 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Diseases[MeSHID:D006331] discontinued in phase 3 adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs1093 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD hexanoic acid (2,6-diphenylpyrimidin-4-yl)amide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n(6)-cyclohexyladenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD tonapofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adenosine a1 receptor ADORA1 Successful target antagonist 1.95 TTD , DGIDB cyclopentyl-(9-phenyl-9h-purin-6-yl)-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-amino-4,6-di-thiophen-2-yl-nicotinonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 5-cl-5-deoxy-(+/-)-enba NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-phenylpropoxyadenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2,4-dichloro-n-(4-phenyl-thiazol-2-yl)-benzamide NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD n6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-ethoxy-7-((e)-styryl)-furo[3,2-g]chromen-5-one NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-amino-2,6-diphenyl-pyrimidine-5-carbonitrile NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a1 ADORA1 NA inhibitor NA drugbank 8-bromo-9-(but-3-enyl)-9h-adenine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs1042 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD (e)-8-(3-chlorostyryl)-caffeine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD mrs923 NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD (1h-imidazo[4,5-c]quinolin-4-yl)-phenyl-amine hcl NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD as100 NA NA investigative adenosine a1 receptor ADORA1 Successful target antagonist NA TTD , DGIDB gw-493838 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adenosine a1 receptor ADORA1 Successful target unknown NA TTD 6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD bay 60-6583 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary Arteriosclerosis[MeSHID:D003324],Myocardial Ischemia[MeSHID:D017202] preclinical adenosine a1 receptor ADORA1 Successful target agonist NA TTD , DGIDB 1,3-diallyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine NA NA investigative adenosine a1 receptor ADORA1 Successful target unknown NA TTD 2-cyclopentyl-1h-imidazo[4,5-c]quinolin-4-ylamine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-ethyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD gw-328267 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 adenosine a2a receptor ADORA2A Successful target unknown 2.45 TTD , DGIDB n6-[(4-nitro)-phenyl]-9-benzyl-2-phenyladenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-methoxy-2-phenylethynyladenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-methyl-8-[1,2,3]triazol-2-yl-9h-purin-6-ylamine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 4-amino-2,6-diphenyl-pyrimidine-5-carbonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-isobutyl-9h-purin-6-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved adenosine receptor a2a ADORA2A NA antagonist 0.57 drugbank , DGIDB 9-(sec-butyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD pbf509 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 adenosine a2a receptor ADORA2A Successful target unknown NA TTD , DGIDB pentoxifylline small molecule Blood Vessel[MeSHID:D001808],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Intermittent Claudication[MeSHID:D007383],Arterial Occlusive Diseases[MeSHID:D001157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a2a ADORA2A NA agonist,antagonist 0.07 drugbank , DGIDB n6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD phenyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1,3,7-tripropyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD r-n6-(phenylisopropyl)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-(2-hydroxyethyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1h-imidazo[4,5-c]quinolin-4-ylamine hcl NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-(2-hydroxypropyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD apadenoson small molecule Cardiovascular Diseases[MeSHID:D002318],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] investigational adenosine receptor a2a ADORA2A NA unknown 1.63 drugbank , DGIDB binodenoson small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigational adenosine receptor a2a ADORA2A NA unknown 1.53 drugbank , DGIDB regadenoson NA Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adenosine a2a receptor ADORA2A Successful target unknown 1.22 TTD , DGIDB (s)-dhpa NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-cyclopentyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD tonapofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adenosine a2a receptor ADORA2A Successful target antagonist 0.61 TTD , DGIDB 2-amino-4,6-diphenyl-nicotinonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD msx-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-propyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 4-(furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD uk-432097 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 adenosine a2a receptor ADORA2A Successful target unknown 2.45 TTD , DGIDB 8-bromo-9-cyclobutyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1-aminoanthracene-9,10-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n*6*-cyclohexyl-n*2*-phenyl-9h-purine-2,6-diamine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD regadenoson NA Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adenosine a2a receptor ADORA2A Successful target agonist 1.22 TTD , DGIDB 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-isopropyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-indolylethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-butyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-((+/-)-endo-norborn-2-yl)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD (3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD sch-63390 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD lu-aa47070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 1 adenosine a2a receptor ADORA2A Successful target unknown NA TTD mefloquine small molecule Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational adenosine receptor a2a ADORA2A NA antagonist 0.82 drugbank , DGIDB n-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2,6-dphenyl-8-propyl-1-deazapurine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1-methyl-8-phenyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-ethynyl-n6-methoxyadenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(4-methyl-1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 5,7-diphenyl-3h-imidazo[4,5-b]pyridin-2-ol NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-phenyl-1h-imidazo[4,5-c]quinolin-4-ylamine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-(3-aminobenzyl)-6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 7-isopropyl-7h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5957 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD v81444 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Parkinson Disease[MeSHID:D010300] phase 1/2 adenosine a2a receptor ADORA2A Successful target unknown NA TTD , DGIDB n-(3-phenyl-[1,2,4]thiadiazol-5-yl)-benzamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)acetamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD pbf-999 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Huntington Disease[MeSHID:D006816] phase 1 adenosine a2a receptor ADORA2A Successful target antagonist 0.61 TTD , DGIDB n-(2,6-diphenylpyrimidin-4-yl)isobutyramide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-phenylethyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-br-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD (e,e)-8-(4-phenylbutadien-1-yl)caffeine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD isobutylmethylxanthine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 5-azido-6-benzyl-2-methyl-[1,8]naphthyridine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD gnf-pf-2224 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2,6-diphenyl-8-ethyl-1-deazapurine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5433 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-[(4-acetylphenyl)ethynyl]-n6-methoxyadenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD azd4635 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 adenosine a2a receptor ADORA2A Successful target unknown NA TTD , DGIDB 9-benzyl-6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD tozadenant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 adenosine a2a receptor ADORA2A Successful target antagonist 1.84 TTD , DGIDB 8-chlorotheophylline small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Vertigo[MeSHID:D014717],Vomiting[MeSHID:D014839] experimental adenosine receptor a2a ADORA2A NA antagonist NA drugbank 1-amino-2,4-bis(phenylthio)anthracene-9,10-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-(2-butyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-amino-4,6-diphenyl-pyrimidin-5-carbonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(4-hydroxypent-1-yl)-n6-methoxyadenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-cycloheptyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-p-tolyl-2h-pyrazolo[3,4-c]quinolin-4-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2,6-diphenyl-8-methyl-1-deazapurine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD adenosine small molecule Sinus Tachycardia[MeSHID:D013616],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved,investigational adenosine receptor a2a ADORA2A NA agonist 1.11 drugbank , DGIDB binodenoson small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigational adenosine receptor a2a ADORA2A NA agonist 1.53 drugbank , DGIDB 8-bromo-9-isopropyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD [3h]neca NA NA investigative adenosine a2a receptor ADORA2A Successful target agonist NA TTD , DGIDB 2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1,3-dipropyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD ab928 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 adenosine a2a receptor ADORA2A Successful target unknown 0.61 TTD , DGIDB 2-(2-furyl)-6-(1h-pyrazol-1-yl)pyrimidin-4-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD psb-601 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5981 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-phenyl theophylline NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n-(5-benzoyl-4-phenylthiazol-2-yl)benzamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD sch 420814 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 adenosine a2a receptor ADORA2A Successful target unknown NA TTD , DGIDB amp-579 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 adenosine a2a receptor ADORA2A Successful target unknown 1.22 TTD , DGIDB 8-bromo-9-methyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-phenylethyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD (e,e)-8-[4-(3-bromophenyl)butadien-1-yl]caffeine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-(4-hydroxybenzyl)adenine riboside NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5978 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2,6-diphenyl-1-deazapurine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD kuanoniamine d NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2,5'-dichloro-5'-deoxy-n6-cyclopentyladenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD cgs 21680 NA NA investigative adenosine a2a receptor ADORA2A Successful target agonist NA TTD , DGIDB bvt-115959 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)propionamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 4-amino-2-p-tolylisoindoline-1,3-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-ethyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD binodenoson NA Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 3 adenosine a2a receptor ADORA2A Successful target unknown 1.53 TTD , DGIDB 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-amino-6-phenyl-4-p-tolylnicotinonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD atl146e small molecule Disease[MeSHID:D004194] investigational adenosine receptor a2a ADORA2A NA unknown NA drugbank 2-amino-4,6-di-thiophen-2-yl-nicotinonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-amino-3-(m-tolylamino)naphthalene-1,4-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD mefloquine small molecule Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a2a ADORA2A NA antagonist 0.82 drugbank , DGIDB (e,e)-8-[4-(3-fluorophenyl)butadien-1-yl]caffeine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD pf-1913539 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-benzyl-8-bromo-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n-(7-methoxy-4-phenylbenzofuran-2-yl)acetamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1,3-diallyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD mre-0094 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] phase 2 adenosine a2a receptor ADORA2A Successful target unknown 2.45 TTD , DGIDB 3-benzyl-7-methyl-[1,8]naphthyridine-4-thiol NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n-(4,6-diphenylpyrimidin-2-yl)propionamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-pyrrolylethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD defibrotide biotech Lung[MeSHID:D008168],Hepatic Veno-Occlusive Disease[MeSHID:D006504],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational adenosine receptor a2a ADORA2A NA unknown NA drugbank doxofylline small molecule Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Muscle Spasticity[MeSHID:D009128],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchial Diseases[MeSHID:D001982],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental adenosine receptor a2a ADORA2A NA antagonist NA drugbank 8-bromo-9-(but-3-enyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD t-62 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 adenosine a2a receptor ADORA2A Successful target unknown NA TTD (2r,3s)-3-(6-amino-purin-9-yl)-nonan-2-ol NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD cyclohexyl-(2-phenylsulfanyl-9h-purin-6-yl)-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 5-butyl-8-phenyl-3h-[1,2,4]triazolo[5,1-i]purine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1-phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-(2-hydroxypropyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD methyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-methyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2,6-diphenyl-8-tbutyl-1-deazapurine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1,3-diethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1,3-diisobutyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-phenylpropoxyadenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD [3h]osip339391 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD psb-0788 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD oxtriphylline small molecule Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved adenosine receptor a2a ADORA2A NA antagonist 0.37 drugbank , DGIDB 2-amino-4-furan-2-yl-6-phenyl-nicotinonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD theobromine small molecule Disease Management[MeSHID:D019468],Hypotension, Orthostatic[MeSHID:D007024],Fatigue[MeSHID:D005221],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational adenosine receptor a2a ADORA2A NA antagonist NA drugbank 1-methylxanthine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD (1h-imidazo[4,5-c]quinolin-4-yl)-phenyl-amine hcl NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-phenyl-1-propyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD galangin NA NA investigative adenosine a2a receptor ADORA2A Successful target antagonist 0.15 TTD , DGIDB 1,3-dibenzyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-propyl-2,6-diphenyl-9h-purine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD (z)-8-(3-chlorostyryl)caffeine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5962 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-cyclobutyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1-amino-4-chloroanthracene-9,10-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 3-isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD regadenoson small molecule Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a2a ADORA2A NA agonist 1.22 drugbank , DGIDB 2,6-diphenyl-pyrimidin-4-ylamine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-(2,3-dihydroxypropyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 6-furan-2-yl-9-phenethyl-9h-purin-2-ylamine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD sb-298 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-allyl-8-bromo-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved adenosine receptor a2a ADORA2A NA antagonist 0.26 drugbank , DGIDB istradefylline NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] approved adenosine a2a receptor ADORA2A Successful target antagonist 1.53 TTD , DGIDB 7-allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD opa-6566 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 1/2 adenosine a2a receptor ADORA2A Successful target unknown NA TTD , DGIDB caffeine NA Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved adenosine a2a receptor ADORA2A Successful target antagonist 0.57 TTD , DGIDB 3-benzyl-7-methyl-[1,8]naphthyridin-4-ol NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(hex-1-ynyl)-n6-methoxyadenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(6-amino-8-bromo-9h-purin-9-yl)ethanol NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD sch-442416 NA NA phase 1 adenosine a2a receptor ADORA2A Successful target unknown 0.41 TTD , DGIDB 2-(4-chlorophenyl)-6-phenyl-9h-purine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD dyphylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adenosine receptor a2a ADORA2A NA antagonist NA drugbank 2,6-diphenyl-9h-purine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1,3,8-trimethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 6-furan-2-yl-9-phenyl-9h-purin-2-ylamine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-phenyl-2h-pyrazolo[3,4-c]quinolin-4-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD gnf-pf-2700 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 3-noradamantyl-1,3-dipropylxanthine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD atl-313 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 1/2 adenosine a2a receptor ADORA2A Successful target unknown 2.45 TTD , DGIDB 7-propyl-7h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD eos100850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 adenosine a2a receptor ADORA2A Successful target unknown NA TTD fr-166124 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD isoguanosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-amino-n-benzyl-6-phenyl-9h-purine-9-carboxamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5417 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-cyclopentyladenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-but-3-enyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD apadenoson NA Cardiovascular Diseases[MeSHID:D002318],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 3 adenosine a2a receptor ADORA2A Successful target unknown 1.63 TTD , DGIDB 1,3-diallyl-7-methyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD istradefylline small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] approved,investigational adenosine receptor a2a ADORA2A NA antagonist 1.53 drugbank , DGIDB luf-5956 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD tonapofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adenosine a2a receptor ADORA2A Successful target unknown 0.61 TTD , DGIDB psb-09120 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 5,7-dibromo-9h-pyrido[3,4-b]indol-6-ol NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-(sec-butyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-tolyl-6-phenyl-9h-purine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-ethyl-8-phenylethynyl-9h-purin-6-ylamine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-(3-hydroxypropyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(2''-indolylethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-m-tolyl-2h-pyrazolo[3,4-c]quinolin-4-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD kf-17837 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 adenosine a2a receptor ADORA2A Successful target unknown 0.41 TTD , DGIDB [3h]ccpa NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD (e,e)-8-[4-(3-chlorophenyl)butadien-1-yl]caffeine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-(3-hydroxypropyl)-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-amino-6-furan-2-yl-4-phenyl-nicotinonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-propyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD st-1535 NA NA investigative adenosine a2a receptor ADORA2A Successful target antagonist 0.61 TTD , DGIDB 2,6,8-triphenyl-9h-purine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD v81444 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Parkinson Disease[MeSHID:D010300] phase 1/2 adenosine a2a receptor ADORA2A Successful target antagonist NA TTD , DGIDB 1-ethyl-3-methyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-(3-nitrobenzyl)-6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5437 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-cyclohexyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a2a ADORA2A NA inhibitor NA drugbank defibrotide biotech Lung[MeSHID:D008168],Hepatic Veno-Occlusive Disease[MeSHID:D006504],Kidney[MeSHID:D007668],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a2a ADORA2A NA unknown NA drugbank 9-(4-nitrobenzyl)-6-(furan-2-yl)-9h-purin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD caffeine NA Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved adenosine a2a receptor ADORA2A Successful target unknown 0.57 TTD , DGIDB 1-allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD biib014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 adenosine a2a receptor ADORA2A Successful target unknown NA TTD , DGIDB enprofylline small molecule Disease Management[MeSHID:D019468],Anemia, Sickle Cell[MeSHID:D000755],Peripheral Vascular Diseases[MeSHID:D016491],Asthma[MeSHID:D001249],Cerebrovascular Insufficiency[MeSHID:D002561],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental adenosine receptor a2a ADORA2A NA inhibitor NA drugbank n-(4-pyridin-2-yl-thiazol-2-yl)-benzamide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD apadenoson NA Cardiovascular Diseases[MeSHID:D002318],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 3 adenosine a2a receptor ADORA2A Successful target agonist 1.63 TTD , DGIDB 2-amino-4,6-diphenyl-pyrimidine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-benzyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-[(4-fluorophenyl)ethynyl]-n6-methoxyadenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD binodenoson NA Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 3 adenosine a2a receptor ADORA2A Successful target agonist 1.53 TTD , DGIDB 6-guanidino-2-(3''-indolylethyloxy)adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1-amino-2-phenoxyanthracene-9,10-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)butyramide NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1-amino-4-methoxyanthracene-9,10-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1,4-diaminoanthracene-9,10-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 9-cyclopropyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 8-bromo-9-cyclopentyl-9h-adenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol small molecule NA experimental adenosine receptor a2a ADORA2A NA unknown NA drugbank n6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-amino-4,6-di-furan-2-yl-nicotinonitrile NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD dexefaroxan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Parkinson Disease[MeSHID:D010300] phase 2 adenosine a2a receptor ADORA2A Successful target unknown 0.41 TTD , DGIDB apadenoson small molecule Cardiovascular Diseases[MeSHID:D002318],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] investigational adenosine receptor a2a ADORA2A NA agonist 1.63 drugbank , DGIDB 4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD tozadenant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 adenosine a2a receptor ADORA2A Successful target unknown 1.84 TTD , DGIDB pd-115199 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5980 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD luf-5767 NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 2-(5-cyano-1-pent-1-ynyl)-n6-methoxyadenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-[(4-amino)-phenyl]-9-benzyl-2-phenyladenine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 7-allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD alloxazine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD cyclohexyl-(2-phenoxy-9h-purin-6-yl)-amine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD n6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD 1-butyl-8-phenyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2a receptor ADORA2A Successful target unknown NA TTD xanthine amine congener NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB as99 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB 1-methylxanthine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD yt-146 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 adenosine a2b receptor ADORA2B Successful target unknown NA TTD , DGIDB n6-cyclopentyladenosine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD luf-5980 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD (e)-8-(3-chlorostyryl)-caffeine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 8-bromo-9-(sec-butyl)-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD [3h]zm 241385 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB cv-1674 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD st-1535 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist 0.43 TTD , DGIDB psb36 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB xcc NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB cvt-6694 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1041 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD ab928 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 adenosine a2b receptor ADORA2B Successful target unknown 0.86 TTD , DGIDB 2-(6-amino-8-bromo-9h-purin-9-yl)ethanol NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD cpfpx NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD psb-11 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 1-butyl-8-phenyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD psb-10 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1523 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB enprofylline small molecule Disease Management[MeSHID:D019468],Anemia, Sickle Cell[MeSHID:D000755],Peripheral Vascular Diseases[MeSHID:D016491],Asthma[MeSHID:D001249],Cerebrovascular Insufficiency[MeSHID:D002561],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental adenosine receptor a2b ADORA2B NA antagonist NA drugbank 8-bromo-9-ethyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD psb603 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB atl-844 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD (r,s)-phpneca NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1086 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs928 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD bay 60-6583 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary Arteriosclerosis[MeSHID:D003324],Myocardial Ischemia[MeSHID:D017202] preclinical adenosine a2b receptor ADORA2B Successful target agonist NA TTD , DGIDB 3-methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD gnf-pf-2700 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 8-bromo-9-(2-hydroxypropyl)-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD n-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 9-cyclobutyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD pbf-1129 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 adenosine a2b receptor ADORA2B Successful target unknown NA TTD , DGIDB luf-5816 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD psb-0788 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist 1.72 TTD , DGIDB 8-phenyl-1-propyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD luf-5981 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD kf26777 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB 2,5'-dichloro-5'-deoxy-n6-cyclopentyladenosine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD [3h]ccpa NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD depx NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB 2-chloroadenosine NA NA investigative adenosine a2b receptor ADORA2B Successful target agonist 0.16 TTD , DGIDB 1h-imidazo[4,5-c]quinolin-4-ylamine hcl NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD cvt-6883 NA Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 adenosine a2b receptor ADORA2B Successful target unknown 0.69 TTD , DGIDB [125i]zm-241385 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD as95 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB gnf-pf-2224 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD as16 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB 4-ethoxy-7-((e)-styryl)-furo[3,2-g]chromen-5-one NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 8-bromo-9-isopropyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 2-cyclopentyl-1h-imidazo[4,5-c]quinolin-4-ylamine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD [125i]abopx NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB mrs1132 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD [3h]hemado NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD isobutylmethylxanthine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 1,3-diallyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD kf-17837 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 adenosine a2b receptor ADORA2B Successful target unknown 0.57 TTD , DGIDB tonapofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adenosine a2b receptor ADORA2B Successful target unknown 0.86 TTD , DGIDB as100 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB mrs5151 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD las-101057 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] preclinical adenosine a2b receptor ADORA2B Successful target unknown 3.44 TTD , DGIDB 8-bromo-9-(3-hydroxypropyl)-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD luf-5978 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 2-amino-4,6-di-furan-2-yl-nicotinonitrile NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1088 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD cgs 24012 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD (s)-pia NA NA investigative adenosine a2b receptor ADORA2B Successful target agonist NA TTD , DGIDB n(6)-cyclohexyladenosine NA NA investigative adenosine a2b receptor ADORA2B Successful target agonist NA TTD , DGIDB 9-isopropyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD atl802 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB psb-09120 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD pf-1913539 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 adenosine a2b receptor ADORA2B Successful target unknown NA TTD psb-1115 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD atl-801 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD isoguanosine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 8-bromo-9-cyclopentyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD as70 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB 8-bromo-9-(2-butyl)-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD defibrotide biotech Lung[MeSHID:D008168],Hepatic Veno-Occlusive Disease[MeSHID:D006504],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational adenosine receptor a2b ADORA2B NA unknown NA drugbank 8-bromo-9-methyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD cgs 21680 NA NA investigative adenosine a2b receptor ADORA2B Successful target agonist NA TTD , DGIDB 1,3-diethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD adenosine small molecule Sinus Tachycardia[MeSHID:D013616],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved,investigational adenosine receptor a2b ADORA2B NA agonist 1.56 drugbank , DGIDB vuf5574 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD [3h]neca NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 2-amino-6-furan-2-yl-4-phenyl-nicotinonitrile NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD vidarabine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Herpes Simplex Infections[MeSHID:D006561] approved adenosine a2b receptor ADORA2B Successful target unknown 0.86 TTD , DGIDB 8-(3-fluoro-phenyl)-9-methyl-9h-purin-6-ylamine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 8-bromo-9-propyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 8-bromo-9-cyclobutyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1191 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved adenosine receptor a2b ADORA2B NA antagonist 0.72 drugbank , DGIDB defibrotide biotech Lung[MeSHID:D008168],Hepatic Veno-Occlusive Disease[MeSHID:D006504],Kidney[MeSHID:D007668],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosine receptor a2b ADORA2B NA unknown NA drugbank 9-allyl-8-bromo-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD psb-601 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 1-benzyl-3-methyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD ab-neca NA NA investigative adenosine a2b receptor ADORA2B Successful target agonist NA TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved adenosine receptor a2b ADORA2B NA antagonist 0.23 drugbank , DGIDB cv-1808 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mre 3008f20 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB as96 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB sakuranetin NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1065 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD sb-298 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD peneca NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD apnea NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD (1h-imidazo[4,5-c]quinolin-4-yl)-phenyl-amine hcl NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD adenosine NA Sinus Tachycardia[MeSHID:D013616],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved adenosine a2b receptor ADORA2B Successful target agonist 1.56 TTD , DGIDB visnagin NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1084 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD i-abopx NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB tonapofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adenosine a2b receptor ADORA2B Successful target antagonist 0.86 TTD , DGIDB 2-chloro-2'-c-methyl-tecadenoson NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD cvt-6883 NA Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 adenosine a2b receptor ADORA2B Successful target antagonist 0.69 TTD , DGIDB [3h]dpcpx NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB xanthine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Apnea[MeSHID:D001049] phase 1 adenosine a2b receptor ADORA2B Successful target unknown 1.72 TTD , DGIDB tcpa NA NA investigative adenosine a2b receptor ADORA2B Successful target agonist NA TTD , DGIDB 8-bromo-9-(2,3-dihydroxypropyl)-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 1,3-dipropyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 9-(sec-butyl)-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 8-phenyl theophylline NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD kf 17837s NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD adenosine NA Sinus Tachycardia[MeSHID:D013616],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved adenosine a2b receptor ADORA2B Successful target unknown 1.56 TTD , DGIDB n6-((+/-)-endo-norborn-2-yl)adenosine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 1-propyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD ab-meca NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 2-amino-4-furan-2-yl-6-phenyl-nicotinonitrile NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1042 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 8-bromo-9-isobutyl-9h-purin-6-amine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1706 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD flavone NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 3-noradamantyl-1,3-dipropylxanthine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD [3h]osip339391 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB 2'-me-tecadenoson NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD as74 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB alloxazine NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist 0.86 TTD , DGIDB mrs923 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mre 2029f20 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 2-phenyl-1h-imidazo[4,5-c]quinolin-4-ylamine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD r-n6-(phenylisopropyl)adenosine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD 3-isobutyl-8-pyrrolidinoxanthine NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB as94 NA NA investigative adenosine a2b receptor ADORA2B Successful target antagonist NA TTD , DGIDB cvt-6883 small molecule Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational adenosine receptor a2b ADORA2B NA antagonist 0.69 drugbank , DGIDB 9-propyl-9h-adenine NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD pd-115199 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD cvt-7124 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD mrs1093 NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD cvt-6883 small molecule Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational adenosine receptor a2b ADORA2B NA unknown 0.69 drugbank , DGIDB beta-hydroxyethyl theophylline NA NA investigative adenosine a2b receptor ADORA2B Successful target unknown NA TTD [3h]hemado NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB luf-5956 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-butyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)acetamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD [1,2,4]triazolo[1,5-a]quinoxalin-4(5h)-one NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-cyclopentyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(4-chlorophenyl)-6-phenyl-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD acn-1052 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 8-phenyl theophylline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD isobutylmethylxanthine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)isobutyramide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2,5'-dichloro-5'-deoxy-n6-cyclopentyladenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)propionamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD (+)-butaclamol NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD serotonin NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-phenylethylyl-adenosine derivative NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB n-(2,6-diphenylpyrimidin-4-yl)butyramide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 8-bromo-9-cyclobutyl-9h-adenine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD cf102 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 2 adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD , DGIDB 4-methoxy-2-phenyl-2h-pyrazolo[4,3-c]quinoline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2,6-dphenyl-8-propyl-1-deazapurine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1067 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB cf502 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD , DGIDB 4-methoxy-n-(3-phenyl-isoquinolin-1-yl)-benzamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD [3h]ccpa NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 5,7-dibromo-9h-pyrido[3,4-b]indol-6-ol NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-benzoylaminoquinazoline-4-carboxyanilide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2,6-diphenyl-1-deazapurine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1088 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB n*6*-cyclooctyl-n*2*-phenyl-9h-purine-2,6-diamine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 4-ethoxy-7-((e)-styryl)-furo[3,2-g]chromen-5-one NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD gnf-pf-2224 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-ethynyl-n6-methoxyadenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD bay 60-6583 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary Arteriosclerosis[MeSHID:D003324],Myocardial Ischemia[MeSHID:D017202] preclinical adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(4-methyl-1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs5151 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB psb603 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB nipecotic acid NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD [3h]neca NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB 2-chloroadenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD galangin NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist 0.2 TTD , DGIDB 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5816 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD methoctramine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n*2*-benzyl-n*6*-cyclohexyl-9h-purine-2,6-diamine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2,6-bis(4-methoxyphenyl)-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1177 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(4,6-diphenylpyrimidin-2-yl)propionamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 5,6,7-trimethyl-2-p-tolyl-chromen-4-one NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 8-bromo-9-cyclopentyl-9h-adenine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2,6,8-triphenyl-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD [125i]ab-meca NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB 2-aminoquinazoline-4-carboxyanilide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD cf102 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 2 adenosine a3 receptor ADORA3 Clinical trial target agonist 1.91 TTD , DGIDB 1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5980 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(5-chloro-1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD psb36 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB cyclohexyl-(2-phenylsulfanyl-9h-purin-6-yl)-amine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mpc-meca NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB 2-(5-cyano-1-pent-1-ynyl)-n6-methoxyadenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs928 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 2-azido-n6-methyl-9-(beta-d-ribofuranosyl)adenine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD i-aba NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB 2-phenyl-2h-pyrazolo[4,3-d]pyrimidin-7(6h)-one NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD nitd609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] phase 2 adenosine a3 receptor ADORA3 Clinical trial target unknown 0.8 TTD , DGIDB 3-noradamantyl-1,3-dipropylxanthine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD atl802 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB peneca NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB kf26777 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB [125i]apnea NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB 2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD [3h]kainate NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD [3h]osip339391 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5957 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1097 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 2,6-bis(4-chlorophenyl)-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-methoxy-2-phenylethynyladenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(2''-indolylethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD bemesetron NA NA discontinued in phase 3 adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD cf602 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD , DGIDB mrs1523 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 2,6-bis(4-tolyl)-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mre 2029f20 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 6-hydroxy-5,7-dimethyl-beta-carboline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(2,6-diphenylpyrimidin-4-yl)benzamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1476 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 2-phenylpropoxyadenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD vuf-8507 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-[(4-fluorophenyl)ethynyl]-n6-methoxyadenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs5698 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB sch-442416 NA NA phase 1 adenosine a3 receptor ADORA3 Clinical trial target unknown 0.53 TTD , DGIDB psb-11 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved adenosine receptor a3 ADORA3 NA antagonist 0.16 drugbank , DGIDB tonapofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adenosine a3 receptor ADORA3 Clinical trial target antagonist 0.8 TTD , DGIDB 2-(1h-imidazo[4,5-c]pyridin-2-yl)quinoxaline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1505 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 8-hydroxy-5,7,9-trimethyl-delta-carboline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5978 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD vuf-8504 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD sb-298 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD i-abopx NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 2-(3''-(benzotriazole-1''-yl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1486 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 1-benzyl-3-methyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mre 3010f20 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 1-phenethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''-indolylethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD nsc-407228 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 8-bromo-9-isobutyl-9h-purin-6-amine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5962 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-chloro-2'-c-methyl-tecadenoson NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5417 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 9h-purine derivative NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD hexanoic acid (2,6-diphenylpyrimidin-4-yl)amide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1186 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB visnagin NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist 0.53 TTD , DGIDB 1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-acetylaminoquinazoline-4-carboxyanilide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-phenyl-3-(quinazolin-4-yl)urea NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 8-hydroxy-7,9-dimethyl-delta-carboline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD l-249313 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 8-bromo-9-isopropyl-9h-adenine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(4-chloro-1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD cf102 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 2 adenosine a3 receptor ADORA3 Clinical trial target unknown 1.91 TTD , DGIDB n-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-cyclopentyladenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown 0.68 TTD , DGIDB 8-bromo-9-(3-hydroxypropyl)-9h-adenine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2,6-diphenyl-8-tbutyl-1-deazapurine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD (r,s)-phpneca NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB 2-(3''-pyrrolylethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 3-(3-chloro-1h-pyrazol-5-yl)quinoxalin-2(1h)-one NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD xanthine amine congener NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB cirsimaritin NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 8-propyl-2,6-diphenyl-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD ab-meca NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist 0.8 TTD , DGIDB reversine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(4-nitro-1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-prop-2-ynyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1042 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB mrs1041 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 8-bromo-9-(sec-butyl)-9h-adenine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-allyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD enprofylline small molecule Disease Management[MeSHID:D019468],Anemia, Sickle Cell[MeSHID:D000755],Peripheral Vascular Diseases[MeSHID:D016491],Asthma[MeSHID:D001249],Cerebrovascular Insufficiency[MeSHID:D002561],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental adenosine receptor a3 ADORA3 NA inhibitor NA drugbank (s)-pia NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB n*6*-cyclohexyl-n*2*-ethyl-9h-purine-2,6-diamine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(hex-1-ynyl)-n6-methoxyadenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD piclidenoson small molecule Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Disorder of eye[MeSHID:D005128],Gastrointestinal Diseases[MeSHID:D005767],Eye Infections[MeSHID:D015817],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Keratoconjunctivitis Sicca[MeSHID:D007638],Dry Eye Syndromes[MeSHID:D015352],Coronavirus Infections[MeSHID:D018352] investigational adenosine receptor a3 ADORA3 NA agonist 0.8 drugbank , DGIDB 2-phenyl-2h-pyrazolo[4,3-c]quinoline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 3-methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-tolyl-6-phenyl-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 6-guanidino-2-(3''-indolylethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(1h-benzo[d]imidazol-2-yl)quinoxaline NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1,2-dihydro-2-oxoquinazoline-4-carboxyanilide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD ib-meca NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Malignant Neoplasms[MeSHID:D009369],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] phase 3 adenosine a3 receptor ADORA3 Clinical trial target unknown 2.12 TTD , DGIDB 9-cyclopentyl-9h-adenine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mesulergine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-propyl-3,7-dihydro-purine-2,6-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD sakuranetin NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist 0.8 TTD , DGIDB 2,6-diphenyl-8-methyl-1-deazapurine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(4,5-diphenylpyrimidin-2-yl)acetamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD flavone NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist 0.27 TTD , DGIDB 5-butyl-8-phenyl-3h-[1,2,4]triazolo[5,1-i]purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD (2r,3s)-3-(6-amino-purin-9-yl)-nonan-2-ol NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-[(4-acetylphenyl)ethynyl]-n6-methoxyadenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1191 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 2-(4-methoxyphenyl)-6-phenyl-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 8-bromo-9-cyclohexyl-9h-adenine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-benzyl-1h-1,3,4b,9-tetraaza-fluorene-2,4-dione NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 9-ethyl-8-phenylethynyl-9h-purin-6-ylamine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-(3-iodobenzyl)-2'-o-methyladenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2,6-diphenyl-8-ethyl-1-deazapurine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n-(5-benzoyl-4-phenylthiazol-2-yl)benzamide NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD tcpa NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB n6-((+/-)-endo-norborn-2-yl)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD cp608,039 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB psb-10 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB 2'-me-ccpa NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational adenosine receptor a3 ADORA3 NA antagonist NA drugbank cyclohexyl-(2-phenoxy-9h-purin-6-yl)-amine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(4-hydroxypent-1-yl)-n6-methoxyadenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD vuf5574 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB mre 3008f20 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist,antagonist NA TTD , DGIDB (e)-8-(3-chlorostyryl)-caffeine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD mrs1093 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB mrs-1220 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD [3h]psb-11 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target antagonist NA TTD , DGIDB adenosine small molecule Sinus Tachycardia[MeSHID:D013616],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved,investigational adenosine receptor a3 ADORA3 NA agonist 1.45 drugbank , DGIDB 2,6-diphenyl-9h-purine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5981 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5433 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-benzyl-2h-pyrazolo[3,4-c]quinolin-4(5h)-one NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD tonapofylline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 adenosine a3 receptor ADORA3 Clinical trial target unknown 0.8 TTD , DGIDB ib-meca NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Malignant Neoplasms[MeSHID:D009369],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] phase 3 adenosine a3 receptor ADORA3 Clinical trial target agonist 2.12 TTD , DGIDB n6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD r-n6-(phenylisopropyl)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n(6)-cyclohexyladenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target agonist NA TTD , DGIDB luf-5767 NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD n*6*-cyclohexyl-n*2*-phenyl-9h-purine-2,6-diamine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD luf-5833 NA Ischemia[MeSHID:D007511],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD 5,7-diphenyl-3h-imidazo[4,5-b]pyridin-2-ol NA NA investigative adenosine a3 receptor ADORA3 Clinical trial target unknown NA TTD aminophylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adenosine receptor a3 ADORA3 NA antagonist 0.32 drugbank , DGIDB alfuzosin small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1A NA antagonist 1.38 drugbank , DGIDB 1-(pyridin-2-yl)piperazine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD prochlorperazine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Headache[MeSHID:D006261],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Emergencies [Disease/Finding][MeSHID:D004630],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank flupentixol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Asthenia[MeSHID:D001247],Hyperactive behavior[MeSHID:D006948],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] approved,investigational,withdrawn alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank 1-(3-fluoro-pyridin-2-yl)-4-methyl-piperazine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental alpha adrenergic receptor ADRA1A NA agonist NA drugbank apraclonidine small molecule Vision[MeSHID:D014785],Term Birth[MeSHID:D047929],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypotension[MeSHID:D015814],Eye[MeSHID:D005123],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank 4-(4-chlorobenzyl)phthalazin-1(2h)-one NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-1 adrenergic receptors ADRA1A NA inhibitor 0.22 drugbank , DGIDB pmid30124346-compound-ldt66 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD , DGIDB gg-818 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank synephrine small molecule NA experimental alpha-1 adrenergic receptors ADRA1A NA unknown NA drugbank niguldipine small molecule NA experimental alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank rwj-38063 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD (2-bromo-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD mazapertine NA NA discontinued in phase 2 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD ro-11-04253 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved alpha adrenergic receptor ADRA1A NA agonist 1.18 drugbank , DGIDB isometheptene small molecule Vascular constriction (function)[MeSHID:D014661],Tension Headache[MeSHID:D018781],Migraine Disorders[MeSHID:D008881] approved alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank terazosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.53 drugbank , DGIDB thioproperazine small molecule Manic[MeSHID:D001714],Syndrome[MeSHID:D013577],Schizophrenia[MeSHID:D012559] experimental alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.54 drugbank , DGIDB ephedrine small molecule Asthma[MeSHID:D001249],Nose[MeSHID:D009666],Hypotension[MeSHID:D007022],Bronchial Diseases[MeSHID:D001982],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA agonist 1.18 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.54 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-1 adrenergic receptors ADRA1A NA inhibitor NA drugbank sou-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD , DGIDB dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit alpha adrenergic receptor ADRA1A NA inhibitor,inducer NA drugbank methoxamine small molecule Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational alpha-1a adrenergic receptor ADRA1A NA agonist 1.77 drugbank , DGIDB nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn alpha-1a adrenergic receptor ADRA1A NA antagonist 0.21 drugbank , DGIDB besipirdine NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 adrenergic receptor alpha-1a ADRA1A Successful target unknown 0.59 TTD , DGIDB sdz-nvi-085 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 1 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved alpha-1a adrenergic receptor ADRA1A NA agonist 0.2 drugbank , DGIDB indigotindisulfonic acid small molecule Ureter[MeSHID:D014513] approved alpha adrenergic receptor ADRA1A NA agonist NA drugbank (2,6-dichloro-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD a-315456 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD pmid30124346-compound-ldt8 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD , DGIDB 4-(1-naphthalen-1-yl-ethyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist,potentiator 0.22 drugbank , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-1 adrenergic receptors ADRA1A NA inhibitor,antagonist 0.22 drugbank , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1A NA agonist NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-1 adrenergic receptors ADRA1A NA inhibitor 0.22 drugbank , DGIDB silodosin NA Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1a ADRA1A Successful target unknown 1.18 TTD , DGIDB 5-bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 4-(4-chlorobenzyl)-2-allylphthalazin-1(2h)-one NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD xatral NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1a ADRA1A Successful target unknown 0.39 TTD , DGIDB isoclozapine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1A NA binder NA drugbank desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank perospirone small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] experimental alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank 4-(1-naphthalen-1-yl-vinyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.06 drugbank , DGIDB doxazosin small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 1.65 drugbank , DGIDB epicept np-1 small molecule Pain[MeSHID:D010146] investigational alpha-1a adrenergic receptor ADRA1A NA unknown NA drugbank r450 small molecule Urinary Incontinence[MeSHID:D014549] investigational alpha-1a adrenergic receptor ADRA1A NA unknown NA drugbank propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.25 drugbank , DGIDB 1-(2-chloro-phenyl)-piperazine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1A NA inhibitor NA drugbank buspirone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1A NA partial agonist NA drugbank 4-(3,4-dihydro-1h-isoquinolin-2-yl)-quinoline NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 4-benzyl-2-methylphthalazin-1(2h)-one NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD labetalol small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1A NA antagonist 0.41 drugbank , DGIDB alfuzosin small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist 1.38 drugbank , DGIDB metaraminol small molecule Brain Injuries[MeSHID:D001930],Hemorrhage[MeSHID:D006470],Hypotension[MeSHID:D007022],Shock[MeSHID:D012769],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA agonist 0.42 drugbank , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved alpha-1a adrenergic receptor ADRA1A NA binder,antagonist 0.08 drugbank , DGIDB 4-(4-isopropyl-morpholin-2-yl)-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD snap-94847 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD tiospirone NA NA discontinued in phase 3 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD tizanidine small molecule Muscle Spasticity[MeSHID:D009128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational alpha-1 adrenergic receptors ADRA1A NA agonist NA drugbank 4-(4-methyl-indan-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD acepromazine small molecule Anxiety[MeSHID:D001007] experimental,vet_approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank nicergoline small molecule Blood Vessel[MeSHID:D001808],Blood Platelets[MeSHID:D001792],Ischemia[MeSHID:D007511],Hyperactive behavior[MeSHID:D006948],Age related macular degeneration[MeSHID:D008268],Migraine Disorders[MeSHID:D008881],Brain Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist 0.88 drugbank , DGIDB rbx-2258 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank phenylephrine small molecule Hypotension[MeSHID:D007022],Priapism[MeSHID:D011317],Regional Blood Flow[MeSHID:D012039],Pupil[MeSHID:D011680],Vascular constriction (function)[MeSHID:D014661],Shock[MeSHID:D012769],Eye[MeSHID:D005123],Hemorrhoids[MeSHID:D006484],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid associated opthalmopathies[MeSHID:D049970],Fecal Incontinence[MeSHID:D005242] approved alpha-1a adrenergic receptor ADRA1A NA agonist 0.25 drugbank , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank rec-15-2739 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.08 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist 0.07 drugbank , DGIDB 4-morpholin-2-yl-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD dihydroergocornine small molecule NA approved alpha adrenergic receptor ADRA1A NA antagonist,agonist NA drugbank epinephrine small molecule Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved alpha-1a adrenergic receptor ADRA1A NA agonist 0.16 drugbank , DGIDB rwj-68141 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 2-(4-tert-butyl-phenyl)-4,5-dihydro-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist 0.03 drugbank , DGIDB fenoldopam small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Malignant Hypertension[MeSHID:D006974],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA inhibitor NA drugbank rwj-69736 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha-1 adrenergic receptors ADRA1A NA inhibitor NA drugbank dapiprazole small molecule Mydriasis[MeSHID:D015878],Eye[MeSHID:D005123],Physical Examination[MeSHID:D010808],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.74 drugbank , DGIDB epinastine small molecule Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA unknown NA drugbank rs-100329 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target antagonist 0.15 TTD , DGIDB rs-100975 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 1',2',3',6'-tetrahydro-[2,4']bipyridinyl NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved alpha-1a adrenergic receptor ADRA1A NA unknown NA drugbank n-(5-bromo-quinoxalin-6-yl)-guanidine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank propiverine small molecule Urinary Incontinence[MeSHID:D014549],Neurogenic Urinary Bladder[MeSHID:D001750],Urinary tract[MeSHID:D014551],Overactive Bladder[MeSHID:D053201],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank droperidol small molecule Nausea[MeSHID:D009325],Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank tamsulosin NA prostatitis[MeSHID:D011472],Urination[MeSHID:D014554],Ureterolithiasis[MeSHID:D053039],Off-Label Use[MeSHID:D056687],Ureteral Calculi[MeSHID:D014514],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1a ADRA1A Successful target unknown 1.18 TTD , DGIDB [3h]rx821002 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD cm-2236 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Post-Traumatic Stress Disorder[MeSHID:D013313] preclinical adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD , DGIDB phentolamine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Neoplasms[MeSHID:D009369],Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Coronary Artery Vasospasm[MeSHID:D003329],Left-Sided Heart Failure[MeSHID:D006333],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Erectile dysfunction[MeSHID:D007172],Left ventricular structure[MeSHID:D006352],Infarction[MeSHID:D007238],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.23 drugbank , DGIDB zuclopenthixol small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Manic[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Behavior[MeSHID:D001519],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank indoramin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,withdrawn alpha-1a adrenergic receptor ADRA1A NA antagonist 0.59 drugbank , DGIDB moxisylyte small molecule Arteries[MeSHID:D001158],Disease Management[MeSHID:D019468],Anterior chamber of eye structure[MeSHID:D000867],Thrombus[MeSHID:D013927],Glaucoma[MeSHID:D005901],Mydriasis[MeSHID:D015878],Aqueous Humor[MeSHID:D001082],Trabecular meshwork structure[MeSHID:D014129],Hand[MeSHID:D006225],Pupil[MeSHID:D011680],Lens, Crystalline[MeSHID:D007908],Cerebral Infarction[MeSHID:D002544],Erectile dysfunction[MeSHID:D007172],Precipitating Factors[MeSHID:D015985],Pressure- physical agent[MeSHID:D011312],Angle Closure Glaucoma[MeSHID:D015812],Hemorrhage[MeSHID:D006470],Iris (Eye)[MeSHID:D007498],Eye[MeSHID:D005123],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA1A NA antagonist NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank snap-8719 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD snap-5036 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD clonidine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Malignant Neoplasms[MeSHID:D009369],Attention deficit hyperactivity disorder[MeSHID:D001289],Nicotine Dependence[MeSHID:D014029],Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank levonordefrin NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD [3h]spiperone NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD snap-7915 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD fluanisone NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 4-(3-hydroxy-piperidin-3-yl)-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.08 drugbank , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1a adrenergic receptor ADRA1A NA antagonist,inhibitor NA drugbank naftopidil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved adrenergic receptor alpha-1a ADRA1A Successful target unknown 0.12 TTD , DGIDB lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank 4-(4-chlorobenzyl)-2-methylphthalazin-1(2h)-one NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD cirazoline small molecule NA experimental alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank 4-benzo[b]thiophen-4-yl-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist,potentiator 0.22 drugbank , DGIDB pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank medetomidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 adrenergic receptor alpha-1a ADRA1A Successful target unknown 0.1 TTD , DGIDB droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA agonist 0.44 drugbank , DGIDB l-771688 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-1 adrenergic receptors ADRA1A NA inhibitor,antagonist 0.22 drugbank , DGIDB naphazoline small molecule Vascular constriction (function)[MeSHID:D014661],Nose[MeSHID:D009666],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Hyperemia[MeSHID:D006940],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] approved,investigational alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank trazodone small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist 0.13 drugbank , DGIDB prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1 adrenergic receptors ADRA1A NA unknown 0.54 drugbank , DGIDB sk&f-86466 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational alpha-1a adrenergic receptor ADRA1A NA unknown NA drugbank prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1 adrenergic receptors ADRA1A NA antagonist 0.54 drugbank , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.02 drugbank , DGIDB a-123189 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target antagonist 0.2 TTD , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank sunepitron NA NA discontinued in phase 3 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD phendimetrazine small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit alpha-1a adrenergic receptor ADRA1A NA agonist 2.06 drugbank , DGIDB tamsulosin small molecule prostatitis[MeSHID:D011472],Urination[MeSHID:D014554],Ureterolithiasis[MeSHID:D053039],Off-Label Use[MeSHID:D056687],Ureteral Calculi[MeSHID:D014514],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist 1.18 drugbank , DGIDB tamsulosin NA prostatitis[MeSHID:D011472],Urination[MeSHID:D014554],Ureterolithiasis[MeSHID:D053039],Off-Label Use[MeSHID:D056687],Ureteral Calculi[MeSHID:D014514],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1a ADRA1A Successful target antagonist 1.18 TTD , DGIDB corynantheine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved alpha-1a adrenergic receptor ADRA1A NA partial agonist NA drugbank bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist,agonist NA drugbank promazine small molecule Psychomotor Agitation[MeSHID:D011595],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.2 drugbank , DGIDB r-226161 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD xylometazoline small molecule Respiratory Hypersensitivity[MeSHID:D012130],Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA agonist,partial agonist NA drugbank sk&f-105854 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD uh-301 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 8-piperazin-1-yl-imidazo[1,2-a]pyrazine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank beta-methoxyamphetamine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD tetryzoline small molecule Lubricants[MeSHID:D054327],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Nose[MeSHID:D009666],Mucous Membrane[MeSHID:D009092],Nasopharynx[MeSHID:D009305] approved alpha-1 adrenergic receptors ADRA1A NA agonist NA drugbank haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA unknown NA drugbank tolazoline small molecule Pulmonary artery structure[MeSHID:D011651],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] approved,vet_approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.71 drugbank , DGIDB dutasteride + tamsulosin NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD , DGIDB verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational alpha adrenergic receptor ADRA1A NA agonist 0.12 drugbank , DGIDB dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.29 drugbank , DGIDB agn-192172 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 4-(2,3-dihydro-1h-phenalen-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 2-pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD l-765314 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational alpha-1a adrenergic receptor ADRA1A NA partial agonist,agonist 0.39 drugbank , DGIDB rec2615 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational alpha-1a adrenergic receptor ADRA1A NA partial agonist 0.39 drugbank , DGIDB dl-methylephedrine small molecule NA approved alpha adrenergic receptor ADRA1A NA agonist NA drugbank midodrine small molecule Hypotension, Orthostatic[MeSHID:D007024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA agonist 0.42 drugbank , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1A NA antagonist 0.04 drugbank , DGIDB silodosin NA Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1a ADRA1A Successful target antagonist 1.18 TTD , DGIDB ergometrine small molecule Uterine Inertia[MeSHID:D014593],Hemorrhage[MeSHID:D006470],Postabortion[MeSHID:D000359],Postpartum Hemorrhage[MeSHID:D006473] approved alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank sertindole small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn alpha-1a adrenergic receptor ADRA1A NA unknown 0.12 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA1A NA antagonist NA drugbank dobutamine small molecule Heart Decompensation[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Depressed Level of Consciousness[MeSHID:D003244],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved alpha-1 adrenergic receptors ADRA1A NA agonist NA drugbank (+/-)-nantenine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD sk&f-106686 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 1-(2-methoxy-phenyl)-piperazine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank silodosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 1.18 drugbank , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha adrenergic receptor ADRA1A NA antagonist,agonist NA drugbank , DGIDB taprizosin NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist 0.17 drugbank , DGIDB rs-513815 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD rwj-68157 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 4-methoxyamphetamine small molecule NA experimental,illicit alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank imidazolidin-2-ylidene-o-tolyl-amine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1A NA unknown 0.54 drugbank , DGIDB 4-((e)-1-naphthalen-1-yl-propenyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD a-119637 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target antagonist 0.2 TTD , DGIDB imidazolidin-2-ylidene-quinoxalin-6-yl-amine NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD 4-(1-naphthalen-1-yl-propyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD quinidine small molecule Preexcitation Syndrome[MeSHID:D011226],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Conduction disorder of the heart[MeSHID:D000075224] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha adrenergic receptor ADRA1A NA antagonist NA drugbank bevantolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA agonist 0.21 drugbank , DGIDB prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1A NA antagonist 0.54 drugbank , DGIDB (-)-snap-5399 NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD thioridazine small molecule Anxiety Disorders[MeSHID:D001008],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn alpha-1a adrenergic receptor ADRA1A NA antagonist 0.12 drugbank , DGIDB lofexidine small molecule Disease Management[MeSHID:D019468],Abdominal Pain[MeSHID:D015746],Opiate Addiction[MeSHID:D009293],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Diarrhea[MeSHID:D003967],Mydriasis[MeSHID:D015878],Piloerection[MeSHID:D010863],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank phenoxybenzamine small molecule Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved alpha-1a adrenergic receptor ADRA1A NA antagonist 0.52 drugbank , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank 4-((z)-1-naphthalen-1-yl-propenyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental alpha adrenergic receptor ADRA1A NA antagonist,agonist NA drugbank benzphetamine small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit alpha-1a adrenergic receptor ADRA1A NA agonist 0.98 drugbank , DGIDB dipivefrin small molecule Glaucoma, Open-Angle[MeSHID:D005902],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA inhibitor NA drugbank loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1a adrenergic receptor ADRA1A NA binder NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational alpha adrenergic receptor ADRA1A NA antagonist NA drugbank trifluoperazine small molecule Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist 0.13 drugbank , DGIDB doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-1a adrenergic receptor ADRA1A NA antagonist NA drugbank arotinolol small molecule Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],heart rate[MeSHID:D006339],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300] investigational alpha-1 adrenergic receptors ADRA1A NA antagonist NA drugbank octoclothepin NA NA investigative adrenergic receptor alpha-1a ADRA1A Successful target unknown NA TTD racepinephrine small molecule Asthma[MeSHID:D001249] approved alpha-1a adrenergic receptor ADRA1A NA agonist NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-1 adrenergic receptors ADRA1B NA inhibitor,antagonist 0.09 drugbank , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA1B NA antagonist NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist 0.09 drugbank , DGIDB phenylephrine small molecule Hypotension[MeSHID:D007022],Priapism[MeSHID:D011317],Regional Blood Flow[MeSHID:D012039],Pupil[MeSHID:D011680],Vascular constriction (function)[MeSHID:D014661],Shock[MeSHID:D012769],Eye[MeSHID:D005123],Hemorrhoids[MeSHID:D006484],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid associated opthalmopathies[MeSHID:D049970],Fecal Incontinence[MeSHID:D005242] approved alpha-1b adrenergic receptor ADRA1B NA agonist 0.29 drugbank , DGIDB xylometazoline small molecule Respiratory Hypersensitivity[MeSHID:D012130],Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b adrenergic receptor ADRA1B NA agonist NA drugbank terazosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist 0.57 drugbank , DGIDB corynantheine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD synephrine small molecule NA experimental alpha-1 adrenergic receptors ADRA1B NA unknown NA drugbank doxazosin small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist 1.47 drugbank , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank tiospirone NA NA discontinued in phase 3 adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved alpha adrenergic receptor ADRA1B NA agonist NA drugbank dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit alpha adrenergic receptor ADRA1B NA inhibitor,inducer NA drugbank [3h]rx821002 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD 4-(3-hydroxy-piperidin-3-yl)-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD cyclazosin NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD 4-(1-naphthalen-1-yl-propyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank sunepitron NA NA discontinued in phase 3 adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn alpha-1b adrenergic receptor ADRA1B NA unknown 0.37 drugbank , DGIDB levonordefrin NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD rwj-68157 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD phendimetrazine small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit alpha-1b adrenergic receptor ADRA1B NA agonist 3.67 drugbank , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank r450 small molecule Urinary Incontinence[MeSHID:D014549] investigational alpha-1b adrenergic receptor ADRA1B NA unknown NA drugbank 4-(3,4-dihydro-1h-isoquinolin-2-yl)-quinoline NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational alpha adrenergic receptor ADRA1B NA antagonist NA drugbank aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental alpha adrenergic receptor ADRA1B NA agonist NA drugbank prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1B NA unknown 0.68 drugbank , DGIDB alfuzosin small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1B NA antagonist 1.63 drugbank , DGIDB midodrine small molecule Hypotension, Orthostatic[MeSHID:D007024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA agonist 0.35 drugbank , DGIDB propericiazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1b ADRA1B Successful target unknown 0.98 TTD , DGIDB alfuzosin small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist 1.63 drugbank , DGIDB a-119637 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target antagonist 0.27 TTD , DGIDB prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1 adrenergic receptors ADRA1B NA antagonist 0.68 drugbank , DGIDB fenoldopam small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Malignant Hypertension[MeSHID:D006974],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA inhibitor NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1b adrenergic receptor ADRA1B NA antagonist 0.68 drugbank , DGIDB methamphetamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Attention deficit hyperactivity disorder[MeSHID:D001289] approved adrenergic receptor alpha-1b ADRA1B Successful target unknown 0.06 TTD , DGIDB moxisylyte small molecule Arteries[MeSHID:D001158],Disease Management[MeSHID:D019468],Anterior chamber of eye structure[MeSHID:D000867],Thrombus[MeSHID:D013927],Glaucoma[MeSHID:D005901],Mydriasis[MeSHID:D015878],Aqueous Humor[MeSHID:D001082],Trabecular meshwork structure[MeSHID:D014129],Hand[MeSHID:D006225],Pupil[MeSHID:D011680],Lens, Crystalline[MeSHID:D007908],Cerebral Infarction[MeSHID:D002544],Erectile dysfunction[MeSHID:D007172],Precipitating Factors[MeSHID:D015985],Pressure- physical agent[MeSHID:D011312],Angle Closure Glaucoma[MeSHID:D015812],Hemorrhage[MeSHID:D006470],Iris (Eye)[MeSHID:D007498],Eye[MeSHID:D005123],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA1B NA antagonist NA drugbank doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank 2-pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist 0.68 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-1 adrenergic receptors ADRA1B NA inhibitor NA drugbank [125i]be-2254 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target antagonist NA TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA binder NA drugbank verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank phenoxybenzamine small molecule Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank 5-methylurapidil NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target antagonist NA TTD , DGIDB methoxamine small molecule Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational alpha-1b adrenergic receptor ADRA1B NA agonist 2.72 drugbank , DGIDB 4-(4-isopropyl-morpholin-2-yl)-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved alpha-1 adrenergic receptors ADRA1B NA antagonist 0.08 drugbank , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1B NA agonist NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank methoxamine NA Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved adrenergic receptor alpha-1b ADRA1B Successful target agonist 2.72 TTD , DGIDB 4-((z)-1-naphthalen-1-yl-propenyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD imidazolidin-2-ylidene-o-tolyl-amine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD mazapertine NA NA discontinued in phase 2 adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha adrenergic receptor ADRA1B NA antagonist NA drugbank tamsulosin small molecule prostatitis[MeSHID:D011472],Urination[MeSHID:D014554],Ureterolithiasis[MeSHID:D053039],Off-Label Use[MeSHID:D056687],Ureteral Calculi[MeSHID:D014514],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist 1.22 drugbank , DGIDB labetalol small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1B NA antagonist 0.13 drugbank , DGIDB silodosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist 0.54 drugbank , DGIDB methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist 0.23 drugbank , DGIDB dobutamine small molecule Heart Decompensation[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Depressed Level of Consciousness[MeSHID:D003244],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved alpha-1 adrenergic receptors ADRA1B NA agonist NA drugbank doxazosin small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA unknown 1.47 drugbank , DGIDB methoxamine NA Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved adrenergic receptor alpha-1b ADRA1B Successful target unknown 2.72 TTD , DGIDB tetryzoline small molecule Lubricants[MeSHID:D054327],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Nose[MeSHID:D009666],Mucous Membrane[MeSHID:D009092],Nasopharynx[MeSHID:D009305] approved alpha-1 adrenergic receptors ADRA1B NA agonist NA drugbank brexpiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist 0.02 drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist 0.07 drugbank , DGIDB buspirone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1B NA partial agonist NA drugbank rec 15/2615 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target antagonist NA TTD , DGIDB acepromazine small molecule Anxiety[MeSHID:D001007] experimental,vet_approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank clonidine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Malignant Neoplasms[MeSHID:D009369],Attention deficit hyperactivity disorder[MeSHID:D001289],Nicotine Dependence[MeSHID:D014029],Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved alpha-1b adrenergic receptor ADRA1B NA agonist NA drugbank sou-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD , DGIDB ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved alpha-1b adrenergic receptor ADRA1B NA partial agonist NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha adrenergic receptor ADRA1B NA antagonist,agonist NA drugbank n-(5-bromo-quinoxalin-6-yl)-guanidine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD perospirone small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] experimental alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank fluanisone NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn alpha-1b adrenergic receptor ADRA1B NA agonist NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist,agonist NA drugbank oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational alpha-1b adrenergic receptor ADRA1B NA agonist 0.27 drugbank , DGIDB [125i]heat NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target antagonist NA TTD , DGIDB 4-(4-methyl-indan-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD 4-(2,3-dihydro-1h-phenalen-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank a-123189 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target antagonist 0.27 TTD , DGIDB prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1B NA antagonist 0.68 drugbank , DGIDB sk&f-86466 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD dapiprazole small molecule Mydriasis[MeSHID:D015878],Eye[MeSHID:D005123],Physical Examination[MeSHID:D010808],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved alpha-1b adrenergic receptor ADRA1B NA antagonist 1.22 drugbank , DGIDB 4-((e)-1-naphthalen-1-yl-propenyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1B NA antagonist 0.05 drugbank , DGIDB epinephrine small molecule Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved alpha-1b adrenergic receptor ADRA1B NA agonist 0.19 drugbank , DGIDB epicept np-1 small molecule Pain[MeSHID:D010146] investigational alpha-1b adrenergic receptor ADRA1B NA unknown NA drugbank desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank indigotindisulfonic acid small molecule Ureter[MeSHID:D014513] approved alpha adrenergic receptor ADRA1B NA agonist NA drugbank 6-fluoronorepinehprine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1B NA inhibitor NA drugbank phentolamine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Neoplasms[MeSHID:D009369],Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Coronary Artery Vasospasm[MeSHID:D003329],Left-Sided Heart Failure[MeSHID:D006333],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Erectile dysfunction[MeSHID:D007172],Left ventricular structure[MeSHID:D006352],Infarction[MeSHID:D007238],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1b adrenergic receptor ADRA1B NA antagonist 0.13 drugbank , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational alpha adrenergic receptor ADRA1B NA agonist NA drugbank prochlorperazine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Headache[MeSHID:D006261],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Emergencies [Disease/Finding][MeSHID:D004630],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank ah 11110 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target antagonist NA TTD , DGIDB norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved alpha-1b adrenergic receptor ADRA1B NA agonist 0.35 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha-1 adrenergic receptors ADRA1B NA inhibitor NA drugbank octoclothepin NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD dihydroergocornine small molecule NA approved alpha adrenergic receptor ADRA1B NA antagonist,agonist NA drugbank thioproperazine small molecule Manic[MeSHID:D001714],Syndrome[MeSHID:D013577],Schizophrenia[MeSHID:D012559] experimental alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank imidazolidin-2-ylidene-quinoxalin-6-yl-amine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD thioridazine small molecule Anxiety Disorders[MeSHID:D001008],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank spiroxatrine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target antagonist 0.08 TTD , DGIDB pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank medetomidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 adrenergic receptor alpha-1b ADRA1B Successful target unknown 0.14 TTD , DGIDB verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank isoclozapine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD (2-bromo-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD racepinephrine small molecule Asthma[MeSHID:D001249] approved alpha-1b adrenergic receptor ADRA1B NA agonist NA drugbank risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist 0.1 drugbank , DGIDB ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational alpha-1b adrenergic receptor ADRA1B NA unknown NA drugbank quinidine small molecule Preexcitation Syndrome[MeSHID:D011226],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Conduction disorder of the heart[MeSHID:D000075224] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank dl-methylephedrine small molecule NA approved alpha adrenergic receptor ADRA1B NA agonist NA drugbank droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b adrenergic receptor ADRA1B NA agonist 0.51 drugbank , DGIDB (2,6-dichloro-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD agn-192172 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental alpha adrenergic receptor ADRA1B NA antagonist,agonist NA drugbank mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank sertindole small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn alpha-1b adrenergic receptor ADRA1B NA unknown 0.13 drugbank , DGIDB sk&f-106686 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD tizanidine small molecule Muscle Spasticity[MeSHID:D009128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational alpha-1 adrenergic receptors ADRA1B NA agonist NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank snap-8719 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD uh-301 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD 4-benzo[b]thiophen-4-yl-1h-imidazole NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD sk&f-105854 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank rwj-69736 NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD periciazine small molecule Aggressive behavior[MeSHID:D000374],Impulsive Behavior[MeSHID:D007175],Hostility[MeSHID:D006791] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank cirazoline small molecule NA experimental alpha-1b adrenergic receptor ADRA1B NA partial agonist NA drugbank modafinil small molecule Narcolepsy[MeSHID:D009290],Wakefulness[MeSHID:D014851],Hypersomnia[MeSHID:D006970],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714],Brain Injuries[MeSHID:D001930] approved,investigational alpha-1b adrenergic receptor ADRA1B NA partial agonist NA drugbank 4-morpholin-2-yl-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank arotinolol small molecule Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],heart rate[MeSHID:D006339],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300] investigational alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank (+/-)-nantenine NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1 adrenergic receptors ADRA1B NA unknown 0.68 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved alpha-1b adrenergic receptor ADRA1B NA binder NA drugbank maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational alpha-1 adrenergic receptors ADRA1B NA antagonist NA drugbank 4-(1-naphthalen-1-yl-vinyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD phendimetrazine NA Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1b ADRA1B Successful target unknown 3.67 TTD , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-1b adrenergic receptor ADRA1B NA antagonist 0.09 drugbank , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-1 adrenergic receptors ADRA1B NA inhibitor,antagonist 0.09 drugbank , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1B NA binder NA drugbank 4-(1-naphthalen-1-yl-ethyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1b ADRA1B Successful target unknown NA TTD dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit alpha-1b adrenergic receptor ADRA1B NA antagonist NA drugbank doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank dl-methylephedrine small molecule NA approved alpha adrenergic receptor ADRA1D NA agonist NA drugbank silodosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA antagonist 0.9 drugbank , DGIDB methoxamine small molecule Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational alpha-1d adrenergic receptor ADRA1D NA binder,agonist 1.35 drugbank , DGIDB pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank labetalol small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1D NA antagonist 0.1 drugbank , DGIDB dapiprazole small molecule Mydriasis[MeSHID:D015878],Eye[MeSHID:D005123],Physical Examination[MeSHID:D010808],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved alpha-1d adrenergic receptor ADRA1D NA antagonist 2.37 drugbank , DGIDB dabuzalgron NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit alpha adrenergic receptor ADRA1D NA inhibitor,inducer NA drugbank alfuzosin small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1D NA antagonist 2.71 drugbank , DGIDB rwj-68157 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD [3h]rx821002 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD terazosin NA Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1d ADRA1D Successful target unknown 0.68 TTD , DGIDB 4-benzo[b]thiophen-4-yl-1h-imidazole NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1D NA antagonist 0.08 drugbank , DGIDB terazosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA antagonist 0.68 drugbank , DGIDB sl-89.0591 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank clonidine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Malignant Neoplasms[MeSHID:D009369],Attention deficit hyperactivity disorder[MeSHID:D001289],Nicotine Dependence[MeSHID:D014029],Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved alpha-1d adrenergic receptor ADRA1D NA agonist NA drugbank 1-(2-methoxy-phenyl)-piperazine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD epicept np-1 small molecule Pain[MeSHID:D010146] investigational alpha-1d adrenergic receptor ADRA1D NA unknown NA drugbank 4-(1-naphthalen-1-yl-vinyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD doxazosin NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1d ADRA1D Successful target antagonist 2.71 TTD , DGIDB bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha-1d adrenergic receptor ADRA1D NA agonist NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank sertindole small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn alpha-1d adrenergic receptor ADRA1D NA unknown 0.21 drugbank , DGIDB sk&f-86466 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD 4-(1-naphthalen-1-yl-propyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD quinidine small molecule Preexcitation Syndrome[MeSHID:D011226],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Conduction disorder of the heart[MeSHID:D000075224] approved,investigational alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank armodafinil NA Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Schizoaffective Disorder[MeSHID:D011618],Sleep Apnea, Obstructive[MeSHID:D020181],Sleep Disorders[MeSHID:D012893],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved adrenergic receptor alpha-1d ADRA1D Successful target unknown 1.35 TTD , DGIDB snap-8719 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD doxazosin NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1d ADRA1D Successful target unknown 2.71 TTD , DGIDB prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1d adrenergic receptor ADRA1D NA antagonist 0.68 drugbank , DGIDB octoclothepin NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD 8-piperazin-1-yl-imidazo[1,2-a]pyrazine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-1 adrenergic receptors ADRA1D NA inhibitor NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank uh-301 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD tetryzoline small molecule Lubricants[MeSHID:D054327],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Nose[MeSHID:D009666],Mucous Membrane[MeSHID:D009092],Nasopharynx[MeSHID:D009305] approved alpha-1 adrenergic receptors ADRA1D NA agonist NA drugbank (+/-)-nantenine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD 4-morpholin-2-yl-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD alfuzosin small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1d adrenergic receptor ADRA1D NA antagonist 2.71 drugbank , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha adrenergic receptor ADRA1D NA antagonist,agonist NA drugbank droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1d adrenergic receptor ADRA1D NA agonist NA drugbank bunazosin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved adrenergic receptor alpha-1d ADRA1D Successful target unknown 1.35 TTD , DGIDB indoramin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] withdrawn from market adrenergic receptor alpha-1d ADRA1D Successful target antagonist 0.45 TTD , DGIDB dl-017 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 1 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD , DGIDB fce-22716 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1D NA antagonist 0.68 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA1D NA antagonist NA drugbank etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational alpha adrenergic receptor ADRA1D NA antagonist NA drugbank (2,6-dichloro-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD rwj-38063 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD moxisylyte NA Arteries[MeSHID:D001158],Disease Management[MeSHID:D019468],Anterior chamber of eye structure[MeSHID:D000867],Thrombus[MeSHID:D013927],Glaucoma[MeSHID:D005901],Mydriasis[MeSHID:D015878],Aqueous Humor[MeSHID:D001082],Trabecular meshwork structure[MeSHID:D014129],Hand[MeSHID:D006225],Pupil[MeSHID:D011680],Lens, Crystalline[MeSHID:D007908],Cerebral Infarction[MeSHID:D002544],Erectile dysfunction[MeSHID:D007172],Precipitating Factors[MeSHID:D015985],Pressure- physical agent[MeSHID:D011312],Angle Closure Glaucoma[MeSHID:D015812],Hemorrhage[MeSHID:D006470],Iris (Eye)[MeSHID:D007498],Eye[MeSHID:D005123],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1d ADRA1D Successful target unknown 0.68 TTD , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank 4-(4-chlorobenzyl)-2-methylphthalazin-1(2h)-one NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD ns-49 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target agonist 0.45 TTD , DGIDB 4-((z)-1-naphthalen-1-yl-propenyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD fluanisone NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank 1-(2-chloro-phenyl)-piperazine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha-1 adrenergic receptors ADRA1D NA inhibitor NA drugbank 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD xylometazoline small molecule Respiratory Hypersensitivity[MeSHID:D012130],Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1d adrenergic receptor ADRA1D NA agonist NA drugbank tiospirone NA NA discontinued in phase 3 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD deriglidole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD phenylephrine small molecule Hypotension[MeSHID:D007022],Priapism[MeSHID:D011317],Regional Blood Flow[MeSHID:D012039],Pupil[MeSHID:D011680],Vascular constriction (function)[MeSHID:D014661],Shock[MeSHID:D012769],Eye[MeSHID:D005123],Hemorrhoids[MeSHID:D006484],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid associated opthalmopathies[MeSHID:D049970],Fecal Incontinence[MeSHID:D005242] approved alpha-1d adrenergic receptor ADRA1D NA agonist 0.19 drugbank , DGIDB beta-methoxyamphetamine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD tizanidine small molecule Muscle Spasticity[MeSHID:D009128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational alpha-1 adrenergic receptors ADRA1D NA agonist NA drugbank escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1D NA inhibitor NA drugbank sk&f-105854 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD n-(5-bromo-quinoxalin-6-yl)-guanidine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD imidazolidin-2-ylidene-o-tolyl-amine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD alfuzosin NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1d ADRA1D Successful target unknown 2.71 TTD , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank racepinephrine small molecule Asthma[MeSHID:D001249] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank 4-(3,4-dihydro-1h-isoquinolin-2-yl)-quinoline NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD phenoxybenzamine small molecule Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank 4-(1-naphthalen-1-yl-ethyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD opc-28326 NA Peripheral Vascular Diseases[MeSHID:D016491],Raynaud Disease[MeSHID:D011928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-1 adrenergic receptors ADRA1D NA inhibitor NA drugbank corynantheine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD doxazosin small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA antagonist 2.71 drugbank , DGIDB buspirone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1D NA partial agonist NA drugbank sun-9221 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD r450 small molecule Urinary Incontinence[MeSHID:D014549] investigational alpha-1d adrenergic receptor ADRA1D NA unknown NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-1d adrenergic receptor ADRA1D NA antagonist 0.39 drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank 4-(2,3-dihydro-1h-phenalen-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD gyki-16084 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD synephrine small molecule NA experimental alpha-1 adrenergic receptors ADRA1D NA unknown NA drugbank pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank dobutamine small molecule Heart Decompensation[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Depressed Level of Consciousness[MeSHID:D003244],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved alpha-1 adrenergic receptors ADRA1D NA agonist NA drugbank sunepitron NA NA discontinued in phase 3 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD sk&f-106686 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-1 adrenergic receptors ADRA1D NA inhibitor NA drugbank indigotindisulfonic acid small molecule Ureter[MeSHID:D014513] approved alpha adrenergic receptor ADRA1D NA agonist NA drugbank 4-((e)-1-naphthalen-1-yl-propenyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn alpha-1d adrenergic receptor ADRA1D NA agonist NA drugbank dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1D NA agonist NA drugbank prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1 adrenergic receptors ADRA1D NA antagonist 0.68 drugbank , DGIDB tamsulosin small molecule prostatitis[MeSHID:D011472],Urination[MeSHID:D014554],Ureterolithiasis[MeSHID:D053039],Off-Label Use[MeSHID:D056687],Ureteral Calculi[MeSHID:D014514],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1d adrenergic receptor ADRA1D NA antagonist 2.26 drugbank , DGIDB fenoldopam small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Malignant Hypertension[MeSHID:D006974],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA inhibitor NA drugbank 4-(4-chlorobenzyl)phthalazin-1(2h)-one NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD 4-(4-chlorobenzyl)-2-allylphthalazin-1(2h)-one NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved alpha-1d adrenergic receptor ADRA1D NA partial agonist NA drugbank methoxamine small molecule Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational alpha-1d adrenergic receptor ADRA1D NA binder 1.35 drugbank , DGIDB epinephrine small molecule Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved alpha-1d adrenergic receptor ADRA1D NA antagonist 0.27 drugbank , DGIDB arotinolol small molecule Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],heart rate[MeSHID:D006339],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300] investigational alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank jth-601 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD 4-(4-methyl-indan-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD 1-(pyridin-2-yl)piperazine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD perospirone small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] experimental alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank sl-25.1039 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD (2-bromo-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational alpha-1d adrenergic receptor ADRA1D NA agonist 0.45 drugbank , DGIDB aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental alpha adrenergic receptor ADRA1D NA agonist NA drugbank mazapertine NA NA discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational alpha-1d adrenergic receptor ADRA1D NA unknown NA drugbank quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank 4-(4-isopropyl-morpholin-2-yl)-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD 1',2',3',6'-tetrahydro-[2,4']bipyridinyl NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank 5-bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA antagonist 0.68 drugbank , DGIDB mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved alpha adrenergic receptor ADRA1D NA agonist NA drugbank sou-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD , DGIDB trimazosin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved adrenergic receptor alpha-1d ADRA1D Successful target unknown 1.35 TTD , DGIDB moxisylyte small molecule Arteries[MeSHID:D001158],Disease Management[MeSHID:D019468],Anterior chamber of eye structure[MeSHID:D000867],Thrombus[MeSHID:D013927],Glaucoma[MeSHID:D005901],Mydriasis[MeSHID:D015878],Aqueous Humor[MeSHID:D001082],Trabecular meshwork structure[MeSHID:D014129],Hand[MeSHID:D006225],Pupil[MeSHID:D011680],Lens, Crystalline[MeSHID:D007908],Cerebral Infarction[MeSHID:D002544],Erectile dysfunction[MeSHID:D007172],Precipitating Factors[MeSHID:D015985],Pressure- physical agent[MeSHID:D011312],Angle Closure Glaucoma[MeSHID:D015812],Hemorrhage[MeSHID:D006470],Iris (Eye)[MeSHID:D007498],Eye[MeSHID:D005123],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA1D NA antagonist 0.68 drugbank , DGIDB 1-(3-fluoro-pyridin-2-yl)-4-methyl-piperazine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD phentolamine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Neoplasms[MeSHID:D009369],Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Coronary Artery Vasospasm[MeSHID:D003329],Left-Sided Heart Failure[MeSHID:D006333],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Erectile dysfunction[MeSHID:D007172],Left ventricular structure[MeSHID:D006352],Infarction[MeSHID:D007238],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA antagonist 0.31 drugbank , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank pmid30124346-compound-ldt8 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD , DGIDB agn-192172 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational alpha adrenergic receptor ADRA1D NA agonist NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank midodrine small molecule Hypotension, Orthostatic[MeSHID:D007024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA agonist NA drugbank 6-hydroxy-3-(3',5'-dihydroxyphenyl)coumarin NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1 adrenergic receptors ADRA1D NA unknown 0.68 drugbank , DGIDB imidazolidin-2-ylidene-quinoxalin-6-yl-amine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD 4-benzyl-2-methylphthalazin-1(2h)-one NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD rwj-69736 NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved alpha-1d adrenergic receptor ADRA1D NA agonist 0.59 drugbank , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved alpha-1d adrenergic receptor ADRA1D NA binder NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1 adrenergic receptors ADRA1D NA binder NA drugbank medetomidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown 0.23 TTD , DGIDB prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-1 adrenergic receptors ADRA1D NA unknown 0.68 drugbank , DGIDB ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha adrenergic receptor ADRA1D NA antagonist NA drugbank prochlorperazine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Headache[MeSHID:D006261],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Emergencies [Disease/Finding][MeSHID:D004630],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank pmid30124346-compound-ldt66 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD , DGIDB 2-pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank terazosin NA Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1d ADRA1D Successful target antagonist 0.68 TTD , DGIDB cirazoline small molecule NA experimental alpha-1d adrenergic receptor ADRA1D NA partial agonist NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental alpha adrenergic receptor ADRA1D NA antagonist,agonist NA drugbank levonordefrin NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD rec-15-2739 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD isoclozapine NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-1d adrenergic receptor ADRA1D NA antagonist NA drugbank 4-(3-hydroxy-piperidin-3-yl)-benzene-1,2-diol NA NA investigative adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD alfuzosin NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-1d ADRA1D Successful target antagonist 2.71 TTD , DGIDB fiduxosin hydrochloride NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-1d ADRA1D Successful target unknown NA TTD dihydroergocornine small molecule NA approved alpha adrenergic receptor ADRA1D NA antagonist,agonist NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational alpha-1 adrenergic receptors ADRA1D NA antagonist NA drugbank xylazine small molecule NA vet_approved alpha-2 adrenergic receptors ADRA2A NA agonist 0.49 drugbank , DGIDB 2,3,4,5-tetrahydro-1h-benzo[c]azepine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD guanabenz small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist 1.67 drugbank , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved alpha-2a adrenergic receptor ADRA2A NA antagonist 0.2 drugbank , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA antagonist 0.07 drugbank , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved alpha-2a adrenergic receptor ADRA2A NA unknown NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-2a adrenergic receptor ADRA2A NA antagonist,agonist NA drugbank maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2 adrenergic receptors ADRA2A NA inhibitor NA drugbank methyldopa small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA agonist 0.29 drugbank , DGIDB 8-methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 1,2,3,4-tetrahydro-benzo[h]isoquinolin-8-ol NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD (3-ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD (1h-imidazol-2-yl)-quinoxalin-6-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-2a adrenergic receptor ADRA2A NA antagonist 0.51 drugbank , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-2a adrenergic receptor ADRA2A NA antagonist 0.69 drugbank , DGIDB levonordefrin small molecule NA approved alpha-2 adrenergic receptors ADRA2A NA agonist 0.12 drugbank , DGIDB 4-(1-naphthalen-1-yl-ethyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD gnf-pf-2857 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved alpha-2a adrenergic receptor ADRA2A NA agonist 0.42 drugbank , DGIDB dsp-1200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] phase 1 adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD , DGIDB epinephrine small molecule Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved alpha-2a adrenergic receptor ADRA2A NA agonist 0.25 drugbank , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank (3-methyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 4-benzo[b]thiophen-4-yl-1h-imidazole NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank benzphetamine small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit alpha-2a adrenergic receptor ADRA2A NA agonist 1.23 drugbank , DGIDB brimonidine small molecule Rosacea[MeSHID:D012393],Glaucoma, Open-Angle[MeSHID:D005902],Erythema[MeSHID:D004890],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved alpha-2a adrenergic receptor ADRA2A NA agonist 0.9 drugbank , DGIDB dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit alpha adrenergic receptor ADRA2A NA inhibitor,inducer NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational alpha adrenergic receptor ADRA2A NA antagonist NA drugbank tizanidine small molecule Muscle Spasticity[MeSHID:D009128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational alpha-2 adrenergic receptors ADRA2A NA agonist 1.3 drugbank , DGIDB sk&f-29661 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD beta-methoxyamphetamine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD dexmedetomidine small molecule Environmental air flow[MeSHID:D014691],intensive care[MeSHID:D003422],Anxiety Disorders[MeSHID:D001008],Pain[MeSHID:D010146],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,vet_approved alpha-2a adrenergic receptor ADRA2A NA agonist 1.11 drugbank , DGIDB lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist 0.09 drugbank , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist,partial agonist 0.56 drugbank , DGIDB (1,2,3,4-tetrahydro-isoquinolin-3-yl)-methanol NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD dipivefrin small molecule Glaucoma, Open-Angle[MeSHID:D005902],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA agonist 1.85 drugbank , DGIDB 1,2,3,4-tetrahydroisoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD celiprolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank phentolamine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Neoplasms[MeSHID:D009369],Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Coronary Artery Vasospasm[MeSHID:D003329],Left-Sided Heart Failure[MeSHID:D006333],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Erectile dysfunction[MeSHID:D007172],Left ventricular structure[MeSHID:D006352],Infarction[MeSHID:D007238],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA antagonist 0.74 drugbank , DGIDB snap-5150 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD clonidine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Malignant Neoplasms[MeSHID:D009369],Attention deficit hyperactivity disorder[MeSHID:D001289],Nicotine Dependence[MeSHID:D014029],Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved alpha-2a adrenergic receptor ADRA2A NA agonist 1.04 drugbank , DGIDB 2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD flupirtine small molecule Fibromyalgia[MeSHID:D005356],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] investigational alpha-2a adrenergic receptor ADRA2A NA unknown NA drugbank lurasidone small molecule Schizophrenia[MeSHID:D012559] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist 0.25 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank dihydroergocornine small molecule NA approved alpha adrenergic receptor ADRA2A NA antagonist,agonist NA drugbank lofexidine small molecule Disease Management[MeSHID:D019468],Abdominal Pain[MeSHID:D015746],Opiate Addiction[MeSHID:D009293],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Diarrhea[MeSHID:D003967],Mydriasis[MeSHID:D015878],Piloerection[MeSHID:D010863],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist 1.3 drugbank , DGIDB (+/-)-nantenine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2A NA inducer NA drugbank lofexidine NA Disease Management[MeSHID:D019468],Abdominal Pain[MeSHID:D015746],Opiate Addiction[MeSHID:D009293],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Diarrhea[MeSHID:D003967],Mydriasis[MeSHID:D015878],Piloerection[MeSHID:D010863],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-2a ADRA2A Successful target agonist 1.3 TTD , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank butyl-indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD cirazoline small molecule NA experimental alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank 1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 7-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD rilmenidine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational alpha-2a adrenergic receptor ADRA2A NA unknown NA drugbank periciazine small molecule Aggressive behavior[MeSHID:D000374],Impulsive Behavior[MeSHID:D007175],Hostility[MeSHID:D006791] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank (1h-benzoimidazol-5-yl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD phenoxybenzamine small molecule Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank 4-(4-methyl-indan-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha adrenergic receptor ADRA2A NA antagonist,agonist NA drugbank , DGIDB setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental alpha adrenergic receptor ADRA2A NA agonist NA drugbank piperoxan NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD (2-bromo-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-2a adrenergic receptor ADRA2A NA unknown NA drugbank akuammigine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist 0.14 drugbank , DGIDB pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved alpha-2a adrenergic receptor ADRA2A NA partial agonist NA drugbank tracizoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD dl-methylephedrine small molecule NA approved alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank gnf-pf-3878 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2A NA binder NA drugbank etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank 1-(pyridin-2-yl)piperazine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank c-naphthalen-1-yl-methylamine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD indol-1-yl-methyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD mazapertine NA NA discontinued in phase 2 adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA binder NA drugbank bethanidine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved alpha-2 adrenergic receptors ADRA2A NA agonist 0.37 drugbank , DGIDB moxonidine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist 1.48 drugbank , DGIDB zuclopenthixol small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Manic[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Behavior[MeSHID:D001519],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank epicept np-1 small molecule Pain[MeSHID:D010146] investigational alpha-2a adrenergic receptor ADRA2A NA unknown NA drugbank prochlorperazine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Headache[MeSHID:D006261],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Emergencies [Disease/Finding][MeSHID:D004630],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank tolazoline small molecule Pulmonary artery structure[MeSHID:D011651],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] approved,vet_approved alpha-2a adrenergic receptor ADRA2A NA antagonist 0.3 drugbank , DGIDB 2,3-dihydro-1h-isoindole NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD r-226161 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD moxonidine NA Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved adrenergic receptor alpha-2a ADRA2A Successful target unknown 1.48 TTD , DGIDB 6,7,8,9-tetrahydro-5-thia-8-aza-benzocycloheptene NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD phenylpropanolamine small molecule Urinary Incontinence[MeSHID:D014549],Obesity[MeSHID:D009765],Priapism[MeSHID:D011317],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved,withdrawn alpha-2 adrenergic receptors ADRA2A NA unknown 1.85 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA2A NA antagonist NA drugbank s-34324 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental alpha adrenergic receptor ADRA2A NA antagonist,agonist NA drugbank apraclonidine small molecule Vision[MeSHID:D014785],Term Birth[MeSHID:D047929],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypotension[MeSHID:D015814],Eye[MeSHID:D005123],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA agonist 5.55 drugbank , DGIDB tramazoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD [3h]rx821002 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target antagonist NA TTD , DGIDB tryptoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational alpha-2 adrenergic receptors ADRA2A NA binder NA drugbank 2-bfi NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD methylnoradrenaline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA inhibitor NA drugbank 3-methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD trazodone small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist 0.32 drugbank , DGIDB ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha adrenergic receptor ADRA2A NA antagonist NA drugbank racepinephrine small molecule Asthma[MeSHID:D001249] approved alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank 3-methoxymethyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 1-((s)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational alpha adrenergic receptor ADRA2A NA agonist 0.05 drugbank , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank xylometazoline small molecule Respiratory Hypersensitivity[MeSHID:D012130],Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank medetomidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 adrenergic receptor alpha-2a ADRA2A Successful target unknown 0.12 TTD , DGIDB chloroethylclonidine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved alpha adrenergic receptor ADRA2A NA agonist NA drugbank 5-aminomethyl-naphthalen-2-ol NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD lofexidine NA Disease Management[MeSHID:D019468],Abdominal Pain[MeSHID:D015746],Opiate Addiction[MeSHID:D009293],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Diarrhea[MeSHID:D003967],Mydriasis[MeSHID:D015878],Piloerection[MeSHID:D010863],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-2a ADRA2A Successful target unknown 1.3 TTD , DGIDB 3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 2,3,4,5-tetrahydro-1h-benzo[e][1,4]diazepine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 1-(3-fluoro-pyridin-2-yl)-4-methyl-piperazine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-2 adrenergic receptors ADRA2A NA inhibitor,antagonist 0.05 drugbank , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist 0.37 drugbank , DGIDB (s)-3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD esmirtazapine small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319] investigational alpha-2 adrenergic receptors ADRA2A NA antagonist 0.49 drugbank , DGIDB naphazoline small molecule Vascular constriction (function)[MeSHID:D014661],Nose[MeSHID:D009666],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Hyperemia[MeSHID:D006940],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank mezilamine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD connexyn NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] approved adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD , DGIDB ar-129330 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 4-methoxyamphetamine small molecule NA experimental,illicit alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank jp1302 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA unknown NA drugbank pirlindole small molecule Major Depressive Disorder[MeSHID:D003865],Hypertensive disease[MeSHID:D006973],Unipolar Depression[MeSHID:D003866],Psychological inhibition[MeSHID:D007266],Headache[MeSHID:D006261],Patient Care Management[MeSHID:D010346],Fibromyalgia[MeSHID:D005356],Genetic Selection[MeSHID:D012641],Pain Disorder[MeSHID:D013001],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Syndrome[MeSHID:D013577] experimental alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank (r)-3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD (2-methyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 1,2,3,4-tetrahydro-isoquinolin-7-ol NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 7-nitro-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-2 adrenergic receptors ADRA2A NA antagonist NA drugbank sk&f-64139 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational alpha-2a adrenergic receptor ADRA2A NA unknown NA drugbank 1',2',3',6'-tetrahydro-[2,4']bipyridinyl NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-2a adrenergic receptor ADRA2A NA binder,antagonist 0.25 drugbank , DGIDB bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist,antagonist 0.11 drugbank , DGIDB ethyl-indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD tetryzoline small molecule Lubricants[MeSHID:D054327],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Nose[MeSHID:D009666],Mucous Membrane[MeSHID:D009092],Nasopharynx[MeSHID:D009305] approved alpha-2 adrenergic receptors ADRA2A NA agonist NA drugbank c-(6-methoxy-naphthalen-1-yl)-methylamine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD (2,6-dichloro-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD moxisylyte small molecule Arteries[MeSHID:D001158],Disease Management[MeSHID:D019468],Anterior chamber of eye structure[MeSHID:D000867],Thrombus[MeSHID:D013927],Glaucoma[MeSHID:D005901],Mydriasis[MeSHID:D015878],Aqueous Humor[MeSHID:D001082],Trabecular meshwork structure[MeSHID:D014129],Hand[MeSHID:D006225],Pupil[MeSHID:D011680],Lens, Crystalline[MeSHID:D007908],Cerebral Infarction[MeSHID:D002544],Erectile dysfunction[MeSHID:D007172],Precipitating Factors[MeSHID:D015985],Pressure- physical agent[MeSHID:D011312],Angle Closure Glaucoma[MeSHID:D015812],Hemorrhage[MeSHID:D006470],Iris (Eye)[MeSHID:D007498],Eye[MeSHID:D005123],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA2A NA antagonist NA drugbank epinastine small molecule Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA unknown NA drugbank dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2A NA agonist NA drugbank 3-fluoromethyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD fenoldopam small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Malignant Hypertension[MeSHID:D006974],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA antagonist 0.33 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha-2 adrenergic receptors ADRA2A NA inhibitor,antagonist 0.05 drugbank , DGIDB pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn alpha-2 adrenergic receptors ADRA2A NA agonist 0.15 drugbank , DGIDB indigotindisulfonic acid small molecule Ureter[MeSHID:D014513] approved alpha adrenergic receptor ADRA2A NA agonist NA drugbank ciproxifan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD 1,2,3,4,5,6-hexahydro-benzo[c]azocine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA binder,antagonist 0.25 drugbank , DGIDB guanfacine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist 0.95 drugbank , DGIDB pramipexole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist NA drugbank nmi-870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-2a ADRA2A Successful target unknown NA TTD nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn alpha-2a adrenergic receptor ADRA2A NA antagonist NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2a adrenergic receptor ADRA2A NA agonist 0.22 drugbank , DGIDB apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2a adrenergic receptor ADRA2A NA agonist 0.07 drugbank , DGIDB dl-methylephedrine small molecule NA approved alpha adrenergic receptor ADRA2A NA agonist NA drugbank brl 44408 NA NA investigative adrenergic receptor alpha-2a ADRA2A Successful target antagonist NA TTD , DGIDB 1-(pyridin-2-yl)piperazine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2B NA agonist NA drugbank 1',2',3',6'-tetrahydro-[2,4']bipyridinyl NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank dl-methylephedrine small molecule NA approved alpha adrenergic receptor ADRA2B NA agonist NA drugbank escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2 adrenergic receptors ADRA2B NA inhibitor NA drugbank prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved alpha-2b adrenergic receptor ADRA2B NA binder,antagonist 0.45 drugbank , DGIDB c-naphthalen-1-yl-methylamine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD rotigotine small molecule Restless Legs Syndrome[MeSHID:D012148],Parkinson Disease[MeSHID:D010300] approved alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank indoramin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] withdrawn from market adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2b adrenergic receptor ADRA2B NA agonist,antagonist 0.08 drugbank , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA binder NA drugbank epinephrine small molecule Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved alpha-2b adrenergic receptor ADRA2B NA agonist 0.27 drugbank , DGIDB snap-5150 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD medetomidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 adrenergic receptor alpha-2b ADRA2B Successful target unknown 0.15 TTD , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA antagonist 0.09 drugbank , DGIDB 3-fluoromethyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD apraclonidine small molecule Vision[MeSHID:D014785],Term Birth[MeSHID:D047929],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypotension[MeSHID:D015814],Eye[MeSHID:D005123],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA agonist NA drugbank brimonidine small molecule Rosacea[MeSHID:D012393],Glaucoma, Open-Angle[MeSHID:D005902],Erythema[MeSHID:D004890],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved alpha-2b adrenergic receptor ADRA2B NA agonist 0.51 drugbank , DGIDB 4-(1-naphthalen-1-yl-ethyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved alpha-2b adrenergic receptor ADRA2B NA unknown NA drugbank celiprolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787] approved,investigational alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank phenoxybenzamine small molecule Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved alpha-2b adrenergic receptor ADRA2B NA antagonist 0.23 drugbank , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank esmirtazapine small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319] investigational alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank c-(6-methoxy-naphthalen-1-yl)-methylamine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-2 adrenergic receptors ADRA2B NA inhibitor,antagonist 0.03 drugbank , DGIDB 2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved alpha-2b adrenergic receptor ADRA2B NA agonist 0.4 drugbank , DGIDB moxisylyte small molecule Arteries[MeSHID:D001158],Disease Management[MeSHID:D019468],Anterior chamber of eye structure[MeSHID:D000867],Thrombus[MeSHID:D013927],Glaucoma[MeSHID:D005901],Mydriasis[MeSHID:D015878],Aqueous Humor[MeSHID:D001082],Trabecular meshwork structure[MeSHID:D014129],Hand[MeSHID:D006225],Pupil[MeSHID:D011680],Lens, Crystalline[MeSHID:D007908],Cerebral Infarction[MeSHID:D002544],Erectile dysfunction[MeSHID:D007172],Precipitating Factors[MeSHID:D015985],Pressure- physical agent[MeSHID:D011312],Angle Closure Glaucoma[MeSHID:D015812],Hemorrhage[MeSHID:D006470],Iris (Eye)[MeSHID:D007498],Eye[MeSHID:D005123],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA2B NA antagonist NA drugbank bethanidine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved alpha-2 adrenergic receptors ADRA2B NA agonist 0.23 drugbank , DGIDB sk&f-64139 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD (s)-3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn alpha-2 adrenergic receptors ADRA2B NA agonist 0.18 drugbank , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank fenoldopam small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Malignant Hypertension[MeSHID:D006974],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA antagonist 0.4 drugbank , DGIDB racepinephrine small molecule Asthma[MeSHID:D001249] approved alpha-2b adrenergic receptor ADRA2B NA agonist NA drugbank 1,2,3,4-tetrahydro-benzo[h]isoquinolin-8-ol NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD ethyl-indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD guanabenz small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2b adrenergic receptor ADRA2B NA binder,agonist 0.45 drugbank , DGIDB agn-199981 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD , DGIDB risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank prochlorperazine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Headache[MeSHID:D006261],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Emergencies [Disease/Finding][MeSHID:D004630],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA2B NA antagonist NA drugbank bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha-2b adrenergic receptor ADRA2B NA agonist,antagonist 0.13 drugbank , DGIDB [3h]rx821002 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target antagonist NA TTD , DGIDB (r)-3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD 1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-2b adrenergic receptor ADRA2B NA unknown NA drugbank nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational alpha adrenergic receptor ADRA2B NA antagonist NA drugbank dihydroergocornine small molecule NA approved alpha adrenergic receptor ADRA2B NA antagonist,agonist NA drugbank 2,3-dihydro-1h-isoindole NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD (3-ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank 4-benzo[b]thiophen-4-yl-1h-imidazole NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD tizanidine small molecule Muscle Spasticity[MeSHID:D009128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational alpha-2 adrenergic receptors ADRA2B NA agonist 0.45 drugbank , DGIDB tramazoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD gnf-pf-2857 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2b adrenergic receptor ADRA2B NA agonist 0.45 drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank phenylpropanolamine small molecule Urinary Incontinence[MeSHID:D014549],Obesity[MeSHID:D009765],Priapism[MeSHID:D011317],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved,withdrawn alpha-2 adrenergic receptors ADRA2B NA unknown NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank indigotindisulfonic acid small molecule Ureter[MeSHID:D014513] approved alpha adrenergic receptor ADRA2B NA agonist NA drugbank 2-bfi NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved alpha-2b adrenergic receptor ADRA2B NA antagonist 0.3 drugbank , DGIDB amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational alpha adrenergic receptor ADRA2B NA agonist NA drugbank opc-28326 small molecule Peripheral Vascular Diseases[MeSHID:D016491],Raynaud Disease[MeSHID:D011928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational alpha-2b adrenergic receptor ADRA2B NA unknown NA drugbank , DGIDB etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA agonist 0.21 drugbank , DGIDB tolazoline small molecule Pulmonary artery structure[MeSHID:D011651],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] approved,vet_approved alpha-2b adrenergic receptor ADRA2B NA binder,antagonist 0.36 drugbank , DGIDB s-34324 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD indol-1-yl-methyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD (3-methyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD 1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA unknown NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha adrenergic receptor ADRA2B NA antagonist,agonist NA drugbank indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-2b adrenergic receptor ADRA2B NA antagonist 0.65 drugbank , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2B NA binder NA drugbank piperoxan NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational alpha-2b adrenergic receptor ADRA2B NA antagonist,ligand NA drugbank 7-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD tryptoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD r-226161 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD spiroxatrine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target antagonist 0.09 TTD , DGIDB dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit alpha adrenergic receptor ADRA2B NA inhibitor,inducer NA drugbank 1,2,3,4-tetrahydroisoquinoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha-2 adrenergic receptors ADRA2B NA inhibitor,antagonist 0.03 drugbank , DGIDB metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit alpha-2b adrenergic receptor ADRA2B NA agonist NA drugbank xylazine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target agonist 0.3 TTD , DGIDB ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational alpha-2b adrenergic receptor ADRA2B NA unknown NA drugbank ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical alpha-2b adrenergic receptor ADRA2B NA agonist NA drugbank gnf-pf-3878 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha adrenergic receptor ADRA2B NA antagonist NA drugbank (+/-)-nantenine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD [3h]rauwolscine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target antagonist NA TTD , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank tracizoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD mezilamine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD butyl-indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-2b adrenergic receptor ADRA2B NA unknown NA drugbank 8-methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD (2-methyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental alpha adrenergic receptor ADRA2B NA agonist NA drugbank lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational alpha-2b adrenergic receptor ADRA2B NA antagonist 0.11 drugbank , DGIDB prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA binder,antagonist 0.45 drugbank , DGIDB etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank 6,7,8,9-tetrahydro-5-thia-8-aza-benzocycloheptene NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank tetryzoline small molecule Lubricants[MeSHID:D054327],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Nose[MeSHID:D009666],Mucous Membrane[MeSHID:D009092],Nasopharynx[MeSHID:D009305] approved alpha-2 adrenergic receptors ADRA2B NA agonist NA drugbank [3h]mk-912 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target antagonist NA TTD , DGIDB imiloxan NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD xylometazoline small molecule Respiratory Hypersensitivity[MeSHID:D012130],Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2b adrenergic receptor ADRA2B NA agonist NA drugbank 1-(3-fluoro-pyridin-2-yl)-4-methyl-piperazine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD levonordefrin small molecule NA approved alpha-2 adrenergic receptors ADRA2B NA agonist 0.08 drugbank , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational alpha-2 adrenergic receptors ADRA2B NA binder NA drugbank methylnoradrenaline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD 3-methoxymethyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD 4-(4-methyl-indan-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD clonidine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Malignant Neoplasms[MeSHID:D009369],Attention deficit hyperactivity disorder[MeSHID:D001289],Nicotine Dependence[MeSHID:D014029],Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved alpha-2b adrenergic receptor ADRA2B NA agonist 0.45 drugbank , DGIDB jp1302 NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD epicept np-1 small molecule Pain[MeSHID:D010146] investigational alpha-2b adrenergic receptor ADRA2B NA unknown NA drugbank 1,2,3,4-tetrahydro-isoquinolin-7-ol NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD moxonidine NA Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved adrenergic receptor alpha-2b ADRA2B Successful target unknown 0.3 TTD , DGIDB 2,3,4,5-tetrahydro-1h-benzo[e][1,4]diazepine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved alpha adrenergic receptor ADRA2B NA agonist NA drugbank 3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD guanfacine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289] approved,investigational alpha-2b adrenergic receptor ADRA2B NA binder,agonist 0.26 drugbank , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2b adrenergic receptor ADRA2B NA antagonist NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental alpha adrenergic receptor ADRA2B NA antagonist,agonist NA drugbank tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2B NA inducer NA drugbank (1,2,3,4-tetrahydro-isoquinolin-3-yl)-methanol NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD 1,2,3,4,5,6-hexahydro-benzo[c]azocine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD xylazine small molecule NA vet_approved alpha-2 adrenergic receptors ADRA2B NA agonist 0.3 drugbank , DGIDB 2,3,4,5-tetrahydro-1h-benzo[c]azepine NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD mazapertine NA NA discontinued in phase 2 adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD cirazoline small molecule NA experimental alpha-2 adrenergic receptors ADRA2B NA antagonist NA drugbank 5-aminomethyl-naphthalen-2-ol NA NA investigative adrenergic receptor alpha-2b ADRA2B Successful target unknown NA TTD oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational alpha-2b adrenergic receptor ADRA2B NA agonist 0.23 drugbank , DGIDB tracizoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 1,2,3,4-tetrahydroisoquinoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha adrenergic receptor ADRA2C NA antagonist,agonist NA drugbank 5-(n,n-hexamethylene)-amiloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] preclinical adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 8-methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD (2-methyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha-2c adrenergic receptor ADRA2C NA agonist,antagonist 0.11 drugbank , DGIDB opc-28326 small molecule Peripheral Vascular Diseases[MeSHID:D016491],Raynaud Disease[MeSHID:D011928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational alpha-2c adrenergic receptor ADRA2C NA unknown NA drugbank , DGIDB racepinephrine small molecule Asthma[MeSHID:D001249] approved alpha-2c adrenergic receptor ADRA2C NA agonist NA drugbank c-naphthalen-1-yl-methylamine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit alpha-2c adrenergic receptor ADRA2C NA agonist NA drugbank (2,6-dichloro-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD medetomidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.13 TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist, NA drugbank agmatine small molecule Diabetes Mellitus[MeSHID:D003920],Small Fiber Neuropathy[MeSHID:D000071075],Neuroprotection[MeSHID:D000066829],Glaucoma[MeSHID:D005901],Diagnosis[MeSHID:D003933],Epilepsy[MeSHID:D004827],Kidney[MeSHID:D007668],Anxiety Disorders[MeSHID:D001008],Blind Vision[MeSHID:D001766],Mental Depression[MeSHID:D003863],Cognition[MeSHID:D003071],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Traumatic injury[MeSHID:D014947],Cerebrovascular accident[MeSHID:D020521],Anxiety[MeSHID:D001007] experimental alpha-2c adrenergic receptor ADRA2C NA agonist NA drugbank [3h]rauwolscine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target antagonist NA TTD , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank idazoxan hydrochloride NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD , DGIDB a61603 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational alpha adrenergic receptor ADRA2C NA antagonist NA drugbank [3h]mk-912 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target antagonist NA TTD , DGIDB butyl-indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA unknown NA drugbank lurasidone small molecule Schizophrenia[MeSHID:D012559] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist 0.38 drugbank , DGIDB tramazoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved alpha adrenergic receptor ADRA2C NA agonist NA drugbank (1,2,3,4-tetrahydro-isoquinolin-3-yl)-methanol NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD skf 89748 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD fluparoxan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] discontinued in phase 3 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD nmi-870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD gyki-16084 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD tnx-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Post-Traumatic Stress Disorder[MeSHID:D013313],Fibromyalgia[MeSHID:D005356] phase 3 adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.15 TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank 2-bfi NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD chloroethylclonidine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD fenoldopam small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Malignant Hypertension[MeSHID:D006974],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA antagonist 0.34 drugbank , DGIDB prochlorperazine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Headache[MeSHID:D006261],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Emergencies [Disease/Finding][MeSHID:D004630],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank phenylpropanolamine small molecule Urinary Incontinence[MeSHID:D014549],Obesity[MeSHID:D009765],Priapism[MeSHID:D011317],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved,withdrawn alpha-2 adrenergic receptors ADRA2C NA unknown NA drugbank brimonidine NA Rosacea[MeSHID:D012393],Glaucoma, Open-Angle[MeSHID:D005902],Erythema[MeSHID:D004890],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved adrenergic receptor alpha-2c ADRA2C Successful target agonist 0.68 TTD , DGIDB lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist 0.1 drugbank , DGIDB 1,2,3,4,5,6-hexahydro-benzo[c]azocine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD tizanidine small molecule Muscle Spasticity[MeSHID:D009128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational alpha-2 adrenergic receptors ADRA2C NA agonist 0.38 drugbank , DGIDB v-103 NA Contusions[MeSHID:D003288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD sk&f-64139 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational alpha adrenergic receptor ADRA2C NA agonist NA drugbank gnf-pf-2857 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2c adrenergic receptor ADRA2C NA agonist,antagonist 0.07 drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank brexpiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit alpha adrenergic receptor ADRA2C NA inhibitor,inducer NA drugbank 3-methoxymethyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD brimonidine NA Rosacea[MeSHID:D012393],Glaucoma, Open-Angle[MeSHID:D005902],Erythema[MeSHID:D004890],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.68 TTD , DGIDB pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank nolomirole hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] discontinued in phase 3 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD brimonidine small molecule Rosacea[MeSHID:D012393],Glaucoma, Open-Angle[MeSHID:D005902],Erythema[MeSHID:D004890],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved alpha-2c adrenergic receptor ADRA2C NA agonist 0.68 drugbank , DGIDB gyki-12743 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD (1h-benzoimidazol-5-yl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD dl-methylephedrine small molecule NA approved alpha adrenergic receptor ADRA2C NA agonist NA drugbank orm-12741 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.77 TTD , DGIDB ethyl-indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD xylometazoline NA Respiratory Hypersensitivity[MeSHID:D012130],Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 4 adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.77 TTD , DGIDB epicept np-1 small molecule Pain[MeSHID:D010146] investigational alpha-2c adrenergic receptor ADRA2C NA unknown NA drugbank indoramin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] withdrawn from market adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved alpha-2c adrenergic receptor ADRA2C NA agonist 0.33 drugbank , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank jp1302 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target antagonist NA TTD , DGIDB indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD indigotindisulfonic acid small molecule Ureter[MeSHID:D014513] approved alpha adrenergic receptor ADRA2C NA agonist NA drugbank c-(6-methoxy-naphthalen-1-yl)-methylamine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD dihydroergocornine small molecule NA approved alpha adrenergic receptor ADRA2C NA antagonist,agonist NA drugbank methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank amosulalol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.38 TTD , DGIDB aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental alpha adrenergic receptor ADRA2C NA agonist NA drugbank sgb-1534 NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD (+/-)-nantenine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD r-226161 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD celiprolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank 6-fluoro-noradrenaline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD (3-methyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA binder NA drugbank tetryzoline small molecule Lubricants[MeSHID:D054327],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Nose[MeSHID:D009666],Mucous Membrane[MeSHID:D009092],Nasopharynx[MeSHID:D009305] approved alpha-2 adrenergic receptors ADRA2C NA agonist NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha-2 adrenergic receptors ADRA2C NA inhibitor,antagonist 0.02 drugbank , DGIDB 2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD tryptoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD [125i]heat NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD moxonidine NA Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.26 TTD , DGIDB iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA antagonist 0.05 drugbank , DGIDB esmirtazapine small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319] investigational alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank v-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erythema[MeSHID:D004890] phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.77 TTD , DGIDB ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved alpha-2c adrenergic receptor ADRA2C NA unknown NA drugbank 3-fluoromethyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD ethoxy-idazoxan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational alpha-2 adrenergic receptors ADRA2C NA binder NA drugbank asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA antagonist 0.08 drugbank , DGIDB setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank indol-1-yl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational alpha adrenergic receptor ADRA2C NA antagonist NA drugbank mazapertine NA NA discontinued in phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD [125i]be-2254 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD (s)-3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-2c adrenergic receptor ADRA2C NA antagonist 0.55 drugbank , DGIDB xylometazoline small molecule Respiratory Hypersensitivity[MeSHID:D012130],Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2c adrenergic receptor ADRA2C NA agonist 0.77 drugbank , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved alpha-2c adrenergic receptor ADRA2C NA antagonist 0.2 drugbank , DGIDB spiroxatrine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target antagonist 0.08 TTD , DGIDB tetrahydrozoline NA Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.77 TTD , DGIDB 2,3-dihydro-1h-isoindole NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD rilmenidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.26 TTD , DGIDB 5-methylurapidil NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD piribedil NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target antagonist 0.06 TTD , DGIDB levonordefrin small molecule NA approved alpha-2 adrenergic receptors ADRA2C NA agonist 0.06 drugbank , DGIDB gnf-pf-3878 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD moxisylyte small molecule Arteries[MeSHID:D001158],Disease Management[MeSHID:D019468],Anterior chamber of eye structure[MeSHID:D000867],Thrombus[MeSHID:D013927],Glaucoma[MeSHID:D005901],Mydriasis[MeSHID:D015878],Aqueous Humor[MeSHID:D001082],Trabecular meshwork structure[MeSHID:D014129],Hand[MeSHID:D006225],Pupil[MeSHID:D011680],Lens, Crystalline[MeSHID:D007908],Cerebral Infarction[MeSHID:D002544],Erectile dysfunction[MeSHID:D007172],Precipitating Factors[MeSHID:D015985],Pressure- physical agent[MeSHID:D011312],Angle Closure Glaucoma[MeSHID:D015812],Hemorrhage[MeSHID:D006470],Iris (Eye)[MeSHID:D007498],Eye[MeSHID:D005123],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA2C NA antagonist NA drugbank 1-((s)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD snap-5150 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD methylnoradrenaline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 7-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD deriglidole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD all-trans-4-oxo-retinoic acid NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target antagonist NA TTD , DGIDB indanidine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD conessine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD bay1193397 NA Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral Vascular Diseases[MeSHID:D016491] phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD , DGIDB 2,3,4,5-tetrahydro-1h-benzo[e][1,4]diazepine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 6,7,8,9-tetrahydro-5-thia-8-aza-benzocycloheptene NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 1,2,3,4-tetrahydro-isoquinolin-7-ol NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD xylazine small molecule NA vet_approved alpha-2 adrenergic receptors ADRA2C NA agonist 0.26 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha adrenergic receptor ADRA2C NA antagonist NA drugbank fadolmidine NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.38 TTD , DGIDB tolazoline small molecule Pulmonary artery structure[MeSHID:D011651],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] approved,vet_approved alpha-2c adrenergic receptor ADRA2C NA binder,antagonist 0.31 drugbank , DGIDB ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical alpha-2c adrenergic receptor ADRA2C NA agonist NA drugbank (3-ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD propylhexedrine NA Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] approved adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.77 TTD , DGIDB etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2C NA binder NA drugbank paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA agonist NA drugbank bethanidine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved alpha-2 adrenergic receptors ADRA2C NA agonist 0.19 drugbank , DGIDB clonidine small molecule Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Malignant Neoplasms[MeSHID:D009369],Attention deficit hyperactivity disorder[MeSHID:D001289],Nicotine Dependence[MeSHID:D014029],Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved alpha-2c adrenergic receptor ADRA2C NA agonist 0.46 drugbank , DGIDB [3h]rx821002 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target antagonist NA TTD , DGIDB 3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD ecabapide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] discontinued in preregistration adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD indol-1-yl-methyl-pyridin-4-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank mezilamine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD dihydroergocristine NA Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.19 TTD , DGIDB 4-(1-naphthalen-1-yl-ethyl)-1h-imidazole NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD xylazine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target agonist 0.26 TTD , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2C NA agonist NA drugbank tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2 adrenergic receptors ADRA2C NA inducer NA drugbank escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2 adrenergic receptors ADRA2C NA inhibitor NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental alpha adrenergic receptor ADRA2C NA antagonist,agonist 0.19 drugbank , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank amezinium NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor alpha-2c ADRA2C Successful target unknown 0.77 TTD , DGIDB pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn alpha-2 adrenergic receptors ADRA2C NA agonist 0.15 drugbank , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational alpha-2c adrenergic receptor ADRA2C NA unknown NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha-2 adrenergic receptors ADRA2C NA inhibitor,antagonist 0.02 drugbank , DGIDB jth-601 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD (r)-3-methyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2c adrenergic receptor ADRA2C NA agonist 0.38 drugbank , DGIDB risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational alpha-2c adrenergic receptor ADRA2C NA agonist 0.13 drugbank , DGIDB (2-bromo-phenyl)-(1h-imidazol-2-yl)-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 4-(4-methyl-indan-1-yl)-1h-imidazole NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD s-34324 NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational alpha-2c adrenergic receptor ADRA2C NA unknown NA drugbank piperoxan NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank ciproxifan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD (1h-imidazol-2-yl)-quinoxalin-6-yl-amine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD amidephrine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD cirazoline small molecule NA experimental alpha-2 adrenergic receptors ADRA2C NA antagonist NA drugbank 5-aminomethyl-naphthalen-2-ol NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 1,2,3,4-tetrahydro-benzo[h]isoquinolin-8-ol NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD phenoxybenzamine small molecule Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved alpha-2c adrenergic receptor ADRA2C NA antagonist NA drugbank haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved alpha-2c adrenergic receptor ADRA2C NA unknown NA drugbank mk-912 NA NA discontinued in phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD cirazoline NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD delequamine hydrochloride NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD 2,3,4,5-tetrahydro-1h-benzo[c]azepine NA NA investigative adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD agn-xx/yy NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] phase 2 adrenergic receptor alpha-2c ADRA2C Successful target unknown NA TTD , DGIDB ephedrine small molecule Asthma[MeSHID:D001249],Nose[MeSHID:D009666],Hypotension[MeSHID:D007022],Bronchial Diseases[MeSHID:D001982],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank 2-hydroxymethyl-6-octylsulfanyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental beta-1 adrenergic receptor ADRB1 NA unknown NA drugbank norepinephrine NA Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.27 TTD , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist 0.95 drugbank , DGIDB bucindolol NA Atrial Fibrillation[MeSHID:D001281],Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 adrenergic receptor beta-1 ADRB1 Successful target unknown 4.38 TTD , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB1 NA inhibitor NA drugbank epinephrine small molecule Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved beta-1 adrenergic receptor ADRB1 NA agonist 0.23 drugbank , DGIDB bufuralol small molecule NA experimental beta adrenergic receptor ADRB1 NA antagonist 2.08 drugbank , DGIDB nadolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 1.8 drugbank , DGIDB droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA agonist 0.35 drugbank , DGIDB ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational beta-1 adrenergic receptor ADRB1 NA ligand NA drugbank carteolol small molecule Hypertensive disease[MeSHID:D006973],Glaucoma, Open-Angle[MeSHID:D005902],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved beta-1 adrenergic receptor ADRB1 NA partial agonist 3.11 drugbank , DGIDB propafenone small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Diseases[MeSHID:D006331],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 0.13 drugbank , DGIDB atenolol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Disease Management[MeSHID:D019468],Hypertensive disease[MeSHID:D006973],Cardiac Arrhythmia[MeSHID:D001145],Systolic Pressure[MeSHID:D001794],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Thyrotoxicosis[MeSHID:D013971],Supraventricular tachycardia[MeSHID:D013617],heart rate[MeSHID:D006339],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Arrhythmogenic Right Ventricular Dysplasia[MeSHID:D019571],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 0.61 drugbank , DGIDB betaxolol NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 3.81 TTD , DGIDB dihydroergocornine small molecule NA approved beta adrenergic receptor ADRB1 NA antagonist,agonist NA drugbank bretylium NA Ventricular Fibrillation[MeSHID:D014693],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.69 TTD , DGIDB acebutolol NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Premature ventricular contractions[MeSHID:D018879],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 3.81 TTD , DGIDB levobetaxolol small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist 0.69 drugbank , DGIDB dobutamine NA Heart Decompensation[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Depressed Level of Consciousness[MeSHID:D003244],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 2.54 TTD , DGIDB clenbuterol small molecule Asthma[MeSHID:D001249],Chronic disease[MeSHID:D002908],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank salbutamol small molecule Bronchial Spasm[MeSHID:D001986],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Lung Diseases, Obstructive[MeSHID:D008173],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank labetalol small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 0.59 drugbank , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB1 NA inhibitor,partial agonist 1.5 drugbank , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA partial agonist,agonist 1.5 drugbank , DGIDB pirbuterol small molecule Asthma[MeSHID:D001249],Bronchial Spasm[MeSHID:D001986],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank esmolol NA Tachycardia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Sinus Tachycardia[MeSHID:D013616],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 6.92 TTD , DGIDB nadolol NA Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 1.8 TTD , DGIDB acebutolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Premature ventricular contractions[MeSHID:D018879],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA partial agonist 3.81 drugbank , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB1 NA inhibitor,agonist 1.5 drugbank , DGIDB sotalol small molecule Solutions[MeSHID:D012996],Maintenance[MeSHID:D008283],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved beta-1 adrenergic receptor ADRB1 NA antagonist 0.69 drugbank , DGIDB levobunolol NA Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 2.31 TTD , DGIDB metoprolol small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Atrial Flutter[MeSHID:D001282],Smoking[MeSHID:D012907],Diet therapy[MeSHID:D004035],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Cardiovascular Diseases[MeSHID:D002318],Tobacco smoking behavior[MeSHID:D000073869],Heart[MeSHID:D006321],Supraventricular tachycardia[MeSHID:D013617],Cause of Death[MeSHID:D002423],Obesity[MeSHID:D009765],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Eye[MeSHID:D005123],Thyroid Crisis[MeSHID:D013958],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist 2.42 drugbank , DGIDB isoetharine small molecule Asthma[MeSHID:D001249],Bronchitis, Chronic[MeSHID:D029481],Wheezing[MeSHID:D012135],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA agonist 1.21 drugbank , DGIDB bupranolol small molecule Glaucoma[MeSHID:D005901],Tachycardia[MeSHID:D013610],Hypertensive disease[MeSHID:D006973] experimental beta-1 adrenergic receptor ADRB1 NA antagonist 0.92 drugbank , DGIDB nebivolol NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 1.21 TTD , DGIDB putrescine small molecule Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Burn injury[MeSHID:D002056] experimental beta-1 adrenergic receptor ADRB1 NA unknown NA drugbank 4-{[(2s)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3h-indole-2-carbonitrile small molecule NA experimental beta-1 adrenergic receptor ADRB1 NA unknown NA drugbank propranolol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Pheochromocytoma[MeSHID:D010673],Hypertensive disease[MeSHID:D006973],Essential Tremor[MeSHID:D020329],Angina Pectoris[MeSHID:D000787],Strawberry nevus of skin[MeSHID:D018324],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Idiopathic hypertrophic subaortic stenosis[MeSHID:D024741],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist 0.45 drugbank , DGIDB esmolol NA Tachycardia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Sinus Tachycardia[MeSHID:D013616],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 6.92 TTD , DGIDB alprenolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,withdrawn beta-1 adrenergic receptor ADRB1 NA antagonist 3.46 drugbank , DGIDB isoprenaline small molecule Shock, Cardiogenic[MeSHID:D012770],Bronchial Spasm[MeSHID:D001986],Congestive heart failure[MeSHID:D006333],Heart Block[MeSHID:D006327],Tachycardia, Ventricular[MeSHID:D017180],Hypovolemic Shock[MeSHID:D012769],Body Fluids[MeSHID:D001826],Hypovolemic[MeSHID:D020896],Cardiac Arrest[MeSHID:D006323],Septic Shock[MeSHID:D012772] approved,investigational beta-1 adrenergic receptor ADRB1 NA agonist 0.26 drugbank , DGIDB metipranolol NA Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 1.84 TTD , DGIDB cryptenamine small molecule Hypertensive disease[MeSHID:D006973] approved beta adrenergic receptor ADRB1 NA inhibitor,potentiator NA drugbank acebutolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Premature ventricular contractions[MeSHID:D018879],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA partial agonist,antagonist 3.81 drugbank , DGIDB galnobax NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] phase 1/2 adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD , DGIDB isoproterenol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Block[MeSHID:D006327],melanoma[MeSHID:D008545] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.26 TTD , DGIDB timolol NA Hypertensive disease[MeSHID:D006973],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Eye[MeSHID:D005123],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 3 TTD , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA partial agonist 1.5 drugbank , DGIDB norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved beta-1 adrenergic receptor ADRB1 NA agonist 0.27 drugbank , DGIDB levobunolol NA Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 2.31 TTD , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta adrenergic receptor ADRB1 NA antagonist,agonist NA drugbank bopindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental beta-1 adrenergic receptor ADRB1 NA partial agonist NA drugbank timolol NA Hypertensive disease[MeSHID:D006973],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Eye[MeSHID:D005123],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 3 TTD , DGIDB timolol small molecule Hypertensive disease[MeSHID:D006973],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Eye[MeSHID:D005123],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 3 drugbank , DGIDB alprenolol NA Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market adrenergic receptor beta-1 ADRB1 Successful target unknown 3.46 TTD , DGIDB betaxolol NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 3.81 TTD , DGIDB epinephrine NA Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.23 TTD , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA inhibitor NA drugbank pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB1 NA inhibitor 1.5 drugbank , DGIDB [3h]cgp12177 NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved beta adrenergic receptor ADRB1 NA agonist NA drugbank racepinephrine small molecule Asthma[MeSHID:D001249] approved beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank pindolol NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 1.5 TTD , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist 0.95 drugbank , DGIDB fenoterol small molecule Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank anisodine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral Neuropathy[MeSHID:D010523] approved adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD , DGIDB nebivolol NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 1.21 TTD , DGIDB betaxolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist 3.81 drugbank , DGIDB dobutamine NA Heart Decompensation[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Depressed Level of Consciousness[MeSHID:D003244],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved adrenergic receptor beta-1 ADRB1 Successful target agonist 2.54 TTD , DGIDB esmolol small molecule Tachycardia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Sinus Tachycardia[MeSHID:D013616],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Supraventricular tachycardia[MeSHID:D013617] approved beta-1 adrenergic receptor ADRB1 NA antagonist 6.92 drugbank , DGIDB practolol NA Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 7.61 TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA binder NA drugbank nebivolol small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist 1.21 drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB1 NA inhibitor NA drugbank epinephrine NA Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved adrenergic receptor beta-1 ADRB1 Successful target agonist 0.23 TTD , DGIDB penbutolol NA Hypertensive disease[MeSHID:D006973],Shock, Cardiogenic[MeSHID:D012770],Atrioventricular Block[MeSHID:D054537],Neoplasm Metastasis[MeSHID:D009362],Asthma[MeSHID:D001249],Bradycardia[MeSHID:D001919],Hypersensitivity[MeSHID:D006967],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 2.42 TTD , DGIDB (+/-)-nantenine NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist NA drugbank carazolol NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA agonist,partial agonist NA drugbank dichloroisoproterenol NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown 0.69 TTD , DGIDB dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 0.35 drugbank , DGIDB 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD dipivefrin NA Glaucoma, Open-Angle[MeSHID:D005902],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.35 TTD , DGIDB pindolol NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target partial agonist 1.5 TTD , DGIDB cor-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Heart failure[MeSHID:D006333] phase 2 adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD , DGIDB carteolol NA Hypertensive disease[MeSHID:D006973],Glaucoma, Open-Angle[MeSHID:D005902],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 3.11 TTD , DGIDB bethanidine NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] withdrawn from market adrenergic receptor beta-1 ADRB1 Successful target unknown 0.35 TTD , DGIDB ajmalicine NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD , DGIDB befunolol small molecule Glaucoma, Open-Angle[MeSHID:D005902],Disease Management[MeSHID:D019468] experimental beta-1 adrenergic receptor ADRB1 NA unknown NA drugbank nadolol NA Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 1.8 TTD , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational beta-1 adrenergic receptor ADRB1 NA other 0.3 drugbank , DGIDB xamoterol small molecule NA approved beta-1 adrenergic receptor ADRB1 NA partial agonist,agonist 1.38 drugbank , DGIDB dobutamine small molecule Heart Decompensation[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Depressed Level of Consciousness[MeSHID:D003244],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved beta-1 adrenergic receptor ADRB1 NA agonist 2.54 drugbank , DGIDB sotalol NA Solutions[MeSHID:D012996],Maintenance[MeSHID:D008283],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 0.69 TTD , DGIDB dl-methylephedrine small molecule NA approved beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD terbutaline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist NA drugbank arbutamine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA agonist 4.15 drugbank , DGIDB practolol small molecule Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 7.61 drugbank , DGIDB propranolol NA Coronary Arteriosclerosis[MeSHID:D003324],Pheochromocytoma[MeSHID:D010673],Hypertensive disease[MeSHID:D006973],Essential Tremor[MeSHID:D020329],Angina Pectoris[MeSHID:D000787],Strawberry nevus of skin[MeSHID:D018324],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Idiopathic hypertrophic subaortic stenosis[MeSHID:D024741],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.45 TTD , DGIDB 1-(1h-indol-4-yloxy)-3-phenethylamino-propan-2-ol NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved beta adrenergic receptor ADRB1 NA antagonist NA drugbank bevantolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental beta-1 adrenergic receptor ADRB1 NA antagonist 2.42 drugbank , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB1 NA inhibitor,downregulator 0.16 drugbank , DGIDB anisodamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral Neuropathy[MeSHID:D010523] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.69 TTD , DGIDB acebutolol NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Premature ventricular contractions[MeSHID:D018879],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 3.81 TTD , DGIDB celiprolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist 1.73 drugbank , DGIDB practolol NA Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 7.61 TTD , DGIDB bethanidine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved beta adrenergic receptor ADRB1 NA antagonist 0.35 drugbank , DGIDB levobunolol small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 2.31 drugbank , DGIDB l-796568 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1 adrenergic receptor beta-1 ADRB1 Successful target unknown 0.35 TTD , DGIDB atenolol NA Coronary Arteriosclerosis[MeSHID:D003324],Disease Management[MeSHID:D019468],Hypertensive disease[MeSHID:D006973],Cardiac Arrhythmia[MeSHID:D001145],Systolic Pressure[MeSHID:D001794],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Thyrotoxicosis[MeSHID:D013971],Supraventricular tachycardia[MeSHID:D013617],heart rate[MeSHID:D006339],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Arrhythmogenic Right Ventricular Dysplasia[MeSHID:D019571],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 0.61 TTD , DGIDB penbutolol small molecule Hypertensive disease[MeSHID:D006973],Shock, Cardiogenic[MeSHID:D012770],Atrioventricular Block[MeSHID:D054537],Neoplasm Metastasis[MeSHID:D009362],Asthma[MeSHID:D001249],Bradycardia[MeSHID:D001919],Hypersensitivity[MeSHID:D006967],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist,partial agonist 2.42 drugbank , DGIDB ym-16151-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 1 adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational beta-1 adrenergic receptor ADRB1 NA antagonist NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved beta adrenergic receptor ADRB1 NA binder NA drugbank vortioxetine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved,investigational beta-1 adrenergic receptor ADRB1 NA ligand NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental beta adrenergic receptor ADRB1 NA antagonist,agonist NA drugbank levobetaxolol NA Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 0.69 TTD , DGIDB pindolol NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target agonist 1.5 TTD , DGIDB cebutolol NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD arotinolol small molecule Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],heart rate[MeSHID:D006339],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300] investigational beta-1 adrenergic receptor ADRB1 NA antagonist NA drugbank oxprenolol small molecule Hypertensive disease[MeSHID:D006973],Cardiac Arrhythmia[MeSHID:D001145],Angina Pectoris[MeSHID:D000787],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 3.11 drugbank , DGIDB formoterol small molecule Solutions[MeSHID:D012996],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Unmarried[MeSHID:D012847],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank protokylol hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD , DGIDB arbutamine NA Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 4.15 TTD , DGIDB oxprenolol NA Hypertensive disease[MeSHID:D006973],Cardiac Arrhythmia[MeSHID:D001145],Angina Pectoris[MeSHID:D000787],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 3.11 TTD , DGIDB spermidine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] experimental beta-1 adrenergic receptor ADRB1 NA unknown NA drugbank metoprolol NA Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Atrial Flutter[MeSHID:D001282],Smoking[MeSHID:D012907],Diet therapy[MeSHID:D004035],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Cardiovascular Diseases[MeSHID:D002318],Tobacco smoking behavior[MeSHID:D000073869],Heart[MeSHID:D006321],Supraventricular tachycardia[MeSHID:D013617],Cause of Death[MeSHID:D002423],Obesity[MeSHID:D009765],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Eye[MeSHID:D005123],Thyroid Crisis[MeSHID:D013958],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 2.42 TTD , DGIDB atenolol NA Coronary Arteriosclerosis[MeSHID:D003324],Disease Management[MeSHID:D019468],Hypertensive disease[MeSHID:D006973],Cardiac Arrhythmia[MeSHID:D001145],Systolic Pressure[MeSHID:D001794],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Thyrotoxicosis[MeSHID:D013971],Supraventricular tachycardia[MeSHID:D013617],heart rate[MeSHID:D006339],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Arrhythmogenic Right Ventricular Dysplasia[MeSHID:D019571],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.61 TTD , DGIDB (r,r)-(-)-fenoterol NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD metoprolol NA Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Atrial Flutter[MeSHID:D001282],Smoking[MeSHID:D012907],Diet therapy[MeSHID:D004035],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Cardiovascular Diseases[MeSHID:D002318],Tobacco smoking behavior[MeSHID:D000073869],Heart[MeSHID:D006321],Supraventricular tachycardia[MeSHID:D013617],Cause of Death[MeSHID:D002423],Obesity[MeSHID:D009765],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Eye[MeSHID:D005123],Thyroid Crisis[MeSHID:D013958],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target antagonist 2.42 TTD , DGIDB brl 35135 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD , DGIDB cgp 20712a NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target antagonist NA TTD , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational beta adrenergic receptor ADRB1 NA inhibitor,downregulator 0.16 drugbank , DGIDB mirabegron small molecule Neurogenesis[MeSHID:D055495],Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA agonist 0.17 drugbank , DGIDB phenylpropanolamine small molecule Urinary Incontinence[MeSHID:D014549],Obesity[MeSHID:D009765],Priapism[MeSHID:D011317],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved,withdrawn beta-1 adrenergic receptor ADRB1 NA agonist NA drugbank levobetaxolol NA Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.69 TTD , DGIDB 1-(2-allylphenoxy)-3-morpholinopropan-2-ol NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD (r,s)-(-)-fenoterol NA NA investigative adrenergic receptor beta-1 ADRB1 Successful target unknown NA TTD spermine small molecule NA experimental,nutraceutical beta-1 adrenergic receptor ADRB1 NA unknown NA drugbank dl-methylephedrine small molecule NA approved beta adrenergic receptor ADRB1 NA agonist NA drugbank amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational beta adrenergic receptor ADRB1 NA agonist NA drugbank cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved beta-1 adrenergic receptor ADRB1 NA binder NA drugbank metipranolol small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 1.84 drugbank , DGIDB salmeterol small molecule Maintenance[MeSHID:D008283],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA inverse agonist 0.35 drugbank , DGIDB bisoprolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Off-Label Use[MeSHID:D056687],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-1 adrenergic receptor ADRB1 NA antagonist 4.5 drugbank , DGIDB bisoprolol NA Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Off-Label Use[MeSHID:D056687],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 4.5 TTD , DGIDB sotalol NA Solutions[MeSHID:D012996],Maintenance[MeSHID:D008283],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved adrenergic receptor beta-1 ADRB1 Successful target unknown 0.69 TTD , DGIDB nadolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist 1.11 drugbank , DGIDB metaproterenol sulfate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB olodaterol small molecule Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist 1.84 drugbank , DGIDB pirbuterol NA Asthma[MeSHID:D001249],Bronchial Spasm[MeSHID:D001986],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 2.31 TTD , DGIDB ici 118,551 NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB levosalbutamol small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Disease Management[MeSHID:D019468],Asthma[MeSHID:D001249] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist 0.46 drugbank , DGIDB gsk159802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 adrenergic receptor beta-2 ADRB2 Successful target agonist 0.46 TTD , DGIDB 2-fluoronorepinehprine NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD fenoterol NA Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 5.07 TTD , DGIDB timolol small molecule Hypertensive disease[MeSHID:D006973],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Eye[MeSHID:D005123],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist 1.69 drugbank , DGIDB etafedrine small molecule Disease[MeSHID:D004194],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Bronchitis, Chronic[MeSHID:D029481],Bronchi[MeSHID:D001980] approved beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank formoterol NA Solutions[MeSHID:D012996],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Unmarried[MeSHID:D012847],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 2.61 TTD , DGIDB olodaterol NA Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 1.84 TTD , DGIDB gsk-159797 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD milveterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 adrenergic receptor beta-2 ADRB2 Successful target agonist 0.92 TTD , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB2 NA inhibitor NA drugbank sibenadet NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 3 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD vilanterol small molecule Maintenance[MeSHID:D008283],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Lung Diseases, Obstructive[MeSHID:D008173],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist 1.38 drugbank , DGIDB isoprenaline small molecule Shock, Cardiogenic[MeSHID:D012770],Bronchial Spasm[MeSHID:D001986],Congestive heart failure[MeSHID:D006333],Heart Block[MeSHID:D006327],Tachycardia, Ventricular[MeSHID:D017180],Hypovolemic Shock[MeSHID:D012769],Body Fluids[MeSHID:D001826],Hypovolemic[MeSHID:D020896],Cardiac Arrest[MeSHID:D006323],Septic Shock[MeSHID:D012772] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist,binder 0.32 drugbank , DGIDB (s,r)-(+)-fenoterol NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD azd-3199 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown 1.38 TTD , DGIDB propranolol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Pheochromocytoma[MeSHID:D010673],Hypertensive disease[MeSHID:D006973],Essential Tremor[MeSHID:D020329],Angina Pectoris[MeSHID:D000787],Strawberry nevus of skin[MeSHID:D018324],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Idiopathic hypertrophic subaortic stenosis[MeSHID:D024741],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA antagonist 0.3 drugbank , DGIDB penbutolol small molecule Hypertensive disease[MeSHID:D006973],Shock, Cardiogenic[MeSHID:D012770],Atrioventricular Block[MeSHID:D054537],Neoplasm Metastasis[MeSHID:D009362],Asthma[MeSHID:D001249],Bradycardia[MeSHID:D001919],Hypersensitivity[MeSHID:D006967],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA antagonist,partial agonist 1.84 drugbank , DGIDB bucindolol NA Atrial Fibrillation[MeSHID:D001281],Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 adrenergic receptor beta-2 ADRB2 Successful target unknown 0.31 TTD , DGIDB milveterol+fluticasone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD carteolol small molecule Hypertensive disease[MeSHID:D006973],Glaucoma, Open-Angle[MeSHID:D005902],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved beta-2 adrenergic receptor ADRB2 NA antagonist 1.61 drugbank , DGIDB doxofylline small molecule Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Muscle Spasticity[MeSHID:D009128],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchial Diseases[MeSHID:D001982],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank protokylol small molecule NA approved,vet_approved beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank procaterol small molecule Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist 2.31 drugbank , DGIDB isoetharine small molecule Asthma[MeSHID:D001249],Bronchitis, Chronic[MeSHID:D029481],Wheezing[MeSHID:D012135],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist 0.23 drugbank , DGIDB procaterol NA Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 2.31 TTD , DGIDB procaterol NA Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 2.31 TTD , DGIDB atenolol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Disease Management[MeSHID:D019468],Hypertensive disease[MeSHID:D006973],Cardiac Arrhythmia[MeSHID:D001145],Systolic Pressure[MeSHID:D001794],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Thyrotoxicosis[MeSHID:D013971],Supraventricular tachycardia[MeSHID:D013617],heart rate[MeSHID:D006339],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Arrhythmogenic Right Ventricular Dysplasia[MeSHID:D019571],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist 0.05 drugbank , DGIDB propafenone small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Diseases[MeSHID:D006331],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist 0.08 drugbank , DGIDB formoterol NA Solutions[MeSHID:D012996],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Unmarried[MeSHID:D012847],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 2.61 TTD , DGIDB arformoterol small molecule Bronchoconstriction[MeSHID:D016084],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist 1.38 drugbank , DGIDB salmeterol NA Maintenance[MeSHID:D008283],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 2.08 TTD , DGIDB arformoterol NA Bronchoconstriction[MeSHID:D016084],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 1.38 TTD , DGIDB tulobuterol small molecule NA investigational beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank metoprolol small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Atrial Flutter[MeSHID:D001282],Smoking[MeSHID:D012907],Diet therapy[MeSHID:D004035],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Cardiovascular Diseases[MeSHID:D002318],Tobacco smoking behavior[MeSHID:D000073869],Heart[MeSHID:D006321],Supraventricular tachycardia[MeSHID:D013617],Cause of Death[MeSHID:D002423],Obesity[MeSHID:D009765],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Eye[MeSHID:D005123],Thyroid Crisis[MeSHID:D013958],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA antagonist 0.23 drugbank , DGIDB spermine small molecule NA experimental,nutraceutical beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank ta-2005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown 0.92 TTD , DGIDB bambuterol small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational beta-2 adrenergic receptor ADRB2 NA agonist 1.84 drugbank , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA partial agonist 1 drugbank , DGIDB gw642444 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 1.38 TTD , DGIDB vilanterol NA Maintenance[MeSHID:D008283],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Lung Diseases, Obstructive[MeSHID:D008173],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 1.38 TTD , DGIDB picumeterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB2 NA inhibitor NA drugbank nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved beta adrenergic receptor ADRB2 NA antagonist NA drugbank ephedrine small molecule Asthma[MeSHID:D001249],Nose[MeSHID:D009666],Hypotension[MeSHID:D007022],Bronchial Diseases[MeSHID:D001982],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist 0.77 drugbank , DGIDB epinephrine small molecule Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved beta-2 adrenergic receptor ADRB2 NA agonist 0.14 drugbank , DGIDB phenylpropanolamine small molecule Urinary Incontinence[MeSHID:D014549],Obesity[MeSHID:D009765],Priapism[MeSHID:D011317],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved,withdrawn beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank isoetharine NA Asthma[MeSHID:D001249],Bronchitis, Chronic[MeSHID:D029481],Wheezing[MeSHID:D012135],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 0.23 TTD , DGIDB orciprenaline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481] approved beta-2 adrenergic receptor ADRB2 NA agonist 4.61 drugbank , DGIDB bupranolol small molecule Glaucoma[MeSHID:D005901],Tachycardia[MeSHID:D013610],Hypertensive disease[MeSHID:D006973] experimental beta-2 adrenergic receptor ADRB2 NA antagonist 0.61 drugbank , DGIDB fenoterol small molecule Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist 5.07 drugbank , DGIDB levobunolol small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist 1.54 drugbank , DGIDB r-salbutamol sulphate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Skin Diseases, Infectious[MeSHID:D012874] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB2 NA inhibitor 1 drugbank , DGIDB dipivefrin small molecule Glaucoma, Open-Angle[MeSHID:D005902],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank labetalol small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist 0.35 drugbank , DGIDB bambuterol NA Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 1.84 TTD , DGIDB meluadrine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Ejaculation[MeSHID:D061686] discontinued in preregistration adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD metaproterenol sulfate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 0.46 TTD , DGIDB gnf-pf-1694 NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD arotinolol small molecule Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],heart rate[MeSHID:D006339],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300] investigational beta-2 adrenergic receptor ADRB2 NA antagonist NA drugbank terbutaline NA Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 6.46 TTD , DGIDB las 100977 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB formoterol small molecule Solutions[MeSHID:D012996],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Unmarried[MeSHID:D012847],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist 2.61 drugbank , DGIDB kul-7211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurogenic Urinary Bladder[MeSHID:D001750] phase 1 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB2 NA inhibitor,agonist 1 drugbank , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved beta adrenergic receptor ADRB2 NA binder NA drugbank phenoxybenzamine small molecule Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank ritodrine NA Premature Obstetric Labor[MeSHID:D007752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 2.31 TTD , DGIDB 1-(2-allylphenoxy)-3-morpholinopropan-2-ol NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD bitolterol small molecule Disease[MeSHID:D004194],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Chronic Obstructive Airway Disease[MeSHID:D029424],Air (substance)[MeSHID:D000388],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank befunolol small molecule Glaucoma, Open-Angle[MeSHID:D005902],Disease Management[MeSHID:D019468] experimental beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank apd-209 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB dobutamine small molecule Heart Decompensation[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Depressed Level of Consciousness[MeSHID:D003244],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank pf-610355 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD pirbuterol small molecule Asthma[MeSHID:D001249],Bronchial Spasm[MeSHID:D001986],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist 2.31 drugbank , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist NA drugbank mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved beta adrenergic receptor ADRB2 NA agonist NA drugbank d 2343 NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational beta adrenergic receptor ADRB2 NA agonist NA drugbank salmeterol small molecule Maintenance[MeSHID:D008283],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist 2.08 drugbank , DGIDB l-796568 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1 adrenergic receptor beta-2 ADRB2 Successful target unknown 0.23 TTD , DGIDB dichloroisoproterenol NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown 0.46 TTD , DGIDB ncx 950 small molecule Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD dl-methylephedrine small molecule NA approved beta adrenergic receptor ADRB2 NA agonist NA drugbank mn-221 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249],Aging[MeSHID:D000375] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown 1.38 TTD , DGIDB dihydroergocornine small molecule NA approved beta adrenergic receptor ADRB2 NA antagonist,agonist NA drugbank bisoprolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Heart failure[MeSHID:D006333],Off-Label Use[MeSHID:D056687],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist NA drugbank indacaterol small molecule Maintenance[MeSHID:D008283],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved beta-2 adrenergic receptor ADRB2 NA agonist 0.58 drugbank , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA partial agonist,agonist 1 drugbank , DGIDB salbutamol NA Bronchial Spasm[MeSHID:D001986],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Lung Diseases, Obstructive[MeSHID:D008173],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 1.61 TTD , DGIDB cryptenamine small molecule Hypertensive disease[MeSHID:D006973] approved beta adrenergic receptor ADRB2 NA inhibitor,potentiator NA drugbank olodaterol NA Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 1.84 TTD , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB2 NA inhibitor,downregulator NA drugbank azd-2115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational beta-2 adrenergic receptor ADRB2 NA antagonist 0.34 drugbank , DGIDB racepinephrine small molecule Asthma[MeSHID:D001249] approved beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank alprenolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,withdrawn beta-2 adrenergic receptor ADRB2 NA antagonist 1.84 drugbank , DGIDB bopindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental beta-2 adrenergic receptor ADRB2 NA partial agonist NA drugbank fenoterol NA Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 5.07 TTD , DGIDB nebivolol small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA antagonist 0.23 drugbank , DGIDB qva-149 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 3 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB bedoradrine small molecule Asthma[MeSHID:D001249],Labor (Childbirth)[MeSHID:D007743] investigational beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA partial agonist 0.11 drugbank , DGIDB thrx-198321 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB vilanterol NA Maintenance[MeSHID:D008283],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Lung Diseases, Obstructive[MeSHID:D008173],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 1.38 TTD , DGIDB salmeterol NA Maintenance[MeSHID:D008283],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 2.08 TTD , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational beta-2 adrenergic receptor ADRB2 NA antagonist 0.2 drugbank , DGIDB putrescine small molecule Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Burn injury[MeSHID:D002056] experimental beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental beta adrenergic receptor ADRB2 NA antagonist,agonist NA drugbank broxaterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 3 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD clenbuterol small molecule Asthma[MeSHID:D001249],Chronic disease[MeSHID:D002908],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beta-2 adrenergic receptor ADRB2 NA agonist 5.07 drugbank , DGIDB gsk642444 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 3 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB sotalol small molecule Solutions[MeSHID:D012996],Maintenance[MeSHID:D008283],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved beta-2 adrenergic receptor ADRB2 NA antagonist 0.37 drugbank , DGIDB (r,s)-(-)-fenoterol NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational beta-2 adrenergic receptor ADRB2 NA antagonist 0.34 drugbank , DGIDB carmoterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown 0.92 TTD , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved beta-2 adrenergic receptor ADRB2 NA binder NA drugbank isoproterenol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Block[MeSHID:D006327],melanoma[MeSHID:D008545] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 0.32 TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational beta-2 adrenergic receptor ADRB2 NA ligand NA drugbank levalbuterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 0.46 TTD , DGIDB gsk961081 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown 0.31 TTD , DGIDB bevantolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental beta-2 adrenergic receptor ADRB2 NA antagonist NA drugbank arformoterol NA Bronchoconstriction[MeSHID:D016084],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 1.38 TTD , DGIDB indacaterol NA Maintenance[MeSHID:D008283],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 0.58 TTD , DGIDB pt005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 3 adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD , DGIDB (s)-carazolol small molecule NA experimental beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist 0.35 drugbank , DGIDB oxprenolol small molecule Hypertensive disease[MeSHID:D006973],Cardiac Arrhythmia[MeSHID:D001145],Angina Pectoris[MeSHID:D000787],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist 1.61 drugbank , DGIDB norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved beta-2 adrenergic receptor ADRB2 NA agonist 0.2 drugbank , DGIDB bamosiran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 2 adrb2 messenger rna ADRB2 Clinical trial target unknown NA TTD (r,r)-(-)-fenoterol NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD salbutamol small molecule Bronchial Spasm[MeSHID:D001986],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Lung Diseases, Obstructive[MeSHID:D008173],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved beta-2 adrenergic receptor ADRB2 NA agonist 1.61 drugbank , DGIDB celiprolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank [3h]cgp12177 NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target agonist NA TTD , DGIDB clenbuterol NA Asthma[MeSHID:D001249],Chronic disease[MeSHID:D002908],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 5.07 TTD , DGIDB syl-040012 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] phase 2 adrb2 messenger rna ADRB2 Clinical trial target unknown NA TTD acebutolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Premature ventricular contractions[MeSHID:D018879],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA partial agonist NA drugbank terbutaline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist 6.46 drugbank , DGIDB ritodrine small molecule Premature Obstetric Labor[MeSHID:D007752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA agonist 2.31 drugbank , DGIDB milveterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 adrenergic receptor beta-2 ADRB2 Successful target unknown 0.92 TTD , DGIDB bethanidine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved beta adrenergic receptor ADRB2 NA antagonist NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational beta adrenergic receptor ADRB2 NA inhibitor,downregulator NA drugbank indacaterol NA Maintenance[MeSHID:D008283],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-2 ADRB2 Successful target agonist 0.58 TTD , DGIDB salbutamol NA Bronchial Spasm[MeSHID:D001986],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Lung Diseases, Obstructive[MeSHID:D008173],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 1.61 TTD , DGIDB spermidine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] experimental beta-2 adrenergic receptor ADRB2 NA unknown NA drugbank terbutaline NA Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-2 ADRB2 Successful target unknown 6.46 TTD , DGIDB arbutamine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA agonist NA drugbank carmoterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 adrenergic receptor beta-2 ADRB2 Successful target agonist 0.92 TTD , DGIDB butoxamine NA NA investigative adrenergic receptor beta-2 ADRB2 Successful target unknown NA TTD metipranolol small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-2 adrenergic receptor ADRB2 NA antagonist 1.23 drugbank , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta adrenergic receptor ADRB2 NA antagonist,agonist NA drugbank betaxolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2 adrenergic receptor ADRB2 NA antagonist 0.46 drugbank , DGIDB bufuralol small molecule NA experimental beta adrenergic receptor ADRB2 NA antagonist NA drugbank pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB2 NA inhibitor,partial agonist 1 drugbank , DGIDB 1-(1h-indol-4-yloxy)-3-phenethylamino-propan-2-ol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD solabegron small molecule Urinary Incontinence[MeSHID:D014549],Irritable Bowel Syndrome[MeSHID:D043183],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational beta-3 adrenergic receptor ADRB3 NA agonist 2.23 drugbank , DGIDB ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank kul-7211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurogenic Urinary Bladder[MeSHID:D001750] phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB l-748337 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target antagonist NA TTD , DGIDB tienoxolol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD ro-16-8714 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD bms-196085 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown 1.68 TTD , DGIDB (-)-ro 363 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD nihp NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD sb251023 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD formoterol small molecule Solutions[MeSHID:D012996],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Unmarried[MeSHID:D012847],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank amosulalol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved adrenergic receptor beta-3 ADRB3 Successful target unknown 0.84 TTD , DGIDB cp-114271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB bupranolol small molecule Glaucoma[MeSHID:D005901],Tachycardia[MeSHID:D013610],Hypertensive disease[MeSHID:D006973] experimental beta-3 adrenergic receptor ADRB3 NA antagonist 1.68 drugbank , DGIDB mirabegron small molecule Neurogenesis[MeSHID:D055495],Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-3 adrenergic receptor ADRB3 NA agonist 2.09 drugbank , DGIDB isoprenaline small molecule Shock, Cardiogenic[MeSHID:D012770],Bronchial Spasm[MeSHID:D001986],Congestive heart failure[MeSHID:D006333],Heart Block[MeSHID:D006327],Tachycardia, Ventricular[MeSHID:D017180],Hypovolemic Shock[MeSHID:D012769],Body Fluids[MeSHID:D001826],Hypovolemic[MeSHID:D020896],Cardiac Arrest[MeSHID:D006323],Septic Shock[MeSHID:D012772] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist 0.17 drugbank , DGIDB vibegron NA Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-3 ADRB3 Successful target agonist 5.03 TTD , DGIDB l-742791 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB bopindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental beta-3 adrenergic receptor ADRB3 NA unknown 1.68 drugbank , DGIDB norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank nebivolol small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist,antagonist 2.51 drugbank , DGIDB rimiterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved adrenergic receptor beta-3 ADRB3 Successful target unknown 1.68 TTD , DGIDB arbutamine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank nipradilol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved adrenergic receptor beta-3 ADRB3 Successful target unknown 1.68 TTD , DGIDB amibegron NA Irritable Bowel Syndrome[MeSHID:D043183],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Major Depressive Disorder[MeSHID:D003865],Mood Disorders[MeSHID:D019964] discontinued in phase 3 adrenergic receptor beta-3 ADRB3 Successful target agonist 5.03 TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved beta adrenergic receptor ADRB3 NA antagonist NA drugbank kuc-7483 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown 5.03 TTD , DGIDB bethanidine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved beta adrenergic receptor ADRB3 NA antagonist NA drugbank bufuralol small molecule NA experimental beta adrenergic receptor ADRB3 NA antagonist NA drugbank cl-316,243 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB [125i]icyp NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target agonist NA TTD , DGIDB cryptenamine small molecule Hypertensive disease[MeSHID:D006973] approved beta adrenergic receptor ADRB3 NA inhibitor,potentiator NA drugbank [3h]cgp12177 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD mn-246 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB salmeterol small molecule Maintenance[MeSHID:D008283],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-3 adrenergic receptor ADRB3 NA inverse agonist NA drugbank salbutamol small molecule Bronchial Spasm[MeSHID:D001986],Bronchospasm, Exercise-Induced[MeSHID:D001250],Asthma[MeSHID:D001249],Lung Diseases, Obstructive[MeSHID:D008173],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved beta-3 adrenergic receptor ADRB3 NA unknown NA drugbank zd2079 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB clenbuterol small molecule Asthma[MeSHID:D001249],Chronic disease[MeSHID:D002908],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank ncx 950 NA Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1/2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental beta adrenergic receptor ADRB3 NA antagonist,agonist NA drugbank ono-2506 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Cerebrovascular accident[MeSHID:D020521],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Expiration, function[MeSHID:D045853] phase 2/3 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB alprenolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,withdrawn beta-3 adrenergic receptor ADRB3 NA antagonist NA drugbank t-0509 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD amibegron NA Irritable Bowel Syndrome[MeSHID:D043183],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Major Depressive Disorder[MeSHID:D003865],Mood Disorders[MeSHID:D019964] discontinued in phase 3 adrenergic receptor beta-3 ADRB3 Successful target unknown 5.03 TTD , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB3 NA inhibitor,downregulator NA drugbank pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB3 NA inhibitor NA drugbank racepinephrine small molecule Asthma[MeSHID:D001249] approved beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank sb 418790 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD oberadilol monoethyl maleate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD trimetoquinol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD h87/07 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD fmp-825 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD dihydroergocornine small molecule NA approved beta adrenergic receptor ADRB3 NA antagonist,agonist NA drugbank l748328 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target antagonist NA TTD , DGIDB pw-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in preregistration adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD amibegron small molecule Irritable Bowel Syndrome[MeSHID:D043183],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Major Depressive Disorder[MeSHID:D003865],Mood Disorders[MeSHID:D019964] investigational beta-3 adrenergic receptor ADRB3 NA unknown 5.03 drugbank , DGIDB n-5984 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB lk 204-545 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD proxodolol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] discontinued in phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank cp-331684 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta adrenergic receptor ADRB3 NA antagonist,agonist NA drugbank xamoterol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD prenalterol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD ly-362884 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB iodocyanopindolol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD gw-427353 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational beta adrenergic receptor ADRB3 NA agonist NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational beta adrenergic receptor ADRB3 NA inhibitor,downregulator NA drugbank cl-314698 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD fenoterol small molecule Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank mepindolol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved adrenergic receptor beta-3 ADRB3 Successful target unknown 1.12 TTD , DGIDB ym-430 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB zinterol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD amibegron small molecule Irritable Bowel Syndrome[MeSHID:D043183],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Major Depressive Disorder[MeSHID:D003865],Mood Disorders[MeSHID:D019964] investigational beta-3 adrenergic receptor ADRB3 NA agonist 5.03 drugbank , DGIDB propranolol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Pheochromocytoma[MeSHID:D010673],Hypertensive disease[MeSHID:D006973],Essential Tremor[MeSHID:D020329],Angina Pectoris[MeSHID:D000787],Strawberry nevus of skin[MeSHID:D018324],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Idiopathic hypertrophic subaortic stenosis[MeSHID:D024741],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-3 adrenergic receptor ADRB3 NA antagonist 0.3 drugbank , DGIDB adaprolol maleate-sme NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] discontinued in phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD terbutaline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank epanolol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in preregistration adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD dl-methylephedrine small molecule NA approved beta adrenergic receptor ADRB3 NA agonist NA drugbank gcr-1087 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB zd7114 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank trihexyphenidyl NA Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dystonia[MeSHID:D004421],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Obesity[MeSHID:D009765] approved adrenergic receptor beta-3 ADRB3 Successful target unknown 0.56 TTD , DGIDB mystilol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist 1.05 drugbank , DGIDB alprenoxime hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] discontinued in phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD cicloprolol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD trecadrine NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD l-751250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB3 NA inhibitor 0.05 drugbank , DGIDB qlt-091568 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 1/2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB mephentermine small molecule Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved beta adrenergic receptor ADRB3 NA agonist NA drugbank celiprolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist NA drugbank mirabegron NA Neurogenesis[MeSHID:D055495],Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-3 ADRB3 Successful target agonist 2.09 TTD , DGIDB [3h](-)cgp 12177 NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta adrenergic receptor ADRB3 NA inhibitor NA drugbank bopindolol NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-3 ADRB3 Successful target unknown 1.68 TTD , DGIDB carazolol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target agonist 0.84 TTD , DGIDB oxprenolol small molecule Hypertensive disease[MeSHID:D006973],Cardiac Arrhythmia[MeSHID:D001145],Angina Pectoris[MeSHID:D000787],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved beta-3 adrenergic receptor ADRB3 NA unknown NA drugbank bitolterol NA Disease[MeSHID:D004194],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Chronic Obstructive Airway Disease[MeSHID:D029424],Air (substance)[MeSHID:D000388],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-3 ADRB3 Successful target unknown 1.68 TTD , DGIDB mirabegron NA Neurogenesis[MeSHID:D055495],Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adrenergic receptor beta-3 ADRB3 Successful target unknown 2.09 TTD , DGIDB laevo-bambuterol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB 1-(2-allylphenoxy)-3-morpholinopropan-2-ol NA NA investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD vibegron small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-3 adrenergic receptor ADRB3 NA agonist 5.03 drugbank , DGIDB pafenolol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD az-40140 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved beta adrenergic receptor ADRB3 NA binder NA drugbank asp-3652 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD , DGIDB er-23006 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative adrenergic receptor beta-3 ADRB3 Successful target unknown NA TTD rafabegron NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 adrenergic receptor beta-3 ADRB3 Successful target agonist 1.68 TTD , DGIDB ly-377604 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 adrenergic receptor beta-3 ADRB3 Successful target unknown 1.68 TTD , DGIDB atp small molecule NA investigational,nutraceutical beta-adrenergic receptor kinase 1 ADRBK1 NA unknown NA drugbank atp small molecule NA investigational,nutraceutical beta-adrenergic receptor kinase 2 ADRBK2 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical adenylosuccinate synthetase isozyme 2 ADSS NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical adenylosuccinate synthetases ADSS NA substrate NA drugbank alanosine small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of brain[MeSHID:D001932] investigational adenylosuccinate synthetase isozyme 2 ADSS NA unknown NA drugbank inosinic acid small molecule NA experimental adenylosuccinate synthetase isozyme 1 ADSSL1 NA unknown NA drugbank adenylosuccinic acid small molecule NA experimental adenylosuccinate synthetase isozyme 1 ADSSL1 NA unknown NA drugbank hadacidin small molecule NA experimental adenylosuccinate synthetase isozyme 1 ADSSL1 NA unknown NA drugbank alanosine small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of brain[MeSHID:D001932] investigational adenylosuccinate synthetase isozyme 1 ADSSL1 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical adenylosuccinate synthetases ADSSL1 NA substrate NA drugbank 6-o-phosphoryl inosine monophosphate small molecule NA experimental adenylosuccinate synthetase isozyme 1 ADSSL1 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental adenylosuccinate synthetase isozyme 1 ADSSL1 NA unknown NA drugbank guanosine-5'-triphosphate small molecule NA experimental adenylosuccinate synthetase isozyme 1 ADSSL1 NA unknown NA drugbank atp small molecule NA investigational,nutraceutical afg3-like protein 2 AFG3L2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational afamin AFM NA unknown NA drugbank mm-093 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 2 alpha-fetoprotein AFP Clinical trial target unknown NA TTD , DGIDB dbt-066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative advanced glycosylation end product receptor AGER Clinical trial target unknown NA TTD ttp-448 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 advanced glycosylation end product receptor AGER Clinical trial target unknown NA TTD , DGIDB pf-4494700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 advanced glycosylation end product receptor AGER Clinical trial target unknown NA TTD , DGIDB ttp-4000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 advanced glycosylation end product receptor AGER Clinical trial target unknown NA TTD , DGIDB alagebrium chloride NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 advanced glycosylation end product receptor AGER Clinical trial target unknown NA TTD , DGIDB pyridoxamine NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 advanced glycosylation end product receptor AGER Clinical trial target unknown 31.83 TTD , DGIDB ttp435 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 agouti-related protein AGRP Clinical trial target unknown NA TTD , DGIDB sparsentan small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Focal glomerulosclerosis[MeSHID:D005923],Myocardial Infarction[MeSHID:D009203] investigational angiotensinogen AGT NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational angiotensinogen AGT NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational angiotensinogen AGT NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational angiotensinogen AGT NA unknown NA drugbank trv027 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD , DGIDB irbesartan small molecule Hypertensive disease[MeSHID:D006973],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],hypertensive nephropathy[MeSHID:C563161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational type-1 angiotensin ii receptor AGTR1 NA antagonist 2.13 drugbank , DGIDB saralasin acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 1.3 TTD , DGIDB 5-butyl-methyl immidazole carboxylate 30 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target antagonist NA TTD , DGIDB angiotensin ii small molecule Systemic arterial pressure[MeSHID:D062186],Sepsis[MeSHID:D018805],Shock[MeSHID:D012769],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational type-1 angiotensin ii receptor AGTR1 NA agonist NA drugbank , DGIDB telmisartan NA Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 3.53 TTD , DGIDB candesartan small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] experimental type-1 angiotensin ii receptor AGTR1 NA antagonist 2.45 drugbank , DGIDB tak-591 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD telmisartan small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational type-1 angiotensin ii receptor AGTR1 NA antagonist 3.53 drugbank , DGIDB zolasartan NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD valsartan NA Hypertensive disease[MeSHID:D006973],treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Ventricular Dysfunction, Left[MeSHID:D018487],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Infarction[MeSHID:D007238],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 7.14 TTD , DGIDB losartan small molecule Hypertensive disease[MeSHID:D006973],Left Ventricular Hypertrophy[MeSHID:D017379],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved type-1 angiotensin ii receptor AGTR1 NA antagonist 2.31 drugbank , DGIDB olmesartan small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hospitalization[MeSHID:D006760],Heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Cerebrovascular accident[MeSHID:D020521],Off-Label Use[MeSHID:D056687],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674] approved,investigational type-1 angiotensin ii receptor AGTR1 NA antagonist 6.5 drugbank , DGIDB ly301875 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target antagonist NA TTD , DGIDB angiotensin ii NA Systemic arterial pressure[MeSHID:D062186],Sepsis[MeSHID:D018805],Shock[MeSHID:D012769],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD , DGIDB tasosartan NA Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 10.39 TTD , DGIDB angiotensin iii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target agonist NA TTD , DGIDB forasartan NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 9.09 TTD , DGIDB pratosartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 3 angiotensin ii receptor type-1 AGTR1 Successful target unknown 0.65 TTD , DGIDB azilsartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 5.2 TTD , DGIDB valsartan NA Hypertensive disease[MeSHID:D006973],treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Ventricular Dysfunction, Left[MeSHID:D018487],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Infarction[MeSHID:D007238],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 7.14 TTD , DGIDB eprosartan NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 19.49 TTD , DGIDB [sar1,bpa2]angii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD candesartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 2.45 TTD , DGIDB losartan NA Hypertensive disease[MeSHID:D006973],Left Ventricular Hypertrophy[MeSHID:D017379],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 2.31 TTD , DGIDB 4-[(diphenylmethyl)amino]-2-phenylquinazoline NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD l-162313 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD 4-(2-butyl-benzoimidazol-1-ylmethyl)-phenol NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD valsartan small molecule Hypertensive disease[MeSHID:D006973],treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Ventricular Dysfunction, Left[MeSHID:D018487],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Infarction[MeSHID:D007238],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational type-1 angiotensin ii receptor AGTR1 NA antagonist 7.14 drugbank , DGIDB [sar1,bpa8]angii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD valsartan small molecule Hypertensive disease[MeSHID:D006973],treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Ventricular Dysfunction, Left[MeSHID:D018487],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Infarction[MeSHID:D007238],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational type-1 angiotensin ii receptor AGTR1 NA antagonist 7.14 drugbank , DGIDB [125i]exp985 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD ly303336 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target antagonist NA TTD , DGIDB exp3174 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target antagonist NA TTD , DGIDB trv027 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 angiotensin ii receptor type-1 AGTR1 Successful target antagonist NA TTD , DGIDB [bpa1]angii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD azilsartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 5.2 TTD , DGIDB olmesartan medoxomil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 0.65 TTD , DGIDB sparsentan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Focal glomerulosclerosis[MeSHID:D005923],Myocardial Infarction[MeSHID:D009203] phase 3 angiotensin ii receptor type-1 AGTR1 Successful target unknown 1.95 TTD , DGIDB l-163,101 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target agonist NA TTD , DGIDB saprisartan small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental type-1 angiotensin ii receptor AGTR1 NA antagonist 6.5 drugbank , DGIDB 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD micardis telmisartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD , DGIDB olmesartan medoxomil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD , DGIDB [sar1,tdf3]angii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD tak-491 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 3 angiotensin ii receptor type-1 AGTR1 Successful target unknown 1.3 TTD , DGIDB ym-358 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 angiotensin ii receptor type-1 AGTR1 Successful target unknown 1.3 TTD , DGIDB [sar1,tdf8]angii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD telmisartan NA Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 3.53 TTD , DGIDB angiotensin ii NA Systemic arterial pressure[MeSHID:D062186],Sepsis[MeSHID:D018805],Shock[MeSHID:D012769],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target agonist NA TTD , DGIDB s-474474 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Syndrome X[MeSHID:D024821] phase 3 angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD , DGIDB telmisartan small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational type-1 angiotensin ii receptor AGTR1 NA antagonist 3.53 drugbank , DGIDB irbesartan NA Hypertensive disease[MeSHID:D006973],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],hypertensive nephropathy[MeSHID:C563161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 2.13 TTD , DGIDB pratosartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 3 angiotensin ii receptor type-1 AGTR1 Successful target antagonist 0.65 TTD , DGIDB (e)-n-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD eprosartan small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved type-1 angiotensin ii receptor AGTR1 NA antagonist 19.49 drugbank , DGIDB irbesartan small molecule Hypertensive disease[MeSHID:D006973],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],hypertensive nephropathy[MeSHID:C563161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational type-1 angiotensin ii receptor AGTR1 NA antagonist 2.13 drugbank , DGIDB losartan small molecule Hypertensive disease[MeSHID:D006973],Left Ventricular Hypertrophy[MeSHID:D017379],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved type-1 angiotensin ii receptor AGTR1 NA antagonist 2.31 drugbank , DGIDB [3h]gbr12935 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD cyt006-angqb biotech Hypertensive disease[MeSHID:D006973] investigational type-1 angiotensin ii receptor AGTR1 NA unknown NA drugbank losartan NA Hypertensive disease[MeSHID:D006973],Left Ventricular Hypertrophy[MeSHID:D017379],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 2.31 TTD , DGIDB [sar1,tdf2]angii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD tasosartan small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental type-1 angiotensin ii receptor AGTR1 NA antagonist 10.39 drugbank , DGIDB gnf-pf-2307 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown 0.43 TTD , DGIDB cl-329167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 angiotensin ii receptor type-1 AGTR1 Successful target unknown 1.3 TTD , DGIDB tasosartan NA Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 10.39 TTD , DGIDB krh-594 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD l-159093 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD valsartan NA Hypertensive disease[MeSHID:D006973],treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Ventricular Dysfunction, Left[MeSHID:D018487],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Infarction[MeSHID:D007238],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 7.14 TTD , DGIDB fimasartan small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333] investigational type-1 angiotensin ii receptor AGTR1 NA antagonist NA drugbank azilsartan medoxomil small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Disease Progression[MeSHID:D018450],Atrial Fibrillation[MeSHID:D001281],Albuminuria[MeSHID:D000419],Cardiac Arrest[MeSHID:D006323],Recurrence (disease attribute)[MeSHID:D012008] approved,investigational type-1 angiotensin ii receptor AGTR1 NA antagonist NA drugbank saprisartan NA Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 6.5 TTD , DGIDB n,n`-bis-alkyl butylimmidazole 12b NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target antagonist NA TTD , DGIDB valsartan NA Hypertensive disease[MeSHID:D006973],treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Ventricular Dysfunction, Left[MeSHID:D018487],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Infarction[MeSHID:D007238],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 7.14 TTD , DGIDB inc-106 NA Stenosis[MeSHID:D003251],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteries[MeSHID:D001158] investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD gnf-pf-2812 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown 0.14 TTD , DGIDB l-162782 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD cv-11194 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD irbesartan NA Hypertensive disease[MeSHID:D006973],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],hypertensive nephropathy[MeSHID:C563161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 2.13 TTD , DGIDB losartan NA Hypertensive disease[MeSHID:D006973],Left Ventricular Hypertrophy[MeSHID:D017379],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 2.31 TTD , DGIDB candesartan cilexetil small molecule Hypertensive disease[MeSHID:D006973],Left Ventricular Hypertrophy[MeSHID:D017379],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Neoplasm Metastasis[MeSHID:D009362],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450] approved type-1 angiotensin ii receptor AGTR1 NA antagonist 0.22 drugbank , DGIDB eprosartan NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 19.49 TTD , DGIDB saralasin acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD , DGIDB ripisartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD telmisartan NA Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 3.53 TTD , DGIDB losartan NA Hypertensive disease[MeSHID:D006973],Left Ventricular Hypertrophy[MeSHID:D017379],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 2.31 TTD , DGIDB candesartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 2.45 TTD , DGIDB [sar1,bpa3]angii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD irbesartan NA Hypertensive disease[MeSHID:D006973],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],hypertensive nephropathy[MeSHID:C563161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 2.13 TTD , DGIDB 5-oxo-1-2-4-oxadiazol biphenyl NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD [tdf1]angii NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD telmisartan NA Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved angiotensin ii receptor type-1 AGTR1 Successful target antagonist 3.53 TTD , DGIDB irbesartan NA Hypertensive disease[MeSHID:D006973],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],hypertensive nephropathy[MeSHID:C563161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 2.13 TTD , DGIDB cgp-49870 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD saralasin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-1 AGTR1 Successful target unknown 0.65 TTD , DGIDB gnf-pf-3832 NA NA investigative angiotensin ii receptor type-1 AGTR1 Successful target unknown 0.26 TTD , DGIDB milfasartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD forasartan small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental type-1 angiotensin ii receptor AGTR1 NA antagonist 9.09 drugbank , DGIDB sparsentan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Focal glomerulosclerosis[MeSHID:D005923],Myocardial Infarction[MeSHID:D009203] phase 3 angiotensin ii receptor type-1 AGTR1 Successful target antagonist 1.95 TTD , DGIDB ur-7198 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 angiotensin ii receptor type-1 AGTR1 Successful target unknown NA TTD pmid25416646-compound-figure5-e NA NA patented angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD , DGIDB 1-(biphenyl-4-yl-methyl)-1h-imidazole derivative 1 NA NA patented angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD , DGIDB pd123177 NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD angiotensin ii NA Systemic arterial pressure[MeSHID:D062186],Sepsis[MeSHID:D018805],Shock[MeSHID:D012769],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-2 AGTR2 Successful target agonist NA TTD , DGIDB pmid22802221c21 NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD sar-arg-val-tyr-ile-his-pro-ile NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD phenylpyridine derivative 3 NA NA patented angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD , DGIDB mp-157 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 1 angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD , DGIDB sc-52892 NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD ema-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Postherpetic neuralgia[MeSHID:D051474],Peripheral Neuropathy[MeSHID:D010523] phase 2 angiotensin ii receptor type-2 AGTR2 Successful target unknown 21.22 TTD , DGIDB sar-arg-val-tyr-ile-his-pro-phe-oh NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD sc-55634 NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD cyt006-angqb biotech Hypertensive disease[MeSHID:D006973] investigational type-2 angiotensin ii receptor AGTR2 NA unknown NA drugbank saralasin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin ii receptor type-2 AGTR2 Successful target unknown 5.3 TTD , DGIDB tak-591 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD tasosartan small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental type-2 angiotensin ii receptor AGTR2 NA antagonist NA drugbank angiotensin ii NA Systemic arterial pressure[MeSHID:D062186],Sepsis[MeSHID:D018805],Shock[MeSHID:D012769],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD , DGIDB l-158282 NA NA discontinued in phase 2 angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD [125i]cgp42112 NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target agonist NA TTD , DGIDB l-162313 NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD l-159093 NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD sar-arg-val-tyr-ile-his-pro-ala NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD fonsartan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensin ii receptor type-2 AGTR2 Successful target unknown NA TTD angiotensin iii NA NA investigative angiotensin ii receptor type-2 AGTR2 Successful target agonist NA TTD , DGIDB n(6)-(pyridoxal phosphate)-l-lysine small molecule NA experimental serine--pyruvate aminotransferase AGXT NA unknown NA drugbank aminooxyacetic acid small molecule NA experimental serine--pyruvate aminotransferase AGXT NA unknown NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved serine--pyruvate aminotransferase AGXT NA substrate NA drugbank serine small molecule NA investigational,nutraceutical serine--pyruvate aminotransferase AGXT NA unknown NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical serine--pyruvate aminotransferase AGXT NA unknown NA drugbank 4-(2-aminophenyl)-4-oxobutanoic acid small molecule NA experimental serine--pyruvate aminotransferase AGXT NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine--pyruvate aminotransferase AGXT NA cofactor NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical alanine--glyoxylate aminotransferase 2, mitochondrial AGXT2 NA unknown NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved alanine--glyoxylate aminotransferase 2, mitochondrial AGXT2 NA product of NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical alanine--glyoxylate aminotransferase 2, mitochondrial AGXT2 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical alanine--glyoxylate aminotransferase 2, mitochondrial AGXT2 NA cofactor NA drugbank 5'-deoxy-5'-ureidoadenosine NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD fluoro-neplanocin a NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD neplanocin a NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD 5'-s-ethyl-5'-thioadenosine NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD (1'r,2's)-9-(2-hydroxy-3'-keto-cyclopenten-1-yl)adenine small molecule NA experimental adenosylhomocysteinase AHCY NA unknown NA drugbank 5-methylenearisteromycin NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD dznep NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD d-eritadenine small molecule NA experimental,investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD , drugbank nicotinamide-adenine-dinucleotide NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD 2-propanol, isopropanol NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD 4(z)-(5'-deoxyadenosin-5'-ylidene)butanoic acid NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD 5(e)-(5'-deoxyadenosin-5'-ylidene)pentanoic acid NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD noraristeromycin NA NA investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD 3'-oxo-adenosine small molecule NA experimental,investigative adenosylhomocysteinase AHCY Literature-reported target unknown NA TTD , drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adenosylhomocysteinase AHCY NA allosteric modulator NA drugbank cantharidin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Herpes zoster disease[MeSHID:D006562],Leishmaniasis, Cutaneous[MeSHID:D016773],Skin callus[MeSHID:D002145],Molluscum Contagiosum[MeSHID:D008976],Warts[MeSHID:D014860],Bone callus[MeSHID:D002146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aryl hydrocarbon receptor AHR NA agonist NA drugbank omeprazole small molecule Esophagitis[MeSHID:D004941],Maintenance[MeSHID:D008283],Pathologic Processes[MeSHID:D010335],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved aryl hydrocarbon receptor AHR NA agonist 0.09 drugbank , DGIDB flutamide small molecule Disease Management[MeSHID:D019468],Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational aryl hydrocarbon receptor AHR NA agonist NA drugbank ik-175 NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 aryl hydrocarbon receptor AHR Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational aryl hydrocarbon receptor AHR NA unknown 0.04 drugbank , DGIDB rvt-505 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Eczema[MeSHID:D004485] phase 2 aryl hydrocarbon receptor AHR Successful target unknown NA TTD , DGIDB 1-[(4s)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine small molecule NA experimental aryl hydrocarbon receptor AHR NA unknown NA drugbank 2-(1h-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] preclinical aryl hydrocarbon receptor AHR Successful target unknown NA TTD ch-223191 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative aryl hydrocarbon receptor AHR Successful target unknown NA TTD diosmin small molecule Blood capillaries[MeSHID:D002196],Veins[MeSHID:D014680],Hemorrhoids[MeSHID:D006484],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aryl hydrocarbon receptor AHR NA agonist NA drugbank romiplostim NA Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved aryl hydrocarbon receptor AHR Successful target unknown 0.27 TTD , DGIDB emodin small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational aryl hydrocarbon receptor AHR NA agonist 0.08 drugbank , DGIDB beta-naphthoflavone small molecule NA experimental aryl hydrocarbon receptor AHR NA unknown 1.77 drugbank , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational aryl hydrocarbon receptor AHR NA unknown 0.04 drugbank , DGIDB leflunomide small molecule Disease Management[MeSHID:D019468],Disease Progression[MeSHID:D018450],Physical Examination[MeSHID:D010808],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Multiple Sclerosis[MeSHID:D009103],Disease[MeSHID:D004194] approved,investigational aryl hydrocarbon receptor AHR NA agonist NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational aryl hydrocarbon receptor AHR NA unknown NA drugbank ginseng biotech NA investigational,nutraceutical aryl hydrocarbon receptor AHR NA agonist NA drugbank epigallocatechin gallate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] investigational aryl hydrocarbon receptor AHR NA unknown NA drugbank atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved aryl hydrocarbon receptor AHR NA agonist NA drugbank indigotindisulfonic acid small molecule Ureter[MeSHID:D014513] approved aryl hydrocarbon receptor AHR NA unknown NA drugbank bay 2416964 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aryl hydrocarbon receptor AHR Successful target unknown NA TTD kynurenic acid small molecule NA investigational aryl hydrocarbon receptor AHR NA unknown NA drugbank atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aryl hydrocarbon receptor AHR NA agonist NA drugbank cb7993113 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical aryl hydrocarbon receptor AHR Successful target unknown NA TTD indirubin-3'-monoxime small molecule NA experimental aryl hydrocarbon receptor AHR NA agonist NA drugbank 6-formylindolo[3,2-b]carbazole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] investigative aryl hydrocarbon receptor AHR Successful target unknown NA TTD indirubin small molecule NA investigational aryl hydrocarbon receptor AHR NA agonist NA drugbank mexiletine small molecule Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Premature ventricular contractions[MeSHID:D018879],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aryl hydrocarbon receptor AHR NA agonist NA drugbank leflunomide small molecule Disease Management[MeSHID:D019468],Disease Progression[MeSHID:D018450],Physical Examination[MeSHID:D010808],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103],Arthritis[MeSHID:D001168] approved,investigational aryl hydrocarbon receptor AHR NA agonist NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational aryl hydrocarbon receptor AHR NA agonist NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational alpha-2-hs-glycoprotein AHSG NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2-hs-glycoprotein AHSG NA unknown NA drugbank cbx-129801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 connecting peptide AHSG Clinical trial target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational alpha-2-hs-glycoprotein AHSG NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental alpha-2-hs-glycoprotein AHSG NA chelator NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational alpha-2-hs-glycoprotein AHSG NA chelator NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-hemoglobin-stabilizing protein AHSP NA unknown NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved alpha-hemoglobin-stabilizing protein AHSP NA unknown NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved alpha-hemoglobin-stabilizing protein AHSP NA unknown NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved alpha-hemoglobin-stabilizing protein AHSP NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved alpha-hemoglobin-stabilizing protein AHSP NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved alpha-hemoglobin-stabilizing protein AHSP NA unknown NA drugbank jx-929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytosine deaminase AICDA Clinical trial target unknown NA TTD , DGIDB mcc small molecule Malignant neoplasm of urinary bladder[MeSHID:D001749] investigational apoptosis-inducing factor 1, mitochondrial AIFM1 NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved apoptosis-inducing factor 1, mitochondrial AIFM1 NA unknown NA drugbank bis(adenosine)-5'-pentaphosphate small molecule NA experimental adenylate kinase isoenzyme 1 AK1 NA unknown NA drugbank bis(adenosine)-5'-pentaphosphate small molecule NA experimental adenylate kinase 2, mitochondrial AK2 NA unknown NA drugbank imidazole small molecule NA experimental,investigational adenylate kinase 2, mitochondrial AK2 NA unknown NA drugbank bis(adenosine)-5'-pentaphosphate small molecule NA experimental adenylate kinase 8 AK8 NA unknown NA drugbank tolrestat small molecule Complications of Diabetes Mellitus[MeSHID:D048909] withdrawn alcohol dehydrogenase [nadp(+)] AKR1A1 NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental alcohol dehydrogenase [nadp(+)] AKR1A1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alcohol dehydrogenase [nadp(+)] AKR1A1 NA unknown NA drugbank quercitrin NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-(benzofuran-2-sulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD daidzein NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD lidorestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational,phase 2 aldose reductase AKR1B1 Successful target inhibitor 14.69 TTD , drugbank , DGIDB hydroxydimethylarsine oxide NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 4-(3-benzoyl-1h-pyrrol-1-yl)butanoic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD citric acid small molecule NA approved,nutraceutical,vet_approved aldose reductase AKR1B1 NA inhibitor NA drugbank apigenin-7-o-beta-d-glucuronide NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD nicotinamide adenine dinucleotide phosphate small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank palbinone NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 7-hydroxy-4-phenylcoumarin NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD lidorestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational,phase 2 aldose reductase AKR1B1 Successful target unknown 14.69 TTD , drugbank , DGIDB pimagedine small molecule Diabetic Nephropathy[MeSHID:D003928] investigational aldose reductase AKR1B1 NA unknown NA drugbank 3,5-dichlorosalicylic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD m-16209 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 aldose reductase AKR1B1 Successful target unknown NA TTD , DGIDB tamarixetin 3-glucoside-7-sulfate NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD imirestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 3 aldose reductase AKR1B1 Successful target unknown NA TTD o7-nitrooxyethyl chrysin NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 2-(carboxymethyl)-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank n-acetylalanine small molecule NA experimental,investigative aldose reductase AKR1B1 Successful target unknown NA TTD , drugbank 6-(3-chloro-benzenesulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD nsc-94258 NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD jtt-811 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 aldose reductase AKR1B1 Successful target unknown NA TTD 6-phenylmethanesulfonyl-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD quercetin 3-o-neohesperidoside NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD astragalin NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD triptocalline a NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-(2-bromo-benzenesulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-(1h-indole-2-sulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD o5-acetyl-o7-nitrooxyethyl chrysin NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD contigoside b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2/3 aldose reductase AKR1B1 Successful target unknown NA TTD , DGIDB 2-benzyl-7-hydroxy-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6,7-dihydroxy-2-phenyl-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD cp-744809 small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank 2-benzhydryl-7-hydroxy-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD (4-methyl-2-oxo-2h-quinolin-1-yl)-acetic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD patuletin 3-o-beta-d-galactoside NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 2-(3,4-dihydroxy-benzyl)-7-hydroxy-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD (2-{[(4-bromo-2-fluorobenzyl)amino]carbonyl}-5-chlorophenoxy)acetic acid small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank isorhamnetin 3,7-disulfate NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-(4-chloro-benzenesulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD ari-809 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] preclinical aldose reductase AKR1B1 Successful target unknown NA TTD , DGIDB 2,3-dihydroxypropanal NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD alpha-d-glucose-6-phosphate NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD idd552 small molecule NA experimental,investigative aldose reductase AKR1B1 Successful target unknown NA TTD , drugbank admva NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 aldose reductase AKR1B1 Successful target unknown NA TTD , DGIDB 6-(naphthalene-1-sulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD apigenin NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 4-(3-methoxy-phenyl)-isoxazolidine-3,5-dione NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD (5-chloro-2-{[(3-nitrobenzyl)amino]carbonyl}phenoxy)acetic acid small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank idd594 small molecule NA experimental,investigative aldose reductase AKR1B1 Successful target unknown NA TTD , drugbank bnv-222 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] phase 2/3 aldose reductase AKR1B1 Successful target unknown NA TTD {4-[(carboxymethoxy)carbonyl]-3,3-dioxido-1-oxonaphtho[1,2-d]isothiazol-2(1h)-yl}acetic acid small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank 6-(naphthalene-2-sulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD mangiferin NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 2-(phenylsulfonamido)acetic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD isorhamnetin 3-o-rhamnoside NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 4-[3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank inhibitor idd 384 small molecule NA experimental,investigative aldose reductase AKR1B1 Successful target unknown NA TTD , drugbank tolrestat small molecule Complications of Diabetes Mellitus[MeSHID:D048909] withdrawn aldose reductase AKR1B1 NA inhibitor 7.34 drugbank , DGIDB 6-(4-methoxy-benzenesulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD (6-methoxy-2-oxo-2h-quinolin-1-yl)-acetic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldose reductase AKR1B1 NA unknown NA drugbank tingenin b NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD kaempferol NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 2-(3,4-dihydroxy-phenyl)-7-hydroxy-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-(2-chloro-benzenesulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 7-hydroxy-6-nitro-2-phenyl-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD (8-hydroxy-2-oxo-2h-quinolin-1-yl)-acetic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD ponalrestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Gout[MeSHID:D006073] discontinued in phase 3 aldose reductase AKR1B1 Successful target unknown NA TTD ctl-102-gdept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cytotoxic T-Lymphocytes[MeSHID:D013602],Cancer of Head and Neck[MeSHID:D006258] discontinued in phase 2 aldose reductase AKR1B1 Successful target unknown NA TTD 3-(3-benzoyl-1h-pyrrol-1-yl)propanoic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD tingenone NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD zopolrestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] experimental,discontinued in phase 2 aldose reductase AKR1B1 Successful target inhibitor 9.79 TTD , drugbank , DGIDB patuletin 3-o-beta-d-robinobioside NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD (r)-minalrestat small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank fidarestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] experimental,phase 3 aldose reductase AKR1B1 Successful target inhibitor 9.79 TTD , drugbank , DGIDB {3-[(5-chloro-1,3-benzothiazol-2-yl)methyl]-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl}acetic acid small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank 7-hydroxy-2-(4-methoxy-benzyl)-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid small molecule NA experimental,investigative aldose reductase AKR1B1 Successful target unknown NA TTD , drugbank alpha-d-glucose 6-phosphate small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank t2c-003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] phase 1/2 aldose reductase AKR1B1 Successful target unknown NA TTD , DGIDB 6-(2-fluoro-benzenesulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD ad-5467 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 aldose reductase AKR1B1 Successful target unknown NA TTD ranirestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] investigational,phase 3 aldose reductase AKR1B1 Successful target unknown 9.79 TTD , drugbank , DGIDB glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical aldose reductase AKR1B1 NA unknown NA drugbank 7-hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD gavorestat small molecule NA investigational aldose reductase AKR1B1 NA inhibitor NA drugbank 6-benzenesulfonyl-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD epalrestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Pain[MeSHID:D010146] approved aldose reductase AKR1B1 Successful target unknown 1.22 TTD , DGIDB fidarestat(stereoisomer) NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD {[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank ssr-125047 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Cataract[MeSHID:D002386] phase 1 aldose reductase AKR1B1 Successful target unknown NA TTD , DGIDB epalrestate NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD sorbinil small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Cataract[MeSHID:D002386],Expiration, function[MeSHID:D045853] experimental,investigational,terminated aldose reductase AKR1B1 Successful target inhibitor 3.67 TTD , drugbank , DGIDB minalrestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 3 aldose reductase AKR1B1 Successful target unknown NA TTD 6-(toluene-4-sulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD (6-hydroxy-2-oxo-2h-quinolin-1-yl)-acetic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-methoxykaempferol 3-o-beta-d-robinobioside NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-(4-bromo-benzenesulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD cacodylic acid small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank (s,r)-fidarestat small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank zenarestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] experimental,terminated aldose reductase AKR1B1 Successful target inhibitor 4.9 TTD , drugbank , DGIDB 6-(4-fluoro-benzenesulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD bnv-222 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] investigative aldose reductase AKR1B1 Successful target unknown NA TTD 2'-monophosphoadenosine 5'-diphosphoribose NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-(benzothiazole-2-sulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD apigenin-7-o-beta-d-glucuronide methyl ester NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 6-hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD alrestatin small molecule NA experimental,discontinued in phase 2 aldose reductase AKR1B1 Successful target unknown NA TTD , drugbank 6-(biphenyl-2-sulfonyl)-2h-pyridazin-3-one NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD chrysin NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD alo-1567 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 1 aldose reductase AKR1B1 Successful target unknown NA TTD , DGIDB ak198 NA NA investigative aldose reductase AKR1B1 Successful target inhibitor NA TTD , DGIDB 2-(3-benzoyl-1h-pyrrol-1-yl)acetic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD 2-(4-aminophenylsulfonamido)acetic acid NA NA investigative aldose reductase AKR1B1 Successful target unknown NA TTD sulindac small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aldose reductase AKR1B1 Successful target inhibitor 1.9 TTD , drugbank , DGIDB qr-333 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] investigational,phase 2 aldose reductase AKR1B1 Successful target unknown NA TTD , drugbank , DGIDB 2-(3-((4,5,7-trifluorobenzo[d]thiazol-2-yl)methyl)-1h-pyrrolo[2,3-b]pyridin-1-yl)acetic acid small molecule NA experimental aldose reductase AKR1B1 NA unknown NA drugbank exisulind small molecule Disease[MeSHID:D004194],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Esophagus[MeSHID:D004947],Colonic Polyps[MeSHID:D003111],Barrett Esophagus[MeSHID:D001471],Esophageal Diseases[MeSHID:D004935],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational aldose reductase AKR1B1 NA inhibitor NA drugbank fidarestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] experimental aldo-keto reductase family 1 member b10 AKR1B10 NA inhibitor NA drugbank tolrestat small molecule Complications of Diabetes Mellitus[MeSHID:D048909] withdrawn aldo-keto reductase family 1 member b10 AKR1B10 NA unknown 23.87 drugbank , DGIDB zopolrestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] experimental aldo-keto reductase family 1 member b10 AKR1B10 NA unknown NA drugbank sulindac small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aldo-keto reductase family 1 member b10 AKR1B10 NA inhibitor NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental aldo-keto reductase family 1 member b10 AKR1B10 NA unknown NA drugbank exisulind small molecule Disease[MeSHID:D004194],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Esophagus[MeSHID:D004947],Colonic Polyps[MeSHID:D003111],Barrett Esophagus[MeSHID:D001471],Esophageal Diseases[MeSHID:D004935],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational aldo-keto reductase family 1 member b10 AKR1B10 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved aldo-keto reductase family 1 member c1 AKR1C1 NA inhibitor NA drugbank 2-hydroxy-3,5-diiodobenzoic acid small molecule NA experimental aldo-keto reductase family 1 member c1 AKR1C1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldo-keto reductase family 1 member c1 AKR1C1 NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental aldo-keto reductase family 1 member c1 AKR1C1 NA unknown NA drugbank salicylic acid small molecule Acne Vulgaris[MeSHID:D000152],Keratosis pilaris[MeSHID:C537412],Skin callus[MeSHID:D002145],Warts[MeSHID:D014860],Psoriasis[MeSHID:D011565],Bone callus[MeSHID:D002146] approved,investigational,vet_approved aldo-keto reductase family 1 member c1 AKR1C1 NA inhibitor NA drugbank naringenin small molecule NA experimental aldo-keto reductase family 1 member c1 AKR1C1 NA antagonist NA drugbank hexestrol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn aldo-keto reductase family 1 member c1 AKR1C1 NA unknown NA drugbank epitestosterone small molecule NA experimental aldo-keto reductase family 1 member c1 AKR1C1 NA unknown NA drugbank chenodeoxycholic acid small molecule Gallbladder[MeSHID:D005704],Calculi[MeSHID:D002137],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641] approved aldo-keto reductase family 1 member c2 AKR1C2 NA substrate NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental aldo-keto reductase family 1 member c2 AKR1C2 NA unknown NA drugbank ursodeoxycholic acid small molecule Biliary calculi[MeSHID:D042882],Cholecystolithiasis[MeSHID:D041761],Operative Surgical Procedures[MeSHID:D013514],Cholelithiasis[MeSHID:D002769],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary biliary cirrhosis[MeSHID:D008105] approved,investigational aldo-keto reductase family 1 member c2 AKR1C2 NA inducer NA drugbank , DGIDB epitestosterone small molecule NA experimental aldo-keto reductase family 1 member c2 AKR1C2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldo-keto reductase family 1 member c2 AKR1C2 NA unknown NA drugbank 2-methyl-2,4-pentanediol NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldo-keto reductase family 1 member c3 AKR1C3 NA unknown NA drugbank n-(benzimidazolylcarbonyl)-piperidine derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB n-(phenylamino)-benzoate derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB isoquinolone derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB indomethacin analog 2 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB nitrogen/sulfur-substituted estrene derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB 2,2-dibenzylcyclopentanol NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD 2-(4-chlorobenzylidene)cyclopentanone NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD acetate ion NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD m-phenoxybenzoic acid for cis-isomer NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD 2-(4-chlorobenzylidene)cyclopentylmethyl ether NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD indomethacin analog 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB 2-(4-chlorobenzylidene)cyclopentyl ethyl ether NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD 3-phenylcyclopentanecarboxylic acid NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD 4-androstene-3-17-dione NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD nicotinamide adenine dinucleotide phosphate small molecule NA experimental aldo-keto reductase family 1 member c3 AKR1C3 NA unknown NA drugbank em-1424 NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD flufenamic acid small molecule Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aldo-keto reductase family 1 member c3 AKR1C3 NA unknown NA drugbank , DGIDB indomethacin analog 3 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB em1396 NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD n-(naphthylamino)-benzoate derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB 3-carboxamido-1,3,5(10)-estratrien-17(r)-spiro-2'(5',5'-dimethyl-6'oxo)tetrahydropyran small molecule NA experimental aldo-keto reductase family 1 member c3 AKR1C3 NA unknown NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational aldo-keto reductase family 1 member c3 AKR1C3 NA inhibitor 0.5 drugbank , DGIDB n-(pyridinepyrroylylcarbonyl)-piperidine derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB n-(indolylcarbonyl)-piperidine derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB 2-[(2,2-diphenylacetyl)amino]benzoic acid NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aldo-keto reductase family 1 member c3 AKR1C3 NA inhibitor 0.5 drugbank , DGIDB androstenedione small molecule NA experimental,illicit aldo-keto reductase family 1 member c3 AKR1C3 NA inducer NA drugbank n-(benzimidazole/indole) benzoic acid derivative 2 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB rutin NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD beta-naphthylacetic acids derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB rutin small molecule NA approved,experimental,investigational aldo-keto reductase family 1 member c3 AKR1C3 NA unknown NA drugbank 2'-monophosphoadenosine 5'-diphosphoribose NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD 3-bromo-5-phenylsalicylc acid NA NA investigative dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD asp-9521 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB prostaglandin d2 small molecule NA investigational aldo-keto reductase family 1 member c3 AKR1C3 NA unknown NA drugbank n-(benzimidazole/indole) benzoic acid derivative 1 NA NA patented dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB flufenamic acid NA Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dihydrodiol dehydrogenase type i AKR1C3 Successful target unknown NA TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldo-keto reductase family 1 member c4 AKR1C4 NA unknown NA drugbank 3,20-pregnanedione small molecule NA experimental 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 NA unknown NA drugbank finasteride small molecule Operative Surgical Procedures[MeSHID:D013514],Urinary Retention[MeSHID:D016055],Androgenetic Alopecia[MeSHID:D000505],Prostate[MeSHID:D011467],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 NA inhibitor 9.79 drugbank , DGIDB azelaic acid small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 NA inhibitor NA drugbank 5beta-dihydrotestosterone small molecule NA experimental 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 NA unknown NA drugbank archexin small molecule Neoplasms[MeSHID:D009369] investigational rac-alpha serine/threonine-protein kinase AKT1 NA unknown NA drugbank enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational,phase 3 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.1 TTD , drugbank , DGIDB (z)-3-((1h-pyrrol-2-yl)methylene)indolin-2-one NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD ptx-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Parkinson Disease[MeSHID:D010300],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943] phase 2 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD , DGIDB n-[2-(5-methyl-4h-1,2,4-triazol-3-yl)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine small molecule NA experimental rac-alpha serine/threonine-protein kinase AKT1 NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational rac-alpha serine/threonine-protein kinase AKT1 NA inhibitor 0.05 drugbank , DGIDB m2698 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.29 TTD , DGIDB atp small molecule NA investigational,nutraceutical rac-alpha serine/threonine-protein kinase AKT1 NA unknown NA drugbank bms-754807 NA NA phase 1 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.07 TTD , DGIDB bms-536924 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD pmid20005102c1 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD akt inhibitor viii NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.87 TTD , DGIDB a-674563 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target inhibitor 0.87 TTD , DGIDB akt inhibitor viii NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target allosteric modulator NA TTD , DGIDB bx-517 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational rac-alpha serine/threonine-protein kinase AKT1 NA inhibitor 0.05 drugbank , DGIDB rx-0201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292] phase 2 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.87 TTD , DGIDB genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational rac-alpha serine/threonine-protein kinase AKT1 NA unknown NA drugbank gdc-0068 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of breast[MeSHID:D001943] phase 3 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target inhibitor 1.2 TTD , DGIDB a-443654 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target inhibitor 0.2 TTD , DGIDB bisindolylmaleimide-i NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD gdc-0068 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of breast[MeSHID:D001943] phase 3 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 1.2 TTD , DGIDB ci-1040 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.04 TTD , DGIDB vli-27 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD ld-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD perifosine small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of brain[MeSHID:D001932],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational rac-alpha serine/threonine-protein kinase AKT1 NA unknown 1.05 drugbank , DGIDB ro-316233 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD kn-62 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD azd5363 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target inhibitor 1.07 TTD , DGIDB staurosporinone NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD nu-1001-41 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD alm-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD arq 092 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Proteus Syndrome[MeSHID:D016715] phase 2 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD , DGIDB triciribine prodrug NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD , DGIDB sb-747651a NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD lactoquinomycin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD a-443654 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.2 TTD , DGIDB 4,5,6-trihydroxy-3-methylphthalide NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD gsk2110183 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant Neoplasms[MeSHID:D009369],leukemia[MeSHID:D007938] phase 2 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.65 TTD , DGIDB trametinib + 2141795 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD , DGIDB cmx-2043 NA Myocardial Reperfusion Injury[MeSHID:D015428],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Diseases[MeSHID:D006331] phase 2 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.44 TTD , DGIDB inositol 1,3,4,5-tetrakisphosphate small molecule NA experimental,investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD , drugbank ro31-8220 NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD myriocin NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD arq 751 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD , DGIDB 5-(5-chloro-7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine small molecule NA experimental rac-alpha serine/threonine-protein kinase AKT1 NA unknown NA drugbank 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD perifosine small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of brain[MeSHID:D001932],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational rac-alpha serine/threonine-protein kinase AKT1 NA inhibitor 1.05 drugbank , DGIDB pmid28460551-compound-6 NA NA patented rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown NA TTD , DGIDB ci-1033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 0.12 TTD , DGIDB arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational rac-alpha serine/threonine-protein kinase AKT1 NA inducer NA drugbank azd5363 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 rac-alpha serine/threonine-protein kinase AKT1 Clinical trial target unknown 1.07 TTD , DGIDB isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)ethylamino)ethyl)amide small molecule NA experimental rac-beta serine/threonine-protein kinase AKT2 NA unknown NA drugbank pht-427 NA NA investigative rac-beta serine/threonine-protein kinase AKT2 Literature-reported target inhibitor NA TTD , DGIDB (2s)-1-(1h-indol-3-yl)-3-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}propan-2-amine small molecule NA experimental rac-beta serine/threonine-protein kinase AKT2 NA unknown NA drugbank n-[(1s)-2-amino-1-phenylethyl]-5-(1h-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide small molecule NA experimental rac-beta serine/threonine-protein kinase AKT2 NA unknown NA drugbank 4-(4-chlorophenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine small molecule NA experimental rac-beta serine/threonine-protein kinase AKT2 NA unknown NA drugbank pmid20005102c1 NA NA investigative rac-beta serine/threonine-protein kinase AKT2 Literature-reported target unknown NA TTD akt inhibitor viii NA NA investigative rac-beta serine/threonine-protein kinase AKT2 Literature-reported target allosteric modulator NA TTD , DGIDB isis 29112 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29176 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29135 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29138 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD arq 092 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Proteus Syndrome[MeSHID:D016715] phase 2 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown NA TTD , DGIDB isis 29160 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD mk-2206 NA Rectum[MeSHID:D012007],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 2 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown 0.98 TTD , DGIDB akt inhibitor viii NA NA investigative rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target allosteric modulator NA TTD , DGIDB isis 29156 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29161 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29201 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD tcn-p NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown NA TTD , DGIDB lys-6kakt1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown NA TTD , DGIDB azd5363 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown 0.92 TTD , DGIDB sb-747651a NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD sr13668 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown 0.92 TTD , DGIDB isis 29200 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD xl418 NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown 2.21 TTD , DGIDB gsk2141795 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown 1.38 TTD , DGIDB mk-2206 NA Rectum[MeSHID:D012007],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 2 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target allosteric modulator 0.98 TTD , DGIDB isis 29177 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD mk-2206 NA Rectum[MeSHID:D012007],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 2 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target inhibitor 0.98 TTD , DGIDB isis 29155 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29154 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD ly2780301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown NA TTD , DGIDB isis 29202 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29137 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29139 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD gsk690693 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target inhibitor 0.38 TTD , DGIDB isis 29136 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29178 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD isis 29159 NA NA investigative akt3 messenger rna AKT3 Literature-reported target unknown NA TTD gsk690693 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown 0.38 TTD , DGIDB pmid20005102c1 NA NA investigative rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown NA TTD isc-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown NA TTD bay1125976 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown NA TTD , DGIDB m2698 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 rac-gamma serine/threonine-protein kinase AKT3 Clinical trial target unknown 0.92 TTD , DGIDB formic acid NA NA investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD 4-oxosebacic acid small molecule NA experimental,investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD , drugbank 3-(2-aminoethyl)-4-(aminomethyl)heptanedioic acid small molecule NA experimental,investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD , drugbank 5-fluorolevulinic acid NA NA investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD aminolevulinic acid hci NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623] approved delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD , DGIDB 2-sulfhydryl-ethanol NA NA investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD delta-amino valeric acid small molecule NA experimental,investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD , drugbank aminolevulinic acid small molecule Scalp structure[MeSHID:D012535],Actinic keratosis[MeSHID:D055623],Light[MeSHID:D008027] approved delta-aminolevulinic acid dehydratase ALAD NA inducer NA drugbank porphobilinogen small molecule NA experimental,phase 2 delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD , drugbank , DGIDB 5-hydroxyvaleric acid small molecule NA experimental,investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD , drugbank s,s-(2-hydroxyethyl)thiocysteine NA NA investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD 4,7-dioxosebacic acid small molecule NA experimental,investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD , drugbank laevulinic acid small molecule NA experimental,investigative delta-aminolevulinic acid dehydratase ALAD Successful target unknown NA TTD , drugbank givosiran NA Porphobilinogen synthase deficiency[MeSHID:C562618],Acute intermittent porphyria[MeSHID:D017118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alas1 messenger rna ALAS1 Successful target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical 5-aminolevulinate synthase ALAS1 NA cofactor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical 5-aminolevulinate synthase, nonspecific, mitochondrial ALAS1 NA cofactor NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved 5-aminolevulinate synthase, nonspecific, mitochondrial ALAS1 NA substrate NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved 5-aminolevulinate synthase, erythroid-specific, mitochondrial ALAS2 NA substrate NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical 5-aminolevulinate synthase, erythroid-specific, mitochondrial ALAS2 NA cofactor NA drugbank albumin human NA Solutions[MeSHID:D012996],Ascites[MeSHID:D001201],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Hypoalbuminemia[MeSHID:D034141],Nephrosis[MeSHID:D009401],Nephrotic Syndrome[MeSHID:D009404],Burn injury[MeSHID:D002056],Hypovolemia[MeSHID:D020896],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serum albumin ALB Successful target unknown NA TTD , DGIDB iodipamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gall Bladder Diseases[MeSHID:D005705] approved serum albumin ALB Successful target unknown 3.03 TTD , DGIDB bismuth NA Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serum albumin ALB Successful target unknown NA TTD , DGIDB vobarilizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Rheumatoid Arthritis[MeSHID:D001172] phase 2 serum albumin ALB Successful target unknown NA TTD gadofosveset NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serum albumin ALB Successful target unknown 3.03 TTD , DGIDB evans blue NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aortic Aneurysm, Abdominal[MeSHID:D017544] approved serum albumin ALB Successful target unknown NA TTD , DGIDB aniline small molecule NA experimental serum albumin ALB NA unknown NA drugbank guaiacol small molecule Cell Proliferation[MeSHID:D049109],Dental Pulp[MeSHID:D003782] approved serum albumin ALB NA unknown NA drugbank cefotaxime small molecule Gonorrhea[MeSHID:D006069],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Pyelonephritis[MeSHID:D011704],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serum albumin ALB NA unknown NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational serum albumin ALB NA binder NA drugbank activated recombinant fvii-albumin fusion protein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 2/3 serum albumin ALB Successful target unknown NA TTD , DGIDB spi-1005 NA Reperfusion Injury[MeSHID:D015427],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serum albumin ALB Successful target unknown NA TTD patent blue small molecule Arteries[MeSHID:D001158],Lymphatic vessel[MeSHID:D042601],Malignant neoplasm of breast[MeSHID:D001943],lymph nodes[MeSHID:D008198] approved serum albumin ALB NA binder NA drugbank norelgestromin small molecule Malignant neoplasm of breast[MeSHID:D001943],Pregnancy[MeSHID:D011247] approved,investigational serum albumin ALB NA unknown NA drugbank amsacrine small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational serum albumin ALB NA unknown NA drugbank ru-101 NA Xerophthalmia[MeSHID:D014985],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 serum albumin ALB Successful target unknown NA TTD , DGIDB spi-1005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194] approved serum albumin ALB Successful target unknown NA TTD sodium lauryl sulfate NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serum albumin ALB Successful target unknown NA TTD , DGIDB gadobenate dimeglumine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved serum albumin ALB Successful target unknown NA TTD , DGIDB phenol small molecule Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Aphthous Stomatitis[MeSHID:D013281],Pharyngitis[MeSHID:D010612] approved,experimental serum albumin ALB NA unknown NA drugbank oxyphenbutazone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved serum albumin ALB Successful target unknown 0.23 TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational serum albumin ALB NA ligand NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical delta-1-pyrroline-5-carboxylate synthase ALDH18A1 NA unknown NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinal dehydrogenase 1 ALDH1A1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical retinal dehydrogenase 1 ALDH1A1 NA unknown NA drugbank 1,4-dithiothreitol small molecule NA experimental retinal dehydrogenase 1 ALDH1A1 NA unknown NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved retinal dehydrogenase 1 ALDH1A1 NA substrate NA drugbank , DGIDB vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved retinal dehydrogenase 2 ALDH1A2 NA substrate NA drugbank , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical retinal dehydrogenase 2 ALDH1A2 NA unknown NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinal dehydrogenase 2 ALDH1A2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldehyde dehydrogenase family 1 member a3 ALDH1A3 NA unknown NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved aldehyde dehydrogenase family 1 member a3 ALDH1A3 NA substrate NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldehyde dehydrogenase x, mitochondrial ALDH1B1 NA unknown NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical cytosolic 10-formyltetrahydrofolate dehydrogenase ALDH1L1 NA cofactor NA drugbank crotonaldehyde small molecule NA experimental aldehyde dehydrogenase, mitochondrial ALDH2 NA unknown NA drugbank disulfiram small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aldehyde dehydrogenase, mitochondrial ALDH2 NA inhibitor 1.63 drugbank , DGIDB nicotinamide-adenine-dinucleotide NA NA investigative mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target unknown NA TTD isoformonentin NA NA investigative mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target unknown NA TTD ald-401 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenoleukodystrophy[MeSHID:D000326] phase 2 mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target unknown NA TTD , DGIDB gs-6637 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] phase 1 mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target unknown NA TTD , DGIDB disulfiram small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved aldehyde dehydrogenase, mitochondrial ALDH2 NA inhibitor 1.63 drugbank , DGIDB prunetin NA NA investigative mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target inhibitor 12.73 TTD , DGIDB fp-045 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target unknown NA TTD , DGIDB guanidine small molecule Lambert-Eaton Myasthenic Syndrome[MeSHID:D015624],Paresis[MeSHID:D010291],Muscle Weakness[MeSHID:D018908],Myasthenia Gravis[MeSHID:D009157] approved aldehyde dehydrogenase, mitochondrial ALDH2 NA inhibitor NA drugbank daidzin small molecule NA experimental aldehyde dehydrogenase, mitochondrial ALDH2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldehyde dehydrogenase, mitochondrial ALDH2 NA unknown NA drugbank cvt-10216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigative mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target unknown NA TTD ans-6637 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] phase 1 mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target unknown NA TTD , DGIDB crotylaldehyde NA NA investigative mitochondrial aldehyde dehydrogenase ALDH2 Clinical trial target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldehyde dehydrogenase, dimeric nadp-preferring ALDH3A1 NA unknown NA drugbank s-methyl 4-methyl-4-morpholinopent-2-ynethioate NA NA investigative fatty aldehyde dehydrogenase ALDH3A2 Successful target unknown NA TTD disulfiram NA Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved fatty aldehyde dehydrogenase ALDH3A2 Successful target unknown 1.63 TTD , DGIDB disulfiram NA Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fatty aldehyde dehydrogenase ALDH3A2 Successful target unknown 1.63 TTD , DGIDB aloe-emodin NA NA investigative fatty aldehyde dehydrogenase ALDH3A2 Successful target unknown NA TTD nps 1776 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nail-Patella Syndrome[MeSHID:D009261],Epilepsy[MeSHID:D004827] discontinued in phase 2 fatty aldehyde dehydrogenase ALDH3A2 Successful target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical fatty aldehyde dehydrogenase ALDH3A2 NA unknown NA drugbank nsc-527035 NA NA investigative fatty aldehyde dehydrogenase ALDH3A2 Successful target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldehyde dehydrogenase family 3 member b1 ALDH3B1 NA unknown NA drugbank calcium carbimide small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn aldehyde dehydrogenase family 3 member b2 ALDH3B2 NA antagonist,inhibitor NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aldehyde dehydrogenase family 3 member b2 ALDH3B2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial ALDH4A1 NA unknown NA drugbank t83193 NA NA patented succinate-semialdehyde dehydrogenase ALDH5A1 Successful target unknown NA TTD , DGIDB chlormerodrin small molecule Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn succinate-semialdehyde dehydrogenase, mitochondrial ALDH5A1 NA inhibitor 26.52 drugbank , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical succinate-semialdehyde dehydrogenase, mitochondrial ALDH5A1 NA unknown NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational succinate-semialdehyde dehydrogenase, mitochondrial ALDH5A1 NA inhibitor 1.77 drugbank , DGIDB chlormerodrin NA Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved succinate-semialdehyde dehydrogenase ALDH5A1 Successful target unknown 26.52 TTD , DGIDB succinic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical succinate-semialdehyde dehydrogenase, mitochondrial ALDH5A1 NA inhibitor NA drugbank , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational succinate-semialdehyde dehydrogenase, mitochondrial ALDH5A1 NA inhibitor NA drugbank , DGIDB 1-(4-hydroxyphenyl)prop-2-en-1-one NA NA investigative succinate-semialdehyde dehydrogenase ALDH5A1 Successful target unknown NA TTD succinic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved succinate-semialdehyde dehydrogenase ALDH5A1 Successful target unknown NA TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial ALDH6A1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational alpha-aminoadipic semialdehyde dehydrogenase ALDH7A1 NA ligand NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical alpha-aminoadipic semialdehyde dehydrogenase ALDH7A1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental fructose-bisphosphate aldolase a ALDOA NA ligand NA drugbank dihydroxyacetone phosphate small molecule NA investigational fructose-bisphosphate aldolase a ALDOA NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational fructose-bisphosphate aldolase a ALDOA NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational fructose-bisphosphate aldolase a ALDOA NA ligand NA drugbank 1,6-di-o-phosphono-d-mannitol small molecule NA experimental fructose-bisphosphate aldolase a ALDOA NA unknown NA drugbank n-(4-chlorophenyl)-3-(phosphonooxy)naphthalene-2-carboxamide small molecule NA experimental fructose-bisphosphate aldolase a ALDOA NA unknown NA drugbank 1,6-fructose diphosphate (linear form) small molecule NA experimental fructose-bisphosphate aldolase a ALDOA NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational fructose-bisphosphate aldolase a ALDOA NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational fructose-bisphosphate aldolase a ALDOA NA ligand NA drugbank 1,6-fructose diphosphate (linear form) small molecule NA experimental fructose-bisphosphate aldolase b ALDOB NA unknown NA drugbank sn-glycerol 3-phosphate small molecule NA experimental fructose-bisphosphate aldolase b ALDOB NA unknown NA drugbank dihydroxyacetone phosphate small molecule NA investigational fructose-bisphosphate aldolase b ALDOB NA unknown NA drugbank crl-37212 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD tsr-011 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 alk tyrosine kinase receptor ALK Successful target inhibitor NA TTD , DGIDB ceritinib small molecule Neoplasms[MeSHID:D009369],Continuance of life[MeSHID:D013534],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alk tyrosine kinase receptor ALK Successful target antagonist,inhibitor 4.37 TTD , drugbank , DGIDB azd3463 NA NA investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD , DGIDB asp3026 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1 alk tyrosine kinase receptor ALK Successful target unknown 2.51 TTD , DGIDB gsk-1838705a NA NA investigative alk tyrosine kinase receptor ALK Successful target inhibitor NA TTD , DGIDB x-396 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1/2 alk tyrosine kinase receptor ALK Successful target inhibitor 4.09 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational alk tyrosine kinase receptor ALK NA inhibitor NA drugbank tsr-011 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 alk tyrosine kinase receptor ALK Successful target unknown NA TTD , DGIDB atp small molecule NA investigational,nutraceutical alk tyrosine kinase receptor ALK NA unknown NA drugbank benzimidazole derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented alk tyrosine kinase receptor ALK Successful target unknown NA TTD , DGIDB x-396 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1/2 alk tyrosine kinase receptor ALK Successful target unknown 4.09 TTD , DGIDB brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational alk tyrosine kinase receptor ALK Successful target inhibitor 4.02 TTD , drugbank , DGIDB 1,2,4-triazolo[1,5a]pyridine derivative 2 NA NA patented alk tyrosine kinase receptor ALK Successful target unknown NA TTD , DGIDB gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alk tyrosine kinase receptor ALK NA inhibitor 0.56 drugbank , DGIDB pf-06463922 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 alk tyrosine kinase receptor ALK Successful target unknown 2.55 TTD , DGIDB pmid20483621c5n NA NA investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD ceritinib small molecule Neoplasms[MeSHID:D009369],Continuance of life[MeSHID:D013534],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alk tyrosine kinase receptor ALK Successful target antagonist 4.37 TTD , drugbank , DGIDB crizotinib small molecule Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alk tyrosine kinase receptor ALK Successful target inhibitor 5.03 TTD , drugbank , DGIDB tpx-0005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 alk tyrosine kinase receptor ALK Successful target unknown NA TTD , DGIDB carboxamide derivative 4 NA NA patented alk tyrosine kinase receptor ALK Successful target unknown NA TTD , DGIDB ap26113 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 alk tyrosine kinase receptor ALK Successful target unknown 3.16 TTD , DGIDB pmid24900237c15 NA NA investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD ensartinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 alk tyrosine kinase receptor ALK Successful target inhibitor 4.09 TTD , DGIDB ensartinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 alk tyrosine kinase receptor ALK Successful target unknown 4.09 TTD , DGIDB alectinib small molecule Neoplasms[MeSHID:D009369],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] approved,investigational alk tyrosine kinase receptor ALK Successful target inhibitor 5.16 TTD , drugbank , DGIDB pmid20483621c5g NA NA investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD cep-28122 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD entrectinib NA Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved alk tyrosine kinase receptor ALK Successful target unknown 0.11 TTD , DGIDB lorlatinib small molecule Neoplasm Metastasis[MeSHID:D009362],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alk tyrosine kinase receptor ALK Successful target inhibitor 2.55 TTD , drugbank , DGIDB cep-18050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD pmid28270010-compound-figure21-b NA Brain[MeSHID:D001921],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented alk tyrosine kinase receptor ALK Successful target unknown NA TTD , DGIDB dlx-521 NA NA investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD azd3463 NA NA investigative alk tyrosine kinase receptor ALK Successful target inhibitor NA TTD , DGIDB pmid24432909c8e NA NA investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD pmid22564207c25b NA NA investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD ap26113 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 alk tyrosine kinase receptor ALK Successful target inhibitor 3.16 TTD , DGIDB pmid20483621c5m NA NA investigative alk tyrosine kinase receptor ALK Successful target unknown NA TTD asp3026 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1 alk tyrosine kinase receptor ALK Successful target inhibitor 2.51 TTD , DGIDB ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical alpha-ketoglutarate-dependent dioxygenase alkb homolog 2 ALKBH2 NA activator NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical alpha-ketoglutarate-dependent dioxygenase alkb homolog 3 ALKBH3 NA activator NA drugbank puupehedione NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD dimethylnordihydroguarierate acid NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD puupehenone NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD dysidenin NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD 3,4,6-tribromo-2-(2,4-dibromo-phenoxy)-phenol NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD jaspic acid NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD nsc-292213 NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD mangostin NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD chloropuupehenone NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD (-)-7-n-methyldibromophakellin NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD neodysidenin NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD (+)-(5s,8s,9r,10s)-20-methoxypuupehenone NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD nsc-125034 NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD nsc-172033 NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD (+)-(5s,8s,10s)-20-methoxy-9,15-ene-puupehenol NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD 2,3,4,5-tetrabromo-6-(2,4-dibromo-phenoxy)-phenol NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD polybrominated diphenyl ether derivative NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD isojaspic acid NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD (+)-(5s,8s,10s)-20-methoxypuupehenol NA NA investigative arachidonate 12-lipoxygenase ALOX12 Literature-reported target unknown NA TTD nsc-172033 NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown 0.07 TTD , DGIDB mangostin NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD jaspaquinol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD 3,6,8-tribromo-dibenzo[1,4]dioxin-1-ol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD polybrominated diphenyl ether derivative NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD chloropuupehenone NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD 3,4,6-tribromo-2-(2,4-dibromo-phenoxy)-phenol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD triazole derivative 3 NA NA patented arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , DGIDB tri-substituted benzene derivative 1 NA NA patented arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , DGIDB halisulfate 1 NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD imidazole derivative 10 NA NA patented arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , DGIDB jaspic acid NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD (+)-(5s,8s,10s)-20-methoxypuupehenol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD 2,3,4,5-tetrabromo-6-(2,4-dibromo-phenoxy)-phenol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD (+)-(5s,8s,10s)-20-methoxy-9,15-ene-puupehenol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD subersic acid NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD dysidenin NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational arachidonate 15-lipoxygenase ALOX15 NA unknown NA drugbank (-)-pinoresinol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD indole and benzimidazole derivative 1 NA NA patented arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , DGIDB (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid small molecule NA experimental,investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , drugbank igernellin NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD isoscopoletin NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD kaempferol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD indolizine derivative 1 NA NA patented arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , DGIDB (-)-3,3'-bisdemethylpinoresinol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD puupehenone NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational arachidonate 15-lipoxygenase ALOX15 NA unknown NA drugbank isothiazolone derivative 1 NA NA patented arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , DGIDB dimethylnordihydroguarierate acid NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD (+)-(5s,8s,9r,10s)-20-methoxypuupehenone NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD puupehedione NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD imidazole derivative 11 NA NA patented arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , DGIDB 3,4-dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD scopoletin NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD (+)-3,3'-bisdemethyltanegool NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD isojaspic acid NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD spongiadioxin a NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD pmid26560362-compound-90 NA NA patented arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD , DGIDB hydrohalisulfate 1 NA NA investigative arachidonate 15-lipoxygenase ALOX15 Patented-recorded target unknown NA TTD pyrogallol NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-n-methyl-2,3,3-triphenyl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD morniflumate small molecule Nose[MeSHID:D009666],Disease[MeSHID:D004194],Ear structure[MeSHID:D004423],Gastrointestinal Diseases[MeSHID:D005767],Pharyngeal structure[MeSHID:D010614],Affect (mental function)[MeSHID:D000339],Upper Respiratory Infections[MeSHID:D012141],Bone Tissue[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Otitis Media[MeSHID:D010033] experimental arachidonate 5-lipoxygenase ALOX5 NA antagonist NA drugbank montelukast small molecule Bronchoconstriction[MeSHID:D016084],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Hypersensitivity[MeSHID:D006967],Inspiration function[MeSHID:D001239],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved arachidonate 5-lipoxygenase ALOX5 NA unknown 0.28 drugbank , DGIDB vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved arachidonate 5-lipoxygenase ALOX5 NA unknown NA drugbank ucb-35440 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB mk-591 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 1-furan-2-yl-3-pyridin-2-yl-propenone (fpp-3) NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD puupehedione NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD montelukast small molecule Bronchoconstriction[MeSHID:D016084],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Hypersensitivity[MeSHID:D006967],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved arachidonate 5-lipoxygenase ALOX5 NA unknown 0.28 drugbank , DGIDB sc-45662 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-4-isobutyl-benzamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved arachidonate 5-lipoxygenase ALOX5 NA inhibitor 0.42 drugbank , DGIDB 5-methyl-n-phenylbenzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD anthracene-2-carboxylic acid hydroxyamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD isis 1831 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD zileuton small molecule Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn arachidonate 5-lipoxygenase ALOX5 Successful target inhibitor 7.32 TTD , drugbank , DGIDB 2-(4-phenyl-butyl)-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD tepoxalin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 1.27 TTD , DGIDB 1,2-dihydroxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD mesalazine small molecule Crohn's disease of large bowel[MeSHID:D003424],ileum[MeSHID:D007082],Ulcerative Colitis[MeSHID:D003093],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved arachidonate 5-lipoxygenase ALOX5 NA inhibitor 0.64 drugbank , DGIDB 5,3'-dipropyl-biphenyl-2,4'-diol NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD n-(1,3,4-thiadiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD dup-654 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD rilopirox NA Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 2.55 TTD , DGIDB n-(5-methylthiazol-2-yl)-2-phenylacetamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 3-biphenyl-3-yl-n-hydroxy-n-methyl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 3-methoxy-n-(4-methylthiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 5-chloro-n-(4-ethylphenyl)benzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 10-acetyl-1,8-dihydroxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational arachidonate 5-lipoxygenase ALOX5 NA inhibitor NA drugbank cylindol a NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD chebulagic acid NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-3-phenyl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational arachidonate 5-lipoxygenase ALOX5 NA inhibitor NA drugbank e-6080 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-methyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD wy-50295-tromethamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB sb-202235 NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2,4,5-triarylimidazole analogue NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 2-pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD bf-389 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB 2-(4-methoxy-phenyl)-5-phenyl-thiazol-4-ol NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD (-)-3,3'-bisdemethylpinoresinol NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD n-hydroxy-3-naphthalen-2-yl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-(4-methylthiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD zd-2138 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD eth615 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD (n-(3-phenoxycinnamyl)-acetohydroxamic acid NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD (+)-3,3'-bisdemethyltanegool NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD pd-169316 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 2-(3-phenyl-propyl)-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD phenanthrene-2-carboxylic acid hydroxyamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD kaempferol NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD fpl-62064 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] phase 3 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB ta-270 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB 4-methoxy-n-(thiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD phenanthrene-3-carboxylic acid hydroxyamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-(4-butoxy-phenoxy)-n-hydroxy-acetamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 4-butoxy-n-hydroxy-n-methyl-benzamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2,4'-diacetoxy-5,3'-di-(2-propenyl)-biphenyl NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 2-phenyl-n-(1,3,4-thiadiazol-2-yl)acetamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD licofelone small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 1 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 3.82 TTD , drugbank , DGIDB 3,4-dihydroxycinnamic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] phase 4 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-n-methyl-2-naphthalen-2-yl-propionamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD sc-41661a NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD l-689065 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD hexanoic acid 2,5-diphenyl-thiazol-4-yl ester NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD meclofenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Menorrhagia[MeSHID:D008595],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthralgia[MeSHID:D018771] approved,vet_approved arachidonate 5-lipoxygenase ALOX5 NA inhibitor NA drugbank , DGIDB 2-phenyl-n-(thiazol-2-yl)acetamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 1-benzyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD l-746530 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD l-702-539 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD (-)-pinoresinol NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD tebufelone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 1-(4-methoxyphenyl)-3-(4-methylthiazol-2-yl)urea NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD tipelukast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 1.27 TTD , DGIDB 1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD mk-886 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD jaspaquinol NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD n-hydroxy-4-(naphthalen-1-yl)benzamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-4-naphthalen-2-yl-benzamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-n-methyl-3-phenanthren-9-yl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 1,8-dichloro-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-(4-methylthiazol-2-yl)-2-phenylacetamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 2-(4-butoxy-phenyl)-n-hydroxy-n-methyl-acetamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD bw-a137c NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD mk-866 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB skf-105809 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB e-3040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD mln-977 small molecule Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , drugbank ptc299 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Rheumatoid Arthritis[MeSHID:D001172] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB anthrone NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD bw a360c NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD flobufen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 3 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB 2-benzyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD isaindigotone NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD n-(5-methylthiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 15-hydroxyeicosatetraenoic acid NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-phenylbenzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-(2-ethylphenyl)-5-methylbenzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD phenidone NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-(4-ethylphenyl)benzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD cgs-23885 NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD hyperforin small molecule NA nutraceutical,investigative arachidonate 5-lipoxygenase ALOX5 Successful target inhibitor NA TTD , drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational arachidonate 5-lipoxygenase ALOX5 NA inhibitor NA drugbank ici-211965 NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-n-methyl-benzamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD puupehenone NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 4'-methoxy-5,3'-dipropyl-biphenyl-2ol NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 1-methyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD cv-6504 NA NA discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-3-naphthalen-2-yl-n-p-tolyl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-3-naphthalen-2-yl-n-phenyl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD avastin+/-tarceva NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 3 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB tebufelone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD opc-21268 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Diseases[MeSHID:D006331] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD isojaspic acid NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 2-(4-butoxy-phenoxy)-n-hydroxy-propionamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-(4-butoxy-phenoxy)-n-hydroxy-n-methyl-acetamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-n-methyl-3-phenanthren-2-yl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD abt-761 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 5.09 TTD , DGIDB 3-biphenyl-4-yl-n-hydroxy-n-methyl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD pf-4191834 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 5.09 TTD , DGIDB l-652,343 NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-n-methyl-3-naphthalen-2-yl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-n-methyl-3-naphthalen-1-yl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 4-(dimethylamino)-n-(thiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD isis 1822 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD isis 2177 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD aminosalicylic acid small molecule Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Lung[MeSHID:D008168] approved arachidonate 5-lipoxygenase ALOX5 NA inhibitor NA drugbank 2-phenyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (dhdmbf30) NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD q301 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD d-alpha-tocopherol acetate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Skin Aging[MeSHID:D015595],Premenstrual syndrome[MeSHID:D011293],Fertility[MeSHID:D005298],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Asthma[MeSHID:D001249],Muscle Cramp[MeSHID:D009120],Cataract[MeSHID:D002386],Disorder of eye[MeSHID:D005128],Ultraviolet Rays[MeSHID:D014466] approved,nutraceutical,vet_approved arachidonate 5-lipoxygenase ALOX5 NA unknown NA drugbank methylhonokiol NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD naphthalene-2-carboxylic acid hydroxyamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-2-naphthalen-2-yl-acetamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved arachidonate 5-lipoxygenase ALOX5 NA unknown NA drugbank azd-4407 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD baicalein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-(4-hydroxylphenyl)-3-(3,5-dihydroxylphenyl) propenoic acid (nnu-hdpa) NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD cd-581 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] discontinued in phase 1 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 1,3,8-trihydroxy-6-methyl-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD isis 1820 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 3,4,5-trimethoxy-n-(thiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 4-bromo-n-hydroxy-benzamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational arachidonate 5-lipoxygenase ALOX5 NA unknown NA drugbank tzi-41127 NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD bw b218c NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD tenidap NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 3 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 1.27 TTD , DGIDB 1-hydroxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational arachidonate 5-lipoxygenase ALOX5 NA unknown NA drugbank 2-pyridin-3-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD acanthus ilicifolius linn NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-n-methyl-3-phenanthren-3-yl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD honokiol NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD balsalazide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] approved,investigational arachidonate 5-lipoxygenase ALOX5 NA inhibitor 1.91 drugbank , DGIDB 3-benzoyl-n-hydroxy-benzamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-4-iodo-benzamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 1-hydroxy-8-methoxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD sk&f 107649 NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 4-hydroxy-5-methoxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-phenethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD masoprocol small molecule Precancerous Conditions[MeSHID:D011230],Growth[MeSHID:D006128],Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational arachidonate 5-lipoxygenase ALOX5 NA inhibitor NA drugbank n-hydroxy-n-methyl-3-naphthalen-2-yl-propionamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 4,5-dihydroxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 3,4-dihydroxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD darbufelone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2/3 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 1.27 TTD , DGIDB rhein small molecule NA experimental arachidonate 5-lipoxygenase ALOX5 NA inhibitor NA drugbank methyl 2-(benzylamino)-1h-indole-3-carboxylate NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD cmi-392 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB r-68151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-hydroxy-3-naphthalen-2-yl-propionamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 5,8-dihydroxy-1,4-naphthoquinone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 5-methyl-2-p-tolyl-thiazol-4-ol NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD e-6700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB bw-858c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Body Weight[MeSHID:D001835],Asthma[MeSHID:D001249] investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 4,5-dimethoxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2'-nitro-biphenyl-4-carboxylic acid hydroxyamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 5s-hete NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 5-chloro-n-phenylbenzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD buddledin a NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 5-methoxy-n-phenylbenzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 1,5-dihydroxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 4-(1h-indol-3-yl)-1-morpholinobutan-1-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD fpl-64170 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD isis 1827 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD silymarin NA NA phase 4 arachidonate 5-lipoxygenase ALOX5 Successful target unknown 0.85 TTD , DGIDB 1,8,9-trimethoxy-9,10-dihydro-anthracene NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD cj-13610 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-(4-ethylphenyl)-5-methylbenzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-(thiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 3-methoxy-n-(1,3,4-thiadiazol-2-yl)benzamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 2,4'-dimethoxy-5,3'-di-(2-propenyl)-biphenyl NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD acacetin NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown 0.34 TTD , DGIDB bim23a760 NA Acromegaly[MeSHID:D000172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Carcinoid Syndrome[MeSHID:D008303],Psoriasis[MeSHID:D011565] phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD , DGIDB heme NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 4-pentadeca-1,3,6-trienylsulfanyl-butyric acid NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD biphenyl-4-carboxylic acid hydroxyamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-(4-methoxyphenyl)-n-(thiazol-2-yl)acetamide NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD ibuproxam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] withdrawn from market arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD isis 1821 NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 2-biphenyl-4-yl-n-hydroxy-n-methyl-acetamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD n-(3-bromophenyl)-5-methoxybenzo[d]oxazol-2-amine NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 1-(4-methoxyphenyl)-3-(5-methylthiazol-2-yl)urea NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD diethylcarbamazine small molecule Disease[MeSHID:D004194],Communicable Diseases[MeSHID:D003141],Eosinophilia, Tropical[MeSHID:D004802],Filarial Elephantiases[MeSHID:D004605],Infection[MeSHID:D007239],Loiasis[MeSHID:D008118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved arachidonate 5-lipoxygenase ALOX5 Successful target inhibitor 17.82 TTD , drugbank , DGIDB 10-benzoyl-1,8-dihydroxy-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD methyl 2-(diallylamino)-1h-indole-3-carboxylate NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD n-hydroxy-n-[1-(4-isobutylphenyl)ethyl]urea NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD 3-(4-butoxy-phenyl)-n-hydroxy-n-methyl-acrylamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD biphenyl-3-carboxylic acid hydroxyamide NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 1,8-dihydroxy-2-propionyl-10h-anthracen-9-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-furan-2-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD linetastine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] discontinued in phase 2 arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-(benzyloxy)naphthalene NA NA investigative lox-5 messenger rna ALOX5 Discontinued target unknown NA TTD n-hydroxy-n-[1-(4-isobutylphenyl)ethyl]urea NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD fr-122788 NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD 2-(1h-indol-3-ylmethyl)-1,2-dihydro-indazol-3-one NA NA investigative arachidonate 5-lipoxygenase ALOX5 Successful target unknown NA TTD dg031 small molecule Myocardial Infarction[MeSHID:D009203],Heart Diseases[MeSHID:D006331],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational arachidonate 5-lipoxygenase-activating protein ALOX5AP NA unknown NA drugbank , DGIDB fiboflapon small molecule Disease[MeSHID:D004194] investigational arachidonate 5-lipoxygenase-activating protein ALOX5AP NA inhibitor 63.65 drugbank , DGIDB l-689,037 NA NA investigative arachidonate 5-lipoxygenase activating protein ALOX5AP Discontinued target unknown NA TTD l-671,480 NA NA investigative arachidonate 5-lipoxygenase activating protein ALOX5AP Discontinued target unknown NA TTD gsk2190914 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 arachidonate 5-lipoxygenase activating protein ALOX5AP Discontinued target unknown NA TTD am103 NA Asthma[MeSHID:D001249],Cardiovascular Diseases[MeSHID:D002318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 arachidonate 5-lipoxygenase activating protein ALOX5AP Discontinued target unknown NA TTD am103 small molecule Asthma[MeSHID:D001249],Cardiovascular Diseases[MeSHID:D002318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational arachidonate 5-lipoxygenase-activating protein ALOX5AP NA unknown NA drugbank dg031 NA Myocardial Infarction[MeSHID:D009203],Heart Diseases[MeSHID:D006331],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 3 arachidonate 5-lipoxygenase activating protein ALOX5AP Discontinued target unknown NA TTD , DGIDB gsk2190915 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 arachidonate 5-lipoxygenase activating protein ALOX5AP Discontinued target unknown NA TTD azd4769 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 arachidonate 5-lipoxygenase activating protein ALOX5AP Discontinued target unknown NA TTD mersalyl small molecule Hypertensive disease[MeSHID:D006973],Edema[MeSHID:D004487] experimental alkaline phosphatase, tissue-nonspecific isozyme ALPL NA antagonist NA drugbank levamisole NA melanoma[MeSHID:D008545],Cutaneous Melanoma[MeSHID:C562393],Cancer of Head and Neck[MeSHID:D006258],Operative Surgical Procedures[MeSHID:D013514],Malignant tumor of colon[MeSHID:D003110],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parasitic Diseases[MeSHID:D010272] approved alkaline phosphatase tissue-nonspecific ALPL Successful target unknown 1.18 TTD , DGIDB asfotase alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hereditary Diseases[MeSHID:D030342] approved alkaline phosphatase tissue-nonspecific ALPL Successful target unknown NA TTD , DGIDB methyl-phosphonic acid mono-(4-nitro-phenyl) ester small molecule NA experimental alkaline phosphatase, placental type ALPP NA unknown NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical alkaline phosphatase, placental type ALPP NA unknown NA drugbank levamisole small molecule melanoma[MeSHID:D008545],Cutaneous Melanoma[MeSHID:C562393],Cancer of Head and Neck[MeSHID:D006258],Operative Surgical Procedures[MeSHID:D013514],Malignant tumor of colon[MeSHID:D003110],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parasitic Diseases[MeSHID:D010272] approved,investigational,vet_approved,withdrawn alkaline phosphatase, placental-like ALPPL2 NA inhibitor NA drugbank amifostine small molecule Radiation[MeSHID:D011827],Cancer of Head and Neck[MeSHID:D006258],Xerostomia[MeSHID:D014987],Malignant neoplasm of ovary[MeSHID:D010051],Kidney[MeSHID:D007668],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory disease of mucous membrane[MeSHID:D052016] approved,investigational alkaline phosphatase, placental-like ALPPL2 NA inducer NA drugbank 5'-([(z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine NA NA investigative s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD 5'-deoxy-5'-(n,n-dimethylamino)adenosine NA NA investigative s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD ademetionine small molecule Emotions[MeSHID:D004644],Degenerative polyarthritis[MeSHID:D010003],Depressive disorder[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Liver diseases[MeSHID:D008107],Bone Tissue[MeSHID:D001842],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] approved,investigational,nutraceutical s-adenosylmethionine decarboxylase proenzyme AMD1 NA cofactor NA drugbank 5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine NA NA investigative s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD 5'-{[4-(aminooxy)butyl](methyl)amino}-5'-deoxy-8-ethenyladenosine small molecule NA experimental s-adenosylmethionine decarboxylase proenzyme AMD1 NA unknown NA drugbank hydroxyalanine NA NA investigative s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD org 34517/34850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Mood Disorders[MeSHID:D019964] phase 2 s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD , DGIDB 5'-deoxy-5'-(n,n-dimethylamino)-8-methyladenosine NA NA investigative s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD 5'-deoxy-5'-dimethylsulfonioadenosine chloride NA NA investigative s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD [(2-aminooxyethyl)methylamino]-5'-deoxyadenosine NA NA investigative s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD tromethamine NA Metabolic acidosis[MeSHID:D000138],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acidosis[MeSHID:D000138] approved s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown 190.95 TTD , DGIDB putrescine small molecule Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Burn injury[MeSHID:D002056] experimental,discontinued in phase 2 s-adenosylmethionine decarboxylase proenzyme AMD1 Successful target unknown NA TTD , drugbank atp small molecule NA investigational,nutraceutical anti-muellerian hormone type-2 receptor AMHR2 NA unknown NA drugbank hydroxocobalamin small molecule Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Diet, Macrobiotic[MeSHID:D015623],Malignant neoplasm of pancreas[MeSHID:D010190],Biliary Tract Diseases[MeSHID:D001660],Diarrhea[MeSHID:D003967],Cestode Infections[MeSHID:D002590],Malabsorption Syndrome[MeSHID:D008286],Poisoning[MeSHID:D011041],Alcoholic Intoxication, Chronic[MeSHID:D000437],Hyperthyroidism[MeSHID:D006980],Vegan diet[MeSHID:D000067269],Anemia, Pernicious[MeSHID:D000752],ileum[MeSHID:D007082],Vitamin B 12 Deficiency[MeSHID:D014806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Injury[MeSHID:D055370] approved protein amnionless AMN NA other NA drugbank 5-methyltetrahydrofolic acid small molecule NA investigational,nutraceutical aminomethyltransferase, mitochondrial AMT NA unknown NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical aminomethyltransferase, mitochondrial AMT NA cofactor NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical aminomethyltransferase, mitochondrial AMT NA unknown NA drugbank beta-d-glucose small molecule NA experimental alpha-amylase 1 AMY1A NA unknown NA drugbank 4,6-dideoxy-4-amino-alpha-d-glucose small molecule NA experimental alpha-amylase 1 AMY1A NA unknown NA drugbank tris(hydroxyethyl)aminomethane small molecule NA experimental alpha-amylase 1 AMY1A NA unknown NA drugbank 5-hydroxymethyl-chonduritol small molecule NA experimental alpha-amylase 1 AMY1A NA unknown NA drugbank n-[4-hydroxymethyl-cyclohexan-6-yl-1,2,3-triol]-4,6-dideoxy-4-aminoglucopyranoside small molecule NA experimental pancreatic alpha-amylase AMY2A NA unknown NA drugbank 5-hydroxymethyl-chonduritol small molecule NA experimental,investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD , drugbank beta-d-glucose small molecule NA experimental,investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD , drugbank acarbose derived hexasaccharide small molecule NA experimental,investigative pancreatic alpha-amylase AMY2A Clinical trial target ligand NA TTD , drugbank 6-deoxy-alpha-d-glucose NA NA investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD hydroxycitric acid NA NA investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD alpha-acarviosinyl-(1-->9)-3-alpha-d-glucopyranosylpropen NA NA investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD 4-o-(4,6-dideoxy-4-{[4-[(4-o-hexopyranosylhexopyranosyl)oxy]-5,6-dihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}hexopyranosyl)hexopyranose small molecule NA experimental pancreatic alpha-amylase AMY2A NA ligand NA drugbank 4,6-dideoxy-4-amino-alpha-d-glucose small molecule NA experimental,investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD , drugbank pancrecarb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] nda filed pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD , DGIDB acarbose small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Cardiovascular Diseases[MeSHID:D002318] approved,investigational pancreatic alpha-amylase AMY2A NA inhibitor 18.19 drugbank , DGIDB 4,6-dideoxy-4-{[4-[(4-o-hexopyranosylhexopyranosyl)oxy]-5,6-dihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}hexopyranosyl-(1->4)hexopyranosyl-(1->4)hexopyranose small molecule NA experimental pancreatic alpha-amylase AMY2A NA unknown NA drugbank 4-o-(4,6-dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-beta-d-lyxo-hexopyranosyl)-alpha-d-erythro-hexopyranose small molecule NA experimental pancreatic alpha-amylase AMY2A NA unknown NA drugbank pyroglutamic acid NA NA investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational pancreatic alpha-amylase AMY2A NA unknown NA drugbank 4,6-dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-d-lyxo-hexopyranosyl-(1->4)-alpha-d-threo-hexopyranosyl-(1->6)-alpha-l-threo-hexopyranose small molecule NA experimental pancreatic alpha-amylase AMY2A NA unknown NA drugbank alpha-d-quinovopyranose small molecule NA experimental pancreatic alpha-amylase AMY2A NA unknown NA drugbank liprotamase NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 pancreatic alpha-amylase AMY2A Clinical trial target unknown 10.61 TTD , DGIDB alpha-acarviosinyl-(1-->7)-3-alpha-d-glucopyranosylpropen NA NA investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD acanthus ilicifolius linn NA NA investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD maltosyl-alpha (1,4)-d-gluconhydroximo-1,5-lactam small molecule NA experimental,investigative pancreatic alpha-amylase AMY2A Clinical trial target unknown NA TTD , drugbank alpha-maltotriose small molecule NA experimental alpha-amylase 2b AMY2B NA unknown NA drugbank 1,4-dithio-alpha-d-glucopyranose small molecule NA experimental alpha-amylase 2b AMY2B NA unknown NA drugbank beta-d-glucose small molecule NA experimental alpha-amylase 2b AMY2B NA unknown NA drugbank p-nitrophenol small molecule NA experimental alpha-amylase 2b AMY2B NA unknown NA drugbank pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational alpha-amylase 2b AMY2B NA unknown NA drugbank maltose small molecule NA experimental,investigational alpha-amylase 2b AMY2B NA unknown NA drugbank 4-methylthio-alpha-d-mannose small molecule NA experimental alpha-amylase 2b AMY2B NA unknown NA drugbank 5-hydroxymethyl-chonduritol small molecule NA experimental alpha-amylase 2b AMY2B NA unknown NA drugbank n-[4-hydroxymethyl-cyclohexan-6-yl-1,2,3-triol]-4,6-dideoxy-4-aminoglucopyranoside small molecule NA experimental alpha-amylase 2b AMY2B NA unknown NA drugbank pyrophosphate 2- NA NA investigative angiogenin ANG Literature-reported target unknown NA TTD pyroglutamic acid NA NA investigative angiogenin ANG Literature-reported target unknown NA TTD trebananib NA Renal Cell Carcinoma[MeSHID:D002292],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 angiopoietin-1 ANGPT1 Clinical trial target inhibitor 31.83 TTD , DGIDB amg 386 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Asthma[MeSHID:D001249] phase 3 angiopoietin-1 ANGPT1 Clinical trial target unknown NA TTD , DGIDB amg 780 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 angiopoietin-1 ANGPT1 Clinical trial target unknown NA TTD , DGIDB trebananib NA Renal Cell Carcinoma[MeSHID:D002292],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 angiopoietin-2 ANGPT2 Clinical trial target inhibitor 7.96 TTD , DGIDB nesvacumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 angiopoietin-2 ANGPT2 Clinical trial target inhibitor 47.74 TTD , DGIDB ro5520985 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD , DGIDB amg 386 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Asthma[MeSHID:D001249] phase 3 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD , DGIDB cvx-060 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cervix Uteri[MeSHID:D002584] phase 1/2 angiopoietin-2 ANGPT2 Clinical trial target antibody NA TTD , DGIDB medi3617 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD faricimab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] investigational,phase 3 angiopoietin-2 ANGPT2 Clinical trial target antagonist NA TTD , drugbank rg7221 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD , DGIDB regn910-3 NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Pathologic Neovascularization[MeSHID:D009389],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD bi 836880 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268] phase 1 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD cvx-241 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cervix Uteri[MeSHID:D002584] phase 1 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD , DGIDB cvx-060 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cervix Uteri[MeSHID:D002584] phase 1/2 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD , DGIDB ly3127804 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD , DGIDB ly3127804 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD , DGIDB abtaa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] investigative angiopoietin-2 ANGPT2 Clinical trial target unknown NA TTD regn-910 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 angiopoietin-2 ANGPT2 Clinical trial target unknown 47.74 TTD , DGIDB vupanorsen NA Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] phase 2 angptl3 messenger rna ANGPTL3 Clinical trial target unknown NA TTD akcea-angptl3-lrx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 angiopoietin-related protein 3 ANGPTL3 Successful target unknown 31.83 TTD , DGIDB evinacumab biotech Homozygote[MeSHID:D006720],Hypercholesterolemia, Familial[MeSHID:D006938],Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational angiopoietin-related protein 3 ANGPTL3 Successful target inhibitor,binder,antibody 31.83 TTD , drugbank , DGIDB isis-angptl3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 1 angptl3 messenger rna ANGPTL3 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ankyrin repeat and protein kinase domain-containing protein 1 ANKK1 NA inhibitor NA drugbank dids NA NA investigative calcium-dependent chloride channel anoctamin ANO1 Successful target blocker NA TTD , DGIDB crofelemer small molecule HIV Seropositivity[MeSHID:D006679],Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Dysentery[MeSHID:D004403],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved anoctamin-1 ANO1 NA antagonist,inhibitor 31.83 drugbank , DGIDB benzbromarone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] approved calcium-dependent chloride channel anoctamin ANO1 Successful target unknown NA TTD crofelemer small molecule HIV Seropositivity[MeSHID:D006679],Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Dysentery[MeSHID:D004403],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved anoctamin-1 ANO1 NA antagonist,blocker 31.83 drugbank , DGIDB crofelemer NA HIV Seropositivity[MeSHID:D006679],Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Dysentery[MeSHID:D004403],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-dependent chloride channel anoctamin ANO1 Successful target inhibitor 31.83 TTD , DGIDB dcdpc NA NA investigative calcium-dependent chloride channel anoctamin ANO1 Successful target blocker NA TTD , DGIDB sits NA NA investigative calcium-dependent chloride channel anoctamin ANO1 Successful target blocker NA TTD , DGIDB ins(3,4,5,6)p4 NA NA investigative calcium-dependent chloride channel anoctamin ANO1 Successful target blocker NA TTD , DGIDB 9-anthroic acid NA NA investigative calcium-dependent chloride channel anoctamin ANO1 Successful target blocker NA TTD , DGIDB nppb NA NA investigative calcium-dependent chloride channel anoctamin ANO1 Successful target blocker NA TTD , DGIDB tannic acid NA NA investigative calcium-dependent chloride channel anoctamin ANO1 Successful target blocker NA TTD , DGIDB crofelemer NA HIV Seropositivity[MeSHID:D006679],Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Dysentery[MeSHID:D004403],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-dependent chloride channel anoctamin ANO1 Successful target blocker 31.83 TTD , DGIDB n1-(3-phenoxybenzyl)-n3-hydroxymalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n1-(3,3-diphenylpropyl)-n3-hydroxymalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD icatibant small molecule Angioedemas, Hereditary[MeSHID:D054179],Burn injury[MeSHID:D002056],Liver diseases[MeSHID:D008107],Infection[MeSHID:D007239],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aminopeptidase n ANPEP NA inhibitor NA drugbank 2-benzyl-n1-hydroxy-n3-phenethylmalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD ip10 c8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 aminopeptidase n ANPEP Clinical trial target unknown NA TTD , DGIDB (1-amino-2-phenyl-ethyl)-phosphinic acid NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (1-amino-3-phenyl-propyl)-phosphinic acid NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n1-hydroxy-2-isobutyl-n3-phenethylmalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 2-amino-n1-benzyl-n3-hydroxymalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (s)-2-amino-3-phenyl-propane-1-thiol NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 2-cinnamamido-n4-hexyl-n1-hydroxysuccinamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n1-(4-chlorobenzyl)-2-benzyl-n3-hydroxymalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD angiotensin iv NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (1-amino-3-methyl-butyl)-phosphinic acid NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 2-cinnamamido-n1-hydroxy-n4-pentylsuccinamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n1-benzyl-n3-hydroxy-2-isobutylmalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (1-amino-3-methylsulfanyl-propyl)-phosphinic acid NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n1,2-dibenzyl-n3-hydroxymalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 2-benzyl-n1-hydroxy-n3-(3-phenylpropyl)malonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD ezetimibe small molecule Homozygote[MeSHID:D006720],Hyperlipidemia, Familial Combined[MeSHID:D006950],Hyperlipidemia[MeSHID:D006949],Sitosterolemia[MeSHID:C537345],Hypercholesterolemia, Familial[MeSHID:D006938],Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aminopeptidase n ANPEP NA other NA drugbank (amino-phenyl-methyl)-phosphinic acid NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n1-(4-chlorobenzyl)-2-amino-n3-hydroxymalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (s)-2-amino-4-methyl-pentane-1-thiol NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 1-aminopentylphosphonic acid monophenyl ester NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (1-amino-ethyl)-phosphinic acid NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n4-butyl-2-cinnamamido-n1-hydroxysuccinamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n-hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 1-aminobutylphosphonic acid NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (s)-2-amino-4-methylsulfanyl-butane-1-thiol NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD kelatorphan NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 2-cinnamamido-n1-hydroxy-n4-octylsuccinamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 1-aminohexylphosphonic acid NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (s)-2-amino-propane-1-thiol NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 2-benzyl-n1-hydroxy-n3-(4-phenylbutyl)malonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (s)-2-amino-4-phenyl-butane-1-thiol NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD [(125)i] rb129 NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n1-(4-fluorobenzyl)-2-benzyl-n3-hydroxymalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD pmid23428964ci3 NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD (s)-2-amino-2-phenyl-ethanethiol NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n1,2-dibenzyl-n3-hydroxy-n1-phenethylmalonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD n-biphenyl-3-ylmethyl-n'-hydroxy-malonamide NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD 1-aminohexylphosphonic acid monophenyl ester NA NA investigative aminopeptidase n ANPEP Clinical trial target unknown NA TTD mdx-1303 biotech Anthrax disease[MeSHID:D000881],Bacterial Infections[MeSHID:D001424] investigational anthrax toxin receptor 1 ANTXR1 NA unknown NA drugbank mdx-1303 biotech Anthrax disease[MeSHID:D000881],Bacterial Infections[MeSHID:D001424] investigational anthrax toxin receptor 2 ANTXR2 NA unknown NA drugbank hydrocortisone probutate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved annexin a1 ANXA1 NA unknown NA drugbank hydrocortisone small molecule External auditory canal structure[MeSHID:D004424],Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Hypoaldosteronism[MeSHID:D006994],Dermatologic disorders[MeSHID:D012871],Ulcerative Colitis[MeSHID:D003093],Ear structure[MeSHID:D004423],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Infection[MeSHID:D007239],Herpes Labialis[MeSHID:D006560],Cytoplasmic Granules[MeSHID:D003594],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congenital adrenal hyperplasia[MeSHID:D000312] approved,vet_approved annexin a1 ANXA1 NA agonist 0.5 drugbank , DGIDB hydrocortisone valerate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved annexin a1 ANXA1 NA unknown NA drugbank methylprednisolone small molecule Neoplasms[MeSHID:D009369],Degenerative polyarthritis[MeSHID:D010003],Alopecia Areata[MeSHID:D000506],Keloid[MeSHID:D007627],Neurological observations[MeSHID:D009461],Granuloma Annulare[MeSHID:D016460],Bursitis[MeSHID:D002062],Senile Plaques[MeSHID:D058225],Lichen Simplex Chronicus[MeSHID:D009450],Tenosynovitis[MeSHID:D013717],Synovitis[MeSHID:D013585],Necrobiosis Lipoidica Diabeticorum[MeSHID:D009335],Term Birth[MeSHID:D047929],Lupus Erythematosus, Discoid[MeSHID:D008179],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Hypertrophy[MeSHID:D006984],Alopecia[MeSHID:D000505],Eye[MeSHID:D005123],Lichen Planus[MeSHID:D008010],Spinal Cord Injuries[MeSHID:D013119],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved annexin a1 ANXA1 NA agonist 0.4 drugbank , DGIDB cortisone acetate small molecule Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Gastrointestinal Diseases[MeSHID:D005767],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational annexin a1 ANXA1 NA inducer NA drugbank dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved annexin a1 ANXA1 NA agonist 0.27 drugbank , DGIDB methylprednisolone small molecule Neoplasms[MeSHID:D009369],Degenerative polyarthritis[MeSHID:D010003],Alopecia Areata[MeSHID:D000506],Keloid[MeSHID:D007627],Neurological observations[MeSHID:D009461],Granuloma Annulare[MeSHID:D016460],Bursitis[MeSHID:D002062],Senile Plaques[MeSHID:D058225],Lichen Simplex Chronicus[MeSHID:D009450],Tenosynovitis[MeSHID:D013717],Synovitis[MeSHID:D013585],Necrobiosis Lipoidica Diabeticorum[MeSHID:D009335],Term Birth[MeSHID:D047929],Lupus Erythematosus, Discoid[MeSHID:D008179],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Hypertrophy[MeSHID:D006984],Alopecia[MeSHID:D000505],Eye[MeSHID:D005123],Lichen Planus[MeSHID:D008010],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,vet_approved annexin a1 ANXA1 NA agonist 0.4 drugbank , DGIDB betamethasone phosphate small molecule Neoplasms[MeSHID:D009369],Alopecia Areata[MeSHID:D000506],Keloid[MeSHID:D007627],Senile Plaques[MeSHID:D058225],Hypersensitivity[MeSHID:D006967],Trichinellosis[MeSHID:D014235],Rheumatoid Arthritis[MeSHID:D001172],Hematological Disease[MeSHID:D006402],Disorder of eye[MeSHID:D005128],Respiration Disorders[MeSHID:D012120],Alopecia[MeSHID:D000505],Endocrine System Diseases[MeSHID:D004700],Lichen Planus[MeSHID:D008010],Kidney Diseases[MeSHID:D007674],Degenerative polyarthritis[MeSHID:D010003],Tuberculosis, Meningeal[MeSHID:D014390],Neurological observations[MeSHID:D009461],Granuloma Annulare[MeSHID:D016460],Bursitis[MeSHID:D002062],Lichen Simplex Chronicus[MeSHID:D009450],Tenosynovitis[MeSHID:D013717],Synovitis[MeSHID:D013585],Necrobiosis Lipoidica Diabeticorum[MeSHID:D009335],Lupus Erythematosus, Discoid[MeSHID:D008179],Dermatologic disorders[MeSHID:D012871],Myocardium[MeSHID:D009206],Gastrointestinal Diseases[MeSHID:D005767],Arthritis, Gouty[MeSHID:D015210],Hypertrophy[MeSHID:D006984],Rheumatism[MeSHID:D012216] approved,vet_approved annexin a1 ANXA1 NA agonist NA drugbank fluocinolone acetonide small molecule Eczema[MeSHID:D004485],Communicable Diseases[MeSHID:D003141],Keloid[MeSHID:D007627],Posterior eyeball segment structure[MeSHID:D057972],Ear structure[MeSHID:D004423],Affect (mental function)[MeSHID:D000339],Dermatitis[MeSHID:D003872],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Physiologic Intraocular Pressure[MeSHID:D007429],Body tissue[MeSHID:D014024],Dermatologic disorders[MeSHID:D012871],Otitis Externa[MeSHID:D010032],Hypertrophy[MeSHID:D006984],Macular Edema, Cystoid[MeSHID:D008269],Dermatitis, Atopic[MeSHID:D003876],Hemorrhoids[MeSHID:D006484],Seborrheic dermatitis of scalp[MeSHID:D063807],Uveitis[MeSHID:D014605],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational,vet_approved annexin a1 ANXA1 NA inducer NA drugbank prednisolone phosphate small molecule Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Dermatologic disorders[MeSHID:D012871],Hematological Disease[MeSHID:D006402],Gastrointestinal Diseases[MeSHID:D005767],Disorder of eye[MeSHID:D005128],Neurological observations[MeSHID:D009461],Respiration Disorders[MeSHID:D012120],Rheumatism[MeSHID:D012216],Hypersensitivity[MeSHID:D006967],Endocrine System Diseases[MeSHID:D004700] approved,vet_approved annexin a1 ANXA1 NA ligand NA drugbank amcinonide small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved annexin a1 ANXA1 NA agonist 1.82 drugbank , DGIDB hydrocortisone phosphate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved annexin a1 ANXA1 NA unknown NA drugbank hydrocortisone butyrate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved annexin a1 ANXA1 NA unknown NA drugbank hydrocortisone cypionate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,investigational,vet_approved annexin a1 ANXA1 NA unknown NA drugbank budesonide small molecule Inspiration function[MeSHID:D001239],IGA Glomerulonephritis[MeSHID:D005922],Respiratory Hypersensitivity[MeSHID:D012130],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Crohn Disease[MeSHID:D003424],Disease Progression[MeSHID:D018450],Asthma[MeSHID:D001249],Proteinuria[MeSHID:D011507],Rectum[MeSHID:D012007],Chronic Obstructive Airway Disease[MeSHID:D029424],Nose[MeSHID:D009666],Patient Discharge[MeSHID:D010351],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved annexin a1 ANXA1 NA substrate NA drugbank clobetasol propionate small molecule Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Dermatologic disorders[MeSHID:D012871],Psoriasis[MeSHID:D011565] approved annexin a1 ANXA1 NA inducer NA drugbank hydrocortisone small molecule External auditory canal structure[MeSHID:D004424],Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Hypoaldosteronism[MeSHID:D006994],Dermatologic disorders[MeSHID:D012871],Ulcerative Colitis[MeSHID:D003093],Ear structure[MeSHID:D004423],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Infection[MeSHID:D007239],Herpes Labialis[MeSHID:D006560],Cytoplasmic Granules[MeSHID:D003594],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved annexin a1 ANXA1 NA agonist 0.5 drugbank , DGIDB difluprednate NA Vision[MeSHID:D014785],Operative Surgical Procedures[MeSHID:D013514],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye pain[MeSHID:D058447] approved phospholipase a2 inhibitory protein ANXA1 Successful target unknown NA TTD hydrocortisone acetate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved annexin a1 ANXA1 NA unknown NA drugbank budesonide small molecule Inspiration function[MeSHID:D001239],IGA Glomerulonephritis[MeSHID:D005922],Respiratory Hypersensitivity[MeSHID:D012130],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Crohn Disease[MeSHID:D003424],Disease Progression[MeSHID:D018450],Asthma[MeSHID:D001249],Proteinuria[MeSHID:D011507],Rectum[MeSHID:D012007],Chronic Obstructive Airway Disease[MeSHID:D029424],Nose[MeSHID:D009666],Patient Discharge[MeSHID:D010351],Ulcerative Colitis[MeSHID:D003093],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved annexin a1 ANXA1 NA substrate NA drugbank dexamethasone acetate small molecule NA approved,investigational,vet_approved annexin a1 ANXA1 NA agonist NA drugbank dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational,vet_approved annexin a1 ANXA1 NA agonist 0.27 drugbank , DGIDB hydrocortisone aceponate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] experimental,vet_approved annexin a1 ANXA1 NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational annexin a2 ANXA2 NA unknown NA drugbank fluocinolone acetonide small molecule Eczema[MeSHID:D004485],Communicable Diseases[MeSHID:D003141],Keloid[MeSHID:D007627],Posterior eyeball segment structure[MeSHID:D057972],Ear structure[MeSHID:D004423],Affect (mental function)[MeSHID:D000339],Dermatitis[MeSHID:D003872],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Physiologic Intraocular Pressure[MeSHID:D007429],Body tissue[MeSHID:D014024],Dermatologic disorders[MeSHID:D012871],Otitis Externa[MeSHID:D010032],Hypertrophy[MeSHID:D006984],Macular Edema, Cystoid[MeSHID:D008269],Dermatitis, Atopic[MeSHID:D003876],Hemorrhoids[MeSHID:D006484],Seborrheic dermatitis of scalp[MeSHID:D063807],Uveitis[MeSHID:D014605],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational,vet_approved annexin a2 ANXA2 NA inducer NA drugbank tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved annexin a2 ANXA2 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational annexin a2 ANXA2 NA ligand NA drugbank fluocinolone acetonide small molecule Eczema[MeSHID:D004485],Communicable Diseases[MeSHID:D003141],Keloid[MeSHID:D007627],Posterior eyeball segment structure[MeSHID:D057972],Ear structure[MeSHID:D004423],Affect (mental function)[MeSHID:D000339],Dermatitis[MeSHID:D003872],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Physiologic Intraocular Pressure[MeSHID:D007429],Body tissue[MeSHID:D014024],Dermatologic disorders[MeSHID:D012871],Otitis Externa[MeSHID:D010032],Hypertrophy[MeSHID:D006984],Macular Edema, Cystoid[MeSHID:D008269],Dermatitis, Atopic[MeSHID:D003876],Hemorrhoids[MeSHID:D006484],Seborrheic dermatitis of scalp[MeSHID:D063807],Uveitis[MeSHID:D014605],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational,vet_approved annexin a3 ANXA3 NA inducer NA drugbank ethanolamine small molecule NA experimental annexin a3 ANXA3 NA unknown NA drugbank difluocortolone small molecule Pruritus[MeSHID:D011537],Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Dermatologic disorders[MeSHID:D012871],Erythema[MeSHID:D004890],Seborrheic dermatitis[MeSHID:D012628],Psoriasis[MeSHID:D011565],Lichen Planus[MeSHID:D008010] approved,investigational,withdrawn annexin a3 ANXA3 NA inducer NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational annexin a4 ANXA4 NA unknown NA drugbank fluocinolone acetonide small molecule Eczema[MeSHID:D004485],Communicable Diseases[MeSHID:D003141],Keloid[MeSHID:D007627],Posterior eyeball segment structure[MeSHID:D057972],Ear structure[MeSHID:D004423],Affect (mental function)[MeSHID:D000339],Dermatitis[MeSHID:D003872],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Physiologic Intraocular Pressure[MeSHID:D007429],Body tissue[MeSHID:D014024],Dermatologic disorders[MeSHID:D012871],Otitis Externa[MeSHID:D010032],Hypertrophy[MeSHID:D006984],Macular Edema, Cystoid[MeSHID:D008269],Dermatitis, Atopic[MeSHID:D003876],Hemorrhoids[MeSHID:D006484],Seborrheic dermatitis of scalp[MeSHID:D063807],Uveitis[MeSHID:D014605],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational,vet_approved annexin a4 ANXA4 NA inducer NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational annexin a5 ANXA5 NA unknown NA drugbank l-alpha-glycerophosphorylserine small molecule NA experimental annexin a5 ANXA5 NA unknown NA drugbank k201 free base small molecule NA experimental,investigational annexin a5 ANXA5 NA unknown NA drugbank 1,4-dideoxy-o2-sulfo-glucuronic acid small molecule NA experimental annexin a5 ANXA5 NA unknown NA drugbank sn-glycero-3-phosphoethanolamine small molecule NA experimental annexin a5 ANXA5 NA unknown NA drugbank diannexin NA Myocardial Reperfusion Injury[MeSHID:D015428],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 annexin a5 ANXA5 Clinical trial target unknown NA TTD , DGIDB n,o6-disulfo-glucosamine small molecule NA experimental annexin a5 ANXA5 NA unknown NA drugbank l-thioproline small molecule NA experimental annexin a5 ANXA5 NA unknown NA drugbank fluocinolone acetonide small molecule Eczema[MeSHID:D004485],Communicable Diseases[MeSHID:D003141],Keloid[MeSHID:D007627],Posterior eyeball segment structure[MeSHID:D057972],Ear structure[MeSHID:D004423],Affect (mental function)[MeSHID:D000339],Dermatitis[MeSHID:D003872],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Physiologic Intraocular Pressure[MeSHID:D007429],Body tissue[MeSHID:D014024],Dermatologic disorders[MeSHID:D012871],Otitis Externa[MeSHID:D010032],Hypertrophy[MeSHID:D006984],Macular Edema, Cystoid[MeSHID:D008269],Dermatitis, Atopic[MeSHID:D003876],Hemorrhoids[MeSHID:D006484],Seborrheic dermatitis of scalp[MeSHID:D063807],Uveitis[MeSHID:D014605],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational,vet_approved annexin a5 ANXA5 NA inducer NA drugbank 1,4-dideoxy-5-dehydro-o2-sulfo-glucuronic acid small molecule NA experimental annexin a5 ANXA5 NA unknown NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical amiloride-sensitive amine oxidase [copper-containing] AOC1 NA unknown NA drugbank amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive amine oxidase [copper-containing] AOC1 NA inhibitor NA drugbank diminazene small molecule NA experimental amiloride-sensitive amine oxidase [copper-containing] AOC1 NA unknown NA drugbank diminazene NA NA investigative diamine oxidase AOC1 Literature-reported target unknown NA TTD btt-1023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 membrane copper amine oxidase AOC3 Successful target unknown 31.83 TTD , DGIDB clonidine NA Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Malignant Neoplasms[MeSHID:D009369],Attention deficit hyperactivity disorder[MeSHID:D001289],Nicotine Dependence[MeSHID:D014029],Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved membrane copper amine oxidase AOC3 Successful target unknown 1.06 TTD , DGIDB pxs-4159 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative membrane copper amine oxidase AOC3 Successful target unknown NA TTD fp-1102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vascular Diseases[MeSHID:D014652] investigative membrane copper amine oxidase AOC3 Successful target unknown NA TTD vapill NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative membrane copper amine oxidase AOC3 Successful target unknown NA TTD hydralazine NA treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Essential Hypertension[MeSHID:D000075222],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved membrane copper amine oxidase AOC3 Successful target unknown 9.19 TTD , DGIDB 6-hydroxydopa quinone NA NA investigative membrane copper amine oxidase AOC3 Successful target unknown NA TTD rtu-1096 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] investigative membrane copper amine oxidase AOC3 Successful target unknown NA TTD 6-hydroxydopa quinone small molecule NA experimental membrane primary amine oxidase AOC3 NA unknown NA drugbank asp8232 NA Diabetic Nephropathy[MeSHID:D003928],Macular Edema, Cystoid[MeSHID:D008269],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 membrane copper amine oxidase AOC3 Successful target unknown NA TTD , DGIDB hydralazine small molecule treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Essential Hypertension[MeSHID:D000075222],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved membrane primary amine oxidase AOC3 NA inhibitor 9.19 drugbank , DGIDB psx-4206 NA Lung diseases[MeSHID:D008171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative membrane copper amine oxidase AOC3 Successful target unknown NA TTD phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved membrane primary amine oxidase AOC3 NA inhibitor 5.71 drugbank , DGIDB ljp-1207 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative membrane copper amine oxidase AOC3 Successful target unknown NA TTD bi 1467335 NA Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 membrane copper amine oxidase AOC3 Successful target unknown NA TTD isovanillin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved aldehyde oxidase AOX1 Successful target unknown 12.73 TTD , DGIDB cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved aldehyde oxidase AOX1 NA inhibitor NA drugbank eniluracil small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] investigational aldehyde oxidase AOX1 NA unknown NA drugbank menadione NA Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved aldehyde oxidase AOX1 Successful target unknown 0.45 TTD , DGIDB atp small molecule NA investigational,nutraceutical apoptotic protease-activating factor 1 APAF1 NA unknown NA drugbank cphpc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 serum amyloid p-component APCS Clinical trial target inhibitor 95.48 TTD , DGIDB bis-1,2-{[(z)-2-carboxy-2-methyl-1,3-dioxane]-5-yloxycarbamoyl}-ethane small molecule NA experimental serum amyloid p-component APCS NA unknown NA drugbank gsk2398852 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686] phase 1 serum amyloid p-component APCS Clinical trial target unknown 63.65 TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational serum amyloid p-component APCS NA unknown NA drugbank cphpc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 serum amyloid p-component APCS Clinical trial target unknown 95.48 TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serum amyloid p-component APCS NA unknown NA drugbank bis-1,2-{[(z)-2carboxy-2-methyl-1,3-dioxane]-5-yloxycarbonyl}-piperazine small molecule NA experimental serum amyloid p-component APCS NA unknown NA drugbank gsk-2315698 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686] phase 1 serum amyloid p-component APCS Clinical trial target unknown 95.48 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational serum amyloid p-component APCS NA unknown NA drugbank methyl 4,6-o-[(1r)-1-carboxyethylidene]-beta-d-galactopyranoside small molecule NA experimental serum amyloid p-component APCS NA unknown NA drugbank 1,3-bis(1,3-benzothiazol-2-ylthio)acetone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],melanoma[MeSHID:D008545] investigative ap endonuclease 1 APEX1 Clinical trial target unknown NA TTD 3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],melanoma[MeSHID:D008545] investigative ap endonuclease 1 APEX1 Clinical trial target unknown NA TTD apx-3330 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant tumor of eye[MeSHID:D005134] phase 1 ap endonuclease 1 APEX1 Clinical trial target unknown NA TTD , DGIDB lucanthone small molecule Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna-(apurinic or apyrimidinic site) lyase APEX1 NA inhibitor NA drugbank 5-fluoro-1h-indole-2-carboxylic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],melanoma[MeSHID:D008545] investigative ap endonuclease 1 APEX1 Clinical trial target unknown NA TTD apx3330 NA Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 ap endonuclease 1 APEX1 Clinical trial target unknown NA TTD e-2012 small molecule NA investigational gamma-secretase subunit aph-1a APH1A NA unknown NA drugbank apelin-13 NA NA investigative apelin receptor APLNR Clinical trial target agonist NA TTD , DGIDB amg 986 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 1 apelin receptor APLNR Clinical trial target unknown NA TTD , DGIDB e339-3d6 NA NA investigative apelin receptor APLNR Clinical trial target agonist NA TTD , DGIDB ml233 NA NA investigative apelin receptor APLNR Clinical trial target agonist NA TTD , DGIDB ml221 NA NA investigative apelin receptor APLNR Clinical trial target antagonist NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational amyloid-like protein 1 APLP1 NA cofactor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational amyloid-like protein 1 APLP1 NA cofactor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational amyloid-like protein 1 APLP1 NA ligand NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental amyloid-like protein 1 APLP1 NA ligand NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational amyloid-like protein 1 APLP1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational amyloid-like protein 2 APLP2 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational amyloid-like protein 2 APLP2 NA cofactor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational amyloid-like protein 2 APLP2 NA ligand NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental amyloid-like protein 2 APLP2 NA ligand NA drugbank mdco-216 NA Acute Coronary Syndrome[MeSHID:D054058],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 1 apolipoprotein a-i APOA1 Clinical trial target unknown NA TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apolipoprotein a-i APOA1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational apolipoprotein a-i APOA1 NA unknown NA drugbank app-018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 apolipoprotein a-i APOA1 Clinical trial target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational apolipoprotein a-i APOA1 NA inducer,ligand NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational apolipoprotein a-i APOA1 NA unknown NA drugbank csl-112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161] phase 2 apolipoprotein a-i APOA1 Clinical trial target unknown NA TTD , DGIDB cer-522 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aortic Valve Stenosis[MeSHID:D001024] phase 1 apolipoprotein a-i APOA1 Clinical trial target unknown NA TTD , DGIDB crd-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Retinitis Pigmentosa[MeSHID:D012174] discontinued in phase 2 apolipoprotein a-i APOA1 Clinical trial target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental apolipoprotein a-i APOA1 NA inducer,ligand NA drugbank cer-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Acute Coronary Syndrome[MeSHID:D054058] phase 2 apolipoprotein a-i APOA1 Clinical trial target unknown NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational apolipoprotein a-ii APOA2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apolipoprotein a-ii APOA2 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational apolipoprotein a-ii APOA2 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational apolipoprotein a-iv APOA4 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apolipoprotein a-iv APOA4 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational apolipoprotein a-iv APOA4 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational apolipoprotein b-100 APOB NA ligand NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental apolipoprotein b-100 APOB NA ligand NA drugbank isis 147483 NA NA investigative apob messenger rna APOB Successful target unknown NA TTD mipomersen NA Homozygote[MeSHID:D006720],Diet therapy[MeSHID:D004035],Hypercholesterolemia, Familial[MeSHID:D006938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved apob messenger rna APOB Successful target unknown 1.77 TTD , DGIDB spc4955 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 apolipoprotein b-100 APOB Clinical trial target unknown NA TTD , DGIDB tkm-apob NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 4 apob messenger rna APOB Successful target unknown NA TTD , DGIDB isis 147788 NA NA investigative apob messenger rna APOB Successful target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental c->u-editing enzyme apobec-1 APOBEC1 NA cofactor,chelator NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational c->u-editing enzyme apobec-1 APOBEC1 NA cofactor,chelator NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational apolipoprotein b receptor APOBR NA inducer NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental apolipoprotein b receptor APOBR NA inducer NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apolipoprotein b receptor APOBR NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational apolipoprotein b receptor APOBR NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational apolipoprotein b receptor APOBR NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apolipoprotein c-ii APOC2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apolipoprotein c-iii APOC3 NA unknown NA drugbank volanesorsen biotech Hyperlipoproteinemia Type I[MeSHID:D008072],Diet therapy[MeSHID:D004035],Pancreatitis[MeSHID:D010195],Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Familial hyperchylomicronemia syndrome[MeSHID:C538489],Hyperlipoproteinemias[MeSHID:D006951] approved,investigational apolipoprotein c-iii APOC3 NA inhibitor,antisense oligonucleotide NA drugbank isis-apociii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Hyperlipidemia[MeSHID:D006949],Metabolic Syndrome X[MeSHID:D024821] phase 1 apoc-iii messenger rna APOC3 Successful target unknown NA TTD volanesorsen NA Hyperlipoproteinemia Type I[MeSHID:D008072],Diet therapy[MeSHID:D004035],Pancreatitis[MeSHID:D010195],Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Familial hyperchylomicronemia syndrome[MeSHID:C538489],Hyperlipoproteinemias[MeSHID:D006951] approved apoc-iii messenger rna APOC3 Successful target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apolipoprotein d APOD NA unknown NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved apolipoprotein d APOD NA ligand NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational apolipoprotein e APOE NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational apolipoprotein e APOE NA antagonist NA drugbank cn-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Hemorrhage[MeSHID:D002543],Cyclic neutropenia[MeSHID:C536227] phase 2 apolipoprotein e APOE Clinical trial target unknown NA TTD , DGIDB aem-28 NA Episodic ataxia type 1[MeSHID:C563278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Hypercholesterolemia, Familial[MeSHID:D006938] phase 2 apolipoprotein e APOE Clinical trial target unknown NA TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apolipoprotein e APOE NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental apolipoprotein e APOE NA antagonist NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational apolipoprotein e APOE NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2-glycoprotein 1 APOH NA unknown NA drugbank alpha-d-mannose NA NA investigative beta-2-glycoprotein 1 APOH Discontinued target unknown NA TTD ljp-1082 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acromegaloid facial appearance syndrome[MeSHID:C535655],Antiphospholipid Syndrome[MeSHID:D016736] discontinued in phase 1 beta-2-glycoprotein 1 APOH Discontinued target unknown NA TTD ljp 1082 small molecule Cerebrovascular accident[MeSHID:D020521],Thrombosis[MeSHID:D013927],Autoimmune Diseases[MeSHID:D001327] investigational beta-2-glycoprotein 1 APOH NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational apolipoprotein l1 APOL1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental apolipoprotein l1 APOL1 NA inhibitor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational apolipoprotein l1 APOL1 NA inhibitor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational apolipoprotein l1 APOL1 NA unknown NA drugbank aci-24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB florbetapir (18f) small molecule Amyloidosis[MeSHID:D000686],Brain[MeSHID:D001921],Cognition Disorders[MeSHID:D003072],Senile Plaques[MeSHID:D058225],Cognition[MeSHID:D003071] approved,investigational amyloid beta a4 protein APP NA binder NA drugbank 1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD 1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD tramiprosate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 amyloid beta a4 protein APP Successful target unknown 2.05 TTD , DGIDB crenezumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 amyloid beta a4 protein APP Successful target unknown 6.16 TTD , DGIDB in-n01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] investigative amyloid beta a4 protein APP Successful target unknown NA TTD nic5-15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown 0.68 TTD , DGIDB 2,5-bis(4-nitrophenyl)thiophene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD 2,5-bis(2-methoxyphenyl)thiophene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD sem-606 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 6-iodo-4'-hydroxyflavone NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD pf-03084014 NA Fibromatosis, Aggressive[MeSHID:D018222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 amyloid beta a4 protein APP Successful target unknown 0.41 TTD , DGIDB flutemetamol (18f) small molecule Amyloidosis[MeSHID:D000686],Brain[MeSHID:D001921],Cognition Disorders[MeSHID:D003072],Senile Plaques[MeSHID:D058225],Cognition[MeSHID:D003071] approved,investigational amyloid beta a4 protein APP NA binder NA drugbank arn-2966 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 6-iodo-4'-dimethyaminoflavone NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD gsk933776a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 2 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB dimercaprol small molecule Mercury Poisoning[MeSHID:D008630],Lead Poisoning[MeSHID:D007855],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amyloid beta a4 protein APP NA unknown NA drugbank sar228810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB a-887755 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD chrysamine -g NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD ponezumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown 6.16 TTD , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational amyloid beta a4 protein APP NA unknown 0.13 drugbank , DGIDB vk-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative amyloid beta a4 protein APP Successful target unknown NA TTD eb-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epidermolysis Bullosa Dystrophica[MeSHID:D016108] phase 1/2 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 amyloid beta a4 protein APP Successful target unknown 0.12 TTD , DGIDB ni-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational amyloid beta a4 protein APP NA unknown 0.13 drugbank , DGIDB t-817ma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown 1.03 TTD , DGIDB 18f-av-45 dimer NA Cerebral Amyloid Angiopathy[MeSHID:D016657],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD systebryl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686] phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB 2,5-bis(4-methoxyphenyl)thiophene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD 5-hydroxy-2-(4-methylaminophenyl)benzofuran NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD cd45rb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] investigative amyloid beta a4 protein APP Successful target unknown NA TTD cad106 small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational amyloid beta a4 protein APP NA unknown NA drugbank solanezumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 amyloid beta a4 protein APP Successful target unknown 6.16 TTD , DGIDB 4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD recall-vax NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Recall[MeSHID:D011939] investigative amyloid beta a4 protein APP Successful target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational amyloid beta a4 protein APP NA unknown NA drugbank 5-methoxy-2-(4-methylaminophenyl)benzofuran NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD tetrathiomolybdate small molecule Liver diseases[MeSHID:D008107],Pulmonary Fibrosis[MeSHID:D011658] investigational amyloid beta a4 protein APP NA unknown NA drugbank ban2401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target inhibitor 6.16 TTD , DGIDB gantenerumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 amyloid beta a4 protein APP Successful target unknown 6.16 TTD , DGIDB knx-monoclonal204 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD elnd-007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD rn6g NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 amyloid beta a4 protein APP Successful target unknown NA TTD tkp-1001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD ct-003230 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD myo-inositol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB ub-311 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB pf-05236812 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD aab-003/pf-05236812 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB aci-636 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD cad-106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB mito-4509 small molecule Retinal Diseases[MeSHID:D012164],Parkinson Disease[MeSHID:D010300] investigational amyloid beta a4 protein APP NA unknown NA drugbank ana-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD ban-2203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD sb-13 NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD 11c-6-me-bta-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB 2,5-bis(4-hydroxyphenyl)thiophene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD l-methionine (r)-s-oxide small molecule NA experimental amyloid beta a4 protein APP NA unknown NA drugbank az4800 NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD alz-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB kms-88009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 11c-azd-2184 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB 4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD aluminium phosphate small molecule NA approved,investigational amyloid beta a4 protein APP NA unknown NA drugbank 6-iodo-4'-methylaminoflavone NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD 5-hydroxy-2-(4-aminophenyl)benzofuran NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD dehydrozingerone NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD phenserine small molecule NA investigational amyloid beta a4 protein APP NA unknown NA drugbank dwp-09031 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB gamma-secretase modulators NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 6-iodo-4'-methoxyflavone NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD deferoxamine small molecule Anemia[MeSHID:D000740],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational amyloid beta a4 protein APP NA unknown NA drugbank pa-1637 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD abloid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 4-(5-(4-aminophenyl)thiophen-2-yl)phenol NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD 4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD 5-methoxy-2-(4-dimethylaminophenyl)benzofuran NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD sen-1500 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD methionine sulfoxide NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD sr-973 NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD anti-n3pg-abeta antibody NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB florbetaben (18f) small molecule Amyloidosis[MeSHID:D000686],Brain[MeSHID:D001921],Radioactivity[MeSHID:D011851],Diagnosis[MeSHID:D003933],Cognition Disorders[MeSHID:D003072],Senile Plaques[MeSHID:D058225],Cognition[MeSHID:D003071] approved amyloid beta a4 protein APP NA binder NA drugbank alzt-op1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB edonerpic small molecule NA investigational amyloid beta a4 protein APP NA unknown NA drugbank aluminium small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperhidrosis disorder[MeSHID:D006945] approved,investigational amyloid beta a4 protein APP NA unknown NA drugbank affitope ad-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB affitope ad-02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 amyloid beta a4 protein APP Successful target unknown NA TTD arc-069 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD florbetapir f-18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB mimovax NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD aducanumab biotech NA approved,investigational amyloid beta a4 protein APP NA antagonist,binder,antibody 2.05 drugbank , DGIDB acu-0101979 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD as-602704 NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD vk-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational amyloid beta a4 protein APP NA ligand NA drugbank edn-ol1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 11a1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 5-hydroxy-2-(4-dimethylaminophenyl)benzofuran NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD ban2401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown 6.16 TTD , DGIDB aab-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 0 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB an-1792 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB aluminum acetate small molecule NA approved,investigational amyloid beta a4 protein APP NA unknown NA drugbank turmeric extracts NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental amyloid beta a4 protein APP NA ligand NA drugbank sp-08 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD dbt-1339 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD bapineuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 amyloid beta a4 protein APP Successful target unknown 6.16 TTD , DGIDB tromethamine small molecule Metabolic acidosis[MeSHID:D000138],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acidosis[MeSHID:D000138] approved amyloid beta a4 protein APP NA inhibitor NA drugbank 1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational amyloid beta a4 protein APP NA binder NA drugbank 5-methoxy-2-(4-aminophenyl)benzofuran NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational amyloid beta a4 protein APP NA cofactor NA drugbank 123i-drm-106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYOPATHY, MYOFIBRILLAR, DESMIN-RELATED[MeSHID:C563319] investigative amyloid beta a4 protein APP Successful target unknown NA TTD 1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD anticalin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD gelsolin NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD frm-0962 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB pepticlere NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB 1,6-bis(4'-hydroxyphenyl)-hexa-1,3,5-triene NA NA investigative amyloid beta a4 protein APP Successful target unknown NA TTD nn-818 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174]VAJO NEUROHEPATOPATHY[MeSHID:C538344],Brain Injuries[MeSHID:D001930] preclinical amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB biib037 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 amyloid beta a4 protein APP Successful target unknown NA TTD , DGIDB ad-0802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative amyloid beta a4 protein APP Successful target unknown NA TTD citric acid small molecule NA approved,nutraceutical,vet_approved adenine phosphoribosyltransferase APRT NA unknown NA drugbank adenine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical adenine phosphoribosyltransferase APRT NA unknown NA drugbank 5-o-phosphono-alpha-d-ribofuranosyl diphosphate small molecule NA approved,experimental,investigational adenine phosphoribosyltransferase APRT NA unknown NA drugbank 5h-pyrrolo[3,2-d]pyrimidin-4-amine small molecule NA experimental adenine phosphoribosyltransferase APRT NA unknown NA drugbank b-nonylglucoside small molecule NA experimental aquaporin-1 AQP1 NA unknown NA drugbank mersalyl small molecule Hypertensive disease[MeSHID:D006973],Edema[MeSHID:D004487] experimental aquaporin-1 AQP1 NA unknown NA drugbank acetazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,vet_approved aquaporin-1 AQP1 NA inhibitor 9.79 drugbank , DGIDB bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aquaporin-3 AQP3 NA negative modulator NA drugbank sennosides small molecule Constipation[MeSHID:D003248] experimental aquaporin-3 AQP3 NA inhibitor NA drugbank 1-testosterone small molecule NA experimental,illicit,investigational androgen receptor AR NA agonist NA drugbank bay 86-5044 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 androgen receptor messenger rna AR Clinical trial target unknown NA TTD palodesangren c NA NA investigative androgen receptor AR Successful target unknown NA TTD tas3681 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 androgen receptor AR Successful target unknown NA TTD , DGIDB mk-0773 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 androgen receptor AR Successful target unknown 0.15 TTD , DGIDB lgd-5552 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD fluoxymesterone small molecule Malignant neoplasm of breast[MeSHID:D001943],Malnutrition[MeSHID:D044342],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit androgen receptor AR Successful target agonist 0.29 TTD , drugbank , DGIDB np-619 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] discontinued in phase 2 androgen receptor AR Successful target unknown NA TTD drostanolone small molecule NA illicit androgen receptor AR NA agonist NA drugbank cyproterone acetate small molecule Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277] approved,investigational androgen receptor AR NA antagonist 0.02 drugbank , DGIDB 2-chloro-4-(o-tolyloxy)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD dihydrotestosterone NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 4 androgen receptor AR Successful target agonist 0.02 TTD , DGIDB bisphenol a NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown 0.02 TTD , DGIDB 3-methoxy-4-(m-tolyloxy)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD [3h]methyltrienolone NA NA investigative androgen receptor AR Successful target agonist NA TTD , DGIDB ethylestrenol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved androgen receptor AR Successful target agonist 0.15 TTD , DGIDB 2'-hydroxy-3-methoxy-biphenyl-4-carbonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD boldenone small molecule NA illicit,vet_approved,investigative androgen receptor AR Successful target agonist NA TTD , drugbank opterone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 1 androgen receptor AR Successful target unknown NA TTD bms-564929 small molecule NA experimental androgen receptor AR NA unknown 0.15 drugbank , DGIDB ru-58841 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 androgen receptor messenger rna AR Clinical trial target unknown NA TTD mitotane small molecule Tumors of Adrenal Cortex[MeSHID:D000306],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] approved androgen receptor AR NA antagonist NA drugbank 4-(cyclobutylmethylthio)-2-methoxybenzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD nandrolone phenpropionate small molecule Refractory anemias[MeSHID:D000753],Antithrombin III Deficiency[MeSHID:D020152],Failure to Thrive[MeSHID:D005183],Angioedemas, Hereditary[MeSHID:D054179],Malignant neoplasm of breast[MeSHID:D001943],Turner Syndrome[MeSHID:D014424],Erythropoiesis[MeSHID:D004920] approved,illicit,investigational androgen receptor AR NA agonist 0.59 drugbank , DGIDB 11-methyl-6,11-dihydro-5h-benzo[a]carbazol-9-ol NA NA investigative androgen receptor AR Successful target unknown NA TTD testosterone cypionate small molecule Testicular hypogonadism[MeSHID:D005058],Radiation[MeSHID:D011827],Disease[MeSHID:D004194],Testis[MeSHID:D013737],Orchitis[MeSHID:D009920],Cryptorchidism[MeSHID:D003456],Traumatic injury[MeSHID:D014947],Hypothalamic-Pituitary Neoplasms[MeSHID:D007029],Klinefelter Syndrome[MeSHID:D007713],Hypogonadotropic hypogonadism[MeSHID:D007006],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Electromagnetic Radiation[MeSHID:D060733] approved androgen receptor AR NA agonist 0.07 drugbank , DGIDB 3-methoxy-4-(p-tolyloxy)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD estrone small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR NA unknown 0.02 drugbank , DGIDB ezn-4176 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 androgen receptor messenger rna AR Clinical trial target unknown NA TTD , DGIDB lgd2941 small molecule Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 1 androgen receptor AR Successful target unknown NA TTD , drugbank 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD oxymetholone small molecule Pyridoxine Deficiency[MeSHID:D026681],Fanconi Anemia[MeSHID:D005199],Primary Myelofibrosis[MeSHID:D055728],Aplastic Anemia[MeSHID:D000741],Anemia[MeSHID:D000740],Erythropoiesis[MeSHID:D004920],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit androgen receptor AR NA agonist,activator 0.02 drugbank , DGIDB dihydrotestosterone NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 4 androgen receptor AR Successful target unknown 0.02 TTD , DGIDB oxendlone NA NA investigative androgen receptor AR Successful target unknown NA TTD norethynodrel small molecule NA approved androgen receptor AR NA unknown 0.07 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical androgen receptor AR Successful target agonist 0.02 TTD , drugbank , DGIDB testogen tds NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 androgen receptor AR Successful target unknown NA TTD , DGIDB nandrolone NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR Successful target agonist 0.18 TTD , DGIDB cyproterone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved androgen receptor AR Successful target unknown 0.04 TTD , DGIDB arn-509 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of prostate[MeSHID:D011471] approved androgen receptor AR Successful target unknown 0.52 TTD , DGIDB lgd-2226 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD testosterone glucoside NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 androgen receptor AR Successful target unknown NA TTD oxandrolone small molecule Weight Gain[MeSHID:D015430],Operative Surgical Procedures[MeSHID:D013514],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis, Alcoholic[MeSHID:D006519] approved,investigational androgen receptor AR Successful target agonist 0.33 TTD , drugbank , DGIDB 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD metribolone small molecule NA experimental androgen receptor AR NA unknown NA drugbank al-43 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD ru-56187 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown 0.15 TTD , DGIDB isis-ar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 androgen receptor messenger rna AR Clinical trial target unknown NA TTD 5-methoxyflavone NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD 6-n-propyl -4-trifluoromethylquinolin-2(1h)-one NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD palodesangren e NA NA investigative androgen receptor AR Successful target unknown NA TTD drug 2881078 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 1 androgen receptor AR Successful target unknown NA TTD , DGIDB triclosan small molecule Health Care[MeSHID:D003695],Operative Surgical Procedures[MeSHID:D013514],Hand[MeSHID:D006225],Hyperostosis, Diffuse Idiopathic Skeletal[MeSHID:D004057],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Trypanosomiasis[MeSHID:D014352],Malaria[MeSHID:D008288],Communicable Diseases[MeSHID:D003141] approved,investigational androgen receptor AR NA unknown 0.02 drugbank , DGIDB 6-amino-4-trifluoromethylquinolin-2(1h)-one NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD 4-[(7r,7as)-7-hydroxy-1,3-dioxotetrahydro-1h-pyrrolo[1,2-c]imidazol-2(3h)-yl]-1-naphthonitrile small molecule NA experimental androgen receptor AR NA unknown NA drugbank gestrinone small molecule Infertility[MeSHID:D007246],Unmarried[MeSHID:D012847],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved androgen receptor AR NA antagonist 0.04 drugbank , DGIDB asc-j9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927],Kidney Failure, Chronic[MeSHID:D007676] phase 2 androgen receptor AR Successful target unknown NA TTD , DGIDB flufenamic acid small molecule Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR Successful target unknown NA TTD , drugbank , DGIDB 3-methoxy-4-(o-tolyloxy)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD fludrocortisone NA Adrenogenital Syndrome[MeSHID:D047808],Addison Disease[MeSHID:D000224],Hypoaldosteronism[MeSHID:D006994],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Wasting Syndrome[MeSHID:D019282] approved androgen receptor AR Successful target unknown 0.15 TTD , DGIDB 2-methoxy-4-(2-methoxyphenylthio)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD 4-(butylthio)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD gw-275919 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 androgen receptor AR Successful target unknown NA TTD tok-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 androgen receptor AR Successful target unknown 0.22 TTD , DGIDB eugenol small molecule Dental caries[MeSHID:D003731],Toothache[MeSHID:D014098] approved androgen receptor AR NA antagonist NA drugbank [3h]mibolerone NA NA investigative androgen receptor messenger rna AR Clinical trial target agonist NA TTD , DGIDB testosterone small molecule Hypogonadotropic hypogonadism[MeSHID:D007006],Klinefelter Syndrome[MeSHID:D007713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342],Osteoporosis[MeSHID:D010024] approved,investigational androgen receptor AR Successful target agonist 0.02 TTD , drugbank , DGIDB sx-arpc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative androgen receptor AR Successful target unknown NA TTD 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD apc-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 androgen receptor AR Successful target unknown 0.22 TTD , DGIDB 4-(isopropylthio)-2-methoxybenzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved androgen receptor AR NA antagonist 0.01 drugbank , DGIDB norgestimate small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational androgen receptor AR NA partial agonist 0.03 drugbank , DGIDB ru-59063 NA NA investigative androgen receptor AR Successful target unknown NA TTD 4-{[(1r,2s)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile small molecule NA experimental androgen receptor AR NA unknown NA drugbank fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR NA unknown NA drugbank [3h]methyltrienolone NA NA investigative androgen receptor messenger rna AR Clinical trial target agonist NA TTD , DGIDB cyproterone acetate small molecule Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277] approved,investigational androgen receptor AR NA antagonist NA drugbank , DGIDB (3aalpha,4alpha,7alpha,7aalpha)- 3a,4,7,7a-tetrahydro-2-(4-nitro-1-naphthalenyl)-4,7-ethano-1h-isoindole-1,3(2h)-dione small molecule NA experimental androgen receptor AR NA unknown NA drugbank clascoterone small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational androgen receptor AR Successful target antagonist NA TTD , drugbank arn-509 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of prostate[MeSHID:D011471] approved androgen receptor AR Successful target antagonist 0.52 TTD , DGIDB dimethylcurcumin small molecule Acne Vulgaris[MeSHID:D000152],Alopecia[MeSHID:D000505] investigational androgen receptor AR NA inhibitor NA drugbank 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD apc-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 androgen receptor AR Successful target antagonist 0.22 TTD , DGIDB 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD lgd-2226 small molecule NA experimental androgen receptor AR NA unknown NA drugbank 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD nsc-26745 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD esculin small molecule Muscle strain[MeSHID:D013180],Identification (Psychology)[MeSHID:D007062],Bile fluid[MeSHID:D001646] approved androgen receptor AR NA agonist 0.04 drugbank , DGIDB 1-tert-butyl-3-(2,5-dimethylbenzyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine small molecule NA experimental androgen receptor AR NA unknown NA drugbank stanolone acetate small molecule NA experimental androgen receptor AR NA unknown NA drugbank periciazine small molecule Aggressive behavior[MeSHID:D000374],Impulsive Behavior[MeSHID:D007175],Hostility[MeSHID:D006791] approved,investigational androgen receptor AR NA unknown 0.03 drugbank , DGIDB nilutamide small molecule Bone Tissue[MeSHID:D001842],Malignant neoplasm of prostate[MeSHID:D011471],lymph nodes[MeSHID:D008198],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational androgen receptor AR Successful target antagonist 0.16 TTD , drugbank , DGIDB 4-(mesitylthio)-2-methoxybenzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD azd-3514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 androgen receptor AR Successful target unknown 0.15 TTD , DGIDB norgestrel small molecule Pregnancy[MeSHID:D011247] approved androgen receptor AR NA agonist 0.02 drugbank , DGIDB tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR NA unknown NA drugbank mk-0773 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 androgen receptor AR Successful target modulator 0.15 TTD , DGIDB oxybenzone small molecule Sunscreening Agents[MeSHID:D013473] approved,investigational androgen receptor AR NA antagonist NA drugbank progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved androgen receptor AR NA agonist,potentiator 0 drugbank , DGIDB segesterone acetate small molecule Reproduction[MeSHID:D012098],Vagina[MeSHID:D014621],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational androgen receptor AR NA agonist NA drugbank (5s,8r,9s,10s,13r,14s,17s)-13-{2-[(3,5-difluorobenzyl)oxy]ethyl}-17-hydroxy-10-methylhexadecahydro-3h-cyclopenta[a]phenanthren-3-one small molecule NA experimental androgen receptor AR NA unknown NA drugbank 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD testosterone propionate small molecule Growth[MeSHID:D006128] approved,investigational,vet_approved,withdrawn androgen receptor AR NA agonist 0.12 drugbank , DGIDB 6,11-dihydrothiochromeno[4,3-b]indol-8-ol NA NA investigative androgen receptor AR Successful target unknown NA TTD (2s)-n-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide small molecule NA experimental androgen receptor AR NA unknown NA drugbank testosterone buciclate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 androgen receptor AR Successful target unknown NA TTD , DGIDB dienogest small molecule Endometriosis[MeSHID:D004715] approved androgen receptor AR NA antagonist NA drugbank ulipristal small molecule Coitus[MeSHID:D003075],Uterine Fibroids[MeSHID:D007889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR NA unknown NA drugbank diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational androgen receptor AR NA antagonist 0 drugbank , DGIDB andarine small molecule NA experimental androgen receptor AR NA agonist NA drugbank , DGIDB flutamide small molecule Disease Management[MeSHID:D019468],Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational androgen receptor AR Successful target antagonist 0.06 TTD , drugbank , DGIDB he-2000 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 androgen receptor AR Successful target unknown NA TTD progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved androgen receptor AR NA agonist,potentiator 0 drugbank , DGIDB danazol small molecule Breast Fibrocystic Disease[MeSHID:D005348],Angioedemas, Hereditary[MeSHID:D054179],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menorrhagia[MeSHID:D008595],Malignant neoplasm of breast[MeSHID:D001943] approved androgen receptor AR NA agonist 0.03 drugbank , DGIDB ligandrol small molecule NA investigational androgen receptor AR NA antagonist,agonist NA drugbank hyg-440 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] investigative androgen receptor AR Successful target unknown NA TTD azd5312 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 androgen receptor AR Successful target unknown 0.07 TTD , DGIDB delta1-dihydrotestosterone NA NA investigative androgen receptor AR Successful target unknown NA TTD fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved androgen receptor AR NA unknown NA drugbank enzacamene small molecule Sunscreening Agents[MeSHID:D013473] approved androgen receptor AR NA antagonist NA drugbank cp-394531 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD enzalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved androgen receptor AR Successful target inhibitor 0.37 TTD , drugbank , DGIDB boldenone undecylenate small molecule NA illicit,vet_approved androgen receptor AR NA unknown NA drugbank cc-94676 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 androgen receptor AR Successful target unknown NA TTD dt-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 androgen receptor AR Successful target unknown 0.22 TTD , DGIDB bicalutamide small molecule Operative Surgical Procedures[MeSHID:D013514],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR Successful target antagonist 0.23 TTD , drugbank , DGIDB 4-(cyclopropylmethylthio)-2-methoxybenzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD arn34 NA NA investigative androgen receptor AR Successful target unknown NA TTD phenothiazine small molecule NA experimental,vet_approved androgen receptor AR NA unknown NA drugbank rad-140 NA Osteoporosis[MeSHID:D010024],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 androgen receptor AR Successful target unknown 0.07 TTD , DGIDB mibolerone small molecule NA vet_approved androgen receptor AR NA agonist 0.22 drugbank , DGIDB echinacoside small molecule NA experimental androgen receptor AR NA agonist NA drugbank ps-178990 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Atrophy[MeSHID:D009133] phase 1 androgen receptor AR Successful target unknown NA TTD , DGIDB enzalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved androgen receptor AR Successful target inhibitor,antagonist 0.37 TTD , drugbank , DGIDB kaempferol NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD eugenol NA Dental caries[MeSHID:D003731],Toothache[MeSHID:D014098] patented androgen receptor messenger rna AR Clinical trial target unknown NA TTD andarine NA NA investigative androgen receptor messenger rna AR Clinical trial target agonist NA TTD , DGIDB lg-121071 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD dromostanolone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mammary Neoplasms[MeSHID:D001943],Animal Mammary Neoplasms[MeSHID:D015674] approved androgen receptor AR Successful target unknown 0.22 TTD , DGIDB nandrolone NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR Successful target unknown 0.18 TTD , DGIDB 6-hydroxyflavanone NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD norelgestromin small molecule Malignant neoplasm of breast[MeSHID:D001943],Pregnancy[MeSHID:D011247] approved,investigational androgen receptor AR NA partial agonist 0.05 drugbank , DGIDB (r)-3-bromo-2-hydroxy-2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]propanamide small molecule NA experimental androgen receptor AR NA unknown NA drugbank andromustine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative androgen receptor AR Successful target unknown NA TTD 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD dihydrotestosterone NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 4 androgen receptor messenger rna AR Clinical trial target agonist 0.02 TTD , DGIDB gsk2849466 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] discontinued in phase 1 androgen receptor AR Successful target modulator 0.07 TTD , DGIDB s-23 small molecule NA experimental androgen receptor AR NA unknown NA drugbank (r)-bicalutamide small molecule NA experimental androgen receptor AR NA unknown 0.22 drugbank , DGIDB darolutamide small molecule Diagnosis[MeSHID:D003933],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational androgen receptor AR Successful target antagonist 0.44 TTD , drugbank , DGIDB ascj-9 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] phase 2 androgen receptor AR Successful target unknown NA TTD tetrahydrogestrinone small molecule NA experimental androgen receptor AR NA unknown NA drugbank palodesangren d NA NA investigative androgen receptor AR Successful target unknown NA TTD pf-0998425 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD arv-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 androgen receptor AR Successful target unknown NA TTD sarms NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative androgen receptor AR Successful target unknown NA TTD testetrol NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative androgen receptor AR Successful target unknown NA TTD stanozolol small molecule Pathogenicity[MeSHID:D014774],Cardiac Arrest[MeSHID:D006323],Angioedemas, Hereditary[MeSHID:D054179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved androgen receptor AR NA agonist 0.1 drugbank , DGIDB 2-methoxy-4-(m-tolyloxy)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit androgen receptor AR NA agonist 0.22 drugbank , DGIDB way-255348 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational androgen receptor AR NA antagonist 0.52 drugbank , DGIDB 2-methoxy-4-(propylthio)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD testosterone enanthate small molecule Systemic arterial pressure[MeSHID:D062186],Sexual Development[MeSHID:D046468],Neoplasms[MeSHID:D009369],Pituitary Gland[MeSHID:D010902],Klinefelter Syndrome[MeSHID:D007713],Myocardial Infarction[MeSHID:D009203],Syndrome[MeSHID:D013577],Pituitary Diseases[MeSHID:D010900],Idiopathic hypogonadotropic hypogonadism[MeSHID:C562785],Mammary gland[MeSHID:D042361],Testicular hypogonadism[MeSHID:D005058],Thyroid Gland[MeSHID:D013961],Testis[MeSHID:D013737],Orchitis[MeSHID:D009920],Neoplasm Metastasis[MeSHID:D009362],Cryptorchidism[MeSHID:D003456],Hypothalamic structure[MeSHID:D007031],Malignant neoplasm of breast[MeSHID:D001943],Cerebrovascular accident[MeSHID:D020521],Electromagnetic Radiation[MeSHID:D060733],Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Cessation of life[MeSHID:D003643],Blood Pressure[MeSHID:D001794],Maintenance[MeSHID:D008283],Pathologic Processes[MeSHID:D010335],Primary hypogonadism[MeSHID:D007006],Malnutrition[MeSHID:D044342],Adrenal Cortex[MeSHID:D000302],Disease[MeSHID:D004194],Delayed Puberty[MeSHID:D011628],Traumatic injury[MeSHID:D014947],Malignant Carcinoid Syndrome[MeSHID:D008303] approved androgen receptor AR NA agonist 0.07 drugbank , DGIDB cp-409069 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD gtx-027 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative androgen receptor AR Successful target unknown NA TTD 2-methoxy-4-(p-tolyloxy)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD apigenin NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD ru-43044 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD [3h]mibolerone NA NA investigative androgen receptor AR Successful target agonist NA TTD , DGIDB glpg-0492 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100] preclinical androgen receptor AR Successful target unknown 0.22 TTD , DGIDB epi-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative androgen receptor AR Successful target unknown NA TTD s-3-(4-fluorophenoxy)-2-hydroxy-2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]propanamide small molecule NA experimental androgen receptor AR NA unknown NA drugbank 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane NA NA investigative androgen receptor AR Successful target unknown NA TTD 2-methoxy-4-(o-tolyloxy)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD methyltestosterone small molecule Mastodynia[MeSHID:D059373],Edema[MeSHID:D004487],Pregnancy[MeSHID:D011247],Malignant neoplasm of breast[MeSHID:D001943],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved androgen receptor AR NA agonist 0.15 drugbank , DGIDB hydroxyflutamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved androgen receptor AR Successful target antagonist 0.18 TTD , DGIDB bms-564929 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown 0.15 TTD , DGIDB arv-471 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 androgen receptor AR Successful target unknown NA TTD 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD stanolone small molecule NA illicit,investigational androgen receptor AR NA unknown 0.05 drugbank , DGIDB (2s)-2-hydroxy-2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide small molecule NA experimental androgen receptor AR NA unknown NA drugbank flavone NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD 3-[(4-amino-1-tert-butyl-1h-pyrazolo[3,4-d]pyrimidin-3-yl)methyl]phenol small molecule NA experimental androgen receptor AR NA unknown NA drugbank bisphenol a NA NA investigative androgen receptor messenger rna AR Clinical trial target antagonist NA TTD , DGIDB drospirenone small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Hirsutism[MeSHID:D006628],Menarche[MeSHID:D008572],Acne Vulgaris[MeSHID:D000152],Postmenopause[MeSHID:D017698],Menstruation[MeSHID:D008598],Atrophic[MeSHID:D001284],Osteoporosis[MeSHID:D010024],Dysmenorrhea[MeSHID:D004412],Premenstrual Dysphoric Disorder[MeSHID:D065446],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR NA antagonist 0.09 drugbank , DGIDB 4-(butylthio)-2-methoxybenzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD 4-(propylthio)-2-(trifluoromethyl)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR NA antagonist 0.01 drugbank , DGIDB ethylestrenol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved androgen receptor AR Successful target unknown 0.15 TTD , DGIDB hc-1119 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 androgen receptor AR Successful target unknown NA TTD onc1-13b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 androgen receptor AR Successful target unknown NA TTD , DGIDB ch-4933468 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cyclic neutropenia[MeSHID:C536227],Malignant neoplasm of prostate[MeSHID:D011471] investigative androgen receptor AR Successful target unknown NA TTD 4-(isopentylthio)-2-methoxybenzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD trc-253 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 androgen receptor messenger rna AR Clinical trial target unknown NA TTD homosalate small molecule Malignant neoplasm of skin[MeSHID:D012878],Sunburn[MeSHID:D013471],Sunscreening Agents[MeSHID:D013473],Skin Aging[MeSHID:D015595] approved,investigational androgen receptor AR NA antagonist NA drugbank epierenone NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD flufenamic acid small molecule Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved androgen receptor AR Successful target unknown 0.04 TTD , drugbank , DGIDB acetophenazine small molecule Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Thinking, function[MeSHID:D013850],Perception[MeSHID:D010465],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] approved androgen receptor AR NA unknown 0.05 drugbank , DGIDB dl-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative androgen receptor AR Successful target unknown NA TTD norethisterone small molecule Atrophic[MeSHID:D001284],Endometriosis[MeSHID:D004715],Osteoporosis, Postmenopausal[MeSHID:D015663] approved androgen receptor AR NA agonist NA drugbank testosterone undecanoate small molecule Malnutrition[MeSHID:D044342],Disease[MeSHID:D004194],Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational androgen receptor AR NA agonist 0.07 drugbank , DGIDB pf-06260414 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100],Pain[MeSHID:D010146] discontinued in phase 1 androgen receptor AR Successful target unknown NA TTD 3-chloro-4-(o-tolyloxy)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD lg-120838 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD ym-175735 NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD asc-jmx2 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative androgen receptor AR Successful target unknown NA TTD levonorgestrel small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Patient Discharge[MeSHID:D010351],Coitus[MeSHID:D003075],Menorrhagia[MeSHID:D008595],Endometrial Hyperplasia[MeSHID:D004714],Off-Label Use[MeSHID:D056687],Unmarried[MeSHID:D012847],Osteoporosis[MeSHID:D010024],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational androgen receptor AR NA binder NA drugbank ketodarolutamide small molecule NA experimental androgen receptor AR NA antagonist NA drugbank 3-chloro-4-(o-tolylthio)benzonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD ketoconazole small molecule Paracoccidioidomycosis[MeSHID:D010229],Mycoses[MeSHID:D009181],Coccidioidomycosis[MeSHID:D003047],Cushing Syndrome[MeSHID:D003480],Candidiasis[MeSHID:D002177],Chromoblastomycosis[MeSHID:D002862],Blastomycosis[MeSHID:D001759],Histoplasmosis[MeSHID:D006660],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational androgen receptor AR NA binder NA drugbank calusterone small molecule Breast[MeSHID:D001940],Body tissue[MeSHID:D014024],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Muscle[MeSHID:D009132] experimental,illicit,investigative androgen receptor AR Successful target unknown NA TTD , drugbank asc-jmz1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] investigative androgen receptor AR Successful target unknown NA TTD mx-4509 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 androgen receptor AR Successful target unknown NA TTD hydroxyflutamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved androgen receptor AR Successful target unknown 0.18 TTD , DGIDB dihydrotestosterone NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 4 androgen receptor messenger rna AR Clinical trial target unknown 0.02 TTD , DGIDB 2-chloro-4-{[(1r,3z,7s,7as)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1h-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile small molecule NA experimental androgen receptor AR NA unknown NA drugbank zanoterone NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 androgen receptor AR Successful target unknown 0.07 TTD , DGIDB testosterone propionate small molecule Growth[MeSHID:D006128] approved,investigational,vet_approved,withdrawn androgen receptor AR NA agonist NA drugbank , DGIDB 3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile NA NA investigative androgen receptor messenger rna AR Clinical trial target unknown NA TTD epi-7386 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 androgen receptor AR Successful target unknown NA TTD isis 9064 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9063 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9065 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9071 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9062 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD rg7304 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 10228 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9061 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9066 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9060 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9067 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9069 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD atp small molecule NA investigational,nutraceutical serine/threonine-protein kinase a-raf ARAF NA unknown NA drugbank isis 9068 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD isis 9070 NA NA investigative a-raf messenger rna ARAF Clinical trial target unknown NA TTD glycerin small molecule NA approved,investigational adp-ribosylation factor 1 ARF1 NA unknown NA drugbank guanosine-3'-monophosphate-5'-diphosphate small molecule NA experimental adp-ribosylation factor 1 ARF1 NA unknown NA drugbank brefeldin a small molecule NA experimental adp-ribosylation factor 1 ARF1 NA unknown NA drugbank guanosine-5'-triphosphate small molecule NA experimental adp-ribosylation factor 1 ARF1 NA unknown NA drugbank myristic acid small molecule NA experimental adp-ribosylation factor 1 ARF1 NA unknown NA drugbank 1,3-propanediol small molecule NA experimental adp-ribosylation factor 1 ARF1 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental adp-ribosylation factor 1 ARF1 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental adp-ribosylation factor 4 ARF4 NA unknown NA drugbank myristic acid small molecule NA experimental adp-ribosylation factor 6 ARF6 NA unknown NA drugbank 5'-guanosine-diphosphate-monothiophosphate small molecule NA experimental adp-ribosylation factor 6 ARF6 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental adp-ribosylation factor 6 ARF6 NA unknown NA drugbank s-2-(boronoethyl)-l-cysteine small molecule NA experimental arginase-1 ARG1 NA unknown NA drugbank s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental arginase-1 ARG1 NA unknown NA drugbank n(5)-[(hydroxyamino)(imino)methyl]-l-ornithine small molecule NA experimental arginase-1 ARG1 NA unknown NA drugbank urea small molecule Catabolism[MeSHID:D008660],Disease[MeSHID:D004194],Nail plate[MeSHID:D009262],patient care[MeSHID:D005791],Proteolysis[MeSHID:D059748],Lanugo[MeSHID:D006197],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved,investigational arginase-1 ARG1 NA unknown NA drugbank dehydro-2(s)-amino-6-boronohexanoic acid small molecule NA experimental arginase-1 ARG1 NA unknown NA drugbank ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical arginase-1 ARG1 NA unknown NA drugbank descarboxy-nor-n(omega)-hydroxy-l-arginine small molecule NA experimental arginase-1 ARG1 NA unknown NA drugbank manganese small molecule Plasma[MeSHID:D010949],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved,nutraceutical arginase-1 ARG1 NA unknown NA drugbank nor-noha small molecule NA investigational arginase-1 ARG1 NA unknown NA drugbank 2(s)-amino-6-boronohexanoic acid small molecule NA experimental arginase-1 ARG1 NA inhibitor NA drugbank , DGIDB s-{2-[amino(dihydroxy)-lambda~4~-sulfanyl]ethyl}-d-cysteine small molecule NA experimental arginase-1 ARG1 NA unknown NA drugbank dinor-n(omega)-hydroxy-l-arginine small molecule NA experimental arginase-1 ARG1 NA unknown NA drugbank s-propylamine-l-cysteine small molecule NA experimental arginase-1 ARG1 NA unknown NA drugbank s-(2-boronoethyl)-l-cysteine NA NA investigative kidney-type arginase ARG2 Clinical trial target unknown NA TTD s-2-(boronoethyl)-l-cysteine small molecule NA experimental arginase-2, mitochondrial ARG2 NA unknown NA drugbank ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical arginase-2, mitochondrial ARG2 NA unknown NA drugbank arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical arginase-2, mitochondrial ARG2 NA unknown NA drugbank n-hydroxy-nor-l-arginine NA NA investigative kidney-type arginase ARG2 Clinical trial target unknown NA TTD guanosine-5'-diphosphate small molecule NA experimental adp-ribosylation factor-like protein 1 ARL1 NA unknown NA drugbank tagraxofusp biotech Plasmacytoid Dendritic Cells[MeSHID:D003713],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Biological Markers[MeSHID:D015415],Intention - mental process[MeSHID:D033182],Lymph[MeSHID:D008196],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] approved,investigational adp-ribosylation factor-like protein 2 ARL2 NA binder NA drugbank 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental adp-ribosylation factor-like protein 3 ARL3 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental adp-ribosylation factor-like protein 3 ARL3 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental adp-ribosylation factor-like protein 5a ARL5A NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental adp-ribosylation factor-like protein 5b ARL5B NA unknown NA drugbank (2s)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one small molecule NA experimental actin-related protein 2/3 complex subunit 1b ARPC1B NA unknown NA drugbank n-[2-(2-methyl-1h-indol-3-yl)ethyl]thiophene-2-carboxamide small molecule NA experimental actin-related protein 2/3 complex subunit 1b ARPC1B NA unknown NA drugbank n-[2-(2-methyl-1h-indol-3-yl)ethyl]thiophene-2-carboxamide small molecule NA experimental actin-related protein 2/3 complex subunit 2 ARPC2 NA unknown NA drugbank (2s)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one small molecule NA experimental actin-related protein 2/3 complex subunit 2 ARPC2 NA unknown NA drugbank (2s)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one small molecule NA experimental actin-related protein 2/3 complex subunit 3 ARPC3 NA unknown NA drugbank n-[2-(2-methyl-1h-indol-3-yl)ethyl]thiophene-2-carboxamide small molecule NA experimental actin-related protein 2/3 complex subunit 3 ARPC3 NA unknown NA drugbank n-[2-(2-methyl-1h-indol-3-yl)ethyl]thiophene-2-carboxamide small molecule NA experimental actin-related protein 2/3 complex subunit 4 ARPC4 NA unknown NA drugbank (2s)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one small molecule NA experimental actin-related protein 2/3 complex subunit 4 ARPC4 NA unknown NA drugbank (2s)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one small molecule NA experimental actin-related protein 2/3 complex subunit 5 ARPC5 NA unknown NA drugbank n-[2-(2-methyl-1h-indol-3-yl)ethyl]thiophene-2-carboxamide small molecule NA experimental actin-related protein 2/3 complex subunit 5 ARPC5 NA unknown NA drugbank 2-amino-3-hydroxy-3-phosphonooxy-propionic acid small molecule NA experimental arylsulfatase a ARSA NA unknown NA drugbank 4-nitrocatechol sulfate small molecule NA experimental arylsulfatase a ARSA NA unknown NA drugbank otl-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukodystrophy, Metachromatic[MeSHID:D007966] approved cerebroside-sulfatase ARSA Successful target unknown NA TTD hgt-1111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukodystrophy, Metachromatic[MeSHID:D007966] phase 2 cerebroside-sulfatase ARSA Successful target unknown NA TTD , DGIDB galsulfase NA Mucopolysaccharidosis VI[MeSHID:D009087],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] approved n-acetylgalactosamine-4-sulfatase ARSB Successful target unknown 31.83 TTD , DGIDB 5-bromonicotinamide small molecule NA experimental gpi-linked nad(p)(+)--arginine adp-ribosyltransferase 1 ART1 NA unknown NA drugbank ademetionine small molecule Emotions[MeSHID:D004644],Degenerative polyarthritis[MeSHID:D010003],Depressive disorder[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Liver diseases[MeSHID:D008107],Bone Tissue[MeSHID:D001842],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] approved,investigational,nutraceutical arsenite methyltransferase AS3MT NA unknown NA drugbank amg 529 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 asialoglycoprotein receptor 1 ASGR1 Clinical trial target unknown NA TTD , DGIDB moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved asialoglycoprotein receptor 2 ASGR2 NA binder NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational asialoglycoprotein receptor 2 ASGR2 NA binder NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational asialoglycoprotein receptor 2 ASGR2 NA binder NA drugbank ppc-5650 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 acid-sensing ion channel 1 ASIC1 Successful target unknown NA TTD , DGIDB amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acid-sensing ion channel 1 ASIC1 Successful target inhibitor,blocker 6.37 TTD , drugbank , DGIDB pctx1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative acid-sensing ion channel 1 ASIC1 Successful target unknown NA TTD amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acid-sensing ion channel 1 ASIC1 Successful target inhibitor 6.37 TTD , drugbank , DGIDB amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acid-sensing ion channel 2 ASIC2 NA inhibitor,blocker 5.46 drugbank , DGIDB agmatine small molecule Diabetes Mellitus[MeSHID:D003920],Small Fiber Neuropathy[MeSHID:D000071075],Neuroprotection[MeSHID:D000066829],Glaucoma[MeSHID:D005901],Diagnosis[MeSHID:D003933],Epilepsy[MeSHID:D004827],Kidney[MeSHID:D007668],Anxiety Disorders[MeSHID:D001008],Blind Vision[MeSHID:D001766],Mental Depression[MeSHID:D003863],Cognition[MeSHID:D003071],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Traumatic injury[MeSHID:D014947],Cerebrovascular accident[MeSHID:D020521],Anxiety[MeSHID:D001007] experimental acid-sensing ion channel 3 ASIC3 NA agonist,activator 15.91 drugbank , DGIDB 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental argininosuccinate lyase ASL NA unknown NA drugbank argininosuccinate small molecule NA experimental argininosuccinate lyase ASL NA unknown NA drugbank arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical argininosuccinate lyase ASL NA unknown NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved acetylserotonin o-methyltransferase ASMT NA unknown NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved acetylserotonin o-methyltransferase ASMT NA unknown NA drugbank atp small molecule NA investigational,nutraceutical atpase asna1 ASNA1 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical asparagine synthetase [glutamine-hydrolyzing] ASNS NA substrate NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical asparagine synthetase [glutamine-hydrolyzing] ASNS NA unknown NA drugbank atp small molecule NA investigational,nutraceutical asparagine synthetase [glutamine-hydrolyzing] ASNS NA unknown NA drugbank asparagine small molecule NA approved,investigational,nutraceutical asparagine synthetase [glutamine-hydrolyzing] ASNS NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational aspartoacylase ASPA NA cofactor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational aspartoacylase ASPA NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational aspartoacylase ASPA NA cofactor NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental aspartoacylase ASPA NA cofactor NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical aspartoacylase ASPA NA unknown NA drugbank procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 60 kda lysophospholipase ASPG NA inhibitor NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical aspartyl/asparaginyl beta-hydroxylase ASPH NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical isoaspartyl peptidase/l-asparaginase ASRGL1 NA unknown NA drugbank graspa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 3 asparaginase ASRGL1 Successful target unknown NA TTD asparagine small molecule NA approved,investigational,nutraceutical isoaspartyl peptidase/l-asparaginase ASRGL1 NA substrate NA drugbank calaspargase pegol NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Lymphocytes[MeSHID:D001402],Serum[MeSHID:D044967],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved asparaginase ASRGL1 Successful target unknown NA TTD citrulline small molecule NA investigational,nutraceutical argininosuccinate synthetase, isoform cra_a ASS NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical argininosuccinate synthetase, isoform cra_a ASS NA unknown NA drugbank arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical argininosuccinate synthase ASS1 NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical argininosuccinate synthase ASS1 NA unknown NA drugbank atp small molecule NA investigational,nutraceutical argininosuccinate synthase ASS1 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical argininosuccinate synthase ASS1 NA unknown NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 ATF1 NA inhibitor NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 ATF2 NA inhibitor NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 ATF3 NA inhibitor NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 ATF4 NA inhibitor NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 ATF5 NA inhibitor NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 ATF6 NA inhibitor NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 ATF7 NA inhibitor NA drugbank guanosine-5'-monophosphate small molecule NA experimental bifunctional purine biosynthesis protein purh ATIC NA unknown NA drugbank pemetrexed small molecule Malignant mesothelioma[MeSHID:C562839],Disease[MeSHID:D004194],Pleura[MeSHID:D010994],Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational bifunctional purine biosynthesis protein purh ATIC NA inhibitor 11.37 drugbank , DGIDB tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical bifunctional purine biosynthesis protein purh ATIC NA cofactor NA drugbank acid yellow 54 free acid small molecule NA experimental bifunctional purine biosynthesis protein purh ATIC NA unknown NA drugbank aica ribonucleotide small molecule NA experimental,investigational bifunctional purine biosynthesis protein purh ATIC NA unknown NA drugbank n-[4-([(2-amino-4-oxo-1,4-dihydropyrido[3,2-d]pyrimidin-6-yl)methyl]{(2e)-3-[4-carbamoyl-1-(5-o-phosphono-beta-d-ribofuranosyl)-1h-imidazol-5-yl]-2-propenoyl}amino)benzoyl]-l-glutamic acid small molecule NA experimental bifunctional purine biosynthesis protein purh ATIC NA unknown NA drugbank methotrexate small molecule Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved bifunctional purine biosynthesis protein purh ATIC NA inhibitor 4.13 drugbank , DGIDB 5-monophosphate-9-beta-d-ribofuranosyl xanthine small molecule NA experimental bifunctional purine biosynthesis protein purh ATIC NA unknown NA drugbank methotrexate small molecule Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Proliferative vitreoretinopathy[MeSHID:D018630],leukemia[MeSHID:D007938],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369] approved bifunctional purine biosynthesis protein purh ATIC NA inhibitor 4.13 drugbank , DGIDB ku-60019 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial atm serine/threonine kinase ATM Clinical trial target unknown NA TTD , DGIDB azd1390 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1 atm serine/threonine kinase ATM Clinical trial target unknown NA TTD , DGIDB cgk733 NA NA investigative atm serine/threonine kinase ATM Clinical trial target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved serine-protein kinase atm ATM NA inhibitor NA drugbank m3541 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 atm serine/threonine kinase ATM Clinical trial target unknown NA TTD , DGIDB azd0156 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 atm serine/threonine kinase ATM Clinical trial target unknown 2.36 TTD , DGIDB azd0156 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 atm serine/threonine kinase ATM Clinical trial target inhibitor 2.36 TTD , DGIDB ku-60019 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial atm serine/threonine kinase ATM Clinical trial target inhibitor NA TTD , DGIDB cisplatin small molecule ovarian neoplasm[MeSHID:D010051],Testicular Neoplasms[MeSHID:D013736],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Osteosarcoma[MeSHID:D012516] approved copper transport protein atox1 ATOX1 NA unknown NA drugbank sucrose small molecule NA approved,experimental,investigational copper transport protein atox1 ATOX1 NA unknown NA drugbank benzamidine small molecule NA experimental copper transport protein atox1 ATOX1 NA unknown NA drugbank acetyldigitoxin NA Congestive heart failure[MeSHID:D006333],Fasting[MeSHID:D005215],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium pump subunit alpha-1 ATP1A1 Successful target inhibitor 3.98 TTD , DGIDB trichlormethiazide small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor NA drugbank digoxin small molecule Disease[MeSHID:D004194],Myocardial Contraction[MeSHID:D009200],Maintenance[MeSHID:D008283],treatment failure[MeSHID:D017211],Diagnosis[MeSHID:D003933],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor 1.4 drugbank , DGIDB acocantherin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown NA TTD magnesium lactate small molecule NA nutraceutical sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank tegoprazan small molecule NA investigational sodium/potassium transporting atpase subunits ATP1A1 NA inhibitor NA drugbank bretylium small molecule Ventricular Fibrillation[MeSHID:D014693],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor NA drugbank acetyldigitoxin NA Congestive heart failure[MeSHID:D006333],Fasting[MeSHID:D005215],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown 3.98 TTD , DGIDB digitoxin small molecule Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor 2.95 drugbank , DGIDB almitrine NA Chronic Obstructive Airway Disease[MeSHID:D029424],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown 42.43 TTD , DGIDB magnesium acetate small molecule NA approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank unbs-1450 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 sodium pump subunit alpha-1 ATP1A1 Successful target unknown NA TTD , DGIDB deslanoside small molecule Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor 4.13 drugbank , DGIDB aluminium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperhidrosis disorder[MeSHID:D006945] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown NA TTD , DGIDB digitoxigenin NA NA investigative sodium pump subunit alpha-1 ATP1A1 Successful target unknown NA TTD chloroprocaine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown 1.33 TTD , DGIDB almitrine NA Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown 42.43 TTD , DGIDB diazoxide small molecule insulinoma[MeSHID:D007340],Neoplasm Metastasis[MeSHID:D009362],Hypoglycemia[MeSHID:D007003],Emergencies [Disease/Finding][MeSHID:D004630],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA other NA drugbank magnesium levulinate small molecule NA nutraceutical sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inducer NA drugbank lumefantrine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown 1.33 TTD , DGIDB bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor 3.38 drugbank , DGIDB almitrine small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA binder 42.43 drugbank , DGIDB potassium small molecule Solutions[MeSHID:D012996],Disease Management[MeSHID:D019468],Cardiac Arrhythmia[MeSHID:D001145],Calculi[MeSHID:D002137],Kidney Calculi[MeSHID:D007669],Malabsorption Syndrome[MeSHID:D008286],Water consumption[MeSHID:D004326],Drinking Water[MeSHID:D060766],Alkalosis[MeSHID:D000471],Nephrolithiasis[MeSHID:D053040],Patient Discharge[MeSHID:D010351],Disease[MeSHID:D004194],Hypokalemia[MeSHID:D007008],Renal tubular acidosis[MeSHID:D000141],Mental concentration[MeSHID:D001288],Potassium Deficiency[MeSHID:D011191],Urine[MeSHID:D014556],Hypernatremia[MeSHID:D006955],Comprehension[MeSHID:D032882],Hypokalemic periodic paralysis[MeSHID:D020514],Body Fluids[MeSHID:D001826],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA regulator NA drugbank aluminum acetate small molecule NA approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank potassium acetate small molecule Hypokalemia[MeSHID:D007008],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Kidney Calculi[MeSHID:D007669],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nephrolithiasis[MeSHID:D053040] approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank potassium cation small molecule Hypokalemia[MeSHID:D007008],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362] approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank magnesium cation small molecule NA approved,nutraceutical sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank acetyldigitoxin small molecule Congestive heart failure[MeSHID:D006333],Fasting[MeSHID:D005215],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor 3.98 drugbank , DGIDB aluminium small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperhidrosis disorder[MeSHID:D006945] approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA binder NA drugbank , DGIDB deslanoside NA Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium pump subunit alpha-1 ATP1A1 Successful target inhibitor 4.13 TTD , DGIDB bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium transporting atpase subunits ATP1A1 NA inhibitor NA drugbank aluminium phosphate small molecule NA approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank deslanoside NA Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown 4.13 TTD , DGIDB ouabain small molecule Heart failure[MeSHID:D006333],Atrial Fibrillation[MeSHID:D001281] approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor 5.3 drugbank , DGIDB acocantherin NA Atrial Fibrillation[MeSHID:D001281],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown NA TTD artemether NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved sodium pump subunit alpha-1 ATP1A1 Successful target unknown 1.06 TTD , DGIDB etacrynic acid small molecule Hypertensive disease[MeSHID:D006973],Kidney Failure[MeSHID:D051437],Liver Failure[MeSHID:D017093],Edema[MeSHID:D004487],Congestive heart failure[MeSHID:D006333] approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA inhibitor NA drugbank potassium sulfate small molecule Hypokalemia[MeSHID:D007008],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362] approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown NA drugbank ciclopirox small molecule Immunocompetence[MeSHID:D007121],Onychomycosis[MeSHID:D014009],Structure of nail of toe[MeSHID:D009262],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA binder NA drugbank istaroxime small molecule Heart Diseases[MeSHID:D006331],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA unknown 5.3 drugbank , DGIDB almitrine small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium-transporting atpase subunit alpha-1 ATP1A1 NA binder 42.43 drugbank , DGIDB tegoprazan small molecule NA investigational sodium/potassium transporting atpase subunits ATP1A2 NA inhibitor NA drugbank bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium transporting atpase subunits ATP1A2 NA inhibitor NA drugbank ouabain small molecule Heart failure[MeSHID:D006333],Atrial Fibrillation[MeSHID:D001281] approved sodium/potassium-transporting atpase subunit alpha-2 ATP1A2 NA inhibitor NA drugbank bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium transporting atpase subunits ATP1A3 NA inhibitor NA drugbank tegoprazan small molecule NA investigational sodium/potassium transporting atpase subunits ATP1A3 NA inhibitor NA drugbank ouabain small molecule Heart failure[MeSHID:D006333],Atrial Fibrillation[MeSHID:D001281] approved sodium/potassium-transporting atpase subunit alpha-3 ATP1A3 NA inhibitor NA drugbank bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium transporting atpase subunits ATP1A4 NA inhibitor NA drugbank tegoprazan small molecule NA investigational sodium/potassium transporting atpase subunits ATP1A4 NA inhibitor NA drugbank tegoprazan small molecule NA investigational sodium/potassium transporting atpase subunits ATP1B1 NA inhibitor NA drugbank bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium transporting atpase subunits ATP1B1 NA inhibitor NA drugbank bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium transporting atpase subunits ATP1B2 NA inhibitor NA drugbank tegoprazan small molecule NA investigational sodium/potassium transporting atpase subunits ATP1B2 NA inhibitor NA drugbank tegoprazan small molecule NA investigational sodium/potassium transporting atpase subunits ATP1B3 NA inhibitor NA drugbank bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium transporting atpase subunits ATP1B3 NA inhibitor NA drugbank adenosine-5'-[beta, gamma-methylene]triphosphate small molecule NA experimental sarcoplasmic/endoplasmic reticulum calcium atpase 1 ATP2A1 NA unknown NA drugbank tetrafluoroaluminate ion small molecule NA experimental sarcoplasmic/endoplasmic reticulum calcium atpase 1 ATP2A1 NA unknown NA drugbank 2,5-di-tert-butylhydroquinone small molecule NA experimental sarcoplasmic/endoplasmic reticulum calcium atpase 1 ATP2A1 NA unknown NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium transporting atpases ATP2A1 NA inhibitor NA drugbank (6ar,11as,11br)-10-acetyl-9-hydroxy-7,7-dimethyl-2,6,6a,7,11a,11b-hexahydro-11h-pyrrolo[1',2':2,3]isoindolo[4,5,6-cd]indol-11-one small molecule NA experimental sarcoplasmic/endoplasmic reticulum calcium atpase 1 ATP2A1 NA unknown NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sarcoplasmic/endoplasmic reticulum calcium atpase 1 ATP2A1 NA inhibitor,stimulator NA drugbank gallopamil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Asthma[MeSHID:D001249] phase 2 sarcoplasmic/endoplasmic reticulum calcium atpase 2 ATP2A2 Clinical trial target unknown 7.07 TTD , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium transporting atpases ATP2A2 NA inhibitor NA drugbank istaroxime small molecule Heart Diseases[MeSHID:D006331],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sarcoplasmic/endoplasmic reticulum calcium atpase 2 ATP2A2 NA unknown 21.22 drugbank , DGIDB mydicar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 sarcoplasmic/endoplasmic reticulum calcium atpase 2 ATP2A2 Clinical trial target unknown NA TTD , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved plasma membrane calcium-transporting atpase ATP2B1 NA inhibitor NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium transporting atpases ATP2B1 NA inhibitor NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium transporting atpases ATP2B2 NA inhibitor NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved plasma membrane calcium-transporting atpase ATP2B2 NA inhibitor NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium transporting atpases ATP2B3 NA inhibitor NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved plasma membrane calcium-transporting atpase ATP2B3 NA inhibitor NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium transporting atpases ATP2B4 NA inhibitor NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved plasma membrane calcium-transporting atpase ATP2B4 NA inhibitor NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved calcium-transporting atpase type 2c member 1 ATP2C1 NA inhibitor 2.74 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-transporting atpase type 2c member 1 ATP2C1 NA inhibitor 2.05 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium transporting atpases ATP2C1 NA inhibitor 2.65 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved calcium-transporting atpase type 2c member 1 ATP2C1 NA inhibitor 3.38 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved calcium-transporting atpase type 2c member 1 ATP2C1 NA inhibitor 3.38 drugbank , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-transporting atpase type 2c member 1 ATP2C1 NA inhibitor NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical calcium-transporting atpase type 2c member 1 ATP2C1 NA agonist NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium transporting atpases ATP2C2 NA inhibitor NA drugbank dexlansoprazole NA Esophagitis[MeSHID:D004941],Maintenance[MeSHID:D008283],Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276] approved gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown 4.55 TTD , DGIDB esomeprazole magnesium + aspirin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] phase 3 gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD , DGIDB dexlansoprazole small molecule Esophagitis[MeSHID:D004941],Maintenance[MeSHID:D008283],Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276] approved,investigational potassium-transporting atpase alpha chain 1 ATP4A NA inhibitor 4.55 drugbank , DGIDB pa-10040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] investigative gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD esomeprazole small molecule Zollinger-Ellison syndrome[MeSHID:D015043],Esophagitis[MeSHID:D004941],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Pathologic Processes[MeSHID:D010335],Gastrointestinal Hemorrhage[MeSHID:D006471],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Peptic Ulcer[MeSHID:D010437],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium-transporting atpase alpha chain 1 ATP4A NA inhibitor 4.04 drugbank , DGIDB omeprazole small molecule Esophagitis[MeSHID:D004941],Maintenance[MeSHID:D008283],Pathologic Processes[MeSHID:D010335],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved potassium-transporting atpase alpha chain 1 ATP4A NA inhibitor 1.74 drugbank , DGIDB dexlansoprazole NA Esophagitis[MeSHID:D004941],Maintenance[MeSHID:D008283],Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276] approved gastric h(+)/k(+) atpase alpha ATP4A Successful target inhibitor 4.55 TTD , DGIDB rabeprazole small molecule Peptic Ulcer[MeSHID:D010437],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Gastroesophageal reflux disease[MeSHID:D005764],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium-transporting atpase alpha chain 1 ATP4A NA inhibitor 2.27 drugbank , DGIDB ag-spt201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 3 gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD , DGIDB arh-1029 NA Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE[MeSHID:C566331] investigative gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD api-023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] phase 1 gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD , DGIDB pantoprazole small molecule Zollinger-Ellison syndrome[MeSHID:D015043],Esophagitis[MeSHID:D004941],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Pathologic Processes[MeSHID:D010335],Peptic Esophagitis[MeSHID:D004942],Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Patient Discharge[MeSHID:D010351],Relapse[MeSHID:D012008],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium-transporting atpase alpha chain 1 ATP4A NA inhibitor 4.55 drugbank , DGIDB lansoprazole small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Gastric Acid[MeSHID:D005744],Stomach Diseases[MeSHID:D013272],Peptic Esophagitis[MeSHID:D004942],Recurrence (disease attribute)[MeSHID:D012008],Term Birth[MeSHID:D047929],Zollinger-Ellison syndrome[MeSHID:D015043],Esophagitis[MeSHID:D004941],Bodily secretions[MeSHID:D012634],Stomach[MeSHID:D013270],Gastroesophageal reflux disease[MeSHID:D005764],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Wound Healing[MeSHID:D014945] approved,investigational potassium-transporting atpase alpha chain 1 ATP4A NA inhibitor 1.05 drugbank , DGIDB ca-50040 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hippocampus Proper[MeSHID:D006624] investigative gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD opc-22575 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] investigative gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD saliphenylhalamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD rabeprazole NA Peptic Ulcer[MeSHID:D010437],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Gastroesophageal reflux disease[MeSHID:D005764],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown 2.27 TTD , DGIDB cdri-85/92 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276] investigative gastric h(+)/k(+) atpase alpha ATP4A Successful target unknown NA TTD dexlansoprazole small molecule Esophagitis[MeSHID:D004941],Maintenance[MeSHID:D008283],Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276] approved,investigational potassium-transporting atpase subunit beta ATP4B NA inhibitor 2.12 drugbank , DGIDB 1-acetyl-2-carboxypiperidine small molecule NA experimental atp synthase subunit alpha, mitochondrial ATP5A1 NA unknown NA drugbank aurovertin b small molecule NA experimental atp synthase subunit alpha, mitochondrial ATP5A1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational atp synthase subunit alpha, mitochondrial ATP5A1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational atp synthase subunit alpha, mitochondrial ATP5A1 NA ligand NA drugbank piceatannol small molecule NA experimental atp synthase subunit alpha, mitochondrial ATP5A1 NA unknown NA drugbank n1-(2-amino-4-methylpentyl)octahydro-pyrrolo[1,2-a] pyrimidine small molecule NA experimental atp synthase subunit alpha, mitochondrial ATP5A1 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational atp synthase subunit beta, mitochondrial ATP5B NA unknown NA drugbank 1-acetyl-2-carboxypiperidine small molecule NA experimental atp synthase subunit beta, mitochondrial ATP5B NA unknown NA drugbank piceatannol small molecule NA experimental atp synthase subunit beta, mitochondrial ATP5B NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational atp synthase subunit beta, mitochondrial ATP5B NA unknown NA drugbank aurovertin b small molecule NA experimental atp synthase subunit beta, mitochondrial ATP5B NA unknown NA drugbank n1-(2-amino-4-methylpentyl)octahydro-pyrrolo[1,2-a] pyrimidine small molecule NA experimental atp synthase subunit beta, mitochondrial ATP5B NA unknown NA drugbank aurovertin b small molecule NA experimental atp synthase subunit gamma, mitochondrial ATP5C1 NA unknown NA drugbank n1-(2-amino-4-methylpentyl)octahydro-pyrrolo[1,2-a] pyrimidine small molecule NA experimental atp synthase subunit gamma, mitochondrial ATP5C1 NA unknown NA drugbank piceatannol small molecule NA experimental atp synthase subunit gamma, mitochondrial ATP5C1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational atp synthase subunit gamma, mitochondrial ATP5C1 NA unknown NA drugbank 1-acetyl-2-carboxypiperidine small molecule NA experimental atp synthase subunit gamma, mitochondrial ATP5C1 NA unknown NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atp synthase subunit delta, mitochondrial ATP5D NA unknown NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved atp synthase subunit delta, mitochondrial ATP5D NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational atp synthase subunit e, mitochondrial ATP5I NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational atp synthase subunit g, mitochondrial ATP5L NA ligand NA drugbank phenethyl isothiocyanate small molecule NA investigational atp synthase subunit g, mitochondrial ATP5L NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational atp synthase subunit o, mitochondrial ATP5O NA ligand NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6AP1 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0A1 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0A2 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0A4 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0B NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0C NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0D1 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0D2 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0E1 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V0E2 NA inhibitor NA drugbank alendronic acid small molecule Osteoporosis[MeSHID:D010024],Osteitis Deformans[MeSHID:D010001] approved v-type proton atpase catalytic subunit a ATP6V1A NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1A NA inhibitor NA drugbank bafilomycin b1 small molecule NA experimental v-type proton atpase catalytic subunit a ATP6V1A NA inhibitor NA drugbank bafilomycin a1 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Burkitt Lymphoma[MeSHID:D002051] experimental v-type proton atpase catalytic subunit a ATP6V1A NA inhibitor NA drugbank etidronic acid small molecule Osteogenesis[MeSHID:D010012],Strabismus[MeSHID:D013285],Spinal Cord Injuries[MeSHID:D013119],Osteitis Deformans[MeSHID:D010001],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved v-type proton atpase catalytic subunit a ATP6V1A NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1B1 NA inhibitor NA drugbank 4-(2-aminoethyl)benzenesulfonyl fluoride small molecule NA experimental v-type proton atpase subunit b, brain isoform ATP6V1B2 NA unknown NA drugbank gallium nitrate small molecule Hypercalcemia[MeSHID:D006934],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational v-type proton atpase subunit b, brain isoform ATP6V1B2 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1B2 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1C1 NA inhibitor NA drugbank d-tartaric acid small molecule NA experimental v-type proton atpase subunit c 1 ATP6V1C1 NA unknown NA drugbank thonzonium small molecule Cells[MeSHID:D002477] approved v-type proton atpase subunit c 1 ATP6V1C1 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1C2 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1D NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1E1 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1E2 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1F NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1G1 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1G2 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1G3 NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits ATP6V1H NA inhibitor NA drugbank phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical probable phospholipid-transporting atpase ia ATP8A1 NA unknown NA drugbank bay1895344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 serine/threonine-protein kinase atr ATR Clinical trial target inhibitor NA TTD , DGIDB az20 NA NA investigative serine/threonine-protein kinase atr ATR Clinical trial target inhibitor NA TTD , DGIDB vx-970 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase atr ATR Clinical trial target inhibitor 2.36 TTD , DGIDB vx-970 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase atr ATR Clinical trial target unknown 2.36 TTD , DGIDB rp-3500 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase atr ATR Clinical trial target unknown NA TTD cgk733 NA NA investigative serine/threonine-protein kinase atr ATR Clinical trial target unknown NA TTD m1774 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase atr ATR Clinical trial target unknown NA TTD ceralasertib small molecule NA investigational serine/threonine-protein kinase atr ATR NA inhibitor 5.3 drugbank , DGIDB m4344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase atr ATR Clinical trial target unknown NA TTD , DGIDB ve-821 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase atr ATR Clinical trial target inhibitor NA TTD , DGIDB azd6738 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Small cell carcinoma of lung[MeSHID:D055752],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 serine/threonine-protein kinase atr ATR Clinical trial target unknown 5.3 TTD , DGIDB bay1895344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 serine/threonine-protein kinase atr ATR Clinical trial target unknown NA TTD , DGIDB cyc116 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 aurora kinase a AURKA Clinical trial target inhibitor NA TTD , drugbank , DGIDB enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational aurora kinase a AURKA NA unknown NA drugbank indirubin-3-acetoxime NA NA investigative aurora kinase a AURKA Clinical trial target unknown NA TTD 1-(5-{2-[(1-methyl-1h-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea small molecule NA experimental aurora kinase a AURKA NA unknown NA drugbank zm-447439 NA NA investigative aurora kinase a AURKA Clinical trial target unknown 0.07 TTD , DGIDB enmd-2076 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Liver carcinoma[MeSHID:D006528],Malignant neoplasm of liver[MeSHID:D008113],Triple Negative Breast Neoplasms[MeSHID:D064726] phase 2 aurora kinase a AURKA Clinical trial target unknown 0.37 TTD , DGIDB 7-fluoroindirubin-3-oxime NA NA investigative aurora kinase a AURKA Clinical trial target unknown NA TTD r763 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 aurora kinase a AURKA Clinical trial target unknown NA TTD , DGIDB cenisertib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational aurora kinase a AURKA NA inhibitor 0.04 drugbank , DGIDB indirubin-3'-monoxime NA NA investigative aurora kinase a AURKA Clinical trial target unknown NA TTD alisertib small molecule Malignant Neoplasms[MeSHID:D009369] investigational aurora kinase a AURKA NA inhibitor 0.24 drugbank , DGIDB sns-314 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 aurora kinase a AURKA Clinical trial target inhibitor 0.21 TTD , drugbank , DGIDB rosiglitazone + metformin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 aurora kinase a AURKA Clinical trial target unknown NA TTD , DGIDB sns-314 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 aurora kinase a AURKA Clinical trial target unknown 0.21 TTD , drugbank , DGIDB pha-739358 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 aurora kinase a AURKA Clinical trial target unknown 1.27 TTD , DGIDB ly3295668 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 aurora kinase a AURKA Clinical trial target unknown NA TTD mln8237 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Small cell carcinoma of lung[MeSHID:D055752] phase 3 aurora kinase a AURKA Clinical trial target unknown NA TTD , DGIDB 4-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine NA NA investigative aurora kinase a AURKA Clinical trial target unknown NA TTD n-[3-(1h-benzimidazol-2-yl)-1h-pyrazol-4-yl]benzamide small molecule NA experimental aurora kinase a AURKA NA unknown NA drugbank 2-(1h-pyrazol-3-yl)-1h-benzimidazole small molecule NA experimental,investigative aurora kinase a AURKA Clinical trial target unknown NA TTD , drugbank alisertib small molecule Malignant Neoplasms[MeSHID:D009369] investigational aurora kinase a AURKA NA unknown 0.24 drugbank , DGIDB indirubin-3-methoxime NA NA investigative aurora kinase a AURKA Clinical trial target unknown NA TTD phosphonothreonine small molecule NA experimental,investigative aurora kinase a AURKA Clinical trial target unknown NA TTD , drugbank tas-119 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pentalogy of Cantrell[MeSHID:D058502] phase 1 aurora kinase a AURKA Clinical trial target unknown 2.55 TTD , DGIDB pf-03814735 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 aurora kinase a AURKA Clinical trial target inhibitor 1.91 TTD , DGIDB abt-348 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 2 aurora kinase a AURKA Clinical trial target unknown 0.05 TTD , DGIDB mk-5108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase a AURKA Clinical trial target unknown 2.12 TTD , DGIDB 6-bromoindirubin-3-oxime NA NA investigative aurora kinase a AURKA Clinical trial target unknown NA TTD cenisertib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational aurora kinase a AURKA NA unknown 0.04 drugbank , DGIDB amg 900 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase a AURKA Clinical trial target unknown NA TTD , DGIDB hpp-607 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hereditary pyropoikilocytosis[MeSHID:C563004],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase a AURKA Clinical trial target unknown NA TTD , DGIDB mln8054 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 aurora kinase a AURKA Clinical trial target unknown NA TTD , drugbank , DGIDB vx-680 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 aurora kinase a AURKA Clinical trial target unknown 0.13 TTD , DGIDB enmd-2076 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Liver carcinoma[MeSHID:D006528],Malignant neoplasm of liver[MeSHID:D008113],Triple Negative Breast Neoplasms[MeSHID:D064726] phase 2 aurora kinase a AURKA Clinical trial target inhibitor 0.37 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational aurora kinase a AURKA NA inhibitor NA drugbank tas-119 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pentalogy of Cantrell[MeSHID:D058502] phase 1 aurora kinase a AURKA Clinical trial target inhibitor 2.55 TTD , DGIDB 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea small molecule NA experimental aurora kinase a AURKA NA unknown NA drugbank n-butyl-3-{[6-(9h-purin-6-ylamino)hexanoyl]amino}benzamide small molecule NA experimental aurora kinase a AURKA NA unknown NA drugbank n-{3-[(4-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}cyclopropanecarboxamide small molecule NA experimental aurora kinase a AURKA NA unknown NA drugbank cyc116 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 aurora kinase a AURKA Clinical trial target unknown NA TTD , drugbank , DGIDB vic-1911 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase a AURKA Clinical trial target unknown NA TTD mln8237 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Small cell carcinoma of lung[MeSHID:D055752] phase 3 aurora kinase a AURKA Clinical trial target inhibitor 0.24 TTD , DGIDB at9283 small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 3 aurora kinase a AURKA Clinical trial target unknown 0.59 TTD , drugbank , DGIDB 4-(4-methylpiperazin-1-yl)-n-[5-(2-thienylacetyl)-1,5-dihydropyrrolo[3,4-c]pyrazol-3-yl]benzamide small molecule NA experimental aurora kinase a AURKA NA unknown NA drugbank mk-5108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase a AURKA Clinical trial target inhibitor 2.12 TTD , DGIDB aki-001 small molecule NA experimental aurora kinase a AURKA NA unknown NA drugbank at9283 small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 3 aurora kinase a AURKA Clinical trial target inhibitor 0.59 TTD , drugbank , DGIDB cgp-57380 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD indirubin-3-methoxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational aurora kinase b AURKB NA inhibitor NA drugbank 4-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD r763 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 aurora kinase b AURKB Clinical trial target unknown NA TTD , DGIDB gsk1070916a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown NA TTD , DGIDB isis 173848 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD reversine small molecule NA experimental aurora kinase b AURKB NA unknown NA drugbank rosiglitazone + metformin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 aurora kinase b AURKB Clinical trial target unknown NA TTD , DGIDB pmid20855207c25 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD 7-bromoindirubin-3-oxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD tak-901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 aurora kinase b AURKB Clinical trial target inhibitor 2.12 TTD , DGIDB 6-bromoindirubin-3-oxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD at9283 small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 3 aurora kinase b AURKB Clinical trial target unknown 0.49 TTD , drugbank , DGIDB bi-831266 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown NA TTD , DGIDB quinazoline deriv. 1 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational aurora kinase b AURKB NA unknown NA drugbank cyc116 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target inhibitor NA TTD , DGIDB 7-fluoroindirubin-3-oxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD bi-811283 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 aurora kinase b AURKB Clinical trial target unknown 3.18 TTD , DGIDB hpp-607 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hereditary pyropoikilocytosis[MeSHID:C563004],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown NA TTD , DGIDB bi-847325 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown NA TTD , DGIDB amg 900 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown NA TTD , DGIDB at9283 small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 3 aurora kinase b AURKB Clinical trial target inhibitor 0.49 TTD , drugbank , DGIDB indirubin-3-acetoxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD pf-03814735 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 aurora kinase b AURKB Clinical trial target inhibitor 1.59 TTD , DGIDB gsk1070916 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown 1.77 TTD , DGIDB pmid16451062c46 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD isis 173813 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD hesperadin NA NA investigative aurora b messenger rna AURKB Clinical trial target inhibitor 0.04 TTD , DGIDB sns-314 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target inhibitor 0.15 TTD , DGIDB tak-901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 aurora kinase b AURKB Clinical trial target unknown 2.12 TTD , DGIDB mk-5108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target inhibitor 0.71 TTD , DGIDB hesperidin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vascular purpura[MeSHID:C537256] approved,investigational aurora kinase b AURKB NA unknown NA drugbank isis 173840 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD su 6656 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD gsk1070916 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target inhibitor 1.77 TTD , DGIDB bi-811283 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 aurora kinase b AURKB Clinical trial target inhibitor 3.18 TTD , DGIDB pha-739358 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 aurora b messenger rna AURKB Clinical trial target unknown 1.06 TTD , DGIDB deguelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Squamous cell carcinoma of esophagus[MeSHID:C562729] investigative aurora kinase b AURKB Clinical trial target unknown NA TTD abt-348 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 2 aurora kinase b AURKB Clinical trial target unknown 0.04 TTD , DGIDB azd-1152-hqpa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown 0.14 TTD , DGIDB 7-iodoindirubin-3-oxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD sns-314 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown 0.15 TTD , DGIDB indirubin-3'-monoxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD cyc116 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown NA TTD , DGIDB 7-chloroindirubin-3-oxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD mk-5108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase b AURKB Clinical trial target unknown 0.71 TTD , DGIDB pmid21742770c1 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD 7-fluoroindirubin-3-acetoxime NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD vx-680 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 aurora kinase b AURKB Clinical trial target unknown 0.12 TTD , DGIDB pha-739358 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 aurora kinase b AURKB Clinical trial target unknown 1.06 TTD , DGIDB isis 173831 NA NA investigative aurora b messenger rna AURKB Clinical trial target unknown NA TTD indirubin-3-methoxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD hpp-607 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hereditary pyropoikilocytosis[MeSHID:C563004],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase c AURKC Clinical trial target unknown NA TTD , DGIDB 7-iodoindirubin-3-oxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD 7-bromoindirubin-3-oxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD 7-fluoroindirubin-3-acetoxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD indirubin-3'-monoxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD 7-chloroindirubin-3-oxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD bms-739562 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative aurora kinase c AURKC Clinical trial target unknown NA TTD amg 900 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase c AURKC Clinical trial target unknown NA TTD , DGIDB gsk1070916a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 aurora kinase c AURKC Clinical trial target unknown NA TTD , DGIDB sns-314 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 aurora kinase c AURKC Clinical trial target inhibitor 0.69 TTD , drugbank , DGIDB 7-fluoroindirubin-3-oxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD sns-314 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 aurora kinase c AURKC Clinical trial target unknown 0.69 TTD , drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational aurora kinase c AURKC NA inhibitor NA drugbank indirubin-3-acetoxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD abt-348 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 2 aurora kinase c AURKC Clinical trial target unknown 0.17 TTD , DGIDB gsk1070916 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 aurora kinase c AURKC Clinical trial target inhibitor 9.64 TTD , DGIDB bpr1k-0224 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative aurora kinase c AURKC Clinical trial target unknown NA TTD su 6656 NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD pmid16451062c46 NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD 7-bromoindirubin-3-acetoxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD pmid20855207c25 NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD mk-6592 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 aurora kinase c AURKC Clinical trial target inhibitor 1.93 TTD , DGIDB 6-bromoindirubin-3-oxime NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD glycyl-h 1152 NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD mp-529 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative aurora kinase c AURKC Clinical trial target unknown NA TTD pha-739358 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 aurora kinase c AURKC Clinical trial target unknown 4.63 TTD , DGIDB quinazoline deriv. 1 NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD gsk1070916 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 aurora kinase c AURKC Clinical trial target unknown 9.64 TTD , DGIDB 2np8 NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD k00244 NA NA investigative aurora kinase c AURKC Clinical trial target unknown NA TTD [ho1][orn8(5/6c-rhm)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD pf-3274167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] discontinued in phase 1 vasopressin v1a receptor AVPR1A Successful target unknown NA TTD rg7314 NA Autism Spectrum Disorders[MeSHID:D000067877],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659] phase 2 vasopressin v1a receptor AVPR1A Successful target antagonist NA TTD , DGIDB l-372662 NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD mozavaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyponatremia[MeSHID:D007010] approved vasopressin v1a receptor AVPR1A Successful target unknown 1.77 TTD , DGIDB [ho1][thr4,orn8(5/6c-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[leu4,dap8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD [thr4,gly7]ot NA NA investigative vasopressin v1a receptor AVPR1A Successful target agonist NA TTD , DGIDB oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vasopressin v1a receptor AVPR1A Successful target unknown 0.59 TTD , DGIDB oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659],Breast Feeding[MeSHID:D001942],Lactation[MeSHID:D007774],Autism Spectrum Disorders[MeSHID:D000067877] approved vasopressin v1a receptor AVPR1A Successful target agonist 0.59 TTD , DGIDB hoo-phe-orn-pro-hle-pff-phe-nh2 NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD mozavaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyponatremia[MeSHID:D007010] approved vasopressin v1a receptor AVPR1A Successful target antagonist 1.77 TTD , DGIDB ssr126768a NA NA investigative vasopressin v1a receptor AVPR1A Successful target antagonist NA TTD , DGIDB felypressin small molecule Ischemia[MeSHID:D007511],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,approved vasopressin v1a receptor AVPR1A Successful target agonist 18.56 TTD , drugbank , DGIDB d[orn4,lys8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD pmid25776143-compound-7 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB tetra-azabenzo[e]azulene derivative 1 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB atosiban small molecule Nulliparity[MeSHID:D010298],Uterine Contraction[MeSHID:D014590],Premature Birth[MeSHID:D047928],Cervical dilatation (function)[MeSHID:D007747],Heart Rate, Fetal[MeSHID:D006340],Birth[MeSHID:D036801],Gestational Age[MeSHID:D005865] approved,investigational,phase 4 vasopressin v1a receptor AVPR1A Successful target antagonist 1.99 TTD , drugbank , DGIDB dvdavp NA NA investigative vasopressin v1a receptor AVPR1A Successful target agonist 0.88 TTD , DGIDB d[arg4,lys8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[orn4]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD [lys8(alexa 488) ]pva NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD pmid25776143-compound-8 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB srx-251 NA Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 vasopressin v1a receptor AVPR1A Successful target unknown 5.3 TTD , DGIDB d[d-3-pal2]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD ym 218 NA NA investigative vasopressin v1a receptor AVPR1A Successful target antagonist NA TTD , DGIDB pmx-53 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB [phe3]ot NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD balovaptan NA Autism Spectrum Disorders[MeSHID:D000067877],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659] phase 3 vasopressin v1a receptor AVPR1A Successful target antagonist 0.66 TTD , DGIDB oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659],Breast Feeding[MeSHID:D001942],Lactation[MeSHID:D007774],Autism Spectrum Disorders[MeSHID:D000067877] approved vasopressin v1a receptor AVPR1A Successful target unknown 0.59 TTD , DGIDB d[orn4,orn8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD cl-385004 NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD [ho1][thr4,lys8(5/6c-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD desmopressin small molecule von Willebrand Disease, Type 1[MeSHID:D056725],Disease Management[MeSHID:D019468],Hemostatic function[MeSHID:D006487],Urination[MeSHID:D014554],Maintenance[MeSHID:D008283],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Polyuria[MeSHID:D011141],Nocturia[MeSHID:D053158],Hemophilia A[MeSHID:D006467],Polydipsia[MeSHID:D059606],Pituitary Diseases[MeSHID:D010900],Craniocerebral Trauma[MeSHID:D006259],Central Diabetes Insipidus[MeSHID:D020790],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved vasopressin v1a receptor AVPR1A Successful target agonist 5.3 TTD , drugbank , DGIDB lypressin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amnesia[MeSHID:D000647] approved vasopressin v1a receptor AVPR1A NA agonist 5.3 drugbank , DGIDB desgly-nh2,d(ch2)5[d-tyr2,thr4,orn8(5/6c-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[leu4,dab8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD tolvaptan small molecule Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Cirrhosis[MeSHID:D005355],Hyponatremia[MeSHID:D007010],Inappropriate ADH Syndrome[MeSHID:D007177],Body Fluids[MeSHID:D001826],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved vasopressin v1a receptor AVPR1A NA antagonist 1.77 drugbank , DGIDB l023103 NA NA investigative vasopressin v1a receptor AVPR1A Successful target antagonist NA TTD , DGIDB ho-lva NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD ym 471 NA NA investigative vasopressin v1a receptor AVPR1A Successful target antagonist NA TTD , DGIDB srx246 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fear (Mental Process)[MeSHID:D005239],Anxiety Disorders[MeSHID:D001008],Post-Traumatic Stress Disorder[MeSHID:D013313],Disease[MeSHID:D004194],Huntington Disease[MeSHID:D006816] phase 2 vasopressin v1a receptor AVPR1A Successful target antagonist 5.3 TTD , DGIDB [lys8(alexa 546) ]pva NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vasopressin v1a receptor AVPR1A Successful target agonist 0.59 TTD , DGIDB [ho1][orn8(5/6c-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD va-111913 NA Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB d[arg4,orn8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD ph-284 small molecule Malignant Neoplasms[MeSHID:D009369],Desire for food[MeSHID:D001066],Disease[MeSHID:D004194],Anorexia[MeSHID:D000855],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Physical Examination[MeSHID:D010808],Pregnancy[MeSHID:D011247],Cachexia[MeSHID:D002100],Fatigue[MeSHID:D005221],Aging[MeSHID:D000375],Weight decreased[MeSHID:D015431],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational vasopressin v1a receptor AVPR1A NA unknown NA drugbank conivaptan small molecule Hypothyroidism[MeSHID:D007037],Lung diseases[MeSHID:D008171],Hyponatremia[MeSHID:D007010],Inappropriate ADH Syndrome[MeSHID:D007177],Adrenal gland hypofunction[MeSHID:D000309],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vasopressin v1a receptor AVPR1A Successful target antagonist 18.56 TTD , drugbank , DGIDB a-987306 NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[cha4,orn8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD rg7314 NA Autism Spectrum Disorders[MeSHID:D000067877],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659] phase 2 vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB d[cha4]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target agonist NA TTD , DGIDB srx-246 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Post-Traumatic Stress Disorder[MeSHID:D013313] phase 2 vasopressin v1a receptor AVPR1A Successful target unknown 5.3 TTD , DGIDB d[cha4,lys8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD ssr149415 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Anxiety Disorders[MeSHID:D001008],Unipolar Depression[MeSHID:D003866] phase 2 vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB relcovaptan small molecule NA investigational,investigative vasopressin v1a receptor AVPR1A Successful target antagonist 1.52 TTD , drugbank , DGIDB pmid25776143-compound-2 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB pmid25776143-compound-1 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB d[arg4,dab8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD vasopressin small molecule Systemic arterial pressure[MeSHID:D062186],Shock[MeSHID:D012769],Body Fluids[MeSHID:D001826],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Insipidus[MeSHID:D003919],Bedwetting[MeSHID:D053206],Enuresis[MeSHID:D004775],Polyuria[MeSHID:D011141],Urinary Incontinence[MeSHID:D014549] approved vasopressin v1a receptor AVPR1A NA agonist 1.4 drugbank , DGIDB desmopressin small molecule von Willebrand Disease, Type 1[MeSHID:D056725],Disease Management[MeSHID:D019468],Hemostatic function[MeSHID:D006487],Urination[MeSHID:D014554],Maintenance[MeSHID:D008283],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Polyuria[MeSHID:D011141],Nocturia[MeSHID:D053158],Hemophilia A[MeSHID:D006467],Polydipsia[MeSHID:D059606],Pituitary Diseases[MeSHID:D010900],Craniocerebral Trauma[MeSHID:D006259],Central Diabetes Insipidus[MeSHID:D020790],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved vasopressin v1a receptor AVPR1A Successful target unknown 5.3 TTD , drugbank , DGIDB d[leu4,orn8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD argenine vasopressin NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD [val4]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target agonist NA TTD , DGIDB tetra-azabenzo[e]azulene derivative 2 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB opc-21268 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Diseases[MeSHID:D006331] discontinued in phase 2 vasopressin v1a receptor AVPR1A Successful target antagonist 0.88 TTD , DGIDB pyrrolidine derivative 13 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB ls-192629 NA NA investigative vasopressin v1a receptor AVPR1A Successful target antagonist NA TTD , DGIDB d[thr4,orn8(5/6c-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD pmid25776143-compound-3 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB fe-202158 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] phase 2 vasopressin v1a receptor AVPR1A Successful target unknown 5.3 TTD , DGIDB terlipressin small molecule Varicosity[MeSHID:D014648],Esophagus[MeSHID:D004947],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational vasopressin v1a receptor AVPR1A Successful target stimulator 7.96 TTD , drugbank , DGIDB d[cha4,dab8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[cha4,dap8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[pen1,tyr(me)2]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target antagonist NA TTD , DGIDB d(ch2)5[tyr(me)2,thr4,orn8(5/6c-flu),tyr-nh29]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[thr4,lys8(5/6c-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD [ho1][lys8(5/6c-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[lys8(5/6-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD pmid28906174-compound-figure1g NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB d[orn8(5/6c-flu)]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d(ch2)5[tyr(me)2,thr4,orn8,tyr9-nh2]vt NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[arg4]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d(ch2)5[tyr(me)2]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target antagonist NA TTD , DGIDB d[leu4,lys8]vp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD v1a f/u NA Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD nox-f37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] preclinical vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB d[leu4]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target agonist NA TTD , DGIDB 1'-tosylspiro[indene-1,4'-piperidine] NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD d[val4]avp NA NA investigative vasopressin v1a receptor AVPR1A Successful target unknown NA TTD pmid25776143-compound-4 NA NA patented vasopressin v1a receptor AVPR1A Successful target unknown NA TTD , DGIDB terlipressin small molecule Varicosity[MeSHID:D014648],Esophagus[MeSHID:D004947],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational vasopressin v1b receptor AVPR1B NA unknown 8.25 drugbank , DGIDB oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659],Breast Feeding[MeSHID:D001942],Lactation[MeSHID:D007774],Autism Spectrum Disorders[MeSHID:D000067877] approved vasopressin v1b receptor AVPR1B Successful target agonist 0.79 TTD , DGIDB d[cha4,orn8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[arg4,dab8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD atosiban small molecule Nulliparity[MeSHID:D010298],Uterine Contraction[MeSHID:D014590],Premature Birth[MeSHID:D047928],Cervical dilatation (function)[MeSHID:D007747],Heart Rate, Fetal[MeSHID:D006340],Birth[MeSHID:D036801],Gestational Age[MeSHID:D005865] approved,investigational,phase 4 vasopressin v1b receptor AVPR1B Successful target antagonist 2.65 TTD , drugbank , DGIDB d[leu4,lys8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[d-3-pal2]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD sr 121463 small molecule Inappropriate ADH Syndrome[MeSHID:D007177],Cardiovascular Diseases[MeSHID:D002318],Bodily secretions[MeSHID:D012634],Hyponatremia[MeSHID:D007010] investigational vasopressin v1b receptor AVPR1B NA unknown NA drugbank d[arg4]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD argenine vasopressin NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vasopressin v1b receptor AVPR1B Successful target agonist 0.79 TTD , DGIDB d[lys8(5/6-flu)]vt NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[thr4,lys8(5/6c-flu)]vt NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[leu4]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target agonist NA TTD , DGIDB d[cha4,dab8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD [ho1][lys8(5/6c-flu)]vt NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD desmopressin small molecule von Willebrand Disease, Type 1[MeSHID:D056725],Disease Management[MeSHID:D019468],Hemostatic function[MeSHID:D006487],Urination[MeSHID:D014554],Maintenance[MeSHID:D008283],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Polyuria[MeSHID:D011141],Nocturia[MeSHID:D053158],Hemophilia A[MeSHID:D006467],Polydipsia[MeSHID:D059606],Pituitary Diseases[MeSHID:D010900],Craniocerebral Trauma[MeSHID:D006259],Central Diabetes Insipidus[MeSHID:D020790],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved vasopressin v1b receptor AVPR1B Successful target agonist 6.19 TTD , drugbank , DGIDB d[orn4,lys8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[arg4,orn8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[orn8(5/6c-flu)]vt NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD [ho1][thr4,lys8(5/6c-flu)]vt NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[orn4]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD ym 218 NA NA investigative vasopressin v1b receptor AVPR1B Successful target antagonist NA TTD , DGIDB d[cha4,dap8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[arg4,lys8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD lypressin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amnesia[MeSHID:D000647] approved vasopressin v1b receptor AVPR1B NA agonist 7.07 drugbank , DGIDB d[cha4]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target agonist NA TTD , DGIDB d[pen1,tyr(me)2]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target antagonist NA TTD , DGIDB d[orn4,orn8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD [ho1][orn8(5/6c-flu)]vt NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD [3h]nelivaptan NA NA investigative vasopressin v1b receptor AVPR1B Successful target antagonist NA TTD , DGIDB d[cha4,lys8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD ph-284 small molecule Malignant Neoplasms[MeSHID:D009369],Desire for food[MeSHID:D001066],Disease[MeSHID:D004194],Anorexia[MeSHID:D000855],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Physical Examination[MeSHID:D010808],Pregnancy[MeSHID:D011247],Cachexia[MeSHID:D002100],Fatigue[MeSHID:D005221],Aging[MeSHID:D000375],Weight decreased[MeSHID:D015431],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational vasopressin v1b receptor AVPR1B NA unknown NA drugbank vasopressin small molecule Systemic arterial pressure[MeSHID:D062186],Shock[MeSHID:D012769],Body Fluids[MeSHID:D001826],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Insipidus[MeSHID:D003919],Bedwetting[MeSHID:D053206],Enuresis[MeSHID:D004775],Polyuria[MeSHID:D011141],Urinary Incontinence[MeSHID:D014549] approved vasopressin v1b receptor AVPR1B NA agonist 1.87 drugbank , DGIDB oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vasopressin v1b receptor AVPR1B Successful target unknown 0.79 TTD , DGIDB d[val4]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[leu4,dab8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659],Breast Feeding[MeSHID:D001942],Lactation[MeSHID:D007774],Autism Spectrum Disorders[MeSHID:D000067877] approved vasopressin v1b receptor AVPR1B Successful target unknown 0.79 TTD , DGIDB [ho1][thr4,orn8(5/6c-flu)]vt NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD d[leu4,orn8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD abt-436 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 vasopressin v1b receptor AVPR1B Successful target unknown NA TTD , DGIDB d[thr4,orn8(5/6c-flu)]vt NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD desmopressin small molecule von Willebrand Disease, Type 1[MeSHID:D056725],Disease Management[MeSHID:D019468],Hemostatic function[MeSHID:D006487],Urination[MeSHID:D014554],Maintenance[MeSHID:D008283],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Polyuria[MeSHID:D011141],Nocturia[MeSHID:D053158],Hemophilia A[MeSHID:D006467],Polydipsia[MeSHID:D059606],Pituitary Diseases[MeSHID:D010900],Craniocerebral Trauma[MeSHID:D006259],Central Diabetes Insipidus[MeSHID:D020790],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved vasopressin v1b receptor AVPR1B Successful target unknown 6.19 TTD , drugbank , DGIDB d(ch2)5[tyr(me)2]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target antagonist NA TTD , DGIDB mozavaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyponatremia[MeSHID:D007010] approved vasopressin v1b receptor AVPR1B Successful target antagonist 2.36 TTD , DGIDB [val4]avp NA NA investigative vasopressin v1b receptor AVPR1B Successful target agonist NA TTD , DGIDB d[leu4,dap8]vp NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD mozavaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyponatremia[MeSHID:D007010] approved vasopressin v1b receptor AVPR1B Successful target unknown 2.36 TTD , DGIDB ssr149415 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Anxiety Disorders[MeSHID:D001008],Unipolar Depression[MeSHID:D003866] phase 2 vasopressin v1b receptor AVPR1B Successful target unknown NA TTD , DGIDB ym 471 NA NA investigative vasopressin v1b receptor AVPR1B Successful target antagonist NA TTD , DGIDB [lys8(alexa 488) ]pva NA NA investigative vasopressin v1b receptor AVPR1B Successful target unknown NA TTD lixivaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Hyponatremia[MeSHID:D007010],Skin Diseases, Infectious[MeSHID:D012874] phase 3 vasopressin v2 receptor AVPR2 Successful target antagonist 5.09 TTD , DGIDB d[leu4,dap8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD argenine vasopressin NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d[d-3-pal2]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD mozavaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyponatremia[MeSHID:D007010] approved vasopressin v2 receptor AVPR2 Successful target unknown 1.7 TTD , DGIDB demeclocycline small molecule Gingival Diseases[MeSHID:D005882],Gonorrhea[MeSHID:D006069],Lyme Disease[MeSHID:D008193],Attention[MeSHID:D001288],Malaria[MeSHID:D008288],Hyponatremia[MeSHID:D007010],Blood[MeSHID:D001769],Bacterial Infections[MeSHID:D001424],Acne Vulgaris[MeSHID:D000152],Inappropriate ADH Syndrome[MeSHID:D007177],Bronchitis[MeSHID:D001991],Body Fluids[MeSHID:D001826],Urinary tract infection[MeSHID:D014552],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vasopressin v2 receptor AVPR2 NA inhibitor NA drugbank conivaptan small molecule Hypothyroidism[MeSHID:D007037],Lung diseases[MeSHID:D008171],Hyponatremia[MeSHID:D007010],Inappropriate ADH Syndrome[MeSHID:D007177],Adrenal gland hypofunction[MeSHID:D000309],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vasopressin v2 receptor AVPR2 Successful target antagonist 20.37 TTD , drugbank , DGIDB cl-385004 NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD ym 471 NA NA investigative vasopressin v2 receptor AVPR2 Successful target antagonist NA TTD , DGIDB m0002 small molecule Drinking Water[MeSHID:D060766],Kidney[MeSHID:D007668],Psychological inhibition[MeSHID:D007266],Urinary tract[MeSHID:D014551] investigational vasopressin v2 receptor AVPR2 NA unknown NA drugbank , DGIDB opc-51803 small molecule Urinary Incontinence[MeSHID:D014549],Urination[MeSHID:D014554],Nocturia[MeSHID:D053158],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 1 vasopressin v2 receptor AVPR2 Successful target agonist NA TTD , drugbank , DGIDB d[arg4,orn8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659],Breast Feeding[MeSHID:D001942],Lactation[MeSHID:D007774],Autism Spectrum Disorders[MeSHID:D000067877] approved vasopressin v2 receptor AVPR2 Successful target agonist 0.57 TTD , DGIDB mozavaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyponatremia[MeSHID:D007010] approved vasopressin v2 receptor AVPR2 Successful target antagonist 1.7 TTD , DGIDB d(ch2)5[tyr(me)2,thr4,orn8,tyr9-nh2]vt NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD vna-932 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 1 vasopressin v2 receptor AVPR2 Successful target unknown NA TTD ssr149415 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Anxiety Disorders[MeSHID:D001008],Unipolar Depression[MeSHID:D003866] phase 2 vasopressin v2 receptor AVPR2 Successful target unknown NA TTD , DGIDB d[leu4]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target agonist NA TTD , DGIDB d[arg4,dab8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD fr161282 NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d[cha4,orn8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD [val4]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target agonist NA TTD , DGIDB d[arg4]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d(ch2)5[tyr(me)2]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target antagonist NA TTD , DGIDB desmopressin small molecule von Willebrand Disease, Type 1[MeSHID:D056725],Disease Management[MeSHID:D019468],Hemostatic function[MeSHID:D006487],Urination[MeSHID:D014554],Maintenance[MeSHID:D008283],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Polyuria[MeSHID:D011141],Nocturia[MeSHID:D053158],Hemophilia A[MeSHID:D006467],Polydipsia[MeSHID:D059606],Pituitary Diseases[MeSHID:D010900],Craniocerebral Trauma[MeSHID:D006259],Central Diabetes Insipidus[MeSHID:D020790],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved vasopressin v2 receptor AVPR2 Successful target agonist 3.82 TTD , drugbank , DGIDB oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659],Breast Feeding[MeSHID:D001942],Lactation[MeSHID:D007774],Autism Spectrum Disorders[MeSHID:D000067877] approved vasopressin v2 receptor AVPR2 Successful target unknown 0.57 TTD , DGIDB ym 218 NA NA investigative vasopressin v2 receptor AVPR2 Successful target antagonist NA TTD , DGIDB d[pen1,tyr(me)2]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target antagonist NA TTD , DGIDB tolvaptan small molecule Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Cirrhosis[MeSHID:D005355],Hyponatremia[MeSHID:D007010],Inappropriate ADH Syndrome[MeSHID:D007177],Body Fluids[MeSHID:D001826],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved vasopressin v2 receptor AVPR2 Successful target antagonist 5.94 TTD , drugbank , DGIDB ox 19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 1 vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d[cha4,dap8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d[val4]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d[leu4,orn8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d[leu4,dab8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD lypressin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amnesia[MeSHID:D000647] approved vasopressin v2 receptor AVPR2 NA agonist 5.09 drugbank , DGIDB vasopressin small molecule Systemic arterial pressure[MeSHID:D062186],Shock[MeSHID:D012769],Body Fluids[MeSHID:D001826],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Insipidus[MeSHID:D003919],Bedwetting[MeSHID:D053206],Enuresis[MeSHID:D004775],Polyuria[MeSHID:D011141],Urinary Incontinence[MeSHID:D014549] approved vasopressin v2 receptor AVPR2 Successful target agonist 1.5 TTD , drugbank , DGIDB atosiban small molecule Nulliparity[MeSHID:D010298],Uterine Contraction[MeSHID:D014590],Premature Birth[MeSHID:D047928],Cervical dilatation (function)[MeSHID:D007747],Heart Rate, Fetal[MeSHID:D006340],Birth[MeSHID:D036801],Gestational Age[MeSHID:D005865] approved,investigational,phase 4 vasopressin v2 receptor AVPR2 Successful target antagonist 1.91 TTD , drugbank , DGIDB satavaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 3 vasopressin v2 receptor AVPR2 Successful target unknown 2.55 TTD , DGIDB d[leu4,lys8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD lixivaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Hyponatremia[MeSHID:D007010],Skin Diseases, Infectious[MeSHID:D012874] phase 3 vasopressin v2 receptor AVPR2 Successful target unknown 5.09 TTD , DGIDB opc-51803 small molecule Urinary Incontinence[MeSHID:D014549],Urination[MeSHID:D014554],Nocturia[MeSHID:D053158],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 1 vasopressin v2 receptor AVPR2 Successful target unknown NA TTD , drugbank , DGIDB d[cha4]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target agonist NA TTD , DGIDB satavaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 3 vasopressin v2 receptor AVPR2 Successful target antagonist 2.55 TTD , DGIDB va-106483 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nocturia[MeSHID:D053158] phase 2 vasopressin v2 receptor AVPR2 Successful target unknown 2.55 TTD , DGIDB d[arg4,lys8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vasopressin v2 receptor AVPR2 Successful target unknown 0.57 TTD , DGIDB asp-7035 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nocturia[MeSHID:D053158] phase 2 vasopressin v2 receptor AVPR2 Successful target unknown NA TTD , DGIDB d[orn4,orn8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d[orn4]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD ym-35278 NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD terlipressin small molecule Varicosity[MeSHID:D014648],Esophagus[MeSHID:D004947],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational vasopressin v2 receptor AVPR2 NA agonist 5.09 drugbank , DGIDB d(ch2)5[d-ile2,ile4]avp NA NA investigative vasopressin v2 receptor AVPR2 Successful target antagonist NA TTD , DGIDB oxytocin NA Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vasopressin v2 receptor AVPR2 Successful target agonist 0.57 TTD , DGIDB d[cha4,dab8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD d[cha4,lys8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD [phe3]ot NA NA investigative vasopressin v2 receptor AVPR2 Successful target agonist NA TTD , DGIDB d[orn4,lys8]vp NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD dvdavp NA NA investigative vasopressin v2 receptor AVPR2 Successful target agonist 0.85 TTD , DGIDB spd-556 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Symphysis Pubis Dysfunction[MeSHID:D059388],Heart failure[MeSHID:D006333] phase 2 vasopressin v2 receptor AVPR2 Successful target unknown NA TTD , DGIDB vp-343 NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD l-372662 NA NA investigative vasopressin v2 receptor AVPR2 Successful target unknown NA TTD 1,4-dithiothreitol small molecule NA experimental axin-1 AXIN1 NA unknown NA drugbank bpi-9016 m NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD avb-s6-500 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD , DGIDB gilteritinib NA Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase ufo AXL Successful target inhibitor 1.7 TTD , DGIDB gilteritinib NA Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase ufo AXL Successful target unknown 1.7 TTD , DGIDB dp-3975 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mesothelioma[MeSHID:D008654] preclinical tyrosine-protein kinase ufo AXL Successful target unknown NA TTD ldc1267 NA NA investigative tyrosine-protein kinase ufo AXL Successful target inhibitor NA TTD , DGIDB ono-7475 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD , DGIDB rxdx-106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase receptor ufo AXL NA inhibitor 1.7 drugbank , DGIDB mgcd265 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tyrosine-protein kinase ufo AXL Successful target unknown 0.28 TTD , DGIDB yw327.6s2 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical tyrosine-protein kinase ufo AXL Successful target unknown NA TTD ono-7475 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase receptor ufo AXL NA inhibitor NA drugbank ds-1205 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD , DGIDB ono-7475 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD , DGIDB ono-7475 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD , DGIDB incb81776 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD enapotamab vedotin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD bemcentinib NA Triple Negative Breast Neoplasms[MeSHID:D064726],Non-Small Cell Lung Carcinoma[MeSHID:D002289],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tyrosine-protein kinase ufo AXL Successful target inhibitor 4.55 TTD , DGIDB pf-07265807 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase ufo AXL Successful target unknown NA TTD gl21.t NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical tyrosine-protein kinase ufo AXL Successful target unknown NA TTD bi-505 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 tyrosine-protein kinase ufo AXL Successful target unknown 1.14 TTD , DGIDB tp-0903 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 tyrosine-protein kinase ufo AXL Successful target unknown 1.52 TTD , DGIDB cu-anti-haxl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] preclinical tyrosine-protein kinase ufo AXL Successful target unknown NA TTD bgb-324 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 2 tyrosine-protein kinase ufo AXL Successful target unknown 4.55 TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational zinc-alpha-2-glycoprotein AZGP1 NA unknown NA drugbank n-acetyl-alpha-neuraminic acid small molecule NA experimental zinc-alpha-2-glycoprotein AZGP1 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical arginine decarboxylase AZIN2 NA cofactor NA drugbank arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical arginine decarboxylase AZIN2 NA unknown NA drugbank benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved arginine decarboxylase AZIN2 NA activator NA drugbank n-formylmethionine small molecule NA experimental beta-2-microglobulin B2M NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational beta-2-microglobulin B2M NA unknown NA drugbank 3-indolebutyric acid small molecule NA experimental beta-2-microglobulin B2M NA unknown NA drugbank d-tartaric acid small molecule NA experimental galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 B3GAT1 NA unknown NA drugbank uridine-5'-diphosphate small molecule NA experimental galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 B3GAT1 NA unknown NA drugbank udp-alpha-d-glucuronic acid small molecule NA experimental galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 B3GAT3 NA unknown NA drugbank uridine-5'-diphosphate small molecule NA experimental galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 B3GAT3 NA unknown NA drugbank n-acetyl-beta-d-glucosaminyl-(1->4)-n-acetyl-beta-d-glucosamine small molecule NA experimental beta-1,4-galactosyltransferase 1 B4GALT1 NA unknown NA drugbank galactose-uridine-5'-diphosphate small molecule NA experimental beta-1,4-galactosyltransferase 1 B4GALT1 NA unknown NA drugbank n-acetylglucosamine small molecule Degenerative polyarthritis[MeSHID:D010003] approved,investigational,nutraceutical beta-1,4-galactosyltransferase 1 B4GALT1 NA unknown NA drugbank 6-aminohexyl-uridine-c1,5'-diphosphate small molecule NA experimental beta-1,4-galactosyltransferase 1 B4GALT1 NA unknown NA drugbank 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental beta-1,4-galactosyltransferase 1 B4GALT1 NA unknown NA drugbank uridine monophosphate small molecule NA experimental beta-1,4-galactosyltransferase 1 B4GALT1 NA unknown NA drugbank n-acetylglucosamine small molecule Degenerative polyarthritis[MeSHID:D010003] approved,investigational,nutraceutical beta-1,4-galactosyltransferase 4 B4GALT4 NA unknown NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved bile acid-coa:amino acid n-acyltransferase BAAT NA substrate NA drugbank amg520 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 beta-secretase 1 BACE1 Clinical trial target unknown NA TTD , DGIDB 4-(4-fluorobenzyl)piperidine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank 2-amino-6-[2-(1h-indol-6-yl)ethyl]pyrimidin-4(3h)-one small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank (2s)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank 6-[2-(1h-indol-6-yl)ethyl]pyridin-2-amine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n~3~-(3-pyridin-3-ylbenzyl)pyridine-2,3-diamine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank (2s)-4-(4-fluorobenzyl)-n-(2-sulfanylethyl)piperazine-2-carboxamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank cts-21166 small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Carpal Tunnel Syndrome[MeSHID:D002349] investigational beta-secretase 1 BACE1 NA inhibitor NA drugbank , DGIDB 3-(2-amino-6-benzoylquinazolin-3(4h)-yl)-n-cyclohexyl-n-methylpropanamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank 6-[2-(3'-methoxybiphenyl-3-yl)ethyl]pyridin-2-amine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n~3~-[5-(1h-indol-6-yl)-2-(pyridin-2-ylmethoxy)benzyl]pyridine-2,3-diamine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n~3~-[3-(5-methoxypyridin-3-yl)benzyl]pyridine-2,3-diamine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n~3~-benzylpyridine-2,3-diamine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank 4-[(1s)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1h-imidazol-2-amine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank 4-(2-aminoethyl)-2-ethylphenol small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank 4-(2-aminoethyl)-2-cyclohexylphenol small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank mmi-175 small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank verubecestat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 beta-secretase 1 BACE1 Clinical trial target inhibitor 3.54 TTD , drugbank , DGIDB n~3~-[3-(1h-indol-6-yl)benzyl]pyridine-2,3-diamine small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank (6s)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3h)-one small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n-[(5r,14r)-5-amino-5,14-dimethyl-4-oxo-3-oxa-18-azatricyclo[15.3.1.1~7,11~]docosa-1(21),7(22),8,10,17,19-hexaen-19-yl]-n-methylmethanesulfonamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank (6r)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3h)-one small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank (2s)-4-(4-fluorobenzyl)-n-(3-sulfanylpropyl)piperazine-2-carboxamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank n-[amino(imino)methyl]-2-(2,5-diphenyl-1h-pyrrol-1-yl)acetamide small molecule NA experimental beta-secretase 1 BACE1 NA unknown NA drugbank e-2609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 beta-secretase 1 BACE1 Clinical trial target unknown 14.14 TTD , DGIDB pmid21907142cj NA NA investigative beta-site app-cleaving enzyme 2 BACE2 Clinical trial target unknown NA TTD 2ewy NA NA investigative beta-site app-cleaving enzyme 2 BACE2 Clinical trial target unknown NA TTD example 20 (wo2010128058) NA NA investigative beta-site app-cleaving enzyme 2 BACE2 Clinical trial target unknown NA TTD example 92 (wo2012095521) NA NA investigative beta-site app-cleaving enzyme 2 BACE2 Clinical trial target unknown NA TTD example 98 (wo2011020806) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Focal glomerulosclerosis[MeSHID:D005923] clinical trial beta-site app-cleaving enzyme 2 BACE2 Clinical trial target unknown NA TTD , DGIDB example 41 (wo2012028563) NA NA investigative beta-site app-cleaving enzyme 2 BACE2 Clinical trial target unknown NA TTD example 2 (wo2013004676) NA NA investigative beta-site app-cleaving enzyme 2 BACE2 Clinical trial target unknown NA TTD navitoclax small molecule NA investigational bcl2 antagonist of cell death BAD NA unknown NA drugbank (2r,3r,4s,5r)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol small molecule NA experimental bag family molecular chaperone regulator 1 BAG1 NA unknown NA drugbank thymoquinone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Polycystic Ovary Syndrome[MeSHID:D011085] phase 2/3 apoptosis regulator bax BAX Clinical trial target unknown NA TTD baz2-icr NA NA investigative bromodomain adjacent to zinc finger 2a BAZ2A Literature-reported target inhibitor NA TTD , DGIDB gsk2801 NA NA investigative bromodomain adjacent to zinc finger 2a BAZ2A Literature-reported target inhibitor NA TTD , DGIDB pmid25719566c1 NA NA investigative bromodomain adjacent to zinc finger 2b BAZ2B Literature-reported target unknown NA TTD baz2-icr NA NA investigative bromodomain adjacent to zinc finger 2b BAZ2B Literature-reported target inhibitor NA TTD , DGIDB gsk2801 NA NA investigative bromodomain adjacent to zinc finger 2b BAZ2B Literature-reported target inhibitor NA TTD , DGIDB pmid25719566c7 NA NA investigative bromodomain adjacent to zinc finger 2b BAZ2B Literature-reported target unknown NA TTD ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical gamma-butyrobetaine dioxygenase BBOX1 NA cofactor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical branched-chain-amino-acid aminotransferase, cytosolic BCAT1 NA cofactor NA drugbank isoleucine small molecule Dyskinetic syndrome[MeSHID:D020820] investigational,nutraceutical branched-chain-amino-acid aminotransferase, cytosolic BCAT1 NA unknown NA drugbank n'-(5-chlorobenzofuran-2-carbonyl)-2-(trifluoromethyl)benzenesulfonohydrazide small molecule NA experimental branched-chain-amino-acid aminotransferase, cytosolic BCAT1 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical branched-chain-amino-acid aminotransferase, cytosolic BCAT1 NA unknown NA drugbank leucine small molecule Catabolism[MeSHID:D008660],Traumatic injury[MeSHID:D014947] investigational,nutraceutical branched-chain-amino-acid aminotransferase, cytosolic BCAT1 NA unknown NA drugbank valine small molecule Emotions[MeSHID:D004644],Respiratory Diaphragm[MeSHID:D003964],Hepatic Encephalopathy[MeSHID:D006501],Phenylketonurias[MeSHID:D010661],Muscle[MeSHID:D009132] approved,nutraceutical branched-chain-amino-acid aminotransferase, cytosolic BCAT1 NA unknown NA drugbank n-[o-phosphono-pyridoxyl]-isoleucine small molecule NA experimental branched-chain-amino-acid aminotransferase, mitochondrial BCAT2 NA unknown NA drugbank pyridoxamine-5'-phosphate small molecule NA experimental branched-chain-amino-acid aminotransferase, mitochondrial BCAT2 NA unknown NA drugbank alpha-ketoisovalerate NA NA investigative branched-chain-amino-acid transaminase 2 BCAT2 Literature-reported target unknown NA TTD pyridoxamine-5'-phosphate NA NA investigative branched-chain-amino-acid transaminase 2 BCAT2 Literature-reported target unknown NA TTD leucine small molecule Catabolism[MeSHID:D008660],Traumatic injury[MeSHID:D014947] investigational,nutraceutical branched-chain-amino-acid aminotransferase, mitochondrial BCAT2 NA unknown NA drugbank n'-(phenylsulfonyl)quinoline-6-carbohydrazide NA NA investigative branched-chain-amino-acid transaminase 2 BCAT2 Literature-reported target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical branched-chain-amino-acid aminotransferase, mitochondrial BCAT2 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical branched-chain-amino-acid aminotransferase, mitochondrial BCAT2 NA cofactor NA drugbank alpha-ketoisovalerate small molecule NA experimental branched-chain-amino-acid aminotransferase, mitochondrial BCAT2 NA unknown NA drugbank isoleucine small molecule Dyskinetic syndrome[MeSHID:D020820] investigational,nutraceutical branched-chain-amino-acid aminotransferase, mitochondrial BCAT2 NA unknown NA drugbank n'-(phenylsulfonyl)benzofuran-2-carbohydrazide NA NA investigative branched-chain-amino-acid transaminase 2 BCAT2 Literature-reported target unknown NA TTD n-[o-phosphono-pyridoxyl]-isoleucine NA NA investigative branched-chain-amino-acid transaminase 2 BCAT2 Literature-reported target unknown NA TTD quinazoline alkaloid derivative 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB jes-9501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cholinesterase BCHE Successful target unknown NA TTD , DGIDB 9-o-[3-(phenylol-1-yloxy)propyl]berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD pmid29757691-compound-8a NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB plasma derived human butyrylcholinesterase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurotoxicity Syndromes[MeSHID:D020258],Plasma[MeSHID:D010949] phase 1 cholinesterase BCHE Successful target unknown NA TTD , DGIDB phenyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1-(10h-phenothiazin-10-yl)-2-phenylethanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1,9-bis(pyridinium)-nonane dibromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (4-nitrophenyl)(10h-phenothiazin-10-yl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD beta-d-mannose NA NA investigative cholinesterase BCHE Successful target unknown NA TTD phenserine small molecule NA investigational cholinesterase BCHE NA inhibitor NA drugbank 9-o-[2-(phenylol-1-yloxy)ethyl]berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD naphthalen-2-yl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-benzylcarbamate-5-propionate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 5,6-dinitroacenaphthoquinone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD huprine-tacrine heterodimer NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-(benzylcarbamate)-5-benzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (-)-phenethylcymserine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-di-(benzylcarbamate) NA NA investigative cholinesterase BCHE Successful target unknown NA TTD bis-cyclosal-d4tmp NA NA investigative cholinesterase BCHE Successful target unknown NA TTD malathion small molecule Scalp structure[MeSHID:D012535],Ovum[MeSHID:D010063],Hair[MeSHID:D006197],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parasitic Diseases[MeSHID:D010272] approved,investigational cholinesterase BCHE NA inhibitor NA drugbank isosorbide-2-(propylcarbamate)-5-mononitrate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-neopentyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1-(3,4-dichlorobenzyl)-1h-indole-2,3-dione NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n'-(1',9'-nonylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-isopr-sal-cyclosal-d4tmp NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-(2-n-pyrrolyl-acetamino)-rutaecarpine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD monoisopropyl ester phosphonic acid group NA NA investigative cholinesterase BCHE Successful target unknown NA TTD ethyl hydrogen diethylamidophosphate small molecule NA experimental,investigative cholinesterase BCHE Successful target unknown NA TTD , drugbank phenanthrene-9,10-dione NA NA investigative cholinesterase BCHE Successful target unknown NA TTD butyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD morpholino(1'h-phenothiazin-1'-yl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD demecarium small molecule Glaucoma, Open-Angle[MeSHID:D005902] approved cholinesterase BCHE NA inhibitor NA drugbank donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cholinesterase BCHE NA inducer 5.2 drugbank , DGIDB n-n-pentyl-7-methoxytacrine hydrochloride NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 6-hydroxy-1,2-dimethyl-9h-beta-carbolin-2-ium NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-benzyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 6-hydroxy-2-methyl-9h-beta-carbolin-2-ium NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n'-(1',4'-butylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD rivastigmine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cholinesterase BCHE NA inhibitor 15.91 drugbank , DGIDB cyclosal-d4tmp NA NA investigative cholinesterase BCHE Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 4 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB (10h-phenothiazin-10-yl)(phenyl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-di-(propylcarbamate) NA NA investigative cholinesterase BCHE Successful target unknown NA TTD mf-8623 NA NA investigative cholinesterase BCHE Successful target unknown NA TTD chloranil NA NA investigative cholinesterase BCHE Successful target unknown NA TTD protexia NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cholinesterase BCHE Successful target unknown NA TTD , DGIDB 9-o-[3-(4-nitro-phenoxyl)butyl]-berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1,11-bis(pyridinium)-undecane dibromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n-dipropyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 9-o-[3-(phenylamino)propyl]-berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1-(10h-phenothiazin-10-yl)-3-phenylpropan-1-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3,4,5,6-tetrachloro-[1,2]benzoquinone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (-)-tolserine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD butyric acid small molecule NA experimental,investigational cholinesterase BCHE NA unknown NA drugbank pyridostigmine small molecule Myasthenia Gravis[MeSHID:D009157],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cholinesterase BCHE NA inhibitor 1.73 drugbank , DGIDB pyridostigmine small molecule Myasthenia Gravis[MeSHID:D009157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cholinesterase BCHE NA inhibitor 1.73 drugbank , DGIDB (1'h-phenothiazin-1'-yl)(piperidin-1-yl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD diethylphosphono group NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-o-tolyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 2-methyl-beta-carboline-2-ium iodide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD tolserine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-tert-butyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (rs)-tacrine(10)-hupyridone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD methyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-(adamant-1-yl)-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD meptazinol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved cholinesterase BCHE Successful target unknown 3.03 TTD , DGIDB n,n-diisopropyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-p-tolyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isopropyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1,3-di(berberine-9-o-yl)ethane dibromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD fucose NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 6-methoxy-1,2-dimethyl-9h-beta-carbolin-2-ium NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1,2-naphthoquinone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD rvt-103+rvt-104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cholinesterase BCHE Successful target unknown NA TTD , DGIDB naphthalen-1-yl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1-(10h-phenothiazin-10-yl)-4-phenylbutan-1-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1-(10h-phenothiazin-10-yl)-2-phenylbutan-1-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n'-(1',10'-decylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (10h-phenothiazin-10-yl)(p-tolyl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved cholinesterase BCHE NA inhibitor NA drugbank 9-n-phenylmethylamino-tacrine small molecule NA experimental,investigative cholinesterase BCHE Successful target unknown NA TTD , drugbank isosorbide-2-benzylcarbamate-5-nicotinate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD pmid29757691-compound-8b NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB tacrine small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn cholinesterase BCHE NA inhibitor 2.53 drugbank , DGIDB n-n-octyl-7-methoxytacrine hydrochloride NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-benzylcarbamate-5-pentanoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD methylphosphinic acid small molecule NA experimental cholinesterase BCHE NA unknown NA drugbank indoline derivative 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB 4-chlorophenyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 2-methoxyphenyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1,2-di(10h-phenothiazin-10-yl)ethane-1,2-dione NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n'-(1',5'-pentylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-benzylcarbamate-5-acetate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD memoquin NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-di-(ethylcarbamate) NA NA investigative cholinesterase BCHE Successful target unknown NA TTD tert-butyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-isopropyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD diethyl phosphonate small molecule NA experimental cholinesterase BCHE NA unknown NA drugbank 9-o-[4-(phenylol-1-yloxy)butyl]berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-methoxyphenyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD naphthalen-1-yl(10h-phenothiazin-10-yl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD p-tolyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (24s)-ethylcholesta-7,9(11),22(e)-triene-3b-ol NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-benzylcarbamate-5-isonicotinate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[4-(benzylmethylamino)butoxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (-)-phenserine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 cholinesterase BCHE Successful target unknown NA TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved cholinesterase BCHE NA inhibitor NA drugbank choline salicylate small molecule Exanthema[MeSHID:D005076],Teething syndrome[MeSHID:D014078],Oral Ulcer[MeSHID:D019226],Pain[MeSHID:D010146],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,nutraceutical cholinesterase BCHE NA product of NA drugbank n-n-nonyl-7-methoxytacrine hydrochloride NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 6-chlorotacrine hydrochloride NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-cyclopentyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1-(10h-phenothiazin-10-yl)-3-phenylbutan-1-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD recombinant human butyrylcholinesterase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cholinesterase BCHE Successful target unknown NA TTD as-1397 NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1,10-bis(pyridinium)-decane dibromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 9-o-[2-(phenylol-1-yloxy)hexyl]berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD butanoic acid NA NA investigative cholinesterase BCHE Successful target unknown NA TTD nsc-23180 NA NA investigative cholinesterase BCHE Successful target unknown NA TTD hexafluronium bromide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved cholinesterase BCHE Successful target unknown NA TTD , DGIDB xanthostigmine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n'-(1',2'-ethylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD di-substituted piperidine derivative 2 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB n-n-heptyl-7-methoxytacrine hydrochloride NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 6-methoxy-1,9-dimethyl-9h-pyrido[3,4-b]indole NA NA investigative cholinesterase BCHE Successful target unknown NA TTD haloxysterol a NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 9-[5-(beta-carboline-9-yl)pentyl]-beta-carboline NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 24-ethyl-cholest-7-ene-3,5,6-triol NA NA investigative cholinesterase BCHE Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 3 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB isosorbide-2-benzylcarbamate-5-cyclopentanoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-benzylcarbamate-5-cyclopropanoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 6-methoxy-2-methyl-9h-beta-carbolin-2-ium NA NA investigative cholinesterase BCHE Successful target unknown NA TTD di-substituted piperidine derivative 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB 9-o-[5-(phenylol-1-yloxy)pentyl]berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[10-(benzylmethylamino)decyloxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 5-methyl-cyclosal-d4tmp NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-(methylcarbamate)-5-mononitrate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD pmid29757691-compound-10 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB pmid29757691-compound-8d NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB naphthalen-2-yl(10h-phenothiazin-10-yl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental cholinesterase BCHE NA unknown NA drugbank dichlorvos small molecule NA vet_approved cholinesterase BCHE NA unknown NA drugbank n,n-dimethyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n-diethyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1-methyl-3-(phenylcarbamoyloxy)pyridinium bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD non-pegylated butyrylcholinesterase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cholinesterase BCHE Successful target unknown NA TTD n-benzyl-2-thiomorpholinopyrimidin-4-amine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD haloxysterol c NA NA investigative cholinesterase BCHE Successful target unknown NA TTD acenaphthoquinone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1h)-imine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 24-ethylcholest-6-ene-3,5-diol NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 9-[9-(beta-carboline-9-yl)nonyl]-beta-carboline NA NA investigative cholinesterase BCHE Successful target unknown NA TTD choline small molecule NA approved,nutraceutical cholinesterase BCHE NA product of NA drugbank 4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD pmid29757691-compound-2a NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB 1-(10h-phenothiazin-10-yl)-2-phenylpropan-1-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD benzoquinone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isochroman-4-ketone derivative 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB oxime derivative 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB isosorbide-2-benzylcarbamate-5-(o-toluate) NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (1s)-menthyl hexyl phosphonate group small molecule NA experimental,investigative cholinesterase BCHE Successful target unknown NA TTD , drugbank 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-sal-cyclosal-d4tmp NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n'-(1',3'-propylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD iso-ompa NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 4-[4-(benzyloxy)piperidino]butyl benzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD tacrine heterodimer derivative 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB eptastigmine NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 cholinesterase BCHE Successful target unknown 1.52 TTD , DGIDB 4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD pmid29757691-compound-2a-i NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB nostocarboline NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1,2-di(berberine-9-o-yl)ethane dibromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD dipivefrin small molecule Glaucoma, Open-Angle[MeSHID:D005902],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cholinesterase BCHE NA substrate NA drugbank n,n'-(1',11'-undecydene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-cyclobutyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (3-bromophenyl)(10h-phenothiazin-10-yl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD m-tolyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-(dimethylamino)phenyl phenylcarbamate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-chlorophenyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD egonol compound 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB isosorbide-2-benzyl carbamate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD demethyldebromoflustramine b NA NA investigative cholinesterase BCHE Successful target unknown NA TTD pralidoxime small molecule Poisoning[MeSHID:D011041],Myasthenia Gravis[MeSHID:D009157] approved,vet_approved cholinesterase BCHE NA activator NA drugbank anthracen-10-yl(10h-phenothiazin-10-yl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-(2-n-piperidyl-propionamino)-rutaecarpine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (1r)-menthyl hexyl phosphonate group small molecule NA experimental,investigative cholinesterase BCHE Successful target unknown NA TTD , drugbank (4-bromophenyl)(10h-phenothiazin-10-yl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD cyclopentyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB 9-ethyl-2-methyl-beta-carboline-2-ium iodide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 9-(3-iodobenzylamino)-1,2,3,4-tetrahydroacridine small molecule NA experimental,investigative cholinesterase BCHE Successful target unknown NA TTD , drugbank np-0336 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cholinesterase BCHE Successful target unknown NA TTD 1,4-di(berberine-9-o-yl)ethane dibromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD bis-7-tacrine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-(cyclohexylcarbamate)-5-mononitrate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD edrophonium small molecule Myasthenia Gravis[MeSHID:D009157],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cholinesterase BCHE NA inhibitor NA drugbank pmid29757691-compound-7 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB isoflurophate small molecule Glaucoma[MeSHID:D005901],Esotropia[MeSHID:D004948],Disorder of eye[MeSHID:D005128],Eye[MeSHID:D005123],Visual Accommodation[MeSHID:D000065],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] approved,investigational,withdrawn cholinesterase BCHE NA inhibitor 10.61 drugbank , DGIDB 7-oxo-7h-dibenzo[de,g]quinoline NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n'-(1',8'-octylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD pmid29757691-compound-8c NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB 2-(n-morpholino)-ethanesulfonic acid NA NA investigative cholinesterase BCHE Successful target unknown NA TTD dodecanesulfonate ion small molecule NA experimental,investigative cholinesterase BCHE Successful target unknown NA TTD , drugbank isosorbide-2-(ethylcarbamate)-5-mononitrate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 2 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB n,n'-(1',12'-dodecydene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n,n'-(1',7'-heptylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD mivacurium small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cholinesterase BCHE NA unknown 4.04 drugbank , DGIDB decyle nelycorine dibromo salt derivative 1 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB n,n'-(1',6-hexylene)-bis-(-)-nor-mep NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-(butylcarbamate)-5-mononitrate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-(2-diethylamino-propionamino)-rutaecarpine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD lawsaritol NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-n-hexyl-7-methoxytacrine hydrochloride NA NA investigative cholinesterase BCHE Successful target unknown NA TTD alpha-d-mannose NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-(2-diethylamino-acetamino)-rutaecarpine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD o-tolyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-cyclohexyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD di-substituted piperidine derivative 3 NA NA patented cholinesterase BCHE Successful target unknown NA TTD , DGIDB ethyl dihydrogen phosphate small molecule NA experimental,investigative cholinesterase BCHE Successful target unknown NA TTD , drugbank hexafluronium small molecule Muscle relaxation phase[MeSHID:D009126],Muscular fasciculation[MeSHID:D005207] approved cholinesterase BCHE NA inhibitor NA drugbank n-methyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD caproctamine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-benzylcarbamate-5-triflate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD chf-2819 NA NA investigative cholinesterase BCHE Successful target unknown NA TTD methyl phosphinic acid NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-phenyl-cyclosal-d4tmp NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (10h-phenothiazin-10-yl)(o-tolyl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 1,2-indanedione NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[3-(benzylmethylamino)propoxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 2-propyl-beta-carboline-2-ium iodide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (-)-debromoflustramine b NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-(benzylcarbamate)-5-mononitrate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-di-(butylcarbamate) NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 9-o-[3-(4-bromo-phenoxyl)butyl]-berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD lipocrine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD haloxysterol b NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 4-methoxyphenyl 10h-phenothiazine-10-carboxylate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD n-phenyl-1'h-phenothiazine-1'-carboxamide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD haloxysterol d NA NA investigative cholinesterase BCHE Successful target unknown NA TTD vaganine d NA NA investigative cholinesterase BCHE Successful target unknown NA TTD huprine x NA NA investigative cholinesterase BCHE Successful target unknown NA TTD butyrylthiocholine small molecule NA experimental,investigative cholinesterase BCHE Successful target substrate NA TTD , drugbank 9-o-[3-(2-pyridinoxyl)butyl]-berberine bromide NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 3-(2-n-pyrrolyl-propionamino)-rutaecarpine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD echothiophate small molecule Operative Surgical Procedures[MeSHID:D013514],Angle Closure Glaucoma[MeSHID:D015812] approved cholinesterase BCHE NA inhibitor NA drugbank galantamine small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cholinesterase BCHE NA inhibitor 3.64 drugbank , DGIDB 6-hydroxy-1,2,9-trimethyl-9h-beta-carbolin-2-ium NA NA investigative cholinesterase BCHE Successful target unknown NA TTD (10h-phenothiazin-10-yl)(m-tolyl)methanone NA NA investigative cholinesterase BCHE Successful target unknown NA TTD 4-isopropylphenserine NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-(methylcarbamate)-5-benzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD isosorbide-2-(butylcarbamate)-5-benzoate NA NA investigative cholinesterase BCHE Successful target unknown NA TTD adenosine 5'-[gamma-thio]triphosphate small molecule NA experimental [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial BCKDK NA unknown NA drugbank ctx001 NA Anemia, Sickle Cell[MeSHID:D000755],beta Thalassemia[MeSHID:D017086],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 b-cell lymphoma/leukemia 11a BCL11A Clinical trial target unknown NA TTD bcl11a shrna NA Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 bcl11a messenger rna BCL11A Clinical trial target unknown NA TTD pmid27744724-compound-10 NA NA patented apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB oblimersen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],melanoma[MeSHID:D008545] phase 3 apoptosis regulator bcl-2 BCL2 Successful target unknown 4.34 TTD , DGIDB n-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide NA NA investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved apoptosis regulator bcl-2 BCL2 NA modulator NA drugbank 5,10-dioxy-2-phenyl-benzo[g]pteridin-4-ylamine NA NA investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD paclitaxel docosahexaenoic acid small molecule Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],Malignant neoplasm of skin[MeSHID:D012878],Malignant neoplasm of kidney[MeSHID:D007680],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943] investigational apoptosis regulator bcl-2 BCL2 NA unknown NA drugbank vob560 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Leukemia, Myelocytic, Acute[MeSHID:D015470],Multiple Myeloma[MeSHID:D009101] phase 1 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD apoptone small molecule Neoplasms[MeSHID:D009369] investigational apoptosis regulator bcl-2 BCL2 NA unknown NA drugbank 4,5-dibenzylbenzene-1,2-diol NA NA investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD tw-37 NA NA investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD paclitaxel small molecule Breast[MeSHID:D001940],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Ovary[MeSHID:D010053] approved,vet_approved apoptosis regulator bcl-2 BCL2 NA inhibitor 0.16 drugbank , DGIDB eribulin small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apoptosis regulator bcl-2 BCL2 NA unknown NA drugbank pmid27744724-compound-18 NA NA patented apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB navitoclax small molecule NA investigational apoptosis regulator bcl-2 BCL2 NA unknown 0.72 drugbank , DGIDB beclanorsen NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD betaine small molecule Metabolism[MeSHID:D008660],Malnutrition[MeSHID:D044342],Blood[MeSHID:D001769],Homocystinuria[MeSHID:D006712],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inborn Errors of Metabolism[MeSHID:D008661] approved,nutraceutical apoptosis regulator bcl-2 BCL2 NA unknown NA drugbank pc4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD venetoclax small molecule Deletion Mutation[MeSHID:D017384],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved,investigational apoptosis regulator bcl-2 BCL2 NA antagonist,inhibitor 1.45 drugbank , DGIDB bp1002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymph[MeSHID:D008196],Hematopoietic Neoplasms[MeSHID:D019337] phase 1 bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD bgb-11417 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD thymoquinone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Polycystic Ovary Syndrome[MeSHID:D011085] phase 2/3 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD indole-based analog 3 NA NA patented apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB pmid27744724-compound-21 NA NA patented apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB bcl201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 1 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB 2,3,4-trihydroxy-5-isopropyl-n-phenyl-benzamide NA NA investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD g3139 + irinotecan NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD g3139 + paclitaxel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD g3139 + dacarbazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD irofulven/taxotere NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB indole-based analog 2 NA NA patented apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB modified ha14-1 compounds (cancer) NA NA investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD navitoclax small molecule NA investigational apoptosis regulator bcl-2 BCL2 NA antagonist 0.72 drugbank , DGIDB g3139 + dexamethasone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD apogossypol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD pi-88/taxotere NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB oblimersen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],melanoma[MeSHID:D008545] phase 3 apoptosis regulator bcl-2 BCL2 Successful target antisense oligonucleotide 4.34 TTD , DGIDB lp-108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Lateral posterior nucleus of thalamus[MeSHID:D020647], Myelomonocytic, Chronic[MeSHID:D015477],Spinal Puncture[MeSHID:D013129] phase 1 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD rg7601 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 3 apoptosis regulator bcl-2 BCL2 Successful target unknown 1.45 TTD , DGIDB ai-850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB obatoclax small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 2 apoptosis regulator bcl-2 BCL2 Successful target inhibitor 1.45 TTD , drugbank , DGIDB g3139 + thalidomide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD obatoclax small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 2 apoptosis regulator bcl-2 BCL2 Successful target unknown 1.45 TTD , drugbank , DGIDB abt-263 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant Neoplasms[MeSHID:D009369],Relapse[MeSHID:D012008] phase 3 apoptosis regulator bcl-2 BCL2 Successful target unknown 0.72 TTD , DGIDB rasagiline small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of skin[MeSHID:D012878] approved apoptosis regulator bcl-2 BCL2 NA activator NA drugbank taxol/paraplatin/herceptin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB wl-276 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD taxol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943] approved apoptosis regulator bcl-2 BCL2 Successful target unknown 0.16 TTD , DGIDB dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational apoptosis regulator bcl-2 BCL2 NA negative modulator NA drugbank mci-186 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690] approved apoptosis regulator bcl-2 BCL2 Successful target unknown 0.29 TTD , DGIDB pnt-2258 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 2 bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD navitoclax small molecule NA investigational apoptosis regulator bcl-2 BCL2 NA inhibitor 0.72 drugbank , DGIDB g3139 + cytarabine (ara-c) NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD gossypol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 apoptosis regulator bcl-2 BCL2 Successful target unknown 0.03 TTD , DGIDB azd0466 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD qediirniarhlaqvgdsmdr NA NA investigative apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD bp-100-1.02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD g3139 + fludarabine NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD g3139 + g-csf NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative bcl-2 messenger rna BCL2 Clinical trial target unknown NA TTD gdc-0199 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved apoptosis regulator bcl-2 BCL2 Successful target unknown 1.45 TTD , DGIDB apg-1252 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Small cell carcinoma of lung[MeSHID:D055752] phase 1/2 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD , DGIDB docetaxel small molecule Cancer of Head and Neck[MeSHID:D006258],Stomach[MeSHID:D013270],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational apoptosis regulator bcl-2 BCL2 NA unknown 0.16 drugbank , DGIDB apg-2575 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 apoptosis regulator bcl-2 BCL2 Successful target unknown NA TTD us8937193-compound-7 NA NA patented bcl-2-related protein a1 BCL2A1 Patented-recorded target unknown NA TTD , DGIDB apogossypolone NA NA patented bcl-2-related protein a1 BCL2A1 Patented-recorded target unknown NA TTD , DGIDB us8937193-compound-6b NA NA patented bcl-2-related protein a1 BCL2A1 Patented-recorded target unknown NA TTD , DGIDB pmid27744724-compound-10 NA NA patented apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD , DGIDB qediirniarhlaqvgdsmdr NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD isis 11221 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD isis 16010 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD azd0466 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD eapb0203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] investigative apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD gossypol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigational bcl-2-like protein 1 BCL2L1 NA unknown 0.5 drugbank , DGIDB abt-263 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant Neoplasms[MeSHID:D009369],Relapse[MeSHID:D012008] phase 3 apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown 2.65 TTD , DGIDB isis 11219 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD isis 11224 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD isis 16009 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD isis 16005 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD e-003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD obatoclax NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown 1.59 TTD , DGIDB 4'-fluoro-1,1'-biphenyl-4-carboxylic acid small molecule NA experimental bcl-2-like protein 1 BCL2L1 NA unknown NA drugbank isis 15998 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD 4,5-dibenzylbenzene-1,2-diol NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD indole-based analog 2 NA NA patented apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD , DGIDB indole-based analog 3 NA NA patented apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD , DGIDB apg-1252 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Small cell carcinoma of lung[MeSHID:D055752] phase 1/2 apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD , DGIDB wehi-0103122 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD tw-37 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD pmid27744724-compound-21 NA NA patented apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-18 NA NA patented apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD , DGIDB 4'-fluoro-1,1'-biphenyl-4-carboxylic acid NA NA investigative apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD isis 11223 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD pmid27744724-compound-26 NA NA patented apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-27 NA NA patented apoptosis regulator bcl-xl BCL2L1 Clinical trial target unknown NA TTD , DGIDB isis 11220 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD isis 15999 NA NA investigative bcl-x messenger rna BCL2L1 Literature-reported target unknown NA TTD navitoclax small molecule NA investigational bcl-2-like protein 2 BCL2L2 NA inhibitor 2.65 drugbank , DGIDB abt-263 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant Neoplasms[MeSHID:D009369],Relapse[MeSHID:D012008] phase 3 apoptosis regulator bcl-w BCL2L2 Clinical trial target unknown 2.65 TTD , DGIDB pmid27744724-compound-18 NA NA patented apoptosis regulator bcl-w BCL2L2 Clinical trial target unknown NA TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved breakpoint cluster region protein BCR NA inhibitor 0.83 drugbank , DGIDB bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved breakpoint cluster region protein BCR NA inhibitor 0.56 drugbank , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved breakpoint cluster region protein BCR NA inhibitor 0.83 drugbank , DGIDB ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational breakpoint cluster region protein BCR NA inhibitor 0.79 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational breakpoint cluster region protein BCR NA unknown 0.29 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational breakpoint cluster region protein BCR NA inhibitor 0.29 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational breakpoint cluster region protein BCR NA unknown 0.29 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational breakpoint cluster region protein BCR NA inhibitor 0.29 drugbank , DGIDB cmlvax100 biotech leukemia[MeSHID:D007938],Cessation of life[MeSHID:D003643],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Expiration, function[MeSHID:D045853] investigational bcr/abl p210 fusion protein BCR/ABL fusion NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical d-beta-hydroxybutyrate dehydrogenase, mitochondrial BDH1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational b1 bradykinin receptor BDKRB1 NA unknown NA drugbank captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved b1 bradykinin receptor BDKRB1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental b1 bradykinin receptor BDKRB1 NA agonist NA drugbank enalaprilat small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b1 bradykinin receptor BDKRB1 NA unknown NA drugbank safotibant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 b1 bradykinin receptor BDKRB1 Clinical trial target unknown 21.22 TTD , DGIDB ac-lys-[leu(8)]-des-arg(9)-bk NA NA investigative b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD des-arg10-kallidin NA NA investigative b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD ramipril small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Cerebrovascular accident[MeSHID:D020521],Kidney[MeSHID:D007668],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved b1 bradykinin receptor BDKRB1 NA unknown NA drugbank ramipril small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Cerebrovascular accident[MeSHID:D020521],Kidney[MeSHID:D007668],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b1 bradykinin receptor BDKRB1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational b1 bradykinin receptor BDKRB1 NA unknown NA drugbank jmv1431 NA NA investigative b1 bradykinin receptor BDKRB1 Clinical trial target antagonist NA TTD , DGIDB h-lys-arg-pro-hyp-gly-thi-ser-d-bt-oh(jmv1669) NA NA investigative b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD nvp-saa164 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative b1 bradykinin receptor BDKRB1 Clinical trial target antagonist NA TTD , DGIDB h-darg-arg-pro-hyp-gly-igl-ser-d-bt-oh(jmv1638) NA NA investigative b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD des-arg10-leu9-kallidin NA NA investigative b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD h-lys-arg-pro-hyp-gly-igl-ser-d-bt-oh(jmv1645) NA NA investigative b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD ssr-240612 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD , DGIDB captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved b1 bradykinin receptor BDKRB1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational b1 bradykinin receptor BDKRB1 NA agonist NA drugbank des-arg(9)-[leu(8)]-bk NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperargininemia[MeSHID:D020162],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigative b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD bi 113823 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b1 bradykinin receptor BDKRB1 Clinical trial target unknown NA TTD , DGIDB safotibant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 b1 bradykinin receptor BDKRB1 Clinical trial target antagonist 21.22 TTD , DGIDB (d)arg-arg-pro-hyp-gly-thi-cys-(d)phe-phe-cys-arg NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD breceptin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD npc-349 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target antagonist NA TTD , DGIDB jmv1431 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target antagonist NA TTD , DGIDB pmid12812482c11 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD kallidin NA NA investigative b2 bradykinin receptor BDKRB2 Successful target agonist NA TTD , DGIDB t-kinin NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD dm199 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Ischemia[MeSHID:D002545],Cerebrovascular accident[MeSHID:D020521],Cerebral Infarction[MeSHID:D002544],Diabetic Nephropathy[MeSHID:D003928],Diabetes, Autoimmune[MeSHID:D003922] phase 2 b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD h-lys-arg-pro-hyp-gly-igl-ser-d-bt-oh(jmv1645) NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD icatibant small molecule Angioedemas, Hereditary[MeSHID:D054179],Burn injury[MeSHID:D002056],Liver diseases[MeSHID:D008107],Infection[MeSHID:D007239],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational b2 bradykinin receptor BDKRB2 Successful target antagonist 14.69 TTD , drugbank , DGIDB h-darg-arg-pro-hyp-gly-igl-ser-d-bt-oh(jmv1638) NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD [des-arg9]bradykinin NA NA investigative b2 bradykinin receptor BDKRB2 Successful target agonist NA TTD , DGIDB lf-160335 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD fr190997 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target agonist NA TTD , DGIDB pmid12723943c12 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD fasitibant chloride NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 b2 bradykinin receptor BDKRB2 Successful target antagonist 4.9 TTD , DGIDB bradykinin NA NA phase 1 b2 bradykinin receptor BDKRB2 Successful target agonist 4.9 TTD , DGIDB (d)arg-arg-pro-hyp-gly-thi-ser-(d)tic-aoc-arg NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD h-lys-arg-pro-hyp-gly-thi-ser-d-bt-oh(jmv1669) NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD bradykinin NA NA phase 1 b2 bradykinin receptor BDKRB2 Successful target unknown 4.9 TTD , DGIDB met-lys-bradykinin NA NA investigative b2 bradykinin receptor BDKRB2 Successful target agonist NA TTD , DGIDB npc-567 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] discontinued in phase 2 b2 bradykinin receptor BDKRB2 Successful target antagonist 4.9 TTD , DGIDB fasitibant chloride NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD , DGIDB [leu8,des-arg9]bradykinin NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD quinapril analogue NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD labradimil small molecule Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 b2 bradykinin receptor BDKRB2 Successful target agonist 24.48 TTD , drugbank , DGIDB ps020990 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD (d)arg-arg-pro-hyp-gly-phe-ser-(d)phe-phe-arg NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD win 64338 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target antagonist NA TTD , DGIDB deltibant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] phase 2 b2 bradykinin receptor BDKRB2 Successful target unknown 4.9 TTD , DGIDB fr167344 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target antagonist NA TTD , DGIDB chroman 28 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD [sar,d-phe8,des-arg9]bradykinin NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD (d)arg-arg-pro-hyp-gly-thi-ser-(d)tic-tic-arg NA NA investigative b2 bradykinin receptor BDKRB2 Successful target unknown NA TTD anatibant small molecule Traumatic Brain Injury[MeSHID:D000070642],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 b2 bradykinin receptor BDKRB2 Successful target antagonist 24.48 TTD , drugbank , DGIDB fr191413 NA NA investigative b2 bradykinin receptor BDKRB2 Successful target agonist NA TTD , DGIDB bradyzide NA NA investigative b2 bradykinin receptor BDKRB2 Successful target antagonist NA TTD , DGIDB cx-717 small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit,investigational brain-derived neurotrophic factor BDNF NA unknown NA drugbank esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational brain-derived neurotrophic factor BDNF NA agonist NA drugbank pym-50028 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 brain-derived neurotrophic factor BDNF Clinical trial target unknown NA TTD , DGIDB chondroitin sulfate small molecule Catabolism[MeSHID:D008660],Bone Tissue[MeSHID:D001842],Degenerative polyarthritis[MeSHID:D010003],Cartilage[MeSHID:D002356],Sclerosis[MeSHID:D012598],Body tissue[MeSHID:D014024],Inflammation[MeSHID:D007249],Synovial Membrane[MeSHID:D013583],Disease Progression[MeSHID:D018450],Pain[MeSHID:D010146] approved,investigational,nutraceutical brain-derived neurotrophic factor BDNF NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational brain-derived neurotrophic factor BDNF NA cofactor NA drugbank estradiol small molecule Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beclin-1 BECN1 NA binder NA drugbank estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beclin-1 BECN1 NA unknown NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved beclin-1 BECN1 NA unknown NA drugbank estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beclin-1 BECN1 NA unknown NA drugbank estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beclin-1 BECN1 NA unknown NA drugbank estradiol dienanthate small molecule NA approved,investigational,vet_approved beclin-1 BECN1 NA unknown NA drugbank menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical osteocalcin BGLAP NA agonist NA drugbank gallium nitrate small molecule Hypercalcemia[MeSHID:D006934],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational osteocalcin BGLAP NA antagonist NA drugbank phylloquinone small molecule Metabolism[MeSHID:D008660],Blood Coagulation Disorders[MeSHID:D001778],Vitamin K Deficiency[MeSHID:D014813],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved,investigational osteocalcin BGLAP NA agonist NA drugbank gamma-carboxy-l-glutamic acid small molecule NA experimental osteocalcin BGLAP NA unknown NA drugbank s-(d-carboxybutyl)-l-homocysteine small molecule NA experimental betaine--homocysteine s-methyltransferase 1 BHMT NA unknown NA drugbank methionine small molecule Protein Biosynthesis[MeSHID:D014176] approved,nutraceutical betaine--homocysteine s-methyltransferase 1 BHMT NA product of NA drugbank methionine small molecule Protein Biosynthesis[MeSHID:D014176] approved,nutraceutical s-methylmethionine--homocysteine s-methyltransferase bhmt2 BHMT2 NA product of NA drugbank at-406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 3 cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown 13.64 TTD , DGIDB pmid25980951-compound-27 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-17 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-44 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-42 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-22 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-1 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-4 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-37 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB at-406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 3 cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target antagonist 13.64 TTD , DGIDB pmid25980951-compound-5 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB azd5582 NA NA investigative cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target antagonist NA TTD , DGIDB pmid25980951-compound-20 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB birinapant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 2 cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target antagonist 15.16 TTD , DGIDB pmid25980951-compound-16 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-18 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB eapb0203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] investigative cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD pmid25980951-compound-3 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-43 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-21 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-41 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-19 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB bv-6 NA NA investigative cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target inhibitor NA TTD , DGIDB pmid25980951-compound-6 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB birinapant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 2 cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target inhibitor 15.16 TTD , DGIDB pmid25980951-compound-36 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-38 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB birinapant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 2 cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown 15.16 TTD , DGIDB pmid25980951-compound-7 NA NA patented cellular inhibitor of apoptosis 1 BIRC2 Clinical trial target unknown NA TTD , DGIDB at-406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 3 cellular inhibitor of apoptosis 2 BIRC3 Clinical trial target unknown 9.09 TTD , DGIDB sm-131 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target unknown NA TTD isis 23452 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target unknown NA TTD sm-122 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target inhibitor 3.03 TTD , DGIDB isis 23414 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target unknown NA TTD pmid25980951-compound-43 NA NA patented cellular inhibitor of apoptosis 2 BIRC3 Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-44 NA NA patented cellular inhibitor of apoptosis 2 BIRC3 Clinical trial target unknown NA TTD , DGIDB isis 23412 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target unknown NA TTD isis 23416 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target unknown NA TTD isis 23454 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target unknown NA TTD azd5582 NA NA investigative cellular inhibitor of apoptosis 2 BIRC3 Clinical trial target antagonist NA TTD , DGIDB pmid25980951-compound-1 NA NA patented cellular inhibitor of apoptosis 2 BIRC3 Clinical trial target unknown NA TTD , DGIDB isis 23459 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target unknown NA TTD at-406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 3 cellular inhibitor of apoptosis 2 BIRC3 Clinical trial target antagonist 9.09 TTD , DGIDB sm-337 NA NA investigative apoptosis-2 messenger rna BIRC3 Literature-reported target antagonist 3.03 TTD , DGIDB pmid25980951-compound-27 NA NA patented cellular inhibitor of apoptosis 2 BIRC3 Clinical trial target unknown NA TTD , DGIDB reserpine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational baculoviral iap repeat-containing protein 5 BIRC5 NA unknown NA drugbank ly2181308 small molecule Neoplasms[MeSHID:D009369] investigational baculoviral iap repeat-containing protein 5 BIRC5 NA antisense oligonucleotide 3.54 drugbank , DGIDB isis 23722 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 apoptosis inhibitor survivin BIRC5 Clinical trial target unknown NA TTD , DGIDB cv-9201 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 apoptosis inhibitor survivin BIRC5 Clinical trial target unknown NA TTD , DGIDB survaxm NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Glioblastoma[MeSHID:D005909],Brain[MeSHID:D001921] phase 2 apoptosis inhibitor survivin BIRC5 Clinical trial target unknown NA TTD , DGIDB ly2181308 small molecule Neoplasms[MeSHID:D009369] investigational baculoviral iap repeat-containing protein 5 BIRC5 NA unknown 3.54 drugbank , DGIDB ezn-3042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 apoptosis inhibitor survivin BIRC5 Clinical trial target unknown NA TTD , DGIDB berberine small molecule NA approved,investigational baculoviral iap repeat-containing protein 5 BIRC5 NA unknown NA drugbank pmid25980951-compound-6 NA NA patented melanoma inhibitor of apoptosis protein BIRC7 Patented-recorded target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase blk BLK NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase blk BLK NA inhibitor NA drugbank pyrazolo[4,3-c]pyridine derivative 2 NA NA patented b lymphocyte kinase BLK Patented-recorded target unknown NA TTD , DGIDB pmid24915291c38 NA NA investigative b lymphocyte kinase BLK Patented-recorded target unknown NA TTD pmid15546730c2 NA NA investigative b lymphocyte kinase BLK Patented-recorded target unknown NA TTD pmid24915291c31 NA NA investigative b lymphocyte kinase BLK Patented-recorded target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase blk BLK NA inhibitor NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical biliverdin reductase a BLVRA NA unknown NA drugbank ursodeoxycholic acid NA Biliary calculi[MeSHID:D042882],Cholecystolithiasis[MeSHID:D041761],Operative Surgical Procedures[MeSHID:D013514],Cholelithiasis[MeSHID:D002769],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary biliary cirrhosis[MeSHID:D008105] approved biliverdin reductase a BLVRA Successful target unknown NA TTD , DGIDB nicotinamide-adenine-dinucleotide NA NA investigative biliverdin reductase a BLVRA Successful target unknown NA TTD flavin mononucleotide small molecule NA approved,investigational flavin reductase (nadph) BLVRB NA unknown NA drugbank lumichrome small molecule NA experimental flavin reductase (nadph) BLVRB NA unknown NA drugbank mesobiliverdin iv alpha small molecule NA experimental flavin reductase (nadph) BLVRB NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical flavin reductase (nadph) BLVRB NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental flavin reductase (nadph) BLVRB NA unknown NA drugbank biliverdine ix alpha small molecule NA experimental flavin reductase (nadph) BLVRB NA unknown NA drugbank riboflavin small molecule Riboflavin Deficiency[MeSHID:D012257],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical,vet_approved flavin reductase (nadph) BLVRB NA product of NA drugbank riboflavin small molecule Riboflavin Deficiency[MeSHID:D012257],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congenital Abnormality[MeSHID:D000013],Keratoconus[MeSHID:D007640],Ultraviolet Rays[MeSHID:D014466],Cornea[MeSHID:D003315] approved,investigational,nutraceutical,vet_approved flavin reductase (nadph) BLVRB NA product of NA drugbank uk-383367 NA NA investigative bone morphogenetic protein 1 BMP1 Literature-reported target unknown NA TTD pmid11934595c2 NA NA investigative bone morphogenetic protein 1 BMP1 Literature-reported target unknown NA TTD dwp-431 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bone Diseases, Developmental[MeSHID:D001848] phase 3 bone morphogenetic protein 2 BMP2 Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational bmp-2-inducible protein kinase BMP2K NA inhibitor NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical bone morphogenetic protein 4 BMP4 NA unknown NA drugbank ly3113593 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2 bone morphogenetic protein 6 BMP6 Clinical trial target unknown NA TTD thr-184 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney[MeSHID:D007668],Fibrosis[MeSHID:D005355] phase 2 bone morphogenetic protein 7 BMP7 Clinical trial target unknown NA TTD dibotermin alfa biotech Transplanted tissue[MeSHID:D019737],Intervertebral Disc Degeneration[MeSHID:D055959],Disease[MeSHID:D004194],Fracture[MeSHID:D050723],Bone structure of tibia[MeSHID:D013977],Bone structure of lumbar vertebra[MeSHID:D008159],Fractures, Open[MeSHID:D005597],Unmarried[MeSHID:D012847] approved,investigational bone morphogenetic protein receptor type-1a BMPR1A NA ligand NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational bone morphogenetic protein receptor type-1b BMPR1B NA inhibitor NA drugbank pmid23639540c13a NA NA investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD ldn-214117 NA NA investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD aa-123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD pmid23639540c13r NA NA investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD pmid23639540c13d NA NA investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD dibotermin alfa biotech Transplanted tissue[MeSHID:D019737],Intervertebral Disc Degeneration[MeSHID:D055959],Disease[MeSHID:D004194],Fracture[MeSHID:D050723],Bone structure of tibia[MeSHID:D013977],Bone structure of lumbar vertebra[MeSHID:D008159],Fractures, Open[MeSHID:D005597],Unmarried[MeSHID:D012847] approved,investigational bone morphogenetic protein receptor type-2 BMPR2 NA ligand NA drugbank aa-166 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Structure of articular cartilage[MeSHID:D002358],Articulation Disorders[MeSHID:D001184],Cartilage[MeSHID:D002356],Cartilage Diseases[MeSHID:D002357],Arthropathy[MeSHID:D007592],Disease[MeSHID:D004194] investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational bone morphogenetic protein receptor type-2 BMPR2 NA inhibitor NA drugbank aa-204 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney Diseases[MeSHID:D007674] investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD ml347 NA NA investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD aa-184 NA Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney[MeSHID:D007668] investigative bone morphogenetic protein receptor BMPR2 Literature-reported target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational cytoplasmic tyrosine-protein kinase bmx BMX NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cytoplasmic tyrosine-protein kinase bmx BMX NA inhibitor NA drugbank zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytoplasmic tyrosine-protein kinase bmx BMX NA inhibitor NA drugbank l-tyrosinamide small molecule NA experimental valacyclovir hydrolase BPHL NA unknown NA drugbank xoma-629 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 protein bactericidal permeability-increasing BPI Clinical trial target unknown NA TTD , DGIDB di-stearoyl-3-sn-phosphatidylcholine small molecule NA experimental bactericidal permeability-increasing protein BPI NA unknown NA drugbank az-628 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase b-raf BRAF Successful target unknown NA TTD isis 13741 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD bgb-283 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase b-raf BRAF Successful target inhibitor 0.55 TTD , DGIDB (1e)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime small molecule NA experimental serine/threonine-protein kinase b-raf BRAF NA unknown NA drugbank bgb-283 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase b-raf BRAF Successful target unknown 0.55 TTD , DGIDB bms-908662 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase b-raf BRAF Successful target unknown 0.66 TTD , DGIDB isis 13740 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD asn003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase b-raf BRAF Successful target unknown NA TTD , DGIDB arq 736 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase b-raf BRAF Successful target unknown NA TTD , DGIDB isis 13730 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD cep-32496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase b-raf BRAF Successful target inhibitor 0.82 TTD , DGIDB ro-5212054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase b-raf BRAF Successful target unknown 1.31 TTD , DGIDB plx-ori3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD lgx818 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved serine/threonine-protein kinase b-raf BRAF Successful target unknown 1.64 TTD , DGIDB abm-1310 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase b-raf BRAF Successful target unknown NA TTD sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serine/threonine-protein kinase b-raf BRAF NA inhibitor 0.3 drugbank , DGIDB isis 13727 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD pmid26061392c2 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD vemurafenib small molecule Blood Vessel[MeSHID:D001808],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],melanoma[MeSHID:D008545],Cutaneous Melanoma[MeSHID:C562393],Histiocytes[MeSHID:D006644],Mutation[MeSHID:D009154],Rare Diseases[MeSHID:D035583],Mental association[MeSHID:D001244],Lung[MeSHID:D008168],Affect (mental function)[MeSHID:D000339],Erdheim-Chester Disease[MeSHID:D031249],Skeletal bone[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serine/threonine-protein kinase b-raf BRAF Successful target inhibitor 3.63 TTD , drugbank , DGIDB lgx818 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved serine/threonine-protein kinase b-raf BRAF Successful target inhibitor 1.64 TTD , DGIDB 2-(benzylamino)-6-(3-acetamidophenyl)pyrazine NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD ripretinib small molecule Diagnosis[MeSHID:D003933],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Mastocytosis, Systemic[MeSHID:D034721] approved serine/threonine-protein kinase b-raf BRAF NA inhibitor NA drugbank plx-4720 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cutaneous Melanoma[MeSHID:C562393],melanoma[MeSHID:D008545] phase 1 b-raf messenger rna BRAF Clinical trial target inhibitor 1.38 TTD , DGIDB isis 13743 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase b-raf BRAF NA inhibitor NA drugbank plx8394 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 2 serine/threonine-protein kinase b-raf BRAF Successful target inhibitor 1.97 TTD , DGIDB plx-4720 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cutaneous Melanoma[MeSHID:C562393],melanoma[MeSHID:D008545] experimental serine/threonine-protein kinase b-raf BRAF NA inhibitor 1.38 drugbank , DGIDB n-{2,4-difluoro-3-[(5-pyridin-3-yl-1h-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide small molecule NA experimental serine/threonine-protein kinase b-raf BRAF NA unknown NA drugbank rg7304 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 b-raf messenger rna BRAF Clinical trial target unknown NA TTD 2-(phenylamino)-6-(3-acetamidophenyl)pyrazine NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD rg-7256 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 1 serine/threonine-protein kinase b-raf BRAF Successful target inhibitor 1.31 TTD , DGIDB regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serine/threonine-protein kinase b-raf BRAF NA inhibitor 0.19 drugbank , DGIDB raf-265 small molecule melanoma[MeSHID:D008545] investigational serine/threonine-protein kinase b-raf BRAF NA unknown NA drugbank dabrafenib small molecule melanoma[MeSHID:D008545],Disease[MeSHID:D004194],Anaplastic thyroid carcinoma[MeSHID:D065646],Mutation[MeSHID:D009154],Continuance of life[MeSHID:D013534],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serine/threonine-protein kinase b-raf BRAF Successful target antagonist,inhibitor 4.94 TTD , drugbank , DGIDB encorafenib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational serine/threonine-protein kinase b-raf BRAF NA inhibitor 1.64 drugbank , DGIDB xl281 small molecule Neoplasms[MeSHID:D009369] investigational serine/threonine-protein kinase b-raf BRAF NA unknown NA drugbank , DGIDB xl281 small molecule Neoplasms[MeSHID:D009369] investigational serine/threonine-protein kinase b-raf BRAF NA inhibitor 0.66 drugbank , DGIDB zm-336372 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD plx8394 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 2 serine/threonine-protein kinase b-raf BRAF Successful target unknown 1.97 TTD , DGIDB mln2480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 2 b-raf messenger rna BRAF Clinical trial target unknown NA TTD , DGIDB l-779450 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD spn-803 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Solitary Pulmonary Nodule[MeSHID:D003074],Parkinson Disease[MeSHID:D010300] phase 1 b-raf messenger rna BRAF Clinical trial target unknown NA TTD cep-32496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase b-raf BRAF Successful target unknown 0.82 TTD , DGIDB ar-00341677 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase b-raf BRAF Successful target unknown NA TTD isis 14144 NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD pyrazolo[1,5-a]pyrimidine-3-carboxylate NA NA investigative b-raf messenger rna BRAF Clinical trial target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational lys-63-specific deubiquitinase brcc36 BRCC3 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental lys-63-specific deubiquitinase brcc36 BRCC3 NA cofactor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational lys-63-specific deubiquitinase brcc36 BRCC3 NA cofactor NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational lys-63-specific deubiquitinase brcc36 BRCC3 NA unknown NA drugbank abbv-744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 bromodomain-containing protein 2 BRD2 Clinical trial target unknown 2.36 TTD , DGIDB pmid26924192-compound-105 NA NA patented bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD , DGIDB gw841819x NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target inhibitor 2.36 TTD , DGIDB pmid24000170c36 NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD pmid26924192-compound-103 NA NA patented bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD , DGIDB i-bet151 NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target inhibitor NA TTD , DGIDB me bromodomain inhibitor NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target inhibitor NA TTD , DGIDB abbv-744 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 bromodomain-containing protein 2 BRD2 Clinical trial target unknown 2.36 TTD , DGIDB bic1 NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target inhibitor NA TTD , DGIDB pyrrolo-pyrrolone derivative 1 NA NA patented bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-102 NA NA patented bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD , DGIDB pmid24000170c38 NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD xd14 NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target inhibitor NA TTD , DGIDB pmid26924192-compound-106 NA NA patented bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD , DGIDB otx-015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] phase 1/2 bromodomain-containing protein 2 BRD2 Clinical trial target unknown 1.77 TTD , DGIDB pmid21851057c4d NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD pmid26924192-compound-104 NA NA patented bromodomain-containing protein 2 BRD2 Clinical trial target unknown NA TTD , DGIDB et bromodomain inhibitor NA NA investigative bromodomain-containing protein 2 BRD2 Clinical trial target inhibitor NA TTD , DGIDB pmid26924192-compound-103 NA NA patented bromodomain-containing protein 3 BRD3 Clinical trial target unknown NA TTD , DGIDB i-bet151 NA NA investigative bromodomain-containing protein 3 BRD3 Clinical trial target inhibitor NA TTD , DGIDB gw841819x NA NA investigative bromodomain-containing protein 3 BRD3 Clinical trial target inhibitor 2.65 TTD , DGIDB pmid26924192-compound-105 NA NA patented bromodomain-containing protein 3 BRD3 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrrolone derivative 1 NA NA patented bromodomain-containing protein 3 BRD3 Clinical trial target unknown NA TTD , DGIDB abbv-744 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 bromodomain-containing protein 3 BRD3 Clinical trial target unknown 2.65 TTD , DGIDB xd14 NA NA investigative bromodomain-containing protein 3 BRD3 Clinical trial target inhibitor NA TTD , DGIDB pmid26924192-compound-104 NA NA patented bromodomain-containing protein 3 BRD3 Clinical trial target unknown NA TTD , DGIDB pmid24000170c38 NA NA investigative bromodomain-containing protein 3 BRD3 Clinical trial target unknown NA TTD pmid24000170c36 NA NA investigative bromodomain-containing protein 3 BRD3 Clinical trial target unknown NA TTD pmid26924192-compound-102 NA NA patented bromodomain-containing protein 3 BRD3 Clinical trial target unknown NA TTD , DGIDB abbv-744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 bromodomain-containing protein 3 BRD3 Clinical trial target unknown 2.65 TTD , DGIDB plx2853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-105 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB benzothiazepine analog 11 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-33 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB i-bet151 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB pmid26924192-compound-32 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB benzothiazepine analog 12 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB abbv-744 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 bromodomain-containing protein 4 BRD4 Clinical trial target unknown 1.25 TTD , DGIDB cpi-0610 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Myeloproliferative disease[MeSHID:D009196] phase 3 bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pyrazole and thiophene derivative 4 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrrolone derivative 5 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pyrazole and thiophene derivative 1 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB incb57643 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-20 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB bzt-7 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB pmid26924192-compound-24 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pfi-1 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB ms417 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB pmid26924192-compound-103 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrrolone derivative 1 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-102 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB azd5153 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 bromodomain-containing protein 4 BRD4 Clinical trial target unknown 1.25 TTD , DGIDB aminocyclopentenone compound 5 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid21851057c4d NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD pmid26924192-compound-104 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB gsk525762 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1 bromodomain-containing protein 4 BRD4 Clinical trial target unknown 1.87 TTD , DGIDB aminocyclopentenone compound 3 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid24000170c38 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD pmid23517011c9 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD pyrrolo-pyrrolone derivative 2 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB aminocyclopentenone compound 1 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB xd1 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB otx-015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] phase 1/2 bromodomain-containing protein 4 BRD4 Clinical trial target unknown 2.81 TTD , DGIDB abbv-744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 bromodomain-containing protein 4 BRD4 Clinical trial target unknown 1.25 TTD , DGIDB gw841819x NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor 1.25 TTD , DGIDB cpi-0610 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Myeloproliferative disease[MeSHID:D009196] phase 3 bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB pmid25408830c2 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD isoxazole azepine compound 3 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB pmid26924192-compound-30 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-23 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB rvx-208 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 bromodomain-containing protein 4 BRD4 Clinical trial target unknown 1.87 TTD , DGIDB pyrazole and thiophene derivative 3 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrrolone derivative 3 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB aminocyclopentenone compound 6 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid25408830c3 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD pyrazole and thiophene derivative 2 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid25408830c1 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD pmid24000170c36 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD pmid26924192-compound-22 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB ten010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB (+)-jq1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of testis[MeSHID:D013736] phase 1 bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB benzothiazepine analog 10 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB aminocyclopentenone compound 4 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB xd14 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB (+)-jq1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of testis[MeSHID:D013736] phase 1 bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB cpi-203 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB ms436 NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target inhibitor NA TTD , DGIDB aminocyclopentenone compound 2 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid25703523c7d NA NA investigative bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD pmid26924192-compound-21 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-25 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrrolone derivative 4 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-31 NA NA patented bromodomain-containing protein 4 BRD4 Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-102 NA NA patented bromodomain testis-specific protein BRDT Clinical trial target unknown NA TTD , DGIDB (+)-jq1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of testis[MeSHID:D013736] phase 1 bromodomain testis-specific protein BRDT Clinical trial target unknown NA TTD , DGIDB (+)-jq1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of testis[MeSHID:D013736] phase 1 bromodomain testis-specific protein BRDT Clinical trial target inhibitor NA TTD , DGIDB xd14 NA NA investigative bromodomain testis-specific protein BRDT Clinical trial target inhibitor NA TTD , DGIDB pmid26924192-compound-105 NA NA patented bromodomain testis-specific protein BRDT Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-104 NA NA patented bromodomain testis-specific protein BRDT Clinical trial target unknown NA TTD , DGIDB pmid26924192-compound-103 NA NA patented bromodomain testis-specific protein BRDT Clinical trial target unknown NA TTD , DGIDB ni-57 NA NA investigative bromodomain and phd finger containing 3 BRPF3 Literature-reported target unknown NA TTD , DGIDB mk-7725 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative bombesin-like receptor 3 BRS3 Literature-reported target agonist 31.83 TTD , DGIDB cct244747 NA NA investigative br serine/threonine kinase 1 BRSK1 Literature-reported target inhibitor 1.06 TTD , DGIDB cct244747 NA NA investigative br serine/threonine kinase 2 BRSK2 Literature-reported target inhibitor 10.61 TTD , DGIDB gavilimomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft-vs-Host Disease[MeSHID:D006086] phase 2/3 basigin BSG Clinical trial target unknown 127.3 TTD , DGIDB [131i]-metuximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] phase 2 basigin BSG Clinical trial target unknown NA TTD nicotinamide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved,investigational adp-ribosyl cyclase 2 BST1 NA product of NA drugbank adenosine 5'-[gamma-thio]triphosphate small molecule NA experimental adp-ribosyl cyclase 2 BST1 NA unknown NA drugbank nicotinamide mononucleotide small molecule NA experimental adp-ribosyl cyclase 2 BST1 NA unknown NA drugbank etheno-nadp small molecule NA experimental adp-ribosyl cyclase 2 BST1 NA unknown NA drugbank etheno-nad small molecule NA experimental adp-ribosyl cyclase 2 BST1 NA unknown NA drugbank pmid24900538c2c NA NA investigative tyrosine-protein kinase btk BTK Successful target unknown NA TTD pmid27774824-compound-figure12example1 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase btk BTK NA unknown 0.05 drugbank , DGIDB acalabrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase btk BTK Successful target inhibitor 0.26 TTD , drugbank , DGIDB pyrrolo[2,3-d]pyrimidine derivative 14 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB hm71224 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD pmid24915291c38 NA NA investigative tyrosine-protein kinase btk BTK Successful target unknown NA TTD pyrrolo[2,3-d]pyrimidine derivative 28 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 20 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB arq 531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 2 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 26 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase btk BTK Successful target inhibitor 9.09 TTD , drugbank , DGIDB m7583 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pirtobrutinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 3 tyrosine-protein kinase btk BTK Successful target unknown NA TTD bms-986142 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tyrosine-protein kinase btk BTK Successful target inhibitor 3.64 TTD , DGIDB prn1008 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pemphigus Vulgaris[MeSHID:D010392] phase 2 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB cc-292 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 tyrosine-protein kinase btk BTK Successful target unknown 5.46 TTD , DGIDB cg-806 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 tyrosine-protein kinase btk BTK Successful target unknown NA TTD imidazopyridine derivative 4 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB inositol 1,3,4,5-tetrakisphosphate small molecule NA experimental,investigative tyrosine-protein kinase btk BTK Successful target unknown NA TTD , drugbank jnj-64264681 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD dtrm-555 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 tyrosine-protein kinase btk BTK Successful target unknown NA TTD ibrutinib small molecule Lymphocyte[MeSHID:D008214],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Diagnosis[MeSHID:D003933],Waldenstrom Macroglobulinemia[MeSHID:D008258],Fatigue[MeSHID:D005221],Protein Biosynthesis[MeSHID:D014176],B-Cell Lymphomas[MeSHID:D016393],Neurological observations[MeSHID:D009461],Chronic Lymphocytic Leukemia[MeSHID:D015451],Lymphadenopathy[MeSHID:D000072281],Bone Marrow[MeSHID:D001853],Lymphoma, Non-Hodgkin[MeSHID:D008228],Vision[MeSHID:D014785],lymph nodes[MeSHID:D008198],Liver[MeSHID:D008099],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],leukemia[MeSHID:D007938],Hemorrhage[MeSHID:D006470],Spleen[MeSHID:D013154],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Pancreatic carcinoma[MeSHID:C562463], Follicular[MeSHID:D008224] approved tyrosine-protein kinase btk BTK Successful target inhibitor 1.34 TTD , drugbank , DGIDB ibrutinib small molecule Lymphocyte[MeSHID:D008214],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Diagnosis[MeSHID:D003933],Waldenstrom Macroglobulinemia[MeSHID:D008258],Fatigue[MeSHID:D005221],Protein Biosynthesis[MeSHID:D014176],B-Cell Lymphomas[MeSHID:D016393],Neurological observations[MeSHID:D009461],Chronic Lymphocytic Leukemia[MeSHID:D015451],Lymphadenopathy[MeSHID:D000072281],Bone Marrow[MeSHID:D001853],Lymphoma, Non-Hodgkin[MeSHID:D008228],Vision[MeSHID:D014785],lymph nodes[MeSHID:D008198],Liver[MeSHID:D008099],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],leukemia[MeSHID:D007938],Hemorrhage[MeSHID:D006470],Spleen[MeSHID:D013154],Deletion Mutation[MeSHID:D017384],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase btk BTK Successful target inhibitor 1.34 TTD , drugbank , DGIDB lou064 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urticaria[MeSHID:D014581] phase 2 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB bgb-3113 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 25 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB gs-4059 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tyrosine-protein kinase btk BTK Successful target unknown 5.46 TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 15 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pci-45292 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] preclinical tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB acalabrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase btk BTK Successful target inhibitor 0.26 TTD , drugbank , DGIDB cgi-1316 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative tyrosine-protein kinase btk BTK Successful target unknown NA TTD vecabrutinib small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] investigational,phase 1/2 tyrosine-protein kinase btk BTK Successful target inhibitor 3.64 TTD , drugbank , DGIDB pyrrolo[2,3-d]pyrimidine derivative 16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Autoimmune Diseases[MeSHID:D001327] patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB biib068 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB rn486 NA NA investigative tyrosine-protein kinase btk BTK Successful target inhibitor NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 13 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 29 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 32 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB dtrmwxhs-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD bms-986142 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tyrosine-protein kinase btk BTK Successful target unknown 3.64 TTD , DGIDB pmid27774824-compound-figure12example10 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB tak-020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase btk BTK NA unknown 0.05 drugbank , DGIDB acp-319 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB ono-4059 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 tyrosine-protein kinase btk BTK Successful target unknown 5.46 TTD , DGIDB pyrazolo[4,3-c]pyridine derivative 2 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 30 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB tg-1701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD prn2246 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 23 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB ono-4059 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 tyrosine-protein kinase btk BTK Successful target inhibitor 5.46 TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 27 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 33 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase btk BTK Successful target inhibitor 9.09 TTD , drugbank , DGIDB gdc-0853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327],Urticaria[MeSHID:D014581],Malignant Neoplasms[MeSHID:D009369],Multiple Sclerosis[MeSHID:D009103] phase 3 tyrosine-protein kinase btk BTK Successful target unknown 3.64 TTD , DGIDB pmid27774824-compound-figure12example61 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB bgb-3112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] phase 2 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 12 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB m2951 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Multiple Sclerosis[MeSHID:D009103],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 18 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 31 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 19 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 21 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB abivertinib small molecule NA investigational tyrosine-protein kinase btk BTK NA inhibitor 0.61 drugbank , DGIDB pmid24915291c31 NA NA investigative tyrosine-protein kinase btk BTK Successful target unknown NA TTD xl418 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tyrosine-protein kinase btk BTK NA unknown NA drugbank pyrrolo[2,3-d]pyrimidine derivative 17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Autoimmune Diseases[MeSHID:D001327] patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB lfm-a13 NA NA investigative tyrosine-protein kinase btk BTK Successful target inhibitor 1.82 TTD , DGIDB ac0058ta NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327] phase 1 tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB icp-022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 3 tyrosine-protein kinase btk BTK Successful target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase btk BTK NA inhibitor NA drugbank pyrrolo[2,3-d]pyrimidine derivative 22 NA NA patented tyrosine-protein kinase btk BTK Successful target unknown NA TTD , DGIDB js004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 b- and t-lymphocyte attenuator BTLA Clinical trial target unknown NA TTD pmid24900824c2-1-1 NA NA investigative bub1 mitotic checkpoint serine/threonine kinase BUB1 Patented-recorded target unknown NA TTD pmid24900824c2-3-1 NA NA investigative bub1 mitotic checkpoint serine/threonine kinase BUB1 Patented-recorded target unknown NA TTD pmid24900824c2-13-1 NA NA investigative bub1 mitotic checkpoint serine/threonine kinase BUB1 Patented-recorded target unknown NA TTD schembl16365841 NA NA patented bub1 mitotic checkpoint serine/threonine kinase BUB1 Patented-recorded target unknown NA TTD , DGIDB pmid24900824c2-3-2 NA NA investigative bub1 mitotic checkpoint serine/threonine kinase BUB1 Patented-recorded target unknown NA TTD schembl17766424 NA NA patented bub1 mitotic checkpoint serine/threonine kinase BUB1 Patented-recorded target unknown NA TTD , DGIDB schembl16322760 NA NA patented bub1 mitotic checkpoint serine/threonine kinase BUB1 Patented-recorded target unknown NA TTD , DGIDB bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational complement c1q subcomponent subunit a C1QA NA unknown NA drugbank cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved complement c1q subcomponent subunit a C1QA NA binder NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn complement c1q subcomponent subunit a C1QA NA unknown NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational complement component 1q (c1q) C1QA NA ligand NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational complement c1q subcomponent subunit a C1QA NA unknown NA drugbank palivizumab biotech Respiration Disorders[MeSHID:D012120],Respiratory Syncytial Virus Infections[MeSHID:D018357],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c1q subcomponent subunit a C1QA NA unknown NA drugbank cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved complement c1q subcomponent subunit b C1QB NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement c1q subcomponent subunit b C1QB NA unknown NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational complement c1q subcomponent subunit b C1QB NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement c1q subcomponent subunit b C1QB NA unknown NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational complement component 1q (c1q) C1QB NA ligand NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn complement c1q subcomponent subunit b C1QB NA unknown NA drugbank palivizumab biotech Respiration Disorders[MeSHID:D012120],Respiratory Syncytial Virus Infections[MeSHID:D018357],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c1q subcomponent subunit b C1QB NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational complement c1q subcomponent subunit b C1QB NA modulator NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental complement c1q subcomponent subunit b C1QB NA modulator NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational complement c1q subcomponent subunit b C1QB NA unknown NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved complement component 1 q subcomponent-binding protein, mitochondrial C1QBP NA binder NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement component 1 q subcomponent-binding protein, mitochondrial C1QBP NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c1q subcomponent subunit c C1QC NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement c1q subcomponent subunit c C1QC NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational complement c1q subcomponent subunit c C1QC NA modulator NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement c1q subcomponent subunit c C1QC NA unknown NA drugbank palivizumab biotech Respiration Disorders[MeSHID:D012120],Respiratory Syncytial Virus Infections[MeSHID:D018357],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c1q subcomponent subunit c C1QC NA unknown NA drugbank cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved complement c1q subcomponent subunit c C1QC NA binder NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn complement c1q subcomponent subunit c C1QC NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental complement c1q subcomponent subunit c C1QC NA modulator NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational complement c1q subcomponent subunit c C1QC NA unknown NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational complement c1q subcomponent subunit c C1QC NA unknown NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational complement component 1q (c1q) C1QC NA ligand NA drugbank conestat alfa biotech Angioedemas, Hereditary[MeSHID:D054179] approved,investigational complement c1r subcomponent C1R NA inhibitor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational complement c1r subcomponent C1R NA modulator NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental complement c1r subcomponent C1R NA modulator NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn complement c1r subcomponent C1R NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement c1r subcomponent C1R NA unknown NA drugbank palivizumab biotech Respiration Disorders[MeSHID:D012120],Respiratory Syncytial Virus Infections[MeSHID:D018357],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c1r subcomponent C1R NA unknown NA drugbank human c1-esterase inhibitor biotech Angioedemas, Hereditary[MeSHID:D054179] approved complement c1r subcomponent C1R NA inhibitor NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement c1r subcomponent C1R NA unknown NA drugbank anx005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] phase 1 complement c1s component C1S Successful target unknown NA TTD , DGIDB sutimlimab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cold Hemagglutinin Disease[MeSHID:D000744] phase 3 complement c1s component C1S Successful target antibody 31.83 TTD , DGIDB pmid16460935c28 NA NA investigative complement c1s component C1S Successful target unknown NA TTD fucose NA NA investigative complement c1s component C1S Successful target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement c1s subcomponent C1S NA unknown NA drugbank ts01 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 complement c1s component C1S Successful target unknown NA TTD , DGIDB conestat alfa biotech Angioedemas, Hereditary[MeSHID:D054179] approved,investigational complement c1s subcomponent C1S NA inhibitor NA drugbank cinryze NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angioedemas, Hereditary[MeSHID:D054179] approved complement c1s component C1S Successful target unknown 15.91 TTD , DGIDB shp616 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuromyelitis Optica[MeSHID:D009471] phase 1 complement c1s component C1S Successful target unknown NA TTD , DGIDB tnt009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cold Hemagglutinin Disease[MeSHID:D000744],Bullous pemphigoid[MeSHID:D010391] phase 1 complement c1s component C1S Successful target unknown NA TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c1s subcomponent C1S NA unknown NA drugbank human c1-esterase inhibitor biotech Angioedemas, Hereditary[MeSHID:D054179] approved complement c1s subcomponent C1S NA inhibitor NA drugbank 2-(2-hydroxy-1,1-dihydroxymethyl-ethylamino)-ethanesulfonic acid small molecule NA experimental complement c1s subcomponent C1S NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental complement c1s subcomponent C1S NA modulator NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement c1s subcomponent C1S NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational complement c1s subcomponent C1S NA modulator NA drugbank ac-i[cv(bta)qdwgahrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvwqdwgahrc]t NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cv(dht)qdwgahrc]t NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvsqdwghhrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvfqdwghhrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-icv(5fw)qdwgahrct-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD pegcetacoplan biotech Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457] approved complement c3 C3 NA binder,regulator NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational complement c3 C3 NA inhibitor,ligand NA drugbank mirococept biotech Rheumatoid Arthritis[MeSHID:D001172],Transplanted tissue[MeSHID:D019737],Kidney Diseases[MeSHID:D007674] investigational complement c3 C3 NA unknown NA drugbank ac-i[cv(bta)qdwgahrc]t NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cv(bpa)qdwgahrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental complement c3 C3 NA inhibitor,ligand NA drugbank ac-i[cv(yphs)qdwgahrc]i-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-icv(1mew)qdwgahrct-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-icvwqdwgahrct-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cv(2igl)qdwgahrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvhqdwghhrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvyqdwgahrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD apl-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457] phase 3 complement c3 C3 Clinical trial target unknown 21.22 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement c3 C3 NA unknown NA drugbank ac-icv(5mew)qdwgahrct-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvwqdwg(abu)hrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD imprime pgg NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],melanoma[MeSHID:D008545],Cancer of Head and Neck[MeSHID:D006258],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of breast[MeSHID:D001943] phase 2/3 complement c3 C3 Clinical trial target unknown NA TTD amy-101 NA Gingivitis[MeSHID:D005891],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvwqdwgwhrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD pot-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268],Marijuana Abuse[MeSHID:D002189] phase 2 complement c3 C3 Clinical trial target unknown NA TTD , DGIDB cysteine sulfenic acid NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvwqdwgahrc]dt NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c3 C3 NA unknown NA drugbank ac-icvwqd(5fw)gahrct-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cv(1nal)qdwgahrc]t NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD s-hydroxycysteine small molecule NA experimental complement c3 C3 NA unknown NA drugbank human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational complement c3 C3 NA binder NA drugbank ac-i[cvwqdwghhrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvvqdwgahrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cv(2nal)qdwgahrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement c3 C3 NA unknown NA drugbank ac-i[cv(bpa)qdwgahrc]t NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cv(2igl)qdwgahrc]t NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cv(2nal)qdwgahrc]t NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD ac-i[cvtqdwghhrc]t-nh2 NA NA investigative complement c3 C3 Clinical trial target unknown NA TTD pmid25259874c4 NA NA investigative c3a anaphylatoxin chemotactic receptor C3AR1 Literature-reported target unknown NA TTD pmid25259874c21 NA NA investigative c3a anaphylatoxin chemotactic receptor C3AR1 Literature-reported target unknown NA TTD sb290157 NA NA investigative c3a anaphylatoxin chemotactic receptor C3AR1 Literature-reported target antagonist NA TTD , DGIDB human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational complement c4-a C4A NA binder NA drugbank human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational complement c4-b C4B NA binder NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational complement c4-b C4B NA modulator NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement c4-b C4B NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement c4-b C4B NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c4-b C4B NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental complement c4-b C4B NA modulator NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational c4b-binding protein alpha chain C4BPA NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational c4b-binding protein alpha chain C4BPA NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational c4b-binding protein alpha chain C4BPA NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental c4b-binding protein alpha chain C4BPA NA modulator NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational c4b-binding protein alpha chain C4BPA NA modulator NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental c4b-binding protein beta chain C4BPB NA modulator NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational c4b-binding protein beta chain C4BPB NA modulator NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational c4b-binding protein beta chain C4BPB NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational c4b-binding protein beta chain C4BPB NA unknown NA drugbank abp959 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457] phase 3 complement c5 C5 Successful target unknown NA TTD nnc-0151-0000-0000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 complement c5 C5 Successful target unknown NA TTD , DGIDB eculizumab biotech Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457],Atypical Hemolytic Uremic Syndrome[MeSHID:D065766],Neuromyelitis Optica[MeSHID:D009471],Hemolysis (disorder)[MeSHID:D006461],Cardiac Arrest[MeSHID:D006323],Thrombotic Microangiopathies[MeSHID:D057049],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c5 C5 NA antibody,inhibitor 45.47 drugbank , DGIDB eculizumab biotech Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457],Atypical Hemolytic Uremic Syndrome[MeSHID:D065766],Neuromyelitis Optica[MeSHID:D009471],Hemolysis (disorder)[MeSHID:D006461],Cardiac Arrest[MeSHID:D006323],Thrombotic Microangiopathies[MeSHID:D057049],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c5 C5 NA antibody 45.47 drugbank , DGIDB pexelizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] discontinued in phase 3 complement c5 C5 Successful target inhibitor 9.09 TTD , DGIDB tesidolumab NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 complement c5 C5 Successful target unknown NA TTD arc-1905 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 complement c5 C5 Successful target unknown 18.19 TTD , DGIDB ifx-1 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 complement c5 C5 Successful target unknown NA TTD , DGIDB zimura NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 3 complement c5 C5 Successful target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c5 C5 NA unknown NA drugbank ra101495 NA Myasthenia Gravis[MeSHID:D009157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457] phase 3 complement c5 C5 Successful target unknown 9.09 TTD , DGIDB ravulizumab biotech Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement c5 C5 Successful target inhibitor 9.09 TTD , drugbank , DGIDB eculizumab biotech Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457],Atypical Hemolytic Uremic Syndrome[MeSHID:D065766],Neuromyelitis Optica[MeSHID:D009471],Hemolysis (disorder)[MeSHID:D006461],Cardiac Arrest[MeSHID:D006323],Thrombotic Microangiopathies[MeSHID:D057049],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational complement c5 C5 NA antibody 45.47 drugbank , DGIDB ifx-1 NA Hidradenitis Suppurativa[MeSHID:D017497],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 complement c5 C5 Successful target unknown NA TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement c5 C5 NA unknown NA drugbank aln-cc5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemolytic-Uremic Syndrome[MeSHID:D006463] phase 2 c5 messenger rna C5 Clinical trial target unknown NA TTD cemdisiran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457],Hemolytic-Uremic Syndrome[MeSHID:D006463] phase 2 c5 messenger rna C5 Clinical trial target unknown NA TTD eculizumab biotech Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457],Atypical Hemolytic Uremic Syndrome[MeSHID:D065766],Neuromyelitis Optica[MeSHID:D009471],Hemolysis (disorder)[MeSHID:D006461],Cardiac Arrest[MeSHID:D006323],Thrombotic Microangiopathies[MeSHID:D057049],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational complement c5 C5 NA antibody,inhibitor 45.47 drugbank , DGIDB sb12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457] phase 3 complement c5 C5 Successful target unknown NA TTD sky59 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemolytic-Uremic Syndrome[MeSHID:D006463] phase 3 complement c5 C5 Successful target unknown NA TTD lfg-316 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 2 complement c5 C5 Successful target unknown 18.19 TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational complement c5 C5 NA ligand NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement c5 C5 NA unknown NA drugbank pozelimab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457] phase 2 complement c5 C5 Successful target unknown NA TTD human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational complement c5 C5 NA binder NA drugbank ravulizumab biotech Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational complement c5 C5 Successful target inhibitor 9.09 TTD , drugbank , DGIDB coversin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457] phase 3 complement c5 C5 Successful target unknown NA TTD rev-576 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 complement c5 C5 Successful target unknown 9.09 TTD , DGIDB vilobelimab biotech NA investigational complement c5 C5 NA inhibitor NA drugbank medi7814 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 complement c5 C5 Successful target unknown NA TTD , DGIDB sand-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glomerulonephritis[MeSHID:D005921] preclinical complement c5 C5 Successful target unknown NA TTD , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental complement c5 C5 NA ligand NA drugbank mp-435 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 complement c5 C5 Successful target unknown NA TTD nn8210 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1 c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target unknown NA TTD nn8209 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target unknown NA TTD w54011 NA NA investigative c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target antagonist NA TTD , DGIDB avacopan small molecule Microscopic Polyarteritis[MeSHID:D055953],Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis[MeSHID:D056648],Cytoplasm[MeSHID:D003593],Granulomatosis with polyangiitis[MeSHID:D014890],neutrophil[MeSHID:D009504] approved,investigational c5a anaphylatoxin chemotactic receptor 1 C5AR1 NA antagonist 63.65 drugbank , DGIDB ndt9520492 NA NA investigative c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target antagonist NA TTD , DGIDB pmx205 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target antagonist NA TTD , DGIDB ccx-168 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Granulomatosis with polyangiitis[MeSHID:D014890],Anemia, Hemolytic, Congenital[MeSHID:D000745],Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis[MeSHID:D056648],eosinophil[MeSHID:D004804],Eosinophilia[MeSHID:D004802] phase 3 c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target unknown 63.65 TTD , DGIDB pmx-53 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target unknown NA TTD , DGIDB rpr121154 NA NA investigative c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target antagonist NA TTD , DGIDB c5ar pepducins NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative c5a anaphylatoxin chemotactic receptor C5AR1 Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement component c8 alpha chain C8A NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement component c8 alpha chain C8A NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement component c8 beta chain C8B NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement component c8 beta chain C8B NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement component c8 beta chain C8B NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement component c8 gamma chain C8G NA unknown NA drugbank lauric acid small molecule NA approved,experimental complement component c8 gamma chain C8G NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement component c8 gamma chain C8G NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved complement component c8 gamma chain C8G NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement component c9 C9 NA unknown NA drugbank ionis-c9rx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690] phase 2 c9orf72 messenger rna C9orf72 Clinical trial target unknown NA TTD 4-amino-6-chlorobenzene-1,3-disulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 3-(3-phenyl-ureido)-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD hexane-1,6-diamine NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD nsc-654077 NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD chlorothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved carbonic anhydrase 1 CA1 NA inhibitor 1.57 drugbank , DGIDB phenyl boronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved carbonic anhydrase 1 CA1 NA inhibitor 0.16 drugbank , DGIDB aminobenzolamide derivative NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD phenoxyarsonous acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-azidobenzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn carbonic anhydrase 1 CA1 NA inhibitor NA drugbank 7-methoxy-2-oxo-2h-chromene-4-carboxylic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-mercapto-n-(4-sulfamoyl-phenyl)-benzamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfamic acid 7-sulfamoyloxy-heptyl ester NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD phenol NA Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Aphthous Stomatitis[MeSHID:D013281],Pharyngitis[MeSHID:D010612] phase 2/3 carbonic anhydrase i CA1 Successful target unknown 1.01 TTD , DGIDB ferulic acid NA NA patented carbonic anhydrase i CA1 Successful target unknown NA TTD , DGIDB cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 1 CA1 NA inhibitor NA drugbank n-(pentafluorophenyl)sulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD acetazolamide NA Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase i CA1 Successful target inhibitor 1.99 TTD , DGIDB dichlorphenamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved carbonic anhydrase i CA1 Successful target unknown 5.89 TTD , DGIDB ethoxzolamide NA Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] approved carbonic anhydrase i CA1 Successful target unknown 1.99 TTD , DGIDB paraoxon NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 5-hydroxy-1-tosyl-1h-pyrrol-2(5h)-one NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 3-mercapto-n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 3-bromophenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-oxo-2h-thiochromene-3-carboxylic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-acetamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD syringic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD methazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Angle Closure Glaucoma[MeSHID:D015812],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase 1 CA1 NA inhibitor 2.62 drugbank , DGIDB trichlormethiazide small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved carbonic anhydrase 1 CA1 NA inhibitor 1.96 drugbank , DGIDB n-(5-mercapto-[1,3,4]thiadiazol-2-yl)-acetamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD methocarbamol small molecule Pain[MeSHID:D010146],Rheumatism[MeSHID:D012216],Prescription procedure[MeSHID:D055656],Spasm[MeSHID:D013035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Diseases[MeSHID:D009140] approved,vet_approved carbonic anhydrase 1 CA1 NA inhibitor 1.41 drugbank , DGIDB l-693612 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD phenylsulfamate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4,4'-thiodipyridine-3-sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-morpholin-4-yl-n-(4-sulfamoyl-phenyl)-acetamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD thioureido sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD pentane-1,5-diamine NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 6-methyl-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-methyl-8-quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfamic acid 4-sulfamoyloxy-butyl ester NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD phenethylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 carbonic anhydrase i CA1 Successful target unknown 0.03 TTD , DGIDB decyl sulfamate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD dichlorphenamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved carbonic anhydrase i CA1 Successful target inhibitor 5.89 TTD , DGIDB 6-hydroxy-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-[2-(2-thienyl)acetamido]benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-hydroxysulfonamides NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD cyanate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-phenylacetamido)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4,6-dinitro salicylic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD brinzolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 1 CA1 NA inhibitor 1.41 drugbank , DGIDB 4-chloro-n-(5-sulfamoyl-indan-2-yl)-benzamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 1-pentafluorophenylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD diazoxide small molecule insulinoma[MeSHID:D007340],Neoplasm Metastasis[MeSHID:D009362],Hypoglycemia[MeSHID:D007003],Emergencies [Disease/Finding][MeSHID:D004630],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved carbonic anhydrase 1 CA1 NA inhibitor NA drugbank n-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-bromophenylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sodium trithiocarbonate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-ethynyl benzene sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 3-(4-sulfamoylphenyl)propanoic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 5-chlorosalicylic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-[2-(3-phenyl-ureido)-ethyl]-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 6-amino-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD herniarin NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 3-phenylprop-1-enylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-amino-3-iodo-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD catechin NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD beta-naphthylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-(4-sulfamoyl-phenyl)-benzamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD ethoxzolamide NA Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] approved carbonic anhydrase i CA1 Successful target inhibitor 1.99 TTD , DGIDB 5-oxo-1-tosyl-2,5-dihydro-1hpyrrol-2-yl acetate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD cl-5343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-isothiocyanatobenzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD (2-bromophenyl)difluoromethanesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD azide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD cynooxide anion NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfamic acid 16-sulfamoyloxy-hexadecyl ester NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD acetazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,vet_approved carbonic anhydrase 1 CA1 NA inhibitor 1.99 drugbank , DGIDB benzolamide NA NA investigative carbonic anhydrase i CA1 Successful target inhibitor 2.36 TTD , DGIDB amlodipine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 1 CA1 NA inhibitor NA drugbank chlorthalidone small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Renal Insufficiency[MeSHID:D051437],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Nephrotic Syndrome[MeSHID:D009404],Chronic Kidney Diseases[MeSHID:D051436],Kidney Failure, Chronic[MeSHID:D007676],Glomerulonephritis[MeSHID:D005921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 1 CA1 NA inhibitor 0.47 drugbank , DGIDB 3-chloro-4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 1-acetamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-benzenesulfonylamino-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD decane-1,10-diyl disulfamate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD dorzolamide small molecule Disease Management[MeSHID:D019468],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Eye[MeSHID:D005123],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 1 CA1 NA inhibitor 1.89 drugbank , DGIDB sodium sulfate small molecule Intestines[MeSHID:D007422],Roentgen Rays[MeSHID:D014965] approved,vet_approved carbonic anhydrase 1 CA1 NA inhibitor NA drugbank (4-bromophenyl)difluoromethanesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD coumarin NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-aminoethyl)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-propynylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2,3-dihydro-1h-indene-5-sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-nitrophenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfamic acid 12-sulfamoyloxy-dodecyl ester NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 1 CA1 NA inhibitor 1.02 drugbank , DGIDB 4-(2-pyridin-4-ylacetamido)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(4-fluorophenoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD biphenyl-4-ylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(n-oxide-2-pyridylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD quinethazone small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 1 CA1 NA inhibitor NA drugbank 4-methylthiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD phenylmethanesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD prop-2-ynyl 4-sulfamoylbenzoate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD [cu(cn)2]- NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-amino-3-chloro-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2,4-disulfamyltrifluoromethylaniline NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD phenyldifluoromethanesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 1-benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-butylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-pyridin-2-ylacetamido)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-propynyl amidebenzenesulphonide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-methoxyphenylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD hydrosulfide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD [au(cn)2]- NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD diclofenamide small molecule Glaucoma[MeSHID:D005901],Glaucoma, Open-Angle[MeSHID:D005902],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Angle Closure Glaucoma[MeSHID:D015812],Physiologic Intraocular Pressure[MeSHID:D007429] approved,investigational carbonic anhydrase 1 CA1 NA inhibitor 5.89 drugbank , DGIDB n-(4-cyanophenyl)sulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfamate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-[2-(2-thienyl)acetamidoethyl]benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD octane-1,8-diyl disulfamate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD ethinamate small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn carbonic anhydrase 1 CA1 NA inhibitor NA drugbank 4-methanesulfonylamino-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD methyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn carbonic anhydrase 1 CA1 NA inhibitor NA drugbank 1,4-dihydro-1-methyl-4-oxo-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD carzenide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-fluoro-n-(4-sulfamoylbenzyl)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-amino-3-fluoro-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-1,3,4-thiadiazol-2-ylsulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-phenoxyphenylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-cyclohexylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-methoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD ethoxzolamide small molecule Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] withdrawn carbonic anhydrase 1 CA1 NA inhibitor 1.99 drugbank , DGIDB 2-amino-indan-5-sulfonic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-butylphenylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD salicyclic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved carbonic anhydrase i CA1 Successful target unknown NA TTD , DGIDB 4-(2-phenylacetamido)-3-chlorobenzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-amino-3-bromo-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(4-cyanophenoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 5-amino-[1,3,4]thiadiazole-2-thiol NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(methylhydrazino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-acetylamino-indan-5-sulfonic acid hydrate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD paraben NA NA phase 3 carbonic anhydrase i CA1 Successful target unknown 0.34 TTD , DGIDB pentanoic acid (4-sulfamoyl-phenyl)-amide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA1 NA inhibitor NA drugbank 2-propylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(carbamolymethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD methazolamide NA Glaucoma, Open-Angle[MeSHID:D005902],Angle Closure Glaucoma[MeSHID:D015812],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase i CA1 Successful target unknown 2.62 TTD , DGIDB coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 carbonic anhydrase i CA1 Successful target unknown NA TTD , DGIDB benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 1 CA1 NA inhibitor NA drugbank 4-(hydroxymethyl)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-ethoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-hydrazino-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-{2-[4-(aminosulfonyl)phenyl]ethyl}acetamide small molecule NA experimental carbonic anhydrase 1 CA1 NA unknown NA drugbank 2-ethylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 1-cyclohexylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-hydroxycinnamic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD carbamoyl phosphate disodium NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD ethyl 3-[4-(aminosulfonyl)phenyl]propanoate small molecule NA experimental carbonic anhydrase 1 CA1 NA unknown NA drugbank ethyl 3-[4-(aminosulfonyl)phenyl]propanoate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-pentafluorophenylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD bendroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 1 CA1 NA inhibitor NA drugbank saccharin NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD iodide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD nitrate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 3-fluoro-4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2,4-dichloro-5-sulfamoylbenzoic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 3-phenyl-5-sulfamoyl-1h-indole-2-carboxamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sodium carbonate small molecule Solutions[MeSHID:D012996],Eczema[MeSHID:D004485],Dermatitis[MeSHID:D003872],Tinea[MeSHID:D014005],Emergencies [Disease/Finding][MeSHID:D004630] approved carbonic anhydrase 1 CA1 NA inhibitor NA drugbank 2-(4-chlorobenzyloxyamino)-n-hydroxypropanamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD cg-100649 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] phase 3 carbonic anhydrase i CA1 Successful target unknown 2.36 TTD , DGIDB cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA1 NA inhibitor NA drugbank 2,2,2-trifluoro-n-(4-sulfamoyl-phenyl)-acetamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 1-valproylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-methylstyrylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-(4-sulfamoyl-phenyl)-butyramide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfamic acid 6-sulfamoyloxy-hexyl ester NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD trecadrine NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 3-[4-(aminosulfonyl)phenyl]propanoic acid small molecule NA experimental carbonic anhydrase 1 CA1 NA unknown NA drugbank n-[4-(trifluoromethyl)phenyl]sulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-nonylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 1 CA1 NA inhibitor NA drugbank 4-(2-phenylacetamido)-3-fluorobenzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-benzythiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 6-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfamic acid 3-sulfamoyloxy-phenyl ester NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-methylphenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD octyl sulfamate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD styrylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD acetazolamide NA Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase i CA1 Successful target unknown 1.99 TTD , DGIDB methazolamide NA Glaucoma, Open-Angle[MeSHID:D005902],Angle Closure Glaucoma[MeSHID:D015812],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase i CA1 Successful target inhibitor 2.62 TTD , DGIDB 2-(4-chlorobenzyloxyamino)-n-hydroxyacetamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-hydrazinocarbonyl-benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD gallicacid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-phenylacetamidoethyl)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 8-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-nitrophenyl phosphate NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(5-methyl-2-pirazolino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(cyanomethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-phenylacetamidomethyl)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-amino-n-(4-sulfamoylbenzyl)benzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(2-phenylacetamido)-3-bromobenzenesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-(biphenyl-4-yl)vinylboronic acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-valproylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-hydroxysulfamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD n-{2-[4-(aminosulfonyl)phenyl]ethyl}acetamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 6-(aminomethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 2-(4-chlorobenzyloxyamino)-n-hydroxyhexanamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD 4-(allylamino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD p-coumaric acid NA NA investigative carbonic anhydrase i CA1 Successful target unknown NA TTD sulfamide NA NA phase 1 carbonic anhydrase i CA1 Successful target unknown 0.59 TTD , DGIDB ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative carbonic anhydrase i CA1 Successful target unknown NA TTD zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase-related protein 10 CA10 NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase-related protein 11 CA11 NA inhibitor NA drugbank 4-(4'-n-methylphenyl)diazenylbenzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 2-oxo-2h-thiochromene-3-carboxylic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD octane-1,8-diyl disulfamate NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD paraben NA NA phase 3 carbonic anhydrase xii CA12 Successful target unknown 0.76 TTD , DGIDB acetylsulfanilamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD acetazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,vet_approved carbonic anhydrase 12 CA12 NA inhibitor 1.63 drugbank , DGIDB n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-amino-3-fluoro-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-methoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 12 CA12 NA inhibitor 1.61 drugbank , DGIDB 2-amino-2,3-dihydro-1h-indene-5-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(n-methyl-hydrazino)-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 2,4-disulfamyltrifluoromethylaniline NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD saccharin NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 6-(aminomethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD sulfamylon NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase xii CA12 Successful target unknown 1.06 TTD , DGIDB 2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD cl-5343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n1-(2-aminoethyl)ethane-1,2-diamine NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n1-(naphthalen-1-yl)ethane-1,2-diamine NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(allylamino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD sodium n-methylphenylaminomethanesulfonate NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-benzythiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(carbamolymethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(2-hydroxy-ethyl)-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-[2-(3-phenyl-ureido)-ethyl]-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD pentane-1,5-diamine NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD octyl sulfamate NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD benzolamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD sodium phenylaminomethanesulfonate NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 6-(hydroxymethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 6-hydroxy-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 7-propoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-methanesulfonylamino-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4,4'-thiodipyridine-3-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD ethyl 7-methoxy-2-oxo-2h-chromene-3-carboxylate NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD resorcinol NA Seborrheic dermatitis[MeSHID:D012628],Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Acne Vulgaris[MeSHID:D000152] investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(2-propynylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(2-aminoethyl)benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(n-oxide-2-pyridylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(4-fluorophenoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD thioureido sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(5-methyl-2-pirazolino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 3-amino-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 3-((4-aminophenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD hexane-1,6-diamine NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-hydrazino-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-benzenesulfonylamino-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n-(pentafluorophenyl)sulfamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 7-(benzyloxy)-2h-chromen-2-one NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-amino-3-iodo-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n-(4-sulfamoyl-phenyl)-isobutyramide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 7-phenethoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-methylamino-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 2-amino-indan-5-sulfonic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n-propynyl amidebenzenesulphonide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD coumarin NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD ferulic acid NA NA patented carbonic anhydrase xii CA12 Successful target unknown NA TTD , DGIDB ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 3-(4'-hydroxyphenyl)diazenylbenzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD carzenide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n-hydroxysulfamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 12 CA12 NA inhibitor NA drugbank 4-amino-3-bromo-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 2-amino-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD catechol NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 12 CA12 NA inhibitor NA drugbank 6-methyl-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD decyl sulfamate NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 7-butoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(methylhydrazino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD gallicacid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD p-coumaric acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(2-methyl-8-quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD ethoxycoumarin NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n-(4-cyanophenyl)sulfamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-ethoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD catechin NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 carbonic anhydrase xii CA12 Successful target unknown NA TTD , DGIDB 4-(4-cyanophenoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n-(4-sulfamoyl-phenyl)-benzamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD phenol NA Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Aphthous Stomatitis[MeSHID:D013281],Pharyngitis[MeSHID:D010612] phase 2/3 carbonic anhydrase xii CA12 Successful target unknown 0.76 TTD , DGIDB 6-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-cyanophenol NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(cyanomethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD decane-1,10-diyl disulfamate NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 2,3-dihydro-1h-indene-5-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 3-(3-phenyl-ureido)-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 1,4-dihydro-1-methyl-4-oxo-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 1-benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD p-toluenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-amino-3-chloro-benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD syringic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 carbonic anhydrase xii CA12 Successful target unknown 0.07 TTD , DGIDB 2-hydrazinylbenzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD herniarin NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 2-acetamido-2,3-dihydro-1h-indene-5-sulfonic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(hydroxymethyl)benzenesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn carbonic anhydrase 12 CA12 NA inhibitor NA drugbank n-(4-sulfamoyl-phenyl)-butyramide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD salicyclic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved carbonic anhydrase xii CA12 Successful target unknown NA TTD , DGIDB pentanoic acid (4-sulfamoyl-phenyl)-amide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 7-methoxy-2-oxo-2h-chromene-4-carboxylic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 2,2-dimethyl-n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-(quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 8-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 4-methylthiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD 2,2,2-trifluoro-n-(4-sulfamoyl-phenyl)-acetamide NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD prop-2-ynyl 4-sulfamoylbenzoate NA NA investigative carbonic anhydrase xii CA12 Successful target unknown NA TTD n-(4-chlorobenzyl)-n-methylbenzene-1,4-disulfonamide small molecule NA experimental carbonic anhydrase 13 CA13 NA unknown NA drugbank benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA13 NA inhibitor NA drugbank cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA13 NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 13 CA13 NA inhibitor NA drugbank pentane-1,5-diamine NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD resorcinol NA Seborrheic dermatitis[MeSHID:D012628],Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Acne Vulgaris[MeSHID:D000152] investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA14 NA inhibitor NA drugbank ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 14 CA14 NA inhibitor NA drugbank 2,4-disulfamyltrifluoromethylaniline NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-amino-3-fluoro-benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 carbonic anhydrase xiv CA14 Successful target unknown 0.07 TTD , DGIDB ferulic acid NA NA patented carbonic anhydrase xiv CA14 Successful target unknown NA TTD , DGIDB ethoxycoumarin NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(methylhydrazino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD cl-5343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD catechin NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD p-coumaric acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 6-methyl-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 2-amino-indan-5-sulfonic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD paraben NA NA phase 3 carbonic anhydrase xiv CA14 Successful target unknown 0.76 TTD , DGIDB 2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(2-hydroxy-ethyl)-benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4,4'-thiodipyridine-3-sulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD herniarin NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD sulfamylon NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase xiv CA14 Successful target unknown 1.06 TTD , DGIDB syringic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-amino-3-chloro-benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD n1-(naphthalen-1-yl)ethane-1,2-diamine NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD carzenide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(carbamolymethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 8-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD octyl sulfamate NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD hexane-1,6-diamine NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD ethyl 7-methoxy-2-oxo-2h-chromene-3-carboxylate NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD coumarin NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-aminophenol NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD prop-2-ynyl 4-sulfamoylbenzoate NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 14 CA14 NA inhibitor NA drugbank phenol NA Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Aphthous Stomatitis[MeSHID:D013281],Pharyngitis[MeSHID:D010612] phase 2/3 carbonic anhydrase xiv CA14 Successful target unknown 0.76 TTD , DGIDB benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA14 NA inhibitor NA drugbank 4-(2-aminoethyl)benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(allylamino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-amino-3-iodo-benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 6-hydroxy-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 7-phenethoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(2-propynylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 2-acetamido-2,3-dihydro-1h-indene-5-sulfonic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD decane-1,10-diyl disulfamate NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-methylthiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(hydroxymethyl)benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 7-methoxy-2-oxo-2h-chromene-4-carboxylic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 7-propoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 3-amino-benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 7-(benzyloxy)-2h-chromen-2-one NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-hydrazino-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD trientine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inborn Errors of Metabolism[MeSHID:D008661] approved carbonic anhydrase xiv CA14 Successful target unknown 5.3 TTD , DGIDB 6-(aminomethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(5-methyl-2-pirazolino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 carbonic anhydrase xiv CA14 Successful target unknown NA TTD , DGIDB beta-d-mannose NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD benzolamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(2-methyl-8-quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD acetazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,vet_approved carbonic anhydrase 14 CA14 NA inhibitor 0.82 drugbank , DGIDB 6-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 2-oxo-2h-thiochromene-3-carboxylic acid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 6-(hydroxymethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 2-amino-benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD n-propynyl amidebenzenesulphonide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 2,3-dihydro-1h-indene-5-sulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-benzythiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-(cyanomethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-amino-3-bromo-benzenesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD decyl sulfamate NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 7-butoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 2-amino-2,3-dihydro-1h-indene-5-sulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 4-ethoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD n1-(2-aminoethyl)ethane-1,2-diamine NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD gallicacid NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD octane-1,8-diyl disulfamate NA NA investigative carbonic anhydrase xiv CA14 Successful target unknown NA TTD 2-hydrazinylbenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4,6-dinitro salicylic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-sulfhydryl-ethanol NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al6528 small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank al7099a NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-chloro-n-(5-sulfamoyl-indan-2-yl)-benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 2 CA2 NA inhibitor 1.04 drugbank , DGIDB 2-sulfamoyl-benzoic acid methyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-amino-3-chloro-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD butylatedhydroxytoluene NA NA phase 1 carbonic anhydrase ii CA2 Successful target unknown NA TTD , DGIDB n-(2,6-diflouro-benzyl)-4-sulfamoyl-benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-phenylacetamidoethyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-amino-indan-5-sulfonic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ethoxzolamide NA Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] approved carbonic anhydrase ii CA2 Successful target inhibitor 0.64 TTD , DGIDB 6-chloro-3-(dichloromethyl)-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-[2-(2-thienyl)acetamido]benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD trecadrine NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(benzylideneamino)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD cl-5343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-methyl-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-methoxyestradiol-17-o-sulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-methyl-8-quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 3,5-difluorobenzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 3-amino-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-amino-3-fluoro-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-morpholin-4-yl-n-(4-sulfamoyl-phenyl)-acetamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2,6-difluorobenzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 3-phenyl-5-sulfamoyl-1h-indole-2-carboxamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-sulfonamide-[1-(4-aminobutane)]benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank paraben NA NA phase 3 carbonic anhydrase ii CA2 Successful target unknown 0.4 TTD , DGIDB n-{2-[4-(aminosulfonyl)phenyl]ethyl}acetamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (17beta)-17-(cyanomethyl)-2-methoxyestra-1(10),2,4-trien-3-yl sulfamate small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank pentanoic acid (4-sulfamoyl-phenyl)-amide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-(4-chlorobenzyloxyamino)-n-hydroxyhexanamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-[(4-o-sulfamoylbenzyl)(4-cyanophenyl)amino]-4h-[1,2,4]-triazole small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank saccharin NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(benzylideneamino)benzoic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD phenylmethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD nsc-654077 NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2,6-di-t-butylphenol NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-amino-n-(4-sulfamoylbenzyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamic acid 6-sulfamoyloxy-hexyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(aminosulfonyl)-n-[(4-fluorophenyl)methyl]-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-(4-cyanophenoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-oxo-2h-thiochromene-3-carboxylic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(hydroxymethyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD acetylsulfanilamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-hydrazino-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD dichlorphenamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved carbonic anhydrase ii CA2 Successful target unknown 2.08 TTD , DGIDB 4-nitrophenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-phenylacetamido)-3-bromobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (4-bromophenyl)difluoromethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-aminoethyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD iodide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-mercuri-4-aminobenzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 3-(3-phenyl-ureido)-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-hydroxy-1,3-benzothiazole-2-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD prontocil NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(n-methyl-hydrazino)-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(carbamolymethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamylon NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase ii CA2 Successful target unknown 0.55 TTD , DGIDB 4-methylimidazole NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-methoxyphenylsulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD dansylamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 2-(4-chlorobenzyloxyamino)-n-hydroxyacetamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-(cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank acetazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,vet_approved carbonic anhydrase 2 CA2 NA inhibitor 1.06 drugbank , DGIDB n-hydroxysulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-benzythiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2,2,2-trifluoro-n-(4-sulfamoyl-phenyl)-acetamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (s)-n-(3-indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank al6528 NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(hydroxymercury)benzoic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(2,3-difluoro-benzyl)-4-sulfamoyl-benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-[4-(trifluoromethyl)phenyl]sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ethinamate NA Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase ii CA2 Successful target unknown 8.3 TTD , DGIDB 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD salicyclic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved carbonic anhydrase ii CA2 Successful target unknown NA TTD , DGIDB sulfamic acid 7-sulfamoyloxy-heptyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved carbonic anhydrase 2 CA2 NA inhibitor 0.51 drugbank , DGIDB celecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational carbonic anhydrase 2 CA2 NA inhibitor NA drugbank 4-methylamino-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-hydroxybenzo[d][1,3]oxathiol-2-one NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(4-fluorophenoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 5-hydroxy-1-tosyl-1h-pyrrol-2(5h)-one NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sodium carbonate small molecule Solutions[MeSHID:D012996],Eczema[MeSHID:D004485],Dermatitis[MeSHID:D003872],Tinea[MeSHID:D014005],Emergencies [Disease/Finding][MeSHID:D004630] approved carbonic anhydrase 2 CA2 NA inhibitor NA drugbank n-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(n-oxide-2-pyridylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-[4-(aminosulfonyl)phenyl]-2-mercaptobenzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 1-methyl-3-oxo-1,3-dihydro-benzo[c]isothiazole-5-sulfonic acid amide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank methyl 4-(4-tert-butylbenzylideneamino)benzoate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD methyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn carbonic anhydrase 2 CA2 NA inhibitor NA drugbank bendroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 2 CA2 NA inhibitor NA drugbank n-(2,3,4,5,6-pentaflouro-benzyl)-4-sulfamoyl-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank phenyl-phosphonic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD resorcinol NA Seborrheic dermatitis[MeSHID:D012628],Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Acne Vulgaris[MeSHID:D000152] investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD trichlormethiazide small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved carbonic anhydrase 2 CA2 NA inhibitor 2.31 drugbank , DGIDB n-benzyl-4-sulfamoyl-benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-amino-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 1-pentafluorophenylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al4623 NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ethoxzolamide NA Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] approved carbonic anhydrase ii CA2 Successful target unknown 0.64 TTD , DGIDB mmi270 NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al5300 small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 2-(benzylideneamino)ethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-[2-(3-phenyl-ureido)-ethyl]-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD aminobenzolamide derivative NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamic acid 16-sulfamoyloxy-hexadecyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (9beta,13alpha,14beta,17alpha)-2-methoxyestra-1,3,5(10)-triene-3,17-diyl disulfamate small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-(2-hydroxy-ethyl)-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2,6-di-tert-butyl-4-methoxyphenol NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 1,2,4-triazole small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank benzolamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD di(2,6-diisopropylphenol) NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-valproylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ferulic acid NA NA patented carbonic anhydrase ii CA2 Successful target unknown NA TTD , DGIDB (r)-n-(3-indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank benzthiazide NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase ii CA2 Successful target unknown 2.77 TTD , DGIDB 4-sulfonamide-[1-(4-aminobutane)]benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-((4-aminophenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al7089a NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ethinamate small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn carbonic anhydrase 2 CA2 NA inhibitor 8.3 drugbank , DGIDB 2-(4-chlorobenzyloxyamino)-n-hydroxypropanamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD cyanamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank al7099a small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-(aminosulfonyl)-n-[(3,4,5-trifluorophenyl)methyl]-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank dorzolamide NA Disease Management[MeSHID:D019468],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Eye[MeSHID:D005123],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase ii CA2 Successful target unknown 6.64 TTD , DGIDB n-benzyl-4-sulfamoyl-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-methylthiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-({[(4-methylpiperazin-1-yl)amino]carbonothioyl}amino)benzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank phenethylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-sulfonamide-[4-(thiomethylaminobutane)]benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank sulthiame NA NA phase 3 carbonic anhydrase ii CA2 Successful target unknown 5.53 TTD , DGIDB 4-hydrazinocarbonyl-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2,4-dichloro-5-sulfamoylbenzoic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-(aminosulfonyl)-n-[(2,4-difluorophenyl)methyl]-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 3-nitro-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD cg-100649 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] phase 3 carbonic anhydrase ii CA2 Successful target unknown 1.84 TTD , DGIDB sodium sulfate small molecule Intestines[MeSHID:D007422],Roentgen Rays[MeSHID:D014965] approved,vet_approved carbonic anhydrase 2 CA2 NA inhibitor NA drugbank catechol NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD gallicacid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(methylhydrazino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD paraoxon NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-pentafluorophenylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sodium perfluorohexanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2,2-dimethyl-n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-phenylprop-1-enylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA2 NA inhibitor 1.04 drugbank , DGIDB 4-(5-methyl-2-pirazolino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD chlorothiazide NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase ii CA2 Successful target unknown 3.23 TTD , DGIDB diazoxide small molecule insulinoma[MeSHID:D007340],Neoplasm Metastasis[MeSHID:D009362],Hypoglycemia[MeSHID:D007003],Emergencies [Disease/Finding][MeSHID:D004630],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved carbonic anhydrase 2 CA2 NA inhibitor NA drugbank guaiacol NA Cell Proliferation[MeSHID:D049109],Dental Pulp[MeSHID:D003782] phase 3 carbonic anhydrase ii CA2 Successful target unknown 2.77 TTD , DGIDB acetate ion NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD p-coumaric acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al-6629, [2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide,2-(3-methoxyphenyl)-3-(4-morpholinyl)-, 1,1-dioxide] small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 5-chlorosalicylic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD brinzolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 2 CA2 NA inhibitor 5.53 drugbank , DGIDB p-toluenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-mercapto-n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-benzenesulfonylamino-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-butylphenylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-1,3,4-thiadiazol-2-ylsulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-phenylacetamido)-3-chlorobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-hydroxy-1,3-benzothiazole-2-sulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank n-(1-benzofuran-3-ylmethyl)sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-methoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD thioureido sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (2-bromophenyl)difluoromethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(5-mercapto-[1,3,4]thiadiazol-2-yl)-acetamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD octane-1,8-diyl disulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD di(2,6-dimethylphenol) NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD phenylalanylaminodi(ethyloxy)ethyl benzenesulfonamideaminocarbonylbenzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-cyanophenol NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-(1,3-thiazol-4-yl)-1h-benzimidazole-5-sulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 1-pentenyl-4-(aminosulfonyl)benzoate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(2-flouro-benzyl)-4-sulfamoyl-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 1-n-(4-sulfamoylphenyl-ethyl)-2,4,6-trimethylpyridinium small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 1,4-dihydro-1-methyl-4-oxo-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD beta-naphthylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-[(2r)-5-(aminosulfonyl)-2,3-dihydro-1h-inden-2-yl]-2-propylpentanamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank phenoxyarsonous acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 1-cyclohexylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-methanesulfonylamino-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-mercapto-n-(4-sulfamoyl-phenyl)-benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(4-tert-butylbenzylideneamino)benzoic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-(4-sulfamoylphenyl)propanoic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-nitrophenyl phosphate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-(4'-hydroxyphenyl)diazenylbenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-(4-tert-butylbenzylideneamino)ethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD aminodi(ethyloxy)ethylaminocarbonylbenzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank n-(4-cyanophenyl)sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD formic acid small molecule NA experimental,investigational carbonic anhydrase 2 CA2 NA unknown NA drugbank ethoxzolamide small molecule Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] withdrawn carbonic anhydrase 2 CA2 NA inhibitor 0.64 drugbank , DGIDB n-hydroxysulfonamides NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD dichlorphenamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved carbonic anhydrase ii CA2 Successful target inhibitor 2.08 TTD , DGIDB syringic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-{2-[4-(aminosulfonyl)phenyl]ethyl}acetamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-flourobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(aminosulfonyl)-n-[(2,3,4-trifluorophenyl)methyl]-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 1-benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 1,2,4-triazole NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 1,4-phenylene disulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamic acid 12-sulfamoyloxy-dodecyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD phenol NA Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Aphthous Stomatitis[MeSHID:D013281],Pharyngitis[MeSHID:D010612] phase 2/3 carbonic anhydrase ii CA2 Successful target unknown 0.4 TTD , DGIDB n-(pentafluorophenyl)sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(4-hydroxybenzylideneamino)benzoic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(4-sulfamoyl-phenyl)-benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD methyl mercury ion NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD nitrate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD phenyldifluoromethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD cyclothiazide NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase ii CA2 Successful target unknown 1.04 TTD , DGIDB 2-(n''-acetyl-hydrazino)-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamic acid benzo[1,3]dioxol-2-ylmethyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD irosustat small molecule NA investigational carbonic anhydrase 2 CA2 NA unknown NA drugbank thiophene-2,5-disulfonic acid 2-amide-5-(4-methyl-benzylamide) small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-phenoxyphenylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-(hydroxymethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(allylamino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-[(3-bromo-4-o-sulfamoylbenzyl)(4-cyanophenyl)amino]-4h-[1,2,4]-triazole small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank sulfamic acid chroman-2-ylmethyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulpiride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 2 CA2 NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 2 CA2 NA inhibitor NA drugbank 4-amino-3-bromo-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(phosphonacetyl)-l-aspartate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 1-(3,4-dichlorophenyl)-3-hydroxyurea NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD decane-1,10-diyl disulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2,6-difluorobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-azidobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-hydroxy-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulthiame small molecule NA approved carbonic anhydrase 2 CA2 NA unknown 5.53 drugbank , DGIDB 2-(benzyloxyamino)-n-hydroxyhexanamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD carzenide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(aminosulfonyl)-n-[(2,5-difluorophenyl)methyl]-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-amino-6-chlorobenzene-1,3-disulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-({[4-(aminosulfonyl)phenyl]amino}carbonyl)-4-methylbenzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4,4'-thiodipyridine-3-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA2 NA inhibitor 2.77 drugbank , DGIDB 4-(cyanomethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-methylimidazole small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank n-(2,6-diflouro-benzyl)-4-sulfamoyl-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 carbonic anhydrase ii CA2 Successful target unknown 0.04 TTD , DGIDB azide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD furosemide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Nephrotic Syndrome[MeSHID:D009404],Diuresis[MeSHID:D004231],Pulmonary Edema[MeSHID:D011654],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved carbonic anhydrase 2 CA2 NA inhibitor NA drugbank diclofenamide small molecule Glaucoma[MeSHID:D005901],Glaucoma, Open-Angle[MeSHID:D005902],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Angle Closure Glaucoma[MeSHID:D015812],Physiologic Intraocular Pressure[MeSHID:D007429] approved,investigational carbonic anhydrase 2 CA2 NA inhibitor NA drugbank 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD emate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-cyclohexylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ethyl 3-[4-(aminosulfonyl)phenyl]propanoate small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-thiocyanato-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamic acid 4-sulfamoyloxy-butyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD phenylsulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-methylphenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD prop-2-ynyl 4-sulfamoylbenzoate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-chloro-5-[(1s)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank n-(2-flouro-benzyl)-4-sulfamoyl-benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-bromophenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD di(2,6-di-t-butylphenol) NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 5-amino-[1,3,4]thiadiazole-2-thiol NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-flourobenzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank dorzolamide small molecule Disease Management[MeSHID:D019468],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Eye[MeSHID:D005123],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 2 CA2 NA inhibitor 6.64 drugbank , DGIDB chlorothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved carbonic anhydrase 2 CA2 NA inhibitor 3.23 drugbank , DGIDB n-(4-sulfamoyl-phenyl)-isobutyramide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-hydroxy-2-methoxybenzaldehyde NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-nitro-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-propynyl amidebenzenesulphonide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD urea small molecule Catabolism[MeSHID:D008660],Disease[MeSHID:D004194],Nail plate[MeSHID:D009262],patient care[MeSHID:D005791],Proteolysis[MeSHID:D059748],Lanugo[MeSHID:D006197],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved,investigational carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-[2-(2-thienyl)acetamidoethyl]benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ethyl 3-[4-(aminosulfonyl)phenyl]propanoate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-[2-(1h-indol-5-yl)-butyl]-4-sulfamoyl-benzamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 2 CA2 NA inhibitor 2.77 drugbank , DGIDB al5424 NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-pyridin-4-ylacetamido)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-aminoethyl)benzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 2-hydrazinocarbonyl-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD stx-140 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 carbonic anhydrase ii CA2 Successful target unknown NA TTD , DGIDB n-(2-thienylmethyl)-2,5-thiophenedisulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD allyl 4-(aminosulfonyl)benzoate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD octyl sulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD methyl 4-(4-hydroxybenzylideneamino)benzoate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 5-{[(4-amino-3-chloro-5-fluorophenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank (4s-trans)-4-(methylamino)-5,6-dihydro-6-methyl-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 3-chloro-4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD valdecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn carbonic anhydrase 2 CA2 NA inhibitor NA drugbank al5927 small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-(2-propynylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-amino-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamic acid 4-sulfamoyloxymethyl-benzyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al-4623 small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank al-6619, [2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide,2-(3-hydroxyphenyl)-3-(4-morpholinyl)-, 1,1-dioxide] small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank sulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD methazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Angle Closure Glaucoma[MeSHID:D015812],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase 2 CA2 NA inhibitor 0.61 drugbank , DGIDB p-hydroxymercuribenzoic acid small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank mercuribenzoic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-hydroxycinnamic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-phenylacetamidomethyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (4as,4br,10bs,12as)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 3-mercuri-4-aminobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-nitrophenylsulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD hydrosulfide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-((benzylideneamino)methyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD coumarin NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD dansylamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2,4-disulfamyltrifluoromethylaniline NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al5300 NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (s)-indapamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank biphenyl-4-ylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3,5-difluorobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 6-(aminomethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 1-acetamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al5424 small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-bromophenylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-(hydrazinocarbonyl)-3-phenyl-1h-indole-5-sulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-fluoro-n-(4-sulfamoylbenzyl)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn carbonic anhydrase 2 CA2 NA inhibitor NA drugbank 2-propylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD mercuribenzoic acid small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-amino-3-iodo-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD quinethazone small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 2 CA2 NA inhibitor NA drugbank 4-methoxyphenylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-ethynyl benzene sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-acetamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(4-sulfamoyl-phenyl)-butyramide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-butylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-(2,3-difluoro-benzyl)-4-sulfamoyl-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank al7182 small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank sulfamic acid 3-sulfamoyloxy-phenyl ester NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD phenylsulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-acetylamino-indan-5-sulfonic acid hydrate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamide NA NA phase 1 carbonic anhydrase ii CA2 Successful target unknown 0.69 TTD , DGIDB n-(2-thienylmethyl)-2,5-thiophenedisulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 3-[4-(aminosulfonyl)phenyl]propanoic acid small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 4-(2-pyridin-2-ylacetamido)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD al7182 NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-phenylacetamido)-3-fluorobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD phenyl boronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD n-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD quinoline-8-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD catechin NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(aminosulfonyl)-n-[(2,4,6-trifluorophenyl)methyl]-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank n-[2-(1h-indol-5-yl)-butyl]-4-sulfamoyl-benzamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank 6-nitro-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-(2-phenylacetamido)benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-(4-hydroxybenzylideneamino)ethanesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-methoxyestrrone-3-o-sulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-ethoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-isothiocyanatobenzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD indane-5-sulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank n-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 3-nitro-4-(2-oxo-pyrrolidin-1-yl)-benzenesulfonamide small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank al7089a small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank al5927 NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD (4-sulfamoyl-phenyl)-thiocarbamic acid o-(2-thiophen-3-yl-ethyl) ester small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank formic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sodium 2,3,5,6-tetrafluorobenzoate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 carbonic anhydrase ii CA2 Successful target unknown NA TTD , DGIDB 3-fluoro-4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 2 CA2 NA inhibitor NA drugbank 2,3-dihydro-1h-indene-5-sulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD pentane-1,5-diamine NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sulfamic acid 2,3-o-(1-methylethylidene)-4,5-o-sulfonyl-beta-fructopyranose ester small molecule NA experimental carbonic anhydrase 2 CA2 NA unknown NA drugbank p-tolylboronic acid NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD decyl sulfamate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD sodium trithiocarbonate NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-ethylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 1-valproylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD 2-nonylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ii CA2 Successful target unknown NA TTD acetazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,vet_approved carbonic anhydrase 3 CA3 NA inhibitor 4.9 drugbank , DGIDB celecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational carbonic anhydrase 3 CA3 NA inhibitor NA drugbank diclofenamide small molecule Glaucoma[MeSHID:D005901],Glaucoma, Open-Angle[MeSHID:D005902],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Angle Closure Glaucoma[MeSHID:D015812],Physiologic Intraocular Pressure[MeSHID:D007429] approved,investigational carbonic anhydrase 3 CA3 NA inhibitor NA drugbank sulpiride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 3 CA3 NA inhibitor NA drugbank dorzolamide small molecule Disease Management[MeSHID:D019468],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Eye[MeSHID:D005123],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 3 CA3 NA inhibitor NA drugbank cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA3 NA inhibitor NA drugbank ethoxzolamide small molecule Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] withdrawn carbonic anhydrase 3 CA3 NA inhibitor 3.26 drugbank , DGIDB ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 3 CA3 NA inhibitor NA drugbank methazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Angle Closure Glaucoma[MeSHID:D015812],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase 3 CA3 NA inhibitor NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved carbonic anhydrase 3 CA3 NA inhibitor NA drugbank valdecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn carbonic anhydrase 3 CA3 NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 3 CA3 NA inhibitor NA drugbank benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA3 NA inhibitor NA drugbank brinzolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 3 CA3 NA inhibitor NA drugbank saccharin small molecule NA investigational carbonic anhydrase 3 CA3 NA inhibitor NA drugbank n-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD catechol NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD n-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD n-hydroxysulfonamides NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD sodium carbonate small molecule Solutions[MeSHID:D012996],Eczema[MeSHID:D004485],Dermatitis[MeSHID:D003872],Tinea[MeSHID:D014005],Emergencies [Disease/Finding][MeSHID:D004630] approved carbonic anhydrase 4 CA4 NA inhibitor NA drugbank ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD benzolamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD syl-040003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD carbamoyl phosphate disodium NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD n-1,3,4-thiadiazol-2-ylsulfamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD sodium trithiocarbonate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 2-propyl-pentanoic acid 4-sulfamoyl-benzyl ester NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD n1-(naphthalen-1-yl)ethane-1,2-diamine NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD bendroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 4 CA4 NA inhibitor NA drugbank benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 4 CA4 NA inhibitor NA drugbank gallicacid NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD coumarin NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 6-methyl-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD aminocarbonyl dihydrogen phosphate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 4-amino-3-iodo-benzenesulfonamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD catechin NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD methyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn carbonic anhydrase 4 CA4 NA inhibitor NA drugbank sodium pyruvate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1/2 carbonic anhydrase iv CA4 Successful target unknown NA TTD , DGIDB trisodium phosphate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD decane-1,10-diyl disulfamate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 2-propyl-pentanoic acid 4-sulfamoyl-benzylamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD octane-1,8-diyl disulfamate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD p-coumaric acid NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 4-amino-3-fluoro-benzenesulfonamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD syringic acid NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD [fe(cn)6]4- NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA4 NA inhibitor NA drugbank ferulic acid NA NA patented carbonic anhydrase iv CA4 Successful target unknown NA TTD , DGIDB n-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD dorzolamide small molecule Disease Management[MeSHID:D019468],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Eye[MeSHID:D005123],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 4 CA4 NA inhibitor NA drugbank sulfamate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD diclofenamide small molecule Glaucoma[MeSHID:D005901],Glaucoma, Open-Angle[MeSHID:D005902],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Angle Closure Glaucoma[MeSHID:D015812],Physiologic Intraocular Pressure[MeSHID:D007429] approved,investigational carbonic anhydrase 4 CA4 NA inhibitor 3.18 drugbank , DGIDB ethoxzolamide small molecule Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] withdrawn carbonic anhydrase 4 CA4 NA inhibitor 0.65 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 4 CA4 NA inhibitor NA drugbank paraben NA NA phase 3 carbonic anhydrase iv CA4 Successful target unknown 0.61 TTD , DGIDB 1-(3,4-dichlorophenyl)-3-hydroxyurea NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 4-amino-3-bromo-benzenesulfonamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD brinzolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 4 CA4 NA inhibitor 1.7 drugbank , DGIDB sulfamylon NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase iv CA4 Successful target unknown 0.85 TTD , DGIDB curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 carbonic anhydrase iv CA4 Successful target unknown 0.06 TTD , DGIDB 6-(aminomethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD methazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Angle Closure Glaucoma[MeSHID:D015812],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase 4 CA4 NA inhibitor 1.41 drugbank , DGIDB phenyl-phosphonic acid NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD n-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD decyl sulfamate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD trichlormethiazide small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved carbonic anhydrase 4 CA4 NA inhibitor 3.54 drugbank , DGIDB n-(phosphonacetyl)-l-aspartate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD brinzolamide NA Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase iv CA4 Successful target unknown 1.7 TTD , DGIDB n-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD phenyl boronic acid NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD octyl sulfamate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD sodium phenylarsonate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD salicyclic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved carbonic anhydrase iv CA4 Successful target unknown NA TTD , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved carbonic anhydrase 4 CA4 NA inhibitor 0.79 drugbank , DGIDB ethyl 7-methoxy-2-oxo-2h-chromene-3-carboxylate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD trecadrine NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD sodium sulfamate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD hexane-1,6-diamine NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA4 NA inhibitor NA drugbank pentane-1,5-diamine NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD cl-5343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD herniarin NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 carbonic anhydrase iv CA4 Successful target unknown NA TTD , DGIDB 2,4-disulfamyltrifluoromethylaniline NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 6-(hydroxymethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 4-amino-3-chloro-benzenesulfonamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD phenylarsonic acid NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD phenol NA Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Aphthous Stomatitis[MeSHID:D013281],Pharyngitis[MeSHID:D010612] phase 2/3 carbonic anhydrase iv CA4 Successful target unknown 0.61 TTD , DGIDB 3-amino-benzenesulfonamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD acetazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,vet_approved carbonic anhydrase 4 CA4 NA inhibitor 1.31 drugbank , DGIDB n-(5-sulfamoyl-[1,3,4]thiadiazol-2-yl)-benzamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD malonate sodium NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD sodium citrate NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn carbonic anhydrase 4 CA4 NA inhibitor NA drugbank 7-(benzyloxy)-2h-chromen-2-one NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD sodium phosphate, dibasic, anhydrous NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 4 CA4 NA inhibitor NA drugbank [cu(cn)2]- NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD 4-(2-aminoethyl)benzenesulfonamide NA NA investigative carbonic anhydrase iv CA4 Successful target unknown NA TTD sulfamide NA NA phase 1 carbonic anhydrase iv CA4 Successful target unknown 1.06 TTD , DGIDB cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA5A NA inhibitor NA drugbank benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA5A NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 5a, mitochondrial CA5A NA inhibitor NA drugbank ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 5a, mitochondrial CA5A NA inhibitor NA drugbank 4-methylimidazole small molecule NA experimental carbonic anhydrase 5a, mitochondrial CA5A NA unknown NA drugbank brinzolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 5a, mitochondrial CA5A NA inhibitor NA drugbank cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA5B NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 5b, mitochondrial CA5B NA inhibitor NA drugbank benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA5B NA inhibitor NA drugbank ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 5b, mitochondrial CA5B NA inhibitor NA drugbank pentane-1,5-diamine NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 4-amino-6-chlorobenzene-1,3-disulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD decyl sulfamate NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD salicyclic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved carbonic anhydrase vi CA6 Successful target unknown NA TTD , DGIDB benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA6 NA inhibitor NA drugbank ethyl 7-methoxy-2-oxo-2h-chromene-3-carboxylate NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD coumarin NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD cl-5343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 4-amino-3-iodo-benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD octyl sulfamate NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD syringic acid NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD herniarin NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 4-amino-3-fluoro-benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD sar566658 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 carbonic anhydrase vi CA6 Successful target unknown 6.37 TTD , DGIDB coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 carbonic anhydrase vi CA6 Successful target unknown NA TTD , DGIDB 4-amino-3-chloro-benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 2-hydrazinylbenzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 7-butoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 4-(2-hydroxy-ethyl)-benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD n1-(naphthalen-1-yl)ethane-1,2-diamine NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD n1-(2-aminoethyl)ethane-1,2-diamine NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 4-amino-n-(4-sulfamoylbenzyl)benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 6-(aminomethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD mafenide small molecule Injury wounds[MeSHID:D014947],Burn injury[MeSHID:D002056],Bacterial Infections[MeSHID:D001424] approved,vet_approved carbonic anhydrase 6 CA6 NA antagonist NA drugbank p-toluenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 6-(hydroxymethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD gallicacid NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 4-(hydroxymethyl)benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD ferulic acid NA NA patented carbonic anhydrase vi CA6 Successful target unknown NA TTD , DGIDB 4-cyanophenol NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 6-hydroxy-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 2-amino-benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA6 NA inhibitor NA drugbank 4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD sulfamylon NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase vi CA6 Successful target unknown 2.55 TTD , DGIDB 7-propoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 4-amino-3-bromo-benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD p-coumaric acid NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 2,4-disulfamyltrifluoromethylaniline NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD carzenide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD catechin NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD paraben NA NA phase 3 carbonic anhydrase vi CA6 Successful target unknown 1.82 TTD , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 6 CA6 NA inhibitor NA drugbank octane-1,8-diyl disulfamate NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD hexane-1,6-diamine NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD decane-1,10-diyl disulfamate NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 6 CA6 NA inhibitor NA drugbank benzolamide NA NA investigative carbonic anhydrase vi CA6 Successful target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 carbonic anhydrase vi CA6 Successful target unknown 0.18 TTD , DGIDB ethoxzolamide small molecule Duodenal Ulcer[MeSHID:D004381],Epilepsy[MeSHID:D004827],Glaucoma[MeSHID:D005901],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] withdrawn carbonic anhydrase 7 CA7 NA inhibitor 1.13 drugbank , DGIDB ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 7 CA7 NA inhibitor NA drugbank acetazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Epilepsy[MeSHID:D004827],Edema[MeSHID:D004487],Edema, Cardiac[MeSHID:D004489],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,vet_approved carbonic anhydrase 7 CA7 NA inhibitor 0.75 drugbank , DGIDB hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn carbonic anhydrase 7 CA7 NA inhibitor NA drugbank cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA7 NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 7 CA7 NA inhibitor 1.28 drugbank , DGIDB benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA7 NA inhibitor NA drugbank methazolamide small molecule Glaucoma, Open-Angle[MeSHID:D005902],Angle Closure Glaucoma[MeSHID:D015812],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved carbonic anhydrase 7 CA7 NA inhibitor 1.63 drugbank , DGIDB diclofenamide small molecule Glaucoma[MeSHID:D005901],Glaucoma, Open-Angle[MeSHID:D005902],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Angle Closure Glaucoma[MeSHID:D015812],Physiologic Intraocular Pressure[MeSHID:D007429] approved,investigational carbonic anhydrase 7 CA7 NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase-related protein CA8 NA inhibitor NA drugbank sulfamate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD indisulam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 carbonic anhydrase ix CA9 Clinical trial target unknown 1.93 TTD , DGIDB girentuximab i-124 NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA9 NA inhibitor NA drugbank 1-(3,4-dichlorophenyl)-3-hydroxyurea NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-pentafluorophenylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 8-acetyl-7-hydroxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(cyanomethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD aminobenzolamide derivative NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-amino-6-chlorobenzene-1,3-disulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(methylhydrazino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 8-acetyl-7-propoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 3-(3-phenyl-ureido)-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 6-acetyl-7-propoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-phenethoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 1-valproylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 3-((4-aminophenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 8-acetyl-7-(benzyloxy)-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-(benzyloxyamino)-n-hydroxy-3-methylpentanamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(4-fluorophenoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD hexane-1,6-diamine NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-nitrophenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD benzolamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-ethoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 5-amino-[1,3,4]thiadiazole-2-thiol NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 8-acetyl-7-methoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD phenyldifluoromethanesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-(4-chlorobenzyloxyamino)-n-hydroxyhexanamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(2-methyl-8-quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 6-(aminomethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sodium carbonate small molecule Solutions[MeSHID:D012996],Eczema[MeSHID:D004485],Dermatitis[MeSHID:D003872],Tinea[MeSHID:D014005],Emergencies [Disease/Finding][MeSHID:D004630] approved carbonic anhydrase 9 CA9 NA inhibitor NA drugbank 3-(4'-hydroxyphenyl)diazenylbenzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-(4-sulfamoyl-phenyl)-isobutyramide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB saccharin NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD carzenide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 6-hydroxy-benzothiazole-2-sulfonic acid amide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 1-acetamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-amino-3-bromo-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfonamide derivative 12 NA NA patented carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB n-(4-sulfamoyl-phenyl)-butyramide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-butoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 1-pentafluorophenylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-amino-3-chloro-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-ethylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-azidobenzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD quinoline-8-sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 8-acetyl-7-butoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 3-amino-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(2-hydroxy-ethyl)-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfamic acid 6-sulfamoyloxy-hexyl ester NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD mmi270 NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 6-acetyl-7-hydroxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 8-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfamic acid 12-sulfamoyloxy-dodecyl ester NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-amino-n-(4-sulfamoylbenzyl)benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-propylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-(benzyloxyamino)-n-hydroxyhexanamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4,4'-thiodipyridine-3-sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD syringic acid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-hydrazino-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-hydroxy-8-propionyl-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-butylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-amino-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-(4-cyanophenyl)sulfamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD decane-1,10-diyl disulfamate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-mercapto-n-(4-sulfamoyl-phenyl)-benzamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-propoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(quinolinoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-ethoxy-8-propionyl-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-(benzyloxy)-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-sulfamoyl-benzoic acid methyl ester NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-(5-mercapto-[1,3,4]thiadiazol-2-yl)-acetamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 6-acetyl-7-ethoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-valproylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(allylamino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD azide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(2-aminoethyl)benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD octane-1,8-diyl disulfamate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-acetamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase 9 CA9 NA inhibitor NA drugbank 4-amino-3-fluoro-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-hydroxy-6-propionyl-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD prop-2-ynyl 4-sulfamoylbenzoate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-methylphenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD pmid30074415-compound-12 NA NA patented carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB sulfonamide-thiadiazole derivative 2 NA NA patented carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB 4-methylthiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD p-coumaric acid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 6-methyl-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfamic acid 3-sulfamoyloxy-phenyl ester NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 1-benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfamic acid 4-sulfamoyloxy-butyl ester NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD (4-bromophenyl)difluoromethanesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-oxo-2h-thiochromene-3-carboxylic acid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-fluoro-n-(4-sulfamoylbenzyl)benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 3-mercapto-n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 1-cyclohexylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(4'-n-methylphenyl)diazenylbenzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD pentane-1,5-diamine NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-hydrazinocarbonyl-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-ethynyl benzene sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfonamide-thiadiazole derivative 1 NA NA patented carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB ethoxycoumarin NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-[2-(3-phenyl-ureido)-ethyl]-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-methoxy-2-oxo-2h-chromene-4-carboxylic acid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 3-bromophenyl-difluoromethanesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-methoxy-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-(pentafluorophenyl)sulfamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-methoxy-8-propionyl-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD phenylsulfamate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfamic acid 7-sulfamoyloxy-heptyl ester NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD acetylsulfanilamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD (2-bromophenyl)difluoromethanesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 6-(hydroxymethyl)-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 8-acetyl-7-ethoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 90y-cg250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational carbonic anhydrase 9 CA9 NA inhibitor NA drugbank 2,2-dimethyl-n-(4-sulfamoyl-phenyl)-propionamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD cl-5343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-hydroxysulfamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-amino-3-iodo-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2,4-disulfamyltrifluoromethylaniline NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD girentuximab biotech Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of gallbladder[MeSHID:D005706] investigational carbonic anhydrase 9 CA9 NA unknown 5.79 drugbank , DGIDB 8-propionyl-7-propoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(5-methyl-2-pirazolino)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sodium phenylaminomethanesulfonate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD pmid30074415-compound-gs3 NA NA patented carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB 2-(4-chlorobenzyloxyamino)-n-hydroxypropanamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 1,4-phenylene disulfamate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD nsc-654077 NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-benzythiopyridine-3-sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-morpholin-4-yl-n-(4-sulfamoyl-phenyl)-acetamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n1-(naphthalen-1-yl)ethane-1,2-diamine NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n1-(2-aminoethyl)ethane-1,2-diamine NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 3-fluoro-4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD (4-sulfamoylphenylethylthioureido)fluorescein NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD paraben NA NA phase 3 carbonic anhydrase ix CA9 Clinical trial target unknown 0.83 TTD , DGIDB bay 79-4620 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB sulfamide NA NA phase 1 carbonic anhydrase ix CA9 Clinical trial target unknown 1.45 TTD , DGIDB hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn carbonic anhydrase 9 CA9 NA inhibitor NA drugbank decyl sulfamate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-(n''-acetyl-hydrazino)-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD herniarin NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD ferulic acid NA NA patented carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD , DGIDB 2-hydrazinocarbonyl-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD ethyl 7-methoxy-2-oxo-2h-chromene-3-carboxylate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD phenylmethanesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-propynyl amidebenzenesulphonide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-cyclohexylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(carbamolymethylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-hydrazinylbenzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD bicarbonate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(hydroxymethyl)benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carbonic anhydrase 9 CA9 NA inhibitor NA drugbank 3-chloro-4-hydrazino-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbonic anhydrase CA9 NA inhibitor NA drugbank 4-(2-propynylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD pentanoic acid (4-sulfamoyl-phenyl)-amide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sodium n-methylphenylaminomethanesulfonate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 carbonic anhydrase ix CA9 Clinical trial target unknown 0.08 TTD , DGIDB catechin NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-methanesulfonylamino-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-(benzyloxyamino)-n-hydroxyacetamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD hydrosulfide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfamic acid 4-sulfamoyloxymethyl-benzyl ester NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 6-methoxy-2-oxo-2h-chromene-3-carboxylic acid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(4-cyanophenoxy)-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD gallicacid NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-(4-chlorobenzyloxyamino)-n-hydroxyacetamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD octyl sulfamate NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD sulfamic acid 16-sulfamoyloxy-hexadecyl ester NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD p-toluenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD coumarin NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD ca9-adc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD phenol NA Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Aphthous Stomatitis[MeSHID:D013281],Pharyngitis[MeSHID:D010612] phase 2/3 carbonic anhydrase ix CA9 Clinical trial target unknown 0.83 TTD , DGIDB 6-acetyl-7-methoxy-2h-chromen-2-one NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-benzenesulfonylamino-benzenesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2-nonylamido-5-sulfonamidoindane NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 4-(n-oxide-2-pyridylthio)pyridine-3-sulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 1,4-dihydro-1-methyl-4-oxo-3-pyridinesulfonamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 7-hydroxycoumarin NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD 2,2,2-trifluoro-n-(4-sulfamoyl-phenyl)-acetamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD n-(4-sulfamoyl-phenyl)-benzamide NA NA investigative carbonic anhydrase ix CA9 Clinical trial target unknown NA TTD bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent p/q-type calcium channel CACNA1A NA blocker NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1A NA inhibitor NA drugbank cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNA1A NA antagonist NA drugbank flunarizine NA Vertigo[MeSHID:D014717],Epilepsy[MeSHID:D004827],Peripheral Vascular Diseases[MeSHID:D016491],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated calcium channel alpha cav2.1 CACNA1A Successful target unknown 0.64 TTD , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNA1A NA inhibitor NA drugbank verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent p/q-type calcium channel subunit alpha-1a CACNA1A NA inhibitor NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1A NA antagonist NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1A NA blocker NA drugbank verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved voltage-dependent p/q-type calcium channel subunit alpha-1a CACNA1A NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1A NA inhibitor NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNA1A NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1A NA inducer NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1A NA inhibitor NA drugbank bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn voltage-dependent p/q-type calcium channel subunit alpha-1a CACNA1A NA inhibitor 2.63 drugbank , DGIDB dotarizine small molecule Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational voltage-dependent p/q-type calcium channel subunit alpha-1a CACNA1A NA unknown NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNA1A NA antagonist NA drugbank xen007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 1 voltage-gated calcium channel alpha cav2.1 CACNA1A Successful target unknown NA TTD , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNA1A NA blocker NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1A NA inhibitor,activator NA drugbank loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent p/q-type calcium channel subunit alpha-1a CACNA1A NA inhibitor NA drugbank cpu-228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] investigative voltage-gated calcium channel alpha cav2.1 CACNA1A Successful target unknown NA TTD drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNA1A NA inhibitor NA drugbank loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved voltage-dependent p/q-type calcium channel subunit alpha-1a CACNA1A NA inhibitor NA drugbank levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNA1A NA antagonist NA drugbank omega-conotoxin gvia NA NA investigative voltage-gated calcium channel alpha cav2.1 CACNA1A Successful target unknown NA TTD alpha-eudesmol NA NA investigative voltage-gated calcium channel alpha cav2.1 CACNA1A Successful target unknown NA TTD magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNA1A NA inhibitor,blocker NA drugbank ziconotide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Traumatic Brain Injury[MeSHID:D000070642] approved voltage-dependent p/q-type calcium channel subunit alpha-1a CACNA1A NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1A NA agonist NA drugbank amlodipine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA inhibitor 1.52 drugbank , DGIDB verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA inhibitor NA drugbank cpu-228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA antagonist 1.52 drugbank , DGIDB conotoxin NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD levetiracetam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Epilepsy[MeSHID:D004827],Myoclonic Epilepsy, Juvenile[MeSHID:D020190],Idiopathic generalized epilepsy[MeSHID:C562694],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA inhibitor 1.3 drugbank , DGIDB benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA antagonist NA drugbank hesperidin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vascular purpura[MeSHID:C537256] approved voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown 0.91 TTD , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1B NA inhibitor NA drugbank gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational voltage-dependent n-type calcium channel CACNA1B NA inhibitor 0.45 drugbank , DGIDB cnsb-004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] preclinical voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD , DGIDB levetiracetam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Epilepsy[MeSHID:D004827],Myoclonic Epilepsy, Juvenile[MeSHID:D020190],Idiopathic generalized epilepsy[MeSHID:C562694],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA inhibitor,blocker 1.3 drugbank , DGIDB nsc-87509 NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD ralfinamide NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target blocker 0.24 TTD , DGIDB ziconotide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Traumatic Brain Injury[MeSHID:D000070642] approved voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA inhibitor 20.46 drugbank , DGIDB gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational voltage-dependent n-type calcium channel CACNA1B NA inhibitor,modulator 0.45 drugbank , DGIDB seletracetam small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA blocker NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1B NA agonist NA drugbank ritanserin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1B NA inhibitor NA drugbank contulakin-g small molecule Pain[MeSHID:D010146] investigational voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA unknown NA drugbank verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1B NA inhibitor NA drugbank gnf-pf-3464 NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown 0.28 TTD , DGIDB nsc-180246 NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown 0.21 TTD , DGIDB pd-167341 NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD ralfinamide NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown 0.24 TTD , DGIDB pd-151307 NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD cilnidipine NA Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown 1.52 TTD , DGIDB ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1B NA inducer NA drugbank pd-32577 NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD agmatine small molecule Diabetes Mellitus[MeSHID:D003920],Small Fiber Neuropathy[MeSHID:D000071075],Neuroprotection[MeSHID:D000066829],Glaucoma[MeSHID:D005901],Diagnosis[MeSHID:D003933],Epilepsy[MeSHID:D004827],Kidney[MeSHID:D007668],Anxiety Disorders[MeSHID:D001008],Blind Vision[MeSHID:D001766],Mental Depression[MeSHID:D003863],Cognition[MeSHID:D003071],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Traumatic injury[MeSHID:D014947],Cerebrovascular accident[MeSHID:D020521],Anxiety[MeSHID:D001007] experimental voltage-dependent n-type calcium channel subunit alpha-1b CACNA1B NA antagonist NA drugbank kys-05090 NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1B NA inhibitor,activator NA drugbank cnv-2197944 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown 6.82 TTD , DGIDB trox-1 NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target inhibitor NA TTD , DGIDB omega-conotoxin gvia NA NA investigative voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown NA TTD amlodipine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent n-type calcium channel CACNA1B NA inhibitor 1.52 drugbank , DGIDB lomerizine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown 0.76 TTD , DGIDB ziconotide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Traumatic Brain Injury[MeSHID:D000070642] approved voltage-gated calcium channel alpha cav2.2 CACNA1B Successful target unknown 20.46 TTD , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor,blocker 0.67 drugbank , DGIDB efonidipine small molecule Hypertensive disease[MeSHID:D006973] experimental voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA unknown NA drugbank verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor,blocker 0.42 drugbank , DGIDB [3h](+)-cis-diltiazem NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD sz(+)-(s)-202-791 NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target activator NA TTD , DGIDB isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor 1.87 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1C NA inhibitor,activator NA drugbank mebudipine NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD (-)-(r)-efonidipine NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD propiverine small molecule Urinary Incontinence[MeSHID:D014549],Neurogenic Urinary Bladder[MeSHID:D001750],Urinary tract[MeSHID:D014551],Overactive Bladder[MeSHID:D053201],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA antagonist NA drugbank ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA activator 1.87 drugbank , DGIDB nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor 1.17 drugbank , DGIDB manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1C NA blocker NA drugbank [3h](+)-isradipine NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target inhibitor NA TTD , DGIDB ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1C NA inducer NA drugbank isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical voltage gated l-type calcium channel CACNA1C NA inhibitor NA drugbank (-)-(s)-bayk8644 NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target activator NA TTD , DGIDB rauwolfia serpentina root NA Hypertensive disease[MeSHID:D006973],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tooth root structure[MeSHID:D014092] approved voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD , DGIDB drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNA1C NA inhibitor NA drugbank nilvadipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Disease Management[MeSHID:D019468] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA ligand NA drugbank clevidipine small molecule Hypotension[MeSHID:D007022] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA blocker 0.94 drugbank , DGIDB [3h](-)devapamil NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD corynantheine NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD clevidipine small molecule Hypotension[MeSHID:D007022] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA unknown 0.94 drugbank , DGIDB cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNA1C NA antagonist NA drugbank nisoldipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor 0.75 drugbank , DGIDB verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor 0.42 drugbank , DGIDB levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNA1C NA antagonist NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage gated l-type calcium channel CACNA1C NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA unknown 0.07 drugbank , DGIDB trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNA1C NA inhibitor NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor,blocker 1.17 drugbank , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor 0.67 drugbank , DGIDB nisoldipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor,blocker 0.75 drugbank , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational voltage gated l-type calcium channel CACNA1C NA inhibitor NA drugbank cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1C NA antagonist NA drugbank barnidipine small molecule Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Essential Hypertension[MeSHID:D000075222] experimental voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA antagonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1C NA inhibitor NA drugbank nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor,blocker 0.14 drugbank , DGIDB benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNA1C NA antagonist,blocker 3.74 drugbank , DGIDB butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1C NA inhibitor NA drugbank aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA antagonist NA drugbank magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNA1C NA inhibitor,blocker NA drugbank cv-4093 NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage gated l-type calcium channel CACNA1C NA antagonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1C NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage gated l-type calcium channel CACNA1C NA inhibitor NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage gated l-type calcium channel CACNA1C NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1C NA agonist NA drugbank levamlodipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA antagonist NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNA1C NA blocker NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor 0.37 drugbank , DGIDB amlodipine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor 0.62 drugbank , DGIDB pd-32577 NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD arc029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD , DGIDB verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor,blocker 0.42 drugbank , DGIDB mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor,blocker 0.55 drugbank , DGIDB nitrendipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor NA drugbank fpl64176 NA NA investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor 0.42 drugbank , DGIDB diltiazem small molecule Cardiomyopathy, Familial Idiopathic[MeSHID:D002311],Tachycardia, Atrioventricular Nodal Reentry[MeSHID:D013611],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468], Reciprocating[MeSHID:D054139],Heart Atrium[MeSHID:D006325],Atrial Flutter[MeSHID:D001282],Blood Pressure[MeSHID:D001794],Exercise Tolerance[MeSHID:D017079],Wolff-Parkinson-White Syndrome[MeSHID:D014927],Anal Fissure[MeSHID:D005401],Supraventricular tachycardia[MeSHID:D013617],SHORT syndrome[MeSHID:C537327],Stable angina[MeSHID:D060050],Proteinuria[MeSHID:D011507],Pulmonary Hypertension[MeSHID:D006976],pathologic fistula[MeSHID:D005402],Accessory Atrioventricular Bundle (disorder)[MeSHID:D058606],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Ventricular Flutter[MeSHID:D054141],Diabetic Nephropathy[MeSHID:D003928],Muscle Cramp[MeSHID:D009120],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Angina Pectoris, Variant[MeSHID:D000788],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA blocker 0.31 drugbank , DGIDB cpu-228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] investigative voltage-gated calcium channel alpha cav1.2 CACNA1C Successful target unknown NA TTD isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1c CACNA1C NA inhibitor,blocker 1.87 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNA1C NA inhibitor NA drugbank cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1D NA antagonist NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical voltage gated l-type calcium channel CACNA1D NA inhibitor NA drugbank drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNA1D NA inhibitor NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage gated l-type calcium channel CACNA1D NA antagonist NA drugbank isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor,blocker 1.4 drugbank , DGIDB sipatrigine NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target unknown NA TTD mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor NA drugbank isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor 1.4 drugbank , DGIDB nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor,blocker 0.18 drugbank , DGIDB cpu-228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] investigative voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target unknown NA TTD trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNA1D NA inhibitor NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1D NA blocker NA drugbank clevidipine small molecule Hypotension[MeSHID:D007022] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA unknown 1.22 drugbank , DGIDB ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1D NA inducer NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNA1D NA blocker NA drugbank levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNA1D NA antagonist NA drugbank nisoldipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor,blocker 0.33 drugbank , DGIDB levamlodipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA antagonist NA drugbank aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA antagonist NA drugbank azidopine NA NA investigative voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target inhibitor 2.45 TTD , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1D NA inhibitor,activator NA drugbank magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNA1D NA inhibitor,blocker NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1D NA inhibitor NA drugbank n,n'-di-acenaphthen-5-yl-guanidine NA NA investigative voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target unknown NA TTD amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage gated l-type calcium channel CACNA1D NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage gated l-type calcium channel CACNA1D NA inhibitor NA drugbank cv-4093 NA NA investigative voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target unknown NA TTD mebudipine NA NA investigative voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target unknown NA TTD pd-32577 NA NA investigative voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target unknown NA TTD phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNA1D NA inhibitor NA drugbank arc029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target unknown NA TTD , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage gated l-type calcium channel CACNA1D NA inhibitor NA drugbank nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor 0.18 drugbank , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor,blocker 0.52 drugbank , DGIDB dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1D NA inhibitor NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor NA drugbank [3h](+)-isradipine NA NA investigative voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target inhibitor NA TTD , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1D NA agonist NA drugbank felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor 0.52 drugbank , DGIDB nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor,blocker 1.07 drugbank , DGIDB nilvadipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Disease Management[MeSHID:D019468] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor NA drugbank nitrendipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA inhibitor 0.92 drugbank , DGIDB (-)-(s)-bayk8644 NA NA investigative voltage-gated calcium channel alpha cav1.3 CACNA1D Clinical trial target activator NA TTD , DGIDB clevidipine small molecule Hypotension[MeSHID:D007022] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA blocker 1.22 drugbank , DGIDB cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNA1D NA antagonist NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational voltage gated l-type calcium channel CACNA1D NA inhibitor NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNA1D NA antagonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1D NA inhibitor NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1d CACNA1D NA unknown NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent r-type calcium channel subunit alpha-1e (cacna1e) CACNA1E NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1E NA agonist NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-dependent r-type calcium channel CACNA1E NA antagonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1E NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1E NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1E NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1E NA inhibitor,activator NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1E NA inducer NA drugbank magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNA1F NA inhibitor,blocker NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1F NA inhibitor,activator NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational voltage gated l-type calcium channel CACNA1F NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1F NA inhibitor NA drugbank cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1f CACNA1F NA inhibitor NA drugbank clevidipine small molecule Hypotension[MeSHID:D007022] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1f CACNA1F NA unknown 1.33 drugbank , DGIDB cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNA1F NA antagonist NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1F NA blocker NA drugbank aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental voltage-dependent l-type calcium channel subunit alpha-1f CACNA1F NA antagonist NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNA1F NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNA1F NA blocker NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1F NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage gated l-type calcium channel CACNA1F NA inhibitor NA drugbank drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNA1F NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1F NA inhibitor NA drugbank mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent l-type calcium channel subunit alpha-1f CACNA1F NA inhibitor NA drugbank levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNA1F NA antagonist NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1f CACNA1F NA inhibitor NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1f CACNA1F NA inhibitor,blocker 0.99 drugbank , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage gated l-type calcium channel CACNA1F NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1F NA agonist NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage gated l-type calcium channel CACNA1F NA inhibitor NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNA1F NA inhibitor NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage gated l-type calcium channel CACNA1F NA antagonist NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1f CACNA1F NA inhibitor 0.99 drugbank , DGIDB clevidipine small molecule Hypotension[MeSHID:D007022] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1f CACNA1F NA blocker 1.33 drugbank , DGIDB ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1F NA inducer NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical voltage gated l-type calcium channel CACNA1F NA inhibitor NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1F NA antagonist NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNA1F NA antagonist NA drugbank kkht-10608 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent t-type calcium channel CACNA1G NA blocker NA drugbank kys-05077 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kys-05040 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1G NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1G NA inhibitor NA drugbank kkht-10609 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD penfluridol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown 1.06 TTD , DGIDB kys-05070 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD trimethadione small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Epilepsy[MeSHID:D004827] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor 7.16 drugbank , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA unknown NA drugbank ethosuximide NA Absence Epilepsy[MeSHID:D004832],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target blocker 5.09 TTD , DGIDB paramethadione NA Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827],Fetal trimethadione syndrome[MeSHID:C537798] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown 2.12 TTD , DGIDB kys-05057 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1G NA agonist NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA unknown NA drugbank nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-dependent t-type calcium channel CACNA1G NA inhibitor NA drugbank kys-05001 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1G NA inhibitor,activator NA drugbank ml218 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target blocker NA TTD , DGIDB trimethadione NA Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Epilepsy[MeSHID:D004827] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown 7.16 TTD , DGIDB kkht-10618 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kkht-10318 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor 0.48 drugbank , DGIDB trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel CACNA1G NA activator NA drugbank kkht-11018 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent t-type calcium channel CACNA1G NA antagonist NA drugbank kys-05055 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor 0.48 drugbank , DGIDB kys-05080 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD methsuximide NA Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target blocker 6.37 TTD , DGIDB kkht-20718 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kys-05042 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD trimethadione small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Epilepsy[MeSHID:D004827] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor,blocker 7.16 drugbank , DGIDB kys-05050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD ngd 94-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD , DGIDB ethosuximide small molecule Absence Epilepsy[MeSHID:D004832],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor,blocker 5.09 drugbank , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent t-type calcium channel CACNA1G NA blocker NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor 1.94 drugbank , DGIDB ethosuximide NA Absence Epilepsy[MeSHID:D004832],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown 5.09 TTD , DGIDB ethosuximide small molecule Absence Epilepsy[MeSHID:D004832],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor 5.09 drugbank , DGIDB ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1G NA inducer NA drugbank methsuximide NA Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown 6.37 TTD , DGIDB kys-05071 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kkht-20818 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kkht-20918 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD alpha-methyl-alpha-phenylsuccinimide (mps) NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD methsuximide small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor 6.37 drugbank , DGIDB methsuximide small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor,blocker 6.37 drugbank , DGIDB cis-n,5-dibenzyl-6-oxomorpholine-3-carboxamide NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD trimethadione NA Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Epilepsy[MeSHID:D004827] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target blocker 7.16 TTD , DGIDB verapamil NA Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown 0.48 TTD , DGIDB kys-05074 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD verapamil NA Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown 0.48 TTD , DGIDB kys-05090 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1G NA inhibitor NA drugbank mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor,blocker 1.31 drugbank , DGIDB paramethadione NA Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827],Fetal trimethadione syndrome[MeSHID:C537798] approved voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target blocker 2.12 TTD , DGIDB kys-05041 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD flunarizine small molecule Vertigo[MeSHID:D014717],Epilepsy[MeSHID:D004827],Peripheral Vascular Diseases[MeSHID:D016491],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA inhibitor 2.12 drugbank , DGIDB nickel chloride NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kkht-10613 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kys-05056 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD (-)-(r)-efonidipine NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kys-05065 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD kys-05064 NA NA investigative voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational voltage-dependent t-type calcium channel subunit alpha-1g CACNA1G NA unknown NA drugbank pd-200390 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 voltage-gated calcium channel alpha cav3.1 CACNA1G Successful target unknown NA TTD , DGIDB medical cannabis biotech NA experimental,investigational voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA unknown NA drugbank ttl-1177 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD kys-05040 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD gnf-pf-4599 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor 1.34 drugbank , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1H NA inhibitor NA drugbank isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor NA drugbank verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor NA drugbank kys-05050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD nitrendipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA unknown NA drugbank sodium bicarbonate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic acidosis[MeSHID:D000138] approved voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD , DGIDB tta-a8 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD , DGIDB cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA unknown NA drugbank kys-05041 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD abt-639 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target blocker 1.52 TTD , DGIDB mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor,blocker 1.34 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1H NA inhibitor,activator NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent t-type calcium channel CACNA1H NA blocker NA drugbank bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent t-type calcium channel CACNA1H NA antagonist NA drugbank kys-05080 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD flunarizine NA Vertigo[MeSHID:D014717],Epilepsy[MeSHID:D004827],Peripheral Vascular Diseases[MeSHID:D016491],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown 2.02 TTD , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor 1.09 drugbank , DGIDB kst-5468 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD abt-639 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown 1.52 TTD , DGIDB mibefradil NA Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] phase 1 voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown 1.34 TTD , DGIDB ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1H NA inducer NA drugbank ml218 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target blocker NA TTD , DGIDB z 944 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD flunarizine small molecule Vertigo[MeSHID:D014717],Epilepsy[MeSHID:D004827],Peripheral Vascular Diseases[MeSHID:D016491],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor 2.02 drugbank , DGIDB trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel CACNA1H NA activator NA drugbank felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent t-type calcium channel CACNA1H NA blocker NA drugbank nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-dependent t-type calcium channel CACNA1H NA inhibitor NA drugbank gnf-pf-1967 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel subunit alpha-1h CACNA1H NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1H NA inhibitor NA drugbank kys-05042 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD kys-05001 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD mibefradil NA Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] phase 1 voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target blocker 1.34 TTD , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1H NA agonist NA drugbank cis-n,5-dibenzyl-6-oxomorpholine-3-carboxamide NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD dp-3005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1H NA inhibitor NA drugbank hyp-10 NA Hypophosphatemic Rickets, X-Linked Dominant[MeSHID:D053098],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD kys-05077 NA NA investigative voltage-gated calcium channel alpha cav3.2 CACNA1H Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1I NA inhibitor NA drugbank nylidrin small molecule Disease[MeSHID:D004194],Peripheral Vascular Diseases[MeSHID:D016491],Premature Obstetric Labor[MeSHID:D007752],Arteriosclerosis[MeSHID:D001161],Thromboangiitis Obliterans[MeSHID:D013919],Raynaud Disease[MeSHID:D011928],Cerebrovascular Disorders[MeSHID:D002561],Thrombophlebitis[MeSHID:D013924] approved voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA antagonist,agonist NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor 1.52 drugbank , DGIDB cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor NA drugbank medical cannabis biotech NA experimental,investigational voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA unknown NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel CACNA1I NA activator NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA unknown NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1I NA inhibitor,activator NA drugbank efonidipine small molecule Hypertensive disease[MeSHID:D006973] experimental voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA antagonist NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1I NA inducer NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent t-type calcium channel CACNA1I NA antagonist NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1I NA inhibitor NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent t-type calcium channel CACNA1I NA blocker NA drugbank flunarizine small molecule Vertigo[MeSHID:D014717],Epilepsy[MeSHID:D004827],Peripheral Vascular Diseases[MeSHID:D016491],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor 2.12 drugbank , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1I NA agonist NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA unknown NA drugbank paramethadione small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827],Fetal trimethadione syndrome[MeSHID:C537798] approved voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor 6.37 drugbank , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1I NA inhibitor NA drugbank paramethadione small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827],Fetal trimethadione syndrome[MeSHID:C537798] approved voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor,blocker 6.37 drugbank , DGIDB mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor,blocker 0.94 drugbank , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent t-type calcium channel CACNA1I NA blocker NA drugbank amlodipine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent t-type calcium channel subunit alpha-1i CACNA1I NA inhibitor NA drugbank nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-dependent t-type calcium channel CACNA1I NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor NA drugbank nitrendipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNA1S NA blocker NA drugbank cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor NA drugbank clevidipine small molecule Hypotension[MeSHID:D007022] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA unknown 0.99 drugbank , DGIDB cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNA1S NA antagonist NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage gated l-type calcium channel CACNA1S NA inhibitor NA drugbank nisoldipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor,blocker 0.27 drugbank , DGIDB trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNA1S NA inhibitor NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor 0.99 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA unknown NA drugbank mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA1S NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical voltage gated l-type calcium channel CACNA1S NA inhibitor NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational voltage gated l-type calcium channel CACNA1S NA inhibitor NA drugbank felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor,blocker 0.43 drugbank , DGIDB ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA1S NA inducer NA drugbank levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNA1S NA antagonist NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage gated l-type calcium channel CACNA1S NA inhibitor NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor,blocker 0.99 drugbank , DGIDB manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1S NA blocker NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA1S NA inhibitor NA drugbank magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNA1S NA inhibitor,blocker NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage gated l-type calcium channel CACNA1S NA antagonist NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNA1S NA antagonist NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNA1S NA antagonist NA drugbank nilvadipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Disease Management[MeSHID:D019468] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor NA drugbank pinaverium small molecule Irritable Bowel Syndrome[MeSHID:D043183],Biliary Tract Diseases[MeSHID:D001660] approved voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA antagonist,inhibitor NA drugbank isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor,blocker 0.57 drugbank , DGIDB butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA1S NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA1S NA inhibitor,activator 0.32 drugbank , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage gated l-type calcium channel CACNA1S NA inhibitor NA drugbank aranidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787] experimental voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA antagonist NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA1S NA agonist NA drugbank drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNA1S NA inhibitor NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNA1S NA inhibitor NA drugbank nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor,blocker 0.08 drugbank , DGIDB clevidipine small molecule Hypotension[MeSHID:D007022] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA blocker 0.99 drugbank , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel subunit alpha-1s CACNA1S NA inhibitor 0.43 drugbank , DGIDB 4-(4-bromobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 2-amino-2-(2,3-difluorophenyl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(3-fluorobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD (s)-2-amino-2-cyclohexylacetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD (s)-2-amino-2-p-tolylacetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD pregabalin small molecule Postherpetic neuralgia[MeSHID:D051474],Fibromyalgia[MeSHID:D005356],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Spinal Cord Injuries[MeSHID:D013119],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA modulator 0.42 drugbank , DGIDB nilvadipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Disease Management[MeSHID:D019468] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor NA drugbank 2-amino-2-(3-chloro-4-fluorophenyl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 3-aminomethyl-5-methyl-hexanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD nitrendipine NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown 0.88 TTD , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor 1.26 drugbank , DGIDB nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor NA drugbank rac-2-amino-4-phenylbutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD nitrendipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor 0.88 drugbank , DGIDB 4-(2-methoxybenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(2-nitrobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 1-benzhydryl-4-(3,3-diphenylpropyl)piperazine NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD diltiazem NA Cardiomyopathy, Familial Idiopathic[MeSHID:D002311],Tachycardia, Atrioventricular Nodal Reentry[MeSHID:D013611],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468], Reciprocating[MeSHID:D054139],Heart Atrium[MeSHID:D006325],Atrial Flutter[MeSHID:D001282],Blood Pressure[MeSHID:D001794],Exercise Tolerance[MeSHID:D017079],Wolff-Parkinson-White Syndrome[MeSHID:D014927],Anal Fissure[MeSHID:D005401],Supraventricular tachycardia[MeSHID:D013617],SHORT syndrome[MeSHID:C537327],Stable angina[MeSHID:D060050],Proteinuria[MeSHID:D011507],Pulmonary Hypertension[MeSHID:D006976],pathologic fistula[MeSHID:D005402],Accessory Atrioventricular Bundle (disorder)[MeSHID:D058606],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Ventricular Flutter[MeSHID:D054141],Diabetic Nephropathy[MeSHID:D003928],Muscle Cramp[MeSHID:D009120],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Angina Pectoris, Variant[MeSHID:D000788],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown 0.29 TTD , DGIDB 4-(3-bromobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD amlodipine NA Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown 0.88 TTD , DGIDB 1-benzhydryl-4-(4,4-diphenylbutyl)piperazine NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD pd-144550 NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD pregabalin small molecule Postherpetic neuralgia[MeSHID:D051474],Fibromyalgia[MeSHID:D005356],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Spinal Cord Injuries[MeSHID:D013119],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA unknown 0.42 drugbank , DGIDB np-118809 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(3-chlorobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(4-chlorobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 3-(aminomethyl)-4-(furan-2-yl)butanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD rac-2-amino-5-cyclohexylpentanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(3-nitrobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD n'-acridin-9-yl-n,n-diethyl-butane-1,4-diamine NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA activator 2.83 drugbank , DGIDB nisoldipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor NA drugbank 4-(4-tert-butylbenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD imagabalin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 3 voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown 0.28 TTD , DGIDB pregabalin NA Postherpetic neuralgia[MeSHID:D051474],Fibromyalgia[MeSHID:D005356],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Spinal Cord Injuries[MeSHID:D013119],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target modulator 0.42 TTD , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA2D1 NA inhibitor,activator NA drugbank 2-amino-2-(2,4-difluorophenyl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD mirogabalin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Fibromyalgia[MeSHID:D005356],Peripheral Neuropathy[MeSHID:D010523] registered voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown 3.54 TTD , DGIDB gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor 1.06 drugbank , DGIDB (s)-2-amino-2-o-tolylacetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA2D1 NA inducer NA drugbank gabapentin enacarbil small molecule Postherpetic neuralgia[MeSHID:D051474],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA modulator 0.28 drugbank , DGIDB lercanidipine NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Raynaud Phenomenon[MeSHID:D011928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown 0.88 TTD , DGIDB (s)-2-amino-4-(benzylthio)butanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD pregabalin NA Postherpetic neuralgia[MeSHID:D051474],Fibromyalgia[MeSHID:D005356],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Spinal Cord Injuries[MeSHID:D013119],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown 0.42 TTD , DGIDB gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor,modulator 1.06 drugbank , DGIDB ethionine NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA2D1 NA agonist NA drugbank 4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD cyclandelate small molecule Vascular Diseases[MeSHID:D014652],Muscle Cramp[MeSHID:D009120],Arteriosclerosis[MeSHID:D001161],Raynaud Disease[MeSHID:D011928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor NA drugbank 4-(2-cyanobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD (s)-2-amino-3-(benzylthio)propanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD (r)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 NA inhibitor 2.53 drugbank , DGIDB gababutin NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(2-bromobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 2-amino-2-(3-bromophenyl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD (s)-2-amino-3-cyclohexylpropanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA2D1 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA2D1 NA inhibitor NA drugbank 4-(3-methoxybenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 2-amino-2-(2-fluorophenyl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD imagabalin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 3 voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target modulator 0.28 TTD , DGIDB (s)-2-amino-2-phenylpropanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(3-cyanobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD (s)-phenylglycine NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 3-(aminomethyl)-4-(furan-3-yl)butanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 2-amino-2-(3-chlorophenyl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD (s)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD n,4-dibenzhydrylpiperazine-1-carboxamide NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD trans-dimethyl gababutin NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD 2-amino-2-(thiophen-2-yl)acetic acid NA NA investigative voltage-gated calcium channel alpha-2/delta-1 CACNA2D1 Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA2D1 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA2D2 NA inducer NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA2D2 NA agonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA2D2 NA inhibitor NA drugbank gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 NA inhibitor,modulator 1.7 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA2D2 NA inhibitor,activator NA drugbank isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 NA inhibitor NA drugbank nitrendipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 NA inhibitor NA drugbank felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 NA inhibitor NA drugbank bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 NA inhibitor NA drugbank gabapentin enacarbil small molecule Postherpetic neuralgia[MeSHID:D051474],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 NA modulator 0.51 drugbank , DGIDB gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 NA inhibitor 1.7 drugbank , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA2D2 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA2D2 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA2D3 NA inhibitor,activator NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA2D3 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA2D3 NA inducer NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA2D3 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA2D3 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA2D3 NA agonist NA drugbank amlodipine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel subunit alpha-2/delta-3 CACNA2D3 NA inhibitor NA drugbank nilvadipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Disease Management[MeSHID:D019468] approved,investigational voltage-dependent calcium channel subunit alpha-2/delta-3 CACNA2D3 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNA2D4 NA inducer NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNA2D4 NA inhibitor,activator NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNA2D4 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNA2D4 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNA2D4 NA agonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNA2D4 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNB1 NA inhibitor NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNB1 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNB1 NA inducer NA drugbank magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNB1 NA inhibitor,blocker NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage gated l-type calcium channel CACNB1 NA inhibitor NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage gated l-type calcium channel CACNB1 NA inhibitor NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational voltage gated l-type calcium channel CACNB1 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNB1 NA inhibitor NA drugbank levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNB1 NA antagonist NA drugbank amlodipine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit beta-1 CACNB1 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNB1 NA agonist NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNB1 NA blocker NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNB1 NA antagonist NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit beta-1 CACNB1 NA inhibitor NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage gated l-type calcium channel CACNB1 NA antagonist NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNB1 NA inhibitor NA drugbank drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNB1 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage gated l-type calcium channel CACNB1 NA inhibitor NA drugbank mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent l-type calcium channel subunit beta-1 CACNB1 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNB1 NA blocker NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNB1 NA inhibitor NA drugbank ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit beta-1 CACNB1 NA activator 5.66 drugbank , DGIDB cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNB1 NA antagonist NA drugbank azelnidipine small molecule Hypertensive disease[MeSHID:D006973] investigational voltage-dependent l-type calcium channel subunit beta-1 CACNB1 NA agonist NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit beta-1 CACNB1 NA inhibitor NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit beta-1 CACNB1 NA unknown NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNB1 NA inhibitor,activator NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical voltage gated l-type calcium channel CACNB1 NA inhibitor NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNB1 NA antagonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNB2 NA inhibitor NA drugbank levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNB2 NA antagonist NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNB2 NA inducer NA drugbank nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNB2 NA antagonist NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational voltage gated l-type calcium channel CACNB2 NA inhibitor NA drugbank magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNB2 NA inhibitor,blocker NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNB2 NA blocker NA drugbank nisoldipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNB2 NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical voltage gated l-type calcium channel CACNB2 NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor 1.82 drugbank , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNB2 NA agonist NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage gated l-type calcium channel CACNB2 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNB2 NA inhibitor,activator NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage gated l-type calcium channel CACNB2 NA antagonist NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage gated l-type calcium channel CACNB2 NA inhibitor NA drugbank isradipine small molecule Disease Management[MeSHID:D019468],Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Herpes Simplex Infections[MeSHID:D006561] approved,investigational voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank nilvadipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Disease Management[MeSHID:D019468] approved,investigational voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNB2 NA inhibitor NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNB2 NA inhibitor NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNB2 NA antagonist NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage gated l-type calcium channel CACNB2 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNB2 NA blocker NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNB2 NA inhibitor NA drugbank drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNB2 NA inhibitor NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNB2 NA antagonist NA drugbank nitrendipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel subunit beta-2 CACNB2 NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit beta-3 CACNB3 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNB3 NA agonist NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNB3 NA antagonist NA drugbank magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNB3 NA inhibitor,blocker NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational voltage gated l-type calcium channel CACNB3 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage gated l-type calcium channel CACNB3 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNB3 NA inhibitor NA drugbank drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNB3 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNB3 NA inhibitor,activator NA drugbank levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNB3 NA antagonist NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage gated l-type calcium channel CACNB3 NA antagonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNB3 NA inhibitor NA drugbank cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNB3 NA antagonist NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical voltage gated l-type calcium channel CACNB3 NA inhibitor NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage gated l-type calcium channel CACNB3 NA inhibitor NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit beta-3 CACNB3 NA inhibitor NA drugbank mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent l-type calcium channel subunit beta-3 CACNB3 NA inhibitor NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNB3 NA blocker NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNB3 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNB3 NA blocker NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNB3 NA antagonist NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNB3 NA inhibitor NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage gated l-type calcium channel CACNB3 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNB3 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNB3 NA inducer NA drugbank benidipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318] experimental voltage-dependent l-type calcium channel CACNB4 NA antagonist NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical voltage gated l-type calcium channel CACNB4 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNB4 NA inhibitor,activator NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage gated l-type calcium channel CACNB4 NA inhibitor NA drugbank levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved voltage-dependent l-type calcium channel CACNB4 NA antagonist NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational voltage gated l-type calcium channel CACNB4 NA inhibitor NA drugbank nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational voltage-dependent l-type calcium channel subunit beta-4 CACNB4 NA inhibitor NA drugbank drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent l-type calcium channel CACNB4 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNB4 NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel subunit beta-4 CACNB4 NA inhibitor NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational voltage gated l-type calcium channel CACNB4 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent l-type calcium channel CACNB4 NA blocker NA drugbank magnesium sulfate small molecule Hypocalcemia[MeSHID:D006996],Nephritis[MeSHID:D009393],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Eclampsia[MeSHID:D004461],Uterus[MeSHID:D014599],Septic Toxemia[MeSHID:D014115],Tetany[MeSHID:D013746],Pre-Eclampsia[MeSHID:D011225],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved,investigational,vet_approved voltage-dependent l-type calcium channel CACNB4 NA inhibitor,blocker NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage gated l-type calcium channel CACNB4 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNB4 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNB4 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNB4 NA inducer NA drugbank manidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNB4 NA blocker NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved voltage-dependent l-type calcium channel CACNB4 NA inhibitor NA drugbank mibefradil small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] investigational,withdrawn voltage-dependent l-type calcium channel subunit beta-4 CACNB4 NA inhibitor NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent l-type calcium channel CACNB4 NA inhibitor NA drugbank lacidipine small molecule Hypertensive disease[MeSHID:D006973] approved,investigational voltage-dependent l-type calcium channel CACNB4 NA antagonist NA drugbank cilnidipine small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468],Blood Vessel[MeSHID:D001808],Diabetes Mellitus[MeSHID:D003920],Blood Pressure[MeSHID:D001794],Blood[MeSHID:D001769],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Albuminuria[MeSHID:D000419],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational voltage-dependent l-type calcium channel CACNB4 NA antagonist NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNB4 NA agonist NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage gated l-type calcium channel CACNB4 NA antagonist NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNG1 NA agonist NA drugbank fluspirilene small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent calcium channel gamma-1 subunit CACNG1 NA inhibitor NA drugbank diltiazem small molecule Cardiomyopathy, Familial Idiopathic[MeSHID:D002311],Tachycardia, Atrioventricular Nodal Reentry[MeSHID:D013611],Systemic arterial pressure[MeSHID:D062186],Disease Management[MeSHID:D019468], Reciprocating[MeSHID:D054139],Heart Atrium[MeSHID:D006325],Atrial Flutter[MeSHID:D001282],Blood Pressure[MeSHID:D001794],Exercise Tolerance[MeSHID:D017079],Wolff-Parkinson-White Syndrome[MeSHID:D014927],Anal Fissure[MeSHID:D005401],Supraventricular tachycardia[MeSHID:D013617],SHORT syndrome[MeSHID:C537327],Stable angina[MeSHID:D060050],Proteinuria[MeSHID:D011507],Pulmonary Hypertension[MeSHID:D006976],pathologic fistula[MeSHID:D005402],Accessory Atrioventricular Bundle (disorder)[MeSHID:D058606],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Ventricular Flutter[MeSHID:D054141],Diabetic Nephropathy[MeSHID:D003928],Muscle Cramp[MeSHID:D009120],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Angina Pectoris, Variant[MeSHID:D000788],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent calcium channel gamma-1 subunit CACNG1 NA blocker 2.45 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNG1 NA inhibitor,activator NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNG1 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNG1 NA inducer NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel gamma-1 subunit CACNG1 NA unknown NA drugbank lercanidipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Raynaud Phenomenon[MeSHID:D011928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-dependent calcium channel gamma-1 subunit CACNG1 NA inhibitor 6.12 drugbank , DGIDB ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel gamma-1 subunit CACNG1 NA activator NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNG1 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNG1 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNG2 NA inhibitor,activator NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel gamma-2 subunit CACNG2 NA unknown NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNG2 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNG2 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNG2 NA inducer NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNG2 NA agonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNG2 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNG3 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNG3 NA inducer NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNG3 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNG3 NA inhibitor,activator NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNG3 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNG3 NA agonist NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNG4 NA agonist NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNG4 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNG4 NA inhibitor,activator NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNG4 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNG4 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNG4 NA inducer NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNG5 NA agonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNG5 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNG5 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNG5 NA inhibitor,activator NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNG5 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNG5 NA inducer NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNG6 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNG6 NA agonist NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNG6 NA inhibitor,activator NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNG6 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNG6 NA inducer NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNG6 NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNG7 NA agonist NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNG7 NA inducer NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNG7 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNG7 NA inhibitor,activator NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNG7 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNG7 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn voltage-dependent calcium channel CACNG8 NA inhibitor NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical voltage-dependent calcium channel CACNG8 NA inducer NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved voltage-dependent calcium channel CACNG8 NA inhibitor NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-dependent calcium channel CACNG8 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved voltage-dependent calcium channel CACNG8 NA inhibitor,activator NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-dependent calcium channel CACNG8 NA agonist NA drugbank sparfosic acid small molecule NA experimental cad protein CAD NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calcium-dependent secretion activator 1 CADPS NA agonist NA drugbank calcium phosphate small molecule NA approved calcium-dependent secretion activator 1 CADPS NA agonist NA drugbank calcium phosphate dihydrate small molecule NA approved calcium-dependent secretion activator 1 CADPS NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calcium-dependent secretion activator 2 CADPS2 NA agonist NA drugbank calcium phosphate dihydrate small molecule NA approved calcium-dependent secretion activator 2 CADPS2 NA unknown NA drugbank calcium phosphate small molecule NA approved calcium-dependent secretion activator 2 CADPS2 NA agonist NA drugbank calcium phosphate dihydrate small molecule NA approved calretinin CALB2 NA unknown NA drugbank calcium phosphate small molecule NA approved calretinin CALB2 NA ligand NA drugbank calcium citrate small molecule NA approved,investigational calretinin CALB2 NA ligand NA drugbank calcium levulinate small molecule Milk (body substance)[MeSHID:D008892],Nutritional status[MeSHID:D009752] approved,experimental calretinin CALB2 NA agonist NA drugbank ac-wvth[cit]lagllsrsggvvrknfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD eptinezumab biotech Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcitonin gene-related peptide 1 CALCA NA binder,antibody,inhibitor 1.52 drugbank , DGIDB olcegepant small molecule Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational calcitonin gene-related peptide 1 CALCA NA unknown NA drugbank ac-vthrlagllsrsggvvknnfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD telcagepant small molecule Cluster Headache[MeSHID:D003027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] investigational calcitonin gene-related peptide 1 CALCA NA unknown NA drugbank fremanezumab biotech Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved,investigational calcitonin gene-related peptide 1 CALCA NA binder,antibody NA drugbank wvthrlagllsrsggvvknnfvptnvgskaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD cizolirtine NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 calcitonin gene-related peptide 1 CALCA Clinical trial target unknown 3.03 TTD , DGIDB ac-wvehrlkgelsrkggvv[harg]knfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD ac-wvthrlaglls[cit]sggvvrknfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD ac-vthrlagllsrsggvvrknfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD fv-aib-tdvgpfaf NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD ac-wvthqlagllsqsggvvrknfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD ac-wvthrlagllsrsggvvrknfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD ac-wvth[cit]laglls[cit]sggvvrknfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD vthrlagllsrsggvvknnfvptnvgskaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD ac-wvth[harg]laglls[harg]sggvvrknfvptdvgpfaf-nh2 NA NA investigative calcitonin gene-related peptide 1 CALCA Clinical trial target unknown NA TTD galcanezumab biotech Episodic Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved,investigational calcitonin gene-related peptide 1 CALCA NA antibody NA drugbank fremanezumab biotech Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved,investigational calcitonin gene-related peptide 2 CALCB NA binder,antibody NA drugbank telcagepant small molecule Cluster Headache[MeSHID:D003027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] investigational calcitonin gene-related peptide 2 CALCB NA unknown NA drugbank eptinezumab biotech Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcitonin gene-related peptide 2 CALCB NA binder,antibody,inhibitor 31.83 drugbank , DGIDB galcanezumab biotech Episodic Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved,investigational calcitonin gene-related peptide 2 CALCB NA antibody NA drugbank csnlstcvlgklsqelnklhbyprtntgsgtp-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD csnlstcvlgklsqelc[dklho]yprtntgsgtp-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD cgnlstcmlgtytqdfnpfhtfpqtaigvgap-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD cgnlstcblgtytqdfnkfhzypqtaigvgap-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD calcitonin human NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoporosis, Postmenopausal[MeSHID:D015663],Pain[MeSHID:D010146],Osteitis Deformans[MeSHID:D010001] approved calcitonin receptor CALCR Successful target unknown NA TTD , DGIDB cgnlstcmlgtytqdfc[dkfho]fpqtaigvgap-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD cgnlstcmlgtytqdfnkfhtfpqtaigvgap-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD pramlintide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved,investigational calcitonin receptor CALCR NA agonist 11.32 drugbank , DGIDB cgnlstcblgtytqdf[dkfho]ypqtaigvgap-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD cgnlstcmlgtytqdfc[dkfhk]fpqtaigvgap-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD dacra 089 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 calcitonin receptor CALCR Successful target unknown NA TTD csnlstcvlgklsqelhklqtyprtntgsgtp-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD salmon calcitonin biotech Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Azotemia[MeSHID:D053099],Serum[MeSHID:D044967],Hypercalcemia[MeSHID:D006934],Osteitis Deformans[MeSHID:D010001],Heart[MeSHID:D006321],Postmenopause[MeSHID:D017698],Body Fluids[MeSHID:D001826],Emergencies [Disease/Finding][MeSHID:D004630],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcitonin receptor CALCR Successful target agonist NA TTD , drugbank , DGIDB cgnlstcmlgtytqdfnpkhtfpqtaigvgap-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD cgnlstcmlgtytqdfnkphtfpqtaigvgap-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD csnlstcvlgklsqelc[dklhk]yprtntgsgtp-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD calcitonin human NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoporosis, Postmenopausal[MeSHID:D015663],Pain[MeSHID:D010146],Osteitis Deformans[MeSHID:D010001] approved calcitonin receptor CALCR Successful target agonist 7.07 TTD , DGIDB csnlstcvlgklsqelc[dklqk]yprtntgsgtp-amide NA NA investigative calcitonin receptor CALCR Successful target unknown NA TTD rimegepant small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcitonin gene-related peptide type 1 receptor CALCRL NA antagonist 12.73 drugbank , DGIDB vazegepant small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational calcitonin gene-related peptide type 1 receptor CALCRL NA antagonist NA drugbank olcegepant small molecule Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational calcitonin gene-related peptide type 1 receptor CALCRL NA antagonist 19.1 drugbank , DGIDB ubrogepant small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcitonin gene-related peptide type 1 receptor CALCRL NA antagonist 3.18 drugbank , DGIDB isomer a NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD fremanezumab NA Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved calcitonin gene-related peptide receptor CALCRL Successful target unknown 6.37 TTD , DGIDB fv-hyp-tdvgpfaf NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD atogepant small molecule Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcitonin gene-related peptide type 1 receptor CALCRL NA antagonist NA drugbank epimer a NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD fvptdvg-tic-faf-tic NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD bms-694153 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD erenumab NA Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved calcitonin gene-related peptide receptor CALCRL Successful target antagonist 12.73 TTD , DGIDB erenumab NA Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved calcitonin gene-related peptide receptor CALCRL Successful target unknown 12.73 TTD , DGIDB telcagepant NA Cluster Headache[MeSHID:D003027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 2 calcitonin gene-related peptide receptor CALCRL Successful target antagonist 19.1 TTD , DGIDB telcagepant small molecule Cluster Headache[MeSHID:D003027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] investigational calcitonin gene-related peptide type 1 receptor CALCRL NA unknown 19.1 drugbank , DGIDB fvatdvgpfaf NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD ubrogepant NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcitonin gene-related peptide receptor CALCRL Successful target antagonist 3.18 TTD , DGIDB fv-tic-tdvgpfaf NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD fvptdvgpfaf NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD amg 334 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 2 calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD , DGIDB olcegepant small molecule Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational calcitonin gene-related peptide type 1 receptor CALCRL NA unknown 19.1 drugbank , DGIDB fv-aib-tdvgpfaf NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD olcegepant NA Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 calcitonin gene-related peptide receptor CALCRL Successful target antagonist 19.1 TTD , DGIDB fvptdvgafaf NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD erenumab biotech Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved,investigational calcitonin gene-related peptide type 1 receptor CALCRL NA antagonist 12.73 drugbank , DGIDB hcgrpalpha NA NA investigative calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD telcagepant small molecule Cluster Headache[MeSHID:D003027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] investigational calcitonin gene-related peptide type 1 receptor CALCRL NA antagonist 19.1 drugbank , DGIDB mk-3207 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 2 calcitonin gene-related peptide receptor CALCRL Successful target unknown 12.73 TTD , DGIDB lbr-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 1 calcitonin gene-related peptide receptor CALCRL Successful target unknown 6.37 TTD , DGIDB erenumab biotech Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved,investigational calcitonin gene-related peptide type 1 receptor CALCRL NA unknown 12.73 drugbank , DGIDB olcegepant NA Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 calcitonin gene-related peptide receptor CALCRL Successful target unknown 19.1 TTD , DGIDB rimegepant NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcitonin gene-related peptide receptor CALCRL Successful target antagonist 12.73 TTD , DGIDB telcagepant NA Cluster Headache[MeSHID:D003027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 2 calcitonin gene-related peptide receptor CALCRL Successful target unknown 19.1 TTD , DGIDB galcanezumab NA Episodic Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved calcitonin gene-related peptide receptor CALCRL Successful target unknown 6.37 TTD , DGIDB bi-44370 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 2 calcitonin gene-related peptide receptor CALCRL Successful target unknown NA TTD loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calmodulin CALM1 NA inhibitor NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved calmodulin CALM1 NA unknown NA drugbank aprindine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] experimental calmodulin CALM1 NA inhibitor 21.22 drugbank , DGIDB calcium phosphate small molecule NA approved calmodulin CALM1 NA agonist NA drugbank prenylamine small molecule NA approved,withdrawn calmodulin CALM1 NA unknown NA drugbank felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational calmodulin CALM1 NA other NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical calmodulin CALM1 NA unknown NA drugbank nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved calmodulin CALM1 NA inhibitor NA drugbank calcium citrate small molecule NA approved,investigational calmodulin CALM1 NA agonist NA drugbank fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calmodulin CALM1 NA inhibitor NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calmodulin CALM1 NA inhibitor NA drugbank phenoxybenzamine small molecule Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved calmodulin CALM1 NA inhibitor NA drugbank calcium phosphate dihydrate small molecule NA approved calmodulin CALM1 NA unknown NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved calmodulin CALM1 NA unknown NA drugbank deacetoxyvinzolidine small molecule NA experimental calmodulin CALM1 NA unknown NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved calmodulin CALM1 NA inhibitor NA drugbank trimethyllysine small molecule NA experimental calmodulin CALM1 NA unknown NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calmodulin CALM1 NA unknown NA drugbank loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved calmodulin CALM1 NA inhibitor NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational calmodulin CALM1 NA inhibitor NA drugbank (3z)-n,n-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1h-indol-2-ylmethylidene)-2,3-dihydro-1h-indole-5-sulfonamide small molecule NA experimental calmodulin CALM1 NA unknown NA drugbank n-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide small molecule NA experimental calmodulin CALM1 NA unknown NA drugbank flunarizine small molecule Vertigo[MeSHID:D014717],Epilepsy[MeSHID:D004827],Peripheral Vascular Diseases[MeSHID:D016491],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calmodulin CALM1 NA antagonist 14.14 drugbank , DGIDB myristic acid small molecule NA experimental calmodulin CALM1 NA unknown NA drugbank cinchocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525] approved,vet_approved calmodulin CALM1 NA inhibitor NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calmodulin CALM1 NA inhibitor NA drugbank fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved calmodulin CALM1 NA inhibitor NA drugbank trifluoperazine small molecule Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational calmodulin CALM1 NA inhibitor NA drugbank calcium levulinate small molecule Milk (body substance)[MeSHID:D008892],Nutritional status[MeSHID:D009752] approved,experimental calmodulin CALM1 NA agonist NA drugbank pimozide small molecule Gilles de la Tourette syndrome[MeSHID:D005879],Tic, Vocal[MeSHID:D020323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved calmodulin CALM1 NA inhibitor NA drugbank tert-butanol small molecule NA experimental calmodulin CALM1 NA unknown NA drugbank perphenazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved calmodulin CALM1 NA inhibitor NA drugbank bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn calmodulin CALM1 NA binder 5.79 drugbank , DGIDB melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved calmodulin CALM1 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calmodulin-2 CALM2 NA agonist NA drugbank calcium phosphate small molecule NA approved calmodulin-2 CALM2 NA agonist NA drugbank calcium phosphate dihydrate small molecule NA approved calmodulin-2 CALM2 NA unknown NA drugbank calcium phosphate dihydrate small molecule NA approved calmodulin-3 CALM3 NA unknown NA drugbank calcium phosphate small molecule NA approved calmodulin-3 CALM3 NA agonist NA drugbank calcium citrate small molecule NA approved,investigational calmodulin-3 CALM3 NA agonist NA drugbank tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calreticulin CALR NA unknown NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational calreticulin CALR NA chaperone NA drugbank calcium phosphate dihydrate small molecule NA approved calreticulin CALR NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational calreticulin CALR NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calreticulin CALR NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calreticulin CALR NA ligand NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved calreticulin CALR NA unknown NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved calreticulin CALR NA unknown NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calreticulin CALR NA chaperone NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational calreticulin CALR NA chaperone NA drugbank calcium phosphate small molecule NA approved calreticulin CALR NA ligand NA drugbank calcium phosphate small molecule NA approved calreticulin-3 CALR3 NA ligand NA drugbank calcium citrate small molecule NA approved,investigational calreticulin-3 CALR3 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved calreticulin-3 CALR3 NA unknown NA drugbank apomorphine sl NA NA investigative neuron-specific vesicular protein calcyon CALY Discontinued target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuron-specific vesicular protein calcyon CALY NA unknown NA drugbank trifluoperazine small molecule Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational neuron-specific vesicular protein calcyon CALY NA antagonist 5.68 drugbank , DGIDB das-431 iv small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Addictive Behavior[MeSHID:D016739],Cerebrovascular accident[MeSHID:D020521],Parkinson Disease[MeSHID:D010300] investigational neuron-specific vesicular protein calcyon CALY NA unknown NA drugbank cy-208243 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 neuron-specific vesicular protein calcyon CALY Discontinued target unknown NA TTD adx-10061 small molecule Cessation of smoking[MeSHID:D016540],Sleep Disorders[MeSHID:D012893],Substance abuse problem[MeSHID:D019966],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] investigational neuron-specific vesicular protein calcyon CALY NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase type 1 CAMK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase type 1d CAMK1D NA inhibitor NA drugbank n-(5-methyl-1h-pyrazol-3-yl)-2-phenylquinazolin-4-amine small molecule NA experimental calcium/calmodulin-dependent protein kinase type 1d CAMK1D NA unknown NA drugbank su-11652 small molecule NA experimental calcium/calmodulin-dependent protein kinase type 1g CAMK1G NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase type 1g CAMK1G NA inhibitor NA drugbank 1,4-dithiothreitol small molecule NA experimental calcium/calmodulin-dependent protein kinase type ii subunit alpha CAMK2A NA unknown NA drugbank (2z,3e)-2,3'-biindole-2',3(1h,1'h)-dione 3-{o-[(3r)-3,4-dihydroxybutyl]oxime} small molecule NA experimental calcium/calmodulin-dependent protein kinase type ii subunit alpha CAMK2A NA unknown NA drugbank hexatantalum dodecabromide small molecule NA experimental calcium/calmodulin-dependent protein kinase type ii subunit alpha CAMK2A NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase type ii subunit alpha CAMK2A NA inhibitor NA drugbank [4-({4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile small molecule NA experimental calcium/calmodulin-dependent protein kinase type ii subunit beta CAMK2B NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase type ii subunit beta CAMK2B NA inhibitor NA drugbank (3z)-n,n-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1h-indol-2-ylmethylidene)-2,3-dihydro-1h-indole-5-sulfonamide small molecule NA experimental calcium/calmodulin-dependent protein kinase type ii subunit delta CAMK2D NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase type ii subunit delta CAMK2D NA inhibitor NA drugbank 2-[4-[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile small molecule NA experimental calcium/calmodulin-dependent protein kinase type ii subunit delta CAMK2D NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase type ii subunit gamma CAMK2G NA inhibitor NA drugbank 1-tert-butyl-3-(3-methylbenzyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine small molecule NA experimental calcium/calmodulin-dependent protein kinase type ii subunit gamma CAMK2G NA unknown NA drugbank bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved calcium/calmodulin-dependent protein kinase type ii subunit gamma CAMK2G NA inhibitor 0.35 drugbank , DGIDB 3-({[(3s)-3,4-dihydroxybutyl]oxy}amino)-1h,2'h-2,3'-biindol-2'-one small molecule NA experimental calcium/calmodulin-dependent protein kinase type iv CAMK4 NA unknown NA drugbank k-00546 small molecule NA experimental calcium/calmodulin-dependent protein kinase type iv CAMK4 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase kinase 1 CAMKK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational calcium/calmodulin-dependent protein kinase kinase 2 CAMKK2 NA inhibitor NA drugbank voclosporin small molecule Lupus Nephritis[MeSHID:D008181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Kidney Diseases[MeSHID:D007674] approved,investigational calcium signal-modulating cyclophilin ligand CAMLG NA binder NA drugbank cyclosporine small molecule Eczema[MeSHID:D004485],Graft-vs-Host Disease[MeSHID:D006086],Rupture[MeSHID:D012421],Keratoconjunctivitis, Vernal[MeSHID:D003233],Eye[MeSHID:D005123],Nephrotic Syndrome[MeSHID:D009404],Connective Tissue Diseases[MeSHID:D003240],Kidney[MeSHID:D007668],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Mental Suffering[MeSHID:D013315],Immune thrombocytopenic purpura[MeSHID:D016553],Psoriasis[MeSHID:D011565],Keratoconjunctivitis Sicca[MeSHID:D007638],Liver[MeSHID:D008099],Rheumatoid Arthritis[MeSHID:D001172],Segmental glomerulosclerosis[MeSHID:C538457],Dental Plaque[MeSHID:D003773],Membranous glomerulonephritis[MeSHID:D015433],Bulla[MeSHID:D001768],Tears body substance[MeSHID:D013666],Lipoid nephrosis[MeSHID:D009402],Ulcerative Colitis[MeSHID:D003093],Immunocompromised Host[MeSHID:D016867],Disease[MeSHID:D004194],Graft Rejection[MeSHID:D006084],Dry Eye Syndromes[MeSHID:D015352],Kidney Glomerulus[MeSHID:D007678],Dermatitis, Atopic[MeSHID:D003876],Laceration[MeSHID:D022125],Uveitis[MeSHID:D014605] approved,investigational,vet_approved calcium signal-modulating cyclophilin ligand CAMLG NA binder 9.24 drugbank , DGIDB scy-635 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 calcium signal-modulating cyclophilin ligand CAMLG; CAML Clinical trial target unknown NA TTD scy-641 NA Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Vision[MeSHID:D014785] preclinical calcium signal-modulating cyclophilin ligand CAMLG; CAML Clinical trial target unknown NA TTD alisporivir NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 calcium signal-modulating cyclophilin ligand CAMLG; CAML Clinical trial target unknown NA TTD alisporivir NA Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Hepatitis C[MeSHID:D006526] phase 3 calcium signal-modulating cyclophilin ligand CAMLG; CAML Clinical trial target unknown NA TTD colforsin daropate hci NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved cathelicidin antimicrobial peptide CAMP Successful target unknown NA TTD , DGIDB selenocysteine small molecule NA experimental cathelicidin antimicrobial peptide CAMP NA unknown NA drugbank phosphomethylphosphonic acid guanosyl ester small molecule NA experimental soluble calcium-activated nucleotidase 1 CANT1 NA unknown NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational calnexin CANX NA chaperone NA drugbank calcium phosphate small molecule NA approved calnexin CANX NA ligand NA drugbank tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calnexin CANX NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calnexin CANX NA ligand NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational calnexin CANX NA chaperone NA drugbank calcium phosphate dihydrate small molecule NA approved calnexin CANX NA unknown NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calnexin CANX NA chaperone NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational calnexin CANX NA unknown NA drugbank n-[(benzyloxy)carbonyl]-l-leucyl-n-[(1s)-3-fluoro-1-(4-hydroxybenzyl)-2-oxopropyl]-l-leucinamide small molecule NA experimental calpain-1 catalytic subunit CAPN1 NA unknown NA drugbank undecylenic acid derivative 1 NA NA patented calpain-1 CAPN1 Patented-recorded target unknown NA TTD , DGIDB (2s)-4-methyl-2-(3-phenylthioureido)-n-((3s)-tetrahydro-2-hydroxy-3-furanyl)pentanamide small molecule NA experimental calpain-1 catalytic subunit CAPN1 NA unknown NA drugbank 4-[[(2s)-2-[[(2s)-3-carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium small molecule NA experimental calpain-1 catalytic subunit CAPN1 NA unknown NA drugbank (1-benzyl-2-oxo-ethyl)-carbamic acid benzyl ester NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD carboxamide derivative 7 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB carboxamide derivative 11 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB epoxysuccinate derivative 10 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB abt-957 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB carboxamide derivative 8 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB pmid20690647c4b NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD carboxamide derivative 5 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB mercaptoacrylate inhibitor of calpain 1 NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD epoxysuccinate derivative 7 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB aw-00430 NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD pmid8831774c19 NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD epoxysuccinate derivative 6 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB dihydroxanthohumol NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD epoxysuccinate derivative 2 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB 3-(1h-pyrrol-3-yl)-propionamide NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD epoxysuccinate derivative 3 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB epoxysuccinate derivative 1 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB a-558693 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD carboxamide derivative 9 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB n-(1-benzyl-2-oxo-ethyl)-benzamide NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD carboxamide derivative 10 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB 5-azolone derivative 1 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB pmid20690647c5a NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD aloxistatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] discontinued in phase 3 calpain-2 CAPN2 Clinical trial target unknown NA TTD bithionol NA Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market calpain-2 CAPN2 Clinical trial target unknown NA TTD calpastatin NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD carboxamide derivative 6 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB epoxysuccinate derivative 9 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB epoxysuccinate derivative 4 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB epoxysuccinate derivative 5 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB gnf-pf-4453 NA NA investigative calpain-2 CAPN2 Clinical trial target unknown NA TTD pmid25399719-compound-17 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB epoxysuccinate derivative 8 NA NA patented calpain-2 CAPN2 Clinical trial target unknown NA TTD , DGIDB l-aminocarnityl-succinyl-leucyl-argininal-diethylacetal small molecule Muscular Dystrophy[MeSHID:D009136] investigational calpain-3 CAPN3 NA unknown NA drugbank pd150606 small molecule NA experimental calpain small subunit 1 CAPNS1 NA unknown NA drugbank calcium phosphate dihydrate small molecule NA approved calcyphosin CAPS NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calcyphosin CAPS NA ligand NA drugbank calcium phosphate small molecule NA approved calcyphosin CAPS NA ligand NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical cysteine--trna ligase, cytoplasmic CARS NA substrate NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical probable cysteine--trna ligase, mitochondrial CARS2 NA substrate NA drugbank amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational cocaine- and amphetamine-regulated transcript protein CARTPT NA agonist 7.43 drugbank , DGIDB formic acid small molecule NA experimental,investigational peripheral plasma membrane protein cask CASK NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational peripheral plasma membrane protein cask CASK NA inhibitor NA drugbank emricasan small molecule Body tissue[MeSHID:D014024],Liver diseases[MeSHID:D008107],Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] investigational caspase-1 CASP1 NA inhibitor 0.22 drugbank , DGIDB ac-yvad-fmk NA Dermatitis, Irritant[MeSHID:D017453],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Photoallergic[MeSHID:D017454], Allergic Contact[MeSHID:D017449] patented caspase-1 CASP1 Clinical trial target unknown NA TTD , DGIDB z-val-ala-asp fluoromethyl ketone small molecule NA experimental caspase-1 CASP1 NA unknown NA drugbank z-yvad-fmk NA NA investigative caspase-1 CASP1 Clinical trial target inhibitor NA TTD , DGIDB nivocasan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355] phase 2 caspase-1 CASP1 Clinical trial target unknown 1.77 TTD , DGIDB pralnacasan small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 caspase-1 CASP1 Clinical trial target inhibitor 7.96 TTD , drugbank , DGIDB ac-201 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 caspase-1 CASP1 Clinical trial target unknown 0.29 TTD , DGIDB ac-yvad-cmk NA Dermatitis, Irritant[MeSHID:D017453],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Photoallergic[MeSHID:D017454], Allergic Contact[MeSHID:D017449] patented caspase-1 CASP1 Clinical trial target unknown NA TTD , DGIDB z-yvad-cho NA NA investigative caspase-1 CASP1 Clinical trial target unknown NA TTD yvad NA NA investigative caspase-1 CASP1 Clinical trial target unknown NA TTD pralnacasan small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 caspase-1 CASP1 Clinical trial target unknown 7.96 TTD , drugbank , DGIDB acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved caspase-1 CASP1 NA inhibitor,downregulator NA drugbank belnacasan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 2 caspase-1 CASP1 Clinical trial target unknown 5.3 TTD , DGIDB lax-101 small molecule Huntington Disease[MeSHID:D006816],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigational caspase-1 CASP1 NA unknown NA drugbank 3-{6-[(8-hydroxy-quinoline-2-carbonyl)-amino]-2-thiophen-2-yl-hexanoylamino}-4-oxo-butyri acid small molecule NA experimental caspase-1 CASP1 NA unknown NA drugbank 1-methyl-3-trifluoromethyl-1h-thieno[2,3-c]pyrazole-5-carboxylic acid (2-mercapto-ethyl)-amide small molecule NA experimental caspase-1 CASP1 NA unknown NA drugbank vx-765 small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational caspase-1 CASP1 NA unknown 5.3 drugbank , DGIDB z-vad-cho NA NA investigative caspase-1 CASP1 Clinical trial target unknown NA TTD nivocasan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355] phase 2 caspase-1 CASP1 Clinical trial target inhibitor 1.77 TTD , DGIDB minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational caspase-1 CASP1 NA negative modulator NA drugbank m826 NA NA investigative caspase-1 CASP1 Clinical trial target inhibitor NA TTD , DGIDB qpi-1007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901],Ocular Hypertension[MeSHID:D009798],Arteritis[MeSHID:D001167],Optic Neuropathy, Ischemic[MeSHID:D018917] phase 3 caspase 2 messenger rna CASP2 Clinical trial target unknown NA TTD 2-phenethylisoquinoline-1,3,4-trione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD [n-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank glionitrin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative caspase-3 CASP3 Clinical trial target unknown NA TTD pac1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909],Anaplastic astrocytoma[MeSHID:D001254] phase 1 caspase-3 CASP3 Clinical trial target activator NA TTD , DGIDB 4-[5-(2-carboxy-1-formyl-ethylcarbamoyl)-pyridin-3-yl]-benzoic acid small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank (1s)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational caspase-3 CASP3 NA negative modulator NA drugbank incadronic acid small molecule leukemia[MeSHID:D007938],Malignant Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390] experimental caspase-3 CASP3 NA activator NA drugbank petcm NA NA investigative caspase-3 CASP3 Clinical trial target activator NA TTD , DGIDB 5-[4-(1-carboxymethyl-2-oxo-propylcarbamoyl)-benzylsulfamoyl]-2-hydroxy-benzoic acid small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank (1s)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank 2-allylisoquinoline-1,3,4-trione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD m826 NA NA investigative caspase-3 CASP3 Clinical trial target inhibitor NA TTD , DGIDB 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD 2-hydroxy-5-(2-mercapto-ethylsulfamoyl)-benzoic acid small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank pamidronic acid small molecule Lytic lesion[MeSHID:D010014],Breast[MeSHID:D001940],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Malignant Bone Neoplasm[MeSHID:D001859],Malignant neoplasm of breast[MeSHID:D001943],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101] approved caspase-3 CASP3 NA activator NA drugbank methyl (3s)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank emricasan small molecule Body tissue[MeSHID:D014024],Liver diseases[MeSHID:D008107],Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] investigational caspase-3 CASP3 NA inhibitor 0.16 drugbank , DGIDB 2-methylisoquinoline-1,3,4-trione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD 1-methyl-5-(2-phenoxymethyl-pyrrolidine-1-sulfonyl)-1h-indole-2,3-dione small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank pac1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909],Anaplastic astrocytoma[MeSHID:D001254] phase 1 caspase-3 CASP3 Clinical trial target unknown NA TTD , DGIDB ac-devd-cho NA NA investigative caspase-3 CASP3 Clinical trial target inhibitor NA TTD , DGIDB sj-8002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative caspase-3 CASP3 Clinical trial target unknown NA TTD isoquinoline-1,3,4(2h)-trione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD glycyrrhizic acid small molecule Neoplasms[MeSHID:D009369],Premenstrual syndrome[MeSHID:D011293],Stomach Diseases[MeSHID:D013272],Ulcer[MeSHID:D014456],Virus Diseases[MeSHID:D014777],Peptic Ulcer[MeSHID:D010437] approved,experimental caspase-3 CASP3 NA antagonist NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved caspase-3 CASP3 NA inhibitor,downregulator NA drugbank az10417808 NA NA investigative caspase-3 CASP3 Clinical trial target inhibitor NA TTD , DGIDB 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD 5-(azepan-1-ylsulfonyl)indoline-2,3-dione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD n-[3-(2-fluoroethoxy)phenyl]-n'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide small molecule NA experimental caspase-3 CASP3 NA unknown NA drugbank 2-benzylisoquinoline-1,3,4-trione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD ac-asp-glu-val-asp-cho NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD 5-(azetidin-1-ylsulfonyl)indoline-2,3-dione NA NA investigative caspase-3 CASP3 Clinical trial target unknown NA TTD incadronic acid small molecule leukemia[MeSHID:D007938],Malignant Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390] experimental caspase-4 CASP4 NA activator NA drugbank m826 NA NA investigative caspase-4 CASP4 Patented-recorded target inhibitor NA TTD , DGIDB casp 4 inhib NA NA investigative caspase-4 CASP4 Patented-recorded target inhibitor NA TTD , DGIDB m826 NA NA investigative caspase-5 CASP5 Patented-recorded target inhibitor NA TTD , DGIDB isis 134604 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134605 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134608 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134609 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134583 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134528 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134607 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134563 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134499 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isoquinoline-1,3,4(2h)-trione NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134603 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134606 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134532 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134602 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD ac-veid-cho NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target inhibitor NA TTD , DGIDB isis 134566 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134601 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134565 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134564 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD isis 134524 NA NA investigative caspase 6 messenger rna CASP6 Literature-reported target unknown NA TTD emricasan small molecule Body tissue[MeSHID:D014024],Liver diseases[MeSHID:D008107],Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] investigational caspase-7 CASP7 NA inhibitor 0.27 drugbank , DGIDB fica small molecule NA experimental caspase-7 CASP7 NA unknown NA drugbank isatin sulfonamide 34 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial caspase-7 CASP7 Clinical trial target unknown NA TTD , DGIDB m826 NA NA investigative caspase-7 CASP7 Clinical trial target inhibitor NA TTD , DGIDB incadronic acid small molecule leukemia[MeSHID:D007938],Malignant Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390] experimental caspase-7 CASP7 NA activator NA drugbank bardoxolone small molecule NA investigational caspase-8 CASP8 NA unknown NA drugbank bryostatin 1 small molecule NA investigational caspase-8 CASP8 NA inhibitor NA drugbank acetyl-ile-glu-thr-asp-aldehyde NA NA investigative caspase-8 CASP8 Patented-recorded target unknown NA TTD isis 107612 NA NA investigative caspase 8 messenger rna CASP8 Literature-reported target unknown NA TTD acetyl-ile-glu-thr-asp-aldehyde NA NA investigative caspase 8 messenger rna CASP8 Literature-reported target unknown NA TTD isis 107642 NA NA investigative caspase 8 messenger rna CASP8 Literature-reported target unknown NA TTD isis 107652 NA NA investigative caspase 8 messenger rna CASP8 Literature-reported target unknown NA TTD glionitrin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative caspase-8 CASP8 Patented-recorded target unknown NA TTD amooranin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative caspase-8 CASP8 Patented-recorded target unknown NA TTD isis 107681 NA NA investigative caspase 8 messenger rna CASP8 Literature-reported target unknown NA TTD isoquinoline-1,3,4(2h)-trione NA NA investigative caspase 8 messenger rna CASP8 Literature-reported target unknown NA TTD isis 107676 NA NA investigative caspase 8 messenger rna CASP8 Literature-reported target unknown NA TTD nvx-207 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative caspase-9 CASP9 Clinical trial target unknown NA TTD z-lehd-fmk NA NA investigative caspase-9 CASP9 Clinical trial target inhibitor NA TTD , DGIDB pamidronic acid small molecule Lytic lesion[MeSHID:D010014],Breast[MeSHID:D001940],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Malignant Bone Neoplasm[MeSHID:D001859],Malignant neoplasm of breast[MeSHID:D001943],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101] approved caspase-9 CASP9 NA activator NA drugbank isatin sulfonamide 34 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial caspase-9 CASP9 Clinical trial target unknown NA TTD , DGIDB glionitrin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative caspase-9 CASP9 Clinical trial target unknown NA TTD calcium phosphate small molecule NA approved calsequestrin-1 CASQ1 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved calsequestrin-1 CASQ1 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calsequestrin-1 CASQ1 NA ligand NA drugbank calcium levulinate small molecule Milk (body substance)[MeSHID:D008892],Nutritional status[MeSHID:D009752] approved,experimental calsequestrin-1 CASQ1 NA agonist NA drugbank calcium phosphate small molecule NA approved calsequestrin-2 CASQ2 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved calsequestrin-2 CASQ2 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calsequestrin-2 CASQ2 NA ligand NA drugbank spermine small molecule NA experimental,nutraceutical extracellular calcium-sensing receptor CASR NA agonist 0.88 drugbank , DGIDB calhex 231 NA NA investigative extracellular calcium-sensing receptor CASR Successful target allosteric modulator NA TTD , DGIDB etelcalcetide small molecule Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational extracellular calcium-sensing receptor CASR Successful target agonist 15.91 TTD , drugbank , DGIDB calcium phosphate small molecule NA approved extracellular calcium-sensing receptor CASR NA agonist NA drugbank atf-936 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 extracellular calcium-sensing receptor CASR Successful target unknown NA TTD , DGIDB nps-2143 small molecule Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 extracellular calcium-sensing receptor CASR Successful target unknown 3.98 TTD , drugbank , DGIDB axt-914 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 extracellular calcium-sensing receptor CASR Successful target unknown NA TTD , DGIDB cinacalcet small molecule Hypercalcemia[MeSHID:D006934],Parathyroid Gland Adenocarcinoma[MeSHID:D010282],Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperparathyroidism[MeSHID:D006961],Kidney Diseases[MeSHID:D007674] approved extracellular calcium-sensing receptor CASR Successful target agonist 27.85 TTD , drugbank , DGIDB ronacaleret small molecule Osteoporosis, Postmenopausal[MeSHID:D015663],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 extracellular calcium-sensing receptor CASR Successful target antagonist 15.91 TTD , drugbank , DGIDB mk-5442 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 extracellular calcium-sensing receptor CASR Successful target unknown 3.98 TTD , DGIDB pmid15300839c17 NA NA investigative extracellular calcium-sensing receptor CASR Successful target unknown NA TTD neomycin small molecule Disease[MeSHID:D004194],Vision[MeSHID:D014785],Bacterial Infections[MeSHID:D001424],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Hepatic Coma[MeSHID:D006501],Intestines[MeSHID:D007422],Infection[MeSHID:D007239],External auditory canal structure[MeSHID:D004424],Dental caries[MeSHID:D003731] approved,vet_approved extracellular calcium-sensing receptor CASR NA unknown NA drugbank 2-furan-2-yl-3-phenethyl-3h-quinazolin-4-one NA NA investigative extracellular calcium-sensing receptor CASR Successful target unknown NA TTD ronacaleret small molecule Osteoporosis, Postmenopausal[MeSHID:D015663],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 extracellular calcium-sensing receptor CASR Successful target antagonist,allosteric modulator 15.91 TTD , drugbank , DGIDB 3-phenethyl-2-phenyl-3h-quinazolin-4-one NA NA investigative extracellular calcium-sensing receptor CASR Successful target unknown NA TTD pmid15686947c(s)-3h NA NA investigative extracellular calcium-sensing receptor CASR Successful target unknown NA TTD tak-075 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative extracellular calcium-sensing receptor CASR Successful target unknown NA TTD cinacalcet small molecule Hypercalcemia[MeSHID:D006934],Parathyroid Gland Adenocarcinoma[MeSHID:D010282],Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperparathyroidism[MeSHID:D006961],Kidney Diseases[MeSHID:D007674] approved extracellular calcium-sensing receptor CASR Successful target agonist,allosteric modulator 27.85 TTD , drugbank , DGIDB asp7991 NA Hyperparathyroidism[MeSHID:D006961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 extracellular calcium-sensing receptor CASR Successful target unknown 7.96 TTD , DGIDB calcium phosphate dihydrate small molecule NA approved extracellular calcium-sensing receptor CASR NA unknown NA drugbank asp7991 NA Hyperparathyroidism[MeSHID:D006961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 extracellular calcium-sensing receptor CASR Successful target positive modulator 7.96 TTD , DGIDB nps-2390 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical extracellular calcium-sensing receptor CASR Successful target unknown NA TTD , DGIDB r-568 NA NA discontinued in phase 2 extracellular calcium-sensing receptor CASR Successful target unknown NA TTD ac265347 NA NA investigative extracellular calcium-sensing receptor CASR Successful target allosteric modulator NA TTD , DGIDB 2-methyl-3-phenethyl-3h-pyrimidin-4-one NA NA investigative extracellular calcium-sensing receptor CASR Successful target antagonist NA TTD , DGIDB calcium citrate small molecule NA approved,investigational extracellular calcium-sensing receptor CASR NA agonist NA drugbank 1-arylmethylpyrrolidin-2-yl ethanol amine NA NA investigative extracellular calcium-sensing receptor CASR Successful target unknown NA TTD calindol NA NA investigative extracellular calcium-sensing receptor CASR Successful target allosteric modulator 3.98 TTD , DGIDB calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical calpastatin CAST NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational calpastatin CAST NA ligand NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational catalase CAT NA inhibitor NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational catalase CAT NA inhibitor NA drugbank medical cannabis biotech NA experimental,investigational catalase CAT NA inhibitor NA drugbank benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved catalase CAT NA inhibitor NA drugbank fomepizole small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved catalase CAT NA inhibitor NA drugbank euk-189 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Burn injury[MeSHID:D002056] phase 1 catalase CAT Clinical trial target unknown NA TTD , DGIDB nnc55-0396 NA NA investigative cation channel sperm-associated protein 1 CATSPER1 Literature-reported target blocker NA TTD , DGIDB pgf1alpha NA NA investigative cation channel sperm-associated protein 1 CATSPER1 Literature-reported target unknown NA TTD hc-056456 NA NA investigative cation channel sperm-associated protein 1 CATSPER1 Literature-reported target blocker NA TTD , DGIDB nnc55-0396 NA NA investigative cation channel sperm-associated protein 2 CATSPER2 Literature-reported target blocker NA TTD , DGIDB pgf1alpha NA NA investigative cation channel sperm-associated protein 2 CATSPER2 Literature-reported target unknown NA TTD nnc55-0396 NA NA investigative cation channel sperm-associated protein 3 CATSPER3 Literature-reported target blocker NA TTD , DGIDB pgf1alpha NA NA investigative cation channel sperm-associated protein 3 CATSPER3 Literature-reported target unknown NA TTD apn401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 cblb messenger rna CBLB Clinical trial target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational carbonyl reductase [nadph] 1 CBR1 NA inhibitor NA drugbank heptaethylene glycol small molecule NA experimental carbonyl reductase [nadph] 1 CBR1 NA unknown NA drugbank curcumin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational carbonyl reductase [nadph] 1 CBR1 NA unknown NA drugbank 2-(2-{2-[2-(2-{2-[2-(2-ethoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethanol, polyethyleneglycol peg400 small molecule NA experimental carbonyl reductase [nadph] 1 CBR1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational carbonyl reductase [nadph] 1 CBR1 NA unknown NA drugbank n6022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 s-nitrosoglutathione reductase CBR1 Clinical trial target unknown 10.61 TTD , DGIDB curcumin sulfate small molecule NA experimental carbonyl reductase [nadph] 1 CBR1 NA unknown NA drugbank rutin small molecule NA approved,experimental,investigational carbonyl reductase [nadph] 1 CBR1 NA unknown NA drugbank 3-(4-amino-1-tert-butyl-1h-pyrazolo[3,4-d]pyrimidin-3-yl)phenol small molecule NA experimental carbonyl reductase [nadph] 1 CBR1 NA ligand NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational carbonyl reductase [nadph] 1 CBR1 NA inhibitor NA drugbank ademetionine small molecule Emotions[MeSHID:D004644],Degenerative polyarthritis[MeSHID:D010003],Depressive disorder[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Liver diseases[MeSHID:D008107],Bone Tissue[MeSHID:D001842],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] approved,investigational,nutraceutical cystathionine beta-synthase CBS NA activator NA drugbank aminooxyacetic acid NA NA investigative cystathionine beta-synthase CBS Clinical trial target inhibitor NA TTD , DGIDB serine small molecule NA investigational,nutraceutical cystathionine beta-synthase CBS NA unknown NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical cystathionine beta-synthase CBS NA unknown NA drugbank heme NA NA investigative cystathionine beta-synthase CBS Clinical trial target unknown NA TTD ot-58 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Homocystinuria[MeSHID:D006712],Occupational therapy regime[MeSHID:D009788] phase 1/2 cystathionine beta-synthase CBS Clinical trial target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical cystathionine beta-synthase CBS NA cofactor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational chromobox protein homolog 5 CBX5 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical kynurenine--oxoglutarate transaminase 1 CCBL1 NA cofactor NA drugbank pyridoxamine-5'-phosphate small molecule NA experimental kynurenine--oxoglutarate transaminase 1 CCBL1 NA unknown NA drugbank indoleacetic acid small molecule NA experimental kynurenine--oxoglutarate transaminase 1 CCBL1 NA unknown NA drugbank d-phenylalanine small molecule NA experimental kynurenine--oxoglutarate transaminase 1 CCBL1 NA unknown NA drugbank n(6)-(pyridoxal phosphate)-l-lysine small molecule NA experimental kynurenine--oxoglutarate transaminase 1 CCBL1 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical kynurenine--oxoglutarate transaminase 3 CCBL2 NA cofactor NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved mitochondrial potassium channel CCDC51 NA activator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved mitochondrial potassium channel CCDC51 NA activator NA drugbank camostat small molecule Pancreatitis, Chronic[MeSHID:D050500],Hereditary pancreatitis[MeSHID:C537262],Lung Injury[MeSHID:D055370],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental cholecystokinin CCK NA inhibitor NA drugbank ci-1015 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-ala-gly-d-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD jmv180 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target agonist NA TTD , DGIDB 1-(3,3-diphenyl-allyl)-3-m-tolyl-urea NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD boc-tyr(so3h)-nle-gly-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-137337 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD cholecystokinin small molecule Exocrine pancreatic insufficiency[MeSHID:D010188],Diagnosis[MeSHID:D003933],Gall Bladder Diseases[MeSHID:D005705] approved,investigational cholecystokinin receptor type a CCKAR NA agonist NA drugbank ar-r-1589 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eating[MeSHID:D004435],Obesity[MeSHID:D009765],Disease[MeSHID:D004194] preclinical cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD , DGIDB tyr-d-nle-gly-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD boc-d-glu-tyr(so3h)-nle-d-lys-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD vl-0494 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD gi 181771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 2 cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD l-708474 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-140723 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-phe-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD cr-2345 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD ssr-125180 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD jnj-17156516 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target antagonist NA TTD , DGIDB pd-138916 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD cck-33 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target agonist NA TTD , DGIDB tyr-d-ala-gly-phe-nh-nh-phe-asp-nmenle-d-trp-boc NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD ucl-2000; butabindide NA NA discontinued in phase 1 cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-135158 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD boc-cyclo-(glu-tyr-nle-d-lys)-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD asp-tyr(oso3h)-met-gly-trp-met-asp-phe NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD iqm-97423 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD proglumide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 cholecystokinin receptor type a CCKAR Clinical trial target unknown 7.96 TTD , DGIDB dexloxiglumide small molecule Irritable Bowel Syndrome[MeSHID:D043183],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] investigational,phase 2 cholecystokinin receptor type a CCKAR Clinical trial target unknown 23.87 TTD , drugbank , DGIDB pd-137342 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD boc-d-glu-tyr(so3h)-nle-d-nle-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD dexloxiglumide small molecule Irritable Bowel Syndrome[MeSHID:D043183],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] investigational,phase 2 cholecystokinin receptor type a CCKAR Clinical trial target antagonist 23.87 TTD , drugbank , DGIDB gw-5823 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target agonist NA TTD , DGIDB tp-680 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD 1-(4-chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD a-71378 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD , DGIDB 2-nap NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD gg-8573 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD , DGIDB h-tyr-d-ala-gly-phe-nh-nh-trp-d-nle-d-asp-d-phe-h NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pranazepide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] discontinued in phase 2 cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD l-740093 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD lintitript small molecule Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],Appetite Disorders[MeSHID:D001068],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigational,discontinued in phase 2 cholecystokinin receptor type a CCKAR Clinical trial target antagonist 3.98 TTD , drugbank , DGIDB t-0632 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] discontinued in phase 1 cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-ala-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-ala-gly-trp-nmenle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tarazepide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] discontinued in phase 2 cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tetragastrin NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD a-74498 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD , DGIDB glaxo-11p NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target agonist NA TTD , DGIDB fpl-14294 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD , DGIDB h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-trp-boc NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-135118 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-140547 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-140548 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-136621 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD boc-glu-tyr(so3h)-nle-d-lys-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-phe-gly-trp-nmenle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD vl-0699 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD ceruletide small molecule Diagnosis[MeSHID:D003933],Paralytic Ileus[MeSHID:D007418],Pancreas[MeSHID:D010179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],pancreatic juice[MeSHID:D010189] approved cholecystokinin receptor type a CCKAR NA inducer 31.83 drugbank , DGIDB 1-(4-chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD asperlicin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD sr-146131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD vl-0395 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-170292 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cholecystokinin receptor type a CCKAR Clinical trial target unknown 3.98 TTD , DGIDB devazepide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD vl-1499 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-ala-gly-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-138915 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-d-trp-nle-asp-phe-h NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD 3,4-dichloro-n-(3,3-diphenyl-allyl)-benzamide NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-phe-gly-d-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-d-trp-h NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD bis(31/31')[[cys(31), nva(34)]npy(27-36)-nh(2)] NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD vl-2799 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD ce-326597 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 2 cholecystokinin receptor type a CCKAR Clinical trial target agonist 7.96 TTD , DGIDB boc-asp-tyr(so3-)-nle-gly-trp-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD cck-8 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target agonist 7.96 TTD , DGIDB [3h]devazepide NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target antagonist NA TTD , DGIDB ksg-504 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD fr-175985 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-phe-gly-trp-nle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD tyr-d-nle-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD sc-50998 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD l-736380 NA NA investigative cholecystokinin receptor type a CCKAR Clinical trial target unknown NA TTD pd-140723 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pd-137337 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pd-149164 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-phe-gly-trp-nle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pentagastrin small molecule Gastric Acid[MeSHID:D005744],Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gastrin/cholecystokinin type b receptor CCKBR Successful target agonist 27.28 TTD , drugbank , DGIDB pd-136621 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD itriglumide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown 9.09 TTD , DGIDB h-tyr-d-ala-gly-phe-nh-nh-d-trp-nle-asp-phe-bo NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD desulfated cholecystokinin-8 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target agonist NA TTD , DGIDB [3h]jb-93182 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pd-170292 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical gastrin/cholecystokinin type b receptor CCKBR Successful target unknown 1.52 TTD , DGIDB pd-135118 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD z 360 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD , DGIDB s-0509 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD , DGIDB demogastrin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid carcinoma[MeSHID:D013964] phase 1 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD , DGIDB tyr-d-nle-gly-d-trp-nle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD l-365260 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target antagonist 9.09 TTD , DGIDB [3h]pd140376 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD gastrazole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Duodenal Ulcer[MeSHID:D004381] phase 3 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD , DGIDB ceruletide NA Diagnosis[MeSHID:D003933],Paralytic Ileus[MeSHID:D007418],Pancreas[MeSHID:D010179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],pancreatic juice[MeSHID:D010189] approved gastrin/cholecystokinin type b receptor CCKBR Successful target unknown 1.52 TTD , DGIDB tyr-d-ala-gly-d-trp-nle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pd-138917 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD cholecystokinin-9 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tetragastrin NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pd-138915 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pd-135158 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target antagonist NA TTD , DGIDB cholecystokinin small molecule Exocrine pancreatic insufficiency[MeSHID:D010188],Diagnosis[MeSHID:D003933],Gall Bladder Diseases[MeSHID:D005705] approved,investigational gastrin/cholecystokinin type b receptor CCKBR NA agonist NA drugbank rpr-107836 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-trp-boc NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-pro-gly-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tp-680 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD ci-1015 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD [3h]pbc-264 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD gg-8573 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD , DGIDB tyr-d-ala-gly-trp-nle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-phe-gly-d-trp-nle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD [125i]-bdz2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target antagonist NA TTD , DGIDB pd-140547 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD rp-72540 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD dexloxiglumide NA Irritable Bowel Syndrome[MeSHID:D043183],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD rp73870 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD asp-tyr(oso3h)-met-gly-trp-met-asp-phe NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tetronothiodin NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target antagonist NA TTD , DGIDB tt-223 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD , DGIDB pd-140548 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD cck-33 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target agonist NA TTD , DGIDB pd-138916 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-pro-gly-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pbc-264 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD boc-asp-tyr(so3-)-nle-gly-trp-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD jnj-26070109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] preclinical gastrin/cholecystokinin type b receptor CCKBR Successful target antagonist NA TTD , DGIDB tyr-d-ala-gly-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-phe-gly-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-ala-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-nle-gly-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD bc-264 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-phe-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD [125i]pd142308 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD cck-8 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target agonist 1.52 TTD , DGIDB yf-476 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target antagonist 9.09 TTD , DGIDB pd-134308 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-ala-gly-phe-nh-nh-phe-asp-nmenle-d-trp-boc NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD gw-5823 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target antagonist NA TTD , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-d-trp-h NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD rp-69758 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD spiroglumide NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach Diseases[MeSHID:D013272] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown 1.52 TTD , DGIDB rb-400 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD pd-137342 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-gly-gly-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD gv-150013 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD itriglumide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target antagonist 9.09 TTD , DGIDB cr-2093 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Intestinal Cancer[MeSHID:D007414] discontinued in phase 1 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD tyr-d-nle-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-d-trp-nle-asp-phe-h NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-trp-ac NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD jnj-26070109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] preclinical gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD , DGIDB tyr-d-nle-gly-trp-nle-asp-phe-nh2 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD yf-476 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276] phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown 9.09 TTD , DGIDB l-365260 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 gastrin/cholecystokinin type b receptor CCKBR Successful target unknown 9.09 TTD , DGIDB rp-71483 NA NA investigative gastrin/cholecystokinin type b receptor CCKBR Successful target unknown NA TTD cat-213 biotech Allergic rhinitis (disorder)[MeSHID:D065631] investigational eotaxin CCL11 NA unknown NA drugbank bertilimumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Ulcerative Colitis[MeSHID:D003093],Psoriasis[MeSHID:D011565],Bullous pemphigoid[MeSHID:D010391],Eye[MeSHID:D005123] phase 2 small-inducible cytokine a11 CCL11 Clinical trial target inhibitor 42.43 TTD , DGIDB bertilimumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Ulcerative Colitis[MeSHID:D003093],Psoriasis[MeSHID:D011565],Bullous pemphigoid[MeSHID:D010391],Eye[MeSHID:D005123] phase 2 small-inducible cytokine a11 CCL11 Clinical trial target unknown 42.43 TTD , DGIDB rs-504393 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] preclinical monocyte chemotactic and activating factor CCL2 Clinical trial target unknown NA TTD , DGIDB abn-912 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 monocyte chemotactic and activating factor CCL2 Clinical trial target unknown NA TTD mcp-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] preclinical monocyte chemotactic and activating factor CCL2 Clinical trial target unknown NA TTD , DGIDB chondroitin sulfate small molecule Catabolism[MeSHID:D008660],Bone Tissue[MeSHID:D001842],Degenerative polyarthritis[MeSHID:D010003],Cartilage[MeSHID:D002356],Sclerosis[MeSHID:D012598],Body tissue[MeSHID:D014024],Inflammation[MeSHID:D007249],Synovial Membrane[MeSHID:D013583],Disease Progression[MeSHID:D018450],Pain[MeSHID:D010146] approved,investigational,nutraceutical c-c motif chemokine 2 CCL2 NA unknown NA drugbank cnto888 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 monocyte chemotactic and activating factor CCL2 Clinical trial target unknown NA TTD danazol small molecule Breast Fibrocystic Disease[MeSHID:D005348],Angioedemas, Hereditary[MeSHID:D054179],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menorrhagia[MeSHID:D008595],Malignant neoplasm of breast[MeSHID:D001943] approved c-c motif chemokine 2 CCL2 NA inhibitor NA drugbank nox-e36 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 monocyte chemotactic and activating factor CCL2 Clinical trial target unknown NA TTD , DGIDB carlumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] phase 2 monocyte chemotactic and activating factor CCL2 Clinical trial target unknown 42.43 TTD , DGIDB mimosine small molecule NA experimental c-c motif chemokine 2 CCL2 NA inhibitor NA drugbank bindarit NA Nephritis[MeSHID:D009393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 monocyte chemotactic and activating factor CCL2 Clinical trial target unknown 21.22 TTD , DGIDB carlumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] phase 2 monocyte chemotactic and activating factor CCL2 Clinical trial target inhibitor 42.43 TTD , DGIDB gsk3050002 NA Arthritis, Psoriatic[MeSHID:D015535],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 liver and activation-regulated chemokine CCL20 Clinical trial target unknown 63.65 TTD , DGIDB rox-888 small molecule Pain[MeSHID:D010146] investigational c-c motif chemokine 3 CCL3 NA unknown NA drugbank nagrestipen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 macrophage inflammatory protein 1-alpha CCL3 Clinical trial target unknown 31.83 TTD , DGIDB heparin disaccharide iii-s small molecule NA experimental c-c motif chemokine 5 CCL5 NA unknown NA drugbank ni-0701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 t-cell-specific protein rantes CCL5 Clinical trial target unknown NA TTD , DGIDB heparin disaccharide i-s small molecule NA experimental c-c motif chemokine 5 CCL5 NA unknown NA drugbank pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational c-c motif chemokine 8 CCL8 NA unknown NA drugbank olx10010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cicatrix, Hypertrophic[MeSHID:D017439] phase 2 ccn2 messenger rna CCN2 Clinical trial target unknown NA TTD pf-06473871 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cicatrix, Hypertrophic[MeSHID:D017439] phase 2 ccn2 messenger rna CCN2 Clinical trial target unknown NA TTD rxi-109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cicatrix, Hypertrophic[MeSHID:D017439],Fibrosis[MeSHID:D005355] phase 2 ccn2 messenger rna CCN2 Clinical trial target unknown NA TTD , DGIDB 3-({2-[(4-{[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino}phenyl)sulfonyl]ethyl}amino)propan-1-ol small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 3-(6-cyclohexylmethoxy-9h-purin-2-ylamino)-benzenesulfonamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 1-[4-(aminosulfonyl)phenyl]-1,6-dihydropyrazolo[3,4-e]indazole-3-carboxamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-{[5-(cyclohexyloxy)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]amino}benzenesulfonamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-[(7-oxo-7h-thiazolo[5,4-e]indol-8-ylmethyl)-amino]-n-pyridin-2-yl-benzenesulfonamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank n-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank variolin b small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank n-(3-cyclopropyl-1h-pyrazol-5-yl)-2-(2-naphthyl)acetamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-{5-[(z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}benzenesulfonamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-{5-[(z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}-2-(trifluoromethyl)benzenesulfonamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-{[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino}benzamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-methyl-5-[(2z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank (2r)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-{5-[(z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}benzoic acid small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 1-methyl-8-(phenylamino)-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxylic acid small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 6-o-cyclohexylmethyl guanine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-{5-[(z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]-2-furyl}-n-methylbenzenesulfonamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank hydroxy(oxo)(3-{[(2z)-4-[3-(1h-1,2,4-triazol-1-ylmethyl)phenyl]pyrimidin-2(5h)-ylidene]amino}phenyl)ammonium small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank (2r)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9h-purin-2-yl}amino)butan-1-ol small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 6-cyclohexylmethoxy-2-(3'-chloroanilino) purine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank (2s)-n-[(3e)-5-cyclopropyl-3h-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank o6-cyclohexylmethoxy-2-(4'-sulphamoylanilino) purine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-(6-cyclohexylmethoxy-9h-purin-2-ylamino)--benzamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 5-[5,6-bis(methyloxy)-1h-benzimidazol-1-yl]-3-{[1-(2-chlorophenyl)ethyl]oxy}-2-thiophenecarboxamide small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank n-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-n',n'-dimethyl-benzene-1,4-diamine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 1-(3,5-dichlorophenyl)-5-methyl-1h-1,2,4-triazole-3-carboxylic acid small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-(4-propoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 2-anilino-6-cyclohexylmethoxypurine small molecule NA experimental cyclin-a2 CCNA2 NA unknown NA drugbank 4-(quinolin-3-yl)-n-p-tolylpyrimidin-2-amine NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD thieno analogue of kenpaullone NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD bisindolylmaleimide-i NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD azakenpaullone NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD ro-316233 NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD kenpaullone NA NA patented g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown 0.45 TTD , DGIDB 3,4-bis(indol-3-yl)maleimide derivative NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD 4-(quinolin-4-yl)-n-p-tolylpyrimidin-2-amine NA NA investigative g2/mitotic-specific cyclin b1 CCNB1 Patented-recorded target unknown NA TTD bryostatin 1 small molecule NA investigational g1/s-specific cyclin-d1 CCND1 NA inhibitor NA drugbank 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative g1/s-specific cyclin-d1 CCND1 Clinical trial target unknown NA TTD briciclib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 g1/s-specific cyclin-d1 CCND1 Clinical trial target unknown 6.37 TTD , DGIDB abt-263 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant Neoplasms[MeSHID:D009369],Relapse[MeSHID:D012008] phase 3 g1/s-specific cyclin-d1 CCND1 Clinical trial target unknown 0.27 TTD , DGIDB 7-hydroxycoumarin NA NA investigative g1/s-specific cyclin-d1 CCND1 Clinical trial target unknown NA TTD 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative g1/s-specific cyclin-d1 CCND1 Clinical trial target unknown NA TTD encorafenib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational g1/s-specific cyclin-d1 CCND1 NA inhibitor NA drugbank 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative g1/s-specific cyclin-d1 CCND1 Clinical trial target unknown NA TTD acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved g1/s-specific cyclin-d1 CCND1 NA downregulator NA drugbank 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative g1/s-specific cyclin-d1 CCND1 Clinical trial target unknown NA TTD 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative g1/s-specific cyclin-d1 CCND1 Clinical trial target unknown NA TTD briciclib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 g1/s-specific cyclin-d1 CCND1 Clinical trial target inhibitor 6.37 TTD , DGIDB arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational g1/s-specific cyclin-d1 CCND1 NA antagonist NA drugbank , DGIDB a-987306 NA NA investigative c-c chemokine receptor type 1 CCR1 Clinical trial target unknown NA TTD mln3897 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 c-c chemokine receptor type 1 CCR1 Clinical trial target unknown NA TTD ave1701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 c-c chemokine receptor type 1 CCR1 Clinical trial target unknown NA TTD , DGIDB bms-817399 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 c-c chemokine receptor type 1 CCR1 Clinical trial target antagonist 25.46 TTD , DGIDB azd4818 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 c-c chemokine receptor type 1 CCR1 Clinical trial target antagonist 12.73 TTD , DGIDB ccx-354 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922],Rheumatoid Arthritis[MeSHID:D001172] phase 2 c-c chemokine receptor type 1 CCR1 Clinical trial target unknown 50.92 TTD , DGIDB bx 471 NA NA investigative c-c chemokine receptor type 1 CCR1 Clinical trial target antagonist NA TTD , DGIDB cosalane derivative NA NA investigative c-c chemokine receptor type 1 CCR1 Clinical trial target unknown NA TTD bms-817399 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 c-c chemokine receptor type 1 CCR1 Clinical trial target unknown 25.46 TTD , DGIDB cntx-6970 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , DGIDB ccx915 small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 1 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , drugbank rs-504393 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] preclinical c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , DGIDB aminoguanidine NA Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] phase 1 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown 2.89 TTD , DGIDB ccx-140 NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown 17.36 TTD , DGIDB plozalizumab biotech NA investigational c-c chemokine receptor type 2 CCR2 NA antibody 17.36 drugbank , DGIDB teijin-lead_cmp_5 NA NA investigative c-c chemokine receptor type 2 CCR2 Clinical trial target antagonist NA TTD , DGIDB incb3284 small molecule Disease[MeSHID:D004194] investigational c-c chemokine receptor type 2 CCR2 NA unknown NA drugbank , DGIDB incb-10820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD viral macrophage inflammatory protein-ii NA NA investigative c-c chemokine receptor type 2 CCR2 Clinical trial target antagonist NA TTD , DGIDB (s)-3-(2',2'-dimethyl-propionyl)amino-caprolactam NA NA investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD rs-136270 NA NA investigative c-c chemokine receptor type 2 CCR2 Clinical trial target antagonist NA TTD , DGIDB incb3284 small molecule Disease[MeSHID:D004194] investigational c-c chemokine receptor type 2 CCR2 NA antagonist NA drugbank , DGIDB tak-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 1 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , DGIDB nsc-651016 NA NA investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD mcp-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] preclinical c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , DGIDB mk-0812 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown 5.79 TTD , DGIDB cenicriviroc NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],HIV Infections[MeSHID:D015658] phase 2 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown 5.79 TTD , DGIDB gsk-1344386b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD rap-310 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD bms-a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD rap-103 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD (s)-3-(1'-adamantanecarbonyl)amino-caprolactam NA NA investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD ccx872 NA Diabetic Nephropathy[MeSHID:D003928],Pancreatic Neoplasm[MeSHID:D010190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , DGIDB opl-ccl2-lpm NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] phase 1 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , DGIDB azd-2423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown 17.36 TTD , DGIDB mln1202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Neoplasm Metastasis[MeSHID:D009362],Respiratory Syncytial Virus Infections[MeSHID:D018357],Multiple Sclerosis[MeSHID:D009103],Expiration, function[MeSHID:D045853] phase 2 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , DGIDB (r)-3-(1'-adamantanecarbonyl)amino-caprolactam NA NA investigative c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD cenicriviroc NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],HIV Infections[MeSHID:D015658] phase 2 c-c chemokine receptor type 2 CCR2 Clinical trial target antagonist 5.79 TTD , DGIDB incb8696 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] discontinued in phase 1 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD rs-504393 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] preclinical c-c chemokine receptor type 2 CCR2 Clinical trial target antagonist NA TTD , DGIDB rs-102895 NA NA investigative c-c chemokine receptor type 2 CCR2 Clinical trial target antagonist NA TTD , DGIDB bms-813160 NA Diabetic Nephropathy[MeSHID:D003928],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 c-c chemokine receptor type 2 CCR2 Clinical trial target unknown NA TTD , DGIDB ro116-4875/608 NA NA investigative ccr3 messenger rna CCR3 Clinical trial target antagonist NA TTD , DGIDB ro330-0802/001 NA NA investigative ccr3 messenger rna CCR3 Clinical trial target antagonist NA TTD , DGIDB ro116-9132/238 NA NA investigative ccr3 messenger rna CCR3 Clinical trial target antagonist NA TTD , DGIDB ym-344031 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] preclinical c-c chemokine receptor type 3 CCR3 Discontinued target unknown NA TTD , DGIDB ym-355179 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] preclinical c-c chemokine receptor type 3 CCR3 Discontinued target unknown NA TTD , DGIDB asm8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 ccr3 messenger rna CCR3 Clinical trial target unknown NA TTD azd-1744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 c-c chemokine receptor type 3 CCR3 Discontinued target unknown NA TTD banyu (i) NA NA investigative ccr3 messenger rna CCR3 Clinical trial target antagonist NA TTD , DGIDB dpc-168 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 c-c chemokine receptor type 3 CCR3 Discontinued target unknown NA TTD ro320-2947/001 NA NA investigative ccr3 messenger rna CCR3 Clinical trial target antagonist NA TTD , DGIDB ym-355179 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] preclinical c-c chemokine receptor type 3 CCR3 Discontinued target antagonist NA TTD , DGIDB mogamulizumab biotech Mycosis Fungoides[MeSHID:D009182],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sezary Syndrome[MeSHID:D012751],Leukemia, T-Cell[MeSHID:D015458],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Malignant Neoplasms[MeSHID:D009369] approved,investigational c-c chemokine receptor type 4 CCR4 Successful target antagonist 148.52 TTD , drugbank , DGIDB rs-1748 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD azd-1678 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] preclinical c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD , DGIDB 4-tert-butyl-n-m-tolylthiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD gsk-2239633 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 c-c chemokine receptor type 4 CCR4 Successful target unknown 21.22 TTD , DGIDB 4-tert-butyl-n-(naphthalen-1-yl)thiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD c-014c NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD 4-tert-butyl-n-phenylthiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD 4-isopropyl-n-(naphthalen-1-yl)thiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD at-008 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD mogamulizumab biotech Mycosis Fungoides[MeSHID:D009182],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sezary Syndrome[MeSHID:D012751],Leukemia, T-Cell[MeSHID:D015458],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Malignant Neoplasms[MeSHID:D009369] approved,investigational c-c chemokine receptor type 4 CCR4 Successful target antagonist,antibody 148.52 TTD , drugbank , DGIDB 4-methyl-n-(naphthalen-1-yl)thiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD 4-tert-butyl-n-(2-isopropylphenyl)thiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD n-(naphthalen-1-yl)-4-phenylthiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD flx475 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1/2 c-c chemokine receptor type 4 CCR4 Successful target antagonist NA TTD , drugbank , DGIDB 4-tert-butyl-n-(naphthalen-1-yl)oxazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD n-(naphthalen-1-yl)-4-neopentylthiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD atlcar.cd30.ccr4 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Lymphatic Diseases[MeSHID:D008206],Immunoproliferative Disorders[MeSHID:D007160],Immune System Diseases[MeSHID:D007154],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 1 c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD , DGIDB 4-tert-butyl-n-o-tolylthiazol-2-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD n-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD n-(4-tert-butylthiazol-2-yl)-1h-indol-4-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD n-(4-tert-butylthiazol-2-yl)quinolin-5-amine NA NA investigative c-c chemokine receptor type 4 CCR4 Successful target unknown NA TTD sch-c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] discontinued in phase 1 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD cenicriviroc NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],HIV Infections[MeSHID:D015658] phase 2 c-c chemokine receptor type 5 CCR5 Successful target antagonist 8.49 TTD , DGIDB incb9471 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2a c-c chemokine receptor type 5 CCR5 Successful target unknown 8.49 TTD , DGIDB aplaviroc small molecule HIV Infections[MeSHID:D015658] investigational c-c chemokine receptor type 5 CCR5 NA antagonist 4.24 drugbank , DGIDB maraviroc NA Muscle strain[MeSHID:D013180],Virus Replication[MeSHID:D014779],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],HIV Infections[MeSHID:D015658] approved ccr5 messenger rna CCR5 Successful target antagonist 27.58 TTD , DGIDB viral macrophage inflammatory protein-ii NA NA investigative ccr5 messenger rna CCR5 Successful target antagonist NA TTD , DGIDB gw873140 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] discontinued in phase 3 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD vch-286 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 1 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , DGIDB azd8566 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD ibalizumab biotech HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Communicable Diseases[MeSHID:D003141],Blood[MeSHID:D001769],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational c-c chemokine receptor type 5 CCR5 NA antagonist NA drugbank amd-070 small molecule HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],WHIM syndrome[MeSHID:C536697],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Merkel cell carcinoma[MeSHID:D015266] investigational c-c chemokine receptor type 5 CCR5 NA unknown NA drugbank cmpd-167 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD bms-813160 NA Diabetic Nephropathy[MeSHID:D003928],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , DGIDB sch-c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] discontinued in phase 1 ccr5 messenger rna CCR5 Successful target unknown NA TTD sb-728-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , DGIDB tak-220 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] phase 1 c-c chemokine receptor type 5 CCR5 Successful target unknown 16.97 TTD , DGIDB maraviroc NA Muscle strain[MeSHID:D013180],Virus Replication[MeSHID:D014779],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],HIV Infections[MeSHID:D015658] approved ccr5 messenger rna CCR5 Successful target unknown 27.58 TTD , DGIDB pro-140 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 3 c-c chemokine receptor type 5 CCR5 Successful target antagonist 21.22 TTD , DGIDB pro 140 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] phase 2/3 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , DGIDB vicriviroc small molecule Virus Diseases[MeSHID:D014777],HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 c-c chemokine receptor type 5 CCR5 Successful target unknown 21.22 TTD , drugbank , DGIDB 4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine NA NA investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD maraviroc small molecule Muscle strain[MeSHID:D013180],Virus Replication[MeSHID:D014779],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],HIV Infections[MeSHID:D015658] approved,investigational c-c chemokine receptor type 5 CCR5 Successful target antagonist 27.58 TTD , drugbank , DGIDB nifeviroc NA NA investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD gsk-706769 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , DGIDB ccr5 mab biotech HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , drugbank , DGIDB pro-140 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 3 c-c chemokine receptor type 5 CCR5 Successful target unknown 21.22 TTD , DGIDB e-913 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 3 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , DGIDB incb-9471 small molecule NA investigational c-c chemokine receptor type 5 CCR5 NA antagonist 8.49 drugbank , DGIDB tak-220 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] phase 1 c-c chemokine receptor type 5 CCR5 Successful target antagonist 16.97 TTD , DGIDB ddrnai therapy rhiv7-shl-tar-ccr5rz, stem cells NA Thrombocytopenia-Absent Radius Syndrome[MeSHID:C536940],Stem cells[MeSHID:D013234],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 1/2 ccr5 messenger rna CCR5 Successful target unknown NA TTD (2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine NA NA investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD pf-232798 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 c-c chemokine receptor type 5 CCR5 Successful target unknown 4.24 TTD , DGIDB anibamine NA NA investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD vicriviroc small molecule Virus Diseases[MeSHID:D014777],HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 c-c chemokine receptor type 5 CCR5 Successful target antagonist 21.22 TTD , drugbank , DGIDB variecolin NA NA investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD sch-210971 NA NA investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD cenicriviroc NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],HIV Infections[MeSHID:D015658] phase 2 c-c chemokine receptor type 5 CCR5 Successful target unknown 8.49 TTD , DGIDB n-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine NA NA investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD incb15050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 1 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , DGIDB leronlimab biotech HIV Seropositivity[MeSHID:D006679],Malignant Neoplasms[MeSHID:D009369],HIV Infections[MeSHID:D015658],Vision[MeSHID:D014785],Traumatic injury[MeSHID:D014947],CD8-Positive T-Lymphocytes[MeSHID:D018414],CD4 Positive T Lymphocytes[MeSHID:D015496],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational c-c chemokine receptor type 5 CCR5 NA antagonist,antibody 21.22 drugbank , DGIDB gt-1282 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD cal-1 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] phase 1/2 c-c chemokine receptor type 5 CCR5 Successful target unknown NA TTD , DGIDB viral macrophage inflammatory protein-ii NA NA investigative c-c chemokine receptor type 8 CCR8 Discontinued target antagonist NA TTD , DGIDB n-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide NA NA investigative c-c chemokine receptor type 8 CCR8 Discontinued target unknown NA TTD ccx-832 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 1 c-c chemokine receptor type 8 CCR8 Discontinued target unknown NA TTD i-309 NA NA investigative c-c chemokine receptor type 8 CCR8 Discontinued target unknown NA TTD n-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide NA NA investigative c-c chemokine receptor type 8 CCR8 Discontinued target unknown NA TTD zk 756326 NA NA investigative c-c chemokine receptor type 8 CCR8 Discontinued target agonist NA TTD , DGIDB ccx-025 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 1 c-c chemokine receptor type 9 CCR9 Clinical trial target unknown NA TTD , DGIDB vercirnon small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] investigational,phase 3 c-c chemokine receptor type 9 CCR9 Clinical trial target allosteric modulator 95.48 TTD , drugbank , DGIDB ccx507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 1 c-c chemokine receptor type 9 CCR9 Clinical trial target unknown NA TTD , DGIDB vercirnon small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] investigational,phase 3 c-c chemokine receptor type 9 CCR9 Clinical trial target unknown 95.48 TTD , drugbank , DGIDB mln-3126 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859] phase 1 c-c chemokine receptor type 9 CCR9 Clinical trial target unknown 63.65 TTD , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental copper chaperone for superoxide dismutase CCS NA cofactor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational copper chaperone for superoxide dismutase CCS NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational copper chaperone for superoxide dismutase CCS NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational copper chaperone for superoxide dismutase CCS NA cofactor NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational t-complex protein 1 subunit gamma CCT3 NA ligand NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental t-complex protein 1 subunit gamma CCT3 NA unknown NA drugbank ic14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] phase 2 monocyte differentiation antigen cd14 CD14 Clinical trial target inhibitor 95.48 TTD , DGIDB ic14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] phase 2 monocyte differentiation antigen cd14 CD14 Clinical trial target unknown 95.48 TTD , DGIDB ic14 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 monocyte differentiation antigen cd14 CD14 Clinical trial target unknown 95.48 TTD , DGIDB ic14 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 monocyte differentiation antigen cd14 CD14 Clinical trial target inhibitor 95.48 TTD , DGIDB atibuclimab biotech Sepsis[MeSHID:D018805],Pneumonia[MeSHID:D011014] investigational monocyte differentiation antigen cd14 CD14 NA unknown NA drugbank tetrachlorodecaoxide small molecule Neoplasms[MeSHID:D009369],HIV Infections[MeSHID:D015658],Disease[MeSHID:D004194],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Infection[MeSHID:D007239] approved,investigational scavenger receptor cysteine-rich type 1 protein m130 CD163 NA unknown NA drugbank 4scar19 and 4scar20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB bcma-cd19 ccar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cd19-car-t2 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19.car-ankt cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Myeloid Leukemia[MeSHID:D007951],Chronic Lymphocytic Leukemia[MeSHID:D015451],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19/20-car vector-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Prolymphocytic Leukemia[MeSHID:D015463],Lymphoma, Follicular[MeSHID:D008224] clinical trial b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB carvac NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD allogeneic cart-19 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB ucart019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB ic9-car19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immunoproliferative Disorders[MeSHID:D007160],Immune System Diseases[MeSHID:D007154],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reticulosarcoma[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB blinatumomab biotech Philadelphia Chromosome[MeSHID:D010677],Relapse[MeSHID:D012008],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] approved,investigational b-lymphocyte antigen cd19 CD19 NA activator 3.5 drugbank , DGIDB cart-19/bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-car t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 and cd22 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 autologous t-cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-targeting car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB ft-819 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cd19-car and cd28-car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19-car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB mdx-1342 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 9.79 TTD , DGIDB anti-cd19-car pbl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],B-Cell Lymphomas[MeSHID:D016393],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-meso-19 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB blinatumomab NA Philadelphia Chromosome[MeSHID:D010677],Relapse[MeSHID:D012008],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] approved b-lymphocyte surface antigen b4 CD19 Successful target antibody 3.5 TTD , DGIDB car-20/19-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],T-Lymphocyte[MeSHID:D013601],Pancreatic carcinoma[MeSHID:C562463],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB ctx-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cd19/cd22 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19.car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Lymphoma, Follicular[MeSHID:D008224] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19/22 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB kte-c19 car NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car gene transduced t lymphocytes NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB hucart19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematopoietic Neoplasms[MeSHID:D019337],Lymph[MeSHID:D008196],Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB autologous cd19-targeting car t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB inebilizumab NA Neuromyelitis Optica[MeSHID:D009471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-lymphocyte surface antigen b4 CD19 Successful target antibody 29.38 TTD , DGIDB anti-cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reticulosarcoma[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 2/3 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 and cd22 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car-t lymphocytes NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB inebilizumab NA Neuromyelitis Optica[MeSHID:D009471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-lymphocyte surface antigen b4 CD19 Successful target unknown 29.38 TTD , DGIDB cd19-tcrz-41bb and cd22-tcrz-41bb car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymph[MeSHID:D008196],T-Lymphocyte[MeSHID:D013601],Hematopoietic Neoplasms[MeSHID:D019337] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t-cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Burkitt Lymphoma[MeSHID:D002051],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Recurrence (disease attribute)[MeSHID:D012008] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 redirected autologous t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-targeting car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB loncastuximab tesirine biotech Reticulosarcoma[MeSHID:D008228],B-Lymphocytes[MeSHID:D001402],Relapse[MeSHID:D012008],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] approved,investigational b-lymphocyte antigen cd19 CD19 NA binder NA drugbank tafasitamab biotech Relapse[MeSHID:D012008],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved,investigational b-lymphocyte antigen cd19 CD19 NA binder,antibody NA drugbank car19 t cells carrying cytoplasmic activated pd-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Carrying[MeSHID:D017770],Cytoplasm[MeSHID:D003593] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB ata3219 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] preclinical b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD brexucabtagene autoleucel biotech Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Unmarried[MeSHID:D012847],Relapse[MeSHID:D012008],Burkitt Lymphoma[MeSHID:D002051] approved b-lymphocyte antigen cd19 CD19 NA binder NA drugbank car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB pz01 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB ctl019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 4.9 TTD , DGIDB cd19-directed car-t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19+ car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB auto1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cd19 car t-cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-targeted cart cells NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],leukemia[MeSHID:D007938],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematopoietic Neoplasms[MeSHID:D019337],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],Lymph[MeSHID:D008196],Prolymphocytic Leukemia[MeSHID:D015463], Follicular[MeSHID:D008224] phase 2/3 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB cd19-ucart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] clinical trial b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymph[MeSHID:D008196],Hematopoietic Neoplasms[MeSHID:D019337] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB 4scar19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart19 cell NA Leukemia, Prolymphocytic, B-Cell[MeSHID:D054403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB allo-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cd19-targeting car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart 19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB pcar-019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Prolymphocytic, B-Cell[MeSHID:D054403],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphoma, Follicular[MeSHID:D008224] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD human cd19 targeted t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB bcma cart and hucart19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB 4scar19 and 4scar38 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB pbcar0191 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB 4scar19 and 4scar123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB loncastuximab tesirine NA Reticulosarcoma[MeSHID:D008228],B-Lymphocytes[MeSHID:D001402],Relapse[MeSHID:D012008],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] approved b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD anti-cd19-car-t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB icar19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB xlcart001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-targeting car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reticulosarcoma[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19-car t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 specific car t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB 4scar19 and 4scar70 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB clic-1901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB im19 car-t NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 2/3 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19-car vector-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematopoietic Neoplasms[MeSHID:D019337],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],Lymph[MeSHID:D008196],Prolymphocytic Leukemia[MeSHID:D015463],Lymphoma, Follicular[MeSHID:D008224] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB sleeping beauty car-tcr NA Sleep[MeSHID:D012890],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-directed car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB coltuximab ravtansine NA Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cc-97540 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD ytb323 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD 4scar19/22 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Prolymphocytic, B-Cell[MeSHID:D054403],T-Lymphocyte[MeSHID:D013601],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphoma, Follicular[MeSHID:D008224] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB axicabtagene ciloleucel biotech B-Cell Lymphomas[MeSHID:D016393],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Lymphoma, Large-Cell, Follicular[MeSHID:D008224],High Grade Lymphoma (neoplasm)[MeSHID:D008228],B-Lymphocytes[MeSHID:D001402],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved b-lymphocyte antigen cd19 CD19 NA antibody NA drugbank , DGIDB sjcar19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB jcar017 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Multiple Myeloma[MeSHID:D009101],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],leukemia[MeSHID:D007938],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393], Follicular[MeSHID:D008224] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 4.9 TTD , DGIDB cd19cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393] clinical trial b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 anti-cd20 bispecific car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB mor-208 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Diabetes, Autoimmune[MeSHID:D003922] phase 2/3 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB medi-551 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Neuromyelitis Optica[MeSHID:D009471] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 29.38 TTD , DGIDB cd20-cd19 ccar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD ic9-car19 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],Immunoproliferative Disorders[MeSHID:D007160],B-Cell Lymphomas[MeSHID:D016393],Immune System Diseases[MeSHID:D007154] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 and anti-cd20 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB scri-hucar19v1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-tricar-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB tak-007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB tricar-t-cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB blinatumomab NA Philadelphia Chromosome[MeSHID:D010677],Relapse[MeSHID:D012008],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] approved b-lymphocyte surface antigen b4 CD19 Successful target unknown 3.5 TTD , DGIDB auto3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anticd19 cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-directed car-t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Prolymphocytic, B-Cell[MeSHID:D054403],T-Lymphocyte[MeSHID:D013601],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphoma, Follicular[MeSHID:D008224] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB kur-502 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD kymriah NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB combotox NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB inebilizumab biotech Neuromyelitis Optica[MeSHID:D009471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational b-lymphocyte antigen cd19 CD19 NA binder,antibody 29.38 drugbank , DGIDB anti-cd20 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],T-Lymphocyte[MeSHID:D013601] phase 0 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB axicabtagene ciloleucel NA B-Cell Lymphomas[MeSHID:D016393],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Lymphoma, Large-Cell, Follicular[MeSHID:D008224],High Grade Lymphoma (neoplasm)[MeSHID:D008228],B-Lymphocytes[MeSHID:D001402],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB amg 562 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD medl-551 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Scleroderma[MeSHID:D012594] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymph[MeSHID:D008196],Hematopoietic Neoplasms[MeSHID:D019337] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-directed car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB anti-cd22/cd19 mab-toxin conjugate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] investigative b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD anti-cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB inebilizumab biotech Neuromyelitis Optica[MeSHID:D009471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational b-lymphocyte antigen cd19 CD19 NA binder 29.38 drugbank , DGIDB cart-19 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB ata2431 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] preclinical b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB lisocabtagene maraleucel NA B-Cell Lymphomas[MeSHID:D016393],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Lymphoma, Follicular[MeSHID:D008224],High Grade Lymphoma (neoplasm)[MeSHID:D008228],B-Lymphocytes[MeSHID:D001402],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Syndrome[MeSHID:D013577] approved b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cart-19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],leukemia[MeSHID:D007938],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematopoietic Neoplasms[MeSHID:D019337],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],Lymph[MeSHID:D008196],Prolymphocytic Leukemia[MeSHID:D015463], Follicular[MeSHID:D008224] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB anti-cd19 ebv ctl therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cytotoxic T-Lymphocytes[MeSHID:D013602],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB anti-cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2/3 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19.car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphoma, Follicular[MeSHID:D008224] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 2/3 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB cartmeso/19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB xmab 5871 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Diabetes, Autoimmune[MeSHID:D003922],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 0 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 chimeric antigen receptor t cells NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD jcar015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 4.9 TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 2/3 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Cells[MeSHID:D002477] phase 0 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB jcar014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Cell Lymphomas[MeSHID:D016393],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 2/3 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB tecartus NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] approved b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD afm11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Cell Lymphomas[MeSHID:D016393],leukemia[MeSHID:D007938] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart-19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB chimeric antigen receptor modified t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB carcik-cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB im19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hematologic Neoplasms[MeSHID:D019337] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB tisagenlecleucel biotech Relapse[MeSHID:D012008],Neoplasm Metastasis[MeSHID:D009362],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphoma, Follicular[MeSHID:D008224] approved,investigational b-lymphocyte antigen cd19 CD19 NA antibody 2.45 drugbank , DGIDB cd19-targeted car-t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB egfrt/19-28z/4-1bbl car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-targeted car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] clinical trial b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB 19-28z t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB lisocabtagene maraleucel biotech B-Cell Lymphomas[MeSHID:D016393],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Lymphoma, Follicular[MeSHID:D008224],High Grade Lymphoma (neoplasm)[MeSHID:D008228],B-Lymphocytes[MeSHID:D001402],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Syndrome[MeSHID:D013577] approved b-lymphocyte antigen cd19 CD19 NA binder NA drugbank car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB c-car011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB sgn-19a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] preclinical b-lymphocyte surface antigen b4 CD19 Successful target unknown 4.9 TTD , DGIDB duvortuxizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown 4.9 TTD , DGIDB tc-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD tg-1801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD cd19 car t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 and cd20 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematopoietic Neoplasms[MeSHID:D019337],Lymph[MeSHID:D008196],Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB jwcar029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19/cd22 chimeric antigen receptor t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB car-cd19 t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] clinical trial b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB sar-3419 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown 14.69 TTD , DGIDB cd19-directed car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB blinatumomab biotech Philadelphia Chromosome[MeSHID:D010677],Relapse[MeSHID:D012008],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] approved,investigational b-lymphocyte antigen cd19 CD19 NA activator,antibody 3.5 drugbank , DGIDB 4scar19 and 4scar30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19/22-car vector-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Prolymphocytic Leukemia[MeSHID:D015463],Lymphoma, Follicular[MeSHID:D008224] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB tnb-486 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD anti-cd19 cart cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19/bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 targeted chimeric antigen receptor t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB tbi-1501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Traumatic Brain Injury[MeSHID:D000070642] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19/cd22 car t-cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Leukemia, Prolymphocytic, B-Cell[MeSHID:D054403],T-Lymphocyte[MeSHID:D013601],leukemia[MeSHID:D007938],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-directed car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19t-hank NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD 4scar19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cart22-65s cells and hucart19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB ari-0001 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB mb-cart19.1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19cat-41bbz car t-cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB tisagenlecleucel NA Relapse[MeSHID:D012008],Neoplasm Metastasis[MeSHID:D009362],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphoma, Follicular[MeSHID:D008224] approved b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB cart-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],leukemia[MeSHID:D007938],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematopoietic Neoplasms[MeSHID:D019337],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393],Lymph[MeSHID:D008196],Prolymphocytic Leukemia[MeSHID:D015463], Follicular[MeSHID:D008224] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown 2.45 TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB 4scar19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Cells[MeSHID:D002477] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reticulosarcoma[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB anti-cd19-car NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],leukemia[MeSHID:D007938],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD patient-derived cd19- and cd22 specific car NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB cd19-car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] clinical trial b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB 4scar19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Cells[MeSHID:D002477] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB coltuximab ravtansine biotech Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] investigational b-lymphocyte antigen cd19 CD19 NA unknown NA drugbank , DGIDB car-t cells targeting cd19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB 4scar19 and 4scar22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB donor-derived cd19/22 bispecific car-t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB humanized cd19 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-lymphocyte surface antigen b4 CD19 Successful target unknown NA TTD , DGIDB antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved t-cell surface glycoprotein cd1a CD1A NA inhibitor NA drugbank antithymocyte globulin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aplastic Anemia[MeSHID:D000741] approved t-cell surface glycoprotein cd1a CD1A Successful target unknown NA TTD , DGIDB cis-tetracosenoyl sulfatide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] experimental antigen-presenting glycoprotein cd1d CD1D NA unknown NA drugbank alefacept biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,withdrawn t-cell surface antigen cd2 CD2 NA inhibitor 106.09 drugbank , DGIDB pen(acm)aqfrkeketfc(acm)-oh NA NA investigative t-cell surface antigen cd2 CD2 Clinical trial target unknown NA TTD cyclo(1,11)h-esiydpgddik-oh NA NA investigative t-cell surface antigen cd2 CD2 Clinical trial target unknown NA TTD cyclo(1,12)peniydtkgknvlc-oh NA NA investigative t-cell surface antigen cd2 CD2 Clinical trial target unknown NA TTD alpha-d-mannose NA NA investigative t-cell surface antigen cd2 CD2 Clinical trial target unknown NA TTD siplizumab biotech Transplanted tissue[MeSHID:D019737],Disease[MeSHID:D004194],Graft-vs-Host Disease[MeSHID:D006086],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 t-cell surface antigen cd2 CD2 Clinical trial target inhibitor 63.65 TTD , drugbank , DGIDB siplizumab biotech Transplanted tissue[MeSHID:D019737],Disease[MeSHID:D004194],Graft-vs-Host Disease[MeSHID:D006086],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 t-cell surface antigen cd2 CD2 Clinical trial target unknown 63.65 TTD , drugbank , DGIDB cyclo(1,10)eiydpgddik NA NA investigative t-cell surface antigen cd2 CD2 Clinical trial target unknown NA TTD cyclo(1,10)h-eiydpgddik-oh NA NA investigative t-cell surface antigen cd2 CD2 Clinical trial target unknown NA TTD alxn6000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 membrane glycoprotein ox2 CD200 Clinical trial target unknown 190.95 TTD , DGIDB inotuzumab ozogamicin biotech Relapse[MeSHID:D012008],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational b-cell receptor cd22 CD22 Successful target antibody NA TTD , drugbank , DGIDB anti-cd19/22-car vector-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Prolymphocytic Leukemia[MeSHID:D015463],Lymphoma, Follicular[MeSHID:D008224] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB jcar018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB ucart-22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Burkitt Lymphoma[MeSHID:D002051] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD cd22-targeted car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB car-t cells targeting cd22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB lumoxiti NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hairy Cell Leukemia[MeSHID:D007943] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD epratuzumab biotech Lymphoma[MeSHID:D008223],Lupus Erythematosus, Systemic[MeSHID:D008180],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Graft Rejection[MeSHID:D006084] investigational,phase 3 b-cell receptor cd22 CD22 Successful target unknown 53.04 TTD , drugbank , DGIDB bl-22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Burkitt Lymphoma[MeSHID:D002051] phase 2 b-cell receptor cd22 CD22 Successful target unknown 21.22 TTD , DGIDB cd19 and cd22 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cd22 car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],T-Cell Lymphoma[MeSHID:D016399] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cd19/cd22 chimeric antigen receptor t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB donor-derived cd19/22 bispecific car-t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cart-22 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB rg7593 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] discontinued in phase 2 b-cell receptor cd22 CD22 Successful target unknown NA TTD 4scar19 and 4scar22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB moxetumomab pasudotox biotech Lymphocyte[MeSHID:D008214],Malignant Neoplasms[MeSHID:D009369],Renal Insufficiency[MeSHID:D051437],Splenomegaly[MeSHID:D013163],Relapse[MeSHID:D012008],Hypertrichosis[MeSHID:D006983],Hirsutism[MeSHID:D006628],leukemia[MeSHID:D007938],Hair[MeSHID:D006197],Hepatomegaly[MeSHID:D006529],Hairy Cell Leukemia[MeSHID:D007943],B-Lymphocytes[MeSHID:D001402],Cell Surface Extensions[MeSHID:D022081],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved,investigational b-cell receptor cd22 CD22 Successful target binder NA TTD , drugbank , DGIDB car-t cells targeting cd22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB retroviral vector-transduced autologous t cells to express cd22-specific cars NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Lymphoma, Follicular[MeSHID:D008224] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB trph-222 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD moxetumomab pasudotox biotech Lymphocyte[MeSHID:D008214],Malignant Neoplasms[MeSHID:D009369],Renal Insufficiency[MeSHID:D051437],Splenomegaly[MeSHID:D013163],Relapse[MeSHID:D012008],Hypertrichosis[MeSHID:D006983],Hirsutism[MeSHID:D006628],leukemia[MeSHID:D007938],Hair[MeSHID:D006197],Hepatomegaly[MeSHID:D006529],Hairy Cell Leukemia[MeSHID:D007943],B-Lymphocytes[MeSHID:D001402],Cell Surface Extensions[MeSHID:D022081],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved,investigational b-cell receptor cd22 CD22 Successful target binder 31.83 TTD , drugbank , DGIDB car-t cells targeting cd22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB 4scar19/22 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB inotuzumab ozogamicin biotech Relapse[MeSHID:D012008],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational b-cell receptor cd22 CD22 Successful target antibody 21.22 TTD , drugbank , DGIDB cd19-tcrz-41bb and cd22-tcrz-41bb car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymph[MeSHID:D008196],T-Lymphocyte[MeSHID:D013601],Hematopoietic Neoplasms[MeSHID:D019337] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cart22 cells expressing anti-cd22 scfv tcrz:41bb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB anti-cd22 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Cells[MeSHID:D002477] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cart22 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB anti-cd22-car-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Cells[MeSHID:D002477] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cart-19/22 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cart22-65s cells and hucart19 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB moxetumomab pasudotox biotech Lymphocyte[MeSHID:D008214],Malignant Neoplasms[MeSHID:D009369],Renal Insufficiency[MeSHID:D051437],Splenomegaly[MeSHID:D013163],Relapse[MeSHID:D012008],Hypertrichosis[MeSHID:D006983],Hirsutism[MeSHID:D006628],leukemia[MeSHID:D007938],Hair[MeSHID:D006197],Hepatomegaly[MeSHID:D006529],Hairy Cell Leukemia[MeSHID:D007943],B-Lymphocytes[MeSHID:D001402],Cell Surface Extensions[MeSHID:D022081],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved,investigational b-cell receptor cd22 CD22 Successful target binder,antibody NA TTD , drugbank , DGIDB auto3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB ospa lipoprotein NA Lyme Disease[MeSHID:D008193],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB dcdt-2980s NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] discontinued in phase 2 b-cell receptor cd22 CD22 Successful target unknown NA TTD cd22-cart NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cd22-specific car t-cells also expressing an egfrt NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB patient-derived cd19- and cd22 specific car NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB anti-cd22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB anti-cd22 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Cells[MeSHID:D002477] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cd19 and cd22 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB ata2431 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] preclinical b-cell receptor cd22 CD22 Successful target unknown NA TTD cd19/cd22 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cart22-65s cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB cd19/cd22 car t-cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Leukemia, Prolymphocytic, B-Cell[MeSHID:D054403],T-Lymphocyte[MeSHID:D013601],leukemia[MeSHID:D007938],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Cell Lymphomas[MeSHID:D016393] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB anti-cd22/cd19 mab-toxin conjugate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] investigative b-cell receptor cd22 CD22 Successful target unknown NA TTD combotox NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB medi-553 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative b-cell receptor cd22 CD22 Successful target unknown NA TTD car-t cells targeting cd22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 2 b-cell receptor cd22 CD22 Successful target unknown NA TTD , DGIDB bsab cg7-mica NA NA investigative small cell lung carcinoma cluster 4 antigen CD24 Literature-reported target unknown NA TTD muromonab biotech Transplanted organ[MeSHID:D019737],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational t-cell surface glycoprotein cd3 zeta chain CD247 NA unknown 15.91 drugbank , DGIDB morab-004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Colorectal Cancer[MeSHID:D015179],Sarcoma[MeSHID:D012509],Merkel cell carcinoma[MeSHID:D015266] phase 2 endosialin CD248 Clinical trial target inhibitor 190.95 TTD , DGIDB morab-004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Colorectal Cancer[MeSHID:D015179],Sarcoma[MeSHID:D012509],Merkel cell carcinoma[MeSHID:D015266] phase 2 endosialin CD248 Clinical trial target unknown 190.95 TTD , DGIDB ontuxizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Colorectal Cancer[MeSHID:D015179],Sarcoma[MeSHID:D012509],Merkel cell carcinoma[MeSHID:D015266] phase 2 endosialin CD248 Clinical trial target unknown 190.95 TTD , DGIDB varlilumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Colorectal Cancer[MeSHID:D015179],Renal Cell Carcinoma[MeSHID:D002292],Recurrence (disease attribute)[MeSHID:D012008],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] phase 2 t-cell activation antigen cd27 CD27 Clinical trial target unknown 63.65 TTD , DGIDB cdx-527 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 t-cell activation antigen cd27 CD27 Clinical trial target unknown NA TTD cdx-1127 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] phase 1 t-cell activation antigen cd27 CD27 Clinical trial target unknown 63.65 TTD , DGIDB durvalumab biotech Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Disease[MeSHID:D004194],Carcinoma, Transitional Cell[MeSHID:D002295],Small cell carcinoma of lung[MeSHID:D055752],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Biliary Tract Cancer[MeSHID:D001661],melanoma[MeSHID:D008545],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant Neoplasms[MeSHID:D009369], Pancreatic Ductal[MeSHID:D021441] approved,investigational programmed cell death 1 ligand 1 CD274 Successful target inhibitor,antibody 7.96 TTD , drugbank , DGIDB ibi318 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD bgb-a333 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD cx-072 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Medulloblastoma[MeSHID:D008527],Lymphoma[MeSHID:D008223] phase 2 programmed cell death 1 ligand 1 CD274 Successful target unknown 5.3 TTD , DGIDB pmid30247903-compound-general structure7 NA NA investigative programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD ly3415244 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD atezolizumab biotech Triple Negative Breast Neoplasms[MeSHID:D064726],Neoplasms[MeSHID:D009369],Cultured Cell Line[MeSHID:D002460],Congenital Abnormality[MeSHID:D000013],Germ Cells[MeSHID:D005854],Malignant neoplasm of lung[MeSHID:D008175],Small cell carcinoma of lung[MeSHID:D055752],Disease Progression[MeSHID:D018450],Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Adenocarcinoma[MeSHID:D000230],Colorectal Cancer[MeSHID:D015179],Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of urinary bladder[MeSHID:D001749],Bronchioloalveolar Adenocarcinoma[MeSHID:D002282],Ulcer[MeSHID:D014456],Malignant neoplasm of prostate[MeSHID:D011471],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Lymphoma, Follicular[MeSHID:D008224],Squamous cell carcinoma[MeSHID:D002294],Stomach[MeSHID:D013270],Pancreatic carcinoma[MeSHID:C562463],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of pancreas[MeSHID:D010190],Liver carcinoma[MeSHID:D006528],melanoma[MeSHID:D008545],Hematologic Neoplasms[MeSHID:D019337],Malignant Neoplasms[MeSHID:D009369] approved,investigational programmed cell death 1 ligand 1 CD274 Successful target inhibitor,antibody 5.3 TTD , drugbank , DGIDB c-met/pd-l1 car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD , DGIDB inbrx-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD medi4736 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 programmed cell death 1 ligand 1 CD274 Successful target unknown 7.96 TTD , DGIDB tak-252 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD avelumab biotech Merkel cell carcinoma[MeSHID:D015266],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational programmed cell death 1 ligand 1 CD274 Successful target inhibitor,antibody 23.87 TTD , drugbank , DGIDB pidilizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 2 programmed cell death 1 ligand 1 CD274 Successful target unknown 2.65 TTD , DGIDB alpn-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD anti-pd-l1 csr t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Glioblastoma[MeSHID:D005909] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD , DGIDB pmid30107136-compound-example1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD , DGIDB bintrafusp alfa NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD m7824 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 programmed cell death 1 ligand 1 CD274 Successful target unknown 1.77 TTD , DGIDB mcla-145 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD aunp-12 biotech NA investigational programmed cell death 1 ligand 1 CD274 NA inhibitor,antibody NA drugbank pmid30107136-compound-example2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD , DGIDB pd-l1 t-hank NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD ly3300054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown 5.3 TTD , DGIDB bms-986189 NA NA phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD , DGIDB incb86550 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD fs118 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD , DGIDB ca-327 NA NA investigative programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD kn046 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD kd033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD cosibelimab biotech Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 programmed cell death 1 ligand 1 CD274 Successful target inhibitor,antibody NA TTD , drugbank pmid30247903-compound-general structure6 NA NA investigative programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD gen1046 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD mpdl-3280a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 programmed cell death 1 ligand 1 CD274 Successful target unknown 5.3 TTD , DGIDB msb2311 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD , DGIDB bavencio NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of testis[MeSHID:D013736],melanoma[MeSHID:D008545],Adenocarcinoma[MeSHID:D000230],Malignant tumor of colon[MeSHID:D003110],Hematologic Neoplasms[MeSHID:D019337],Cancer of Head and Neck[MeSHID:D006258],Merkel cell carcinoma[MeSHID:D015266],Squamous cell carcinoma[MeSHID:D002294],Malignant neoplasm of breast[MeSHID:D001943] approved programmed cell death 1 ligand 1 CD274 Successful target unknown 23.87 TTD , DGIDB envafolimab biotech NA investigational programmed cell death 1 ligand 1 CD274 NA inhibitor,antibody NA drugbank cs1001 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD pmid30247903-compound-general structure8 NA NA investigative programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD ca-170 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hippocampus Proper[MeSHID:D006624],Lymphoma[MeSHID:D008223] investigational,phase 1 programmed cell death 1 ligand 1 CD274 Successful target inhibitor NA TTD , drugbank , DGIDB kn035 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509] phase 2 programmed cell death 1 ligand 1 CD274 Successful target unknown 5.3 TTD , DGIDB nm21-1480 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD faz053 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD , DGIDB rg-7446 NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] approved programmed cell death 1 ligand 1 CD274 Successful target unknown 5.3 TTD , DGIDB anti-pd-l1 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Infection[MeSHID:D007239] phase 1 programmed cell death 1 ligand 1 CD274 Successful target unknown 5.3 TTD , DGIDB pmid30247903-compound-general structure5 NA NA investigative programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD pmid30247903-compound-general structure12 NA NA investigative programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD gs-4224 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD pmid30247903-compound-general structure10 NA NA investigative programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD anti-ox40 antibody bms 986178 biotech NA investigational programmed cell death 1 ligand 1 CD274 NA inhibitor NA drugbank pmid30247903-compound-general structure9 NA NA investigative programmed cell death 1 ligand 1 CD274 Successful target unknown NA TTD rg6084 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cd274 messenger rna CD274 Clinical trial target unknown NA TTD omburtamab i-124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] phase 1/2 b7 homolog 3 CD276 Clinical trial target unknown NA TTD , DGIDB ds-7300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 b7 homolog 3 CD276 Clinical trial target unknown NA TTD mga271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362] phase 1 b7 homolog 3 CD276 Clinical trial target unknown 190.95 TTD , DGIDB enoblituzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 b7 homolog 3 CD276 Clinical trial target antibody 190.95 TTD , DGIDB omburtamab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroblastoma[MeSHID:D009447] investigational cd276 antigen CD276 NA binder NA drugbank 131 i-omburtamab NA Central Nervous System Neoplasms[MeSHID:D016543],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroblastoma[MeSHID:D009447],Brain[MeSHID:D001921] phase 2/3 b7 homolog 3 CD276 Clinical trial target unknown NA TTD enoblituzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 b7 homolog 3 CD276 Clinical trial target unknown 190.95 TTD , DGIDB mgd009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 b7 homolog 3 CD276 Clinical trial target unknown NA TTD , DGIDB 124i-8h9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 b7 homolog 3 CD276 Clinical trial target unknown NA TTD , DGIDB mgc018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 b7 homolog 3 CD276 Clinical trial target unknown NA TTD omburtamab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroblastoma[MeSHID:D009447] phase 2/3 b7 homolog 3 CD276 Clinical trial target unknown NA TTD omburtamab i-131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroblastoma[MeSHID:D009447],Desmoplastic Small Round Cell Tumor[MeSHID:D058405] phase 2/3 b7 homolog 3 CD276 Clinical trial target unknown NA TTD , DGIDB lulizumab pegol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 t-cell-specific surface glycoprotein cd28 CD28 Successful target antibody NA TTD , DGIDB lulizumab pegol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD , DGIDB fr-104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD cd19-car and cd28-car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD , DGIDB tgn-1412 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] discontinued in phase 1 t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD belatacept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Kidney[MeSHID:D007668],Graft Rejection[MeSHID:D006084] approved t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown 3.54 TTD , DGIDB sar442257 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD regn5678 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD anti-cd28 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] investigative t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD au101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoma[MeSHID:D012509],Respiratory Tract Infections[MeSHID:D012141],Recurrence (disease attribute)[MeSHID:D012008],Osteosarcoma[MeSHID:D012516],Glioblastoma[MeSHID:D005909] phase 1/2 t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD , DGIDB ab-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Soft Tissue Infections[MeSHID:D018461] phase 3 t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown 10.61 TTD , DGIDB cd28 and cd137 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 t-cell-specific surface glycoprotein cd28 CD28 Successful target unknown NA TTD , DGIDB cd33-car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601],Hematopoietic Neoplasms[MeSHID:D019337],Lymph[MeSHID:D008196] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB vadastuximab talirine NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB gem333 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD lintuzumab NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 myeloid cell surface antigen cd33 CD33 Successful target antibody 31.83 TTD , DGIDB gemtuzumab ozogamicin biotech Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational myeloid cell surface antigen cd33 CD33 Successful target antibody 5.3 TTD , drugbank , DGIDB 225ac-labelled acd33 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD anti-cd33 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Cells[MeSHID:D002477] phase 1/2 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB cd33-specific gene-engineered t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1/2 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB hum-195-bi-213 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] discontinued in phase 1/2 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD bi-836858 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB actimab-a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB cll1-cd33 ccart cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD ave9633 biotech leukemia[MeSHID:D007938] investigational myeloid cell surface antigen cd33 CD33 NA unknown NA drugbank gemtuzumab ozogamicin biotech Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational myeloid cell surface antigen cd33 CD33 Successful target antibody NA TTD , drugbank , DGIDB gtb-3550 NA Leukemia, Mast-Cell[MeSHID:D007946],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190], Myelocytic, Acute[MeSHID:D015470],Mastocytosis, Systemic[MeSHID:D034721] phase 1/2 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD oncolysin m NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown 10.61 TTD , DGIDB hum195/rgel NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB cd123-cd33 ccar NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD amg 330 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB allogeneic cart-33 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB cart33 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Cells[MeSHID:D002477] phase 1/2 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB amv564 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown 10.61 TTD , DGIDB sgn-cd33a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 myeloid cell surface antigen cd33 CD33 Successful target unknown 10.61 TTD , DGIDB vadastuximab talirine NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 myeloid cell surface antigen cd33 CD33 Successful target antibody NA TTD , DGIDB hum-195-ac-225 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB cart-33 cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB car-t cells targeting cd33 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] preclinical myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB actimab-m NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB lintuzumab NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 myeloid cell surface antigen cd33 CD33 Successful target unknown 31.83 TTD , DGIDB jnj-67571244 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD amg 673 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid cell surface antigen cd33 CD33 Successful target unknown NA TTD , DGIDB amr-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 hematopoietic progenitor cell antigen cd34 CD34 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting cd34 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] preclinical hematopoietic progenitor cell antigen cd34 CD34 Clinical trial target unknown NA TTD , DGIDB cart-34 cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 hematopoietic progenitor cell antigen cd34 CD34 Clinical trial target unknown NA TTD , DGIDB otlertuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral T-Cell Lymphoma[MeSHID:D016411],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 leukocyte antigen cd37 CD37 Clinical trial target antibody 95.48 TTD , DGIDB naratuximab emtansine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 2 leukocyte antigen cd37 CD37 Clinical trial target antibody NA TTD , DGIDB bi-836826 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant Neoplasms[MeSHID:D009369] phase 2 leukocyte antigen cd37 CD37 Clinical trial target unknown NA TTD , DGIDB gen3009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 leukocyte antigen cd37 CD37 Clinical trial target unknown NA TTD 212pb-labelled acd37 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical leukocyte antigen cd37 CD37 Clinical trial target unknown NA TTD imgn529 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 2 leukocyte antigen cd37 CD37 Clinical trial target unknown 31.83 TTD , DGIDB tru-016 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 leukocyte antigen cd37 CD37 Clinical trial target unknown 95.48 TTD , DGIDB otlertuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral T-Cell Lymphoma[MeSHID:D016411],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 leukocyte antigen cd37 CD37 Clinical trial target unknown 95.48 TTD , DGIDB mor-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB humax-cd38b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD isb 1342 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD 4scar19 and 4scar38 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB daratumumab biotech Amyloidosis[MeSHID:D000686],Multiple Myeloma[MeSHID:D009101],Light[MeSHID:D008027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adp-ribosyl cyclase 1 CD38 NA antibody 127.3 drugbank , DGIDB cd38-specific gene-engineered t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB cart-38 cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB amg 424 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD cd38 and bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB cd38 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB anti-cd38 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB sar442257 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD isatuximab biotech Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational adp-ribosyl cyclase 1 CD38 NA binder,antibody 42.43 drugbank , DGIDB daratumumab NA Amyloidosis[MeSHID:D000686],Multiple Myeloma[MeSHID:D009101],Light[MeSHID:D008027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cyclic adp-ribose hydrolase 1 CD38 Successful target inhibitor 127.3 TTD , DGIDB sar442085 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD anti-cd38 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB tak-169 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD car-t cells targeting cd38 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] clinical trial cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB daratumumab NA Amyloidosis[MeSHID:D000686],Multiple Myeloma[MeSHID:D009101],Light[MeSHID:D008027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cyclic adp-ribose hydrolase 1 CD38 Successful target antibody 127.3 TTD , DGIDB cd38 car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD cd38 car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD , DGIDB daratumumab biotech Amyloidosis[MeSHID:D000686],Multiple Myeloma[MeSHID:D009101],Light[MeSHID:D008027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adp-ribosyl cyclase 1 CD38 NA antibody,inhibitor 127.3 drugbank , DGIDB sar-650984 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown 42.43 TTD , DGIDB tak-573 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD 225ac-labelled acd38 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 cyclic adp-ribose hydrolase 1 CD38 Successful target unknown NA TTD mezagitamab biotech NA investigational adp-ribosyl cyclase 1 CD38 NA inhibitor,antibody NA drugbank , DGIDB daratumumab NA Amyloidosis[MeSHID:D000686],Multiple Myeloma[MeSHID:D009101],Light[MeSHID:D008027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cyclic adp-ribose hydrolase 1 CD38 Successful target unknown 127.3 TTD , DGIDB muromonab biotech Transplanted organ[MeSHID:D019737],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational t-cell surface glycoprotein cd3 delta chain CD3D NA unknown 9.09 drugbank , DGIDB blinatumomab biotech Philadelphia Chromosome[MeSHID:D010677],Relapse[MeSHID:D012008],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] approved,investigational t-cell surface glycoprotein cd3 delta chain CD3D NA activator 3.9 drugbank , DGIDB autologous t-cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 t-cell surface glycoprotein cd3 epsilon CD3E Successful target unknown NA TTD , DGIDB teplizumab biotech Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] investigational t-cell surface glycoprotein cd3 epsilon chain CD3E NA antagonist 6.37 drugbank , DGIDB catumaxomab biotech Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Pleural Effusion, Malignant[MeSHID:D016066] approved,investigational,withdrawn t-cell surface glycoprotein cd3 epsilon chain CD3E NA agonist,antibody 4.77 drugbank , DGIDB catumaxomab biotech Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Pleural Effusion, Malignant[MeSHID:D016066] approved,investigational,withdrawn t-cell surface glycoprotein cd3 epsilon chain CD3E NA agonist 4.77 drugbank , DGIDB muromonab biotech Transplanted organ[MeSHID:D019737],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational t-cell surface glycoprotein cd3 epsilon chain CD3E NA binder 12.73 drugbank , DGIDB ertumaxomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 t-cell surface glycoprotein cd3 epsilon CD3E Successful target unknown 4.24 TTD , DGIDB resimmune NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],melanoma[MeSHID:D008545] phase 2 t-cell surface glycoprotein cd3 epsilon CD3E Successful target unknown 6.37 TTD , DGIDB muromonab NA Transplanted organ[MeSHID:D019737],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved t-cell surface glycoprotein cd3 epsilon CD3E Successful target unknown 12.73 TTD , DGIDB mt-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 t-cell surface glycoprotein cd3 epsilon CD3E Successful target unknown NA TTD , DGIDB muromonab biotech Transplanted organ[MeSHID:D019737],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational t-cell surface glycoprotein cd3 gamma chain CD3G NA unknown 4.9 drugbank , DGIDB ertumaxomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 t-cell surface glycoprotein cd3 gamma CD3G Clinical trial target unknown 1.63 TTD , DGIDB medi-565 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] phase 1 t-cell surface glycoprotein cd3 gamma CD3G Clinical trial target unknown 4.9 TTD , DGIDB autologous t-cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 t-cell surface glycoprotein cd3 gamma CD3G Clinical trial target unknown NA TTD , DGIDB mgd007 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 t-cell surface glycoprotein cd3 gamma CD3G Clinical trial target unknown 2.45 TTD , DGIDB mt-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 t-cell surface glycoprotein cd3 gamma CD3G Clinical trial target unknown NA TTD , DGIDB teplizumab NA Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 t-cell surface glycoprotein cd3 gamma CD3G Clinical trial target unknown 2.45 TTD , DGIDB imcgp100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cutaneous Melanoma[MeSHID:C562393],melanoma[MeSHID:D008545] phase 2 t-cell surface glycoprotein cd3 gamma CD3G Clinical trial target unknown 1.63 TTD , DGIDB cel-1000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD lipo-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 1 t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD , DGIDB clenoliximab biotech Rheumatoid Arthritis[MeSHID:D001172] investigational t-cell surface glycoprotein cd4 CD4 NA inhibitor 7.07 drugbank , DGIDB ibalizumab biotech HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Communicable Diseases[MeSHID:D003141],Blood[MeSHID:D001769],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational t-cell surface glycoprotein cd4 CD4 NA antagonist,inhibitor 21.22 drugbank , DGIDB zanolimumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 3 t-cell surface glycoprotein cd4 CD4 Successful target unknown 21.22 TTD , DGIDB magrolimab NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD idec-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD vrc07-523ls NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] phase 1 t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD fluoropeptide vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD , DGIDB tmb-365 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] phase 1 t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD ibalizumab biotech HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Communicable Diseases[MeSHID:D003141],Blood[MeSHID:D001769],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational t-cell surface glycoprotein cd4 CD4 NA antagonist 21.22 drugbank , DGIDB bt-061 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Asthma[MeSHID:D001249] phase 2 t-cell surface glycoprotein cd4 CD4 Successful target unknown 28.29 TTD , DGIDB cd4car NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] phase 1 t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD tnx-355 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 3 t-cell surface glycoprotein cd4 CD4 Successful target unknown 21.22 TTD , DGIDB antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved t-cell surface glycoprotein cd4 CD4 NA unknown NA drugbank combinectin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 1 t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD ibalizumab NA NA approved t-cell surface glycoprotein cd4 CD4 Successful target unknown NA TTD ibalizumab biotech HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Communicable Diseases[MeSHID:D003141],Blood[MeSHID:D001769],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational t-cell surface glycoprotein cd4 CD4 NA antagonist,antibody 21.22 drugbank , DGIDB abbv-323 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 1 cd40l receptor CD40 Clinical trial target unknown 5.79 TTD , DGIDB pg-120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative cd40l receptor CD40 Clinical trial target unknown NA TTD askp-1240 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft Rejection[MeSHID:D006084] phase 2 cd40l receptor CD40 Clinical trial target unknown 5.79 TTD , DGIDB human cd40 agonist ligand NA NA investigative cd40l receptor CD40 Clinical trial target unknown NA TTD bi 655064 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179],Thrombocytopenia[MeSHID:D013921],Lupus Vulgaris[MeSHID:D008177],Rheumatoid Arthritis[MeSHID:D001172] phase 2 cd40l receptor CD40 Clinical trial target unknown NA TTD , DGIDB cd154 NA NA investigative cd40l receptor CD40 Clinical trial target unknown NA TTD anti-cd40-xten NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative cd40l receptor CD40 Clinical trial target unknown NA TTD cp-870,893 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cd40l receptor CD40 Clinical trial target unknown NA TTD sl-172154 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 cd40l receptor CD40 Clinical trial target unknown NA TTD cfz533 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859],Graves Disease[MeSHID:D006111],Myasthenia Gravis[MeSHID:D009157],Rheumatoid Arthritis[MeSHID:D001172] phase 2 cd40l receptor CD40 Clinical trial target unknown 11.57 TTD , DGIDB cfz533 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859],Graves Disease[MeSHID:D006111],Myasthenia Gravis[MeSHID:D009157],Rheumatoid Arthritis[MeSHID:D001172] phase 2 cd40l receptor CD40 Clinical trial target antibody 11.57 TTD , DGIDB gen1042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cd40l receptor CD40 Clinical trial target unknown NA TTD lucatumumab biotech leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tumor necrosis factor receptor superfamily member 5 CD40 NA unknown 2.89 drugbank , DGIDB apx005m NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant neoplasm of brain[MeSHID:D001932],Malignant Neoplasms[MeSHID:D009369] phase 2 cd40l receptor CD40 Clinical trial target unknown 5.79 TTD , DGIDB ng-350a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cd40l receptor CD40 Clinical trial target unknown NA TTD dacetuzumab biotech Lymphoma[MeSHID:D008223],Multiple Myeloma[MeSHID:D009101],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Expiration, function[MeSHID:D045853] investigational tumor necrosis factor receptor superfamily member 5 CD40 NA inhibitor 17.36 drugbank , DGIDB dacetuzumab biotech Lymphoma[MeSHID:D008223],Multiple Myeloma[MeSHID:D009101],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Expiration, function[MeSHID:D045853] investigational tumor necrosis factor receptor superfamily member 5 CD40 NA unknown 17.36 drugbank , DGIDB cdx-1140 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 1 cd40l receptor CD40 Clinical trial target unknown NA TTD trimixdc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] investigative tnf related activation protein CD40LG Clinical trial target unknown NA TTD pg-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 2 tnf related activation protein CD40LG Clinical trial target unknown 2.89 TTD , DGIDB abbv-428 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB dapirolizumab pegol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB ruplizumab biotech Transplanted tissue[MeSHID:D019737],Multiple Sclerosis[MeSHID:D009103],Lupus Erythematosus, Systemic[MeSHID:D008180],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Thrombocytopenia[MeSHID:D013921] investigational cd40 ligand CD40LG NA inhibitor 5.79 drugbank , DGIDB medi4920 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859],Rheumatoid Arthritis[MeSHID:D001172] phase 1 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB bpx-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB ultracd40l NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB bi 655064 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179],Thrombocytopenia[MeSHID:D013921],Lupus Vulgaris[MeSHID:D008177],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB cdp-7657 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 tnf related activation protein CD40LG Clinical trial target unknown 11.57 TTD , DGIDB isf35 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 2 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB il-2/cd40l-expressing leukemia vaccine NA leukemia[MeSHID:D007938],Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB idec-131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] discontinued in phase 1 tnf related activation protein CD40LG Clinical trial target unknown NA TTD cdp-7657 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 tnf related activation protein CD40LG Clinical trial target inhibitor 11.57 TTD , DGIDB chi lob 7/4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 tnf related activation protein CD40LG Clinical trial target unknown NA TTD , DGIDB lucatumumab NA leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tnf related activation protein CD40LG Clinical trial target unknown 5.79 TTD , DGIDB biwa 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular matrix receptor iii CD44 Clinical trial target unknown NA TTD , DGIDB spl-108 NA Epithelial ovarian cancer[MeSHID:C538090],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 extracellular matrix receptor iii CD44 Clinical trial target unknown NA TTD a-6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 2 extracellular matrix receptor iii CD44 Clinical trial target unknown NA TTD , DGIDB bivatuzumab biotech Cancer of Head and Neck[MeSHID:D006258],Neoplasms[MeSHID:D009369] investigational cd44 antigen CD44 NA unknown NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved cd44 antigen CD44 NA binder NA drugbank dsp-107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD cc-90002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],leukemia[MeSHID:D007938],Malignant Neoplasms[MeSHID:D009369] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD , DGIDB tjc4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD alx148 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Malignant Neoplasms[MeSHID:D009369] phase 1/2 leukocyte surface antigen cd47 CD47 Clinical trial target unknown 21.22 TTD , DGIDB imc-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD ao-176 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD tti-621 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Hematologic Neoplasms[MeSHID:D019337],Malignant Neoplasms[MeSHID:D009369],Mycosis Fungoides[MeSHID:D009182],Merkel cell carcinoma[MeSHID:D015266],Squamous cell carcinoma[MeSHID:D002294] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD , DGIDB ibi188 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD tg-1801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD sl-172154 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD zl-1201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD hu5f9-g4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],Colorectal Cancer[MeSHID:D015179] phase 3 leukocyte surface antigen cd47 CD47 Clinical trial target unknown 21.22 TTD , DGIDB tti-622 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Lymphoma[MeSHID:D008223] phase 1 leukocyte surface antigen cd47 CD47 Clinical trial target unknown NA TTD gz402668 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 cambridge pathology 1 antigen CD52 Successful target unknown NA TTD , DGIDB alemtuzumab NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved cambridge pathology 1 antigen CD52 Successful target inhibitor 509.21 TTD , DGIDB alemtuzumab NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved cambridge pathology 1 antigen CD52 Successful target unknown 509.21 TTD , DGIDB alemtuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational campath-1 antigen CD52 NA antibody 509.21 drugbank , DGIDB alemtuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational campath-1 antigen CD52 NA antibody,inhibitor 509.21 drugbank , DGIDB alemtuzumab NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved cambridge pathology 1 antigen CD52 Successful target antibody 509.21 TTD , DGIDB coxsackievirus a21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Coxsackievirus Infections[MeSHID:D003384],melanoma[MeSHID:D008545],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Glioblastoma[MeSHID:D005909] phase 2 complement decay-accelerating factor CD55 Clinical trial target unknown NA TTD , DGIDB onyvax-105 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 complement decay-accelerating factor CD55 Clinical trial target unknown NA TTD pat-sc1 NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 complement decay-accelerating factor CD55 Clinical trial target unknown NA TTD , DGIDB chloramphenicol small molecule Diarrhea[MeSHID:D003967],Bacterial conjunctivitis[MeSHID:D003234],Cholera[MeSHID:D002771],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved complement decay-accelerating factor CD55 NA other NA drugbank alefacept NA Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved surface glycoprotein lfa-3 CD58 Successful target unknown 15.91 TTD , DGIDB itolizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 t-cell differentiation antigen cd6 CD6 Clinical trial target antibody 63.65 TTD , DGIDB itolizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 t-cell differentiation antigen cd6 CD6 Clinical trial target unknown 63.65 TTD , DGIDB anti-cd7 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1 t-cell antigen cd7 CD7 Clinical trial target unknown NA TTD , DGIDB cd7.car/28zeta car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601], T-Cell, Cutaneous[MeSHID:D016410],Burkitt Lymphoma[MeSHID:D002051] phase 1 t-cell antigen cd7 CD7 Clinical trial target unknown NA TTD , DGIDB sgn-70 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD , DGIDB bms-936561 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD , DGIDB jnj-74494550 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 cd70 antigen CD70 Clinical trial target unknown NA TTD 4scar19 and 4scar70 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 cd70 antigen CD70 Clinical trial target unknown NA TTD , DGIDB mdx-1203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD , DGIDB anti-hcd70 car transduced pbl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD , DGIDB sea-cd70 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD amg 172 NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD , DGIDB sgn-cd70a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD , DGIDB trimixdc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] investigative cd70 antigen CD70 Clinical trial target unknown NA TTD cusatuzumab biotech NA investigational cd70 antigen CD70 NA antibody NA drugbank ctx130 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Cell Lymphoma[MeSHID:D016399] phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD mdx-1411 NA MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cd70 antigen CD70 Clinical trial target unknown 63.65 TTD , DGIDB vorsetuzumab mafodotin NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 cd70 antigen CD70 Clinical trial target unknown NA TTD milatuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1/2 hla-dr antigens-associated invariant CD74 Clinical trial target antibody 318.26 TTD , DGIDB milatuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1/2 hla-dr antigens-associated invariant CD74 Clinical trial target unknown 318.26 TTD , DGIDB milatuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1/2 hla-dr antigens-associated invariant CD74 Clinical trial target antagonist 318.26 TTD , DGIDB mgd010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327] phase 1 b-cell-specific glycoprotein b29 CD79B Successful target unknown 15.91 TTD , DGIDB polatuzumab vedotin biotech Relapse[MeSHID:D012008],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Hematologic Neoplasms[MeSHID:D019337] approved,investigational b-cell antigen receptor complex-associated protein beta chain CD79B NA unknown NA drugbank , DGIDB polatuzumab vedotin biotech Relapse[MeSHID:D012008],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Hematologic Neoplasms[MeSHID:D019337] approved,investigational b-cell antigen receptor complex-associated protein beta chain CD79B NA antibody NA drugbank , DGIDB dcds-4501a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 2 b-cell-specific glycoprotein b29 CD79B Successful target unknown 63.65 TTD , DGIDB cd79-targeted immunotoxins NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] investigative b-cell-specific glycoprotein b29 CD79B Successful target unknown NA TTD polivy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 2 b-cell-specific glycoprotein b29 CD79B Successful target unknown NA TTD polatuzumab vedotin NA Relapse[MeSHID:D012008],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Hematologic Neoplasms[MeSHID:D019337] approved b-cell-specific glycoprotein b29 CD79B Successful target unknown NA TTD , DGIDB rg7596 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 2 b-cell-specific glycoprotein b29 CD79B Successful target unknown 63.65 TTD , DGIDB polatuzumab vedotin NA Relapse[MeSHID:D012008],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Hematologic Neoplasms[MeSHID:D019337] approved b-cell-specific glycoprotein b29 CD79B Successful target antibody NA TTD , DGIDB hs-110 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 activation b7-1 antigen CD80 Successful target unknown 3.98 TTD , DGIDB galiximab biotech Disease[MeSHID:D004194],Lymphoma, Non-Hodgkin[MeSHID:D008228],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of prostate[MeSHID:D011471],Lymphoma[MeSHID:D008223],Neoplasm Metastasis[MeSHID:D009362],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational t-lymphocyte activation antigen cd80 CD80 NA antibody,inhibitor 47.74 drugbank , DGIDB abatacept NA Rheumatoid Arthritis[MeSHID:D001172],Graft-vs-Host Disease[MeSHID:D006086],Arthritis, Psoriatic[MeSHID:D015535],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activation b7-1 antigen CD80 Successful target unknown 42.43 TTD , DGIDB galiximab NA Disease[MeSHID:D004194],Lymphoma, Non-Hodgkin[MeSHID:D008228],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of prostate[MeSHID:D011471],Lymphoma[MeSHID:D008223],Neoplasm Metastasis[MeSHID:D009362],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 activation b7-1 antigen CD80 Successful target unknown 47.74 TTD , DGIDB maxy-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 activation b7-1 antigen CD80 Successful target unknown NA TTD , DGIDB abatacept biotech Rheumatoid Arthritis[MeSHID:D001172],Graft-vs-Host Disease[MeSHID:D006086],Arthritis, Psoriatic[MeSHID:D015535],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved t-lymphocyte activation antigen cd80 CD80 NA antagonist 42.43 drugbank , DGIDB car-t cells targeting cd80/86 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 activation b7-1 antigen CD80 Successful target unknown NA TTD , DGIDB abatacept biotech Rheumatoid Arthritis[MeSHID:D001172],Graft-vs-Host Disease[MeSHID:D006086],Arthritis, Psoriatic[MeSHID:D015535],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved t-lymphocyte activation antigen cd80 CD80 NA antagonist,inhibitor 42.43 drugbank , DGIDB rhudex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2a activation b7-1 antigen CD80 Successful target unknown NA TTD , DGIDB galiximab NA Disease[MeSHID:D004194],Lymphoma, Non-Hodgkin[MeSHID:D008228],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of prostate[MeSHID:D011471],Lymphoma[MeSHID:D008223],Neoplasm Metastasis[MeSHID:D009362],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 activation b7-1 antigen CD80 Successful target inhibitor 47.74 TTD , DGIDB belatacept biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Kidney[MeSHID:D007668],Graft Rejection[MeSHID:D006084] approved,investigational t-lymphocyte activation antigen cd80 CD80 NA antagonist 13.26 drugbank , DGIDB belatacept biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Kidney[MeSHID:D007668],Graft Rejection[MeSHID:D006084] approved,investigational t-lymphocyte activation antigen cd80 CD80 NA antagonist,inhibitor 13.26 drugbank , DGIDB abatacept NA Rheumatoid Arthritis[MeSHID:D001172],Graft-vs-Host Disease[MeSHID:D006086],Arthritis, Psoriatic[MeSHID:D015535],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activation b7-1 antigen CD80 Successful target inhibitor 42.43 TTD , DGIDB galiximab biotech Disease[MeSHID:D004194],Lymphoma, Non-Hodgkin[MeSHID:D008228],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of prostate[MeSHID:D011471],Lymphoma[MeSHID:D008223],Neoplasm Metastasis[MeSHID:D009362],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational t-lymphocyte activation antigen cd80 CD80 NA antibody 47.74 drugbank , DGIDB belatacept biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Kidney[MeSHID:D007668],Graft Rejection[MeSHID:D006084] approved,investigational t-lymphocyte activation antigen cd86 CD86 NA antagonist 12.12 drugbank , DGIDB maxy-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 t-lymphocyte activation antigen cd86 CD86 Successful target unknown NA TTD , DGIDB abatacept biotech Rheumatoid Arthritis[MeSHID:D001172],Graft-vs-Host Disease[MeSHID:D006086],Arthritis, Psoriatic[MeSHID:D015535],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved t-lymphocyte activation antigen cd86 CD86 Successful target antagonist,inhibitor 42.43 TTD , drugbank , DGIDB abatacept biotech Rheumatoid Arthritis[MeSHID:D001172],Graft-vs-Host Disease[MeSHID:D006086],Arthritis, Psoriatic[MeSHID:D015535],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved t-lymphocyte activation antigen cd86 CD86 Successful target antagonist 42.43 TTD , drugbank , DGIDB belatacept biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Kidney[MeSHID:D007668],Graft Rejection[MeSHID:D006084] approved,investigational t-lymphocyte activation antigen cd86 CD86 NA antagonist,inhibitor 12.12 drugbank , DGIDB antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved t-lymphocyte activation antigen cd86 CD86 NA binder NA drugbank bryostatin 1 small molecule NA investigational t-lymphocyte activation antigen cd86 CD86 NA inducer NA drugbank c31g small molecule HIV Infections[MeSHID:D015658] investigational cd9 antigen CD9 NA unknown NA drugbank gsk6097608 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 t-cell surface protein tactile CD96 Clinical trial target unknown NA TTD cedazuridine small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Refractory anemias[MeSHID:D000753],Leukemia, Myelomonocytic, Chronic[MeSHID:D015477] approved,investigational cytidine deaminase CDA NA inhibitor NA drugbank 1-beta-ribofuranosyl-1,3-diazepinone small molecule NA experimental cytidine deaminase CDA NA unknown NA drugbank tetrahydrouridine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 cytidine deaminase CDA Clinical trial target unknown 15.91 TTD , DGIDB tosyl-l-arginine methyl ester NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical cell division cycle protein 20 homolog CDC20 Preclinical target unknown NA TTD (z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD (e)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD 3-isopropyl-4-phenylnaphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD nsc-95397 NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD 3-isopropylnaphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD 1-dodecyl-1h-indole-2,3-dione NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD 2-(1-dodecyl-1h-indol-3-yl)acetic acid NA NA investigative m-phase inducer phosphatase 1 CDC25A Literature-reported target unknown NA TTD cysteinesulfonic acid NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD avastin+/-tarceva NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 3 m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD , DGIDB 5,6,7,8-tetrahydroanthracene-1,4-dione NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD l-cysteic acid small molecule NA experimental m-phase inducer phosphatase 2 CDC25B NA unknown NA drugbank 2-sulfhydryl-ethanol NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD methyl mercury ion NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD double oxidized cysteine NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD 6,7-dibromoquinoline-5,8-dione NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD nsc-95397 NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD cysteine sulfenic acid NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD 4-ethoxynaphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD anthraquinone NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD adociaquinone b NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD 3-isopropyl-4-phenylnaphthalene-1,2-dione NA NA investigative m-phase inducer phosphatase 2 CDC25B Clinical trial target unknown NA TTD nsc-663284 NA NA investigative m-phase inducer phosphatase 3 CDC25C Literature-reported target unknown NA TTD bn-82002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative m-phase inducer phosphatase 3 CDC25C Literature-reported target unknown NA TTD bn-82685 NA NA investigative m-phase inducer phosphatase 3 CDC25C Literature-reported target unknown NA TTD guanosine-5'-diphosphate small molecule NA experimental cell division control protein 42 homolog CDC42 NA unknown NA drugbank aminophosphonic acid-guanylate ester small molecule NA experimental cell division control protein 42 homolog CDC42 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase mrck gamma CDC42BPG NA inhibitor NA drugbank bms-863233 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 cdc7-related kinase CDC7 Clinical trial target inhibitor 14.69 TTD , DGIDB pmid19115845c89s NA NA investigative cdc7-related kinase CDC7 Clinical trial target unknown NA TTD bms-863233 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 cdc7-related kinase CDC7 Clinical trial target unknown 14.69 TTD , DGIDB pmid26161698-compound-44 NA NA patented cdc7-related kinase CDC7 Clinical trial target unknown NA TTD , DGIDB pmid24793884c77 NA NA investigative cdc7-related kinase CDC7 Clinical trial target unknown NA TTD pha-767491 NA NA investigative cdc7-related kinase CDC7 Clinical trial target unknown 0.15 TTD , DGIDB tak-931 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cdc7-related kinase CDC7 Clinical trial target unknown 9.79 TTD , DGIDB pmid24793884c74 NA NA investigative cdc7-related kinase CDC7 Clinical trial target unknown NA TTD pmid20873740c18 NA NA investigative cdc7-related kinase CDC7 Clinical trial target unknown NA TTD celecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational cadherin-11 CDH11 NA inhibitor NA drugbank rg6125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 osteoblast cadherin CDH11 Clinical trial target unknown NA TTD , DGIDB exherin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 neural cadherin CDH2 Clinical trial target unknown NA TTD , DGIDB pf-06671008 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 placental cadherin CDH3 Clinical trial target unknown 63.65 TTD , DGIDB pf-3732010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 placental cadherin CDH3 Clinical trial target unknown NA TTD , DGIDB lenalidomide small molecule Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cadherin-5 CDH5 NA antagonist NA drugbank fx06 biotech Reperfusion Injury[MeSHID:D015427],Heart Injuries[MeSHID:D006335],Heart[MeSHID:D006321],Traumatic injury[MeSHID:D014947],Myocardial Infarction[MeSHID:D009203] investigational cadherin-5 CDH5 NA unknown NA drugbank , DGIDB lenalidomide small molecule Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cadherin-5 CDH5 NA antagonist NA drugbank scyllo-inositol small molecule NA investigational cdp-diacylglycerol--inositol 3-phosphatidyltransferase CDIPT NA inhibitor NA drugbank zk 304709 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD sch 727965 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] discontinued in phase 3 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD chir-99021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Graft Rejection[MeSHID:D006084] patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown 0.21 TTD , DGIDB in1535 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD aloisine a NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor NA TTD , DGIDB 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD azakenpaullone NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD indirubin-3'-monoxime small molecule NA experimental,investigative cyclin-dependent kinase 1 CDK1 Clinical trial target binder 2.36 TTD , drugbank , DGIDB aminopurvalanol a NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor NA TTD , DGIDB olomoucine small molecule NA experimental,terminated cyclin-dependent kinase 1 CDK1 Clinical trial target binder NA TTD , drugbank p276-00 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 2 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown 1.18 TTD , DGIDB isoquinoline 1,3-dione derivative 1 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB 4-(quinolin-3-yl)-n-p-tolylpyrimidin-2-amine NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD bisindolylmaleimide-i NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cyclin-dependent kinase 1 CDK1 NA inhibitor NA drugbank ag-024322 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown 0.79 TTD , DGIDB 9-nitropaullone NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor 0.27 TTD , DGIDB l-751250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB at-7519 small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369] investigational cyclin-dependent kinase 1 CDK1 NA inhibitor 0.22 drugbank , DGIDB r-roscovitine NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 2 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown 0.29 TTD , DGIDB rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown 0.27 TTD , DGIDB alsterpaullone 2-cyanoethyl NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor NA TTD , DGIDB avotaciclib small molecule NA investigational cyclin-dependent kinase 1 CDK1 NA inhibitor NA drugbank 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD tricyclic benzimidazole derivative 1 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD purvalanol a NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD su9516 small molecule NA experimental,investigative cyclin-dependent kinase 1 CDK1 Clinical trial target binder,inhibitor NA TTD , drugbank , DGIDB naphthyridine and isoquinoline derivative 1 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB indole-based analog 13 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB pf-228 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD pmid18986805c9b NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD nu6140 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD 4-(thiazol-5-yl)-pyrimidine derivative 2 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD on-01135 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB kenpaullone NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown 0.03 TTD , DGIDB pmid25991433-compound-a1 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB pmid19115845c89s NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD roscovitine derivative 1 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB 10z-hymenialdisine NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD cdk1 inhibitor NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor NA TTD , DGIDB r547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor NA TTD , DGIDB cgp74514a NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor NA TTD , DGIDB microxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD pha-793887 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor 0.11 TTD , DGIDB cvt-313 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD pha-793887 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown 0.11 TTD , DGIDB indirubin-5-sulfonate NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD quinoxaline1 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD p-276 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB k00024 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD bay 10-00394 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] discontinued in phase 2 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB 3,4-bis(indol-3-yl)maleimide derivative NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD pyrrolo[2,3-d]pyrimidine derivative 10 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB alsterpaullone small molecule NA experimental cyclin-dependent kinase 1 CDK1 NA inhibitor 0.07 drugbank , DGIDB bms-265246 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor NA TTD , DGIDB ro 31-7453 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 9 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD 4-(quinolin-4-yl)-n-p-tolylpyrimidin-2-amine NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 1 CDK1 NA unknown 0.26 drugbank , DGIDB cdk1/2 inhibitor iii NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor NA TTD , DGIDB alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 1 CDK1 NA inhibitor 0.26 drugbank , DGIDB chir-99021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Graft Rejection[MeSHID:D006084] patented cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor 0.21 TTD , DGIDB ro-316233 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD pyrazolo[1,5-a]-1,3,5-triazine derivative 1 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB thieno analogue of kenpaullone NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD hymenialdisine small molecule NA experimental cyclin-dependent kinase 1 CDK1 NA unknown NA drugbank at-7519 small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369] investigational cyclin-dependent kinase 1 CDK1 NA unknown 0.22 drugbank , DGIDB (2,6-diamino-pyridin-3-yl)-phenyl-methanone NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD jnj-7706621 NA NA investigative cyclin-dependent kinase 1 CDK1 Clinical trial target inhibitor 0.02 TTD , DGIDB seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational cyclin-dependent kinase 1 CDK1 NA inhibitor 0.29 drugbank , DGIDB oxazolyl methylthiothiazole derivative 1 NA NA patented cyclin-dependent kinase 1 CDK1 Clinical trial target unknown NA TTD , DGIDB thz531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative cyclin-dependent kinase 12 CDK12 Clinical trial target unknown NA TTD gsk3186899 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leishmaniasis[MeSHID:D007896] phase 1 cyclin-dependent kinase 12 CDK12 Clinical trial target unknown NA TTD thz531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative cyclin-dependent kinase 13 CDK13 Literature-reported target unknown NA TTD enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational cyclin-dependent kinase 15 CDK15 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cyclin-dependent kinase 15 CDK15 NA inhibitor NA drugbank atp small molecule NA investigational,nutraceutical cyclin-dependent kinase 15 CDK15 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cyclin-dependent kinase 16 CDK16 NA inhibitor NA drugbank (2z,3e)-2,3'-biindole-2',3(1h,1'h)-dione 3-{o-[(3r)-3,4-dihydroxybutyl]oxime} small molecule NA experimental cyclin-dependent kinase 16 CDK16 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cyclin-dependent kinase 17 CDK17 NA inhibitor NA drugbank sel120 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cyclin-dependent kinase 19 CDK19 Clinical trial target unknown NA TTD [2-amino-6-(2,6-difluoro-benzoyl)-imidazo[1,2-a]pyridin-3-yl]-phenyl-methanone small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2'z,3'e)-5-chloro-5'-hydroxy-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD o6-cyclohexylmethoxy-2-(4'-sulphamoylanilino) purine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-(acetylamino)-n-(4-fluorophenyl)-1h-pyrazole-3-carboxamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 6-(3,4-dihydroxybenzyl)-3-ethyl-1-(2,4,6-trichlorophenyl)-1h-pyrazolo[3,4-d]pyrimidin-4(5h)-one small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank nu6140 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD nitrogen mustard derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 1,5-di-substituted pyridine derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB (2s)-1-[4-({4-[(2,5-dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank pmid18986805c9b NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD pf-228 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD n'-[4-(2,4-dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-n-hydroxyimidoformamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 5-nitroindirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD azd-5438 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.09 TTD , DGIDB aminopurvalanol a NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , DGIDB (2'z,3'e)-5-nitro-5'-methoxy-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 2 CDK2 NA inhibitor 0.31 drugbank , DGIDB 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB pyrazolopyridazine 1 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-{[(2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl]amino}-n-(1,3-thiazol-2-yl)benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank sch-546909 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD fn-1501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 1-[4-(aminosulfonyl)phenyl]-1,6-dihydropyrazolo[3,4-e]indazole-3-carboxamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 2-[trans-(4-aminocyclohexyl)amino]-6-(benzyl-amino)-9-cyclopentylpurine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank pha848125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of thymus[MeSHID:D013953] phase 2 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB at-7519 small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369] investigational cyclin-dependent kinase 2 CDK2 NA inhibitor 0.31 drugbank , DGIDB 2-anilino-6-cyclohexylmethoxypurine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank 4-amino-3,5-di-substituted-thiazole derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 10z-hymenialdisine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 6-cyclohexylmethyloxy-5-nitroso-pyrimidine-2,4-diamine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank meriolin 6 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-{5-[(z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]-2-furyl}-n-methylbenzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank meriolin 2 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD isosteric imidazolyl pyrimidine derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB aloisine a NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , DGIDB oxindole 95 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD (2s)-1-{4-[(4-anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank bms-536924 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 6-(3-methyl-benzyloxy)-9h-purin-2-ylamine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-{[5-(cyclohexylmethoxy)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]amino}benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank hymenialdisine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA inhibitor NA drugbank (2s)-1-[4-({6-[(2,6-difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2s)-n-[(3e)-5-cyclopropyl-3h-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank naphthyridine and isoquinoline derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD cdk4 inhibitor iii NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , DGIDB fluorinated compound 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 3-bromo-6-phenyl-n-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.21 TTD , DGIDB inoc-005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB diamidothiazole derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB n-phenyl-1h-pyrazole-3-carboxamide small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank 4-{[4-(1-cyclopropyl-2-methyl-1h-imidazol-5-yl)pyrimidin-2-yl]amino}-n-methylbenzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 1-(3,5-dichlorophenyl)-5-methyl-1h-1,2,4-triazole-3-carboxylic acid small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2'z,3'e)-5-nitro-5'-hydroxy-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-[(5-isopropyl-1,3-thiazol-2-yl)amino]benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-(5-bromo-2-oxo-2h-indol-3-ylazo)-benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 5-[5,6-bis(methyloxy)-1h-benzimidazol-1-yl]-3-{[1-(2-chlorophenyl)ethyl]oxy}-2-thiophenecarboxamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-{5-[(z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank double oxidized cysteine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2'z,3'e)-5-fluoro-5'-chloro-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD (2e,3s)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'h)-one small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational cyclin-dependent kinase 2 CDK2 NA unknown 0.61 drugbank , DGIDB triazolopyrimidine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.21 TTD , DGIDB (5-chloropyrazolo[1,5-a]pyrimidin-7-yl)-(4-methanesulfonylphenyl)amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank nsc-625987 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD n-[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]acetamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2r)-1-[4-({4-[(2,5-dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD trilaciclib small molecule Small cell carcinoma of lung[MeSHID:D055752],Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cyclin-dependent kinase 2 CDK2 NA inhibitor 0.15 drugbank , DGIDB k00024 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD n-(5-isopropyl-thiazol-2-yl)-2-pyridin-3-yl-acetamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-methyl-5-[(2z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD cdk1/2 inhibitor iii NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , DGIDB 1-(3-(2,4-dimethylthiazol-5-yl)-4-oxo-2,4-dihydroindeno[1,2-c]pyrazol-5-yl)-3-(4-methylpiperazin-1-yl)urea small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank nu-6027 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD aloisine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.31 TTD , DGIDB 5-[(4-aminocyclohexyl)amino]-7-(propan-2-ylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 2 CDK2 NA inhibitor NA drugbank (5e)-2-amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5h)-one small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 6-(3-amino-benzyloxy)-9h-purin-2-ylamine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-{5-[(1z)-1-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)ethyl]-2-furyl}benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3-({2-[(4-{[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino}phenyl)sulfonyl]ethyl}amino)propan-1-ol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 5-(2,3-dichlorophenyl)-n-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 9-nitropaullone NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD tg02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anaplastic astrocytoma[MeSHID:D001254],Malignant Neoplasms[MeSHID:D009369],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1/2 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.42 TTD , DGIDB pha-793887 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.09 TTD , DGIDB pha-793887 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.09 TTD , DGIDB (2'z,3'e)-5-nitro-5'-methyl-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD staurosporine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank gw-8510 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-{5-[(z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}benzoic acid small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 6-cyclohexylmethoxy-pyrimidine-2,4,5-triamine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD indirubin-5-sulfonate NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank sch 727965 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] discontinued in phase 3 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-[4-(4-methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank r547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , DGIDB 2-amino-6-chloropyrazine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank phenylaminoimidazo(1,2-alpha)pyridine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank 4-({5-[(4-aminocyclohexyl)amino][1,2,4]triazolo[1,5-a]pyrimidin-7-yl}amino)benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank ag-024322 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.61 TTD , DGIDB at7519 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.31 TTD , DGIDB rescovitine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD hydroxy(oxo)(3-{[(2z)-4-[3-(1h-1,2,4-triazol-1-ylmethyl)phenyl]pyrimidin-2(5h)-ylidene]amino}phenyl)ammonium small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-(thiazol-5-yl)-pyrimidine derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB (2'z,3'e)-5-chloro-5'-methyl-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD (2r)-1-{4-[(4-anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 1-amino-6-cyclohex-3-enylmethyloxypurine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank 3-pyridin-4-yl-2,4-dihydro-indeno[1,2-.c.]pyrazole small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 3-cyclopropyl-5-phenyl-n-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (3r)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5h-[1]benzothieno[3,2-e][1,4]diazepin-5-one small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank alkyl sulfone derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB n-(5-cyclopropyl-1h-pyrazol-3-yl)benzamide small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank meriolin 5 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD cvt-313 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD {[(2,6-difluorophenyl)carbonyl]amino}-n-(4-fluorophenyl)-1h-pyrazole-3-carboxamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-phenyl-pyrimidin-4-amine derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 4-{5-[(z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank pyrazolopyridazine 2 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD can-508 small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 5-[(2-aminoethyl)amino]-6-fluoro-3-(1h-pyrrol-2-yl)benzo[cd]indol-2(1h)-one small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 6-bromo-13-thia-2,4,8,12,19-pentaazatricyclo[12.3.1.1~3,7~]nonadeca-1(18),3(19),4,6,14,16-hexaene 13,13-dioxide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank pha-690509 NA Pelger-Huet Anomaly[MeSHID:D010381],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD sns-032 NA leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.31 TTD , DGIDB 6-(cyclohexylmethoxy)-8-isopropyl-9h-purin-2-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank l-751250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB indirubin-3'-monoxime small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , drugbank sns-032 NA leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.31 TTD , DGIDB palbociclib/ribociclib analog 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 2-(4-(aminomethyl)piperidin-1-yl)-n-(3_cyclohexyl-4-oxo-2,4-dihydroindeno[1,2-c]pyrazol-5-yl)acetamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-{5-[(z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}-2-(trifluoromethyl)benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank jnj-7706621 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.02 TTD , DGIDB n'-(pyrrolidino[2,1-b]isoindolin-4-on-8-yl)-n-(pyridin-2-yl)urea small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 5-(2-fluorophenyl)-n-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2r)-1-[4-({6-[(2,6-difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-n',n'-dimethyl-benzene-1,4-diamine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational cyclin-dependent kinase 2 CDK2 NA inhibitor 0.61 drugbank , DGIDB variolin b small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3-bromo-5-phenyl-n-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (5r)-5-{[(2-amino-3h-purin-6-yl)oxy]methyl}-2-pyrrolidinone small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank bms-265246 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , DGIDB ro 31-7453 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB oxazolyl methylthiothiazole derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB (2'z,3'e)-5-fluoro-5'-hydroxy-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD (2'z,3'e)-5-nitro-5'-fluoro-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD pyrrolo[2,3-d]pyrimidine derivative 9 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2-ylamine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank bohemine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.46 TTD , DGIDB ver-54505 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 3-bromo-5-phenyl-n-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank aniline derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 6-(cyclohex-3-enylmethoxy)-9h-purin-2-ylamine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD (2s)-1-(dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank isoquinoline 1,3-dione derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB pf-07104091 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Small cell carcinoma of lung[MeSHID:D055752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-(6-cyclohexylmethoxy-9h-purin-2-ylamino)--benzamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank olomoucine ii small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 2-(3,4-dihydroxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-3-hydroxy-6-methyl-4h-chromen-4-one small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-methyl-4-{[(2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl]amino}benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank roscovitine derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 1-(5-oxo-2,3,5,9b-tetrahydro-1h-pyrrolo[2,1-a]isoindol-9-yl)-3-(5-pyrrolidin-2-yl-1h-pyrazol-3-yl)-urea small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank indole-based analog 11 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB (2'z,3'e)-5-chloro-5'-chloro-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD (4e)-n-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4h-pyrazole-3-carboxamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank tg02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anaplastic astrocytoma[MeSHID:D001254],Malignant Neoplasms[MeSHID:D009369],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1/2 cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.42 TTD , DGIDB 4-{[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino}benzamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank zk 304709 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD cyc065 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.46 TTD , DGIDB pmid19115845c89s NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD azd-5438 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.09 TTD , DGIDB (2r)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9h-purin-2-yl}amino)butan-1-ol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank flavopiridol analog 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB bx-912 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , DGIDB n-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 6-o-cyclohexylmethyl guanine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank (13r,15s)-13-methyl-16-oxa-8,9,12,22,24-pentaazahexacyclo[15.6.2.16,9.1,12,15.0,2,7.0,21,25]heptacosa-1(24),2,4,6,17(25),18,20-heptaene-23,26-dione small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2'z,3'e)-5-nitro-5'-chloro-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD (2'z,3'e)-5-fluoro-5'-methoxy-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD n(6)-dimethylallyladenine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3-methyl-n-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank meriolin 4 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD benzyl-(9-isopropyl-9h-purin-6-yl)-amine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD n-(4-{[(3s)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1h-imidazol-5-yl]pyrimidin-2-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-(2-methoxyethyl)-4-({4-[2-methyl-1-(1-methylethyl)-1h-imidazol-5-yl]pyrimidin-2-yl}amino)benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-[5-(1,1-dioxidoisothiazolidin-2-yl)-1h-indazol-3-yl]-2-(4-piperidin-1-ylphenyl)acetamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank su9516 small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , drugbank , DGIDB 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 5-hydroxynaphthalene-1-sulfonamide small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank 5-(2,3-dichlorophenyl)-n-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 6-cyclohexylmethoxy-2-(3'-chloroanilino) purine small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank meriolin 1 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD n-methyl-{4-[2-(7-oxo-6,7-dihydro-8h-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-[(7-oxo-7h-thiazolo[5,4-e]indol-8-ylmethyl)-amino]-n-pyridin-2-yl-benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank purvalanol a NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor NA TTD , DGIDB diaryl amine derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB (2'z,3'e)-5-chloro-5'-fluoro-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-{[(2,6-difluorophenyl)carbonyl]amino}-n-[(3s)-piperidin-3-yl]-1h-pyrazole-3-carboxamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank purvalanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 5-bromoindirubin small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank pmid26161698-compound-25 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB (5z)-5-(3-bromocyclohexa-2,5-dien-1-ylidene)-n-(pyridin-4-ylmethyl)-1,5-dihydropyrazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3-(6-cyclohexylmethoxy-9h-purin-2-ylamino)-benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank pmid25991433-compound-a1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB lysine nz-carboxylic acid small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank 3-bromo-5-phenyl-n-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-{[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]amino}benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-(pyridin-2-yl)pyridine methylsulfone derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 4-[5-(trans-4-aminocyclohexylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-7-ylamino]-n,n-dimethylbenzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank n-(pyridin-2-yl)pyrimidin-4-amine derivative 2 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB indole-based analog 13 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB at-7519 small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369] investigational cyclin-dependent kinase 2 CDK2 NA unknown 0.31 drugbank , DGIDB 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1h-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank pyrazolo[1,5-a]-1,3,5-triazine derivative 1 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB n-(4-sulfamoylphenyl)-1h-indazole-3-carboxamide small molecule NA experimental,investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , drugbank olomoucine small molecule NA experimental,terminated cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 1.15 TTD , drugbank , DGIDB (2'z,3'e)-5-fluoro-5'-methyl-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD nu-6102 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 4-(thiazol-5-yl)-pyrimidine derivative 2 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 4-((3r,4s,5r)-4-amino-3,5-dihydroxy-hex-1-ynyl)-5-fluoro-3-[1-(3-methoxy-1h-pyrrol-2-yl)-meth-(z)-ylidene]-1,3-dihydro-indol-2-one small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-(4-propoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-(3-cyclopropyl-1h-pyrazol-5-yl)-2-(2-naphthyl)acetamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank bx-795 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target inhibitor 0.15 TTD , DGIDB 4-[(6-amino-4-pyrimidinyl)amino]benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank bay 10-00394 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] discontinued in phase 2 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 2-((3,5-diamino-1h-pyrazol-4-yl)diazenyl)phenol NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD n-(3-methylbut-2-en-1-yl)-9h-purin-6-amine NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD pyrazolo-triazine derivative 2 NA NA patented cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD , DGIDB 1-[(2-amino-6,9-dihydro-1h-purin-6-yl)oxy]-3-methyl-2-butanol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 4-{[5-(cyclohexyloxy)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]amino}benzenesulfonamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-[3-(1h-benzimidazol-2-yl)-1h-pyrazol-4-yl]benzamide small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank r-roscovitine NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 2 cyclin-dependent kinase 2 CDK2 Clinical trial target unknown 0.61 TTD , DGIDB 6-(3-aminophenyl)-n-(tert-butyl)-2-(trifluoromethyl)quinazolin-4-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank meriolin 8 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 6-(2-fluorophenyl)-n-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank n-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3-((3,5-diamino-1h-pyrazol-4-yl)diazenyl)phenol NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD ro-4584820 small molecule NA investigational cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank meriolin 3 NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2h-indol-2-one small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2r)-1-(dimethylamino)-3-{4-[(6-{[2-fluoro-5-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenoxy}propan-2-ol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1h-indole small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2'z,3'e)-5-fluoro-5'-fluoro-indirubin-3'-oxime NA NA investigative cyclin-dependent kinase 2 CDK2 Clinical trial target unknown NA TTD 1-methyl-8-(phenylamino)-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxylic acid small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank (2r)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol small molecule NA experimental cyclin-dependent kinase 2 CDK2 NA unknown NA drugbank rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 3 CDK3 Clinical trial target inhibitor 3.26 TTD , DGIDB pmid26161698-compound-17 NA NA patented cyclin-dependent kinase 3 CDK3 Clinical trial target unknown NA TTD , DGIDB nitrogen mustard derivative 1 NA NA patented cyclin-dependent kinase 3 CDK3 Clinical trial target unknown NA TTD , DGIDB oxazolyl methylthiothiazole derivative 1 NA NA patented cyclin-dependent kinase 3 CDK3 Clinical trial target unknown NA TTD , DGIDB rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 3 CDK3 Clinical trial target unknown 3.26 TTD , DGIDB pha-793887 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 4 CDK4 Successful target unknown 0.2 TTD , DGIDB ly2835219 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 4 CDK4 Successful target unknown 1.03 TTD , DGIDB trilaciclib small molecule Small cell carcinoma of lung[MeSHID:D055752],Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cyclin-dependent kinase 4 CDK4 Successful target inhibitor 0.68 TTD , drugbank , DGIDB n-(2-(1h-indol-3-yl)ethyl)biphenyl-4-carboxamide NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD pmid18986805c9b NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD imidazo pyridine derivative 3 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD r547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 4 CDK4 Successful target inhibitor NA TTD , DGIDB bay 10-00394 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] discontinued in phase 2 cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB 1-(1h-indazol-6-yl)-3-pyridin-2-yl-urea NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD lee011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 3 cyclin-dependent kinase 4 CDK4 Successful target unknown 1.28 TTD , DGIDB pmid25726713-compound-50 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB pmid26161698-compound-17 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB ro-0505124 NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown 3.08 TTD , DGIDB abemaciclib small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disease Progression[MeSHID:D018450] approved,investigational cyclin-dependent kinase 4 CDK4 NA inhibitor 1.03 drugbank , DGIDB oxazolyl methylthiothiazole derivative 1 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB inoc-005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB zk 304709 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD palbociclib small molecule Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Triple Negative Breast Neoplasms[MeSHID:D064726],Sarcoma[MeSHID:D012509],Disease Progression[MeSHID:D018450],Paget's Disease, Mammary[MeSHID:D010144],Lymphoma, Non-Hodgkin[MeSHID:D008228],Ductal Carcinoma[MeSHID:D044584],Psychological inhibition[MeSHID:D007266],Body tissue[MeSHID:D014024],Carcinoma, Lobular[MeSHID:D018275],Body part[MeSHID:D018594],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Inflammatory Breast Carcinoma[MeSHID:D058922],Growth[MeSHID:D006128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Schizophrenia[MeSHID:D012559] approved,investigational cyclin-dependent kinase 4 CDK4 Successful target inhibitor 0.71 TTD , drugbank , DGIDB 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 4 CDK4 NA inhibitor 0.68 drugbank , DGIDB ribociclib succinate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB g1t28-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 4 CDK4 Successful target inhibitor 2.05 TTD , DGIDB pmid25726713-compound-51 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB k00024 NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD isoquinoline 1,3-dione derivative 1 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB p-276 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB ro 31-7453 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB palbociclib/ribociclib analog 1 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB pmid25726713-compound-48 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 4 CDK4 NA unknown 0.68 drugbank , DGIDB nsc-625987 NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD indole-based analog 13 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB pmid25991433-compound-a1 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB g1t28-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 4 CDK4 Successful target unknown 2.05 TTD , DGIDB 10-hydroxy-18-methoxybetaenone NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 4 CDK4 Successful target unknown 0.47 TTD , DGIDB ly2835219 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 4 CDK4 Successful target inhibitor 1.03 TTD , DGIDB 1-pyridin-2-yl-3-quinolin-5-yl-urea NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD nu-6102 NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD lee011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 3 cyclin-dependent kinase 4 CDK4 Successful target inhibitor 1.28 TTD , DGIDB ribociclib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Cardiac Arrest[MeSHID:D006323],Genetic Selection[MeSHID:D012641],Disease Progression[MeSHID:D018450] approved,investigational cyclin-dependent kinase 4 CDK4 NA antagonist,inhibitor 1.28 drugbank , DGIDB ribociclib succinate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 4 CDK4 Successful target inhibitor 1.03 TTD , DGIDB fcn-437 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD 1-(9-oxo-9h-fluoren-4-yl)-3-pyridin-2-yl-urea NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD fn-1501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD pha-793887 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 4 CDK4 Successful target inhibitor 0.2 TTD , DGIDB pf-07220060 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471],liposarcoma[MeSHID:D008080] phase 1 cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD pyrrolo[2,3-d]pyrimidine derivative 10 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB nu6140 NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD glr2007 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921] phase 1/2 cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD cdk4 inhibitor iii NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target inhibitor NA TTD , DGIDB 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD ro-0505124 NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target inhibitor 3.08 TTD , DGIDB p1446a-05 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 4 CDK4 Successful target unknown 0.41 TTD , DGIDB apremilast NA Dental Plaque[MeSHID:D003773],Behcet Syndrome[MeSHID:D001528],Oral Ulcer[MeSHID:D019226],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cyclin-dependent kinase 4 CDK4 Successful target unknown 0.34 TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 9 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cyclin-dependent kinase 4 CDK4 NA inhibitor NA drugbank pyrazolopyridazine 2 NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD p276-00 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 2 cyclin-dependent kinase 4 CDK4 Successful target unknown 2.05 TTD , DGIDB 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD purvalanol small molecule NA experimental cyclin-dependent kinase 4 CDK4 NA unknown NA drugbank pmid25726713-compound-47 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB pyrazolopyridazine 1 NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD pmid25726713-compound-49 NA NA patented cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD , DGIDB g1t38 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 cyclin-dependent kinase 4 CDK4 Successful target unknown 2.05 TTD , DGIDB rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 4 CDK4 Successful target inhibitor 0.47 TTD , DGIDB ag-024322 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 4 CDK4 Successful target unknown 1.37 TTD , DGIDB fascaplysin NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target inhibitor 2.05 TTD , DGIDB 1-(7-hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea NA NA investigative cyclin-dependent kinase 4 CDK4 Successful target unknown NA TTD indirubin-5-sulfonate NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD pyrazolo[1,5-a]-1,3,5-triazine derivative 1 NA NA patented cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD , DGIDB 10z-hymenialdisine NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD olomoucine small molecule NA experimental,terminated cyclin-dependent kinase 5 CDK5 Patented-recorded target inhibitor 0.71 TTD , drugbank , DGIDB flavonoid derivative 7 NA NA patented cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD , DGIDB kenpaullone NA NA patented cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown 0.06 TTD , DGIDB oxindole 95 NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD quinoxaline1 NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD roscovitine derivative 1 NA NA patented cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD , DGIDB alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 5 CDK5 NA inhibitor 0.24 drugbank , DGIDB 6-phenyl[5h]pyrrolo[2,3-b]pyrazine small molecule NA experimental cyclin-dependent kinase 5 CDK5 NA unknown NA drugbank tricyclic benzimidazole derivative 1 NA NA patented cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD , DGIDB thieno analogue of kenpaullone NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD 4-(thiazol-5-yl)-pyrimidine derivative 2 NA NA patented cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD , DGIDB azakenpaullone NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD naphthyridine and isoquinoline derivative 1 NA NA patented cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD , DGIDB indirubin-3'-monoxime small molecule NA experimental,investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target inhibitor NA TTD , drugbank alsterpaullone small molecule NA experimental cyclin-dependent kinase 5 CDK5 NA unknown 0.06 drugbank , DGIDB aminopurvalanol a NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target inhibitor NA TTD , DGIDB aloisine a NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target inhibitor NA TTD , DGIDB 9-nitropaullone NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 5 CDK5 NA unknown 0.24 drugbank , DGIDB 3-(2-phenylthiazol-4-yl)quinolin-2(1h)-one NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD l-751250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD , DGIDB manzamine a NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD hymenialdisine small molecule NA experimental cyclin-dependent kinase 5 CDK5 NA inhibitor NA drugbank 1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD nu6140 NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD su9516 small molecule NA experimental,investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target inhibitor NA TTD , drugbank , DGIDB oxindole 16 (compound 3) NA NA investigative cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD pmid26161698-compound-18 NA NA patented cyclin-dependent kinase 5 CDK5 Patented-recorded target unknown NA TTD , DGIDB trilaciclib small molecule Small cell carcinoma of lung[MeSHID:D055752],Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cyclin-dependent kinase 5 CDK5 NA inhibitor NA drugbank indirubin-3'-monoxime small molecule NA experimental cyclin-dependent kinase 5 activator 1 CDK5R1 NA unknown NA drugbank 6-phenyl[5h]pyrrolo[2,3-b]pyrazine small molecule NA experimental cyclin-dependent kinase 5 activator 1 CDK5R1 NA unknown NA drugbank lee011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 3 cyclin-dependent kinase 6 CDK6 Successful target inhibitor 1.55 TTD , DGIDB pmid25726713-compound-51 NA NA patented cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB (2s)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9h-purin-2-yl}amino)-3-methyl-1-butanol small molecule NA experimental cyclin-dependent kinase 6 CDK6 NA unknown NA drugbank ly2835219 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 6 CDK6 Successful target inhibitor 1.26 TTD , DGIDB trilaciclib small molecule Small cell carcinoma of lung[MeSHID:D055752],Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cyclin-dependent kinase 6 CDK6 Successful target inhibitor 1.18 TTD , drugbank , DGIDB fn-1501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD deschloroflavopiridol NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD glr2007 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921] phase 1/2 cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD g1t28-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 6 CDK6 Successful target inhibitor 3.54 TTD , DGIDB apremilast NA Dental Plaque[MeSHID:D003773],Behcet Syndrome[MeSHID:D001528],Oral Ulcer[MeSHID:D019226],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cyclin-dependent kinase 6 CDK6 Successful target unknown 0.59 TTD , DGIDB isoquinoline 1,3-dione derivative 1 NA NA patented cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB ribociclib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Cardiac Arrest[MeSHID:D006323],Genetic Selection[MeSHID:D012641],Disease Progression[MeSHID:D018450] approved,investigational cyclin-dependent kinase 6 CDK6 NA antagonist,inhibitor 1.55 drugbank , DGIDB ly2835219 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 6 CDK6 Successful target unknown 1.26 TTD , DGIDB chrysin NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD ribociclib succinate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 6 CDK6 Successful target inhibitor 1.77 TTD , DGIDB pmid25726713-compound-48 NA NA patented cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB inoc-005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB g1t28-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 6 CDK6 Successful target unknown 3.54 TTD , DGIDB apigenin NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 6 CDK6 NA unknown 0.98 drugbank , DGIDB palbociclib small molecule Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Triple Negative Breast Neoplasms[MeSHID:D064726],Sarcoma[MeSHID:D012509],Disease Progression[MeSHID:D018450],Paget's Disease, Mammary[MeSHID:D010144],Lymphoma, Non-Hodgkin[MeSHID:D008228],Ductal Carcinoma[MeSHID:D044584],Psychological inhibition[MeSHID:D007266],Body tissue[MeSHID:D014024],Carcinoma, Lobular[MeSHID:D018275],Body part[MeSHID:D018594],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Inflammatory Breast Carcinoma[MeSHID:D058922],Growth[MeSHID:D006128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Schizophrenia[MeSHID:D012559] approved,investigational cyclin-dependent kinase 6 CDK6 Successful target inhibitor 0.54 TTD , drugbank , DGIDB 3,7,3',4'-tetrahydroxyflavone NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD pmid25726713-compound-50 NA NA patented cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB oxazolyl methylthiothiazole derivative 1 NA NA patented cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB ribociclib succinate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943] approved cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB pmid25726713-compound-47 NA NA patented cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD fascaplysin NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD pmid25726713-compound-49 NA NA patented cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD , DGIDB alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 6 CDK6 NA inhibitor 0.98 drugbank , DGIDB g1t38 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 cyclin-dependent kinase 6 CDK6 Successful target unknown 3.54 TTD , DGIDB fcn-437 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD abemaciclib small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disease Progression[MeSHID:D018450] approved,investigational cyclin-dependent kinase 6 CDK6 NA inhibitor 1.26 drugbank , DGIDB lee011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 3 cyclin-dependent kinase 6 CDK6 Successful target unknown 1.55 TTD , DGIDB rgb-286147 NA NA investigative cyclin-dependent kinase 6 CDK6 Successful target unknown NA TTD fisetin small molecule NA experimental cyclin-dependent kinase 6 CDK6 NA unknown NA drugbank sns-032 small molecule leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 cyclin-dependent kinase 7 CDK7 Clinical trial target unknown 0.82 TTD , drugbank , DGIDB zk 304709 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD tricyclic benzimidazole derivative 1 NA NA patented cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD , DGIDB 2,5-dichloro-n-p-tolylthiophene-3-sulfonamide NA NA investigative cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD sy-1365 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD , DGIDB sns-032 small molecule leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 cyclin-dependent kinase 7 CDK7 Clinical trial target inhibitor 0.82 TTD , drugbank , DGIDB seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational cyclin-dependent kinase 7 CDK7 NA unknown 1.02 drugbank , DGIDB rgb-286147 NA NA investigative cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD pyrazolo-triazine derivative 2 NA NA patented cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD , DGIDB alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 7 CDK7 NA unknown 0.82 drugbank , DGIDB ly3405105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD btx-a51 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD pmid26161698-compound-34 NA NA patented cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD , DGIDB sy-5609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD roscovitine derivative 1 NA NA patented cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD , DGIDB pyrazolo-triazine derivative 1 NA NA patented cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD , DGIDB nu6140 NA NA investigative cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD r547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 7 CDK7 NA inhibitor 0.82 drugbank , DGIDB trilaciclib small molecule Small cell carcinoma of lung[MeSHID:D055752],Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cyclin-dependent kinase 7 CDK7 NA inhibitor 0.41 drugbank , DGIDB oxazolyl methylthiothiazole derivative 1 NA NA patented cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD , DGIDB phosphonothreonine small molecule NA experimental,investigative cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD , drugbank seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational cyclin-dependent kinase 7 CDK7 NA inhibitor 1.02 drugbank , DGIDB thz1 NA Nasopharyngeal carcinoma[MeSHID:C538339],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cyclin-dependent kinase 7 CDK7 Clinical trial target inhibitor NA TTD , DGIDB r-roscovitine NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 2 cyclin-dependent kinase 7 CDK7 Clinical trial target unknown 1.02 TTD , DGIDB pf-228 NA NA investigative cyclin-dependent kinase 7 CDK7 Clinical trial target unknown NA TTD macrocycle derivative 14 NA NA patented cyclin-dependent kinase 8 CDK8 Clinical trial target unknown NA TTD , DGIDB tricyclic benzimidazole derivative 1 NA NA patented cyclin-dependent kinase 8 CDK8 Clinical trial target unknown NA TTD , DGIDB sel120 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cyclin-dependent kinase 8 CDK8 Clinical trial target unknown NA TTD oxindole 94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative cyclin-dependent kinase 8 CDK8 Clinical trial target unknown NA TTD alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 8 CDK8 NA unknown 0.32 drugbank , DGIDB cct251545 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cyclin-dependent kinase 8 CDK8 Clinical trial target inhibitor NA TTD , DGIDB oxindole 16 (compound 3) NA NA investigative cyclin-dependent kinase 8 CDK8 Clinical trial target unknown NA TTD 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD diaryl amine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB cyc065 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown 1.22 TTD , DGIDB pmid26161698-compound-32 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB pmid19115845c89s NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD pyrazinylpyridine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB tricyclic benzimidazole derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB meriolin 7 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD benzothiazine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB n-(pyridin-2-yl)pyrimidin-4-amine derivative 2 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB flavopiridol analog 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB sch 727965 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] discontinued in phase 3 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD 3-((3,5-diamino-1h-pyrazol-4-yl)diazenyl)phenol NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD phenylpyridine derivative 2 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational cyclin-dependent kinase 9 CDK9 NA inhibitor 1.02 drugbank , DGIDB 4-(thiazol-5-yl)-pyrimidine derivative 2 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB p276-00 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 2 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown 2.45 TTD , DGIDB zk 304709 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD nitrogen mustard derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB meriolin 5 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD sns-032 NA leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target inhibitor 0.98 TTD , DGIDB seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational cyclin-dependent kinase 9 CDK9 NA unknown 1.02 drugbank , DGIDB alkyl sulfone derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB bay 10-00394 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] discontinued in phase 2 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB roscovitine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 9 CDK9 NA inhibitor 0.95 drugbank , DGIDB indole-based analog 13 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB deschloroflavopiridol NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD btx-a51 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD azd4573 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target inhibitor 0.56 TTD , DGIDB n-(pyridin-2-yl)pyrimidin-4-amine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB meriolin 6 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD trilaciclib small molecule Small cell carcinoma of lung[MeSHID:D055752],Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cyclin-dependent kinase 9 CDK9 NA inhibitor 0.41 drugbank , DGIDB meriolin 8 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD n-phenyl-pyrimidin-4-amine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB meriolin 2 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD aryl pyrimidine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB tp-1287 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD flavopiridol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD aminoarylpyridine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB pmid26161698-compound-25 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB 1,5-di-substituted pyridine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB phenylpyridine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB meriolin 4 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD nvp-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical cyclin-dependent kinase 9 CDK9 Clinical trial target inhibitor NA TTD , DGIDB pyrazolo[1,5-a]-1,3,5-triazine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB bipyridine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational cyclin-dependent kinase 9 CDK9 NA unknown 0.95 drugbank , DGIDB sns-032 NA leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown 0.98 TTD , DGIDB 4-(thiazol-5-yl)-pyrimidine derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB rgb-286638 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 cyclin-dependent kinase 9 CDK9 Clinical trial target unknown 0.56 TTD , DGIDB n-(pyridin-2-yl)pyridine methylsulfone derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB 4-(phenyldiazenyl)-1h-pyrazole-3,5-diamine NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD meriolin 1 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD pmid20873740c18 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD meriolin 3 NA NA investigative cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD oxazolyl methylthiothiazole derivative 1 NA NA patented cyclin-dependent kinase 9 CDK9 Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cyclin-dependent kinase-like 1 CDKL1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cyclin-dependent kinase-like 2 CDKL2 NA inhibitor NA drugbank arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational cyclin-dependent kinase inhibitor 1 CDKN1A NA unknown NA drugbank , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical cysteine dioxygenase type 1 CDO1 NA unknown NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical cysteine dioxygenase type 1 CDO1 NA unknown NA drugbank technetium tc-99m arcitumomab biotech Colorectal Neoplasms[MeSHID:D015179] experimental carcinoembryonic antigen-related cell adhesion molecule 1 CEACAM1 NA unknown NA drugbank neo-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 biliary glycoprotein 1 CEACAM1 Clinical trial target unknown NA TTD arcitumomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved carcinoembryonic antigen cgm1 CEACAM3 Successful target unknown 31.83 TTD , DGIDB rg7813 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown 12.73 TTD , DGIDB car-t cells targeting cea NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB ceavac NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting cea NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601] phase 1/2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB ict-037 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],COPPER TOXICOSIS, IDIOPATHIC[MeSHID:C565846] investigative carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD sar408701 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown 12.73 TTD , DGIDB ksb-303 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1/2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD bdc-1001 NA Collecting Duct Carcinoma of the Kidney[MeSHID:D002292],Brachydactyly type C[MeSHID:C537093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD cea car-t NA Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peritoneum[MeSHID:D010537],Neoplasm Metastasis[MeSHID:D009362] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD car-t cells targeting cea NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB pentacea NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] phase 2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB anti-cea car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB neo-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD labetuzumab i-131 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB labetuzumab biotech Malignant Neoplasms[MeSHID:D009369] investigational carcinoembryonic antigen-related cell adhesion molecule 5 CEACAM5 NA inhibitor 38.19 drugbank , DGIDB gi-6207 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid carcinoma[MeSHID:D013964] phase 2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB amg 211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB s-[(1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1h-pyrrol-3-yl)methyl] methanesulfonothioate small molecule NA experimental carcinoembryonic antigen-related cell adhesion molecule 5 CEACAM5 NA unknown NA drugbank car-t cells targeting cea NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1/2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB idm-2101 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB labetuzumab biotech Malignant Neoplasms[MeSHID:D009369] investigational carcinoembryonic antigen-related cell adhesion molecule 5 CEACAM5 NA inhibitor,antibody 38.19 drugbank , DGIDB 123-iodine-labeled mfe-23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB cigb-m3 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB hll1-fab-a3b3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD anti-cea-car t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB cap1-6d NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB avx701 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB ct84.66 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB anti-cea car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Peritoneum[MeSHID:D010537],Colorectal Cancer[MeSHID:D015179] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB mv-cea NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 carcinoembryonic antigen cea CEACAM5 Clinical trial target unknown NA TTD , DGIDB mtl-cepba NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1/2 cebpa messenger rna CEBPA Clinical trial target unknown NA TTD quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational ccaat/enhancer-binding protein beta CEBPB NA inhibitor NA drugbank pmid24556381c10f NA NA investigative bile-salt-activated lipase CEL Clinical trial target unknown NA TTD pmid24556381c10l NA NA investigative bile-salt-activated lipase CEL Clinical trial target unknown NA TTD taurocholic acid NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 bile-salt-activated lipase CEL Clinical trial target unknown NA TTD , DGIDB tgbssl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] investigative bile-salt-activated lipase CEL Clinical trial target unknown NA TTD taurocholic acid small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental bile salt-activated lipase CEL NA unknown NA drugbank , DGIDB bucelipase alfa NA Exocrine pancreatic insufficiency[MeSHID:D010188],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 bile-salt-activated lipase CEL Clinical trial target unknown NA TTD , DGIDB erdosteine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bronchitis[MeSHID:D001991] approved pancreatic elastase 1 CELA1 Successful target unknown 10.61 TTD , DGIDB acetyl-ala-ala-pro-ala-trifluromethane NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD alpha 1-pi NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],alpha 1-Antitrypsin Deficiency[MeSHID:D019896],alpha-1-Antitrypsin Deficiency, Autosomal Recessive[MeSHID:C566273],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] approved pancreatic elastase 1 CELA1 Successful target unknown NA TTD , DGIDB dimethylformamide NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD (2-bromoethyl)(2-'formyl-4'-aminophenyl) acetate small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank methyl(2-acetoxy-2-(2-carboxy-4-amino-phenyl))acetate small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank freselestat small molecule Chronic Obstructive Airway Disease[MeSHID:D029424] experimental,investigational chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank (tert-butyloxycarbonyl)-alanyl-amino ethyl-formamide small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank (2s,3s)-3-formyl-2-({[(4-methylphenyl)sulfonyl]amino}methyl)pentanoic acid small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank 2-[5-methanesulfonylamino-2-(4-aminophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-n-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank (2r)-3-{[(benzylamino)carbonyl]amino}-2-hydroxypropanoic acid small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank sivelestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spondylarthritis[MeSHID:D025241],Ulcerative Colitis[MeSHID:D003093],Pyoderma Gangrenosum[MeSHID:D017511],Multiple Sclerosis[MeSHID:D009103],Arthritis, Psoriatic[MeSHID:D015535],Anterior uveitis[MeSHID:D014606],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 3 pancreatic elastase 1 CELA1 Successful target unknown 10.61 TTD , DGIDB [1-(3-chloro-2-formyl-phenylcarbamoyl)-2-methyl-propyl]-carbamic acid tert-butyl ester small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank (tert-butyloxycarbonyl)-alanyl-alanyl-amine NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD mdl 101,146 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Inflammation[MeSHID:D007249],Expiration, function[MeSHID:D045853] experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank n,n-dimethylformamide small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank para-isopropylaniline NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD n-{4-[(carboxymethyl)carbamoyl]benzoyl}-l-valyl-n-[(3s)-1,1,1-trifluoro-4-methyl-2-oxo-3-pentanyl]-l-prolinamide small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank (2-bromoethyl)(2-'formyl-4'-aminophenyl) acetate NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD acetate ion NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD (2s,3s)-3-formyl-2-({[(4-nitrophenyl)sulfonyl]amino}methyl)pentanoic acid small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank 3-[[(methylamino)sulfonyl]amino]-2-oxo-6-phenyl-n-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxophenyl]-1(2h)-pyridine acetamide small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank molassamide NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD acetyl-pro-ala-pro-ala-trifluoro methane NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD (3r)-3-ethyl-n-[(4-methylphenyl)sulfonyl]-l-aspartic acid small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank cumidine small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank grassystatin a NA NA investigative pancreatic elastase 1 CELA1 Successful target unknown NA TTD n-{[(2-methyl-2-propanyl)oxy]carbonyl}-l-alanyl-l-alaninamide small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank n-[2-(1-formyl-2-methyl-propyl)-1-(4-piperidin-1-yl-but-2-enoyl)-pyrrolidin-3-yl]-methanesulfonamide small molecule NA experimental chymotrypsin-like elastase family member 1 CELA1 NA unknown NA drugbank 2-(2-hydroxy-cyclopentyl)-pent-4-enal small molecule NA experimental chymotrypsin-like elastase family member 2a CELA2A NA unknown NA drugbank gsk-923295 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Malignant Neoplasms[MeSHID:D009369],Expiration, function[MeSHID:D045853] investigational centromere-associated protein e CENPE NA inhibitor NA drugbank , DGIDB sepofarsen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leber Congenital Amaurosis[MeSHID:D057130] phase 2/3 cep290 messenger rna CEP290 Clinical trial target unknown NA TTD nvp 231 NA NA investigative ceramide kinase CERK Literature-reported target inhibitor NA TTD , DGIDB 1-(4-chloro-phenyl)-2-p-tolyl-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis-(3-methoxy-phenyl)-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD gr148672x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] clinical trial liver carboxylesterase CES1 Successful target unknown NA TTD , DGIDB pactimibe NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 2/3 liver carboxylesterase CES1 Successful target unknown 5.79 TTD , DGIDB 1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD benzil NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-dicyclohexylethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD diamorphine small molecule Operative Surgical Procedures[MeSHID:D013514],Myocardial Infarction[MeSHID:D009203],Pain[MeSHID:D010146],Pulmonary Edema[MeSHID:D011654],Dyspnea[MeSHID:D004417] approved,illicit,investigational liver carboxylesterase 1 CES1 NA unknown NA drugbank 1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational liver carboxylesterase 1 CES1 NA unknown NA drugbank nsc-23180 NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD acenanthrene-9,10-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD rp-64477 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 liver carboxylesterase CES1 Successful target unknown NA TTD (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate small molecule NA experimental liver carboxylesterase 1 CES1 NA unknown NA drugbank 1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD probucol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] approved,investigational liver carboxylesterase 1 CES1 NA unknown NA drugbank 1,2-bis(2,6-difluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-benzyl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 447c88 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 1 liver carboxylesterase CES1 Successful target unknown NA TTD 4-chloro-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD (1s,7s,8s,8ar)-1,2,3,7,8,8a-hexahydro-7-methyl-8-[2-[(2r,4r)-tetrahydro-4-hy droxy-6-oxo-2h-pyran-2-yl]ethyl]-1-naphthalenol small molecule NA experimental liver carboxylesterase 1 CES1 NA unknown NA drugbank heptane-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD cl-277082 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 liver carboxylesterase CES1 Successful target unknown NA TTD 1-(3,4-dimethyl-phenyl)-2-phenyl-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD avasimibe small molecule Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational liver carboxylesterase 1 CES1 NA unknown NA drugbank ym-17e NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 1 liver carboxylesterase CES1 Successful target unknown NA TTD diethyl 2,2,2-trifluoro-1-phenylethyl phosphate NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 5-(trifluoromethoxy)-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD smp-797 NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD k-604 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 2 liver carboxylesterase CES1 Successful target unknown NA TTD , DGIDB 4,5-dichloro-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD e-5324 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 liver carboxylesterase CES1 Successful target unknown NA TTD 1-propionyl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-hexadecyl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD ky-382 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] investigative liver carboxylesterase CES1 Successful target unknown NA TTD cl-283796 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 liver carboxylesterase CES1 Successful target unknown NA TTD 4-piperidino-piperidine NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2-fluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis-(4-bromo-phenyl)-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 6,7-dichloro-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 7-(trifluoromethyl)-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-(4-nitro-phenyl)-2-phenyl-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-butyryl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3-(butylthio)-1,1,1-trifluoropropan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis-(2-chloro-phenyl)-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-naphthoquinone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(4-fluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD phenanthrene-9,10-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,1,1-trifluoro-3-(hexylsulfonyl)propan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-(4-chlorobenzyl)-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 11,12-dihydro-dibenzo[a,e]cyclooctene-5,6-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-indanedione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,10-phenanthroline-5,6-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-(2-bromoethyl)-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 5,6-dinitroacenaphthoquinone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD gr148672x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] clinical trial liver carboxylesterase CES1 Successful target inhibitor NA TTD , DGIDB 5-chloro-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 2,2-dimethyl-3-methyleneheptadecane NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD thieno[3,2-e][1]benzothiophene-4,5-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD vulm-1457 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] investigative liver carboxylesterase CES1 Successful target unknown NA TTD eflucimibe NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 liver carboxylesterase CES1 Successful target unknown NA TTD ym-750 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 1 liver carboxylesterase CES1 Successful target unknown NA TTD 1-phenyl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis-(3-nitro-phenyl)-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(3,4-difluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-phenyl-2-p-tolyl-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(3-fluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD (e)-octadec-9-enoic acid phenylamide NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-phenyl-propane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-(3,4-dichlorobenzyl)-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD pyripyropene a NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2,5-difluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3,4,5,6-tetrachloro-[1,2]benzoquinone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD eldacimibe NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 liver carboxylesterase CES1 Successful target unknown 5.79 TTD , DGIDB 1-(2-iodoethyl)-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD hydroxy-phenyl-acetic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester small molecule NA experimental liver carboxylesterase 1 CES1 NA unknown NA drugbank n-methylnaloxonium NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-(4-chloro-phenyl)-2-phenyl-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3-(decylthio)-1,1,1-trifluoropropan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD f-1394 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 liver carboxylesterase CES1 Successful target unknown NA TTD o-sialic acid NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD avasimibe NA Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 liver carboxylesterase CES1 Successful target unknown NA TTD 7-chloro-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis-(4-chloro-phenyl)-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD chloranil NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD ci-976 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 liver carboxylesterase CES1 Successful target unknown NA TTD benzoin NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,1,1-trifluoro-3-(hexylthio)propan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-methyl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 4,6-dichloro-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2-fluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,1,1-trifluoro-3-(octylthio)propan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1-dodecyl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD cholic acid NA Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved liver carboxylesterase CES1 Successful target unknown NA TTD , DGIDB naloxone small molecule Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved,vet_approved liver carboxylesterase 1 CES1 NA binder NA drugbank tacrine small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn liver carboxylesterase 1 CES1 NA unknown NA drugbank 1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit liver carboxylesterase 1 CES1 NA binder NA drugbank oleic acid anilide NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 6-bromo-5-methyl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2,4-difluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 4-chloro-7-methyl-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-di-naphthalen-2-yl-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(3-fluorophenyl)-2-hydroxyethanon NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD thenoyltrifluoroacetone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(3,5-difluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3,5-di-tert-butyl-[1,2]benzoquinone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD alpha-d-mannose NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD acenaphthoquinone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 4-(2-oxo-2-phenyl-acetyl)-benzoic acid NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD sch-48375 NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-di-p-tolyl-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 4,7-dichloro-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved liver carboxylesterase 1 CES1 NA unknown NA drugbank hl-004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] preclinical liver carboxylesterase CES1 Successful target unknown NA TTD , DGIDB n-acetyl-alpha-neuraminic acid small molecule NA experimental liver carboxylesterase 1 CES1 NA unknown NA drugbank dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD cyclandelate small molecule Vascular Diseases[MeSHID:D014652],Muscle Cramp[MeSHID:D009120],Arteriosclerosis[MeSHID:D001161],Raynaud Disease[MeSHID:D011928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved liver carboxylesterase 1 CES1 NA unknown NA drugbank 1-(4-methoxy-phenyl)-2-phenyl-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,1,1-trifluorododecan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 4-piperidino-piperidine small molecule NA experimental liver carboxylesterase 1 CES1 NA unknown NA drugbank thenoyltrifluoroacetone small molecule NA experimental liver carboxylesterase 1 CES1 NA unknown NA drugbank 2,2-dimethoxy-1,2-diphenyl-ethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 3-(butylsulfinyl)-1,1,1-trifluoropropan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD dextropropoxyphene small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn liver carboxylesterase 1 CES1 NA unknown NA drugbank 5,7-dichloro-1h-indole-2,3-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved liver carboxylesterase 1 CES1 NA unknown NA drugbank , DGIDB 2-methoxy-3,4-methylenedioxybenzophenone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,1,1-trifluoro-3-(hexylsulfinyl)propan-2-one NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,2-bis-(4-methoxy-phenyl)-ethane-1,2-dione NA NA investigative liver carboxylesterase CES1 Successful target unknown NA TTD 1,1,1-trifluoro-3-(octylthio)acetone small molecule NA experimental putative inactive carboxylesterase 4 CES1P1 NA unknown NA drugbank ta-8995 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Cardiovascular Diseases[MeSHID:D002318] phase 2 cholesteryl ester transfer protein CETP Clinical trial target unknown 5.3 TTD , DGIDB sc-795 NA NA investigative cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD tetrahydroquinoline b NA NA investigative cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD dalcetrapib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Acute Coronary Syndrome[MeSHID:D054058] phase 3 cholesteryl ester transfer protein CETP Clinical trial target inhibitor 5.3 TTD , DGIDB evacetrapib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 3 cholesteryl ester transfer protein CETP Clinical trial target unknown 10.61 TTD , DGIDB jtt-302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 2 cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD , DGIDB ds-1442 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] discontinued in phase 1 cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD dalcetrapib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Acute Coronary Syndrome[MeSHID:D054058] phase 3 cholesteryl ester transfer protein CETP Clinical trial target unknown 5.3 TTD , DGIDB ceti-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 2 cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD r7232 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] discontinued in phase 1 cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD anacetrapib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161] phase 3 cholesteryl ester transfer protein CETP Clinical trial target inhibitor 15.91 TTD , DGIDB bay-60-5521 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 1 cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD , DGIDB nsc-89508 NA NA investigative cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD cp-800569 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD tetrahydroquinoline a NA NA investigative cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD evacetrapib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 3 cholesteryl ester transfer protein CETP Clinical trial target inhibitor 10.61 TTD , DGIDB pf-3185043 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD anacetrapib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161] phase 3 cholesteryl ester transfer protein CETP Clinical trial target unknown 15.91 TTD , DGIDB nsc-40331 NA NA investigative cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD drl-17822 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 2 cholesteryl ester transfer protein CETP Clinical trial target unknown NA TTD , DGIDB bay-38-1315 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] preclinical cholesteryl ester transfer protein CETP Clinical trial target unknown 5.3 TTD , DGIDB torcetrapib small molecule Peripheral Vascular Diseases[MeSHID:D016491],Hyperlipidemia[MeSHID:D006949],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 cholesteryl ester transfer protein CETP Clinical trial target antagonist 15.91 TTD , drugbank , DGIDB mln2222 biotech Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327] investigational complement factor b CFB NA unknown NA drugbank diisopropylphosphono group small molecule NA experimental complement factor b CFB NA unknown NA drugbank pmid19743866c51 NA NA investigative complement factor b CFB Clinical trial target unknown NA TTD cab-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] discontinued in phase 1 complement factor b CFB Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement factor b CFB NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement factor b CFB NA unknown NA drugbank 4-guanidinobenzoic acid small molecule NA experimental complement factor b CFB NA unknown NA drugbank lpn023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],IGA Glomerulonephritis[MeSHID:D005922] phase 2 complement factor b CFB Clinical trial target unknown NA TTD ta-106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative complement factor b CFB Clinical trial target unknown NA TTD lnp023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],IGA Glomerulonephritis[MeSHID:D005922],Paroxysmal nocturnal hemoglobinuria[MeSHID:D006457] phase 3 complement factor b CFB Clinical trial target inhibitor NA TTD , DGIDB nm-9308 NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative complement factor b CFB Clinical trial target unknown NA TTD ionis-fb-lrx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],IGA Glomerulonephritis[MeSHID:D005922] phase 2 cfb messenger rna CFB Clinical trial target unknown NA TTD ach-4471 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glomerulonephritis[MeSHID:D005921],Anemia[MeSHID:D000740] phase 2 complement factor d CFD Clinical trial target unknown NA TTD , DGIDB example 373 [wo2012093101] NA NA investigative complement factor d CFD Clinical trial target inhibitor NA TTD , DGIDB hc3-1496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative complement factor d CFD Clinical trial target unknown NA TTD 3,4-dichloroisocoumarin small molecule NA experimental complement factor d CFD NA unknown NA drugbank lampalizumab NA Geographic Atrophy[MeSHID:D057092],Retina[MeSHID:D012160],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 complement factor d CFD Clinical trial target antibody 63.65 TTD , DGIDB 2-aminobenzyl alcohol small molecule NA experimental complement factor d CFD NA unknown NA drugbank anti-factor d NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 complement factor d CFD Clinical trial target unknown NA TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement factor h CFH NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental complement factor h CFH NA ligand NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational complement factor h CFH NA ligand NA drugbank trumenba NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Meningitis[MeSHID:D008581] approved complement factor h CFH Clinical trial target unknown NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement factor h CFH NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement factor h CFH NA unknown NA drugbank tt-30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 complement factor h CFH Clinical trial target unknown NA TTD , DGIDB gt103 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 complement factor h CFH Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational complement factor i CFI NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational complement factor i CFI NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational complement factor i CFI NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational cofilin-1 CFL1 NA ligand NA drugbank dodecyldimethylamine n-oxide small molecule NA experimental cofilin-1 CFL1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cofilin-1 CFL1 NA unknown NA drugbank cftrinh-172 NA NA investigative camp-dependent chloride channel CFTR Successful target blocker NA TTD , DGIDB vx-661 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 camp-dependent chloride channel CFTR Successful target unknown 24.91 TTD , DGIDB glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved cystic fibrosis transmembrane conductance regulator CFTR NA antagonist NA drugbank phenylglycine-01 NA NA investigative camp-dependent chloride channel CFTR Successful target activator NA TTD , DGIDB elexacaftor small molecule Cystic Fibrosis[MeSHID:D003550],Mutation[MeSHID:D009154] approved,investigational cystic fibrosis transmembrane conductance regulator CFTR NA modulator 5.53 drugbank , DGIDB ivacaftor small molecule Homozygote[MeSHID:D006720],Disease Management[MeSHID:D019468],Mutation[MeSHID:D009154],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cystic fibrosis transmembrane conductance regulator CFTR NA potentiator 9.69 drugbank , DGIDB lumacaftor + ivacaftor NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] approved camp-dependent chloride channel CFTR Successful target unknown NA TTD , DGIDB crofelemer NA HIV Seropositivity[MeSHID:D006679],Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Dysentery[MeSHID:D004403],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved camp-dependent chloride channel CFTR Successful target inhibitor 6.92 TTD , DGIDB colforsin small molecule NA experimental,investigational cystic fibrosis transmembrane conductance regulator CFTR NA inhibitor NA drugbank abbv-3067 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 camp-dependent chloride channel CFTR Successful target unknown NA TTD , DGIDB crofelemer small molecule HIV Seropositivity[MeSHID:D006679],Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Dysentery[MeSHID:D004403],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cystic fibrosis transmembrane conductance regulator CFTR NA antagonist,inhibitor 6.92 drugbank , DGIDB ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cystic fibrosis transmembrane conductance regulator CFTR NA inhibitor NA drugbank uccf-029 NA NA investigative camp-dependent chloride channel CFTR Successful target activator 1.38 TTD , DGIDB glyh-101 NA NA investigative camp-dependent chloride channel CFTR Successful target blocker NA TTD , DGIDB ivacaftor NA Homozygote[MeSHID:D006720],Disease Management[MeSHID:D019468],Mutation[MeSHID:D009154],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved camp-dependent chloride channel CFTR Successful target unknown 9.69 TTD , DGIDB abbv-2222 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 camp-dependent chloride channel CFTR Successful target unknown 2.77 TTD , DGIDB sulfonamide-01 NA NA investigative camp-dependent chloride channel CFTR Successful target activator NA TTD , DGIDB bumetanide small molecule Nephrotic Syndrome[MeSHID:D009404],Congestive heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cystic fibrosis transmembrane conductance regulator CFTR NA antagonist NA drugbank glpg-1837 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 camp-dependent chloride channel CFTR Successful target unknown NA TTD , DGIDB lumacaftor small molecule Homozygote[MeSHID:D006720],Cystic Fibrosis[MeSHID:D003550],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cystic fibrosis transmembrane conductance regulator CFTR NA modulator 63.65 drugbank , DGIDB phosphoaminophosphonic acid-adenylate ester small molecule NA experimental cystic fibrosis transmembrane conductance regulator CFTR NA unknown NA drugbank abbv-2737 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 camp-dependent chloride channel CFTR Successful target unknown NA TTD , DGIDB lonidamine small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Neoplasms[MeSHID:D009369],Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cystic fibrosis transmembrane conductance regulator CFTR NA unknown NA drugbank crofelemer NA HIV Seropositivity[MeSHID:D006679],Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Dysentery[MeSHID:D004403],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved camp-dependent chloride channel CFTR Successful target unknown 6.92 TTD , DGIDB tezacaftor small molecule Mutation[MeSHID:D009154],Cystic Fibrosis[MeSHID:D003550] approved,investigational cystic fibrosis transmembrane conductance regulator CFTR NA activator 24.91 drugbank , DGIDB tezacaftor and ivacaftor NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] approved camp-dependent chloride channel CFTR Successful target unknown NA TTD , DGIDB uccf-339 NA NA investigative camp-dependent chloride channel CFTR Successful target activator NA TTD , DGIDB atp small molecule NA investigational,nutraceutical cystic fibrosis transmembrane conductance regulator CFTR NA cofactor NA drugbank abbv-2451 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 camp-dependent chloride channel CFTR Successful target unknown NA TTD , DGIDB lumacaftor NA Homozygote[MeSHID:D006720],Cystic Fibrosis[MeSHID:D003550],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 camp-dependent chloride channel CFTR Successful target unknown 63.65 TTD , DGIDB iowh032 NA Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 camp-dependent chloride channel CFTR Successful target unknown 2.77 TTD , DGIDB lumacaftor + ivacaftor NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] approved camp-dependent chloride channel f508 deletion CFTR Successful target unknown NA TTD , DGIDB dexfosfoserine small molecule NA experimental cystic fibrosis transmembrane conductance regulator CFTR NA unknown NA drugbank crofelemer small molecule HIV Seropositivity[MeSHID:D006679],Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Dysentery[MeSHID:D004403],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cystic fibrosis transmembrane conductance regulator CFTR NA antagonist 6.92 drugbank , DGIDB dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cystic fibrosis transmembrane conductance regulator CFTR NA inhibitor NA drugbank ivacaftor NA Homozygote[MeSHID:D006720],Disease Management[MeSHID:D019468],Mutation[MeSHID:D009154],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved camp-dependent chloride channel CFTR Successful target activator 9.69 TTD , DGIDB ivacaftor small molecule Homozygote[MeSHID:D006720],Disease Management[MeSHID:D019468],Mutation[MeSHID:D009154],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cystic fibrosis transmembrane conductance regulator CFTR NA potentiator,activator 9.69 drugbank , DGIDB cbiq NA NA investigative camp-dependent chloride channel CFTR Successful target activator NA TTD , DGIDB uccf-853 NA NA investigative camp-dependent chloride channel CFTR Successful target activator NA TTD , DGIDB alpha-d-mannose NA NA investigative glycoprotein hormones alpha CGA Literature-reported target unknown NA TTD cdx-1307 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] phase 2 choriogonadotropin beta CGB3 Clinical trial target unknown NA TTD nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved choline o-acetyltransferase CHAT NA inhibitor NA drugbank 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-cyanopyrazin-2-yl)urea small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 4-(6-{[(4-methylcyclohexyl)amino]methyl}-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzoic acid small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank ci-1040 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown 0.08 TTD , DGIDB ly2880070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD pmid19364658c33 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD sch-900776 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 checkpoint kinase-1 CHEK1 Clinical trial target inhibitor 2.65 TTD , DGIDB kn-62 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD v158411 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 6-(3-aminopropyl)benzo[h]isoquinolin-1(2h)-one NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD chir-124 small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA inhibitor NA drugbank , DGIDB cct244747 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target inhibitor 1.77 TTD , DGIDB gdc-0425 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 checkpoint kinase-1 CHEK1 Clinical trial target unknown 1.77 TTD , DGIDB nu-6102 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 1-(5-chloro-2-methoxyphenyl)-3-{6-[2-(dimethylamino)-1-methylethoxy]pyrazin-2-yl}urea small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 2-(cyclohexylamino)benzoic acid NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD ly2603618 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD , DGIDB (5,6-diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank bx-912 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target inhibitor NA TTD , DGIDB mk-8776 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689] phase 1 checkpoint kinase-1 CHEK1 Clinical trial target inhibitor 2.65 TTD , DGIDB rel-(9r,12s)-9,10,11,12-tetrahydro-9,12-epoxy-1h-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2h)-dione small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank sb218078 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD sb 218078 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target inhibitor NA TTD , DGIDB n-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)glycine small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank (2r)-1-[(5,6-diphenyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]propan-2-ol small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 3-(1h-benzimidazol-2-yl)-1h-indazole small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 5-ethyl-3-methyl-1,5-dihydro-4h-pyrazolo[4,3-c]quinolin-4-one small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank pf-477736 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 checkpoint kinase-1 CHEK1 Clinical trial target inhibitor 0.51 TTD , DGIDB (2r)-3-{[(4z)-5,6-diphenyl-6,7-dihydro-4h-pyrrolo[2,3-d]pyrimidin-4-ylidene]amino}propane-1,2-diol small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 9-chlorobenzo[h]isoquinolin-1(2h)-one NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD n-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)glycine NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD isogranulatimide NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target inhibitor 0.59 TTD , DGIDB 2,2'-{[9-(hydroxyimino)-9h-fluorene-2,7-diyl]bis(oxy)}diacetic acid small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 6-morpholin-4-yl-9h-purine NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD (5-{3-[5-(piperidin-1-ylmethyl)-1h-indol-2-yl]-1h-indazol-6-yl}-2h-1,2,3-triazol-4-yl)methanol small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank cct244747 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown 1.77 TTD , DGIDB arry-575 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD ucn-01 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 checkpoint kinase-1 CHEK1 Clinical trial target unknown 0.35 TTD , DGIDB xl844 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD , DGIDB s-024 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase chk1 CHEK1 NA inhibitor NA drugbank pmid17935989c25 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD azd7762 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 checkpoint kinase-1 CHEK1 Clinical trial target inhibitor 1.77 TTD , DGIDB xl844 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank , DGIDB s-070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 6-morpholin-4-yl-9h-purine small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank ly2606368 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anus[MeSHID:D001003],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258],Small cell carcinoma of lung[MeSHID:D055752],Malignant neoplasm of ovary[MeSHID:D010051],Squamous cell carcinoma[MeSHID:D002294] phase 2 checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD , DGIDB chk1-a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 3-(5-{[4-(aminomethyl)piperidin-1-yl]methyl}-1h-indol-2-yl)-1h-indazole-6-carbonitrile small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]ethanol small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1h-pyrrolo[2,3-b]pyridine-3-carboxylate small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 2-[5,6-bis-(4-methoxy-phenyl)-furo[2,3-d]pyrimidin-4-ylamino]-ethanol small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 2-(cyclohexylamino)benzoic acid small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3h)-one small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank (2s)-1-amino-3-[(5-nitroquinolin-8-yl)amino]propan-2-ol small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 1-[(2s)-4-(5-bromo-1h-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank diamidothiazole derivative 1 NA NA patented checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD , DGIDB rg7741 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD , DGIDB pmid20855207c25 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 3-(5-{[4-(aminomethyl)piperidin-1-yl]methyl}-1h-indol-2-yl)quinolin-2(1h)-one small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank n-{5-[4-(4-methylpiperazin-1-yl)phenyl]-1h-pyrrolo[2,3-b]pyridin-3-yl}nicotinamide small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1h-imidazol-4-ol small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank azd7762 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 checkpoint kinase-1 CHEK1 Clinical trial target unknown 1.77 TTD , DGIDB 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD a-432411 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank debromohymenialdisine NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD bx-795 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target inhibitor 0.29 TTD , DGIDB bis-imide a NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD rg7602 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] discontinued in phase 1 checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 2-(1h-indazol-3-yl)-1h-benzo[d]imidazole NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 3-amino-3-benzyl-[4.3.0]bicyclo-1,6-diazanonan-2-one small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank bisindolylmaleimide-i NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 18-chloro-11,12,13,14-tetrahydro-1h,10h-8,4-(azeno)-9,15,1,3,6-benzodioxatriazacycloheptadecin-2-one small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank sch-900776 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 checkpoint kinase-1 CHEK1 Clinical trial target unknown 2.65 TTD , DGIDB granulatimide NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD n-(4-oxo-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-c]azepin-2-yl)acetamide small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank ro-316233 NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 1-[(2s)-4-(5-phenyl-1h-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank 3-(1h-indol-2-yl)-1h-quinolin-2-one NA NA investigative checkpoint kinase-1 CHEK1 Clinical trial target unknown NA TTD 4-[3-(1h-benzimidazol-2-yl)-1h-indazol-6-yl]-2-methoxyphenol small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank (3z)-6-(4-hydroxy-3-methoxyphenyl)-3-(1h-pyrrol-2-ylmethylene)-1,3-dihydro-2h-indol-2-one small molecule NA experimental serine/threonine-protein kinase chk1 CHEK1 NA unknown NA drugbank pmid22564207c25b NA NA investigative serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD debromohymenialdisine NA NA investigative serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD xl844 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,discontinued in phase 1 serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD , drugbank , DGIDB 5-nitro-2-(4-phenoxy-phenyl)-1h-benzoimidazole NA NA investigative serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD cct-241533 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD 2-(4-phenoxy-phenyl)-1h-benzoimidazol-5-ylamine NA NA investigative serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD e7850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase chk2 CHEK2 NA inhibitor NA drugbank enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational serine/threonine-protein kinase chk2 CHEK2 NA unknown NA drugbank pv-1019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD chk2 inhibitor ii NA NA investigative serine/threonine-protein kinase chk2 CHEK2 Clinical trial target inhibitor NA TTD , DGIDB pmid27410995-compound-figure3j NA NA patented serine/threonine-protein kinase chk2 CHEK2 Clinical trial target unknown NA TTD argadin small molecule NA experimental chitotriosidase-1 CHIT1 NA unknown NA drugbank 2-(acetylamino)-2-deoxy-6-o-methyl-alpha-d-allopyranose small molecule NA experimental chitotriosidase-1 CHIT1 NA unknown NA drugbank allosamizoline small molecule NA experimental chitotriosidase-1 CHIT1 NA unknown NA drugbank 2-acetylamino-2-deoxy-b-d-allopyranose small molecule NA experimental chitotriosidase-1 CHIT1 NA unknown NA drugbank argifin small molecule NA experimental chitotriosidase-1 CHIT1 NA unknown NA drugbank tcd-717 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Choroideremia[MeSHID:D015794],Malignant Neoplasms[MeSHID:D009369] phase 1 choline kinase CHKA Clinical trial target inhibitor 63.65 TTD , DGIDB tcd-717 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Choroideremia[MeSHID:D015794],Malignant Neoplasms[MeSHID:D009369] phase 1 choline kinase CHKA Clinical trial target unknown 63.65 TTD , DGIDB spk-7001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Choroid[MeSHID:D002829] phase 1/2 rab proteins geranylgeranyltransferase component a 1 CHM Clinical trial target unknown NA TTD calcium citrate small molecule NA approved,investigational calcineurin b homologous protein 1 CHP1 NA agonist NA drugbank calcium phosphate small molecule NA approved calcineurin b homologous protein 1 CHP1 NA agonist NA drugbank calcium phosphate dihydrate small molecule NA approved calcineurin b homologous protein 1 CHP1 NA unknown NA drugbank (3-exo)-3-(10,11-dihydro-5h-dibenzo[a,d][7]annulen-5-yloxy)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane small molecule NA experimental chrna7-fam7a fusion protein CHRFAM7A NA unknown NA drugbank epibatidine small molecule NA experimental chrna7-fam7a fusion protein CHRFAM7A NA unknown NA drugbank thiacloprid small molecule NA experimental chrna7-fam7a fusion protein CHRFAM7A NA unknown NA drugbank imidacloprid small molecule NA vet_approved chrna7-fam7a fusion protein CHRFAM7A NA unknown NA drugbank sulfoarecoline NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD dau-6202 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD 6-dimethylamino-2-methyl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD n-(4-dimethylamino-but-2-ynyl)-n-methyl-acetamide NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD metixene small molecule Secondary Parkinson Disease[MeSHID:D010302],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor CHRM1 NA antagonist 1.03 drugbank , DGIDB pirenzepine small molecule Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 0.43 TTD , drugbank , DGIDB pyrantel small molecule Nematode infections[MeSHID:D009349],Ascariasis[MeSHID:D001196],Hookworm Infections[MeSHID:D006725],Enterobiasis[MeSHID:D017229],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Helminthiasis[MeSHID:D006373] approved,vet_approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist,agonist NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA ligand NA drugbank tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank caramipen NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD gallamine triethiodide small molecule Disease Management[MeSHID:D019468],Skeletal muscle structure[MeSHID:D018482],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA unknown NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank fesoterodine fumarate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB a-987306 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD glycopyrronium small molecule Solutions[MeSHID:D012996],Cardiac Arrhythmia[MeSHID:D001145],Drooling[MeSHID:D012798],Maintenance[MeSHID:D008283],Operative Surgical Procedures[MeSHID:D013514],Heart[MeSHID:D006321],Vagus nerve structure[MeSHID:D014630],Heartburn[MeSHID:D006356],Chronic Obstructive Airway Disease[MeSHID:D029424],Cardiac Arrest[MeSHID:D006323],Peptic Ulcer[MeSHID:D010437],Term Birth[MeSHID:D047929],Hyperhidrosis disorder[MeSHID:D006945],Reflex action[MeSHID:D012018],Bodily secretions[MeSHID:D012634],Gastric Juice (substance)[MeSHID:D005750],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 2.87 drugbank , DGIDB oxybutynin small molecule Disease Management[MeSHID:D019468],Urinary Bladder[MeSHID:D001743],Spasm[MeSHID:D013035],Off-Label Use[MeSHID:D056687],Urinary tract[MeSHID:D014551],Urge Incontinence[MeSHID:D053202],Spina Bifida[MeSHID:D016135],Muscle[MeSHID:D009132],Overactive Bladder[MeSHID:D053201],Ureter[MeSHID:D014513] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.74 drugbank , DGIDB glycopyrrolate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown 0.57 TTD , DGIDB staurosporine small molecule NA experimental muscarinic acetylcholine receptor m1 CHRM1 NA allosteric modulator 0.03 drugbank , DGIDB propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM1 NA antagonist 0.33 drugbank , DGIDB sdz-210-086 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD cevimeline small molecule Syndrome[MeSHID:D013577],Xerostomia[MeSHID:D014987],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859] approved muscarinic acetylcholine receptor m1 CHRM1 NA agonist 0.69 drugbank , DGIDB tolterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.34 drugbank , DGIDB n-methoxyquinuclidine-3-carboximidoyl chloride NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD flavoxate small molecule prostatitis[MeSHID:D011472],Nocturia[MeSHID:D053158],Urethritis[MeSHID:D014526],Cystitis[MeSHID:D003556],Pain[MeSHID:D010146],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.72 drugbank , DGIDB tak-071 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB 7-dimethylamino-3-methyl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD arecoline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] experimental,phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown 0.57 TTD , drugbank , DGIDB clidinium small molecule Colicky Pain[MeSHID:D015746],Spasm[MeSHID:D013035],Diverticulitis[MeSHID:D004238],Stomach[MeSHID:D013270],Irritable Bowel Syndrome[MeSHID:D043183],Muscle Cramp[MeSHID:D009120],Peptic Ulcer[MeSHID:D010437],Abdominal colic[MeSHID:D003085],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Abdominal Pain[MeSHID:D015746] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 1.72 TTD , drugbank , DGIDB 1,1-diphenyl-2-(3-tropanyl)ethanol NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA unknown NA drugbank anavex 2-73 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cognition Disorders[MeSHID:D003072],Rett Syndrome[MeSHID:D015518],Parkinson Disease[MeSHID:D010300],West Syndrome[MeSHID:D013036] phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB benzatropine small molecule Bradykinesia[MeSHID:D018476],Dystonia[MeSHID:D004421],Disease[MeSHID:D004194],Dyskinetic syndrome[MeSHID:D020820],Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Akathisia[MeSHID:D011595],Movement[MeSHID:D009068],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Term Birth[MeSHID:D047929] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank cremastrine NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD fm1-43 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM1 NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.11 drugbank , DGIDB benzquinamide small molecule Nausea[MeSHID:D009325],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.25 drugbank , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.14 drugbank , DGIDB fesoterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.23 drugbank , DGIDB solifenacin small molecule Urinary Incontinence[MeSHID:D014549],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.8 drugbank , DGIDB tazomeline NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM1 NA ligand,antagonist 0.14 drugbank , DGIDB triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.36 drugbank , DGIDB diphemanil methylsulfate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 0.29 TTD , DGIDB fm1-10 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD procyclidine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 1.15 drugbank , DGIDB ngx-267 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown 1.15 TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank acp-104 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618] investigational muscarinic acetylcholine receptor m1 CHRM1 NA unknown NA drugbank , DGIDB 7-dimethylamino-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD rr(17)pz NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD 1-methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD sabcomeline NA NA discontinued in phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target agonist 0.14 TTD , DGIDB 2-methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD aclidinium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Inspiration function[MeSHID:D001239],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.23 drugbank , DGIDB dau-5884 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD diphenidol small molecule Vertigo[MeSHID:D014717],Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Meniere Disease[MeSHID:D008575],Labyrinth[MeSHID:D007758],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.57 drugbank , DGIDB telenzepine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in preregistration muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Middle East Respiratory Syndrome[MeSHID:D018352] approved,vet_approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.36 drugbank , DGIDB doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.16 drugbank , DGIDB brompheniramine small molecule Pruritus[MeSHID:D011537],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Common Cold[MeSHID:D003139],Drinking Water[MeSHID:D060766],Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank oxyphenonium small molecule Spasm[MeSHID:D013035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 2.01 TTD , drugbank , DGIDB 3-(3-benzylamino)-piperidin-2-one NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD ac-262271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB n-desmethylclozapine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618] phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target allosteric modulator 0.19 TTD , DGIDB itameline NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD fp-1097 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB wst-057 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral Neuropathy[MeSHID:D010523] phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB trospium small molecule Urge Incontinence[MeSHID:D053202],Urination[MeSHID:D014554],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurogenesis[MeSHID:D055495],Overactive Detrusor[MeSHID:D053201] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 1.43 drugbank , DGIDB r-dimethindene NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD darotropium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD brl-55473 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD benztropine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown 0.57 TTD , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.18 drugbank , DGIDB propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank n-desmethylclozapine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618] phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown 0.19 TTD , DGIDB darotropium + 642444 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 3 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB aminobenztropine NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD alks 27 small molecule Chronic Obstructive Airway Disease[MeSHID:D029424] investigational muscarinic acetylcholine receptor m1 CHRM1 NA unknown NA drugbank profenamine small molecule Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank pilocarpine small molecule Radiation[MeSHID:D011827],Presbyopia[MeSHID:D011305],Xerostomia[MeSHID:D014987],Syndrome[MeSHID:D013577],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA agonist 0.37 drugbank , DGIDB atropine small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Organophosphate poisoning[MeSHID:D062025] approved,vet_approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.43 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank glycopyrrolate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 0.57 TTD , DGIDB tropicamide small molecule Ophthalmoplegia[MeSHID:D009886],Mydriasis[MeSHID:D015878],Diagnosis[MeSHID:D003933],Eyelash[MeSHID:D005140],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA binder NA drugbank methantheline small molecule Reflex action[MeSHID:D012018],Neurogenic Urinary Bladder[MeSHID:D001750],Gastritis[MeSHID:D005756],Irritable Bowel Syndrome[MeSHID:D043183],Biliary Dyskinesia[MeSHID:D001657],Peptic Ulcer[MeSHID:D010437],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.96 drugbank , DGIDB escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA inhibitor NA drugbank declopramide NA Inflammatory Bowel Diseases[MeSHID:D015212],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD dicyclomine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Intestinal Diseases[MeSHID:D007410],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 0.51 TTD , drugbank , DGIDB thiopilocarpine NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB biperiden small molecule Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 0.9 TTD , drugbank , DGIDB azd-6088 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB bo(15)pz NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD metixene NA Secondary Parkinson Disease[MeSHID:D010302],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown 1.03 TTD , DGIDB terfenadine small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,withdrawn muscarinic acetylcholine receptor m1 CHRM1 NA binder NA drugbank sr-46559a NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank umeclidinium small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.19 drugbank , DGIDB trihexyphenidyl small molecule Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dystonia[MeSHID:D004421],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Obesity[MeSHID:D009765] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 2.29 TTD , drugbank , DGIDB 2-(4-diethylamino-but-2-ynyl)-isoindole-1,3-dione NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD rispenzepine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.16 drugbank , DGIDB cyclopentolate small molecule Mydriasis[MeSHID:D015878],Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye[MeSHID:D005123],Vision[MeSHID:D014785] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 2.58 drugbank , DGIDB 1'-benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM1 NA binder NA drugbank bqca NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target allosteric modulator NA TTD , DGIDB trospium small molecule Urge Incontinence[MeSHID:D053202],Urination[MeSHID:D014554],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 1.43 drugbank , DGIDB promazine small molecule Psychomotor Agitation[MeSHID:D011595],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.16 drugbank , DGIDB n-methoxyquinuclidine-3-carboximidoyl fluoride NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD isoclozapine NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank carbamoylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Miosis disorder[MeSHID:D015877],Physiologic Intraocular Pressure[MeSHID:D007429] approved muscarinic acetylcholine receptor m1 CHRM1 NA agonist NA drugbank hyoscyamine small molecule Renal Colic[MeSHID:D056844],Bodily secretions[MeSHID:D012634],Pancreas[MeSHID:D010179],Respiratory tract structure[MeSHID:D012137],Bile fluid[MeSHID:D001646],Stomach[MeSHID:D013270],Irritable Bowel Syndrome[MeSHID:D043183],Heart Block[MeSHID:D006327],cell motility[MeSHID:D002465],Acute Coryza[MeSHID:D003139],Kidney[MeSHID:D007668],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank methacholine small molecule Asthma[MeSHID:D001249],Diagnosis[MeSHID:D003933],Bronchial Hyperreactivity[MeSHID:D016535] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA agonist NA drugbank quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.05 drugbank , DGIDB dau-5750 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD 3-tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD anisotropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 1.72 drugbank , DGIDB flumezapine NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD propiverine small molecule Urinary Incontinence[MeSHID:D014549],Neurogenic Urinary Bladder[MeSHID:D001750],Urinary tract[MeSHID:D014551],Overactive Bladder[MeSHID:D053201],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank talsaclidine fumarate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD darifenacin small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.29 drugbank , DGIDB etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn muscarinic acetylcholine receptor CHRM1 NA antagonist NA drugbank oxyphencyclimine small molecule Gastrointestinal Diseases[MeSHID:D005767],Peptic Ulcer[MeSHID:D010437],Spasm[MeSHID:D013035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.86 drugbank , DGIDB mepenzolate small molecule Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank af150(s) NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD aceclidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown 0.11 TTD , DGIDB tridihexethyl small molecule Peptic Ulcer[MeSHID:D010437],Nystagmus[MeSHID:D009759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.57 drugbank , DGIDB minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA agonist NA drugbank homatropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uveitis[MeSHID:D014605] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank , DGIDB xanomeline tartrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB 3alpha-(bis-chloro-phenylmethoxy)tropane NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank metoclopramide small molecule Disease Management[MeSHID:D019468],Radiation[MeSHID:D011827],Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Gastroparesis[MeSHID:D018589],Nose[MeSHID:D009666],Pain[MeSHID:D010146],Hiccup[MeSHID:D006606],Recurrence (disease attribute)[MeSHID:D012008],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Stomach[MeSHID:D013270],Vomiting[MeSHID:D014839],Gastroesophageal reflux disease[MeSHID:D005764],Intestines, Small[MeSHID:D007421],Gastric Emptying[MeSHID:D005746],Bezoars[MeSHID:D001630],Electromagnetic Radiation[MeSHID:D060733],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA agonist 0.29 drugbank , DGIDB isoloxapine NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD buclizine small molecule Vertigo[MeSHID:D014717],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 1.15 drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank propantheline small molecule Urinary Incontinence[MeSHID:D014549],Hyperhidrosis disorder[MeSHID:D006945],Spasm[MeSHID:D013035],Urinary Bladder[MeSHID:D001743],Bedwetting[MeSHID:D053206],Stomach[MeSHID:D013270],Enuresis[MeSHID:D004775],Muscle Cramp[MeSHID:D009120],Intestines[MeSHID:D007422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276],Sweating[MeSHID:D013546] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 0.96 TTD , drugbank , DGIDB arecoline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] experimental,phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target agonist 0.57 TTD , drugbank , DGIDB ipratropium small molecule Expiration, function[MeSHID:D045853],Sialorrhea[MeSHID:D012798],Sneezing[MeSHID:D012912],Drinking Water[MeSHID:D060766],Nose[MeSHID:D009666],Patient Discharge[MeSHID:D010351],Recurrence (disease attribute)[MeSHID:D012008],Pulmonary Emphysema[MeSHID:D011656],Dyspnea[MeSHID:D004417],Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disease[MeSHID:D004194],Hay fever[MeSHID:D006255],Pathological accumulation of air in tissues[MeSHID:D004646],Comprehension[MeSHID:D032882],Common Cold[MeSHID:D003139],Bronchitis, Chronic[MeSHID:D029481],Unmarried[MeSHID:D012847],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Diseases, Obstructive[MeSHID:D008173] approved,experimental muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.38 drugbank , DGIDB b7-2/gm-csf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Dyslipidemias[MeSHID:D050171],Schizophrenia[MeSHID:D012559] phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB ly-593039 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM1 NA binder NA drugbank diphemanil methylsulfate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM1 NA binder NA drugbank (s)-oxybutynin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD difluorobenztropine NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD molindone small molecule Disease Management[MeSHID:D019468],Mental disorders[MeSHID:D001523],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved muscarinic acetylcholine receptor m1 CHRM1 NA unknown NA drugbank ngx267 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618] investigational muscarinic acetylcholine receptor m1 CHRM1 NA unknown 1.15 drugbank , DGIDB mcd-386 NA Malonic aciduria[MeSHID:C535702],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular dystrophy, corneal type 1[MeSHID:C537834] phase 1 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB ym-796 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved muscarinic acetylcholine receptor CHRM1 NA binder NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank homatropine small molecule Mydriasis[MeSHID:D015878],Drug Overdose[MeSHID:D062787] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank gnf-pf-5618 NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank 7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD bethanechol small molecule Urinary Retention[MeSHID:D016055],Retention (Psychology)[MeSHID:D012153],Neurogenic Urinary Bladder, Atonic[MeSHID:D001750],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA agonist 0.46 drugbank , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist,allosteric modulator 0.02 drugbank , DGIDB scopolamine small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Postoperative Nausea and Vomiting[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.86 drugbank , DGIDB nebracetam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown 0.57 TTD , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank methscopolamine bromide small molecule Nausea[MeSHID:D009325],Peptic Ulcer[MeSHID:D010437],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.29 drugbank , DGIDB flupentixol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Asthenia[MeSHID:D001247],Hyperactive behavior[MeSHID:D006948],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] approved,investigational,withdrawn muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM1 NA inhibitor NA drugbank cycrimine small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist 4.01 TTD , drugbank , DGIDB tiotropium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.57 drugbank , DGIDB smt-d002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD , DGIDB pd-151832 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 1/2 muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD hexocyclium small molecule Functional Gastrointestinal Disorders[MeSHID:D005767],Diarrhea[MeSHID:D003967],Peptic Ulcer[MeSHID:D010437] approved,investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target antagonist NA TTD , drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM1 NA antagonist NA drugbank acetylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Lens, Crystalline[MeSHID:D007908],Miosis disorder[MeSHID:D015877],Iris (Eye)[MeSHID:D007498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cataract[MeSHID:D002386] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA agonist 0.19 drugbank , DGIDB doxylamine small molecule Cold Temperature[MeSHID:D003080],Drug Allergy[MeSHID:D004342],Morning Sickness[MeSHID:D048968],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Sleep[MeSHID:D012890],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM1 NA antagonist NA drugbank revefenacin small molecule Solutions[MeSHID:D012996],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Cause of Death[MeSHID:D002423],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM1 NA antagonist 0.46 drugbank , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM1 NA binder NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist 0.11 drugbank , DGIDB imidafenacin small molecule Overactive Bladder[MeSHID:D053201] investigational muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank anisotropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank , DGIDB 2,8-dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD 3-methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m1 CHRM1 Successful target unknown NA TTD rociverine small molecule NA experimental muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank thonzylamine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Signs and Symptoms, Respiratory[MeSHID:D012818] approved muscarinic acetylcholine receptor m1 CHRM1 NA antagonist NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM2 NA antagonist NA drugbank metixene small molecule Secondary Parkinson Disease[MeSHID:D010302],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor CHRM2 NA antagonist 0.61 drugbank , DGIDB ipratropium small molecule Expiration, function[MeSHID:D045853],Sialorrhea[MeSHID:D012798],Sneezing[MeSHID:D012912],Drinking Water[MeSHID:D060766],Nose[MeSHID:D009666],Patient Discharge[MeSHID:D010351],Recurrence (disease attribute)[MeSHID:D012008],Pulmonary Emphysema[MeSHID:D011656],Dyspnea[MeSHID:D004417],Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disease[MeSHID:D004194],Hay fever[MeSHID:D006255],Pathological accumulation of air in tissues[MeSHID:D004646],Comprehension[MeSHID:D032882],Common Cold[MeSHID:D003139],Bronchitis, Chronic[MeSHID:D029481],Unmarried[MeSHID:D012847],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Diseases, Obstructive[MeSHID:D008173] approved,experimental muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.51 drugbank , DGIDB alks 27 small molecule Chronic Obstructive Airway Disease[MeSHID:D029424] investigational muscarinic acetylcholine receptor m2 CHRM2 NA unknown NA drugbank 3-(3-benzylamino)-piperidin-2-one NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD isoclozapine NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD homatropine small molecule Mydriasis[MeSHID:D015878],Drug Overdose[MeSHID:D062787] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank fm1-43 NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.24 drugbank , DGIDB flumezapine NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD oxybutynin small molecule Disease Management[MeSHID:D019468],Urinary Bladder[MeSHID:D001743],Spasm[MeSHID:D013035],Off-Label Use[MeSHID:D056687],Urinary tract[MeSHID:D014551],Urge Incontinence[MeSHID:D053202],Spina Bifida[MeSHID:D016135],Muscle[MeSHID:D009132],Overactive Bladder[MeSHID:D053201],Ureter[MeSHID:D014513] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 1.1 drugbank , DGIDB 7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn muscarinic acetylcholine receptor CHRM2 NA antagonist NA drugbank 6-dimethylamino-2-methyl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD mivacurium small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist,partial agonist 1.28 drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank solifenacin small molecule Urinary Incontinence[MeSHID:D014549],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.61 drugbank , DGIDB revefenacin small molecule Solutions[MeSHID:D012996],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Cause of Death[MeSHID:D002423],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM2 NA antagonist 0.15 drugbank , DGIDB atropine small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Organophosphate poisoning[MeSHID:D062025] approved,vet_approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.64 drugbank , DGIDB diphenidol small molecule Vertigo[MeSHID:D014717],Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Meniere Disease[MeSHID:D008575],Labyrinth[MeSHID:D007758],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 1.53 drugbank , DGIDB bethanechol small molecule Urinary Retention[MeSHID:D016055],Retention (Psychology)[MeSHID:D012153],Neurogenic Urinary Bladder, Atonic[MeSHID:D001750],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA agonist 0.92 drugbank , DGIDB propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD green tea NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD methylscopolamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] approved muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown 0.26 TTD , DGIDB flavoxate small molecule prostatitis[MeSHID:D011472],Nocturia[MeSHID:D053158],Urethritis[MeSHID:D014526],Cystitis[MeSHID:D003556],Pain[MeSHID:D010146],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 1.34 drugbank , DGIDB gnf-pf-5618 NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD pilocarpine small molecule Radiation[MeSHID:D011827],Presbyopia[MeSHID:D011305],Xerostomia[MeSHID:D014987],Syndrome[MeSHID:D013577],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA agonist 0.33 drugbank , DGIDB scopolamine small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Postoperative Nausea and Vomiting[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.77 drugbank , DGIDB (r)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (ro-320-6206) NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.06 drugbank , DGIDB umeclidinium small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.26 drugbank , DGIDB brompheniramine small molecule Pruritus[MeSHID:D011537],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Common Cold[MeSHID:D003139],Drinking Water[MeSHID:D060766],Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank benzquinamide small molecule Nausea[MeSHID:D009325],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.34 drugbank , DGIDB propiverine small molecule Urinary Incontinence[MeSHID:D014549],Neurogenic Urinary Bladder[MeSHID:D001750],Urinary tract[MeSHID:D014551],Overactive Bladder[MeSHID:D053201],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank hyoscyamine small molecule Renal Colic[MeSHID:D056844],Bodily secretions[MeSHID:D012634],Pancreas[MeSHID:D010179],Respiratory tract structure[MeSHID:D012137],Bile fluid[MeSHID:D001646],Stomach[MeSHID:D013270],Irritable Bowel Syndrome[MeSHID:D043183],Heart Block[MeSHID:D006327],cell motility[MeSHID:D002465],Acute Coryza[MeSHID:D003139],Kidney[MeSHID:D007668],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank terfenadine small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,withdrawn muscarinic acetylcholine receptor m2 CHRM2 NA binder NA drugbank tolterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.54 drugbank , DGIDB tridihexethyl small molecule Peptic Ulcer[MeSHID:D010437],Nystagmus[MeSHID:D009759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.77 drugbank , DGIDB sulfoarecoline NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD pancuronium small molecule Operative Surgical Procedures[MeSHID:D013514],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank hexocyclium small molecule Functional Gastrointestinal Disorders[MeSHID:D005767],Diarrhea[MeSHID:D003967],Peptic Ulcer[MeSHID:D010437] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.38 drugbank , DGIDB nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.15 drugbank , DGIDB propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM2 NA antagonist 0.22 drugbank , DGIDB fp-1097 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] phase 2 muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD , DGIDB tiotropium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.61 drugbank , DGIDB imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.12 drugbank , DGIDB 7-dimethylamino-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Middle East Respiratory Syndrome[MeSHID:D018352] approved,vet_approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.48 drugbank , DGIDB methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.22 drugbank , DGIDB caramipen NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD 1,1-diphenyl-2-(3-tropanyl)ethanol NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD 2-methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.19 drugbank , DGIDB 3-tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD aceclidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown 0.15 TTD , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA unknown NA drugbank succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved muscarinic acetylcholine receptor m2 CHRM2 NA agonist NA drugbank n-methoxyquinuclidine-3-carboximidoyl chloride NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD diphenhydramine small molecule Pruritus[MeSHID:D011537],Exanthema[MeSHID:D005076],Disease[MeSHID:D004194],Insect Bites and Stings[MeSHID:D007299],Nausea[MeSHID:D009325],Parkinsonian Disorders[MeSHID:D020734],Prescription procedure[MeSHID:D055656],Blood[MeSHID:D001769],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Urticaria[MeSHID:D014581],Plasma[MeSHID:D010949],Pharyngeal structure[MeSHID:D010614],Motion Sickness[MeSHID:D009041],Drinking Water[MeSHID:D060766],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Meniere Disease[MeSHID:D008575] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank oxyphencyclimine small molecule Gastrointestinal Diseases[MeSHID:D005767],Peptic Ulcer[MeSHID:D010437],Spasm[MeSHID:D013035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 1.15 drugbank , DGIDB a-987306 NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD tropicamide small molecule Ophthalmoplegia[MeSHID:D009886],Mydriasis[MeSHID:D015878],Diagnosis[MeSHID:D003933],Eyelash[MeSHID:D005140],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD 1'-benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD 7-dimethylamino-3-methyl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank methacholine small molecule Asthma[MeSHID:D001249],Diagnosis[MeSHID:D003933],Bronchial Hyperreactivity[MeSHID:D016535] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA agonist NA drugbank methscopolamine bromide small molecule Nausea[MeSHID:D009325],Peptic Ulcer[MeSHID:D010437],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank smt-d002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD , DGIDB trihexyphenidyl small molecule Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dystonia[MeSHID:D004421],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Obesity[MeSHID:D009765] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank rocuronium small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.64 drugbank , DGIDB cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank acetylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Lens, Crystalline[MeSHID:D007908],Miosis disorder[MeSHID:D015877],Iris (Eye)[MeSHID:D007498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cataract[MeSHID:D002386] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA agonist 0.26 drugbank , DGIDB dicyclomine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Intestinal Diseases[MeSHID:D007410],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.17 drugbank , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank thonzylamine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Signs and Symptoms, Respiratory[MeSHID:D012818] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank fesoterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.31 drugbank , DGIDB rapacuronium small molecule NA approved,withdrawn muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank profenamine small molecule Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank aclidinium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Inspiration function[MeSHID:D001239],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.31 drugbank , DGIDB butylscopolamine small molecule Muscle Cramp[MeSHID:D009120],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank glycopyrronium small molecule Solutions[MeSHID:D012996],Cardiac Arrhythmia[MeSHID:D001145],Drooling[MeSHID:D012798],Maintenance[MeSHID:D008283],Operative Surgical Procedures[MeSHID:D013514],Heart[MeSHID:D006321],Vagus nerve structure[MeSHID:D014630],Heartburn[MeSHID:D006356],Chronic Obstructive Airway Disease[MeSHID:D029424],Cardiac Arrest[MeSHID:D006323],Peptic Ulcer[MeSHID:D010437],Term Birth[MeSHID:D047929],Hyperhidrosis disorder[MeSHID:D006945],Reflex action[MeSHID:D012018],Bodily secretions[MeSHID:D012634],Gastric Juice (substance)[MeSHID:D005750],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA binder NA drugbank n-methoxyquinuclidine-3-carboximidoyl fluoride NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA ligand NA drugbank brl-55473 NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank darifenacin small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.38 drugbank , DGIDB methoctramine NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target antagonist 0.13 TTD , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved muscarinic acetylcholine receptor m2 CHRM2 NA ligand NA drugbank 1-methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD methantheline small molecule Reflex action[MeSHID:D012018],Neurogenic Urinary Bladder[MeSHID:D001750],Gastritis[MeSHID:D005756],Irritable Bowel Syndrome[MeSHID:D043183],Biliary Dyskinesia[MeSHID:D001657],Peptic Ulcer[MeSHID:D010437],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA unknown NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM2 NA binder NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM2 NA binder NA drugbank otenzepad NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] discontinued in phase 2 muscarinic acetylcholine receptor m2 CHRM2 Successful target antagonist 0.15 TTD , DGIDB doxacurium small molecule Skeletal muscle structure[MeSHID:D018482],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 1.92 drugbank , DGIDB psd-506 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] discontinued in phase 2 muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD , DGIDB methacholine chloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bronchial Hyperreactivity[MeSHID:D016535],Asthma[MeSHID:D001249] approved muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD , DGIDB pipecuronium small molecule Operative Surgical Procedures[MeSHID:D013514],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank doxylamine small molecule Cold Temperature[MeSHID:D003080],Drug Allergy[MeSHID:D004342],Morning Sickness[MeSHID:D048968],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Sleep[MeSHID:D012890],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM2 NA antagonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM2 NA inhibitor NA drugbank 3-methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD sch-211803 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 1 muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank carbamoylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Miosis disorder[MeSHID:D015877],Physiologic Intraocular Pressure[MeSHID:D007429] approved muscarinic acetylcholine receptor m2 CHRM2 NA agonist NA drugbank cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM2 NA binder NA drugbank cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM2 NA ligand,antagonist 0.08 drugbank , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM2 NA antagonist NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved muscarinic acetylcholine receptor CHRM2 NA binder NA drugbank af-dx-384 NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD 2,8-dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD procyclidine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 1.53 drugbank , DGIDB n-(4-dimethylamino-but-2-ynyl)-n-methyl-acetamide NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD fm1-10 NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD ptac NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD isoloxapine NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD anisotropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.15 drugbank , DGIDB imidafenacin small molecule Overactive Bladder[MeSHID:D053201] investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank dimetindene small molecule Pruritus[MeSHID:D011537],Exanthema[MeSHID:D005076],Eczema[MeSHID:D004485],Tooth eruption function[MeSHID:D014078],Insect Bites[MeSHID:D007299],Respiratory Hypersensitivity[MeSHID:D012130],Skin Diseases, Genetic[MeSHID:D012873],Dermatologic disorders[MeSHID:D012871],Drug Allergy[MeSHID:D004342],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Cholestasis[MeSHID:D002779],Fever[MeSHID:D005334],Allergic Reaction[MeSHID:D006967],Chickenpox[MeSHID:D002644] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.17 drugbank , DGIDB cmi-936 NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM2 NA binder NA drugbank 2-(4-diethylamino-but-2-ynyl)-isoindole-1,3-dione NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD homatropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uveitis[MeSHID:D014605] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank , DGIDB rociverine small molecule NA experimental muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank cryptenamine small molecule Hypertensive disease[MeSHID:D006973] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank gallamine triethiodide small molecule Disease Management[MeSHID:D019468],Skeletal muscle structure[MeSHID:D018482],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 Successful target antagonist NA TTD , drugbank , DGIDB triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist 0.48 drugbank , DGIDB metocurine small molecule Muscle[MeSHID:D009132] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m2 CHRM2 NA antagonist NA drugbank cmi-1145 NA NA investigative muscarinic acetylcholine receptor m2 CHRM2 Successful target unknown NA TTD revefenacin small molecule Solutions[MeSHID:D012996],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Cause of Death[MeSHID:D002423],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM3 NA antagonist 0.13 drugbank , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD methylscopolamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown 0.21 TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM3 NA binder NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA ligand NA drugbank nnc 11-1585 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist NA TTD , DGIDB hexahydrodifenidol NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank 3-(3-benzylamino)-piperidin-2-one NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD bethanechol small molecule Urinary Retention[MeSHID:D016055],Retention (Psychology)[MeSHID:D012153],Neurogenic Urinary Bladder, Atonic[MeSHID:D001750],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA agonist 0.25 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.13 drugbank , DGIDB tridihexethyl small molecule Peptic Ulcer[MeSHID:D010437],Nystagmus[MeSHID:D009759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.64 drugbank , DGIDB noccardimicin e NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD nnc 11-1607 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist NA TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved muscarinic acetylcholine receptor CHRM3 NA binder NA drugbank acetylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Lens, Crystalline[MeSHID:D007908],Miosis disorder[MeSHID:D015877],Iris (Eye)[MeSHID:D007498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cataract[MeSHID:D002386] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA agonist 0.21 drugbank , DGIDB methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.18 drugbank , DGIDB gnf-pf-5618 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD fesoterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.51 drugbank , DGIDB vu0255035 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB thonzylamine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Signs and Symptoms, Respiratory[MeSHID:D012818] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA unknown NA drugbank succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist 0.32 TTD , drugbank , DGIDB n-methoxyquinuclidine-3-carboximidoyl chloride NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD arecoline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] experimental muscarinic acetylcholine receptor m3 CHRM3 NA agonist 0.32 drugbank , DGIDB 4-damp NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 0.11 TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM3 NA antagonist NA drugbank chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank pilocarpine small molecule Radiation[MeSHID:D011827],Presbyopia[MeSHID:D011305],Xerostomia[MeSHID:D014987],Syndrome[MeSHID:D013577],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA agonist 0.23 drugbank , DGIDB 7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.13 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.16 drugbank , DGIDB procyclidine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved muscarinic acetylcholine receptor m3 CHRM3 NA unknown NA drugbank dau-5884 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD win 51,708 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target allosteric modulator NA TTD , DGIDB brl-55473 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD glycopyrronium small molecule Solutions[MeSHID:D012996],Cardiac Arrhythmia[MeSHID:D001145],Drooling[MeSHID:D012798],Maintenance[MeSHID:D008283],Operative Surgical Procedures[MeSHID:D013514],Heart[MeSHID:D006321],Vagus nerve structure[MeSHID:D014630],Heartburn[MeSHID:D006356],Chronic Obstructive Airway Disease[MeSHID:D029424],Cardiac Arrest[MeSHID:D006323],Peptic Ulcer[MeSHID:D010437],Term Birth[MeSHID:D047929],Hyperhidrosis disorder[MeSHID:D006945],Reflex action[MeSHID:D012018],Bodily secretions[MeSHID:D012634],Gastric Juice (substance)[MeSHID:D005750],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank j-104135 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA unknown NA drugbank rociverine small molecule NA experimental muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank methscopolamine bromide small molecule Nausea[MeSHID:D009325],Peptic Ulcer[MeSHID:D010437],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , drugbank , DGIDB 3-methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD mcn-a-343 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist NA TTD , DGIDB oxybutynine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.05 drugbank , DGIDB thiochrome NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target allosteric modulator NA TTD , DGIDB olterodine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD silahexocyclium NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB pipecuronium small molecule Operative Surgical Procedures[MeSHID:D013514],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank solifenacin small molecule Urinary Incontinence[MeSHID:D014549],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 1.27 TTD , drugbank , DGIDB a-987306 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD tolterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 0.51 TTD , drugbank , DGIDB benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM3 NA binder NA drugbank cremastrine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank nocardimicin d NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD arecaidine propargyl ester NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist NA TTD , DGIDB methantheline small molecule Reflex action[MeSHID:D012018],Neurogenic Urinary Bladder[MeSHID:D001750],Gastritis[MeSHID:D005756],Irritable Bowel Syndrome[MeSHID:D043183],Biliary Dyskinesia[MeSHID:D001657],Peptic Ulcer[MeSHID:D010437],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA unknown NA drugbank 2-methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD n-chloromethyl-brucine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target allosteric modulator NA TTD , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank terfenadine small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,withdrawn muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank 1'-benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD ptac NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD brucine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target allosteric modulator 0.11 TTD , DGIDB methacholine small molecule Asthma[MeSHID:D001249],Diagnosis[MeSHID:D003933],Bronchial Hyperreactivity[MeSHID:D016535] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA agonist NA drugbank n-benzyl brucine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target allosteric modulator NA TTD , DGIDB doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.14 drugbank , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank darifenacin small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 0.85 TTD , drugbank , DGIDB hyoscyamine small molecule Renal Colic[MeSHID:D056844],Bodily secretions[MeSHID:D012634],Pancreas[MeSHID:D010179],Respiratory tract structure[MeSHID:D012137],Bile fluid[MeSHID:D001646],Stomach[MeSHID:D013270],Irritable Bowel Syndrome[MeSHID:D043183],Heart Block[MeSHID:D006327],cell motility[MeSHID:D002465],Acute Coryza[MeSHID:D003139],Kidney[MeSHID:D007668],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank ipratropium small molecule Expiration, function[MeSHID:D045853],Sialorrhea[MeSHID:D012798],Sneezing[MeSHID:D012912],Drinking Water[MeSHID:D060766],Nose[MeSHID:D009666],Patient Discharge[MeSHID:D010351],Recurrence (disease attribute)[MeSHID:D012008],Pulmonary Emphysema[MeSHID:D011656],Dyspnea[MeSHID:D004417],Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Disease[MeSHID:D004194],Hay fever[MeSHID:D006255],Pathological accumulation of air in tissues[MeSHID:D004646],Comprehension[MeSHID:D032882],Common Cold[MeSHID:D003139],Bronchitis, Chronic[MeSHID:D029481],Unmarried[MeSHID:D012847],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Diseases, Obstructive[MeSHID:D008173] approved,experimental muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 0.35 TTD , drugbank , DGIDB scopolamine small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Postoperative Nausea and Vomiting[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.32 drugbank , DGIDB n-methoxyquinuclidine-3-carboximidoyl fluoride NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor m3 CHRM3 NA unknown NA drugbank p-f-hhsid NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB methacholine chloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bronchial Hyperreactivity[MeSHID:D016535],Asthma[MeSHID:D001249] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD , DGIDB umeclidinium small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.21 drugbank , DGIDB acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD vinburnine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target allosteric modulator 0.11 TTD , DGIDB trn-157 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD , DGIDB cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM3 NA binder NA drugbank zamifenacin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 3 muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown 0.32 TTD , DGIDB aclidinium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Inspiration function[MeSHID:D001239],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.25 drugbank , DGIDB isopropamide small molecule Irritable Mood[MeSHID:D007508],Disease[MeSHID:D004194],Spasm[MeSHID:D013035],Duodenitis[MeSHID:D004382],Gastritis[MeSHID:D005756],Diarrhea[MeSHID:D003967],Cholelithiasis[MeSHID:D002769],Gastroenteritis[MeSHID:D005759],Gastrointestinal Diseases[MeSHID:D005767],Muscle Cramp[MeSHID:D009120],Irritable Bowel Syndrome[MeSHID:D043183],Biliary Dyskinesia[MeSHID:D001657],Peptic Ulcer[MeSHID:D010437] approved,vet_approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank furtrethonium NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist 0.16 TTD , DGIDB pentylthio-tztp NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist NA TTD , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM3 NA ligand,antagonist 0.06 drugbank , DGIDB aceclidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown 0.13 TTD , DGIDB ucb-101333-3 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD tiotropium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 1.02 TTD , drugbank , DGIDB methacholine chloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bronchial Hyperreactivity[MeSHID:D016535],Asthma[MeSHID:D001249] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist 0.21 TTD , DGIDB nocardimicin c NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD revatropate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD tripitramine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 0.13 TTD , DGIDB 3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (app) NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD hexocyclium small molecule Functional Gastrointestinal Disorders[MeSHID:D005767],Diarrhea[MeSHID:D003967],Peptic Ulcer[MeSHID:D010437] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.32 drugbank , DGIDB oxyphencyclimine small molecule Gastrointestinal Diseases[MeSHID:D005767],Peptic Ulcer[MeSHID:D010437],Spasm[MeSHID:D013035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.95 drugbank , DGIDB 3-tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn muscarinic acetylcholine receptor CHRM3 NA antagonist NA drugbank ml381 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB 6-dimethylamino-2-methyl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD dicyclomine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Intestinal Diseases[MeSHID:D007410],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.07 drugbank , DGIDB chf 5407 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD , DGIDB 7-dimethylamino-3-methyl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD metixene small molecule Secondary Parkinson Disease[MeSHID:D010302],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor CHRM3 NA antagonist 0.51 drugbank , DGIDB 1,1-diphenyl-2-(3-tropanyl)ethanol NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD brompheniramine small molecule Pruritus[MeSHID:D011537],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Common Cold[MeSHID:D003139],Drinking Water[MeSHID:D060766],Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank 2,8-dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM3 NA inhibitor NA drugbank atropine small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Organophosphate poisoning[MeSHID:D062025] approved,vet_approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.37 drugbank , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA binder NA drugbank anisotropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 1.27 drugbank , DGIDB cevimeline small molecule Syndrome[MeSHID:D013577],Xerostomia[MeSHID:D014987],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist 1.02 TTD , drugbank , DGIDB diphenidol small molecule Vertigo[MeSHID:D014717],Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Meniere Disease[MeSHID:D008575],Labyrinth[MeSHID:D007758],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.89 drugbank , DGIDB doxylamine small molecule Cold Temperature[MeSHID:D003080],Drug Allergy[MeSHID:D004342],Morning Sickness[MeSHID:D048968],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Sleep[MeSHID:D012890],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM3 NA antagonist NA drugbank tarafenacin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] phase 2 muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 1.91 TTD , DGIDB [3h]oxotremorine-m NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD mepenzolate small molecule Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank homatropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uveitis[MeSHID:D014605] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank , DGIDB oxybutynin small molecule Disease Management[MeSHID:D019468],Urinary Bladder[MeSHID:D001743],Spasm[MeSHID:D013035],Off-Label Use[MeSHID:D056687],Urinary tract[MeSHID:D014551],Urge Incontinence[MeSHID:D053202],Spina Bifida[MeSHID:D016135],Muscle[MeSHID:D009132],Overactive Bladder[MeSHID:D053201],Ureter[MeSHID:D014513] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 1.18 drugbank , DGIDB smt-d002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD , DGIDB diphemanil small molecule Hyperhidrosis disorder[MeSHID:D006945],Sweating[MeSHID:D013546],Gastritis[MeSHID:D005756],Stomach[MeSHID:D013270],Sweat[MeSHID:D013542],Peptic Ulcer[MeSHID:D010437] approved,vet_approved,withdrawn muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank propiverine small molecule Urinary Incontinence[MeSHID:D014549],Neurogenic Urinary Bladder[MeSHID:D001750],Urinary tract[MeSHID:D014551],Overactive Bladder[MeSHID:D053201],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank uh-ah 37 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB benzquinamide small molecule Nausea[MeSHID:D009325],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.28 drugbank , DGIDB lithocholylcholine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB n-(4-dimethylamino-but-2-ynyl)-n-methyl-acetamide NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD alks 27 small molecule Chronic Obstructive Airway Disease[MeSHID:D029424] investigational muscarinic acetylcholine receptor m3 CHRM3 NA unknown NA drugbank maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank isoloxapine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD trospium small molecule Urge Incontinence[MeSHID:D053202],Urination[MeSHID:D014554],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved muscarinic acetylcholine receptor m3 CHRM3 NA unknown NA drugbank nocardimicin a NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD psd-506 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] discontinued in phase 2 muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD , DGIDB anisotropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank , DGIDB mivacurium small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM3 NA antagonist 0.18 drugbank , DGIDB fm1-43 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD fm1-10 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD tarafenacin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] phase 2 muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown 1.91 TTD , DGIDB methylfurmethide NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist NA TTD , DGIDB carbamoylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Miosis disorder[MeSHID:D015877],Physiologic Intraocular Pressure[MeSHID:D007429] approved muscarinic acetylcholine receptor m3 CHRM3 NA agonist NA drugbank butylscopolamine small molecule Muscle Cramp[MeSHID:D009120],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank trospium small molecule Urge Incontinence[MeSHID:D053202],Urination[MeSHID:D014554],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurogenesis[MeSHID:D055495],Overactive Detrusor[MeSHID:D053201] approved muscarinic acetylcholine receptor m3 CHRM3 NA unknown NA drugbank desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank ae-9c90cb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD [3h]qnb NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB sulfoarecoline NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD hexahydrosiladifenidol NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist NA TTD , DGIDB homatropine small molecule Mydriasis[MeSHID:D015878],Drug Overdose[MeSHID:D062787] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank methscopolamine bromide small molecule Nausea[MeSHID:D009325],Peptic Ulcer[MeSHID:D010437],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target antagonist 0.32 TTD , drugbank , DGIDB isoclozapine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD pancuronium small molecule Operative Surgical Procedures[MeSHID:D013514],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank nnc 11-1314 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target agonist NA TTD , DGIDB tropicamide small molecule Ophthalmoplegia[MeSHID:D009886],Mydriasis[MeSHID:D015878],Diagnosis[MeSHID:D003933],Eyelash[MeSHID:D005140],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist 0.95 drugbank , DGIDB 1-methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD imidafenacin small molecule Overactive Bladder[MeSHID:D053201] investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank 7-dimethylamino-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM3 NA binder NA drugbank guanylpirenzepine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD trihexyphenidyl small molecule Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dystonia[MeSHID:D004421],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Obesity[MeSHID:D009765] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank dau-5750 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM3 NA antagonist NA drugbank las-34273 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown 1.27 TTD , DGIDB flumezapine NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m3 CHRM3 NA antagonist NA drugbank win 62,577 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target allosteric modulator NA TTD , DGIDB nocardimicin f NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD go7874 NA NA investigative muscarinic acetylcholine receptor m3 CHRM3 Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM4 NA ligand,antagonist 0.11 drugbank , DGIDB propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD vu10010 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown 2.16 TTD , DGIDB alks 27 small molecule Chronic Obstructive Airway Disease[MeSHID:D029424] investigational muscarinic acetylcholine receptor m4 CHRM4 NA unknown NA drugbank scopolamine small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Postoperative Nausea and Vomiting[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.54 drugbank , DGIDB benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD bethanechol small molecule Urinary Retention[MeSHID:D016055],Retention (Psychology)[MeSHID:D012153],Neurogenic Urinary Bladder, Atonic[MeSHID:D001750],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA agonist 0.43 drugbank , DGIDB 1'-benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD 3-(3-benzylamino)-piperidin-2-one NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD 6-dimethylamino-2-methyl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD brl-55473 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD carbamoylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Miosis disorder[MeSHID:D015877],Physiologic Intraocular Pressure[MeSHID:D007429] approved muscarinic acetylcholine receptor m4 CHRM4 NA agonist NA drugbank pilocarpine small molecule Radiation[MeSHID:D011827],Presbyopia[MeSHID:D011305],Xerostomia[MeSHID:D014987],Syndrome[MeSHID:D013577],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA partial agonist,agonist 0.15 drugbank , DGIDB revefenacin small molecule Solutions[MeSHID:D012996],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Cause of Death[MeSHID:D002423],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM4 NA antagonist 0.22 drugbank , DGIDB 2,8-dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn muscarinic acetylcholine receptor CHRM4 NA antagonist NA drugbank tropicamide small molecule Ophthalmoplegia[MeSHID:D009886],Mydriasis[MeSHID:D015878],Diagnosis[MeSHID:D003933],Eyelash[MeSHID:D005140],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 Successful target antagonist 4.32 TTD , drugbank , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM4 NA antagonist NA drugbank rociverine small molecule NA experimental muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank 3-methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD solifenacin small molecule Urinary Incontinence[MeSHID:D014549],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.65 drugbank , DGIDB tolterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.32 drugbank , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.27 drugbank , DGIDB benzquinamide small molecule Nausea[MeSHID:D009325],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.48 drugbank , DGIDB tiotropium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA unknown NA drugbank flumezapine NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD fesoterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank atropine small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Organophosphate poisoning[MeSHID:D062025] approved,vet_approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.54 drugbank , DGIDB 1-methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.24 drugbank , DGIDB 3-tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD n-methoxyquinuclidine-3-carboximidoyl chloride NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD methantheline small molecule Reflex action[MeSHID:D012018],Neurogenic Urinary Bladder[MeSHID:D001750],Gastritis[MeSHID:D005756],Irritable Bowel Syndrome[MeSHID:D043183],Biliary Dyskinesia[MeSHID:D001657],Peptic Ulcer[MeSHID:D010437],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA unknown NA drugbank isoclozapine NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD 2-methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM4 NA binder NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.08 drugbank , DGIDB thonzylamine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Signs and Symptoms, Respiratory[MeSHID:D012818] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank sulfoarecoline NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD glycopyrronium small molecule Solutions[MeSHID:D012996],Cardiac Arrhythmia[MeSHID:D001145],Drooling[MeSHID:D012798],Maintenance[MeSHID:D008283],Operative Surgical Procedures[MeSHID:D013514],Heart[MeSHID:D006321],Vagus nerve structure[MeSHID:D014630],Heartburn[MeSHID:D006356],Chronic Obstructive Airway Disease[MeSHID:D029424],Cardiac Arrest[MeSHID:D006323],Peptic Ulcer[MeSHID:D010437],Term Birth[MeSHID:D047929],Hyperhidrosis disorder[MeSHID:D006945],Reflex action[MeSHID:D012018],Bodily secretions[MeSHID:D012634],Gastric Juice (substance)[MeSHID:D005750],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank 7-dimethylamino-3-methyl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD terfenadine small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,withdrawn muscarinic acetylcholine receptor m4 CHRM4 NA binder NA drugbank methacholine small molecule Asthma[MeSHID:D001249],Diagnosis[MeSHID:D003933],Bronchial Hyperreactivity[MeSHID:D016535] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA agonist NA drugbank procyclidine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 2.16 drugbank , DGIDB umeclidinium small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.36 drugbank , DGIDB propiverine small molecule Urinary Incontinence[MeSHID:D014549],Neurogenic Urinary Bladder[MeSHID:D001750],Urinary tract[MeSHID:D014551],Overactive Bladder[MeSHID:D053201],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank hyoscyamine small molecule Renal Colic[MeSHID:D056844],Bodily secretions[MeSHID:D012634],Pancreas[MeSHID:D010179],Respiratory tract structure[MeSHID:D012137],Bile fluid[MeSHID:D001646],Stomach[MeSHID:D013270],Irritable Bowel Syndrome[MeSHID:D043183],Heart Block[MeSHID:D006327],cell motility[MeSHID:D002465],Acute Coryza[MeSHID:D003139],Kidney[MeSHID:D007668],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank acetylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Lens, Crystalline[MeSHID:D007908],Miosis disorder[MeSHID:D015877],Iris (Eye)[MeSHID:D007498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cataract[MeSHID:D002386] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA agonist 0.36 drugbank , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM4 NA binder NA drugbank metixene small molecule Secondary Parkinson Disease[MeSHID:D010302],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor CHRM4 NA antagonist 0.86 drugbank , DGIDB diphenidol NA Vertigo[MeSHID:D014717],Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Meniere Disease[MeSHID:D008575],Labyrinth[MeSHID:D007758],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown 0.22 TTD , DGIDB gnf-pf-5618 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank fm1-43 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank n-methoxyquinuclidine-3-carboximidoyl fluoride NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA unknown NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM4 NA binder NA drugbank doxylamine small molecule Cold Temperature[MeSHID:D003080],Drug Allergy[MeSHID:D004342],Morning Sickness[MeSHID:D048968],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Sleep[MeSHID:D012890],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM4 NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.22 drugbank , DGIDB acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD darifenacin small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.54 drugbank , DGIDB isoloxapine NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD af-dx-384 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD hexocyclium small molecule Functional Gastrointestinal Disorders[MeSHID:D005767],Diarrhea[MeSHID:D003967],Peptic Ulcer[MeSHID:D010437] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.54 drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM4 NA binder NA drugbank 7-dimethylamino-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD pf-3409409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM4 NA antagonist 0.31 drugbank , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.22 drugbank , DGIDB brompheniramine small molecule Pruritus[MeSHID:D011537],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Common Cold[MeSHID:D003139],Drinking Water[MeSHID:D060766],Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank fm1-10 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA binder NA drugbank aceclidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown 0.22 TTD , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved muscarinic acetylcholine receptor m4 CHRM4 NA ligand NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA ligand NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank cmi-1145 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD trihexyphenidyl small molecule Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dystonia[MeSHID:D004421],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Obesity[MeSHID:D009765] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.31 drugbank , DGIDB n-(4-dimethylamino-but-2-ynyl)-n-methyl-acetamide NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD homatropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uveitis[MeSHID:D014605] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank , DGIDB isopropamide small molecule Irritable Mood[MeSHID:D007508],Disease[MeSHID:D004194],Spasm[MeSHID:D013035],Duodenitis[MeSHID:D004382],Gastritis[MeSHID:D005756],Diarrhea[MeSHID:D003967],Cholelithiasis[MeSHID:D002769],Gastroenteritis[MeSHID:D005759],Gastrointestinal Diseases[MeSHID:D005767],Muscle Cramp[MeSHID:D009120],Irritable Bowel Syndrome[MeSHID:D043183],Biliary Dyskinesia[MeSHID:D001657],Peptic Ulcer[MeSHID:D010437] approved,vet_approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank methacholine chloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bronchial Hyperreactivity[MeSHID:D016535],Asthma[MeSHID:D001249] approved muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM4 NA inhibitor NA drugbank homatropine small molecule Mydriasis[MeSHID:D015878],Drug Overdose[MeSHID:D062787] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank a-987306 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD vu10007 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM4 NA antagonist NA drugbank cremastrine NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD cmi-936 NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD aclidinium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Inspiration function[MeSHID:D001239],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist 0.22 drugbank , DGIDB ptac NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved muscarinic acetylcholine receptor CHRM4 NA binder NA drugbank 7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m4 CHRM4 Successful target unknown NA TTD ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m4 CHRM4 NA antagonist NA drugbank fesoterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank 6-dimethylamino-2-methyl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD prifinium NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB aceclidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.2 TTD , DGIDB acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD ispaghula NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.33 TTD , DGIDB cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM5 NA binder NA drugbank vu0119498 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB isoclozapine NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD alks 27 small molecule Chronic Obstructive Airway Disease[MeSHID:D029424] investigational muscarinic acetylcholine receptor m5 CHRM5 NA unknown NA drugbank choline alfoscerate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amnesia[MeSHID:D000647] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB bht-3034 NA Myasthenia Gravis[MeSHID:D009157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD mepenzolate NA Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.33 TTD , DGIDB ddp-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD belladonna NA Colitis[MeSHID:D003092],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB thonzylamine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Signs and Symptoms, Respiratory[MeSHID:D012818] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank vu0238429 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target allosteric modulator 0.99 TTD , DGIDB metixene small molecule Secondary Parkinson Disease[MeSHID:D010302],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved muscarinic acetylcholine receptor CHRM5 NA antagonist 0.99 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.2 drugbank , DGIDB tolterodine small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.3 drugbank , DGIDB oxitropium bromide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB doxylamine small molecule Cold Temperature[MeSHID:D003080],Drug Allergy[MeSHID:D004342],Morning Sickness[MeSHID:D048968],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Sleep[MeSHID:D012890],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM5 NA antagonist NA drugbank terfenadine small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,withdrawn muscarinic acetylcholine receptor m5 CHRM5 NA binder NA drugbank 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD isoloxapine NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD benactyzine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] withdrawn from market muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD flumezapine NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD flavoxate NA prostatitis[MeSHID:D011472],Nocturia[MeSHID:D053158],Urethritis[MeSHID:D014526],Cystitis[MeSHID:D003556],Pain[MeSHID:D010146],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.25 TTD , DGIDB cyclopentolate NA Mydriasis[MeSHID:D015878],Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye[MeSHID:D005123],Vision[MeSHID:D014785] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.5 TTD , DGIDB atropine small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Organophosphate poisoning[MeSHID:D062025] approved,vet_approved muscarinic acetylcholine receptor m5 CHRM5 Successful target antagonist 0.66 TTD , drugbank , DGIDB methantheline small molecule Reflex action[MeSHID:D012018],Neurogenic Urinary Bladder[MeSHID:D001750],Gastritis[MeSHID:D005756],Irritable Bowel Syndrome[MeSHID:D043183],Biliary Dyskinesia[MeSHID:D001657],Peptic Ulcer[MeSHID:D010437],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.66 TTD , drugbank , DGIDB 3-tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD aprophen NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD l-651582 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.25 drugbank , DGIDB meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM5 NA binder NA drugbank benzquinamide small molecule Nausea[MeSHID:D009325],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.44 drugbank , DGIDB sulfoarecoline NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD hyoscyamine NA Renal Colic[MeSHID:D056844],Bodily secretions[MeSHID:D012634],Pancreas[MeSHID:D010179],Respiratory tract structure[MeSHID:D012137],Bile fluid[MeSHID:D001646],Stomach[MeSHID:D013270],Irritable Bowel Syndrome[MeSHID:D043183],Heart Block[MeSHID:D006327],cell motility[MeSHID:D002465],Acute Coryza[MeSHID:D003139],Kidney[MeSHID:D007668],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB cremastrine NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved muscarinic acetylcholine receptor CHRM5 NA binder NA drugbank pilocarpine NA Radiation[MeSHID:D011827],Presbyopia[MeSHID:D011305],Xerostomia[MeSHID:D014987],Syndrome[MeSHID:D013577],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target agonist 0.14 TTD , DGIDB propiverine small molecule Urinary Incontinence[MeSHID:D014549],Neurogenic Urinary Bladder[MeSHID:D001750],Urinary tract[MeSHID:D014551],Overactive Bladder[MeSHID:D053201],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 1.99 TTD , drugbank , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved muscarinic acetylcholine receptor m5 CHRM5 NA ligand NA drugbank homatropine small molecule Mydriasis[MeSHID:D015878],Drug Overdose[MeSHID:D062787] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank [125i]epibatidine NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD n-methoxyquinuclidine-3-carboximidoyl chloride NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA ligand NA drugbank benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD alpha-conotoxin pnia NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD promazine NA Psychomotor Agitation[MeSHID:D011595],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.33 TTD , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank n-methoxyquinuclidine-3-carboximidoyl fluoride NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM5 NA ligand,antagonist 0.1 drugbank , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM5 NA inhibitor NA drugbank pf-3409409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD aclidinium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Chronic Obstructive Airway Disease[MeSHID:D029424],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Inspiration function[MeSHID:D001239],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.2 drugbank , DGIDB cimetropium bromide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],cell motility[MeSHID:D002465],Muscle Cramp[MeSHID:D009120],Stomach Diseases[MeSHID:D013272] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM5 NA antagonist NA drugbank maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank methacholine small molecule Asthma[MeSHID:D001249],Diagnosis[MeSHID:D003933],Bronchial Hyperreactivity[MeSHID:D016535] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA agonist NA drugbank 3-methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD butylscopolamine NA Muscle Cramp[MeSHID:D009120],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB org-23366 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB 1'-benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD darifenacin small molecule Urge Incontinence[MeSHID:D053202],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.5 drugbank , DGIDB 3-(3-benzylamino)-piperidin-2-one NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD solifenacin small molecule Urinary Incontinence[MeSHID:D014549],Overactive Bladder[MeSHID:D053201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.6 drugbank , DGIDB brl-55473 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD scopolamine small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Postoperative Nausea and Vomiting[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank homatropine methylbromide small molecule Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uveitis[MeSHID:D014605] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target antagonist NA TTD , drugbank , DGIDB tiotropium small molecule Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Asthma[MeSHID:D001249],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 NA unknown NA drugbank am-831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD trihexyphenidyl small molecule Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dystonia[MeSHID:D004421],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Obesity[MeSHID:D009765] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM5 NA binder NA drugbank alpha-conotoxin auib NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD gsk233705 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.28 drugbank , DGIDB 7-dimethylamino-3-methyl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank crtx-070 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD glycopyrronium small molecule Solutions[MeSHID:D012996],Cardiac Arrhythmia[MeSHID:D001145],Drooling[MeSHID:D012798],Maintenance[MeSHID:D008283],Operative Surgical Procedures[MeSHID:D013514],Heart[MeSHID:D006321],Vagus nerve structure[MeSHID:D014630],Heartburn[MeSHID:D006356],Chronic Obstructive Airway Disease[MeSHID:D029424],Cardiac Arrest[MeSHID:D006323],Peptic Ulcer[MeSHID:D010437],Term Birth[MeSHID:D047929],Hyperhidrosis disorder[MeSHID:D006945],Reflex action[MeSHID:D012018],Bodily secretions[MeSHID:D012634],Gastric Juice (substance)[MeSHID:D005750],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank a-867744 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD 7-pyrrolidin-1-yl-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD rociverine small molecule NA experimental muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.22 drugbank , DGIDB bethanechol small molecule Urinary Retention[MeSHID:D016055],Retention (Psychology)[MeSHID:D012153],Neurogenic Urinary Bladder, Atonic[MeSHID:D001750],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target agonist 0.2 TTD , drugbank , DGIDB ns1738 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved muscarinic acetylcholine receptor CHRM5 NA antagonist NA drugbank propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor CHRM5 NA antagonist 0.28 drugbank , DGIDB pramiracetam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Diseases[MeSHID:D001927] approved (orphan drug) muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved muscarinic acetylcholine receptor CHRM5 NA binder NA drugbank aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA unknown NA drugbank muscarine NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD emepronium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB procyclidine NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.25 TTD , DGIDB anisotropine methylbromide NA Bodily secretions[MeSHID:D012634],Gastric Acid[MeSHID:D005744],Gastric Juice (substance)[MeSHID:D005750],Gastric Emptying[MeSHID:D005746],Peptic Ulcer[MeSHID:D010437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB fm1-10 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD gnf-pf-5618 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD brompheniramine small molecule Pruritus[MeSHID:D011537],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Common Cold[MeSHID:D003139],Drinking Water[MeSHID:D060766],Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank 2-methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD mebeverine NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.99 TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 NA binder NA drugbank fm1-43 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD oxyphencyclimine NA Gastrointestinal Diseases[MeSHID:D005767],Peptic Ulcer[MeSHID:D010437],Spasm[MeSHID:D013035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.25 TTD , DGIDB pilocarpine NA Radiation[MeSHID:D011827],Presbyopia[MeSHID:D011305],Xerostomia[MeSHID:D014987],Syndrome[MeSHID:D013577],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.14 TTD , DGIDB umeclidinium small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target antagonist 0.5 TTD , drugbank , DGIDB orm3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2b muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB 1-methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD recombinant botulinum toxin NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD alpha-conotoxin gi NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD bms-181168 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD dexpirronium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB fk-584 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral Neuropathy[MeSHID:D010523] discontinued in phase 2 muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD n-(4-dimethylamino-but-2-ynyl)-n-methyl-acetamide NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD anisodine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral Neuropathy[MeSHID:D010523] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB trospium NA Urge Incontinence[MeSHID:D053202],Urination[MeSHID:D014554],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.5 TTD , DGIDB flutropium bromide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn muscarinic acetylcholine receptor CHRM5 NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational muscarinic acetylcholine receptor m5 CHRM5 NA antagonist 0.2 drugbank , DGIDB [3h]cytisine NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD gallamine triethiodide small molecule Disease Management[MeSHID:D019468],Skeletal muscle structure[MeSHID:D018482],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 NA unknown NA drugbank cryptenamine acetates NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD , DGIDB revefenacin small molecule Solutions[MeSHID:D012996],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Cause of Death[MeSHID:D002423],Chronic Obstructive Airway Disease[MeSHID:D029424],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational muscarinic acetylcholine receptor CHRM5 NA antagonist 0.2 drugbank , DGIDB vu0119498 NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target allosteric modulator 0.99 TTD , DGIDB 2,8-dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD tridihexethyl NA Peptic Ulcer[MeSHID:D010437],Nystagmus[MeSHID:D009759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.25 TTD , DGIDB jwb-1-84-1 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank 7-dimethylamino-hept-5-yn-2-one NA NA investigative muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn muscarinic acetylcholine receptor m5 CHRM5 NA antagonist NA drugbank trospium NA Urge Incontinence[MeSHID:D053202],Urination[MeSHID:D014554],Overactive Bladder[MeSHID:D053201],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurogenesis[MeSHID:D055495],Overactive Detrusor[MeSHID:D053201] approved muscarinic acetylcholine receptor m5 CHRM5 Successful target unknown 0.5 TTD , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational acetylcholine receptor subunit alpha CHRNA1 NA inhibitor NA drugbank agmatine small molecule Diabetes Mellitus[MeSHID:D003920],Small Fiber Neuropathy[MeSHID:D000071075],Neuroprotection[MeSHID:D000066829],Glaucoma[MeSHID:D005901],Diagnosis[MeSHID:D003933],Epilepsy[MeSHID:D004827],Kidney[MeSHID:D007668],Anxiety Disorders[MeSHID:D001008],Blind Vision[MeSHID:D001766],Mental Depression[MeSHID:D003863],Cognition[MeSHID:D003071],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Traumatic injury[MeSHID:D014947],Cerebrovascular accident[MeSHID:D020521],Anxiety[MeSHID:D001007] experimental acetylcholine receptor subunit alpha CHRNA1 NA antagonist NA drugbank decamethonium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved neuronal acetylcholine receptor alpha-1 CHRNA1 Successful target unknown 1.06 TTD , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNA10 NA inhibitor NA drugbank nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA agonist,antagonist 1.52 drugbank , DGIDB [3h]methyllycaconitine NA NA investigative neuronal acetylcholine receptor alpha-10 CHRNA10 Clinical trial target antagonist NA TTD , DGIDB atg003 small molecule Age related macular degeneration[MeSHID:D008268] investigational neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA unknown NA drugbank diroximel fumarate small molecule Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008] approved,investigational neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA agonist NA drugbank succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNA10 NA agonist NA drugbank trimethaphan small molecule Operative Surgical Procedures[MeSHID:D013514],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Emergencies [Disease/Finding][MeSHID:D004630],Aneurysm[MeSHID:D000783] approved,investigational neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA antagonist 31.83 drugbank , DGIDB pentolinium small molecule Operative Surgical Procedures[MeSHID:D013514],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA antagonist 31.83 drugbank , DGIDB rpi-78m small molecule Pain[MeSHID:D010146],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA unknown NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA unknown NA drugbank nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA agonist 1.52 drugbank , DGIDB acv-1 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neuronal acetylcholine receptor alpha-10 CHRNA10 Clinical trial target unknown NA TTD , DGIDB lobeline small molecule Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] investigational neuronal acetylcholine receptor subunit alpha-10 CHRNA10 NA unknown NA drugbank carbachol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 3.18 TTD , DGIDB gallamine triethiodide small molecule Disease Management[MeSHID:D019468],Skeletal muscle structure[MeSHID:D018482],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist NA drugbank , DGIDB vecuronium NA Muscle[MeSHID:D009132],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 6.37 TTD , DGIDB choline NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown NA TTD ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA unknown NA drugbank nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA agonist 0.45 drugbank , DGIDB dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist NA drugbank atracurium besylate small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist NA drugbank levallorphan NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Respiratory Depression[MeSHID:D012131],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 1.59 TTD , DGIDB 1,1-dimethyl-4-phenyl-piperazin-1-ium iodide NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown NA TTD rocuronium NA Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 4.77 TTD , DGIDB pancuronium small molecule Operative Surgical Procedures[MeSHID:D013514],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 5.3 drugbank , DGIDB mivacurium small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 9.55 drugbank , DGIDB epibatidine small molecule NA experimental neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA agonist NA drugbank mivacurium NA Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 9.55 TTD , DGIDB fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist NA drugbank ly2087101 NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target allosteric modulator NA TTD , DGIDB mecamylamine small molecule Essential Hypertension[MeSHID:D000075222],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist,blocker 2.55 drugbank , DGIDB 1-(piperidin-4-ylmethyl)pyridin-2(1h)-one NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown NA TTD succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNA2 NA agonist NA drugbank rpi-78m small molecule Pain[MeSHID:D010146],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA unknown NA drugbank fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist NA drugbank procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNA2 NA inhibitor NA drugbank 2-pyridin-3-yl-7-aza-bicyclo[2.2.1]heptane NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown NA TTD hexamethonium small molecule NA experimental neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist,blocker 2.39 drugbank , DGIDB carbamoylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Miosis disorder[MeSHID:D015877],Physiologic Intraocular Pressure[MeSHID:D007429] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA agonist NA drugbank pipecuronium small molecule Operative Surgical Procedures[MeSHID:D013514],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 25.46 drugbank , DGIDB [125i]epibatidine NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target agonist NA TTD , DGIDB cytisine NA Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] phase 3 neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 0.64 TTD , DGIDB cisatracurium NA Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 12.73 TTD , DGIDB doxacurium small molecule Skeletal muscle structure[MeSHID:D018482],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 9.55 drugbank , DGIDB pipecuronium NA Operative Surgical Procedures[MeSHID:D013514],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 25.46 TTD , DGIDB decamethonium small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA partial agonist 7.43 drugbank , DGIDB 5-(1-methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown NA TTD (s)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown NA TTD tubocurarine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 6.37 drugbank , DGIDB cisatracurium small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 12.73 drugbank , DGIDB metocurine iodide small molecule Skeletal muscle structure[MeSHID:D018482],Relaxation[MeSHID:D012063],Intention - mental process[MeSHID:D033182],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist NA drugbank , DGIDB vecuronium small molecule Muscle[MeSHID:D009132],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 6.37 drugbank , DGIDB metocurine small molecule Muscle[MeSHID:D009132] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 22.28 drugbank , DGIDB tubocurarine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown 6.37 TTD , DGIDB 1-(piperidin-3-ylmethyl)pyridin-2(1h)-one NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown NA TTD mecamylamine small molecule Essential Hypertension[MeSHID:D000075222],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 2.55 drugbank , DGIDB [3h]cytisine NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target agonist NA TTD , DGIDB 3-((s)-azetidin-2-yloxy)-5-iodo-pyridine NA NA investigative neuronal acetylcholine receptor alpha-2 CHRNA2 Successful target unknown NA TTD rocuronium small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved neuronal acetylcholine receptor subunit alpha-2 CHRNA2 NA antagonist 4.77 drugbank , DGIDB levacetylmethadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Opiate Addiction[MeSHID:D009293] approved,investigational neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA agonist 0.58 drugbank , DGIDB amantadine small molecule Adverse reaction to drug[MeSHID:D064420],Communicable Diseases[MeSHID:D003141],Parkinsonian Disorders[MeSHID:D020734],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank varenicline small molecule Cessation of smoking[MeSHID:D016540],Nose[MeSHID:D009666],Disorder of eye[MeSHID:D005128],Desiccation[MeSHID:D003890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved,investigational neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA partial agonist 1.36 drugbank , DGIDB epibatidine small molecule NA experimental neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA agonist 4.77 drugbank , DGIDB cytisine small molecule Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] experimental neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA agonist NA drugbank fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank pentolinium small molecule Operative Surgical Procedures[MeSHID:D013514],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank gantacurium small molecule NA investigational neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA unknown 0.11 drugbank , DGIDB bupropion small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Diet therapy[MeSHID:D004035],Weight Gain[MeSHID:D015430],Body Weight[MeSHID:D001835],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Seasonal Affective Disorder[MeSHID:D016574],Cessation of smoking[MeSHID:D016540],Mood (psychological function)[MeSHID:D000339],Obesity[MeSHID:D009765],Off-Label Use[MeSHID:D056687],Overweight[MeSHID:D050177],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank varenicline small molecule Cessation of smoking[MeSHID:D016540],Nose[MeSHID:D009666],Disorder of eye[MeSHID:D005128],Desiccation[MeSHID:D003890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved,investigational neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA partial agonist,agonist 1.36 drugbank , DGIDB succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNA3 NA agonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNA3 NA inhibitor NA drugbank methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank levamisole small molecule melanoma[MeSHID:D008545],Cutaneous Melanoma[MeSHID:C562393],Cancer of Head and Neck[MeSHID:D006258],Operative Surgical Procedures[MeSHID:D013514],Malignant tumor of colon[MeSHID:D003110],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parasitic Diseases[MeSHID:D010272] approved,investigational,vet_approved,withdrawn neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA agonist NA drugbank fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-3 CHRNA3 NA antagonist NA drugbank nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA agonist 0.7 drugbank , DGIDB epibatidine small molecule NA experimental neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA agonist NA drugbank cytisine NA Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] phase 3 neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown 0.93 TTD , DGIDB methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.65 drugbank , DGIDB 6'-methylepibatidine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD trimethaphan NA Operative Surgical Procedures[MeSHID:D013514],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Emergencies [Disease/Finding][MeSHID:D004630],Aneurysm[MeSHID:D000783] approved neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown 0.78 TTD , DGIDB phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.21 drugbank , DGIDB n,n-dimethyl-2-(pyridin-3-yloxy)ethanamine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD cmi-489 NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD pentolinium NA Operative Surgical Procedures[MeSHID:D013514],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown 0.78 TTD , DGIDB dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown 0.07 drugbank , DGIDB physostigmine small molecule Glaucoma[MeSHID:D005901],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Xerostomia[MeSHID:D014987] approved,investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.39 drugbank , DGIDB boldine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD pozanicline small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Attention deficit hyperactivity disorder[MeSHID:D001289] investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown 0.78 drugbank , DGIDB estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank mecamylamine small molecule Essential Hypertension[MeSHID:D000075222],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown 0.47 drugbank , DGIDB estradiol small molecule Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA binder NA drugbank predicentrine methiodide NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD cytisine small molecule Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] experimental neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA agonist 0.93 drugbank , DGIDB thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.71 drugbank , DGIDB amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.24 drugbank , DGIDB barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.39 drugbank , DGIDB amantadine small molecule Adverse reaction to drug[MeSHID:D064420],Communicable Diseases[MeSHID:D003141],Parkinsonian Disorders[MeSHID:D020734],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank varenicline small molecule Cessation of smoking[MeSHID:D016540],Nose[MeSHID:D009666],Disorder of eye[MeSHID:D005128],Desiccation[MeSHID:D003890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved,investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA partial agonist 2.22 drugbank , DGIDB aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNA4 NA inhibitor 0.78 drugbank , DGIDB succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNA4 NA agonist NA drugbank n,n-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD (2s,3s)-2-phenyl-3,5,5-trimethylmorpholin-2-ol NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD n-methyl-2-(pyridin-3-yloxy)ethanamine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank (2s,3s)-2-(m-tolyl)-3,5,5-trimethylmorpholin-2-ol NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank varenicline small molecule Cessation of smoking[MeSHID:D016540],Nose[MeSHID:D009666],Disorder of eye[MeSHID:D005128],Desiccation[MeSHID:D003890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved,investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA partial agonist,agonist 2.22 drugbank , DGIDB 3-[2-(n,n,n-trimethylammonium)ethoxy]pyridine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD n,n-dimethyl(pyridin-3-yl)methanamine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD estradiol dienanthate small molecule NA approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank n-methyl-4-(pyridin-3-yl)but-3-yn-1-amine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD pozanicline small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Attention deficit hyperactivity disorder[MeSHID:D001289] investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA partial agonist 0.78 drugbank , DGIDB estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank rpi-78m small molecule Pain[MeSHID:D010146],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.78 drugbank , DGIDB n-ethyl-n-methyl-4-(pyridin-3-yl)but-3-yn-1-amine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.39 drugbank , DGIDB mecamylamine small molecule Essential Hypertension[MeSHID:D000075222],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA blocker 0.47 drugbank , DGIDB n-methyl-n-(pyridin-3-ylmethyl)ethanamine NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD decamethonium small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank scopolamine small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Postoperative Nausea and Vomiting[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194] approved,investigational neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA inhibitor,inducer NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist NA drugbank barbituric acid derivative NA NA investigative neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD atropine small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Organophosphate poisoning[MeSHID:D062025] approved,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA unknown NA drugbank abt-594 NA NA discontinued in phase 2 neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD abt-418 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neuronal acetylcholine receptor alpha-4 CHRNA4 Successful target unknown NA TTD secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.78 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit neuronal acetylcholine receptor subunit alpha-4 CHRNA4 NA antagonist 0.39 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-5 CHRNA5 NA unknown 0.56 drugbank , DGIDB nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-5 CHRNA5 NA agonist NA drugbank succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNA5 NA agonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNA5 NA inhibitor NA drugbank succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNA6 NA agonist NA drugbank nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-6 CHRNA6 NA agonist NA drugbank cytisine small molecule Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] experimental neuronal acetylcholine receptor subunit alpha-6 CHRNA6 NA agonist NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-6 CHRNA6 NA unknown NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNA6 NA inhibitor NA drugbank varenicline small molecule Cessation of smoking[MeSHID:D016540],Nose[MeSHID:D009666],Disorder of eye[MeSHID:D005128],Desiccation[MeSHID:D003890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved,investigational neuronal acetylcholine receptor subunit alpha-6 CHRNA6 NA partial agonist NA drugbank tc-6987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 4.34 TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved alpha-7 nicotinic cholinergic receptor subunit CHRNA7 NA antagonist NA drugbank jnj-1930942 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD tenocyclidine small molecule NA experimental,illicit,investigational alpha-7 nicotinic cholinergic receptor subunit CHRNA7 NA antagonist NA drugbank butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist NA drugbank [3h]a-585539 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist NA TTD , DGIDB epibatidine small molecule NA experimental neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank rpi-78m small molecule Pain[MeSHID:D010146],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-7 nicotinic cholinergic receptor subunit CHRNA7 NA antagonist NA drugbank avl-3288 NA Cognition Disorders[MeSHID:D003072],Testicular Feminization[MeSHID:D013734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 2.89 TTD , DGIDB jnj-39393406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Cognition Disorders[MeSHID:D003072],Tobacco Dependence[MeSHID:D014029] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target positive modulator 2.89 TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-7 nicotinic cholinergic receptor subunit CHRNA7 NA antagonist NA drugbank ly2087101 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target allosteric modulator NA TTD , DGIDB gts-21 NA Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 7.23 TTD , DGIDB bradanicline small molecule nervous system disorder[MeSHID:D009422] investigational alpha-7 nicotinic cholinergic receptor subunit CHRNA7 NA agonist 1.08 drugbank , DGIDB phetqs NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD a-582941 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist 1.45 TTD , DGIDB phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.2 drugbank , DGIDB ziprasidone NA Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 0.07 TTD , DGIDB methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA agonist NA drugbank choline salicylate small molecule Exanthema[MeSHID:D005076],Teething syndrome[MeSHID:D014078],Oral Ulcer[MeSHID:D019226],Pain[MeSHID:D010146],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,nutraceutical neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.66 drugbank , DGIDB bnc375 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD , DGIDB amg 386 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Asthma[MeSHID:D001249] phase 3 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.36 drugbank , DGIDB abt-107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] discontinued in phase 1 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist 1.45 TTD , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNA7 NA inhibitor 0.72 drugbank , DGIDB encenicline small molecule NA investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA partial agonist 7.23 drugbank , DGIDB pha-568487 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD , DGIDB tc-6987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist 4.34 TTD , DGIDB alcuronium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 0.29 TTD , DGIDB toxiferine NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.36 drugbank , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank choline small molecule NA approved,nutraceutical neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank [3h]methyllycaconitine NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD abt-126 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist 2.89 TTD , DGIDB hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.72 drugbank , DGIDB ns1738 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target allosteric modulator NA TTD , DGIDB psab-ofp NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist NA TTD , DGIDB galantamine small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA allosteric modulator 2.89 drugbank , DGIDB azd-9684 NA Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD cp-810123 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank evp-4473 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD 3,8-dibromoboldine NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD r4996 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD , DGIDB barbituric acid derivative NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD gccsnpvchlehsnlc* NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD cytisine small molecule Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] experimental neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA agonist 0.87 drugbank , DGIDB bms-933043 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD , DGIDB aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist NA drugbank [125i]epibatidine NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD ph-709829 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD rmg-40083 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD , DGIDB a-867744 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target allosteric modulator 0.48 TTD , DGIDB abt-126 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 2.89 TTD , DGIDB lobeline small molecule Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.6 drugbank , DGIDB tubocurarine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.72 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.36 drugbank , DGIDB gccshpacagnnqhic* NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.23 drugbank , DGIDB 4bp-tqs NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist NA TTD , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist 0.36 drugbank , DGIDB barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist NA drugbank azd0328 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist 2.89 TTD , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist NA drugbank varenicline small molecule Cessation of smoking[MeSHID:D016540],Nose[MeSHID:D009666],Disorder of eye[MeSHID:D005128],Desiccation[MeSHID:D003890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved,investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA agonist 0.62 drugbank , DGIDB mecamylamine small molecule Essential Hypertension[MeSHID:D000075222],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA blocker 0.29 drugbank , DGIDB dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist NA drugbank heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist NA drugbank [3h]az11637326 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target agonist NA TTD , DGIDB avl-3288 NA Cognition Disorders[MeSHID:D003072],Testicular Feminization[MeSHID:D013734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target positive modulator 2.89 TTD , DGIDB pnu-120596 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target allosteric modulator 4.34 TTD , DGIDB tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-7 nicotinic cholinergic receptor subunit CHRNA7 NA antagonist NA drugbank evp-6124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 7.23 TTD , DGIDB nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA agonist 0.3 drugbank , DGIDB pnu-120596 NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 4.34 TTD , DGIDB dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist NA drugbank 3-bromoboldine NA NA investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD amantadine small molecule Adverse reaction to drug[MeSHID:D064420],Communicable Diseases[MeSHID:D003141],Parkinsonian Disorders[MeSHID:D020734],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA antagonist NA drugbank jn-711 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD encenicline small molecule NA investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA partial agonist,agonist 7.23 drugbank , DGIDB aqw-051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD , DGIDB gts-21 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown 7.23 drugbank , DGIDB mem-3454 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 0.48 TTD , DGIDB bnc375 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target allosteric modulator NA TTD , DGIDB succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNA7 NA agonist NA drugbank jnj-39393406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Cognition Disorders[MeSHID:D003072],Tobacco Dependence[MeSHID:D014029] phase 2 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 2.89 TTD , DGIDB azd-6319 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown NA TTD acetylcholine small molecule Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Lens, Crystalline[MeSHID:D007908],Miosis disorder[MeSHID:D015877],Iris (Eye)[MeSHID:D007498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cataract[MeSHID:D002386] approved,investigational neuronal acetylcholine receptor subunit alpha-7 CHRNA7 NA unknown NA drugbank cytisine NA Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] phase 3 neuronal acetylcholine receptor alpha-7 CHRNA7 Successful target unknown 0.87 TTD , DGIDB nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-9 CHRNA9 NA agonist,antagonist 2.27 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNA9 NA inhibitor NA drugbank atg003 small molecule Age related macular degeneration[MeSHID:D008268] investigational neuronal acetylcholine receptor subunit alpha-9 CHRNA9 NA unknown NA drugbank succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNA9 NA agonist NA drugbank lobeline small molecule Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] investigational neuronal acetylcholine receptor subunit alpha-9 CHRNA9 NA unknown NA drugbank tetraethylammonium small molecule NA experimental,investigational neuronal acetylcholine receptor subunit alpha-9 CHRNA9 NA agonist,inhibitor NA drugbank [3h]methyllycaconitine NA NA investigative neuronal acetylcholine receptor alpha-9 CHRNA9 Literature-reported target antagonist NA TTD , DGIDB rpi-78m small molecule Pain[MeSHID:D010146],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational neuronal acetylcholine receptor subunit alpha-9 CHRNA9 NA unknown NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit alpha-9 CHRNA9 NA unknown NA drugbank nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit alpha-9 CHRNA9 NA agonist 2.27 drugbank , DGIDB n,n-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD [3h]cytisine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD varenicline small molecule Cessation of smoking[MeSHID:D016540],Nose[MeSHID:D009666],Disorder of eye[MeSHID:D005128],Desiccation[MeSHID:D003890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved,investigational neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA partial agonist 1.14 drugbank , DGIDB rpi-78m small molecule Pain[MeSHID:D010146],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA antagonist NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA antagonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNB2 NA inhibitor NA drugbank (2s,3s)-2-phenyl-3,5,5-trimethylmorpholin-2-ol NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNB2 NA agonist NA drugbank n-methyl-2-(pyridin-3-yloxy)ethanamine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD pozanicline small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Attention deficit hyperactivity disorder[MeSHID:D001289] investigational neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA partial agonist 1.99 drugbank , DGIDB [125i]epibatidine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD tc-5214 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperhidrosis disorder[MeSHID:D006945] phase 2 neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown 5.97 TTD , DGIDB cytisine small molecule Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] experimental neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA partial agonist 1.59 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown NA drugbank 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD ns9283 NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA agonist 1.06 drugbank , DGIDB methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA antagonist NA drugbank boldine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD n,n-dimethyl(pyridin-3-yl)methanamine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD epibatidine small molecule NA experimental neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown NA drugbank tc-2559 NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD scopolamine small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Postoperative Nausea and Vomiting[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194] approved,investigational neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA inhibitor,inducer NA drugbank 3-[2-(n,n,n-trimethylammonium)ethoxy]pyridine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD cmi-489 NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD atropine small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Organophosphate poisoning[MeSHID:D062025] approved,vet_approved neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown NA drugbank cytisine NA Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] phase 3 neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown 1.59 TTD , DGIDB decamethonium small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown NA drugbank n-methyl-n-(pyridin-3-ylmethyl)ethanamine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD azd-9684 NA Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD mecamylamine small molecule Essential Hypertension[MeSHID:D000075222],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown NA drugbank gccsnpvchlehsnlc* NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD n,n-dimethyl-2-(pyridin-3-yloxy)ethanamine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD a-867744 NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD abt-418 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD ly2087101 NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD n-methyl-4-(pyridin-3-yl)but-3-yn-1-amine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD 6'-methylepibatidine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD ns1738 NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD gccshpacagnnqhic* NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD abt-594 NA NA discontinued in phase 2 neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD n-ethyl-n-methyl-4-(pyridin-3-yl)but-3-yn-1-amine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD physostigmine small molecule Glaucoma[MeSHID:D005901],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Xerostomia[MeSHID:D014987] approved,investigational neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown NA drugbank predicentrine methiodide NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD pozanicline small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Attention deficit hyperactivity disorder[MeSHID:D001289] investigational neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown 1.99 drugbank , DGIDB suvn-911 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD , DGIDB (2s,3s)-2-(m-tolyl)-3,5,5-trimethylmorpholin-2-ol NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD [3h]nicotine NA NA investigative neuronal acetylcholine receptor beta-2 CHRNB2 Clinical trial target unknown NA TTD rivanicline small molecule Ulcerative Colitis[MeSHID:D003093] investigational neuronal acetylcholine receptor subunit beta-2 CHRNB2 NA unknown NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit beta-3 CHRNB3 NA unknown NA drugbank succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNB3 NA agonist NA drugbank nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit beta-3 CHRNB3 NA agonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNB3 NA inhibitor NA drugbank 18-methylaminocoronaridine NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD (2s,3s)-2-phenyl-3,5,5-trimethylmorpholin-2-ol NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit beta-4 CHRNB4 NA antagonist NA drugbank 18-methoxycoronaridinate 2-methoxyethylamide NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD 2-methoxyethyl 18-methoxycoronaridinate NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit neuronal acetylcholine (nach) receptor subunits CHRNB4 NA inhibitor NA drugbank 2-acetylaminoethyl 18-methoxycoronaridinate NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD 18-dimethylaminocoronaridine NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit beta-4 CHRNB4 NA antagonist NA drugbank cytisine NA Cessation of smoking[MeSHID:D016540],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tobacco Dependence[MeSHID:D014029] phase 3 neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown 0.98 TTD , DGIDB pentolinium small molecule Operative Surgical Procedures[MeSHID:D013514],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit beta-4 CHRNB4 NA antagonist NA drugbank (2s,3s)-2-(m-tolyl)-3,5,5-trimethylmorpholin-2-ol NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD gccsnpvchlehsnlc* NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD 2-hydroxyethyl 18-methoxycoronaridinate NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD epibatidine small molecule NA experimental neuronal acetylcholine receptor subunit beta-4 CHRNB4 NA agonist 7.34 drugbank , DGIDB levacetylmethadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Opiate Addiction[MeSHID:D009293] approved,investigational neuronal acetylcholine receptor subunit beta-4 CHRNB4 NA unknown NA drugbank fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuronal acetylcholine receptor subunit beta-4 CHRNB4 NA antagonist NA drugbank 18-methoxycoronaridinate 2-hydroxyethylamide NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD succinylcholine small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved neuronal acetylcholine (nach) receptor subunits CHRNB4 NA agonist NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuronal acetylcholine receptor subunit beta-4 CHRNB4 NA unknown NA drugbank 15-nor-18-methoxycornaridine NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved neuronal acetylcholine receptor subunit beta-4 CHRNB4 NA agonist 0.6 drugbank , DGIDB n,n-dimethylaminoethyl 18-methoxycoronaridinate NA NA investigative neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD sib-1553a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neuronal acetylcholine receptor beta-4 CHRNB4 Clinical trial target unknown NA TTD mesalazine small molecule Crohn's disease of large bowel[MeSHID:D003424],ileum[MeSHID:D007082],Ulcerative Colitis[MeSHID:D003093],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inhibitor of nuclear factor kappa-b kinase subunit alpha CHUK NA inhibitor NA drugbank acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational inhibitor of nuclear factor kappa-b kinase subunit alpha CHUK NA inhibitor NA drugbank 5-bromo-6-methoxy-9h-beta-carboline NA NA investigative ikka messenger rna CHUK Literature-reported target unknown NA TTD isis 23544 NA NA investigative ikka messenger rna CHUK Literature-reported target unknown NA TTD aminosalicylic acid small molecule Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Lung[MeSHID:D008168] approved inhibitor of nuclear factor kappa-b kinase subunit alpha CHUK NA inhibitor NA drugbank n-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide NA NA investigative ikka messenger rna CHUK Literature-reported target unknown NA TTD isis 23559 NA NA investigative ikka messenger rna CHUK Literature-reported target unknown NA TTD sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inhibitor of nuclear factor kappa-b kinase subunit alpha CHUK NA inhibitor NA drugbank iki-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative inhibitor of nuclear factor kappa-b kinase alpha CHUK Literature-reported target unknown NA TTD calcium phosphate small molecule NA approved calcium and integrin-binding protein 1 CIB1 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved calcium and integrin-binding protein 1 CIB1 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calcium and integrin-binding protein 1 CIB1 NA ligand NA drugbank calcium phosphate small molecule NA approved calcium and integrin-binding family member 2 CIB2 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved calcium and integrin-binding family member 2 CIB2 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational calcium and integrin-binding family member 2 CIB2 NA ligand NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational citron rho-interacting kinase CIT NA inhibitor NA drugbank creatine small molecule NA approved,investigational,nutraceutical creatine kinase b-type CKB NA ligand NA drugbank phosphocreatine small molecule Disease[MeSHID:D004194],Cardiovascular Diseases[MeSHID:D002318],Skeletal muscle structure[MeSHID:D018482],Cerebrovascular accident[MeSHID:D020521],Muscle Strength[MeSHID:D053580],Cerebrovascular Disorders[MeSHID:D002561] nutraceutical creatine kinase b-type CKB NA ligand NA drugbank creatine small molecule NA approved,investigational,nutraceutical creatine kinase m-type CKM NA ligand NA drugbank d-arginine small molecule NA experimental creatine kinase m-type CKM NA unknown NA drugbank (diaminomethyl-methyl-amino)-acetic acid small molecule NA experimental creatine kinase m-type CKM NA unknown NA drugbank phosphocreatine small molecule Disease[MeSHID:D004194],Cardiovascular Diseases[MeSHID:D002318],Skeletal muscle structure[MeSHID:D018482],Cerebrovascular accident[MeSHID:D020521],Muscle Strength[MeSHID:D053580],Cerebrovascular Disorders[MeSHID:D002561] nutraceutical creatine kinase m-type CKM NA ligand NA drugbank creatine small molecule NA approved,investigational,nutraceutical creatine kinase u-type, mitochondrial CKMT1A NA ligand NA drugbank phosphocreatine small molecule Disease[MeSHID:D004194],Cardiovascular Diseases[MeSHID:D002318],Skeletal muscle structure[MeSHID:D018482],Cerebrovascular accident[MeSHID:D020521],Muscle Strength[MeSHID:D053580],Cerebrovascular Disorders[MeSHID:D002561] nutraceutical creatine kinase u-type, mitochondrial CKMT1A NA ligand NA drugbank phosphocreatine small molecule Disease[MeSHID:D004194],Cardiovascular Diseases[MeSHID:D002318],Skeletal muscle structure[MeSHID:D018482],Cerebrovascular accident[MeSHID:D020521],Muscle Strength[MeSHID:D053580],Cerebrovascular Disorders[MeSHID:D002561] nutraceutical creatine kinase s-type, mitochondrial CKMT2 NA ligand NA drugbank creatine small molecule NA approved,investigational,nutraceutical creatine kinase s-type, mitochondrial CKMT2 NA ligand NA drugbank fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved cyclin-dependent kinases regulatory subunit 1 CKS1B NA unknown NA drugbank 2,8-bis[oxido(oxo)vanadio]-1,1,1,3,5,5,7,7,9,9,9-undecaoxopentavanadoxane-2,8-diium small molecule NA experimental cyclin-dependent kinases regulatory subunit 1 CKS1B NA unknown NA drugbank fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved cyclin-dependent kinases regulatory subunit 1 CKS1B NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational clip-associating protein 1 CLASP1 NA inhibitor NA drugbank n-ethylmaleimide small molecule NA experimental galectin-10 CLC NA unknown NA drugbank para-mercury-benzenesulfonic acid small molecule NA experimental galectin-10 CLC NA unknown NA drugbank nppb NA NA investigative chloride channel protein 2 CLCN2 Successful target blocker NA TTD , DGIDB lubiprostone small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational chloride channel protein 2 CLCN2 Successful target inducer 148.52 TTD , drugbank , DGIDB diphenylamine-2-carboxylic acid NA NA investigative chloride channel protein 2 CLCN2 Successful target blocker NA TTD , DGIDB rk-023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] phase 2 chloride channel protein 2 CLCN2 Successful target unknown NA TTD , DGIDB cobiprostone small molecule Cystic Fibrosis[MeSHID:D003550] investigational chloride channel protein 2 CLCN2 NA activator 21.22 drugbank , DGIDB lubiprostone small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational chloride channel protein 2 CLCN2 Successful target inducer,activator 148.52 TTD , drugbank , DGIDB acid-activated omeprazole NA NA investigative chloride channel protein 2 CLCN2 Successful target unknown NA TTD niflumic acid small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental chloride channel protein clc-ka CLCNKA NA inducer,blocker,activator NA drugbank , DGIDB niflumic acid small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental chloride channel protein clc-ka CLCNKA NA inducer NA drugbank , DGIDB talniflumate small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Cystic Fibrosis[MeSHID:D003550] experimental chloride channel protein clc-ka CLCNKA NA antagonist NA drugbank zolbetuximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Neoplasms[MeSHID:D009369] phase 3 claudin-18 CLDN18 Clinical trial target unknown NA TTD tst001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 claudin-18 CLDN18 Clinical trial target unknown NA TTD amg 910 NA Adenocarcinoma[MeSHID:D000230],Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 claudin-18 CLDN18 Clinical trial target unknown NA TTD claudiximab NA Esophageal Neoplasms[MeSHID:D004938],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenocarcinoma[MeSHID:D000230] phase 3 claudin-18 CLDN18 Clinical trial target unknown 190.95 TTD , DGIDB car-cld18 t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],T-Lymphocyte[MeSHID:D013601],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463] clinical trial claudin-18 CLDN18 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting cll1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 1/2 myeloid inhibitory c-type lectin-like receptor CLEC12A Clinical trial target unknown NA TTD , DGIDB cd123/cll1 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 2/3 myeloid inhibitory c-type lectin-like receptor CLEC12A Clinical trial target unknown NA TTD , DGIDB tepoditamab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid inhibitory c-type lectin-like receptor CLEC12A Clinical trial target antibody NA TTD , DGIDB cll1 car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 2/3 myeloid inhibitory c-type lectin-like receptor CLEC12A Clinical trial target unknown NA TTD , DGIDB ucart-cll1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] preclinical myeloid inhibitory c-type lectin-like receptor CLEC12A Clinical trial target unknown NA TTD cll1-cd33 ccart cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid inhibitory c-type lectin-like receptor CLEC12A Clinical trial target unknown NA TTD clt030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 myeloid inhibitory c-type lectin-like receptor CLEC12A Clinical trial target unknown NA TTD cll1-specific gene-engineered t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1/2 myeloid inhibitory c-type lectin-like receptor CLEC12A Clinical trial target unknown NA TTD , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational c-type lectin domain family 14 member a CLEC14A NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational c-type lectin domain family 14 member a CLEC14A NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational tetranectin CLEC3B NA unknown NA drugbank tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tetranectin CLEC3B NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tetranectin CLEC3B NA unknown NA drugbank cholesterol small molecule NA approved,investigational c-type lectin domain family 4 member e CLEC4E NA ligand NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational chloride intracellular channel protein 1 CLIC1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational chloride intracellular channel protein 1 CLIC1 NA ligand NA drugbank debromohymenialdisine small molecule NA experimental dual specificity protein kinase clk1 CLK1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity protein kinase clk1 CLK1 NA inhibitor NA drugbank chgn111 small molecule Dermatologic disorders[MeSHID:D012871],Skin Diseases, Infectious[MeSHID:D012874],Infection[MeSHID:D007239],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dual specificity protein kinase clk1 CLK1 NA unknown NA drugbank ml315 NA NA investigative cdc-like kinase 1 CLK1 Patented-recorded target inhibitor NA TTD , DGIDB pmid23642479c17 NA NA investigative cdc-like kinase 1 CLK1 Patented-recorded target unknown NA TTD leucettine l41 NA NA investigative cdc-like kinase 1 CLK1 Patented-recorded target unknown NA TTD ethyl 3-[(e)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1h-indole-2-carboxylate small molecule NA experimental dual specificity protein kinase clk1 CLK1 NA unknown NA drugbank tg003 NA NA patented cdc-like kinase 1 CLK1 Patented-recorded target unknown NA TTD , DGIDB kh-cb19 NA NA investigative cdc-like kinase 1 CLK1 Patented-recorded target inhibitor NA TTD , DGIDB pmid23642479c17 NA NA investigative cdc-like kinase 2 CLK2 Patented-recorded target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity protein kinase clk2 CLK2 NA inhibitor NA drugbank tg003 NA NA patented cdc-like kinase 2 CLK2 Patented-recorded target unknown NA TTD , DGIDB ml315 NA NA investigative cdc-like kinase 2 CLK2 Patented-recorded target inhibitor NA TTD , DGIDB ethyl 3-[(e)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1h-indole-2-carboxylate small molecule NA experimental dual specificity protein kinase clk3 CLK3 NA unknown NA drugbank k-00546 small molecule NA experimental dual specificity protein kinase clk3 CLK3 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity protein kinase clk3 CLK3 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity protein kinase clk4 CLK4 NA inhibitor NA drugbank n-formylmethionine small molecule NA experimental putative atp-dependent clp protease proteolytic subunit, mitochondrial CLPP NA unknown NA drugbank methoxyundecylphosphinic acid small molecule NA experimental colipase CLPS NA unknown NA drugbank (hydroxyethyloxy)tri(ethyloxy)octane small molecule NA experimental colipase CLPS NA unknown NA drugbank b-nonylglucoside small molecule NA experimental colipase CLPS NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental clusterin CLU NA inducer NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational clusterin CLU NA unknown NA drugbank custirsen NA Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 clusterin messenger rna CLU Clinical trial target antisense oligonucleotide 21.22 TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational clusterin CLU NA inducer NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational clusterin CLU NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational clusterin CLU NA unknown NA drugbank rac-2q NA NA investigative chymase CMA1 Clinical trial target unknown NA TTD sun-c8257 NA NA investigative chymase CMA1 Clinical trial target unknown NA TTD bay 11-42524 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487] phase 2 chymase CMA1 Clinical trial target unknown NA TTD , DGIDB 2-[3-({methyl[1-(2-naphthoyl)piperidin-4-yl]amino}carbonyl)-2-naphthyl]-1-(1-naphthyl)-2-oxoethylphosphonic acid small molecule NA experimental chymase CMA1 NA unknown NA drugbank asb17061 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 chymase CMA1 Clinical trial target unknown NA TTD , DGIDB benzylsulfinic acid NA NA investigative chymase CMA1 Clinical trial target unknown NA TTD jnj-10311795 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 chymase CMA1 Clinical trial target inhibitor 63.65 TTD , DGIDB km-01221 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] investigative chymase CMA1 Clinical trial target unknown NA TTD benzylsulfonic acid small molecule NA experimental chymase CMA1 NA unknown NA drugbank phenylalanylmethane NA NA investigative chymase CMA1 Clinical trial target unknown NA TTD bay 1142524 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 2 chymase CMA1 Clinical trial target unknown NA TTD bceab NA NA investigative chymase CMA1 Clinical trial target unknown NA TTD 2-(n-morpholino)-ethanesulfonic acid NA NA investigative chymase CMA1 Clinical trial target unknown NA TTD jnj-10311795 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 chymase CMA1 Clinical trial target unknown 63.65 TTD , DGIDB sun13834 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] phase 2 chymase CMA1 Clinical trial target unknown NA TTD , DGIDB 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental chymase CMA1 NA unknown NA drugbank chymostatin NA NA investigative chymase CMA1 Clinical trial target unknown NA TTD y-40613 NA NA investigative chymase CMA1 Clinical trial target unknown NA TTD nk3201 NA NA investigative chymase CMA1 Clinical trial target inhibitor NA TTD , DGIDB [(1s)-1-(5-chloro-1-benzothien-3-yl)-2-(2-naphthylamino)-2-oxoethyl]phosphonic acid small molecule NA experimental chymase CMA1 NA unknown NA drugbank cytidine-5'-monophosphate-5-n-acetylneuraminic acid small molecule NA experimental n-acylneuraminate cytidylyltransferase CMAS NA unknown NA drugbank [3h]resolvin e1 NA NA investigative chemerin receptor CMKLR1 Literature-reported target agonist NA TTD , DGIDB tetrafluoroaluminate ion small molecule NA experimental ump-cmp kinase CMPK1 NA unknown NA drugbank cytidine-5'-monophosphate small molecule NA experimental ump-cmp kinase CMPK1 NA unknown NA drugbank gemcitabine small molecule Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved ump-cmp kinase CMPK1 NA inhibitor 2.36 drugbank , DGIDB uridine-5'-diphosphate small molecule NA experimental ump-cmp kinase CMPK1 NA unknown NA drugbank p1-(adenosine-5'-p5-(uridine-5')pentaphosphate small molecule NA experimental ump-cmp kinase CMPK1 NA unknown NA drugbank gemcitabine small molecule Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Severe Acute Respiratory Syndrome[MeSHID:D045169],Middle East Respiratory Syndrome[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ump-cmp kinase CMPK1 NA inhibitor 2.36 drugbank , DGIDB ademetionine small molecule Emotions[MeSHID:D004644],Degenerative polyarthritis[MeSHID:D010003],Depressive disorder[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Liver diseases[MeSHID:D008107],Bone Tissue[MeSHID:D001842],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] approved,investigational,nutraceutical cap-specific mrna (nucleoside-2'-o-)-methyltransferase 1 CMTR1 NA unknown NA drugbank h-8 NA NA investigative cyclic nucleotide-gated channel alpha-1 CNGA1 Clinical trial target unknown NA TTD dequalinium small molecule Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cgmp-gated cation channel alpha-1 CNGA1 NA blocker 15.91 drugbank , DGIDB dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial cyclic nucleotide-gated channel alpha-1 CNGA1 Clinical trial target blocker 15.91 TTD , DGIDB dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial cyclic nucleotide-gated channel alpha-1 CNGA1 Clinical trial target unknown 15.91 TTD , DGIDB l-(cis)-diltiazem NA NA investigative cyclic nucleotide-gated channel alpha-1 CNGA1 Clinical trial target blocker NA TTD , DGIDB l-(cis)-diltiazem NA NA investigative cyclic nucleotide-gated channel alpha-2 CNGA2 Clinical trial target unknown NA TTD all-trans-retinal NA NA investigative cyclic nucleotide-gated channel alpha-2 CNGA2 Clinical trial target unknown NA TTD dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial cyclic nucleotide-gated channel alpha-2 CNGA2 Clinical trial target blocker 10.61 TTD , DGIDB dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial cyclic nucleotide-gated channel alpha-2 CNGA2 Clinical trial target unknown 10.61 TTD , DGIDB pip3 NA NA investigative cyclic nucleotide-gated channel alpha-2 CNGA2 Clinical trial target unknown NA TTD l-(cis)-diltiazem NA NA investigative cyclic nucleotide-gated channel alpha-3 CNGA3 Clinical trial target inhibitor NA TTD , DGIDB aav-cnga3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Achromatopsia 1[MeSHID:C536021],Achromatopsia[MeSHID:D003117] phase 1/2 cyclic nucleotide-gated channel alpha-3 CNGA3 Clinical trial target unknown NA TTD achm-cnga3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Achromatopsia 1[MeSHID:C536021],Achromatopsia[MeSHID:D003117] phase 1/2 cyclic nucleotide-gated channel alpha-3 CNGA3 Clinical trial target unknown NA TTD achm-cngb3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Achromatopsia 1[MeSHID:C536021],Achromatopsia[MeSHID:D003117] phase 1/2 cyclic nucleotide-gated channel beta-3 CNGB3 Clinical trial target unknown NA TTD l-(cis)-diltiazem NA NA investigative cyclic nucleotide-gated channel beta-3 CNGB3 Clinical trial target unknown NA TTD aav-cngb3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Achromatopsia 1[MeSHID:C536021],Achromatopsia[MeSHID:D003117] phase 1/2 cyclic nucleotide-gated channel beta-3 CNGB3 Clinical trial target unknown NA TTD 4-methyl-4,5-dihydro-1h-pyrazole-3-carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-297 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD paraoxon NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrrole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB (e)-n-(4-methoxyphenethyl)undec-2-enamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-366 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 3-benzyl-5-methoxy-7-methylchromen-2-one NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD cb1 antagonist, bayer NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB diphenyl purine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB taranabant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 3 cannabinoid receptor 1 CNR1 Successful target antagonist 4.08 TTD , DGIDB zy01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] phase 1 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational cannabinoid receptor 1 CNR1 NA unknown NA drugbank n-methyl-5,6-dip-tolylpyrazine-2-carboxamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pmid26161824-compound-68 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(7-(2-chlorophenyl)-6-(4-chlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-2-hydroxyacetamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-ethyl-5,6-dip-tolylpyrazine-2-carboxamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(7'-(2-chlorophenyl)-6'-(4-chlorophenyl)-3',4'-dihydrospiro[cyclohexane-1,2'-pyrano[2,3-b]pyridine]-4'-yl)-2-hydroxy-2-methylpropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD azd1704 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 1 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD imidazole derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrrole derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB rimonabant small molecule Dyslipidemias[MeSHID:D050171],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational cannabinoid receptor 1 CNR1 NA antagonist 2.24 drugbank , DGIDB 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-133 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD am-411 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD diaryl piperazine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-407 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(2-chloroethyl)icosa-5,8,11,14-tetraenamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD tricyclic phytocannabinoid derivative 1 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB phytocannabinoid/aminoalkylindole derivative 1 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pmid26161824-compound-69 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-372 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD methyl icosylphosphonofluoridate NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-229 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 33 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 28 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-344 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD [123i]am251 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(3-phenyl)propyl-2,2-diphenylacetamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-442 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD sulfonylated piperazine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB diphenyl purine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB am-404 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1-(bis(4-bromophenyl)methyl)-3-phenylurea NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 29 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB tricyclic phytocannabinoid derivative 2 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB conatumumab NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 cannabinoid receptor 1 CNR1 Successful target unknown 0.41 TTD , DGIDB n-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-268 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-245 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD o-1812 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 3-benzyl-5-isopropyl-8-methylchromen-2-one NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD chlorphrifos oxon NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD tetra-hydro-1h-1,2,6-triazaazulene derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-phenyl-5,6-dip-tolylpyrazine-2-carboxamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD methanandamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD az-599 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 32 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(arylalkyl)-1h-indole-2-sulfonic acid amide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB purine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB sch-356036 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD sulfonylated piperazine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB gw-42004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 2 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-arachidonoyl-o-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyridotriazolopyrimidine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-147 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,2,4-triazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n,n-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 54 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyridotriazolopyrimidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 3-benzyl-5-methoxychromen-2-one NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD {[(9z)-octadec-9-en-1-yl]sulfamoyl}amine NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD azetidine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-292 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-arachidonoyl-n-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD hu210 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrrole derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pravadoline NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1-(bis(4-chlorophenyl)methyl)-3-phenylurea NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD purine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pmid27215781-compound-1 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD kds-2000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Postherpetic neuralgia[MeSHID:D051474] discontinued in phase 2 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD kn-38-7271 NA Ischemia[MeSHID:D007511],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB (e)-n-(3,5-dimethoxyphenethyl)undec-2-enamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD furopyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyridotriazolopyrimidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB imidazole derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB sulfonylated piperazine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 59 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB isopropyl dodecylfluorophosphonate NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,3,5-triphenylimidazolidine-2,4-dione NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB amide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 36 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrano[2,3-b]pyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB sr-147778 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 cannabinoid receptor 1 CNR1 Successful target unknown 3.26 TTD , DGIDB tm38837 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765] phase 1 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB sulfonylated piperazine derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB cis-n-oleoylcyclopropanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD diaryl piperazine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB (e)-n-(4-methoxyphenyl)undec-2-enamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 2-benzylbenzo[f]chromen-3-one NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD semiplenamide b NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,2,4-triazole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-347 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazolo[1,5-a]pyrimidine derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pf-514273 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD [3h]cp55940 NA NA investigative cannabinoid receptor 1 CNR1 Successful target agonist NA TTD , DGIDB aef0117 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cannabis Smoking[MeSHID:D008385] phase 2 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(methylsulfinyl)-n-(piperidin-1-yl)-1h-imidazole-4-carboxamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 2-cycloalkyl resorcinol cannabinoid ligand derivative 2 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-365 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1-(2-morpholinoethyl)-1h-indol-3-yl acetate NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD aminoazetidine derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrrole derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(1h-indazol-5-yl)icosa-5,8,11,14-tetraenamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD (1r,2s)-n-arachidonoylcyclopropanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD (1r,2r)-n-arachidonoylcyclopropanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(4-morpholinophenyl)docos-13-enamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-363 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD [3h]hu-243 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD nimacimab NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,2,4-tri-substituted imidazoline derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-120 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD heterocyclic-substituted 3-alkyl azetidine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 1-[bis(4-bromophenyl)methyl]-3-phenylthiourea NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD diphenyl purine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(2,4-dimethoxyphenethyl)oleamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD cxb-029 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD azetidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB semiplenamide a NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-342 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD (1s,2s)-n-oleoylcyclopropanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB ver-156084 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD (2r)-n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-2-hydroxypropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD bms-812204 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrano[2,3-b]pyridine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB anandamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target agonist 0.1 TTD , DGIDB pyrazole derivative 14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB benzimidazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 1,2,3-triazole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n,n-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 4-benzhydryl-n-butylpiperazine-1-carboxamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 4-cyanophenyl ethyl dodecylphosphonate NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB aminoazetidine derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB dronabinol small molecule Malignant Neoplasms[MeSHID:D009369],Nausea[MeSHID:D009325],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Anorexia[MeSHID:D000855],Vomiting[MeSHID:D014839],Weight decreased[MeSHID:D015431] approved,illicit cannabinoid receptor 1 CNR1 NA agonist 1.84 drugbank , DGIDB mk-5596 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(2-adamantyl)-n'-propylsulfamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 39 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-n-(1-hydroxy-2-methylpropan-2-yl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD hydrazide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazoline derivative 11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB taranabant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 3 cannabinoid receptor 1 CNR1 Successful target inverse agonist 4.08 TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational cannabinoid receptor 1 CNR1 NA antagonist,modulator,allosteric modulator 0.98 drugbank , DGIDB jd-5037 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] preclinical cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB am-1714 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-337 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 57 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-309 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(3,3-diphenyl)propyl-2-phenylacetamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD tak-937 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD heterocyclic-substituted 3-alkyl azetidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB aminoazetidine derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-373 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-oleoylethanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazoline derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB rac-cis-n-arachidonoylcyclopropanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD km-233-m NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazoline derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-348 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD azetidine-1-carboxamide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB diphenyl purine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-244 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD carbazole-3-carboxamide analog 1 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB heterocyclic-substituted 3-alkyl azetidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB marinol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100],Nausea[MeSHID:D009325],Anorexia Nervosa[MeSHID:D000856] approved cannabinoid receptor 1 CNR1 Successful target unknown 4.9 TTD , DGIDB am-630 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD azetidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-yl]-4,4,4-trifluoro-3-hydroxybutanamide (diastereomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown 1.63 TTD , DGIDB 1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,3,5-tris(4-chlorophenyl)imidazolidine-2,4-dione NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB aminoazetidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB sulfonamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB diphenyl purine derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-146 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 26 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-octadecyl-n'-propylsulfamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD imidazolidine-2,4-dione derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrrole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 53 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB am-4768 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD piperazine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(cis-9-cis-12-octadecadienyl)sulfamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD ver-156085 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB cbd cannabis derivative NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,2,4,5-tetra-substituted imidazole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB imidazole derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB propacetamol small molecule Fever[MeSHID:D005334],Dysmenorrhea[MeSHID:D004412] experimental cannabinoid receptor 1 CNR1 NA antagonist NA drugbank pyrazole derivative 35 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(4-methoxybenzyl)oleamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,2,3-triazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB azd2207 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] discontinued in phase 2 cannabinoid receptor 1 CNR1 Successful target antagonist 1.63 TTD , DGIDB pyrido[2,3-d]pyrimidine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB [3h]win55212-2 NA NA investigative cannabinoid receptor 1 CNR1 Successful target agonist NA TTD , DGIDB ave1625 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 2 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD taranabant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 3 cannabinoid receptor 1 CNR1 Successful target unknown 4.08 TTD , DGIDB phytocannabinoid/aminoalkylindole derivative 2 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 58 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-401 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-440 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-402 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-385 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-392 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD aminoazetidine derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB imidazolidine-2,4-dione derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazolo[1,5-a]pyrimidine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(arylalkyl)-1h-indole-2-sulfonic acid amide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(1-adamantyl)-n'-propylsulfamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD cp-4497 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB am-1241 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD purine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(4-methoxyphenethyl)oleamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pmid26161824c70 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 5-biphenyl-4-ylmethyl-2-isobutyl-2h-tetrazole NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-403 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD rac-trans-n-oleoylcyclopropanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-243 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD orlistat NA Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Overweight[MeSHID:D050177],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cannabinoid receptor 1 CNR1 Successful target unknown 0.16 TTD , DGIDB 3,4-diarylpyrazoline derivative NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,5-diphenylpyrrolidin-2-one derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB tetra-hydro-1h-1,2,6-triazaazulene derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB ricinoleic acid small molecule NA experimental cannabinoid receptor 1 CNR1 NA unknown NA drugbank n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-2-hydroxyacetamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-406 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-368 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(3-phenyl)propyl-2-(4-bromophenylacetamide) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD imidazole derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB (2s)-n-(7'-(2-chlorophenyl)-6'-(4-chlorophenyl)-3',4'-dihydrospiro[cyclohexane-1,2'-pyrano[2,3-b]pyridine]-4'-yl)-2-hydroxypropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD acea NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-308 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD cp-945598 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 3 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-346 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD sr141716a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] approved cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-367 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(3,3-diphenyl)propyl-2,2-diphenylacetamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD furopyridine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazoline derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 25 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB delta 8-tetrahydrocannobinol NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD a-796260 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazolo[1,5-a]pyrimidine derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB otenabant small molecule NA investigational cannabinoid receptor 1 CNR1 NA antagonist 3.26 drugbank , DGIDB jwh-293 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD benzimidazole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(3,5-dimethoxyphenethyl)oleamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD am-281 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 40 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB dodecane-1-sulfonyl fluoride NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational cannabinoid receptor 1 CNR1 NA antagonist,modulator 0.98 drugbank , DGIDB 1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)- NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(4-methoxyphenyl)oleamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(3,5-dimethoxyphenethyl)docos-13-enamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB cannabinol NA NA investigative cannabinoid receptor 1 CNR1 Successful target agonist 0.54 TTD , DGIDB diaryl morpholine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 31 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB imidazole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-246 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD (1r,2s)-n-oleoylcyclopropanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 5-methoxy-3-(2-methoxybenzyl)-2h-chromen-2-one NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 38 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB am-1715 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD nabilone small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cannabinoid receptor 1 CNR1 Successful target partial agonist 8.98 TTD , drugbank , DGIDB n-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-364 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pmid27215781-compound-37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB isopropyl 4-nitrophenyl dodecylphosphonate NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-3-hydroxy-2,2-dimethylpropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrido[2,3-d]pyrimidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 34 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-345 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD ly320135 NA NA investigative cannabinoid receptor 1 CNR1 Successful target antagonist NA TTD , DGIDB (2r)-n-(7'-(2-chlorophenyl)-6'-(4-chlorophenyl)-3',4'-dihydrospiro[cyclohexane-1,2'-pyrano[2,3-b]pyridine]-4'-yl)-2-hydroxypropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD o-arachidonoyl-n-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD imidazole derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB am-1710 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD km-233 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 60 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB tebipenem NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Nicotine Dependence[MeSHID:D014029],Urinary tract infection[MeSHID:D014552] phase 3 cannabinoid receptor 1 CNR1 Successful target unknown 1.63 TTD , DGIDB piperazine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-371 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazoline derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB ave-1625 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Obesity[MeSHID:D009765] investigational cannabinoid receptor 1 CNR1 NA unknown 3.26 drugbank , DGIDB (1s,2s)-n-arachidonoylcyclopropanolamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD aminoazetidine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazolo[1,5-a]pyrimidine derivative 13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB azd1175 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] discontinued in phase 1 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD semiplenamide g NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD am251 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pmid27215781-compound-2 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-405 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD slv319 small molecule Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , drugbank imidazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-156 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-324 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrrole derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-145 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-307 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-150 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD octane-1-sulfonyl fluoride NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB azetidine-1-carboxamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 27 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB medical cannabis biotech NA experimental,investigational cannabinoid receptor 1 CNR1 NA negative modulator NA drugbank pyrazole derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-404 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazoline derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 1,5-diphenylpyrrolidin-2-one derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB aminoazetidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB arachidonylcyclopropylamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-325 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-n-((r)-1-hydroxyethyl)-1,2,2-trimethyl-1,2,3,4-tetrahydro-1,8-naphthyridine-4-carboxamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(2,4-dimethoxyphenethyl)docos-13-enamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-3-hydroxypropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD dibenzothiazepines NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD nabilone small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cannabinoid receptor 1 CNR1 Successful target partial agonist,agonist 8.98 TTD , drugbank , DGIDB pyrazoline derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB tetrahydrocannabivarin small molecule NA investigational cannabinoid receptor 1 CNR1 NA antagonist NA drugbank 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-n-(hydroxymethyl)-1,2,2-trimethyl-1,2,3,4-tetrahydro-1,8-naphthyridine-4-carboxamide (enantiomeric mix) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD v-24343 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB naphthyridinone NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD azetidine-1-carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 1,5-bis(4-chlorophenyl)-1h-1,2,3-triazole NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD jwh-369 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 4-benzhydryl-n-cyclohexylpiperazine-1-carboxamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD v24343 small molecule Cardiovascular Diseases[MeSHID:D002318],Obesity[MeSHID:D009765],Disease[MeSHID:D004194],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational cannabinoid receptor 1 CNR1 NA unknown NA drugbank , DGIDB pyrazolo[1,5-a]pyrimidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB jwh-370 NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD 1,4-dihydroindeno[1,2-c]-pyrazole NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD aminoazetidine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 2-cycloalkyl resorcinol cannabinoid ligand derivative 1 NA NA patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB sulfonylated piperazine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB 1,2,4,5-tetra-substituted imidazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB n-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide NA NA investigative cannabinoid receptor 1 CNR1 Successful target unknown NA TTD pyrazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented cannabinoid receptor 1 CNR1 Successful target unknown NA TTD , DGIDB org27569 NA NA investigative cannabinoid receptor 1 CNR1 Successful target allosteric modulator NA TTD , DGIDB 4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-204 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-348 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-296 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD cis-n-oleoylcyclopropanolamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-368 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-369 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-314 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD rac-cis-n-arachidonoylcyclopropanolamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD isoquinoline derivative 2 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-365 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 1,3,5-triazine derivative 1 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB (e)-n-(4-methoxyphenyl)undec-2-enamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] patented cannabinoid receptor 2 CNR2 Successful target unknown 0.55 TTD , DGIDB 3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD km-233-m NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 5-biphenyl-4-ylmethyl-1-isobutyl-1h-tetrazole NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-372 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-(3,3-diphenyl)propyl-2,2-diphenylacetamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD hu-433 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD ar-xyz NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-11 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB [3h]cp55940 NA NA investigative cannabinoid receptor 2 CNR2 Successful target agonist NA TTD , DGIDB jwh-325 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-403 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD mda-19 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD sch-225336 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD tedalinab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 cannabinoid receptor 2 CNR2 Successful target agonist 4.39 TTD , DGIDB jwh-297 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-303 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-arachidonoyl-n-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-243 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD beta-caryophyllene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-308 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (2s)-n-(7'-(2-chlorophenyl)-6'-(4-chlorophenyl)-3',4'-dihydrospiro[cyclohexane-1,2'-pyrano[2,3-b]pyridine]-4'-yl)-2-hydroxypropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-133 NA NA investigative cannabinoid receptor 2 CNR2 Successful target agonist 2.19 TTD , DGIDB nabilone small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cannabinoid receptor 2 CNR2 Successful target partial agonist 9.88 TTD , drugbank , DGIDB sch-036 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-151 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD tetrahydrocannabivarin small molecule NA investigational cannabinoid receptor 2 CNR2 NA partial agonist NA drugbank jwh-401 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-248 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD gnf-pf-5188 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-402 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-307 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD dodeca-2e,4e-dienoic acid isobutylamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-305 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD gw-42004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 2 cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB sr144528 NA NA investigative cannabinoid receptor 2 CNR2 Successful target antagonist NA TTD , DGIDB jwh-244 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD tricyclic phytocannabinoid derivative 1 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-120 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD a-796260 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD apd371 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 2 cannabinoid receptor 2 CNR2 Successful target agonist NA TTD , DGIDB jwh-371 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD carbazole-3-carboxamide analog 1 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-312 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational cannabinoid receptor 2 CNR2 NA antagonist NA drugbank pravadoline NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (1r,2s)-n-oleoylcyclopropanolamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (e)-n-(3,5-dimethoxyphenethyl)undec-2-enamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-373 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-n-((r)-1-hydroxyethyl)-1,2,2-trimethyl-1,2,3,4-tetrahydro-1,8-naphthyridine-4-carboxamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (2r)-n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-2-hydroxypropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-(3-phenyl)propyl-2-(4-bromophenylacetamide) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD l-759,656 NA NA investigative cannabinoid receptor 2 CNR2 Successful target agonist NA TTD , DGIDB 4'-(1,1-dimethyl-heptyl)-3,5-dimethyl-biphenyl NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-249 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-364 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-344 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-347 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-207 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 842166x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB pmid27215781-compound-31 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-441 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-1714 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-167 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-407 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n,n-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB l-759,633 NA NA investigative cannabinoid receptor 2 CNR2 Successful target agonist NA TTD , DGIDB pmid27215781-compound-2 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB 4-benzhydryl-n-butylpiperazine-1-carboxamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-1241 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-205 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD [3h]hu-243 NA NA investigative cannabinoid receptor 2 CNR2 Successful target agonist NA TTD , DGIDB ver-156085 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n,n-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB tricyclic phytocannabinoid derivative 2 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB n-(2-chloroethyl)icosa-5,8,11,14-tetraenamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-29 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-406 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-404 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-313 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-306 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-343 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-370 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 1,4-dihydroindeno[1,2-c]-pyrazole NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 2-(2-methoxybenzyl)-3h-benzo[f]chromen-3-one NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-209 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD ricinoleic acid small molecule NA experimental cannabinoid receptor 2 CNR2 NA unknown NA drugbank guanfacine extended release NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Patient Discharge[MeSHID:D010351],Attention deficit hyperactivity disorder[MeSHID:D001289] approved cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB 4-benzhydryl-n-cyclohexylpiperazine-1-carboxamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-3-hydroxy-2,2-dimethylpropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-30 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB sch-356036 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-440 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-12 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-268 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-324 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD phytocannabinoid/aminoalkylindole derivative 2 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-345 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD rac-trans-n-oleoylcyclopropanolamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-27 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB nabilone small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cannabinoid receptor 2 CNR2 Successful target partial agonist,agonist 9.88 TTD , drugbank , DGIDB 3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-251 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-1715 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD naphthyridinone NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-3-hydroxypropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-19 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-392 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-34 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-202 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-145 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-206 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD o-arachidonoyl-n-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-n-(hydroxymethyl)-1,2,2-trimethyl-1,2,3,4-tetrahydro-1,8-naphthyridine-4-carboxamide (enantiomeric mix) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD isoquinoline derivative 1 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB pmid27215781-compound-28 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-245 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (2r)-n-(7'-(2-chlorophenyl)-6'-(4-chlorophenyl)-3',4'-dihydrospiro[cyclohexane-1,2'-pyrano[2,3-b]pyridine]-4'-yl)-2-hydroxypropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-367 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 5-biphenyl-4-ylmethyl-2-isobutyl-2h-tetrazole NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-281 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational cannabinoid receptor 2 CNR2 NA unknown NA drugbank jwh-346 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-(7'-(2-chlorophenyl)-6'-(4-chlorophenyl)-3',4'-dihydrospiro[cyclohexane-1,2'-pyrano[2,3-b]pyridine]-4'-yl)-2-hydroxy-2-methylpropanamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-385 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD rq-00202730 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-25 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB kn-38-7271 NA Ischemia[MeSHID:D007511],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-252 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-33 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB medical cannabis biotech NA experimental,investigational cannabinoid receptor 2 CNR2 NA unknown NA drugbank pmid27215781-compound-4 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-246 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (1r,2r)-n-arachidonoylcyclopropanolamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD dronabinol small molecule Malignant Neoplasms[MeSHID:D009369],Nausea[MeSHID:D009325],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Anorexia[MeSHID:D000855],Vomiting[MeSHID:D014839],Weight decreased[MeSHID:D015431] approved,illicit cannabinoid receptor 2 CNR2 NA agonist 0.82 drugbank , DGIDB jwh-302 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-309 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n1-(4-bromophenyl)-n2,n2-dipentylphthalamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD s-777469 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 cannabinoid receptor 2 CNR2 Successful target unknown 2.19 TTD , DGIDB khk-6188 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-292 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-4768 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD tedalinab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 cannabinoid receptor 2 CNR2 Successful target unknown 4.39 TTD , DGIDB jwh-150 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-(1h-indazol-5-yl)icosa-5,8,11,14-tetraenamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD delta 8-tetrahydrocannobinol NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n,n-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB (1r,2s)-n-arachidonoylcyclopropanolamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD tak-937 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-13 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-201 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD km-233 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-295 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD ly-2828360 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 cannabinoid receptor 2 CNR2 Successful target unknown 4.39 TTD , DGIDB n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-2-hydroxyacetamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD lasofoxifene small molecule Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Vagina[MeSHID:D014621],Fracture[MeSHID:D050723],Malignant neoplasm of breast[MeSHID:D001943],Risk Reduction[MeSHID:D040242],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844],Virus Diseases[MeSHID:D014777],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cannabinoid receptor 2 CNR2 NA inverse agonist NA drugbank 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-n-(1-hydroxy-2-methylpropan-2-yl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-323 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD phytocannabinoid/aminoalkylindole derivative 1 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB pmid27215781-compound-37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB 4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD ver-156084 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-294 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-208 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-405 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-arachidonoyl-o-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-363 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (1s,2s)-n-oleoylcyclopropanolamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-oleoyl-o-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-366 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-146 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-147 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-253 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD pmid27215781-compound-32 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB 3-benzyl-5-isopropyl-8-methylchromen-2-one NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-(7-(2-chlorophenyl)-6-(4-chlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-2-hydroxyacetamide (enantiomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD adamantyl derivative 1 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-442 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-203 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-237 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD isoquinoline derivative 3 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB 5-methoxy-3-(2-methoxybenzyl)-2h-chromen-2-one NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-311 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-yl]-4,4,4-trifluoro-3-hydroxybutanamide (diastereomeric mix) NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown 2.19 TTD , DGIDB jwh-404 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD [3h]win55212-2 NA NA investigative cannabinoid receptor 2 CNR2 Successful target agonist NA TTD , DGIDB 3,4-diarylpyrazoline derivative NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-337 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-1710 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-315 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-156 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-411 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD prs-211375 iv NA Prieto X-linked mental retardation syndrome[MeSHID:C535274],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD 2-cycloalkyl resorcinol cannabinoid ligand derivative 1 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB o-oleoyl-n-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD apd371 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 2 cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB 2-cycloalkyl resorcinol cannabinoid ligand derivative 2 NA NA patented cannabinoid receptor 2 CNR2 Successful target unknown NA TTD , DGIDB jwh-293 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-342 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-229 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD (e)-n-(4-methoxyphenethyl)undec-2-enamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD jwh-250 NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD n-oleoyl-n-(2-hydroxyethyl)hydroxylamine NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD am-630 NA NA investigative cannabinoid receptor 2 CNR2 Successful target antagonist 0.44 TTD , DGIDB (1s,2s)-n-arachidonoylcyclopropanolamide NA NA investigative cannabinoid receptor 2 CNR2 Successful target unknown NA TTD nt-501 cntf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 ciliary neurotrophic factor CNTF Clinical trial target unknown NA TTD , DGIDB nt-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Vision[MeSHID:D014785],Retinal macula[MeSHID:D008266],Eye[MeSHID:D005123],Retinitis Pigmentosa[MeSHID:D012174],Telangiectasis[MeSHID:D013684] phase 2/3 ciliary neurotrophic factor receptor alpha CNTFR Clinical trial target unknown 63.65 TTD , DGIDB pegcntf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1 ciliary neurotrophic factor receptor alpha CNTFR Clinical trial target unknown NA TTD , DGIDB endo-cd NA NA investigative endostatin COL18A1 Clinical trial target unknown NA TTD retinostat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 2 endostatin COL18A1 Clinical trial target unknown NA TTD , DGIDB clove oil biotech Disease[MeSHID:D004194],Abdominal colic[MeSHID:D003085],Flatulence[MeSHID:D005414],Toothache[MeSHID:D014098] approved,nutraceutical collagen alpha-1(i) chain COL1A1 NA unknown NA drugbank vonicog alfa biotech Disease[MeSHID:D004194],Diagnosis[MeSHID:D003933],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Hereditary Diseases[MeSHID:D030342],von Willebrand Disease[MeSHID:D014842],Malnutrition[MeSHID:D044342] approved,investigational collagen alpha-1(i) chain COL1A1 NA binder NA drugbank collagenase clostridium histolyticum biotech Cellulitis[MeSHID:D002481],Skin Ulcer[MeSHID:D012883],Congenital Abnormality[MeSHID:D000013],Body tissue[MeSHID:D014024],Diagnosis[MeSHID:D003933],Dupuytren Contracture[MeSHID:D004387],Burn injury[MeSHID:D002056],Peyronie Disease[MeSHID:D010411],Senile Plaques[MeSHID:D058225],penis[MeSHID:D010413],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] approved,investigational collagen alpha-1(i) chain COL1A1 NA binder NA drugbank , DGIDB halofuginone small molecule Scleroderma[MeSHID:D012594],Malignant Neoplasms[MeSHID:D009369],Systemic Scleroderma[MeSHID:D012595] investigational,vet_approved collagen alpha-1(i) chain COL1A1 NA unknown NA drugbank von willebrand factor human biotech Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Hereditary Diseases[MeSHID:D030342],von Willebrand Disease[MeSHID:D014842],Malnutrition[MeSHID:D044342] approved,investigational collagen alpha-1(i) chain COL1A1 NA binder NA drugbank collagenase clostridium histolyticum biotech Cellulitis[MeSHID:D002481],Skin Ulcer[MeSHID:D012883],Congenital Abnormality[MeSHID:D000013],Body tissue[MeSHID:D014024],Diagnosis[MeSHID:D003933],Dupuytren Contracture[MeSHID:D004387],Burn injury[MeSHID:D002056],Peyronie Disease[MeSHID:D010411],Senile Plaques[MeSHID:D058225],penis[MeSHID:D010413],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] approved,investigational collagen alpha-1(i) chain COL1A1 NA binder 2.27 drugbank , DGIDB solubilized type 1 native bovine collagen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Scleroderma[MeSHID:D012594] phase 2 collagen i COL1A2 Clinical trial target unknown NA TTD , DGIDB collagenase clostridium histolyticum biotech Cellulitis[MeSHID:D002481],Skin Ulcer[MeSHID:D012883],Congenital Abnormality[MeSHID:D000013],Body tissue[MeSHID:D014024],Diagnosis[MeSHID:D003933],Dupuytren Contracture[MeSHID:D004387],Burn injury[MeSHID:D002056],Peyronie Disease[MeSHID:D010411],Senile Plaques[MeSHID:D058225],penis[MeSHID:D010413],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] approved,investigational collagen alpha-1(ii) chain COL2A1 NA binder NA drugbank , DGIDB collagenase clostridium histolyticum biotech Cellulitis[MeSHID:D002481],Skin Ulcer[MeSHID:D012883],Congenital Abnormality[MeSHID:D000013],Body tissue[MeSHID:D014024],Diagnosis[MeSHID:D003933],Dupuytren Contracture[MeSHID:D004387],Burn injury[MeSHID:D002056],Peyronie Disease[MeSHID:D010411],Senile Plaques[MeSHID:D058225],penis[MeSHID:D010413],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] approved,investigational collagen alpha-1(ii) chain COL2A1 NA binder 2.27 drugbank , DGIDB collagenase clostridium histolyticum biotech Cellulitis[MeSHID:D002481],Skin Ulcer[MeSHID:D012883],Congenital Abnormality[MeSHID:D000013],Body tissue[MeSHID:D014024],Diagnosis[MeSHID:D003933],Dupuytren Contracture[MeSHID:D004387],Burn injury[MeSHID:D002056],Peyronie Disease[MeSHID:D010411],Senile Plaques[MeSHID:D058225],penis[MeSHID:D010413],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] approved,investigational collagen alpha-1(iii) chain COL3A1 NA binder 2.27 drugbank , DGIDB collagenase clostridium histolyticum biotech Cellulitis[MeSHID:D002481],Skin Ulcer[MeSHID:D012883],Congenital Abnormality[MeSHID:D000013],Body tissue[MeSHID:D014024],Diagnosis[MeSHID:D003933],Dupuytren Contracture[MeSHID:D004387],Burn injury[MeSHID:D002056],Peyronie Disease[MeSHID:D010411],Senile Plaques[MeSHID:D058225],penis[MeSHID:D010413],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] approved,investigational collagen alpha-1(iii) chain COL3A1 NA binder NA drugbank , DGIDB trc093 biotech Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational collagen alpha-4(iv) chain COL4A4 NA unknown NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical cartilage oligomeric matrix protein COMP NA unknown NA drugbank nialamide small molecule NA approved,withdrawn catechol o-methyltransferase COMT NA unknown NA drugbank opicapone small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational catechol o-methyltransferase COMT NA inhibitor 7.96 drugbank , DGIDB 6,7-dihydroxy-8-nitro-1-tetralone NA NA investigative catechol-o-methyl-transferase COMT Successful target unknown NA TTD bia small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental catechol o-methyltransferase COMT NA unknown NA drugbank tolcapone small molecule Secondary Parkinson Disease[MeSHID:D010302],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,withdrawn catechol o-methyltransferase COMT NA inhibitor 15.91 drugbank , DGIDB (3,4-dihydroxy-2-nitrophenyl)(phenyl)methanone NA NA investigative catechol-o-methyl-transferase COMT Successful target unknown NA TTD 1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone NA NA investigative catechol-o-methyl-transferase COMT Successful target unknown NA TTD bia 3-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 catechol-o-methyl-transferase COMT Successful target unknown NA TTD , DGIDB 5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one NA NA investigative catechol-o-methyl-transferase COMT Successful target unknown NA TTD bia NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative catechol-o-methyl-transferase COMT Successful target unknown NA TTD entacapone NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved catechol-o-methyl-transferase COMT Successful target inhibitor 16.91 TTD , DGIDB cgp-28014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 catechol-o-methyl-transferase COMT Successful target unknown NA TTD , DGIDB entacapone NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved catechol-o-methyl-transferase COMT Successful target unknown 16.91 TTD , DGIDB n-[(e)-3-[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]-2,3-dihydroxy-5-nitrobenzamide small molecule NA experimental catechol o-methyltransferase COMT NA unknown NA drugbank 3,5-dinitrocatechol small molecule NA experimental catechol o-methyltransferase COMT NA unknown NA drugbank nitecapone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 catechol-o-methyl-transferase COMT Successful target unknown NA TTD ademetionine small molecule Emotions[MeSHID:D004644],Degenerative polyarthritis[MeSHID:D010003],Depressive disorder[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Liver diseases[MeSHID:D008107],Bone Tissue[MeSHID:D001842],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] approved,investigational,nutraceutical catechol o-methyltransferase COMT NA cofactor NA drugbank 2-methoxyestradiol small molecule Arthritis[MeSHID:D001168],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of breast[MeSHID:D001943],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational catechol o-methyltransferase COMT NA unknown NA drugbank 7,8-dihydroxy-4-phenyl-2h-chromen-2-one NA NA investigative catechol-o-methyl-transferase COMT Successful target unknown NA TTD entacapone+levodopa+carbidopa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Restless Legs Syndrome[MeSHID:D012148] phase 3 catechol-o-methyl-transferase COMT Successful target unknown NA TTD , DGIDB entacapone small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational catechol o-methyltransferase COMT NA inhibitor 16.91 drugbank , DGIDB (3,4-dihydroxy-2-nitrophenyl)(phenyl)methanone small molecule NA experimental catechol o-methyltransferase COMT NA unknown NA drugbank 3,5-dinitrocatechol NA NA investigative catechol-o-methyl-transferase COMT Successful target unknown NA TTD tolcapone NA Secondary Parkinson Disease[MeSHID:D010302],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved catechol-o-methyl-transferase COMT Successful target unknown 15.91 TTD , DGIDB pgx-200097 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical catechol-o-methyl-transferase COMT Successful target unknown NA TTD , DGIDB 7,8-dihydroxy-4-phenyl-2h-chromen-2-one small molecule NA experimental catechol o-methyltransferase COMT NA unknown NA drugbank tolcapone NA Secondary Parkinson Disease[MeSHID:D010302],Parkinsonian Disorders[MeSHID:D020734],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved catechol-o-methyl-transferase COMT Successful target inhibitor 15.91 TTD , DGIDB opicapone NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved catechol-o-methyl-transferase COMT Successful target inhibitor 7.96 TTD , DGIDB opicapone NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved catechol-o-methyl-transferase COMT Successful target unknown 7.96 TTD , DGIDB 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone NA NA investigative catechol-o-methyl-transferase COMT Successful target unknown NA TTD sinapoyl coenzyme a small molecule NA experimental catechol o-methyltransferase domain-containing protein 1 COMTD1 NA unknown NA drugbank s-adenosyl-l-homocysteine small molecule NA experimental catechol o-methyltransferase domain-containing protein 1 COMTD1 NA unknown NA drugbank feruloyl coenzyme a small molecule NA experimental catechol o-methyltransferase domain-containing protein 1 COMTD1 NA unknown NA drugbank s-(dimethylarsenic)cysteine small molecule NA experimental coatomer subunit gamma-1 COPG1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational atypical kinase coq8a, mitochondrial COQ8A NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational atypical kinase coq8b, mitochondrial COQ8B NA inhibitor NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 4 isoform 1, mitochondrial COX4I1 NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 4 isoform 1, mitochondrial COX4I1 NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 5a, mitochondrial COX5A NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 5a, mitochondrial COX5A NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 5b, mitochondrial COX5B NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 5b, mitochondrial COX5B NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 6a2, mitochondrial COX6A2 NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 6a2, mitochondrial COX6A2 NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 6b1 COX6B1 NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 6b1 COX6B1 NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 6c COX6C NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 6c COX6C NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 7a1, mitochondrial COX7A1 NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 7a1, mitochondrial COX7A1 NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 7b, mitochondrial COX7B NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 7b, mitochondrial COX7B NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 7c, mitochondrial COX7C NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 7c, mitochondrial COX7C NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 8a, mitochondrial COX8A NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 8a, mitochondrial COX8A NA unknown NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical ceruloplasmin CP NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved ceruloplasmin CP NA unknown NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved ceruloplasmin CP NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational ceruloplasmin CP NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational ceruloplasmin CP NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ceruloplasmin CP NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental ceruloplasmin CP NA ligand NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational ceruloplasmin CP NA ligand NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved ceruloplasmin CP NA unknown NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved ceruloplasmin CP NA unknown NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved ceruloplasmin CP NA unknown NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational ceruloplasmin CP NA binder NA drugbank (s)-3-phenyllactic acid small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank dl-benzylsuccinic acid NA NA investigative carboxypeptidase a1 CPA1 Literature-reported target unknown NA TTD 2-benzyl-3-iodopropanoic acid small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank o-(((1r)-((n-phenylmethoxycarbonyl-l-alanyl)amino)ethyl)hydroxyphosphono)-l-benzylacetic acid small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank (2r)-2-benzyl-3-nitropropanoic acid small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank pmid18078750c1b NA NA investigative carboxypeptidase a1 CPA1 Literature-reported target unknown NA TTD l-[(n-hydroxyamino)carbonyl]phenylalanine small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank phenylalanine-n-sulfonamide small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank l-benzylsuccinic acid small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank d-[(n-hydroxyamino)carbonyl]phenylalanine small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank d-cysteine small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank o-(((1r)-((n-(phenyl-methoxy-carbonyl)-alanyl)-amino)methyl)hydroxyphosphinyl)3-l-phenyllactate small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank sq-14603 NA NA investigative carboxypeptidase a1 CPA1 Literature-reported target unknown NA TTD 2-thiomethyl-3-phenylpropanoic acid NA NA investigative carboxypeptidase a1 CPA1 Literature-reported target unknown NA TTD octane-1,3,5,7-tetracarboxylic acid small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank (2r)-4,4-dihydroxy-5-nitro-2-(phenylmethyl)pentanoic acid small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank n-carbamoylphenylalanine small molecule NA experimental carboxypeptidase a1 CPA1 NA unknown NA drugbank (2s)-2-[3-(aminomethyl)phenyl]-3-{(s)-hydroxy[(1r)-2-methyl-1-{[(2-phenylethyl)sulfonyl]amino}propyl]phosphoryl}propanoic acid small molecule NA experimental carboxypeptidase b CPB1 NA unknown NA drugbank us8710232, 7 NA NA patented carboxypeptidase b1 CPB1 Patented-recorded target unknown NA TTD , DGIDB (2s)-2-[3-(aminomethyl)phenyl]-3-[(r)-hydroxy{(1r)-2-methyl-1-[(phenylsulfonyl)amino]propyl}phosphoryl]propanoic acid small molecule NA experimental carboxypeptidase b CPB1 NA unknown NA drugbank 2-(3-guanidinophenyl)-3-mercaptopropanoic acid small molecule NA experimental carboxypeptidase b CPB1 NA unknown NA drugbank pmid14640538c3 NA NA investigative carboxypeptidase b1 CPB1 Patented-recorded target unknown NA TTD bx-528 small molecule NA experimental carboxypeptidase b CPB1 NA unknown NA drugbank us8710232, 1 NA NA patented carboxypeptidase b1 CPB1 Patented-recorded target unknown NA TTD , DGIDB (5r,6s,8s)-8-[3-(aminomethyl)phenyl]-6-hydroxy-5-isopropyl-3-oxo-1-phenyl-2,7-dioxa-4-aza-6-phosphanonan-9-oic acid 6-oxide small molecule NA experimental carboxypeptidase b CPB1 NA unknown NA drugbank pmid19954973c4 NA NA investigative carboxypeptidase b1 CPB1 Patented-recorded target unknown NA TTD (2s)-2-[3-(aminomethyl)phenyl]-3-[(r)-[(1r)-1-{[(benzyloxy)carbonyl]amino}-2-methylpropyl](hydroxy)phosphoryl]propanoic acid small molecule NA experimental carboxypeptidase b CPB1 NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved carboxypeptidase b CPB1 NA unknown NA drugbank (2s)-2-(3-carbamimidamidophenyl)-3-[hydroxy(3-phenylpropyl)phosphoryl]propanoic acid small molecule NA experimental carboxypeptidase b CPB1 NA unknown NA drugbank us8710232, 8 NA NA patented carboxypeptidase b1 CPB1 Patented-recorded target unknown NA TTD , DGIDB uk-396082 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 carboxypeptidase b2 CPB2 Clinical trial target unknown 63.65 TTD , DGIDB pmid14640538c3 NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD 2-(4-benzoylpiperidine-1-carbonyl)benzoic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD prothrombin biotech Malnutrition[MeSHID:D044342],Emergencies [Disease/Finding][MeSHID:D004630] approved carboxypeptidase b2 CPB2 NA agonist NA drugbank (+/-)-5-amino-2-(mercaptomethyl)pentanoic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD 2-(3-guanidinophenyl)-3-mercaptopropanoic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD sq-24798 NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD 2-(3-aminophenyl)-3-mercaptopropanoic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD mn-462 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD 3-mercapto-2-(piperidin-4-yl)propanoic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD 6-amino-2-(1h-imidazol-4-yl)-hexanoic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD sar-126119 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD , DGIDB dl-guanidinoethylmercaptosuccinic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD ds-1040 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD , DGIDB sar-104772 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD , DGIDB azd-9684 small molecule Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD , drugbank dl-benzylsuccinic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD pmid19954973c4 NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD 3-mercapto-2-(piperidin-3-yl)propanoic acid NA NA investigative carboxypeptidase b2 CPB2 Clinical trial target unknown NA TTD guanidinoethylmercaptosuccinic acid small molecule NA experimental carboxypeptidase d CPD NA unknown NA drugbank insulin human biotech Diabetes Mellitus[MeSHID:D003920] approved,investigational carboxypeptidase e CPE NA modulator,product of NA drugbank pmid14640538c3 NA NA investigative carboxypeptidase m CPM Literature-reported target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental carboxypeptidase n catalytic chain CPN1 NA cofactor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational carboxypeptidase n catalytic chain CPN1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational carboxypeptidase n catalytic chain CPN1 NA cofactor NA drugbank ore-1001 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational carboxypeptidase n catalytic chain CPN1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational carboxypeptidase n catalytic chain CPN1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational carboxypeptidase n subunit 2 CPN2 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational carboxypeptidase n subunit 2 CPN2 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental carboxypeptidase n subunit 2 CPN2 NA cofactor NA drugbank ore-1001 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational carboxypeptidase n subunit 2 CPN2 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational carboxypeptidase n subunit 2 CPN2 NA cofactor NA drugbank theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved copine-1 CPNE1 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical carboxypeptidase q CPQ NA unknown NA drugbank carglumic acid NA Hyperammonemia[MeSHID:D022124],Hyperammonemia, type III[MeSHID:C536109],Blood[MeSHID:D001769],Neurotoxicity Syndromes[MeSHID:D020258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbamoyl-phosphate synthetase i CPS1 Successful target positive modulator 31.83 TTD , DGIDB carglumic acid small molecule Hyperammonemia[MeSHID:D022124],Hyperammonemia, type III[MeSHID:C536109],Blood[MeSHID:D001769],Neurotoxicity Syndromes[MeSHID:D020258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbamoyl-phosphate synthase [ammonia], mitochondrial CPS1 NA allosteric modulator,positive modulator 31.83 drugbank , DGIDB carglumic acid NA Hyperammonemia[MeSHID:D022124],Hyperammonemia, type III[MeSHID:C536109],Blood[MeSHID:D001769],Neurotoxicity Syndromes[MeSHID:D020258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbamoyl-phosphate synthetase i CPS1 Successful target unknown NA TTD , DGIDB carglumic acid small molecule Hyperammonemia[MeSHID:D022124],Hyperammonemia, type III[MeSHID:C536109],Blood[MeSHID:D001769],Neurotoxicity Syndromes[MeSHID:D020258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbamoyl-phosphate synthase [ammonia], mitochondrial CPS1 NA allosteric modulator NA drugbank , DGIDB polidocanol - bioform medical/chemische fabrik kreussler & co NA Varicosity[MeSHID:D014648],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carbamoyl-phosphate synthetase i CPS1 Successful target unknown NA TTD , DGIDB levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational carnitine o-palmitoyltransferase 1, liver isoform CPT1A NA activator NA drugbank perhexiline small molecule Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carnitine o-palmitoyltransferase 1, liver isoform CPT1A NA inhibitor 81.84 drugbank , DGIDB glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved carnitine o-palmitoyltransferase 1, liver isoform CPT1A NA inhibitor NA drugbank perhexiline NA Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved carnitine o-palmitoyltransferase i CPT1B Successful target unknown 9.09 TTD , DGIDB levacecarnine hci NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved carnitine o-palmitoyltransferase i CPT1B Successful target unknown NA TTD , DGIDB c75 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative carnitine o-palmitoyltransferase i CPT1B Successful target unknown NA TTD sdz-cpi-975 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 1 carnitine o-palmitoyltransferase i CPT1B Successful target unknown NA TTD levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational carnitine o-palmitoyltransferase 2, mitochondrial CPT2 NA unknown NA drugbank perhexiline small molecule Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational carnitine o-palmitoyltransferase 2, mitochondrial CPT2 NA inhibitor 45.47 drugbank , DGIDB cdx-1135 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 complement receptor type 1 CR1 Clinical trial target unknown 31.83 TTD , DGIDB tt-30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 complement receptor type 2 CR2 Clinical trial target unknown NA TTD , DGIDB teglicar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 carnitine acyltransferase CRAT Discontinued target unknown NA TTD coenzyme a NA NA investigative carnitine acyltransferase CRAT Discontinued target unknown NA TTD levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational carnitine o-acetyltransferase CRAT NA unknown NA drugbank coenzyme a small molecule NA investigational,nutraceutical carnitine o-acetyltransferase CRAT NA unknown NA drugbank (3-carboxy-2-(r)-hydroxy-propyl)-trimethyl-ammonium small molecule NA experimental carnitine o-acetyltransferase CRAT NA unknown NA drugbank cc-220 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Sarcoidosis[MeSHID:D012507],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 protein cereblon CRBN Clinical trial target unknown 10.61 TTD , DGIDB thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved,investigational,withdrawn protein cereblon CRBN NA inhibitor 0.91 drugbank , DGIDB thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational,withdrawn protein cereblon CRBN NA inhibitor 0.91 drugbank , DGIDB pomalidomide small molecule Disease Progression[MeSHID:D018450],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595] approved protein cereblon CRBN NA inhibitor 18.56 drugbank , DGIDB lenalidomide small molecule Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein cereblon CRBN NA inhibitor 3.79 drugbank , DGIDB cc-122 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Liver carcinoma[MeSHID:D006528],Lymphoma[MeSHID:D008223],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant Neoplasms[MeSHID:D009369],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1 protein cereblon CRBN Clinical trial target unknown 21.22 TTD , DGIDB lenalidomide small molecule Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein cereblon CRBN NA inhibitor 3.79 drugbank , DGIDB adenosine phosphate small molecule NA approved,investigational,nutraceutical cyclic amp-responsive element-binding protein 1 CREB1 NA activator NA drugbank naloxone small molecule Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved,vet_approved cyclic amp-responsive element-binding protein 1 CREB1 NA unknown NA drugbank pri-724 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 creb-binding protein CREBBP Clinical trial target unknown 3.18 TTD , DGIDB ft-7051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 creb-binding protein CREBBP Clinical trial target unknown NA TTD 9-acetyl-2,3,4,9-tetrahydro-1h-carbazol-1-one small molecule NA experimental creb-binding protein CREBBP NA unknown NA drugbank ischemin NA NA investigative creb-binding protein CREBBP Clinical trial target inhibitor 3.18 TTD , DGIDB i-cbp112 NA NA investigative creb-binding protein CREBBP Clinical trial target inhibitor NA TTD , DGIDB pyrrolo-pyrrolone derivative 6 NA NA patented creb-binding protein CREBBP Clinical trial target unknown NA TTD , DGIDB c 82 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Scleroderma[MeSHID:D012594] phase 1/2 creb-binding protein CREBBP Clinical trial target unknown NA TTD , DGIDB sgc-cbp30 NA NA investigative creb-binding protein CREBBP Clinical trial target inhibitor NA TTD , DGIDB ccs1477 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 creb-binding protein CREBBP Clinical trial target unknown NA TTD corticotropin biotech Hypoaldosteronism[MeSHID:D006994],Diagnosis[MeSHID:D003933],Screening procedure[MeSHID:D008403],Autoimmune Diseases[MeSHID:D001327],Diabetic Nephropathy[MeSHID:D003928],Pituitary-dependent Cushing's disease[MeSHID:D047748],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved corticoliberin CRH NA agonist NA drugbank d-phenylalanine small molecule NA experimental corticoliberin CRH NA unknown NA drugbank 2-aminoisobutyric acid small molecule NA experimental corticoliberin CRH NA unknown NA drugbank pexacerfont NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2/3 corticotropin-releasing factor receptor 1 CRHR1 Successful target antagonist 15.91 TTD , DGIDB cp-376395 NA NA investigative corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD n-mesityl-6-methyl-3-tosylpyridin-2-amine NA NA investigative corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD cra1000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] preclinical corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD , DGIDB telavancin NA Staphylococcal Infections[MeSHID:D013203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown 5.3 TTD , DGIDB des-arg(9)-[leu(8)]-bk NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperargininemia[MeSHID:D020162],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigative corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD gsk586529 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] phase 1 corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD , DGIDB ono-2333ms NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown 15.91 TTD , DGIDB cp-316,311 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Mood Disorders[MeSHID:D019964],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 corticotropin-releasing factor receptor 1 CRHR1 Successful target antagonist NA TTD , DGIDB bms-561388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD ssr125543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Congenital adrenal hyperplasia[MeSHID:D000312] phase 2 corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown 10.61 TTD , DGIDB cp154,526 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigative corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD gsk561679 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Alcoholic Intoxication, Chronic[MeSHID:D000437],Unipolar Depression[MeSHID:D003866] phase 2 corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown 15.91 TTD , DGIDB pexacerfont NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2/3 corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown 15.91 TTD , DGIDB ono-2333ms NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 corticotropin-releasing factor receptor 1 CRHR1 Successful target antagonist 15.91 TTD , DGIDB ssr125543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Congenital adrenal hyperplasia[MeSHID:D000312] phase 2 corticotropin-releasing factor receptor 1 CRHR1 Successful target antagonist 10.61 TTD , DGIDB gw876008 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD cra1000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] preclinical corticotropin-releasing factor receptor 1 CRHR1 Successful target antagonist NA TTD , DGIDB pd-171729 NA NA investigative corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD n-mesityl-4,6-dimethyl-3-tosylpyridin-2-amine NA NA investigative corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD dmp-695/696 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigative corticotropin-releasing factor receptor 1 CRHR1 Successful target unknown NA TTD astressin NA NA investigative corticotropin-releasing factor receptor 2 CRHR2 Clinical trial target antagonist NA TTD , DGIDB rt-400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 corticotropin-releasing factor receptor 2 CRHR2 Clinical trial target unknown NA TTD urocortin 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 corticotropin-releasing factor receptor 2 CRHR2 Clinical trial target agonist NA TTD , DGIDB nbi-34041 NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 corticotropin-releasing factor receptor 2 CRHR2 Clinical trial target unknown NA TTD , DGIDB urocortin 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 2 corticotropin-releasing factor receptor 2 CRHR2 Clinical trial target unknown NA TTD , DGIDB levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational peroxisomal carnitine o-octanoyltransferase CROT NA unknown NA drugbank (3-carboxy-2-(r)-hydroxy-propyl)-trimethyl-ammonium small molecule NA experimental peroxisomal carnitine o-octanoyltransferase CROT NA unknown NA drugbank 3-carboxy-n,n,n-trimethyl-2-(octanoyloxy)propan-1-aminium small molecule NA experimental peroxisomal carnitine o-octanoyltransferase CROT NA unknown NA drugbank isis 329956 NA NA investigative crp messenger rna CRP Clinical trial target unknown NA TTD isis 133726 NA NA investigative crp messenger rna CRP Clinical trial target unknown NA TTD isis 140180 NA NA investigative crp messenger rna CRP Clinical trial target unknown NA TTD phosphocholine NA NA investigative crp messenger rna CRP Clinical trial target unknown NA TTD isis 330012 NA NA investigative crp messenger rna CRP Clinical trial target unknown NA TTD isis-crp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Inflammation[MeSHID:D007249] phase 1 crp messenger rna CRP Clinical trial target unknown NA TTD n,n,n-trimethyl-2-(phosphonooxy)ethanaminium small molecule NA experimental c-reactive protein CRP NA unknown NA drugbank isis 133712 NA NA investigative crp messenger rna CRP Clinical trial target unknown NA TTD crx-139 small molecule Rheumatoid Arthritis[MeSHID:D001172] investigational c-reactive protein CRP NA unknown NA drugbank isis-crprx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 2 crp messenger rna CRP Clinical trial target unknown NA TTD , DGIDB isis 330031 NA NA investigative crp messenger rna CRP Clinical trial target unknown NA TTD rtb101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Respiratory Tract Infections[MeSHID:D012141],Disease[MeSHID:D004194] phase 3 creb-regulated transcription coactivator 1 CRTC1 Clinical trial target unknown NA TTD shp656 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] preclinical cryptochrome circadian clock 1 CRY1 Preclinical target unknown NA TTD kl001 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] preclinical cryptochrome circadian clock 1 CRY1 Preclinical target unknown NA TTD th301 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] preclinical cryptochrome circadian clock 1 CRY1 Preclinical target unknown NA TTD 2-ethoxypropanoic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] preclinical cryptochrome circadian clock 1 CRY1 Preclinical target unknown NA TTD kl044 NA NA investigative cryptochrome circadian clock 1 CRY1 Preclinical target unknown NA TTD , DGIDB th301 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] preclinical cryptochrome-2 CRY2 Preclinical target unknown NA TTD shp656 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] preclinical cryptochrome-2 CRY2 Preclinical target unknown NA TTD kl001 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] preclinical cryptochrome-2 CRY2 Preclinical target unknown NA TTD 2-ethoxypropanoic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] preclinical cryptochrome-2 CRY2 Preclinical target unknown NA TTD nrp409 small molecule Hypothyroidism[MeSHID:D007037],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational ketimine reductase mu-crystallin CRYM NA unknown NA drugbank medical cannabis biotech NA experimental,investigational quinone oxidoreductase CRYZ NA inhibitor NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental quinone oxidoreductase CRYZ NA unknown NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational quinone oxidoreductase CRYZ NA inhibitor NA drugbank dicoumarol small molecule Deep Vein Thrombosis[MeSHID:D020246],Blood coagulation[MeSHID:D001777] approved quinone oxidoreductase CRYZ NA inhibitor NA drugbank coenzyme a small molecule NA investigational,nutraceutical citrate synthase, mitochondrial CS NA unknown NA drugbank trifluoroacetonyl coenzyme a small molecule NA experimental citrate synthase, mitochondrial CS NA unknown NA drugbank alpha-fluoro-carboxymethyldethia coenzyme a complex small molecule NA experimental citrate synthase, mitochondrial CS NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved citrate synthase, mitochondrial CS NA unknown NA drugbank oxaloacetate ion small molecule NA experimental citrate synthase, mitochondrial CS NA unknown NA drugbank nitromethyldethia coenzyme a small molecule NA experimental citrate synthase, mitochondrial CS NA unknown NA drugbank d-malic acid small molecule NA experimental citrate synthase, mitochondrial CS NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical cysteine sulfinic acid decarboxylase CSAD NA cofactor NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical cysteine sulfinic acid decarboxylase CSAD NA unknown NA drugbank plx73086 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 macrophage colony-stimulating factor 1 CSF1 Clinical trial target unknown NA TTD , DGIDB emactuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 macrophage colony-stimulating factor 1 CSF1 Clinical trial target unknown 15.91 TTD , DGIDB rg7155 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 macrophage colony-stimulating factor 1 CSF1 Clinical trial target unknown NA TTD , DGIDB msc110 NA Pigmented villonodular synovitis[MeSHID:D013586],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 macrophage colony-stimulating factor 1 CSF1 Clinical trial target unknown NA TTD arry-382 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 colony stimulating factor-1 receptor CSF1R Clinical trial target unknown 3.18 TTD , DGIDB sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown 0.21 TTD , DGIDB pmid28270010-compound-figure24-a NA NA patented macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB fpa-008 NA Pigmented villonodular synovitis[MeSHID:D013586],Diabetes, Autoimmune[MeSHID:D003922],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Tumors[MeSHID:D005870] phase 1/2 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB 5-cyano-furan-2-carboxylic acid [5-hydroxymethyl-2-(4-methyl-piperidin-1-yl)-phenyl]-amide small molecule NA experimental macrophage colony-stimulating factor 1 receptor CSF1R NA unknown NA drugbank pexidartinib small molecule Giant Cell Tumors[MeSHID:D005870],Operative Surgical Procedures[MeSHID:D013514],Testicular Germ Cell Tumor[MeSHID:C563236],Pigmented villonodular synovitis[MeSHID:D013586],Neurofibromatosis 1[MeSHID:D009456],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational macrophage colony-stimulating factor 1 receptor CSF1R Successful target inhibitor 0.96 TTD , drugbank , DGIDB dcc-3014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB arry-382 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 colony stimulating factor-1 receptor CSF1R Clinical trial target inhibitor 3.18 TTD , DGIDB tpx-0022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD pyridine derivative 22 NA NA patented macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB mcs-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Giant Cell Tumors[MeSHID:D005870],Malignant Neoplasms[MeSHID:D009369],Triple Negative Breast Neoplasms[MeSHID:D064726],Bone Tissue[MeSHID:D001842],Malignant neoplasm of breast[MeSHID:D001943] phase 2 colony stimulating factor-1 receptor CSF1R Clinical trial target unknown 1.06 TTD , DGIDB ei1071 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD gw-2580 NA NA investigative csf1r messenger rna CSF1R Literature-reported target inhibitor NA TTD , DGIDB rg7155 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 colony stimulating factor-1 receptor CSF1R Clinical trial target unknown NA TTD , DGIDB pd-360324 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 colony stimulating factor-1 receptor CSF1R Clinical trial target unknown 1.06 TTD , DGIDB arry-382 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 macrophage colony-stimulating factor 1 receptor CSF1R Successful target inhibitor 3.18 TTD , DGIDB amg 820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 colony stimulating factor-1 receptor CSF1R Clinical trial target unknown NA TTD , DGIDB 6-chloro-3-(3-methylisoxazol-5-yl)-4-phenylquinolin-2(1h)-one small molecule NA experimental macrophage colony-stimulating factor 1 receptor CSF1R NA unknown NA drugbank pyridine derivative 18 NA NA patented macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB plx7486 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved macrophage colony-stimulating factor 1 receptor CSF1R NA antagonist 0.22 drugbank , DGIDB cabiralizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 macrophage colony-stimulating factor 1 receptor CSF1R Successful target antibody 1.06 TTD , DGIDB axatilamab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational macrophage colony-stimulating factor 1 receptor CSF1R NA unknown 0.06 drugbank , DGIDB erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational macrophage colony-stimulating factor 1 receptor CSF1R NA substrate NA drugbank jnj-40346527 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689] phase 2 colony stimulating factor-1 receptor CSF1R Clinical trial target unknown 1.06 TTD , DGIDB dcc-3014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB arry-382 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown 3.18 TTD , DGIDB cabiralizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown 1.06 TTD , DGIDB pyridine derivative 19 NA NA patented macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB gtp-14564 NA NA investigative csf1r messenger rna CSF1R Literature-reported target inhibitor 0.27 TTD , DGIDB ki-20227 NA NA investigative csf1r messenger rna CSF1R Literature-reported target inhibitor 0.27 TTD , DGIDB fpa-008 NA Pigmented villonodular synovitis[MeSHID:D013586],Diabetes, Autoimmune[MeSHID:D003922],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Tumors[MeSHID:D005870] phase 1/2 colony stimulating factor-1 receptor CSF1R Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational macrophage colony-stimulating factor 1 receptor CSF1R NA inhibitor NA drugbank pyridine derivative 20 NA NA patented macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational macrophage colony-stimulating factor 1 receptor CSF1R NA inhibitor 0.06 drugbank , DGIDB jnj-28312141 NA NA investigative csf1r messenger rna CSF1R Literature-reported target inhibitor 0.21 TTD , DGIDB jnj-40346527 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689] phase 2 colony stimulating factor-1 receptor CSF1R Clinical trial target inhibitor 1.06 TTD , DGIDB absk021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD blz-945 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Malignant Neoplasms[MeSHID:D009369] phase 2 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB pyridine derivative 21 NA NA patented macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB imc-cs4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 colony stimulating factor-1 receptor CSF1R Clinical trial target unknown 1.06 TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved macrophage colony-stimulating factor 1 receptor CSF1R NA antagonist 0.22 drugbank , DGIDB sunitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved,investigational macrophage colony-stimulating factor 1 receptor CSF1R NA inhibitor 0.08 drugbank , DGIDB sndx-6352 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB dcc-3014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB gw-2580 NA NA investigative csf1r messenger rna CSF1R Literature-reported target unknown NA TTD , DGIDB dcc-3014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 macrophage colony-stimulating factor 1 receptor CSF1R Successful target unknown NA TTD , DGIDB gsk3196165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 2.33 TTD , DGIDB lenzilumab NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 3.1 TTD , DGIDB autologous melanoma cell vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Cells[MeSHID:D002477] phase 1 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown NA TTD , DGIDB jx-594 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Malignant neoplasm of liver[MeSHID:D008113] phase 3 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 1.55 TTD , DGIDB kb002 small molecule Rheumatoid Arthritis[MeSHID:D001172] investigational granulocyte-macrophage colony-stimulating factor CSF2 NA unknown NA drugbank , DGIDB kb-003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target inhibitor 3.1 TTD , DGIDB cabiralizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 0.78 TTD , DGIDB morab-022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922],Rheumatoid Arthritis[MeSHID:D001172] phase 1 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 1.55 TTD , DGIDB cgtg-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown NA TTD , DGIDB kb-003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 3.1 TTD , DGIDB talimogene laherparepvec NA Brain[MeSHID:D001921],melanoma[MeSHID:D008545],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Lung[MeSHID:D008168],Bone Tissue[MeSHID:D001842],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown NA TTD , DGIDB kb002/003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown NA TTD , DGIDB cdna vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown NA TTD , DGIDB mavrilimumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 0.78 TTD , DGIDB human monoclonal antibodies (gm-csf) NA NA investigative granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown NA TTD mt203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 4.66 TTD , DGIDB lenzilumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464],Disease[MeSHID:D004194] phase 2 granulocyte-macrophage colony-stimulating factor CSF2 Successful target unknown 3.1 TTD , DGIDB regramostim biotech NA investigational granulocyte-macrophage colony-stimulating factor receptor subunit alpha CSF2RA NA unknown NA drugbank sargramostim NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gmcsfr-alpha CSF2RA Successful target unknown 47.74 TTD , DGIDB bbt-007 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] investigative gmcsfr-alpha CSF2RA Successful target unknown NA TTD foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved granulocyte-macrophage colony-stimulating factor receptor subunit alpha CSF2RA NA agonist NA drugbank mor-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1/2 gmcsfr-alpha CSF2RA Successful target unknown 5.3 TTD , DGIDB kb002 small molecule Rheumatoid Arthritis[MeSHID:D001172] investigational granulocyte-macrophage colony-stimulating factor receptor subunit alpha CSF2RA NA unknown NA drugbank kb002 small molecule Rheumatoid Arthritis[MeSHID:D001172] investigational gm-csf receptor alpha subunit CSF2RA NA unknown NA drugbank sargramostim biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational granulocyte-macrophage colony-stimulating factor receptor subunit alpha CSF2RA NA agonist 47.74 drugbank , DGIDB regramostim biotech NA investigational gm-csf receptor alpha subunit CSF2RA NA unknown NA drugbank mavrilimumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 gmcsfr-alpha CSF2RA Successful target unknown 15.91 TTD , DGIDB aftvac NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 gmcsfr-alpha CSF2RA Successful target unknown NA TTD , DGIDB mavrilimumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 gmcsfr-alpha CSF2RA Successful target antibody 15.91 TTD , DGIDB clove oil biotech Disease[MeSHID:D004194],Abdominal colic[MeSHID:D003085],Flatulence[MeSHID:D005414],Toothache[MeSHID:D014098] approved,nutraceutical granulocyte-macrophage colony-stimulating factor receptor subunit alpha CSF2RA NA unknown NA drugbank molgramostim NA Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],PULMONARY ALVEOLAR PROTEINOSIS, ACQUIRED[MeSHID:C567049] phase 3 gmcsfr-alpha CSF2RA Successful target unknown 10.61 TTD , DGIDB kh-901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 gmcsfr-alpha CSF2RA Successful target unknown NA TTD , DGIDB foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved granulocyte-macrophage colony-stimulating factor receptor subunit alpha CSF2RA NA agonist NA drugbank gm-csf cancer vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 gmcsfr-alpha CSF2RA Successful target unknown NA TTD , DGIDB b-cell lymphoma vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],B-Cell Lymphomas[MeSHID:D016393] preregistration gmcsfr-alpha CSF2RA Successful target unknown NA TTD , DGIDB myeloma cancer vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 gmcsfr-alpha CSF2RA Successful target unknown NA TTD , DGIDB pixykine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 3 gmcsfr-alpha CSF2RA Successful target unknown 10.61 TTD , DGIDB sargramostim NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gmcsfr-alpha CSF2RA Successful target agonist 47.74 TTD , DGIDB leukemia cancer vaccine NA leukemia[MeSHID:D007938],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gmcsfr-alpha CSF2RA Successful target unknown NA TTD , DGIDB dt388il-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 interleukin 3 receptor CSF2RB Clinical trial target unknown NA TTD , DGIDB csl-362 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 interleukin 3 receptor CSF2RB Clinical trial target unknown 7.96 TTD , DGIDB tpi asm8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 interleukin 3 receptor CSF2RB Clinical trial target unknown NA TTD , DGIDB sl-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Leukemia, Myelocytic, Acute[MeSHID:D015470],Myeloproliferative disease[MeSHID:D009196],Neoplasms[MeSHID:D009369],Plasmacytoid Dendritic Cells[MeSHID:D003713] phase 1/2 interleukin 3 receptor CSF2RB Clinical trial target unknown 7.96 TTD , DGIDB resatorvid small molecule Sepsis[MeSHID:D018805],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cytokine receptor common subunit beta CSF2RB NA unknown NA drugbank sargramostim biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytokine receptor common subunit beta CSF2RB NA agonist 47.74 drugbank , DGIDB npi 32101 small molecule Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876] investigational cytokine receptor common subunit beta CSF2RB NA unknown NA drugbank leridistim NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] phase 2 interleukin 3 receptor CSF2RB Clinical trial target unknown 15.91 TTD , DGIDB neugranin NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] preregistration granulocyte colony-stimulating factor CSF3 Successful target unknown NA TTD , DGIDB f-627 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 2 granulocyte colony-stimulating factor CSF3 Successful target unknown 15.91 TTD , DGIDB interleukin-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aplastic Anemia[MeSHID:D000741] approved granulocyte colony-stimulating factor CSF3 Successful target unknown 7.96 TTD , DGIDB da-3031 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 3 granulocyte colony-stimulating factor CSF3 Successful target unknown NA TTD , DGIDB la-ep2006 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 3 granulocyte colony-stimulating factor CSF3 Successful target unknown NA TTD , DGIDB spi-2012 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 granulocyte colony-stimulating factor CSF3 Successful target unknown 15.91 TTD , DGIDB mk-4214 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 3 granulocyte colony-stimulating factor CSF3 Successful target unknown NA TTD , DGIDB zp-g-csf NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] investigative granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD tg-3003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD maxy-g34 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 2 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD , DGIDB csl-324 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD amg 820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD , DGIDB filgrastim biotech Malignant Neoplasms[MeSHID:D009369],Radiation[MeSHID:D011827],Severe congenital neutropenia[MeSHID:C537592],Communicable Diseases[MeSHID:D003141],Febrile Neutropenia[MeSHID:D064147],Cyclic neutropenia[MeSHID:C536227],Leukopenia[MeSHID:D007970],Infection[MeSHID:D007239],Neutropenia[MeSHID:D009503],Leukemia, Myelocytic, Acute[MeSHID:D015470],Blood[MeSHID:D001769],Ulcer[MeSHID:D014456],Leukocytes[MeSHID:D007962],Fever[MeSHID:D005334],Hematopoietic stem cells[MeSHID:D006412],Electromagnetic Radiation[MeSHID:D060733],neutrophil[MeSHID:D009504] approved granulocyte colony-stimulating factor receptor CSF3R NA stimulator 8.27 drugbank , DGIDB blz-945 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Malignant Neoplasms[MeSHID:D009369] phase 2 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD , DGIDB sbc-014 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 2 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD , DGIDB g-csf NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative granulocyte colony-stimulating factor receptor CSF3R Successful target agonist 8.27 TTD , DGIDB peg-g-csf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD , DGIDB azd-7507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD n-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide NA NA investigative granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD ac-710 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD tbo-filgrastim NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] approved granulocyte colony-stimulating factor receptor CSF3R Successful target unknown 8.27 TTD , DGIDB pegfilgrastim biotech Malignant Neoplasms[MeSHID:D009369],Communicable Diseases[MeSHID:D003141],Febrile Neutropenia[MeSHID:D064147],Exposure to radiation[MeSHID:D000069079],Continuance of life[MeSHID:D013534],Infection[MeSHID:D007239],Acute Radiation Syndrome[MeSHID:D054508],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved granulocyte colony-stimulating factor receptor CSF3R Successful target agonist 100.02 TTD , drugbank , DGIDB plx7486 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD , DGIDB lipegfilgrastim biotech Malignant Neoplasms[MeSHID:D009369],Febrile Neutropenia[MeSHID:D064147],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukopenia[MeSHID:D007970],Neutropenia[MeSHID:D009503],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational granulocyte colony-stimulating factor receptor CSF3R NA agonist 9.09 drugbank , DGIDB mk-6302 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 1 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD , DGIDB ax-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown NA TTD , DGIDB filgrastim biotech Malignant Neoplasms[MeSHID:D009369],Radiation[MeSHID:D011827],Severe congenital neutropenia[MeSHID:C537592],Communicable Diseases[MeSHID:D003141],Febrile Neutropenia[MeSHID:D064147],Cyclic neutropenia[MeSHID:C536227],Leukopenia[MeSHID:D007970],Infection[MeSHID:D007239],Neutropenia[MeSHID:D009503],Leukemia, Myelocytic, Acute[MeSHID:D015470],Blood[MeSHID:D001769],Ulcer[MeSHID:D014456],Leukocytes[MeSHID:D007962],Fever[MeSHID:D005334],Hematopoietic stem cells[MeSHID:D006412],Electromagnetic Radiation[MeSHID:D060733],neutrophil[MeSHID:D009504] approved granulocyte colony-stimulating factor receptor CSF3R NA stimulator,agonist 8.27 drugbank , DGIDB plx-5622 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 granulocyte colony-stimulating factor receptor CSF3R Successful target unknown 9.09 TTD , DGIDB lenograstim biotech Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Severe congenital neutropenia[MeSHID:C537592],Communicable Diseases[MeSHID:D003141],Neutropenia, severe chronic[MeSHID:C535815],Blood Cells[MeSHID:D001773],Leukopenia[MeSHID:D007970],Infection[MeSHID:D007239],Neutropenia[MeSHID:D009503] approved,investigational granulocyte colony-stimulating factor receptor CSF3R NA agonist NA drugbank favid small molecule B-Cell Lymphomas[MeSHID:D016393] investigational granulocyte colony-stimulating factor receptor CSF3R NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase csk CSK NA unknown NA drugbank tg-100801 small molecule Age related macular degeneration[MeSHID:D008268] investigational tyrosine-protein kinase csk CSK NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase csk CSK NA unknown NA drugbank staurosporine small molecule NA experimental tyrosine-protein kinase csk CSK NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase csk CSK NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational kappa-casein CSN3 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational casein kinase i isoform alpha CSNK1A1 NA inhibitor NA drugbank umbralisib NA Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved casein kinase i epsilon CSNK1E Successful target inhibitor 4.55 TTD , DGIDB pf-4800567 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] preclinical casein kinase i epsilon CSNK1E Successful target inhibitor 4.55 TTD , DGIDB ic261 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] preclinical casein kinase i epsilon CSNK1E Successful target inhibitor 1.01 TTD , DGIDB umbralisib small molecule Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved,investigational casein kinase i isoform epsilon CSNK1E NA inhibitor 4.55 drugbank , DGIDB seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational casein kinase i isoform epsilon CSNK1E NA unknown NA drugbank pf-670462 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] preclinical casein kinase i epsilon CSNK1E Successful target inhibitor 2.27 TTD , DGIDB 2-({6-[(3-chlorophenyl)amino]-9-isopropyl-9h-purin-2-yl}amino)ethanol small molecule NA experimental casein kinase i isoform gamma-1 CSNK1G1 NA unknown NA drugbank n-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide small molecule NA experimental casein kinase i isoform gamma-2 CSNK1G2 NA unknown NA drugbank 5-iodotubercidin small molecule NA experimental casein kinase i isoform gamma-2 CSNK1G2 NA unknown NA drugbank ic261 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] experimental casein kinase i isoform gamma-2 CSNK1G2 NA unknown NA drugbank {4-amino-2-[(4-methoxyphenyl)amino]-1,3-thiazol-5-yl}(4-methoxyphenyl)methanone small molecule NA experimental casein kinase i isoform gamma-3 CSNK1G3 NA unknown NA drugbank k-00546 small molecule NA experimental casein kinase i isoform gamma-3 CSNK1G3 NA unknown NA drugbank purvalanol a small molecule NA experimental casein kinase i isoform gamma-3 CSNK1G3 NA unknown NA drugbank 4-amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium small molecule NA experimental casein kinase i isoform gamma-3 CSNK1G3 NA unknown NA drugbank cx-5011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD n,n'-diphenylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank atp small molecule NA investigational,nutraceutical casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD 1,8-di-hydroxy-4-nitro-anthraquinone small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank n1,n2-ethylene-2-methylamino-4,5,6,7-tetrabromo-benzimidazole small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank pmid22115617c2c NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD 5,6,8-trichloroquinoline-4-one-3-carboxylic acid NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD cgp-029482 NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5h-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9h)-one small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank benzamidine small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank 5,8-di-amino-1,4-dihydroxy-anthraquinone small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank 7,8-dichloroquinoline-4-one-3-carboxylic acid NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD 2-(cyclohexylmethylamino)-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank tetrabromo-2-benzotriazole small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank s-methyl-4,5,6,7-tetrabromo-benzimidazole small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational casein kinase ii subunit alpha CSNK2A1 NA inhibitor NA drugbank apigenin NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD 2-(4-chlorobenzylamino)-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational casein kinase ii subunit alpha CSNK2A1 NA inhibitor NA drugbank emodin small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank pmid24900749c1a NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzimidazole NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD n-(3-(8-cyano-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazin-2-ylamino)phenyl)acetamide small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank cx-4945 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Coronavirus Infections[MeSHID:D018352],Cholangiocarcinoma[MeSHID:D018281] phase 2 casein kinase ii alpha CSNK2A1 Clinical trial target unknown 3.18 TTD , DGIDB cx-7000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD phosphoaminophosphonic acid-adenylate ester small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank adoc(dpr)2alaarg6 NA NA investigative casein kinase ii alpha CSNK2A1 Clinical trial target unknown NA TTD quinalizarin small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank dichlororibofuranosylbenzimidazole small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank 3,8-dibromo-7-hydroxy-4-methyl-2h-chromen-2-one small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank 2-(4-ethylpiperazin-1-yl)-4-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank 1,8-di-hydroxy-4-nitro-xanthen-9-one small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank 4-(2-(1h-imidazol-4-yl)ethylamino)-2-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile small molecule NA experimental casein kinase ii subunit alpha CSNK2A1 NA unknown NA drugbank [1-(6-{6-[(1-methylethyl)amino]-1h-indazol-1-yl}pyrazin-2-yl)-1h-pyrrol-3-yl]acetic acid small molecule NA experimental casein kinase ii subunit alpha' CSNK2A2 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational casein kinase ii subunit alpha' CSNK2A2 NA inhibitor NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational casein kinase ii subunit beta CSNK2B NA unknown NA drugbank atp small molecule NA investigational,nutraceutical casein kinase ii subunit beta CSNK2B NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational cysteine and glycine-rich protein 1 CSRP1 NA ligand NA drugbank cupric chloride small molecule Solutions[MeSHID:D012996],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cystatin-b CSTB NA unknown NA drugbank gsk-2241658a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 cancer/testis antigen 1 CTAG1A Clinical trial target unknown NA TTD ny-eso-1 vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cancer/testis antigen 1 CTAG1A Clinical trial target unknown NA TTD anti-ny-eso-1 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Esophageal Neoplasms[MeSHID:D004938],synovial sarcoma[MeSHID:D013584],Malignant neoplasm of lung[MeSHID:D008175],Cells[MeSHID:D002477] phase 1/2 cancer/testis antigen 1 CTAG1A Clinical trial target unknown NA TTD cv-9201 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 cancer/testis antigen 1 CTAG1A Clinical trial target unknown NA TTD gsk3901961 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cancer/testis antigen 1 CTAG1A Clinical trial target unknown NA TTD gsk3845097 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cancer/testis antigen 1 CTAG1A Clinical trial target unknown NA TTD melanoma vaccine (alvac) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 2 cancer/testis antigen 1 CTAG1A Clinical trial target unknown NA TTD cdx-1401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 cancer/testis antigen 1 CTAG1A Clinical trial target unknown NA TTD formic acid small molecule NA experimental,investigational c-terminal-binding protein 1 CTBP1 NA unknown NA drugbank aspartate beryllium trifluoride small molecule NA experimental carboxy-terminal domain rna polymerase ii polypeptide a small phosphatase 1 CTDSP1 NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved carboxy-terminal domain rna polymerase ii polypeptide a small phosphatase 1 CTDSP1 NA unknown NA drugbank cardiotrophin-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver Failure, Acute[MeSHID:D017114] phase 1 cardiotrophin-1 CTF1 Clinical trial target unknown NA TTD , DGIDB ocaperidone NA Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] phase 2 connective tissue growth factor CTGF Clinical trial target unknown NA TTD exc 001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355] phase 2 ctgf messenger rna CTGF Clinical trial target unknown NA TTD 2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-imino]-5-phosphono-pent-3-enoic acid small molecule NA experimental cystathionine gamma-lyase CTH NA unknown NA drugbank carboxymethylthio-3-(3-chlorophenyl)-1,2,4-oxadiazol small molecule NA experimental cystathionine gamma-lyase CTH NA unknown NA drugbank l-2-amino-3-butynoic acid small molecule NA experimental cystathionine gamma-lyase CTH NA unknown NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical cystathionine gamma-lyase CTH NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical cystathionine gamma-lyase CTH NA cofactor NA drugbank ipilimumab biotech melanoma[MeSHID:D008545],Cutaneous Melanoma[MeSHID:C562393],Renal Cell Carcinoma[MeSHID:D002292],Neoplasm Metastasis[MeSHID:D009362],Mismatch Repair[MeSHID:D053843],Liver carcinoma[MeSHID:D006528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytotoxic t-lymphocyte protein 4 CTLA4 Successful target inhibitor,antibody 6.37 TTD , drugbank , DGIDB tremelimumab + medi0562 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD , DGIDB xmab20717 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],melanoma[MeSHID:D008545] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD concatameric ctla4ig NA NA investigative cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD gx-c4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD alpha-d-mannose NA NA investigative cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD kn046 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD xmab22841 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD ak104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],cervical cancer[MeSHID:D002583] phase 2 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD tremelimumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant mesothelioma[MeSHID:C562839],Malignant Neoplasms[MeSHID:D009369] investigational,phase 3 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target inhibitor,antibody 21.22 TTD , drugbank , DGIDB adg116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD agen1181 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD onc-392 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD fucose NA NA investigative cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD alpn-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD ctla-4-xten NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD mgd019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD mk-1308 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD , DGIDB bms-986249 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD agen1884 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],cervical cancer[MeSHID:D002583] phase 1/2 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown 3.54 TTD , DGIDB si-b003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD del 60 tetramer NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Chromosome Deletion[MeSHID:D002872] investigative cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD bms-986288 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD medi5752 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cytotoxic t-lymphocyte protein 4 CTLA4 Successful target unknown NA TTD urea small molecule Catabolism[MeSHID:D008660],Disease[MeSHID:D004194],Nail plate[MeSHID:D009262],patient care[MeSHID:D005791],Proteolysis[MeSHID:D059748],Lanugo[MeSHID:D006197],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved,investigational catenin beta-1 CTNNB1 NA unknown NA drugbank ceq-508 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenomatous Polyposis Coli[MeSHID:D011125] phase 1/2 beta-catenin CTNNB1 Successful target unknown NA TTD , DGIDB c 82 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Scleroderma[MeSHID:D012594] phase 1/2 beta-catenin CTNNB1 Successful target unknown NA TTD , DGIDB recombinant human endostatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved beta-catenin CTNNB1 Successful target unknown NA TTD , DGIDB cystine small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] approved,nutraceutical cystinosin CTNS NA unknown NA drugbank cylopentenyl cytosine NA NA investigative ctp synthase CTPS1 Clinical trial target unknown NA TTD l-glutamine small molecule Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Short Bowel Syndrome[MeSHID:D012778] approved,investigational,nutraceutical ctp synthase 1 CTPS1 NA antagonist,substrate NA drugbank carbodine NA NA investigative ctp synthase CTPS1 Clinical trial target unknown NA TTD acivicin NA NA discontinued in phase 3 ctp synthase CTPS1 Clinical trial target unknown NA TTD cyclopentenylcytosine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ctp synthase CTPS1 Clinical trial target unknown NA TTD , DGIDB 2-methyl-2,4-pentanediol NA NA investigative ctp synthase CTPS1 Clinical trial target unknown NA TTD cyclopentylcytosine NA NA investigative ctp synthase CTPS1 Clinical trial target unknown NA TTD alpha-methyl-2-hydroxy-4-diethylaminocinnamic acid small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank l-1-naphthyl-2-acetamido-ethane boronic acid small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank aprotinin biotech Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn chymotrypsinogen b CTRB1 NA unknown NA drugbank d-1-naphthyl-2-acetamido-ethane boronic acid small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank 1,1,1-trifluoro-3-acetamido-4-phenyl butan-2-one(n-acetyl-l-phenylalanyl trifluoromethyl ketone) small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank phenylethane boronic acid small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank phenylalanylmethylchloride small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank 2,4-dihydroxy-trans cinnamic acid small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank trans-o-hydroxy-alpha-methyl cinnamate small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank l-1-(4-chlorophenyl)-2-(acetamido)ethane boronic acid small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank 1,1,1-trifluoro-3-((n-acetyl)-l-leucylamido)-4-phenyl-butan-2-one(n-acetyl-l-leucyl-l-phenylalanyl trifluoromethyl ketone) small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank 2-acetylamino-4-methyl-pentanoic acid (1-formyl-2-phenyl-ethyl)-amide small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank (2s) n-acetyl-l-alanyl-αl-phenylalanyl-chloroethylketone small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank n-(1-benzyl-3,3,3-trifluoro-2,2-dihydroxy-propyl)-acetamide small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank d-1-(4-chlorophenyl)-2-(acetamido)ethane boronic acid small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank phosphorylisopropane small molecule NA experimental chymotrypsinogen b CTRB1 NA unknown NA drugbank example 166 (wo2014154727) NA NA investigative cathepsin a CTSA Clinical trial target unknown NA TTD pmid22861813c8a NA NA investigative cathepsin a CTSA Clinical trial target unknown NA TTD sar164653 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 cathepsin a CTSA Clinical trial target unknown NA TTD , DGIDB l-873724 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative cathepsin b CTSB Preclinical target unknown NA TTD z-arg-leu-val-agly-val-ala-nh2 NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD ac-hphe-leu-phe-leuvsme NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD pmid27998201-compound-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB z-ala-leu-phe-agly-ile-val-ome NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD z-arg-leu-val-agly-ile-val-ome NA NA investigative cathepsin b CTSB Preclinical target inhibitor NA TTD , DGIDB sd1002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin b CTSB Preclinical target unknown NA TTD ac-hphe-leu-ala-leuvsme NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 NA Cerebral Ischemia[MeSHID:D002545],Cerebral Infarction[MeSHID:D002544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB ca-074me NA Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cystic Fibrosis[MeSHID:D003550],Pulmonary Fibrosis[MeSHID:D011658] preclinical cathepsin b CTSB Preclinical target unknown NA TTD cbz-ile-t-butylhomoglu-ala-leuvsme NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD n-{[(2s,3s)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl}-l-isoleucyl-l-isoleucine small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank z-ala-leu-lle-agly-ile-val-nhbzl NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD [(3-bromophenyl)-p-tolyl-ketone]thiosemicarbazone NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD diphenylacetic acid small molecule NA experimental,investigative cathepsin b CTSB Preclinical target unknown NA TTD , drugbank z-ala-leu-tyr(me)-agly-ile-val-ome NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD z-phe-ala-diazomethylketone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin b CTSB Preclinical target unknown NA TTD z-arg-leu-val-agly-ile-val-trp-nh2 NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD pmid27998201-compound-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Malignant Bone Neoplasm[MeSHID:D001859] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB z-ala-leu-his-agly-ile-val-ome NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD n-({(2s,3s)-3-[(benzylamino)carbonyl]oxiran-2-yl}carbonyl)-l-isoleucyl-l-proline small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank pmid27998201-compound-22 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatitis[MeSHID:D010195] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB z-leu-val-agly-val-obzl NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD pmid27998201-compound-13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD z-arg-leu-val-agly-ileu-val-ome NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD methyl n-({(2s,3s)-3-[(propylamino)carbonyl]oxiran-2-yl}carbonyl)-l-isoleucyl-l-prolinate small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank (s)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD pmid27998201-compound-17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB 1-(phenyl(p-tolyl)methylene)thiosemicarbazide NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD 3-amino-4-oxybenzyl-2-butanone small molecule NA experimental,investigative cathepsin b CTSB Preclinical target unknown NA TTD , drugbank l-006235-1 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin b CTSB Preclinical target unknown NA TTD 2-aminoethanimidic acid small molecule NA experimental,investigative cathepsin b CTSB Preclinical target unknown NA TTD , drugbank pmid27998201-compound-24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Meningioma[MeSHID:D008579],Glioma[MeSHID:D005910] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB gnf-pf-5434 NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD n-[1-hydroxycarboxyethyl-carbonyl]leucylamino-2-methyl-butane small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank n-{[(2s,3s)-3-(ethoxycarbonyl)-2-oxiranyl]carbonyl}-l-threonyl-l-isoleucine small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank n-{[(2s,3s)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl}-l-isoleucine small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank pmid27998201-compound-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB z-ala-leu-lle-agly-ile-val-ome NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD benzyl n-({(2s,3s)-3-[(propylamino)carbonyl]oxiran-2-yl}carbonyl)-l-isoleucyl-l-prolinate small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank z-arg-leu-val-agly-trp-val-ala-nh2 NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD z-arg-leu-val-agly-ala-gly-nh2 NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD gold trichloride sodium chloride NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD sd1003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin b CTSB Preclinical target unknown NA TTD n-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank cbz-ile-leu-ala-leuvsme NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD n-{[(2s,3s)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl}-l-isoleucyl-l-alanine small molecule NA experimental cathepsin b CTSB NA unknown NA drugbank pmid27998201-compound-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Chronic Obstructive Airway Disease[MeSHID:D029424],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103],Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB z-ala-leu-nal-agly-ile-val-ome NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD pmid27998201-compound-9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] patented cathepsin b CTSB Preclinical target unknown NA TTD , DGIDB 3-methylphenylalanine small molecule NA experimental,investigative cathepsin b CTSB Preclinical target unknown NA TTD , drugbank ptosyl-glu(otbu)-ala-leuvsme NA NA investigative cathepsin b CTSB Preclinical target unknown NA TTD 2-pyridinethiol small molecule NA experimental,investigative cathepsin b CTSB Preclinical target unknown NA TTD , drugbank gnf-pf-5434 NA NA investigative dipeptidyl peptidase i CTSC Clinical trial target unknown NA TTD pmid3941405c3d NA NA investigative dipeptidyl peptidase i CTSC Clinical trial target unknown NA TTD (s)-2-amino-n-(1-cyano-2-phenylethyl)acetamide NA NA investigative dipeptidyl peptidase i CTSC Clinical trial target unknown NA TTD gsk2793660 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bronchiectasis[MeSHID:D001987] phase 1 dipeptidyl peptidase i CTSC Clinical trial target unknown NA TTD , DGIDB kni-10006 NA NA investigative cathepsin d CTSD Clinical trial target unknown NA TTD s-methylcysteine small molecule NA experimental,investigative cathepsin d CTSD Clinical trial target unknown NA TTD , drugbank 1h-benoximidazole-2-carboxylic acid small molecule NA experimental,investigative cathepsin d CTSD Clinical trial target unknown NA TTD , drugbank alpha-d-mannose NA NA investigative cathepsin d CTSD Clinical trial target unknown NA TTD pmid8410973c3 NA NA investigative cathepsin d CTSD Clinical trial target unknown NA TTD carbocyclic peptidomimetic NA NA investigative cathepsin d CTSD Clinical trial target unknown NA TTD grl-7234 NA NA investigative cathepsin d CTSD Clinical trial target unknown NA TTD 2-morpholinoethylamine small molecule NA experimental cathepsin d CTSD NA unknown NA drugbank grassystatin a NA NA investigative cathepsin d CTSD Clinical trial target inhibitor NA TTD , DGIDB 5-amino-6-cyclohexyl-4-hydroxy-2-isobutyl-hexanoic acid small molecule NA experimental cathepsin d CTSD NA unknown NA drugbank n-aminoethylmorpholine NA NA investigative cathepsin d CTSD Clinical trial target unknown NA TTD pmid10498202c1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] clinical trial cathepsin d CTSD Clinical trial target unknown NA TTD , DGIDB cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylamide small molecule NA experimental cathepsin d CTSD NA unknown NA drugbank pmid8410973c2 NA NA investigative cathepsin e CTSE Literature-reported target unknown NA TTD pmid8410973c3 NA NA investigative cathepsin e CTSE Literature-reported target unknown NA TTD [1-(1-benzyl-3-hydroxy-2-oxo-propylcarbamoyl)-2-phenyl-ethyl]-carbamic acid benzyl ester small molecule NA experimental cathepsin f CTSF NA unknown NA drugbank pmid27998201-compound-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Chronic Obstructive Airway Disease[MeSHID:D029424],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103],Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355] patented cathepsin f CTSF Patented-recorded target unknown NA TTD , DGIDB wrr-99 small molecule NA experimental,investigative cathepsin f CTSF Patented-recorded target unknown NA TTD , drugbank 4-morpholin-4-yl-piperidine-1-carboxylic acid [1-(3-benzenesulfonyl-1-propyl-allylcarbamoyl)-2-phenylethyl]-amide small molecule NA experimental cathepsin f CTSF NA unknown NA drugbank [1-(1-methyl-4,5-dioxo-pent-2-enylcarbamoyl)-2-phenyl-ethyl]-carbamic acid benzyl ester small molecule NA experimental cathepsin f CTSF NA unknown NA drugbank benzoyl-tyrosine-alanine-methyl ketone NA NA investigative cathepsin f CTSF Patented-recorded target unknown NA TTD benzoyl-tyrosine-alanine-fluoro-methyl ketone small molecule NA experimental cathepsin f CTSF NA unknown NA drugbank homophenylalaninylmethane small molecule NA experimental,investigative cathepsin f CTSF Patented-recorded target unknown NA TTD , drugbank pmid27998201-compound-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Malignant Bone Neoplasm[MeSHID:D001859] patented cathepsin f CTSF Patented-recorded target unknown NA TTD , DGIDB wrr-112 small molecule NA experimental,investigative cathepsin f CTSF Patented-recorded target unknown NA TTD , drugbank benzoyl-arginine-alanine-methyl ketone NA NA investigative cathepsin f CTSF Patented-recorded target unknown NA TTD benzyl n-[(2s)-5-(diaminomethylamino)-1-[[(2s)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate small molecule NA experimental cathepsin f CTSF NA unknown NA drugbank pmid22686657c(r)-26 NA NA investigative cathepsin f CTSF Patented-recorded target unknown NA TTD peptide analog 62 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB peptide analog 59 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB peptide analog 57 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB peptide analog 60 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB peptide analog 70 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB jnj-10311795 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 cathepsin g CTSG Clinical trial target unknown 10.61 TTD , DGIDB 2-[3-({methyl[1-(2-naphthoyl)piperidin-4-yl]amino}carbonyl)-2-naphthyl]-1-(1-naphthyl)-2-oxoethylphosphonic acid small molecule NA experimental cathepsin g CTSG NA unknown NA drugbank pmid22595175c4g NA NA investigative cathepsin g CTSG Clinical trial target unknown NA TTD dermolastin NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] discontinued in phase 2 cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB peptide analog 56 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB bis-napthyl beta-ketophosphonic acid small molecule NA experimental,investigative cathepsin g CTSG Clinical trial target unknown NA TTD , drugbank peptide analog 55 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB 1,3-dibenzyl-[1,3]diazetidine-2,4-dione NA NA investigative cathepsin g CTSG Clinical trial target unknown NA TTD peptide analog 58 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB peptide analog 61 NA NA patented cathepsin g CTSG Clinical trial target unknown NA TTD , DGIDB aloxistatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] discontinued in phase 3 cathepsin g CTSG Clinical trial target inhibitor 10.61 TTD , DGIDB carbobenzyloxy-(l)-leucinyl-(l)leucinyl methoxymethylketone small molecule NA experimental pro-cathepsin h CTSH NA unknown NA drugbank p-toluenesulfonic acid small molecule NA experimental pro-cathepsin h CTSH NA unknown NA drugbank n1-(1-dimethylcarbamoyl-2-phenyl-ethyl)-2-oxo-n4-(2-pyridin-2-yl-ethyl)-succinamide small molecule NA experimental pro-cathepsin h CTSH NA unknown NA drugbank n-[1-hydroxycarboxyethyl-carbonyl]leucylamino-2-methyl-butane small molecule NA experimental pro-cathepsin h CTSH NA unknown NA drugbank relacatib small molecule Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 cathepsin k CTSK Clinical trial target unknown 25.46 TTD , drugbank , DGIDB pmid25399719-compound-17 NA NA patented cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB l-006235-1 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin k CTSK Clinical trial target unknown NA TTD n-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD pmid27998201-compound-15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] patented cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB relacatib small molecule Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 cathepsin k CTSK Clinical trial target inhibitor 25.46 TTD , drugbank , DGIDB vel-0230 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 cathepsin k CTSK Clinical trial target unknown 25.46 TTD , DGIDB miv-701 small molecule Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 1 cathepsin k CTSK Clinical trial target unknown NA TTD , drugbank , DGIDB pmid16290936c1b NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD (1r,2r)-n-(2-aminoethyl)-2-{[(4-methoxyphenyl)sulfonyl]methyl}cyclohexanecarboxamide small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank 2-cyclohexylamino-pyrimidine-4-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD l-873724 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative cathepsin k CTSK Clinical trial target unknown NA TTD cyanamide small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank relacatib small molecule Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Neoplasm Metastasis[MeSHID:D009362],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 cathepsin k CTSK Clinical trial target inhibitor 25.46 TTD , drugbank , DGIDB pmid27998201-compound-8 NA NA patented cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB n-(tert-butoxycarbonyl)-valyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-leucyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD z-ala-leu-phe-agly-ile-val-ome NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD tert-butyl 2-cyano-2-methylhydrazinecarboxylate small molecule NA experimental,investigative cathepsin k CTSK Clinical trial target unknown NA TTD , drugbank n-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD 4-cyclohexylamino-pyrimidine-2-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD relacatib small molecule Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Neoplasm Metastasis[MeSHID:D009362],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 cathepsin k CTSK Clinical trial target unknown 25.46 TTD , drugbank , DGIDB 1-(phenylmethyl)cyclopentyl[(1s)-1-formylpentyl]carbamate small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank n-benzoyl-phenylalanyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD 3-amino-5-phenylpentane small molecule NA experimental,investigative cathepsin k CTSK Clinical trial target unknown NA TTD , drugbank pyrrolidine-1-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD 4-propyl-6-m-tolylpyrimidine-2-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD [1-(4-fluorobenzyl)cyclobutyl]methyl (1s)-1-[oxo(1h-pyrazol-5-ylamino)acetyl]pentylcarbamate small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank am-3701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Bone Tissue[MeSHID:D001842] investigative cathepsin k CTSK Clinical trial target unknown NA TTD 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD (s)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD odanacatib small molecule Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 cathepsin k CTSK Clinical trial target inhibitor 15.91 TTD , drugbank , DGIDB 4-cyclohexyl-6-propylpyrimidine-2-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD boc-agly-val-agly-oet NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD miv-711 small molecule NA investigational cathepsin k CTSK NA inhibitor NA drugbank n-(tert-butoxycarbonyl)-methionyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD (s)-tert-butyl 1-oxohexan-2-ylcarbamate NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD 1-{7-cyclohexyl-6-[4-(4-methylpiperazin-1-yl)benzyl]-7h-pyrrolo[2,3-d]pyrimidin-2-yl}methanamine small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank tert-butyl(1s)-1-cyclohexyl-2-oxoethylcarbamate small molecule NA experimental,investigative cathepsin k CTSK Clinical trial target unknown NA TTD , drugbank tert-butyl (2s)-1-cyanopyrrolidine-2-carboxylate NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD z-ala-leu-nal-agly-ile-val-ome NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD balicatib NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 cathepsin k CTSK Clinical trial target inhibitor 25.46 TTD , DGIDB n-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD z-arg-leu-val-agly-trp-val-ala-nh2 NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD gw-2592x NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bone Diseases[MeSHID:D001847] preclinical cathepsin k CTSK Clinical trial target unknown NA TTD (s)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD sar-114137 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB z-leu-val-agly-val-obzl NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD z-ala-leu-his-agly-ile-val-ome NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD p2,p3 ketoamide derivative NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD n-acetyl-phenylalanyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD n-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD n-(benzyloxycarbonyl)-leucyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD z-ala-leu-lle-agly-ile-val-nhbzl NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD n2-({[(4-bromophenyl)methyl]oxy}carbonyl)-n1-[(1s)-1-formylpentyl]-l-leucinamide small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank n-(cyanomethyl)cyclohex-1-ene-1-carboxamide NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD gnf-pf-5434 NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD (2r)-2-(3-biphenylyl)-n-{(2r)-2-hydroxy-3-[(2-pyridinylsulfonyl)amino]propyl}-4-methylpentanamide small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank n2-[(benzyloxy)carbonyl]-n-[(3r)-1-{n-[(benzyloxy)carbonyl]-l-leucyl}-4-oxo-3-pyrrolidinyl]-l-leucinamide small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank 2-cyclohexylamino-pyridine-2-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD miv-710 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Bone Tissue[MeSHID:D001842] investigative cathepsin k CTSK Clinical trial target unknown NA TTD 9-cyclopentyl-6-[2-(3-imidazol-1-yl-propoxy)-phenylamino]-9h-purine-2-carbonitrile small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank pmid27998201-compound-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Chronic Obstructive Airway Disease[MeSHID:D029424],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103],Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355] patented cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB (2r)-3-methyl-1-phenyl-2-butanyl [(2s)-1-oxo-2-hexanyl]carbamate small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank pmid27998201-compound-9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] patented cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB ono-5334 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 cathepsin k CTSK Clinical trial target unknown NA TTD 6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9h-purine-2-carbonitrile small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank z-arg-leu-val-agly-val-ala-nh2 NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD z-arg-leu-val-agly-ile-val-trp-nh2 NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD 4-phenyl-6-propylpyrimidine-2-carbonitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD pmid27998201-compound-10 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB pmid27998201-compound-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Malignant Bone Neoplasm[MeSHID:D001859] patented cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB n-(2-aminoethyl)-n~2~-{(1s)-1-[4'-(aminosulfonyl)biphenyl-4-yl]-2,2,2-trifluoroethyl}-l-leucinamide small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank z-ala-leu-tyr(me)-agly-ile-val-ome NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD oxotetrahydro-2-h-furo[3.2-b]pyrrol-4(5-h)-yl derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] patented cathepsin k CTSK Clinical trial target unknown NA TTD , DGIDB n2-[(benzyloxy)carbonyl]-n1-[(3s)-1-cyanopyrrolidin-3-yl]-l-leucinamide small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank n-[(2s)-4-methyl-1-oxo-1-{[(4s)-3-oxo-1-(2-pyridinylsulfonyl)-4-azepanyl]amino}-2-pentanyl]-1-benzofuran-2-carboxamide small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank z-arg-leu-val-agly-ileu-val-ome NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD z-arg-leu-val-agly-ala-gly-nh2 NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD z-ala-leu-lle-agly-ile-val-ome NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD bf/pc-21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Pyruvate Carboxylase Deficiency Disease[MeSHID:D015324] investigative cathepsin k CTSK Clinical trial target unknown NA TTD ono-5334 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 cathepsin k CTSK Clinical trial target unknown NA TTD dibenzyl (carbonylbis{2,1-hydrazinediyl[(2s)-4-methyl-1-oxo-1,2-pentanediyl]})biscarbamate small molecule NA experimental cathepsin k CTSK NA unknown NA drugbank n-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile NA NA investigative cathepsin k CTSK Clinical trial target unknown NA TTD (s)-tert-butyl 1-oxohexan-2-ylcarbamate NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD caa0225 NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD kgp94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] clinical trial cathepsin l CTSL Clinical trial target inhibitor NA TTD , DGIDB sd1002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin l CTSL Clinical trial target unknown NA TTD n-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD pmid27998201-compound-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB [(3-bromophenyl)-p-tolyl-ketone]thiosemicarbazone NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD l-cysteic acid small molecule NA experimental cathepsin l1 CTSL NA unknown NA drugbank bis(3-fluorophenyl)-ketone]thiosemicarbazone NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD pmid27998201-compound-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Encephalitis[MeSHID:D004660] patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cathepsin l1 CTSL NA inhibitor NA drugbank z-phe-ala-diazomethylketone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin l CTSL Clinical trial target unknown NA TTD l-873724 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative cathepsin l CTSL Clinical trial target unknown NA TTD felbinac small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] experimental cathepsin l1 CTSL NA unknown NA drugbank pmid27998201-compound-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Malignant Bone Neoplasm[MeSHID:D001859] patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD 1-(1,3-diphenylpropylidene)thiosemicarbazide NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD 9-benzyl-6-(benzylamino)-9h-purine-2-carbonitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD pmid27998201-compound-17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB peptide alpha-keto-beta-aldehyde-based inhibitors NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD (s)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD pmid25399719-compound-17 NA NA patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB clik-181 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] preclinical cathepsin l CTSL Clinical trial target unknown NA TTD (3-bromobenzoylpyridine)thiosemicarbazone NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD pmid27998201-compound-6 NA NA patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB n-(benzyloxycarbonyl)-leucyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-leucyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-methionyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD [2-phenylacetophenone]thiosemicarbazone NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD l-006235-1 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin l CTSL Clinical trial target unknown NA TTD [(3-bromophenyl)-m-tolyl-ketone]thiosemicarbazone NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD n-acetyl-phenylalanyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD sd1003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin l CTSL Clinical trial target unknown NA TTD pmid27998201-compound-9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB clik-148 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] preclinical cathepsin l CTSL Clinical trial target unknown NA TTD pmid27998201-compound-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Chronic Obstructive Airway Disease[MeSHID:D029424],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103],Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355] patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB cysteinesulfonic acid NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD 6-(benzylamino)-9-butyl-9h-purine-2-carbonitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD n-benzoyl-phenylalanyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-valyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD pmid27998201-compound-7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aortic Aneurysm, Abdominal[MeSHID:D017544] patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB n-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD kgp94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] clinical trial cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB 1-(phenyl(p-tolyl)methylene)thiosemicarbazide NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD biphenyl-4-yl-acetaldehyde NA NA investigative cathepsin l CTSL Clinical trial target unknown NA TTD phenylalanine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] patented cathepsin l CTSL Clinical trial target unknown NA TTD , DGIDB cbz-ile-hphe-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD pmid25399719-compound-17 NA NA patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB morpholine-4-carboxylic acid (1-(3-benzenesulfonyl-1-phenethylallylcarbamoyl)-3-methylbutyl)-amide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank n-[1-(aminomethyl)cyclopropyl]-3-(benzylsulfonyl)-n~2~-[(1s)-2,2,2-trifluoro-1-(4-hydroxyphenyl)ethyl]-l-alaninamide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank vby- 285 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative cathepsin s CTSS Clinical trial target unknown NA TTD n-(1-cyanocyclopropyl)-3-({[(2s)-5-oxopyrrolidin-2-yl]methyl}sulfonyl)-n~2~-[(1s)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]-l-alaninamide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank cbz-ile-phe-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD vby-129 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Diabetes, Autoimmune[MeSHID:D003922] phase 1 cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB n-(tert-butoxycarbonyl)-leucyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD pmid27998201-compound-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Malignant Bone Neoplasm[MeSHID:D001859] patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB n-[(1s)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank n-(benzyloxycarbonyl)-leucyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD gnf-pf-5434 NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD fucose NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD 6-(3-(trifluoromethyl)phenyl)picolinonitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD pmid22686657c(r)-26 NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD am-3840 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative cathepsin s CTSS Clinical trial target unknown NA TTD cbz-glu(otbu)-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD phenylalanine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cathepsin s CTSS NA inhibitor NA drugbank 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD ro5461111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] preclinical cathepsin s CTSS Clinical trial target unknown NA TTD n-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD l-873724 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative cathepsin s CTSS Clinical trial target unknown NA TTD p2,p3 ketoamide derivative NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD l-006235-1 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical cathepsin s CTSS Clinical trial target unknown NA TTD (1r)-2-[(cyanomethyl)amino]-1-({[2-(difluoromethoxy)benzyl]sulfonyl}methyl)-2-oxoethyl morpholine-4-carboxylate small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank n~2~-1,3-benzoxazol-2-yl-3-cyclohexyl-n-{2-[(4-methoxyphenyl)amino]ethyl}-l-alaninamide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank n-(tert-butoxycarbonyl)-valyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD ac-hphe-leu-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD pmid27998201-compound-7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aortic Aneurysm, Abdominal[MeSHID:D017544] patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB morpholine-4-carboxylic acid [1-(2-benzylsulfanyl-1-formyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank n-benzoyl-phenylalanyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD n-[(1s)-2-{[(1r)-2-(benzyloxy)-1-cyano-1-methylethyl]amino}-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank pmid27998201-compound-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Chronic Obstructive Airway Disease[MeSHID:D029424],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103],Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355] patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB ac-hphe-leu-phe-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD pmid27998201-compound-15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB cbz-ile-pro-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD cbz-ile-t-butylhomoglu-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD 2-[(2',3',4'-trifluorobiphenyl-2-yl)oxy]ethanol small molecule NA experimental,investigative cathepsin s CTSS Clinical trial target unknown NA TTD , drugbank morpholine-4-carboxylic acid [1s-(2-benzyloxy-1r-cyano-ethylcarbamoyl)-3-methyl-butyl]amide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank n-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD rg7625 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859],Celiac Disease[MeSHID:D002446],Autoimmune Diseases[MeSHID:D001327] phase 2 cathepsin s CTSS Clinical trial target unknown 31.83 TTD , DGIDB n-(2-naphthylsulfonyl)-glycyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD vby- 036 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB jnj-10329670 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative cathepsin s CTSS Clinical trial target unknown NA TTD n-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD ac-hphe-leu-gly-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD bf/pc-18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Pyruvate Carboxylase Deficiency Disease[MeSHID:D015324] investigative cathepsin s CTSS Clinical trial target unknown NA TTD pmid27998201-compound-17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB oxotetrahydro-2-h-furo[3.2-b]pyrrol-4(5-h)-yl derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB pmid27998201-compound-9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB cbz-ile-meto2-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD n-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD n-[1-(aminomethyl)cyclopropyl]-3-(morpholin-4-ylsulfonyl)-n~2~-[(1s)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]-l-alaninamide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank cbz-ile-t-butylgln-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD rg-7236 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] discontinued in phase 1 cathepsin s CTSS Clinical trial target unknown NA TTD n-[(1s)-1-{1-[(1r,3e)-1-acetylpent-3-en-1-yl]-1h-1,2,3-triazol-4-yl}-1,2-dimethylpropyl]benzamide small molecule NA experimental cathepsin s CTSS NA unknown NA drugbank n-(tert-butoxycarbonyl)-methionyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD fsn-0503 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative cathepsin s CTSS Clinical trial target unknown NA TTD clik60 NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD sar-114137 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB cbz-ile-leu-ala-leuvsme NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD vby- 891 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB pmid27998201-compound-6 NA NA patented cathepsin s CTSS Clinical trial target unknown NA TTD , DGIDB 4-propyl-6-m-tolylpyrimidine-2-carbonitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD n-acetyl-phenylalanyl-glycine-nitrile NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD e-64 NA NA investigative cathepsin s CTSS Clinical trial target unknown NA TTD 3-amino-5-phenylpentane small molecule NA experimental cathepsin l2 CTSV NA unknown NA drugbank pmid27998201-compound-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Malignant Bone Neoplasm[MeSHID:D001859] patented cathepsin v CTSV Patented-recorded target unknown NA TTD , DGIDB 4-methylpiperazin-1-yl carbonyl group small molecule NA experimental cathepsin l2 CTSV NA unknown NA drugbank pmid21277783c7 NA NA investigative cathepsin v CTSV Patented-recorded target unknown NA TTD hydroxocobalamin small molecule Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Diet, Macrobiotic[MeSHID:D015623],Malignant neoplasm of pancreas[MeSHID:D010190],Biliary Tract Diseases[MeSHID:D001660],Diarrhea[MeSHID:D003967],Cestode Infections[MeSHID:D002590],Malabsorption Syndrome[MeSHID:D008286],Poisoning[MeSHID:D011041],Alcoholic Intoxication, Chronic[MeSHID:D000437],Hyperthyroidism[MeSHID:D006980],Vegan diet[MeSHID:D000067269],Anemia, Pernicious[MeSHID:D000752],ileum[MeSHID:D007082],Vitamin B 12 Deficiency[MeSHID:D014806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Injury[MeSHID:D055370] approved cubilin CUBN NA other NA drugbank n-methylleucine small molecule NA experimental,investigative c-x-c motif chemokine 10 CXCL10 Clinical trial target unknown NA TTD , drugbank mdx-1100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 2 c-x-c motif chemokine 10 CXCL10 Clinical trial target unknown 10.61 TTD , DGIDB bms-936557 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] phase 2 c-x-c motif chemokine 10 CXCL10 Clinical trial target unknown 10.61 TTD , DGIDB ng-641 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 c-x-c motif chemokine 10 CXCL10 Clinical trial target unknown NA TTD ni-0801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 2 c-x-c motif chemokine 10 CXCL10 Clinical trial target unknown 10.61 TTD , DGIDB ni-0801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 2 c-x-c motif chemokine 10 CXCL10 Clinical trial target inhibitor 10.61 TTD , DGIDB jt02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 c-x-c motif chemokine 10 CXCL10 Clinical trial target unknown NA TTD , DGIDB anti-ip10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] phase 2 c-x-c motif chemokine 10 CXCL10 Clinical trial target unknown NA TTD , DGIDB clove oil biotech Disease[MeSHID:D004194],Abdominal colic[MeSHID:D003085],Flatulence[MeSHID:D005414],Toothache[MeSHID:D014098] approved,nutraceutical c-x-c motif chemokine 10 CXCL10 NA unknown NA drugbank eldelumab biotech Ulcerative Colitis[MeSHID:D003093] investigational c-x-c motif chemokine 10 CXCL10 NA unknown NA drugbank myocell sdf-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 3 stromal cell-derived factor 1 CXCL12 Clinical trial target unknown NA TTD , DGIDB dociparstat sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 stromal cell-derived factor 1 CXCL12 Clinical trial target unknown NA TTD sdf-1 NA Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333],Peripheral Vascular Diseases[MeSHID:D016491] phase 2 stromal cell-derived factor 1 CXCL12 Clinical trial target unknown NA TTD , DGIDB ctce-0214 small molecule Vascular Diseases[MeSHID:D014652],Neoplasms[MeSHID:D009369],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] investigational stromal cell-derived factor 1 CXCL12 NA unknown NA drugbank tinzaparin small molecule Venous Thrombosis[MeSHID:D020246],Pulmonary Embolism[MeSHID:D011655],Venous Thromboembolism[MeSHID:D054556] approved stromal cell-derived factor 1 CXCL12 NA binder NA drugbank nox-a12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 stromal cell-derived factor 1 CXCL12 Clinical trial target unknown NA TTD , DGIDB rec-02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 1 stromal cell-derived factor 1 CXCL12 Clinical trial target unknown NA TTD , DGIDB laquinamod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 3 c-x-c motif chemokine 2 CXCL2 Clinical trial target unknown NA TTD , DGIDB 2-(2-(2-fluorophenoxy)phenyl)acetic acid NA NA investigative interleukin-8 CXCL8 Successful target unknown NA TTD 2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid NA NA investigative interleukin-8 CXCL8 Successful target unknown NA TTD 2-(2-(2-chlorophenoxy)phenyl)acetic acid NA NA investigative interleukin-8 CXCL8 Successful target unknown NA TTD bms-986253 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] phase 2 interleukin-8 CXCL8 Successful target unknown NA TTD r-ketoprofen NA NA discontinued in phase 2 interleukin-8 CXCL8 Successful target unknown NA TTD rivanicline small molecule Ulcerative Colitis[MeSHID:D003093] investigational interleukin-8 CXCL8 NA antagonist NA drugbank 2-(2-(2-fluorophenylamino)phenyl)acetic acid NA NA investigative interleukin-8 CXCL8 Successful target unknown NA TTD ibuprofen NA Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-8 CXCL8 Successful target unknown 0.03 TTD , DGIDB tapinarof small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational interleukin-8 CXCL8 NA unknown NA drugbank abx-il8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 interleukin-8 CXCL8 Successful target unknown 2.27 TTD , DGIDB 2-(2-(2-chlorophenylamino)phenyl)acetic acid NA NA investigative interleukin-8 CXCL8 Successful target unknown NA TTD abt-510 small molecule Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational interleukin-8 CXCL8 NA unknown NA drugbank bms-986253 NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-8 CXCL8 Successful target unknown NA TTD abx-il8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 interleukin-8 CXCL8 Successful target inhibitor 2.27 TTD , DGIDB mdx-018 small molecule Disease[MeSHID:D004194],Autoimmune Diseases[MeSHID:D001327],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Diabetes, Autoimmune[MeSHID:D003922] investigational,phase 1 interleukin-8 CXCL8 Successful target unknown NA TTD , drugbank , DGIDB ng-641 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 c-x-c motif chemokine 9 CXCL9 Clinical trial target unknown NA TTD sx-682 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD (r)-n-hydroxy-2-(4-isobutyl-phenyl)-propionamide NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD reparixin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reperfusion Injury[MeSHID:D015427],Graft Rejection[MeSHID:D006084] phase 3 c-x-c chemokine receptor type 1 CXCR1 Successful target modulator 19.1 TTD , DGIDB 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD indoprofen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] withdrawn from market c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD (r)-2-(4-isobutyl-phenyl)-propionamide NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD 2-[3-(1-hydroxy-propyl)-phenyl]-propionic acid NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD reparixin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reperfusion Injury[MeSHID:D015427],Graft Rejection[MeSHID:D006084] phase 3 c-x-c chemokine receptor type 1 CXCR1 Successful target allosteric modulator 19.1 TTD , DGIDB sch-527123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Chronic Obstructive Airway Disease[MeSHID:D029424],Ulcerative Colitis[MeSHID:D003093],Malignant Neoplasms[MeSHID:D009369] phase 2 c-x-c chemokine receptor type 1 CXCR1 Successful target unknown 12.73 TTD , DGIDB 1-(2-bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD reparixin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reperfusion Injury[MeSHID:D015427],Graft Rejection[MeSHID:D006084] phase 3 c-x-c chemokine receptor type 1 CXCR1 Successful target unknown 19.1 TTD , DGIDB 2-[3-(1-phenyl-ethyl)-phenyl]-propionic acid NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD (r)-2-(4-isobutyl-phenyl)-n-methoxy-propionamide NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD il-8((3-73))k11r NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD ibuprofen NA Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved c-x-c chemokine receptor type 1 CXCR1 Successful target unknown 0.37 TTD , DGIDB ketoprofen small molecule Degenerative polyarthritis[MeSHID:D010003],Ankylosing spondylitis[MeSHID:D013167],Dental Health Services[MeSHID:D003752],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Traumatic injury[MeSHID:D014947],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Pain[MeSHID:D059352],Migraine Disorders[MeSHID:D008881] approved,vet_approved c-x-c chemokine receptor type 1 CXCR1 NA other NA drugbank 2-(3-isopropyl-phenyl)-propionic acid NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD r-ketoprofen NA NA discontinued in phase 2 c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD 2-(3-isobutyl-phenyl)-propionic acid NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD 2-[3-(2-methyl-butyl)-phenyl]-propionic acid NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD (r)-3-(4-isobutyl-phenyl)-butan-2-one NA NA investigative c-x-c chemokine receptor type 1 CXCR1 Successful target unknown NA TTD sb-656933 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown 11.57 TTD , DGIDB gsk1325756 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown 17.36 TTD , DGIDB pd-157695 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD , DGIDB (r)-2-(4-isobutyl-phenyl)-propionamide NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD azd-5122 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD , DGIDB sb 272844 NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 1-(3-cyano-2-hydroxyphenyl)-3-phenylurea NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 1-(2-hydroxy-3-nitro-phenyl)-3-phenyl-urea NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD sx-517 NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target antagonist NA TTD , DGIDB 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 2-(3-isopropyl-phenyl)-propionic acid NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD clotrimazole NA Tinea Pedis[MeSHID:D014008],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Mycoses[MeSHID:D009181],Skin Diseases, Infectious[MeSHID:D012874],Diaper Rash[MeSHID:D003963],Tinea Versicolor[MeSHID:D014010],Candidiasis[MeSHID:D002177],leukemia[MeSHID:D007938],Tinea[MeSHID:D014005],Immunocompromised Host[MeSHID:D016867],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved c-x-c chemokine receptor type 2 CXCR2 Successful target unknown 0.17 TTD , DGIDB ps-938285 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD , DGIDB (r)-n-hydroxy-2-(4-isobutyl-phenyl)-propionamide NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD azd-5069 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 2-[3-(1-hydroxy-propyl)-phenyl]-propionic acid NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD il-8((3-73))k11r NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 2-(3-isobutyl-phenyl)-propionic acid NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 2-[3-(1-phenyl-ethyl)-phenyl]-propionic acid NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD indoprofen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] withdrawn from market c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 2-[3-(2-methyl-butyl)-phenyl]-propionic acid NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 1-(2-hydroxy-5-nitro-phenyl)-3-phenyl-urea NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD (r)-3-(4-isobutyl-phenyl)-butan-2-one NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-ol NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD sb-332235 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD sx-682 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD 1-(4-cyano-2-hydroxyphenyl)-3-phenylurea NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD cxcl8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] investigative c-x-c chemokine receptor type 2 CXCR2 Successful target agonist NA TTD , DGIDB azd4721 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD , DGIDB (r)-2-(4-isobutyl-phenyl)-n-methoxy-propionamide NA NA investigative c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD ibuprofen NA Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved c-x-c chemokine receptor type 2 CXCR2 Successful target unknown 0.17 TTD , DGIDB reparixin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reperfusion Injury[MeSHID:D015427],Graft Rejection[MeSHID:D006084] phase 3 c-x-c chemokine receptor type 2 CXCR2 Successful target modulator 8.68 TTD , DGIDB sch-527123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Chronic Obstructive Airway Disease[MeSHID:D029424],Ulcerative Colitis[MeSHID:D003093],Malignant Neoplasms[MeSHID:D009369] phase 2 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown 11.57 TTD , DGIDB reparixin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reperfusion Injury[MeSHID:D015427],Graft Rejection[MeSHID:D006084] phase 3 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown 8.68 TTD , DGIDB r-ketoprofen NA NA discontinued in phase 2 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD reparixin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reperfusion Injury[MeSHID:D015427],Graft Rejection[MeSHID:D006084] phase 3 c-x-c chemokine receptor type 2 CXCR2 Successful target allosteric modulator 8.68 TTD , DGIDB sb-265610 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Asthma[MeSHID:D001249] phase 2 c-x-c chemokine receptor type 2 CXCR2 Successful target unknown NA TTD , DGIDB hypoglaucin a NA NA investigative c-x-c chemokine receptor type 3 CXCR3 Preclinical target antagonist NA TTD , DGIDB nbi-74330 NA NA investigative c-x-c chemokine receptor type 3 CXCR3 Preclinical target antagonist NA TTD , DGIDB sch-900875 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative c-x-c chemokine receptor type 3 CXCR3 Preclinical target unknown NA TTD jt07 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical c-x-c chemokine receptor type 3 CXCR3 Preclinical target unknown NA TTD t487 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Disease[MeSHID:D004194] discontinued in phase 2 c-x-c chemokine receptor type 3 CXCR3 Preclinical target unknown NA TTD dioscin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] preclinical c-x-c chemokine receptor type 3 CXCR3 Preclinical target antagonist 21.22 TTD , DGIDB kallstroemin d NA NA investigative c-x-c chemokine receptor type 3 CXCR3 Preclinical target antagonist NA TTD , DGIDB cyclo(-d-tyr-l-ala-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-d-arg-l-arg-l-menal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD lp-0067 NA Lateral posterior nucleus of thalamus[MeSHID:D020647],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spinal Puncture[MeSHID:D013129],Diabetes, Autoimmune[MeSHID:D003922] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-l-arg-l-arg-l-nal-beta-ala-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD isothiourea-1a NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist NA TTD , DGIDB cyclo(-d-tyr-l-arg-l-arg-l-menal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD plerixafor small molecule Hematopoietic stem cells[MeSHID:D006412],Multiple Myeloma[MeSHID:D009101],Lymphoma, Non-Hodgkin[MeSHID:D008228],Blood[MeSHID:D001769],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist 8.91 TTD , drugbank , DGIDB pf-06747143 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 3.18 TTD , DGIDB cyclo(-d-tyr-d-arg-l-arg-l-nal-beta-ala-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-l-arg-l-arg-l-ala-sar-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD at-009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD ati-2341 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD msx-122 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist 9.55 TTD , DGIDB bms-936564 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 6.37 TTD , DGIDB cyclo(-d-tyr-d-arg-l-arg-l-nal-sar-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-d-arg-l-arg-l-nal-d-ala-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-metyr-l-arg-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD kur-cxcr4 NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-l-arg-l-arg-l-nal-l-ala-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD nb-325 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cx-02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD mab173 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] preclinical c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-d-arg-l-mearg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-metyr-d-arg-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD bl-8040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Pancreatic carcinoma[MeSHID:C562463] phase 3 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 12.73 TTD , DGIDB ly2624587 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD pol-6326 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],HIV Infections[MeSHID:D015658] phase 2 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 6.37 TTD , DGIDB cyclo(-d-tyr-l-arg-l-arg-l-nal-d-ala-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-d-ala-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD ctce-0324 NA Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD framycetin small molecule Injury of cornea[MeSHID:D065306],Blepharitis[MeSHID:D001762],Foreign Bodies[MeSHID:D005547],Corneal Ulcer[MeSHID:D003320],Eye Infections[MeSHID:D015817],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver Failure, Acute[MeSHID:D017114],Liver Cirrhosis, Alcoholic[MeSHID:D008104],Bacterial Infections[MeSHID:D001424] approved c-x-c chemokine receptor type 4 CXCR4 NA antagonist NA drugbank cyclo(-d-tyr-l-arg-l-mearg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD ulocuplumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Hematologic Neoplasms[MeSHID:D019337] phase 3 c-x-c chemokine receptor type 4 CXCR4 Successful target antibody 6.37 TTD , DGIDB gsk-812397 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-d-arg-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cxcl8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD suradista NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD alx-0651 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD , DGIDB ulocuplumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Hematologic Neoplasms[MeSHID:D019337] phase 3 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 6.37 TTD , DGIDB isothiourea-1t NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist NA TTD , DGIDB amd-070 small molecule HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],WHIM syndrome[MeSHID:C536697],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Merkel cell carcinoma[MeSHID:D015266] investigational,phase 3 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 15.91 TTD , drugbank , DGIDB cyclo(-d-tyr-l-arg-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD garnocestim NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-arg-arg-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-ala-d-arg-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD plerixafor small molecule Hematopoietic stem cells[MeSHID:D006412],Multiple Myeloma[MeSHID:D009101],Lymphoma, Non-Hodgkin[MeSHID:D008228],Blood[MeSHID:D001769],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist,partial agonist 8.91 TTD , drugbank , DGIDB balixafortide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943] phase 3 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 3.18 TTD , DGIDB cyclo(-d-tyr-l-mearg-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD t140 NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist 12.73 TTD , DGIDB usl311 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Respiratory Tract Infections[MeSHID:D012141] phase 1/2 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 3.18 TTD , DGIDB cyclo(-d-tyr-d-mearg-l-arg-l-nal-gly-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD t22 NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist NA TTD , DGIDB gmi-1359 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD , DGIDB cxcr4 gene disrupted t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],HIV Infections[MeSHID:D015658] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD ctce-9908 NA Sarcoma[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist 6.37 TTD , DGIDB ctce-0214 NA Vascular Diseases[MeSHID:D014652],Neoplasms[MeSHID:D009369],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD , DGIDB msx-122 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 9.55 TTD , DGIDB viral macrophage inflammatory protein-ii NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist NA TTD , DGIDB tn-14003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD cyclo(-d-tyr-d-arg-l-arg-l-nal-l-pic-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD nd-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD ctce-9908 NA Sarcoma[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 6.37 TTD , DGIDB tg-0054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 2 c-x-c chemokine receptor type 4 CXCR4 Successful target unknown 9.55 TTD , DGIDB t134 NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target antagonist NA TTD , DGIDB ibalizumab biotech HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Communicable Diseases[MeSHID:D003141],Blood[MeSHID:D001769],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational c-x-c chemokine receptor type 4 CXCR4 NA antagonist NA drugbank cyclo(-d-tyr-d-arg-l-arg-l-nal-l-ala-) NA NA investigative c-x-c chemokine receptor type 4 CXCR4 Successful target unknown NA TTD sar113244 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 c-x-c chemokine receptor type 5 CXCR5 Clinical trial target unknown NA TTD , DGIDB jt08 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical c-x-c chemokine receptor type 5 CXCR5 Clinical trial target unknown NA TTD chromic nitrate small molecule Serum[MeSHID:D044967],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved cytochrome b5 CYB5A NA unknown NA drugbank dimethyl propionate ester heme small molecule NA experimental cytochrome b5 CYB5A NA unknown NA drugbank chromium small molecule Serum[MeSHID:D044967],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved cytochrome b5 CYB5A NA substrate NA drugbank chromium nicotinate small molecule Serum[MeSHID:D044967],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved,experimental cytochrome b5 CYB5A NA unknown NA drugbank chromic citrate small molecule Serum[MeSHID:D044967],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] experimental cytochrome b5 CYB5A NA unknown NA drugbank chromium gluconate small molecule Serum[MeSHID:D044967],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved cytochrome b5 CYB5A NA unknown NA drugbank chromous sulfate small molecule Serum[MeSHID:D044967],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved cytochrome b5 CYB5A NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational cytochrome b5 type b CYB5B NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved nadh-cytochrome b5 reductase 1 CYB5R1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nadh-cytochrome b5 reductase 3 CYB5R3 NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved nadh-cytochrome b5 reductase 3 CYB5R3 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-cytochrome b5 reductase 3 CYB5R3 NA unknown NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadph oxidase CYBA NA inhibitor NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadph oxidase CYBB NA inhibitor NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome c1, heme protein, mitochondrial CYC1 NA unknown NA drugbank trimethyllysine small molecule NA experimental cytochrome c CYCS NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational cytochrome c CYCS NA ligand NA drugbank ferroheme c small molecule NA experimental cytochrome c CYCS NA unknown NA drugbank zinc substituted heme c small molecule NA experimental cytochrome c CYCS NA unknown NA drugbank minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational cytochrome c CYCS NA negative modulator NA drugbank protoporphyrin ix containing co small molecule NA experimental cytochrome c CYCS NA unknown NA drugbank imidazole small molecule NA experimental,investigational cytochrome c CYCS NA unknown NA drugbank zinc protoporphyrin small molecule NA experimental cytochrome c CYCS NA unknown NA drugbank 3-(4-amino-phenyl)-3-pentyl-piperidine-2,6-dione NA NA investigative cholesterol desmolase CYP11A1 Successful target unknown NA TTD aminoglutethimide NA Malignant neoplasm of breast[MeSHID:D001943],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved cholesterol desmolase CYP11A1 Successful target unknown 22.73 TTD , DGIDB aminoglutethimide small molecule Malignant neoplasm of breast[MeSHID:D001943],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 NA inhibitor 22.73 drugbank , DGIDB aminoglutethimide NA Malignant neoplasm of breast[MeSHID:D001943],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved cholesterol desmolase CYP11A1 Successful target inhibitor 22.73 TTD , DGIDB 3-(4-amino-phenyl)-3-butyl-piperidine-2,6-dione NA NA investigative cholesterol desmolase CYP11A1 Successful target unknown NA TTD 3-[5-methoxy-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-phenyl-2-pyridin-3-yl-propan-1-one NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[4-fluoro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-(4-(thiophen-2-yl)benzyl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 2-methyl-1,2-di-pyridin-3-yl-propane NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[(z)-2-phenylvinyl]pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[4-methyl-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-indan-(1e)-ylidenemethyl-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD osilodrostat small molecule Pituitary-dependent Cushing's disease[MeSHID:D047748],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 11b1, mitochondrial CYP11B1 NA inhibitor 7.96 drugbank , DGIDB 3-(naphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 6-(pyridin-3-yl)-2-naphthonitrile NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 6-isoquinolin-4-yl-3,4-dihydroquinolin-2(1h)-one NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-(2-fluorophenyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-[5-bromo-indan-(1z)-ylidenemethyl]-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-ethoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(3-methoxy-naphthalen-2-yl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-3-amine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD sl125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperaldosteronism[MeSHID:D006929],Myocardium[MeSHID:D009206],Congestive heart failure[MeSHID:D006333],Fibrosis[MeSHID:D005355] investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-ethyl-3-imidazol-1-ylmethyl-1h-indole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-[5-bromo-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-indan-(1z)-ylidenemethyl-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-ethoxy-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-naphthalen-2-yl-oxazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD (3-((1h-imidazol-1-yl)methyl)phenyl)methanol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD (4-((1h-imidazol-1-yl)methyl)phenyl)methanol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-aminobenzyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD levoketoconazole small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] approved,investigational cytochrome p450 11b1, mitochondrial CYP11B1 NA unknown NA drugbank 6-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 2-methyl-1,2-di-pyridin-3-yl-propylchloride NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-(4-(thiophen-3-yl)benzyl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-(3-methylphenyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-[(3'-hydroxybiphenyl-4-yl)methyl]pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-4-amine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-[4-(pyridin-4-ylmethyl)phenyl]-1h-indole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-bromo-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-chloro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(5-methoxy-1h-inden-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[3-(4-methoxybenzyl)naphthalen-2-yl]pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-chloro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-[5-bromo-indan-(1e)-ylidenemethyl]-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-fluoro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(1-chloro-7-methoxy-naphthalen-2-yl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-pyridin-3-yl-2,3-dihydro-1h-inden-1-one NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[4-chloro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-[5-fluoro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 7-pyridin-3-yl-2h-1,4-benzothiazin-3(4h)-one NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 2-methyl-1,2-di-pyridin-3-yl-propyliodide NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-naphthalen-2-yl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD fadrozole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved steroid 11-beta-hydroxylase CYP11B1 Successful target inhibitor 5.3 TTD , DGIDB 3-(6-methoxynaphthalen-2-yl)-5-phenylpyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-formyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(3-benzylnaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(5-chloro-6-methoxy-naphthalen-2-yl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-[5-fluoro-indan-(1e)-ylidenemethyl]-pyrimidine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(6-methoxy-naphthalen-2-yl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-(4-pyridyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-bromo-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-methoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-bromobenzyl)-5-phenyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-3,4-diamine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD fadrozole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved steroid 11-beta-hydroxylase CYP11B1 Successful target unknown 5.3 TTD , DGIDB 3-(6-bromo-naphthalen-2-yl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(5-bromo-6-methoxy-naphthalen-2-yl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD mitotane small molecule Tumors of Adrenal Cortex[MeSHID:D000306],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] approved cytochrome p450 11b1, mitochondrial CYP11B1 NA inducer,inhibitor 5.97 drugbank , DGIDB 3-(6-methoxy-3-methylnaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-hydroxymethyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD methyl 3-(1-benzyl-1h-imidazol-5-yl)-propanoate NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-indan-(1e)-ylidenemethyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 2-methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-((3',4'-difluorobiphenyl-4-yl)methyl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-(4-methylphenyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(1h-inden-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(3,4-dihydronaphthalen-2-yl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD metyrapone NA Pituitary Gland[MeSHID:D010902],Diagnosis[MeSHID:D003933],Cushing Syndrome[MeSHID:D003480],Hypothalamic structure[MeSHID:D007031],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved steroid 11-beta-hydroxylase CYP11B1 Successful target inhibitor 42.43 TTD , DGIDB 4-(4'-fluoro-biphenyl-4-ylmethyl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-fluorobenzyl)-5-phenyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-indan-(1z)-ylidenemethyl-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 6-pyridin-3-yl-3,4-dihydronaphthalen-2(1h)-one NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-imidazol-1-ylmethyl-1h-indole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-[5-chloro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-benzyl-5-phenyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-bromo-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-methoxybenzyl)-5-phenyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[4-chloro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(1,2-dihydroacenaphthylen-3-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-imidazol-1-ylmethyl-2-isopropyl-1h-indole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-(6-methoxynaphthalen-2-yl)pyridin-3-ol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-(4-fluorophenyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD benzylimidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD metyrapone small molecule Pituitary Gland[MeSHID:D010902],Diagnosis[MeSHID:D003933],Cushing Syndrome[MeSHID:D003480],Hypothalamic structure[MeSHID:D007031],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational cytochrome p450 11b1, mitochondrial CYP11B1 NA inhibitor 42.43 drugbank , DGIDB 3-ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[5-fluoro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD r-fadrozole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-((1h-imidazol-1-yl)methyl)aniline NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-(6-methoxy-3-methylnaphthalen-2-yl)isoquinoline NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-[(4'-hydroxybiphenyl-4-yl)methyl]pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-bromobenzyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-indan-(1z)-ylidenemethyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-methyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-3,4-diol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[1-(4-cyanobenzyl)-1h-imidazol-5-yl]-1-propanol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-imidazol-1-yl-quinoline NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-fluorobenzyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-phenyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-meso2-dde NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 2-methyl-1,2-di-pyridin-3-yl-propan-1-one oxime NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-pyridin-3-yl-1,3-dihydro-2h-indol-2-one NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 5-naphthalen-2-yl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 7-(1-(1h-imidazol-1-yl)ethyl)-9h-fluoren-2-ol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-[5-bromo-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 6-[4-(pyridin-4-ylmethyl)phenyl]naphthalen-2-ol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(3-chlorobenzyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(6-methoxynaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD metyrapol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 6-(4-methylpyridin-3-yl)-2-naphthonitrile NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[7-methoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(6-methoxynaphthalen-2-yl)pyridin-4-amine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(6-methoxynaphthalen-2-yl)-4-methylpyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-((1h-imidazol-1-yl)methyl)benzonitrile NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-(2-methylphenyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD osilodrostat NA Pituitary-dependent Cushing's disease[MeSHID:D047748],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved steroid 11-beta-hydroxylase CYP11B1 Successful target inhibitor 7.96 TTD , DGIDB 3-(3-benzyl-6-methoxynaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-(2-imidazol-1-yl-ethoxy)-benzamide NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 2-methyl-1,2-di-pyridin-3-yl-1-methoxypropane NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(2-chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD n-(4'-isonicotinoylbiphenyl-3-yl)acetamide NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(4-chlorobenzyl)-5-phenyl-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(2-phenoxy-ethyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(6-ethoxy-naphthalen-2-yl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-[5-fluoro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(1,1-dimethyl-2-phenyl-ethyl)-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(1-benzyl-1h-imidazol-5-yl)-1-propanol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 6-pyridin-3-yl-naphthalen-2-ol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(1,2-dihydroacenaphthylen-5-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-[1-(4-bromobenzyl)-1h-imidazol-5-yl]-1-propanol NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(3-fluorobenzyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-(6-methoxynaphthalen-2-yl)isoquinoline NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD metyrapone NA Pituitary Gland[MeSHID:D010902],Diagnosis[MeSHID:D003933],Cushing Syndrome[MeSHID:D003480],Hypothalamic structure[MeSHID:D007031],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved steroid 11-beta-hydroxylase CYP11B1 Successful target unknown 42.43 TTD , DGIDB 1-(4-cyanobenzyl)-5-(3-fluorophenyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 4-[5-chloro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-phenanthren-9-yl-pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 1-(3-bromobenzyl)-1h-imidazole NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 2-methyl-1-phenyl-2-pyridin-3-yl-propan-1-one NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 6-pyridin-3-yl-3,4-dihydroquinoline-2(1h)-thione NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative steroid 11-beta-hydroxylase CYP11B1 Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome p450 11b2, mitochondrial CYP11B2 NA antagonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved cytochrome p450 11b2, mitochondrial CYP11B2 NA antagonist NA drugbank osilodrostat small molecule Pituitary-dependent Cushing's disease[MeSHID:D047748],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 11b2, mitochondrial CYP11B2 NA inhibitor 10.61 drugbank , DGIDB 4'-(2-methyl-1-(pyridin-4-yl)propyl)biphenyl-3-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-(4'-fluoro-biphenyl-4-ylmethyl)pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-3,4-diamine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3-(4-fluorophenyl)propyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD rac-4'-(1-imidazol-1-yl-propyl)-biphenyl-4-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-((1h-imidazol-1-yl)methyl)phenol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD tak-700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown 36.37 TTD , DGIDB abiraterone acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved steroid 17-alpha-monooxygenase CYP17A1 Successful target inhibitor 9.09 TTD , DGIDB isoconazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD cfg920 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown 9.09 TTD , DGIDB 1-(4-bromophenethyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4'-(1-(pyridin-4-yl)propyl)biphenyl-3-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-[5-chloro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 2,3,5,6-tetrafluoro-4-pentafluorophenylazo-phenol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD abiraterone NA Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved steroid 17-alpha-monooxygenase CYP17A1 Successful target inhibitor 10.91 TTD , DGIDB rac-4'-(1-imidazol-1-yl-propyl)-biphenyl-3-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD n-3-(4-bromophenyl)propyl imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-[5-bromo-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-((9h-fluoren-2-yl)ethyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 5-[4-(pyridin-4-ylmethyl)phenyl]-1h-indole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-(1-chloro-7-methoxy-naphthalen-2-yl)-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 5-[5-fluoro-indan-(1e)-ylidenemethyl]-pyrimidine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3,5-dichlorobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA inhibitor NA drugbank 4-[5-chloro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(4-fluorobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-(6-methoxynaphthalen-2-yl)pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-((3',4'-difluorobiphenyl-4-yl)methyl)pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA inhibitor NA drugbank 3-fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-3-amine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA substrate,inhibitor NA drugbank 1-(1-biphenyl-4-yl-ethyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3,5-bis(trifluoromethyl)benzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-biphenyl-4-yl-2-methyl-propyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 6-pyridin-3-yl-3,4-dihydroquinoline-2(1h)-thione NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD n-(4'-isonicotinoylbiphenyl-3-yl)acetamide NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-4-carboxamide NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 2,3,4,5-tetrafluoro-6-pentafluorophenylazo-phenol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3-phenylpropyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA unknown NA drugbank 4-[1-(4'-methoxybiphenyl-4-yl)propyl]pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD rac-4'-(1-imidazol-1-yl-propyl)-biphenyl-3,5-diol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-(biphenyl-4-yl)allyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-[(4'-hydroxybiphenyl-4-yl)methyl]pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD rac-4'-(1-imidazol-1-yl-propyl)-biphenyl-3,4-diol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-biphenyl-4-yl-3-methyl-butyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-biphenyl-4-yl-pentyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3,5-dibromobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(4-iodobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3-(4-chlorophenyl)propyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(4-bromobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-(4-(thiophen-2-yl)benzyl)pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-(4-thiophen-3-ylphenyl)ethyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA antagonist NA drugbank abiraterone NA Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown 10.91 TTD , DGIDB 6-[4-(pyridin-4-ylmethyl)phenyl]naphthalen-2-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD seviteronel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown 9.09 TTD , DGIDB 4-[5-bromo-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD dst-2970 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-indan-(1z)-ylidenemethyl-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3,4-difluorobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3,5-difluorobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-[4-fluoro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-[(4'-hydroxybiphenyl-4-yl)methyl]pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-(4-(thiophen-3-yl)benzyl)pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-imidazol-1-ylmethylxanthen-9-one NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-(6-ethoxy-naphthalen-2-yl)-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(4-methyl-benzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-(4-thiophen-3-yl-phenyl)propyl)-1himidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-bromo-1-imidazol-1-ylmethyl-xanthen-9-one NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(3,4-dichlorobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-biphenyl-4-yl-2-phenyl-ethyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-ethyl-5-(imidazol-1-yl-phenyl-methyl)-1h-indole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-imidazol-1-ylmethyl-4-nitro-xanthen-9-one NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA inhibitor NA drugbank progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA substrate,inhibitor NA drugbank abiraterone small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA inhibitor 10.91 drugbank , DGIDB 4-[(3'-hydroxybiphenyl-4-yl)methyl]pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-(4'-ethylbiphenyl-4-yl)propyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-[5-fluoro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(4-nitrobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-3,4-diol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-4-amine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(bis-biphenyl-4-yl-methyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-fluoro-4'-(1-(pyridin-4-yl)propyl)biphenyl-4-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD vn/107-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 6-(pyridin-3-yl)-2-naphthonitrile NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 7-(1-(1h-imidazol-1-yl)ethyl)-9h-fluoren-2-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(4-chlorobenzyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-[5-fluoro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 2-(1-imidazol-1-yl-ethyl)-9h-carbazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD abiraterone acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD , DGIDB 1-(1-biphenyl-4-yl-propyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(1-biphenyl-4-yl-butyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 6-pyridin-3-yl-naphthalen-2-ol NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA antagonist NA drugbank ang-3407 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 4-((1h-imidazol-1-yl)methyl)benzonitrile NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-(4-chlorophenethyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 1-((9h-fluoren-2-yl)methyl)-1h-imidazole NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine NA NA investigative steroid 17-alpha-monooxygenase CYP17A1 Successful target unknown NA TTD ketoconazole small molecule Paracoccidioidomycosis[MeSHID:D010229],Mycoses[MeSHID:D009181],Coccidioidomycosis[MeSHID:D003047],Cushing Syndrome[MeSHID:D003480],Candidiasis[MeSHID:D002177],Chromoblastomycosis[MeSHID:D002862],Blastomycosis[MeSHID:D001759],Histoplasmosis[MeSHID:D006660],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 NA inhibitor NA drugbank nsc-356483 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD letrozole small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 19a1 CYP19A1 NA antagonist 1.89 drugbank , DGIDB 5-[5-methoxy-indan-(1z)-ylidenemethyl]-thiazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(4-nitro-2-phenoxybenzyl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-indan-(1z)-ylidenemethyl-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD dehydroleucodin NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-[5-methoxy-indan-(1e)-ylidenemethyl]-thiazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-(1-imidazol-1-yl-vinyl)-benzonitrile NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(imidazolylmethyl)-4'-nitroflavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-((1h-imidazol-1-yl)methyl)-2h-chromen-2-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2,3,4-trimethoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-imidazol-1-yl-2-phenyl-chroman-7-ol NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-androstene-3-17-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-imidazol-1-ylmethylxanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD atamestane + toremifene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 aromatase CYP19A1 Successful target unknown NA TTD gamma-mangostin NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 9-hydroxy-7,8-benzoflavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[5-methoxy-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-bromo-1-imidazol-1-ylmethyl-xanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(imidazolylmethyl)flavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD mr-20814 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD isogemichalcone c NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3,5-dihydroxyl-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-((1h-imidazol-1-yl)methyl)-7,8-dihydroquinoline NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2-imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD aminoglutethimide small molecule Malignant neoplasm of breast[MeSHID:D001943],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational cytochrome p450 19a1 CYP19A1 NA inhibitor 3.54 drugbank , DGIDB 1-(4-aminophenyl)-2-(1h-imidazol-1-yl)ethanone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-75308 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[6-methoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD exemestane small molecule Malignant neoplasm of breast[MeSHID:D001943],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 19a1 CYP19A1 NA inhibitor 2.27 drugbank , DGIDB letrozole small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 19a1 CYP19A1 NA antagonist,inhibitor 1.89 drugbank , DGIDB 3-[5-ethoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[6-methyl-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-nitro-4'-nitro-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(4-amino-phenyl)-3-hexyl-piperidine-2,6-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD naringenin small molecule NA experimental cytochrome p450 19a1 CYP19A1 NA inhibitor 0.44 drugbank , DGIDB 1-(9-phenyl-9h-fluoren-9-yl)1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(3-methoxy-naphthalen-2-yl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-fluoro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD naringenin NA NA phase 1 aromatase CYP19A1 Successful target unknown 0.44 TTD , DGIDB 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[(3'-hydroxybiphenyl-4-yl)methyl]pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3,5-dimethoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD n-(2-nonyloxy-4-nitrophenyl)methanesulfonamide NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4'-bromo-3-(imidazolylmethyl)flavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3,5-diacetoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(2-(benzo[b]thiophen-4-yl)ethyl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[6-methyl-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[6-methoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4'-cyano-3-(imidazolylmethyl)flavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD gossypetin NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD n-[2-(4'-nitrophenyl)ethyl]-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-imidazol-1-ylmethylxanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD finrozole NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 aromatase CYP19A1 Successful target unknown NA TTD 5-pyridin-3-yl-1,3-dihydro-2h-indol-2-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[5-fluoro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD alpha-naphthoflavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-[5-fluoro-indan-(1z)-ylidenemethyl]-pyrimidine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD letrozole NA Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatase CYP19A1 Successful target unknown 1.89 TTD , DGIDB 2-(3-hydroxyphenyl)-7-methoxychroman-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2-methoxyestradiol small molecule Arthritis[MeSHID:D001168],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of breast[MeSHID:D001943],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cytochrome p450 19a1 CYP19A1 NA unknown NA drugbank 1-(1-benzyl-2-biphenyl-4-yl-ethyl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(imidazolylmethyl)-4'-methoxyflavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD fadrozole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved aromatase CYP19A1 Successful target inhibitor 0.59 TTD , DGIDB 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD (2s)-5,7,2',4'-tetrahydroxyflavanone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-ethyl-5-(imidazol-1-yl-phenyl-methyl)-1h-indole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-122427 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[6-methoxy-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-naphthalen-2-yl-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD testolactone small molecule Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 19a1 CYP19A1 NA inhibitor 5.89 drugbank , DGIDB 2-phenyl-3-pyridin-4-ylmethylene-chroman-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(2-phenoxybenzyl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 7,4'-dihydroxyflavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2,5-dimethoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-imidazol-1-ylmethyl-3-nitroxanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-methoxyl-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3,4-bis(3,4-dimethoxyphenyl)furan-2(5h)-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[4-chloro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 7-[1,2,4]triazol-4-ylmethyl-chromen-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD letrozole NA Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatase CYP19A1 Successful target inhibitor 1.89 TTD , DGIDB 3-fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-131736 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-289311 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-369087 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD mdl-18962 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-368280 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2,3-dimethoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[6-methyl-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD androstenedone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-(2-(1h-imidazol-1-yl)ethyl)quinoline NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD mr-16089 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD (2s)-abyssinone ii NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD mpi-674 small molecule Menstruation Disturbances[MeSHID:D008599] investigational cytochrome p450 19a1 CYP19A1 NA unknown NA drugbank , DGIDB 4-(3,4,5-trimethoxyphenethyl)aniline NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD mr-20494 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD aminoglutethimide NA Malignant neoplasm of breast[MeSHID:D001943],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved aromatase CYP19A1 Successful target inhibitor 3.54 TTD , DGIDB nsc-368272 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[3-methyl-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD estrone small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome p450 19a1 CYP19A1 NA unknown NA drugbank 3-[3-methyl-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[(4'-hydroxybiphenyl-4-yl)methyl]pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-indan-(1z)-ylidenemethyl-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD anastrozole small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 19a1 CYP19A1 NA inhibitor 2.99 drugbank , DGIDB 3-(5-bromo-6-methoxy-naphthalen-2-yl)-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(6-ethoxy-naphthalen-2-yl)-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD isolicoflavonol NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2-phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-ethoxy-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-3-amine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 aromatase CYP19A1 Successful target unknown NA TTD , DGIDB testolactone NA Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatase CYP19A1 Successful target inhibitor 5.89 TTD , DGIDB 4-[5-fluoro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 8-imidazol-1-ylmethyl-5-nitro-chromen-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3,5-diamino-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-[(7-fluoronaphth-2-yl)methyl]-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-((1h-imidazol-1-yl)methyl)-9h-xanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD exemestane NA Malignant neoplasm of breast[MeSHID:D001943],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatase CYP19A1 Successful target inhibitor 2.27 TTD , DGIDB 2,4-dimethoxy-3'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-[5-bromo-indan-(1e)-ylidenemethyl]-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(2,2-diphenyl-vinyl)-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-imidazol-1-ylmethylthioxanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2,4-dimethoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD org-33201 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(naphthalen-2-yl)pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(9-phenyl-9h-fluoren-9-yl)-1h-1,2,4-triazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-[5-bromo-indan-(1z)-ylidenemethyl]-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD garcinone d NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 6-((1h-imidazol-1-yl)methyl)-2h-chromene-2-thione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 6-imidazol-1-yl-isoquinoline NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 7-(2-(1h-imidazol-1-yl)ethoxy)-2h-chromen-2-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-fluoren-9-ylidenemethyl-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(5-chloro-6-methoxy-naphthalen-2-yl)-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-625409 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(4-amino-phenyl)-3-heptyl-piperidine-2,6-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD mr-20492 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD vorozole NA NA discontinued in phase 2 aromatase CYP19A1 Successful target unknown NA TTD cgs-18320b NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-[5-fluoro-indan-(1e)-ylidenemethyl]-pyrimidine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-bromo-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(biphenyl-3-ylmethyl)-1h-1,2,4-triazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2,3,5-trimethoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD monodictyochromone b NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-((1h-imidazol-1-yl)methyl)benzonitrile NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-bromo-4-imidazol-1-ylmethyl-xanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 7-((1h-imidazol-1-yl)methyl)-2h-chromen-2-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-methoxy-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD broussoflavonol f NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-(3,4-dimethoxyphenethyl)aniline NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD formestane NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] withdrawn from market aromatase CYP19A1 Successful target unknown NA TTD 5-indan-(1e)-ylidenemethyl-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[4-methyl-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD n-(2-propyloxy-4-nitrophenyl)methanesulfonamide NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 7-((1h-imidazol-1-yl)methyl)-4h-chromen-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(4-amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2-(4-hydroxyphenyl)-7-methoxychroman-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[5-chloro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[5-chloro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-imidazol-1-ylmethyl-2-nitroxanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-94891 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD bgs-649 NA Baller-Gerold syndrome[MeSHID:C536788],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 aromatase CYP19A1 Successful target unknown NA TTD , DGIDB (+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-93358 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD anastrozole NA Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatase CYP19A1 Successful target inhibitor 2.99 TTD , DGIDB 3-[4-methyl-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD fadrozole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved aromatase CYP19A1 Successful target unknown 0.59 TTD , DGIDB n-(2-benzyloxy-4-nitrophenyl)methanesulfonamide NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(4-amino-phenyl)-3-butyl-piperidine-2,6-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3,4'-(ethane-1,2-diyl)dibenzenamine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(9h-fluoren-9-yl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 7-((1h-imidazol-1-yl)methyl)isoquinoline NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD docosapentaenoic acid NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-indan-(1e)-ylidenemethyl-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-indan-(1e)-ylidenemethyl-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[4-chloro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nicotine small molecule Cessation of smoking[MeSHID:D016540],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nicotine Dependence[MeSHID:D014029] approved cytochrome p450 19a1 CYP19A1 NA inhibitor NA drugbank 10-epi-8-deoxy-cumambrin b NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-fluoren-9-ylidenemethyl-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD albanol a NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(3-(4-fluorophenyl)propyl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD glyphosate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] experimental cytochrome p450 19a1 CYP19A1 NA unknown NA drugbank 4-[6-methyl-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD flavone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2-imidazol-1-ylmethylxanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[4-fluoro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD apigenin NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD morachalcone a NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[3-phenyl-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD anastrozole NA Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatase CYP19A1 Successful target unknown 2.99 TTD , DGIDB 3,4,5-trimethoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 2-(1h-imidazol-1-yl)-1-(4-nitrophenyl)ethanone NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-(2-(1h-imidazol-1-yl)ethoxy)-2h-chromen-2-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD (+/-)-7-methoxy-2-phenylchroman-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD biochanin a NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3,4-dimethoxy-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-94258 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nks-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] discontinued in phase 2 aromatase CYP19A1 Successful target unknown NA TTD liquirtigenin NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD (2s)-euchrenone a7 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-683634 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD aminoglutethimide NA Malignant neoplasm of breast[MeSHID:D001943],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved aromatase CYP19A1 Successful target unknown 3.54 TTD , DGIDB 3-[7-methoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(4-cyanobenzyl)-5-methyl-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD dextromethorphan+quinidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] phase 2 aromatase CYP19A1 Successful target unknown NA TTD , DGIDB 4-(2,2-diphenyl-vinyl)-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-imidazol-1-ylmethyl-4-nitro-xanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-amino-4'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-imidazol-1-ylmethyl-1-nitro-xanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-356781 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-pyridin-3-yl-2,3-dihydro-1h-inden-1-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[4-fluoro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 11beta,13-dihydro-10-epi-8-deoxycumam-brin b NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD testolactone NA Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatase CYP19A1 Successful target unknown 5.89 TTD , DGIDB 3-(4-amino-phenyl)-3-pentyl-piperidine-2,6-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-bromo-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(4-amino-phenyl)-pyrrolidine-2,5-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-indan-(1z)-ylidenemethyl-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3,4,5-trimethoxy-3'-amino-trans-stilbene NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 5-bromo-8-imidazol-1-ylmethyl-chromen-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(6-methoxynaphthalen-2-yl)pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 7-hydroxy-2-phenylchroman-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-fluoro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-chloro-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4'-(pyridin-4-ylmethyl)biphenyl-3,4-diol NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(4-nitro-2-phenylsulfanylbenzyl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD liarozole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] phase 2/3 aromatase CYP19A1 Successful target unknown 0.59 TTD , DGIDB 4-[5-bromo-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD n-(2-hexyloxy-4-nitrophenyl)methanesulfonamide NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-chloro-indan-(1z)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD ludartin NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD mr-20496 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(4-amino-phenyl)-3-methyl-pyrrolidine-2,5-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 1-(7-methoxy-2-phenyl-chroman-4-yl)-1h-imidazole NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-12999 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-(4-amino-phenyl)-1-methyl-pyrrolidine-2,5-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 4-[5-methoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-666292 NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD 3-[5-methoxy-indan-(1e)-ylidenemethyl]-pyridine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD ym-511 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 2 aromatase CYP19A1 Successful target unknown NA TTD 3-(4-amino-phenyl)-3-propyl-piperidine-2,6-dione NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD chrysin NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nsc-613604 NA NA investigative aromatase CYP19A1 Successful target unknown 3.54 TTD , DGIDB 4-imidazol-1-ylmethyl-1-nitrothioxanthen-9-one NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD exemestane NA Malignant neoplasm of breast[MeSHID:D001943],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatase CYP19A1 Successful target unknown 2.27 TTD , DGIDB 4-(3,5-dimethoxyphenethyl)benzenamine NA NA investigative aromatase CYP19A1 Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational cytochrome p450 1a1 CYP1A1 NA inhibitor NA drugbank 2-methoxyestradiol small molecule Arthritis[MeSHID:D001168],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of breast[MeSHID:D001943],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cytochrome p450 1a1 CYP1A1 NA unknown NA drugbank indirubin small molecule NA investigational cytochrome p450 1a1 CYP1A1 NA substrate NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational cytochrome p450 1a2 CYP1A2 NA inhibitor NA drugbank isoniazid small molecule Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 1a2 CYP1A2 NA unknown 0.03 drugbank , DGIDB diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational cytochrome p450 1a2 CYP1A2 NA inhibitor NA drugbank alpha-naphthoflavone small molecule NA experimental cytochrome p450 1a2 CYP1A2 NA unknown NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational cytochrome p450 1a2 CYP1A2 NA inhibitor NA drugbank 2-[2-(3,5-dimethoxy-phenyl)-vinyl]-thiophene NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD kaempferide NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD isorhamnetin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD flavone small molecule NA approved,experimental cytochrome p450 1b1 CYP1B1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational cytochrome p450 1b1 CYP1B1 NA unknown NA drugbank homoeriodictyol NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD chrysoeriol NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD isosakutanetin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD galangin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational cytochrome p450 1b1 CYP1B1 NA inhibitor NA drugbank 3-[2-(3,5-dimethoxy-phenyl)-vinyl]-furan NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD acacetin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown 0.3 TTD , DGIDB pinocembrin NA NA phase 2 cytochrome p450 1b1 CYP1B1 Clinical trial target unknown 2.27 TTD , DGIDB chrysin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target inhibitor 0.45 TTD , DGIDB naringenin small molecule NA experimental,phase 1 cytochrome p450 1b1 CYP1B1 Clinical trial target unknown 0.57 TTD , drugbank , DGIDB eriodictyol NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD diosmetin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD kaempferol NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cytochrome p450 1b1 CYP1B1 NA unknown NA drugbank apigenin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD trismethoxyresveratrol NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD n-(2,4-dimethoxy-phenyl)-3,5-dimethoxy-benzamide NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD 2-methoxyestradiol small molecule Arthritis[MeSHID:D001168],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of breast[MeSHID:D001943],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cytochrome p450 1b1 CYP1B1 NA unknown NA drugbank tamarixetin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD chrysin NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown 0.45 TTD , DGIDB 4-[2-(3,5-dimethoxy-phenyl)-vinyl]-pyridine NA NA investigative cytochrome p450 1b1 CYP1B1 Clinical trial target unknown NA TTD beta-naphthoflavone small molecule NA experimental cytochrome p450 1b1 CYP1B1 NA unknown 2.27 drugbank , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational cytochrome p450 1b1 CYP1B1 NA inhibitor NA drugbank ketoconazole small molecule Paracoccidioidomycosis[MeSHID:D010229],Mycoses[MeSHID:D009181],Coccidioidomycosis[MeSHID:D003047],Cushing Syndrome[MeSHID:D003480],Candidiasis[MeSHID:D002177],Chromoblastomycosis[MeSHID:D002862],Blastomycosis[MeSHID:D001759],Histoplasmosis[MeSHID:D006660],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational steroid 21-hydroxylase CYP21A2 NA inhibitor NA drugbank lunacalcipol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 cytochrome p450 24 CYP24A1 Clinical trial target unknown 12.73 TTD , DGIDB cta018 small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Kidney Diseases[MeSHID:D007674] investigational 1,25-dihydroxyvitamin d(3) 24-hydroxylase, mitochondrial CYP24A1 NA unknown 12.73 drugbank , DGIDB liarozole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] phase 2/3 cytochrome p450 26 CYP26A1 Clinical trial target unknown 21.22 TTD , DGIDB talarozole small molecule NA investigational cytochrome p450 26a1 CYP26A1 NA inhibitor 31.83 drugbank , DGIDB rambazole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Asthma[MeSHID:D001249] phase 2 cytochrome p450 26 CYP26A1 Clinical trial target unknown 31.83 TTD , DGIDB talarozole small molecule NA investigational cytochrome p450 26a1 CYP26A1 NA unknown 31.83 drugbank , DGIDB 4-((+/-)-(1h-imidazol-1-yl)-(e)-retinoic acid NA NA investigative cytochrome p450 26 CYP26A1 Clinical trial target unknown NA TTD tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical cytochrome p450 26a1 CYP26A1 NA unknown NA drugbank 4-((+/-)-(1h-imidazol-1-yl)-(e)-methylretinoate NA NA investigative cytochrome p450 26 CYP26A1 Clinical trial target unknown NA TTD tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical cytochrome p450 26b1 CYP26B1 NA unknown NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical cytochrome p450 26c1 CYP26C1 NA unknown NA drugbank alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational cytochrome p450 26c1 CYP26C1 NA unknown NA drugbank alfacalcidol small molecule Disease Management[MeSHID:D019468],Adult Rickets[MeSHID:D010018],Hypocalcemia[MeSHID:D006996],Malabsorption Syndrome[MeSHID:D008286],Hypophosphatemic Rickets, X-Linked Dominant[MeSHID:D053098],Vitamin D-resistant rickets[MeSHID:D063730],Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],Rickets[MeSHID:D012279],Kidney Failure, Chronic[MeSHID:D007676] approved,nutraceutical 25-hydroxyvitamin d-1 alpha hydroxylase, mitochondrial CYP27B1 NA unknown NA drugbank n-methyl(5-(pyridin-3-yl)furan-2-yl)methanamine small molecule NA experimental cytochrome p450 2a6 CYP2A6 NA unknown NA drugbank coumarin small molecule NA experimental cytochrome p450 2a6 CYP2A6 NA unknown 4.2 drugbank , DGIDB 4,4'-dipyridyl disulfide small molecule NA experimental cytochrome p450 2a6 CYP2A6 NA unknown NA drugbank n,n-dimethyl(5-(pyridin-3-yl)furan-2-yl)methanamine small molecule NA experimental cytochrome p450 2a6 CYP2A6 NA unknown NA drugbank methoxsalen NA Psoriasis[MeSHID:D011565],Vitiligo[MeSHID:D014820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410] approved cytochrome p450 2a6 CYP2A6 Successful target unknown 0.33 TTD , DGIDB (5-(pyridin-3-yl)furan-2-yl)methanamine small molecule NA experimental cytochrome p450 2a6 CYP2A6 NA unknown NA drugbank cyclohexyl-pentyl-maltoside small molecule NA experimental cytochrome p450 2b6 CYP2B6 NA unknown NA drugbank bifonazole small molecule Tinea Pedis[MeSHID:D014008],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 2b6 CYP2B6 NA unknown NA drugbank 4-(4-chlorophenyl)imidazole small molecule NA experimental cytochrome p450 2b6 CYP2B6 NA unknown NA drugbank 1-(biphenyl-4-ylmethyl)-1h-imidazole small molecule NA experimental cytochrome p450 2b6 CYP2B6 NA unknown NA drugbank n,4-dimethyl-n-(1-phenyl-1h-pyrazol-5-yl)benzenesulfonamide small molecule NA experimental cytochrome p450 2c18 CYP2C18 NA unknown NA drugbank isoniazid small molecule Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 2c19 CYP2C19 NA unknown 0.02 drugbank , DGIDB benzbromarone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] investigational,withdrawn cytochrome p450 2c19 CYP2C19 NA inhibitor NA drugbank palmitic acid small molecule NA approved cytochrome p450 2c8 CYP2C8 NA unknown NA drugbank isoniazid small molecule Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 2c8 CYP2C8 NA unknown NA drugbank (5r)-5-(4-{[(2r)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2h-chromen-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione small molecule NA experimental cytochrome p450 2c8 CYP2C8 NA unknown NA drugbank sulfaphenazole NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved s-mephenytoin 4-hydroxylase CYP2C9 Successful target unknown 0.06 TTD , DGIDB benzbromarone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] investigational,withdrawn cytochrome p450 2c9 CYP2C9 NA inhibitor 0.06 drugbank , DGIDB ferroheme c small molecule NA experimental cytochrome p450 2c9 CYP2C9 NA unknown NA drugbank diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational cytochrome p450 2c9 CYP2C9 NA inhibitor NA drugbank bs 9106 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD kaempferol-3-o-methyl ether NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD bs 7840 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD gnf-pf-2094 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 3-(6-methoxynaphthalen-2-yl)pyridin-4-amine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD desethyl isoquine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 4-[5-(3-hydroxyphenyl)-2-thienyl)-2-methyl]phenol NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD ml-3163 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational cytochrome p450 2d6 CYP2D6 NA substrate,inhibitor NA drugbank gnf-pf-4292 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 4-(3-phenylethynyl-benzyl)-1h-imidazole NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD isoquine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] phase 1 debrisoquine 4-hydroxylase CYP2D6 Successful target unknown 0.04 TTD , DGIDB ici-199441 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD gbr 12530 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD (2-hydroxy-3-phenoxypropyl)(propan-2-yl)amine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD go-y022 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD bs 7581 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 1-(4-butoxy-phenyl)-1h-imidazole NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD glutethimide NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved debrisoquine 4-hydroxylase CYP2D6 Successful target unknown 0.01 TTD , DGIDB 1-(methoxymethyl)-6-(naphthalen-2-yl)-3-azabicyclo[4.1.0]heptane (enantiomeric mix) NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD prodipine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 2-hexyloxy-5-imidazol-1-yl-pyridine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD gbr-12289 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 2-(2-(4-tert-butylphenylthio)ethyl)-1h-imidazole NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational cytochrome p450 2d6 CYP2D6 NA inhibitor NA drugbank 4-[5-(3-hydroxyphenyl)-3-thienyl]-2-methylphenol NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD gnf-pf-5411 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 1h-1,2,3-benzotriazol-1-amine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 3-[3-(4-imidazol-1-yl-phenoxy)-propyl]-pyridine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD (5-phenylfuran-2-yl)methanamine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD sb-210313 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 2-[3-(4-imidazol-1-yl-phenoxy)-propyl]-pyridine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane (enantiomeric mix) NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 2-(4-imidazol-1-yl-phenoxymethyl)-pyridine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 2-fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational cytochrome p450 2d6 CYP2D6 NA inhibitor NA drugbank (5-(pyridin-3-yl)furan-2-yl)methanamine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD dihydrocubebin NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 4-methylaminomethyl-7-methoxycoumarin NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 4-[2-(4-imidazol-1-yl-phenoxy)-ethyl]-morpholine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 4-[3-(4-imidazol-1-yl-phenoxy)-propyl]-pyridine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 4-(3-pent-1-ynyl-benzyl)-1h-imidazole NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD gb-12819 NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD (5-pyridin-3-yl-furan-2-yl)methanethiol NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD 6-(3,4-dichlorophenyl)-1-[1-(methyloxy)-3-buten-1-yl]-3-azabicyclo[4.1.0]heptane (diastereomeric mix) NA NA investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD bms-694153 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] investigative debrisoquine 4-hydroxylase CYP2D6 Successful target unknown NA TTD diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational cytochrome p450 2e1 CYP2E1 NA inhibitor NA drugbank heme NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (-)-dihydroclusin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 1-acetoxy-2-tert-butyldimethylsilyl-oxylycorine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD palmatine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 1-(methoxymethyl)-6-(naphthalen-2-yl)-3-azabicyclo[4.1.0]heptane (enantiomeric mix) NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 1-acetoxylycorine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD go-y026 NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 4-[5-(3-hydroxyphenyl)-2-thienyl)-2-methyl]phenol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 1h-1,2,3-benzotriazol-1-amine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD jatrorrhizine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD ml-3375 NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 3-(5-((methylthio)methyl)furan-2-yl)pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 1,1':4',1''-terphenyl-3,3''-diol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD pmx-53 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD , DGIDB 6-pyridin-3-yl-3,4-dihydronaphthalen-2(1h)-one NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 4-[3-(4-imidazol-1-yl-phenoxy)-propyl]-pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD ml-3403 NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD alpha-methylcubebin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 2-[3-(4-imidazol-1-yl-phenoxy)-propyl]-pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 1-(4-butoxy-phenyl)-1h-imidazole NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD ml-3163 NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD bms-536924 NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target inhibitor 0.02 TTD , DGIDB bergaptol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown 0.02 TTD , DGIDB gsk-8062 NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 3-[5-(4-hydroxyphenyl)-3-thienyl]phenol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (-)-clusin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD pradefovir mesylate small molecule Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506] investigational cytochrome p450 3a4 CYP3A4 NA unknown NA drugbank isoniazid small molecule Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytochrome p450 3a4 CYP3A4 NA unknown 0.01 drugbank , DGIDB tiliroside NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical cytochrome p450 3a4 CYP3A4 NA unknown NA drugbank 5-(2-phenethylpiperazin-1-yl)-1h-indazole NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (8r,8'r,9's)-5-methoxyclusin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane (enantiomeric mix) NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (-)-yatein NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 2-(2-(4-tert-butylphenylthio)ethyl)-1h-imidazole NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 albendazole monooxygenase CYP3A4 Clinical trial target unknown 0 TTD , DGIDB (8r,8'r)-4-hydroxycubebinone NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational cytochrome p450 3a subfamily CYP3A4 NA inhibitor NA drugbank 3-[3-(4-imidazol-1-yl-phenoxy)-propyl]-pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 3,3-(1,3-thiazole-2,5-diyl)diphenol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (5-pyridin-3-yl-furan-2-yl)methanethiol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 2-fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 4-[2-(4-imidazol-1-yl-phenoxy)-ethyl]-morpholine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD avi-4557 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 cyp3a4 messenger rna CYP3A4 Clinical trial target unknown NA TTD , DGIDB casopitant small molecule Urinary Incontinence[MeSHID:D014549],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] investigational cytochrome p450 3a4 CYP3A4 NA unknown NA drugbank 2-tert-butyldimethylsilyloxylycorine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD alpha-hydroxy-midazolam NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 4-[5-(3-hydroxyphenyl)-3-thienyl]-2-methylphenol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (-)-cubebininolide NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD diethoxyflourescein NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 3-(pyridin-3-yl)prop-2-yn-1-amine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 6-(3-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD geranylcoumarin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 5-pyridin-3-yl-thiophene-2-carbaldehyde oxime NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD hinokinin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 2,5-bis(4-hydroxybenzylidene)cyclopentanone NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 2-(4-imidazol-1-yl-phenoxymethyl)-pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (-)-cubebinin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 6-(3,4-dichlorophenyl)-1-[1-(methyloxy)-3-buten-1-yl]-3-azabicyclo[4.1.0]heptane (diastereomeric mix) NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (-)-cubebin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD dihydrocubebin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD medioresinol NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 3-(3-methylthiophen-2-yl)pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD (-)-thujaplicatintrimethyl ether NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD ethoxyclusin NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 3-[3-(4-methoxybenzyl)naphthalen-2-yl]pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 4-(6-methoxynaphthalen-2-yl)isoquinoline NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 1,2-diacetoxylycorine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD 2-fluoro-5-(3-methylthiophen-2-yl)pyridine NA NA investigative albendazole monooxygenase CYP3A4 Clinical trial target unknown NA TTD diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational cytochrome p450 3a subfamily CYP3A43 NA inhibitor NA drugbank diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational cytochrome p450 3a subfamily CYP3A5 NA inhibitor NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational cytochrome p450 3a5 CYP3A5 NA inhibitor NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational cytochrome p450 3a5 CYP3A5 NA inhibitor NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational cytochrome p450 3a7 CYP3A7 NA inhibitor NA drugbank diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational cytochrome p450 3a subfamily CYP3A7 NA inhibitor NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational cytochrome p450 3a7 CYP3A7 NA inhibitor NA drugbank pmid25514969-compound-13 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB pmid25514969-compound-9 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB tak-935 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Tuberous Sclerosis[MeSHID:D014402] phase 2 cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown 63.65 TTD , DGIDB pmid25514969-compound-11 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB pmid25514969-compound-figure2-4 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB rc-8800 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 cholesterol 24-monooxygenase CYP46A1 Discontinued target unknown NA TTD , DGIDB pmid25514969-compound-12 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB pmid25514969-compound-figure2-2 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB pmid25514969-compound-figure2-3 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB pmid25514969-compound-8 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB pmid25514969-compound-10 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB pmid25514969-compound-figure3 NA NA patented cholesterol 24-hydroxylase CYP46A1 Clinical trial target unknown NA TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical cytochrome p450 4a11 CYP4A11 NA unknown NA drugbank vt-1129 NA Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Onchocerciasis[MeSHID:D009855],Meningitis, Cryptococcal[MeSHID:D016919],Onychomycosis[MeSHID:D014009],Communicable Diseases[MeSHID:D003141] phase 2 lanosterol 14-alpha demethylase CYP51A1 Clinical trial target unknown NA TTD , DGIDB levoketoconazole small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] approved,investigational lanosterol 14-alpha demethylase CYP51A1 NA unknown NA drugbank tioconazole small molecule Candidiasis, Vulvovaginal[MeSHID:D002181],Candidiasis[MeSHID:D002177],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Onychomycosis[MeSHID:D014009] approved lanosterol 14-alpha demethylase CYP51A1 NA inhibitor NA drugbank (s)-econazole small molecule NA experimental lanosterol 14-alpha demethylase CYP51A1 NA unknown NA drugbank itraconazole small molecule Mycoses[MeSHID:D009181],Onychomycosis[MeSHID:D014009],Lung[MeSHID:D008168],Immunocompromised Host[MeSHID:D016867],Blastomycosis[MeSHID:D001759],Histoplasmosis[MeSHID:D006660],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational lanosterol 14-alpha demethylase CYP51A1 NA inhibitor NA drugbank masilukast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD , DGIDB iralukast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist 4.55 TTD , DGIDB cinalukast small molecule Asthma[MeSHID:D001249],Bronchoconstriction[MeSHID:D016084],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental cysteinyl leukotriene receptor 1 CYSLTR1 NA antagonist 9.09 drugbank , DGIDB zafirlukast small molecule Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cysteinyl leukotriene receptor 1 CYSLTR1 NA antagonist 3.21 drugbank , DGIDB nedocromil small molecule Asthma[MeSHID:D001249] approved,investigational cysteinyl leukotriene receptor 1 CYSLTR1 NA antagonist 15.91 drugbank , DGIDB montelukast NA Bronchoconstriction[MeSHID:D016084],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Hypersensitivity[MeSHID:D006967],Inspiration function[MeSHID:D001239],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 2.78 TTD , DGIDB pranlukast NA Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 25.01 TTD , DGIDB fk-011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD ym-57158 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD , DGIDB as-35 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD xgp-510 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] investigative leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD montelukast small molecule Bronchoconstriction[MeSHID:D016084],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Hypersensitivity[MeSHID:D006967],Inspiration function[MeSHID:D001239],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cysteinyl leukotriene receptor 1 CYSLTR1 NA antagonist 2.78 drugbank , DGIDB leukotriene d4 small molecule NA investigational cysteinyl leukotriene receptor 1 CYSLTR1 NA unknown NA drugbank pranlukast small molecule Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational cysteinyl leukotriene receptor 1 CYSLTR1 NA antagonist 25.01 drugbank , DGIDB ly-2300559 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 2.27 TTD , DGIDB cinalukast NA Asthma[MeSHID:D001249],Bronchoconstriction[MeSHID:D016084],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 9.09 TTD , DGIDB lm-1507.na NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD , DGIDB sulukast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist 4.55 TTD , DGIDB kp-496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD , DGIDB montelukast small molecule Bronchoconstriction[MeSHID:D016084],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Hypersensitivity[MeSHID:D006967],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cysteinyl leukotriene receptor 1 CYSLTR1 NA antagonist 2.78 drugbank , DGIDB claritin/singulair NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD , DGIDB zafirlukast NA Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist 3.21 TTD , DGIDB n-methyl ltc4 NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target agonist NA TTD , DGIDB pranlukast NA Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist 25.01 TTD , DGIDB ltc4 NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target agonist NA TTD , DGIDB baycyslt2 NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist NA TTD , DGIDB cgp-57698 NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD bay-x-7195 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 2.27 TTD , DGIDB cr-3465 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] phase 1 leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist 9.09 TTD , DGIDB montelukast NA Bronchoconstriction[MeSHID:D016084],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Hypersensitivity[MeSHID:D006967],Inspiration function[MeSHID:D001239],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist 2.78 TTD , DGIDB rg-7152 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD leukotriene c4 small molecule NA experimental,investigational cysteinyl leukotriene receptor 1 CYSLTR1 NA unknown NA drugbank wy-46016 NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD l-660771 NA NA discontinued in phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD lte4 NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target agonist NA TTD , DGIDB zafirlukast NA Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 3.21 TTD , DGIDB ablukast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 3 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD pobilukast NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist 2.27 TTD , DGIDB montelukast NA Bronchoconstriction[MeSHID:D016084],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Hypersensitivity[MeSHID:D006967],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 2.78 TTD , DGIDB ltd4 NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target agonist NA TTD , DGIDB iralukast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 4.55 TTD , DGIDB bayu9773 NA NA investigative leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist NA TTD , DGIDB cr-3465 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] phase 1 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown 9.09 TTD , DGIDB montelukast NA Bronchoconstriction[MeSHID:D016084],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Hypersensitivity[MeSHID:D006967],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukotriene cyslt1 receptor CYSLTR1 Successful target antagonist 2.78 TTD , DGIDB ds-4574 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene cyslt1 receptor CYSLTR1 Successful target unknown NA TTD leukotriene d4 small molecule NA investigational cysteinyl leukotriene receptor 2 CYSLTR2 NA unknown NA drugbank [3h]ltc4 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target agonist NA TTD , DGIDB ds-4574 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene cyslt2 receptor CYSLTR2 Clinical trial target unknown NA TTD nedocromil small molecule Asthma[MeSHID:D001249] approved,investigational cysteinyl leukotriene receptor 2 CYSLTR2 NA antagonist NA drugbank cgp-57698 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target unknown NA TTD leukotriene c4 small molecule NA experimental,investigational cysteinyl leukotriene receptor 2 CYSLTR2 NA unknown NA drugbank lte4 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target agonist NA TTD , DGIDB sulukast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene cyslt2 receptor CYSLTR2 Clinical trial target unknown NA TTD pobilukast NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target antagonist 6.37 TTD , DGIDB bayu9773 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target agonist,antagonist NA TTD , DGIDB as-35 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene cyslt2 receptor CYSLTR2 Clinical trial target unknown NA TTD baycyslt2 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target antagonist NA TTD , DGIDB n-methyl ltc4 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target agonist NA TTD , DGIDB ltc4 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target agonist NA TTD , DGIDB ltd4 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target agonist NA TTD , DGIDB bay-x-7195 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 leukotriene cyslt2 receptor CYSLTR2 Clinical trial target unknown 6.37 TTD , DGIDB hami3379 NA NA investigative leukotriene cyslt2 receptor CYSLTR2 Clinical trial target antagonist NA TTD , DGIDB inositol 1,3,4,5-tetrakisphosphate small molecule NA experimental cytohesin-2 CYTH2 NA unknown NA drugbank brefeldin a small molecule NA experimental cytohesin-2 CYTH2 NA unknown NA drugbank 1d-myo-inositol 1,4,5-trisphosphate small molecule NA experimental cytohesin-2 CYTH2 NA unknown NA drugbank formic acid small molecule NA experimental,investigational cytohesin-2 CYTH2 NA unknown NA drugbank s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental cytohesin-2 CYTH2 NA unknown NA drugbank inositol 1,3,4,5-tetrakisphosphate small molecule NA experimental cytohesin-3 CYTH3 NA unknown NA drugbank inositol-(1,3,4,5,6)-pentakisphosphate small molecule NA experimental cytohesin-3 CYTH3 NA unknown NA drugbank cannabidivarin small molecule Fragile X Syndrome[MeSHID:D005600],Rett Syndrome[MeSHID:D015518] investigational sn1-specific diacylglycerol lipase alpha DAGLA NA inhibitor NA drugbank pmid29053063-compound-15 NA NA patented diacylglycerol lipase alpha DAGLA Patented-recorded target unknown NA TTD , DGIDB rhc80267 NA NA investigative diacylglycerol lipase alpha DAGLA Patented-recorded target inhibitor NA TTD , DGIDB rhc80267 NA NA investigative diacylglycerol lipase beta DAGLB Literature-reported target inhibitor NA TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational dan domain family member 5 DAND5 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational dan domain family member 5 DAND5 NA cofactor NA drugbank (2e)-3-(3,4-dihydroxyphenyl)-2-iminopropanoic acid small molecule NA experimental d-amino-acid oxidase DAO NA unknown NA drugbank tak-831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Friedreich Ataxia[MeSHID:D005621] phase 2 d-amino acid oxidase DAO Clinical trial target unknown NA TTD , DGIDB anthranilic acid small molecule NA experimental d-amino-acid oxidase DAO NA unknown NA drugbank tak-831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Friedreich Ataxia[MeSHID:D005621],Schizophrenia[MeSHID:D012559] phase 2 d-amino acid oxidase DAO Clinical trial target unknown NA TTD , DGIDB flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved d-amino-acid oxidase DAO NA unknown NA drugbank flavin-adenine dinucleotide-n5-isobutyl ketone small molecule NA experimental d-amino-acid oxidase DAO NA unknown NA drugbank imino-tryptophan small molecule NA experimental d-amino-acid oxidase DAO NA unknown NA drugbank d-tryptophan small molecule NA experimental d-amino-acid oxidase DAO NA unknown NA drugbank 3,4-dihydro-2h-pyrrolium-5-carboxylate small molecule NA experimental d-amino-acid oxidase DAO NA unknown NA drugbank benzoic acid small molecule Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d-amino-acid oxidase DAO NA unknown 31.83 drugbank , DGIDB 6-(3-aminopropyl)-4,9-dimethylpyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione small molecule NA experimental death-associated protein kinase 1 DAPK1 NA unknown NA drugbank 5,6-dihydro-benzo[h]cinnolin-3-ylamine small molecule NA experimental death-associated protein kinase 1 DAPK1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational death-associated protein kinase 1 DAPK1 NA inhibitor NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental death-associated protein kinase 1 DAPK1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational death-associated protein kinase 2 DAPK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational death-associated protein kinase 3 DAPK3 NA inhibitor NA drugbank 4-(6-{[(1r)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid small molecule NA experimental death-associated protein kinase 3 DAPK3 NA unknown NA drugbank 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one small molecule NA experimental death-associated protein kinase 3 DAPK3 NA unknown NA drugbank (4r)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile small molecule NA experimental death-associated protein kinase 3 DAPK3 NA unknown NA drugbank urmc-099 NA NA investigative death-associated protein kinase 3 DAPK3 Literature-reported target inhibitor NA TTD , DGIDB inositol 1,3,4,5-tetrakisphosphate small molecule NA experimental dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide DAPP1 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical aspartate--trna ligase, cytoplasmic DARS NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical aspartate--trna ligase, mitochondrial DARS2 NA unknown NA drugbank etamicastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 dopamine beta hydroxylase DBH Clinical trial target unknown NA TTD , DGIDB ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical dopamine beta-hydroxylase DBH NA cofactor NA drugbank dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved dopamine beta-hydroxylase DBH NA ligand NA drugbank disulfiram small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved dopamine beta-hydroxylase DBH NA inhibitor 0.47 drugbank , DGIDB disulfiram small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine beta-hydroxylase DBH NA inhibitor 0.47 drugbank , DGIDB nepicastat oral NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Post-Traumatic Stress Disorder[MeSHID:D013313] phase 2 dopamine beta hydroxylase DBH Clinical trial target unknown NA TTD , DGIDB coenzyme a small molecule NA investigational,nutraceutical acyl-coa-binding protein DBI NA unknown NA drugbank hexadecanal small molecule NA experimental acyl-coa-binding protein DBI NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental dermcidin DCD NA stabilization NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational dermcidin DCD NA stabilization NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational dermcidin DCD NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational dermcidin DCD NA unknown NA drugbank lp-661438 NA NA investigative deoxycytidine kinase DCK Literature-reported target unknown NA TTD 2'-deoxycytidine small molecule NA experimental,investigational deoxycytidine kinase DCK NA unknown NA drugbank fludarabine small molecule Chronic Lymphocytic Leukemia[MeSHID:D015451],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved deoxycytidine kinase DCK NA agonist 1.16 drugbank , DGIDB elacytarabine small molecule leukemia[MeSHID:D007938],melanoma[MeSHID:D008545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] investigational deoxycytidine kinase DCK NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase dclk1 DCLK1 NA inhibitor NA drugbank pmid20483621c5g NA NA investigative doublecortin-like kinase 1 DCLK1 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase dclk2 DCLK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase dclk3 DCLK3 NA inhibitor NA drugbank 7-methyl-7,8-dihydroguanosine-5'-diphosphate small molecule NA experimental m7gpppx diphosphatase DCPS NA unknown NA drugbank rg3039 NA Spinal Muscular Atrophy[MeSHID:D009134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 scavenger decapping enzyme dcps DCPS Clinical trial target unknown NA TTD , DGIDB 7-methyl-gpppa small molecule NA experimental m7gpppx diphosphatase DCPS NA unknown NA drugbank 5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine small molecule NA experimental m7gpppx diphosphatase DCPS NA unknown NA drugbank 7-methyl-5'-guanylic acid small molecule NA experimental m7gpppx diphosphatase DCPS NA unknown NA drugbank 5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine small molecule NA experimental m7gpppx diphosphatase DCPS NA unknown NA drugbank 7-methyl-guanosine-5'-triphosphate-5'-guanosine small molecule NA experimental m7gpppx diphosphatase DCPS NA unknown NA drugbank 5-[(1s)-1-(3-chlorophenyl)ethoxy]quinazoline-2,4-diamine small molecule NA experimental m7gpppx diphosphatase DCPS NA unknown NA drugbank dihydrogenphosphate small molecule NA experimental l-xylulose reductase DCXR NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental l-xylulose reductase DCXR NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical n(g),n(g)-dimethylarginine dimethylaminohydrolase 1 DDAH1 NA unknown NA drugbank esomeprazole small molecule Zollinger-Ellison syndrome[MeSHID:D015043],Esophagitis[MeSHID:D004941],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Pathologic Processes[MeSHID:D010335],Gastrointestinal Hemorrhage[MeSHID:D006471],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Peptic Ulcer[MeSHID:D010437],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational n(g),n(g)-dimethylarginine dimethylaminohydrolase 1 DDAH1 NA unknown NA drugbank pantoprazole small molecule Zollinger-Ellison syndrome[MeSHID:D015043],Esophagitis[MeSHID:D004941],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Pathologic Processes[MeSHID:D010335],Peptic Esophagitis[MeSHID:D004942],Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Patient Discharge[MeSHID:D010351],Relapse[MeSHID:D012008],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved n(g),n(g)-dimethylarginine dimethylaminohydrolase 1 DDAH1 NA inhibitor NA drugbank dexlansoprazole small molecule Esophagitis[MeSHID:D004941],Maintenance[MeSHID:D008283],Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276] approved,investigational n(g),n(g)-dimethylarginine dimethylaminohydrolase 1 DDAH1 NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical n(g),n(g)-dimethylarginine dimethylaminohydrolase 2 DDAH2 NA unknown NA drugbank carbidopa small molecule Parkinson Disease, Postencephalitic[MeSHID:D010301],Nausea[MeSHID:D009325],Secondary Parkinson Disease[MeSHID:D010302],Vomiting[MeSHID:D014839],Intrinsic drive[MeSHID:D004328],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatic-l-amino-acid decarboxylase DDC Successful target inhibitor 22.99 TTD , drugbank , DGIDB vy-aadc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 aromatic-l-amino-acid decarboxylase DDC Successful target unknown NA TTD 3-hydroxybenzylhydrazine NA NA investigative aromatic-l-amino-acid decarboxylase DDC Successful target inhibitor NA TTD , DGIDB vitamin b6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin B 6 Deficiency[MeSHID:D026681] approved aromatic-l-amino-acid decarboxylase DDC Successful target unknown NA TTD , DGIDB methyldopa small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aromatic-l-amino-acid decarboxylase DDC NA inhibitor NA drugbank prosavin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 aromatic-l-amino-acid decarboxylase DDC Successful target unknown NA TTD , DGIDB pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical aromatic-l-amino-acid decarboxylase DDC NA cofactor NA drugbank gt-aadc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aromatic amino acid decarboxylase deficiency[MeSHID:C537437] phase 2 aromatic-l-amino-acid decarboxylase DDC Successful target unknown NA TTD benserazide small molecule beta Thalassemia[MeSHID:D017086],Restless Legs Syndrome[MeSHID:D012148],Parkinsonian Disorders[MeSHID:D020734],Parkinson Disease[MeSHID:D010300] approved,investigational,phase 3 aromatic-l-amino-acid decarboxylase DDC Successful target inhibitor 6.37 TTD , drugbank , DGIDB pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical ddc protein DDC NA cofactor NA drugbank patrome NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 aromatic-l-amino-acid decarboxylase DDC Successful target unknown NA TTD , DGIDB av-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 aromatic-l-amino-acid decarboxylase DDC Successful target unknown NA TTD , DGIDB oxb-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 aromatic-l-amino-acid decarboxylase DDC Successful target unknown NA TTD noradrenalone (arterenone) NA NA investigative aromatic-l-amino-acid decarboxylase DDC Successful target unknown NA TTD pf-4523655 NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 rtp801 messenger rna DDIT4 Clinical trial target unknown NA TTD pf-04523655 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 hif-1 responsive protein rtp801 DDIT4 Clinical trial target unknown NA TTD , DGIDB pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epithelial discoidin domain-containing receptor 1 DDR1 NA inhibitor NA drugbank imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved epithelial discoidin domain-containing receptor 1 DDR1 NA antagonist,inhibitor 2.65 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational epithelial discoidin domain-containing receptor 1 DDR1 NA inhibitor NA drugbank imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved epithelial discoidin domain-containing receptor 1 DDR1 NA antagonist 2.65 drugbank , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved epithelial discoidin domain-containing receptor 1 DDR1 NA antagonist,inhibitor 2.65 drugbank , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved epithelial discoidin domain-containing receptor 1 DDR1 NA antagonist 2.65 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational discoidin domain-containing receptor 2 DDR2 NA inhibitor NA drugbank regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved discoidin domain-containing receptor 2 DDR2 NA inhibitor 0.57 drugbank , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational spliceosome rna helicase ddx39b DDX39B NA ligand NA drugbank rx-5902 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 atp-dependent rna helicase ddx5 DDX5 Clinical trial target unknown NA TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational probable atp-dependent rna helicase ddx5 DDX5 NA ligand NA drugbank rx-5902 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 phosphorylated p68 rna helicase DDX5 Clinical trial target unknown NA TTD , DGIDB cv8102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Squamous cell carcinoma[MeSHID:D002294],melanoma[MeSHID:D008545] phase 1 retinoic acid-inducible gene-1 DDX58 Clinical trial target unknown NA TTD sb-9200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 retinoic acid-inducible gene-1 DDX58 Clinical trial target unknown NA TTD mk-4621 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 retinoic acid-inducible gene-1 DDX58 Clinical trial target unknown NA TTD d-tartaric acid small molecule NA experimental probable atp-dependent rna helicase ddx6 DDX6 NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental 2,4-dienoyl-coa reductase, mitochondrial DECR1 NA unknown NA drugbank 6-methyl-2(propane-1-sulfonyl)-2h-thieno[3,2-d][1,2,3]diazaborinin-1-ol small molecule NA experimental 2,4-dienoyl-coa reductase, mitochondrial DECR1 NA unknown NA drugbank azd7687 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] phase 1 diacylglycerol acyltransferase 1 DGAT1 Successful target unknown 31.83 TTD , DGIDB amidepsines NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB pmid25470667-compound-pf-04620110 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB isis 191761 NA NA investigative dgat1 messenger rna DGAT1 Literature-reported target unknown NA TTD pmid25470667-compound-azd3988 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB hesperetin NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved diacylglycerol acyltransferase 1 DGAT1 Successful target unknown 1.77 TTD , DGIDB p-7435 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB azd7687 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] phase 1 diacylglycerol acyltransferase 1 DGAT1 Successful target inhibitor 31.83 TTD , DGIDB t863 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB pmid25470667-compound-figure4-1a NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB jtt-553 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD lcq908 NA Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Familial hyperchylomicronemia syndrome[MeSHID:C538489],Hepatitis C[MeSHID:D006526] phase 3 diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB lactam derivative 5 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB ds-7250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 1 diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD isis 191755 NA NA investigative dgat1 messenger rna DGAT1 Literature-reported target unknown NA TTD isis 191756 NA NA investigative dgat1 messenger rna DGAT1 Literature-reported target unknown NA TTD pyridine-carboximide derivative 1 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB pyridine-carboximide derivative 2 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 29 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB pmid25470667-compound-bay744113 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB isis 191759 NA NA investigative dgat1 messenger rna DGAT1 Literature-reported target unknown NA TTD carbamide derivative 3 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB lactam derivative 1 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB lactam derivative 4 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB isis 191731 NA NA investigative dgat1 messenger rna DGAT1 Literature-reported target unknown NA TTD isis 191729 NA NA investigative dgat1 messenger rna DGAT1 Literature-reported target unknown NA TTD lactam derivative 3 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 28 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB pyrazine carboxamide derivative 1 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB t863 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target inhibitor NA TTD , DGIDB benzamide derivative 19 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB azole derivative 7 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB lactam derivative 2 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB pyridine-amide derivative 1 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB azole derivative 6 NA NA patented diacylglycerol acyltransferase 1 DGAT1 Successful target unknown NA TTD , DGIDB fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical diacylglycerol o-acyltransferase 2 DGAT2 NA agonist NA drugbank pmid25470667-compound-figure4-1a NA NA patented diacylglycerol o-acyltransferase 2 DGAT2 Successful target unknown NA TTD , DGIDB ari-3037mo NA Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Dyslipidemias[MeSHID:D050171] phase 2 diacylglycerol o-acyltransferase 2 DGAT2 Successful target unknown NA TTD , DGIDB pmid25470667-compound-roselipins NA NA patented diacylglycerol o-acyltransferase 2 DGAT2 Successful target unknown NA TTD , DGIDB ion 224 NA Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dgat2 messenger rna DGAT2 Clinical trial target unknown NA TTD omega-3-carboxylic acids small molecule Hippocampus Proper[MeSHID:D006624],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Alcohol consumption[MeSHID:D000428],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Neoplasm Metastasis[MeSHID:D009362],Plasma[MeSHID:D010949],Obesity[MeSHID:D009765],Metabolic Syndrome X[MeSHID:D024821] approved,investigational diacylglycerol o-acyltransferase 2 DGAT2 NA antagonist NA drugbank vitamin b3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] approved diacylglycerol o-acyltransferase 2 DGAT2 Successful target unknown NA TTD , DGIDB pf-06427878 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Cardiovascular Diseases[MeSHID:D002318] phase 1 diacylglycerol o-acyltransferase 2 DGAT2 Successful target unknown NA TTD , DGIDB vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved diacylglycerol kinase alpha DGKA NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKA NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKB NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKD NA unknown NA drugbank phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical diacylglycerol kinase delta DGKD NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKE NA unknown NA drugbank phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical diacylglycerol kinase gamma DGKG NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKG NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKH NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKI NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKK NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKQ NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved diacylglycerol kinase DGKZ NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 7-dehydrocholesterol reductase DHCR7 NA unknown NA drugbank 1954u89 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical dihydrofolate reductase DHFR Successful target unknown NA TTD , DGIDB pyrimethamine small molecule Toxoplasmosis[MeSHID:D014123],Acute malaria[MeSHID:C531736],Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dihydrofolate reductase DHFR NA inhibitor 2.17 drugbank , DGIDB 5-[(3r)-3-(5-methoxy-3',5'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank pemetrexed small molecule Malignant mesothelioma[MeSHID:C562839],Disease[MeSHID:D004194],Pleura[MeSHID:D010994],Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dihydrofolate reductase DHFR NA inhibitor 5.4 drugbank , DGIDB iclaprim small molecule Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Skin Diseases, Infectious[MeSHID:D012874],Bacterial Infections[MeSHID:D001424],Pneumonia[MeSHID:D011014],Obesity[MeSHID:D009765],Liver diseases[MeSHID:D008107],Infection[MeSHID:D007239],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Bacterial[MeSHID:D017192] investigational,phase 3 dihydrofolate reductase DHFR Successful target inhibitor 7.96 TTD , drugbank , DGIDB 2,4-diamino-6-[n-(3',4',5'-trimethoxybenzyl)-n-methylamino]pyrido[2,3-d]pyrimidine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank sri-9662 small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank mdam (y-methylene-10-deazaaminopterin) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dihydrofolate reductase DHFR Successful target unknown NA TTD , DGIDB methotrexate small molecule Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved dihydrofolate reductase DHFR NA inhibitor 1.03 drugbank , DGIDB iclaprim small molecule Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Skin Diseases, Infectious[MeSHID:D012874],Bacterial Infections[MeSHID:D001424],Pneumonia[MeSHID:D011014],Obesity[MeSHID:D009765],Liver diseases[MeSHID:D008107],Infection[MeSHID:D007239],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Bacterial[MeSHID:D017192] investigational,phase 3 dihydrofolate reductase DHFR Successful target unknown 7.96 TTD , drugbank , DGIDB trimetrexate small molecule Malignant Neoplasms[MeSHID:D009369],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Pneumonia[MeSHID:D011014],Malignant tumor of colon[MeSHID:D003110],Pneumocystis jiroveci pneumonia[MeSHID:D011020],Immunocompromised Host[MeSHID:D016867],Toxoplasmosis[MeSHID:D014123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dihydrofolate reductase DHFR NA inhibitor 4.86 drugbank , DGIDB vyr 006 NA Toxoplasmosis[MeSHID:D014123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dihydrofolate reductase DHFR Successful target unknown NA TTD pralatrexate small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,investigational dihydrofolate reductase DHFR NA inhibitor 7.96 drugbank , DGIDB 2,4-diamino-6-[n-(3',5'-dimethoxybenzyl)-n-methylamino]pyrido[2,3-d]pyrimidine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank gentamicin small molecule Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved dihydrofolate reductase DHFR NA unknown NA drugbank methotrexate sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved dihydrofolate reductase DHFR Successful target unknown NA TTD , DGIDB 5-[(3r)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank 5-[(3r)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank (4as)-5-[(2,4-diaminopteridin-6-yl)methyl]-4a,5-dihydro-2h-dibenzo[b,f]azepin-8-ol small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank 6-(octahydro-1h-indol-1-ylmethyl)decahydroquinazoline-2,4-diamine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank methotrexate sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved dihydrofolate reductase DHFR Successful target inhibitor 3.98 TTD , DGIDB methotrexate small molecule Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Proliferative vitreoretinopathy[MeSHID:D018630],leukemia[MeSHID:D007938],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369] approved dihydrofolate reductase DHFR NA inhibitor 1.03 drugbank , DGIDB 5-[(3r)-3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank proguanil small molecule Muscle strain[MeSHID:D013180],Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dihydrofolate reductase DHFR NA inhibitor NA drugbank l-mdam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dihydrofolate reductase DHFR Successful target unknown NA TTD , DGIDB nicotinamide adenine dinucleotide phosphate small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidin-1-ium small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank aminosalicylic acid NA Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Lung[MeSHID:D008168] approved dihydrofolate reductase DHFR Successful target unknown NA TTD , DGIDB ch-4051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cyclic neutropenia[MeSHID:C536227],Rheumatoid Arthritis[MeSHID:D001172] phase 2 dihydrofolate reductase DHFR Successful target unknown NA TTD , DGIDB biopterin small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank [n-(2,4-diaminopteridin-6-yl)-methyl]-dibenz[b,f]azepine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank piritrexim small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] investigational,phase 2 dihydrofolate reductase DHFR Successful target unknown 15.91 TTD , drugbank , DGIDB leucovorin calcium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved dihydrofolate reductase DHFR Successful target unknown NA TTD , DGIDB 5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical dihydrofolate reductase DHFR NA unknown NA drugbank sri-9439 small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank n6-(2,5-dimethoxy-benzyl)-n6-methyl-pyrido[2,3-d]pyrimidine-2,4,6-triamine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxy-n-methylanilino)methyl]pyrido[2,3-d]pyrimidine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank tnp-351 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 dihydrofolate reductase DHFR Successful target unknown NA TTD 2,4-diamino-6-[n-(2',5'-dimethoxybenzyl)-n-methylamino]quinazoline small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank trimethoprim NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary tract infection[MeSHID:D014552] approved dihydrofolate reductase DHFR Successful target unknown 2.53 TTD , DGIDB (2r,6s)-6-{[methyl(3,4,5-trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-hexahydroquinazoline-2,4-diamine small molecule NA experimental dihydrofolate reductase DHFR NA unknown NA drugbank 7-[2-methoxy-1-(methoxymethyl)ethyl]-7h-pyrrolo[3,2-f] quinazoline-1,3-diamine small molecule NA experimental dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank 5-(4-morpholin-4-yl-phenylsulfanyl)-2,4-quinazolinediamine small molecule NA experimental dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank 5-(4-methoxyphenoxy)-2,4-quinazolinediamine small molecule NA experimental dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank 5-phenylsulfanyl-2,4-quinazolinediamine small molecule NA experimental dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank 5-[4-tert-butylphenylsulfanyl]-2,4-quinazolinediamine small molecule NA experimental dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank 7-(1-ethyl-propyl)-7h-pyrrolo-[3,2-f]quinazoline-1,3-diamine small molecule NA experimental dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank 5-chloryl-2,4,6-quinazolinetriamine small molecule NA experimental dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank epigallocatechin gallate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] investigational dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank 5-[(4-methylphenyl)sulfanyl]-2,4-quinazolinediamine small molecule NA experimental dihydrofolate reductase, mitochondrial DHFRL1 NA unknown NA drugbank n-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank vidofludimus NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Rheumatoid Arthritis[MeSHID:D001172] phase 2 dihydroorotate dehydrogenase DHODH Successful target inhibitor 9.55 TTD , DGIDB leflunomide small molecule Disease Management[MeSHID:D019468],Disease Progression[MeSHID:D018450],Physical Examination[MeSHID:D010808],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103],Arthritis[MeSHID:D001168] approved,investigational dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA inhibitor 25.2 drugbank , DGIDB 3-{[(3-fluoro-3'-methoxybiphenyl-4-yl)amino]carbonyl}thiophene-2-carboxylic acid small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank (2z)-n-biphenyl-4-yl-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank 2-({[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino}carbonyl)cyclopenta-1,3-diene-1-carboxylic acid small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank leflunomide small molecule Disease Management[MeSHID:D019468],Disease Progression[MeSHID:D018450],Physical Examination[MeSHID:D010808],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Multiple Sclerosis[MeSHID:D009103],Disease[MeSHID:D004194] approved,investigational dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA inhibitor 25.2 drugbank , DGIDB teriflunomide small molecule Multiple Sclerosis[MeSHID:D009103],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Rheumatoid Arthritis[MeSHID:D001172] approved dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA inhibitor 47.74 drugbank , DGIDB teriflunomide NA Multiple Sclerosis[MeSHID:D009103],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Rheumatoid Arthritis[MeSHID:D001172] approved dihydroorotate dehydrogenase DHODH Successful target unknown 47.74 TTD , DGIDB fk778 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Kidney[MeSHID:D007668],Graft Rejection[MeSHID:D006084] discontinued in phase 2 dihydroorotate dehydrogenase DHODH Successful target unknown NA TTD 5-methyl-n-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank 5-carbamoyl-1,1':4',1''-terphenyl-3-carboxylic acid small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank atovaquone small molecule Pneumocystis jiroveci pneumonia[MeSHID:D011020],Pneumonia[MeSHID:D011014],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA inhibitor NA drugbank vidofludimus NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Rheumatoid Arthritis[MeSHID:D001172] phase 2 dihydroorotate dehydrogenase DHODH Successful target unknown 9.55 TTD , DGIDB 3,6,9,12,15-pentaoxatricosan-1-ol small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank dodecyldimethylamine n-oxide small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank manitimus small molecule Transplanted tissue[MeSHID:D019737] investigational dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank capric dimethyl amine oxide small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank (2z)-n-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank flavin mononucleotide small molecule NA approved,investigational dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank hr325 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 dihydroorotate dehydrogenase DHODH Successful target unknown NA TTD (2z)-n-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank brequinar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disease[MeSHID:D004194] phase 2 dihydroorotate dehydrogenase DHODH Successful target inhibitor 63.65 TTD , DGIDB 3-({[3,5-difluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino}carbonyl)thiophene-2-carboxylic acid small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank orotic acid small molecule NA investigational dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank las-186323 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 dihydroorotate dehydrogenase DHODH Successful target unknown NA TTD , DGIDB teriflunomide NA Multiple Sclerosis[MeSHID:D009103],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Rheumatoid Arthritis[MeSHID:D001172] approved dihydroorotate dehydrogenase DHODH Successful target inhibitor 47.74 TTD , DGIDB (2z)-2-cyano-n-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank (2z)-2-cyano-n-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank brequinar small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disease[MeSHID:D004194] experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA inhibitor 63.65 drugbank , DGIDB 2-({[3,5-difluoro-3'-(trifluoromethoxy)biphenyl-4-yl]amino}carbonyl)cyclopent-1-ene-1-carboxylic acid small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank sc12267 small molecule Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103] investigational dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank brequinar analog small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank bay2402234 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951] phase 1 dihydroorotate dehydrogenase DHODH Successful target unknown NA TTD , DGIDB undecylamine-n,n-dimethyl-n-oxide small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank 2-[4-(4-chlorophenyl)cyclohexylidene]-3,4-dihydroxy-1(2h)-naphthalenone small molecule NA experimental dihydroorotate dehydrogenase (quinone), mitochondrial DHODH NA unknown NA drugbank nicotinamide-adenine-dinucleotide NA NA investigative deoxyhypusine synthase DHPS Literature-reported target unknown NA TTD n1-guanyl-1,7-diaminoheptane NA NA investigative deoxyhypusine synthase DHPS Literature-reported target unknown NA TTD n-guanyl-1,7-diaminoheptane NA NA investigative deoxyhypusine synthase DHPS Literature-reported target unknown NA TTD 1-guanidinium-7-aminoheptane small molecule NA experimental,investigative deoxyhypusine synthase DHPS Literature-reported target inhibitor NA TTD , drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental dehydrogenase/reductase sdr family member 11 DHRS11 NA unknown NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved short-chain dehydrogenase/reductase 3 DHRS3 NA substrate NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved dehydrogenase/reductase sdr family member 4 DHRS4 NA substrate NA drugbank 2,4,6-triaminoquinazoline small molecule NA experimental putative dehydrogenase/reductase sdr family member 4-like 2 DHRS4L1 NA unknown NA drugbank methyl 1-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)piperidine-4-carboxylate small molecule NA experimental putative dehydrogenase/reductase sdr family member 4-like 2 DHRS4L1 NA unknown NA drugbank methyl 1-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)piperidine-4-carboxylate small molecule NA experimental putative dehydrogenase/reductase sdr family member 4-like 2 DHRS4L1 NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental putative dehydrogenase/reductase sdr family member 4-like 2 DHRS4L1 NA unknown NA drugbank 10-propargyl-5,8-dideazafolic acid small molecule NA experimental putative dehydrogenase/reductase sdr family member 4-like 2 DHRS4L1 NA unknown NA drugbank matairesinol small molecule NA experimental dehydrogenase/reductase sdr family member 4-like 2 DHRS4L2 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational diablo homolog, mitochondrial DIABLO NA unknown NA drugbank isis 138648 NA NA investigative helicase-moi messenger rna DICER1 Literature-reported target unknown NA TTD isis 138647 NA NA investigative helicase-moi messenger rna DICER1 Literature-reported target unknown NA TTD isis 138678 NA NA investigative helicase-moi messenger rna DICER1 Literature-reported target unknown NA TTD isis 138616 NA NA investigative helicase-moi messenger rna DICER1 Literature-reported target unknown NA TTD isis 138649 NA NA investigative helicase-moi messenger rna DICER1 Literature-reported target unknown NA TTD isis 138612 NA NA investigative helicase-moi messenger rna DICER1 Literature-reported target unknown NA TTD isis 138613 NA NA investigative helicase-moi messenger rna DICER1 Literature-reported target unknown NA TTD propylthiouracil NA Graves Disease[MeSHID:D006111],Hyperthyroidism[MeSHID:D006980],Thyroid Gland[MeSHID:D013961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved iodothyronine deiodinase type i DIO1 Successful target inhibitor 7.49 TTD , DGIDB propylthiouracil NA Graves Disease[MeSHID:D006111],Hyperthyroidism[MeSHID:D006980],Thyroid Gland[MeSHID:D013961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved iodothyronine deiodinase type i DIO1 Successful target unknown 7.49 TTD , DGIDB iopodic acid small molecule Gallbladder[MeSHID:D005704],Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Stomach[MeSHID:D013270],Graves Disease[MeSHID:D006111],Hyperthyroidism[MeSHID:D006980],Ionizing radiation[MeSHID:D011839],Spleen[MeSHID:D013154],Intestines[MeSHID:D007422] approved,investigational,withdrawn thyroxine 5-deiodinase DIO3 NA antagonist NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ferrochelatase DKFZp686P18130 NA unknown NA drugbank pf-04840082 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dickkopf-related protein 1 DKK1 Clinical trial target unknown NA TTD , DGIDB bhq880 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 dickkopf-related protein 1 DKK1 Clinical trial target unknown NA TTD dkn-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Endometrial Carcinoma[MeSHID:D016889],Esophageal Neoplasms[MeSHID:D004938],Biliary Tract Cancer[MeSHID:D001661],Cholangiocarcinoma[MeSHID:D018281],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 dickkopf-related protein 1 DKK1 Clinical trial target unknown NA TTD reic gene therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 dickkopf-related protein 3 DKK3 Clinical trial target unknown NA TTD , DGIDB radicicol small molecule NA experimental dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial DLAT NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial DLAT NA unknown NA drugbank dihydrolipoic acid small molecule NA experimental dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial DLAT NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved dihydrolipoyl dehydrogenase, mitochondrial DLD NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical dihydrolipoyl dehydrogenase, mitochondrial DLD NA unknown NA drugbank guanidine small molecule Lambert-Eaton Myasthenic Syndrome[MeSHID:D015624],Paresis[MeSHID:D010291],Muscle Weakness[MeSHID:D018908],Myasthenia Gravis[MeSHID:D009157] approved disks large homolog 4 DLG4 NA unknown NA drugbank guanosine-5'-monophosphate small molecule NA experimental disks large homolog 4 DLG4 NA unknown NA drugbank ksg-yeklssiesdv NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-ethyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-(3,4-dichlorophenyl)propyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-(3,4-difluorophenyl)propyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-propyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-phenylethyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-benzyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-cyclohexylethyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD tat-nr2b9c NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebrovascular accident[MeSHID:D020521] phase 3 presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD , DGIDB guanosine-5'-monophosphate NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-cyclohexylmethyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD 2-methyl-2,4-pentanediol NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-phenylpropyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-methyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-butyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD ksg-ldtknykqtsv NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD fetav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD n-(naphthalene-2-yl)ethyl-etav NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD ygrkkrrqrrr-klssiesdv NA NA investigative presynaptic density protein 95 DLG4 Clinical trial target unknown NA TTD gdc0134 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690] phase 1 protein delta homolog 1 DLK1 Clinical trial target unknown NA TTD , DGIDB amg 757 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] phase 1 delta-like protein 3 DLL3 Clinical trial target unknown NA TTD amg 119 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] phase 1 delta-like protein 3 DLL3 Clinical trial target unknown NA TTD , DGIDB hpn328 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] phase 1/2 delta-like protein 3 DLL3 Clinical trial target unknown NA TTD rova-t NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] phase 3 delta-like protein 3 DLL3 Clinical trial target unknown 63.65 TTD , DGIDB omp-21m18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 delta-like protein 4 DLL4 Clinical trial target unknown 15.91 TTD , DGIDB abt-165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 delta-like protein 4 DLL4 Clinical trial target unknown NA TTD , DGIDB dilpacimab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 delta-like protein 4 DLL4 Clinical trial target unknown NA TTD navicixizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fallopian Tube Carcinoma[MeSHID:D005185],Malignant Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 delta-like protein 4 DLL4 Clinical trial target unknown 10.61 TTD , DGIDB nov1501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 delta-like protein 4 DLL4 Clinical trial target unknown NA TTD regn-421 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 delta-like protein 4 DLL4 Clinical trial target unknown 21.22 TTD , DGIDB imidazole small molecule NA experimental,investigational meiotic recombination protein dmc1/lim15 homolog DMC1 NA unknown NA drugbank pro-044 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dystrophin messenger rna DMD Clinical trial target unknown NA TTD suvodirsen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 dystrophin messenger rna DMD Clinical trial target unknown NA TTD gsk2402968 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dystrophin messenger rna DMD Clinical trial target unknown NA TTD myodys NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dystrophin DMD Clinical trial target unknown NA TTD , DGIDB golodirsen biotech Muscular Dystrophy, Duchenne[MeSHID:D020388],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dystrophin DMD NA inducer 127.3 drugbank , DGIDB srp-9001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dystrophin DMD Clinical trial target unknown NA TTD eteplirsen NA Muscular Dystrophy, Duchenne[MeSHID:D020388],Skeletal muscle structure[MeSHID:D018482],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dystrophin messenger rna DMD Clinical trial target unknown 42.43 TTD , DGIDB biostrophin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dystrophin DMD Clinical trial target unknown NA TTD , DGIDB ataluren NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Dystrophy[MeSHID:D009136],Mucopolysaccharidoses[MeSHID:D009083],Cystic Fibrosis[MeSHID:D003550],Aniridia[MeSHID:D015783],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] phase 3 dystrophin nonsense mutant DMD Clinical trial target unknown 7.07 TTD , DGIDB drisapersen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dystrophin messenger rna DMD Clinical trial target unknown NA TTD wve-210201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 dystrophin DMD Clinical trial target unknown NA TTD , DGIDB bisindolylmaleimide viii small molecule NA experimental myotonin-protein kinase DMPK NA unknown NA drugbank pro-135 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myotonic Dystrophy[MeSHID:D009223] investigative dmpk messenger rna DMPK Clinical trial target unknown NA TTD 2-moe phosphorothioate gapmers NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myotonic Dystrophy[MeSHID:D009223] investigative dmpk messenger rna DMPK Clinical trial target unknown NA TTD rki-1447 NA NA investigative dmpk messenger rna DMPK Clinical trial target inhibitor NA TTD , DGIDB isis-dmpk NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myotonic Dystrophy[MeSHID:D009223] phase 1/2 dmpk messenger rna DMPK Clinical trial target unknown NA TTD 1-[6-(triphenylmethoxy)hexyl]thymine NA NA investigative thymidine kinase 2 dnk Clinical trial target unknown NA TTD 1-[5-(triphenylmethoxy)pentyl]thymine NA NA investigative thymidine kinase 2 dnk Clinical trial target unknown NA TTD 1-[(z)-4-(triphenylmethoxy)-2-butenyl]thymine NA NA investigative thymidine kinase 2 dnk Clinical trial target unknown NA TTD mt-1621 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 3 thymidine kinase 2 dnk Clinical trial target unknown NA TTD ionis-dnm2-2.5rx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Centronuclear myopathy[MeSHID:D020914] phase 2 dnm2 messenger rna DNM2 Clinical trial target unknown NA TTD cp-4200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD pmid27376512-compound-table1example11 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB sgi110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB palifosfamide small molecule Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dna (cytosine-5)-methyltransferase 1 DNMT1 NA unknown 2.36 drugbank , DGIDB epigallocatechin gallate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] investigational dna (cytosine-5)-methyltransferase 1 DNMT1 NA inhibitor NA drugbank pmid27376512-compound-table1example16 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB pmid27376512-compound-mtc-422 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD procainamide small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna (cytosine-5)-methyltransferase 1 DNMT1 NA other NA drugbank flucytosine small molecule Endocarditis[MeSHID:D004696],Sepsis[MeSHID:D018805],Lung[MeSHID:D008168],Muscle strain[MeSHID:D013180],Urinary tract infection[MeSHID:D014552],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna (cytosine-5)-methyltransferase 1 DNMT1 NA other NA drugbank pmid27376512-compound-mir-155-5p NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB azacitidine small molecule Refractory anemias[MeSHID:D000753],Leukemia, Myelocytic, Acute[MeSHID:D015470],Refractory anaemia with excess blasts[MeSHID:D000754],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukopenia[MeSHID:D007970], Myelomonocytic, Chronic[MeSHID:D015477],Thrombocytopenia[MeSHID:D013921],Sideroblastic anemia[MeSHID:D000756],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna (cytosine-5)-methyltransferase 1 DNMT1 NA inhibitor 1.18 drugbank , DGIDB pmid27376512-compound-table1example30 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB xb-05 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD pmid27376512-compound-mtc-423 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB decitabine small molecule Refractory anemias[MeSHID:D000753],Refractory anaemia with excess blasts[MeSHID:D000754],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelomonocytic, Chronic[MeSHID:D015477],Sideroblastic anemia[MeSHID:D000756],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna (cytosine-5)-methyltransferase 1 DNMT1 NA inhibitor 3.43 drugbank , DGIDB pmid27376512-compound-table1example8 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB pmid27376512-compound-ascebp-1 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dna (cytosine-5)-methyltransferase 1 DNMT1 NA inhibitor NA drugbank pmid27376512-compound-table1example5 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB rx-3117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369] phase 2 dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown 2.36 TTD , DGIDB pmid27376512-compound-ascebp-1hpe NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB pmid27376512-compound-table1example4 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB s-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470],Myeloid Leukemia, Chronic[MeSHID:D015464] phase 3 dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB pmx-700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] investigative dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD pmid27376512-compound-ascebp-2 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB pmid27376512-compound-mtc-424 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB pmid27376512-compound-ascebp-2hpe NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB guadecitabine NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown 2.36 TTD , DGIDB pmid27376512-compound-mtc-433 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB pmid27376512-compound-mtc-427 NA NA patented dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB antroquinonol NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown 2.36 TTD , DGIDB palifosfamide NA Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown 2.36 TTD , DGIDB cc-486 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] phase 3 dna [cytosine-5]-methyltransferase 1 DNMT1 Clinical trial target unknown NA TTD , DGIDB pmid27376512-compound-mtc-423 NA NA patented dna [cytosine-5]-methyltransferase 3a DNMT3A Patented-recorded target unknown NA TTD , DGIDB procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dna (cytosine-5)-methyltransferase 3a DNMT3A NA inhibitor NA drugbank decitabine small molecule Refractory anemias[MeSHID:D000753],Refractory anaemia with excess blasts[MeSHID:D000754],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelomonocytic, Chronic[MeSHID:D015477],Sideroblastic anemia[MeSHID:D000756],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna (cytosine-5)-methyltransferase 3a DNMT3A NA inhibitor 7.23 drugbank , DGIDB pmid27376512-compound-mtc-422 NA NA patented dna [cytosine-5]-methyltransferase 3a DNMT3A Patented-recorded target unknown NA TTD pmid27376512-compound-figure3cm NA NA patented dna [cytosine-5]-methyltransferase 3a DNMT3A Patented-recorded target unknown NA TTD , DGIDB pmid27376512-compound-figure2aexample1 NA NA patented dna [cytosine-5]-methyltransferase 3a DNMT3A Patented-recorded target unknown NA TTD , DGIDB pmid27376512-compound-mtc-424 NA NA patented dna [cytosine-5]-methyltransferase 3a DNMT3A Patented-recorded target unknown NA TTD , DGIDB pmid27376512-compound-figure3cn NA NA patented dna [cytosine-5]-methyltransferase 3a DNMT3A Patented-recorded target unknown NA TTD , DGIDB pmid27376512-compound-figure3cg NA NA patented dna [cytosine-5]-methyltransferase 3a DNMT3A Patented-recorded target unknown NA TTD , DGIDB pmid27376512-compound-mtc-427 NA NA patented dna [cytosine-5]-methyltransferase 3a DNMT3A Patented-recorded target unknown NA TTD , DGIDB nsc-138419 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD pmid27376512-compound-mtc-423 NA NA patented dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD , DGIDB nsc-623548 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD s-tubercidinylhomocysteine NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-56071 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-319745 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD pmid27376512-compound-mtc-422 NA NA patented dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-345763 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-54162 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-622444 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD decitabine small molecule Refractory anemias[MeSHID:D000753],Refractory anaemia with excess blasts[MeSHID:D000754],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelomonocytic, Chronic[MeSHID:D015477],Sideroblastic anemia[MeSHID:D000756],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna (cytosine-5)-methyltransferase 3b DNMT3B NA inhibitor NA drugbank nsc-348926 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-154957 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-622445 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD pmid27376512-compound-mtc-424 NA NA patented dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD , DGIDB nsc-401077 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-57893 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-106084 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD pmid27376512-compound-mtc-427 NA NA patented dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD , DGIDB curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown 0.9 TTD , DGIDB (l-)-s-adenosyl-l-homocysteine NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-137546 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD nsc-158324 NA NA investigative dna [cytosine-5]-methyltransferase 3b DNMT3B Clinical trial target unknown NA TTD pmid27376512-compound-figure2aexample1 NA NA patented dna [cytosine-5]-methyltransferase 3-like DNMT3L Patented-recorded target unknown NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical aspartyl aminopeptidase DNPEP NA unknown NA drugbank qgc-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 aspartyl aminopeptidase DNPEP Clinical trial target unknown NA TTD , DGIDB pmid1738140c9 NA NA investigative aspartyl aminopeptidase DNPEP Clinical trial target unknown NA TTD 2',3'-dideoxyadenosine triphosphate small molecule NA experimental dna nucleotidylexotransferase DNTT NA unknown NA drugbank bromo-deaza-sah NA NA investigative histone-lysine n-methyltransferase DOT1L Clinical trial target inhibitor NA TTD , DGIDB epz-5676 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 histone-lysine n-methyltransferase DOT1L Clinical trial target unknown NA TTD epz-004777 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative histone-lysine n-methyltransferase DOT1L Clinical trial target unknown NA TTD sgc0946 NA NA investigative histone-lysine n-methyltransferase DOT1L Clinical trial target inhibitor NA TTD , DGIDB cilastatin NA Endocarditis[MeSHID:D004696],Sepsis[MeSHID:D018805],Bacterial Infections[MeSHID:D001424],Urinary tract[MeSHID:D014551],Bone Tissue[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dehydropeptidase i DPEP1 Successful target unknown 275.82 TTD , DGIDB cilastatin small molecule Endocarditis[MeSHID:D004696],Sepsis[MeSHID:D018805],Bacterial Infections[MeSHID:D001424],Urinary tract[MeSHID:D014551],Bone Tissue[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dipeptidase 1 DPEP1 NA inhibitor 275.82 drugbank , DGIDB s-adenosyl-l-homocysteine small molecule NA experimental diphthine synthase DPH5 NA unknown NA drugbank denagliptin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 dipeptidyl peptidase 4 DPP4 Successful target unknown 2.55 TTD , DGIDB (2-(2-chlorophenyl)pyridin-3-yl)methanamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (7r,8r)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank cyclohexylglycine-(2s)-cyanopyrrolidine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD peptide analog 45 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB n-isoleucylthiazolidine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD peptide analog 46 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (2r)-4-(2-benzoyl-1,2-diazepan-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1h-benzimidazole-5-carbonitrile small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank imidazo cyclohexylamine derivative 2 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pyrimidine derivative 31 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB 1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD triazolo-pyrimidinedione derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB 4-[(3r)-3-{[2-(4-fluorophenyl)-2-oxoethyl]amino}butyl]benzamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank 2-({2-[(3r)-3-aminopiperidin-1-yl]-4-oxoquinazolin-3(4h)-yl}methyl)benzonitrile small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank abt-341 small molecule NA experimental,investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , drugbank teneligliptin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dipeptidyl peptidase 4 DPP4 Successful target unknown 1.7 TTD , DGIDB peptide analog 47 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB retagliptin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-56 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB emc-0901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Extraskeletal Myxoid Chondrosarcoma[MeSHID:C563195] investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD als 2-0426 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB xanthine derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB quinazoline derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB db-160 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-21 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (2s,3s)-4-cyclopropyl-3-{(3r,5r)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3s)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank triazolo-pyrimidinedione derivative 2 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB saxadapa fdc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Familial dilated cardiomyopathy[MeSHID:C536231] phase 3 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (2r)-4-[(8r)-8-methyl-2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8h)-yl]-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank n-({(2s)-1-[(3r)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank r-1438 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-50 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB aminopiperidine derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB l-ala-l-boropro NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pt630 NA Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] preclinical dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-11 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (+/-)-6-(2-chlorophenyl)cyclohex-3-enamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD lc-150444 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dipeptidyl peptidase 4 DPP4 Successful target unknown 2.55 TTD , DGIDB (3r)-4-[(3r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank 5-(aminomethyl)-6-(2,4-dichlorophenyl)-2-(3,5-dimethoxyphenyl)pyrimidin-4-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank linagliptin small molecule Diabetic Ketoacidosis[MeSHID:D016883],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Diet therapy[MeSHID:D004035], Non-Insulin-Dependent[MeSHID:D003924],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved dipeptidyl peptidase 4 DPP4 Successful target inhibitor 5.09 TTD , drugbank , DGIDB bisegliptin small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank c-(2'-chloro-biphenyl-2-yl)-methylamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD fe 999011 NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD ly-2463665 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (1s)-2-[(2s,5r)-2-(aminomethyl)-5-prop-1-yn-1-ylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank mk-3102 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dipeptidyl peptidase 4 DPP4 Successful target unknown 3.82 TTD , DGIDB pk-44 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-6 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB melogliptin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB ta-6666 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-69 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB n-(trans-4-{(1s,2s)-2-amino-3-[(3s)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl}cyclohexyl)-n-methylacetamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank peptide analog 44 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB ip10 c8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (1s,2r,5s)-5-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-2-(2,4,5-trifluorophenyl)cyclohexanamine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank fucose NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD iodo-phenylalanine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD alpha-d-mannose NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD dapagliflozin propanediol; saxagliptin hydrochloride NA NA approved dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB beta-phe compound 3 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pmid20684603c24dd NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-15 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB asc-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD 4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD 2-amino-3-methyl-1-pyrrolidin-1-yl-butan-1-one small molecule NA experimental,investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , drugbank psn-9301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD vildagliptin small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dipeptidyl peptidase 4 DPP4 Successful target inhibitor 8.91 TTD , drugbank , DGIDB alogliptin small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dipeptidyl peptidase 4 DPP4 Successful target inhibitor 7.64 TTD , drugbank , DGIDB 1-benzhydryl-3-butylpiperidin-4-amine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD iddbcp161883 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB syr-472 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] phase 3 dipeptidyl peptidase 4 DPP4 Successful target unknown 2.55 TTD , DGIDB pyrimidine derivative 32 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB kombiglyze xr/komboglyze fdc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Familial dilated cardiomyopathy[MeSHID:C536231] approved dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB d-420720 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-71 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (s)-2-[(r)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank amg-222 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank 4-iodo-l-phenylalanine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank kr-62436 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (1r,2r)-1,2-diphenylethane-1,2-diamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD saxagliptin small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dipeptidyl peptidase 4 DPP4 Successful target inhibitor 12.73 TTD , drugbank , DGIDB 3-butyl-1-(naphthalen-1-yl)piperidin-4-amine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD 6-(4-{(1s,2s)-2-amino-1-[(dimethylamino)carbonyl]-3-[(3s)-3-fluoropyrrolidin-1-yl]-3-oxopropyl}phenyl)-1h-[1,2,4]triazolo[1,5-a]pyridin-4-ium small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank (s)-2-amino-1-thiazolidin-3-yl-propane-1-thione NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (1s)-2-[(2s,5r)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank zydpla 1 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB 1-biphenyl-2-ylmethanamine small molecule NA experimental,investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , drugbank n4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD 4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD anagliptin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dipeptidyl peptidase 4 DPP4 Successful target unknown 5.09 TTD , DGIDB (3s,4r)-3-butyl-1-phenylpiperidin-4-amine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD linagliptin small molecule Diabetic Ketoacidosis[MeSHID:D016883],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Diet therapy[MeSHID:D004035], Non-Insulin-Dependent[MeSHID:D003924],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dipeptidyl peptidase 4 DPP4 Successful target inhibitor 5.09 TTD , drugbank , DGIDB l-val-l-boropro NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD yscma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB triazole piperazine derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB ari-2243 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB sand-26 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 3 dipeptidyl peptidase 4 DPP4 Successful target unknown 7.64 TTD , DGIDB gosogliptin small molecule NA investigational dipeptidyl peptidase 4 DPP4 NA inhibitor 10.18 drugbank , DGIDB pmid25482888-compound-37 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB er-319711-15 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pmid25482888-compound-13 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pyrrolo[1,2-f]triazine derivative 2 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB 2-(2-chlorophenyl)-2-morpholinoethanamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD sitagliptin small molecule Disease Management[MeSHID:D019468],Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Peripheral Vascular Diseases[MeSHID:D016491] approved,investigational dipeptidyl peptidase 4 DPP4 Successful target inhibitor 13.58 TTD , drugbank , DGIDB pmid25482888-compound-18 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB 4'-[(1r)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank peptide analog 51 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB 2-({8-[(3r)-3-aminopiperidin-1-yl]-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7h-purin-7-yl}methyl)benzonitrile small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank peptide analog 50 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB beta-phe compound 2 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB peptide analog 48 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB diprotin a NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD pmid25482888-compound-16 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB dihydropyrrolopyrazole derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (2s,3s)-3-amino-4-[(3s)-3-fluoropyrrolidin-1-yl]-n,n-dimethyl-4-oxo-2-(trans-4-[1,2,4]triazolo[1,5-a]pyridin-5-ylcyclohexyl)butanamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank pmid25482888-compound-12 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB da-1229 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dipeptidyl peptidase 4 DPP4 Successful target unknown 2.55 TTD , DGIDB (5-phenyl-3h-benzo[d]imidazol-4-yl)methanamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dipeptidyl peptidase 4 DPP4 NA inhibitor NA drugbank diisopropylphosphono group small molecule NA experimental,investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , drugbank ssr-162369 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD imidazo pyridine derivative 2 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB e-3024 NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (2r,3r)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank pyrimidinedione derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (2s,3s)-3-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-oxo-1-pyrrolidin-1-ylbutan-2-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank asp8497 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB psn9301 small molecule Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] investigational dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank 1-[2-(s)-amino-3-biphenyl-4-yl-propionyl]-pyrrolidine-2-(s)-carbonitrile small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank tak-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 1 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (3r,4s)-1-[6-(6-methoxypyridin-3-yl)pyrimidin-4-yl]-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank pmid25482888-compound-72 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB tricyclic heterocycle derivative 6 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pyrimidine derivative 30 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (3r,4r)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank aminopiperidine derivative 2 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB d-val-l-boropro NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD 7-benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank methyl 4-{[({[(2r,5s)-5-{[(2s)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl}pyrrolidin-2-yl]methyl}amino)carbonyl]amino}benzoate small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank (2r)-n-[(2r)-2-(dihydroxyboryl)-1-l-prolylpyrrolidin-2-yl]-n-[(5r)-5-(dihydroxyboryl)-1-l-prolylpyrrolidin-2-yl]-l-prolinamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank pyrrolo[1,2-f]triazine derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pf-00734200 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown 10.18 TTD , DGIDB 4-iodophenyl-alaninyl-(s)-2-cyano-pyrrolidine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD 1-(1-phenylcyclopentyl)methylamine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank pmid25482888-compound-34 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (3r,4s)-1-{6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank imidazo cyclohexylamine derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB n-({(2s)-1-[(3r)-3-amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-yl}methyl)benzamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank imidazo cyclohexylamine derivative 3 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (s)-2-amino-1-azetidin-1-yl-2-cyclohexyl-ethanone NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (2s)-pyrrolidin-2-ylmethylamine small molecule NA experimental,investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , drugbank (s)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (4r,5r)-5-amino-1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank pmid25482888-compound-70 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pyrimidine derivative 33 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pmid25482888-compound-38 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB beta-phe compound 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (1r,2s)-1,2-diphenylethane-1,2-diamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (3r,4s)-1-(3,4-dimethoxyphenyl)-3-(3-methylphenyl)piperidin-4-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank thiomorpholine derivative 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (1-phenylcyclopentyl)methanamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (3r,4r)-1-{6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl}-4-(2,4,5-trifluorophenyl)piperidin-3-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank pmid25482888-compound-52 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB thiomorpholine derivative 2 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB pmid25482888-compound-14 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB bpi-711001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypoglycemia[MeSHID:D007003] investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (2s,3s)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank pmid25482888-compound-17 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB (2-chloro-6-phenoxyphenyl)methanamine NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD dutogliptin small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 dipeptidyl peptidase 4 DPP4 Successful target unknown 5.09 TTD , drugbank , DGIDB (s)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD peptide analog 49 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB 4-[(3r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank gemigliptin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 dipeptidyl peptidase 4 DPP4 Successful target unknown 2.55 TTD , DGIDB abt-279 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (1s,3s,5s)-2-{(2s)-2-amino-2-[(1r,3s,5r,7s)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved dipeptidyl peptidase 4 DPP4 NA inhibitor NA drugbank xanthine/amino piperidine compound 1 NA NA patented dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB krp-104 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown 5.09 TTD , DGIDB (2s,3s)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-n,n-dimethyl-4-oxo-2-(trans-4-[1,2,4]triazolo[1,5-a]pyridin-6-ylcyclohexyl)butanamide small molecule NA experimental dipeptidyl peptidase 4 DPP4 NA unknown NA drugbank nvp-dpp728 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD (r)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid NA NA investigative dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD teneligliptin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dipeptidyl peptidase 4 DPP4 Successful target inhibitor 1.7 TTD , DGIDB p32/98 NA Autism Spectrum Disorders[MeSHID:D000067877],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659] phase 2 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB rec-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 1 dipeptidyl peptidase 4 DPP4 Successful target unknown NA TTD , DGIDB thiomorpholine derivative 2 NA NA patented dipeptidyl peptidase 8 DPP8 Clinical trial target unknown NA TTD , DGIDB talabostat NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukopenia[MeSHID:D007970] phase 3 dipeptidyl peptidase 8 DPP8 Clinical trial target inhibitor 12.73 TTD , DGIDB pmid15664838c18 NA NA investigative dipeptidyl peptidase 8 DPP8 Clinical trial target unknown NA TTD thiomorpholine derivative 1 NA NA patented dipeptidyl peptidase 8 DPP8 Clinical trial target unknown NA TTD , DGIDB pmid20684603c24dd NA NA investigative dipeptidyl peptidase 8 DPP8 Clinical trial target unknown NA TTD 1g244 NA NA investigative dipeptidyl peptidase 8 DPP8 Clinical trial target inhibitor NA TTD , DGIDB talabostat NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukopenia[MeSHID:D007970] phase 3 dipeptidyl peptidase 8 DPP8 Clinical trial target unknown 12.73 TTD , DGIDB pmid20684603c24dd NA NA investigative dipeptidyl peptidase 9 DPP9 Clinical trial target unknown NA TTD thiomorpholine derivative 1 NA NA patented dipeptidyl peptidase 9 DPP9 Clinical trial target unknown NA TTD , DGIDB talabostat NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukopenia[MeSHID:D007970] phase 3 dipeptidyl peptidase 9 DPP9 Clinical trial target unknown 12.73 TTD , DGIDB thiomorpholine derivative 2 NA NA patented dipeptidyl peptidase 9 DPP9 Clinical trial target unknown NA TTD , DGIDB talabostat NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukopenia[MeSHID:D007970] phase 3 dipeptidyl peptidase 9 DPP9 Clinical trial target inhibitor 12.73 TTD , DGIDB 1g244 NA NA investigative dipeptidyl peptidase 9 DPP9 Clinical trial target inhibitor NA TTD , DGIDB (5s)-5-iododihydro-2,4(1h,3h)-pyrimidinedione small molecule NA experimental dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA unknown NA drugbank gimeracil small molecule Malignant neoplasm of stomach[MeSHID:D013274],Stomach[MeSHID:D013270] approved dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA inhibitor NA drugbank tegafur-uracil small molecule Diagnosis[MeSHID:D003933],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179] approved,investigational dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA antagonist NA drugbank 5-iodouracil small molecule NA experimental dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA unknown NA drugbank 5-iodouracil NA NA investigative dihydrothymine dehydrogenase DPYD Successful target unknown NA TTD (5s)-5-iododihydro-2,4(1h,3h)-pyrimidinedione NA NA investigative dihydrothymine dehydrogenase DPYD Successful target unknown NA TTD flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA unknown NA drugbank 6-carboxymethyluracil small molecule NA experimental dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA unknown NA drugbank fl-386 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 dihydrothymine dehydrogenase DPYD Successful target unknown NA TTD 6-carboxymethyluracil NA NA investigative dihydrothymine dehydrogenase DPYD Successful target unknown NA TTD eniluracil small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] investigational dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA unknown 10.61 drugbank , DGIDB eniluracil NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 dihydrothymine dehydrogenase DPYD Successful target unknown 10.61 TTD , DGIDB uracil small molecule NA experimental,investigational dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA unknown NA drugbank uracil NA NA investigative dihydrothymine dehydrogenase DPYD Successful target unknown NA TTD nadph small molecule NA experimental dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA unknown NA drugbank flavin mononucleotide small molecule NA approved,investigational dihydropyrimidine dehydrogenase [nadp(+)] DPYD NA unknown NA drugbank flavin-adenine dinucleotide NA NA investigative dihydrothymine dehydrogenase DPYD Successful target unknown NA TTD fluorouracil NA Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Biliary tract structure[MeSHID:D001659],Cells[MeSHID:D002477],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Colon structure (body structure)[MeSHID:D003106],Pancreas[MeSHID:D010179],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Carcinoid Tumor[MeSHID:D002276],Rectum[MeSHID:D012007],Kidney[MeSHID:D007668],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] approved dihydrothymine dehydrogenase DPYD Successful target unknown 0.74 TTD , DGIDB ro-09-4889 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dihydrothymine dehydrogenase DPYD Successful target unknown NA TTD , DGIDB lacosamide NA Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved dihydropyrimidinase related protein 2 DPYSL2 Successful target unknown 10.61 TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational dihydropyrimidinase-related protein 2 DPYSL2 NA ligand NA drugbank (+)-butaclamol NA NA investigative dopamine d1 receptor DRD1 Successful target antagonist NA TTD , DGIDB isoloxapine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist 0.06 drugbank , DGIDB dihydrexidine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] investigational,phase 1/2 dopamine d1 receptor DRD1 Successful target unknown 0.22 TTD , drugbank , DGIDB 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD sch-23390 NA NA investigative dopamine d1 receptor DRD1 Successful target antagonist 0.06 TTD , DGIDB (+/-)-nantenine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD1 NA antagonist 0.05 drugbank , DGIDB 1-benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD methylergonovine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spontaneous abortion[MeSHID:D000022] approved dopamine d1 receptor DRD1 Successful target unknown 0.32 TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved dopamine d1 receptor DRD1 NA antagonist 0.03 drugbank , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist 0.03 drugbank , DGIDB 3-chloroboldine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 3-bromoboldine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d1 receptor DRD1 NA antagonist NA drugbank dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved d(1) dopamine receptor DRD1 NA agonist 0.14 drugbank , DGIDB flupentixol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Asthenia[MeSHID:D001247],Hyperactive behavior[MeSHID:D006948],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] approved,investigational,withdrawn dopamine d1 receptor DRD1 NA antagonist 0.33 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved d(1) dopamine receptor DRD1 NA inhibitor,antagonist 0.04 drugbank , DGIDB ro-21-7767 NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved dopamine d1 receptor DRD1 NA antagonist 0.08 drugbank , DGIDB (r,s)-homoaromaline hydrochloride NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD (r)-(-)-11-hydroxy-n-n-propylnoraporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD (+)-(1r,1's)-berbamunine hydrochloride NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn dopamine d1 receptor DRD1 Successful target agonist 0.21 TTD , drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d1 receptor DRD1 NA antagonist 0.05 drugbank , DGIDB triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Middle East Respiratory Syndrome[MeSHID:D018352] approved,vet_approved dopamine d1 receptor DRD1 NA antagonist 0.39 drugbank , DGIDB (r)-(-)-n-ethyl-2-methoxy-11-hydroxynoraporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d1 receptor DRD1 NA antagonist NA drugbank lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational dopamine d1 receptor DRD1 NA antagonist 0.15 drugbank , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA agonist 0.32 drugbank , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn dopamine d1 receptor DRD1 NA antagonist 0.28 drugbank , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved d(1) dopamine receptor DRD1 NA agonist 0.16 drugbank , DGIDB pipotiazine small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational dopamine d1 receptor DRD1 NA antagonist NA drugbank fenoldopam small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Malignant Hypertension[MeSHID:D006974],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 Successful target agonist 0.34 TTD , drugbank , DGIDB 1-[2-(2-benzyl-phenoxy)-ethyl]-pyrrolidine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD carphenazine small molecule Sleeplessness[MeSHID:D007319],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn dopamine d1 receptor DRD1 NA antagonist 0.49 drugbank , DGIDB skf-83959 NA NA investigative dopamine d1 receptor DRD1 Successful target agonist 0.13 TTD , DGIDB imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved d(1) dopamine receptor DRD1 NA binder 0.06 drugbank , DGIDB 2-methoxyapomorphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD bam-1110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 2 dopamine d1 receptor DRD1 Successful target unknown NA TTD (s)-bulbocapnine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist 0.05 drugbank , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d1 receptor DRD1 NA unknown NA drugbank skf-75670 NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD das-431 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dopamine d1 receptor DRD1 Successful target unknown NA TTD melosmine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD (+)-adtn NA NA investigative dopamine d1 receptor DRD1 Successful target agonist NA TTD , DGIDB thioridazine small molecule Anxiety Disorders[MeSHID:D001008],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn dopamine d1 receptor DRD1 NA antagonist 0.1 drugbank , DGIDB (r)-2,11-diaminoaporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 4-[2-(2-benzyl-phenoxy)-ethyl]-morpholine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 1-(4-(1h-pyrazol-1-yl)benzyl)-4-phenylpiperazine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved d(1) dopamine receptor DRD1 NA binder 0.13 drugbank , DGIDB lumateperone small molecule Schizophrenia[MeSHID:D012559] approved,investigational dopamine d1 receptor DRD1 NA unknown NA drugbank isoclozapine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD etoloxamine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 9-aminomethyl-9h-fluorene-2,5,6-triol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 2-{[r-(-)-apomorphine-2'-oxy]ethoxy}-ethanol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD ecopipam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970],Gilles de la Tourette syndrome[MeSHID:D005879] phase 3 dopamine d1 receptor DRD1 Successful target unknown 0.58 TTD , DGIDB 1-aminomethyl-3-cyclohexyl-isochroman-5,6-diol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD sdz-glc-756 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] discontinued in phase 1 dopamine d1 receptor DRD1 Successful target unknown NA TTD dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved dopamine d1 receptor DRD1 NA agonist 0.14 drugbank , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist 0.04 drugbank , DGIDB (s,s)-oxandrine hydrochloride NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 11-hexanoyloxy-n-n-propylnoraporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 1-benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved dopamine d1 receptor DRD1 NA antagonist 0.39 drugbank , DGIDB rotigotine small molecule Restless Legs Syndrome[MeSHID:D012148],Parkinson Disease[MeSHID:D010300] approved dopamine d1 receptor DRD1 NA agonist 0.19 drugbank , DGIDB thiothixene small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist NA drugbank zelandopam hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 dopamine d1 receptor DRD1 Successful target unknown NA TTD sb-271046 NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD berupipam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 dopamine d1 receptor DRD1 Successful target unknown NA TTD quinagolide small molecule Hyperprolactinemia[MeSHID:D006966],Pituitary Gland[MeSHID:D010902],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD1 NA agonist NA drugbank pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d1 receptor DRD1 NA antagonist NA drugbank 9-aminomethyl-9h-fluorene-3,4-diol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD bsf-78438 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d1 receptor DRD1 Successful target unknown NA TTD , DGIDB adrogolide hydrochloride NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 dopamine d1 receptor DRD1 Successful target unknown NA TTD zicronapine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 dopamine d1 receptor DRD1 Successful target unknown 0.1 TTD , DGIDB cy-208243 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 dopamine d1 receptor DRD1 Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist 0.13 drugbank , DGIDB (r)-(+)-coclaurine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 1-aminomethyl-3-phenyl-isochroman-5,6-diol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD1 NA inhibitor NA drugbank 1,2-bis-[r-(-)-apomorphine-2'-oxy]ethane NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD flutroline NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD ecopipam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970],Gilles de la Tourette syndrome[MeSHID:D005879] phase 3 dopamine d1 receptor DRD1 Successful target antagonist 0.58 TTD , DGIDB (r)-(-)-10-methyl-11-hydroxyaporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dopamine d1 receptor DRD1 NA antagonist 0.04 drugbank , DGIDB 1-aminomethyl-isochroman-5,6-diol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational dopamine d1 receptor DRD1 NA antagonist,agonist 0.15 drugbank , DGIDB zuclopenthixol small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Manic[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Behavior[MeSHID:D001519],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d1 receptor DRD1 NA antagonist 0.31 drugbank , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine receptor DRD1 NA antagonist,agonist NA drugbank dihydro-alpha-ergocryptine small molecule Peripheral Vascular Diseases[MeSHID:D016491],Parkinson Disease[MeSHID:D010300],Hypotension[MeSHID:D007022],Migraine Disorders[MeSHID:D008881] approved d(1) dopamine receptor DRD1 NA partial agonist NA drugbank (r)-11-amino-2-methoxyaporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 6-(2-dipropylamino-ethyl)-biphenyl-2,3,4'-triol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 11-propionyloxy-n-n-propylnoraporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 3,8-dibromoboldine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD1 NA binder 0.02 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved d(1) dopamine receptor DRD1 NA inhibitor,antagonist 0.04 drugbank , DGIDB levodopa small molecule Secondary Parkinson Disease[MeSHID:D010302],Parkinson Disease, Postencephalitic[MeSHID:D010301],Inspiration function[MeSHID:D001239],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA agonist 0.06 drugbank , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved d(1) dopamine receptor DRD1 NA binder 0.1 drugbank , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved dopamine d1 receptor DRD1 NA agonist 0.16 drugbank , DGIDB 1-[2-(2-benzyl-phenoxy)-ethyl]-piperidine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD (s)apomorphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD flumezapine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved d(1) dopamine receptor DRD1 NA agonist NA drugbank odapipam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 dopamine d1 receptor DRD1 Successful target unknown NA TTD 1-[3-(2-benzyl-phenoxy)-propyl]-pyrrolidine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD norstephalagine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD epicriptine small molecule Isomerism[MeSHID:D007536] approved dopamine receptor DRD1 NA agonist NA drugbank periciazine small molecule Aggressive behavior[MeSHID:D000374],Impulsive Behavior[MeSHID:D007175],Hostility[MeSHID:D006791] approved,investigational dopamine d1 receptor DRD1 NA antagonist 0.16 drugbank , DGIDB fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist 0.21 drugbank , DGIDB pipradrol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Fatigue[MeSHID:D005221],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863] approved d(1) dopamine receptor DRD1 NA agonist NA drugbank quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved dopamine d1 receptor DRD1 NA antagonist 0.05 drugbank , DGIDB 1-dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist 0.13 drugbank , DGIDB boldine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD n-propylnorapomorphine NA NA investigative dopamine d1 receptor DRD1 Successful target agonist NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved dopamine d1 receptor DRD1 NA antagonist 0.04 drugbank , DGIDB ibzm NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD (-)-(1s,1'r)-o,o-dimethylgrisbine hydrochloride NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental dopamine receptor DRD1 NA antagonist,agonist 0.19 drugbank , DGIDB 6-(2-amino-ethyl)-biphenyl-2,3-diol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 6-(2-amino-ethyl)-biphenyl-2,3,4'-triol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 3-iodoboldine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD thioproperazine small molecule Manic[MeSHID:D001714],Syndrome[MeSHID:D013577],Schizophrenia[MeSHID:D012559] experimental dopamine d1 receptor DRD1 NA antagonist NA drugbank apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d1 receptor DRD1 NA agonist 0.12 drugbank , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d1 receptor DRD1 NA antagonist NA drugbank nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit dopamine receptor DRD1 NA modulator NA drugbank 11-butyryloxy-n-n-propylnoraporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD falcarindiol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD bts-73947 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 dopamine d1 receptor DRD1 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational dopamine d1 receptor DRD1 NA antagonist,partial agonist,ligand NA drugbank 11-heptanoyloxy-n-n-propylnoraporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD pukateine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 1-benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 2-methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD adx-10061 NA Cessation of smoking[MeSHID:D016540],Sleep Disorders[MeSHID:D012893],Substance abuse problem[MeSHID:D019966],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 2 dopamine d1 receptor DRD1 Successful target unknown NA TTD fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved dopamine d1 receptor DRD1 NA antagonist 0.21 drugbank , DGIDB tepa (possesses cytotoxic activity) NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD methylergometrine small molecule Birth[MeSHID:D036801],Hemorrhage[MeSHID:D006470],Vagina[MeSHID:D014621] approved dopamine d1 receptor DRD1 NA antagonist NA drugbank zotepine small molecule Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,investigational,withdrawn d(1) dopamine receptor DRD1 NA antagonist NA drugbank acepromazine small molecule Anxiety[MeSHID:D001007] experimental,vet_approved dopamine d1 receptor DRD1 NA antagonist NA drugbank bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d1 receptor DRD1 NA agonist 0.04 drugbank , DGIDB skf-83556 NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD1 NA unknown NA drugbank perphenazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d1 receptor DRD1 NA antagonist 0.1 drugbank , DGIDB sch-12679 NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD glaucine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD tetrahydropalmatine small molecule NA investigational dopamine d1 receptor DRD1 NA antagonist NA drugbank (r)-(-)-2-methoxy-11-hydroxyaporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD n-(4-propylaminobutyl)-4-biphenylcarboxamide NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 6-(2-dipropylamino-ethyl)-biphenyl-2,3-diol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD [125i]sch23982 NA NA investigative dopamine d1 receptor DRD1 Successful target antagonist NA TTD , DGIDB (r)-(-)-n-propyl-2-methoxy-11-hydroxynoraporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD (+)-(1r,1's)-thaligrisine hydrochloride NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 5-(2-amino-ethyl)-2-chloro-phenol hydrobromide NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD phenyltoloxamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved dopamine d1 receptor DRD1 Successful target unknown 0.1 TTD , DGIDB phenylpropanolamine small molecule Urinary Incontinence[MeSHID:D014549],Obesity[MeSHID:D009765],Priapism[MeSHID:D011317],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved,withdrawn dopamine d1 receptor DRD1 NA partial agonist NA drugbank (r)-(-)-2-methoxy-n-npropylnorapomorphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD n-(4-dipropylaminobutyl)-4-biphenylcarboxamide NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD [r-(-)-apomorphine-2-yl]-(2'-hydroxy-ethyl)ether NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD sch-24518 NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 11-valeryloxynoraporphine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD 1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD sk&f-89626 NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD mcl-516 NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD1 NA binder NA drugbank quinpirole NA NA investigative dopamine d1 receptor DRD1 Successful target unknown NA TTD stepholidine NA NA investigative dopamine d1 receptor DRD1 Successful target unknown 0.39 TTD , DGIDB acp-104 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618] investigational dopamine d2 receptor DRD2 NA unknown NA drugbank , DGIDB 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD nomifensine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] withdrawn from market dopamine d2 receptor DRD2 Successful target unknown NA TTD (r)-(-)-n-propyl-2-methoxy-11-hydroxynoraporphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD metoclopramide small molecule Disease Management[MeSHID:D019468],Radiation[MeSHID:D011827],Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Gastroparesis[MeSHID:D018589],Nose[MeSHID:D009666],Pain[MeSHID:D010146],Hiccup[MeSHID:D006606],Recurrence (disease attribute)[MeSHID:D012008],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Stomach[MeSHID:D013270],Vomiting[MeSHID:D014839],Gastroesophageal reflux disease[MeSHID:D005764],Intestines, Small[MeSHID:D007421],Gastric Emptying[MeSHID:D005746],Bezoars[MeSHID:D001630],Electromagnetic Radiation[MeSHID:D060733],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist 0.33 TTD , drugbank , DGIDB 3-(3,5-dimethyl-phenyl)-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-propyl-3-p-tolyl-piperidine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn dopamine d2 receptor DRD2 Successful target antagonist 0.41 TTD , drugbank , DGIDB bevantolol NA Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target unknown 0.18 TTD , DGIDB (+)-(1r,1's)-thaligrisine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD benzo[d]oxazol-2(3h)-one derivative 2 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved dopamine d2 receptor DRD2 NA agonist,partial agonist NA drugbank 3-naphthalen-1-yl-1-propyl-pyrrolidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD skl-10406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB pd-135146 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD iodopride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD levodopa small molecule Secondary Parkinson Disease[MeSHID:D010302],Parkinson Disease, Postencephalitic[MeSHID:D010301],Inspiration function[MeSHID:D001239],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target agonist 0.12 TTD , drugbank , DGIDB fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 NA antagonist 0.17 drugbank , DGIDB bis-{[r-(-)-apomorphine-2-oxy]ethyl} ether NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (+/-)-nantenine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(2,3-dimethyl-phenyl)-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pf-03800130 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3,8-dibromoboldine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (4-ethynyl-cyclohex-3-enyl)-dipropyl-amine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-butyl-2,3,4,5-tetrahydro-1h-benzo[d]azepin-6-ol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD [3h]n-methylspiperone NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD epicriptine small molecule Isomerism[MeSHID:D007536] approved dopamine receptor DRD2 NA agonist NA drugbank pmid29334795-compound-62 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB slv-314 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD methyldopa NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target unknown 0.01 TTD , DGIDB apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target agonist 0.21 TTD , drugbank , DGIDB propyl-(4,5,6,7-tetrahydro-2h-indazol-5-yl)-amine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD stepholidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown 0.36 TTD , DGIDB iodosulpiride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD trifluoperazine small molecule Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational dopamine d2 receptor DRD2 NA antagonist 0.12 drugbank , DGIDB rotigotine small molecule Restless Legs Syndrome[MeSHID:D012148],Parkinson Disease[MeSHID:D010300] approved dopamine d2 receptor DRD2 NA agonist 0.3 drugbank , DGIDB uh-301 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD preclamol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 NA antagonist 0.18 drugbank , DGIDB f-15063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 3-(4-phenyl-piperidin-1-ylmethyl)-1h-indole NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target antagonist,inverse agonist 0.25 TTD , drugbank , DGIDB 7-(2-dipropylamino-ethyl)-3h-benzothiazol-2-one NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD cariprazine small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] approved,investigational dopamine d2 receptor DRD2 Successful target agonist,partial agonist 0.48 TTD , drugbank , DGIDB buspirone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 NA antagonist 0.36 drugbank , DGIDB iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target antagonist 0.14 TTD , drugbank , DGIDB lurasidone hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB naphazoline NA Vascular constriction (function)[MeSHID:D014661],Nose[MeSHID:D009666],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Hyperemia[MeSHID:D006940],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] approved dopamine d2 receptor DRD2 Successful target unknown 0.18 TTD , DGIDB fluanisone NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved dopamine d2 receptor DRD2 NA binder NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 NA agonist,inhibitor NA drugbank acetophenazine small molecule Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Thinking, function[MeSHID:D013850],Perception[MeSHID:D010465],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] approved dopamine d2 receptor DRD2 Successful target antagonist 0.96 TTD , drugbank , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved dopamine d2 receptor DRD2 Successful target antagonist 0.13 TTD , drugbank , DGIDB slv-313 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD n-ethyl-2-phenylnorapomorphine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1,2-bis-[r-(-)-apomorphine-2'-oxy]ethane NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD boldine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-chloroboldine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pmid29334795-compound-67 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB roxindole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 dopamine d2 receptor DRD2 Successful target unknown 0.05 TTD , DGIDB anonaine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(3,4-dimethyl-phenyl)-1-propyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD lumateperone tosylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d2 receptor DRD2 Successful target unknown NA TTD tetrabenazine small molecule Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Hemiballismus[MeSHID:D020820],Gilles de la Tourette syndrome[MeSHID:D005879],Huntington Disease[MeSHID:D006816],Tic disorder[MeSHID:D013981],Tardive Dyskinesia[MeSHID:D000071057],Chorea, Senile[MeSHID:D002819],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 NA inhibitor NA drugbank carphenazine small molecule Sleeplessness[MeSHID:D007319],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn,approved dopamine d2 receptor DRD2 Successful target antagonist 0.63 TTD , drugbank , DGIDB pmid29334795-compound-66 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target antagonist 0.25 TTD , drugbank , DGIDB (r)-(-)-2-phenyl-apomorphine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD sulpiride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist 0.32 TTD , drugbank , DGIDB nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit dopamine receptor DRD2 NA modulator NA drugbank rbp-7000 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 3-(4-benzyl-piperazin-1-yl)-phenol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pg-01037 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD blonanserin small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 dopamine d2 receptor DRD2 Successful target antagonist 0.54 TTD , drugbank , DGIDB quinpirole NA NA investigative dopamine d2 receptor DRD2 Successful target agonist 0.25 TTD , DGIDB bim23a760 NA Acromegaly[MeSHID:D000172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Carcinoid Syndrome[MeSHID:D008303],Psoriasis[MeSHID:D011565] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 2-{[r-(-)-apomorphine-2'-oxy]ethoxy}-ethanol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD onc206 NA Central Nervous System Neoplasms[MeSHID:D016543],Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD benzo[d]oxazol-2(3h)-one derivative 3 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 2,3-dihydro-1h-indol-5-ol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pmid30124346-compound-34table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB sdz-glc-756 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] discontinued in phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD romergoline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-propyl-3-m-tolyl-piperidine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD n-ethyl-2-methylnorapomorphine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (+)-s-14297 NA NA investigative dopamine d2 receptor DRD2 Successful target antagonist NA TTD , DGIDB 5-oh-dpat NA NA investigative dopamine d2 receptor DRD2 Successful target unknown 0.72 TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dopamine d2 receptor DRD2 Successful target antagonist 0.24 TTD , drugbank , DGIDB (r)-(-)-2-methoxy-11-hydroxyaporphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD lu-02-750 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB cgs-15873a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 1-[3-(2-benzyl-phenoxy)-propyl]-pyrrolidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD promazine small molecule Psychomotor Agitation[MeSHID:D011595],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved dopamine d2 receptor DRD2 NA antagonist 0.14 drugbank , DGIDB pd-135188 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD flupenthixol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] withdrawn from market dopamine d2 receptor DRD2 Successful target unknown 0.09 TTD , DGIDB itopride small molecule Gastrointestinal Diseases[MeSHID:D005767],Disease[MeSHID:D004194] investigational dopamine d2 receptor DRD2 NA unknown 0.36 drugbank , DGIDB mephentermine NA Systemic arterial pressure[MeSHID:D062186],Maintenance[MeSHID:D008283],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved dopamine d2 receptor DRD2 Successful target unknown 0.18 TTD , DGIDB zuclopenthixol small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Manic[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Behavior[MeSHID:D001519],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist 0.5 TTD , drugbank , DGIDB roxindole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 dopamine d2 receptor DRD2 Successful target agonist,antagonist 0.05 TTD , DGIDB 1-aminomethyl-3-cyclohexyl-isochroman-5,6-diol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD domperidone small molecule Disease Management[MeSHID:D019468],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Dyspepsia[MeSHID:D004415],Heartburn[MeSHID:D006356],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational,vet_approved dopamine d2 receptor DRD2 Successful target antagonist 0.54 TTD , drugbank , DGIDB fencamfamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fatigue[MeSHID:D005221] withdrawn from market dopamine d2 receptor DRD2 Successful target unknown NA TTD clr-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ml321 NA NA investigative dopamine d2 receptor DRD2 Successful target antagonist NA TTD , DGIDB (s,r)-pseudoxandrine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist 0.22 TTD , drugbank , DGIDB brasofensine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d2 receptor DRD2 NA unknown NA drugbank meglitinides NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] approved dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB mazapertine NA NA discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist,partial agonist,agonist 0.83 TTD , drugbank , DGIDB quinagolide small molecule Hyperprolactinemia[MeSHID:D006966],Pituitary Gland[MeSHID:D010902],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target agonist 0.36 TTD , drugbank , DGIDB ethyl-(4,5,6,7-tetrahydro-2h-indazol-5-yl)-amine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 NA antagonist 0.11 drugbank , DGIDB 1-aminomethyl-isochroman-5,6-diol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD tak-906 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroparesis[MeSHID:D018589] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD bl-1020 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 dopamine d2 receptor DRD2 Successful target unknown 0.36 TTD , drugbank , DGIDB benzo[d]oxazol-2(3h)-one derivative 1 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB (5-methoxy-chroman-3-yl)-dipropyl-amine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-benzyl-4-[3-(methylsulfonyl)phenyl]piperazine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD n-propyl-2-phenylnorapomorphine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pukateine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-benzyl-4-pyrrol-1-yl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD dihydroergotoxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB sibenadet NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD aryl piperazine derivative 1 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB nolomirole hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] discontinued in phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD perospirone small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] experimental dopamine d2 receptor DRD2 NA antagonist 0.24 drugbank , DGIDB unc9975 NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB aryl piperazine derivative 6 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB etoloxamine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD skf-89124a NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-iodoboldine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist 0.37 TTD , drugbank , DGIDB apd-403 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vomiting[MeSHID:D014839] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 3-phenyl-1-propyl-pyrrolidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD onc201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Endometrial Carcinoma[MeSHID:D016889],Lymphoma[MeSHID:D008223],Carcinoma, Neuroendocrine[MeSHID:D018278],leukemia[MeSHID:D007938],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Respiratory Tract Infections[MeSHID:D012141] phase 2 dopamine d2 receptor DRD2 Successful target unknown 0.07 TTD , DGIDB phenylephrine NA Hypotension[MeSHID:D007022],Priapism[MeSHID:D011317],Regional Blood Flow[MeSHID:D012039],Pupil[MeSHID:D011680],Vascular constriction (function)[MeSHID:D014661],Shock[MeSHID:D012769],Eye[MeSHID:D005123],Hemorrhoids[MeSHID:D006484],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid associated opthalmopathies[MeSHID:D049970],Fecal Incontinence[MeSHID:D005242] approved dopamine d2 receptor DRD2 Successful target unknown 0.03 TTD , DGIDB brl-26175 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (s,r)-antioquine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank pipotiazine small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational dopamine d2 receptor DRD2 NA antagonist 2.88 drugbank , DGIDB prochlorperazine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Headache[MeSHID:D006261],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Emergencies [Disease/Finding][MeSHID:D004630],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved dopamine d2 receptor DRD2 Successful target antagonist 0.21 TTD , drugbank , DGIDB lurasidone small molecule Schizophrenia[MeSHID:D012559] approved,investigational dopamine d2 receptor DRD2 NA antagonist 0.18 drugbank , DGIDB 3-(3,5-dimethyl-phenyl)-1-propyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD nor-roefractine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ephedrine NA Asthma[MeSHID:D001249],Nose[MeSHID:D009666],Hypotension[MeSHID:D007022],Bronchial Diseases[MeSHID:D001982],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target unknown 0.12 TTD , DGIDB pd-135222 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD d-210 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 NA antagonist 0.4 drugbank , DGIDB (r)-(-)-2-methoxy-n-npropylnorapomorphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD brexpiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866] approved,investigational dopamine d2 receptor DRD2 NA agonist,partial agonist 0.36 drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational dopamine d2 receptor DRD2 NA binder NA drugbank way-208466 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD savoxepin mesylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD org-23366 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d2 receptor DRD2 NA partial agonist 0.12 drugbank , DGIDB 1,6-bis(4-m-tolylpiperazin-1-yl)hexane NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD aplindore fumarate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 dopamine d2 receptor DRD2 Successful target partial agonist 0.36 TTD , DGIDB a-690344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD benzyl-[2-(1h-indazol-4-yloxy)-ethyl]-amine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD n-propylnorapomorphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD benzyl-[2-(1h-indol-4-yloxy)-ethyl]-amine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank tbr-760 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary Adenoma[MeSHID:D010911] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational dopamine d2 receptor DRD2 NA binder 0.05 drugbank , DGIDB unc9994 NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB (r)-(-)-10-methyl-11-hydroxyaporphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved dopamine d2 receptor DRD2 Successful target antagonist 0.24 TTD , drugbank , DGIDB thioridazine small molecule Anxiety Disorders[MeSHID:D001008],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn dopamine d2 receptor DRD2 Successful target antagonist 0.16 TTD , drugbank , DGIDB carmoxirole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 1 dopamine d2 receptor DRD2 Successful target unknown 0.36 TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist,partial agonist 0.83 TTD , drugbank , DGIDB (r)-(-)-11-hydroxy-n-n-propylnoraporphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD jnj-37822681 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] investigational,phase 2 dopamine d2 receptor DRD2 Successful target antagonist 1.08 TTD , drugbank , DGIDB d-219 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD methamphetamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Attention deficit hyperactivity disorder[MeSHID:D001289] approved dopamine d2 receptor DRD2 Successful target unknown 0.01 TTD , DGIDB epidepride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD brl-25594 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ergonovine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Postpartum Hemorrhage[MeSHID:D006473] approved dopamine d2 receptor DRD2 Successful target unknown 0.09 TTD , DGIDB 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 NA antagonist 0.2 drugbank , DGIDB amantadine small molecule Adverse reaction to drug[MeSHID:D064420],Communicable Diseases[MeSHID:D003141],Parkinsonian Disorders[MeSHID:D020734],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 NA agonist NA drugbank (s,r)-isotetrandrine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-bromoboldine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD perazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] approved dopamine d2 receptor DRD2 Successful target unknown 0.18 TTD , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational,approved dopamine d2 receptor DRD2 Successful target blocker 0.36 TTD , drugbank , DGIDB pd-135478 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-[2-(2-benzyl-phenoxy)-ethyl]-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD naxagolide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD ro-21-7767 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD lp-211 NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB uh-232 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ibopamine hci NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Diseases[MeSHID:D006331] approved dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB tetrahydropalmatine small molecule NA investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank (s)-secoantioquine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD d-190 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental dopamine receptor DRD2 NA antagonist,agonist NA drugbank amitifadine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Alcoholic Intoxication, Chronic[MeSHID:D000437],Mood Disorders[MeSHID:D019964] investigational dopamine d2 receptor DRD2 NA unknown NA drugbank lumateperone small molecule Schizophrenia[MeSHID:D012559] approved,investigational dopamine d2 receptor DRD2 NA partial agonist,antagonist 0.29 drugbank , DGIDB mcl-515 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD thioproperazine small molecule Manic[MeSHID:D001714],Syndrome[MeSHID:D013577],Schizophrenia[MeSHID:D012559] experimental dopamine d2 receptor DRD2 NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank octoclothepin NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d2 receptor DRD2 Successful target agonist 1.17 TTD , drugbank , DGIDB sertindole small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn,withdrawn from market dopamine d2 receptor DRD2 Successful target antagonist 0.15 TTD , drugbank , DGIDB tiospirone NA NA discontinued in phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD acepromazine small molecule Anxiety[MeSHID:D001007] experimental,vet_approved dopamine d2 receptor DRD2 NA antagonist NA drugbank pd-172938 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved dopamine d2 receptor DRD2 Successful target antagonist,inverse agonist 0.25 TTD , drugbank , DGIDB pd-172939 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved dopamine d2 receptor DRD2 NA agonist NA drugbank loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target antagonist 0.48 TTD , drugbank , DGIDB phentolamine NA Hypertensive disease[MeSHID:D006973],Pheochromocytoma[MeSHID:D010673],Neoplasms[MeSHID:D009369],Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Coronary Artery Vasospasm[MeSHID:D003329],Left-Sided Heart Failure[MeSHID:D006333],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Erectile dysfunction[MeSHID:D007172],Left ventricular structure[MeSHID:D006352],Infarction[MeSHID:D007238],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target unknown 0.03 TTD , DGIDB molindone small molecule Disease Management[MeSHID:D019468],Mental disorders[MeSHID:D001523],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d2 receptor DRD2 Successful target antagonist 0.58 TTD , drugbank , DGIDB 1-benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved dopamine d2 receptor DRD2 NA antagonist 0.07 drugbank , DGIDB levomepromazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618] approved dopamine d2 receptor DRD2 Successful target antagonist 0.13 TTD , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved dopamine d2 receptor DRD2 Successful target agonist 0.36 TTD , drugbank , DGIDB 3-(octahydro-quinolizin-3-yl)-phenol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD dopexamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved dopamine d2 receptor DRD2 Successful target unknown 0.36 TTD , DGIDB 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD s32504 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Major Depressive Disorder[MeSHID:D003865],Expiration, function[MeSHID:D045853] preclinical dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 NA agonist 0.3 drugbank , DGIDB 7-trans-oh-pipat NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB d-264 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD mesoridazine small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Schizophrenia[MeSHID:D012559],Neurotic Disorders[MeSHID:D009497],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist 0.31 TTD , drugbank , DGIDB [r-(-)-apomorphine-2-yl]-(2'-hydroxy-ethyl)ether NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD anti-d NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune thrombocytopenic purpura[MeSHID:D016553] investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD quinpirole NA NA investigative dopamine d2 receptor DRD2 Successful target unknown 0.25 TTD , DGIDB [3h]7-oh-dpat NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (-)-(1s,1'r)-o,o-dimethylgrisbine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD dapiprazole NA Mydriasis[MeSHID:D015878],Eye[MeSHID:D005123],Physical Examination[MeSHID:D010808],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] approved dopamine d2 receptor DRD2 Successful target unknown 0.09 TTD , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational dopamine d2 receptor DRD2 NA binder NA drugbank n-propyl-2-methylnorapomorphine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved dopamine d2 receptor DRD2 NA unknown NA drugbank 4-(2-benzylamino-ethoxy)-1,3-dihydro-indol-2-one NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD d-193 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD lp-44 NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB lu-ae04621 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB d-366 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved dopamine d2 receptor DRD2 Successful target agonist 0.07 TTD , drugbank , DGIDB eticlopride NA NA investigative dopamine d2 receptor DRD2 Successful target antagonist 0.06 TTD , DGIDB lu af35700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB snap-94847 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD remoxipride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn,withdrawn from market dopamine d2 receptor DRD2 Successful target antagonist 0.3 TTD , drugbank , DGIDB metaraminol NA Brain Injuries[MeSHID:D001930],Hemorrhage[MeSHID:D006470],Hypotension[MeSHID:D007022],Shock[MeSHID:D012769],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target unknown 0.05 TTD , DGIDB xp-21279 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 4-benzyl-1-chroman-3-ylmethyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD sdz-208911 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (s)apomorphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD perphenazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d2 receptor DRD2 Successful target antagonist 0.2 TTD , drugbank , DGIDB 2-(4-dipropylamino-cyclohexylidene)-malononitrile NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD thiethylperazine small molecule Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,withdrawn dopamine d2 receptor DRD2 Successful target antagonist 0.2 TTD , drugbank , DGIDB 3-(4-phenyl-piperazin-1-ylmethyl)-1h-indole NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD flupentixol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Asthenia[MeSHID:D001247],Hyperactive behavior[MeSHID:D006948],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] approved,investigational,withdrawn dopamine d2 receptor DRD2 NA antagonist 0.51 drugbank , DGIDB isoloxapine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD sch-24518 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD n-(4-dipropylaminobutyl)-4-biphenylcarboxamide NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pramipexole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d2 receptor DRD2 Successful target agonist 1.2 TTD , drugbank , DGIDB l-741626 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pd-135540 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD dsp-1200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational dopamine d2 receptor DRD2 Successful target agonist 0.13 TTD , drugbank , DGIDB pd 128907 NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB clebopride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(2,6-dimethyl-phenyl)-1-propyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved dopamine d2 receptor DRD2 NA antagonist 0.17 drugbank , DGIDB declopramide NA Inflammatory Bowel Diseases[MeSHID:D015212],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD amisulpride small molecule Emotions[MeSHID:D004644],Disease[MeSHID:D004194],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Vomiting[MeSHID:D014839],Neoplasm Metastasis[MeSHID:D009362],Hostility[MeSHID:D006791],Mood Disorders[MeSHID:D019964],Affect (mental function)[MeSHID:D000339],Postoperative Nausea[MeSHID:D020250],Behavior[MeSHID:D001519],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Thinking, function[MeSHID:D013850],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist 0.36 TTD , drugbank , DGIDB 1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(4-methyl-piperidin-1-ylmethyl)-1h-indole NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved dopamine d2 receptor DRD2 NA antagonist 0.36 drugbank , DGIDB 1-(4-(1h-pyrazol-1-yl)benzyl)-4-phenylpiperazine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved dopamine d2 receptor DRD2 NA agonist,partial agonist NA drugbank bam-1110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn dopamine d2 receptor DRD2 NA antagonist NA drugbank s-(-)-sulpiride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD clr-3001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB aniracetam small molecule Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,approved dopamine d2 receptor DRD2 Successful target unknown 0.08 TTD , drugbank , DGIDB am-831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD bicifadine small molecule Low Back Pain[MeSHID:D017116],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437] investigational dopamine d2 receptor DRD2 NA unknown NA drugbank droperidol small molecule Nausea[MeSHID:D009325],Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved dopamine d2 receptor DRD2 Successful target antagonist 0.48 TTD , drugbank , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target antagonist 0.17 TTD , drugbank , DGIDB pridopidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816] phase 3 dopamine d2 receptor DRD2 Successful target modulator 1.08 TTD , DGIDB 4-(4-benzyl-piperazin-1-yl)-1h-benzoimidazole NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (r)-(-)-2-methyl-apomorphine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD levomepromazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618] approved dopamine d2 receptor DRD2 Successful target unknown 0.13 TTD , DGIDB 3-phenyl-1-propyl-piperidine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD talipexole NA NA phase 4 dopamine d2 receptor DRD2 Successful target unknown 0.18 TTD , DGIDB lamectacin NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD (s)-bulbocapnine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD flumezapine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD anolobine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD d-237 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn dopamine d2 receptor DRD2 Successful target agonist 0.34 TTD , drugbank , DGIDB nemonapride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d2 receptor DRD2 Successful target unknown 3.6 TTD , DGIDB [2-(1h-benzoimidazol-4-yloxy)-ethyl]-benzyl-amine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD thiothixene small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target antagonist 0.65 TTD , drugbank , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine receptor DRD2 NA antagonist,agonist NA drugbank mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank 4-(4-benzyl-piperazin-1-yl)-5-chloro-1h-indole NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD azaperone NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD melperone small molecule Schizophrenia[MeSHID:D012559],Confusion[MeSHID:D003221],Disease[MeSHID:D004194],Sleep[MeSHID:D012890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank 3-phenyl-pyrrolidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD lurasidone hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d2 receptor DRD2 Successful target antagonist 0.18 TTD , DGIDB 1-benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(2,3-dimethyl-phenyl)-1-propyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-[3-(methylsulfonyl)phenyl]-4-propylpiperazine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD p2b-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB ordopidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 dopamine d2 receptor DRD2 Successful target modulator 0.36 TTD , DGIDB piribedil small molecule NA investigational,investigative dopamine d2 receptor DRD2 Successful target agonist 0.06 TTD , drugbank , DGIDB bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d2 receptor DRD2 Successful target agonist 0.15 TTD , drugbank , DGIDB zicronapine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 dopamine d2 receptor DRD2 Successful target unknown 0.09 TTD , DGIDB triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Middle East Respiratory Syndrome[MeSHID:D018352] approved,vet_approved dopamine d2 receptor DRD2 NA antagonist 0.36 drugbank , DGIDB 1-(3-hydroxyphenyl)-4-propylpiperazine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ssr-181507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB pridopidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816] phase 3 dopamine d2 receptor DRD2 Successful target unknown 1.08 TTD , DGIDB d-218 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD d-220 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-(benzyloxy)-2-(2-phenylethyl)benzene NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD bromopride small molecule Nausea[MeSHID:D009325],Postoperative Nausea[MeSHID:D020250],Gastroesophageal reflux disease[MeSHID:D005764],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415] investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank bifeprunox small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 dopamine d2 receptor DRD2 Successful target unknown 0.24 TTD , drugbank , DGIDB uinagolide NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD zotepine small molecule Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,investigational,withdrawn dopamine d2 receptor DRD2 NA antagonist 0.05 drugbank , DGIDB pf-217830 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714] discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD glaucine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(1-propyl-pyrrolidin-3-yl)-phenol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(2,4-dimethyl-phenyl)-1-propyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD s-18327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD bifeprunox small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 dopamine d2 receptor DRD2 Successful target partial agonist 0.24 TTD , drugbank , DGIDB abaperidone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 dopamine d2 receptor DRD2 Successful target unknown 0.18 TTD , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 NA unknown NA drugbank pd-135111 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pardoprunox small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational,phase 2 dopamine d2 receptor DRD2 Successful target unknown 0.15 TTD , drugbank , DGIDB sb269652 NA NA investigative dopamine d2 receptor DRD2 Successful target allosteric modulator NA TTD , DGIDB tolazoline NA Pulmonary artery structure[MeSHID:D011651],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] approved dopamine d2 receptor DRD2 Successful target unknown 0.07 TTD , DGIDB d-203 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (-)-3-(1-propyl-piperidin-3-yl)-benzonitrile NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pmid30124346-compound-60table5 NA Dyskinetic syndrome[MeSHID:D020820],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB ws-50030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD fluspirilene small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target antagonist 0.13 TTD , drugbank , DGIDB phenoxybenzamine NA Pheochromocytoma[MeSHID:D010673],Benign prostatic hypertrophy[MeSHID:D011470],Malignant Hypertension[MeSHID:D006974],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved dopamine d2 receptor DRD2 Successful target unknown 0.04 TTD , DGIDB opc-34712 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved dopamine d2 receptor DRD2 Successful target unknown 0.36 TTD , DGIDB [3h]spiperone NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational,phase 2 dopamine d2 receptor DRD2 Successful target unknown 0.12 TTD , drugbank , DGIDB 3-(octahydro-indolizin-8-yl)-phenol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD unc0006 NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB (+)-(1r,1's)-berbamunine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD mcl-516 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD piperacetazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d2 receptor DRD2 Successful target unknown 0.12 TTD , DGIDB mls1547 NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB 3-ethyl-2,3,4,5-tetrahydro-1h-benzo[d]azepin-6-ol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-naphthalen-1-yl-pyrrolidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 4-(4-benzyl-piperazin-1-yl)-7-bromo-1h-indole NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 2-methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pgx-200097 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB sumanirole small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 dopamine d2 receptor DRD2 Successful target agonist 0.72 TTD , drugbank , DGIDB phenyltoloxamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved dopamine d2 receptor DRD2 Successful target unknown 0.09 TTD , DGIDB lp-12 NA NA investigative dopamine d2 receptor DRD2 Successful target agonist NA TTD , DGIDB ibzm NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD alizapride small molecule Nausea[MeSHID:D009325],Postoperative Nausea[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d2 receptor DRD2 NA antagonist NA drugbank raclopride small molecule NA investigational dopamine d2 receptor DRD2 NA antagonist 0.14 drugbank , DGIDB sk&f-89626 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pardoprunox small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational,phase 2 dopamine d2 receptor DRD2 Successful target partial agonist 0.15 TTD , drugbank , DGIDB 1-benzyl-4-[3-(methylsulfonyl)phenyl]piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD flutroline NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 2-methoxyapomorphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD a-706149 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD sumanirole small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 dopamine d2 receptor DRD2 Successful target unknown 0.72 TTD , drugbank , DGIDB escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 NA inhibitor NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 NA antagonist,agonist NA drugbank 7-(2-amino-ethyl)-4-hydroxy-3h-benzothiazol-2-one NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD sb-258719 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(octahydro-quinolizin-1-yl)-phenol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD nafadotride NA NA investigative dopamine d2 receptor DRD2 Successful target antagonist 0.12 TTD , DGIDB isoclozapine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dopamine d2 receptor DRD2 NA antagonist NA drugbank slv-310 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(2-benzylamino-ethoxy)-phenol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD cqa 206-291 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB sb-271046 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pimozide small molecule Gilles de la Tourette syndrome[MeSHID:D005879],Tic, Vocal[MeSHID:D020323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d2 receptor DRD2 Successful target antagonist 0.16 TTD , drugbank , DGIDB as-8112 small molecule Expiration, function[MeSHID:D045853],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Vomiting[MeSHID:D014839] experimental dopamine d2 receptor DRD2 NA antagonist NA drugbank d-189 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pd-157695 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB (r)-(-)-n-ethyl-2-methoxy-11-hydroxynoraporphine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD rolicyclidine small molecule NA experimental,illicit,investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD , drugbank du-29894 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD (-)-3ppp, maryland NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB rp5063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Bipolar Disorder[MeSHID:D001714],Attention deficit hyperactivity disorder[MeSHID:D001289],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB denopamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Diseases[MeSHID:D006331] approved dopamine d2 receptor DRD2 Successful target unknown 0.18 TTD , DGIDB 3-(n-propylpiperidin-4-yl)phenol NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved dopamine d2 receptor DRD2 NA antagonist NA drugbank (4-quinolin-2-ylpiperazin-1-yl)acetic acid NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pd-168077 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD n-benzyl-4-(2-diphenyl)-1-piperazinehexanamide NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD (+)-butaclamol NA NA investigative dopamine d2 receptor DRD2 Successful target antagonist NA TTD , DGIDB thiethylperazine small molecule Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn dopamine d2 receptor DRD2 Successful target antagonist 0.2 TTD , drugbank , DGIDB sdz-mar-327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Psychotic Disorders[MeSHID:D011618],Schizophrenia[MeSHID:D012559] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB (s)-amisulpride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 4 dopamine d2 receptor DRD2 Successful target unknown NA TTD dihydro-alpha-ergocryptine small molecule Peripheral Vascular Diseases[MeSHID:D016491],Parkinson Disease[MeSHID:D010300],Hypotension[MeSHID:D007022],Migraine Disorders[MeSHID:D008881] approved dopamine d2 receptor DRD2 NA agonist NA drugbank docarpamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved dopamine d2 receptor DRD2 Successful target unknown 0.36 TTD , DGIDB 4-(4-benzyl-piperazin-1-yl)-1h-indole NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved dopamine d2 receptor DRD2 Successful target antagonist 0.25 TTD , drugbank , DGIDB pd-135385 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(3,4-dimethyl-phenyl)-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-cyclohexyl-1-propyl-piperidine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD l-piperazino-3-phenyl-indane derivative 1 NA NA patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB d-192 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 NA unknown NA drugbank mazapertine succinate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 3-(2,5-dimethyl-phenyl)-1-propyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD sel-73 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD umespirone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 1 dopamine d2 receptor DRD2 Successful target unknown 0.18 TTD , DGIDB pd-137821 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 3-(4-benzyl-piperidin-1-ylmethyl)-chroman-4-one NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-propyl-3-o-tolyl-piperidine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ati-9242 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB bis(olanzapine) pamoate monohydrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 4-benzyl-1-indan-2-ylmethyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pd-158771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB entacapone+levodopa+carbidopa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Restless Legs Syndrome[MeSHID:D012148] phase 3 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB pd-143188 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB rotigitine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pseudoephedrine NA Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d2 receptor DRD2 Successful target unknown 0.02 TTD , DGIDB sarizotan small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Rett Syndrome[MeSHID:D015518],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2/3 dopamine d2 receptor DRD2 Successful target partial agonist 0.36 TTD , drugbank , DGIDB (r)-(+)-coclaurine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 1,6-bis(4-phenylpiperazin-1-yl)hexane NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD ykp-1358 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 dopamine d2 receptor DRD2 Successful target antagonist NA TTD , drugbank , DGIDB sep--4199 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD 1-benzyl-4-(3-hydroxyphenyl)piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD 4-benzyl-1-chroman-2-ylmethyl-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD n-0923 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 1192u90 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Psychotic Disorders[MeSHID:D011618],Schizophrenia[MeSHID:D012559] phase 1 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB pd-137789 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD fosopamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD (s,s)-oxandrine hydrochloride NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD pmid30124346-compound-13table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB aplindore fumarate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 dopamine d2 receptor DRD2 Successful target unknown NA TTD , DGIDB 1-benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d2 receptor DRD2 Successful target agonist 0.04 TTD , drugbank , DGIDB d-315 NA NA investigative dopamine d2 receptor DRD2 Successful target unknown NA TTD d-218 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD pardoprunox small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational dopamine d3 receptor DRD3 NA unknown 0.21 drugbank , DGIDB (r)-2-(benzylamino-methyl)-chroman-7-ol NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD ave-5997ef NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Psychotic Disorders[MeSHID:D011618],Schizophrenia[MeSHID:D012559] discontinued in phase 1 dopamine d3 receptor DRD3 Successful target unknown NA TTD pd-157533 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d3 receptor DRD3 NA agonist 0.17 drugbank , DGIDB blonanserin small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d3 receptor DRD3 NA antagonist NA drugbank l-741626 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 3-(4-phenyl-piperazin-1-ylmethyl)-1h-indole NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD domperidone small molecule Disease Management[MeSHID:D019468],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Dyspepsia[MeSHID:D004415],Heartburn[MeSHID:D006356],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational,vet_approved dopamine d3 receptor DRD3 NA antagonist 0.24 drugbank , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA antagonist NA drugbank ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d3 receptor DRD3 Successful target agonist 1.65 TTD , drugbank , DGIDB tak-906 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroparesis[MeSHID:D018589] phase 2 dopamine d3 receptor DRD3 Successful target unknown NA TTD (4-ethynyl-cyclohex-3-enyl)-dipropyl-amine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD s-33084 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] preclinical dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB (+/-)-nantenine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d3 receptor DRD3 NA antagonist 0.09 drugbank , DGIDB 4-(2-benzylamino-ethoxy)-1,3-dihydro-indol-2-one NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD pd-158771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB mazapertine NA NA discontinued in phase 2 dopamine d3 receptor DRD3 Successful target unknown NA TTD 1-propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 7-trans-oh-pipat NA NA investigative dopamine d3 receptor DRD3 Successful target agonist NA TTD , DGIDB methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d3 receptor DRD3 NA antagonist 0.21 drugbank , DGIDB flutroline NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD r-226161 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD aryl piperazine derivative 6 NA NA patented dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB d-203 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD (r)-(-)-2-methyl-apomorphine hydrochloride NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 1-(4-(1h-pyrazol-1-yl)benzyl)-4-phenylpiperazine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved dopamine d3 receptor DRD3 NA inhibitor,antagonist 0.07 drugbank , DGIDB 3-(1-propyl-pyrrolidin-3-yl)-phenol NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD gsk598809 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] phase 2 dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB captodiame small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007] experimental dopamine d3 receptor DRD3 NA agonist NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA antagonist 0.14 drugbank , DGIDB quinpirole NA NA investigative dopamine d3 receptor DRD3 Successful target unknown 0.22 TTD , DGIDB (+)-butaclamol NA NA investigative dopamine d3 receptor DRD3 Successful target antagonist NA TTD , DGIDB d-210 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA binder,antagonist 0.16 drugbank , DGIDB flumezapine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dopamine d3 receptor DRD3 NA antagonist NA drugbank acp-104 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618] investigational dopamine d3 receptor DRD3 NA unknown NA drugbank , DGIDB lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational dopamine d3 receptor DRD3 NA agonist 0.09 drugbank , DGIDB [2-(1h-benzoimidazol-4-yloxy)-ethyl]-benzyl-amine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD d-219 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 1-[3-(2-benzyl-phenoxy)-propyl]-pyrrolidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 5-oh-dpat NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD (+)-aj76 NA NA investigative dopamine d3 receptor DRD3 Successful target antagonist NA TTD , DGIDB amisulpride small molecule Emotions[MeSHID:D004644],Disease[MeSHID:D004194],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Vomiting[MeSHID:D014839],Neoplasm Metastasis[MeSHID:D009362],Hostility[MeSHID:D006791],Mood Disorders[MeSHID:D019964],Affect (mental function)[MeSHID:D000339],Postoperative Nausea[MeSHID:D020250],Behavior[MeSHID:D001519],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Thinking, function[MeSHID:D013850],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational dopamine d3 receptor DRD3 NA antagonist 0.41 drugbank , DGIDB 1-benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD nafadotride NA NA investigative dopamine d3 receptor DRD3 Successful target antagonist 0.24 TTD , DGIDB sb-271046 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD d-190 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 1-benzyl-4-pyrrol-1-yl-piperidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental dopamine receptor DRD3 NA antagonist,agonist NA drugbank a-706149 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD cariprazine small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] approved,investigational dopamine d3 receptor DRD3 Successful target agonist,partial agonist 0.98 TTD , drugbank , DGIDB [3h]7-oh-dpat NA NA investigative dopamine d3 receptor DRD3 Successful target agonist NA TTD , DGIDB quinelorane NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 dopamine d3 receptor DRD3 Successful target agonist 0.24 TTD , DGIDB 4-(4-benzyl-piperazin-1-yl)-7-bromo-1h-indole NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 1-benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD d-189 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD l-741742 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD rp5063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Bipolar Disorder[MeSHID:D001714],Attention deficit hyperactivity disorder[MeSHID:D001289],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 2 dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB sb269652 NA NA investigative dopamine d3 receptor DRD3 Successful target allosteric modulator NA TTD , DGIDB 3-(2-benzylamino-ethoxy)-phenol NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD benzyl-[2-(1h-indol-4-yloxy)-ethyl]-amine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved dopamine d3 receptor DRD3 NA antagonist 0.1 drugbank , DGIDB pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn dopamine d3 receptor DRD3 NA agonist 0.2 drugbank , DGIDB levodopa small molecule Secondary Parkinson Disease[MeSHID:D010302],Parkinson Disease, Postencephalitic[MeSHID:D010301],Inspiration function[MeSHID:D001239],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA agonist 0.16 drugbank , DGIDB isoloxapine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD [3h]spiperone NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 4-(4-benzyl-piperazin-1-yl)-1h-indole NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA inverse agonist,antagonist 0.07 drugbank , DGIDB dihydro-alpha-ergocryptine small molecule Peripheral Vascular Diseases[MeSHID:D016491],Parkinson Disease[MeSHID:D010300],Hypotension[MeSHID:D007022],Migraine Disorders[MeSHID:D008881] approved dopamine d3 receptor DRD3 NA partial agonist NA drugbank bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d3 receptor DRD3 NA agonist 0.1 drugbank , DGIDB pg-01037 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD uh-232 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD d-315 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD d-220 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved dopamine d3 receptor DRD3 NA inverse agonist 0.07 drugbank , DGIDB 1-benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD n-(4-dipropylaminobutyl)-4-biphenylcarboxamide NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA antagonist 0.15 drugbank , DGIDB piribedil small molecule NA investigational,investigative dopamine d3 receptor DRD3 Successful target agonist 0.12 TTD , drugbank , DGIDB u-99194a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB rotigotine small molecule Restless Legs Syndrome[MeSHID:D012148],Parkinson Disease[MeSHID:D010300] approved dopamine d3 receptor DRD3 NA agonist 0.49 drugbank , DGIDB flupentixol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Asthenia[MeSHID:D001247],Hyperactive behavior[MeSHID:D006948],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] approved,investigational,withdrawn dopamine d3 receptor DRD3 NA antagonist 0.1 drugbank , DGIDB sulpiride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d3 receptor DRD3 NA antagonist 0.37 drugbank , DGIDB pd 128907 NA NA investigative dopamine d3 receptor DRD3 Successful target agonist NA TTD , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn dopamine d3 receptor DRD3 NA antagonist 0.63 drugbank , DGIDB pd-157695 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB pf-592379 NA NA investigative dopamine d3 receptor DRD3 Successful target agonist NA TTD , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d3 receptor DRD3 NA unknown NA drugbank dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved dopamine d3 receptor DRD3 NA agonist 0.07 drugbank , DGIDB onc201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Endometrial Carcinoma[MeSHID:D016889],Lymphoma[MeSHID:D008223],Carcinoma, Neuroendocrine[MeSHID:D018278],leukemia[MeSHID:D007938],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Respiratory Tract Infections[MeSHID:D012141] phase 2 dopamine d3 receptor DRD3 Successful target unknown 0.15 TTD , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA antagonist 0.05 drugbank , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d3 receptor DRD3 NA agonist NA drugbank cm-2395 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB (4-phenylethynyl-cyclohex-3-enyl)-dipropyl-amine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD sarizotan small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Rett Syndrome[MeSHID:D015518],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d3 receptor DRD3 NA ligand NA drugbank ngb 2904 NA NA investigative dopamine d3 receptor DRD3 Successful target antagonist NA TTD , DGIDB p2b-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD pardoprunox small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational dopamine d3 receptor DRD3 NA partial agonist 0.21 drugbank , DGIDB azaperone NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD (r)-(-)-2-phenyl-apomorphine hydrochloride NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD s32504 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Major Depressive Disorder[MeSHID:D003865],Expiration, function[MeSHID:D045853] preclinical dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d3 receptor DRD3 NA binder NA drugbank d-237 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD pimozide small molecule Gilles de la Tourette syndrome[MeSHID:D005879],Tic, Vocal[MeSHID:D020323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved dopamine d3 receptor DRD3 NA antagonist 0.07 drugbank , DGIDB benzyl-[2-(1h-indazol-4-yloxy)-ethyl]-amine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational dopamine d3 receptor DRD3 NA blocker NA drugbank quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved dopamine d3 receptor DRD3 NA ligand 0.12 drugbank , DGIDB (4-dipropylamino-cyclohexylidene)-acetonitrile NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD epicriptine small molecule Isomerism[MeSHID:D007536] approved dopamine receptor DRD3 NA agonist NA drugbank 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 1-[2-(2-benzyl-phenoxy)-ethyl]-pyrrolidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 3-(4-methyl-piperidin-1-ylmethyl)-1h-indole NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD n-(4-propylaminobutyl)-4-biphenylcarboxamide NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD tianeptine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d3 receptor DRD3 NA agonist NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine receptor DRD3 NA antagonist,agonist NA drugbank 2-(4-dipropylamino-cyclohexylidene)-malononitrile NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD d-264 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational dopamine d3 receptor DRD3 NA antagonist,partial agonist NA drugbank haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA inverse agonist 0.07 drugbank , DGIDB sumanirole small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d3 receptor DRD3 NA unknown NA drugbank a-437203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 2 dopamine d3 receptor DRD3 Successful target unknown NA TTD 4-(4-benzyl-piperazin-1-yl)-1h-benzoimidazole NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 4-(4-benzyl-piperazin-1-yl)-5-chloro-1h-indole NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 4-dipropylamino-cyclohex-1-enecarbonitrile NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD quinpirole NA NA investigative dopamine d3 receptor DRD3 Successful target agonist 0.22 TTD , DGIDB pramipexole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d3 receptor DRD3 Successful target agonist 3.17 TTD , drugbank , DGIDB remoxipride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn dopamine d3 receptor DRD3 NA antagonist NA drugbank pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d3 receptor DRD3 NA unknown NA drugbank isoclozapine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 3-(4-benzyl-piperazin-1-yl)-phenol NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 1-benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD a-690344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dopamine d3 receptor DRD3 NA inhibitor,antagonist 0.07 drugbank , DGIDB n-propylnorapomorphine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD as-8112 small molecule Expiration, function[MeSHID:D045853],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Vomiting[MeSHID:D014839] experimental,terminated dopamine d3 receptor DRD3 Successful target antagonist NA TTD , drugbank buspirone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d3 receptor DRD3 NA antagonist NA drugbank a-987306 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD gsk618334 NA Nasopharyngeal carcinoma[MeSHID:C538339],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] phase 1 dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB 1-dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD stepholidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit dopamine receptor DRD3 NA modulator NA drugbank d-366 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD (2-benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD s-33138 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 dopamine d3 receptor DRD3 Successful target unknown NA TTD 1-[2-(2-benzyl-phenoxy)-ethyl]-piperidine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD pd-152255 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 3-(4-phenyl-piperidin-1-ylmethyl)-1h-indole NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD (+)-s-14297 NA NA investigative dopamine d3 receptor DRD3 Successful target antagonist NA TTD , DGIDB etoloxamine NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD as-9705 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cell motility[MeSHID:D002465],Stomach Diseases[MeSHID:D013272],Vomiting[MeSHID:D014839] investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD f-15063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d3 receptor DRD3 NA antagonist 0.1 drugbank , DGIDB aryl piperazine derivative 1 NA NA patented dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB d-192 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD d-193 NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved dopamine d3 receptor DRD3 NA agonist 0.2 drugbank , DGIDB pfizer 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] phase 1 dopamine d3 receptor DRD3 Successful target unknown NA TTD , DGIDB bp-897 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970] discontinued in phase 2 dopamine d3 receptor DRD3 Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved dopamine d3 receptor DRD3 NA inverse agonist,antagonist 0.07 drugbank , DGIDB (-)-3-(1-propyl-piperidin-3-yl)-benzonitrile NA NA investigative dopamine d3 receptor DRD3 Successful target unknown NA TTD 3-(4-phenyl-piperidin-1-ylmethyl)-1h-indole NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD ngd 94-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 dopamine d4 receptor DRD4 Successful target unknown NA TTD , DGIDB 4-(4-benzyl-piperazin-1-yl)-5-chloro-1h-indole NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD u101958 NA NA investigative dopamine d4 receptor DRD4 Successful target antagonist NA TTD , DGIDB methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d4 receptor DRD4 NA antagonist NA drugbank flutroline NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational dopamine d4 receptor DRD4 NA antagonist,partial agonist NA drugbank lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational dopamine d4 receptor DRD4 NA agonist 0.12 drugbank , DGIDB pardoprunox small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational dopamine d4 receptor DRD4 NA unknown 0.14 drugbank , DGIDB pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d4 receptor DRD4 NA antagonist NA drugbank sb-271046 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD abt-670 NA NA investigative dopamine d4 receptor DRD4 Successful target agonist 0.99 TTD , DGIDB benzyl-[2-(1h-indazol-4-yloxy)-ethyl]-amine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD nafadotride NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 1-dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d4 receptor DRD4 NA antagonist NA drugbank ngd-94-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 dopamine d4 receptor DRD4 Successful target unknown NA TTD 4-(4-benzyl-piperazin-1-yl)-7-bromo-1h-indole NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD lu-35138 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 2 dopamine d4 receptor DRD4 Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved dopamine d4 receptor DRD4 NA binder,antagonist 0.1 drugbank , DGIDB n-(4-dipropylaminobutyl)-4-biphenylcarboxamide NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 1-[2-(2-benzyl-phenoxy)-ethyl]-pyrrolidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD phenyltoloxamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved dopamine d4 receptor DRD4 Successful target unknown 0.25 TTD , DGIDB a-381393 NA NA investigative dopamine d4 receptor DRD4 Successful target antagonist NA TTD , DGIDB [125i]l750667 NA NA investigative dopamine d4 receptor DRD4 Successful target antagonist NA TTD , DGIDB cp-226269 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d4 receptor DRD4 NA antagonist 0.09 drugbank , DGIDB remoxipride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn dopamine d4 receptor DRD4 NA antagonist NA drugbank loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d4 receptor DRD4 NA binder,antagonist 0.22 drugbank , DGIDB rbi257 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD flumezapine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD isoclozapine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD n-(4-propylaminobutyl)-4-biphenylcarboxamide NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD fauc 113 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d4 receptor DRD4 NA unknown NA drugbank l-741742 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d4 receptor DRD4 NA agonist 0.5 drugbank , DGIDB (4-ethynyl-cyclohex-3-enyl)-dipropyl-amine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental dopamine receptor DRD4 NA antagonist,agonist NA drugbank isoloxapine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d4 receptor DRD4 Successful target antagonist 0.14 TTD , drugbank , DGIDB 1-benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 1-benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD [2-(1h-benzoimidazol-4-yloxy)-ethyl]-benzyl-amine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD rotigotine small molecule Restless Legs Syndrome[MeSHID:D012148],Parkinson Disease[MeSHID:D010300] approved dopamine d4 receptor DRD4 NA agonist 0.66 drugbank , DGIDB pf-592379 NA NA investigative dopamine d4 receptor DRD4 Successful target agonist NA TTD , DGIDB flupentixol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Asthenia[MeSHID:D001247],Hyperactive behavior[MeSHID:D006948],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] approved,investigational,withdrawn dopamine d4 receptor DRD4 NA antagonist NA drugbank pg-01037 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved dopamine d4 receptor DRD4 NA antagonist 0.13 drugbank , DGIDB uh-232 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved dopamine d4 receptor DRD4 NA ligand NA drugbank 4-(4-benzyl-piperazin-1-yl)-1h-indole NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD spi-376 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d4 receptor DRD4 Successful target unknown NA TTD , DGIDB 1-benzyl-4-pyrrol-1-yl-piperidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD a-425444 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD l-741626 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 4-(4-benzyl-piperazin-1-yl)-1h-benzoimidazole NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD flibanserin small molecule Hypoactive Sexual Desire Disorder[MeSHID:D020018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] approved,investigational dopamine d4 receptor DRD4 NA antagonist,agonist NA drugbank tkp-1002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 1-benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD epicriptine small molecule Isomerism[MeSHID:D007536] approved dopamine receptor DRD4 NA agonist NA drugbank nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit dopamine receptor DRD4 NA modulator NA drugbank levodopa small molecule Secondary Parkinson Disease[MeSHID:D010302],Parkinson Disease, Postencephalitic[MeSHID:D010301],Inspiration function[MeSHID:D001239],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d4 receptor DRD4 NA agonist 0.11 drugbank , DGIDB sumanirole small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dopamine d4 receptor DRD4 NA unknown NA drugbank (4-phenylethynyl-cyclohex-3-enyl)-dipropyl-amine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD ml398 NA NA investigative dopamine d4 receptor DRD4 Successful target antagonist NA TTD , DGIDB 1-[2-(2-benzyl-phenoxy)-ethyl]-piperidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD a412997 NA NA investigative dopamine d4 receptor DRD4 Successful target agonist NA TTD , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d4 receptor DRD4 NA antagonist 0.19 drugbank , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d4 receptor DRD4 NA agonist NA drugbank ro 10-4548 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 3-(2-benzylamino-ethoxy)-phenol NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 1-(4-(1h-pyrazol-1-yl)benzyl)-4-phenylpiperazine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d4 receptor DRD4 NA antagonist 0.07 drugbank , DGIDB 3-(4-methyl-piperidin-1-ylmethyl)-1h-indole NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD fauc213 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD [3h]n-methylspiperone NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 1-benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD ropinirole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d4 receptor DRD4 NA agonist 0.99 drugbank , DGIDB rp5063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Bipolar Disorder[MeSHID:D001714],Attention deficit hyperactivity disorder[MeSHID:D001289],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 2 dopamine d4 receptor DRD4 Successful target unknown NA TTD , DGIDB 4-[2-(2-benzyl-phenoxy)-ethyl]-morpholine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD stepholidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD 3-(4-phenyl-piperazin-1-ylmethyl)-1h-indole NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD quinpirole NA NA investigative dopamine d4 receptor DRD4 Successful target agonist 0.1 TTD , DGIDB piribedil NA NA investigative dopamine d4 receptor DRD4 Successful target antagonist 0.08 TTD , DGIDB l-750,667 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD pramipexole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d4 receptor DRD4 NA agonist 2.32 drugbank , DGIDB (+/-)-nantenine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD jl-18 NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD benzyl-[2-(1h-indol-4-yloxy)-ethyl]-amine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD e-1455 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD buspirone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d4 receptor DRD4 NA antagonist NA drugbank 1-[3-(2-benzyl-phenoxy)-propyl]-pyrrolidine NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn dopamine d4 receptor DRD4 NA agonist 0.2 drugbank , DGIDB dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved dopamine d4 receptor DRD4 NA agonist 0.09 drugbank , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d4 receptor DRD4 NA antagonist 0.2 drugbank , DGIDB sulpiride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d4 receptor DRD4 NA antagonist NA drugbank perospirone small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] experimental dopamine d4 receptor DRD4 NA antagonist 0.66 drugbank , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine receptor DRD4 NA antagonist,agonist NA drugbank pd-165167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d4 receptor DRD4 Successful target unknown NA TTD , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved dopamine d4 receptor DRD4 NA agonist 0.2 drugbank , DGIDB u-99363e NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d4 receptor DRD4 Successful target unknown NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dopamine d4 receptor DRD4 NA binder,antagonist 0.1 drugbank , DGIDB [3h]spiperone NA NA investigative dopamine d4 receptor DRD4 Successful target antagonist NA TTD , DGIDB 4-(2-benzylamino-ethoxy)-1,3-dihydro-indol-2-one NA NA investigative dopamine d4 receptor DRD4 Successful target unknown NA TTD cm-2395 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 dopamine d4 receptor DRD4 Successful target unknown NA TTD , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d4 receptor DRD4 NA antagonist NA drugbank l-745,870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 dopamine d4 receptor DRD4 Successful target unknown NA TTD , DGIDB abt-724 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] discontinued in phase 2 dopamine d4 receptor DRD4 Successful target unknown NA TTD fenoldopam small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Malignant Hypertension[MeSHID:D006974],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d5 receptor DRD5 NA agonist 1.33 drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD5 NA antagonist 0.12 drugbank , DGIDB apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d5 receptor DRD5 NA agonist 0.45 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dopamine d5 receptor DRD5 NA inhibitor,antagonist 0.13 drugbank , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD5 NA binder NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental dopamine receptor DRD5 NA antagonist,agonist NA drugbank isoloxapine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational dopamine d5 receptor DRD5 NA antagonist,partial agonist,ligand NA drugbank zuclopenthixol small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Manic[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Behavior[MeSHID:D001519],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d5 receptor DRD5 NA antagonist 1.59 drugbank , DGIDB quinagolide small molecule Hyperprolactinemia[MeSHID:D006966],Pituitary Gland[MeSHID:D010902],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD5 NA agonist NA drugbank (+)-adtn NA NA investigative dopamine d5 receptor DRD5 Successful target agonist NA TTD , DGIDB dihydro-alpha-ergocryptine small molecule Peripheral Vascular Diseases[MeSHID:D016491],Parkinson Disease[MeSHID:D010300],Hypotension[MeSHID:D007022],Migraine Disorders[MeSHID:D008881] approved d(1) dopamine receptor DRD5 NA partial agonist NA drugbank olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dopamine d5 receptor DRD5 NA antagonist 0.12 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved d(1) dopamine receptor DRD5 NA inhibitor,antagonist 0.13 drugbank , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d5 receptor DRD5 NA antagonist NA drugbank 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d5 receptor DRD5 NA binder NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved d(1) dopamine receptor DRD5 NA binder NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD5 NA unknown NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved d(1) dopamine receptor DRD5 NA binder NA drugbank dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved d(1) dopamine receptor DRD5 NA agonist 0.18 drugbank , DGIDB levodopa small molecule Secondary Parkinson Disease[MeSHID:D010302],Parkinson Disease, Postencephalitic[MeSHID:D010301],Inspiration function[MeSHID:D001239],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine d5 receptor DRD5 NA agonist 0.22 drugbank , DGIDB rotigotine small molecule Restless Legs Syndrome[MeSHID:D012148],Parkinson Disease[MeSHID:D010300] approved dopamine d5 receptor DRD5 NA agonist 0.66 drugbank , DGIDB (+/-)-nantenine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD n-propylnorapomorphine NA NA investigative dopamine d5 receptor DRD5 Successful target agonist NA TTD , DGIDB 1-[2-(2-benzyl-phenoxy)-ethyl]-pyrrolidine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD 1-[2-(2-benzyl-phenoxy)-ethyl]-piperidine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational dopamine d5 receptor DRD5 NA antagonist,agonist 0.25 drugbank , DGIDB pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn dopamine d5 receptor DRD5 NA agonist 0.27 drugbank , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved dopamine d5 receptor DRD5 NA agonist 0.53 drugbank , DGIDB pipradrol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Fatigue[MeSHID:D005221],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863] approved d(1) dopamine receptor DRD5 NA agonist NA drugbank skf-83556 NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational dopamine d5 receptor DRD5 NA agonist 0.14 drugbank , DGIDB dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved dopamine d5 receptor DRD5 NA agonist 0.18 drugbank , DGIDB 1-dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine receptor DRD5 NA antagonist,agonist NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved dopamine d5 receptor DRD5 NA inhibitor,antagonist 0.13 drugbank , DGIDB cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD5 NA binder NA drugbank beta-ergocriptine NA NA investigative dopamine d5 receptor DRD5 Successful target agonist NA TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved d(1) dopamine receptor DRD5 NA binder NA drugbank epicriptine small molecule Isomerism[MeSHID:D007536] approved dopamine receptor DRD5 NA agonist NA drugbank [125i]sch23982 NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD 4-[2-(2-benzyl-phenoxy)-ethyl]-morpholine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD stepholidine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD carphenazine small molecule Sleeplessness[MeSHID:D007319],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn dopamine d5 receptor DRD5 NA antagonist 2.49 drugbank , DGIDB flutroline NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved d(1) dopamine receptor DRD5 NA inhibitor,antagonist 0.13 drugbank , DGIDB phenyltoloxamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved dopamine d5 receptor DRD5 Successful target unknown 0.5 TTD , DGIDB nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit dopamine receptor DRD5 NA modulator NA drugbank 1-[3-(2-benzyl-phenoxy)-propyl]-pyrrolidine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(1) dopamine receptor DRD5 NA inhibitor NA drugbank isoclozapine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD le-300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical dopamine d5 receptor DRD5 Successful target unknown NA TTD , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d5 receptor DRD5 NA unknown NA drugbank zotepine small molecule Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,investigational,withdrawn d(1) dopamine receptor DRD5 NA antagonist NA drugbank ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved d(1) dopamine receptor DRD5 NA agonist NA drugbank cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved d(1) dopamine receptor DRD5 NA agonist 0.53 drugbank , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved dopamine d5 receptor DRD5 NA ligand NA drugbank methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational dopamine d5 receptor DRD5 NA antagonist NA drugbank flumezapine NA NA investigative dopamine d5 receptor DRD5 Successful target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational desmoplakin DSP NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational desmoplakin DSP NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational desmoplakin DSP NA ligand NA drugbank dodecyldimethylamine n-oxide small molecule NA experimental destrin DSTN NA unknown NA drugbank thymidine monophosphate small molecule NA experimental thymidylate kinase DTYMK NA unknown NA drugbank zidovudine monophosphate small molecule NA experimental thymidylate kinase DTYMK NA unknown NA drugbank 2',3'-dideoxythymidine-5'-monophosphate small molecule NA experimental thymidylate kinase DTYMK NA unknown NA drugbank p1-(5'-adenosyl)p5-(5'-thymidyl)pentaphosphate small molecule NA experimental thymidylate kinase DTYMK NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental thymidylate kinase DTYMK NA unknown NA drugbank 3'-fluoro-3'-deoxythymidine 5'-monophosphate small molecule NA experimental thymidylate kinase DTYMK NA unknown NA drugbank p1-(5'-adenosyl)p5-(5'-(3'azido-3'-deoxythymidyl))pentaphosphate small molecule NA experimental thymidylate kinase DTYMK NA unknown NA drugbank 3'-deoxy-3'-aminothymidine monophosphate small molecule NA experimental thymidylate kinase DTYMK NA unknown NA drugbank adociaquinone b NA NA investigative dual specificity protein phosphatase 1 DUSP1 Clinical trial target unknown NA TTD avastin+/-tarceva NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 3 dual specificity protein phosphatase 1 DUSP1 Clinical trial target unknown NA TTD , DGIDB 4-ethoxynaphthalene-1,2-dione NA NA investigative dual specificity protein phosphatase 1 DUSP1 Clinical trial target unknown NA TTD okadaic acid NA NA investigative dual specificity protein phosphatase 1 DUSP1 Clinical trial target unknown NA TTD 4-nitrophenyl phosphate small molecule NA experimental dual specificity protein phosphatase 23 DUSP23 NA unknown NA drugbank isis 133242 NA NA investigative dusp5 messenger rna DUSP5 Literature-reported target unknown NA TTD isis 133245 NA NA investigative dusp5 messenger rna DUSP5 Literature-reported target unknown NA TTD isis 133206 NA NA investigative dusp5 messenger rna DUSP5 Literature-reported target unknown NA TTD isis 133208 NA NA investigative dusp5 messenger rna DUSP5 Literature-reported target unknown NA TTD isis 133244 NA NA investigative dusp5 messenger rna DUSP5 Literature-reported target unknown NA TTD isis 133211 NA NA investigative dusp5 messenger rna DUSP5 Literature-reported target unknown NA TTD isis 133243 NA NA investigative dusp5 messenger rna DUSP5 Literature-reported target unknown NA TTD isis 133207 NA NA investigative dusp5 messenger rna DUSP5 Literature-reported target unknown NA TTD isis 103386 NA NA investigative dusp8 messenger rna DUSP8 Literature-reported target unknown NA TTD isis 103375 NA NA investigative dusp8 messenger rna DUSP8 Literature-reported target unknown NA TTD isis 103387 NA NA investigative dusp8 messenger rna DUSP8 Literature-reported target unknown NA TTD isis 103471 NA NA investigative dusp9 messenger rna DUSP9 Literature-reported target unknown NA TTD isis 103489 NA NA investigative dusp9 messenger rna DUSP9 Literature-reported target unknown NA TTD isis 103473 NA NA investigative dusp9 messenger rna DUSP9 Literature-reported target unknown NA TTD isis 103486 NA NA investigative dusp9 messenger rna DUSP9 Literature-reported target unknown NA TTD deoxyuridine-5'-diphosphate small molecule NA experimental deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial DUT NA unknown NA drugbank 1-{(2s,5s)-4-fluoro-5-[(trityloxy)methyl]tetrahydrofuran-2-yl}pyrimidine-2,4(1h,3h)-dione small molecule NA experimental deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial DUT NA unknown NA drugbank tas-114 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Pentalogy of Cantrell[MeSHID:D058502],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dutp pyrophosphatase DUT Clinical trial target unknown NA TTD , DGIDB pmid28766366-compound-scheme5 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme7wo2012/098070upper NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme18 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme11 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme25-2 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme12-4 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme4bottom NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme9eht5372 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme8ncgc-00189310 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme12-3 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme8ncgc-00010037 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme7wo2012/098070bottom NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme21right NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme16dmat NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme1wo2011135259 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid24900699c68 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD wo2013026806c72 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD pmid23642479c17 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD harmine NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target inhibitor 0.77 TTD , DGIDB pmid28766366-compound-scheme25-3 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme27leucettinel41 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme12-1 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme27leucettinel41derivatives NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB n-(5-{[(2s)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1h-indazol-3-yl)benzamide small molecule NA experimental dual specificity tyrosine-phosphorylation-regulated kinase 1a DYRK1A NA unknown NA drugbank pmid28766366-compound-scheme24-11h-pyrido[4,3-a]carbazole NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme4upper NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme12-2 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme15-1 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme25-4 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme23mppderivatives NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme24paprotrain NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme8ncgc-00185981 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme6pyrrolo[2,3-d]pyrimidines NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB kh-cb19 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target inhibitor NA TTD , DGIDB pmid28766366-compound-scheme14bindy NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme15-3 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity tyrosine-phosphorylation-regulated kinase 1a DYRK1A NA inhibitor NA drugbank pmid28766366-compound-scheme9eht3356 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB benzimidazole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cytomegalovirus Infections[MeSHID:D003586] patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown 2.89 TTD , DGIDB harmine NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown 0.77 TTD , DGIDB pmid28766366-compound-scheme9eht1610 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme21left NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme2wo2012/098065bottom NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB tg003 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme27leucettamineb NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB ml315 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target inhibitor NA TTD , DGIDB pmid28766366-compound-scheme15-2 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme9eht9851 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme2wo2012/098065upper NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme13indy NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB leucettine l41 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD pmid28766366-compound-scheme9eht6840 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1a DYRK1A Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity tyrosine-phosphorylation-regulated kinase 1b DYRK1B NA inhibitor NA drugbank pmid28766366-compound-scheme4bottom NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme9eht3356 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme9eht6840 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme9eht5372 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB wo2013026806c72 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD pmid24900699c68 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD pmid28766366-compound-scheme9eht9851 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme7wo2012/098070upper NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme7wo2012/098070bottom NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme21right NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme9eht1610 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme5 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme25-4 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme4upper NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme2wo2012/098065bottom NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid23642479c17 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD pmid28766366-compound-scheme25-2 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme2wo2012/098065upper NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme21left NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme14bindy NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme25-3 NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 1b DYRK1B Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme14bindy NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 2 DYRK2 Patented-recorded target unknown NA TTD , DGIDB pmid28766366-compound-scheme21left NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 2 DYRK2 Patented-recorded target unknown NA TTD , DGIDB harmine NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 2 DYRK2 Patented-recorded target unknown 6.37 TTD , DGIDB pmid28766366-compound-scheme21right NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 2 DYRK2 Patented-recorded target unknown NA TTD , DGIDB leucettine l41 NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 2 DYRK2 Patented-recorded target inhibitor NA TTD , DGIDB pmid28766366-compound-scheme16dmat NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 2 DYRK2 Patented-recorded target unknown NA TTD , DGIDB harmine NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 3 DYRK3 Patented-recorded target unknown 0.39 TTD , DGIDB pmid28766366-compound-scheme21left NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 3 DYRK3 Patented-recorded target unknown NA TTD , DGIDB pmid24900749c1a NA NA investigative dual-specificity tyrosine-phosphorylation regulated kinase 3 DYRK3 Patented-recorded target unknown NA TTD pmid28766366-compound-scheme21right NA NA patented dual-specificity tyrosine-phosphorylation regulated kinase 3 DYRK3 Patented-recorded target unknown NA TTD , DGIDB arq-171 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 e2f transcription factor 1 E2F1 Clinical trial target unknown NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical probable glutamate--trna ligase, mitochondrial EARS2 NA unknown NA drugbank sr-31747 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 cholestenol delta-isomerase EBP Clinical trial target unknown NA TTD , DGIDB tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase EBP NA inhibitor NA drugbank pmid19899765c22 NA NA investigative endothelin-converting enzyme 1 ECE1 Literature-reported target unknown NA TTD po3 2-leu-nal-o-3k NA NA investigative endothelin-converting enzyme 1 ECE1 Literature-reported target unknown NA TTD po3 2-ile-trp-o-3k NA NA investigative endothelin-converting enzyme 1 ECE1 Literature-reported target unknown NA TTD po3 2-nle-trp-o-3k NA NA investigative endothelin-converting enzyme 1 ECE1 Literature-reported target unknown NA TTD po3 2-leu-trp-o-3k NA NA investigative endothelin-converting enzyme 1 ECE1 Literature-reported target unknown NA TTD pd159790 NA NA investigative endothelin-converting enzyme 1 ECE1 Literature-reported target inhibitor NA TTD , DGIDB cgs 35066 NA NA investigative endothelin-converting enzyme 1 ECE1 Literature-reported target unknown NA TTD 5-(2-hydroxyethyl)nonane-1,9-diol small molecule NA experimental,investigative endothelin-converting enzyme 1 ECE1 Literature-reported target unknown NA TTD , drugbank ly-292223 NA NA investigative endothelin-converting enzyme 1 ECE1 Literature-reported target unknown NA TTD 4-(n,n-dimethylamino)cinnamoyl-coa small molecule NA experimental enoyl-coa hydratase, mitochondrial ECHS1 NA unknown NA drugbank octanoyl-coenzyme a small molecule NA experimental enoyl-coa hydratase, mitochondrial ECHS1 NA unknown NA drugbank acetoacetyl-coa small molecule NA experimental enoyl-coa hydratase, mitochondrial ECHS1 NA unknown NA drugbank omega-3-carboxylic acids small molecule Hippocampus Proper[MeSHID:D006624],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Alcohol consumption[MeSHID:D000428],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Neoplasm Metastasis[MeSHID:D009362],Plasma[MeSHID:D010949],Obesity[MeSHID:D009765],Metabolic Syndrome X[MeSHID:D024821] approved,investigational enoyl-coa hydratase, mitochondrial ECHS1 NA potentiator NA drugbank hexanoyl-coa small molecule NA experimental enoyl-coa hydratase, mitochondrial ECHS1 NA unknown NA drugbank octanoyl-coenzyme a small molecule NA experimental enoyl-coa delta isomerase 1, mitochondrial ECI1 NA unknown NA drugbank benzamidine small molecule NA experimental enoyl-coa delta isomerase 1, mitochondrial ECI1 NA unknown NA drugbank myristic acid small molecule NA experimental enoyl-coa delta isomerase 2, mitochondrial ECI2 NA unknown NA drugbank tbc-3711 small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Pulmonary Hypertension[MeSHID:D006976],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 EDN1 NA unknown NA drugbank atrasentan small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 receptor EDNRA NA unknown 7.07 drugbank , DGIDB w-f-f-n--y-y-w NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD fr139317 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008] phase 2 endothelin a receptor EDNRA Successful target antagonist NA TTD , DGIDB bosentan small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational endothelin-1 receptor EDNRA NA antagonist 8.84 drugbank , DGIDB pd164333 NA NA investigative endothelin a receptor EDNRA Successful target antagonist NA TTD , DGIDB ambrisentan NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Hospitalization[MeSHID:D006760],Connective Tissue Diseases[MeSHID:D003240],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved endothelin a receptor EDNRA Successful target unknown 10.61 TTD , DGIDB asterric acid NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD tbc 11251 (tbc) NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market endothelin a receptor EDNRA Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD macitentan small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved endothelin-1 receptor EDNRA NA antagonist 12.38 drugbank , DGIDB hjp-272 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] investigative endothelin a receptor EDNRA Successful target unknown NA TTD sparsentan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Focal glomerulosclerosis[MeSHID:D005923],Myocardial Infarction[MeSHID:D009203] phase 3 endothelin a receptor EDNRA Successful target unknown 5.3 TTD , DGIDB sitaxsentan NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market endothelin a receptor EDNRA Successful target antagonist 31.83 TTD , DGIDB edonentan hydrate NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 endothelin a receptor EDNRA Successful target unknown NA TTD darusentan NA Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 endothelin a receptor EDNRA Successful target antagonist 10.61 TTD , DGIDB ac-bhg-f-n-y-y-w NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD pd-163140 NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD pd-145065 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 endothelin a receptor EDNRA Successful target unknown NA TTD , DGIDB sitaxsentan NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market endothelin a receptor EDNRA Successful target unknown 31.83 TTD , DGIDB macitentan NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved endothelin a receptor EDNRA Successful target antagonist 12.38 TTD , DGIDB sparsentan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Focal glomerulosclerosis[MeSHID:D005923],Myocardial Infarction[MeSHID:D009203] phase 3 endothelin a receptor EDNRA Successful target antagonist 5.3 TTD , DGIDB clazosentan small molecule Cerebrovascular accident[MeSHID:D020521],Vascular constriction (function)[MeSHID:D014661],Cerebral Vasospasm[MeSHID:D020301],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 receptor EDNRA NA antagonist 14.14 drugbank , DGIDB 2-hydroxy-3,5-diiodobenzoic acid NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD 97-139 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebrovascular Disorders[MeSHID:D002561] discontinued in phase 2 endothelin a receptor EDNRA Successful target unknown NA TTD clazosentan small molecule Cerebrovascular accident[MeSHID:D020521],Vascular constriction (function)[MeSHID:D014661],Cerebral Vasospasm[MeSHID:D020301],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 receptor EDNRA NA unknown 14.14 drugbank , DGIDB trp-ile-ile-asp-leu-hisc(cys-val-tyr-phe-cys) NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD zibotentan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 3 endothelin a receptor EDNRA Successful target unknown 14.14 TTD , DGIDB macitentan NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved endothelin a receptor EDNRA Successful target unknown 12.38 TTD , DGIDB avosentan NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 endothelin a receptor EDNRA Successful target unknown 10.61 TTD , DGIDB ac-w-f-f-n-y-y-w NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD atrasentan NA Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 endothelin a receptor EDNRA Successful target antagonist 7.07 TTD , DGIDB a-216546 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 endothelin a receptor EDNRA Successful target unknown NA TTD et-1 NA NA phase 0 endothelin a receptor EDNRA Successful target unknown NA TTD , DGIDB sparsentan small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Focal glomerulosclerosis[MeSHID:D005923],Myocardial Infarction[MeSHID:D009203] investigational endothelin-1 receptor EDNRA NA unknown 5.3 drugbank , DGIDB sb-234551 NA Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] discontinued in phase 1 endothelin a receptor EDNRA Successful target unknown NA TTD ambrisentan NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Hospitalization[MeSHID:D006760],Connective Tissue Diseases[MeSHID:D003240],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved endothelin a receptor EDNRA Successful target antagonist 10.61 TTD , DGIDB zibotentan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 3 endothelin a receptor EDNRA Successful target antagonist 14.14 TTD , DGIDB [125i]pd151242 NA NA investigative endothelin a receptor EDNRA Successful target antagonist NA TTD , DGIDB sitaxentan small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Connective Tissue Diseases[MeSHID:D003240],Pulmonary Hypertension[MeSHID:D006976] approved,investigational,withdrawn endothelin-1 receptor EDNRA NA antagonist NA drugbank tezosentan small molecule Liver diseases[MeSHID:D008107],Congestive heart failure[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 receptor EDNRA NA antagonist 3.54 drugbank , DGIDB pmz-2123 NA Diabetic Ketoacidosis[MeSHID:D016883],Cerebral Edema[MeSHID:D001929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 endothelin a receptor EDNRA Successful target unknown NA TTD , DGIDB ambrisentan small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Hospitalization[MeSHID:D006760],Connective Tissue Diseases[MeSHID:D003240],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational endothelin-1 receptor EDNRA NA antagonist 10.61 drugbank , DGIDB trp-ile-ile-asp-leu-hisc(cys-ser-val-tyr-phe-cys) NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD actelion-1 small molecule Hypertensive disease[MeSHID:D006973],Pulmonary Hypertension[MeSHID:D006976],Cardiovascular Diseases[MeSHID:D002318] investigational endothelin-1 receptor EDNRA NA unknown NA drugbank clazosentan NA Cerebrovascular accident[MeSHID:D020521],Vascular constriction (function)[MeSHID:D014661],Cerebral Vasospasm[MeSHID:D020301],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 endothelin a receptor EDNRA Successful target antagonist 14.14 TTD , DGIDB clazosentan NA Cerebrovascular accident[MeSHID:D020521],Vascular constriction (function)[MeSHID:D014661],Cerebral Vasospasm[MeSHID:D020301],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 endothelin a receptor EDNRA Successful target unknown 14.14 TTD , DGIDB darusentan small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 receptor EDNRA NA unknown 10.61 drugbank , DGIDB bosentan NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved endothelin a receptor EDNRA Successful target unknown 8.84 TTD , DGIDB avosentan NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 endothelin a receptor EDNRA Successful target antagonist 10.61 TTD , DGIDB ym-598 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 endothelin a receptor EDNRA Successful target unknown 14.14 TTD , DGIDB atrasentan small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 receptor EDNRA NA antagonist 7.07 drugbank , DGIDB lu302872 NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD darusentan NA Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 endothelin a receptor EDNRA Successful target unknown 10.61 TTD , DGIDB sarafotoxin s6b NA NA investigative endothelin a receptor EDNRA Successful target agonist NA TTD , DGIDB endothelin-2 NA NA investigative endothelin a receptor EDNRA Successful target agonist NA TTD , DGIDB zd-1611 NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 endothelin a receptor EDNRA Successful target unknown NA TTD pf-1228305 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] phase 3 endothelin a receptor EDNRA Successful target unknown NA TTD , DGIDB bosentan NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved endothelin a receptor EDNRA Successful target antagonist 8.84 TTD , DGIDB j-104132 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 endothelin a receptor EDNRA Successful target unknown NA TTD [3h]bq123 NA NA investigative endothelin a receptor EDNRA Successful target antagonist NA TTD , DGIDB bms-193884 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 endothelin a receptor EDNRA Successful target unknown NA TTD [3h]s0139 NA NA investigative endothelin a receptor EDNRA Successful target antagonist NA TTD , DGIDB darusentan small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 receptor EDNRA NA antagonist 10.61 drugbank , DGIDB spp 301 small molecule Cardiovascular Diseases[MeSHID:D002318] investigational endothelin-1 receptor EDNRA NA unknown NA drugbank 2-hydroxy-3,5-diiodobenzoic acid small molecule NA experimental endothelin-1 receptor EDNRA NA unknown NA drugbank enrasentan small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Benign Prostatic Hyperplasia[MeSHID:D011470],Congestive heart failure[MeSHID:D006333],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin-1 receptor EDNRA NA antagonist 3.54 drugbank , DGIDB bms-187308 NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD bq-123 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 endothelin a receptor EDNRA Successful target unknown 7.07 TTD , DGIDB bhg-f-n-y-y-w NA NA investigative endothelin a receptor EDNRA Successful target unknown NA TTD atrasentan NA Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 endothelin a receptor EDNRA Successful target unknown 7.07 TTD , DGIDB fr139317 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008] phase 2 endothelin a receptor EDNRA Successful target unknown NA TTD , DGIDB tbc-3711 NA Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Pulmonary Hypertension[MeSHID:D006976],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 endothelin a receptor EDNRA Successful target unknown NA TTD , DGIDB enrasentan NA Chronic Obstructive Airway Disease[MeSHID:D029424],Benign Prostatic Hyperplasia[MeSHID:D011470],Congestive heart failure[MeSHID:D006333],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 endothelin a receptor EDNRA Successful target antagonist 3.54 TTD , DGIDB sb-209670 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] discontinued in phase 2 endothelin a receptor EDNRA Successful target unknown NA TTD lu302146 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] approved endothelin a receptor EDNRA Successful target unknown NA TTD , DGIDB acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved endothelin-1 receptor EDNRA NA inhibitor NA drugbank sparsentan small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Focal glomerulosclerosis[MeSHID:D005923],Myocardial Infarction[MeSHID:D009203] investigational endothelin-1 receptor EDNRA NA antagonist 5.3 drugbank , DGIDB bosentan small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational endothelin b receptor EDNRB Successful target antagonist 17.5 TTD , drugbank , DGIDB ro 46-8443 NA NA investigative endothelin b receptor EDNRB Successful target antagonist NA TTD , DGIDB et-1 NA NA phase 0 endothelin b receptor EDNRB Successful target unknown NA TTD , DGIDB macitentan small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved endothelin b receptor EDNRB Successful target antagonist 22.28 TTD , drugbank , DGIDB sarafotoxin 6c NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD j-104132 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 endothelin b receptor EDNRB Successful target unknown NA TTD res-701-1-c-terminal analogue NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD [125i]irl1620 NA NA investigative endothelin b receptor EDNRB Successful target agonist NA TTD , DGIDB endothelin-3 NA NA investigative endothelin b receptor EDNRB Successful target agonist NA TTD , DGIDB spi-1620 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 endothelin b receptor EDNRB Successful target unknown 6.37 TTD , DGIDB irl-1841 NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD bq 3020 NA NA investigative endothelin b receptor EDNRB Successful target agonist NA TTD , DGIDB w-f-f-n--y-y-w NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD enrasentan small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Benign Prostatic Hyperplasia[MeSHID:D011470],Congestive heart failure[MeSHID:D006333],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 endothelin b receptor EDNRB Successful target antagonist 6.37 TTD , drugbank , DGIDB sb-209670 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] discontinued in phase 2 endothelin b receptor EDNRB Successful target unknown NA TTD a192621 NA NA investigative endothelin b receptor EDNRB Successful target antagonist NA TTD , DGIDB sitaxentan small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Connective Tissue Diseases[MeSHID:D003240],Pulmonary Hypertension[MeSHID:D006976] approved,investigational,withdrawn endothelin b receptor EDNRB NA antagonist NA drugbank trp-ile-ile-asp-leu-hisc(cys-val-tyr-phe-cys) NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD tezosentan small molecule Liver diseases[MeSHID:D008107],Congestive heart failure[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational endothelin b receptor EDNRB NA antagonist 6.37 drugbank , DGIDB bhg-f-n-y-y-w NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD ambrisentan small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Hospitalization[MeSHID:D006760],Connective Tissue Diseases[MeSHID:D003240],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational endothelin b receptor EDNRB NA antagonist 12.73 drugbank , DGIDB ac-bhg-f-n-y-y-w NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD linear peptide of res-701-1 NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD trp-ile-ile-asp-leu-hisc(cys-ser-val-tyr-phe-cys) NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD lu302872 NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD irl-1620 small molecule Neoplasms[MeSHID:D009369] investigational endothelin b receptor EDNRB NA unknown NA drugbank irl-1722 NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD bq788 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Acute kidney injury[MeSHID:D058186],Myasthenia Gravis[MeSHID:D009157],Neuromyelitis Optica[MeSHID:D009471] phase 3 endothelin b receptor EDNRB Successful target unknown NA TTD , DGIDB pd-145065 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 endothelin b receptor EDNRB Successful target unknown NA TTD , DGIDB ac-w-f-f-n-y-y-w NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD endg-4010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative endothelin b receptor EDNRB Successful target unknown NA TTD pd-163140 NA NA investigative endothelin b receptor EDNRB Successful target unknown NA TTD bq788 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Acute kidney injury[MeSHID:D058186],Myasthenia Gravis[MeSHID:D009157],Neuromyelitis Optica[MeSHID:D009471] phase 3 endothelin b receptor EDNRB Successful target antagonist NA TTD , DGIDB inositol 1,3-bisphosphate small molecule NA experimental early endosome antigen 1 EEA1 NA unknown NA drugbank mak683 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1/2 embryonic ectoderm development protein EED Clinical trial target allosteric modulator NA TTD , DGIDB a-395 NA NA investigative embryonic ectoderm development protein EED Clinical trial target inhibitor NA TTD , DGIDB mak683 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 1/2 embryonic ectoderm development protein EED Clinical trial target unknown NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational elongation factor 1-alpha 1 EEF1A1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational elongation factor 1-alpha 1 EEF1A1 NA binder NA drugbank guanosine-5'-diphosphate small molecule NA experimental elongation factor 1-alpha 1 EEF1A1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational elongation factor 1-alpha 1 EEF1A1 NA ligand NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational elongation factor 1-alpha 1 EEF1A1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental elongation factor 1-alpha 1 EEF1A1 NA binder NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational elongation factor 1-alpha 1 EEF1A1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational translation elongation factor 1 alpha 1-like 14 EEF1A1L14 NA unknown NA drugbank adenosine-5-diphosphoribose small molecule NA experimental elongation factor 2 EEF2 NA unknown NA drugbank n~2~,n~2~-dimethyl-n~1~-(6-oxo-5,6-dihydrophenanthridin-2-yl)glycinamide small molecule NA experimental elongation factor 2 EEF2 NA unknown NA drugbank diphthamide small molecule NA experimental elongation factor 2 EEF2 NA unknown NA drugbank esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational elongation factor 2 EEF2 NA inhibitor NA drugbank moxetumomab pasudotox biotech Lymphocyte[MeSHID:D008214],Malignant Neoplasms[MeSHID:D009369],Renal Insufficiency[MeSHID:D051437],Splenomegaly[MeSHID:D013163],Relapse[MeSHID:D012008],Hypertrichosis[MeSHID:D006983],Hirsutism[MeSHID:D006628],leukemia[MeSHID:D007938],Hair[MeSHID:D006197],Hepatomegaly[MeSHID:D006529],Hairy Cell Leukemia[MeSHID:D007943],B-Lymphocytes[MeSHID:D001402],Cell Surface Extensions[MeSHID:D022081],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved,investigational elongation factor 2 EEF2 NA inactivator NA drugbank guanosine-5'-diphosphate small molecule NA experimental elongation factor 2 EEF2 NA unknown NA drugbank lapatinib NA Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Epidermis[MeSHID:D004817],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved eukaryotic elongation factor 2 kinase EEF2K Successful target unknown 2.36 TTD , DGIDB deoxycholic acid small molecule NA approved elongation factor tu gtp-binding domain-containing protein 1 EFTUD1 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental elongation factor tu gtp-binding domain-containing protein 1 EFTUD1 NA unknown NA drugbank s-(methylmercury)-l-cysteine small molecule NA experimental elongation factor tu gtp-binding domain-containing protein 1 EFTUD1 NA unknown NA drugbank cholecystokinin small molecule Exocrine pancreatic insufficiency[MeSHID:D010188],Diagnosis[MeSHID:D003933],Gall Bladder Diseases[MeSHID:D005705] approved,investigational pro-epidermal growth factor EGF NA unknown NA drugbank sucralfate small molecule Maintenance[MeSHID:D008283],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved pro-epidermal growth factor EGF NA inducer NA drugbank hebervis NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Oral Mucositis[MeSHID:D013280] investigative epidermal growth factor EGF Successful target unknown NA TTD tesevatinib small molecule NA investigational pro-epidermal growth factor EGF NA unknown NA drugbank alpha-aminobutyric acid small molecule NA experimental pro-epidermal growth factor EGF NA unknown NA drugbank epidermal growth factor NA Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor EGF Successful target unknown NA TTD , DGIDB rg7414 NA Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 epidermal growth factor-like protein 7 EGFL7 Clinical trial target unknown NA TTD megf0444a NA Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 epidermal growth factor-like protein 7 EGFL7 Clinical trial target unknown 190.95 TTD , DGIDB megf0444a NA Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 epidermal growth factor-like protein 7 EGFL7 Clinical trial target antibody 190.95 TTD , DGIDB anti-egfl7 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 epidermal growth factor-like protein 7 EGFL7 Clinical trial target unknown NA TTD , DGIDB ac0010 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 egfr messenger rna EGFR Clinical trial target unknown NA TTD neratinib maleate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB sym015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure9example2down NA NA patented egfr t790m mutant EGFR Patented-recorded target unknown NA TTD mg-111 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD pf 5208766 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD lapatinib small molecule Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Epidermis[MeSHID:D004817],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist 0.62 TTD , drugbank , DGIDB sym-004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 3 epidermal growth factor receptor EGFR Successful target unknown 0.36 TTD , DGIDB bms-599626 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.89 TTD , DGIDB vatalanib NA Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.03 TTD , DGIDB erlotinib small molecule Pancreatic carcinoma[MeSHID:C562463],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreas[MeSHID:D010179],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Missense Mutation[MeSHID:D020125],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist 1.28 TTD , drugbank , DGIDB n-(4-(phenylamino)quinazolin-6-yl)acrylamide NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD anti-egfr v iii car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Tidal Volume[MeSHID:D013990],Glioma[MeSHID:D005910],Malignant neoplasm of lung[MeSHID:D008175],Cells[MeSHID:D002477] phase 1/2 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD zalutumumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] investigational,phase 3 epidermal growth factor receptor EGFR Successful target antagonist,antibody 1.79 TTD , drugbank , DGIDB anti-egfr humanized mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD egfrviii car NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1/2 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD (s)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD n4-(3-chlorophenyl)quinazoline-4,6-diamine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD de-766 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Nasopharyngeal carcinoma[MeSHID:C538339],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 3 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB 10-hydroxy-18-methoxybetaenone NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD afm-21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD co-1686 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] phase 3 epidermal growth factor receptor EGFR Successful target unknown 2.86 TTD , DGIDB cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor receptor EGFR Successful target binder,antibody 0.91 TTD , drugbank , DGIDB (3-bromo-phenyl)-quinazolin-4-yl-amine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 5-acrylamido-n-(3-bromophenyl)-2-hydroxybenzamide NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 4-(3-bromo-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD nitroglycerin NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Relaxation[MeSHID:D012063],Angina Pectoris[MeSHID:D000787],Coronary Artery Vasospasm[MeSHID:D003329],Heart failure[MeSHID:D006333],Cardiovascular Diseases[MeSHID:D002318],Muscle Spasticity[MeSHID:D009128],Hemorrhage[MeSHID:D006470],Uterus[MeSHID:D014599],Off-Label Use[MeSHID:D056687],Myocardial Infarction[MeSHID:D009203],Chest Pain[MeSHID:D002637],Pain[MeSHID:D010146],Emergencies [Disease/Finding][MeSHID:D004630],Anal Fissure[MeSHID:D005401],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved epidermal growth factor receptor EGFR Successful target unknown 0.04 TTD , DGIDB 5,6-bis-p-tolylamino-isoindole-1,3-dione NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD egfr antisense dna NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 1/2 egfr messenger rna EGFR Clinical trial target unknown NA TTD panitumumab biotech Colorectal Carcinoma[MeSHID:D015179],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] approved,investigational epidermal growth factor receptor EGFR Successful target suppressor,inhibitor 0.8 TTD , drugbank , DGIDB n*4*-(3-bromo-phenyl)-quinazoline-4,7-diamine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD erlotinib small molecule Pancreatic carcinoma[MeSHID:C562463],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreas[MeSHID:D010179],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Missense Mutation[MeSHID:D020125],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist,inhibitor 1.28 TTD , drugbank , DGIDB gefitinib small molecule Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258],Urethral Carcinoma[MeSHID:D014523] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist 0.73 TTD , drugbank , DGIDB 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD varlitinib small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Biliary Tract Neoplasm[MeSHID:D001661] investigational,phase 2/3 epidermal growth factor receptor EGFR Successful target inhibitor 0.54 TTD , drugbank , DGIDB d2c7 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD mt-062 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD pp121 NA NA investigative epidermal growth factor receptor EGFR Successful target inhibitor NA TTD , DGIDB co-1686 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] phase 3 epidermal growth factor receptor EGFR Successful target inhibitor 2.86 TTD , DGIDB pd182905 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD almonertinib small molecule Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational receptor protein-tyrosine kinase EGFR NA inhibitor NA drugbank n-(4-m-tolylamino-quinazolin-7-yl)-acrylamide NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD theliatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target inhibitor 0.36 TTD , DGIDB hegf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational epidermal growth factor receptor EGFR NA inhibitor 0.5 drugbank , DGIDB necitumumab biotech Non-Small Cell Lung Carcinoma[MeSHID:D002289],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist 1.25 TTD , drugbank , DGIDB egfr/igfr tandem adnectin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB ign311 biotech Malignant Neoplasms[MeSHID:D009369] investigational epidermal growth factor receptor EGFR NA unknown NA drugbank zn-e4 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD hts-02876 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD icotinib small molecule Epidermis[MeSHID:D004817],Non-Small Cell Lung Carcinoma[MeSHID:D002289] experimental,investigational epidermal growth factor receptor EGFR NA antagonist 1.97 drugbank , DGIDB bevacizumab + erlotinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Squamous cell carcinoma[MeSHID:D002294] phase 3 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB anti-egfr mab NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor receptor EGFR Successful target binder,inhibitor 0.91 TTD , drugbank , DGIDB sorafenib NA Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor receptor EGFR Successful target unknown 0.03 TTD , DGIDB neratinib small molecule Malignant neoplasm of breast[MeSHID:D001943] approved,investigational epidermal growth factor receptor EGFR NA inhibitor 0.88 drugbank , DGIDB egfr806-specific car t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],pineoblastoma[MeSHID:D010871],Medulloblastoma[MeSHID:D008527],Stomach[MeSHID:D013270],T-Lymphocyte[MeSHID:D013601],Adenocarcinoma[MeSHID:D000230],Germ cell tumor[MeSHID:D009373],Glioma[MeSHID:D005910],Ependymoma[MeSHID:D004806],Teratoid Rhabdoid Tumor[MeSHID:C000597569],Choroid Plexus Carcinoma[MeSHID:C562943] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB cipatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB bibw 2992 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor receptor EGFR Successful target inhibitor NA TTD , DGIDB 6-chloro-n-(3-chlorophenyl)quinazolin-4-amine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD mobocertinib small molecule Insertion Mutation[MeSHID:D016254],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epidermal growth factor receptor EGFR NA inhibitor NA drugbank , DGIDB merimepodib NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved epidermal growth factor receptor EGFR Successful target unknown NA TTD ci-1033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.36 TTD , DGIDB mabionher2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD sym013 NA Epithelial ovarian cancer[MeSHID:C538090],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB depatuxizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Glioblastoma[MeSHID:D005909],Brain[MeSHID:D001921] phase 2 epidermal growth factor receptor EGFR Successful target unknown 1.43 TTD , DGIDB canertinib small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of lung[MeSHID:D008175] investigational epidermal growth factor receptor EGFR NA unknown 0.36 drugbank , DGIDB agt-2000 NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD imgn289 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB car-t cells targeting egfrviii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD necitumumab biotech Non-Small Cell Lung Carcinoma[MeSHID:D002289],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist,inhibitor 1.25 TTD , drugbank , DGIDB mm-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target antibody NA TTD , DGIDB cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor receptor EGFR Successful target binder 0.91 TTD , drugbank , DGIDB depatuxizumab mafodotin biotech NA investigational epidermal growth factor receptor EGFR NA antibody NA drugbank anti-egfr car t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB ast-1306 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown 0.36 TTD , DGIDB 111in-hegf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] preclinical epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB ips-01003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD (e)-5-(4-hydroxybenzylidene)-1-phenethylhydantoin NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD abt-414 NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.72 TTD , DGIDB rindopepimut small molecule Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] investigational,phase 3 epidermal growth factor receptor EGFR Successful target unknown 1.43 TTD , drugbank , DGIDB rg-50810 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD tak165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD pyrotinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 egfr messenger rna EGFR Clinical trial target inhibitor 0.36 TTD , DGIDB 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD n*4*-benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD pyrrolo[2,3-d]pyrimidine derivative 24 NA NA patented epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB bms-599626 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 epidermal growth factor receptor EGFR Successful target inhibitor 0.89 TTD , DGIDB bpiq-i NA NA investigative epidermal growth factor receptor EGFR Successful target inhibitor NA TTD , DGIDB tarloxotinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 epidermal growth factor receptor EGFR Successful target inhibitor 0.36 TTD , DGIDB hki-9924129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD hki-272 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 epidermal growth factor receptor EGFR Successful target unknown 0.88 TTD , DGIDB almonertinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 epidermal growth factor receptor EGFR Successful target unknown NA TTD sym-011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD pd-153035 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 1 epidermal growth factor receptor EGFR Successful target unknown 0.09 TTD , DGIDB lavendustin a NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD ly3164530 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown 0.18 TTD , DGIDB mcla-158 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD ski-758 NA Ischemia[MeSHID:D007511],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor receptor EGFR Successful target unknown 0.12 TTD , DGIDB osi-75 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 4-(2-nitroprop-1-enyl)benzene-1,2-diol NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD egfr cart NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB osimertinib small molecule Mutation[MeSHID:D009154],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved epidermal growth factor receptor EGFR Successful target inhibitor 2.43 TTD , drugbank , DGIDB bibw 2992 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB hts-05058 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD wz-3146 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD n*4*-(3-bromo-phenyl)-quinazoline-4,6,7-triamine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD zalutumumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] investigational,phase 3 epidermal growth factor receptor EGFR Successful target antagonist 1.79 TTD , drugbank , DGIDB pazopanib + tyverb/tykerb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Breast Carcinoma[MeSHID:D058922] phase 2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB hm-78136b NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 4-(2-nitrovinyl)benzene-1,2-diol NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD her1-vssp vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved epidermal growth factor receptor EGFR NA antagonist 0.04 drugbank , DGIDB 4-(3-bromo-phenylamino)-quinazoline-6,7-diol NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD icotinib hydrochloride NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] registered epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB anti-her3/egfr daf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epithelioma[MeSHID:D009375] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB (3-bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD bms-690514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 epidermal growth factor receptor EGFR Successful target inhibitor 0.36 TTD , DGIDB tt-100 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB n4-(3-methylphenyl)-4,6-quinazolinediamine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD varlitinib small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Biliary Tract Neoplasm[MeSHID:D001661] investigational,phase 2/3 epidermal growth factor receptor EGFR Successful target unknown 0.54 TTD , drugbank , DGIDB foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved epidermal growth factor receptor EGFR NA agonist NA drugbank benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD pf-05230907 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Hemorrhage[MeSHID:D002543] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB gi-3000 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD emd 55900 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB anti-egfrviii car transduced pbl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Glioma[MeSHID:D005910],Malignant neoplasm of brain[MeSHID:D001932],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1/2 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epidermal growth factor receptor EGFR NA inhibitor NA drugbank la22-radioimmunoconjugates NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD cetugex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB pelitinib small molecule Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] investigational,phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.95 TTD , drugbank , DGIDB bibx-1382 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 epidermal growth factor receptor EGFR Successful target unknown 0.27 TTD , DGIDB necitumumab biotech Non-Small Cell Lung Carcinoma[MeSHID:D002289],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist,antibody 1.25 TTD , drugbank , DGIDB car-t cells targeting egfrviii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Glioblastoma[MeSHID:D005909] phase 1 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD 4557w NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD cudc-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target inhibitor 0.18 TTD , DGIDB pmid24915291c38 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD edp-13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD fht-2107 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD n*4*-(3-bromo-phenyl)-quinazoline-4,6-diamine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD egfrviii-cars NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD pmid8568816c56 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD av-412 small molecule Neoplasms[MeSHID:D009369] investigational epidermal growth factor receptor EGFR NA unknown 0.48 drugbank , DGIDB amg 596 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD vandetanib small molecule Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved epidermal growth factor receptor EGFR Successful target inhibitor 0.17 TTD , drugbank , DGIDB s-222611 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1b epidermal growth factor receptor EGFR Successful target inhibitor 0.89 TTD , DGIDB ck-101 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 egfr messenger rna EGFR Clinical trial target unknown NA TTD gefitinib small molecule Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258],Urethral Carcinoma[MeSHID:D014523] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist,inhibitor 0.73 TTD , drugbank , DGIDB amg 595 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB afatinib small molecule Neoplasms[MeSHID:D009369],Mutation[MeSHID:D009154],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved epidermal growth factor receptor EGFR NA inhibitor 4.65 drugbank , DGIDB pd-0166326 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD cochliobolic acid NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD ap32788 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB mm-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB hts-00213 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD anti-egfrviii car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909],Cells[MeSHID:D002477] phase 1 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD indium-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2/3 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB matuzumab biotech Malignant neoplasm of stomach[MeSHID:D013274],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of lung[MeSHID:D008175],cervical cancer[MeSHID:D002583],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.72 TTD , drugbank , DGIDB mdp-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational epidermal growth factor receptor EGFR NA inhibitor NA drugbank d2c7 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD al-6802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD syn004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD s-222611 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1b epidermal growth factor receptor EGFR Successful target unknown 0.89 TTD , DGIDB bms-690514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.36 TTD , DGIDB ro-4396686 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD emb-01 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD ag-538 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD cart-egfrviii t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Glioma[MeSHID:D005910],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD her-2/her-1 vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB bca101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD ag 112 NA NA investigative epidermal growth factor receptor EGFR Successful target inhibitor NA TTD , DGIDB 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 4-(3-bromo-phenoxy)-6,7-dimethoxy-quinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target inhibitor 0.08 TTD , DGIDB dacomitinib small molecule Malignant Neoplasms[MeSHID:D009369],lymph nodes[MeSHID:D008198],Disease[MeSHID:D004194],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Cause of Death[MeSHID:D002423],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Missense Mutation[MeSHID:D020125],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epidermal growth factor receptor EGFR Successful target inhibitor 2.07 TTD , drugbank , DGIDB abivertinib small molecule NA investigational epidermal growth factor receptor EGFR NA inhibitor 0.12 drugbank , DGIDB nrc-2694 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD cln-081 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD pd-168393 small molecule NA experimental,investigative epidermal growth factor receptor EGFR Successful target unknown 0.89 TTD , drugbank , DGIDB abx-egf NA NA phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.8 TTD , DGIDB rm-6427 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cryptosporidiosis[MeSHID:D003457] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 4-(5-bromoindole-3-yl)-6,7-dimethoxyquinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD canertinib small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of lung[MeSHID:D008175] investigational epidermal growth factor receptor EGFR NA inhibitor 0.36 drugbank , DGIDB egf816 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB benzyl-quinazolin-4-yl-amine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD cart-egfr NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB mehd-7945a NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.36 TTD , DGIDB epitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown 0.72 TTD , DGIDB hds-029 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD panitumumab biotech Colorectal Carcinoma[MeSHID:D015179],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] approved,investigational epidermal growth factor receptor EGFR Successful target suppressor 0.8 TTD , drugbank , DGIDB 6,7-dimethoxy-n-m-tolylquinazolin-4-amine NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 2-(5,6-dihydroxy-indan-1-ylidene)-malononitrile NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD mr1-1 NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB olmutinib small molecule Mutation[MeSHID:D009154],Non-Small Cell Lung Carcinoma[MeSHID:D002289] investigational epidermal growth factor receptor EGFR NA inhibitor 1.43 drugbank , DGIDB ag 9 NA NA investigative epidermal growth factor receptor EGFR Successful target inhibitor NA TTD , DGIDB pki166 NA Esophageal Neoplasms[MeSHID:D004938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 epidermal growth factor receptor EGFR Successful target inhibitor NA TTD , DGIDB matuzumab biotech Malignant neoplasm of stomach[MeSHID:D013274],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of lung[MeSHID:D008175],cervical cancer[MeSHID:D002583],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 epidermal growth factor receptor EGFR Successful target inhibitor 0.72 TTD , drugbank , DGIDB 4-(2-nitrovinyl)phenol NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD ag-213 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD cudc-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown 0.18 TTD , DGIDB epidermal growth factor NA Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB rx-1792 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 4-acrylamido-n-(3-bromophenyl)-2-hydroxybenzamide NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD asp8273 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.54 TTD , DGIDB mobocertinib NA Insertion Mutation[MeSHID:D016254],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 egfr exon20ins mutant EGFR Clinical trial target inhibitor NA TTD , DGIDB alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational epidermal growth factor receptor EGFR NA unknown NA drugbank n-(4-m-tolylamino-quinazolin-6-yl)-acrylamide NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational epidermal growth factor receptor EGFR NA inhibitor NA drugbank 6,7-diethoxy-4-styrylquinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 3-pyridin-4-yl-quinoline-6,7-diol NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD icr 62 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD hm-61713b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD icotinib small molecule Epidermis[MeSHID:D004817],Non-Small Cell Lung Carcinoma[MeSHID:D002289] experimental,investigational epidermal growth factor receptor EGFR NA antagonist,inhibitor 1.97 drugbank , DGIDB 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD pd-158780 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD azd4769 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD cl-387785 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD s-{3-[(4-anilinoquinazolin-6-yl)amino]-3-oxopropyl}-l-cysteine small molecule NA experimental epidermal growth factor receptor EGFR NA unknown NA drugbank 2-methoxy-4-(2-nitrovinyl)phenol NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD arx-ahd NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Alpers Syndrome (disorder)[MeSHID:D002549] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD panitumumab biotech Colorectal Carcinoma[MeSHID:D015179],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] approved,investigational epidermal growth factor receptor EGFR Successful target suppressor,antibody 0.8 TTD , drugbank , DGIDB sn-32793 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB dzd9008 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 egfr exon20ins mutant EGFR Clinical trial target unknown NA TTD on-128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD si-b001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epithelioma[MeSHID:D009375] phase 1 epidermal growth factor receptor EGFR Successful target unknown NA TTD 3-(3-chloro-phenyl)-5,7-dihydroxy-chromen-4-one NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD egf816 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 epidermal growth factor receptor EGFR Successful target inhibitor NA TTD , DGIDB merimepodib NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Cancer of Head and Neck[MeSHID:D006258],Malignant neoplasm of breast[MeSHID:D001943] approved epidermal growth factor receptor EGFR Successful target unknown NA TTD bmab-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD tyrphostin ag-1478 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown 0.12 TTD , DGIDB whi-p154 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD afm24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD , DGIDB epitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative epidermal growth factor receptor EGFR Successful target inhibitor 0.72 TTD , DGIDB rg7160 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 epidermal growth factor receptor EGFR Successful target unknown NA TTD amivantamab biotech Insertion Mutation[MeSHID:D016254],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,phase 3 epidermal growth factor receptor EGFR Successful target antibody,downregulator NA TTD , drugbank egfrviii car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],T-Lymphocyte[MeSHID:D013601],Glioblastoma[MeSHID:D005909] phase 1 epidermal growth factor receptor variant iii EGFR Clinical trial target unknown NA TTD tgf alpha NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD bdtx-189 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 epidermal growth factor receptor EGFR Successful target unknown NA TTD jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 epidermal growth factor receptor EGFR Successful target unknown 0.08 TTD , DGIDB lapatinib small molecule Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Epidermis[MeSHID:D004817],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational epidermal growth factor receptor EGFR Successful target antagonist,inhibitor 0.62 TTD , drugbank , DGIDB pd-0173956 NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD 2-(4,5-dihydroxy-indan-1-ylidene)-malononitrile NA NA investigative epidermal growth factor receptor EGFR Successful target unknown NA TTD pelitinib small molecule Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] investigational,phase 2 epidermal growth factor receptor EGFR Successful target inhibitor 0.95 TTD , drugbank , DGIDB rm-1929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 2 epidermal growth factor receptor EGFR Successful target unknown 0.36 TTD , DGIDB asp1929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258] phase 3 epidermal growth factor receptor EGFR Successful target unknown NA TTD egfr inhibitor NA NA investigative epidermal growth factor receptor EGFR Successful target inhibitor NA TTD , DGIDB us8536181, c35 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB roxadustat small molecule Anemia[MeSHID:D000740],Chronic disease[MeSHID:D002908] approved,investigational egl nine homolog 1 EGLN1 NA inhibitor 5.97 drugbank , DGIDB iox2 NA NA investigative hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target inhibitor NA TTD , DGIDB us10100051, compound 2 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical egl nine homolog 1 EGLN1 NA cofactor NA drugbank us8598210, table xv, 2 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us8921389, 210 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us9409892, 136 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved egl nine homolog 1 EGLN1 NA unknown NA drugbank us10149841, compound 19 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved egl nine homolog 1 EGLN1 NA unknown NA drugbank us8598210, table xv, 1 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB n-[(4-hydroxy-8-iodoisoquinolin-3-yl)carbonyl]glycine small molecule NA experimental egl nine homolog 1 EGLN1 NA unknown NA drugbank us8921389, 2 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us10149841, compound 5 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us10100051, compound 11 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us9409892, 59 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us9409892, 19 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us9422240, 1-298 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB roxadustat small molecule Anemia[MeSHID:D000740],Chronic disease[MeSHID:D002908] approved,investigational egl nine homolog 1 EGLN1 NA unknown 5.97 drugbank , DGIDB us8536181, a41 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us8598210, table xv, 4 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us8921389, 123 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us9422240, 1-286 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us8536181, c17 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved egl nine homolog 1 EGLN1 NA unknown NA drugbank us9422240, 1-297 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved egl nine homolog 1 EGLN1 NA unknown NA drugbank us8536181, c14 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved egl nine homolog 1 EGLN1 NA unknown NA drugbank krh-102053 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD us9340511, 2 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB fg-4592 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740],Kidney Diseases[MeSHID:D007674] phase 3 hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown 5.97 TTD , DGIDB us10149841, compound 9 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us8598210, table xv, 5 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us8921389, 22 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us9340511, 5 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us9340511, 7 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB fg-2216 small molecule Anemia[MeSHID:D000740],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational egl nine homolog 1 EGLN1 NA unknown NA drugbank , DGIDB us9409892, 148 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us10100051, compound 1 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us8921389, 1 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us10149841, compound 1 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB iox1 NA NA investigative hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target inhibitor NA TTD , DGIDB us10100051, compound 10 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB us9422240, 1-282 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved egl nine homolog 1 EGLN1 NA unknown NA drugbank us9340511, 6 NA NA patented hif-prolyl hydroxylase 2 EGLN1 Patented-recorded target unknown NA TTD , DGIDB bay-85-3934 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2 hif-prolyl hydroxylase 1 EGLN2 Clinical trial target unknown NA TTD , DGIDB pyridine-2,4-dicarboxylic acid NA NA investigative hif-prolyl hydroxylase 1 EGLN2 Clinical trial target unknown NA TTD gsk1278863 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659],Anemia[MeSHID:D000740],Diabetic Foot[MeSHID:D017719],Autism Spectrum Disorders[MeSHID:D000067877] phase 3 hif-prolyl hydroxylase 1 EGLN2 Clinical trial target unknown 10.61 TTD , DGIDB roxadustat small molecule Anemia[MeSHID:D000740],Chronic disease[MeSHID:D002908] approved,investigational egl nine homolog 2 EGLN2 NA inhibitor 15.91 drugbank , DGIDB fg-4592 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740],Kidney Diseases[MeSHID:D007674] phase 3 hif-prolyl hydroxylase 1 EGLN2 Clinical trial target unknown 15.91 TTD , DGIDB ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical egl nine homolog 2 EGLN2 NA cofactor NA drugbank 2-(carboxymethylamino)-2-oxoacetic acid NA NA investigative hif-prolyl hydroxylase 1 EGLN2 Clinical trial target unknown NA TTD roxadustat small molecule Anemia[MeSHID:D000740],Chronic disease[MeSHID:D002908] approved,investigational egl nine homolog 3 EGLN3 NA inhibitor 15.91 drugbank , DGIDB ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical egl nine homolog 3 EGLN3 NA cofactor NA drugbank brivoligide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain, Postoperative[MeSHID:D010149] phase 2 egr1 messenger rna EGR1 Clinical trial target unknown NA TTD ayx-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 early growth response protein 1 EGR1 Clinical trial target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical peroxisomal bifunctional enzyme EHHADH NA unknown NA drugbank pmid19854648c27 NA NA investigative eukaryotic translation initiation factor 2-alpha kinase 1 EIF2AK1 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational eukaryotic translation initiation factor 2-alpha kinase 1 EIF2AK1 NA inhibitor NA drugbank us9650366, 2 NA NA patented tyrosine-protein kinase eif2ak2 EIF2AK2 Patented-recorded target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational interferon-induced, double-stranded rna-activated protein kinase EIF2AK2 NA inhibitor NA drugbank nu6140 NA NA investigative tyrosine-protein kinase eif2ak2 EIF2AK2 Patented-recorded target unknown NA TTD indirubin derivative e804 NA NA investigative tyrosine-protein kinase eif2ak2 EIF2AK2 Patented-recorded target inhibitor NA TTD , DGIDB us9650366, 12 NA NA patented tyrosine-protein kinase eif2ak2 EIF2AK2 Patented-recorded target unknown NA TTD indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon-induced, double-stranded rna-activated protein kinase EIF2AK2 NA inducer NA drugbank us9650366, 9 NA NA patented tyrosine-protein kinase eif2ak2 EIF2AK2 Patented-recorded target unknown NA TTD indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational interferon-induced, double-stranded rna-activated protein kinase EIF2AK2 NA inducer NA drugbank asn-11124542 NA NA investigative tyrosine-protein kinase eif2ak2 EIF2AK2 Patented-recorded target unknown NA TTD phenylpyrrolidinone derivative 4 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB phenylpyrrolidinone derivative 1 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB tricyclic isoxazoloquinazoline derivative 1 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB indoline derivative 3 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB phenylpyrrolidinone derivative 5 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB indoline derivative 6 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB indoline derivative 7 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB indoline derivative 9 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB phenylpyrrolidinone derivative 3 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB tricyclic isoxazoloquinazoline derivative 4 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB indoline derivative 8 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB indoline derivative 2 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB tricyclic isoxazoloquinazoline derivative 2 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB gsk2606414 NA NA investigative prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target inhibitor 95.48 TTD , DGIDB gsk2606414 NA NA investigative prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown 95.48 TTD , DGIDB indoline derivative 11 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB indoline derivative 10 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB tricyclic isoxazoloquinazoline derivative 3 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB phenylpyrrolidinone derivative 2 NA NA patented prkr-like endoplasmic reticulum kinase EIF2AK3 Patented-recorded target unknown NA TTD , DGIDB wo2013110309ca127 NA NA investigative eukaryotic translation initiation factor 2-alpha kinase 4 EIF2AK4 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational eif-2-alpha kinase gcn2 EIF2AK4 NA inhibitor NA drugbank guanosine-5'-diphosphate small molecule NA experimental eukaryotic translation initiation factor 2 subunit 3 EIF2S3 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational eukaryotic translation initiation factor 3 subunit f EIF3F NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational eukaryotic initiation factor 4a-i EIF4A1 NA unknown NA drugbank 7n-methyl-8-hydroguanosine-5'-diphosphate NA NA investigative eif4e messenger rna EIF4E Literature-reported target unknown NA TTD s-[(1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1h-pyrrol-3-yl)methyl] methanesulfonothioate small molecule NA experimental eukaryotic translation initiation factor 4e EIF4E NA unknown NA drugbank 7-methyl-gpppa NA NA investigative eif4e messenger rna EIF4E Literature-reported target unknown NA TTD 7-methyl-guanosine-5'-triphosphate NA NA investigative eif4e messenger rna EIF4E Literature-reported target unknown NA TTD 7-methyl-7,8-dihydroguanosine-5'-diphosphate small molecule NA experimental eukaryotic translation initiation factor 4e EIF4E NA unknown NA drugbank 7-methyl-gpppa small molecule NA experimental eukaryotic translation initiation factor 4e EIF4E NA unknown NA drugbank 7-methyl-guanosine-5'-triphosphate small molecule NA experimental eukaryotic translation initiation factor 4e EIF4E NA unknown NA drugbank ly2275796 small molecule Neoplasms[MeSHID:D009369] investigational eukaryotic translation initiation factor 4e EIF4E NA unknown NA drugbank , DGIDB isis 347577 NA NA investigative eif4e-bp2 messenger rna EIF4EBP2 Clinical trial target unknown NA TTD isis 347573 NA NA investigative eif4e-bp2 messenger rna EIF4EBP2 Clinical trial target unknown NA TTD isis 232828 NA NA investigative eif4e-bp2 messenger rna EIF4EBP2 Clinical trial target unknown NA TTD isis-eif4e NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 eif4e-bp2 messenger rna EIF4EBP2 Clinical trial target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational eukaryotic translation initiation factor 6 EIF6 NA unknown NA drugbank win-63395 NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD peptide analog 69 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 6-heptyl-4-hydroxy-3-octanoyl-pyran-2-one NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD (4-nitro-1h-pyrazol-1-yl)(o-tolyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 3,3-diethyl-1-o-tolylazetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD ce-1037 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 neutrophil elastase ELANE Clinical trial target unknown NA TTD epigallocatechin gallate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] phase 3 neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 2-pyrazinone derivative 4 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 4-pyridone derivative 1 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 2-pyrazinone derivative 3 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB peptide analog 58 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 1-benzyl-3,3-dimethylazetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD tei-8362 NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 2-pyrazinone derivative 7 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB (4-bromo-1h-pyrazol-1-yl)(o-tolyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 4-pyridone derivative 2 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB ed1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Myocardial Reperfusion Injury[MeSHID:D015428],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Christ-Siemens-Touraine syndrome[MeSHID:D053358] investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD azd9668 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchiectasis[MeSHID:D001987] phase 2 neutrophil elastase ELANE Clinical trial target unknown NA TTD peptide analog 64 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB peptide analog 67 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB filgrastim biotech Malignant Neoplasms[MeSHID:D009369],Radiation[MeSHID:D011827],Severe congenital neutropenia[MeSHID:C537592],Communicable Diseases[MeSHID:D003141],Febrile Neutropenia[MeSHID:D064147],Cyclic neutropenia[MeSHID:C536227],Leukopenia[MeSHID:D007970],Infection[MeSHID:D007239],Neutropenia[MeSHID:D009503],Leukemia, Myelocytic, Acute[MeSHID:D015470],Blood[MeSHID:D001769],Ulcer[MeSHID:D014456],Leukocytes[MeSHID:D007962],Fever[MeSHID:D005334],Hematopoietic stem cells[MeSHID:D006412],Electromagnetic Radiation[MeSHID:D060733],neutrophil[MeSHID:D009504] approved neutrophil elastase ELANE NA unknown NA drugbank peptide analog 60 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB n,n-bis(cyanomethyl)-3,4-dimethoxybenzamide NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD elafin small molecule Disease[MeSHID:D004194] investigational neutrophil elastase ELANE NA unknown NA drugbank , DGIDB (4-nitro-1h-pyrazol-1-yl)(phenyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD tetra-hydro-pyrrolopyrimidinedione derivative 1 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB ac-ala-pro-val-(2-benzoxazole) NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD pol-6014 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB pmid24556381c10f NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD ici 200,355 NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 2-pyrazinone derivative 6 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB (4-bromo-1h-pyrazol-1-yl)(p-tolyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD mr-889 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] discontinued in phase 3 neutrophil elastase ELANE Clinical trial target unknown NA TTD azd-6553 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 neutrophil elastase ELANE Clinical trial target unknown NA TTD bornyl (3,4,5-trihydroxy)-cinnamate NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 3-butyl-3-ethyl-1-phenylazetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD dermolastin NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] discontinued in phase 2 neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB (3-nitro-1h-pyrazol-1-yl)(p-tolyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 3,4-dichloroisocoumarin NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD cbz-val-pro-val-(2-benzoxazole) NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD zd-0892 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 neutrophil elastase ELANE Clinical trial target unknown NA TTD fucose NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD peptide analog 65 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 2-pyrazinone derivative 5 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB pmid22595175c4g NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 3,3-diethyl-1-phenylazetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 1-benzyl-3,3-diethylazetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD fr167653 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB (3-nitro-1h-pyrazol-1-yl)(phenyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD dihydropyrimidinone derivative 1 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 2-methylbut-3-yn-2-yl 4-methoxybenzoate NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 1-(3,3-dimethyl-2-oxo-butyl)-1h-indole-2,3-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD dihydropyrimidinone derivative 2 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB peptide analog 62 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB peptide analog 61 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB peptide analog 63 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB peptide analog 55 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB tetra-hydro-triazolopyrimidine derivative 2 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 2-pyrazinone derivative 1 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 4-hydroxy-3-nonanoyl-6-octyl-pyran-2-one NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 3-ethyl-3-isobutyl-1-phenylazetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD ed45 NA Myocardial Reperfusion Injury[MeSHID:D015428],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Respiratory Distress Syndrome, Adult[MeSHID:D012128] investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD peptide analog 66 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB zk-814048 NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD ae-3763 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 neutrophil elastase ELANE Clinical trial target unknown NA TTD 3-benzyl-3-ethyl-1-phenylazetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD pyrimidine derivative 34 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB (4-chloro-1h-pyrazol-1-yl)(o-tolyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD dx-890 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] phase 2 neutrophil elastase ELANE Clinical trial target unknown 7.07 TTD , DGIDB dd7 NA Myocardial Reperfusion Injury[MeSHID:D015428],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Respiratory Distress Syndrome, Adult[MeSHID:D012128] investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD hypersulfated disaccharide compound 1 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB ax-9657 NA Lung diseases[MeSHID:D008171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD pyrimidinone derivative 4 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 3-decanoyl-4-hydroxy-6-nonyl-pyran-2-one NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD peptide analog 68 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB tiprelestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 2 neutrophil elastase ELANE Clinical trial target unknown 3.54 TTD , DGIDB bay 85-8501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bronchiectasis[MeSHID:D001987] phase 2 neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB peptide analog 59 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB ici 200,880 NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD freselestat small molecule Chronic Obstructive Airway Disease[MeSHID:D029424] experimental,investigational neutrophil elastase ELANE NA inhibitor NA drugbank 4-methoxy-n'-(2-phenylacetyl)benzohydrazide NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD peptide analog 56 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB mdl 101,146 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Inflammation[MeSHID:D007249],Expiration, function[MeSHID:D045853] experimental,terminated neutrophil elastase ELANE Clinical trial target unknown NA TTD , drugbank l-658,758 NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD zd-8321 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] discontinued in phase 2 neutrophil elastase ELANE Clinical trial target unknown NA TTD adc-7828 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD alpha-1-proteinase inhibitor biotech Pulmonary Emphysema[MeSHID:D011656],alpha 1-Antitrypsin Deficiency[MeSHID:D019896],Pathological accumulation of air in tissues[MeSHID:D004646],Maintenance[MeSHID:D008283] approved neutrophil elastase ELANE NA inhibitor NA drugbank , DGIDB uracil derivative 1 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB azd-9819 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB peptide analog 70 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB l-694,458 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB 1-benzoyl-n-phenyl-1h-pyrazole-3-carboxamide NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD gw-311616 NA NA discontinued in phase 1 neutrophil elastase ELANE Clinical trial target unknown NA TTD (4-bromo-1h-pyrazol-1-yl)(m-tolyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 3,3-diethyl-1-(pyridin-3-yl)azetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD (3,4-dichlorophenyl)(1h-pyrazol-1-yl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD (1h-pyrazol-1-yl)(o-tolyl)methanone NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 2-pyrazinone derivative 2 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB pmid24556381c10l NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD 3-benzyl-3-methyl-1-phenylazetidine-2,4-dione NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD e-6-o-p-methoxycinnamoyl scandoside methyl ester NA NA investigative neutrophil elastase ELANE Clinical trial target unknown NA TTD sivelestat sodium hydrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pneumonia[MeSHID:D011014],Acute Lung Injury[MeSHID:D055371] phase 4 neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB sivelestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spondylarthritis[MeSHID:D025241],Ulcerative Colitis[MeSHID:D003093],Pyoderma Gangrenosum[MeSHID:D017511],Multiple Sclerosis[MeSHID:D009103],Arthritis, Psoriatic[MeSHID:D015535],Anterior uveitis[MeSHID:D014606],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 3 neutrophil elastase ELANE Clinical trial target inhibitor 17.68 TTD , DGIDB sivelestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spondylarthritis[MeSHID:D025241],Ulcerative Colitis[MeSHID:D003093],Pyoderma Gangrenosum[MeSHID:D017511],Multiple Sclerosis[MeSHID:D009103],Arthritis, Psoriatic[MeSHID:D015535],Anterior uveitis[MeSHID:D014606],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 3 neutrophil elastase ELANE Clinical trial target unknown 17.68 TTD , DGIDB peptide analog 57 NA NA patented neutrophil elastase ELANE Clinical trial target unknown NA TTD , DGIDB fk-706 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Emphysema[MeSHID:D011656] discontinued in phase 2 neutrophil elastase ELANE Clinical trial target unknown NA TTD rofecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Rheumatoid Arthritis[MeSHID:D001172],Aura[MeSHID:D004827],Dysmenorrhea[MeSHID:D004412],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn elastin ELN NA unknown NA drugbank alpha-linolenic acid small molecule NA approved,investigational,nutraceutical elongation of very long chain fatty acids protein 2 ELOVL2 NA substrate NA drugbank omega-3-carboxylic acids small molecule Hippocampus Proper[MeSHID:D006624],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Alcohol consumption[MeSHID:D000428],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Neoplasm Metastasis[MeSHID:D009362],Plasma[MeSHID:D010949],Obesity[MeSHID:D009765],Metabolic Syndrome X[MeSHID:D024821] approved,investigational elongation of very long chain fatty acids protein 4 ELOVL4 NA potentiator NA drugbank alpha-linolenic acid small molecule NA approved,investigational,nutraceutical elongation of very long chain fatty acids protein 5 ELOVL5 NA substrate NA drugbank n,n,n-trimethyl-2-(phosphonooxy)ethanaminium small molecule NA experimental epididymal sperm-binding protein 1 ELSPBP1 NA unknown NA drugbank n-cyclohexyltaurine small molecule NA experimental homeobox protein engrailed-2 EN2 NA unknown NA drugbank trc105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Liver carcinoma[MeSHID:D006528],Fallopian Tube Carcinoma[MeSHID:D005185],Hemangiosarcoma[MeSHID:D006394],Peritoneum[MeSHID:D010537],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Sarcoma[MeSHID:D012509],Renal Cell Carcinoma[MeSHID:D002292],Recurrence (disease attribute)[MeSHID:D012008],Age related macular degeneration[MeSHID:D008268],Malignant neoplasm of breast[MeSHID:D001943],Glioblastoma[MeSHID:D005909] phase 3 endoglin cd105 ENG Clinical trial target unknown NA TTD , DGIDB carotuximab biotech Neoplasms[MeSHID:D009369] investigational endoglin ENG NA antibody 127.3 drugbank , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental alpha-enolase ENO1 NA binder NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational alpha-enolase ENO1 NA ligand NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational alpha-enolase ENO1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-enolase ENO1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational alpha-enolase ENO1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational alpha-enolase ENO1 NA binder NA drugbank 2-phosphoglycolic acid small molecule NA experimental gamma-enolase ENO2 NA unknown NA drugbank phosphoenolpyruvate small molecule NA experimental beta-enolase ENO3 NA unknown NA drugbank 2-phosphoglycolic acid small molecule NA experimental beta-enolase ENO3 NA unknown NA drugbank 2-phospho-d-glyceric acid small molecule NA experimental beta-enolase ENO3 NA unknown NA drugbank phosphonoacetohydroxamic acid small molecule NA experimental beta-enolase ENO3 NA unknown NA drugbank 2-oxoheptylphosphonic acid small molecule NA experimental enolase-phosphatase e1 ENOPH1 NA unknown NA drugbank idronoxil small molecule Malignant Neoplasms[MeSHID:D009369] investigational ecto-nox disulfide-thiol exchanger 2 ENOX2 NA unknown NA drugbank qgc-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 glutamyl aminopeptidase ENPEP Clinical trial target unknown NA TTD , DGIDB ec33 NA NA investigative glutamyl aminopeptidase ENPEP Clinical trial target unknown NA TTD pmid10602705c40 NA NA investigative glutamyl aminopeptidase ENPEP Clinical trial target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamyl aminopeptidase ENPEP NA unknown NA drugbank kelatorphan NA NA investigative glutamyl aminopeptidase ENPEP Clinical trial target unknown NA TTD taribavirin small molecule Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506] investigational ectonucleotide pyrophosphatase/phosphodiesterase family member 1 ENPP1 NA unknown NA drugbank polyethylene glycol 400 small molecule Dry Eye Syndromes[MeSHID:D015352],Desiccation[MeSHID:D003890] approved ectonucleotide pyrophosphatase/phosphodiesterase family member 1 ENPP1 NA other NA drugbank pyrazolo[3,4-c]pyridine derivative 1 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-27 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-14 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD complex heterocyclic compound 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD octahydro-pyrrolo[3,4-c]-pyrrole derivative 1 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD imidazopyrimidinone derivative 1 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-22 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pyrimidinone derivative 5 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-20 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-24 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD tetra-hydro-carboline derivative 1 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD tetra-hydro-carboline derivative 2 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD piperazine derivative 8 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD heteroaromatic ring derivative 2 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pyrazole derivative 87 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-4 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD heteroaromatic ring derivative 1 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pyridine and pyrimidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Fibrosis[MeSHID:D005355] patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-23 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD heteroaromatic ring derivative 4 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-11 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-21 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pyrido/pyrrolo-fused pyrimidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-26 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD dihydropyrido pyrimidine derivative 1 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD heteroaromatic ring derivative 3 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD pmid28447479-compound-10 NA NA patented extracellular lysophospholipase d ENPP2 Patented-recorded target unknown NA TTD ags-16c3f NA AICARDI-GOUTIERES SYNDROME 1[MeSHID:C535607],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase i beta ENPP3 Clinical trial target unknown NA TTD , DGIDB psb-0963 NA NA investigative ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 Clinical trial target inhibitor 63.65 TTD , DGIDB psb-6426 NA NA investigative ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 Clinical trial target unknown NA TTD iph5201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 Clinical trial target unknown NA TTD srf617 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 Clinical trial target unknown NA TTD ttx-030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 Clinical trial target unknown NA TTD isis 222039 NA NA investigative hif2-alpha messenger rna EPAS1 Clinical trial target unknown NA TTD isis 222041 NA NA investigative hif2-alpha messenger rna EPAS1 Clinical trial target unknown NA TTD pt2385 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of brain[MeSHID:D001932],Von Hippel-Lindau Syndrome[MeSHID:D006623],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 hypoxia-inducible factor 2 alpha EPAS1 Clinical trial target unknown NA TTD aro-hif2 NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 hif2-alpha messenger rna EPAS1 Clinical trial target unknown NA TTD pt2977 NA Renal Cell Carcinoma[MeSHID:D002292],Von Hippel-Lindau Syndrome[MeSHID:D006623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 hypoxia-inducible factor 2 alpha EPAS1 Clinical trial target unknown NA TTD isis 222043 NA NA investigative hif2-alpha messenger rna EPAS1 Clinical trial target unknown NA TTD pt2385 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of brain[MeSHID:D001932],Von Hippel-Lindau Syndrome[MeSHID:D006623],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 hif2-alpha messenger rna EPAS1 Clinical trial target unknown NA TTD isis 222001 NA NA investigative hif2-alpha messenger rna EPAS1 Clinical trial target unknown NA TTD belzutifan small molecule Islet Cell Tumor[MeSHID:D007516],Renal Cell Carcinoma[MeSHID:D002292],Operative Surgical Procedures[MeSHID:D013514],Von Hippel-Lindau Syndrome[MeSHID:D006623],Hemangioblastoma[MeSHID:D018325] approved,investigational endothelial pas domain-containing protein 1 EPAS1 NA inhibitor NA drugbank isis 222035 NA NA investigative hif2-alpha messenger rna EPAS1 Clinical trial target unknown NA TTD catumaxomab biotech Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Pleural Effusion, Malignant[MeSHID:D016066] approved,investigational,withdrawn epithelial cell adhesion molecule EPCAM NA ligand,antibody 5.97 drugbank , DGIDB oportuzumab monatox biotech Cancer of Head and Neck[MeSHID:D006258],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational epithelial cell adhesion molecule EPCAM NA unknown 15.91 drugbank , DGIDB epcam-targeted car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],T-Lymphocyte[MeSHID:D013601],Adenocarcinoma[MeSHID:D000230],Malignant neoplasm of liver[MeSHID:D008113] clinical trial tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD , DGIDB car-t cells targeting epcam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],T-Lymphocyte[MeSHID:D013601],Adenocarcinoma[MeSHID:D000230] phase 1 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD , DGIDB car-t cells targeting epcam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],T-Lymphocyte[MeSHID:D013601],Adenocarcinoma[MeSHID:D000230] phase 1/2 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD , DGIDB a-337 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD hypromellose small molecule Diagnosis[MeSHID:D003933],Eye[MeSHID:D005123],Lubricants[MeSHID:D054327] approved epithelial cell adhesion molecule EPCAM NA unknown NA drugbank car-t cells targeting epcam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Esophageal Neoplasms[MeSHID:D004938],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471],Malignant tumor of colon[MeSHID:D003110] phase 1/2 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD , DGIDB car-t cells targeting epcam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Esophageal Neoplasms[MeSHID:D004938],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471],Malignant tumor of colon[MeSHID:D003110] phase 1 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD , DGIDB ing-1 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational epithelial cell adhesion molecule EPCAM NA unknown 23.87 drugbank , DGIDB mt-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD , DGIDB vicineum NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] phase 3 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD citatuzumab bogatox NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown 15.91 TTD , DGIDB catumaxomab biotech Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Pleural Effusion, Malignant[MeSHID:D016066] approved,investigational,withdrawn epithelial cell adhesion molecule EPCAM NA ligand 5.97 drugbank , DGIDB technetium tc-99m nofetumomab merpentan small molecule Cells[MeSHID:D002477],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Growth[MeSHID:D006128],Syndrome[MeSHID:D013577] approved,withdrawn epithelial cell adhesion molecule EPCAM NA binder NA drugbank car-t cells recognizing epcam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of breast[MeSHID:D001943],melanoma[MeSHID:D008545] phase 1 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD , DGIDB ing-1 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown 23.87 TTD , DGIDB vb4-845 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 2/3 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown 15.91 TTD , DGIDB ign-101 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD citatuzumab bogatox NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tumor-associated calcium signal transducer 1 EPCAM Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-a receptor 1 EPHA1 NA inhibitor NA drugbank regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ephrin type-a receptor 2 EPHA2 NA inhibitor 0.13 drugbank , DGIDB medi-547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-a receptor 2 EPHA2 NA inhibitor NA drugbank ds-8895 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD , DGIDB medi-543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD , DGIDB bt5528 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational ephrin type-a receptor 2 EPHA2 NA antagonist 0.64 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational ephrin type-a receptor 2 EPHA2 NA antagonist,inhibitor 0.64 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational ephrin type-a receptor 2 EPHA2 NA antagonist 0.64 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational ephrin type-a receptor 2 EPHA2 NA antagonist,inhibitor 0.64 drugbank , DGIDB pmid21561767c8h NA NA investigative ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD phosphoaminophosphonic acid-adenylate ester small molecule NA experimental ephrin type-a receptor 2 EPHA2 NA unknown NA drugbank amp-pnp NA NA investigative ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD car-t cells targeting epha2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant Glioma[MeSHID:D005910] phase 1/2 ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD , DGIDB pmid19788238c66 NA NA investigative ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD pmid23489211c20 NA NA investigative ephrin type-a receptor 2 EPHA2 Clinical trial target unknown NA TTD pmid23489211c20 NA NA investigative ephrin type-a receptor 3 EPHA3 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-a receptor 3 EPHA3 NA inhibitor NA drugbank pmid19788238c66 NA NA investigative ephrin type-a receptor 3 EPHA3 Clinical trial target unknown NA TTD ifabotuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 ephrin type-a receptor 3 EPHA3 Clinical trial target unknown NA TTD , DGIDB pmid21561767c8h NA NA investigative ephrin type-a receptor 3 EPHA3 Clinical trial target unknown NA TTD kb-004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 ephrin type-a receptor 3 EPHA3 Clinical trial target unknown 15.91 TTD , DGIDB pmid19788238c66 NA NA investigative ephrin type-a receptor 4 EPHA4 Literature-reported target unknown NA TTD pmid23489211c20 NA NA investigative ephrin type-a receptor 4 EPHA4 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-a receptor 4 EPHA4 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-a receptor 5 EPHA5 NA inhibitor NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational ephrin type-a receptor 5 EPHA5 NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational ephrin type-a receptor 5 EPHA5 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-a receptor 6 EPHA6 NA inhibitor NA drugbank 5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide small molecule NA experimental ephrin type-a receptor 7 EPHA7 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-a receptor 7 EPHA7 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-a receptor 8 EPHA8 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-b receptor 1 EPHB1 NA inhibitor NA drugbank ko-947 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ephrin type-b receptor 2 EPHB2 Clinical trial target unknown NA TTD , DGIDB sephb4-hsa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Kaposi Sarcoma[MeSHID:D012514] phase 2 ephrin type-b receptor 2 EPHB2 Clinical trial target unknown NA TTD pmid19788238c66 NA NA investigative ephrin type-b receptor 2 EPHB2 Clinical trial target unknown NA TTD snewiqprlpqh NA NA investigative ephrin type-b receptor 2 EPHB2 Clinical trial target unknown NA TTD phosphoaminophosphonic acid-adenylate ester small molecule NA experimental ephrin type-b receptor 2 EPHB2 NA unknown NA drugbank mk-8353 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ephrin type-b receptor 2 EPHB2 Clinical trial target unknown 7.07 TTD , DGIDB amp-pnp NA NA investigative ephrin type-b receptor 2 EPHB2 Clinical trial target unknown NA TTD pmid23489211c20 NA NA investigative ephrin type-b receptor 2 EPHB2 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-b receptor 2 EPHB2 NA inhibitor NA drugbank bvd-523 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369] phase 2 ephrin type-b receptor 2 EPHB2 Clinical trial target unknown 5.3 TTD , DGIDB 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzamide small molecule NA experimental ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-b receptor 4 EPHB4 NA inhibitor NA drugbank pmid23489211c20 NA NA investigative ephrin type-b receptor 4 EPHB4 Clinical trial target unknown NA TTD kd019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Neoplasm Metastasis[MeSHID:D009362],Polycystic Kidney Diseases[MeSHID:D007690],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Recurrence (disease attribute)[MeSHID:D012008],Meningioma[MeSHID:D008579],Glioblastoma[MeSHID:D005909] phase 2 ephrin type-b receptor 4 EPHB4 Clinical trial target unknown 13.64 TTD , DGIDB tg-100435 NA NA investigative ephrin type-b receptor 4 EPHB4 Clinical trial target unknown NA TTD n'-(5-chloro-1,3-benzodioxol-4-yl)-n-(3,4,5- trimethoxyphenyl)pyrimidine-2,4-diamine small molecule NA experimental ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank n-[3-[[4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide small molecule NA experimental ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank n-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine small molecule NA experimental ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank n'-(3-chloro-4-methoxy-phenyl)-n-(3,4,5-trimethoxyphenyl)-1,3,5-triazine-2,4-diamine small molecule NA experimental ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank n'-(5-chloro-1,3-benzodioxol-4-yl)-n-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine small molecule NA experimental ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank ephb4-131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative ephrin type-b receptor 4 EPHB4 Clinical trial target unknown NA TTD 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide small molecule NA experimental ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank tesevatinib small molecule NA investigational ephrin type-b receptor 4 EPHB4 NA inhibitor 13.64 drugbank , DGIDB pmid19788238c66 NA NA investigative ephrin type-b receptor 4 EPHB4 Clinical trial target unknown NA TTD n'-(5-chloro-1,3-benzodioxol-4-yl)-n-(3-morpholin-4-ylphenyl)pyrimidine-2,4-diamine small molecule NA experimental ephrin type-b receptor 4 EPHB4 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ephrin type-b receptor 6 EPHB6 NA inhibitor NA drugbank 1-adamantan-1-yl-3-(3-hydroxypropyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 6-{[(cyclohexylamino)carbonyl]amino}hexanoic acid small molecule NA experimental bifunctional epoxide hydrolase 2 EPHX2 NA unknown NA drugbank 13-(3-n-pentylureido)tridec-5(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-((r)-1-phenyl-ethyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(4-pentyloxybutyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-(3-n-pentylureido)tridec-8(e)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD ar-9281 small molecule Hypertensive disease[MeSHID:D006973] investigational bifunctional epoxide hydrolase 2 EPHX2 NA unknown NA drugbank n-(3-chloro-phenyl)-2-cyclohexyl-acetamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-n'-(propyl)phenyl urea small molecule NA experimental bifunctional epoxide hydrolase 2 EPHX2 NA unknown NA drugbank 1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-piperidin-4-yl-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-(n-isopropylheptanamido)tridec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-(3-n-pentylureido)tridec-8-ynoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-2-phenyl-acetamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD ebselen small molecule NA investigational bifunctional epoxide hydrolase 2 EPHX2 NA inhibitor NA drugbank 1-phenyl-3-(1-propionylpiperidin-4-yl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(2-methoxy-phenyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 9-(3-n-pentylureido)non-4(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-n'-(4-iodophenyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 2-cyclohexyl-n-phenethyl-acetamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(4-methoxy-phenyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(4-hydroxy-decyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 2-cyclohexyl-n-(4-methoxy-phenyl)-acetamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-cycloheptyl-3-(1-propionylpiperidin-4-yl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-cyclohexyl-3-(4-methoxy-phenyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(5-hydroxypentyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(3-hexyloxypropyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-[(cyclohexylamino)carbonyl]glycine NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-(3-n-pentylthioureido)tridec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 9-(3-n-pentylureido)non-4-ynoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-n'-decylurea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-4-phenyl-butyramide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-2-(4-methoxy-phenyl)-acetamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-(5-n-pentylfuran-2-yl)tridec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-n'-(propyl)phenyl urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD dodecanoic acid adamantan-1-ylamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 4-(3-cyclohexylureido)butanoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD trans,trans-1,3-bis-(4-hydroxycyclohexyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-cyclohexyl-3-(1-propionylpiperidin-4-yl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-phenyl-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-(3-chloro-phenyl)-3-cyclohexyl-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-decyl-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(6-hydroxyhexyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 16-(3-ethylureido)hexadec-11(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-[(cyclohexylamino)carbonyl]glycine small molecule NA experimental bifunctional epoxide hydrolase 2 EPHX2 NA unknown NA drugbank 4-{[(cyclohexylamino)carbonyl]amino}butanoic acid small molecule NA experimental bifunctional epoxide hydrolase 2 EPHX2 NA unknown NA drugbank 13-(3-pentyluredo)tridec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(3-methoxy-phenyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(2-hydroxy-phenyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 6-{[(cyclohexylamino)carbonyl]amino}hexanoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD methyl 4-(3-cyclohexylureido)butanoate NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 6-amino-n-(2,4-dichlorobenzyl)nicotinamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 4,4-diphenyl-n-(pyridin-3-yl)-butyramide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-(n-methyl-n-heptnamido)tridec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-(1-propionylpiperidin-4-yl)-3-p-tolylurea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-(biphenyl-3-yl)benzo[d]isoxazol-3-amine NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD methyl 14-(3-n-butylureido)tetradec-8(z)-enoate NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-(3,3-diphenyl-propyl)-isonicotinamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1,3-diphenylurea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(2-hydroxyethyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 12-(3-adamantan-1-yl-ureido)-dodeca noic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(4-hydroxybutyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-adamantyl-n'-cyclohexylurea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD [4-(3-adamantan-1-yl-ureido)-phenyl]-acetic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-(3-chloro-phenyl)-3-(4-hydroxy-decyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-(3-phenyl-propyl)-nicotinamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-(1-propionylpiperidin-4-yl)-3-m-tolylurea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-[3,3-bis-(4-fluorophenyl)-propyl]-benzamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 14-(n-hexylamino)-14-oxotetradec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD gsk2256294 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD , DGIDB 3-(3-adamantan-1-yl-ureido)-benzoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-n'-(4-iodophenyl)urea small molecule NA experimental bifunctional epoxide hydrolase 2 EPHX2 NA unknown NA drugbank methyl 6-(3-cyclohexylureido)hexanoate NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD gsk2256294 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 soluble epoxide hydrolase EPHX2 Clinical trial target inhibitor NA TTD , DGIDB 1-adamantan-1-yl-3-(5-butoxypentyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-(n-pentylcarbamoyloxy)tridec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-cyclohexyl-3-phenyl-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 2-cyclohexyl-n-phenyl-acetamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(6-propyloxyhexyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 7-{[(cyclohexylamino)carbonyl]amino}heptanoic acid small molecule NA experimental bifunctional epoxide hydrolase 2 EPHX2 NA unknown NA drugbank 2-adamantan-1-yl-n-decyl-acetamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 6-amino-n-(3,3-diphenylpropyl)nicotinamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-(1-propionylpiperidin-4-yl)-3-o-tolylurea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n,n'-dicyclohexyl-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 12-(3-n-pentylureidooxy)dodec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD exrd-4605 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-(3,3-diphenyl-propyl)-2-pyridine-3-ylacetamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(4-hydroxy-phenyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-(3,3-diphenyl-propyl)-nicotinamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(3-hydroxy-phenyl)-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 12-(3-n-hexylureido)dodec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-(naphthalen-1-yl)benzo[d]isoxazol-3-amine NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(2-heptyloxyethyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-n-heptanamidotridec-8(z)-enoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-[3,3-bis-(4-fluorophenyl)-propyl]-nicotinamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 4-(3-adamantan-1-yl-ureido)-benzoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 13-n-heptanamidotridec-5-ynoic acid NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-cyclohexyl-n'-decylurea small molecule NA experimental bifunctional epoxide hydrolase 2 EPHX2 NA unknown NA drugbank 1-cyclohexyl-3-phenethyl-urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-(biphenyl-4-yl)benzo[d]isoxazol-3-amine NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD n-(naphthalen-2-yl)benzo[d]isoxazol-3-amine NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD ar9281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 soluble epoxide hydrolase EPHX2 Clinical trial target unknown 11.93 TTD , DGIDB n-(4,4-diphenyl-butyl)-nicotinamide NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1-octyl-3-(1-propionylpiperidin-4-yl)urea NA NA investigative soluble epoxide hydrolase EPHX2 Clinical trial target unknown NA TTD 1d-myo-inositol 1,4,5-trisphosphate small molecule NA experimental epsin-1 EPN1 NA unknown NA drugbank 1,4-dioxane small molecule NA experimental epsin-1 EPN1 NA unknown NA drugbank gc-1113 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 1 erythropoietin EPO Clinical trial target unknown NA TTD , DGIDB mk-2578 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2 erythropoietin EPO Clinical trial target unknown NA TTD , DGIDB long-acting erythropoietin conjugate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 1 erythropoietin EPO Clinical trial target unknown NA TTD , DGIDB erythropoietin-transfected autologous cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 1/2 erythropoietin EPO Clinical trial target unknown NA TTD , DGIDB fc epo NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] discontinued in phase 1 erythropoietin EPO Clinical trial target unknown NA TTD lka651 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 erythropoietin EPO Clinical trial target unknown NA TTD p-1116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] investigative erythropoietin receptor EPOR Successful target unknown NA TTD epo-derived peptide NA Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative erythropoietin receptor EPOR Successful target unknown NA TTD epoetin alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved erythropoietin receptor EPOR Successful target agonist 0.48 TTD , DGIDB erythropoietin biotech Erythrocytes[MeSHID:D004912],Infantile Neuroaxonal Dystrophy[MeSHID:D019150],HIV Infections[MeSHID:D015658],Physical Dialysis[MeSHID:D003956],Chronic Kidney Diseases[MeSHID:D051436],Anemia[MeSHID:D000740],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigative erythropoietin receptor EPOR Successful target agonist 3.25 TTD , drugbank , DGIDB darbepoetin alfa biotech HIV Seropositivity[MeSHID:D006679],Anemia[MeSHID:D000740],HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational erythropoietin receptor EPOR Successful target agonist NA TTD , drugbank , DGIDB pt-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] investigative erythropoietin receptor EPOR Successful target unknown NA TTD epo peptide mimetics NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] investigative erythropoietin receptor EPOR Successful target unknown NA TTD epoetin alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved erythropoietin receptor EPOR Successful target unknown NA TTD , DGIDB cibinetide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Macular Edema, Cystoid[MeSHID:D008269],Peripheral Neuropathy[MeSHID:D010523] phase 2 erythropoietin receptor EPOR Successful target unknown 18.19 TTD , DGIDB cibinetide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Macular Edema, Cystoid[MeSHID:D008269],Peripheral Neuropathy[MeSHID:D010523] phase 2 erythropoietin receptor EPOR Successful target agonist 18.19 TTD , DGIDB nova-epo NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] investigative erythropoietin receptor EPOR Successful target unknown NA TTD bbt-021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] investigative erythropoietin receptor EPOR Successful target unknown NA TTD bbt-009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] investigative erythropoietin receptor EPOR Successful target unknown NA TTD erepoxen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 3 erythropoietin receptor EPOR Successful target unknown NA TTD , DGIDB epoetin zeta NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 3 erythropoietin receptor EPOR Successful target unknown NA TTD , DGIDB peg-epo NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] investigative erythropoietin receptor EPOR Successful target unknown NA TTD 3,5 dibromotyrosine NA NA investigative erythropoietin receptor EPOR Successful target unknown NA TTD rhuepo NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved erythropoietin receptor EPOR Successful target unknown NA TTD , DGIDB darbepoetin alfa biotech HIV Seropositivity[MeSHID:D006679],Anemia[MeSHID:D000740],HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational erythropoietin receptor EPOR Successful target agonist 9.09 TTD , drugbank , DGIDB dibromotyrosine small molecule NA experimental erythropoietin receptor EPOR NA unknown NA drugbank hematide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 3 erythropoietin receptor EPOR Successful target unknown 45.47 TTD , DGIDB methoxy polyethylene glycol-epoetin beta biotech Erythrocytes[MeSHID:D004912],Anemia[MeSHID:D000740],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney[MeSHID:D007668],Graft Rejection[MeSHID:D006084] approved erythropoietin receptor EPOR Successful target stimulator NA TTD , drugbank , DGIDB peginesatide biotech Physical Dialysis[MeSHID:D003956],Anemia[MeSHID:D000740],Chronic Kidney Diseases[MeSHID:D051436] approved,investigational erythropoietin receptor EPOR NA stimulator,agonist 45.47 drugbank , DGIDB glycopegylated erythropoietin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 erythropoietin receptor EPOR Successful target unknown NA TTD proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical bifunctional glutamate/proline--trna ligase EPRS NA unknown NA drugbank 5'-o-(l-prolylsulfamoyl)adenosine small molecule NA experimental bifunctional glutamate/proline--trna ligase EPRS NA unknown NA drugbank 5'-o-(n-(alanyl)sulfamoyl)adenosine small molecule NA experimental bifunctional glutamate/proline--trna ligase EPRS NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical bifunctional glutamate/proline--trna ligase EPRS NA unknown NA drugbank ht-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hashimoto Disease[MeSHID:D050031] phase 2 bifunctional aminoacyl-trna synthetase EPRS Clinical trial target unknown NA TTD 5'-o-(l-cysteinylsulfamoyl)adenosine small molecule NA experimental bifunctional glutamate/proline--trna ligase EPRS NA unknown NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved eosinophil peroxidase EPX NA inhibitor NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved eosinophil peroxidase EPX NA inhibitor NA drugbank margetuximab NA Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Adenocarcinoma[MeSHID:D000230] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.5 TTD , DGIDB isis 12883 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD gq1001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD 227th-labelled her2-ttc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD vm-206 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB tas-0728 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pentalogy of Cantrell[MeSHID:D058502] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD her2-car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB taxol/paraplatin/herceptin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB neuvax NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB trastuzumab biotech Breast[MeSHID:D001940],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA binder,antibody 1.89 drugbank , DGIDB 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD 4557w NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD neratinib maleate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB trastuzumab biotech Breast[MeSHID:D001940],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA binder,antibody,inhibitor 1.89 drugbank , DGIDB car-t cells targeting her2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB her-2-bi-armed atc NA Ataxia Telangiectasia[MeSHID:D001260],Alveolar rhabdomyosarcoma[MeSHID:D018232],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD redoxal NA NA investigative erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD her-2 protein autovac NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB bms-690514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 erbb2 messenger rna ERBB2 Clinical trial target unknown 0.37 TTD , DGIDB trastuzumab NA Breast[MeSHID:D001940],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.89 TTD , DGIDB ta1-rta NA NA investigative erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD 4-(4-isopropylphenyl)-5-cyano-2h-1,2,3-triazole NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD mm-302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.85 TTD , DGIDB margetuximab biotech Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Adenocarcinoma[MeSHID:D000230] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA antagonist,antibody 1.5 drugbank , DGIDB au105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB mva her-2 autovac NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB pd-168393 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD tarloxotinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD her2/neu peptide vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD sbt6050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD masoprocol NA Precancerous Conditions[MeSHID:D011230],Growth[MeSHID:D006128],Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.43 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA inhibitor NA drugbank a166 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD geldanamycin-estradiol hybrid NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD (1-benzyl-1h-indazol-5-yl)-quinazolin-4-yl-amine NA NA investigative erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD tak-285 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.28 TTD , DGIDB arry-380 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.14 TTD , DGIDB tak165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD lapatinib small molecule Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Epidermis[MeSHID:D004817],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA antagonist,inhibitor 1.2 drugbank , DGIDB margetuximab biotech Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Adenocarcinoma[MeSHID:D000230] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA antagonist,inhibitor 1.5 drugbank , DGIDB isis 12884 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD mt-5111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD mgah22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.5 TTD , DGIDB 4-(4-chlorophenyl)-5-cyano-2h-1,2,3-triazole NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD azd8931 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1 TTD , DGIDB m802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD margetuximab NA Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Adenocarcinoma[MeSHID:D000230] approved erbb2 tyrosine kinase receptor ERBB2 Successful target antibody 1.5 TTD , DGIDB pf 5208766 NA NA investigative erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD hki-272 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 erbb2 messenger rna ERBB2 Clinical trial target unknown 1.48 TTD , DGIDB mbs301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD mrg002 NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD her2p63-71 peptide vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB car-t cells targeting her2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB bms-599626 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.07 TTD , DGIDB trastuzumab emtansine biotech Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA antibody,inhibitor 0.03 drugbank , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA inhibitor NA drugbank njh395 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD trasgex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB her2-targeted autologous t-cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB nelipepimut s NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Malignant neoplasm of breast[MeSHID:D001943] phase 3 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB agn-208397 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinal Vein Occlusion[MeSHID:D012170] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB anti-her2 car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Glioma[MeSHID:D005910],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB mcla-128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.43 TTD , DGIDB margetuximab NA Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Adenocarcinoma[MeSHID:D000230] approved erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.5 TTD , DGIDB pertuzumab NA Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.23 TTD , DGIDB 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD isis 12882 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD tucatinib NA Breast[MeSHID:D001940],Brain[MeSHID:D001921],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.14 TTD , DGIDB s-222611 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1b erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.07 TTD , DGIDB aip-303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD margetuximab biotech Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Adenocarcinoma[MeSHID:D000230] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA antagonist 1.5 drugbank , DGIDB bevacizumab + trastuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB isb 1302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD pmid24915291c38 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD bms-599626 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.07 TTD , DGIDB brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA inhibitor NA drugbank isis 9003 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD afatinib small molecule Neoplasms[MeSHID:D009369],Mutation[MeSHID:D009154],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved receptor tyrosine-protein kinase erbb-2 ERBB2 NA inhibitor 1.32 drugbank , DGIDB mm-111 NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target antibody 1.07 TTD , DGIDB her2-specific car t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],pineoblastoma[MeSHID:D010871],Medulloblastoma[MeSHID:D008527],Stomach[MeSHID:D013270],T-Lymphocyte[MeSHID:D013601],Adenocarcinoma[MeSHID:D000230],Germ cell tumor[MeSHID:D009373],Glioma[MeSHID:D005910],Ependymoma[MeSHID:D004806],Teratoid Rhabdoid Tumor[MeSHID:C000597569],Choroid Plexus Carcinoma[MeSHID:C562943] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB tucatinib small molecule Breast[MeSHID:D001940],Brain[MeSHID:D001921],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA inhibitor 1.14 drugbank , DGIDB medi4276 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.43 TTD , DGIDB s-222611 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1b erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.07 TTD , DGIDB pertuzumab biotech Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved receptor tyrosine-protein kinase erbb-2 ERBB2 NA binder,antibody 1.23 drugbank , DGIDB trastuzumab emtansine biotech Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA antibody NA drugbank , DGIDB trastuzumab-dm1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.43 TTD , DGIDB pnt-500 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD bibw 2992 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB her2-specific t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],T-Lymphocyte[MeSHID:D013601],Glioblastoma[MeSHID:D005909] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB 4-(3-phenoxylphenyl)-5-cyano-2h-1,2,3-triazole NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD 4-(4-bromophenyl)-5-cyano-2h-1,2,3-triazole NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD bms-536924 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD avx901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB varlitinib NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Biliary Tract Neoplasm[MeSHID:D001661] phase 2/3 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.85 TTD , DGIDB mb-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD merimepodib NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Cancer of Head and Neck[MeSHID:D006258],Malignant neoplasm of breast[MeSHID:D001943] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD azd8931 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1 TTD , DGIDB dacomitinib NA Malignant Neoplasms[MeSHID:D009369],lymph nodes[MeSHID:D008198],Disease[MeSHID:D004194],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Cause of Death[MeSHID:D002423],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Missense Mutation[MeSHID:D020125],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.2 TTD , DGIDB hds-029 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD dzd1516 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD cl-387785 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD cp-724714 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.28 TTD , DGIDB zenocutuzomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD n-(4-m-tolylamino-quinazolin-6-yl)-acrylamide NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD pertuzumab NA Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target antibody 1.23 TTD , DGIDB lapatinib small molecule Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Epidermis[MeSHID:D004817],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA antagonist 1.2 drugbank , DGIDB (1-benzyl-1h-indol-5-yl)-quinazolin-4-yl-amine NA NA investigative erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD cart-her-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB ertumaxomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.28 TTD , DGIDB pertuzumab NA Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.23 TTD , DGIDB gbr1302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD anti-cd3 and anti-her2/neu bispecific antibody-armed activated t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of breast[MeSHID:D001943] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB ign311 biotech Malignant Neoplasms[MeSHID:D009369] investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA unknown NA drugbank pazopanib + tyverb/tykerb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Breast Carcinoma[MeSHID:D058922] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB dn24-02 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Genitourinary Cancer[MeSHID:D014565] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB cudc-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 0.21 TTD , DGIDB cipatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB cudc-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.21 TTD , DGIDB pf-05280014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB varlitinib small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Biliary Tract Neoplasm[MeSHID:D001661] investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA inhibitor 0.85 drugbank , DGIDB jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.09 TTD , DGIDB sym013 NA Epithelial ovarian cancer[MeSHID:C538090],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB ag-213 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD aby-025 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB pertuzumab biotech Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved receptor tyrosine-protein kinase erbb-2 ERBB2 NA binder,antibody,inhibitor 1.23 drugbank , DGIDB merimepodib NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD lapatinib NA Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Epidermis[MeSHID:D004817],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.2 TTD , DGIDB zemab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB 4-(bis(2-chloroethyl)amino)-n-p-tolylbenzamide NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD recombinant human erbb3 fragment therapeutic tumor vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA inhibitor NA drugbank bdtx-189 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD tucatinib NA Breast[MeSHID:D001940],Brain[MeSHID:D001921],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.14 TTD , DGIDB lapatinib NA Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Epidermis[MeSHID:D004817],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.2 TTD , DGIDB arry-380 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.14 TTD , DGIDB 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD varlitinib small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Biliary Tract Neoplasm[MeSHID:D001661] investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA unknown 0.85 drugbank , DGIDB dacomitinib NA Malignant Neoplasms[MeSHID:D009369],lymph nodes[MeSHID:D008198],Disease[MeSHID:D004194],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Cause of Death[MeSHID:D002423],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Missense Mutation[MeSHID:D020125],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.2 TTD , DGIDB av-412 small molecule Neoplasms[MeSHID:D009369] investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA unknown 0.71 drugbank , DGIDB trastuzumab NA Breast[MeSHID:D001940],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.89 TTD , DGIDB varlitinib NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Biliary Tract Neoplasm[MeSHID:D001661] phase 2/3 erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 0.85 TTD , DGIDB hki-272 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.48 TTD , DGIDB bay 2701439 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD her-2-targeting car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 0.09 TTD , DGIDB tesevatinib small molecule NA investigational receptor tyrosine-protein kinase erbb-2 ERBB2 NA inhibitor 0.49 drugbank , DGIDB hm-78136b NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD , DGIDB bms-690514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 erbb2 messenger rna ERBB2 Clinical trial target inhibitor 0.37 TTD , DGIDB zw49 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD isis 9005 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD trastuzumab NA Breast[MeSHID:D001940],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target antibody 1.89 TTD , DGIDB kn026 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown NA TTD (1-benzyl-1h-indol-5-yl)-quinazolin-4-yl-amine NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD tak-285 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.28 TTD , DGIDB mm-111 NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 1.07 TTD , DGIDB cp-724714 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor 1.28 TTD , DGIDB bibw 2992 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb2 tyrosine kinase receptor ERBB2 Successful target inhibitor NA TTD , DGIDB ci-1033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 erbb2 tyrosine kinase receptor ERBB2 Successful target unknown 0.31 TTD , DGIDB isis 9002 NA NA investigative erbb2 messenger rna ERBB2 Clinical trial target unknown NA TTD ezn-3920 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative erbb3 messenger rna ERBB3 Literature-reported target unknown NA TTD mp-rm-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD drug 2849330 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB ktn3379 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB mm-141 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown 1.41 TTD , DGIDB tucatinib small molecule Breast[MeSHID:D001940],Brain[MeSHID:D001921],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-3 ERBB3 NA inhibitor NA drugbank patritumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target inhibitor 2.12 TTD , DGIDB zenocutuzomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD recombinant human erbb3 fragment therapeutic tumor vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB gsk2849330 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB cdx-3379 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Squamous cell carcinoma[MeSHID:D002294] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB patritumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown 2.12 TTD , DGIDB elisidepsin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB mm-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB mehd-7945a NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown 2.12 TTD , DGIDB sym-011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD mm-121 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown 8.49 TTD , DGIDB av-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target antibody 4.24 TTD , DGIDB mm-121 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target antibody 8.49 TTD , DGIDB av-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown 4.24 TTD , DGIDB seribantumab NA Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Cancer of Head and Neck[MeSHID:D006258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target antibody 1.41 TTD , DGIDB rg7116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB mm-121 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target antagonist 8.49 TTD , DGIDB regn1400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB amg888/u3-1287 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB sym013 NA Epithelial ovarian cancer[MeSHID:C538090],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB ljm716 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown 2.12 TTD , DGIDB anti-her3/egfr daf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epithelioma[MeSHID:D009375] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD , DGIDB seribantumab NA Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Cancer of Head and Neck[MeSHID:D006258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown 1.41 TTD , DGIDB soluble erbb3 theragnostics NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD si-b001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epithelioma[MeSHID:D009375] phase 1 erbb3 tyrosine kinase receptor ERBB3 Clinical trial target unknown NA TTD ci-1033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 erbb4 tyrosine kinase receptor ERBB4 Successful target unknown NA TTD hds-029 NA NA investigative erbb4 tyrosine kinase receptor ERBB4 Successful target unknown NA TTD isis 19647 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD isis 19675 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD isis 19651 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD pmid24915291c38 NA NA investigative erbb4 tyrosine kinase receptor ERBB4 Successful target unknown NA TTD dacomitinib NA Malignant Neoplasms[MeSHID:D009369],lymph nodes[MeSHID:D008198],Disease[MeSHID:D004194],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Cause of Death[MeSHID:D002423],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Missense Mutation[MeSHID:D020125],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb4 tyrosine kinase receptor ERBB4 Successful target inhibitor 2.01 TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor tyrosine-protein kinase erbb-4 ERBB4 NA inhibitor NA drugbank isis 19657 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational receptor tyrosine-protein kinase erbb-4 ERBB4 NA inhibitor NA drugbank cl-387785 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD isis 19677 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD isis 19639 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD isis 19659 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD isis 19649 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational receptor tyrosine-protein kinase erbb-4 ERBB4 NA inhibitor NA drugbank rg7388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Hematologic Neoplasms[MeSHID:D019337],Malignant Neoplasms[MeSHID:D009369],Polycythemia Vera[MeSHID:D011087] phase 3 erbb4 tyrosine kinase receptor ERBB4 Successful target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational receptor tyrosine-protein kinase erbb-4 ERBB4 NA inhibitor NA drugbank isis 19650 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD isis 19658 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD dacomitinib NA Malignant Neoplasms[MeSHID:D009369],lymph nodes[MeSHID:D008198],Disease[MeSHID:D004194],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Cause of Death[MeSHID:D002423],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Missense Mutation[MeSHID:D020125],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved erbb4 tyrosine kinase receptor ERBB4 Successful target unknown 2.01 TTD , DGIDB jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 erbb4 tyrosine kinase receptor ERBB4 Successful target inhibitor 0.19 TTD , DGIDB isis 19634 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD ji-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 erbb4 tyrosine kinase receptor ERBB4 Successful target unknown NA TTD afatinib small molecule Neoplasms[MeSHID:D009369],Mutation[MeSHID:D009154],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved receptor tyrosine-protein kinase erbb-4 ERBB4 NA inhibitor 0.34 drugbank , DGIDB isis 19676 NA NA investigative her4 messenger rna ERBB4 Literature-reported target unknown NA TTD ly3016859 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Kidney Diseases[MeSHID:D051436] phase 1/2 epiregulin EREG Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase/endoribonuclease ire1 ERN1 NA inhibitor NA drugbank n~2~-1h-benzimidazol-5-yl-n~4~-(3-cyclopropyl-1h-pyrazol-5-yl)pyrimidine-2,4-diamine small molecule NA experimental serine/threonine-protein kinase/endoribonuclease ire1 ERN1 NA unknown NA drugbank 1-ethyl-pyrrolidine-2,5-dione small molecule NA experimental ero1-like protein beta ERO1B NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved ero1-like protein beta ERO1B NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical s-formylglutathione hydrolase ESD NA unknown NA drugbank 4-chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD toremifene NA Prostatic Intraepithelial Neoplasias[MeSHID:D019048],Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of breast[MeSHID:D001943],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.72 TTD , DGIDB estradiol cypionate NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.16 TTD , DGIDB 6-phenyl-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 1-bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2,3-diphenyl-1h-indole NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD geldanamycin-estradiol hybrid NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD fluoxymesterone small molecule Malignant neoplasm of breast[MeSHID:D001943],Malnutrition[MeSHID:D044342],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit estrogen receptor alpha ESR1 NA antagonist NA drugbank raloxifene small molecule Osteopenia[MeSHID:D001851],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA agonist,antagonist 0.19 drugbank , DGIDB 4-(5-hydroxy-benzooxazol-2-yl)-benzene-1,3-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 1,8-dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD sr 16234 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD azd9833 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 estrogen receptor ESR1 Successful target unknown NA TTD 3,8-dihydroxy-4-methyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD [5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]acetonitrile small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 2-(5-hydroxy-naphthalen-1-yl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental estrogen receptor alpha ESR1 NA binder NA drugbank 4-[(1s,2s,5s)-5-(hydroxymethyl)-6,8,9-trimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 8-(3-methylbutyl)naringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist NA drugbank , DGIDB broussonin a NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD op-1250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 estrogen receptor ESR1 Successful target unknown NA TTD 2-(4-hydroxyphenyl)-1,2'-spirobi[1h-indene]-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD bazedoxifene NA Uterus[MeSHID:D014599],Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteopetrosis[MeSHID:D010022] approved estrogen receptor ESR1 Successful target antagonist 0.32 TTD , DGIDB propyl gallate small molecule NA investigational estrogen receptor alpha ESR1 NA unknown NA drugbank estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist 0.32 drugbank , DGIDB 2-(4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(3-fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD cp-394531 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(4-hydroxy-2-methyl-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(7-chloro-1-cyclopentyl-1h-indazol-3-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 3-(4-hydroxyphenyl)-7-isopropoxychromen-4-one NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD era-923 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 2 estrogen receptor ESR1 Successful target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor alpha ESR1 NA antagonist,agonist 0.11 drugbank , DGIDB he2100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] discontinued in phase 1 estrogen receptor ESR1 Successful target unknown NA TTD diethyl (1r,2s,3r,4s)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank eugenol small molecule Dental caries[MeSHID:D003731],Toothache[MeSHID:D014098] approved estrogen receptor alpha ESR1 NA unknown NA drugbank 4-(1-cyclopentyl-7-fluoro-1h-indazol-3-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD trilostane small molecule Cushing Syndrome[MeSHID:D003480],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational,vet_approved,withdrawn estrogen receptor alpha ESR1 NA allosteric modulator NA drugbank 4-hydroxy-n-isopropyl-n-phenylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD bn-ao-014 NA Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB tamoxifen isopropyl bromide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD ospemifene small molecule Atrophic[MeSHID:D001284],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Vulva[MeSHID:D014844],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA antagonist,agonist,modulator 0.4 drugbank , DGIDB 2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD testosterone enanthate small molecule Systemic arterial pressure[MeSHID:D062186],Sexual Development[MeSHID:D046468],Neoplasms[MeSHID:D009369],Pituitary Gland[MeSHID:D010902],Klinefelter Syndrome[MeSHID:D007713],Myocardial Infarction[MeSHID:D009203],Syndrome[MeSHID:D013577],Pituitary Diseases[MeSHID:D010900],Idiopathic hypogonadotropic hypogonadism[MeSHID:C562785],Mammary gland[MeSHID:D042361],Testicular hypogonadism[MeSHID:D005058],Thyroid Gland[MeSHID:D013961],Testis[MeSHID:D013737],Orchitis[MeSHID:D009920],Neoplasm Metastasis[MeSHID:D009362],Cryptorchidism[MeSHID:D003456],Hypothalamic structure[MeSHID:D007031],Malignant neoplasm of breast[MeSHID:D001943],Cerebrovascular accident[MeSHID:D020521],Electromagnetic Radiation[MeSHID:D060733],Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Cessation of life[MeSHID:D003643],Blood Pressure[MeSHID:D001794],Maintenance[MeSHID:D008283],Pathologic Processes[MeSHID:D010335],Primary hypogonadism[MeSHID:D007006],Malnutrition[MeSHID:D044342],Adrenal Cortex[MeSHID:D000302],Disease[MeSHID:D004194],Delayed Puberty[MeSHID:D011628],Traumatic injury[MeSHID:D014947],Malignant Carcinoid Syndrome[MeSHID:D008303] approved estrogen receptor alpha ESR1 NA unknown NA drugbank testosterone undecanoate small molecule Malnutrition[MeSHID:D044342],Disease[MeSHID:D004194],Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA unknown NA drugbank 4-hydroxy-n-neopentyl-n-phenylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-ethyl-2,4-diisobutylaminopyrimidine NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4,7-dimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD testosterone small molecule Hypogonadotropic hypogonadism[MeSHID:D007006],Klinefelter Syndrome[MeSHID:D007713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342],Osteoporosis[MeSHID:D010024] approved,investigational estrogen receptor alpha ESR1 NA inhibitor 0.04 drugbank , DGIDB quinestrol small molecule Hot flushes[MeSHID:D019584],Breast[MeSHID:D001940],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor alpha ESR1 NA agonist,modulator 0.51 drugbank , DGIDB phenolphthalein small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn estrogen receptor alpha ESR1 NA agonist 0.08 drugbank , DGIDB octocrylene small molecule Evaluation[MeSHID:None] approved,investigational estrogen receptor alpha ESR1 NA unknown NA drugbank 4-[(1s,2s,5s,9r)-5-(hydroxymethyl)-8,9-dimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank zk-164015 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD tamoxifen ethyl bromide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 17-methyl-17-alpha-dihydroequilenin small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank tamoxifen NA Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist,antagonist 0.11 TTD , DGIDB promestriene NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB phthalic acid small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 5-bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD tibolone small molecule Osteoporosis[MeSHID:D010024],Postmenopause[MeSHID:D017698],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolism[MeSHID:D008660] approved,investigational estrogen receptor alpha ESR1 NA antagonist,agonist 0.21 drugbank , DGIDB 4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(3-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD mestranol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor alpha ESR1 NA agonist 0.25 drugbank , DGIDB 2-(3-hydroxyphenyl)-1,2'-spirobi[1h-indene]-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD trimegestone/ethinyl estradiol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB fulvestrant NA Disease Progression[MeSHID:D018450],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target antagonist 0.66 TTD , DGIDB n,n,n-triisobutyl-pyrimidine-2,4,6-triamine NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD nomegestrol acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB stx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigative estrogen receptor ESR1 Successful target unknown NA TTD n-butyl-4-hydroxy-n-phenylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD gestrinone NA Infertility[MeSHID:D007246],Unmarried[MeSHID:D012847],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor ESR1 Successful target unknown 0.16 TTD , DGIDB testosterone cypionate small molecule Testicular hypogonadism[MeSHID:D005058],Radiation[MeSHID:D011827],Disease[MeSHID:D004194],Testis[MeSHID:D013737],Orchitis[MeSHID:D009920],Cryptorchidism[MeSHID:D003456],Traumatic injury[MeSHID:D014947],Hypothalamic-Pituitary Neoplasms[MeSHID:D007029],Klinefelter Syndrome[MeSHID:D007713],Hypogonadotropic hypogonadism[MeSHID:D007006],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Electromagnetic Radiation[MeSHID:D060733] approved estrogen receptor alpha ESR1 NA unknown NA drugbank 1-[4-(octahydro-pyrido[1,2-a]pyrazin-2-yl)-phenyl]-2-phenyl-1,2,3,4-tetrahydro-isoquinolin-6-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 7-phenyl-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD norgestimate small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA agonist 0.38 drugbank , DGIDB 8-n-nonylnaringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD danazol small molecule Breast Fibrocystic Disease[MeSHID:D005348],Angioedemas, Hereditary[MeSHID:D054179],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menorrhagia[MeSHID:D008595],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor alpha ESR1 NA agonist 0.16 drugbank , DGIDB ractopamine small molecule NA vet_approved estrogen receptor alpha ESR1 NA unknown NA drugbank 2-(4-hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 3-chloro-4-(4-hydroxyphenyl)salicylaldoxime NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD gestrinone small molecule Infertility[MeSHID:D007246],Unmarried[MeSHID:D012847],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor alpha ESR1 NA antagonist,agonist 0.16 drugbank , DGIDB synthetic conjugated estrogen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vaginal Diseases[MeSHID:D014623] phase 3 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB lasofoxifene NA Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Vagina[MeSHID:D014621],Fracture[MeSHID:D050723],Malignant neoplasm of breast[MeSHID:D001943],Risk Reduction[MeSHID:D040242],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844],Virus Diseases[MeSHID:D014777],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.63 TTD , DGIDB compound 18 small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical estrogen receptor alpha ESR1 NA binder NA drugbank gtx-758 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 estrogen receptor ESR1 Successful target agonist 0.32 TTD , DGIDB rg6046 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigative estrogen receptor ESR1 Successful target unknown NA TTD 8-n-heptylnaringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved estrogen receptor alpha ESR1 NA agonist,inhibitor,downregulator 0.04 drugbank , DGIDB (9beta,11alpha,13alpha,14beta,17alpha)-11-(methoxymethyl)estra-1(10),2,4-triene-3,17-diol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank npc-01 NA Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB effusol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD mestranol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.25 TTD , DGIDB estropipate NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.63 TTD , DGIDB estradiol valerate NA Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 7-butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD dienestrol small molecule Vulvar Lichen Sclerosus[MeSHID:D007724],Atrophic Vaginitis[MeSHID:D059268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA agonist 0.54 drugbank , DGIDB lasofoxifene small molecule Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Vagina[MeSHID:D014621],Fracture[MeSHID:D050723],Malignant neoplasm of breast[MeSHID:D001943],Risk Reduction[MeSHID:D040242],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844],Virus Diseases[MeSHID:D014777],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA antagonist,agonist,negative modulator 0.63 drugbank , DGIDB estrone NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.32 TTD , DGIDB afimoxifene small molecule Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] investigational estrogen receptor alpha ESR1 NA modulator 0.15 drugbank , DGIDB np-50301 NA Disorder of eye[MeSHID:D005128],Eye Infections[MeSHID:D015817],Infection[MeSHID:D007239],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 estrogen receptor ESR1 Successful target unknown NA TTD n-[(1r)-3-(4-hydroxyphenyl)-1-methylpropyl]-2-(2-phenyl-1h-indol-3-yl)acetamide small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational estrogen receptor alpha ESR1 NA unknown NA drugbank (2r,3r,4s)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]chroman-6-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank raloxifene small molecule Osteopenia[MeSHID:D001851],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA agonist 0.19 drugbank , DGIDB 6-(4-hydroxy-phenyl)-1-nitro-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD tseram NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative estrogen receptor ESR1 Successful target unknown NA TTD elacestrant small molecule Malnutrition[MeSHID:D044342],Congenital Abnormality[MeSHID:D000013] investigational estrogen receptor alpha ESR1 NA unknown NA drugbank doxorubicin-formaldehyde conjugate NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(4-hydroxy-phenyl)-1-methoxy-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 5-hydroxy-2-phenylisoindoline-1,3-dione NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD estrone NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB 4,6,7-trimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD bn-cb-045 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] preclinical estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB propylpyrazoletriol NA NA investigative estrogen receptor ESR1 Successful target unknown 0.06 TTD , DGIDB jnj-19398990 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(6-hydroxy-1h-indazol-3-yl)benzene-1,3-diol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 2-(4-hydroxy-phenyl)-7-propyl-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4',5,7-trihydroxy-6,8-dimethylisoflavone NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD clomifene NA Anovulation[MeSHID:D000858],Polycystic Ovary Syndrome[MeSHID:D011085],Female infertility[MeSHID:D007247],Ovulation[MeSHID:D010060],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 1.37 TTD , DGIDB toremifene NA Prostatic Intraepithelial Neoplasias[MeSHID:D019048],Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.72 TTD , DGIDB hexestrol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn estrogen receptor alpha ESR1 NA antagonist 0.63 drugbank , DGIDB way-169916 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD polyestradiol phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved estrogen receptor alpha ESR1 NA agonist 0.32 drugbank , DGIDB arzoxifene small molecule Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA unknown 0.32 drugbank , DGIDB arzoxifene NA Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB 3-hydroxy-8,10-dimethyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD gw7604 NA NA investigative estrogen receptor ESR1 Successful target unknown 0.63 TTD , DGIDB 7-ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD dienestrol NA Vulvar Lichen Sclerosus[MeSHID:D007724],Atrophic Vaginitis[MeSHID:D059268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.54 TTD , DGIDB bn-gu-005-dhp NA Arthralgia[MeSHID:D018771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 4-(2-amino-1-methyl-1h-imidazo[4,5-b]pyridin-6-yl)phenol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank naloxone small molecule Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved,vet_approved estrogen receptor alpha ESR1 NA antagonist, NA drugbank conjugated estrogens b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB sng-163 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative estrogen receptor ESR1 Successful target unknown NA TTD bazedoxifene NA Uterus[MeSHID:D014599],Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteopetrosis[MeSHID:D010022] approved estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB raloxifene NA Osteopenia[MeSHID:D001851],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist,antagonist 0.19 TTD , DGIDB lterhkilhrllqegspsd NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD azd9496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 estrogen receptor ESR1 Successful target unknown 0.63 TTD , DGIDB estrogen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB (9alpha,13beta,17beta)-2-[(1z)-but-1-en-1-yl]estra-1,3,5(10)-triene-3,17-diol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank ap1081 small molecule NA investigational estrogen receptor alpha ESR1 NA unknown NA drugbank 4-(1-butyl-7-chloro-1h-indazol-3-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational estrogen receptor alpha ESR1 NA unknown NA drugbank chf 4227 small molecule Osteoporosis[MeSHID:D010024] investigational estrogen receptor alpha ESR1 NA unknown NA drugbank , DGIDB 4-[(1s,2r,5s)-4,4,8-trimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank estriol small molecule Fetal Tissue[MeSHID:D005333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342],Multiple Sclerosis[MeSHID:D009103] approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist 0.63 drugbank , DGIDB 3-(4-hydroxyphenyl)-7-isobutoxychromen-4-one NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD fulvestrant small molecule Disease Progression[MeSHID:D018450],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA antagonist 0.66 drugbank , DGIDB 3-(2-hydroxy-phenyl)-benzo[d]isoxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational estrogen receptor alpha ESR1 NA unknown 0.02 drugbank , DGIDB estradiol dienanthate small molecule NA approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist NA drugbank 3-ethyl-2-(4-hydroxyphenyl)-2h-indazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD sng-8023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigative estrogen receptor ESR1 Successful target unknown NA TTD bithionol NA Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market estrogen receptor ESR1 Successful target unknown 0.01 TTD , DGIDB 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 6-(4-hydroxy-phenyl)-1-methyl-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(2-phenyl-1h-indol-3-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD gtx-758 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB 2-(4-hydroxy-phenyl)-7-methyl-benzofuran-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD jnj-26529152 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(6-hydroxy-naphthalen-2-yl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD idoxifene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 3 estrogen receptor ESR1 Successful target modulator 0.08 TTD , DGIDB conjugated estrogens small molecule Carcinoma[MeSHID:D002277],Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Vagina[MeSHID:D014621],Neoplasm Metastasis[MeSHID:D009362],Ovarian Failure, Premature[MeSHID:D016649],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor alpha ESR1 NA agonist NA drugbank , DGIDB 4-naphthalen-2-yl-phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD acolbifene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 estrogen receptor ESR1 Successful target modulator 0.32 TTD , DGIDB estradiol valerate NA Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.11 TTD , DGIDB mestranol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.25 TTD , DGIDB permethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532],Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] approved,investigational estrogen receptor alpha ESR1 NA unknown NA drugbank dihydroraloxifene NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD estradiol NA Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.19 TTD , DGIDB 4-[(1s,2s,5s)-5-(hydroxymethyl)-8-methyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank cenestin NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB 6-(2-chloro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(7-methyl-1-propyl-1h-indazol-3-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved estrogen receptor alpha ESR1 NA agonist,inhibitor,downregulator 0.04 drugbank , DGIDB estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist NA drugbank , DGIDB mx-4509 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 estrogen receptor ESR1 Successful target unknown NA TTD 4-hydroxy-n-phenyl-n-propylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD methyl-piperidino-pyrazole NA NA investigative estrogen receptor ESR1 Successful target antagonist NA TTD , DGIDB cyclofenil NA Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.11 TTD , DGIDB coumestrol NA NA investigative estrogen receptor ESR1 Successful target unknown 0.04 TTD , DGIDB 2-phenyl-1,2'-spirobi[1h-indene]-5'-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD ospemifene NA Atrophic[MeSHID:D001284],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Vulva[MeSHID:D014844],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.4 TTD , DGIDB 3-chloro-2-(4-hydroxyphenyl)-2h-indazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD premarin/trimegestone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 4-benzo[d]isoxazol-3-yl-benzene-1,3-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(3-chloro-4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD zn-c5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 estrogen receptor ESR1 Successful target unknown NA TTD ethinyl estradiol NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.26 TTD , DGIDB 4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD r,r-thc NA NA investigative estrogen receptor ESR1 Successful target agonist NA TTD , DGIDB gsk-5182 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD ethynodiol diacetate small molecule Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor alpha ESR1 NA agonist NA drugbank , DGIDB estriol tripropionate small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 3-chloro-2-(4-hydroxyphenyl)-2h-indazol-5-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank d-0502 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 estrogen receptor ESR1 Successful target unknown NA TTD cp-409069 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 8-n-undecylnaringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 7-allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD ospemifene small molecule Atrophic[MeSHID:D001284],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Vulva[MeSHID:D014844],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA antagonist,agonist 0.4 drugbank , DGIDB ospemifene NA Atrophic[MeSHID:D001284],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Vulva[MeSHID:D014844],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target modulator 0.4 TTD , DGIDB 3-ethyl-2-(4-hydroxyphenyl)-2h-indazol-5-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD atd transdermal gel NA Ataxia Telangiectasia[MeSHID:D001260],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB desogestrel small molecule Ovulation[MeSHID:D010060],Pregnancy[MeSHID:D011247],Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor alpha ESR1 NA agonist 0.4 drugbank , DGIDB afimoxifene NA Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] phase 2 estrogen receptor ESR1 Successful target unknown 0.15 TTD , DGIDB mprp NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 3'-methoxy-4'hydroxyclomiphene NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD chf-4227 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB benzophenone small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 2-(3-butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-hydroxy-n,n-diphenylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD estrone small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor alpha ESR1 NA agonist 0.32 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational estrogen receptor alpha ESR1 NA agonist NA drugbank 3-(5-hydroxy-benzooxazol-2-yl)-benzene-1,2-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD afimoxifene NA Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] phase 2 estrogen receptor ESR1 Successful target modulator 0.15 TTD , DGIDB estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist 0.16 drugbank , DGIDB synthetic conjugated estrogens, a small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Vulva[MeSHID:D014844] approved estrogen receptor alpha ESR1 NA ligand NA drugbank ethinyl estradiol NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB custirsen small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigational estrogen receptor alpha ESR1 NA unknown NA drugbank panomifene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 estrogen receptor ESR1 Successful target unknown NA TTD 7-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-ethyl-4,7-dimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 3-(4-hydroxy-phenyl)-benzo[d]isoxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational estrogen receptor alpha ESR1 NA unknown 0.01 drugbank , DGIDB homosalate small molecule Malignant neoplasm of skin[MeSHID:D012878],Sunburn[MeSHID:D013471],Sunscreening Agents[MeSHID:D013473],Skin Aging[MeSHID:D015595] approved,investigational estrogen receptor alpha ESR1 NA unknown NA drugbank endoxifen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 estrogen receptor ESR1 Successful target unknown 0.63 TTD , DGIDB clomiphene citrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 4,10-dimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(3-hydroxy-phenyl)-naphthalen-1-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine small molecule NA investigational estrogen receptor alpha ESR1 NA unknown NA drugbank 6-(3-fluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD beta-naphthoflavone small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank n-ethyl-4-hydroxy-n-phenylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 8-n-pentylnaringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD conjugated estrogens a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational estrogen receptor alpha ESR1 NA binder NA drugbank dienestrol NA Vulvar Lichen Sclerosus[MeSHID:D007724],Atrophic Vaginitis[MeSHID:D059268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.54 TTD , DGIDB 3,8-dihydroxy-7-methyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 7-chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(3-hydroxyphenyl)-1,2'-spirobi[1h-indene]-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD propylpyrazoletriol NA NA investigative estrogen receptor ESR1 Successful target agonist 0.06 TTD , DGIDB mitotane small molecule Tumors of Adrenal Cortex[MeSHID:D000306],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] approved estrogen receptor alpha ESR1 NA unknown 0.08 drugbank , DGIDB 4-benzyl-2,6-diisobutylamino-pyrimidine NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD pyrazole small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank sophoraflavanone b NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-methoxy-benzofuran-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(3-chloro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(4-hydroxy-naphthalen-1-yl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(7-chloro-1-cyclohexyl-1h-indazol-3-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(4-hydroxy-2-methoxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(6-hydroxy-naphthalen-2-yl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD estradiol acetate NA Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB synthetic conjugated estrogens, b small molecule Vagina[MeSHID:D014621],Coitus[MeSHID:D003075],Desiccation[MeSHID:D003890],Atrophic[MeSHID:D001284],Pain[MeSHID:D010146],Vulva[MeSHID:D014844] approved estrogen receptor alpha ESR1 NA ligand,agonist 0.16 drugbank , DGIDB hrt NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 1 estrogen receptor ESR1 Successful target unknown NA TTD 8-(2-methylpropyl)naringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD fosfestrol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB ethinylestradiol small molecule Acne Vulgaris[MeSHID:D000152],Osteoporosis, Postmenopausal[MeSHID:D015663],Premenstrual Dysphoric Disorder[MeSHID:D065446] approved estrogen receptor alpha ESR1 NA agonist 0.26 drugbank , DGIDB 2-(4-hydroxy-phenyl)-4-methoxy-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD premarin/pravachol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 3 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 3-(6-hydroxy-benzooxazol-2-yl)-benzene-1,2-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD org-37663 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD (3as,4r,9br)-2,2-difluoro-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank estetrol small molecule Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] approved,investigational estrogen receptor alpha ESR1 NA agonist,modulator,regulator 0.32 drugbank , DGIDB tamoxifen butyl bromide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD ly3484356 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 estrogen receptor ESR1 Successful target unknown NA TTD way200070 NA NA investigative estrogen receptor ESR1 Successful target agonist NA TTD , DGIDB 4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(7-chloro-1-propyl-1h-indazol-3-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 1,2-bis-(4-hydroxy-phenyl)-3h-inden-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(2,6-difluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD compound 4-d small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank compound 19 small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank n-allyl-4-hydroxy-n-phenylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD (3as,4r,9br)-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 17-methyl-17-alpha-dihydroequilenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD sng-8033 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative estrogen receptor ESR1 Successful target unknown NA TTD 8-(2,2-dimethylpropyl)naringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 7-bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD n-benzyl-4-hydroxy-n-phenylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD chlorotrianisene small molecule Infertility[MeSHID:D007246],Breast[MeSHID:D001940],Hyperemia[MeSHID:D006940],Malignant neoplasm of prostate[MeSHID:D011471],Birth[MeSHID:D036801],Malnutrition[MeSHID:D044342],Ovary[MeSHID:D010053],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,withdrawn estrogen receptor alpha ESR1 NA agonist 0.51 drugbank , DGIDB serm-3339 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 estrogen receptor ESR1 Successful target unknown NA TTD bn-aa-003-ny NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] preclinical estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB bn-od-026 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Familial Osteochondritis Dissecans[MeSHID:C580095],Malignant Neoplasms[MeSHID:D009369] preclinical estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB serms NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative estrogen receptor ESR1 Successful target unknown NA TTD droloxifene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 2 estrogen receptor ESR1 Successful target modulator 0.05 TTD , DGIDB lasofoxifene NA Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Vagina[MeSHID:D014621],Fracture[MeSHID:D050723],Malignant neoplasm of breast[MeSHID:D001943],Risk Reduction[MeSHID:D040242],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844],Virus Diseases[MeSHID:D014777],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.63 TTD , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational estrogen receptor alpha ESR1 NA unknown 0.01 drugbank , DGIDB 1-fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD [1,1':2',1'']terphenyl-4'-carbaldehyde oxime NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2,4-diisobutylamino-6-isopentylpyrimidine NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD esterified estrogens NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 4-(6-hydroxy-1h-indazol-3-yl)benzene-1,3-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD sng-8006 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative estrogen receptor ESR1 Successful target unknown NA TTD h3b-6545 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB diethylstilbestrol NA Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved estrogen receptor ESR1 Successful target unknown 0.15 TTD , DGIDB 8-fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD norethynodrel small molecule NA approved estrogen receptor alpha ESR1 NA unknown NA drugbank chlorotrianisene NA Infertility[MeSHID:D007246],Breast[MeSHID:D001940],Hyperemia[MeSHID:D006940],Malignant neoplasm of prostate[MeSHID:D011471],Birth[MeSHID:D036801],Malnutrition[MeSHID:D044342],Ovary[MeSHID:D010053],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market estrogen receptor ESR1 Successful target unknown 0.51 TTD , DGIDB trans-hydroxytamoxifen NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD toremifene small molecule Prostatic Intraepithelial Neoplasias[MeSHID:D019048],Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of breast[MeSHID:D001943],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA modulator 0.72 drugbank , DGIDB estradiol acetate NA Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target agonist 0.32 TTD , DGIDB fluoroestradiol f-18 small molecule Breast[MeSHID:D001940],Radioactivity[MeSHID:D011851],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Recurrence (disease attribute)[MeSHID:D012008] approved estrogen receptor alpha ESR1 NA binder NA drugbank estetrol NA Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 2 estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB 4-[1-allyl-7-(trifluoromethyl)-1h-indazol-3-yl]benzene-1,3-diol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist NA drugbank afimoxifene small molecule Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] investigational estrogen receptor alpha ESR1 NA unknown 0.15 drugbank , DGIDB diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational estrogen receptor alpha ESR1 NA agonist 0.15 drugbank , DGIDB 7-ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-4-vinyl-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(4-hydroxy-phenyl)-naphthalen-1-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD sco-120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 estrogen receptor ESR1 Successful target unknown NA TTD erteberel small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,investigational estrogen receptor alpha ESR1 NA unknown NA drugbank estriol NA Fetal Tissue[MeSHID:D005333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342],Multiple Sclerosis[MeSHID:D009103] approved estrogen receptor ESR1 Successful target agonist 0.63 TTD , DGIDB 6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD iogen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 3 estrogen receptor ESR1 Successful target unknown NA TTD melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved estrogen receptor alpha ESR1 NA antagonist NA drugbank 3-(4-hydroxy-phenyl)-benzo[d]isoxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD miproxifene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 3 estrogen receptor ESR1 Successful target unknown NA TTD allylestrenol small molecule Premature Obstetric Labor[MeSHID:D007752],Benign Prostatic Hyperplasia[MeSHID:D011470],Spontaneous abortion[MeSHID:D000022] experimental estrogen receptor alpha ESR1 NA agonist NA drugbank tztx-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 3 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB dobutamine small molecule Heart Decompensation[MeSHID:D006333],Heart Diseases[MeSHID:D006331],Depressed Level of Consciousness[MeSHID:D003244],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved estrogen receptor alpha ESR1 NA unknown NA drugbank estrone sulfate small molecule Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Ovarian Failure, Premature[MeSHID:D016649],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844] approved estrogen receptor alpha ESR1 NA agonist NA drugbank clomiphene citrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] approved estrogen receptor ESR1 Successful target modulator 0.32 TTD , DGIDB 6-butyl-2,4-dipropylaminopyrimidine NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD tas-108 small molecule Malignant neoplasm of breast[MeSHID:D001943] investigational estrogen receptor alpha ESR1 NA unknown 0.32 drugbank , DGIDB estriol NA Fetal Tissue[MeSHID:D005333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342],Multiple Sclerosis[MeSHID:D009103] approved estrogen receptor ESR1 Successful target unknown 0.63 TTD , DGIDB estriol e3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigative estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 4-(1-benzyl-7-chloro-1h-indazol-3-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4,6,10-trimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(3-phenyl-1h-indol-2-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD danazol NA Breast Fibrocystic Disease[MeSHID:D005348],Angioedemas, Hereditary[MeSHID:D054179],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menorrhagia[MeSHID:D008595],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor ESR1 Successful target unknown 0.16 TTD , DGIDB 7-(3-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(2,5-difluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(2-phenyl-1h-benzo[d]imidazol-1-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 8-n-propylnaringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(3-chloro-4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD bn-df-037 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB em-800 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 3 estrogen receptor ESR1 Successful target unknown NA TTD 4-bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 6-(3,5-difluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 5-chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-methoxy-6-{(e)-[(4-methylphenyl)imino]methyl}phenol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank (3as,4r,9br)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-9-ol small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank enzacamene small molecule Sunscreening Agents[MeSHID:D013473] approved estrogen receptor alpha ESR1 NA unknown NA drugbank stanolone small molecule NA illicit,investigational estrogen receptor alpha ESR1 NA unknown 0.11 drugbank , DGIDB equilin small molecule Carcinoma[MeSHID:D002277],Ovarian Failure, Premature[MeSHID:D016649],Malignant neoplasm of breast[MeSHID:D001943],Atrophic Vaginitis[MeSHID:D059268],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Osteoporosis[MeSHID:D010024],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental estrogen receptor alpha ESR1 NA unknown NA drugbank methyltestosterone small molecule Mastodynia[MeSHID:D059373],Edema[MeSHID:D004487],Pregnancy[MeSHID:D011247],Malignant neoplasm of breast[MeSHID:D001943],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved estrogen receptor alpha ESR1 NA unknown 0.13 drugbank , DGIDB nafoxidine NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD levonorgestrel small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Patient Discharge[MeSHID:D010351],Coitus[MeSHID:D003075],Menorrhagia[MeSHID:D008595],Endometrial Hyperplasia[MeSHID:D004714],Off-Label Use[MeSHID:D056687],Unmarried[MeSHID:D012847],Osteoporosis[MeSHID:D010024],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA unknown 1.06 drugbank , DGIDB fulvestrant NA Disease Progression[MeSHID:D018450],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.66 TTD , DGIDB jnj-26529126 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4,6,7,10-tetramethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 7-cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4,6,6,7-tetramethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD clomifene small molecule Anovulation[MeSHID:D000858],Polycystic Ovary Syndrome[MeSHID:D011085],Female infertility[MeSHID:D007247],Ovulation[MeSHID:D010060],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA antagonist,agonist 1.37 drugbank , DGIDB dimethyl (1r,4s)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank 8-chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-naphthalen-1-yl-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(2-chloro-4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist 0.11 drugbank , DGIDB ttc-352 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 8-methylnaringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD bazedoxifene small molecule Uterus[MeSHID:D014599],Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteopetrosis[MeSHID:D010022] approved,investigational estrogen receptor alpha ESR1 NA antagonist,agonist 0.32 drugbank , DGIDB estradiol cypionate NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB estropipate NA Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.63 TTD , DGIDB oxybenzone small molecule Sunscreening Agents[MeSHID:D013473] approved,investigational estrogen receptor alpha ESR1 NA unknown NA drugbank acolbifene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB 1-chloro-6-(4-hydroxyphenyl)-2-naphthol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(6-hydroxy-naphthalen-1-yl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD n-cyclohexyl-4-hydroxy-n-phenylbenzenesulfonamide NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational estrogen receptor alpha ESR1 NA cofactor NA drugbank 6-(4-hydroxy-phenyl)-1-phenyl-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD arn-810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 estrogen receptor ESR1 Successful target unknown 0.63 TTD , DGIDB zeranol small molecule NA experimental,vet_approved estrogen receptor alpha ESR1 NA unknown 0.09 drugbank , DGIDB daidzein NA NA investigative estrogen receptor ESR1 Successful target unknown 0.03 TTD , DGIDB mitotane NA Tumors of Adrenal Cortex[MeSHID:D000306],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] approved estrogen receptor ESR1 Successful target unknown 0.08 TTD , DGIDB 2-(3-fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(6-hydroxy-naphthalen-1-yl)-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 8-benzylnaringenin NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD quinestrol NA Hot flushes[MeSHID:D019584],Breast[MeSHID:D001940],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor ESR1 Successful target agonist 0.51 TTD , DGIDB sr-90067 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 2 estrogen receptor ESR1 Successful target unknown NA TTD icaritin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB jnj-17148066 NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn estrogen receptor alpha ESR1 NA unknown NA drugbank cc-8490 NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB 4-(3-(4-hydroxyphenyl)-1h-indol-2-yl)phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD naringenin small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank levormeloxifene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor ESR1 Successful target unknown NA TTD np-50301 small molecule Disorder of eye[MeSHID:D005128],Eye Infections[MeSHID:D015817],Infection[MeSHID:D007239],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational estrogen receptor alpha ESR1 NA unknown NA drugbank hexestrol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market estrogen receptor ESR1 Successful target antagonist 0.63 TTD , DGIDB 4-(6-hydroxy-benzooxazol-2-yl)-benzene-1,3-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD estradiol small molecule Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist 0.19 drugbank , DGIDB 2,4-dibenzylamino-6-isopentylpyrimidine NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD carboron cluster with phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved estrogen receptor alpha ESR1 NA antagonist NA drugbank 4-(6-hydroxy-benzooxazol-2-yl)-benzene-1,2-diol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD hexachlorophene small molecule Disease Outbreaks[MeSHID:D004196],Communicable Diseases[MeSHID:D003141],Infectious disease prevention / control[MeSHID:D017053],Infection[MeSHID:D007239],Surgical Scrubbing[MeSHID:D006235],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn estrogen receptor alpha ESR1 NA unknown 0.02 drugbank , DGIDB 2-(4-hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD quinestrol NA Hot flushes[MeSHID:D019584],Breast[MeSHID:D001940],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved estrogen receptor ESR1 Successful target unknown 0.51 TTD , DGIDB 2-(4-hydroxy-phenyl)benzofuran-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD estramustine small molecule Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational estrogen receptor alpha ESR1 NA agonist NA drugbank 5-chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-(1,2-diphenyl-but-1-enyl)-phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD ttc-352 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 estrogen receptor ESR1 Successful target unknown NA TTD , DGIDB estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor alpha ESR1 NA agonist NA drugbank , DGIDB toremifene small molecule Prostatic Intraepithelial Neoplasias[MeSHID:D019048],Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor alpha ESR1 NA modulator 0.72 drugbank , DGIDB rad-1901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Symmetrical dyschromatosis of extremities[MeSHID:C535729],Malignant neoplasm of breast[MeSHID:D001943] phase 3 estrogen receptor ESR1 Successful target unknown 0.32 TTD , DGIDB g1t-48 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 estrogen receptor ESR1 Successful target unknown NA TTD 4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD 4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD raloxifene NA Osteopenia[MeSHID:D001851],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.19 TTD , DGIDB 6-(2-fluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor ESR1 Successful target unknown NA TTD diethylstilbestrol NA Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved estrogen receptor ESR1 Successful target agonist 0.15 TTD , DGIDB stanolone acetate small molecule NA experimental estrogen receptor alpha ESR1 NA unknown NA drugbank estradiol NA Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.19 TTD , DGIDB tamoxifen NA Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor ESR1 Successful target unknown 0.11 TTD , DGIDB enzacamene small molecule Sunscreening Agents[MeSHID:D013473] approved estrogen receptor beta ESR2 NA unknown NA drugbank raloxifene small molecule Osteopenia[MeSHID:D001851],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor beta ESR2 NA agonist,antagonist 0.37 drugbank , DGIDB 7-bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 8-benzylnaringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD fluoroestradiol f-18 small molecule Breast[MeSHID:D001940],Radioactivity[MeSHID:D011851],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Recurrence (disease attribute)[MeSHID:D012008] approved estrogen receptor beta ESR2 NA binder NA drugbank diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational estrogen receptor beta ESR2 NA agonist 0.09 drugbank , DGIDB 6-(3,5-difluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD hpte NA NA investigative estrogen receptor beta ESR2 Successful target antagonist NA TTD , DGIDB estrogen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor beta ESR2 Successful target unknown 0.92 TTD , DGIDB coumestrol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD erb-257 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] phase 1 estrogen receptor beta ESR2 Successful target unknown NA TTD , DGIDB 8-methylnaringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(4-hydroxy-2-methoxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(3-chloro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD bithionol NA Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market estrogen receptor beta ESR2 Successful target unknown 0.04 TTD , DGIDB conjugated estrogens small molecule Carcinoma[MeSHID:D002277],Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Vagina[MeSHID:D014621],Neoplasm Metastasis[MeSHID:D009362],Ovarian Failure, Premature[MeSHID:D016649],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor beta ESR2 Successful target agonist NA TTD , drugbank , DGIDB 3'-methoxy-4'hydroxyclomiphene NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor beta ESR2 NA agonist NA drugbank 7-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD bazedoxifene small molecule Uterus[MeSHID:D014599],Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteopetrosis[MeSHID:D010022] approved,investigational estrogen receptor beta ESR2 NA unknown 0.69 drugbank , DGIDB mf101 small molecule NA investigational estrogen receptor beta ESR2 NA agonist 2.77 drugbank , DGIDB 4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 8-(2-methylpropyl)naringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3,4,6-trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 5-bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD cp-409069 NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-ethyl-4,7-dimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD benzophenone small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 6-(2,5-difluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD (3as,4r,9br)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 8-chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD gtx-822 NA Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative estrogen receptor beta ESR2 Successful target unknown NA TTD estradiol dienanthate small molecule NA approved,investigational,vet_approved estrogen receptor beta ESR2 NA agonist NA drugbank 4-(6-hydroxy-benzo[d]isoxazol-3-yl)benzene-1,3-diol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 2-(3-hydroxyphenyl)-1,2'-spirobi[1h-indene]-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor beta ESR2 NA antagonist,agonist 0.23 drugbank , DGIDB 2-(3-fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD erteberel small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,investigational,phase 2 estrogen receptor beta ESR2 Successful target unknown 2.77 TTD , drugbank , DGIDB pyrazole small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank premarin/pravachol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 3 estrogen receptor beta ESR2 Successful target unknown NA TTD , DGIDB 3-hydroxy-4,7-dimethyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 5,7-dihydroxy-3-phenyl-3h-quinazolin-4-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3,6-dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 5-chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(3-butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD tupichinol c NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD doxorubicin-formaldehyde conjugate NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD afimoxifene small molecule Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] investigational estrogen receptor beta ESR2 NA modulator 0.14 drugbank , DGIDB 4-benzo[d]isoxazol-3-yl-benzene-1,3-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-hydroxy-8,10-dimethyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD ndc-1022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 8-n-nonylnaringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4,6,10-trimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD broussonin a NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-(5-hydroxy-benzooxazol-2-yl)-benzene-1,2-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4,10-dimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 1-bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD daidzein NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(2-fluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2,3-diphenyl-1h-indole NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 1-chloro-6-(4-hydroxyphenyl)-2-naphthol small molecule NA experimental,investigative estrogen receptor beta ESR2 Successful target unknown NA TTD , drugbank eugenol small molecule Dental caries[MeSHID:D003731],Toothache[MeSHID:D014098] approved estrogen receptor beta ESR2 NA unknown NA drugbank cp-394531 NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 7-chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-(6-hydroxy-benzooxazol-2-yl)-benzene-1,3-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-methoxy-benzofuran-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD bazedoxifene small molecule Uterus[MeSHID:D014599],Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteopetrosis[MeSHID:D010022] approved,investigational estrogen receptor beta ESR2 NA antagonist 0.69 drugbank , DGIDB 4-naphthalen-2-yl-phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD dihydroraloxifene NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD octocrylene small molecule Evaluation[MeSHID:None] approved,investigational estrogen receptor beta ESR2 NA unknown NA drugbank 4-(3-phenyl-1h-indol-2-yl)phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(4-hydroxy-phenyl)-1-methyl-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 8-n-undecylnaringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-(5-hydroxy-benzooxazol-2-yl)-benzene-1,3-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD thiogenistein NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD erteberel small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,investigational,phase 2 estrogen receptor beta ESR2 Successful target agonist 2.77 TTD , drugbank , DGIDB 3,8-dihydroxy-7-methyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD raloxifene small molecule Osteopenia[MeSHID:D001851],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor beta ESR2 NA agonist 0.37 drugbank , DGIDB estriol tripropionate small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank geldanamycin-estradiol hybrid NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 7-(3-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(6-hydroxy-naphthalen-1-yl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD em-800 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 3 estrogen receptor beta ESR2 Successful target unknown NA TTD progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved estrogen receptor beta ESR2 NA agonist,downregulator NA drugbank 5-alpha-androstane-3-beta,17beta-diol small molecule NA experimental estrogen receptor beta ESR2 NA agonist NA drugbank 2-(3-fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD phthalic acid small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank para-mercury-benzenesulfonic acid small molecule NA experimental,investigative estrogen receptor beta ESR2 Successful target unknown NA TTD , drugbank 2-(4-hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(6-hydroxy-naphthalen-2-yl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD way-169916 NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD hexestrol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market estrogen receptor beta ESR2 Successful target unknown NA TTD 4-(4-hydroxyphenyl)-1-naphthaldehyde oxime small molecule NA experimental,investigative estrogen receptor beta ESR2 Successful target unknown NA TTD , drugbank 3-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1h-inden-1-one small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank acetate ion NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD arzoxifene small molecule Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor beta ESR2 Successful target unknown 0.46 TTD , drugbank , DGIDB 6-(4-hydroxy-2-methyl-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD vg-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 estrogen receptor beta ESR2 Successful target unknown NA TTD , DGIDB 2-(5-hydroxy-naphthalen-1-yl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-(6-hydroxy-benzooxazol-2-yl)-benzene-1,2-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD (3as,4r,9br)-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 7-ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD gtx-878 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(5-hydroxy-naphthalen-1-yl)-1,3-benzooxazol-6-ol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 1,2-bis-(4-hydroxy-phenyl)-3h-inden-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-methoxy-6-{(e)-[(4-methylphenyl)imino]methyl}phenol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 2-(3-chloro-4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 7-butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-hydroxy-4,10-dimethyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4,6,7,10-tetramethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD chf 4227 small molecule Osteoporosis[MeSHID:D010024] investigational estrogen receptor beta ESR2 NA unknown NA drugbank , DGIDB mf-101 NA Myotonia Fluctuans (disorder)[MeSHID:D020967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 estrogen receptor beta ESR2 Successful target unknown 2.77 TTD , DGIDB he2100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] discontinued in phase 1 estrogen receptor beta ESR2 Successful target unknown NA TTD kb-9520 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-(2-phenyl-1h-benzo[d]imidazol-1-yl)phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-(2-phenyl-1h-indol-3-yl)phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD naringenin small molecule NA experimental,phase 1 estrogen receptor beta ESR2 Successful target partial agonist 0.23 TTD , drugbank , DGIDB aus-131 NA Hot flushes[MeSHID:D019584],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 estrogen receptor beta ESR2 Successful target unknown 4.61 TTD , DGIDB 1,8-dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-(4-hydroxy-phenyl)-benzo[d]isoxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved estrogen receptor beta ESR2 NA agonist,downregulator NA drugbank 4-chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 1-fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD nafoxidine NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-phenyl-1,2'-spirobi[1h-indene]-5'-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 7-phenyl-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD phtpp NA NA investigative estrogen receptor beta ESR2 Successful target antagonist NA TTD , DGIDB prinaberel small molecule NA investigational estrogen receptor beta ESR2 NA agonist 1.84 drugbank , DGIDB trilostane small molecule Cushing Syndrome[MeSHID:D003480],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational,vet_approved,withdrawn estrogen receptor beta ESR2 Successful target allosteric modulator 0.61 TTD , drugbank , DGIDB lasofoxifene small molecule Disease[MeSHID:D004194],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Vagina[MeSHID:D014621],Fracture[MeSHID:D050723],Malignant neoplasm of breast[MeSHID:D001943],Risk Reduction[MeSHID:D040242],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844],Virus Diseases[MeSHID:D014777],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational estrogen receptor beta ESR2 NA agonist 0.92 drugbank , DGIDB bisphenol a NA NA investigative estrogen receptor beta ESR2 Successful target agonist NA TTD , DGIDB 2-(4-hydroxy-phenyl)-1-p-tolyl-3h-inden-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(3-fluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 8-n-pentylnaringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-(3-(4-hydroxyphenyl)-1h-indol-2-yl)phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2/3 estrogen receptor beta ESR2 Successful target unknown 0.09 TTD , drugbank , DGIDB erb-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)benzofuran-5-ol small molecule NA experimental,investigative estrogen receptor beta ESR2 Successful target unknown NA TTD , drugbank 3-(4-hydroxy-phenyl)-4h-chromen-7-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 8-fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD way200070 NA NA investigative estrogen receptor beta ESR2 Successful target agonist NA TTD , DGIDB 6-(4-hydroxy-phenyl)-1-nitro-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 5-chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD estetrol small molecule Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] approved,investigational estrogen receptor beta ESR2 NA agonist NA drugbank estramustine small molecule Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational estrogen receptor beta ESR2 NA unknown NA drugbank estriol small molecule Fetal Tissue[MeSHID:D005333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342],Multiple Sclerosis[MeSHID:D009103] approved,investigational,vet_approved estrogen receptor beta ESR2 NA agonist 0.61 drugbank , DGIDB 6-(3-hydroxy-phenyl)-naphthalen-1-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD oxybenzone small molecule Sunscreening Agents[MeSHID:D013473] approved,investigational estrogen receptor beta ESR2 NA unknown NA drugbank 2-(4-hydroxyphenyl)-1,2'-spirobi[1h-indene]-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-chloro-4-(4-hydroxyphenyl)salicylaldoxime NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-4-methoxy-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(4-hydroxy-phenyl)-naphthalen-1-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD [1,1':2',1'']terphenyl-4'-carbaldehyde oxime NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD estradiol small molecule Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor beta ESR2 NA agonist 0.31 drugbank , DGIDB estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor beta ESR2 NA agonist NA drugbank 8-n-heptylnaringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD effusol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD sophoraflavanone b NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD zk-164015 NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4,6,7-trimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 17alpha-estriol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational estrogen receptor beta ESR2 NA unknown NA drugbank 2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD erb-196 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] experimental,discontinued in phase 1 estrogen receptor beta ESR2 Successful target unknown NA TTD , drugbank 6-(4-hydroxy-phenyl)-1-methoxy-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(6-hydroxy-naphthalen-1-yl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD (3as,4r,9br)-2,2-difluoro-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 2-(3-chloro-4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-propyl-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-phenyl-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-(4-hydroxy-phenyl)-benzo[d]isoxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(2-chloro-4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 8-(3-methylbutyl)naringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4,6,6,7-tetramethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD estrone sulfate small molecule Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Ovarian Failure, Premature[MeSHID:D016649],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Vulva[MeSHID:D014844] approved estrogen receptor beta ESR2 NA agonist NA drugbank 6-(2,6-difluoro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD diarylpropionitril NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(6-hydroxy-naphthalen-2-yl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-(6-hydroxy-benzooxazol-2-yl)-benzene-1,2-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4',5,7-trihydroxy-6,8-dimethylisoflavone NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD mf101 small molecule NA investigational estrogen receptor beta ESR2 NA unknown 2.77 drugbank , DGIDB 3,8-dihydroxy-4-methyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-naphthalen-1-yl)-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 7-allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2/3 estrogen receptor beta ESR2 Successful target agonist 0.09 TTD , drugbank , DGIDB trans-hydroxytamoxifen NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-(2-{[4-{[3-(4-chlorophenyl)propyl]sulfanyl}-6-(1-piperazinyl)-1,3,5-triazin-2-yl]amino}ethyl)phenol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank era-923 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 2 estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(2-chloro-4-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD morin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD estradiol benzoate small molecule NA approved,investigational,vet_approved estrogen receptor beta ESR2 NA agonist NA drugbank r,r-thc NA NA investigative estrogen receptor beta ESR2 Successful target antagonist NA TTD , DGIDB 5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-carbonitrile small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 7-ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-7-methyl-benzofuran-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 8-(2,2-dimethylpropyl)naringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-4-vinyl-quinolin-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical estrogen receptor beta ESR2 NA activator NA drugbank 2-(3-hydroxyphenyl)-1,2'-spirobi[1h-indene]-5-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD equol small molecule NA investigational estrogen receptor beta ESR2 NA agonist 4.61 drugbank , DGIDB 3-hydroxy-4-methyl-6h-benzo[c]chromen-6-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-(6-hydroxy-naphthalen-2-yl)-benzo[d]isooxazol-6-ol small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank tas-108 small molecule Malignant neoplasm of breast[MeSHID:D001943] investigational estrogen receptor beta ESR2 NA unknown 0.46 drugbank , DGIDB 4,7-dimethyl-6h-benzo[c]chromene-3,8-diol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD erb-041 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 estrogen receptor beta ESR2 Successful target unknown 1.84 TTD , DGIDB 8-n-propylnaringenin NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 3-(2-hydroxy-phenyl)-benzo[d]isoxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD estrone small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen receptor beta ESR2 NA agonist 0.31 drugbank , DGIDB 4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 7-hydroxy-3-(4-hydroxyphenyl)-3h-quinazolin-4-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 6-(3-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen receptor beta ESR2 NA agonist NA drugbank 6-(2-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD 7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD gnf-pf-3037 NA NA investigative estrogen receptor beta ESR2 Successful target unknown 0.08 TTD , DGIDB 2-naphthalen-1-yl-benzooxazol-6-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD ici-164384 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Malignant neoplasm of breast[MeSHID:D001943],Expiration, function[MeSHID:D045853] experimental,terminated estrogen receptor beta ESR2 Successful target unknown 2.31 TTD , drugbank , DGIDB [5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]acetonitrile small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank 6-(4-hydroxy-phenyl)-1-phenyl-naphthalen-2-ol NA NA investigative estrogen receptor beta ESR2 Successful target unknown NA TTD (9as)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3h-fluoren-3-one small molecule NA experimental estrogen receptor beta ESR2 NA unknown NA drugbank dexamethasone palmitate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Choroidal Neovascularization[MeSHID:D020256] phase 1/2 estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD , DGIDB 7-ethyl-6h-chromeno[4,3-b]quinoline-3,9-diol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD biochanin a NA NA investigative estrogen-related receptor-alpha ESRRA Successful target agonist NA TTD , DGIDB gw-250495 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD rofleponide NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD 4-ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD rimexolone NA Vision[MeSHID:D014785],Operative Surgical Procedures[MeSHID:D013514],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Anterior uveitis[MeSHID:D014606],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved estrogen-related receptor-alpha ESRRA Successful target unknown 1.82 TTD , DGIDB daidzein NA NA investigative estrogen-related receptor-alpha ESRRA Successful target agonist 0.4 TTD , DGIDB 4-bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD chlordane NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD pregnenolone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 4 estrogen-related receptor-alpha ESRRA Successful target unknown 4.55 TTD , DGIDB genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational steroid hormone receptor err1 ESRRA NA agonist 0.51 drugbank , DGIDB 7-ethynyl-6h-chromeno[4,3-b]quinoline-3,9-diol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD 7-chloro-6h-chromeno[4,3-b]quinoline-3,9-diol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD tdt-044 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD pmid17556356c1a NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD 4-ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD flavone small molecule NA approved,experimental steroid hormone receptor err1 ESRRA NA agonist NA drugbank 4-chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-4-vinyl-quinolin-6-ol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD 7-vinyl-6h-chromeno[4,3-b]quinoline-3,9-diol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn steroid hormone receptor err1 ESRRA NA inverse agonist NA drugbank 1-cyclohexyl-n-{[1-(4-methylphenyl)-1h-indol-3-yl]methyl}methanamine small molecule NA experimental steroid hormone receptor err1 ESRRA NA unknown NA drugbank rpr-106541 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD 7-bromo-6h-chromeno[4,3-b]quinoline-3,9-diol NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD ad-121 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1/2 estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD ncx-1047 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational steroid hormone receptor err1 ESRRA NA unknown NA drugbank d-5519 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD , DGIDB beta-naphthoflavone small molecule NA experimental steroid hormone receptor err1 ESRRA NA unknown NA drugbank xct790 NA NA investigative estrogen-related receptor-alpha ESRRA Successful target antagonist 1.14 TTD , DGIDB toxaphene NA NA investigative estrogen-related receptor-alpha ESRRA Successful target unknown NA TTD afimoxifene small molecule Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] investigational steroid hormone receptor err1 ESRRA NA inhibitor NA drugbank flavone small molecule NA approved,experimental steroid hormone receptor err2 ESRRB NA agonist NA drugbank diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational steroid hormone receptor err2 ESRRB NA antagonist 2.83 drugbank , DGIDB diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational steroid hormone receptor err2 ESRRB NA unknown 2.83 drugbank , DGIDB genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational steroid hormone receptor err2 ESRRB NA agonist 0.79 drugbank , DGIDB cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen-related receptor gamma ESRRG NA unknown NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved estrogen-related receptor gamma ESRRG NA ligand NA drugbank bisphenol a small molecule NA experimental estrogen-related receptor gamma ESRRG NA unknown NA drugbank diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational estrogen-related receptor gamma ESRRG NA agonist,antagonist 1.82 drugbank , DGIDB tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen-related receptor gamma ESRRG NA unknown NA drugbank bisphenol z small molecule NA experimental estrogen-related receptor gamma ESRRG NA unknown NA drugbank p-cumylphenol small molecule NA experimental estrogen-related receptor gamma ESRRG NA unknown NA drugbank estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen-related receptor gamma ESRRG NA ligand NA drugbank estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen-related receptor gamma ESRRG NA ligand NA drugbank estradiol dienanthate small molecule NA approved,investigational,vet_approved estrogen-related receptor gamma ESRRG NA ligand NA drugbank 4-hydroxy-n'-(4-isopropylbenzyl)benzohydrazide small molecule NA experimental estrogen-related receptor gamma ESRRG NA unknown NA drugbank troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn estrogen-related receptor gamma ESRRG NA inverse agonist NA drugbank diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational estrogen-related receptor gamma ESRRG NA agonist 1.82 drugbank , DGIDB estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estrogen-related receptor gamma ESRRG NA ligand NA drugbank afimoxifene small molecule Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] investigational estrogen-related receptor gamma ESRRG NA antagonist 1.4 drugbank , DGIDB metformin small molecule Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial ETFDH NA inhibitor NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial ETFDH NA unknown NA drugbank metformin small molecule Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial ETFDH NA inhibitor NA drugbank tk216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ewings sarcoma[MeSHID:D012512] phase 1 protein c-ets-2 ETS2 Clinical trial target unknown NA TTD , DGIDB uridine-5'-diphosphate small molecule NA experimental exostosin-like 2 EXTL2 NA unknown NA drugbank uridine-diphosphate-n-acetylglucosamine small molecule NA experimental exostosin-like 2 EXTL2 NA unknown NA drugbank uridine-diphosphate-n-acetylgalactosamine small molecule NA experimental exostosin-like 2 EXTL2 NA unknown NA drugbank ds-3201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 enhancer of zeste homolog 1 EZH1 Clinical trial target unknown NA TTD , DGIDB tazemetostat small molecule Sarcoma, Epithelioid[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rhabdoid Tumor[MeSHID:D018335],Malignant Neoplasms[MeSHID:D009369],synovial sarcoma[MeSHID:D013584],Central Nervous System Neoplasms[MeSHID:D016543],Lymphoma, Follicular[MeSHID:D008224],Mesothelioma[MeSHID:D008654] approved,investigational histone-lysine n-methyltransferase ezh1 EZH1 NA inhibitor NA drugbank ds-3201b NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458], Myelocytic, Acute[MeSHID:D015470],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Renal Cell Carcinoma[MeSHID:D002292],Small cell carcinoma of lung[MeSHID:D055752] phase 2 enhancer of zeste homolog 1 EZH1 Clinical trial target unknown NA TTD gsk343 NA NA investigative enhancer of zeste homolog 1 EZH1 Clinical trial target inhibitor NA TTD , DGIDB hh2853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1 enhancer of zeste homolog 1 EZH1 Clinical trial target unknown NA TTD pmid28394193-compound-33 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-31 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB unc1999 NA NA investigative enhancer of zeste homolog 2 EZH2 Successful target inhibitor NA TTD , DGIDB pmid28394193-compound-20 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-50 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-24 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB gsk343 NA NA investigative enhancer of zeste homolog 2 EZH2 Successful target inhibitor NA TTD , DGIDB tazemetostat small molecule Sarcoma, Epithelioid[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rhabdoid Tumor[MeSHID:D018335],Malignant Neoplasms[MeSHID:D009369],synovial sarcoma[MeSHID:D013584],Central Nervous System Neoplasms[MeSHID:D016543],Lymphoma, Follicular[MeSHID:D008224],Mesothelioma[MeSHID:D008654] approved,investigational histone-lysine n-methyltransferase ezh2 EZH2 NA inhibitor 14.32 drugbank , DGIDB pmid28394193-compound-46 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-figure5aviii NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-28 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB tazemetostat NA Sarcoma, Epithelioid[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rhabdoid Tumor[MeSHID:D018335],Malignant Neoplasms[MeSHID:D009369],synovial sarcoma[MeSHID:D013584],Central Nervous System Neoplasms[MeSHID:D016543],Lymphoma, Follicular[MeSHID:D008224],Mesothelioma[MeSHID:D008654] approved enhancer of zeste homolog 2 EZH2 Successful target inhibitor 14.32 TTD , DGIDB pmid28394193-compound-45 NA NA patented ezh2 y641n mutant EZH2 Patented-recorded target unknown NA TTD , DGIDB pmid28394193-compound-15 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-49 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-56 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-16 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB gsk343 NA NA investigative enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-39 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-36 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-22 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-figure3biii NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-11 NA NA patented ezh2 y641f mutant EZH2 Patented-recorded target unknown NA TTD pmid28394193-compound-14 NA NA patented ezh2 y641f mutant EZH2 Patented-recorded target unknown NA TTD , DGIDB gsk2816126 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-figure3bi NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB epz005687 NA NA investigative enhancer of zeste homolog 2 EZH2 Successful target inhibitor NA TTD , DGIDB tazemetostat NA Sarcoma, Epithelioid[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rhabdoid Tumor[MeSHID:D018335],Malignant Neoplasms[MeSHID:D009369],synovial sarcoma[MeSHID:D013584],Central Nervous System Neoplasms[MeSHID:D016543],Lymphoma, Follicular[MeSHID:D008224],Mesothelioma[MeSHID:D008654] approved enhancer of zeste homolog 2 EZH2 Successful target unknown 14.32 TTD , DGIDB pmid28394193-compound-14 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB epz005687 NA NA investigative enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB hh2853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1 enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD pmid28394193-compound-37 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-35 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-56 NA NA patented ezh2 y641n mutant EZH2 Patented-recorded target unknown NA TTD , DGIDB cpi-0209 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD pf-06821497 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant neoplasm of prostate[MeSHID:D011471],Lymphoma, Follicular[MeSHID:D008224],Small cell carcinoma of lung[MeSHID:D055752] phase 1 enhancer of zeste homolog 2 EZH2 Successful target inhibitor 7.96 TTD , DGIDB pmid28394193-compound-13 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB cpi-1205 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 enhancer of zeste homolog 2 EZH2 Successful target unknown 23.87 TTD , DGIDB pmid28394193-compound-53 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB ds-3201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-18 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB cpi-1205 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 enhancer of zeste homolog 2 EZH2 Successful target inhibitor 23.87 TTD , DGIDB pmid28394193-compound-42 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-25 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-10 NA NA patented ezh2 y641f mutant EZH2 Patented-recorded target unknown NA TTD pmid28394193-compound-45 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-29 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-40 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-12 NA NA patented ezh2 y641f mutant EZH2 Patented-recorded target unknown NA TTD , DGIDB pmid28394193-compound-12 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-21 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB cpi-1205 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Malignant neoplasm of prostate[MeSHID:D011471] investigational histone-lysine n-methyltransferase ezh2 EZH2 NA inhibitor 23.87 drugbank , DGIDB ds-3201b NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458], Myelocytic, Acute[MeSHID:D015470],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Renal Cell Carcinoma[MeSHID:D002292],Small cell carcinoma of lung[MeSHID:D055752] phase 2 enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD pmid28394193-compound-32 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-57 NA NA patented ezh2 y641n mutant EZH2 Patented-recorded target unknown NA TTD , DGIDB pmid28394193-compound-13 NA NA patented ezh2 y641f mutant EZH2 Patented-recorded target unknown NA TTD , DGIDB pmid28394193-compound-55 NA NA patented ezh2 y641n mutant EZH2 Patented-recorded target unknown NA TTD , DGIDB pmid28394193-compound-17 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-46 NA NA patented ezh2 y641n mutant EZH2 Patented-recorded target unknown NA TTD , DGIDB pmid26882240-compound-1 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-figure3bii NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-27 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-52 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB shr2554 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymph[MeSHID:D008196],Malignant neoplasm of prostate[MeSHID:D011471],Hematopoietic Neoplasms[MeSHID:D019337] phase 1/2 enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD pmid28394193-compound-41 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB ei1 NA NA investigative enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-51 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-19 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-30 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-34 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB ei1 NA NA investigative enhancer of zeste homolog 2 EZH2 Successful target inhibitor NA TTD , DGIDB pmid28394193-compound-38 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-44 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB ms1943 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigative enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD pmid28394193-compound-57 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-47 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-26 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-43 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-54 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB unc1999 NA NA investigative enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-55 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB pmid28394193-compound-23 NA NA patented enhancer of zeste homolog 2 EZH2 Successful target unknown NA TTD , DGIDB gw-813893 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] experimental coagulation factor x F10 NA unknown NA drugbank , DGIDB tellimagrandin ii NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD 1,2,3,4,6-penta-o-galloyl-beta-d-glucose NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD rivaroxaban NA Coronary Arteriosclerosis[MeSHID:D003324],Congenital Disorders[MeSHID:D009358],Renal Insufficiency[MeSHID:D051437],Peripheral Arterial Diseases[MeSHID:D058729],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Birth[MeSHID:D036801],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xa F10 Successful target unknown 8.68 TTD , DGIDB du-176b NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xa F10 Successful target unknown 5.79 TTD , DGIDB sr-123781a NA Cardiovascular Diseases[MeSHID:D002318],Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Venous Thrombosis[MeSHID:D020246] phase 2/3 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational coagulation factor x F10 NA unknown NA drugbank 3-chlorophenyl 2-oxo-2h-chromene-3-carboxylate NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD pedunculagin NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD casuariin NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD 5-chloro-n-(2-(4-(2-oxopyridin-1(2h)-yl)benzamido)ethyl)thiophene-2-carboxamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor x F10 NA activator NA drugbank apixaban NA Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Bone structure of ischium[MeSHID:D007512],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Hip structure[MeSHID:D006615],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved coagulation factor xa F10 Successful target unknown 5.79 TTD , DGIDB dx-9065 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] discontinued in phase 2 coagulation factor xa F10 Successful target unknown NA TTD recombinant factor x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] investigative coagulation factor xa F10 Successful target unknown NA TTD bi-11634 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB apixaban NA Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Bone structure of ischium[MeSHID:D007512],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Hip structure[MeSHID:D006615],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved coagulation factor xa F10 Successful target inhibitor 5.79 TTD , DGIDB turoctocog alfa biotech Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hemorrhagic Disorders[MeSHID:D006474],Blood Platelets[MeSHID:D001792],Hemophilia A[MeSHID:D006467],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Intrinsic drive[MeSHID:D004328],Malnutrition[MeSHID:D044342],X Chromosome[MeSHID:D014960],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational coagulation factor x F10 NA activator NA drugbank zk-813039 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD phso2-gly-(me-gly)-arg-(2-thiazole) NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD nonacog beta pegol biotech Disease Management[MeSHID:D019468],Hemophilia B[MeSHID:D002836],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Malnutrition[MeSHID:D044342],Wound Healing[MeSHID:D014945] approved,investigational coagulation factor x F10 NA agonist NA drugbank fondaparinux small molecule Hip Fractures[MeSHID:D006620],Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Thrombosis[MeSHID:D013927],Cessation of life[MeSHID:D003643],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Myocardium[MeSHID:D009206],Knee[MeSHID:D007717],Myocardial Infarction[MeSHID:D009203] approved,investigational coagulation factor x F10 NA inhibitor NA drugbank betrixaban NA Disease[MeSHID:D004194],Venous Thromboembolism[MeSHID:D054556],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xa F10 Successful target unknown 23.15 TTD , DGIDB 5-chloro-n-{(3s)-1-[(2s)-1-(4-morpholinyl)-1-oxo-2-propanyl]-2-oxo-3-pyrrolidinyl}-1h-indole-2-sulfonamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank 5-chloro-thiophene-2-carboxylic acid ((3s,4s)-4-fluoro- 1-{[2-fluoro-4-(2-oxo-2h-pyridin-1-yl)-phenylcarbamoyl]-methyl}-pyrrolidin-3-yl)-amide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank gamma-carboxy-glutamic acid NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD gamma-carboxy-l-glutamic acid small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank emicizumab NA Serum[MeSHID:D044967],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Blood Coagulation Disorders[MeSHID:D001778],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] approved coagulation factor xa F10 Successful target antibody 10.13 TTD , DGIDB anti-inhibitor coagulant complex biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor x F10 NA agonist NA drugbank ave-3247 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 coagulation factor xa F10 Successful target unknown NA TTD prt-064445 NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative coagulation factor xa F10 Successful target unknown NA TTD 6-chloro-n-{(3s)-1-[(1s)-1-methyl-2-(4-morpholinyl)-2-oxo ethyl]-2-oxo-3-pyrrolidinyl}-2-naphthalenesulfonamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank coagulation factor ix human biotech Plasma[MeSHID:D010949],Operative Surgical Procedures[MeSHID:D013514],Hemophilia B[MeSHID:D002836],Hemorrhage[MeSHID:D006470] approved coagulation factor x F10 NA activator NA drugbank bms-740808 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD 4-[(5-chloroindol-2-yl)sulfonyl]-2-(2-methylpropyl)-1-[[5-(pyridin-4-yl)pyrimidin-2-yl]carbonyl]piperazine small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank otamixaban small molecule Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] investigational coagulation factor x F10 NA inhibitor 11.57 drugbank , DGIDB darexaban maleate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] discontinued in phase 3 coagulation factor xa F10 Successful target unknown NA TTD eribaxaban small molecule NA experimental coagulation factor x F10 NA inhibitor 5.79 drugbank , DGIDB antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor x F10 NA activator NA drugbank turoctocog alfa pegol biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved coagulation factor x F10 NA activator NA drugbank rivaroxaban small molecule Coronary Arteriosclerosis[MeSHID:D003324],Congenital Disorders[MeSHID:D009358],Renal Insufficiency[MeSHID:D051437],Peripheral Arterial Diseases[MeSHID:D058729],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Birth[MeSHID:D036801],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor x F10 NA antagonist 8.68 drugbank , DGIDB nadroparin calcium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved coagulation factor xa F10 Successful target unknown NA TTD , DGIDB enoxaparin small molecule Hospitalization[MeSHID:D006760],ambulatory care services[MeSHID:D000553],Deep Vein Thrombosis[MeSHID:D020246],Patient Care Management[MeSHID:D010346],Angina, Unstable[MeSHID:D000789],Operative Surgical Procedures[MeSHID:D013514],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655] approved coagulation factor x F10 NA inhibitor NA drugbank rivaroxaban small molecule Coronary Arteriosclerosis[MeSHID:D003324],Congenital Disorders[MeSHID:D009358],Renal Insufficiency[MeSHID:D051437],Peripheral Arterial Diseases[MeSHID:D058729],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Birth[MeSHID:D036801],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor x F10 NA antagonist,inhibitor 8.68 drugbank , DGIDB rivaroxaban NA Coronary Arteriosclerosis[MeSHID:D003324],Congenital Disorders[MeSHID:D009358],Renal Insufficiency[MeSHID:D051437],Peripheral Arterial Diseases[MeSHID:D058729],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Birth[MeSHID:D036801],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xa F10 Successful target inhibitor 8.68 TTD , DGIDB n-((1r,2r)-2-(5-chloro-1h-indole-2-carboxamido)cyclohexyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank otamixaban small molecule Thrombosis[MeSHID:D013927],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational coagulation factor x F10 NA unknown 11.57 drugbank , DGIDB idraparinux NA Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 coagulation factor xa F10 Successful target unknown 2.89 TTD , DGIDB 1-[[(1e)-2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]piperazine small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank human coagulation factor x NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] bla submitted coagulation factor xa F10 Successful target unknown NA TTD , DGIDB razaxaban NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD zd-4927 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 coagulation factor xa F10 Successful target unknown NA TTD 5-chloro-n-((1r,2s)-2-(4-(2-oxopyridin-1(2h)-yl)benzamido) cyclopentyl)thiophene-2-carboxamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank albutrepenonacog alfa biotech Blood coagulation[MeSHID:D001777],Hemophilia B[MeSHID:D002836],Blood Coagulation Disorders[MeSHID:D001778],Operative Surgical Procedures[MeSHID:D013514],Mutation[MeSHID:D009154],Hemarthrosis[MeSHID:D006395],Neoplasm Metastasis[MeSHID:D009362],Hemophilia A[MeSHID:D006467],Traumatic injury[MeSHID:D014947],Plasma[MeSHID:D010949],Hemorrhage[MeSHID:D006470],Muscle[MeSHID:D009132],Phenotype[MeSHID:D010641] approved coagulation factor x F10 NA activator NA drugbank otamixaban NA Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 3 coagulation factor xa F10 Successful target unknown 11.57 TTD , DGIDB ci-1031 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD antistasin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 2 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB otamixaban NA Thrombosis[MeSHID:D013927],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 coagulation factor xa F10 Successful target inhibitor 11.57 TTD , DGIDB rivaroxaban small molecule Coronary Arteriosclerosis[MeSHID:D003324],Congenital Disorders[MeSHID:D009358],Renal Insufficiency[MeSHID:D051437],Peripheral Arterial Diseases[MeSHID:D058729],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Birth[MeSHID:D036801],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor x F10 NA antagonist,inhibitor 8.68 drugbank , DGIDB ym-96765 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD 5-chloro-n-{(3s)-1-[(1s)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank zk-810388 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD lefaxin NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD 5-chloro-n-[(3r)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2h)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank ep-37 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative coagulation factor xa F10 Successful target unknown NA TTD rivaroxaban small molecule Coronary Arteriosclerosis[MeSHID:D003324],Congenital Disorders[MeSHID:D009358],Renal Insufficiency[MeSHID:D051437],Peripheral Arterial Diseases[MeSHID:D058729],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Birth[MeSHID:D036801],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor x F10 NA antagonist 8.68 drugbank , DGIDB n-(1-isopropylpiperidin-4-yl)-1-(3-methoxybenzyl)-1h-indole-2-carboxamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank antihemophilic factor human biotech Blood coagulation[MeSHID:D001777],Maintenance[MeSHID:D008283],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemophilia A[MeSHID:D006467],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Recurrence (disease attribute)[MeSHID:D012008] approved coagulation factor x F10 NA activator NA drugbank kappadione small molecule Metabolism[MeSHID:D008660],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Hemorrhagic Disease of Newborn[MeSHID:D006475],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved coagulation factor x F10 NA agonist NA drugbank molecule 11 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD 5-desgalloylstachyurin NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD emicizumab biotech Serum[MeSHID:D044967],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Blood Coagulation Disorders[MeSHID:D001778],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] approved,investigational coagulation factor x F10 NA activator 10.13 drugbank , DGIDB rnapc2 biotech Coronary Arteriosclerosis[MeSHID:D003324],Veins[MeSHID:D014680],Thrombosis[MeSHID:D013927],Coronary heart disease[MeSHID:D003327],Angina Pectoris[MeSHID:D000787],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational coagulation factor x F10 NA unknown NA drugbank 4-({4-[(6-chloro-1-benzothien-2-yl)sulfonyl]-2-oxopiperazin-1-yl}methyl)benzenecarboximidamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank coagulation factor ix NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] approved coagulation factor xa F10 Successful target unknown NA TTD , DGIDB bemiparin small molecule Blood coagulation[MeSHID:D001777],Veins[MeSHID:D014680],Thrombus[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Thromboembolism[MeSHID:D013923],Recurrence (disease attribute)[MeSHID:D012008] approved,investigational coagulation factor x F10 NA antagonist NA drugbank d-pro-phe-arg chloromethyl ketone NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational coagulation factor x F10 NA inhibitor 0.6 drugbank , DGIDB sc-83157 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD sn429 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] investigative coagulation factor xa F10 Successful target unknown NA TTD melagatran NA NA phase 3 coagulation factor xa F10 Successful target unknown 0.48 TTD , DGIDB nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Disease[MeSHID:D004194] investigational coagulation factor x F10 NA inhibitor NA drugbank dpc 423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 coagulation factor xa F10 Successful target unknown NA TTD beta-hydroxy aspartic acid NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD emicizumab biotech Serum[MeSHID:D044967],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Blood Coagulation Disorders[MeSHID:D001778],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] approved,investigational coagulation factor x F10 NA activator,antibody 10.13 drugbank , DGIDB certoparin sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Deep Vein Thrombosis[MeSHID:D020246] approved coagulation factor xa F10 Successful target unknown NA TTD , DGIDB protein s human biotech Malnutrition[MeSHID:D044342],Emergencies [Disease/Finding][MeSHID:D004630] approved coagulation factor x F10 NA antagonist NA drugbank octopamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2a coagulation factor xa F10 Successful target unknown NA TTD idraparinux small molecule Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational coagulation factor x F10 NA unknown 2.89 drugbank , DGIDB dx-9065a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 2 coagulation factor xa F10 Successful target unknown NA TTD jtv-803 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 coagulation factor xa F10 Successful target unknown NA TTD otamixaban NA Thrombosis[MeSHID:D013927],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 coagulation factor xa F10 Successful target unknown 11.57 TTD , DGIDB emicizumab NA Serum[MeSHID:D044967],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Blood Coagulation Disorders[MeSHID:D001778],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] approved coagulation factor xa F10 Successful target unknown 10.13 TTD , DGIDB sk509 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD bibt986 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor xa F10 Successful target unknown 2.89 TTD , DGIDB lmw heparin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematological Disease[MeSHID:D006402],Blood Coagulation Disorders[MeSHID:D001778] approved coagulation factor xa F10 Successful target unknown NA TTD , DGIDB dt-831j NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] investigative coagulation factor xa F10 Successful target unknown NA TTD m55113 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD betrixaban small molecule Disease[MeSHID:D004194],Venous Thromboembolism[MeSHID:D054556],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational coagulation factor x F10 NA inhibitor 23.15 drugbank , DGIDB 4-(4-benzyloxy-3-methoxy-benzylamino)-benzamidine NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD gcc-4401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB coagulation factor viia recombinant human biotech Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved coagulation factor x F10 NA unknown NA drugbank pd-348292 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2 coagulation factor xa F10 Successful target unknown NA TTD (2r)-2-(5-chloro-2-thienyl)-n-{(3s)-1-[(1s)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}propene-1-sulfonamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank danaparoid NA Deep Vein Thrombosis[MeSHID:D020246],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Veins[MeSHID:D014680] approved coagulation factor xa F10 Successful target unknown 1.45 TTD , DGIDB bms-269223 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD zk-814048 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD otamixaban NA Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 3 coagulation factor xa F10 Successful target inhibitor 11.57 TTD , DGIDB gw-813893 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB prt4445 NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Pancreatitis[MeSHID:D010195] investigational coagulation factor x F10 NA inhibitor NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor x F10 NA activator NA drugbank gc-2107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] investigative coagulation factor xa F10 Successful target unknown NA TTD ep-217609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB edoxaban small molecule Deep Vein Thrombosis[MeSHID:D020246],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655] approved coagulation factor x F10 NA inhibitor 8.68 drugbank , DGIDB apixaban small molecule Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Bone structure of ischium[MeSHID:D007512],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Hip structure[MeSHID:D006615],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved coagulation factor x F10 NA inhibitor 5.79 drugbank , DGIDB 2-({4-[(5-chloro-1h-indol-2-yl)sulfonyl]piperazin-1-yl}carbonyl)thieno[3,2-b]pyridine 4-oxide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank thieno[3,2-b]pyridine-2-sulfonic acid [1-(1-amino-isoquinolin-7-ylmethyl)-2-oxo-pyrroldin-3-yl]-amide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank otamixaban small molecule Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] investigational coagulation factor x F10 NA unknown 11.57 drugbank , DGIDB 1-{2-[(4-chlorophenyl)amino]-2-oxoethyl}-n-(1-isopropylpiperidin-4-yl)-1h-indole-2-carboxamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank 6-chloro-n-{(3s)-1-[(1s)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank n-((1r,2s)-2-(5-chloro-1h-indole-2-carboxamido)cyclohexyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank ym-75466 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 coagulation factor xa F10 Successful target unknown NA TTD bms-344577 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD 2-(5-chloro-2-thienyl)-n-{(3s)-1-[(1s)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethanesulfonamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank 5-(5-chloro-2-thienyl)-n-{(3s)-1-[(1s)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-1h-1,2,4-triazole-3-sulfonamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank protamine sulfate biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Kidney[MeSHID:D007668] approved coagulation factor x F10 NA unknown NA drugbank ep-42675 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB valspodar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] discontinued in phase 3 coagulation factor xa F10 Successful target unknown NA TTD ssr-128428 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB 5-chloro-thiophene-2-carboxylic acid ((3s,4s)-1-{[2-fluoro-4-(2-oxo-2h-pyridin-1-yl)-phenylcarbamoyl]-methyl}-4-hydroxy-pyrrolidin-3-yl)-amide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank tak-442 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2 coagulation factor xa F10 Successful target unknown 5.79 TTD , DGIDB coagulation factor vii human biotech Thrombasthenia[MeSHID:D013915],Cerebral Hemorrhage[MeSHID:D002543],Operative Surgical Procedures[MeSHID:D013514],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Off-Label Use[MeSHID:D056687],Factor VII Deficiency[MeSHID:D005168] approved,investigational coagulation factor x F10 NA activator NA drugbank betrixaban NA Disease[MeSHID:D004194],Venous Thromboembolism[MeSHID:D054556],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xa F10 Successful target inhibitor 23.15 TTD , DGIDB recombinant coagulation factors NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] investigative coagulation factor xa F10 Successful target unknown NA TTD 4-[[(1e)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]piperazinone small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank ly-517717 small molecule Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational coagulation factor x F10 NA unknown 5.79 drugbank , DGIDB n-(2-(((5-chloro-2-pyridinyl)amino)sulfonyl)phenyl)-4-(2-oxo-1(2h)-pyridinyl)benzamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank ssr-126517e NA Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB ly-517717 NA Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 coagulation factor xa F10 Successful target unknown 5.79 TTD , DGIDB sk554 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD rivaroxaban NA Coronary Arteriosclerosis[MeSHID:D003324],Congenital Disorders[MeSHID:D009358],Renal Insufficiency[MeSHID:D051437],Peripheral Arterial Diseases[MeSHID:D058729],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Birth[MeSHID:D036801],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xa F10 Successful target unknown 8.68 TTD , DGIDB emd-503982 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 coagulation factor xa F10 Successful target unknown NA TTD antithrombin alfa biotech Thromboembolism[MeSHID:D013923],Hereditary Antithrombin Deficiency[MeSHID:D020152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational coagulation factor x F10 NA inhibitor NA drugbank trimidox NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical coagulation factor xa F10 Successful target unknown 1.45 TTD , DGIDB 4-{[(e)-2-(5-chlorothien-2-yl)vinyl]sulfonyl}-1-(1h-pyrrolo[3,2-c]pyridin-2-ylmethyl)piperazin-2-one small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank sk549 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD otamixaban small molecule Thrombosis[MeSHID:D013927],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational coagulation factor x F10 NA inhibitor 11.57 drugbank , DGIDB fondaparinux sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Venous Thrombosis[MeSHID:D020246] approved coagulation factor xa F10 Successful target unknown NA TTD , DGIDB sf303 NA NA investigative coagulation factor xa F10 Successful target unknown NA TTD rivaroxaban NA Coronary Arteriosclerosis[MeSHID:D003324],Congenital Disorders[MeSHID:D009358],Renal Insufficiency[MeSHID:D051437],Peripheral Arterial Diseases[MeSHID:D058729],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Birth[MeSHID:D036801],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xa F10 Successful target inhibitor 8.68 TTD , DGIDB cs-3030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] preclinical coagulation factor xa F10 Successful target unknown NA TTD , DGIDB coagulation factor ix (recombinant) biotech Hemophilia B[MeSHID:D002836],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor x F10 NA activator NA drugbank r-68151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 coagulation factor xa F10 Successful target unknown NA TTD ssr-126517e small molecule Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational coagulation factor x F10 NA unknown NA drugbank , DGIDB thieno[3,2-b]pyridine-2-sulfonic acid [2-oxo-1-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)-pyrrolidin-3-yl]-amide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank r-1663 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] phase 1 coagulation factor xa F10 Successful target unknown NA TTD , DGIDB 3-({4-[(6-chloro-1-benzothien-2-yl)sulfonyl]-2-oxopiperazin-1-yl}methyl)benzenecarboximidamide small molecule NA experimental coagulation factor x F10 NA unknown NA drugbank ionis-416858 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 factor xi messenger rna F11 Clinical trial target unknown NA TTD coagulation factor ix human biotech Plasma[MeSHID:D010949],Operative Surgical Procedures[MeSHID:D013514],Hemophilia B[MeSHID:D002836],Hemorrhage[MeSHID:D006470] approved coagulation factor xi F11 NA ligand NA drugbank human c1-esterase inhibitor biotech Angioedemas, Hereditary[MeSHID:D054179] approved coagulation factor xi F11 NA inhibitor NA drugbank bms-986177 NA Cerebral Ischemia[MeSHID:D002545],Cerebral Infarction[MeSHID:D002544],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 factor xi messenger rna F11 Clinical trial target unknown NA TTD alpha-ketothiazole analogue 36 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial factor xi messenger rna F11 Clinical trial target inhibitor NA TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational coagulation factor xi F11 NA activator NA drugbank conestat alfa biotech Angioedemas, Hereditary[MeSHID:D054179] approved,investigational coagulation factor xi F11 NA inhibitor NA drugbank ep-7041 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor xi F11 Clinical trial target unknown NA TTD , DGIDB human thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xi F11 NA activator NA drugbank thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational coagulation factor xi F11 NA activator 3.98 drugbank , DGIDB 6-carbamimidoyl-4-(3-hydroxy-2-methyl-benzoylamino)-naphthalene-2-carboxylic acid methyl ester small molecule NA experimental coagulation factor xi F11 NA unknown NA drugbank bms-986177 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 factor xi messenger rna F11 Clinical trial target unknown NA TTD fxi-as1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] investigative factor xi messenger rna F11 Clinical trial target unknown NA TTD coagulation factor ix (recombinant) biotech Hemophilia B[MeSHID:D002836],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor xi F11 NA ligand NA drugbank (r)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)benzyl)guanidine small molecule NA experimental coagulation factor xi F11 NA unknown NA drugbank (r)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenyl)guanidine small molecule NA experimental coagulation factor xi F11 NA unknown NA drugbank 3-hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate small molecule NA experimental coagulation factor xi F11 NA unknown NA drugbank ab023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney Failure, Chronic[MeSHID:D007676] phase 1 coagulation factor xi F11 Clinical trial target unknown NA TTD n-(7-carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide small molecule NA experimental coagulation factor xi F11 NA unknown NA drugbank (1r)-2-[(diaminomethylene)amino]-1-{4-[(4r)-4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl]phenyl}ethyl nicotinate small molecule NA experimental coagulation factor xi F11 NA unknown NA drugbank 4-methyl-pentanoic acid {1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-methyl-propyl}-amide small molecule NA experimental coagulation factor xi F11 NA unknown NA drugbank isis-fxi NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] phase 2 factor xi messenger rna F11 Clinical trial target unknown NA TTD (r)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenethyl)guanidine small molecule NA experimental coagulation factor xi F11 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental coagulation factor xi F11 NA activator NA drugbank csl312 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angioedemas, Hereditary[MeSHID:D054179] phase 3 coagulation factor xii F12 Clinical trial target unknown NA TTD nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Disease[MeSHID:D004194] investigational coagulation factor xii F12 NA inhibitor NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational coagulation factor xii F12 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational coagulation factor xii F12 NA unknown NA drugbank conestat alfa biotech Angioedemas, Hereditary[MeSHID:D054179] approved,investigational coagulation factor xii F12 NA inhibitor NA drugbank ethanolamine oleate small molecule Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xii F12 NA activator NA drugbank methyl 5-[(4-tert-butylbenzoyl)amino]-2h-1,2,4-triazole-3-carboxylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial factor xii messenger rna F12 Clinical trial target inhibitor NA TTD , DGIDB human c1-esterase inhibitor biotech Angioedemas, Hereditary[MeSHID:D054179] approved coagulation factor xii F12 NA inhibitor NA drugbank nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Pancreatitis[MeSHID:D010195] investigational coagulation factor xii F12 NA inhibitor NA drugbank prothrombin biotech Malnutrition[MeSHID:D044342],Emergencies [Disease/Finding][MeSHID:D004630] approved coagulation factor xiii a chain F13A1 NA agonist NA drugbank pmid26560530-compound-13 NA NA patented coagulation factor xiiia F13A1 Patented-recorded target unknown NA TTD , DGIDB human thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xiii a chain F13A1 NA activator NA drugbank thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational coagulation factor xiii a chain F13A1 NA activator NA drugbank anti-inhibitor coagulant complex biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor xiii a chain F13A1 NA agonist NA drugbank n-acetyl-serine small molecule NA experimental coagulation factor xiii a chain F13A1 NA unknown NA drugbank catridecacog biotech Factor XIII Deficiency[MeSHID:D005177],Hemorrhage[MeSHID:D006470] approved coagulation factor xiii b chain F13B NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational coagulation factor xiii b chain F13B NA unknown NA drugbank nn8717 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft-vs-Host Disease[MeSHID:D006086] phase 3 coagulation factor xiii F13B Clinical trial target unknown NA TTD , DGIDB nn1841 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 3 coagulation factor xiii F13B Clinical trial target unknown NA TTD , DGIDB human thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor xiii b chain F13B NA activator NA drugbank thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational coagulation factor xiii b chain F13B NA activator NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational coagulation factor xiii b chain F13B NA unknown NA drugbank ac-(d)phe-pro-borolys-oh small molecule NA experimental prothrombin F2 NA unknown NA drugbank proflavine small molecule Injury wounds[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved prothrombin F2 NA unknown NA drugbank 2-(6-chloro-3-{[2,2-difluoro-2-(2-pyridinyl)ethyl]amino}-2-oxo-1(2h)-pyrazinyl)-n-[(2-fluoro-6-pyridinyl)methyl]acetamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank lepirudin biotech Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prothrombin F2 NA inhibitor 7.78 drugbank , DGIDB ximelagatran NA Deep Vein Thrombosis[MeSHID:D020246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] withdrawn from market coagulation factor iia F2 Successful target unknown 16.97 TTD , DGIDB cra_8696 small molecule NA experimental prothrombin F2 NA unknown NA drugbank coagulation factor ix (recombinant) biotech Hemophilia B[MeSHID:D002836],Hemophilia A[MeSHID:D006467] approved,investigational prothrombin F2 NA unknown NA drugbank drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn prothrombin F2 NA unknown NA drugbank argatroban NA Thrombosis[MeSHID:D013927],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target unknown 10.61 TTD , DGIDB 4-iodobenzo[b]thiophene-2-carboxamidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank anti-inhibitor coagulant complex biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational prothrombin F2 NA agonist NA drugbank bbs-arg-(d-pip)-gly-s-(gs)3-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD n-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 4-[3-(4-chlorophenyl)-1h-pyrazol-5-yl]piperidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank bbs-arg-(d-pip)-gly-s-(gs)11-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD (3z,6s)-6-chloro-1-(2-{[(5-chloro-1-benzothiophen-3-yl)methyl]amino}ethyl)-3-({2-[(2r)-2-piperidinyl]ethyl}imino)-2-piperazinol small molecule NA experimental prothrombin F2 NA unknown NA drugbank 2-[n'-(4-amino-butyl)-hydrazinocarbonyl]-pyrrolidine-1-carboxylic acid benzyl ester small molecule NA experimental prothrombin F2 NA unknown NA drugbank dp-4088 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] phase 1 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB 1-[2-amino-2-cyclohexyl-acetyl]-pyrrolidine-3-carboxylic acid 5-chloro-2-(2-ethylcarbamoyl-ethoxy)-benzylamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 4-tert-butylbenzenesulfonic acid small molecule NA experimental prothrombin F2 NA unknown NA drugbank hemi-babim NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD bbs-arg-(d-pip)-gly-s-(gs)13-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD d-phenylalanyl-n-(3-methylbenzyl)-l-prolinamide NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD n7-butyl-n2-(5-chloro-2-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine-2,7-diamine small molecule NA experimental prothrombin F2 NA unknown NA drugbank turoctocog alfa biotech Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hemorrhagic Disorders[MeSHID:D006474],Blood Platelets[MeSHID:D001792],Hemophilia A[MeSHID:D006467],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Intrinsic drive[MeSHID:D004328],Malnutrition[MeSHID:D044342],X Chromosome[MeSHID:D014960],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prothrombin F2 NA binder NA drugbank bivalirudin NA Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Acute Coronary Syndrome[MeSHID:D054058],Thrombosis[MeSHID:D013927],Angina, Unstable[MeSHID:D000789],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target inhibitor 23.34 TTD , DGIDB argatroban NA Thrombosis[MeSHID:D013927],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target inhibitor 10.61 TTD , DGIDB heparin-cantithrombin iii NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 4-(2,5-diamino-5-hydroxy-pentyl)-phenol small molecule NA experimental prothrombin F2 NA unknown NA drugbank (s)-n-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank (2r)-2-(5-chloro-2-thienyl)-n-{(3s)-1-[(1s)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}propene-1-sulfonamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank ve-04051645 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative coagulation factor iia F2 Successful target unknown NA TTD (s)-n-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank chlorodysinosin a NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD rwj-671818 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor iia F2 Successful target unknown 2.12 TTD , DGIDB bbs-arg-(d-pip)-gly-(sph(py)ekvs)-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD bbs-arg-(d-pip)-gly-(eqkliseedl)-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 4-[3-(4-chlorophenyl)-1h-pyrazol-5-yl]piperidine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD d-leucyl-n-(4-carbamimidoylbenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 5-(dimethylamino)-1-naphthalenesulfonic acid(dansyl acid) small molecule NA experimental prothrombin F2 NA unknown NA drugbank rwj-50353 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD melogatran NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD n-[(2r,3s)-3-amino-2-hydroxy-4-phenylbutyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 6-(2-hydroxy-cyclopentyl)-7-oxo-heptanamidine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 1-benzoyl-n-phenyl-1h-pyrazole-3-carboxamide NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD tb-101 NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative coagulation factor iia F2 Successful target unknown NA TTD 5-desgalloylstachyurin NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD gamma-carboxy-glutamic acid NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD azd0837 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927],Atrial Fibrillation[MeSHID:D001281] discontinued in phase 2 coagulation factor iia F2 Successful target unknown NA TTD ac-(d)phe-pro-borolys-oh NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD ximelegatran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Myocardial Infarction[MeSHID:D009203],Expiration, function[MeSHID:D045853],Asthma[MeSHID:D001249] approved coagulation factor iia F2 Successful target unknown NA TTD , DGIDB beta-phenyl-d-phenylalanyl-n-propyl-l-prolinamide NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD tellimagrandin ii NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 6-chloro-2-(2-hydroxy-biphenyl-3-yl)-1h-indole-5-carboxamidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank napsagatran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] discontinued in phase 2 coagulation factor iia F2 Successful target unknown NA TTD 1-(2-{[(6-amino-2-methylpyridin-3-yl)methyl]amino}ethyl)-6-chloro-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-1,4-dihydropyrazin-2-ol small molecule NA experimental prothrombin F2 NA unknown NA drugbank 2-(6-chloro-3-{[2,2-difluoro-2-(2-pyridinyl)ethyl]amino}-2-oxo-1(2h)-pyrazinyl)-n-[(2-fluoro-3-methyl-6-pyridinyl)methyl]acetamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank n-cyclooctylglycyl-n-(4-carbamimidoylbenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank odiparcil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 coagulation factor iia F2 Successful target unknown 2.12 TTD , DGIDB bbs-arg-(d-pip)-gly-s-(gs)5-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD bbs-arg-(d-pip)-gly-s-(gs)7-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 2-[2-(4-chloro-phenylsulfanyl)-acetylamino]-3-(4-guanidino-phenyl)-propionamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank cyclotheonamide e4 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD flovagatran small molecule Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational prothrombin F2 NA unknown NA drugbank , DGIDB cochinchinenene b NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD n-[(2r,3s)-3-amino-2-hydroxy-4-phenylbutyl]naphthalene-2-sulfonamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 2-(2-hydroxy-phenyl)-3h-benzoimidazole-5-carboxamidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank 4-(4-benzyloxy-3-methoxy-benzylamino)-benzamidine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD (4-nitro-1h-pyrazol-1-yl)(phenyl)methanone NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD ssr-182289 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] discontinued in phase 2 coagulation factor iia F2 Successful target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prothrombin F2 NA unknown NA drugbank ac-(d)phe-pro-borohomolys-oh small molecule NA experimental prothrombin F2 NA unknown NA drugbank licostinel NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD dabigatran NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target inhibitor 1.18 TTD , DGIDB lepirudin NA Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target unknown 7.78 TTD , DGIDB dabigatran NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target unknown 1.18 TTD , DGIDB bbs-arg-(d-pip)-gly-s-(gs)1-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD (3-nitro-1h-pyrazol-1-yl)(p-tolyl)methanone NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD dysinosin a NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD bcx-1470 NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD ep-217609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB n-{3-methyl-5-[2-(pyridin-4-ylamino)-ethoxy]-phenyl}-benzenesulfonamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank methyl-phe-pro-amino-cyclohexylglycine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 2-naphthalenesulfonic acid small molecule NA experimental prothrombin F2 NA unknown NA drugbank 1-(hydroxymethyleneamino)-8-hydroxy-octane small molecule NA experimental prothrombin F2 NA unknown NA drugbank 4-oxo-2-phenylmethanesulfonyl-octahydro-pyrrolo[1,2-a]pyrazine-6-carboxylic acid [1-(n-hydroxycarbamimidoyl)-piperidin-4-ylmethyl]-amide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 4-tert-butylbenzenesulfonic acid NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD d-leucyl-n-(4-carbamimidoylbenzyl)-l-prolinamide NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD enoxaparin small molecule Hospitalization[MeSHID:D006760],ambulatory care services[MeSHID:D000553],Deep Vein Thrombosis[MeSHID:D020246],Patient Care Management[MeSHID:D010346],Angina, Unstable[MeSHID:D000789],Operative Surgical Procedures[MeSHID:D013514],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655] approved prothrombin F2 NA inhibitor 0.71 drugbank , DGIDB ac-(d)phe-pro-borohomolys-oh NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD lb-30870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 2 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB gw-813893 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] experimental prothrombin F2 NA unknown NA drugbank (3,4-dichlorophenyl)(1h-pyrazol-1-yl)methanone NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD trans-4-(guanidinomethyl)-cyclohexane-l-yl-d-3-cyclohexylalanyl-l-azetidine-2-yl-d-tyrosinyl-l-homoargininamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank beta-(2-naphthyl)-alanine small molecule NA experimental prothrombin F2 NA unknown NA drugbank n4-(n,n-diphenylcarbamoyl)-aminoguanidine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD hirudin NA NA phase 4 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB nu-172 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB vitamin k NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 4-(1r,3as,4r,8as,8br)-[1-difluoromethyl-2-(4-fluorobenzyl)-3-oxodecahydropyrrolo[3,4-a]pyrrolizin-4-yl]benzamidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank ximelagatran small molecule Deep Vein Thrombosis[MeSHID:D020246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved,investigational,withdrawn prothrombin F2 NA inhibitor 16.97 drugbank , DGIDB lysophosphotidylserine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD anisindione NA Venous Thrombosis[MeSHID:D020246],Pulmonary Embolism[MeSHID:D011655],Atrial Fibrillation[MeSHID:D001281],Coronary Occlusion[MeSHID:D054059],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved coagulation factor iia F2 Successful target unknown 0.35 TTD , DGIDB l-370,518 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 2-[3-chloro-6-[2,2-difluoro-2-(1-oxidopyridin-1-ium-2-yl)ethyl]imino-1-hydroxypyridin-2-yl]-n-[(1r)-1-(3-chlorophenyl)ethyl]acetamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank kappadione small molecule Metabolism[MeSHID:D008660],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Hemorrhagic Disease of Newborn[MeSHID:D006475],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved prothrombin F2 NA agonist NA drugbank thrombomodulin alfa biotech Sepsis[MeSHID:D018805],Blood[MeSHID:D001769],Thrombosis[MeSHID:D013927],Hematological Disease[MeSHID:D006402] approved,investigational prothrombin F2 NA inhibitor NA drugbank ep-42675 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB cvs-1123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD 6-carbamimidoyl-2-[2-hydroxy-6-(4-hydroxy-phenyl)-indan-1-yl]-hexanoic acid small molecule NA experimental prothrombin F2 NA unknown NA drugbank (3-nitro-1h-pyrazol-1-yl)(phenyl)methanone NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD lysophosphotidylserine small molecule NA experimental prothrombin F2 NA unknown NA drugbank [(2r)-1-[(2s)-2-[[(2s,3s)-1-chloro-6-(diaminomethylideneamino)-2-hydroxyhexan-3-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]azanium small molecule NA experimental prothrombin F2 NA unknown NA drugbank argatroban small molecule Thrombosis[MeSHID:D013927],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prothrombin F2 NA inhibitor 10.61 drugbank , DGIDB nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Pancreatitis[MeSHID:D010195] investigational prothrombin F2 NA inhibitor NA drugbank 4-hydroxyphenylpyruvic acid NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD bivalirudin small molecule Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Acute Coronary Syndrome[MeSHID:D054058],Thrombosis[MeSHID:D013927],Angina, Unstable[MeSHID:D000789],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prothrombin F2 NA inhibitor 23.34 drugbank , DGIDB human c1-esterase inhibitor biotech Angioedemas, Hereditary[MeSHID:D054179] approved prothrombin F2 NA inhibitor NA drugbank 2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1h-1,3-benzodiazole-5-carboximidamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 1-ethoxycarbonyl-d-phe-pro-2(4-aminobutyl)hydrazine small molecule NA experimental prothrombin F2 NA unknown NA drugbank n-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank cvs-1578 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD n-allyl-5-amidinoaminooxy-propyloxy-3-chloro-n-cyclopentylbenzamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 1,2,3,4,6-penta-o-galloyl-beta-d-glucose NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD oscillarin NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD gamma-carboxy-l-glutamic acid small molecule NA experimental prothrombin F2 NA unknown NA drugbank melagatran NA NA phase 3 coagulation factor iia F2 Successful target inhibitor 0.71 TTD , DGIDB 3-(7-diaminomethyl-naphthalen-2-yl)-propionic acid ethyl ester small molecule NA experimental prothrombin F2 NA unknown NA drugbank gr-133686 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD d-leucyl-n-(3-chlorobenzyl)-l-prolinamide NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD coagulation factor ix human biotech Plasma[MeSHID:D010949],Operative Surgical Procedures[MeSHID:D013514],Hemophilia B[MeSHID:D002836],Hemorrhage[MeSHID:D006470] approved prothrombin F2 NA unknown NA drugbank 1-butanoyl-n-(4-carbamimidoylbenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 4-(5-benzenesulfonylamino-1-methyl-1h-benzoimidazol-2-ylmethyl)-benzamidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational prothrombin F2 NA inhibitor NA drugbank dermolastin NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] discontinued in phase 2 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB conestat alfa biotech Angioedemas, Hereditary[MeSHID:D054179] approved,investigational prothrombin F2 NA inhibitor NA drugbank d-phenylalanyl-n-(3-fluorobenzyl)-l-prolinamide NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 4-hydroxyphenylpyruvic acid small molecule NA experimental prothrombin F2 NA unknown NA drugbank 1-guanidino-4-(n-phenylmethanesulfonyl-l-leucyl-l-prolylamino)butane small molecule NA experimental prothrombin F2 NA unknown NA drugbank suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] investigational prothrombin F2 NA inhibitor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational prothrombin F2 NA unknown NA drugbank cjc-1004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD 1-[(4s)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank uk-156406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD 2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD atryn antithrombin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved coagulation factor iia F2 Successful target unknown NA TTD , DGIDB 1-[(2r)-2-aminobutanoyl]-n-(4-carbamimidoylbenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank cyclotheonamide e NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD tf0023 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203],Cerebrovascular accident[MeSHID:D020521] phase 2 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB (s)-n-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank (3r)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline small molecule NA experimental prothrombin F2 NA unknown NA drugbank pyridoxal phosphate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved coagulation factor iia F2 Successful target unknown NA TTD , DGIDB (4-nitro-1h-pyrazol-1-yl)(o-tolyl)methanone NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD d-phenylalanyl-n-(3-chlorobenzyl)-l-prolinamide NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD azd-8165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor iia F2 Successful target unknown 2.12 TTD , DGIDB macrocyclic tripeptide motif NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD n-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 3-carbamimidamido-1,1-diphenylurea small molecule NA experimental prothrombin F2 NA unknown NA drugbank 4-(3,4-diethoxy-benzylamino)-benzamidine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD [phenylalaninyl-prolinyl]-[2-(pyridin-4-ylamino)-ethyl]-amine small molecule NA experimental prothrombin F2 NA unknown NA drugbank bms-344577 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD d-phenylalanyl-n-benzyl-l-prolinamide NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD ac-(d)phe-pro-borohomoornithine-oh NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD desirudine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD turoctocog alfa pegol biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved prothrombin F2 NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational prothrombin F2 NA unknown NA drugbank haempatch NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative coagulation factor iia F2 Successful target unknown NA TTD n-ethyl-n-isopropyl-3-methyl-5-{[(2s)-2-(pyridin-4-ylamino)propyl]oxy}benzamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank beta-phenyl-d-phenylalanyl-n-propyl-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 1-(hydroxymethyleneamino)-8-hydroxy-octane NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD tumor vascular thrombogen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Vascular Neoplasms[MeSHID:D019043] investigative coagulation factor iia F2 Successful target unknown NA TTD n-(3-chlorobenzyl)-1-(4-methylpentanoyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 3-(4-chlorophenyl)-5-(methylthio)-4h-1,2,4-triazole small molecule NA experimental prothrombin F2 NA unknown NA drugbank sr-123781a NA Cardiovascular Diseases[MeSHID:D002318],Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Venous Thrombosis[MeSHID:D020246] phase 2/3 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB 2-naphthalenesulfonic acid NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD pegmusirudin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 2 coagulation factor iia F2 Successful target unknown 2.12 TTD , DGIDB d-phenylalanyl-n-(3-fluorobenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank n-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 3-cyclohexyl-d-alanyl-n-(3-chlorobenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank antithrombin alfa biotech Thromboembolism[MeSHID:D013923],Hereditary Antithrombin Deficiency[MeSHID:D020152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational prothrombin F2 NA inhibitor NA drugbank dabigatran etexilate small molecule Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prothrombin F2 NA inhibitor NA drugbank benzothiazole NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD n-{2,2-difluoro-2-[(2r)-piperidin-2-yl]ethyl}-2-[2-(1h-1,2,4-triazol-1-yl)benzyl][1,3]oxazolo[4,5-c]pyridin-4-amine small molecule NA experimental prothrombin F2 NA unknown NA drugbank n-cycloheptylglycyl-n-(4-carbamimidoylbenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank (s)-n-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank methyl l-phenylalaninate NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD d-phenylalanyl-n-(3-chlorobenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 4-(2,5-diamino-5-hydroxy-pentyl)-phenol NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD solulin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB lb30812 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD (s)-n-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank efegatran sulfate hydrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 2 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB (s)-n-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 2-(5-chloro-2-thienyl)-n-{(3s)-1-[(1s)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethanesulfonamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank casuariin NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD gw-473178 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD melagatran NA NA phase 3 coagulation factor iia F2 Successful target unknown 0.71 TTD , DGIDB 4-iodobenzo[b]thiophene 2-carboxamidine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 4-[(3as,4r,7r,8as,8br)-2-(1,3-benzodioxol-5-ylmethyl)-7-hydroxy-1,3-dioxodecahydropyrrolo[3,4-a]pyrrolizin-4-yl]benzenecarboximidamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank d-phenylalanyl-n-benzyl-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank d-phenylalanyl-n-{4-[amino(iminio)methyl]benzyl}-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 2-(6-chloro-3-{[2,2-difluoro-2-(1-oxido-2-pyridinyl)ethyl]amino}-2-oxo-1(2h)-pyrazinyl)-n-[(2-fluorophenyl)methyl]acetamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank cochinchinenin b NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD bivalirudin NA Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Acute Coronary Syndrome[MeSHID:D054058],Thrombosis[MeSHID:D013927],Angina, Unstable[MeSHID:D000789],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target unknown 23.34 TTD , DGIDB d-pro-phe-arg chloromethyl ketone NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical prothrombin F2 NA activator 0.45 drugbank , DGIDB 3-amino-3-benzyl-9-carboxamide[4.3.0]bicyclo-1,6-diazanonan-2-one small molecule NA experimental prothrombin F2 NA unknown NA drugbank methyl l-phenylalaninate small molecule NA experimental prothrombin F2 NA unknown NA drugbank d-leucyl-n-(3-chlorobenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank sc-79407 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD inogatran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] discontinued in phase 2 coagulation factor iia F2 Successful target unknown NA TTD tb-102 NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative coagulation factor iia F2 Successful target unknown NA TTD {(2s)-1-[n-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate small molecule NA experimental prothrombin F2 NA unknown NA drugbank bufrudin NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD human prothrombin complex concentrate NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target unknown NA TTD , DGIDB (4-bromo-1h-pyrazol-1-yl)(p-tolyl)methanone NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 6-(2-hydroxy-cyclopentyl)-7-oxo-heptanamidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank bbs-arg-(d-pip)-gly-(sphyekvs)-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD recombinant rgd-hirudin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB razaxaban NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 3-chlorophenyl 2-oxo-2h-chromene-3-carboxylate NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD arc-183 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematological Disease[MeSHID:D006402] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Disease[MeSHID:D004194] investigational prothrombin F2 NA inhibitor NA drugbank (3asr,4rs,8asr,8brs)-4-(2-(4-fluorobenzyl)-1,3-dioxodeacahydropyrrolo[3,4-a] pyrrolizin-4-yl)benzamidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank hemi-babim small molecule NA experimental prothrombin F2 NA unknown NA drugbank 6-carbamimidoyl-2-[2-hydroxy-5-(3-methoxy-phenyl)-indan-1-yl]-hexanoic acid small molecule NA experimental prothrombin F2 NA unknown NA drugbank s-2238 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD vasoflux NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] discontinued in phase 2 coagulation factor iia F2 Successful target unknown NA TTD d-phenylalanyl-n-(3-methylbenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank [[cyclohexanesulfonyl-glycyl]-3[pyridin-4-yl-aminomethyl]alanyl]piperidine small molecule NA experimental prothrombin F2 NA unknown NA drugbank ac-(d)phe-pro-borohomoornithine-oh small molecule NA experimental prothrombin F2 NA unknown NA drugbank cra_8696 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD ssr-128428 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB s-18326 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD n-(5-chloro-benzo[b]thiophen-3-ylmethyl)-2-[6-chloro-oxo-3-(2-pyridin-2-yl-ethylamino)-2h-pyrazin-1-yl]-acetamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank beta-(2-naphthyl)-alanine NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 4-({[4-(3-methylbenzoyl)pyridin-2-yl]amino}methyl)benzenecarboximidamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank lepirudin NA Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor iia F2 Successful target inhibitor 7.78 TTD , DGIDB desirudin recombinant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved coagulation factor iia F2 Successful target unknown NA TTD , DGIDB ximelagatran NA Deep Vein Thrombosis[MeSHID:D020246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] withdrawn from market coagulation factor iia F2 Successful target inhibitor 16.97 TTD , DGIDB mpc-0920 NA Mesenchymal Stem Cells[MeSHID:D059630],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 coagulation factor iia F2 Successful target unknown NA TTD , DGIDB bms-740808 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD 1-[(2r)-2-aminobutanoyl]-n-(3-chlorobenzyl)-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank gabexate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatitis[MeSHID:D010195] investigational prothrombin F2 NA inhibitor NA drugbank pedunculagin NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD enoxaprin NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD n-methylphenylalanyl-n-[(trans-4-aminocyclohexyl)methyl]-l-prolinamide small molecule NA experimental prothrombin F2 NA unknown NA drugbank 1-guanidino-4-(n-nitro-benzoylamino-l-leucyl-l-prolylamino)butane small molecule NA experimental prothrombin F2 NA unknown NA drugbank bbs-arg-(d-pip)-gly-s-(gs)9-gly-hir NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD cyclotheonamide e5 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD l-375378 NA NA investigative coagulation factor iia F2 Successful target unknown NA TTD vorapaxar small molecule Myocardial Infarction[MeSHID:D009203],Peripheral Vascular Diseases[MeSHID:D016491],Thrombus[MeSHID:D013927],Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proteinase-activated receptor 1 F2R NA antagonist 5.3 drugbank , DGIDB streptokinase biotech Arteries[MeSHID:D001158],Thrombosis[MeSHID:D013927],Deep Vein Thrombosis[MeSHID:D020246],Dental Occlusion[MeSHID:D003766],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational proteinase-activated receptor 1 F2R NA activator NA drugbank sr-123781a small molecule Cardiovascular Diseases[MeSHID:D002318],Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Venous Thrombosis[MeSHID:D020246] investigational proteinase-activated receptor 1 F2R NA unknown NA drugbank thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational proteinase-activated receptor 1 F2R NA unknown 1.82 drugbank , DGIDB sch-205831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] investigative proteinase activated receptor 1 F2R Successful target unknown NA TTD e5555 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] phase 2 proteinase activated receptor 1 F2R Successful target unknown 11.93 TTD , DGIDB pz-128 NA Arterial Occlusive Diseases[MeSHID:D001157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 proteinase activated receptor 1 F2R Successful target unknown NA TTD rwj-56110 NA NA investigative proteinase activated receptor 1 F2R Successful target antagonist NA TTD , DGIDB vorapaxar NA Myocardial Infarction[MeSHID:D009203],Peripheral Vascular Diseases[MeSHID:D016491],Thrombus[MeSHID:D013927],Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proteinase activated receptor 1 F2R Successful target antagonist 5.3 TTD , DGIDB streptokinase biotech Arteries[MeSHID:D001158],Thrombosis[MeSHID:D013927],Deep Vein Thrombosis[MeSHID:D020246],Dental Occlusion[MeSHID:D003766],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational proteinase-activated receptor 1 F2R NA activator NA drugbank vorapaxar NA Myocardial Infarction[MeSHID:D009203],Peripheral Vascular Diseases[MeSHID:D016491],Thrombus[MeSHID:D013927],Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proteinase activated receptor 1 F2R Successful target unknown 5.3 TTD , DGIDB sch-602539 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] investigative proteinase activated receptor 1 F2R Successful target unknown NA TTD pmid26936077-compound-34 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276],Metabolic Diseases[MeSHID:D008659] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD pmid26936077-compound-13 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276],Metabolic Diseases[MeSHID:D008659] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD imidazopyridazine derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzothiazine-carboxamide compound 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzothiazine-carboxamide compound 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD imidazopyridazine derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD amidine compound 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzimidazole derivative 8 NA NA patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzothiazine-carboxamide compound 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD askh95 NA NA investigative proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzothiazine-carboxamide compound 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD imidazopyridazine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD piperidine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD piperidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD amidine compound 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD peptide analog 71 NA NA patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzothiazine-carboxamide compound 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD quinazoline derivative 12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Chronic Obstructive Airway Disease[MeSHID:D029424],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103],Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD imidazopyridazine derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD gb88 NA NA investigative proteinase activated receptor 2 F2RL1 Patented-recorded target antagonist NA TTD , DGIDB imidazopyridazine derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD peptide analog 72 NA NA patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD amidine compound 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD imidazopyridazine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzimidazole derivative 10 NA NA patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD amidine compound 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD quinazoline derivative 11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Chronic Obstructive Airway Disease[MeSHID:D029424],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103],Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD amidine compound 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD peptidomimetic analog 6 NA NA patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzimidazole derivative 9 NA NA patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD piperazine urea derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD piperazine urea derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD quinazoline derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103],Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD piperazine derivative 5 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD benzothiazine-carboxamide compound 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD amidine compound 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD gb110 NA NA investigative proteinase activated receptor 2 F2RL1 Patented-recorded target agonist NA TTD , DGIDB quinazoline derivative 13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Arteriosclerosis[MeSHID:D001161],Gastrointestinal Diseases[MeSHID:D005767],Dermatitis, Atopic[MeSHID:D003876],Multiple Sclerosis[MeSHID:D009103] patented proteinase activated receptor 2 F2RL1 Patented-recorded target unknown NA TTD thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational proteinase-activated receptor 4 F2RL3 NA unknown NA drugbank ethyl 4-(1-benzyl-1h-indazol-3-yl)benzoate NA NA investigative proteinase activated receptor 4 F2RL3 Literature-reported target unknown NA TTD morab-066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 tissue factor F3 Clinical trial target unknown NA TTD , DGIDB [5-(5-amino-1h-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid small molecule NA experimental tissue factor F3 NA unknown NA drugbank rnapc2 biotech Coronary Arteriosclerosis[MeSHID:D003324],Veins[MeSHID:D014680],Thrombosis[MeSHID:D013927],Coronary heart disease[MeSHID:D003327],Angina Pectoris[MeSHID:D000787],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tissue factor F3 NA unknown NA drugbank [2'-hydroxy-3'-(1h-pyrrolo[3,2-c]pyridin-2-yl)-biphenyl-3-ylmethyl]-urea small molecule NA experimental tissue factor F3 NA unknown NA drugbank coagulation factor viia recombinant human biotech Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved tissue factor F3 NA unknown NA drugbank alt-836 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128] phase 2 tissue factor F3 Clinical trial target unknown NA TTD , DGIDB d-pro-phe-arg chloromethyl ketone NA NA investigative tissue factor F3 Clinical trial target unknown NA TTD coagulation factor vii human biotech Thrombasthenia[MeSHID:D013915],Cerebral Hemorrhage[MeSHID:D002543],Operative Surgical Procedures[MeSHID:D013514],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Off-Label Use[MeSHID:D056687],Factor VII Deficiency[MeSHID:D005168] approved,investigational tissue factor F3 NA activator NA drugbank tisotumab vedotin biotech Disease Progression[MeSHID:D018450],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] approved tissue factor F3 NA antibody NA drugbank 2-(4-hydroxy-5-phenyl-1h-pyrazol-3-yl)-1h-benzoimidazole-5-carboxamidine small molecule NA experimental tissue factor F3 NA unknown NA drugbank tt-173 NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tissue factor F3 Clinical trial target unknown NA TTD , DGIDB phenylmercury NA NA investigative coagulation factor va F5 Successful target unknown NA TTD anti-inhibitor coagulant complex biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor v F5 NA agonist NA drugbank protein s human biotech Malnutrition[MeSHID:D044342],Emergencies [Disease/Finding][MeSHID:D004630] approved coagulation factor v F5 NA antagonist NA drugbank thrombomodulin alfa biotech Sepsis[MeSHID:D018805],Blood[MeSHID:D001769],Thrombosis[MeSHID:D013927],Hematological Disease[MeSHID:D006402] approved,investigational coagulation factor v F5 NA unknown NA drugbank razaxaban NA NA investigative coagulation factor va F5 Successful target unknown NA TTD drotrecogin alfa NA Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor va F5 Successful target unknown NA TTD , DGIDB thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational coagulation factor v F5 NA activator 0.66 drugbank , DGIDB drotrecogin alfa NA Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor va F5 Successful target inhibitor NA TTD , DGIDB protein c biotech Venous Thrombosis[MeSHID:D020246],Purpura Fulminans[MeSHID:D055665],Protein C Deficiency[MeSHID:D020151] approved coagulation factor v F5 NA inactivator NA drugbank drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn coagulation factor v F5 NA inhibitor NA drugbank , DGIDB human thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor v F5 NA activator NA drugbank thrombin alfa biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved coagulation factor v F5 NA activator NA drugbank human recombinant factor viia NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] investigative coagulation factor vii F7 Successful target unknown NA TTD kappadione small molecule Metabolism[MeSHID:D008660],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Hemorrhagic Disease of Newborn[MeSHID:D006475],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved coagulation factor vii F7 NA agonist NA drugbank nonacog beta pegol biotech Disease Management[MeSHID:D019468],Hemophilia B[MeSHID:D002836],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Malnutrition[MeSHID:D044342],Wound Healing[MeSHID:D014945] approved,investigational coagulation factor vii F7 NA cofactor NA drugbank [2'-hydroxy-3'-(1h-pyrrolo[3,2-c]pyridin-2-yl)-biphenyl-3-ylmethyl]-urea small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank fucose NA NA investigative coagulation factor vii F7 Successful target unknown NA TTD [5-(5-amino-1h-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank 3-({1-[3-carbamimidoyl-1-(4-carbamimidoyl-benzylcarbamoyl)-propylcarbamoyl]-2-methyl-butylsulfamoyl}-methyl)-benzoic acid small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank 2-[2-ethanesulfonylamino-3-(5-propoxy-1h-indol-3-yl)-propionylamino]-pentanedioic acid 5-amide 1-(4-carbamimidoyl-benzylamide) small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank rnapc2 biotech Coronary Arteriosclerosis[MeSHID:D003324],Veins[MeSHID:D014680],Thrombosis[MeSHID:D013927],Coronary heart disease[MeSHID:D003327],Angina Pectoris[MeSHID:D000787],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 coagulation factor vii F7 Successful target unknown NA TTD , drugbank 2-[2-ethanesulfonylamino-3-(1h-indol-3-yl)-propionylamino]-pentanedioic acid 5-amide 1-(4-carbamim idoyl-benzylamide) small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank 4-(4-benzyloxy-3-methoxy-benzylamino)-benzamidine NA NA investigative coagulation factor vii F7 Successful target unknown NA TTD f-7tg NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 1 coagulation factor vii F7 Successful target unknown NA TTD , DGIDB n-[1-(4-carbamimidoyl-benzylcarbamoyl)-3-methylsulfanyl-propyl]-3-hydroxy-2-propoxyamino-butyramid small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank bay 86-6150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] discontinued in phase 2/3 coagulation factor vii F7 Successful target unknown NA TTD anti-inhibitor coagulant complex biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor vii F7 NA agonist NA drugbank 5-(dimethylamino)-1-naphthalenesulfonic acid(dansyl acid) small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank (2r)-({4-[amino(imino)methyl]phenyl}amino){5-ethoxy-2-fluoro-3-[(3r)-tetrahydrofuran-3-yloxy]phenyl}aceticacid small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank 2-(4-hydroxy-5-phenyl-1h-pyrazol-3-yl)-1h-benzoimidazole-5-carboxamidine small molecule NA experimental coagulation factor vii F7 NA unknown NA drugbank coagulation factor ix human biotech Plasma[MeSHID:D010949],Operative Surgical Procedures[MeSHID:D013514],Hemophilia B[MeSHID:D002836],Hemorrhage[MeSHID:D006470] approved coagulation factor vii F7 NA ligand NA drugbank cb-813 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 1 coagulation factor vii F7 Successful target unknown NA TTD , DGIDB recombinant factor viia pegylated liposomal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VII Deficiency[MeSHID:D005168] phase 1/2 coagulation factor vii F7 Successful target unknown NA TTD , DGIDB eptacog alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 1 coagulation factor vii F7 Successful target unknown NA TTD mod-5023 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] investigative coagulation factor vii F7 Successful target unknown NA TTD long-acting factor vii conjugate NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative coagulation factor vii F7 Successful target unknown NA TTD vatreptacog alfa (activated) NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 coagulation factor vii F7 Successful target unknown NA TTD , DGIDB factor viia NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] approved coagulation factor vii F7 Successful target unknown NA TTD , DGIDB 4-(3,4-diethoxy-benzylamino)-benzamidine NA NA investigative coagulation factor vii F7 Successful target unknown NA TTD factor-viia-xten NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] investigative coagulation factor vii F7 Successful target unknown NA TTD coagulation factor ix (recombinant) biotech Hemophilia B[MeSHID:D002836],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor vii F7 NA ligand NA drugbank bax-817 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 3 coagulation factor vii F7 Successful target unknown NA TTD , DGIDB activated recombinant fvii-albumin fusion protein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 2/3 coagulation factor vii F7 Successful target unknown NA TTD , DGIDB coagulation factor viia recombinant human biotech Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved coagulation factor vii F7 NA unknown NA drugbank von willebrand factor human biotech Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Hereditary Diseases[MeSHID:D030342],von Willebrand Disease[MeSHID:D014842],Malnutrition[MeSHID:D044342] approved,investigational coagulation factor viii F8 NA stabilization NA drugbank full-length factor viii molecule NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD coagulation factor ix (recombinant) biotech Hemophilia B[MeSHID:D002836],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor viii F8 NA cofactor NA drugbank thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational coagulation factor viii F8 NA activator 0.44 drugbank , DGIDB factor 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] approved coagulation factor viii F8 Successful target unknown NA TTD , DGIDB anti-inhibitor coagulant complex biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor viii F8 NA agonist NA drugbank eloctate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] approved coagulation factor viii F8 Successful target unknown 10.61 TTD , DGIDB protein c biotech Venous Thrombosis[MeSHID:D020246],Purpura Fulminans[MeSHID:D055665],Protein C Deficiency[MeSHID:D020151] approved coagulation factor viii F8 NA inactivator NA drugbank sk-nbp601 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] preregistration coagulation factor viii F8 Successful target unknown NA TTD , DGIDB human thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor viii F8 NA activator NA drugbank la-n8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD bay 794980 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 coagulation factor viii F8 Successful target unknown NA TTD , DGIDB recombinant von willebrand factor/recombinant factor viii complex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],von Willebrand Disease[MeSHID:D014842] phase 3 coagulation factor viii F8 Successful target unknown NA TTD , DGIDB vonicog alfa biotech Disease[MeSHID:D004194],Diagnosis[MeSHID:D003933],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Hereditary Diseases[MeSHID:D030342],von Willebrand Disease[MeSHID:D014842],Malnutrition[MeSHID:D044342] approved,investigational coagulation factor viii F8 NA stabilization NA drugbank bay 94-9027 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 3 coagulation factor viii F8 Successful target unknown NA TTD , DGIDB factor viii-xten NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD turoctocog alfa NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hemorrhagic Disorders[MeSHID:D006474],Blood Platelets[MeSHID:D001792],Hemophilia A[MeSHID:D006467],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Intrinsic drive[MeSHID:D004328],Malnutrition[MeSHID:D044342],X Chromosome[MeSHID:D014960],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 coagulation factor viii F8 Successful target unknown NA TTD , DGIDB spk-8016 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 1/2 coagulation factor viii F8 Successful target unknown NA TTD thrombin alfa biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved coagulation factor viii F8 NA activator NA drugbank obi-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] phase 3 coagulation factor viii F8 Successful target unknown NA TTD , DGIDB pf-07055480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 3 coagulation factor viii F8 Successful target unknown NA TTD damoctocog alfa pegol biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor viii F8 NA binder NA drugbank tb-402 biotech Atrial Fibrillation[MeSHID:D001281],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Venous Thromboembolism[MeSHID:D054556] investigational,phase 2 coagulation factor viii F8 Successful target unknown 31.83 TTD , drugbank , DGIDB spk-8011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 1/2 coagulation factor viii F8 Successful target unknown NA TTD human recombinant factor viii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD plasma derived factor viii pegylated liposomal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467],Plasma[MeSHID:D010949] phase 3 coagulation factor viii F8 Successful target unknown NA TTD , DGIDB coagulation factor ix human biotech Plasma[MeSHID:D010949],Operative Surgical Procedures[MeSHID:D013514],Hemophilia B[MeSHID:D002836],Hemorrhage[MeSHID:D006470] approved coagulation factor viii F8 NA cofactor NA drugbank gpg-290 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] investigative coagulation factor viii F8 Successful target unknown NA TTD simoctocog alfa NA Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD lg-888 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD valoctocogene roxaparvovec NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 3 coagulation factor viii F8 Successful target unknown NA TTD iatx-fviii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn coagulation factor viii F8 Successful target inhibitor NA TTD , drugbank , DGIDB tb-402 biotech Atrial Fibrillation[MeSHID:D001281],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Venous Thromboembolism[MeSHID:D054556] investigational,phase 2 coagulation factor viii F8 Successful target inhibitor 31.83 TTD , drugbank , DGIDB smart fviii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD lg-889 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] investigative coagulation factor viii F8 Successful target unknown NA TTD n8-gp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] phase 3 coagulation factor viii F8 Successful target unknown NA TTD , DGIDB nonacog beta pegol biotech Disease Management[MeSHID:D019468],Hemophilia B[MeSHID:D002836],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Malnutrition[MeSHID:D044342],Wound Healing[MeSHID:D014945] approved,investigational coagulation factor viii F8 NA cofactor NA drugbank long-acting factor viii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] investigative coagulation factor viii F8 Successful target unknown NA TTD sb-fix NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] phase 1/2 coagulation factor ix F9 Successful target unknown NA TTD csl-654 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] phase 3 coagulation factor ix F9 Successful target unknown NA TTD , DGIDB emicizumab biotech Serum[MeSHID:D044967],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Blood Coagulation Disorders[MeSHID:D001778],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] approved,investigational coagulation factor ix F9 Successful target cofactor,antibody 27.85 TTD , drugbank , DGIDB coagulation factor vii human biotech Thrombasthenia[MeSHID:D013915],Cerebral Hemorrhage[MeSHID:D002543],Operative Surgical Procedures[MeSHID:D013514],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Off-Label Use[MeSHID:D056687],Factor VII Deficiency[MeSHID:D005168] approved,investigational coagulation factor ix F9 NA activator NA drugbank turoctocog alfa biotech Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hemorrhagic Disorders[MeSHID:D006474],Blood Platelets[MeSHID:D001792],Hemophilia A[MeSHID:D006467],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Intrinsic drive[MeSHID:D004328],Malnutrition[MeSHID:D044342],X Chromosome[MeSHID:D014960],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational coagulation factor ix F9 NA activator NA drugbank 5-benzyloxy-benzo[b]thiophene-2-carboxamidine NA NA investigative coagulation factor ix F9 Successful target unknown NA TTD 4-benzyloxybenzo[b]thiophene-2-carboxamidine NA NA investigative coagulation factor ix F9 Successful target unknown NA TTD antihemophilic factor human biotech Blood coagulation[MeSHID:D001777],Maintenance[MeSHID:D008283],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemophilia A[MeSHID:D006467],Traumatic injury[MeSHID:D014947],Hemorrhage[MeSHID:D006470],Recurrence (disease attribute)[MeSHID:D012008] approved coagulation factor ix F9 NA activator NA drugbank sb 249417 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 1 coagulation factor ix F9 Successful target unknown NA TTD ttp889 small molecule Venous Thromboembolism[MeSHID:D054556],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Respiratory Syncytial Virus Infections[MeSHID:D018357],Expiration, function[MeSHID:D045853] investigational,phase 2 coagulation factor ix F9 Successful target unknown NA TTD , drugbank , DGIDB lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor ix F9 NA cofactor NA drugbank recombinant factor ix NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Hemorrhage[MeSHID:D006470],Expiration, function[MeSHID:D045853],Disease[MeSHID:D004194],Hemophilia B[MeSHID:D002836] approved coagulation factor ix F9 Successful target unknown NA TTD , DGIDB f-9tg NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] investigative coagulation factor ix F9 Successful target unknown NA TTD factor ix-xten NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] investigative coagulation factor ix F9 Successful target unknown NA TTD menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical coagulation factor ix F9 NA activator 0.57 drugbank , DGIDB mg-1104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] investigative coagulation factor ix F9 Successful target unknown NA TTD rb-006 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Vascular Diseases[MeSHID:D014652] discontinued in phase 3 coagulation factor ix F9 Successful target unknown NA TTD bnp-fix NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] investigative coagulation factor ix F9 Successful target unknown NA TTD amt-060 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] phase 1/2 coagulation factor ix F9 Successful target unknown NA TTD , DGIDB 4-phenyl-benzo[b]thiophene-2-carboxamidine NA NA investigative coagulation factor ix F9 Successful target unknown NA TTD kappadione small molecule Metabolism[MeSHID:D008660],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Hemorrhagic Disease of Newborn[MeSHID:D006475],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved coagulation factor ix F9 NA agonist NA drugbank fidanacogene elaparvovec NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] phase 3 coagulation factor ix F9 Successful target unknown NA TTD n9-gp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] phase 1 coagulation factor ix F9 Successful target unknown NA TTD , DGIDB trenonacog alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 coagulation factor ix F9 Successful target unknown NA TTD , DGIDB turoctocog alfa pegol biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved coagulation factor ix F9 NA activator NA drugbank pmid20121197c57 NA NA investigative coagulation factor ix F9 Successful target unknown NA TTD rg6013 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 3 coagulation factor ix F9 Successful target unknown NA TTD , DGIDB aav2-hfix16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] phase 1 coagulation factor ix F9 Successful target unknown NA TTD , DGIDB moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved coagulation factor ix F9 NA cofactor NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational coagulation factor ix F9 NA cofactor NA drugbank mod-3012 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] investigative coagulation factor ix F9 Successful target unknown NA TTD gamma-carboxy-glutamic acid NA NA investigative coagulation factor ix F9 Successful target unknown NA TTD 6-benzyloxybenzo[b]thiophene-2-carboxamidine NA NA investigative coagulation factor ix F9 Successful target unknown NA TTD amt-061 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] phase 3 coagulation factor ix F9 Successful target unknown NA TTD emicizumab biotech Serum[MeSHID:D044967],Hemophilia A[MeSHID:D006467],Hemorrhage[MeSHID:D006470],Blood Coagulation Disorders[MeSHID:D001778],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Factor VIII Deficiency[MeSHID:D006467] approved,investigational coagulation factor ix F9 Successful target cofactor 27.85 TTD , drugbank , DGIDB 4-iodobenzo[b]thiophene 2-carboxamidine NA NA investigative coagulation factor ix F9 Successful target unknown NA TTD razaxaban NA NA investigative coagulation factor ix F9 Successful target unknown NA TTD methoxy arachidonyl fluorophosphonate small molecule NA experimental fatty-acid amide hydrolase 1 FAAH NA unknown NA drugbank medical cannabis biotech NA experimental,investigational fatty-acid amide hydrolase 1 FAAH NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational fatty-acid amide hydrolase 1 FAAH NA inhibitor NA drugbank 4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acid small molecule NA experimental fatty-acid amide hydrolase 1 FAAH NA unknown NA drugbank 1-dodecanol small molecule NA experimental fatty-acid amide hydrolase 1 FAAH NA unknown NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational fatty-acid amide hydrolase 1 FAAH NA inhibitor,inducer NA drugbank thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved fatty-acid amide hydrolase 1 FAAH NA inhibitor 0.83 drugbank , DGIDB 4-(quinolin-3-ylmethyl)piperidine-1-carboxylic acid small molecule NA experimental fatty-acid amide hydrolase 1 FAAH NA unknown NA drugbank piperazine urea derivative 2 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD carbamate derivative 6 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD carbamate derivative 2 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD ethylaminopyrimidine derivative 1 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD carbamate derivative 5 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD carbamate derivative 4 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD pyrimidinyl ethylenediamine derivative 1 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD carbamide derivative 1 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD pmid26413912-compound-84 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD carbamoyl oxime derivative 1 NA NA patented fatty-acid amide hydrolase 1 FAAH1 Patented-recorded target unknown NA TTD 1-anilinonaphthalene-8-sulfonic acid NA NA investigative fatty acid-binding protein 1 FABP1 Successful target unknown NA TTD fenofibric acid NA Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved fatty acid-binding protein 1 FABP1 Successful target unknown NA TTD , DGIDB oleic acid NA NA investigative fatty acid-binding protein 1 FABP1 Successful target unknown NA TTD indoprofen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] withdrawn from market fatty acid-binding protein 1 FABP1 Successful target unknown NA TTD dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fatty acid-binding protein, intestinal FABP2 NA binder NA drugbank ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fatty acid-binding protein, intestinal FABP2 NA binder NA drugbank pmid27109571-compound-19 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB oleic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD 5-carbazol-9-yl-pentanoic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD 4-carbazol-9-yl-butyric acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD pmid27109571-compound-17 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB 2-(6-methoxy-indole-1-sulfonyl)-benzoic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD pmid27109571-compound-18 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-10 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB 2-(4-methyl-indole-1-sulfonyl)-benzoic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD pmid27109571-compound-25 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB hexadecanoic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD pmid27109571-compound-27 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-24 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-31 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-15 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-23 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB 3-carbazol-9-yl-propionic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD 2-(3-methyl-indole-1-sulfonyl)-benzoic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD 2-(5-bromo-indole-1-sulfonyl)-benzoic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD pmid27109571-compound-28 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-30 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB 1-benzyl-2,3-dimethyl-1h-indole-7-carboxylic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD pmid27109571-compound-7 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-22 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-26 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-20 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-12 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-8 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-14 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-13 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-9 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB 2-(4-fluoro-indole-1-sulfonyl)-benzoic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD linoleic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD pmid27109571-compound-21 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-16 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-11 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB 2-(carbazole-9-sulfonyl)-benzoic acid NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD bms-480404 NA NA investigative fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD pmid27109571-compound-29 NA NA patented fatty acid-binding protein 4 FABP4 Patented-recorded target unknown NA TTD , DGIDB 5-carbazol-9-yl-pentanoic acid NA NA investigative fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD 2-(carbazole-9-sulfonyl)-benzoic acid NA NA investigative fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD pmid27109571-compound-23 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-13 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-16 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid NA NA investigative fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD pmid27109571-compound-29 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-22 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-20 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB 4-carbazol-9-yl-butyric acid NA NA investigative fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD pmid27109571-compound-12 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-31 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-18 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-14 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB bms-480404 NA NA investigative fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD pmid27109571-compound-25 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB hexadecanoic acid NA NA investigative fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD pmid27109571-compound-21 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-19 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-24 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-30 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-28 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-26 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-15 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-27 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB pmid27109571-compound-17 NA NA patented fatty acid-binding protein 5 FABP5 Patented-recorded target unknown NA TTD , DGIDB cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gastrotropin FABP6 NA unknown NA drugbank glycocholic acid small molecule NA experimental,investigational gastrotropin FABP6 NA unknown NA drugbank taurocholic acid small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental gastrotropin FABP6 NA ligand NA drugbank icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical fatty acid-binding protein, brain FABP7 NA agonist NA drugbank icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical fatty acid desaturase 1 FADS1 NA agonist NA drugbank alpha-linolenic acid small molecule NA approved,investigational,nutraceutical fatty acid desaturase 1 FADS1 NA ligand NA drugbank alpha-linolenic acid small molecule NA approved,investigational,nutraceutical fatty acid desaturase 2 FADS2 NA ligand NA drugbank km-819 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 fas-associated factor 1 FAF1 Clinical trial target unknown NA TTD 4-[hydroxy-[methyl-phosphinoyl]]-3-oxo-butanoic acid small molecule NA experimental fumarylacetoacetase FAH NA unknown NA drugbank fumaric acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pustulosis of Palms and Soles[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103] investigational fumarylacetoacetase FAH NA unknown NA drugbank acetoacetic acid small molecule NA experimental fumarylacetoacetase FAH NA unknown NA drugbank rp-l102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fanconi Anemia[MeSHID:D005199] phase 2 fanconi anemia group a protein FANCA Clinical trial target unknown NA TTD ari-3099 NA NA investigative prolyl endopeptidase fap FAP Clinical trial target inhibitor NA TTD , DGIDB va-119930 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] investigative prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD amg 506 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD pt630 NA Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] preclinical prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD mip-1231 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD rg7461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD , DGIDB fe-999040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD fap5-dm1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD sibrotuzumab NA Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD bibh 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD , DGIDB ng-641 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 prolyl endopeptidase fap FAP Clinical trial target unknown NA TTD talabostat NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukopenia[MeSHID:D007970] phase 3 prolyl endopeptidase fap FAP Clinical trial target unknown 12.73 TTD , DGIDB sibrotuzumab biotech Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational seprase FAP NA unknown NA drugbank phenylalanine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Tardive Dyskinesia[MeSHID:D000071057],Vitiligo[MeSHID:D014820] approved,investigational,nutraceutical phenylalanine--trna ligase, mitochondrial FARS2 NA unknown NA drugbank phenylalanine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Tardive Dyskinesia[MeSHID:D000071057],Vitiligo[MeSHID:D014820] approved,investigational,nutraceutical phenylalanine--trna ligase alpha subunit FARSA NA unknown NA drugbank phenylalanine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Tardive Dyskinesia[MeSHID:D000071057],Vitiligo[MeSHID:D014820] approved,investigational,nutraceutical phenylalanine--trna ligase beta subunit FARSB NA unknown NA drugbank apg-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative apoptosis mediating surface antigen fas FAS Clinical trial target unknown NA TTD f61f12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative apoptosis mediating surface antigen fas FAS Clinical trial target unknown NA TTD 2-aminophenoxazine-3-one NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] investigative apoptosis mediating surface antigen fas FAS Clinical trial target unknown NA TTD apo-010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 apoptosis mediating surface antigen fas FAS Clinical trial target unknown NA TTD , DGIDB apg-101 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 apoptosis mediating surface antigen fas FAS Clinical trial target unknown 1.68 TTD , DGIDB vb-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Glioma[MeSHID:D005910],Recurrence (disease attribute)[MeSHID:D012008],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] phase 3 apoptosis mediating surface antigen fas FAS Clinical trial target unknown 3.35 TTD , DGIDB de-098 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 apoptosis mediating surface antigen fas FAS Clinical trial target unknown NA TTD , DGIDB morin NA NA investigative fatty acid synthase FASN Successful target unknown NA TTD biochanin a NA NA investigative fatty acid synthase FASN Successful target unknown NA TTD fsa2 NA Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical fatty acid synthase FASN Successful target unknown NA TTD , DGIDB 3,7,3',4'-tetrahydroxyflavone NA NA investigative fatty acid synthase FASN Successful target unknown NA TTD c75 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative fatty acid synthase FASN Successful target unknown NA TTD (-)-catechingallate NA NA investigative fatty acid synthase FASN Successful target unknown NA TTD gsk2194069 NA NA investigative fatty acid synthase FASN Successful target inhibitor NA TTD , DGIDB 4-hydroxy-6-nitro-3-phenylquinolin-2(1h)-one NA NA investigative fatty acid synthase FASN Successful target unknown NA TTD fas1 NA Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical fatty acid synthase FASN Successful target unknown NA TTD , DGIDB epigallocatechin gallate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] phase 3 fatty acid synthase FASN Successful target unknown NA TTD , DGIDB mt-061 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative fatty acid synthase FASN Successful target unknown NA TTD 2-hexadecynoic acid NA NA investigative fatty acid synthase FASN Successful target unknown NA TTD tvb-2640 NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 fatty acid synthase FASN Successful target unknown NA TTD , DGIDB tvb-2640 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Malignant tumor of colon[MeSHID:D003110],Astrocytoma[MeSHID:D001254] phase 2 fatty acid synthase FASN Successful target unknown NA TTD , DGIDB cerulenin small molecule Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,approved fatty acid synthase FASN Successful target inhibitor 24.25 TTD , drugbank , DGIDB mg-28 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fatty acid synthase FASN Successful target unknown NA TTD fas-031 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fatty acid synthase FASN Successful target unknown NA TTD anti-fas mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fatty acid synthase FASN Successful target unknown NA TTD 4-hydroxy-8-nitro-3-phenylquinolin-2(1h)-one NA NA investigative fatty acid synthase FASN Successful target unknown NA TTD gallocatechin gallate NA NA investigative fatty acid synthase FASN Successful target unknown NA TTD orlistat small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Overweight[MeSHID:D050177],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fatty acid synthase FASN NA inhibitor 2.12 drugbank , DGIDB calcium citrate small molecule NA approved,investigational fibrillin-2 FBN2 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved fibrillin-2 FBN2 NA unknown NA drugbank calcium phosphate small molecule NA approved fibrillin-2 FBN2 NA ligand NA drugbank calcium phosphate small molecule NA approved fibrillin-3 FBN3 NA ligand NA drugbank calcium citrate small molecule NA approved,investigational fibrillin-3 FBN3 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved fibrillin-3 FBN3 NA unknown NA drugbank managlinat dialanetil small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank , DGIDB adenosine phosphate small molecule NA approved,investigational,nutraceutical fructose-1,6-bisphosphatase 1 FBP1 NA antagonist NA drugbank mb-07803 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank 4-amino-n-[(2-sulfanylethyl)carbamoyl]benzenesulfonamide small molecule NA experimental fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank 2,5-anhydroglucitol-1,6-biphosphate small molecule NA experimental fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank fructose-6-phosphate small molecule NA experimental fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank n-[7-(3-aminophenyl)-5-methoxy-1,3-benzoxazol-2-yl]-2,5-dichlorobenzenesulfonamide small molecule NA experimental fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank 2,5-dichloro-n-(5-chloro-1,3-benzoxazol-2-yl)benzenesulfonamide small molecule NA experimental fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank {4-[3-(6,7-diethoxy-quinazolin-4-ylamino)-phenyl]-thiazol-2-yl}-methanol small molecule NA experimental fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank 2,5-dichloro-n-[5-methoxy-7-(6-methoxypyridin-3-yl)-1,3-benzoxazol-2-yl]benzenesulfonamide small molecule NA experimental fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank mdl-29951 small molecule NA experimental fructose-1,6-bisphosphatase 1 FBP1 NA unknown NA drugbank bc-1215 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical f-box only protein 3 FBXO3 Preclinical target unknown NA TTD phenethyl isothiocyanate small molecule NA investigational f-box only protein 41 FBXO41 NA unknown NA drugbank mdx-214 NA MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] discontinued in phase 1/2 immunoglobulin alpha fc receptor FCAR Discontinued target unknown NA TTD tnx-901 biotech Allergic Reaction[MeSHID:D006967] investigational high affinity immunoglobulin epsilon receptor subunit alpha FCER1A NA unknown NA drugbank benzylpenicilloyl polylysine small molecule Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved high affinity immunoglobulin epsilon receptor subunit alpha FCER1A NA agonist NA drugbank , DGIDB omalizumab biotech Asthma[MeSHID:D001249],Inspiration function[MeSHID:D001239],Urticaria[MeSHID:D014581],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational high affinity immunoglobulin epsilon receptor subunit alpha FCER1A NA inhibitor 28.29 drugbank , DGIDB fucose NA NA investigative immunoglobulin epsilon fc receptor gamma FCER1G Successful target unknown NA TTD alpha-d-mannose NA NA investigative immunoglobulin epsilon fc receptor gamma FCER1G Successful target unknown NA TTD omalizumab NA Asthma[MeSHID:D001249],Inspiration function[MeSHID:D001239],Urticaria[MeSHID:D014581],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved immunoglobulin epsilon fc receptor gamma FCER1G Successful target unknown NA TTD benzylpenicilloyl polylysine NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved immunoglobulin epsilon fc receptor gamma FCER1G Successful target unknown NA TTD , DGIDB benzylpenicilloyl polylysine small molecule Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved high affinity immunoglobulin epsilon receptor subunit gamma FCER1G NA agonist NA drugbank , DGIDB lumiliximab NA Asthma[MeSHID:D001249],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 lymphocyte ige receptor FCER2 Clinical trial target unknown 254.61 TTD , DGIDB lumiliximab biotech Asthma[MeSHID:D001249],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational low affinity immunoglobulin epsilon fc receptor FCER2 NA unknown 254.61 drugbank , DGIDB lumiliximab NA Asthma[MeSHID:D001249],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 lymphocyte ige receptor FCER2 Clinical trial target antagonist 254.61 TTD , DGIDB lumiliximab biotech Asthma[MeSHID:D001249],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational low affinity immunoglobulin epsilon fc receptor FCER2 NA antagonist 254.61 drugbank , DGIDB gemtuzumab ozogamicin biotech Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved high affinity immunoglobulin gamma fc receptor i FCGR1A NA binder NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA ligand NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank natalizumab biotech Multiple Sclerosis[MeSHID:D009103] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank porfimer sodium small molecule Esophageal Neoplasms[MeSHID:D004938],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA antagonist NA drugbank catumaxomab biotech Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Pleural Effusion, Malignant[MeSHID:D016066] approved,investigational,withdrawn high affinity immunoglobulin gamma fc receptor i FCGR1A NA agonist NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank palivizumab biotech Respiration Disorders[MeSHID:D012120],Respiratory Syncytial Virus Infections[MeSHID:D018357],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank trastuzumab deruxtecan biotech Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA antibody NA drugbank human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA antagonist NA drugbank alemtuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational high affinity immunoglobulin gamma fc receptor i FCGR1A NA unknown NA drugbank human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational high affinity immunoglobulin gamma fc receptor ib FCGR1B NA antagonist NA drugbank cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA binder 1.69 drugbank , DGIDB alemtuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA unknown NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA unknown NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA unknown NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA unknown NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA unknown NA drugbank sm-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune thrombocytopenic purpura[MeSHID:D016553],Diabetic Nephropathy[MeSHID:D003928],Lupus Erythematosus, Systemic[MeSHID:D008180] approved (orphan drug) immunoglobulin gamma fc receptor iia FCGR2A Successful target unknown 3.03 TTD , DGIDB abciximab biotech Angina, Unstable[MeSHID:D000789],Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA unknown NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA ligand 3.35 drugbank , DGIDB human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA antagonist NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA unknown NA drugbank catumaxomab biotech Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Pleural Effusion, Malignant[MeSHID:D016066] approved,investigational,withdrawn low affinity immunoglobulin gamma fc region receptor ii-a FCGR2A NA agonist NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank alemtuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank mgd010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327] phase 1 immunoglobulin gamma fc receptor iib FCGR2B Clinical trial target unknown 10.61 TTD , DGIDB bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA ligand NA drugbank palivizumab biotech Respiration Disorders[MeSHID:D012120],Respiratory Syncytial Virus Infections[MeSHID:D018357],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank bi 1206 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 immunoglobulin gamma fc receptor iib FCGR2B Clinical trial target unknown NA TTD tositumomab biotech Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA antagonist NA drugbank abciximab biotech Angina, Unstable[MeSHID:D000789],Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-b FCGR2B NA unknown NA drugbank xmab 5871 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Diabetes, Autoimmune[MeSHID:D003922],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172] phase 2 immunoglobulin gamma fc receptor iib FCGR2B Clinical trial target unknown NA TTD , DGIDB alemtuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-c FCGR2C NA unknown NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-c FCGR2C NA ligand NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-c FCGR2C NA unknown NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-c FCGR2C NA unknown NA drugbank human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational low affinity immunoglobulin gamma fc region receptor ii-c FCGR2C NA antagonist NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn low affinity immunoglobulin gamma fc region receptor ii-c FCGR2C NA unknown NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank alefacept biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,withdrawn low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank rg6296 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 immunoglobulin gamma fc receptor iiia FCGR3A Clinical trial target unknown NA TTD human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA antagonist NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank alemtuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank palivizumab biotech Respiration Disorders[MeSHID:D012120],Respiratory Syncytial Virus Infections[MeSHID:D018357],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA binder 0.56 drugbank , DGIDB gemtuzumab ozogamicin biotech Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank benralizumab biotech Maintenance[MeSHID:D008283],Serum[MeSHID:D044967],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Phenotype[MeSHID:D010641],eosinophil[MeSHID:D004804],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA binding NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA ligand 0.98 drugbank , DGIDB afm24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 immunoglobulin gamma fc receptor iiia FCGR3A Clinical trial target unknown NA TTD bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA unknown NA drugbank amivantamab biotech Insertion Mutation[MeSHID:D016254],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA inducer NA drugbank catumaxomab biotech Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Pleural Effusion, Malignant[MeSHID:D016066] approved,investigational,withdrawn low affinity immunoglobulin gamma fc region receptor iii-a FCGR3A NA agonist NA drugbank afm13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Mycosis Fungoides[MeSHID:D009182],Peripheral T-Cell Lymphoma[MeSHID:D016411],Hodgkin Disease[MeSHID:D006689] phase 2 immunoglobulin gamma fc receptor iiia FCGR3A Clinical trial target antibody NA TTD , DGIDB muromonab biotech Transplanted organ[MeSHID:D019737],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank gemtuzumab ozogamicin biotech Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank palivizumab biotech Respiration Disorders[MeSHID:D012120],Respiratory Syncytial Virus Infections[MeSHID:D018357],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank alemtuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank catumaxomab biotech Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Ascites[MeSHID:D001201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Pleural Effusion, Malignant[MeSHID:D016066] approved,investigational,withdrawn low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA agonist NA drugbank etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA ligand NA drugbank alefacept biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,withdrawn low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank cetuximab biotech Disease[MeSHID:D004194],Colorectal Cancer[MeSHID:D015179],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Squamous cell carcinoma[MeSHID:D002294],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA binder NA drugbank natalizumab biotech Multiple Sclerosis[MeSHID:D009103] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank human immunoglobulin g biotech Hypogammaglobulinemia[MeSHID:D000361],Disease[MeSHID:D004194],Immunologic Deficiency Syndromes[MeSHID:D007153],Dermatologic disorders[MeSHID:D012871],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Wiskott-Aldrich Syndrome[MeSHID:D014923],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polyradiculoneuropathy, Chronic Inflammatory Demyelinating[MeSHID:D020277],Syndrome[MeSHID:D013577],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Immune thrombocytopenic purpura[MeSHID:D016553] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA antagonist NA drugbank daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational low affinity immunoglobulin gamma fc region receptor iii-b FCGR3B NA unknown NA drugbank efgartigimod alfa biotech Myasthenia Gravis, Generalized[MeSHID:D009157] approved,investigational igg receptor fcrn large subunit p51 FCGRT NA binder,antibody NA drugbank , DGIDB argx-113 NA Myasthenia Gravis[MeSHID:D009157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 neonatal fc receptor FCGRT Clinical trial target unknown NA TTD syn-1327 NA NA investigative neonatal fc receptor FCGRT Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational ficolin-3 FCN3 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational ficolin-3 FCN3 NA unknown NA drugbank 3-[7'-(methoxy)-napht-2'-yl]-quinuclidine-2-ene NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid18754614c10 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD 2-[4-(2-thienyl)phenyl]-4-methylmorpholin-2-ol NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19191557c14 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD sq-32709 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 2 squalene synthetase FDFT1 Discontinued target unknown NA TTD 1-allyl-2-[3-(isopropylamino)propoxy]-9h-xanthen-9-one NA NA investigative squalene synthetase FDFT1 Discontinued target inhibitor NA TTD , DGIDB l-731120 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7966163c3f NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7473541c11 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid12238936c3a NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7650673c4q NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19191557c8 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid18754614c4 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7473541c20 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid18754614c18 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid22464687c15a NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD cp-294838 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD j-104123 NA NA investigative squalene synthetase FDFT1 Discontinued target inhibitor NA TTD , DGIDB pmid20299227c20 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19456099c15 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD zaragozic acid d2 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD 3-[1'-{4'-(benzyloxy)-phenyl}]-quinuclidine-2-ene NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7629799c6 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD (z)-3-[2-(9h-fluoren-2-yloxy)ethylidene]-quinuclidine hydrochloride 31 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19191557c19 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid8709131c15 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19191557c32 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7629799c2d NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7966163c6d NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD zaragozic acid d NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid8709131c4 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19191557c3 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD ym-75440 NA NA investigative squalene synthetase FDFT1 Discontinued target inhibitor NA TTD , DGIDB pmid8576905c4 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19191557c35 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid8496919c7 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD er-119884 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19191557c21 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid8709131c17 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid12238936c3f NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD e5700 NA NA investigative squalene synthetase FDFT1 Discontinued target inhibitor NA TTD , DGIDB bph-652 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid18754614c19 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7473541c19 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid8709131c2a (+) NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid19456099c13 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid8709131c23 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD l-731128 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7473541c21 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7966163c6c NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7966163c4e NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD zaragozic acid b NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid7966163c6g NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid20299227c12 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid9871507c14 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid18754614c7 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD j-104118 NA NA investigative squalene synthetase FDFT1 Discontinued target inhibitor NA TTD , DGIDB pmid7629799c2e NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid18754614c8 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD lapaquistat acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 3 squalene synthetase FDFT1 Discontinued target inhibitor 15.91 TTD , DGIDB pmid18754614c9 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD bph-830 NA NA investigative squalene synthetase FDFT1 Discontinued target inhibitor 15.91 TTD , DGIDB pmid17709461c4g NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD zaragozic acid c NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid18754614c17 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD tak-475 small molecule Hyperlipidemia[MeSHID:D006949] investigational squalene synthase FDFT1 NA unknown NA drugbank 1-allyl-2-[3-(isopropylamino)propoxy]-9h-carbazole NA NA investigative squalene synthetase FDFT1 Discontinued target inhibitor NA TTD , DGIDB pmid9216829c5j NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD l-735021 NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD pmid9216829c5m NA NA investigative squalene synthetase FDFT1 Discontinued target unknown NA TTD bms-187745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 squalene synthetase FDFT1 Discontinued target unknown NA TTD geranyl diphosphate small molecule NA experimental farnesyl pyrophosphate synthase FDPS NA unknown NA drugbank zoledronic acid small molecule Multiple Myeloma[MeSHID:D009101],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Bone neoplasms[MeSHID:D001859],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Postmenopause[MeSHID:D017698],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024] approved farnesyl pyrophosphate synthase FDPS NA inhibitor 4.55 drugbank , DGIDB 1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD pg-1014491 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bone Diseases[MeSHID:D001847] investigative geranyltranstransferase FDPS Successful target unknown NA TTD alendronic acid small molecule Osteoporosis[MeSHID:D010024],Osteitis Deformans[MeSHID:D010001] approved farnesyl pyrophosphate synthase FDPS NA inhibitor NA drugbank bph-608 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD (1-hydroxy-1-phosphono-heptyl)-phosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD risedronic acid small molecule Osteitis Deformans[MeSHID:D010001] approved,investigational farnesyl pyrophosphate synthase FDPS NA inhibitor 14.78 drugbank , DGIDB diphosphoric acid NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB zoledronate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypercalcemia[MeSHID:D006934] approved geranyltranstransferase FDPS Successful target unknown 4.55 TTD , DGIDB risedronate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteitis Deformans[MeSHID:D010001] approved geranyltranstransferase FDPS Successful target unknown 14.78 TTD , DGIDB pmid17975902c5e NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD ibandronate small molecule Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational farnesyl pyrophosphate synthase FDPS NA inhibitor 15.91 drugbank , DGIDB zarnestra NA Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Pancreatic carcinoma[MeSHID:C562463],Communicable Diseases[MeSHID:D003141],Colorectal Cancer[MeSHID:D015179],Peripheral T-Cell Lymphoma[MeSHID:D016411],Myeloid Leukemia, Chronic[MeSHID:D015464] phase 3 geranyltranstransferase FDPS Successful target unknown 0.91 TTD , DGIDB minodronate NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved geranyltranstransferase FDPS Successful target unknown NA TTD , DGIDB pamidronate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypercalcemia[MeSHID:D006934] approved geranyltranstransferase FDPS Successful target unknown 8.18 TTD , DGIDB bph-628 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD ne58062 NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB incadronic acid small molecule leukemia[MeSHID:D007938],Malignant Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390] experimental farnesyl pyrophosphate synthase FDPS NA inhibitor NA drugbank zoledronic acid small molecule Multiple Myeloma[MeSHID:D009101],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Bone neoplasms[MeSHID:D001859],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Postmenopause[MeSHID:D017698],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024] approved farnesyl pyrophosphate synthase FDPS NA inhibitor NA drugbank , DGIDB digeranyl bisphosphonate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD ct-10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative geranyltranstransferase FDPS Successful target unknown NA TTD ne21650 NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB isopentyl pyrophosphate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD geranylgeranyl diphosphate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD pmid17963374c31 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD bph-675 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD bph-252 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD bph-742 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD [2-(6-chloro-purin-9-yl)ethyl]-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD dimethylallyl diphosphate small molecule NA experimental farnesyl pyrophosphate synthase FDPS NA unknown NA drugbank pmid18800762c11 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD pmid18800762c16 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD homorisedronate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD geranylgeranyl diphosphate small molecule NA experimental farnesyl pyrophosphate synthase FDPS NA unknown NA drugbank 1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD neridronic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complex Regional Pain Syndromes[MeSHID:D020918],Bone Diseases[MeSHID:D001847] approved geranyltranstransferase FDPS Successful target unknown NA TTD , DGIDB pmid18295483c2 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD risedronate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteitis Deformans[MeSHID:D010001] approved geranyltranstransferase FDPS Successful target inhibitor 14.78 TTD , DGIDB pmid18800762c14 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD 1-(but-2-ylamino)ethyl 1,i-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD 1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD isopentyl pyrophosphate small molecule NA experimental farnesyl pyrophosphate synthase FDPS NA unknown NA drugbank [2-(purin-9-yl)ethyl]-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD [2-(imidazol-1-yl)ethyl]-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD ne11808 NA NA investigative geranyltranstransferase FDPS Successful target inhibitor 4.55 TTD , DGIDB [2-(benzoimidazol-1-yl)ethyl]-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD pamidronic acid small molecule Lytic lesion[MeSHID:D010014],Breast[MeSHID:D001940],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Malignant Bone Neoplasm[MeSHID:D001859],Malignant neoplasm of breast[MeSHID:D001943],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101] approved farnesyl pyrophosphate synthase FDPS NA inhibitor NA drugbank , DGIDB ne10790 NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB 1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD geranyl diphosphate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD piridronic acid NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB pmid12014956c12 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD isopentenyl pyrophosphate small molecule NA experimental farnesyl pyrophosphate synthase FDPS NA unknown NA drugbank bph-629 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD ne58043 NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB (biphenyl-3-ylamino)methylenediphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD (2e, 6e)-farnesylbisphosphonate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD 1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD dimethylallyl diphosphate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD alendronate NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteitis Deformans[MeSHID:D010001] approved geranyltranstransferase FDPS Successful target unknown 2.27 TTD , DGIDB pmid18800762c47 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD ne58018 NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB 1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD bph-676 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD bph-715 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD incadronate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypercalcemia[MeSHID:D006934] approved geranyltranstransferase FDPS Successful target unknown NA TTD , DGIDB [2-(imidazol-2-yl-thio)ethyl]-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD ne58027 NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB ne-10575 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD pmid18800762c19 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD olpadronic acid sodium salt NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bone Resorption[MeSHID:D001862] investigative geranyltranstransferase FDPS Successful target unknown NA TTD farnesyl diphosphate small molecule NA experimental farnesyl pyrophosphate synthase FDPS NA unknown NA drugbank alendronate NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteitis Deformans[MeSHID:D010001] approved geranyltranstransferase FDPS Successful target inhibitor 2.27 TTD , DGIDB pmid18800762c51 NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD 3-azageranylgeranyl diphosphate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD isopentenyl pyrophosphate NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD 1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD ne97220 NA NA investigative geranyltranstransferase FDPS Successful target inhibitor NA TTD , DGIDB ibandronate NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved geranyltranstransferase FDPS Successful target unknown 15.91 TTD , DGIDB minodronic acid small molecule Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Malignant neoplasm of lung[MeSHID:D008175] investigational farnesyl pyrophosphate synthase FDPS NA inhibitor NA drugbank , DGIDB [2-(pyrazol-1-yl)ethyl]-bisphosphonic acid NA NA investigative geranyltranstransferase FDPS Successful target unknown NA TTD mitotane small molecule Tumors of Adrenal Cortex[MeSHID:D000306],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] approved adrenodoxin, mitochondrial FDX1 NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental nadph:adrenodoxin oxidoreductase, mitochondrial FDXR NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved nadph:adrenodoxin oxidoreductase, mitochondrial FDXR NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ferrochelatase, mitochondrial FECH NA unknown NA drugbank , DGIDB n-methylmesoporphyrin NA NA investigative ferrochelatase FECH Successful target unknown NA TTD methyl aminolevulinate NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ferrochelatase FECH Successful target unknown NA TTD , DGIDB cholic acid NA Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ferrochelatase FECH Successful target unknown NA TTD , DGIDB lead acetate NA NA investigative ferrochelatase FECH Successful target unknown NA TTD n-methylmesoporphyrin containing copper NA NA investigative ferrochelatase FECH Successful target unknown NA TTD ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved flap endonuclease 1 FEN1 NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved flap endonuclease 1 FEN1 NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved flap endonuclease 1 FEN1 NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved flap endonuclease 1 FEN1 NA unknown NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved flap endonuclease 1 FEN1 NA unknown NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved flap endonuclease 1 FEN1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase fer FER NA inhibitor NA drugbank pmid22564207c25b NA NA investigative proto-oncogene c-fes FES Literature-reported target unknown NA TTD pmid24432909c8e NA NA investigative proto-oncogene c-fes FES Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase fes/fps FES NA inhibitor NA drugbank ds-1558 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD tug-770 NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target agonist NA TTD , DGIDB gw9508 NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target agonist 2.45 TTD , DGIDB amg-837 NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target unknown 9.79 TTD , DGIDB shr0534 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD alpha-linolenic acid NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD gw1100 NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target antagonist NA TTD , DGIDB cnx-011-67 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD medica 16 NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target agonist NA TTD , DGIDB ly2922470 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD ly-2881835 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 free fatty acid receptor 1 FFAR1 Clinical trial target unknown 14.69 TTD , DGIDB tug-424 NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target agonist NA TTD , DGIDB p-1736 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD , DGIDB pmid18477808cb NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD tug-469 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD jtt-851 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD , DGIDB p11187 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD , DGIDB tak-875 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 free fatty acid receptor 1 FFAR1 Clinical trial target unknown 14.69 TTD , DGIDB bms-986118 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD cnx-011 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD fasiglifam hemihydrate NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD , DGIDB icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical free fatty acid receptor 1 FFAR1 NA agonist NA drugbank amg-837 NA NA investigative free fatty acid receptor 1 FFAR1 Clinical trial target agonist 9.79 TTD , DGIDB cpl207-280ca NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD pbi-4050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] phase 2 free fatty acid receptor 1 FFAR1 Clinical trial target unknown NA TTD glpg0974 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 free fatty acid receptor 2 FFAR2 Clinical trial target antagonist 127.3 TTD , DGIDB amg7703 NA NA investigative free fatty acid receptor 2 FFAR2 Clinical trial target allosteric modulator NA TTD , DGIDB glpg0974 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 free fatty acid receptor 2 FFAR2 Clinical trial target unknown 127.3 TTD , DGIDB trans-2-methylcrotonic acid NA NA investigative free fatty acid receptor 2 FFAR2 Clinical trial target agonist NA TTD , DGIDB hl-018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 free fatty acid receptor 2 FFAR2 Clinical trial target unknown NA TTD , DGIDB pentanoic acid NA NA investigative free fatty acid receptor 2 FFAR2 Clinical trial target agonist NA TTD , DGIDB 1-methylcyclopropanecarboxylic acid NA NA investigative free fatty acid receptor 2 FFAR2 Clinical trial target agonist NA TTD , DGIDB pmid23589301c1 NA NA investigative free fatty acid receptor 2 FFAR2 Clinical trial target unknown NA TTD (s)-4-cmtb NA NA investigative free fatty acid receptor 2 FFAR2 Clinical trial target agonist NA TTD , DGIDB isobutyric acid NA NA investigative free fatty acid receptor 2 FFAR2 Clinical trial target agonist NA TTD , DGIDB catpb NA NA investigative free fatty acid receptor 2 FFAR2 Clinical trial target antagonist NA TTD , DGIDB fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical free fatty acid receptor 4 FFAR4 NA agonist,inhibits downstream inflammation cascades NA drugbank alpha-linolenic acid NA NA investigative g-protein coupled receptor 120 FFAR4 Literature-reported target unknown NA TTD ncg21 NA NA investigative g-protein coupled receptor 120 FFAR4 Literature-reported target agonist NA TTD , DGIDB pmid24997608ca NA NA investigative g-protein coupled receptor 120 FFAR4 Literature-reported target unknown NA TTD tug-891 NA NA investigative g-protein coupled receptor 120 FFAR4 Literature-reported target unknown NA TTD bms-488043 small molecule HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational free fatty acid receptor 4 FFAR4 NA unknown NA drugbank grifolic acid NA NA investigative g-protein coupled receptor 120 FFAR4 Literature-reported target agonist NA TTD , DGIDB pro-542 biotech Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Infection[MeSHID:D007239] investigational free fatty acid receptor 4 FFAR4 NA unknown NA drugbank gw9508 NA NA investigative g-protein coupled receptor 120 FFAR4 Literature-reported target agonist 31.83 TTD , DGIDB tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibrinogen alpha chain FGA NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational fibrinogen alpha chain FGA NA unknown NA drugbank ancrod biotech Hypertensive disease[MeSHID:D006973],Insertion Mutation[MeSHID:D016254],Deep Vein Thrombosis[MeSHID:D020246],Femoral Neck Fractures[MeSHID:D005265],Retinal Vein Occlusion[MeSHID:D012170],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematological Disease[MeSHID:D006402] approved,investigational fibrinogen alpha chain FGA NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental fibrinogen alpha chain FGA NA binder NA drugbank ep-2104r biotech Cardiovascular Diseases[MeSHID:D002318],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational fibrinogen alpha chain FGA NA unknown NA drugbank anti-inhibitor coagulant complex biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational fibrinogen alpha chain FGA NA cleavage NA drugbank alteplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Pulmonary Embolism[MeSHID:D011655],Acute Cerebrovascular Accidents[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibrinogen alpha chain FGA NA unknown 1.68 drugbank , DGIDB lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational fibrinogen alpha chain FGA NA unknown NA drugbank alfimeprase biotech Arteries[MeSHID:D001158],Dental Occlusion[MeSHID:D003766],Acute Cerebrovascular Accidents[MeSHID:D020521],Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational fibrinogen alpha chain FGA NA unknown 5.3 drugbank , DGIDB thrombin alfa biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved fibrinogen alpha chain FGA NA activator NA drugbank anistreplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Embolus[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] approved fibrinogen alpha chain FGA NA unknown 19.89 drugbank , DGIDB prothrombin biotech Malnutrition[MeSHID:D044342],Emergencies [Disease/Finding][MeSHID:D004630] approved fibrinogen alpha chain FGA NA cleavage NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational fibrinogen alpha chain FGA NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational fibrinogen alpha chain FGA NA binder NA drugbank thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational fibrinogen alpha chain FGA NA activator NA drugbank reteplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Embolus[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibrinogen alpha chain FGA NA unknown 15.91 drugbank , DGIDB human thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibrinogen alpha chain FGA NA activator NA drugbank sucralfate small molecule Maintenance[MeSHID:D008283],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibrinogen FGA NA binder NA drugbank human thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibrinogen beta chain FGB NA activator NA drugbank prothrombin biotech Malnutrition[MeSHID:D044342],Emergencies [Disease/Finding][MeSHID:D004630] approved fibrinogen beta chain FGB NA cleavage NA drugbank sucralfate small molecule Maintenance[MeSHID:D008283],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibrinogen FGB NA binder NA drugbank anti-inhibitor coagulant complex biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational fibrinogen beta chain FGB NA cleavage NA drugbank thrombin alfa biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved fibrinogen beta chain FGB NA activator NA drugbank thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational fibrinogen beta chain FGB NA activator NA drugbank alfimeprase biotech Arteries[MeSHID:D001158],Dental Occlusion[MeSHID:D003766],Acute Cerebrovascular Accidents[MeSHID:D020521],Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational fibrinogen beta chain FGB NA unknown 6.06 drugbank , DGIDB n,o6-disulfo-glucosamine small molecule NA experimental fibroblast growth factor 1 FGF1 NA unknown NA drugbank 5-amino-naphtalene-2-monosulfonate NA NA investigative heparin-binding growth factor 1 FGF1 Clinical trial target unknown NA TTD o2-sulfo-glucuronic acid NA NA investigative heparin-binding growth factor 1 FGF1 Clinical trial target unknown NA TTD foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved fibroblast growth factor 1 FGF1 NA agonist NA drugbank pentosan polysulfate small molecule Pain[MeSHID:D010146],Interstitial Cystitis[MeSHID:D018856],Urinary Bladder[MeSHID:D001743],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor 1 FGF1 NA antagonist NA drugbank , DGIDB formic acid small molecule NA experimental,investigational fibroblast growth factor 1 FGF1 NA unknown NA drugbank n,o6-disulfo-glucosamine NA NA investigative heparin-binding growth factor 1 FGF1 Clinical trial target unknown NA TTD foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved fibroblast growth factor 1 FGF1 NA agonist NA drugbank sucrosofate small molecule NA experimental fibroblast growth factor 1 FGF1 NA unknown NA drugbank naphthalene trisulfonate small molecule NA experimental fibroblast growth factor 1 FGF1 NA unknown NA drugbank sucrose octasulfate NA NA investigative heparin-binding growth factor 1 FGF1 Clinical trial target unknown NA TTD pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved fibroblast growth factor 1 FGF1 NA inhibitor NA drugbank formic acid NA NA investigative heparin-binding growth factor 1 FGF1 Clinical trial target unknown NA TTD 5-aminonaphthalene-2-sulfonic acid small molecule NA experimental fibroblast growth factor 1 FGF1 NA unknown NA drugbank heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational fibroblast growth factor 1 FGF1 NA unknown NA drugbank naphthalene trisulfonate NA NA investigative heparin-binding growth factor 1 FGF1 Clinical trial target unknown NA TTD amlexanox small molecule Paste substance[MeSHID:D009824],Aphthous Stomatitis[MeSHID:D013281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] approved,investigational,withdrawn fibroblast growth factor 1 FGF1 NA inhibitor NA drugbank o2-sulfo-glucuronic acid small molecule NA experimental fibroblast growth factor 1 FGF1 NA unknown NA drugbank riferminogene pecaplasmid NA Ischemia[MeSHID:D007511],Limb structure[MeSHID:D005121],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 heparin-binding growth factor 1 FGF1 Clinical trial target unknown NA TTD cvbt-141h NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Peripheral Arterial Diseases[MeSHID:D058729],Peripheral Vascular Diseases[MeSHID:D016491] phase 2 heparin-binding growth factor 1 FGF1 Clinical trial target unknown NA TTD , DGIDB repifermin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Oral Mucositis[MeSHID:D013280] discontinued in phase 2 fibroblast growth factor-10 FGF10 Discontinued target unknown NA TTD as-902330 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthropathy[MeSHID:D007592] phase 2 fibroblast growth factor-18 FGF18 Clinical trial target unknown 63.65 TTD , DGIDB heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational fibroblast growth factor 19 FGF19 NA unknown NA drugbank 1,4-dideoxy-5-dehydro-o2-sulfo-glucuronic acid NA NA investigative fibroblast growth factor-2 FGF2 Successful target unknown NA TTD dvc1-0101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 2 fibroblast growth factor-2 FGF2 Successful target unknown NA TTD , DGIDB sucralfate small molecule Maintenance[MeSHID:D008283],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor 2 FGF2 NA agonist,inducer 6.06 drugbank , DGIDB 2-sulfhydryl-ethanol NA NA investigative fibroblast growth factor-2 FGF2 Successful target unknown NA TTD bibf100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative fibroblast growth factor-2 FGF2 Successful target unknown NA TTD squalamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Macular Edema, Cystoid[MeSHID:D008269] phase 3 fibroblast growth factor-2 FGF2 Successful target unknown 0.76 TTD , DGIDB sucralfate NA Maintenance[MeSHID:D008283],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor-2 FGF2 Successful target unknown 6.06 TTD , DGIDB tgp-580 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] discontinued in phase 2 fibroblast growth factor-2 FGF2 Successful target unknown NA TTD n,o6-disulfo-glucosamine NA NA investigative fibroblast growth factor-2 FGF2 Successful target unknown NA TTD n,o6-disulfo-glucosamine small molecule NA experimental fibroblast growth factor 2 FGF2 NA unknown NA drugbank abt-510 small molecule Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational fibroblast growth factor 2 FGF2 NA unknown 1.52 drugbank , DGIDB 1,4-dideoxy-5-dehydro-o2-sulfo-glucuronic acid small molecule NA experimental fibroblast growth factor 2 FGF2 NA unknown NA drugbank 1,4-dideoxy-o2-sulfo-glucuronic acid small molecule NA experimental fibroblast growth factor 2 FGF2 NA unknown NA drugbank fpa144 NA Adenocarcinoma[MeSHID:D000230],Malignant neoplasm of urinary bladder[MeSHID:D001749],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 fibroblast growth factor-2 FGF2 Successful target unknown NA TTD , DGIDB bemarituzumab NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 fibroblast growth factor-2 FGF2 Successful target unknown NA TTD , DGIDB 1,4-dideoxy-o2-sulfo-glucuronic acid NA NA investigative fibroblast growth factor-2 FGF2 Successful target unknown NA TTD pentosan polysulfate small molecule Pain[MeSHID:D010146],Interstitial Cystitis[MeSHID:D018856],Urinary Bladder[MeSHID:D001743],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor 2 FGF2 NA antagonist NA drugbank , DGIDB heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational fibroblast growth factor 2 FGF2 NA unknown NA drugbank pf-05231023 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 fibroblast growth factor-21 FGF21 Clinical trial target unknown NA TTD , DGIDB bms-986036 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 fibroblast growth factor-21 FGF21 Clinical trial target unknown 63.65 TTD , DGIDB fgf-21 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1/2 fibroblast growth factor-21 FGF21 Clinical trial target unknown NA TTD burosumab NA Bone Diseases[MeSHID:D001847],Hypophosphatemic Rickets, X-Linked Dominant[MeSHID:D053098],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor-23 FGF23 Successful target inhibitor 254.61 TTD , DGIDB burosumab biotech Bone Diseases[MeSHID:D001847],Hypophosphatemic Rickets, X-Linked Dominant[MeSHID:D053098],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor 23 FGF23 NA antagonist,inhibitor 254.61 drugbank , DGIDB burosumab NA Bone Diseases[MeSHID:D001847],Hypophosphatemic Rickets, X-Linked Dominant[MeSHID:D053098],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor-23 FGF23 Successful target unknown 254.61 TTD , DGIDB burosumab biotech Bone Diseases[MeSHID:D001847],Hypophosphatemic Rickets, X-Linked Dominant[MeSHID:D053098],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor 23 FGF23 NA antagonist 254.61 drugbank , DGIDB ad5fgf-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 3 fibroblast growth factor-4 FGF4 Successful target unknown NA TTD , DGIDB tp-508 small molecule Injury wounds[MeSHID:D014947],Fracture[MeSHID:D050723],Diabetic Foot[MeSHID:D017719] investigational fibroblast growth factor 4 FGF4 NA unknown NA drugbank heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational fibroblast growth factor 4 FGF4 NA unknown 4.39 drugbank , DGIDB generx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 3 fibroblast growth factor-4 FGF4 Successful target unknown NA TTD pentosan polysulfate NA Pain[MeSHID:D010146],Interstitial Cystitis[MeSHID:D018856],Urinary Bladder[MeSHID:D001743],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor-4 FGF4 Successful target unknown NA TTD , DGIDB pentosan polysulfate small molecule Pain[MeSHID:D010146],Interstitial Cystitis[MeSHID:D018856],Urinary Bladder[MeSHID:D001743],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor 4 FGF4 NA inhibitor NA drugbank , DGIDB alferminogene tadenovec NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787],Heart Diseases[MeSHID:D006331] phase 3 fibroblast growth factor-4 FGF4 Successful target unknown NA TTD , DGIDB keratinocyte growth factor NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 keratinocyte growth factor FGF7 Clinical trial target unknown NA TTD ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor 0.26 drugbank , DGIDB fgf-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 2 fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.18 TTD , DGIDB pmid26080733c7r NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor 0.62 drugbank , DGIDB bgj398 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cholangiocarcinoma[MeSHID:D018281] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.43 TTD , DGIDB ngm313 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD , DGIDB palifermin biotech Inflammatory disease of mucous membrane[MeSHID:D052016],Oral Mucositis[MeSHID:D013280],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor receptor 1 FGFR1 NA agonist 0.71 drugbank , DGIDB pemigatinib small molecule Cholangiocarcinoma[MeSHID:D018281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Malignant neoplasm of urinary bladder[MeSHID:D001749] approved,investigational fibroblast growth factor receptor 1 FGFR1 Successful target inhibitor 0.71 TTD , drugbank , DGIDB lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor 0.24 drugbank , DGIDB infigratinib small molecule Cholangiocarcinoma[MeSHID:D018281] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor 0.43 drugbank , DGIDB pmid24900538c2c NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD azd4547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2/3 fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD , DGIDB tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor NA drugbank arq-087 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cholangiocarcinoma[MeSHID:D018281] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target inhibitor 0.53 TTD , DGIDB kw-2449 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.14 TTD , DGIDB sar-106881 NA Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral Vascular Diseases[MeSHID:D016491] investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor 0.07 drugbank , DGIDB pd-0179483 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD rosiglitazone + metformin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD , DGIDB np-506 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target inhibitor 0.08 TTD , DGIDB azd4547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2/3 fibroblast growth factor receptor 1 FGFR1 Successful target inhibitor NA TTD , DGIDB am-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871] phase 2 fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD , DGIDB 3-benzimidazol-2-ylhydroquinolin-2-one NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 fibroblast growth factor receptor 1 FGFR1 Successful target inhibitor 0.1 TTD , DGIDB bms-695735 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.35 TTD , DGIDB actb-1003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone small molecule NA experimental fibroblast growth factor receptor 1 FGFR1 NA unknown NA drugbank pd-0173958 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved fibroblast growth factor receptor 1 FGFR1 NA inhibitor 0.34 drugbank , DGIDB ro-4396686 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD pd-0173955 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor NA drugbank (e)-[4-(3,5-difluorophenyl)-3h-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol small molecule NA experimental fibroblast growth factor receptor 1 FGFR1 NA unknown NA drugbank aal-993 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor NA drugbank romiplostim NA Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.09 TTD , DGIDB pmid22765894c8h NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD hki-9924129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD fp-1039 NA Endometrial Carcinoma[MeSHID:D016889],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.71 TTD , DGIDB pd-0173956 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD 2-(1h-indazol-3-yl)-1h-benzo[d]imidazole NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD intedanib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hamman-Rich syndrome[MeSHID:D011658],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of ovary[MeSHID:D010051],Mesothelioma[MeSHID:D008654] approved fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.34 TTD , DGIDB bgj398 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cholangiocarcinoma[MeSHID:D018281] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target inhibitor 0.43 TTD , DGIDB debio 1347 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 2 fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD , DGIDB 3-(3-methoxybenzyl)-1h-pyrrolo[2,3-b]pyridine small molecule NA experimental,investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD , drugbank sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target inhibitor 0.42 TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.1 TTD , DGIDB pd-0173952 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD pd-0166326 NA NA investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD anti-fgfr1 mab program NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fibroblast growth factor receptor 1 FGFR1 Successful target unknown NA TTD heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA unknown NA drugbank xl999 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational fibroblast growth factor receptor 1 FGFR1 NA unknown NA drugbank , DGIDB e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.08 TTD , DGIDB arq-087 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cholangiocarcinoma[MeSHID:D018281] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.53 TTD , DGIDB selpercatinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational fibroblast growth factor receptor 1 FGFR1 NA inhibitor NA drugbank regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor receptor 1 FGFR1 NA inhibitor 0.05 drugbank , DGIDB sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 fibroblast growth factor receptor 1 FGFR1 Successful target unknown 0.42 TTD , DGIDB 3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone small molecule NA experimental fibroblast growth factor receptor 1 FGFR1 NA unknown NA drugbank heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational fibroblast growth factor receptor 2 FGFR2 NA unknown NA drugbank pemigatinib small molecule Cholangiocarcinoma[MeSHID:D018281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Malignant neoplasm of urinary bladder[MeSHID:D001749] approved,investigational fibroblast growth factor receptor 2 FGFR2 Successful target inhibitor 2.08 TTD , drugbank , DGIDB thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved,investigational,withdrawn fibroblast growth factor receptor 2 FGFR2 NA antagonist 0.11 drugbank , DGIDB sucrosofate small molecule NA experimental fibroblast growth factor receptor 2 FGFR2 NA ligand NA drugbank pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor receptor 2 FGFR2 NA inhibitor NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational,withdrawn fibroblast growth factor receptor 2 FGFR2 NA antagonist 0.11 drugbank , DGIDB ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor receptor 2 FGFR2 NA inhibitor 0.65 drugbank , DGIDB pemigatinib small molecule Cholangiocarcinoma[MeSHID:D018281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Malignant neoplasm of urinary bladder[MeSHID:D001749] approved,investigational fibroblast growth factor receptor 2 FGFR2 Successful target inhibitor,activator 2.08 TTD , drugbank , DGIDB foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved fibroblast growth factor receptor 2 FGFR2 NA agonist NA drugbank anti-fgfr2 humanized mab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD ly2874455 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 fibroblast growth factor receptor 2 FGFR2 Successful target inhibitor 0.75 TTD , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved fibroblast growth factor receptor 2 FGFR2 NA inhibitor 0.53 drugbank , DGIDB infigratinib small molecule Cholangiocarcinoma[MeSHID:D018281] approved,investigational fibroblast growth factor receptor 2 FGFR2 NA inhibitor 1.03 drugbank , DGIDB lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational fibroblast growth factor receptor 2 FGFR2 NA inhibitor 0.21 drugbank , DGIDB interferon alfa-2a, recombinant NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] approved fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD , DGIDB foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved fibroblast growth factor receptor 2 FGFR2 NA agonist NA drugbank 4-[4-(1-amino-1-methylethyl)phenyl]-5-chloro-n-[4-(2-morpholin-4-ylethyl)phenyl]pyrimidin-2-amine small molecule NA experimental fibroblast growth factor receptor 2 FGFR2 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational fibroblast growth factor receptor 2 FGFR2 NA inhibitor NA drugbank regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor receptor 2 FGFR2 NA inhibitor 0.09 drugbank , DGIDB alofanib NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD rly-4008 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 fibroblast growth factor receptor 2 FGFR2 Successful target unknown 0.18 TTD , DGIDB ro-4396686 NA NA investigative fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD debio 1347 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 2 fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD , DGIDB 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone small molecule NA experimental fibroblast growth factor receptor 2 FGFR2 NA unknown NA drugbank mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 fibroblast growth factor receptor 2 FGFR2 Successful target inhibitor 0.18 TTD , DGIDB tg-100435 NA NA investigative fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD platelet factor 4 (pf-4) NA NA investigative fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 fibroblast growth factor receptor 2 FGFR2 Successful target inhibitor 0.15 TTD , DGIDB palifermin biotech Inflammatory disease of mucous membrane[MeSHID:D052016],Oral Mucositis[MeSHID:D013280],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibroblast growth factor receptor 2 FGFR2 Successful target agonist,binder 2.7 TTD , drugbank , DGIDB trafermin NA Periodontitis[MeSHID:D010518],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 fibroblast growth factor receptor 2 FGFR2 Successful target unknown 0.62 TTD , DGIDB ly2874455 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 fibroblast growth factor receptor 2 FGFR2 Successful target unknown 0.75 TTD , DGIDB erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational fibroblast growth factor receptor 2 FGFR2 NA inhibitor 1.4 drugbank , DGIDB actb-1003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD pk 11195 NA NA investigative fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD selpercatinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational fibroblast growth factor receptor 2 FGFR2 NA inhibitor NA drugbank bay1179470 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fibroblast growth factor receptor 2 FGFR2 Successful target unknown NA TTD , DGIDB aee-788 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 fibroblast growth factor receptor 2 FGFR2 Successful target unknown 0.18 TTD , DGIDB e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 fibroblast growth factor receptor 2 FGFR2 Successful target unknown 0.15 TTD , DGIDB ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor receptor 3 FGFR3 NA inhibitor 0.3 drugbank , DGIDB aee-788 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 fibroblast growth factor receptor 3 FGFR3 Successful target unknown 0.15 TTD , DGIDB actb-1003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD infigratinib small molecule Cholangiocarcinoma[MeSHID:D018281] approved,investigational fibroblast growth factor receptor 3 FGFR3 NA inhibitor 0.89 drugbank , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved fibroblast growth factor receptor 3 FGFR3 NA inhibitor 0.44 drugbank , DGIDB lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational fibroblast growth factor receptor 3 FGFR3 NA inhibitor NA drugbank xl999 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational fibroblast growth factor receptor 3 FGFR3 NA unknown NA drugbank bms-582664 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 3 fibroblast growth factor receptor 3 FGFR3 Successful target unknown 0.29 TTD , DGIDB pmid21493067c1d NA NA investigative fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational fibroblast growth factor receptor 3 FGFR3 NA inhibitor NA drugbank erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational fibroblast growth factor receptor 3 FGFR3 NA inhibitor 1.41 drugbank , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 fibroblast growth factor receptor 3 FGFR3 Successful target inhibitor 0.15 TTD , DGIDB trapidil NA Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] phase 4 fibroblast growth factor receptor 3 FGFR3 Successful target unknown 0.51 TTD , DGIDB ro-4396686 NA NA investigative fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 fibroblast growth factor receptor 3 FGFR3 Successful target unknown 0.12 TTD , DGIDB b-701 NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] phase 2 fibroblast growth factor receptor 3 FGFR3 Successful target unknown 2.05 TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 fibroblast growth factor receptor 3 FGFR3 Successful target unknown 0.15 TTD , DGIDB pemigatinib small molecule Cholangiocarcinoma[MeSHID:D018281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Malignant neoplasm of urinary bladder[MeSHID:D001749] approved,investigational fibroblast growth factor receptor 3 FGFR3 Successful target inhibitor 1.03 TTD , drugbank , DGIDB tki258 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Endometrial Carcinoma[MeSHID:D016889],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 fibroblast growth factor receptor 3 FGFR3 Successful target unknown 0.21 TTD , DGIDB debio 1347 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 2 fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD , DGIDB anti-fgfr3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD , DGIDB av-370 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD 5,11-dimethyl-6h-pyrido[4,3-b]carbazol-9-ol NA NA investigative fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD selpercatinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational fibroblast growth factor receptor 3 FGFR3 NA inhibitor NA drugbank pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved fibroblast growth factor receptor 3 FGFR3 NA inhibitor 0.13 drugbank , DGIDB su5402 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD , DGIDB recifercept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Achondroplasia[MeSHID:D000130] phase 2 fibroblast growth factor receptor 3 FGFR3 Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 fibroblast growth factor receptor 3 FGFR3 Successful target inhibitor 0.12 TTD , DGIDB actb-1003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative fibroblast growth factor receptor 4 FGFR4 Clinical trial target unknown NA TTD h3b-6527 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1 fgfr4 messenger rna FGFR4 Clinical trial target unknown NA TTD isis-fgfr4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 fgfr4 messenger rna FGFR4 Clinical trial target unknown NA TTD lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational fibroblast growth factor receptor 4 FGFR4 NA inhibitor NA drugbank heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational fibroblast growth factor receptor 4 FGFR4 NA unknown NA drugbank ro-4396686 NA NA investigative fgfr4 messenger rna FGFR4 Clinical trial target unknown NA TTD pemigatinib small molecule Cholangiocarcinoma[MeSHID:D018281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Malignant neoplasm of urinary bladder[MeSHID:D001749] approved,investigational fibroblast growth factor receptor 4 FGFR4 NA inhibitor NA drugbank blu-554 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1 fgfr4 messenger rna FGFR4 Clinical trial target unknown NA TTD fgf401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Liver carcinoma[MeSHID:D006528] phase 1/2 fgfr4 messenger rna FGFR4 Clinical trial target inhibitor 2.19 TTD , DGIDB abc-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Bone Cysts, Aneurysmal[MeSHID:D017824] investigative fibroblast growth factor receptor 4 FGFR4 Clinical trial target unknown NA TTD erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational fibroblast growth factor receptor 4 FGFR4 NA inhibitor 0.82 drugbank , DGIDB infigratinib small molecule Cholangiocarcinoma[MeSHID:D018281] approved,investigational fibroblast growth factor receptor 4 FGFR4 NA inhibitor 0.29 drugbank , DGIDB ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational fibroblast growth factor receptor 4 FGFR4 NA inhibitor 0.24 drugbank , DGIDB incb62079 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] phase 1/2 fibroblast growth factor receptor 4 FGFR4 Clinical trial target unknown NA TTD , DGIDB sucralfate small molecule Maintenance[MeSHID:D008283],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibrinogen FGG NA binder NA drugbank human thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibrinogen gamma chain FGG NA activator NA drugbank thrombin biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved,investigational fibrinogen gamma chain FGG NA activator NA drugbank thrombin alfa biotech Blood capillaries[MeSHID:D002196],Hemostatic function[MeSHID:D006487],Structure of venule[MeSHID:D014699],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Hemorrhage[MeSHID:D006470] approved fibrinogen gamma chain FGG NA activator NA drugbank zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase fgr FGR NA inhibitor NA drugbank zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase fgr FGR NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase fgr FGR NA inhibitor NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase fgr FGR NA inhibitor 0.22 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase fgr FGR NA inhibitor 0.22 drugbank , DGIDB adenosine monotungstate small molecule NA experimental bis(5'-adenosyl)-triphosphatase FHIT NA unknown NA drugbank ado-p-ch2-p-ps-ado small molecule NA experimental bis(5'-adenosyl)-triphosphatase FHIT NA unknown NA drugbank fructose NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vomiting[MeSHID:D014839] approved fragile histidine triad protein FHIT Successful target unknown 95.48 TTD , DGIDB ado-p-ch2-p-ps-ado NA NA investigative fragile histidine triad protein FHIT Successful target unknown NA TTD adenosine monotungstate NA NA investigative fragile histidine triad protein FHIT Successful target unknown NA TTD heptyl glucoside small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank ap1903 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft Rejection[MeSHID:D006084] phase 1/2 fk506-binding protein 1a FKBP1A Successful target unknown 4.55 TTD , DGIDB fkb-001 NA NA investigative fk506-binding protein 1a FKBP1A Successful target unknown NA TTD tacrolimus small molecule Eczema[MeSHID:D004485],Transplanted tissue[MeSHID:D019737],Dermatitis, Atopic[MeSHID:D003876],Pancreas[MeSHID:D010179],Trachea[MeSHID:D014132],Heart[MeSHID:D006321],Limb structure[MeSHID:D005121],Lung[MeSHID:D008168],Cornea[MeSHID:D003315],Kidney[MeSHID:D007668],Intestines, Small[MeSHID:D007421],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved,investigational peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA inhibitor 0.8 drugbank , DGIDB heptyl-beta-d-glucopyranoside NA NA investigative fk506-binding protein 1a FKBP1A Successful target unknown NA TTD gpi-1485 NA Parkinson Disease[MeSHID:D010300],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 fk506-binding protein 1a FKBP1A Successful target unknown 9.09 TTD , DGIDB rapamycin immunosuppressant drug NA NA investigative fk506-binding protein 1a FKBP1A Successful target unknown NA TTD (3r)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-l-phenylalanine ethyl ester small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank l-709,587 NA NA investigative fk506-binding protein 1a FKBP1A Successful target unknown NA TTD gpi-1046 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Parkinson Disease[MeSHID:D010300],Expiration, function[MeSHID:D045853] experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank l-709,587 small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank sdz-281-240 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] phase 2 fk506-binding protein 1a FKBP1A Successful target unknown NA TTD , DGIDB pimecrolimus small molecule Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA potentiator,inhibitor 4.55 drugbank , DGIDB gpi-1485 small molecule Parkinson Disease[MeSHID:D010300],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown 9.09 drugbank , DGIDB methyl methylsulfinylmethyl sulfide small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank myristic acid NA NA investigative fk506-binding protein 1a FKBP1A Successful target unknown NA TTD methyl methylsulfinylmethyl sulfide NA NA investigative fk506-binding protein 1a FKBP1A Successful target unknown NA TTD pimecrolimus small molecule Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA potentiator 4.55 drugbank , DGIDB 4-hydroxy-2-butanone NA NA investigative fk506-binding protein 1a FKBP1A Successful target unknown NA TTD (3r)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-l-leucine small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank (21s)-1aza-4,4-dimethyl-6,19-dioxa-2,3,7,20-tetraoxobicyclo[19.4.0] pentacosane small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank 4-hydroxybutan-2-one small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank fkb-001 small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank dorsomorphin small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank {3-[3-(3,4-dimethoxy-phenyl)-1-(1-{1-[2-(3,4,5-trimethoxy-phenyl)-butyryl]-piperidin-2yl}-vinyloxy)-propyl]-phenoxy}-acetic acid small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank myristic acid small molecule NA experimental peptidyl-prolyl cis-trans isomerase fkbp1a FKBP1A NA unknown NA drugbank pti-125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 filamin a FLNA Clinical trial target unknown NA TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational filamin-a FLNA NA ligand NA drugbank pti-125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 filamin a FLNA Clinical trial target unknown NA TTD , DGIDB vatalanib NA Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 vegfr1 messenger rna FLT1 Successful target inhibitor 0.4 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor NA drugbank 3,6-di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD 4-chloro-n-(2-chloro-benzoyl)-benzenesulfonamide NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD sunitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved,investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.26 drugbank , DGIDB sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown 0.3 TTD , DGIDB telbermin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] discontinued in phase 2 vascular endothelial growth factor receptor 1 FLT1 Successful target agonist 0.37 TTD , DGIDB (2-methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD cep-11981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 1 FLT1 Successful target inhibitor 0.12 TTD , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.25 drugbank , DGIDB famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 vascular endothelial growth factor receptor 1 FLT1 Successful target inhibitor 0.21 TTD , DGIDB 3-(5-phenyl-oxazol-2-ylamino)-benzonitrile NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD 4-(5-phenyl-oxazol-2-ylamino)-benzenesulfonamide NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 1 FLT1 Successful target inhibitor 0.3 TTD , DGIDB x-82 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268] phase 2 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown 0.45 TTD , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 1 FLT1 NA unknown 0.05 drugbank , DGIDB 4-chloro-n-(4-nitro-benzoyl)-benzenesulfonamide NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD osi-930 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.21 drugbank , DGIDB aal-993 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 1 FLT1 Successful target inhibitor 0.87 TTD , drugbank , DGIDB n-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide small molecule NA experimental vascular endothelial growth factor receptor 1 FLT1 NA unknown NA drugbank pmid17935989c25 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD imc-1c11 biotech Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 1 FLT1 NA unknown NA drugbank su-11652 NA NA investigative vascular endothelial growth factor receptor 1 FLT1 Successful target unknown NA TTD ew-a-401 NA Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown NA TTD , DGIDB denibulin small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 1 FLT1 NA unknown NA drugbank lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.19 drugbank , DGIDB vatalanib small molecule Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 1 FLT1 NA unknown 0.4 drugbank , DGIDB axitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Pancreas[MeSHID:D010179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.52 drugbank , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.05 drugbank , DGIDB 4-chloro-n-(2-methyl-benzoyl)-benzenesulfonamide NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD cdk1/2 inhibitor iii NA NA investigative vegfr1 messenger rna FLT1 Successful target inhibitor NA TTD , DGIDB aal-993 NA NA investigative vascular endothelial growth factor receptor 1 FLT1 Successful target unknown NA TTD 4-(isoquinolin-5-yl)-n-m-tolylphthalazin-1-amine NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD 2-(5-phenyl-oxazol-2-ylamino)-benzonitrile NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD otsgc-a24 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown NA TTD , DGIDB tg-100801 small molecule Age related macular degeneration[MeSHID:D008268] investigational vascular endothelial growth factor receptor 1 FLT1 NA unknown NA drugbank c[yydeglee]-nh2 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD x-82 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268] phase 2 vascular endothelial growth factor receptor 1 FLT1 Successful target inhibitor 0.45 TTD , DGIDB n3-ghqmfyypra-nh2 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD fruquintinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 1 FLT1 Successful target inhibitor 1 TTD , DGIDB vatalanib NA Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 vegfr1 messenger rna FLT1 Successful target unknown 0.4 TTD , DGIDB 4-chloro-n-(3-chloro-benzoyl)-benzenesulfonamide NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD ocv-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown NA TTD , DGIDB ly3012212 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Arteriosclerosis[MeSHID:D001161] phase 2 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown NA TTD , DGIDB romiplostim NA Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved vegfr1 messenger rna FLT1 Successful target unknown NA TTD mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vegfr1 messenger rna FLT1 Successful target inhibitor 0.05 TTD , DGIDB vatalanib small molecule Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.4 drugbank , DGIDB sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.07 drugbank , DGIDB lycogarubin b NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD n-(3-bromo-benzoyl)-4-chloro-benzenesulfonamide NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD fruquintinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown 1 TTD , DGIDB cep-11981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown 0.12 TTD , DGIDB n-(2,4-dichloro-benzoyl)-benzenesulfonamide NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD polaprezinc small molecule Peptic Ulcer[MeSHID:D010437],Dyspepsia[MeSHID:D004415],Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcer[MeSHID:D014456] experimental vascular endothelial growth factor receptor 1 FLT1 NA agonist NA drugbank 2-(1h-indazol-3-yl)-1h-benzo[d]imidazole NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD im-094882 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD 4-chloro-n-(4-chloro-benzoyl)-benzenesulfonamide NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD c[yydeklee]-nh2 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD sirna-027 NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Pathologic Neovascularization[MeSHID:D009389],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vegfr1 messenger rna FLT1 Successful target unknown NA TTD c[homophe-hca-glu-gly-leu-glu-glu]-nh2 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD selpercatinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational vascular endothelial growth factor receptor 1 FLT1 NA inhibitor NA drugbank c[yyaeglee]-nh2 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.11 drugbank , DGIDB pmid22765894c8h NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown 0.09 TTD , DGIDB (5-phenyl-oxazol-2-yl)-m-tolyl-amine NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD phenyl-(5-phenyl-oxazol-2-yl)-amine NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 1 FLT1 Successful target inhibitor 0.09 TTD , DGIDB angiozyme NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown NA TTD cb-676475 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved vascular endothelial growth factor receptor 1 FLT1 NA inhibitor 0.13 drugbank , DGIDB im-094261 NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved vascular endothelial growth factor receptor 1 FLT1 NA agonist NA drugbank famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 vascular endothelial growth factor receptor 1 FLT1 Successful target unknown 0.21 TTD , DGIDB 4-(isoquinolin-5-yl)-n-o-tolylphthalazin-1-amine NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD [3-(5-phenyl-oxazol-2-ylamino)-phenyl]-methanol NA NA investigative vegfr1 messenger rna FLT1 Successful target unknown NA TTD akn-028 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] investigative fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.66 TTD , DGIDB fn-1501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD g749 NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target inhibitor NA TTD , DGIDB amg 427 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD midostaurin NA Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved fms-like tyrosine kinase 3 FLT3 Successful target unknown 1.27 TTD , DGIDB lestaurtinib small molecule leukemia[MeSHID:D007938],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Leukemia, Myelocytic, Acute[MeSHID:D015470],Psoriasis[MeSHID:D011565] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA unknown 1.99 drugbank , DGIDB (5-fluoro-1h-indol-2-yl)-(1h-indol-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD pexidartinib NA Giant Cell Tumors[MeSHID:D005870],Operative Surgical Procedures[MeSHID:D013514],Testicular Germ Cell Tumor[MeSHID:C563236],Pigmented villonodular synovitis[MeSHID:D013586],Neurofibromatosis 1[MeSHID:D009456],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.54 TTD , DGIDB ponatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.76 TTD , DGIDB gilteritinib NA Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fms-like tyrosine kinase 3 FLT3 Successful target unknown 1.16 TTD , DGIDB sel-24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor NA drugbank hm43239 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD (1h-indol-2-yl)(5-methoxy-1h-indol-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD xl999 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA unknown NA drugbank , DGIDB (1h-indol-2-yl)(6-methoxy-1h-indol-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 1.16 drugbank , DGIDB bis(5-aminobenzo[b]furan-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 0.38 drugbank , DGIDB intedanib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hamman-Rich syndrome[MeSHID:D011658],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of ovary[MeSHID:D010051],Mesothelioma[MeSHID:D008654] approved fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.09 TTD , DGIDB 4-(4-aminophenyl)-1h-indazol-3yl-amine NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD gtp-14564 NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.17 TTD , DGIDB cdx-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant Neoplasms[MeSHID:D009369] phase 2 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD , DGIDB ki23819 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD , DGIDB famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.19 TTD , DGIDB pyridine derivative 18 NA NA patented fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD , DGIDB tandutinib small molecule leukemia[MeSHID:D007938],Anaplasia[MeSHID:D000708],Mixed Oligodendroglioma-Astrocytoma[MeSHID:D009837],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mixed oligoastrocytoma[MeSHID:D001254] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 0.73 drugbank , DGIDB pacritinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] phase 3 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.66 TTD , DGIDB sunitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 0.45 drugbank , DGIDB in1479 NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD mc-2001 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD , DGIDB (benzo[b]furan-2-yl)-(1h-indol-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD imc-eb10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.66 TTD , DGIDB gilteritinib NA Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 1.16 TTD , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 0.04 drugbank , DGIDB urmc-099 NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target inhibitor NA TTD , DGIDB tcs-359 NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.09 TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.09 TTD , DGIDB amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA unknown 0.38 drugbank , DGIDB ff-10101-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD , DGIDB jnj-28312141 NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.13 TTD , DGIDB pexidartinib NA Giant Cell Tumors[MeSHID:D005870],Operative Surgical Procedures[MeSHID:D013514],Testicular Germ Cell Tumor[MeSHID:C563236],Pigmented villonodular synovitis[MeSHID:D013586],Neurofibromatosis 1[MeSHID:D009456],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.54 TTD , DGIDB quizartinib small molecule NA investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA unknown 2.8 drugbank , DGIDB pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor NA drugbank di(1h-indol-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor NA drugbank bms-690514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.19 TTD , DGIDB (5-hydroxy-1h-indol-2-yl)(1h-indol-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD tak-659 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Hematologic Neoplasms[MeSHID:D019337] phase 2 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.33 TTD , DGIDB fedratinib small molecule Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 0.11 drugbank , DGIDB (1h-indol-2-yl)(5-phenoxy-1h-indol-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD ff-10101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD tandutinib small molecule leukemia[MeSHID:D007938],Anaplasia[MeSHID:D000708],Mixed Oligodendroglioma-Astrocytoma[MeSHID:D009837],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mixed oligoastrocytoma[MeSHID:D001254] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA unknown 0.73 drugbank , DGIDB pexidartinib small molecule Giant Cell Tumors[MeSHID:D005870],Operative Surgical Procedures[MeSHID:D013514],Testicular Germ Cell Tumor[MeSHID:C563236],Pigmented villonodular synovitis[MeSHID:D013586],Neurofibromatosis 1[MeSHID:D009456],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 0.54 drugbank , DGIDB bis(6-hydroxybenzo[b]furan-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD 2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD lestaurtinib small molecule leukemia[MeSHID:D007938],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Leukemia, Myelocytic, Acute[MeSHID:D015470],Psoriasis[MeSHID:D011565] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 1.99 drugbank , DGIDB bms-690514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.19 TTD , DGIDB 4sc-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.33 TTD , DGIDB kw-2449 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.4 TTD , DGIDB midostaurin small molecule Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA antagonist,inhibitor 1.27 drugbank , DGIDB ast-487 NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.04 TTD , DGIDB pacritinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] phase 3 fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.66 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor NA drugbank sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA antagonist 0.33 drugbank , DGIDB brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor NA drugbank fedratinib small molecule Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Polycythemia Vera[MeSHID:D011087],Disease[MeSHID:D004194] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 0.11 drugbank , DGIDB pmid21982499c14k NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD carboxamide derivative 4 NA NA patented fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD , DGIDB tandutinib NA leukemia[MeSHID:D007938],Anaplasia[MeSHID:D000708],Mixed Oligodendroglioma-Astrocytoma[MeSHID:D009837],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mixed oligoastrocytoma[MeSHID:D001254] discontinued in phase 2 fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.73 TTD , DGIDB xl999 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor NA drugbank , DGIDB ac220 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 fms-like tyrosine kinase 3 FLT3 Successful target unknown 2.8 TTD , DGIDB kw-2449 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.4 TTD , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA unknown 0.04 drugbank , DGIDB famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.19 TTD , DGIDB pmid24900538c2c NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD quizartinib small molecule NA investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 2.8 drugbank , DGIDB sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA antagonist,inhibitor 0.33 drugbank , DGIDB pmid22765894c8h NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor-type tyrosine-protein kinase flt3 FLT3 NA inhibitor 0.76 drugbank , DGIDB midostaurin NA Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 1.27 TTD , DGIDB ski-g-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD lestaurtinib NA leukemia[MeSHID:D007938],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Leukemia, Myelocytic, Acute[MeSHID:D015470],Psoriasis[MeSHID:D011565] approved (orphan drug) fms-like tyrosine kinase 3 FLT3 Successful target unknown 1.99 TTD , DGIDB 4sc-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.33 TTD , DGIDB n-[4-(3-amino-1h-indazol-4-yl)phenyl]benzamide NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD sel24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD ponatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 0.76 TTD , DGIDB zidovudine NA Infection[MeSHID:D007239],Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.02 TTD , DGIDB lestaurtinib NA leukemia[MeSHID:D007938],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Leukemia, Myelocytic, Acute[MeSHID:D015470],Psoriasis[MeSHID:D011565] approved (orphan drug) fms-like tyrosine kinase 3 FLT3 Successful target inhibitor 1.99 TTD , DGIDB bis(5-hydroxybenzo[b]furan-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD bis(5-acetoxybenzo[b]furan-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD bis-(5-hydroxy-1h-indol-2-yl)-methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD tandutinib NA leukemia[MeSHID:D007938],Anaplasia[MeSHID:D000708],Mixed Oligodendroglioma-Astrocytoma[MeSHID:D009837],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mixed oligoastrocytoma[MeSHID:D001254] discontinued in phase 2 fms-like tyrosine kinase 3 FLT3 Successful target unknown 0.73 TTD , DGIDB bis(benzo[b]furan-2-yl)methanone NA NA investigative fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD mrx-2843 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Mental Retardation, X-Linked 1[MeSHID:C567906] phase 1 fms-like tyrosine kinase 3 FLT3 Successful target unknown NA TTD , DGIDB pi-88 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471],Liver carcinoma[MeSHID:D006528] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.15 TTD , DGIDB lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational vascular endothelial growth factor receptor 3 FLT4 NA inhibitor 0.3 drugbank , DGIDB mgcd516 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 vascular endothelial growth factor receptor 3 FLT4 Successful target inhibitor 0.21 TTD , DGIDB (2-methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD fruquintinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.98 TTD , DGIDB pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved vascular endothelial growth factor receptor 3 FLT4 NA inhibitor 0.16 drugbank , DGIDB axitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Pancreas[MeSHID:D010179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 3 FLT4 NA inhibitor 0.39 drugbank , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vascular endothelial growth factor receptor 3 FLT4 Successful target inhibitor 0.1 TTD , DGIDB n-(2,4-dichloro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.21 TTD , DGIDB 4-chloro-n-(3-chloro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target inhibitor 0.09 TTD , DGIDB phenyl-(5-phenyl-oxazol-2-yl)-amine NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD cep-6331 NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD abt-869 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.06 TTD , DGIDB pmid22765894c8h NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 3 FLT4 NA antagonist,inhibitor 0.11 drugbank , DGIDB sar-131675 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD n-(3-bromo-benzoyl)-4-chloro-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD fruquintinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target inhibitor 0.98 TTD , DGIDB 4-chloro-n-(2-methyl-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD 2-(5-phenyl-oxazol-2-ylamino)-benzonitrile NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 3 FLT4 NA unknown 0.06 drugbank , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.1 TTD , DGIDB denibulin small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 3 FLT4 NA unknown NA drugbank 3,6-di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD 4-chloro-n-(4-nitro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD 4-chloro-n-(2-chloro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD 3-(5-phenyl-oxazol-2-ylamino)-benzonitrile NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD [3-(5-phenyl-oxazol-2-ylamino)-phenyl]-methanol NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD vatalanib small molecule Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 2 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.39 TTD , drugbank , DGIDB sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.29 TTD , DGIDB sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target inhibitor 0.29 TTD , DGIDB 4-(5-phenyl-oxazol-2-ylamino)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational vascular endothelial growth factor receptor 3 FLT4 NA inhibitor NA drugbank pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved vascular endothelial growth factor receptor 3 FLT4 NA unknown 0.16 drugbank , DGIDB e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.09 TTD , DGIDB taberminogene vadenovec NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Vessel[MeSHID:D001808] phase 3 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD , DGIDB cb-676475 NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD 4-chloro-n-(4-chloro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 3 FLT4 Successful target inhibitor 0.85 TTD , drugbank , DGIDB imc-3c5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 2.19 TTD , DGIDB (5-phenyl-oxazol-2-yl)-m-tolyl-amine NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD selpercatinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational vascular endothelial growth factor receptor 3 FLT4 NA inhibitor NA drugbank anti-vegfr 3 mab NA NA investigative vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD vatalanib small molecule Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 2 vascular endothelial growth factor receptor 3 FLT4 Successful target inhibitor 0.39 TTD , drugbank , DGIDB pyrimidine derivative 15 NA NA patented vascular endothelial growth factor receptor 3 FLT4 Successful target unknown NA TTD , DGIDB sunitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved,investigational vascular endothelial growth factor receptor 3 FLT4 NA inhibitor 0.24 drugbank , DGIDB jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 3 FLT4 Successful target unknown 0.16 TTD , DGIDB imc-1c11 biotech Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 3 FLT4 NA unknown NA drugbank regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vascular endothelial growth factor receptor 3 FLT4 NA inhibitor 0.1 drugbank , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved vascular endothelial growth factor receptor 3 FLT4 NA inhibitor 0.24 drugbank , DGIDB tg-100801 small molecule Age related macular degeneration[MeSHID:D008268] investigational vascular endothelial growth factor receptor 3 FLT4 NA unknown NA drugbank jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 3 FLT4 Successful target inhibitor 0.16 TTD , DGIDB sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 3 FLT4 NA antagonist 0.11 drugbank , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 3 FLT4 NA inhibitor 0.06 drugbank , DGIDB l19-tnf-alpha NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 fibronectin FN1 Clinical trial target unknown NA TTD , DGIDB ocriplasmin biotech Tissue Adhesions[MeSHID:D000267],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved fibronectin FN1 Clinical trial target cleavage 1.29 TTD , drugbank , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational fibronectin FN1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental fibronectin FN1 NA modulator,ligand NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational fibronectin FN1 NA modulator,ligand NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational fibronectin FN1 NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational fibronectin FN1 NA unknown NA drugbank geranylgeranyl diphosphate small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank lonafarnib small molecule Homozygote[MeSHID:D006720],Body Surface Area[MeSHID:D001830],Progeria[MeSHID:D011371],Mutation[MeSHID:D009154],Heterozygote[MeSHID:D006579],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hepatitis D Infection[MeSHID:D003699] approved,investigational protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA inhibitor 15.91 drugbank , DGIDB farnesyl diphosphate small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank azd3409 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Malignant Neoplasms[MeSHID:D009369],Expiration, function[MeSHID:D045853] investigational protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank (20s)-19,20,22,23-tetrahydro-19-oxo-5h,21h-18,20-ethano-12,14-etheno-6,10-methenobenz[d]imidazo[4,3-l][1,6,9,13]oxatriazacyclonoadecosine-9-carbonitrile small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank 2-[methyl-(5-geranyl-4-methyl-pent-3-enyl)-amino]-ethyl-diphosphate small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank l-778123 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank alpha-hydroxyfarnesylphosphonic acid small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank 2-chloro-5-(3-chloro-phenyl)-6-[(4-cyano-phenyl)-(3-methyl-3h-imidazol-4-yl)- methoxymethyl]-nicotinonitrile small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank (11s)-8-chloro-11-[1-(methylsulfonyl)piperidin-4-yl]-6-piperazin-1-yl-11h-benzo[5,6]cyclohepta[1,2-b]pyridine small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank (20s)-19,20,21,22-tetrahydro-19-oxo-5h-18,20-ethano-12,14-etheno-6,10-metheno-18h-benz[d]imidazo[4,3-k][1,6,9,12]oxatriaza-cyclooctadecosine-9-carbonitrile small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank [(3,7,11-trimethyl-dodeca-2,6,10-trienyloxycarbamoyl)-methyl]-phosphonic acid small molecule NA experimental protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA NA unknown NA drugbank (20s)-19,20,21,22-tetrahydro-19-oxo-5h-18,20-ethano-12,14-etheno-6,10-metheno-18h-benz[d]imidazo[4,3-k][1,6,9,12]oxatriaza-cyclooctadecosine-9-carbonitrile small molecule NA experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank actinoplanic acid a NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD [(3,7,11-trimethyl-dodeca-2,6,10-trienyloxycarbamoyl)-methyl]-phosphonic acid small molecule NA experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank pd-83176 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD arteminolide NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD (11s)-8-chloro-11-[1-(methylsulfonyl)piperidin-4-yl]-6-piperazin-1-yl-11h-benzo[5,6]cyclohepta[1,2-b]pyridine small molecule NA experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank 2-chloro-5-(3-chloro-phenyl)-6-[(4-cyano-phenyl)-(3-methyl-3h-imidazol-4-yl)- methoxymethyl]-nicotinonitrile small molecule NA experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank alpha-hydroxyfarnesylphosphonic acid small molecule NA experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank fti 276 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target inhibitor NA TTD , DGIDB clavarinone NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD a-313326 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD bms-316810 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD f-12458 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD pb-81 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD farnesyl diphosphate small molecule NA experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank geranylgeranyl diphosphate small molecule NA experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank bms-404683 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD tipifarnib small molecule Pancreatic carcinoma[MeSHID:C562463],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Colorectal Cancer[MeSHID:D015179],leukemia[MeSHID:D007938] investigational protein farnesyltransferase subunit beta FNTB NA unknown 10.18 drugbank , DGIDB pb-80 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD lonafarnib small molecule Homozygote[MeSHID:D006720],Body Surface Area[MeSHID:D001830],Progeria[MeSHID:D011371],Mutation[MeSHID:D009154],Heterozygote[MeSHID:D006579],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hepatitis D Infection[MeSHID:D003699] approved,investigational protein farnesyltransferase subunit beta FNTB NA inhibitor 6.37 drugbank , DGIDB farnesyl NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD preussomerin NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD geranylgeranyl diphosphate NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD h-smglpcvvm-oh NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD cylindrol a NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD prenyl pyrophosphate analogue NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD l-739750 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD (z)-2-methyl-3-tetradecyl-but-2-enedioic acid NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD tipifarnib small molecule Pancreatic carcinoma[MeSHID:C562463],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Colorectal Cancer[MeSHID:D015179],leukemia[MeSHID:D007938] investigational protein farnesyltransferase subunit beta FNTB NA inhibitor 10.18 drugbank , DGIDB l-778123 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank (20s)-19,20,22,23-tetrahydro-19-oxo-5h,21h-18,20-ethano-12,14-etheno-6,10-methenobenz[d]imidazo[4,3-l][1,6,9,13]oxatriazacyclonoadecosine-9-carbonitrile small molecule NA experimental protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank alpha-hydroxyfarnesylphosphonic acid NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD pb-27 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target unknown NA TTD lb42908 NA NA investigative caax farnesyltransferase beta FNTB Literature-reported target inhibitor NA TTD , DGIDB azd3409 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Malignant Neoplasms[MeSHID:D009369],Expiration, function[MeSHID:D045853] investigational protein farnesyltransferase subunit beta FNTB NA unknown NA drugbank 4-(2-carboxy-5-mercaptopentyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 99mtc-mip-1404 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 glutamate carboxypeptidase ii FOLH1 Successful target unknown 5.79 TTD , DGIDB capromab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved glutamate carboxypeptidase ii FOLH1 Successful target antibody 52.08 TTD , DGIDB 227th-labelled psma-ttc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-mercapto-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 4scar-psma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] phase 1/2 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB apvo414 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB 5-mercapto-pentanoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD jnj-63898081 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD amg 160 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(3-mercapto-propyl)-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD mdx-070 NA MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 2 glutamate carboxypeptidase ii FOLH1 Successful target unknown 5.79 TTD , DGIDB psma-targeted tubulysin b conjugates NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB 177-lu-psma-r2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(3-carboxybenzyl)succinic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD j 591 lu-177 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB g-202 NA Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glutamate carboxypeptidase ii FOLH1 Successful target unknown 5.79 TTD , DGIDB 2-(3-hydroxycarbamoyl-propyl)-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-hydroxycarbamoyl-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 3-(2-carbamoyl-5-mercaptopentyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-benzyl-5-mercaptopentanoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 177-lu-psma-617 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD atl101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB regn5678 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-phosphonooxy-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(2-carboxy-7-mercaptoheptyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-hydroxycarbamoylmethyl-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD ctt-54 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD (2s)-2-{[hydroxy(4-iodobenzyl)phosphoryl]methyl}pentanedioic acid small molecule NA experimental glutamate carboxypeptidase 2 FOLH1 NA unknown NA drugbank 2-mercaptomethyl-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD car-t cells targeting psma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],cervical cancer[MeSHID:D002583] phase 1/2 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB irx-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] preclinical glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB mln-2704 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 glutamate carboxypeptidase ii FOLH1 Successful target unknown 5.79 TTD , DGIDB psma-vrp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB 3-(1-carboxy-4-mercaptobutoxy)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate carboxypeptidase 2 FOLH1 NA unknown NA drugbank mdx-1147 NA MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD ctt1403 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 3-(2-carboxy-3-mercaptopropyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD psma car-t cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD mln-591rl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 glutamate carboxypeptidase ii FOLH1 Successful target unknown 5.79 TTD , DGIDB 99mtc-mip-1405 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB 3-(2-carboxy-4-mercaptobutyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD spaglumic acid small molecule Allergic Conjunctivitis[MeSHID:D003233] experimental glutamate carboxypeptidase 2 FOLH1 NA ligand NA drugbank j591-ac-225 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 99mtc-mip-1340 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 177lu-labelled ctt-1403 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 177lu-labelled psma-617 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 3-(2-carboxy-3-phosphonopropyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD gpi-16072 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB 2-(2-hydroxycarbamoyl-ethyl)-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(2-mercapto-ethyl)-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD piflufolastat f 18 small molecule Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008] approved,investigational glutamate carboxypeptidase 2 FOLH1 NA binder NA drugbank 2-(4-mercapto-butyl)-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(5-mercapto-pentyl)-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD autologous t-cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB [3h]quisqualate NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD psma subunit vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB pgi-02749 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD ccw702 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD iofolastat i-124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB 2-pmpa NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD hpn424 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD pmid15027864c8d NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD capromab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved glutamate carboxypeptidase ii FOLH1 Successful target unknown 52.08 TTD , DGIDB 3-(2-carboxy-5-mercaptopentyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 3-(2-carboxy-6-mercaptohexyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD capromab pendetide biotech Pelvis[MeSHID:D010388],Diagnosis[MeSHID:D003933],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362] approved glutamate carboxypeptidase 2 FOLH1 NA unknown NA drugbank psma-11 ga-68 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 177lu-labelled psma-r2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(3-cyanobenzyl)-5-mercaptopentanoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(3-methylsulfanyl-propyl)-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD bay-1075553 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB 99mtc-ec-0652 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD dcfbc small molecule NA experimental glutamate carboxypeptidase 2 FOLH1 NA unknown NA drugbank 3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD mip-1375 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(2-carboxy-5-mercaptopentyl)benzoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD 2-(2-phosphonooxy-ethyl)-pentanedioic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD mt-112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD , DGIDB 2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid NA NA investigative glutamate carboxypeptidase ii FOLH1 Successful target unknown NA TTD bms-753493 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 folate receptor alpha FOLR1 Successful target unknown 6.37 TTD , DGIDB mk-8109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 3 folate receptor alpha FOLR1 Successful target unknown NA TTD , DGIDB folateimmune NA Renal Cell Carcinoma[MeSHID:D002292],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 folate receptor alpha FOLR1 Successful target unknown NA TTD , DGIDB pafolacianine small molecule Identification (Psychology)[MeSHID:D007062],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational folate receptor alpha FOLR1 NA ligand NA drugbank vintafolide small molecule Neoplasms[MeSHID:D009369] investigational folate receptor alpha FOLR1 NA unknown 9.55 drugbank , DGIDB folic acid small molecule Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Avitaminosis[MeSHID:D001361] approved,nutraceutical,vet_approved folate receptor alpha FOLR1 NA unknown NA drugbank , DGIDB folic acid small molecule Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved folate receptor alpha FOLR1 NA unknown NA drugbank , DGIDB ec0489 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 folate receptor alpha FOLR1 Successful target unknown NA TTD , DGIDB talotrexin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 folate receptor alpha FOLR1 Successful target unknown 4.24 TTD , DGIDB pyrimethamine NA Toxoplasmosis[MeSHID:D014123],Acute malaria[MeSHID:C531736],Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved folate receptor alpha FOLR1 Successful target unknown 0.58 TTD , DGIDB mirvetuximab soravtansine NA Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 folate receptor alpha FOLR1 Successful target unknown NA TTD , DGIDB imgn-853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 folate receptor alpha FOLR1 Successful target unknown 6.37 TTD , DGIDB folic acid small molecule Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Avitaminosis[MeSHID:D001361] approved,nutraceutical,vet_approved folate receptor alpha FOLR1 NA unknown 6.37 drugbank , DGIDB folic acid small molecule Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved folate receptor alpha FOLR1 NA unknown 6.37 drugbank , DGIDB farletuzumab biotech Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 folate receptor alpha FOLR1 Successful target antibody,inhibitor 25.46 TTD , drugbank , DGIDB stro-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 folate receptor alpha FOLR1 Successful target unknown NA TTD ec20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 3 folate receptor alpha FOLR1 Successful target unknown NA TTD , DGIDB ec-145 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 folate receptor alpha FOLR1 Successful target unknown 9.55 TTD , DGIDB farletuzumab biotech Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 folate receptor alpha FOLR1 Successful target antibody 25.46 TTD , drugbank , DGIDB vintafolide small molecule Neoplasms[MeSHID:D009369] investigational folate receptor beta FOLR2 NA unknown NA drugbank folic acid small molecule Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Avitaminosis[MeSHID:D001361] approved,nutraceutical,vet_approved folate receptor beta FOLR2 NA binder 63.65 drugbank , DGIDB folic acid small molecule Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved folate receptor beta FOLR2 NA binder 63.65 drugbank , DGIDB vintafolide small molecule Neoplasms[MeSHID:D009369] investigational folate receptor gamma FOLR3 NA unknown NA drugbank folic acid small molecule Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved folate receptor gamma FOLR3 NA binder NA drugbank folic acid small molecule Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Avitaminosis[MeSHID:D001361] approved,nutraceutical,vet_approved folate receptor gamma FOLR3 NA binder NA drugbank nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit proto-oncogene c-fos FOS NA inducer NA drugbank nadroparin small molecule Blood coagulation[MeSHID:D001777],Angina, Unstable[MeSHID:D000789],Deep Vein Thrombosis[MeSHID:D020246],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923] approved,investigational proto-oncogene c-fos FOS NA inhibitor NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 FOS NA inhibitor NA drugbank azd8701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 foxp3 messenger rna FOXP3 Clinical trial target unknown NA TTD raltitrexed small molecule Rectum[MeSHID:D012007],Malignant tumor of colon[MeSHID:D003110],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational folylpolyglutamate synthase, mitochondrial FPGS NA antagonist NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical folylpolyglutamate synthase, mitochondrial FPGS NA unknown NA drugbank ag-11/03 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target agonist NA TTD , DGIDB pmid22607879cr-(-)-5f NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target unknown NA TTD fmet-leu-phe NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target agonist NA TTD , DGIDB ag-09/1 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target agonist NA TTD , DGIDB ag-14 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target agonist 27.28 TTD , DGIDB 3570-0208 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target unknown NA TTD nedocromil small molecule Asthma[MeSHID:D001249] approved,investigational fmet-leu-phe receptor FPR1 NA antagonist NA drugbank diamide 7 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target antagonist NA TTD , DGIDB ag-14 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target unknown 27.28 TTD , DGIDB pyrazolone, 1 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target unknown NA TTD rebamipide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] phase 3 n-formyl peptide receptor FPR1 Clinical trial target unknown 3.03 TTD , DGIDB methionine benzimidazole 6 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target antagonist NA TTD , DGIDB group e 1682-2106 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target unknown NA TTD bvt173187 NA NA investigative n-formyl peptide receptor FPR1 Clinical trial target antagonist NA TTD , DGIDB cgen-855 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative n-formyl peptide receptor FPR1 Clinical trial target unknown NA TTD humanin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical n-formyl peptide receptor 3 FPR3 Literature-reported target agonist NA TTD , DGIDB lxa4 NA NA investigative n-formyl peptide receptor 3 FPR3 Literature-reported target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase frk FRK NA inhibitor 0.06 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase frk FRK NA inhibitor 0.06 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase frk FRK NA inhibitor NA drugbank regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase frk FRK NA inhibitor 0.16 drugbank , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase frk FRK NA inhibitor NA drugbank zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase frk FRK NA inhibitor NA drugbank np-g2-044 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fascin FSCN1 Clinical trial target unknown 63.65 TTD , DGIDB akp-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] phase 1 follicle stimulating hormone FSHB Clinical trial target unknown NA TTD , DGIDB follicle stimulating hormone NA Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 follicle stimulating hormone FSHB Clinical trial target unknown NA TTD , DGIDB suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] investigational,phase 1 follicle-stimulating hormone receptor FSHR Successful target antagonist 1.26 TTD , drugbank , DGIDB fshr nam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Native American myopathy[MeSHID:C538343] investigative follicle-stimulating hormone receptor FSHR Successful target unknown NA TTD corifollitropin alfa biotech Fertility[MeSHID:D005298],Ovum[MeSHID:D010063],Ovary[MeSHID:D010053],Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational follicle-stimulating hormone receptor FSHR NA agonist NA drugbank , DGIDB menotropins biotech Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved follicle-stimulating hormone receptor FSHR Successful target binder 79.56 TTD , drugbank , DGIDB recombinant follicle stimulating hormone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] investigative follicle-stimulating hormone receptor FSHR Successful target unknown NA TTD follitropin beta NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] approved follicle-stimulating hormone receptor FSHR Successful target unknown NA TTD , DGIDB follitropin biotech Fertility[MeSHID:D005298],Diagnosis[MeSHID:D003933],Ovarian Failure, Premature[MeSHID:D016649],Klinefelter Syndrome[MeSHID:D007713],Spermatogenesis[MeSHID:D013091],Hypogonadotropic hypogonadism[MeSHID:D007006],Ovulation[MeSHID:D010060],Hair follicle structure[MeSHID:D018859],Ovary[MeSHID:D010053] approved follicle-stimulating hormone receptor FSHR NA agonist NA drugbank urofollitropin biotech Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved follicle-stimulating hormone receptor FSHR Successful target agonist 190.95 TTD , drugbank , DGIDB choriogonadotropin alfa biotech Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved follicle-stimulating hormone receptor FSHR NA binder NA drugbank , DGIDB long-acting fsh conjugate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] investigative follicle-stimulating hormone receptor FSHR Successful target unknown NA TTD suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 follicle-stimulating hormone receptor FSHR Successful target antagonist 1.26 TTD , drugbank , DGIDB menotropins biotech Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved follicle-stimulating hormone receptor FSHR Successful target binder,agonist 79.56 TTD , drugbank , DGIDB prx-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] investigative follicle-stimulating hormone receptor FSHR Successful target unknown NA TTD d-myo-inositol-hexasulphate small molecule NA experimental follistatin FST NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical formimidoyltransferase-cyclodeaminase FTCD NA unknown NA drugbank (6r)-folinic acid small molecule NA experimental formimidoyltransferase-cyclodeaminase FTCD NA unknown NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical formimidoyltransferase-cyclodeaminase FTCD NA cofactor NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved ferritin heavy chain FTH1 NA unknown NA drugbank ferric pyrophosphate citrate small molecule Ectoparasitic Infestations[MeSHID:D004478],Blood Coagulation Disorders[MeSHID:D001778],Maintenance[MeSHID:D008283],Hematuria[MeSHID:D006417],Epistaxis[MeSHID:D004844],Gastrointestinal Hemorrhage[MeSHID:D006471],Blood Platelet Disorders[MeSHID:D001791],Hemorrhage[MeSHID:D006470],Thrombocytopenia[MeSHID:D013921],Malnutrition[MeSHID:D044342],Erythropoiesis[MeSHID:D004920] approved,investigational ferritin heavy chain FTH1 NA binder NA drugbank ferritarg p NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1/2 ferritin FTH1 Clinical trial target unknown NA TTD , DGIDB iron dextran small molecule Physical Dialysis[MeSHID:D003956],Pervasive Development Disorder[MeSHID:D002659],Camurati-Engelmann Syndrome[MeSHID:D003966],Chronic Kidney Diseases[MeSHID:D051436],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Iron deficiency anemia[MeSHID:D018798] approved,vet_approved ferritin heavy chain FTH1 NA other NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved ferritin heavy chain FTH1 NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved ferritin heavy chain FTH1 NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved ferritin heavy chain FTH1 NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ferritin heavy chain FTH1 NA unknown NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved ferritin heavy chain FTH1 NA unknown NA drugbank protoporphyrin small molecule NA experimental ferritin light chain FTL NA unknown NA drugbank sodium ferric gluconate complex small molecule Iron deficiency anemia[MeSHID:D018798],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ferritin light chain FTL NA binding NA drugbank ferric pyrophosphate small molecule Ectoparasitic Infestations[MeSHID:D004478],Blood Coagulation Disorders[MeSHID:D001778],Hematuria[MeSHID:D006417],Epistaxis[MeSHID:D004844],Gastrointestinal Hemorrhage[MeSHID:D006471],Blood Platelet Disorders[MeSHID:D001791],Hemorrhage[MeSHID:D006470],Thrombocytopenia[MeSHID:D013921],Malnutrition[MeSHID:D044342],Erythropoiesis[MeSHID:D004920] experimental ferritin light chain FTL NA binder NA drugbank iron dextran small molecule Physical Dialysis[MeSHID:D003956],Pervasive Development Disorder[MeSHID:D002659],Camurati-Engelmann Syndrome[MeSHID:D003966],Chronic Kidney Diseases[MeSHID:D051436],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Iron deficiency anemia[MeSHID:D018798] approved,vet_approved ferritin light chain FTL NA other NA drugbank ferric pyrophosphate citrate small molecule Ectoparasitic Infestations[MeSHID:D004478],Blood Coagulation Disorders[MeSHID:D001778],Maintenance[MeSHID:D008283],Hematuria[MeSHID:D006417],Epistaxis[MeSHID:D004844],Gastrointestinal Hemorrhage[MeSHID:D006471],Blood Platelet Disorders[MeSHID:D001791],Hemorrhage[MeSHID:D006470],Thrombocytopenia[MeSHID:D013921],Malnutrition[MeSHID:D044342],Erythropoiesis[MeSHID:D004920] approved,investigational ferritin light chain FTL NA binder NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational alpha-ketoglutarate-dependent dioxygenase fto FTO NA ligand NA drugbank sacituzumab govitecan biotech Triple Negative Breast Neoplasms[MeSHID:D064726],Urothelium[MeSHID:D019459],Neoplasm Metastasis[MeSHID:D009362],Cessation of life[MeSHID:D003643] approved,investigational far upstream element-binding protein 1 FUBP1 NA inhibitor NA drugbank irofulven small molecule Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],Sarcoma[MeSHID:D012509],Malignant neoplasm of liver[MeSHID:D008113],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] investigational far upstream element-binding protein 1 FUBP1 NA unknown NA drugbank us9266828, c NA NA patented dibasic-processing enzyme FURIN Preclinical target unknown NA TTD , DGIDB furin inhibitor peptide NA NA investigative dibasic-processing enzyme FURIN Preclinical target inhibitor NA TTD , DGIDB us9266828, e NA NA patented dibasic-processing enzyme FURIN Preclinical target unknown NA TTD , DGIDB capric acid small molecule NA experimental furin FURIN NA unknown NA drugbank decrvkrcmk NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] preclinical dibasic-processing enzyme FURIN Preclinical target unknown NA TTD mi-1148 NA NA investigative dibasic-processing enzyme FURIN Preclinical target inhibitor NA TTD , DGIDB us9266828, b NA NA patented dibasic-processing enzyme FURIN Preclinical target unknown NA TTD , DGIDB peptide 18 NA NA investigative dibasic-processing enzyme FURIN Preclinical target unknown NA TTD rebmab-100 NA Fallopian Tube Carcinoma[MeSHID:D005185],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 galactoside 3(4)-l-fucosyltransferase FUT3 Clinical trial target unknown NA TTD , DGIDB 99mtc-fanolesomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Appendicitis[MeSHID:D001064] approved fucosyltransferase iv FUT4 Successful target unknown NA TTD , DGIDB ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved frataxin, mitochondrial FXN NA unknown NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved frataxin, mitochondrial FXN NA unknown NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved frataxin, mitochondrial FXN NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved frataxin, mitochondrial FXN NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved frataxin, mitochondrial FXN NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved frataxin, mitochondrial FXN NA unknown NA drugbank bisacodyl small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium transporting atpase subunits FXYD2 NA inhibitor NA drugbank tegoprazan small molecule NA investigational sodium/potassium transporting atpase subunits FXYD2 NA inhibitor NA drugbank thimerosal small molecule NA approved sodium/potassium-transporting atpase subunit gamma FXYD2 NA antagonist NA drugbank cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/potassium-transporting atpase subunit gamma FXYD2 NA inhibitor 6.37 drugbank , DGIDB dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved fyn tyrosine protein kinase FYN Successful target inhibitor 0.19 TTD , DGIDB cep-5104 NA NA investigative fyn tyrosine protein kinase FYN Successful target unknown NA TTD cep-6331 NA NA investigative fyn tyrosine protein kinase FYN Successful target unknown NA TTD dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved fyn tyrosine protein kinase FYN Successful target unknown 0.19 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase fyn FYN NA multitarget 0.19 drugbank , DGIDB 1-methoxy-2-[2-(2-methoxy-ethoxy]-ethane NA NA investigative fyn tyrosine protein kinase FYN Successful target unknown NA TTD ro-4396686 NA NA investigative fyn tyrosine protein kinase FYN Successful target unknown NA TTD jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fyn tyrosine protein kinase FYN Successful target inhibitor 0.38 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase fyn FYN NA multitarget 0.19 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase fyn FYN NA inhibitor NA drugbank jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 fyn tyrosine protein kinase FYN Successful target unknown 0.38 TTD , DGIDB triglyme small molecule NA experimental tyrosine-protein kinase fyn FYN NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase fyn FYN NA multitarget,inhibitor 0.19 drugbank , DGIDB pmid15546730c2 NA NA investigative fyn tyrosine protein kinase FYN Successful target unknown NA TTD dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved fyn tyrosine protein kinase FYN Successful target unknown 0.19 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase fyn FYN NA multitarget,inhibitor 0.19 drugbank , DGIDB jnj-10198409 NA NA investigative fyn tyrosine protein kinase FYN Successful target unknown NA TTD dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved fyn tyrosine protein kinase FYN Successful target inhibitor 0.19 TTD , DGIDB otsa-101-dtpa-90y NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],synovial sarcoma[MeSHID:D013584] phase 1 frizzled-10 FZD10 Clinical trial target unknown NA TTD omp-18r5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 frizzled-7 receptor FZD7 Clinical trial target unknown 27.28 TTD , DGIDB hydroxyacetic acid NA NA investigative glucose-6-phosphate dehydrogenase G6PD Successful target unknown NA TTD cbf-bs2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 glucose-6-phosphate dehydrogenase G6PD Successful target unknown NA TTD artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational glucose-6-phosphate 1-dehydrogenase G6PD NA ligand NA drugbank 2'-monophosphoadenosine 5'-diphosphoribose NA NA investigative glucose-6-phosphate dehydrogenase G6PD Successful target unknown NA TTD nicotinamide adenine dinucleotide phosphate small molecule NA experimental glucose-6-phosphate 1-dehydrogenase G6PD NA unknown NA drugbank 16-bromoepiandrosterone small molecule HIV Infections[MeSHID:D015658],Hepatitis A[MeSHID:D006506],Hepatitis[MeSHID:D006505],Malaria[MeSHID:D008288],Cystic Fibrosis[MeSHID:D003550] investigational glucose-6-phosphate 1-dehydrogenase G6PD NA unknown NA drugbank epiandrosterone NA NA phase 3 glucose-6-phosphate dehydrogenase G6PD Successful target unknown 0.45 TTD , DGIDB prasterone NA Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved glucose-6-phosphate dehydrogenase G6PD Successful target unknown 0.05 TTD , DGIDB metazamide NA NA investigative glucose-6-phosphate dehydrogenase G6PD Successful target unknown NA TTD glycolic acid small molecule NA approved,investigational glucose-6-phosphate 1-dehydrogenase G6PD NA inhibitor NA drugbank salacinol NA NA phase 1/2 lysosomal alpha-glucosidase GAA Clinical trial target unknown 0.47 TTD , DGIDB 7-o-b-d-glucopyranosyl-a-homonojirimycin NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD uniflorine b NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD alpha-7-deoxyhomonojirimycin NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD 5-(4-(4-acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glycogen storage disease type II[MeSHID:D006009] preclinical lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD (-)-uniflorine a NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD acarbose small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Cardiovascular Diseases[MeSHID:D002318] approved,investigational lysosomal alpha-glucosidase GAA NA inhibitor 1.47 drugbank , DGIDB bmn-701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glycogen storage disease type II[MeSHID:D006009] phase 3 lysosomal alpha-glucosidase GAA Clinical trial target unknown 0.94 TTD , DGIDB miglitol small molecule Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved lysosomal alpha-glucosidase GAA NA antagonist,inhibitor 1.87 drugbank , DGIDB alpha-homonojirimycin NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD gz402666 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glycogen storage disease type II[MeSHID:D006009] phase 1 lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD , DGIDB at2220 small molecule Glycogen storage disease type II[MeSHID:D006009],Germ-Line Mutation[MeSHID:D018095],Lysosomal Storage Diseases[MeSHID:D016464] investigational lysosomal alpha-glucosidase GAA NA unknown NA drugbank avalglucosidase alfa NA Hydrolysis[MeSHID:D006868],Late Onset Disorders[MeSHID:D000067562],Lysosomes[MeSHID:D008247],Glycogen storage disease type II[MeSHID:D006009],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD miglitol small molecule Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved lysosomal alpha-glucosidase GAA NA antagonist 1.87 drugbank , DGIDB n-adamantanemethyloxypentyl-1-deoxynojirimycin NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD (r)-2,6-bis-hydroxymethyl-piperidine-3,4,5-triol NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD valiolamine NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD deoxynojirimycin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glycogen storage disease type II[MeSHID:D006009] phase 3 lysosomal alpha-glucosidase GAA Clinical trial target unknown 0.94 TTD , DGIDB 2,5-imino-2,5,6-trideoxy-d-manno-heptitol NA NA investigative lysosomal alpha-glucosidase GAA Clinical trial target unknown NA TTD arbaclofen placarbil small molecule Muscle Spasticity[MeSHID:D009128],Multiple Sclerosis[MeSHID:D009103],Gastroesophageal reflux disease[MeSHID:D005764],Spasm[MeSHID:D013035],Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA agonist 45.47 drugbank , DGIDB acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA inhibitor NA drugbank baclofen small molecule Disease Management[MeSHID:D019468],Muscle Rigidity[MeSHID:D009127],Disease[MeSHID:D004194],Spasm[MeSHID:D013035],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Spinal Cord Injuries[MeSHID:D013119],Term Birth[MeSHID:D047929],Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA agonist 15.46 drugbank , DGIDB arbaclofen small molecule Multiple Sclerosis[MeSHID:D009103],Autism Spectrum Disorders[MeSHID:D000067877],Muscle Spasticity[MeSHID:D009128],Pervasive Development Disorder[MeSHID:D002659],Substance Withdrawal Syndrome[MeSHID:D013375] investigational gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA agonist 25.01 drugbank , DGIDB gamma-aminobutyric acid small molecule NA approved,investigational gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA unknown NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA agonist NA drugbank sgs-742 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Attention deficit hyperactivity disorder[MeSHID:D001289],Amnesia[MeSHID:D000647],Memory Loss[MeSHID:D008569] investigational gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA unknown NA drugbank tezampanel small molecule Cluster Headache[MeSHID:D003027],Pain[MeSHID:D010146],Migraine Disorders[MeSHID:D008881] investigational gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA unknown NA drugbank progabide small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental gamma-aminobutyric acid type b receptor subunit 1 GABBR1 NA agonist 22.73 drugbank , DGIDB sgs-742 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Attention deficit hyperactivity disorder[MeSHID:D001289],Amnesia[MeSHID:D000647],Memory Loss[MeSHID:D008569] investigational gamma-aminobutyric acid type b receptor subunit 2 GABBR2 NA unknown NA drugbank baclofen small molecule Disease Management[MeSHID:D019468],Muscle Rigidity[MeSHID:D009127],Disease[MeSHID:D004194],Spasm[MeSHID:D013035],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Spinal Cord Injuries[MeSHID:D013119],Term Birth[MeSHID:D047929],Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid type b receptor subunit 2 GABBR2 NA agonist 16.55 drugbank , DGIDB arbaclofen placarbil small molecule Muscle Spasticity[MeSHID:D009128],Multiple Sclerosis[MeSHID:D009103],Gastroesophageal reflux disease[MeSHID:D005764],Spasm[MeSHID:D013035],Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational gamma-aminobutyric acid type b receptor subunit 2 GABBR2 NA agonist 57.29 drugbank , DGIDB gamma-aminobutyric acid small molecule NA approved,investigational gamma-aminobutyric acid type b receptor subunit 2 GABBR2 NA unknown NA drugbank arbaclofen small molecule Multiple Sclerosis[MeSHID:D009103],Autism Spectrum Disorders[MeSHID:D000067877],Muscle Spasticity[MeSHID:D009128],Pervasive Development Disorder[MeSHID:D002659],Substance Withdrawal Syndrome[MeSHID:D013375] investigational gamma-aminobutyric acid type b receptor subunit 2 GABBR2 NA agonist 31.83 drugbank , DGIDB ginkgo biloba biotech Memory[MeSHID:D008568],Cognition[MeSHID:D003071] approved,investigational,nutraceutical gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA negative modulator NA drugbank 4-benzyl-5-(4-piperidyl)isothiazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD barbiturate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD , DGIDB 6-bromo-3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD methyprylon NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.33 TTD , DGIDB (9-benzyl-9h-purin-6-yl)-cyclopropyl-amine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.16 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator,positive modulator 0.39 drugbank , DGIDB 3,3-diethyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.85 drugbank , DGIDB evt-201 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator,positive modulator 0.26 drugbank , DGIDB heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator NA drugbank zk-93423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 3 gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.16 TTD , DGIDB 9h-beta-carboline-3-carboxylic acid ethyl ester NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator 0.19 drugbank , DGIDB 3-demethoxy-3-d-mannopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.26 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.27 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.23 drugbank , DGIDB 4-naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-(2,2-dimethyl-propoxy)-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 6,6-dimethyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD oxazepam acetate small molecule NA experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.33 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRA1 NA antagonist NA drugbank meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.26 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.21 drugbank , DGIDB 2-thiophen-2-yl-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD thiamylal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 1.64 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA antagonist NA drugbank 3-methoxycarbonyl-2-methyl-9h-beta-carbolin-2-ium NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist,positive modulator 0.16 drugbank , DGIDB 3-ethoxycarbonyl-6-propyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD gnf-pf-3645 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD methyprylon NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target positive modulator 0.33 TTD , DGIDB 2-(3-bromo-phenyl)-6-nitro-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-isothiocyanato-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD ry-066 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD zolpidem NA Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target allosteric modulator 0.8 TTD , DGIDB benzyl-(9h-beta-carbolin-6-yl)-amine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD primidone NA Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor alpha-1 GABRA1 Successful target positive modulator 0.25 TTD , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,allosteric modulator 0.17 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank pentobarbital NA Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target positive modulator 0.49 TTD , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.22 drugbank , DGIDB 6,9-dimethyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.21 drugbank , DGIDB 3-ethoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator,positive modulator 0.33 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank (beta-cce)9h-beta-carboline-3-carboxylic acid NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD [3h]ro154513 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.39 drugbank , DGIDB 2-furan-2-yl-6h-pyrazolo[1,5-c]quinazolin-5-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist,positive modulator 0.12 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB 3-butoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.27 drugbank , DGIDB 5-[(1r)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator,allosteric modulator 0.17 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,agonist 0.26 drugbank , DGIDB 3,3-diisopropyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD norharmane NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 1-methyl-5-oxa-spiro[2.4]heptan-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD ethchlorvynol NA Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.12 TTD , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.24 drugbank , DGIDB butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator NA drugbank zolpidem NA Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.8 TTD , DGIDB loprazolam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank 2-phenyl-6h-pyrazolo[1,5-c]quinazolin-5-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA1 NA potentiator 0.13 drugbank , DGIDB 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD butethal NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.66 TTD , DGIDB 7,12-dihydro-5,7,12-triaza-indeno[1,2-a]fluorene NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD clobazam - lundbeck NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD , DGIDB nitrazepam NA Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.31 TTD , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA1 NA positive allosteric modulator 0.33 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.2 drugbank , DGIDB 4-methoxymethyl-3,6-dipropoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 6-ethyl-3-i-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD methohexital NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 4.59 TTD , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.17 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank ethanol NA Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.05 TTD , DGIDB cgs-9895 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD ro-145975 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD barbituric acid derivative NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-isopropoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD zopiclone small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.92 drugbank , DGIDB 2-(1h-indol-3-yl)-2-oxo-n-phenethyl-acetamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 9h-beta-carbolin-6-ylamine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank 6-bromo-2-(3-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.2 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.11 drugbank , DGIDB 3-butoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD secobarbital NA Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.85 TTD , DGIDB u-89267 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 6-ethyl-3-propylaminocarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD amobarbital NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 3.94 TTD , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.39 drugbank , DGIDB n-indan-1-yl-2-(1h-indol-3-yl)-2-oxo-acetamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD pyrrolidin-3-yl-acetic acid NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD l-655708 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,allosteric modulator 0.22 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.23 drugbank , DGIDB etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.42 drugbank , DGIDB 3-nitro-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA antagonist 0.24 drugbank , DGIDB 1,1-dimethyl-5-oxa-spiro[2.4]heptan-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA inhibitor NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank (2-amino-4,5-dihydro-thiazol-4-yl)-acetic acid NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-carboxy-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.49 drugbank , DGIDB 3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.24 drugbank , DGIDB 3-isobutoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD primidone NA Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.25 TTD , DGIDB 3-methyl-2-phenyl-2h-chromeno[4,3-c]pyrazol-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.2 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA antagonist,allosteric modulator 0.24 drugbank , DGIDB 3-methoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRA1 NA antagonist NA drugbank n-benzyl-2-(5-nitro-1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD zolpidem small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.8 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.19 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank picrotoxin NA Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] approved gaba(a) receptor alpha-1 GABRA1 Successful target blocker 0.26 TTD , DGIDB 6-benzyl-3-propylaminocarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA inhibitor NA drugbank loprazolam small molecule NA experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.22 drugbank , DGIDB 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD amentoflavone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD butalbital NA Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved gaba(a) receptor alpha-1 GABRA1 Successful target positive modulator 0.39 TTD , DGIDB indiplon NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved gaba(a) receptor alpha-1 GABRA1 Successful target allosteric modulator 2.62 TTD , DGIDB sec-butyl 9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.33 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator 0.21 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator 0.26 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA1 NA positive allosteric modulator 0.19 drugbank , DGIDB 6-bromo-2-(3-bromo-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-amino-3-demethoxythiocolchicine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,allosteric modulator 0.2 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank adipiplon small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA partial agonist 0.07 drugbank , DGIDB methohexital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA antagonist 4.59 drugbank , DGIDB 7,12-dihydro-7,12-diaza-indeno[1,2-a]fluorene NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.26 drugbank , DGIDB 3-methyl-1-phenyl-1h-chromeno[4,3-c]pyrazol-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD butabarbital NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.33 TTD , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA1 NA antagonist 0.39 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.17 drugbank , DGIDB 2-phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 2-pyridin-2-yl-6h-pyrazolo[1,5-c]quinazolin-5-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.42 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator,positive modulator 0.49 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.49 drugbank , DGIDB picrotoxin NA Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.26 TTD , DGIDB ro-054520 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.39 drugbank , DGIDB 2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank 3-chloro-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 4-benzyl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.26 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.14 drugbank , DGIDB (9h-beta-carbolin-3-yl)-carbamic acid ethyl ester NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD ridine-5-carboxylic acid ethyl ester NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.27 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.18 drugbank , DGIDB 3-ethyl-3-methyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 2-(3-chloro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB 1,3-diphenyl-1h-chromeno[4,3-c]pyrazol-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 6-nitro-2-phenyl-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 6-bromo-2-(4-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.33 drugbank , DGIDB ro-194603 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 4-naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA antagonist,inducer NA drugbank nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.31 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank ro-145974 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator 0.17 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.19 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.24 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRA1 NA agonist,positive allosteric modulator NA drugbank 3-demethoxy-3d-glucopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-propoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.33 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB 2-(9-benzyl-9h-purin-6-ylamino)-ethanol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 3.28 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,allosteric modulator 0.23 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.16 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRA1 NA agonist NA drugbank 2-phenyl-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD eltanolone NA Premenstrual syndrome[MeSHID:D011293],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.16 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.33 drugbank , DGIDB nsc-73613 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.25 drugbank , DGIDB 1-(9h-beta-carbolin-3-yl)-butan-1-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 2-isoxazol-5-yl-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD isoquinoline-3-carboxylic acid methyl ester NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA1 NA positive allosteric modulator 0.33 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator 0.19 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank 2-p-tolyl-6h-pyrazolo[1,5-c]quinazolin-5-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD n-butyl-2-(1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-tert-butyl-3-ethyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-(3-methyl-butoxy)-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.18 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank 1-(9h-beta-carbolin-3-yl)-ethanone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.23 drugbank , DGIDB 6-benzyl-3-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD ro-15-3505 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator,allosteric modulator 0.24 drugbank , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank gnf-pf-4421 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD butalbital NA Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.39 TTD , DGIDB 3-demethoxy-3-d-lyxopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.12 drugbank , DGIDB 6-bromo-2-(2-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.42 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.18 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.33 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.33 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.27 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank 6-fluoro-2-(3-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRA1 NA positive allosteric modulator 0.23 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.23 drugbank , DGIDB hexobarbital NA Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.72 TTD , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRA1 NA inhibitor NA drugbank clomethiazole small molecule Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA unknown NA drugbank delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.12 drugbank , DGIDB muscimol small molecule NA investigational gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.15 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank doxefazepam small molecule NA experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.16 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator,positive modulator 0.25 drugbank , DGIDB nsc-93394 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD n-benzyl-2-(1h-indol-3-yl)-2-oxo-acetamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.33 drugbank , DGIDB ethyl 6-iodo-9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD u-78875 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 2-(4-chloro-phenyl)-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank 4-phenyl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.33 drugbank , DGIDB allopregnanolone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Depression, Postpartum[MeSHID:D019052],Tremor[MeSHID:D014202],Status Epilepticus[MeSHID:D013226],Seizures[MeSHID:D012640],Essential Tremor[MeSHID:D020329] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.13 TTD , DGIDB picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA antagonist,blocker 0.26 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.23 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.05 drugbank , DGIDB hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.72 drugbank , DGIDB 4-methyl-5-(4-piperidyl)isothiazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank 3-sec-butoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRA1 NA binder NA drugbank 5,7,2′-trihydroxy-6,8-dimethoxyflavone small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank 6-nitro-2-(4-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD (9h-beta-carbolin-3-yl)-methanol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.08 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.25 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.33 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,allosteric modulator 0.17 drugbank , DGIDB amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 3.94 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.33 drugbank , DGIDB 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-isopropyl-3-methyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.2 drugbank , DGIDB 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD carisoprodol small molecule Rheumatism[MeSHID:D012216],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Diseases[MeSHID:D009140] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA activator,modulator NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,allosteric modulator 0.22 drugbank , DGIDB meprobamate NA Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved gaba(a) receptor alpha-1 GABRA1 Successful target agonist 0.26 TTD , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.17 drugbank , DGIDB 3-ethyl-3-isopropyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD n-butyl-2-(5-nitro-1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD n-(9h-beta-carbolin-3-yl)-acetamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 1-(4-chlorophenyl)-4-phenyl-1h-imidazole NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-butylaminocarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,allosteric modulator 0.23 drugbank , DGIDB ripazepam NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD cgs-13767 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.17 drugbank , DGIDB zaleplon small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator,positive modulator 1.64 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.23 drugbank , DGIDB n-(9h-beta-carbolin-3-yl)-formamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator 0.11 drugbank , DGIDB ro-4938581 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB (6-benzylamino-9h-beta-carbolin-3-yl)-methanol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD n-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-(benzyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD doxefazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank ci-218872 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-demethoxy-3-d-xylopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.33 drugbank , DGIDB zolpidem small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist,allosteric modulator 0.8 drugbank , DGIDB barbital NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 3.28 TTD , DGIDB zaleplon NA Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 1.64 TTD , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator 0.17 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.08 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.25 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.17 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.31 drugbank , DGIDB 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 6-ethyl-3-pentoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB methoxyflurane NA Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.24 TTD , DGIDB 3-demethoxy-3-l-fucopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.23 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA1 NA positive allosteric modulator 0.12 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.17 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 0.12 drugbank , DGIDB (4r)-4-ammoniopentanoate NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD indiplon NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved gaba(a) receptor alpha-1 GABRA1 Successful target positive modulator 2.62 TTD , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA positive modulator 0.11 drugbank , DGIDB beta-ccm NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA binder NA drugbank 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 2-(3-bromo-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 0.66 drugbank , DGIDB 3-methyl-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD thiocolchicoside NA Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.39 TTD , DGIDB zaleplon NA Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target positive modulator 1.64 TTD , DGIDB 6-chloro-2-phenyl-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA1 NA unknown 0.03 drugbank , DGIDB 5-(piperidin-4-yl)isothiazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 2-isoxazol-3-yl-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD zaleplon small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator 1.64 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.2 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist,positive modulator 0.33 drugbank , DGIDB (4s)-4-ammoniopentanoate NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD quinidine barbiturate small molecule NA approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.17 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.33 drugbank , DGIDB rwj-16979 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD flavone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.22 drugbank , DGIDB 5-[(1s)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD [3h]cgs8216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative gaba(a) receptor alpha-1 GABRA1 Successful target allosteric modulator NA TTD , DGIDB progabide small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist 2.3 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,allosteric modulator 0.2 drugbank , DGIDB 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD pentobarbital NA Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.49 TTD , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.33 drugbank , DGIDB 6-bromo-2-phenyl-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA1 NA positive allosteric modulator 0.33 drugbank , DGIDB 9h-beta-carboline-3-carboxylic acid propyl ester NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.12 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.2 drugbank , DGIDB 5-(piperidin-4-yl)isoxazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD dihydroquinidine barbiturate small molecule NA experimental gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator,positive modulator 0.33 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.16 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.19 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand NA drugbank ganaxolone small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depression, Postpartum[MeSHID:D019052] investigational gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA unknown 0.07 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.19 drugbank , DGIDB [3h]cgp27492 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 6-chloro-2-(3-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA potentiator NA drugbank 9h-beta-carbolin-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.18 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA agonist,positive modulator 0.12 drugbank , DGIDB 6-methyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA1 NA positive allosteric modulator,positive modulator 0.33 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand 0.11 drugbank , DGIDB picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental gamma-aminobutyric acid receptor subunit alpha-1 GABRA1 NA antagonist 0.26 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator,allosteric modulator 0.17 drugbank , DGIDB 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-(hexa-1,3-dienyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.49 drugbank , DGIDB 6-ethyl-3-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD medazepam small molecule NA experimental gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank 6-benzyl-3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD , DGIDB 6-nitro-2-(3-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD ro-147437 NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD (2e,4s)-4-ammoniopent-2-enoate NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 5-(4-piperidyl)-4-propylisothiazol-3-ol NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA1 NA positive allosteric modulator 0.12 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRA1 NA positive allosteric modulator NA drugbank bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA1 NA positive allosteric modulator 0.16 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA1 NA ligand,positive modulator 0.21 drugbank , DGIDB 3-butoxycarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD beta-carboline-3-carboxylic acid t-butyl ester NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD indiplon NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 2.62 TTD , DGIDB methylphenobarbital NA Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.66 TTD , DGIDB meprobamate NA Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved gaba(a) receptor alpha-1 GABRA1 Successful target unknown 0.26 TTD , DGIDB (9h-beta-carbolin-3-yl)-ethyl-amine NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone NA NA investigative gaba(a) receptor alpha-1 GABRA1 Successful target unknown NA TTD butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA2 NA positive allosteric modulator 0.19 drugbank , DGIDB tetrahydrodeoxycorticosterone NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target allosteric modulator NA TTD , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRA2 NA positive allosteric modulator 0.18 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.18 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.18 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB zolpidem small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA agonist,allosteric modulator 0.67 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.76 drugbank , DGIDB gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.13 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.1 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator 0.17 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.13 drugbank , DGIDB methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.32 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.76 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA2 NA antagonist NA drugbank meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.21 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRA2 NA antagonist NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.15 drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA inhibitor NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.13 drugbank , DGIDB isonipecotic acid NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target agonist NA TTD , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB quinidine barbiturate small molecule NA approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.18 drugbank , DGIDB 5,7,2′-trihydroxy-6,8-dimethoxyflavone small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank ci-218872 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.14 drugbank , DGIDB mrk016 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target allosteric modulator NA TTD , DGIDB adipiplon small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA partial agonist 0.08 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,allosteric modulator 0.76 drugbank , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.19 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator 0.11 drugbank , DGIDB (2e,4s)-4-ammoniopent-2-enoate NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD pagoclone small molecule Anxiety Disorders[MeSHID:D001008],Panic[MeSHID:D010200],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA unknown 0.51 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.14 drugbank , DGIDB 3-(benzyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD nordazepam small molecule NA experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.15 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRA2 NA antagonist NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.15 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.14 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.19 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA2 NA positive allosteric modulator 0.05 drugbank , DGIDB ganaxolone small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depression, Postpartum[MeSHID:D019052] investigational gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA unknown 0.08 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA binder NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.11 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.2 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.08 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.04 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRA2 NA inhibitor NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,allosteric modulator 0.18 drugbank , DGIDB [3h]ro154513 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.19 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.19 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator,positive modulator 0.19 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.16 drugbank , DGIDB thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.28 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank tbps NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target blocker NA TTD , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.08 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank flumazenil NA Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-2 GABRA2 Successful target allosteric modulator 0.2 TTD , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.19 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,allosteric modulator 0.13 drugbank , DGIDB 3-(hexa-1,3-dienyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,allosteric modulator 0.1 drugbank , DGIDB tp003 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target allosteric modulator NA TTD , DGIDB 3-propoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator,positive modulator 0.19 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.15 drugbank , DGIDB ro-15-3505 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,allosteric modulator 0.18 drugbank , DGIDB alpha5ia NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA agonist 0.21 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.13 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA agonist,positive modulator 0.17 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA agonist 0.17 drugbank , DGIDB dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator NA drugbank zopiclone small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.76 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator,allosteric modulator 0.1 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.11 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.19 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA inhibitor NA drugbank delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA antagonist,inducer NA drugbank 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank dmcm NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target allosteric modulator NA TTD , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.17 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator,positive modulator 0.19 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank amentoflavone NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB 3-(3-methyl-butoxy)-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD oxazepam acetate small molecule NA experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank [3h]cgs8216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative gaba(a) receptor alpha-2 GABRA2 Successful target allosteric modulator NA TTD , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA unknown NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank alpha3ia NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator,positive modulator 0.19 drugbank , DGIDB l-655708 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD 3-ethoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator,allosteric modulator 0.2 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.13 drugbank , DGIDB 9h-beta-carboline-3-carboxylic acid ethyl ester NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator 0.11 drugbank , DGIDB hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.3 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.19 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.19 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.1 drugbank , DGIDB aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator NA drugbank pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank barbituric acid derivative NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.19 drugbank , DGIDB ro-4938581 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD cinazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA2 NA positive allosteric modulator 0.13 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,allosteric modulator 0.76 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB sec-butyl 9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.16 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA2 NA unknown NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,allosteric modulator 0.15 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.1 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank [35s]tbps NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target blocker NA TTD , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank zolpidem small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA agonist 0.67 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.14 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.12 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.15 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank nordazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.13 drugbank , DGIDB [18f]fluoroethylflumazenil NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target allosteric modulator NA TTD , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator 0.17 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.1 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.1 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB mk-0343 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator,positive modulator 0.12 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.19 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB beta-carboline-3-carboxylic acid t-butyl ester NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator,allosteric modulator 0.15 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator 0.1 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.11 drugbank , DGIDB heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator NA drugbank stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRA2 NA agonist,positive allosteric modulator NA drugbank ry-066 NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA2 NA potentiator 0.02 drugbank , DGIDB 5-[(1r)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRA2 NA binder NA drugbank flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator 0.14 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,allosteric modulator 0.13 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.14 drugbank , DGIDB pf-4480682 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.11 drugbank , DGIDB azd-7325 small molecule NA investigational gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA positive allosteric modulator NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB 5-[(1s)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD flumazenil NA Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-2 GABRA2 Successful target unknown 0.2 TTD , DGIDB isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.11 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.15 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,agonist 0.21 drugbank , DGIDB secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.3 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.14 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.16 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank oxazepam acetate small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand NA drugbank 3-butoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.18 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.17 drugbank , DGIDB ethyl 6-iodo-9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.12 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.13 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand,positive modulator 0.11 drugbank , DGIDB 3-isobutoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.19 drugbank , DGIDB barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator NA drugbank ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRA2 NA agonist NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator 0.03 drugbank , DGIDB piperidine-4-sulphonic acid NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target agonist NA TTD , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA2 NA positive allosteric modulator 0.15 drugbank , DGIDB (4r)-4-ammoniopentanoate NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.16 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA2 NA positive allosteric modulator 0.19 drugbank , DGIDB (4s)-4-ammoniopentanoate NA NA investigative gaba(a) receptor alpha-2 GABRA2 Successful target unknown NA TTD halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA2 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator 0.19 drugbank , DGIDB fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-2 GABRA2 NA potentiator 0.13 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRA2 NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA2 NA ligand 0.18 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,allosteric modulator 0.15 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRA3 NA antagonist NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,allosteric modulator 0.13 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.19 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.14 drugbank , DGIDB butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator NA drugbank azd-7325 small molecule NA investigational gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA positive allosteric modulator NA drugbank butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.19 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRA3 NA agonist NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.14 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator 0.15 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator 0.15 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.19 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank 5-[(1r)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD zolpidem small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA agonist 0.68 drugbank , DGIDB 3-ethoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.19 drugbank , DGIDB pagoclone small molecule Anxiety Disorders[MeSHID:D001008],Panic[MeSHID:D010200],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA unknown NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator,allosteric modulator 0.15 drugbank , DGIDB 3-isobutoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator 0.17 drugbank , DGIDB ns-2710 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 gaba(a) receptor alpha-3 GABRA3 Successful target unknown 0.77 TTD , DGIDB 6-benzyl-3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.15 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.12 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.13 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA3 NA antagonist NA drugbank aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator NA drugbank ro-15-3505 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.13 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,allosteric modulator 0.1 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.11 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA3 NA potentiator 0.02 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.11 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank mk-0343 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.15 drugbank , DGIDB barbituric acid derivative NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRA3 NA inhibitor NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator,positive modulator 0.19 drugbank , DGIDB (2e,4s)-4-ammoniopent-2-enoate NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.19 drugbank , DGIDB [3h]cgs8216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative gaba(a) receptor alpha-3 GABRA3 Successful target allosteric modulator NA TTD , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.11 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRA3 NA positive allosteric modulator 0.18 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank ethyl 6-iodo-9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD cinazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank alpha3ia NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank 3-(3-methyl-butoxy)-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.19 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank isonipecotic acid NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target agonist NA TTD , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.51 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.11 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.14 drugbank , DGIDB flumazenil NA Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-3 GABRA3 Successful target allosteric modulator 0.2 TTD , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.18 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.14 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.12 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator,positive modulator 0.12 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRA3 NA binder NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA agonist 0.17 drugbank , DGIDB amentoflavone NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.17 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA agonist 0.21 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,allosteric modulator 0.51 drugbank , DGIDB sec-butyl 9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,allosteric modulator 0.51 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.18 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.08 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank alpha5ia NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.32 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.19 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.18 drugbank , DGIDB dmcm NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target allosteric modulator NA TTD , DGIDB 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.15 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.1 drugbank , DGIDB 3-butoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank ry-066 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator 0.11 drugbank , DGIDB hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.31 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.13 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA3 NA positive allosteric modulator 0.14 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank adipiplon small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA partial agonist 0.12 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,allosteric modulator 0.13 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator,positive modulator 0.19 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,agonist 0.21 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.19 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.14 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.31 drugbank , DGIDB (4r)-4-ammoniopentanoate NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD ci-218872 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.15 drugbank , DGIDB adipiplon NA Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gaba(a) receptor alpha-3 GABRA3 Successful target unknown 0.12 TTD , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.15 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB [35s]tbps NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target blocker NA TTD , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRA3 NA antagonist NA drugbank ganaxolone small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depression, Postpartum[MeSHID:D019052] investigational gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA unknown 0.09 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.15 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.1 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.19 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator NA drugbank brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.19 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.2 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.17 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA antagonist,inducer NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.15 drugbank , DGIDB 5-[(1s)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.19 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.17 drugbank , DGIDB 3-propoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD tp003 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target allosteric modulator NA TTD , DGIDB 3-(hexa-1,3-dienyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA binder NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.08 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.21 drugbank , DGIDB 5,7,2′-trihydroxy-6,8-dimethoxyflavone small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator NA drugbank 3-(benzyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.15 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank zolpidem small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA agonist,allosteric modulator 0.68 drugbank , DGIDB beta-carboline-3-carboxylic acid t-butyl ester NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD carisoprodol small molecule Rheumatism[MeSHID:D012216],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Diseases[MeSHID:D009140] approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA modulator NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator,allosteric modulator 0.2 drugbank , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.14 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.15 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.51 drugbank , DGIDB 9h-beta-carboline-3-carboxylic acid ethyl ester NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.17 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA3 NA positive allosteric modulator 0.05 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank [3h]ro154513 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator 0.17 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.17 drugbank , DGIDB isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.1 drugbank , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator 0.03 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator,positive modulator 0.19 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,allosteric modulator 0.18 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.1 drugbank , DGIDB ro-4938581 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD piperidine-4-sulphonic acid NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target agonist NA TTD , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA3 NA positive allosteric modulator 0.19 drugbank , DGIDB azd6280 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 gaba(a) receptor alpha-3 GABRA3 Successful target positive modulator 0.38 TTD , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.28 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.11 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA3 NA positive allosteric modulator 0.19 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.05 drugbank , DGIDB adipiplon NA Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gaba(a) receptor alpha-3 GABRA3 Successful target partial agonist 0.12 TTD , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.11 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator 0.1 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA inhibitor NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,allosteric modulator 0.18 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator 0.11 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank loprazolam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank mrk016 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target allosteric modulator NA TTD , DGIDB (4s)-4-ammoniopentanoate NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD zopiclone small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.77 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank 6-bromo-3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank flumazenil NA Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-3 GABRA3 Successful target unknown 0.2 TTD , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.1 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank [18f]fluoroethylflumazenil NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target allosteric modulator NA TTD , DGIDB tbps NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target blocker NA TTD , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator,positive modulator 0.19 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA unknown NA drugbank fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA potentiator 0.14 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA3 NA positive allosteric modulator 0.19 drugbank , DGIDB l-655708 NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target unknown NA TTD alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator,allosteric modulator 0.1 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand,positive modulator 0.18 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRA3 NA agonist,positive allosteric modulator NA drugbank delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA3 NA unknown NA drugbank 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.18 drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA3 NA inhibitor NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA3 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA3 NA ligand 0.14 drugbank , DGIDB tetrahydrodeoxycorticosterone NA NA investigative gaba(a) receptor alpha-3 GABRA3 Successful target allosteric modulator NA TTD , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid receptor subunit alpha-3 GABRA3 NA agonist,positive modulator 0.17 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA4 NA positive allosteric modulator 0.17 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator 0.17 drugbank , DGIDB methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.29 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA4 NA positive allosteric modulator 0.17 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.09 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.17 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank medazepam small molecule NA experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA4 NA positive allosteric modulator 0.05 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator,positive modulator 0.11 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRA4 NA antagonist NA drugbank butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator NA drugbank temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA agonist 0.24 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator 0.12 drugbank , DGIDB hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.26 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA4 NA antagonist NA drugbank bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator 0.12 drugbank , DGIDB brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator 0.04 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank nordazepam small molecule NA experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator,positive modulator 0.17 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRA4 NA antagonist NA drugbank meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.24 drugbank , DGIDB taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRA4 NA agonist NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator,positive modulator 0.17 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.26 drugbank , DGIDB heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator NA drugbank adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA4 NA unknown NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA4 NA antagonist,inducer NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.17 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.68 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA4 NA positive allosteric modulator 0.11 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator 0.15 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRA4 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA4 NA potentiator 0.03 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator,agonist 0.24 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank cinazepam small molecule NA experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator 0.2 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.11 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator 0.17 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.17 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA4 NA positive allosteric modulator 0.05 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator,positive modulator 0.17 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator 0.09 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRA4 NA binder NA drugbank bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.24 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRA4 NA agonist,positive allosteric modulator NA drugbank butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA4 NA positive allosteric modulator 0.17 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator 0.11 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.17 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.17 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.17 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.05 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator 0.12 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA4 NA binder NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.11 drugbank , DGIDB ganaxolone small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depression, Postpartum[MeSHID:D019052] investigational gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA unknown 0.1 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA4 NA positive allosteric modulator 0.15 drugbank , DGIDB aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator,positive modulator 0.17 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA unknown NA drugbank dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA4 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-4 GABRA4 NA potentiator 0.17 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.16 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator 0.15 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA agonist 0.22 drugbank , DGIDB 3-(3-methyl-butoxy)-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD oxazepam acetate small molecule NA experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.11 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.11 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.14 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.1 drugbank , DGIDB tp003 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator NA TTD , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank rg-7816 NA Autism Spectrum Disorders[MeSHID:D000067877],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659] phase 1 gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD , DGIDB [3h]ro154513 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank tetrahydrodeoxycorticosterone NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator NA TTD , DGIDB sec-butyl 9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA antagonist,inducer NA drugbank delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.2 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA agonist,positive modulator 0.18 drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA inhibitor NA drugbank ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA5 NA potentiator 0.03 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.17 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA5 NA positive allosteric modulator 0.14 drugbank , DGIDB ro-15-3505 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD 3-isobutoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.1 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.16 drugbank , DGIDB gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.04 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.16 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.15 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank barbituric acid derivative NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.2 drugbank , DGIDB tbps NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target blocker NA TTD , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.15 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator 0.11 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB piperidine-4-sulphonic acid NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target agonist NA TTD , DGIDB butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator 0.11 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.11 drugbank , DGIDB ry024 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator NA TTD , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank ro-4938581 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA binder NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank ethyl 6-iodo-9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD 5-[(1r)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.11 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.2 drugbank , DGIDB heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator NA drugbank methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator,allosteric modulator 0.11 drugbank , DGIDB secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.32 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.62 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.25 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.14 drugbank , DGIDB 3-propoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.32 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.14 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.15 drugbank , DGIDB beta-carboline-3-carboxylic acid t-butyl ester NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.16 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator 0.11 drugbank , DGIDB [3h]l655708 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator NA TTD , DGIDB dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator NA drugbank brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator,positive modulator 0.2 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA5 NA positive allosteric modulator 0.2 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.17 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.2 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.2 drugbank , DGIDB barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.02 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank adipiplon small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA partial agonist 0.08 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.16 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank (2e,4s)-4-ammoniopent-2-enoate NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.2 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA unknown NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA agonist 0.18 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.14 drugbank , DGIDB ganaxolone small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depression, Postpartum[MeSHID:D019052] investigational gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA unknown 0.09 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA5 NA antagonist NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.1 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA antagonist 0.25 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.16 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.17 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRA5 NA positive allosteric modulator 0.19 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank ht-2678 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hashimoto Disease[MeSHID:D050031] investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB carisoprodol small molecule Rheumatism[MeSHID:D012216],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Diseases[MeSHID:D009140] approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA modulator NA drugbank clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank [35s]tbps NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target blocker NA TTD , DGIDB taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRA5 NA agonist NA drugbank isonipecotic acid NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target agonist NA TTD , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator 0.18 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.05 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank nordazepam small molecule NA experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,agonist 0.22 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator,positive modulator 0.2 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator 0.18 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.14 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank [18f]fluoroethylflumazenil NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator NA TTD , DGIDB nordazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.14 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB alpha3ia NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD flumazenil NA Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator 0.25 TTD , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.18 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.1 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.18 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.1 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.62 drugbank , DGIDB methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.33 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.14 drugbank , DGIDB thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.29 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.15 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.15 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.11 drugbank , DGIDB (4r)-4-ammoniopentanoate NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD basmisanil NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Testicular Feminization[MeSHID:D013734] phase 2 gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator 1.59 TTD , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,allosteric modulator 0.62 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.15 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA5 NA positive allosteric modulator 0.05 drugbank , DGIDB 3-(hexa-1,3-dienyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD cinazepam small molecule NA experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRA5 NA antagonist NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.2 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.09 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.12 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator,positive modulator 0.12 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank 9h-beta-carboline-3-carboxylic acid ethyl ester NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.18 drugbank , DGIDB amentoflavone NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD [3h]cgs8216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator NA TTD , DGIDB [3h]ry80 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.2 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator,positive modulator 0.2 drugbank , DGIDB 3-ethoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.2 drugbank , DGIDB flumazenil NA Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor alpha-5 GABRA5 Successful target unknown 0.25 TTD , DGIDB loprazolam small molecule NA experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator 0.16 drugbank , DGIDB zopiclone small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.95 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator,positive modulator 0.2 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.18 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.11 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRA5 NA agonist,positive allosteric modulator NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRA5 NA binder NA drugbank basmisanil NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Testicular Feminization[MeSHID:D013734] phase 2 gaba(a) receptor alpha-5 GABRA5 Successful target unknown 1.59 TTD , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator 0.16 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA5 NA positive allosteric modulator 0.2 drugbank , DGIDB amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator NA drugbank 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.11 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,allosteric modulator 0.11 drugbank , DGIDB 5-[(1s)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.19 drugbank , DGIDB (4s)-4-ammoniopentanoate NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.2 drugbank , DGIDB alpha5ia NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA inhibitor NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.16 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,allosteric modulator 0.16 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA5 NA positive allosteric modulator,allosteric modulator 0.16 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA antagonist,allosteric modulator 0.25 drugbank , DGIDB l-655708 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA5 NA unknown NA drugbank 3-(benzyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.2 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA5 NA positive allosteric modulator,allosteric modulator 0.25 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.09 drugbank , DGIDB dmcm NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target allosteric modulator NA TTD , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator 0.22 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB 5,7,2′-trihydroxy-6,8-dimethoxyflavone small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand 0.2 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.14 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRA5 NA inhibitor NA drugbank pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA5 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA5 NA positive allosteric modulator,allosteric modulator 0.62 drugbank , DGIDB 3-butoxy-9h-beta-carboline NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.11 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRA5 NA ligand,positive modulator 0.1 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-5 GABRA5 NA potentiator 0.12 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRA5 NA antagonist NA drugbank doxefazepam small molecule NA experimental gaba(a) receptor GABRA5 NA positive allosteric modulator NA drugbank ci-218872 NA NA investigative gaba(a) receptor alpha-5 GABRA5 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.07 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.13 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator NA drugbank meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator,agonist 0.24 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator 0.11 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA agonist 0.24 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRA6 NA antagonist NA drugbank apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRA6 NA antagonist NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator 0.04 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator,positive modulator 0.22 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator 0.2 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.22 drugbank , DGIDB taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRA6 NA agonist NA drugbank bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator 0.12 drugbank , DGIDB amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank loprazolam small molecule NA experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRA6 NA agonist,positive allosteric modulator NA drugbank doxefazepam small molecule NA experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.22 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator 0.16 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA6 NA antagonist NA drugbank brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.22 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA6 NA potentiator 0.03 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator,positive modulator 0.22 drugbank , DGIDB dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.48 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator,positive modulator 0.22 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator NA drugbank meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.24 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA6 NA unknown NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator 0.09 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator 0.12 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator,positive modulator 0.13 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.22 drugbank , DGIDB butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator NA drugbank adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator 0.09 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA6 NA binder NA drugbank remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.05 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.12 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.22 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator 0.17 drugbank , DGIDB etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator 0.15 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.17 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRA6 NA positive allosteric modulator 0.05 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRA6 NA binder NA drugbank cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRA6 NA inhibitor NA drugbank methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.36 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.22 drugbank , DGIDB ganaxolone small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depression, Postpartum[MeSHID:D019052] investigational gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA unknown 0.1 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator 0.09 drugbank , DGIDB secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.34 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator 0.13 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA unknown NA drugbank nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator 0.16 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA6 NA positive allosteric modulator 0.14 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator,allosteric modulator 0.09 drugbank , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator 0.22 drugbank , DGIDB hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.34 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator 0.31 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRA6 NA positive allosteric modulator 0.22 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gamma-aminobutyric acid receptor subunit alpha-6 GABRA6 NA potentiator,positive modulator 0.22 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRA6 NA antagonist,inducer NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRA6 NA positive allosteric modulator,positive modulator 0.07 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRA6 NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator 0.17 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRB1 NA antagonist NA drugbank flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator 0.19 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator 0.14 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator 0.18 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB1 NA positive allosteric modulator 0.06 drugbank , DGIDB taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRB1 NA agonist NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator 0.1 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator 0.14 drugbank , DGIDB brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator 0.11 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRB1 NA antagonist NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB1 NA positive allosteric modulator 0.05 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.23 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRB1 NA agonist,positive allosteric modulator NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB gamma-hydroxybutyric acid small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Athletic Performance[MeSHID:D054874],Narcolepsy[MeSHID:D009290],Alcoholic Intoxication, Chronic[MeSHID:D000437],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] approved,illicit,investigational gamma-aminobutyric acid receptor subunit beta-1 GABRB1 NA agonist NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB1 NA potentiator 0.03 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank loprazolam small molecule NA experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator 0.06 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.18 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator 0.13 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn gamma-aminobutyric acid receptor subunit beta-1 GABRB1 NA antagonist NA drugbank cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRB1 NA positive allosteric modulator 0.18 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB1 NA positive allosteric modulator 0.19 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator 0.18 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRB1 NA positive allosteric modulator 0.23 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.25 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB1 NA binder NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit beta-1 GABRB1 NA unknown NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB1 NA positive allosteric modulator 0.13 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.25 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB1 NA positive allosteric modulator 0.19 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB1 NA antagonist,inducer NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRB1 NA inhibitor NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRB1 NA antagonist NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB1 NA positive allosteric modulator 0.18 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator,agonist 0.06 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator 0.25 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit beta-1 GABRB1 NA potentiator 0.18 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB1 NA positive allosteric modulator 0.25 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator 0.17 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRB1 NA unknown NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB1 NA positive allosteric modulator 0.22 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator 0.14 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator 0.05 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank medazepam small molecule NA experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank nordazepam small molecule NA experimental gaba(a) receptor GABRB1 NA positive allosteric modulator NA drugbank temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB1 NA positive allosteric modulator 0.23 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRB1 NA binder NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRB1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.05 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank [3h]cgs8216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6-ethyl-3-propylaminocarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA potentiator 0.16 drugbank , DGIDB cgs-13767 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator,agonist 0.05 drugbank , DGIDB 2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD u-78875 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD ro-147437 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank 1,1-dimethyl-5-oxa-spiro[2.4]heptan-4-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD cinazepam small molecule NA experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB ro-145974 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD (4r)-4-ammoniopentanoate NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator 0.17 drugbank , DGIDB 3-demethoxy-3d-glucopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 3-demethoxy-3-d-xylopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.04 drugbank , DGIDB 6-ethyl-3-pentoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.13 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator 0.05 drugbank , DGIDB 5-[(1s)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 4-naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 2-thiophen-2-yl-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6-benzyl-3-propylaminocarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD , DGIDB 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB 3,3-diethyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD thiocolchicoside NA Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved gaba(a) receptor beta-2 GABRB2 Successful target unknown 0.18 TTD , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB 3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA potentiator 0.13 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB 3-demethoxy-3-l-fucopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB fospropofol small molecule Patient Monitoring[MeSHID:D008991],patient care[MeSHID:D005791],Diagnosis[MeSHID:D003933] approved,illicit,investigational gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA potentiator 0.68 drugbank , DGIDB 3-ethoxycarbonyl-6-propyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank 4-benzyl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator 0.17 drugbank , DGIDB carisoprodol small molecule Rheumatism[MeSHID:D012216],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Diseases[MeSHID:D009140] approved gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA modulator NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD eltanolone NA Premenstrual syndrome[MeSHID:D011293],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 4-naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD (2e,4s)-4-ammoniopent-2-enoate NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA potentiator,positive modulator 0.13 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank amentoflavone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA potentiator,positive modulator 0.13 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank loprazolam small molecule NA experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank n-indan-1-yl-2-(1h-indol-3-yl)-2-oxo-acetamide NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.17 drugbank , DGIDB 6-bromo-3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD ridine-5-carboxylic acid ethyl ester NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRB2 NA antagonist NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRB2 NA inhibitor NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA potentiator 0.13 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank u-89267 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank 2-(9-benzyl-9h-purin-6-ylamino)-ethanol NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6-benzyl-3-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6-ethyl-3-i-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6-methyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 3-carboxy-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator 0.13 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator 0.13 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.21 drugbank , DGIDB 2-isoxazol-5-yl-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 1-(4-chlorophenyl)-4-phenyl-1h-imidazole NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank ro-194603 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.12 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB2 NA binder NA drugbank gnf-pf-3645 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRB2 NA agonist NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.15 drugbank , DGIDB n-benzyl-2-(5-nitro-1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD n-butyl-2-(1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 3-butylaminocarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRB2 NA antagonist NA drugbank 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.23 drugbank , DGIDB beta-ccm NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 1-methyl-5-oxa-spiro[2.4]heptan-4-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 3-butoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB 3-butoxycarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator 0.21 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRB2 NA unknown NA drugbank 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank 3-methyl-9h-beta-carboline NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRB2 NA agonist,positive allosteric modulator NA drugbank (9-benzyl-9h-purin-6-yl)-cyclopropyl-amine NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6-benzyl-3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator 0.13 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB2 NA positive allosteric modulator 0.23 drugbank , DGIDB 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD allopregnanolone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Depression, Postpartum[MeSHID:D019052],Tremor[MeSHID:D014202],Status Epilepticus[MeSHID:D013226],Seizures[MeSHID:D012640],Essential Tremor[MeSHID:D020329] approved gaba(a) receptor beta-2 GABRB2 Successful target unknown 0.18 TTD , DGIDB n-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD n-butyl-2-(5-nitro-1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 3-ethyl-3-isopropyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6-ethyl-3-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator 0.16 drugbank , DGIDB 4-phenyl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD nordazepam small molecule NA experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank 3-isopropyl-3-methyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.17 drugbank , DGIDB 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD gnf-pf-4421 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator 0.15 drugbank , DGIDB 3-amino-3-demethoxythiocolchicine NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD ro-145975 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRB2 NA positive allosteric modulator 0.09 drugbank , DGIDB 3-ethyl-3-methyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD n-benzyl-2-(1h-indol-3-yl)-2-oxo-acetamide NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRB2 NA positive allosteric modulator 0.21 drugbank , DGIDB ci-218872 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 3-demethoxy-3-d-mannopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank 3-tert-butyl-3-ethyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB 5-(piperidin-4-yl)isoxazol-3-ol NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator 0.12 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA unknown NA drugbank ginkgo biloba biotech Memory[MeSHID:D008568],Cognition[MeSHID:D003071] approved,investigational,nutraceutical gamma-aminobutyric acid receptor subunit beta-2 GABRB2 NA negative modulator NA drugbank zk-93423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 3 gaba(a) receptor beta-2 GABRB2 Successful target unknown 0.23 TTD , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB2 NA potentiator 0.03 drugbank , DGIDB 6,9-dimethyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 3-demethoxy-3-d-lyxopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD [3h]ro154513 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD ro-15-3505 NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRB2 NA positive allosteric modulator 0.16 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRB2 NA antagonist 0.18 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator 0.2 drugbank , DGIDB 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD 6,6-dimethyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB2 NA positive allosteric modulator 0.11 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB 3-isothiocyanato-9h-beta-carboline NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB (4s)-4-ammoniopentanoate NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB2 NA antagonist,inducer NA drugbank 3,3-diisopropyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank tbps NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target blocker NA TTD , DGIDB 5-[(1r)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor beta-2 GABRB2 Successful target unknown NA TTD halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ethchlorvynol NA Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor beta-2 GABRB2 Successful target unknown 0.11 TTD , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator 0.1 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRB2 NA binder NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.13 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB2 NA positive allosteric modulator 0.21 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRB2 NA positive allosteric modulator NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.05 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.13 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator 0.11 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator 0.1 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRB3 NA antagonist NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.25 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB3 NA positive allosteric modulator 0.06 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRB3 NA unknown NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB3 NA positive allosteric modulator 0.25 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator 0.25 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRB3 NA binder NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRB3 NA agonist NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB3 NA potentiator 0.03 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.23 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.14 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.17 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator 0.18 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator,agonist 0.06 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator 0.19 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.18 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.25 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.14 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator 0.18 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB piperazine small molecule Disease[MeSHID:D004194],Oxyuriasis[MeSHID:D010123],Nematode infections[MeSHID:D009349],Ascariasis[MeSHID:D001196],Intestinal Obstruction[MeSHID:D007415],Enterobiasis[MeSHID:D017229],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA agonist NA drugbank muscimol small molecule NA investigational gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA unknown NA drugbank doxefazepam small molecule NA experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank loprazolam small molecule NA experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.19 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA potentiator,positive modulator 0.14 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.18 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator 0.22 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank cinazepam small molecule NA experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA potentiator 0.14 drugbank , DGIDB fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA potentiator 0.18 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA potentiator,positive modulator 0.14 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator 0.17 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRB3 NA antagonist NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator 0.14 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRB3 NA inhibitor NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator 0.14 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator 0.23 drugbank , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.05 drugbank , DGIDB fospropofol small molecule Patient Monitoring[MeSHID:D008991],patient care[MeSHID:D005791],Diagnosis[MeSHID:D003933] approved,illicit,investigational gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA potentiator 0.76 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator 0.14 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB3 NA antagonist,inducer NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRB3 NA positive allosteric modulator 0.24 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRB3 NA antagonist NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB3 NA positive allosteric modulator 0.19 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB3 NA binder NA drugbank cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRB3 NA positive allosteric modulator 0.18 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA potentiator 0.14 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA unknown NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRB3 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator 0.06 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRB3 NA positive allosteric modulator NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRB3 NA positive allosteric modulator 0.13 drugbank , DGIDB lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn gamma-aminobutyric acid receptor subunit beta-3 GABRB3 NA unknown NA drugbank stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRB3 NA agonist,positive allosteric modulator NA drugbank prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator 0.19 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank sage-217b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 gaba(a) receptor delta GABRD Successful target unknown NA TTD , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRD NA positive allosteric modulator 0.2 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator 0.22 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB gaboxadol NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor delta GABRD Successful target unknown 0.13 TTD , DGIDB tbps NA NA investigative gaba(a) receptor delta GABRD Successful target blocker NA TTD , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRD NA antagonist NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator 0.15 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRD NA positive allosteric modulator 0.2 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRD NA positive allosteric modulator 0.13 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRD NA positive allosteric modulator 0.15 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank pf-4480682 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 gaba(a) receptor delta GABRD Successful target unknown NA TTD pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator 0.18 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.26 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator 0.26 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.26 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRD NA inhibitor NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRD NA positive allosteric modulator 0.18 drugbank , DGIDB ru-5135 NA NA investigative gaba(a) receptor delta GABRD Successful target unknown NA TTD cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRD NA positive allosteric modulator 0.26 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRD NA antagonist NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRD NA positive allosteric modulator 0.06 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank gaboxadol NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor delta GABRD Successful target agonist 0.13 TTD , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator,agonist 0.06 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator 0.06 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRD NA unknown NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit delta GABRD NA unknown NA drugbank ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRD NA antagonist,inducer NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRD NA positive allosteric modulator 0.18 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB ganaxolone NA Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depression, Postpartum[MeSHID:D019052] phase 3 gaba(a) receptor delta GABRD Successful target unknown 0.11 TTD , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator 0.11 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit delta GABRD NA potentiator 0.18 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRD NA positive allosteric modulator 0.23 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank allopregnanolone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Depression, Postpartum[MeSHID:D019052],Tremor[MeSHID:D014202],Status Epilepticus[MeSHID:D013226],Seizures[MeSHID:D012640],Essential Tremor[MeSHID:D020329] approved gaba(a) receptor delta GABRD Successful target unknown 0.21 TTD , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator 0.17 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRD NA positive allosteric modulator 0.15 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRD NA antagonist NA drugbank nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRD NA positive allosteric modulator 0.2 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRD NA binder NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRD NA positive allosteric modulator 0.05 drugbank , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator 0.05 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRD NA positive allosteric modulator 0.24 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRD NA potentiator 0.03 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.23 drugbank , DGIDB brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRD NA agonist NA drugbank oxazepam acetate small molecule NA experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRD NA binder NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRD NA positive allosteric modulator 0.17 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRD NA agonist,positive allosteric modulator NA drugbank pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRD NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRD NA positive allosteric modulator 0.13 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank pf-2393296 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 gaba(a) receptor delta GABRD Successful target unknown NA TTD ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRD NA positive allosteric modulator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRD NA positive allosteric modulator 0.1 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.24 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRE NA antagonist NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRE NA positive allosteric modulator 0.1 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRE NA binder NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRE NA positive allosteric modulator 0.26 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRE NA positive allosteric modulator 0.24 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank loprazolam small molecule NA experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator 0.19 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRE NA unknown NA drugbank remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank tbps NA NA investigative gaba(a) receptor epsilon GABRE Literature-reported target blocker NA TTD , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator 0.11 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRE NA positive allosteric modulator 0.17 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator 0.17 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator 0.14 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator 0.15 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRE NA positive allosteric modulator 0.2 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRE NA positive allosteric modulator 0.15 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator,agonist 0.06 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRE NA agonist,positive allosteric modulator NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRE NA positive allosteric modulator 0.18 drugbank , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank doxefazepam small molecule NA experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit epsilon GABRE NA potentiator 0.18 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRE NA binder NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRE NA positive allosteric modulator 0.05 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRE NA positive allosteric modulator 0.25 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit epsilon GABRE NA unknown NA drugbank glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator 0.06 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRE NA positive allosteric modulator 0.18 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRE NA positive allosteric modulator 0.15 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRE NA inhibitor NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.23 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.26 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator 0.26 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRE NA potentiator 0.03 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRE NA positive allosteric modulator 0.14 drugbank , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRE NA agonist NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRE NA positive allosteric modulator 0.2 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRE NA positive allosteric modulator 0.07 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank cinazepam small molecule NA experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRE NA antagonist NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.26 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator 0.18 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator 0.23 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRE NA antagonist,inducer NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator 0.05 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.07 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRE NA positive allosteric modulator 0.2 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRE NA positive allosteric modulator NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRE NA antagonist NA drugbank butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRE NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.14 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator 0.18 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA inhibitor NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit gamma-1 GABRG1 NA unknown NA drugbank temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.23 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.09 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.1 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.25 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.18 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRG1 NA positive allosteric modulator 0.24 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRG1 NA inhibitor NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG1 NA positive allosteric modulator 0.19 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.19 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG1 NA positive allosteric modulator 0.05 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.17 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank loprazolam small molecule NA experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator 0.19 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.18 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRG1 NA agonist NA drugbank cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.18 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.19 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.23 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator 0.1 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.25 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit gamma-1 GABRG1 NA potentiator 0.18 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank adipiplon small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA partial agonist 0.11 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.25 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator 0.14 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator 0.23 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.23 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.09 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator 0.25 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG1 NA positive allosteric modulator 0.13 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator 0.06 drugbank , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.14 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank cinazepam small molecule NA experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.25 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.14 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.25 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRG1 NA antagonist NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator 0.22 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator,agonist 0.06 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.11 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG1 NA positive allosteric modulator 0.25 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.19 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA inhibitor NA drugbank stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRG1 NA agonist,positive allosteric modulator NA drugbank ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG1 NA positive allosteric modulator 0.06 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.19 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator 0.09 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRG1 NA positive allosteric modulator 0.18 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.17 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator 0.14 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank medazepam small molecule NA experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator 0.14 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.24 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator 0.11 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.13 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator 0.17 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRG1 NA antagonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG1 NA potentiator 0.03 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.17 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRG1 NA unknown NA drugbank lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.1 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator 0.24 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.22 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG1 NA positive allosteric modulator 0.19 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator 0.17 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.22 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRG1 NA antagonist NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.13 drugbank , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator 0.05 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.17 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.14 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand,positive modulator 0.14 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRG1 NA binder NA drugbank brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand 0.24 drugbank , DGIDB etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG1 NA positive allosteric modulator 0.18 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG1 NA antagonist,inducer NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank 5,7,2′-trihydroxy-6,8-dimethoxyflavone small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG1 NA ligand NA drugbank prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.18 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.25 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRG1 NA positive allosteric modulator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG1 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG1 NA binder NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.06 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG2 NA positive allosteric modulator 0.2 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator 0.09 drugbank , DGIDB 2-(9-benzyl-9h-purin-6-ylamino)-ethanol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 1,1-dimethyl-5-oxa-spiro[2.4]heptan-4-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.14 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank eltanolone NA Premenstrual syndrome[MeSHID:D011293],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD l-655708 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator 0.13 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank 5-(4-piperidyl)-4-propylisothiazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 4-benzyl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator 0.13 drugbank , DGIDB 1,3-diphenyl-1h-chromeno[4,3-c]pyrazol-4-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB amentoflavone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 9h-beta-carboline-3-carboxylic acid ethyl ester NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG2 NA positive allosteric modulator 0.14 drugbank , DGIDB 3,3-diisopropyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-ethyl-3-isopropyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD ridine-5-carboxylic acid ethyl ester NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-ethoxycarbonyl-6-propyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD beta-carboline-3-carboxylic acid t-butyl ester NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.08 drugbank , DGIDB 6-ethyl-3-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.13 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator 0.09 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator 0.13 drugbank , DGIDB 6-nitro-2-(4-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator 0.04 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG2 NA binder NA drugbank 3-methyl-2-phenyl-2h-chromeno[4,3-c]pyrazol-4-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.14 drugbank , DGIDB zolpidem small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 NA agonist NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB 4-methyl-5-(4-piperidyl)isothiazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.17 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator 0.06 drugbank , DGIDB 5-[(1s)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-demethoxy-3d-glucopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRG2 NA positive allosteric modulator 0.11 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.19 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank u-89267 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.09 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank muscimol small molecule NA investigational gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 NA unknown NA drugbank estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.17 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.13 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 3-ethyl-3-methyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-tert-butyl-3-ethyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD tbps NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target blocker NA TTD , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRG2 NA inhibitor NA drugbank allopregnanolone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Depression, Postpartum[MeSHID:D019052],Tremor[MeSHID:D014202],Status Epilepticus[MeSHID:D013226],Seizures[MeSHID:D012640],Essential Tremor[MeSHID:D020329] approved gaba(a) receptor gamma-2 GABRG2 Successful target unknown 0.19 TTD , DGIDB 3-butylaminocarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD zk-93423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 3 gaba(a) receptor gamma-2 GABRG2 Successful target unknown 0.24 TTD , DGIDB 2-isoxazol-5-yl-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD n-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 6,6-dimethyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 6-nitro-2-(3-nitro-phenyl)-chromen-4-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD thiocolchicoside NA Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved gaba(a) receptor gamma-2 GABRG2 Successful target unknown 0.19 TTD , DGIDB 4-phenyl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-(3-methyl-butoxy)-9h-beta-carboline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB 1-methyl-5-oxa-spiro[2.4]heptan-4-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank n-butyl-2-(1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG2 NA positive allosteric modulator 0.19 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG2 NA antagonist,inducer NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.15 drugbank , DGIDB [3h]cgs8216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-amino-3-demethoxythiocolchicine NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-demethoxy-3-l-fucopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD ro-15-3505 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRG2 NA agonist,positive allosteric modulator NA drugbank medazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator 0.17 drugbank , DGIDB carisoprodol small molecule Rheumatism[MeSHID:D012216],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Diseases[MeSHID:D009140] approved gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 NA unknown NA drugbank n-benzyl-2-(1h-indol-3-yl)-2-oxo-acetamide NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank gnf-pf-3645 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.11 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.06 drugbank , DGIDB 3-isothiocyanato-9h-beta-carboline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD ro-145975 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 6-methyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD (9-benzyl-9h-purin-6-yl)-cyclopropyl-amine NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRG2 NA antagonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 3-propoxy-9h-beta-carboline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.17 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.13 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRG2 NA binder NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 3-methyl-9h-beta-carboline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator 0.14 drugbank , DGIDB 3-demethoxy-3-d-xylopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB 6-benzyl-3-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD beta-ccm NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-(benzyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD cgs-9895 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.09 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB 2-(1h-indol-3-yl)-2-oxo-n-phenethyl-acetamide NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA inhibitor NA drugbank 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.08 drugbank , DGIDB ginkgo biloba biotech Memory[MeSHID:D008568],Cognition[MeSHID:D003071] approved,investigational,nutraceutical gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 NA negative modulator NA drugbank 6-ethyl-3-pentoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.19 drugbank , DGIDB etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG2 NA positive allosteric modulator 0.22 drugbank , DGIDB ro-4938581 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 6-ethyl-3-propylaminocarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA inhibitor NA drugbank clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator 0.22 drugbank , DGIDB 4-naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD (2e,4s)-4-ammoniopent-2-enoate NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.08 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB 5,7,2′-trihydroxy-6,8-dimethoxyflavone small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank 3-demethoxy-3-d-mannopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator,agonist 0.05 drugbank , DGIDB 4-naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 3-(hexa-1,3-dienyloxy)-9h-pyrido[3,4-b]indole NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.08 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.13 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG2 NA positive allosteric modulator 0.06 drugbank , DGIDB 3-isobutoxy-9h-beta-carboline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB 6-ethyl-3-i-propoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD (4r)-4-ammoniopentanoate NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 6-benzyl-3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD n-butyl-2-(5-nitro-1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 5-(piperidin-4-yl)isothiazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD medazepam small molecule NA experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD , DGIDB 6-bromo-3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-ethoxy-9h-beta-carboline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 3-methyl-1-phenyl-1h-chromeno[4,3-c]pyrazol-4-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 4-benzyl-5-(4-piperidyl)isothiazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 9h-beta-carboline-3-carboxylic acid propyl ester NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 NA potentiator 0.11 drugbank , DGIDB 3-demethoxy-3-d-lyxopyranosylaminothiocolchicine NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator 0.17 drugbank , DGIDB ethyl 6-iodo-9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD n-benzyl-2-(5-nitro-1h-indol-3-yl)-2-oxoacetamide NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.08 drugbank , DGIDB 3,3-diethyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRG2 NA positive allosteric modulator 0.17 drugbank , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRG2 NA unknown NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ro-145974 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD (4s)-4-ammoniopentanoate NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD ro-147437 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRG2 NA antagonist NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.19 drugbank , DGIDB 3-carboxy-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.17 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 3-butoxycarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 1-(4-chlorophenyl)-4-phenyl-1h-imidazole NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD loprazolam small molecule NA experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.13 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB u-78875 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRG2 NA antagonist 0.19 drugbank , DGIDB 6-benzyl-3-propylaminocarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator 0.09 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.09 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.22 drugbank , DGIDB 5-[(1r)-1-ammonioethyl]isoxazol-3-olate NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank 2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ro-194603 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD cinazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG2 NA positive allosteric modulator 0.15 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank n-indan-1-yl-2-(1h-indol-3-yl)-2-oxo-acetamide NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD (beta-cce)9h-beta-carboline-3-carboxylic acid NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 2-thiophen-2-yl-3h-imidazo[4,5-c]quinoline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 6,9-dimethyl-2-oxa-spiro[4.4]nonan-1-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.17 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.13 drugbank , DGIDB ci-218872 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD doxefazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.09 drugbank , DGIDB 5-(piperidin-4-yl)isoxazol-3-ol NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator 0.08 drugbank , DGIDB adipiplon small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA partial agonist 0.05 drugbank , DGIDB ry-066 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD oxazepam acetate small molecule NA experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 3-ethoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRG2 NA agonist NA drugbank 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG2 NA positive allosteric modulator 0.08 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank 3-isopropyl-3-methyl-dihydro-furan-2-one NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator 0.19 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG2 NA potentiator 0.03 drugbank , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 NA antagonist 0.2 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.13 drugbank , DGIDB cgs-13767 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD sec-butyl 9h-pyrido[3,4-b]indole-3-carboxylate NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRG2 NA positive allosteric modulator 0.06 drugbank , DGIDB 3-butoxycarbonyl-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator 0.08 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRG2 NA positive allosteric modulator NA drugbank [3h]ro154513 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.19 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand,positive modulator 0.09 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand 0.15 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.08 drugbank , DGIDB 3-butoxy-9h-beta-carboline NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG2 NA ligand NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG2 NA positive allosteric modulator,positive modulator 0.08 drugbank , DGIDB gnf-pf-4421 NA NA investigative gaba(a) receptor gamma-2 GABRG2 Successful target unknown NA TTD adipiplon small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA partial agonist 0.09 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator 0.12 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator 0.2 drugbank , DGIDB remimazolam NA Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.1 TTD , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.15 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.15 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRG3 NA positive allosteric modulator 0.87 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator 0.15 drugbank , DGIDB cp-409092 NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD medazepam small molecule NA experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.15 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank talbutal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.09 TTD , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.09 drugbank , DGIDB dmcm NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA inhibitor NA drugbank clobazam - lundbeck NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD , DGIDB apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRG3 NA antagonist NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG3 NA potentiator 0.03 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank tp003 NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD isonipecotic acid NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD oxazepam acetate small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank medazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank ocinaplon NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.05 TTD , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.19 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.12 drugbank , DGIDB brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG3 NA positive allosteric modulator 0.11 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB thiamylal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.22 TTD , DGIDB etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG3 NA positive allosteric modulator 0.21 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank nsd-788 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],N-Acetylneuraminic acid storage disease[MeSHID:C535525] phase 1 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRG3 NA positive allosteric modulator 0.09 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.12 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.19 drugbank , DGIDB resequinil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] discontinued in phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target inverse agonist 0.1 TTD , DGIDB saripidem NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.87 TTD , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRG3 NA agonist,positive allosteric modulator 0.87 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.17 drugbank , DGIDB c-21191 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRG3 NA antagonist NA drugbank flumazenil NA Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.09 TTD , DGIDB [3h]cgs8216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.09 drugbank , DGIDB ganaxolone NA Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depression, Postpartum[MeSHID:D019052] phase 3 gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.1 TTD , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.12 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB ngd 96-3 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB rwj-51204 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] preclinical gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.22 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.2 drugbank , DGIDB alpha3ia NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit gamma-3 GABRG3 NA potentiator 0.15 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator 0.15 drugbank , DGIDB loreclezole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] discontinued in phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.17 drugbank , DGIDB alpha5ia NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ccd-3693 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD etomidate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.21 TTD , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.16 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRG3 NA unknown NA drugbank eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.2 drugbank , DGIDB evt-201 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.16 drugbank , DGIDB azd-3043 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.87 TTD , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.1 drugbank , DGIDB sage-217 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Depression, Postpartum[MeSHID:D019052],Parkinson Disease[MeSHID:D010300],Tremor[MeSHID:D014202],Major Depressive Disorder[MeSHID:D003865],Essential Tremor[MeSHID:D020329] phase 3 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.22 drugbank , DGIDB stiripentol NA Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.87 TTD , DGIDB 5,7,2′-trihydroxy-6,8-dimethoxyflavone small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank ngd 91-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD ro-48-8684 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.12 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG3 NA positive allosteric modulator 0.17 drugbank , DGIDB isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.11 drugbank , DGIDB suritozole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD t-2007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG3 NA binder NA drugbank flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.17 drugbank , DGIDB nordazepam small molecule NA experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank y-23684 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank sl-65.1498 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD etazolate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.05 TTD , DGIDB allopregnanolone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Depression, Postpartum[MeSHID:D019052],Tremor[MeSHID:D014202],Status Epilepticus[MeSHID:D013226],Seizures[MeSHID:D012640],Essential Tremor[MeSHID:D020329] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.17 TTD , DGIDB pazinaclone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB org-21465 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank cinazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA inhibitor NA drugbank methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.17 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.22 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.21 drugbank , DGIDB flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG3 NA positive allosteric modulator 0.09 drugbank , DGIDB hz-166 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRG3 NA positive allosteric modulator 0.21 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG3 NA positive allosteric modulator 0.05 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.15 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.15 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank piperidine-4-sulphonic acid NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG3 NA positive allosteric modulator 0.17 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.12 drugbank , DGIDB uc-2029 NA Premenstrual syndrome[MeSHID:D011293],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD gidazepam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.09 drugbank , DGIDB ro-48-6791 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD talbutal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved gaba(a) receptor gamma-3 GABRG3 Successful target positive modulator 0.09 TTD , DGIDB tbps NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target blocker NA TTD , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.22 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.09 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.11 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator 0.17 drugbank , DGIDB zolpidem NA Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.1 TTD , DGIDB remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator 0.1 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator 0.09 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRG3 NA agonist NA drugbank mebutamate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.87 TTD , DGIDB methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator 0.04 drugbank , DGIDB [18f]fluoroethylflumazenil NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRG3 NA antagonist NA drugbank nordazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.87 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRG3 NA inhibitor NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRG3 NA antagonist,inducer NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.12 drugbank , DGIDB org-25435 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 1 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.16 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB metharbital NA Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.09 TTD , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.09 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB aa-29504 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRG3 NA positive allosteric modulator 0.22 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.16 drugbank , DGIDB meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator,agonist 0.05 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank dov-51892 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Panic Disorder[MeSHID:D016584] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD pnu 101017 NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB suriclone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in preregistration gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank clomethiazole NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.17 TTD , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank metharbital NA Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor gamma-3 GABRG3 Successful target positive modulator 0.09 TTD , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank uc-1011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.11 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.15 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.11 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.15 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator 0.12 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.05 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRG3 NA binder NA drugbank [35s]tbps NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand 0.12 drugbank , DGIDB tetrahydrodeoxycorticosterone NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD jm-1232(-) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand,positive modulator 0.11 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.19 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.22 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit gamma-3 GABRG3 NA unknown NA drugbank midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRG3 NA positive allosteric modulator 0.09 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRG3 NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB uc-2024 NA Premenstrual syndrome[MeSHID:D011293],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD [3h]ro154513 NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD ro-15-3505 NA NA investigative gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank bentazepam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.87 TTD , DGIDB arbaclofen placarbil NA Muscle Spasticity[MeSHID:D009128],Multiple Sclerosis[MeSHID:D009103],Gastroesophageal reflux disease[MeSHID:D005764],Spasm[MeSHID:D013035],Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 3 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank ctp-354 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 1 gaba(a) receptor gamma-3 GABRG3 Successful target unknown NA TTD cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRG3 NA positive allosteric modulator 0.15 drugbank , DGIDB doxefazepam small molecule NA experimental gaba(a) receptor benzodiazepine binding site GABRG3 NA ligand NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRG3 NA positive allosteric modulator NA drugbank pagoclone NA Anxiety Disorders[MeSHID:D001008],Panic[MeSHID:D010200],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 gaba(a) receptor gamma-3 GABRG3 Successful target unknown 0.29 TTD , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator 0.17 drugbank , DGIDB fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit pi GABRP NA potentiator 0.18 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB oxazepam acetate small molecule NA experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator 0.05 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRP NA binder NA drugbank etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRP NA positive allosteric modulator 0.15 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator 0.23 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank nordazepam small molecule NA experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.26 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRP NA antagonist NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRP NA positive allosteric modulator 0.05 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRP NA antagonist,inducer NA drugbank ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRP NA positive allosteric modulator 0.07 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator 0.14 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRP NA positive allosteric modulator 0.2 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.14 drugbank , DGIDB isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator 0.15 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator 0.26 drugbank , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit pi GABRP NA unknown NA drugbank brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRP NA antagonist NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRP NA positive allosteric modulator 0.1 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRP NA positive allosteric modulator 0.18 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRP NA inhibitor NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank doxefazepam small molecule NA experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRP NA antagonist NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRP NA agonist,positive allosteric modulator NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRP NA binder NA drugbank meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator,agonist 0.06 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.23 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRP NA positive allosteric modulator 0.24 drugbank , DGIDB methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.07 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator 0.19 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRP NA positive allosteric modulator 0.2 drugbank , DGIDB midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator 0.11 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRP NA positive allosteric modulator 0.15 drugbank , DGIDB ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRP NA positive allosteric modulator 0.26 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator 0.06 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRP NA positive allosteric modulator 0.25 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.17 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRP NA agonist NA drugbank lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRP NA positive allosteric modulator 0.14 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator 0.18 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.2 drugbank , DGIDB cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRP NA positive allosteric modulator 0.18 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRP NA positive allosteric modulator 0.2 drugbank , DGIDB triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRP NA positive allosteric modulator 0.17 drugbank , DGIDB tbps NA NA investigative gaba(a) receptor pi GABRP Literature-reported target blocker NA TTD , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.24 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRP NA unknown NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.1 drugbank , DGIDB quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRP NA positive allosteric modulator,positive modulator 0.26 drugbank , DGIDB lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRP NA positive allosteric modulator NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRP NA potentiator 0.03 drugbank , DGIDB ketazolam small molecule Anxiety Disorders[MeSHID:D001008],Irritable Mood[MeSHID:D007508],Anxiety[MeSHID:D001007] approved gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRQ NA binder NA drugbank meprobamate small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator,agonist 0.06 drugbank , DGIDB mexazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disease[MeSHID:D004194] experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank lormetazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasal Polyps[MeSHID:D009298] approved gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank brexanolone small molecule Depression, Postpartum[MeSHID:D019052] approved,investigational gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator 0.19 drugbank , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRQ NA potentiator 0.04 drugbank , DGIDB clorazepic acid small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank quazepam small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB bromazepam small molecule Panic Attacks[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRQ NA positive allosteric modulator 0.16 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB cinazepam small molecule NA experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical gaba(a) receptor GABRQ NA agonist NA drugbank glutethimide small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator 0.07 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRQ NA positive allosteric modulator 0.15 drugbank , DGIDB lorazepam small molecule Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.15 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRQ NA unknown NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRQ NA positive allosteric modulator 0.11 drugbank , DGIDB oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRQ NA positive allosteric modulator 0.22 drugbank , DGIDB cloxazolam small molecule Operative Surgical Procedures[MeSHID:D013514],Anxiety Disorders[MeSHID:D001008],Unmarried[MeSHID:D012847],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929] experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank remimazolam small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank flunitrazepam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank etomidate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRQ NA positive allosteric modulator 0.2 drugbank , DGIDB halazepam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB medazepam small molecule NA experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRQ NA antagonist NA drugbank delorazepam small molecule Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank camazepam small molecule Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] experimental,illicit gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank apalutamide small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129] approved,investigational gaba(a) receptor GABRQ NA antagonist NA drugbank midazolam small molecule Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator 0.12 drugbank , DGIDB stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved gaba(a) receptor GABRQ NA agonist,positive allosteric modulator NA drugbank doxefazepam small molecule NA experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank alprazolam small molecule Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,illicit,investigational gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.11 drugbank , DGIDB adinazolam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank flumazenil small molecule Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRQ NA positive allosteric modulator 0.06 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved gaba(a) receptor GABRQ NA binder NA drugbank nordazepam small molecule NA experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator 0.05 drugbank , DGIDB loprazolam small molecule NA experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank tbps NA NA investigative gaba(a) receptor theta GABRQ Literature-reported target blocker NA TTD , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.26 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gamma-aminobutyric acid receptor subunit theta GABRQ NA unknown NA drugbank cinolazepam small molecule Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRQ NA positive allosteric modulator 0.16 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical gaba(a) receptor GABRQ NA antagonist NA drugbank methyprylon small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.07 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.16 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB 1,2-benzodiazepine small molecule NA approved,investigational gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator 0.15 drugbank , DGIDB eszopiclone small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB bentazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB chlordiazepoxide small molecule Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.16 drugbank , DGIDB temazepam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRQ NA positive allosteric modulator 0.26 drugbank , DGIDB pinazepam small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank oxazepam acetate small molecule NA experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank brotizolam small molecule Sleeplessness[MeSHID:D007319] investigational,withdrawn gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational gaba(a) receptor GABRQ NA inhibitor NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.03 drugbank , DGIDB clobazam small molecule Disease Management[MeSHID:D019468],Epilepsy[MeSHID:D004827],Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator 0.16 drugbank , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.04 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.06 drugbank , DGIDB flurazepam small molecule Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational gaba(a) receptor GABRQ NA positive allosteric modulator 0.22 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRQ NA positive allosteric modulator 0.22 drugbank , DGIDB ethchlorvynol small molecule Disease Management[MeSHID:D019468],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,withdrawn gaba(a) receptor GABRQ NA positive allosteric modulator 0.07 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRQ NA antagonist,inducer NA drugbank triazolam small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gaba(a) receptor GABRQ NA positive allosteric modulator 0.19 drugbank , DGIDB prazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB clotiazepam small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank ethyl loflazepate small molecule NA experimental,illicit gaba(a) receptor GABRQ NA positive allosteric modulator NA drugbank oxazepam small molecule Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.22 drugbank , DGIDB diazepam small molecule Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,vet_approved gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.19 drugbank , DGIDB estazolam small molecule Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit gaba(a) receptor GABRQ NA positive allosteric modulator,positive modulator 0.05 drugbank , DGIDB (+/-)-cis-2-camp NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target unknown NA TTD picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental gamma-aminobutyric acid receptor subunit rho-1 GABRR1 NA antagonist 0.65 drugbank , DGIDB tpmpa NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target antagonist NA TTD , DGIDB picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental gamma-aminobutyric acid receptor subunit rho-1 GABRR1 NA antagonist,blocker 0.65 drugbank , DGIDB cis-3-acpbpa NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target antagonist NA TTD , DGIDB isonipecotic acid NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target unknown 1.06 TTD , DGIDB lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn gamma-aminobutyric acid receptor subunit rho-1 GABRR1 NA unknown NA drugbank isonipecotic acid NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target antagonist NA TTD , DGIDB piperidine-4-sulphonic acid NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target antagonist NA TTD , DGIDB tbps NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target blocker NA TTD , DGIDB caca NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target unknown NA TTD aza-thip NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target antagonist NA TTD , DGIDB trans-3-acpbpa NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target antagonist NA TTD , DGIDB fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit rho-1 GABRR1 NA potentiator 0.37 drugbank , DGIDB 5-me-iaa NA NA investigative gaba(a) receptor rho1 GABRR1 Literature-reported target agonist NA TTD , DGIDB piperidine-4-sulphonic acid NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target antagonist NA TTD , DGIDB aza-thip NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target antagonist NA TTD , DGIDB fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit rho-2 GABRR2 NA potentiator 0.39 drugbank , DGIDB (+/-)-cis-2-camp NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target unknown NA TTD trans-3-acpbpa NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target antagonist NA TTD , DGIDB tpmpa NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target antagonist NA TTD , DGIDB cis-3-acpbpa NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target antagonist NA TTD , DGIDB isonipecotic acid NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target antagonist NA TTD , DGIDB tbps NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target blocker NA TTD , DGIDB 5-me-iaa NA NA investigative gaba(a) receptor rho2 GABRR2 Literature-reported target agonist NA TTD , DGIDB cis-3-acpbpa NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target antagonist NA TTD , DGIDB tbps NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target blocker NA TTD , DGIDB piperidine-4-sulphonic acid NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target antagonist NA TTD , DGIDB aza-thip NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target antagonist NA TTD , DGIDB fludiazepam small molecule Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit gamma-aminobutyric acid receptor subunit rho-3 GABRR3 NA potentiator 0.39 drugbank , DGIDB tpmpa NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target antagonist NA TTD , DGIDB 5-me-iaa NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target agonist NA TTD , DGIDB (+/-)-cis-2-camp NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target unknown NA TTD trans-3-acpbpa NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target antagonist NA TTD , DGIDB isonipecotic acid NA NA investigative gaba(a) receptor rho3 GABRR3 Literature-reported target antagonist NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate decarboxylase 1 GAD1 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glutamate decarboxylase 1 GAD1 NA cofactor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glutamate decarboxylase 1 (brain, 67kda) GAD1 NA cofactor NA drugbank s-allylglycine NA NA investigative glutamate decarboxylase 2 GAD2 Clinical trial target inhibitor NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate decarboxylase 2 GAD2 NA unknown NA drugbank diamyd NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 glutamate decarboxylase 2 GAD2 Clinical trial target unknown NA TTD , DGIDB pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glutamate decarboxylase 2 (pancreatic islets and brain, 65kda) GAD2 NA cofactor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glutamic acid decarboxylase GAD65 NA cofactor NA drugbank phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamic acid decarboxylase GAD65 NA inhibitor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glutamate decarboxylase-like protein 1 GADL1 NA cofactor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cyclin-g-associated kinase GAK NA inhibitor NA drugbank phenyl-uridine-5'-diphosphate NA NA investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD uridine-5'-diphosphate NA NA investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD galactose-uridine-5'-diphosphate small molecule NA experimental udp-glucose 4-epimerase GALE NA unknown NA drugbank uridine diphosphate glucose small molecule NA experimental udp-glucose 4-epimerase GALE NA unknown NA drugbank psammaplin a NA NA investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD udp-alpha-d-glucuronic acid small molecule NA experimental udp-glucose 4-epimerase GALE NA substrate NA drugbank uridine diphosphate galactose NA NA investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD nicotinamide-adenine-dinucleotide NA NA investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD tetramethylammonium ion NA NA investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD uridine-diphosphate-n-acetylgalactosamine small molecule NA experimental,investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD , drugbank udp-glucose NA NA investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD uridine-5'-diphosphate-mannose NA NA investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD tetramethylammonium small molecule NA experimental udp-glucose 4-epimerase GALE NA unknown NA drugbank uridine-diphosphate-n-acetylglucosamine small molecule NA experimental,investigative udp-glucose 4-epimerase GALE Literature-reported target unknown NA TTD , drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental galactokinase GALK1 NA unknown NA drugbank elosulfase alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] approved n-acetylgalactosamine 6 sulfatase GALNS Successful target unknown NA TTD , DGIDB bmn-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidosis IV[MeSHID:D009085] phase 3 n-acetylgalactosamine 6 sulfatase GALNS Successful target unknown 63.65 TTD , DGIDB gwtlnsagyllgpppalala-conh2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD wtlnsagyll-conh2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD gwtlnsagyllgphav-nh2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD galb2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD gwtlnsagyllgprpkpqqwfwll-conh2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD [n-me,des-sar]gal-b2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target agonist NA TTD , DGIDB gal-b5 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target agonist 15.91 TTD , DGIDB (sar)wtlnsagyllgpkk(lys-lauroyl)k NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD (sar)wtlnsagyllgpkk(lys-decanoyl)k NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD galantide NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD (sar)wtlnsagyllgpkkkk NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD wtlnsagyllgphavgnhpsfsdknglts-conh2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD galanin NA NA investigative galanin receptor type 2 GALR2 Literature-reported target agonist 10.61 TTD , DGIDB (sar)wtlnsagyllgpkk(lys-mpeg4)k NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD [sar1gly]gal-b2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD gwtlnsagyllgpppgfspfr-conh2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD (sar)wtlnsagyllgpkk(lys-palmitoyl)k NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD (sar)wtlnsagyllgpkk(lys-myristoyl)k NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD [n-ac,des-sar]gal-b2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD gwtlnsagyllgprhyinlitrqry-conh2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD gwtlnsagyllgphavgnhrsfsdknglts-conh2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD (sar)wtlnsagyllgpkk(lys-stearoyl)k NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD [sar1ala]gal-b2 NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD (sar)wtlnsagyllgpkk(lys-octanoyl)k NA NA investigative galanin receptor type 2 GALR2 Literature-reported target unknown NA TTD s-adenosyl-l-homocysteine small molecule NA experimental guanidinoacetate n-methyltransferase GAMT NA unknown NA drugbank creatine small molecule NA approved,investigational,nutraceutical guanidinoacetate n-methyltransferase GAMT NA product of NA drugbank guanidine small molecule Lambert-Eaton Myasthenic Syndrome[MeSHID:D015624],Paresis[MeSHID:D010291],Muscle Weakness[MeSHID:D018908],Myasthenia Gravis[MeSHID:D009157] approved guanidinoacetate n-methyltransferase GAMT NA unknown NA drugbank phosphocreatine small molecule Disease[MeSHID:D004194],Cardiovascular Diseases[MeSHID:D002318],Skeletal muscle structure[MeSHID:D018482],Cerebrovascular accident[MeSHID:D020521],Muscle Strength[MeSHID:D053580],Cerebrovascular Disorders[MeSHID:D002561] nutraceutical guanidinoacetate n-methyltransferase GAMT NA product of NA drugbank glycocyamine small molecule NA experimental guanidinoacetate n-methyltransferase GAMT NA unknown NA drugbank miglitol small molecule Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved neutral alpha-glucosidase ab GANAB NA antagonist NA drugbank miglitol small molecule Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved neutral alpha-glucosidase c GANC NA antagonist NA drugbank thionicotinamide-adenine-dinucleotide small molecule NA experimental glyceraldehyde-3-phosphate dehydrogenase GAPDH NA unknown NA drugbank xanthinol small molecule Metabolism[MeSHID:D008660],Brain[MeSHID:D001921],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Hyperlipidemia[MeSHID:D006949],Peripheral Vascular Diseases[MeSHID:D016491],Memory[MeSHID:D008568],Blood[MeSHID:D001769],Awareness[MeSHID:D001364] approved,withdrawn glyceraldehyde-3-phosphate dehydrogenase GAPDH NA cofactor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glyceraldehyde-3-phosphate dehydrogenase GAPDH NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational glyceraldehyde-3-phosphate dehydrogenase GAPDH NA ligand NA drugbank saframycin a NA NA investigative glyceraldehyde-3-phosphate dehydrogenase GAPDH Clinical trial target unknown NA TTD 4-(2-aminoethyl)benzenesulfonyl fluoride small molecule NA experimental glyceraldehyde-3-phosphate dehydrogenase GAPDH NA unknown NA drugbank adenosine-5-diphosphoribose small molecule NA experimental glyceraldehyde-3-phosphate dehydrogenase GAPDH NA unknown NA drugbank omigapil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Dystrophy[MeSHID:D009136],Lateral Sclerosis[MeSHID:D016472] phase 2 glyceraldehyde-3-phosphate dehydrogenase GAPDH Clinical trial target unknown 4.24 TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical glyceraldehyde-3-phosphate dehydrogenase GAPDH NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA unknown NA drugbank n-naphthalen-1-ylmethyl-2'-[3,5-dimethoxybenzamido]-2'-deoxy-adenosine small molecule NA experimental glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA ligand NA drugbank 2'-deoxy-2'-[(3,5-dimethoxybenzoyl)amino]-n-[(1r)-1,2,3,4-tetrahydro-1-naphthalenyl]adenosine small molecule NA experimental glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA unknown NA drugbank (+)-rutamarin alcohol small molecule NA experimental glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA binder NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS NA binder NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine--trna ligase GARS NA substrate NA drugbank pemetrexed small molecule Malignant mesothelioma[MeSHID:C562839],Disease[MeSHID:D004194],Pleura[MeSHID:D010994],Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational trifunctional purine biosynthetic protein adenosine-3 GART NA inhibitor 18.19 drugbank , DGIDB n-({4-[(1r)-4-[(2r,4s,5s)-2,4-diamino-6-oxohexahydropyrimidin-5-yl]-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl}carbonyl)-l-glutamic acid small molecule NA experimental trifunctional purine biosynthetic protein adenosine-3 GART NA unknown NA drugbank glycinamide ribonucleotide small molecule NA experimental trifunctional purine biosynthetic protein adenosine-3 GART NA unknown NA drugbank 10-cf3c(oh)2-ddacthf NA NA investigative glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown NA TTD glycinamide ribonucleotide NA NA investigative glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown NA TTD ly309887 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown NA TTD , DGIDB dideazafolate NA NA investigative glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown NA TTD dideazaacyclotetrahydrofolic acid NA NA investigative glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown NA TTD 10-trifluoroacetyl-ddacthf NA NA investigative glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown NA TTD ag2034 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 gar transformylase GART Clinical trial target unknown NA TTD , DGIDB 10-formyl-5,8,10-trideazafolic acid NA NA investigative glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown NA TTD ddathf NA NA investigative gar transformylase GART Clinical trial target unknown NA TTD (10r)-10-formyl-5,8,10-trideazafolic acid NA NA investigative glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown NA TTD pelitrexol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 glycinamide ribonucleotide formyltransferase GART Clinical trial target unknown 21.22 TTD , DGIDB avb-500 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],IGA Glomerulonephritis[MeSHID:D005922] phase 2 axl receptor tyrosine kinase ligand GAS6 Clinical trial target unknown NA TTD g17dt NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 gastrin GAST Clinical trial target unknown NA TTD , DGIDB oxetacaine small molecule Esophagitis[MeSHID:D004941],Gastritis[MeSHID:D005756],Anorexia[MeSHID:D000855],Heartburn[MeSHID:D006356],Peptic Ulcer[MeSHID:D010437],Pain[MeSHID:D010146],Hiatal Hernia[MeSHID:D006551] approved,investigational gastrin GAST NA inhibition of synthesis NA drugbank alpha-aminobutyric acid small molecule NA experimental glycine amidinotransferase, mitochondrial GATM NA unknown NA drugbank delta-amino valeric acid small molecule NA experimental glycine amidinotransferase, mitochondrial GATM NA unknown NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine amidinotransferase, mitochondrial GATM NA substrate NA drugbank norvaline small molecule NA experimental glycine amidinotransferase, mitochondrial GATM NA unknown NA drugbank gamma-aminobutyric acid small molecule NA approved,investigational glycine amidinotransferase, mitochondrial GATM NA unknown NA drugbank ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical glycine amidinotransferase, mitochondrial GATM NA unknown NA drugbank velaglucerase alfa biotech Gaucher Disease[MeSHID:D005776],Lysosomes[MeSHID:D008247],Term Birth[MeSHID:D047929],Hydrolysis[MeSHID:D006868],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] approved,investigational glucosylceramidase GBA Successful target unknown NA TTD , drugbank , DGIDB (2r,3s,4s,5r)-2-hexylpiperidine-3,4,5-triol NA NA investigative glucosylceramidase GBA Successful target unknown NA TTD (2r,3s,4s,5r)-2-nonylpiperidine-3,4,5-triol NA NA investigative glucosylceramidase GBA Successful target unknown NA TTD n-acetyl-alpha-d-glucosamine small molecule NA experimental glucosylceramidase GBA NA unknown NA drugbank 1,5-dideoxy-1,5-imino-d-xylitol NA NA investigative glucosylceramidase GBA Successful target unknown NA TTD afegostat NA Gaucher Disease[MeSHID:D005776],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glucosylceramidase GBA Successful target unknown 6.37 TTD , DGIDB (2r,3r,4r,5s)-2-(hydroxymethyl)-1-nonylpiperidine-3,4,5-triol small molecule NA experimental glucosylceramidase GBA NA unknown NA drugbank scyllo-inositol small molecule NA investigational glucosylceramidase GBA NA unknown NA drugbank ncgc607 NA Gaucher Disease[MeSHID:D005776],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical glucosylceramidase GBA Successful target unknown NA TTD , DGIDB isofagomine tartrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] phase 2 glucosylceramidase GBA Successful target unknown NA TTD , DGIDB n-(propylamide-benzophenone)-1-deoxynojirimycin NA NA investigative glucosylceramidase GBA Successful target unknown NA TTD l-isofagomine NA NA investigative glucosylceramidase GBA Successful target unknown NA TTD taliglucerase alfa NA Gaucher Disease[MeSHID:D005776],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] approved glucosylceramidase GBA Successful target unknown NA TTD , DGIDB (2r,3s,4s,5r)-2-propylpiperidine-3,4,5-triol NA NA investigative glucosylceramidase GBA Successful target unknown NA TTD 2-(acetylamino)-2-deoxy-a-d-glucopyranose NA NA investigative glucosylceramidase GBA Successful target unknown NA TTD n-(propylamide-acetophenone)-1-deoxynojirimycin NA NA investigative glucosylceramidase GBA Successful target unknown NA TTD n-octyl-beta-valienamine NA Gaucher Disease[MeSHID:D005776],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical glucosylceramidase GBA Successful target unknown NA TTD vitamin d small molecule Familial hypophosphatemia[MeSHID:D007015],Hypoparathyroidism[MeSHID:D007011],Familial Hypophosphatemic Rickets[MeSHID:D053098],Vitamin D-resistant rickets[MeSHID:D063730],Rickets[MeSHID:D012279] approved,nutraceutical,vet_approved vitamin d-binding protein GC NA unknown NA drugbank , DGIDB calcium phosphate small molecule NA approved grancalcin GCA NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved grancalcin GCA NA unknown NA drugbank calcium citrate small molecule NA approved,investigational grancalcin GCA NA ligand NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved 2-amino-3-ketobutyrate coenzyme a ligase, mitochondrial GCAT NA substrate NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical 2-amino-3-ketobutyrate coenzyme a ligase, mitochondrial GCAT NA cofactor NA drugbank s-4-nitrobutyryl-coa small molecule NA experimental glutaryl-coa dehydrogenase, mitochondrial GCDH NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved glutaryl-coa dehydrogenase, mitochondrial GCDH NA unknown NA drugbank sar425899 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucagon GCG Clinical trial target unknown 1.33 TTD , DGIDB pb-1023 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon GCG Clinical trial target unknown NA TTD , DGIDB jnj-64565111 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 glucagon GCG Clinical trial target unknown 3.98 TTD , DGIDB medi0382 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon GCG Clinical trial target unknown 3.98 TTD , DGIDB zp2929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Obesity[MeSHID:D009765] phase 1 glucagon GCG Clinical trial target unknown NA TTD , DGIDB mk-8521 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon GCG Clinical trial target unknown NA TTD , DGIDB dsr-17759 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucagon receptor GCGR Successful target unknown NA TTD isis 325568 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon receptor messenger rna GCGR Clinical trial target unknown NA TTD , DGIDB pmid25828189-compound-21 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB ionis-gcgr-rx NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon receptor messenger rna GCGR Clinical trial target unknown NA TTD glucagon biotech Movement[MeSHID:D009068],Cardiac Arrest[MeSHID:D006323],Hypoglycemia[MeSHID:D007003],Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucagon receptor GCGR NA agonist 7.43 drugbank , DGIDB [des-his1,tyr5,glu9,d-phe10]glucagon-nh2 NA NA investigative glucagon receptor GCGR Successful target unknown NA TTD isis-gcgr NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucagon receptor messenger rna GCGR Clinical trial target unknown NA TTD biphenyl carboxamidopropanoic acid derivative 2 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB remd 477 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 2 glucagon receptor GCGR Successful target unknown NA TTD zp2929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Obesity[MeSHID:D009765] phase 1 glucagon receptor GCGR Successful target unknown NA TTD , DGIDB dasiglucagon biotech Diabetes Mellitus[MeSHID:D003920],Hypoglycemia[MeSHID:D007003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperinsulinism[MeSHID:D006946] approved,investigational glucagon receptor GCGR Successful target agonist NA TTD , drugbank [des-his1,tyr5,glu9,d-tyr10]glucagon-nh2 NA NA investigative glucagon receptor GCGR Successful target unknown NA TTD nnc 92-1687 NA NA investigative glucagon receptor GCGR Successful target antagonist NA TTD , DGIDB aromatic ring compound 1 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB lgd-6972 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon receptor GCGR Successful target unknown 10.61 TTD , DGIDB biphenyl carboxamidopropanoic acid derivative 4 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB [des-his1,tyr5,glu9,d-ala10]glucagon-nh2 NA NA investigative glucagon receptor GCGR Successful target unknown NA TTD aromatic ring compound 4 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB spiroimidazolone derivative 6 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB heterocycle-containing compound 3 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB tt-401 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon receptor GCGR Successful target unknown NA TTD , DGIDB bay-73-7977 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 1 glucagon receptor GCGR Successful target unknown NA TTD regn1193 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon receptor GCGR Successful target unknown NA TTD [des-his1,tyr5,glu9]glucagon-nh2 NA NA investigative glucagon receptor GCGR Successful target unknown NA TTD hgcgr antagonist NA NA investigative glucagon receptor GCGR Successful target antagonist NA TTD , DGIDB dwlip-gcgrrx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucagon receptor GCGR Successful target unknown NA TTD ly-2409021 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon receptor GCGR Successful target unknown 10.61 TTD , DGIDB spiroimidazolone derivative 7 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB 3-substituted-2-furancarboxylic acid hydrazide derivative 1 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB picolinamido propanoic acid derivative 3 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB picolinamido propanoic acid derivative 1 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB heterocycle-containing compound 2 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB pf-06291874 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon receptor GCGR Successful target antagonist 10.61 TTD , DGIDB bi-32169 NA NA investigative glucagon receptor GCGR Successful target unknown NA TTD pyrrolidine derivative 6 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB quinolinyl compound 1 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB aromatic ring compound 2 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB glucagon recombinant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypoglycemia[MeSHID:D007003] approved glucagon receptor GCGR Successful target unknown NA TTD , DGIDB heterocycle-containing compound 1 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB 3-substituted-2-furancarboxylic acid hydrazide derivative 5 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB bay-27-9955 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 glucagon receptor GCGR Successful target unknown NA TTD pmid25828189-compound-22 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB spiroimidazolone derivative 4 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB l-168049 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucagon receptor GCGR Successful target unknown NA TTD sar425899 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucagon receptor GCGR Successful target agonist 3.54 TTD , DGIDB heterocycle-containing compound 4 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB pyrrolidine derivative 8 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB mar-531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypoglycemia[MeSHID:D007003] investigative glucagon receptor GCGR Successful target unknown NA TTD ly2944876 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucagon receptor GCGR Successful target unknown 2.65 TTD , DGIDB spiroimidazolone derivative 5 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB spiroimidazolone derivative 1 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB picolinamido propanoic acid derivative 2 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB pyrrolidine derivative 7 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB biphenyl carboxamidopropanoic acid derivative 3 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB aromatic ring compound 3 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB pmid25828189-compound-19 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB des-his1[glu9]glucagon-nh2 NA NA investigative glucagon receptor GCGR Successful target unknown NA TTD heterocycle-containing compound 5 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB mk-8521 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon receptor GCGR Successful target unknown NA TTD , DGIDB biphenyl carboxamidopropanoic acid derivative 1 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB glucagon-(1-6) NA NA investigative glucagon receptor GCGR Successful target unknown NA TTD spiroimidazolone derivative 3 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB nn-2501 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174]VAJO NEUROHEPATOPATHY[MeSHID:C538344] discontinued in phase 1 glucagon receptor GCGR Successful target unknown NA TTD spiroimidazolone derivative 2 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB sar425899 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucagon receptor GCGR Successful target unknown 3.54 TTD , DGIDB quinolinyl compound 2 NA NA patented glucagon receptor GCGR Successful target unknown NA TTD , DGIDB pf-06291874 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon receptor GCGR Successful target unknown 10.61 TTD , DGIDB prosavin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 gtp cyclohydrolase-i GCH1 Clinical trial target unknown NA TTD , DGIDB guanine NA NA phase 3 gtp cyclohydrolase-i GCH1 Clinical trial target unknown 127.3 TTD , DGIDB oxb-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 gtp cyclohydrolase-i GCH1 Clinical trial target unknown NA TTD guanine small molecule NA experimental gtp cyclohydrolase 1 GCH1 NA inhibitor 127.3 drugbank , DGIDB guanosine-5'-triphosphate NA NA investigative gtp cyclohydrolase-i GCH1 Clinical trial target unknown NA TTD 8-hydroxyguanine NA NA investigative gtp cyclohydrolase-i GCH1 Clinical trial target unknown NA TTD 2-propanol, isopropanol NA NA investigative gtp cyclohydrolase-i GCH1 Clinical trial target unknown NA TTD bms-820132 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB azd1656 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucokinase GCK Clinical trial target activator 18.19 TTD , DGIDB 3-[(4-fluorophenyl)sulfanyl]-n-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4h-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide small molecule NA experimental glucokinase GCK NA unknown NA drugbank pf-04937319 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucokinase GCK Clinical trial target unknown 9.09 TTD , DGIDB azd6370 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glucokinase GCK Clinical trial target unknown NA TTD 2-amino-4-fluoro-5-[(1-methyl-1h-imidazol-2-yl)sulfanyl]-n-(1,3-thiazol-2-yl)benzamide small molecule NA experimental glucokinase GCK NA unknown NA drugbank skl-19014 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucokinase GCK Clinical trial target unknown NA TTD azd1656 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucokinase GCK Clinical trial target unknown 18.19 TTD , DGIDB 2-amino-n-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4h-1,2,4-triazol-3-yl)sulfanyl]benzamide small molecule NA experimental glucokinase GCK NA unknown NA drugbank ds-7309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB amg 151 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB 2-(methylamino)-n-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4h-1,2,4-triazol-3-yl)sulfanyl]benzamide small molecule NA experimental glucokinase GCK NA unknown NA drugbank piragliatin NA NA investigative glucokinase GCK Clinical trial target unknown 18.19 TTD , DGIDB zygk-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB ly-2608204 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucokinase GCK Clinical trial target unknown 9.09 TTD , DGIDB ttp-547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB hms5552 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucokinase GCK Clinical trial target unknown 9.09 TTD , DGIDB ly-2599506 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB tak-329 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB azd5658 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] phase 1 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB psn-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucokinase GCK Clinical trial target unknown NA TTD gka-23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucokinase GCK Clinical trial target unknown NA TTD adv-1002401 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB ttp-355 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 glucokinase GCK Clinical trial target unknown NA TTD beta-d-glucose small molecule NA experimental,investigative glucokinase GCK Clinical trial target unknown NA TTD , drugbank gka1 NA NA investigative glucokinase GCK Clinical trial target unknown NA TTD pf-04991532 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucokinase GCK Clinical trial target unknown 9.09 TTD , DGIDB azd-6714 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 glucokinase GCK Clinical trial target unknown NA TTD gk1-399 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucokinase GCK Clinical trial target unknown NA TTD , DGIDB ttp399 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 2 glucokinase GCK Clinical trial target unknown NA TTD cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical glutamate--cysteine ligase catalytic subunit GCLC NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate--cysteine ligase catalytic subunit GCLC NA substrate NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate--cysteine ligase regulatory subunit GCLM NA unknown NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical glutamate--cysteine ligase regulatory subunit GCLM NA unknown NA drugbank 6-(hydroxyethyldithio)-8-(aminomethylthio)octanoic acid small molecule NA experimental glycine cleavage system h protein, mitochondrial GCSH NA unknown NA drugbank dihydrolipoic acid small molecule NA experimental glycine cleavage system h protein, mitochondrial GCSH NA unknown NA drugbank ace-041 NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 growth/differentiation factor 2 GDF2 Clinical trial target unknown 47.74 TTD , DGIDB rhgdf-5 NA Periodontal Diseases[MeSHID:D010510],Gingival Diseases[MeSHID:D005882],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 growth/differentiation factor 5 GDF5 Clinical trial target unknown NA TTD , DGIDB chondroitin sulfate small molecule Catabolism[MeSHID:D008660],Bone Tissue[MeSHID:D001842],Degenerative polyarthritis[MeSHID:D010003],Cartilage[MeSHID:D002356],Sclerosis[MeSHID:D012598],Body tissue[MeSHID:D014024],Inflammation[MeSHID:D007249],Synovial Membrane[MeSHID:D013583],Disease Progression[MeSHID:D018450],Pain[MeSHID:D010146] approved,investigational,nutraceutical glial cell line-derived neurotrophic factor GDNF NA unknown NA drugbank liatermin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lateral Sclerosis[MeSHID:D016472] phase 1/2 glial cell line-derived neurotrophic factor GDNF Clinical trial target unknown 10.61 TTD , DGIDB lirilumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant Neoplasms[MeSHID:D009369] phase 2 ras-like protein kir GEM Clinical trial target unknown 15.91 TTD , DGIDB flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved fad-linked sulfhydryl oxidase alr GFER NA unknown NA drugbank neublastin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 gdnf receptor alpha-3 GFRA3 Clinical trial target unknown NA TTD , DGIDB ngm120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 gdnf family receptor alpha-like GFRAL Clinical trial target unknown NA TTD formic acid small molecule NA experimental,investigational gamma-glutamylaminecyclotransferase GGACT NA unknown NA drugbank coagulation factor viia recombinant human biotech Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved vitamin k-dependent gamma-carboxylase GGCX NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical vitamin k-dependent gamma-carboxylase GGCX NA unknown NA drugbank menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical vitamin k-dependent gamma-carboxylase GGCX NA cofactor 2.84 drugbank , DGIDB kappadione small molecule Metabolism[MeSHID:D008660],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Hemorrhagic Disease of Newborn[MeSHID:D006475],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved vitamin k-dependent gamma-carboxylase GGCX NA agonist NA drugbank anisindione small molecule Venous Thrombosis[MeSHID:D020246],Pulmonary Embolism[MeSHID:D011655],Atrial Fibrillation[MeSHID:D001281],Coronary Occlusion[MeSHID:D054059],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved vitamin k-dependent gamma-carboxylase GGCX NA inhibitor 15.91 drugbank , DGIDB coagulation factor ix human biotech Plasma[MeSHID:D010949],Operative Surgical Procedures[MeSHID:D013514],Hemophilia B[MeSHID:D002836],Hemorrhage[MeSHID:D006470] approved vitamin k-dependent gamma-carboxylase GGCX NA unknown NA drugbank phytonadione NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemorrhage[MeSHID:D006470],Vitamin K Deficiency[MeSHID:D014813],Disease[MeSHID:D004194] approved vitamin k-dependent gamma-carboxylase GGCX Successful target unknown 143.22 TTD , DGIDB phylloquinone small molecule Metabolism[MeSHID:D008660],Blood Coagulation Disorders[MeSHID:D001778],Vitamin K Deficiency[MeSHID:D014813],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved,investigational vitamin k-dependent gamma-carboxylase GGCX NA substrate,inducer,cofactor NA drugbank coagulation factor ix (recombinant) biotech Hemophilia B[MeSHID:D002836],Hemophilia A[MeSHID:D006467] approved,investigational vitamin k-dependent gamma-carboxylase GGCX NA unknown NA drugbank zoledronic acid small molecule Multiple Myeloma[MeSHID:D009101],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Bone neoplasms[MeSHID:D001859],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Postmenopause[MeSHID:D017698],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024] approved geranylgeranyl pyrophosphate synthase GGPS1 NA inhibitor NA drugbank pamidronic acid small molecule Lytic lesion[MeSHID:D010014],Breast[MeSHID:D001940],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Malignant Bone Neoplasm[MeSHID:D001859],Malignant neoplasm of breast[MeSHID:D001943],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101] approved geranylgeranyl pyrophosphate synthase GGPS1 NA inhibitor NA drugbank [2-(3-dibenzofuran-4-yl-phenyl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank (1-hydroxyheptane-1,1-diyl)bis(phosphonic acid) small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank (6e,11e)-heptadeca-6,11-diene-9,9-diylbis(phosphonic acid) small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank farnesyl diphosphate small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank geranylgeranyl diphosphate small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA inhibitor NA drugbank , DGIDB ibandronate small molecule Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational geranylgeranyl pyrophosphate synthase GGPS1 NA inhibitor NA drugbank lauryl alcohol diphosphonic acid small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank (2,2-diphosphonoethyl)(dodecyl)dimethylphosphonium small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank (1-hydroxynonane-1,1-diyl)bis(phosphonic acid) small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank geranyl diphosphate small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank minodronic acid small molecule Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Malignant neoplasm of lung[MeSHID:D008175] investigational geranylgeranyl pyrophosphate synthase GGPS1 NA inhibitor NA drugbank , DGIDB farnesyl thiopyrophosphate small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank isopentenyl pyrophosphate small molecule NA experimental geranylgeranyl pyrophosphate synthase GGPS1 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical gamma-glutamyltranspeptidase 1 GGT1 NA unknown NA drugbank vrs-317 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 3 somatotropin GH1 Clinical trial target unknown 31.83 TTD , DGIDB arx-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Failure to Thrive[MeSHID:D005183] discontinued in phase 2 somatotropin GH1 Clinical trial target unknown NA TTD somatropin intranasal rhgh NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 2 somatotropin GH1 Clinical trial target unknown NA TTD , DGIDB hgh-ctp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 3 somatotropin GH1 Clinical trial target unknown NA TTD , DGIDB albutropin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Failure to Thrive[MeSHID:D005183] phase 3 somatotropin GH1 Clinical trial target unknown NA TTD , DGIDB acp-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 2 somatotropin GH1 Clinical trial target unknown 15.91 TTD , DGIDB ypeg-somatropin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 1 somatotropin GH1 Clinical trial target unknown NA TTD , DGIDB aod-9604 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 2 growth hormone receptor GHR Successful target unknown NA TTD nnc-26-0194 NA NA investigative growth hormone receptor GHR Successful target unknown NA TTD ph-794428 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 2 growth hormone receptor GHR Successful target unknown NA TTD , DGIDB skf-110679 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 2 growth hormone receptor GHR Successful target unknown NA TTD , DGIDB somatotropin biotech Hypothalamic Diseases[MeSHID:D007027],Bodily secretions[MeSHID:D012634],Prader-Willi Syndrome[MeSHID:D011218],treatment failure[MeSHID:D017211],Body Weight[MeSHID:D001835],Operative Surgical Procedures[MeSHID:D013514],Failure to Thrive[MeSHID:D005183],Short Bowel Syndrome[MeSHID:D012778],Cachexia[MeSHID:D002100],Traumatic injury[MeSHID:D014947],Dwarfism[MeSHID:D004392],Hypopituitarism[MeSHID:D007018],Chronic Kidney Diseases[MeSHID:D051436],Turner Syndrome[MeSHID:D014424],Birth[MeSHID:D036801],Growth[MeSHID:D006128],Gestational Age[MeSHID:D005865],Pituitary Diseases[MeSHID:D010900],Macrophage Activation Syndrome[MeSHID:D055501],Malnutrition[MeSHID:D044342] approved,investigational growth hormone receptor GHR NA ligand NA drugbank lonapegsomatropin biotech treatment failure[MeSHID:D017211],Growth[MeSHID:D006128],Failure to Thrive[MeSHID:D005183],Bodily secretions[MeSHID:D012634] approved,investigational growth hormone receptor GHR NA ligand NA drugbank pegvisomant biotech Acromegaly[MeSHID:D000172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved growth hormone receptor GHR Successful target antagonist 114.57 TTD , drugbank , DGIDB ep-51216 NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 growth hormone receptor GHR Successful target unknown NA TTD , DGIDB somatropin recombinant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved growth hormone receptor GHR Successful target unknown NA TTD , DGIDB ep-51389 NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 growth hormone receptor GHR Successful target unknown NA TTD , DGIDB somatrem biotech Growth Disorders[MeSHID:D006130],Failure to Thrive[MeSHID:D005183],Dwarfism[MeSHID:D004392],Turner Syndrome[MeSHID:D014424],Chronic Kidney Diseases[MeSHID:D051436],Malnutrition[MeSHID:D044342],Kidney Failure, Chronic[MeSHID:D007676],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn growth hormone receptor GHR NA agonist 12.73 drugbank , DGIDB bvt-a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acromegaly[MeSHID:D000172] preclinical growth hormone receptor GHR Successful target unknown NA TTD , DGIDB syntropin NA Dwarfism[MeSHID:D004392],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 growth hormone receptor GHR Successful target unknown NA TTD , DGIDB somapacitan biotech Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational growth hormone receptor GHR NA agonist NA drugbank atl1103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acromegaly[MeSHID:D000172] phase 1 ghr messenger rna GHR Clinical trial target unknown NA TTD sermorelin biotech HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Dwarfism[MeSHID:D004392],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Growth Disorders[MeSHID:D006130] approved,withdrawn growth hormone-releasing hormone receptor GHRHR Successful target agonist 95.48 TTD , drugbank , DGIDB akl-0707 NA Lipodystrophy[MeSHID:D008060],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 growth hormone-releasing hormone receptor GHRHR Successful target unknown NA TTD , DGIDB l-692429 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 1 growth hormone-releasing hormone receptor GHRHR Successful target unknown NA TTD tesamorelin small molecule HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Maintenance[MeSHID:D008283],Abdominal Fat[MeSHID:D050153],Hypothalamic structure[MeSHID:D007031],Lipodystrophy[MeSHID:D008060],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational growth hormone-releasing hormone receptor GHRHR Successful target binder 79.56 TTD , drugbank , DGIDB mutated growth hormone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acromegaly[MeSHID:D000172] investigative growth hormone-releasing hormone receptor GHRHR Successful target unknown NA TTD tesamorelin small molecule HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Maintenance[MeSHID:D008283],Abdominal Fat[MeSHID:D050153],Hypothalamic structure[MeSHID:D007031],Lipodystrophy[MeSHID:D008060],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational growth hormone-releasing hormone receptor GHRHR Successful target binder,agonist 79.56 TTD , drugbank , DGIDB examorelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 2 growth hormone-releasing hormone receptor GHRHR Successful target unknown NA TTD unacylated ghrelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 1 ghrelin GHRL Clinical trial target unknown NA TTD , DGIDB macimorelin small molecule Diagnosis[MeSHID:D003933],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational growth hormone secretagogue receptor type 1 GHSR NA agonist 8.68 drugbank , DGIDB gsk1614343 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target antagonist NA TTD , DGIDB [35s]ibutamoren NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target agonist NA TTD , DGIDB rq-00000005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD , DGIDB ipamorelin NA Ileus[MeSHID:D045823],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 growth hormone secretagogue receptor 1 GHSR Successful target unknown 5.79 TTD , DGIDB macimorelin NA Diagnosis[MeSHID:D003933],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved growth hormone secretagogue receptor 1 GHSR Successful target unknown 8.68 TTD , DGIDB wfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD sm-130,686 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target agonist NA TTD , DGIDB dwfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD awfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD ghrp-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD , DGIDB macimorelin NA Diagnosis[MeSHID:D003933],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved growth hormone secretagogue receptor 1 GHSR Successful target agonist 8.68 TTD , DGIDB ibutamoren NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved growth hormone secretagogue receptor 1 GHSR Successful target agonist 11.57 TTD , DGIDB jmv3008 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target antagonist NA TTD , DGIDB wfwgg-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD tzp-101 NA Ileus[MeSHID:D045823],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Gastroparesis[MeSHID:D018589] phase 2b growth hormone secretagogue receptor 1 GHSR Successful target unknown 23.15 TTD , DGIDB st-1141 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Intestinal Diseases[MeSHID:D007410] phase 1 growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD , DGIDB pf-05190457 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 growth hormone secretagogue receptor 1 GHSR Successful target unknown 11.57 TTD , DGIDB ex-1314 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100] investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD qwfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD yil781 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target antagonist NA TTD , DGIDB kwfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD gtp-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD , DGIDB rwfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD ibutamoren NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved growth hormone secretagogue receptor 1 GHSR Successful target unknown 11.57 TTD , DGIDB echinacoside small molecule NA experimental growth hormone secretagogue receptor type 1 GHSR NA agonist NA drugbank abbott 14c NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target antagonist NA TTD , DGIDB hwfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD rpkpfqwfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD pf-05190457 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 growth hormone secretagogue receptor 1 GHSR Successful target antagonist 11.57 TTD , DGIDB 4-(3-hexylureido)-n-phenylbenzenesulfonamide NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD ep-01492 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD , DGIDB aezs-123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acrodermatitis enteropathica[MeSHID:C538178],Alcoholic Intoxication, Chronic[MeSHID:D000437] preclinical growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD , DGIDB gsk-894281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cell motility[MeSHID:D002465],Stomach Diseases[MeSHID:D013272] investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD tabimorelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 2 growth hormone secretagogue receptor 1 GHSR Successful target agonist 3.86 TTD , DGIDB tzp-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] preclinical growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD , DGIDB ex-1311 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD nox-b11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD ulimorelin small molecule NA investigational growth hormone secretagogue receptor type 1 GHSR NA unknown NA drugbank ly-444711 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 1 growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD tabimorelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 2 growth hormone secretagogue receptor 1 GHSR Successful target unknown 3.86 TTD , DGIDB dprwfwll-nh2 NA NA investigative growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD anamorelin NA Disease[MeSHID:D004194],Carbohydrate Metabolism[MeSHID:D050260],Metabolic Diseases[MeSHID:D008659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 growth hormone secretagogue receptor 1 GHSR Successful target unknown 5.79 TTD , DGIDB cyt-009-ghrqb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1/2 growth hormone secretagogue receptor 1 GHSR Successful target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical aspartate aminotransferase GIG18 NA cofactor NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical aspartate aminotransferase GIG18 NA substrate,product of NA drugbank rg7685 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 gastric inhibitory polypeptide receptor GIPR Clinical trial target unknown NA TTD ct 868 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 gastric inhibitory polypeptide receptor GIPR Clinical trial target unknown NA TTD sar438335 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 gastric inhibitory polypeptide receptor GIPR Clinical trial target unknown NA TTD , DGIDB rg7697 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 gastric inhibitory polypeptide receptor GIPR Clinical trial target unknown NA TTD octanol NA NA investigative gap junction alpha-1 protein GJA1 Clinical trial target inhibitor 0.38 TTD , DGIDB act1 NA Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 gap junction alpha-1 protein GJA1 Clinical trial target unknown NA TTD , DGIDB granexin gel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Radiation Syndrome[MeSHID:D011832],Operative Surgical Procedures[MeSHID:D013514],Diabetic Foot[MeSHID:D017719],Keloid[MeSHID:D007627] phase 3 gap junction alpha-1 protein GJA1 Clinical trial target unknown NA TTD , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational gap junction alpha-1 protein GJA1 NA other 1.26 drugbank , DGIDB hcb1019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 gap junction alpha-1 protein GJA1 Clinical trial target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational gap junction alpha-1 protein GJA1 NA other 1.26 drugbank , DGIDB octanol NA NA investigative connexin-62 GJA10 Literature-reported target inhibitor 1.52 TTD , DGIDB octanol NA NA investigative gap junction alpha-3 protein GJA3 Literature-reported target inhibitor 1.52 TTD , DGIDB octanol NA NA investigative gap junction beta-4 protein GJB4 Literature-reported target inhibitor 1.52 TTD , DGIDB octanol NA NA investigative connexin-25 GJB7 Literature-reported target inhibitor 1.52 TTD , DGIDB octanol NA NA investigative gap junction gamma-2 protein GJC2 Literature-reported target inhibitor 1.52 TTD , DGIDB octanol NA NA investigative gap junction gamma-3 protein GJC3 Literature-reported target inhibitor 1.52 TTD , DGIDB octanol NA NA investigative gap junction delta-3 protein GJD3 Literature-reported target inhibitor 1.52 TTD , DGIDB octanol NA NA investigative gap junction delta-4 protein GJD4 Literature-reported target inhibitor 1.52 TTD , DGIDB avr-rd-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fabry Disease[MeSHID:D000795] phase 1/2 alpha-galactosidase a GLA Successful target unknown NA TTD calystegine b2 NA NA investigative alpha-galactosidase a GLA Successful target unknown NA TTD alpha-d-mannose NA NA investigative alpha-galactosidase a GLA Successful target unknown NA TTD prx-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fabry Disease[MeSHID:D000795] phase 1/2 alpha-galactosidase a GLA Successful target unknown 5.3 TTD , DGIDB fucose NA NA investigative alpha-galactosidase a GLA Successful target unknown NA TTD beta-1-c-butyl-1-deoxygalactonojirimycin NA NA investigative alpha-galactosidase a GLA Successful target unknown NA TTD beta-1-c-butenyl-1-deoxygalactonojirimycin NA NA investigative alpha-galactosidase a GLA Successful target unknown NA TTD migalastat small molecule Blood capillaries[MeSHID:D002196],Structure of interstitial cell of Leydig[MeSHID:D007985],Mutation[MeSHID:D009154],Diagnosis[MeSHID:D003933],Kidney[MeSHID:D007668],Fabry Disease[MeSHID:D000795],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-galactosidase a GLA Successful target unknown 5.3 TTD , drugbank , DGIDB 2,5-dideoxy-2,5-imino-d-altritol NA NA investigative alpha-galactosidase a GLA Successful target unknown NA TTD (+)-5-deoxyadeenophorine NA NA investigative alpha-galactosidase a GLA Successful target unknown NA TTD lactose small molecule NA approved,experimental,investigational beta-galactosidase GLB1 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glycine dehydrogenase [decarboxylating], mitochondrial GLDC NA cofactor NA drugbank isoflavone derivative 6 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB isoflavone derivative 2 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB pmid26666870-compound-16 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB isoflavone derivative 3 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB isoflavone derivative 9 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB isoflavone derivative 1 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB isoflavone derivative 8 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB isoflavone derivative 7 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB imidazo bicyclic iminium derivative 1 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB isoflavone derivative 4 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB imidazo bicyclic iminium derivative 2 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB isoflavone derivative 5 NA NA patented zinc finger protein gli1 GLI1 Patented-recorded target unknown NA TTD , DGIDB adrtvp-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 glioma pathogenesis-related protein 1 GLIPR1 Clinical trial target unknown NA TTD , DGIDB sot-107 biotech Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glioma pathogenesis-related protein 1 GLIPR1 NA unknown NA drugbank l-cysteic acid small molecule NA experimental golgi-associated plant pathogenesis-related protein 1 GLIPR2 NA unknown NA drugbank s-(n-ethyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-(n-4chlorophenyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical lactoylglutathione lyase GLO1 NA unknown NA drugbank s-(n-butyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD kaempferol NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD naringenin NA NA phase 1 lactoylglutathione lyase GLO1 Clinical trial target unknown 3.98 TTD , DGIDB s-(n-hexyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD cyanidin NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-(n-4bromophenyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-p-bromobenzyl glutatione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD 2-sulfhydryl-ethanol NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-(n-pentyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-p-nitrobenzyloxycarbonylglutathione small molecule NA experimental,investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD , drugbank mercaptoethanol small molecule NA experimental lactoylglutathione lyase GLO1 NA unknown NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational lactoylglutathione lyase GLO1 NA inhibitor NA drugbank s-benzyl-glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD methyl 4-(2,3-dihydroxy-5-methylphenoxy)-2-hydroxy-6-methylbenzoate small molecule NA experimental lactoylglutathione lyase GLO1 NA unknown NA drugbank baicalein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-(n-phenyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD pelargonidin chloride NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-(n-hydroxy-n-iodophenylcarbamoyl)glutathione small molecule NA experimental,investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD , drugbank s-benzylglutathione small molecule NA experimental lactoylglutathione lyase GLO1 NA unknown NA drugbank s-(n-methyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-(n-heptyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-(n-propyl-n-hydroxycarbamoyl)glutathione NA NA investigative lactoylglutathione lyase GLO1 Clinical trial target unknown NA TTD s-hexylglutathione small molecule NA experimental lactoylglutathione lyase GLO1 NA unknown NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational lactoylglutathione lyase GLO1 NA inhibitor NA drugbank sar425899 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown 0.14 TTD , DGIDB cm-glp-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] discontinued in phase 1/2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD zp-3022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD liraglutide biotech Cardiovascular Diseases[MeSHID:D002318],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] approved glucagon-like peptide 1 receptor GLP1R Successful target agonist 3.35 TTD , drugbank , DGIDB semaglutide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Diabetic Ketoacidosis[MeSHID:D016883],Hypercholesterolemia[MeSHID:D006937],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Diet therapy[MeSHID:D004035],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Diagnosis[MeSHID:D003933], Non-Insulin-Dependent[MeSHID:D003924],Obesity[MeSHID:D009765],Overweight[MeSHID:D050177],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glucagon-like peptide 1 receptor GLP1R Successful target agonist 2.09 TTD , drugbank , DGIDB gx-g6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD albiglutide biotech Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucagon-like peptide 1 receptor GLP1R Successful target agonist 1.68 TTD , drugbank , DGIDB lixisenatide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucagon-like peptide 1 receptor GLP1R Successful target agonist 1.26 TTD , drugbank , DGIDB pf-4603629 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB [gly8, aib22]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD pramlintide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved glucagon-like peptide 1 receptor GLP1R Successful target unknown 0.08 TTD , DGIDB c[glu18-lys22][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD jnj-54728518 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB ly-307161 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD tirzepatide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD ly-2428757 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB betp NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target allosteric modulator NA TTD , DGIDB taspoglutide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 glucagon-like peptide 1 receptor GLP1R Successful target unknown 1.26 TTD , DGIDB gtp-010 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB c[glu22-orn26][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD ac-3174 NA Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD sx-glp1 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD gma102 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 3 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD pgc glp-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD cm3.1-ac100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB dulaglutide biotech Cardiovascular Diseases[MeSHID:D002318],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glucagon-like peptide 1 receptor GLP1R Successful target agonist 1.68 TTD , drugbank , DGIDB c[glu19-lys23][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD [gly8,glu22]glp-1(7,37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD taspoglutide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 glucagon-like peptide 1 receptor GLP1R Successful target agonist 1.26 TTD , DGIDB bi 456906 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD glu20-lys24][gly8][glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD [gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD zyog1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB c[glu22-lys26][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD ampe4l NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD zp2929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Obesity[MeSHID:D009765] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB cam-2036 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD c[hglu22-lys26][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD haegtftsdvssylegqaakeifawlvkgr NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD c[cpa19-lys26][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD c[glu24-lys28][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD f-18 exendin-4 derivative pet tracers NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD pb-1023 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB pf-06882961 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD glp-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 glucagon-like peptide 1 receptor GLP1R Successful target unknown 0.42 TTD , DGIDB nn-9926 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174]VAJO NEUROHEPATOPATHY[MeSHID:C538344] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB efpeglenatide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB c[glu21-lys25][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD gma105 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 3 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD latin t1d NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB c[glu21-lys26][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD haegtftsdvssylegqaakefiawlvkgrg-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD ly2944876 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown 0.21 TTD , DGIDB exenatide biotech Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,investigational glucagon-like peptide 1 receptor GLP1R Successful target agonist 7.96 TTD , drugbank , DGIDB glutazumab biotech NA investigational glucagon-like peptide 1 receptor GLP1R NA agonist NA drugbank ly-315902 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD rg7685 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD og987sc NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB ormd-0901 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB uni-re-4 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB skl-18287 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD glp-17-(7-36) derivative NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD oi338gt NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB glucagon biotech Movement[MeSHID:D009068],Cardiac Arrest[MeSHID:D006323],Hypoglycemia[MeSHID:D007003],Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucagon-like peptide 1 receptor GLP1R NA agonist 0.21 drugbank , DGIDB cnto-3649 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB cnto-736 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD ttp-054 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB sar438335 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB glucagon-like peptide-1 analog NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD ttp273 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB c[glu23-lys27][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD [123i] iodobenzoyl 12-ex4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD tt-401 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB ct 868 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD c[asp22-lys26][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD cjc-1131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] discontinued in phase 2 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD cvx 096 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cervix Uteri[MeSHID:D002584] phase 1 glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD , DGIDB c[glu26-lys30][gly8]glp-1(7-37)-nh2 NA NA investigative glucagon-like peptide 1 receptor GLP1R Successful target unknown NA TTD fe-203799 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] investigative glucagon-like peptide 2 receptor GLP2R Successful target unknown NA TTD glucagon biotech Movement[MeSHID:D009068],Cardiac Arrest[MeSHID:D006323],Hypoglycemia[MeSHID:D007003],Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucagon-like peptide 2 receptor GLP2R NA agonist NA drugbank elsiglutide NA Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 2 receptor GLP2R Successful target unknown 42.43 TTD , DGIDB teduglutide biotech Intestines[MeSHID:D007422],Short Bowel Syndrome[MeSHID:D012778],Malabsorption Syndrome[MeSHID:D008286],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucagon-like peptide 2 receptor GLP2R Successful target agonist 84.87 TTD , drugbank , DGIDB amx-256 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Short Bowel Syndrome[MeSHID:D012778] investigative glucagon-like peptide 2 receptor GLP2R Successful target unknown NA TTD elsiglutide NA Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucagon-like peptide 2 receptor GLP2R Successful target agonist 42.43 TTD , DGIDB san-134 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucagon-like peptide 2 receptor GLP2R Successful target unknown NA TTD , DGIDB zp-1848 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 1 glucagon-like peptide 2 receptor GLP2R Successful target unknown 42.43 TTD , DGIDB [3h]strychnine NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target antagonist NA TTD , DGIDB atropine small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Organophosphate poisoning[MeSHID:D062025] approved,vet_approved glycine receptor subunit alpha-1 GLRA1 NA antagonist NA drugbank 3-demethoxy-3-l-fucopyranosylaminothiocolchicine NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD 3-demethoxy-3d-glucopyranosylaminothiocolchicine NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD 3-demethoxy-3-d-xylopyranosylaminothiocolchicine NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glycine receptor subunit alpha-1 GLRA1 NA agonist 0.55 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glycine receptor subunit alpha-1 GLRA1 NA agonist 0.55 drugbank , DGIDB ginkgolide a NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental glycine receptor subunit alpha-1 GLRA1 NA antagonist,blocker 0.26 drugbank , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational glycine receptor (alpha-1/beta) GLRA1 NA allosteric modulator NA drugbank medical cannabis biotech NA experimental,investigational glycine receptor subunit alpha-1 GLRA1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental glycine receptor subunit alpha-1 GLRA1 NA inhibitor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational glycine receptor subunit alpha-1 GLRA1 NA inhibitor NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glycine receptor subunit alpha-1 GLRA1 NA potentiator 0.59 drugbank , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational glycine receptor subunit alpha-1 GLRA1 NA unknown NA drugbank d-serine small molecule NA approved,experimental glycine receptor subunit alpha-1 GLRA1 NA unknown 0.87 drugbank , DGIDB gw 468816 small molecule Tobacco Dependence[MeSHID:D014029],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glycine receptor subunit alpha-1 GLRA1 NA unknown NA drugbank isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glycine receptor subunit alpha-1 GLRA1 NA agonist 0.63 drugbank , DGIDB glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine receptor subunit alpha-1 GLRA1 NA ligand NA drugbank ginkgolide j NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational glycine receptor (alpha-1/beta) GLRA1 NA unknown NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational glycine receptor subunit alpha-1 GLRA1 NA unknown NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glycine receptors GLRA1 NA inhibitor NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glycine receptor subunit alpha-1 GLRA1 NA agonist 0.55 drugbank , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glycine receptor subunit alpha-1 GLRA1 NA allosteric modulator 0.39 drugbank , DGIDB thiocolchicoside NA Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved strychnine-binding glycine receptor GLRA1 Successful target unknown 1.21 TTD , DGIDB 3-demethoxy-3-d-mannopyranosylaminothiocolchicine NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD d-serine NA NA phase 4 strychnine-binding glycine receptor GLRA1 Successful target unknown 0.87 TTD , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glycine receptor subunit alpha-1 GLRA1 NA agonist 0.61 drugbank , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational glycine receptor subunit alpha-1 GLRA1 NA unknown NA drugbank medical cannabis biotech NA experimental,investigational glycine receptor (alpha-1/beta) GLRA1 NA unknown NA drugbank seletracetam small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glycine receptor (alpha-1/beta) GLRA1 NA binding NA drugbank 10-methoxy-ginkgolide c NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glycine receptor subunit alpha-1 GLRA1 NA unknown NA drugbank thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental glycine receptor subunit alpha-1 GLRA1 NA antagonist 1.21 drugbank , DGIDB 3,14-didehydroginkgolide a NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD 3-demethoxy-3-d-lyxopyranosylaminothiocolchicine NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical glycine receptor subunit alpha-1 GLRA1 NA agonist NA drugbank lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn glycine receptor subunit alpha-1 GLRA1 NA antagonist NA drugbank ginkgolide c NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glycine receptor subunit alpha-1 GLRA1 NA agonist NA drugbank ginkgo biloba biotech Memory[MeSHID:D008568],Cognition[MeSHID:D003071] approved,investigational,nutraceutical glycine receptor subunit alpha-1 GLRA1 NA antagonist NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational glycine receptor subunit alpha-1 GLRA1 NA unknown NA drugbank ginkgolide m NA NA investigative strychnine-binding glycine receptor GLRA1 Successful target unknown NA TTD ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glycine receptor subunit alpha-2 GLRA2 NA agonist NA drugbank lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn glycine receptor subunit alpha-2 GLRA2 NA antagonist NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical glycine receptor subunit alpha-2 GLRA2 NA agonist NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine receptor subunit alpha-2 GLRA2 NA ligand NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glycine receptors GLRA2 NA inhibitor NA drugbank picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental glycine receptor subunit alpha-2 GLRA2 NA antagonist 1.11 drugbank , DGIDB picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental glycine receptor subunit alpha-2 GLRA2 NA antagonist,blocker 1.11 drugbank , DGIDB glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine receptor subunit alpha-3 GLRA3 NA ligand NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational glycine receptor subunit alpha-3 GLRA3 NA potentiator NA drugbank medical cannabis biotech NA experimental,investigational glycine receptor subunit alpha-3 GLRA3 NA unknown NA drugbank taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical glycine receptor subunit alpha-3 GLRA3 NA agonist NA drugbank lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn glycine receptor subunit alpha-3 GLRA3 NA antagonist NA drugbank picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental glycine receptor subunit alpha-3 GLRA3 NA antagonist 1.19 drugbank , DGIDB picrotoxin small molecule Poisoning[MeSHID:D011041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128], Newborn[MeSHID:D012127] experimental glycine receptor subunit alpha-3 GLRA3 NA antagonist,blocker 1.19 drugbank , DGIDB memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glycine receptors GLRA3 NA inhibitor NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational glycine receptor subunit alpha-3 GLRA3 NA unknown NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glycine receptors GLRA4 NA inhibitor NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine receptor subunit beta GLRB NA ligand NA drugbank medical cannabis biotech NA experimental,investigational glycine receptor (alpha-1/beta) GLRB NA unknown NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational glycine receptor (alpha-1/beta) GLRB NA unknown NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational glycine receptor (alpha-1/beta) GLRB NA allosteric modulator NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glycine receptors GLRB NA inhibitor NA drugbank seletracetam small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glycine receptor (alpha-1/beta) GLRB NA binding NA drugbank lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn glycine receptor subunit beta GLRB NA antagonist NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutaredoxin-1 GLRX NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutaredoxin-2, mitochondrial GLRX2 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutaminase kidney isoform, mitochondrial GLS NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutaminase liver isoform, mitochondrial GLS2 NA unknown NA drugbank beta-d-glucose small molecule NA experimental glycosyltransferase 6 domain-containing protein 1 GLT6D1 NA unknown NA drugbank uridine-5'-diphosphate small molecule NA experimental glycosyltransferase 6 domain-containing protein 1 GLT6D1 NA unknown NA drugbank uridine monophosphate small molecule NA experimental glycosyltransferase 6 domain-containing protein 1 GLT6D1 NA unknown NA drugbank lactose small molecule NA approved,experimental,investigational glycosyltransferase 6 domain-containing protein 1 GLT6D1 NA unknown NA drugbank uridine diphosphate glucose small molecule NA experimental glycosyltransferase 6 domain-containing protein 1 GLT6D1 NA unknown NA drugbank lactose small molecule NA approved,experimental,investigational glycolipid transfer protein GLTP NA unknown NA drugbank sphingosine small molecule NA experimental glycolipid transfer protein GLTP NA unknown NA drugbank lauric acid small molecule NA approved,experimental glycolipid transfer protein GLTP NA unknown NA drugbank capric acid small molecule NA experimental glycolipid transfer protein GLTP NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical glutamate dehydrogenase 1, mitochondrial GLUD1 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate dehydrogenase 1, mitochondrial GLUD1 NA unknown NA drugbank hexachlorophene small molecule Disease Outbreaks[MeSHID:D004196],Communicable Diseases[MeSHID:D003141],Infectious disease prevention / control[MeSHID:D017053],Infection[MeSHID:D007239],Surgical Scrubbing[MeSHID:D006235],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn glutamate dehydrogenase 1, mitochondrial GLUD1 NA inhibitor NA drugbank aluminum chloride small molecule Sweating[MeSHID:D013546],Hemorrhage[MeSHID:D006470],Sweat[MeSHID:D013542] approved,investigational glutamate dehydrogenase 1, mitochondrial GLUD1 NA inactivator NA drugbank guanosine-5'-triphosphate small molecule NA experimental glutamate dehydrogenase 1, mitochondrial GLUD1 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate dehydrogenase 2, mitochondrial GLUD2 NA substrate NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical glutamate dehydrogenase 2, mitochondrial GLUD2 NA unknown NA drugbank l-glutamine small molecule Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Short Bowel Syndrome[MeSHID:D012778] approved,investigational,nutraceutical glutamine synthetase GLUL NA product of NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamine synthetase GLUL NA unknown NA drugbank nlx-p101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 2 glutamate decarboxylase GLUL Discontinued target unknown NA TTD glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine n-acyltransferase GLYAT NA substrate NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine n-acyltransferase-like protein 1 GLYATL1 NA substrate NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine n-acyltransferase-like protein 2 GLYATL2 NA substrate NA drugbank choline alfoscerate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amnesia[MeSHID:D000647] experimental,investigational ganglioside gm2 activator GM2A NA unknown NA drugbank lauric acid small molecule NA approved,experimental ganglioside gm2 activator GM2A NA unknown NA drugbank platelet activating factor small molecule NA experimental ganglioside gm2 activator GM2A NA unknown NA drugbank myristic acid small molecule NA experimental ganglioside gm2 activator GM2A NA unknown NA drugbank biw-8962 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 ganglioside gm2 activator GM2A Clinical trial target unknown 63.65 TTD , DGIDB lpc-ether small molecule NA experimental ganglioside gm2 activator GM2A NA unknown NA drugbank guanosine-5'-diphosphate-rhamnose small molecule NA experimental gdp-mannose 4,6 dehydratase GMDS NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental gdp-mannose 4,6 dehydratase GMDS NA unknown NA drugbank guanosine-5'-monophosphate small molecule NA experimental gmp reductase 1 GMPR NA unknown NA drugbank 3,5-dibromo-2-(2,4-dibromophenoxy)phenol NA NA investigative glutamine amidotransferase GMPS Literature-reported target unknown NA TTD 2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol NA NA investigative glutamine amidotransferase GMPS Literature-reported target unknown NA TTD pyrophosphate 2- NA NA investigative glutamine amidotransferase GMPS Literature-reported target unknown NA TTD decoyinine NA NA investigative glutamine amidotransferase GMPS Literature-reported target unknown NA TTD 3,4,5-tribromo-2-(2', 4'-dibromo-phenoxy)phenol NA NA investigative glutamine amidotransferase GMPS Literature-reported target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical gmp synthase [glutamine-hydrolyzing] GMPS NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental guanine nucleotide-binding protein g(i) subunit alpha-1 GNAI1 NA unknown NA drugbank tetrafluoroaluminate ion small molecule NA experimental guanine nucleotide-binding protein g(i) subunit alpha-1 GNAI1 NA unknown NA drugbank colforsin small molecule NA experimental,investigational guanine nucleotide-binding protein g(s) subunit alpha isoforms short GNAS NA unknown NA drugbank 2',5'-dideoxy-adenosine 3'-monophosphate small molecule NA experimental guanine nucleotide-binding protein g(s) subunit alpha isoforms short GNAS NA unknown NA drugbank cacodylic acid small molecule NA experimental guanine nucleotide-binding protein g(t) subunit alpha-1 GNAT1 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental guanine nucleotide-binding protein g(t) subunit alpha-1 GNAT1 NA unknown NA drugbank tetrafluoroaluminate ion small molecule NA experimental guanine nucleotide-binding protein g(t) subunit alpha-1 GNAT1 NA unknown NA drugbank gne lipoplex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myopathy[MeSHID:D009135] phase 1 n-acetylmannosamine kinase GNE Clinical trial target unknown NA TTD , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved guanine nucleotide-binding protein g(i)/g(s)/g(o) subunit gamma-2 GNG2 NA unknown NA drugbank 3-(n-morpholino)propanesulfonic acid small molecule NA experimental granulysin GNLY NA unknown NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glycine n-methyltransferase GNMT NA substrate NA drugbank s-adenosyl-l-homocysteine small molecule NA experimental glycine n-methyltransferase GNMT NA unknown NA drugbank ademetionine small molecule Emotions[MeSHID:D004644],Degenerative polyarthritis[MeSHID:D010003],Depressive disorder[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Liver diseases[MeSHID:D008107],Bone Tissue[MeSHID:D001842],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] approved,investigational,nutraceutical glycine n-methyltransferase GNMT NA cofactor NA drugbank beta-d-glucose small molecule NA experimental glucosamine-6-phosphate isomerase 1 GNPDA1 NA unknown NA drugbank 2-deoxy-2-amino glucitol-6-phosphate small molecule NA experimental glucosamine-6-phosphate isomerase 1 GNPDA1 NA unknown NA drugbank n-acetyl-d-glucosamine-6-phosphate small molecule NA experimental glucosamine-6-phosphate isomerase 1 GNPDA1 NA unknown NA drugbank cg201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 leutinizing-hormone-releasing hormone GNRH1 Successful target unknown NA TTD , DGIDB goserelin NA Disease Management[MeSHID:D019468],Carcinoma[MeSHID:D002277],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Metrorrhagia[MeSHID:D008796],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leutinizing-hormone-releasing hormone GNRH1 Successful target unknown 0.83 TTD , DGIDB tak-810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 1 leutinizing-hormone-releasing hormone GNRH1 Successful target unknown NA TTD norelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 2 leutinizing-hormone-releasing hormone GNRH1 Successful target unknown NA TTD , DGIDB anti-gnrh spiegelmer NA NA investigative leutinizing-hormone-releasing hormone GNRH1 Successful target unknown NA TTD leuprolide NA Precocious Puberty, Central[MeSHID:C562787],Malignant neoplasm of prostate[MeSHID:D011471],Endometriosis[MeSHID:D004715],Uterine Fibroids[MeSHID:D007889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leutinizing-hormone-releasing hormone GNRH1 Successful target unknown 0.72 TTD , DGIDB nal-glu NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2/3 leutinizing-hormone-releasing hormone GNRH1 Successful target unknown 5.79 TTD , DGIDB way-207024 NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 1.77 TTD , DGIDB [d-gln3,d-ncy(so,isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD leuprorelin acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD , DGIDB [ncy(2-naphthyl)1]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD an-207 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD triptorelin small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,vet_approved gonadotropin-releasing hormone receptor GNRHR Successful target agonist 1.77 TTD , drugbank , DGIDB org-30850 NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD elagolix small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uterine Fibroids[MeSHID:D007889] approved,investigational,phase 3 gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 3.54 TTD , drugbank , DGIDB lxt-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [ncy(isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD degarelix small molecule Disease Management[MeSHID:D019468],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 7.07 TTD , drugbank , DGIDB cetrorelix small molecule Psychological inhibition[MeSHID:D007266],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 5.89 TTD , drugbank , DGIDB antarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target antagonist NA TTD , DGIDB pep-223/covaccine ht NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471],Hashimoto Disease[MeSHID:D050031] phase 1/2 gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD , DGIDB buserelin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Uterine Fibroids[MeSHID:D007889],Malignant neoplasm of prostate[MeSHID:D011471],Endometriosis[MeSHID:D004715],Malignant neoplasm of breast[MeSHID:D001943],Reproduction[MeSHID:D012098] approved,investigational gonadotropin-releasing hormone receptor GNRHR NA unknown 3.54 drugbank , DGIDB nbi-42902 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 1 gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 1.77 TTD , DGIDB ozarelix NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target unknown 2.65 TTD , DGIDB relugolix small molecule Patient Care Management[MeSHID:D010346],Menorrhagia[MeSHID:D008595],Malignant neoplasm of prostate[MeSHID:D011471],Uterine Fibroids[MeSHID:D007889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] approved,investigational gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 2.65 TTD , drugbank , DGIDB [d-ncy(2-naphthyl)1]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD sufugolix small molecule Uterine Fibroids[MeSHID:D007889],Endometriosis[MeSHID:D004715] investigational gonadotropin-releasing hormone receptor GNRHR NA antagonist 3.54 drugbank , DGIDB gonadorelin small molecule Gonadotrophs[MeSHID:D052681],Pituitary Neoplasms[MeSHID:D010911],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Pituitary Diseases[MeSHID:D010900],Hypogonadism[MeSHID:D007006],Hypothalamic structure[MeSHID:D007031],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved gonadotropin-releasing hormone receptor GNRHR Successful target agonist 7.96 TTD , drugbank , DGIDB aezs-115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acrodermatitis enteropathica[MeSHID:C538178],Malignant Neoplasms[MeSHID:D009369] investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD prostate cancer vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Prostate[MeSHID:D011467],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 1 gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD histrelin small molecule Precocious Puberty, Central[MeSHID:C562787],Malignant neoplasm of prostate[MeSHID:D011471],Polycystic Ovary Syndrome[MeSHID:D011085],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gonadotropin-releasing hormone receptor GNRHR NA agonist 1.77 drugbank , DGIDB [d-4aph(co-nh-oh)6]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-dab(co-nh-och3)3]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD gestrinone small molecule Infertility[MeSHID:D007246],Unmarried[MeSHID:D012847],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved gonadotropin-releasing hormone receptor GNRHR NA antagonist NA drugbank ramorelix NA Esophageal Neoplasms[MeSHID:D004938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD 5-(n,n-hexamethylene)-amiloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] preclinical gonadotropin-releasing hormone receptor GNRHR Successful target allosteric modulator NA TTD , DGIDB [ncy(so,methyl)10]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD azaline b NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-dab(co-nh-oh)3]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD gnrh NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] phase 3 gonadotropin-releasing hormone receptor GNRHR Successful target unknown 0.88 TTD , DGIDB abarelix small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 5.3 TTD , drugbank , DGIDB [d-gln3,d-ncy(isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD detirelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD klh-2109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target unknown 3.54 TTD , DGIDB [4aph(co-nh-oh)5]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD in-3 NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target antagonist NA TTD , DGIDB pglu-his-trp-ser-tyr-gly-leu-arg-pro-gly-nh2 NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-ncy(methyl)10] acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD t-98475 NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 1.77 TTD , DGIDB [d-dap(co-nh-oh)3]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [4aph(co-(c2h4o)3-c2h4-nh-co-nh-och3)5]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD aezs-108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 3 gonadotropin-releasing hormone receptor GNRHR Successful target unknown 3.54 TTD , DGIDB [ncy(methyl)4]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD teverelix small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Malignant neoplasm of prostate[MeSHID:D011471],Endometriosis[MeSHID:D004715] investigational gonadotropin-releasing hormone receptor GNRHR NA antagonist NA drugbank [d-ncy(so,methyl)10]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-ncy(methyl)4]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-ncy(so,isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD nbi-42902 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 1 gonadotropin-releasing hormone receptor GNRHR Successful target unknown 1.77 TTD , DGIDB gonadimmune NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [4aph(co-nh-och3)5]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD pglu-his-trp-ser-his-d-tyr-leu-arg-pro-gly-nh2 NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-4aph(co-nh-(c2h4o)2-c2h5)6]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [125i]cetrorelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target antagonist NA TTD , DGIDB leuprolide small molecule Precocious Puberty, Central[MeSHID:C562787],Malignant neoplasm of prostate[MeSHID:D011471],Endometriosis[MeSHID:D004715],Uterine Fibroids[MeSHID:D007889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gonadotropin-releasing hormone receptor GNRHR NA agonist 1.77 drugbank , DGIDB [d-gln3,ncy(isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD ozarelix NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 2.65 TTD , DGIDB buserelin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Uterine Fibroids[MeSHID:D007889],Malignant neoplasm of prostate[MeSHID:D011471],Endometriosis[MeSHID:D004715],Malignant neoplasm of breast[MeSHID:D001943],Reproduction[MeSHID:D012098] approved,investigational gonadotropin-releasing hormone receptor GNRHR NA agonist 3.54 drugbank , DGIDB acyline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target unknown 1.77 TTD , DGIDB nafarelin small molecule sex[MeSHID:D012723],Precocious Puberty, Central[MeSHID:C562787],Endometriosis[MeSHID:D004715],Gender[MeSHID:D005783],Coitus[MeSHID:D003075],Precocious Puberty[MeSHID:D011629],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gonadotropin-releasing hormone receptor GNRHR Successful target agonist 12.38 TTD , drugbank , DGIDB a-75998 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] discontinued in phase 1 gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [4aph(co-nh-(c2h4o)2-c2h5)5]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD asp-1707 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target unknown 1.77 TTD , DGIDB [d-gln3,ncy(so,isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD ganirelix small molecule Psychological inhibition[MeSHID:D007266],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ovulation[MeSHID:D010060] approved gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 7.07 TTD , drugbank , DGIDB danazol small molecule Breast Fibrocystic Disease[MeSHID:D005348],Angioedemas, Hereditary[MeSHID:D054179],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menorrhagia[MeSHID:D008595],Malignant neoplasm of breast[MeSHID:D001943] approved gonadotropin-releasing hormone receptor GNRHR NA negative modulator 0.66 drugbank , DGIDB [ncy(so,isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD antide NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-4aph(co-nh-och3)6]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [4aph(co-nh-och3)5,d-4aph(co-nh-och3)6]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD tak-013 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uterine Fibroids[MeSHID:D007889] discontinued in phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-gln3,d-ncy(so2,isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [ncy(methyl)10]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD fd-1 NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target antagonist,allosteric modulator NA TTD , DGIDB klh-2109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 2 gonadotropin-releasing hormone receptor GNRHR Successful target antagonist 3.54 TTD , DGIDB goserelin small molecule Disease Management[MeSHID:D019468],Carcinoma[MeSHID:D002277],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Metrorrhagia[MeSHID:D008796],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved gonadotropin-releasing hormone receptor GNRHR NA agonist 0.51 drugbank , DGIDB furan-1 NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD elagolix small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uterine Fibroids[MeSHID:D007889] approved,investigational,phase 3 gonadotropin-releasing hormone receptor GNRHR Successful target unknown 3.54 TTD , drugbank , DGIDB lhrh NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-ncy(isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-ncy(so,methyl)4]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD elagolix sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] approved gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD , DGIDB [d-dap(co-nh-och3)3]degarelix NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [ncy(so,methyl)4]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD [d-gln3,ncy(so2,isopropyl)7]acyline NA NA investigative gonadotropin-releasing hormone receptor GNRHR Successful target unknown NA TTD danazol small molecule Breast Fibrocystic Disease[MeSHID:D005348],Angioedemas, Hereditary[MeSHID:D054179],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menorrhagia[MeSHID:D008595],Malignant neoplasm of breast[MeSHID:D001943] approved putative gonadotropin-releasing hormone ii receptor GNRHR2 NA negative modulator 2.98 drugbank , DGIDB nafarelin small molecule sex[MeSHID:D012723],Precocious Puberty, Central[MeSHID:C562787],Endometriosis[MeSHID:D004715],Gender[MeSHID:D005783],Coitus[MeSHID:D003075],Precocious Puberty[MeSHID:D011629],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved putative gonadotropin-releasing hormone ii receptor GNRHR2 NA agonist 51.72 drugbank , DGIDB gonadorelin small molecule Gonadotrophs[MeSHID:D052681],Pituitary Neoplasms[MeSHID:D010911],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Pituitary Diseases[MeSHID:D010900],Hypogonadism[MeSHID:D007006],Hypothalamic structure[MeSHID:D007031],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved putative gonadotropin-releasing hormone ii receptor GNRHR2 NA agonist 27.85 drugbank , DGIDB adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved aspartate aminotransferase, cytoplasmic GOT1 NA inhibitor NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical aspartate aminotransferase, cytoplasmic GOT1 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical aspartate aminotransferase, cytoplasmic GOT1 NA unknown NA drugbank aminooxyacetic acid NA NA investigative cytoplasmic aspartate aminotransferase GOT1 Literature-reported target unknown NA TTD cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical aspartate aminotransferase, cytoplasmic GOT1 NA substrate NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational aspartate aminotransferase, cytoplasmic GOT1 NA unknown NA drugbank maleic acid small molecule NA experimental aspartate aminotransferase, cytoplasmic GOT1 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical aspartate aminotransferase, cytoplasmic GOT1 NA activator NA drugbank maleic acid NA NA investigative cytoplasmic aspartate aminotransferase GOT1 Literature-reported target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical aspartate aminotransferase, mitochondrial GOT2 NA cofactor NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical aspartate aminotransferase, mitochondrial GOT2 NA unknown NA drugbank 4'-deoxy-4'-acetylyamino-pyridoxal-5'-phosphate small molecule NA experimental aspartate aminotransferase, mitochondrial GOT2 NA unknown NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical aspartate aminotransferase, mitochondrial GOT2 NA substrate NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical aspartate aminotransferase, mitochondrial GOT2 NA unknown NA drugbank tgx-6b4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] preclinical platelet glycoprotein ib alpha GP1BA Clinical trial target unknown NA TTD , DGIDB ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved platelet glycoprotein ib alpha chain GP1BA NA inducer NA drugbank dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet glycoprotein ib alpha chain GP1BA NA unknown NA drugbank egaptivon pegol biotech Platelet aggregation[MeSHID:D010974],Acute Coronary Syndrome[MeSHID:D054058],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational platelet glycoprotein ib alpha chain GP1BA NA unknown NA drugbank zk-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1/2 platelet glycoprotein ib alpha GP1BA Clinical trial target unknown NA TTD , DGIDB liposomal prostaglandin e1 small molecule Peripheral Vascular Diseases[MeSHID:D016491] investigational platelet glycoprotein ib alpha chain GP1BA NA unknown NA drugbank act017 NA Cerebral Ischemia[MeSHID:D002545],Cerebral Infarction[MeSHID:D002544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 platelet glycoprotein vi GP6 Clinical trial target unknown NA TTD revacept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 2 platelet glycoprotein vi GP6 Clinical trial target unknown NA TTD , DGIDB quinine small molecule Muscle Cramp[MeSHID:D009120],Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved platelet glycoprotein ix GP9 NA other NA drugbank hua33 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cell surface a33 antigen GPA33 Clinical trial target unknown 21.22 TTD , DGIDB krn-330 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 cell surface a33 antigen GPA33 Clinical trial target unknown 42.43 TTD , DGIDB radiolabelled-hua33 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 cell surface a33 antigen GPA33 Clinical trial target unknown NA TTD , DGIDB mgd007 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 cell surface a33 antigen GPA33 Clinical trial target unknown 10.61 TTD , DGIDB sodium taurocholate NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 g-protein coupled bile acid receptor 1 GPBAR1 Clinical trial target unknown NA TTD , DGIDB int-777 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] investigative g-protein coupled bile acid receptor 1 GPBAR1 Clinical trial target unknown NA TTD pmid29649907-compound-int767 NA NA patented g-protein coupled bile acid receptor 1 GPBAR1 Clinical trial target unknown NA TTD , DGIDB int-767 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] preclinical g-protein coupled bile acid receptor 1 GPBAR1 Clinical trial target agonist NA TTD , DGIDB deoxycholic acid small molecule NA approved g-protein coupled bile acid receptor 1 GPBAR1 NA agonist NA drugbank , DGIDB pmid29649907-compound-8 NA NA patented g-protein coupled bile acid receptor 1 GPBAR1 Clinical trial target unknown NA TTD , DGIDB cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved g-protein coupled bile acid receptor 1 GPBAR1 NA agonist NA drugbank , DGIDB bile acid NA NA investigative g-protein coupled bile acid receptor 1 GPBAR1 Clinical trial target unknown NA TTD xl475 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical g-protein coupled bile acid receptor 1 GPBAR1 Clinical trial target unknown NA TTD , DGIDB chenodeoxycholic acid small molecule Gallbladder[MeSHID:D005704],Calculi[MeSHID:D002137],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641] approved g-protein coupled bile acid receptor 1 GPBAR1 NA agonist NA drugbank , DGIDB gpc-3298306 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 2 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB gpc3 targeting car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528],Lung[MeSHID:D008168],Squamous cell carcinoma[MeSHID:D002294] phase 1 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB car-gpc3 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung[MeSHID:D008168],T-Lymphocyte[MeSHID:D013601],Squamous cell carcinoma[MeSHID:D002294] clinical trial glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB anti-gpc3 car t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB car-gpc3 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] phase 1 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB retroviral vector-transduced autologous t cells to express anti-gpc3 cars NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] phase 1/2 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB tak-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 glypican-3 GPC3 Clinical trial target unknown NA TTD car-gpc3 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung[MeSHID:D008168],T-Lymphocyte[MeSHID:D013601],Squamous cell carcinoma[MeSHID:D002294] phase 1 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB ery974 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 glypican-3 GPC3 Clinical trial target unknown 31.83 TTD , DGIDB car-t cells targeting glypican-3 (gpc3) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] phase 1/2 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB glycar t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] phase 1 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB car-gpc3 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] clinical trial glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting gpc3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] phase 1/2 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB gpc3-cart cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Cells[MeSHID:D002477] phase 1/2 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB rg7686 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 2 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB tai-gpc3-cart cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Cells[MeSHID:D002477] phase 1/2 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB codrituzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362] phase 2 glypican-3 GPC3 Clinical trial target antibody 63.65 TTD , DGIDB car-gpc3 t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] clinical trial glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB codrituzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362] phase 2 glypican-3 GPC3 Clinical trial target unknown 63.65 TTD , DGIDB gap t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 glypican-3 GPC3 Clinical trial target unknown NA TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical glycerol-3-phosphate dehydrogenase [nad(+)], cytoplasmic GPD1 NA unknown NA drugbank metformin small molecule Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glycerol-3-phosphate dehydrogenase [nad(+)], cytoplasmic GPD1 NA inhibitor NA drugbank metformin small molecule Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved glycerol-3-phosphate dehydrogenase [nad(+)], cytoplasmic GPD1 NA inhibitor NA drugbank estradiol small molecule Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved g-protein coupled estrogen receptor 1 GPER1 NA binder 1.7 drugbank , DGIDB estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved g-protein coupled estrogen receptor 1 GPER1 NA unknown NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved g-protein coupled estrogen receptor 1 GPER1 NA unknown NA drugbank estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved g-protein coupled estrogen receptor 1 GPER1 NA unknown NA drugbank estradiol dienanthate small molecule NA approved,investigational,vet_approved g-protein coupled estrogen receptor 1 GPER1 NA unknown NA drugbank g1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1/2 g-protein coupled estrogen receptor 1 GPER1 Successful target unknown NA TTD genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational g-protein coupled estrogen receptor 1 GPER1 NA unknown NA drugbank g36 NA NA investigative g-protein coupled estrogen receptor 1 GPER1 Successful target antagonist NA TTD , DGIDB segesterone acetate; ethinyl estradiol NA NA approved g-protein coupled estrogen receptor 1 GPER1 Successful target unknown NA TTD mk-0354 small molecule Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161] investigational g-protein coupled estrogen receptor 1 GPER1 NA unknown NA drugbank g15 NA NA investigative g-protein coupled estrogen receptor 1 GPER1 Successful target antagonist NA TTD , DGIDB estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved g-protein coupled estrogen receptor 1 GPER1 NA unknown NA drugbank propanoic acid small molecule Uterine Cervicitis[MeSHID:D002575],Cervix Uteri[MeSHID:D002584],Tears body substance[MeSHID:D013666],Wound Epithelialization[MeSHID:D062326],Consumption of goods[MeSHID:D004467],Wound Healing[MeSHID:D014945] approved,vet_approved gephyrin GPHN NA unknown NA drugbank imidazole small molecule NA experimental,investigational gephyrin GPHN NA unknown NA drugbank formic acid small molecule NA experimental,investigational gephyrin GPHN NA unknown NA drugbank d-erythrose 4-phosphate small molecule NA experimental glucose-6-phosphate isomerase GPI NA unknown NA drugbank fructose-6-phosphate small molecule NA experimental glucose-6-phosphate isomerase GPI NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glucose-6-phosphate isomerase GPI NA unknown NA drugbank 5-phosphoarabinonic acid small molecule NA experimental glucose-6-phosphate isomerase GPI NA unknown NA drugbank alpha-d-glucose 6-phosphate small molecule NA experimental glucose-6-phosphate isomerase GPI NA unknown NA drugbank d-glucitol 6-phosphate small molecule NA experimental glucose-6-phosphate isomerase GPI NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational glucose-6-phosphate isomerase GPI NA ligand NA drugbank 6-phospho-d-gluconic acid small molecule NA experimental glucose-6-phosphate isomerase GPI NA unknown NA drugbank glucose-6-phosphate small molecule NA experimental glucose-6-phosphate isomerase GPI NA unknown NA drugbank 5-phospho-d-arabinohydroxamic acid small molecule NA experimental glucose-6-phosphate isomerase GPI NA unknown NA drugbank glembatumumab vedotin biotech melanoma[MeSHID:D008545] investigational transmembrane glycoprotein nmb GPNMB NA binder 190.95 drugbank , DGIDB pmid21310611c3 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD (s)-n-oleoyltyrosinol NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB 1-oleoyl glycerol NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB psn632408 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB 2-oleoyl glycerol NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB n-oleoylethanolamide NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB ar-7947 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD pmid21444206c23 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD pmid21273063c36 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD pmid21536438c36j NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD bms-903452 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucose-dependent insulinotropic receptor GPR119 Successful target unknown 9.09 TTD , DGIDB 1-palmitoyl-lysophosphatidylcholine NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB oleoyl-lysophosphatidylcholine NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB pmid22545772c42 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD ar231453 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB ro-5212651 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD lysophosphatidylethanolamine NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB pmid21536438c20f NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD pmid21444206c3a NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD lc34ad3 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD (r)-n-oleoyltyrosinol NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB sar-260093 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD , DGIDB ds-8500 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD , DGIDB guanfacine extended release NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Patient Discharge[MeSHID:D010351],Attention deficit hyperactivity disorder[MeSHID:D001289] approved glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD , DGIDB psn375963 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB as-1907417 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD apd-597 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD , DGIDB lysophosphatidylinositol NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB da-1241 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD mbx-3254 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD 1-stearoyl-lysophosphatidylcholine NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB sea NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB pmid21273063c58 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD pmid21273063c1 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD pmid21444206c8g NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD pmid21444206c3j NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD gsk1292263 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucose-dependent insulinotropic receptor GPR119 Successful target unknown 9.09 TTD , DGIDB pmid21939274c2 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD as1269574 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target agonist NA TTD , DGIDB pmid21939274c1 NA NA investigative glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD apd668 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 1 glucose-dependent insulinotropic receptor GPR119 Successful target unknown NA TTD , drugbank , DGIDB medical cannabis biotech NA experimental,investigational g-protein coupled receptor 12 GPR12 NA inverse agonist NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational g-protein coupled receptor 12 GPR12 NA inverse agonist NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational g-protein coupled receptor 12 GPR12 NA inverse agonist NA drugbank sphingosylphosphorylcholine NA NA investigative g-protein coupled receptor 12 GPR12 Literature-reported target agonist NA TTD , DGIDB 9-hydroxyoctadecadienoic acid NA NA investigative g2 accumulation protein GPR132 Literature-reported target agonist NA TTD , DGIDB pmid24900311c1a NA NA investigative g-protein-coupled receptor pgr3 GPR139 Clinical trial target unknown NA TTD tak-041 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disorders of Sex Development[MeSHID:D012734] phase 1 g-protein-coupled receptor pgr3 GPR139 Clinical trial target unknown NA TTD , DGIDB udp-glucose NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target agonist 7.96 TTD , DGIDB asn04421891 NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target agonist NA TTD , DGIDB asn04885796 NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target agonist NA TTD , DGIDB ltc4 NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target agonist NA TTD , DGIDB lte4 NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target unknown NA TTD asn02563583 NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target agonist NA TTD , DGIDB ltd4 NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target agonist NA TTD , DGIDB asn06917370 NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target agonist NA TTD , DGIDB asn04450772 NA NA investigative uracil nucleotide/cysteinyl leukotriene receptor GPR17 Literature-reported target agonist NA TTD , DGIDB lysophosphatidylserine NA NA investigative g-protein coupled receptor 174 GPR174 Literature-reported target agonist NA TTD , DGIDB arachidonylcyclopropylamide NA NA investigative n-arachidonyl glycine receptor GPR18 Literature-reported target agonist NA TTD , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational n-arachidonyl glycine receptor GPR18 NA unknown NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved n-arachidonyl glycine receptor GPR18 NA substrate NA drugbank abnormal cannabidiol NA NA investigative n-arachidonyl glycine receptor GPR18 Literature-reported target agonist NA TTD , DGIDB o-1602 NA NA investigative n-arachidonyl glycine receptor GPR18 Literature-reported target agonist NA TTD , DGIDB medical cannabis biotech NA experimental,investigational n-arachidonyl glycine receptor GPR18 NA unknown NA drugbank n-arachidonoylglycine NA NA investigative n-arachidonyl glycine receptor GPR18 Literature-reported target agonist 1.12 TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational n-arachidonyl glycine receptor GPR18 NA agonist 8.49 drugbank , DGIDB 27-hydroxycholesterol NA NA investigative ebv-induced g-protein coupled receptor 2 GPR183 Literature-reported target agonist NA TTD , DGIDB 7beta-hydroxycholesterol NA NA investigative ebv-induced g-protein coupled receptor 2 GPR183 Literature-reported target unknown NA TTD 7alpha-hydroxycholesterol NA NA investigative ebv-induced g-protein coupled receptor 2 GPR183 Literature-reported target unknown NA TTD 7alpha,25-dihydroxycholesterol NA NA investigative ebv-induced g-protein coupled receptor 2 GPR183 Literature-reported target unknown NA TTD 7alpha,27-dihydroxycholesterol NA NA investigative ebv-induced g-protein coupled receptor 2 GPR183 Literature-reported target unknown NA TTD 7beta, 25-dihydroxycholesterol NA NA investigative ebv-induced g-protein coupled receptor 2 GPR183 Literature-reported target unknown NA TTD 7beta, 27-dihydroxycholesterol NA NA investigative ebv-induced g-protein coupled receptor 2 GPR183 Literature-reported target unknown NA TTD 25-hydroxycholesterol NA NA investigative ebv-induced g-protein coupled receptor 2 GPR183 Literature-reported target agonist 21.22 TTD , DGIDB ds-6157 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Stromal Tumors[MeSHID:D046152] phase 1 g-protein coupled receptor 20 GPR20 Clinical trial target unknown NA TTD diphenyleneiodonium chloride NA NA investigative g protein-coupled receptor 3 GPR3 Literature-reported target agonist NA TTD , DGIDB 12s-hete NA NA investigative g-protein coupled receptor 31 GPR31 Literature-reported target unknown NA TTD lxa4 NA NA investigative g-protein coupled receptor 32 GPR32 Literature-reported target agonist NA TTD , DGIDB rvd1-me NA NA investigative g-protein coupled receptor 32 GPR32 Literature-reported target agonist NA TTD , DGIDB [3h]resolvin d1 NA NA investigative g-protein coupled receptor 32 GPR32 Literature-reported target agonist NA TTD , DGIDB lysophosphatidylserine NA NA investigative g-protein coupled receptor 34 GPR34 Literature-reported target agonist NA TTD , DGIDB kynurenic acid small molecule NA investigational g-protein coupled receptor 35 GPR35 NA agonist NA drugbank , DGIDB pyrantel small molecule Nematode infections[MeSHID:D009349],Ascariasis[MeSHID:D001196],Hookworm Infections[MeSHID:D006725],Enterobiasis[MeSHID:D017229],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Helminthiasis[MeSHID:D006373] approved,vet_approved g-protein coupled receptor 35 GPR35 NA unknown NA drugbank furosemide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Nephrotic Syndrome[MeSHID:D009404],Diuresis[MeSHID:D004231],Pulmonary Edema[MeSHID:D011654],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved g-protein coupled receptor 35 GPR35 NA agonist 1.31 drugbank , DGIDB cid2440433 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB 2-arachidonoylglycerolphosphoinositol NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB cp55,667 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target antagonist NA TTD , DGIDB abnormal cannabidiol NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB cid1792197 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB cid16020046 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target antagonist NA TTD , DGIDB o-1602 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB t1117 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB [3h]cp55940 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB tetrahydrocannabivarin small molecule NA investigational g-protein coupled receptor 55 GPR55 NA partial agonist NA drugbank cp55,244 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB n-oleoylethanolamide NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB rimonabant small molecule Dyslipidemias[MeSHID:D050171],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational g-protein coupled receptor 55 GPR55 NA antagonist 0.94 drugbank , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational g-protein coupled receptor 55 GPR55 NA unknown NA drugbank guanfacine extended release NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Patient Discharge[MeSHID:D010351],Attention deficit hyperactivity disorder[MeSHID:D001289] approved g-protein coupled receptor 55 GPR55 Successful target unknown NA TTD , DGIDB cid1172084 NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB gsk575594a NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB o-arachidonoyl ethanolamine NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB medical cannabis biotech NA experimental,investigational g-protein coupled receptor 55 GPR55 NA unknown NA drugbank gsk494581a NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB lysophosphatidylinositol NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational g-protein coupled receptor 55 GPR55 NA antagonist 2.25 drugbank , DGIDB 2-arachidonyl glyceryl ether NA NA investigative g-protein coupled receptor 55 GPR55 Successful target agonist NA TTD , DGIDB dioleoylphosphatidic acid NA NA investigative g-protein coupled receptor 63 GPR63 Literature-reported target agonist NA TTD , DGIDB dihydrosphingosine-1-phosphate NA NA investigative g-protein coupled receptor 63 GPR63 Literature-reported target unknown NA TTD shr0534 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 inflammation-related gpcr ex33 GPR84 Clinical trial target unknown NA TTD 2-hydroxylauric acid NA NA investigative inflammation-related gpcr ex33 GPR84 Clinical trial target agonist NA TTD , DGIDB 6-n-octylaminouracil NA NA investigative inflammation-related gpcr ex33 GPR84 Clinical trial target agonist NA TTD , DGIDB 3-hydroxy capric acid NA NA investigative inflammation-related gpcr ex33 GPR84 Clinical trial target agonist NA TTD , DGIDB 2-hydroxy capric acid NA NA investigative inflammation-related gpcr ex33 GPR84 Clinical trial target agonist NA TTD , DGIDB undecanoic acid NA NA investigative inflammation-related gpcr ex33 GPR84 Clinical trial target agonist NA TTD , DGIDB pbi-4050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] phase 2 inflammation-related gpcr ex33 GPR84 Clinical trial target unknown NA TTD 3-hydroxylauric acid NA NA investigative inflammation-related gpcr ex33 GPR84 Clinical trial target agonist NA TTD , DGIDB pmid24793972c2 NA NA investigative striatum-specific g-protein coupled receptor GPR88 Literature-reported target unknown NA TTD tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid-induced protein 3 GPRC5A NA unknown NA drugbank gprc5d car-t cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 g-protein coupled receptor c 5d GPRC5D Clinical trial target unknown NA TTD l-ornithine NA NA investigative g-protein coupled receptor gpcr33 GPRC6A Literature-reported target agonist 7.96 TTD , DGIDB l-citrulline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] phase 3 g-protein coupled receptor gpcr33 GPRC6A Literature-reported target agonist 7.96 TTD , DGIDB l-serine NA NA investigative g-protein coupled receptor gpcr33 GPRC6A Literature-reported target agonist 7.96 TTD , DGIDB calindol NA NA investigative g-protein coupled receptor gpcr33 GPRC6A Literature-reported target unknown NA TTD l-lysine NA NA investigative g-protein coupled receptor gpcr33 GPRC6A Literature-reported target agonist 3.98 TTD , DGIDB phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alanine aminotransferase 1 GPT NA inhibitor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical alanine aminotransferase 1 GPT NA cofactor NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical alanine aminotransferase 1 GPT NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical alanine aminotransferase 1 GPT NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical alanine aminotransferase 2 GPT2 NA cofactor NA drugbank phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alanine aminotransferase 2 GPT2 NA inhibitor NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical alanine aminotransferase 2 GPT2 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical alanine aminotransferase 2 GPT2 NA substrate,product of NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational glutathione peroxidase 1 GPX1 NA stimulator NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational glutathione peroxidase 1 GPX1 NA stimulator NA drugbank medical cannabis biotech NA experimental,investigational glutathione peroxidase 1 GPX1 NA inducer NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione peroxidase GPX1 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione peroxidase 1 GPX1 NA cofactor NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione peroxidase 2 GPX2 NA cofactor NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione peroxidase 3 GPX3 NA cofactor NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical phospholipid hydroperoxide glutathione peroxidase, mitochondrial GPX4 NA cofactor NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical epididymal secretory glutathione peroxidase GPX5 NA cofactor NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione peroxidase 6 GPX6 NA cofactor NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione peroxidase 7 GPX7 NA cofactor NA drugbank 4-[(10s,14s,18s)-18-(2-amino-2-oxoethyl)-14-(1-naphthylmethyl)-8,17,20-trioxo-7,16,19-triazaspiro[5.14]icos-11-en-10-yl]benzylphosphonic acid small molecule NA experimental growth factor receptor-bound protein 2 GRB2 NA unknown NA drugbank bp-100-1-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Hematologic Neoplasms[MeSHID:D019337],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Myeloid Leukemia, Chronic[MeSHID:D015464] phase 2 grb2 messenger rna GRB2 Clinical trial target unknown NA TTD pegademase biotech Severe combined immunodeficiency due to adenosine deaminase deficiency[MeSHID:C531816] approved growth factor receptor-bound protein 2 GRB2 NA binder NA drugbank antibodie derivative 5 NA NA patented gremlin-1 GREM1 Patented-recorded target unknown NA TTD ym-90k NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD talampanel small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational glutamate receptor 1 GRIA1 NA unknown 2.36 drugbank , DGIDB cx-717 small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit,investigational glutamate receptor 1 GRIA1 NA unknown NA drugbank (s)-ampa NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD tianeptine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glutamate receptor 1 GRIA1 NA modulator NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor 1 GRIA1 NA unknown NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate receptor 1 GRIA1 NA antagonist NA drugbank dnqx NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD perampanel small molecule Seizures, Focal[MeSHID:D012640] approved glutamate receptor 1 GRIA1 NA antagonist 2.36 drugbank , DGIDB 7-chloro-3-hydroxyquinazoline-2,4-dione NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD philanthotoxin-343 NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD (s)-willardiine NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor 1 GRIA1 NA antagonist 0.39 drugbank , DGIDB n-(4-hydroxyphenylpropanyl)-spermine NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD cx516 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Attention deficit hyperactivity disorder[MeSHID:D001289],Amnesia[MeSHID:D000647],Autistic Disorder[MeSHID:D001321],Sleep Disorders[MeSHID:D012893],Memory Loss[MeSHID:D008569] investigational glutamate receptor 1 GRIA1 NA allosteric modulator 0.59 drugbank , DGIDB [3h]cnqx NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target antagonist NA TTD , DGIDB argiotoxin-636 NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor 1 GRIA1 NA antagonist 0.36 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor 1 GRIA1 NA unknown NA drugbank piriqualone NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD atpo NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target antagonist NA TTD , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor 1 GRIA1 NA antagonist NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate receptor 1 GRIA1 NA inhibitor NA drugbank joro toxin NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target blocker NA TTD , DGIDB e-2007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Parkinson Disease[MeSHID:D010300] approved glutamate receptor ampa 1 GRIA1 Successful target unknown 2.36 TTD , DGIDB [3h]ampa NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target agonist NA TTD , DGIDB rpr-118723 NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD (s)-5-fluorowillardiine NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target agonist NA TTD , DGIDB nbqx NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate receptor ampa 1 GRIA1 Successful target unknown 0.31 TTD , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate receptor 1 GRIA1 NA inhibitor NA drugbank farampator NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 1 glutamate receptor ampa 1 GRIA1 Successful target positive modulator 0.59 TTD , DGIDB nbqx NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate receptor ampa 1 GRIA1 Successful target antagonist 0.31 TTD , DGIDB [3h]kainate NA NA investigative glutamate receptor ampa 1 GRIA1 Successful target unknown NA TTD isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor 1 GRIA1 NA antagonist 0.33 drugbank , DGIDB sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor 1 GRIA1 NA antagonist 0.36 drugbank , DGIDB n,n'-[biphenyl-4,4'-diyldi(2r)propane-2,1-diyl]dimethanesulfonamide small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank willardiine small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank (s)-ampa small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank (s)-des-me-ampa small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank talampanel small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational glutamate receptor 2 GRIA2 NA unknown 1.93 drugbank , DGIDB paliroden NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 glutamate receptor ampa 2 GRIA2 Successful target unknown 1.93 TTD , DGIDB hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental glutamate receptor 2 GRIA2 NA antagonist 0.77 drugbank , DGIDB butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit glutamate receptor 2 GRIA2 NA antagonist NA drugbank 2,3,6a,7,8,9-hexahydro-11h-[1,4]dioxino[2,3-g]pyrrolo[2,1-b][1,3]benzoxazin-11-one small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental glutamate receptor 2 GRIA2 NA antagonist NA drugbank thio-atpa small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank quinidine barbiturate small molecule NA approved glutamate receptor 2 GRIA2 NA antagonist NA drugbank aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit glutamate receptor 2 GRIA2 NA antagonist NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved glutamate receptor 2 GRIA2 NA antagonist 0.24 drugbank , DGIDB (3r)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2h-1,2-benzothiazine 1,1-dioxide small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn glutamate receptor 2 GRIA2 NA antagonist 0.39 drugbank , DGIDB iodo-willardiine small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank 2-amino-3-(3-hydroxy-7,8-dihydro-6h-cyclohepta[d]-4-isoxazolyl)propionic acid small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank [3h]cnqx NA NA investigative glutamate receptor ampa 2 GRIA2 Successful target antagonist NA TTD , DGIDB fg-9041 small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank cx-717 small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit,investigational glutamate receptor 2 GRIA2 NA unknown NA drugbank quisqualic acid small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational glutamate receptor 2 GRIA2 NA antagonist 0.26 drugbank , DGIDB aniracetam small molecule Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental glutamate receptor 2 GRIA2 NA allosteric modulator 0.43 drugbank , DGIDB talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit glutamate receptor 2 GRIA2 NA antagonist 0.39 drugbank , DGIDB atpo NA NA investigative glutamate receptor ampa 2 GRIA2 Successful target antagonist NA TTD , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit glutamate receptor 2 GRIA2 NA antagonist 0.39 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor 2 GRIA2 NA unknown NA drugbank (2s)-2-ammonio-3-[5-(2-methyl-2-propanyl)-3-oxido-1,2-oxazol-4-yl]propanoate small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank fluoro-willardiine small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank (s)-5-fluorowillardiine NA NA investigative glutamate receptor ampa 2 GRIA2 Successful target agonist NA TTD , DGIDB e-2007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Parkinson Disease[MeSHID:D010300] approved glutamate receptor ampa 2 GRIA2 Successful target unknown 1.45 TTD , DGIDB [3h]ampa NA NA investigative glutamate receptor ampa 2 GRIA2 Successful target agonist NA TTD , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor 2 GRIA2 NA antagonist 0.77 drugbank , DGIDB (3s)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxide small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank (3r)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2h-1,2-benzothiazine 1,1-dioxide small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor 2 GRIA2 NA antagonist 0.64 drugbank , DGIDB secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor 2 GRIA2 NA antagonist 0.77 drugbank , DGIDB bromo-willardiine small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit glutamate receptor 2 GRIA2 NA antagonist NA drugbank 2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor 2 GRIA2 NA unknown NA drugbank (s)-2-amino-3-(1,3,5,7-pentahydro-2,4-dioxo-cyclopenta[e]pyrimidin-1-yl) proionic acid small molecule NA experimental glutamate receptor 2 GRIA2 NA unknown NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate receptor 2 GRIA2 NA inhibitor NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate receptor 2 GRIA2 NA antagonist 0.39 drugbank , DGIDB thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor 2 GRIA2 NA antagonist 0.7 drugbank , DGIDB dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit glutamate receptor 2 GRIA2 NA antagonist NA drugbank amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor 2 GRIA2 NA antagonist NA drugbank e-2007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Parkinson Disease[MeSHID:D010300] approved glutamate receptor ampa 3 GRIA3 Successful target unknown 2.17 TTD , DGIDB cx-717 small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit,investigational glutamate receptor 3 GRIA3 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor 3 GRIA3 NA unknown NA drugbank lithium carbonate small molecule Bipolar Disorder[MeSHID:D001714],Mood (psychological function)[MeSHID:D000339],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor 3 GRIA3 NA unknown NA drugbank talampanel small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational glutamate receptor 3 GRIA3 NA unknown 2.89 drugbank , DGIDB [3h]cnqx NA NA investigative glutamate receptor ampa 3 GRIA3 Successful target unknown NA TTD , DGIDB lithium succinate small molecule NA experimental glutamate receptor 3 GRIA3 NA unknown NA drugbank aniracetam small molecule Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental glutamate receptor 3 GRIA3 NA allosteric modulator 0.64 drugbank , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor 3 GRIA3 NA unknown NA drugbank (s)-5-fluorowillardiine NA NA investigative glutamate receptor ampa 3 GRIA3 Successful target agonist NA TTD , DGIDB [3h]ampa NA NA investigative glutamate receptor ampa 3 GRIA3 Successful target unknown NA TTD , DGIDB joro toxin NA NA investigative glutamate receptor ampa 3 GRIA3 Successful target blocker NA TTD , DGIDB lithium cation small molecule Bipolar Disorder[MeSHID:D001714],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Depressive disorder[MeSHID:D003866] experimental glutamate receptor 3 GRIA3 NA potentiator NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor 3 GRIA3 NA antagonist NA drugbank atpo NA NA investigative glutamate receptor ampa 3 GRIA3 Successful target antagonist NA TTD , DGIDB lithium citrate small molecule Bipolar Disorder[MeSHID:D001714],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor 3 GRIA3 NA unknown NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate receptor 3 GRIA3 NA inhibitor NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate receptor 4 GRIA4 NA inhibitor NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor 4 GRIA4 NA antagonist NA drugbank amg-889436 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigative glutamate receptor ampa 4 GRIA4 Successful target unknown NA TTD cx-717 small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit,investigational glutamate receptor 4 GRIA4 NA unknown NA drugbank [3h]cnqx NA NA investigative glutamate receptor ampa 4 GRIA4 Successful target unknown NA TTD , DGIDB (s)-5-fluorowillardiine NA NA investigative glutamate receptor ampa 4 GRIA4 Successful target agonist NA TTD , DGIDB atpo NA NA investigative glutamate receptor ampa 4 GRIA4 Successful target antagonist NA TTD , DGIDB [3h]ampa NA NA investigative glutamate receptor ampa 4 GRIA4 Successful target agonist NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor 4 GRIA4 NA unknown NA drugbank talampanel small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational glutamate receptor 4 GRIA4 NA unknown 3.35 drugbank , DGIDB joro toxin NA NA investigative glutamate receptor ampa 4 GRIA4 Successful target blocker NA TTD , DGIDB e-2007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Parkinson Disease[MeSHID:D010300] approved glutamate receptor ampa 4 GRIA4 Successful target unknown 2.51 TTD , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor 4 GRIA4 NA unknown NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved kainate receptors GRIK1 NA antagonist 3.26 drugbank , DGIDB dihydrokainate NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD tezampanel small molecule Cluster Headache[MeSHID:D003027],Pain[MeSHID:D010146],Migraine Disorders[MeSHID:D008881] investigational glutamate receptor ionotropic, kainate 1 GRIK1 NA antagonist 4.24 drugbank , DGIDB 2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD ubp-302 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD 2-(3-bromobenzoylamino)-4-chlorobenzoic acid NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD dysiherbaine NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD tqx-173 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor ionotropic, kainate 1 GRIK1 NA antagonist NA drugbank topiramate NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown 3.26 TTD , DGIDB 8-deoxy-neodysiherbaine NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target agonist NA TTD , DGIDB dnqx NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD ns 1209 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 2 glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD , DGIDB domoric acid NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD nbqx NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown 0.85 TTD , DGIDB (s)-5-iodowillardiine NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target agonist NA TTD , DGIDB s-atpo NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD (s)-4-ahcp NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target agonist NA TTD , DGIDB [3h]kainate NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target agonist NA TTD , DGIDB ns3763 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target antagonist NA TTD , DGIDB ym-90k NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD tezampanel small molecule Cluster Headache[MeSHID:D003027],Pain[MeSHID:D010146],Migraine Disorders[MeSHID:D008881] investigational glutamate receptor ionotropic, kainate 1 GRIK1 NA unknown 4.24 drugbank , DGIDB (2s,4r)-4-(3-methoxy-3-oxopropyl)glutamic acid NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD ly339434 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target agonist NA TTD , DGIDB ubp310 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target antagonist NA TTD , DGIDB 2s,4r-4-methylglutamate NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD ly293558 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD , DGIDB atpa NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target agonist NA TTD , DGIDB acet NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target antagonist NA TTD , DGIDB ly382884 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target antagonist NA TTD , DGIDB msviii-19 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target antagonist NA TTD , DGIDB 2-amino-3-(4-hydroxy-1,2,5-oxadiazol-3-yl)propionic acid (structural mix) NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD sym2081 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target agonist NA TTD , DGIDB [3h]quisqualate NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, kainate 1 GRIK1 NA unknown NA drugbank 2,4-epi-neodysiherbaine NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target antagonist NA TTD , DGIDB topiramate NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved glutamate receptor ionotropic kainate 1 GRIK1 Successful target antagonist 3.26 TTD , DGIDB ly466195 NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target antagonist NA TTD , DGIDB domoic acid NA NA investigative glutamate receptor ionotropic kainate 1 GRIK1 Successful target agonist NA TTD , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved kainate receptors GRIK2 NA antagonist 0.1 drugbank , DGIDB secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 1.7 drugbank , DGIDB heptabarbital small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 0.85 drugbank , DGIDB butalbital small molecule Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,illicit glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 0.85 drugbank , DGIDB 2s,4r-4-methylglutamate small molecule NA experimental glutamate receptor ionotropic, kainate 2 GRIK2 NA unknown NA drugbank domoic acid small molecule NA experimental glutamate receptor ionotropic, kainate 2 GRIK2 NA agonist NA drugbank , DGIDB amobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist NA drugbank dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1h,5h)-pyrimidinedione small molecule NA experimental,illicit glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist NA drugbank barbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 1.7 drugbank , DGIDB thiopental small molecule Intracranial Hypertension[MeSHID:D019586],Muscle relaxation phase[MeSHID:D009126],Abnormal behavior[MeSHID:D000066553],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 1.54 drugbank , DGIDB butobarbital small molecule Sleeplessness[MeSHID:D007319] approved,illicit glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist NA drugbank aprobarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist NA drugbank phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 0.46 drugbank , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, kainate 2 GRIK2 NA unknown NA drugbank talbutal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved,illicit glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 0.85 drugbank , DGIDB methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 1.41 drugbank , DGIDB metharbital small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 0.85 drugbank , DGIDB quisqualic acid small molecule NA experimental glutamate receptor ionotropic, kainate 2 GRIK2 NA unknown NA drugbank primidone small molecule Disease Management[MeSHID:D019468],Essential Tremor[MeSHID:D020329],Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 0.53 drugbank , DGIDB hexobarbital small molecule Diagnosis[MeSHID:D003933],Pain[MeSHID:D010146],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental glutamate receptor ionotropic, kainate 2 GRIK2 NA antagonist 1.7 drugbank , DGIDB dysiherbaine NA NA investigative glutamate receptor ionotropic kainate 3 GRIK3 Literature-reported target agonist 5.3 TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, kainate 3 GRIK3 NA unknown NA drugbank ubp310 NA NA investigative glutamate receptor ionotropic kainate 3 GRIK3 Literature-reported target unknown NA TTD sym2081 NA NA investigative glutamate receptor ionotropic kainate 3 GRIK3 Literature-reported target unknown NA TTD [3h]kainate NA NA investigative glutamate receptor ionotropic kainate 3 GRIK3 Literature-reported target agonist NA TTD , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved kainate receptors GRIK3 NA antagonist 0.37 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor ionotropic, kainate 3 GRIK3 NA antagonist NA drugbank domoic acid NA NA investigative glutamate receptor ionotropic kainate 4 GRIK4 Literature-reported target agonist NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, kainate 4 GRIK4 NA unknown NA drugbank sym2081 NA NA investigative glutamate receptor ionotropic kainate 4 GRIK4 Literature-reported target agonist NA TTD , DGIDB [3h]kainate NA NA investigative glutamate receptor ionotropic kainate 4 GRIK4 Literature-reported target agonist NA TTD , DGIDB dysiherbaine NA NA investigative glutamate receptor ionotropic kainate 4 GRIK4 Literature-reported target agonist 4.24 TTD , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved kainate receptors GRIK4 NA antagonist 0.3 drugbank , DGIDB butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor ionotropic, kainate 4 GRIK4 NA antagonist NA drugbank domoic acid NA NA investigative glutamate receptor ionotropic kainate 5 GRIK5 Literature-reported target agonist NA TTD , DGIDB sym2081 NA NA investigative glutamate receptor ionotropic kainate 5 GRIK5 Literature-reported target agonist NA TTD , DGIDB dysiherbaine NA NA investigative glutamate receptor ionotropic kainate 5 GRIK5 Literature-reported target agonist 10.61 TTD , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved kainate receptors GRIK5 NA antagonist NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, kainate 5 GRIK5 NA unknown NA drugbank butabarbital small molecule Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glutamate receptor ionotropic, kainate 5 GRIK5 NA antagonist NA drugbank [3h]kainate NA NA investigative glutamate receptor ionotropic kainate 5 GRIK5 Literature-reported target agonist NA TTD , DGIDB n,n'-bis-(4-butyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 5,7-dichlorokynurenic acid small molecule NA experimental glutamate receptor ionotropic, nmda 1 GRIN1 NA antagonist NA drugbank , DGIDB 4-[2-(4-benzyl-piperidin-1-yl)-ethoxy]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN1 NA downregulator NA drugbank d-serine small molecule NA approved,experimental glutamate receptor ionotropic, nmda 1 GRIN1 NA agonist 1.06 drugbank , DGIDB gly-pip-glu NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational glutamate receptor ionotropic, nmda 1 GRIN1 NA activator NA drugbank [3h]dizocilpine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target antagonist NA TTD , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate (nmda) receptor GRIN1 NA antagonist NA drugbank 2-(4-phenoxy-benzyl)-3h-benzoimidazol-4-ol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN1 NA inhibitor NA drugbank (+)-ha966 NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target agonist NA TTD , DGIDB 3-hydroxy-8-methyl-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 8-chloro-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD gly-hyp-glu NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN1 NA blocker NA drugbank gly-amp-glu NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 2-(4-phenoxy-benzyl)-1h-benzoimidazole NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, nmda 1 GRIN1 NA unknown NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational glutamate (nmda) receptor GRIN1 NA ligand NA drugbank 6,7-dichloro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 8-fluoro-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD n-(2-methoxybenzyl)cinnamamidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD n,n'-bis-(4-butoxy-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nmda receptor GRIN1 NA antagonist NA drugbank magnesium acetate tetrahydrate small molecule Hypertensive disease[MeSHID:D006973],Retention (Psychology)[MeSHID:D012153],Defecation[MeSHID:D003672],Hypoglycemia[MeSHID:D007003],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Constipation[MeSHID:D003248],Drinking Water[MeSHID:D060766],Intestines[MeSHID:D007422] approved glutamate (nmda) receptor GRIN1 NA ligand NA drugbank ala-pro-glu NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 7-chloro-3-hydroxyquinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 1,3-ditolylguanidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD gly-b7pro-glu NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 6-chloro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD guaifenesin small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved nmda receptor GRIN1 NA antagonist NA drugbank cns-5161 small molecule Cluster Headache[MeSHID:D003027],Pain[MeSHID:D010146],Migraine Disorders[MeSHID:D008881],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glutamate receptor ionotropic, nmda 1 GRIN1 NA blocker 0.42 drugbank , DGIDB 3-hydroxy-6-methyl-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD phe-pro-glu NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4,6-dichloro-1h-indole-2-carboxylic acid NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD n,n'-bis-(4-ethyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 2-pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD agmatine small molecule Diabetes Mellitus[MeSHID:D003920],Small Fiber Neuropathy[MeSHID:D000071075],Neuroprotection[MeSHID:D000066829],Glaucoma[MeSHID:D005901],Diagnosis[MeSHID:D003933],Epilepsy[MeSHID:D004827],Kidney[MeSHID:D007668],Anxiety Disorders[MeSHID:D001008],Blind Vision[MeSHID:D001766],Mental Depression[MeSHID:D003863],Cognition[MeSHID:D003071],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Traumatic injury[MeSHID:D014947],Cerebrovascular accident[MeSHID:D020521],Anxiety[MeSHID:D001007] experimental glutamate receptor ionotropic, nmda 1 GRIN1 NA antagonist NA drugbank cycloserine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obsessive-Compulsive Disorder[MeSHID:D009771],Bacterial Infections[MeSHID:D001424],Obsessive compulsive behavior[MeSHID:D003192],Tuberculosis[MeSHID:D014376] approved glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown 0.49 TTD , DGIDB esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN1 NA antagonist 0.42 drugbank , DGIDB (d)-ala-pro-glu NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-(3,4-dihydro-1h-isoquinolin-2-yl)-quinoline NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD magnesium carbonate small molecule NA approved,investigational glutamate (nmda) receptor GRIN1 NA blocker NA drugbank 3-hydroxy-7-nitro-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 1 GRIN1 NA antagonist NA drugbank transtorine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 2-methylamino-succinic acid(nmda) NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 5,7-dichloro-3-hydroxy-1h-quinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD ap-7 NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-[2-(4-phenyl-butoxy)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD n,n'-bis-(4-sec-butyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-bromo-5,7-dichloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD n,n'-bis-(4-isopropyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD cgp61594 NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD n,n'-bis-(4-hexyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD homoquinolinic acid NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target agonist NA TTD , DGIDB 5,7-dichloro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 3-benzoyl-7-chloro-4-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 6-nitro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD orphenadrine small molecule Acute onset pain[MeSHID:D059787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved glutamate receptor ionotropic, nmda 1 GRIN1 NA antagonist 1.48 drugbank , DGIDB 4-[2-(5-phenyl-pentylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 6-nitro-2-(4-phenoxy-benzyl)-1h-benzoimidazole NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD cycloleucine small molecule NA experimental glutamate receptor ionotropic, nmda 1 GRIN1 NA unknown NA drugbank phenethyl-(3-phenyl-propyl)-amine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 5,7-dichlorokynurenic acid NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target antagonist NA TTD , DGIDB 5,7-dibromo-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD rpr-118723 NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-benzyl-1-phenethyl-piperidine hydrochloride NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-[2-(3-phenyl-propylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 6,7-dichloro-3-hydroxy-1h-quinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 6-methoxy-2-(4-phenoxy-benzyl)-1h-benzoimidazole NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4,5,7-trichloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD ym-90k NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-{2-[ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD phenethyl-(4-phenyl-butyl)-amine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-[2-(4-phenyl-piperidin-1-yl)-ethoxy]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD dnqx NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 8-ethyl-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD benzyl 4-aminobutyl(3-aminopropyl)carbamate NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate (nmda) receptor GRIN1 NA inhibitor NA drugbank d-serine NA NA phase 4 glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown 1.06 TTD , DGIDB 4-[2-(6-phenyl-hexylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD d-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target agonist NA TTD , DGIDB (rs)-(tetrazol-5-yl)glycine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target agonist NA TTD , DGIDB 4-[3-(4-phenyl-butylamino)-propyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 5,6,7-trichloro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-chloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-[2-(4-phenyl-butylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD phencyclidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD [3h]cgs19755 NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target antagonist NA TTD , DGIDB acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN1 NA antagonist NA drugbank ifenprodil small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,withdrawn glutamate receptor ionotropic, nmda 1 GRIN1 NA antagonist NA drugbank eliprodil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown 0.37 TTD , DGIDB 4-benzyl-1-(2-phenoxy-ethyl)-piperidine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD (r)-2-amino-7-phosphono-heptanoic acid NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 3-carbamoyl-6-chloro-1h-indole-2-carboxylic acid NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD [3h]mdl105519 NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nmda receptor GRIN1 NA antagonist NA drugbank 5,7-dinitro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD cycloleucine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational nmda receptor GRIN1 NA antagonist NA drugbank 3-phenyl-4-hydroxyquinolin-2(1h)-one NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD cns-5161 small molecule Cluster Headache[MeSHID:D003027],Pain[MeSHID:D010146],Migraine Disorders[MeSHID:D008881],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glutamate receptor ionotropic, nmda 1 GRIN1 NA unknown 0.42 drugbank , DGIDB d-serine small molecule NA approved,experimental glutamate receptor ionotropic, nmda 1 GRIN1 NA unknown 1.06 drugbank , DGIDB 5,7-dichloro-4-hydroxy-3-phenyl-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD [3h]cgp39653 NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target antagonist NA TTD , DGIDB methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved nmda receptor GRIN1 NA antagonist NA drugbank nle-pro-glu NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-bromo-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD (r)-2-amino-5-phosphono-pentanoic acid NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD gavestinel small molecule Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] investigational glutamate (nmda) receptor GRIN1 NA antagonist NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN1 NA antagonist 2.07 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nmda receptor GRIN1 NA agonist NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate receptor ionotropic, nmda 1 GRIN1 NA binder 2.07 drugbank , DGIDB h-gly-dmp-glu-oh NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD h-gly-d-dmp-glu-oh NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7h)-one NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD nbqx NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown 0.1 TTD , DGIDB 2-(4-phenoxy-benzyl)-3h-benzoimidazol-5-ol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nmda receptor GRIN1 NA inhibitor NA drugbank l-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target agonist NA TTD , DGIDB 2-(4-phenoxy-benzyl)-3h-benzoimidazol-5-ylamine NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nmda receptor GRIN1 NA antagonist NA drugbank 8-bromo-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD d-serine NA NA phase 4 glutamate receptor ionotropic nmda 1 GRIN1 Successful target agonist 1.06 TTD , DGIDB [3h]cpp NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target antagonist NA TTD , DGIDB 4-[3-(5-phenyl-pentylamino)-propyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 1 GRIN1 Successful target unknown NA TTD atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN2A NA blocker NA drugbank d-ccpene NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7h)-one NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD tenocyclidine small molecule NA experimental,illicit,investigational glutamate receptor ionotropic, nmda 2a GRIN2A NA antagonist NA drugbank glycine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown 1.32 TTD , DGIDB 4-[3-(5-phenyl-pentylamino)-propyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD mdl 100,453 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD phencyclidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target blocker 0.45 TTD , DGIDB acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN2A NA antagonist NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, nmda 2a GRIN2A NA unknown NA drugbank 3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD gavestinel small molecule Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] investigational glutamate (nmda) receptor GRIN2A NA antagonist NA drugbank nle-pro-glu NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nmda receptor GRIN2A NA antagonist NA drugbank 6-nitro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD nbqx NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown 0.12 TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational glutamate (nmda) receptor GRIN2A NA ligand NA drugbank dnqx NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD (d)-ala-pro-glu NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD conantokin-r NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 8-bromo-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 3-hydroxy-8-methyl-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD transtorine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD d-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target agonist NA TTD , DGIDB ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational nmda receptor GRIN2A NA antagonist NA drugbank ap-7 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD gly-hyp-glu NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD gly-pip-glu NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD magnesium acetate tetrahydrate small molecule Hypertensive disease[MeSHID:D006973],Retention (Psychology)[MeSHID:D012153],Defecation[MeSHID:D003672],Hypoglycemia[MeSHID:D007003],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Constipation[MeSHID:D003248],Drinking Water[MeSHID:D060766],Intestines[MeSHID:D007422] approved glutamate (nmda) receptor GRIN2A NA ligand NA drugbank 4-[2-(6-phenyl-hexylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 7-chloro-3-hydroxyquinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD n,n'-bis-(4-butoxy-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN2A NA antagonist 0.26 drugbank , DGIDB felbamate small molecule Aplastic Anemia[MeSHID:D000741],Epilepsy[MeSHID:D004827],Liver Failure[MeSHID:D017093],Light[MeSHID:D008027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 2a GRIN2A NA antagonist 0.45 drugbank , DGIDB acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational glutamate receptor ionotropic, nmda 2a GRIN2A NA activator NA drugbank 4,6-dichloro-1h-indole-2-carboxylic acid NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 4-chloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD n-(2-methoxybenzyl)cinnamamidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD phe-pro-glu NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD cgp61594 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 3-phenyl-4-hydroxyquinolin-2(1h)-one NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD n,n'-bis-(4-isopropyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD glycine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved glutamate receptor ionotropic nmda 2a GRIN2A Successful target agonist 1.32 TTD , DGIDB milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN2A NA inhibitor NA drugbank n,n'-bis-(4-butyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nmda receptor GRIN2A NA agonist NA drugbank phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nmda receptor GRIN2A NA antagonist NA drugbank meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 2a GRIN2A NA antagonist NA drugbank 4,5,7-trichloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 3-hydroxy-6-methyl-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD (r)-2-amino-7-phosphono-heptanoic acid NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 8-ethyl-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 4-[3-(4-phenyl-butylamino)-propyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD guaifenesin small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved nmda receptor GRIN2A NA antagonist NA drugbank methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved nmda receptor GRIN2A NA antagonist NA drugbank 5,7-dichloro-3-hydroxy-1h-quinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD n,n'-bis-(4-hexyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD ly233053 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB (+)-ha966 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target agonist NA TTD , DGIDB rpr-118723 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD l-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target agonist NA TTD , DGIDB gly-amp-glu NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD [3h]cgp39653 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB tcn-201 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target allosteric modulator NA TTD , DGIDB [3h]mdl105519 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor ionotropic, nmda 2a GRIN2A NA antagonist NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate (nmda) receptor GRIN2A NA inhibitor NA drugbank 4-[2-(4-phenyl-butylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 4-bromo-5,7-dichloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD n,n'-bis-(4-ethyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 5,7-dinitro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 6-chloro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 6,7-dichloro-3-hydroxy-1h-quinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD benzyl 4-aminobutyl(3-aminopropyl)carbamate NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD [3h]cpp NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate (nmda) receptor GRIN2A NA antagonist NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nmda receptor GRIN2A NA antagonist NA drugbank ala-pro-glu NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD n,n'-bis-(4-sec-butyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD nvp-aam077 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB tenocyclidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD homoquinolinic acid NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target agonist NA TTD , DGIDB glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glutamate receptor ionotropic, nmda 2a GRIN2A NA antagonist,agonist 1.32 drugbank , DGIDB 3-hydroxy-7-nitro-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD (r)-2-amino-5-phosphono-pentanoic acid NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD d-ap5 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB gly-b7pro-glu NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN2A NA antagonist 2.91 drugbank , DGIDB ubp141 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB 4-bromo-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD h-gly-d-dmp-glu-oh NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 1,3-ditolylguanidine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glutamate receptor ionotropic, nmda 2a GRIN2A NA antagonist 1.32 drugbank , DGIDB magnesium carbonate small molecule NA approved,investigational glutamate (nmda) receptor GRIN2A NA blocker NA drugbank [3h]dizocilpine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target blocker NA TTD , DGIDB 4-[2-(5-phenyl-pentylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD [3h]cgs19755 NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target antagonist NA TTD , DGIDB 3-benzoyl-7-chloro-4-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD h-gly-dmp-glu-oh NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD n1-dansyl-spermine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target blocker NA TTD , DGIDB 8-fluoro-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 2-methylamino-succinic acid(nmda) NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD (rs)-(tetrazol-5-yl)glycine NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target agonist NA TTD , DGIDB ym-90k NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN2A NA downregulator NA drugbank 8-chloro-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD 5,7-dichloro-4-hydroxy-3-phenyl-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2a GRIN2A Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nmda receptor GRIN2A NA inhibitor NA drugbank 2-(4-phenoxy-benzyl)-3h-benzoimidazol-4-ol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD ro 63-1908 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-[3-(4-phenyl-butylamino)-propyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nmda receptor GRIN2B NA antagonist NA drugbank 6-chloro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD nvp-aam077 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB d-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target agonist NA TTD , DGIDB n-(4-(benzyloxy)phenethyl)pyridin-4-amine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD mij821 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-benzyl-1-phenethyl-piperidine hydrochloride NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, nmda 2b GRIN2B NA unknown NA drugbank magnesium carbonate small molecule NA approved,investigational glutamate (nmda) receptor GRIN2B NA blocker NA drugbank 2-methylamino-succinic acid(nmda) NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD n,n'-bis-(4-ethyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 3-hydroxy-6-methyl-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD evt-101 NA Pain[MeSHID:D010146],Parkinson Disease[MeSHID:D010300],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist 1.38 TTD , DGIDB 4-[2-(6-phenyl-hexylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD conantokin-r NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 2-(4-phenoxy-benzyl)-1h-benzoimidazole NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD benzyl 4-aminobutyl(3-aminopropyl)carbamate NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nmda receptor GRIN2B NA antagonist NA drugbank neu-2000 NA Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD , DGIDB 3-benzoyl-7-chloro-4-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-[2-(4-phenyl-butoxy)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD cp-101,606 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD , DGIDB evt-101 small molecule Pain[MeSHID:D010146],Parkinson Disease[MeSHID:D010300],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glutamate receptor ionotropic, nmda 2b GRIN2B NA antagonist 1.38 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nmda receptor GRIN2B NA agonist NA drugbank transtorine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD n,n'-bis-(4-sec-butyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD ubp141 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB ap-7 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD [3h]dizocilpine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target blocker NA TTD , DGIDB magnesium acetate tetrahydrate small molecule Hypertensive disease[MeSHID:D006973],Retention (Psychology)[MeSHID:D012153],Defecation[MeSHID:D003672],Hypoglycemia[MeSHID:D007003],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Constipation[MeSHID:D003248],Drinking Water[MeSHID:D060766],Intestines[MeSHID:D007422] approved glutamate (nmda) receptor GRIN2B NA ligand NA drugbank conantokins t NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 5,7-dichloro-3-hydroxy-1h-quinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 3-hydroxy-8-methyl-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD n,n'-bis-(4-butoxy-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD np93-31 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD (r)-2-amino-7-phosphono-heptanoic acid NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-(3,4-dihydro-1h-isoquinolin-2-yl)-quinoline NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 3-phenyl-4-hydroxyquinolin-2(1h)-one NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 6,7-dichloro-3-hydroxy-1h-quinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD phenethyl-(4-phenyl-butyl)-amine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nmda receptor GRIN2B NA inhibitor NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nmda receptor GRIN2B NA antagonist NA drugbank 2-(4-benzyl-piperidin-1-ylmethyl)-1h-indol-6-ol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD n,n'-bis-(4-isopropyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 7-chloro-3-hydroxyquinazoline-2,4-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD gavestinel small molecule Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] investigational glutamate (nmda) receptor GRIN2B NA antagonist NA drugbank 5,7-dinitro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN2B NA downregulator NA drugbank conantokins g NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD gly-b7pro-glu NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 2-(4-phenoxy-benzyl)-3h-benzoimidazol-5-ylamine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 2b GRIN2B NA antagonist NA drugbank gly-pip-glu NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD ly233053 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN2B NA inhibitor NA drugbank 4-[2-(4-phenyl-piperidin-1-yl)-ethoxy]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational glutamate receptor ionotropic, nmda 2b GRIN2B NA activator NA drugbank 4-[2-(4-phenyl-butylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD homoquinolinic acid NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target agonist NA TTD , DGIDB methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved nmda receptor GRIN2B NA antagonist NA drugbank acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN2B NA antagonist 0.92 drugbank , DGIDB 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7h)-one NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 3-hydroxy-7-nitro-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-bromo-5,7-dichloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN2B NA antagonist 1.94 drugbank , DGIDB n,n'-bis-(4-hexyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 5,7-dichloro-4-hydroxy-3-phenyl-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 6-methoxy-2-(4-phenoxy-benzyl)-1h-benzoimidazole NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD h-gly-d-dmp-glu-oh NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD [3h]cgs19755 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational nmda receptor GRIN2B NA antagonist NA drugbank gly-hyp-glu NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4,6-dichloro-1h-indole-2-carboxylic acid NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-benzyl-1-(2-phenoxy-ethyl)-piperidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate (nmda) receptor GRIN2B NA antagonist NA drugbank ala-pro-glu NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD (r)-2-amino-5-phosphono-pentanoic acid NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-chloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-[2-(4-benzyl-piperidin-1-yl)-ethoxy]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD cerc-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown 1.38 TTD , DGIDB phe-pro-glu NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD nle-pro-glu NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD (rs)-(tetrazol-5-yl)glycine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target agonist NA TTD , DGIDB 1,3-ditolylguanidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD n1-dansyl-spermine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target blocker NA TTD , DGIDB taurine small molecule Weight decreased[MeSHID:D015431],Intestinal Absorption[MeSHID:D007408],Gastrointestinal Absorption[MeSHID:D065569] approved,nutraceutical glutamate receptor ionotropic, nmda 2b GRIN2B NA inhibitor NA drugbank d-ccpene NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN2B NA blocker NA drugbank phencyclidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target blocker 0.35 TTD , DGIDB 4-[3-(5-phenyl-pentylamino)-propyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD l-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target agonist NA TTD , DGIDB 8-bromo-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-[2-(5-phenyl-pentylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD evt-101 small molecule Pain[MeSHID:D010146],Parkinson Disease[MeSHID:D010300],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glutamate receptor ionotropic, nmda 2b GRIN2B NA unknown 1.38 drugbank , DGIDB 6-nitro-2-(4-phenoxy-benzyl)-1h-benzoimidazole NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 2b GRIN2B NA antagonist 0.18 drugbank , DGIDB d-ap5 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB guaifenesin small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved nmda receptor GRIN2B NA antagonist NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate (nmda) receptor GRIN2B NA inhibitor NA drugbank 8-ethyl-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD nbqx NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown 0.09 TTD , DGIDB 2-pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD ifenprodil small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,withdrawn glutamate receptor ionotropic, nmda 2b GRIN2B NA antagonist NA drugbank conantokin-g NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB 4-[2-(3-phenyl-propylamino)-ethyl]-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD h-gly-dmp-glu-oh NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD n-(2-methoxybenzyl)cinnamamidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD phenethyl-(3-phenyl-propyl)-amine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD [3h]mdl105519 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB (d)-ala-pro-glu NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD rpr-118723 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD ym-90k NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD tenocyclidine small molecule NA experimental,illicit,investigational glutamate receptor ionotropic, nmda 2b GRIN2B NA antagonist NA drugbank esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational glutamate receptor ionotropic, nmda 2b GRIN2B NA antagonist 0.4 drugbank , DGIDB rgh-896 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peripheral Neuropathy[MeSHID:D010523],Epilepsy[MeSHID:D004827] phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown 1.38 TTD , DGIDB 4-bromo-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 6-nitro-1,4-dihydro-quinoxaline-2,3-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD cerc-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist 1.38 TTD , DGIDB eliprodil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown 0.35 TTD , DGIDB besonprodil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 1 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD dqp-1105 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD evt-101 NA Pain[MeSHID:D010146],Parkinson Disease[MeSHID:D010300],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown 1.38 TTD , DGIDB 4,5,7-trichloro-3-hydroxy-1h-quinolin-2-one NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD n-(3-phenethoxybenzyl)-4-hydroxybenzamide NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD (+)-ha966 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target agonist NA TTD , DGIDB 2-(4-phenoxy-benzyl)-3h-benzoimidazol-5-ol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD evt-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 1 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved glutamate receptor ionotropic, nmda 2b GRIN2B NA antagonist 0.18 drugbank , DGIDB alpha 1-pi NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],alpha 1-Antitrypsin Deficiency[MeSHID:D019896],alpha-1-Antitrypsin Deficiency, Autosomal Recessive[MeSHID:C566273],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] approved glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD , DGIDB lumateperone small molecule Schizophrenia[MeSHID:D012559] approved,investigational glutamate receptor ionotropic, nmda 2b GRIN2B NA unknown NA drugbank tenocyclidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD felbamate small molecule Aplastic Anemia[MeSHID:D000741],Epilepsy[MeSHID:D004827],Liver Failure[MeSHID:D017093],Light[MeSHID:D008027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 2b GRIN2B NA antagonist 0.92 drugbank , DGIDB [3h]cpp NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB [3h]cgp39653 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target antagonist NA TTD , DGIDB cn-2097 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cyclic neutropenia[MeSHID:C536227] investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN2B NA antagonist 0.4 drugbank , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational glutamate (nmda) receptor GRIN2B NA ligand NA drugbank 8-chloro-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD dnqx NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 8-fluoro-3-hydroxy-1h-benzo[b]azepine-2,5-dione NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD evt100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD , DGIDB gly-amp-glu NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD cgp61594 NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD n,n'-bis-(4-butyl-phenyl)-guanidine NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD 4-{2-[ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol NA NA investigative glutamate receptor ionotropic nmda 2b GRIN2B Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational glutamate (nmda) receptor GRIN2C NA ligand NA drugbank meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 2c GRIN2C NA antagonist NA drugbank [3h]mdl105519 NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target antagonist NA TTD , DGIDB phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nmda receptor GRIN2C NA antagonist NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, nmda 2c GRIN2C NA unknown NA drugbank gavestinel small molecule Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] investigational glutamate (nmda) receptor GRIN2C NA antagonist NA drugbank l-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target agonist NA TTD , DGIDB (rs)-(tetrazol-5-yl)glycine NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target agonist NA TTD , DGIDB tenocyclidine small molecule NA experimental,illicit,investigational glutamate receptor ionotropic, nmda 2c GRIN2C NA antagonist NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate (nmda) receptor GRIN2C NA inhibitor NA drugbank d-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target agonist NA TTD , DGIDB cgp61594 NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target unknown NA TTD pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nmda receptor GRIN2C NA antagonist NA drugbank milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN2C NA inhibitor NA drugbank donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN2C NA downregulator NA drugbank [3h]cpp NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target antagonist NA TTD , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nmda receptor GRIN2C NA agonist NA drugbank 2-methylamino-succinic acid(nmda) NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nmda receptor GRIN2C NA inhibitor NA drugbank atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN2C NA blocker NA drugbank d-ccpene NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target antagonist NA TTD , DGIDB methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved nmda receptor GRIN2C NA antagonist NA drugbank n1-dansyl-spermine NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target blocker NA TTD , DGIDB enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate (nmda) receptor GRIN2C NA antagonist NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glutamate receptor ionotropic, nmda 2c GRIN2C NA agonist 1.02 drugbank , DGIDB ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational nmda receptor GRIN2C NA antagonist NA drugbank ubp141 NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target antagonist NA TTD , DGIDB ly233053 NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target antagonist NA TTD , DGIDB homoquinolinic acid NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target agonist NA TTD , DGIDB magnesium acetate tetrahydrate small molecule Hypertensive disease[MeSHID:D006973],Retention (Psychology)[MeSHID:D012153],Defecation[MeSHID:D003672],Hypoglycemia[MeSHID:D007003],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Constipation[MeSHID:D003248],Drinking Water[MeSHID:D060766],Intestines[MeSHID:D007422] approved glutamate (nmda) receptor GRIN2C NA ligand NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN2C NA antagonist NA drugbank esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN2C NA antagonist 0.27 drugbank , DGIDB [3h]cgs19755 NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target antagonist NA TTD , DGIDB guaifenesin small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved nmda receptor GRIN2C NA antagonist NA drugbank [3h]dizocilpine NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target blocker NA TTD , DGIDB d-ap5 NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target antagonist NA TTD , DGIDB acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN2C NA antagonist NA drugbank [3h]cgp39653 NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target antagonist NA TTD , DGIDB secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nmda receptor GRIN2C NA antagonist NA drugbank magnesium carbonate small molecule NA approved,investigational glutamate (nmda) receptor GRIN2C NA blocker NA drugbank dqp-1105 NA NA investigative glutamate receptor ionotropic nmda 2c GRIN2C Literature-reported target unknown NA TTD dqp-1105 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target unknown NA TTD d-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target agonist NA TTD , DGIDB orphenadrine small molecule Acute onset pain[MeSHID:D059787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved glutamate receptor ionotropic, nmda 2d GRIN2D NA antagonist 1.93 drugbank , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational glutamate (nmda) receptor GRIN2D NA ligand NA drugbank tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nmda receptor GRIN2D NA inhibitor NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate (nmda) receptor GRIN2D NA inhibitor NA drugbank gavestinel small molecule Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] investigational glutamate (nmda) receptor GRIN2D NA antagonist NA drugbank d-ap5 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target antagonist NA TTD , DGIDB acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational glutamate receptor ionotropic, nmda 2d GRIN2D NA activator NA drugbank [3h]mdl105519 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target antagonist NA TTD , DGIDB methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved nmda receptor GRIN2D NA antagonist NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN2D NA antagonist NA drugbank ubp141 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target antagonist NA TTD , DGIDB esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN2D NA antagonist 0.28 drugbank , DGIDB (rs)-(tetrazol-5-yl)glycine NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target agonist NA TTD , DGIDB acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN2D NA antagonist NA drugbank secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nmda receptor GRIN2D NA antagonist NA drugbank [3h]cgs19755 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target antagonist NA TTD , DGIDB ly233053 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target antagonist NA TTD , DGIDB magnesium carbonate small molecule NA approved,investigational glutamate (nmda) receptor GRIN2D NA blocker NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nmda receptor GRIN2D NA agonist NA drugbank magnesium acetate tetrahydrate small molecule Hypertensive disease[MeSHID:D006973],Retention (Psychology)[MeSHID:D012153],Defecation[MeSHID:D003672],Hypoglycemia[MeSHID:D007003],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Constipation[MeSHID:D003248],Drinking Water[MeSHID:D060766],Intestines[MeSHID:D007422] approved glutamate (nmda) receptor GRIN2D NA ligand NA drugbank guaifenesin small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved nmda receptor GRIN2D NA antagonist NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate (nmda) receptor GRIN2D NA antagonist NA drugbank donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN2D NA downregulator NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nmda receptor GRIN2D NA antagonist NA drugbank d-ccpene NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target antagonist NA TTD , DGIDB l-aspartic acid NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target agonist NA TTD , DGIDB milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN2D NA inhibitor NA drugbank n1-dansyl-spermine NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target blocker NA TTD , DGIDB atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN2D NA blocker NA drugbank qnz 46 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target unknown NA TTD tenocyclidine small molecule NA experimental,illicit,investigational glutamate receptor ionotropic, nmda 2d GRIN2D NA antagonist NA drugbank 2-methylamino-succinic acid(nmda) NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 2d GRIN2D NA antagonist NA drugbank cgp61594 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target unknown NA TTD [3h]dizocilpine NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target blocker NA TTD , DGIDB phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nmda receptor GRIN2D NA antagonist NA drugbank [3h]cpp NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target antagonist NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, nmda 2d GRIN2D NA unknown NA drugbank ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational nmda receptor GRIN2D NA antagonist NA drugbank homoquinolinic acid NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target agonist NA TTD , DGIDB [3h]cgp39653 NA NA investigative glutamate receptor ionotropic nmda 2d GRIN2D Literature-reported target antagonist NA TTD , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nmda receptor GRIN3A NA antagonist NA drugbank profenamine small molecule Parkinson Disease[MeSHID:D010300] approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist NA drugbank gavestinel small molecule Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] investigational glutamate (nmda) receptor GRIN3A NA antagonist NA drugbank phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nmda receptor GRIN3A NA antagonist NA drugbank magnesium acetate tetrahydrate small molecule Hypertensive disease[MeSHID:D006973],Retention (Psychology)[MeSHID:D012153],Defecation[MeSHID:D003672],Hypoglycemia[MeSHID:D007003],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Constipation[MeSHID:D003248],Drinking Water[MeSHID:D060766],Intestines[MeSHID:D007422] approved glutamate (nmda) receptor GRIN3A NA ligand NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate (nmda) receptor GRIN3A NA antagonist NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate (nmda) receptor GRIN3A NA inhibitor NA drugbank esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN3A NA antagonist 0.3 drugbank , DGIDB orphenadrine small molecule Acute onset pain[MeSHID:D059787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist 2.12 drugbank , DGIDB tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nmda receptor GRIN3A NA inhibitor NA drugbank tenocyclidine small molecule NA experimental,illicit,investigational glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist 1.82 drugbank , DGIDB acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN3A NA antagonist 0.71 drugbank , DGIDB dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist 2.12 drugbank , DGIDB milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN3A NA inhibitor NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational glutamate (nmda) receptor GRIN3A NA ligand NA drugbank magnesium carbonate small molecule NA approved,investigational glutamate (nmda) receptor GRIN3A NA blocker NA drugbank neramexane small molecule hearing impairment[MeSHID:D034381],Pain[MeSHID:D010146],Deafness[MeSHID:D003638],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational glutamate receptor ionotropic, nmda 3a GRIN3A NA unknown 0.71 drugbank , DGIDB donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN3A NA downregulator NA drugbank secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nmda receptor GRIN3A NA antagonist NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nmda receptor GRIN3A NA agonist NA drugbank rolicyclidine small molecule NA experimental,illicit glutamate receptor ionotropic, nmda 3a GRIN3A NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamate receptor ionotropic, nmda 3a GRIN3A NA unknown NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist 1.82 drugbank , DGIDB ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational nmda receptor GRIN3A NA antagonist NA drugbank guaifenesin small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved nmda receptor GRIN3A NA antagonist NA drugbank acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational glutamate receptor ionotropic, nmda 3a GRIN3A NA activator NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN3A NA antagonist 2.97 drugbank , DGIDB procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist NA drugbank methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved nmda receptor GRIN3A NA antagonist NA drugbank phencyclidine small molecule NA illicit glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist NA drugbank atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN3A NA blocker NA drugbank amantadine small molecule Adverse reaction to drug[MeSHID:D064420],Communicable Diseases[MeSHID:D003141],Parkinsonian Disorders[MeSHID:D020734],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutamate receptor ionotropic, nmda 3a GRIN3A NA antagonist NA drugbank magnesium acetate tetrahydrate small molecule Hypertensive disease[MeSHID:D006973],Retention (Psychology)[MeSHID:D012153],Defecation[MeSHID:D003672],Hypoglycemia[MeSHID:D007003],Pregnancy[MeSHID:D011247],Magnesium Deficiency[MeSHID:D008275],Constipation[MeSHID:D003248],Drinking Water[MeSHID:D060766],Intestines[MeSHID:D007422] approved glutamate (nmda) receptor GRIN3B NA ligand NA drugbank methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved nmda receptor GRIN3B NA antagonist NA drugbank phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nmda receptor GRIN3B NA antagonist NA drugbank magnesium carbonate small molecule NA approved,investigational glutamate (nmda) receptor GRIN3B NA blocker NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational glutamate (nmda) receptor GRIN3B NA ligand NA drugbank tenocyclidine small molecule NA experimental,illicit,investigational glutamate receptor ionotropic, nmda 3b GRIN3B NA antagonist NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glutamate receptor ionotropic, nmda 3b GRIN3B NA substrate NA drugbank secobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nmda receptor GRIN3B NA antagonist NA drugbank enflurane small molecule Maintenance[MeSHID:D008283],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutamate (nmda) receptor GRIN3B NA antagonist NA drugbank esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN3B NA antagonist 0.38 drugbank , DGIDB atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN3B NA blocker NA drugbank pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nmda receptor GRIN3B NA antagonist NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glutamate receptor ionotropic, nmda 3b GRIN3B NA antagonist NA drugbank tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nmda receptor GRIN3B NA inhibitor NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved glutamate (nmda) receptor GRIN3B NA inhibitor NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN3B NA antagonist NA drugbank ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational nmda receptor GRIN3B NA antagonist NA drugbank donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nmda receptor GRIN3B NA downregulator NA drugbank orphenadrine small molecule Acute onset pain[MeSHID:D059787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved glutamate receptor ionotropic, nmda 3b GRIN3B NA antagonist 2.65 drugbank , DGIDB gavestinel small molecule Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] investigational glutamate (nmda) receptor GRIN3B NA antagonist NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nmda receptor GRIN3B NA agonist NA drugbank guaifenesin small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Inspiration function[MeSHID:D001239] approved,investigational,vet_approved nmda receptor GRIN3B NA antagonist NA drugbank milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational nmda receptor GRIN3B NA inhibitor NA drugbank acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutamate (nmda) receptor GRIN3B NA antagonist NA drugbank us9493490, c NA NA patented beta-adrenergic receptor kinase 1 GRK2 Patented-recorded target unknown NA TTD , DGIDB pmid24210504c1o NA NA investigative beta-adrenergic receptor kinase 1 GRK2 Patented-recorded target unknown NA TTD us9493490, d NA NA patented beta-adrenergic receptor kinase 1 GRK2 Patented-recorded target unknown NA TTD , DGIDB betaarkct NA NA investigative beta-adrenergic receptor kinase 1 GRK2 Patented-recorded target unknown NA TTD pmid21596927c101 NA NA investigative beta-adrenergic receptor kinase 1 GRK2 Patented-recorded target unknown NA TTD us9493490, l NA NA patented beta-adrenergic receptor kinase 1 GRK2 Patented-recorded target unknown NA TTD , DGIDB us9493490, e NA NA patented beta-adrenergic receptor kinase 1 GRK2 Patented-recorded target unknown NA TTD , DGIDB bdbm50173306 NA NA patented beta-adrenergic receptor kinase 1 GRK2 Patented-recorded target unknown NA TTD , DGIDB phccc NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB (s)-3hpg NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD a-850002 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB vu-71 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid17929793c23h NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pyrazine-2-carboxylic acid adamantan-1-ylamide NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD (1s,3r)-acpd NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ftidc NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB pmid23084894c10i NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD a-794282 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB (s)-(+)-cbpg NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid17064898c29 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD 3,5-dhpg NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ym-202074 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD l-ccg-i NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ly456066 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB quinoline-3-carboxylic acid adamantan-1-ylamide NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD cfmmc NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB [11c]mmtp NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB pmid19289283c22 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD 3-matida NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD quinoline-2-carboxylic acid adamantan-1-ylamide NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid12470711c3 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD fptq NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD (e)-1-adamantan-1-yl-3-quinolin-3-yl-propenone NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD n-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD n-phenethylquinoxaline-2-carboxamide NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD 2-methyl-6-(phenylethynyl)pyridine NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid16099654c3a NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical metabotropic glutamate receptor 1 GRM1 NA unknown NA drugbank pmid17532216c2f NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD bay 367620 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid20346665c24 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD 3,5-dimethyl ppp NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pf-1913539 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid19289283c32 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD [3h]em-tbpc NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD [18f]fitm NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB pmid22266036c12e NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ro67-4853 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid16099654c4b NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD n-(2,3-dihydro-1h-inden-2-yl)isoquinolin-1-amine NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD a-841720 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] preclinical metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD , DGIDB (+)-mcpg NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ibotenate NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD mk-5435 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB a-794278 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB cfmti NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB n-(3-bromophenyl)-6-chloroquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD nps-2390 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD , DGIDB 4-(cyclohexyloxy)quinazoline NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid23084894c9n NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD [3h]quisqualate NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid17929793c23c NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid17929793c11c NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD vu0469650 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB pmid19433355c11s NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid17929793c23i NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid17929793c23e NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD (3,4-dimethylphenyl)(4-phenoxyphenyl)methanone NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid17276684c22 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD azd-9272 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD [18f]mk-1312 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB jnj-16567083 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD (s)-4cpg NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ro67-7476 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ro0711401 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD n-(2-phenylpropyl)quinoxaline-2-carboxamide NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ym298198 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB ly-3390334 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid20346665c27 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD (s)-tbpg NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ly456236 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB r214127 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB (e)-4,4-dimethyl-1-quinolin-3-yl-pent-1-en-3-one NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD aida NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target antagonist NA TTD , DGIDB dm-ppp NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD azd8529 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 2 metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD 6-bromo-n-(3-chlorophenyl)quinazolin-4-amine NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD vu0080241 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD n-cyclohexylquinolin-4-amine NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD n-(3-bromophenyl)-6-fluoroquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD cpccoet NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator 12.73 TTD , DGIDB a-841720 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] preclinical metabotropic glutamate receptor 1 GRM1 Discontinued target allosteric modulator NA TTD , DGIDB n-cyclohexylquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD (s)-alpha-methyl-4-carboxyphenylglycine small molecule NA experimental metabotropic glutamate receptor 1 GRM1 NA unknown NA drugbank (s)-4c3hpg NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target antagonist NA TTD , DGIDB n-(2,3-dihydro-1h-inden-2-yl)quinazolin-4-amine NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid19433355c11q NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid22266036c9a NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD ro01-6128 NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD [18f]fpit NA NA investigative metabotropic glutamate receptor 1 GRM1 Discontinued target unknown NA TTD pmid25435285-compound-22 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB (+)-mcpg NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target antagonist NA TTD , DGIDB pmid25435285-compound-46 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB dt-2228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD eglu NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD gsk1331268 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator 5.79 TTD , DGIDB mp-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD pmid25435285-compound-43 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB bci-632 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB heteroaryl-pyrazole derivative 2 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 4 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB cyppts NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB ly2140023 small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] investigational metabotropic glutamate receptor 2 GRM2 NA unknown NA drugbank , DGIDB cbipes NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB quinoline derivative 6 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB dcg iv NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD ly-379268 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD thiic NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB pmid25435285-compound-42 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-26 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB 4-mppts NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB quinoline derivative 7 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB [3h]quisqualate NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD [3h]jnj-40068782 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB quinoline derivative 5 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-40 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-53 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pomaglumetad NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 6 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ro64-5229 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD n-substituted pyrazole derivative 2 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-50 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-39 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB n-substituted pyrazole derivative 1 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB mgs0028 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD pmid25435285-compound-45 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-20 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-52 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB mni-136 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB pyrazole derivative 79 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB quinoline derivative 4 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ts-032 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB mni-137 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 3 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 1 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ro5488608 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD pmid22364337c48 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 2 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB biphenylindanone a NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB 4-appes NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB pmid25435285-compound-38 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ethinyl-pyrazole derivative 2 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-37 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pccg-4 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD bci-838 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 5 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 78 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid21155570c14 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD pmid25435285-compound-49 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB quinoline derivative 9 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB jnj-42153605 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator 5.79 TTD , DGIDB heteroaryl-pyrazole derivative 3 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB adx71149 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827] phase 1 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB l-ccg-i NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target agonist NA TTD , DGIDB r-1578 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD jnj-42491293 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ly354740 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD [3h]ly341495 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target antagonist NA TTD , DGIDB rg1578 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD pmid25435285-compound-16 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-41 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ly-2979165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] phase 1 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown 11.57 TTD , DGIDB ethinyl-pyrazole derivative 3 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 76 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-47 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB oleoyl-estrone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Psychotic Disorders[MeSHID:D011618] phase 2 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ro4491533 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB ly-2300559 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 2 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown 2.89 TTD , DGIDB ly-544344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD ly-389795 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD mni-135 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB n-substituted pyrazole derivative 3 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-10 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB 3-mppts NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB [3h]2,2,2-temps NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD quinoline derivative 8 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB (s)-4c3hpg NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD (1s,3r)-acpd NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target agonist NA TTD , DGIDB ptbe NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target allosteric modulator NA TTD , DGIDB heteroaryl-pyrazole derivative 1 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ro4988546 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD pmid25435285-compound-25 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 77 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB (2r,4r)-4-aminopyrrolidine-2,4-dicarboxylate NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD pmid20409708c34 NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD pmid25435285-compound-15 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-51 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB quinoline derivative 3 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-44 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB alpha-methylserine-o-phosphate NA NA investigative metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD ethinyl-pyrazole derivative 1 NA NA patented metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown NA TTD , DGIDB ro-4995819 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 metabotropic glutamate receptor 2 GRM2 Clinical trial target unknown 8.68 TTD , DGIDB bci-632 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD , DGIDB ro4491533 NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target allosteric modulator NA TTD , DGIDB bci-838 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD , DGIDB ly404039 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown 7.96 TTD , DGIDB (1s,3r)-acpd NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target agonist NA TTD , DGIDB oleoyl-estrone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Psychotic Disorders[MeSHID:D011618] phase 2 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD , DGIDB ly2140023 small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] investigational metabotropic glutamate receptor 3 GRM3 NA unknown NA drugbank , DGIDB pmid25435285-compound-16 NA NA patented metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD , DGIDB l-ccg-i NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target agonist NA TTD , DGIDB mni-137 NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD ly-389795 NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD pmid25435285-compound-22 NA NA patented metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD , DGIDB ly-544344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD mni-135 NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD mp-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD eglu NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD ly-379268 NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD ly404039 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 metabotropic glutamate receptor 3 GRM3 Clinical trial target agonist 7.96 TTD , DGIDB (+)-mcpg NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target antagonist NA TTD , DGIDB [3h]quisqualate NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD naag NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target agonist 7.96 TTD , DGIDB pmid25435285-compound-15 NA NA patented metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD , DGIDB [3h]ly341495 NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target antagonist NA TTD , DGIDB r-1578 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD vu0463597 NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD ro-4995819 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown 11.93 TTD , DGIDB pomaglumetad NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD , DGIDB pmid25435285-compound-20 NA NA patented metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD , DGIDB mni-136 NA NA investigative metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD ly354740 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 metabotropic glutamate receptor 3 GRM3 Clinical trial target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical metabotropic glutamate receptor 4 GRM4 NA unknown NA drugbank 5-mpep NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-m-tolyl-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-6-(4-phenylpent-1-ynyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(3-pyridylethynyl)-2-thiazolylamine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-alkylamide derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB afq056 NA Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown 6.7 TTD , DGIDB tetra-hydro-oxazolopyridine derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 6-(4-chlorophenylamino)-n,n-diethylnicotinamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyridine derivative 16 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB bicarboxylic and tricarboxylic ethynyl derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-methyl-6-(phenylethynyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD (e)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-4-p-tolylethynyl-thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrrolidine derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB vu0285683 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-7-phenyl-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD imidazopyridine and triazolopyridine compound 4 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD ncfp NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD br-5mpepy NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid19931453c16m NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-((6-methylpyridin-2-yl)ethynyl)nicotinonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-bromo-n-(6-methylpyridin-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 6-chloro-n-(3-chlorophenyl)quinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-4-(m-tolylethynyl)thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyridine derivative 12 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-chloro-n-(4-methylthiazol-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD (s)-4c3hpg NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD acamprosate small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Alcohol Abstinence[MeSHID:D064829],Maintenance[MeSHID:D008283],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational metabotropic glutamate receptor 5 GRM5 NA antagonist 2.23 drugbank , DGIDB 3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(2-methyl-thiazol-4-ylethynyl)-pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-cyano-n-(3-ethylphenyl)-5-fluorobenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD rg-7090 NA Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown 13.4 TTD , DGIDB n-cyclopentyl-6-(2-phenylethynyl)nicotinamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(4-methoxypyrimidin-2-yl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(3-bromophenyl)-7-methyl-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD tetra-hydro-oxazolopyridine derivative 6 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-methyl-7-m-tolylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid23374867c24 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(4-pyridin-2-yl-pyrazol-1-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(substituted ethynyl)quinoline derivative 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB lsn2463359 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB 2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD [3h]methoxy-pepy NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD vu-1545 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB pmid28067079-compound-98 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-methyl-7-phenylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-phenylethynyl-7,8-dihydro-6h-quinolin-5-one NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD [14c]mtep NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD heterocyclic derivative 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB pmid21927650c18 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyridine derivative 17 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-6-(4-phenylbut-1-ynyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD central azetidine derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-phenylethynyl-5,6,7,8-tetrahydro-quinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD vu0360172 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD ly-3390334 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD (3-(2-methylquinolin-7-yl)phenyl)methanol NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-phenyl-5-(2-methylthiazol-4ylethynyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid28067079-compound-95 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-chloro-n-(3-isobutyramidophenyl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid20598884c8 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD bicyclic heteroaryl carboxamide analog 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB ctep NA Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB 3-chloro-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD diazepinone derivative 4 NA Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Disease[MeSHID:D004194] patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-(3-pyridin-2-yl-pyrrol-1-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrrolidine derivative 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrrolidine derivative 5 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB ethynyl compound 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB imidazopyridine and triazolopyridine compound 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB pyrazolopyrimidine derivative 6 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB vu0240382 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD tetra-hydro-pyrazolopyrazine derivative 4 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 5-(phenylethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-chloro-2-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-ethoxy-5-(m-tolylethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD central azetidine derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-ethynyl-4-(3-fluorophenylethynyl)thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-benzoxy-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 6-bromo-n-m-tolylquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD bicarboxylic and tricarboxylic ethynyl derivative 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD l-ccg-i NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD rti-4229-982 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Infections[MeSHID:D012141] investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(4-methoxyphenyl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-alkylamide derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB adx-63365 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(substituted ethynyl)quinoline derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB (s)-4cpg NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD (3-ethoxy-pyridin-2-yl)-pyridin-2-yl-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid15686941c13 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid20809633c29b NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(2-methoxyphenylethynyl)-2-methylthiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyridine derivative 15 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-methyl-4-(2-thienylethynyl)thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD bicarboxylic and tricarboxylic ethynyl derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB adx-48621 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Mood Disorders[MeSHID:D019964],Dyskinetic syndrome[MeSHID:D020820] phase 2/3 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown 10.05 TTD , DGIDB 3-cyano-5-fluoro-n-m-tolylbenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(substituted ethynyl)quinoline derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 5pam523 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB tetra-hydro-pyrazolopyrazine derivative 5 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB n-(3-bromophenyl)-6-chloroquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(3-bromophenoxy)-6-chloroquinazoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD imidazopyridine and triazolopyridine compound 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB azd2066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Gastroesophageal reflux disease[MeSHID:D005764],Neuralgia[MeSHID:D009437],Major Depressive Disorder[MeSHID:D003865] discontinued in phase 2 metabotropic glutamate receptor 5 GRM5 Clinical trial target modulator 6.7 TTD , DGIDB pyrazolopyrimidine derivative 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-(substituted ethynyl)quinoline derivative 4 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-m-tolyl-1,5-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(m-tolylethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD tetra-hydro-pyrazolopyrazine derivative 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB tetra-hydro-oxazolopyridine derivative 4 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB diazepinone derivative 5 NA Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Disease[MeSHID:D004194] patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 4-(3,5-difluorophenylethynyl)-2-methylthiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-cyano-n-(6-ethylpyridin-2-yl)-5-fluorobenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-iodo-n-(6-methylpyridin-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(3-chlorophenyl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD tetra-hydro-oxazolopyridine derivative 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 7-(3-fluorophenyl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 6-phenylethynyl-nicotinic acid methyl ester NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-cyclohex-1-enylethynyl-pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid14697765c11a NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-7-m-tolyl-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(3-chlorophenylethynyl)-2-methylthiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid21757343c30 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-methyl-n-(6-methylpyridin-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-7-(pyridin-3-yl)quinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD ethynyl compound 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB (s)-(+)-cbpg NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD vu0424465 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD rufinamide small molecule Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved metabotropic glutamate receptor 5 GRM5 NA inhibitor NA drugbank 2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-cyclopent-1-enylethynyl-pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(3-chlorophenyl)-6-methoxyquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-6-(5-phenylpent-1-ynyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-cyano-5-fluoro-n-(pyridin-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid15482906c10 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD m-5mpep NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-cyano-n-(1,4-diphenyl-1h-pyrazol-5-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-4-phenylethynyl-thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid21295468c47 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD imidazopyridine and triazolopyridine compound 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-(1-pyridin-2-yl-1h-pyrazol-3-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(3-methoxyphenyl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD vu0404251 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB 1-(3-(2-methylquinolin-7-yl)phenyl)ethanone NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(2-methoxyphenyl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD diazepinone derivative 2 NA Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Disease[MeSHID:D004194] patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB bicyclic heteroaryl carboxamide analog 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-methyl-4-o-tolylethynyl-thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pteb NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB 4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 6-bromo-n-(3-bromophenyl)quinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD acdpp NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target antagonist NA TTD , DGIDB 3-(2-methylquinolin-7-yl)phenol NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD [3h]methoxymethyl-mtep NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrazolopyrimidine derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 5-methyl-3-phenylethynyl[1,2,4]triazine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-bromo-4-(3-fluorophenylethynyl)thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD imidazo[1,2-a]pyridine derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-(3,4-dimethylphenyl)-1,5-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-(2-methylquinolin-7-yl)-2-phenylnicotinonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD rg7342 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown 6.7 TTD , DGIDB mcn3377 NA Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-cyano-5-fluoro-n-(3-fluorophenyl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD vu0364289 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-chloro-5-(2-methylquinolin-7-yl)nicotinonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD alloswitch-1 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD vu0092273 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD heterocyclic derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 6-fluoro-n-m-tolylquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid14697765c16a NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD dipraglurant small molecule NA investigational metabotropic glutamate receptor 5 GRM5 NA modulator 10.05 drugbank , DGIDB 2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD tetra-hydro-pyrazolopyrazine derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 7-bromo-n-(3-bromophenyl)isoquinolin-1-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid17936624c36 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD (e)-1-adamantan-1-yl-3-quinolin-3-yl-propenone NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(3-chlorophenyl)-6-nitroquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD adx10059 small molecule Anxiety Disorders[MeSHID:D001008],Cluster Headache[MeSHID:D003027],Gastroesophageal reflux disease[MeSHID:D005764],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown 10.05 TTD , drugbank , DGIDB 3-chloro-n-(6-methylpyridin-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-methyl-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-cyclohexylethynyl-pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrazolopyrimidine derivative 5 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB pmid23434029c53 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-(2-(3-chlorophenyl)ethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-methyl-2-phenylpyrido[2,3-d]pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid17189691c42 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-cyano-n-(3-ethynylphenyl)-5-fluorobenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(2-pyridin-2-yl-2h-tetrazol-5-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-cyano-n-(6-methylpyridin-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(3-bromophenyl)-6-fluoroquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrrolidine derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 5-(2-m-tolylethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-[(2-methyl-4-thiazolyl)ethynyl]benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD tetra-hydro-pyrazolopyrazine derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB lsn2814617 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB ethynyl compound 4 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB pyridine derivative 14 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 4-cyano-n-(1,3-diphenyl-1h-pyrazol-5-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 6-bromo-n-(3-fluorophenyl)quinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(3-chlorophenyl)-3-cyano-5-fluorobenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-(2-methylquinolin-7-yl)isophthalonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD vu0463841 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(3,5-dimethoxyphenyl)-1,6-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(2-methyl-thiazol-4-ylethynyl)-pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD heterocyclic derivative 1 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(6-methylpyridin-2-yl)biphenyl-3-carboxamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(1,8-naphthyridin-2-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-bromo-5-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-(2-methylquinolin-7-yl)nicotinonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid17723296c18 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-cyano-5-fluoro-n-phenylbenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD ethynyl compound 5 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB ibotenate NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD cppz NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB 4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-(3-(methoxymethyl)phenyl)-2-methylquinoline NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD [3h]resolvin e1 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD tetra-hydro-oxazolopyridine derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB pmid28067079-compound-97 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-(3-pyridin-2-yl-pyrazol-1-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(3,5-dimethoxyphenyl)-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD (s)-3hpg NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(3-methoxyphenylethynyl)-2-methylthiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(3,4-dimethylphenyl)-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD boma NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB vu0357121 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(1,4-diphenyl-1h-pyrazol-5-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD bicyclic heteroaryl carboxamide analog 3 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB sib-1893 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator 0.67 TTD , DGIDB tetra-hydro-oxazolopyridine derivative 5 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 5-(2-methylquinolin-7-yl)-2-phenylbenzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD grn-529 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB chpg NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target agonist NA TTD , DGIDB 3-cyano-n-(3-cyanophenyl)-5-fluorobenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-cyano-n-(1,3-diphenyl-1h-pyrazol-5-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD vu0361747 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD diazepinone derivative 3 NA Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Disease[MeSHID:D004194] patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB n-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD (1s,3r)-acpd NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD diazepinone derivative 1 NA Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Disease[MeSHID:D004194] patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-[(2-methyl-4-thiazolyl)ethynyl]benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrazolopyrimidine derivative 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrazolopyrimidine derivative 4 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-methoxy-n-(6-methylpyridin-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD dipraglurant small molecule NA investigational metabotropic glutamate receptor 5 GRM5 NA allosteric modulator 10.05 drugbank , DGIDB 3-phenyl-1-(2-methylthiazol-4-ylethynyl)benzene NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(2-fluorophenylethynyl)-2-methylthiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-methoxy-n-(4-methylthiazol-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD sp203 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 6-bromo-n-(3-chlorophenyl)quinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD ethynyl compound 6 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB ethynyl compound 2 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB (+)-mcpg NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD rg7342 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 metabotropic glutamate receptor 5 GRM5 Clinical trial target modulator 6.7 TTD , DGIDB stx-107 NA Autism Spectrum Disorders[MeSHID:D000067877],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659] phase 2 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown 13.4 TTD , DGIDB vu0366058 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-(3-fluorophenylethynyl)-2-thiazolylamine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-biphenyl-4-ylethynyl-pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid15482908c8 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(4-pyridin-2-yl-imidazol-1-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-4-(3-thienylethynyl)thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(phenylethynyl)pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-methyl-7-m-tolyl-1,6-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD azd2066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Gastroesophageal reflux disease[MeSHID:D005764],Neuralgia[MeSHID:D009437],Major Depressive Disorder[MeSHID:D003865] discontinued in phase 2 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown 6.7 TTD , DGIDB n-(3-chlorophenyl)-6-fluoroquinazolin-4-amine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid23357634c24d NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD azd2516 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown 3.35 TTD , DGIDB n-(1,3-diphenyl-1h-pyrazol-5-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(6-methylpyridin-2-yl)-6-phenylnicotinamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-phenyl-1,8-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(3-acetamidophenyl)-3-chlorobenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD mk-3328 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB [3h]quisqualate NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-[(2-methyl-4-thiazolyl)ethynyl]phenol NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-chloro-n-(6-chloropyridin-2-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(5-pyridin-2-yl-tetrazol-2-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-biphenyl-4-ylethynyl-2-methyl-thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 4-biphenyl-2-ylethynyl-2-methyl-thiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(3-bromophenyl)pyrido[2,3-d]pyrimidine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD [3h]fenobam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allodynia[MeSHID:D006930] phase 1 metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB 4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid16439120c26 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-benzyloxy-7,8-dihydro-6h-quinolin-5-one NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid23434029c41 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3,3'-difluorobenzaldazine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB gsk-2210875 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3,5-dhpg NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD n-(6-methylpyridin-2-yl)-5-phenylpicolinamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyrrolidine derivative 4 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 7-m-tolyl-1,6-naphthyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD cppha NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator NA TTD , DGIDB 2-chloro-n-(3-(3-chlorobenzamido)phenyl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-[(6-methylpyridin-2-yl)ethynyl]benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(1-pyridin-2-yl-1h-pyrrol-3-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD sib-1757 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target allosteric modulator 0.48 TTD , DGIDB 3-(6-fluoroquinazolin-4-ylamino)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(1,5-naphthyridin-3-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-(2-methylquinolin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD ethynyl compound 7 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-nitro-n-(1,3-diphenyl-1h-pyrazol-5-yl)benzamide NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pyridine derivative 13 NA NA patented metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD , DGIDB 3-(1-pyridin-2-yl-1h-pyrazol-4-yl)-benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD pmid16439120c20 NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD 3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile NA NA investigative metabotropic glutamate receptor 5 GRM5 Clinical trial target unknown NA TTD mccg NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target antagonist NA TTD , DGIDB lsp4-2022 NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target agonist NA TTD , DGIDB (1s,3r)-acpd NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target agonist NA TTD , DGIDB alpha-methylserine-o-phosphate NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target unknown NA TTD lsp1-2111 NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target unknown NA TTD l-ap4 NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target agonist NA TTD , DGIDB [3h]ly341495 NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target antagonist NA TTD , DGIDB [3h]quisqualate NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target unknown NA TTD amn082 NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target allosteric modulator NA TTD , DGIDB (+)-mcpg NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target antagonist NA TTD , DGIDB mmpip NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target unknown NA TTD mppg NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target antagonist NA TTD , DGIDB l-ccg-i NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target agonist NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical metabotropic glutamate receptor 7 GRM7 NA unknown NA drugbank msoppe NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target antagonist NA TTD , DGIDB l-serine-o-phosphate NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target agonist NA TTD , DGIDB adx71743 NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target allosteric modulator NA TTD , DGIDB map4 NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target antagonist NA TTD , DGIDB xap044 NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target allosteric modulator NA TTD , DGIDB ppg NA NA investigative metabotropic glutamate receptor 7 GRM7 Literature-reported target agonist NA TTD , DGIDB d-ap4 NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target agonist NA TTD , DGIDB l-ccg-i NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target agonist NA TTD , DGIDB cppg NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target unknown NA TTD l-serine-o-phosphate NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target agonist NA TTD , DGIDB map4 NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target unknown NA TTD l-ap4 NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target agonist NA TTD , DGIDB [3h]quisqualate NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target unknown NA TTD az12216052 NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target allosteric modulator NA TTD , DGIDB acpt-i NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target unknown NA TTD mppg NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target antagonist NA TTD , DGIDB (s)-3,4-dcpg NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target agonist NA TTD , DGIDB (1s,3r)-acpd NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target agonist NA TTD , DGIDB 2-amino-4-phosphono-butyric acid NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target unknown NA TTD alpha-methylserine-o-phosphate NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical metabotropic glutamate receptor 8 GRM8 NA unknown NA drugbank (r,s)-4-phosphonophenylglycine NA NA investigative metabotropic glutamate receptor 8 GRM8 Literature-reported target unknown NA TTD jmv 1719 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD jmv 1801 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD jmv 1802 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD neuromedin b NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target agonist NA TTD , DGIDB jmv 1535 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD jmv 1803 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD (ch3)cco-his-trp-ala-val-gly-his-leu-met-nh2 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD 177-lu-neob NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD jmv 1813 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD ac-his-trp-ala-val-ala-his-leu-met-nh2 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD [tyr4]bombesin NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD (d)phe-gln-trp-ala-val-gly-his-leu-leu-nh2 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD [(n4-bzdig)0]bb(7-14) NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD [n40,pro1,tyr4,nle 14]bb NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD bantag-1 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target antagonist NA TTD , DGIDB jmv 1799 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD jmv 1693 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD [(n4-bzdig)0,nle14]bb(7-14) NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD rc-3095 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD , DGIDB 177lu-labelled neobomb1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD kuwanon h NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD ac-his-trp-ala-val-d-ala-his-leu-met-nh2 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD mk-5046 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target agonist 10.61 TTD , DGIDB bombesin NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target agonist 15.91 TTD , DGIDB pd 168368 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target antagonist NA TTD , DGIDB [n40,pro1,tyr4]bb NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD 177lu-amba NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD , DGIDB ranatensin NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target agonist NA TTD , DGIDB 177lu-labelled rm2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD ac-his-trp-ala-val-gly-his-leu-met-nh2 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD pd 176252 NA NA investigative gastrin-releasing peptide receptor GRPR Clinical trial target antagonist NA TTD , DGIDB bim-26226 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD asp-7147 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 gastrin-releasing peptide receptor GRPR Clinical trial target unknown NA TTD , DGIDB 5-iodotubercidin small molecule NA experimental serine/threonine-protein kinase haspin GSG2 NA unknown NA drugbank 3-(3-aminophenyl)-n-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine small molecule NA experimental serine/threonine-protein kinase haspin GSG2 NA unknown NA drugbank h-89 small molecule NA experimental serine/threonine-protein kinase haspin GSG2 NA unknown NA drugbank (2s)-2-{[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino}-3-methylbutan-1-ol small molecule NA experimental serine/threonine-protein kinase haspin GSG2 NA unknown NA drugbank thiadiazolidindione derivative 1 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB ar-534 NA NA investigative glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD isis 116631 NA NA investigative gsk3a messenger rna GSK3A Literature-reported target unknown NA TTD ly2090314 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 glycogen synthase kinase-3 alpha GSK3A Successful target unknown 0.17 TTD , DGIDB thiadiazolidindione derivative 2 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB pmid27828716-compound-15 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB pyrazolodihydropyridine derivative 1 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB pmid27828716-compound-bio-acetoxime NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Glioma[MeSHID:D005910] patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB chir-98014 NA NA investigative gsk3a messenger rna GSK3A Literature-reported target inhibitor NA TTD , DGIDB kenpaullone NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown 0.1 TTD , DGIDB pmid27828716-compound-17 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB isis 116648 NA NA investigative gsk3a messenger rna GSK3A Literature-reported target unknown NA TTD benzofuran-3-yl-(indol-3-yl)maleimides NA NA investigative glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD maleimides derivative 1 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB indazole derivative 6 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB quinoline derivative 15 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB chir-99021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Graft Rejection[MeSHID:D006084] patented glycogen synthase kinase-3 alpha GSK3A Successful target inhibitor 0.62 TTD , DGIDB isis 116670 NA NA investigative gsk3a messenger rna GSK3A Literature-reported target unknown NA TTD tricyclic 5-quinolone derivative 1 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB chir-99021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Graft Rejection[MeSHID:D006084] patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown 0.62 TTD , DGIDB pmid27828716-compound-20 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB n-naphtyl-n-benzylurea derivative 1 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB leucettamine b NA NA investigative gsk3a messenger rna GSK3A Literature-reported target unknown NA TTD isis 116654 NA NA investigative gsk3a messenger rna GSK3A Literature-reported target unknown NA TTD isis 116632 NA NA investigative gsk3a messenger rna GSK3A Literature-reported target unknown NA TTD aloisine a NA NA investigative gsk3a messenger rna GSK3A Literature-reported target inhibitor NA TTD , DGIDB pmid27828716-compound-18 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB pmid27828716-compound-19 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB maleimides derivative 3 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB indirubin deriv. 8a NA NA investigative gsk3a messenger rna GSK3A Literature-reported target unknown NA TTD spiroquinolone derivative 1 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB quinolinyl pyrazinyl urea derivative 2 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB pmid27828716-compound-16 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB pmid27828716-compound-21 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB isis 116625 NA NA investigative gsk3a messenger rna GSK3A Literature-reported target unknown NA TTD sb216763 NA NA investigative glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD quinoline derivative 14 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB thiadiazolidindione derivative 3 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB maleimides derivative 2 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB tdzd-8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Glioma[MeSHID:D005910] patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB ar-a014418 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown 0.76 TTD , DGIDB quinolinyl pyrazinyl urea derivative 1 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational glycogen synthase kinase-3 alpha GSK3A NA inhibitor NA drugbank lithium chloride NA NA investigative glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD pyrazole and benzimidazole derivative 1 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB indirubin derivative 2 NA NA patented glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB lithium NA Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD valproate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD , DGIDB 6-bromoindirubin-3-oxime NA NA investigative glycogen synthase kinase-3 alpha GSK3A Successful target unknown NA TTD chir-98023 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-(pyridin-4-yl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD azd-1080 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 0.14 TTD , DGIDB lithium NA Fragile X Syndrome[MeSHID:D005600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 0.21 TTD , DGIDB (2s)-1-(1h-indol-3-yl)-3-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}propan-2-amine small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank cp-70949 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD neu-120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD , DGIDB n-(6-benzyl-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 6-deoxymanzamine x NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 9-ing-41 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Malignant Neoplasms[MeSHID:D009369] phase 2 glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD alsterpaullone small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA inhibitor 0.12 drugbank , DGIDB k00244 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD l-779450 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD (e)-n-(6-(prop-1-enyl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-chloro-5-phenyl-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 5-(5-chloro-7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank n-(6-(trifluoromethyl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD tdzd-8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Glioma[MeSHID:D005910] patented glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD , DGIDB sb-409513 small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank n-(6-(4-hydroxyphenyl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD im-12 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor NA TTD , DGIDB azakenpaullone NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 0.12 TTD , DGIDB ly2090314 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor 0.14 TTD , DGIDB gsk-3beta inhibitor xi NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD (2'z,3'e)-7-azaindirubin-3'-oxime NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD lithium cation small molecule Bipolar Disorder[MeSHID:D001714],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Depressive disorder[MeSHID:D003866] experimental glycogen synthase kinase-3 beta GSK3B NA inhibitor NA drugbank bx-795 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor 0.2 TTD , DGIDB pmid19115845c89s NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(8-(3-cyanophenyl)-9h-purin-6-yl)pentanamide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 4-(4-chlorophenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD neo-kauluamine NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-phenethyl-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD nu-6102 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD phosphoaminophosphonic acid-adenylate ester small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank tideglusib small molecule Amyloidosis[MeSHID:D000686],Brain[MeSHID:D001921],Transcriptional Activation[MeSHID:D015533],Disease[MeSHID:D004194],Cessation of life[MeSHID:D003643],Progressive supranuclear palsy[MeSHID:D013494],Cell Survival[MeSHID:D002470],Up-Regulation (Physiology)[MeSHID:D015854],Precipitating Factors[MeSHID:D015985],Neurons[MeSHID:D009474],Transcription, Genetic[MeSHID:D014158],Dental caries[MeSHID:D003731],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteosarcoma[MeSHID:D012516] investigational,withdrawn,phase 2 glycogen synthase kinase-3 beta GSK3B Clinical trial target antagonist,inhibitor 3.06 TTD , drugbank , DGIDB as-601245 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational glycogen synthase kinase-3 beta GSK3B NA inhibitor NA drugbank manzamine e NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD sb-415286 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor 0.06 TTD , DGIDB rgb-286147 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-chloro-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD gsk-3beta inhibitor ii NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor NA TTD , DGIDB alsterpaullone 2-cyanoethyl NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor NA TTD , DGIDB indirubin deriv. 8a NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD indirubin-3'-monoxime small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA inhibitor NA drugbank , DGIDB n-(6-(4-fluorophenyl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-bromo-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD chir-99021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Graft Rejection[MeSHID:D006084] patented glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor 0.33 TTD , DGIDB tideglusib small molecule Amyloidosis[MeSHID:D000686],Brain[MeSHID:D001921],Transcriptional Activation[MeSHID:D015533],Disease[MeSHID:D004194],Cessation of life[MeSHID:D003643],Progressive supranuclear palsy[MeSHID:D013494],Cell Survival[MeSHID:D002470],Up-Regulation (Physiology)[MeSHID:D015854],Precipitating Factors[MeSHID:D015985],Neurons[MeSHID:D009474],Transcription, Genetic[MeSHID:D014158],Dental caries[MeSHID:D003731],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] investigational,withdrawn,phase 2 glycogen synthase kinase-3 beta GSK3B Clinical trial target antagonist,inhibitor 3.06 TTD , drugbank , DGIDB staurosporinone NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 3-[3-(2,3-dihydroxy-propylamino)-phenyl]-4-(5-fluoro-1-methyl-1h-indol-3-yl)-pyrrole-2,5-dione small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank n-(6-chloro-5-p-tolyl-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD ci-1040 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 0.05 TTD , DGIDB 9-n-ethyl-8-ethoxy-manzamine a NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD ly2090314 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 0.14 TTD , DGIDB i-5 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-(4-aminophenyl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 6-bromoindirubin-3'-oxime small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank pf-228 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD tws-119 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD staurosporine small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank lithium carbonate small molecule Bipolar Disorder[MeSHID:D001714],Mood (psychological function)[MeSHID:D000339],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glycogen synthase kinase-3 beta GSK3B NA inhibitor 0.41 drugbank , DGIDB ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n,8-diphenyl-9h-purin-6-amine NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD tideglusib small molecule Amyloidosis[MeSHID:D000686],Brain[MeSHID:D001921],Transcriptional Activation[MeSHID:D015533],Disease[MeSHID:D004194],Cessation of life[MeSHID:D003643],Progressive supranuclear palsy[MeSHID:D013494],Cell Survival[MeSHID:D002470],Up-Regulation (Physiology)[MeSHID:D015854],Precipitating Factors[MeSHID:D015985],Neurons[MeSHID:D009474],Transcription, Genetic[MeSHID:D014158],Dental caries[MeSHID:D003731],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteosarcoma[MeSHID:D012516] investigational,withdrawn,phase 2 glycogen synthase kinase-3 beta GSK3B Clinical trial target antagonist 3.06 TTD , drugbank , DGIDB thieno analogue of kenpaullone NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD manzamine y NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-(thiophen-3-yl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD quinoxaline1 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD dm-204 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-(2-chlorophenyl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD (7s)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank tideglusib small molecule Amyloidosis[MeSHID:D000686],Brain[MeSHID:D001921],Transcriptional Activation[MeSHID:D015533],Disease[MeSHID:D004194],Cessation of life[MeSHID:D003643],Progressive supranuclear palsy[MeSHID:D013494],Cell Survival[MeSHID:D002470],Up-Regulation (Physiology)[MeSHID:D015854],Precipitating Factors[MeSHID:D015985],Neurons[MeSHID:D009474],Transcription, Genetic[MeSHID:D014158],Dental caries[MeSHID:D003731],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] investigational,withdrawn,phase 2 glycogen synthase kinase-3 beta GSK3B Clinical trial target antagonist 3.06 TTD , drugbank , DGIDB 9-n-methyl-8-methoxy-manzamine a NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-(pyridin-3-yl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 3-({[(3s)-3,4-dihydroxybutyl]oxy}amino)-1h,2'h-2,3'-biindol-2'-one small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank kenpaullone NA NA patented glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor 0.08 TTD , DGIDB isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)ethylamino)ethyl)amide small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank 3-(6-(phenylamino)-9h-purin-8-yl)benzonitrile NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD lithium succinate small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank n-[(1s)-2-amino-1-phenylethyl]-5-(1h-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank 3-phenyl-4-(phenylamino)-1h-pyrrole-2,5-dione NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD chir-98014 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor NA TTD , DGIDB azd-1080 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor 0.14 TTD , DGIDB 12,13-dehydro-8-o-acetylmanzamine a NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 4-(5-bromo-1h-indol-3-yl)pyrimidin-2-amine NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD pyrazolopyridazine 1 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 8-o-(4-chlorobenzenesulfonyl)manzamine f NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD pyrazolopyridazine 2 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD manzamine a NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 2.45 TTD , DGIDB amo-02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myotonic Dystrophy[MeSHID:D009223] phase 2/3 glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD , DGIDB leucettamine b NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD pmid26161698-compound-18 NA NA patented glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD , DGIDB paullone NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 8-o-(4-toluenesulfonyl)manzamine a NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD amp-pnp NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD 8-oh-manzamine a NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD kenpaullone NA NA patented glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 0.08 TTD , DGIDB 12,13-dehydromanzamine a NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD bx-912 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target inhibitor NA TTD , DGIDB ct-98024 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD ro31-8220 NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD lithium citrate small molecule Bipolar Disorder[MeSHID:D001714],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank ar-ao-14418 small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank 8-o-(4-bromobenzenesulfonyl)manzamine f NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-(3-hydroxyphenyl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-[2-(5-methyl-4h-1,2,4-triazol-3-yl)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank 5-[1-(4-methoxyphenyl)-1h-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3h)-thione small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown NA drugbank ar-a014418 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] patented glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 1.02 TTD , DGIDB bisindolylmaleimide-i NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD chir-99021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Graft Rejection[MeSHID:D006084] patented glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown 0.33 TTD , DGIDB alsterpaullone small molecule NA experimental glycogen synthase kinase-3 beta GSK3B NA unknown 0.12 drugbank , DGIDB n-(6-(furan-3-yl)-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD n-(6-phenyl-1h-indazol-3-yl)butyramide NA NA investigative glycogen synthase kinase-3 beta GSK3B Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational gelsolin GSN NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational gelsolin GSN NA unknown NA drugbank latrunculin a small molecule NA experimental gelsolin GSN NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gelsolin GSN NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental eukaryotic peptide chain release factor gtp-binding subunit erf3a GSPT1 NA unknown NA drugbank 4-nitrobenzo[c][1,2,5]thiadiazole NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD golden phosphorous acetyletic compound 1 NA NA patented glutathione reductase GSR Patented-recorded target unknown NA TTD glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione reductase, mitochondrial GSR NA unknown NA drugbank terpyridineplatinum(ii) complexe 4 NA NA patented glutathione reductase GSR Patented-recorded target unknown NA TTD 3-nitro-l-tyrosine small molecule NA experimental glutathione reductase, mitochondrial GSR NA unknown NA drugbank terpyridineplatinum(ii) complexe 3 NA NA patented glutathione reductase GSR Patented-recorded target unknown NA TTD n-6547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] investigative glutathione reductase GSR Patented-recorded target unknown NA TTD 3-(prop-2-ene-1-sulfinyl)-propene-1-thiol NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD carmustine small molecule Multiple Myeloma[MeSHID:D009101],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],Brain Neoplasms[MeSHID:D001932] approved,investigational glutathione reductase, mitochondrial GSR NA inhibitor 4.24 drugbank , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational glutathione reductase, mitochondrial GSR NA stimulator NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved glutathione reductase, mitochondrial GSR NA unknown NA drugbank 3-sulfino-l-alanine small molecule NA experimental glutathione reductase, mitochondrial GSR NA unknown NA drugbank 6-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)hexanoic acid small molecule NA experimental glutathione reductase, mitochondrial GSR NA unknown NA drugbank n-9xxx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vascular Diseases[MeSHID:D014652] investigative glutathione reductase GSR Patented-recorded target unknown NA TTD trans-(r(s))-2-hydroxy-1-phenylethyl nitrate NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD nicotinamide-adenine-dinucleotide NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD glutathionylspermidine disulfide small molecule NA experimental glutathione reductase, mitochondrial GSR NA unknown NA drugbank 1-(2'-chlorophenyl)penta-1,4-dien-3-one NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD 3,6-dihydroxy-xanthene-9-propionic acid NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD oxidized glutathione NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Bacterial Infections[MeSHID:D001424] approved glutathione reductase GSR Patented-recorded target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical glutathione reductase, mitochondrial GSR NA unknown NA drugbank glutathionylspermidine disulfide NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD trans-(1s(r),2s(r))-2-hydroxycyclooctyl nitrate NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD 2,4,6 trinitrobenzene sulfonate 1,3-bis (2-chlorethyl)-1-nitrosourea NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD medical cannabis biotech NA experimental,investigational glutathione reductase, mitochondrial GSR NA inducer NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational glutathione reductase, mitochondrial GSR NA stimulator NA drugbank flavin-adenine dinucleotide NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD 2-(2-phenyl-3-pyridin-2-yl-4,5,6,7-tetrahydro-2h-isophosphindol-1-yl)pyridine small molecule NA experimental glutathione reductase, mitochondrial GSR NA unknown NA drugbank 3,6-dihydroxy-xanthene-9-propionic acid small molecule NA experimental glutathione reductase, mitochondrial GSR NA unknown NA drugbank meta-nitro-tyrosine NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD acyl oxymethyl acrylamide ester derivative 1 NA NA patented glutathione reductase GSR Patented-recorded target unknown NA TTD golden phosphorous acetyletic compound 2 NA NA patented glutathione reductase GSR Patented-recorded target unknown NA TTD n-6060 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative glutathione reductase GSR Patented-recorded target unknown NA TTD 3-(prop-2-ene-1-sulfinyl)-propene-1-thiol small molecule NA experimental glutathione reductase, mitochondrial GSR NA unknown NA drugbank 3-sulfinoalanine NA NA investigative glutathione reductase GSR Patented-recorded target unknown NA TTD glutathione disulfide small molecule NA approved,experimental,investigational glutathione reductase, mitochondrial GSR NA substrate NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutathione reductase, mitochondrial GSR NA unknown NA drugbank acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational glutathione synthetase GSS NA stimulator NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved glutathione synthetase GSS NA substrate NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutathione synthetase GSS NA unknown NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical glutathione synthetase GSS NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental glutathione synthetase GSS NA unknown NA drugbank gamma-glutamylcysteine small molecule NA experimental glutathione synthetase GSS NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione synthetase GSS NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTA1 NA activator NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase a1 GSTA1 NA unknown NA drugbank glutathione sulfonic acid small molecule NA experimental glutathione s-transferase a1 GSTA1 NA unknown NA drugbank n-(4-aminobutanoyl)-s-(4-methoxybenzyl)-l-cysteinylglycine small molecule NA experimental glutathione s-transferase a1 GSTA1 NA unknown NA drugbank s-hexylglutathione small molecule NA experimental glutathione s-transferase a1 GSTA1 NA ligand NA drugbank s-hydroxycysteine small molecule NA experimental glutathione s-transferase a1 GSTA1 NA unknown NA drugbank s-benzylglutathione small molecule NA experimental glutathione s-transferase a1 GSTA1 NA unknown NA drugbank hypericin small molecule NA investigational glutathione s-transferase a1 GSTA1 NA unknown NA drugbank 2-hydroxyethyl disulfide small molecule NA experimental glutathione s-transferase a1 GSTA1 NA unknown NA drugbank chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved,investigational,vet_approved glutathione s-transferase a2 GSTA2 NA inhibitor NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase a2 GSTA2 NA unknown NA drugbank chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Malaria[MeSHID:D008288],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved glutathione s-transferase a2 GSTA2 NA inhibitor NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTA2 NA activator NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase a3 GSTA3 NA unknown NA drugbank 4-s-glutathionyl-5-pentyl-tetrahydro-furan-2-ol small molecule NA experimental glutathione s-transferase a3 GSTA3 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase a4 GSTA4 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase a5 GSTA5 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase kappa 1 GSTK1 NA unknown NA drugbank glutathione sulfinate small molecule NA experimental glutathione s-transferase kappa 1 GSTK1 NA unknown NA drugbank chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Malaria[MeSHID:D008288],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved glutathione s-transferase mu 1 GSTM1 NA inhibitor NA drugbank (9r,10r)-9-(s-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene small molecule NA experimental glutathione s-transferase mu 1 GSTM1 NA unknown NA drugbank 5-fluorotryptophan small molecule NA experimental glutathione s-transferase mu 1 GSTM1 NA unknown NA drugbank s-(2,4-dinitrophenyl)glutathione small molecule NA experimental glutathione s-transferase mu 1 GSTM1 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTM1 NA activator NA drugbank zinc trihydroxide small molecule NA experimental glutathione s-transferase mu 1 GSTM1 NA unknown NA drugbank (9s,10s)-9-(s-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene small molecule NA experimental glutathione s-transferase mu 1 GSTM1 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase mu 1 GSTM1 NA unknown NA drugbank chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved,investigational,vet_approved glutathione s-transferase mu 1 GSTM1 NA inhibitor NA drugbank s-(2,4-dinitrophenyl)glutathione small molecule NA experimental glutathione s-transferase mu 2 GSTM2 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferase mu 2 GSTM2 NA activator NA drugbank s-methyl glutathione small molecule NA experimental glutathione s-transferase mu 2 GSTM2 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase mu 2 GSTM2 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTM2 NA activator NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase mu 3 GSTM3 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTM3 NA activator NA drugbank glutathione sulfonic acid small molecule NA experimental glutathione s-transferase mu 4 GSTM4 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTM4 NA activator NA drugbank 1-hydroxy-2-s-glutathionyl-3-para-nitrophenoxy-propane small molecule NA experimental glutathione s-transferase mu 4 GSTM4 NA unknown NA drugbank s-hexylglutathione small molecule NA experimental glutathione s-transferase mu 4 GSTM4 NA unknown NA drugbank s-octylglutathione small molecule NA experimental glutathione s-transferase mu 4 GSTM4 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase mu 4 GSTM4 NA unknown NA drugbank gamma-glutamyl[s-(2-iodobenzyl)cysteinyl]glycine small molecule NA experimental glutathione s-transferase mu 4 GSTM4 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase mu 5 GSTM5 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTM5 NA activator NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase omega-1 GSTO1 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase omega-2 GSTO2 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTP1 NA activator NA drugbank dinitrochlorobenzene small molecule NA investigational glutathione s-transferase p GSTP1 NA unknown NA drugbank troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn glutathione s-transferase p GSTP1 NA unknown NA drugbank etacrynic acid small molecule Hypertensive disease[MeSHID:D006973],Kidney Failure[MeSHID:D051437],Liver Failure[MeSHID:D017093],Edema[MeSHID:D004487],Congestive heart failure[MeSHID:D006333] approved,investigational glutathione s-transferase p GSTP1 NA inhibitor NA drugbank cibacron blue small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank s-(4-bromobenzyl)cysteine small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase p GSTP1 NA unknown NA drugbank curcumin sulfate small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank clomipramine small molecule Premature Ejaculation[MeSHID:D061686],Premenstrual syndrome[MeSHID:D011293],Stuttering[MeSHID:D013342],Narcolepsy[MeSHID:D009290],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Trichotillomania[MeSHID:D014256],Obsessive-Compulsive Disorder[MeSHID:D009771],Pain[MeSHID:D010146],Mental Depression[MeSHID:D003863],Chronic pain[MeSHID:D059350],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autistic Disorder[MeSHID:D001321],Tension Headache[MeSHID:D018781],Neuralgia[MeSHID:D009437],Cataplexy[MeSHID:D002385],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Personality[MeSHID:D003193],Pain Disorder[MeSHID:D013001],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glutathione s-transferase p GSTP1 NA inhibitor NA drugbank s-hexylglutathione small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank s-(4-nitrobenzyl)glutathione small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank exisulind small molecule Disease[MeSHID:D004194],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Esophagus[MeSHID:D004947],Colonic Polyps[MeSHID:D003111],Barrett Esophagus[MeSHID:D001471],Esophageal Diseases[MeSHID:D004935],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glutathione s-transferase p GSTP1 NA inhibitor NA drugbank s-hydroxycysteine small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank deoxycholic acid small molecule NA approved glutathione s-transferase p GSTP1 NA unknown NA drugbank ezatiostat small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 glutathione s-transferase p GSTP1 Clinical trial target unknown 3.98 TTD , drugbank , DGIDB 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank hypericin small molecule NA investigational glutathione s-transferase p GSTP1 NA unknown NA drugbank clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glutathione s-transferase p GSTP1 NA unknown NA drugbank s-nonyl-cysteine small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank (9r,10r)-9-(s-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank curcumin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational glutathione s-transferase p GSTP1 NA unknown 0.06 drugbank , DGIDB canfosfamide small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 glutathione s-transferase p GSTP1 Clinical trial target unknown 5.3 TTD , drugbank , DGIDB nbf-006 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 1 gstp1 messenger rna GSTP1 Clinical trial target unknown NA TTD glutathione sulfonic acid small molecule NA experimental glutathione s-transferase p GSTP1 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTT1 NA activator NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical glutathione s-transferase theta-1 GSTT1 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTT2 NA activator NA drugbank s-hexylglutathione small molecule NA experimental glutathione s-transferase theta-2 GSTT2 NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) GSTT2B NA activator NA drugbank dichloroacetic acid small molecule NA approved,investigational maleylacetoacetate isomerase GSTZ1 NA unknown NA drugbank , DGIDB 1,4-dithiothreitol small molecule NA experimental maleylacetoacetate isomerase GSTZ1 NA unknown NA drugbank glycerin small molecule NA approved,investigational maleylacetoacetate isomerase GSTZ1 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical maleylacetoacetate isomerase GSTZ1 NA unknown NA drugbank myristic acid small molecule NA experimental guanylyl cyclase-activating protein 1 GUCA1A NA unknown NA drugbank isosorbide small molecule Glaucoma[MeSHID:D005901],Ocular Hypotension[MeSHID:D015814] approved,investigational guanylate cyclase GUCY1A1 NA activator NA drugbank isosorbide small molecule Glaucoma[MeSHID:D005901],Ocular Hypotension[MeSHID:D015814] approved,investigational guanylate cyclase GUCY1A2 NA activator NA drugbank nitric oxide small molecule Hypoxia[MeSHID:D000860],Respiratory Failure[MeSHID:D012131],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA inducer,activator 1.52 drugbank , DGIDB isosorbide mononitrate small molecule Coronary Arteriosclerosis[MeSHID:D003324],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hydrocephalus[MeSHID:D006849] approved guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA activator 1.82 drugbank , DGIDB methylene blue small molecule Hypotension[MeSHID:D007022],Hypoxia[MeSHID:D000860],Liver Cirrhosis[MeSHID:D008103],Hepatopulmonary Syndrome[MeSHID:D020065],Methemoglobinemia[MeSHID:D008708],Urinary tract infection[MeSHID:D014552],Neurotoxicity Syndromes[MeSHID:D020258],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA inhibitor NA drugbank nitric oxide small molecule Hypoxia[MeSHID:D000860],Respiratory Failure[MeSHID:D012131],Term Birth[MeSHID:D047929],Tinea Pedis[MeSHID:D014008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA inducer NA drugbank , DGIDB riociguat small molecule Familial primary pulmonary hypertension[MeSHID:D065627],Operative Surgical Procedures[MeSHID:D013514],Connective Tissue Diseases[MeSHID:D003240],Pulmonary Hypertension[MeSHID:D006976],Recurrence (disease attribute)[MeSHID:D012008],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA agonist,stimulator,positive modulator 7.27 drugbank , DGIDB nitric oxide small molecule Hypoxia[MeSHID:D000860],Respiratory Failure[MeSHID:D012131],Term Birth[MeSHID:D047929],Tinea Pedis[MeSHID:D014008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA inducer,activator 1.52 drugbank , DGIDB methylene blue small molecule Hypotension[MeSHID:D007022],Hypoxia[MeSHID:D000860],Liver Cirrhosis[MeSHID:D008103],Hepatopulmonary Syndrome[MeSHID:D020065],Methemoglobinemia[MeSHID:D008708],Urinary tract infection[MeSHID:D014552],Neurotoxicity Syndromes[MeSHID:D020258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA inhibitor NA drugbank nitric oxide small molecule Hypoxia[MeSHID:D000860],Respiratory Failure[MeSHID:D012131],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA inducer NA drugbank , DGIDB plecanatide small molecule Defecation[MeSHID:D003672],Intestinal Secretions[MeSHID:D007419],Body Fluids[MeSHID:D001826],Upper Gastrointestinal Tract[MeSHID:D041742],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Constipation[MeSHID:D003248] approved,investigational guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA agonist NA drugbank riociguat small molecule Familial primary pulmonary hypertension[MeSHID:D065627],Operative Surgical Procedures[MeSHID:D013514],Connective Tissue Diseases[MeSHID:D003240],Pulmonary Hypertension[MeSHID:D006976],Recurrence (disease attribute)[MeSHID:D012008],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA agonist,stimulator 7.27 drugbank , DGIDB molsidomine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Angina Pectoris[MeSHID:D000787],Myocardial Ischemia[MeSHID:D017202],Congestive heart failure[MeSHID:D006333],Pulmonary Hypertension[MeSHID:D006976],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational guanylate cyclase soluble subunit alpha-2 GUCY1A2 NA agonist NA drugbank vericigiuat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 guanylate cyclase soluble beta-1 GUCY1B1 Clinical trial target unknown NA TTD , DGIDB rig-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 guanylate cyclase soluble beta-1 GUCY1B1 Clinical trial target unknown NA TTD isosorbide small molecule Glaucoma[MeSHID:D005901],Ocular Hypotension[MeSHID:D015814] approved,investigational guanylate cyclase GUCY1B1 NA activator NA drugbank cinaciguat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 guanylate cyclase soluble beta-1 GUCY1B1 Clinical trial target unknown 9.09 TTD , DGIDB vericiguat small molecule Heart failure[MeSHID:D006333],Cessation of life[MeSHID:D003643],Hospitalization[MeSHID:D006760],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational guanylate cyclase soluble subunit beta-1 GUCY1B1 NA stimulator NA drugbank isosorbide small molecule Glaucoma[MeSHID:D005901],Ocular Hypotension[MeSHID:D015814] approved,investigational guanylate cyclase GUCY1B2 NA activator NA drugbank linaclotide small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved heat-stable enterotoxin receptor GUCY2C NA agonist 79.56 drugbank , DGIDB sp-333 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 2 guanylyl cyclase c GUCY2C Successful target unknown 31.83 TTD , DGIDB md-1100 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Constipation[MeSHID:D003248] approved guanylyl cyclase c GUCY2C Successful target unknown 79.56 TTD , DGIDB pf-07062119 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 guanylyl cyclase c GUCY2C Successful target unknown NA TTD linaclotide NA Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved guanylyl cyclase c GUCY2C Successful target unknown 79.56 TTD , DGIDB mln0264 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] phase 2 guanylyl cyclase c GUCY2C Successful target unknown 15.91 TTD , DGIDB plecanatide NA Defecation[MeSHID:D003672],Intestinal Secretions[MeSHID:D007419],Body Fluids[MeSHID:D001826],Upper Gastrointestinal Tract[MeSHID:D041742],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Constipation[MeSHID:D003248] approved guanylyl cyclase c GUCY2C Successful target agonist 63.65 TTD , DGIDB plecanatide NA Defecation[MeSHID:D003672],Intestinal Secretions[MeSHID:D007419],Body Fluids[MeSHID:D001826],Upper Gastrointestinal Tract[MeSHID:D041742],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Constipation[MeSHID:D003248] approved guanylyl cyclase c GUCY2C Successful target unknown 63.65 TTD , DGIDB linaclotide NA Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved guanylyl cyclase c GUCY2C Successful target agonist 79.56 TTD , DGIDB bay412272 NA NA investigative soluble guanylyl cyclase GUCY2D Successful target unknown NA TTD vericiguat NA Heart failure[MeSHID:D006333],Cessation of life[MeSHID:D003643],Hospitalization[MeSHID:D006760],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved soluble guanylyl cyclase GUCY2D Successful target unknown NA TTD fk-409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 2 soluble guanylyl cyclase GUCY2D Successful target unknown 31.83 TTD , DGIDB odq NA NA investigative soluble guanylyl cyclase GUCY2D Successful target unknown NA TTD riociguat NA Familial primary pulmonary hypertension[MeSHID:D065627],Operative Surgical Procedures[MeSHID:D013514],Connective Tissue Diseases[MeSHID:D003240],Pulmonary Hypertension[MeSHID:D006976],Recurrence (disease attribute)[MeSHID:D012008],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved soluble guanylyl cyclase GUCY2D Successful target unknown 6.37 TTD , DGIDB ns 2028 NA NA investigative soluble guanylyl cyclase GUCY2D Successful target unknown NA TTD guanosine-5'-monophosphate small molecule NA experimental guanylate kinase GUK1 NA unknown NA drugbank vestronidase alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] approved beta-glucuronidase GUSB Successful target unknown NA TTD , DGIDB periopatch NA Periodontal Diseases[MeSHID:D010510],Gingival Diseases[MeSHID:D005882],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 beta-glucuronidase GUSB Successful target unknown NA TTD , DGIDB uridine-5'-diphosphate small molecule NA experimental glycogenin-1 GYG1 NA unknown NA drugbank uridine diphosphate glucose small molecule NA experimental glycogenin-1 GYG1 NA unknown NA drugbank pmid12127536c20 NA NA investigative granzyme b GZMB Literature-reported target unknown NA TTD vda-1124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aortic Aneurysm[MeSHID:D001014] investigative granzyme b GZMB Literature-reported target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical gdh/6pgl endoplasmic bifunctional protein H6PD NA unknown NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved hyaluronan-binding protein 2 HABP2 NA binder NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved intracellular hyaluronan-binding protein 4 HABP4 NA binder NA drugbank omega-3-carboxylic acids small molecule Hippocampus Proper[MeSHID:D006624],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Alcohol consumption[MeSHID:D000428],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Neoplasm Metastasis[MeSHID:D009362],Plasma[MeSHID:D010949],Obesity[MeSHID:D009765],Metabolic Syndrome X[MeSHID:D024821] approved,investigational hydroxyacyl-coenzyme a dehydrogenase, mitochondrial HADH NA potentiator NA drugbank acetoacetyl-coa small molecule NA experimental hydroxyacyl-coenzyme a dehydrogenase, mitochondrial HADH NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical hydroxyacyl-coenzyme a dehydrogenase, mitochondrial HADH NA unknown NA drugbank 3-hydroxybutyryl-coenzyme a small molecule NA experimental hydroxyacyl-coenzyme a dehydrogenase, mitochondrial HADH NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical trifunctional enzyme subunit alpha, mitochondrial HADHA NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical hydroxyacylglutathione hydrolase, mitochondrial HAGH NA unknown NA drugbank s-(n-hydroxy-n-bromophenylcarbamoyl)glutathione small molecule NA experimental hydroxyacylglutathione hydrolase, mitochondrial HAGH NA unknown NA drugbank histidine small molecule Serum[MeSHID:D044967],Uremia[MeSHID:D014511],Anemia[MeSHID:D000740],Rheumatoid Arthritis[MeSHID:D001172] investigational,nutraceutical histidine ammonia-lyase HAL NA unknown NA drugbank hepcidin mab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 1 hepcidin HAMP Clinical trial target unknown NA TTD , DGIDB nox-h94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2 hepcidin HAMP Clinical trial target unknown 63.65 TTD , DGIDB ptg-300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemochromatosis[MeSHID:D006432],Polycythemia Vera[MeSHID:D011087] phase 2 hepcidin HAMP Clinical trial target unknown NA TTD ly2787106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 1 hepcidin HAMP Clinical trial target unknown NA TTD ljpc-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],beta Thalassemia[MeSHID:D017086],Hemochromatosis[MeSHID:D006432] phase 2 hepcidin HAMP Clinical trial target unknown NA TTD 12b9m NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] preclinical hepcidin HAMP Clinical trial target unknown NA TTD lumasiran NA Primary hyperoxaluria, type I[MeSHID:C536414],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperoxaluria[MeSHID:D006959] approved hao1 messenger rna HAO1 Clinical trial target unknown NA TTD 5-(dodecylthio)-1h-1,2,3-triazole-4-carboxylic acid small molecule NA experimental hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank 3-decyl-2,5-dioxo-4-hydroxy-3-pyrroline small molecule NA experimental hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank lumasiran biotech Primary hyperoxaluria, type I[MeSHID:C536414],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperoxaluria[MeSHID:D006959] approved,investigational hydroxyacid oxidase 1 HAO1 NA antisense oligonucleotide NA drugbank n-sulfo-flavin mononucleotide small molecule NA experimental hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank phenylpyruvic acid small molecule NA experimental hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank 4-carboxy-5-(1-pentyl)hexylsulfanyl-1,2,3-triazole small molecule NA experimental hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank benzoylformic acid small molecule NA experimental hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank flavin mononucleotide small molecule NA approved,investigational hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank (2s)-2-hydroxyoctanoic acid small molecule NA experimental hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank 3-(indol-3-yl) lactate small molecule NA experimental hydroxyacid oxidase 1 HAO1 NA unknown NA drugbank flavin mononucleotide small molecule NA approved,investigational hydroxyacid oxidase 2 HAO2 NA unknown NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved hyaluronan and proteoglycan link protein 1 HAPLN1 NA binder NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved hyaluronan and proteoglycan link protein 3 HAPLN3 NA binder NA drugbank histidine small molecule Serum[MeSHID:D044967],Uremia[MeSHID:D014511],Anemia[MeSHID:D000740],Rheumatoid Arthritis[MeSHID:D001172] investigational,nutraceutical histidine--trna ligase, cytoplasmic HARS NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved hemoglobin subunit alpha HBA1 NA unknown NA drugbank pentaerythritol tetranitrate small molecule Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hemoglobin subunit alpha HBA1 NA agonist NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved hemoglobin subunit alpha HBA1 NA unknown NA drugbank 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine small molecule NA experimental hemoglobin subunit alpha HBA1 NA unknown NA drugbank trimesic acid small molecule NA experimental hemoglobin subunit alpha HBA1 NA unknown NA drugbank iron dextran small molecule Physical Dialysis[MeSHID:D003956],Pervasive Development Disorder[MeSHID:D002659],Camurati-Engelmann Syndrome[MeSHID:D003966],Chronic Kidney Diseases[MeSHID:D051436],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Iron deficiency anemia[MeSHID:D018798] approved,vet_approved hemoglobin subunit alpha HBA1 NA activator NA drugbank 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine small molecule NA experimental hemoglobin subunit alpha HBA1 NA unknown NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved hemoglobin subunit alpha HBA1 NA unknown NA drugbank ferric derisomaltose small molecule Iron deficiency anemia[MeSHID:D018798],Chronic Kidney Diseases[MeSHID:D051436] approved hemoglobin subunit alpha HBA1 NA binder NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved hemoglobin subunit alpha HBA1 NA unknown NA drugbank sebacic acid small molecule NA experimental hemoglobin subunit alpha HBA1 NA unknown NA drugbank 2,6-dicarboxynaphthalene small molecule NA experimental hemoglobin subunit alpha HBA1 NA unknown NA drugbank sodium ferric gluconate complex small molecule Iron deficiency anemia[MeSHID:D018798],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hemoglobin subunit alpha HBA1 NA binding NA drugbank voxelotor small molecule Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hemoglobin subunit alpha HBA1 NA binder NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational hemoglobin subunit alpha HBA1 NA inducer NA drugbank 4-carboxycinnamic acid small molecule NA experimental hemoglobin subunit alpha HBA1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational hemoglobin subunit alpha HBA1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental hemoglobin subunit alpha HBA1 NA inducer NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational hemoglobin subunit alpha HBA1 NA unknown NA drugbank nitrous acid small molecule Poisoning[MeSHID:D011041] approved,investigational hemoglobin subunit alpha HBA1 NA oxidizer NA drugbank ferric pyrophosphate small molecule Ectoparasitic Infestations[MeSHID:D004478],Blood Coagulation Disorders[MeSHID:D001778],Hematuria[MeSHID:D006417],Epistaxis[MeSHID:D004844],Gastrointestinal Hemorrhage[MeSHID:D006471],Blood Platelet Disorders[MeSHID:D001791],Hemorrhage[MeSHID:D006470],Thrombocytopenia[MeSHID:D013921],Malnutrition[MeSHID:D044342],Erythropoiesis[MeSHID:D004920] experimental hemoglobin subunit alpha HBA1 NA binder NA drugbank ferrous sulfate anhydrous small molecule Iron deficiency anemia[MeSHID:D018798] approved hemoglobin subunit alpha HBA1 NA binder NA drugbank ferric pyrophosphate citrate small molecule Ectoparasitic Infestations[MeSHID:D004478],Blood Coagulation Disorders[MeSHID:D001778],Maintenance[MeSHID:D008283],Hematuria[MeSHID:D006417],Epistaxis[MeSHID:D004844],Gastrointestinal Hemorrhage[MeSHID:D006471],Blood Platelet Disorders[MeSHID:D001791],Hemorrhage[MeSHID:D006470],Thrombocytopenia[MeSHID:D013921],Malnutrition[MeSHID:D044342],Erythropoiesis[MeSHID:D004920] approved,investigational hemoglobin subunit alpha HBA1 NA binder NA drugbank 2-[4-({[(3,5-dichlorophenyl)amino]carbonyl}amino)phenoxy]-2-methylpropanoic acid small molecule NA experimental hemoglobin subunit alpha HBA1 NA unknown NA drugbank efaproxiral small molecule NA investigational hemoglobin subunit alpha HBA1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hemoglobin subunit alpha HBA1 NA unknown NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved hemoglobin subunit alpha HBA1 NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hemoglobin subunit alpha HBA1 NA unknown NA drugbank 2,6-dicarboxynaphthalene NA NA investigative hemoglobin HBA2 Successful target unknown NA TTD sebacic acid NA NA investigative hemoglobin HBA2 Successful target unknown NA TTD fbs-0701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemochromatosis[MeSHID:D006432] phase 2 hemoglobin HBA2 Successful target unknown NA TTD hemoglobin raffimer NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2/3 hemoglobin HBA2 Successful target unknown NA TTD hrc-302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia, Chronic[MeSHID:D015464] discontinued in phase 1 hemoglobin HBA2 Successful target unknown NA TTD 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine NA NA investigative hemoglobin HBA2 Successful target unknown NA TTD iron NA Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hemoglobin HBA2 Successful target unknown NA TTD 5-hydroxymethyl-2-furfural NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2 hemoglobin HBA2 Successful target unknown NA TTD iron dextran NA Physical Dialysis[MeSHID:D003956],Pervasive Development Disorder[MeSHID:D002659],Camurati-Engelmann Syndrome[MeSHID:D003966],Chronic Kidney Diseases[MeSHID:D051436],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Iron deficiency anemia[MeSHID:D018798] approved hemoglobin HBA2 Successful target unknown NA TTD 1,3,5-benzenetricarboxylic acid NA NA investigative hemoglobin HBA2 Successful target unknown NA TTD polyheme NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematological Disease[MeSHID:D006402] phase 3 hemoglobin HBA2 Successful target unknown NA TTD heme NA NA investigative hemoglobin HBA2 Successful target unknown NA TTD 4-carboxycinnamic acid NA NA investigative hemoglobin HBA2 Successful target unknown NA TTD hemoximer NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 hemoglobin HBA2 Successful target unknown NA TTD hqk-1001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],beta Thalassemia[MeSHID:D017086] phase 2 hemoglobin HBA2 Successful target unknown NA TTD voxelotor NA Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hemoglobin HBA2 Successful target unknown NA TTD 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine NA NA investigative hemoglobin HBA2 Successful target unknown NA TTD efaproxyn NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] phase 3 hemoglobin HBA2 Successful target unknown NA TTD ctx110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1/2 hemoglobin HBA2 Successful target unknown NA TTD oxy-111a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1/2 hemoglobin HBA2 Successful target unknown NA TTD vx-366 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] discontinued in phase 2 hemoglobin HBA2 Successful target unknown NA TTD efaproxiral small molecule NA investigational hemoglobin subunit beta HBB NA negative modulator 2.27 drugbank , DGIDB 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine small molecule NA experimental hemoglobin subunit beta HBB NA unknown NA drugbank 4-carboxycinnamic acid small molecule NA experimental hemoglobin subunit beta HBB NA unknown NA drugbank sebacic acid small molecule NA experimental hemoglobin subunit beta HBB NA unknown NA drugbank pentaerythritol tetranitrate small molecule Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hemoglobin subunit beta HBB NA agonist NA drugbank ferric pyrophosphate citrate small molecule Ectoparasitic Infestations[MeSHID:D004478],Blood Coagulation Disorders[MeSHID:D001778],Maintenance[MeSHID:D008283],Hematuria[MeSHID:D006417],Epistaxis[MeSHID:D004844],Gastrointestinal Hemorrhage[MeSHID:D006471],Blood Platelet Disorders[MeSHID:D001791],Hemorrhage[MeSHID:D006470],Thrombocytopenia[MeSHID:D013921],Malnutrition[MeSHID:D044342],Erythropoiesis[MeSHID:D004920] approved,investigational hemoglobin subunit beta HBB NA binder NA drugbank nitrous acid small molecule Poisoning[MeSHID:D011041] approved,investigational hemoglobin subunit beta HBB NA oxidizer NA drugbank otl-300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],beta Thalassemia[MeSHID:D017086] phase 1/2 hemoglobin subunit beta HBB Clinical trial target unknown NA TTD 2-[4-({[(3,5-dichlorophenyl)amino]carbonyl}amino)phenoxy]-2-methylpropanoic acid small molecule NA experimental hemoglobin subunit beta HBB NA unknown NA drugbank sodium ferric gluconate complex small molecule Iron deficiency anemia[MeSHID:D018798],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hemoglobin subunit beta HBB NA binding NA drugbank 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine small molecule NA experimental hemoglobin subunit beta HBB NA unknown NA drugbank trimesic acid small molecule NA experimental hemoglobin subunit beta HBB NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental hemoglobin subunit beta HBB NA inducer NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational hemoglobin subunit beta HBB NA unknown NA drugbank 2,6-dicarboxynaphthalene small molecule NA experimental hemoglobin subunit beta HBB NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational hemoglobin subunit beta HBB NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hemoglobin subunit beta HBB NA unknown NA drugbank ferric pyrophosphate small molecule Ectoparasitic Infestations[MeSHID:D004478],Blood Coagulation Disorders[MeSHID:D001778],Hematuria[MeSHID:D006417],Epistaxis[MeSHID:D004844],Gastrointestinal Hemorrhage[MeSHID:D006471],Blood Platelet Disorders[MeSHID:D001791],Hemorrhage[MeSHID:D006470],Thrombocytopenia[MeSHID:D013921],Malnutrition[MeSHID:D044342],Erythropoiesis[MeSHID:D004920] experimental hemoglobin subunit beta HBB NA binder NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational hemoglobin subunit beta HBB NA inducer NA drugbank lentiglobin NA Anemia, Sickle Cell[MeSHID:D000755],beta Thalassemia[MeSHID:D017086],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 hemoglobin subunit beta HBB Clinical trial target unknown NA TTD , DGIDB iron dextran small molecule Physical Dialysis[MeSHID:D003956],Pervasive Development Disorder[MeSHID:D002659],Camurati-Engelmann Syndrome[MeSHID:D003966],Chronic Kidney Diseases[MeSHID:D051436],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Iron deficiency anemia[MeSHID:D018798] approved,vet_approved hemoglobin subunit beta HBB NA activator NA drugbank , DGIDB khk-2866 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 proheparin-binding egf-like growth factor HBEGF Clinical trial target unknown 21.22 TTD , DGIDB u3-1565 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proheparin-binding egf-like growth factor HBEGF Clinical trial target unknown NA TTD , DGIDB sch-900271 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nicotinic acid receptor HCAR2 Successful target unknown 10.61 TTD , DGIDB monomethylfumarate NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD niacin small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Myocardial Infarction[MeSHID:D009203],Avitaminosis[MeSHID:D001361],Dyslipidemias[MeSHID:D050171] approved,investigational,nutraceutical hydroxycarboxylic acid receptor 2 HCAR2 NA agonist 9.43 drugbank , DGIDB mk-0354 NA Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161] phase 2 nicotinic acid receptor HCAR2 Successful target unknown 10.61 TTD , DGIDB 5-isopropyl-1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD vitamin b3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] approved nicotinic acid receptor HCAR2 Successful target unknown NA TTD , DGIDB 5-(3-chloro-benzyl)-1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD pmid22420767c42 NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 5-butyl-1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD clotrimazole small molecule Tinea Pedis[MeSHID:D014008],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Mycoses[MeSHID:D009181],Skin Diseases, Infectious[MeSHID:D012874],Diaper Rash[MeSHID:D003963],Tinea Versicolor[MeSHID:D014010],Candidiasis[MeSHID:D002177],leukemia[MeSHID:D007938],Tinea[MeSHID:D014005],Immunocompromised Host[MeSHID:D016867],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved hydroxycarboxylic acid receptor 2 HCAR2 NA partial agonist NA drugbank mk-1903 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] phase 2 nicotinic acid receptor HCAR2 Successful target unknown NA TTD , DGIDB gsk-256073 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 nicotinic acid receptor HCAR2 Successful target unknown NA TTD , DGIDB 1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD inositol nicotinate small molecule Serum[MeSHID:D044967],Raynaud Phenomenon[MeSHID:D011928],Intermittent Claudication[MeSHID:D007383] approved,withdrawn hydroxycarboxylic acid receptor 2 HCAR2 NA agonist NA drugbank pmid21185185c21 NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD pmid18752940c9n NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 2-(4-phenylbutyl)pyrido[2,3-d]pyrimidin-4(3h)-one NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD (+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target agonist NA TTD , DGIDB incb19602 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 nicotinic acid receptor HCAR2 Successful target unknown NA TTD 2-(3-(naphthalen-2-yl)propanamido)benzoic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 2-(3-biphenyl-4-yl-propionylamino)-benzoic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 2-(6-phenylhexyl)pyrido[2,3-d]pyrimidin-4(3h)-one NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD pmid20363624c(+)17a NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 4,5,6,7-tetrahydro-1h-indazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD pmid19309152c2g NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 3-pyridine-acetic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target agonist NA TTD , DGIDB cinnamic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target agonist NA TTD , DGIDB pmid20615702c8f NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD isonicotinic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD ari-3037mo NA Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Dyslipidemias[MeSHID:D050171] phase 2 nicotinic acid receptor HCAR2 Successful target unknown NA TTD , DGIDB 5-phenethyl-1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD nia-114 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] clinical trial nicotinic acid receptor HCAR2 Successful target unknown NA TTD , DGIDB 5-methyl nicotinic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target agonist NA TTD , DGIDB 5-benzyl-1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD mk-6892 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 2-(cinnamyloxy)pyrido[2,3-d]pyrimidin-4(3h)-one NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD sazetidine-a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD beta-d-hydroxybutyric acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 5-propyl-1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 5-(4-chloro-benzyl)-1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD 5-(3-phenyl-propyl)-1h-pyrazole-3-carboxylic acid NA NA investigative nicotinic acid receptor HCAR2 Successful target unknown NA TTD nia-114 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] clinical trial hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target unknown NA TTD , DGIDB d-kynurenine NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target agonist NA TTD , DGIDB 2-hydroxyoctanoic acid NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target agonist NA TTD , DGIDB pmid17358052c5b NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target unknown NA TTD 3-hydroxyoctanoic acid NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target agonist NA TTD , DGIDB pmid19524438c6o NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target unknown NA TTD ari-3037mo NA Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Dyslipidemias[MeSHID:D050171] phase 2 hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target unknown NA TTD , DGIDB ibc 293 NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target agonist NA TTD , DGIDB inositol nicotinate small molecule Serum[MeSHID:D044967],Raynaud Phenomenon[MeSHID:D011928],Intermittent Claudication[MeSHID:D007383] approved,withdrawn hydroxycarboxylic acid receptor 3 HCAR3 NA agonist NA drugbank 5-methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target agonist NA TTD , DGIDB niacin small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Myocardial Infarction[MeSHID:D009203],Avitaminosis[MeSHID:D001361],Dyslipidemias[MeSHID:D050171] approved,investigational,nutraceutical hydroxycarboxylic acid receptor 3 HCAR3 NA agonist 9.9 drugbank , DGIDB 4-(n-propyl)amino-3-nitrobenzoic acid NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target agonist NA TTD , DGIDB d-tryptophan NA NA investigative hydroxycarboxylic acid receptor 3 HCAR3 Clinical trial target agonist 4.24 TTD , DGIDB pp121 NA NA investigative hematopoietic cell kinase HCK Patented-recorded target inhibitor NA TTD , DGIDB bk3 NA NA patented hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD , DGIDB phosphonotyrosine small molecule NA experimental tyrosine-protein kinase hck HCK NA unknown NA drugbank us9108950, 1 NA NA patented hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD , DGIDB unii-i92mu0v408 NA NA patented hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD , DGIDB us8933228, ref 2 NA NA patented hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD , DGIDB doramapimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] patented hematopoietic cell kinase HCK Patented-recorded target unknown 0.14 TTD , DGIDB 1-ter-butyl-3-p-tolyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine small molecule NA experimental tyrosine-protein kinase hck HCK NA unknown NA drugbank pmid15546730c2 NA NA investigative hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD bk7 NA NA patented hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD , DGIDB quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational tyrosine-protein kinase hck HCK NA unknown NA drugbank bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved tyrosine-protein kinase hck HCK NA inhibitor 0.17 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase hck HCK NA inhibitor NA drugbank sb19065 NA NA patented hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD , DGIDB us8933228, 3 NA NA patented hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD , DGIDB 3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine NA NA patented hematopoietic cell kinase HCK Patented-recorded target unknown NA TTD , DGIDB cyclic adenosine monophosphate small molecule NA experimental potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 HCN2 NA unknown NA drugbank ivabradine small molecule Cardiomyopathy, Dilated[MeSHID:D002311],Ventricular Ejection Fraction[MeSHID:D013318],Hospitalization[MeSHID:D006760],treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],heart rate[MeSHID:D006339],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 HCN2 NA inhibitor NA drugbank cyclic gmp small molecule NA experimental potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 HCN2 NA unknown NA drugbank pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational orexin HCRT NA unknown NA drugbank sb-334867 NA NA investigative orexin receptor type 1 HCRTR1 Clinical trial target antagonist 1.14 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 22 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 27 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 16 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 5 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 26 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 10 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 24 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB sb-408124 NA NA investigative orexin receptor type 1 HCRTR1 Clinical trial target antagonist 0.57 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 34 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 6 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 8 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 19 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 14 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 12 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB sb-649868 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 orexin receptor type 1 HCRTR1 Clinical trial target unknown 6.82 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 21 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 29 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 4 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB jnj-61393215 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD suvorexant small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational orexin receptor type 1 HCRTR1 NA antagonist 9.09 drugbank , DGIDB 1,2-diamino cyclopentane-based derivative 23 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 18 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 9 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 11 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 31 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 13 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 30 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB sb-649868 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 orexin receptor type 1 HCRTR1 Clinical trial target antagonist 6.82 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 20 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB pmid15261275c1 NA NA investigative orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD 1,2-diamino cyclopentane-based derivative 7 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 32 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB sb-410220 NA NA investigative orexin receptor type 1 HCRTR1 Clinical trial target antagonist 4.55 TTD , DGIDB [3h]sb-674042 NA NA investigative orexin receptor type 1 HCRTR1 Clinical trial target antagonist NA TTD , DGIDB orexin-b NA NA investigative orexin receptor type 1 HCRTR1 Clinical trial target agonist 2.27 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 25 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 2 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB lemborexant small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational orexin receptor type 1 HCRTR1 NA antagonist 4.55 drugbank , DGIDB 1,2-diamino cyclopentane-based derivative 3 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 17 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 1 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 15 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 33 NA NA patented orexin receptor type 1 HCRTR1 Clinical trial target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 22 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 25 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB pmid15261275c1 NA NA investigative orexin receptor type 2 HCRTR2 Successful target unknown NA TTD 1,2-diamino cyclopentane-based derivative 1 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 27 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 30 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 34 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB tcs-ox2-29 NA NA investigative orexin receptor type 2 HCRTR2 Successful target antagonist NA TTD , DGIDB mk-3697 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 orexin receptor type 2 HCRTR2 Successful target antagonist NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 31 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB mk-3697 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB suvorexant small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational orexin receptor type 2 HCRTR2 Successful target antagonist 13.26 TTD , drugbank , DGIDB 1,2-diamino cyclopentane-based derivative 21 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB min-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 orexin receptor type 2 HCRTR2 Successful target unknown 5.3 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 33 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB jnj-10397049 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative orexin receptor type 2 HCRTR2 Successful target antagonist 2.65 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 23 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB lemborexant small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational orexin receptor type 2 HCRTR2 NA antagonist 5.3 drugbank , DGIDB 1,2-diamino cyclopentane-based derivative 2 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 6 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB [3h]sb-674042 NA NA investigative orexin receptor type 2 HCRTR2 Successful target antagonist NA TTD , DGIDB orexin-b NA NA investigative orexin receptor type 2 HCRTR2 Successful target agonist 2.65 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 4 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 18 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 24 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 3 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB sb-408124 NA NA investigative orexin receptor type 2 HCRTR2 Successful target antagonist 0.66 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 8 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 17 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 26 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 19 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 32 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 11 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 14 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 9 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 29 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 13 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 5 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 16 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 10 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 15 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB empa NA NA investigative orexin receptor type 2 HCRTR2 Successful target antagonist NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 20 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB sb-334867 NA NA investigative orexin receptor type 2 HCRTR2 Successful target antagonist 1.33 TTD , DGIDB 1,2-diamino cyclopentane-based derivative 12 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 1,2-diamino cyclopentane-based derivative 7 NA NA patented orexin receptor type 2 HCRTR2 Successful target unknown NA TTD , DGIDB 7-(3-benzoyl-ureido)-heptanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 4-chloro-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD sndx-275 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943] phase 3 histone deacetylase 1 HDAC1 Successful target unknown 0.78 TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ph4-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 9,9,9-trifluoro-8-oxo-nonanoic acid phenylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 8-(3-benzoyl-ureido)-octanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-mercapto-heptanoic acid quinolin-3-ylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32j NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB gymnochrome e NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC1 NA inhibitor 0.75 drugbank , DGIDB n-hydroxybenzo[b]thiophene-2-carboxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32r NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB psammaplin a NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown 0.39 TTD , DGIDB pmid29671355-compound-57 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid28092474-compound-33k NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB resminostat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 2 histone deacetylase 1 HDAC1 Successful target unknown 0.35 TTD , DGIDB pmid28092474-compound-32s NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational histone deacetylase 1 HDAC1 NA cofactor NA drugbank n-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32u NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB octanedioic acid hydroxyamide pyridin-4-ylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n1-(biphenyl-3-yl)-n8-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33d NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32p NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB itf2357 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Thrombocythemia, Essential[MeSHID:D013920],Polycythemia Vera[MeSHID:D011087] phase 3 histone deacetylase 1 HDAC1 Successful target unknown 0.42 TTD , DGIDB 8-(biphenyl-4-yloxy)-2-oxo-octanoic acid NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-succinamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32n NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 1 HDAC1 NA inhibitor NA drugbank pmid28092474-compound-34b NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid28092474-compound-32d NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid28092474-compound-32o NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid29671355-compound-31 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB ads-102550 NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-4-(phenylacetylamino-methyl)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD panobinostat NA Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved histone deacetylase 1 HDAC1 Successful target unknown 0.75 TTD , DGIDB st-2986 NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-56 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 8-(biphenyl-4-yl)-n-hydroxy-8-oxooctanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(3,4-dimethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD depudecin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target unknown 1.27 TTD , DGIDB pmid28092474-compound-34a NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-6-oxo-6-phenylhexanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(4-ethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD chlamydocin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target unknown 1.27 TTD , DGIDB 8-(biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD desclasinose azithromycinarylalkyl hydroxamate NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 4sc-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target unknown 0.42 TTD , DGIDB sb-623 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Ischemia[MeSHID:D002545],Traumatic Brain Injury[MeSHID:D000070642] phase 2 histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-4-(5-phenyl-pentanoylamino)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33p NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 6-mercapto-hexanoic acid phenylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-4-(4-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-n'-(4-methylphenyl)octanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(2,6-dimethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33g NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-7-(naphthalen-2-yloxy)heptanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 8-mercapto-octanoic acid phenylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-(biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD isosteric imidazolyl pyrimidine derivative 1 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-(2-aminophenyl)quinoxaline-6-carboxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32t NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB vorinostat small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 1 HDAC1 Successful target inhibitor 0.58 TTD , drugbank , DGIDB st-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-4-((r)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD scriptaid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target unknown 0.42 TTD , DGIDB 7-(biphenyl-4-yloxy)-heptanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 4-tert-butyl-n-hydroxybenzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(2-ethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-34c NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid29671355-compound-23 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-4-(3-phenyl-propionylamino)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-(biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n,8-dihydroxy-8-(naphthalen-2-yl)octanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-25 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid28092474-compound-32i NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 5-mercapto-pentanoic acid phenylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32h NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-(2-aminophenyl)-4-methoxybenzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-24 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB hc-toxin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB sk-7068 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target unknown 1.27 TTD , DGIDB pmid29671355-compound-42 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-l-2mephe-l-ala-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD octanedioic acid hydroxyamide pyridin-2-ylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 6-(2-bromo-acetylamino)-hexanoic acid phenylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32x NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 8-oxo-8-phenyl-octanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD abexinostat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Peripheral T-Cell Lymphoma[MeSHID:D016411],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Lymphoma, Follicular[MeSHID:D008224],Malignant neoplasm of breast[MeSHID:D001943] investigational histone deacetylase 1 HDAC1 NA inhibitor 0.35 drugbank , DGIDB pmid28092474-compound-33l NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ser(bzl)-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32m NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-(2,3-dimethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclo(-l-am7(s2py)-d-2mephe-l-ala-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-ala-d-tic-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33m NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 8-(4-bromophenyl)-n-hydroxy-8-oxooctanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD chr-3996 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1/2 histone deacetylase 1 HDAC1 Successful target inhibitor 0.64 TTD , DGIDB 7-biphenyl-4-yl-heptanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD st-3050 NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD diaryl amine derivative 2 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB ads-100380 NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational histone deacetylase 1 HDAC1 NA unknown NA drugbank n-(2,4-dimethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-26 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational histone deacetylase 1 HDAC1 NA cofactor NA drugbank n-hydroxy-9-oxo-9-phenylnonanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 6-phenoxy-hexane-1-thiol NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-ph5-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-43 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB nvp-laq824 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Mood Disorders[MeSHID:D019964],leukemia[MeSHID:D007938] phase 3 histone deacetylase 1 HDAC1 Successful target unknown 0.23 TTD , DGIDB 5-(4-hydroxyphenyl)-3h-1,2-dithiole-3-thione NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-4-((s)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-11 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ser-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-phg-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33h NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB azumamide b NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-oxalamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32l NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid29671355-compound-61 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB chr-3996 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1/2 histone deacetylase 1 HDAC1 Successful target unknown 0.64 TTD , DGIDB resminostat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 2 histone deacetylase 1 HDAC1 Successful target inhibitor 0.35 TTD , DGIDB pmid28092474-compound-33c NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 7-(biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclo(-l-am7(s2py)-l-a1in-l-ala-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 1,1,1-trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD phenylbutyrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urea Cycle Disorders, Inborn[MeSHID:D056806] phase 2 histone deacetylase 1 HDAC1 Successful target unknown 0.27 TTD , DGIDB 4-dimethylamino-n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-(4-(dimethylamino)phenoxy)-n-hydroxyheptanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD sk-7041 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target unknown 1.27 TTD , DGIDB n-(6-hydroxycarbamoyl-hexyl)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD an-9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 2 histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-n'-(2-methylphenyl)octanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33f NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB azithromycin-n-benzyltriazolyldecahydroxamic acid NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclostellettamine derivative NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n1-(biphenyl-4-yl)-n8-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD nexturastat a NA NA investigative histone deacetylase 1 HDAC1 Successful target inhibitor NA TTD , DGIDB rg-2833 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Friedreich Ataxia[MeSHID:D005621] phase 1 histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB sb-639 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB mgcd-0103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant Neoplasms[MeSHID:D009369],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 2 histone deacetylase 1 HDAC1 Successful target unknown 0.88 TTD , DGIDB pmid28092474-compound-33e NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pracinostat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] investigational histone deacetylase 1 HDAC1 NA unknown 0.21 drugbank , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC1 NA inhibitor 0.78 drugbank , DGIDB pmid29671355-compound-67 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 6-benzenesulfinylhexanoic acid hydroxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-62 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-8-(naphthalen-2-yl)oct-7-enamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 6-(9h-carbazol-9-yl)-n-hydroxyhexanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 4-benzoylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33a NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB diaryl amine derivative 3 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 8-phenyl-octanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-ala-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-3-ylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational histone deacetylase 1 HDAC1 NA inhibitor NA drugbank sk-683 NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD scriptaid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target inhibitor 0.42 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational histone deacetylase 1 HDAC1 NA unknown NA drugbank hbi-8000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Merkel cell carcinoma[MeSHID:D015266],Non-Small Cell Lung Carcinoma[MeSHID:D002289] registered histone deacetylase 1 HDAC1 Successful target unknown 1.27 TTD , DGIDB pmid29671355-compound-44 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid29671355-compound-13 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid29671355-compound-65a NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid28092474-compound-32z NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pyroxamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33i NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-(2-aminophenyl)nicotinamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-n'-(3-methylphenyl)octanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 6-phenylsulfanylhexanoic acid hydroxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 4-benzenesulfonylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclo(-l-am7(s2py)-d-a1in-l-ala-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-mercapto-n-(4-phenylthiazol-2-yl)heptanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 5-(4-chloro-phenyl)-pentanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32k NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-39 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid29671355-compound-28 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 8-oxo-8-phenyl-octanoic acid NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(2,5-dimethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-73 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 7-(1h-indol-5-yloxy)-n-hydroxyheptanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33b NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-(5-hydroxycarbamoyl-pentyl)-4-nitro-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD tacedinaline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 histone deacetylase 1 HDAC1 Successful target unknown 0.46 TTD , DGIDB sodium butyrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Ulcer[MeSHID:D014456],Cells[MeSHID:D002477] phase 2 histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB obp-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 histone deacetylase 1 HDAC1 Successful target unknown 0.64 TTD , DGIDB pmid29671355-compound-19 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 1,1,1-trifluoro-8-phenoxy-octan-2-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 4-butyrylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-38a NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-phe-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-18 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB thioacetic acid s-(6-phenylcarbamoyl-hexyl) ester NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-27 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-8-(naphthalen-2-yl)octanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-mercapto-heptanoic acid pyridin-3-ylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33j NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-5-phenylthiophene-2-carboxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-4-(pentanoylamino-methyl)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-22 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB (e)-8-biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32b NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 7-phenoxy-heptanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD azithromycin-n-benzyltriazolylnonahydroxamic acid NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(4-hydroxybiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD romidepsin small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Continuance of life[MeSHID:D013534],Peripheral T-Cell Lymphoma[MeSHID:D016411],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 1 HDAC1 Successful target antagonist,inhibitor 0.54 TTD , drugbank , DGIDB pmid29671355-compound-59 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n1-hydroxy-n8-(4-phenylthiazol-2-yl)octanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-55 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-(4-aminobiphenyl-3-yl)nicotinamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD azumamide c NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-(3,5-dimethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD azithromycin-n-benzyltriazolylhexahydroxamic acid NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD cyclo(-l-am7(s2py)-a2in-l-ala-d-pro-) NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 4-phenylbutyrohydroxamic acid NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-4-ylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD nsc-746457 NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32g NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB panobinostat NA Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved histone deacetylase 1 HDAC1 Successful target inhibitor 0.75 TTD , DGIDB pmid29671355-compound-21 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 2-(methylsulfonylthio)ethyl 2-propylpentanoate NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32a NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-7-oxo-7-phenylheptanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 4-hydroxy-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 6-benzenesulfonylhexanoic acid hydroxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-4-(2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 8-(biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32f NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid29671355-compound-8 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-hydroxy-n'-(4-methoxyphenyl)octanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-9 NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pracinostat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] investigational histone deacetylase 1 HDAC1 NA inhibitor 0.21 drugbank , DGIDB n-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-(naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD 7-mercapto-heptanoic acid benzothiazol-2-ylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD largazole NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown 0.22 TTD , DGIDB octanedioic acid bis-hydroxyamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-8-(naphthalen-2-yl)non-8-enamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-2,2'-bithiophene-5-carboxamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32c NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB azithromycinarylalkylhydroxamic acid NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD n-hydroxy-4-phenylacetylamino-benzamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD mocetinostat small molecule NA investigational histone deacetylase 1 HDAC1 NA inhibitor 0.88 drugbank , DGIDB 7-mercapto-heptanoic acid phenylamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD azumamide e NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-32y NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid28092474-compound-32q NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB n-(3-ethylphenyl)-n'-hydroxyoctanediamide NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid29671355-compound-38b NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB m-carboxycinnamic acid bishydroxamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 9-(biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD mocetinostat small molecule NA investigational histone deacetylase 1 HDAC1 NA unknown 0.88 drugbank , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental histone deacetylase 1 HDAC1 NA cofactor NA drugbank tacedinaline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 histone deacetylase 1 HDAC1 Successful target inhibitor 0.46 TTD , DGIDB pmid28092474-compound-32v NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB azithromycin-n-benzyltriazolyloctahydroxamic acid NA NA investigative histone deacetylase 1 HDAC1 Successful target unknown NA TTD pmid28092474-compound-33o NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB pmid28092474-compound-32e NA NA patented histone deacetylase 1 HDAC1 Successful target unknown NA TTD , DGIDB 9,9,9-trifluoro-8-oxo-nonanoic acid phenylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD octanedioic acid hydroxyamide pyridin-4-ylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 7-(biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-succinamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC10 NA inhibitor 0.21 drugbank , DGIDB (e)-8-biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD bufexamac small molecule Dermatologic disorders[MeSHID:D012871],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] approved,withdrawn histone deacetylase 10 HDAC10 NA inhibitor 0.91 drugbank , DGIDB pmid29671355-compound-44 NA NA patented histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD , DGIDB st-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 6-phenoxy-hexane-1-thiol NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD st-2986 NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD cyclostellettamine derivative NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC10 NA inhibitor 0.7 drugbank , DGIDB 6-benzenesulfinylhexanoic acid hydroxamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD pmid29671355-compound-25 NA NA patented histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD , DGIDB 9-(biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-(5-phenyl-pentanoylamino)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD pmid29671355-compound-62 NA NA patented histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD , DGIDB n-(2-mercapto-ethyl)-n'-phenyl-oxalamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD pmid29671355-compound-56 NA NA patented histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD , DGIDB 7-mercapto-heptanoic acid biphenyl-4-ylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 8-(biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 5-mercapto-pentanoic acid phenylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 7-(naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 6-benzenesulfonylhexanoic acid hydroxamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-((r)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-3-ylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 6-mercapto-hexanoic acid phenylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-(6-hydroxycarbamoyl-hexyl)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-(phenylacetylamino-methyl)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 6-phenylsulfanylhexanoic acid hydroxamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-phenylacetylamino-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD pmid29671355-compound-43 NA NA patented histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD , DGIDB 7-(biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 7-mercapto-heptanoic acid quinolin-3-ylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 4-hydroxy-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 5-(4-chloro-phenyl)-pentanoic acid hydroxyamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD st-3050 NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-(4-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 6-(2-bromo-acetylamino)-hexanoic acid phenylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD thioacetic acid s-(6-phenylcarbamoyl-hexyl) ester NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 7-(biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 4-butyrylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-(5-hydroxycarbamoyl-pentyl)-4-nitro-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD pmid29671355-compound-21 NA NA patented histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD , DGIDB 4-chloro-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 4-dimethylamino-n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-(pentanoylamino-methyl)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 7-mercapto-heptanoic acid benzothiazol-2-ylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 8-mercapto-octanoic acid phenylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 4-benzoylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 7-mercapto-heptanoic acid phenylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 5-(4-hydroxyphenyl)-3h-1,2-dithiole-3-thione NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 8-oxo-8-phenyl-octanoic acid NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-(3-phenyl-propionylamino)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD psammaplin a NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown 0.28 TTD , DGIDB octanedioic acid hydroxyamide pyridin-2-ylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-((s)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 2-(methylsulfonylthio)ethyl 2-propylpentanoate NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD n-hydroxy-4-(2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD 7-mercapto-heptanoic acid pyridin-3-ylamide NA NA investigative histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD pmid29671355-compound-8 NA NA patented histone deacetylase 10 HDAC10 Patented-recorded target unknown NA TTD , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC11 NA inhibitor 0.63 drugbank , DGIDB pmid29671355-compound-23 NA NA patented histone deacetylase 11 HDAC11 Patented-recorded target unknown NA TTD , DGIDB panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC11 NA inhibitor 0.24 drugbank , DGIDB pmid29671355-compound-21 NA NA patented histone deacetylase 11 HDAC11 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-36 NA NA patented histone deacetylase 11 HDAC11 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-44 NA NA patented histone deacetylase 11 HDAC11 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-25 NA NA patented histone deacetylase 11 HDAC11 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-43 NA NA patented histone deacetylase 11 HDAC11 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-62 NA NA patented histone deacetylase 11 HDAC11 Patented-recorded target unknown NA TTD , DGIDB 8-(biphenyl-4-yloxy)-2-oxo-octanoic acid NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD tixocortol small molecule Solutions[MeSHID:D012996],Disease[MeSHID:D004194],Contact hypersensitivity[MeSHID:D003877],Rhinitis[MeSHID:D012220],Pharyngitis[MeSHID:D010612],Screening procedure[MeSHID:D008403],Nose[MeSHID:D009666],Ulcerative Colitis[MeSHID:D003093] approved,withdrawn histone deacetylase 2 HDAC2 NA stimulator NA drugbank theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved histone deacetylase 2 HDAC2 NA activator NA drugbank n8,2-dihydroxy-n1-phenyloctanediamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 8-phenyl-octanoic acid hydroxyamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD mocetinostat small molecule NA investigational histone deacetylase 2 HDAC2 NA unknown 0.8 drugbank , DGIDB n-(2-amino-5-(thiazol-2-yl)phenyl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(4-amino-3'-methylbiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD aminophylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histone deacetylase 2 HDAC2 NA activator NA drugbank 1,1,1-trifluoro-8-phenoxy-octan-2-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 6-benzenesulfinylhexanoic acid hydroxamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 5-(4-hydroxyphenyl)-3h-1,2-dithiole-3-thione NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 4-dimethylamino-n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-25 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC2 NA inhibitor 0.68 drugbank , DGIDB 8-oxo-8-phenyl-octanoic acid hydroxyamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-31 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB 4-benzoylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n8-hydroxy-2-methoxy-n1-phenyloctanediamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD octanedioic acid hydroxyamide pyridin-2-ylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 4-chloro-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-23 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB pravastatin small molecule Serum[MeSHID:D044967],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Myocardial Infarction[MeSHID:D009203],Transient Cerebral Ischemia[MeSHID:D002546],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Cardiac Death[MeSHID:D003643],Premature Birth[MeSHID:D047928],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Term Birth[MeSHID:D047929],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia, Familial[MeSHID:D006938],Disease[MeSHID:D004194],Myocardium[MeSHID:D009206],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Risk Reduction[MeSHID:D040242],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histone deacetylase 2 HDAC2 NA inhibitor NA drugbank 5-mercapto-pentanoic acid phenylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-74 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB octanedioic acid hydroxyamide pyridin-4-ylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid phenylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD chr-3996 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1/2 histone deacetylase 2 HDAC2 Clinical trial target unknown 0.74 TTD , DGIDB n-hydroxy-4-(5-phenyl-pentanoylamino)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 8-(biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-hydroxy-e-3-(4'-cyanobiphenyl-4-yl)-acrylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-hydroxy-4-(4-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(4-aminobiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 8-(biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-67 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-4-(phenylacetylamino-methyl)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 8-oxo-8-phenyl-octanoic acid NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 6-(2-bromo-acetylamino)-hexanoic acid phenylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-hydroxy-4-(pentanoylamino-methyl)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD vorinostat small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 2 HDAC2 NA inhibitor 0.61 drugbank , DGIDB n-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD santacruzamate a NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target inhibitor NA TTD , DGIDB pmid29671355-compound-43 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-e-3-(4'-chlorobiphenyl-4-yl)-acrylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD thioacetic acid s-(6-phenylcarbamoyl-hexyl) ester NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(4-hydroxybiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD octanedioic acid bis-hydroxyamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-(biphenyl-4-yloxy)-heptanoic acid hydroxyamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 6-mercapto-hexanoic acid phenylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-hydroxy-4-((r)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD mocetinostat small molecule NA investigational histone deacetylase 2 HDAC2 NA inhibitor 0.8 drugbank , DGIDB 6-phenylsulfanylhexanoic acid hydroxamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-succinamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pracinostat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] investigational histone deacetylase 2 HDAC2 NA unknown 0.12 drugbank , DGIDB n-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-3-ylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(4-amino-4'-vinylbiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 2 HDAC2 NA inhibitor 0.19 drugbank , DGIDB 7-phenoxy-heptanoic acid hydroxyamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-11 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB n-(2-aminophenyl)-4-methoxybenzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD oxtriphylline small molecule Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved histone deacetylase 2 HDAC2 NA activator NA drugbank psammaplin a NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown 0.23 TTD , DGIDB 7-biphenyl-4-yl-heptanoic acid hydroxyamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-21 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB n-(2-aminophenyl)quinoxaline-6-carboxamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(2-amino-5-(furan-3-yl)phenyl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-hydroxy-4-((s)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 2-(benzyloxy)-n7-hydroxy-n1-phenylheptanediamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(2-aminophenyl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n7-hydroxy-2-methoxy-n1-phenylheptanediamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 1,1,1-trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD romidepsin small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Continuance of life[MeSHID:D013534],Peripheral T-Cell Lymphoma[MeSHID:D016411],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 2 HDAC2 NA antagonist,inhibitor 0.47 drugbank , DGIDB 5-(4-chloro-phenyl)-pentanoic acid hydroxyamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD cyclostellettamine derivative NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-56 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB n-(4-amino-4'-bromobiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD (e)-8-biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-hydroxy-4-(2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n7-hydroxy-n1-phenyl-2-propoxyheptanediamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histone deacetylase 2 HDAC2 NA inhibitor NA drugbank n-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 2-(allyloxy)-n8-hydroxy-n1-phenyloctanediamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid quinolin-3-ylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-(biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 6-phenoxy-hexane-1-thiol NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 9,9,9-trifluoro-8-oxo-nonanoic acid phenylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-hydroxy-4-(3-phenyl-propionylamino)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(6-hydroxycarbamoyl-hexyl)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-(naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved histone deacetylase 2 HDAC2 NA inhibitor NA drugbank 7-(biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-oxalamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 6-benzenesulfonylhexanoic acid hydroxamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-8 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB n-(4-amino-3'-methoxybiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-hydroxy-e-3-(biphenyl-4-yl)-acrylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-61 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB n-(5-hydroxycarbamoyl-pentyl)-4-nitro-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-44 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB 2-(methylsulfonylthio)ethyl 2-propylpentanoate NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC2 NA inhibitor 0.44 drugbank , DGIDB fluvastatin small molecule Coronary Arteriosclerosis[MeSHID:D003324],Disease Progression[MeSHID:D018450],Hypercholesterolemia[MeSHID:D006937],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histone deacetylase 2 HDAC2 NA inhibitor NA drugbank n-(4-aminobiphenyl-3-yl)nicotinamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(4-amino-4'-methoxybiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(2-amino-5-(pyridin-4-yl)phenyl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-4-ylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD st-2986 NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 4-phenylbutyrohydroxamic acid NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD chr-3996 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1/2 histone deacetylase 2 HDAC2 Clinical trial target inhibitor 0.74 TTD , DGIDB 7-mercapto-heptanoic acid benzothiazol-2-ylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 4-butyrylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD st-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD kar-1880 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-(biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid pyridin-3-ylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 4-hydroxy-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(2-amino-5-(furan-2-yl)phenyl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD lovastatin small molecule Diabetes Mellitus[MeSHID:D003920],Angina, Unstable[MeSHID:D000789],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Premature Birth[MeSHID:D047928],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Neoplasm Metastasis[MeSHID:D009362],Menarche[MeSHID:D008572],Cerebrovascular accident[MeSHID:D020521],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 2 HDAC2 NA inhibitor NA drugbank 5-(biphenyl-4-yl)-pentanoic acid n-hydroxyamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-62 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-9 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB n-(2-aminophenyl)nicotinamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD simvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Peripheral Vascular Diseases[MeSHID:D016491],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Cerebrovascular Disorders[MeSHID:D002561],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia[MeSHID:D006937],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Hyperlipidemia[MeSHID:D006949],Coronary heart disease[MeSHID:D003327],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histone deacetylase 2 HDAC2 NA inhibitor NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 2 HDAC2 NA inhibitor 0.33 drugbank , DGIDB n-hydroxy-4-phenylacetylamino-benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD 8-mercapto-octanoic acid phenylamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-59 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB 9-(biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD n-(4-amino-4'-fluorobiphenyl-3-yl)benzamide NA NA investigative histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD pmid29671355-compound-55 NA NA patented histone deacetylase 2 HDAC2 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-31 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-25 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC3 NA inhibitor 0.7 drugbank , DGIDB pmid29671355-compound-55 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-21 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB mocetinostat small molecule NA investigational histone deacetylase 3 HDAC3 NA unknown 0.82 drugbank , DGIDB pmid29671355-compound-9 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB diaryl amine derivative 4 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB vorinostat small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 3 HDAC3 NA inhibitor 0.59 drugbank , DGIDB pracinostat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] investigational histone deacetylase 3 HDAC3 NA inhibitor 0.25 drugbank , DGIDB pmid29671355-compound-43 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB rgfp966 NA NA investigative histone deacetylase 3 HDAC3 Clinical trial target inhibitor NA TTD , DGIDB chr-3996 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1/2 histone deacetylase 3 HDAC3 Clinical trial target inhibitor 0.76 TTD , DGIDB pmid29671355-compound-56 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-59 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB pracinostat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] investigational histone deacetylase 3 HDAC3 NA unknown 0.25 drugbank , DGIDB panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC3 NA inhibitor 0.45 drugbank , DGIDB droxinostat NA NA investigative histone deacetylase 3 HDAC3 Clinical trial target inhibitor NA TTD , DGIDB pmid29671355-compound-67 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-8 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-11 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-44 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-62 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB mocetinostat small molecule NA investigational histone deacetylase 3 HDAC3 NA inhibitor 0.82 drugbank , DGIDB pmid29671355-compound-61 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB chr-3996 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1/2 histone deacetylase 3 HDAC3 Clinical trial target unknown 0.76 TTD , DGIDB pmid29671355-compound-57 NA NA patented histone deacetylase 3 HDAC3 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-4-(phenylacetylamino-methyl)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-9h-xanthene-9-carboxamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD romidepsin small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Continuance of life[MeSHID:D013534],Peripheral T-Cell Lymphoma[MeSHID:D016411],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 4 HDAC4 NA inhibitor 0.42 drugbank , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational histone deacetylase 4 HDAC4 NA unknown NA drugbank 9-(biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-4-((s)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD azumamide c NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid phenylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 4-dimethylamino-n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC4 NA inhibitor 0.37 drugbank , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC4 NA inhibitor 0.86 drugbank , DGIDB n-(2-mercapto-ethyl)-n'-phenyl-succinamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-3-ylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid pyridin-3-ylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-12 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ser(bzl)-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD tmp269 NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target inhibitor NA TTD , DGIDB pmid29671355-compound-47d NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)carbonyl]thiophene-2-carboxamide small molecule NA experimental histone deacetylase 4 HDAC4 NA unknown NA drugbank pmid29671355-compound-47a NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB 4-benzoylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 6-phenylsulfanylhexanoic acid hydroxamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD thioacetic acid s-(6-phenylcarbamoyl-hexyl) ester NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-d-2mephe-l-ala-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-ala-d-tic-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-phe-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-ph4-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 6-phenoxy-hexane-1-thiol NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-61 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-72b NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB psammaplin a NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown 0.24 TTD , DGIDB pmid29671355-compound-71a NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB octanedioic acid hydroxyamide pyridin-4-ylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 4-hydroxy-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid quinolin-3-ylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-4-(3-phenyl-propionylamino)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-phg-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-45a NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB azumamide b NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-(biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-4-(4-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 4-chloro-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-ser-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 5-mercapto-pentanoic acid phenylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational histone deacetylase 4 HDAC4 NA cofactor NA drugbank cyclo(-l-am7(s2py)-d-a1in-l-ala-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-a2in-l-ala-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational histone deacetylase 4 HDAC4 NA cofactor NA drugbank pmid29671355-compound-50 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-2,2-diphenylacetamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-67 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB 8-oxo-8-phenyl-octanoic acid hydroxyamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-72a NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-2,2-diphenylpropanamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-9,10-dihydroanthracene-9-carboxamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-4-ylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-4-(5-phenyl-pentanoylamino)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-4-phenylacetylamino-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-oxalamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 5-(4-hydroxyphenyl)-3h-1,2-dithiole-3-thione NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-68b NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB st-3050 NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 6-benzenesulfonylhexanoic acid hydroxamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-43 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB 2,2-bis(3-fluorophenyl)-n-hydroxyacetamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-4-(2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-l-a1in-l-ala-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-70 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB 8-(biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD st-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-21 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB (e)-8-biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 2,2-bis(4-fluorophenyl)-n-hydroxyacetamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-62 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ph5-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 4-butyrylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental histone deacetylase 4 HDAC4 NA cofactor NA drugbank 7-(biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-4-(pentanoylamino-methyl)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 8-oxo-8-phenyl-octanoic acid NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-52 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB 5-(4-chloro-phenyl)-pentanoic acid hydroxyamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 6-(2-bromo-acetylamino)-hexanoic acid phenylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-56 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-l-2mephe-l-ala-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-(5-hydroxycarbamoyl-pentyl)-4-nitro-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-47b NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB octanedioic acid hydroxyamide pyridin-2-ylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-mercapto-n-(4-phenylthiazol-2-yl)heptanamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD santacruzamate a NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target inhibitor NA TTD , DGIDB 7-(biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-hydroxy-4-((r)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD cyclostellettamine derivative NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD octanedioic acid bis-hydroxyamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 6-mercapto-hexanoic acid phenylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid benzothiazol-2-ylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 2,2,2-trifluoro-1-{5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)carbonyl]thiophen-2-yl}ethane-1,1-diol small molecule NA experimental histone deacetylase 4 HDAC4 NA unknown NA drugbank azumamide e NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD n-(6-hydroxycarbamoyl-hexyl)-benzamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 8-mercapto-octanoic acid phenylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 7-(naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 2,2-bis(4-chlorophenyl)-n-hydroxyacetamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-31 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB 9,9,9-trifluoro-8-oxo-nonanoic acid phenylamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 6-benzenesulfinylhexanoic acid hydroxamide NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-47c NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-23 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ala-d-pro-) NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD 2-(methylsulfonylthio)ethyl 2-propylpentanoate NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD pmid29671355-compound-71b NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB largazole NA NA investigative histone deacetylase 4 HDAC4 Clinical trial target unknown 0.22 TTD , DGIDB pmid29671355-compound-25 NA NA patented histone deacetylase 4 HDAC4 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-23 NA NA patented histone deacetylase 5 HDAC5 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-67 NA NA patented histone deacetylase 5 HDAC5 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-62 NA NA patented histone deacetylase 5 HDAC5 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-43 NA NA patented histone deacetylase 5 HDAC5 Patented-recorded target unknown NA TTD , DGIDB panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC5 NA inhibitor 0.2 drugbank , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC5 NA inhibitor 0.77 drugbank , DGIDB pmid29671355-compound-31 NA NA patented histone deacetylase 5 HDAC5 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-45a NA NA patented histone deacetylase 5 HDAC5 Patented-recorded target unknown NA TTD , DGIDB tmp269 NA NA investigative histone deacetylase 5 HDAC5 Patented-recorded target inhibitor NA TTD , DGIDB pmid29671355-compound-25 NA NA patented histone deacetylase 5 HDAC5 Patented-recorded target unknown NA TTD , DGIDB pmid28092474-compound-33p NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-4-((r)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 4-benzoylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD citarinostat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 histone deacetylase 6 HDAC6 Clinical trial target unknown 0.58 TTD , DGIDB n-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32u NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-15 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n1-hydroxy-n8-(4-phenylthiazol-2-yl)octanediamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 6-benzenesulfonylhexanoic acid hydroxamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-39 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-24 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB bufexamac small molecule Dermatologic disorders[MeSHID:D012871],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] approved,withdrawn histone deacetylase 6 HDAC6 NA inhibitor 0.72 drugbank , DGIDB pmid29671355-compound-11 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 8-(biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-34a NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB (s)-2-amino-n-cyclopentyl-7-mercaptoheptanamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-(5-hydroxycarbamoyl-pentyl)-4-nitro-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-33g NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB droxinostat NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target inhibitor NA TTD , DGIDB pmid29671355-compound-22 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-56 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-4-(3-phenyl-propionylamino)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-ser-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 7-(biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32y NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-32v NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-38b NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-32j NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 7-(biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32i NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 8-oxo-8-phenyl-octanoic acid hydroxyamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-67 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 5-(4-hydroxyphenyl)-3h-1,2-dithiole-3-thione NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD (e)-8-biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32r NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33o NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-62 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33c NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-32m NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 7-(biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-19 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33j NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 6-mercapto-hexanoic acid phenylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 6-phenylsulfanylhexanoic acid hydroxamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-74 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-26 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-25 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 7-mercapto-n-(4-phenylthiazol-2-yl)heptanamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD santacruzamate a NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target inhibitor NA TTD , DGIDB 6-benzenesulfinylhexanoic acid hydroxamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-33e NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 7-(naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD diaryl amine derivative 3 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n-[5-(formyl-hydroxy-amino)-pentyl]-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD tubacin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative histone deacetylase 6 HDAC6 Clinical trial target inhibitor 1.45 TTD , DGIDB n1-(biphenyl-4-yl)-n8-hydroxyoctanediamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32p NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33m NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n-phenyl-6-(sulfamoylamino)hexanamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD nexturastat a NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target inhibitor NA TTD , DGIDB ucl-67022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-61 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ph4-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pracinostat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] investigational histone deacetylase 6 HDAC6 NA unknown 0.12 drugbank , DGIDB pmid28092474-compound-32l NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ph5-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-18 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC6 NA inhibitor 0.43 drugbank , DGIDB n-(2-mercapto-ethyl)-n'-phenyl-succinamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-hydroxy-4-(phenylacetylamino-methyl)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-d-a1in-l-ala-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-8 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB thioacetic acid s-(6-phenylcarbamoyl-hexyl) ester NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-34c NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ser(bzl)-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32f NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-32c NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 4-phenylbutyrohydroxamic acid NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid quinolin-3-ylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32n NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 9,9,9-trifluoro-8-oxo-nonanoic acid phenylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32k NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 4-butyrylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD st-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32t NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-13 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33f NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n1-(biphenyl-3-yl)-n8-hydroxyoctanediamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD vorinostat small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 6 HDAC6 NA inhibitor 0.66 drugbank , DGIDB pmid29671355-compound-23 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-ala-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-28 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-38a NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 8-mercapto-octanoic acid phenylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-l-a1in-l-ala-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD st-2986 NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC6 NA inhibitor 0.67 drugbank , DGIDB 5-mercapto-pentanoic acid phenylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD cyclostellettamine derivative NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD st-2741 NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-44 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-d-2mephe-l-ala-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD sulfonamide derivative 16 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-65a NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-31 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-32a NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB cyclo(-l-am7(s2py)-aib-l-phe-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 8-oxo-8-phenyl-octanoic acid NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-oxalamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-33k NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-4-(2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32z NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB niltubacin NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD romidepsin small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Continuance of life[MeSHID:D013534],Peripheral T-Cell Lymphoma[MeSHID:D016411],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 6 HDAC6 NA inhibitor 0.53 drugbank , DGIDB nqn-1 NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target inhibitor NA TTD , DGIDB 4-chloro-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-phg-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-34b NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33i NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-32d NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 4-dimethylamino-n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-a2in-l-ala-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32o NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 7-mercapto-heptanoic acid benzothiazol-2-ylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32q NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33l NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid19111466c7d NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-hydroxy-4-(pentanoylamino-methyl)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 9-(biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid phenylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 4-hydroxy-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-aib-l-ala-d-tic-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-21 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 6-phenoxy-hexane-1-thiol NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD ka2507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-32g NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-32e NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid20947351c16 NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-hydroxy-4-((s)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32x NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-16 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD psammaplin a NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown 0.33 TTD , DGIDB 7-mercapto-heptanoic acid pyridin-3-ylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32b NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 6-(2-bromo-acetylamino)-hexanoic acid phenylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-43 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB diaryl amine derivative 2 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-9 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB ikh-25 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 5-(4-chloro-phenyl)-pentanoic acid hydroxyamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD st-3050 NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-27 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 7-mercapto-heptanoic acid biphenyl-4-ylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-(6-hydroxycarbamoyl-hexyl)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid29671355-compound-73 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33a NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB octanedioic acid hydroxyamide pyridin-2-ylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 2-(methylsulfonylthio)ethyl 2-propylpentanoate NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-3-ylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-33h NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-4-phenylacetylamino-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD n-hydroxy-4-(5-phenyl-pentanoylamino)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32s NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB octanedioic acid bis-hydroxyamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-33d NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-14 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-4-(4-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD pmid28092474-compound-32h NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB 6-(9h-carbazol-9-yl)-n-hydroxyhexanamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD cyclo(-l-am7(s2py)-l-2mephe-l-ala-d-pro-) NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD diaryl amine derivative 4 NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB pmid28092474-compound-33b NA NA patented histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD , DGIDB octanedioic acid hydroxyamide pyridin-4-ylamide NA NA investigative histone deacetylase 6 HDAC6 Clinical trial target unknown NA TTD citarinostat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 histone deacetylase 6 HDAC6 Clinical trial target inhibitor 0.58 TTD , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC7 NA inhibitor 0.93 drugbank , DGIDB panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC7 NA inhibitor 0.4 drugbank , DGIDB pmid29671355-compound-31 NA NA patented histone deacetylase 7 HDAC7 Patented-recorded target unknown NA TTD , DGIDB tmp269 NA NA investigative histone deacetylase 7 HDAC7 Patented-recorded target inhibitor NA TTD , DGIDB pmid29671355-compound-45a NA NA patented histone deacetylase 7 HDAC7 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-21 NA NA patented histone deacetylase 7 HDAC7 Patented-recorded target unknown NA TTD , DGIDB trichostatin a small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental histone deacetylase 7 HDAC7 NA inhibitor NA drugbank , DGIDB pmid29671355-compound-62 NA NA patented histone deacetylase 7 HDAC7 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-43 NA NA patented histone deacetylase 7 HDAC7 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-56 NA NA patented histone deacetylase 7 HDAC7 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-25 NA NA patented histone deacetylase 7 HDAC7 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-67 NA NA patented histone deacetylase 7 HDAC7 Patented-recorded target unknown NA TTD , DGIDB st-3050 NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 4-benzoylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD st-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved histone deacetylase 8 HDAC8 NA unknown NA drugbank pmid29671355-compound-67 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-61 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB 7-mercapto-heptanoic acid quinolin-3-ylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 5-(4-methyl-benzoylamino)-biphenyl-3,4'-dicarboxylic acid 3-dimethylamide-4'-hydroxyamide small molecule NA experimental histone deacetylase 8 HDAC8 NA unknown NA drugbank 6-benzenesulfinylhexanoic acid hydroxamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 4-butyrylamino-n-hydroxy-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-(4-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD thioacetic acid s-(6-phenylcarbamoyl-hexyl) ester NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD trichostatin a small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental histone deacetylase 8 HDAC8 NA inhibitor NA drugbank , DGIDB 6-benzenesulfonylhexanoic acid hydroxamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 4-chloro-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-(3-phenyl-propionylamino)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 5-(4-chloro-phenyl)-pentanoic acid hydroxyamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-succinamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD (e)-8-biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-(methyl{[5-(2-pyridinyl)-2-thienyl]sulfonyl}amino)benzamide small molecule NA experimental histone deacetylase 8 HDAC8 NA unknown NA drugbank niltubacin NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental histone deacetylase 8 HDAC8 NA cofactor NA drugbank s-2,9-dioxo-9-(phenylamino)nonyl ethanethioate NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-((r)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 7-(naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD azithromycin-n-benzyltriazolylhexahydroxamic acid NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 8-mercapto-octanoic acid phenylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD pmid29671355-compound-13 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved histone deacetylase 8 HDAC8 NA unknown NA drugbank pmid29671355-compound-36 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB octanedioic acid bis-hydroxyamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 9,9,9-trifluoro-8-oxo-nonanoic acid phenylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD nmb-t-bmx-os01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histone deacetylase 8 HDAC8 NA cofactor NA drugbank vorinostat small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 8 HDAC8 NA inhibitor 0.44 drugbank , DGIDB 7-(biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-(5-hydroxycarbamoyl-pentyl)-4-nitro-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-(6-hydroxycarbamoyl-hexyl)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved histone deacetylase 8 HDAC8 NA unknown NA drugbank cyclostellettamine derivative NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-4-ylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-(pentanoylamino-methyl)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid biphenyl-3-ylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD desclasinose azithromycinarylalkyl hydroxamate NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 9-(biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 7-(biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD pmid29671355-compound-25 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB octanedioic acid hydroxyamide pyridin-4-ylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 2-(methylsulfonylthio)ethyl 2-propylpentanoate NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-(2-mercapto-ethyl)-n'-phenyl-oxalamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 4-phenylbutyrohydroxamic acid NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD azithromycin-n-benzyltriazolyloctahydroxamic acid NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD pmid29671355-compound-44 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB pmid29671355-compound-43 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB 4-dimethylamino-n-(6-mercapto-hexyl)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC8 NA inhibitor 0.27 drugbank , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC8 NA inhibitor 0.72 drugbank , DGIDB 4-(dimethylamino)-n-[7-(hydroxyamino)-7-oxoheptyl]benzamide small molecule NA experimental histone deacetylase 8 HDAC8 NA unknown NA drugbank 6-(2-mercaptoacetamido)-n-phenylhexanamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD pci-34051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-(5-phenyl-pentanoylamino)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD octanedioic acid hydroxyamide pyridin-2-ylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 6-mercapto-hexanoic acid phenylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD vorinostat small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 8 HDAC8 NA unknown 0.44 drugbank , DGIDB pmid29671355-compound-68b NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB nbm-bmx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD pmid29671355-compound-62 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB 7-mercapto-heptanoic acid pyridin-3-ylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-(naphthalen-1-yl)benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD azithromycinarylalkylhydroxamic acid NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD psammaplin a NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown 0.24 TTD , DGIDB 6-phenylsulfanylhexanoic acid hydroxamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD pmid29671355-compound-56 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB 5-(4-hydroxyphenyl)-3h-1,2-dithiole-3-thione NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-3-(naphthalen-1-yl)acrylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 6-phenoxy-hexane-1-thiol NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational histone deacetylase 8 HDAC8 NA unknown NA drugbank 7-(biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD pmid29671355-compound-37 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB 8-(biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-phenylacetylamino-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-4-(2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD st-2986 NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid benzothiazol-2-ylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD (2e)-n-hydroxy-3-[1-methyl-4-(phenylacetyl)-1h-pyrrol-2-yl]prop-2-enamide small molecule NA experimental histone deacetylase 8 HDAC8 NA unknown NA drugbank n-hydroxy-4-((s)-2-phenyl-butyrylamino)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 9-mercapto-8-oxo-n-phenylnonanamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational histone deacetylase 8 HDAC8 NA cofactor NA drugbank 6-(2-bromo-acetylamino)-hexanoic acid phenylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-3-phenoxybenzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 8-oxo-8-phenyl-octanoic acid NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational histone deacetylase 8 HDAC8 NA cofactor NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved histone deacetylase 8 HDAC8 NA unknown NA drugbank pmid29671355-compound-31 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB azithromycin-n-benzyltriazolylnonahydroxamic acid NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD pmid29671355-compound-23 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB n-hydroxy-4-(phenylacetylamino-methyl)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved histone deacetylase 8 HDAC8 NA unknown NA drugbank 4-hydroxy-n-(5-hydroxycarbamoyl-pentyl)-benzamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD 7-mercapto-heptanoic acid phenylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD droxinostat NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target inhibitor NA TTD , DGIDB coumarin 120 small molecule NA experimental histone deacetylase 8 HDAC8 NA unknown NA drugbank pmid29671355-compound-21 NA NA patented histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD , DGIDB 5-mercapto-pentanoic acid phenylamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD n-hydroxy-1-naphthamide NA NA investigative histone deacetylase 8 HDAC8 Clinical trial target unknown NA TTD valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 9 HDAC9 NA inhibitor NA drugbank , DGIDB panobinostat small molecule Multiple Myeloma[MeSHID:D009101],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] approved,investigational histone deacetylase HDAC9 NA inhibitor 0.44 drugbank , DGIDB pmid29671355-compound-62 NA NA patented histone deacetylase 9 HDAC9 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-21 NA NA patented histone deacetylase 9 HDAC9 Patented-recorded target unknown NA TTD , DGIDB belinostat small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Thrombocytopenia[MeSHID:D013921] approved,investigational histone deacetylase HDAC9 NA inhibitor 0.86 drugbank , DGIDB pmid29671355-compound-25 NA NA patented histone deacetylase 9 HDAC9 Patented-recorded target unknown NA TTD , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 9 HDAC9 NA inhibitor 0.23 drugbank , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone deacetylase 9 HDAC9 NA inhibitor 0.42 drugbank , DGIDB pmid29671355-compound-73 NA NA patented histone deacetylase 9 HDAC9 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-43 NA NA patented histone deacetylase 9 HDAC9 Patented-recorded target unknown NA TTD , DGIDB pmid29671355-compound-45a NA NA patented histone deacetylase 9 HDAC9 Patented-recorded target unknown NA TTD , DGIDB tmp269 NA NA investigative histone deacetylase 9 HDAC9 Patented-recorded target inhibitor NA TTD , DGIDB pmid29671355-compound-31 NA NA patented histone deacetylase 9 HDAC9 Patented-recorded target unknown NA TTD , DGIDB pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical histidine decarboxylase HDC NA cofactor NA drugbank alpha-fmh NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] phase 1 histidine decarboxylase HDC Clinical trial target unknown NA TTD , DGIDB brocresine NA NA investigative histidine decarboxylase HDC Clinical trial target unknown NA TTD histidine small molecule Serum[MeSHID:D044967],Uremia[MeSHID:D014511],Anemia[MeSHID:D000740],Rheumatoid Arthritis[MeSHID:D001172] investigational,nutraceutical histidine decarboxylase HDC NA unknown NA drugbank lixivaptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Hyponatremia[MeSHID:D007010],Skin Diseases, Infectious[MeSHID:D012874] phase 3 histidine decarboxylase HDC Clinical trial target unknown 15.91 TTD , DGIDB ama NA NA investigative histidine decarboxylase HDC Clinical trial target inhibitor NA TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hepatoma-derived growth factor HDGF NA unknown NA drugbank incagn2390 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 hepatitis a virus cellular receptor 2 Hepatitis A virus HAVCR2 Clinical trial target unknown NA TTD ly3415244 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 hepatitis a virus cellular receptor 2 Hepatitis A virus HAVCR2 Clinical trial target unknown NA TTD mbg453 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 hepatitis a virus cellular receptor 2 Hepatitis A virus HAVCR2 Clinical trial target unknown NA TTD bgb-a425 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 hepatitis a virus cellular receptor 2 Hepatitis A virus HAVCR2 Clinical trial target unknown NA TTD gsk4069889 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 hepatitis a virus cellular receptor 2 Hepatitis A virus HAVCR2 Clinical trial target unknown NA TTD ly3321367 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 hepatitis a virus cellular receptor 2 Hepatitis A virus HAVCR2 Clinical trial target unknown NA TTD ro7121661 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Squamous cell carcinoma of esophagus[MeSHID:C562729] phase 2 hepatitis a virus cellular receptor 2 Hepatitis A virus HAVCR2 Clinical trial target unknown NA TTD sym023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 hepatitis a virus cellular receptor 2 Hepatitis A virus HAVCR2 Clinical trial target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hephaestin-like protein 1 HEPHL1 NA cofactor NA drugbank n-acetyl-glucosamine thiazoline small molecule NA experimental beta-hexosaminidase subunit beta HEXB NA unknown NA drugbank (2r,3r,4s,5r)-2-acetamido-3,4-dihydroxy-5-hydroxymethyl-piperidine small molecule NA experimental beta-hexosaminidase subunit beta HEXB NA unknown NA drugbank pyrimethamine small molecule Toxoplasmosis[MeSHID:D014123],Acute malaria[MeSHID:C531736],Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beta-hexosaminidase subunit beta HEXB NA unknown NA drugbank 2-acetamido-2-deoxy-d-glucono-1,5-lactone small molecule NA experimental beta-hexosaminidase subunit beta HEXB NA unknown NA drugbank ficlatuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Pancreatic carcinoma[MeSHID:C562463],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Squamous cell carcinoma[MeSHID:D002294] phase 2 hepatocyte growth factor HGF Clinical trial target antibody 13.26 TTD , DGIDB abi-011 NA Ankle brachial pressure index (observable entity)[MeSHID:D055109],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 hepatocyte growth factor HGF Clinical trial target unknown NA TTD , DGIDB vm-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Peripheral Arterial Diseases[MeSHID:D058729],Diabetic Foot[MeSHID:D017719],Peripheral Vascular Diseases[MeSHID:D016491],Angina Pectoris[MeSHID:D000787],Peripheral Neuropathy[MeSHID:D010523] phase 3 hepatocyte growth factor HGF Clinical trial target unknown NA TTD , DGIDB rilotumumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Glioma[MeSHID:D005910] discontinued in phase 2 hepatocyte growth factor HGF Clinical trial target antibody 13.26 TTD , DGIDB donaperminogene seltoplasmid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Diabetic Neuropathies[MeSHID:D003929] phase 3 hepatocyte growth factor HGF Clinical trial target unknown NA TTD foretinib small molecule NA investigational hepatocyte growth factor HGF NA unknown NA drugbank o2-sulfo-glucuronic acid small molecule NA experimental,investigative hepatocyte growth factor HGF Clinical trial target unknown NA TTD , drugbank ficlatuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Pancreatic carcinoma[MeSHID:C562463],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Squamous cell carcinoma[MeSHID:D002294] phase 2 hepatocyte growth factor HGF Clinical trial target unknown 13.26 TTD , DGIDB mp0250 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 hepatocyte growth factor HGF Clinical trial target unknown 2.65 TTD , DGIDB abt-510 small molecule Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational hepatocyte growth factor HGF NA unknown NA drugbank rilotumumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Glioma[MeSHID:D005910] discontinued in phase 2 hepatocyte growth factor HGF Clinical trial target inhibitor 13.26 TTD , DGIDB tak-701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 hepatocyte growth factor HGF Clinical trial target unknown NA TTD , DGIDB ficlatuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Pancreatic carcinoma[MeSHID:C562463],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Squamous cell carcinoma[MeSHID:D002294] phase 2 hepatocyte growth factor HGF Clinical trial target inhibitor 13.26 TTD , DGIDB heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational hepatocyte growth factor HGF NA unknown NA drugbank n,o6-disulfo-glucosamine small molecule NA experimental,investigative hepatocyte growth factor HGF Clinical trial target unknown NA TTD , drugbank citric acid small molecule NA approved,nutraceutical,vet_approved hepatocyte growth factor-regulated tyrosine kinase substrate HGS NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 3-hydroxyisobutyrate dehydrogenase, mitochondrial HIBADH NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational 3-hydroxyisobutyryl-coa hydrolase, mitochondrial HIBCH NA unknown NA drugbank enmd-1198 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 hypoxia-inducible factor 1 alpha HIF1A Clinical trial target unknown NA TTD , DGIDB isis 175510 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD hif-1alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 4 hypoxia-inducible factor 1 alpha HIF1A Clinical trial target unknown NA TTD , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational hypoxia-inducible factor 1-alpha HIF1A NA modulator NA drugbank enmd-1198 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational hypoxia-inducible factor 1-alpha HIF1A NA unknown NA drugbank , DGIDB 2-methoxyestradiol NA Arthritis[MeSHID:D001168],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of breast[MeSHID:D001943],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 hypoxia-inducible factor 1 alpha HIF1A Clinical trial target unknown NA TTD px-478 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational hypoxia-inducible factor 1-alpha HIF1A NA unknown 0.47 drugbank , DGIDB (5-(1-benzyl-1h-indazol-3-yl)furan-2-yl)methanol NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD pyrrolidine carboxamide derivative 1 NA NA patented hypoxia-inducible factor 1 alpha HIF1A Clinical trial target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational hypoxia-inducible factor 1-alpha HIF1A NA modulator NA drugbank isis 298699 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD px-478 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 hypoxia-inducible factor 1 alpha HIF1A Clinical trial target unknown 0.47 TTD , DGIDB fg-2216 small molecule Anemia[MeSHID:D000740],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational hypoxia-inducible factor 1-alpha HIF1A NA unknown NA drugbank pt2385 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of brain[MeSHID:D001932],Von Hippel-Lindau Syndrome[MeSHID:D006623],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD isis 298744 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD 2-methoxyestradiol small molecule Arthritis[MeSHID:D001168],Rheumatoid Arthritis[MeSHID:D001172],Malignant neoplasm of breast[MeSHID:D001943],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational hypoxia-inducible factor 1-alpha HIF1A NA unknown NA drugbank isis 298702 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD hydralazine small molecule treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Essential Hypertension[MeSHID:D000075222],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved hypoxia-inducible factor 1-alpha HIF1A NA inducer NA drugbank isis 298746 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD isis 298697 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD ezn-2968 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 hypoxia-inducible factor 1 alpha HIF1A Clinical trial target antagonist NA TTD , DGIDB isis 298743 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD isis 298712 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD isis 298711 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD isis 298700 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD px-478 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational hypoxia-inducible factor 1-alpha HIF1A NA inhibitor 0.47 drugbank , DGIDB isis 298701 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD px-478 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 hypoxia-inducible factor 1 alpha HIF1A Clinical trial target inhibitor 0.47 TTD , DGIDB it-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 hypoxia-inducible factor 1 alpha HIF1A Clinical trial target unknown NA TTD isis 298745 NA NA investigative hif1-alpha messenger rna HIF1A Clinical trial target unknown NA TTD n-(carboxycarbonyl)-d-phenylalanine small molecule NA experimental hypoxia-inducible factor 1-alpha inhibitor HIF1AN NA unknown NA drugbank d-tartaric acid small molecule NA experimental hypoxia-inducible factor 1-alpha inhibitor HIF1AN NA unknown NA drugbank guanosine-5'-monophosphate small molecule NA experimental histidine triad nucleotide-binding protein 1 HINT1 NA unknown NA drugbank 8-bromo-adenosine-5'-monophosphate small molecule NA experimental histidine triad nucleotide-binding protein 1 HINT1 NA unknown NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical histidine triad nucleotide-binding protein 1 HINT1 NA product of NA drugbank 5'-o-(n-ethyl-sulfamoyl)adenosine small molecule NA experimental histidine triad nucleotide-binding protein 1 HINT1 NA unknown NA drugbank adenosine-5'-ditungstate small molecule NA experimental histidine triad nucleotide-binding protein 1 HINT1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational homeodomain-interacting protein kinase 2 HIPK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational homeodomain-interacting protein kinase 3 HIPK3 NA inhibitor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone h1.4 HIST1H1E NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histone h2b type 1-c/e/f/g/i HIST1H2BC NA unknown NA drugbank alpha-d-glucose 6-phosphate small molecule NA experimental hexokinase-1 HK1 NA unknown NA drugbank beta-d-glucose small molecule NA experimental hexokinase-1 HK1 NA unknown NA drugbank lonidamine small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Neoplasms[MeSHID:D009369],Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational hexokinase-1 HK1 NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental hexokinase-1 HK1 NA unknown NA drugbank vda-1102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623] phase 2 hexokinase-2 HK2 Clinical trial target unknown NA TTD 3-indolebutyric acid small molecule NA experimental hla class i histocompatibility antigen, a-2 alpha chain HLA-A NA unknown NA drugbank coccidioides immitis spherule biotech Coccidioidomycosis[MeSHID:D003047],Lung[MeSHID:D008168],Delayed Hypersensitivity[MeSHID:D006968] approved hla class i histocompatibility antigen, a-3 alpha chain HLA-A NA unknown NA drugbank nelipepimut-s biotech Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471] investigational hla class i histocompatibility antigen, a-3 alpha chain HLA-A NA unknown NA drugbank nelipepimut-s biotech Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471] investigational hla class i histocompatibility antigen, a-2 alpha chain HLA-A NA unknown NA drugbank coccidioides immitis spherule biotech Coccidioidomycosis[MeSHID:D003047],Lung[MeSHID:D008168],Delayed Hypersensitivity[MeSHID:D006968] approved hla class i histocompatibility antigen, a-2 alpha chain HLA-A NA binder NA drugbank coccidioides immitis spherule biotech Coccidioidomycosis[MeSHID:D003047],Lung[MeSHID:D008168],Delayed Hypersensitivity[MeSHID:D006968] approved hla class i histocompatibility antigen, b-27 alpha chain HLA-B NA unknown NA drugbank n-formylmethionine small molecule NA experimental hla class i histocompatibility antigen, b-27 alpha chain HLA-B NA unknown NA drugbank velimogene aliplasmid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 hla class i antigen b-7 HLA-B Clinical trial target unknown NA TTD , DGIDB abacavir small molecule HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hla class i histocompatibility antigen, b-57 alpha chain HLA-B NA unknown 0.46 drugbank , DGIDB 1d09c3 biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational hla-dr HLA-DRA NA unknown NA drugbank coccidioides immitis spherule biotech Coccidioidomycosis[MeSHID:D003047],Lung[MeSHID:D008168],Delayed Hypersensitivity[MeSHID:D006968] approved hla-dr HLA-DRA NA binder NA drugbank glatiramer biotech Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Relapse[MeSHID:D012008] approved,investigational hla class ii histocompatibility antigen, drb1-1 beta chain HLA-DRB1 NA binder NA drugbank coccidioides immitis spherule biotech Coccidioidomycosis[MeSHID:D003047],Lung[MeSHID:D008168],Delayed Hypersensitivity[MeSHID:D006968] approved hla-dr HLA-DRB1 NA binder NA drugbank glatiramer acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved mhc class ii antigen drb1*1 HLA-DRB1 Successful target unknown NA TTD , DGIDB 1d09c3 biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational hla-dr HLA-DRB1 NA unknown NA drugbank coccidioides immitis spherule biotech Coccidioidomycosis[MeSHID:D003047],Lung[MeSHID:D008168],Delayed Hypersensitivity[MeSHID:D006968] approved hla-dr HLA-DRB3 NA binder NA drugbank 1d09c3 biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational hla-dr HLA-DRB3 NA unknown 7.07 drugbank , DGIDB 1d09c3 biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational hla-dr HLA-DRB4 NA unknown 21.22 drugbank , DGIDB coccidioides immitis spherule biotech Coccidioidomycosis[MeSHID:D003047],Lung[MeSHID:D008168],Delayed Hypersensitivity[MeSHID:D006968] approved hla-dr HLA-DRB4 NA binder NA drugbank 1d09c3 biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational hla-dr HLA-DRB5 NA unknown 5.3 drugbank , DGIDB coccidioides immitis spherule biotech Coccidioidomycosis[MeSHID:D003047],Lung[MeSHID:D008168],Delayed Hypersensitivity[MeSHID:D006968] approved hla-dr HLA-DRB5 NA binder NA drugbank ttx-080 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 mhc class i antigen g HLA-G Clinical trial target unknown NA TTD biotin small molecule NA approved,investigational,nutraceutical biotin--protein ligase HLCS NA substrate NA drugbank theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved minor histocompatibility antigen h13 HM13 NA unknown NA drugbank p-9808 NA Disorders of Porphyrin Metabolism[MeSHID:D011164],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 porphobilinogen deaminase HMBS Clinical trial target unknown NA TTD , DGIDB chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Malaria[MeSHID:D008288],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved high mobility group protein b1 HMGB1 NA inhibitor NA drugbank ethyl pyruvate small molecule Sepsis[MeSHID:D018805],Reperfusion Injury[MeSHID:D015427],Disease[MeSHID:D004194],Burn injury[MeSHID:D002056],Infection[MeSHID:D007239] investigational high mobility group protein b1 HMGB1 NA unknown NA drugbank chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved,investigational,vet_approved high mobility group protein b1 HMGB1 NA inhibitor NA drugbank 3-hydroxyglutaric acid small molecule NA experimental hydroxymethylglutaryl-coa lyase, mitochondrial HMGCL NA unknown NA drugbank quinoline derivative 16 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB hexahydro naphthalene derivative 3 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB cerivastatin NA Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Multiple Myeloma[MeSHID:D009101] approved hmg-coa reductase HMGCR Successful target inhibitor 6.37 TTD , DGIDB fluvastatin small molecule Coronary Arteriosclerosis[MeSHID:D003324],Disease Progression[MeSHID:D018450],Hypercholesterolemia[MeSHID:D006937],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 2.12 drugbank , DGIDB poly-substituted azoles statin lactone derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB tocotrienol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] approved hmg-coa reductase HMGCR Successful target unknown 3.18 TTD , DGIDB premarin/pravachol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 3 hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB quinoline derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid1527791c29 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD rosuvastatin NA Homozygote[MeSHID:D006720],Diabetes Mellitus[MeSHID:D003920],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Coronary artery[MeSHID:D003331],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Cerebrovascular accident[MeSHID:D020521],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target unknown 2.94 TTD , DGIDB atorvastatin NA Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved hmg-coa reductase HMGCR Successful target unknown 1.01 TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA stimulator NA drugbank bervastatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2 hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1656041c4ff NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid8246233c28 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD rosuvastatin small molecule Homozygote[MeSHID:D006720],Diabetes Mellitus[MeSHID:D003920],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Coronary artery[MeSHID:D003331],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Cerebrovascular accident[MeSHID:D020521],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 2.94 drugbank , DGIDB pmid1992149c13 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pravastatin NA Serum[MeSHID:D044967],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Myocardial Infarction[MeSHID:D009203],Transient Cerebral Ischemia[MeSHID:D002546],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Cardiac Death[MeSHID:D003643],Premature Birth[MeSHID:D047928],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Term Birth[MeSHID:D047929],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia, Familial[MeSHID:D006938],Disease[MeSHID:D004194],Myocardium[MeSHID:D009206],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Risk Reduction[MeSHID:D040242],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target unknown 1.27 TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA unknown NA drugbank pitavastatin small molecule Coronary Arteriosclerosis[MeSHID:D003324],Diabetes Mellitus[MeSHID:D003920],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipidemia[MeSHID:D006949],Coronary heart disease[MeSHID:D003327],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Cerebrovascular accident[MeSHID:D020521],Chronic Kidney Diseases[MeSHID:D051436],Myocardial Infarction[MeSHID:D009203],Aortic Aneurysm, Abdominal[MeSHID:D017544],Dyslipidemias[MeSHID:D050171],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938] approved 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 3.18 drugbank , DGIDB lovastatin NA Diabetes Mellitus[MeSHID:D003920],Angina, Unstable[MeSHID:D000789],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Premature Birth[MeSHID:D047928],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Neoplasm Metastasis[MeSHID:D009362],Menarche[MeSHID:D008572],Cerebrovascular accident[MeSHID:D020521],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target inhibitor 1.7 TTD , DGIDB teriflunomide NA Multiple Sclerosis[MeSHID:D009103],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Rheumatoid Arthritis[MeSHID:D001172] approved hmg-coa reductase HMGCR Successful target unknown 1.59 TTD , DGIDB pmid1656041c4rr NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2231594c3k NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD ncx-6560 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid17574412c33 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD atorvastatin NA Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved hmg-coa reductase HMGCR Successful target inhibitor 1.01 TTD , DGIDB pitavastatin calcium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] approved hmg-coa reductase HMGCR Successful target inhibitor 1.59 TTD , DGIDB pmid1656041c11dd NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD mevastatin small molecule NA experimental 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 6.37 drugbank , DGIDB xzk-monascus NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid2231594c3j NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD aspirin NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target unknown 0.04 TTD , DGIDB pmid2153213c1e NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inducer NA drugbank pmid2231594c3u NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD simvastatin NA Diabetes Mellitus[MeSHID:D003920],Peripheral Vascular Diseases[MeSHID:D016491],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Cerebrovascular Disorders[MeSHID:D002561],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia[MeSHID:D006937],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Hyperlipidemia[MeSHID:D006949],Coronary heart disease[MeSHID:D003327],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target unknown 1.24 TTD , DGIDB fluvastatin NA Coronary Arteriosclerosis[MeSHID:D003324],Disease Progression[MeSHID:D018450],Hypercholesterolemia[MeSHID:D006937],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target unknown 2.12 TTD , DGIDB crilvastatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 hmg-coa reductase HMGCR Successful target unknown 3.18 TTD , DGIDB pmid7932551c9 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 1.01 drugbank , DGIDB pitavastatin calcium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] approved hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid2153213c2f NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid17574411c41 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2153213c2c NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD gfptgg NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1656041c11jj NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD (z)-7-octedecan-9-ynoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1992149c9 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD sterol derivative 3 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid8246234c3h NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD lovastatin NA Diabetes Mellitus[MeSHID:D003920],Angina, Unstable[MeSHID:D000789],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Premature Birth[MeSHID:D047928],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Neoplasm Metastasis[MeSHID:D009362],Menarche[MeSHID:D008572],Cerebrovascular accident[MeSHID:D020521],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target unknown 1.7 TTD , DGIDB pmid8246233c5ab NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2153213c1a NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid27537201-compound-figure13b NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB 3-hydroxy-3-methyl-glutaric acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD sterol derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB (r)-mevalonate NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD 7,9-tetradecadiynoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD bmy-21950 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 hmg-coa reductase HMGCR Successful target unknown NA TTD pmid17560788c29f NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD 1,4-dithiothreitol NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pravastatin small molecule Serum[MeSHID:D044967],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Myocardial Infarction[MeSHID:D009203],Transient Cerebral Ischemia[MeSHID:D002546],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Cardiac Death[MeSHID:D003643],Premature Birth[MeSHID:D047928],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Term Birth[MeSHID:D047929],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia, Familial[MeSHID:D006938],Disease[MeSHID:D004194],Myocardium[MeSHID:D009206],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Risk Reduction[MeSHID:D040242],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 1.27 drugbank , DGIDB pmid27537201-compound-figure15a NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB simvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Peripheral Vascular Diseases[MeSHID:D016491],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Cerebrovascular Disorders[MeSHID:D002561],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia[MeSHID:D006937],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Hyperlipidemia[MeSHID:D006949],Coronary heart disease[MeSHID:D003327],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 1.24 drugbank , DGIDB poly-substituted azoles statin lactone derivative 2 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB cerivastatin small molecule Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Multiple Myeloma[MeSHID:D009101] approved,withdrawn 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 6.37 drugbank , DGIDB nicotinamide adenine dinucleotide phosphate small molecule NA experimental 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA unknown NA drugbank pmid17574411c42 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD quinoline derivative 17 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB 5-ketodihydromevinolin NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid15686906c29 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid8426367c18 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2909732c7 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD glpdgg peptide NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid27537201-compound-figure17 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB gfpegg NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD 1,4-dithiothreitol small molecule NA experimental 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA unknown NA drugbank tak-475 small molecule Hyperlipidemia[MeSHID:D006949] investigational 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA unknown NA drugbank pmid27537201-compound-figure15b NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB aspirin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Myocardial Infarction[MeSHID:D009203],Cardiovascular Diseases[MeSHID:D002318] approved hmg-coa reductase HMGCR Successful target unknown 0.04 TTD , DGIDB pmid1656041c11nn NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD coenzyme a NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1656041c74 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD (s)-hmg-coa small molecule NA experimental 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA unknown NA drugbank pmid2153213c2d NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD brutieridin NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pitavastatin derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid2296027c25 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2296036c2g NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD nicotinamide-adenine-dinucleotide NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1895299c4p NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD ncx-1067 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD dalvastatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 3 hmg-coa reductase HMGCR Successful target unknown NA TTD coenzyme a small molecule NA investigational,nutraceutical 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA unknown NA drugbank 2'-monophosphoadenosine 5'-diphosphoribose NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid27537201-compound-figure13c NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid2153213c13b NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 1.01 drugbank , DGIDB pmid2231594c3q NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid27537201-compound-figure11 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pravastatin derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB 9-octadecynoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD 7,9-octadecadiynoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD laropiprant NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161] phase 4 hmg-coa reductase HMGCR Successful target unknown 0.45 TTD , DGIDB bpl-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1875346c18 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid8246237c18t NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD fpyvae peptide NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD gfpdgg NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD glptgg NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pf-3052334 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2296027c29 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD 2-cyclopropyl-4-substituted-phenoxy-quinoline derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pravastatin NA Serum[MeSHID:D044967],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Myocardial Infarction[MeSHID:D009203],Transient Cerebral Ischemia[MeSHID:D002546],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Cardiac Death[MeSHID:D003643],Premature Birth[MeSHID:D047928],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Term Birth[MeSHID:D047929],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia, Familial[MeSHID:D006938],Disease[MeSHID:D004194],Myocardium[MeSHID:D009206],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Risk Reduction[MeSHID:D040242],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target inhibitor 1.27 TTD , DGIDB pmid2153213c13g NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1895299c6v NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid19502059c25d NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD crestor/trilipix NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] approved hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB lactol derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB statin NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative hmg-coa reductase HMGCR Successful target unknown NA TTD hexahydro naphthalene derivative 2 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB cerivastatin NA Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Multiple Myeloma[MeSHID:D009101] approved hmg-coa reductase HMGCR Successful target unknown 6.37 TTD , DGIDB o-hydroxyatorvastatin NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD atorvastatin NA Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target inhibitor 1.01 TTD , DGIDB f(4-fluoro)vae NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD (e)-5-octadecen-7,9-diynoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid18072721c50 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2296036c2t NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid15686906c17 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2153213c1f NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1992138c8b NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD poly-substituted miazine derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid1656041c11ff NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD hexahydro naphthalene derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid8246233c35 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD rawsonol NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid2296036c4i NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD lactol derivative 2 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB pmid18155906c16f NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD 6-hydroxy-7,9-octadecadiynoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD fluvastatin NA Coronary Arteriosclerosis[MeSHID:D003324],Disease Progression[MeSHID:D018450],Hypercholesterolemia[MeSHID:D006937],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target inhibitor 2.12 TTD , DGIDB mt-001 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative hmg-coa reductase HMGCR Successful target unknown NA TTD (e)-octadecan-9-ynoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid1895299c1 NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD 3-(1,3 dodecadiynyl)-6-oxiranebutanoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA stimulator NA drugbank sterol derivative 2 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB simvastatin NA Diabetes Mellitus[MeSHID:D003920],Peripheral Vascular Diseases[MeSHID:D016491],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Cerebrovascular Disorders[MeSHID:D002561],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia[MeSHID:D006937],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Hyperlipidemia[MeSHID:D006949],Coronary heart disease[MeSHID:D003327],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target inhibitor 1.24 TTD , DGIDB pmid2296036c4d NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD pmid18412317c13b NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD dfgyvae NA NA investigative hmg-coa reductase HMGCR Successful target inhibitor NA TTD , DGIDB meglutol small molecule NA experimental 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA unknown NA drugbank rbx10558 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 hmg-coa reductase HMGCR Successful target unknown NA TTD atorvastatin lactole derivative 1 NA NA patented hmg-coa reductase HMGCR Successful target unknown NA TTD , DGIDB (z)-5-octadecen-7,9-diynoic acid NA NA investigative hmg-coa reductase HMGCR Successful target unknown NA TTD lovastatin small molecule Diabetes Mellitus[MeSHID:D003920],Angina, Unstable[MeSHID:D000789],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Premature Birth[MeSHID:D047928],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Neoplasm Metastasis[MeSHID:D009362],Menarche[MeSHID:D008572],Cerebrovascular accident[MeSHID:D020521],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR NA inhibitor 1.7 drugbank , DGIDB glenvastatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 hmg-coa reductase HMGCR Successful target unknown NA TTD rosuvastatin NA Homozygote[MeSHID:D006720],Diabetes Mellitus[MeSHID:D003920],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Coronary artery[MeSHID:D003331],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Cerebrovascular accident[MeSHID:D020521],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target inhibitor 2.94 TTD , DGIDB atorvastatin NA Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hmg-coa reductase HMGCR Successful target unknown 1.01 TTD , DGIDB (7r,12r,13r)-13-formyl-12,14-dihydroxy-3,5,7-trimethyltetradeca-2,4-dienoic acid small molecule NA experimental hydroxymethylglutaryl-coa synthase, cytoplasmic HMGCS1 NA unknown NA drugbank 3-sulfinoalanine NA NA investigative hydroxymethylglutaryl-coa synthase 2 HMGCS2 Literature-reported target unknown NA TTD acetoacetyl-coenzyme a NA NA investigative hydroxymethylglutaryl-coa synthase 2 HMGCS2 Literature-reported target unknown NA TTD hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved hyaluronan mediated motility receptor HMMR NA binder NA drugbank biliverdine ix alpha small molecule NA experimental,investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD , drugbank 2-propanol, isopropanol NA NA investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD heme NA NA investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD 1-(adamantan-1-yl)-2-(1h-imidazol-1-yl)ethanone small molecule NA experimental,investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD , drugbank 12-phenylheme small molecule NA experimental,investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD , drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical heme oxygenase 1 HMOX1 NA unknown NA drugbank 1-({2-[2-(4-chlorophenyl)ethyl]-1,3-dioxolan-2-yl}methyl)-1h-imidazole small molecule NA experimental heme oxygenase 1 HMOX1 NA unknown NA drugbank formic acid small molecule NA experimental,investigational,investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD , drugbank 2-phenylheme small molecule NA experimental,investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD , drugbank stannsoporfin small molecule Liver diseases[MeSHID:D008107],Metabolic Diseases[MeSHID:D008659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperbilirubinemia, Neonatal[MeSHID:D051556] investigational,phase 2 heme oxygenase 1 HMOX1 Clinical trial target unknown 55.69 TTD , drugbank , DGIDB verdoheme small molecule NA experimental,investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD , drugbank tin protoporphyrin NA NA investigative heme oxygenase 1 HMOX1 Clinical trial target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical heme oxygenase 2 HMOX2 NA unknown NA drugbank stannsoporfin small molecule Liver diseases[MeSHID:D008107],Metabolic Diseases[MeSHID:D008659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperbilirubinemia, Neonatal[MeSHID:D051556] investigational heme oxygenase 2 HMOX2 NA unknown 63.65 drugbank , DGIDB d-norleucine small molecule NA experimental hepatocyte nuclear factor 1-alpha HNF1A NA unknown NA drugbank norleucine NA NA phase 1/2 hepatocyte nuclear factor 1-alpha HNF1A Clinical trial target unknown 127.3 TTD , DGIDB myristic acid small molecule NA experimental hepatocyte nuclear factor 4-alpha HNF4A NA unknown NA drugbank avi-4557 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigational hepatocyte nuclear factor 4-alpha HNF4A NA unknown NA drugbank lauric acid small molecule NA approved,experimental hepatocyte nuclear factor 4-alpha HNF4A NA unknown NA drugbank palmitic acid small molecule NA approved hepatocyte nuclear factor 4-gamma HNF4G NA unknown NA drugbank amodiaquine small molecule Acute malaria[MeSHID:C531736],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational histamine n-methyltransferase HNMT Successful target inhibitor 12.73 TTD , drugbank , DGIDB diphenhydramine NA Pruritus[MeSHID:D011537],Exanthema[MeSHID:D005076],Disease[MeSHID:D004194],Insect Bites and Stings[MeSHID:D007299],Nausea[MeSHID:D009325],Parkinsonian Disorders[MeSHID:D020734],Prescription procedure[MeSHID:D055656],Blood[MeSHID:D001769],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Urticaria[MeSHID:D014581],Plasma[MeSHID:D010949],Pharyngeal structure[MeSHID:D010614],Motion Sickness[MeSHID:D009041],Drinking Water[MeSHID:D060766],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Meniere Disease[MeSHID:D008575] approved histamine n-methyltransferase HNMT Successful target unknown 1.82 TTD , DGIDB 4-(dimethylamino)butyl imidothiocarbamate NA NA investigative histamine n-methyltransferase HNMT Successful target unknown NA TTD skf-91488 small molecule NA experimental histamine n-methyltransferase HNMT NA unknown NA drugbank metoprine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,phase 2 histamine n-methyltransferase HNMT Successful target unknown 8.49 TTD , drugbank , DGIDB harmaline small molecule NA experimental histamine n-methyltransferase HNMT NA inhibitor NA drugbank s-adenosyl-l-homocysteine small molecule NA experimental histamine n-methyltransferase HNMT NA unknown NA drugbank (l-)-s-adenosyl-l-homocysteine NA NA investigative histamine n-methyltransferase HNMT Successful target unknown NA TTD amodiaquine small molecule Acute malaria[MeSHID:C531736],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved,investigational histamine n-methyltransferase HNMT Successful target inhibitor 12.73 TTD , drugbank , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational heterogeneous nuclear ribonucleoproteins a2/b1 HNRNPA2B1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational heterogeneous nuclear ribonucleoproteins a2/b1 HNRNPA2B1 NA ligand NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational heterogeneous nuclear ribonucleoprotein d0 HNRNPD NA ligand NA drugbank phenethyl isothiocyanate small molecule NA investigational heterogeneous nuclear ribonucleoprotein f HNRNPF NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational heterogeneous nuclear ribonucleoprotein h HNRNPH1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational heterogeneous nuclear ribonucleoprotein h3 HNRNPH3 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational heterogeneous nuclear ribonucleoprotein k HNRNPK NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational heterogeneous nuclear ribonucleoprotein k HNRNPK NA ligand NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational heterogeneous nuclear ribonucleoprotein l HNRNPL NA unknown NA drugbank calcitriol small molecule Familial hypophosphatemia[MeSHID:D007015],Disease Management[MeSHID:D019468],Hypoparathyroidism[MeSHID:D007011],Kidney Failure, Chronic[MeSHID:D007676],Hypocalcemia[MeSHID:D006996],Familial Hypophosphatemic Rickets[MeSHID:D053098],Physical Dialysis[MeSHID:D003956],Vitamin D-resistant rickets[MeSHID:D063730],Chronic Kidney Diseases[MeSHID:D051436],Vitamin D Deficiency[MeSHID:D014808],Renal Osteodystrophy[MeSHID:D012080],Rickets[MeSHID:D012279],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congenital alopecia X-linked[MeSHID:C535981] approved,nutraceutical homeobox protein hox-a10 HOXA10 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational haptoglobin HP NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental haptoglobin HP NA binder NA drugbank at1001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 3 haptoglobin HP Clinical trial target unknown NA TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational heterochromatin protein 1-binding protein 3 HP1BP3 NA ligand NA drugbank 2-(2-iodo-benzoyl)-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD 2-propionyl-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD nitisinone small molecule Tyrosinemia, Type I[MeSHID:D020176],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 4-hydroxyphenylpyruvate dioxygenase HPD NA inhibitor 636.51 drugbank , DGIDB 3-hydroxy-2-propionylcyclohex-2-enone NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD (4-hydroxy-phenoxy)-acetic acid NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD 2-(2-bromo-benzoyl)-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD 2-(2-methyl-benzoyl)-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD 2-(2-methoxy-benzoyl)-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD nitisinone NA Tyrosinemia, Type I[MeSHID:D020176],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hydroxyphenylpyruvate dioxygenase HPD Successful target inhibitor 636.51 TTD , DGIDB 3-hydroxy-4-phenyl-5h-furan-2-one NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD 2-acetyl-3-hydroxycyclohex-2-enone NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD 2-acetyl-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD nitisinone NA Tyrosinemia, Type I[MeSHID:D020176],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hydroxyphenylpyruvate dioxygenase HPD Successful target unknown 636.51 TTD , DGIDB das869 small molecule NA experimental 4-hydroxyphenylpyruvate dioxygenase HPD NA unknown NA drugbank 2-cyclopropanecarbonyl-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD 2-(2-chloro-benzoyl)-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD acetate ion NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD 2-(2-nitro-benzoyl)-cyclohexane-1,3-dione NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD diketonitrile NA NA investigative hydroxyphenylpyruvate dioxygenase HPD Successful target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 15-hydroxyprostaglandin dehydrogenase [nad(+)] HPGD NA unknown NA drugbank formic acid NA NA investigative glutathione-dependent pgd synthase HPGDS Successful target unknown NA TTD glutathione disulfide small molecule NA approved,experimental,investigational glutathione s-transferases (cytosolic) HPGDS NA activator NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank praziquantel NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] approved glutathione-dependent pgd synthase HPGDS Successful target unknown 31.83 TTD , DGIDB hql-79 NA NA investigative glutathione-dependent pgd synthase HPGDS Successful target inhibitor 127.3 TTD , DGIDB 3-(4-nitrophenyl)-1h-pyrazole small molecule NA experimental hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank protoporphyrin ix NA NA investigative glutathione-dependent pgd synthase HPGDS Successful target unknown NA TTD hql-79 NA NA investigative glutathione-dependent pgd synthase HPGDS Successful target unknown 127.3 TTD , DGIDB cibacron blue NA NA investigative glutathione-dependent pgd synthase HPGDS Successful target unknown NA TTD glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank 3-phenyl-5-(1h-pyrazol-3-yl)isoxazole small molecule NA experimental hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank 4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid small molecule NA experimental hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank nocodazole small molecule NA experimental hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank phenyl-5-(1h-pyrazol-3-yl)-1,3-thiazole small molecule NA experimental hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank hf-0220 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glutathione-dependent pgd synthase HPGDS Successful target unknown NA TTD , DGIDB tranilast small molecule Eczema[MeSHID:D004485],Allergic rhinitis (disorder)[MeSHID:D065631],Keloid[MeSHID:D007627],Asthma[MeSHID:D001249],Cicatrix, Hypertrophic[MeSHID:D017439],Dermatitis, Atopic[MeSHID:D003876],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye[MeSHID:D005123],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967] investigational hematopoietic prostaglandin d synthase HPGDS NA inhibitor NA drugbank s-hexylglutathione NA NA investigative glutathione-dependent pgd synthase HPGDS Successful target unknown NA TTD 4-(benzhydryloxy)-1-[3-(1h-tetraazol-5-yl)propyl]piperidine small molecule NA experimental hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank 1-phenyl-1h-pyrazole-4-carboxylic acid small molecule NA experimental hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank 2-(2f-benzothiazolyl)-5-styryl-3-(4f-phthalhydrazidyl)tetrazolium chloride small molecule NA experimental hematopoietic prostaglandin d synthase HPGDS NA unknown NA drugbank bentiromide small molecule Exocrine pancreatic insufficiency[MeSHID:D010188],Patient Monitoring[MeSHID:D008991],Pancreas[MeSHID:D010179],Screening procedure[MeSHID:D008403],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] investigational,withdrawn serine protease hepsin HPN NA ligand 190.95 drugbank , DGIDB benzylsulfonic acid small molecule NA experimental serine protease hepsin HPN NA unknown NA drugbank benzylsulfinic acid NA NA investigative serine protease hepsin HPN Patented-recorded target unknown NA TTD cra_1144 small molecule NA experimental,investigative serine protease hepsin HPN Patented-recorded target unknown NA TTD , drugbank ac1lfxa6 NA NA patented serine protease hepsin HPN Patented-recorded target unknown NA TTD , DGIDB 6-chloro-2-(2-hydroxy-biphenyl-3-yl)-1h-indole-5-carboxamidine small molecule NA experimental serine protease hepsin HPN NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational haptoglobin-related protein HPR NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational haptoglobin-related protein HPR NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational haptoglobin-related protein HPR NA unknown NA drugbank 9-deazaguanine small molecule NA experimental hypoxanthine-guanine phosphoribosyltransferase HPRT1 NA unknown NA drugbank mercaptopurine small molecule Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Middle East Respiratory Syndrome[MeSHID:D018352] approved hypoxanthine-guanine phosphoribosyltransferase HPRT1 NA inhibitor 2.65 drugbank , DGIDB 3h-pyrazolo[4,3-d]pyrimidin-7-ol small molecule NA experimental hypoxanthine-guanine phosphoribosyltransferase HPRT1 NA unknown NA drugbank mercaptopurine small molecule Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Crohn Disease[MeSHID:D003424] approved hypoxanthine-guanine phosphoribosyltransferase HPRT1 NA inhibitor 2.65 drugbank , DGIDB 5-o-phosphono-alpha-d-ribofuranosyl diphosphate small molecule NA approved,experimental,investigational hypoxanthine-guanine phosphoribosyltransferase HPRT1 NA unknown NA drugbank 5-monophosphate-9-beta-d-ribofuranosyl xanthine small molecule NA experimental hypoxanthine-guanine phosphoribosyltransferase HPRT1 NA unknown NA drugbank pg-545 NA Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 heparanase HPSE Successful target unknown NA TTD , DGIDB suramin NA Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 heparanase HPSE Successful target unknown 0.13 TTD , DGIDB neutralase NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 heparanase HPSE Successful target unknown NA TTD suramin NA Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] phase 1 heparanase HPSE Successful target unknown 0.13 TTD , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental hemopexin HPX NA ligand NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational hemopexin HPX NA ligand NA drugbank guanosine-5'-triphosphate small molecule NA experimental gtpase hras HRAS NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental gtpase hras HRAS NA unknown NA drugbank hexane-1,6-diol small molecule NA experimental gtpase hras HRAS NA unknown NA drugbank trifluoroethanol small molecule NA experimental gtpase hras HRAS NA unknown NA drugbank isis 13920 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative h-ras messenger rna HRAS Discontinued target unknown NA TTD isis 2503 NA NA discontinued in phase 2 h-ras messenger rna HRAS Discontinued target unknown NA TTD isis 6186 NA NA investigative h-ras messenger rna HRAS Discontinued target unknown NA TTD isis 2502 NA NA investigative h-ras messenger rna HRAS Discontinued target unknown NA TTD n,n'-dimethyl-n-(acetyl)-n'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine small molecule NA experimental gtpase hras HRAS NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental histidine-rich glycoprotein HRG NA cofactor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational histidine-rich glycoprotein HRG NA cofactor NA drugbank obe101 small molecule Obesity[MeSHID:D009765],Hyperlipidemia[MeSHID:D006949] investigational histamine h1 receptor HRH1 NA unknown NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 0.3 TTD , drugbank , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved histamine h1 receptor HRH1 NA antagonist 0.05 drugbank , DGIDB rupatadine small molecule Urticaria[MeSHID:D014581],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221] approved,phase 4 histamine h1 receptor HRH1 Successful target antagonist 0.61 TTD , drugbank , DGIDB cetirizine small molecule Pruritus[MeSHID:D011537],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221],Vision[MeSHID:D014785],Hay fever[MeSHID:D006255],Rupture[MeSHID:D012421],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Urticaria[MeSHID:D014581],Sneezing[MeSHID:D012912],Dander[MeSHID:D063607],Tears body substance[MeSHID:D013666],Laceration[MeSHID:D022125],Patient Discharge[MeSHID:D010351],Excessive tearing[MeSHID:D007766],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 0.98 TTD , drugbank , DGIDB chlophedianol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved histamine h1 receptor HRH1 Successful target unknown 2.86 TTD , DGIDB mdl-28163 NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD phenindamine small molecule Pruritus[MeSHID:D011537],Exanthema[MeSHID:D005076],Nose[MeSHID:D009666],Urticaria[MeSHID:D014581],Sneezing[MeSHID:D012912],Common Cold[MeSHID:D003139],Drinking Water[MeSHID:D060766],Hypersensitivity[MeSHID:D006967],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 2.45 TTD , drugbank , DGIDB dimenhydrinate small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Vertigo[MeSHID:D014717],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 1.22 TTD , drugbank , DGIDB risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 NA antagonist 0.03 drugbank , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA antagonist NA drugbank dimethindene NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved histamine h1 receptor HRH1 Successful target unknown 1.22 TTD , DGIDB histamine small molecule Gastric Acid[MeSHID:D005744],Diagnosis[MeSHID:D003933] approved,investigational histamine h1 receptor HRH1 NA agonist 0.22 drugbank , DGIDB diphenhydramine small molecule Pruritus[MeSHID:D011537],Exanthema[MeSHID:D005076],Disease[MeSHID:D004194],Insect Bites and Stings[MeSHID:D007299],Nausea[MeSHID:D009325],Parkinsonian Disorders[MeSHID:D020734],Prescription procedure[MeSHID:D055656],Blood[MeSHID:D001769],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Urticaria[MeSHID:D014581],Plasma[MeSHID:D010949],Pharyngeal structure[MeSHID:D010614],Motion Sickness[MeSHID:D009041],Drinking Water[MeSHID:D060766],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Meniere Disease[MeSHID:D008575] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 0.64 TTD , drugbank , DGIDB (s)-(+)-dimethindene maleate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] approved histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational histamine h1 receptor HRH1 NA antagonist NA drugbank rp5063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Bipolar Disorder[MeSHID:D001714],Attention deficit hyperactivity disorder[MeSHID:D001289],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB olopatadine small molecule Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved histamine h1 receptor HRH1 Successful target antagonist 4.9 TTD , drugbank , DGIDB terfenadine small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,withdrawn,withdrawn from market histamine h1 receptor HRH1 Successful target antagonist 0.24 TTD , drugbank , DGIDB 2-(2-thiazolyl)ethanamine NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB pheniramine small molecule Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Influenza[MeSHID:D007251],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target inverse agonist 4.49 TTD , drugbank , DGIDB levocabastine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Allergic Conjunctivitis[MeSHID:D003233],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 1.84 TTD , drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved histamine h1 receptor HRH1 NA antagonist NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved histamine h1 receptor HRH1 NA antagonist NA drugbank clemastine small molecule Pruritus[MeSHID:D011537],Sneezing[MeSHID:D012912],Urticaria[MeSHID:D014581],Common Cold[MeSHID:D003139],Allergic rhinitis (disorder)[MeSHID:D065631],Self Medication[MeSHID:D012651],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 0.63 TTD , drugbank , DGIDB dexbrompheniramine small molecule Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Common Cold[MeSHID:D003139],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 1.84 TTD , drugbank , DGIDB diphenyl(piperidin-4-yl)methanol NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD promazine small molecule Psychomotor Agitation[MeSHID:D011595],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved histamine h1 receptor HRH1 NA antagonist 0.14 drugbank , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA antagonist 0.08 drugbank , DGIDB n-methyl-3,3-diphenylpropan-1-amine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD oxo-arpromidine NA NA investigative histamine h1 receptor HRH1 Successful target agonist 0.2 TTD , DGIDB 2-(9,10-dihydroanthracen-9-yl)-n-methylethanamine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD dimetindene small molecule Pruritus[MeSHID:D011537],Exanthema[MeSHID:D005076],Eczema[MeSHID:D004485],Tooth eruption function[MeSHID:D014078],Insect Bites[MeSHID:D007299],Respiratory Hypersensitivity[MeSHID:D012130],Skin Diseases, Genetic[MeSHID:D012873],Dermatologic disorders[MeSHID:D012871],Drug Allergy[MeSHID:D004342],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Cholestasis[MeSHID:D002779],Fever[MeSHID:D005334],Allergic Reaction[MeSHID:D006967],Chickenpox[MeSHID:D002644] approved,investigational histamine h1 receptor HRH1 NA antagonist NA drugbank cinnarizine small molecule Vertigo[MeSHID:D014717],Meniere Disease[MeSHID:D008575],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 0.29 TTD , drugbank , DGIDB diphenylpyraline small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 2.04 TTD , drugbank , DGIDB alcaftadine small molecule Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 2.04 TTD , drugbank , DGIDB (-)-trans-h2-pat NA NA investigative histamine h1 receptor HRH1 Successful target antagonist NA TTD , DGIDB impromidine NA NA investigative histamine h1 receptor HRH1 Successful target antagonist 0.1 TTD , DGIDB n,n-dimethyl-3,3-diphenylpropan-1-amine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD 9-(2-aminoethyl)-9,10-dihydroanthracene NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD aceprometazine small molecule Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,approved histamine h1 receptor HRH1 Successful target antagonist 2.86 TTD , drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 0.3 TTD , drugbank , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 NA antagonist 0.13 drugbank , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA antagonist 0.01 drugbank , DGIDB mepyramine small molecule Dermatologic disorders[MeSHID:D012871],Hypersensitivity[MeSHID:D006967],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved histamine h1 receptor HRH1 Successful target antagonist 0.58 TTD , drugbank , DGIDB hydroxyzine small molecule Pruritus[MeSHID:D011537],Neurotic Disorders[MeSHID:D009497],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Dental Health Services[MeSHID:D003752],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Pregnancy[MeSHID:D011247],Urticaria[MeSHID:D014581],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target inverse agonist 0.51 TTD , drugbank , DGIDB benzquinamide small molecule Nausea[MeSHID:D009325],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn histamine h1 receptor HRH1 NA antagonist 0.27 drugbank , DGIDB tripelennamine small molecule Hypersensitivity[MeSHID:D006967],Coughing[MeSHID:D003371],Common Cold[MeSHID:D003139],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved histamine h1 receptor HRH1 Successful target antagonist 4.08 TTD , drugbank , DGIDB levocetirizine dihydrochloride NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA antagonist 0.1 drugbank , DGIDB n,n-dimethyl-4,4-diphenylbutan-1-amine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD (+)-cis-h2-pat NA NA investigative histamine h1 receptor HRH1 Successful target antagonist NA TTD , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA antagonist 0.03 drugbank , DGIDB 4,4-diphenylbutan-1-amine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD bilastine small molecule Urticaria[MeSHID:D014581],Nose[MeSHID:D009666],Rhinitis[MeSHID:D012220] approved,investigational histamine h1 receptor HRH1 NA antagonist NA drugbank 8r-lisuride NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD azelastine small molecule Pruritus[MeSHID:D011537],Hay fever[MeSHID:D006255],Allergic Conjunctivitis[MeSHID:D003233],Rhinitis, Vasomotor[MeSHID:D012223],Hypersensitivity[MeSHID:D006967],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 5.3 TTD , drugbank , DGIDB mizolastine NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 0.41 TTD , DGIDB ur-pg146 NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB dexchlorpheniramine maleate small molecule Skin Manifestations[MeSHID:D012877],Hay fever[MeSHID:D006255],Allergic Conjunctivitis[MeSHID:D003233],Blood[MeSHID:D001769],Urticaria[MeSHID:D014581],Plasma[MeSHID:D010949],Allergic Reaction[MeSHID:D006967],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] approved histamine h1 receptor HRH1 Successful target antagonist NA TTD , drugbank , DGIDB vapitadine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypersensitivity[MeSHID:D006967] phase 2 histamine h1 receptor HRH1 Successful target unknown 0.82 TTD , DGIDB methylhistaprodifen NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB dexchlorpheniramine maleate small molecule Skin Manifestations[MeSHID:D012877],Hay fever[MeSHID:D006255],Allergic Conjunctivitis[MeSHID:D003233],Blood[MeSHID:D001769],Urticaria[MeSHID:D014581],Plasma[MeSHID:D010949],Allergic Reaction[MeSHID:D006967],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] approved histamine h1 receptor HRH1 Successful target antagonist 0.41 TTD , drugbank , DGIDB desloratadine small molecule Urticaria[MeSHID:D014581],Hay fever[MeSHID:D006255],Pruritus[MeSHID:D011537],Rhinitis, Allergic, Perennial[MeSHID:D012221],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 1.53 TTD , drugbank , DGIDB gsk1004723 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 histamine h1 receptor HRH1 Successful target unknown NA TTD n-methyl-4,4-diphenylbutan-1-amine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational histamine h1 receptor HRH1 NA antagonist 0.1 drugbank , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved histamine h1 receptor HRH1 NA antagonist 0.08 drugbank , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational histamine h1 receptor HRH1 NA antagonist 0.08 drugbank , DGIDB vuf-10148 NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD butriptyline small molecule NA approved,withdrawn histamine h1 receptor HRH1 NA antagonist NA drugbank norastemizole NA NA discontinued in preregistration histamine h1 receptor HRH1 Successful target unknown NA TTD doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 0.34 TTD , drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved histamine h1 receptor HRH1 NA antagonist 0.08 drugbank , DGIDB astemizole small molecule Allergic Reaction[MeSHID:D006967],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Cardiac Arrhythmia[MeSHID:D001145],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn,withdrawn from market histamine h1 receptor HRH1 Successful target antagonist 0.35 TTD , drugbank , DGIDB cyclizine small molecule Vertigo[MeSHID:D014717],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 2.45 TTD , drugbank , DGIDB 9-phenyl-2,3-dihydro-1h-indeno[2,1-c]pyridine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD benzatropine small molecule Bradykinesia[MeSHID:D018476],Dystonia[MeSHID:D004421],Disease[MeSHID:D004194],Dyskinetic syndrome[MeSHID:D020820],Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Akathisia[MeSHID:D011595],Movement[MeSHID:D009068],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Term Birth[MeSHID:D047929] approved histamine h1 receptor HRH1 NA antagonist NA drugbank isothipendyl small molecule Pruritus[MeSHID:D011537],Allergic Reaction[MeSHID:D006967] experimental histamine h1 receptor HRH1 NA antagonist NA drugbank mepyramine maleate NA Headache[MeSHID:D006261],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB carbinoxamine small molecule Rhinitis, Allergic, Perennial[MeSHID:D012221],Allergic Conjunctivitis[MeSHID:D003233],Blood[MeSHID:D001769],Angioedema[MeSHID:D000799],Urticaria[MeSHID:D014581],Plasma[MeSHID:D010949], Vasomotor[MeSHID:D012223],Allergic Reaction[MeSHID:D006967],Inspiration function[MeSHID:D001239],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 1.63 TTD , drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved histamine h1 receptor HRH1 NA antagonist 0.08 drugbank , DGIDB pmid29334795-compound-61 NA NA patented histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB ketotifen small molecule Asthma[MeSHID:D001249],Pruritus[MeSHID:D011537],Eye[MeSHID:D005123],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 1.5 TTD , drugbank , DGIDB clofedanol small molecule Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved,withdrawn histamine h1 receptor HRH1 NA antagonist NA drugbank citalopram derivative 1 NA NA patented histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 0.23 TTD , drugbank , DGIDB dimethylhistaprodifen NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB kf-a6 NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD trazodone small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational histamine h1 receptor HRH1 NA antagonist 0.12 drugbank , DGIDB 2-(3-chlorophenyl)histamine NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB azd-1744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 histamine h1 receptor HRH1 Successful target unknown NA TTD octoclothepin NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD azatadine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Signs and Symptoms, Respiratory[MeSHID:D012818],Mucous Membrane[MeSHID:D009092],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 3.26 TTD , drugbank , DGIDB methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational histamine h1 receptor HRH1 NA antagonist 0.09 drugbank , DGIDB prochlorperazine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Headache[MeSHID:D006261],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Emergencies [Disease/Finding][MeSHID:D004630],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved histamine h1 receptor HRH1 NA antagonist 0.03 drugbank , DGIDB buclizine small molecule Vertigo[MeSHID:D014717],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 1.22 TTD , drugbank , DGIDB ac-170 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Conjunctivitis[MeSHID:D003233] phase 3 histamine h1 receptor HRH1 Successful target unknown 0.98 TTD , DGIDB escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA inhibitor NA drugbank (s)-cetirizine NA NA investigative histamine h1 receptor HRH1 Successful target antagonist NA TTD , DGIDB doxylamine small molecule Cold Temperature[MeSHID:D003080],Drug Allergy[MeSHID:D004342],Morning Sickness[MeSHID:D048968],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Sleep[MeSHID:D012890],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved histamine h1 receptor HRH1 Successful target antagonist 1.22 TTD , drugbank , DGIDB bromodiphenhydramine small molecule Hay fever[MeSHID:D006255],Allergic Reaction[MeSHID:D006967],Coughing[MeSHID:D003371],Bodily secretions[MeSHID:D012634],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 2.45 TTD , drugbank , DGIDB iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA antagonist 0.05 drugbank , DGIDB r-dimethindene NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD ly-2624803 NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h1 receptor HRH1 Successful target unknown 0.82 TTD , DGIDB epinastine small molecule Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 0.95 TTD , drugbank , DGIDB ur-pg153 NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB bu-e 47 NA NA investigative histamine h1 receptor HRH1 Successful target antagonist NA TTD , DGIDB ur-pg131a NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB ucb-35440 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB 3,3-diphenylpropan-1-amine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD 9-(2-aminopropyl)-9,10-dihydroanthracene NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 NA inhibitor NA drugbank mequitamium iodide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD tranilast NA Eczema[MeSHID:D004485],Allergic rhinitis (disorder)[MeSHID:D065631],Keloid[MeSHID:D007627],Asthma[MeSHID:D001249],Cicatrix, Hypertrophic[MeSHID:D017439],Dermatitis, Atopic[MeSHID:D003876],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye[MeSHID:D005123],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967] approved histamine h1 receptor HRH1 Successful target unknown 0.04 TTD , DGIDB mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved histamine h1 receptor HRH1 NA antagonist NA drugbank trimeprazine NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target unknown 2.04 TTD , DGIDB n,n-dimethyl-2,2-diphenylethanamine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD obe-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB hydroxyzine small molecule Pruritus[MeSHID:D011537],Neurotic Disorders[MeSHID:D009497],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Dental Health Services[MeSHID:D003752],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Pregnancy[MeSHID:D011247],Urticaria[MeSHID:D014581],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target inverse agonist,antagonist 0.51 TTD , drugbank , DGIDB mizolastine NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target unknown 0.41 TTD , DGIDB acrivastine small molecule Sneezing[MeSHID:D012912],Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 0.82 TTD , drugbank , DGIDB fexofenadine small molecule Urticaria[MeSHID:D014581],Carrying[MeSHID:D017770],Hay fever[MeSHID:D006255],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 1.9 TTD , drugbank , DGIDB tolazoline small molecule Pulmonary artery structure[MeSHID:D011651],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] approved,vet_approved histamine h1 receptor HRH1 NA agonist NA drugbank ergotidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB betahistine small molecule Recurrent Vestibular Neuritis[MeSHID:D020338] approved,investigational histamine h1 receptor HRH1 NA agonist 0.61 drugbank , DGIDB ethopropazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved histamine h1 receptor HRH1 Successful target unknown 0.1 TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved histamine h1 receptor HRH1 NA antagonist NA drugbank chloropyramine small molecule Asthma[MeSHID:D001249],Allergic rhinitis (disorder)[MeSHID:D065631],Allergic Conjunctivitis[MeSHID:D003233],Disease[MeSHID:D004194] experimental histamine h1 receptor HRH1 NA antagonist NA drugbank loratadine small molecule Urticaria[MeSHID:D014581],Allergic rhinitis (disorder)[MeSHID:D065631],Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,investigational histamine h1 receptor HRH1 Successful target antagonist 0.38 TTD , drugbank , DGIDB triprolidine small molecule Skin Manifestations[MeSHID:D012877],Rhinitis, Allergic, Perennial[MeSHID:D012221],Allergic Conjunctivitis[MeSHID:D003233],Urticaria[MeSHID:D014581],Common Cold[MeSHID:D003139],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hay fever[MeSHID:D006255] approved histamine h1 receptor HRH1 Successful target antagonist 2.86 TTD , drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational histamine h1 receptor HRH1 NA antagonist NA drugbank meclizine small molecule Disease Management[MeSHID:D019468],Vertigo[MeSHID:D014717],Labyrinthine disorder[MeSHID:D007759],Meniere Disease[MeSHID:D008575],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Labyrinthitis[MeSHID:D007762],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA antagonist 0.41 drugbank , DGIDB chlorpheniramine small molecule Hay fever[MeSHID:D006255],Rhinitis[MeSHID:D012220],Asthma[MeSHID:D001249],Urticaria[MeSHID:D014581],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 1.36 TTD , drugbank , DGIDB 9-(aminomethyl)-9,10-dihydroanthracene NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD hydroxyclemastine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 0.23 TTD , drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 NA antagonist NA drugbank oxatomide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hay fever[MeSHID:D006255] approved histamine h1 receptor HRH1 Successful target unknown 0.07 TTD , DGIDB r-226161 NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD e-4716 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved histamine h1 receptor HRH1 NA antagonist 0.01 drugbank , DGIDB carebastine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye[MeSHID:D005123],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967] phase 3 histamine h1 receptor HRH1 Successful target unknown 0.41 TTD , DGIDB thonzylamine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Signs and Symptoms, Respiratory[MeSHID:D012818] approved histamine h1 receptor HRH1 NA antagonist NA drugbank sun-1334h NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD noberastine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 histamine h1 receptor HRH1 Successful target unknown 0.41 TTD , DGIDB epicept np-1 small molecule Pain[MeSHID:D010146] investigational histamine h1 receptor HRH1 NA unknown NA drugbank (+)-trans-h2-pat NA NA investigative histamine h1 receptor HRH1 Successful target antagonist NA TTD , DGIDB mequitazine small molecule Urticaria[MeSHID:D014581],Hay fever[MeSHID:D006255],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] experimental,approved histamine h1 receptor HRH1 Successful target antagonist 4.08 TTD , drugbank , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved histamine h1 receptor HRH1 NA antagonist 0.1 drugbank , DGIDB flunarizine small molecule Vertigo[MeSHID:D014717],Epilepsy[MeSHID:D004827],Peripheral Vascular Diseases[MeSHID:D016491],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA antagonist 0.23 drugbank , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn histamine h1 receptor HRH1 NA antagonist 0.35 drugbank , DGIDB levocetirizine dihydrochloride NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 0.41 TTD , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 NA antagonist 0.06 drugbank , DGIDB so-101 small molecule Sleeplessness[MeSHID:D007319] investigational histamine h1 receptor HRH1 NA unknown NA drugbank piperidine derivative 1 NA NA patented histamine h1 receptor HRH1 Successful target unknown NA TTD , DGIDB citalopram small molecule Depressive disorder[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Mental Depression[MeSHID:D003863],Alcohol abuse[MeSHID:D000437],Cerebrovascular accident[MeSHID:D020521],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA binder NA drugbank arpromidine NA NA investigative histamine h1 receptor HRH1 Successful target antagonist 0.2 TTD , DGIDB chlorcyclizine small molecule NA approved histamine h1 receptor HRH1 NA antagonist NA drugbank dimebolin NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD alimemazine small molecule Urticaria[MeSHID:D014581],Pruritus[MeSHID:D011537],Allergic Reaction[MeSHID:D006967],Disease[MeSHID:D004194] approved,vet_approved histamine h1 receptor HRH1 NA antagonist NA drugbank 1-[(furan-2(5h)-one)-4-methyl]-desloratadine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD 9-oh-risperidone NA NA investigative histamine h1 receptor HRH1 Successful target antagonist NA TTD , DGIDB lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved histamine h1 receptor HRH1 NA antagonist NA drugbank hy10275 small molecule Sleeplessness[MeSHID:D007319] investigational histamine h1 receptor HRH1 NA unknown NA drugbank 2-(3-iodophenyl)histamine NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB 1-(4-p-tolyl-butyl)-piperidine NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD ren-1869 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD methdilazine small molecule Dermatologic disorders[MeSHID:D012871],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 3.67 TTD , drugbank , DGIDB histaprodifen NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB antazoline small molecule Nose[MeSHID:D009666],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 0.41 TTD , drugbank , DGIDB hsr-609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] discontinued in phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD (+/-)-cis-h2-pat NA NA investigative histamine h1 receptor HRH1 Successful target unknown NA TTD emedastine small molecule Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 4.08 TTD , drugbank , DGIDB cariprazine small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] approved,investigational histamine h1 receptor HRH1 NA antagonist NA drugbank perospirone small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] experimental histamine h1 receptor HRH1 NA inverse agonist NA drugbank brompheniramine small molecule Pruritus[MeSHID:D011537],Eye[MeSHID:D005123],Sneezing[MeSHID:D012912],Common Cold[MeSHID:D003139],Drinking Water[MeSHID:D060766],Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 3.67 TTD , drugbank , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 NA binder,antagonist 0.05 drugbank , DGIDB zuclopenthixol small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Manic[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Behavior[MeSHID:D001519],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h1 receptor HRH1 NA antagonist NA drugbank ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational histamine h1 receptor HRH1 NA unknown NA drugbank pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved histamine h1 receptor HRH1 NA antagonist NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved histamine h1 receptor HRH1 NA antagonist NA drugbank tesmilifene small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational histamine h1 receptor HRH1 NA antagonist NA drugbank esmirtazapine small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319] investigational histamine h1 receptor HRH1 NA inverse agonist NA drugbank gsk835726 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 histamine h1 receptor HRH1 Successful target unknown NA TTD ur-pg55b NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB pemirolast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Conjunctivitis[MeSHID:D003233] approved histamine h1 receptor HRH1 Successful target unknown 1.22 TTD , DGIDB bepotastine small molecule Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Cell Degranulation[MeSHID:D015550],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h1 receptor HRH1 Successful target antagonist 2.04 TTD , drugbank , DGIDB 2-(3-bromophenyl)histamine NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB 2-pyridylethylamine NA NA investigative histamine h1 receptor HRH1 Successful target agonist NA TTD , DGIDB levocetirizine small molecule Urticaria[MeSHID:D014581],Allergic Reaction[MeSHID:D006967],Skin Manifestations[MeSHID:D012877],Rhinitis, Allergic, Perennial[MeSHID:D012221] approved histamine h1 receptor HRH1 NA antagonist,inhibitor 1.22 drugbank , DGIDB orphenadrine small molecule Acute onset pain[MeSHID:D059787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved histamine h1 receptor HRH1 NA antagonist 0.41 drugbank , DGIDB iodoaminopotentidine NA NA investigative histamine h2 receptor HRH2 Successful target unknown NA TTD tolazoline small molecule Pulmonary artery structure[MeSHID:D011651],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] approved,vet_approved histamine h2 receptor HRH2 NA agonist NA drugbank roxatidine acetate small molecule Disease[MeSHID:D004194],Stomach[MeSHID:D013270],Gastrointestinal Diseases[MeSHID:D005767],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Recurrence (disease attribute)[MeSHID:D012008],Upper Gastrointestinal Tract[MeSHID:D041742] experimental histamine h2 receptor HRH2 NA antagonist NA drugbank impromidine NA NA investigative histamine h2 receptor HRH2 Successful target agonist 0.61 TTD , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative histamine h2 receptor HRH2 Successful target unknown NA TTD trm-115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276] discontinued in phase 1 histamine h2 receptor HRH2 Successful target unknown NA TTD hzt-501 small molecule Pain[MeSHID:D010146] investigational histamine h2 receptor HRH2 NA unknown NA drugbank cp-66948 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276] discontinued in phase 1 histamine h2 receptor HRH2 Successful target unknown NA TTD cimetidine small molecule Zollinger-Ellison syndrome[MeSHID:D015043],Disease Management[MeSHID:D019468],Mastocytosis, Systemic[MeSHID:D034721],Bodily secretions[MeSHID:D012634],Disease[MeSHID:D004194],Gastric Acid[MeSHID:D005744],Stomach[MeSHID:D013270],Cystic Fibrosis[MeSHID:D003550],Gastroesophageal reflux disease[MeSHID:D005764],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Recurrence (disease attribute)[MeSHID:D012008],Multiple Endocrine Neoplasia[MeSHID:D009377],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h2 receptor HRH2 Successful target antagonist 1.69 TTD , drugbank , DGIDB ranitidine small molecule Mastocytosis, Systemic[MeSHID:D034721],Esophagitis[MeSHID:D004941],Zollinger-Ellison syndrome[MeSHID:D015043],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Gastric Acid[MeSHID:D005744],Diagnosis[MeSHID:D003933],Stomach[MeSHID:D013270],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] approved,withdrawn histamine h2 receptor HRH2 Successful target antagonist 1.22 TTD , drugbank , DGIDB ur-pg146 NA NA investigative histamine h2 receptor HRH2 Successful target agonist NA TTD , DGIDB dimaprit NA NA investigative histamine h2 receptor HRH2 Successful target unknown NA TTD azelastine small molecule Pruritus[MeSHID:D011537],Hay fever[MeSHID:D006255],Allergic Conjunctivitis[MeSHID:D003233],Rhinitis, Vasomotor[MeSHID:D012223],Hypersensitivity[MeSHID:D006967],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h2 receptor HRH2 NA inhibitor NA drugbank ebrotidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Duodenal Ulcer[MeSHID:D004381] withdrawn from market histamine h2 receptor HRH2 Successful target unknown NA TTD metiamide small molecule Disease Management[MeSHID:D019468],Dyspepsia[MeSHID:D004415],Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Peptic Ulcer[MeSHID:D010437] experimental,investigative histamine h2 receptor HRH2 Successful target antagonist NA TTD , drugbank pibutidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] discontinued in phase 3 histamine h2 receptor HRH2 Successful target unknown NA TTD amthamine NA NA investigative histamine h2 receptor HRH2 Successful target agonist 2.45 TTD , DGIDB [125i]iodoaminopotentidine NA NA investigative histamine h2 receptor HRH2 Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h2 receptor HRH2 NA binder NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved histamine h2 receptor HRH2 NA blocker NA drugbank famotidine small molecule Disease Management[MeSHID:D019468],Pathologic Processes[MeSHID:D010335],Body Weight[MeSHID:D001835],Diagnosis[MeSHID:D003933],Heartburn[MeSHID:D006356],Peptic Esophagitis[MeSHID:D004942],Gastric ulcer[MeSHID:D013276],Recurrence (disease attribute)[MeSHID:D012008],Term Birth[MeSHID:D047929],Zollinger-Ellison syndrome[MeSHID:D015043],Esophagitis[MeSHID:D004941],Multiple Endocrine Neoplasia[MeSHID:D009377],Disease[MeSHID:D004194],Duodenal Ulcer[MeSHID:D004381],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Urticaria[MeSHID:D014581],Gastroesophageal reflux disease[MeSHID:D005764],Risk Reduction[MeSHID:D040242],Critical Illness[MeSHID:D016638],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] approved histamine h2 receptor HRH2 Successful target antagonist 10.4 TTD , drugbank , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h2 receptor HRH2 NA antagonist 0.37 drugbank , DGIDB oxo-arpromidine NA NA investigative histamine h2 receptor HRH2 Successful target agonist 1.22 TTD , DGIDB z-300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastric ulcer[MeSHID:D013276] discontinued in phase 1 histamine h2 receptor HRH2 Successful target unknown NA TTD osutidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Duodenal Ulcer[MeSHID:D004381] discontinued in phase 3 histamine h2 receptor HRH2 Successful target unknown NA TTD nizatidine small molecule Disease[MeSHID:D004194],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h2 receptor HRH2 Successful target antagonist 12.24 TTD , drugbank , DGIDB epinastine small molecule Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h2 receptor HRH2 NA antagonist 2.45 drugbank , DGIDB vuf-10148 NA NA investigative histamine h2 receptor HRH2 Successful target unknown NA TTD famotidine small molecule Disease Management[MeSHID:D019468],Pathologic Processes[MeSHID:D010335],Body Weight[MeSHID:D001835],Diagnosis[MeSHID:D003933],Heartburn[MeSHID:D006356],Peptic Esophagitis[MeSHID:D004942],Gastric ulcer[MeSHID:D013276],Recurrence (disease attribute)[MeSHID:D012008],Term Birth[MeSHID:D047929],Zollinger-Ellison syndrome[MeSHID:D015043],Esophagitis[MeSHID:D004941],Multiple Endocrine Neoplasia[MeSHID:D009377],Disease[MeSHID:D004194],Duodenal Ulcer[MeSHID:D004381],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Urticaria[MeSHID:D014581],Gastroesophageal reflux disease[MeSHID:D005764],Risk Reduction[MeSHID:D040242],Critical Illness[MeSHID:D016638],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h2 receptor HRH2 Successful target antagonist 10.4 TTD , drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational histamine h2 receptor HRH2 NA antagonist NA drugbank doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h2 receptor HRH2 NA antagonist 0.41 drugbank , DGIDB (+/-)-nantenine NA NA investigative histamine h2 receptor HRH2 Successful target unknown NA TTD cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h2 receptor HRH2 NA antagonist NA drugbank betazole small molecule Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach Diseases[MeSHID:D013272] approved histamine h2 receptor HRH2 Successful target agonist 22.03 TTD , drugbank , DGIDB ku-1257 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Duodenal Ulcer[MeSHID:D004381] discontinued in phase 3 histamine h2 receptor HRH2 Successful target unknown NA TTD promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h2 receptor HRH2 NA antagonist NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational histamine h2 receptor HRH2 NA ligand NA drugbank arpromidine NA NA investigative histamine h2 receptor HRH2 Successful target agonist 1.22 TTD , DGIDB methantheline small molecule Reflex action[MeSHID:D012018],Neurogenic Urinary Bladder[MeSHID:D001750],Gastritis[MeSHID:D005756],Irritable Bowel Syndrome[MeSHID:D043183],Biliary Dyskinesia[MeSHID:D001657],Peptic Ulcer[MeSHID:D010437],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h2 receptor HRH2 NA antagonist NA drugbank way-207024 NA NA investigative histamine h2 receptor HRH2 Successful target unknown NA TTD lavoltidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] discontinued in phase 2 histamine h2 receptor HRH2 Successful target unknown NA TTD tiotidine NA NA investigative histamine h2 receptor HRH2 Successful target unknown NA TTD burimamide NA NA investigative histamine h2 receptor HRH2 Successful target agonist 0.82 TTD , DGIDB histamine small molecule Gastric Acid[MeSHID:D005744],Diagnosis[MeSHID:D003933] approved,investigational histamine h2 receptor HRH2 NA agonist 0.89 drugbank , DGIDB olopatadine small molecule Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved histamine h2 receptor HRH2 NA antagonist NA drugbank ign-2098 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Duodenal Ulcer[MeSHID:D004381] discontinued in phase 2 histamine h2 receptor HRH2 Successful target unknown NA TTD benzo[d]oxazol-2(3h)-one derivative 2 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB (s)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (r)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (s)-1-(3-methoxyphenethyl)-2-methylpyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD proxyfan NA NA investigative histamine h3 receptor HRH3 Successful target agonist,antagonist 1.41 TTD , DGIDB 4-[3-(4-butyl-phenoxy)-propyl]-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD [123i]iodoproxyfan NA NA investigative histamine h3 receptor HRH3 Successful target antagonist NA TTD , DGIDB 1-(3-methoxyphenethyl)pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-((2r,3s)-2-methyl-pyrrolidin-3-yl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD mk-7288 NA Hypersomnia[MeSHID:D006970],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB azd-5213 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB pmid29334795-compound-67 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB a-331440 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pmid29334795-compound-28 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB gsk239512 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h3 receptor HRH3 Successful target unknown 2.83 TTD , DGIDB gsk189254a NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 2-[4-(1-ethyl-propyl)-piperazin-1-yl]-quinoline NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (s)-1-(4-nitrophenethyl)-2-methylpyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD phenylsulfonyl derivative 2 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 4-isopropyl-2-(phenoxymethyl)morpholine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 1-(3-(3-phenylpropoxy)propyl)piperidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD abt-239 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 histamine h3 receptor HRH3 Successful target antagonist 0.94 TTD , DGIDB abt-288 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h3 receptor HRH3 Successful target antagonist 2.83 TTD , DGIDB steroidal carboxamide derivative 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 3-((1h-imidazol-4-yl)methyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pmid29334795-compound-23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB (s)-3-(1h-imidazol-4-yl)propyl sec-butylcarbamate NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pmid29334795-compound-21 NA Progressive supranuclear palsy[MeSHID:D013494],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB impromidine NA NA investigative histamine h3 receptor HRH3 Successful target agonist 0.35 TTD , DGIDB 2-(3-methyl-3h-imidazol-4-yl)-ethylamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 5-(2-(pyrrolidin-1-yl)ethyl)isothiazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD hpp404 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB a-317920 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] investigative histamine h3 receptor HRH3 Successful target antagonist 0.71 TTD , DGIDB ucl-2138 NA NA investigative histamine h3 receptor HRH3 Successful target antagonist 1.41 TTD , DGIDB vuf 5207 NA NA investigative histamine h3 receptor HRH3 Successful target agonist NA TTD , DGIDB st-1025 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-butyl-1-[3-(phenylpropoxy)propyl]piperidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD biphenyl derivative 4 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB clobenpropit NA NA investigative histamine h3 receptor HRH3 Successful target antagonist 0.16 TTD , DGIDB 4-((1h-imidazol-4-yl)methyl)-1-phenylpiperidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-[3-(4-ethynyl-phenoxy)-propyl]-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (s)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD triazolo-benzodiazepine derivative 2 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 4-[3-(4-methoxy-phenoxy)-propyl]-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD jnj-17216498 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] phase 2 histamine h3 receptor HRH3 Successful target unknown 2.83 TTD , DGIDB benzo[d]oxazol-2(3h)-one derivative 3 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB pmid29334795-compound-24 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB bavisant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 2 histamine h3 receptor HRH3 Successful target unknown 2.83 TTD , DGIDB piperazine carbamate/urea derivative 3 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 2-(2-(pyrrolidin-1-yl)ethyl)-1h-indole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 2-(2-(4-tert-butylphenylthio)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD acrylamide compound 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 4-(2-(3-tert-butylphenylamino)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD ath-90879 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD immepip NA NA investigative histamine h3 receptor HRH3 Successful target agonist 0.71 TTD , DGIDB a-304121 NA NA investigative histamine h3 receptor HRH3 Successful target antagonist 1.41 TTD , DGIDB piperazine carbamate/urea derivative 4 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 2-[2-(1h-imidazol-4-yl)-cyclopropyl]-ethylamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD phenylsulfonyl derivative 3 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB sar-110894 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB (s)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pitolisant small molecule Narcolepsy[MeSHID:D009290],Cataplexy[MeSHID:D002385],Hypersomnia[MeSHID:D006970],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h3 receptor HRH3 Successful target antagonist,inverse agonist 1.7 TTD , drugbank , DGIDB 4-benzyl-1-[3-phenylpropoxy)propyl]piperidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD conessine NA NA investigative histamine h3 receptor HRH3 Successful target antagonist 0.35 TTD , DGIDB mk-0249 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial histamine h3 receptor HRH3 Successful target agonist,antagonist 1.06 TTD , DGIDB piperazine carbamate/urea derivative 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 2-(2-(pyrrolidin-1-yl)ethyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 1-(2-p-tolyl-ethyl)-pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(7-methyl-oct-3-ynyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (r)-1-(3-methoxyphenethyl)-2-methylpyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD abt-239 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 histamine h3 receptor HRH3 Successful target unknown 0.94 TTD , DGIDB pmid29334795-compound-61 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB pmid29334795-compound-56 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 4-(6-cyclopentyl-hex-3-ynyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 2-(ethoxycarbonyl)-1h-indole-5-carboxylic acid NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD vuf5391 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 5-ethyl-2-(2-(pyrrolidin-1-yl)ethyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD suvn-g1031 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(2-(4-methylphenylamino)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (1r,2r)-2-(1h-imidazol-4-yl)-1-methyl-propylamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD mk-3134 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 2-(4-cyclopentyl-piperazin-1-yl)-quinoline NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD mk-0249 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial histamine h3 receptor HRH3 Successful target inverse agonist 1.06 TTD , DGIDB pmid29334795-compound-62 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 2-(4-propyl-piperazin-1-yl)-quinoline NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD ciproxifan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative histamine h3 receptor HRH3 Successful target antagonist 0.35 TTD , DGIDB ucb-2892 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pmid29334795-compound-58 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB (s)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD imbutamine NA NA investigative histamine h3 receptor HRH3 Successful target agonist 1.41 TTD , DGIDB 4-((1h-imidazol-4-yl)methyl)-1-heptylpiperidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-((2s,3r)-2-methyl-pyrrolidin-3-yl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD vuf-10214 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD piperazine carbamate/urea derivative 5 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB sch79687 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD ucl1972 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(2-(pyrrolidin-1-yl)ethyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD suvn-g3031 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 histamine h3 receptor HRH3 Successful target unknown 2.83 TTD , DGIDB 1-[2-(2,4,6-trimethyl-phenyl)-ethyl]-pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD c-[2-(1h-imidazol-4-yl)-cyclopropyl]-methylamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD vuf 8328 NA NA investigative histamine h3 receptor HRH3 Successful target agonist NA TTD , DGIDB (r)-alpha-methylhistamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (s)-1-(2-methoxyphenethyl)-2-methylpyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD piperidine derivative 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 4-hept-3-ynyl-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 2-((1h-imidazol-4-yl)methyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD bp-2.94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 histamine h3 receptor HRH3 Successful target unknown NA TTD methimepip NA NA investigative histamine h3 receptor HRH3 Successful target agonist 0.71 TTD , DGIDB carcinine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD triazolo-benzodiazepine derivative 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 2-(2-(pyrrolidin-1-yl)ethyl)phenol NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD mk-0249 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial histamine h3 receptor HRH3 Successful target unknown 1.06 TTD , DGIDB 2-(4-methyl-piperazin-1-yl)-quinoline NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD phenylsulfonyl derivative 4 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 4-(2-(cyclohexylamino)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pmid29334795-compound-22 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 1-(2-m-tolyl-ethyl)-pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(2-(4-tert-butylphenylamino)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(3-phenoxy-propyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (r)-3-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-propyl-1-[3-(phenylpropoxy)propyl]piperidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-benzylidene-1-(cyclobutylo)piperidine derivative 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB [125i]iodophenpropit NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD piperazine carbamate/urea derivative 6 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 2-(4-cyclopropyl-piperazin-1-yl)-quinoline NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pyridazin-3(2h)-one derivative 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB n-[3h]alpha-methylhistamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (1s,2s)-2-(1h-imidazol-4-yl)-cyclopentylamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD sar-152954 NA Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 histamine h3 receptor HRH3 Successful target unknown NA TTD obe101 small molecule Obesity[MeSHID:D009765],Hyperlipidemia[MeSHID:D006949] investigational histamine h3 receptor HRH3 NA unknown NA drugbank pmid29334795-compound-25 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB acrylamide compound 4 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD fub 349 NA NA investigative histamine h3 receptor HRH3 Successful target antagonist NA TTD , DGIDB phenoxypiperidine derivative 2 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational histamine h3 receptor HRH3 NA ligand NA drugbank suvn-g3031 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 histamine h3 receptor HRH3 Successful target agonist 2.83 TTD , DGIDB imetit NA NA investigative histamine h3 receptor HRH3 Successful target agonist 0.24 TTD , DGIDB s-38093 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB (r)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD des-bromoaplysamine-1 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (r)-1-(4-methoxyphenethyl)-2-methylpyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (r)-1-(4-nitrophenethyl)-2-methylpyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pmid29334795-compound-55 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB gt2394 NA NA investigative histamine h3 receptor HRH3 Successful target antagonist NA TTD , DGIDB phenoxypiperidine derivative 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB n-benzyl-4-cyclopentylpiperazine-1-carboxamide NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD vuf 4904 NA NA investigative histamine h3 receptor HRH3 Successful target antagonist NA TTD , DGIDB (r)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD evt-501 NA Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pf-3900422 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 5-methoxy-2-(2-(pyrrolidin-1-yl)ethyl)-1h-indole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 1-(4-nitrophenethyl)pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(6-cyclohexyl-hex-3-ynyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD gsk-334429 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 2-(4-isopropyl-piperazin-1-yl)-quinoline NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (s)-alpha-methylhistamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD benzo[d]oxazol-2(3h)-one derivative 1 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB gsk1004723 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 histamine h3 receptor HRH3 Successful target unknown NA TTD acrylamide compound 2 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB 4-(7,7-dimethyl-oct-3-ynyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD vuf 5681 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD jb 98064 NA NA investigative histamine h3 receptor HRH3 Successful target antagonist NA TTD , DGIDB phenylsulfonyl derivative 1 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB acrylamide compound 3 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB (r)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD gsk239512 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h3 receptor HRH3 Successful target antagonist 2.83 TTD , DGIDB jnj-17216498 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] phase 2 histamine h3 receptor HRH3 Successful target antagonist 2.83 TTD , DGIDB aplysamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (1r,2s)-2-(1h-imidazol-4-yl)-1-methyl-propylamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD iodoproxyfan NA NA investigative histamine h3 receptor HRH3 Successful target agonist 1.41 TTD , DGIDB 4-(2-(4-cyclohexylphenylamino)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (1h-indol-2-yl)(piperazin-1-yl)methanone NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pmid29334795-compound-57 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB jnj-39220675 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 2 histamine h3 receptor HRH3 Successful target unknown 1.41 TTD , DGIDB bavisant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 2 histamine h3 receptor HRH3 Successful target antagonist 2.83 TTD , DGIDB irdabisant NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 histamine h3 receptor HRH3 Successful target antagonist 2.83 TTD , DGIDB 1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(2-(3,4-dimethylphenylamino)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (s)-1-(4-methoxyphenethyl)-2-methylpyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (r)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD gsk835726 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 histamine h3 receptor HRH3 Successful target unknown NA TTD st-1093 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD pmid29334795-compound-66 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB (r)-1-(2-methoxyphenethyl)-2-methylpyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD immethridine NA NA investigative histamine h3 receptor HRH3 Successful target agonist 1.41 TTD , DGIDB apd-916 NA Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB (r)-3-(1h-imidazol-4-yl)propyl sec-butylcarbamate NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 4-(2-(phenylamino)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD vuf-5297 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (r)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD irdabisant NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 histamine h3 receptor HRH3 Successful target unknown 2.83 TTD , DGIDB 4-(2-(4-methoxyphenylamino)ethyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD jnj-28583867 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD abt-652 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Musculoskeletal Pain[MeSHID:D059352] phase 2 histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB histamine small molecule Gastric Acid[MeSHID:D005744],Diagnosis[MeSHID:D003933] approved,investigational histamine h3 receptor HRH3 NA agonist 0.64 drugbank , DGIDB fub-130 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative histamine h3 receptor HRH3 Successful target unknown NA TTD (s)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD betahistine small molecule Recurrent Vestibular Neuritis[MeSHID:D020338] approved,investigational histamine h3 receptor HRH3 NA antagonist 2.83 drugbank , DGIDB 1-(2-(naphthalen-2-yl)ethyl)pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD cipralisant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] discontinued in phase 2 histamine h3 receptor HRH3 Successful target agonist 1.41 TTD , DGIDB verongamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD olopatadine small molecule Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved histamine h3 receptor HRH3 NA antagonist NA drugbank 4-(8-phenyl-oct-3-ynyl)-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD aerophobin-1 NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD jnj-5207852 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] investigative histamine h3 receptor HRH3 Successful target antagonist 0.71 TTD , DGIDB abt-288 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h3 receptor HRH3 Successful target unknown 2.83 TTD , DGIDB piperazine carbamate/urea derivative 2 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB piperazine carbamate/urea derivative 7 NA NA patented histamine h3 receptor HRH3 Successful target unknown NA TTD , DGIDB impentamine NA NA investigative histamine h3 receptor HRH3 Successful target agonist,antagonist 1.41 TTD , DGIDB 4-hex-3-ynyl-1h-imidazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD burimamide NA NA investigative histamine h3 receptor HRH3 Successful target antagonist 0.47 TTD , DGIDB 5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD n-methylhistamine NA NA investigative histamine h3 receptor HRH3 Successful target agonist 0.47 TTD , DGIDB n-[3h]methylhistamine NA NA investigative histamine h3 receptor HRH3 Successful target agonist NA TTD , DGIDB 1-(4-(benzyloxy)phenethyl)pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 1-(2-methoxyphenethyl)pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD n-methyl-2-(pyridin-2-yl)ethanamine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD 1-(4-methoxyphenethyl)pyrrolidine NA NA investigative histamine h3 receptor HRH3 Successful target unknown NA TTD a-943931 NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD rev131 small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Allergic Reaction[MeSHID:D006967],Cataract[MeSHID:D002386] investigational histamine h4 receptor HRH4 NA unknown NA drugbank , DGIDB jnj-38518168 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] phase 2 histamine h4 receptor HRH4 Clinical trial target unknown 9.43 TTD , DGIDB improgan NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist 2.36 TTD , DGIDB ur-63325 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h4 receptor HRH4 Clinical trial target unknown 4.71 TTD , DGIDB n-methylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist 0.79 TTD , DGIDB (s)-alpha-methylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational histamine h4 receptor HRH4 NA ligand NA drugbank ur-60427 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD 4-methylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist 2.36 TTD , DGIDB ur-63325 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 histamine h4 receptor HRH4 Clinical trial target antagonist 4.71 TTD , DGIDB n-ethylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist NA TTD , DGIDB n-[3h]methylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist NA TTD , DGIDB imetit NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist 0.39 TTD , DGIDB 6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD 2-methylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist 2.36 TTD , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h4 receptor HRH4 NA antagonist 0.23 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved histamine h4 receptor HRH4 NA binder NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved histamine h4 receptor HRH4 NA binder NA drugbank 6-(4-methylpiperazin-1-yl)-9hpurine NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD 6-(4-methylpiperazin-1-yl)-9h-purin-2-amine NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD clobenpropit NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist 0.26 TTD , DGIDB (r)-3-(1h-imidazol-4-yl)propyl sec-butylcarbamate NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD [125i]iodophenpropit NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD jnj-10191584 NA NA investigative histamine h4 receptor HRH4 Clinical trial target antagonist 2.36 TTD , DGIDB n-[3h]alpha-methylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD burimamide NA NA investigative histamine h4 receptor HRH4 Clinical trial target antagonist 0.79 TTD , DGIDB pf-3893787 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Dental Plaque[MeSHID:D003773],Dermatitis, Atopic[MeSHID:D003876],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Asthma[MeSHID:D001249] phase 2 histamine h4 receptor HRH4 Clinical trial target unknown 5.89 TTD , DGIDB 2-(3-bromophenyl)histamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist NA TTD , DGIDB (r)-alpha-methylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD histamine small molecule Gastric Acid[MeSHID:D005744],Diagnosis[MeSHID:D003933] approved,investigational histamine h4 receptor HRH4 NA agonist 1.5 drugbank , DGIDB vuf 8430 NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist NA TTD , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h4 receptor HRH4 NA binder NA drugbank [3h]jnj 7777120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative histamine h4 receptor HRH4 Clinical trial target antagonist NA TTD , DGIDB 9-benzyl-6-(4-methylpiperazin-1-yl)-9h-purine NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD pheniramine small molecule Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Influenza[MeSHID:D007251],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h4 receptor HRH4 NA inverse agonist NA drugbank loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved histamine h4 receptor HRH4 NA binder NA drugbank n,n-dimethylhistamine NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist NA TTD , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved histamine h4 receptor HRH4 NA binder NA drugbank doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational histamine h4 receptor HRH4 NA binder NA drugbank (1h-indol-2-yl)(piperazin-1-yl)methanone NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved histamine h4 receptor HRH4 NA binder NA drugbank 2-(2-(4-tert-butylphenylthio)ethyl)-1h-imidazole NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD a-846714 NA NA investigative histamine h4 receptor HRH4 Clinical trial target unknown NA TTD htmt NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist NA TTD , DGIDB impromidine NA NA investigative histamine h4 receptor HRH4 Clinical trial target agonist 0.59 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational hornerin HRNR NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational hornerin HRNR NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental heparan sulfate glucosamine 3-o-sulfotransferase 1 HS3ST1 NA unknown NA drugbank o2-sulfo-glucuronic acid small molecule NA experimental heparan sulfate glucosamine 3-o-sulfotransferase 3a1 HS3ST3A1 NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental heparan sulfate glucosamine 3-o-sulfotransferase 3a1 HS3ST3A1 NA unknown NA drugbank n,o6-disulfo-glucosamine small molecule NA experimental heparan sulfate glucosamine 3-o-sulfotransferase 3a1 HS3ST3A1 NA unknown NA drugbank 1,4-dideoxy-5-dehydro-o2-sulfo-glucuronic acid small molecule NA experimental heparan sulfate glucosamine 3-o-sulfotransferase 3a1 HS3ST3A1 NA unknown NA drugbank 2-(2-chlorophenylamino)-5-methylthiazol-4(5h)-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD abietic acid NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD fig 1 NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(phenylsulfonyl)butan-2-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD ly-2523199 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 2'-monophosphoadenosine 5'-diphosphoribose NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(3-methylpyridin-2-yl)-4-tosylpiperazine NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD corticosterone small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank glycyrrhizic acid small molecule Neoplasms[MeSHID:D009369],Premenstrual syndrome[MeSHID:D011293],Stomach Diseases[MeSHID:D013272],Ulcer[MeSHID:D014456],Virus Diseases[MeSHID:D014777],Peptic Ulcer[MeSHID:D010437] approved,experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA antagonist NA drugbank a-849531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD azd8329 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] phase 1 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target inhibitor NA TTD , DGIDB adamantan-2-yl-piperidin-1-yl-methanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank (5s)-2-(cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4(5h)-one small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 2-(6-{[(3-chloro-2-methylphenyl)sulfonyl]amino}pyridin-2-yl)-n,n-diethylacetamide small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 1-{[(3r)-3-methyl-4-({4-[(1s)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]phenyl}sulfonyl)piperazin-1-yl]methyl}cyclopropanecarboxamide small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 2-(adamantan-1-ylamino)-5,5-diethyl-oxazol-4-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 2-(2-chloro-4-fluorophenoxy)-2-methyl-n-[(1r,2s,3s,5s,7s)-5-(methylsulfonyl)-2-adamantyl]propanamide small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 1-(4-tert-butylphenylsulfonyl)azepan-4-ol NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(2-adamantyl)-3-benzylpyrrolidin-2-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD pf-915275 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 3-epicorosolic acid methyl ester NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown 14.14 TTD , DGIDB adamantan-1-yl-piperazin-1-yl-methanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(4-chlorophenyl)-2-(phenylsulfonyl)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD incb13739 small molecule Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank , DGIDB (5s)-2-{[(1s)-1-(4-fluorophenyl)ethyl]amino}-5-(2-hydroxy-2-propanyl)-5-methyl-1,3-thiazol-4(5h)-one small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD corosolic acid NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD cnx-010 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD bvt.2733 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179], Systemic[MeSHID:D008180],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Myasthenia Gravis[MeSHID:D009157],Lupus Vulgaris[MeSHID:D008177] phase 3 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB carbenoxolone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD piperidine-1-carboxylic acid adamantan-2-ylamide NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 2-(o-toluidino)-5-isopropylthiazol-4(5h)-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 2-(benzylamino)-5,5-diethyloxazol-4(5h)-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD azd-4017 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] phase 2 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown 4.71 TTD , DGIDB ski-2852 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Syndrome X[MeSHID:D024821] investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD (5s)-2-{[(1s)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5h)-one small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD adamantan-1-yl-piperidin-1-yl-methanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD bms-816336 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 1 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB azd8329 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] phase 1 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB glycyrrhizin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 3 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown 1.77 TTD , DGIDB (3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank bms-770767 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB 1-phenyl-4-(1-phenyl-1h-tetrazol-5-yl)butan-2-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(3-chloropyridin-2-yl)-4-tosylpiperazine NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 3-acetyl-11-keto-ursolic acid NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 5,5-diethyl-2-(phenethylamino)oxazol-4(5h)-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD pf-877423 NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD ursolic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Syndrome X[MeSHID:D024821] phase 2 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown 1.18 TTD , DGIDB [(125)i] rb129 NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 3-acetyl-11-keto-beta-boswellic acid NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 2-(n-morpholino)-ethanesulfonic acid NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 2-(phenylsulfonyl)-1-p-tolylethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD adamantan-1-yl-pyrrolidin-1-yl-methanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD n-cyclopropyl-n-(trans-4-pyridin-3-ylcyclohexyl)-4-[(1s)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank n-benzyl-n-(phenylsulfonyl)benzamide NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD carbenoxolone small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA inhibitor NA drugbank (11-beta)-11,21-dihydroxy-pregn-4-ene-3,20-dione NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD ue-2343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB 1-phenyl-2-(1-phenyl-1h-tetrazol-5-yloxy)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD tormentic acid methyl ester NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown 14.14 TTD , DGIDB (2r)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank (1s,3r,4s,5s,7s)-4-{[2-(4-methoxyphenoxy)-2-methylpropanoyl]amino}adamantane-1-carboxamide small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 2-(cyclooctylamino)-5,5-diethyloxazol-4(5h)-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 11-keto-ursolic acid NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD bi-135585 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(4-ethylpiperazin-1-yl)-2-phenylethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD amg-221 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] discontinued in phase 1 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD nicotinamide adenine dinucleotide phosphate small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD n-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-n-cyclopropyl-4-[(1s)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 5-isopropyl-2-(phenylamino)thiazol-4(5h)-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD piperidine-1-carboxylic acid adamantan-2-yl ester NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(3-nitropyridin-2-yl)-4-tosylpiperazine NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD flavanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown 0.79 TTD , DGIDB (5r)-2-[(2-fluorophenyl)amino]-5-isopropyl-1,3-thiazol-4(5h)-one small molecule NA experimental corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 NA unknown NA drugbank 2-(o-toluidino)-5-ethylthiazol-4(5h)-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 11-keto-beta-boswellicacid NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD jtt-654 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB incb13739 NA Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2a corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB 1-(1-phenyl-1h-tetrazol-5-ylthio)propan-2-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD merck-544 NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD eq-1280 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-phenyl-3-(phenylsulfonyl)propan-1-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD (4-methoxyphenyl)(4-phenylazepan-1-yl)methanone NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 3-benzyl-1-cyclohexylpyrrolidin-2-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD rg-4929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] phase 2 corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB 2-(4-tosylpiperazin-1-yl)nicotinonitrile NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD 1,1-diphenyl-3-(phenylsulfonyl)propan-2-one NA NA investigative corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD hpp-851 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hereditary pyropoikilocytosis[MeSHID:C563004],Metabolic Diseases[MeSHID:D008659] preclinical corticosteroid 11-beta-dehydrogenase 1 HSD11B1 Clinical trial target unknown NA TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA unknown NA drugbank hydrocortisone valerate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA unknown NA drugbank formebolone small molecule Pituitary Gland[MeSHID:D010902],Pituitary Diseases[MeSHID:D010900],Growth[MeSHID:D006128] experimental,illicit corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA inhibitor NA drugbank hydrocortisone probutate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA unknown NA drugbank rg-7234 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 corticosteroid 11-beta-dehydrogenase 2 HSD11B2 Clinical trial target unknown NA TTD , DGIDB [(125)i] rb129 NA NA investigative corticosteroid 11-beta-dehydrogenase 2 HSD11B2 Clinical trial target unknown NA TTD hydrocortisone butyrate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA unknown NA drugbank 3-acetyl-11-keto-beta-boswellic acid NA NA investigative corticosteroid 11-beta-dehydrogenase 2 HSD11B2 Clinical trial target unknown NA TTD ganoderic acid a NA NA investigative corticosteroid 11-beta-dehydrogenase 2 HSD11B2 Clinical trial target unknown NA TTD hydrocortisone aceponate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] experimental,vet_approved corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA unknown NA drugbank 11-keto-beta-boswellicacid NA NA investigative corticosteroid 11-beta-dehydrogenase 2 HSD11B2 Clinical trial target unknown NA TTD hydrocortisone cypionate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,investigational,vet_approved corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA unknown NA drugbank hydrocortisone phosphate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA unknown NA drugbank hydrocortisone acetate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA unknown NA drugbank fluoxymesterone small molecule Malignant neoplasm of breast[MeSHID:D001943],Malnutrition[MeSHID:D044342],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 NA inhibitor NA drugbank 1-bromo-6-(3-hydroxyphenyl)-2-naphthol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-thiene-2,5-diyldiphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 6-(3-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-(furan-2-ylmethyl)estradiol-16-carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-(2-naphthyl)phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3'-(5-chloro-2-thienyl)biphenyl-3-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-methyl-n-ethyl estradiol-16-carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-methoxyethyl estrone-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 2-fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD nicotinamide-adenine-dinucleotide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 4-androstene-3-17-dione NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[5-(4-hydroxyphenyl)-2-thienyl]-5-methylphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[5-(4-hydroxyphenyl)-2-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-methyl estradiol-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(2',2'-dimethyl)-propylidene-estrone NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-(3-methylthiene-2,5-diyl]diphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 6-(3-hydroxyphenyl)-1-phenyl-2-naphthol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD methyl estradiol-16-beta-carboxylate NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 2-fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[4-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD naringenin NA NA phase 1 estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 6-oxo-16-formyl-estrone NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16beta-cyano-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 2-(3-hydroxyphenyl)quinolin-6-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[5-(3-fluorophenyl)-2-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-isopropyl estrone-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 4-[5-(3-hydroxyphenyl)-3-thienyl]-2-methylphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD kaempferol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[5-(4-hydroxyphenyl)-3-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(pyridin-2-yl)methylene-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-isopropyl estradiol-16-carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 1,1':4',1''-terphenyl-3,3''-diol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD nsc-94258 NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 1,1':4',1''-terphenyl-3,4''-diol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[4-(5-chloro-2-thienyl)pyridin-2-yl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,4'-(thiophene-2,4-diyl)diphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[5-(3,4-difluorophenyl)-2-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(pyridin-3-yl)methyl-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(4-cyano-benzylidene)-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3',3''-thiene-2,3,5-triyltriphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3'-(1-benzothien-2-yl)biphenyl-3-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-isobutylidene-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-(4'-methyl-piperazinyl) estradiol-16-carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-(6-hydroxy-2-naphthyl)benzoic acid NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-beta-ethoxymethyl-estrone NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-(pyridin-3-ylmethyl) estradiol-16-carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[2-(5-chloro-2-thienyl)pyridin-4-yl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-methyl-n-ethyl estrone-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 4-[5-(3-hydroxyphenyl)-2-thienyl)-2-methyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(pyridin-3-yl)methylene-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(thiophen-2-yl)methylene-estrone NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 2-fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-methyl estrone-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-thiene-2,4-diyldiphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(4-dimethylamino-benzylidene)-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD apigenin NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(4-dimethylamino-benzylidene)-estrone NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 4'-(5-chloro-2-thienyl)biphenyl-3-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-ethyl estrone-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-(pyridin-4-ylmethyl) estradiol-16-carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 4'-(6-methoxypyridin-3-yl)biphenyl-3-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-n-diethyl estradiol-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-(1,2,4-thiadiazol-2,5-diyl)diphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-(1'-phenyl-ethyl) estradiol-16-carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 5-(6-hydroxy-2-naphthyl)pyridin-3-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3-(1,3-thiazole-2,5-diyl)diphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 4-methyl-1,1':4',1''-terphenyl-3,4''-diol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[5-(4-fluorophenyl)-2-thienyl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-(5-phenyl-2-thienyl)phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 4-[5-(3-hydroxyphenyl)-2-thienyl]benzene-1,2-diol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD androstanedione small molecule NA experimental,illicit estradiol 17-beta-dehydrogenase 1 HSD17B1 NA unknown NA drugbank 3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-(1,3-thiazol-2,4-diyl)diphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD equilin small molecule Carcinoma[MeSHID:D002277],Ovarian Failure, Premature[MeSHID:D016649],Malignant neoplasm of breast[MeSHID:D001943],Atrophic Vaginitis[MeSHID:D059268],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Osteoporosis[MeSHID:D010024],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental estradiol 17-beta-dehydrogenase 1 HSD17B1 NA unknown NA drugbank n-ethyl estradiol-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD nicotinamide adenine dinucleotide phosphate small molecule NA experimental estradiol 17-beta-dehydrogenase 1 HSD17B1 NA unknown NA drugbank 16-(pyridin-4-yl)methyl-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD em-1745 small molecule NA experimental estradiol 17-beta-dehydrogenase 1 HSD17B1 NA unknown NA drugbank 4-fluoro-1,1':4',1''-terphenyl-3,3''-diol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n-isopropyl estradiol-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-(3-phenylthiene-2,5-diyl)diphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-pyrazine-2,5-diyldiphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-isobutylidene-estrone NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical estradiol 17-beta-dehydrogenase 1 HSD17B1 NA unknown NA drugbank androstenedione small molecule NA experimental,illicit estradiol 17-beta-dehydrogenase 1 HSD17B1 NA inducer NA drugbank 5alpha-androstan-3,17-dione NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 6-oxo-estrone NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD ethyl estrone-16-methylcarboxylate NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[6-(5-chloro-2-thienyl)pyridin-2-yl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD equilin NA Carcinoma[MeSHID:D002277],Ovarian Failure, Premature[MeSHID:D016649],Malignant neoplasm of breast[MeSHID:D001943],Atrophic Vaginitis[MeSHID:D059268],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Osteoporosis[MeSHID:D010024],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-beta-hydroxymethyl-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-[3-(4-hydroxyphenyl)isoxazol-5-yl]phenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3,3'-pyridine-2,5-diyldiphenol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 6-(4-hydroxy-phenyl)-naphthalen-1-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(pyridin-2-yl)methyl-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 2-hydroxy-n,6-bis(3-hydroxyphenyl)-1-naphthamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD n,n-diethyl estrone-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(pyridin-4-yl)methylene-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 2'-monophosphoadenosine 5'-diphosphoribose NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 16-(2',2'-dimethyl)-propylidene-estradiol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD stanolone acetate small molecule NA experimental estradiol 17-beta-dehydrogenase 1 HSD17B1 NA unknown NA drugbank 7-hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD stanolone small molecule NA illicit,investigational estradiol 17-beta-dehydrogenase 1 HSD17B1 NA unknown NA drugbank n-(furan-2-ylmethyl)-estrone-16-methyl carboxamide NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 7-(3-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD 3-(3-hydroxyphenyl)quinolin-7-ol NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD em-1745 NA NA investigative estradiol 17 beta-dehydrogenase 1 HSD17B1 Clinical trial target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 3-hydroxyacyl-coa dehydrogenase type-2 HSD17B10 NA unknown NA drugbank 1-azepan-1-yl-2-phenyl-2-(4-thioxo-1,4-dihydro-pyrazolo[3,4-d]pyrimidin-5-yl)ethanone adduct small molecule NA experimental 3-hydroxyacyl-coa dehydrogenase type-2 HSD17B10 NA unknown NA drugbank omega-3-carboxylic acids small molecule Hippocampus Proper[MeSHID:D006624],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Alcohol consumption[MeSHID:D000428],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Neoplasm Metastasis[MeSHID:D009362],Plasma[MeSHID:D010949],Obesity[MeSHID:D009765],Metabolic Syndrome X[MeSHID:D024821] approved,investigational 3-hydroxyacyl-coa dehydrogenase type-2 HSD17B10 NA potentiator NA drugbank aetiocholanolone small molecule NA experimental estradiol 17-beta-dehydrogenase 11 HSD17B11 NA unknown NA drugbank estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estradiol 17-beta-dehydrogenase 2 HSD17B2 NA unknown NA drugbank estradiol dienanthate small molecule NA approved,investigational,vet_approved estradiol 17-beta-dehydrogenase 2 HSD17B2 NA unknown NA drugbank estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estradiol 17-beta-dehydrogenase 2 HSD17B2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical estradiol 17-beta-dehydrogenase 2 HSD17B2 NA unknown NA drugbank estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved estradiol 17-beta-dehydrogenase 2 HSD17B2 NA unknown NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved estradiol 17-beta-dehydrogenase 2 HSD17B2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical testosterone 17-beta-dehydrogenase 3 HSD17B3 NA unknown NA drugbank (r)-3-hydroxydecanoyl-coa small molecule NA experimental peroxisomal multifunctional enzyme type 2 HSD17B4 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical peroxisomal multifunctional enzyme type 2 HSD17B4 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 3-keto-steroid reductase HSD17B7 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical estradiol 17-beta-dehydrogenase 8 HSD17B8 NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental estradiol 17-beta-dehydrogenase 8 HSD17B8 NA unknown NA drugbank hydrocortisone butyrate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA unknown NA drugbank hydrocortisone aceponate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] experimental,vet_approved 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA unknown NA drugbank hydrocortisone probutate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA unknown NA drugbank hydrocortisone cypionate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,investigational,vet_approved 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA unknown NA drugbank trilostane small molecule Cushing Syndrome[MeSHID:D003480],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational,vet_approved,withdrawn 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA inhibitor 95.48 drugbank , DGIDB hydrocortisone acetate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA unknown NA drugbank hydrocortisone phosphate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA unknown NA drugbank androstenedione small molecule NA experimental,illicit 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA positive allosteric modulator NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA unknown NA drugbank hydrocortisone valerate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 1 HSD3B1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 2 HSD3B2 NA unknown NA drugbank trilostane small molecule Cushing Syndrome[MeSHID:D003480],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational,vet_approved,withdrawn 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type 2 HSD3B2 NA inhibitor 106.09 drugbank , DGIDB bimoclomol small molecule Injury wounds[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational heat shock factor protein 1 HSF1 NA unknown 42.43 drugbank , DGIDB 4-(1h-imidazol-4-yl)-3-(5-ethyl-2,4-dihydroxy-phenyl)-1h-pyrazole small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank rta-901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Renal tubular acidosis[MeSHID:D000141] phase 1 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB 9-butyl-8-(2,5-dimethoxy-benzyl)-2-fluoro-9h-purin-6-ylamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 4-(1,3-benzodioxol-5-yl)-5-(5-ethyl-2,4-dihydroxyphenyl)-2h-pyrazole-3-carboxylic acid small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank nedocromil small molecule Asthma[MeSHID:D001249] approved,investigational heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)-adenine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank geldanamycin-estradiol hybrid NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD n-(4-acetylphenyl)-5-(5-chloro-2,4-dihydroxyphenyl)-1h-pyrazole-4-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank tanespimycin small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943] investigational heat shock protein hsp 90-alpha HSP90AA1 NA inhibitor 0.36 drugbank , DGIDB tanespimycin small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943] investigational heat shock protein hsp 90-alpha HSP90AA1 NA unknown 0.36 drugbank , DGIDB 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD ver 50589 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB 6-(3-bromo-2-naphthyl)-1,3,5-triazine-2,4-diamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank alvespimycin small molecule Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470] investigational heat shock protein hsp 90-alpha HSP90AA1 NA inhibitor 0.59 drugbank , DGIDB 9-butyl-8-(4-methoxybenzyl)-9h-purin-6-amine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank pu3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank ver-49009 NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD cromoglicate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Allergic rhinitis (disorder)[MeSHID:D065631],Asthma[MeSHID:D001249] approved heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD 2-(1h-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD 2-amino-4-(2,4-dichlorophenyl)-n-ethylthieno[2,3-d]pyrimidine-6-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank kw-2478 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.47 TTD , DGIDB nvp-auy922 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant Neoplasms[MeSHID:D009369] phase 2 heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.35 TTD , DGIDB 2-(1h-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 4-methyl-7,8-dihydro-5h-thiopyrano[4,3-d]pyrimidin-2-amine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank (3e)-3-[(phenylamino)methylidene]dihydrofuran-2(3h)-one small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 3-({2-[(2-amino-6-methylpyrimidin-4-yl)ethynyl]benzyl}amino)-1,3-oxazol-2(3h)-one small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank gnf-pf-67 NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.02 TTD , DGIDB cct-018159 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cataract, total congenital with posterior sutural opacities in Heterozygotes[MeSHID:C535338] experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank , DGIDB 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-n-ethylthieno[2,3-d]pyrimidine-6-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank pu-ad NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB 9-butyl-8-(3-methoxybenzyl)-9h-purin-6-amine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank tanespimycin NA leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943] phase 2 heat shock protein 90 alpha HSP90AA1 Successful target inhibitor 0.36 TTD , DGIDB hbp-347 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] discontinued in phase 3 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD 8-(2,5-dimethoxy-benzyl)-2-fluoro-9-pent-9h-purin-6-ylamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank biib-021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.47 TTD , DGIDB 4-chloro-6-(4-piperazin-1-yl-1h-pyrazol-5-yl)benzene-1,3-diol small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 9-butyl-8-(2,5-dimethoxy-benzyl)-9h-purin-6-ylamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank debio 0932 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB 9-butyl-8-(3-methoxybenzyl)-9h-purin-6-amine NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD amlexanox NA Paste substance[MeSHID:D009824],Aphthous Stomatitis[MeSHID:D013281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] approved heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.03 TTD , DGIDB radicicol NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.31 TTD , DGIDB 6-(3-bromo-2-naphthyl)-1,3,5-triazine-2,4-diamine NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD 9-butyl-8-(3,4,5-trimethoxybenzyl)-9h-purin-6-amine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 9-butyl-8-(2-chloro-3,4,5-trimethoxy-benzyl)-9h-purin-6-ylamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 5-(5-chloro-2,4-dihydroxyphenyl)-n-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank alvespimycin hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Hematologic Neoplasms[MeSHID:D019337] phase 1 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB tanespimycin NA leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943] phase 2 heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.36 TTD , DGIDB 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9h-carbazol-9-yl)benzamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank (5e,7s)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6h)-one oxime small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank biib 028 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB 2-methyl-2,4-pentanediol NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD pu24s NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD snx-5422 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Carcinoma, Neuroendocrine[MeSHID:D018278],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematologic Neoplasms[MeSHID:D019337],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 1/2 heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.47 TTD , DGIDB rifabutin small molecule HIV Infections[MeSHID:D015658],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mycobacterium Infections[MeSHID:D009164],Tuberculosis[MeSHID:D014376] approved,investigational heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 3,6-diamino-5-cyano-4-(4-ethoxyphenyl)thieno[2,3-b]pyridine-2-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank zearalanone NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.23 TTD , DGIDB macbecin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD 9-butyl-8-(4-methoxybenzyl)-9h-purin-6-amine NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 8-(2-chloro-3,4,5-trimethoxy-benzyl)-2-fluoro-9-pent-4-ylnyl-9h-purin-6-ylamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 8-(2,5-dimethoxy-benzyl)-2-fluoro-9h-purin-6-ylamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 4-{[(2r)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank snx-2112 NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD rhein NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.02 TTD , DGIDB kos-2484 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB kosn1559 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD 8-benzo[1,3]dioxol-,5-ylmethyl-9-butyl-9h- small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 8-(2-chloro-3,4,5-trimethoxy-benzyl)-9-pent-4-ylnyl-9h-purin-6-ylamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank polaprezinc small molecule Peptic Ulcer[MeSHID:D010437],Dyspepsia[MeSHID:D004415],Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcer[MeSHID:D014456] experimental heat shock protein hsp 90-alpha HSP90AA1 NA agonist NA drugbank snx-5422 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Carcinoma, Neuroendocrine[MeSHID:D018278],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematologic Neoplasms[MeSHID:D019337],Non-Small Cell Lung Carcinoma[MeSHID:D002289] investigational heat shock protein hsp 90-alpha HSP90AA1 NA unknown 0.47 drugbank , DGIDB ipi-493 NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD cct-018159 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cataract, total congenital with posterior sutural opacities in Heterozygotes[MeSHID:C535338] preclinical heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB n-[(2-amino-6-methylpyrimidin-4-yl)methyl]-3-{[(e)-(2-oxodihydrofuran-3(2h)-ylidene)methyl]amino}benzenesulfonamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 8-benzo[1,3]dioxol-,5-ylmethyl-9-butyl-2-fluoro-9h-purin-6-ylamine small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 5-(5-chloro-2,4-dihydroxyphenyl)-n-ethyl-4-(4-methoxyphenyl)isoxazole-3-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 4-chloro-6-(4-{4-[4-(methylsulfonyl)benzyl]piperazin-1-yl}-1h-pyrazol-5-yl)benzene-1,3-diol small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank geldanamycin small molecule Peripheral Nerve Injuries[MeSHID:D059348],Malignant neoplasm of kidney[MeSHID:D007680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,investigational heat shock protein hsp 90-alpha HSP90AA1 NA unknown 0.4 drugbank , DGIDB efungumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.47 TTD , DGIDB 17-desmethoxy-17-aminogeldanamycin NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD at13387 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD , DGIDB geldanamycin NA Peripheral Nerve Injuries[MeSHID:D059348],Malignant neoplasm of kidney[MeSHID:D007680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 heat shock protein 90 alpha HSP90AA1 Successful target unknown 0.4 TTD , DGIDB 5-(5-chloro-2,4-dihydroxyphenyl)-n-ethyl-4-piperazin-1-yl-1h-pyrazole-3-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 8-benzo[1,3]dioxol-,5-ylmethyl-9-butyl-9h- NA NA investigative heat shock protein 90 alpha HSP90AA1 Successful target unknown NA TTD 5-(5-chloro-2,4-dihydroxyphenyl)-n-ethyl-4-(4-methoxyphenyl)-1h-pyrazole-3-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank at13387 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 heat shock protein 90 alpha HSP90AA1 Successful target inhibitor 0.23 TTD , DGIDB n-[4-(aminosulfonyl)benzyl]-5-(5-chloro-2,4-dihydroxyphenyl)-1h-pyrazole-4-carboxamide small molecule NA experimental heat shock protein hsp 90-alpha HSP90AA1 NA unknown NA drugbank polaprezinc small molecule Peptic Ulcer[MeSHID:D010437],Dyspepsia[MeSHID:D004415],Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcer[MeSHID:D014456] experimental heat shock protein hsp 90-beta HSP90AB1 NA agonist NA drugbank (5e)-14-chloro-15,17-dihydroxy-4,7,8,9,10,11-hexahydro-2-benzoxacyclopentadecine-1,12(3h,13h)-dione small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank 4-{4-[4-(3-aminopropoxy)phenyl]-1h-pyrazol-5-yl}-6-chlorobenzene-1,3-diol small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank radicicol small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown 2.79 drugbank , DGIDB snx-5422 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Carcinoma, Neuroendocrine[MeSHID:D018278],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematologic Neoplasms[MeSHID:D019337],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 1/2 heat shock protein 90 beta HSP90AB1 Clinical trial target unknown 1.68 TTD , DGIDB geldanamycin small molecule Peripheral Nerve Injuries[MeSHID:D059348],Malignant neoplasm of kidney[MeSHID:D007680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,investigational heat shock protein hsp 90-beta HSP90AB1 NA inhibitor 1.79 drugbank , DGIDB 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)-adenine small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank tas-116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 heat shock protein 90 beta HSP90AB1 Clinical trial target unknown 1.68 TTD , DGIDB (5e)-12-chloro-13,15-dihydroxy-4,7,8,9-tetrahydro-2-benzoxacyclotridecine-1,10(3h,11h)-dione small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank cct-018159 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cataract, total congenital with posterior sutural opacities in Heterozygotes[MeSHID:C535338] experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank tanespimycin small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943] investigational heat shock protein hsp 90-beta HSP90AB1 NA inhibitor 1.29 drugbank , DGIDB methyl 3-chloro-2-{3-[(2,5-dihydroxy-4-methoxyphenyl)amino]-3-oxopropyl}-4,6-dihydroxybenzoate small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank geldanamycin small molecule Peripheral Nerve Injuries[MeSHID:D059348],Malignant neoplasm of kidney[MeSHID:D007680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,investigational heat shock protein hsp 90-beta HSP90AB1 NA unknown 1.79 drugbank , DGIDB (5z)-12-chloro-13,15-dihydroxy-4,7,8,9-tetrahydro-2-benzoxacyclotridecine-1,10(3h,11h)-dione small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank (5z)-13-chloro-14,16-dihydroxy-3,4,7,8,9,10-hexahydro-1h-2-benzoxacyclotetradecine-1,11(12h)-dione small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank tanespimycin small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943] investigational heat shock protein hsp 90-beta HSP90AB1 NA unknown 1.29 drugbank , DGIDB snx-5422 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Carcinoma, Neuroendocrine[MeSHID:D018278],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematologic Neoplasms[MeSHID:D019337],Non-Small Cell Lung Carcinoma[MeSHID:D002289] investigational heat shock protein hsp 90-beta HSP90AB1 NA unknown 1.68 drugbank , DGIDB pu-h71 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Malignant neoplasm of breast[MeSHID:D001943],Malignant Neoplasms[MeSHID:D009369] phase 1 heat shock protein 90 beta HSP90AB1 Clinical trial target unknown 1.68 TTD , DGIDB 2-(3-amino-2,5,6-trimethoxyphenyl)ethyl 5-chloro-2,4-dihydroxybenzoate small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank 9-butyl-8-(3,4,5-trimethoxybenzyl)-9h-purin-6-amine small molecule NA experimental heat shock protein hsp 90-beta HSP90AB1 NA unknown NA drugbank radicicol small molecule NA experimental endoplasmin HSP90B1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational endoplasmin HSP90B1 NA unknown NA drugbank n-ethyl-5'-carboxamido adenosine small molecule NA experimental endoplasmin HSP90B1 NA unknown NA drugbank rifabutin small molecule HIV Infections[MeSHID:D015658],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mycobacterium Infections[MeSHID:D009164],Tuberculosis[MeSHID:D014376] approved,investigational endoplasmin HSP90B1 NA unknown NA drugbank 2-chlorodideoxyadenosine small molecule NA experimental endoplasmin HSP90B1 NA unknown NA drugbank geldanamycin small molecule Peripheral Nerve Injuries[MeSHID:D059348],Malignant neoplasm of kidney[MeSHID:D007680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,investigational endoplasmin HSP90B1 NA inhibitor NA drugbank diglyme small molecule NA experimental endoplasmin HSP90B1 NA unknown NA drugbank methyl 3-chloro-2-{3-[(2,5-dihydroxy-4-methoxyphenyl)amino]-3-oxopropyl}-4,6-dihydroxybenzoate small molecule NA experimental endoplasmin HSP90B1 NA unknown NA drugbank hs-110 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 endoplasmin HSP90B1 Clinical trial target unknown 15.91 TTD , DGIDB 2-(3-amino-2,5,6-trimethoxyphenyl)ethyl 5-chloro-2,4-dihydroxybenzoate small molecule NA experimental endoplasmin HSP90B1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational heat shock 70 kda protein 13 HSPA13 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational heat shock-related 70 kda protein 2 HSPA2 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational heat shock 70 kda protein 4 HSPA4 NA unknown NA drugbank it-139 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 endoplasmic reticulum chaperone bip HSPA5 Clinical trial target unknown 2.12 TTD , DGIDB antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational 78 kda glucose-regulated protein HSPA5 NA chaperone NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 78 kda glucose-regulated protein HSPA5 NA chaperone NA drugbank nkp-1339 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 endoplasmic reticulum chaperone bip HSPA5 Clinical trial target unknown 2.12 TTD , DGIDB sam-6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 endoplasmic reticulum chaperone bip HSPA5 Clinical trial target unknown NA TTD , DGIDB lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational 78 kda glucose-regulated protein HSPA5 NA chaperone NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 78 kda glucose-regulated protein HSPA5 NA unknown NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved 78 kda glucose-regulated protein HSPA5 NA inhibitor,binder NA drugbank nsc-119913 NA NA investigative lipopolysaccharide-associated protein 1 HSPA8 Literature-reported target unknown 2.27 TTD , DGIDB (2r,3r,4s,5r)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol small molecule NA experimental heat shock cognate 71 kda protein HSPA8 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational heat shock cognate 71 kda protein HSPA8 NA ligand NA drugbank nsc-119911 NA NA investigative lipopolysaccharide-associated protein 1 HSPA8 Literature-reported target unknown 2.27 TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational heat shock cognate 71 kda protein HSPA8 NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational heat shock cognate 71 kda protein HSPA8 NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational heat shock cognate 71 kda protein HSPA8 NA unknown NA drugbank mkt-077 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 mortalin HSPA9 Clinical trial target unknown 190.95 TTD , DGIDB sb-242235 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] discontinued in phase 1 hspb1 messenger rna HSPB1 Discontinued target unknown NA TTD phenethyl isothiocyanate small molecule NA investigational heat shock protein beta-1 HSPB1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational heat shock protein beta-1 HSPB1 NA ligand NA drugbank ogx-427 + paclitaxel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943] investigative hspb1 messenger rna HSPB1 Discontinued target unknown NA TTD azx-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 heat shock protein 20 HSPB1 Clinical trial target unknown NA TTD apatorsen small molecule Neoplasms[MeSHID:D009369] investigational heat shock protein beta-1 HSPB1 NA unknown NA drugbank nk-1001 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Natural Killer Cells[MeSHID:D007694] discontinued in phase 2 heat shock protein 27 HSPB3 Clinical trial target unknown NA TTD ogx-427 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943] phase 2 heat shock protein 27 HSPB3 Clinical trial target unknown NA TTD diapep-277 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 3 mitochondrial matrix protein p1 HSPD1 Clinical trial target unknown 10.61 TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 60 kda heat shock protein, mitochondrial HSPD1 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational 10 kda heat shock protein, mitochondrial HSPE1 NA unknown NA drugbank xtoll NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1/2 mitochondrial 10kda heat shock protein HSPE1 Clinical trial target unknown NA TTD , DGIDB rus 3108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 perlecan HSPG2 Discontinued target unknown NA TTD palifermin biotech Inflammatory disease of mucous membrane[MeSHID:D052016],Oral Mucositis[MeSHID:D013280],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved basement membrane-specific heparan sulfate proteoglycan core protein HSPG2 NA ligand 17.68 drugbank , DGIDB phenethyl isothiocyanate small molecule NA investigational heat shock protein 105 kda HSPH1 NA unknown NA drugbank polyethylene glycol 400 small molecule Dry Eye Syndromes[MeSHID:D015352],Desiccation[MeSHID:D003890] approved oxidoreductase htatip2 HTATIP2 NA unknown NA drugbank pd-158771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1A NA inhibitor 0.05 drugbank , DGIDB 3-(4-benzyl-piperidin-1-ylmethyl)-chromen-4-one NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD sun n4057 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist,agonist 0.12 drugbank , DGIDB 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 8-methoxy-2-(4-methyl-piperazin-1-yl)-quinoline NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-ethyl-2,3,4,5-tetrahydro-1h-benzo[d]azepin-6-ol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD flibanserin NA Hypoactive Sexual Desire Disorder[MeSHID:D020018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] approved 5-ht 1a receptor HTR1A Successful target agonist 0.4 TTD , DGIDB 1192u90 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Psychotic Disorders[MeSHID:D011618],Schizophrenia[MeSHID:D012559] phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB sel-73 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD adatanserin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD aryl piperazine derivative 1 NA NA patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB av-965 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB (r)-(-)-10-methyl-11-hydroxyaporphine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD tiospirone NA NA discontinued in phase 3 5-ht 1a receptor HTR1A Successful target antagonist 0.2 TTD , DGIDB gr-127607 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD nerisopam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD lysergic acid diethylamide NA Disease[MeSHID:D004194],Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market 5-ht 1a receptor HTR1A Successful target unknown NA TTD mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA blocker NA drugbank 4-benzyl-1-chroman-3-ylmethyl-piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD gr 125,743 NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1A NA unknown 0.19 drugbank , DGIDB fkw00ga NA Phobia, Social[MeSHID:D000072861],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1A NA antagonist NA drugbank risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.04 drugbank , DGIDB acepromazine small molecule Anxiety[MeSHID:D001007] experimental,vet_approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank vilazodone small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.43 drugbank , DGIDB gsk-958108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Ejaculation[MeSHID:D061686] phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB mn-305 small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown 1.82 drugbank , DGIDB cm-2236 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Post-Traumatic Stress Disorder[MeSHID:D013313] preclinical 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB binospirone mesylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD [3h]8-oh-dpat NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD cp 93129 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB ebalzotan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD flibanserin small molecule Hypoactive Sexual Desire Disorder[MeSHID:D020018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.4 drugbank , DGIDB 1-(3-nitro-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD a-987306 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD cinitapride small molecule Ulcer[MeSHID:D014456],Gastrointestinal Diseases[MeSHID:D005767],Dyspepsia[MeSHID:D004415],cell motility[MeSHID:D002465],Gastroparesis[MeSHID:D018589],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR1A NA antagonist NA drugbank gsk163090 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Anxiety Disorders[MeSHID:D001008],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target antagonist 0.15 TTD , DGIDB ap-521 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD sun-8399 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD pmid30124346-compound-13table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB brl-15572 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist 0.07 TTD , DGIDB min-117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.06 drugbank , DGIDB (r)-2,11-diaminoaporphine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD naratriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.48 drugbank , DGIDB uh-232 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.06 drugbank , DGIDB 3-amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD snap-8719 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD flibanserin NA Hypoactive Sexual Desire Disorder[MeSHID:D020018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] approved 5-ht 1a receptor HTR1A Successful target unknown 0.4 TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA binder NA drugbank iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.12 drugbank , DGIDB 1-(2-methoxy-phenyl)-4-propyl-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD sunepitron NA NA discontinued in phase 3 5-ht 1a receptor HTR1A Successful target unknown NA TTD lecozotan hydrochloride NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.29 drugbank , DGIDB 4-(3-fluoro-2-phenoxyphenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD l-772,405 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB molindone small molecule Disease Management[MeSHID:D019468],Mental disorders[MeSHID:D001523],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank tgba01ad NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB cyamemazine NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist 0.15 TTD , DGIDB 8-methoxy-quinolin-2-ylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR1A NA antagonist NA drugbank buspirone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist,agonist 0.95 drugbank , DGIDB zalospirone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 5-ht 1a receptor HTR1A Successful target unknown 1.21 TTD , DGIDB 4-(2-(benzyloxy)-3-fluorophenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD sb-656104 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD lofexidine small molecule Disease Management[MeSHID:D019468],Abdominal Pain[MeSHID:D015746],Opiate Addiction[MeSHID:D009293],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Diarrhea[MeSHID:D003967],Mydriasis[MeSHID:D015878],Piloerection[MeSHID:D010863],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank sep-363856 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 3 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB org-13011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Major Depressive Disorder[MeSHID:D003865],Psychotic Disorders[MeSHID:D011618] phase 2 5-ht 1a receptor HTR1A Successful target unknown 1.21 TTD , DGIDB way-466 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD nlx-101 NA Rett Syndrome[MeSHID:D015518],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB lesopitron dihydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD 4-(2-(benzyloxy)-6-fluorophenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 4-benzyl-1-chroman-2-ylmethyl-piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR1A NA inhibitor NA drugbank cariprazine small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist,partial agonist NA drugbank 8-methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD lp-44 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB aryl piperazine derivative 15 NA NA patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank mazapertine succinate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB 1-(2-(phenoxymethyl)phenyl)piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD opc-14523 NA Bulimia[MeSHID:D002032],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive-Compulsive Personality[MeSHID:D003193],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB 2-(2-amino-propyl)-5-bromo-4-methoxy-phenol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD npt-500 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-phenyl-1-propyl-pyrrolidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD mn-305 NA Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 2 5-ht 1a receptor HTR1A Successful target unknown 1.82 TTD , DGIDB buspirone NA Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1a receptor HTR1A Successful target unknown 0.95 TTD , DGIDB 1-ethyl-4-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 4-(2-(benzyloxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD penbutolol small molecule Hypertensive disease[MeSHID:D006973],Shock, Cardiogenic[MeSHID:D012770],Atrioventricular Block[MeSHID:D054537],Neoplasm Metastasis[MeSHID:D009362],Asthma[MeSHID:D001249],Bradycardia[MeSHID:D001919],Hypersensitivity[MeSHID:D006967],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank bifeprunox small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist 0.51 drugbank , DGIDB (r)-flurocarazolol NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB 2-piperazin-1-yl-benzonitrile NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 4-(2-(4-fluorophenoxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD chlorophenylpiperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-naphthalen-1-yl-pyrrolidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.34 drugbank , DGIDB 4-(2-(2-fluorobenzyloxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2-(benzyloxy)phenyl)piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-(4-benzyl-piperidin-1-ylmethyl)-chroman-4-one NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD prx-00023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target unknown 3.03 TTD , DGIDB 1-(4-bromo-2,5-dimethoxy-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-(3-bromophenylthio)-n,n-dimethylethanamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-naphthalen-1-yl-1-propyl-pyrrolidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-(4-methyl-piperazin-1-yl)-4-phenyl-pyrimidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD tianeptine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1a HTR1A NA inhibitor NA drugbank [3h]p-mppf NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB jnj-10392980 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1a HTR1A NA activator NA drugbank 1-benzyl-4-chroman-2-ylmethyl-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD p-[18f]mppf NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.12 drugbank , DGIDB escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA inhibitor NA drugbank pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist,inhibitor,ligand 0.71 drugbank , DGIDB slv-313 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD skl-psy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD rs-30199 NA NA investigative 5-ht 1a receptor HTR1A Successful target allosteric modulator NA TTD , DGIDB medical cannabis biotech NA experimental,investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA binder NA drugbank xaliproden small molecule Amyotrophic Lateral Sclerosis[MeSHID:D000690],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lateral Sclerosis[MeSHID:D016472],Dental Plaque[MeSHID:D003773],Juvenile arthritis[MeSHID:D001171],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Esthesia[MeSHID:D012677],Peripheral Neuropathy[MeSHID:D010523] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown 1.21 drugbank , DGIDB doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.09 drugbank , DGIDB sumatriptan small molecule Cluster Headache[MeSHID:D003027],Nose[MeSHID:D009666],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.1 drugbank , DGIDB 1-butyl-4-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD alverine small molecule Cells[MeSHID:D002477],Disease[MeSHID:D004194],Spasm[MeSHID:D013035],Stomach[MeSHID:D013270],Irritable Bowel Syndrome[MeSHID:D043183],Muscle Cramp[MeSHID:D009120],Malignant neoplasm of breast[MeSHID:D001943],Intestines[MeSHID:D007422],Dysmenorrhea[MeSHID:D004412] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank du 125530 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(benzyloxy)-2-(2-phenylethyl)benzene NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD repinotan NA Depressive disorder[MeSHID:D003866],Cerebral Ischemia[MeSHID:D002545],Cerebral Infarction[MeSHID:D002544],Cerebrovascular accident[MeSHID:D020521],Mental Depression[MeSHID:D003863] investigative 5-ht 1a receptor HTR1A Successful target antagonist 1.21 TTD , DGIDB pmid30124346-compound-34table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank pirlindole small molecule Major Depressive Disorder[MeSHID:D003865],Hypertensive disease[MeSHID:D006973],Unipolar Depression[MeSHID:D003866],Psychological inhibition[MeSHID:D007266],Headache[MeSHID:D006261],Patient Care Management[MeSHID:D010346],Fibromyalgia[MeSHID:D005356],Genetic Selection[MeSHID:D012641],Pain Disorder[MeSHID:D013001],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Syndrome[MeSHID:D013577] experimental 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank rec-15/3079 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD flesinoxan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 5-ht 1a receptor HTR1A Successful target agonist 0.61 TTD , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist 0.2 drugbank , DGIDB aryl piperazine derivative 6 NA NA patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD [3h]robalzotan NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB pmid30124346-compound-ldt8 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR1A NA antagonist NA drugbank tgfk08aa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD lp-211 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB 1-naphthalen-2-yl-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.02 drugbank , DGIDB s-16924 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB (r)-11-amino-2-methoxyaporphine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD edmt NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-(2-benzylamino-ethoxy)-phenol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR1A NA antagonist,agonist NA drugbank pmid30124346-compound-ldt66 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB bms-181100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 3 5-ht 1a receptor HTR1A Successful target unknown NA TTD lp-12 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB ly 165,163 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD pmid30124346-compound-60table5 NA Dyskinetic syndrome[MeSHID:D020820],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB neu-p11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sleeplessness[MeSHID:D007319] phase 2 5-ht 1a receptor HTR1A Successful target unknown 0.2 TTD , DGIDB 4-(2-fluoro-6-phenoxyphenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD trazodone NA Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-ht 1a receptor HTR1A Successful target unknown 0.3 TTD , DGIDB 1-naphthylpiperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB bifeprunox NA Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 5-ht 1a receptor HTR1A Successful target unknown 0.51 TTD , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1A NA inhibitor,agonist 0.05 drugbank , DGIDB rp5063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Bipolar Disorder[MeSHID:D001714],Attention deficit hyperactivity disorder[MeSHID:D001289],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank 1-(2-(2-fluorobenzyloxy)phenyl)piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD vortioxetine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.27 drugbank , DGIDB ssr-181507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB cgs-19480a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD [3h]nlx-112 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB ondansetron small molecule Malignant Neoplasms[MeSHID:D009369],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Postoperative Nausea[MeSHID:D020250],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Subacute Bacterial Endocarditis[MeSHID:D004698],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1a HTR1A NA inhibitor,inducer NA drugbank 8-methoxy-2-piperazin-1-yl-quinoline NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-(2-amino-propyl)-1h-indol-5-ol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD dsp-1053 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB fenfluramine small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Obesity[MeSHID:D009765] approved,illicit,investigational,withdrawn 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank eltoprazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Dyskinetic syndrome[MeSHID:D020820],Parkinson Disease[MeSHID:D010300],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 3 5-ht 1a receptor HTR1A Successful target unknown 0.2 TTD , DGIDB pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist,antagonist 1.21 drugbank , DGIDB 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD tgwooaa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Phobia, Social[MeSHID:D000072861],Anxiety Disorders[MeSHID:D001008] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB piribedil NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist 0.05 TTD , DGIDB serdexmethylphenidate small molecule Attention deficit hyperactivity disorder[MeSHID:D001289] approved 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank pardoprunox small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown 0.17 drugbank , DGIDB lecozotan hydrochloride NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 5-ht 1a receptor HTR1A Successful target antagonist 0.61 TTD , DGIDB 2-(3-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2,5-dimethoxy-4-methyl-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD opc-34712 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-ht 1a receptor HTR1A Successful target unknown 0.48 TTD , DGIDB way 100135 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2,5-dimethoxyphenyl)propan-2-amine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist,partial agonist,agonist 0.18 drugbank , DGIDB 1-methyl-1,3-dihydro-indol-2-one NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 4-(2-phenoxyphenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2-phenoxyphenyl)piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD aryl piperazine derivative 14 NA NA patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB mpdt NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB 7-methoxy-1-naphthylpiperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB eletriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.2 drugbank , DGIDB pb-28 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD bopindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank spiroxatrine NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist 0.06 TTD , DGIDB nafadotride NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist 0.2 TTD , DGIDB tertatolol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved 5-ht 1a receptor HTR1A Successful target unknown 0.15 TTD , DGIDB lesopitron small molecule Anxiety Disorders[MeSHID:D001008] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank du-29894 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD s-15535 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank 1-(2-fluoro-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD propranolol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Pheochromocytoma[MeSHID:D010673],Hypertensive disease[MeSHID:D006973],Essential Tremor[MeSHID:D020329],Angina Pectoris[MeSHID:D000787],Strawberry nevus of skin[MeSHID:D018324],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Idiopathic hypertrophic subaortic stenosis[MeSHID:D024741],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank li-301 small molecule Premature Ejaculation[MeSHID:D061686] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank 1-(2,5-dimethoxy-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD aryl piperazine derivative 16 NA NA patented 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB alprenolol small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris[MeSHID:D000787],Cardiac Arrhythmia[MeSHID:D001145],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,withdrawn 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank n-benzyl-4-(2-diphenyl)-1-piperazinehexanamide NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD zolmitriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.51 drugbank , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist 0.38 drugbank , DGIDB [3h]spiperone NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD sb 272183 NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist,agonist 0.09 drugbank , DGIDB lysergic acid diethylamide small molecule Disease[MeSHID:D004194],Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit,investigational,withdrawn 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank sep-363856 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 3 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB tetrahydrocannabivarin small molecule NA investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.16 drugbank , DGIDB 1-(3-fluoro-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD u92016a NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB 1,6-bis(4-m-tolylpiperazin-1-yl)hexane NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD tgfk09sd NA Hypokinesia[MeSHID:D018476],Libido[MeSHID:D007989],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD quipazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2-butoxy-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 5-chloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1A NA inhibitor NA drugbank ly433221 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD s-14671 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB naluzotan small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 3.03 drugbank , DGIDB nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank bifeprunox small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown 0.51 drugbank , DGIDB sb 714786 NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB 3-butyl-2,3,4,5-tetrahydro-1h-benzo[d]azepin-6-ol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD n-(3-(1h-indol-4-yloxy)propyl)cyclohexanamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2-(4-fluorophenoxy)phenyl)piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD e2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Cervical Dystonia[MeSHID:D014103],Muscle Cramp[MeSHID:D009120] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD vilazodone NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1a receptor HTR1A Successful target unknown 0.43 TTD , DGIDB 3-(3-methanesulfonyl-phenyl)-1-propyl-pyrrolidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.12 drugbank , DGIDB 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD fg-5893 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB pipotiazine small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank treximet NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB sep-363856 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank , DGIDB alnespirone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD n-[4-(4-phenyl-piperazin-1-yl)-butyl]-benzamide NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1A NA antagonist NA drugbank [11c]way100635 NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB brolamfetamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD n-methyllaurotetanine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD (s)-flurocarazolol NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD u-93385 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD 5-methoxy-n,n-dimethyltryptamine small molecule NA experimental,illicit 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1,2,3,4-tetrahydro-naphthalen-2-ylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 4-(2-(4-fluorobenzyloxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.02 drugbank , DGIDB 1-propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD tfmpp NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD brexpiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist,partial agonist 0.48 drugbank , DGIDB sarizotan NA Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Rett Syndrome[MeSHID:D015518],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 5-ht 1a receptor HTR1A Successful target unknown 0.91 TTD , DGIDB dapoxetine small molecule Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank dihydroergocornine small molecule NA approved serotonin receptors HTR1A NA antagonist,agonist NA drugbank (3-chloro-phenyl)-piperazin-1-yl-methanone NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD methysergide small molecule Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.25 drugbank , DGIDB sr-59026 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-((s)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD zalospirone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 5-ht 1a receptor HTR1A Successful target agonist 1.21 TTD , DGIDB 9-oh-risperidone NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.06 drugbank , DGIDB lurasidone small molecule Schizophrenia[MeSHID:D012559] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 0.4 drugbank , DGIDB 1-(2-(3-fluorophenoxy)phenyl)piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 4-(2-(3-chlorophenoxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD sb-271046 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD bifeprunox NA Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 5-ht 1a receptor HTR1A Successful target partial agonist 0.51 TTD , DGIDB sdz-mar-327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Psychotic Disorders[MeSHID:D011618],Schizophrenia[MeSHID:D012559] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB s-15535 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB 2-dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1,6-bis(4-phenylpiperazin-1-yl)hexane NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD eptapirone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD repinotan small molecule Depressive disorder[MeSHID:D003866],Cerebral Ischemia[MeSHID:D002545],Cerebral Infarction[MeSHID:D002544],Cerebrovascular accident[MeSHID:D020521],Mental Depression[MeSHID:D003863] investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 1.21 drugbank , DGIDB xaliproden NA Amyotrophic Lateral Sclerosis[MeSHID:D000690],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lateral Sclerosis[MeSHID:D016472],Dental Plaque[MeSHID:D003773],Juvenile arthritis[MeSHID:D001171],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Esthesia[MeSHID:D012677],Peripheral Neuropathy[MeSHID:D010523] phase 3 5-ht 1a receptor HTR1A Successful target unknown 1.21 TTD , DGIDB agroclavine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD n-(3-(1h-indol-4-yloxy)propyl)cyclopentanamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-(2-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD pardoprunox small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.17 drugbank , DGIDB 1-(7-methoxy-naphthalen-2-yl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD robalzotan NA Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 5-ht 1a receptor HTR1A Successful target antagonist 2.42 TTD , DGIDB serotonin NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-phenoxy-3-(piperidin-4-yl)pyridine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD trazodone small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist,partial agonist 0.3 drugbank , DGIDB sarizotan small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Rett Syndrome[MeSHID:D015518],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown 0.91 drugbank , DGIDB cm-2395 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB buspirone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist 0.95 drugbank , DGIDB 1-(2-ethoxy-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD rotigotine small molecule Restless Legs Syndrome[MeSHID:D012148],Parkinson Disease[MeSHID:D010300] approved 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.3 drugbank , DGIDB emd 56551 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD fkb01md NA NA phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD dotarizine small molecule Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank 2-(biphenyl-3-ylthio)-n,n-dimethylethanamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD mazapertine NA NA discontinued in phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD nlx-101 NA Rett Syndrome[MeSHID:D015518],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB p-mppi NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB 2-(4-bromo-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-(4-bromo-2-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD buspirone NA Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1a receptor HTR1A Successful target agonist 0.95 TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist,agonist 0.38 drugbank , DGIDB dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved 5-hydroxytryptamine receptor 1a HTR1A NA binder NA drugbank 4-(1h-indol-4-yloxy)-1-(isopropylamino)butan-2-ol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-(5-methoxy-1h-indol-3-yl)-1-methyl-ethylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 1-(2-isopropoxy-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD escholtzine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist,antagonist 0.13 drugbank , DGIDB apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist 0.08 drugbank , DGIDB pg-01037 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-piperazin-1-yl-phenol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD urapidil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Inflammation[MeSHID:D007249] approved 5-ht 1a receptor HTR1A Successful target unknown 0.12 TTD , DGIDB uh-301 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1h-indole NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 5-ct NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB 4-(2-(3-fluorophenoxy)phenyl)piperidine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 2-(4-benzyl-piperidin-1-ylmethyl)-chroman-4-one NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist,partial agonist 0.18 drugbank , DGIDB vilazodone NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1a receptor HTR1A Successful target agonist 0.43 TTD , DGIDB 5,6-dichloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank etisulergine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD methylphenidate small molecule Narcolepsy[MeSHID:D009290],Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Traumatic Brain Injury[MeSHID:D000070642] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA unknown NA drugbank 2-(2'-methyl-biphenyl-3-yl)-ethylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD umespirone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 1 5-ht 1a receptor HTR1A Successful target unknown 0.3 TTD , DGIDB sb 216641 NA NA investigative 5-ht 1a receptor HTR1A Successful target agonist NA TTD , DGIDB 3-(1-propyl-pyrrolidin-3-yl)-phenol NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD mcl-516 NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD 9-methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD sb 649915 NA NA investigative 5-ht 1a receptor HTR1A Successful target antagonist NA TTD , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1a HTR1A NA antagonist NA drugbank pramipexole small molecule Secondary Parkinson Disease[MeSHID:D010302],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational 5-hydroxytryptamine receptor 1a HTR1A NA agonist NA drugbank 1-(2-chloro-phenyl)-piperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD perospirone small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] experimental 5-hydroxytryptamine receptor 1a HTR1A NA partial agonist NA drugbank ensaculin hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 5-ht 1a receptor HTR1A Successful target unknown NA TTD , DGIDB robalzotan small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1a HTR1A NA antagonist 2.42 drugbank , DGIDB 1-(2-methoxyphenyl)-4-pentylpiperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD phenylpiperazine NA NA investigative 5-ht 1a receptor HTR1A Successful target unknown NA TTD eltoprazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Dyskinetic syndrome[MeSHID:D020820],Parkinson Disease[MeSHID:D010300],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 3 5-ht 1b receptor HTR1B Successful target unknown 0.33 TTD , DGIDB vortioxetine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA partial agonist 0.33 drugbank , DGIDB oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 0.08 drugbank , DGIDB vortioxetine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA partial agonist,agonist 0.33 drugbank , DGIDB elzasonan hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1b HTR1B NA binder NA drugbank 1-naphthalen-2-yl-piperazine NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD dipropyl-5-ct NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist NA drugbank 5-isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1h-indole NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD (+/-)-nantenine NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1b HTR1B NA antagonist NA drugbank lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 0.12 drugbank , DGIDB pindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA ligand NA drugbank pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn 5-hydroxytryptamine receptor 1b HTR1B NA agonist 0.2 drugbank , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1b HTR1B NA binder NA drugbank propranolol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Pheochromocytoma[MeSHID:D010673],Hypertensive disease[MeSHID:D006973],Essential Tremor[MeSHID:D020329],Angina Pectoris[MeSHID:D000787],Strawberry nevus of skin[MeSHID:D018324],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Idiopathic hypertrophic subaortic stenosis[MeSHID:D024741],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA unknown NA drugbank brl-15572 NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist 0.11 TTD , DGIDB sb 649915 NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB eletriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 1.47 drugbank , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1B NA unknown 0.08 drugbank , DGIDB l-772,405 NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB lysergol NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1b HTR1B NA antagonist,agonist 0.03 drugbank , DGIDB 1-(7-methoxy-naphthalen-2-yl)-piperazine NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD metergolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-ht 1b receptor HTR1B Successful target unknown NA TTD , DGIDB zolmitriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target unknown 2.61 TTD , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1B NA inhibitor 0.04 drugbank , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR1B NA inhibitor NA drugbank sb 216641 NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB alniditan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 3 5-ht 1b receptor HTR1B Successful target agonist 0.49 TTD , DGIDB gr55562 NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD eletriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target unknown 1.47 TTD , DGIDB dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR1B NA antagonist NA drugbank frovatriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 5.22 drugbank , DGIDB 2-methyl-5-ht NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB l-747201 NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD frovatriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target unknown 5.22 TTD , DGIDB yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 1b HTR1B NA partial agonist,antagonist 0.21 drugbank , DGIDB naratriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target agonist 2.74 TTD , DGIDB 1-naphthylpiperazine NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB rizatriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1b HTR1B NA agonist 1.96 drugbank , DGIDB dihydroergocornine small molecule NA approved serotonin receptors HTR1B NA antagonist,agonist NA drugbank [11c]az10419369 NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB (r)-flurocarazolol NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB donitriptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] preclinical 5-ht 1b receptor HTR1B Successful target unknown 0.33 TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA antagonist,ligand,agonist 0.18 drugbank , DGIDB frovatriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target agonist 5.22 TTD , DGIDB pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 1b HTR1B NA antagonist NA drugbank sb236057 NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 0.86 drugbank , DGIDB 5-ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1h-indole NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD 5-amino-3-(n-methylpiperidin-4-yl)-1h-indole NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-hydroxytryptamine receptor 1b HTR1B NA agonist 0.2 drugbank , DGIDB is-159 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 2 5-ht 1b receptor HTR1B Successful target unknown NA TTD sb 272183 NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB tfmpp NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB prolixin decanoate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved 5-ht 1b receptor HTR1B Successful target unknown NA TTD , DGIDB bopindolol small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental 5-hydroxytryptamine receptor 1b HTR1B NA unknown NA drugbank fluphenazine NA Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target unknown 0.07 TTD , DGIDB zolmitriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target agonist 2.61 TTD , DGIDB 2-(5-nonyloxy-1h-indol-3-yl)-ethylamine NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD nxn-188 NA Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 1b receptor HTR1B Successful target unknown NA TTD , DGIDB 9-oh-risperidone NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB nxn-188 small molecule Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1b HTR1B NA unknown NA drugbank , DGIDB 2-(5-thiophen-2-yl-1h-indol-3-yl)-ethylamine NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit 5-hydroxytryptamine receptor 1b HTR1B NA modulator NA drugbank eletriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target agonist 1.47 TTD , DGIDB naratriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 2.74 drugbank , DGIDB dapoxetine small molecule Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1b HTR1B NA unknown NA drugbank 5-ct NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB almotriptan small molecule Migraine Disorders[MeSHID:D008881] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 4.41 drugbank , DGIDB [125i]gti NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD sb 224289 NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB [3h]8-oh-dpat NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1B NA antagonist NA drugbank serotonin NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD (s)-flurocarazolol NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1B NA inhibitor,agonist 0.04 drugbank , DGIDB ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved 5-hydroxytryptamine receptor 1b HTR1B NA agonist 0.65 drugbank , DGIDB 7-methoxy-1-naphthylpiperazine NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB a-987306 NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD [3h]sumatriptan NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB methysergide small molecule Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 1b HTR1B NA binder,antagonist 0.12 drugbank , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA unknown NA drugbank asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1b HTR1B NA antagonist 0.2 drugbank , DGIDB [3h]gr 125,743 NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 0.1 drugbank , DGIDB gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1B NA inhibitor NA drugbank sumatriptan small molecule Cluster Headache[MeSHID:D003027],Nose[MeSHID:D009666],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 0.82 drugbank , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1b HTR1B NA antagonist,agonist 0.2 drugbank , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1B NA antagonist NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1b HTR1B NA antagonist,agonist 0.14 drugbank , DGIDB sb 714786 NA NA investigative 5-ht 1b receptor HTR1B Successful target antagonist NA TTD , DGIDB [n-methyl-3h(3)]az-10419369 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 1 5-ht 1b receptor HTR1B Successful target unknown NA TTD , DGIDB [2-(5-ethyl-1h-indol-3-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD cp-94,253 NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD zolmitriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA agonist 2.61 drugbank , DGIDB [3h]eletriptan NA NA investigative 5-ht 1b receptor HTR1B Successful target agonist NA TTD , DGIDB penbutolol small molecule Hypertensive disease[MeSHID:D006973],Shock, Cardiogenic[MeSHID:D012770],Atrioventricular Block[MeSHID:D054537],Neoplasm Metastasis[MeSHID:D009362],Asthma[MeSHID:D001249],Bradycardia[MeSHID:D001919],Hypersensitivity[MeSHID:D006967],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1b HTR1B NA antagonist NA drugbank setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR1B NA antagonist NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR1B NA antagonist,agonist NA drugbank 5-oh-dpat NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD donitriptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] preclinical 5-ht 1b receptor HTR1B Successful target agonist 0.33 TTD , DGIDB ondansetron small molecule Malignant Neoplasms[MeSHID:D009369],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Postoperative Nausea[MeSHID:D020250],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Subacute Bacterial Endocarditis[MeSHID:D004698],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 1b HTR1B NA unknown NA drugbank way-466 NA NA investigative 5-ht 1b receptor HTR1B Successful target unknown NA TTD fluphenazine NA Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved 5-ht 1b receptor HTR1B Successful target unknown 0.07 TTD , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR1B NA antagonist NA drugbank quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 1b HTR1B NA ligand NA drugbank naratriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1b receptor HTR1B Successful target unknown 2.74 TTD , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1D NA unknown NA drugbank 1-(2-fluoro-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD frovatriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target agonist 5.3 TTD , DGIDB agroclavine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD metergolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-ht 1d receptor HTR1D Successful target unknown NA TTD , DGIDB etisulergine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD donitriptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] preclinical 5-ht 1d receptor HTR1D Successful target agonist 0.35 TTD , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1D NA inhibitor 0.05 drugbank , DGIDB sb 216641 NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB naratriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 3.18 drugbank , DGIDB mpdt NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB zolmitriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target unknown 2.83 TTD , DGIDB ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved 5-hydroxytryptamine receptor 1d HTR1D NA agonist 0.94 drugbank , DGIDB alx-0646 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 1 5-ht 1d receptor HTR1D Successful target unknown NA TTD 2-piperazin-1-yl-phenol NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR1D NA antagonist,agonist NA drugbank 1-naphthalen-2-yl-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD [125i]gti NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD lysergol NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB 5-ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1h-indole NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD sb 649915 NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB 2-piperazin-1-yl-benzonitrile NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD almotriptan small molecule Migraine Disorders[MeSHID:D008881] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 3.71 drugbank , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 1.33 drugbank , DGIDB nxn-188 NA Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 1d receptor HTR1D Successful target unknown NA TTD , DGIDB 2-methyl-5-ht NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1d HTR1D NA binder NA drugbank sumatriptan small molecule Cluster Headache[MeSHID:D003027],Nose[MeSHID:D009666],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 0.94 drugbank , DGIDB frovatriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target unknown 5.3 TTD , DGIDB brl-15572 NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist 0.12 TTD , DGIDB sb 272183 NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB 2-(4-bromo-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 2-(5-thiophen-2-yl-1h-indol-3-yl)-ethylamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 1-(2,5-dimethoxyphenyl)propan-2-amine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 1-(2-ethoxy-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 1-(2,5-dimethoxy-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD donitriptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] preclinical 5-ht 1d receptor HTR1D Successful target unknown 0.35 TTD , DGIDB sumatriptan NA Cluster Headache[MeSHID:D003027],Nose[MeSHID:D009666],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target unknown 0.94 TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1d HTR1D NA binder NA drugbank 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA antagonist 0.03 drugbank , DGIDB clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1d HTR1D NA antagonist,agonist 0.03 drugbank , DGIDB 2-(2-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD brolamfetamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA antagonist,ligand,agonist 0.2 drugbank , DGIDB 1-(2,5-dimethoxy-4-methyl-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR1D NA antagonist NA drugbank chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR1D NA inhibitor NA drugbank rizatriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1d HTR1D NA agonist 2.76 drugbank , DGIDB m-chlorophenylpiperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB zolmitriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 2.83 drugbank , DGIDB sb 714786 NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB nxn-188 small molecule Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 1d HTR1D NA unknown NA drugbank , DGIDB 1-((s)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD eletriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target agonist 1.77 TTD , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR1D NA antagonist NA drugbank l-772,405 NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB 1-(3-nitro-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD avitriptan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 3 5-ht 1d receptor HTR1D Successful target agonist 0.53 TTD , DGIDB dipropyl-5-ct NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB 2-(2-amino-propyl)-5-bromo-4-methoxy-phenol NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD quipazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 1-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 1d HTR1D NA ligand,agonist 0.1 drugbank , DGIDB neu-p11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sleeplessness[MeSHID:D007319] phase 2 5-ht 1d receptor HTR1D Successful target unknown 0.35 TTD , DGIDB eletriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 1.77 drugbank , DGIDB 1-naphthylpiperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB 2-(3-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-hydroxytryptamine receptor 1d HTR1D NA agonist 0.21 drugbank , DGIDB 1,2,3,4-tetrahydro-naphthalen-2-ylamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 1-(3-fluoro-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD [3h]eletriptan NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB bufotenine NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist 0.35 TTD , DGIDB dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR1D NA antagonist NA drugbank 2-(4-tert-butyl-phenyl)-4,5-dihydro-1h-imidazole NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD fenfluramine small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Obesity[MeSHID:D009765] approved,illicit,investigational,withdrawn 5-hydroxytryptamine receptor 1d HTR1D NA agonist NA drugbank 1-(7-methoxy-naphthalen-2-yl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist NA drugbank tidembersat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 1 5-ht 1d receptor HTR1D Successful target unknown NA TTD phenylpiperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD frovatriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 5.3 drugbank , DGIDB bms-181101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 1d receptor HTR1D Successful target unknown NA TTD edmt NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD [3h]8-oh-dpat NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB oxymetazoline small molecule Rosacea[MeSHID:D012393],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Blepharoptosis[MeSHID:D001763],Pharyngeal structure[MeSHID:D010614],Off-Label Use[MeSHID:D056687],Postoperative Hemorrhage[MeSHID:D019106],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 0.09 drugbank , DGIDB alpha-methyl-5-ht NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD rizatriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target agonist 2.76 TTD , DGIDB pnu-142633 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 2 5-ht 1d receptor HTR1D Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 1d HTR1D NA binder NA drugbank [2-(5-ethyl-1h-indol-3-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 5-ct NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB chlorophenylpiperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 9-oh-risperidone NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB 8-methoxy-quinolin-2-ylamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1D NA inhibitor NA drugbank [3h]sumatriptan NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1D NA antagonist NA drugbank l-760790 NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn 5-hydroxytryptamine receptor 1d HTR1D NA agonist 0.21 drugbank , DGIDB 8-methoxy-2-(4-methyl-piperazin-1-yl)-quinoline NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1D NA inhibitor,agonist 0.05 drugbank , DGIDB dihydroergocornine small molecule NA approved serotonin receptors HTR1D NA antagonist,agonist NA drugbank 5-isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1h-indole NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1d HTR1D NA antagonist NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1d HTR1D NA antagonist 0.4 drugbank , DGIDB tgba01ad NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 2 5-ht 1d receptor HTR1D Successful target unknown NA TTD , DGIDB lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 0.13 drugbank , DGIDB 2-(4-bromo-2-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD sumatriptan NA Cluster Headache[MeSHID:D003027],Nose[MeSHID:D009666],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target agonist 0.94 TTD , DGIDB (3-chloro-phenyl)-piperazin-1-yl-methanone NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 7-methoxy-1-naphthylpiperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB 3-amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD rizatriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target unknown 2.76 TTD , DGIDB serotonin NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 2-(5-nonyloxy-1h-indol-3-yl)-ethylamine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 1d HTR1D NA partial agonist,antagonist 0.15 drugbank , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1D NA antagonist NA drugbank 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 5,6-dichloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD l-747201 NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 5-amino-3-(n-methylpiperidin-4-yl)-1h-indole NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD 1-(4-bromo-2,5-dimethoxy-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD lysergic acid NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB 1-(2-isopropoxy-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist 0.11 drugbank , DGIDB eletriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target unknown 1.77 TTD , DGIDB way-466 NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD is-159 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 2 5-ht 1d receptor HTR1D Successful target unknown NA TTD ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1d HTR1D NA antagonist,agonist 0.4 drugbank , DGIDB elzasonan hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB [3h]gr 125,743 NA NA investigative 5-ht 1d receptor HTR1D Successful target antagonist NA TTD , DGIDB 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD cp-122288 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 2 5-ht 1d receptor HTR1D Successful target agonist 0.53 TTD , DGIDB (+/-)-nantenine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD tfmpp NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB 2-(2,6-dimethyl-benzyl)-4,5-dihydro-1h-imidazole NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD alniditan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 3 5-ht 1d receptor HTR1D Successful target agonist 0.53 TTD , DGIDB 1-(2-butoxy-phenyl)-piperazine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD [3h]5-ct NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB fkb01md NA NA phase 2 5-ht 1d receptor HTR1D Successful target unknown NA TTD , DGIDB [3h]5-ht NA NA investigative 5-ht 1d receptor HTR1D Successful target agonist NA TTD , DGIDB 8-methoxy-2-piperazin-1-yl-quinoline NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD almogran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-ht 1d receptor HTR1D Successful target unknown NA TTD , DGIDB zolmitriptan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1d receptor HTR1D Successful target agonist 2.83 TTD , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA unknown NA drugbank 5-chloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 1d receptor HTR1D Successful target unknown NA TTD tonabersat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 2 5-ht 1d receptor HTR1D Successful target unknown 2.12 TTD , DGIDB lofexidine small molecule Disease Management[MeSHID:D019468],Abdominal Pain[MeSHID:D015746],Opiate Addiction[MeSHID:D009293],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Diarrhea[MeSHID:D003967],Mydriasis[MeSHID:D015878],Piloerection[MeSHID:D010863],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1d HTR1D NA agonist NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 1e HTR1E NA antagonist,ligand NA drugbank metergolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-ht 1e receptor HTR1E Successful target unknown NA TTD , DGIDB [3h]5-ht NA NA investigative 5-ht 1e receptor HTR1E Successful target agonist NA TTD , DGIDB dihydroergocornine small molecule NA approved serotonin receptors HTR1E NA antagonist,agonist NA drugbank clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1e HTR1E NA antagonist,agonist 0.05 drugbank , DGIDB zolmitriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1e HTR1E NA agonist 0.96 drugbank , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1e HTR1E NA antagonist,agonist 0.18 drugbank , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 1e HTR1E NA unknown NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR1E NA antagonist NA drugbank 5-ct NA NA investigative 5-ht 1e receptor HTR1E Successful target agonist NA TTD , DGIDB tfmpp NA NA investigative 5-ht 1e receptor HTR1E Successful target agonist NA TTD , DGIDB edmt NA NA investigative 5-ht 1e receptor HTR1E Successful target unknown NA TTD brl-15572 NA NA investigative 5-ht 1e receptor HTR1E Successful target agonist 0.21 TTD , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR1E NA antagonist NA drugbank olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1E NA inhibitor,agonist 0.09 drugbank , DGIDB 9-oh-risperidone NA NA investigative 5-ht 1e receptor HTR1E Successful target antagonist NA TTD , DGIDB b173 NA NA investigative 5-ht 1e receptor HTR1E Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1E NA antagonist NA drugbank lysergol NA NA investigative 5-ht 1e receptor HTR1E Successful target agonist NA TTD , DGIDB 1-naphthylpiperazine NA NA investigative 5-ht 1e receptor HTR1E Successful target antagonist NA TTD , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 1e HTR1E NA ligand,agonist 0.12 drugbank , DGIDB brl54443 NA NA investigative 5-ht 1e receptor HTR1E Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1e HTR1E NA binder NA drugbank alpha-methyl-5-ht NA NA investigative 5-ht 1e receptor HTR1E Successful target unknown NA TTD 2-methyl-5-ht NA NA investigative 5-ht 1e receptor HTR1E Successful target agonist NA TTD , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1e HTR1E NA agonist 0.24 drugbank , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1E NA antagonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1E NA unknown NA drugbank olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1E NA inhibitor 0.09 drugbank , DGIDB methysergide small molecule Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 1e HTR1E NA binder,antagonist 0.23 drugbank , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR1E NA antagonist,agonist NA drugbank setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR1E NA antagonist NA drugbank gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1E NA inhibitor NA drugbank 5-bodmt NA NA investigative 5-ht 1e receptor HTR1E Successful target agonist NA TTD , DGIDB 2-(5-fluoro-1h-indol-3-yl)ethanamine NA NA investigative 5-ht 1e receptor HTR1E Successful target unknown NA TTD m-chlorophenylpiperazine NA NA investigative 5-ht 1e receptor HTR1E Successful target agonist NA TTD , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR1E NA inhibitor NA drugbank metergolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-ht 1f receptor HTR1F Successful target unknown NA TTD , DGIDB naratriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1f HTR1F NA agonist 4.39 drugbank , DGIDB alpha-methyl-5-ht NA NA investigative 5-ht 1f receptor HTR1F Successful target unknown NA TTD brl-15572 NA NA investigative 5-ht 1f receptor HTR1F Successful target agonist 0.24 TTD , DGIDB tfmpp NA NA investigative 5-ht 1f receptor HTR1F Successful target agonist NA TTD , DGIDB lasmiditan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1f HTR1F NA agonist 10.97 drugbank , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1F NA antagonist NA drugbank sumatriptan small molecule Cluster Headache[MeSHID:D003027],Nose[MeSHID:D009666],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1f HTR1F NA agonist 1.34 drugbank , DGIDB methysergide small molecule Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 1f HTR1F NA binder,antagonist 0.26 drugbank , DGIDB eletriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1f HTR1F NA agonist 1.46 drugbank , DGIDB 5-ct NA NA investigative 5-ht 1f receptor HTR1F Successful target agonist NA TTD , DGIDB 2-methyl-5-ht NA NA investigative 5-ht 1f receptor HTR1F Successful target agonist NA TTD , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1f HTR1F NA agonist 0.27 drugbank , DGIDB lasmiditan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1f receptor HTR1F Successful target unknown 10.97 TTD , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR1F NA inhibitor NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 1 HTR1F NA antagonist NA drugbank ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved 5-hydroxytryptamine receptor 1f HTR1F NA agonist 0.49 drugbank , DGIDB dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR1F NA antagonist NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR1F NA antagonist,agonist NA drugbank setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR1F NA antagonist NA drugbank [125i]lsd NA NA investigative 5-ht 1f receptor HTR1F Successful target unknown NA TTD dipropyl-5-ct NA NA investigative 5-ht 1f receptor HTR1F Successful target agonist NA TTD , DGIDB way-466 NA NA investigative 5-ht 1f receptor HTR1F Successful target unknown NA TTD 5-bodmt NA NA investigative 5-ht 1f receptor HTR1F Successful target agonist NA TTD , DGIDB lasmiditan NA Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 1f receptor HTR1F Successful target agonist 10.97 TTD , DGIDB rizatriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 1f HTR1F NA agonist 2.63 drugbank , DGIDB ly-334370 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 2 5-ht 1f receptor HTR1F Successful target unknown 2.19 TTD , DGIDB gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1F NA inhibitor NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR1F NA unknown NA drugbank olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1 HTR1F NA inhibitor,agonist 0.03 drugbank , DGIDB ly344864 NA NA investigative 5-ht 1f receptor HTR1F Successful target agonist NA TTD , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1f HTR1F NA binder NA drugbank zolmitriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 1f HTR1F NA agonist 4.02 drugbank , DGIDB dihydroergocornine small molecule NA approved serotonin receptors HTR1F NA antagonist,agonist NA drugbank tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR1F NA antagonist NA drugbank 1-naphthylpiperazine NA NA investigative 5-ht 1f receptor HTR1F Successful target antagonist NA TTD , DGIDB trazodone small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.34 drugbank , DGIDB cyamemazine NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist 0.11 TTD , DGIDB amisulpride small molecule Emotions[MeSHID:D004644],Disease[MeSHID:D004194],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Vomiting[MeSHID:D014839],Neoplasm Metastasis[MeSHID:D009362],Hostility[MeSHID:D006791],Mood Disorders[MeSHID:D019964],Affect (mental function)[MeSHID:D000339],Postoperative Nausea[MeSHID:D020250],Behavior[MeSHID:D001519],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Thinking, function[MeSHID:D013850],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank acp-106 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD clomipramine small molecule Premature Ejaculation[MeSHID:D061686],Premenstrual syndrome[MeSHID:D011293],Stuttering[MeSHID:D013342],Narcolepsy[MeSHID:D009290],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Trichotillomania[MeSHID:D014256],Obsessive-Compulsive Disorder[MeSHID:D009771],Pain[MeSHID:D010146],Mental Depression[MeSHID:D003863],Chronic pain[MeSHID:D059350],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autistic Disorder[MeSHID:D001321],Tension Headache[MeSHID:D018781],Neuralgia[MeSHID:D009437],Cataplexy[MeSHID:D002385],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Personality[MeSHID:D003193],Pain Disorder[MeSHID:D013001],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 3-dimethylaminomethyl-1-methyl-1h-indol-4-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 2 HTR2A NA antagonist NA drugbank n-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine small molecule NA experimental 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank n-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD iti-007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sleeplessness[MeSHID:D007319],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 3 5-ht 2a receptor HTR2A Successful target unknown 0.44 TTD , DGIDB cinanserin NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank ym-992 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] discontinued in phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 2 HTR2A NA antagonist NA drugbank 1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (r,s)-1-(6-fluoro-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.06 drugbank , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-hydroxytryptamine receptor 2a HTR2A NA agonist 0.15 drugbank , DGIDB serazapine hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.02 drugbank , DGIDB lysergic acid diethylamide NA Disease[MeSHID:D004194],Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market 5-ht 2a receptor HTR2A Successful target unknown NA TTD 2-(9,10-dihydroanthracen-9-yl)-n-methylethanamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.1 drugbank , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.31 drugbank , DGIDB mdl-11939 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-(2,5-dimethoxyphenyl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (2s)-1-(5-fluoro-1h-indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD [2-(4-fluoro-1h-indol-3-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.13 drugbank , DGIDB sb 221284 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB tryptamine NA NA phase 3 5-ht 2a receptor HTR2A Successful target agonist 0.07 TTD , DGIDB 2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pyrimidine derivative 28 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.11 drugbank , DGIDB ritanserin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigational 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist,antagonist 0.04 drugbank , DGIDB pyrazole derivative 75 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB ketanserin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigational 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist,antagonist 0.09 drugbank , DGIDB pyrazole derivative 72 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB serotonin small molecule NA investigational,nutraceutical 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank 6-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.44 drugbank , DGIDB 1-((s)-2-aminopropyl)-7-fluoro-1h-indazol-6-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist,agonist 0.11 drugbank , DGIDB altanserin NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR2A NA antagonist NA drugbank chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR2A NA inhibitor,antagonist 0.31 drugbank , DGIDB 1-((r)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sarpogrelate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist,antagonist 0.44 drugbank , DGIDB 11-hexanoyloxy-n-n-propylnoraporphine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD racemic doi NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD syn120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-(4-bromo-2,5-difluorophenyl)-2-aminopropane NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 5-ct NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB n-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD zicronapine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 5-ht 2a receptor HTR2A Successful target unknown 0.11 TTD , DGIDB pyrimidine derivative 27 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB eplivanserin small molecule NA investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.44 drugbank , DGIDB a-987306 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pmid26609882-compound-35 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 7-chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD amperozide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Alcoholic Intoxication, Chronic[MeSHID:D000437],Expiration, function[MeSHID:D045853] experimental 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank dsp-1200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] phase 1 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR2A NA antagonist NA drugbank fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.06 drugbank , DGIDB mescaline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD nuplazid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank min-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 5-ht 2a receptor HTR2A Successful target unknown 0.22 TTD , DGIDB racemic dotfm NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.02 drugbank , DGIDB zuclopenthixol small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Manic[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Behavior[MeSHID:D001519],Emergencies [Disease/Finding][MeSHID:D004630],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank l-piperazino-3-phenyl-indane derivative 1 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB fluanisone NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 5-methoxy-4,9-dihydro-3h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.21 drugbank , DGIDB 8-methoxy-2-(4-methyl-piperazin-1-yl)-quinoline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sl65.0472 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] discontinued in phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-(10-bromoanthracen-9-yl)-2-aminopropane NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD fce-22716 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD n-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.44 drugbank , DGIDB thioridazine small molecule Anxiety Disorders[MeSHID:D001008],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.2 drugbank , DGIDB (e)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD benzoyl-piperidine derivative 2 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank tiospirone NA NA discontinued in phase 3 5-ht 2a receptor HTR2A Successful target unknown NA TTD apd791 small molecule Arteries[MeSHID:D001158],Thrombosis[MeSHID:D013927] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank , DGIDB 3-(2-dimethylamino-ethyl)-1-methyl-1h-indol-4-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD hy10275 small molecule Sleeplessness[MeSHID:D007319] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank lurasidone small molecule Schizophrenia[MeSHID:D012559] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.15 drugbank , DGIDB propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.25 drugbank , DGIDB 4-methoxy-9-aminomethyl-9,10-dihydroanthracene NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1,2,3,4-tetrahydro-naphthalen-2-ylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD methysergide small molecule Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.21 drugbank , DGIDB dup-734 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-(2-dimethylamino-ethyl)-1h-indol-6-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD zotepine NA Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved 5-ht 2a receptor HTR2A Successful target unknown 0.06 TTD , DGIDB 9-(aminomethyl)-9,10-dihydroanthracene NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD m-chlorophenylpiperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB zotepine NA Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved 5-ht 2a receptor HTR2A Successful target antagonist 0.06 TTD , DGIDB blonanserin small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.65 drugbank , DGIDB ocaperidone NA Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] phase 2 5-ht 2a receptor HTR2A Successful target unknown 0.15 TTD , DGIDB 8-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD lumateperone tosylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved 5-ht 2a receptor HTR2A Successful target unknown NA TTD isoclozapine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-(2-dimethylamino-ethyl)-2-methyl-1h-indol-4-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.09 drugbank , DGIDB ykp-1358 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank , DGIDB tryptamine NA NA phase 3 5-ht 2a receptor HTR2A Successful target unknown 0.07 TTD , DGIDB 1,6-bis(4-phenylpiperazin-1-yl)hexane NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 5-methoxytryptamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR2A NA antagonist,agonist NA drugbank 3-naphthalen-1-yl-pyrrolidine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sb 228357 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB iloperidone NA Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 2a receptor HTR2A Successful target antagonist 0.15 TTD , DGIDB 2,5-dimethoxy-4-bromophenethylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD alpha-methyl-5-ht NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-ethyl-4-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD brolamfetamine NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist 0.15 TTD , DGIDB pimavanserin NA Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 2a receptor HTR2A Successful target unknown 1.74 TTD , DGIDB phenethylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.34 drugbank , DGIDB n-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 2,2-diphenyl-ethylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-(2-pyrrolidin-1-yl-ethyl)-1h-indol-4-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA inhibitor NA drugbank risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.1 drugbank , DGIDB dihydroergocornine small molecule NA approved serotonin receptors HTR2A NA antagonist,agonist NA drugbank pimavanserin NA Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 2a receptor HTR2A Successful target antagonist 1.74 TTD , DGIDB diarylamine and arylheteroarylamine pyrazole derivative 2 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 6,7-dichloro-2,3,4,5-tetrahydro-1h-3-benzazepine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n-(1-phenethylpiperidin-4-yl)-1-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pyrimidine derivative 29 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB iferanserin-ventrus NA Hemorrhoids[MeSHID:D006484],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD brexpiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.26 drugbank , DGIDB pmid26609882-compound-36 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB blonanserin NA Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 2a receptor HTR2A Successful target antagonist 0.65 TTD , DGIDB cisapride small molecule Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank 1,6-bis(4-m-tolylpiperazin-1-yl)hexane NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sr46349b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Sleep Disorders[MeSHID:D012893],Primary Insomnia[MeSHID:D007319] phase 3 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 2-piperazin-1-yl-phenol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD acepromazine small molecule Anxiety[MeSHID:D001007] experimental,vet_approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 5-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD egis-7625 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB temanogrel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 5-ht 2a receptor HTR2A Successful target unknown 0.87 TTD , DGIDB aniracetam NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 2a receptor HTR2A Successful target unknown 0.1 TTD , DGIDB 1192u90 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853],Psychotic Disorders[MeSHID:D011618],Schizophrenia[MeSHID:D012559] phase 1 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB dom NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine 2 receptor HTR2A NA binder,antagonist 0.07 drugbank , DGIDB ver-5593 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 2,5-dimethoxy-4-ethylthioamphetamine small molecule NA experimental 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank 5-methoxy-n,n-dimethyltryptamine small molecule NA experimental,illicit 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank 3-methoxy-9-aminomethyl-9,10-dihydroanthracene NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pyrimidine derivative 25 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB n-(1-benzylpiperidine-4-yl)-2-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 9-(2-aminoethyl)-9,10-dihydroanthracene NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-(2-dimethylamino-propyl)-1h-indol-4-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (2s)-1-(6-methoxy-1h-indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pyrimidine derivative 24 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.44 drugbank , DGIDB (r,s)-1-(5-bromo-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ykp-1358 NA Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 7-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD nelotanserin small molecule Sleep Disorders[MeSHID:D012893],Lewy Body Disease[MeSHID:D020961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown 0.87 drugbank , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.11 drugbank , DGIDB adatanserin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD flupentixol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Asthenia[MeSHID:D001247],Hyperactive behavior[MeSHID:D006948],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank lurasidone hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB bufotenine NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist 0.15 TTD , DGIDB 4-(10h-anthracen-9-ylidene)-1-methyl-piperidine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-(2-amino-propyl)-1h-indol-5-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (r,s)-1-(5-fluoro-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR2A NA antagonist NA drugbank 2-phenyl-3-(2-piperidin-1-yl-ethyl)-1h-indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown 0.15 drugbank , DGIDB iti-007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sleeplessness[MeSHID:D007319],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 3 5-ht 2a receptor HTR2A Successful target antagonist 0.44 TTD , DGIDB pyrazole derivative 67 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB blonanserin NA Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 2a receptor HTR2A Successful target unknown 0.65 TTD , DGIDB methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 8-methoxy-2-piperazin-1-yl-quinoline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n-1-isopropyltryptamine NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB (r)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n-methyl-3,3-diphenylpropan-1-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ketanserin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigational 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist 0.09 drugbank , DGIDB 1-((s)-2-aminopropyl)-7-chloro-1h-indazol-6-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD tryptoline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD [3h]n-methylspiperone NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.52 drugbank , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.11 drugbank , DGIDB n-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (2-indol-1-yl-ethyl)-dimethyl-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD bvt.28949 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.19 drugbank , DGIDB zolmitriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank [2-(6-methoxy-indol-1-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n-1-isopropyl-5-meot NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB pyrazole derivative 73 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank c-(9h-xanthen-9-yl)-methylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sb 215505 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA inhibitor 0.07 drugbank , DGIDB 3-dimethylaminomethyl-1h-indol-4-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 2-(4-bromo-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-butyl-4-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ly320954 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB pg-01037 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 11-propionyloxy-n-n-propylnoraporphine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (s)-1-(5,6-difluoro-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (2s)-1-(1h-furo[2,3-g]indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pyrazole derivative 71 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 5-chloro-n-(pyridin-3-yl)indoline-1-carboxamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-butyl-3-(2-dimethylamino-ethyl)-1h-indol-4-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank pmid30124346-compound-34table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 8-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank flibanserin small molecule Hypoactive Sexual Desire Disorder[MeSHID:D020018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.29 drugbank , DGIDB 2-(5-methoxy-1h-indol-3-yl)-1-methyl-ethylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sarpogrelate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist 0.44 drugbank , DGIDB metergolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB lp-12 NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB eplivanserin mesilate NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.07 drugbank , DGIDB butriptyline small molecule NA approved,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 2-methoxy-9-aminomethyl-9,10-dihydroanthracene NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD al-37350a NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB m100907 NA Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 2-phenyl-3-piperidin-4-yl-1h-indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-(1-benzyl-piperidin-4-yl)-2-phenyl-1h-indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 8-chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD fluspirilene small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.04 drugbank , DGIDB org 12962 NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB 5-chloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist 0.08 drugbank , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA binder NA drugbank (1-phenethyl-piperidin-4-yl)-phenyl-methanone NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.15 drugbank , DGIDB org-23366 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 1-(4-bromo-2,5-dimethoxy-phenyl)-piperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n-(1-phenethylpiperidin-4-yl)-2-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD nelotanserin small molecule Sleep Disorders[MeSHID:D012893],Lewy Body Disease[MeSHID:D020961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist 0.87 drugbank , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist 0.16 drugbank , DGIDB 1-((s)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ym-348 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n,n-dimethyl-2,2-diphenylethanamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-(1-methyl-piperidin-4-yl)-2-phenyl-1h-indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pyrimidine derivative 23 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.15 drugbank , DGIDB 3-(1-phenethyl-piperidin-4-yl)-2-phenyl-1h-indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD tfmpp NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB n-methyl-4,4-diphenylbutan-1-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD temanogrel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 5-ht 2a receptor HTR2A Successful target inverse agonist 0.87 TTD , DGIDB bl-1020 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank fenfluramine small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Obesity[MeSHID:D009765] approved,illicit,investigational,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank pruvanserin NA Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 2a receptor HTR2A Successful target antagonist 0.87 TTD , DGIDB 1-methoxy-9-aminomethyl-9,10-dihydroanthracene NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist 0.06 drugbank , DGIDB pyrazole derivative 74 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank epinastine small molecule Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank (r,s)-1-(5-methyl-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD deramciclane small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank n-3'-ethylaplysinopsin NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 4-bromo-2,5-dimethoxyphenethylamine small molecule NA experimental,illicit 5-hydroxytryptamine receptor 2a HTR2A NA partial agonist NA drugbank methylenedioxymethamphetamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown 0.26 TTD , DGIDB [11c]volinanserin NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB 3-amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pyrazole derivative 70 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 2-(2-amino-propyl)-5-bromo-4-methoxy-phenol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 6-chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (+/-)-nantenine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 7,8,9,10-tetrahydro-6h-furo-[3,2-g][3]benzazepine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pruvanserin NA Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 2a receptor HTR2A Successful target unknown 0.87 TTD , DGIDB (r)-(-)-11-hydroxy-n-n-propylnoraporphine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD brl-15572 NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist 0.05 TTD , DGIDB mmda small molecule NA experimental,illicit 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank 11-valeryloxynoraporphine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 4,4-diphenylbutan-1-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD dimethyltryptamine small molecule NA experimental,illicit 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank lumateperone small molecule Schizophrenia[MeSHID:D012559] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.44 drugbank , DGIDB pmid30124346-compound-13table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB molindone small molecule Disease Management[MeSHID:D019468],Mental disorders[MeSHID:D001523],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.17 drugbank , DGIDB rp5063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Bipolar Disorder[MeSHID:D001714],Attention deficit hyperactivity disorder[MeSHID:D001289],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank [18f]altanserin NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB cariprazine small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 4-benzyl-1-methyl-piperidine hydrochloride NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD deramciclane NA Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 5-ht 2a receptor HTR2A Successful target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine 2 receptor HTR2A NA binder,antagonist 0.07 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.07 drugbank , DGIDB 1-propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-((s)-2-aminopropyl)-7-iodo-1h-indazol-6-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD bw723c86 NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB lurasidone hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved 5-ht 2a receptor HTR2A Successful target antagonist 0.22 TTD , DGIDB 8-methoxy-4,9-dihydro-3h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 5-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sb 242084 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB ly215840 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB (2s)-1-(6-fluoro-1h-indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 2-(3-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD epicept np-1 small molecule Pain[MeSHID:D010146] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank sb 216641 NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB sb-271046 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD piperazine derivative 4 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB nelotanserin NA Sleep Disorders[MeSHID:D012893],Lewy Body Disease[MeSHID:D020961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 2a receptor HTR2A Successful target unknown 0.87 TTD , DGIDB quipazine NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist 0.11 TTD , DGIDB mmda NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD tegaserod small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 1-(3-(phenylthio)propyl)-4-m-tolylpiperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD cinitapride small molecule Ulcer[MeSHID:D014456],Gastrointestinal Diseases[MeSHID:D005767],Dyspepsia[MeSHID:D004415],cell motility[MeSHID:D002465],Gastroparesis[MeSHID:D018589],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank pyrimidine derivative 26 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB iloperidone NA Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 2a receptor HTR2A Successful target unknown 0.15 TTD , DGIDB diarylamine and arylheteroarylamine pyrazole derivative 1 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB fkw00ga NA Phobia, Social[MeSHID:D000072861],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank nelotanserin NA Sleep Disorders[MeSHID:D012893],Lewy Body Disease[MeSHID:D020961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 2a receptor HTR2A Successful target inverse agonist 0.87 TTD , DGIDB ati-9242 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 1-(2,5-dimethoxy-4-methyl-phenyl)-piperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ly063518 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR2A NA inhibitor 0.31 drugbank , DGIDB c-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank ly108742 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n,n-dimethyl-3,3-diphenylpropan-1-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 4-(4-fluoro-benzyl)-piperidine hydrochloride NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ver-2692 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 6-chloro-n-(pyridin-3-yl)indoline-1-carboxamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD perospirone small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] experimental 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist NA drugbank midomafetamine small molecule Anxiety Disorders[MeSHID:D001008],Malignant Neoplasms[MeSHID:D009369],Anxiety[MeSHID:D001007],Post-Traumatic Stress Disorder[MeSHID:D013313] experimental,illicit,investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist NA drugbank aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist,partial agonist,agonist 0.22 drugbank , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist,partial agonist 0.22 drugbank , DGIDB ver-3323 NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist 0.07 TTD , DGIDB nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit 5-hydroxytryptamine 2 receptor HTR2A NA modulator NA drugbank 2-(4-methyl-piperazin-1-yl)-4-phenyl-pyrimidine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD volinanserin small molecule NA investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.44 drugbank , DGIDB c-(5h-dibenzo[a,d]cyclohepten-5-yl)-methylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD remoxipride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank zotepine small molecule Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.06 drugbank , DGIDB 2-(2-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank (r)-3-(4-propylmorpholin-2-yl)phenol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD etisulergine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (r,s)-1-(5-chloro-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD psilocin NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD thiothixene small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.35 drugbank , DGIDB pimavanserin small molecule Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist 1.74 drugbank , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.07 drugbank , DGIDB phenylpiperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-phenyl pyrazole derivative 1 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD piperazine derivative 3 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB [125i]doi NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD flibanserin NA Hypoactive Sexual Desire Disorder[MeSHID:D020018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] approved 5-ht 2a receptor HTR2A Successful target unknown 0.29 TTD , DGIDB very low dose (vld) cyclobenzaprine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ly433222 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 9-oh-risperidone NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA agonist 0.15 drugbank , DGIDB [3h]spiperone NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 9-(2-aminopropyl)-9,10-dihydroanthracene NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD abaperidone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 5-ht 2a receptor HTR2A Successful target unknown 0.22 TTD , DGIDB c-(9h-thioxanthen-9-yl)-methylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD diarylamine and arylheteroarylamine pyrazole derivative 3 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB lp-44 NA NA investigative 5-ht 2a receptor HTR2A Successful target agonist NA TTD , DGIDB 1-(2-aminoethyl)-1h-indazol-6-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.28 drugbank , DGIDB barettin NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sarpogrelate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved 5-ht 2a receptor HTR2A Successful target unknown 0.44 TTD , DGIDB aryl piperazine derivative 1 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB sertindole small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.14 drugbank , DGIDB pmid26609882-compound-34 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 11-heptanoyloxy-n-n-propylnoraporphine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD tnx-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Post-Traumatic Stress Disorder[MeSHID:D013313],Fibromyalgia[MeSHID:D005356] phase 3 5-ht 2a receptor HTR2A Successful target unknown 0.52 TTD , DGIDB pyrazole derivative 69 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB aryl piperazine derivative 9 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB mesoridazine small molecule Alcoholic Intoxication, Chronic[MeSHID:D000437],Schizophrenia[MeSHID:D012559],Neurotic Disorders[MeSHID:D009497],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.33 drugbank , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 8-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD flibanserin NA Hypoactive Sexual Desire Disorder[MeSHID:D020018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] approved 5-ht 2a receptor HTR2A Successful target antagonist 0.29 TTD , DGIDB 1-((s)-2-aminopropyl)-7-methyl-1h-indazol-6-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 6-bromoaplysinopsin NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR2A NA unknown 0.16 drugbank , DGIDB 1-(2,5-dimethoxy-phenyl)-piperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD aniracetam small molecule Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental 5-hydroxytryptamine receptor 2a HTR2A NA unknown 0.1 drugbank , DGIDB 7,8,9,10-tetrahydro-6h-furo-[2,3-g][3]benzazepine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-naphthylpiperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD skl-10406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB ly314228 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB 5,6-dichloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist,antagonist 0.06 drugbank , DGIDB ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved 5-hydroxytryptamine receptor 2a HTR2A NA agonist 0.19 drugbank , DGIDB am-831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 5-ht 2a receptor HTR2A Successful target unknown NA TTD spiramide NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist 0.07 TTD , DGIDB pmid30124346-compound-ldt8 NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB amesergide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 2a receptor HTR2A Successful target antagonist 0.44 TTD , DGIDB sarpogrelate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved 5-ht 2a receptor HTR2A Successful target antagonist 0.44 TTD , DGIDB serotonin NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-(2-methoxy-phenyl)-4-propyl-piperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-(3-dimethylamino-propyl)-1h-indol-4-ol NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-methyl-1,3-dihydro-indol-2-one NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD esmirtazapine small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319] investigational 5-hydroxytryptamine receptor 2 HTR2A NA inverse agonist 0.29 drugbank , DGIDB mazapertine NA NA discontinued in phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR2A NA inhibitor NA drugbank pimavanserin small molecule Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA inverse agonist,antagonist 1.74 drugbank , DGIDB n-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2a HTR2A NA inducer NA drugbank aryl piperazine derivative 6 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 5-meo-dmt NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD benzoyl-piperidine derivative 1 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 2-(1h-indol-3-yl)-n,n-dimethylethanamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD n,n-dimethyl-4,4-diphenylbutan-1-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD mpdt NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (s)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD way-208466 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD (e)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sel-73 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ly86057 NA NA investigative 5-ht 2a receptor HTR2A Successful target antagonist NA TTD , DGIDB ritanserin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 5-ht 2a receptor HTR2A Successful target antagonist 0.04 TTD , DGIDB promazine small molecule Psychomotor Agitation[MeSHID:D011595],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 2a HTR2A NA antagonist 0.17 drugbank , DGIDB pyrazole derivative 68 NA NA patented 5-ht 2a receptor HTR2A Successful target unknown NA TTD , DGIDB 9-(n-benzylaminomethyl)-9,10-dihydroanthracene NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD chlorophenylpiperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD norfluoxetine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 3-naphthalen-1-yl-1-propyl-pyrrolidine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 1-naphthalen-2-yl-piperazine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD sergolexole maleate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 2 5-ht 2a receptor HTR2A Successful target unknown NA TTD dotarizine small molecule Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational 5-hydroxytryptamine receptor 2a HTR2A NA unknown NA drugbank pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2a HTR2A NA agonist,antagonist 0.17 drugbank , DGIDB (r)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD ver-5384 NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD pipotiazine small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational 5-hydroxytryptamine receptor 2a HTR2A NA antagonist NA drugbank 11-butyryloxy-n-n-propylnoraporphine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD 2-(4-bromo-2-methoxy-phenyl)-1-methyl-ethylamine NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD aplysinopsin NA NA investigative 5-ht 2a receptor HTR2A Successful target unknown NA TTD adrenoglomerulotropin NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD pyrimidine derivative 24 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB quinoline derivative 2 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB alpha-methyl-5-ht NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD spiramide NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist 0.16 TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA inverse agonist NA drugbank ads-103274 NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR2B NA antagonist NA drugbank m-chlorophenylpiperazine NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB ver-3323 NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist 0.16 TTD , DGIDB pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn 5-hydroxytryptamine receptor 2b HTR2B NA agonist 0.37 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine 2 receptor HTR2B NA binder NA drugbank 3-dimethylaminomethyl-1h-indol-4-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD [125i]doi NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB ver-2692 NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD pyrazole-3-carboxamide derivative 1 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR2B NA inhibitor 0.53 drugbank , DGIDB sb 204741 NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD ly86057 NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD brl-15572 NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist 0.1 TTD , DGIDB opc-28326 small molecule Peripheral Vascular Diseases[MeSHID:D016491],Raynaud Disease[MeSHID:D011928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2b HTR2B NA unknown NA drugbank ads-103253 NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD ym-348 NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD 7,8,9,10-tetrahydro-6h-furo-[2,3-g][3]benzazepine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA agonist,antagonist 0.13 drugbank , DGIDB zolmitriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA agonist NA drugbank setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR2B NA antagonist NA drugbank pyrimidine derivative 29 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB egis-7625 NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB [3h]rauwolscine NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB [2-(4-fluoro-1h-indol-3-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD 3-(2-amino-propyl)-1h-indol-5-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA agonist NA drugbank ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational 5-hydroxytryptamine receptor 2b HTR2B NA unknown NA drugbank lysergic acid diethylamide small molecule Disease[MeSHID:D004194],Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit,investigational,withdrawn 5-hydroxytryptamine receptor 2b HTR2B NA agonist NA drugbank 2-methyl-5-ht NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD ritanserin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 5-ht 2b receptor HTR2B Successful target antagonist 0.04 TTD , DGIDB cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist NA drugbank 2-(5-methoxy-1h-indol-3-yl)-1-methyl-ethylamine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD 1-((s)-2-aminopropyl)-7-fluoro-1h-indazol-6-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD fendiline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] withdrawn from market 5-ht 2b receptor HTR2B Successful target unknown NA TTD chlorophenylpiperazine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 0.14 drugbank , DGIDB triflupromazine NA Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Middle East Respiratory Syndrome[MeSHID:D018352] approved 5-ht 2b receptor HTR2B Successful target unknown 0.82 TTD , DGIDB nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit 5-hydroxytryptamine 2 receptor HTR2B NA modulator NA drugbank prx-08066 NA Chronic Obstructive Airway Disease[MeSHID:D029424],Pulmonary Hypertension[MeSHID:D006976],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 2b receptor HTR2B Successful target unknown 2.81 TTD , DGIDB sb 216641 NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR2B NA unknown NA drugbank 7,8,9,10-tetrahydro-6h-furo-[3,2-g][3]benzazepine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 0.16 drugbank , DGIDB triflupromazine NA Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 2b receptor HTR2B Successful target unknown 0.82 TTD , DGIDB methylergometrine small molecule Birth[MeSHID:D036801],Hemorrhage[MeSHID:D006470],Vagina[MeSHID:D014621] approved 5-hydroxytryptamine receptor 2b HTR2B NA unknown NA drugbank ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved 5-hydroxytryptamine receptor 2b HTR2B NA agonist 0.21 drugbank , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA binder,antagonist 0.06 drugbank , DGIDB cariprazine small molecule Manic[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA antagonist NA drugbank yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 0.2 drugbank , DGIDB a-987306 NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD racemic doi NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD (5-methoxy-1h-indol-3-yl)methanamine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD 5-meo-dmt NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD 1-((s)-2-aminopropyl)-7-chloro-1h-indazol-6-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD piribedil NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist 0.08 TTD , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR2B NA antagonist NA drugbank norfenfluramine NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB metergolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB ver-5384 NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD pyrimidine derivative 26 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB 1-((r)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD spn-812 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Solitary Pulmonary Nodule[MeSHID:D003074],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 4 5-ht 2b receptor HTR2B Successful target unknown NA TTD pyrimidine derivative 25 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 1.25 drugbank , DGIDB (+/-)-nantenine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD methylenedioxymethamphetamine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown 0.37 TTD , DGIDB 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD bw723c86 NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB pyrimidine derivative 27 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB fenfluramine small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Obesity[MeSHID:D009765] approved,illicit,investigational,withdrawn 5-hydroxytryptamine receptor 2b HTR2B NA agonist NA drugbank 3-(2-pyrrolidin-1-yl-ethyl)-1h-indol-4-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD dihydroergocryptine NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist 0.94 TTD , DGIDB sb 228357 NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB spiroxatrine NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist 0.09 TTD , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-hydroxytryptamine receptor 2b HTR2B NA agonist 0.37 drugbank , DGIDB lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 0.12 drugbank , DGIDB prx-08066 small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Pulmonary Hypertension[MeSHID:D006976],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 2.81 drugbank , DGIDB tfmpp NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB rq-00310941 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist NA drugbank al-37350a NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB methysergide small molecule Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist,agonist 0.11 drugbank , DGIDB 1-((s)-2-aminopropyl)-7-methyl-1h-indazol-6-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD pyrimidine derivative 23 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB [3h]lsd NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB serotonin NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD sb 221284 NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB 6-fluoromelatonin NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD minaprine NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 2b receptor HTR2B Successful target unknown 1.25 TTD , DGIDB 1-((s)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD esmirtazapine small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319] investigational 5-hydroxytryptamine receptor 2 HTR2B NA inverse agonist NA drugbank 3-(2-dimethylamino-ethyl)-1-methyl-1h-indol-4-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD 6,7-dichloro-2,3,4,5-tetrahydro-1h-3-benzazepine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD vabicaserin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 5-ht 2b receptor HTR2B Successful target unknown 0.47 TTD , DGIDB 1-(2-aminoethyl)-1h-indazol-6-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD 3-(2-dimethylamino-propyl)-1h-indol-4-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD sb 242084 NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 2 HTR2B NA antagonist NA drugbank 1-naphthylpiperazine NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB clomipramine small molecule Premature Ejaculation[MeSHID:D061686],Premenstrual syndrome[MeSHID:D011293],Stuttering[MeSHID:D013342],Narcolepsy[MeSHID:D009290],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Trichotillomania[MeSHID:D014256],Obsessive-Compulsive Disorder[MeSHID:D009771],Pain[MeSHID:D010146],Mental Depression[MeSHID:D003863],Chronic pain[MeSHID:D059350],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autistic Disorder[MeSHID:D001321],Tension Headache[MeSHID:D018781],Neuralgia[MeSHID:D009437],Cataplexy[MeSHID:D002385],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Personality[MeSHID:D003193],Pain Disorder[MeSHID:D013001],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist NA drugbank 3-(2-dimethylamino-ethyl)-1h-indol-6-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD [3h]mesulergine NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Middle East Respiratory Syndrome[MeSHID:D018352] approved,vet_approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 0.82 drugbank , DGIDB 3-(3-dimethylamino-propyl)-1h-indol-4-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist NA drugbank (-)-norfenfluramine NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB 1-butyl-3-(2-dimethylamino-ethyl)-1h-indol-4-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD norfluoxetine NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist 0.47 TTD , DGIDB dihydroergocornine small molecule NA approved serotonin receptors HTR2B NA antagonist,agonist NA drugbank tegaserod small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 1.25 drugbank , DGIDB [3h]5-ht NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD pyrimidine derivative 28 NA NA patented 5-ht 2b receptor HTR2B Successful target unknown NA TTD , DGIDB epicept np-1 small molecule Pain[MeSHID:D010146] investigational 5-hydroxytryptamine receptor 2b HTR2B NA unknown NA drugbank org 12962 NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine 2 receptor HTR2B NA binder NA drugbank gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR2B NA inhibitor NA drugbank pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist NA drugbank r-1 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR2B NA antagonist,agonist NA drugbank apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA agonist,antagonist 0.13 drugbank , DGIDB (2s)-1-(6-methoxy-1h-indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD 5-ct NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB triflupromazine small molecule Nausea[MeSHID:D009325],Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 2b HTR2B NA antagonist 0.82 drugbank , DGIDB mt-500 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 1 5-ht 2b receptor HTR2B Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2b HTR2B NA agonist NA drugbank midomafetamine small molecule Anxiety Disorders[MeSHID:D001008],Malignant Neoplasms[MeSHID:D009369],Anxiety[MeSHID:D001007],Post-Traumatic Stress Disorder[MeSHID:D013313] experimental,illicit,investigational 5-hydroxytryptamine receptor 2b HTR2B NA agonist NA drugbank sb 215505 NA NA investigative 5-ht 2b receptor HTR2B Successful target antagonist NA TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 2 HTR2B NA antagonist NA drugbank (+)-norfenfluramine NA NA investigative 5-ht 2b receptor HTR2B Successful target agonist NA TTD , DGIDB 3-dimethylaminomethyl-1-methyl-1h-indol-4-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD ver-5593 NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD pipamperone small molecule Aggressive behavior[MeSHID:D000374],Psychotic Disorders[MeSHID:D011618],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2b HTR2B NA unknown NA drugbank 1-((s)-2-aminopropyl)-7-iodo-1h-indazol-6-ol NA NA investigative 5-ht 2b receptor HTR2B Successful target unknown NA TTD pizotifen small molecule Disease Management[MeSHID:D019468],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank 6-chloro-n-(pyridin-3-yl)indoline-1-carboxamide NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 3-(2-dimethylamino-ethyl)-2-methyl-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD methysergide NA Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-ht 2c receptor HTR2C Successful target unknown 0.23 TTD , DGIDB tricyclic pyrrolidine derivative 3 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB pg-01037 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD bw723c86 NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB 5-ct NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.18 drugbank , DGIDB bvt 933 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD lorcaserin NA Obesity[MeSHID:D009765],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] approved 5-ht 2c receptor HTR2C Successful target agonist 1.11 TTD , DGIDB sb 216641 NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB sarpogrelate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.33 drugbank , DGIDB n-(pyridin-3-yl)indoline-1-carboxamide NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD ritanserin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 5-ht 2c receptor HTR2C Successful target antagonist 0.03 TTD , DGIDB mirtazapine NA Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-ht 2c receptor HTR2C Successful target unknown 0.35 TTD , DGIDB methysergide small molecule Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.23 drugbank , DGIDB fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank nuplazid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 2c receptor HTR2C Successful target unknown NA TTD 2-(5-methoxy-1h-indol-3-yl)-1-methyl-ethylamine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 1-((s)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 5-chloro-n-(pyridin-3-yl)indoline-1-carboxamide NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD apomorphine small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist,antagonist 0.09 drugbank , DGIDB cp-809101 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD tricyclic pyrrolidine derivative 4 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB heteroaryl-azepine derivative 10 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB 3-(2-dimethylamino-ethyl)-1h-indol-6-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD pyrimidine derivative 26 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB heteroaryl-azepine derivative 12 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB 1-((s)-2-aminopropyl)-7-iodo-1h-indazol-6-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD quinoline derivative 2 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB 1-((s)-2-aminopropyl)-7-methyl-1h-indazol-6-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.25 drugbank , DGIDB sb 243213 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB benzazepine derivative 2 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.17 drugbank , DGIDB [2-(4-fluoro-1h-indol-3-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD ver-2692 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD barettin NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 1-(piperazin-1-yl)isoquinoline NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 4-(piperazin-1-yl)-7h-pyrrolo[2,3-d]pyrimidine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD pyrimidine derivative 23 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB n-(6-phenoxypyridin-3-yl)-1h-indole-3-carboxamide NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD ly334362 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB promazine small molecule Psychomotor Agitation[MeSHID:D011595],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.18 drugbank , DGIDB mk-212 NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist 0.09 TTD , DGIDB tedatioxetine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Anxiety Disorders[MeSHID:D001008],Unipolar Depression[MeSHID:D003866] phase 1 5-ht 2c receptor HTR2C Successful target unknown 0.15 TTD , DGIDB imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist,binder NA drugbank heteroaryl-azepine derivative 13 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB agomelatine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.33 drugbank , DGIDB deramciclane NA Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 5-ht 2c receptor HTR2C Successful target unknown NA TTD al-37350a NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved 5-hydroxytryptamine receptor 2c HTR2C NA unknown 0.03 drugbank , DGIDB ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR2C NA antagonist,agonist NA drugbank ym-348 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD ver-3323 NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist 0.11 TTD , DGIDB (2s)-1-(6-fluoro-1h-indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 5,6-dichloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-hydroxytryptamine receptor 2c HTR2C NA agonist 0.22 drugbank , DGIDB eltoprazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Dyskinetic syndrome[MeSHID:D020820],Parkinson Disease[MeSHID:D010300],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 3 5-ht 2c receptor HTR2C Successful target unknown 0.22 TTD , DGIDB 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD (r,s)-1-(6-fluoro-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD cyclo[(6-bromotryptophan)arginine] NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.35 drugbank , DGIDB brl-15572 NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist 0.07 TTD , DGIDB aryl piperazine derivative 9 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB 6-bromoaplysinopsin NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.22 drugbank , DGIDB yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank dexfenfluramine small molecule Disease Management[MeSHID:D019468],Diet therapy[MeSHID:D004035],Maintenance[MeSHID:D008283],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn 5-hydroxytryptamine receptor 2c HTR2C NA agonist NA drugbank 2,5-dimethoxy-4-ethylthioamphetamine small molecule NA experimental 5-hydroxytryptamine receptor 2c HTR2C NA agonist NA drugbank tedatioxetine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Anxiety Disorders[MeSHID:D001008],Unipolar Depression[MeSHID:D003866] phase 1 5-ht 2c receptor HTR2C Successful target antagonist 0.15 TTD , DGIDB 3-(2-pyrrolidin-1-yl-ethyl)-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD trazodone small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist 0.33 drugbank , DGIDB paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank sb 228357 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB sertindole small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.17 drugbank , DGIDB heteroaryl-azepine derivative 14 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.18 drugbank , DGIDB pyrimidine derivative 28 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB lorcaserin NA Obesity[MeSHID:D009765],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] approved 5-ht 2c receptor HTR2C Successful target unknown 1.11 TTD , DGIDB tegaserod small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank (r,s)-1-(5-bromo-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 6-(piperazin-1-yl)-9-propyl-9h-purine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD propiomazine small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.33 drugbank , DGIDB tricyclic pyrrolidine derivative 1 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank epicept np-1 small molecule Pain[MeSHID:D010146] investigational 5-hydroxytryptamine receptor 2c HTR2C NA unknown NA drugbank mirtazapine NA Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-ht 2c receptor HTR2C Successful target antagonist 0.35 TTD , DGIDB aryl piperazine derivative 8 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB pimavanserin small molecule Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA inverse agonist NA drugbank sb-271046 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 6,7-dichloro-2,3,4,5-tetrahydro-1h-3-benzazepine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD (2s)-1-(1h-furo[2,3-g]indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD methotrimeprazine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank way-163909 NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist 0.66 TTD , DGIDB ver-5593 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank dihydroergocornine small molecule NA approved serotonin receptors HTR2C NA antagonist,agonist NA drugbank sb 215505 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB 3-(3-dimethylamino-propyl)-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist,partial agonist,agonist 0.12 drugbank , DGIDB norfluoxetine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 2c HTR2C NA ligand 0.13 drugbank , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA unknown 0.03 drugbank , DGIDB 1-((s)-2-aminopropyl)-7-fluoro-1h-indazol-6-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD spiramide NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist 0.11 TTD , DGIDB mpdt NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD ver-5384 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD cyamemazine NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist 0.17 TTD , DGIDB methylenedioxymethamphetamine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown 0.4 TTD , DGIDB tricyclic pyrrolidine derivative 2 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB heteroaryl-azepine derivative 2 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA binder NA drugbank (e)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA unknown NA drugbank ergotamine small molecule Cluster Headache[MeSHID:D003027],Vascular Headaches[MeSHID:D014653],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] approved 5-hydroxytryptamine receptor 2c HTR2C NA agonist 0.15 drugbank , DGIDB 1-(2-aminoethyl)-1h-indazol-6-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD (2s)-1-(6-methoxy-1h-indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD lorcaserin small molecule Obesity[MeSHID:D009765],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] approved 5-hydroxytryptamine receptor 2c HTR2C NA agonist 1.11 drugbank , DGIDB 3-(2-dimethylamino-ethyl)-1-methyl-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist 0.09 drugbank , DGIDB r-1065 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 5-ht 2c receptor HTR2C Successful target unknown NA TTD heteroaryl-azepine derivative 8 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB pmid26609882-compound-83 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB way-466 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD nefazodone NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved 5-ht 2c receptor HTR2C Successful target unknown 0.18 TTD , DGIDB cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank (r,s)-1-(5-fluoro-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD (r,s)-1-(5-methyl-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 5-meo-dmt NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist 0.13 TTD , DGIDB eplivanserin small molecule NA investigational 5-hydroxytryptamine receptor 2c HTR2C NA unknown NA drugbank 3-(2-dimethylamino-propyl)-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD serotonin NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD (r,s)-1-(5-chloro-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 5-chloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD benzazepine derivative 3 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB [3h]lsd NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR2C NA antagonist NA drugbank pyrimidine derivative 29 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB tfmpp NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB ocaperidone small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pancreatic carcinoma[MeSHID:C562463],Hamman-Rich syndrome[MeSHID:D011658],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diabetic Nephropathy[MeSHID:D003928] investigational 5-hydroxytryptamine receptor 2c HTR2C NA unknown NA drugbank chromene derivative 1 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB fenfluramine small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Obesity[MeSHID:D009765] approved,illicit,investigational,withdrawn 5-hydroxytryptamine receptor 2c HTR2C NA agonist NA drugbank heteroaryl-azepine derivative 11 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB aplysinopsin NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 1-(2-dimethylamino-ethyl)-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD org 12962 NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB sb 242084 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB methysergide NA Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-ht 2c receptor HTR2C Successful target antagonist 0.23 TTD , DGIDB benzazepine derivative 1 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB n-3'-ethylaplysinopsin NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 2 HTR2C NA antagonist NA drugbank 1-((r)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD dapoxetine small molecule Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2c HTR2C NA unknown NA drugbank dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2c HTR2C NA binder,antagonist 0.04 drugbank , DGIDB 4-(piperazin-1-yl)thieno[3,2-c]pyridine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.13 drugbank , DGIDB 3-dimethylaminomethyl-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD pmid26609882-compound-58 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB heteroaryl-azepine derivative 15 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB [125i]doi NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB heteroaryl-azepine derivative 4 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB 6-bromo-2'-de-n-methylaplysinopsin NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD benzazepine derivative 5 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.66 drugbank , DGIDB mcpp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 5-ht 2c receptor HTR2C Successful target unknown NA TTD midomafetamine small molecule Anxiety Disorders[MeSHID:D001008],Malignant Neoplasms[MeSHID:D009369],Anxiety[MeSHID:D001007],Post-Traumatic Stress Disorder[MeSHID:D013313] experimental,illicit,investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist NA drugbank 3-(2-amino-propyl)-1h-indol-5-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD octoclothepin NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD [3h]mesulergine NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR2C NA inhibitor,antagonist 0.47 drugbank , DGIDB benzazepine derivative 6 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB m100907 NA Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR2C NA inhibitor NA drugbank m-chlorophenylpiperazine small molecule NA investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist NA drugbank , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR2C NA antagonist NA drugbank 6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD (2s)-1-(5-fluoro-1h-indazol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD csc-500297 NA Central Serous Chorioretinopathy[MeSHID:D056833],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.14 drugbank , DGIDB 7,8,9,10-tetrahydro-6h-furo-[3,2-g][3]benzazepine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD (+/-)-nantenine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 1-butyl-3-(2-dimethylamino-ethyl)-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD way-208466 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 4-bromo-2,5-dimethoxyphenethylamine small molecule NA experimental,illicit 5-hydroxytryptamine receptor 2c HTR2C NA partial agonist NA drugbank esmirtazapine small molecule Sleep Disorders[MeSHID:D012893],Sleeplessness[MeSHID:D007319] investigational 5-hydroxytryptamine receptor 2 HTR2C NA inverse agonist NA drugbank 3-dimethylaminomethyl-1-methyl-1h-indol-4-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA binder NA drugbank doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.11 drugbank , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 2 HTR2C NA antagonist NA drugbank chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR2C NA inhibitor 0.47 drugbank , DGIDB (s)-1-(5,6-difluoro-1h-indol-1-yl)propan-2-amine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 4-(piperazin-1-yl)furo[3,2-c]pyridine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD aryl piperazine derivative 10 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB 4-(piperazin-1-yl)thieno[2,3-d]pyrimidine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD metergolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB 1-((s)-2-aminopropyl)-7-chloro-1h-indazol-6-ol NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD heteroaryl-azepine derivative 1 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB prx00933 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] phase 2 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB fr260010 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB flupentixol small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Asthenia[MeSHID:D001247],Hyperactive behavior[MeSHID:D006948],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007] approved,investigational,withdrawn 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank captodiame small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007] experimental 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank chlorophenylpiperazine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD heteroaryl-azepine derivative 7 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB heteroaryl-azepine derivative 9 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB lorcaserin small molecule Obesity[MeSHID:D009765],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] approved 5-hydroxytryptamine receptor 2c HTR2C NA unknown 1.11 drugbank , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR2C NA unknown NA drugbank puerarin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 2 5-ht 2c receptor HTR2C Successful target unknown 0.33 TTD , DGIDB lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank heteroaryl-azepine derivative 3 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB pyrimidine derivative 25 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB tramadol NA Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 2c receptor HTR2C Successful target unknown 0.18 TTD , DGIDB trazodone small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist,antagonist 0.33 drugbank , DGIDB fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved 5-hydroxytryptamine receptor 2c HTR2C NA unknown NA drugbank 4-(piperazin-1-yl)thieno[3,2-d]pyrimidine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD benzazepine derivative 4 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB 2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD alpha-methyl-5-ht NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.18 drugbank , DGIDB deramciclane small molecule Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 2c HTR2C NA inverse agonist NA drugbank lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist 0.12 drugbank , DGIDB fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank pergolide small molecule Disease Management[MeSHID:D019468],Secondary Parkinson Disease[MeSHID:D010302],Heart valve disease[MeSHID:D006349],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational,vet_approved,withdrawn 5-hydroxytryptamine receptor 2c HTR2C NA agonist 0.18 drugbank , DGIDB lofexidine small molecule Disease Management[MeSHID:D019468],Abdominal Pain[MeSHID:D015746],Opiate Addiction[MeSHID:D009293],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Diarrhea[MeSHID:D003967],Mydriasis[MeSHID:D015878],Piloerection[MeSHID:D010863],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA agonist NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2c HTR2C NA binder,antagonist 0.04 drugbank , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 2c HTR2C NA antagonist 0.26 drugbank , DGIDB cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank athx-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB fluphenazine small molecule Disease Management[MeSHID:D019468],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA unknown NA drugbank egis-7625 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB pyrimidine derivative 27 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine 2 receptor HTR2C NA binder,antagonist 0.04 drugbank , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank heteroaryl-azepine derivative 5 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist,downregulator NA drugbank tq-1017 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD 7,8,9,10-tetrahydro-6h-furo-[2,3-g][3]benzazepine NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR2C NA antagonist NA drugbank nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit 5-hydroxytryptamine 2 receptor HTR2C NA modulator NA drugbank sr46349b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Sleep Disorders[MeSHID:D012893],Primary Insomnia[MeSHID:D007319] phase 3 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB sb-247853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 5-ht 2c receptor HTR2C Successful target unknown NA TTD dotarizine small molecule Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational 5-hydroxytryptamine receptor 2c HTR2C NA unknown NA drugbank m-chlorophenylpiperazine NA NA investigative 5-ht 2c receptor HTR2C Successful target agonist NA TTD , DGIDB sb 204741 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB pyrimidine derivative 24 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB rs-102,221 NA NA investigative 5-ht 2c receptor HTR2C Successful target unknown NA TTD escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 2c HTR2C NA inhibitor 0.11 drugbank , DGIDB sb 221284 NA NA investigative 5-ht 2c receptor HTR2C Successful target antagonist NA TTD , DGIDB vabicaserin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 5-ht 2c receptor HTR2C Successful target unknown 0.33 TTD , DGIDB heteroaryl-azepine derivative 6 NA NA patented 5-ht 2c receptor HTR2C Successful target unknown NA TTD , DGIDB clomipramine small molecule Premature Ejaculation[MeSHID:D061686],Premenstrual syndrome[MeSHID:D011293],Stuttering[MeSHID:D013342],Narcolepsy[MeSHID:D009290],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Trichotillomania[MeSHID:D014256],Obsessive-Compulsive Disorder[MeSHID:D009771],Pain[MeSHID:D010146],Mental Depression[MeSHID:D003863],Chronic pain[MeSHID:D059350],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autistic Disorder[MeSHID:D001321],Tension Headache[MeSHID:D018781],Neuralgia[MeSHID:D009437],Cataplexy[MeSHID:D002385],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Personality[MeSHID:D003193],Pain Disorder[MeSHID:D013001],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 2c HTR2C NA antagonist NA drugbank etoperidone small molecule Tremor[MeSHID:D014202],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Erectile dysfunction[MeSHID:D007172] withdrawn 5-hydroxytryptamine receptor 2c HTR2C NA agonist NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine 2 receptor HTR2C NA binder,antagonist 0.04 drugbank , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 3a HTR3A NA antagonist NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved 5-hydroxytryptamine receptor 3a HTR3A NA potentiator NA drugbank ddp733 small molecule Disease[MeSHID:D004194],Gastrointestinal Diseases[MeSHID:D005767],Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Gastroesophageal reflux disease[MeSHID:D005764] investigational 5-hydroxytryptamine receptor 3a HTR3A NA unknown NA drugbank levetiracetam NA Epilepsies, Myoclonic[MeSHID:D004831],Epilepsy[MeSHID:D004827],Myoclonic Epilepsy, Juvenile[MeSHID:D020190],Idiopathic generalized epilepsy[MeSHID:C562694],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved 5-ht 3a receptor HTR3A Successful target unknown 0.21 TTD , DGIDB rocuronium small molecule Skeletal muscle structure[MeSHID:D018482],Operative Surgical Procedures[MeSHID:D013514],Relaxation[MeSHID:D012063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 0.48 drugbank , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD 10,11-dihydro-5h-dibenzo[b,f]azepine NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR3A NA antagonist NA drugbank 6-(4-methyl-piperazin-1-yl)-phenanthridine NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 1.08 drugbank , DGIDB tapentadol small molecule Acute onset pain[MeSHID:D059787],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Patient Discharge[MeSHID:D010351],Chronic pain[MeSHID:D059350] approved 5-hydroxytryptamine receptor 3a HTR3A NA unknown NA drugbank ondansetron small molecule Malignant Neoplasms[MeSHID:D009369],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Postoperative Nausea[MeSHID:D020250],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Subacute Bacterial Endocarditis[MeSHID:D004698],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 2.73 drugbank , DGIDB tropisetron small molecule Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 0.14 drugbank , DGIDB 5,6-dichloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD quipazine NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD cilansetron NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 3a receptor HTR3A Successful target unknown 3.62 TTD , DGIDB dolasetron NA Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Postoperative Nausea[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 3a receptor HTR3A Successful target unknown 2.35 TTD , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 0.06 drugbank , DGIDB serotonin small molecule NA investigational,nutraceutical 5-hydroxytryptamine receptor 3a HTR3A NA unknown NA drugbank vortioxetine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 0.32 drugbank , DGIDB metoclopramide small molecule Disease Management[MeSHID:D019468],Radiation[MeSHID:D011827],Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Gastroparesis[MeSHID:D018589],Nose[MeSHID:D009666],Pain[MeSHID:D010146],Hiccup[MeSHID:D006606],Recurrence (disease attribute)[MeSHID:D012008],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Stomach[MeSHID:D013270],Vomiting[MeSHID:D014839],Gastroesophageal reflux disease[MeSHID:D005764],Intestines, Small[MeSHID:D007421],Gastric Emptying[MeSHID:D005746],Bezoars[MeSHID:D001630],Electromagnetic Radiation[MeSHID:D060733],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist NA drugbank tmb-8 NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD granisetron small molecule Malignant Neoplasms[MeSHID:D009369],Radiation[MeSHID:D011827],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 1.45 drugbank , DGIDB 4-((naphthalen-2-yloxy)methyl)piperidine NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD ticalopride small molecule Gastroparesis[MeSHID:D018589],Gastroesophageal reflux disease[MeSHID:D005764] investigational 5-hydroxytryptamine receptor 3a HTR3A NA unknown NA drugbank bemesetron NA NA discontinued in phase 3 5-ht 3a receptor HTR3A Successful target unknown NA TTD norcisapride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] discontinued in phase 2 5-ht 3a receptor HTR3A Successful target unknown NA TTD tropisetron NA Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved 5-ht 3a receptor HTR3A Successful target unknown 0.14 TTD , DGIDB methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved 5-hydroxytryptamine receptor 3a HTR3A NA antagonist NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR3A NA antagonist,agonist NA drugbank aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA unknown NA drugbank bilobalide NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD trichloroethanol NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD 7-(piperidin-4-ylmethoxy)-2-naphthonitrile NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 3a HTR3A NA unknown NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine 3 receptor HTR3A NA antagonist NA drugbank (s)-zacopride NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD flupentixole NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD alosetron small molecule Irritable Bowel Syndrome[MeSHID:D043183],Diarrhea[MeSHID:D003967],Congenital Abnormality[MeSHID:D000013],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 20.25 drugbank , DGIDB gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3A NA inhibitor NA drugbank 1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD [3h](s)-zacopride NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD 2-(4-benzyl-piperazin-1-yl)-benzothiazole NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD palonosetron NA Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Postoperative Nausea[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 3a receptor HTR3A Successful target unknown 7.72 TTD , DGIDB cilansetron NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 3a receptor HTR3A Successful target antagonist 3.62 TTD , DGIDB dihydroergocornine small molecule NA approved serotonin receptors HTR3A NA antagonist,agonist NA drugbank cilansetron small molecule Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 3.62 drugbank , DGIDB cisapride small molecule Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational,withdrawn 5-hydroxytryptamine receptor 3a HTR3A NA agonist 1.45 drugbank , DGIDB cilansetron small molecule Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 3a HTR3A NA unknown 3.62 drugbank , DGIDB [3h]gr65630 NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD palonosetron small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Postoperative Nausea[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 7.72 drugbank , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR3A NA inhibitor NA drugbank renzapride small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 3a HTR3A NA unknown 0.87 drugbank , DGIDB 2-methyl-5-ht NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist NA drugbank dolasetron small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Postoperative Nausea[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 2.35 drugbank , DGIDB cp-810123 NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD ym-114 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] discontinued in phase 2 5-ht 3a receptor HTR3A Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved 5-hydroxytryptamine receptor 3a HTR3A NA potentiator NA drugbank 5-hydroxyindole NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD brl-24682 NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD bupropion small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Diet therapy[MeSHID:D004035],Weight Gain[MeSHID:D015430],Body Weight[MeSHID:D001835],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Seasonal Affective Disorder[MeSHID:D016574],Cessation of smoking[MeSHID:D016540],Mood (psychological function)[MeSHID:D000339],Obesity[MeSHID:D009765],Off-Label Use[MeSHID:D056687],Overweight[MeSHID:D050177],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved 5-hydroxytryptamine receptor 3a HTR3A NA negative modulator NA drugbank ddp-225 small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Diarrhea[MeSHID:D003967],Gastrointestinal Diseases[MeSHID:D005767],Irritable Bowel Syndrome[MeSHID:D043183],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vomiting[MeSHID:D014839] investigational 5-hydroxytryptamine receptor 3a HTR3A NA unknown NA drugbank , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 3a HTR3A NA binder NA drugbank 2-(1h-imidazol-4-ylmethyl)-4-phenyl-thiazole NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD 3alpha-(2'-indolecarbonyloxy)-nortropane NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD serotonin NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3A NA unknown NA drugbank (4-quinolin-2-ylpiperazin-1-yl)acetic acid NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist NA drugbank memantine small molecule Behavioral Symptoms[MeSHID:D001526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist NA drugbank procaine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 3a receptor HTR3A Successful target unknown 1.08 TTD , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 3a HTR3A NA inhibitor NA drugbank a-987306 NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD meta-chlorphenylbiguanide NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD mesulergine NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD 2-(4-methyl-piperazin-1-yl)-quinoline NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD tubocurarine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved 5-hydroxytryptamine receptor 3a HTR3A NA antagonist NA drugbank clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 0.08 drugbank , DGIDB tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR3A NA antagonist NA drugbank 5-chloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD palonosetron + fosnetupitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] approved 5-ht 3a receptor HTR3A Successful target unknown NA TTD [3h]ramosetron NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD 3alpha-(1'-methyl-2'-indolecarbonyloxy)-tropane NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR3A NA antagonist NA drugbank loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 3a HTR3A NA binder NA drugbank alosetron NA Irritable Bowel Syndrome[MeSHID:D043183],Diarrhea[MeSHID:D003967],Congenital Abnormality[MeSHID:D000013],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 3a receptor HTR3A Successful target unknown 20.25 TTD , DGIDB ph-709829 NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD ati-17000 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical 5-ht 3a receptor HTR3A Successful target unknown NA TTD , DGIDB dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved 5-hydroxytryptamine receptor 3a HTR3A NA unknown NA drugbank 1-phenylbiguanide NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD ramosetron small molecule Nausea[MeSHID:D009325],Irritable Bowel Syndrome[MeSHID:D043183],Diarrhea[MeSHID:D003967],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 3a HTR3A NA antagonist 2.89 drugbank , DGIDB [3h]granisetron NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD 4-benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane NA NA investigative 5-ht 3a receptor HTR3A Successful target unknown NA TTD quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 3a HTR3A NA ligand NA drugbank dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved 5-hydroxytryptamine receptor 3b HTR3B NA unknown NA drugbank trichloroethanol NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3B NA inhibitor NA drugbank serotonin small molecule NA investigational,nutraceutical 5-hydroxytryptamine receptor 3b HTR3B NA unknown NA drugbank setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR3B NA antagonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3B NA unknown 0.64 drugbank , DGIDB 1-phenylbiguanide NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD 2-methyl-5-ht NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD 2-(4-methyl-piperazin-1-yl)-quinoline NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD bemesetron NA NA discontinued in phase 3 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD quipazine NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD (s)-zacopride NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR3B NA antagonist,agonist NA drugbank 6-(4-methyl-piperazin-1-yl)-phenanthridine NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD 2-(1h-imidazol-4-ylmethyl)-4-phenyl-thiazole NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD serotonin NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD dihydroergocornine small molecule NA approved serotonin receptors HTR3B NA antagonist,agonist NA drugbank bilobalide NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR3B NA inhibitor NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR3B NA antagonist NA drugbank [3h]granisetron NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD 2-(4-benzyl-piperazin-1-yl)-benzothiazole NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD mesulergine NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD meta-chlorphenylbiguanide NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR3B NA antagonist NA drugbank brl-24682 NA NA investigative 5-ht 3b receptor HTR3B Discontinued target unknown NA TTD ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine 3 receptor HTR3B NA antagonist NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 3b HTR3B NA unknown NA drugbank gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3C NA inhibitor NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine 3 receptor HTR3C NA antagonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3C NA unknown NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR3C NA antagonist NA drugbank setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR3C NA antagonist NA drugbank tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR3C NA antagonist NA drugbank dihydroergocornine small molecule NA approved serotonin receptors HTR3C NA antagonist,agonist NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 3c HTR3C NA unknown NA drugbank chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR3C NA inhibitor NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR3C NA antagonist,agonist NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR3D NA antagonist,agonist NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 3d HTR3D NA unknown NA drugbank gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3D NA inhibitor NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine 3 receptor HTR3D NA antagonist NA drugbank tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR3D NA antagonist NA drugbank dihydroergocornine small molecule NA approved serotonin receptors HTR3D NA antagonist,agonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3D NA unknown NA drugbank setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR3D NA antagonist NA drugbank chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR3D NA inhibitor NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR3D NA antagonist NA drugbank chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR3E NA inhibitor NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3E NA unknown NA drugbank tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR3E NA antagonist NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR3E NA antagonist,agonist NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 3e HTR3E NA unknown NA drugbank dihydroergocornine small molecule NA approved serotonin receptors HTR3E NA antagonist,agonist NA drugbank gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR3E NA inhibitor NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine 3 receptor HTR3E NA antagonist NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR3E NA antagonist NA drugbank setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR3E NA antagonist NA drugbank gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR4 NA inhibitor NA drugbank td-8954 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] phase 2 5-ht 4 receptor HTR4 Successful target unknown 4.11 TTD , DGIDB barettin NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD sb-207266a NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB tegaserod NA Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764] approved 5-ht 4 receptor HTR4 Successful target unknown 5.48 TTD , DGIDB piboserod small molecule Irritable Bowel Syndrome[MeSHID:D043183],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 4 HTR4 NA unknown 4.11 drugbank , DGIDB rs 116 0086 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD mddr 287569 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD m-0004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] phase 1 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB [123i]sb 207710 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD renzapride NA Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 4 receptor HTR4 Successful target agonist 1.23 TTD , DGIDB e-3620 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cell motility[MeSHID:D002465],Stomach Diseases[MeSHID:D013272] discontinued in phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD rs 100235 NA NA investigative 5-ht 4 receptor HTR4 Successful target antagonist NA TTD , DGIDB ml 10375 NA NA investigative 5-ht 4 receptor HTR4 Successful target antagonist NA TTD , DGIDB (r)-zacopride NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR4 NA antagonist NA drugbank dsp-6952 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB bimu-1 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB fabesetron NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD rs67506 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD rs 67333 NA NA investigative 5-ht 4 receptor HTR4 Successful target agonist NA TTD , DGIDB tegaserod small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764] approved,investigational,withdrawn 5-hydroxytryptamine receptor 4 HTR4 NA antagonist,partial agonist 5.48 drugbank , DGIDB sc-54750 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD serotonin NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD sdz-205-557 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD naronapride NA Gastroparesis[MeSHID:D018589],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 5-ht 4 receptor HTR4 Successful target agonist 2.05 TTD , DGIDB metoclopramide small molecule Disease Management[MeSHID:D019468],Radiation[MeSHID:D011827],Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Gastroparesis[MeSHID:D018589],Nose[MeSHID:D009666],Pain[MeSHID:D010146],Hiccup[MeSHID:D006606],Recurrence (disease attribute)[MeSHID:D012008],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Stomach[MeSHID:D013270],Vomiting[MeSHID:D014839],Gastroesophageal reflux disease[MeSHID:D005764],Intestines, Small[MeSHID:D007421],Gastric Emptying[MeSHID:D005746],Bezoars[MeSHID:D001630],Electromagnetic Radiation[MeSHID:D060733],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 4 HTR4 NA agonist NA drugbank r0-93877 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Constipation[MeSHID:D003248] approved 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD rq-00000010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cell motility[MeSHID:D002465],Stomach Diseases[MeSHID:D013272] investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD gr 125487 NA NA investigative 5-ht 4 receptor HTR4 Successful target antagonist NA TTD , DGIDB pf-885706 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB td-2749 small molecule Disease[MeSHID:D004194],Gastrointestinal Diseases[MeSHID:D005767],Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Gastroparesis[MeSHID:D018589],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 4 HTR4 NA unknown NA drugbank 1-((s)-2-aminopropyl)-1h-indazol-6-ol NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD mosapride NA NA phase 4 5-ht 4 receptor HTR4 Successful target unknown 2.05 TTD , DGIDB sc-52491 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD suvn-1004028 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD ro 116 1148 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD suvn-d4010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 4 receptor HTR4 Successful target unknown 2.05 TTD , DGIDB tegaserod small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764] approved,investigational,withdrawn 5-hydroxytryptamine receptor 4 HTR4 NA antagonist,partial agonist,agonist 5.48 drugbank , DGIDB prucalopride small molecule Esthesia[MeSHID:D012677],Feces[MeSHID:D005243],Defecation[MeSHID:D003672],Diagnosis[MeSHID:D003933],Functional Gastrointestinal Disorders[MeSHID:D005767],Constipation[MeSHID:D003248],Muscle strain[MeSHID:D013180] approved 5-hydroxytryptamine receptor 4 HTR4 NA agonist 3.08 drugbank , DGIDB pf-04995274 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 4 receptor HTR4 Successful target agonist 4.11 TTD , DGIDB cisapride small molecule Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational,withdrawn 5-hydroxytryptamine receptor 4 HTR4 NA agonist 6.16 drugbank , DGIDB sb-207710 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown 4.11 TTD , DGIDB tegaserod NA Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764] approved 5-ht 4 receptor HTR4 Successful target agonist 5.48 TTD , DGIDB htf 919 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB prx-3140 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Post-Traumatic Stress Disorder[MeSHID:D013313] phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB velusetrag small molecule NA investigational 5-hydroxytryptamine receptor 4 HTR4 NA agonist 3.08 drugbank , DGIDB renzapride NA Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 4 receptor HTR4 Successful target unknown 1.23 TTD , DGIDB cisapride NA Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved 5-ht 4 receptor HTR4 Successful target agonist 6.16 TTD , DGIDB sb 204070 NA NA investigative 5-ht 4 receptor HTR4 Successful target antagonist NA TTD , DGIDB spd-557 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Symphysis Pubis Dysfunction[MeSHID:D059388],Gastroparesis[MeSHID:D018589] phase 2 5-ht 4 receptor HTR4 Successful target unknown 4.11 TTD , DGIDB ykp-gi NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR4 NA unknown NA drugbank er-21018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD ml-10302 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR4 NA antagonist NA drugbank alpha-methyl-5-ht NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD cinitapride small molecule Ulcer[MeSHID:D014456],Gastrointestinal Diseases[MeSHID:D005767],Dyspepsia[MeSHID:D004415],cell motility[MeSHID:D002465],Gastroparesis[MeSHID:D018589],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 4 HTR4 NA agonist NA drugbank td-8954 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] phase 2 5-ht 4 receptor HTR4 Successful target agonist 4.11 TTD , DGIDB norcisapride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] discontinued in phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD ondansetron small molecule Malignant Neoplasms[MeSHID:D009369],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Postoperative Nausea[MeSHID:D020250],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Subacute Bacterial Endocarditis[MeSHID:D004698],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 4 HTR4 NA agonist NA drugbank gr-113808 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD ticalopride small molecule Gastroparesis[MeSHID:D018589],Gastroesophageal reflux disease[MeSHID:D005764] investigational 5-hydroxytryptamine receptor 4 HTR4 NA unknown NA drugbank td-2749 NA Disease[MeSHID:D004194],Gastrointestinal Diseases[MeSHID:D005767],Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Gastroparesis[MeSHID:D018589],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 5-ht 4 receptor HTR4 Successful target unknown NA TTD ser-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 1 5-ht 4 receptor HTR4 Successful target unknown NA TTD , DGIDB dihydroergocornine small molecule NA approved serotonin receptors HTR4 NA antagonist,agonist NA drugbank td-5108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroparesis[MeSHID:D018589] phase 2 5-ht 4 receptor HTR4 Successful target unknown 3.08 TTD , DGIDB chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR4 NA inhibitor NA drugbank rs 57639 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR4 NA antagonist NA drugbank [11c]sb207145 NA NA investigative 5-ht 4 receptor HTR4 Successful target antagonist NA TTD , DGIDB af-3473 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD vrx-03011 NA NA investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD renzapride small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 4 HTR4 NA agonist 1.23 drugbank , DGIDB cisapride NA Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved 5-ht 4 receptor HTR4 Successful target unknown 6.16 TTD , DGIDB piboserod NA Irritable Bowel Syndrome[MeSHID:D043183],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 4 receptor HTR4 Successful target unknown 4.11 TTD , DGIDB mosapride NA NA phase 4 5-ht 4 receptor HTR4 Successful target agonist 2.05 TTD , DGIDB lintopride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] phase 2 5-ht 4 receptor HTR4 Successful target unknown 1.03 TTD , DGIDB dihydroergotamine small molecule Disease Management[MeSHID:D019468],Basilar-Type Migraine[MeSHID:D020325],Episodic Cluster Headache[MeSHID:D003027],Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 4 HTR4 NA agonist NA drugbank naronapride small molecule Gastroparesis[MeSHID:D018589],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 4 HTR4 NA agonist 2.05 drugbank , DGIDB r-116712 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative 5-ht 4 receptor HTR4 Successful target unknown NA TTD piboserod small molecule Irritable Bowel Syndrome[MeSHID:D043183],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 4 HTR4 NA antagonist 4.11 drugbank , DGIDB da-6886 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 4 receptor HTR4 Successful target unknown 2.05 TTD , DGIDB piboserod NA Irritable Bowel Syndrome[MeSHID:D043183],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 4 receptor HTR4 Successful target antagonist 4.11 TTD , DGIDB sl65.0155 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 2 5-ht 4 receptor HTR4 Successful target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR4 NA antagonist,agonist NA drugbank pf-04995274 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 4 receptor HTR4 Successful target unknown 4.11 TTD , DGIDB renzapride small molecule Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 4 HTR4 NA unknown 1.23 drugbank , DGIDB 4-methyl-n-propyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD 5-chloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD 8-chloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD (+/-)-nantenine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD sb-699551-a NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD edmt NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD lysergic acid NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 5a HTR5A NA antagonist 0.68 drugbank , DGIDB [3h]5-ct NA NA investigative 5-ht 5a receptor HTR5A Successful target agonist NA TTD , DGIDB 3,4-dihydroquinazolin-2-amine hydrobromide NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD tfmpp NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD [125i]lsd NA NA investigative 5-ht 5a receptor HTR5A Successful target agonist NA TTD , DGIDB aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 5a HTR5A NA ligand NA drugbank sb 699551 NA NA investigative 5-ht 5a receptor HTR5A Successful target antagonist NA TTD , DGIDB 5,6-dichloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD 4-propyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD n,n-dimethyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD bufotenine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD n-butyl-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD metergolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-ht 5a receptor HTR5A Successful target unknown NA TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 5a HTR5A NA binder NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 5a HTR5A NA antagonist NA drugbank mpdt NA NA investigative 5-ht 5a receptor HTR5A Successful target antagonist NA TTD , DGIDB methiothepin NA NA investigative 5-ht 5a receptor HTR5A Successful target antagonist 0.22 TTD , DGIDB serotonin NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD n,4-dimethyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD 5-ct NA NA investigative 5-ht 5a receptor HTR5A Successful target agonist NA TTD , DGIDB 4-ethyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 5a receptor HTR5A Successful target unknown NA TTD [3h]5-ct NA NA investigative 5-ht 5b receptor HTR5B Literature-reported target unknown NA TTD [125i]lsd NA NA investigative 5-ht 5b receptor HTR5B Literature-reported target unknown NA TTD bufotenine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR6 NA antagonist NA drugbank dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR6 NA antagonist NA drugbank 1-benzenesulfonyl-3-piperidin-4-yl-1h-indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD syn-114 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD alpha-methyl-5-ht NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD serotonin NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD way-208466 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target agonist 1.48 TTD , DGIDB avn 101 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 6 HTR6 NA antagonist NA drugbank 2-(1-(phenylsulfonyl)-1h-indol-3-yl)ethanamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD [3h]5-ct NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target agonist NA TTD , DGIDB 2-(1h-indol-3-yl)-n,n-dimethylethanamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD suvn-502 small molecule nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 6 HTR6 NA unknown 4.44 drugbank , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 6 HTR6 NA antagonist NA drugbank tfmpp NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target agonist NA TTD , DGIDB e6801 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target agonist NA TTD , DGIDB 1-naphthylpiperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(6-methoxy-1h-indol-1-ylsulfonyl)benzenamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD pf-05212377 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 6 receptor HTR6 Clinical trial target antagonist 2.96 TTD , DGIDB 1-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR6 NA antagonist,agonist NA drugbank (+/-)-nantenine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD brl-15572 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target agonist 0.16 TTD , DGIDB 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1h-indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 5,6-dichloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD ly 165,163 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD e-6837 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sb-214111 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(3-methyl-indole-1-sulfonyl)-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 6 HTR6 NA antagonist 0.2 drugbank , DGIDB 5-(4-methylpiperazin-1-yl)-3-tosyl-1h-indazole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD n-(3-aminophenyl)benzenesulfonamide NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sb399885 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target antagonist NA TTD , DGIDB 4-(2-benzenesulfonylphenyl)piperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR6 NA inhibitor NA drugbank [3h]spiperone NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(indan-1-ylsulfanyl)-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD dimebolin NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sertindole small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn 5-hydroxytryptamine receptor 6 HTR6 NA antagonist 0.31 drugbank , DGIDB methiothepin NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target antagonist 0.07 TTD , DGIDB 4-(4-benzenesulfonamidophenyl)piperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 6 HTR6 NA unknown NA drugbank dm-1451 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD dihydroergocornine small molecule NA approved serotonin receptors HTR6 NA antagonist,agonist NA drugbank 4-(piperazin-1-yl)-3-tosyl-1h-indazole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 2-(3-benzenesulfonyl)phenyl-1-aminoethane NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD avn 322 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB n-(3-(2-aminoethyl)phenyl)benzenesulfonamide NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD n-(3-(aminomethyl)phenyl)benzenesulfonamide NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD avn 211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2/3 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB sam-531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 6 receptor HTR6 Clinical trial target unknown 4.44 TTD , DGIDB 4-inden-(1e)-ylidenemethyl-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD fluperlapine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target antagonist 0.74 TTD , DGIDB 4-(4-benzenesulfonylphenyl)piperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(1h-indol-1-ylsulfonyl)benzenamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(3-benzenesulfonylphenyl)piperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(4,6-dinitro-1h-indol-1-ylsulfonyl)benzenamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 2-benzyl-4-piperazin-1-yl-1h-benzimidazole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR6 NA unknown NA drugbank m-chlorophenylpiperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(1h-inden-1-ylmethyl)-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 5-methoxytryptamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-indan-1-ylmethyl-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 11c-gsk-215083 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] phase 1 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 6 HTR6 NA binder,antagonist 0.1 drugbank , DGIDB pmid30124346-compound-13table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB amr-six-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD avn-322 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB [2-(3h-indol-1-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 2-(3-phenylthio)phenyl)-1-aminoethane NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(4-methoxy-1h-indol-1-ylsulfonyl)benzenamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sb 258585 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 6 HTR6 NA binder NA drugbank 3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1h-indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sb-742457 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 6 receptor HTR6 Clinical trial target antagonist 8.88 TTD , DGIDB 2-(3-(phenylsulfonyl)-1h-indol-1-yl)ethanamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD way-181187 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 1 5-ht 6 receptor HTR6 Clinical trial target agonist 1.48 TTD , DGIDB suvn-501 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 1-benzenesulfonyl-3-piperidin-3-yl-1h-indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD alpha-ergocryptine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved 5-hydroxytryptamine receptor 6 HTR6 NA unknown NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 6 HTR6 NA antagonist 0.22 drugbank , DGIDB [2-(3-benzyl-3h-indol-1-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 6 HTR6 NA unknown NA drugbank 4-(indane-1-sulfonyl)-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 6 HTR6 NA antagonist 0.04 drugbank , DGIDB 6-(piperazin-1-yl)-3-tosyl-1h-indazole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD n-(4-(2-aminoethyl)phenyl)benzenesulfonamide NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD pf-05212377 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 6 receptor HTR6 Clinical trial target unknown 2.96 TTD , DGIDB 2-methyl-5-ht NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD abt-354 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 6 HTR6 NA antagonist 0.3 drugbank , DGIDB n,n-diethyl-2-(1h-indol-3-yl)ethanamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD opc 4392 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD prx-07034 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational 5-hydroxytryptamine receptor 6 HTR6 NA unknown NA drugbank , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 6 HTR6 NA binder,antagonist 0.09 drugbank , DGIDB suvn-502 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 6 receptor HTR6 Clinical trial target unknown 4.44 TTD , DGIDB [2-(3-benzyl-indol-1-yl)-ethyl]-dimethyl-amine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sb-271046 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD [2-(3-benzyl-3h-inden-1-yl)-ethyl]-methyl-amine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD avn 397 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(naphthalene-1-sulfonyl)-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sb-357134 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sb-742457 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 5-ht 6 receptor HTR6 Clinical trial target unknown 8.88 TTD , DGIDB olanzapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Abnormal behavior[MeSHID:D000066553],Depressive disorder[MeSHID:D003866],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychomotor Agitation[MeSHID:D011595],Affect (mental function)[MeSHID:D000339],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 6 HTR6 NA antagonist 0.09 drugbank , DGIDB zotepine small molecule Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,investigational,withdrawn 5-hydroxytryptamine receptor 6 HTR6 NA antagonist 0.1 drugbank , DGIDB dimethyltryptamine small molecule NA experimental,illicit 5-hydroxytryptamine receptor 6 HTR6 NA agonist NA drugbank , DGIDB 4-(3h-inden-1-ylmethyl)-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD syn120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(piperazin-1-yl)-1h-indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD prx-07034 NA Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB way-466 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 3-(phenylsulfonyl)-1-(piperidin-4-yl)-1h-indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sgs518 small molecule Schizophrenia[MeSHID:D012559],nervous system disorder[MeSHID:D009422],Schizoaffective Disorder[MeSHID:D011618] investigational 5-hydroxytryptamine receptor 6 HTR6 NA unknown NA drugbank n-(3-(3-aminopropyl)phenyl)benzenesulfonamide NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD [3h]lsd NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target agonist NA TTD , DGIDB lergotrile NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD quipazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 6 HTR6 NA binder,antagonist 0.16 drugbank , DGIDB 5-ct NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target agonist NA TTD , DGIDB octoclothepin NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 6 HTR6 NA antagonist 0.3 drugbank , DGIDB ro-04-6790 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-(3-benzenesulfonamidophenyl)piperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 2-bromo-lsd NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 6 HTR6 NA antagonist NA drugbank mpdt NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target antagonist NA TTD , DGIDB lysergic acid diethylamide small molecule Disease[MeSHID:D004194],Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] illicit,investigational,withdrawn 5-hydroxytryptamine receptor 6 HTR6 NA unknown NA drugbank emd-386088 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target agonist NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine receptor 6 HTR6 NA binder,antagonist 0.1 drugbank , DGIDB suvn-504 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vomiting[MeSHID:D014839] investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD suvn-507 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 1-phenylthio-n,n-dimethyltryptamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD syn-120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 5-ht 6 receptor HTR6 Clinical trial target unknown 2.96 TTD , DGIDB 1-(3-(benzyloxy)-2-methylphenyl)piperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 6 HTR6 NA antagonist NA drugbank 2-ethyl-5-methoxy-3-piperidin-4-yl-1h-indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD n-phenyl-3-(2-aminoethyl)benzenesulfonamide NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 2-(1-benzyl-1h-indol-3-yl)-n,n-dimethylethanamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD lu ae58054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB [125i]sb-258585 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR6 NA inhibitor NA drugbank 4-(1h-indol-3-ylmethyl)-phenylamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 4-((1h-indol-1-yl)methyl)benzenamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 2-(4-(benzenesulfonyl)phenyl)-1-aminoethane NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD pmid30124346-compound-34table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB edmt NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD sel-73 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 2-(1-benzyl-1h-inden-3-yl)-n,n-dimethylethanamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD chlorophenylpiperazine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 6 HTR6 NA binder NA drugbank bvt-74316 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD , DGIDB 3-(phenylsulfonyl)-1-(piperidin-3-yl)-1h-indole NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 2-(1-tosyl-1h-indol-3-yl)ethanamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD [3h]ro 63-0563 NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target antagonist NA TTD , DGIDB setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR6 NA antagonist NA drugbank n,n-dimethyl-2-(1-tosyl-1h-indol-3-yl)ethanamine NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD 5-meo-dmt NA NA investigative 5-ht 6 receptor HTR6 Clinical trial target unknown NA TTD setiptiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental serotonin receptors HTR7 NA antagonist NA drugbank 2-[1-(2-chloro-phenyl)-1h-pyrrol-2-yl]-ethylamine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD lisuride small molecule Disease Management[MeSHID:D019468],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fibrosis[MeSHID:D005355] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA unknown NA drugbank 2-(biphenyl-2-yloxy)-n,n-dimethylethanamine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD paliperidone small molecule Schizophrenia[MeSHID:D012559],Mood (psychological function)[MeSHID:D000339],Patient Discharge[MeSHID:D010351],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 7 HTR7 NA unknown NA drugbank way-466 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 4-oxadiazole derivative 1 NA NA patented 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.17 drugbank , DGIDB cyproheptadine small molecule Disease Management[MeSHID:D019468],Vascular Headaches[MeSHID:D014653],Pruritus[MeSHID:D011537],Serotonin Syndrome[MeSHID:D020230],Desire for food[MeSHID:D001066],anaphylaxis[MeSHID:D000707],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Off-Label Use[MeSHID:D056687],Malignant Carcinoid Syndrome[MeSHID:D008303],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.29 drugbank , DGIDB methysergide small molecule Vascular Headaches[MeSHID:D014653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.31 drugbank , DGIDB dm-1451 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD sb-258719 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD amisulpride small molecule Emotions[MeSHID:D004644],Disease[MeSHID:D004194],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Vomiting[MeSHID:D014839],Neoplasm Metastasis[MeSHID:D009362],Hostility[MeSHID:D006791],Mood Disorders[MeSHID:D019964],Affect (mental function)[MeSHID:D000339],Postoperative Nausea[MeSHID:D020250],Behavior[MeSHID:D001519],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Thinking, function[MeSHID:D013850],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank ziprasidone small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.38 drugbank , DGIDB edmt NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD falcarindiol NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 5-chloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD way-208466 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 2-(2-bromophenoxy)-n,n-dimethylethanamine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 2-(biphenyl-2-ylthio)-n,n-dimethylethanamine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.04 drugbank , DGIDB cabergoline small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Parkinsonian Disorders[MeSHID:D020734],Prolactinoma[MeSHID:D015175],Syndrome[MeSHID:D013577],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperprolactinemia[MeSHID:D006966] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank ati-9242 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD , DGIDB lurasidone small molecule Schizophrenia[MeSHID:D012559] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.66 drugbank , DGIDB cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR7 NA unknown NA drugbank tiapride small molecule Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigational serotonin receptors HTR7 NA antagonist NA drugbank epinastine small molecule Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank ergoloid mesylate small molecule Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Cognition Disorders[MeSHID:D003072],Neoplasm Metastasis[MeSHID:D009362],Delirium[MeSHID:D003693],Respiratory Diaphragm[MeSHID:D003964],Mood (psychological function)[MeSHID:D000339],Mental Suffering[MeSHID:D013315],Conditioning (Psychology)[MeSHID:D003213],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin receptors HTR7 NA antagonist,agonist NA drugbank lp-12 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB 2-bromo-lsd NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target antagonist NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine receptor 7 HTR7 NA binder 0.13 drugbank , DGIDB p-hydroxyphenethyl trans-ferulate NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD n-methyl-pip-f-homof-vinyl sulfonyl phenyl (n-methyl-pip-f-hf-vs phi) NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD pirenperone NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target antagonist 0.33 TTD , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 7 HTR7 NA binder NA drugbank clozapine small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.11 drugbank , DGIDB quetiapine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Bipolar Disorder[MeSHID:D001714],Psychotic Disorders[MeSHID:D011618],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Post-Traumatic Stress Disorder[MeSHID:D013313],Parkinson Disease[MeSHID:D010300],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved 5-hydroxytryptamine receptor 7 HTR7 NA ligand NA drugbank jnj-18038683 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 5-ht 7 receptor HTR7 Clinical trial target antagonist 2.65 TTD , DGIDB dihydroergocryptine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD tfmpp NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved 5-hydroxytryptamine receptor 7 HTR7 NA binder,antagonist 0.13 drugbank , DGIDB e55888 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB aripiprazole lauroxil small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA unknown NA drugbank mesulergine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target antagonist 0.27 TTD , DGIDB [3h]5-ht NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB (r)-8-phenyl-n,n-dipropylchroman-3-amine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 7 HTR7 NA binder,antagonist 0.13 drugbank , DGIDB (+/-)-nantenine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD dihydroergocornine small molecule NA approved serotonin receptors HTR7 NA antagonist,agonist NA drugbank lp-44 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank 2-(2'-methyl-biphenyl-3-yl)-ethylamine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD lp-211 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD as-19 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB lofexidine small molecule Disease Management[MeSHID:D019468],Abdominal Pain[MeSHID:D015746],Opiate Addiction[MeSHID:D009293],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Diarrhea[MeSHID:D003967],Mydriasis[MeSHID:D015878],Piloerection[MeSHID:D010863],Substance Withdrawal Syndrome[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA agonist NA drugbank dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved 5-hydroxytryptamine receptor 7 HTR7 NA binder NA drugbank zotepine small molecule Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,investigational,withdrawn 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.09 drugbank , DGIDB vortioxetine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.44 drugbank , DGIDB sb-258741 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD rp5063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Bipolar Disorder[MeSHID:D001714],Attention deficit hyperactivity disorder[MeSHID:D001289],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 2 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD , DGIDB 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD m-chlorophenylpiperazine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD disulergine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD gilteritinib small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853],Disease Progression[MeSHID:D018450],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotonin receptors HTR7 NA inhibitor NA drugbank [3h]spiperone NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 1-(2-methoxy-phenyl)-piperazine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist,partial agonist NA drugbank dr-4004 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target antagonist NA TTD , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank methiothepin NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target antagonist 0.06 TTD , DGIDB [3h]5-ct NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB jnj-18038683 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 5-ht 7 receptor HTR7 Clinical trial target unknown 2.65 TTD , DGIDB cyamemazine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target antagonist 0.33 TTD , DGIDB zolmitriptan small molecule Aura[MeSHID:D004827],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA agonist NA drugbank risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.04 drugbank , DGIDB [125i]lsd NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD sb 269970-a NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD dihydroergocristine small molecule Blood Vessel[MeSHID:D001808],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,experimental serotonin receptors HTR7 NA antagonist NA drugbank sb-269970 small molecule Sleep Disorders[MeSHID:D012893],Cessation of life[MeSHID:D003643],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Expiration, function[MeSHID:D045853] investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 1.99 drugbank , DGIDB 5-ct NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.04 drugbank , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved 5-hydroxytryptamine receptor 7 HTR7 NA binder 0.13 drugbank , DGIDB pmid30124346-compound-34table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD , DGIDB iloperidone small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.27 drugbank , DGIDB [3h]lsd NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB mpdt NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target antagonist NA TTD , DGIDB 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD (2-biphenyl-3-yl-ethyl)-dimethyl-amine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 5,6-dichloro-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD dipropyl-5-ct NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB sel-73 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD imperatorin NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 2-(2-bromophenylthio)-n,n-dimethylethanamine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD serotonin NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD fluperlapine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target antagonist 0.66 TTD , DGIDB pmid30124346-compound-13table4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] patented 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD , DGIDB asenapine small molecule Manic Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist 0.2 drugbank , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank carbamide derivative 2 NA NA patented 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD , DGIDB sb-656104 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD bufotenine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD bromocriptine small molecule Infertility[MeSHID:D007246],Neuroleptic Malignant Syndrome[MeSHID:D009459],Testicular hypogonadism[MeSHID:D005058],Operative Surgical Procedures[MeSHID:D013514],Menstruation Disturbances[MeSHID:D008599],Galactorrhea not associated with childbirth[MeSHID:C537072],Hyperprolactinemia[MeSHID:D006966],Prolactinoma[MeSHID:D015175],Acromegaly[MeSHID:D000172],Off-Label Use[MeSHID:D056687],Galactorrhea[MeSHID:D005687],Syndrome[MeSHID:D013577],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational 5-hydroxytryptamine receptor 7 HTR7 NA antagonist NA drugbank opc 4392 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD ucm-5600 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD chlorprothixene small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational,withdrawn serotonin receptors HTR7 NA inhibitor NA drugbank 2-(1-o-tolyl-1h-pyrrol-3-yl)ethanamine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD avn-101 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD elaidoylamide NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD 1-naphthylpiperazine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target agonist NA TTD , DGIDB 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD n,n-dimethyl-2-(2'-methylbiphenyl-3-yl)ethanamine NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD sb-271046 NA NA investigative 5-ht 7 receptor HTR7 Clinical trial target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational huntingtin HTT NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational islet amyloid polypeptide IAPP NA unknown NA drugbank isoleucine small molecule Dyskinetic syndrome[MeSHID:D020820] investigational,nutraceutical isoleucine--trna ligase, cytoplasmic IARS NA unknown NA drugbank isoleucine small molecule Dyskinetic syndrome[MeSHID:D020820] investigational,nutraceutical isoleucine--trna ligase, mitochondrial IARS2 NA unknown NA drugbank isis 11665 NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD aic100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid carcinoma[MeSHID:D013964] phase 1 intercellular adhesion molecule icam-1 ICAM1 Successful target unknown NA TTD nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Pancreatitis[MeSHID:D010195] investigational intercellular adhesion molecule 1 ICAM1 NA inhibitor NA drugbank pipernonaline NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD a-286982 NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD isis 3224 NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD dehydropipernonaline NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD isis 11159 NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD alicaforsen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424],Inflammation[MeSHID:D007249] phase 3 icam1 messenger rna ICAM1 Successful target unknown 25.46 TTD , DGIDB isis 1570 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved icam1 messenger rna ICAM1 Successful target unknown NA TTD bi-505 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 intercellular adhesion molecule icam-1 ICAM1 Successful target unknown 19.1 TTD , DGIDB lifitegrast NA Dry Eye Syndromes[MeSHID:D015352],Keratoconjunctivitis Sicca[MeSHID:D007638],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Desiccation[MeSHID:D003890],Disorder of eye[MeSHID:D005128],Allergic Conjunctivitis[MeSHID:D003233],Disease[MeSHID:D004194] approved intercellular adhesion molecule icam-1 ICAM1 Successful target unknown 8.49 TTD , DGIDB isis-1939 NA NA investigative intercellular adhesion molecule icam-1 ICAM1 Successful target unknown NA TTD isis 2974 NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Disease[MeSHID:D004194] investigational intercellular adhesion molecule 1 ICAM1 NA inhibitor NA drugbank apc-8015f NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 intercellular adhesion molecule icam-1 ICAM1 Successful target unknown NA TTD , DGIDB natalizumab biotech Multiple Sclerosis[MeSHID:D009103] approved,investigational intercellular adhesion molecule 1 ICAM1 NA unknown NA drugbank isis 11158 NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD alicaforsen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424],Inflammation[MeSHID:D007249] phase 3 intercellular adhesion molecule icam-1 ICAM1 Successful target unknown 25.46 TTD , DGIDB piperrolein b NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD isis 3067 NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved intercellular adhesion molecule 1 ICAM1 NA inhibitor,binder NA drugbank pellitorin NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD bi-505 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 intercellular adhesion molecule icam-1 ICAM1 Successful target antagonist 19.1 TTD , DGIDB isis 1931 NA NA investigative icam1 messenger rna ICAM1 Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase ick ICK NA inhibitor NA drugbank xmab23104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 inducible t-cell costimulator ICOS Clinical trial target unknown NA TTD ky1044 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 inducible t-cell costimulator ICOS Clinical trial target unknown NA TTD jtx-2011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 inducible t-cell costimulator ICOS Clinical trial target unknown 31.83 TTD , DGIDB medi-570 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 inducible t-cell costimulator ICOS Clinical trial target unknown 31.83 TTD , DGIDB amg 557 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 b7-related protein 1 ICOSLG Clinical trial target unknown NA TTD , DGIDB amg 570 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 b7-related protein 1 ICOSLG Clinical trial target unknown NA TTD nte-2 NA NA investigative insulin-degrading enzyme IDE Successful target inhibitor NA TTD , DGIDB bacitracin small molecule Secondary Infections[MeSHID:D060085],Dermatologic disorders[MeSHID:D012871],Streptococcal pneumonia[MeSHID:D011018],Skin Diseases, Infectious[MeSHID:D012874],Empyema[MeSHID:D004653],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved insulin-degrading enzyme IDE Successful target inhibitor 12.73 TTD , drugbank , DGIDB gnf-pf-4478 NA NA investigative insulin-degrading enzyme IDE Successful target unknown NA TTD quinoline 2 NA NA investigative insulin-degrading enzyme IDE Successful target inhibitor NA TTD , DGIDB nte-1 NA NA investigative insulin-degrading enzyme IDE Successful target inhibitor NA TTD , DGIDB pro-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinitis Pigmentosa[MeSHID:D012174] phase 2 insulin-degrading enzyme IDE Successful target unknown NA TTD , DGIDB ivosidenib NA Mutation[MeSHID:D009154],Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cholangiocarcinoma[MeSHID:D018281],Hematologic Neoplasms[MeSHID:D019337] approved oxalosuccinate decarboxylase IDH1 Successful target unknown 1.98 TTD , DGIDB ivosidenib small molecule Mutation[MeSHID:D009154],Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cholangiocarcinoma[MeSHID:D018281],Hematologic Neoplasms[MeSHID:D019337] approved,investigational isocitrate dehydrogenase [nadp] cytoplasmic IDH1 NA inhibitor 1.98 drugbank , DGIDB ly3410738 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 oxalosuccinate decarboxylase IDH1 Successful target unknown NA TTD isocitric acid small molecule NA experimental isocitrate dehydrogenase [nadp] cytoplasmic IDH1 NA unknown NA drugbank ivosidenib NA Mutation[MeSHID:D009154],Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cholangiocarcinoma[MeSHID:D018281],Hematologic Neoplasms[MeSHID:D019337] approved oxalosuccinate decarboxylase IDH1 Successful target inhibitor 1.98 TTD , DGIDB bay1436032 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 mutated oxalosuccinate decarboxylase IDH1 Clinical trial target unknown NA TTD , DGIDB idh305 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 oxalosuccinate decarboxylase IDH1 Successful target unknown NA TTD , DGIDB nicotinamide adenine dinucleotide phosphate small molecule NA experimental isocitrate dehydrogenase [nadp] cytoplasmic IDH1 NA unknown NA drugbank isocitric acid small molecule NA experimental isocitrate dehydrogenase [nadp], mitochondrial IDH2 NA unknown NA drugbank enasidenib small molecule Mutation[MeSHID:D009154],Relapse[MeSHID:D012008],Leukemia, Myelocytic, Acute[MeSHID:D015470] approved,investigational isocitrate dehydrogenase [nadp], mitochondrial IDH2 NA inhibitor 47.74 drugbank , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical isocitrate dehydrogenase [nad] subunit alpha, mitochondrial IDH3A NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational isocitrate dehydrogenase [nad] subunit alpha, mitochondrial IDH3A NA unknown NA drugbank xanthinol small molecule Metabolism[MeSHID:D008660],Brain[MeSHID:D001921],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Hyperlipidemia[MeSHID:D006949],Peripheral Vascular Diseases[MeSHID:D016491],Memory[MeSHID:D008568],Blood[MeSHID:D001769],Awareness[MeSHID:D001364] approved,withdrawn isocitrate dehydrogenase [nad] subunit alpha, mitochondrial IDH3A NA cofactor NA drugbank manganese small molecule Plasma[MeSHID:D010949],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved,nutraceutical isocitrate dehydrogenase [nad] subunit alpha, mitochondrial IDH3A NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical isocitrate dehydrogenase [nad] subunit beta, mitochondrial IDH3B NA unknown NA drugbank manganese small molecule Plasma[MeSHID:D010949],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved,nutraceutical isocitrate dehydrogenase [nad] subunit gamma, mitochondrial IDH3G NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical isocitrate dehydrogenase [nad] subunit gamma, mitochondrial IDH3G NA unknown NA drugbank dimethylallyl diphosphate small molecule NA experimental isopentenyl-diphosphate delta-isomerase 1 IDI1 NA unknown NA drugbank pmid29473428-compound-14 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pyridine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB imidazoleisoindoles derivative 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-6 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 6 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid27172114-compound-30 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-(benzylamino)-1-naphthol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2,3-diamino-benzo[b]thiophene derivative 8 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pf-06840003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] phase 1 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown 9.09 TTD , DGIDB seco-exiguamine NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2,3-dihydrobenzo[d]thiazole-2-thiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 4-(propylamino)naphthalen-1-ol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD imidazoleisoindoles derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 3-(1h-imidazol-4-yl)benzenethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-17 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-(isopropylamino)-1-naphthol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD s-benzyl-brassinin NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD hydroxy amidine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB biphenyl derivative 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-34 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-47 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 5-phenyl-1h-1,2,3-triazole NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 1-methyl-l-tryptophan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical indoleamine 2,3-dioxygenase 1 IDO1 Successful target inhibitor NA TTD , DGIDB s-(4-ethylbenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD monoaryl-1,2-diamine derivative 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-(tert-butylamino)naphthalen-1-ol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-15 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-29 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 1,2-naphthoquinone NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD acyl piperidine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB aryl sulphoxide imine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB bms-986205 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],melanoma[MeSHID:D008545],Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292] phase 3 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown 9.09 TTD , DGIDB 2-hydroxygarveatin e NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 5-aminoquinolin-8-ol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD nlg802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-amino-1,2,5-oxadiazole-3-carboximidamide NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD sulfamic acid ester derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 3-(4h-imidazol-4-yl)benzenethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-72 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-(methylamino)naphthalen-1-ol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2,3-diamino-benzo[b]thiophene derivative 7 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 5 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 1h-indole-4,7-dione NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD imidazo isoindole derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB nitric oxide small molecule Hypoxia[MeSHID:D000860],Respiratory Failure[MeSHID:D012131],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved indoleamine 2,3-dioxygenase 1 IDO1 NA unknown NA drugbank 4-fluorobenzenemethanethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid24099220c5i NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD s-(2-chlorobenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-70 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB sulfonamide derivative 7 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB indazole derivative 3 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB sulfonamide derivative 8 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-39 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-11 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB exiguamine b NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational indoleamine 2,3-dioxygenase 1 IDO1 NA inhibitor NA drugbank benzimidazole and imadazopyridine carboximidamide compound 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB s-(3-chlorobenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-76 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB garveatin e NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD imidazo[1,5-a]pyridine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB l-tryptophan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown 0.57 TTD , DGIDB 1,4-naphthoquinone NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD rg70099 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2-(1h-imidazol-4-yl)benzene-1,3-diol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD incb24360 NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],Cancer of Head and Neck[MeSHID:D006258],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Recurrence (disease attribute)[MeSHID:D012008],Merkel cell carcinoma[MeSHID:D015266],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] phase 3 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB annulin a NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD amg-1 NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target inhibitor NA TTD , DGIDB pmid29473428-compound-16 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB epl-1410 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2-methoxy-1,4-naphthoquinone NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD annulin b NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2,3-diamino-benzo[b]thiophene derivative 3 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-71 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB cyclic hydroxamate derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-41 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB biphenyl 1,2-diamine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 2,2-dimethyl-2h-benzo[g]chromene-5,10-dione NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-33 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB five-membered heteroaromatic compound 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB garveatin c NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD monofluorine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB annulin c NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD aryl 1,2-diamine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-phenylthiazole-2-thiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pf-06840003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] phase 1 indoleamine 2,3-dioxygenase 1 IDO1 Successful target inhibitor 9.09 TTD , DGIDB naphthalene-1,4-diol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 4-chlorobenzenemethanethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pyrrolo[1,2-c]pyrazole derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB monoaryl-1,2-diamine derivative 4 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-(2-(diethylamino)ethylamino)-1-naphthol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 4-methoxynaphthalen-1-amine NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-59 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 4 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 2,4-dichlorobenzenemethanethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-54 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-(1h-1,2,3-triazol-5-yl)pyridine NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-4 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB five-membered heteroaromatic compound 3 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-21 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB dn1406131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD five-membered heteroaromatic compound 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB medical cannabis biotech NA experimental,investigational indoleamine 2,3-dioxygenase 1 IDO1 NA inhibitor NA drugbank nitric oxide small molecule Hypoxia[MeSHID:D000860],Respiratory Failure[MeSHID:D012131],Term Birth[MeSHID:D047929],Tinea Pedis[MeSHID:D014008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved indoleamine 2,3-dioxygenase 1 IDO1 NA unknown NA drugbank pmid29473428-compound-48 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB nlg8189 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of brain[MeSHID:D001932] phase 2/3 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB blv-0801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD s-(4-methoxybenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD amide derivative 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB avastin+/-tarceva NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 3 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 3,4-dichlorobenzenemethanethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD hti-1090 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD sulfamoylamide derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-(cyclohexylamino)-1-naphthol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD hexahydro quinoline derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB exiguamine a NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD s-(4-cyanobenzyl)isothiourea hydrobromide NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD biphenyl derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB s-(4-fluorobenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2,3-diamino-benzo[b]thiophene derivative 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-22 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB s-(4-chlorobenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2-(1h-imidazol-4-yl)phenol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD mk-7162 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 2-chlorobenzenemethanethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD s-(4-methylbenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD sulfonamide derivative 6 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB carbamide derivative 13 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB hydoxyamidine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB n-[2-(indol-3-yl)ethyl]-s-benzyl-dithiocarbamate NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD benzimidazole and imadazopyridine carboximidamide compound 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB ly3381916 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 2-hydroxygarvin a NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD hydroxy amidine derivative 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pyridino tricyclic compound 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-50 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-(ethylamino)naphthalen-1-ol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid29473428-compound-10 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB monoaryl-1,2-diamine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-53 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB azetidine derivative 5 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB khk2455 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB indazole derivative 4 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB benzenemethanethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 4-methoxybenzenemethanethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 5-(isopropylamino)quinolin-8-ol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD garveatin a NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 4-aminonaphthalen-1-ol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD indazole derivative 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-methylbenzenemethanethiol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD s-(4-nitrobenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD s-(3,4-dichlorobenzyl)isothiourea hydrochloride NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD thieno[2,3-c]pyridine derivative 1 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 4-phenylimidazole NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown 9.09 TTD , DGIDB pmid29473428-compound-43 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-60 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-58 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB tryptanthrin NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target inhibitor 0.91 TTD , DGIDB imidazo[1,5-a]pyridine derivative 2 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational indoleamine 2,3-dioxygenase 1 IDO1 NA inhibitor NA drugbank 4-(pent-3-ylamino)-1-naphthol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD monoaryl-1,2-diamine derivative 3 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB 2,3-dichloro-1,4-naphthoquinone NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD s-(2,4-dichlorobenzyl)isothiourea hydrobromide NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD 4-(2-hydroxyethoxy)-1-naphthol NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD biphenyl derivative 3 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-52 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB pmid29473428-compound-80 NA NA patented indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD , DGIDB s-(4-bromobenzyl)isothiourea hydrobromide NA NA investigative indoleamine 2,3-dioxygenase 1 IDO1 Successful target unknown NA TTD pmid27172114-compound-30 NA NA patented indoleamine 2,3-dioxygenase 2 IDO2 Patented-recorded target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 7 NA NA patented indoleamine 2,3-dioxygenase 2 IDO2 Patented-recorded target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 2 NA NA patented indoleamine 2,3-dioxygenase 2 IDO2 Patented-recorded target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 4 NA NA patented indoleamine 2,3-dioxygenase 2 IDO2 Patented-recorded target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 6 NA NA patented indoleamine 2,3-dioxygenase 2 IDO2 Patented-recorded target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 1 NA NA patented indoleamine 2,3-dioxygenase 2 IDO2 Patented-recorded target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 5 NA NA patented indoleamine 2,3-dioxygenase 2 IDO2 Patented-recorded target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 8 NA NA patented indoleamine 2,3-dioxygenase 2 IDO2 Patented-recorded target unknown NA TTD , DGIDB rgx-121 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] phase 1/2 iduronate 2-sulfatase IDS Successful target unknown NA TTD idursulfase NA Mucopolysaccharidosis II[MeSHID:D016532],Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved iduronate 2-sulfatase IDS Successful target unknown 31.83 TTD , DGIDB sb-913 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] phase 1/2 iduronate 2-sulfatase IDS Successful target unknown NA TTD recombinant human iduronate-2-sulfatase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidosis II[MeSHID:D016532] phase 3 iduronate 2-sulfatase IDS Successful target unknown NA TTD , DGIDB rgx-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] phase 1 alpha-l-iduronidase IDUA Clinical trial target unknown NA TTD sb-318 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] phase 1/2 alpha-l-iduronidase IDUA Clinical trial target unknown NA TTD hap-ifn NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative interferon-alpha 2 IFNA2 Successful target unknown NA TTD novaferon NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB hebergel NA Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB interferon alpha 2a NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB albinterferon alfa-2b NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB subalin NA NA investigative interferon-alpha 2 IFNA2 Successful target unknown NA TTD interferon alpha-2b NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB cigb-128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Basal cell carcinoma[MeSHID:D002280] phase 1 interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB interferon alfa-2b NA Hairy Cell Leukemia[MeSHID:D007943],melanoma[MeSHID:D008545],AIDS with Kaposi's sarcoma[MeSHID:C554498],Cutaneous Melanoma[MeSHID:C562393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB sifalimumab biotech Renal Cell Carcinoma[MeSHID:D002292],Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational interferon alpha-2 IFNA2 NA unknown NA drugbank p-1101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Thrombocythemia, Essential[MeSHID:D013920] phase 3 interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB sch-721015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mesothelioma[MeSHID:D008654] phase 1 interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB instiladrin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] phase 2 interferon-alpha 2 IFNA2 Successful target unknown 63.65 TTD , DGIDB peginterferon alfa-2b NA Genotype[MeSHID:D005838],NOONAN SYNDROME 3[MeSHID:C537847],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB peginterferon alfa-2a NA Hepatitis B[MeSHID:D006509],Liver diseases[MeSHID:D008107],Virus Replication[MeSHID:D014779],Hepatitis[MeSHID:D006505],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hairy Cell Leukemia[MeSHID:D007943] approved interferon-alpha 2 IFNA2 Successful target unknown NA TTD , DGIDB nahe-001 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 interferon-alpha 5 IFNA5 Clinical trial target unknown NA TTD , DGIDB interferon alpha 5 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 interferon-alpha 5 IFNA5 Clinical trial target unknown NA TTD , DGIDB interferon alfa-2b biotech Hairy Cell Leukemia[MeSHID:D007943],melanoma[MeSHID:D008545],AIDS with Kaposi's sarcoma[MeSHID:C554498],Cutaneous Melanoma[MeSHID:C562393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon alpha/beta receptor 1 IFNAR1 NA binder,agonist 13.26 drugbank , DGIDB human interferon omega-1 biotech Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506] investigational interferon alpha/beta receptor 1 IFNAR1 NA unknown NA drugbank interferon beta-1a biotech Condylomata Acuminata[MeSHID:D003218],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Multiple Sclerosis[MeSHID:D009103],Disease[MeSHID:D004194] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist 2.65 drugbank , DGIDB ropeginterferon alfa-2b biotech Polycythemia Vera[MeSHID:D011087],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon alpha/beta receptor (ifnar) IFNAR1 NA binder NA drugbank ceplene/peg-intron/rebetol NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative interferon alpha/beta receptor 1 IFNAR1 Clinical trial target unknown NA TTD interferon beta-1b biotech Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved interferon alpha/beta receptor 1 IFNAR1 NA agonist 2.65 drugbank , DGIDB interferon beta-1b biotech Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved interferon alpha/beta receptor 1 IFNAR1 NA agonist NA drugbank , DGIDB omega interferon NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 interferon alpha/beta receptor 1 IFNAR1 Clinical trial target unknown NA TTD r-ifn-1a NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interferon alpha/beta receptor 1 IFNAR1 Clinical trial target unknown NA TTD , DGIDB peginterferon alfa-2a biotech Hepatitis B[MeSHID:D006509],Liver diseases[MeSHID:D008107],Virus Replication[MeSHID:D014779],Hepatitis[MeSHID:D006505],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hairy Cell Leukemia[MeSHID:D007943] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist 2.65 drugbank , DGIDB peginterferon alfa-2b biotech Genotype[MeSHID:D005838],NOONAN SYNDROME 3[MeSHID:C537847],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon alpha/beta receptor 1 IFNAR1 NA agonist 2.65 drugbank , DGIDB interferon beta-1a biotech Condylomata Acuminata[MeSHID:D003218],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Multiple Sclerosis[MeSHID:D009103],Disease[MeSHID:D004194] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist NA drugbank , DGIDB interferon alfa-n1 biotech Condylomata Acuminata[MeSHID:D003218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist NA drugbank , DGIDB interferon alfa-2a biotech HIV Infections[MeSHID:D015658],AIDS with Kaposi's sarcoma[MeSHID:C554498],Hepatitis C, Chronic[MeSHID:D019698],Hairy Cell Leukemia[MeSHID:D007943],Warts[MeSHID:D014860],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist 2.65 drugbank , DGIDB interferon beta-1a biotech Condylomata Acuminata[MeSHID:D003218],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist NA drugbank , DGIDB peginterferon alfa-2a biotech Hepatitis B[MeSHID:D006509],Liver diseases[MeSHID:D008107],Virus Replication[MeSHID:D014779],Hepatitis[MeSHID:D006505],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hairy Cell Leukemia[MeSHID:D007943] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist NA drugbank , DGIDB interferon alfa-n3 biotech Condylomata Acuminata[MeSHID:D003218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist NA drugbank , DGIDB zadaxin/lamivudine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interferon alpha/beta receptor 1 IFNAR1 Clinical trial target unknown NA TTD , DGIDB human interferon beta biotech Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA binder NA drugbank interferon alfa biotech melanoma[MeSHID:D008545],Hepatitis A[MeSHID:D006506],Hepatitis[MeSHID:D006505],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196] investigational interferon alpha/beta receptor 1 IFNAR1 NA unknown NA drugbank interferon alfacon-1 biotech Hairy Cell Leukemia[MeSHID:D007943],melanoma[MeSHID:D008545],AIDS with Kaposi's sarcoma[MeSHID:C554498],Cutaneous Melanoma[MeSHID:C562393],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA binder,agonist 2.65 drugbank , DGIDB medi-546 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 interferon alpha/beta receptor 1 IFNAR1 Clinical trial target unknown 5.3 TTD , DGIDB peginterferon alfa-2b biotech Genotype[MeSHID:D005838],NOONAN SYNDROME 3[MeSHID:C537847],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon alpha/beta receptor 1 IFNAR1 NA agonist NA drugbank , DGIDB interferon alfa-n3 biotech Condylomata Acuminata[MeSHID:D003218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist 15.91 drugbank , DGIDB peginterferon beta-1a biotech Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362] approved interferon alpha/beta receptor 1 IFNAR1 NA activator,downregulator,agonist 2.65 drugbank , DGIDB blx-883 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 interferon alpha/beta receptor 1 IFNAR1 Clinical trial target unknown NA TTD emz701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interferon alpha/beta receptor 1 IFNAR1 Clinical trial target unknown NA TTD , DGIDB anifrolumab biotech Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA inhibitor,antibody 5.3 drugbank , DGIDB interferon beta-1a biotech Condylomata Acuminata[MeSHID:D003218],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA agonist 2.65 drugbank , DGIDB interferon alfacon-1 biotech Hairy Cell Leukemia[MeSHID:D007943],melanoma[MeSHID:D008545],AIDS with Kaposi's sarcoma[MeSHID:C554498],Cutaneous Melanoma[MeSHID:C562393],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon alpha/beta receptor 1 IFNAR1 NA binder NA drugbank , DGIDB belerofon NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 interferon alpha/beta receptor 1 IFNAR1 Clinical trial target unknown NA TTD , DGIDB interferon beta-1b biotech Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved interferon alpha/beta receptor 2 IFNAR2 Successful target agonist 2.65 TTD , drugbank , DGIDB interferon alfa-2a biotech HIV Infections[MeSHID:D015658],AIDS with Kaposi's sarcoma[MeSHID:C554498],Hepatitis C, Chronic[MeSHID:D019698],Hairy Cell Leukemia[MeSHID:D007943],Warts[MeSHID:D014860],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational interferon alpha/beta receptor 2 IFNAR2 NA agonist 2.65 drugbank , DGIDB interferon beta-1a biotech Condylomata Acuminata[MeSHID:D003218],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved,investigational interferon alpha/beta receptor 2 IFNAR2 NA agonist 2.65 drugbank , DGIDB anifrolumab NA Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 interferon alpha/beta receptor 2 IFNAR2 Successful target unknown 2.65 TTD , DGIDB alfa-interferon NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 1 interferon alpha/beta receptor 2 IFNAR2 Successful target unknown NA TTD , DGIDB interferon beta-1b biotech Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved interferon alpha/beta receptor 2 IFNAR2 Successful target agonist NA TTD , drugbank , DGIDB interferon alfa-n3 biotech Condylomata Acuminata[MeSHID:D003218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational interferon alpha/beta receptor 2 IFNAR2 NA agonist 18.56 drugbank , DGIDB interferon alfa-2b, recombinant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hairy Cell Leukemia[MeSHID:D007943] approved interferon alpha/beta receptor 2 IFNAR2 Successful target unknown NA TTD , DGIDB peginterferon alfa-2a biotech Hepatitis B[MeSHID:D006509],Liver diseases[MeSHID:D008107],Virus Replication[MeSHID:D014779],Hepatitis[MeSHID:D006505],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hairy Cell Leukemia[MeSHID:D007943] approved,investigational interferon alpha/beta receptor 2 IFNAR2 NA agonist 2.65 drugbank , DGIDB interferon alfacon-1 biotech Hairy Cell Leukemia[MeSHID:D007943],melanoma[MeSHID:D008545],AIDS with Kaposi's sarcoma[MeSHID:C554498],Cutaneous Melanoma[MeSHID:C562393],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon alpha/beta receptor 2 IFNAR2 Successful target binder,agonist 2.65 TTD , drugbank , DGIDB human interferon omega-1 biotech Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506] investigational interferon alpha/beta receptor 2 IFNAR2 NA unknown NA drugbank interferon alfa-n3 biotech Condylomata Acuminata[MeSHID:D003218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational interferon alpha/beta receptor 2 IFNAR2 NA agonist NA drugbank , DGIDB nylidrin small molecule Disease[MeSHID:D004194],Peripheral Vascular Diseases[MeSHID:D016491],Premature Obstetric Labor[MeSHID:D007752],Arteriosclerosis[MeSHID:D001161],Thromboangiitis Obliterans[MeSHID:D013919],Raynaud Disease[MeSHID:D011928],Cerebrovascular Disorders[MeSHID:D002561],Thrombophlebitis[MeSHID:D013924] approved interferon alpha/beta receptor 2 IFNAR2 NA agonist NA drugbank sifalimumab NA Renal Cell Carcinoma[MeSHID:D002292],Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon alpha/beta receptor 2 IFNAR2 Successful target unknown 2.65 TTD , DGIDB interferon beta-1a biotech Condylomata Acuminata[MeSHID:D003218],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Multiple Sclerosis[MeSHID:D009103],Disease[MeSHID:D004194] approved,investigational interferon alpha/beta receptor 2 IFNAR2 NA agonist 2.65 drugbank , DGIDB peginterferon alfa-2b biotech Genotype[MeSHID:D005838],NOONAN SYNDROME 3[MeSHID:C537847],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon alpha/beta receptor 2 IFNAR2 NA agonist 2.65 drugbank , DGIDB interferon alfacon-1 biotech Hairy Cell Leukemia[MeSHID:D007943],melanoma[MeSHID:D008545],AIDS with Kaposi's sarcoma[MeSHID:C554498],Cutaneous Melanoma[MeSHID:C562393],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon alpha/beta receptor 2 IFNAR2 Successful target binder NA TTD , drugbank , DGIDB interferon alfa-2b biotech Hairy Cell Leukemia[MeSHID:D007943],melanoma[MeSHID:D008545],AIDS with Kaposi's sarcoma[MeSHID:C554498],Cutaneous Melanoma[MeSHID:C562393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon alpha/beta receptor 2 IFNAR2 NA binder,agonist 13.26 drugbank , DGIDB interferon alfa-n1 biotech Condylomata Acuminata[MeSHID:D003218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational interferon alpha/beta receptor 2 IFNAR2 Successful target agonist NA TTD , drugbank , DGIDB ropeginterferon alfa-2b biotech Polycythemia Vera[MeSHID:D011087],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon alpha/beta receptor (ifnar) IFNAR2 NA binder NA drugbank gene therapy, ifn-b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB plegridy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved interferon-beta IFNB1 Successful target unknown 31.83 TTD , DGIDB tv-1390 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tidal Volume[MeSHID:D013990],Multiple Sclerosis[MeSHID:D009103] preclinical interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB beta-d-glucose small molecule NA experimental interferon beta IFNB1 NA unknown NA drugbank pf-06823859 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179],Dermatomycoses[MeSHID:D003881],Lupus Vulgaris[MeSHID:D008177],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interferon-beta IFNB1 Successful target unknown 31.83 TTD , DGIDB arx-424 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB interferon beta 1a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interferon-beta IFNB1 Successful target unknown NA TTD interferon beta-1a NA Condylomata Acuminata[MeSHID:D003218],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB biferonex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 3 interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB fp-1201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] phase 3 interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB az-01, pegylated interferon-beta NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB nu-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 3 interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB pegylated ifn beta 1-a NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB interferon beta-1a NA Condylomata Acuminata[MeSHID:D003218],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Multiple Sclerosis[MeSHID:D009103],Disease[MeSHID:D004194] approved interferon-beta IFNB1 Successful target unknown NA TTD , DGIDB tak-603 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] discontinued in phase 2 interferon-gamma IFNG Successful target unknown NA TTD cigb-128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Basal cell carcinoma[MeSHID:D002280] phase 1 interferon-gamma IFNG Successful target unknown NA TTD , DGIDB fumaric acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pustulosis of Palms and Soles[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103] phase 3 interferon-gamma IFNG Successful target unknown NA TTD , DGIDB vir201 biotech HIV Infections[MeSHID:D015658] investigational interferon gamma IFNG NA unknown NA drugbank foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved interferon gamma IFNG NA agonist NA drugbank emapalumab NA Disease[MeSHID:D004194],Cessation of life[MeSHID:D003643],macrophage[MeSHID:D008264],Lymphohistiocytosis, Hemophagocytic[MeSHID:D051359],Fever[MeSHID:D005334],Intrinsic drive[MeSHID:D004328],Hepatomegaly[MeSHID:D006529],Spleen[MeSHID:D013154],T-Lymphocyte[MeSHID:D013601],Thinking, function[MeSHID:D013850],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Familial Hemophagocytic Lymphocytosis[MeSHID:D051359],Coronavirus Infections[MeSHID:D018352] approved interferon-gamma IFNG Successful target unknown 0.94 TTD , DGIDB vpm-4-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Structure of ventral posteromedial nucleus of thalamus[MeSHID:D020651],Malignant neoplasm of prostate[MeSHID:D011471] preclinical interferon-gamma IFNG Successful target unknown NA TTD , DGIDB amg 811 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179], Systemic[MeSHID:D008180] phase 1 interferon-gamma IFNG Successful target unknown NA TTD , DGIDB fontolizumab biotech Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Rheumatoid Arthritis[MeSHID:D001172] investigational interferon gamma IFNG NA unknown 7.49 drugbank , DGIDB emapalumab NA Disease[MeSHID:D004194],Cessation of life[MeSHID:D003643],macrophage[MeSHID:D008264],Lymphohistiocytosis, Hemophagocytic[MeSHID:D051359],Fever[MeSHID:D005334],Intrinsic drive[MeSHID:D004328],Hepatomegaly[MeSHID:D006529],Spleen[MeSHID:D013154],T-Lymphocyte[MeSHID:D013601],Thinking, function[MeSHID:D013850],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Familial Hemophagocytic Lymphocytosis[MeSHID:D051359] approved interferon-gamma IFNG Successful target unknown 0.94 TTD , DGIDB glucosamine small molecule Arthralgia[MeSHID:D018771],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon gamma IFNG NA inhibitor NA drugbank olsalazine small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon gamma IFNG NA unknown NA drugbank foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved interferon gamma IFNG NA agonist NA drugbank fontolizumab biotech Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Rheumatoid Arthritis[MeSHID:D001172] investigational interferon gamma IFNG NA inhibitor 7.49 drugbank , DGIDB emapalumab biotech Disease[MeSHID:D004194],Cessation of life[MeSHID:D003643],macrophage[MeSHID:D008264],Lymphohistiocytosis, Hemophagocytic[MeSHID:D051359],Fever[MeSHID:D005334],Intrinsic drive[MeSHID:D004328],Hepatomegaly[MeSHID:D006529],Spleen[MeSHID:D013154],T-Lymphocyte[MeSHID:D013601],Thinking, function[MeSHID:D013850],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Familial Hemophagocytic Lymphocytosis[MeSHID:D051359] approved,investigational interferon gamma IFNG NA neutralizer 0.94 drugbank , DGIDB vir-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 1/2 interferon-gamma IFNG Successful target unknown NA TTD , DGIDB fontolizumab NA Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 interferon-gamma IFNG Successful target inhibitor 7.49 TTD , DGIDB tg-1042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] discontinued in phase 2 interferon-gamma IFNG Successful target unknown NA TTD crx-191 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 interferon-gamma IFNG Successful target unknown NA TTD fontolizumab NA Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 interferon-gamma IFNG Successful target unknown 7.49 TTD , DGIDB emapalumab biotech Disease[MeSHID:D004194],Cessation of life[MeSHID:D003643],macrophage[MeSHID:D008264],Lymphohistiocytosis, Hemophagocytic[MeSHID:D051359],Fever[MeSHID:D005334],Intrinsic drive[MeSHID:D004328],Hepatomegaly[MeSHID:D006529],Spleen[MeSHID:D013154],T-Lymphocyte[MeSHID:D013601],Thinking, function[MeSHID:D013850],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Familial Hemophagocytic Lymphocytosis[MeSHID:D051359],Coronavirus Infections[MeSHID:D018352] approved,investigational interferon gamma IFNG NA neutralizer 0.94 drugbank , DGIDB interferon gamma-1b biotech Chronic granulomatous disease[MeSHID:D006105],Osteopetrosis[MeSHID:D010022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon gamma receptor 1 IFNGR1 NA binder NA drugbank , DGIDB interferon gamma-1b NA Chronic granulomatous disease[MeSHID:D006105],Osteopetrosis[MeSHID:D010022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interferon gamma receptor IFNGR2 Successful target unknown NA TTD , DGIDB interferon gamma-1b biotech Chronic granulomatous disease[MeSHID:D006105],Osteopetrosis[MeSHID:D010022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interferon gamma receptor 2 IFNGR2 NA binder NA drugbank , DGIDB peg-interferon lambda (il-29) NA Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 interleukin-29 IFNL1 Clinical trial target unknown NA TTD , DGIDB peginterferon lambda-1a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 interleukin-29 IFNL1 Clinical trial target unknown NA TTD , DGIDB peginterferon lambda-1a NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 interleukin-29 IFNL1 Clinical trial target unknown NA TTD , DGIDB itca-638 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interferon-omega IFNW1 Clinical trial target unknown NA TTD , DGIDB n,n-bis(3-(d-gluconamido)propyl)deoxycholamide small molecule NA experimental insulin-like growth factor i IGF1 NA unknown NA drugbank xentuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 insulin-like growth factor-i IGF1 Clinical trial target unknown 15.91 TTD , DGIDB bi-836845 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 insulin-like growth factor-i IGF1 Clinical trial target unknown 15.91 TTD , DGIDB n-dodecyl-n,n-dimethyl-3-ammonio-1-propanesulfonate small molecule NA experimental insulin-like growth factor i IGF1 NA unknown NA drugbank medi-573 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 insulin-like growth factor-i IGF1 Clinical trial target unknown 31.83 TTD , DGIDB 4-((1h-indazol-6-ylamino)methyl)benzene-1,2-diol NA NA investigative insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD axl-1717 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 insulin-like growth factor i receptor IGF1R Successful target unknown 5.03 TTD , DGIDB ag 1024 NA NA investigative igf1r messenger rna IGF1R Literature-reported target inhibitor NA TTD , DGIDB amg 479 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB figitumumab NA Adrenal Cancer[MeSHID:D000310],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 insulin-like growth factor i receptor IGF1R Successful target antagonist 6.7 TTD , DGIDB tt-100 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB biib 022 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB azd3463 NA NA investigative igf1r messenger rna IGF1R Literature-reported target inhibitor NA TTD , DGIDB mm-141 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 insulin-like growth factor i receptor IGF1R Successful target unknown 1.12 TTD , DGIDB cyclolignan picropodophyllin NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB mecasermin biotech Hypothyroidism[MeSHID:D007037],Failure to Thrive[MeSHID:D005183],long-term care[MeSHID:D008134],Neoplasm Metastasis[MeSHID:D009362],Malnutrition[MeSHID:D044342],Gene Deletion[MeSHID:D017353],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational insulin-like growth factor 1 receptor IGF1R NA agonist 10.05 drugbank , DGIDB insulin beef biotech NA approved insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank figitumumab NA Adrenal Cancer[MeSHID:D000310],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 insulin-like growth factor i receptor IGF1R Successful target unknown 6.7 TTD , DGIDB insulin aspart biotech Diabetes Mellitus[MeSHID:D003920] approved insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank r1507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid associated opthalmopathies[MeSHID:D049970] phase 2 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB insulin tregopil biotech NA investigational insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank insulin degludec biotech Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank figitumumab NA Adrenal Cancer[MeSHID:D000310],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 insulin-like growth factor i receptor IGF1R Successful target antibody 6.7 TTD , DGIDB bms-695735 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical insulin-like growth factor i receptor IGF1R Successful target unknown 0.84 TTD , DGIDB atl-1101 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical igf1r messenger rna IGF1R Literature-reported target unknown NA TTD cixutumumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] phase 2 insulin-like growth factor i receptor IGF1R Successful target unknown 5.03 TTD , DGIDB ave-1642 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 2 insulin-like growth factor i receptor IGF1R Successful target antagonist 1.68 TTD , DGIDB rhigfbp-3 biotech Neoplasms[MeSHID:D009369] investigational insulin-like growth factor 1 receptor IGF1R NA unknown NA drugbank cixutumumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] phase 2 insulin-like growth factor i receptor IGF1R Successful target antagonist 5.03 TTD , DGIDB bms-754807 small molecule NA investigational insulin-like growth factor 1 receptor IGF1R NA inhibitor 0.64 drugbank , DGIDB rinfabate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2/3 insulin-like growth factor i receptor IGF1R Successful target unknown 1.68 TTD , DGIDB somatrem biotech Growth Disorders[MeSHID:D006130],Failure to Thrive[MeSHID:D005183],Dwarfism[MeSHID:D004392],Turner Syndrome[MeSHID:D014424],Chronic Kidney Diseases[MeSHID:D051436],Malnutrition[MeSHID:D044342],Kidney Failure, Chronic[MeSHID:D007676],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn insulin-like growth factor 1 receptor IGF1R NA unknown NA drugbank teprotumumab NA Disorder of eye[MeSHID:D005128],Thyroid Gland[MeSHID:D013961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269],Graves Disease[MeSHID:D006111] approved insulin-like growth factor i receptor IGF1R Successful target antagonist 1.68 TTD , DGIDB insulin detemir biotech Diabetes Mellitus[MeSHID:D003920] approved insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank jb-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD pq401 NA NA investigative igf1r messenger rna IGF1R Literature-reported target inhibitor NA TTD , DGIDB bms-536924 NA NA investigative insulin-like growth factor i receptor IGF1R Successful target inhibitor 0.84 TTD , DGIDB aew-541 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 insulin-like growth factor i receptor IGF1R Successful target inhibitor 0.84 TTD , DGIDB amp-pnp NA NA investigative insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD insulin pork biotech Diabetes Mellitus[MeSHID:D003920] approved insulin-like growth factor 1 receptor IGF1R NA unknown NA drugbank gsk1511931 NA NA investigative igf1r messenger rna IGF1R Literature-reported target inhibitor NA TTD , DGIDB fpi-1434 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD mecasermin NA Hypothyroidism[MeSHID:D007037],Failure to Thrive[MeSHID:D005183],long-term care[MeSHID:D008134],Neoplasm Metastasis[MeSHID:D009362],Malnutrition[MeSHID:D044342],Gene Deletion[MeSHID:D017353],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved insulin-like growth factor i receptor IGF1R Successful target unknown 10.05 TTD , DGIDB rg-7010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] phase 1 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB insulin peglispro biotech NA investigational insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank gsk-1838705a NA NA investigative igf1r messenger rna IGF1R Literature-reported target inhibitor NA TTD , DGIDB kw-2450 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 1/2 insulin-like growth factor i receptor IGF1R Successful target inhibitor 0.84 TTD , DGIDB teprotumumab biotech Disorder of eye[MeSHID:D005128],Thyroid Gland[MeSHID:D013961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269],Graves Disease[MeSHID:D006111] approved,investigational insulin-like growth factor 1 receptor IGF1R NA binder,antibody 1.68 drugbank , DGIDB hf-0299 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB insulin human biotech Diabetes Mellitus[MeSHID:D003920] approved,investigational insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank cixutumumab biotech Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] investigational insulin-like growth factor 1 receptor IGF1R NA antagonist 5.03 drugbank , DGIDB xl228 small molecule leukemia[MeSHID:D007938],Lymph[MeSHID:D008196] investigational insulin-like growth factor 1 receptor IGF1R NA inhibitor 0.42 drugbank , DGIDB cixutumumab biotech Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] investigational insulin-like growth factor 1 receptor IGF1R NA antibody 5.03 drugbank , DGIDB insulin glulisine biotech Diabetes Mellitus[MeSHID:D003920] approved insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank xl228 small molecule leukemia[MeSHID:D007938],Lymph[MeSHID:D008196] investigational insulin-like growth factor 1 receptor IGF1R NA unknown 0.42 drugbank , DGIDB atl1101 small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational insulin-like growth factor 1 receptor IGF1R NA unknown NA drugbank insulin argine biotech NA experimental insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank vpi-2690b NA Diabetic Nephropathy[MeSHID:D003928],Structure of ventral posterior inferior nucleus[MeSHID:D020651],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB teprotumumab NA Disorder of eye[MeSHID:D005128],Thyroid Gland[MeSHID:D013961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269],Graves Disease[MeSHID:D006111] approved insulin-like growth factor i receptor IGF1R Successful target antibody 1.68 TTD , DGIDB nvp-adw742 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD nandrolone decanoate small molecule Disease Management[MeSHID:D019468],Kidney Failure[MeSHID:D051437],Osteoporosis, Postmenopausal[MeSHID:D015663],Senility[MeSHID:D000375],Anemia[MeSHID:D000740] approved,illicit insulin-like growth factor 1 receptor IGF1R NA inducer NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental insulin-like growth factor 1 receptor IGF1R NA unknown NA drugbank kw-2450 free base small molecule NA experimental insulin-like growth factor 1 receptor IGF1R NA inhibitor NA drugbank (4z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2h,4h)-dione small molecule NA experimental insulin-like growth factor 1 receptor IGF1R NA unknown NA drugbank insulin lispro biotech Diabetes Mellitus[MeSHID:D003920] approved insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank mecasermin rinfabate biotech HIV Seropositivity[MeSHID:D006679],Myotonic Dystrophy[MeSHID:D009223],adiposity[MeSHID:D050154],HIV Infections[MeSHID:D015658],Disease[MeSHID:D004194],Insulin Resistance[MeSHID:D007333],Dwarfism[MeSHID:D004392],Obesity[MeSHID:D009765],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Disease Resistance[MeSHID:D060467],Gene Deletion[MeSHID:D017353] approved insulin-like growth factor 1 receptor IGF1R NA agonist 1.68 drugbank , DGIDB mecasermin NA Hypothyroidism[MeSHID:D007037],Failure to Thrive[MeSHID:D005183],long-term care[MeSHID:D008134],Neoplasm Metastasis[MeSHID:D009362],Malnutrition[MeSHID:D044342],Gene Deletion[MeSHID:D017353],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved insulin-like growth factor i receptor IGF1R Successful target agonist 10.05 TTD , DGIDB brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational insulin-like growth factor 1 receptor IGF1R NA inhibitor 1.01 drugbank , DGIDB aew-541 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 insulin-like growth factor i receptor IGF1R Successful target unknown 0.84 TTD , DGIDB amg 479 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 insulin-like growth factor i receptor IGF1R Successful target antibody NA TTD , DGIDB osi-906 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 insulin-like growth factor i receptor IGF1R Successful target unknown 1.68 TTD , DGIDB teprotumumab biotech Disorder of eye[MeSHID:D005128],Thyroid Gland[MeSHID:D013961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269],Graves Disease[MeSHID:D006111] approved,investigational insulin-like growth factor 1 receptor IGF1R NA binder,antibody,antagonist 1.68 drugbank , DGIDB linsitinib small molecule Neoplasms[MeSHID:D009369] investigational insulin-like growth factor 1 receptor IGF1R NA inhibitor 1.68 drugbank , DGIDB insulin glargine biotech Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922], Non-Insulin-Dependent[MeSHID:D003924] approved insulin-like growth factor 1 receptor IGF1R NA activator NA drugbank alpha-d-mannose NA NA investigative insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD egfr/igfr tandem adnectin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB fucose NA NA investigative insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol NA NA investigative insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD 3-[5-(1h-imidazol-1-yl)-7-methyl-1h-benzimidazol-2-yl]-4-[(pyridin-2-ylmethyl)amino]pyridin-2(1h)-one small molecule NA experimental insulin-like growth factor 1 receptor IGF1R NA unknown NA drugbank somatomedin-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved insulin-like growth factor i receptor IGF1R Successful target unknown NA TTD , DGIDB cixutumumab biotech Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] investigational insulin-like growth factor 1 receptor IGF1R NA unknown 5.03 drugbank , DGIDB cixutumumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] phase 2 insulin-like growth factor i receptor IGF1R Successful target antibody 5.03 TTD , DGIDB xentuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 insulin-like growth factor-ii IGF2 Clinical trial target unknown 2.27 TTD , DGIDB dusigitumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 insulin-like growth factor-ii IGF2 Clinical trial target unknown 4.55 TTD , DGIDB dusigitumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 insulin-like growth factor-ii IGF2 Clinical trial target inhibitor 4.55 TTD , DGIDB juvidex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] phase 2 ci man-6-p receptor IGF2R Clinical trial target unknown 127.3 TTD , DGIDB mecasermin rinfabate biotech HIV Seropositivity[MeSHID:D006679],Myotonic Dystrophy[MeSHID:D009223],adiposity[MeSHID:D050154],HIV Infections[MeSHID:D015658],Disease[MeSHID:D004194],Insulin Resistance[MeSHID:D007333],Dwarfism[MeSHID:D004392],Obesity[MeSHID:D009765],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Disease Resistance[MeSHID:D060467],Gene Deletion[MeSHID:D017353] approved cation-independent mannose-6-phosphate receptor IGF2R NA unknown NA drugbank mecasermin biotech Hypothyroidism[MeSHID:D007037],Failure to Thrive[MeSHID:D005183],long-term care[MeSHID:D008134],Neoplasm Metastasis[MeSHID:D009362],Malnutrition[MeSHID:D044342],Gene Deletion[MeSHID:D017353],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cation-independent mannose-6-phosphate receptor IGF2R NA unknown NA drugbank avalglucosidase alfa biotech Hydrolysis[MeSHID:D006868],Late Onset Disorders[MeSHID:D000067562],Lysosomes[MeSHID:D008247],Glycogen storage disease type II[MeSHID:D006009],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cation-independent mannose-6-phosphate receptor IGF2R NA ligand NA drugbank cerliponase alfa biotech Disease[MeSHID:D004194],Ataxia[MeSHID:D001259],Cessation of life[MeSHID:D003643],Cerebellar Ataxia[MeSHID:D002524],Rare Diseases[MeSHID:D035583],Lysosomes[MeSHID:D008247],Neuronal Ceroid-Lipofuscinoses[MeSHID:D009472],Blind Vision[MeSHID:D001766],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational cation-independent mannose-6-phosphate receptor IGF2R NA ligand NA drugbank pxs-25 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355] phase 1 ci man-6-p receptor IGF2R Clinical trial target unknown NA TTD , DGIDB ep-128504 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical ci man-6-p receptor IGF2R Clinical trial target unknown NA TTD , DGIDB alpha-d-mannose 6-phosphate small molecule NA experimental cation-independent mannose-6-phosphate receptor IGF2R NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational insulin-like growth factor-binding protein complex acid labile subunit IGFALS NA inducer NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental insulin-like growth factor-binding protein complex acid labile subunit IGFALS NA inducer NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational insulin-like growth factor-binding protein complex acid labile subunit IGFALS NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational insulin-like growth factor-binding protein complex acid labile subunit IGFALS NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational insulin-like growth factor-binding protein complex acid labile subunit IGFALS NA unknown NA drugbank mecasermin biotech Hypothyroidism[MeSHID:D007037],Failure to Thrive[MeSHID:D005183],long-term care[MeSHID:D008134],Neoplasm Metastasis[MeSHID:D009362],Malnutrition[MeSHID:D044342],Gene Deletion[MeSHID:D017353],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational insulin-like growth factor-binding protein 3 IGFBP3 NA unknown NA drugbank alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational insulin-like growth factor-binding protein 3 IGFBP3 NA unknown NA drugbank insulin human biotech Diabetes Mellitus[MeSHID:D003920] approved,investigational insulin-like growth factor-binding protein 7 IGFBP7 NA inhibitor,binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational ig alpha-1 chain c region IGHA1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational ig alpha-1 chain c region IGHA1 NA unknown NA drugbank dansyllysine small molecule NA experimental ig alpha-2 chain c region IGHA2 NA unknown NA drugbank ligelizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urticaria[MeSHID:D014581] investigational immunoglobulin heavy constant epsilon IGHE NA antibody 25.46 drugbank , DGIDB ligelizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urticaria[MeSHID:D014581] investigational immunoglobulin heavy constant epsilon IGHE NA antibody,inhibitor 25.46 drugbank , DGIDB n-[4-(4-nitrophenylphospho)butanoyl]-d-alanine small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 3-{[(9-cyano-9,10-dihydro-10-methylacridin-9-yl)carbonyl]amino}propanoic acid small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank para-nitrophenylphosphonobutanoyl-glycine small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 2-(4-hydroxy-3-nitrophenyl)acetic acid small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank n-(p-cyanophenyl)-n'-diphenylmethyl-guanidine-acetic acid small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank (2-amino-3-phenyl-bicyclo[2.2.1]hept-2-yl)-phenyl-methanone small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank n-[4-(4-nitrophenylphospho)butanoyl]-l-alanine small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank etiocholanedione small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 5-(para-nitrophenyl phosphonate)-pentanoic acid small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 6-{4-[hydroxy-(4-nitro-phenoxy)-phosphoryl]-butyrylamino}-hexanoic acid small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 4-nitro-benzylphosphonobutanoyl-glycine small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 4-(4-styryl-phenylcarbamoyl)-butyric acid small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank biphenylalanine small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank n-{[2-({[1-(4-carboxybutanoyl)amino]-2-phenylethyl}-hydroxyphosphinyl)oxy]acetyl}-2-phenylethylamine small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank alpha-l-fucose small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational ig gamma-1 chain c region IGHG1 NA unknown NA drugbank fluorescin small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank n-acetyl-alpha-d-glucosamine small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank para-nitrobenzyl glutaryl glycinic acid small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank (1s,2s,5s)2-(4-glutaridylbenzyl)-5-phenyl-1-cyclohexanol small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank trans-2-(dimethylphenylsilyl)-piperidine-n-oxide small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 9-(2-carboxyethyl)-10-methylanthracene endoperoxide small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 3-(10-methyl-9-anthryl)propanoic acid small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank methyl nonanoate small molecule NA experimental ig gamma-1 chain c region IGHG1 NA unknown NA drugbank 3-(hydroxy-phenyl-phosphinoyloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank methylecgonine small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank aetiocholanolone small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank 3-oxo-n-[(3s)-2-oxopyrrolidin-3-yl]dodecanamide small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank etiocholanedione small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank 5-alpha-pregnane-3-beta-ol-hemisuccinate small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank progesterone-11-alpha-ol-hemisuccinate small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank 1-[n-4'-nitrobenzyl-n-4'-carboxybutylamino]methylphosphonic acid small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank 4-nitro-benzylphosphonobutanoyl-glycine small molecule NA experimental ig gamma-2 chain c region IGHG2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational ig gamma-4 chain c region IGHG4 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational ig mu chain c region IGHM NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational ig mu chain c region IGHM NA unknown NA drugbank 4-hydroxy-5-iodo-3-nitrophenylacetyl-epsilon-aminocaproic acid anion small molecule NA experimental ig heavy chain v-i region nd IGHV1-2 NA unknown NA drugbank 4-hydroxy-3-nitrophenylacetyl-epsilon-aminocaproic acid anion small molecule NA experimental ig heavy chain v-i region nd IGHV1-2 NA unknown NA drugbank 2-(4-hydroxy-3-nitrophenyl)acetic acid small molecule NA experimental ig heavy chain v-i region nd IGHV1-2 NA unknown NA drugbank dodecyldimethylamine n-oxide small molecule NA experimental ig heavy chain v-iii region vh26 IGHV3-23 NA unknown NA drugbank n-(trans-4'-nitro-4-stilbenyl)-n-methyl-5-amino-pentanoic acid small molecule NA experimental ig heavy chain v-iii region cam IGHV3-30 NA unknown NA drugbank 4-{[(z)-(5-oxo-2-phenyl-1,3-oxazol-4(5h)-ylidene)methyl]amino}butanoic acid small molecule NA experimental ig heavy chain v-iii region cam IGHV3-30 NA unknown NA drugbank (2s)-2-(butyryloxy)-3-hydroxypropyl nonanoate small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank phenyl[1-(n-succinylamino)pentyl]phosphonate small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank etiocholanedione small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank 4-{4-[2-(1a,7a-dimethyl-4-oxy-octahydro-1-oxa-4-aza-cyclopropa[a]naphthalen-4-yl) -acetylamino]-phenylcarbamoyl}-butyric acid small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank methyl-phosphonic acid mono-(4-nitro-phenyl) ester small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank n-(para-glutaramidophenyl-ethyl)-piperidinium-n-oxide small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank trazeolide small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank 4-(4-styryl-phenylcarbamoyl)-butyric acid small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank (4z)-2,8:7,12:11,15:14,18:17,22-pentaanhydro-4,5,6,9,10,13,19,20,21-nonadeoxy-d-arabino-d-allo-d-allo-docosa-4,9,20-trienitol small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank 3-{[(9-cyano-9,10-dihydro-10-methylacridin-9-yl)carbonyl]amino}propanoic acid small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank (1s,2s,5s)2-(4-glutaridylbenzyl)-5-phenyl-1-cyclohexanol small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank methylecgonine small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank tetrabutylammonium ion small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank [4-(4-acetylamino-phenyl)-3,5-dioxo-4-aza-tricyclo[5.2.2.0 2,6]undec-1-ylcarbamoyloxy]-acetic acid small molecule NA experimental ig kappa chain c region IGKC NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational immunoglobulin kappa variable 1-17 IGKV1-17 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational immunoglobulin kappa variable 1-17 IGKV1-17 NA unknown NA drugbank 4-(4-styryl-phenylcarbamoyl)-butyric acid small molecule NA experimental ig kappa chain v-ii region tew IGKV2D-28 NA unknown NA drugbank pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational ig lambda-1 chain c regions IGLC1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational immunoglobulin lambda-like polypeptide 1 IGLL1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational immunoglobulin lambda variable 3-21 IGLV3-21 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational immunoglobulin lambda variable 3-21 IGLV3-21 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical immunoglobulin superfamily member 10 IGSF10 NA cofactor NA drugbank 3-amino-benzo[b]thiophene-2-carboxylic acid amide NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD sar-113945 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown 8.68 TTD , DGIDB 6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD pf-228 NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD 5-bromo-6-methoxy-9h-beta-carboline NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD sc-514 NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown 2.89 TTD , DGIDB staurosporine NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown 0.07 TTD , DGIDB imd-1041 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown 5.79 TTD , DGIDB sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA inhibitor NA drugbank parthenolide NA NA phase 2 inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown 0.72 TTD , DGIDB mln0415 small molecule Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] investigational inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA unknown NA drugbank imd-0354 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown 5.79 TTD , DGIDB 2-amino-quinoline-3-carboxylic acid amide NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA inhibitor NA drugbank auranofin small molecule Arthritis[MeSHID:D001168],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA inhibitor 5.79 drugbank , DGIDB 4-amino-biphenyl-3-carboxylic acid amide NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA inhibitor NA drugbank sar-113945 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target inhibitor 8.68 TTD , DGIDB mesalazine small molecule Crohn's disease of large bowel[MeSHID:D003424],ileum[MeSHID:D007082],Ulcerative Colitis[MeSHID:D003093],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA inhibitor NA drugbank 5-amino-2-phenyl-oxazole-4-carboxylic acid amide NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD arsenic trioxide NA Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD , DGIDB imd-1041 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target inhibitor 5.79 TTD , DGIDB ertiprotafib small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA unknown NA drugbank mln0415 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] discontinued in phase 1 inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD imd-0354 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target inhibitor 5.79 TTD , DGIDB 2-amino-5-phenylthiophene-3-carboxamide NA NA investigative inhibitor of nuclear factor kappa-b kinase beta IKBKB Clinical trial target unknown NA TTD arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA inducer NA drugbank , DGIDB acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved inhibitor of nuclear factor kappa-b kinase subunit beta IKBKB NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational inhibitor of nuclear factor kappa-b kinase subunit epsilon IKBKE NA inhibitor NA drugbank tarenflurbil small molecule Malignant neoplasm of prostate[MeSHID:D011471] investigational nf-kappa-b essential modulator IKBKG NA unknown NA drugbank agro100 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of kidney[MeSHID:D007680],leukemia[MeSHID:D007938] investigational nf-kappa-b essential modulator IKBKG NA unknown NA drugbank dky709 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 zinc finger protein helios IKZF2 Clinical trial target unknown NA TTD lll-3348 biotech Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational interleukin-10 IL10 NA unknown NA drugbank f-8-il-10 fusion protein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Endometriosis[MeSHID:D004715],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-10 IL10 Clinical trial target unknown NA TTD , DGIDB ankinara NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Psoriasis[MeSHID:D011565],Rheumatoid Arthritis[MeSHID:D001172] investigative interleukin-10 IL10 Clinical trial target unknown NA TTD crx-139 small molecule Rheumatoid Arthritis[MeSHID:D001172] investigational interleukin-10 IL10 NA unknown NA drugbank ilodecakin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] phase 2 interleukin-10 IL10 Clinical trial target unknown 3.74 TTD , DGIDB am0010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Carcinoma, Pancreatic Ductal[MeSHID:D021441],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 3 interleukin-10 IL10 Clinical trial target unknown 3.74 TTD , DGIDB ag019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 1/2 interleukin-10 IL10 Clinical trial target unknown NA TTD vm-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] phase 3 interleukin-11 IL11 Clinical trial target unknown NA TTD , DGIDB bmtp-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 interleukin 11 receptor alpha IL11RA Successful target unknown NA TTD , DGIDB oprelvekin NA Malignant Neoplasms[MeSHID:D009369],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin 11 receptor alpha IL11RA Successful target agonist 106.09 TTD , DGIDB oprelvekin biotech Malignant Neoplasms[MeSHID:D009369],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-11 receptor subunit alpha IL11RA NA agonist 106.09 drugbank , DGIDB oprelvekin NA Malignant Neoplasms[MeSHID:D009369],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin 11 receptor alpha IL11RA Successful target unknown 106.09 TTD , DGIDB uni-rhil-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] phase 3 interleukin 11 receptor alpha IL11RA Successful target unknown NA TTD , DGIDB ustekinumab NA Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Psoriasis[MeSHID:D011565],Crohn Disease[MeSHID:D003424],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Malaria[MeSHID:D008288] approved interleukin-12 alpha IL12A Successful target inhibitor 6.37 TTD , DGIDB ustekinumab NA Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Psoriasis[MeSHID:D011565],Crohn Disease[MeSHID:D003424],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Malaria[MeSHID:D008288] approved interleukin-12 alpha IL12A Successful target unknown 6.37 TTD , DGIDB mirikizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 3 interleukin-12 alpha IL12A Successful target unknown 15.91 TTD , DGIDB sta-5326 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-12 alpha IL12A Successful target unknown 7.96 TTD , DGIDB ustekinumab biotech Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Psoriasis[MeSHID:D011565],Crohn Disease[MeSHID:D003424],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Malaria[MeSHID:D008288] approved,investigational interleukin-23 IL12B NA inhibitor 12.73 drugbank , DGIDB briakinumab biotech Disease[MeSHID:D004194],Crohn Disease[MeSHID:D003424],Multiple Sclerosis[MeSHID:D009103],Rheumatoid Arthritis[MeSHID:D001172],Autoimmune Diseases[MeSHID:D001327],Psoriasis[MeSHID:D011565] investigational interleukin-12 subunit beta IL12B NA unknown 12.73 drugbank , DGIDB tapinarof small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational interleukin-12 subunit beta IL12B NA unknown NA drugbank ad-il-12 dna therapeutic NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909],melanoma[MeSHID:D008545] phase 1/2 interleukin-12 beta IL12B Successful target unknown NA TTD , DGIDB egen-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fallopian Tube Carcinoma[MeSHID:D005185],Malignant Neoplasms[MeSHID:D009369],Peritoneum[MeSHID:D010537],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 interleukin-12 beta IL12B Successful target unknown NA TTD , DGIDB tildrakizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-23 IL12B NA antagonist NA drugbank isoproterenol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Block[MeSHID:D006327],melanoma[MeSHID:D008545] approved interleukin-12 beta IL12B Successful target unknown 0.44 TTD , DGIDB 5-mercapto-2-nitro-benzoic acid small molecule NA experimental interleukin-12 subunit beta IL12B NA unknown NA drugbank humanized smart anti-il-12 antibody biotech Disease[MeSHID:D004194],Autoimmune Diseases[MeSHID:D001327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigational interleukin-12 subunit beta IL12B NA unknown NA drugbank , DGIDB briakinumab biotech Disease[MeSHID:D004194],Crohn Disease[MeSHID:D003424],Multiple Sclerosis[MeSHID:D009103],Rheumatoid Arthritis[MeSHID:D001172],Autoimmune Diseases[MeSHID:D001327],Psoriasis[MeSHID:D011565] investigational interleukin-12 subunit beta IL12B NA inhibitor 12.73 drugbank , DGIDB ustekinumab biotech Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Psoriasis[MeSHID:D011565],Crohn Disease[MeSHID:D003424],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Malaria[MeSHID:D008288] approved,investigational interleukin-12 subunit beta IL12B NA inhibitor 12.73 drugbank , DGIDB risankizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis, Psoriatic[MeSHID:D015535] approved,investigational interleukin-23 IL12B NA inhibitor NA drugbank abt-874 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 3 interleukin-12 beta IL12B Successful target unknown 12.73 TTD , DGIDB nhs-il 12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Nance-Horan syndrome[MeSHID:C538336] phase 1 interleukin-12 beta IL12B Successful target unknown NA TTD , DGIDB sfv il-12 gene therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 interleukin-12 beta IL12B Successful target unknown NA TTD , DGIDB lebrikizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Chronic Obstructive Airway Disease[MeSHID:D029424],Hamman-Rich syndrome[MeSHID:D011658],Dermatitis, Atopic[MeSHID:D003876],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Asthma[MeSHID:D001249] investigational,phase 3 interleukin-13 IL13 Clinical trial target inhibitor 15.91 TTD , drugbank , DGIDB lebrikizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Chronic Obstructive Airway Disease[MeSHID:D029424],Hamman-Rich syndrome[MeSHID:D011658],Dermatitis, Atopic[MeSHID:D003876],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Asthma[MeSHID:D001249] investigational,phase 3 interleukin-13 IL13 Clinical trial target unknown 15.91 TTD , drugbank , DGIDB tralokinumab biotech Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249] approved,investigational,phase 3 interleukin-13 IL13 Clinical trial target antibody,inhibitor 11.93 TTD , drugbank , DGIDB anrukinzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249] phase 2 interleukin-13 IL13 Clinical trial target inhibitor 15.91 TTD , DGIDB tralokinumab biotech Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249] approved,investigational,phase 3 interleukin-13 IL13 Clinical trial target antibody 11.93 TTD , drugbank , DGIDB pegylated pitrakinra NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249],Allergic Reaction[MeSHID:D006967] phase 2 interleukin-13 IL13 Clinical trial target unknown NA TTD , DGIDB qax-576 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-13 IL13 Clinical trial target inhibitor 15.91 TTD , DGIDB romilkimab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] phase 2 interleukin-13 IL13 Clinical trial target unknown NA TTD lebrikizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Chronic Obstructive Airway Disease[MeSHID:D029424],Hamman-Rich syndrome[MeSHID:D011658],Dermatitis, Atopic[MeSHID:D003876],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Asthma[MeSHID:D001249] investigational il13 protein IL13 NA unknown 15.91 drugbank , DGIDB cnto-5825 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 interleukin-13 IL13 Clinical trial target unknown 7.96 TTD , DGIDB dectrekumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] phase 2 interleukin-13 IL13 Clinical trial target unknown NA TTD ro7040547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 interleukin-13 IL13 Clinical trial target unknown NA TTD qax-576 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-13 IL13 Clinical trial target unknown 15.91 TTD , DGIDB anrukinzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249] phase 2 interleukin-13 IL13 Clinical trial target unknown 15.91 TTD , DGIDB cintredekin besudotox biotech Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational interleukin-13 IL13 NA unknown NA drugbank lebrikizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Chronic Obstructive Airway Disease[MeSHID:D029424],Hamman-Rich syndrome[MeSHID:D011658],Dermatitis, Atopic[MeSHID:D003876],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Asthma[MeSHID:D001249] investigational il13 protein IL13 NA inhibitor 15.91 drugbank , DGIDB sar-156597 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pulmonary Fibrosis[MeSHID:D011658] phase 2 interleukin-13 IL13 Clinical trial target unknown 2.65 TTD , DGIDB abt-308 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eosinophilic esophagitis[MeSHID:D057765],Asthma[MeSHID:D001249] phase 2 interleukin 13 receptor alpha-2 IL13RA2 Clinical trial target unknown 21.22 TTD , DGIDB tralokinumab NA Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249] phase 3 interleukin 13 receptor alpha-2 IL13RA2 Clinical trial target unknown 10.61 TTD , DGIDB mb-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1 interleukin 13 receptor alpha-2 IL13RA2 Clinical trial target unknown NA TTD , DGIDB aer001 small molecule Asthma[MeSHID:D001249] investigational interleukin-13 receptor subunit alpha-2 IL13RA2 NA unknown NA drugbank ict-107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of brain[MeSHID:D001932],COPPER TOXICOSIS, IDIOPATHIC[MeSHID:C565846],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 3 interleukin 13 receptor alpha-2 IL13RA2 Clinical trial target unknown NA TTD , DGIDB n-803 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 1 interleukin-15 IL15 Clinical trial target unknown NA TTD amg-714 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Celiac Disease[MeSHID:D002446],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-15 IL15 Clinical trial target unknown 25.46 TTD , DGIDB bnz-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410], Large Granular Lymphocytic[MeSHID:D054066] phase 2 interleukin-15 IL15 Clinical trial target unknown NA TTD amg-714 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Celiac Disease[MeSHID:D002446],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-15 IL15 Clinical trial target inhibitor 25.46 TTD , DGIDB cefazolin small molecule Operative Surgical Procedures[MeSHID:D013514],Stomach[MeSHID:D013270],Bacterial Infections[MeSHID:D001424],Blood[MeSHID:D001769],Skin Diseases, Bacterial[MeSHID:D017192],Heart Valves[MeSHID:D006351],Lung[MeSHID:D008168],Urinary tract[MeSHID:D014551],Bone Tissue[MeSHID:D001842],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-15 IL15 NA inhibitor NA drugbank nktr-255 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 1/2 interleukin 15 receptor alpha IL15RA Clinical trial target unknown NA TTD alt-803 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Multiple Myeloma[MeSHID:D009101],HIV Infections[MeSHID:D015658],Malignant neoplasm of urinary bladder[MeSHID:D001749],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 2 interleukin 15 receptor alpha IL15RA Clinical trial target unknown 31.83 TTD , DGIDB cova322 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1/2a interleukin-17 IL17A Successful target unknown NA TTD , DGIDB ixekizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis, Psoriatic[MeSHID:D015535] approved,investigational interleukin-17a IL17A NA antibody 7.96 drugbank , DGIDB abt-122 NA Arthritis, Psoriatic[MeSHID:D015535],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-17 IL17A Successful target unknown 1.99 TTD , DGIDB ixekizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis, Psoriatic[MeSHID:D015535] approved,investigational interleukin-17a IL17A NA antibody,inhibitor 7.96 drugbank , DGIDB sch-900117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 interleukin-17 IL17A Successful target unknown NA TTD , DGIDB ixekizumab NA Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis, Psoriatic[MeSHID:D015535] approved interleukin-17 IL17A Successful target inhibitor 7.96 TTD , DGIDB rg-4934 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] discontinued in phase 1 interleukin-17 IL17A Successful target unknown NA TTD abbv-257 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 interleukin-17 IL17A Successful target unknown 1.99 TTD , DGIDB brodalumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Asthma[MeSHID:D001249] approved interleukin-17 IL17A Successful target unknown 1.99 TTD , DGIDB alx-0761 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 interleukin-17 IL17A Successful target unknown 1.99 TTD , DGIDB secukinumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Desiccation[MeSHID:D003890],Eczema[MeSHID:D004485],Disorder of eye[MeSHID:D005128],Dermatitis, Atopic[MeSHID:D003876],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Multiple Sclerosis[MeSHID:D009103],Dry Eye Syndromes[MeSHID:D015352],Disease[MeSHID:D004194],Arthritis, Psoriatic[MeSHID:D015535],Alopecia[MeSHID:D000505],Rheumatoid Arthritis[MeSHID:D001172] approved interleukin-17a IL17A NA antagonist,inhibitor 7.96 drugbank , DGIDB cnto-6785 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-17 IL17A Successful target unknown NA TTD , DGIDB bimekizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535] phase 3 interleukin-17 IL17A Successful target unknown 1.99 TTD , DGIDB ixekizumab NA Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis, Psoriatic[MeSHID:D015535] approved interleukin-17 IL17A Successful target unknown 7.96 TTD , DGIDB cjm112 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Dental Plaque[MeSHID:D003773],Malignant Neoplasms[MeSHID:D009369],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225] phase 2 interleukin-17 IL17A Successful target unknown 3.98 TTD , DGIDB ro7040547 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 interleukin-17 IL17A Successful target unknown NA TTD shr-1314 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 1/2 interleukin-17 IL17A Successful target unknown 3.98 TTD , DGIDB srf388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of liver[MeSHID:D008113] phase 1 interleukin-27 IL17D Clinical trial target unknown NA TTD bimekizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535] phase 3 cytokine ml-1 IL17F Clinical trial target unknown 31.83 TTD , DGIDB gsk-1070806 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-18 IL18 Clinical trial target unknown 18.19 TTD , DGIDB iboctadekin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 interleukin-18 IL18 Clinical trial target unknown 9.09 TTD , DGIDB iboctadekin + rituximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Atrial Fibrillation[MeSHID:D001281], Non-Hodgkin[MeSHID:D008228] phase 1 interleukin-18 IL18 Clinical trial target unknown NA TTD , DGIDB iboctadekin + doxil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 interleukin-18 IL18 Clinical trial target unknown NA TTD , DGIDB tadekinig alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoproliferative Syndrome, X-Linked, 2[MeSHID:C564469] phase 3 interleukin-18 IL18 Clinical trial target unknown NA TTD medi-2338 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 interleukin-18 IL18 Clinical trial target unknown 18.19 TTD , DGIDB il-18bp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1 interleukin-18 IL18 Clinical trial target unknown NA TTD mabp1 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Dental Plaque[MeSHID:D003773],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hidradenitis Suppurativa[MeSHID:D017497],Dermatitis, Atopic[MeSHID:D003876],Psoriasis[MeSHID:D011565],Pyoderma Gangrenosum[MeSHID:D017511],Senile Plaques[MeSHID:D058225],Colorectal Cancer[MeSHID:D015179],Peripheral Vascular Diseases[MeSHID:D016491] phase 3 interleukin-1 alpha IL1A Clinical trial target unknown 10.61 TTD , DGIDB abt-981 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-1 alpha IL1A Clinical trial target unknown NA TTD , DGIDB ix207-887 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 interleukin-1 alpha IL1A Clinical trial target unknown NA TTD interleukin-1-alpha - amgen/roche NA NA investigative interleukin-1 alpha IL1A Clinical trial target unknown NA TTD rilonacept biotech Gout[MeSHID:D006073],Voting[MeSHID:D011057],Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved,investigational interleukin-1 alpha IL1A NA binder 21.22 drugbank , DGIDB xilonix NA Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Orthomyxoviridae Infections[MeSHID:D009976],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 interleukin-1 alpha IL1A Clinical trial target unknown 21.22 TTD , DGIDB rilonacept biotech Gout[MeSHID:D006073],Voting[MeSHID:D011057],Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved,investigational interleukin-1 beta IL1B Successful target binder 3.44 TTD , drugbank , DGIDB etiprednol dicloacetate small molecule Asthma[MeSHID:D001249],Crohn Disease[MeSHID:D003424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] investigational interleukin-1 beta IL1B NA unknown NA drugbank binimetinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational interleukin-1 beta IL1B NA unknown NA drugbank abt-981 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-1 beta IL1B Successful target unknown NA TTD , DGIDB celastrol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] preclinical interleukin-1 beta IL1B Successful target unknown 0.43 TTD , DGIDB donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-1 beta IL1B NA inhibitor,inducer NA drugbank canakinumab biotech Rheumatoid Arthritis, Systemic Juvenile[MeSHID:C565798],Muckle-Wells Syndrome[MeSHID:D056587],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vasculitis[MeSHID:D014657],Urticaria[MeSHID:D014581],Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational interleukin-1 beta IL1B Successful target binder,inhibitor 10.32 TTD , drugbank , DGIDB minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational interleukin-1 beta IL1B NA modulator NA drugbank cdp-484 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] discontinued in phase 1/2 interleukin-1 beta IL1B Successful target unknown NA TTD xoma 052 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 interleukin-1 beta IL1B Successful target unknown NA TTD , DGIDB foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved interleukin-1 beta IL1B NA agonist NA drugbank gevokizumab biotech NA investigational interleukin-1 beta IL1B NA unknown 3.44 drugbank , DGIDB cyt-013-il1bqb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] phase 1 interleukin-1 beta IL1B Successful target unknown NA TTD , DGIDB vp025 small molecule Disease[MeSHID:D004194] investigational interleukin-1 beta IL1B NA unknown NA drugbank ly-2189102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 interleukin-1 beta IL1B Successful target unknown NA TTD , DGIDB diacerein NA Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] phase 4 interleukin-1 beta IL1B Successful target unknown 0.38 TTD , DGIDB vx-702 small molecule Coronary Arteriosclerosis[MeSHID:D003324],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigational interleukin-1 beta IL1B NA unknown NA drugbank dvd-ig NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative interleukin-1 beta IL1B Successful target unknown NA TTD canakinumab biotech Rheumatoid Arthritis, Systemic Juvenile[MeSHID:C565798],Muckle-Wells Syndrome[MeSHID:D056587],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vasculitis[MeSHID:D014657],Urticaria[MeSHID:D014581],Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational interleukin-1 beta IL1B Successful target binder,antibody 10.32 TTD , drugbank , DGIDB ac-201 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-1 beta IL1B Successful target unknown 0.38 TTD , DGIDB canakinumab biotech Rheumatoid Arthritis, Systemic Juvenile[MeSHID:C565798],Muckle-Wells Syndrome[MeSHID:D056587],Juvenile arthritis[MeSHID:D001171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vasculitis[MeSHID:D014657],Urticaria[MeSHID:D014581],Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational interleukin-1 beta IL1B Successful target binder 10.32 TTD , drugbank , DGIDB andrographolide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dysentery, Bacillary[MeSHID:D004405] investigational interleukin-1 beta IL1B NA unknown NA drugbank dilmapimod small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Nerve Tissue[MeSHID:D009417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] investigational interleukin-1 beta IL1B NA unknown NA drugbank talmapimod small molecule Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146] investigational interleukin-1 beta IL1B NA unknown NA drugbank glucosamine NA Arthralgia[MeSHID:D018771],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-1 beta IL1B Successful target unknown 1.72 TTD , DGIDB rilonacept biotech Gout[MeSHID:D006073],Voting[MeSHID:D011057],Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved,investigational interleukin-1 beta IL1B Successful target binder,inhibitor 3.44 TTD , drugbank , DGIDB gallium nitrate small molecule Hypercalcemia[MeSHID:D006934],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-1 beta IL1B Successful target antagonist NA TTD , drugbank , DGIDB vx-765 small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational interleukin-1 beta IL1B NA unknown NA drugbank tt-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 interleukin-1 beta IL1B Successful target unknown 3.44 TTD , DGIDB anakinra NA Rheumatoid Arthritis[MeSHID:D001172],Chronic Infantile Neurological, Cutaneous, and Articular Syndrome[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin 1 receptor type 1 IL1R1 Successful target antagonist 17.24 TTD , DGIDB oms-103hp small molecule Pain[MeSHID:D010146],Disease[MeSHID:D004194] investigational interleukin-1 receptor type 1 IL1R1 NA unknown NA drugbank sd118 small molecule Neuralgia[MeSHID:D009437] investigational interleukin-1 receptor type 1 IL1R1 NA unknown NA drugbank anakinra biotech Rheumatoid Arthritis[MeSHID:D001172],Chronic Infantile Neurological, Cutaneous, and Articular Syndrome[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved interleukin-1 receptor type 1 IL1R1 NA antagonist 17.24 drugbank , DGIDB anakinra biotech Rheumatoid Arthritis[MeSHID:D001172],Chronic Infantile Neurological, Cutaneous, and Articular Syndrome[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-1 receptor type 1 IL1R1 NA antagonist 17.24 drugbank , DGIDB anakinra NA Rheumatoid Arthritis[MeSHID:D001172],Chronic Infantile Neurological, Cutaneous, and Articular Syndrome[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved interleukin 1 receptor type 1 IL1R1 Successful target unknown 17.24 TTD , DGIDB anakinra NA Rheumatoid Arthritis[MeSHID:D001172],Chronic Infantile Neurological, Cutaneous, and Articular Syndrome[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved interleukin 1 receptor type 1 IL1R1 Successful target antagonist 17.24 TTD , DGIDB anakinra NA Rheumatoid Arthritis[MeSHID:D001172],Chronic Infantile Neurological, Cutaneous, and Articular Syndrome[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin 1 receptor type 1 IL1R1 Successful target unknown 17.24 TTD , DGIDB foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved interleukin-1 receptor type 1 IL1R1 NA agonist NA drugbank gsk-1827771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 interleukin 1 receptor type 2 IL1R2 Clinical trial target unknown NA TTD , DGIDB amg 108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 interleukin 1 receptor type 2 IL1R2 Clinical trial target unknown NA TTD bi-655130 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pustulosis of Palms and Soles[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 2 il-1 receptor-like 2 IL1RL2 Clinical trial target unknown NA TTD rilonacept biotech Gout[MeSHID:D006073],Voting[MeSHID:D011057],Cryopyrin-Associated Periodic Syndromes[MeSHID:D056587],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved,investigational interleukin-1 receptor antagonist protein IL1RN NA binder NA drugbank tapinarof small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational interleukin-2 IL2 NA unknown NA drugbank tg-1024 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 interleukin-2 IL2 Successful target unknown NA TTD vlts-587 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] discontinued in phase 2 interleukin-2 IL2 Successful target unknown NA TTD biwb-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 2 interleukin-2 IL2 Successful target unknown NA TTD leuvectin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB n(2)-carbamimidoyl-n-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1h-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-d-leucinamide small molecule NA experimental interleukin-2 IL2 NA unknown NA drugbank pmi-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177] discontinued in phase 3 interleukin-2 IL2 Successful target unknown NA TTD 3-mercapto-1-(1,3,4,9-tetrahydro-b-carbolin-2-yl)-propan-1-one small molecule NA experimental interleukin-2 IL2 NA unknown NA drugbank bnz-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410], Large Granular Lymphocytic[MeSHID:D054066] phase 2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB l19-il-2 fusion protein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB il-2 antibody (anti-tumor) NA NA investigative interleukin-2 IL2 Successful target unknown NA TTD keyhole limpet hemocyanin biotech Neoplasms[MeSHID:D009369],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-2 IL2 NA unknown NA drugbank il-2/cd40l-expressing leukemia vaccine NA leukemia[MeSHID:D007938],Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB vpm-4-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Structure of ventral posteromedial nucleus of thalamus[MeSHID:D020651],Malignant neoplasm of prostate[MeSHID:D011471] preclinical interleukin-2 IL2 Successful target unknown NA TTD , DGIDB human interleukin-2 NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB air-insulin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Air (substance)[MeSHID:D000388] phase 3 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB thymoctonan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] phase 2 interleukin-2 IL2 Successful target unknown 1.99 TTD , DGIDB tg-2001 NA NA investigative interleukin-2 IL2 Successful target unknown NA TTD sp2456 small molecule NA experimental,investigative interleukin-2 IL2 Successful target unknown NA TTD , drugbank cefazolin small molecule Operative Surgical Procedures[MeSHID:D013514],Stomach[MeSHID:D013270],Bacterial Infections[MeSHID:D001424],Blood[MeSHID:D001769],Skin Diseases, Bacterial[MeSHID:D017192],Heart Valves[MeSHID:D006351],Lung[MeSHID:D008168],Urinary tract[MeSHID:D014551],Bone Tissue[MeSHID:D001842],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-2 IL2 NA inhibitor NA drugbank sar444245 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 interleukin-2 IL2 Successful target unknown NA TTD asp9801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 interleukin-2 IL2 Successful target unknown NA TTD roquinimex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1 interleukin-2 IL2 Successful target unknown NA TTD il-2/gene-modified lymphocytes NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphocyte[MeSHID:D008214],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB nuleusin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 3 interleukin-2 IL2 Successful target unknown NA TTD il-2 xl NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB 2-[2-(2-cyclohexyl-2-guanidino-acetylamino)-acetylamino]-n-(3-mercapto-propyl)-propionamide small molecule NA experimental interleukin-2 IL2 NA unknown NA drugbank tg4010 biotech Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational interleukin-2 IL2 NA unknown NA drugbank (1h-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid small molecule NA experimental interleukin-2 IL2 NA unknown NA drugbank methyl (2s)-2-[[2-[(3r)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate small molecule NA experimental interleukin-2 IL2 NA unknown NA drugbank medusa il-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB tg-4010 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Bipolar Disorder[MeSHID:D001714],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB vcl-1m01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB sp4160 small molecule NA experimental,investigative interleukin-2 IL2 Successful target unknown NA TTD , drugbank interleukin-2, roussel uclaf NA NA investigative interleukin-2 IL2 Successful target unknown NA TTD aldesleukin NA Renal Cell Carcinoma[MeSHID:D002292],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-2 IL2 Successful target unknown 0.5 TTD , DGIDB pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-2 IL2 NA inhibitor NA drugbank carboxyamidotriazole orotate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB girentuximab biotech Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of gallbladder[MeSHID:D005706] investigational interleukin-2 IL2 NA unknown NA drugbank daclizumab NA Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved interleukin-2 IL2 Successful target unknown 0.5 TTD , DGIDB tg-1031 NA NA investigative interleukin-2 IL2 Successful target unknown NA TTD apn-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroblastoma[MeSHID:D009447],melanoma[MeSHID:D008545] phase 2 interleukin-2 IL2 Successful target unknown NA TTD , DGIDB nn-8226 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174]VAJO NEUROHEPATOPATHY[MeSHID:C538344],Psoriasis[MeSHID:D011565] phase 2 interleukin-20 IL20 Clinical trial target unknown NA TTD , DGIDB nn-8828 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174]VAJO NEUROHEPATOPATHY[MeSHID:C538344],Diabetes, Autoimmune[MeSHID:D003922] phase 1 interleukin-21 IL21 Clinical trial target unknown 31.83 TTD , DGIDB il-21 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-21 IL21 Clinical trial target unknown 15.91 TTD , DGIDB ab-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] phase 2 interleukin 21 receptor IL21R Clinical trial target unknown NA TTD , DGIDB atr-107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 1 interleukin 21 receptor IL21R Clinical trial target unknown NA TTD , DGIDB amg 256 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 interleukin 21 receptor IL21R Clinical trial target unknown NA TTD ilv-095 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 interleukin-22 IL22 Clinical trial target unknown NA TTD , DGIDB fezakinumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 interleukin-22 IL22 Clinical trial target unknown 190.95 TTD , DGIDB fezakinumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 interleukin-22 IL22 Clinical trial target inhibitor 190.95 TTD , DGIDB rg7880 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Diabetic Foot[MeSHID:D017719] phase 2 interleukin-22 IL22 Clinical trial target unknown NA TTD , DGIDB guselkumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565] approved,investigational interleukin-23 subunit alpha IL23A NA blocker,inhibitor 31.83 drugbank , DGIDB briakinumab biotech Disease[MeSHID:D004194],Crohn Disease[MeSHID:D003424],Multiple Sclerosis[MeSHID:D009103],Rheumatoid Arthritis[MeSHID:D001172],Autoimmune Diseases[MeSHID:D001327],Psoriasis[MeSHID:D011565] investigational interleukin-23 subunit alpha IL23A NA inhibitor 7.07 drugbank , DGIDB cnto-1959 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Asthma[MeSHID:D001249] approved interleukin-23 IL23A Successful target unknown 31.83 TTD , DGIDB mrna-2752 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 interleukin-23 IL23A Successful target unknown NA TTD tildrakizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-23 IL23A Successful target antagonist 10.61 TTD , drugbank , DGIDB briakinumab biotech Disease[MeSHID:D004194],Crohn Disease[MeSHID:D003424],Multiple Sclerosis[MeSHID:D009103],Rheumatoid Arthritis[MeSHID:D001172],Autoimmune Diseases[MeSHID:D001327],Psoriasis[MeSHID:D011565] investigational interleukin-23 subunit alpha IL23A NA unknown 7.07 drugbank , DGIDB cnt0-1959 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-23 IL23A Successful target unknown NA TTD , DGIDB amg-139 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 1 interleukin-23 IL23A Successful target unknown 10.61 TTD , DGIDB ustekinumab biotech Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Psoriasis[MeSHID:D011565],Crohn Disease[MeSHID:D003424],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Malaria[MeSHID:D008288] approved,investigational interleukin-23 IL23A Successful target inhibitor 6.37 TTD , drugbank , DGIDB bi 655066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Ankylosing spondylitis[MeSHID:D013167],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Crohn Disease[MeSHID:D003424] phase 3 interleukin-23 IL23A Successful target unknown NA TTD , DGIDB risankizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis, Psoriatic[MeSHID:D015535] approved,investigational interleukin-23 IL23A Successful target inhibitor 10.61 TTD , drugbank , DGIDB mk-3222 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Hairy Cell Leukemia[MeSHID:D007943] phase 3 interleukin-23 IL23A Successful target unknown 10.61 TTD , DGIDB tildrakizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-23 IL23A Successful target antagonist,inhibitor 10.61 TTD , drugbank , DGIDB anti-il-23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] phase 3 interleukin 23 receptor IL23R Clinical trial target unknown NA TTD , DGIDB fm-303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] investigative interleukin 23 receptor IL23R Clinical trial target unknown NA TTD adc-1012 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative interleukin 23 receptor IL23R Clinical trial target unknown NA TTD apg-2305 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative interleukin 23 receptor IL23R Clinical trial target unknown NA TTD ingn-241 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 interleukin-24 IL24 Clinical trial target unknown NA TTD , DGIDB alx-0761 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 interleukin-25 IL25 Clinical trial target unknown 15.91 TTD , DGIDB rg6292 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 interleukin 2 receptor alpha IL2RA Successful target unknown NA TTD cht-25 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689] phase 1 interleukin 2 receptor alpha IL2RA Successful target unknown NA TTD , DGIDB denileukin diftitox biotech Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Non-Small Cell Lung Carcinoma[MeSHID:D002289],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-2 receptor subunit alpha IL2RA NA binder 4.39 drugbank , DGIDB basiliximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved interleukin 2 receptor alpha IL2RA Successful target antibody 8.05 TTD , DGIDB denileukin diftitox biotech Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Non-Small Cell Lung Carcinoma[MeSHID:D002289],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-2 receptor subunit alpha IL2RA NA binder NA drugbank , DGIDB inolimomab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Graft Rejection[MeSHID:D006084] investigational interleukin-2 receptor subunit alpha IL2RA NA antibody 4.39 drugbank , DGIDB daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn interleukin-2 receptor subunit alpha IL2RA NA antibody 6.04 drugbank , DGIDB inolimomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Graft Rejection[MeSHID:D006084] phase 3 interleukin 2 receptor alpha IL2RA Successful target unknown 4.39 TTD , DGIDB basiliximab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved,investigational interleukin-2 receptor subunit alpha IL2RA NA antibody 8.05 drugbank , DGIDB aldesleukin biotech Renal Cell Carcinoma[MeSHID:D002292],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-2 receptor subunit alpha IL2RA NA agonist,modulator 5.49 drugbank , DGIDB rft-5.dga NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 interleukin 2 receptor alpha IL2RA Successful target unknown NA TTD , DGIDB basiliximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved interleukin 2 receptor alpha IL2RA Successful target inhibitor 8.05 TTD , DGIDB lmb-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 interleukin 2 receptor alpha IL2RA Successful target unknown 4.39 TTD , DGIDB inolimomab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Graft Rejection[MeSHID:D006084] investigational interleukin-2 receptor subunit alpha IL2RA NA antibody,antagonist 4.39 drugbank , DGIDB inolimomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Graft Rejection[MeSHID:D006084] phase 3 interleukin 2 receptor alpha IL2RA Successful target antagonist 4.39 TTD , DGIDB daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn interleukin-2 receptor subunit alpha IL2RA NA antibody,inhibitor 6.04 drugbank , DGIDB basiliximab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved,investigational interleukin-2 receptor subunit alpha IL2RA NA antibody,inhibitor 8.05 drugbank , DGIDB basiliximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved interleukin 2 receptor alpha IL2RA Successful target unknown 8.05 TTD , DGIDB denileukin diftitox biotech Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Non-Small Cell Lung Carcinoma[MeSHID:D002289],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-2 receptor subunit beta IL2RB NA agonist NA drugbank , DGIDB aftvac NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 interleukin 2 receptor beta IL2RB Clinical trial target unknown NA TTD , DGIDB basiliximab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved,investigational interleukin-2 receptor subunit beta IL2RB NA antibody,inhibitor 24.75 drugbank , DGIDB dab-486-il-2 NA NA investigative interleukin 2 receptor beta IL2RB Clinical trial target unknown NA TTD nktr 214 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Colorectal Cancer[MeSHID:D015179],Sarcoma[MeSHID:D012509] phase 3 interleukin 2 receptor beta IL2RB Clinical trial target unknown NA TTD , DGIDB daclizumab biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigational,withdrawn interleukin-2 receptor subunit beta IL2RB NA antibody,inhibitor 18.56 drugbank , DGIDB aldesleukin biotech Renal Cell Carcinoma[MeSHID:D002292],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-2 receptor subunit beta IL2RB NA agonist,modulator 23.87 drugbank , DGIDB leukocyte interleukin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Leukocytes[MeSHID:D007962],HIV Infections[MeSHID:D015658] phase 1 interleukin 2 receptor beta IL2RB Clinical trial target unknown NA TTD , DGIDB denileukin diftitox biotech Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Non-Small Cell Lung Carcinoma[MeSHID:D002289],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-2 receptor subunit beta IL2RB NA agonist 15.91 drugbank , DGIDB nktr-214 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 interleukin 2 receptor beta IL2RB Clinical trial target unknown NA TTD denileukin diftitox biotech Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Non-Small Cell Lung Carcinoma[MeSHID:D002289],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytokine receptor common subunit gamma IL2RG NA unknown NA drugbank , DGIDB aldesleukin biotech Renal Cell Carcinoma[MeSHID:D002292],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytokine receptor common subunit gamma IL2RG NA agonist 25.46 drugbank , DGIDB denileukin diftitox biotech Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Non-Small Cell Lung Carcinoma[MeSHID:D002289],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cytokine receptor common subunit gamma IL2RG NA unknown 12.73 drugbank , DGIDB resatorvid small molecule Sepsis[MeSHID:D018805],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cytokine receptor common subunit gamma IL2RG NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational interleukin-3 IL3 NA binder NA drugbank polaprezinc small molecule Peptic Ulcer[MeSHID:D010437],Dyspepsia[MeSHID:D004415],Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcer[MeSHID:D014456] experimental interleukin-3 IL3 NA inhibitor NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental interleukin-3 IL3 NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational interleukin-3 IL3 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational interleukin-3 IL3 NA unknown NA drugbank amlexanox small molecule Paste substance[MeSHID:D009824],Aphthous Stomatitis[MeSHID:D013281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] approved,investigational,withdrawn interleukin-3 IL3 NA antagonist NA drugbank kpl-716 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Prurigo[MeSHID:D011536] phase 1 interleukin-31 IL31 Clinical trial target unknown NA TTD , DGIDB nemolizumab NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 3 interleukin 31 receptor IL31RA Clinical trial target antibody 63.65 TTD , DGIDB amg 282 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 interleukin-33 IL33 Clinical trial target unknown NA TTD , DGIDB mrna-2752 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 interleukin-36 gamma IL36G Clinical trial target unknown NA TTD tildrakizumab NA Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-37 IL37 Successful target unknown 31.83 TTD , DGIDB car-t cells targeting cd123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] preclinical interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB autologous anti-cd 123 car tcr/4-1bb-expressing t-lymphocytes NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphocyte[MeSHID:D008214],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 0 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB ucart123 NA Plasmacytoid Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB cart123 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Cells[MeSHID:D002477] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB sar440234 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD apvo436 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD cart-123 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Cells[MeSHID:D002477] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB jnj-63709178 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB cd123car-41bb-cd3zeta-egfrt-expressing t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB cd123/cll1 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 2/3 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB flotetuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute biphenotypic leukemia[MeSHID:D015456],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] phase 2 interleukin 3 receptor alpha IL3RA Successful target unknown 12.73 TTD , DGIDB cart-123 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Cells[MeSHID:D002477] phase 1/2 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB cd123-specific gene-engineered t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1/2 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB cart-123 cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1/2 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB 4scar19 and 4scar123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB tagraxofusp NA Plasmacytoid Dendritic Cells[MeSHID:D003713],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Biological Markers[MeSHID:D015415],Intention - mental process[MeSHID:D033182],Lymph[MeSHID:D008196],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] approved interleukin 3 receptor alpha IL3RA Successful target unknown 6.37 TTD , DGIDB anti-cd123 car-t treatment NA NA phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB mgd006 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphoma[MeSHID:D008223] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown 12.73 TTD , DGIDB im23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB talacotuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 interleukin 3 receptor alpha IL3RA Successful target unknown 6.37 TTD , DGIDB anti-cd123 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB cart-123 cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB sargramostim biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-3 receptor subunit alpha IL3RA NA agonist NA drugbank anti-cd123-car-transduced t cells NA leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB cd123-cd33 ccar NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD csl-362-aml NA leukemia[MeSHID:D007938],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 interleukin 3 receptor alpha IL3RA Successful target unknown NA TTD , DGIDB mb-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Acute kidney injury[MeSHID:D058186] phase 2 interleukin 3 receptor alpha IL3RA Successful target unknown 12.73 TTD , DGIDB tagraxofusp biotech Plasmacytoid Dendritic Cells[MeSHID:D003713],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Biological Markers[MeSHID:D015415],Intention - mental process[MeSHID:D033182],Lymph[MeSHID:D008196],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] approved,investigational interleukin-3 receptor subunit alpha IL3RA NA binder 6.37 drugbank , DGIDB pascolizumab biotech Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 interleukin-4 IL4 Clinical trial target inhibitor 47.74 TTD , drugbank , DGIDB sar-156597 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pulmonary Fibrosis[MeSHID:D011658] phase 2 interleukin-4 IL4 Clinical trial target unknown 5.3 TTD , DGIDB tepoxalin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 interleukin-4 IL4 Clinical trial target unknown 7.96 TTD , DGIDB pascolizumab biotech Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 interleukin-4 IL4 Clinical trial target unknown 47.74 TTD , drugbank , DGIDB pegylated pitrakinra NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249],Allergic Reaction[MeSHID:D006967] phase 2 interleukin-4 IL4 Clinical trial target unknown NA TTD , DGIDB il-4r NA NA phase 2 interleukin-4 IL4 Clinical trial target unknown NA TTD , DGIDB romilkimab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] phase 2 interleukin-4 IL4 Clinical trial target unknown NA TTD vinylglycine small molecule NA experimental l-amino-acid oxidase IL4I1 NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved l-amino-acid oxidase IL4I1 NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved l-amino-acid oxidase IL4I1 NA unknown NA drugbank anthranilic acid small molecule NA experimental l-amino-acid oxidase IL4I1 NA unknown NA drugbank dupilumab NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Status Asthmaticus[MeSHID:D013224],Dermatitis, Atopic[MeSHID:D003876],Nasal Polyps[MeSHID:D009298],eosinophil[MeSHID:D004804],Phenotype[MeSHID:D010641],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin 4 receptor alpha IL4R Successful target antagonist 50.92 TTD , DGIDB dupilumab biotech Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Status Asthmaticus[MeSHID:D013224],Dermatitis, Atopic[MeSHID:D003876],Nasal Polyps[MeSHID:D009298],eosinophil[MeSHID:D004804],Phenotype[MeSHID:D010641],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-4 receptor subunit alpha IL4R NA antagonist 50.92 drugbank , DGIDB aer001 small molecule Asthma[MeSHID:D001249] investigational interleukin-4 receptor subunit alpha IL4R NA unknown NA drugbank prx-321 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 interleukin 4 receptor alpha IL4R Successful target unknown 25.46 TTD , DGIDB sar-156597 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Pulmonary Fibrosis[MeSHID:D011658] phase 2 interleukin 4 receptor alpha IL4R Successful target unknown 4.24 TTD , DGIDB dupilumab NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Status Asthmaticus[MeSHID:D013224],Dermatitis, Atopic[MeSHID:D003876],Nasal Polyps[MeSHID:D009298],eosinophil[MeSHID:D004804],Phenotype[MeSHID:D010641],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin 4 receptor alpha IL4R Successful target antibody 50.92 TTD , DGIDB altrakincept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 interleukin 4 receptor alpha IL4R Successful target unknown NA TTD , DGIDB dupilumab biotech Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Status Asthmaticus[MeSHID:D013224],Dermatitis, Atopic[MeSHID:D003876],Nasal Polyps[MeSHID:D009298],eosinophil[MeSHID:D004804],Phenotype[MeSHID:D010641],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational interleukin-4 receptor subunit alpha IL4R NA antagonist,antibody 50.92 drugbank , DGIDB amg 317 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 interleukin 4 receptor alpha IL4R Successful target unknown NA TTD dupilumab NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Status Asthmaticus[MeSHID:D013224],Dermatitis, Atopic[MeSHID:D003876],Nasal Polyps[MeSHID:D009298],eosinophil[MeSHID:D004804],Phenotype[MeSHID:D010641],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin 4 receptor alpha IL4R Successful target unknown 50.92 TTD , DGIDB apg-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative interleukin 4 receptor alpha IL4R Successful target unknown NA TTD sar231893 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Asthma[MeSHID:D001249] phase 3 interleukin 4 receptor alpha IL4R Successful target unknown 50.92 TTD , DGIDB aerovant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2a interleukin 4 receptor alpha IL4R Successful target unknown NA TTD , DGIDB prs-060 NA Prieto X-linked mental retardation syndrome[MeSHID:C535274],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative interleukin 4 receptor alpha IL4R Successful target unknown NA TTD reslizumab biotech Maintenance[MeSHID:D008283],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],eosinophil[MeSHID:D004804],Phenotype[MeSHID:D010641],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Eosinophilia[MeSHID:D011657] approved,investigational interleukin-5 IL5 Successful target antagonist,inhibitor 27.28 TTD , drugbank , DGIDB sophoricoside NA NA investigative interleukin-5 IL5 Successful target unknown NA TTD mepolizumab biotech Pulmonary Eosinophilia[MeSHID:D011657],Maintenance[MeSHID:D008283],Eosinophilia[MeSHID:D004802],Neoplasm Metastasis[MeSHID:D009362],Systemic Vasculitis[MeSHID:D056647],Hypereosinophilic syndrome[MeSHID:D017681],eosinophil[MeSHID:D004804],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved,investigational interleukin-5 IL5 Successful target antagonist,inhibitor 45.47 TTD , drugbank , DGIDB reslizumab biotech Maintenance[MeSHID:D008283],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],eosinophil[MeSHID:D004804],Phenotype[MeSHID:D010641],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Eosinophilia[MeSHID:D011657] approved,investigational interleukin-5 IL5 Successful target antagonist 27.28 TTD , drugbank , DGIDB mepolizumab biotech Pulmonary Eosinophilia[MeSHID:D011657],Maintenance[MeSHID:D008283],Eosinophilia[MeSHID:D004802],Neoplasm Metastasis[MeSHID:D009362],Systemic Vasculitis[MeSHID:D056647],Hypereosinophilic syndrome[MeSHID:D017681],eosinophil[MeSHID:D004804],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved,investigational interleukin-5 IL5 Successful target antagonist 45.47 TTD , drugbank , DGIDB pranlukast small molecule Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational interleukin-5 IL5 NA antagonist NA drugbank benralizumab NA Maintenance[MeSHID:D008283],Serum[MeSHID:D044967],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Phenotype[MeSHID:D010641],eosinophil[MeSHID:D004804],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved interleukin-5 IL5 Successful target unknown 9.09 TTD , DGIDB benralizumab biotech Maintenance[MeSHID:D008283],Serum[MeSHID:D044967],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Phenotype[MeSHID:D010641],eosinophil[MeSHID:D004804],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational interleukin-5 receptor subunit alpha IL5RA NA antibody,inhibitor 222.78 drugbank , DGIDB ym90709 NA NA investigative interleukin 5 receptor alpha IL5RA Successful target unknown NA TTD benralizumab biotech Maintenance[MeSHID:D008283],Serum[MeSHID:D044967],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Phenotype[MeSHID:D010641],eosinophil[MeSHID:D004804],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational interleukin-5 receptor subunit alpha IL5RA NA antibody 222.78 drugbank , DGIDB benralizumab NA Maintenance[MeSHID:D008283],Serum[MeSHID:D044967],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Phenotype[MeSHID:D010641],eosinophil[MeSHID:D004804],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved interleukin 5 receptor alpha IL5RA Successful target unknown 222.78 TTD , DGIDB benralizumab NA Maintenance[MeSHID:D008283],Serum[MeSHID:D044967],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Phenotype[MeSHID:D010641],eosinophil[MeSHID:D004804],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved interleukin 5 receptor alpha IL5RA Successful target inhibitor 222.78 TTD , DGIDB benralizumab NA Maintenance[MeSHID:D008283],Serum[MeSHID:D044967],Eosinophilia[MeSHID:D004802],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Phenotype[MeSHID:D010641],eosinophil[MeSHID:D004804],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved interleukin 5 receptor alpha IL5RA Successful target antibody 222.78 TTD , DGIDB clazakizumab NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-6 IL6 Successful target inhibitor 7.64 TTD , DGIDB ginseng biotech NA investigational,nutraceutical interleukin-6 IL6 NA antagonist NA drugbank clazakizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-6 IL6 Successful target unknown 7.64 TTD , DGIDB atiprimod small molecule Rheumatoid Arthritis[MeSHID:D001172],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational interleukin-6 IL6 NA unknown NA drugbank olokizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] investigational,phase 3 interleukin-6 IL6 Successful target antagonist 10.18 TTD , drugbank , DGIDB pf-04236921 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 interleukin-6 IL6 Successful target unknown 2.55 TTD , DGIDB medi5117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 interleukin-6 IL6 Successful target unknown 2.55 TTD , DGIDB pf-04236921 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 interleukin-6 IL6 Successful target inhibitor 2.55 TTD , DGIDB ald-518 NA Arthritis, Psoriatic[MeSHID:D015535],Adrenoleukodystrophy[MeSHID:D000326],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-6 IL6 Successful target unknown 7.64 TTD , DGIDB vx-702 small molecule Coronary Arteriosclerosis[MeSHID:D003324],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigational interleukin-6 IL6 NA unknown NA drugbank dilmapimod small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Nerve Tissue[MeSHID:D009417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] investigational interleukin-6 IL6 NA unknown NA drugbank siltuximab biotech Multi-centric Castleman's Disease[MeSHID:C537372],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194] approved,investigational interleukin-6 IL6 Successful target antagonist,antibody 10.18 TTD , drugbank , DGIDB c326 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 1 interleukin-6 IL6 Successful target unknown NA TTD , DGIDB cdp-6038 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-6 IL6 Successful target unknown 10.18 TTD , DGIDB siltuximab biotech Multi-centric Castleman's Disease[MeSHID:C537372],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Anemia[MeSHID:D000740] approved,investigational interleukin-6 IL6 Successful target antagonist,antibody 10.18 TTD , drugbank , DGIDB sirukumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] phase 3 interleukin-6 IL6 Successful target inhibitor 2.55 TTD , DGIDB sirukumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Giant Cell Arteritis[MeSHID:D013700],Lupus Erythematosus, Cutaneous[MeSHID:D008178],Major Depressive Disorder[MeSHID:D003865],Rheumatoid Arthritis[MeSHID:D001172] phase 3 interleukin-6 IL6 Successful target inhibitor 2.55 TTD , DGIDB clazakizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 2 interleukin-6 IL6 Successful target inhibitor 7.64 TTD , DGIDB olokizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational,phase 3 interleukin-6 IL6 Successful target antagonist 10.18 TTD , drugbank , DGIDB siltuximab biotech Multi-centric Castleman's Disease[MeSHID:C537372],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194] approved,investigational interleukin-6 IL6 Successful target antagonist,antibody,inhibitor 10.18 TTD , drugbank , DGIDB andrographolide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dysentery, Bacillary[MeSHID:D004405] investigational interleukin-6 IL6 NA unknown NA drugbank crx-139 small molecule Rheumatoid Arthritis[MeSHID:D001172] investigational interleukin-6 IL6 NA unknown NA drugbank clazakizumab NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 interleukin-6 IL6 Successful target unknown 7.64 TTD , DGIDB sirukumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Giant Cell Arteritis[MeSHID:D013700],Lupus Erythematosus, Cutaneous[MeSHID:D008178],Major Depressive Disorder[MeSHID:D003865],Rheumatoid Arthritis[MeSHID:D001172] phase 3 interleukin-6 IL6 Successful target unknown 2.55 TTD , DGIDB foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved interleukin-6 IL6 NA agonist NA drugbank binimetinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational interleukin-6 IL6 NA unknown NA drugbank polaprezinc small molecule Peptic Ulcer[MeSHID:D010437],Dyspepsia[MeSHID:D004415],Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcer[MeSHID:D014456] experimental interleukin-6 IL6 NA inhibitor NA drugbank olokizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] investigational,phase 3 interleukin-6 IL6 Successful target antagonist,inhibitor 10.18 TTD , drugbank , DGIDB sirukumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] phase 3 interleukin-6 IL6 Successful target unknown 2.55 TTD , DGIDB gerilimzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 interleukin-6 IL6 Successful target unknown NA TTD , DGIDB foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved interleukin-6 IL6 NA agonist NA drugbank tapinarof small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational interleukin-6 IL6 NA unknown NA drugbank olokizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational,phase 3 interleukin-6 IL6 Successful target antagonist,inhibitor 10.18 TTD , drugbank , DGIDB op-r003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 interleukin-6 IL6 Successful target unknown NA TTD , DGIDB ysil6 small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 interleukin-6 IL6 Successful target unknown NA TTD , drugbank , DGIDB siltuximab biotech Multi-centric Castleman's Disease[MeSHID:C537372],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Anemia[MeSHID:D000740] approved,investigational interleukin-6 IL6 Successful target antagonist,antibody,inhibitor 10.18 TTD , drugbank , DGIDB tocilizumab biotech Rheumatoid Arthritis, Systemic Juvenile[MeSHID:C565798],Rheumatoid Arthritis[MeSHID:D001172],Giant Cell Arteritis[MeSHID:D013700],Juvenile arthritis[MeSHID:D001171],Syndrome[MeSHID:D013577],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved interleukin-6 receptor subunit alpha IL6R NA inhibitor,antibody 17.68 drugbank , DGIDB satralizumab biotech Neuromyelitis Optica[MeSHID:D009471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-6 receptor subunit alpha IL6R NA binder,antibody NA drugbank sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational interleukin-6 receptor subunit alpha IL6R NA antagonist,antibody 56.58 drugbank , DGIDB sarilumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] approved,investigational interleukin-6 receptor subunit alpha IL6R NA antagonist,antibody 56.58 drugbank , DGIDB tocilizumab biotech Rheumatoid Arthritis, Systemic Juvenile[MeSHID:C565798],Rheumatoid Arthritis[MeSHID:D001172],Giant Cell Arteritis[MeSHID:D013700],Juvenile arthritis[MeSHID:D001171],Syndrome[MeSHID:D013577],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved interleukin-6 receptor subunit alpha IL6R NA inhibitor,antibody 17.68 drugbank , DGIDB gsk2618960 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859],Multiple Sclerosis[MeSHID:D009103] phase 1 interleukin-7 IL7 Clinical trial target unknown NA TTD , DGIDB asp9801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 interleukin-7 IL7 Clinical trial target unknown NA TTD pf-06342674 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 1 interleukin 7 receptor alpha IL7R Clinical trial target unknown NA TTD , DGIDB cyt 99007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acquired Immunodeficiency Syndrome[MeSHID:D000163] phase 2 interleukin 7 receptor alpha IL7R Clinical trial target unknown NA TTD , DGIDB bnz-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410], Large Granular Lymphocytic[MeSHID:D054066] phase 2 interleukin-9 IL9 Clinical trial target unknown NA TTD , DGIDB medi-528 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 interleukin-9 IL9 Clinical trial target unknown 190.95 TTD , DGIDB bay 1905254 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ig-like domain-containing receptor 2 ILDR2 Clinical trial target unknown NA TTD pmid21823616c22 NA NA investigative integrin-linked protein kinase 1 ILK Patented-recorded target unknown NA TTD us8754233, 4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2h-pyrazol-3-ylamine NA NA patented integrin-linked protein kinase 1 ILK Patented-recorded target unknown NA TTD , DGIDB us8754233, (4-benzothiazol-2-yl-1h-pyrazol-3-yl)-[2-(1h-imidazol-4-yl)-ethyl]-amine NA NA patented integrin-linked protein kinase 1 ILK Patented-recorded target unknown NA TTD , DGIDB us8754233, 2-(3-amino-1h-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide NA NA patented integrin-linked protein kinase 1 ILK Patented-recorded target unknown NA TTD , DGIDB mst-400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative integrin-linked protein kinase 1 ILK Patented-recorded target unknown NA TTD lithium carbonate small molecule Bipolar Disorder[MeSHID:D001714],Mood (psychological function)[MeSHID:D000339],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inositol monophosphatase 1 IMPA1 NA inhibitor 10.61 drugbank , DGIDB lithium cation small molecule Bipolar Disorder[MeSHID:D001714],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Depressive disorder[MeSHID:D003866] experimental inositol monophosphatase 1 IMPA1 NA inhibitor NA drugbank lithium succinate small molecule NA experimental inositol monophosphatase 1 IMPA1 NA unknown NA drugbank lithium citrate small molecule Bipolar Disorder[MeSHID:D001714],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inositol monophosphatase 1 IMPA1 NA unknown NA drugbank l-myo-inositol-1-phosphate small molecule NA experimental inositol monophosphatase 1 IMPA1 NA unknown NA drugbank l-myo-inositol-1-phosphate NA NA investigative inositol-1(or4)-monophosphatase IMPA2 Literature-reported target unknown NA TTD lithium cation small molecule Bipolar Disorder[MeSHID:D001714],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Depressive disorder[MeSHID:D003866] experimental inositol monophosphatase 2 IMPA2 NA inhibitor NA drugbank lithium succinate small molecule NA experimental inositol monophosphatase 2 IMPA2 NA unknown NA drugbank lithium carbonate small molecule Bipolar Disorder[MeSHID:D001714],Mood (psychological function)[MeSHID:D000339],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inositol monophosphatase 2 IMPA2 NA unknown NA drugbank lithium citrate small molecule Bipolar Disorder[MeSHID:D001714],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inositol monophosphatase 2 IMPA2 NA unknown NA drugbank urea and carbamate bioisostere derivative 10 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mercaptopurine small molecule Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Crohn Disease[MeSHID:D003424] approved inosine-5'-monophosphate dehydrogenase IMPDH1 NA inhibitor 0.53 drugbank , DGIDB merimepodib NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Cancer of Head and Neck[MeSHID:D006258],Malignant neoplasm of breast[MeSHID:D001943] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD tad NA NA investigative inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD ribavirin small molecule Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355],Intention - mental process[MeSHID:D033182],Hepatitis C, Chronic[MeSHID:D019698],Genotype[MeSHID:D005838],Infection[MeSHID:D007239],Relapse[MeSHID:D012008],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target inhibitor 1.35 TTD , drugbank , DGIDB urea and carbamate bioisostere derivative 3 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20100022547c83 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20100022547c86 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB vx-148 small molecule Virus Diseases[MeSHID:D014777],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Autoimmune Diseases[MeSHID:D001327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , drugbank , DGIDB quinolone derivative 1 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB urea and carbamate bioisostere derivative 16 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB urea and carbamate bioisostere derivative 13 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20120264760c83 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20100022547c87 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid small molecule Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA inhibitor 0.8 drugbank , DGIDB pmid28074661-compound-us20120264760c82 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB inosinic acid NA NA investigative inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD pmid28074661-compound-us20100022547c88 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB 6-chloropurine riboside, 5'-monophosphate small molecule NA experimental inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA unknown NA drugbank mycophenolic acid/nucleotide derivative 11 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB carbamide derivative 8 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737],Pemphigus Vulgaris[MeSHID:D010392],Immune System Diseases[MeSHID:D007154] approved,investigational inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA inhibitor,inducer NA drugbank , DGIDB pmid28074661-compound-us20169447134c85 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20120264760c81 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 5 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB tiazofurin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown 6.37 TTD , DGIDB mercaptopurine NA Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Middle East Respiratory Syndrome[MeSHID:D018352] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown 0.53 TTD , DGIDB urea and carbamate bioisostere derivative 7 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20120264760c88 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB taribavirin small molecule Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506] investigational inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA unknown NA drugbank carbamide derivative 10 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB carbamide derivative 11 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB viramidine NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown 6.37 TTD , DGIDB urea and carbamate bioisostere derivative 11 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB carbamide derivative 5 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20100022547c82 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 4 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB urea and carbamate bioisostere derivative 9 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 12 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mercaptopurine small molecule Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Middle East Respiratory Syndrome[MeSHID:D018352] approved inosine-5'-monophosphate dehydrogenase IMPDH1 NA inhibitor 0.53 drugbank , DGIDB carbamide derivative 6 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB urea and carbamate bioisostere derivative 15 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB phenacetin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD mycophenolic acid/nucleotide derivative 3 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB urea and carbamate bioisostere derivative 14 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid small molecule Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA inhibitor NA drugbank , DGIDB merimepodib NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD mercaptopurine NA Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Crohn Disease[MeSHID:D003424] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown 0.53 TTD , DGIDB urea and carbamate bioisostere derivative 5 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA inhibitor,inducer NA drugbank , DGIDB pmid28074661-compound-us20120264760c86 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 1 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-wo2009018344c78 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20120264760c80 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mizoribine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft Rejection[MeSHID:D006084] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown 3.18 TTD , DGIDB urea and carbamate bioisostere derivative 4 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA inhibitor,inducer 1.06 drugbank , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA unknown NA drugbank 6-cl-imp NA NA investigative inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD quinazolinone derivative 1 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 2 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB selenazofurin NA NA investigative inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD pmid28074661-compound-us20100022547c81 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-wo2009018344c79 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20128202889c90 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20120264760c87 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB urea and carbamate bioisostere derivative 6 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 7 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 6 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20158969342c84 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB carbamide derivative 9 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 10 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 9 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737],Pemphigus Vulgaris[MeSHID:D010392],Immune System Diseases[MeSHID:D007154] approved,investigational inosine-5'-monophosphate dehydrogenase 1 IMPDH1 NA inhibitor,inducer 1.06 drugbank , DGIDB ribavirin small molecule Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355],Intention - mental process[MeSHID:D033182],Hepatitis C, Chronic[MeSHID:D019698],Genotype[MeSHID:D005838],Infection[MeSHID:D007239],Relapse[MeSHID:D012008],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target inhibitor 1.35 TTD , drugbank , DGIDB carbamide derivative 7 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB urea and carbamate bioisostere derivative 18 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB quinazolinone derivative 2 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB pmid28074661-compound-us20100022547c80 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB vx-944 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB carbamide derivative 4 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB urea and carbamate bioisostere derivative 2 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB mycophenolic acid/nucleotide derivative 8 NA NA patented inosine-5'-monophosphate dehydrogenase 1 IMPDH1 Successful target unknown NA TTD , DGIDB 1-methoxy-3-(3-(pyridin-4-yl)-1h-indol-6-yl)urea NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD c2-mad NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 3-(pyridin-4-yl)-1h-indol-6-amine NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737],Pemphigus Vulgaris[MeSHID:D010392],Immune System Diseases[MeSHID:D007154] approved,investigational inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target inhibitor NA TTD , drugbank , DGIDB 3-(thiophen-3-yl)-1h-indol-6-amine NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD ethyl 3-(pyridin-4-yl)-1h-indole-6-carboxylate NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 2-methyl-3-(pyridin-4-yl)-1h-indol-6-amine NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD mercaptopurine small molecule Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Middle East Respiratory Syndrome[MeSHID:D018352] approved inosine-5'-monophosphate dehydrogenase IMPDH2 NA inhibitor NA drugbank 1-(3-cyano-1-methyl-1h-indol-6-yl)-3-phenylurea NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 6-phenyl-3-(pyridin-4-yl)-1h-indole NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 2-methyl-3-(pyridin-4-yl)-1h-indole NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 1-methyl-1h-indole-3-carbonitrile NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 3-(furan-3-yl)-1h-indole NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 3-(3-cyano-1h-indol-6-yl)-1-methyl-1-phenylurea NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD mycophenolic acid small molecule Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194] approved inosine-5'-monophosphate dehydrogenase 2 IMPDH2 NA inhibitor NA drugbank , DGIDB 6-bromo-1-methyl-3-(pyridin-4-yl)-1h-indole NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD mycophenolic acid small molecule Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194] approved inosine-5'-monophosphate dehydrogenase 2 IMPDH2 NA inhibitor 0.88 drugbank , DGIDB selenazole-4-carboxyamide-adenine dinucleotide small molecule NA experimental,investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD , drugbank mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target inhibitor NA TTD , drugbank , DGIDB mercaptopurine small molecule Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Crohn Disease[MeSHID:D003424] approved inosine-5'-monophosphate dehydrogenase IMPDH2 NA inhibitor NA drugbank urea and carbamate bioisostere derivative 1 NA NA patented inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD , DGIDB rockout NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD ribavirin small molecule Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355],Intention - mental process[MeSHID:D033182],Hepatitis C, Chronic[MeSHID:D019698],Genotype[MeSHID:D005838],Infection[MeSHID:D007239],Relapse[MeSHID:D012008],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inosine-5'-monophosphate dehydrogenase 2 IMPDH2 NA inhibitor 1.07 drugbank , DGIDB 6-bromo-3-(pyridin-4-yl)-1h-indole NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target inhibitor 1.18 TTD , drugbank , DGIDB inosinic acid small molecule NA experimental,investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD , drugbank 6-chloropurine riboside, 5'-monophosphate small molecule NA experimental,investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD , drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical inosine-5'-monophosphate dehydrogenase 2 IMPDH2 NA unknown NA drugbank mycophenolic bis(sulfonamide) NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD tiazofurin adenine dinucleotide NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 3-(pyridin-4-yl)-1h-indol-7-amine NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 6-methoxy-5-oxazol-5-yl-2-phenyl-1h-indole NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 1-methyl-1h-indole-3-carbaldehyde NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD ribavirin small molecule Liver Cirrhosis[MeSHID:D008103],Cirrhosis[MeSHID:D005355],Intention - mental process[MeSHID:D033182],Hepatitis C, Chronic[MeSHID:D019698],Genotype[MeSHID:D005838],Infection[MeSHID:D007239],Relapse[MeSHID:D012008],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved inosine-5'-monophosphate dehydrogenase 2 IMPDH2 NA inhibitor 1.07 drugbank , DGIDB 3-methoxy-4-(oxazol-5-yl)aniline NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD vx-148 small molecule Virus Diseases[MeSHID:D014777],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Autoimmune Diseases[MeSHID:D001327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational inosine-5'-monophosphate dehydrogenase 2 IMPDH2 NA unknown NA drugbank n-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 1-methyl-1h-indole-3-carboxamide NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD 2-benzyl-6-methoxy-5-oxazol-5-yl-1h-indole NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD mycophenolic hydroxamic acid NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD c4-mad NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737],Pemphigus Vulgaris[MeSHID:D010392],Immune System Diseases[MeSHID:D007154] approved,investigational inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target inhibitor 1.18 TTD , drugbank , DGIDB 3-(furan-3-yl)-1-methyl-1h-indole NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD nicotinamide-adenine-dinucleotide NA NA investigative inosine-5'-monophosphate dehydrogenase 2 IMPDH2 Successful target unknown NA TTD hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved interphotoreceptor matrix proteoglycan 2 IMPG2 NA binder NA drugbank reversine small molecule NA experimental inner centromere protein INCENP NA unknown NA drugbank garetosmab biotech NA investigational inhibin beta a chain INHBA NA binder NA drugbank d-myo-inositol-1,4-bisphosphate small molecule NA experimental type ii inositol 1,4,5-trisphosphate 5-phosphatase INPP5B NA unknown NA drugbank aqx-1125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 sh2 domain inositol 5'-phosphatase 1 INPP5D Clinical trial target unknown 63.65 TTD , DGIDB oi287gt NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 1 insulin INS Successful target unknown NA TTD , DGIDB adjustable basal insulin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 insulin INS Successful target unknown NA TTD , DGIDB insulin degludec NA Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved insulin INS Successful target unknown NA TTD , DGIDB insulin zinc susp recombinant human NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin INS Successful target unknown NA TTD , DGIDB mer-3001 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 2 insulin INS Successful target unknown NA TTD , DGIDB insulin-glargine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Malaria[MeSHID:D008288], Insulin-Dependent[MeSHID:D003922],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin INS Successful target unknown NA TTD , DGIDB m-cresol small molecule NA experimental insulin INS NA unknown NA drugbank ly2963016 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 3 insulin INS Successful target unknown 10.61 TTD , DGIDB ft-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 1 insulin INS Successful target unknown NA TTD u300 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 insulin INS Successful target unknown NA TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational insulin INS NA stabilization NA drugbank myristic acid small molecule NA experimental insulin INS NA unknown NA drugbank inulin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney[MeSHID:D007668] approved insulin INS Successful target unknown 21.22 TTD , DGIDB insulin molecules, novo NA NA investigative insulin INS Successful target unknown NA TTD insulin susp protamine zinc beef/pork NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin INS Successful target unknown NA TTD , DGIDB np-500 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Syndrome X[MeSHID:D024821] phase 1 insulin INS Successful target unknown NA TTD , DGIDB insulin determir NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin INS Successful target unknown NA TTD , DGIDB nbi-6024 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] discontinued in phase 2 insulin INS Successful target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational insulin INS NA unknown NA drugbank nnc-0123-0000-0338 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 insulin INS Successful target unknown NA TTD , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental insulin INS NA stabilization NA drugbank sar342434 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909], Insulin-Dependent[MeSHID:D003922] phase 3 insulin INS Successful target unknown NA TTD , DGIDB ibc-vs01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 1 insulin INS Successful target unknown NA TTD , DGIDB sbs-1000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 insulin INS Successful target unknown NA TTD , DGIDB insulin susp isophane recombinant human NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin INS Successful target unknown NA TTD , DGIDB s-15261 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 insulin INS Successful target unknown NA TTD ly2605541 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 3 insulin INS Successful target unknown 10.61 TTD , DGIDB pc-dac:insulin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922],Pyruvate Carboxylase Deficiency Disease[MeSHID:D015324] phase 3 insulin INS Successful target unknown NA TTD , DGIDB oi362gt NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 1 insulin INS Successful target unknown NA TTD , DGIDB insulin-aspart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin INS Successful target unknown NA TTD , DGIDB sar-161271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 1/2 insulin INS Successful target unknown NA TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational insulin INS NA unknown NA drugbank insulin-detemir NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved insulin INS Successful target unknown NA TTD , DGIDB rhiip NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative insulin receptor INSR Successful target unknown NA TTD nvp-tae684 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] investigative insulin receptor INSR Successful target unknown NA TTD insulin-lispro NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB insulin aspart biotech Diabetes Mellitus[MeSHID:D003920] approved insulin receptor INSR NA agonist NA drugbank , DGIDB insulin detemir biotech Diabetes Mellitus[MeSHID:D003920] approved insulin receptor INSR NA agonist NA drugbank , DGIDB ryzodeq NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB np-01 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin receptor INSR Successful target unknown NA TTD , DGIDB insulin-glulisine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB insulin aspart biotech Diabetes Mellitus[MeSHID:D003920] approved insulin receptor INSR NA agonist 1.03 drugbank , DGIDB isf-402 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 insulin receptor INSR Successful target unknown NA TTD , DGIDB brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational insulin receptor INSR NA binding,inhibitor 0.21 drugbank , DGIDB nn-1218 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174]VAJO NEUROHEPATOPATHY[MeSHID:C538344],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924], Insulin-Dependent[MeSHID:D003922],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 insulin receptor INSR Successful target unknown NA TTD , DGIDB nn344 small molecule Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational insulin receptor INSR NA unknown NA drugbank vvp-808 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin receptor INSR Successful target unknown 0.11 TTD , DGIDB insulin detemir biotech Diabetes Mellitus[MeSHID:D003920] approved insulin receptor INSR NA agonist 1.03 drugbank , DGIDB dm-71 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin receptor INSR Successful target unknown NA TTD , DGIDB tak-379 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin receptor INSR Successful target unknown NA TTD , DGIDB insulin argine biotech NA experimental insulin receptor INSR NA agonist NA drugbank insulin transdermal NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 1 insulin receptor INSR Successful target unknown NA TTD , DGIDB dm-99 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin receptor INSR Successful target unknown NA TTD , DGIDB pmid24900237c15 NA NA investigative insulin receptor INSR Successful target unknown NA TTD insulin human biotech Diabetes Mellitus[MeSHID:D003920] approved,investigational insulin receptor INSR NA agonist 0.08 drugbank , DGIDB insulin glargine biotech Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922], Non-Insulin-Dependent[MeSHID:D003924] approved insulin receptor INSR NA agonist NA drugbank , DGIDB insulin lispro biotech Diabetes Mellitus[MeSHID:D003920] approved insulin receptor INSR NA agonist 1.03 drugbank , DGIDB insulin glulisine biotech Diabetes Mellitus[MeSHID:D003920] approved insulin receptor INSR NA agonist 1.03 drugbank , DGIDB s-707106 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin receptor INSR Successful target unknown NA TTD , DGIDB aew-541 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 insulin receptor INSR Successful target unknown 0.17 TTD , DGIDB insulin, porcine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB 4-((1h-indazol-6-ylamino)methyl)benzene-1,2-diol NA NA investigative insulin receptor INSR Successful target unknown NA TTD insulin degludec biotech Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved insulin receptor INSR NA agonist 1.03 drugbank , DGIDB tesofensine NA Obesity[MeSHID:D009765],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 insulin receptor INSR Successful target unknown 0.34 TTD , DGIDB vvp-100x NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative insulin receptor INSR Successful target unknown NA TTD insulin beef biotech NA approved insulin receptor INSR NA agonist NA drugbank xmetd NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypoglycemia[MeSHID:D007003] investigative insulin receptor INSR Successful target unknown NA TTD dm-83 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 insulin receptor INSR Successful target unknown NA TTD insulin oral sublingual NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 1 insulin receptor INSR Successful target unknown NA TTD , DGIDB at1391 small molecule Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] investigational insulin receptor INSR NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational insulin receptor INSR NA inhibitor NA drugbank insulin peglispro biotech NA investigational insulin receptor INSR NA agonist 0.51 drugbank , DGIDB mecasermin biotech Hypothyroidism[MeSHID:D007037],Failure to Thrive[MeSHID:D005183],long-term care[MeSHID:D008134],Neoplasm Metastasis[MeSHID:D009362],Malnutrition[MeSHID:D044342],Gene Deletion[MeSHID:D017353],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational insulin receptor INSR NA unknown NA drugbank nn5401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 insulin receptor INSR Successful target unknown NA TTD , DGIDB insulin pork biotech Diabetes Mellitus[MeSHID:D003920] approved insulin receptor INSR NA binder,agonist 1.03 drugbank , DGIDB linsitinib small molecule Neoplasms[MeSHID:D009369] investigational insulin receptor INSR NA inhibitor 0.38 drugbank , DGIDB human neutral insulin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB mitoglitazone NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin receptor INSR Successful target unknown 0.51 TTD , DGIDB metformin glycinate NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 insulin receptor INSR Successful target unknown NA TTD , DGIDB akp-020 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 insulin receptor INSR Successful target unknown NA TTD metformin arginine-hemisuccinimide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol NA NA investigative insulin receptor INSR Successful target unknown NA TTD fpt-038 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative insulin receptor INSR Successful target unknown NA TTD agt-182 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidosis II[MeSHID:D016532] phase 1 insulin receptor INSR Successful target unknown NA TTD , DGIDB l-betagamma-meatp NA NA investigative insulin receptor INSR Successful target unknown NA TTD insulin glargine biotech Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922], Non-Insulin-Dependent[MeSHID:D003924] approved insulin receptor INSR NA agonist 0.51 drugbank , DGIDB eml-336 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 insulin receptor INSR Successful target unknown NA TTD kw-2450 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 1/2 insulin receptor INSR Successful target inhibitor 0.51 TTD , DGIDB meglitinides NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB xmets NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative insulin receptor INSR Successful target unknown NA TTD egs-21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 2 insulin receptor INSR Successful target unknown NA TTD , DGIDB bms-754807 small molecule NA investigational insulin receptor INSR NA inhibitor 0.16 drugbank , DGIDB adenosine-5'-[beta, gamma-methylene]triphosphate small molecule NA experimental insulin receptor INSR NA unknown NA drugbank insulin lyspro recombinant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB kw-2450 free base small molecule NA experimental insulin receptor INSR NA inhibitor NA drugbank msdc-0602 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 insulin receptor INSR Successful target unknown NA TTD , DGIDB insulin tregopil biotech NA investigational insulin receptor INSR NA agonist NA drugbank gsk-1838705a NA NA investigative insulin receptor INSR Successful target inhibitor NA TTD , DGIDB ad10-1025 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative insulin receptor INSR Successful target unknown NA TTD insulin recombinant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved insulin receptor INSR Successful target unknown NA TTD , DGIDB mecasermin rinfabate biotech HIV Seropositivity[MeSHID:D006679],Myotonic Dystrophy[MeSHID:D009223],adiposity[MeSHID:D050154],HIV Infections[MeSHID:D015658],Disease[MeSHID:D004194],Insulin Resistance[MeSHID:D007333],Dwarfism[MeSHID:D004392],Obesity[MeSHID:D009765],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Disease Resistance[MeSHID:D060467],Gene Deletion[MeSHID:D017353] approved insulin receptor INSR NA unknown NA drugbank [4-({5-(aminocarbonyl)-4-[(3-methylphenyl)amino]pyrimidin-2-yl}amino)phenyl]acetic acid small molecule NA experimental insulin receptor INSR NA unknown NA drugbank chromic chloride small molecule Solutions[MeSHID:D012996],Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved insulin receptor INSR NA activator NA drugbank quick-acting insulin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative insulin receptor INSR Successful target unknown NA TTD insulin glulisine biotech Diabetes Mellitus[MeSHID:D003920] approved insulin receptor INSR NA agonist NA drugbank , DGIDB dc-9703 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative insulin receptor INSR Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational insulin receptor-related protein INSRR NA inhibitor NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational ras gtpase-activating-like protein iqgap1 IQGAP1 NA ligand NA drugbank indazoletriazolephenyl derivative 1 NA NA patented il-1 receptor-associated kinase 1 IRAK1 Patented-recorded target unknown NA TTD , DGIDB pyrazolopyrimidine and thienopyrimidine amide derivative 1 NA NA patented il-1 receptor-associated kinase 1 IRAK1 Patented-recorded target unknown NA TTD , DGIDB indazoletriazolephenyl derivative 2 NA NA patented il-1 receptor-associated kinase 1 IRAK1 Patented-recorded target unknown NA TTD , DGIDB irak-1/4 inhibitor NA NA investigative il-1 receptor-associated kinase 1 IRAK1 Patented-recorded target inhibitor NA TTD , DGIDB wo2012007375c1 NA NA investigative il-1 receptor-associated kinase 1 IRAK1 Patented-recorded target unknown NA TTD pyrazolopyrimidine and thienopyrimidine amide derivative 2 NA NA patented il-1 receptor-associated kinase 1 IRAK1 Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational interleukin-1 receptor-associated kinase 1 IRAK1 NA inhibitor NA drugbank wo2012007375c7 NA NA investigative il-1 receptor-associated kinase 1 IRAK1 Patented-recorded target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational interleukin-1 receptor-associated kinase 3 IRAK3 NA inhibitor NA drugbank macrolactam derivative 2 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB isis 156474 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD irak4 inhibitor 4b NA NA investigative renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational interleukin-1 receptor-associated kinase 4 IRAK4 NA inhibitor NA drugbank diaminopyridine analog 5 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB indazoletriazolephenyl derivative 2 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB isis 156472 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD pyrazole n-1 aryl and heteroaryl derivative 1 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB isis 156449 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD indazole amide derivative 2 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB irak4 inhibitor rac-45 NA NA investigative renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD amidopyrazole derivative 6 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB bay1834845 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB isis 156471 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD pf-05313261 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD irak-1/4 inhibitor NA NA investigative renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target inhibitor NA TTD , DGIDB macrolactam derivative 3 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB indazole amide derivative 1 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB isis 156451 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD amidopyrazole derivative 5 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB ca-4948 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hippocampus Proper[MeSHID:D006624],Lymphoma[MeSHID:D008223] phase 1 renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB isis 156475 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD 1-(3-hydroxypropyl)-2-[(3-nitrobenzoyl)amino]-1h-benzimidazol-5-yl pivalate small molecule NA experimental interleukin-1 receptor-associated kinase 4 IRAK4 NA unknown NA drugbank nd-2158 NA NA investigative renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target inhibitor NA TTD , DGIDB isis 156473 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD n-(1h-benzo[d]imidazol-2-yl)-3-cyanobenzamide NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD nd-2110 NA NA investigative renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target inhibitor NA TTD , DGIDB pyrazolopyrimidine and thienopyrimidine amide derivative 1 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB amidopyrazole derivative 4 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB isis 156453 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD fused benzoheterocycle amide derivative 2 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB amidopyrazole derivative 2 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB fused benzoheterocycle amide derivative 1 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB amidopyrazole derivative 1 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB wo2012007375c7 NA NA investigative renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD isis 156452 NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD indazoletriazolephenyl derivative 1 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB wo2012007375c1 NA NA investigative renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD n-(1h-benzo[d]imidazol-2-yl)-3-nitrobenzamide NA NA investigative irak4 messenger rna IRAK4 Literature-reported target unknown NA TTD amidopyrazole derivative 3 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB macrolactam derivative 4 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB ca-4948 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hippocampus Proper[MeSHID:D006624],Lymphoma[MeSHID:D008223] phase 1 renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target inhibitor NA TTD , DGIDB macrolactam derivative 1 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB pyrazolopyrimidine and thienopyrimidine amide derivative 2 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB diaminopyridine analog 4 NA NA patented renal carcinoma antigen ny-ren-64 IRAK4 Clinical trial target unknown NA TTD , DGIDB guanosine-5'-diphosphate small molecule NA experimental interferon-inducible gtpase 5 IRGC NA unknown NA drugbank 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental interferon-inducible gtpase 5 IRGC NA unknown NA drugbank [4-({5-(aminocarbonyl)-4-[(3-methylphenyl)amino]pyrimidin-2-yl}amino)phenyl]acetic acid small molecule NA experimental insulin receptor substrate 1 IRS1 NA unknown NA drugbank nt219 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 insulin receptor substrate 2 IRS2 Clinical trial target unknown NA TTD uridine monophosphate small molecule NA experimental interferon-stimulated gene 20 kda protein ISG20 NA unknown NA drugbank 2-deoxy-d-glucitol 6-(e)-vinylhomophosphonate small molecule NA experimental inositol-3-phosphate synthase 1 ISYNA1 NA unknown NA drugbank glycerin small molecule NA approved,investigational inositol-3-phosphate synthase 1 ISYNA1 NA unknown NA drugbank 2-deoxy-glucitol-6-phosphate small molecule NA experimental inositol-3-phosphate synthase 1 ISYNA1 NA unknown NA drugbank san-300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 integrin alpha-1 ITGA1 Clinical trial target unknown 63.65 TTD , DGIDB maggiemycin NA NA investigative integrin alpha-2 ITGA2 Clinical trial target unknown NA TTD 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid NA NA investigative integrin alpha-2 ITGA2 Clinical trial target unknown NA TTD 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid NA NA investigative integrin alpha-2 ITGA2 Clinical trial target unknown NA TTD 3-(3-(carbamoyl)benzamido)propanoic acid NA NA investigative integrin alpha-2 ITGA2 Clinical trial target unknown NA TTD e7820 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 integrin alpha-2 ITGA2 Clinical trial target unknown 15.91 TTD , DGIDB abciximab biotech Angina, Unstable[MeSHID:D000789],Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved integrin alpha-iib ITGA2B NA antagonist 9.43 drugbank , DGIDB fradafiban small molecule Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Thrombosis[MeSHID:D013927],Expiration, function[MeSHID:D045853] investigational integrin alpha-iib ITGA2B NA unknown NA drugbank tirofiban small molecule Acute Coronary Syndrome[MeSHID:D054058],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved integrin alpha-iib ITGA2B NA antagonist 14.14 drugbank , DGIDB abciximab biotech Angina, Unstable[MeSHID:D000789],Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved integrin alpha-iib ITGA2B NA antagonist,inhibitor 9.43 drugbank , DGIDB lefradafiban small molecule Angina, Unstable[MeSHID:D000789],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] investigational integrin alpha-iib ITGA2B NA unknown NA drugbank gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 integrin alpha-4 ITGA4 Successful target unknown NA TTD , DGIDB amg-181 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] phase 2 integrin alpha-4 ITGA4 Successful target unknown 5.3 TTD , DGIDB mk-0668 small molecule NA experimental vla-4 (very late antigen-4) ITGA4 NA unknown NA drugbank isis 24477 NA NA investigative itga4 messenger rna ITGA4 Clinical trial target unknown NA TTD atl1102 NA Asthma[MeSHID:D001249],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 itga4 messenger rna ITGA4 Clinical trial target unknown NA TTD , DGIDB natalizumab biotech Multiple Sclerosis[MeSHID:D009103] approved,investigational integrin alpha-4 ITGA4 NA antibody 31.83 drugbank , DGIDB isis 24448 NA NA investigative itga4 messenger rna ITGA4 Clinical trial target unknown NA TTD isis 24453 NA NA investigative itga4 messenger rna ITGA4 Clinical trial target unknown NA TTD isis 24454 NA NA investigative itga4 messenger rna ITGA4 Clinical trial target unknown NA TTD vedolizumab biotech emotional dependency[MeSHID:D003858] approved integrin alpha-4 ITGA4 NA antibody 15.91 drugbank , DGIDB bio-1211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 integrin alpha-4 ITGA4 Successful target unknown 10.61 TTD , DGIDB elnd-004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 integrin alpha-4 ITGA4 Successful target unknown NA TTD , DGIDB tinzaparin small molecule Venous Thrombosis[MeSHID:D020246],Pulmonary Embolism[MeSHID:D011655],Venous Thromboembolism[MeSHID:D054556] approved integrin alpha-4 ITGA4 NA inhibitor NA drugbank vedolizumab biotech emotional dependency[MeSHID:D003858] approved integrin alpha-4 ITGA4 NA antibody,inhibitor 15.91 drugbank , DGIDB ptg-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 1 integrin alpha-4 ITGA4 Successful target unknown NA TTD , DGIDB vedolizmab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] approved integrin alpha-4 ITGA4 Successful target unknown NA TTD , DGIDB senktide NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 2 integrin alpha-4 ITGA4 Successful target unknown 5.3 TTD , DGIDB antegren NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] approved integrin alpha-4 ITGA4 Successful target unknown NA TTD , DGIDB ct301 NA NA investigative integrin alpha-4 ITGA4 Successful target unknown NA TTD isis 24475 NA NA investigative itga4 messenger rna ITGA4 Clinical trial target unknown NA TTD elnd-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 integrin alpha-4 ITGA4 Successful target unknown NA TTD , DGIDB r411 small molecule Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational integrin alpha-4 ITGA4 NA unknown NA drugbank asp-2002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] investigative integrin alpha-4 ITGA4 Successful target unknown NA TTD cdp323 small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational integrin alpha-4 ITGA4 NA unknown NA drugbank r1295 small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational integrin alpha-4 ITGA4 NA unknown NA drugbank , DGIDB natalizumab biotech Multiple Sclerosis[MeSHID:D009103] approved,investigational integrin alpha-4 ITGA4 NA antibody,inhibitor 31.83 drugbank , DGIDB atl1102 small molecule Asthma[MeSHID:D001249],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational integrin alpha-4 ITGA4 NA unknown NA drugbank , DGIDB mk-0668 NA NA investigative itga4 messenger rna ITGA4 Clinical trial target unknown NA TTD dw-908e NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] discontinued in phase 1 integrin alpha-5 ITGA5 Clinical trial target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational integrin alpha-5 ITGA5 NA unknown NA drugbank c(-grgdfl-) NA NA investigative integrin alpha-5 ITGA5 Clinical trial target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational integrin alpha-5 ITGA5 NA unknown NA drugbank jsm 6427 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 integrin alpha-5 ITGA5 Clinical trial target unknown NA TTD , DGIDB tr-14531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 integrin alpha-5 ITGA5 Clinical trial target unknown NA TTD gw-559090 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 integrin alpha-5 ITGA5 Clinical trial target unknown NA TTD zd-7349 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] discontinued in phase 1 integrin alpha-5 ITGA5 Clinical trial target unknown NA TTD simvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Peripheral Vascular Diseases[MeSHID:D016491],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Cerebrovascular Disorders[MeSHID:D002561],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia[MeSHID:D006937],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Hyperlipidemia[MeSHID:D006949],Coronary heart disease[MeSHID:D003327],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type IV[MeSHID:D006953],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved integrin alpha-l ITGAL NA inhibitory allosteric modulator NA drugbank 3-({4-[(1e)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline small molecule NA experimental integrin alpha-l ITGAL NA unknown NA drugbank pitavastatin small molecule Coronary Arteriosclerosis[MeSHID:D003324],Diabetes Mellitus[MeSHID:D003920],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipidemia[MeSHID:D006949],Coronary heart disease[MeSHID:D003327],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Cerebrovascular accident[MeSHID:D020521],Chronic Kidney Diseases[MeSHID:D051436],Myocardial Infarction[MeSHID:D009203],Aortic Aneurysm, Abdominal[MeSHID:D017544],Dyslipidemias[MeSHID:D050171],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938] approved integrin alpha-l ITGAL NA unknown NA drugbank lifitegrast small molecule Dry Eye Syndromes[MeSHID:D015352],Keratoconjunctivitis Sicca[MeSHID:D007638],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Desiccation[MeSHID:D003890],Disorder of eye[MeSHID:D005128],Allergic Conjunctivitis[MeSHID:D003233],Disease[MeSHID:D004194] approved integrin alpha-l ITGAL Successful target antagonist 4.99 TTD , drugbank , DGIDB lfa703 small molecule NA experimental,investigative integrin alpha-l ITGAL Successful target unknown NA TTD , drugbank a-286982 NA NA investigative integrin alpha-l ITGAL Successful target unknown NA TTD rosuvastatin small molecule Homozygote[MeSHID:D006720],Diabetes Mellitus[MeSHID:D003920],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Coronary artery[MeSHID:D003331],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Cerebrovascular accident[MeSHID:D020521],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved integrin alpha-l ITGAL NA inhibitory allosteric modulator NA drugbank 1-acetyl-4-(4-{4-[(2-ethoxyphenyl)thio]-3-nitrophenyl}pyridin-2-yl)piperazine small molecule NA experimental integrin alpha-l ITGAL NA unknown NA drugbank ic-747 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 integrin alpha-l ITGAL Successful target unknown NA TTD cytolin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] preclinical integrin alpha-l ITGAL Successful target unknown NA TTD , DGIDB efalizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational integrin alpha-l ITGAL Successful target antibody 16.85 TTD , drugbank , DGIDB leukotoxin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative integrin alpha-l ITGAL Successful target unknown NA TTD (s)-2-((s)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-n-methyl-3-naphtalen-2-yl-propionamide small molecule NA experimental integrin alpha-l ITGAL NA unknown NA drugbank antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved integrin alpha-l ITGAL NA unknown NA drugbank efalizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational integrin alpha-l ITGAL Successful target antibody,inhibitor 16.85 TTD , drugbank , DGIDB bms-587101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 integrin alpha-l ITGAL Successful target unknown NA TTD lovastatin small molecule Diabetes Mellitus[MeSHID:D003920],Angina, Unstable[MeSHID:D000789],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Premature Birth[MeSHID:D047928],Atherosclerosis[MeSHID:D050197],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Dyslipidemias[MeSHID:D050171],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Prescription of drug (procedure)[MeSHID:D011307],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Neoplasm Metastasis[MeSHID:D009362],Menarche[MeSHID:D008572],Cerebrovascular accident[MeSHID:D020521],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational integrin alpha-l ITGAL NA inhibitor NA drugbank 7a-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7a-tetrahydro-1h-pyrrolo[1,2-a]pyrrole-7-carbonitrile small molecule NA experimental integrin alpha-l ITGAL NA unknown NA drugbank c-[-arg-gly-asp-acpca32-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclo-[-arg-gly-asp-amp27-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[-arg-gly-asp-acpca21-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclo-[-arg-gly-asp-amp28-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgd-(r)-alpha-tfmfv] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cypate-[(rgd)2-nh2]2 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[-arg-gly-asp-acpca35-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclo-[-arg-gly-asp-amp24-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD tv-1102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tidal Volume[MeSHID:D013990],Multiple Sclerosis[MeSHID:D009103] phase 2 itgav messenger rna ITGAV Clinical trial target unknown NA TTD antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved integrin alpha-v ITGAV NA unknown NA drugbank c(-grgdfl-) NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(r)-alpha-tfmv] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[-arg-gly-asp-acpca19-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD imgn-388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 integrin alpha-v ITGAV Clinical trial target unknown 6.37 TTD , DGIDB cypate-[(rgd)4-nh2]2 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclo[rgdfk(cypate)] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD n-(3,5-dichlorophenyl)imidodicarbonimidic diamide NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(s)-alpha-tfmv] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cypate-[(rgd)2-nh2]1 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD rgdechi NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(r)-n-me-alpha-tfmf] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD g(d-pen)-g-h-r-g-d-l-r-c-a NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cypate-[(rgd)3-nh2]2 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c-[-arg-gly-asp-acpca30-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(3r)-carboxymorpholine] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[-arg-gly-asp-acpca34-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD e[c(rgdyk)]2-ptx conjugate NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(s)-n-me-alpha-tfmf] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclorgdfv NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c-[-arg-gly-asp-acpca33-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c(rgdfmef) NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[-arg-gly-asp-acpca36-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(3s)-carboxymorpholine] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgd-(s)-alpha-tfmfv] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[-arg-gly-asp-acpca20-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD st-1646 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD abituzumab NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 integrin alpha-v ITGAV Clinical trial target unknown 2.55 TTD , DGIDB cyclo-[-arg-gly-asp-amp25-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD sb-265123 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c-[-arg-gly-asp-acpca31-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclo-[-arg-gly-asp-amp21-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(s)-alpha-tfmf] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD acdrgds NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c(rgdff) NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cypate-[(rgd)3-nh2]1 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD isonipecotamide NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD gly-arg-gly-asp-ser NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD levothyroxine small molecule Disease Management[MeSHID:D019468],Hypothyroidism[MeSHID:D007037],Thyroid Gland[MeSHID:D013961],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Hypothalamic structure[MeSHID:D007031],Cell Differentiation process[MeSHID:D002454],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved integrin alpha-v ITGAV NA unknown NA drugbank cyclo-[-arg-gly-asp-amp23-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(s,r)-alpha-dfm-f] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD ac-asp-arg-leu-asp-ser-oh NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cypate-[(rgd)4-nh2]1 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[-arg-gly-asp-acpca22-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclo-[-arg-gly-asp-amp26-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD e[c(rgdyk)]2 NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclo(rgdfv) (control) NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD navpnlrgdlqvlaqkvart NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD gly-arg-gly-asp-ser-pro-lys NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD cyclo-[-arg-gly-asp-amp22-] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c(arg-gly-asp-d-phe-val) NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD c[rgdf-(r)-alpha-tfmf] NA NA investigative integrin alpha-v ITGAV Clinical trial target unknown NA TTD efalizumab biotech Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational integrin alpha-x ITGAX NA antibody NA drugbank mk-0668 NA NA investigative integrin beta-1 ITGB1 Clinical trial target unknown NA TTD 131i-radretumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 integrin beta-1 ITGB1 Clinical trial target unknown NA TTD , DGIDB c(-grgdfl-) NA NA investigative integrin beta-1 ITGB1 Clinical trial target unknown NA TTD mk-0668 small molecule NA experimental vla-4 (very late antigen-4) ITGB1 NA unknown NA drugbank jsm 6427 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 integrin beta-1 ITGB1 Clinical trial target unknown NA TTD , DGIDB sb-265123 NA NA investigative integrin beta-1 ITGB1 Clinical trial target unknown NA TTD antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved integrin beta-1 ITGB1 NA unknown NA drugbank os2966 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 integrin beta-1 ITGB1 Clinical trial target unknown NA TTD a-286982 NA NA investigative integrin beta-2 ITGB2 Clinical trial target unknown NA TTD rp-l201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukocyte adhesion deficiency type 1[MeSHID:C535887] phase 1/2 integrin beta-2 ITGB2 Clinical trial target unknown NA TTD bms-587101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 integrin beta-2 ITGB2 Clinical trial target unknown NA TTD uk-279,276 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 integrin beta-2 ITGB2 Clinical trial target unknown NA TTD mln-2201 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 integrin beta-2 ITGB2 Clinical trial target unknown NA TTD c[-arg-gly-asp-acpca21-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD eptifibatide biotech Myocardial Infarction[MeSHID:D009203],Acute Coronary Syndrome[MeSHID:D054058],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321] approved,investigational integrin beta-3 ITGB3 NA inhibitor 10.91 drugbank , DGIDB cyclo-[-arg-gly-asp-amp25-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD lm-609 biotech Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Psoriasis[MeSHID:D011565] investigational integrin beta-3 ITGB3 NA unknown NA drugbank gly-arg-gly-asp-ser-pro-lys NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo(rgdfv) (control) NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD ac-asp-arg-leu-asp-ser-oh NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[-arg-gly-asp-acpca36-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD sb-265123 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD l-739758 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cypate-[(rgd)4-nh2]2 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c-[-arg-gly-asp-acpca32-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclorgdfv NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c(-grgdfl-) NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c(rgdfmef) NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational integrin beta-3 ITGB3 NA unknown NA drugbank l-746233 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[rgdf-(s)-alpha-tfmf] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cypate-[(rgd)3-nh2]2 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[-arg-gly-asp-acpca22-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD sc-54701a NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cypate-[(rgd)2-nh2]2 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c(arg-gly-asp-d-phe-val) NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD fradafiban small molecule Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Thrombosis[MeSHID:D013927],Expiration, function[MeSHID:D045853] investigational integrin beta-3 ITGB3 NA unknown NA drugbank cypate-[(rgd)3-nh2]1 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD ferric maltol small molecule Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Onychomycosis[MeSHID:D014009],Iron deficiency anemia[MeSHID:D018798] approved integrin beta-3 ITGB3 NA substrate NA drugbank l-734115 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[rgd-(s)-alpha-tfmfv] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo[rgdfk(cypate)] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD isis 25237 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo-[-arg-gly-asp-amp28-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo-[-arg-gly-asp-amp24-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[rgd-(r)-alpha-tfmfv] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD n-(3,5-dichlorophenyl)imidodicarbonimidic diamide NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD lefradafiban small molecule Angina, Unstable[MeSHID:D000789],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] investigational integrin beta-3 ITGB3 NA unknown NA drugbank dmp-802 NA NA discontinued in phase 1 itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD sb-207043 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c-[-arg-gly-asp-acpca33-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cypate-[(rgd)2-nh2]1 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[-arg-gly-asp-acpca20-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD st-1646 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD abciximab biotech Angina, Unstable[MeSHID:D000789],Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved integrin beta-3 ITGB3 NA antagonist,inhibitor 8.34 drugbank , DGIDB acdrgds NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD rwj-53419 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c-[-arg-gly-asp-acpca31-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo-[-arg-gly-asp-amp26-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo-[-arg-gly-asp-amp27-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo-[-arg-gly-asp-amp22-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cypate-[(rgd)4-nh2]1 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo-[-arg-gly-asp-amp23-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[rgdf-(r)-n-me-alpha-tfmf] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD abciximab biotech Angina, Unstable[MeSHID:D000789],Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved integrin beta-3 ITGB3 NA antagonist 8.34 drugbank , DGIDB antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved integrin beta-3 ITGB3 NA unknown NA drugbank c[rgdf-(r)-alpha-tfmf] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[-arg-gly-asp-acpca19-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD levothyroxine small molecule Disease Management[MeSHID:D019468],Hypothyroidism[MeSHID:D007037],Thyroid Gland[MeSHID:D013961],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Hypothalamic structure[MeSHID:D007031],Cell Differentiation process[MeSHID:D002454],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved integrin beta-3 ITGB3 NA unknown NA drugbank rgdechi NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[rgdf-(s)-n-me-alpha-tfmf] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[rgdf-(s,r)-alpha-dfm-f] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c(rgdff) NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[rgdf-(r)-alpha-tfmv] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD l-767679 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c-[-arg-gly-asp-acpca30-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational integrin beta-3 ITGB3 NA unknown NA drugbank c[-arg-gly-asp-acpca35-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[rgdf-(s)-alpha-tfmv] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD isonipecotamide NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD gly-arg-gly-asp-ser NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD e[c(rgdyk)]2-ptx conjugate NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD e[c(rgdyk)]2 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD cyclo-[-arg-gly-asp-amp21-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD c[-arg-gly-asp-acpca34-] NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD tirofiban small molecule Acute Coronary Syndrome[MeSHID:D054058],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved integrin beta-3 ITGB3 NA antagonist 6.37 drugbank , DGIDB roxifiban NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD l-756568 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD isis 196103 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD xemilofiban NA Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] discontinued in phase 3 itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD 3-(3-(carbamoyl)benzamido)propanoic acid NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD l-750034 NA NA investigative itgb3 messenger rna ITGB3 Discontinued target unknown NA TTD eptifibatide biotech Myocardial Infarction[MeSHID:D009203],Acute Coronary Syndrome[MeSHID:D054058],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321] approved,investigational integrin beta-3 ITGB3 NA unknown 10.91 drugbank , DGIDB r1295 small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational integrin beta-4 ITGB4 NA unknown NA drugbank sgn-b6a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 integrin beta-6 ITGB6 Clinical trial target unknown NA TTD r1295 small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational integrin beta-7 ITGB7 NA unknown NA drugbank , DGIDB vedolizumab biotech emotional dependency[MeSHID:D003858] approved integrin beta-7 ITGB7 NA antibody,inhibitor 19.1 drugbank , DGIDB rhumab beta7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 3 integrin beta-7 ITGB7 Successful target unknown NA TTD , DGIDB ptg-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 1 integrin beta-7 ITGB7 Successful target unknown NA TTD , DGIDB vedolizmab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] approved integrin beta-7 ITGB7 Successful target unknown NA TTD , DGIDB vedolizumab biotech emotional dependency[MeSHID:D003858] approved integrin beta-7 ITGB7 NA antibody 19.1 drugbank , DGIDB amg-181 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] phase 2 integrin beta-7 ITGB7 Successful target unknown 6.37 TTD , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental inter-alpha-trypsin inhibitor heavy chain h1 ITIH1 NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational inter-alpha-trypsin inhibitor heavy chain h1 ITIH1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational inter-alpha-trypsin inhibitor heavy chain h1 ITIH1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational inter-alpha-trypsin inhibitor heavy chain h1 ITIH1 NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational inter-alpha-trypsin inhibitor heavy chain h2 ITIH2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational inter-alpha-trypsin inhibitor heavy chain h2 ITIH2 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational inter-alpha-trypsin inhibitor heavy chain h2 ITIH2 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational inter-alpha-trypsin inhibitor heavy chain h2 ITIH2 NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental inter-alpha-trypsin inhibitor heavy chain h2 ITIH2 NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational inter-alpha-trypsin inhibitor heavy chain h3 ITIH3 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational inter-alpha-trypsin inhibitor heavy chain h3 ITIH3 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational inter-alpha-trypsin inhibitor heavy chain h3 ITIH3 NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental inter-alpha-trypsin inhibitor heavy chain h3 ITIH3 NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational inter-alpha-trypsin inhibitor heavy chain h4 ITIH4 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental inter-alpha-trypsin inhibitor heavy chain h4 ITIH4 NA binder NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational inter-alpha-trypsin inhibitor heavy chain h4 ITIH4 NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational inter-alpha-trypsin inhibitor heavy chain h4 ITIH4 NA unknown NA drugbank staurosporine small molecule NA experimental tyrosine-protein kinase itk/tsk ITK NA unknown NA drugbank cpi-818 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Cell Lymphoma[MeSHID:D016399] phase 1 t-cell-specific kinase ITK Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase itk/tsk ITK NA inhibitor NA drugbank bms-488516 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative t-cell-specific kinase ITK Clinical trial target unknown NA TTD pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved tyrosine-protein kinase itk/tsk ITK NA inhibitor NA drugbank jte-051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225] phase 2 t-cell-specific kinase ITK Clinical trial target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase itk/tsk ITK NA inhibitor NA drugbank pmid27774824-compound-figure3example7 NA NA patented t-cell-specific kinase ITK Clinical trial target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase itk/tsk ITK NA inhibitor NA drugbank bms-509744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative t-cell-specific kinase ITK Clinical trial target inhibitor 1.68 TTD , DGIDB pyrazolo[4,3-c]pyridine derivative 2 NA NA patented t-cell-specific kinase ITK Clinical trial target unknown NA TTD , DGIDB citric acid small molecule NA approved,nutraceutical,vet_approved inosine triphosphate pyrophosphatase ITPA NA unknown NA drugbank inositol 1,3,4,5-tetrakisphosphate small molecule NA experimental inositol-trisphosphate 3-kinase a ITPKA NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental inositol-trisphosphate 3-kinase a ITPKA NA unknown NA drugbank 1d-myo-inositol 1,4,5-trisphosphate small molecule NA experimental inositol-trisphosphate 3-kinase a ITPKA NA unknown NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved inositol 1,4,5-trisphosphate receptor ITPR1 NA inhibitor,antagonist 1.41 drugbank , DGIDB decavanadate NA NA investigative ip3 receptor isoform 1 ITPR1 Literature-reported target antagonist NA TTD , DGIDB 1d-myo-inositol 1,4,5-trisphosphate small molecule NA experimental inositol 1,4,5-trisphosphate receptor type 1 ITPR1 NA unknown NA drugbank xestospongin c NA NA investigative ip3 receptor isoform 1 ITPR1 Literature-reported target antagonist NA TTD , DGIDB glycerin small molecule NA approved,investigational inositol 1,4,5-trisphosphate receptor type 1 ITPR1 NA unknown NA drugbank pip2 NA NA investigative ip3 receptor isoform 1 ITPR1 Literature-reported target antagonist NA TTD , DGIDB inositol 2,4,5-trisphosphate NA NA investigative ip3 receptor isoform 1 ITPR1 Literature-reported target activator NA TTD , DGIDB inositol 2,4,5-trisphosphate NA NA investigative ip3 receptor isoform 2 ITPR2 Literature-reported target activator NA TTD , DGIDB decavanadate NA NA investigative ip3 receptor isoform 2 ITPR2 Literature-reported target antagonist NA TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved inositol 1,4,5-trisphosphate receptor ITPR2 NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved inositol 1,4,5-trisphosphate receptor ITPR3 NA inhibitor NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved isovaleryl-coa dehydrogenase, mitochondrial IVD NA unknown NA drugbank coenzyme a persulfide small molecule NA experimental isovaleryl-coa dehydrogenase, mitochondrial IVD NA unknown NA drugbank 3,5-diiodotyrosine small molecule NA experimental iodotyrosine dehalogenase 1 IYD NA unknown NA drugbank isoxazole derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB ati-502 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Vitiligo[MeSHID:D014820] phase 2 janus kinase 1 JAK1 Successful target unknown NA TTD baricitinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor 1.33 drugbank , DGIDB tricyclic compound 11 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB cyclic cyanoethypypazole derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure6example6 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB triazolo-pyridine derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor 0.47 drugbank , DGIDB asp-015k NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Rheumatoid Arthritis[MeSHID:D001172] phase 3 janus kinase 1 JAK1 Successful target unknown 1.7 TTD , DGIDB pyrazolopyridine derivative 3 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB tricyclic pyrrolopyridine compound 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB cyclohexyl azetidine derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB baricitinib NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved janus kinase 1 JAK1 Successful target inhibitor 1.33 TTD , DGIDB pmid27774824-compound-figure9example2up NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB ruxolitinib derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 7 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB fedratinib small molecule Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor 0.71 drugbank , DGIDB benzimidazole derivative 7 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB baricitinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor 1.33 drugbank , DGIDB imidazo[4,5-c]pyridine derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB ati-502 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505],Eczema[MeSHID:D004485] phase 2 janus kinase 1 JAK1 Successful target unknown NA TTD tricyclic heterocycle derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 8 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure7example63 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB baricitinib NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved janus kinase 1 JAK1 Successful target unknown 1.33 TTD , DGIDB pyrrole derivative 7 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB n-methylmethanesulfonamide derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrrolo-pyridone derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB incb47986 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 janus kinase 1 JAK1 Successful target unknown NA TTD bis-aminopyrimidine derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB zm-39923 NA NA investigative janus kinase 1 JAK1 Successful target unknown NA TTD cycloalkyl nitrile pyrazole carboxamide derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one small molecule NA experimental tyrosine-protein kinase jak1 JAK1 NA unknown NA drugbank ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved janus kinase 1 JAK1 Successful target inhibitor 2.33 TTD , DGIDB bis-aminopyrimidine derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB incb54707 NA Hidradenitis Suppurativa[MeSHID:D017497],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrrole six-membered heteroaryl ring derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrimidopyridazinone derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor NA drugbank ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved janus kinase 1 JAK1 Successful target unknown 2.33 TTD , DGIDB ruxolitinib small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved tyrosine-protein kinase jak1 JAK1 NA inhibitor 2.33 drugbank , DGIDB myricetin small molecule NA experimental tyrosine-protein kinase jak1 JAK1 NA unknown NA drugbank ctp-543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 6 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB tricyclic compound 3 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB cerdulatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],B-Cell Lymphomas[MeSHID:D016393],Vitiligo[MeSHID:D014820] phase 2 janus kinase 1 JAK1 Successful target inhibitor 0.71 TTD , DGIDB pf-06700841 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Asthma[MeSHID:D001249] phase 2 janus kinase 1 JAK1 Successful target unknown 1.06 TTD , DGIDB pmid27774824-compound-figure3example18 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB whi-p154 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] investigative janus kinase 1 JAK1 Successful target unknown NA TTD pmid24359159c19a NA NA investigative janus kinase 1 JAK1 Successful target unknown NA TTD baricitinib NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved janus kinase 1 JAK1 Successful target inhibitor 1.33 TTD , DGIDB bis-aminopyrimidine derivative 3 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB upadacitinib NA Eczema[MeSHID:D004485],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Dermatitis, Atopic[MeSHID:D003876],Arthritis, Psoriatic[MeSHID:D015535],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] approved janus kinase 1 JAK1 Successful target inhibitor 1.41 TTD , DGIDB baricitinib NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved janus kinase 1 JAK1 Successful target unknown 1.33 TTD , DGIDB ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved janus kinase 1 JAK1 Successful target unknown 2.33 TTD , DGIDB tricyclic compound 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure6example12 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB tricyclic heterocycle derivative 5 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB five-and-six-membered heterocyclic compound 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure2example4 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB filgotinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Ulcerative Colitis[MeSHID:D003093] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor 1.59 drugbank , DGIDB fedratinib small molecule Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Polycythemia Vera[MeSHID:D011087],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor 0.71 drugbank , DGIDB imidazo[4,5-c]pyridine derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB ruxolitinib small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved tyrosine-protein kinase jak1 JAK1 NA inhibitor 2.33 drugbank , DGIDB cycloalkyl nitrile pyrazolo pyridone derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB bipyrazole derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 11 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB geminally-substituted cyanoethylpypazolo pyridone derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB geminally-substituted cyanoethylpypazolo pyridone derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB cyanomethyl pypazole carboxamide derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB imidazopyridazine derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure1example20 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB incb039110 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 janus kinase 1 JAK1 Successful target unknown 2.12 TTD , DGIDB ctp-543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] phase 2 janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrazolo[4,3-c]pyridine derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrrolo-pyridone derivative 2 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB cycloalkyl nitrile pyrazolo pyridone derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB ati-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] phase 2 janus kinase 1 JAK1 Successful target unknown NA TTD pyrazolopyridine derivative 4 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor NA drugbank imidazopyridazine derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB gsk2586184 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Arthritis[MeSHID:D001168] phase 2 janus kinase 1 JAK1 Successful target unknown 1.59 TTD , DGIDB glpg-0634 NA Lupus Erythematosus, Cutaneous[MeSHID:D008178],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 2 janus kinase 1 JAK1 Successful target unknown 1.59 TTD , DGIDB pmid27774822-compound-figure11example5 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure9example2down NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved janus kinase 1 JAK1 Successful target inhibitor 2.33 TTD , DGIDB pyrrolo-pyridone derivative 3 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB n-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB aminooxazole carboxamide derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB cerdulatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],B-Cell Lymphomas[MeSHID:D016393],Vitiligo[MeSHID:D014820] phase 2 janus kinase 1 JAK1 Successful target unknown 0.71 TTD , DGIDB pmid27774824-compound-figure7example10 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor 0.47 drugbank , DGIDB bis-aminopyrimidine derivative 4 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB isoxazole derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure11example1up NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB pyrrolo-pyridine derivative 3 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB upadacitinib small molecule Eczema[MeSHID:D004485],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Dermatitis, Atopic[MeSHID:D003876],Arthritis, Psoriatic[MeSHID:D015535],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] approved,investigational tyrosine-protein kinase jak1 JAK1 NA inhibitor 1.41 drugbank , DGIDB aminotriazolopyridine derivative 1 NA NA patented janus kinase 1 JAK1 Successful target unknown NA TTD , DGIDB ctp-543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 6 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB fedratinib NA Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved janus kinase 2 JAK2 Successful target unknown 1.31 TTD , DGIDB 4-(3-amino-1h-indazol-5-yl)-n-tert-butylbenzenesulfonamide small molecule NA experimental tyrosine-protein kinase jak2 JAK2 NA unknown NA drugbank tricyclic pyrrolopyridine compound 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB fedratinib small molecule Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Polycythemia Vera[MeSHID:D011087],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor 1.31 drugbank , DGIDB pyrimidopyridazinone derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved janus kinase 2 JAK2 Successful target inhibitor 4.01 TTD , DGIDB bis-aminopyrimidine derivative 4 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 3 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB ruxolitinib small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved tyrosine-protein kinase jak2 JAK2 NA inhibitor 4.01 drugbank , DGIDB cycloalkyl nitrile pyrazolo pyridone derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB tricyclic heterocycle derivative 5 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure7example10 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrazolopyridine derivative 3 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB aromatic bicyclic compound 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB curcumin analog 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 5 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB baricitinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor 0.54 drugbank , DGIDB momelotinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocytosis[MeSHID:D013922] phase 3 janus kinase 2 JAK2 Successful target unknown 1.31 TTD , DGIDB momelotinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocytosis[MeSHID:D013922] phase 3 janus kinase 2 JAK2 Successful target inhibitor 1.31 TTD , DGIDB xl019 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Polycythemia Vera[MeSHID:D011087] investigational tyrosine-protein kinase jak2 JAK2 NA unknown 1.16 drugbank , DGIDB curcumin analog 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure10example1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB sb-1578 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 janus kinase 2 JAK2 Successful target unknown 0.44 TTD , DGIDB baricitinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor 0.54 drugbank , DGIDB 1,2,4-triazolo[1,5a]pyridine derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor NA drugbank atropisomer 1 NA NA investigative janus kinase 2 JAK2 Successful target unknown NA TTD tricyclic heterocycle derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB cerdulatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],B-Cell Lymphomas[MeSHID:D016393],Vitiligo[MeSHID:D014820] phase 2 janus kinase 2 JAK2 Successful target unknown 0.19 TTD , DGIDB pyrrole derivative 7 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure8example99 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB 5-phenyl-1h-indazol-3-amine NA NA investigative janus kinase 2 JAK2 Successful target unknown NA TTD 4-[(2-{4-[(cyclopropylcarbamoyl)amino]-1h-pyrazol-3-yl}-1h-benzimidazol-6-yl)methyl]morpholin-4-ium small molecule NA experimental tyrosine-protein kinase jak2 JAK2 NA unknown NA drugbank ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved janus kinase 2 JAK2 Successful target unknown 4.01 TTD , DGIDB geminally-substituted cyanoethylpypazolo pyridone derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB tricyclic heterocycle derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrrolo-pyridone derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB imidazo[4,5-c]pyridine derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB fedratinib small molecule Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor 1.31 drugbank , DGIDB pyrrolo[2,3-d]pyrimidine derivative 8 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB azd1480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577] phase 2 janus kinase 2 JAK2 Successful target inhibitor 0.87 TTD , DGIDB pmid27774822-compound-figure3compoundi-165 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB cmp-6 NA NA investigative janus kinase 2 JAK2 Successful target unknown NA TTD pmid27774824-compound-figure8example22 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrazolopyridine derivative 7 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB fedratinib NA Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved janus kinase 2 JAK2 Successful target inhibitor 1.31 TTD , DGIDB aminooxazole carboxamide derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB ly2784544 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloproliferative disease[MeSHID:D009196],Malignant neoplasm of breast[MeSHID:D001943] phase 2 janus kinase 2 JAK2 Successful target inhibitor 1.74 TTD , DGIDB baricitinib NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved janus kinase 2 JAK2 Successful target unknown 0.54 TTD , DGIDB pmid27774822-compound-figure2example1-1right NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB fedratinib NA Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Polycythemia Vera[MeSHID:D011087],Disease[MeSHID:D004194] approved janus kinase 2 JAK2 Successful target unknown 1.31 TTD , DGIDB 5-phenyl-1h-indazol-3-amine small molecule NA experimental tyrosine-protein kinase jak2 JAK2 NA unknown NA drugbank ctp-543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] phase 2 janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB five-and-six-membered heterocyclic compound 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB cycloalkyl nitrile pyrazole carboxamide derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB cyanomethyl pypazole carboxamide derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrrolo-pyridone derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase jak2 JAK2 NA antagonist,inhibitor 0.39 drugbank , DGIDB aromatic bicyclic compound 5 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak2 JAK2 NA antagonist,inhibitor 0.39 drugbank , DGIDB ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved janus kinase 2 JAK2 Successful target unknown 4.01 TTD , DGIDB sgi-1252 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative janus kinase 2 JAK2 Successful target unknown NA TTD cyclic cyanoethypypazole derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor NA drugbank pyrrolo[2,3-d]pyrimidine derivative 7 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB k-454 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative janus kinase 2 JAK2 Successful target unknown NA TTD pmid27774824-compound-figure3example18 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB itf2357 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Thrombocythemia, Essential[MeSHID:D013920],Polycythemia Vera[MeSHID:D011087] phase 3 janus kinase 2 JAK2 Successful target unknown 0.07 TTD , DGIDB xl019 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Polycythemia Vera[MeSHID:D011087] investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor 1.16 drugbank , DGIDB pmid27774824-compound-figure9example2down NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB baricitinib NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved janus kinase 2 JAK2 Successful target inhibitor 0.54 TTD , DGIDB baricitinib NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved janus kinase 2 JAK2 Successful target unknown 0.54 TTD , DGIDB baricitinib NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved janus kinase 2 JAK2 Successful target inhibitor 0.54 TTD , DGIDB pacritinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] phase 3 janus kinase 2 JAK2 Successful target inhibitor 0.7 TTD , DGIDB tricyclic compound 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB geminally-substituted cyanoethylpypazolo pyridone derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB isoxazole derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved janus kinase 2 JAK2 Successful target inhibitor 4.01 TTD , DGIDB ac430 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 janus kinase 2 JAK2 Successful target unknown 3.49 TTD , DGIDB amg-jak2-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577] investigative janus kinase 2 JAK2 Successful target unknown NA TTD ruxolitinib small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved tyrosine-protein kinase jak2 JAK2 NA inhibitor 4.01 drugbank , DGIDB aminotriazolopyridine derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure2example1-1left NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure10example19 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure8example5 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB n-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB aromatic bicyclic compound 4 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrrolo-pyridine derivative 3 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB xl019 NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Polycythemia Vera[MeSHID:D011087] phase 3 janus kinase 2 JAK2 Successful target unknown 1.16 TTD , DGIDB pmid24359159c19a NA NA investigative janus kinase 2 JAK2 Successful target unknown NA TTD az960 NA NA investigative janus kinase 2 JAK2 Successful target inhibitor NA TTD , DGIDB pmid27774822-compound-figure10compound4 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure2example4 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pacritinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] phase 3 janus kinase 2 JAK2 Successful target unknown 0.7 TTD , DGIDB triazolo-pyridine derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB benzimidazole derivative 7 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrimidopyridazinone derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure6example12 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure11example1up NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB 1,2,4-triazolo[1,5a]pyridine derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor NA drugbank ns-018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] phase 1/2 janus kinase 2 JAK2 Successful target inhibitor 0.65 TTD , DGIDB az960 NA NA investigative janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB azd1480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577] phase 2 janus kinase 2 JAK2 Successful target unknown 0.87 TTD , DGIDB peginterferon beta NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB alkynyl-substituted pyrimidinyl-pyrrole derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrrole six-membered heteroaryl ring derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure10compound12 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB fedratinib NA Primary Myelofibrosis[MeSHID:D055728],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Polycythemia Vera[MeSHID:D011087],Disease[MeSHID:D004194] approved janus kinase 2 JAK2 Successful target inhibitor 1.31 TTD , DGIDB aromatic bicyclic compound 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB bvb-808 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative janus kinase 2 JAK2 Successful target unknown NA TTD pmid27774822-compound-figure11example5 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pyrazolopyridine derivative 6 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB aromatic bicyclic compound 6 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure7example63 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB incb039110 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 janus kinase 2 JAK2 Successful target unknown 0.58 TTD , DGIDB 1,2,3,4,5,6-hexabromocyclohexane NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] investigative janus kinase 2 JAK2 Successful target unknown NA TTD cerdulatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],B-Cell Lymphomas[MeSHID:D016393],Vitiligo[MeSHID:D014820] phase 2 janus kinase 2 JAK2 Successful target inhibitor 0.19 TTD , DGIDB ns-018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] phase 1/2 janus kinase 2 JAK2 Successful target unknown 0.65 TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 11 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure6example6 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure1example20 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB bms-911543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] phase 2 janus kinase 2 JAK2 Successful target inhibitor 0.65 TTD , DGIDB ac430 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 janus kinase 2 JAK2 Successful target inhibitor 3.49 TTD , DGIDB 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one small molecule NA experimental tyrosine-protein kinase jak2 JAK2 NA unknown NA drugbank whi-p154 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] investigative janus kinase 2 JAK2 Successful target unknown 0.44 TTD , DGIDB pyrazolo[4,3-c]pyridine derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor NA drugbank pyrazolopyridine derivative 4 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB on-044580 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative janus kinase 2 JAK2 Successful target unknown NA TTD pmid21493067c1d NA NA investigative janus kinase 2 JAK2 Successful target unknown NA TTD tricyclic compound 11 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB nsc-1771 NA NA investigative janus kinase 2 JAK2 Successful target unknown NA TTD cycloalkyl nitrile pyrazolo pyridone derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB entrectinib small molecule Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved,investigational tyrosine-protein kinase jak2 JAK2 NA inhibitor 0.01 drugbank , DGIDB aromatic bicyclic compound 3 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB xl019 NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Polycythemia Vera[MeSHID:D011087] phase 3 janus kinase 2 JAK2 Successful target inhibitor 1.16 TTD , DGIDB bms-911543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728] phase 2 janus kinase 2 JAK2 Successful target unknown 0.65 TTD , DGIDB pmid27774824-compound-figure9example2up NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB isoxazole derivative 1 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB ly2784544 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloproliferative disease[MeSHID:D009196],Malignant neoplasm of breast[MeSHID:D001943] phase 2 janus kinase 2 JAK2 Successful target unknown 1.74 TTD , DGIDB ruxolitinib derivative 2 NA NA patented janus kinase 2 JAK2 Successful target unknown NA TTD , DGIDB r-348 small molecule Autoimmune Diseases[MeSHID:D001327] investigational tyrosine-protein kinase jak3 JAK3 NA inhibitor 1.22 drugbank , DGIDB pmid27774824-compound-figure3example18 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB imidazo[4,5-c]pyridine derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tofacitinib NA Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved janus kinase 3 JAK3 Successful target inhibitor 1.77 TTD , DGIDB pyrazolopyridine derivative 7 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB ati-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] phase 2 janus kinase 3 JAK3 Successful target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak3 JAK3 NA inhibitor NA drugbank benzimidazole derivative 7 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure12example1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB n-methylmethanesulfonamide derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure3example7 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 4 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB ad-412 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative janus kinase 3 JAK3 Successful target unknown NA TTD pyrrolo[2,3-d]pyrimidine derivative 8 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrrolo-pyrazine derivative 4 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure6example2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB isoxazole derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure6example3 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB ati-502 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505],Eczema[MeSHID:D004485] phase 2 janus kinase 3 JAK3 Successful target unknown NA TTD pyrrolo[2,3-d]pyrimidine derivative 6 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB aminotriazolopyridine derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrimidopyridazinone derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase jak3 JAK3 NA inhibitor 1.77 drugbank , DGIDB ruxolitinib small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved tyrosine-protein kinase jak3 JAK3 NA inhibitor 0.61 drugbank , DGIDB pyrrolo[2,3-d]pyrimidine derivative 7 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB benzimidazole derivative 5 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB imidazopyridine derivative 4 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrazolopyridine derivative 6 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure11example1up NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrazolopyridine derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure1example20 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tricyclic compound 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB ruxolitinib small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved tyrosine-protein kinase jak3 JAK3 NA inhibitor 0.61 drugbank , DGIDB pyrrolo-pyrazine derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB ruxolitinib derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 3 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrazolopyridine derivative 4 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB vx-467 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative janus kinase 3 JAK3 Successful target unknown NA TTD 6-o-tolylquinazolin-2-amine NA NA investigative janus kinase 3 JAK3 Successful target unknown NA TTD tofacitinib NA Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved janus kinase 3 JAK3 Successful target unknown 1.77 TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase jak3 JAK3 NA inhibitor NA drugbank imidazopyridazine derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure8example5 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrrolo-pyridine derivative 3 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrazolopyridine derivative 3 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB n-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB cerdulatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],B-Cell Lymphomas[MeSHID:D016393],Vitiligo[MeSHID:D014820] phase 2 janus kinase 3 JAK3 Successful target unknown 0.41 TTD , DGIDB pmid27774824-compound-figure6example12 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tricyclic pyrrolopyridine compound 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure2example1-1right NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB nc1153 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative janus kinase 3 JAK3 Successful target unknown NA TTD pmid27774822-compound-figure10example1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrrole six-membered heteroaryl ring derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid21493067c1d NA NA investigative janus kinase 3 JAK3 Successful target unknown NA TTD pmid27774824-compound-figure12example61 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure9example2down NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB 1,2,4-triazolo[1,5a]pyridine derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB whi-p154 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] investigative janus kinase 3 JAK3 Successful target unknown NA TTD aminooxazole carboxamide derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak3 JAK3 NA inhibitor 1.77 drugbank , DGIDB pmid27774824-compound-figure9example2up NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tricyclic heterocycle derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one small molecule NA experimental tyrosine-protein kinase jak3 JAK3 NA unknown NA drugbank isoxazole derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB atropisomer 1 NA NA investigative janus kinase 3 JAK3 Successful target unknown NA TTD pyrazolo[4,3-c]pyridine derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB five-and-six-membered heterocyclic compound 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tofacitinib NA Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved janus kinase 3 JAK3 Successful target unknown 1.77 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase jak3 JAK3 NA inhibitor NA drugbank asp-015k NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Rheumatoid Arthritis[MeSHID:D001172] phase 3 janus kinase 3 JAK3 Successful target unknown 0.98 TTD , DGIDB pmid27774824-compound-figure2example4 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB cmp-6 NA NA investigative janus kinase 3 JAK3 Successful target unknown NA TTD pmid24359159c19a NA NA investigative janus kinase 3 JAK3 Successful target unknown NA TTD pmid27774824-compound-figure5example13 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pf-956980 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative janus kinase 3 JAK3 Successful target inhibitor NA TTD , DGIDB pmid27774822-compound-figure2example4-3 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrrolo-pyrazine derivative 2 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB imidazopyridazine derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrrolo-pyrazine derivative 3 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pyrazolopyridine derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tricyclic heterocycle derivative 5 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB zm-39923 NA NA investigative janus kinase 3 JAK3 Successful target unknown NA TTD pmid27774822-compound-figure2example1-1left NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tricyclic compound 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid15546730c2 NA NA investigative janus kinase 3 JAK3 Successful target unknown NA TTD ati-502 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Vitiligo[MeSHID:D014820] phase 2 janus kinase 3 JAK3 Successful target unknown NA TTD tricyclic heterocycle derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774824-compound-figure12example10 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tricyclic compound 11 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB pmid27774822-compound-figure10example19 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB baricitinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase jak3 JAK3 NA inhibitor 0.15 drugbank , DGIDB imidazo[4,5-c]pyridine derivative 1 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB tofacitinib NA Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved janus kinase 3 JAK3 Successful target inhibitor 1.77 TTD , DGIDB sna-125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Psoriasis[MeSHID:D011565],Pruritus[MeSHID:D011537] phase 1 janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB baricitinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational tyrosine-protein kinase jak3 JAK3 NA inhibitor 0.15 drugbank , DGIDB cerdulatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],B-Cell Lymphomas[MeSHID:D016393],Vitiligo[MeSHID:D014820] phase 2 janus kinase 3 JAK3 Successful target inhibitor 0.41 TTD , DGIDB pf-06651600 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505],Crohn Disease[MeSHID:D003424],Asthma[MeSHID:D001249] phase 2/3 janus kinase 3 JAK3 Successful target unknown 1.22 TTD , DGIDB pmid27774822-compound-figure11example5 NA NA patented janus kinase 3 JAK3 Successful target unknown NA TTD , DGIDB vx-509 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2/3 janus kinase 3 JAK3 Successful target unknown 1.63 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational immunoglobulin j chain JCHAIN NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational immunoglobulin j chain JCHAIN NA component of NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental immunoglobulin j chain JCHAIN NA component of NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational immunoglobulin j chain JCHAIN NA unknown NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 JDP2 NA inhibitor NA drugbank irbesartan small molecule Hypertensive disease[MeSHID:D006973],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],hypertensive nephropathy[MeSHID:C563161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational transcription factor ap-1 JUN NA unknown NA drugbank [(r)-(+)-deoxytylophorinidine NA NA investigative c-jun messenger rna JUN Literature-reported target unknown NA TTD isis 10582 NA NA investigative c-jun messenger rna JUN Literature-reported target unknown NA TTD pergularinine NA NA investigative c-jun messenger rna JUN Literature-reported target unknown NA TTD t-5224 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 transcription factor ap-1 JUN Discontinued target unknown NA TTD , DGIDB arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational transcription factor ap-1 JUN NA inducer NA drugbank , DGIDB adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transcription factor ap-1 JUN NA antagonist NA drugbank vinblastine small molecule Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Neuroblastoma[MeSHID:D009447],Malignant neoplasm of testis[MeSHID:D013736],Histiocytosis[MeSHID:D015614],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved transcription factor ap-1 JUN NA unknown NA drugbank dcb-3503 NA NA investigative c-jun messenger rna JUN Literature-reported target unknown NA TTD pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved activator protein 1 JUN NA inhibitor NA drugbank pnri-299 NA NA investigative transcription factor ap-1 JUN Discontinued target unknown NA TTD tws-119 NA NA investigative transcription factor ap-1 JUN Discontinued target unknown NA TTD irbesartan small molecule Hypertensive disease[MeSHID:D006973],Serum[MeSHID:D044967],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Proteinuria[MeSHID:D011507],hypertensive nephropathy[MeSHID:C563161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational transcription factor ap-1 JUN NA unknown NA drugbank tam-67 NA NA investigative transcription factor ap-1 JUN Discontinued target unknown NA TTD lgd-1550 small molecule Neoplasms[MeSHID:D009369] investigational transcription factor ap-1 JUN NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational junction plakoglobin JUP NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational junction plakoglobin JUP NA unknown NA drugbank naringenin small molecule NA experimental kat8 regulatory nsl complex subunit 3 KANSL3 NA unknown NA drugbank lysine small molecule Virus Physiological Phenomena[MeSHID:D018406],Herpes Simplex Infections[MeSHID:D006561] approved,nutraceutical lysine--trna ligase KARS NA unknown NA drugbank coenzyme a small molecule NA investigational,nutraceutical histone acetyltransferase kat2a KAT2A NA unknown NA drugbank mb-3 NA NA investigative histone acetyltransferase kat2b KAT2B Literature-reported target unknown NA TTD n-(3-aminopropyl)-2-nitrobenzenamine small molecule NA experimental histone acetyltransferase kat2b KAT2B NA unknown NA drugbank anacardic acid NA NA investigative histone acetyltransferase kat2b KAT2B Literature-reported target unknown NA TTD , DGIDB pmid15724976c1 NA NA investigative histone acetyltransferase kat2b KAT2B Literature-reported target unknown NA TTD anacardic acid NA NA investigative histone acetyltransferase kat2b KAT2B Literature-reported target inhibitor NA TTD , DGIDB ltk-14 NA NA investigative histone acetyltransferase kat2b KAT2B Literature-reported target inhibitor NA TTD , DGIDB (3e)-4-(1-methyl-1h-indol-3-yl)but-3-en-2-one small molecule NA experimental histone acetyltransferase kat2b KAT2B NA unknown NA drugbank coenzyme a small molecule NA investigational,nutraceutical histone acetyltransferase kat2b KAT2B NA unknown NA drugbank garcinol NA NA investigative histone acetyltransferase kat2b KAT2B Literature-reported target inhibitor 1.63 TTD , DGIDB s-acetyl-cysteine small molecule NA experimental histone acetyltransferase kat5 KAT5 NA unknown NA drugbank coenzyme a small molecule NA investigational,nutraceutical histone acetyltransferase kat5 KAT5 NA unknown NA drugbank garcinol NA NA investigative histone acetyltransferase kat6b KAT6B Literature-reported target unknown NA TTD sgc-cbp30 NA NA investigative histone acetyltransferase kat6b KAT6B Literature-reported target unknown NA TTD i-cbp112 NA NA investigative histone acetyltransferase kat6b KAT6B Literature-reported target unknown NA TTD mg149 NA NA investigative histone acetyltransferase kat6b KAT6B Literature-reported target unknown NA TTD anacardic acid NA NA investigative histone acetyltransferase kat6b KAT6B Literature-reported target unknown NA TTD c646 NA NA investigative histone acetyltransferase kat6b KAT6B Literature-reported target unknown NA TTD isoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved potassium voltage-gated channel subfamily a member 1 KCNA1 NA inducer 1 drugbank , DGIDB dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 1 KCNA1 NA antagonist 0.54 drugbank , DGIDB desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 1 KCNA1 NA inducer 0.96 drugbank , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved potassium voltage-gated channel subfamily a member 1 KCNA1 NA inhibitor NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved potassium voltage-gated channel subfamily a member 1 KCNA1 NA inducer NA drugbank tetraethylammonium small molecule NA experimental,investigational potassium voltage-gated channel subfamily a member 1 KCNA1 NA blocker NA drugbank amifampridine small molecule Lambert-Eaton Myasthenic Syndrome[MeSHID:D015624],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily a member 1 KCNA1 NA blocker NA drugbank dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 1 KCNA1 NA antagonist,blocker 0.54 drugbank , DGIDB dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 10 KCNA10 NA antagonist,blocker 0.63 drugbank , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv1.8 KCNA10 Literature-reported target unknown NA TTD dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 2 KCNA2 NA antagonist,blocker 0.49 drugbank , DGIDB clofazimine small molecule Erythema Nodosum[MeSHID:D004893],Leprosy, Lepromatous[MeSHID:D015440],Leprosy[MeSHID:D007918],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Mycobacterium Infections[MeSHID:D009164] approved,investigational potassium voltage-gated channel subfamily a member 3 KCNA3 NA antagonist NA drugbank debio-0824 NA Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1b/2a voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD , DGIDB 1-benzyl-7-chloro-4-hexyloxy-quinolinium NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 3 KCNA3 NA antagonist,blocker 0.49 drugbank , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD 4-(4-phenoxybutoxy)-7h-furo[3,2-g]chromen-7-one NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD correloid NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD 5-(4-phenylbutoxy)psoralen NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD 2-methoxy-n-(3-methyl-2-phenyl-butyl)-benzamide NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD correolide NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target blocker 10.61 TTD , DGIDB dalazatide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inclusion Body Myositis (disorder)[MeSHID:D018979],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225] phase 1b/2a voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown 10.61 TTD , DGIDB cp-339818 NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD [1-benzyl-1h-quinolin-(4e)-ylidene]-hexyl-amine NA NA investigative voltage-gated potassium channel kv1.3 KCNA3 Clinical trial target unknown NA TTD dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 4 KCNA4 NA antagonist,blocker 0.59 drugbank , DGIDB arginineamide small molecule NA experimental potassium voltage-gated channel subfamily a member 4 KCNA4 NA unknown NA drugbank dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 5 KCNA5 NA antagonist,blocker 0.23 drugbank , DGIDB vernakalant small molecule Atrial Fibrillation[MeSHID:D001281],Operative Surgical Procedures[MeSHID:D013514],pathologic fistula[MeSHID:D005402],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily a member 5 KCNA5 NA blocker NA drugbank 3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD 4-(4-phenoxybutoxy)-7h-furo[3,2-g]chromen-7-one NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD s-9947 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD 2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD 2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD n-benzyl-2-(toluene-4-sulfonylamino)-benzamide NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD t-226296 NA Atrial Fibrillation[MeSHID:D001281],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown 1.68 TTD , DGIDB 2-phenyl-1,1-di(pyridin-3-yl)ethanol NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD 3-methyl-2-morpholino-1,1-diphenylbutan-1-ol NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD 2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD dronedarone NA Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown 0.84 TTD , DGIDB clofilium NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target blocker 0.84 TTD , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational potassium voltage-gated channel subfamily a member 5 KCNA5 NA inhibitor NA drugbank 3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD dpo-1 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD rs-100302 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD 2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD xen-d0101 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD , DGIDB n-phenethyl-2-(toluene-4-sulfonylamino)-benzamide NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD xen-d0104 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD iqb-9302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD , DGIDB xen-d0103 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD , DGIDB 2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD 2-morpholino-1,1,2-triphenylethanol NA NA investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD dronedarone NA Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated potassium channel kv1.5 KCNA5 Successful target inhibitor 0.84 TTD , DGIDB bms-394136 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] phase 1 voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown 3.35 TTD , DGIDB bms-919373 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown 3.35 TTD , DGIDB nip-142 NA Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative voltage-gated potassium channel kv1.5 KCNA5 Successful target unknown NA TTD dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 6 KCNA6 NA antagonist,blocker 0.74 drugbank , DGIDB tedisamil NA NA investigative voltage-gated potassium channel kv1.7 KCNA7 Literature-reported target blocker 0.2 TTD , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv1.7 KCNA7 Literature-reported target unknown NA TTD dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily a member 7 KCNA7 NA antagonist,blocker 0.37 drugbank , DGIDB dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily b member 1 KCNB1 NA antagonist,blocker 0.74 drugbank , DGIDB ry796 NA NA investigative voltage-gated potassium channel kv2.2 KCNB2 Literature-reported target inhibitor NA TTD , DGIDB dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily b member 2 KCNB2 NA antagonist,blocker 0.89 drugbank , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv2.2 KCNB2 Literature-reported target unknown NA TTD dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily c member 1 KCNC1 NA antagonist,blocker 0.74 drugbank , DGIDB dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily c member 2 KCNC2 NA antagonist,blocker 0.74 drugbank , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv3.2 KCNC2 Literature-reported target unknown NA TTD dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily c member 3 KCNC3 NA antagonist,blocker 0.74 drugbank , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv3.3 KCNC3 Literature-reported target unknown NA TTD dexfosfoserine small molecule NA experimental potassium voltage-gated channel subfamily c member 4 KCNC4 NA unknown NA drugbank dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily d member 1 KCND1 NA antagonist,blocker 1.11 drugbank , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv4.1 KCND1 Literature-reported target unknown NA TTD disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved potassium voltage-gated channel subfamily d member 2 KCND2 NA inhibitor NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved potassium voltage-gated channel subfamily d member 2 KCND2 NA inhibitor NA drugbank dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily d member 2 KCND2 NA antagonist,blocker 0.74 drugbank , DGIDB nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved potassium voltage-gated channel subfamily d member 3 KCND3 NA inhibitor NA drugbank sodium bicarbonate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic acidosis[MeSHID:D000138] approved voltage-gated potassium channel kv4.3 KCND3 Successful target unknown NA TTD , DGIDB isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational potassium voltage-gated channel subfamily d member 3 KCND3 NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily d member 3 KCND3 NA inhibitor NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved potassium voltage-gated channel subfamily d member 3 KCND3 NA inhibitor NA drugbank disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved potassium voltage-gated channel subfamily d member 3 KCND3 NA inhibitor NA drugbank dalfampridine small molecule Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily d member 3 KCND3 NA antagonist,blocker 0.74 drugbank , DGIDB vernakalant small molecule Atrial Fibrillation[MeSHID:D001281],Operative Surgical Procedures[MeSHID:D013514],pathologic fistula[MeSHID:D005402],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily d member 3 KCND3 NA blocker NA drugbank azimilide small molecule Cardiac Arrhythmia[MeSHID:D001145],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational potassium voltage-gated channel subfamily e member 1 KCNE1 NA unknown NA drugbank astemizole small molecule Allergic Reaction[MeSHID:D006967],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Cardiac Arrhythmia[MeSHID:D001145],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn potassium voltage-gated channel subfamily h member 1 KCNH1 NA blocker 0.76 drugbank , DGIDB imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved potassium voltage-gated channel subfamily h member 1 KCNH1 NA blocker 0.82 drugbank , DGIDB quinoline derivative 11 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB 3-(1-phenethyl-piperidin-3-yl)-2-phenyl-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD (r)-n-isobutyl-n-(pyrrolidin-3-yl)-2-naphthamide NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD ns-1643 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 5-(3-butylpyrrolidin-3-yl)-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank r-dimethindene NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD propafenone small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Diseases[MeSHID:D006331],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.12 drugbank , DGIDB disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor,blocker 0.31 drugbank , DGIDB isoquine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] phase 1 voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown 0.06 TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank 4-((naphthalen-2-yloxy)methyl)piperidine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 7-(piperidin-4-ylmethoxy)-2-naphthonitrile NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD (e)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 3 9-dihydro-n-desmethyl-n-isopropylerythromycin a NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor,blocker 0.34 drugbank , DGIDB pimozide small molecule Gilles de la Tourette syndrome[MeSHID:D005879],Tic, Vocal[MeSHID:D020323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.03 drugbank , DGIDB rpr260243 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target activator NA TTD , DGIDB astemizole small molecule Allergic Reaction[MeSHID:D006967],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Cardiac Arrhythmia[MeSHID:D001145],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.15 drugbank , DGIDB ica-105574 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target activator NA TTD , DGIDB dofetilide small molecule Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Maintenance[MeSHID:D008283],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.23 drugbank , DGIDB desmethylolanzapine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank bms-645737 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD isoindoline derivative 3 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB quinoline derivative 12 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB 4-(p-tolyl)spiro[chromene-2,4'-piperidine] NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 3-(1-phenethyl-piperidin-4-yl)-2-phenyl-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD ciprofloxacin small molecule Solutions[MeSHID:D012996],Sinusitis[MeSHID:D012852],Otitis Media[MeSHID:D010033],Febrile Neutropenia[MeSHID:D064147],Bacterial conjunctivitis[MeSHID:D003234],Skin Diseases, Infectious[MeSHID:D012874],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Intraabdominal Infections[MeSHID:D059413],Anthrax disease[MeSHID:D000881],Pyelonephritis[MeSHID:D011704],Corneal Ulcer[MeSHID:D003320],Urinary tract infection[MeSHID:D014552],Patient Discharge[MeSHID:D010351],Infection[MeSHID:D007239],Plague[MeSHID:D010930],Chronic Bacterial Prostatitis[MeSHID:D011472],Otitis Media with Effusion[MeSHID:D010034],Otitis Externa[MeSHID:D010032],Conjunctivitis[MeSHID:D003231],Pneumonia[MeSHID:D011014],Respiratory Tract Infections[MeSHID:D012141],Bone Tissue[MeSHID:D001842],Inspiration function[MeSHID:D001239],Bronchitis, Chronic[MeSHID:D029481] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank 1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine (enantiomeric mix) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 5-(3-benzylpyrrolidin-3-yl)-1h-indole (structural mix) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.31 drugbank , DGIDB 4-(2-thienyl)benzene-1,2-diamine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB isoindoline derivative 2 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved herg human cardiac k+ channel KCNH2 NA blocker NA drugbank pitolisant small molecule Narcolepsy[MeSHID:D009290],Cataplexy[MeSHID:D002385],Hypersomnia[MeSHID:D006970],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA blocker NA drugbank vesnarinone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown 0.03 TTD , DGIDB 3-(1-methyl-piperidin-2-yl)-2-phenyl-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 4-(spiro[chromene-2,4'-piperidine]-4-yl)phenol NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD pf-526014 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD jnj-10392980 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD mdl-74156 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 3-(1-benzyl-piperidin-3-yl)-2-phenyl-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD erythromycin small molecule Streptococcal pneumonia[MeSHID:D011018],Skin Diseases, Infectious[MeSHID:D012874],Listeriosis[MeSHID:D008088],Pregnancy[MeSHID:D011247],Erythrasma[MeSHID:D004894],Syphilitic chancre[MeSHID:D002601],Pelvic Inflammatory Disease[MeSHID:D000292],Muscle strain[MeSHID:D013180],Hypersensitivity[MeSHID:D006967],Infection[MeSHID:D007239],Nasopharynx[MeSHID:D009305],Legionnaires' Disease[MeSHID:D007877],Urethra[MeSHID:D014521],Conjunctivitis[MeSHID:D003231],Pneumonia[MeSHID:D011014],Urethritis[MeSHID:D014526],Reproduction[MeSHID:D012098],Respiratory Tract Infections[MeSHID:D012141],Rheumatic Fever[MeSHID:D012213],Pertussis[MeSHID:D014917],Gonorrhea[MeSHID:D006069],Chlamydia Infections[MeSHID:D002690],Communicable Diseases[MeSHID:D003141],Carrier of disorder[MeSHID:D002353],Syphilis[MeSHID:D013587],Amebic colitis[MeSHID:D004404],Amebiasis[MeSHID:D000562],Genetic Carriers[MeSHID:D006579],Primary syphilis[MeSHID:C536772],Diphtheria[MeSHID:D004165],Behavior[MeSHID:D001519],Sexually Transmitted Diseases[MeSHID:D012749],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.06 drugbank , DGIDB 2-[4-(2-piperidin-1-ylethyl)phenoxy]benzothiazole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD n-(4-(benzyloxy)phenethyl)pyridin-4-amine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD n-(piperidin-4-yl)-n-propyl-2-naphthamide NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD [1-(4-p-tolyl-butyl)-piperidin-4-yl]-methanol NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 1,6-bis(4-phenylpiperazin-1-yl)hexane NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD silodosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved herg human cardiac k+ channel KCNH2 NA blocker NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank (r)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank isoindoline derivative 4 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB 2-phenyl-3-piperidin-4-yl-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 1-(4-p-tolyl-butyl)-piperidine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD abt-229 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown 0.09 TTD , DGIDB isoindoline derivative 1 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD (r)-3-(naphthalen-2-ylmethoxy)pyrrolidine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.02 drugbank , DGIDB astemizole small molecule Allergic Reaction[MeSHID:D006967],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Cardiac Arrhythmia[MeSHID:D001145],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor,blocker 0.15 drugbank , DGIDB kb-130015 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target activator NA TTD , DGIDB 4-(3-thienyl)benzene-1,2-diamine) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD pd-118057 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target activator NA TTD , DGIDB desmethylastemizole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown 0.19 TTD , DGIDB 1,6-bis(4-m-tolylpiperazin-1-yl)hexane NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine (enantiomeric mix) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD quinidine small molecule Preexcitation Syndrome[MeSHID:D011226],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Conduction disorder of the heart[MeSHID:D000075224] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.09 drugbank , DGIDB (2r)-n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-2-hydroxypropanamide (enantiomeric mix) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 4-benzenesulfonyl-1-(3-phenyl-propyl)-piperidine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD doxazosin small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved herg human cardiac k+ channel KCNH2 NA inhibitor NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank a-935142 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target activator NA TTD , DGIDB prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank isoindoline derivative 5 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB (s)-3-(naphthalen-2-ylmethoxy)pyrrolidine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD gw803430 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD loratadine small molecule Urticaria[MeSHID:D014581],Allergic rhinitis (disorder)[MeSHID:D065631],Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA antagonist NA drugbank pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA antagonist NA drugbank 5-chloro-3-ethyl-1-(4-fluoro-phenyl)-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 4-phenylspiro[chromene-2,4'-piperidine] NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD cisapride small molecule Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.3 drugbank , DGIDB 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-n-(hydroxymethyl)-1,2,2-trimethyl-1,2,3,4-tetrahydro-1,8-naphthyridine-4-carboxamide (enantiomeric mix) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 5-(3-benzylpyrrolidin-3-yl)-1-methyl-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine (enantiomeric mix) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank ketoconazole small molecule Paracoccidioidomycosis[MeSHID:D010229],Mycoses[MeSHID:D009181],Coccidioidomycosis[MeSHID:D003047],Cushing Syndrome[MeSHID:D003480],Candidiasis[MeSHID:D002177],Chromoblastomycosis[MeSHID:D002862],Blastomycosis[MeSHID:D001759],Histoplasmosis[MeSHID:D006660],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank 2-phenyl-3-piperidin-3-yl-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD hydroxyzine small molecule Pruritus[MeSHID:D011537],Neurotic Disorders[MeSHID:D009497],Disease[MeSHID:D004194],Nausea[MeSHID:D009325],Dental Health Services[MeSHID:D003752],Operative Surgical Procedures[MeSHID:D013514],Vomiting[MeSHID:D014839],Pregnancy[MeSHID:D011247],Urticaria[MeSHID:D014581],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.07 drugbank , DGIDB pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB ads-103253 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD perhexiline small molecule Disease Management[MeSHID:D019468],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.09 drugbank , DGIDB tecastemizole small molecule Allergic rhinitis (disorder)[MeSHID:D065631] investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank terazosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank procainamide small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank clarithromycin small molecule Endocarditis[MeSHID:D004696],Bacteremia[MeSHID:D016470],Tonsillitis[MeSHID:D014069],Skin Diseases, Infectious[MeSHID:D012874],Hemolysis (disorder)[MeSHID:D006461],Pharyngitis[MeSHID:D010612],Infection[MeSHID:D007239],Encephalitis[MeSHID:D004660],Legionnaires' Disease[MeSHID:D007877],Pneumonia[MeSHID:D011014],Respiratory Tract Infections[MeSHID:D012141],Duodenal Ulcer[MeSHID:D004381],Cryptosporidiosis[MeSHID:D003457],Maxillary Sinusitis[MeSHID:D015523],Pertussis[MeSHID:D014917],Bartonella Infections[MeSHID:D001474],Otitis Media[MeSHID:D010033],HIV Infections[MeSHID:D015658],Immediate hypersensitivity[MeSHID:D006969],Communicable Diseases[MeSHID:D003141],Lyme Disease[MeSHID:D008193],Bronchitis, Chronic[MeSHID:D029481],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank quinoline derivative 13 NA NA patented voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB dofetilide small molecule Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Maintenance[MeSHID:D008283],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor,blocker 0.23 drugbank , DGIDB pd-307243 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target activator NA TTD , DGIDB terfenadine small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.12 drugbank , DGIDB flecainide small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD halofantrine small molecule Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor,blocker 0.56 drugbank , DGIDB (1r,5r)-30-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaene-17-carbonitrile (structural mix) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD vu0405601 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target activator NA TTD , DGIDB vernakalant small molecule Atrial Fibrillation[MeSHID:D001281],Operative Surgical Procedures[MeSHID:D013514],pathologic fistula[MeSHID:D005402],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA blocker NA drugbank thioridazine small molecule Anxiety Disorders[MeSHID:D001008],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.03 drugbank , DGIDB fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.02 drugbank , DGIDB sertindole small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.08 drugbank , DGIDB n-(6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridin-4-yl)-3-hydroxypropanamide (enantiomeric mix) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 4-benzenesulfonyl-1-phenethyl-piperidine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD mk-499 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] discontinued in phase 2 voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank amsacrine small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank 3-(1h-indol-3-yl)-n-methyl-3-phenylpropan-1-amine NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD fluvoxamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Mental Depression[MeSHID:D003863],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank sotalol small molecule Solutions[MeSHID:D012996],Maintenance[MeSHID:D008283],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.13 drugbank , DGIDB cisapride small molecule Heartburn[MeSHID:D006356],Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor,blocker 0.3 drugbank , DGIDB verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank 5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD potassium nitrate small molecule Dentin Sensitivity[MeSHID:D003807] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA agonist NA drugbank m100907 NA Sleep Disorders[MeSHID:D012893],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD , DGIDB clarithromycin small molecule Endocarditis[MeSHID:D004696],Bacteremia[MeSHID:D016470],Tonsillitis[MeSHID:D014069],Skin Diseases, Infectious[MeSHID:D012874],Hemolysis (disorder)[MeSHID:D006461],Pharyngitis[MeSHID:D010612],Infection[MeSHID:D007239],Encephalitis[MeSHID:D004660],Legionnaires' Disease[MeSHID:D007877],Pneumonia[MeSHID:D011014],Respiratory Tract Infections[MeSHID:D012141],Duodenal Ulcer[MeSHID:D004381],Cryptosporidiosis[MeSHID:D003457],Maxillary Sinusitis[MeSHID:D015523],Pertussis[MeSHID:D014917],Bartonella Infections[MeSHID:D001474],Otitis Media[MeSHID:D010033],HIV Infections[MeSHID:D015658],Immediate hypersensitivity[MeSHID:D006969],Communicable Diseases[MeSHID:D003141],Lyme Disease[MeSHID:D008193],Bronchitis, Chronic[MeSHID:D029481],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational herg human cardiac k+ channel KCNH2 NA inhibitor 0.08 drugbank , DGIDB ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.34 drugbank , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational herg human cardiac k+ channel KCNH2 NA inhibitor 0.08 drugbank , DGIDB 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD mk-1925 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD fluvoxamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Mental Depression[MeSHID:D003863],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor 0.02 drugbank , DGIDB azimilide small molecule Cardiac Arrhythmia[MeSHID:D001145],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank prazosin small molecule Hypertensive disease[MeSHID:D006973],Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory physiology[MeSHID:D012143],Asthma[MeSHID:D001249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333],Benign Prostatic Hyperplasia[MeSHID:D011470] approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor NA drugbank terfenadine small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,withdrawn potassium voltage-gated channel subfamily h member 2 KCNH2 NA inhibitor,blocker 0.12 drugbank , DGIDB ginsenoside rg3 NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target activator NA TTD , DGIDB n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-yl]-4,4,4-trifluoro-3-hydroxybutanamide (diastereomeric mix) NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD hp-184 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown 0 TTD , DGIDB chlorobutanol small molecule NA approved,investigational,vet_approved potassium voltage-gated channel subfamily h member 2 KCNH2 NA unknown NA drugbank nitd609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] phase 2 voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown 0.09 TTD , DGIDB (r)-ondansetron NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD 3-(1-methyl-piperidin-3-yl)-2-phenyl-1h-indole NA NA investigative voltage-gated potassium channel kv11.1 KCNH2 Successful target unknown NA TTD cx4 NA NA investigative voltage-gated potassium channel kv12.2 KCNH3 Literature-reported target unknown NA TTD ly97241 NA NA investigative voltage-gated potassium channel kv10.2 KCNH5 Literature-reported target blocker NA TTD , DGIDB silodosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved herg human cardiac k+ channel KCNH6 NA blocker NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved herg human cardiac k+ channel KCNH6 NA blocker NA drugbank doxazosin small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved herg human cardiac k+ channel KCNH6 NA inhibitor NA drugbank terazosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 6 KCNH6 NA inhibitor NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational herg human cardiac k+ channel KCNH6 NA inhibitor NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational herg human cardiac k+ channel KCNH6 NA inhibitor NA drugbank ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 6 KCNH6 NA inhibitor NA drugbank ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 7 KCNH7 NA inhibitor NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved herg human cardiac k+ channel KCNH7 NA blocker NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational herg human cardiac k+ channel KCNH7 NA inhibitor NA drugbank doxazosin small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Ureterolithiasis[MeSHID:D053039],Nocturia[MeSHID:D053158],Urinary tract[MeSHID:D014551],Ureteral Calculi[MeSHID:D014514],Benign prostatic hypertrophy[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved herg human cardiac k+ channel KCNH7 NA inhibitor NA drugbank terazosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily h member 7 KCNH7 NA inhibitor NA drugbank silodosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved herg human cardiac k+ channel KCNH7 NA blocker NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational herg human cardiac k+ channel KCNH7 NA inhibitor NA drugbank agmatine small molecule Diabetes Mellitus[MeSHID:D003920],Small Fiber Neuropathy[MeSHID:D000071075],Neuroprotection[MeSHID:D000066829],Glaucoma[MeSHID:D005901],Diagnosis[MeSHID:D003933],Epilepsy[MeSHID:D004827],Kidney[MeSHID:D007668],Anxiety Disorders[MeSHID:D001008],Blind Vision[MeSHID:D001766],Mental Depression[MeSHID:D003863],Cognition[MeSHID:D003071],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Traumatic injury[MeSHID:D014947],Cerebrovascular accident[MeSHID:D020521],Anxiety[MeSHID:D001007] experimental atp-sensitive inward rectifier potassium channel 1 KCNJ1 NA antagonist NA drugbank pmid26004420-compound-us20140142115c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014099633e NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014126944a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2010129379b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013039802b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2010129379a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2012058116c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013039802c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2015017305e NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013028474a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2012058134a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014085210b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013062892d NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140142115b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140142115a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014150132c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2012058116a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013028474c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-u2014s0288042c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2015017305f NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014150132b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-u2014s0288042a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014015495c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013039802a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140275020e NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB acetohexamide small molecule Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn atp-sensitive inward rectifier potassium channel 1 KCNJ1 NA inhibitor 10.61 drugbank , DGIDB pmid26004420-compound-wo2010129379c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140031349b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013062900c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014015495d NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013062900a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013062892e NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140336177d NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140336177e NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014085210a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB minoxidil small molecule Hypertensive disease[MeSHID:D006973],Androgenetic Alopecia[MeSHID:D000505],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atp-sensitive inward rectifier potassium channel 1 KCNJ1 NA inducer 3.72 drugbank , DGIDB pmid26004420-compound-wo2014150132a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn atp-sensitive potassium channel KCNJ1 NA antagonist NA drugbank pmid26004420-compound-wo2012058116b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014015495a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB bethanidine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved atp-sensitive inward rectifier potassium channel 1 KCNJ1 NA inhibitor NA drugbank pmid26004420-compound-wo2012058134b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014126944b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB tolbutamide small molecule Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atp-sensitive inward rectifier potassium channel 1 KCNJ1 NA inhibitor 2.84 drugbank , DGIDB pmid26004420-compound-us20140031349c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140031349a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2012058134c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013028474b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB glymidine small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] approved,investigational atp-sensitive inward rectifier potassium channel 1 KCNJ1 NA unknown NA drugbank vu591 NA NA investigative inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD pmid26004420-compound-us20140031349d NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014099633d NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014015495b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp-sensitive potassium channel KCNJ1 NA inhibitor NA drugbank glimepiride small molecule Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hyperglycemia[MeSHID:D006943],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-sensitive inward rectifier potassium channel 1 KCNJ1 NA inhibitor 3.41 drugbank , DGIDB pmid26004420-compound-us20140309213b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2014085210c NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2015017305d NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-wo2013062900b NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140275020d NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB pmid26004420-compound-us20140309213a NA NA patented inward rectifier potassium channel kir1.1 KCNJ1 Patented-recorded target unknown NA TTD , DGIDB glisoxepide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inward rectifier potassium channel kir1.2 KCNJ10 Successful target unknown 7.96 TTD , DGIDB mitiglinide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved inward rectifier potassium channel kir1.2 KCNJ10 Successful target unknown 2.65 TTD , DGIDB gliquidone NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved inward rectifier potassium channel kir1.2 KCNJ10 Successful target unknown 1.14 TTD , DGIDB butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn atp-sensitive potassium channel KCNJ10 NA antagonist NA drugbank glycodiazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved inward rectifier potassium channel kir1.2 KCNJ10 Successful target unknown 3.98 TTD , DGIDB glipizide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved inward rectifier potassium channel kir1.2 KCNJ10 Successful target unknown 1.14 TTD , DGIDB sulfonylthioureas NA NA investigative inward rectifier potassium channel kir1.2 KCNJ10 Successful target unknown NA TTD yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp-sensitive potassium channel KCNJ10 NA inhibitor NA drugbank tolazamide NA Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved inward rectifier potassium channel kir1.2 KCNJ10 Successful target unknown 1.14 TTD , DGIDB chlorpropamide NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inward rectifier potassium channel kir1.2 KCNJ10 Successful target unknown 0.72 TTD , DGIDB yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp-sensitive potassium channel KCNJ11 NA inhibitor NA drugbank glimepiride small molecule Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hyperglycemia[MeSHID:D006943],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inhibitor,blocker 3.57 drugbank , DGIDB glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved mitochondrial atp-sensitive potassium channel KCNJ11 NA inhibitor,blocker 1.34 drugbank , DGIDB glimepiride small molecule Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Hyperglycemia[MeSHID:D006943],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inhibitor 3.57 drugbank , DGIDB butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn atp-sensitive potassium channel KCNJ11 NA antagonist NA drugbank thiamylal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inhibitor 2.74 drugbank , DGIDB verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inhibitor NA drugbank levosimendan small molecule Heart Diseases[MeSHID:D006331],Congestive heart failure[MeSHID:D006333],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976],Cardiac Output[MeSHID:D002302],Heart failure[MeSHID:D006333],Syndrome[MeSHID:D013577] approved,investigational atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inducer 2.19 drugbank , DGIDB diazoxide small molecule insulinoma[MeSHID:D007340],Neoplasm Metastasis[MeSHID:D009362],Hypoglycemia[MeSHID:D007003],Emergencies [Disease/Finding][MeSHID:D004630],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inducer 1.69 drugbank , DGIDB tolazamide small molecule Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational sulfonylurea receptor 1, kir6.2 KCNJ11 NA blocker 0.31 drugbank , DGIDB isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inhibitor NA drugbank hbr-985 NA NA investigative inward rectifier potassium channel kir6.2 KCNJ11 Literature-reported target unknown NA TTD glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved sulfonylurea receptor 1, kir6.2 KCNJ11 NA blocker 1.34 drugbank , DGIDB ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inhibitor NA drugbank verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved atp-sensitive inward rectifier potassium channel 11 KCNJ11 NA inhibitor NA drugbank yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp-sensitive potassium channel KCNJ12 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn atp-sensitive potassium channel KCNJ12 NA antagonist NA drugbank dofetilide small molecule Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Maintenance[MeSHID:D008283],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved,investigational atp-sensitive inward rectifier potassium channel 12 KCNJ12 NA inhibitor 15.91 drugbank , DGIDB miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved inward rectifier potassium channel KCNJ12 NA inhibitor NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational inward rectifier potassium channel KCNJ12 NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inward rectifier potassium channel KCNJ12 NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inward rectifier potassium channel KCNJ14 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved inward rectifier potassium channel KCNJ14 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn atp-sensitive potassium channel KCNJ14 NA antagonist NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational inward rectifier potassium channel KCNJ14 NA inhibitor NA drugbank yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp-sensitive potassium channel KCNJ14 NA inhibitor NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn atp-sensitive potassium channel KCNJ15 NA antagonist NA drugbank yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp-sensitive potassium channel KCNJ15 NA inhibitor NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational inward rectifier potassium channel KCNJ2 NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inward rectifier potassium channel KCNJ2 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved inward rectifier potassium channel KCNJ2 NA inhibitor NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational inward rectifier potassium channel 2 KCNJ2 NA inhibitor NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational inward rectifier potassium channel 2 KCNJ2 NA inhibitor NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved g protein-activated inward rectifier potassium channel 1 KCNJ3 NA inhibitor NA drugbank atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved g protein-activated inward rectifier potassium channel 1 KCNJ3 NA inhibitor NA drugbank ifenprodil small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,withdrawn g protein-activated inward rectifier potassium channel 1 KCNJ3 NA antagonist NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved g protein-activated inward rectifier potassium channel 1 KCNJ3 NA inhibitor NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved g protein-activated inward rectifier potassium channel 1 KCNJ3 NA unknown NA drugbank b-nonylglucoside small molecule NA experimental g protein-activated inward rectifier potassium channel 1 KCNJ3 NA unknown NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational inward rectifier potassium channel KCNJ4 NA inhibitor NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational inward rectifier potassium channel 4 KCNJ4 NA inhibitor NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved inward rectifier potassium channel KCNJ4 NA inhibitor NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational inward rectifier potassium channel 4 KCNJ4 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved inward rectifier potassium channel KCNJ4 NA inhibitor NA drugbank ifenprodil small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,withdrawn g protein-activated inward rectifier potassium channel 4 KCNJ5 NA antagonist NA drugbank phorbol 12-myristate 13-acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 inward rectifier potassium channel kir3.4 KCNJ5 Clinical trial target unknown NA TTD , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved g protein-activated inward rectifier potassium channel 4 KCNJ5 NA unknown NA drugbank pip2 NA NA investigative inward rectifier potassium channel kir3.4 KCNJ5 Clinical trial target activator NA TTD , DGIDB isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational g protein-activated inward rectifier potassium channel 2 KCNJ6 NA inhibitor NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved g protein-activated inward rectifier potassium channel 2 KCNJ6 NA inhibitor NA drugbank ifenprodil small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,withdrawn g protein-activated inward rectifier potassium channel 2 KCNJ6 NA antagonist NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved g protein-activated inward rectifier potassium channel 2 KCNJ6 NA unknown NA drugbank thiamylal small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved atp-sensitive inward rectifier potassium channel 8 KCNJ8 NA inhibitor 9.95 drugbank , DGIDB glisoxepide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational atp-sensitive inward rectifier potassium channel 8 KCNJ8 NA inhibitor NA drugbank phenformin small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn atp-sensitive inward rectifier potassium channel 8 KCNJ8 NA inhibitor NA drugbank levosimendan small molecule Heart Diseases[MeSHID:D006331],Congestive heart failure[MeSHID:D006333],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976],Cardiac Output[MeSHID:D002302],Heart failure[MeSHID:D006333],Syndrome[MeSHID:D013577] approved,investigational atp-sensitive inward rectifier potassium channel 8 KCNJ8 NA inducer NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn atp-sensitive potassium channel KCNJ8 NA antagonist NA drugbank glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved mitochondrial atp-sensitive potassium channel KCNJ8 NA inhibitor NA drugbank gliquidone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational atp-sensitive inward rectifier potassium channel 8 KCNJ8 NA inhibitor NA drugbank yohimbine small molecule Blood Vessel[MeSHID:D001808],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp-sensitive potassium channel KCNJ8 NA inhibitor NA drugbank pip2 NA NA investigative inward rectifier potassium channel kir3.3 KCNJ9 Literature-reported target activator NA TTD , DGIDB isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational g protein-activated inward rectifier potassium channel 3 KCNJ9 NA inhibitor NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved g protein-activated inward rectifier potassium channel 3 KCNJ9 NA unknown NA drugbank ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium channel subfamily k member 1 KCNK1 NA inhibitor NA drugbank quinidine barbiturate small molecule NA approved potassium channel subfamily k member 1 KCNK1 NA inhibitor NA drugbank quinidine small molecule Preexcitation Syndrome[MeSHID:D011226],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Conduction disorder of the heart[MeSHID:D000075224] approved,investigational potassium channel subfamily k member 1 KCNK1 NA inhibitor NA drugbank calcineurin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Immune System Diseases[MeSHID:D007154] investigative twik-related spinal cord potassium channel KCNK18 Literature-reported target unknown NA TTD dofetilide small molecule Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Maintenance[MeSHID:D008283],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Paranasal Sinus Diseases[MeSHID:D010254] approved,investigational potassium channel subfamily k member 2 KCNK2 NA inhibitor 2.65 drugbank , DGIDB dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium channel subfamily k member 2 KCNK2 NA inhibitor NA drugbank bay 2253651 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sleep Apnea, Obstructive[MeSHID:D020181] phase 2 twik-related acid-sensitive potassium channel 1 KCNK3 Clinical trial target unknown NA TTD halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved potassium channel subfamily k member 3 KCNK3 NA binder,activator 1.03 drugbank , DGIDB bay-2253651 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sleep Apnea, Obstructive[MeSHID:D020181] phase 2 twik-related acid-sensitive potassium channel 1 KCNK3 Clinical trial target unknown NA TTD doxapram small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory Failure[MeSHID:D012131],Pulmonary Valve Insufficiency[MeSHID:D011665],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] approved,vet_approved potassium channel subfamily k member 3 KCNK3 NA inhibitor NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved potassium channel subfamily k member 3 KCNK3 NA binder 1.03 drugbank , DGIDB ibutilide small molecule Atrial Flutter[MeSHID:D001282],pathologic fistula[MeSHID:D005402],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium channel subfamily k member 6 KCNK6 NA inhibitor NA drugbank quinidine small molecule Preexcitation Syndrome[MeSHID:D011226],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Conduction disorder of the heart[MeSHID:D000075224] approved,investigational potassium channel subfamily k member 6 KCNK6 NA inhibitor NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved potassium channel subfamily k member 9 KCNK9 NA binder,activator 1.17 drugbank , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved potassium channel subfamily k member 9 KCNK9 NA binder 1.17 drugbank , DGIDB doxapram small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Respiratory Failure[MeSHID:D012131],Pulmonary Valve Insufficiency[MeSHID:D011665],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] approved,vet_approved potassium channel subfamily k member 9 KCNK9 NA inhibitor NA drugbank hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn calcium-activated potassium channel subunit alpha-1 KCNMA1 NA inducer NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNMA1 NA inhibitor NA drugbank diazoxide small molecule insulinoma[MeSHID:D007340],Neoplasm Metastasis[MeSHID:D009362],Hypoglycemia[MeSHID:D007003],Emergencies [Disease/Finding][MeSHID:D004630],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved calcium-activated potassium channel subunit alpha-1 KCNMA1 NA other NA drugbank chlorzoxazone small molecule Rheumatism[MeSHID:D012216],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved calcium-activated potassium channel subunit alpha-1 KCNMA1 NA unknown 7.07 drugbank , DGIDB hydrochlorothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Nephrotic Syndrome[MeSHID:D009404],Chronic Kidney Diseases[MeSHID:D051436],Kidney Failure, Chronic[MeSHID:D007676],Glomerulonephritis[MeSHID:D005921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved calcium-activated potassium channel subunit alpha-1 KCNMA1 NA inhibitor NA drugbank bendroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel subunit alpha-1 KCNMA1 NA inducer NA drugbank dequalinium small molecule Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcium-activated potassium channel subunit alpha-1 KCNMA1 NA inhibitor NA drugbank cromoglycate lisetil hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 calcium-activated potassium channel kca1.1 KCNMA1 Literature-reported target unknown NA TTD , DGIDB procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMA1 NA blocker NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved calcium-activated potassium channel subunit alpha-1 KCNMA1 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMA1 NA inhibitor NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNMB1 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMB1 NA inhibitor NA drugbank procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMB1 NA blocker NA drugbank (2r,3r,4s,5r)-2-acetamido-3,4-dihydroxy-5-hydroxymethyl-piperidine small molecule NA experimental calcium-activated potassium channel subunit beta-2 KCNMB2 NA unknown NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMB2 NA inhibitor NA drugbank procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMB2 NA blocker NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNMB2 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMB3 NA inhibitor NA drugbank procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMB3 NA blocker NA drugbank trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNMB3 NA inhibitor NA drugbank slotoxin NA NA investigative charybdotoxin receptor beta-4 KCNMB4 Clinical trial target unknown NA TTD trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNMB4 NA inhibitor NA drugbank bms-223131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] phase 2 charybdotoxin receptor beta-4 KCNMB4 Clinical trial target unknown NA TTD [14c]tea NA NA investigative charybdotoxin receptor beta-4 KCNMB4 Clinical trial target unknown NA TTD procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMB4 NA blocker NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNMB4 NA inhibitor NA drugbank paxilline NA NA investigative charybdotoxin receptor beta-4 KCNMB4 Clinical trial target unknown NA TTD iberiotoxin NA NA investigative charybdotoxin receptor beta-4 KCNMB4 Clinical trial target unknown NA TTD ucl1848 NA NA investigative calcium-activated potassium channel kca2.1 KCNN1 Clinical trial target blocker NA TTD , DGIDB trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNN1 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNN1 NA inhibitor NA drugbank procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNN1 NA blocker NA drugbank ebio NA NA investigative calcium-activated potassium channel kca2.1 KCNN1 Clinical trial target activator NA TTD , DGIDB dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial calcium-activated potassium channel kca2.1 KCNN1 Clinical trial target blocker 2.12 TTD , DGIDB [14c]tea NA NA investigative calcium-activated potassium channel kca2.1 KCNN1 Clinical trial target unknown NA TTD dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial calcium-activated potassium channel kca2.1 KCNN1 Clinical trial target unknown 2.12 TTD , DGIDB rimtuzalcap small molecule NA investigational small conductance calcium-activated potassium channel protein 1 KCNN1 NA positive allosteric modulator NA drugbank ucl1684 NA NA investigative calcium-activated potassium channel kca2.1 KCNN1 Clinical trial target inhibitor NA TTD , DGIDB apamin NA NA investigative calcium-activated potassium channel kca2.1 KCNN1 Clinical trial target inhibitor 4.24 TTD , DGIDB rimtuzalcap small molecule NA investigational small conductance calcium-activated potassium channel protein 2 KCNN2 NA positive allosteric modulator NA drugbank ucl1848 NA NA investigative calcium-activated potassium channel kca2.2 KCNN2 Clinical trial target blocker NA TTD , DGIDB procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNN2 NA blocker NA drugbank dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial calcium-activated potassium channel kca2.2 KCNN2 Clinical trial target unknown 1.77 TTD , DGIDB cyppa NA NA investigative calcium-activated potassium channel kca2.2 KCNN2 Clinical trial target activator NA TTD , DGIDB ebio NA NA investigative calcium-activated potassium channel kca2.2 KCNN2 Clinical trial target activator NA TTD , DGIDB miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNN2 NA inhibitor NA drugbank dc-ebio NA NA investigative calcium-activated potassium channel kca2.2 KCNN2 Clinical trial target activator NA TTD , DGIDB [14c]tea NA NA investigative calcium-activated potassium channel kca2.2 KCNN2 Clinical trial target unknown NA TTD trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNN2 NA inhibitor NA drugbank apamin NA NA investigative calcium-activated potassium channel kca2.2 KCNN2 Clinical trial target inhibitor 7.07 TTD , DGIDB ucl1684 NA NA investigative calcium-activated potassium channel kca2.2 KCNN2 Clinical trial target inhibitor NA TTD , DGIDB ucl1684 NA NA investigative calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target inhibitor NA TTD , DGIDB cyppa NA NA investigative calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target activator NA TTD , DGIDB apamin NA NA investigative calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target inhibitor 5.3 TTD , DGIDB rimtuzalcap small molecule NA investigational small conductance calcium-activated potassium channel protein 3 KCNN3 NA positive allosteric modulator NA drugbank ebio NA NA investigative calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target activator NA TTD , DGIDB trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNN3 NA inhibitor NA drugbank ucl1848 NA NA investigative calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target unknown NA TTD procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNN3 NA blocker NA drugbank [14c]tea NA NA investigative calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target unknown NA TTD miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNN3 NA inhibitor NA drugbank dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target unknown 2.65 TTD , DGIDB dequalinium NA Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target blocker 2.65 TTD , DGIDB dc-ebio NA NA investigative calcium-activated potassium channel kca2.3 KCNN3 Clinical trial target activator NA TTD , DGIDB ska-31 NA NA investigative calcium-activated potassium channel kca3.1 KCNN4 Clinical trial target activator NA TTD , DGIDB pmid15603962crac-16 NA NA investigative calcium-activated potassium channel kca3.1 KCNN4 Clinical trial target unknown NA TTD ebio NA NA investigative calcium-activated potassium channel kca3.1 KCNN4 Clinical trial target activator NA TTD , DGIDB trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium-activated potassium channel KCNN4 NA inhibitor NA drugbank ska-121 NA NA investigative calcium-activated potassium channel kca3.1 KCNN4 Clinical trial target activator NA TTD , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved intermediate conductance calcium-activated potassium channel protein 4 KCNN4 NA inhibitor NA drugbank miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNN4 NA inhibitor NA drugbank ica-17043 NA Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukopenia[MeSHID:D007970] phase 2 calcium-activated potassium channel kca3.1 KCNN4 Clinical trial target unknown 38.19 TTD , DGIDB dc-ebio NA NA investigative calcium-activated potassium channel kca3.1 KCNN4 Clinical trial target activator NA TTD , DGIDB procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved calcium-activated potassium channel KCNN4 NA blocker NA drugbank asp0819 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] phase 2 calcium-activated potassium channel kca3.1 KCNN4 Clinical trial target unknown NA TTD clotrimazole small molecule Tinea Pedis[MeSHID:D014008],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Mycoses[MeSHID:D009181],Skin Diseases, Infectious[MeSHID:D012874],Diaper Rash[MeSHID:D003963],Tinea Versicolor[MeSHID:D014010],Candidiasis[MeSHID:D002177],leukemia[MeSHID:D007938],Tinea[MeSHID:D014005],Immunocompromised Host[MeSHID:D016867],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved intermediate conductance calcium-activated potassium channel protein 4 KCNN4 NA inhibitor,blocker 1.82 drugbank , DGIDB 1-((2-chlorophenyl)diphenylmethyl)-1h-pyrazole NA conjunctiva[MeSHID:D003228],Fibrosis[MeSHID:D005355],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative calcium-activated potassium channel kca3.1 KCNN4 Clinical trial target unknown NA TTD quinine small molecule Muscle Cramp[MeSHID:D009120],Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved intermediate conductance calcium-activated potassium channel protein 4 KCNN4 NA inhibitor NA drugbank (3r,4s)-293b NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target blocker NA TTD , DGIDB xe991 NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target inhibitor NA TTD , DGIDB bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn potassium voltage-gated channel subfamily kqt member 1 KCNQ1 NA inhibitor 2.07 drugbank , DGIDB azimilide small molecule Cardiac Arrhythmia[MeSHID:D001145],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational potassium voltage-gated channel subfamily kqt member 1 KCNQ1 NA unknown NA drugbank n-(3,3-dimethyl-butyl)-4-hexyloxy-benzamide NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target unknown NA TTD indapamide NA Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Retention (Psychology)[MeSHID:D012153],Blood Pressure[MeSHID:D001794],Congestive heart failure[MeSHID:D006333],Body Fluids[MeSHID:D001826],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated potassium channel kv7.1 KCNQ1 Successful target unknown 6.82 TTD , DGIDB n-(2-diethylamino-ethyl)-4-hexyloxy-benzamide NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target unknown NA TTD zinc pyrithione NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target activator NA TTD , DGIDB n-(3,3-dimethyl-butyl)-4-indol-1-yl-benzamide NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target unknown NA TTD ml277 NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target activator NA TTD , DGIDB isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational potassium voltage-gated channel subfamily kqt member 1 KCNQ1 NA inhibitor NA drugbank hmr-1556 NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target blocker 4.55 TTD , DGIDB ica-105665 small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational potassium voltage-gated channel subfamily kqt member 1 KCNQ1 NA unknown NA drugbank , DGIDB dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved potassium voltage-gated channel subfamily kqt member 1 KCNQ1 NA inhibitor NA drugbank 3s,4r-293b NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target blocker NA TTD , DGIDB l-735,821 NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target unknown NA TTD iks124 NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target blocker NA TTD , DGIDB r-l3 NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target activator NA TTD , DGIDB n-(3,3-dimethyl-cyclopentyl)-4-hexyloxy-benzamide NA NA investigative voltage-gated potassium channel kv7.1 KCNQ1 Successful target unknown NA TTD (s)-n-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target activator NA TTD , DGIDB xe991 NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target inhibitor NA TTD , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target unknown NA TTD pip2 NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target activator NA TTD , DGIDB ezogabine small molecule Seizures, Focal[MeSHID:D012640] approved,investigational potassium voltage-gated channel subfamily kqt member 2 KCNQ2 NA unknown 14.14 drugbank , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved potassium voltage-gated channel subfamily kqt member 2 KCNQ2 NA inhibitor NA drugbank qo-58 NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target activator NA TTD , DGIDB ica-69673 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] preclinical voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target unknown NA TTD , DGIDB ica-105665 small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational potassium voltage-gated channel subfamily kqt member 2 KCNQ2 NA unknown NA drugbank , DGIDB pd-32577 NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target unknown NA TTD ica-27243 NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target activator NA TTD , DGIDB ztz240 NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target unknown NA TTD zinc pyrithione NA NA investigative voltage-gated potassium channel kv7.2 KCNQ2 Literature-reported target activator NA TTD , DGIDB ezogabine small molecule Seizures, Focal[MeSHID:D012640] approved,investigational potassium voltage-gated channel subfamily kqt member 2 KCNQ2 NA blocker 14.14 drugbank , DGIDB meclofenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Menorrhagia[MeSHID:D008595],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthralgia[MeSHID:D018771] approved,vet_approved potassium voltage-gated channel subfamily kqt member 2 KCNQ2 NA other NA drugbank ica-69673 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] preclinical voltage-gated potassium channel kv7.3 KCNQ3 Clinical trial target unknown NA TTD , DGIDB ezogabine small molecule Seizures, Focal[MeSHID:D012640] approved,investigational potassium voltage-gated channel subfamily kqt member 3 KCNQ3 NA blocker 12.73 drugbank , DGIDB xen1101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 1 voltage-gated potassium channel kv7.3 KCNQ3 Clinical trial target unknown NA TTD , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved potassium voltage-gated channel subfamily kqt member 3 KCNQ3 NA inhibitor NA drugbank gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational potassium voltage-gated channel subfamily kqt member 3 KCNQ3 NA activator 0.47 drugbank , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv7.3 KCNQ3 Clinical trial target unknown NA TTD ica-105665 NA Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 voltage-gated potassium channel kv7.3 KCNQ3 Clinical trial target unknown NA TTD , DGIDB retigabine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Behcet Syndrome[MeSHID:D001528],Epilepsy[MeSHID:D004827] approved voltage-gated potassium channel kv7.3 KCNQ3 Clinical trial target unknown 12.73 TTD , DGIDB retigabine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Behcet Syndrome[MeSHID:D001528],Epilepsy[MeSHID:D004827] approved voltage-gated potassium channel kv7.3 KCNQ3 Clinical trial target activator 12.73 TTD , DGIDB ica-105665 small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational potassium voltage-gated channel subfamily kqt member 3 KCNQ3 NA unknown NA drugbank , DGIDB pd-32577 NA NA investigative voltage-gated potassium channel kv7.3 KCNQ3 Clinical trial target unknown NA TTD linopirdine NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 voltage-gated potassium channel kv7.3 KCNQ3 Clinical trial target unknown 1.01 TTD , DGIDB meclofenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Menorrhagia[MeSHID:D008595],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthralgia[MeSHID:D018771] approved,vet_approved potassium voltage-gated channel subfamily kqt member 3 KCNQ3 NA other NA drugbank ezogabine small molecule Seizures, Focal[MeSHID:D012640] approved,investigational potassium voltage-gated channel subfamily kqt member 3 KCNQ3 NA unknown 12.73 drugbank , DGIDB pip2 NA NA investigative voltage-gated potassium channel kv7.4 KCNQ4 Literature-reported target activator NA TTD , DGIDB xe991 NA NA investigative voltage-gated potassium channel kv7.4 KCNQ4 Literature-reported target inhibitor NA TTD , DGIDB (s)-n-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide NA NA investigative voltage-gated potassium channel kv7.4 KCNQ4 Literature-reported target activator NA TTD , DGIDB ml213 NA NA investigative voltage-gated potassium channel kv7.4 KCNQ4 Literature-reported target activator NA TTD , DGIDB ica-105665 small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational potassium voltage-gated channel subfamily kqt member 4 KCNQ4 NA unknown NA drugbank , DGIDB nc00075159 NA NA investigative voltage-gated potassium channel kv7.4 KCNQ4 Literature-reported target activator NA TTD , DGIDB zinc pyrithione NA NA investigative voltage-gated potassium channel kv7.4 KCNQ4 Literature-reported target activator NA TTD , DGIDB [14c]tea NA NA investigative voltage-gated potassium channel kv7.4 KCNQ4 Literature-reported target unknown NA TTD ezogabine small molecule Seizures, Focal[MeSHID:D012640] approved,investigational potassium voltage-gated channel subfamily kqt member 4 KCNQ4 NA blocker 8.49 drugbank , DGIDB ica-105665 small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational potassium voltage-gated channel subfamily kqt member 5 KCNQ5 NA unknown NA drugbank , DGIDB ezogabine small molecule Seizures, Focal[MeSHID:D012640] approved,investigational potassium voltage-gated channel subfamily kqt member 5 KCNQ5 NA blocker 7.64 drugbank , DGIDB gabapentin small molecule Generalization (Psychology)[MeSHID:D005793],Postherpetic neuralgia[MeSHID:D051474],Neoplasm Metastasis[MeSHID:D009362],Peripheral Neuropathy[MeSHID:D010523],Pain[MeSHID:D010146],Diabetic Neuralgia[MeSHID:D003929],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational potassium voltage-gated channel subfamily kqt member 5 KCNQ5 NA activator 0.42 drugbank , DGIDB phorbol 12-myristate 13-acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 calcium-activated potassium channel kca4.1 KCNT1 Clinical trial target unknown NA TTD , DGIDB iberiotoxin NA NA investigative calcium-activated potassium channel kca4.1 KCNT1 Clinical trial target unknown NA TTD [14c]tea NA NA investigative calcium-activated potassium channel kca4.1 KCNT1 Clinical trial target unknown NA TTD iberiotoxin NA NA investigative calcium-activated potassium channel kca4.2 KCNT2 Clinical trial target unknown NA TTD [14c]tea NA NA investigative calcium-activated potassium channel kca4.2 KCNT2 Clinical trial target unknown NA TTD phorbol 12-myristate 13-acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 calcium-activated potassium channel kca4.2 KCNT2 Clinical trial target inhibitor NA TTD , DGIDB phorbol 12-myristate 13-acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 calcium-activated potassium channel kca4.2 KCNT2 Clinical trial target unknown NA TTD , DGIDB n-(2-phenylcyclopropyl) amino acid derivative 2 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid25399762-compound-table 6-11 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-28 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-31a NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-16 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 9 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-21c NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 4 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cc-90011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Lymphoma[MeSHID:D008223] phase 2 lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD vafidemstat small molecule NA investigational lysine-specific histone demethylase 1a KDM1A NA inhibitor,binder,modulator NA drugbank n-(2-phenylcyclopropyl) amino acid derivative 3 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-20b NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-28a NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD benzenamine derivative 1 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid25399762-compound-table 6-9 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pyrimidine derivative 17 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pyrimidine derivative 16 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 1 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-42a NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclic peptide derivative 1 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-46 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD img-7289 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] phase 2 lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD tarnylcypromine derivative 3 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 6 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD heteroaryl-cyclopropylamine derivative 2 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pyrimidine derivative 18 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD aryl cyclopropylamine derivative 5 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-50 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid25399762-compound-table 6-15 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD heteroaryl-cyclopropylamine derivative 4 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-41 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid25399762-compound-table 6-10 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD gsk2879552 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] phase 1 lysine-specific histone demethylase 1 KDM1A Clinical trial target inhibitor NA TTD , DGIDB cyclopropylamine derivative 12 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid25399762-compound-table 6-14 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-48 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD og-l002 NA NA investigative lysine-specific histone demethylase 1 KDM1A Clinical trial target inhibitor NA TTD , DGIDB tas-1440 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Pentalogy of Cantrell[MeSHID:D058502] phase 1 lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD gsk-lsd1 NA NA investigative lysine-specific histone demethylase 1 KDM1A Clinical trial target inhibitor NA TTD , DGIDB pmid27019002-compound-31b NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-37b NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-13 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD heteroaryl-cyclopropylamine derivative 1 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-21b NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD benzenamine derivative 4 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 10 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-20a NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD n-(2-phenylcyclopropyl) amino acid derivative 1 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid25399762-compound-table 6-12 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-47 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-49 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD heteroaryl-cyclopropylamine derivative 3 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 7 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD aryl cyclopropylamine derivative 3 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD benzenamine derivative 2 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD seclidemstat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ewings sarcoma[MeSHID:D012512] phase 1 lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-42b NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-7 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid25399762-compound-table 6-13 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cc-90011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Lymphoma[MeSHID:D008223] phase 1 lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD tarnylcypromine derivative 1 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-45 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-43a NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD ncl-1 NA NA investigative lysine-specific histone demethylase 1 KDM1A Clinical trial target inhibitor NA TTD , DGIDB pmid27019002-compound-44 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD incb59872 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 13 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 5 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-17 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD aryl cyclopropylamine derivative 4 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 3 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-43c NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD n6-cyclopropyllydine derivative 1 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-37a NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 11 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD benzenamine derivative 3 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cc-90011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1 lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cyclopropylamine derivative 8 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-21a NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD cc-90011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 2 lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD tarnylcypromine derivative 2 NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-43b NA NA patented lysine-specific histone demethylase 1 KDM1A Clinical trial target unknown NA TTD pmid27019002-compound-47 NA NA patented lysine-specific histone demethylase 1b KDM1B Patented-recorded target unknown NA TTD , DGIDB tarnylcypromine derivative 3 NA NA patented lysine-specific histone demethylase 1b KDM1B Patented-recorded target unknown NA TTD , DGIDB pmid27019002-compound-46 NA NA patented lysine-specific histone demethylase 1b KDM1B Patented-recorded target unknown NA TTD , DGIDB pmid27019002-compound-48 NA NA patented lysine-specific histone demethylase 1b KDM1B Patented-recorded target unknown NA TTD , DGIDB tarnylcypromine derivative 2 NA NA patented lysine-specific histone demethylase 1b KDM1B Patented-recorded target unknown NA TTD , DGIDB selenium compound 2 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB disulfiram analog 1 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB pmid27019002-compound-21b NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB n-(2-phenylcyclopropyl) amino acid derivative 1 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB selenium compound 3 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB selenium compound 1 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB hydroxamate analog 1 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB pmid25468267-compound-46 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB heteroaryl-cyclopropylamine derivative 4 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB disulfiram analog 2 NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB pmid27019002-compound-21c NA NA patented lysine-specific demethylase 4a KDM4A Patented-recorded target unknown NA TTD , DGIDB flavonoid derivative 6 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pyrido[1,2-a]indole-1.-carboxylic acid analog 1 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pyrido[1,2-a]indole-1.-carboxylic acid analog 7 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pyrido[1,2-a]indole-1.-carboxylic acid analog 2 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pmid25468267-compound-46 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pmid25468267-compound-47 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pyrido[1,2-a]indole-1.-carboxylic acid analog 4 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pyrido[1,2-a]indole-1.-carboxylic acid analog 6 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pmid25468267-compound-56 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB iox1 NA NA investigative lysine-specific demethylase 4c KDM4C Patented-recorded target inhibitor NA TTD , DGIDB pmid25468267-compound-55 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pyrido[1,2-a]indole-1.-carboxylic acid analog 5 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB pyrido[1,2-a]indole-1.-carboxylic acid analog 3 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB hydroxamate analog 1 NA NA patented lysine-specific demethylase 4c KDM4C Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 1 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 7 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 5 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB pyridine-2,4-dicarboxylic acid analog 3 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB hydroxyqunoline analog 4 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 2 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 4 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB hydroxyqunoline analog 5 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB hydroxyqunoline analog 3 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB hydroxyqunoline analog 2 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 3 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB hydroxyqunoline analog 1 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB pyridine-2,4-dicarboxylic acid analog 4 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 8 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 9 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB pmid25468267-compound-46 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB pyridine-2,4-dicarboxylic acid analog 2 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB pyridine-2,4-dicarboxylic acid analog 1 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB n-oxalyl-d-tyrosine derivative 6 NA NA patented lysine-specific demethylase 4e KDM4E Patented-recorded target unknown NA TTD , DGIDB ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical lysine-specific demethylase 5d KDM5D NA cofactor NA drugbank 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD quinoline and quinazoline derivative 1 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB bms-690514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.33 TTD , DGIDB bx-912 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target inhibitor NA TTD , DGIDB pp121 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target inhibitor NA TTD , DGIDB rivoceranib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.46 TTD , DGIDB 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3h-benzimidazol-5-yl]oxy]-n-methyl-pyridine-2-carboxamide small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank ramucirumab biotech Unmarried[MeSHID:D012847],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist 0.7 TTD , drugbank , DGIDB sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.28 TTD , DGIDB 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD bms-645737 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD ag-e-85378 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD cediranib small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of liver[MeSHID:D008113],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 3 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.08 TTD , drugbank , DGIDB 2-(1h-indazol-3-yl)-1h-benzo[d]imidazole NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD cabozantinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Medulla Oblongata[MeSHID:D008526],Liver carcinoma[MeSHID:D006528],Adrenal Medulla[MeSHID:D000313],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist,inhibitor 0.27 TTD , drugbank , DGIDB 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1h)-one small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank hki-272 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.04 TTD , DGIDB ripretinib small molecule Diagnosis[MeSHID:D003933],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Mastocytosis, Systemic[MeSHID:D034721] approved vascular endothelial growth factor receptor 2 KDR NA inhibitor NA drugbank pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR NA inhibitor 0.23 drugbank , DGIDB fruquintinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.62 TTD , DGIDB 1-{4-[4-amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank ast-487 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.03 TTD , DGIDB quinazoline derivative 16 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB cabozantinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Medulla Oblongata[MeSHID:D008526],Liver carcinoma[MeSHID:D006528],Adrenal Medulla[MeSHID:D000313],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist 0.27 TTD , drugbank , DGIDB su-11652 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD bay-57-9352 NA Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.46 TTD , DGIDB 3-methyl-1h-thieno[2,3-c]pyrazole-5-carboxamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD delphinidin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.46 TTD , DGIDB cyc116 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , drugbank , DGIDB antibodie derivative 6 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine 3g NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 3-benzimidazol-2-ylhydroquinolin-2-one NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.23 TTD , drugbank , DGIDB quinazoline derivative 15 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB (5-phenyl-oxazol-2-yl)-m-tolyl-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD krn633 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Glioma[MeSHID:D005910] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB pazopanib hcl NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB pyrimidine derivative 4 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB motesanib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.52 TTD , DGIDB pegdinetanib small molecule Neoplasms[MeSHID:D009369],Age related macular degeneration[MeSHID:D008268],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 1.86 TTD , drugbank , DGIDB 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1h)-one small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.05 TTD , DGIDB semaxanib small molecule Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of lung[MeSHID:D008175] investigational vascular endothelial growth factor receptor 2 KDR NA inhibitor 0.15 drugbank , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved vascular endothelial growth factor receptor 2 KDR NA inhibitor 0.2 drugbank , DGIDB bibf-1202 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target inhibitor NA TTD , DGIDB tak-593 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.19 TTD , DGIDB cep-5104 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 3-((3-bromothiophen-2-yl)methylene)indolin-2-one NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist,inhibitor 0.15 TTD , drugbank , DGIDB axitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Pancreas[MeSHID:D010179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.39 TTD , drugbank , DGIDB pegdinetanib small molecule Neoplasms[MeSHID:D009369],Age related macular degeneration[MeSHID:D008268],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown 1.86 TTD , drugbank , DGIDB 6-(1h-benzoimidazol-2-yl)-benzocyclohepten-7-one NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD epi-0030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 4-(isoquinolin-5-yl)-n-m-tolylphthalazin-1-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 4-(5-phenyl-oxazol-2-ylamino)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD brivanib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of liver[MeSHID:D008113] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.3 TTD , DGIDB vandetanib NA Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.11 TTD , DGIDB regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.15 TTD , drugbank , DGIDB 3,6-di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 6-o-tolylquinazolin-2-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD amg-429 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD brivanib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of liver[MeSHID:D008113] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.3 TTD , DGIDB agn211745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Choroidal Neovascularization[MeSHID:D020256] discontinued in phase 2 vegfr2 messenger rna KDR Discontinued target unknown NA TTD plx-4720 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cutaneous Melanoma[MeSHID:C562393],melanoma[MeSHID:D008545] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.05 TTD , DGIDB n-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]-1,3-oxazol-2-amine small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank ttac-0001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD l000021649 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD im-023911 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.54 TTD , drugbank , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 2 KDR NA unknown 0.04 drugbank , DGIDB n~4~-methyl-n~4~-(3-methyl-1h-indazol-6-yl)-n~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank pmid23639540c13a NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD mgcd516 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD phenyl-(5-phenyl-oxazol-2-yl)-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD alacizumab pegol NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target antagonist 0.46 TTD , DGIDB ki-20227 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.12 TTD , DGIDB n-(2,4-dichloro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD motesanib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.52 TTD , DGIDB ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR NA inhibitor 0.03 drugbank , DGIDB 5-(4-methoxy-phenyl)-1-phenyl-1h-benzoimidazole NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD rosiglitazone + metformin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved vascular endothelial growth factor receptor 2 KDR NA inhibitor 0.15 drugbank , DGIDB n-(3-bromo-benzoyl)-4-chloro-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD k-252a analogue NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD xl820 small molecule Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 2 KDR NA inhibitor NA drugbank , DGIDB 4-chloro-n-(3-chloro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 4-chloro-n-(2-chloro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD sunitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.31 TTD , drugbank , DGIDB cb-676475 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD n-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank tak-593 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.19 TTD , DGIDB antibodie derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194] patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD r-84 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD im-094261 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 4-(4-p-tolylamino-phthalazin-1-yl)-benzamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD cediranib small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of liver[MeSHID:D008113],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.08 TTD , drugbank , DGIDB famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.2 TTD , DGIDB tg-100801 small molecule Age related macular degeneration[MeSHID:D008268] investigational vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank (4-phenoxy-phenyl)-quinazolin-4-yl-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD ramucirumab biotech Unmarried[MeSHID:D012847],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist,inhibitor 0.7 TTD , drugbank , DGIDB pyrimidine derivative 12 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB osi-930 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.27 TTD , DGIDB cep-11981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.08 TTD , DGIDB yn-968d1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.46 TTD , DGIDB ro-4396686 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD xl880 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of breast[MeSHID:D001943] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.23 TTD , DGIDB raf265 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.46 TTD , DGIDB su-14813 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] discontinued in phase 2 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.12 TTD , DGIDB pyrimidine derivative 13 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB bms-690514 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.33 TTD , DGIDB 3-(5-phenyl-oxazol-2-ylamino)-benzonitrile NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 3-(1h-indol-2-yl)-1h-quinolin-2-one NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD jnj-38158471 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD ramucirumab biotech Unmarried[MeSHID:D012847],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist,antibody 0.7 TTD , drugbank , DGIDB 2-(5-phenyl-oxazol-2-ylamino)-benzonitrile NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD vatalanib small molecule Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.29 TTD , drugbank , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.07 TTD , DGIDB cp-547632 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.04 TTD , DGIDB pmid22765894c8h NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD bx-795 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.08 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational vascular endothelial growth factor receptor 2 KDR NA inhibitor NA drugbank elpamotide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Biliary Tract Cancer[MeSHID:D001661] phase 1/2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.46 TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.07 TTD , DGIDB otsgc-a24 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB 4-chloro-n-(2-methyl-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD rivoceranib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.46 TTD , DGIDB 4-(4-m-tolylamino-phthalazin-1-yl)-benzamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD n'-(6-aminopyridin-3-yl)-n-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank romiplostim NA Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.06 TTD , DGIDB cep-11981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.08 TTD , DGIDB (3-phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD raf265 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.46 TTD , DGIDB tg-100435 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD cp-547632 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.04 TTD , DGIDB sulfatinib NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.28 TTD , DGIDB xl820 small molecule Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank , DGIDB 3-(5-thiophen-3-yl-pyridin-3-yl)-1h-indole NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD e-7050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.46 TTD , DGIDB pf-00337210 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 1.39 TTD , DGIDB pf-00337210 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown 1.39 TTD , DGIDB aal-993 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD n-(cyclopropylmethyl)-4-(methyloxy)-3-({5-[3-(3-pyridinyl)phenyl]-1,3-oxazol-2-yl}amino)benzenesulfonamide small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank ramucirumab biotech Unmarried[MeSHID:D012847],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist,inhibitor 0.7 TTD , drugbank , DGIDB bms-536924 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD pyridine derivative 18 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB foretinib small molecule NA investigational vascular endothelial growth factor receptor 2 KDR NA inhibitor 0.23 drugbank , DGIDB 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.2 TTD , DGIDB 8-methyl-4h,7h-indolo[6,5,4-cd]indol-5-one NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD alacizumab pegol NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.05 TTD , DGIDB vatalanib small molecule Second Primary Cancers[MeSHID:D016609],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 2 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.29 TTD , drugbank , DGIDB fruquintinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.62 TTD , DGIDB vegf receptor 2 kinase inhibitor i NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 4-(isoquinolin-5-yl)-n-o-tolylphthalazin-1-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD pyrimidine derivative 14 NA NA patented vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB ast-487 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.03 TTD , DGIDB 4-chloro-n-(4-chloro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD indolin-2-one deriv. 4b NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor 0.17 TTD , DGIDB isoindolinone urea derivative NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD im-094882 NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD xl999 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 vascular endothelial growth factor receptor 2 KDR Successful target inhibitor NA TTD , drugbank , DGIDB n~4~-(3-methyl-1h-indazol-6-yl)-n~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank xl999 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , drugbank , DGIDB anti-vegfr2 cd8 cell therapy NA CD8-Positive T-Lymphocytes[MeSHID:D018414],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , DGIDB l-dos47 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] phase 2 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD imc-1c11 biotech Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,discontinued in phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD , drugbank 6-chloro-n-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank raf-265 small molecule melanoma[MeSHID:D008545] investigational vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank 4-chloro-n-(4-nitro-benzoyl)-benzenesulfonamide NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD n-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide small molecule NA experimental vascular endothelial growth factor receptor 2 KDR NA unknown NA drugbank [3-(5-phenyl-oxazol-2-ylamino)-phenyl]-methanol NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD 4-(4-aminophenyl)-1h-indazol-3yl-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD ramucirumab biotech Unmarried[MeSHID:D012847],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist,antibody 0.7 TTD , drugbank , DGIDB 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist 0.15 TTD , drugbank , DGIDB vandetanib NA Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.11 TTD , DGIDB 3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD (2-methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine NA NA investigative vascular endothelial growth factor receptor 2 KDR Successful target unknown NA TTD ramucirumab biotech Unmarried[MeSHID:D012847],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor receptor 2 KDR Successful target antagonist 0.7 TTD , drugbank , DGIDB midostaurin small molecule Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved,investigational vascular endothelial growth factor receptor 2 KDR NA antagonist,inhibitor 0.06 drugbank , DGIDB altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.17 TTD , DGIDB osi-930 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor receptor 2 KDR Successful target unknown 0.27 TTD , DGIDB erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational vascular endothelial growth factor receptor 2 KDR NA substrate,inhibitor 0.06 drugbank , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor receptor 2 KDR NA inhibitor 0.04 drugbank , DGIDB pmid28454500-compound-37 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD dimethyl fumarate small molecule Multiple Sclerosis[MeSHID:D009103],Relapse[MeSHID:D012008] approved,investigational kelch-like ech-associated protein 1 KEAP1 NA binder,inhibitor 31.83 drugbank , DGIDB pmid28454500-compound-35 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD cxa10 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Focal glomerulosclerosis[MeSHID:D005923] phase 2 cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD chalcone derivative 1 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD vcb101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] preclinical cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD diterpenoid derivative 1 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-9 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-40 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pyrazino[2,1-a]isoquinolin derivative 1 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-34 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-12 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pyridyl compound 1 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pyrazino[2,1-a]isoquinolin derivative 4 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD 2-hydroxybenzamide derivative 2 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-8 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-13 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD diterpenoid derivative 2 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD dimethyl fumarate small molecule Multiple Sclerosis[MeSHID:D009103],Relapse[MeSHID:D012008] approved,investigational kelch-like ech-associated protein 1 KEAP1 NA binder 31.83 drugbank , DGIDB pmid28454500-compound-3 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pyrazino[2,1-a]isoquinolin derivative 2 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-32 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD 2-hydroxybenzamide derivative 1 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD trepenoid derivative 1 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-50 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-11 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-33 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-41 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD chalcone derivative 4 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD vcb102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] preclinical cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-10 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD chalcone derivative 2 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD vinyl sulfone derivative 1 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-49 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pyrazino[2,1-a]isoquinolin derivative 3 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD pmid28454500-compound-36 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD chalcone derivative 3 NA NA patented cysteines of keap1 KEAP1 Clinical trial target unknown NA TTD phosphoramidon small molecule NA experimental kell blood group glycoprotein KEL NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational far upstream element-binding protein 2 KHSRP NA ligand NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational far upstream element-binding protein 2 KHSRP NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational far upstream element-binding protein 2 KHSRP NA unknown NA drugbank methyl 9h-carbazole-2-carboxylate NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 4sc-205 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 kinesin-like protein kif11 KIF11 Clinical trial target unknown NA TTD , DGIDB n-[4'-(trifluoromethyl)-4-biphenylyl]urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 11h-benzo[a]carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD (1s)-1-cyclopropyl-2-[(2s)-4-(2,5-difluorophenyl)-2-phenyl-2,5-dihydro-1h-pyrrol-1-yl]-2-oxoethanamine small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank (2s)-4-(2,5-difluorophenyl)-n-methyl-2-phenyl-n-piperidin-4-yl-2,5-dihydro-1h-pyrrole-1-carboxamide small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank [(4r)-4-(3-hydroxyphenyl)-1,6-dimethyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl)methanone small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank n-[4'-(ethylsulfonyl)-3-fluoro-4-biphenylyl]urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 6-fluoro-2-methyl-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD methyl 7-tert-butyl-9h-carbazole-3-carboxylate NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 3-(trifluoromethyl)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 1-(trifluoromethyl)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n-(4'-bromo-3,3'-difluoro-4-biphenylyl)urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n-(4'-isopropyl-4-biphenylyl)urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n-[3'-(trifluoromethyl)-4-biphenylyl]urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD emd-534085 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 2-methyl-6-(trifluoromethyl)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 4'-(trifluoromethyl)-4-biphenylol NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD isis 183910 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD filanesib small molecule Neoplasms[MeSHID:D009369] investigational kinesin-like protein kif11 KIF11 NA unknown NA drugbank 2-tert-butyl-7-(trifluoromethyl)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD isis 183897 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 9h-carbazole-3-carbaldehyde NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 1-tert-butyl-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD sb-731489 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD isis 183883 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD mk-0731 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,phase 1 kinesin-like protein kif11 KIF11 Clinical trial target unknown 12.73 TTD , drugbank , DGIDB (5s)-5-(3-aminopropyl)-3-(2,5-difluorophenyl)-n-ethyl-5-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamide small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank 4'-trifluoromethyl-biphenyl-4-ylamine NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n-{4'-[(trifluoromethyl)thio]-4-biphenyl}urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD ispinesib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258],Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 kinesin-like protein kif11 KIF11 Clinical trial target unknown 12.73 TTD , DGIDB n-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD azd-4877 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 kinesin-like protein kif11 KIF11 Clinical trial target unknown 12.73 TTD , DGIDB methyl[4'-(trifluoromethyl)-4-biphenylyl]amine NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD aln-vsp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] phase 1 kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD , DGIDB isis 183881 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD isis 183911 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD (s)-enastron NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 2,3,4,11-tetrahydro-1h-benzo[a]carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD monastrol small molecule NA experimental,investigative kinesin-like protein kif11 KIF11 Clinical trial target unknown NA TTD , drugbank 4'-(trifluoromethyl)-4-biphenylsulfonamide NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 2-methyl-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD arq 621 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 kinesin-like protein kif11 KIF11 Clinical trial target unknown NA TTD , DGIDB 2-(trifluoromethoxy)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD ly2523355 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 kinesin-like protein kif11 KIF11 Clinical trial target unknown NA TTD , DGIDB 9h-carbazole-2-carbaldehyde NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 4'-(trifluoromethyl)-4-biphenylyl sulfamate NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 2-isopropyl-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 7-tert-butyl-9h-carbazole-3-carboxylic acid NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 4'-(trifluoromethyl)-4-biphenylyl carbamate NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD (s)-dimethylenastron NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 3-methyl-6-(trifluoromethyl)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n-{4'-[(trifluoromethyl)sulfonyl]-4-biphenyl}urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 2-(trifluoromethyl)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD (2s)-4-(2,5-difluorophenyl)-n,n-dimethyl-2-phenyl-2,5-dihydro-1h-pyrrole-1-carboxamide small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank 9-methyl-2-(trifluoromethyl)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 2-tert-butyl-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 1-(7-methyl-9h-carbazol-3-yl)ethanone NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 2-tert-butoxy-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD arry-520 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant Neoplasms[MeSHID:D009369] phase 2 kinesin-like protein kif11 KIF11 Clinical trial target unknown 12.73 TTD , DGIDB n-[4'-(trifluoromethyl)-4-biphenylyl]thiourea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 4-(trifluoromethyl)biphenyl NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n-(4'-methyl-4-biphenylyl)urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 3-tert-butyl-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD isis 183901 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 2-ethyl-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD isis 183882 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD sb-743921 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 kinesin-like protein kif11 KIF11 Clinical trial target unknown 6.37 TTD , DGIDB isis 183912 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD (4r)-4-(3-hydroxyphenyl)-n,n,7,8-tetramethyl-3,4-dihydroisoquinoline-2(1h)-carboxamide small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank 2-(difluoromethyl)-9h-carbazole NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n,n-diethyl-2-[(2-thienylcarbonyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank n-(4'-chloro-4-biphenylyl)methanesulfonamide NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD n-(4'-t-butyl-4-biphenylyl)urea NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD (5r)-n,n-diethyl-5-methyl-2-[(thiophen-2-ylcarbonyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank adociasulfate-2 NA NA investigative kinesin spindle messenger rna KIF11 Clinical trial target unknown NA TTD 3-[(5s)-1-acetyl-3-(2-chlorophenyl)-4,5-dihydro-1h-pyrazol-5-yl]phenol small molecule NA experimental kinesin-like protein kif11 KIF11 NA unknown NA drugbank adenosine-5'-[beta, gamma-methylene]triphosphate small molecule NA experimental kinesin-like protein kif1a KIF1A NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental kinesin-like protein kif1a KIF1A NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental kinesin-like protein kif2c KIF2C NA unknown NA drugbank iph-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2dl1 KIR2DL1 Clinical trial target inhibitor 6.37 TTD , DGIDB mab 1-7f9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2dl1 KIR2DL1 Clinical trial target unknown NA TTD iph-2102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 mhc class i nk cell receptor 2dl1 KIR2DL1 Clinical trial target unknown NA TTD iph-2102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 mhc class i nk cell receptor 2dl2 KIR2DL2 Clinical trial target unknown 15.91 TTD , DGIDB iph-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2dl2 KIR2DL2 Clinical trial target inhibitor 19.1 TTD , DGIDB iph-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2dl2 KIR2DL2 Clinical trial target unknown 19.1 TTD , DGIDB mab 1-7f9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2dl2 KIR2DL2 Clinical trial target unknown NA TTD , DGIDB iph-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2dl3 KIR2DL3 Clinical trial target inhibitor 19.1 TTD , DGIDB iph-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2dl3 KIR2DL3 Clinical trial target unknown 19.1 TTD , DGIDB iph-2102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 mhc class i nk cell receptor 2dl3 KIR2DL3 Clinical trial target unknown 15.91 TTD , DGIDB mab 1-7f9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2dl3 KIR2DL3 Clinical trial target unknown NA TTD , DGIDB iph-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2ds1 KIR2DS1 Clinical trial target unknown 25.46 TTD , DGIDB iph-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 mhc class i nk cell receptor 2ds2 KIR2DS2 Clinical trial target unknown 25.46 TTD , DGIDB iph4102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Cell Lymphoma[MeSHID:D016399] phase 2 mhc class i nk cell receptor 3dl2 KIR3DL2 Clinical trial target unknown 63.65 TTD , DGIDB tak-448 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 metastasis-suppressor kiss-1 KISS1 Clinical trial target unknown 31.83 TTD , DGIDB tak-683 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Allergic Reaction[MeSHID:D006967],Malignant neoplasm of prostate[MeSHID:D011471],Expiration, function[MeSHID:D045853] discontinued in phase 1 g-protein coupled receptor 54 KISS1R Discontinued target unknown NA TTD kisspeptin-10 NA NA investigative g-protein coupled receptor 54 KISS1R Discontinued target agonist 7.07 TTD , DGIDB anz-100 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of liver[MeSHID:D008113] investigational kiss-1 receptor KISS1R NA unknown NA drugbank 4-fluorobenzoyl-phe-gly-leu-arg-trp-nh2 NA NA investigative g-protein coupled receptor 54 KISS1R Discontinued target unknown NA TTD phosphonotyrosine NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD osi-930 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase kit KIT Successful target unknown 0.38 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist 0.45 drugbank , DGIDB ancestim biotech Transplanted tissue[MeSHID:D019737],Stem cells[MeSHID:D013234],Blood[MeSHID:D001769],Bone Marrow[MeSHID:D001853] approved,investigational,withdrawn mast/stem cell growth factor receptor kit KIT NA agonist NA drugbank osi-930 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational mast/stem cell growth factor receptor kit KIT NA inhibitor 0.38 drugbank , DGIDB 5,11-dimethyl-6h-pyrido[4,3-b]carbazol-9-ol NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD osi-930 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase kit KIT Successful target inhibitor 0.38 TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved mast/stem cell growth factor receptor kit KIT NA antagonist,inhibitor 1.35 drugbank , DGIDB regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mast/stem cell growth factor receptor kit KIT NA inhibitor 0.35 drugbank , DGIDB pmid22765894c8h NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mast/stem cell growth factor receptor kit KIT NA inhibitor NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist,inhibitor 0.45 drugbank , DGIDB ripretinib NA Diagnosis[MeSHID:D003933],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Mastocytosis, Systemic[MeSHID:D034721] approved tyrosine-protein kinase kit KIT Successful target inhibitor 2.21 TTD , DGIDB 9-methoxy-5,11-dimethyl-6h-pyrido[4,3-b]carbazole NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD gtp-14564 NA NA investigative tyrosine-protein kinase kit KIT Successful target inhibitor 0.22 TTD , DGIDB sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist 0.3 drugbank , DGIDB 9-bromo-5,11-dimethyl-6h-pyrido[4,3-b]carbazole NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD imatinib NA Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved tyrosine-protein kinase kit KIT Successful target unknown 1.35 TTD , DGIDB motesanib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 tyrosine-protein kinase kit KIT Successful target unknown 0.66 TTD , DGIDB sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist,inhibitor 0.3 drugbank , DGIDB bis-(5-hydroxy-1h-indol-2-yl)-methanone NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD pyridine derivative 18 NA NA patented tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB imatinib NA Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved tyrosine-protein kinase kit KIT Successful target unknown 1.35 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist,inhibitor 0.45 drugbank , DGIDB famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tyrosine-protein kinase kit KIT Successful target inhibitor 0.38 TTD , DGIDB plx9486 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Gastrointestinal Stromal Tumors[MeSHID:D046152] phase 1/2 tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB imatinib NA Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved tyrosine-protein kinase kit KIT Successful target inhibitor 1.35 TTD , DGIDB sunitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved,investigational mast/stem cell growth factor receptor kit KIT NA inhibitor 0.77 drugbank , DGIDB pmid25656651-compound-21b NA NA patented tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB ast-487 NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown 0.05 TTD , DGIDB ast-487 NA NA investigative tyrosine-protein kinase kit KIT Successful target inhibitor 0.05 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mast/stem cell growth factor receptor kit KIT NA inhibitor NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist 0.45 drugbank , DGIDB midostaurin small molecule Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist,inhibitor 0.32 drugbank , DGIDB pyridine derivative 19 NA NA patented tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB pazopanib hcl NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB xl820 small molecule Neoplasms[MeSHID:D009369] investigational mast/stem cell growth factor receptor kit KIT NA unknown NA drugbank , DGIDB sorafenib NA Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase kit KIT Successful target inhibitor 0.3 TTD , DGIDB pmid23521020c7k NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD regorafenib NA Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase kit KIT Successful target unknown 0.35 TTD , DGIDB amg-191 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] phase 1 tyrosine-protein kinase kit KIT Successful target unknown 0.88 TTD , DGIDB pd-0173956 NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved mast/stem cell growth factor receptor kit KIT NA antagonist,inhibitor 1.35 drugbank , DGIDB ponatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase kit KIT Successful target unknown 0.43 TTD , DGIDB nilotinib small molecule leukemia[MeSHID:D007938],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist,inhibitor 1.47 drugbank , DGIDB motesanib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 tyrosine-protein kinase kit KIT Successful target inhibitor 0.66 TTD , DGIDB ki-20227 NA NA investigative tyrosine-protein kinase kit KIT Successful target inhibitor 0.22 TTD , DGIDB pexidartinib NA Giant Cell Tumors[MeSHID:D005870],Operative Surgical Procedures[MeSHID:D013514],Testicular Germ Cell Tumor[MeSHID:C563236],Pigmented villonodular synovitis[MeSHID:D013586],Neurofibromatosis 1[MeSHID:D009456],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase kit KIT Successful target inhibitor 0.64 TTD , DGIDB amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational mast/stem cell growth factor receptor kit KIT NA inhibitor 0.63 drugbank , DGIDB pyridine derivative 22 NA NA patented tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB romiplostim NA Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved tyrosine-protein kinase kit KIT Successful target unknown 0.11 TTD , DGIDB cart-117 cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational mast/stem cell growth factor receptor kit KIT NA unknown 0.03 drugbank , DGIDB osi-930 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational mast/stem cell growth factor receptor kit KIT NA unknown 0.38 drugbank , DGIDB xl-820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tyrosine-protein kinase kit KIT Successful target unknown 0.29 TTD , DGIDB ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mast/stem cell growth factor receptor kit KIT NA inhibitor 0.43 drugbank , DGIDB pd-0166326 NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved mast/stem cell growth factor receptor kit KIT NA antagonist 1.35 drugbank , DGIDB regorafenib NA Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase kit KIT Successful target inhibitor 0.35 TTD , DGIDB amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational mast/stem cell growth factor receptor kit KIT NA unknown 0.63 drugbank , DGIDB apck-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD avapritinib small molecule Gastrointestinal Stromal Tumors[MeSHID:D046152],Mutation[MeSHID:D009154],Leukemia, Mast-Cell[MeSHID:D007946],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mastocytosis, Systemic[MeSHID:D034721] approved,investigational mast/stem cell growth factor receptor kit KIT NA inhibitor 2.21 drugbank , DGIDB pmid25656651-compound-21a NA NA patented tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB car-t cells targeting cd117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] preclinical tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB 4-(4-aminophenyl)-1h-indazol-3yl-amine NA NA investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD linifanib small molecule MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369] investigational mast/stem cell growth factor receptor kit KIT NA inhibitor 0.03 drugbank , DGIDB nilotinib small molecule leukemia[MeSHID:D007938],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mast/stem cell growth factor receptor kit KIT NA antagonist 1.47 drugbank , DGIDB jnj-28312141 NA NA investigative tyrosine-protein kinase kit KIT Successful target inhibitor 0.18 TTD , DGIDB wbz-7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative tyrosine-protein kinase kit KIT Successful target unknown NA TTD mp470 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational mast/stem cell growth factor receptor kit KIT NA substrate NA drugbank sorafenib NA Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine-protein kinase kit KIT Successful target unknown 0.3 TTD , DGIDB xl820 small molecule Neoplasms[MeSHID:D009369] investigational mast/stem cell growth factor receptor kit KIT NA inhibitor NA drugbank , DGIDB famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tyrosine-protein kinase kit KIT Successful target unknown 0.38 TTD , DGIDB pyridine derivative 21 NA NA patented tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB pyridine derivative 20 NA NA patented tyrosine-protein kinase kit KIT Successful target unknown NA TTD , DGIDB xl-820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tyrosine-protein kinase kit KIT Successful target inhibitor 0.29 TTD , DGIDB phosphonotyrosine small molecule NA experimental mast/stem cell growth factor receptor kit KIT NA unknown NA drugbank imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved mast/stem cell growth factor receptor kit KIT NA antagonist 1.35 drugbank , DGIDB ripretinib small molecule Diagnosis[MeSHID:D003933],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Mastocytosis, Systemic[MeSHID:D034721] approved mast/stem cell growth factor receptor kit KIT NA inhibitor 2.21 drugbank , DGIDB cp-673451 NA NA investigative tyrosine-protein kinase kit KIT Successful target inhibitor NA TTD , DGIDB imatinib NA Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved tyrosine-protein kinase kit KIT Successful target inhibitor 1.35 TTD , DGIDB pexidartinib small molecule Giant Cell Tumors[MeSHID:D005870],Operative Surgical Procedures[MeSHID:D013514],Testicular Germ Cell Tumor[MeSHID:C563236],Pigmented villonodular synovitis[MeSHID:D013586],Neurofibromatosis 1[MeSHID:D009456],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mast/stem cell growth factor receptor kit KIT NA inhibitor 0.64 drugbank , DGIDB pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved mast/stem cell growth factor receptor kit KIT NA inhibitor 0.11 drugbank , DGIDB lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational mast/stem cell growth factor receptor kit KIT NA inhibitor 0.15 drugbank , DGIDB ngm313 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 beta-klotho KLB Clinical trial target unknown NA TTD , DGIDB apto-253 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 kruppel like factor 4 KLF4 Clinical trial target unknown 31.83 TTD , DGIDB lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational kallikrein-1 KLK1 NA unknown NA drugbank nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Pancreatitis[MeSHID:D010195] investigational kallikrein-1 KLK1 NA inhibitor NA drugbank benzamidine small molecule NA experimental kallikrein-1 KLK1 NA unknown NA drugbank va-118020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] investigative tissue kallikrein KLK1 Literature-reported target unknown NA TTD nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Disease[MeSHID:D004194] investigational kallikrein-1 KLK1 NA inhibitor NA drugbank aluminium small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperhidrosis disorder[MeSHID:D006945] approved,investigational kallikrein-1 KLK1 NA inhibitor NA drugbank aluminum acetate small molecule NA approved,investigational kallikrein-1 KLK1 NA unknown NA drugbank example 131 [wo2009133348] NA NA investigative tissue kallikrein KLK1 Literature-reported target inhibitor NA TTD , DGIDB aniline small molecule NA experimental kallikrein-1 KLK1 NA unknown NA drugbank aprotinin biotech Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn kallikrein-1 KLK1 NA unknown NA drugbank aluminium phosphate small molecule NA approved,investigational kallikrein-1 KLK1 NA unknown NA drugbank sbti NA NA investigative tissue kallikrein KLK1 Literature-reported target unknown NA TTD pmid23849879c3 NA NA investigative kallikrein-14 KLK14 Patented-recorded target unknown NA TTD pmid25489658c4d NA NA investigative kallikrein-14 KLK14 Patented-recorded target unknown NA TTD dm-107 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] investigative tissue kallikrein KLK2 Clinical trial target unknown NA TTD avoralstat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angioedemas, Hereditary[MeSHID:D054179] phase 2/3 tissue kallikrein KLK2 Clinical trial target unknown 31.83 TTD , DGIDB dermolastin NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] discontinued in phase 2 tissue kallikrein KLK2 Clinical trial target unknown NA TTD jnj-69086420 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 tissue kallikrein KLK2 Clinical trial target unknown NA TTD vda-1102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623] phase 2 tissue kallikrein KLK2 Clinical trial target unknown NA TTD hk2p01 derivative klk2 inhibitor NA NA investigative tissue kallikrein KLK2 Clinical trial target inhibitor NA TTD , DGIDB prx-302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 prostate specific antigen KLK3 Clinical trial target unknown 7.07 TTD , DGIDB cyproterone acetate small molecule Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277] approved,investigational prostate-specific antigen KLK3 NA unknown NA drugbank prostarex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative prostate specific antigen KLK3 Clinical trial target unknown NA TTD mva-bn breast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Breast[MeSHID:D001940],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 prostate specific antigen KLK3 Clinical trial target unknown NA TTD , DGIDB pmid23692593c20 NA NA investigative prostate specific antigen KLK3 Clinical trial target unknown NA TTD motexafin lutetium NA Stenosis[MeSHID:D003251],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteries[MeSHID:D001158] phase 3 prostate specific antigen KLK3 Clinical trial target unknown NA TTD , DGIDB gallium ga-68 gozetotide small molecule Radioactivity[MeSHID:D011851],Serum[MeSHID:D044967],Diagnosis[MeSHID:D003933],Malignant neoplasm of prostate[MeSHID:D011471],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008] approved prostate-specific antigen KLK3 NA binder NA drugbank mifepristone small molecule Hyperglycemia[MeSHID:D006943],Operative Surgical Procedures[MeSHID:D013514],Impaired glucose tolerance[MeSHID:D018149],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Cushing Syndrome[MeSHID:D003480],Adrenal Gland Hyperfunction[MeSHID:D000308],ADULT SYNDROME[MeSHID:C538052],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational prostate-specific antigen KLK3 NA unknown 0.53 drugbank , DGIDB anti-psa mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative prostate specific antigen KLK3 Clinical trial target unknown NA TTD prostavac NA Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 prostate specific antigen KLK3 Clinical trial target unknown NA TTD , DGIDB vtt-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative prostate specific antigen KLK3 Clinical trial target unknown NA TTD adxs-psa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 prostate specific antigen KLK3 Clinical trial target unknown NA TTD , DGIDB rilimogene galvacirepvec NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 prostate specific antigen KLK3 Clinical trial target unknown NA TTD , DGIDB benzoxazinone derivative 2 NA NA patented kallikrein-4 KLK4 Patented-recorded target unknown NA TTD , DGIDB pmid25489658c4d NA NA investigative kallikrein-5 KLK5 Patented-recorded target unknown NA TTD pmid23849879c3 NA NA investigative kallikrein-5 KLK5 Patented-recorded target unknown NA TTD pmid24900446c5 NA NA investigative kallikrein-6 KLK6 Literature-reported target unknown NA TTD benzamidine small molecule NA experimental,investigative kallikrein-6 KLK6 Literature-reported target unknown NA TTD , drugbank antileukoprotease (alp) NA NA investigative kallikrein-7 KLK7 Patented-recorded target unknown NA TTD l-alanyl-n-[(1s,2r)-1-benzyl-2-hydroxypropyl]-l-alaninamide small molecule NA experimental kallikrein-7 KLK7 NA unknown NA drugbank pmid23849879c3 NA NA investigative kallikrein-7 KLK7 Patented-recorded target unknown NA TTD pmid25489658c4d NA NA investigative kallikrein-7 KLK7 Patented-recorded target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental plasma kallikrein KLKB1 NA inhibitor NA drugbank lanadelumab biotech Disease[MeSHID:D004194],Edema[MeSHID:D004487],Angioedemas, Hereditary[MeSHID:D054179],Mutation[MeSHID:D009154],Limb structure[MeSHID:D005121],Genitalia[MeSHID:D005835],Larynx[MeSHID:D007830],Pain[MeSHID:D010146],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasma kallikrein KLKB1 Successful target inhibitor 159.13 TTD , drugbank , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational plasma kallikrein KLKB1 NA inhibitor NA drugbank (3,4-dichlorophenyl)(1h-pyrazol-1-yl)methanone NA NA investigative plasma kallikrein KLKB1 Successful target unknown NA TTD d-pro-phe-arg chloromethyl ketone NA NA investigative plasma kallikrein KLKB1 Successful target unknown NA TTD zk-810388 NA NA investigative plasma kallikrein KLKB1 Successful target unknown NA TTD berotralstat small molecule Angioedemas, Hereditary[MeSHID:D054179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasma kallikrein KLKB1 Successful target inhibitor NA TTD , drugbank kvd824 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 plasma kallikrein KLKB1 Successful target unknown NA TTD thr-149 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 plasma kallikrein KLKB1 Successful target unknown NA TTD kvd001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 plasma kallikrein KLKB1 Successful target unknown NA TTD , DGIDB isis-pkk NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686],Cardiomyopathies[MeSHID:D009202] phase 3 plasma kallikrein messenger rna KLKB1 Clinical trial target unknown NA TTD gabexate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatitis[MeSHID:D010195] investigational plasma kallikrein KLKB1 NA inhibitor NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational plasma kallikrein KLKB1 NA unknown NA drugbank zk-814048 NA NA investigative plasma kallikrein KLKB1 Successful target unknown NA TTD (3-nitro-1h-pyrazol-1-yl)(phenyl)methanone NA NA investigative plasma kallikrein KLKB1 Successful target unknown NA TTD ecallantide biotech Angioedemas, Hereditary[MeSHID:D054179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinal Vein Occlusion[MeSHID:D012170] approved,investigational plasma kallikrein KLKB1 Successful target inhibitor 15.91 TTD , drugbank , DGIDB lanadelumab biotech Disease[MeSHID:D004194],Edema[MeSHID:D004487],Angioedemas, Hereditary[MeSHID:D054179],Mutation[MeSHID:D009154],Limb structure[MeSHID:D005121],Genitalia[MeSHID:D005835],Larynx[MeSHID:D007830],Pain[MeSHID:D010146],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasma kallikrein KLKB1 Successful target inhibitor,antibody 159.13 TTD , drugbank , DGIDB conestat alfa biotech Angioedemas, Hereditary[MeSHID:D054179] approved,investigational plasma kallikrein KLKB1 NA inhibitor NA drugbank (3-nitro-1h-pyrazol-1-yl)(p-tolyl)methanone NA NA investigative plasma kallikrein KLKB1 Successful target unknown NA TTD 1-benzoyl-n-phenyl-1h-pyrazole-3-carboxamide NA NA investigative plasma kallikrein KLKB1 Successful target unknown NA TTD (4-bromo-1h-pyrazol-1-yl)(p-tolyl)methanone NA NA investigative plasma kallikrein KLKB1 Successful target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational plasma kallikrein KLKB1 NA unknown NA drugbank human c1-esterase inhibitor biotech Angioedemas, Hereditary[MeSHID:D054179] approved plasma kallikrein KLKB1 NA inhibitor NA drugbank monalizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 nkg2-a/b-activating nk receptor KLRC1 Clinical trial target unknown 127.3 TTD , DGIDB nn8765 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 nkg2-a/b-activating nk receptor KLRC1 Clinical trial target unknown 127.3 TTD , DGIDB bms-986315 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 nkg2-a/b-activating nk receptor KLRC1 Clinical trial target unknown NA TTD monalizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 nkg2-a/b-activating nk receptor KLRC1 Clinical trial target antibody 127.3 TTD , DGIDB nkr-2 car-t cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 nkg2 d activating nk receptor KLRK1 Clinical trial target unknown NA TTD , DGIDB cm-cs1 t-cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1 nkg2 d activating nk receptor KLRK1 Clinical trial target unknown NA TTD , DGIDB nn8555 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 2 nkg2 d activating nk receptor KLRK1 Clinical trial target unknown NA TTD , DGIDB cyad-101 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 nkg2 d activating nk receptor KLRK1 Clinical trial target unknown NA TTD , DGIDB nkr-2 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Cells[MeSHID:D002477] phase 1 nkg2 d activating nk receptor KLRK1 Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 3 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB upf-648 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] preclinical kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD aryl pyrimidine derivative 2 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB pyrimidine benzenesulfonamide derivative 3 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB benzene sulfonamide derivative 5 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB benzene sulfonamide derivative 7 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 6 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB aryl pyrimidine derivative 9 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 4 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB pyrimidine benzenesulfonamide derivative 2 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB pmid27172114-compound-47 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB aryl pyrimidine derivative 6 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB isoxazoles and isoxazoline derivative 4 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB chdi-340246 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816] preclinical kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD benzene sulfonamide derivative 6 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB benzene sulfonamide derivative 3 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB benzene sulfonamide derivative 4 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 10 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 9 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 2 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB isoxazoles and isoxazoline derivative 3 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB pyrimidine benzenesulfonamide derivative 1 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB gsk366 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatitis[MeSHID:D010195] preclinical kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD aryl pyrimidine derivative 5 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 5 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB isoxazoles and isoxazoline derivative 5 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB aryl pyrimidine derivative 4 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 1 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 8 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB isoxazoles and isoxazoline derivative 1 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB gsk065 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatitis[MeSHID:D010195] phase 1 kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD isoxazoles and isoxazoline derivative 6 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB isoxazoles and isoxazoline derivative 2 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB aryl pyrimidine derivative 8 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB benzene sulfonamide derivative 1 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB aryl pyrimidine derivative 3 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB gsk180 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatitis[MeSHID:D010195] preclinical kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD benzene sulfonamide derivative 2 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB aryl pyrimidine derivative 7 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB pmid27172114-compound-49 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB cyclopropane 1-carboxylic acid derivative 7 NA NA patented kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD , DGIDB ro 61-8048 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] preclinical kynurenine 3-hydroxylase KMO Clinical trial target unknown NA TTD a-196 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical histone-lysine n-methyltransferase kmt5b KMT5B Preclinical target inhibitor NA TTD , DGIDB a-196 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical histone-lysine n-methyltransferase kmt5c KMT5C Preclinical target inhibitor NA TTD , DGIDB avoralstat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angioedemas, Hereditary[MeSHID:D054179] phase 2/3 kininogen KNG1 Clinical trial target unknown 31.83 TTD , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental kininogen-1 KNG1 NA cofactor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kininogen-1 KNG1 NA unknown NA drugbank cu201 (b9870) NA NA investigative kininogen KNG1 Clinical trial target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational kininogen-1 KNG1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational kininogen-1 KNG1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational kininogen-1 KNG1 NA cofactor NA drugbank rg6330 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 kras g12c mutant KRAS Clinical trial target unknown NA TTD bi 1701963 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 gtpase kras KRAS Clinical trial target unknown NA TTD gi-4000 + gemcitabine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 mutated kras KRAS Clinical trial target unknown NA TTD ly3499446 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 kras g12c mutant KRAS Clinical trial target unknown NA TTD sotorasib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 kras g12c mutant KRAS Clinical trial target unknown NA TTD , DGIDB sig12d-loder NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 kras g12d mutant messenger rna KRAS Clinical trial target unknown NA TTD adagrasib small molecule Lung[MeSHID:D008168],Adenocarcinoma[MeSHID:D000230],Colon structure (body structure)[MeSHID:D003106] investigational gtpase kras KRAS NA inhibitor NA drugbank mrtx849 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 kras g12c mutant KRAS Clinical trial target inhibitor NA TTD , DGIDB farnesyl diphosphate small molecule NA experimental gtpase kras KRAS NA unknown NA drugbank jnj-74699157 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 kras g12c mutant KRAS Clinical trial target unknown NA TTD sotorasib small molecule Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gtpase kras KRAS NA inhibitor NA drugbank , DGIDB [(3,7,11-trimethyl-dodeca-2,6,10-trienyloxycarbamoyl)-methyl]-phosphonic acid small molecule NA experimental gtpase kras KRAS NA unknown NA drugbank azd4785 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 gtpase kras KRAS Clinical trial target unknown 1.43 TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational keratin, type ii cytoskeletal 1 KRT1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational keratin, type ii cytoskeletal 1 KRT1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational keratin, type ii cytoskeletal 1 KRT1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational keratin, type i cytoskeletal 10 KRT10 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational keratin, type i cytoskeletal 10 KRT10 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational keratin, type i cytoskeletal 10 KRT10 NA unknown NA drugbank griseofulvin small molecule Tinea Pedis[MeSHID:D014008],Disease[MeSHID:D004194],Nail plate[MeSHID:D009262],Skin Diseases, Infectious[MeSHID:D012874],Hair[MeSHID:D006197],Seborrheic dermatitis[MeSHID:D012628],Tinea[MeSHID:D014005],Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] approved,investigational,vet_approved keratin, type i cytoskeletal 12 KRT12 NA unknown NA drugbank anthralin small molecule Disease Management[MeSHID:D019468],Scalp structure[MeSHID:D012535],Dermatologic disorders[MeSHID:D012871],Alopecia Areata[MeSHID:D000506],Alopecia[MeSHID:D000505],Psoriasis[MeSHID:D011565] approved keratin, type i cytoskeletal 12 KRT12 NA antagonist NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational keratin, type i cytoskeletal 14 KRT14 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational keratin, type i cytoskeletal 14 KRT14 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational keratin, type i cytoskeletal 16 KRT16 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational keratin, type i cytoskeletal 16 KRT16 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational keratin, type ii cytoskeletal 2 epidermal KRT2 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational keratin, type ii cytoskeletal 2 epidermal KRT2 NA unknown NA drugbank anthralin small molecule Disease Management[MeSHID:D019468],Scalp structure[MeSHID:D012535],Dermatologic disorders[MeSHID:D012871],Alopecia Areata[MeSHID:D000506],Alopecia[MeSHID:D000505],Psoriasis[MeSHID:D011565] approved keratin, type ii cytoskeletal 2 epidermal KRT2 NA antagonist NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational keratin, type ii cytoskeletal 2 epidermal KRT2 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational keratin, type ii cytoskeletal 5 KRT5 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational keratin, type ii cytoskeletal 5 KRT5 NA unknown NA drugbank td-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Flavivirus Infections[MeSHID:D018177],Pachyonychia[MeSHID:D009264] phase 2 keratin 6a messenger rna KRT6A Clinical trial target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational keratin, type ii cytoskeletal 6a KRT6A NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational keratin, type ii cytoskeletal 6a KRT6A NA unknown NA drugbank verpasep caltespen biotech Condylomata Acuminata[MeSHID:D003218],Parasitic Diseases[MeSHID:D010272],HIV Infections[MeSHID:D015658],Communicable Diseases[MeSHID:D003141],Virus Diseases[MeSHID:D014777],Anus[MeSHID:D001003],Warts[MeSHID:D014860],Infection[MeSHID:D007239],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cervical Intraepithelial Neoplasia[MeSHID:D018290] investigational keratin, type ii cytoskeletal 7 KRT7 NA unknown NA drugbank primaquine small molecule Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved keratin, type ii cytoskeletal 7 KRT7 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational keratin, type ii cytoskeletal 8 KRT8 NA unknown NA drugbank tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved keratin, type ii cytoskeletal 8 KRT8 NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational keratin, type ii cytoskeletal 8 KRT8 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational keratin, type i cytoskeletal 9 KRT9 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational keratin, type i cytoskeletal 9 KRT9 NA ligand NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental keratin, type i cytoskeletal 9 KRT9 NA ligand NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational keratin, type i cytoskeletal 9 KRT9 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational keratin, type i cytoskeletal 9 KRT9 NA unknown NA drugbank pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational keratin-associated protein 5-2 KRTAP5-2 NA unknown NA drugbank beta-d-glucose small molecule NA experimental keratin-associated protein 5-2 KRTAP5-2 NA unknown NA drugbank beta-d-glucose small molecule NA experimental keratin-associated protein 5-3 KRTAP5-3 NA unknown NA drugbank 3,6,9,12,15-pentaoxaheptadecane NA NA investigative kynureninase KYNU Preclinical target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical kynureninase KYNU NA cofactor NA drugbank m-hydroxyhippuric acid small molecule NA experimental kynureninase KYNU NA unknown NA drugbank 3-hydroxydesaminokynurenine NA NA investigative kynureninase KYNU Preclinical target unknown NA TTD s-(2-aminophenyl)-l-cysteine s,s-dioxide NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical kynureninase KYNU Preclinical target unknown NA TTD 3-hydroxyhippuric acid NA NA investigative kynureninase KYNU Preclinical target unknown NA TTD alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical kynureninase KYNU NA unknown NA drugbank 3-methoxydesaminokynurenine NA NA investigative kynureninase KYNU Preclinical target unknown NA TTD 2-amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] preclinical kynureninase KYNU Preclinical target unknown NA TTD cd171 specific car t cells expressing egfrt NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroblastoma[MeSHID:D009447],Ganglioneuroblastoma[MeSHID:D018305],T-Lymphocyte[MeSHID:D013601] phase 1 neural cell adhesion molecule l1 L1CAM Clinical trial target unknown NA TTD , DGIDB jcar023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroblastoma[MeSHID:D009447] phase 1 neural cell adhesion molecule l1 L1CAM Clinical trial target unknown NA TTD , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neural cell adhesion molecule l1 L1CAM NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical trans-l-3-hydroxyproline dehydratase L3HYPDH NA unknown NA drugbank 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental lethal(3)malignant brain tumor-like protein 1 L3MBTL1 NA unknown NA drugbank unc1215 NA NA investigative lethal(3)malignant brain tumor-like 3 L3MBTL3 Literature-reported target agonist NA TTD , DGIDB gsk2831781 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown 31.83 TTD , DGIDB concatameric lag3ig NA NA investigative lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD bms-986016 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown 95.48 TTD , DGIDB rg6139 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD fs118 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD , DGIDB gsk4074386 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD adpt01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD imp-701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD , DGIDB imp-731 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD anti-lag3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Renal Cell Carcinoma[MeSHID:D002292],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 2 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD , DGIDB imp-321 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] phase 1/2 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD , DGIDB mk-4280 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD incagn2385 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD xmab22841 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD sym022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 lymphocyte activation gene 3 protein LAG3 Clinical trial target unknown NA TTD nc410 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 leukocyte-associated ig-like receptor 1 LAIR1 Clinical trial target unknown NA TTD palmitic acid small molecule NA approved alpha-lactalbumin LALBA NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational laminin subunit alpha-1 LAMA1 NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational laminin subunit alpha-3 LAMA3 NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational laminin subunit alpha-5 LAMA5 NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational laminin subunit beta-1 LAMB1 NA unknown NA drugbank lamb3-transduced autologous epidermal stem cells NA Epidermis[MeSHID:D004817],Epidermolysis Bullosa[MeSHID:D004820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stem cells[MeSHID:D013234] phase 1 laminin beta-3 chain LAMB3 Clinical trial target unknown NA TTD , DGIDB lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational laminin subunit gamma-1 LAMC1 NA unknown NA drugbank bst-1005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical laminin gamma-2 subunit LAMC2 Literature-reported target unknown NA TTD , DGIDB rp-a501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glycogen storage disease type II[MeSHID:D006009] phase 1 lysosome-associated membrane glycoprotein 2 LAMP2 Clinical trial target unknown NA TTD zofenoprilat small molecule NA experimental cytosol aminopeptidase LAP3 NA unknown NA drugbank (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid small molecule NA experimental cytosol aminopeptidase LAP3 NA unknown NA drugbank leucine phosphonic acid small molecule NA experimental cytosol aminopeptidase LAP3 NA unknown NA drugbank leucine small molecule Catabolism[MeSHID:D008660],Traumatic injury[MeSHID:D014947] investigational,nutraceutical leucine--trna ligase, cytoplasmic LARS NA unknown NA drugbank leucine small molecule Catabolism[MeSHID:D008660],Traumatic injury[MeSHID:D014947] investigational,nutraceutical probable leucine--trna ligase, mitochondrial LARS2 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase lats1 LATS1 NA inhibitor NA drugbank pmid20684608c35 NA NA investigative large tumor suppressor homolog 2 LATS2 Literature-reported target unknown NA TTD hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved layilin LAYN NA binder NA drugbank medi6012 NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] phase 2 lecithin-cholesterol acyltransferase LCAT Clinical trial target unknown 31.83 TTD , DGIDB pd-0179483 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD 3-(2-aminoquinazolin-6-yl)-4-methyl-n-[3-(trifluoromethyl)phenyl]benzamide small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank nm-pp1 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD isis-crp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Inflammation[MeSHID:D007249] phase 1 lck tyrosine protein kinase LCK Successful target unknown NA TTD , DGIDB zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase lck LCK NA inhibitor NA drugbank l-779450 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD a-641359 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase lck LCK NA multitarget 0.1 drugbank , DGIDB ro-316233 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD 1-tert-butyl-3-(4-chloro-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank jnj-10198409 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD staurosporinone NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD ap-22408 small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank pd-0173952 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 lck tyrosine protein kinase LCK Successful target unknown 0.24 TTD , DGIDB vx-680 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 lck tyrosine protein kinase LCK Successful target unknown 0.03 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase lck LCK NA multitarget,inhibitor 0.1 drugbank , DGIDB pmid17600705c23 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD ro31-8220 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved lck tyrosine protein kinase LCK Successful target inhibitor 0.1 TTD , DGIDB pmid17280833c30 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase lck LCK NA inhibitor NA drugbank tg-100435 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD 6-o-tolylquinazolin-2-amine NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 lck tyrosine protein kinase LCK Successful target inhibitor 0.24 TTD , DGIDB n-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank 2-(3,4,5-trihydroxy-benzylidene)-malononitrile NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD zm-336372 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD pd-0166326 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD jnj-28312141 NA NA investigative lck tyrosine protein kinase LCK Successful target inhibitor 0.22 TTD , DGIDB phosphoaminophosphonic acid-adenylate ester small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank hki-9924129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD lck inhibitor NA NA investigative lck tyrosine protein kinase LCK Successful target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase lck LCK NA inhibitor NA drugbank n-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved lck tyrosine protein kinase LCK Successful target unknown 0.1 TTD , DGIDB rpr-108518a NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase lck LCK NA multitarget 0.1 drugbank , DGIDB a-420983 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD {4-[(2s)-2-acetamido-3-({(1s)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved tyrosine-protein kinase lck LCK NA inhibitor 0.15 drugbank , DGIDB staurosporine small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank 4-(3-chloro-phenoxy)-6,7-dimethoxy-quinazoline NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD gw-788388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD kn-62 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD y-c[d-pen-(3,5-dii)tyr-gsfc]kr-nh2 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD lavendustin a NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved lck tyrosine protein kinase LCK Successful target inhibitor 0.1 TTD , DGIDB bisindolylmaleimide-i NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD n-(2-chloro-6-methylphenyl)-8-[(3s)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase lck LCK NA multitarget,inhibitor 0.1 drugbank , DGIDB pd-0173955 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD pmid15546730c2 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD pd-0173958 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD cep-5104 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD pd-0173956 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD ci-1040 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown 0.05 TTD , DGIDB y-c[d-pen-(3-i)tyr-gsfc]kr-nh2 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD wh-4-023 NA NA investigative lck tyrosine protein kinase LCK Successful target inhibitor NA TTD , DGIDB dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved lck tyrosine protein kinase LCK Successful target unknown 0.1 TTD , DGIDB 3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD su 6656 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD a-770041 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD 5,6-diphenyl-n-(2-piperazin-1-ylethyl)furo[2,3-d]pyrimidin-4-amine small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase lck LCK NA inhibitor NA drugbank amp-pnp NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD (4-phenoxy-phenyl)-quinazolin-4-yl-amine NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD cgp-57380 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD bms-536924 NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD pmid21855335c19a NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD 4-phenylsulfanyl-7h-pyrrolo[2,3-d]pyrimidine NA NA investigative lck tyrosine protein kinase LCK Successful target unknown NA TTD 2,3-diphenyl-n-(2-piperazin-1-ylethyl)furo[2,3-b]pyridin-4-amine small molecule NA experimental tyrosine-protein kinase lck LCK NA unknown NA drugbank leucine small molecule Catabolism[MeSHID:D008660],Traumatic injury[MeSHID:D014947] investigational,nutraceutical leucine carboxyl methyltransferase 1 LCMT1 NA unknown NA drugbank leucine small molecule Catabolism[MeSHID:D008660],Traumatic injury[MeSHID:D014947] investigational,nutraceutical leucine carboxyl methyltransferase 2 LCMT2 NA unknown NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical lipocalin-1 LCN1 NA unknown NA drugbank methyl nonanoate small molecule NA experimental neutrophil gelatinase-associated lipocalin LCN2 NA unknown NA drugbank carboxymycobactin t small molecule NA experimental neutrophil gelatinase-associated lipocalin LCN2 NA unknown NA drugbank 2,3,-dihydroxybenzoylserine small molecule NA experimental neutrophil gelatinase-associated lipocalin LCN2 NA unknown NA drugbank 2,3-dihydroxy-benzoic acid small molecule NA experimental neutrophil gelatinase-associated lipocalin LCN2 NA unknown NA drugbank carboxymycobactin s small molecule NA experimental neutrophil gelatinase-associated lipocalin LCN2 NA unknown NA drugbank trencam-3,2-hopo small molecule NA experimental neutrophil gelatinase-associated lipocalin LCN2 NA unknown NA drugbank 6-hydroxy-6-methyl-heptan-3-one small molecule NA experimental epididymal-specific lipocalin-9 LCN9 NA unknown NA drugbank 2-methoxy-3-isopropylpyrazine small molecule NA experimental epididymal-specific lipocalin-9 LCN9 NA unknown NA drugbank (4r)-limonene 1α,2α-epoxide small molecule NA experimental epididymal-specific lipocalin-9 LCN9 NA unknown NA drugbank 2-(sec-butyl)thiazole small molecule NA experimental epididymal-specific lipocalin-9 LCN9 NA unknown NA drugbank 2-isobutyl-3-methoxypyrazine small molecule NA experimental epididymal-specific lipocalin-9 LCN9 NA unknown NA drugbank gluconolactone small molecule NA approved,experimental,investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD , drugbank alpha-d-mannose NA NA investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD 2-deoxy-2-fluoro-α-d-glucose small molecule NA experimental lactase-phlorizin hydrolase LCT NA unknown NA drugbank 2-deoxy-2fluoro-glucose NA NA investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD 2,5-dideoxy-2,5-imino-dl-glycero-d-manno-heptitol NA NA investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD alpha-d-xylopyranose small molecule NA experimental lactase-phlorizin hydrolase LCT NA unknown NA drugbank nojirimycine tetrazole small molecule NA experimental,investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD , drugbank hyacinthacine b3 NA NA investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD d-gluconhydroximo-1,5-lactam small molecule NA experimental,investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD , drugbank 2,5-dideoxy-2,5-imino-d-altritol NA NA investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD ethyl (1e)-2-phenyl-n-(sulfooxy)ethanimidothioate small molecule NA experimental,investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD , drugbank 2-hydroxymethyl-6-octylsulfanyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental lactase-phlorizin hydrolase LCT NA unknown NA drugbank fucose NA NA investigative lactase-phlorizin hydrolase LCT Literature-reported target unknown NA TTD (1s,2s,3r,4s,5s)-2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl (1e)-2-phenyl-n-(sulfooxy)ethanimidothioate small molecule NA experimental lactase-phlorizin hydrolase LCT NA unknown NA drugbank 2,4-dihydroxy-7-(methyloxy)-2h-1,4-benzoxazin-3(4h)-one small molecule NA experimental lactase-like protein LCTL NA unknown NA drugbank para-nitrophenyl 1-thio-beta-d-glucopyranoside small molecule NA experimental lactase-like protein LCTL NA unknown NA drugbank beta-d-glucose small molecule NA experimental lactase-like protein LCTL NA unknown NA drugbank (s)-4-hydroxymandelonitrile small molecule NA experimental lactase-like protein LCTL NA unknown NA drugbank nojirimycine tetrazole small molecule NA experimental lactase-like protein LCTL NA unknown NA drugbank stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved l-lactate dehydrogenase a chain LDHA NA inhibitor NA drugbank oxamic acid small molecule NA experimental l-lactate dehydrogenase a chain LDHA NA unknown NA drugbank nicotinamide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved,investigational l-lactate dehydrogenase a chain LDHA NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical l-lactate dehydrogenase a chain LDHA NA unknown NA drugbank etheno-nad small molecule NA experimental l-lactate dehydrogenase a chain LDHA NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational l-lactate dehydrogenase a chain LDHA NA ligand NA drugbank dcr-phxc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperoxaluria[MeSHID:D006959] phase 2 ldha messenger rna LDHA Clinical trial target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational l-lactate dehydrogenase a chain LDHA NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical l-lactate dehydrogenase a-like 6a LDHAL6A NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical l-lactate dehydrogenase a-like 6b LDHAL6B NA unknown NA drugbank 4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid small molecule NA experimental l-lactate dehydrogenase b chain LDHB NA unknown NA drugbank stiripentol small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved l-lactate dehydrogenase b chain LDHB NA inhibitor NA drugbank oxamic acid small molecule NA experimental l-lactate dehydrogenase b chain LDHB NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical l-lactate dehydrogenase b chain LDHB NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational l-lactate dehydrogenase b chain LDHB NA ligand NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical l-lactate dehydrogenase c chain LDHC NA unknown NA drugbank porfimer sodium small molecule Esophageal Neoplasms[MeSHID:D004938],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational low-density lipoprotein receptor LDLR Successful target unknown NA TTD , drugbank , DGIDB alpha-d-mannose NA NA investigative low-density lipoprotein receptor LDLR Successful target unknown NA TTD etacrynic acid small molecule Hypertensive disease[MeSHID:D006973],Kidney Failure[MeSHID:D051437],Liver Failure[MeSHID:D017093],Edema[MeSHID:D004487],Congestive heart failure[MeSHID:D006333] approved,investigational lymphoid enhancer-binding factor 1 LEF1 NA unknown NA drugbank metreleptin biotech Malnutrition[MeSHID:D044342],Diet therapy[MeSHID:D004035],Familial generalized lipodystrophy[MeSHID:D052497],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved leptin receptor LEPR Successful target agonist 63.65 TTD , drugbank , DGIDB bl-5040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100],Burkitt Lymphoma[MeSHID:D002051] investigative leptin receptor LEPR Successful target unknown NA TTD ang-2004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative leptin receptor LEPR Successful target unknown NA TTD leptin small molecule Lipodystrophy[MeSHID:D008060],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,investigative leptin receptor LEPR Successful target unknown NA TTD , drugbank edp-21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative leptin receptor LEPR Successful target unknown NA TTD ampe4l NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative leptin receptor LEPR Successful target unknown NA TTD amppl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative leptin receptor LEPR Successful target unknown NA TTD ampsl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative leptin receptor LEPR Successful target unknown NA TTD peg-lpa-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative leptin receptor LEPR Successful target unknown NA TTD pegylated leptin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative leptin receptor LEPR Successful target unknown NA TTD mercaptoethanol small molecule NA experimental galectin-1 LGALS1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational galectin-1 LGALS1 NA ligand NA drugbank 1,4-dithiothreitol small molecule NA experimental galectin-1 LGALS1 NA unknown NA drugbank thiodigalactoside small molecule NA experimental galectin-1 LGALS1 NA unknown NA drugbank beta-d-glucose small molecule NA experimental galectin-2 LGALS2 NA unknown NA drugbank 2,3,5,6-tetrafluoro-4-methoxy-benzamide small molecule NA experimental,investigative galectin-3 LGALS3 Clinical trial target unknown NA TTD , drugbank gr-md-02 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],melanoma[MeSHID:D008545],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Nonalcoholic Steatohepatitis[MeSHID:D065626] phase 2 galectin-3 LGALS3 Clinical trial target unknown 31.83 TTD , DGIDB lactose small molecule NA approved,experimental,investigational galectin-3 LGALS3 NA unknown NA drugbank pfffff NA NA investigative galectin-3 LGALS3 Clinical trial target unknown NA TTD beta-d-glucose small molecule NA experimental galectin-7 LGALS7 NA unknown NA drugbank beta-d-galactosamine small molecule NA experimental galectin-7 LGALS7 NA unknown NA drugbank (r)-1-para-nitro-phenyl-2-azido-ethanol small molecule NA experimental galectin-9 LGALS9 NA unknown NA drugbank pmid24775305c7u NA NA investigative legumain LGMN Clinical trial target unknown NA TTD legumain-cleavable doxorubicin prodrugs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2/3 legumain LGMN Clinical trial target unknown NA TTD , DGIDB bnc-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical g-protein coupled receptor 48 LGR4 Preclinical target unknown NA TTD bnc-101 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 leucine-rich repeat-containing gpcr 5 LGR5 Clinical trial target unknown NA TTD mcla-158 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 leucine-rich repeat-containing gpcr 5 LGR5 Clinical trial target unknown NA TTD bnc-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical leucine-rich repeat-containing gpcr 5 LGR5 Clinical trial target unknown NA TTD km-4056 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative leucine-rich repeat-containing gpcr 5 LGR5 Clinical trial target unknown NA TTD chorionic gonadotropin NA Fertility[MeSHID:D005298],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved luteinizing hormone receptor LHCGR Successful target unknown NA TTD ldi-200 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 luteinizing hormone receptor LHCGR Successful target unknown NA TTD cetrorelix small molecule Psychological inhibition[MeSHID:D007266],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational lutropin-choriogonadotropic hormone receptor LHCGR NA unknown NA drugbank buserelin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Uterine Fibroids[MeSHID:D007889],Malignant neoplasm of prostate[MeSHID:D011471],Endometriosis[MeSHID:D004715],Malignant neoplasm of breast[MeSHID:D001943],Reproduction[MeSHID:D012098] approved,investigational lutropin-choriogonadotropic hormone receptor LHCGR NA unknown NA drugbank chorionic gonadotropin (human) biotech Infertility[MeSHID:D007246],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Neoplasm Metastasis[MeSHID:D009362],Cryptorchidism[MeSHID:D003456],Klinefelter Syndrome[MeSHID:D007713],Hypogonadism[MeSHID:D007006],Anovulation[MeSHID:D000858],Hypopituitarism[MeSHID:D007018] approved,vet_approved lutropin-choriogonadotropic hormone receptor LHCGR NA ligand NA drugbank menotropins biotech Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lutropin-choriogonadotropic hormone receptor LHCGR NA agonist 18.56 drugbank , DGIDB goserelin small molecule Disease Management[MeSHID:D019468],Carcinoma[MeSHID:D002277],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Metrorrhagia[MeSHID:D008796],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lutropin-choriogonadotropic hormone receptor LHCGR NA agonist 3.79 drugbank , DGIDB menotropins biotech Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lutropin-choriogonadotropic hormone receptor LHCGR NA unknown 18.56 drugbank , DGIDB choriogonadotropin alfa NA Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved luteinizing hormone receptor LHCGR Successful target unknown NA TTD , DGIDB choriogonadotropin alfa biotech Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lutropin-choriogonadotropic hormone receptor LHCGR NA agonist 10.61 drugbank , DGIDB choriogonadotropin alfa biotech Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lutropin-choriogonadotropic hormone receptor LHCGR NA unknown NA drugbank , DGIDB choriogonadotropin alfa NA Female infertility[MeSHID:D007247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved luteinizing hormone receptor LHCGR Successful target agonist 10.61 TTD , DGIDB ml-04 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 luteinizing hormone receptor LHCGR Successful target unknown NA TTD , DGIDB lutropin alfa NA Infertility[MeSHID:D007246],Hypothalamic structure[MeSHID:D007031],Klinefelter Syndrome[MeSHID:D007713],Hypogonadotropic hypogonadism[MeSHID:D007006],Malnutrition[MeSHID:D044342],Hypopituitarism[MeSHID:D007018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] approved luteinizing hormone receptor LHCGR Successful target agonist 5.3 TTD , DGIDB lutropin alfa biotech Infertility[MeSHID:D007246],Hypothalamic structure[MeSHID:D007031],Klinefelter Syndrome[MeSHID:D007713],Hypogonadotropic hypogonadism[MeSHID:D007006],Malnutrition[MeSHID:D044342],Hypopituitarism[MeSHID:D007018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] approved lutropin-choriogonadotropic hormone receptor LHCGR NA agonist NA drugbank , DGIDB lutropin alfa biotech Infertility[MeSHID:D007246],Hypothalamic structure[MeSHID:D007031],Klinefelter Syndrome[MeSHID:D007713],Hypogonadotropic hypogonadism[MeSHID:D007006],Malnutrition[MeSHID:D044342],Hypopituitarism[MeSHID:D007018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] approved lutropin-choriogonadotropic hormone receptor LHCGR NA agonist 5.3 drugbank , DGIDB lutropin alfa NA Infertility[MeSHID:D007246],Hypothalamic structure[MeSHID:D007031],Klinefelter Syndrome[MeSHID:D007713],Hypogonadotropic hypogonadism[MeSHID:D007006],Malnutrition[MeSHID:D044342],Hypopituitarism[MeSHID:D007018],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female infertility[MeSHID:D007247] approved luteinizing hormone receptor LHCGR Successful target unknown NA TTD , DGIDB org-43902 NA Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 luteinizing hormone receptor LHCGR Successful target unknown NA TTD , DGIDB ep-200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative luteinizing hormone receptor LHCGR Successful target unknown NA TTD lipoic acid small molecule NA approved,investigational,nutraceutical lipoyl synthase, mitochondrial LIAS NA unknown NA drugbank emfilermin NA Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 leukemia inhibitory factor receptor LIFR Clinical trial target unknown 127.3 TTD , DGIDB bleomycin small molecule Malignant Neoplasms[MeSHID:D009369],Patient Care Management[MeSHID:D010346],Lymphoma[MeSHID:D008223],Trachea[MeSHID:D014132],Squamous cell carcinoma[MeSHID:D002294],Lung[MeSHID:D008168],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689] approved,investigational dna ligase 1 LIG1 NA inhibitor 10.05 drugbank , DGIDB bleomycin small molecule Malignant Neoplasms[MeSHID:D009369],Patient Care Management[MeSHID:D010346],Lymphoma[MeSHID:D008223],Trachea[MeSHID:D014132],Squamous cell carcinoma[MeSHID:D002294],Lung[MeSHID:D008168],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689] approved,investigational dna ligase 3 LIG3 NA inhibitor NA drugbank mk-4830 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 leukocyte immunoglobulin-like receptor b2 LILRB2 Clinical trial target unknown NA TTD io-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470], Myelomonocytic, Chronic[MeSHID:D015477] phase 1 leukocyte immunoglobulin-like receptor b4 LILRB4 Clinical trial target unknown NA TTD dabrafenib small molecule melanoma[MeSHID:D008545],Disease[MeSHID:D004194],Anaplastic thyroid carcinoma[MeSHID:D065646],Mutation[MeSHID:D009154],Continuance of life[MeSHID:D013534],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational lim domain kinase 1 LIMK1 NA antagonist,inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational lim domain kinase 1 LIMK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational lim domain kinase 2 LIMK2 NA inhibitor NA drugbank biib 033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 leucine-rich repeat neuronal protein 1 LINGO1 Clinical trial target unknown NA TTD sbc-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved lysosomal acid lipase LIPA Successful target unknown 12.73 TTD , DGIDB oxybenzone NA Sunscreening Agents[MeSHID:D013473] investigative hormone sensitive lipase LIPE Successful target unknown NA TTD nci-159878 NA NA investigative hormone sensitive lipase LIPE Successful target unknown NA TTD bifenox NA NA investigative hormone sensitive lipase LIPE Successful target unknown NA TTD ethiofencarb NA NA investigative hormone sensitive lipase LIPE Successful target unknown NA TTD 2-(3-methoxybenzylthio)-2-phenylacetic acid NA NA investigative hormone sensitive lipase LIPE Successful target unknown NA TTD pmid15026062c41 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatitis[MeSHID:D010195] clinical trial hormone sensitive lipase LIPE Successful target unknown NA TTD , DGIDB benzyl benzoate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532],Lice Infestations[MeSHID:D010373] approved hormone sensitive lipase LIPE Successful target unknown NA TTD , DGIDB nci-58425 NA NA investigative hormone sensitive lipase LIPE Successful target unknown NA TTD pmi-008 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative hormone sensitive lipase LIPE Successful target unknown NA TTD cetilistat NA Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 gastric triacylglycerol lipase LIPF Clinical trial target unknown 15.91 TTD , DGIDB b-octylglucoside NA NA investigative gastric triacylglycerol lipase LIPF Clinical trial target unknown NA TTD undecyl-phosphinic acid butyl ester small molecule NA experimental,investigative gastric triacylglycerol lipase LIPF Clinical trial target unknown NA TTD , drugbank orlistat small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Overweight[MeSHID:D050177],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational gastric triacylglycerol lipase LIPF NA inhibitor 31.83 drugbank , DGIDB gsk-264220a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] clinical trial endothelial lipase LIPG Clinical trial target inhibitor NA TTD , DGIDB gsk-264220a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] clinical trial endothelial lipase LIPG Clinical trial target unknown NA TTD , DGIDB lipoic acid small molecule NA approved,investigational,nutraceutical lipoyltransferase 1, mitochondrial LIPT1 NA unknown NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational protein ergic-53 LMAN1 NA chaperone NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein ergic-53 LMAN1 NA chaperone NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational protein ergic-53 LMAN1 NA chaperone NA drugbank beta-aminopropionitrile NA Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical lysyl oxidase homolog 2 LOXL2 Clinical trial target unknown NA TTD gs-6624 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 lysyl oxidase homolog 2 LOXL2 Clinical trial target unknown 190.95 TTD , DGIDB isis-apo(a) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 2 apolipoprotein a messenger rna LPA Clinical trial target unknown NA TTD aminocaproic acid small molecule Postoperative Hemorrhage[MeSHID:D019106],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194] approved,investigational apolipoprotein(a) LPA NA other NA drugbank amg 890 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Fibrosis[MeSHID:D005355] phase 2 apolipoprotein a messenger rna LPA Clinical trial target unknown NA TTD mg-1102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 apolipoprotein(a) LPA Clinical trial target unknown NA TTD , DGIDB alkyl ompt NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target agonist NA TTD , DGIDB phosphoric acid mono-((e)-tetradec-11-enyl) ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD t13 NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD (1,1-difluoro-pentadecyl)-phosphonic acid NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD thiophosphoric acid (e)-dodec-9-enyl ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD phosphoric acid mono-((e)-dodec-9-enyl) ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD ki16425 NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD dodecyl-thiophosphate NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD thiophosphoric acid decyl ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD tetradecyl-phosphonic acid NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD dioctanoylglycerol pyrophosphate NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist NA TTD , DGIDB bms-986020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Psoriasis[MeSHID:D011565],Scleroderma[MeSHID:D012594] phase 2 lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist 127.3 TTD , DGIDB 2-oleoyl-lpa NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target agonist NA TTD , DGIDB oleoyl-thiophosphate NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target agonist NA TTD , DGIDB phosphoric acid mono-((e)-tetradec-9-enyl) ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD thiophosphoric acid dec-9-enyl ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD lpa NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD sar-100842 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Fibrosis[MeSHID:D005355] phase 2 lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD , DGIDB bms-986202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] preclinical lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD , DGIDB vpc32183 NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist NA TTD , DGIDB phosphoric acid monododecyl ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD syn-brp-lpa NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist NA TTD , DGIDB ono-3080573 NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist NA TTD , DGIDB anti-brp-lpa NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist NA TTD , DGIDB ono-9780307 NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist NA TTD , DGIDB phosphoric acid mono-((e)-dec-4-enyl) ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD bms-986020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Psoriasis[MeSHID:D011565],Scleroderma[MeSHID:D012594] phase 2 lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown 127.3 TTD , DGIDB vpc12249 NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD ono-9910539 NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist NA TTD , DGIDB naepa NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD decyl-phosphonic acid NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD thiophosphoric acid (e)-tetradec-9-enyl ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD dodecyl-phosphonic acid NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD phosphoric acid monotetradecyl ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD brp-lpa NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target antagonist NA TTD , DGIDB phosphoric acid monodec-9-enyl ester NA NA investigative lysophosphatidic acid receptor 1 LPAR1 Clinical trial target unknown NA TTD naepa NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target unknown NA TTD 2-oleoyl-lpa NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target agonist NA TTD , DGIDB t13 NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target unknown NA TTD dodecylphosphate NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target antagonist NA TTD , DGIDB vpc32183 NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target antagonist NA TTD , DGIDB ki16425 NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target antagonist NA TTD , DGIDB ompt NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target agonist NA TTD , DGIDB lpa NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target agonist NA TTD , DGIDB sar-100842 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Fibrosis[MeSHID:D005355] phase 2 lysophosphatidate-3 receptor LPAR3 Clinical trial target unknown NA TTD , DGIDB alpha-fluoromethylenephosphonate NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target unknown NA TTD vpc12249 NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target antagonist NA TTD , DGIDB dodecyl-thiophosphate NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target unknown NA TTD dioctanoylglycerol pyrophosphate NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target agonist,antagonist NA TTD , DGIDB alkyl ompt NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target agonist NA TTD , DGIDB pmid19800804c12 NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target unknown NA TTD oleoyl-thiophosphate NA NA investigative lysophosphatidate-3 receptor LPAR3 Clinical trial target unknown NA TTD lpa NA NA investigative lysophosphatidic acid receptor 4 LPAR4 Literature-reported target agonist NA TTD , DGIDB [1-bromo-(3s)-hydrox-4-(palmitoyloxy)butyl]phosphate NA NA investigative lysophosphatidic acid receptor 4 LPAR4 Literature-reported target antagonist NA TTD , DGIDB n-arachidonoylglycine NA NA investigative lysophosphatidic acid receptor 5 LPAR5 Literature-reported target agonist 1.68 TTD , DGIDB lpa NA NA investigative lysophosphatidic acid receptor 5 LPAR5 Literature-reported target agonist NA TTD , DGIDB alkyl glycerol phosphate 18:1 NA NA investigative lysophosphatidic acid receptor 5 LPAR5 Literature-reported target unknown NA TTD octyl thiophosphatidic acid NA NA investigative lysophosphatidic acid receptor 5 LPAR5 Literature-reported target unknown NA TTD lpa NA NA investigative lysophosphatidic acid receptor 6 LPAR6 Literature-reported target agonist NA TTD , DGIDB tyloxapol small molecule Solutions[MeSHID:D012996],Bodily secretions[MeSHID:D012634],Streams[MeSHID:D045483],Cystic Fibrosis[MeSHID:D003550],Pus[MeSHID:D013492],Mucous body substance[MeSHID:D009093],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] approved,investigational lipoprotein lipase LPL NA inhibitor NA drugbank clofibrate NA Hypercholesterolemia[MeSHID:D006937],Hyperlipoproteinemia Type III[MeSHID:D006952],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lipoprotein lipase LPL Successful target unknown 0.24 TTD , DGIDB amt-011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematological Disease[MeSHID:D006402] phase 3 lipoprotein lipase LPL Successful target unknown NA TTD , DGIDB ibrolipim NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 lipoprotein lipase LPL Successful target unknown 3.54 TTD , DGIDB ws-070117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] investigative lipoprotein lipase LPL Successful target unknown NA TTD gemfibrozil NA Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Fasting[MeSHID:D005215],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Serum[MeSHID:D044967],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Weight decreased[MeSHID:D015431],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lipoprotein lipase LPL Successful target unknown 0.29 TTD , DGIDB omega-3-carboxylic acids small molecule Hippocampus Proper[MeSHID:D006624],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Alcohol consumption[MeSHID:D000428],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Neoplasm Metastasis[MeSHID:D009362],Plasma[MeSHID:D010949],Obesity[MeSHID:D009765],Metabolic Syndrome X[MeSHID:D024821] approved,investigational lipoprotein lipase LPL NA stimulator NA drugbank glycyrrhizic acid small molecule Neoplasms[MeSHID:D009369],Premenstrual syndrome[MeSHID:D011293],Stomach Diseases[MeSHID:D013272],Ulcer[MeSHID:D014456],Virus Diseases[MeSHID:D014777],Peptic Ulcer[MeSHID:D010437] approved,experimental lipoprotein lipase LPL NA inducer NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved lecithin retinol acyltransferase LRAT NA substrate NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational leucine-rich alpha-2-glycoprotein LRG1 NA unknown NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prolow-density lipoprotein receptor-related protein 1 LRP1 NA modulator NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational prolow-density lipoprotein receptor-related protein 1 LRP1 NA modulator NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational prolow-density lipoprotein receptor-related protein 1 LRP1 NA unknown NA drugbank coagulation factor ix human biotech Plasma[MeSHID:D010949],Operative Surgical Procedures[MeSHID:D013514],Hemophilia B[MeSHID:D002836],Hemorrhage[MeSHID:D006470] approved prolow-density lipoprotein receptor-related protein 1 LRP1 NA unknown NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational prolow-density lipoprotein receptor-related protein 1 LRP1 NA modulator NA drugbank coagulation factor ix (recombinant) biotech Hemophilia B[MeSHID:D002836],Hemophilia A[MeSHID:D006467] approved,investigational prolow-density lipoprotein receptor-related protein 1 LRP1 NA unknown NA drugbank tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prolow-density lipoprotein receptor-related protein 1 LRP1 NA unknown NA drugbank insulin human biotech Diabetes Mellitus[MeSHID:D003920] approved,investigational low-density lipoprotein receptor-related protein 2 LRP2 NA substrate NA drugbank urokinase biotech Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved,investigational,withdrawn low-density lipoprotein receptor-related protein 2 LRP2 NA substrate NA drugbank bi 905681 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 low-density lipoprotein receptor-related protein 5 LRP5 Clinical trial target unknown NA TTD bi 905677 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 low-density lipoprotein receptor-related protein 5 LRP5 Clinical trial target unknown NA TTD bi 905677 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ldl receptor related protein-6 LRP6 Clinical trial target unknown NA TTD ds-1055 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 transforming growth factor beta activator lrrc32 LRRC32 Clinical trial target unknown NA TTD pmid28117607-compound-20 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB fused thiophene derivative 1 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyridopyrimidinone derivative 3 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyridine derivative 2 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrimidine derivative 9 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB aminopyridine derivative 2 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyridine derivative 2 NA NA patented leucine-rich repeat kinase 2 g2019s mutant LRRK2 Patented-recorded target unknown NA TTD , DGIDB bidentate ligands of markush derivative 1 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB azaindazole derivative 2 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pf-06447475 NA NA investigative leucine-rich repeat kinase 2 LRRK2 Clinical trial target inhibitor NA TTD , DGIDB pyrrolo-pyrimidine derivative 11 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pf-06454589 NA NA investigative leucine-rich repeat kinase 2 LRRK2 Clinical trial target inhibitor NA TTD , DGIDB hydrazide derivative 5 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB gne-9605 NA NA investigative leucine-rich repeat kinase 2 LRRK2 Clinical trial target inhibitor NA TTD , DGIDB azaindazole derivative 4 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pmid28117607-compound-21 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB oxindole derivative 4 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyridazine derivative 1 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB dnl201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyridine derivative 1 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB azaindazole derivative 3 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB bidentate ligands of markush derivative 2 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pmid28117607-compound-4 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB urmc-099 NA NA investigative leucine-rich repeat kinase 2 LRRK2 Clinical trial target inhibitor NA TTD , DGIDB oxindole derivative 3 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational leucine-rich repeat serine/threonine-protein kinase 2 LRRK2 NA inhibitor NA drugbank oxindole derivative 3 NA NA patented leucine-rich repeat kinase 2 g2019s mutant LRRK2 Patented-recorded target unknown NA TTD , DGIDB pmid28117607-compound-6 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrimidine derivative 10 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB gne-7915 NA NA investigative leucine-rich repeat kinase 2 LRRK2 Clinical trial target inhibitor NA TTD , DGIDB pyridopyrimidinone derivative 1 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pmid28117607-compound-7 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB aminopyridine derivative 3 NA NA patented leucine-rich repeat kinase 2 g2019s mutant LRRK2 Patented-recorded target unknown NA TTD , DGIDB azaindazole derivative 1 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB hms3229g13 NA NA investigative leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD pyridopyrimidinone derivative 2 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB oxindole derivative 4 NA NA patented leucine-rich repeat kinase 2 g2019s mutant LRRK2 Patented-recorded target unknown NA TTD , DGIDB dnl151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pmid28117607-compound-5 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrimidine derivative 8 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyrimidine derivative 1 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB hydrazide derivative 3 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB oxindole derivative 2 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB hydrazide derivative 4 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB fused thiophene derivative 1 NA NA patented leucine-rich repeat kinase 2 s935 phosphorylation LRRK2 Patented-recorded target unknown NA TTD , DGIDB aminopyridine derivative 3 NA NA patented leucine-rich repeat kinase 2 LRRK2 Clinical trial target unknown NA TTD , DGIDB uridine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] experimental,investigational u6 snrna-associated sm-like protein lsm6 LSM6 NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved u6 snrna-associated sm-like protein lsm6 LSM6 NA unknown NA drugbank uridine monophosphate small molecule NA experimental u6 snrna-associated sm-like protein lsm6 LSM6 NA unknown NA drugbank tetradecane NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD pmid22533316c4 NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD b-octylglucoside NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD [3-(biphenyl-4-yloxy)-propyl]-dimethyl-amine NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD r048-8071 small molecule NA experimental lanosterol synthase LSS NA unknown NA drugbank pmid22533316c3 NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD pmid22533316c1 NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD 29-methylidene-2,3-oxidosqualene NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD pmid9003518c3 NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD lanosterol small molecule NA experimental,investigative lanosterol synthase LSS Literature-reported target unknown NA TTD , drugbank ro48-8071 NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD pmid9003518c4 NA NA investigative lanosterol synthase LSS Literature-reported target unknown NA TTD etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational lymphotoxin-alpha LTA NA antibody NA drugbank anti-lt alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 lymphotoxin-alpha LTA Clinical trial target unknown NA TTD , DGIDB (r)-2-((4-phenoxyphenoxy)methyl)piperidine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 2-[4-(2-azepan-1-ylethoxy)phenoxy]benzothiazole NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n-[3-[(1-aminoethyl)(hydroxy)phosphoryl]-2-(1,1'-biphenyl-4-ylmethyl)propanoyl]alanine small molecule NA experimental leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank n5-[4-(phenylmethoxy)phenyl]-d-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 4-(4-propoxyphenoxy)phenol NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD (2s)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid small molecule NA experimental leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank n-[4-(benzyloxy)phenyl]glycinamide small molecule NA experimental leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank sa-6541 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD jnj-10392980 NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD acetate ion NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-(2-oxo-3-phenylpropoxy)phenyl]-l-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 1-(4-phenoxyphenyl)piperazine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-(2-phenylethoxy)phenyl]-l-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-(3-phenylpropoxy)phenyl]-l-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n-methyl-1-(2-thiophen-2-ylphenyl)methanamine small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank n-benzyl-4-[(2r)-pyrrolidin-2-ylmethoxy]aniline small molecule NA experimental leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank n5-[4-(4-methylphenoxy)phenyl]-l-glutamamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n6-[4-(4-methylphenoxy)phenyl]-l-homoglutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 2-(7-(benzyloxy)-1h-indol-3-yl)ethanamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-(n-phenylamino)phenyl]-l-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 2-(4-piperidin-1-ylmethylphenoxy)benzothiazole NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 2-[4-(2-piperidin-1-ylethyl)phenoxy]benzothiazole NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-(4-(3-furyl)phenoxy)phenyl]-l-glutamamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD (r)-2-(4-benzylphenoxymethyl)pyrrolidine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 1-[4-(4-iodophenoxy)phenyl]piperazine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n1-[4-(phenylmethoxy)phenyl]-d-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD {4-[(2r)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone small molecule NA experimental leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved leukotriene a-4 hydrolase LTA4H NA inhibitor NA drugbank (r/s)-2-((4-benzylphenoxy)methyl)piperazine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-(phenylmethoxy)phenyl]-l-glutamamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 2-(4-phenoxyphenoxy)ethanamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 2-[4-(2-morpholin-4-ylethoxy)phenoxy]benzooxazole NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 5-[2-(1h-pyrrol-1-yl)ethoxy]-1h-indole small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank ubenimex small molecule Hypercholesterolemia[MeSHID:D006937],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Nasopharyngeal carcinoma[MeSHID:C538339],Cancer of Nasopharynx[MeSHID:D009303] investigational leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank acebilustat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bulla[MeSHID:D001768],Chronic disease[MeSHID:D002908] phase 1 leukotriene a-4 hydrolase LTA4H Successful target unknown 7.07 TTD , DGIDB n4-[4-(phenylmethoxy)phenyl]-l-aspartamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD (r/s)-2-((4-benzylphenoxy)methyl)piperidine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 1-[4-(benzothiazol-2-yloxy)benzyl]piperidin-4-ol NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-(phenylmethoxy)phenyl]-l-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 2-[4-(2-azepan-1-ylethoxy)phenoxy]benzooxazole NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 4-(4-butoxyphenoxy)phenol NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 3-(benzyloxy)pyridin-2-amine small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank n5-[4-(1h-pyrrol-1-yl)phenyl]-l-glutamamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 4s-4,5-diamino-n-(4-phenoxyphenyl)pentanamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 1-(4-thiophen-2-ylphenyl)methanamine small molecule NA experimental leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank bestatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] approved leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , DGIDB (4-(thiophen-2-yl)phenyl)methanamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD (r)-2-((4-benzylphenoxy)methyl)piperidine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 4-(4-(pentyloxy)phenoxy)phenol NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD (s)-2-((4-phenoxyphenoxy)methyl)piperidine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD (r)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol small molecule NA experimental leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank 1-(2,2'-bithiophen-5-yl)methanamine small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank n-(pyridin-3-ylmethyl)aniline small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank n5-[4-(3-methylphenoxy)phenyl]-l-glutamamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 2-(4-benzylphenoxy)ethanamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 4-amino-n-[4-(benzyloxy)phenyl]butanamide small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank n5-(4-phenoxyphenyl)-l-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD (r/s)-2-((4-phenoxyphenoxy)methyl)piperidine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD imidazole small molecule NA experimental,investigational leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank 1-(pentyloxy)-4-phenoxybenzene NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-benzylphenyl]-l-glutamamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 4-[2-(4-benzylphenoxy)ethyl]pyridine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 8(s)-amino-2(r)-methyl-7-oxononanoic acid NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD 5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank 2-amino-n-[4-(phenylmethoxy)phenyl]-acetamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD bestatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] approved leukotriene a-4 hydrolase LTA4H Successful target inhibitor NA TTD , DGIDB 1-butoxy-4-phenoxybenzene NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[(4-phenoxy)-3-pyridyl]-l-glutamamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n1-[4-(phenylmethoxy)phenyl]-l-glutamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n5-[4-(2-methylphenoxy)phenyl]-l-glutamamide NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD tosedostat small molecule NA investigational leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank (r)-n-benzyl-4-(pyrrolidin-2-ylmethoxy)aniline NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD dg051 small molecule Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank , DGIDB n1-[4-(phenylmethoxy)phenyl]-l-aspartamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD n1-[4-(phenylmethoxy)phenyl]-d-aspartamine NA NA investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved leukotriene a-4 hydrolase LTA4H NA inhibitor NA drugbank (4-fluorophenyl)(pyridin-4-yl)methanone small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank kelatorphan small molecule NA experimental leukotriene a-4 hydrolase LTA4H NA unknown NA drugbank 4-(2-amino-1,3-thiazol-4-yl)phenol small molecule NA experimental,investigative leukotriene a-4 hydrolase LTA4H Successful target unknown NA TTD , drugbank biomed 101 NA Renal Cell Carcinoma[MeSHID:D002292],Inflammatory Bowel Diseases[MeSHID:D015212],Malignant neoplasm of kidney[MeSHID:D007680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD , DGIDB morniflumate small molecule Nose[MeSHID:D009666],Disease[MeSHID:D004194],Ear structure[MeSHID:D004423],Gastrointestinal Diseases[MeSHID:D005767],Pharyngeal structure[MeSHID:D010614],Affect (mental function)[MeSHID:D000339],Upper Respiratory Infections[MeSHID:D012141],Bone Tissue[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Otitis Media[MeSHID:D010033] experimental leukotriene b4 receptor 1 LTB4R NA antagonist NA drugbank (3s,4r)-3-benzyl-7-isopropyl-chroman-4-ol NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD leucettamidine NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD cp-195543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target antagonist 12.73 TTD , DGIDB sc-52073 NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD amelubant small molecule Asthma[MeSHID:D001249],Rheumatoid Arthritis[MeSHID:D001172],Cystic Fibrosis[MeSHID:D003550],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung diseases[MeSHID:D008171] investigational,phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target antagonist 38.19 TTD , drugbank , DGIDB ci-949 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD ly-223982 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD tak-683 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Allergic Reaction[MeSHID:D006967],Malignant neoplasm of prostate[MeSHID:D011471],Expiration, function[MeSHID:D045853] discontinued in phase 1 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD (ltb4-(csa)4)2-glu-h conjugate NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD leukotriene b4 small molecule NA investigational leukotriene b4 receptor 1 LTB4R NA unknown NA drugbank ly-282210 NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD ltb4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD , DGIDB cp-195543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown 12.73 TTD , DGIDB sc-50073 NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD sc-53229 NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD dtpa conjugate NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD sc-50135 NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD cp-105696 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] discontinued in phase 1 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD leucettamine a NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD amelubant small molecule Asthma[MeSHID:D001249],Rheumatoid Arthritis[MeSHID:D001172],Cystic Fibrosis[MeSHID:D003550],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung diseases[MeSHID:D008171] investigational,phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown 38.19 TTD , drugbank , DGIDB ltb4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target agonist NA TTD , DGIDB sc-52569 NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD sc-50676 NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD ltb 019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD , DGIDB ly293111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] discontinued in phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD hynic analogue NA NA investigative leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD sb-201993 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 leukotriene b4 receptor 1 LTB4R Clinical trial target unknown NA TTD 20-hydroxy-ltb4 NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD cp-105696 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] discontinued in phase 1 leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD leukotriene b4 small molecule NA investigational leukotriene b4 receptor 2 LTB4R2 NA unknown NA drugbank ono-4057 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] discontinued in phase 2 leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD biil 260 NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD amelubant small molecule Asthma[MeSHID:D001249],Rheumatoid Arthritis[MeSHID:D001172],Cystic Fibrosis[MeSHID:D003550],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung diseases[MeSHID:D008171] investigational leukotriene b4 receptor 2 LTB4R2 NA unknown NA drugbank 12-epi ltb4 NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target agonist NA TTD , DGIDB ltb4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD , DGIDB zk-158252 NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target antagonist NA TTD , DGIDB biomed 101 NA Renal Cell Carcinoma[MeSHID:D002292],Inflammatory Bowel Diseases[MeSHID:D015212],Malignant neoplasm of kidney[MeSHID:D007680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD , DGIDB ly-282210 NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD [3h]ltb4 NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD , DGIDB 12-hydroxyheptadecatrienoic acid NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target agonist NA TTD , DGIDB 12r-hete NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD cay10583 NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target agonist NA TTD , DGIDB (3s,4r)-3-benzyl-7-isopropyl-chroman-4-ol NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD ro5101576 NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target unknown NA TTD 12s-hete NA NA investigative leukotriene b4 receptor 2 LTB4R2 Clinical trial target agonist NA TTD , DGIDB ltb4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 leukotriene b4 receptor 2 LTB4R2 Clinical trial target agonist NA TTD , DGIDB baminercept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 lymphotoxin beta receptor LTBR Clinical trial target unknown 7.96 TTD , DGIDB hcbe-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 lymphotoxin beta receptor LTBR Clinical trial target unknown 31.83 TTD , DGIDB glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical leukotriene c4 synthase LTC4S NA unknown NA drugbank azelastine small molecule Pruritus[MeSHID:D011537],Hay fever[MeSHID:D006255],Allergic Conjunctivitis[MeSHID:D003233],Rhinitis, Vasomotor[MeSHID:D012223],Hypersensitivity[MeSHID:D006967],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukotriene c4 synthase LTC4S NA inhibitor NA drugbank (r)-atenolol small molecule NA experimental lactotransferrin LTF NA unknown NA drugbank parecoxib small molecule Term Birth[MeSHID:D047929] approved,phase 4 lactotransferrin LTF Clinical trial target unknown 15.91 TTD , drugbank , DGIDB alpha-d-mannose NA NA investigative lactotransferrin LTF Clinical trial target unknown NA TTD nimesulide small molecule Degenerative polyarthritis[MeSHID:D010003],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Lymphoma, Non-Hodgkin[MeSHID:D008228],Expiration, function[MeSHID:D045853],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational,withdrawn,terminated lactotransferrin LTF Clinical trial target unknown NA TTD , drugbank fucose NA NA investigative lactotransferrin LTF Clinical trial target unknown NA TTD alpha-d-fucopyranose small molecule NA experimental lactotransferrin LTF NA unknown NA drugbank hlf 1-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Bacteremia[MeSHID:D016470],Bacterial Infections[MeSHID:D001424] phase 1/2 lactotransferrin LTF Clinical trial target unknown NA TTD , DGIDB alpha-d-fucose NA NA investigative lactotransferrin LTF Clinical trial target unknown NA TTD lauric acid small molecule NA approved,experimental,investigative lactotransferrin LTF Clinical trial target unknown NA TTD , drugbank nitrilotriacetic acid small molecule NA experimental,investigative lactotransferrin LTF Clinical trial target unknown NA TTD , drugbank 3h-indole-5,6-diol small molecule NA experimental,investigative lactotransferrin LTF Clinical trial target unknown NA TTD , drugbank talactoferrin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] phase 3 lactotransferrin LTF Clinical trial target unknown 15.91 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational leukocyte tyrosine kinase receptor LTK NA inhibitor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational lumican LUM NA unknown NA drugbank morphine small molecule Disease Management[MeSHID:D019468],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194],Physical Examination[MeSHID:D010808],emotional dependency[MeSHID:D003858],Drug abuse[MeSHID:D019966],Patient Monitoring[MeSHID:D008991],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved,investigational lymphocyte antigen 96 LY96 NA activator NA drugbank lauric acid small molecule NA approved,experimental lymphocyte antigen 96 LY96 NA unknown NA drugbank myristic acid small molecule NA experimental lymphocyte antigen 96 LY96 NA unknown NA drugbank (r)-3-hydroxytetradecanoic acid small molecule NA experimental lymphocyte antigen 96 LY96 NA unknown NA drugbank 1-tert-butyl-3-(4-chloro-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine small molecule NA experimental tyrosine-protein kinase lyn LYN NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase lyn LYN NA inhibitor 0.04 drugbank , DGIDB ng-25 NA NA investigative tyrosine-protein kinase lyn LYN Clinical trial target inhibitor NA TTD , DGIDB bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved tyrosine-protein kinase lyn LYN NA inhibitor 0.16 drugbank , DGIDB bafetinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bone Diseases[MeSHID:D001847] phase 2 tyrosine-protein kinase lyn LYN Clinical trial target unknown 1.48 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase lyn LYN NA inhibitor NA drugbank ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase lyn LYN NA inhibitor NA drugbank jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase lyn LYN Clinical trial target unknown 0.33 TTD , DGIDB bafetinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bone Diseases[MeSHID:D001847] phase 2 tyrosine-protein kinase lyn LYN Clinical trial target inhibitor 1.48 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase lyn LYN NA inhibitor 0.04 drugbank , DGIDB jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase lyn LYN Clinical trial target inhibitor 0.33 TTD , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved tyrosine-protein kinase lyn LYN NA inhibitor 0.21 drugbank , DGIDB pmid17600705c23 NA NA investigative tyrosine-protein kinase lyn LYN Clinical trial target unknown NA TTD alkynyl-substituted pyrimidinyl-pyrrole derivative 1 NA NA patented tyrosine-protein kinase lyn LYN Clinical trial target unknown NA TTD , DGIDB rg-7356 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] discontinued in phase 1 hyaluronic acid receptor LYVE1 Successful target unknown NA TTD hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved lymphatic vessel endothelial hyaluronic acid receptor 1 LYVE1 NA unknown NA drugbank hyaluronate sodium NA Enthesopathy[MeSHID:D000070676],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lubricants[MeSHID:D054327],Pancytopenia[MeSHID:D010198] approved hyaluronic acid receptor LYVE1 Successful target unknown NA TTD , DGIDB sucrose small molecule NA approved,experimental,investigational lysozyme c LYZ NA unknown NA drugbank (s)-aspartimide small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank n-acetyl-beta-d-glucosaminyl-(1->4)-n-acetyl-beta-d-glucosamine small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank (r)-propylene glycol small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank arsanilic acid small molecule NA experimental,vet_approved lysozyme c LYZ NA unknown NA drugbank 4-methyl-umbelliferyl-n-acetyl-chitobiose small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank methylumbelliferyl chitotriose small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank cu-cyclam small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank propyl alcohol small molecule NA approved lysozyme c LYZ NA unknown NA drugbank triacetylchitotriose small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical lysozyme c LYZ NA unknown NA drugbank p-toluenesulfonic acid small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank dodecyl sulfate small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank undeca-3,7-diene-1,3,7,11-tetracarbaldehyde small molecule NA experimental lysozyme c LYZ NA unknown NA drugbank 1-3 sugar ring of pentamannosyl 6-phosphate small molecule NA experimental cation-dependent mannose-6-phosphate receptor M6PR NA unknown NA drugbank alpha-d-mannose 6-phosphate small molecule NA experimental cation-dependent mannose-6-phosphate receptor M6PR NA unknown NA drugbank alglucosidase alfa NA Glycogen storage disease type II[MeSHID:D006009],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mannose-6-phosphate receptor M6PR Successful target unknown NA TTD , DGIDB 1-3 sugar ring of pentamannosyl 6-phosphate NA NA investigative mannose-6-phosphate receptor M6PR Successful target unknown NA TTD alpha-d-mannose-6-phosphate NA NA investigative mannose-6-phosphate receptor M6PR Successful target unknown NA TTD alglucosidase alfa biotech Glycogen storage disease type II[MeSHID:D006009],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cation-dependent mannose-6-phosphate receptor M6PR NA binder NA drugbank , DGIDB sch-527123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Chronic Obstructive Airway Disease[MeSHID:D029424],Ulcerative Colitis[MeSHID:D003093],Malignant Neoplasms[MeSHID:D009369] phase 2 mucosal addressin cell adhesion molecule 1 MADCAM1 Clinical trial target unknown 10.61 TTD , DGIDB shp647 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] phase 3 mucosal addressin cell adhesion molecule 1 MADCAM1 Clinical trial target unknown 63.65 TTD , DGIDB tetrachlorodecaoxide small molecule Neoplasms[MeSHID:D009369],HIV Infections[MeSHID:D015658],Disease[MeSHID:D004194],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Infection[MeSHID:D007239] approved,investigational macrophage erythroblast attacher MAEA NA unknown NA drugbank gsk249320 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 myelin-associated glycoprotein MAG Clinical trial target unknown 31.83 TTD , DGIDB melanoma vaccine (alvac) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 2 melanoma-associated antigen 1 MAGEA1 Clinical trial target unknown NA TTD car-t cells targeting mage-a1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of lung[MeSHID:D008175] phase 1/2 melanoma-associated antigen 1 MAGEA1 Clinical trial target unknown NA TTD , DGIDB melanoma vaccine (alvac) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 2 melanoma-associated antigen 3 MAGEA3 Clinical trial target unknown NA TTD astuprotimut-r NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 melanoma-associated antigen 3 MAGEA3 Clinical trial target unknown 95.48 TTD , DGIDB polynoma-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 melanoma-associated antigen 3 MAGEA3 Clinical trial target unknown NA TTD , DGIDB idm-2101 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 melanoma-associated antigen 3 MAGEA3 Clinical trial target unknown NA TTD , DGIDB gl-0817 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cancer of Head and Neck[MeSHID:D006258],Squamous cell carcinoma[MeSHID:D002294] phase 2 melanoma-associated antigen 3 MAGEA3 Clinical trial target unknown 31.83 TTD , DGIDB kite-718 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 melanoma-associated antigen 3 MAGEA3 Clinical trial target unknown NA TTD , DGIDB adp-a2m4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],synovial sarcoma[MeSHID:D013584] phase 2 melanoma-associated antigen 4 MAGEA4 Clinical trial target unknown NA TTD car-t cells targeting mage-a4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of lung[MeSHID:D008175] phase 1/2 melanoma-associated antigen 4 MAGEA4 Clinical trial target unknown NA TTD , DGIDB kite-718 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 melanoma-associated antigen 6 MAGEA6 Clinical trial target unknown NA TTD cv-9201 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 cancer/testis antigen mage-c1/ct7 MAGEC1 Clinical trial target unknown NA TTD , DGIDB cv-9201 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 melanoma-associated antigen c2 MAGEC2 Clinical trial target unknown NA TTD , DGIDB jnj-67856633 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 malt lymphoma-associated translocation MALT1 Clinical trial target unknown NA TTD kifunensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Muscular Dystrophy[MeSHID:D009136],Expiration, function[MeSHID:D045853] experimental endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase MAN1B1 NA unknown NA drugbank methyl-2-s-(alpha-d-mannopyranosyl)-2-thio-alpha-d-mannopyranoside small molecule NA experimental endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase MAN1B1 NA unknown NA drugbank 1,4-butanediol small molecule NA experimental endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase MAN1B1 NA unknown NA drugbank duvoglustat small molecule NA investigational endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase MAN1B1 NA unknown NA drugbank 2-deoxy-2-fluoro-alpha-d-mannosyl fluoride small molecule NA experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank kifunensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Muscular Dystrophy[MeSHID:D009136],Expiration, function[MeSHID:D045853] experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank ghavamiol small molecule NA experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank 5-fluoro-beta-l-gulosyl fluoride small molecule NA experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank tridolgosir small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank 1-deoxymannojirimycin small molecule NA experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank (1s,2s,3r,6r)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol small molecule NA experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank 5-thio-a/b-d-mannopyranosylamine small molecule NA experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank (1r,2r,3r,4s,5r)-4-(benzylamino)-5-(methylthio)cyclopentane-1,2,3-triol small molecule NA experimental alpha-mannosidase 2 MAN2A1 NA unknown NA drugbank tridolgosir NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 golgi alpha-mannosidase ii MAN2A1 Discontinued target unknown NA TTD (+/-)-2-(4'-butoxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD ethyl 4-(2-oxo-2h-chromene-3-carboxamido)benzoate NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 3-aminoacetamido-4'-methylfuro[3,2-g]coumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-figure2-artoxanthochromane NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB n-(2-phenylcyclopropyl) amino acid derivative 3 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB (e)-5-(3-chlorostyryl)isatin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 1 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB (r)-indan-1-yl-methyl-prop-2-ynyl-amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved monoamine oxidase MAOA NA inhibitor NA drugbank beta-methoxyamphetamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-figure3-fluevirosine a NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB iproniazide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 6-chloro-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD brofaromine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-figure3-aspeverin NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 4-methyl-7-(2-oxocyclopentyloxy)-2h-chromen-2-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD decyl(dimethyl)phosphine oxide small molecule NA experimental amine oxidase [flavin-containing] a MAOA NA unknown NA drugbank as602868 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] discontinued in phase 1 monoamine oxidase type a MAOA Successful target unknown NA TTD 2-phenyl-5h-indeno[1,2-d]pyrimidine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 9-methyl-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD cgs-19281a NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD piperine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitiligo[MeSHID:D014820] phase 1/2 monoamine oxidase type a MAOA Successful target unknown 0.18 TTD , DGIDB n-benzyl-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD nomifensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,withdrawn amine oxidase [flavin-containing] a MAOA NA unknown NA drugbank (s)-2-amino-1-(4-methylthiophenyl)-propane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-bromo-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD ladostigil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 monoamine oxidase type a MAOA Successful target unknown 0.73 TTD , DGIDB cis-(+/-)-2-fluoro-1,2-diphenylcyclopropylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 7-acetonyloxy-3-acetylamino-8-methoxycoumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(propargyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD clorgiline small molecule NA experimental amine oxidase [flavin-containing] a MAOA NA inhibitor 2.19 drugbank , DGIDB trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(2-phenylethyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-furan-2-yl-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(1h-indol-2-ylmethyl)-n-(4-phenylbutyl)amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 7-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 7-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 4-methoxyamphetamine small molecule NA experimental,illicit amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank 7-acetonyloxy-3,4-cyclopentene-8-methylcoumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tranylcypromine NA Melancholia[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Malignant neoplasm of prostate[MeSHID:D011471],Unipolar Depression[MeSHID:D003866] approved monoamine oxidase type a MAOA Successful target inhibitor 12.44 TTD , DGIDB 1-(1-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-figure1-chukrasone a NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB n-methyl,n-phenyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 3,4-benzo-7-acetonyloxy-8-methoxycoumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD hydrazinecarboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD gypensapogenina NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB (6-butoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD gypensapogeninb NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB procarbazine small molecule Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational monoamine oxidase MAOA NA inhibitor NA drugbank esuprone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 monoamine oxidase type a MAOA Successful target unknown NA TTD pirlindole small molecule Major Depressive Disorder[MeSHID:D003865],Hypertensive disease[MeSHID:D006973],Unipolar Depression[MeSHID:D003866],Psychological inhibition[MeSHID:D007266],Headache[MeSHID:D006261],Patient Care Management[MeSHID:D010346],Fibromyalgia[MeSHID:D005356],Genetic Selection[MeSHID:D012641],Pain Disorder[MeSHID:D013001],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Syndrome[MeSHID:D013577] experimental amine oxidase [flavin-containing] a MAOA NA antagonist,inhibitor 4.39 drugbank , DGIDB pmid25399762-compound-table 5-8 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amine oxidase [flavin-containing] a MAOA NA antagonist 2.03 drugbank , DGIDB (6-benzyloxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (7-benzyloxy-2-oxo-2h-chromen-4-yl)acetonitrile NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD clorgyline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved monoamine oxidase type a MAOA Successful target unknown 2.19 TTD , DGIDB (6-methylthio-2-naphthyl)isopropylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 3,4-benzo-7-(beta-bromoallyloxy)-8-methylcoumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (+/-)-2-phenylthiomorpholin-5-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank 2-phenyl-9h-indeno[2,1-d]pyrimidine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-(3-methoxybenzyloxy)caffeine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD bw-1370u87 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 1 monoamine oxidase type a MAOA Successful target unknown NA TTD tranylcypromine small molecule Melancholia[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Malignant neoplasm of prostate[MeSHID:D011471],Unipolar Depression[MeSHID:D003866] approved,investigational amine oxidase [flavin-containing] a MAOA NA inhibitor 12.44 drugbank , DGIDB n-(4-ethylphenyl)-2-oxo-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-(3-fluorobenzyloxy)caffeine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-[(3-trifluoromethyl)benzyloxy]caffeine NA NA investigative monoamine oxidase type a MAOA Successful target unknown 2.19 TTD , DGIDB (s)-2-amino-1-(4-propylthiophenyl)-propane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD selegiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Nausea[MeSHID:D009325],Unipolar Depression[MeSHID:D003866] approved,investigational,vet_approved amine oxidase [flavin-containing] a MAOA NA inhibitor 1.71 drugbank , DGIDB 8-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-(4,5-dihydro-1h-imidazol-2-yl)quinoline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tryptamine NA NA phase 3 monoamine oxidase type a MAOA Successful target unknown 0.18 TTD , DGIDB n-benzyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 1-(2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (r/r)befloxatone NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD psoralen NA NA phase 3 monoamine oxidase type a MAOA Successful target unknown 0.27 TTD , DGIDB pmid25399762-compound-figure1-chukrasone b NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 6-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD myriberinea NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB n-(4-phenylbutyl)-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-chloro-n-(3-morpholinopropyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD trans-2-fluoro-2-phenylcyclopropylamin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD zimelidine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank n-benzyl,n-methyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-[7-(benzyloxy)-2-oxo-2h-chromen-4-yl]acetamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-figure1-aphanamixoid a NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 3-chloro-n-(2-methyl-1h-indol-5-yl)benzamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank 6,11-dihydro-5h-benzo[a]carbazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (+/-)-2-(4'-propoxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(3-phenylpropyl)-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-((1h-indol-2-yl)methyl)(phenyl)methanamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 6-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 5-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 5-hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 4-chloro-n-(3-morpholinopropyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD cs-722 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] discontinued in phase 2 monoamine oxidase type a MAOA Successful target unknown NA TTD kadcoccitonea NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB pmid25399762-compound-figure3-lycojaponicumin b NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB decyl(dimethyl)phosphine oxide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-amino-1-(4-methylthiophenyl)propane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD fa-70 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative monoamine oxidase type a MAOA Successful target unknown NA TTD nialamide small molecule NA approved,withdrawn amine oxidase [flavin-containing] a MAOA NA unknown NA drugbank 6-amino-9-methoxy-7h-furo[3,2-g]chromen-7-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tracizoline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD desoxypeganine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 1 monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 4,8-dimethyl-7-(2'-oxocyclohexyloxy)coumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (6-propoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-table 5-o-methyl-m30 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB (r,s)-n-(r-phenylethyl)-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-(naphthalen-2-yl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD houttuynoida NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 6-methoxy-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD nsc-656158 NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-phenyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD trans-2-fluoro-2-p-tolylcyclopropanamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(1-methyl-1h-indol-2-ylmethyl)-n-phenylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (+/-)-2-(4'-butoxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pargyline small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Dystrophy[MeSHID:D009136] approved amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank c-(1h-indol-3-yl)-methylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD flavin-adenine dinucleotide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-benzyl,n-methyl-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD ginkgo biloba biotech Memory[MeSHID:D008568],Cognition[MeSHID:D003071] approved,investigational,nutraceutical amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank pmid29757691-compound-4 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB toloxatone NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 4-chloro-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tarnylcypromine derivative 3 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 2-bfi NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD isocarboxazid NA Emotions[MeSHID:D004644],Depressive disorder[MeSHID:D003866],Ability[MeSHID:D001076],Mood Disorders[MeSHID:D019964],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved monoamine oxidase type a MAOA Successful target inhibitor 5.12 TTD , DGIDB toloxatone small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] experimental amine oxidase [flavin-containing] a MAOA NA antagonist NA drugbank 2-oxo-n-phenyl-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-figure1-sarcaboside a NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 4-(aminomethyl)-7-(benzyloxy)-2h-chromen-2-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-methyl-n-(prop-2-ynyl)-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD moclobemide NA Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved monoamine oxidase type a MAOA Successful target unknown 5.49 TTD , DGIDB amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational monoamine oxidase MAOA NA inhibitor NA drugbank 6-hydroxy-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD brofaromine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] experimental amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank (+/-)-2-(4'-methoxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD isocarboxazid small molecule Emotions[MeSHID:D004644],Depressive disorder[MeSHID:D003866],Ability[MeSHID:D001076],Mood Disorders[MeSHID:D019964],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amine oxidase [flavin-containing] a MAOA NA inhibitor 5.12 drugbank , DGIDB aphanamgrandiola NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB pmid25399762-compound-figure1-neonectrolide a NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 6-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(3-phenylpropyl)-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (e)-5-styrylisatin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD moclobemide small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational monoamine oxidase MAOA NA antagonist,inhibitor 5.49 drugbank , DGIDB trans-(+/-)-2-fluoro-1,2-diphenylcyclopropylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD rs-8359 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 monoamine oxidase type a MAOA Successful target unknown NA TTD 3,4-benzo-7-acetonyloxy-8-methylcoumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD befloxatone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 3 monoamine oxidase type a MAOA Successful target inhibitor 2.19 TTD , DGIDB 1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (6-methoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-phenethyl-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD moclobemide NA Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved monoamine oxidase type a MAOA Successful target inhibitor 5.49 TTD , DGIDB n-methyl,n-(propargyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 5,6-dichloro-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(benzyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (6-ethoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (+/-)-2-(4'-ethoxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-phenyl-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-2-phenylethyl-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-oxo-n-p-tolyl-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid29324067-compound-25 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB pmid25399762-compound-figure1-sarcaboside b NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD heteroaryl-cyclopropylamine derivative 1 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 2-chloro-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 1-(4-propoxyphenyl)propan-2-amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 1-(3-benzylquinoxalin-2-yl)hydrazine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD schiff base compound 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 5,6-dichloro-n-(3-morpholinopropyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD cis-2-phenylcyclopropylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-figure3-lycojaponicumin a NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB phyllanthoida NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 1-(4-(benzyloxy)phenyl)propan-2-amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-phenoxymethyl-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD moclobemide small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational amine oxidase [flavin-containing] a MAOA NA antagonist,inhibitor 5.49 drugbank , DGIDB (+/-)-2-(4'-benzyloxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-benzyl-n-(1h-indol-2-ylmethyl)-n-methylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 5-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(1h-indol-2-ylmethyl)-n-phenylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(1h-indol-2-ylmethyl)-n-methyl-n-phenylamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-methyl,n-(benzyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-figure3-lycojaponicumin c NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 3-benzyl-n-(2-morpholinoethyl)quinoxalin-2-amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n2-[4-(benzyloxy)benzyl]glycinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (s)-2-amino-1-(4-butylthiophenyl)-propane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved amine oxidase [flavin-containing] a MAOA NA unknown NA drugbank harmine NA NA patented monoamine oxidase type a MAOA Successful target unknown 0.29 TTD , DGIDB (+/-)-2-(4'-ethoxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-((1h-indol-2-yl)methyl)-2-phenylethanamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD posizolid small molecule Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239] investigational amine oxidase [flavin-containing] a MAOA NA unknown NA drugbank pmid25399762-compound-figure1-eryngiolide a NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank 3-methyl-2(1h)-thioxo-4(3h)-quinazolinone NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 4 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB harmine small molecule NA experimental amine oxidase [flavin-containing] a MAOA NA unknown 0.29 drugbank , DGIDB cx157 NA Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 2 monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 2-(4-methoxyphenyl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tacrine-coumarin hybrid derivative 1 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 2-(5-phenyl-furan-2-yl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-(3-chlorobenzyloxy)caffeine NA NA investigative monoamine oxidase type a MAOA Successful target unknown 2.19 TTD , DGIDB incarviatonea NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 4-(2-oxo-2h-chromene-3-carboxamido)benzoic acid NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (+/-)-2-phenylthiomorpholine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(2-methyl-1h-indol-5-yl)cyclohexanecarboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-propargyl-1h-pyrrole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pnu-22394 NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-methoxy-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-benzyloxycaffeine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-oxo-n-m-tolyl-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 8-(3-methylbenzyloxy)caffeine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank n-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD isocarboxazid NA Emotions[MeSHID:D004644],Depressive disorder[MeSHID:D003866],Ability[MeSHID:D001076],Mood Disorders[MeSHID:D019964],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved monoamine oxidase type a MAOA Successful target unknown 5.12 TTD , DGIDB cyclic peptide derivative 1 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amine oxidase [flavin-containing] a MAOA NA antagonist,inhibitor 2.03 drugbank , DGIDB phenyl 4-(4,5-dihydro-1h-imidazol-2-yl)benzoate NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(2-benzyl),n-(1-methylpyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-(3-benzylquinoxalin-2-ylamino)ethanol NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(4-phenylbutyl)-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD mmda NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 7-acetonyloxy-3,4-cyclohexene-8-methylcoumarin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD cx157 small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] investigational amine oxidase [flavin-containing] a MAOA NA unknown NA drugbank , DGIDB 6-chloro-n-(3-morpholinopropyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 7-methoxy-9h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 5-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 5-azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tranylcypromine NA Melancholia[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Malignant neoplasm of prostate[MeSHID:D011471],Unipolar Depression[MeSHID:D003866] approved monoamine oxidase type a MAOA Successful target unknown 12.44 TTD , DGIDB 5-methoxy-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-phenyl-1-methyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 5-methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 2 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB (s)-2-amino-1-(4-ethylthiophenyl)-propane NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tryptoline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (+/-)-2-(4'-methoxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n-(2-phenylethyl)-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 1-(4-butoxyphenyl)propan-2-amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD chf-3381 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 monoamine oxidase type a MAOA Successful target unknown 0.73 TTD , DGIDB pmid25399762-compound-figure2-spirooliganone b NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 7-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD clorgiline small molecule NA experimental amine oxidase [flavin-containing] a MAOA NA unknown 2.19 drugbank , DGIDB 9-(3-aminopropoxy)-7h-furo[3,2-g]chromen-7-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 3,4-dichloro-n-(2-methyl-1h-indol-5-yl)benzamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 6-fluoro-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-(3,4-dimethoxyphenyl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD mmda small molecule NA experimental,illicit amine oxidase [flavin-containing] a MAOA NA inhibitor NA drugbank moclobemide small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational monoamine oxidase MAOA NA antagonist 5.49 drugbank , DGIDB phentermine small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Epidemic[MeSHID:D058872],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Rubella[MeSHID:D012409],Overweight[MeSHID:D050177],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit amine oxidase [flavin-containing] a MAOA NA antagonist NA drugbank (e)-5-(3-fluorostyryl)isatin NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD n'-(2-phenylallyl)hydrazine hydrochloride NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD (+/-)-2-(4'-propoxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD flortaucipir f-18 small molecule Neurofibrillary degeneration (morphologic abnormality)[MeSHID:D016874],Brain Injury, Chronic[MeSHID:D020208],Radioactivity[MeSHID:D011851] approved,investigational amine oxidase [flavin-containing] a MAOA NA binder NA drugbank tarnylcypromine derivative 2 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 1-(4-ethoxyphenyl)propan-2-amine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD secondary and tertiary (hetero)arylamide derivative 2 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 4-methyl-2h-benzofuro[3,2-g]chromen-2-one NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 3 NA NA patented monoamine oxidase type a MAOA Successful target unknown NA TTD , DGIDB 8-(3-bromobenzyloxy)caffeine NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole NA NA investigative monoamine oxidase type a MAOA Successful target unknown NA TTD pmid25399762-compound-table1-c11 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 7-methoxy-2-p-tolyl-4h-chromene-4-thione NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tranylcypromine NA Melancholia[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Malignant neoplasm of prostate[MeSHID:D011471],Unipolar Depression[MeSHID:D003866] approved monoamine oxidase type b MAOB Successful target unknown 7.67 TTD , DGIDB 8-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)-indan-1-yl-methyl-prop-2-ynyl-amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 6-amino-9-methoxy-7h-furo[3,2-g]chromen-7-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (6-benzyloxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid29324067-compound-40 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (6-methoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD rasagiline small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of skin[MeSHID:D012878] approved amine oxidase [flavin-containing] b MAOB NA inhibitor 8.8 drugbank , DGIDB 8-methoxy-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(2-aminoethyl)-p-chlorobenzamide small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank safinamide small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational amine oxidase [flavin-containing] b MAOB NA antagonist,inhibitor 0.81 drugbank , DGIDB deprenyl NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 7-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD selegiline hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table1-c15 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-2-(4'-benzyloxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)(+)-7-methyl-2-p-tolylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)-n2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-(2,4-dichlorophenyl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD benzylcinnamate NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (s)(+)-7-fluoro-2-phenylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD nw-1772 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] investigative monoamine oxidase type b MAOB Successful target unknown NA TTD heteroaryl-cyclopropylamine derivative 3 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (s)-n2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid29324067-compound-38 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 3-phenyl-9h-indeno[1,2-e][1,2,4]triazin-9-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD farnesol NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 2 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pnu-22394 NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 3-(3-methoxyphenyl)-6-methyl-2h-chromen-2-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD selegiline NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Nausea[MeSHID:D009325],Unipolar Depression[MeSHID:D003866] approved monoamine oxidase type b MAOB Successful target unknown 3.01 TTD , DGIDB 2-(4-fluorophenyl)-7-methoxy-4h-chromen-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD safinamide NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved monoamine oxidase type b MAOB Successful target unknown 0.81 TTD , DGIDB tranylcypromine NA Melancholia[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Malignant neoplasm of prostate[MeSHID:D011471],Unipolar Depression[MeSHID:D003866] approved monoamine oxidase type b MAOB Successful target inhibitor 7.67 TTD , DGIDB pmid25399762-compound-table 6-14 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved monoamine oxidase MAOB NA inhibitor NA drugbank pmid25399762-compound-table1-c6 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 8-(3-methylbenzyloxy)caffeine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank safinamide mesylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved monoamine oxidase type b MAOB Successful target inhibitor 1.35 TTD , DGIDB n-benzyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 3 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 1,4-diphenyl-(1e,3e)-1,3-butadiene NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)-n2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-phenethyl-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 3,4-benzo-7-(beta-bromoallyloxy)-8-methylcoumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD chalcone NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table 6-11 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amine oxidase [flavin-containing] b MAOB NA antagonist 1.25 drugbank , DGIDB farnesol small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank nomifensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,withdrawn amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank t83193 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 2-oxo-n-p-tolyl-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c8 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB n-methyl-n-phenyl-2-oxo-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (e)-6-styrylisatin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD rg1577 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (s)-2-amino-1-(4-butylthiophenyl)-propane NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c18 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB skl-pd NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 7-fluoro-2-(4-fluorophenyl)-4h-chromene-4-thione NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c16 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table1-c13 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 4-hydroxy-n-propargyl-1(r)-aminoindan NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 8-bromo-6-methyl-3-(4'-methoxyphenyl)coumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(benzyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD isocarboxazid small molecule Emotions[MeSHID:D004644],Depressive disorder[MeSHID:D003866],Ability[MeSHID:D001076],Mood Disorders[MeSHID:D019964],Mental Depression[MeSHID:D003863],Thinking, function[MeSHID:D013850],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amine oxidase [flavin-containing] b MAOB NA inhibitor 2.26 drugbank , DGIDB pioglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] approved,investigational amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank n-(2-phenylcyclopropyl) amino acid derivative 3 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table 7-vanillic acid NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB heptyl-methyl-prop-2-ynyl-amine hydrochloride NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD [(1e)-4-phenylbut-1-enyl]benzene NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-methyl,n-phenyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD phentermine small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Epidemic[MeSHID:D058872],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Rubella[MeSHID:D012409],Overweight[MeSHID:D050177],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit amine oxidase [flavin-containing] b MAOB NA antagonist NA drugbank 3,4-dichloro-n-(2-methyl-1h-indol-5-yl)benzamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-(4-chlorophenyl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 8-(3-methoxybenzyloxy)caffeine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (7-benzyloxy-2-oxo-2h-chromen-4-yl)acetonitrile NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD iproniazide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD safinamide mesylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-2-(4'-butoxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD coumaricacid NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 7-fluoro-2-(4-methoxyphenyl)-4h-chromen-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n2-[4-(benzyloxy)benzyl]glycinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r/r)befloxatone NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-(naphthalen-2-yl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(2-phenylethyl)-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (6-ethoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD mofegiline NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 monoamine oxidase type b MAOB Successful target unknown 1.35 TTD , DGIDB piperine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitiligo[MeSHID:D014820] phase 1/2 monoamine oxidase type b MAOB Successful target unknown 0.11 TTD , DGIDB nsc-93405 NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-methyl,n-(benzyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 1,2,3,4-tetrahydro-naphthalen-1-ylamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD cgs-19281a NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tacrine-coumarin hybrid derivative 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pargyline small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Dystrophy[MeSHID:D009136] approved amine oxidase [flavin-containing] b MAOB NA inhibitor 23.02 drugbank , DGIDB 5-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD selegiline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Nausea[MeSHID:D009325],Unipolar Depression[MeSHID:D003866] approved,investigational,vet_approved amine oxidase [flavin-containing] b MAOB NA inhibitor 3.01 drugbank , DGIDB lazabemide NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented monoamine oxidase type b MAOB Successful target inhibitor 1.35 TTD , DGIDB ht-1067 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Hashimoto Disease[MeSHID:D050031] discontinued in phase 1 monoamine oxidase type b MAOB Successful target unknown NA TTD 7-methoxy-9h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 3-(4-hydroxyphenyl)-6-methyl-2h-chromen-2-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD schiff base compound 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-2-(4'-benzyloxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD procarbazine small molecule Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational monoamine oxidase MAOB NA inhibitor NA drugbank pmid25399762-compound-table1-c23 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table 7-vanillyl alcohol NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB isopropyl-methyl-prop-2-ynyl-amine hydrochloride NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-phenylthiomorpholin-5-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 2-(4-methoxyphenyl)-4h-chromene-4-thione NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD isatin small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank 4-phenyl-1,2,3,6-tetrahydropyridine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)(+)-7-fluoro-2-phenylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD moclobemide small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational monoamine oxidase MAOB NA antagonist 1.35 drugbank , DGIDB (r)-3-prop-2-ynylamino-indan-5-ol NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tranylcypromine small molecule Melancholia[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Malignant neoplasm of prostate[MeSHID:D011471],Unipolar Depression[MeSHID:D003866] approved,investigational amine oxidase [flavin-containing] b MAOB NA inhibitor 7.67 drugbank , DGIDB selegiline hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved monoamine oxidase type b MAOB Successful target inhibitor 0.68 TTD , DGIDB 3-(2-bromophenyl)-6-methylcoumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 8-(3-fluorobenzyloxy)caffeine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank 8-bromo-6-methyl-3-phenylcoumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-7-fluoro-2-phenylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD sulphadoxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved monoamine oxidase type b MAOB Successful target unknown 1.35 TTD , DGIDB 3-hydroxy-2-butanone NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table1-c5 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 7-fluoro-2-p-tolyl-4h-chromen-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(4-ethylphenyl)-2-oxo-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD nsc-50187 NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD cis-2-fluoro-2-(4-methoxyphenyl)cyclopropylamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table 6-9 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB c-(1h-indol-3-yl)-methylamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 5-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD mmda NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tryptoline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-hydroxy-2,5-dimethyl-3(2h)-furanone NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 7-methyl-2-p-tolyl-4h-chromene-4-thione NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)-n2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(2-phenylethyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD evt-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 monoamine oxidase type b MAOB Successful target unknown NA TTD (s)(+)-7-methyl-2-phenylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD cordoin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-hydroxy-n-propargyl-1(r)-aminoindan small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank (s)-(+)-2-[4-(fluorobenzyloxy-benzylamino)propionamide] small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank (+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 3,4-benzo-7-acetonyloxy-8-methoxycoumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-chloro-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (e)-5-(3-chlorostyryl)isatin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 9-methyl-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 7-fluoro-2-p-tolyl-4h-chromene-4-thione NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD evt302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 2-oxo-n-m-tolyl-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD hydrazinecarboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD rs-1636 NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)-2-amino-1-(4-propylthiophenyl)-propane NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(2-aminoethyl)-2-oxo-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-bfi NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD cis-2-(para-fluorophenyl)cyclopropylamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-methyl-7-(2-oxocyclopentyloxy)-2h-chromen-2-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD ladostigil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 monoamine oxidase type b MAOB Successful target unknown 0.45 TTD , DGIDB pmid25399762-compound-table 6-15 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 2-(4,5-dihydro-1h-imidazol-2-yl)quinoline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 3-(4-methoxyphenyl)-6-methyl-2h-chromen-2-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table1-c9 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 4-oxo-4h-chromene-3-carboxylic acid NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD moclobemide small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational amine oxidase [flavin-containing] b MAOB NA antagonist 1.35 drugbank , DGIDB 2-phenyl-9h-indeno[2,1-d]pyrimidine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD lauryl dimethylamine-n-oxide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-phenoxymethyl-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-7-fluoro-2-(4-fluorophenyl)chroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD flortaucipir f-18 small molecule Neurofibrillary degeneration (morphologic abnormality)[MeSHID:D016874],Brain Injury, Chronic[MeSHID:D020208],Radioactivity[MeSHID:D011851] approved,investigational amine oxidase [flavin-containing] b MAOB NA binder NA drugbank n2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)-n2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c10 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB ethylvanillin NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (r)(+)-7-methyl-2-p-tolylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 1h-indole-2,3-dione NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c19 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB tarnylcypromine derivative 2 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB n-(1h-indol-2-ylmethyl)-n-methyl-n-phenylamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c22 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-2-(4'-ethoxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-methoxyamphetamine small molecule NA experimental,illicit amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank piperonal NA NA patented monoamine oxidase type b MAOB Successful target unknown 0.68 TTD , DGIDB 8-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table 6-10 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-2-(4'-ethoxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table 6-13 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank pmid25399762-compound-table1-c7 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table1-c25 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 7-acetonyloxy-3,4-cyclohexene-8-methylcoumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-7-methyl-2-p-tolylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 1-(4-(benzyloxy)phenyl)propan-2-amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-(4'-propoxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(2-aminoethyl)-p-chlorobenzamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 7-methoxy-2-p-tolyl-4h-chromen-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table 7-veratraldehyde NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB cis-2-phenylcyclopropylamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)-n2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-methyl-n-[(1r)-1-methyl-2-phenylethyl]prop-2-en-1-amine small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank pmid25399762-compound-table1-c4 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 1,2,3,4-tetrahydro-pyrazino[1,2-a]indole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-benzyl-2-oxo-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4,8-dimethyl-7-(2'-oxocyclohexyloxy)coumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD neu-120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational monoamine oxidase MAOB NA inhibitor NA drugbank pf9601n NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB n-(propargyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)-n2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)-n-methyl-n-2-propynyl-1-indanamine small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank 3,4-dihydroxybenzaldehyde NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD butyl-methyl-prop-2-ynyl-amine hydrochloride NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-phenyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(4-phenylbutyl)-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-cyclohexyl-2-oxo-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-(aminomethyl)-7-(benzyloxy)-2h-chromen-2-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(2-phenylcyclopropyl) amino acid derivative 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB chf-3381 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 monoamine oxidase type b MAOB Successful target unknown 0.3 TTD , DGIDB 7-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 8-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-oxo-n-phenyl-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c17 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (e)-8-(3-chlorostyryl)-caffeine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD rasagiline NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of skin[MeSHID:D012878] approved monoamine oxidase type b MAOB Successful target unknown 8.8 TTD , DGIDB var-10200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2h-chromen-2-one small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank moclobemide small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational amine oxidase [flavin-containing] b MAOB NA antagonist,inhibitor 1.35 drugbank , DGIDB heteroaryl-cyclopropylamine derivative 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD moclobemide small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational monoamine oxidase MAOB NA antagonist,inhibitor 1.35 drugbank , DGIDB l-136662 NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-(2-oxo-2h-chromene-3-carboxamido)benzoic acid NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tarnylcypromine derivative 3 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (e)-5-styrylisatin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD rwj-416457 NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical monoamine oxidase type b MAOB Successful target unknown 1.35 TTD , DGIDB (6-propoxy-2-naphthyl)-2-aminopropane NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-fluoroselegiline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(1h-indol-2-ylmethyl)-n-phenylamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)-n2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-bromo-n-(3-morpholinopropyl)nicotinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD lu-53439 NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 6-methoxy-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD phenyl 4-(4,5-dihydro-1h-imidazol-2-yl)benzoate NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 5-methoxy-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD jd-0100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative monoamine oxidase type b MAOB Successful target unknown NA TTD methyl piperate NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-p-tolyl-4h-chromen-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-methyl,n-(propargyl),n-(pyrrol-2-ylmethyl)amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD phenelzine NA Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved monoamine oxidase type b MAOB Successful target unknown 1.25 TTD , DGIDB n-(2-methyl-1h-indol-5-yl)benzamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-(4-fluorophenyl)chroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-(4'-propoxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)-n2-[4-(benzyloxy)benzyl]alaninamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)-n2-[4-(benzyloxy)benzyl]serinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-7-methoxy-2-p-tolylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c12 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB cis-2-fluoro-2-phenylcyclopropanamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pargyline NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Dystrophy[MeSHID:D009136] approved monoamine oxidase type b MAOB Successful target unknown 23.02 TTD , DGIDB 8-(3-chlorobenzyloxy)caffeine NA NA investigative monoamine oxidase type b MAOB Successful target unknown 1.35 TTD , DGIDB indeloxazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved monoamine oxidase type b MAOB Successful target unknown 1.35 TTD , DGIDB mmda small molecule NA experimental,illicit amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank rasagiline NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of skin[MeSHID:D012878] approved monoamine oxidase type b MAOB Successful target inhibitor 8.8 TTD , DGIDB 4-hydroxybenzoicacid NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB safinamide NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved monoamine oxidase type b MAOB Successful target inhibitor 0.81 TTD , DGIDB pmid25399762-compound-table1-c14 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB zimelidine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank n-propargyl-1(s)-aminoindan NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 6-methoxy-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-propargyl-1(s)-aminoindan small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank 2-p-tolyl-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-methoxybenzaldehyde NA NA patented monoamine oxidase type b MAOB Successful target unknown 0.68 TTD , DGIDB n2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 5-aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)(+)-7-fluoro-2-p-tolylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 7-[(3-chlorobenzyl)oxy]-2-oxo-2h-chromene-4-carbaldehyde small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank ferulic acid NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB p2b-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB n-isobutyl-2-oxo-2h-chromene-3-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid29757691-compound-4 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 2-(3-nitrophenyl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tracizoline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD schiff base compound 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB var-10300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-hydroxybenzaldehyde NA NA patented monoamine oxidase type b MAOB Successful target unknown 0.68 TTD , DGIDB vafidemstat small molecule NA investigational amine oxidase [flavin-containing] b MAOB NA inhibitor NA drugbank 8-[(3-trifluoromethyl)benzyloxy]caffeine NA NA investigative monoamine oxidase type b MAOB Successful target unknown 1.35 TTD , DGIDB (1z)-4-(4-fluorophenyl)-2-methylidenebutan-1-imine small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank (r)(+)-7-methyl-2-phenylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-phenyl-cyclopropylamine hydrochloride NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tetra-hydro-oxazolopyridine derivative 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-2-p-tolylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD coumarin/resveratrol hybrid derivative 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB methyl-pentyl-prop-2-ynyl-amine oxalic acid NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD sl-25.1188 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 monoamine oxidase type b MAOB Successful target unknown NA TTD toloxatone NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative monoamine oxidase type b MAOB Successful target unknown NA TTD as602868 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] discontinued in phase 1 monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-(4'-methoxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 8-(3-bromobenzyloxy)caffeine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD cyclic peptide derivative 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 7-acetonyloxy-3,4-cyclopentene-8-methylcoumarin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-7-methyl-2-phenylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD flavin-adenine dinucleotide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c20 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 2-(5-phenyl-furan-2-yl)-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-(3-phenylpropyl)-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-methyl-n-propargyl-1(r)-aminoindan NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 4-hydroxybenzylalcohol NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table 6-12 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 2-methyl-9h-indeno[2,1-d]pyrimidin-9-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (e)-5-(3-fluorostyryl)isatin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 5-hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank (s)-n2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (s)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tetra-hydro-isoquinoline derivative 4 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB benzyl-methyl-[1-(1h-pyrrol-2-yl)-vinyl]-amine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tryptamine NA NA phase 3 monoamine oxidase type b MAOB Successful target unknown 0.11 TTD , DGIDB (+/-)-2-(4'-butoxyphenyl)thiomorpholine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD selegiline NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Nausea[MeSHID:D009325],Unipolar Depression[MeSHID:D003866] approved monoamine oxidase type b MAOB Successful target inhibitor 3.01 TTD , DGIDB n-benzyl,n-methyl-1h-indole-2-carboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD n-benzyl-n-(1h-indol-2-ylmethyl)-n-methylamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-[7-(benzyloxy)-2-oxo-2h-chromen-4-yl]acetamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD phenelzine small molecule Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amine oxidase [flavin-containing] b MAOB NA antagonist,inhibitor 1.25 drugbank , DGIDB 3-chloro-n-(2-methyl-1h-indol-5-yl)benzamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)(+)-7-fluoro-2-p-tolylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD tetra-hydro-oxazolopyridine derivative 2 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB (+/-)-7-fluoro-2-p-tolylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD coumarin/resveratrol hybrid derivative 2 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB secondary and tertiary (hetero)arylamide derivative 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB nialamide small molecule NA approved,withdrawn amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank 2-hydrazino-3-methyl-4(3h)-quinazolinone NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c24 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB flavanone NA NA investigative monoamine oxidase type b MAOB Successful target unknown 0.15 TTD , DGIDB 5-quinoxalin-6-ylmethylene-thiazolidine-2,4-dione NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD dodecyldimethylamine n-oxide small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA ligand NA drugbank n-(2-methyl-1h-indol-5-yl)cyclohexanecarboxamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-(4-fluorophenyl)-7-methoxychroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD safinamide small molecule Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational amine oxidase [flavin-containing] b MAOB NA antagonist 0.81 drugbank , DGIDB 7-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (r)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-bromo-n-(2-morpholinoethyl)nicotinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 8-benzyloxycaffeine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD pmid25399762-compound-table1-c3 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB pmid25399762-compound-table1-c2 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 5-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 3-(phenoxymethyl)-5h-indeno[1,2-c]pyridazin-5-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD eugenol NA Dental caries[MeSHID:D003731],Toothache[MeSHID:D014098] patented monoamine oxidase type b MAOB Successful target unknown 0.68 TTD , DGIDB 2-p-tolyl-4h-chromene-4-thione NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD phenelzine NA Neurotic Disorders[MeSHID:D009497],Desire for food[MeSHID:D001066],Physical Examination[MeSHID:D010808],Paralysed[MeSHID:D010243],Carrying[MeSHID:D017770],Risk Behavior[MeSHID:D012309],Mood (psychological function)[MeSHID:D000339],Anxiety Disorders[MeSHID:D001008],Hypersensitivity[MeSHID:D006967],Mental Depression[MeSHID:D003863],Suicide[MeSHID:D013405],Hypersomnia[MeSHID:D006970],Catatonia[MeSHID:D002389],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Personality Disorders[MeSHID:D010554],Origin of Life[MeSHID:D000069497],Neoplasm Metastasis[MeSHID:D009362],Attitude[MeSHID:D001290],Drug Use Disorders[MeSHID:D019966],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved monoamine oxidase type b MAOB Successful target inhibitor 1.25 TTD , DGIDB trans-2-fluoro-2-p-tolylcyclopropanamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD trans-2-fluoro-2-phenylcyclopropylamin NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-phenylthiomorpholine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-chloro-n-(3-morpholinopropyl)nicotinamide NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-(4'-methoxyphenyl)thiomorpholin-5-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD (+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD budipine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved monoamine oxidase type b MAOB Successful target unknown 1.35 TTD , DGIDB pmid25399762-compound-table1-c21 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB 6-bromo-4,9-dihydro-3h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD lazabemide analog 1 NA NA patented monoamine oxidase type b MAOB Successful target unknown NA TTD , DGIDB beta-methoxyamphetamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 6-bromo-2,3,4,9-tetrahydro-1h-beta-carboline NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 5-hydroxy-n-propargyl-1(r)-aminoindan small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA ligand NA drugbank psoralen NA NA phase 3 monoamine oxidase type b MAOB Successful target unknown 0.17 TTD , DGIDB n-dodecyl-n,n-dimethyl-3-ammonio-1-propanesulfonate small molecule NA experimental amine oxidase [flavin-containing] b MAOB NA unknown NA drugbank (+/-)-7-methoxy-2-phenylchroman-4-one NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD 2-furan-2-yl-4,5-dihydro-1h-imidazole NA NA investigative monoamine oxidase type b MAOB Successful target unknown NA TTD estramustine small molecule Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational microtubule-associated protein 1a MAP1A NA antagonist NA drugbank paclitaxel small molecule Breast[MeSHID:D001940],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Ovary[MeSHID:D010053] approved,vet_approved microtubule-associated protein 2 MAP2 NA unknown NA drugbank estramustine small molecule Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational microtubule-associated protein 2 MAP2 NA antagonist NA drugbank docetaxel small molecule Cancer of Head and Neck[MeSHID:D006258],Stomach[MeSHID:D013270],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational microtubule-associated protein 2 MAP2 NA unknown NA drugbank selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 3 erk activator kinase 1 MAP2K1 Clinical trial target allosteric modulator 0.87 TTD , DGIDB pd-0325901 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA unknown 1.04 drugbank , DGIDB selumetinib small molecule Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Thyroid carcinoma[MeSHID:D013964],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA inhibitor 0.87 drugbank , DGIDB diamidothiazole derivative 1 NA NA patented erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD , DGIDB pyridic ketone derivative 1 NA NA patented erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD , DGIDB 5-phenylamino-4-cyano-3-hydroxy-isothiazole NA NA investigative erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD n-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine small molecule NA experimental dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA unknown NA drugbank (5s)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-n-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide small molecule NA experimental dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA unknown NA drugbank cobimetinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA inhibitor 1.09 drugbank , DGIDB rdea-436 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD 5-bromo-n-[(2s)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide small molecule NA experimental dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA unknown NA drugbank selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 3 erk activator kinase 1 MAP2K1 Clinical trial target inhibitor 0.87 TTD , DGIDB pd98059 NA Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD aldisin NA NA investigative erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD trametinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545],Anaplastic thyroid carcinoma[MeSHID:D065646],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA antagonist,inhibitor 0.67 drugbank , DGIDB trametinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545],Anaplastic thyroid carcinoma[MeSHID:D065646],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA antagonist,inhibitor 0.67 drugbank , DGIDB bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA inhibitor NA drugbank 2-[(4-ethynyl-2-fluorophenyl)amino]-3,4-difluoro-n-(2-hydroxyethoxy)benzamide small molecule NA experimental dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA unknown NA drugbank selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Thyroid carcinoma[MeSHID:D013964],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 3 erk activator kinase 1 MAP2K1 Clinical trial target allosteric modulator 0.87 TTD , DGIDB cobimetinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA inhibitor,allosteric modulator 1.09 drugbank , DGIDB 4,5-dibromo-1h-pyrrole-2-carboxylic acid amide NA NA investigative erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Thyroid carcinoma[MeSHID:D013964],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 3 erk activator kinase 1 MAP2K1 Clinical trial target inhibitor 0.87 TTD , DGIDB selumetinib small molecule Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA inhibitor,allosteric modulator 0.87 drugbank , DGIDB k-252a small molecule NA experimental dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA unknown NA drugbank pd-0325901 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA inhibitor 1.04 drugbank , DGIDB selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Thyroid carcinoma[MeSHID:D013964],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 3 erk activator kinase 1 MAP2K1 Clinical trial target unknown 0.87 TTD , DGIDB reversine NA NA investigative erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD selumetinib small molecule Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Thyroid carcinoma[MeSHID:D013964],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA inhibitor,allosteric modulator 0.87 drugbank , DGIDB oroidin NA NA investigative erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD selumetinib small molecule Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA inhibitor 0.87 drugbank , DGIDB debromohymenialdisine NA NA investigative erk activator kinase 1 MAP2K1 Clinical trial target unknown NA TTD 2-[(2-chloro-4-iodophenyl)amino]-n-{[(2r)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide small molecule NA experimental dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 NA unknown NA drugbank selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 3 erk activator kinase 1 MAP2K1 Clinical trial target unknown 0.87 TTD , DGIDB isis 25080 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25074 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD trametinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545],Anaplastic thyroid carcinoma[MeSHID:D065646],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 NA antagonist,inhibitor 0.3 drugbank , DGIDB isis 25115 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Thyroid carcinoma[MeSHID:D013964],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 3 erk activator kinase 2 MAP2K2 Clinical trial target inhibitor 0.4 TTD , DGIDB isis 25078 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD trametinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545],Anaplastic thyroid carcinoma[MeSHID:D065646],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 NA antagonist,inhibitor 0.3 drugbank , DGIDB isis 25124 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25081 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 3 erk activator kinase 2 MAP2K2 Clinical trial target unknown 0.4 TTD , DGIDB isis 25128 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25126 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25113 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25123 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 3 erk activator kinase 2 MAP2K2 Clinical trial target inhibitor 0.4 TTD , DGIDB pyridic ketone derivative 1 NA NA patented erk activator kinase 2 MAP2K2 Clinical trial target unknown NA TTD , DGIDB rdea-436 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 erk activator kinase 2 MAP2K2 Clinical trial target unknown NA TTD isis 25073 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD selumetinib small molecule Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Thyroid carcinoma[MeSHID:D013964],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 NA inhibitor 0.4 drugbank , DGIDB selumetinib small molecule Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 NA inhibitor 0.4 drugbank , DGIDB isis 25125 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD binimetinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 NA inhibitor,allosteric modulator 0.6 drugbank , DGIDB isis 25079 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25127 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD pd98059 NA Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative erk activator kinase 2 MAP2K2 Clinical trial target unknown NA TTD isis 25118 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD binimetinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 NA inhibitor 0.6 drugbank , DGIDB selumetinib NA Malignant Neoplasms[MeSHID:D009369],Neurofibromatosis 1[MeSHID:D009456],Plexiform Neurofibroma[MeSHID:D018318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Thyroid carcinoma[MeSHID:D013964],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 3 erk activator kinase 2 MAP2K2 Clinical trial target unknown 0.4 TTD , DGIDB isis 25075 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25082 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25114 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25117 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD isis 25116 NA NA investigative mek2 messenger rna MAP2K2 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 NA inhibitor NA drugbank bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved dual specificity mitogen-activated protein kinase kinase 2 MAP2K2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity mitogen-activated protein kinase kinase 3 MAP2K3 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity mitogen-activated protein kinase kinase 5 MAP2K5 NA inhibitor NA drugbank bix 02188 NA NA investigative erk activator kinase 5 MAP2K5 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity mitogen-activated protein kinase kinase 6 MAP2K6 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 1 MAP3K1 NA inhibitor NA drugbank binimetinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational mitogen-activated protein kinase kinase kinase 1 MAP3K1 NA inhibitor NA drugbank llz16406 NA NA investigative mapk/erk kinase kinase 1 MAP3K1 Clinical trial target unknown NA TTD ci-1040 NA NA investigative mapk/erk kinase kinase 1 MAP3K1 Clinical trial target unknown 0.35 TTD , DGIDB u0126 NA NA investigative mapk/erk kinase kinase 1 MAP3K1 Clinical trial target unknown NA TTD ro092210 NA NA investigative mapk/erk kinase kinase 1 MAP3K1 Clinical trial target unknown NA TTD azd-8330 small molecule Neoplasms[MeSHID:D009369] investigational mitogen-activated protein kinase kinase kinase 1 MAP3K1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 10 MAP3K10 NA inhibitor NA drugbank cep-6331 NA NA investigative mixed lineage kinase 2 MAP3K10 Literature-reported target unknown NA TTD urmc-099 NA NA investigative mixed lineage kinase 2 MAP3K10 Literature-reported target inhibitor NA TTD , DGIDB cep1348 NA NA investigative mixed lineage kinase 2 MAP3K10 Literature-reported target unknown NA TTD cep-5104 NA NA investigative mixed lineage kinase 2 MAP3K10 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 11 MAP3K11 NA inhibitor NA drugbank cep1349 NA NA investigative mixed lineage kinase 3 MAP3K11 Literature-reported target unknown NA TTD cep-5104 NA NA investigative mixed lineage kinase 3 MAP3K11 Literature-reported target unknown NA TTD cep-6331 NA NA investigative mixed lineage kinase 3 MAP3K11 Literature-reported target unknown NA TTD pmid24044867c8 NA NA investigative mixed lineage kinase 3 MAP3K11 Literature-reported target unknown NA TTD urmc-099 NA NA investigative mixed lineage kinase 3 MAP3K11 Literature-reported target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 12 MAP3K12 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 13 MAP3K13 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 15 MAP3K15 NA inhibitor NA drugbank quinazoline derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 sps1/ste20-related protein kinase ysk4 MAP3K19 Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 19 MAP3K19 NA inhibitor NA drugbank isis 113858 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD isis 113872 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 2 MAP3K2 NA inhibitor NA drugbank isis 113906 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD isis 113873 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD isis 113871 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD isis 113904 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved mitogen-activated protein kinase kinase kinase 2 MAP3K2 NA inhibitor NA drugbank isis 113903 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD isis 113908 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD ci-1040 NA NA investigative mapk/erk kinase kinase 2 MAP3K2 Clinical trial target unknown 2.77 TTD , DGIDB isis 113902 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD isis 113874 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD isis 113907 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD u0126 NA NA investigative mapk/erk kinase kinase 2 MAP3K2 Clinical trial target unknown NA TTD isis 113905 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD isis 113909 NA NA investigative mekk2 messenger rna MAP3K2 Literature-reported target unknown NA TTD llz16407 NA NA investigative mapk/erk kinase kinase 2 MAP3K2 Clinical trial target unknown NA TTD ro092210 NA NA investigative mapk/erk kinase kinase 2 MAP3K2 Clinical trial target unknown NA TTD urmc-099 NA NA investigative mapk/erk kinase kinase 2 MAP3K2 Clinical trial target inhibitor NA TTD , DGIDB isis 122991 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD isis 122985 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD isis 122970 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD isis 122984 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD isis 122986 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD isis 122975 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 3 MAP3K3 NA inhibitor NA drugbank isis 122976 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD isis 122971 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD pmid20483621c5n NA NA investigative mapk/erk kinase kinase 3 MAP3K3 Literature-reported target unknown NA TTD isis 122974 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD isis 122990 NA NA investigative mekk3 messenger rna MAP3K3 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 4 MAP3K4 NA inhibitor NA drugbank gs-4977 NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 apoptosis signal-regulating kinase 1 MAP3K5 Clinical trial target unknown NA TTD , DGIDB gs-4997 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 apoptosis signal-regulating kinase 1 MAP3K5 Clinical trial target inhibitor 95.48 TTD , DGIDB pmid23147077c10 NA NA investigative apoptosis signal-regulating kinase 1 MAP3K5 Clinical trial target unknown NA TTD msc2032964a NA NA investigative apoptosis signal-regulating kinase 1 MAP3K5 Clinical trial target inhibitor NA TTD , DGIDB gs-4997 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 apoptosis signal-regulating kinase 1 MAP3K5 Clinical trial target unknown 95.48 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 6 MAP3K6 NA inhibitor NA drugbank az-tak1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] investigative tgf-beta-activated kinase 1 MAP3K7 Literature-reported target unknown NA TTD pmid23099093c17d NA NA investigative tgf-beta-activated kinase 1 MAP3K7 Literature-reported target unknown NA TTD ng-25 NA NA investigative tgf-beta-activated kinase 1 MAP3K7 Literature-reported target inhibitor NA TTD , DGIDB isis 116414 NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target unknown NA TTD isis 116363 NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target unknown NA TTD isis 116361 NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target unknown NA TTD isis 116362 NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target unknown NA TTD nsc-686549 NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target unknown NA TTD isis 116359 NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target unknown NA TTD tpl2 kinase inhibitor NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target inhibitor NA TTD , DGIDB 8-chloro-quinoline-3-carbonitrile NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target unknown NA TTD isis 116360 NA NA investigative cot oncogene messenger rna MAP3K8 Literature-reported target unknown NA TTD urmc-099 NA NA investigative mixed lineage kinase 1 MAP3K9 Clinical trial target inhibitor NA TTD , DGIDB cep-6331 NA NA investigative mixed lineage kinase 1 MAP3K9 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase 9 MAP3K9 NA inhibitor NA drugbank cep1347 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2/3 mixed lineage kinase 1 MAP3K9 Clinical trial target unknown NA TTD , DGIDB 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12h)-one small molecule NA experimental mitogen-activated protein kinase kinase kinase 9 MAP3K9 NA unknown NA drugbank cep-5104 NA NA investigative mixed lineage kinase 1 MAP3K9 Clinical trial target unknown NA TTD artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational microtubule-associated protein 4 MAP4 NA ligand NA drugbank docetaxel small molecule Cancer of Head and Neck[MeSHID:D006258],Stomach[MeSHID:D013270],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational microtubule-associated protein 4 MAP4 NA unknown NA drugbank paclitaxel small molecule Breast[MeSHID:D001940],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Ovary[MeSHID:D010053] approved,vet_approved microtubule-associated protein 4 MAP4 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase kinase 1 MAP4K1 NA inhibitor NA drugbank ng-25 NA NA investigative mek kinase kinase 2 MAP4K2 Patented-recorded target inhibitor NA TTD , DGIDB quinazoline derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 mek kinase kinase 2 MAP4K2 Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase kinase 2 MAP4K2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase kinase 3 MAP4K3 NA inhibitor NA drugbank pmid23312943c21 NA NA investigative mek kinase kinase 4 MAP4K4 Patented-recorded target unknown NA TTD pmid24673130c26 NA NA investigative mek kinase kinase 4 MAP4K4 Patented-recorded target unknown NA TTD bdbm50011553 NA NA patented mek kinase kinase 4 MAP4K4 Patented-recorded target unknown NA TTD , DGIDB bdbm50011552 NA NA patented mek kinase kinase 4 MAP4K4 Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4 NA inhibitor NA drugbank 6-phenylquinazolin-4-amine NA NA patented mek kinase kinase 4 MAP4K4 Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase kinase 5 MAP4K5 NA inhibitor NA drugbank ci-1040 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown 0.02 TTD , DGIDB cor-d NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Leukemia, T-Cell[MeSHID:D015458] preclinical extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD aezs-131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acrodermatitis enteropathica[MeSHID:C538178],Malignant Neoplasms[MeSHID:D009369] investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD n,n-dimethyl-4-(4-phenyl-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank hh2710 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved extracellular signal-regulated kinase (erk) MAPK1 NA unknown NA drugbank kt-5720 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD phosphonothreonine NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK1 NA inhibitor NA drugbank gdc-0994 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown 0.79 TTD , DGIDB 4-[4-(4-fluorophenyl)-2-[4-[(r)-methylsulfinyl]phenyl]-1h-imidazol-5-yl]pyridine small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank jsi-1187 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD gdc-0994 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular signal-regulated kinase 2 MAPK1 Clinical trial target inhibitor 0.79 TTD , DGIDB n-benzyl-4-[4-(3-chlorophenyl)-1h-pyrazol-3-yl]-1h-pyrrole-2-carboxamide small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational mitogen-activated protein kinase 1 MAPK1 NA inducer NA drugbank , DGIDB ly3214996 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD , DGIDB (3r,5z,8s,9s,11e)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro-1h-2-benzoxacyclotetradecine-1,7(8h)-dione small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD ro-316233 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD (4-fluoro-phenyl)-(9-methyl-9h-purin-6-yl)-amine NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD fr-180204 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD turpentine small molecule Inflammation[MeSHID:D007249],Multiple Sclerosis[MeSHID:D009103],Psychological inhibition[MeSHID:D007266],Osteoclasts[MeSHID:D010010] approved,experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank ro31-8220 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank bms-536924 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD debromohymenialdisine NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1h-pyrazolo[3,4-c]pyridazin-3-amine small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank [4-({5-(aminocarbonyl)-4-[(3-methylphenyl)amino]pyrimidin-2-yl}amino)phenyl]acetic acid small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank ro-4396686 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD van-10-4-eluting stent NA Stenosis[MeSHID:D003251],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteries[MeSHID:D001158] phase 1 extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD , DGIDB olomoucine small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank chir-99021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Graft Rejection[MeSHID:D006084] patented extracellular signal-regulated kinase 2 MAPK1 Clinical trial target inhibitor 0.07 TTD , DGIDB ulixertinib small molecule NA investigational mitogen-activated protein kinase 1 MAPK1 NA inhibitor 0.4 drugbank , DGIDB chir-99021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Graft Rejection[MeSHID:D006084] patented extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown 0.07 TTD , DGIDB hypothemycin small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank erk inhibitor iii NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target inhibitor NA TTD , DGIDB phosphonothreonine small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD sch772984 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target inhibitor NA TTD , DGIDB kn-62 NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD astx029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD purvalanol small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA inhibitor NA drugbank (s)-n-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide small molecule NA experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank sb220025 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Arthritis[MeSHID:D001168],Expiration, function[MeSHID:D045853] experimental mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank bvd-523 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369] phase 2 extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown 0.4 TTD , DGIDB bisindolylmaleimide-i NA NA investigative extracellular signal-regulated kinase 2 MAPK1 Clinical trial target unknown NA TTD perifosine small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of brain[MeSHID:D001932],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational mitogen-activated protein kinase 1 MAPK1 NA unknown NA drugbank 2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-n-methylacetamide small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank as-601245 NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD eln-864709 NA Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD 7-azaindole derivative 4 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB nsc-656158 NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD pmid25991433-compound-p5 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB n-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank pmid25991433-compound-j5 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB 9-(4-hydroxyphenyl)-2,7-phenanthroline small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank 1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank n-benzyl-4-[4-(3-chlorophenyl)-1h-pyrazol-3-yl]-1h-pyrrole-2-carboxamide small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank pmid25991433-compound-f2 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB (3e)-5-fluoro-1-[(6-fluoro-4h-1,3-benzodioxin-8-yl)methyl]-1h-indole-2,3-dione 3-oxime small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank pmid25991433-compound-a1 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB 7-azaindole derivative 7 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB pmid25991433-compound-j2 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK10 NA inhibitor NA drugbank jnk-in-8 NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target inhibitor NA TTD , DGIDB pyrazolanthrone small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank pmid25991433-compound-p6 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB 9-(4-hydroxyphenyl)-2,7-phenanthroline NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD n-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD (3z)-1-[(6-fluoro-4h-1,3-benzodioxin-8-yl)methyl]-4-[(e)-2-phenylethenyl]-1h-indole-2,3-dione 3-oxime small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank halicin small molecule NA experimental c-jun n-terminal kinases MAPK10 NA inhibitor NA drugbank 7-azaindole derivative 5 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB n-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-n-methylpyrimidin-2-amine small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank pmid25991433-compound-j3 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase 10 MAPK10 NA inhibitor NA drugbank pmid25991433-compound-o3 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB cyclohexyl-{4-[5-(3,4-dichlorophenyl)-2-piperidin-4-yl-3-propyl-3h-imidazol-4-yl]-pyrimidin-2-yl}amine small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank 2,6-dihydroanthra/1,9-cd/pyrazol-6-one NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD 4-{[5-chloro-4-(1h-indol-3-yl)pyrimidin-2-yl]amino}-n-ethylpiperidine-1-carboxamide small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank 5-bromo-n-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank ac1lg8kt NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD (3z)-1-[(6-fluoro-4h-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1h-indole-2,3-dione 3-oxime small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank n-{2'-[(4-fluorophenyl)amino]-4,4'-bipyridin-2-yl}-4-methoxycyclohexanecarboxamide small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank 7-azaindole derivative 1 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB amp-pnp NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD phenyl-(3-phenyl-1h-indazol-6-yl)-amine NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD 7-azaindole derivative 3 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB 7-azaindole derivative 6 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB n-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank cyclopropyl-{4-[5-(3,4-dichlorophenyl)-2-[(1-methyl)-piperidin]-4-yl-3-propyl-3h-imidazol-4-yl]-pyrimidin-2-yl}amine small molecule NA experimental mitogen-activated protein kinase 10 MAPK10 NA unknown NA drugbank pmid25991433-compound-p1 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB aminopyridine deriv. 2 NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD pmid25991433-compound-p4 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB n-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide NA NA investigative stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD 7-azaindole derivative 2 NA NA patented stress-activated protein kinase jnk3 MAPK10 Patented-recorded target unknown NA TTD , DGIDB ml-3375 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD ml-3403 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD staurosporinone NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD sb 235699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 1 stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD vx-745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 stress-activated protein kinase 2b MAPK11 Clinical trial target unknown 0.94 TTD , DGIDB kc706 small molecule Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Inflammatory Bowel Diseases[MeSHID:D015212],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational mitogen-activated protein kinase 11 MAPK11 NA unknown NA drugbank , DGIDB rwj-68354 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD l-779450 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD kn-62 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD bisindolylmaleimide-i NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD ci-1040 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown 0.1 TTD , DGIDB kt-5720 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD ro-316233 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD ro31-8220 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK11 NA inhibitor NA drugbank ml-3163 NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative stress-activated protein kinase 2b MAPK11 Clinical trial target unknown NA TTD regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mitogen-activated protein kinase 11 MAPK11 NA inhibitor 0.17 drugbank , DGIDB phosphonothreonine NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD staurosporinone NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD sb 235699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 1 map kinase p38 MAPK12 Successful target unknown NA TTD cep-1347 small molecule Asthma[MeSHID:D001249],Parkinson Disease[MeSHID:D010300] investigational mitogen-activated protein kinase 12 MAPK12 NA unknown NA drugbank kn-62 NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD phosphoaminophosphonic acid-adenylate ester small molecule NA experimental mitogen-activated protein kinase 12 MAPK12 NA unknown NA drugbank ci-1040 NA NA investigative map kinase p38 MAPK12 Successful target unknown 0.11 TTD , DGIDB kt-5720 NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD phosphonothreonine small molecule NA experimental mitogen-activated protein kinase 12 MAPK12 NA unknown NA drugbank bisindolylmaleimide-i NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK12 NA inhibitor NA drugbank ml-3403 NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD kc706 NA Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Inflammatory Bowel Diseases[MeSHID:D015212],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 map kinase p38 MAPK12 Successful target unknown NA TTD , DGIDB sm-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune thrombocytopenic purpura[MeSHID:D016553],Diabetic Nephropathy[MeSHID:D003928],Lupus Erythematosus, Systemic[MeSHID:D008180] approved (orphan drug) map kinase p38 MAPK12 Successful target unknown 0.82 TTD , DGIDB rwj-68354 NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD arry-797 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Cardiomyopathy, Dilated[MeSHID:D002311] phase 2 map kinase p38 MAPK12 Successful target unknown 1.22 TTD , DGIDB ro31-8220 NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD ro-316233 NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD ml-3375 NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD amp-pnp NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD kc706 small molecule Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Inflammatory Bowel Diseases[MeSHID:D015212],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational mitogen-activated protein kinase 12 MAPK12 NA unknown NA drugbank , DGIDB vx-745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 map kinase p38 MAPK12 Successful target unknown 0.49 TTD , DGIDB ml-3163 NA NA investigative map kinase p38 MAPK12 Successful target unknown NA TTD minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK13 NA inhibitor NA drugbank kc706 small molecule Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Inflammatory Bowel Diseases[MeSHID:D015212],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational mitogen-activated protein kinase 13 MAPK13 NA unknown NA drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase 13 MAPK13 NA inhibitor NA drugbank vx-702 small molecule Coronary Arteriosclerosis[MeSHID:D003324],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigational mitogen-activated protein kinase 14 MAPK14 NA unknown 0.49 drugbank , DGIDB 3-(benzyloxy)pyridin-2-amine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD dihydro-quinolinone NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD bisindolylmaleimide-i NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD sb-218655 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD n-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank ml-3375 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD small molecule 34 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank vx-702 small molecule Coronary Arteriosclerosis[MeSHID:D003324],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigational mitogen-activated protein kinase 14 MAPK14 NA inhibitor 0.49 drugbank , DGIDB 3-fluoro-5-morpholin-4-yl-n-[1-(2-pyridin-4-ylethyl)-1h-indol-6-yl]benzamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank oxindole 94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD n-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank ml-3163 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD n,4-dimethyl-3-[(1-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank ro-3201195 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown 4.3 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational mitogen-activated protein kinase 14 MAPK14 NA unknown 0.02 drugbank , DGIDB 2-fluoro-4-[4-(4-fluorophenyl)-1h-pyrazol-3-yl]pyridine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 6((s)-3-benzylpiperazin-1-yl)-3-(naphthalen-2-yl)-4-(pyridin-4-yl)pyrazine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 4-[3-(4-fluorophenyl)-1h-pyrazol-4-yl]pyridine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank pd-0166326 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD ozagrel NA Xerophthalmia[MeSHID:D014985],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 4 stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD vx-745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 stress-activated protein kinase 2a MAPK14 Clinical trial target inhibitor 1.2 TTD , DGIDB 9-benzyl-6-phenylsulfanyl-9h-purine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-n-(1-methylethyl)-1,3-benzothiazol-2-amine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 2-(2,6-difluorophenoxy)-n-(2-fluorophenyl)-9-isopropyl-9h-purin-8-amine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD ro-3201195 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target inhibitor 4.3 TTD , DGIDB sd-0006 small molecule NA investigational mitogen-activated protein kinase 14 MAPK14 NA inhibitor 1.72 drugbank , DGIDB 6-o-tolylquinazolin-2-amine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-7-piperidin-4-yl-3,4-dihydroquinolin-2(1h)-one small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank zm-336372 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD losmapimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] phase 3 stress-activated protein kinase 2a MAPK14 Clinical trial target unknown 1.29 TTD , DGIDB ph-797804 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigational mitogen-activated protein kinase 14 MAPK14 NA unknown 0.69 drugbank , DGIDB phenyl-(3-phenyl-1h-indazol-6-yl)-amine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational mitogen-activated protein kinase 14 MAPK14 NA unknown 0.02 drugbank , DGIDB sb-227931 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD ro31-8220 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 1-[1-(3-aminophenyl)-3-tert-butyl-1h-pyrazol-5-yl]-3-naphthalen-1-ylurea small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 6-benzylsulfanyl-9h-purine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD vx-745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 stress-activated protein kinase 2a MAPK14 Clinical trial target unknown 1.2 TTD , DGIDB 4-[4-(4-fluorophenyl)-2-[4-[(r)-methylsulfinyl]phenyl]-1h-imidazol-5-yl]pyridine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD n-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1r)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 3-fluoro-n-1h-indol-5-yl-5-morpholin-4-ylbenzamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1h-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank pha-666859 NA Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD sb-242235 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] discontinued in phase 1 stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD ph-797804 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigational mitogen-activated protein kinase 14 MAPK14 NA inhibitor 0.69 drugbank , DGIDB ro-316233 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD inhibitor of p38 kinase small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1h-pyrrolo[3,2-b]pyridine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 2-chlorophenol small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank [5-amino-1-(4-fluorophenyl)-1h-pyrazol-4-yl](3-{[(2r)-2,3-dihydroxypropyl]oxy}phenyl)methanone small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank sb220025 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Arthritis[MeSHID:D001168],Expiration, function[MeSHID:D045853] experimental mitogen-activated protein kinase 14 MAPK14 NA inhibitor NA drugbank , DGIDB n-(4-fluorobenzyl)-n-(pyridin-4-yl)-2-naphthamide NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 9-benzyl-6-(4-fluoro-phenylsulfanyl)-9h-purine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD vx-702 NA Coronary Arteriosclerosis[MeSHID:D003324],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] phase 2a stress-activated protein kinase 2a MAPK14 Clinical trial target unknown 0.49 TTD , DGIDB gsk-280 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-[3-methylsulfanylanilino]-6,7-dimethoxyquinazoline small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank talmapimod NA Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146] investigative stress-activated protein kinase 2a MAPK14 Clinical trial target inhibitor 2.15 TTD , DGIDB 1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-7-piperazin-1-yl-3,4-dihydroquinazolin-2(1h)-one small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank triazolopyridine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD r-1487 NA Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 stress-activated protein kinase 2a MAPK14 Clinical trial target inhibitor 0.19 TTD , DGIDB 4-phenylsulfanyl-7h-pyrrolo[2,3-d]pyrimidine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-(fluorophenyl)-1-cyclopropylmethyl-5-(2-amino-4-pyrimidinyl)imidazole small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank l-779450 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1h-imidazol-2-yl]-piperidine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank ml-3403 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD rwj-68354 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD n-[4-chloro-3-(pyridin-3-yloxymethyl)-phenyl]-3-fluoro- small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank pmid25991433-compound-a1 NA NA patented stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD , DGIDB dp-802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD n-(4-methyl-benzyl)-4-phenoxy-benzamide NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD doramapimod small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] investigational mitogen-activated protein kinase 14 MAPK14 NA inhibitor 0.23 drugbank , DGIDB pmid25991433-compound-f2 NA NA patented stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD , DGIDB neflamapimod small molecule NA investigational mitogen-activated protein kinase 14 MAPK14 NA inhibitor 1.2 drugbank , DGIDB 2-chlorophenol NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD triazolopyridine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 3-(benzyloxy)pyridin-2-amine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 8-(2-chlorophenylamino)-2-(2,6-difluorophenylamino)-9-ethyl-9h-purine-1,7-diium small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank b-octylglucoside NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD talmapimod small molecule Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146] investigational mitogen-activated protein kinase 14 MAPK14 NA inhibitor 2.15 drugbank , DGIDB ci-1040 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown 0.04 TTD , DGIDB sb 235699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 1 stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD n-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 6-phenylsulfanyl-9h-purine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-phenoxy-n-(pyridin-2-ylmethyl)benzamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD kn-62 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD in-1166 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 3-fluoro-5-morpholin-4-yl-n-[3-(2-pyridin-4-ylethyl)-1h-indol-5-yl]benzamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n~3~-cyclopropyl-n~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank pmid25991433-compound-l2 NA NA patented stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD , DGIDB talmapimod NA Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146] investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown 2.15 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase 14 MAPK14 NA inhibitor NA drugbank 3-(2-chlorophenyl)-1-(2-{[(1s)-2-hydroxy-1,2-dimethylpropyl]amino}pyrimidin-4-yl)-1-(4-methoxyphenyl)urea small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank pmid25991433-compound-l1 NA NA patented stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD , DGIDB 4-phenoxy-n-(pyridin-2-ylmethyl)benzamide NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD kc706 small molecule Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Inflammatory Bowel Diseases[MeSHID:D015212],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank , DGIDB kt-5720 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-(2-hydroxybenzylamino)-n-(3-(4-fluorophenoxy)phenyl)piperidine-1-sulfonamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-(3-tert-butyl-1h-pyrazol-5-yl)-n'-{4-chloro-3-[(pyridin-3-yloxy)methyl]phenyl}urea small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 9-(4-fluoro-benzyl)-6-phenylsulfanyl-9h-purine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-(4-fluorophenyl)-1-cycloropropylmethyl-5-(4-pyridyl)-imidazole small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank pmid22521646c12 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 2-(ethoxymethyl)-4-(4-fluorophenyl)-3-[2-(2-hydroxyphenoxy)pyrimidin-4-yl]isoxazol-5(2h)-one small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank r-1487 small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational mitogen-activated protein kinase 14 MAPK14 NA inhibitor 0.19 drugbank , DGIDB tyrphostin ag-1478 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD dilmapimod NA Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Nerve Tissue[MeSHID:D009417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] phase 2 stress-activated protein kinase 2a MAPK14 Clinical trial target unknown 3.44 TTD , DGIDB 3-(1-naphthylmethoxy)pyridin-2-amine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD pd-0173956 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD talmapimod small molecule Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146] investigational mitogen-activated protein kinase 14 MAPK14 NA unknown 2.15 drugbank , DGIDB 6-(4-fluoro-phenylsulfanyl)-9h-purine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD dilmapimod NA Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Nerve Tissue[MeSHID:D009417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] phase 2 stress-activated protein kinase 2a MAPK14 Clinical trial target inhibitor 3.44 TTD , DGIDB doramapimod small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] investigational mitogen-activated protein kinase 14 MAPK14 NA unknown 0.23 drugbank , DGIDB ucb-1277763 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD gw-788388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 1-(5-tert-butyl-2-methyl-2h-pyrazol-3-yl)-3-(4-chloro-phenyl)-urea small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank 4-(2-ethyl-4-m-tolyl-thiazol-5-yl)-pyridine NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD pamapimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 stress-activated protein kinase 2a MAPK14 Clinical trial target inhibitor 0.34 TTD , DGIDB pmid25991433-compound-o2 NA NA patented stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD , DGIDB staurosporinone NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD 4-[5-(3-iodo-phenyl)-2-(4-methanesulfinyl-phenyl)-1h-imidazol-4-yl]-pyridine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank in-1130 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK14 NA inhibitor NA drugbank (5-amino-1-phenyl-1h-pyrazol-4-yl)phenylmethanone NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD pmid25991433-compound-l3 NA NA patented stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD , DGIDB [5-amino-1-(4-fluorophenyl)-1h-pyrazol-4-yl][3-(piperidin-4-yloxy)phenyl]methanone small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank n-[(3z)-5-tert-butyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-ylidene]-n'-(4-chlorophenyl)urea small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank sb-216995 NA NA investigative stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD losmapimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] phase 3 stress-activated protein kinase 2a MAPK14 Clinical trial target inhibitor 1.29 TTD , DGIDB 3-(1-naphthylmethoxy)pyridin-2-amine small molecule NA experimental mitogen-activated protein kinase 14 MAPK14 NA unknown NA drugbank fr167653 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 stress-activated protein kinase 2a MAPK14 Clinical trial target unknown NA TTD , DGIDB vx-702 NA Coronary Arteriosclerosis[MeSHID:D003324],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] phase 2a stress-activated protein kinase 2a MAPK14 Clinical trial target inhibitor 0.49 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase 15 MAPK15 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved extracellular signal-regulated kinase (erk) MAPK15 NA unknown NA drugbank minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK15 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved extracellular signal-regulated kinase (erk) MAPK3 NA unknown NA drugbank jsi-1187 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown NA TTD 6-[(e)-2-(4-fluoro-phenyl)-vinyl]-9h-purine NA NA investigative extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown NA TTD cholecystokinin small molecule Exocrine pancreatic insufficiency[MeSHID:D010188],Diagnosis[MeSHID:D003933],Gall Bladder Diseases[MeSHID:D005705] approved,investigational mitogen-activated protein kinase 3 MAPK3 NA unknown NA drugbank hh2710 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown NA TTD gdc-0994 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular signal-regulated kinase 1 MAPK3 Clinical trial target inhibitor 3.18 TTD , DGIDB purvalanol small molecule NA experimental mitogen-activated protein kinase 3 MAPK3 NA inhibitor NA drugbank astx029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown NA TTD ulixertinib small molecule NA investigational mitogen-activated protein kinase 3 MAPK3 NA inhibitor 1.59 drugbank , DGIDB sulindac small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mitogen-activated protein kinase 3 MAPK3 NA inhibitor NA drugbank gdc-0994 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown 3.18 TTD , DGIDB arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational mitogen-activated protein kinase 3 MAPK3 NA inducer NA drugbank , DGIDB asn007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown NA TTD , DGIDB minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK3 NA inhibitor NA drugbank 5-iodotubercidin small molecule NA experimental mitogen-activated protein kinase 3 MAPK3 NA unknown NA drugbank seliciclib small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101] investigational mitogen-activated protein kinase 3 MAPK3 NA unknown NA drugbank bvd-523 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369] phase 2 extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown 1.59 TTD , DGIDB van-10-4-eluting stent NA Stenosis[MeSHID:D003251],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteries[MeSHID:D001158] phase 1 extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown NA TTD , DGIDB cor-d NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Leukemia, T-Cell[MeSHID:D015458] preclinical extracellular signal-regulated kinase 1 MAPK3 Clinical trial target unknown NA TTD minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK4 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved extracellular signal-regulated kinase (erk) MAPK4 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase 4 MAPK4 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved extracellular signal-regulated kinase (erk) MAPK6 NA unknown NA drugbank minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK6 NA inhibitor NA drugbank pmid26924192-compound-33 NA NA patented extracellular signal-regulated kinase 5 MAPK7 Patented-recorded target unknown NA TTD acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved extracellular signal-regulated kinase (erk) MAPK7 NA unknown NA drugbank minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK7 NA inhibitor NA drugbank pmid26924192-compound-30 NA NA patented extracellular signal-regulated kinase 5 MAPK7 Patented-recorded target unknown NA TTD pmid26924192-compound-32 NA NA patented extracellular signal-regulated kinase 5 MAPK7 Patented-recorded target unknown NA TTD xmd8-92 NA NA investigative extracellular signal-regulated kinase 5 MAPK7 Patented-recorded target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase 7 MAPK7 NA inhibitor NA drugbank pmid25991433-compound-j3 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-g5 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 6-chloro-9-hydroxy-1,3-dimethyl-1,9-dihydro-4h-pyrazolo[3,4-b]quinolin-4-one small molecule NA experimental mitogen-activated protein kinase 8 MAPK8 NA unknown NA drugbank 2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide small molecule NA experimental mitogen-activated protein kinase 8 MAPK8 NA unknown NA drugbank 5-cyano-n-(2,5-dimethoxybenzyl)-6-ethoxypyridine-2-carboxamide small molecule NA experimental mitogen-activated protein kinase 8 MAPK8 NA unknown NA drugbank 7-azaindole derivative 2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB n-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD n-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-a5 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD cor-d NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Leukemia, T-Cell[MeSHID:D015458] preclinical stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD as-601245 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-p4 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-a7 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-k2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB kn-62 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-d2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 2,6-dihydroanthra/1,9-cd/pyrazol-6-one NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD kt-5720 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-k1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-g2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-a10 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-n1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB n-(4-amino-5-cyano-6-ethoxypyridin-2-yl)-2-(4-bromo-2,5-dimethoxyphenyl)acetamide small molecule NA experimental mitogen-activated protein kinase 8 MAPK8 NA unknown NA drugbank pmid25991433-compound-a8 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 2-(2-propoxypyrimidin-4-ylamino)benzoic acid NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-a2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-a3 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB phylomers NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-a11 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-a9 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 7-azaindole derivative 1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-h3 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-e1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-j5 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD n-(6-ethoxypyridin-2-yl)acetamide NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD nm-pp1 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-e2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB jnk-in-8 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target inhibitor NA TTD , DGIDB staurosporinone NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mitogen-activated protein kinase 8 MAPK8 NA modulator NA drugbank pmid25991433-compound-g1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pyrazolanthrone small molecule NA experimental mitogen-activated protein kinase 8 MAPK8 NA unknown NA drugbank bisindolylmaleimide-i NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-eb NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB ro-316233 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-g4 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 2-(2-butoxypyrimidin-4-ylamino)benzoic acid NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-e4 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-d1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-a1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-j2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-p1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-a6 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 7-azaindole derivative 3 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB aminopyridine deriv. 2 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-h2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB ci-1040 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown 0.07 TTD , DGIDB 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-f2 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK8 NA inhibitor NA drugbank halicin small molecule NA experimental c-jun n-terminal kinases MAPK8 NA inhibitor NA drugbank pmid25991433-compound-o3 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB n-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD ro31-8220 NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-p6 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid NA NA investigative stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD pmid25991433-compound-h1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-l1 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB 7-azaindole derivative 5 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-e3 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-p5 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pmid25991433-compound-n3 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB nkp-1339 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown 0.76 TTD , DGIDB 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide small molecule NA experimental mitogen-activated protein kinase 8 MAPK8 NA unknown NA drugbank pmid25991433-compound-e5 NA NA patented stress-activated protein kinase jnk1 MAPK8 Clinical trial target unknown NA TTD , DGIDB pyrazolanthrone small molecule NA experimental c-jun-amino-terminal kinase-interacting protein 1 MAPK8IP1 NA unknown NA drugbank n-(4-amino-5-cyano-6-ethoxypyridin-2-yl)-2-(4-bromo-2,5-dimethoxyphenyl)acetamide small molecule NA experimental c-jun-amino-terminal kinase-interacting protein 1 MAPK8IP1 NA unknown NA drugbank 6-chloro-9-hydroxy-1,3-dimethyl-1,9-dihydro-4h-pyrazolo[3,4-b]quinolin-4-one small molecule NA experimental c-jun-amino-terminal kinase-interacting protein 1 MAPK8IP1 NA unknown NA drugbank 5-cyano-n-(2,5-dimethoxybenzyl)-6-ethoxypyridine-2-carboxamide small molecule NA experimental c-jun-amino-terminal kinase-interacting protein 1 MAPK8IP1 NA unknown NA drugbank anthralin small molecule Disease Management[MeSHID:D019468],Scalp structure[MeSHID:D012535],Dermatologic disorders[MeSHID:D012871],Alopecia Areata[MeSHID:D000506],Alopecia[MeSHID:D000505],Psoriasis[MeSHID:D011565] approved c-jun-amino-terminal kinase-interacting protein 1 MAPK8IP1 NA agonist NA drugbank pmid25991433-compound-n1 NA NA patented jnk-interacting protein 1 peptide MAPK8IP1 Patented-recorded target unknown NA TTD pmid25991433-compound-a2 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-a3 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-p6 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-a7 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-c1 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB n-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide NA NA investigative jnk2 messenger rna MAPK9 Literature-reported target unknown NA TTD pmid25991433-compound-j5 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB 2,6-dihydroanthra/1,9-cd/pyrazol-6-one NA NA investigative stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD pmid25991433-compound-a6 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB jnk-in-8 NA NA investigative jnk2 messenger rna MAPK9 Literature-reported target inhibitor NA TTD , DGIDB halicin small molecule NA experimental c-jun n-terminal kinases MAPK9 NA inhibitor NA drugbank isis 18078 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative jnk2 messenger rna MAPK9 Literature-reported target unknown NA TTD 7-azaindole derivative 5 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational mitogen-activated protein kinases MAPK9 NA inhibitor NA drugbank pmid25991433-compound-a1 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-p5 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB 7-azaindole derivative 3 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase 9 MAPK9 NA inhibitor NA drugbank ac1lg8kt NA NA investigative jnk2 messenger rna MAPK9 Literature-reported target unknown NA TTD n-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide NA NA investigative jnk2 messenger rna MAPK9 Literature-reported target unknown NA TTD aminopyridine deriv. 2 NA NA investigative jnk2 messenger rna MAPK9 Literature-reported target unknown NA TTD n-{3-[5-(1h-1,2,4-triazol-3-yl)-1h-indazol-3-yl]phenyl}furan-2-carboxamide small molecule NA experimental mitogen-activated protein kinase 9 MAPK9 NA unknown NA drugbank pmid25991433-compound-d2 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB as-601245 NA NA investigative jnk2 messenger rna MAPK9 Literature-reported target unknown NA TTD cor-d NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Leukemia, T-Cell[MeSHID:D015458] preclinical stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD n-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide NA NA investigative jnk2 messenger rna MAPK9 Literature-reported target unknown NA TTD pmid25991433-compound-p1 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-a8 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-j3 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-o3 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-a9 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-f2 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-j2 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-a10 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-a11 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB 7-azaindole derivative 2 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-p4 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB pmid25991433-compound-a5 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB 7-azaindole derivative 1 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB in-1166 NA NA investigative jnk2 messenger rna MAPK9 Literature-reported target unknown NA TTD pmid25991433-compound-d1 NA NA patented stress-activated protein kinase jnk2 MAPK9 Preclinical target unknown NA TTD , DGIDB vs-5584 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant mesothelioma[MeSHID:C562839],Malignant Neoplasms[MeSHID:D009369] phase 1 target of rapamycin complex 2 mapkap1 MAPKAP1 Clinical trial target unknown NA TTD me-344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 target of rapamycin complex 2 mapkap1 MAPKAP1 Clinical trial target unknown NA TTD azd2014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 target of rapamycin complex 2 mapkap1 MAPKAP1 Clinical trial target unknown NA TTD palomid-529 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 target of rapamycin complex 2 mapkap1 MAPKAP1 Clinical trial target unknown NA TTD palomid-529 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 target of rapamycin complex 2 mapkap1 MAPKAP1 Clinical trial target unknown NA TTD staurosporine small molecule NA experimental map kinase-activated protein kinase 2 MAPKAPK2 NA unknown NA drugbank (3r)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5h-[1]benzothieno[3,2-e][1,4]diazepin-5-one small molecule NA experimental map kinase-activated protein kinase 2 MAPKAPK2 NA unknown NA drugbank pmid19364658c33 NA NA investigative mapk-activated protein kinase 2 MAPKAPK2 Clinical trial target unknown NA TTD 2-[2-(2-fluorophenyl)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one small molecule NA experimental map kinase-activated protein kinase 2 MAPKAPK2 NA unknown NA drugbank mmi-0100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Fibrosis[MeSHID:D005355] phase 1 mapk-activated protein kinase 2 MAPKAPK2 Clinical trial target unknown NA TTD (10r)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one small molecule NA experimental map kinase-activated protein kinase 2 MAPKAPK2 NA unknown NA drugbank 3-{[(1r)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione small molecule NA experimental map kinase-activated protein kinase 2 MAPKAPK2 NA unknown NA drugbank (4r)-n-[4-({[2-(dimethylamino)ethyl]amino}carbonyl)-1,3-thiazol-2-yl]-4-methyl-1-oxo-2,3,4,9-tetrahydro-1h-beta-carboline-6-carboxamide small molecule NA experimental map kinase-activated protein kinase 2 MAPKAPK2 NA unknown NA drugbank pmid17480064c16 NA NA investigative mapk-activated protein kinase 2 MAPKAPK2 Clinical trial target unknown NA TTD 2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one small molecule NA experimental map kinase-activated protein kinase 2 MAPKAPK2 NA unknown NA drugbank cbp-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Mesothelioma[MeSHID:D008654] phase 1/2 mapk-activated protein kinase 2 MAPKAPK2 Clinical trial target unknown 5.3 TTD , DGIDB cmpd1 NA NA investigative mapk-activated protein kinase 2 MAPKAPK2 Clinical trial target unknown NA TTD pf-3644022 NA NA investigative mapk-activated protein kinase 2 MAPKAPK2 Clinical trial target inhibitor NA TTD , DGIDB 2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one small molecule NA experimental map kinase-activated protein kinase 3 MAPKAPK3 NA unknown NA drugbank 2-[2-(2-fluorophenyl)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one small molecule NA experimental map kinase-activated protein kinase 3 MAPKAPK3 NA unknown NA drugbank pmid17480064c16 NA NA investigative mapk-activated protein kinase 5 MAPKAPK5 Discontinued target unknown NA TTD glpg-0259 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 mapk-activated protein kinase 5 MAPKAPK5 Discontinued target inhibitor 63.65 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational map kinase-activated protein kinase 5 MAPKAPK5 NA inhibitor NA drugbank ly3303560 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 microtubule-associated protein tau MAPT Clinical trial target unknown 0.15 TTD , DGIDB paclitaxel small molecule Breast[MeSHID:D001940],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Ovary[MeSHID:D010053] approved,vet_approved microtubule-associated protein tau MAPT NA unknown NA drugbank rg6100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD , DGIDB trx0237 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD docetaxel small molecule Cancer of Head and Neck[MeSHID:D006258],Stomach[MeSHID:D013270],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational microtubule-associated protein tau MAPT NA unknown NA drugbank blv-0703 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD ni-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] investigative microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD davunetide NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD pti-80 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD , DGIDB flortaucipir f-18 small molecule Neurofibrillary degeneration (morphologic abnormality)[MeSHID:D016874],Brain Injury, Chronic[MeSHID:D020208],Radioactivity[MeSHID:D011851] approved,investigational microtubule-associated protein tau MAPT NA binder NA drugbank astemizole small molecule Allergic Reaction[MeSHID:D006967],Conjunctivitis[MeSHID:D003231],Rhinitis[MeSHID:D012220],Cardiac Arrhythmia[MeSHID:D001145],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn microtubule-associated protein tau MAPT NA unknown NA drugbank tau-binding pet tracer NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD , DGIDB al-408 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD lmt-x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD , DGIDB biib092 NA Progressive supranuclear palsy[MeSHID:D013494],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 microtubule-associated protein tau MAPT Clinical trial target unknown 0.15 TTD , DGIDB lansoprazole small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Gastric Acid[MeSHID:D005744],Stomach Diseases[MeSHID:D013272],Peptic Esophagitis[MeSHID:D004942],Recurrence (disease attribute)[MeSHID:D012008],Term Birth[MeSHID:D047929],Zollinger-Ellison syndrome[MeSHID:D015043],Esophagitis[MeSHID:D004941],Bodily secretions[MeSHID:D012634],Stomach[MeSHID:D013270],Gastroesophageal reflux disease[MeSHID:D005764],Gastric Juice (substance)[MeSHID:D005750],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Wound Healing[MeSHID:D014945] approved,investigational microtubule-associated protein tau MAPT NA unknown 0.01 drugbank , DGIDB pbt-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816],Piebaldism[MeSHID:D016116] phase 2 microtubule-associated protein tau MAPT Clinical trial target unknown NA TTD , DGIDB pmid28766366-compound-scheme22middle NA NA patented microtubule-associated protein tau phosphorylation MAPT Patented-recorded target unknown NA TTD bio-11006 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 myristoylated alanine-rich c-kinase substrate MARCKS Clinical trial target unknown 63.65 TTD , DGIDB bio-11006 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 myristoylated alanine-rich c-kinase substrate MARCKS Clinical trial target unknown 63.65 TTD , DGIDB titanium dioxide small molecule Cardiac Arrest[MeSHID:D006323],Radiation[MeSHID:D011827],Sunscreening Agents[MeSHID:D013473] approved macrophage receptor marco MARCO NA unknown NA drugbank silicon dioxide small molecule NA approved macrophage receptor marco MARCO NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase mark1 MARK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase mark2 MARK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational map/microtubule affinity-regulating kinase 3 MARK3 NA inhibitor NA drugbank pmid23099093c17d NA NA investigative microtubule affinity regulating kinase 3 MARK3 Clinical trial target unknown NA TTD cbp-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Mesothelioma[MeSHID:D008654] phase 1/2 microtubule affinity regulating kinase 3 MARK3 Clinical trial target unknown 1.52 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational map/microtubule affinity-regulating kinase 4 MARK4 NA inhibitor NA drugbank dsc-127 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] phase 3 proto-oncogene mas MAS1 Clinical trial target unknown NA TTD , DGIDB ar244555 NA NA investigative proto-oncogene mas MAS1 Clinical trial target antagonist NA TTD , DGIDB angiotensin-(1-7) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Muscular Dystrophy[MeSHID:D009136],Sarcoma[MeSHID:D012509],Nausea[MeSHID:D009325] phase 3 proto-oncogene mas MAS1 Clinical trial target unknown NA TTD , DGIDB ave 0991 NA NA investigative proto-oncogene mas MAS1 Clinical trial target unknown NA TTD ar234960 NA NA investigative proto-oncogene mas MAS1 Clinical trial target agonist NA TTD , DGIDB narsoplimab biotech NA investigational mannan-binding lectin serine protease 2 MASP2 NA antagonist NA drugbank oms721 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179],Thrombotic Microangiopathies[MeSHID:D057049],Atypical Hemolytic Uremic Syndrome[MeSHID:D065766],Glomerulonephritis[MeSHID:D005921],Lupus Vulgaris[MeSHID:D008177] phase 3 mannan-binding lectin serine protease-2 MASP2 Clinical trial target unknown 63.65 TTD , DGIDB beta-hydroxyasparagine small molecule NA experimental mannan-binding lectin serine protease 2 MASP2 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational microtubule-associated serine/threonine-protein kinase 1 MAST1 NA inhibitor NA drugbank ademetionine small molecule Emotions[MeSHID:D004644],Degenerative polyarthritis[MeSHID:D010003],Depressive disorder[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Liver diseases[MeSHID:D008107],Bone Tissue[MeSHID:D001842],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] approved,investigational,nutraceutical s-adenosylmethionine synthase isoform type-1 MAT1A NA cofactor NA drugbank 3-oxiran-2ylalanine small molecule NA experimental s-adenosylmethionine synthase isoform type-1 MAT1A NA unknown NA drugbank l-2-amino-4-methoxy-cis-but-3-enoic acid small molecule NA experimental s-adenosylmethionine synthase isoform type-1 MAT1A NA unknown NA drugbank ag-270 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 s-adenosylmethionine synthase type-2 MAT2A Clinical trial target unknown NA TTD , DGIDB ademetionine small molecule Emotions[MeSHID:D004644],Degenerative polyarthritis[MeSHID:D010003],Depressive disorder[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Mood (psychological function)[MeSHID:D000339],Liver diseases[MeSHID:D008107],Bone Tissue[MeSHID:D001842],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] approved,investigational,nutraceutical s-adenosylmethionine synthase isoform type-2 MAT2A NA cofactor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational megakaryocyte-associated tyrosine-protein kinase MATK NA inhibitor NA drugbank isocyanomethane small molecule NA experimental myoglobin MB NA unknown NA drugbank tetrazolyl histidine small molecule NA experimental myoglobin MB NA unknown NA drugbank n-propyl isocyanide small molecule NA experimental myoglobin MB NA unknown NA drugbank imidazole small molecule NA experimental,investigational myoglobin MB NA unknown NA drugbank nitrous acid small molecule Poisoning[MeSHID:D011041] approved,investigational myoglobin MB NA oxidizer NA drugbank nitrosoethane small molecule NA experimental myoglobin MB NA unknown NA drugbank methylethylamine small molecule NA experimental myoglobin MB NA unknown NA drugbank n-butyl isocyanide small molecule NA experimental myoglobin MB NA unknown NA drugbank 1-methylimidazole small molecule NA experimental myoglobin MB NA unknown NA drugbank porphyrin fe(iii) small molecule NA experimental myoglobin MB NA unknown NA drugbank beta-d-glucose small molecule NA experimental myoglobin MB NA unknown NA drugbank biliverdine ix alpha small molecule NA experimental myoglobin MB NA unknown NA drugbank ethyl isocyanide small molecule NA experimental myoglobin MB NA unknown NA drugbank 4-methylimidazole small molecule NA experimental myoglobin MB NA unknown NA drugbank carbon monoxide small molecule Pigmentation[MeSHID:D010858],Biological Markers[MeSHID:D015415],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational myoglobin MB NA inhibitor NA drugbank methyl alpha-d-mannoside small molecule NA experimental mannose-binding protein c MBL2 NA unknown NA drugbank 4-(hydrogen sulfate)-beta-d-galactopyranose small molecule NA experimental mannose-binding protein c MBL2 NA unknown NA drugbank n-acetyl-alpha-neuraminic acid small molecule NA experimental mannose-binding protein c MBL2 NA unknown NA drugbank alpha-l-methyl-fucose small molecule NA experimental mannose-binding protein c MBL2 NA unknown NA drugbank methyl beta-l-fucopyranoside small molecule NA experimental mannose-binding protein c MBL2 NA unknown NA drugbank o3-sulfonylgalactose small molecule NA experimental mannose-binding protein c MBL2 NA unknown NA drugbank alpha-methyl-n-acetyl-d-glucosamine small molecule NA experimental mannose-binding protein c MBL2 NA unknown NA drugbank pmid25470667-compound-go-coa-tat NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] patented ghrelin o acyltransferase MBOAT4 Patented-recorded target unknown NA TTD , DGIDB nbi-5788 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 myelin basic protein MBP Clinical trial target unknown 12.73 TTD , DGIDB bht-3009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 myelin basic protein MBP Clinical trial target unknown NA TTD , DGIDB pf-429242 NA NA investigative endopeptidase s1p MBTPS1 Literature-reported target unknown NA TTD ac-tyr-d-phe-arg-2-nal-nhch3 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-his-dphe-arg-trp-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD c[nle-arg-d-phe-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-yr[ceh(d-2alpha-nal)rwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD afamelanotide small molecule Dermatitis, Phototoxic[MeSHID:D017484],Erythropoietic Protoporphyria[MeSHID:D046351],Porphyria, Erythropoietic[MeSHID:D017092],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitiligo[MeSHID:D014820] approved,investigational melanocyte-stimulating hormone receptor MC1R NA agonist 18.56 drugbank , DGIDB ac-dr[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ap-1030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] phase 1/2 melanocortin receptor 1 MC1R Successful target unknown NA TTD , DGIDB ac-yrc(me)*ehdfrwc(me)nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD bremelanotide NA Hypoactive Sexual Desire Disorder[MeSHID:D020018],Hypokinesia[MeSHID:D018476],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Libido[MeSHID:D007989] approved melanocortin receptor 1 MC1R Successful target unknown 6.37 TTD , DGIDB ac-nle-c[asp-his-dnal(2')-pro-trp-lys]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD afamelanotide NA Dermatitis, Phototoxic[MeSHID:D017484],Erythropoietic Protoporphyria[MeSHID:D046351],Porphyria, Erythropoietic[MeSHID:D017092],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitiligo[MeSHID:D014820] approved melanocortin receptor 1 MC1R Successful target unknown 18.56 TTD , DGIDB ac-ycit[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD mt-ii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] investigative melanocortin receptor 1 MC1R Successful target agonist NA TTD , DGIDB c[nle-val-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD c[nle-nle-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-yrmehdfrwg-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ap-1189 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-yr[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD d-phe-arg-2-nal-nhch3 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD tic-d-phe-arg-2-nal-nhch3 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD bremelanotide NA Hypoactive Sexual Desire Disorder[MeSHID:D020018],Hypokinesia[MeSHID:D018476],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Libido[MeSHID:D007989] approved melanocortin receptor 1 MC1R Successful target agonist 6.37 TTD , DGIDB gpyrmehfrwgsppkd-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD czen 002 small molecule Vaginitis[MeSHID:D014627],Candidiasis[MeSHID:D002177] investigational melanocyte-stimulating hormone receptor MC1R NA unknown NA drugbank c[co-(ch2)2-co-nle-d-nal(2)-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD aekkdegpyrmehfrwgsppkd NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD bremelanotide small molecule Hypoactive Sexual Desire Disorder[MeSHID:D020018],Hypokinesia[MeSHID:D018476],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Libido[MeSHID:D007989] approved,investigational melanocyte-stimulating hormone receptor MC1R NA agonist 6.37 drugbank , DGIDB ac-yr[ceh(pcl-df)rwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-nle-c[asp-his-dnai(2')-pro-trp-lys]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-yr[ceh(pf-df)rwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD c[co-o-c6h4-co-pro-d-nal(2)-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-yrmehdfrwgsppkd-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-yr[cehdfrwc]sppkd-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-yr[cehfrwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD afamelanotide NA Dermatitis, Phototoxic[MeSHID:D017484],Erythropoietic Protoporphyria[MeSHID:D046351],Porphyria, Erythropoietic[MeSHID:D017092],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitiligo[MeSHID:D014820] approved melanocortin receptor 1 MC1R Successful target agonist 18.56 TTD , DGIDB c[nle-gln-d-phe-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD c[nle-gln-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD c[nle-arg-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD c[co-2,3-pyrazine-co-d-nal(2)-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-r[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-his-d-phe-arg-2-nal-nhch3 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD c[co-2,3-pyrazine-co-d-phe-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ac-yk[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD ndp-sysmehfrwgkpvg NA NA investigative melanocortin receptor 1 MC1R Successful target unknown NA TTD bremelanotide small molecule Hypoactive Sexual Desire Disorder[MeSHID:D020018],Hypokinesia[MeSHID:D018476],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Libido[MeSHID:D007989] approved,investigational adrenocorticotropic hormone receptor MC2R NA agonist NA drugbank corticotropin biotech Hypoaldosteronism[MeSHID:D006994],Diagnosis[MeSHID:D003933],Screening procedure[MeSHID:D008403],Autoimmune Diseases[MeSHID:D001327],Diabetic Nephropathy[MeSHID:D003928],Pituitary-dependent Cushing's disease[MeSHID:D047748],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved adrenocorticotropic hormone receptor MC2R NA agonist 4.9 drugbank , DGIDB tetracosactide small molecule Hypoaldosteronism[MeSHID:D006994],Diagnosis[MeSHID:D003933],Screening procedure[MeSHID:D008403] approved adrenocorticotropic hormone receptor MC2R NA agonist NA drugbank seractide acetate biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Essential Hypertension[MeSHID:D000075222] approved adrenocorticotropic hormone receptor MC2R NA agonist 7.96 drugbank , DGIDB cosyntropin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypoaldosteronism[MeSHID:D006994] approved melanocortin receptor 2 MC2R Successful target agonist 71.61 TTD , DGIDB cosyntropin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypoaldosteronism[MeSHID:D006994] approved melanocortin receptor 2 MC2R Successful target unknown 71.61 TTD , DGIDB bremelanotide small molecule Hypoactive Sexual Desire Disorder[MeSHID:D020018],Hypokinesia[MeSHID:D018476],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Libido[MeSHID:D007989] approved,investigational melanocortin receptor 3 MC3R NA agonist 5.09 drugbank , DGIDB mk-11 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-dr[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-val-d-phe-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-pro-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD bremelanotide small molecule Hypoactive Sexual Desire Disorder[MeSHID:D020018],Hypokinesia[MeSHID:D018476],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Libido[MeSHID:D007989] approved,investigational melanocortin receptor 4 MC4R Successful target agonist 2.83 TTD , drugbank , DGIDB mt-ii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] investigative melanocortin receptor 4 MC4R Successful target agonist NA TTD , DGIDB c(his-d-phe-arg-trp-aoc) NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c(his-l-phe-arg-trp-aoc) NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD pt-14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] discontinued in phase 2 melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-pro-d-phe-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD gpyrmehfrwgsppkd-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-val-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-gln-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-yrmehdfrwgsppkd-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD thiq NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] investigative melanocortin receptor 4 MC4R Successful target agonist NA TTD , DGIDB ac-yr[cehdfrwc]sppkd-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-yrmehdfrwg-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD mcl0129 NA NA investigative melanocortin receptor 4 MC4R Successful target antagonist NA TTD , DGIDB c[ser-tyr-thr-his-dphe-arg-trp-thr-ile-pro] NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD amylin NA NA phase 4 melanocortin receptor 4 MC4R Successful target unknown 1.77 TTD , DGIDB ac-[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD melanotetan ii NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical melanocortin receptor 4 MC4R Successful target unknown NA TTD , DGIDB hoo-phe-orn-pro-hle-pff-phe-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD setmelanotide small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Proopiomelanocortin Deficiency[MeSHID:C565726],Affect (mental function)[MeSHID:D000339],Obesity[MeSHID:D009765],Signal Transduction[MeSHID:D015398],Malnutrition[MeSHID:D044342],Prader-Willi Syndrome[MeSHID:D011218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Bardet-Biedl Syndrome[MeSHID:D020788] approved,investigational melanocortin receptor 4 MC4R Successful target agonist 2.65 TTD , drugbank , DGIDB ap-1030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] phase 1/2 melanocortin receptor 4 MC4R Successful target unknown NA TTD , DGIDB ac-yr[ceh(pcl-df)rwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD melanocortin-4 receptor antagonist NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100],Anorexia Nervosa[MeSHID:D000856] investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-yk[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-asp-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c(his-d-phe-arg-trp-ahx) NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-r[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD hs014 NA NA investigative melanocortin receptor 4 MC4R Successful target antagonist NA TTD , DGIDB ac-tyr-d-phe-arg-2-nal-nhch3 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-nle-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-arg-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[co-(ch2)3-co-pro-d-nal(2)-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD d-phe-arg-2-nal-nhch3 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-nle-c[asp-his-dphe-pro-trp-lys]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-asp-d-phe-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD 1-methyl-4-(1-phenyl-ethyl)-piperazine NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c(his-d-phe-arg-trp-abu) NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD his-dphe-arg-trp NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[co-(ch2)2-co-nle-d-phe-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD aekkdegpyrmehfrwgsppkd NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-yr[cehfrwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-glu-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD pmx-53 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 melanocortin receptor 4 MC4R Successful target unknown NA TTD , DGIDB ro-27-3225 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical melanocortin receptor 4 MC4R Successful target unknown NA TTD , DGIDB ac-yrc(me)*ehdfrwc(me)nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD amsh NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD amg 386 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Asthma[MeSHID:D001249] phase 3 melanocortin receptor 4 MC4R Successful target unknown NA TTD , DGIDB ac-yr[ce(1-me-h)dfrwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD 1-benzyl-4-methyl-piperazine NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-his-d-phe-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-his-dphe-arg-trp-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-yr[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[co-o-c6h4-co-pro-d-nal(2)-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-yr[ceh(d-2alpha-nal)rwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ml-253764 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD mk-10 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD iddbcp-150101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical melanocortin receptor 4 MC4R Successful target unknown NA TTD , DGIDB c[nle-arg-d-phe-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c(his-d-phe-arg-trp-ahp) NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-nle-c[asp-his-dnai(2')-pro-trp-lys]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD mcl-129 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[co-(ch2)2-co-nle-d-nal(2)-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-his-d-nal(2')-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[co-o-c6h4-co-pro-d-phe-arg-trp-lys]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-yr[ceh(pf-df)rwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-nle-c[asp-his-dnal(2')-pro-trp-lys]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-his-d-phe-arg-2-nal-nhch3 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD methylnaltrexone bromide NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] approved melanocortin receptor 4 MC4R Successful target unknown NA TTD , DGIDB pf-446687 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] phase 2 melanocortin receptor 4 MC4R Successful target unknown NA TTD , DGIDB tic-d-phe-arg-2-nal-nhch3 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ndp-sysmehfrwgkpvg NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ser-tyr-ser-nle-glu-his-dphe-arg NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[thr-tyr-thr-his-dnaf-arg-trp-thr-ile-pro] NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ac-ycit[cehdfrwc]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD ndp-alpha-msh NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD c[nle-nle-d-phe-arg-trp-glu]-nh2 NA NA investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD bl-6020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100],Burkitt Lymphoma[MeSHID:D002051] investigative melanocortin receptor 4 MC4R Successful target unknown NA TTD mt-ii NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] investigative melanocortin receptor 5 MC5R Clinical trial target agonist NA TTD , DGIDB jnj-10229570 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 melanocortin receptor 5 MC5R Clinical trial target unknown NA TTD , DGIDB bremelanotide small molecule Hypoactive Sexual Desire Disorder[MeSHID:D020018],Hypokinesia[MeSHID:D018476],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Libido[MeSHID:D007989] approved,investigational melanocortin receptor 5 MC5R NA agonist 3.18 drugbank , DGIDB mtc-896 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] phase 2 melanocortin receptor 5 MC5R Clinical trial target unknown NA TTD , DGIDB 3,6,9,12,15-pentaoxaheptadecan-1-ol small molecule NA experimental malonyl-coa-acyl carrier protein transacylase, mitochondrial MCAT NA unknown NA drugbank biotin small molecule NA approved,investigational,nutraceutical methylcrotonoyl-coa carboxylase subunit alpha, mitochondrial MCCC1 NA cofactor NA drugbank biotin small molecule NA approved,investigational,nutraceutical methylcrotonoyl-coa carboxylase beta chain, mitochondrial MCCC2 NA cofactor NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational multiple coagulation factor deficiency protein 2 MCFD2 NA modulator NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational multiple coagulation factor deficiency protein 2 MCFD2 NA modulator NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved multiple coagulation factor deficiency protein 2 MCFD2 NA modulator NA drugbank pmid25522065-compound-29 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-cyclohexyloxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD phenyl-n,n-bis(tosylmethyl)methanamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-(3-methyl-cyclopentyloxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-cyclopentylmethoxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-(3,3,3-trifluoropropoxy)quinolin-2-amine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid22490048c(r)-10h NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-9 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB sb-568849 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist 19.1 TTD , DGIDB bms-830216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1 melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown 12.73 TTD , DGIDB pmid25522065-compound-49 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-31 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB melanin-concentrating hormone NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target agonist NA TTD , DGIDB mq1 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target allosteric modulator NA TTD , DGIDB pmid25522065-compound-23 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB ads-103253 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-6 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB amg 076 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pyrrolidine mchr1 antagonist 1 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist NA TTD , DGIDB azd1979 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1 melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-48 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-38 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB n-(4-amino-2-propylquinolin-6-yl)cinnamamide NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-(1-methyl-butoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD ads-103168 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-30 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB ads-103316 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-(2-ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-isopropoxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-cycloheptyloxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD sb-568849 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown 19.1 TTD , DGIDB 8-butoxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD ngd-4715 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-12 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-15 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-41 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-(1-ethyl-propoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved melanin-concentrating hormone receptor 1 MCHR1 NA unknown NA drugbank 8-sec-butoxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-47 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-(2-methoxy-1-methyl-ethoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-32 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-19 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB tpi-1361-17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-50 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-16 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-8 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB atc0065 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist NA TTD , DGIDB t-226296 NA Atrial Fibrillation[MeSHID:D001281],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist 12.73 TTD , DGIDB ads-103254 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-36 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-10 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-13 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB az13483342 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist NA TTD , DGIDB 8-(3-methyl-butoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD ads-103274 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD gnf-pf-2322 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD [3h]snap-7941 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist NA TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved melanin-concentrating hormone receptor 1 MCHR1 NA unknown NA drugbank pmid17125263c17 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD ads-103214 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD ads-103293 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-3 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB ar-129330 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-39 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 4-arylphthalazin-1(2h)-3,4-di-f NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist NA TTD , DGIDB 8-(2-cyclopropyl-ethoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-27 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-21 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB ads-103294 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD t-226293 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB n,n-bis(tosylmethyl)hexan-1-amine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-51 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-28 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-44 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-33 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-propoxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-26 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB gw803430 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist 12.73 TTD , DGIDB 7-fluorochromone-2-carboxamide NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist NA TTD , DGIDB snap-7941 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863],Anxiety Disorders[MeSHID:D001008],Obesity[MeSHID:D009765] preclinical melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown 25.46 TTD , DGIDB ads-102891 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-17 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB tetralin_urea analogue (7o) NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist NA TTD , DGIDB 8-(4-methyl-cyclohexyloxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-hexyloxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-35 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-34 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB gnf-pf-1550 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-5 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-14 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB snap-7941 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863],Anxiety Disorders[MeSHID:D001008],Obesity[MeSHID:D009765] preclinical melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target antagonist 25.46 TTD , DGIDB 8-(1,2-dimethyl-propoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-18 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB a-224940 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-pentyloxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-methoxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-2 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-(3-methoxy-3-methyl-butoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-cyclobutylmethoxy-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-46 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB c3 NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target agonist NA TTD , DGIDB pmid25522065-compound-40 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-45 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-4 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-25 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-24 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-(3-methyl-cyclohexyloxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-22 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-(2-methyl-cyclohexyloxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD n-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-42 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-43 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-(2-methyl-butoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-7 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 8-(1,3,3-trimethyl-butoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-11 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB 2-phenyl-n,n-bis(o-tolylthiomethyl)ethanamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-(2-ethyl-1-methyl-butoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD 8-(3,3-dimethyl-butoxy)-quinolin-2-ylamine NA NA investigative melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD pmid25522065-compound-37 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB pmid25522065-compound-20 NA NA patented melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown NA TTD , DGIDB t-226296 NA Atrial Fibrillation[MeSHID:D001281],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical melanin-concentrating hormone receptor 1 MCHR1 Clinical trial target unknown 12.73 TTD , DGIDB pmid27744724-compound-29 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB gnf-pf-3955 NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.44 TTD , DGIDB nsc-66209 NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.09 TTD , DGIDB pmid27744724-compound-18 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB sulfuretin NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.08 TTD , DGIDB gnf-pf-1591 NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD gnf-pf-5134 NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.11 TTD , DGIDB pmid27744724-compound-5 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB abbv-467 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD pmid27744724-compound-4 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB indole-based analog 1 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB rosmarinic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.17 TTD , DGIDB pmid27744724-compound-19 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB mcl-1-specific antisense oligonucleotide + midostaurin(pkc412) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mastocytosis, Systemic[MeSHID:D034721] investigative mcl-1 messenger rna MCL1 Successful target unknown NA TTD nsc-180246 NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.12 TTD , DGIDB pmid27744724-compound-28 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-21 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-fomula2 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-6 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB azd5991 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 1.33 TTD , DGIDB imatinib NA Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved mcl-1 messenger rna MCL1 Successful target unknown NA TTD pmid27744724-compound-23 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB amg 397 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD pmid27744724-compound-20 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-3 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB indole-based analog 3 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB biphenyl carboxylic acid derivative 1 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB mcl-1-specific antisense oligonucleotide + nilotinib (amn107) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mastocytosis, Systemic[MeSHID:D034721] investigative mcl-1 messenger rna MCL1 Successful target unknown NA TTD amg 176 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-10 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB obatoclax NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.27 TTD , DGIDB indole-based analog 2 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-22 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB amentoflavone NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.17 TTD , DGIDB prt1419 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD pmid27744724-compound-13 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB pmid27744724-compound-27 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB eu-517 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD bithionol NA Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.06 TTD , DGIDB pmid27744724-compound-26 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB imatinib NA Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved mcl-1 messenger rna MCL1 Successful target unknown NA TTD qediirniarhlaqvgdsmdr NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD altenusin NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.13 TTD , DGIDB biphenyl carboxylic acid derivative 2 NA NA patented induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD , DGIDB mik665 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD tw-37 NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown NA TTD morin NA NA investigative induced myeloid leukemia cell differentiation protein mcl-1 MCL1 Clinical trial target unknown 0.07 TTD , DGIDB mk6-83 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical mucolipin-1 MCOLN1 Preclinical target activator NA TTD , DGIDB phosphatidyl (3,5) inositol biphosphate NA NA investigative mucolipin-1 MCOLN1 Preclinical target unknown NA TTD sf-11 NA NA investigative mucolipin-3 MCOLN3 Literature-reported target activator NA TTD , DGIDB sn-2 NA NA investigative mucolipin-3 MCOLN3 Literature-reported target activator NA TTD , DGIDB sn-1 NA NA investigative mucolipin-3 MCOLN3 Literature-reported target activator NA TTD , DGIDB sf-21 NA NA investigative mucolipin-3 MCOLN3 Literature-reported target activator NA TTD , DGIDB nicotinamide adenine dinucleotide phosphate small molecule NA experimental malate dehydrogenase, cytoplasmic MDH1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical malate dehydrogenase, cytoplasmic MDH1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational malate dehydrogenase, cytoplasmic MDH1 NA ligand NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical malate dehydrogenase, mitochondrial MDH2 NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved malate dehydrogenase, mitochondrial MDH2 NA unknown NA drugbank xanthinol small molecule Metabolism[MeSHID:D008660],Brain[MeSHID:D001921],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Hyperlipidemia[MeSHID:D006949],Peripheral Vascular Diseases[MeSHID:D016491],Memory[MeSHID:D008568],Blood[MeSHID:D001769],Awareness[MeSHID:D001364] approved,withdrawn malate dehydrogenase, mitochondrial MDH2 NA cofactor NA drugbank cis-[4,5-bis-(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-[4-(2-hydroxyethyl)piperazin-1-yl]methanone small molecule NA experimental e3 ubiquitin-protein ligase mdm2 MDM2 NA unknown NA drugbank apg-115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Prolymphocytic Leukemia[MeSHID:D015463] phase 2 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown NA TTD , DGIDB alrn-6924 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Hematologic Neoplasms[MeSHID:D019337],Malignant Neoplasms[MeSHID:D009369] phase 2 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown NA TTD , DGIDB cis-[4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihyd roimidazol-1-yl]-piperazin-1-yl-methanone small molecule NA experimental e3 ubiquitin-protein ligase mdm2 MDM2 NA unknown NA drugbank isis 16518 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative mdm2 messenger rna MDM2 Literature-reported target unknown NA TTD rg7388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Hematologic Neoplasms[MeSHID:D019337],Malignant Neoplasms[MeSHID:D009369],Polycythemia Vera[MeSHID:D011087] phase 3 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown 3.98 TTD , DGIDB nutlin-3 NA NA investigative mdm2 messenger rna MDM2 Literature-reported target unknown 13.92 TTD , DGIDB hdm201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],liposarcoma[MeSHID:D008080],Hematologic Neoplasms[MeSHID:D019337] phase 1 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown NA TTD , DGIDB amg 232 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Merkel cell carcinoma[MeSHID:D015266] phase 2 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown NA TTD , DGIDB ds-3032 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown 3.98 TTD , DGIDB rg7775 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown NA TTD , DGIDB nsc-66811 NA NA investigative mdm2 messenger rna MDM2 Literature-reported target unknown NA TTD mi-219 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown NA TTD bi 907828 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown NA TTD astx295 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown NA TTD nu-8231 NA NA investigative mdm2 messenger rna MDM2 Literature-reported target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational e3 ubiquitin-protein ligase mdm2 MDM2 NA binder NA drugbank jnj-26854165 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 ubiquitin-protein ligase e3 mdm2 MDM2 Clinical trial target unknown 1.99 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational e3 ubiquitin-protein ligase mdm2 MDM2 NA unknown NA drugbank isis 16507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative mdm2 messenger rna MDM2 Literature-reported target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational e3 ubiquitin-protein ligase mdm2 MDM2 NA unknown NA drugbank plsqetfsdlwkllpen-nh2 NA NA investigative mdm2 messenger rna MDM2 Literature-reported target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental e3 ubiquitin-protein ligase mdm2 MDM2 NA binder NA drugbank alrn-6924 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Hematologic Neoplasms[MeSHID:D019337],Malignant Neoplasms[MeSHID:D009369] phase 2 p53-binding protein mdm4 MDM4 Clinical trial target unknown NA TTD , DGIDB nsc-207895 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical p53-binding protein mdm4 MDM4 Clinical trial target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadp-dependent malic enzyme ME1 NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental nadp-dependent malic enzyme ME1 NA unknown NA drugbank tartronate small molecule NA experimental nad-dependent malic enzyme, mitochondrial ME2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nad-dependent malic enzyme, mitochondrial ME2 NA unknown NA drugbank mesoxalic acid small molecule NA experimental nad-dependent malic enzyme, mitochondrial ME2 NA unknown NA drugbank d-malic acid small molecule NA experimental nad-dependent malic enzyme, mitochondrial ME2 NA unknown NA drugbank fumaric acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pustulosis of Palms and Soles[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103] investigational nad-dependent malic enzyme, mitochondrial ME2 NA unknown NA drugbank tartronate small molecule NA experimental nadp-dependent malic enzyme, mitochondrial ME3 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadp-dependent malic enzyme, mitochondrial ME3 NA unknown NA drugbank becocalcidiol small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational mediator of rna polymerase ii transcription subunit 1 MED1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational maternal embryonic leucine zipper kinase MELK NA inhibitor NA drugbank otssp167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Myeloproliferative disease[MeSHID:D009196],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943] phase 1 maternal embryonic leucine zipper kinase MELK Clinical trial target inhibitor NA TTD , DGIDB otssp167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Myeloproliferative disease[MeSHID:D009196],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943] phase 1 tyrosine-protein kinase melk MELK Clinical trial target unknown NA TTD , DGIDB otssp167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Myeloproliferative disease[MeSHID:D009196],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943] phase 1 tyrosine-protein kinase melk MELK Clinical trial target inhibitor NA TTD , DGIDB otssp167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Myeloproliferative disease[MeSHID:D009196],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943] phase 1 maternal embryonic leucine zipper kinase MELK Clinical trial target unknown NA TTD , DGIDB sgn-cd228a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 melanotransferrin MELTF Clinical trial target unknown NA TTD ono-7475 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD , DGIDB ldc1267 NA NA investigative tyrosine-protein kinase mer MERTK Clinical trial target inhibitor NA TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 tyrosine-protein kinase mer MERTK Clinical trial target inhibitor 1.52 TTD , DGIDB ono-7475 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD , DGIDB unc2025 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] investigative tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD mrx-2843 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Mental Retardation, X-Linked 1[MeSHID:C567906] phase 1 tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase mer MERTK NA inhibitor NA drugbank rxdx-106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD pf-07265807 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 tyrosine-protein kinase mer MERTK Clinical trial target unknown 1.52 TTD , DGIDB ono-7475 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD , DGIDB incb81776 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD ono-7475 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD , DGIDB g749 NA NA investigative tyrosine-protein kinase mer MERTK Clinical trial target inhibitor NA TTD , DGIDB unc569 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] investigative tyrosine-protein kinase mer MERTK Clinical trial target unknown NA TTD 2-({6-[(3-chlorophenyl)amino]-9-isopropyl-9h-purin-2-yl}amino)ethanol small molecule NA experimental tyrosine-protein kinase mer MERTK NA unknown NA drugbank tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hepatocyte growth factor receptor MET NA inhibitor NA drugbank n-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide small molecule NA experimental hepatocyte growth factor receptor MET NA unknown NA drugbank amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational hepatocyte growth factor receptor MET NA unknown 0.5 drugbank , DGIDB chronseal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355] phase 1/2 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB apl-101 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 proto-oncogene c-met MET Successful target unknown NA TTD 1-benzyl-1h-pyrrolo[3,2-b]pyridine NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD n-(3-chlorophenyl)-n-methyl-2-oxo-3-[(3,4,5-trimethyl-1h-pyrrol-2-yl)methyl]-2h-indole-5-sulfonamide small molecule NA experimental hepatocyte growth factor receptor MET NA unknown NA drugbank jnj-38877605 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target inhibitor 1.17 TTD , DGIDB ly-2875358 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-met MET Successful target unknown 2.92 TTD , DGIDB tivantinib small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Liver carcinoma[MeSHID:D006528] investigational hepatocyte growth factor receptor MET NA inhibitor 4.09 drugbank , DGIDB ly2801653 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Biliary Tract Cancer[MeSHID:D001661] phase 2 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB regn5093 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD mk-8033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown 0.58 TTD , DGIDB tr1801-adc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD ge-137 NA NA investigative proto-oncogene c-met MET Successful target unknown 0.58 TTD , DGIDB amivantamab NA Insertion Mutation[MeSHID:D016254],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 proto-oncogene c-met MET Successful target unknown NA TTD anti-c-met car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Cells[MeSHID:D002477],Colorectal Cancer[MeSHID:D015179],Renal Cell Carcinoma[MeSHID:D002292],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 proto-oncogene c-met MET Successful target unknown 0.17 TTD , DGIDB e-7050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 1 proto-oncogene c-met MET Successful target unknown 0.97 TTD , DGIDB k-252a small molecule NA experimental hepatocyte growth factor receptor MET NA unknown NA drugbank pha-665752 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target inhibitor 0.82 TTD , DGIDB ly3164530 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown 0.29 TTD , DGIDB hm-5016504 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB pmid21967808cr-16 NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD emibetuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-met MET Successful target unknown 2.92 TTD , DGIDB bms-777607 NA NA phase 1/2 proto-oncogene c-met MET Successful target unknown 0.78 TTD , DGIDB nps-1034 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB emd-1204831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown 1.17 TTD , DGIDB prs-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD emibetuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-met MET Successful target antibody 2.92 TTD , DGIDB hepapoietin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB pf-4217903 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown 1.17 TTD , DGIDB savolitinib NA Renal Cell Carcinoma[MeSHID:D002292],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 proto-oncogene c-met MET Successful target inhibitor 3.21 TTD , DGIDB tivantinib small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Liver carcinoma[MeSHID:D006528] investigational hepatocyte growth factor receptor MET NA unknown 4.09 drugbank , DGIDB tivantinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Liver carcinoma[MeSHID:D006528] phase 3 proto-oncogene c-met MET Successful target inhibitor 4.09 TTD , DGIDB sgx523 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB 1-[(2-nitrophenyl)sulfonyl]-1h-pyrrolo[3,2-b]pyridine-6-carboxamide small molecule NA experimental hepatocyte growth factor receptor MET NA unknown NA drugbank rp-1040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD amg 337 NA Sarcoma, Clear Cell[MeSHID:D018227],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB xl880 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of breast[MeSHID:D001943] phase 2 proto-oncogene c-met MET Successful target unknown 0.54 TTD , DGIDB cmet avimer polypeptides NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD mk-8033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target inhibitor 0.58 TTD , DGIDB bpi-9016 m NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD tpx-0022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD sar-125844 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-met MET Successful target unknown 1.17 TTD , DGIDB brigatinib small molecule Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Hematologic Neoplasms[MeSHID:D019337],Mutation[MeSHID:D009154],Growth[MeSHID:D006128],Continuance of life[MeSHID:D013534],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Microtubules[MeSHID:D008870],Signal Transduction[MeSHID:D015398],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] approved,investigational hepatocyte growth factor receptor MET NA inhibitor NA drugbank tepotinib NA Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],epithelial to mesenchymal transition[MeSHID:D058750],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved proto-oncogene c-met MET Successful target unknown 4.67 TTD , DGIDB sar-125844 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-met MET Successful target inhibitor 1.17 TTD , DGIDB abbv-399 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown 1.75 TTD , DGIDB cbt-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901],Color Blindness, Blue[MeSHID:D003117],Malignant Neoplasms[MeSHID:D009369],Ocular Hypertension[MeSHID:D009798] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB crizotinib small molecule Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hepatocyte growth factor receptor MET NA inhibitor 1.85 drugbank , DGIDB crizotinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-met MET Successful target unknown 1.85 TTD , DGIDB sym015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB cmx-2043 NA Myocardial Reperfusion Injury[MeSHID:D015428],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart Diseases[MeSHID:D006331] phase 2 proto-oncogene c-met MET Successful target unknown 0.29 TTD , DGIDB capmatinib NA Neoplasms[MeSHID:D009369],Mutation[MeSHID:D009154],epithelial to mesenchymal transition[MeSHID:D058750],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] approved proto-oncogene c-met MET Successful target inhibitor 2.48 TTD , DGIDB amg 208 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-met MET Successful target inhibitor NA TTD , DGIDB cabozantinib NA Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Medulla Oblongata[MeSHID:D008526],Liver carcinoma[MeSHID:D006528],Adrenal Medulla[MeSHID:D000313],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved proto-oncogene c-met MET Successful target inhibitor 0.75 TTD , DGIDB 2-(4-fluorophenyl)-n-{[3-fluoro-4-(1h-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide small molecule NA experimental hepatocyte growth factor receptor MET NA unknown NA drugbank ald-805 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Adrenoleukodystrophy[MeSHID:D000326] investigative proto-oncogene c-met MET Successful target unknown NA TTD aps-3010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD 1-(phenylsulfonyl)-1h-pyrrolo[3,2-b]pyridine NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD capmatinib small molecule Neoplasms[MeSHID:D009369],Mutation[MeSHID:D009154],epithelial to mesenchymal transition[MeSHID:D058750],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] approved,investigational hepatocyte growth factor receptor MET NA inhibitor 2.48 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational hepatocyte growth factor receptor MET NA inhibitor NA drugbank mab 224g11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD tepotinib small molecule Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],epithelial to mesenchymal transition[MeSHID:D058750],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational hepatocyte growth factor receptor MET NA inhibitor 4.67 drugbank , DGIDB la-480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD tivantinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Liver carcinoma[MeSHID:D006528] phase 3 proto-oncogene c-met MET Successful target unknown 4.09 TTD , DGIDB rxdx-106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 proto-oncogene c-met MET Successful target inhibitor 0.17 TTD , DGIDB ald-806 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Adrenoleukodystrophy[MeSHID:D000326] investigative proto-oncogene c-met MET Successful target unknown NA TTD pmid21123062c27 NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD pf-00614435 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD jnj-38877605 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown 1.17 TTD , DGIDB autologous t cells expressing met scfv car NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],melanoma[MeSHID:D008545],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],Malignant neoplasm of breast[MeSHID:D001943] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB mgcd516 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 proto-oncogene c-met MET Successful target unknown 0.09 TTD , DGIDB 1-(4-fluorophenyl)-n-[3-fluoro-4-(1h-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide small molecule NA experimental hepatocyte growth factor receptor MET NA unknown NA drugbank dp-3590 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD 1-(2-nitrophenethyl)-1h-pyrrolo[3,2-b]pyridine NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD amg 208 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB rg3638 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenocarcinoma[MeSHID:D000230] phase 3 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB tepotinib NA Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],epithelial to mesenchymal transition[MeSHID:D058750],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved proto-oncogene c-met MET Successful target inhibitor 4.67 TTD , DGIDB humax-cmet NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD 3-(phenylsulfonyl)-1h-pyrrolo[2,3-b]pyridine NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD abt-700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown 1.75 TTD , DGIDB telisotuzumab vedotin NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 proto-oncogene c-met MET Successful target unknown NA TTD cabozantinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Medulla Oblongata[MeSHID:D008526],Liver carcinoma[MeSHID:D006528],Adrenal Medulla[MeSHID:D000313],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational hepatocyte growth factor receptor MET NA antagonist 0.75 drugbank , DGIDB crizotinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-met MET Successful target inhibitor 1.85 TTD , DGIDB beperminogene perplasmid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Limb structure[MeSHID:D005121],Ischemia[MeSHID:D007511],Heart Diseases[MeSHID:D006331] phase 3 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB sgx-523 small molecule Neoplasms[MeSHID:D009369] investigational hepatocyte growth factor receptor MET NA inhibitor 1.17 drugbank , DGIDB pf-4217903 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target inhibitor 1.17 TTD , DGIDB abt-700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target inhibitor 1.75 TTD , DGIDB bay-85-3474 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD anti-cmet mab NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD capmatinib NA Neoplasms[MeSHID:D009369],Mutation[MeSHID:D009154],epithelial to mesenchymal transition[MeSHID:D058750],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] approved proto-oncogene c-met MET Successful target unknown 2.48 TTD , DGIDB amivantamab biotech Insertion Mutation[MeSHID:D016254],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hepatocyte growth factor receptor MET NA antagonist,antibody NA drugbank xl092 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target unknown 0.51 TTD , DGIDB mteron-f1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory disease of mucous membrane[MeSHID:D052016] preclinical proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol small molecule NA experimental hepatocyte growth factor receptor MET NA unknown NA drugbank amg-208 small molecule NA investigational hepatocyte growth factor receptor MET NA inhibitor 1.17 drugbank , DGIDB su11274 NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB emd-1204831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target inhibitor 1.17 TTD , DGIDB cabozantinib NA Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Medulla Oblongata[MeSHID:D008526],Liver carcinoma[MeSHID:D006528],Adrenal Medulla[MeSHID:D000313],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved proto-oncogene c-met MET Successful target unknown 0.75 TTD , DGIDB altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-met MET Successful target inhibitor 0.51 TTD , DGIDB bms-777607 NA NA phase 1/2 proto-oncogene c-met MET Successful target inhibitor 0.78 TTD , DGIDB amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational hepatocyte growth factor receptor MET NA inhibitor 0.5 drugbank , DGIDB savolitinib NA Renal Cell Carcinoma[MeSHID:D002292],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 proto-oncogene c-met MET Successful target unknown 3.21 TTD , DGIDB tp-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown NA TTD pha-665752 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-met MET Successful target unknown 0.82 TTD , DGIDB bms-536924 NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD c-met/pd-l1 car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528] phase 1 proto-oncogene c-met MET Successful target unknown NA TTD , DGIDB su11274 NA NA investigative proto-oncogene c-met MET Successful target inhibitor NA TTD , DGIDB pmid24210504c1o NA NA investigative proto-oncogene c-met MET Successful target unknown NA TTD cabozantinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Medulla Oblongata[MeSHID:D008526],Liver carcinoma[MeSHID:D006528],Adrenal Medulla[MeSHID:D000313],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational hepatocyte growth factor receptor MET NA antagonist,inhibitor 0.75 drugbank , DGIDB am7 NA NA investigative proto-oncogene c-met MET Successful target inhibitor NA TTD , DGIDB 3-[(2,2-dimethylpropanoyl)amino]-n-1,3-thiazol-2-ylpyridine-2-carboxamide small molecule NA experimental methionine aminopeptidase 1 METAP1 NA unknown NA drugbank tert-butyl {2-[(1,3-thiazol-2-ylamino)carbonyl]pyridin-3-yl}carbamate small molecule NA experimental methionine aminopeptidase 1 METAP1 NA unknown NA drugbank ovalicin small molecule NA experimental methionine aminopeptidase 1 METAP1 NA unknown NA drugbank 5-chloro-6-methyl-n-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine small molecule NA experimental methionine aminopeptidase 1 METAP1 NA unknown NA drugbank 5-ethyl-2-(phenylsulfonamido)benzoic acid NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD n'-((2s,3r)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoyl)-n-3-chlorobenzoyl hydrazide small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank methionine small molecule Protein Biosynthesis[MeSHID:D014176] approved,nutraceutical methionine aminopeptidase 2 METAP2 NA product of NA drugbank 5-bromo-2-{[(4-chlorophenyl)sulfonyl]amino}benzoic acid small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank 2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank 5-chloro-2-(pyridin-2-yl)-1h-benzo[d]imidazole NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD 2-(pyridin-2-yl)-1h-benzo[d]imidazole NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD beloranib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Obesity[MeSHID:D009765] phase 3 methionine aminopeptidase 2 METAP2 Clinical trial target inhibitor 63.65 TTD , DGIDB xmt-1191 NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target inhibitor NA TTD , DGIDB fumagillin small molecule NA experimental,investigative methionine aminopeptidase 2 METAP2 Clinical trial target ligand NA TTD , drugbank 5-fluoro-2-(pyridin-2-yl)-1h-benzo[d]imidazole NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD m8891 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD , DGIDB 3-anilino-5-benzylthio-1,2,4-triazole NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD 2-methyl-2-propanol NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD a-357300 NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD nitroxoline small molecule NA experimental methionine aminopeptidase 2 METAP2 NA inhibitor NA drugbank 5-methyl-2-[(phenylsulfonyl)amino]benzoic acid small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank 5-methyl-2-(pyridin-2-yl)-1h-benzo[d]imidazole NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD 2-(pyridin-2-yl)-1h-benzo[d]imidazol-5-amine NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD (2r,3r,4s,5r,6e)-3,4,5-trihydroxy-n-[(3s,6r)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank 2-(phenylsulfonamido)-1-naphthoic acid NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD 5-butyl-2-(phenylsulfonamido)benzoic acid NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD (2s,3r)-3-amino-2-hydroxy-5-(ethylsulfanyl)pentanoyl-((s)-(-)-(1-naphthyl)ethyl)amide small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank 3,5,6,8-tetramethyl-n-methyl phenanthrolinium small molecule NA experimental,investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD , drugbank 2-(phenylsulfonamido)-5-propylbenzoic acid NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD 5-methyl-2-(phenylsulfonamido)benzoic acid NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD ovalicin small molecule NA experimental,investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD , drugbank tnp-470 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,discontinued in phase 2 methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD , drugbank oxyquinoline NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD zgn-1061 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD d-methionine small molecule NA approved,experimental,investigational,phase 3 methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD , drugbank , DGIDB sdx-7320 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD , DGIDB 2-(thiazol-4-yl)-1h-benzo[d]imidazol-5-amine NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD 2-(pyridin-2-yl)-1h-imidazo[4,5-c]pyridine NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD 3-ethyl-6-{[(4-fluorophenyl)sulfonyl]amino}-2-methylbenzoic acid small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank tert-butanol small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank 2-[({2-[(1z)-3-(dimethylamino)prop-1-enyl]-4-fluorophenyl}sulfonyl)amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank 2-(4-fluorophenylsulfonamido)-1-naphthoic acid NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD 5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD beloranib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Obesity[MeSHID:D009765] phase 3 methionine aminopeptidase 2 METAP2 Clinical trial target unknown 63.65 TTD , DGIDB ppi-2458 small molecule Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigational,phase 1 methionine aminopeptidase 2 METAP2 Clinical trial target unknown 42.43 TTD , drugbank , DGIDB 3,5-dimethyl-2-(phenylsulfonamido)benzoic acid NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD n'-(2s,3r)-3-amino-4-cyclohexyl-2-hydroxy-butano-n-(4-methylphenyl)hydrazide small molecule NA experimental methionine aminopeptidase 2 METAP2 NA unknown NA drugbank 5-p-tolyl-1h-[1,2,3]triazole NA NA investigative methionine aminopeptidase 2 METAP2 Clinical trial target unknown NA TTD bmn-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glycogen storage disease type II[MeSHID:D006009] investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD ponkoranol NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD rh-alphaglucosidase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glycogen storage disease type II[MeSHID:D006009] approved intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD , DGIDB 2-aminomethyl-pyrrolidine-3,4-diol NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD paz-320 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD , DGIDB double oxidized cysteine NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD acarbose small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Cardiovascular Diseases[MeSHID:D002318] approved,investigational maltase-glucoamylase, intestinal MGAM NA inhibitor 7.27 drugbank , DGIDB miglitol NA Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved intestinal maltase-glucoamylase MGAM Successful target inhibitor 16.97 TTD , DGIDB de-o-sulfonated kotalanol NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD nicotinamide-adenine-dinucleotide NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD voglibose NA Diabetes Mellitus[MeSHID:D003920],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved intestinal maltase-glucoamylase MGAM Successful target unknown 57.29 TTD , DGIDB salacinol NA NA phase 1/2 intestinal maltase-glucoamylase MGAM Successful target unknown 3.18 TTD , DGIDB voglibose small molecule Diabetes Mellitus[MeSHID:D003920],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational maltase-glucoamylase, intestinal MGAM NA inhibitor 57.29 drugbank , DGIDB deoxynojirimycin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glycogen storage disease type II[MeSHID:D006009] phase 3 intestinal maltase-glucoamylase MGAM Successful target unknown 2.12 TTD , DGIDB maltose NA NA phase 1/2 intestinal maltase-glucoamylase MGAM Successful target unknown 3.18 TTD , DGIDB miglitol small molecule Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved maltase-glucoamylase, intestinal MGAM NA antagonist,inhibitor 16.97 drugbank , DGIDB alpha-glucosidase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myopathy[MeSHID:D009135] phase 3 intestinal maltase-glucoamylase MGAM Successful target unknown 6.37 TTD , DGIDB gsc-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperglycemia[MeSHID:D006943] investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD 4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD 3-(4-(4-hydroxyphenyl)phthalazin-1-ylamino)phenol NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD sc-49483 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acquired Immunodeficiency Syndrome[MeSHID:D000163] phase 2 intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD , DGIDB 1,4-dideoxy-1,4-imino-d-arabinito NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD imino sugars NA Dengue Fever[MeSHID:D003715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD miglitol NA Diabetes Mellitus[MeSHID:D003920],Diet therapy[MeSHID:D004035],Hyperglycemia[MeSHID:D006943],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved intestinal maltase-glucoamylase MGAM Successful target unknown 16.97 TTD , DGIDB kotalanol NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD acarbose NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Cardiovascular Diseases[MeSHID:D002318] approved intestinal maltase-glucoamylase MGAM Successful target unknown 7.27 TTD , DGIDB 2-cyclopentylaminomethyl-pyrrolidine-3,4-diol NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD celgosivir NA Dengue Fever[MeSHID:D003715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 intestinal maltase-glucoamylase MGAM Successful target unknown 6.37 TTD , DGIDB 2,5-dideoxy-2,5-imino-d-mannitol NA NA investigative intestinal maltase-glucoamylase MGAM Successful target unknown NA TTD uridine-diphosphate-n-acetylglucosamine small molecule NA experimental alpha-1,3-mannosyl-glycoprotein 2-beta-n-acetylglucosaminyltransferase MGAT1 NA unknown NA drugbank pyrimidine-4(3h)-one derivative 1 NA NA patented mannoside acetylglucosaminyltransferase 2 MGAT2 Patented-recorded target unknown NA TTD , DGIDB n-containing heterocyclic derivative 1 NA NA patented mannoside acetylglucosaminyltransferase 2 MGAT2 Patented-recorded target unknown NA TTD , DGIDB phenylmethanesulfonamide derivative 1 NA NA patented mannoside acetylglucosaminyltransferase 2 MGAT2 Patented-recorded target unknown NA TTD , DGIDB dihydropyrimidinone derivative 4 NA NA patented mannoside acetylglucosaminyltransferase 2 MGAT2 Patented-recorded target unknown NA TTD , DGIDB dihydropyrimidinone derivative 3 NA NA patented mannoside acetylglucosaminyltransferase 2 MGAT2 Patented-recorded target unknown NA TTD , DGIDB bicyclic pyrimidine derivative 1 NA NA patented mannoside acetylglucosaminyltransferase 2 MGAT2 Patented-recorded target unknown NA TTD , DGIDB streptozocin small molecule Pancreatic Endocrine Carcinoma[MeSHID:D018273],Malignant neoplasm of pancreas[MeSHID:D010190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatic carcinoma[MeSHID:C562463] approved,investigational bifunctional protein ncoat MGEA5 NA unknown NA drugbank mk 8719 NA Progressive supranuclear palsy[MeSHID:D013494],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 beta-n-acetylhexosaminidase MGEA5 Clinical trial target unknown NA TTD mk-8719 NA Progressive supranuclear palsy[MeSHID:D013494],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 beta-n-acetylhexosaminidase MGEA5 Clinical trial target unknown NA TTD carbamate derivative 17 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamate derivative 14 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 84 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidinyl-piperidine derivative 3 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidine-benzoxazin-3(4h)-one derivative 3 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-11c NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-7d NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 85 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-14 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-7a NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamate derivative 10 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB piperazine carbamic compound 2 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamide derivative 26 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB piperazine carbamic compound 1 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 83 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidine-benzoxazin-3(4h)-one derivative 2 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-17 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-4 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB piperazine carbamic compound 5 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidinyl-piperazine derivative 2 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-7c NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB piperazine carbamic compound 3 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 82 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidine-benzoxazin-3(4h)-one derivative 1 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB piperazine carbamic compound 4 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 80 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidinyl-piperidine derivative 2 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamide derivative 24 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB jzl184 NA NA investigative monoglyceride lipase MGLL Clinical trial target inhibitor NA TTD , DGIDB carbamate derivative 13 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamide derivative 25 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-15 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamate derivative 16 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-5 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-7e NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidinyl-piperazine derivative 1 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 81 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB abx-1431 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gilles de la Tourette syndrome[MeSHID:D005879] phase 1 monoglyceride lipase MGLL Clinical trial target inhibitor NA TTD , DGIDB pmid29053063-compound-11d NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamate derivative 9 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamate derivative 15 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-7f NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidinyl-piperazine derivative 3 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB azetidinyl-piperidine derivative 1 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB abx-1431 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gilles de la Tourette syndrome[MeSHID:D005879] phase 1 monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB pmid29053063-compound-7b NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamate derivative 12 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB carbamate derivative 11 NA NA patented monoglyceride lipase MGLL Clinical trial target unknown NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational methylated-dna--protein-cysteine methyltransferase MGMT NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational methylated-dna--protein-cysteine methyltransferase MGMT NA stabilization NA drugbank 6-benzyloxy-9h-purin-2-ylamine NA NA investigative o-6-methylguanine-dna-alkyltransferase MGMT Clinical trial target unknown NA TTD s-benzylcysteine small molecule NA experimental methylated-dna--protein-cysteine methyltransferase MGMT NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental methylated-dna--protein-cysteine methyltransferase MGMT NA stabilization NA drugbank s-methylcysteine NA NA investigative o-6-methylguanine-dna-alkyltransferase MGMT Clinical trial target unknown NA TTD 6-benzyloxy-5-nitro-pyrimidine-2,4-diamine NA NA investigative o-6-methylguanine-dna-alkyltransferase MGMT Clinical trial target unknown NA TTD benzylcysteine NA NA investigative o-6-methylguanine-dna-alkyltransferase MGMT Clinical trial target unknown NA TTD o6-benzylguanine alkylade NA Sarcoma[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 o-6-methylguanine-dna-alkyltransferase MGMT Clinical trial target unknown NA TTD , DGIDB s-methylcysteine small molecule NA experimental methylated-dna--protein-cysteine methyltransferase MGMT NA unknown NA drugbank 6-allyloxy-9h-purin-2-ylamine NA NA investigative o-6-methylguanine-dna-alkyltransferase MGMT Clinical trial target unknown NA TTD dinitrochlorobenzene small molecule NA investigational methylated-dna--protein-cysteine methyltransferase MGMT NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational methylated-dna--protein-cysteine methyltransferase MGMT NA unknown NA drugbank 6-benzyloxy-5-nitroso-pyrimidine-2,4-diamine NA NA investigative o-6-methylguanine-dna-alkyltransferase MGMT Clinical trial target unknown NA TTD cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical methylated-dna--protein-cysteine methyltransferase MGMT NA unknown NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical matrix gla protein MGP NA unknown NA drugbank glutathione disulfide small molecule NA approved,experimental,investigational microsomal glutathione s-transferase 1 MGST1 NA activator NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical microsomal glutathione s-transferase 1 MGST1 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical microsomal glutathione s-transferase 2 MGST2 NA unknown NA drugbank glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical microsomal glutathione s-transferase 3 MGST3 NA unknown NA drugbank 3-benzyl-6-methylbenzo[d]oxazol-2(3h)-one NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 2-(4-hydroxystyryl)quinolin-8-ol NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD n-(2-bromobenzoyloxy)-4-chlorobenzamide NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD s-benzo[d]oxazol-2-yl o-butyl carbonothioate NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 4-hydroxyphenylpyruvic acid small molecule NA experimental,investigative macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD , drugbank 7-hydroxy-2-oxo-chromene-3-carboxylic acid ethyl ester small molecule NA experimental macrophage migration inhibitory factor MIF NA unknown NA drugbank isis 112580 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 3-benzyl-5-fluorobenzo[d]oxazol-2(3h)-one NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 4-hydroxybenzaldehyde o-(3,3-dimethylbutanoyl)oxime small molecule NA experimental macrophage migration inhibitory factor MIF NA unknown NA drugbank isis 112592 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 4-(4-benzyl-1h-1,2,3-triazol-1-yl)phenol NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD anti-mif antibodies NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 4 macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD , DGIDB napqi NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327] investigative macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD 4-iodo-6-phenylpyrimidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative mif messenger rna MIF Literature-reported target unknown NA TTD 3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole-acetic acid methyl ester small molecule NA experimental macrophage migration inhibitory factor MIF NA unknown NA drugbank isis 112690 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD ethyl 7-hydroxy-2-oxo-2h-chromene-3-carboxylate NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD avp-13546 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327] investigative macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD isis 112711 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 7-hydroxy-3-phenyl-2h-chromen-2-one NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 3,3,3-tris(4-chlorophenyl)propanoic acid NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD cor100140 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD , DGIDB 3-acetyl-7-hydroxy-2h-chromen-2-one NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD isis 112590 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD avp-13748 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327] investigative macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD 3-fluoro-4-hydroxybenzaldehyde o-(cyclohexylcarbonyl)oxime small molecule NA experimental macrophage migration inhibitory factor MIF NA unknown NA drugbank isis 112696 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD isis 112599 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 3-benzyl-5-methylbenzo[d]oxazol-2(3h)-one NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD iso-1 NA NA phase 1 macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD , DGIDB isis 112694 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 4-hydroxybenzaldehyde o-(cyclohexylcarbonyl)oxime small molecule NA experimental,investigative macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD , drugbank 3,4-dihydroxycinnamic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] experimental,investigational,phase 4 macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD , drugbank benzofuran-2-yl(indolin-1-yl)methanone NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 4-((pyridin-4-ylthio)methyl)benzene-1,2-diol NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 3-(1h-pyrazol-3-yl)benzoic acid NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 6-phenylpyridazin-3-yl thiophene-2-carboxylate NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD isis 112724 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD isis 112699 NA NA investigative mif messenger rna MIF Literature-reported target unknown NA TTD 6-hydroxy-1,3-benzothiazole-2-sulfonamide small molecule NA experimental,investigative macrophage migration inhibitory factor MIF Clinical trial target unknown NA TTD , drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational misshapen-like kinase 1 MINK1 NA inhibitor NA drugbank b-nonylglucoside small molecule NA experimental lens fiber major intrinsic protein MIP NA unknown NA drugbank latrunculin b small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] experimental mkl/myocardin-like protein 1 MKL1 NA unknown NA drugbank eft508 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Liver carcinoma[MeSHID:D006528],Malignant Neoplasms[MeSHID:D009369],Triple Negative Breast Neoplasms[MeSHID:D064726],Colorectal Cancer[MeSHID:D015179] phase 2 mapk signal-integrating kinase 1 MKNK1 Clinical trial target unknown 8.49 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational map kinase-interacting serine/threonine-protein kinase 1 MKNK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational map kinase-interacting serine/threonine-protein kinase 2 MKNK2 NA inhibitor NA drugbank eft508 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Liver carcinoma[MeSHID:D006528],Malignant Neoplasms[MeSHID:D009369],Triple Negative Breast Neoplasms[MeSHID:D064726],Colorectal Cancer[MeSHID:D015179] phase 2 map kinase signal-integrating kinase 2 MKNK2 Clinical trial target unknown 1.59 TTD , DGIDB polynoma-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 mart-1 melanoma antigen MLANA Clinical trial target unknown NA TTD , DGIDB melanoma vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 mart-1 melanoma antigen MLANA Clinical trial target unknown NA TTD , DGIDB mkc-1106-mt NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 mart-1 melanoma antigen MLANA Clinical trial target unknown NA TTD , DGIDB multi-epitope peptide melanoma vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 mart-1 melanoma antigen MLANA Clinical trial target unknown NA TTD , DGIDB f-50040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 1 mart-1 melanoma antigen MLANA Clinical trial target unknown NA TTD melanoma vaccine (alvac) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 2 mart-1 melanoma antigen MLANA Clinical trial target unknown NA TTD (5r)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5h)-one small molecule NA experimental afadin MLLT4 NA unknown NA drugbank kw-5139 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 motilin receptor MLNR Clinical trial target unknown NA TTD camicinal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroparesis[MeSHID:D018589] phase 2 motilin receptor MLNR Clinical trial target agonist 23.87 TTD , DGIDB rq-00201894 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroesophageal reflux disease[MeSHID:D005764] investigative motilin receptor MLNR Clinical trial target unknown NA TTD [leu13]motilin (human) NA NA investigative motilin receptor MLNR Clinical trial target agonist NA TTD , DGIDB ds-3801 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 motilin receptor MLNR Clinical trial target unknown NA TTD , DGIDB motilin NA NA phase 4 motilin receptor MLNR Clinical trial target agonist 15.91 TTD , DGIDB em-523 NA NA investigative motilin receptor MLNR Clinical trial target agonist NA TTD , DGIDB tzp-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyspepsia[MeSHID:D004415] preclinical motilin receptor MLNR Clinical trial target unknown NA TTD , DGIDB ma-2029 NA NA investigative motilin receptor MLNR Clinical trial target antagonist NA TTD , DGIDB gsk-326416 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroparesis[MeSHID:D018589] preclinical motilin receptor MLNR Clinical trial target unknown NA TTD , DGIDB gm-109 NA NA investigative motilin receptor MLNR Clinical trial target unknown NA TTD mitemcinal small molecule Irritable Bowel Syndrome[MeSHID:D043183],Gastroparesis[MeSHID:D018589] investigational motilin receptor MLNR NA unknown 23.87 drugbank , DGIDB me67 NA NA investigative motilin receptor MLNR Clinical trial target agonist NA TTD , DGIDB me4 NA NA investigative motilin receptor MLNR Clinical trial target agonist NA TTD , DGIDB camicinal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroparesis[MeSHID:D018589] phase 2 motilin receptor MLNR Clinical trial target unknown 23.87 TTD , DGIDB erythromycin small molecule Streptococcal pneumonia[MeSHID:D011018],Skin Diseases, Infectious[MeSHID:D012874],Listeriosis[MeSHID:D008088],Pregnancy[MeSHID:D011247],Erythrasma[MeSHID:D004894],Syphilitic chancre[MeSHID:D002601],Pelvic Inflammatory Disease[MeSHID:D000292],Muscle strain[MeSHID:D013180],Hypersensitivity[MeSHID:D006967],Infection[MeSHID:D007239],Nasopharynx[MeSHID:D009305],Legionnaires' Disease[MeSHID:D007877],Urethra[MeSHID:D014521],Conjunctivitis[MeSHID:D003231],Pneumonia[MeSHID:D011014],Urethritis[MeSHID:D014526],Reproduction[MeSHID:D012098],Respiratory Tract Infections[MeSHID:D012141],Rheumatic Fever[MeSHID:D012213],Pertussis[MeSHID:D014917],Gonorrhea[MeSHID:D006069],Chlamydia Infections[MeSHID:D002690],Communicable Diseases[MeSHID:D003141],Carrier of disorder[MeSHID:D002353],Syphilis[MeSHID:D013587],Amebic colitis[MeSHID:D004404],Amebiasis[MeSHID:D000562],Genetic Carriers[MeSHID:D006579],Primary syphilis[MeSHID:C536772],Diphtheria[MeSHID:D004165],Behavior[MeSHID:D001519],Sexually Transmitted Diseases[MeSHID:D012749],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved motilin receptor MLNR NA agonist 1.19 drugbank , DGIDB kos-2187 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767],Gastroesophageal reflux disease[MeSHID:D005764] phase 1 motilin receptor MLNR Clinical trial target unknown NA TTD , DGIDB cem-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cell motility[MeSHID:D002465],Stomach Diseases[MeSHID:D013272] investigative motilin receptor MLNR Clinical trial target unknown NA TTD motilin NA NA phase 4 motilin receptor MLNR Clinical trial target unknown 15.91 TTD , DGIDB tzp-201 NA Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative motilin receptor MLNR Clinical trial target unknown NA TTD me36 NA NA investigative motilin receptor MLNR Clinical trial target agonist NA TTD , DGIDB mitemcinal fumarate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 motilin receptor MLNR Clinical trial target unknown NA TTD , DGIDB kos1326 NA NA investigative motilin receptor MLNR Clinical trial target agonist NA TTD , DGIDB kc-11458 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cell motility[MeSHID:D002465],Stomach Diseases[MeSHID:D013272] discontinued in phase 2 motilin receptor MLNR Clinical trial target unknown NA TTD slv-311 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] discontinued in phase 1 motilin receptor MLNR Clinical trial target unknown NA TTD gsk-1322888 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastroparesis[MeSHID:D018589] phase 1 motilin receptor MLNR Clinical trial target unknown NA TTD , DGIDB slv-305 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cell motility[MeSHID:D002465],Stomach Diseases[MeSHID:D013272] discontinued in phase 2 motilin receptor MLNR Clinical trial target unknown NA TTD rwj-68023 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 motilin receptor MLNR Clinical trial target unknown NA TTD , DGIDB cyanocobalamin small molecule Malignant Neoplasms[MeSHID:D009369],Cestode Infections[MeSHID:D002590],Operative Surgical Procedures[MeSHID:D013514],Pregnancy[MeSHID:D011247],Nose[MeSHID:D009666],Folic Acid Deficiency[MeSHID:D005494],Thyrotoxicosis[MeSHID:D013971],Anemia, Pernicious[MeSHID:D000752],Intestines, Small[MeSHID:D007421],Intestines[MeSHID:D007422],Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Parasitic Diseases[MeSHID:D010272],Celiac Disease[MeSHID:D002446],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Malabsorption Syndrome[MeSHID:D008286],Neurologic Manifestations[MeSHID:D009461],Avitaminosis[MeSHID:D001361],Vitamin B 12 Deficiency[MeSHID:D014806],Malignant neoplasm of pancreas[MeSHID:D010190],Mental concentration[MeSHID:D001288],Hemorrhage[MeSHID:D006470], Hemolytic[MeSHID:D000743],Diphyllobothriasis[MeSHID:D004169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved,nutraceutical methylmalonic aciduria type a protein, mitochondrial MMAA NA binder NA drugbank hydroxocobalamin small molecule Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Diet, Macrobiotic[MeSHID:D015623],Malignant neoplasm of pancreas[MeSHID:D010190],Biliary Tract Diseases[MeSHID:D001660],Diarrhea[MeSHID:D003967],Cestode Infections[MeSHID:D002590],Malabsorption Syndrome[MeSHID:D008286],Poisoning[MeSHID:D011041],Alcoholic Intoxication, Chronic[MeSHID:D000437],Hyperthyroidism[MeSHID:D006980],Vegan diet[MeSHID:D000067269],Anemia, Pernicious[MeSHID:D000752],ileum[MeSHID:D007082],Vitamin B 12 Deficiency[MeSHID:D014806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Injury[MeSHID:D055370] approved methylmalonic aciduria type a protein, mitochondrial MMAA NA unknown NA drugbank cyanocobalamin small molecule Malignant Neoplasms[MeSHID:D009369],Cestode Infections[MeSHID:D002590],Operative Surgical Procedures[MeSHID:D013514],Pregnancy[MeSHID:D011247],Nose[MeSHID:D009666],Folic Acid Deficiency[MeSHID:D005494],Thyrotoxicosis[MeSHID:D013971],Anemia, Pernicious[MeSHID:D000752],Intestines, Small[MeSHID:D007421],Intestines[MeSHID:D007422],Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Parasitic Diseases[MeSHID:D010272],Celiac Disease[MeSHID:D002446],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Malabsorption Syndrome[MeSHID:D008286],Neurologic Manifestations[MeSHID:D009461],Avitaminosis[MeSHID:D001361],Vitamin B 12 Deficiency[MeSHID:D014806],Malignant neoplasm of pancreas[MeSHID:D010190],Mental concentration[MeSHID:D001288],Hemorrhage[MeSHID:D006470], Hemolytic[MeSHID:D000743],Diphyllobothriasis[MeSHID:D004169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved,nutraceutical methylmalonic aciduria and homocystinuria type c protein MMACHC NA cofactor NA drugbank hydroxocobalamin small molecule Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Diet, Macrobiotic[MeSHID:D015623],Malignant neoplasm of pancreas[MeSHID:D010190],Biliary Tract Diseases[MeSHID:D001660],Diarrhea[MeSHID:D003967],Cestode Infections[MeSHID:D002590],Malabsorption Syndrome[MeSHID:D008286],Poisoning[MeSHID:D011041],Alcoholic Intoxication, Chronic[MeSHID:D000437],Hyperthyroidism[MeSHID:D006980],Vegan diet[MeSHID:D000067269],Anemia, Pernicious[MeSHID:D000752],ileum[MeSHID:D007082],Vitamin B 12 Deficiency[MeSHID:D014806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Injury[MeSHID:D055370] approved methylmalonic aciduria and homocystinuria type c protein MMACHC NA unknown NA drugbank fasidotrilat NA NA investigative neutral endopeptidase MME Clinical trial target inhibitor 2.45 TTD , DGIDB sch-32615 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 neutral endopeptidase MME Clinical trial target unknown NA TTD [2(r,s)-2-sulfanylheptanoyl]-phe-ala small molecule NA experimental neprilysin MME NA unknown NA drugbank thiorphan NA NA investigative neutral endopeptidase MME Clinical trial target inhibitor 4.9 TTD , DGIDB slv-334 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] phase 2 neutral endopeptidase MME Clinical trial target unknown 2.45 TTD , DGIDB 9-mercaptomethyl-10-oxo-azecane-2-carboxylic acid NA NA investigative neutral endopeptidase MME Clinical trial target unknown NA TTD lbq657 NA NA investigative neutral endopeptidase MME Clinical trial target unknown NA TTD td-0714 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 1 neutral endopeptidase MME Clinical trial target unknown NA TTD , DGIDB candoxatril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 3 neutral endopeptidase MME Clinical trial target unknown 24.48 TTD , DGIDB gallopamil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Asthma[MeSHID:D001249] phase 2 neutral endopeptidase MME Clinical trial target unknown 1.63 TTD , DGIDB cart-10 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 neutral endopeptidase MME Clinical trial target unknown NA TTD , DGIDB debio 0827 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 1 neutral endopeptidase MME Clinical trial target unknown NA TTD , DGIDB rb-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigative neutral endopeptidase MME Clinical trial target unknown NA TTD candoxatril small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] experimental neprilysin MME NA inhibitor 24.48 drugbank , DGIDB cgs-25462 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 neutral endopeptidase MME Clinical trial target unknown NA TTD sch-42495 NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neutral endopeptidase MME Clinical trial target unknown NA TTD omapatrilat small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational neprilysin MME NA unknown NA drugbank 2-[(1s)-1-benzyl-2-sulfanylethyl]-1h-imidazo[4,5-c]pyridin-5-ium small molecule NA experimental neprilysin MME NA unknown NA drugbank sampatrilat NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 neutral endopeptidase MME Clinical trial target unknown 4.9 TTD , DGIDB m-100240 NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neutral endopeptidase MME Clinical trial target unknown NA TTD n-[3-[(1-aminoethyl)(hydroxy)phosphoryl]-2-(1,1'-biphenyl-4-ylmethyl)propanoyl]alanine small molecule NA experimental neprilysin MME NA unknown NA drugbank [2(r,s)-2-sulfanylheptanoyl]-phe-ala NA NA investigative neutral endopeptidase MME Clinical trial target unknown NA TTD gemopatrilat NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neutral endopeptidase MME Clinical trial target unknown NA TTD phosphoramidon small molecule NA experimental neprilysin MME NA inhibitor NA drugbank daglutril small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333] investigational neprilysin MME NA inhibitor 2.45 drugbank , DGIDB phosphoramidon NA NA investigative neutral endopeptidase MME Clinical trial target unknown NA TTD cd10-cart NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neutral endopeptidase MME Clinical trial target unknown NA TTD , DGIDB slv 306 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 neutral endopeptidase MME Clinical trial target unknown NA TTD , DGIDB ilepatril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Diabetic Nephropathy[MeSHID:D003928],Kidney Failure[MeSHID:D051437],Heart failure[MeSHID:D006333] discontinued in phase 2/3 neutral endopeptidase MME Clinical trial target unknown 2.45 TTD , DGIDB candoxatrilat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] discontinued in phase 1 neutral endopeptidase MME Clinical trial target inhibitor 14.69 TTD , DGIDB sacubitril small molecule Heart failure[MeSHID:D006333] approved neprilysin MME NA antagonist,inhibitor 4.9 drugbank , DGIDB pfizer 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] phase 1 neutral endopeptidase MME Clinical trial target unknown NA TTD , DGIDB n-(3-phenyl-2-sulfanylpropanoyl)phenylalanylalanine small molecule NA experimental neprilysin MME NA unknown NA drugbank sch-34826 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 neutral endopeptidase MME Clinical trial target unknown NA TTD fasidotril NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neutral endopeptidase MME Clinical trial target inhibitor 2.45 TTD , DGIDB thiorphan small molecule NA experimental neprilysin MME NA inhibitor 4.9 drugbank , DGIDB lcz696 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved neutral endopeptidase MME Clinical trial target unknown 4.9 TTD , DGIDB pmid18078750c1b NA NA investigative neutral endopeptidase MME Clinical trial target unknown NA TTD candoxatril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 3 neutral endopeptidase MME Clinical trial target inhibitor 24.48 TTD , DGIDB gw-796406 NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 neutral endopeptidase MME Clinical trial target unknown NA TTD , DGIDB cgs-314447 NA NA investigative neutral endopeptidase MME Clinical trial target unknown NA TTD candoxatrilat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] experimental neprilysin MME NA inhibitor 14.69 drugbank , DGIDB vx-15 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Huntington Disease[MeSHID:D006816],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 neutral endopeptidase MME Clinical trial target unknown 2.45 TTD , DGIDB slv-338 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 neutral endopeptidase MME Clinical trial target unknown NA TTD , DGIDB 3-benzenesulfinyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD bms 275291 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Kaposi Sarcoma[MeSHID:D012514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 3 matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-cyclohexanethiol NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD 3-(4-phenoxy-benzenesulfonyl)-cyclohexanethiol NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD cgs-27023 small molecule NA experimental interstitial collagenase MMP1 NA unknown NA drugbank methylamino-phenylalanyl-leucyl-hydroxamic acid NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD 4-(4-methoxy-benzenesulfonyl)-butane-2-thiol NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD prinomastat NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] approved matrix metalloproteinase-1 MMP1 Successful target unknown 0.45 TTD , DGIDB [[1-[n-hydroxy-acetamidyl]-3-methyl-butyl]-carbonyl-leucinyl]-alanine ethyl ester small molecule NA experimental interstitial collagenase MMP1 NA unknown NA drugbank n-hydroxycarbamoylmethyl-4-methoxy-benzamide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD cipemastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 3 matrix metalloproteinase-1 MMP1 Successful target unknown 3.18 TTD , DGIDB sr-973 NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD pmid29130358-compound-figure18(14a) NA NA patented matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD , DGIDB apratastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 matrix metalloproteinase-1 MMP1 Successful target unknown 2.12 TTD , DGIDB n-hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD n-(ethylphosphoryl)-l-isoleucyl-l-trp-nhch3 NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD 3-cyclohexanesulfonyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD marimastat NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] phase 3 matrix metalloproteinase-1 MMP1 Successful target unknown 2.27 TTD , DGIDB 3-benzenesulfonyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD mmi270 NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD methylamino-phenylalanyl-leucyl-hydroxamic acid small molecule NA experimental interstitial collagenase MMP1 NA unknown NA drugbank marimastat NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] phase 3 matrix metalloproteinase-1 MMP1 Successful target inhibitor 2.27 TTD , DGIDB marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational interstitial collagenase MMP1 NA inhibitor 2.27 drugbank , DGIDB n-hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD 3-(4-phenoxy-benzenesulfonyl)-propane-1-thiol NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD pkf-242-484 NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-pentane-1-thiol NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-hexane-1-thiol NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD rs-39066 NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD xl784 NA Diabetes Mellitus[MeSHID:D003920],Proteinuria[MeSHID:D011507],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD cipemastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 3 matrix metalloproteinase-1 MMP1 Successful target inhibitor 3.18 TTD , DGIDB gm6001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Corneal Ulcer[MeSHID:D003320] discontinued in phase 2 matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD , DGIDB pmid29130358-compound-figure10(2a) NA NA patented matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD , DGIDB n-hydroxy-2-[4-(4-phenoxy-benzenesulfonyl)-tetrahydro-pyran-4-yl]-acetamide small molecule NA experimental interstitial collagenase MMP1 NA unknown NA drugbank apratastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 matrix metalloproteinase-1 MMP1 Successful target inhibitor 2.12 TTD , DGIDB 4-butoxy-n-hydroxycarbamoylmethyl-benzamide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD n-hydroxycarbamoylmethyl-4-phenoxy-benzamide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD rs-130830 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD 4-(4-butoxy-phenyl)-n-hydroxy-4-oxo-butyramide NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD ro-37-9790 NA NA investigative matrix metalloproteinase-1 MMP1 Successful target unknown NA TTD n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide small molecule NA experimental interstitial collagenase MMP1 NA unknown NA drugbank eec NA NA patented matrix metalloproteinase-10 MMP10 Patented-recorded target unknown NA TTD marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational stromelysin-2 MMP10 NA antagonist NA drugbank eea NA NA patented matrix metalloproteinase-10 MMP10 Patented-recorded target unknown NA TTD 3ts4 NA NA patented matrix metalloproteinase-10 MMP10 Patented-recorded target unknown NA TTD cm-352 NA NA investigative matrix metalloproteinase-10 MMP10 Patented-recorded target inhibitor NA TTD , DGIDB n-isobutyl-n-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid small molecule NA experimental stromelysin-2 MMP10 NA unknown NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational stromelysin-3 MMP11 NA antagonist NA drugbank nα-[(2s)-2-{[(s)-[(1s)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl]methyl}-5-phenylpentanoyl]-l-tryptophanamide small molecule NA experimental stromelysin-3 MMP11 NA unknown NA drugbank n-(dibenzo[b,d]thiophen-3-ylsulfonyl)-l-valine small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD pmid24900526c1 NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD ae-941 small molecule Disease[MeSHID:D004194],Malignant neoplasm of kidney[MeSHID:D007680],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Age related macular degeneration[MeSHID:D008268],Multiple Myeloma[MeSHID:D009101],Psoriasis[MeSHID:D011565] investigational macrophage metalloelastase MMP12 NA unknown NA drugbank 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 3-(4-phenylethynylbenzoyl)nonanoic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 2-(biphenyl-4-ylsulfonyl)n-hydroxybenzamide NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD ageladine a NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 5-(biphenyl-4-yl)-3-methoxypentanoic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD acetate ion NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD n-[(4-methoxyphenyl)sulfonyl]-d-alanine NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD n-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD neovastat NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD pmid29130358-compound-figure17(12) NA NA patented matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD , DGIDB pmid29130358-compound-figure17(11) NA NA patented matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD , DGIDB 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 3-benzenesulfonyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD way-644 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Aortic Aneurysm[MeSHID:D001014] investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD rxp470.1 NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target inhibitor NA TTD , DGIDB pmid22153340c20 NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD cp-271485 NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD cp-271485 small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank n-hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 2-[(4-fluorophenyl)sulfonylamino]-n-oxo-ethanamide small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD n-(biphenyl-4-ylsulfonyl)-d-leucine small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank cgs-27023 small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational macrophage metalloelastase MMP12 NA inhibitor NA drugbank 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD n-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank 2-[2-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)ethyl]-4-(4'-ethoxy-1,1'-biphenyl-4-yl)-4-oxobutanoic acid small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank acetohydroxamic acid small molecule Urinary tract infection[MeSHID:D014552],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved macrophage metalloelastase MMP12 NA inhibitor NA drugbank n-oxo-2-(phenylsulfonylamino)ethanamide NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD n-(dibenzo[b,d]thiophen-3-ylsulfonyl)-l-valine NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD batimastat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] experimental macrophage metalloelastase MMP12 NA unknown NA drugbank (1s,5s,7r)-n~7~-(biphenyl-4-ylmethyl)-n~3~-hydroxy-6,8-dioxa-3-azabicyclo[3.2.1]octane-3,7-dicarboxamide small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank n-(biphenyl-4-ylsulfonyl)-d-leucine NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD pup-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD gm6001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Corneal Ulcer[MeSHID:D003320] discontinued in phase 2 matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD , DGIDB n-oxo-2-(phenylsulfonylamino)ethanamide small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank rxp-470 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD v85546 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] discontinued in phase 1 matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 3-cyclohexanesulfonyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD n-hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD pf-00356231 NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD n-isobutyl-n-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank azd1236 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 matrix metalloproteinase-12 MMP12 Clinical trial target inhibitor 5.3 TTD , DGIDB pf-00356231 small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank pmid29130358-compound-figure17(10) NA NA patented matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD , DGIDB mmp-408 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD [2-(biphenyl-4-sulfonyl)phenyl]acetic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD 2-(2-(biphenyl-4-yl)ethylthio)acetic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD fp-025 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD , DGIDB 5-(biphenyl-4-yl)-3-oxopentanoic acid NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD n-[(4-methoxyphenyl)sulfonyl]-d-alanine small molecule NA experimental macrophage metalloelastase MMP12 NA unknown NA drugbank pmid24900526c5 NA NA investigative matrix metalloproteinase-12 MMP12 Clinical trial target unknown NA TTD ik-862 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-hexane-1-thiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD pyrimidine-4,6-dicarboxylic acid bis-(4-fluoro-3-methyl-benzylamide) small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD pyrimidine-4,6-dicarboxylic acid bis-[(pyridin-3-ylmethyl)-amide] small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank pmid29130358-compound-figure16(9c) NA NA patented matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD , DGIDB pmid22017539c15 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD uk-356618 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 4-{[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2h)-yl]methyl}benzoic acid small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank apratastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 matrix metalloproteinase-13 MMP13 Clinical trial target unknown 6.06 TTD , DGIDB ro-37-9790 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD [2-(biphenyl-4-sulfonyl)phenyl]acetic acid NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 3-(4-phenoxy-benzenesulfonyl)-cyclohexanethiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD pyrimidine-4,6-dicarboxylic acid bis-(3-methyl-benzylamide) small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank pmid29130358-compound-figure18(14) NA NA patented matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD , DGIDB way170523 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target inhibitor NA TTD , DGIDB pkf-242-484 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 1-(4-methoxy-benzenesulfonyl)-heptane-3-thiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD way-151693 small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 4-(4-methoxy-benzenesulfonyl)-butane-2-thiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 1-methyloxy-4-sulfone-benzene NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD sl422 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target inhibitor NA TTD , DGIDB rs-130830 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD pmid29130358-compound-figure18(14a) NA NA patented matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD , DGIDB 4-methoxybenzenesulfinate small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 2-(biphenyl-4-ylsulfonyl)n-hydroxybenzamide NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 3-methylpyridine NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 3-(4-phenoxy-benzenesulfonyl)-propane-1-thiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD pmid29130358-compound-figure16(9a) NA NA patented matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD , DGIDB 4-(methyl(4-phenylthiazol-2-yl)amino)phenol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD n1,n3-bis(3-methoxybenzyl)isophthalamide NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD pmid17935984c1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] clinical trial matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD , DGIDB 4-(2,2'-bithiophen-5-ylmethyleneamino)phenol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD n-hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD endostatin biotech Neoplasms[MeSHID:D009369],Diabetic Retinopathy[MeSHID:D003930],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational collagenase 3 MMP13 NA unknown NA drugbank 3-benzenesulfonyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD hydroxyaminovaline small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank 3-methylpyridine small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank 2-(biphenyl-4-ylsulfonamido)pentanedioic acid NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 matrix metalloproteinase-13 MMP13 Clinical trial target unknown 0.13 TTD , DGIDB pmid29130358-compound-figure16(9b) NA NA patented matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD , DGIDB 5-(2-ethoxyethyl)-5-[4-(4-fluorophenoxy)phenoxy]pyrimidine-2,4,6(1h,3h,5h)-trione small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank mmi270 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD way-151693 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD tert-butyl 4-({[4-(but-2-yn-1-ylamino)phenyl]sulfonyl}methyl)-4-[(hydroxyamino)carbonyl]piperidine-1-carboxylate small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank 3-(4-methoxy-benzenesulfonyl)-propane-1-thiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-pentane-1-thiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD benzyl 6-benzyl-5,7-dioxo-6,7-dihydro-5h-[1,3]thiazolo[3,2-c]pyrimidine-2-carboxylate small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank gm6001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Corneal Ulcer[MeSHID:D003320] discontinued in phase 2 matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD , DGIDB pd-156 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD sr-973 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 2-{4-[4-(4-chloro-phenoxy)-benzenesulfonyl]-tetrahydro-pyran-4-yl}-n-hydroxy-acetamide small molecule NA experimental collagenase 3 MMP13 NA unknown NA drugbank ethyl 2-cyano-2-(quinoxalin-2(1h)-ylidene)acetate NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational collagenase 3 MMP13 NA inhibitor NA drugbank apratastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 matrix metalloproteinase-13 MMP13 Clinical trial target inhibitor 6.06 TTD , DGIDB cl82198 NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target inhibitor NA TTD , DGIDB 2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 3-cyclohexanesulfonyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD n4,n6-dibenzylpyrimidine-4,6-dicarboxamide NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD hydroxyaminovaline NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-cyclopentanethiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-cyclohexanethiol NA NA investigative matrix metalloproteinase-13 MMP13 Clinical trial target unknown NA TTD cts-1027 small molecule NA experimental,investigational collagenase 3 MMP13 NA unknown NA drugbank ik-862 NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD epigallocatechin gallate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] phase 3 matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD , DGIDB dx-2400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD 2-(biphenyl-4-ylsulfonamido)-n-hydroxyacetamide NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD 2-(biphenyl-4-ylsulfonyl)n-hydroxybenzamide NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD gm6001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Corneal Ulcer[MeSHID:D003320] discontinued in phase 2 matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD , DGIDB bt1718 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2a matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD n-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD uk-356618 NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD n-hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD sr-973 NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD 2-(4-bromophenylsulfonamido)-n-hydroxyacetamide NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD mmi270 NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD [2-(biphenyl-4-sulfonyl)phenyl]acetic acid NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD pmid23631440c29e NA NA investigative matrix metalloproteinase-14 MMP14 Clinical trial target unknown NA TTD marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-14 MMP14 NA inhibitor NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-15 MMP15 NA inhibitor NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-16 MMP16 NA inhibitor NA drugbank batimastat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] experimental matrix metalloproteinase-16 MMP16 NA unknown NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-17 MMP17 NA inhibitor NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-19 MMP19 NA inhibitor NA drugbank 2-(biphenyl-4-ylsulfonyl)n-hydroxybenzamide NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD methotrexate gamma-hydroxamic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD prinomastat NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] approved matrix metalloproteinase-2 MMP2 Successful target vaccine 0.67 TTD , DGIDB sc-74020 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD pmid29130358-compound-figure10(2a) NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB n-hydroxy-3-(6-methoxy-2-oxo-2h-chromen-3-yl) NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD ro-37-9790 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD bms 275291 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Kaposi Sarcoma[MeSHID:D012514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 3 matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD 5-hexyl-5-phenyl-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD sc-74020 small molecule NA experimental 72 kda type iv collagenase MMP2 NA unknown NA drugbank 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD pmid29130358-compound-figure16(9b) NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB neovastat NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD pd-169469 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD 3-(4-phenylethynylbenzoyl)nonanoic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD n-hydroxy-3-(2-oxo-2h-chromen-3-yl)propanamide NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD epigallocatechin gallate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] phase 3 matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB folate gamma-l-proline-hydroxamic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD halofuginone small molecule Scleroderma[MeSHID:D012594],Malignant Neoplasms[MeSHID:D009369],Systemic Scleroderma[MeSHID:D012595] investigational,vet_approved 72 kda type iv collagenase MMP2 NA unknown NA drugbank gm6001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Corneal Ulcer[MeSHID:D003320] discontinued in phase 2 matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB 5-(4-phenoxy-phenyl)-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD endostatin biotech Neoplasms[MeSHID:D009369],Diabetic Retinopathy[MeSHID:D003930],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational 72 kda type iv collagenase MMP2 NA unknown NA drugbank (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD uk-356618 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD rs-130830 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD n-hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD marimastat NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] phase 3 matrix metalloproteinase-2 MMP2 Successful target unknown 3.37 TTD , DGIDB [2-(biphenyl-4-sulfonyl)phenyl]acetic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD roche 28-2653 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD clinopodic acid c NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD 5-biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD pmid29130358-compound-figure18(14) NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB galarubicin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved 72 kda type iv collagenase MMP2 NA inhibitor NA drugbank lithospermic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD marimastat NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] phase 3 matrix metalloproteinase-2 MMP2 Successful target inhibitor 3.37 TTD , DGIDB 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational 72 kda type iv collagenase MMP2 NA inhibitor 3.37 drugbank , DGIDB pmid29130358-compound-figure16(9a) NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB ik-862 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD ro-26-2853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB pmid29130358-compound-sb-3ct NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB pmid29130358-compound-figure18(14a) NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB folate gamma-hydroxamic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD pmid29130358-compound-figure13(4) NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB tanomastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Degenerative polyarthritis[MeSHID:D010003],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of ovary[MeSHID:D010051] discontinued in phase 3 matrix metalloproteinase-2 MMP2 Successful target inhibitor 2.36 TTD , DGIDB ae-941 small molecule Disease[MeSHID:D004194],Malignant neoplasm of kidney[MeSHID:D007680],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Age related macular degeneration[MeSHID:D008268],Multiple Myeloma[MeSHID:D009101],Psoriasis[MeSHID:D011565] investigational 72 kda type iv collagenase MMP2 NA unknown NA drugbank , DGIDB pmid29130358-compound-figure16(9c) NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB pmid29130358-compound-figure11(3) NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB mmi270 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD sr-973 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD pmid29130358-compound-lonimacranthoidevii NA NA patented matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD , DGIDB methotrexate gamma-l-proline-hydroxamic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD pnu-107859 NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD metastat NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 matrix metalloproteinase-2 MMP2 Successful target unknown 2.36 TTD , DGIDB 5-biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved 72 kda type iv collagenase MMP2 NA inhibitor NA drugbank cis-2-aminocyclohexylcarbamoylphosphonic acid NA NA investigative matrix metalloproteinase-2 MMP2 Successful target unknown NA TTD prinomastat NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] approved matrix metalloproteinase-2 MMP2 Successful target unknown 0.67 TTD , DGIDB marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-20 MMP20 NA inhibitor NA drugbank n-isobutyl-n-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid small molecule NA experimental matrix metalloproteinase-20 MMP20 NA unknown NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-21 MMP21 NA inhibitor NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-23 MMP23A NA inhibitor NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-24 MMP24 NA inhibitor NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-25 MMP25 NA inhibitor NA drugbank fenofibrate small molecule Hypertriglyceridemia[MeSHID:D015228],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved matrix metalloproteinase-25 MMP25 NA inhibitor NA drugbank fenofibric acid small molecule Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved matrix metalloproteinase-25 MMP25 NA unknown NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-26 MMP26 NA inhibitor NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-27 MMP27 NA inhibitor NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-28 MMP28 NA inhibitor NA drugbank uk-356618 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target inhibitor 4.24 TTD , DGIDB pnu-107859 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD n-hydroxy-4-[(4-methoxylphenyl)sulfonyl]-2,2-dimethyl-hexahydro-1,4-thiazepine-3(s)-carboxamide small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank n-isobutyl-n-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 2-[3-(5-mercapto-[1,3,4]thiadiazol-2yl)-ureido]-n-methyl-3-pentafluorophenyl-propionamide small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank n-[[2-methyl-4-hydroxycarbamoyl]but-4-yl-n]-benzyl-p-[phenyl]-p-[methyl]phosphinamid small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 3-[(4'-cyanobiphenyl-4-yl)oxy]-n-hydroxypropanamide small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank n-hydroxy 1n(4-methoxyphenyl)sulfonyl-4-(z,e-n-methoxyimino)pyrrolidine-2r-carboxamide small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank ro-37-9790 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD r-2-{[4'-methoxy-(1,1'-biphenyl)-4-yl]-sulfonyl}-amino-6-methoxy-hex-4-ynoic acid small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 4-methoxybenzenesulfinate small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank rs-130830 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD a disubstituted succinyl caprolactam hydroxymate mmp3inhibitor small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank pd-169469 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD hydroxyaminovaline small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 2-(2-{2-[(biphenyl-4-ylmethyl)-amino]-3-mercapto-pentanoylamino}-acetylamino)-3-methyl-butyric acid methyl ester small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank mmi270 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD pmid29130358-compound-figure10(2a) NA NA patented matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD , DGIDB cm-352 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target inhibitor NA TTD , DGIDB gm6001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Corneal Ulcer[MeSHID:D003320] discontinued in phase 2 matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD , DGIDB am-2s NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD [4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetic acid small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank ik-862 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD pg-530742 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] discontinued in phase 2 matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD 1-methyloxy-4-sulfone-benzene NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD 3-(1h-indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 1-benzyl-3-(4-methoxy-benzenesulfonyl)-6-oxo-hexahydro-pyrimidine-4-carboxylic acid hydroxyamide small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 2-[3-(5-mercapto-[1,3,4]thiadiazol-2-yl)-ureido]-n-methyl-3-phenyl-propionamide small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational stromelysin-1 MMP3 NA antagonist 2.42 drugbank , DGIDB batimastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] preclinical matrix metalloproteinase-3 MMP3 Patented-recorded target inhibitor 1.06 TTD , DGIDB hydroxyaminovaline NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD (1n)-4-n-butoxyphenylsulfonyl-(2r)-n-hydroxycarboxamido-(4s)-methanesulfonylamino-pyrrolidine small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank rs-39066 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD n-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonyl-piperazine-2-carboxamide small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 8-chloro-quinoline-3-carbonitrile NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD pnu-142372 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD pkf-242-484 NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD 3-methylpyridine NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational stromelysin-1 MMP3 NA antagonist,inhibitor 2.42 drugbank , DGIDB [2-(5-mercapto-[1,3,4]thiadiazol-2-ylcarbamoyl)-1-phenyl-ethyl]-carbamic acid benzyl ester small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 5-biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD 3-methylpyridine small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank 5-methyl-5-(4-phenoxy-phenyl)-pyrimidine-2,4,6-trione small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank futoenone NA NA investigative matrix metalloproteinase-3 MMP3 Patented-recorded target unknown NA TTD n~2~-(biphenyl-4-ylsulfonyl)-n-hydroxy-n~2~-(2-hydroxyethyl)glycinamide small molecule NA experimental stromelysin-1 MMP3 NA unknown NA drugbank sl422 NA NA investigative matrix metalloproteinase-7 MMP7 Successful target inhibitor NA TTD , DGIDB marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrilysin MMP7 NA antagonist,inhibitor 6.06 drugbank , DGIDB ik-862 NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD marimastat NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] phase 3 matrix metalloproteinase-7 MMP7 Successful target unknown 6.06 TTD , DGIDB mmi270 NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD sr-973 NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD bms 275291 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Kaposi Sarcoma[MeSHID:D012514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 3 matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD n-hydroxy-2,3-bis(phenylsulfonamido)propanamide NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD n4-hydroxy-2-isobutyl-n1-(9-oxo-1,8-diaza-tricyclo[10.6.1.013,18]nonadeca-12(19),13,15,17-tetraen-10-yl)-succinamide small molecule NA experimental matrilysin MMP7 NA unknown NA drugbank (1r)-n,6-dihydroxy-7-methoxy-2-[(4-methoxyphenyl)sulfonyl]-1,2,3,4-tetrahydroisoquinoline-1-carboxamide small molecule NA experimental matrilysin MMP7 NA unknown NA drugbank folate gamma-hydroxamic acid NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD 3-cyclohexanesulfonyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD marimastat NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] phase 3 matrix metalloproteinase-7 MMP7 Successful target inhibitor 6.06 TTD , DGIDB rs-39066 NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD prinomastat NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] approved matrix metalloproteinase-7 MMP7 Successful target unknown 1.52 TTD , DGIDB 3-benzenesulfonyl-heptanoic acid hydroxyamide NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD folate gamma-l-phenylalaninehydroxamic acid NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD folate gamma-l-proline-hydroxamic acid NA NA investigative matrix metalloproteinase-7 MMP7 Successful target unknown NA TTD marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrilysin MMP7 NA antagonist 6.06 drugbank , DGIDB 5-methyl-3-(9-oxo-1,8-diaza-tricyclo[10.6.1.013,18]nonadeca-12(19),13,15,17-tetraen-10-ylcarbamoyl)-hexanoic acid small molecule NA experimental matrilysin MMP7 NA unknown NA drugbank batimastat small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] experimental neutrophil collagenase MMP8 NA unknown NA drugbank ro-37-9790 NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-propane-1-thiol NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 2-thiomethyl-3-phenylpropanoic acid NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 2-(biphenyl-4-ylsulfonyl)n-hydroxybenzamide NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD n-{2-[(4'-cyano-1,1'-biphenyl-4-yl)oxy]ethyl}-n'-hydroxy-n-methylurea small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank ik-862 NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD but-3-enyl-[5-(4-chloro-phenyl)-3,6-dihydro-[1,3,4]thiadiazin-2-ylidene]-amine small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 2-thiomethyl-3-phenylpropanoic acid small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank (1r)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank glycinamide small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank 1-hydroxyamine-2-isobutylmalonic acid NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 3-(4-methoxy-benzenesulfonyl)-cyclohexanethiol NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD n-hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD [2-(biphenyl-4-sulfonyl)phenyl]acetic acid NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 1-hydroxyamine-2-isobutylmalonic acid small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank sl422 NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target inhibitor NA TTD , DGIDB 5-[4-(2-hydroxyethyl)-1-piperidinyl]-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrione small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank methylamino-phenylalanyl-leucyl-hydroxamic acid small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank 3-(4-phenoxy-benzenesulfonyl)-cyclohexanethiol NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational neutrophil collagenase MMP8 NA inhibitor NA drugbank 3-formyl-2-hydroxy-5-methyl-hexanoic acid hydroxyamide small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank glycinamid NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD (1s)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank cipemastat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 3 matrix metalloproteinase-8 MMP8 Clinical trial target unknown 4.55 TTD , DGIDB 3-(4-phenoxy-benzenesulfonyl)-propane-1-thiol NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 3-amino-azacyclotridecan-2-one small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank (5s)-5-(2-amino-2-oxoethyl)-4-oxo-n-[(3-oxo-3,4-dihydro-2h-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamide small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank 2-hydroxycarbamoyl-4-methyl-pentanoic acid NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD gm6001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Corneal Ulcer[MeSHID:D003320] discontinued in phase 2 matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD , DGIDB methylamino-phenylalanyl-leucyl-hydroxamic acid NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 3-amino-azacyclotridecan-2-one NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD 2-(biphenyl-4-sulfonyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid small molecule NA experimental neutrophil collagenase MMP8 NA unknown NA drugbank 2-(biphenyl-4-ylsulfonamido)pentanedioic acid NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD mmi270 NA NA investigative matrix metalloproteinase-8 MMP8 Clinical trial target unknown NA TTD folate gamma-hydroxamic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD pmid29130358-compound-lonimacranthoidevii NA NA patented matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational matrix metalloproteinase-9 MMP9 NA unknown NA drugbank dx-2802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB gs-5745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Ulcerative Colitis[MeSHID:D003093],Malignant Neoplasms[MeSHID:D009369],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] phase 3 matrix metalloproteinase-9 MMP9 Clinical trial target unknown 12.73 TTD , DGIDB 2-(biphenyl-4-ylsulfonyl)n-hydroxybenzamide NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD methotrexate gamma-l-proline-hydroxamic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD sr-973 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 matrix metalloproteinase-9 MMP9 Clinical trial target unknown 0.06 TTD , DGIDB 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD pmid29130358-compound-figure13(4) NA NA patented matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB pmid29130358-compound-figure17(12) NA NA patented matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB methotrexate gamma-hydroxamic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD 3-(4-phenylethynylbenzoyl)nonanoic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD [2-(biphenyl-4-sulfonyl)phenyl]acetic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational matrix metalloproteinase-9 MMP9 NA unknown NA drugbank n-hydroxy-3-(2-oxo-2h-chromen-3-yl)propanamide NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD pmid15055993c1a NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD andecaliximab NA Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 matrix metalloproteinase-9 MMP9 Clinical trial target unknown 12.73 TTD , DGIDB uk-356618 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD pmid29130358-compound-figure18(14a) NA NA patented matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB 5-hexyl-5-phenyl-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD ik-862 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD dp-b99 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB pmid29130358-compound-figure17(10) NA NA patented matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB pmid29130358-compound-figure17(13) NA NA patented matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB (2r)-2-amino-3,3,3-trifluoro-n-hydroxy-2-{[(4-phenoxyphenyl)sulfonyl]methyl}propanamide small molecule NA experimental matrix metalloproteinase-9 MMP9 NA unknown NA drugbank andecaliximab NA Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 matrix metalloproteinase-9 MMP9 Clinical trial target inhibitor 12.73 TTD , DGIDB (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD blz-100 NA Primary malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] phase 1/2 matrix metalloproteinase-9 MMP9 Clinical trial target unknown 2.12 TTD , DGIDB 5-methyl-5-phenyl-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD ro-37-9790 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD 5-biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD (3r)-4,4-difluoro-3-[(4-methoxyphenyl)sulfonyl]butanoic acid small molecule NA experimental matrix metalloproteinase-9 MMP9 NA unknown NA drugbank minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational matrix metalloproteinase-9 MMP9 NA inhibitor NA drugbank arp100 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD 2-amino-n,3,3-trimethylbutanamide small molecule NA experimental,investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , drugbank 2-(biphenyl-4-ylsulfonamido)pentanedioic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD glutathione small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational,nutraceutical matrix metalloproteinase-9 MMP9 NA unknown NA drugbank 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD marimastat small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175] investigational matrix metalloproteinase-9 MMP9 NA inhibitor 3.64 drugbank , DGIDB pmid29130358-compound-sb-3ct NA NA patented matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB galarubicin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved matrix metalloproteinase-9 MMP9 NA inhibitor NA drugbank mmi270 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD 5-(4-phenoxyphenyl)-5-(4-pyrimidin-2-ylpiperazin-1-yl)pyrimidine-2,4,6(2h,3h)-trione small molecule NA experimental matrix metalloproteinase-9 MMP9 NA unknown NA drugbank ro 28-2653 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD pg-530742 small molecule Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] investigational matrix metalloproteinase-9 MMP9 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental matrix metalloproteinase-9 MMP9 NA binder NA drugbank n-hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD 2-{[formyl(hydroxy)amino]methyl}-4-methylpentanoic acid small molecule NA experimental matrix metalloproteinase-9 MMP9 NA unknown NA drugbank endostatin biotech Neoplasms[MeSHID:D009369],Diabetic Retinopathy[MeSHID:D003930],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational matrix metalloproteinase-9 MMP9 NA unknown NA drugbank n-hydroxy-2,3-bis(phenylsulfonamido)propanamide NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD gm6001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Corneal Ulcer[MeSHID:D003320] discontinued in phase 2 matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB rs-130830 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD methotrexate gamma-l-phenylalaninehydroxamic acid NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD pmid23631440c29e NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD 5-biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD ae-941 small molecule Disease[MeSHID:D004194],Malignant neoplasm of kidney[MeSHID:D007680],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Age related macular degeneration[MeSHID:D008268],Multiple Myeloma[MeSHID:D009101],Psoriasis[MeSHID:D011565] investigational matrix metalloproteinase-9 MMP9 NA unknown NA drugbank , DGIDB neovastat NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational matrix metalloproteinase-9 MMP9 NA binder NA drugbank 5-(4-phenoxy-phenyl)-pyrimidine-2,4,6-trione NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD n-hydroxy-3-(6-methoxy-2-oxo-2h-chromen-3-yl) NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD sl422 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target inhibitor NA TTD , DGIDB pmid29130358-compound-figure17(11) NA NA patented matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD , DGIDB andecaliximab NA Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 matrix metalloproteinase-9 MMP9 Clinical trial target antibody 12.73 TTD , DGIDB carboxylated glucosamine NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown 8.49 TTD , DGIDB roche 28-2653 NA NA investigative matrix metalloproteinase-9 MMP9 Clinical trial target unknown NA TTD captopril small molecule Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved matrix metalloproteinase-9 MMP9 NA inhibitor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical molybdenum cofactor sulfurase MOCOS NA cofactor NA drugbank alxn1101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Combined molybdoflavoprotein enzyme deficiency[MeSHID:C535811] phase 2/3 cyclic pyranopterin monophosphate synthase MOCS1 Clinical trial target unknown NA TTD , DGIDB fosdenopterin small molecule Combined molybdoflavoprotein enzyme deficiency[MeSHID:C535811],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved molybdopterin synthase catalytic subunit MOCS2 NA substrate NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental dna-3-methyladenine glycosylase MPG NA cofactor NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational dna-3-methyladenine glycosylase MPG NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational dna-3-methyladenine glycosylase MPG NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational dna-3-methyladenine glycosylase MPG NA cofactor NA drugbank cisplatin small molecule ovarian neoplasm[MeSHID:D010051],Testicular Neoplasms[MeSHID:D013736],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Osteosarcoma[MeSHID:D012516] approved dna-3-methyladenine glycosylase MPG NA unknown NA drugbank revolade/promacta NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver[MeSHID:D008099],Thrombocytopenia[MeSHID:D013921],Chronic disease[MeSHID:D002908],Immune thrombocytopenic purpura[MeSHID:D016553] approved thrombopoietin receptor MPL Successful target unknown NA TTD , DGIDB sts-t4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] investigative thrombopoietin receptor MPL Successful target unknown NA TTD romiplostim biotech Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved thrombopoietin receptor MPL Successful target agonist 4.34 TTD , drugbank , DGIDB as-1670542 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune thrombocytopenic purpura[MeSHID:D016553],Thrombocytopenia[MeSHID:D013921] approved thrombopoietin receptor MPL Successful target unknown NA TTD , DGIDB sb-559448 small molecule Thrombocytopenia[MeSHID:D013921] investigational thrombopoietin receptor MPL NA unknown NA drugbank , DGIDB thrombomer NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] investigative thrombopoietin receptor MPL Successful target unknown NA TTD sb-559457 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] investigative thrombopoietin receptor MPL Successful target unknown NA TTD avatrombopag small molecule Liver[MeSHID:D008099],Chronic disease[MeSHID:D002908],Thrombocytopenia[MeSHID:D013921] approved,investigational thrombopoietin receptor MPL NA agonist 2.48 drugbank , DGIDB thrombopoietin biotech Thrombocytopenia[MeSHID:D013921] investigational thrombopoietin receptor MPL NA agonist NA drugbank , DGIDB non-peptide tpo mimics NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] investigative thrombopoietin receptor MPL Successful target unknown NA TTD rhtpo NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune thrombocytopenic purpura[MeSHID:D016553] discontinued in phase 3 thrombopoietin receptor MPL Successful target unknown NA TTD eltrombopag small molecule Thrombopoiesis[MeSHID:D034061],Bone Tissue[MeSHID:D001842],Blood Platelets[MeSHID:D001792],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune thrombocytopenic purpura[MeSHID:D016553],Thrombocytopenia[MeSHID:D013921] approved thrombopoietin receptor MPL Successful target agonist 4.13 TTD , drugbank , DGIDB lusutrombopag small molecule Liver[MeSHID:D008099],Chronic disease[MeSHID:D002908],Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational thrombopoietin receptor MPL Successful target agonist 4.82 TTD , drugbank , DGIDB nip-004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] phase 1 thrombopoietin receptor MPL Successful target unknown NA TTD , DGIDB se-et-tp020d NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] investigative thrombopoietin receptor MPL Successful target unknown NA TTD bvi-007 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombus[MeSHID:D013927],Myocardial Infarction[MeSHID:D009203] phase 1 thrombopoietin receptor MPL Successful target unknown NA TTD , DGIDB lgd-4665 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune thrombocytopenic purpura[MeSHID:D016553] phase 2 thrombopoietin receptor MPL Successful target unknown NA TTD , DGIDB hl-034 NA NA investigative thrombopoietin receptor MPL Successful target unknown NA TTD totrombopag NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] discontinued in phase 1 thrombopoietin receptor MPL Successful target unknown NA TTD ri-tpo NA NA investigative thrombopoietin receptor MPL Successful target unknown NA TTD cefdinir small molecule Otitis Media[MeSHID:D010033],Tonsillitis[MeSHID:D014069],Skin Diseases, Infectious[MeSHID:D012874],Pneumonia[MeSHID:D011014],Ear structure[MeSHID:D004423],Pharyngeal structure[MeSHID:D010614],Pharyngitis[MeSHID:D010612],Nose[MeSHID:D009666],Infection[MeSHID:D007239],Maxillary Sinusitis[MeSHID:D015523],Bronchitis, Chronic[MeSHID:D029481],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved myeloperoxidase MPO NA inhibitor NA drugbank nomifensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,withdrawn myeloperoxidase MPO NA unknown NA drugbank azd-3241 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 myeloperoxidase MPO Clinical trial target unknown NA TTD , DGIDB azd5904 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Multiple Sclerosis[MeSHID:D009103] discontinued in phase 1 myeloperoxidase MPO Clinical trial target inhibitor NA TTD , DGIDB mesalazine small molecule Crohn's disease of large bowel[MeSHID:D003424],ileum[MeSHID:D007082],Ulcerative Colitis[MeSHID:D003093],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved myeloperoxidase MPO NA unknown NA drugbank 4-aminobenzoic acid hydrazide NA NA investigative myeloperoxidase MPO Clinical trial target unknown NA TTD inv-311 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chromosome inversion[MeSHID:D007446],Inflammation[MeSHID:D007249] investigative myeloperoxidase MPO Clinical trial target unknown NA TTD e-101 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 myeloperoxidase MPO Clinical trial target unknown NA TTD , DGIDB azd4831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 1 myeloperoxidase MPO Clinical trial target unknown NA TTD , DGIDB levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational myeloperoxidase MPO NA unknown NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved myeloperoxidase MPO NA inhibitor NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved myeloperoxidase MPO NA inhibitor NA drugbank antithymocyte immunoglobulin (rabbit) biotech Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668] approved major histocompatibility complex class i-related gene protein MR1 NA antagonist NA drugbank technetium tc-99m tilmanocept small molecule Disease Management[MeSHID:D019468],Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],lymph nodes[MeSHID:D008198],Squamous cell carcinoma[MeSHID:D002294],Lymphatic vessel[MeSHID:D042601],Malignant neoplasm of breast[MeSHID:D001943],Gamma Rays[MeSHID:D005720],Dental caries[MeSHID:D003731] approved,investigational macrophage mannose receptor 1 MRC1 NA ligand NA drugbank plazomicin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Prostatic Diseases[MeSHID:D011469],Urinary tract infection[MeSHID:D014552],Bronchitis[MeSHID:D001991] approved mitochondrial rrna methyltransferase 2 MRM2 Successful target unknown 63.65 TTD , DGIDB obinutuzumab NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved leukocyte surface antigen leu-16 MS4A1 Successful target unknown 28.29 TTD , DGIDB dxl-625 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] investigative leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD rituximab biotech Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved b-lymphocyte antigen cd20 MS4A1 NA antibody,inhibitor 3.03 drugbank , DGIDB rituximab biotech Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-lymphocyte antigen cd20 MS4A1 NA antibody 3.03 drugbank , DGIDB rituximab biotech Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved b-lymphocyte antigen cd20 MS4A1 NA antibody 3.03 drugbank , DGIDB ibritumomab tiuxetan biotech Lymphoma, Non-Hodgkin[MeSHID:D008228] approved,investigational b-lymphocyte antigen cd20 MS4A1 NA antibody NA drugbank , DGIDB sait101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD ibritumomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] approved leukocyte surface antigen leu-16 MS4A1 Successful target unknown 14.14 TTD , DGIDB 2lm20-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD ofatumumab biotech Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Chronic Lymphocytic Leukemia[MeSHID:D015451],Syndrome[MeSHID:D013577],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rheumatoid Arthritis[MeSHID:D001172] approved b-lymphocyte antigen cd20 MS4A1 NA antibody,inhibitor 31.83 drugbank , DGIDB sbi-087 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103],Rheumatoid Arthritis[MeSHID:D001172] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB obinutuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved,investigational b-lymphocyte antigen cd20 MS4A1 NA antibody,inhibitor 28.29 drugbank , DGIDB rg7828 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown 3.54 TTD , DGIDB anti-cd19/20-car vector-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Prolymphocytic Leukemia[MeSHID:D015463],Lymphoma, Follicular[MeSHID:D008224] clinical trial leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB rg6062 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD obinutuzumab biotech Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved,investigational b-lymphocyte antigen cd20 MS4A1 NA antibody 28.29 drugbank , DGIDB veltuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Lupus Erythematosus, Systemic[MeSHID:D008180],Chronic Lymphocytic Leukemia[MeSHID:D015451],Thrombocytopenia[MeSHID:D013921],Malignant Neoplasms[MeSHID:D009369] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target antibody 10.61 TTD , DGIDB 4scar19 and 4scar20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB cart20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB ocrelizumab NA Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Multiple Sclerosis[MeSHID:D009103] approved leukocyte surface antigen leu-16 MS4A1 Successful target unknown 21.22 TTD , DGIDB cd19 and cd20 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB cd20-car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB veltuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Lupus Erythematosus, Systemic[MeSHID:D008180],Chronic Lymphocytic Leukemia[MeSHID:D015451],Thrombocytopenia[MeSHID:D013921],Malignant Neoplasms[MeSHID:D009369] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown 10.61 TTD , DGIDB cart-20 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Cells[MeSHID:D002477] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB ocrelizumab biotech Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Multiple Sclerosis[MeSHID:D009103] approved,investigational b-lymphocyte antigen cd20 MS4A1 NA antagonist,antibody 21.22 drugbank , DGIDB pbcar20a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD epcoritamab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD iboctadekin + rituximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Atrial Fibrillation[MeSHID:D001281], Non-Hodgkin[MeSHID:D008228] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB atm avi NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB mosunetuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD ofatumumab NA Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Chronic Lymphocytic Leukemia[MeSHID:D015451],Syndrome[MeSHID:D013577],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rheumatoid Arthritis[MeSHID:D001172] approved leukocyte surface antigen leu-16 MS4A1 Successful target unknown 31.83 TTD , DGIDB ame-133v NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Apparent mineralocorticoid excess[MeSHID:C537422] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown 1.77 TTD , DGIDB tru-015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown 3.54 TTD , DGIDB gen3013 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD igm-2323 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD mb-cart20.1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB tositumomab biotech Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational b-lymphocyte antigen cd20 MS4A1 NA antibody 45.97 drugbank , DGIDB di-leu16-il2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Cell Lymphomas[MeSHID:D016393] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB technetium tc-99m nofetumomab merpentan small molecule Cells[MeSHID:D002477],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Growth[MeSHID:D006128],Syndrome[MeSHID:D013577] approved,withdrawn b-lymphocyte antigen cd20 MS4A1 NA binder NA drugbank blx-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] investigative leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD tositumomab biotech Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational b-lymphocyte antigen cd20 MS4A1 NA antibody,inhibitor 45.97 drugbank , DGIDB 227th-rituximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD regn1979 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown 3.54 TTD , DGIDB bevacizumab + rituximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Lymphoma[MeSHID:D008223] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB ublituximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Chronic Lymphocytic Leukemia[MeSHID:D015451],Multiple Sclerosis[MeSHID:D009103] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target antibody 10.61 TTD , DGIDB fbt-a05 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown 3.54 TTD , DGIDB veltuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Lupus Erythematosus, Systemic[MeSHID:D008180],Chronic Lymphocytic Leukemia[MeSHID:D015451],Thrombocytopenia[MeSHID:D013921],Malignant Neoplasms[MeSHID:D009369] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target inhibitor 10.61 TTD , DGIDB ofatumumab NA Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Chronic Lymphocytic Leukemia[MeSHID:D015451],Syndrome[MeSHID:D013577],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rheumatoid Arthritis[MeSHID:D001172] approved leukocyte surface antigen leu-16 MS4A1 Successful target antibody 31.83 TTD , DGIDB car-20/19-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],T-Lymphocyte[MeSHID:D013601],Pancreatic carcinoma[MeSHID:C562463],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB mk-8808 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Rheumatoid Arthritis[MeSHID:D001172] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB ublituximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Chronic Lymphocytic Leukemia[MeSHID:D015451],Multiple Sclerosis[MeSHID:D009103] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target unknown 10.61 TTD , DGIDB rituximab NA Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukocyte surface antigen leu-16 MS4A1 Successful target unknown 3.03 TTD , DGIDB medi-552 NA NA investigative leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD anti-cd20 engineered toxin bodies NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] investigative leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD tositumomab NA Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukocyte surface antigen leu-16 MS4A1 Successful target antibody 45.97 TTD , DGIDB cd20bi aatc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB cd20-cart NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB rituximab NA Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved leukocyte surface antigen leu-16 MS4A1 Successful target inhibitor 3.03 TTD , DGIDB obinutuzumab NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved leukocyte surface antigen leu-16 MS4A1 Successful target inhibitor 28.29 TTD , DGIDB anti-cd20 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],T-Lymphocyte[MeSHID:D013601] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB cd20-specific car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Lymphoma[MeSHID:D008223],T-Lymphocyte[MeSHID:D013601],Chronic Lymphocytic Leukemia[MeSHID:D015451], Follicular[MeSHID:D008224] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB ofatumumab NA Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Chronic Lymphocytic Leukemia[MeSHID:D015451],Syndrome[MeSHID:D013577],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rheumatoid Arthritis[MeSHID:D001172] approved leukocyte surface antigen leu-16 MS4A1 Successful target inhibitor 31.83 TTD , DGIDB rituximab NA Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved leukocyte surface antigen leu-16 MS4A1 Successful target antibody 3.03 TTD , DGIDB anti-cd19 anti-cd20 bispecific car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB car-t cells targeting cd20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB rituximab NA Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukocyte surface antigen leu-16 MS4A1 Successful target inhibitor 3.03 TTD , DGIDB ata2431 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] preclinical leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD iodine-131-tositumomab NA NA phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB anti-cd20-car vector-transduced autologous t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Hematopoietic Neoplasms[MeSHID:D019337],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Prolymphocytic Leukemia[MeSHID:D015463],Lymphoma, Follicular[MeSHID:D008224] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB tositumomab NA Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukocyte surface antigen leu-16 MS4A1 Successful target inhibitor 45.97 TTD , DGIDB pf-05280586 NA Cluster Headache[MeSHID:D003027],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB tositumomab NA Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukocyte surface antigen leu-16 MS4A1 Successful target unknown 45.97 TTD , DGIDB rituximab NA Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved leukocyte surface antigen leu-16 MS4A1 Successful target antibody 3.03 TTD , DGIDB anti-cd20-car-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB rituximab biotech Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-lymphocyte antigen cd20 MS4A1 NA antibody,inhibitor 3.03 drugbank , DGIDB obinutuzumab NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved leukocyte surface antigen leu-16 MS4A1 Successful target antibody 28.29 TTD , DGIDB bvx-20-cd20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] investigative leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD cd20 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB ofatumumab biotech Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Chronic Lymphocytic Leukemia[MeSHID:D015451],Syndrome[MeSHID:D013577],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Rheumatoid Arthritis[MeSHID:D001172] approved b-lymphocyte antigen cd20 MS4A1 NA antibody 31.83 drugbank , DGIDB rituximab NA Microscopic Polyarteritis[MeSHID:D055953],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Granulomatosis with polyangiitis[MeSHID:D014890],Pemphigus Vulgaris[MeSHID:D010392],Unmarried[MeSHID:D012847],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved leukocyte surface antigen leu-16 MS4A1 Successful target unknown 3.03 TTD , DGIDB tisagenlecleucel NA Relapse[MeSHID:D012008],Neoplasm Metastasis[MeSHID:D009362],Burkitt Lymphoma[MeSHID:D002051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphoma, Follicular[MeSHID:D008224] approved leukocyte surface antigen leu-16 MS4A1 Successful target unknown 1.77 TTD , DGIDB mt-3724 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] phase 2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD ibritumomab tiuxetan biotech Lymphoma, Non-Hodgkin[MeSHID:D008228] approved,investigational b-lymphocyte antigen cd20 MS4A1 NA antibody 3.54 drugbank , DGIDB ublituximab + umbralisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 3 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB anti-cd19 and anti-cd20 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],T-Lymphocyte[MeSHID:D013601] phase 1/2 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB ocrelizumab NA Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Multiple Sclerosis[MeSHID:D009103] approved leukocyte surface antigen leu-16 MS4A1 Successful target antibody 21.22 TTD , DGIDB cd20-cd19 ccar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD xmab13676 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Cell Lymphomas[MeSHID:D016393] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown 3.54 TTD , DGIDB anti-cd-20 mab NA NA investigative leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD bm-ca NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hippocampus Proper[MeSHID:D006624] phase 1 leukocyte surface antigen leu-16 MS4A1 Successful target unknown NA TTD , DGIDB omalizumab biotech Asthma[MeSHID:D001249],Inspiration function[MeSHID:D001239],Urticaria[MeSHID:D014581],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational high affinity immunoglobulin epsilon receptor subunit beta MS4A2 NA inhibitor 106.09 drugbank , DGIDB anti-mesothelin car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Cells[MeSHID:D002477],Mesothelioma[MeSHID:D008654] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB amatuximab biotech NA investigational mesothelin MSLN NA unknown 190.95 drugbank , DGIDB cart-meso cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Cells[MeSHID:D002477] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB morab-009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mesothelioma[MeSHID:D008654] phase 2 mesothelin MSLN Clinical trial target unknown 190.95 TTD , DGIDB ss1(dsfv)-pe38 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB car-t cells targeting mesothelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of lung[MeSHID:D008175],cervical cancer[MeSHID:D002583] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB mcy-m11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fallopian Tube Carcinoma[MeSHID:D005185],Malignant Neoplasms[MeSHID:D009369],Peritoneum[MeSHID:D010537],Malignant neoplasm of ovary[MeSHID:D010051],Mesothelioma[MeSHID:D008654] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD anti-mesothelin car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB hu-cart meso cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Malignant neoplasm of lung[MeSHID:D008175],Cells[MeSHID:D002477],Pleura[MeSHID:D010994],Malignant neoplasm of ovary[MeSHID:D010051],Mesothelioma[MeSHID:D008654] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB ata3271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Mesothelioma[MeSHID:D008654] preclinical mesothelin MSLN Clinical trial target unknown NA TTD crs-207 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Craniosynostosis[MeSHID:D003398],Malignant neoplasm of ovary[MeSHID:D010051],Mesothelioma[MeSHID:D008654] phase 2 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB car-t cells targeting mesothelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB anti-mesothelin car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB hucart-meso cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Lymphatic Diseases[MeSHID:D008206],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB ata2271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mesothelioma[MeSHID:D008654] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD cartmeso/19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB cart-meso cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Cells[MeSHID:D002477] clinical trial mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB car-t cells targeting mesothelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1/2 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB 227th-labelled msln-ttc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mesothelioma[MeSHID:D008654] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD rg7882 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Malignant neoplasm of ovary[MeSHID:D010051],Pancreatic carcinoma[MeSHID:C562463] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB anti-meso-car vector transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant mesothelioma[MeSHID:C562839],Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of pancreas[MeSHID:D010190],T-Lymphocyte[MeSHID:D013601],Pancreatic carcinoma[MeSHID:C562463],Triple Negative Breast Neoplasms[MeSHID:D064726],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB hpn536 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 mesothelin MSLN Clinical trial target unknown NA TTD car-t cells targeting mesothelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of lung[MeSHID:D008175],cervical cancer[MeSHID:D002583] phase 1/2 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB bay 94-9343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB meso-cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB cart-meso-19 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB car-t cells targeting mesothelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB anti-mesothelin car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Cells[MeSHID:D002477],Mesothelioma[MeSHID:D008654] phase 1/2 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB mesothelin-targeted t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of breast[MeSHID:D001943] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB anti-meso-car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB anti-mesothelin car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 1/2 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB tc-210 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cholangiocarcinoma[MeSHID:D018281],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of ovary[MeSHID:D010051],Mesothelioma[MeSHID:D008654] phase 1/2 mesothelin MSLN Clinical trial target unknown NA TTD anti-mesothelin car transduced pbl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],cervical cancer[MeSHID:D002583],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of ovary[MeSHID:D010051],Mesothelioma[MeSHID:D008654] phase 1/2 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB amatuximab biotech NA investigational mesothelin MSLN NA inhibitor 190.95 drugbank , DGIDB icasp9m28z t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Pleural Effusion, Malignant[MeSHID:D016066],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Mesothelioma[MeSHID:D008654] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB car-t cells targeting mesothelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1/2 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB autologous t cells transfected with chimeric anti-mesothelin immunoreceptor ss1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 mesothelin MSLN Clinical trial target unknown NA TTD , DGIDB tigapotide NA Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 beta-microseminoprotein MSMB Clinical trial target unknown 63.65 TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical methylsterol monooxygenase 1 MSMO1 NA unknown NA drugbank 1,4-dithiothreitol small molecule NA experimental mitochondrial peptide methionine sulfoxide reductase MSRA NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational macrophage-stimulating protein receptor MST1R NA inhibitor NA drugbank mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 macrophage-stimulating protein receptor MST1R Clinical trial target unknown 0.35 TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 macrophage-stimulating protein receptor MST1R Clinical trial target inhibitor 0.35 TTD , DGIDB anti-ron receptor mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative macrophage-stimulating protein receptor MST1R Clinical trial target unknown NA TTD abc-7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Bone Cysts, Aneurysmal[MeSHID:D017824] investigative macrophage-stimulating protein receptor MST1R Clinical trial target unknown NA TTD aav1-fs344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268],Inclusion Body Myositis (disorder)[MeSHID:D018979] phase 1/2 myostatin MSTN Clinical trial target unknown NA TTD , DGIDB amg 745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Atrophy[MeSHID:D009133] phase 2 growth/differentiation factor 8 MSTN Clinical trial target unknown NA TTD , DGIDB ly2495655 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrophy, Disuse[MeSHID:D020966] phase 2 growth/differentiation factor 8 MSTN Clinical trial target unknown NA TTD , DGIDB domagrozumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 growth/differentiation factor 8 MSTN Clinical trial target unknown 21.22 TTD , DGIDB sar391786 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Atrophy[MeSHID:D009133] phase 2 growth/differentiation factor 8 MSTN Clinical trial target unknown 10.61 TTD , DGIDB stamulumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 growth/differentiation factor 8 MSTN Clinical trial target inhibitor 31.83 TTD , DGIDB srk-015 NA Spinal Muscular Atrophy[MeSHID:D009134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 myostatin MSTN Clinical trial target unknown NA TTD ace-031 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 growth/differentiation factor 8 MSTN Clinical trial target unknown 5.3 TTD , DGIDB myo-029 biotech Muscular Dystrophy[MeSHID:D009136] investigational growth/differentiation factor 8 MSTN NA unknown NA drugbank stamulumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 growth/differentiation factor 8 MSTN Clinical trial target unknown 31.83 TTD , DGIDB pf-06252616 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Dystrophy[MeSHID:D009136] phase 2 growth/differentiation factor 8 MSTN Clinical trial target unknown 21.22 TTD , DGIDB estradiol small molecule Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp synthase subunit a MT-ATP6 NA inhibitor NA drugbank estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp synthase subunit a MT-ATP6 NA unknown NA drugbank estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp synthase subunit a MT-ATP6 NA unknown NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved atp synthase subunit a MT-ATP6 NA unknown NA drugbank estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved atp synthase subunit a MT-ATP6 NA unknown NA drugbank estradiol dienanthate small molecule NA approved,investigational,vet_approved atp synthase subunit a MT-ATP6 NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 1 MT-CO1 NA unknown NA drugbank oxygen small molecule Hypoxia[MeSHID:D000860],Disease[MeSHID:D004194],Body tissue[MeSHID:D014024],Drug Overdose[MeSHID:D062787],Poisoning[MeSHID:D011041],Traumatic injury[MeSHID:D014947],Hyperoxia[MeSHID:D018496],Dyspnea[MeSHID:D004417],Oxygen Consumption[MeSHID:D010101] approved,vet_approved cytochrome c oxidase subunit 1 MT-CO1 NA agonist,activator NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 1 MT-CO1 NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 2 MT-CO2 NA unknown NA drugbank talmapimod small molecule Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146] investigational cytochrome c oxidase subunit 2 MT-CO2 NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 2 MT-CO2 NA unknown NA drugbank cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cytochrome c oxidase subunit 3 MT-CO3 NA unknown NA drugbank n-formylmethionine small molecule NA experimental cytochrome c oxidase subunit 3 MT-CO3 NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b MT-CYB NA unknown NA drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nadh-ubiquinone oxidoreductase chain 1 MT-ND1 NA inhibitor NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-ubiquinone oxidoreductase chain 1 MT-ND1 NA binder NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nadh-ubiquinone oxidoreductase chain 1 MT-ND1 NA unknown 1.61 drugbank , DGIDB n-formylmethionine small molecule NA experimental nadh-ubiquinone oxidoreductase chain 1 MT-ND1 NA unknown NA drugbank methoxyflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nadh-ubiquinone oxidoreductase chain 1 MT-ND1 NA unknown NA drugbank sevoflurane small molecule Maintenance[MeSHID:D008283],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nadh-ubiquinone oxidoreductase chain 1 MT-ND1 NA unknown 1.61 drugbank , DGIDB phenethyl isothiocyanate small molecule NA investigational nadh-ubiquinone oxidoreductase chain 1 MT-ND1 NA unknown NA drugbank desflurane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadh-ubiquinone oxidoreductase chain 1 MT-ND1 NA inhibitor 2.12 drugbank , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-ubiquinone oxidoreductase chain 2 MT-ND2 NA binder NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-ubiquinone oxidoreductase chain 3 MT-ND3 NA binder 63.65 drugbank , DGIDB 6-thiophen-2-yl-imidazo[2,1-b]thiazole NA NA investigative nadh dehydrogenase MT-ND3 Successful target unknown NA TTD 6-thiophen-3-yl-imidazo[2,1-b]thiazole NA NA investigative nadh dehydrogenase MT-ND3 Successful target unknown NA TTD n-formylmethionine NA NA investigative nadh dehydrogenase MT-ND3 Successful target unknown NA TTD nadh NA Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadh dehydrogenase MT-ND3 Successful target unknown 63.65 TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-ubiquinone oxidoreductase chain 4 MT-ND4 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-ubiquinone oxidoreductase chain 4l MT-ND4L NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-ubiquinone oxidoreductase chain 5 MT-ND5 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-ubiquinone oxidoreductase chain 6 MT-ND6 NA unknown NA drugbank nitric oxide small molecule Hypoxia[MeSHID:D000860],Respiratory Failure[MeSHID:D012131],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved metallothionein-1a MT1A NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental metallothionein-1a MT1A NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1A NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational metallothionein-1a MT1A NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational metallothionein-1a MT1A NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational metallothionein-1a MT1A NA unknown NA drugbank nitric oxide small molecule Hypoxia[MeSHID:D000860],Respiratory Failure[MeSHID:D012131],Term Birth[MeSHID:D047929],Tinea Pedis[MeSHID:D014008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved metallothionein-1a MT1A NA unknown NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1B NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1DP NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1E NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1F NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1G NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1H NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1HL1 NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1L NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1M NA binder NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT1X NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational metallothionein-2 MT2A NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational metallothionein-2 MT2A NA unknown NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT2A NA binder NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational metallothionein-2 MT2A NA cofactor NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental metallothionein-2 MT2A NA cofactor NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT3 NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational metallothionein-3 MT3 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental metallothionein-3 MT3 NA cofactor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational metallothionein-3 MT3 NA cofactor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational metallothionein-3 MT3 NA unknown NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MT4 NA binder NA drugbank 5'-deoxy-5'-(methylthio)-tubercidin small molecule NA experimental,investigative s-methyl-5'-thioadenosine phosphorylase MTAP Literature-reported target unknown NA TTD , drugbank 5'-s-methyl-5'-thioadenosine small molecule NA experimental s-methyl-5'-thioadenosine phosphorylase MTAP NA unknown NA drugbank adenine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical s-methyl-5'-thioadenosine phosphorylase MTAP NA unknown NA drugbank formycin small molecule NA experimental,investigative s-methyl-5'-thioadenosine phosphorylase MTAP Literature-reported target unknown NA TTD , drugbank (2s,3s,4r,5s)-2-(4-amino-4,5-dihydro-1h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]-3,4-pyrrolidinediol small molecule NA experimental s-methyl-5'-thioadenosine phosphorylase MTAP NA unknown NA drugbank silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein MTF1 NA binder NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical methionyl-trna formyltransferase, mitochondrial MTFMT NA cofactor NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental c-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 NA unknown NA drugbank ly374571 small molecule NA experimental c-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical c-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 NA unknown NA drugbank ly249543 small molecule NA experimental c-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 NA unknown NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical c-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 NA cofactor NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial MTHFD2 NA cofactor NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial MTHFD2 NA unknown NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical methylenetetrahydrofolate reductase MTHFR NA cofactor NA drugbank ex5 NA NA investigative mthfr messenger rna MTHFR Literature-reported target unknown NA TTD cyanocobalamin small molecule Malignant Neoplasms[MeSHID:D009369],Cestode Infections[MeSHID:D002590],Operative Surgical Procedures[MeSHID:D013514],Pregnancy[MeSHID:D011247],Nose[MeSHID:D009666],Folic Acid Deficiency[MeSHID:D005494],Thyrotoxicosis[MeSHID:D013971],Anemia, Pernicious[MeSHID:D000752],Intestines, Small[MeSHID:D007421],Intestines[MeSHID:D007422],Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Parasitic Diseases[MeSHID:D010272],Celiac Disease[MeSHID:D002446],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Malabsorption Syndrome[MeSHID:D008286],Neurologic Manifestations[MeSHID:D009461],Avitaminosis[MeSHID:D001361],Vitamin B 12 Deficiency[MeSHID:D014806],Malignant neoplasm of pancreas[MeSHID:D010190],Mental concentration[MeSHID:D001288],Hemorrhage[MeSHID:D006470], Hemolytic[MeSHID:D000743],Diphyllobothriasis[MeSHID:D004169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved,nutraceutical methylenetetrahydrofolate reductase MTHFR NA cofactor 5.09 drugbank , DGIDB 677t NA NA investigative mthfr messenger rna MTHFR Literature-reported target unknown NA TTD n-acetylserotonin NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD gr 128107 NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB 2-iodo-melatonin NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB n-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD aae-m-pbp-amine NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB n-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved melatonin receptor type 1a MTNR1A Successful target agonist 3.24 TTD , drugbank , DGIDB n-(3-(3-methoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational melatonin receptor type 1a MTNR1A NA unknown NA drugbank n-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD n-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD agomelatine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational,withdrawn from market melatonin receptor type 1a MTNR1A Successful target agonist 3.98 TTD , drugbank , DGIDB n-(2,3,4,9-tetrahydro-1h-carbazol-3-yl)-acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD ucm 724 NA NA investigative melatonin receptor type 1a MTNR1A Successful target antagonist NA TTD , DGIDB melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved melatonin receptor type 1a MTNR1A Successful target agonist 3.24 TTD , drugbank , DGIDB n-(2,3-dihydro-1h-phenalen-2-yl)-acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD ly-156735 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 melatonin receptor type 1a MTNR1A Successful target unknown NA TTD , DGIDB s26131 NA NA investigative melatonin receptor type 1a MTNR1A Successful target antagonist NA TTD , DGIDB ucm 793 NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB s24773 NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB [125i]div880 NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD tasimelteon small molecule Non-24 Hour Sleep-Wake Disorder[MeSHID:D020178],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational melatonin receptor type 1a MTNR1A Successful target agonist 19.89 TTD , drugbank , DGIDB [125i]sd6 NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB 2-[125i]melatonin NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB dh97 NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD 2-(indolin-1yl)-melatonin NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD (hydroxymethylphenyl)agomelatine NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD s24014 NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB k185 NA NA investigative melatonin receptor type 1a MTNR1A Successful target antagonist NA TTD , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational melatonin receptor type 1a MTNR1A NA unknown NA drugbank n-(3-(2,5-dimethoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD ramelteon small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Sleep Disorders, Circadian Rhythm[MeSHID:D020178],Cessation of life[MeSHID:D003643],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Expiration, function[MeSHID:D045853] approved,investigational melatonin receptor type 1a MTNR1A Successful target multitarget 71.61 TTD , drugbank , DGIDB efppea NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB s22153 NA NA investigative melatonin receptor type 1a MTNR1A Successful target antagonist NA TTD , DGIDB 6-cl-mlt NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB gr 196429 NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB n-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD 5-methoxycarbonylamino-n-acetyltryptamine NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD isoamyl-agomelatine NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD cifea NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD beta,beta-dimethylmelatonin NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD 2-methoxy-alpha,beta-didehydro-agomelatine NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD 6-hydroxymelatonin NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist 1.33 TTD , DGIDB 5-methoxy-luzindole NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD ucm-454 NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD n-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD iik7 NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB s26284 NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB neu-p11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sleeplessness[MeSHID:D007319] phase 2 melatonin receptor type 1a MTNR1A Successful target unknown 2.65 TTD , DGIDB difluoroagomelatine NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB ucm 549 NA NA investigative melatonin receptor type 1a MTNR1A Successful target antagonist NA TTD , DGIDB [125i]s70254 NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD 5-heat NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB 4p-pdot NA NA investigative melatonin receptor type 1a MTNR1A Successful target antagonist NA TTD , DGIDB beta-methylmelatonin NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD n-(3-(3-methoxyphenyl)propyl)propionamide NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD ramelteon small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Sleep Disorders, Circadian Rhythm[MeSHID:D020178],Cessation of life[MeSHID:D003643],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Expiration, function[MeSHID:D045853] approved,investigational melatonin receptor type 1a MTNR1A Successful target multitarget,agonist 71.61 TTD , drugbank , DGIDB cbobnea NA NA investigative melatonin receptor type 1a MTNR1A Successful target agonist NA TTD , DGIDB ucm 765 NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD bomppa NA NA investigative melatonin receptor type 1a MTNR1A Successful target unknown NA TTD n-(3-benzooxazol-7-yl-propyl)-propionamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD beta,beta-dimethylmelatonin NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD tasimelteon small molecule Non-24 Hour Sleep-Wake Disorder[MeSHID:D020178],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational melatonin receptor type 1b MTNR1B Successful target agonist 26.52 TTD , drugbank , DGIDB n-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved melatonin receptor type 1b MTNR1B NA agonist 3.54 drugbank , DGIDB n-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD n-(3-(3-methoxyphenyl)propyl)propionamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD agomelatine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational melatonin receptor type 1b MTNR1B NA agonist 5.3 drugbank , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational melatonin receptor type 1b MTNR1B NA unknown NA drugbank n-(2,3,4,9-tetrahydro-1h-carbazol-3-yl)-acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved melatonin receptor type 1b MTNR1B NA agonist 3.54 drugbank , DGIDB n-(3-(2,5-dimethoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD n-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD n-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational melatonin receptor type 1b MTNR1B NA unknown NA drugbank 2-iodo-melatonin NA NA investigative melatonin receptor type 1b MTNR1B Successful target agonist NA TTD , DGIDB n-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD tepotinib small molecule Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],epithelial to mesenchymal transition[MeSHID:D058750],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational melatonin receptor type 1b MTNR1B NA inhibitor NA drugbank 5-methoxycarbonylamino-n-acetyltryptamine NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD n-(3-benzooxazol-7-yl-propyl)-butyramide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD n-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD ramelteon small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Sleep Disorders, Circadian Rhythm[MeSHID:D020178],Cessation of life[MeSHID:D003643],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Expiration, function[MeSHID:D045853] approved,investigational melatonin receptor type 1b MTNR1B Successful target multitarget,agonist 95.48 TTD , drugbank , DGIDB n-(3-benzooxazol-7-yl-propyl)-acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD ramelteon small molecule Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Sleep Disorders, Circadian Rhythm[MeSHID:D020178],Cessation of life[MeSHID:D003643],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Expiration, function[MeSHID:D045853] approved,investigational melatonin receptor type 1b MTNR1B Successful target multitarget 95.48 TTD , drugbank , DGIDB ucm-454 NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD vlb-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 3 melatonin receptor type 1b MTNR1B Successful target unknown NA TTD , DGIDB n-(3-(3-methoxyphenyl)propyl)acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD beta-methylmelatonin NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD n-[3-(2-ethyl-benzooxazol-7-yl)-propyl]-acetamide NA NA investigative melatonin receptor type 1b MTNR1B Successful target unknown NA TTD pp121 NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target inhibitor NA TTD , DGIDB tafa-93 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft Rejection[MeSHID:D006084] discontinued in phase 1 serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB xl765 small molecule Malignant Neoplasms[MeSHID:D009369] investigational serine/threonine-protein kinase mtor MTOR NA inhibitor 0.11 drugbank , DGIDB ap-21967 NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD cc-223 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.32 TTD , DGIDB ridaforolimus small molecule Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Endometrial Carcinoma[MeSHID:D016889],Bone Tissue[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 1.13 TTD , drugbank , DGIDB pf-05212384 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.12 TTD , DGIDB gdc-0349 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.97 TTD , DGIDB sirolimus small molecule Perivascular Epithelioid Cell Neoplasms[MeSHID:D054973],Lymphangioleiomyomatosis[MeSHID:D018192],Maintenance[MeSHID:D008283],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.17 TTD , drugbank , DGIDB pqr309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Cells[MeSHID:D002477] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.19 TTD , DGIDB 4-(2-(thiophen-2-yl)-9h-purin-6-yl)morpholine NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD bi 860585 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB sar245409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.11 TTD , DGIDB pimecrolimus small molecule Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serine/threonine-protein kinase mtor MTOR NA potentiator 0.32 drugbank , DGIDB 4-(6-morpholino-9h-purin-2-yl)phenol NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD hm-5016699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD pmid25726713-compound-48 NA NA patented serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB xl765 small molecule Malignant Neoplasms[MeSHID:D009369] investigational serine/threonine-protein kinase mtor MTOR NA unknown NA drugbank , DGIDB torin2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD vs-5584 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant mesothelioma[MeSHID:C562839],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.12 TTD , DGIDB rapamycin complexed with immunophilin fkbp12 NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD lam-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphangioleiomyomatosis[MeSHID:D018192] phase 1 serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB bez235 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.09 TTD , DGIDB bgt226 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.32 TTD , DGIDB pf-03772304 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase mtor MTOR NA inhibitor NA drugbank me-344 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.01 TTD , DGIDB 2-morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD everolimus small molecule Subependymal Giant Cell Astrocytoma[MeSHID:D001254],Pancreatic Neoplasm[MeSHID:D010190],Tuberous Sclerosis[MeSHID:D014402],treatment failure[MeSHID:D017211],Renal Cell Carcinoma[MeSHID:D002292],Operative Surgical Procedures[MeSHID:D013514],Angiomyolipoma[MeSHID:D018207],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Kidney[MeSHID:D007668],Malignant neoplasm of kidney[MeSHID:D007680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.36 TTD , drugbank , DGIDB mm-141 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.16 TTD , DGIDB pmid25726713-compound-49 NA NA patented serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB everolimus small molecule Subependymal Giant Cell Astrocytoma[MeSHID:D001254],Pancreatic Neoplasm[MeSHID:D010190],Tuberous Sclerosis[MeSHID:D014402],treatment failure[MeSHID:D017211],Renal Cell Carcinoma[MeSHID:D002292],Operative Surgical Procedures[MeSHID:D013514],Angiomyolipoma[MeSHID:D018207],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Middle East Respiratory Syndrome[MeSHID:D018352],Breast[MeSHID:D001940] approved serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.36 TTD , drugbank , DGIDB 4-(2-(1h-indol-6-yl)-9h-purin-6-yl)morpholine NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD temsirolimus small molecule Renal Cell Carcinoma[MeSHID:D002292],Rheumatoid Arthritis[MeSHID:D001172],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.42 TTD , drugbank , DGIDB salirasib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.05 TTD , DGIDB xl765 small molecule Malignant Neoplasms[MeSHID:D009369] investigational serine/threonine-protein kinase mtor MTOR NA inhibitor NA drugbank , DGIDB ds-7423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.08 TTD , DGIDB pwt-33597 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB novolimus NA Stenosis[MeSHID:D003251],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteries[MeSHID:D001158] approved serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB torin 1 NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target inhibitor NA TTD , DGIDB bez235 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.09 TTD , DGIDB 4-(2-(thiophen-3-yl)-9h-purin-6-yl)morpholine NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD ly3023414 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.15 TTD , DGIDB ds-3078 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB c-16-(s)-3-methylindolerapamycin NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD ink128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of breast[MeSHID:D001943] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.08 TTD , DGIDB ethyl 1-[(1h-benzimidazol-2(3h)one-5-yl)sulfonyl]-1h-pyrrole-2-carboxylate NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD p-2281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD sirolimus small molecule Perivascular Epithelioid Cell Neoplasms[MeSHID:D054973],Lymphangioleiomyomatosis[MeSHID:D018192],Maintenance[MeSHID:D008283],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uveitis[MeSHID:D014605] approved,investigational serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.17 TTD , drugbank , DGIDB sirolimus small molecule Perivascular Epithelioid Cell Neoplasms[MeSHID:D054973],Lymphangioleiomyomatosis[MeSHID:D018192],Maintenance[MeSHID:D008283],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Disease[MeSHID:D004194],Transplanted organ[MeSHID:D019737] approved,investigational serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.17 TTD , drugbank , DGIDB sx-mtr1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD ec-0565 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD x-387 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD p-6915 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD zotarolimus NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved serine/threonine-protein kinase mtor MTOR Successful target unknown 0.24 TTD , DGIDB azd8055 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1/2 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.16 TTD , DGIDB pmid25726713-compound-51 NA NA patented serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB vs-5584 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant mesothelioma[MeSHID:C562839],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.12 TTD , DGIDB sf1126 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Liver carcinoma[MeSHID:D006528] investigational,phase 2 serine/threonine-protein kinase mtor MTOR Successful target inhibitor NA TTD , drugbank , DGIDB pmid25726713-compound-47 NA NA patented serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB ar-mtor-26 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD sb-2280 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD 3-(6-morpholino-9h-purin-2-yl)phenol NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD pp-242 NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target inhibitor NA TTD , DGIDB cu-906 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD cc-223 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.32 TTD , DGIDB pf-04691502 NA Endometrial Carcinoma[MeSHID:D016889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.14 TTD , DGIDB ec-0845 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD osi-027 NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.19 TTD , DGIDB bgt226 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.32 TTD , DGIDB pf-05094037 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD oxa-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD 2-(2-methyl-morpholin-4-yl)-benzo[h]chromen-4-one NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD ridaforolimus small molecule Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Endometrial Carcinoma[MeSHID:D016889],Bone Tissue[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 serine/threonine-protein kinase mtor MTOR Successful target unknown 1.13 TTD , drugbank , DGIDB sf1126 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Liver carcinoma[MeSHID:D006528] investigational,phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , drugbank , DGIDB 2-(6-morpholino-9h-purin-2-yl)phenol NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD 2-chloro-n-(6-cyanopyridin-3-yl)propanamide NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD em-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD pf-04691502 NA Endometrial Carcinoma[MeSHID:D016889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.14 TTD , DGIDB azd2014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.12 TTD , DGIDB (4-(6-morpholino-9h-purin-2-yl)phenyl)methanol NA NA investigative serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD gdc-0980/rg7422 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB rimiducid small molecule Graft-vs-Host Disease[MeSHID:D006086] investigational serine/threonine-protein kinase mtor MTOR NA ligand NA drugbank osi-027 NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown 0.19 TTD , DGIDB pf-04449913 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelomonocytic, Chronic[MeSHID:D015477] approved serine/threonine-protein kinase mtor MTOR Successful target unknown 0.24 TTD , DGIDB abi-009 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Ankle brachial pressure index (observable entity)[MeSHID:D055109],Muscle[MeSHID:D009132],Malignant Neoplasms[MeSHID:D009369],Perivascular Epithelioid Cell Neoplasms[MeSHID:D054973],Malignant neoplasm of muscle[MeSHID:D019042],Urinary Bladder[MeSHID:D001743] phase 2 serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB pmid25726713-compound-50 NA NA patented serine/threonine-protein kinase mtor MTOR Successful target unknown NA TTD , DGIDB ds-7423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase mtor MTOR Successful target inhibitor 0.08 TTD , DGIDB cyanocobalamin small molecule Malignant Neoplasms[MeSHID:D009369],Cestode Infections[MeSHID:D002590],Operative Surgical Procedures[MeSHID:D013514],Pregnancy[MeSHID:D011247],Nose[MeSHID:D009666],Folic Acid Deficiency[MeSHID:D005494],Thyrotoxicosis[MeSHID:D013971],Anemia, Pernicious[MeSHID:D000752],Intestines, Small[MeSHID:D007421],Intestines[MeSHID:D007422],Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Parasitic Diseases[MeSHID:D010272],Celiac Disease[MeSHID:D002446],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Malabsorption Syndrome[MeSHID:D008286],Neurologic Manifestations[MeSHID:D009461],Avitaminosis[MeSHID:D001361],Vitamin B 12 Deficiency[MeSHID:D014806],Malignant neoplasm of pancreas[MeSHID:D010190],Mental concentration[MeSHID:D001288],Hemorrhage[MeSHID:D006470], Hemolytic[MeSHID:D000743],Diphyllobothriasis[MeSHID:D004169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved,nutraceutical methionine synthase MTR NA cofactor NA drugbank thimerosal small molecule NA approved methionine synthase MTR NA antagonist NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical methionine synthase MTR NA cofactor NA drugbank methionine small molecule Protein Biosynthesis[MeSHID:D014176] approved,nutraceutical methionine synthase MTR NA product of NA drugbank hydroxocobalamin small molecule Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Diet, Macrobiotic[MeSHID:D015623],Malignant neoplasm of pancreas[MeSHID:D010190],Biliary Tract Diseases[MeSHID:D001660],Diarrhea[MeSHID:D003967],Cestode Infections[MeSHID:D002590],Malabsorption Syndrome[MeSHID:D008286],Poisoning[MeSHID:D011041],Alcoholic Intoxication, Chronic[MeSHID:D000437],Hyperthyroidism[MeSHID:D006980],Vegan diet[MeSHID:D000067269],Anemia, Pernicious[MeSHID:D000752],ileum[MeSHID:D007082],Vitamin B 12 Deficiency[MeSHID:D014806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Injury[MeSHID:D055370] approved methionine synthase MTR NA cofactor NA drugbank mecobalamin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved,investigational methionine synthase MTR NA cofactor NA drugbank cyanocobalamin small molecule Malignant Neoplasms[MeSHID:D009369],Cestode Infections[MeSHID:D002590],Operative Surgical Procedures[MeSHID:D013514],Pregnancy[MeSHID:D011247],Nose[MeSHID:D009666],Folic Acid Deficiency[MeSHID:D005494],Thyrotoxicosis[MeSHID:D013971],Anemia, Pernicious[MeSHID:D000752],Intestines, Small[MeSHID:D007421],Intestines[MeSHID:D007422],Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Parasitic Diseases[MeSHID:D010272],Celiac Disease[MeSHID:D002446],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Malabsorption Syndrome[MeSHID:D008286],Neurologic Manifestations[MeSHID:D009461],Avitaminosis[MeSHID:D001361],Vitamin B 12 Deficiency[MeSHID:D014806],Malignant neoplasm of pancreas[MeSHID:D010190],Mental concentration[MeSHID:D001288],Hemorrhage[MeSHID:D006470], Hemolytic[MeSHID:D000743],Diphyllobothriasis[MeSHID:D004169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved,nutraceutical methionine synthase reductase MTRR NA cofactor NA drugbank methionine small molecule Protein Biosynthesis[MeSHID:D014176] approved,nutraceutical methionine synthase reductase MTRR NA product of NA drugbank gr-328713 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 microsomal triglyceride transfer protein MTTP Successful target unknown NA TTD dirlotapide NA NA investigative microsomal triglyceride transfer protein MTTP Successful target unknown NA TTD jnj-16269110 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 microsomal triglyceride transfer protein MTTP Successful target unknown 7.96 TTD , DGIDB kd020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney Diseases[MeSHID:D007674] phase 1/2 microsomal triglyceride transfer protein MTTP Successful target unknown NA TTD , DGIDB slx-4090 small molecule Hyperlipidemia[MeSHID:D006949],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Dyslipidemias[MeSHID:D050171] investigational microsomal triglyceride transfer protein large subunit MTTP NA inhibitor 23.87 drugbank , DGIDB slx-4090 NA Hyperlipidemia[MeSHID:D006949],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Dyslipidemias[MeSHID:D050171] phase 2 microsomal triglyceride transfer protein MTTP Successful target unknown 23.87 TTD , DGIDB lomitapide small molecule Homozygote[MeSHID:D006720],Hypercholesterolemia, Familial[MeSHID:D006938] approved,investigational microsomal triglyceride transfer protein large subunit MTTP NA antagonist 1.99 drugbank , DGIDB implitapide NA Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 microsomal triglyceride transfer protein MTTP Successful target unknown 23.87 TTD , DGIDB implitapide small molecule Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] investigational microsomal triglyceride transfer protein large subunit MTTP NA unknown 23.87 drugbank , DGIDB granotapide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 microsomal triglyceride transfer protein MTTP Successful target unknown 7.96 TTD , DGIDB hesperetin small molecule Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental microsomal triglyceride transfer protein large subunit MTTP NA antagonist NA drugbank bms-201038 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypercholesterolemia, Familial[MeSHID:D006938] approved microsomal triglyceride transfer protein MTTP Successful target unknown 7.96 TTD , DGIDB tg4010 biotech Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational mucin-1 MUC1 NA unknown NA drugbank car-t cells targeting muci NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting mucl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] preclinical mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB yttrium (90y) clivatuzumab tetraxetan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 3 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB immucin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB anti-muc1 car-t cells NA Esophageal Neoplasms[MeSHID:D004938],T-Lymphocyte[MeSHID:D013601],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB anti-muc1 mab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB brevarex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB muc1-poly-iclc NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting muc1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB muc1-specific gene-engineered t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB anti-muc1 car t cells NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of lung[MeSHID:D008175] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB g0-203-2c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Pancreatic carcinoma[MeSHID:C562463] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB tg-4010 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Bipolar Disorder[MeSHID:D001714],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting muc1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],cervical cancer[MeSHID:D002583] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB sar-566658 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 mucin-1 MUC1 Clinical trial target unknown 7.96 TTD , DGIDB cart-muc1 cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting muci NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of lung[MeSHID:D008175],Glioblastoma[MeSHID:D005909] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB muc-1 cart cell immunotherapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Intrahepatic Cholangiocarcinoma[MeSHID:D018281],Cells[MeSHID:D002477] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB emepepimut-s NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 mucin-1 MUC1 Clinical trial target unknown 15.91 TTD , DGIDB tg-1031 NA NA investigative mucin-1 MUC1 Clinical trial target unknown NA TTD ico-25 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB go-203-2c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 mucin-1 MUC1 Clinical trial target unknown 31.83 TTD , DGIDB tnmuc-1 car-t cell therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD as-1402 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 mucin-1 MUC1 Clinical trial target unknown 15.91 TTD , DGIDB anti-muc1 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],T-Lymphocyte[MeSHID:D013601],Liver carcinoma[MeSHID:D006528],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting muc1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],cervical cancer[MeSHID:D002583] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB humnc2-car44 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of breast[MeSHID:D001943] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD pankomab-gex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting muci NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of lung[MeSHID:D008175],Glioblastoma[MeSHID:D005909] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB ont-10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB anti-muc1 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],T-Lymphocyte[MeSHID:D013601],Adenocarcinoma[MeSHID:D000230],Malignant Glioma[MeSHID:D005910],Colorectal Cancer[MeSHID:D015179] phase 1/2 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB muc-1 dendritic cancer vaccine NA Dendrites[MeSHID:D003712],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting muc1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting muci NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 mucin-1 MUC1 Clinical trial target unknown NA TTD , DGIDB jcar020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 ovarian carcinoma antigen ca125 MUC16 Clinical trial target unknown NA TTD , DGIDB prgn-3005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 ovarian carcinoma antigen ca125 MUC16 Clinical trial target unknown NA TTD regn4018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 ovarian carcinoma antigen ca125 MUC16 Clinical trial target unknown NA TTD abagovomab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2/3 ovarian carcinoma antigen ca125 MUC16 Clinical trial target unknown 23.87 TTD , DGIDB dmuc-5754a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fallopian Tube Carcinoma[MeSHID:D005185],Malignant Neoplasms[MeSHID:D009369],Peritoneum[MeSHID:D010537],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 ovarian carcinoma antigen ca125 MUC16 Clinical trial target unknown 7.96 TTD , DGIDB oregovomab NA Malignant neoplasm of ovary[MeSHID:D010051],Epithelial ovarian cancer[MeSHID:C538090],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 ovarian carcinoma antigen ca125 MUC16 Clinical trial target unknown 47.74 TTD , DGIDB rg7458 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] discontinued in phase 1 ovarian carcinoma antigen ca125 MUC16 Clinical trial target unknown NA TTD oregovomab biotech Malignant neoplasm of ovary[MeSHID:D010051],Epithelial ovarian cancer[MeSHID:C538090],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational mucin-16 MUC16 NA unknown 47.74 drugbank , DGIDB amg 199 NA Adenocarcinoma[MeSHID:D000230],Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 mucin-17 MUC17 Clinical trial target unknown NA TTD pranlukast small molecule Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational mucin-2 MUC2 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational muscle, skeletal receptor tyrosine-protein kinase MUSK NA inhibitor NA drugbank mrna-3704 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Methylmalonic acidemia[MeSHID:C537358] phase 1/2 methylmalonyl-coa mutase MUT Successful target unknown NA TTD cyanocobalamin small molecule Malignant Neoplasms[MeSHID:D009369],Cestode Infections[MeSHID:D002590],Operative Surgical Procedures[MeSHID:D013514],Pregnancy[MeSHID:D011247],Nose[MeSHID:D009666],Folic Acid Deficiency[MeSHID:D005494],Thyrotoxicosis[MeSHID:D013971],Anemia, Pernicious[MeSHID:D000752],Intestines, Small[MeSHID:D007421],Intestines[MeSHID:D007422],Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Parasitic Diseases[MeSHID:D010272],Celiac Disease[MeSHID:D002446],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Malabsorption Syndrome[MeSHID:D008286],Neurologic Manifestations[MeSHID:D009461],Avitaminosis[MeSHID:D001361],Vitamin B 12 Deficiency[MeSHID:D014806],Malignant neoplasm of pancreas[MeSHID:D010190],Mental concentration[MeSHID:D001288],Hemorrhage[MeSHID:D006470], Hemolytic[MeSHID:D000743],Diphyllobothriasis[MeSHID:D004169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] approved,nutraceutical methylmalonyl-coa mutase, mitochondrial MUT NA cofactor NA drugbank hydroxocobalamin small molecule Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Diet, Macrobiotic[MeSHID:D015623],Malignant neoplasm of pancreas[MeSHID:D010190],Biliary Tract Diseases[MeSHID:D001660],Diarrhea[MeSHID:D003967],Cestode Infections[MeSHID:D002590],Malabsorption Syndrome[MeSHID:D008286],Poisoning[MeSHID:D011041],Alcoholic Intoxication, Chronic[MeSHID:D000437],Hyperthyroidism[MeSHID:D006980],Vegan diet[MeSHID:D000067269],Anemia, Pernicious[MeSHID:D000752],ileum[MeSHID:D007082],Vitamin B 12 Deficiency[MeSHID:D014806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Injury[MeSHID:D055370] approved methylmalonyl-coa mutase, mitochondrial MUT NA cofactor NA drugbank hydroxocobalamin NA Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Diet, Macrobiotic[MeSHID:D015623],Malignant neoplasm of pancreas[MeSHID:D010190],Biliary Tract Diseases[MeSHID:D001660],Diarrhea[MeSHID:D003967],Cestode Infections[MeSHID:D002590],Malabsorption Syndrome[MeSHID:D008286],Poisoning[MeSHID:D011041],Alcoholic Intoxication, Chronic[MeSHID:D000437],Hyperthyroidism[MeSHID:D006980],Vegan diet[MeSHID:D000067269],Anemia, Pernicious[MeSHID:D000752],ileum[MeSHID:D007082],Vitamin B 12 Deficiency[MeSHID:D014806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Injury[MeSHID:D055370] approved methylmalonyl-coa mutase MUT Successful target unknown NA TTD analog 3 (vlattas et al., 1996) NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target unknown NA TTD p'-geranyl 3,5,9-trihydroxy-3-methylnonanate 9-diphosphate NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target unknown NA TTD p'-geranyl 3,5,8-trihydroxy-3-methyloctanate 8-diphosphate NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target unknown NA TTD p'-geranyl 2-fluoromevalonate 5-diphosphate NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target inhibitor NA TTD , DGIDB p'-geranyl 3,5,7-trihydroxy-3-methylheptanate 7-diphosphate NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target unknown NA TTD diphosphoglycolyl proline NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target inhibitor NA TTD , DGIDB 6-fluoromevalonate pyrophosphate NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target inhibitor NA TTD , DGIDB 2-fluoromevalonate 5-diphosphate NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target unknown NA TTD 6-fluoromevalonate 5-diphosphate NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target inhibitor NA TTD , DGIDB pmid17888661c19 NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target unknown NA TTD 2,2-difluoromevalonate 5-diphosphate NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target unknown NA TTD pmid17888661c18 NA NA investigative diphosphomevalonate decarboxylase MVD Literature-reported target unknown NA TTD farnesyl thiopyrophosphate small molecule NA experimental mevalonate kinase MVK NA unknown NA drugbank lr3001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951] phase 2 myb messenger rna MYB Clinical trial target unknown NA TTD omecamtiv mecarbil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 3 cardiac myosin MYBPC3 Clinical trial target unknown NA TTD , DGIDB avi-5126 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 2 myc messenger rna MYC Clinical trial target unknown NA TTD , DGIDB nadroparin small molecule Blood coagulation[MeSHID:D001777],Angina, Unstable[MeSHID:D000789],Deep Vein Thrombosis[MeSHID:D020246],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923] approved,investigational myc proto-oncogene protein MYC NA inhibitor NA drugbank resten-ng NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 2 myc messenger rna MYC Clinical trial target unknown NA TTD acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved myc proto-oncogene protein MYC NA downregulator NA drugbank tws-119 NA NA investigative proto-oncogene c-myc MYC Literature-reported target unknown NA TTD dcr-myc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1/2 mycbp messenger rna MYCBP Clinical trial target unknown NA TTD tetrafluoroaluminate ion small molecule NA experimental myosin-11 MYH11 NA unknown NA drugbank mant-adp small molecule NA experimental myosin-14 MYH14 NA unknown NA drugbank tetrafluoroaluminate ion small molecule NA experimental myosin-14 MYH14 NA unknown NA drugbank trifluoro-[hydroxy-[hydroxy-[2-(n-methyl-2-nitro-anilino)ethoxy]phosphoryl]oxy-phosphoryl]oxy-beryllium(1-) small molecule NA experimental myosin-14 MYH14 NA unknown NA drugbank (3as)-3a-hydroxy-5-methyl-1-phenyl-1,2,3,3a-tetrahydro-4h-pyrrolo[2,3-b]quinolin-4-one small molecule NA experimental myosin-14 MYH14 NA unknown NA drugbank (s)-blebbistatin small molecule NA experimental myosin-14 MYH14 NA unknown NA drugbank (3as)-3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4h-pyrrolo[2,3-b]quinolin-4-one small molecule NA experimental myosin-14 MYH14 NA unknown NA drugbank (3as)-3a-hydroxy-7-methyl-1-phenyl-1,2,3,3a-tetrahydro-4h-pyrrolo[2,3-b]quinolin-4-one small molecule NA experimental myosin-14 MYH14 NA unknown NA drugbank ushstat NA Deafness[MeSHID:D003638],Retinitis Pigmentosa[MeSHID:D012174],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 myosin-7 MYH7 Clinical trial target unknown NA TTD , DGIDB 4-[4-(2,5-dioxo-pyrrolidin-1-yl)-phenylamino]-4-hydroxy-butyric acid small molecule NA experimental myosin-7 MYH7 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational myosin-9 MYH9 NA ligand NA drugbank 4-[4-(2,5-dioxo-pyrrolidin-1-yl)-phenylamino]-4-hydroxy-butyric acid small molecule NA experimental myosin regulatory light chain 12a MYL12A NA unknown NA drugbank 4-[4-(2,5-dioxo-pyrrolidin-1-yl)-phenylamino]-4-hydroxy-butyric acid small molecule NA experimental myosin light chain 6b MYL6B NA unknown NA drugbank me-3407 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Duodenal Ulcer[MeSHID:D004381] phase 2 myosin light kinase MYLK Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational myosin light chain kinase, smooth muscle MYLK NA inhibitor NA drugbank rki-1447 NA NA investigative myosin light kinase MYLK Clinical trial target inhibitor NA TTD , DGIDB prenylamine small molecule NA approved,withdrawn myosin light chain kinase 2, skeletal/cardiac muscle MYLK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational myosin light chain kinase 2, skeletal/cardiac muscle MYLK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational myosin light chain kinase 3 MYLK3 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational myosin light chain kinase family member 4 MYLK4 NA inhibitor NA drugbank imidazole small molecule NA experimental,investigational unconventional myosin-ie MYO1E NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational myosin-iiia MYO3A NA inhibitor NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational n-acylethanolamine-hydrolyzing acid amidase NAAA NA inhibitor NA drugbank ccp NA NA investigative n-acylethanolamine-hydrolyzing acidamidase NAAA Literature-reported target inhibitor NA TTD , DGIDB s-oopp NA NA investigative n-acylethanolamine-hydrolyzing acidamidase NAAA Literature-reported target unknown NA TTD medical cannabis biotech NA experimental,investigational n-acylethanolamine-hydrolyzing acid amidase NAAA NA inhibitor NA drugbank cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational n-acylethanolamine-hydrolyzing acid amidase NAAA NA inhibitor NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical glutamine-dependent nad(+) synthetase NADSYN1 NA product of NA drugbank atp small molecule NA investigational,nutraceutical nedd8-activating enzyme e1 regulatory subunit NAE1 NA unknown NA drugbank glycerin small molecule NA approved,investigational alpha-n-acetylgalactosaminidase NAGA NA unknown NA drugbank n-acetylglucosamine small molecule Degenerative polyarthritis[MeSHID:D010003] approved,investigational,nutraceutical n-acetyl-d-glucosamine kinase NAGK NA unknown NA drugbank abo-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] phase 1/2 alpha-n-acetylglucosaminidase NAGLU Successful target unknown NA TTD n-acetylglucosamine small molecule Degenerative polyarthritis[MeSHID:D010003] approved,investigational,nutraceutical alpha-n-acetylglucosaminidase NAGLU NA activator NA drugbank n-acetyl-d-glucosamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] approved alpha-n-acetylglucosaminidase NAGLU Successful target unknown NA TTD , DGIDB n-acetylglucosamine small molecule Degenerative polyarthritis[MeSHID:D010003] approved,investigational,nutraceutical n-acetylglucosamine-1-phosphodiester alpha-n-acetylglucosaminidase NAGPA NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical n-acetylglutamate synthase, mitochondrial NAGS NA unknown NA drugbank ot-82 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Occupational therapy regime[MeSHID:D009788],Lymphoma[MeSHID:D008223] phase 1 nicotinamide phosphoribosyltransferase NAMPT Clinical trial target unknown NA TTD daporinad small molecule leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 nicotinamide phosphoribosyltransferase NAMPT Clinical trial target unknown 42.43 TTD , drugbank , DGIDB gmx1777 small molecule Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 nicotinamide phosphoribosyltransferase NAMPT Clinical trial target unknown 63.65 TTD , drugbank , DGIDB chs-828 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 nicotinamide phosphoribosyltransferase NAMPT Clinical trial target unknown 21.22 TTD , DGIDB medical cannabis biotech NA experimental,investigational n-acyl-phosphatidylethanolamine-hydrolyzing phospholipase d NAPEPLD NA inhibitor NA drugbank asparagine small molecule NA approved,investigational,nutraceutical asparagine--trna ligase, cytoplasmic NARS NA unknown NA drugbank asparagine small molecule NA approved,investigational,nutraceutical probable asparagine--trna ligase, mitochondrial NARS2 NA unknown NA drugbank car-t cells targeting cd56 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] clinical trial neural cell adhesion molecule 1 NCAM1 Clinical trial target unknown NA TTD , DGIDB cart-56 cells NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 neural cell adhesion molecule 1 NCAM1 Clinical trial target unknown NA TTD , DGIDB cd56 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1/2 neural cell adhesion molecule 1 NCAM1 Clinical trial target unknown NA TTD , DGIDB cd56-specific gene-engineered t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] phase 1/2 neural cell adhesion molecule 1 NCAM1 Clinical trial target unknown NA TTD , DGIDB beta-d-glucose small molecule NA experimental neurocan core protein NCAN NA unknown NA drugbank thiodigalactoside small molecule NA experimental neurocan core protein NCAN NA unknown NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved neurocan core protein NCAN NA binder NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadph oxidase NCF1 NA inhibitor NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadph oxidase NCF2 NA inhibitor NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadph oxidase NCF4 NA inhibitor NA drugbank ax-024 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 nck adaptor protein 1 NCK1 Clinical trial target unknown NA TTD , DGIDB itarnafloxin NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nucleolin NCL Clinical trial target unknown 42.43 TTD , DGIDB act-gro-777 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 nucleolin NCL Clinical trial target unknown NA TTD , DGIDB ipp-204106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 nucleolin NCL Clinical trial target unknown NA TTD , DGIDB (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 3-(6-hydroxy-naphthalen-2-yl)-benzo[d]isooxazol-6-ol small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 3,20-pregnanedione small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank to-901317 small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank indeglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank (1r,3r)-5-[(2e)-3-{(1s,3r)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank corticosterone small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 1,3-cyclohexanediol, 4-methylene-5-[(2e)-[(1s,3as,7as)-octahydro-1-(5-hydroxy-5-methyl-1,3-hexadiynyl)-7a-methyl-4h-inden-4-ylidene]ethylidene]-, (1r,3s,5z) small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank prinaberel small molecule NA investigational nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank aleglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 3-bromo-6-hydroxy-2-(4-hydroxyphenyl)-1h-inden-1-one small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank myristic acid small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank erb-196 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank [5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]acetonitrile small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 2-(5-hydroxy-naphthalen-1-yl)-1,3-benzooxazol-6-ol small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank (2s)-3-(1-{[2-(2-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-1h-indol-5-yl)-2-ethoxypropanoic acid small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 1-chloro-6-(4-hydroxyphenyl)-2-naphthol small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 4-(4-hydroxyphenyl)-1-naphthaldehyde oxime small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-carbonitrile small molecule NA experimental nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank gw-590735 small molecule NA investigational nuclear receptor coactivator 1 NCOA1 NA unknown NA drugbank 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine small molecule NA investigational nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 4-(2-amino-1-methyl-1h-imidazo[4,5-b]pyridin-6-yl)phenol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 4-(6-hydroxy-1h-indazol-3-yl)benzene-1,3-diol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank (9beta,11alpha,13alpha,14beta,17alpha)-11-(methoxymethyl)estra-1(10),2,4-triene-3,17-diol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank metribolone small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank to-901317 small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank dimethyl (1r,4s)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank estradiol dienanthate small molecule NA approved,investigational,vet_approved nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank tributyltin small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 4-[(1s,2s,5s)-5-(hydroxymethyl)-6,8,9-trimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 3-ethyl-2-(4-hydroxyphenyl)-2h-indazol-5-ol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 3-chloro-2-(4-hydroxyphenyl)-2h-indazol-5-ol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 17-methyl-17-alpha-dihydroequilenin small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 4-[(1s,2s,5s)-5-(hydroxymethyl)-8-methyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 4-[1-allyl-7-(trifluoromethyl)-1h-indazol-3-yl]benzene-1,3-diol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 4-[(1s,2r,5s)-4,4,8-trimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 2-chloro-5-nitro-n-phenylbenzamide small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 2-[(2,4-dichlorobenzoyl)amino]-5-(pyrimidin-2-yloxy)benzoic acid small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank (2e,4e)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoic acid small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank 4-[(1s,2s,5s,9r)-5-(hydroxymethyl)-8,9-dimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank (9alpha,13beta,17beta)-2-[(1z)-but-1-en-1-yl]estra-1,3,5(10)-triene-3,17-diol small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank diethyl (1r,2s,3r,4s)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate small molecule NA experimental nuclear receptor coactivator 2 NCOA2 NA unknown NA drugbank gnf-pf-826 NA NA investigative nuclear receptor coactivator 3 NCOA3 Literature-reported target unknown NA TTD gnf-pf-78 NA NA investigative nuclear receptor coactivator 3 NCOA3 Literature-reported target unknown NA TTD 17alpha-estriol small molecule NA experimental nuclear receptor coactivator 5 NCOA5 NA unknown NA drugbank calcium phosphate small molecule NA approved neuronal calcium sensor 1 NCS1 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved neuronal calcium sensor 1 NCS1 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational neuronal calcium sensor 1 NCS1 NA ligand NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental bifunctional heparan sulfate n-deacetylase/n-sulfotransferase 1 NDST1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1 NDUFA1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial NDUFA10 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11 NDUFA11 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 NDUFA12 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 NDUFA13 NA unknown NA drugbank flurpiridaz f 18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiomyopathies[MeSHID:D009202] phase 3 mitochondrial complex i NDUFA13 Clinical trial target unknown NA TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 NDUFA2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 NDUFA3 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 NDUFA4 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2 NDUFA4L2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 NDUFA5 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 NDUFA6 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 NDUFA7 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 NDUFA8 NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial NDUFA9 NA cofactor NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial NDUFA9 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical acyl carrier protein, mitochondrial NDUFAB1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1 NDUFB1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 NDUFB10 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial NDUFB2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 NDUFB3 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 NDUFB4 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial NDUFB5 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 NDUFB6 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 NDUFB7 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial NDUFB8 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 NDUFB9 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 subunit c1, mitochondrial NDUFC1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] 1 subunit c2 NDUFC2 NA unknown NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational nadh dehydrogenase [ubiquinone] 1 subunit c2 NDUFC2 NA inhibitor NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational nadh dehydrogenase [ubiquinone] 1 subunit c2 NDUFC2 NA inhibitor NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh-ubiquinone oxidoreductase 75 kda subunit, mitochondrial NDUFS1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial NDUFS2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial NDUFS3 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial NDUFS4 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] iron-sulfur protein 5 NDUFS5 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial NDUFS6 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial NDUFS7 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial NDUFS8 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial NDUFV1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial NDUFV2 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nadh dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial NDUFV3 NA unknown NA drugbank ubidecarenone small molecule Gingival Diseases[MeSHID:D005882],Diabetes Mellitus[MeSHID:D003920],Periodontal Diseases[MeSHID:D010510],Hypertensive disease[MeSHID:D006973],Diet therapy[MeSHID:D004035],Congestive heart failure[MeSHID:D006333],Fibromyalgia[MeSHID:D005356],Heart[MeSHID:D006321],Parkinson Disease[MeSHID:D010300],Migraine Disorders[MeSHID:D008881] approved,investigational,nutraceutical nadh dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial NDUFV3 NA cofactor NA drugbank enfortumab vedotin biotech Urothelium[MeSHID:D019459],Neoplasm Metastasis[MeSHID:D009362],Cessation of life[MeSHID:D003643] approved,investigational nectin-4 NECTIN4 NA binder,antibody NA drugbank , DGIDB bt8009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 nectin cell adhesion molecule 4 NECTIN4 Successful target unknown NA TTD enfortumab NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nectin cell adhesion molecule 4 NECTIN4 Successful target unknown NA TTD asg-22me NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 nectin cell adhesion molecule 4 NECTIN4 Successful target unknown 190.95 TTD , DGIDB mln4924 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Nasopharyngeal carcinoma[MeSHID:C538339],Malignant Neoplasms[MeSHID:D009369] phase 3 ubiquitin-like protein nedd8 NEDD8 Clinical trial target unknown NA TTD , DGIDB ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 1 NEIL1 NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 1 NEIL1 NA unknown NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 1 NEIL1 NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved endonuclease 8-like 1 NEIL1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational endonuclease 8-like 1 NEIL1 NA unknown NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 1 NEIL1 NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 1 NEIL1 NA unknown NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 2 NEIL2 NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved endonuclease 8-like 2 NEIL2 NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 2 NEIL2 NA unknown NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 2 NEIL2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational endonuclease 8-like 2 NEIL2 NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 2 NEIL2 NA unknown NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved endonuclease 8-like 2 NEIL2 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase nek1 NEK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase nek11 NEK11 NA inhibitor NA drugbank dabrafenib small molecule melanoma[MeSHID:D008545],Disease[MeSHID:D004194],Anaplastic thyroid carcinoma[MeSHID:D065646],Mutation[MeSHID:D009154],Continuance of life[MeSHID:D013534],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serine/threonine-protein kinase nek11 NEK11 NA antagonist,inhibitor NA drugbank 5-[(z)-(5-chloro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl]-n,2,4-trimethyl-1h-pyrrole-3-carboxamide small molecule NA experimental serine/threonine-protein kinase nek2 NEK2 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase nek2 NEK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase nek3 NEK3 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase nek4 NEK4 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase nek5 NEK5 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase nek9 NEK9 NA inhibitor NA drugbank oseltamivir small molecule Disease Outbreaks[MeSHID:D004196],Communicable Diseases[MeSHID:D003141],Diagnosis[MeSHID:D003933],Influenza[MeSHID:D007251],Pandemics[MeSHID:D058873],Infection[MeSHID:D007239],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] approved sialidase-1 NEU1 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved sialidase-1 NEU1 NA inhibitor NA drugbank oseltamivir small molecule Disease Outbreaks[MeSHID:D004196],Communicable Diseases[MeSHID:D003141],Diagnosis[MeSHID:D003933],Influenza[MeSHID:D007251],Pandemics[MeSHID:D058873],Infection[MeSHID:D007239],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Orthomyxoviridae Infections[MeSHID:D009976],Disease[MeSHID:D004194] approved sialidase-1 NEU1 NA inhibitor NA drugbank oseltamivir small molecule Disease Outbreaks[MeSHID:D004196],Communicable Diseases[MeSHID:D003141],Diagnosis[MeSHID:D003933],Influenza[MeSHID:D007251],Pandemics[MeSHID:D058873],Infection[MeSHID:D007239],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] approved sialidase-2 NEU2 NA inhibitor NA drugbank oseltamivir small molecule Disease Outbreaks[MeSHID:D004196],Communicable Diseases[MeSHID:D003141],Diagnosis[MeSHID:D003933],Influenza[MeSHID:D007251],Pandemics[MeSHID:D058873],Infection[MeSHID:D007239],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Orthomyxoviridae Infections[MeSHID:D009976],Disease[MeSHID:D004194] approved sialidase-2 NEU2 NA inhibitor NA drugbank 2-deoxy-2,3-dehydro-n-acetylneuraminic acid small molecule NA experimental sialidase-2 NEU2 NA unknown NA drugbank zanamivir small molecule Influenza[MeSHID:D007251],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] approved,investigational sialidase-2 NEU2 NA inhibitor NA drugbank zanamivir small molecule Influenza[MeSHID:D007251],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] approved,investigational sialidase-2 NEU2 NA inhibitor NA drugbank 5-acetamido-5,6-dihydro-4-hydroxy-6-isobutoxy-4h-pyran-2-carboxylic acid small molecule NA experimental sialidase-2 NEU2 NA unknown NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear factor of activated t-cells, cytoplasmic 1 NFATC1 NA inhibitor NA drugbank dodecyldimethylamine n-oxide small molecule NA experimental nuclear factor erythroid 2-related factor 1 NFE2L1 NA unknown NA drugbank pmid28454500-compound-60 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD benzamide derivative 5 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-32 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD tfm735 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] preclinical nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-50 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 4-(2-cyclohexylethoxy) aniline derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD sfx-01 NA Subarachnoid Hemorrhage[MeSHID:D013345],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 3-phenyl propanoic derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD benzo[d]oxazole derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 1-phenyl-1,3,4-triazole derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD benzo[d]oxazole derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-34 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD benzamide derivative 6 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-96 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD thiazole derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD benzo[d]oxazole derivative 4 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD cat4001 NA alpha-1-Antitrypsin Deficiency, Autosomal Recessive[MeSHID:C566273],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Friedreich Ataxia[MeSHID:D005621],alpha 1-Antitrypsin Deficiency[MeSHID:D019896] preclinical nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-12 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-3 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 3-phenyl propanoic derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD m102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690] preclinical nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD chalcone derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-9 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 1-phenyl-1,3,4-triazole derivative 3 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-94 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pyrazino[2,1-a]isoquinolin derivative 3 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-91 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD abt-rta-408 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD diterpenoid derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pyrazino[2,1-a]isoquinolin derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 2-hydroxybenzamide derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-92 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 1,2,3,4-tetrahydroisoquinoline derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD thiazole derivative 3 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-49 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-10 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD omaveloxolone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Friedreich Ataxia[MeSHID:D005621],melanoma[MeSHID:D008545] phase 2 nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-33 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-11 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD cxa10 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Focal glomerulosclerosis[MeSHID:D005923] phase 2 nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-8 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD chalcone derivative 4 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 3-phenyl propanoic derivative 3 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 2-hydroxybenzamide derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-95 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 4-(2-cyclohexylethoxy) aniline derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-40 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD benzo[d]oxazole derivative 3 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 1-phenyl-1,3,4-triazole derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-93 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-13 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-41 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-58 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD hpp971 NA Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD vinyl sulfone derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-57 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 4-(2-cyclohexylethoxy) aniline derivative 3 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pyrazino[2,1-a]isoquinolin derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD chalcone derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD diterpenoid derivative 2 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pyrazino[2,1-a]isoquinolin derivative 4 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pyridyl compound 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD ot551 NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-35 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-59 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD naphthalene derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD ot-551 NA Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Vision[MeSHID:D014785] phase 2 nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-37 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD pmid28454500-compound-36 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD trepenoid derivative 1 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD chalcone derivative 3 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD 4-(2-cyclohexylethoxy) aniline derivative 4 NA NA patented nuclear factor erythroid 2-related factor 2 NFE2L2 Clinical trial target unknown NA TTD nox-700 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nuclear factor nf-kappa-b p105 subunit NFKB1 NA unknown NA drugbank glycyrrhizic acid small molecule Neoplasms[MeSHID:D009369],Premenstrual syndrome[MeSHID:D011293],Stomach Diseases[MeSHID:D013272],Ulcer[MeSHID:D014456],Virus Diseases[MeSHID:D014777],Peptic Ulcer[MeSHID:D010437] approved,experimental nuclear factor nf-kappa-b NFKB1 NA translocation inhibitor NA drugbank donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear factor nf-kappa-b NFKB1 NA inhibitor NA drugbank triflusal small molecule Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Cerebrovascular accident[MeSHID:D020521] approved,investigational nuclear factor nf-kappa-b p105 subunit NFKB1 NA antagonist NA drugbank p54 NA Degenerative polyarthritis[MeSHID:D010003],Neoplasms[MeSHID:D009369],Crohn Disease[MeSHID:D003424],Inflammatory Bowel Diseases[MeSHID:D015212],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna-binding factor kbf1 NFKB1 Clinical trial target unknown NA TTD he3286 small molecule Rheumatoid Arthritis[MeSHID:D001172],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nuclear factor nf-kappa-b p105 subunit NFKB1 NA unknown NA drugbank cat 1004 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dna-binding factor kbf1 NFKB1 Clinical trial target unknown NA TTD fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical nuclear factor nf-kappa-b NFKB1 NA regulator NA drugbank custirsen small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigational nuclear factor nf-kappa-b p105 subunit NFKB1 NA unknown NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved,investigational,withdrawn nuclear factor nf-kappa-b p105 subunit NFKB1 NA antagonist 0.08 drugbank , DGIDB pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear factor nf-kappa-b p105 subunit NFKB1 NA inhibitor NA drugbank nf-kappab decoy small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Skin Diseases, Infectious[MeSHID:D012874],Dermatitis, Atopic[MeSHID:D003876],Infection[MeSHID:D007239] investigational nuclear factor nf-kappa-b NFKB1 NA inhibitor NA drugbank pranlukast small molecule Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational nuclear factor nf-kappa-b p105 subunit NFKB1 NA unknown NA drugbank sc-236 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Malignant Neoplasms[MeSHID:D009369],Expiration, function[MeSHID:D045853] experimental,investigational nuclear factor nf-kappa-b complex NFKB1 NA inhibitor NA drugbank sgn-30 biotech Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Lymphoma, Non-Hodgkin[MeSHID:D008228],Autoimmune Diseases[MeSHID:D001327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational nuclear factor nf-kappa-b p105 subunit NFKB1 NA unknown NA drugbank p54 small molecule Degenerative polyarthritis[MeSHID:D010003],Neoplasms[MeSHID:D009369],Crohn Disease[MeSHID:D003424],Inflammatory Bowel Diseases[MeSHID:D015212],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational nuclear factor nf-kappa-b p105 subunit NFKB1 NA unknown NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational,withdrawn nuclear factor nf-kappa-b p105 subunit NFKB1 NA antagonist 0.08 drugbank , DGIDB andrographolide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dysentery, Bacillary[MeSHID:D004405] investigational nuclear factor nf-kappa-b p105 subunit NFKB1 NA unknown 0.71 drugbank , DGIDB glycyrrhizic acid small molecule Neoplasms[MeSHID:D009369],Premenstrual syndrome[MeSHID:D011293],Stomach Diseases[MeSHID:D013272],Ulcer[MeSHID:D014456],Virus Diseases[MeSHID:D014777],Peptic Ulcer[MeSHID:D010437] approved,experimental nuclear factor nf-kappa-b NFKB2 NA translocation inhibitor NA drugbank sc-236 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Malignant Neoplasms[MeSHID:D009369],Expiration, function[MeSHID:D045853] experimental,investigational nuclear factor nf-kappa-b complex NFKB2 NA inhibitor NA drugbank p54 small molecule Degenerative polyarthritis[MeSHID:D010003],Neoplasms[MeSHID:D009369],Crohn Disease[MeSHID:D003424],Inflammatory Bowel Diseases[MeSHID:D015212],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational nuclear factor nf-kappa-b p100 subunit NFKB2 NA unknown NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical nuclear factor nf-kappa-b NFKB2 NA regulator NA drugbank he3286 small molecule Rheumatoid Arthritis[MeSHID:D001172],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nuclear factor nf-kappa-b p100 subunit NFKB2 NA unknown NA drugbank nox-700 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nuclear factor nf-kappa-b p100 subunit NFKB2 NA unknown NA drugbank nf-kappab decoy small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Skin Diseases, Infectious[MeSHID:D012874],Dermatitis, Atopic[MeSHID:D003876],Infection[MeSHID:D007239] investigational nuclear factor nf-kappa-b NFKB2 NA inhibitor NA drugbank dims-0150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 3 nfkb messenger rna NFKB2 Clinical trial target unknown NA TTD donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear factor nf-kappa-b NFKB2 NA inhibitor NA drugbank custirsen small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigational nuclear factor nf-kappa-b p100 subunit NFKB2 NA unknown NA drugbank sgn-30 biotech Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Lymphoma, Non-Hodgkin[MeSHID:D008228],Autoimmune Diseases[MeSHID:D001327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational nuclear factor nf-kappa-b p100 subunit NFKB2 NA unknown NA drugbank andrographolide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dysentery, Bacillary[MeSHID:D004405] investigational nuclear factor nf-kappa-b p100 subunit NFKB2 NA unknown NA drugbank bardoxolone methyl small molecule Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Mixed Connective Tissue Disease[MeSHID:D008947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976],Idiopathic pulmonary arterial hypertension[MeSHID:D065627] investigational nf-kappa-b inhibitor alpha NFKBIA NA unknown NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved nf-kappa-b inhibitor alpha NFKBIA NA inhibitor NA drugbank fucoxanthin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Syndrome X[MeSHID:D024821] phase 2 nf-kappa-b inhibitor alpha NFKBIA Clinical trial target unknown NA TTD astaxanthin small molecule Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Asthma[MeSHID:D001249],Disorder of eye[MeSHID:D005128],Infection[MeSHID:D007239],Eye Infections[MeSHID:D015817] investigational nf-kappa-b inhibitor alpha NFKBIA NA unknown NA drugbank i3c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 nf-kappa-b inhibitor alpha NFKBIA Clinical trial target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical cysteine desulfurase, mitochondrial NFS1 NA cofactor NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical cysteine desulfurase, mitochondrial NFS1 NA unknown NA drugbank cysteine small molecule Liver[MeSHID:D008099],Drug Overdose[MeSHID:D062787],Kidney[MeSHID:D007668] approved,nutraceutical cysteine desulfurase, mitochondrial NFS1 NA unknown NA drugbank fasinumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Low Back Pain[MeSHID:D017116],Pain[MeSHID:D010146] phase 3 nerve growth factor NGF Clinical trial target inhibitor 25.46 TTD , DGIDB fasinumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Low Back Pain[MeSHID:D017116],Pain[MeSHID:D010146] phase 3 nerve growth factor NGF Clinical trial target unknown 25.46 TTD , DGIDB abt-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 1 nerve growth factor NGF Clinical trial target unknown NA TTD , DGIDB ri 624 biotech Pain[MeSHID:D010146] investigational beta-nerve growth factor NGF NA unknown NA drugbank tanezumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Low Back Pain[MeSHID:D017116],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] phase 3 nerve growth factor NGF Clinical trial target unknown 38.19 TTD , DGIDB cxb-909 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] phase 1/2 nerve growth factor NGF Clinical trial target unknown NA TTD , DGIDB sar164877 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2/3 nerve growth factor NGF Clinical trial target unknown NA TTD , DGIDB fasinumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Low Back Pain[MeSHID:D017116],Pain[MeSHID:D010146] investigational beta-nerve growth factor NGF NA inhibitor 25.46 drugbank , DGIDB nsg-0202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 nerve growth factor NGF Clinical trial target unknown NA TTD , DGIDB cere-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nerve growth factor NGF Clinical trial target unknown NA TTD , DGIDB clenbuterol small molecule Asthma[MeSHID:D001249],Chronic disease[MeSHID:D002908],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved beta-nerve growth factor NGF NA stimulator NA drugbank polaprezinc small molecule Peptic Ulcer[MeSHID:D010437],Dyspepsia[MeSHID:D004415],Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcer[MeSHID:D014456] experimental beta-nerve growth factor NGF NA agonist NA drugbank medi-578 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 nerve growth factor NGF Clinical trial target unknown 12.73 TTD , DGIDB tanezumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Low Back Pain[MeSHID:D017116],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] phase 3 nerve growth factor NGF Clinical trial target inhibitor 38.19 TTD , DGIDB spi-205 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD , DGIDB fulranumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthralgia[MeSHID:D018771],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146],Back Pain[MeSHID:D001416] phase 3 low-affinity nerve growth factor receptor NGFR Successful target unknown 10.61 TTD , DGIDB ald-901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Adrenoleukodystrophy[MeSHID:D000326] investigative low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD lm11a-31 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD , DGIDB tdi-0033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] investigative low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD axogenesis factor-1 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD tdi-0059 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] investigative low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD nerve growth factor conjugated rap peptide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] investigative low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD org-2766 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD cenegermin NA Corneal Ulcer[MeSHID:D003320],Keratitis[MeSHID:D007634],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved low-affinity nerve growth factor receptor NGFR Successful target unknown 21.22 TTD , DGIDB crb-0022 NA Amaurosis congenita of Leber, type 1[MeSHID:C536600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative low-affinity nerve growth factor receptor NGFR Successful target unknown NA TTD urokinase biotech Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved,investigational,withdrawn nidogen-1 NID1 NA ligand NA drugbank morab-022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922],Rheumatoid Arthritis[MeSHID:D001172] phase 1 immunoglobulin gamma-1 heavy nie NIE Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase nim1 NIM1K NA inhibitor NA drugbank radezolid small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pneumonia[MeSHID:D011014] investigational 60s ribosome subunit biogenesis protein nip7 homolog NIP7 NA unknown NA drugbank tepotinib small molecule Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683],epithelial to mesenchymal transition[MeSHID:D058750],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational nischarin NISCH NA inhibitor NA drugbank tizanidine small molecule Muscle Spasticity[MeSHID:D009128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational nischarin NISCH NA agonist NA drugbank agmatine small molecule Diabetes Mellitus[MeSHID:D003920],Small Fiber Neuropathy[MeSHID:D000071075],Neuroprotection[MeSHID:D000066829],Glaucoma[MeSHID:D005901],Diagnosis[MeSHID:D003933],Epilepsy[MeSHID:D004827],Kidney[MeSHID:D007668],Anxiety Disorders[MeSHID:D001008],Blind Vision[MeSHID:D001766],Mental Depression[MeSHID:D003863],Cognition[MeSHID:D003071],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Neuralgia[MeSHID:D009437],Traumatic injury[MeSHID:D014947],Cerebrovascular accident[MeSHID:D020521],Anxiety[MeSHID:D001007] experimental nischarin NISCH NA agonist NA drugbank moxonidine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved,investigational nischarin NISCH NA agonist NA drugbank muramyl dipeptide NA NA investigative nlr pyrin domain containing 1 NLRP1 Literature-reported target agonist NA TTD , DGIDB dapansutrile NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Pain[MeSHID:D059352],Gout[MeSHID:D006073] phase 2 caterpiller protein 1.1 NLRP3 Clinical trial target inhibitor 14.14 TTD , DGIDB mcc950 NA NA investigative caterpiller protein 1.1 NLRP3 Clinical trial target inhibitor NA TTD , DGIDB dapansutrile NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Pain[MeSHID:D059352],Gout[MeSHID:D006073] phase 2 caterpiller protein 1.1 NLRP3 Clinical trial target unknown 14.14 TTD , DGIDB bms-986299 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 caterpiller protein 1.1 NLRP3 Clinical trial target unknown NA TTD 2'-deoxyguanosine-5'-diphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational nucleoside diphosphate kinase a NME1 NA unknown NA drugbank selenocysteine small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational nucleoside diphosphate kinase a NME1 NA inhibitor NA drugbank guanosine-5'-diphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank 2',3'-dideoxy-3'-fluoro-urididine-5'-diphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank zidovudine diphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental nucleoside diphosphate kinase a NME1 NA inhibitor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nucleoside diphosphate kinase a NME1 NA unknown NA drugbank 2',3'-dehydro-2',3'-deoxy-thymidine 5'-diphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational nucleoside diphosphate kinase a NME1 NA unknown NA drugbank thymidine-5'- diphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank adenosine phosphonoacetic acid small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank 2'-deoxyguanosine-5'-triphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank 3'-deoxy 3'-amino adenosine-5'-diphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank stavudine triphosphate small molecule NA experimental nucleoside diphosphate kinase a NME1 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental nucleoside diphosphate kinase b NME2 NA unknown NA drugbank nicotinamide mononucleotide small molecule NA experimental nicotinamide mononucleotide adenylyltransferase 1 NMNAT1 NA unknown NA drugbank deamido-nad+ small molecule NA experimental nicotinamide mononucleotide adenylyltransferase 1 NMNAT1 NA unknown NA drugbank alpha,beta-methyleneadenosine 5'-triphosphate small molecule NA experimental nicotinamide mononucleotide adenylyltransferase 3 NMNAT3 NA unknown NA drugbank deamido-nad+ small molecule NA experimental nicotinamide mononucleotide adenylyltransferase 3 NMNAT3 NA unknown NA drugbank nicotinamide mononucleotide small molecule NA experimental nicotinamide mononucleotide adenylyltransferase 3 NMNAT3 NA unknown NA drugbank 2-(4-chloro-phenylamino)-nicotinic acid small molecule NA experimental nmra-like family domain-containing protein 1 NMRAL1 NA unknown NA drugbank (1-methyl-1h-imidazol-2-yl)-(3-methyl-4-{3-[(pyridin-3-ylmethyl)-amino]-propoxy}-benzofuran-2-yl)-methanone small molecule NA experimental glycylpeptide n-tetradecanoyltransferase 1 NMT1 NA unknown NA drugbank myristoyl-coa small molecule NA experimental glycylpeptide n-tetradecanoyltransferase 2 NMT2 NA unknown NA drugbank 1-(cyclohexylamino)-3-(6-methyl-3,4-dihydro-1h-carbazol-9(2h)-yl)propan-2-ol small molecule NA experimental glycylpeptide n-tetradecanoyltransferase 2 NMT2 NA unknown NA drugbank s-(2-oxo)pentadecylcoa small molecule NA experimental glycylpeptide n-tetradecanoyltransferase 2 NMT2 NA unknown NA drugbank (z)-3-benzyl-5-(2-hydroxy-3-nitrobenzylidene)-2-thioxothiazolidin-4-one small molecule NA experimental glycylpeptide n-tetradecanoyltransferase 2 NMT2 NA unknown NA drugbank pmid24999562c8d NA NA investigative neuromedin-u receptor 1 NMUR1 Literature-reported target unknown NA TTD pmid24999562c6b NA NA investigative neuromedin-u receptor 2 NMUR2 Literature-reported target unknown NA TTD r-psop NA NA investigative neuromedin-u receptor 2 NMUR2 Literature-reported target antagonist NA TTD , DGIDB niacin small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Myocardial Infarction[MeSHID:D009203],Avitaminosis[MeSHID:D001361],Dyslipidemias[MeSHID:D050171] approved,investigational,nutraceutical nicotinamide n-methyltransferase NNMT NA binder 28.29 drugbank , DGIDB xanthinol small molecule Metabolism[MeSHID:D008660],Brain[MeSHID:D001921],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Hyperlipidemia[MeSHID:D006949],Peripheral Vascular Diseases[MeSHID:D016491],Memory[MeSHID:D008568],Blood[MeSHID:D001769],Awareness[MeSHID:D001364] approved,withdrawn nad(p) transhydrogenase, mitochondrial NNT NA cofactor NA drugbank 7-thionicotinamide-adenine-dinucleotide phosphate small molecule NA experimental nad(p) transhydrogenase, mitochondrial NNT NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical nad(p) transhydrogenase, mitochondrial NNT NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental nad(p) transhydrogenase, mitochondrial NNT NA unknown NA drugbank meso-dap NA NA investigative pattern recognition receptor nod1 NOD1 Literature-reported target agonist NA TTD , DGIDB muramyl dipeptide NA NA investigative pattern recognition receptor nod2 NOD2 Clinical trial target agonist NA TTD , DGIDB sb-9200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 pattern recognition receptor nod2 NOD2 Clinical trial target unknown 5.3 TTD , DGIDB mis-416 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Diabetes, Autoimmune[MeSHID:D003922] phase 2 pattern recognition receptor nod2 NOD2 Clinical trial target unknown NA TTD , DGIDB mifamurtide small molecule Operative Surgical Procedures[MeSHID:D013514],Osteosarcoma[MeSHID:D012516],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,experimental nucleotide-binding oligomerization domain-containing protein 2 NOD2 NA ligand NA drugbank doxorubicin small molecule Epithelial ovarian cancer[MeSHID:C538090],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Bronchogenic Carcinoma[MeSHID:D002283],Carcinoma[MeSHID:D002277],Urinary Bladder[MeSHID:D001743],Nephroblastoma[MeSHID:D009396],lymph nodes[MeSHID:D008198],Leukemia, Myelocytic, Acute[MeSHID:D015470],Thyroid carcinoma[MeSHID:D013964],Body tissue[MeSHID:D014024],Regression - mental defense mechanism[MeSHID:D012043],Lymphoma[MeSHID:D008223],Stomach[MeSHID:D013270],Osteosarcoma[MeSHID:D012516],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Neuroblastoma[MeSHID:D009447],Carcinoma, Transitional Cell[MeSHID:D002295],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational nucleolar and coiled-body phosphoprotein 1 NOLC1 NA unknown NA drugbank theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved nodal modulator 1 NOMO1 NA unknown NA drugbank 4-hydroxy-3-nitrophenylacetyl-epsilon-aminocaproic acid anion small molecule NA experimental ig lambda chain v region 4a None NA unknown NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved serine hydroxymethyltransferase None NA product of NA drugbank 4-hydroxy-5-iodo-3-nitrophenylacetyl-epsilon-aminocaproic acid anion small molecule NA experimental ig lambda chain v region 4a None NA unknown NA drugbank mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved 5ht3 serotonin receptor None NA antagonist NA drugbank dodecyldimethylamine n-oxide small molecule NA experimental ig kappa chain v-i region bi None NA unknown NA drugbank besilesomab biotech Solutions[MeSHID:D012996],Communicable Diseases[MeSHID:D003141],Osteomyelitis[MeSHID:D010019],Diagnosis[MeSHID:D003933],Inflammation[MeSHID:D007249],Bone Tissue[MeSHID:D001842],Infection[MeSHID:D007239] approved carcinoembryonic antigen None NA unknown NA drugbank 4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol small molecule NA experimental met proto-oncogene variant None NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical phosphorylase None NA cofactor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical hepatic peroxysomal alanine:glyoxylate aminotransferase None NA cofactor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine hydroxymethyltransferase None NA cofactor NA drugbank (1s)-1-phenylethyl (4-acetamidobenzyl)phosphonate small molecule NA experimental hepatitis b virus receptor binding protein None NA unknown NA drugbank galantamine small molecule ,Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved muscle nicotinic acetylcholine receptor None NA allosteric modulator NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical serine hydroxymethyltransferase None NA cofactor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational ig kappa chain v-iii region gol None NA unknown NA drugbank etiocholanedione small molecule NA experimental ig kappa chain v-ii region rpmi 6410 None NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical selenocysteine lyase variant None NA cofactor NA drugbank sobetirome small molecule NA investigational thyroid hormone receptor, alpha isoform 1 variant None NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational ig kappa chain v-iii region gol None NA unknown NA drugbank (1s,2s,5s)2-(4-glutaridylbenzyl)-5-phenyl-1-cyclohexanol small molecule NA experimental uncharacterized protein None NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational ig kappa chain v-iii region gol None NA unknown NA drugbank as-8112 small molecule Expiration, function[MeSHID:D045853],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Vomiting[MeSHID:D014839] experimental 5ht3 serotonin receptor None NA antagonist NA drugbank fluorescein small molecule Angioscopy[MeSHID:D017546],Diagnosis[MeSHID:D003933],gastric fundus[MeSHID:D005748],Iris (Eye)[MeSHID:D007498],Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ig kappa chain v-ii region rpmi 6410 None NA other NA drugbank pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational ig lambda chain v-ii region mgc None NA unknown NA drugbank 4-[(2-methyl-1h-imidazol-1-yl)methyl]pyridine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2'-monophosphoadenosine 5'-diphosphoribose NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2-butyl-1-hydroxyguanidine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank heme NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2-amino-4-methylpyridine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 6-bromo-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-[3-(aminomethyl)benzyl]acetamidine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank 1-(benzhydrylamino)ethaniminium bromide NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-omega-propyl-l-arginine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD l-n(omega)-nitroarginine-2,4-l-diaminobutyric amide small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 1-benzyl-2-methyl-1h-imidazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n*1*-(5-methyl-2-nitro-phenyl)-butane-1,4-diamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (5-imino-[1,4]thiazepan-3-yl)-methanol NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-(2-nitro-ethyl)-[1,4]oxazepan-(5z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-n-allyl-arginine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank 4-methyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD octahydro-isoindol-(1z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD alpha-d-mannose NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD s-ethyl-n-phenyl-isothiourea small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank 1-hydroxy-2-isopropylguanidine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank methylene blue small molecule Hypotension[MeSHID:D007022],Hypoxia[MeSHID:D000860],Liver Cirrhosis[MeSHID:D008103],Hepatopulmonary Syndrome[MeSHID:D020065],Methemoglobinemia[MeSHID:D008708],Urinary tract infection[MeSHID:D014552],Neurotoxicity Syndromes[MeSHID:D020258],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nitric oxide synthase, brain NOS1 NA inhibitor NA drugbank 3-bromo-7-nitroindazole small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank thiocitrulline NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-omega-propyl-l-arginine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank 5-bromomethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD nicotinamide adenine dinucleotide phosphate small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank n5-(1-iminobut-3-enyl)-l-ornithine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 1-[(3-methoxybenzyl)amino]ethaniminium chloride NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 7-bromo-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-ethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (r)-3-propyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD hexahydro-cyclopenta[c]pyrrol-(1z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n5-(1-iminopent-3-enyl)-l-ornithine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-omega-propargyl-l-arginine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n(5)-[(hydroxyamino)(imino)methyl]-l-ornithine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank [1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved nitric oxide synthase, brain NOS1 NA unknown NA drugbank 4-butyl-thiazolidin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD piperidin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nitric oxide synthase, brain NOS1 NA inhibitor,inducer NA drugbank formic acid NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD ((e)-7-but-2-enyl)-azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4,5-dimethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD s-ethyl-n-phenyl-isothiourea NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-ethyl-4-propyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (5s,6s)-[octahydro-quinolin-(2e)-ylidene]amine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD nxn-188 NA Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD , DGIDB acetate ion NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-methyl-5-propyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n5-(1-iminobutyl)-l-ornithine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2-aminothiazoline NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-ethyl-4-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-ethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-n-allyl-arginine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved nitric oxide synthase, brain NOS1 NA inhibitor NA drugbank 3-propyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-methyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-methyl-piperidin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-bromo-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD s-ethyl-n-[4-(trifluoromethyl)phenyl]isothiourea NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD [(1s)-4-(1-aminobutylideneamino)-1-carboxybutyl]azanium small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank 4-chloro-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD azocan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 6-chloro-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-(5-amino-6-oxo-heptyl)-acetamidine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD eusynstyelamide b NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 7-chloro-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4,5,6,7-tetrafluoro-3-methyl-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank eusynstyelamide c NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 7-methoxy-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD l-nio NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n5-(1-imino-3-butenyl)-l-ornithine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD [1,4]oxazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-isopropyl-n'-hydroxyguanidine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 7-butyl-azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD s-ethyl-n-[4-(trifluoromethyl)phenyl]isothiourea small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank 7-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-bromo-7-nitro-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-ethyl-3-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-butyl-n'-hydroxyguanidine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-(2-amino-ethyl)-5-imino-[1,4]oxazepane NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD hexahydro-cyclopenta[b]pyrrol-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-isopropyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2-aminopyridine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD nxn-188 small molecule Cluster Headache[MeSHID:D003027],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nitric oxide synthase, brain NOS1 NA unknown NA drugbank , DGIDB 6-isobutyl-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-bromo-1h-indazole-7-carbonitrile NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-ethyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD [1,4]thiazepan-(3e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD [1,3]thiazinan-(2e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD tetrahydro-pyrimidin-2-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (+/-)-2-methyl-1-(1-phenylethyl)-1h-imidazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-isobutyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD flavin-adenine dinucleotide NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD formic acid small molecule NA experimental,investigational nitric oxide synthase, brain NOS1 NA unknown NA drugbank flavin mononucleotide small molecule NA approved,investigational nitric oxide synthase, brain NOS1 NA unknown NA drugbank n-omega-allyl-l-arginine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-bromo-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (6r,1'r,2's)-5,6,7,8 tetrahydrobiopterin NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 6-(2-fluoropropyl)-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (4s,5r)-4,5-diethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-iodo-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-omega-hydroxy-l-arginine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nitric oxide synthase, brain NOS1 NA inhibitor NA drugbank n-{(3r,4s)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-n'-(3-chlorobenzyl)ethane-1,2-diamine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank 3,4-dihydro-1h-quinolin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-chloro-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD methylene blue small molecule Hypotension[MeSHID:D007022],Hypoxia[MeSHID:D000860],Liver Cirrhosis[MeSHID:D008103],Hepatopulmonary Syndrome[MeSHID:D020065],Methemoglobinemia[MeSHID:D008708],Urinary tract infection[MeSHID:D014552],Neurotoxicity Syndromes[MeSHID:D020258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nitric oxide synthase, brain NOS1 NA inhibitor NA drugbank nxn-462 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] phase 2 nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD , DGIDB (4s,5s)-4,5-diethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD nitroarginine small molecule NA experimental,investigational nitric oxide synthase, brain NOS1 NA unknown NA drugbank [1,4]oxazepan-(3e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-{(3s,4s)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-n'-(4-chlorobenzyl)ethane-1,2-diamine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank (4s,5r)-4,5-dimethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD l-n(omega)-nitroarginine-(4r)-amino-l-proline amide small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD [1,3]oxazinan-(2e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2-amino-5-(n-nitro-guanidino)-pentanoic acid NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-iodo-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (s)-3-propyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 1400w NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (s)-6-amino-2-(2-imino-ethylamino)-hexanoic acid NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 5-ethyl-3-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2-(2-amino-ethyl)-7-imino-azepane NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD ar-c102222 NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 7-nitro-1h-indazole NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-ethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 7-(2-nitro-ethyl)-azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3,4-dimethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 3-butyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n-{(4s)-4-amino-5-[(2-aminoethyl)amino]pentyl}-n'-nitroguanidine small molecule NA experimental nitric oxide synthase, brain NOS1 NA unknown NA drugbank (s)-2-amino-5-(n-methyl-guanidino)-pentanoic acid NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD azonan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD citrulline small molecule NA investigational,nutraceutical nitric oxide synthase, brain NOS1 NA unknown NA drugbank ar-c133057xx NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-ethyl-5-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 6-(3-fluoropropyl)-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 2-amino-4,6-dimethylpyridine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD hexahydro-pyrrolizin-(3e)-ylideneamine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD nitroarginine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD n5-(1-iminopropyl)-l-ornithine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD (5s,6r)-[octahydro-quinolin-(2e)-ylidene]amine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 4-methyl-6-propylpyridin-2-amine NA NA investigative nitric-oxide synthase brain NOS1 Clinical trial target unknown NA TTD 6-(2-fluoropropyl)-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD [1,5]thiazocan-(4e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD s-ethylisothiourea small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank (6r,1'r,2's)-5,6,7,8 tetrahydrobiopterin NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD bxt-51072 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 nitric-oxide synthase inducible NOS2 Clinical trial target unknown 2.89 TTD , DGIDB n-[2-(6-amino-4-methylpyridin-2-yl)ethyl]-4-cyanobenzamide small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 4-methyl-piperidin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD mpl-s NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endotoxic shock[MeSHID:D012772] phase 3 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD , DGIDB 6-(4-fluorobutyl)-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n-(5-amino-6-oxo-heptyl)-acetamidine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD octahydro-isoindol-(1z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 6-isobutyl-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-bromomethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD ethyl 4-[(4-chloropyridin-2-yl)amino]piperidine-1-carboxylate small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank (s)-2-amino-5-(n-methyl-guanidino)-pentanoic acid NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 3,4-dihydro-1h-quinolin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD aminoguanidine NA Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] phase 1 nitric-oxide synthase inducible NOS2 Clinical trial target unknown 8.68 TTD , DGIDB 3-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 7-nitroindazole small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 4-(1,3-benzodioxol-5-yloxy)-2-[4-(1h-imidazol-1-yl)phenoxy]-6-methylpyrimidine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 2-aminothiazoline NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD fenoxaprop-ethyl small molecule Coronary Arteriosclerosis[MeSHID:D003324],Angina Pectoris[MeSHID:D000787],Coronary heart disease[MeSHID:D003327] investigational nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 4-ethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 6-methyl-5,6-dihydro-4h-1,3-thiazin-2-amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-methyl-4-propyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD [1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-nitroindazole small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank (3r)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 4-(1,3-benzodioxol-5-yloxy)-2-[4-(1h-imidazol-1-yl)phenoxy]pyrimidine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank [1,4]oxazepan-(3e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 1-(6-cyano-3-pyridylcarbonyl)-5',8'-difluorospiro[piperidine-4,2'(1'h)-quinazoline]-4'-amine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank (4s,5r)-4,5-dipropyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-ethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD ono-1714 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 1 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-ethyl-5-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD ethylisothiourea NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD l-nio NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n-[3-(aminomethyl)benzyl]acetamidine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank heme NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (s)-n-(1-phenylethyl)acetimidamide hydrobromide NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD gw274150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 nitric-oxide synthase inducible NOS2 Clinical trial target inhibitor 1.93 TTD , DGIDB (5s,6s)-[octahydro-quinolin-(2e)-ylidene]amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 1400w NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target inhibitor 5.79 TTD , DGIDB n-[2-(4-amino-5,8-difluoro-1,2-dihydroquinazolin-2-yl)ethyl]-3-furamide small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank n,n-dimethylarginine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD b-octylglucoside NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-(4'-amino-1'-ethyl-5',8'-difluoro-1'h-spiro[piperidine-4,2'-quinazoline]-1-ylcarbonyl)picolinonitrile small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank dexamethasone acetate small molecule NA approved,investigational,vet_approved nitric oxide synthase, inducible NOS2 NA negative modulator NA drugbank 4-methyl-5-propyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4r-fluoro-n6-ethanimidoyl-l-lysine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-methyl-6-(2-methylprop-1-enyl)pyridin-2-amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n5-(1-iminobutyl)-l-ornithine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD thiocitrulline small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 4-(1h-imidazol-1-yl)phenol NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD l-erythro-7,8-dihydrobiopterin small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational,vet_approved nitric oxide synthase, inducible NOS2 NA negative modulator NA drugbank 3-(2-amino-ethyl)-5-imino-[1,4]oxazepane NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1h-imidazol-1-yl)-6-methylpyrimidin-4-yl]-d-prolinamide small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 4-methyl-6-propylpyridin-2-amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-isopropyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4,5-dimethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 2-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 3-ethyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4r-fluoro-n6-ethanimidoyl-l-lysine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank n,n-dimethylarginine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank azocan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 2-(2-amino-ethyl)-7-imino-azepane NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-ethyl-3-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n-omega-propyl-l-arginine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank [1,4]thiazepan-(3e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-ethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (2s)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank cr-3294 NA Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD , DGIDB 2-amino-5-(n-nitro-guanidino)-pentanoic acid NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD kd-7332 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 7-butyl-azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD piperidin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD thiocitrulline NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 3-(2-nitro-ethyl)-[1,4]oxazepan-(5z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 nitric-oxide synthase inducible NOS2 Clinical trial target unknown 0.04 TTD , DGIDB (r)-3-propyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n5-(1-iminobut-3-enyl)-l-ornithine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD ((e)-7-but-2-enyl)-azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n5-(1-iminopropyl)-l-ornithine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-ethyl-4-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-methyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-[(2-methyl-1h-imidazol-1-yl)methyl]pyridine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 2-amino-4-methylpyridine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target inhibitor NA TTD , DGIDB ethyl 4-[(4-methylpyridin-2-yl)amino]piperidine-1-carboxylate small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 4,5,6,7-tetrafluoro-3-methyl-1h-indazole NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 1-[4-(aminomethyl)benzoyl]-5'-fluoro-1'h-spiro[piperidine-4,2'-quinazolin]-4'-amine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical nitric oxide synthase, inducible NOS2 NA unknown NA drugbank n-benzylacetimidamide hydrobromide NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank hexahydro-cyclopenta[c]pyrrol-(1z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (e)-4-methyl-6-(prop-1-enyl)pyridin-2-amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 7-(2-nitro-ethyl)-azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD azonan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 7-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 5-ethyl-4-propyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD ginkgo biloba biotech Memory[MeSHID:D008568],Cognition[MeSHID:D003071] approved,investigational,nutraceutical nitric oxide synthase, inducible NOS2 NA inhibitor NA drugbank 3-bromo-7-nitroindazole small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank n-omega-propyl-l-arginine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-methyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD pimagedine small molecule Diabetic Nephropathy[MeSHID:D003928] investigational nitric oxide synthase, inducible NOS2 NA inhibitor NA drugbank n(5)-[(hydroxyamino)(imino)methyl]-l-ornithine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank byk-191023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD resveratrol potassium4,-sulfate NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD cddo NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nitric oxide synthase, inducible NOS2 NA inhibitor NA drugbank 3-bromo-7-nitro-1h-indazole NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nitric oxide synthase, inducible NOS2 NA negative modulator NA drugbank (s)-6-amino-2-(2-imino-ethylamino)-hexanoic acid NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n-omega-hydroxy-l-arginine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD [1,3]thiazinan-(2e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD aminoguanidine NA Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] phase 1 nitric-oxide synthase inducible NOS2 Clinical trial target inhibitor 8.68 TTD , DGIDB gw274150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 nitric-oxide synthase inducible NOS2 Clinical trial target unknown 1.93 TTD , DGIDB (5-imino-[1,4]thiazepan-3-yl)-methanol NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD [1,3]oxazinan-(2e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (s)-2-amino-6-[(e)-ethylimino]-hexanoic acid NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4,5,6,7-tetrafluoro-3-perfluorophenyl-1h-indazole NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (4s,5r)-4,5-diethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (4s,5s)-4,5-diethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD pimagedine hcl NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD , DGIDB (5s,6r)-[octahydro-quinolin-(2e)-ylidene]amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 6-(3-fluoropropyl)-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational nitric oxide synthase, inducible NOS2 NA inhibitor NA drugbank 3-propyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD sd-6010 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD , DGIDB (4s,5s)-4,5-dipropyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (s)-3-propyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD imidazole small molecule NA experimental,investigational nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 7,8-dihydrobiopterin NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (4s,5r)-4,5-dimethyl-oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 3-bromo-1h-indazole-7-carbonitrile NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD l-thiocitrulline NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n-omega-propargyl-l-arginine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 7-nitro-1h-indazole NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD hp-228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain, Postoperative[MeSHID:D010149] phase 2 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD , DGIDB 3,4-dimethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD sklb-010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 3-butyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD ar-c133057xx NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 6-nitroindazole NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank thiocoumarin NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 3-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD triflusal small molecule Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Cerebrovascular accident[MeSHID:D020521] approved,investigational nitric oxide synthase, inducible NOS2 NA agonist NA drugbank kd7040 small molecule NA investigational nitric oxide synthase, inducible NOS2 NA unknown 2.89 drugbank , DGIDB lt-1951 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 1/2 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD , DGIDB [1,4]oxazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD aminothiazoline NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 3-isobutyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD nostentin NA Stenosis[MeSHID:D003251],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteries[MeSHID:D001158] discontinued in phase 1 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD kd-7040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Pain[MeSHID:D010146],Bulbo-Spinal Atrophy, X-Linked[MeSHID:D055534] phase 2 nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD , DGIDB pibtu NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target inhibitor NA TTD , DGIDB oxazolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 4-(1h-imidazol-1-yl)phenol small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank thiocoumarin small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 4-butyl-thiazolidin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD (3s)-1-(1,3-benzodioxol-5-ylmethyl)-3-[4-(1h-imidazol-1-yl)phenoxy]piperidine small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank 3-butyl-[1,4]oxazepan-(5z)-ylideneamine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD levamlodipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nitric oxide synthase, inducible NOS2 NA agonist NA drugbank 5-nitroindazole NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 1-(6-amino-4-methylpyridin-2-yl)propan-2-ol NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD n-omega-allyl-l-arginine NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD 6-nitroindazole small molecule NA experimental nitric oxide synthase, inducible NOS2 NA unknown NA drugbank ar-c102222 NA NA investigative nitric-oxide synthase inducible NOS2 Clinical trial target unknown NA TTD dipyrithione small molecule Scalp structure[MeSHID:D012535],Seborrheic dermatitis of scalp[MeSHID:D063807] approved nitric oxide synthase, inducible NOS2 NA antagonist NA drugbank 4,5-dimethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD l-n(omega)-nitroarginine-(4r)-amino-l-proline amide small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank canavanine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 3,4-dimethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n,n-dimethylarginine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank (5s,6r)-[octahydro-quinolin-(2e)-ylidene]amine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD thiocitrulline NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD se-ethyl-isoselenourea small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank l-nio NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n-omega-allyl-l-arginine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 6s-5,6,7,8-tetrahydrobiopterin small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank s-isopropyl-isothiourea small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank n-(5-amino-6-oxo-heptyl)-acetamidine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD tilarginine acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787],Myocardial Infarction[MeSHID:D009203] phase 3 nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD , DGIDB [1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n-omega-propargyl-l-arginine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD cacodylate ion NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n-omega-hydroxy-l-arginine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD mtr105 NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD , DGIDB l-homoarginine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD (5-imino-[1,4]thiazepan-3-yl)-methanol NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 3-bromo-1h-indazole-7-carbonitrile NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 7-nitroindazole-2-carboxamidine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n-(chlorophenyl)-n'-hydroxyguanidine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank n(g)-iminoethylornithine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 6-isobutyl-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 4-ethyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n-{(3r,4s)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-n'-(3-chlorobenzyl)ethane-1,2-diamine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 2-methyl-2,4-pentanediol NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 7-nitroindazole-2-carboxamidine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank n-[3-(aminomethyl)benzyl]acetamidine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank (3s,5e)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2h)-imine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 2,4-diamino-6-phenyl-5,6,7,8,-tetrahydropteridine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 4-ethyl-5-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD (s)-6-amino-2-(2-imino-ethylamino)-hexanoic acid NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD se-ethyl-isoselenourea NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD piperidin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n,n-dimethylarginine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 4-methyl-piperidin-(2e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD [1,4]oxazepan-(3e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD s-ethyl-n-phenyl-isothiourea small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 3-bromo-7-nitro-1h-indazole NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 2-amino-4-methylpyridine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n-{(3s,4s)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-n'-(4-chlorobenzyl)ethane-1,2-diamine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank acetate ion NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 1,2,4-triazole-carboxamidine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 5,6-cyclic-tetrahydropteridine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 2-aminothiazoline small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank cacodylic acid small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank n5-(1-iminobut-3-enyl)-l-ornithine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 6-(3-fluoropropyl)-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 6-nitroindazole NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD s-ethyl-n-phenyl-isothiourea NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 7-nitroindazole small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 7-nitro-1h-indazole NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD s-ethylisothiourea small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank [1,4]thiazepan-(3e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 7-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD s-(dimethylarsenic)cysteine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n5-(1-iminopropyl)-l-ornithine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD ethyl 4-[(4-methylpyridin-2-yl)amino]piperidine-1-carboxylate small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 6s-5,6,7,8-tetrahydrobiopterin NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 2-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD hydroxydimethylarsine oxide NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 2-propanol, isopropanol NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD vas-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] phase 2 nitric-oxide synthase endothelial NOS3 Clinical trial target unknown 2.77 TTD , DGIDB s,s'-(1,3-phenylene-bis(1,2-ethanediyl))bis-isothiourea small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank autologous cell based gene therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976],Cells[MeSHID:D002477] phase 1 nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD , DGIDB 5-ethyl-4-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 6-(2-fluoropropyl)-4-methylpyridin-2-amine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD ap-cav NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n-(chlorophenyl)-n'-hydroxyguanidine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD nitroarginine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nitric oxide synthase, endothelial NOS3 NA inhibitor NA drugbank 3-methyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD sapropterin small molecule Malnutrition[MeSHID:D044342] approved,investigational nitric oxide synthase, endothelial NOS3 NA cofactor NA drugbank hexahydro-cyclopenta[c]pyrrol-(1z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD l-2-amino-4-(guanidinooxy)butyric acid NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD levamlodipine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nitric oxide synthase, endothelial NOS3 NA agonist NA drugbank 2,4-diamino-6-phenyl-5,6,7,8,-tetrahydropteridine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank s-(dimethylarsenic)cysteine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank n1,n14-bis((s-methyl)isothioureido)tetradecane small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank n(5)-[(hydroxyamino)(imino)methyl]-l-ornithine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 7-(2-nitro-ethyl)-azepan-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD l-name NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 nitric-oxide synthase endothelial NOS3 Clinical trial target unknown 2.77 TTD , DGIDB 4-methyl-5,6-dihydro-1h-pyridin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 5-nitroindazole NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 3-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD acclaim NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] phase 2 nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD , DGIDB (6r,1'r,2's)-5,6,7,8 tetrahydrobiopterin NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 4-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 6-nitroindazole small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 5-ethyl-3-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 1400w NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD l-homoarginine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank (s)-2-amino-5-(n-methyl-guanidino)-pentanoic acid NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 5-nitroindazole small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank (s)-3-propyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD s-isopropyl-isothiourea NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD nitroarginine small molecule NA experimental,investigational nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank [1,3]thiazinan-(2e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 1,2,4-triazole-carboxamidine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD s,s'-(1,4-phenylene-bis(1,2-ethanediyl))bis-isothiourea small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 4-methyl-6-propylpyridin-2-amine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD (5s,6s)-[octahydro-quinolin-(2e)-ylidene]amine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD heme NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD l-n(omega)-nitroarginine-2,4-l-diaminobutyric amide small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank n5-(1-iminobutyl)-l-ornithine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n-{(4s)-4-amino-5-[(2-aminoethyl)amino]pentyl}-n'-nitroguanidine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 5,6-cyclic-tetrahydropteridine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 2-amino-5-(n-nitro-guanidino)-pentanoic acid NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 4-ethyl-5,6-dihydro-1h-pyridin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 5-{4-[(3,5-difluorobenzyl)amino]phenyl}-6-ethylpyrimidine-2,4-diamine small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank 3-ethyl-[1,4]thiazepan-(5e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 3-bromo-7-nitroindazole small molecule NA experimental nitric oxide synthase, endothelial NOS3 NA unknown NA drugbank [1,3]oxazinan-(2e)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD n1,n14-bis((s-methyl)isothioureido)tetradecane NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 4-methyl-3,6-dihydro-1h-pyridin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 5-methyl-pyrrolidin-(2z)-ylideneamine NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD ethylisothiourea NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD 2-aminothiazoline NA NA investigative nitric-oxide synthase endothelial NOS3 Clinical trial target unknown NA TTD ly3039478 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218],Lymphoma[MeSHID:D008223] phase 1/2 notch-1 receptor NOTCH1 Clinical trial target unknown 3.74 TTD , DGIDB omp-52m51 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 notch-1 receptor NOTCH1 Clinical trial target unknown 11.23 TTD , DGIDB tarextumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Small cell carcinoma of lung[MeSHID:D055752],Pancreatic carcinoma[MeSHID:C562463] phase 2 notch-2 receptor NOTCH2 Clinical trial target antibody 31.83 TTD , DGIDB tarextumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Small cell carcinoma of lung[MeSHID:D055752],Pancreatic carcinoma[MeSHID:C562463] phase 2 notch-2 receptor NOTCH2 Clinical trial target unknown 31.83 TTD , DGIDB tarextumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Small cell carcinoma of lung[MeSHID:D055752],Pancreatic carcinoma[MeSHID:C562463] phase 2 notch-3 receptor NOTCH3 Clinical trial target antibody 63.65 TTD , DGIDB tarextumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Small cell carcinoma of lung[MeSHID:D055752],Pancreatic carcinoma[MeSHID:C562463] phase 2 notch-3 receptor NOTCH3 Clinical trial target unknown 63.65 TTD , DGIDB ly3039478 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218],Lymphoma[MeSHID:D008223] phase 1/2 notch-4 receptor NOTCH4 Clinical trial target unknown 7.96 TTD , DGIDB insulin human biotech Diabetes Mellitus[MeSHID:D003920] approved,investigational protein nov homolog NOV NA downregulator NA drugbank oxygen small molecule Hypoxia[MeSHID:D000860],Disease[MeSHID:D004194],Body tissue[MeSHID:D014024],Drug Overdose[MeSHID:D062787],Poisoning[MeSHID:D011041],Traumatic injury[MeSHID:D014947],Hyperoxia[MeSHID:D018496],Dyspnea[MeSHID:D004417],Oxygen Consumption[MeSHID:D010101] approved,vet_approved nadph oxidase 1 NOX1 NA agonist,activator NA drugbank gkt-137831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355] phase 2 nadph oxidase 4 NOX4 Clinical trial target unknown NA TTD , DGIDB ecabet small molecule Peptic Esophagitis[MeSHID:D004942],Peptic Ulcer[MeSHID:D010437] investigational nadph oxidase organizer 1 NOXO1 NA antagonist NA drugbank ezetimibe small molecule Homozygote[MeSHID:D006720],Hyperlipidemia, Familial Combined[MeSHID:D006950],Hyperlipidemia[MeSHID:D006949],Sitosterolemia[MeSHID:C537345],Hypercholesterolemia, Familial[MeSHID:D006938],Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved niemann-pick c1-like protein 1 NPC1L1 Successful target inhibitor,antagonist 175.04 TTD , drugbank , DGIDB ezetimibe-glucuronide NA NA investigative niemann-pick c1-like protein 1 NPC1L1 Successful target unknown NA TTD ezetimibe small molecule Homozygote[MeSHID:D006720],Hyperlipidemia, Familial Combined[MeSHID:D006950],Hyperlipidemia[MeSHID:D006949],Sitosterolemia[MeSHID:C537345],Hypercholesterolemia, Familial[MeSHID:D006938],Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved niemann-pick c1-like protein 1 NPC1L1 Successful target inhibitor 175.04 TTD , drugbank , DGIDB chr-2797 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Inflammation[MeSHID:D007249],Expiration, function[MeSHID:D045853] phase 2 puromycin-sensitive aminopeptidase NPEPPS Clinical trial target unknown 3.35 TTD , DGIDB tosedostat small molecule NA investigational puromycin-sensitive aminopeptidase NPEPPS NA inhibitor 3.35 drugbank , DGIDB antaq NA NA investigative puromycin-sensitive aminopeptidase NPEPPS Clinical trial target inhibitor 31.83 TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational puromycin-sensitive aminopeptidase NPEPPS NA ligand NA drugbank 1dme NA NA investigative neuropeptide ff receptor 1 NPFFR1 Literature-reported target agonist NA TTD , DGIDB rf9 NA NA investigative neuropeptide ff receptor 1 NPFFR1 Literature-reported target antagonist NA TTD , DGIDB rf9 NA NA investigative neuropeptide ff receptor 2 NPFFR2 Literature-reported target antagonist NA TTD , DGIDB 1dme NA NA investigative neuropeptide ff receptor 2 NPFFR2 Literature-reported target agonist NA TTD , DGIDB ipp-204106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 nucleophosmin NPM1 Clinical trial target unknown NA TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational nucleophosmin NPM1 NA ligand NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational natriuretic peptides b NPPB NA other NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational natriuretic peptides b NPPB NA other NA drugbank oxymetholone small molecule Pyridoxine Deficiency[MeSHID:D026681],Fanconi Anemia[MeSHID:D005199],Primary Myelofibrosis[MeSHID:D055728],Aplastic Anemia[MeSHID:D000741],Anemia[MeSHID:D000740],Erythropoiesis[MeSHID:D004920],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit natriuretic peptides b NPPB NA unknown NA drugbank bmn-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Achondroplasia[MeSHID:D000130] phase 3 c-type natriuretic peptide NPPC Clinical trial target unknown 3.18 TTD , DGIDB nesiritide NA Congestive heart failure[MeSHID:D006333],Dyspnea[MeSHID:D004417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atrial natriuretic peptide receptor a NPR1 Successful target unknown 13.26 TTD , DGIDB nitroglycerin small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Hypotension[MeSHID:D007022],Relaxation[MeSHID:D012063],Angina Pectoris[MeSHID:D000787],Coronary Artery Vasospasm[MeSHID:D003329],Heart failure[MeSHID:D006333],Cardiovascular Diseases[MeSHID:D002318],Muscle Spasticity[MeSHID:D009128],Hemorrhage[MeSHID:D006470],Uterus[MeSHID:D014599],Off-Label Use[MeSHID:D056687],Myocardial Infarction[MeSHID:D009203],Chest Pain[MeSHID:D002637],Pain[MeSHID:D010146],Emergencies [Disease/Finding][MeSHID:D004630],Anal Fissure[MeSHID:D005401],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved,investigational atrial natriuretic peptide receptor 1 NPR1 NA agonist 3.18 drugbank , DGIDB pl-3994 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Asthma[MeSHID:D001249] phase 2 atrial natriuretic peptide receptor a NPR1 Successful target unknown 15.91 TTD , DGIDB erythrityl tetranitrate small molecule Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational atrial natriuretic peptide receptor 1 NPR1 NA agonist NA drugbank , DGIDB nesiritide NA Congestive heart failure[MeSHID:D006333],Dyspnea[MeSHID:D004417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atrial natriuretic peptide receptor a NPR1 Successful target agonist 13.26 TTD , DGIDB cenderitide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333],Heart Diseases[MeSHID:D006331] phase 2 atrial natriuretic peptide receptor a NPR1 Successful target agonist 7.96 TTD , DGIDB amyl nitrite small molecule Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved atrial natriuretic peptide receptor 1 NPR1 NA agonist NA drugbank nesiritide biotech Congestive heart failure[MeSHID:D006333],Dyspnea[MeSHID:D004417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atrial natriuretic peptide receptor 1 NPR1 NA binder 13.26 drugbank , DGIDB isosorbide dinitrate small molecule Coronary Arteriosclerosis[MeSHID:D003324],Angina Pectoris[MeSHID:D000787],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anal Fissure[MeSHID:D005401] approved,investigational atrial natriuretic peptide receptor 1 NPR1 NA agonist NA drugbank , DGIDB cenderitide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333],Heart Diseases[MeSHID:D006331] phase 2 atrial natriuretic peptide receptor a NPR1 Successful target unknown 7.96 TTD , DGIDB ularitide NA Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 3 atrial natriuretic peptide receptor a NPR1 Successful target unknown 7.96 TTD , DGIDB nitroprusside small molecule Congestive heart failure[MeSHID:D006333],Hypotension[MeSHID:D007022],Blood Loss, Surgical[MeSHID:D016063],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational atrial natriuretic peptide receptor 1 NPR1 NA agonist 13.26 drugbank , DGIDB pl-3994 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Asthma[MeSHID:D001249] phase 2 atrial natriuretic peptide receptor a NPR1 Successful target agonist 15.91 TTD , DGIDB ataciguat NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 atrial natriuretic peptide receptor a NPR1 Successful target unknown 7.96 TTD , DGIDB nesiritide biotech Congestive heart failure[MeSHID:D006333],Dyspnea[MeSHID:D004417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atrial natriuretic peptide receptor 1 NPR1 NA binder,agonist 13.26 drugbank , DGIDB ularitide small molecule Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] investigational atrial natriuretic peptide receptor 1 NPR1 NA unknown 7.96 drugbank , DGIDB nesiritide biotech Congestive heart failure[MeSHID:D006333],Dyspnea[MeSHID:D004417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atrial natriuretic peptide receptor 2 NPR2 NA unknown 14.14 drugbank , DGIDB erythrityl tetranitrate small molecule Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational atrial natriuretic peptide receptor 2 NPR2 NA agonist NA drugbank , DGIDB vosoritide biotech Growth[MeSHID:D006128],Achondroplasia[MeSHID:D000130],Epiphysis of bone[MeSHID:D004838] approved,investigational atrial natriuretic peptide receptor 2 NPR2 NA agonist 10.61 drugbank , DGIDB m372049 NA NA investigative natriuretic peptide receptor NPR3 Clinical trial target antagonist NA TTD , DGIDB ap811 NA NA investigative natriuretic peptide receptor NPR3 Clinical trial target antagonist NA TTD , DGIDB nesiritide biotech Congestive heart failure[MeSHID:D006333],Dyspnea[MeSHID:D004417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational atrial natriuretic peptide receptor 3 NPR3 NA unknown 21.22 drugbank , DGIDB anx-042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 1 natriuretic peptide receptor NPR3 Clinical trial target unknown NA TTD , DGIDB oxazolo[3,4-a]pyrazine derivative 6 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pi1 NA NA investigative neuropeptide s receptor NPSR1 Patented-recorded target antagonist NA TTD , DGIDB indandione derivative 1 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB oxazolo[3,4-a]pyrazine derivative 5 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pmid27788040-compound-5 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB sha 68 NA NA investigative neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD indandione derivative 2 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3h)-one derivative 1 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB imidazo pyridine derivative 4 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3h)-one derivative 3 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB oxazolo[3,4-a]pyrazine derivative 1 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3h)-one derivative 4 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB indandione derivative 3 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3h)-one derivative 2 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pmid27788040-compound-5a NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB imidazo pyridine derivative 6 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB oxazolo[3,4-a]pyrazine derivative 3 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pmid27788040-compound-6 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB imidazo pyridine derivative 5 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB indanone and indandione derivative 1 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pmid27788040-compound-6b NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pmid27788040-compound-5b NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pmid27788040-compound-5c NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB qa1 NA NA investigative neuropeptide s receptor NPSR1 Patented-recorded target antagonist NA TTD , DGIDB oxazolo[3,4-a]pyrazine derivative 2 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB oxazolo[3,4-a]pyrazine derivative 7 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pmid27788040-compound-6a NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB oxazolo[3,4-a]pyrazine derivative 4 NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB pmid27788040-compound-6c NA NA patented neuropeptide s receptor NPSR1 Patented-recorded target unknown NA TTD , DGIDB halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neuropeptide s receptor NPSR1 NA unknown NA drugbank prm-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary Myelofibrosis[MeSHID:D055728],Thrombocytosis[MeSHID:D013922],Hamman-Rich syndrome[MeSHID:D011658],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Age related macular degeneration[MeSHID:D008268],Polycythemia Vera[MeSHID:D011087] phase 2 neuronal pentraxin-2 NPTX2 Clinical trial target unknown 63.65 TTD , DGIDB 2-aminoisobutyric acid small molecule NA experimental pro-neuropeptide y NPY NA unknown NA drugbank l-tyrosinamide small molecule NA experimental pro-neuropeptide y NPY NA unknown NA drugbank phentermine small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Epidemic[MeSHID:D058872],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Rubella[MeSHID:D012409],Overweight[MeSHID:D050177],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit pro-neuropeptide y NPY NA inhibitor NA drugbank h-[trp-arg-nva-arg-tyr]3-nh2 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD peptide yy (3-36) small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765] investigational neuropeptide y receptor type 1 NPY1R NA unknown NA drugbank pyy(22-36) NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD npy-1 antagonist NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD adp[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD s-19528 NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD [125i]gr231118 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD neuropeptide-y NA NA phase 2 neuropeptide y receptor type 1 NPY1R Clinical trial target unknown 3.98 TTD , DGIDB bms-245782 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD j-104870 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD s-25585 NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD h-[trp-arg-nva-arg-tyr]2-nh2 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD sub[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD lrhylnlltrqry-nh2 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD bms-193885 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown 7.96 TTD , DGIDB pd-160170 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Obesity[MeSHID:D009765],Heart Diseases[MeSHID:D006331] preclinical neuropeptide y receptor type 1 NPY1R Clinical trial target unknown 2.65 TTD , DGIDB [cys-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD bms-189323 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD pim[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD bibo3304 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target antagonist NA TTD , DGIDB acpyy(22-36) NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD gi-264879a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD , DGIDB h-409/22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] discontinued in phase 2 neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD sub[-tyr-arg-leu-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 1 NPY1R Clinical trial target unknown NA TTD biie0246 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target antagonist NA TTD , DGIDB acpyy(25-36) NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD acnpy(25-36) NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD pegylated pyy-3-36 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD pyy3-36 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 2 neuropeptide y receptor type 2 NPY2R Clinical trial target unknown 3.03 TTD , DGIDB obinepitide small molecule Obesity[MeSHID:D009765] investigational neuropeptide y receptor type 2 NPY2R NA unknown 4.55 drugbank , DGIDB peptide yy (3-36) small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765] investigational neuropeptide y receptor type 2 NPY2R NA unknown NA drugbank acpyy(26-36) NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD ac-162352 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD pd-4048 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD jnj-5207787 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target antagonist 9.09 TTD , DGIDB pyy(25-36) NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD h-[trp-arg-nva-arg-tyr]2-nh2 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD pyy(22-36) NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD cysteamine small molecule Nephropathic cystinosis[MeSHID:D003554],Cornea[MeSHID:D003315],Fanconi Syndrome[MeSHID:D005198],Cystinuria[MeSHID:D003555],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neuropeptide y receptor type 2 NPY2R NA unknown NA drugbank sub[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD sub[-tyr-arg-leu-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD tm30338 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 2 neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD , DGIDB lrhylnlltrqry-nh2 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD pim[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD adp[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD h-[trp-arg-nva-arg-tyr]3-nh2 NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD acpyy(22-36) NA NA investigative neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD bms-192548 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical neuropeptide y receptor type 2 NPY2R Clinical trial target unknown NA TTD , DGIDB neuropeptide-y NA NA phase 2 neuropeptide y receptor type 2 NPY2R Clinical trial target unknown 4.55 TTD , DGIDB peptide yy (3-36) small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765] investigational neuropeptide y receptor type 4 NPY4R NA unknown NA drugbank tm30339 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 neuropeptide y receptor type 4 NPY4R Clinical trial target unknown 47.74 TTD , drugbank , DGIDB sub[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD tm30339 small molecule Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 2 neuropeptide y receptor type 4 NPY4R Clinical trial target agonist 47.74 TTD , drugbank , DGIDB pim[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD obinepitide small molecule Obesity[MeSHID:D009765] investigational neuropeptide y receptor type 4 NPY4R NA unknown 7.96 drugbank , DGIDB sub[-tyr-arg-leu-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD [125i]gr231118 NA NA investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD h-[trp-arg-nva-arg-tyr]3-nh2 NA NA investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD adp[-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD [cys-trp-arg-nva-arg-tyr-nh2]2 NA NA investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD pd-4074 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD tm30338 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 2 neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD , DGIDB h-[trp-arg-nva-arg-tyr]2-nh2 NA NA investigative neuropeptide y receptor type 4 NPY4R Clinical trial target unknown NA TTD fr-79620 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eating[MeSHID:D004435],Obesity[MeSHID:D009765],Disease[MeSHID:D004194],Complications of Diabetes Mellitus[MeSHID:D048909] preclinical neuropeptide y receptor type 5 NPY5R Discontinued target unknown 15.91 TTD , DGIDB fr-226928 NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD peptide yy (3-36) small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765] investigational neuropeptide y receptor type 5 NPY5R NA unknown NA drugbank lu-aa33810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD velneperit NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 2 neuropeptide y receptor type 5 NPY5R Discontinued target antagonist 31.83 TTD , DGIDB velneperit NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 2 neuropeptide y receptor type 5 NPY5R Discontinued target unknown 31.83 TTD , DGIDB s-25585 NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD gw-594884a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD , DGIDB s-19528 NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD axovan-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eating[MeSHID:D004435],Obesity[MeSHID:D009765],Disease[MeSHID:D004194] discontinued in phase 1 neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD ar-129330 NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD fms586 NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target antagonist NA TTD , DGIDB fr-230481 NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD l-152,804 NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target antagonist NA TTD , DGIDB cgp71683a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 3 neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD jcf 109 NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD bis(31/31')[[cys(31), nva(34)]npy(27-36)-nh(2)] NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD fr-233118 NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD s-234462 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] discontinued in phase 1 neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD 2,4,4-triphenylimidazoline NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD npy5ra-972 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD , DGIDB fr-73966 NA NA investigative neuropeptide y receptor type 5 NPY5R Discontinued target unknown NA TTD nsc-65069 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD 5-methoxy-1,2-dimethyl-3-(phenoxymethyl)indole-4,7-dione small molecule NA experimental nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank nsc-621351 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD 2-benzyl-1-hydroxy-3h-benzo[f]chromen-3-one NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD 3-(3,4-dimethylbenzyl)-4-hydroxy-2h-chromen-2-one NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD cibacron blue small molecule NA experimental nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank es-936 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD 4-hydroxy-3-(1-naphthylmethyl)-2h-chromen-2-one NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD nsc-275420 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD 3-(hydroxymethyl)-1-methyl-5-(2-methylaziridin-1-yl)-2-phenyl-1h-indole-4,7-dione small molecule NA experimental nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank coenzyme q10 analog NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leigh Disease[MeSHID:D007888],Rett Syndrome[MeSHID:D015518],Mitochondrial Diseases[MeSHID:D028361],Huntington Disease[MeSHID:D006816],Respiratory Chain[MeSHID:D004579] phase 2 quinone reductase 1 NQO1 Clinical trial target unknown NA TTD , DGIDB nsc-106080 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD duroquinone NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD nsc-645827 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD nsc-73410 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD ethyl bis(4-hydroxy-2-oxo-2h-chromen-3-yl)acetate NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD 3-benzyl-4-hydroxy-6,7-dimethyl-2h-chromen-2-one NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD nsc-339580 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD nsc-224124 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational nad(p)h dehydrogenase [quinone] 1 NQO1 NA inhibitor NA drugbank nsc-354279 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD bishydroxy[2h-1-benzopyran-2-one,1,2-benzopyrone] NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD arq 761 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 quinone reductase 1 NQO1 Clinical trial target unknown NA TTD , DGIDB 3-benzyl-4-hydroxy-2h-chromen-2-one NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD nsc-106547 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD nsc-99528 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD 3-benzyl-4-hydroxy-2h-benzo[h]chromen-2-one NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD dicoumarol small molecule Deep Vein Thrombosis[MeSHID:D020246],Blood coagulation[MeSHID:D001777] approved nad(p)h dehydrogenase [quinone] 1 NQO1 NA inhibitor 3.9 drugbank , DGIDB nsc-339583 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD nsc-645808 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD 4-amino-2h-chromen-2-one NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD bishydroxy[2h-1-benzopyran-2-one,1,2-benzopyrone] small molecule NA experimental nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank nsc-2113 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD rh-1 small molecule NA experimental,investigational nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank 4-hydroxy-3-(2-naphthylmethyl)-2h-chromen-2-one NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown 0.65 drugbank , DGIDB 3-hydroxymethyl-5-aziridinyl-1methyl-2-[1h-indole-4,7-dione]-propanol small molecule NA experimental nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank bioe-743 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pontocerebellar Hypoplasia Type 6[MeSHID:C548074],Leigh Disease[MeSHID:D007888] phase 2 quinone reductase 1 NQO1 Clinical trial target unknown NA TTD , DGIDB es-936 small molecule NA experimental nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank flavin-adenine dinucleotide NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD duroquinone small molecule NA experimental nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved nad(p)h dehydrogenase [quinone] 1 NQO1 NA unknown NA drugbank nsc-316158 NA NA investigative quinone reductase 1 NQO1 Clinical trial target unknown NA TTD flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank nsc-676468 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 1,4-dimethylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA inhibitor NA drugbank 5,6,8-trimethoxy-1,4-dimethylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-637993 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 5,8-dimethoxy-1,4-dimethylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 5,8-dimethoxy-4-methylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-359466 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-645833 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-99528 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-640566 NA NA investigative quinone reductase 2 NQO2 Successful target unknown 4.24 TTD , DGIDB 6,7,8-trimethoxy-1,4-dimethylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 7,8-dimethoxy-1,4-dimethylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD melatonin NA Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved quinone reductase 2 NQO2 Successful target unknown 0.31 TTD , DGIDB nsc-660838 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 5,8-dimethoxy-1,4-dimethylquinolin-2(1h)-one small molecule NA experimental ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank casimiroin small molecule NA experimental ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank nsc-640556 NA NA investigative quinone reductase 2 NQO2 Successful target unknown 4.24 TTD , DGIDB melatonin NA Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved quinone reductase 2 NQO2 Successful target unknown 0.31 TTD , DGIDB nsc-381864 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-77833 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-637991 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-693571 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-640583 NA NA investigative quinone reductase 2 NQO2 Successful target unknown 4.24 TTD , DGIDB nsc-78017 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-306843 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-645811 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 5,6,8-trimethoxy-4-methylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD primaquine small molecule Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA inhibitor NA drugbank nsc-645809 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 quinone reductase 2 NQO2 Successful target unknown 0.85 TTD , DGIDB flavin-adenine dinucleotide NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 6,8-dimethoxy-4-methylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-669977 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-204996 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank nsc-677939 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown 0.31 drugbank , DGIDB melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown 0.31 drugbank , DGIDB nsc-645808 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-99495 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD (3s)-3-hydroxy-1-methyl-2,3-dihydro-1h-indole-5,6-dione small molecule NA experimental ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank nsc-645836 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-637992 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-640558 NA NA investigative quinone reductase 2 NQO2 Successful target unknown 4.24 TTD , DGIDB 3,5-dimethoxy-4'-amino-trans-stilbene NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD prolarix NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 quinone reductase 2 NQO2 Successful target unknown NA TTD , DGIDB 2-iodo-melatonin NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-180969 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-115890 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-238146 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-720622 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD tretazicar small molecule NA investigational ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank nsc-106080 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank nsc-660840 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD cb1954 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 quinone reductase 2 NQO2 Successful target unknown NA TTD 10-propargyl-5,8-dideazafolic acid small molecule NA experimental ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank 8-methoxy-1,4-dimethylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 6-methyl-[1,3]dioxolo[4,5-h]quinolin-8(9h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-300853 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-645835 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-660839 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-660841 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 10-propargyl-5,8-dideazafolic acid NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-640559 NA NA investigative quinone reductase 2 NQO2 Successful target unknown 4.24 TTD , DGIDB nsc-640353 NA NA investigative quinone reductase 2 NQO2 Successful target unknown 4.24 TTD , DGIDB nsc-356819 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-649091 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-645812 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown 0.91 drugbank , DGIDB 3,4,5-trimethoxy-4'-amino-trans-stilbene NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-356820 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-640584 NA NA investigative quinone reductase 2 NQO2 Successful target unknown 4.24 TTD , DGIDB nsc-645831 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-637994 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD n-[2-(2-iodo-5-methoxy-1h-indol-3-yl)ethyl]acetamide small molecule NA experimental ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 NA unknown NA drugbank nsc-665126 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD decynium 22 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-645834 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-78021 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 6,7,8-trimethoxy-4-methylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD nsc-86715 NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD 6,8-dimethoxy-1,4-dimethylquinolin-2(1h)-one NA NA investigative quinone reductase 2 NQO2 Successful target unknown NA TTD dexamethasone acetate small molecule NA approved,investigational,vet_approved nuclear receptor subfamily 0 group b member 1 NR0B1 NA stimulator NA drugbank dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational,vet_approved nuclear receptor subfamily 0 group b member 1 NR0B1 NA stimulator NA drugbank dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor subfamily 0 group b member 1 NR0B1 NA stimulator NA drugbank sr-9011 small molecule NA experimental nuclear receptor subfamily 1 group d member 1 NR1D1 NA agonist NA drugbank sr-9009 small molecule NA experimental nuclear receptor subfamily 1 group d member 1 NR1D1 NA agonist NA drugbank sr-9011 small molecule NA experimental nuclear receptor subfamily 1 group d member 2 NR1D2 NA agonist NA drugbank sr-9009 small molecule NA experimental nuclear receptor subfamily 1 group d member 2 NR1D2 NA agonist NA drugbank 12,17-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational oxysterols receptor lxr-beta NR1H2 NA inhibitor NA drugbank riccardin c NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD 24(s)-hydroxycholesterol NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target agonist NA TTD , DGIDB rhein small molecule NA experimental oxysterols receptor lxr-beta NR1H2 NA inhibitor NA drugbank 4,17-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD benzenesulfonyl NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD 17-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD 24(s), 25-epoxycholesterol NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target agonist NA TTD , DGIDB way-214950 NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD to-901317 small molecule NA experimental oxysterols receptor lxr-beta NR1H2 NA unknown NA drugbank 4-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD 12-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD 1,1,1,3,3,3-hexafluoro-2-{4-[(2,2,2-trifluoroethyl)amino]phenyl}propan-2-ol small molecule NA experimental oxysterols receptor lxr-beta NR1H2 NA unknown NA drugbank 22r-hydroxycholesterol NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target agonist NA TTD , DGIDB way-254011 NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD n-{4-[2-(3-methoxyphenyl)ethyl]phenyl}phthalimide NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD 2-propanol, isopropanol NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD az12260493 NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target agonist NA TTD , DGIDB gsk-9772 NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD desmosterol NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown 6.82 TTD , DGIDB gw-3965 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] experimental,investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD , drugbank sr9238 NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD vtb-38543 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD , DGIDB benzenesulfinic acid small molecule NA experimental oxysterols receptor lxr-beta NR1H2 NA unknown NA drugbank l-783483 NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target agonist NA TTD , DGIDB 27-hydroxycholesterol NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target agonist NA TTD , DGIDB acetyl-podocarpic dimer NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target agonist NA TTD , DGIDB desmosterol NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target agonist 6.82 TTD , DGIDB 2-benzyl-3-phenyl-7-(trifluoromethyl)-2h-indazole NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target unknown NA TTD gsk2033 NA NA investigative oxysterols receptor lxr-beta NR1H2 Clinical trial target antagonist 2.27 TTD , DGIDB us9006244, e1 NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB way-214950 NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD n-{4-[2-(3-methoxyphenyl)ethyl]phenyl}phthalimide NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD az12260493 NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist NA TTD , DGIDB way-254011 NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD us9073931, e2 NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB n-{4-[2-(4-methoxyphenyl)ethyl]phenyl}phthalimide NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD riccardin c NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD n-(tert-butyl)-3,5-dimethyl-n'-[(5-methyl-2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]benzohydrazide small molecule NA experimental oxysterols receptor lxr-alpha NR1H3 NA unknown NA drugbank 27-hydroxycholesterol NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist NA TTD , DGIDB 4-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD sr9238 NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD 24(s), 25-epoxycholesterol NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist NA TTD , DGIDB 24(s)-hydroxycholesterol NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist NA TTD , DGIDB to-901317 small molecule NA experimental oxysterols receptor lxr-alpha NR1H3 NA unknown NA drugbank 2-(2-hexylphenyl)isoindoline-1,3-dione NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD n-{4-[2-(4-hydroxyphenyl)ethyl]phenyl}phthalimide NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD guttiferone i NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD 2-benzyl-3-phenyl-7-(trifluoromethyl)-2h-indazole NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD desmosterol NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist 5.03 TTD , DGIDB 1-benzyl-3-(4-methoxyphenylamino)-4-phenylpyrrole-2,5-dione small molecule NA experimental oxysterols receptor lxr-alpha NR1H3 NA unknown NA drugbank us9006244, e2b NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB paxilline NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist 0.84 TTD , DGIDB diacerein small molecule Degenerative polyarthritis[MeSHID:D010003],Knee[MeSHID:D007717],Bone structure of ischium[MeSHID:D007512],Affect (mental function)[MeSHID:D000339],Hip structure[MeSHID:D006615] approved,investigational oxysterols receptor lxr-alpha NR1H3 NA inhibitor NA drugbank 12-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD 22r-hydroxycholesterol NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist NA TTD , DGIDB n-{4-[2-(3-hydroxyphenyl)ethyl]phenyl}phthalimide NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD desmosterol NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown 5.03 TTD , DGIDB gw-3965 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD us9073931, e3 NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB gsk2033 NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target antagonist 1.68 TTD , DGIDB 67s NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB bdbm50177012 NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB (2e,4e)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoic acid small molecule NA experimental oxysterols receptor lxr-alpha NR1H3 NA unknown NA drugbank l-783483 NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist NA TTD , DGIDB 12,17-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD acetyl-podocarpic dimer NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target agonist NA TTD , DGIDB us9006244, e2a NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB 17-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD 4,17-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD gsk-9772 NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD 4,12,17-dehydroxyriccardin c NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD rhein small molecule NA experimental oxysterols receptor lxr-alpha NR1H3 NA inhibitor NA drugbank 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD bdbm50177019 NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB us9073931, e1 NA NA patented oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD , DGIDB 2-(2-phenethylphenyl)isoindoline-1,3-dione NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD 5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione NA NA investigative oxysterols receptor lxr-alpha NR1H3 Patented-recorded target unknown NA TTD obeticholic acid NA Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Primary biliary cirrhosis[MeSHID:D008105],Fibrosis[MeSHID:D005355],Nonalcoholic Steatohepatitis[MeSHID:D065626],Cholangitis[MeSHID:D002761],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved farnesoid x-activated receptor NR1H4 Successful target agonist NA TTD , DGIDB pmid29649907-compound-26 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB skf-97426 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD 12-o-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin NA NA investigative farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD pmid29649907-compound-30 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB obeticholic acid small molecule Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Primary biliary cirrhosis[MeSHID:D008105],Fibrosis[MeSHID:D005355],Nonalcoholic Steatohepatitis[MeSHID:D065626],Cholangitis[MeSHID:D002761],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved bile acid receptor NR1H4 NA agonist NA drugbank , DGIDB obeticholic acid NA Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Primary biliary cirrhosis[MeSHID:D008105],Fibrosis[MeSHID:D005355],Nonalcoholic Steatohepatitis[MeSHID:D065626],Cholangitis[MeSHID:D002761],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved farnesoid x-activated receptor NR1H4 Successful target unknown 4.68 TTD , DGIDB (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid small molecule NA experimental bile acid receptor NR1H4 NA unknown NA drugbank pmid29649907-compound-31 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB farnesol small molecule NA experimental bile acid receptor NR1H4 NA agonist NA drugbank chenodiol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cholelithiasis[MeSHID:D002769] approved farnesoid x-activated receptor NR1H4 Successful target unknown 1.6 TTD , DGIDB pmid29649907-compound-23 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB tropifexor small molecule NA investigational bile acid receptor NR1H4 NA agonist,binder 1.87 drugbank , DGIDB obeticholic acid NA Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Primary biliary cirrhosis[MeSHID:D008105],Fibrosis[MeSHID:D005355],Nonalcoholic Steatohepatitis[MeSHID:D065626],Cholangitis[MeSHID:D002761],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved farnesoid x-activated receptor NR1H4 Successful target agonist 4.68 TTD , DGIDB pmid29649907-compound-20 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-25 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-24 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid30259754-compound-px-102 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB arachidonic acid small molecule NA experimental bile acid receptor NR1H4 NA ligand NA drugbank pmid29649907-compound-14 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-11 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-19 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB agn-34 NA NA investigative farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD obeticholic acid small molecule Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Primary biliary cirrhosis[MeSHID:D008105],Fibrosis[MeSHID:D005355],Nonalcoholic Steatohepatitis[MeSHID:D065626],Cholangitis[MeSHID:D002761],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved bile acid receptor NR1H4 NA agonist 4.68 drugbank , DGIDB alpha-linolenic acid small molecule NA approved,investigational,nutraceutical bile acid receptor NR1H4 NA agonist NA drugbank int-767 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] preclinical farnesoid x-activated receptor NR1H4 Successful target agonist NA TTD , DGIDB pmid29649907-compound-39 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB cholesten NA NA investigative farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD pmid29649907-compound-38 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid30259754-compound-pyrrole[2,3-d]azepines NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB taurocholic acid small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental bile acid receptor NR1H4 NA unknown NA drugbank guggulsterone NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved farnesoid x-activated receptor NR1H4 Successful target unknown 0.37 TTD , DGIDB pmid29649907-compound-28 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB 22r-hydroxycholesterol NA NA investigative farnesoid x-activated receptor NR1H4 Successful target agonist NA TTD , DGIDB pmid30259754-compound-way-362450 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB edp-305 NA Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bile fluid[MeSHID:D001646],Cholangitis[MeSHID:D002761] phase 2 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD gs-9674 NA Nonalcoholic Steatohepatitis[MeSHID:D065626],Primary sclerosing cholangitis[MeSHID:D015209],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD pmid29649907-compound-12 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB lmb763 NA Diabetic Nephropathy[MeSHID:D003928],Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD pmid29649907-compound-13 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved bile acid receptor NR1H4 NA unknown NA drugbank pmid29649907-compound-22 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB agn-242266 NA Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD pmid29649907-compound-2 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-35 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-8 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-18 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB desmosterol NA NA investigative farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD chenodiol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cholelithiasis[MeSHID:D002769] approved farnesoid x-activated receptor NR1H4 Successful target agonist 1.6 TTD , DGIDB px-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] phase 1 farnesoid x-activated receptor NR1H4 Successful target agonist 0.94 TTD , DGIDB ursodeoxycholic acid small molecule Biliary calculi[MeSHID:D042882],Cholecystolithiasis[MeSHID:D041761],Operative Surgical Procedures[MeSHID:D013514],Cholelithiasis[MeSHID:D002769],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary biliary cirrhosis[MeSHID:D008105] approved,investigational bile acid receptor NR1H4 NA unknown NA drugbank pmid29649907-compound-27 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid30259754-compound-int-767 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB fexaramine NA NA investigative farnesoid x-activated receptor NR1H4 Successful target agonist 2.81 TTD , DGIDB pmid29649907-compound-29 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB obeticholic acid NA Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Primary biliary cirrhosis[MeSHID:D008105],Fibrosis[MeSHID:D005355],Nonalcoholic Steatohepatitis[MeSHID:D065626],Cholangitis[MeSHID:D002761],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-10 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB guggulsterone NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved farnesoid x-activated receptor NR1H4 Successful target antagonist 0.37 TTD , DGIDB pmid29649907-compound-33 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-41 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-1 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB bevacizumab + trastuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB gw4065 NA NA investigative farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD sb-756050 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD pmid29649907-compound-34 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-9 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-int767 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB 1,1-bisphosphonate esters NA NA investigative farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD myrrh small molecule Malignant Neoplasms[MeSHID:D009369],Aphthous Stomatitis[MeSHID:D013281],Menstruation[MeSHID:D008598],Gingivitis[MeSHID:D005891],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Ulcer[MeSHID:D014456],Coughing[MeSHID:D003371],Hemorrhoids[MeSHID:D006484],Leprosy[MeSHID:D007918],Furunculosis[MeSHID:D005667],Syphilis[MeSHID:D013587],Asthma[MeSHID:D001249],Dyspepsia[MeSHID:D004415],Inflammation[MeSHID:D007249],Pressure Ulcer[MeSHID:D003668],Tooth structure[MeSHID:D014070],Halitosis[MeSHID:D006209],Injury wounds[MeSHID:D014947],Pharyngeal structure[MeSHID:D010614],Common Cold[MeSHID:D003139],Lip structure[MeSHID:D008046] approved bile acid receptor NR1H4 NA antagonist NA drugbank ljn452 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bile fluid[MeSHID:D001646],Cholangitis[MeSHID:D002761] phase 2 farnesoid x-activated receptor NR1H4 Successful target unknown 1.87 TTD , DGIDB apomine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteopetrosis[MeSHID:D010022] phase 2 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB fexaramine small molecule NA experimental bile acid receptor NR1H4 NA agonist 2.81 drugbank , DGIDB pmid29649907-compound-36 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-40 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB chenodeoxycholic acid small molecule Gallbladder[MeSHID:D005704],Calculi[MeSHID:D002137],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641] approved bile acid receptor NR1H4 NA other,agonist NA drugbank , DGIDB pmid30259754-compound-ly2562175 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-4 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-32 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB turofexorate isopropyl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 1 farnesoid x-activated receptor NR1H4 Successful target agonist 0.94 TTD , DGIDB met409 NA Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD turofexorate isopropyl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 1 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-42 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB deoxycholic acid small molecule NA approved bile acid receptor NR1H4 NA unknown NA drugbank pmid29649907-compound-15 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-44 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-5 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-3 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB eyp001 NA Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD pmid29649907-compound-37 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pmid29649907-compound-21 NA NA patented farnesoid x-activated receptor NR1H4 Successful target unknown NA TTD , DGIDB pentobarbital small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator NA drugbank cyclophosphamide small molecule Disease[MeSHID:D004194],Adenocarcinoma[MeSHID:D000230],Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Neuroblastoma[MeSHID:D009447],Nephrotic Syndrome, Minimal Change[MeSHID:D009402],Multiple Myeloma[MeSHID:D009101],Retinoblastoma[MeSHID:D012175],Ovary[MeSHID:D010053],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.01 drugbank , DGIDB dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist 0.01 drugbank , DGIDB permethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532],Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.28 drugbank , DGIDB estradiol acetate small molecule Pruritus[MeSHID:D011537],Dyspareunia[MeSHID:D004414],Vagina[MeSHID:D014621],Desiccation[MeSHID:D003890],Urinary tract[MeSHID:D014551],Atrophic[MeSHID:D001284],Dysuria[MeSHID:D053159],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.04 drugbank , DGIDB miconazole small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Pityriasis[MeSHID:D010915],Tinea Versicolor[MeSHID:D014010],Diaper Rash[MeSHID:D003963],Candidiasis[MeSHID:D002177],Immunocompetence[MeSHID:D007121],Pruritus Vulvae[MeSHID:D011539],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Cutaneous Candidiasis[MeSHID:D002179],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA partial agonist 0.08 drugbank , DGIDB paclitaxel small molecule Breast[MeSHID:D001940],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Ovary[MeSHID:D010053] approved,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA inducer 0.02 drugbank , DGIDB diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.08 drugbank , DGIDB dexamethasone acetate small molecule NA approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist NA drugbank estradiol dienanthate small molecule NA approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank mifepristone small molecule Hyperglycemia[MeSHID:D006943],Operative Surgical Procedures[MeSHID:D013514],Impaired glucose tolerance[MeSHID:D018149],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Cushing Syndrome[MeSHID:D003480],Adrenal Gland Hyperfunction[MeSHID:D000308],ADULT SYNDROME[MeSHID:C538052],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist 0.06 drugbank , DGIDB flutamide small molecule Disease Management[MeSHID:D019468],Prostate[MeSHID:D011467],Carcinoma[MeSHID:D002277],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.06 drugbank , DGIDB hyperforin NA NA investigative pregnane x receptor NR1I2 Literature-reported target agonist 0.56 TTD , DGIDB ethinylestradiol small molecule Acne Vulgaris[MeSHID:D000152],Osteoporosis, Postmenopausal[MeSHID:D015663],Premenstrual Dysphoric Disorder[MeSHID:D065446] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist NA drugbank carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator 0.05 drugbank , DGIDB tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.03 drugbank , DGIDB rifampicin small molecule Tuberculosis[MeSHID:D014376],Mycobacterium Infections[MeSHID:D009164] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist 0.21 drugbank , DGIDB clotrimazole small molecule Tinea Pedis[MeSHID:D014008],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Mycoses[MeSHID:D009181],Skin Diseases, Infectious[MeSHID:D012874],Diaper Rash[MeSHID:D003963],Tinea Versicolor[MeSHID:D014010],Candidiasis[MeSHID:D002177],leukemia[MeSHID:D007938],Tinea[MeSHID:D014005],Immunocompromised Host[MeSHID:D016867],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator 0.1 drugbank , DGIDB econazole small molecule Tinea Pedis[MeSHID:D014008],Tinea[MeSHID:D014005],Tinea Versicolor[MeSHID:D014010],Cutaneous Candidiasis[MeSHID:D002179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA partial agonist 0.38 drugbank , DGIDB fenofibric acid small molecule Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA partial agonist NA drugbank bezafibrate small molecule Diabetes Mellitus[MeSHID:D003920],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Neoplasm Metastasis[MeSHID:D009362],Atherosclerosis[MeSHID:D050197],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA partial agonist NA drugbank estradiol valerate small molecule Carcinoma[MeSHID:D002277],Pregnancy[MeSHID:D011247],Ovarian Failure, Premature[MeSHID:D016649],Menorrhagia[MeSHID:D008595],Prostate[MeSHID:D011467],Hypogonadism[MeSHID:D007006],Atrophic[MeSHID:D001284],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.06 drugbank , DGIDB dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist 0.01 drugbank , DGIDB triclosan small molecule Health Care[MeSHID:D003695],Operative Surgical Procedures[MeSHID:D013514],Hand[MeSHID:D006225],Hyperostosis, Diffuse Idiopathic Skeletal[MeSHID:D004057],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Trypanosomiasis[MeSHID:D014352],Malaria[MeSHID:D008288],Communicable Diseases[MeSHID:D003141] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank hexestrol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank oxiconazole small molecule Dermatomycoses[MeSHID:D003881],Tinea Pedis[MeSHID:D014008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA partial agonist 1.13 drugbank , DGIDB nifedipine small molecule Hypertensive disease[MeSHID:D006973],Angina Pectoris, Variant[MeSHID:D000788],Stable angina[MeSHID:D060050],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist 0.03 drugbank , DGIDB way-214950 NA NA investigative pregnane x receptor NR1I2 Literature-reported target unknown NA TTD phenolphthalein small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator 0.06 drugbank , DGIDB afimoxifene small molecule Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank pregnenolone-16alpha-carbonitrile NA NA investigative pregnane x receptor NR1I2 Literature-reported target unknown NA TTD 3-keto-lithocholic acid NA NA investigative pregnane x receptor NR1I2 Literature-reported target agonist NA TTD , DGIDB lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank rifaximin small molecule Diarrhea[MeSHID:D003967],Irritable Bowel Syndrome[MeSHID:D043183],Hepatic Encephalopathy[MeSHID:D006501],Muscle strain[MeSHID:D013180],Recurrence (disease attribute)[MeSHID:D012008],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist 3.94 drugbank , DGIDB paclitaxel small molecule Breast[MeSHID:D001940],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Ovary[MeSHID:D010053] approved,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA inducer,agonist 0.02 drugbank , DGIDB estradiol small molecule Malignant Neoplasms[MeSHID:D009369],Vagina[MeSHID:D014621],Osteoporosis, Postmenopausal[MeSHID:D015663],Endometrium[MeSHID:D004717],Malignant neoplasm of prostate[MeSHID:D011471],Estrogen Effect[MeSHID:D004967],Ovarian Failure, Premature[MeSHID:D016649],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Thromboembolism[MeSHID:D013923],Malignant neoplasm of breast[MeSHID:D001943],Postmenopause[MeSHID:D017698],Endometrial Hyperplasia[MeSHID:D004714],Uterus[MeSHID:D014599],Hypogonadism[MeSHID:D007006],Growth[MeSHID:D006128],Atrophic[MeSHID:D001284],Patient Discharge[MeSHID:D010351],Vulva[MeSHID:D014844],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA binder NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.06 drugbank , DGIDB alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank to-901317 small molecule NA experimental nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank rilpivirine small molecule treatment failure[MeSHID:D017211],HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Cells[MeSHID:D002477],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist NA drugbank docetaxel small molecule Cancer of Head and Neck[MeSHID:D006258],Stomach[MeSHID:D013270],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA binder 0.02 drugbank , DGIDB d-alpha-tocopherol acetate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Skin Aging[MeSHID:D015595],Premenstrual syndrome[MeSHID:D011293],Fertility[MeSHID:D005298],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Asthma[MeSHID:D001249],Muscle Cramp[MeSHID:D009120],Cataract[MeSHID:D002386],Disorder of eye[MeSHID:D005128],Ultraviolet Rays[MeSHID:D014466] approved,nutraceutical,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank pyrethrum extract biotech NA approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank ritonavir small molecule Cessation of life[MeSHID:D003643],Hospitalization[MeSHID:D006760],Communicable Diseases[MeSHID:D003141],Disease Progression[MeSHID:D018450],Infection[MeSHID:D007239],Emergencies [Disease/Finding][MeSHID:D004630],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator 0.08 drugbank , DGIDB fenofibrate small molecule Hypertriglyceridemia[MeSHID:D015228],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA partial agonist NA drugbank dovitinib small molecule Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101] investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA suppressor NA drugbank schisandrin a NA NA investigative pregnane x receptor NR1I2 Literature-reported target agonist NA TTD , DGIDB piperine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitiligo[MeSHID:D014820] investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank ifosfamide small molecule Inferior Colliculus[MeSHID:D007245],Sarcoma[MeSHID:D012509],Malignant neoplasm of urinary bladder[MeSHID:D001749],Testis[MeSHID:D013737],Operative Surgical Procedures[MeSHID:D013514],Malignant neoplasm of ovary[MeSHID:D010051],Osteosarcoma[MeSHID:D012516],Small cell carcinoma of lung[MeSHID:D055752],Germ Cell Cancer[MeSHID:D009373],Lymphoma, Non-Hodgkin[MeSHID:D008228],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown 0.13 drugbank , DGIDB mephenytoin small molecule Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational,withdrawn nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator NA drugbank estradiol benzoate small molecule NA approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank chenodeoxycholic acid small molecule Gallbladder[MeSHID:D005704],Calculi[MeSHID:D002137],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank troleandomycin small molecule Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator 0.23 drugbank , DGIDB myrrh small molecule Malignant Neoplasms[MeSHID:D009369],Aphthous Stomatitis[MeSHID:D013281],Menstruation[MeSHID:D008598],Gingivitis[MeSHID:D005891],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Ulcer[MeSHID:D014456],Coughing[MeSHID:D003371],Hemorrhoids[MeSHID:D006484],Leprosy[MeSHID:D007918],Furunculosis[MeSHID:D005667],Syphilis[MeSHID:D013587],Asthma[MeSHID:D001249],Dyspepsia[MeSHID:D004415],Inflammation[MeSHID:D007249],Pressure Ulcer[MeSHID:D003668],Tooth structure[MeSHID:D014070],Halitosis[MeSHID:D006209],Injury wounds[MeSHID:D014947],Pharyngeal structure[MeSHID:D010614],Common Cold[MeSHID:D003139],Lip structure[MeSHID:D008046] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA partial agonist NA drugbank erlotinib small molecule Pancreatic carcinoma[MeSHID:C562463],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreas[MeSHID:D010179],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Neoplasm Metastasis[MeSHID:D009362],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Missense Mutation[MeSHID:D020125],Deletion Mutation[MeSHID:D017384],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist NA drugbank sr12813 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Arteriosclerosis[MeSHID:D001161],Expiration, function[MeSHID:D045853] experimental nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist NA drugbank , DGIDB quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator NA drugbank trihydroxycholestane NA NA investigative pregnane x receptor NR1I2 Literature-reported target unknown NA TTD estradiol cypionate small molecule Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank hyperforin small molecule NA nutraceutical nuclear receptor subfamily 1 group i member 2 NR1I2 NA agonist 0.56 drugbank , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator NA drugbank sulfinpyrazone small molecule Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator 0.09 drugbank , DGIDB methylphenobarbital small molecule Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator NA drugbank warfarin small molecule Venous Thromboembolism[MeSHID:D054556],Heart Valves[MeSHID:D006351],Cerebrovascular accident[MeSHID:D020521],Rheumatism[MeSHID:D012216],Atrial Fibrillation[MeSHID:D001281],Mitral Valve[MeSHID:D008943],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Collagen Diseases[MeSHID:D003095],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank clotrimazole small molecule Tinea Pedis[MeSHID:D014008],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Mycoses[MeSHID:D009181],Skin Diseases, Infectious[MeSHID:D012874],Diaper Rash[MeSHID:D003963],Tinea Versicolor[MeSHID:D014010],Candidiasis[MeSHID:D002177],leukemia[MeSHID:D007938],Tinea[MeSHID:D014005],Immunocompromised Host[MeSHID:D016867],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator,agonist 0.1 drugbank , DGIDB pregnenolone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,experimental nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank ethotoin small molecule Epilepsy, Temporal Lobe[MeSHID:D004833],Tonic-Clonic Epilepsy[MeSHID:D004830],Tonic - clonic seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator NA drugbank genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA unknown NA drugbank phenobarbital small molecule Absence Epilepsy[MeSHID:D004832],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA activator,agonist 0.06 drugbank , DGIDB clonazepam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Generalization (Psychology)[MeSHID:D005793],Dyskinetic syndrome[MeSHID:D020820], Partial[MeSHID:D004828],Tonic-Clonic Epilepsy[MeSHID:D004830],Lennox-Gastaut syndrome[MeSHID:D065768],Absence Epilepsy[MeSHID:D004832],Myoclonus[MeSHID:D009207],Neoplasm Metastasis[MeSHID:D009362],Epilepsy[MeSHID:D004827],Panic Disorder[MeSHID:D016584],Idiopathic generalized epilepsy[MeSHID:C562694],Agoraphobia[MeSHID:D000379],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit nuclear receptor subfamily 1 group i member 2 NR1I2 NA partial agonist NA drugbank ketoconazole small molecule Paracoccidioidomycosis[MeSHID:D010229],Mycoses[MeSHID:D009181],Coccidioidomycosis[MeSHID:D003047],Cushing Syndrome[MeSHID:D003480],Candidiasis[MeSHID:D002177],Chromoblastomycosis[MeSHID:D002862],Blastomycosis[MeSHID:D001759],Histoplasmosis[MeSHID:D006660],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nuclear receptor subfamily 1 group i member 2 NR1I2 NA antagonist NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 3 NR1I3 NA ligand NA drugbank cholesterol small molecule NA approved,investigational nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank meclizine NA Disease Management[MeSHID:D019468],Vertigo[MeSHID:D014717],Labyrinthine disorder[MeSHID:D007759],Meniere Disease[MeSHID:D008575],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Labyrinthitis[MeSHID:D007762],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved orphan nuclear receptor nr1i3 NR1I3 Successful target antagonist 2.27 TTD , DGIDB tcpobop NA NA investigative orphan nuclear receptor nr1i3 NR1I3 Successful target unknown NA TTD ketoconazole small molecule Paracoccidioidomycosis[MeSHID:D010229],Mycoses[MeSHID:D009181],Coccidioidomycosis[MeSHID:D003047],Cushing Syndrome[MeSHID:D003480],Candidiasis[MeSHID:D002177],Chromoblastomycosis[MeSHID:D002862],Blastomycosis[MeSHID:D001759],Histoplasmosis[MeSHID:D006660],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank meclizine small molecule Disease Management[MeSHID:D019468],Vertigo[MeSHID:D014717],Labyrinthine disorder[MeSHID:D007759],Meniere Disease[MeSHID:D008575],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Labyrinthitis[MeSHID:D007762],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 3 NR1I3 NA inverse agonist,antagonist 2.27 drugbank , DGIDB phenolphthalein small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank 16,17-androstene-3-ol small molecule NA experimental nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank atorvastatin small molecule Diabetes Mellitus[MeSHID:D003920],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Prescription of drug (procedure)[MeSHID:D011307],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Plasma[MeSHID:D010949],Cerebrovascular accident[MeSHID:D020521],Homozygote[MeSHID:D006720],Congestive heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938],Coronary Arteriosclerosis[MeSHID:D003324],Disease[MeSHID:D004194],Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Hyperlipoproteinemia Type III[MeSHID:D006952],Chronic Kidney Diseases[MeSHID:D051436],Aortic Aneurysm, Abdominal[MeSHID:D017544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved nuclear receptor subfamily 1 group i member 3 NR1I3 NA ligand NA drugbank meclizine small molecule Disease Management[MeSHID:D019468],Vertigo[MeSHID:D014717],Labyrinthine disorder[MeSHID:D007759],Meniere Disease[MeSHID:D008575],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Labyrinthitis[MeSHID:D007762],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 3 NR1I3 NA inverse agonist 2.27 drugbank , DGIDB citco NA NA investigative orphan nuclear receptor nr1i3 NR1I3 Successful target agonist NA TTD , DGIDB androstenol NA NA investigative orphan nuclear receptor nr1i3 NR1I3 Successful target unknown NA TTD meclizine NA Disease Management[MeSHID:D019468],Vertigo[MeSHID:D014717],Labyrinthine disorder[MeSHID:D007759],Meniere Disease[MeSHID:D008575],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Radiation Sickness[MeSHID:D011832],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Vestibular Labyrinth[MeSHID:D014722],Labyrinthitis[MeSHID:D007762],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved orphan nuclear receptor nr1i3 NR1I3 Successful target unknown 2.27 TTD , DGIDB pheniramine small molecule Cold Temperature[MeSHID:D003080],Hay fever[MeSHID:D006255],Influenza[MeSHID:D007251],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank (5beta)-pregnane-3,20-dione NA NA investigative orphan nuclear receptor nr1i3 NR1I3 Successful target unknown NA TTD doxylamine small molecule Cold Temperature[MeSHID:D003080],Drug Allergy[MeSHID:D004342],Morning Sickness[MeSHID:D048968],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Sleep[MeSHID:D012890],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank hexestrol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical nuclear receptor subfamily 1 group i member 3 NR1I3 NA activator NA drugbank 3,20-pregnanedione small molecule NA experimental nuclear receptor subfamily 1 group i member 3 NR1I3 NA unknown NA drugbank triclosan small molecule Health Care[MeSHID:D003695],Operative Surgical Procedures[MeSHID:D013514],Hand[MeSHID:D006225],Hyperostosis, Diffuse Idiopathic Skeletal[MeSHID:D004057],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Trypanosomiasis[MeSHID:D014352],Malaria[MeSHID:D008288],Communicable Diseases[MeSHID:D003141] approved,investigational nuclear receptor subfamily 1 group i member 3 NR1I3 NA inverse agonist NA drugbank androstanol NA NA investigative orphan nuclear receptor nr1i3 NR1I3 Successful target unknown NA TTD beta-naphthoflavone small molecule NA experimental coup transcription factor 1 NR2F1 NA unknown NA drugbank prednisolone small molecule Meningism[MeSHID:D008580],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Hematological Disease[MeSHID:D006402],Tuberculosis[MeSHID:D014376],Gastrointestinal Diseases[MeSHID:D005767],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Multiple Sclerosis[MeSHID:D009103] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.13 TTD , drugbank , DGIDB hydrocortisone valerate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved glucocorticoid receptor NR3C1 NA agonist 0.16 drugbank , DGIDB drospirenone small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Hirsutism[MeSHID:D006628],Menarche[MeSHID:D008572],Acne Vulgaris[MeSHID:D000152],Postmenopause[MeSHID:D017698],Menstruation[MeSHID:D008598],Atrophic[MeSHID:D001284],Osteoporosis[MeSHID:D010024],Dysmenorrhea[MeSHID:D004412],Premenstrual Dysphoric Disorder[MeSHID:D065446],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucocorticoid receptor NR3C1 NA binder NA drugbank epierenone NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD cort-125134 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pituitary-dependent Cushing's disease[MeSHID:D047748],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 3 glucocorticoid receptor NR3C1 Successful target unknown 0.97 TTD , DGIDB norethisterone small molecule Atrophic[MeSHID:D001284],Endometriosis[MeSHID:D004715],Osteoporosis, Postmenopausal[MeSHID:D015663] approved glucocorticoid receptor NR3C1 NA agonist NA drugbank azd9567 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 glucocorticoid receptor messenger rna NR3C1 Clinical trial target agonist NA TTD , DGIDB beclomethasone dipropionate small molecule Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Operative Surgical Procedures[MeSHID:D013514],Asthma[MeSHID:D001249],Senility[MeSHID:D000375],Sunburn[MeSHID:D013471],Dermatitis[MeSHID:D003872],Nasal Polyps[MeSHID:D009298],Neurodermatitis[MeSHID:D009450],Intertrigo[MeSHID:D007402],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Pruritus[MeSHID:D011537],Vesicular eczema of hands and/or feet[MeSHID:D011146],Dermatologic disorders[MeSHID:D012871],Contact Dermatitis[MeSHID:D003877],Exfoliative dermatitis[MeSHID:D003873],Rhinitis, Vasomotor[MeSHID:D012223],Dermatitis, Atopic[MeSHID:D003876],Seborrheic dermatitis[MeSHID:D012628],Inspiration function[MeSHID:D001239],Lichen Planus[MeSHID:D008010] approved,investigational glucocorticoid receptor NR3C1 NA agonist NA drugbank , DGIDB ionis-gccrrx NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB prednicarbate small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational glucocorticoid receptor NR3C1 NA agonist 0.49 drugbank , DGIDB azd-5423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD prednisone small molecule Neoplasms[MeSHID:D009369],Transplanted organ[MeSHID:D019737],Communicable Diseases[MeSHID:D003141],Neurological observations[MeSHID:D009461],Kidney[MeSHID:D007668],Infection[MeSHID:D007239],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Inflammation[MeSHID:D007249] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.2 TTD , drugbank , DGIDB dexamethasone sodium phosphate NA Ataxia Telangiectasia[MeSHID:D001260],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucocorticoid receptor NR3C1 Successful target agonist 0.24 TTD , DGIDB ru26988 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD mifepristone small molecule Hyperglycemia[MeSHID:D006943],Operative Surgical Procedures[MeSHID:D013514],Impaired glucose tolerance[MeSHID:D018149],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Cushing Syndrome[MeSHID:D003480],Adrenal Gland Hyperfunction[MeSHID:D000308],ADULT SYNDROME[MeSHID:C538052],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational glucocorticoid receptor NR3C1 Successful target antagonist 0.24 TTD , drugbank , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved glucocorticoid receptor NR3C1 NA antagonist NA drugbank clobetasol propionate small molecule Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Dermatologic disorders[MeSHID:D012871],Psoriasis[MeSHID:D011565] approved glucocorticoid receptor NR3C1 NA agonist 0.16 drugbank , DGIDB betamethasone benzoate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved glucocorticoid receptor NR3C1 Successful target agonist 0.49 TTD , DGIDB fluocinonide small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational glucocorticoid receptor NR3C1 NA agonist 0.65 drugbank , DGIDB ciclesonide small molecule Rhinitis, Allergic, Perennial[MeSHID:D012221],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Diseases, Obstructive[MeSHID:D008173],Asthma[MeSHID:D001249] approved,investigational glucocorticoid receptor NR3C1 NA agonist 0.65 drugbank , DGIDB deoxycorticosterone NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target agonist NA TTD , DGIDB cortisone acetate small molecule Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Gastrointestinal Diseases[MeSHID:D005767],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational glucocorticoid receptor NR3C1 NA agonist 3.89 drugbank , DGIDB hydrocortisone phosphate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved glucocorticoid receptor NR3C1 NA unknown NA drugbank fluorometholone small molecule Structure of bulbar conjunctiva[MeSHID:D003228],Cornea[MeSHID:D003315],Eye[MeSHID:D005123],Blepharitis[MeSHID:D001762],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational glucocorticoid receptor NR3C1 Successful target agonist 1.62 TTD , drugbank , DGIDB wc-3027 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Water consumption[MeSHID:D004326] discontinued in phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD desoximetasone small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved glucocorticoid receptor NR3C1 NA agonist 0.87 drugbank , DGIDB (11-beta)-11,21-dihydroxy-pregn-4-ene-3,20-dione NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD ru-43044 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD onapristone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational glucocorticoid receptor NR3C1 NA antagonist 0.32 drugbank , DGIDB b-octylglucoside NA NA investigative glucocorticoid receptor NR3C1 Successful target unknown NA TTD bay 86-5044 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB paramethasone small molecule Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269],Inflammation[MeSHID:D007249] experimental glucocorticoid receptor NR3C1 NA agonist 1.7 drugbank , DGIDB methylprednisolone small molecule Neoplasms[MeSHID:D009369],Degenerative polyarthritis[MeSHID:D010003],Alopecia Areata[MeSHID:D000506],Keloid[MeSHID:D007627],Neurological observations[MeSHID:D009461],Granuloma Annulare[MeSHID:D016460],Bursitis[MeSHID:D002062],Senile Plaques[MeSHID:D058225],Lichen Simplex Chronicus[MeSHID:D009450],Tenosynovitis[MeSHID:D013717],Synovitis[MeSHID:D013585],Necrobiosis Lipoidica Diabeticorum[MeSHID:D009335],Term Birth[MeSHID:D047929],Lupus Erythematosus, Discoid[MeSHID:D008179],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Hypertrophy[MeSHID:D006984],Alopecia[MeSHID:D000505],Eye[MeSHID:D005123],Lichen Planus[MeSHID:D008010],Spinal Cord Injuries[MeSHID:D013119],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.27 TTD , drugbank , DGIDB difluprednate small molecule Vision[MeSHID:D014785],Operative Surgical Procedures[MeSHID:D013514],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye pain[MeSHID:D058447] approved glucocorticoid receptor NR3C1 NA agonist 0.97 drugbank , DGIDB medrysone small molecule Hypersensitivity[MeSHID:D006967],Conjunctivitis, Vernal[MeSHID:D003233],Episcleritis[MeSHID:D015423],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved glucocorticoid receptor NR3C1 NA agonist 0.61 drugbank , DGIDB oxdex NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD cp-409069 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD fluticasone small molecule Disease Management[MeSHID:D019468],Rhinitis, Allergic, Perennial[MeSHID:D012221],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental glucocorticoid receptor NR3C1 Successful target agonist 1.46 TTD , drugbank , DGIDB budesonide small molecule Inspiration function[MeSHID:D001239],IGA Glomerulonephritis[MeSHID:D005922],Respiratory Hypersensitivity[MeSHID:D012130],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Crohn Disease[MeSHID:D003424],Disease Progression[MeSHID:D018450],Asthma[MeSHID:D001249],Proteinuria[MeSHID:D011507],Rectum[MeSHID:D012007],Chronic Obstructive Airway Disease[MeSHID:D029424],Nose[MeSHID:D009666],Patient Discharge[MeSHID:D010351],Ulcerative Colitis[MeSHID:D003093],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucocorticoid receptor NR3C1 Successful target agonist 0.45 TTD , drugbank , DGIDB 1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1h-indazol-5-yl)ethanol (enantiomeric mix) NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD 1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1h-indazol-5-yl)ethanol (enantiomeric mix) NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD hydrocortisone small molecule External auditory canal structure[MeSHID:D004424],Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Hypoaldosteronism[MeSHID:D006994],Dermatologic disorders[MeSHID:D012871],Ulcerative Colitis[MeSHID:D003093],Ear structure[MeSHID:D004423],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Infection[MeSHID:D007239],Herpes Labialis[MeSHID:D006560],Cytoplasmic Granules[MeSHID:D003594],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congenital adrenal hyperplasia[MeSHID:D000312] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.14 TTD , drugbank , DGIDB 1-methoxy-6-phenyl-6h-benzo[c]chromene NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD isis-gccr NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Glucocorticoid Receptor Deficiency[MeSHID:C564221] phase 2 glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD mometasone furoate small molecule Pruritus[MeSHID:D011537],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Dermatitis[MeSHID:D003872],Nasal Polyps[MeSHID:D009298],Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666] approved,investigational,vet_approved glucocorticoid receptor NR3C1 NA agonist 0.1 drugbank , DGIDB deflazacort small molecule Muscular Dystrophy, Duchenne[MeSHID:D020388],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glucocorticoid receptor NR3C1 Successful target agonist 0.73 TTD , drugbank , DGIDB dexamethasone sodium phosphate NA Ataxia Telangiectasia[MeSHID:D001260],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB methylprednisolone small molecule Neoplasms[MeSHID:D009369],Degenerative polyarthritis[MeSHID:D010003],Alopecia Areata[MeSHID:D000506],Keloid[MeSHID:D007627],Neurological observations[MeSHID:D009461],Granuloma Annulare[MeSHID:D016460],Bursitis[MeSHID:D002062],Senile Plaques[MeSHID:D058225],Lichen Simplex Chronicus[MeSHID:D009450],Tenosynovitis[MeSHID:D013717],Synovitis[MeSHID:D013585],Necrobiosis Lipoidica Diabeticorum[MeSHID:D009335],Term Birth[MeSHID:D047929],Lupus Erythematosus, Discoid[MeSHID:D008179],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Hypertrophy[MeSHID:D006984],Alopecia[MeSHID:D000505],Eye[MeSHID:D005123],Lichen Planus[MeSHID:D008010],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.27 TTD , drugbank , DGIDB mometasone small molecule Asthma[MeSHID:D001249],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] experimental,approved glucocorticoid receptor NR3C1 Successful target agonist 2.19 TTD , drugbank , DGIDB ncx-1015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB gw685698x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved glucocorticoid receptor NR3C1 Successful target unknown 0.97 TTD , DGIDB meprednisone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved glucocorticoid receptor NR3C1 Successful target agonist 0.49 TTD , DGIDB 2,2,2-trifluoro-1-(4-fluorophenyl)-1-(1-(4-fluorophenyl)-1h-indazol-5-yl)ethanol (diastereomeric mix) NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD fluocinolone acetonide small molecule Eczema[MeSHID:D004485],Communicable Diseases[MeSHID:D003141],Keloid[MeSHID:D007627],Posterior eyeball segment structure[MeSHID:D057972],Ear structure[MeSHID:D004423],Affect (mental function)[MeSHID:D000339],Dermatitis[MeSHID:D003872],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Physiologic Intraocular Pressure[MeSHID:D007429],Body tissue[MeSHID:D014024],Dermatologic disorders[MeSHID:D012871],Otitis Externa[MeSHID:D010032],Hypertrophy[MeSHID:D006984],Macular Edema, Cystoid[MeSHID:D008269],Dermatitis, Atopic[MeSHID:D003876],Hemorrhoids[MeSHID:D006484],Seborrheic dermatitis of scalp[MeSHID:D063807],Uveitis[MeSHID:D014605],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational,vet_approved glucocorticoid receptor NR3C1 Successful target agonist NA TTD , drugbank , DGIDB las-41002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB rimexolone small molecule Vision[MeSHID:D014785],Operative Surgical Procedures[MeSHID:D013514],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Anterior uveitis[MeSHID:D014606],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved glucocorticoid receptor NR3C1 NA agonist 0.29 drugbank , DGIDB dexamethasone acetate small molecule NA approved,investigational,vet_approved glucocorticoid receptor NR3C1 NA agonist 0.49 drugbank , DGIDB org-34517 small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 glucocorticoid receptor NR3C1 Successful target antagonist 0.97 TTD , drugbank , DGIDB flurandrenolide small molecule Dermatologic disorders[MeSHID:D012871],Desiccation[MeSHID:D003890],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved glucocorticoid receptor NR3C1 NA agonist 0.81 drugbank , DGIDB triamcinolone small molecule Neoplasms[MeSHID:D009369],Eczema[MeSHID:D004485],Berylliosis[MeSHID:D001607],Crohn Disease[MeSHID:D003424],Keloid[MeSHID:D007627],Cerebral Edema[MeSHID:D001929],Skin Diseases, Bullous[MeSHID:D012872],Senile Plaques[MeSHID:D058225],Vision[MeSHID:D014785],Rheumatoid Arthritis[MeSHID:D001172],Idiopathic Nephrotic Syndrome[MeSHID:C535761],Thrombocytopenia[MeSHID:D013921],Osteoarthritis, Knee[MeSHID:D020370],Disease Management[MeSHID:D019468],Polymyositis[MeSHID:D017285],Mycosis Fungoides[MeSHID:D009182],Tuberculosis, Pulmonary[MeSHID:D014397],Lupus Erythematosus, Systemic[MeSHID:D008180],Proteinuria[MeSHID:D011507],Lichen Simplex Chronicus[MeSHID:D009450],Tenosynovitis[MeSHID:D013717],Ulcerative Colitis[MeSHID:D003093],Synovitis[MeSHID:D013585],Dermatomyositis[MeSHID:D003882],Dermatologic disorders[MeSHID:D012871],Hypoaldosteronism[MeSHID:D006994],Contact Dermatitis[MeSHID:D003877],Arthritis, Gouty[MeSHID:D015210],Pure Red-Cell Aplasia[MeSHID:D012010],leukemia[MeSHID:D007938],Eye[MeSHID:D005123],Uveitis[MeSHID:D014605],Alopecia Areata[MeSHID:D000506],Pemphigus[MeSHID:D010392],Rheumatic Heart Disease[MeSHID:D012214],Patient Discharge[MeSHID:D010351],Dermatitis Herpetiformis[MeSHID:D003874],Sarcoidosis[MeSHID:D012507],Trichinellosis[MeSHID:D014235],Tendon structure[MeSHID:D013710],Stevens-Johnson Syndrome[MeSHID:D013262],Ankylosing spondylitis[MeSHID:D013167],Exfoliative dermatitis[MeSHID:D003873],Neoplasm Metastasis[MeSHID:D009362],Diuresis[MeSHID:D004231],Alopecia[MeSHID:D000505],Macular Edema, Cystoid[MeSHID:D008269],Lichen Planus[MeSHID:D008010],Degenerative polyarthritis[MeSHID:D010003], Meningeal[MeSHID:D014390],Multiple Sclerosis[MeSHID:D009103],Drug Allergy[MeSHID:D004342],Asthma[MeSHID:D001249],Granuloma Annulare[MeSHID:D016460],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Nephrotic Syndrome, Minimal Change[MeSHID:D009402], Psoriatic[MeSHID:D015535],Necrobiosis Lipoidica Diabeticorum[MeSHID:D009335],Congenital adrenal hyperplasia[MeSHID:D000312], Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Eosinophilic Pneumonia[MeSHID:D011657],Anemia, Diamond-Blackfan[MeSHID:D029503],Hypercalcemia[MeSHID:D006934],Hay fever[MeSHID:D006255],Autoimmune hemolytic anemia[MeSHID:D000744],Lymphoma[MeSHID:D008223],Ophthalmia, Sympathetic[MeSHID:D009879],Thyroiditis[MeSHID:D013966],Transfusion Reaction[MeSHID:D065227],Hypertrophy[MeSHID:D006984],Temporal Arteritis[MeSHID:D013700],Dermatitis, Atopic[MeSHID:D003876],Serum Sickness[MeSHID:D012713],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.17 TTD , drugbank , DGIDB fst-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Otitis Externa[MeSHID:D010032] phase 3 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB pf-251802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1 glucocorticoid receptor NR3C1 Successful target unknown NA TTD hexane-1,6-diol small molecule NA experimental,investigative glucocorticoid receptor NR3C1 Successful target unknown NA TTD , drugbank flumethasone small molecule Eczema[MeSHID:D004485],Dermatologic disorders[MeSHID:D012871],Contact Dermatitis[MeSHID:D003877],Diaper Rash[MeSHID:D003963],Dermatitis, Atopic[MeSHID:D003876],Psoriasis[MeSHID:D011565] approved,vet_approved glucocorticoid receptor NR3C1 NA agonist NA drugbank hydrocortisone acetate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved glucocorticoid receptor NR3C1 NA agonist 0.24 drugbank , DGIDB hydrocortisone small molecule External auditory canal structure[MeSHID:D004424],Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Hypoaldosteronism[MeSHID:D006994],Dermatologic disorders[MeSHID:D012871],Ulcerative Colitis[MeSHID:D003093],Ear structure[MeSHID:D004423],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Infection[MeSHID:D007239],Herpes Labialis[MeSHID:D006560],Cytoplasmic Granules[MeSHID:D003594],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.14 TTD , drugbank , DGIDB hydrocortamate small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved glucocorticoid receptor NR3C1 Successful target agonist 1.46 TTD , drugbank , DGIDB gw-870086-x NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB hydrocortisone probutate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved glucocorticoid receptor NR3C1 NA agonist 0.24 drugbank , DGIDB way-214950 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD prednisolone acetate small molecule Neoplasms[MeSHID:D009369],Transplanted organ[MeSHID:D019737],Communicable Diseases[MeSHID:D003141],Kidney[MeSHID:D007668],Nervousness[MeSHID:D001007] approved,vet_approved glucocorticoid receptor NR3C1 NA agonist 0.16 drugbank , DGIDB amcinonide small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved glucocorticoid receptor NR3C1 NA agonist 0.69 drugbank , DGIDB mapracorat NA Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 glucocorticoid receptor NR3C1 Successful target unknown 1.46 TTD , DGIDB levonorgestrel small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Patient Discharge[MeSHID:D010351],Coitus[MeSHID:D003075],Menorrhagia[MeSHID:D008595],Endometrial Hyperplasia[MeSHID:D004714],Off-Label Use[MeSHID:D056687],Unmarried[MeSHID:D012847],Osteoporosis[MeSHID:D010024],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glucocorticoid receptor NR3C1 NA binder NA drugbank desonide small molecule Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] approved,investigational glucocorticoid receptor NR3C1 NA agonist 0.81 drugbank , DGIDB clobetasone small molecule Pruritus[MeSHID:D011537],Eczema[MeSHID:D004485],Erythema[MeSHID:D004890],Dry Eye Syndromes[MeSHID:D015352],Dermatitis[MeSHID:D003872],Syndrome[MeSHID:D013577] approved glucocorticoid receptor NR3C1 NA agonist NA drugbank org-34517 small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 glucocorticoid receptor NR3C1 Successful target unknown 0.97 TTD , drugbank , DGIDB progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved glucocorticoid receptor NR3C1 NA partial agonist 0.03 drugbank , DGIDB ibi-20089 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 1 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD loteprednol etabonate small molecule Vision[MeSHID:D014785],Operative Surgical Procedures[MeSHID:D013514],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Pain[MeSHID:D010146],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved glucocorticoid receptor NR3C1 NA agonist 0.16 drugbank , DGIDB betamethasone valerate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved glucocorticoid receptor NR3C1 Successful target agonist 0.24 TTD , DGIDB oric-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD fludrocortisone small molecule Adrenogenital Syndrome[MeSHID:D047808],Addison Disease[MeSHID:D000224],Hypoaldosteronism[MeSHID:D006994],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Wasting Syndrome[MeSHID:D019282] approved,investigational glucocorticoid receptor NR3C1 NA agonist NA drugbank budesonide small molecule Inspiration function[MeSHID:D001239],IGA Glomerulonephritis[MeSHID:D005922],Respiratory Hypersensitivity[MeSHID:D012130],Maintenance[MeSHID:D008283],Hay fever[MeSHID:D006255],Crohn Disease[MeSHID:D003424],Disease Progression[MeSHID:D018450],Asthma[MeSHID:D001249],Proteinuria[MeSHID:D011507],Rectum[MeSHID:D012007],Chronic Obstructive Airway Disease[MeSHID:D029424],Nose[MeSHID:D009666],Patient Discharge[MeSHID:D010351],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucocorticoid receptor NR3C1 Successful target agonist 0.45 TTD , drugbank , DGIDB hydrocortisone cypionate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,investigational,vet_approved glucocorticoid receptor NR3C1 NA agonist 0.49 drugbank , DGIDB ulipristal small molecule Coitus[MeSHID:D003075],Uterine Fibroids[MeSHID:D007889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucocorticoid receptor NR3C1 NA antagonist NA drugbank lgd-5552 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown 0.97 TTD , DGIDB tixocortol small molecule Solutions[MeSHID:D012996],Disease[MeSHID:D004194],Contact hypersensitivity[MeSHID:D003877],Rhinitis[MeSHID:D012220],Pharyngitis[MeSHID:D010612],Screening procedure[MeSHID:D008403],Nose[MeSHID:D009666],Ulcerative Colitis[MeSHID:D003093] approved,withdrawn glucocorticoid receptor NR3C1 NA binder NA drugbank segesterone acetate small molecule Reproduction[MeSHID:D012098],Vagina[MeSHID:D014621],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational glucocorticoid receptor NR3C1 NA agonist NA drugbank cp-394531 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.08 TTD , drugbank , DGIDB ru28362 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target agonist NA TTD , DGIDB gestrinone small molecule Infertility[MeSHID:D007246],Unmarried[MeSHID:D012847],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved glucocorticoid receptor NR3C1 NA antagonist NA drugbank cort125281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD ulobetasol small molecule Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Dermatologic disorders[MeSHID:D012871],Psoriasis[MeSHID:D011565] approved glucocorticoid receptor NR3C1 NA agonist NA drugbank ciclesonide small molecule Rhinitis, Allergic, Perennial[MeSHID:D012221],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational glucocorticoid receptor NR3C1 NA agonist 0.65 drugbank , DGIDB beclomethasone dipropionate small molecule Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Operative Surgical Procedures[MeSHID:D013514],Asthma[MeSHID:D001249],Senility[MeSHID:D000375],Sunburn[MeSHID:D013471],Dermatitis[MeSHID:D003872],Nasal Polyps[MeSHID:D009298],Neurodermatitis[MeSHID:D009450],Intertrigo[MeSHID:D007402],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Pruritus[MeSHID:D011537],Vesicular eczema of hands and/or feet[MeSHID:D011146],Dermatologic disorders[MeSHID:D012871],Contact Dermatitis[MeSHID:D003877],Exfoliative dermatitis[MeSHID:D003873],Rhinitis, Vasomotor[MeSHID:D012223],Dermatitis, Atopic[MeSHID:D003876],Seborrheic dermatitis[MeSHID:D012628],Inspiration function[MeSHID:D001239],Lichen Planus[MeSHID:D008010] approved,investigational glucocorticoid receptor NR3C1 NA agonist 0.32 drugbank , DGIDB endiandrin a NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD hydrocortisone butyrate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] approved,vet_approved glucocorticoid receptor NR3C1 NA agonist 0.16 drugbank , DGIDB a-348441 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD difluocortolone small molecule Pruritus[MeSHID:D011537],Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Dermatologic disorders[MeSHID:D012871],Erythema[MeSHID:D004890],Seborrheic dermatitis[MeSHID:D012628],Psoriasis[MeSHID:D011565],Lichen Planus[MeSHID:D008010] approved,investigational,withdrawn glucocorticoid receptor NR3C1 NA binder NA drugbank betamethasone valerate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB dexamethasone small molecule Otitis Media[MeSHID:D010033],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Communicable Diseases[MeSHID:D003141],Otitis Externa[MeSHID:D010032],Bacterial Infections[MeSHID:D001424],Ear structure[MeSHID:D004423],Disorder of eye[MeSHID:D005128],Inflammation[MeSHID:D007249],Affect (mental function)[MeSHID:D000339],Macular Edema, Cystoid[MeSHID:D008269],Uveitis, Posterior[MeSHID:D015866],Eye[MeSHID:D005123],Multiple Myeloma[MeSHID:D009101],Infection[MeSHID:D007239],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.08 TTD , drugbank , DGIDB progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved glucocorticoid receptor NR3C1 NA partial agonist 0.03 drugbank , DGIDB hydrocortisone aceponate small molecule Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Crohn Disease[MeSHID:D003424],Addison Disease[MeSHID:D000224],Ulcerative Colitis[MeSHID:D003093],Asthma[MeSHID:D001249],Adrenal gland hypofunction[MeSHID:D000309],Arthritis[MeSHID:D001168],Hypersensitivity[MeSHID:D006967],Psoriasis[MeSHID:D011565] experimental,vet_approved glucocorticoid receptor NR3C1 NA unknown NA drugbank prednisolone phosphate small molecule Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Dermatologic disorders[MeSHID:D012871],Hematological Disease[MeSHID:D006402],Gastrointestinal Diseases[MeSHID:D005767],Disorder of eye[MeSHID:D005128],Neurological observations[MeSHID:D009461],Respiration Disorders[MeSHID:D012120],Rheumatism[MeSHID:D012216],Hypersensitivity[MeSHID:D006967],Endocrine System Diseases[MeSHID:D004700] approved,vet_approved glucocorticoid receptor NR3C1 NA agonist NA drugbank flunisolide small molecule Asthma[MeSHID:D001249],Maintenance[MeSHID:D008283],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glucocorticoid receptor NR3C1 Successful target agonist 0.58 TTD , drugbank , DGIDB fluticasone propionate small molecule Disease Management[MeSHID:D019468],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666] approved glucocorticoid receptor NR3C1 NA agonist 0.49 drugbank , DGIDB alclometasone small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved glucocorticoid receptor NR3C1 NA agonist 0.49 drugbank , DGIDB aldosterone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] experimental,investigational glucocorticoid receptor NR3C1 NA unknown 0.29 drugbank , DGIDB fluticasone propionate small molecule Disease Management[MeSHID:D019468],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666] approved glucocorticoid receptor NR3C1 NA agonist NA drugbank , DGIDB fluocinolone acetonide small molecule Eczema[MeSHID:D004485],Communicable Diseases[MeSHID:D003141],Keloid[MeSHID:D007627],Posterior eyeball segment structure[MeSHID:D057972],Ear structure[MeSHID:D004423],Affect (mental function)[MeSHID:D000339],Dermatitis[MeSHID:D003872],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Physiologic Intraocular Pressure[MeSHID:D007429],Body tissue[MeSHID:D014024],Dermatologic disorders[MeSHID:D012871],Otitis Externa[MeSHID:D010032],Hypertrophy[MeSHID:D006984],Macular Edema, Cystoid[MeSHID:D008269],Dermatitis, Atopic[MeSHID:D003876],Hemorrhoids[MeSHID:D006484],Seborrheic dermatitis of scalp[MeSHID:D063807],Uveitis[MeSHID:D014605],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.24 TTD , drugbank , DGIDB 1-methoxy-6-phenyl-6h-benzo[c]chromen-8-ylamine NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD tpi-1020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB diflorasone small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rosacea[MeSHID:D012393] approved glucocorticoid receptor NR3C1 NA agonist 0.32 drugbank , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucocorticoid receptor NR3C1 NA antagonist NA drugbank betamethasone small molecule Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Gastrointestinal Diseases[MeSHID:D005767],Rheumatism[MeSHID:D012216],Senile Plaques[MeSHID:D058225],Endocrine System Diseases[MeSHID:D004700],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.54 TTD , drugbank , DGIDB megestrol acetate small molecule Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Anorexia[MeSHID:D000855],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Malignant neoplasm of prostate[MeSHID:D011471],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Cachexia[MeSHID:D002100],Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of breast[MeSHID:D001943],Weight decreased[MeSHID:D015431],Recurrence (disease attribute)[MeSHID:D012008] approved,investigational,vet_approved glucocorticoid receptor NR3C1 NA agonist NA drugbank di-o-methylendiandrin a NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD cortivazol small molecule NA investigational glucocorticoid receptor NR3C1 NA unknown NA drugbank loteprednol etabonate small molecule Vision[MeSHID:D014785],Operative Surgical Procedures[MeSHID:D013514],Inflammation[MeSHID:D007249],Eye[MeSHID:D005123],Pain[MeSHID:D010146],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endophthalmitis[MeSHID:D009877] approved glucocorticoid receptor NR3C1 NA agonist NA drugbank , DGIDB fluticasone furoate small molecule Asthma[MeSHID:D001249],Disease Management[MeSHID:D019468],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221] approved glucocorticoid receptor NR3C1 NA agonist NA drugbank , DGIDB prednisone small molecule Neoplasms[MeSHID:D009369],Transplanted organ[MeSHID:D019737],Communicable Diseases[MeSHID:D003141],Neurological observations[MeSHID:D009461],Kidney[MeSHID:D007668],Infection[MeSHID:D007239],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glucocorticoid receptor NR3C1 Successful target agonist 0.2 TTD , drugbank , DGIDB clobetasol propionate small molecule Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Dermatologic disorders[MeSHID:D012871],Psoriasis[MeSHID:D011565] approved glucocorticoid receptor NR3C1 NA agonist NA drugbank , DGIDB fluoxymesterone small molecule Malignant neoplasm of breast[MeSHID:D001943],Malnutrition[MeSHID:D044342],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit glucocorticoid receptor NR3C1 NA antagonist 0.32 drugbank , DGIDB de-110 NA Xerophthalmia[MeSHID:D014985],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB gw-870086-x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB lg-120838 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD org 34517/34850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Mood Disorders[MeSHID:D019964] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB al-43 NA NA investigative glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD betamethasone phosphate small molecule Neoplasms[MeSHID:D009369],Alopecia Areata[MeSHID:D000506],Keloid[MeSHID:D007627],Senile Plaques[MeSHID:D058225],Hypersensitivity[MeSHID:D006967],Trichinellosis[MeSHID:D014235],Rheumatoid Arthritis[MeSHID:D001172],Hematological Disease[MeSHID:D006402],Disorder of eye[MeSHID:D005128],Respiration Disorders[MeSHID:D012120],Alopecia[MeSHID:D000505],Endocrine System Diseases[MeSHID:D004700],Lichen Planus[MeSHID:D008010],Kidney Diseases[MeSHID:D007674],Degenerative polyarthritis[MeSHID:D010003],Tuberculosis, Meningeal[MeSHID:D014390],Neurological observations[MeSHID:D009461],Granuloma Annulare[MeSHID:D016460],Bursitis[MeSHID:D002062],Lichen Simplex Chronicus[MeSHID:D009450],Tenosynovitis[MeSHID:D013717],Synovitis[MeSHID:D013585],Necrobiosis Lipoidica Diabeticorum[MeSHID:D009335],Lupus Erythematosus, Discoid[MeSHID:D008179],Dermatologic disorders[MeSHID:D012871],Myocardium[MeSHID:D009206],Gastrointestinal Diseases[MeSHID:D005767],Arthritis, Gouty[MeSHID:D015210],Hypertrophy[MeSHID:D006984],Rheumatism[MeSHID:D012216] approved,vet_approved glucocorticoid receptor NR3C1 NA agonist NA drugbank clocortolone small molecule Scalp Dermatoses[MeSHID:D012536],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rosacea[MeSHID:D012393] approved glucocorticoid receptor NR3C1 NA agonist 0.65 drugbank , DGIDB fluticasone furoate small molecule Asthma[MeSHID:D001249],Disease Management[MeSHID:D019468],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221] approved glucocorticoid receptor NR3C1 NA agonist 0.97 drugbank , DGIDB mapracorat NA Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 glucocorticoid receptor NR3C1 Successful target agonist 1.46 TTD , DGIDB etiprednol dicloacetate NA Asthma[MeSHID:D001249],Crohn Disease[MeSHID:D003424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB gsk870086 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD meprednisone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved glucocorticoid receptor NR3C1 Successful target unknown 0.49 TTD , DGIDB nm-135 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] discontinued in phase 2 glucocorticoid receptor NR3C1 Successful target unknown NA TTD vbp15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Multiple Sclerosis[MeSHID:D009103],Rheumatoid Arthritis[MeSHID:D001172] phase 2 glucocorticoid receptor messenger rna NR3C1 Clinical trial target unknown NA TTD betamethasone benzoate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved glucocorticoid receptor NR3C1 Successful target unknown NA TTD , DGIDB desoxycorticosterone pivalate small molecule Hypoaldosteronism[MeSHID:D006994],Dog Diseases[MeSHID:D004283],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Cerebral Palsy[MeSHID:D002547],Polyarteritis Nodosa[MeSHID:D010488],Addison Disease[MeSHID:D000224],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,vet_approved,approved mineralocorticoid receptor NR3C2 Successful target agonist NA TTD , drugbank , DGIDB eplerenone small molecule Myocardial Infarction[MeSHID:D009203],Ventricular Dysfunction, Left[MeSHID:D018487],Congestive heart failure[MeSHID:D006333],Continuance of life[MeSHID:D013534],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mineralocorticoid receptor NR3C2 Successful target antagonist 12.45 TTD , drugbank , DGIDB pmid27551786-compound-106 NA NA patented mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB xl550 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 mineralocorticoid receptor NR3C2 Successful target unknown 5.53 TTD , DGIDB ly-2623091 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Kidney Diseases[MeSHID:D051436] phase 2 mineralocorticoid receptor NR3C2 Successful target unknown 5.53 TTD , DGIDB zk-91587 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB finerenone small molecule Cessation of life[MeSHID:D003643],Hospitalization[MeSHID:D006760],Heart failure[MeSHID:D006333],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Chronic Kidney Diseases[MeSHID:D051436],Myocardial Infarction[MeSHID:D009203],Kidney Failure, Chronic[MeSHID:D007676],Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,phase 3 mineralocorticoid receptor NR3C2 Successful target antagonist 8.3 TTD , drugbank , DGIDB fludrocortisone small molecule Adrenogenital Syndrome[MeSHID:D047808],Addison Disease[MeSHID:D000224],Hypoaldosteronism[MeSHID:D006994],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Wasting Syndrome[MeSHID:D019282] approved,investigational mineralocorticoid receptor NR3C2 Successful target agonist 16.6 TTD , drugbank , DGIDB mt-3995 NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 mineralocorticoid receptor NR3C2 Successful target antagonist 5.53 TTD , DGIDB desoxycorticosterone pivalate small molecule Hypoaldosteronism[MeSHID:D006994],Dog Diseases[MeSHID:D004283],Rheumatoid Arthritis[MeSHID:D001172],Multiple Sclerosis[MeSHID:D009103],Cerebral Palsy[MeSHID:D002547],Polyarteritis Nodosa[MeSHID:D010488],Addison Disease[MeSHID:D000224],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,vet_approved,approved mineralocorticoid receptor NR3C2 Successful target agonist 8.3 TTD , drugbank , DGIDB progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved mineralocorticoid receptor NR3C2 NA antagonist,agonist 0.23 drugbank , DGIDB desoxycorticosterone acetate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mineralocorticoid receptor NR3C2 Successful target agonist 2.77 TTD , drugbank , DGIDB al-43 NA NA investigative mineralocorticoid receptor NR3C2 Successful target unknown NA TTD xl550 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 mineralocorticoid receptor NR3C2 Successful target antagonist 5.53 TTD , DGIDB fluticasone furoate small molecule Asthma[MeSHID:D001249],Disease Management[MeSHID:D019468],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221] approved mineralocorticoid receptor NR3C2 NA antagonist NA drugbank testosterone enanthate small molecule Systemic arterial pressure[MeSHID:D062186],Sexual Development[MeSHID:D046468],Neoplasms[MeSHID:D009369],Pituitary Gland[MeSHID:D010902],Klinefelter Syndrome[MeSHID:D007713],Myocardial Infarction[MeSHID:D009203],Syndrome[MeSHID:D013577],Pituitary Diseases[MeSHID:D010900],Idiopathic hypogonadotropic hypogonadism[MeSHID:C562785],Mammary gland[MeSHID:D042361],Testicular hypogonadism[MeSHID:D005058],Thyroid Gland[MeSHID:D013961],Testis[MeSHID:D013737],Orchitis[MeSHID:D009920],Neoplasm Metastasis[MeSHID:D009362],Cryptorchidism[MeSHID:D003456],Hypothalamic structure[MeSHID:D007031],Malignant neoplasm of breast[MeSHID:D001943],Cerebrovascular accident[MeSHID:D020521],Electromagnetic Radiation[MeSHID:D060733],Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Cessation of life[MeSHID:D003643],Blood Pressure[MeSHID:D001794],Maintenance[MeSHID:D008283],Pathologic Processes[MeSHID:D010335],Primary hypogonadism[MeSHID:D007006],Malnutrition[MeSHID:D044342],Adrenal Cortex[MeSHID:D000302],Disease[MeSHID:D004194],Delayed Puberty[MeSHID:D011628],Traumatic injury[MeSHID:D014947],Malignant Carcinoid Syndrome[MeSHID:D008303] approved mineralocorticoid receptor NR3C2 NA unknown NA drugbank pmid27551786-compound-iv NA NA patented mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB pmid27551786-compound-i NA NA patented mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB pmid27551786-compound-ii NA NA patented mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB clobetasol propionate small molecule Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Dermatologic disorders[MeSHID:D012871],Psoriasis[MeSHID:D011565] approved mineralocorticoid receptor NR3C2 NA agonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved mineralocorticoid receptor NR3C2 Successful target antagonist 1.89 TTD , drugbank , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mineralocorticoid receptor NR3C2 Successful target antagonist 1.89 TTD , drugbank , DGIDB nerenone NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB (11-beta)-11,21-dihydroxy-pregn-4-ene-3,20-dione NA NA investigative mineralocorticoid receptor NR3C2 Successful target unknown NA TTD mt-3995 NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 mineralocorticoid receptor NR3C2 Successful target unknown 5.53 TTD , DGIDB kbp-5074 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 1/2 mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB aldosterone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] experimental,investigational,approved mineralocorticoid receptor NR3C2 Successful target unknown 2.77 TTD , drugbank , DGIDB br-4628 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB epierenone NA NA investigative mineralocorticoid receptor NR3C2 Successful target unknown NA TTD progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved mineralocorticoid receptor NR3C2 NA antagonist,agonist 0.23 drugbank , DGIDB drospirenone small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Hirsutism[MeSHID:D006628],Menarche[MeSHID:D008572],Acne Vulgaris[MeSHID:D000152],Postmenopause[MeSHID:D017698],Menstruation[MeSHID:D008598],Atrophic[MeSHID:D001284],Osteoporosis[MeSHID:D010024],Dysmenorrhea[MeSHID:D004412],Premenstrual Dysphoric Disorder[MeSHID:D065446],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mineralocorticoid receptor NR3C2 Successful target antagonist 7.61 TTD , drugbank , DGIDB way-255348 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative mineralocorticoid receptor NR3C2 Successful target unknown NA TTD metribolone small molecule NA experimental mineralocorticoid receptor NR3C2 NA unknown NA drugbank lg-120838 NA NA investigative mineralocorticoid receptor NR3C2 Successful target unknown NA TTD testosterone small molecule Hypogonadotropic hypogonadism[MeSHID:D007006],Klinefelter Syndrome[MeSHID:D007713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342],Osteoporosis[MeSHID:D010024] approved,investigational mineralocorticoid receptor NR3C2 NA ligand NA drugbank eplerenone small molecule Myocardial Infarction[MeSHID:D009203],Ventricular Dysfunction, Left[MeSHID:D018487],Congestive heart failure[MeSHID:D006333],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved mineralocorticoid receptor NR3C2 Successful target antagonist 12.45 TTD , drugbank , DGIDB pmid27551786-compound-138 NA NA patented mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational mineralocorticoid receptor NR3C2 NA antagonist 0.4 drugbank , DGIDB lgd-5552 NA NA investigative mineralocorticoid receptor NR3C2 Successful target unknown NA TTD ru28318 NA NA investigative mineralocorticoid receptor NR3C2 Successful target antagonist NA TTD , DGIDB corticosterone small molecule NA experimental mineralocorticoid receptor NR3C2 NA unknown NA drugbank pmid27551786-compound-iii NA NA patented mineralocorticoid receptor NR3C2 Successful target unknown NA TTD , DGIDB deoxycorticosterone NA NA investigative mineralocorticoid receptor NR3C2 Successful target agonist NA TTD , DGIDB b-octylglucoside NA NA investigative mineralocorticoid receptor NR3C2 Successful target unknown NA TTD fluticasone propionate small molecule Disease Management[MeSHID:D019468],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666] approved mineralocorticoid receptor NR3C2 NA antagonist,agonist NA drugbank , DGIDB stanolone acetate small molecule NA experimental mineralocorticoid receptor NR3C2 NA unknown NA drugbank testosterone cypionate small molecule Testicular hypogonadism[MeSHID:D005058],Radiation[MeSHID:D011827],Disease[MeSHID:D004194],Testis[MeSHID:D013737],Orchitis[MeSHID:D009920],Cryptorchidism[MeSHID:D003456],Traumatic injury[MeSHID:D014947],Hypothalamic-Pituitary Neoplasms[MeSHID:D007029],Klinefelter Syndrome[MeSHID:D007713],Hypogonadotropic hypogonadism[MeSHID:D007006],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Electromagnetic Radiation[MeSHID:D060733] approved mineralocorticoid receptor NR3C2 NA unknown NA drugbank stanolone small molecule NA illicit,investigational mineralocorticoid receptor NR3C2 NA unknown NA drugbank aldosterone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] experimental,investigational,approved mineralocorticoid receptor NR3C2 Successful target agonist 2.77 TTD , drugbank , DGIDB nimodipine small molecule Subarachnoid Hemorrhage, Intracranial[MeSHID:D013345],Rupture[MeSHID:D012421],Neurological observations[MeSHID:D009461],Berry Aneurysm[MeSHID:D002532],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] approved,investigational mineralocorticoid receptor NR3C2 NA antagonist 0.52 drugbank , DGIDB cb-1922 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative mineralocorticoid receptor NR3C2 Successful target unknown NA TTD desoxycorticosterone acetate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mineralocorticoid receptor NR3C2 Successful target agonist NA TTD , drugbank , DGIDB fluticasone small molecule Disease Management[MeSHID:D019468],Rhinitis, Allergic, Perennial[MeSHID:D012221],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental mineralocorticoid receptor NR3C2 NA antagonist NA drugbank testosterone undecanoate small molecule Malnutrition[MeSHID:D044342],Disease[MeSHID:D004194],Hypogonadism[MeSHID:D007006],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mineralocorticoid receptor NR3C2 NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational nuclear receptor subfamily 4 group a member 3 NR4A3 NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational nuclear receptor subfamily 4 group a member 3 NR4A3 NA unknown NA drugbank (2r)-3-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-2-[(9e)-hexadec-9-enoyloxy]propyl (9e)-octadec-9-enoate small molecule NA experimental steroidogenic factor 1 NR5A1 NA unknown NA drugbank phosphatidyl ethanol small molecule NA experimental steroidogenic factor 1 NR5A1 NA unknown NA drugbank apc-300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471] investigative gtpase nras NRAS Clinical trial target unknown NA TTD gi-4000 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 gtpase nras NRAS Clinical trial target unknown NA TTD , DGIDB ka-10x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative gtpase nras NRAS Clinical trial target unknown NA TTD mutant ras vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 gtpase nras NRAS Clinical trial target unknown NA TTD , DGIDB salirasib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of lung[MeSHID:D008175],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 2 gtpase nras NRAS Clinical trial target unknown 0.13 TTD , DGIDB reovirus NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 2 gtpase nras NRAS Clinical trial target unknown NA TTD , DGIDB perillyl alcohol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 gtpase nras NRAS Clinical trial target unknown NA TTD ggf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] phase 1b pro-neuregulin-1 NRG1 Clinical trial target unknown NA TTD neucardin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 3 pro-neuregulin-1 NRG1 Clinical trial target unknown NA TTD ggf-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 1 pro-neuregulin-1 NRG1 Clinical trial target unknown NA TTD 4-hydroxy-n'-(4-isopropylbenzyl)benzohydrazide small molecule NA experimental nuclear receptor-interacting protein 1 NRIP1 NA unknown NA drugbank h-kppr-oh NA NA investigative neuropilin-1 NRP1 Successful target unknown NA TTD rg7347 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 neuropilin-1 NRP1 Successful target unknown NA TTD , DGIDB asp1948 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 neuropilin-1 NRP1 Successful target unknown NA TTD pegaptanib NA Age related macular degeneration[MeSHID:D008268],Pathologic Neovascularization[MeSHID:D009389],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved neuropilin-1 NRP1 Successful target unknown 31.83 TTD , DGIDB atyr1923 biotech NA investigational neuropilin-2 NRP2 NA modulator NA drugbank calcium phosphate small molecule NA approved neurexin-1 NRXN1 NA agonist NA drugbank calcium phosphate dihydrate small molecule NA approved neurexin-1 NRXN1 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational neurexin-1 NRXN1 NA agonist NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating NSDHL NA unknown NA drugbank 1-ethyl-pyrrolidine-2,5-dione small molecule NA experimental vesicle-fusing atpase NSF NA unknown NA drugbank atp small molecule NA investigational,nutraceutical cytosolic purine 5'-nucleotidase NT5C2 NA unknown NA drugbank taribavirin small molecule Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506] investigational cytosolic purine 5'-nucleotidase NT5C2 NA unknown NA drugbank pmid28870136-compound-57 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB rb 2 NA NA investigative ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD pmid28870136-compound-60 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-69 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-44 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-38 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB psb-0963 NA NA investigative ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD pmid28870136-compound-46 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-49 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB cpi-006 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-53 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB nzv930 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD pentoxifylline small molecule Blood Vessel[MeSHID:D001808],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Intermittent Claudication[MeSHID:D007383],Arterial Occlusive Diseases[MeSHID:D001157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 5'-nucleotidase NT5E NA inhibitor NA drugbank pmid28870136-compound-68 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-43 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-52 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB tj4309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD pmid28870136-compound-64 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB gs-1423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD pmid28870136-compound-61 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-58 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-56 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB oleclumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ecto-5'-nucleotidase NT5E Clinical trial target antibody 9.09 TTD , DGIDB pmid28870136-compound-65 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB ab680 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 ecto-5'-nucleotidase NT5E Clinical trial target inhibitor NA TTD , DGIDB pmid28870136-compound-40 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-51 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-62 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-39 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-37 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-54 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-67 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-55 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB oleclumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ecto-5'-nucleotidase NT5E Clinical trial target unknown 9.09 TTD , DGIDB pmid28870136-compound-48 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB psb-0952 NA NA investigative ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD pmid28870136-compound-50 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-36 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB acid blue 25 NA NA investigative ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD ly3475070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD alphabeta-methyleneadp NA NA investigative ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD pmid28870136-compound-63 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-59 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-47 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid29166791-compound-ampcp NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-42 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-41 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB pmid28870136-compound-45 NA NA patented ecto-5'-nucleotidase NT5E Clinical trial target unknown NA TTD , DGIDB cyclic 3',5'-thymidine monophosphate small molecule NA experimental 5'(3')-deoxyribonucleotidase, mitochondrial NT5M NA unknown NA drugbank dpb-t small molecule NA experimental 5'(3')-deoxyribonucleotidase, mitochondrial NT5M NA unknown NA drugbank nt-3 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 neurotrophin-3 NTF3 Discontinued target unknown NA TTD bicyclic heteroaryl benzamide derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 25 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB cep-5104 NA NA investigative tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD pyrazolo[1,5-a]pyrimidine derivative 23 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB bicyclic heteroaryl benzamide derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure16-a NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB tri-substituted urea derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 13 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2013161919example85-117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB six-membered heterocyclic benzamide derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2014129431example8-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure5-2 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB larotrectinib small molecule Neoplasms[MeSHID:D009369],Operative Surgical Procedures[MeSHID:D013514],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational high affinity nerve growth factor receptor NTRK1 NA inhibitor 3.07 drugbank , DGIDB bicyclic heteroaryl benzamide derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB six-membered heterocyclic benzamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 15 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure17-1 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure5-1 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved high affinity nerve growth factor receptor NTRK1 NA inhibitor 0.04 drugbank , DGIDB larotrectinib NA Neoplasms[MeSHID:D009369],Operative Surgical Procedures[MeSHID:D013514],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tropomyosin-related kinase a NTRK1 Successful target inhibitor 3.07 TTD , DGIDB n-acylpyrrolidine ether derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB triazolo[4,3-b]pyridazine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2014078408example26 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB thiazole derivative 4 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB loxo-195 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tropomyosin-related kinase a NTRK1 Successful target unknown 0.74 TTD , DGIDB ct 327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 2 tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 19 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure5-3 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2010077680 103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure17-2 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[4,3-c]pyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB plx7486 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1 tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure16-b-1 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational high affinity nerve growth factor receptor NTRK1 NA inhibitor NA drugbank pyrrolidinyl urea derivative 6 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB azd6918 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] discontinued in phase 1 tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD five membered heterocyclic benzamide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 27 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2010077680 201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB bicyclic heteroaryl benzamide derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB benzimidazole derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 22 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-acylpiperidine ether derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2015042088example4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-acylpyrrolidine ether derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 5 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2015042088example11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine derivative 4 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2016054807example82 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 16 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-acylpiperidine ether derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrido[3,2-d]pyrimidine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB six-membered heterocyclic benzamide derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2010077680 803 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 14 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB bicyclic heteroaryl benzamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB 3-amino-5-benzyl-substituted indazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine derivative 7 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB sna-120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Pruritus[MeSHID:D011537] phase 2 tropomyosin-related kinase a NTRK1 Successful target unknown 2.23 TTD , DGIDB tpx-0005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2016054807example1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine derivative 5 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 17 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-acylpiperidine ether derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB ureido-phenyl-substituted triazine derivative 1 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational high affinity nerve growth factor receptor NTRK1 NA inhibitor NA drugbank pmid28270010-compound-figure24-a NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB cenegermin biotech Corneal Ulcer[MeSHID:D003320],Keratitis[MeSHID:D007634],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational high affinity nerve growth factor receptor NTRK1 NA stimulator NA drugbank pyrazolo[1,5-a]pyrimidine derivative 20 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB six-membered heterocyclic benzamide derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 10 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-arylmethyl-n-phenyl cyclic urea derivative 2 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 12 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-b]pyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB gw-5074 NA NA investigative tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD pyrrolidinyl urea derivative 3 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure16-b-2 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB thiadiazolyl carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB bicyclic heteroaryl benzamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB six-membered heterocyclic benzamide derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB cep-6331 NA NA investigative tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD pmid28270021-compound-wo2015042088example12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB bicyclic heteroaryl benzamide derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-acylpiperidine ether derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 18 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-(phenylpyrazolyl)benzamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolo[3,2-c]pyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB k-252a analogue NA NA investigative tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD imidazo[1,2-b]pyridazine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB five membered heterocyclic benzamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB ureido-phenyl-substituted triazine derivative 2 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-acylpiperidine ether derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 4 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB entrectinib NA Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved tropomyosin-related kinase a NTRK1 Successful target unknown 0.21 TTD , DGIDB imidazo[1,2-b]pyridazine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 26 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tropomyosin-related kinase a NTRK1 Successful target unknown 0.28 TTD , DGIDB n,n-bis(5-pyrazoyl)urea derivative 1 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 8 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2013009582example76 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2010077680 481 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2010077680 811 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved high affinity nerve growth factor receptor NTRK1 NA antagonist 0.12 drugbank , DGIDB pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Thymic Carcinoma[MeSHID:D013945],Chronic pain[MeSHID:D059350],Pruritus[MeSHID:D011537],Malignant neoplasm of thymus[MeSHID:D013953] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure17-3 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-b]pyridine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 11 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 9 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB bicyclic heteroaryl benzamide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2013009582example16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyridine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 7 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-arylmethyl-n-phenyl cyclic urea derivative 1 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB fx-007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] preclinical tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved high affinity nerve growth factor receptor NTRK1 NA antagonist 0.12 drugbank , DGIDB pmid28270021-compound-wo2014152663 701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Pain[MeSHID:D010146],Malignant neoplasm of thymus[MeSHID:D013953],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB tri-substituted urea derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB imidazo pyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2016054807example112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2016054807example80 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB six-membered heterocyclic benzamide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB entrectinib small molecule Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved,investigational high affinity nerve growth factor receptor NTRK1 NA inhibitor 0.21 drugbank , DGIDB n-acylpiperidine ether derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB bicyclic heteroaryl benzamide derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB n-acylpiperidine ether derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 21 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2010077680 109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2014078408example1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2010077680 495 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine derivative 6 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure24-b NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tropomyosin-related kinase a NTRK1 Successful target inhibitor 0.28 TTD , DGIDB ds-6051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB mim-d3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 tropomyosin-related kinase a NTRK1 Successful target unknown 3.35 TTD , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved high affinity nerve growth factor receptor NTRK1 NA agonist,activator NA drugbank vmd-928 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD ono-7579 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB six-membered heterocyclic benzamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolidinyl urea derivative 2 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2016054807example71 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrrolo[2,3-b]pyridine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB larotrectinib NA Neoplasms[MeSHID:D009369],Operative Surgical Procedures[MeSHID:D013514],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tropomyosin-related kinase a NTRK1 Successful target unknown 3.07 TTD , DGIDB five membered heterocyclic benzamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrido[3,2-d]pyrimidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB azaindazole amide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Chronic pain[MeSHID:D059350],Pruritus[MeSHID:D011537],Malignant neoplasm of thymus[MeSHID:D013953] patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pyrazolo[1,5-a]pyrimidine derivative 24 NA NA patented tropomyosin-related kinase a NTRK1 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure5-2 NA NA patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB 3-amino-5-benzyl-substituted indazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB pmid24432909c8e NA NA investigative bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD pmid28270010-compound-figure5-1 NA NA patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2016054807example1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure24-b NA NA patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown 0.2 TTD , DGIDB esketamine small molecule Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational bdnf/nt-3 growth factors receptor NTRK2 NA unknown NA drugbank cyclopenta[d]pyrimidine derivative 1 NA NA patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved bdnf/nt-3 growth factors receptor NTRK2 NA agonist NA drugbank trkb nam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Native American myopathy[MeSHID:C538343] investigative bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational bdnf/nt-3 growth factors receptor NTRK2 NA inhibitor NA drugbank azaindazole amide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Chronic pain[MeSHID:D059350],Pruritus[MeSHID:D011537],Malignant neoplasm of thymus[MeSHID:D013953] patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure5-3 NA NA patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2015042088example4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB entrectinib small molecule Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved,investigational bdnf/nt-3 growth factors receptor NTRK2 Successful target inhibitor 0.22 TTD , drugbank , DGIDB azd1332 NA NA investigative bdnf/nt-3 growth factors receptor NTRK2 Successful target inhibitor NA TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 bdnf/nt-3 growth factors receptor NTRK2 Successful target inhibitor 0.2 TTD , DGIDB gnf-5837 NA NA investigative bdnf/nt-3 growth factors receptor NTRK2 Successful target inhibitor NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB larotrectinib small molecule Neoplasms[MeSHID:D009369],Operative Surgical Procedures[MeSHID:D013514],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational bdnf/nt-3 growth factors receptor NTRK2 Successful target inhibitor 2.48 TTD , drugbank , DGIDB macrocycle derivative 13 NA Hyperplasia[MeSHID:D006965],Disease[MeSHID:D004194],Cell Proliferation[MeSHID:D049109],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented bdnf/nt-3 growth factors receptor NTRK2 Successful target unknown NA TTD , DGIDB azd1332 NA NA investigative nt-3 growth factor receptor NTRK3 Successful target inhibitor NA TTD , DGIDB altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 nt-3 growth factor receptor NTRK3 Successful target inhibitor 0.47 TTD , DGIDB pmid24900538c2c NA NA investigative nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD pyrrolo[2,3-d]pyrimidine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 nt-3 growth factor receptor NTRK3 Successful target unknown 0.47 TTD , DGIDB mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 nt-3 growth factor receptor NTRK3 Successful target unknown 0.13 TTD , DGIDB pmid28270010-compound-figure5-1 NA NA patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB pmid28270021-compound-wo2015042088example4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB cyclopenta[d]pyrimidine derivative 1 NA NA patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB pmid28270010-compound-figure5-3 NA NA patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational nt-3 growth factor receptor NTRK3 NA inhibitor NA drugbank pmid28270021-compound-wo2016054807example1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB larotrectinib small molecule Neoplasms[MeSHID:D009369],Operative Surgical Procedures[MeSHID:D013514],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational nt-3 growth factor receptor NTRK3 Successful target inhibitor 5.62 TTD , drugbank , DGIDB pmid28270010-compound-figure5-2 NA NA patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB azaindazole amide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Chronic pain[MeSHID:D059350],Pruritus[MeSHID:D011537],Malignant neoplasm of thymus[MeSHID:D013953] patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB jnj-28312141 NA NA investigative nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD cep-2563 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 nt-3 growth factor receptor NTRK3 Successful target inhibitor 0.11 TTD , DGIDB pmid28270010-compound-figure24-b NA NA patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB gnf-5837 NA NA investigative nt-3 growth factor receptor NTRK3 Successful target inhibitor NA TTD , DGIDB 3-amino-5-benzyl-substituted indazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of thymus[MeSHID:D013953],Pruritus[MeSHID:D011537],Chronic pain[MeSHID:D059350] patented nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD , DGIDB pmid21493067c1d NA NA investigative nt-3 growth factor receptor NTRK3 Successful target unknown NA TTD entrectinib small molecule Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved,investigational nt-3 growth factor receptor NTRK3 Successful target inhibitor 0.35 TTD , drugbank , DGIDB pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational nt-3 growth factor receptor NTRK3 NA inhibitor NA drugbank sr48527 NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD demotensin 4 NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD hbn-2 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD h-arg-n-me-arg-pro-tyr-ile-leu-oh NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD h-arg-arg-pro-tyr-ile-n-me-leu-oh NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD neurotensin(8-13) NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD nt-69-l NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD sr142948a NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target antagonist NA TTD , DGIDB meclinertant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2/3 neurotensin receptor type 1 NTSR1 Clinical trial target antagonist 13.64 TTD , DGIDB jmv449 NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD jmv458 NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target agonist NA TTD , DGIDB demotensin 3 NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD h-arg-arg-pro-tyr-n-me-ile-leu-oh NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD demotensin 1 NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD neurotensin NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target agonist 4.55 TTD , DGIDB [3h]meclinertant NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD h-arg-arg-pro-tyr-ile-aac-oh NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD demotensin 2 NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD meclinertant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2/3 neurotensin receptor type 1 NTSR1 Clinical trial target unknown 13.64 TTD , DGIDB eisai-1 NA NA investigative neurotensin receptor type 1 NTSR1 Clinical trial target unknown NA TTD xenin NA NA investigative neurotensin receptor type 2 NTSR2 Literature-reported target unknown NA TTD jmv458 NA NA investigative neurotensin receptor type 2 NTSR2 Literature-reported target agonist NA TTD , DGIDB levocabastine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Allergic Conjunctivitis[MeSHID:D003233],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neurotensin receptor type 2 NTSR2 NA partial antagonist,agonist 42.43 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational nuak family snf1-like kinase 1 NUAK1 NA inhibitor NA drugbank wz4003 NA NA investigative nuak family snf1-like kinase 2 NUAK2 Literature-reported target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational nuak family snf1-like kinase 2 NUAK2 NA inhibitor NA drugbank calcium phosphate dihydrate small molecule NA approved nucleobindin-1 NUCB1 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational nucleobindin-1 NUCB1 NA ligand NA drugbank calcium phosphate small molecule NA approved nucleobindin-1 NUCB1 NA ligand NA drugbank kml110 NA NA investigative nucleobindin-1 NUCB1 Literature-reported target antagonist NA TTD , DGIDB mjn228 NA NA investigative nucleobindin-1 NUCB1 Literature-reported target antagonist NA TTD , DGIDB calcium phosphate dihydrate small molecule NA approved nucleobindin-2 NUCB2 NA unknown NA drugbank calcium phosphate small molecule NA approved nucleobindin-2 NUCB2 NA ligand NA drugbank calcium citrate small molecule NA approved,investigational nucleobindin-2 NUCB2 NA ligand NA drugbank phenethyl isothiocyanate small molecule NA investigational nuclear migration protein nudc NUDC NA unknown NA drugbank beta-d-glucose small molecule NA experimental adp-ribose pyrophosphatase, mitochondrial NUDT9 NA unknown NA drugbank beta-d-ribose-5-phosphate small molecule NA experimental adp-ribose pyrophosphatase, mitochondrial NUDT9 NA unknown NA drugbank cysteine-s-acetamide small molecule NA experimental 2'-5'-oligoadenylate synthase 1 OAS1 NA unknown NA drugbank canaline NA NA investigative ornithine delta-aminotransferase OAT Literature-reported target unknown NA TTD canaline small molecule NA experimental ornithine aminotransferase, mitochondrial OAT NA inhibitor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical ornithine aminotransferase, mitochondrial OAT NA cofactor NA drugbank gabaculine small molecule NA experimental ornithine aminotransferase, mitochondrial OAT NA unknown 254.61 drugbank , DGIDB ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical ornithine aminotransferase, mitochondrial OAT NA unknown NA drugbank ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical ornithine decarboxylase antizyme 1 OAZ1 NA unknown NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical odorant-binding protein 2a OBP2A NA unknown NA drugbank n(6)-(pyridoxal phosphate)-l-lysine small molecule NA experimental ornithine decarboxylase ODC1 NA unknown NA drugbank alpha-monofluoromethyl-3,4-dehydroornithine NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD n-pyridoxyl-glycine-5-monophosphate small molecule NA experimental,investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD , drugbank putrescine small molecule Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Burn injury[MeSHID:D002056] experimental,discontinued in phase 2 ornithine decarboxylase ODC1 Successful target unknown NA TTD , drugbank geneticin small molecule NA experimental ornithine decarboxylase ODC1 NA unknown NA drugbank 3-(aminooxy)propan-1-amine hydrochloride NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD lonchocarpusone NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD pyridoxine-5'-phosphate NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD n'-pyridoxyl-lysine-5'-monophosphate NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD (2r,5r)-delta-methyl-alpha-acetylenic putrescine NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD zapotin NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD apa NA NA investigative ornithine decarboxylase ODC1 Successful target inhibitor NA TTD , DGIDB g418 NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD 3-methoxy-4-hydroxylonchocarpin NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD l-eflornithine small molecule NA experimental,investigational ornithine decarboxylase ODC1 NA unknown NA drugbank eflornithine small molecule Hypertrichosis[MeSHID:D006983],Hirsutism[MeSHID:D006628],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],African Trypanosomiasis[MeSHID:D014353],Trypanosomiasis[MeSHID:D014352] approved,withdrawn ornithine decarboxylase ODC1 Successful target antagonist,blocker 42.43 TTD , drugbank , DGIDB eflornithine small molecule Hypertrichosis[MeSHID:D006983],Hirsutism[MeSHID:D006628],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],African Trypanosomiasis[MeSHID:D014353],Trypanosomiasis[MeSHID:D014352] approved,withdrawn ornithine decarboxylase ODC1 Successful target antagonist,blocker,inhibitor 42.43 TTD , drugbank , DGIDB pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical ornithine decarboxylase ODC1 NA cofactor NA drugbank 1-amino-3-(aminoxy)-2-propanol dihydrochloride NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD 4-hydroxylonchocarpin NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD alpha-monofluoromethyl-3,4-dehydroornithine ethyl ester NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD spermine small molecule NA experimental,nutraceutical ornithine decarboxylase ODC1 NA product of NA drugbank amxt-1501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD alpha-monofluoromethyl-3,4-dehydroornithine methyl ester NA NA investigative ornithine decarboxylase ODC1 Successful target unknown NA TTD pyridoxine phosphate small molecule NA experimental ornithine decarboxylase ODC1 NA unknown NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 2-oxoglutarate dehydrogenase, mitochondrial OGDH NA inhibitor NA drugbank , DGIDB cpi-613 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Malignant neoplasm of pancreas[MeSHID:D010190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Pancreatic carcinoma[MeSHID:C562463],Burkitt Lymphoma[MeSHID:D002051],B-Cell Lymphomas[MeSHID:D016393],Colorectal Cancer[MeSHID:D015179],Recurrence (disease attribute)[MeSHID:D012008],T-Cell Lymphoma[MeSHID:D016399] phase 3 alpha-ketoglutarate dehydrogenase OGDH Clinical trial target unknown NA TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 2-oxoglutarate dehydrogenase, mitochondrial OGDH NA unknown NA drugbank xanthinol small molecule Metabolism[MeSHID:D008660],Brain[MeSHID:D001921],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Hyperlipidemia[MeSHID:D006949],Peripheral Vascular Diseases[MeSHID:D016491],Memory[MeSHID:D008568],Blood[MeSHID:D001769],Awareness[MeSHID:D001364] approved,withdrawn 2-oxoglutarate dehydrogenase, mitochondrial OGDH NA cofactor NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1 OGFOD1 NA cofactor NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2 OGFOD2 NA cofactor NA drugbank inno-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 opioid receptor zeta OGFR Clinical trial target unknown NA TTD , DGIDB irt-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 opioid receptor zeta OGFR Clinical trial target unknown NA TTD , DGIDB rg7418 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 lectin-like oxidized ldl receptor OLR1 Discontinued target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical 5-oxoprolinase OPLAH NA unknown NA drugbank naloxone small molecule Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved,vet_approved delta-type opioid receptor OPRD1 NA antagonist 1.07 drugbank , DGIDB rti-5989-23 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD deltorphin NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-nh-bzl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-(2r,3s)-beta-mecha-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD n-benzyl-17-(cyclobutylmethyl)morphinan-3-amine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD norbinaltorphimine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dimethylthiambutene NA Pain[MeSHID:D010146] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational delta-type opioid receptor OPRD1 NA agonist 0.27 drugbank , DGIDB longanine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-phenylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-phe-phe-oc(ch3)3 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dihydromorphine small molecule Pain[MeSHID:D010146] experimental,illicit delta-type opioid receptor OPRD1 NA agonist 1.31 drugbank , DGIDB h-tyr-d-ala-gly-phe-nh-nh-d-trp-nle-asp-phe-h NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-(r)-aba-gly-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-tic-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-nme-bzl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-(nme)phe-asp-nle-trp-ac NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-phenylspiro[chromene-2,4'-piperidine] NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 6beta-naltrexol hcl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD n-methylstephisoferulin NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 6-cinnamoylhernandine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD cis-h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-tic-phe-phe-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD hydromorphone small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Addictive Behavior[MeSHID:D016739],Drug Overdose[MeSHID:D062787],Coughing[MeSHID:D003371],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit delta-type opioid receptor OPRD1 NA partial agonist 1.96 drugbank , DGIDB 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-m-tolylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-445 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ethylketocyclazocine NA NA investigative opioid receptor delta OPRD1 Successful target agonist 0.33 TTD , DGIDB sufentanil small molecule Vagina[MeSHID:D014621],Maintenance[MeSHID:D008283],Labor (Childbirth)[MeSHID:D007743],Environmental air flow[MeSHID:D014691],Health Care[MeSHID:D003695],Operative Surgical Procedures[MeSHID:D013514],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational delta-type opioid receptor OPRD1 NA agonist 0.42 drugbank , DGIDB (-)-eseroline NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD n-alpha-amidino-tyr(me)-pro-trp-p-cl-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD oxymorphone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,vet_approved delta-type opioid receptor OPRD1 NA antagonist 0.73 drugbank , DGIDB 5-(4-((phenethylamino)methyl)phenoxy)picolinamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD c[l-mtyr-d-pro-l-phe-d-trp] NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD d-phe-cys-tyr-d-trp-orn-thr-pen-thr-nh2(ctop) NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD endomorphin-1 NA NA investigative opioid receptor delta OPRD1 Successful target agonist 0.49 TTD , DGIDB dmt-pro-3,5dmp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD rti-5989-31 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD phenazocine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch[(ch2)4-nh-z]-bid NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dslet NA NA investigative opioid receptor delta OPRD1 Successful target agonist NA TTD , DGIDB h-tyr-d-ala-gly-phe-nh-nh-d-phe-d-asp-d-nle-trp-h NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-phe-phe-n(ch3)2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD carboxyfentanyl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-phe-phe-och2ch3 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD eluxadoline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational delta-type opioid receptor OPRD1 NA antagonist 1.96 drugbank , DGIDB oxycodone small molecule Pain[MeSHID:D010146],Patient Discharge[MeSHID:D010351],Back Pain[MeSHID:D001416],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational delta-type opioid receptor OPRD1 NA agonist 0.65 drugbank , DGIDB dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved delta-type opioid receptor OPRD1 NA agonist NA drugbank 6-(2-phenethylisoindolin-5-yloxy)nicotinamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-(r)ch(ch2-cooh)-bid NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD [dcp1]dyn a(1-11)-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved delta-type opioid receptor OPRD1 NA agonist 0.39 drugbank , DGIDB peripentadenine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD naltrexone small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Alcohol consumption[MeSHID:D000428],emotional dependency[MeSHID:D003858],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disease[MeSHID:D004194] approved,investigational,vet_approved delta-type opioid receptor OPRD1 NA antagonist 1.47 drugbank , DGIDB tyr-pro-dmp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-boa NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD c[l-phe-d-pro-l-phe-l-trp] NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-imidph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD naltriben NA NA investigative opioid receptor delta OPRD1 Successful target antagonist 0.24 TTD , DGIDB tyr-pro-l-(nme)phe-pro-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-imp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD vp004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] discontinued in phase 1 opioid receptor delta OPRD1 Successful target unknown NA TTD 4-(spiro[chromene-2,4'-piperidine]-4-yl)phenol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD [3h]diprenorphine NA NA investigative opioid receptor delta OPRD1 Successful target agonist NA TTD , DGIDB h-dmt-d-arg(no2)-phe-lys(z)-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-(2r,3r)-beta-mecha-phe-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-(2r,3r)-beta-mecha-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dmt-pro-mmp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-c[d-allylgly-gly-phe-l-allylgly]nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 3,6-bis(dmt-tic-nh-butyl)-2(1h)-pyrazinone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational delta-type opioid receptor OPRD1 NA unknown NA drugbank h-dmt-tic-d-asp-n(me)-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD d-phe-cys-tyr-d-trp-lys-thr-pen-thr-nh2(ctp) NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD azd-2327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB tyr-d-ala-phe-glu-val-val-gly-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ufp-512 NA NA investigative opioid receptor delta OPRD1 Successful target agonist 0.33 TTD , DGIDB h-cpa-c[pen-gly-phe-pen]oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcp-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-asp-n(me)-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD bbi-11008 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD prostephabyssine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-d-arg(no2)-phe-lys(z)-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD lophocladine a NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-aba-gly-nh-ch2-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-o-tolylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD analog of dynorphin a NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD grandisine f NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-l-phe-pro-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dmt-pro-imp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD somatostatin NA Disease Management[MeSHID:D019468],Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],long-term care[MeSHID:D008134] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-l-phe-d-pro-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD endomorphin 2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD d-phgly-cys-tyr-d-trp-lys-thr-pen-thr-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-139 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dhp-c[d-cys-gly-phe(pno2)-d-cys]nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational delta-type opioid receptor OPRD1 NA ligand NA drugbank h-tyr-c[cys-gly-phe(p-no2)-cys]nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved delta-type opioid receptor OPRD1 NA agonist NA drugbank h-cdp-ala-gly-phe-leu-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-ala-gly-phe-met-pro-leu-trp-nh-bzl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-ch2-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-(4-((phenethylamino)methyl)phenoxy)benzamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational delta-type opioid receptor OPRD1 NA unknown NA drugbank 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 3,6-bis(dmt-tic-nh-ethyl)-2(1h)-pyrazinone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD oxymorphindole NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD samidorphan small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283] approved,investigational delta-type opioid receptor OPRD1 NA partial agonist,antagonist 0.33 drugbank , DGIDB mcp-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB 1,10-bis-(dmt-tic-amino)decane NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 3,6-bis(dmt-tic-nh-propyl)-2(1h)-pyrazinone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-145 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD codeine small molecule Solutions[MeSHID:D012996],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved,illicit delta-type opioid receptor OPRD1 NA agonist 1.22 drugbank , DGIDB h-tyr-c[d-orn-aic-glu]-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-182 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD morphine small molecule Disease Management[MeSHID:D019468],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194],Physical Examination[MeSHID:D010808],emotional dependency[MeSHID:D003858],Drug abuse[MeSHID:D019966],Patient Monitoring[MeSHID:D008991],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved,investigational delta-type opioid receptor OPRD1 NA agonist 0.32 drugbank , DGIDB h-dmt-tic-(2s,3s)-beta-mecha-phe-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD aknadilactam NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD remifentanil small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved delta-type opioid receptor OPRD1 NA agonist NA drugbank h-dmt-tic-asp-nh-bzl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-asp-nh-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD aiko-150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] phase 1 opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB dmt-pro-dmt-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD oxycodone NA Pain[MeSHID:D010146],Patient Discharge[MeSHID:D010351],Back Pain[MeSHID:D001416],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor delta OPRD1 Successful target unknown 0.65 TTD , DGIDB h-dmt-tic-nh-(ch2)6-nh-tic-h NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-d-tca-c[cys-tyr-d-trp-arg-thr-pen]-thr-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-hexylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-(s)ch(ch2-cooh)-bid(n1-me) NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD n-(4-iodophenyl)-n'-(17-methylmorphinan-3-yl)urea NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD beta-endorphin NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 3-methylfentanyl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD diamorphine small molecule Operative Surgical Procedures[MeSHID:D013514],Myocardial Infarction[MeSHID:D009203],Pain[MeSHID:D010146],Pulmonary Edema[MeSHID:D011654],Dyspnea[MeSHID:D004417] approved,illicit,investigational delta-type opioid receptor OPRD1 NA agonist NA drugbank h-dmt-aba-gly-nh-ch2-bid NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ici-199441 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 6-(allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-trp-ac NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-gly-n(me)-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-aba-ser-gly-phe-leu-thr-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ici 154129 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-aba-gly-nh-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD butorphan NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-147 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD naltrexone-6-alpha-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-cdp-gly-gly-phe-leu-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD carfentanil small molecule NA illicit,investigational,vet_approved delta-type opioid receptor OPRD1 NA agonist 1.47 drugbank , DGIDB fentanyl small molecule Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350] approved,illicit,investigational,vet_approved delta-type opioid receptor OPRD1 NA agonist 0.41 drugbank , DGIDB 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-mmp-phe-nh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tapentadol small molecule Acute onset pain[MeSHID:D059787],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Patient Discharge[MeSHID:D010351],Chronic pain[MeSHID:D059350] approved delta-type opioid receptor OPRD1 NA unknown NA drugbank antanal 1 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD codeine NA Solutions[MeSHID:D012996],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved opioid receptor delta OPRD1 Successful target unknown 1.22 TTD , DGIDB isoelaeocarpine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-c[pen-gly-phe-pen]oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-183 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved delta-type opioid receptor OPRD1 NA binder NA drugbank ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved delta-type opioid receptor OPRD1 NA binder NA drugbank 4-phenyl-4-[1h-imidazol-2-yl]-piperidine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-phe-phe-nhnh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-ala-phe-gly-tyr-pro-thr(beta-d-glc)-gly-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD diprenorphine small molecule NA illicit,vet_approved delta-type opioid receptor OPRD1 NA antagonist,agonist 2.28 drugbank , DGIDB tyr-gly-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD n-methylstephuline NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD nrp290 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB butyrfentanyl small molecule Drug abuse[MeSHID:D019966] illicit delta-type opioid receptor OPRD1 NA agonist NA drugbank grandisine d NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dmt-pro-phe-d-1-nal-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-glu-dap(6dmn)-nh(2) NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD hydromorphone NA Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Addictive Behavior[MeSHID:D016739],Drug Overdose[MeSHID:D062787],Coughing[MeSHID:D003371],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor delta OPRD1 Successful target agonist 1.96 TTD , DGIDB dstbulet NA NA investigative opioid receptor delta OPRD1 Successful target agonist NA TTD , DGIDB adl5859 small molecule Pain[MeSHID:D010146] investigational delta-type opioid receptor OPRD1 NA unknown NA drugbank , DGIDB ard-412 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Ejaculation[MeSHID:D061686] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-poa-ser-gly-phe-leu-thr-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD leucine-enkephalin NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-ala-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-trp-boc NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-indl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-imid NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ctop NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD sori-9409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] preclinical opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB [3h]naltrindole NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 6-(4-((benzylamino)methyl)phenoxy)nicotinamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD clocinnamox NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcp-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] phase 1 opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB 1-benzhydryl-4-benzylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dihydromorphine NA Pain[MeSHID:D010146] investigative opioid receptor delta OPRD1 Successful target agonist 1.31 TTD , DGIDB (-)-cyclorphan NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD n-alpha-amidino-tyr(me)-pro-trp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD antanal 2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-butylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD etorphine NA NA investigative opioid receptor delta OPRD1 Successful target agonist 2.61 TTD , DGIDB mc-cam NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-cpa-gly-gly-phe-met-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dimepheptanol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-428 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD bis-((-)-n-propargylmorphinan-3-yl) sebacoylate NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 2-hydroxymethyl-3-hydroxymorphinan NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-d-phe-d-pro-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD trans-h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD htyr-gly-gly-phe-leu-arg-arg-lle-arg-pro-lysnh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD grandisine c NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dpi-221 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-glu-nh-(ch2)5-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-431 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD bio-306 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] preclinical opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB tyr-d-phe-gly-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD metenkefalin small molecule Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529] investigational delta-type opioid receptor OPRD1 NA agonist NA drugbank tyr-d-ala-gly-d-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-phe-phe-och3 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dmt-pro-emp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-phe-gly-d-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-gly-nh-ch2-bid NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-117 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-glu-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-nle-gly-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-aba-gly-gly-phe-leu-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dmt-pro-tmp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-trp-d-nle-d-asp-d-phe-h NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD elaeocarpenine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 3,6-bis(dmt-tic-nh-methyl)-2(1h)-pyrazinone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved delta-type opioid receptor OPRD1 NA agonist 0.14 drugbank , DGIDB mcl-144 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1,6-bis-(dmt-tic-amino)hexane NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD butorphanol small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,vet_approved delta-type opioid receptor OPRD1 NA agonist 1.54 drugbank , DGIDB tyr-d-ala-gly-phe-nh-nh-phe-asp-nmenle-d-trp-boc NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD naldemedine small molecule Constipation[MeSHID:D003248] approved,investigational delta-type opioid receptor OPRD1 NA antagonist 0.49 drugbank , DGIDB h-dmt-tic-lys-nh-ch2-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-446 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-(2r,3s)-beta-mecha-phe-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD d-phe-cys-tyr-d-trp-arg-thr-pen-thr-nh2(ctap) NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcp-205 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary Arteriosclerosis[MeSHID:D003324],Myocardial Ischemia[MeSHID:D017202] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD sn-23 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD loxicodegol small molecule Back Pain[MeSHID:D001416],Drug abuse[MeSHID:D019966],Chronic pain[MeSHID:D059350] investigational delta-type opioid receptor OPRD1 NA agonist NA drugbank etorphine small molecule NA illicit,vet_approved delta-type opioid receptor OPRD1 NA agonist 2.61 drugbank , DGIDB rti-5989-25 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1,6-bis-(n,n-dimethyl-dmt-tic-nh)hexane NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-cpa-gly-gly-phe-met-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dmt-pro-dmp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-phe-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD (-)-isoelaeocarpiline NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD eluxadoline NA Irritable Bowel Syndrome[MeSHID:D043183],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor delta OPRD1 Successful target unknown 1.96 TTD , DGIDB mcl-458 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-nme-d-ala-phe-sar-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational delta-type opioid receptor OPRD1 NA unknown NA drugbank 3-methylfentanyl small molecule NA illicit delta-type opioid receptor OPRD1 NA agonist NA drugbank 1-benzhydryl-4-methoxy-4-phenylpiperidine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-pro-phe-phe-nh-ch2-ch2-nh tic dmt-h NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-cxp-ala-gly-phe-leu-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-ala-gly-phe-met-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD adl5859 small molecule Pain[MeSHID:D010146] investigational delta-type opioid receptor OPRD1 NA agonist NA drugbank , DGIDB hydromorphone NA Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Addictive Behavior[MeSHID:D016739],Drug Overdose[MeSHID:D062787],Coughing[MeSHID:D003371],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor delta OPRD1 Successful target unknown 1.96 TTD , DGIDB h-apa-ala-gly-phe-leu-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-tmp-phe-nh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dadle NA NA investigative opioid receptor delta OPRD1 Successful target agonist 0.49 TTD , DGIDB levorphanol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Cerebrovascular accident[MeSHID:D020521],Expiration, function[MeSHID:D045853] approved delta-type opioid receptor OPRD1 NA agonist NA drugbank 7-benzylidenenaltrexone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-tic-cha-phe-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-nme-3,5-bzl(cf3)2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-c[d-orn-(d or l)atc-glu]-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-444 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-443 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dextropropoxyphene small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn delta-type opioid receptor OPRD1 NA agonist NA drugbank tyr-d-phe-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dcp-c[d-cys-gly-phe(pno2)-d-cys]nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD sb 227122 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD benzyl derivative of m6g NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD falcarindiol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-154 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-ala-phe-thr(-d-glc)-tyr-pro-ser-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-c[d-cys-gly-phe-l-cys]nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-429 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly phe-pro-leu-trp-o-3,5-bzl(cf3)2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-gly-gly-phe-leu-c(cys-arg-ile-arg-cys)-lys NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-ala-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tip NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD normorphine NA NA investigative opioid receptor delta OPRD1 Successful target agonist 0.33 TTD , DGIDB h-dmt-tic-lys(z)-nh-ch2-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD hydrocodone small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Common Cold[MeSHID:D003139],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,illicit,investigational delta-type opioid receptor OPRD1 NA agonist 1.18 drugbank , DGIDB mcl-450 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-met-phe-his-leu-met-asp-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD loperamide NA Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor delta OPRD1 Successful target unknown 0.39 TTD , DGIDB tyr-d-nle-gly-d-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-447 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-d-trp-nle-asp-phe-bo NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD amisulpride small molecule Emotions[MeSHID:D004644],Disease[MeSHID:D004194],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Vomiting[MeSHID:D014839],Neoplasm Metastasis[MeSHID:D009362],Hostility[MeSHID:D006791],Mood Disorders[MeSHID:D019964],Affect (mental function)[MeSHID:D000339],Postoperative Nausea[MeSHID:D020250],Behavior[MeSHID:D001519],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Thinking, function[MeSHID:D013850],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational delta-type opioid receptor OPRD1 NA agonist NA drugbank tyr-pro-dmt-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-d-trp-boc NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD opium small molecule Diarrhea[MeSHID:D003967],Vision[MeSHID:D014785],Chronic pain[MeSHID:D059350] approved,illicit delta-type opioid receptor OPRD1 NA agonist NA drugbank dmt-pro-phe-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dermorphin NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD n-benzyl-17-(cyclopropylmethyl)morphinan-3-amine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-emp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD nalbuphine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Prurigo[MeSHID:D011536] approved delta-type opioid receptor OPRD1 NA antagonist 0.98 drugbank , DGIDB 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 6-desoxonaltrexone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 17-methylmorphinan-3-yl 4-iodophenyl carbamate NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-433 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-ala-phe-asp-val-val-thr[beta-d-glc]-gly-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 3-desoxy-3-carboxamidonaltrexone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD butorphanol NA Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor delta OPRD1 Successful target unknown 1.54 TTD , DGIDB damgo NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-lys(ac)-nh-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD diphenoxylate small molecule Disease Management[MeSHID:D019468],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit delta-type opioid receptor OPRD1 NA agonist NA drugbank 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcp-204 NA Urinary Bladder Diseases[MeSHID:D001745],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative opioid receptor delta OPRD1 Successful target unknown NA TTD n-(17-methylmorphinan-3-yl)-n'-phenylurea NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-indn NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dpi-3290 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-p-tolylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-cyclohexylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-(2s,3s)-beta-mecha-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tipppsi NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD naltrexone small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Alcohol consumption[MeSHID:D000428],emotional dependency[MeSHID:D003858],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],HIV Infections[MeSHID:D015658] approved,investigational,vet_approved delta-type opioid receptor OPRD1 NA antagonist 1.47 drugbank , DGIDB sb-0304 NA NA investigative opioid receptor delta OPRD1 Successful target unknown 0.98 TTD , DGIDB ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational delta-type opioid receptor OPRD1 NA agonist NA drugbank 1-benzhydryl-4-ethoxy-4-phenylpiperidine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-d-phg-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-d-phe-pro-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tonazocine mesylate NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-149 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD deltorphin-ii NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD (h-dmt-tic-glu-nh-(ch(2))(5)-co-dap(6dmn)-nh(2) NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-d-asp-nh-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ethyketazocine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch[(ch2)4-nh2]-bid NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved delta-type opioid receptor OPRD1 NA agonist 0.39 drugbank , DGIDB 8-carboxamidocyclazocine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-c[d-allylgly-gly-phe-d-allylgly]nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD nalmefene small molecule Disease Management[MeSHID:D019468],Respiratory Depression[MeSHID:D012131],Physical Examination[MeSHID:D010808],Alcohol consumption[MeSHID:D000428],Drug Overdose[MeSHID:D062787],Alcoholic Intoxication, Chronic[MeSHID:D000437],Drinking function[MeSHID:D004326],Metabolic Detoxication, Drug[MeSHID:D008658],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] approved,investigational,withdrawn delta-type opioid receptor OPRD1 NA antagonist,agonist 1.31 drugbank , DGIDB 1-benzhydryl-4-phenyl-4-propoxypiperidine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-lys(ac)-nh-ch2-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-mcpa-gly-gly-phe-leu-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 17-methyl-4'-methyldihydromorphinone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-l-(nme)phe-d-pro-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD pholcodine small molecule Sputum[MeSHID:D013183],disease transmission[MeSHID:D018562],Respiratory Muscles[MeSHID:D012132],Structure of intercostal muscle[MeSHID:D007366],Movement[MeSHID:D009068],Coughing[MeSHID:D003371],Medulla Oblongata[MeSHID:D008526],Desiccation[MeSHID:D003890],Motor Neurons[MeSHID:D009046],Inspiration function[MeSHID:D001239] approved,illicit delta-type opioid receptor OPRD1 NA antagonist NA drugbank herkinorin NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-448 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD loperamide NA Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved opioid receptor delta OPRD1 Successful target unknown 0.39 TTD , DGIDB 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-432 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-lys-nh-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dimethylthiambutene small molecule Pain[MeSHID:D010146] experimental,illicit delta-type opioid receptor OPRD1 NA agonist NA drugbank h-2',6'-dimethyltyrosine-tic-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 17-(cyclobutylmethyl)-n-phenylmorphinan-3-amine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-2',6'-dimethyltyrosine-tic-phe-phe-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD diprenorphine NA NA investigative opioid receptor delta OPRD1 Successful target agonist 2.28 TTD , DGIDB met-enkephalin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor delta OPRD1 Successful target unknown 0.49 TTD , DGIDB h-cdp-ser-gly-phe-leu-thr-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-d-tic-c[cys-tyr-d-trp-arg-thr-pen]-thr-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-nh-3,5-bzl(cf3)2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-nle-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD c[l-phe-d-pro-l-mtyr-d-trp] NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 17-(cyclopropylmethyl)-n-phenylmorphinan-3-amine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD metazocine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-ala-gly-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-(ch2)6-nh-phe-h NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-(ch2)6-nh-dmt-h NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ici-174864 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-mcpa-ser-gly-phe-leu-thr-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dpdpe NA NA investigative opioid receptor delta OPRD1 Successful target agonist 0.49 TTD , DGIDB adl-5747 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor delta OPRD1 Successful target unknown 0.98 TTD , DGIDB cyclorphan NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD lofentanil NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-d-trp-h NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD [leu5]enkephalin NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ctap NA NA investigative opioid receptor delta OPRD1 Successful target antagonist NA TTD , DGIDB 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD trk-851 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] discontinued in phase 1 opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-153 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-(nme)ala-l-phe-d-pro-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-(s)-aba-gly-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD o-desmethyl tramadol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-phe-phe-och2oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-pro-dap(6dmn)-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-(r)ch(ch2-cooh)-bid(n1-me) NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dmt-pro-trp-d-2-nal-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-d-trp-c[cys-tyr-d-trp-arg-thr-pen]-thr-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-(p-tolyl)spiro[chromene-2,4'-piperidine] NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD alvimopan small molecule Intestines, Small[MeSHID:D007421],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational delta-type opioid receptor OPRD1 NA antagonist 0.98 drugbank , DGIDB sn-28 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-pro-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-lys(z)-nh-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 14-o-phenylpropylnaltrexone NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-aba-ala-gly-phe-leu-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-phe-phe-nhch3 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD snc-80 NA NA investigative opioid receptor delta OPRD1 Successful target unknown 0.65 TTD , DGIDB mcl-434 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch[(ch2)4-nh-ac]-bid NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-aba-ala-gly-phe-met-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-pro-3,5dmp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD salvinorin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] phase 1 opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB dmt-pro-phe-d-2-nal-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ufp-502 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD carfentanil NA NA phase 2 opioid receptor delta OPRD1 Successful target unknown 1.47 TTD , DGIDB 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tpm-1/morphine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB 1,4-bis-(dmt-tic-amino)butane NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD ly-25582 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical opioid receptor delta OPRD1 Successful target unknown 0.49 TTD , DGIDB h-dmt-tic-gly-nh-ph NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-gly-nh-bzl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD adl-5859 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB hydromorphone small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Addictive Behavior[MeSHID:D016739],Drug Overdose[MeSHID:D062787],Coughing[MeSHID:D003371],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit delta-type opioid receptor OPRD1 NA partial agonist,agonist 1.96 drugbank , DGIDB 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD deprotected cogener of m6g NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD aminofentanyl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD etonitazene NA NA investigative opioid receptor delta OPRD1 Successful target agonist 0.24 TTD , DGIDB h-tyr-c[d-cys-gly-phe-d-cys]nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD morphine glucuronide small molecule Pain[MeSHID:D010146] investigational delta-type opioid receptor OPRD1 NA unknown NA drugbank h-dmt-tic-(2s,3r)-beta-mecha-phe-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 3-methylthiofentanyl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 6-cinnamoyl-n-methylstephasunoline NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD buprenorphine small molecule Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Pain[MeSHID:D010146] approved,illicit,investigational,vet_approved delta-type opioid receptor OPRD1 NA antagonist 0.88 drugbank , DGIDB mcl-451 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-o-bzl NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD sn-11 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD trv250 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 1 opioid receptor delta OPRD1 Successful target unknown NA TTD , DGIDB dynorphin a NA NA discontinued in phase 2 opioid receptor delta OPRD1 Successful target agonist NA TTD , DGIDB mcl-435 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-gly-gly-phe-c(cys-arg-arg-ile-cys)-arg-lys NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-(d)-ch[(ch2)4-nh-z]-bid NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD mcl-449 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD 3-methylthiofentanyl small molecule NA experimental,illicit delta-type opioid receptor OPRD1 NA agonist NA drugbank cyclazocine NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD quadazocine NA NA investigative opioid receptor delta OPRD1 Successful target antagonist 0.33 TTD , DGIDB 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD nalmefene small molecule Disease Management[MeSHID:D019468],Respiratory Depression[MeSHID:D012131],Physical Examination[MeSHID:D010808],Alcohol consumption[MeSHID:D000428],Drug Overdose[MeSHID:D062787],Alcoholic Intoxication, Chronic[MeSHID:D000437],Drinking function[MeSHID:D004326],Metabolic Detoxication, Drug[MeSHID:D008658],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] approved,investigational,withdrawn delta-type opioid receptor OPRD1 NA antagonist 1.31 drugbank , DGIDB nalbuphine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Prurigo[MeSHID:D011536] approved delta-type opioid receptor OPRD1 NA antagonist,agonist 0.98 drugbank , DGIDB 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-(2s,3r)-beta-mecha-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-d-nle-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD tyr-(s)-spiro-aba-gly-phe-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-bta NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-pro-phe-phe-nh-(ch2)5-(c=o)-dap(6dmn)-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-tyr-gly-gly-phe-met-nh2 NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD dynorphin b NA NA investigative opioid receptor delta OPRD1 Successful target agonist NA TTD , DGIDB m6g thiosaccharide analogue NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD h-mcpa-ala-gly-phe-leu-oh NA NA investigative opioid receptor delta OPRD1 Successful target unknown NA TTD salvinorin b NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD cr-845 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350] phase 2/3 opioid receptor kappa OPRK1 Successful target unknown NA TTD bis-((-)-n-propargylmorphinan-3-yl) sebacoylate NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD btrx-335140 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 opioid receptor kappa OPRK1 Successful target antagonist NA TTD , DGIDB nalorphine NA NA investigative opioid receptor kappa OPRK1 Successful target agonist 0.24 TTD , DGIDB 1-benzhydryl-4-hexylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD fentanyl small molecule Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350] approved,illicit,investigational,vet_approved kappa-type opioid receptor OPRK1 NA agonist 0.06 drugbank , DGIDB dmt-pro-dmp-phe-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD cis-h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-434 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD gr-86014 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD tifluadom NA NA investigative opioid receptor kappa OPRK1 Successful target agonist 0.72 TTD , DGIDB progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved kappa-type opioid receptor OPRK1 NA activator,potentiator NA drugbank h-cdp-gly-gly-phe-leu-oh NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD difelikefalin NA Pruritus[MeSHID:D011537],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 opioid receptor kappa OPRK1 Successful target agonist 2.15 TTD , DGIDB mcl-457 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD spiroindanyloxymorphone NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b methylthiomethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD brl-52656 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 opioid receptor kappa OPRK1 Successful target unknown 0.72 TTD , DGIDB beta-endorphin NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD sn-28 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational kappa-type opioid receptor OPRK1 NA ligand NA drugbank progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved kappa-type opioid receptor OPRK1 NA activator,potentiator NA drugbank 4-phenylspiro[chromene-2,4'-piperidine] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 6-desoxonaltrexone NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 3-desoxy-3-carboxamidonaltrexone NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dmt-pro-dmt-phe-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD naltrexone small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Alcohol consumption[MeSHID:D000428],emotional dependency[MeSHID:D003858],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],HIV Infections[MeSHID:D015658] approved,investigational,vet_approved kappa-type opioid receptor OPRK1 NA antagonist 0.8 drugbank , DGIDB enadoline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor kappa OPRK1 Successful target unknown 1.43 TTD , DGIDB clocinnamox NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mirtazapine small molecule Major Depressive Disorder[MeSHID:D003865],Hot flushes[MeSHID:D019584],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Dysthymic Disorder[MeSHID:D019263],Tension Headache[MeSHID:D018781],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Substance abuse problem[MeSHID:D019966],Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank m3pr6s NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n-benzyl[d-pro-10]dyn a-(1-11) NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD c[l-phe-d-pro-l-mtyr-d-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD m3a6s NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD oxymorphindole NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD ici-204448 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mr-2266 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD alvimopan small molecule Intestines, Small[MeSHID:D007421],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational kappa-type opioid receptor OPRK1 NA antagonist 0.72 drugbank , DGIDB etonitazene NA NA investigative opioid receptor kappa OPRK1 Successful target agonist 0.18 TTD , DGIDB salvinorin b fluoromethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD oxycodone small molecule Pain[MeSHID:D010146],Patient Discharge[MeSHID:D010351],Back Pain[MeSHID:D001416],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational kappa-type opioid receptor OPRK1 NA agonist 0.56 drugbank , DGIDB 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-429 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD c[l-phe-d-pro-l-tyr-d-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kappa-type opioid receptor OPRK1 NA agonist 0.2 drugbank , DGIDB endomorphin 2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 3-methylfentanyl small molecule NA illicit kappa-type opioid receptor OPRK1 NA agonist NA drugbank hydromorphone small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Addictive Behavior[MeSHID:D016739],Drug Overdose[MeSHID:D062787],Coughing[MeSHID:D003371],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit kappa-type opioid receptor OPRK1 NA agonist 0.86 drugbank , DGIDB 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD [3h]u69593 NA NA investigative opioid receptor kappa OPRK1 Successful target agonist NA TTD , DGIDB mcl-435 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD sn-11 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-153 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-benzylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD vp004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] discontinued in phase 1 opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b propoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 2-benzylaminomethyl-3-hydroxymorphinan NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 4-phenyl-4-[1h-imidazol-2-yl]-piperidine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 3-methylthiofentanyl small molecule NA experimental,illicit kappa-type opioid receptor OPRK1 NA agonist NA drugbank salvinorin b methoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dm6s NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD quadazocine NA NA investigative opioid receptor kappa OPRK1 Successful target antagonist 0.24 TTD , DGIDB dynorphin(1-8) NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dcp-c[d-cys-gly-phe(pno2)-d-cys]nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD naltriben NA NA investigative opioid receptor kappa OPRK1 Successful target antagonist 0.18 TTD , DGIDB mcp-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB c[l-tyr(ome)-d-pro-l-phe-d-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD c[l-tyr-d-pro-l-phe-d-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD gnti NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB h-tyr-c[d-allylgly-gly-phe-d-allylgly]nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n-isobutylnoroxymorphone NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD morphine small molecule Disease Management[MeSHID:D019468],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194],Physical Examination[MeSHID:D010808],emotional dependency[MeSHID:D003858],Drug abuse[MeSHID:D019966],Patient Monitoring[MeSHID:D008991],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved,investigational kappa-type opioid receptor OPRK1 NA agonist 0.23 drugbank , DGIDB cyclazocine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD butyrfentanyl small molecule Drug abuse[MeSHID:D019966] illicit kappa-type opioid receptor OPRK1 NA agonist NA drugbank remifentanil small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank 6-(4-((benzylamino)methyl)phenoxy)nicotinamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD h-cdp-ala-gly-phe-leu-oh NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 2-epi-2-thiosalvinorin b NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b tetrahydropyran-2-yl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD asimadoline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Diarrhea[MeSHID:D003967] investigational kappa-type opioid receptor OPRK1 NA unknown 1.43 drugbank , DGIDB 1-benzhydryl-4-p-tolylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD [3h]diprenorphine NA NA investigative opioid receptor kappa OPRK1 Successful target antagonist NA TTD , DGIDB c[l-phe-d-pro-l-tyr(ome)-d-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD elaeocarpenine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD h-tyr-c[d-allylgly-gly-phe-l-allylgly]nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD u50,488h NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD l-685,818 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD pholcodine small molecule Sputum[MeSHID:D013183],disease transmission[MeSHID:D018562],Respiratory Muscles[MeSHID:D012132],Structure of intercostal muscle[MeSHID:D007366],Movement[MeSHID:D009068],Coughing[MeSHID:D003371],Medulla Oblongata[MeSHID:D008526],Desiccation[MeSHID:D003890],Motor Neurons[MeSHID:D009046],Inspiration function[MeSHID:D001239] approved,illicit kappa-type opioid receptor OPRK1 NA antagonist NA drugbank mcl-139 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kappa-type opioid receptor OPRK1 NA agonist NA drugbank cyclorphan NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD cr665 small molecule Pain[MeSHID:D010146] investigational kappa-type opioid receptor OPRK1 NA unknown NA drugbank , DGIDB 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-182 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD zyklophin NA NA investigative opioid receptor kappa OPRK1 Successful target antagonist 0.24 TTD , DGIDB 1-benzhydryl-4-tert-butylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-cyclohexylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD h-cpa-gly-gly-phe-met-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-449 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD [u-13c]ascomycin NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-445 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD naltrexone-6-alpha-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD anisocoumarin h NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mr-1029 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mc-cam NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 17-methyl-4'-methyldihydromorphinone NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n-(17-methylmorphinan-3-yl)-n'-phenylurea NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD c[l-mtyr-d-pro-l-phe-d-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n-cpm[d-pro-10]dyn a-(1-11) NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mr-1526 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD ici-199441 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD adl 10-0101 small molecule Behavior[MeSHID:D001519],Pruritus[MeSHID:D011537],Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational kappa-type opioid receptor OPRK1 NA unknown NA drugbank amisulpride small molecule Emotions[MeSHID:D004644],Disease[MeSHID:D004194],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Vomiting[MeSHID:D014839],Neoplasm Metastasis[MeSHID:D009362],Hostility[MeSHID:D006791],Mood Disorders[MeSHID:D019964],Affect (mental function)[MeSHID:D000339],Postoperative Nausea[MeSHID:D020250],Behavior[MeSHID:D001519],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Thinking, function[MeSHID:D013850],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational kappa-type opioid receptor OPRK1 NA agonist NA drugbank ly-25582 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical opioid receptor kappa OPRK1 Successful target unknown 0.36 TTD , DGIDB salvinorin a (ester) NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n-benzyl-17-(cyclobutylmethyl)morphinan-3-amine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD asimadoline NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Diarrhea[MeSHID:D003967] phase 3 opioid receptor kappa OPRK1 Successful target unknown 1.43 TTD , DGIDB salvinorin b isopropoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 2-hydroxymethyl-3-hydroxymorphinan NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-444 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD ethylketocyclazocine NA NA investigative opioid receptor kappa OPRK1 Successful target agonist 0.24 TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank norbinaltorphimine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown 0.54 TTD , DGIDB butorphan NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD nalbzoh NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD rti-5989-23 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD butorphanol small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,vet_approved kappa-type opioid receptor OPRK1 NA agonist 1.33 drugbank , DGIDB tapentadol small molecule Acute onset pain[MeSHID:D059787],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Patient Discharge[MeSHID:D010351],Chronic pain[MeSHID:D059350] approved kappa-type opioid receptor OPRK1 NA unknown NA drugbank dihydromorphine NA Pain[MeSHID:D010146] investigative opioid receptor kappa OPRK1 Successful target agonist 0.95 TTD , DGIDB sn-23 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD apadoline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor kappa OPRK1 Successful target unknown 0.72 TTD , DGIDB mcl-154 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD pf-4455242 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714] phase 1 opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB 1-benzhydryl-4-butylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dezocine NA Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor kappa OPRK1 Successful target unknown 2.86 TTD , DGIDB o-desmethyl tramadol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dezocine NA Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor kappa OPRK1 Successful target antagonist 2.86 TTD , DGIDB difelikefalin small molecule Pruritus[MeSHID:D011537],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kappa-type opioid receptor OPRK1 NA agonist 2.15 drugbank , DGIDB 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD m3p6s NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dmt-pro-mmp-phe-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD ly-2456302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Alcoholic Intoxication, Chronic[MeSHID:D000437],Unipolar Depression[MeSHID:D003866] phase 2 opioid receptor kappa OPRK1 Successful target unknown 0.48 TTD , DGIDB mcl-431 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-432 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dimepheptanol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD h-cpa-gly-gly-phe-met-oh NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dmt-pro-3,5dmp-phe-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD adl 10-0101 NA Behavior[MeSHID:D001519],Pruritus[MeSHID:D011537],Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 opioid receptor kappa OPRK1 Successful target unknown NA TTD r-84760 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor kappa OPRK1 Successful target unknown NA TTD nalbuphine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Prurigo[MeSHID:D011536] approved kappa-type opioid receptor OPRK1 NA agonist 1.79 drugbank , DGIDB mcl-428 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-methoxy-4-phenylpiperidine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD nalbuphine NA Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Prurigo[MeSHID:D011536] approved opioid receptor kappa OPRK1 Successful target agonist 1.79 TTD , DGIDB 6-(allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD naltrexone small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Alcohol consumption[MeSHID:D000428],emotional dependency[MeSHID:D003858],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disease[MeSHID:D004194] approved,investigational,vet_approved kappa-type opioid receptor OPRK1 NA antagonist 0.8 drugbank , DGIDB 4-(spiro[chromene-2,4'-piperidine]-4-yl)phenol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD levorphanol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Cerebrovascular accident[MeSHID:D020521],Expiration, function[MeSHID:D045853] approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 3-methylthiofentanyl NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 3-(1-benzylpiperidin-4-yloxy)benzamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n-allyl[d-pro-10]dyn a-(1-11) NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n-(4-iodophenyl)-n'-(17-methylmorphinan-3-yl)urea NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD damgo NA NA investigative opioid receptor kappa OPRK1 Successful target agonist 0.36 TTD , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kappa-type opioid receptor OPRK1 NA inhibitor NA drugbank falcarindiol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-183 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD methylnaltrexone small molecule Constipation[MeSHID:D003248] approved kappa-type opioid receptor OPRK1 NA antagonist 0.48 drugbank , DGIDB nor-binaltorphimine dihydrochloride NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD morphinan cyclic imine analogue NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD rti-5989-31 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD rti-5989-25 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-443 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD knt-62 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD ethyketazocine NA NA investigative opioid receptor kappa OPRK1 Successful target agonist NA TTD , DGIDB buprenorphine small molecule Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Pain[MeSHID:D010146] approved,illicit,investigational,vet_approved kappa-type opioid receptor OPRK1 NA antagonist,agonist 0.43 drugbank , DGIDB 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD trans-h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD ketocyclazocine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD naloxone small molecule Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved,vet_approved kappa-type opioid receptor OPRK1 NA antagonist 0.33 drugbank , DGIDB 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD nrp290 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank clioquinol NA NA withdrawn from market opioid receptor kappa OPRK1 Successful target unknown 0.04 TTD , DGIDB endomorphin-1 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 4-(p-tolyl)spiro[chromene-2,4'-piperidine] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD herkinorin NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD opium small molecule Diarrhea[MeSHID:D003967],Vision[MeSHID:D014785],Chronic pain[MeSHID:D059350] approved,illicit kappa-type opioid receptor OPRK1 NA agonist NA drugbank m6s NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b ethoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dmt-pro-phe-phe-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b tert-butoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD tpm-1/morphine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB dmt-pro-tmp-phe-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 6beta-naltrexol hcl NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b 2-methoxy-2-propyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD c[l-phe-d-pro-l-phe-d-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD aiko-150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] phase 1 opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB eluxadoline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kappa-type opioid receptor OPRK1 NA agonist NA drugbank m3ibu6s NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD carfentanil NA NA phase 2 opioid receptor kappa OPRK1 Successful target unknown 1.07 TTD , DGIDB dynorphin a NA NA discontinued in phase 2 opioid receptor kappa OPRK1 Successful target agonist NA TTD , DGIDB 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD phn-131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Postherpetic neuralgia[MeSHID:D051474] phase 2/3 opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD phenazocine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-phenylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-448 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dhp-c[d-cys-gly-phe(pno2)-d-cys]nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-isopropylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-ethoxy-4-phenylpiperidine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] phase 1 opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB h-tyr-gly-gly-phe-met-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD c[l-ala-d-pro-l-phe-d-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dmt-pro-imp-phe-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-458 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mk-1925 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD lofentanil NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank 17-(cyclobutylmethyl)-n-phenylmorphinan-3-amine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD oxymorphone semicarbazone hydrochloride NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dezocine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kappa-type opioid receptor OPRK1 NA antagonist 2.86 drugbank , DGIDB 12-epi-salvinorin a NA NA investigative opioid receptor kappa OPRK1 Successful target unknown 1.43 TTD , DGIDB 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b butoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b 2-methoxyethoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-117 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 3-(1-benzylpiperidin-4-yl)-5-chloro-1h-indole NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD chloroxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erythema[MeSHID:D004890] approved opioid receptor kappa OPRK1 Successful target unknown 0.14 TTD , DGIDB diprenorphine NA NA investigative opioid receptor kappa OPRK1 Successful target antagonist 0.48 TTD , DGIDB morphine glucuronide small molecule Pain[MeSHID:D010146] investigational kappa-type opioid receptor OPRK1 NA unknown NA drugbank brl 52974 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n,n-diallyl[d-pro-10]dyn a-(1-11) NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD nalmefene small molecule Disease Management[MeSHID:D019468],Respiratory Depression[MeSHID:D012131],Physical Examination[MeSHID:D010808],Alcohol consumption[MeSHID:D000428],Drug Overdose[MeSHID:D062787],Alcoholic Intoxication, Chronic[MeSHID:D000437],Drinking function[MeSHID:D004326],Metabolic Detoxication, Drug[MeSHID:D008658],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] approved,investigational,withdrawn kappa-type opioid receptor OPRK1 NA partial agonist,antagonist 0.95 drugbank , DGIDB dihydromorphine small molecule Pain[MeSHID:D010146] experimental,illicit kappa-type opioid receptor OPRK1 NA agonist 0.95 drugbank , DGIDB mcl-446 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD metazocine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 17-methylmorphinan-3-yl 4-iodophenyl carbamate NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dpdpe NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b 2-fluoroethoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD cr-665 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB mcl-149 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD htyr-gly-gly-phe-leu-arg-arg-lle-arg-pro-lysnh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD drug 7684380 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-450 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dextropropoxyphene small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn kappa-type opioid receptor OPRK1 NA antagonist NA drugbank h-tyr-c[d-cys-gly-phe-d-cys]nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD spiradoline NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinicin b NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved kappa-type opioid receptor OPRK1 NA partial agonist NA drugbank pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational kappa-type opioid receptor OPRK1 NA agonist NA drugbank 2-(2-methylquinolin-4-ylamino)-n-phenylacetamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD v1003 small molecule Pain[MeSHID:D010146] investigational kappa-type opioid receptor OPRK1 NA unknown NA drugbank mcl-433 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] phase 1 opioid receptor kappa OPRK1 Successful target agonist NA TTD , DGIDB n-benzyl-17-(cyclopropylmethyl)morphinan-3-amine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylethyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 17-(cyclopropylmethyl)-n-phenylmorphinan-3-amine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved kappa-type opioid receptor OPRK1 NA unknown 1.07 drugbank , DGIDB diprenorphine small molecule NA illicit,vet_approved kappa-type opioid receptor OPRK1 NA antagonist 0.48 drugbank , DGIDB 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n,n-dibenzyl[d-pro-10]dyn a-(1-11) NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinicin a NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD benzyl derivative of m6g NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] phase 1 opioid receptor kappa OPRK1 Successful target unknown 1.43 TTD , DGIDB e-2078 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor kappa OPRK1 Successful target unknown NA TTD loxicodegol small molecule Back Pain[MeSHID:D001416],Drug abuse[MeSHID:D019966],Chronic pain[MeSHID:D059350] investigational kappa-type opioid receptor OPRK1 NA agonist NA drugbank naldemedine small molecule Constipation[MeSHID:D003248] approved,investigational kappa-type opioid receptor OPRK1 NA antagonist NA drugbank [leu5]enkephalin NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational kappa-type opioid receptor OPRK1 NA agonist NA drugbank samidorphan small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283] approved,investigational kappa-type opioid receptor OPRK1 NA partial agonist,antagonist 0.24 drugbank , DGIDB niravoline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor kappa OPRK1 Successful target unknown 0.72 TTD , DGIDB 5-(4-((phenethylamino)methyl)phenoxy)picolinamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD nalmefene small molecule Disease Management[MeSHID:D019468],Respiratory Depression[MeSHID:D012131],Physical Examination[MeSHID:D010808],Alcohol consumption[MeSHID:D000428],Drug Overdose[MeSHID:D062787],Alcoholic Intoxication, Chronic[MeSHID:D000437],Drinking function[MeSHID:D004326],Metabolic Detoxication, Drug[MeSHID:D008658],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] approved,investigational,withdrawn kappa-type opioid receptor OPRK1 NA partial agonist 0.95 drugbank , DGIDB 14-o-phenylpropylnaltrexone NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD n,n-dicpm[d-pro-10]dyn a-(1-11) NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD h-tyr-c[d-cys-gly-phe-l-cys]nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD [dcp1]dyn a(1-11)-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank brl 52537 hydrochloride NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD c[l-phe-d-pro-l-phe-l-trp] NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 2-epi-2-thiosalvinorin a NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-phenyl-4-propoxypiperidine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-144 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD m6g thiosaccharide analogue NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank codeine small molecule Solutions[MeSHID:D012996],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved,illicit kappa-type opioid receptor OPRK1 NA agonist 0.63 drugbank , DGIDB carfentanil small molecule NA illicit,investigational,vet_approved kappa-type opioid receptor OPRK1 NA agonist 1.07 drugbank , DGIDB salvinorin b 2,2,2-trifluoroethoxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD gr-38414 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD gr-45809 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD deoxy salvinorin a NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD normorphine NA NA investigative opioid receptor kappa OPRK1 Successful target agonist 0.24 TTD , DGIDB 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD diamorphine small molecule Operative Surgical Procedures[MeSHID:D013514],Myocardial Infarction[MeSHID:D009203],Pain[MeSHID:D010146],Pulmonary Edema[MeSHID:D011654],Dyspnea[MeSHID:D004417] approved,illicit,investigational kappa-type opioid receptor OPRK1 NA agonist NA drugbank salvinorin b benzyloxymethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD nalbuphine NA Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Prurigo[MeSHID:D011536] approved opioid receptor kappa OPRK1 Successful target unknown 1.79 TTD , DGIDB 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-145 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-447 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mr-2034 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved kappa-type opioid receptor OPRK1 NA agonist NA drugbank etorphine small molecule NA illicit,vet_approved kappa-type opioid receptor OPRK1 NA agonist 0.95 drugbank , DGIDB knt-63 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 3-methylfentanyl NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD buprenorphine small molecule Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Pain[MeSHID:D010146] approved,illicit,investigational,vet_approved kappa-type opioid receptor OPRK1 NA antagonist 0.43 drugbank , DGIDB mcl-451 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD (-)-cyclorphan NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dmt-pro-emp-phe-nh2 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD sufentanil small molecule Vagina[MeSHID:D014621],Maintenance[MeSHID:D008283],Labor (Childbirth)[MeSHID:D007743],Environmental air flow[MeSHID:D014691],Health Care[MeSHID:D003695],Operative Surgical Procedures[MeSHID:D013514],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kappa-type opioid receptor OPRK1 NA unknown 0.31 drugbank , DGIDB gr-91272 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD salvinorin b 1-ethoxyethyl ether NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD deprotected cogener of m6g NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD mcl-147 NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-m-tolylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD pentazocine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved kappa-type opioid receptor OPRK1 NA agonist 0.72 drugbank , DGIDB enadoline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor kappa OPRK1 Successful target agonist 1.43 TTD , DGIDB 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD nalfurafine hcl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] approved opioid receptor kappa OPRK1 Successful target unknown NA TTD , DGIDB 2-thiosalvinorin b NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 4-(4-((phenethylamino)methyl)phenoxy)benzamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 1-benzhydryl-4-o-tolylpiperidin-4-ol NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD dynorphin b NA NA investigative opioid receptor kappa OPRK1 Successful target agonist NA TTD , DGIDB 4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD 8-carboxamidocyclazocine NA NA investigative opioid receptor kappa OPRK1 Successful target unknown NA TTD difelikefalin NA Pruritus[MeSHID:D011537],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 opioid receptor kappa OPRK1 Successful target unknown 2.15 TTD , DGIDB ac-ryyrik-k-(nh2)-yafgyps NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD mebut-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fluperamide NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-mea-r-k-s-a-r-k-l-a-n-q-cooh NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ati-17000 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical nociceptin receptor OPRL1 Clinical trial target unknown NA TTD , DGIDB fggftgarksarklfnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD nociceptin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] phase 1 nociceptin receptor OPRL1 Clinical trial target unknown 7.07 TTD , DGIDB sr-14136 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkrwnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD bnd-001 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-phenylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-o-tolylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD cyclo[cys6,cys10]n/ofq(1-13)nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkwanq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD cyclo[cys7,cys10]n/ofq(1-13)nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD isobu-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-mea-r-k-s-a-r-k-l-a-n-q-conh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftcarkcark NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-phenyl-4-propoxypiperidine NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ufp-101 NA NA investigative nociceptin receptor OPRL1 Clinical trial target antagonist NA TTD , DGIDB fggftgarksarklynq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD pf-454583 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkkanq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkfanq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD n/ofq-(1-13)-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target agonist NA TTD , DGIDB piv-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-a-r-k-s-mea-r-k-l-a-n-q-cooh NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-butylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ac-ryyrik-k-(nh2)-yrfb NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarklknq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 2-mepen-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ada-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkkrnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD syn-1020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarklwnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-m-tolylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD etorphine small molecule NA illicit,vet_approved nociceptin receptor OPRL1 NA agonist NA drugbank 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-benzylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-a-r-k-s-a-r-k-l-mea-n-q-conh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD for-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkl NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkkwnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkllnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD pr-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-a-r-k-s-a-r-k-l-aib-n-q-cooh NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-isopropylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkwknq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-tert-butylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD sb-612111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-a-r-k-s-a-r-k-l-aib-n-q-conh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarklvnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-methoxy-4-phenylpiperidine NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-a-r-k-s-aib-r-k-l-a-n-q-cooh NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD pmx-53 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 nociceptin receptor OPRL1 Clinical trial target unknown NA TTD , DGIDB 2,2-dimebut-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-cyclohexylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarkrkrklanq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD isova-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD peptide iii-btd NA NA investigative nociceptin receptor OPRL1 Clinical trial target antagonist NA TTD , DGIDB hex-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ac-ryyrik-ggg-k-(nh2)-yafgyps-gg NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD nox 2149 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD bu-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD buprenorphine small molecule Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Pain[MeSHID:D010146] approved,illicit,investigational,vet_approved nociceptin receptor OPRL1 NA unknown NA drugbank 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-aib-r-k-s-a-r-k-l-a-n-q-cooh NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-hexylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-a-r-k-s-aib-r-k-l-a-n-q-conh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-ethoxy-4-phenylpiperidine NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzyl-4-phenylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ser-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 nociceptin receptor OPRL1 Clinical trial target unknown 7.07 TTD , DGIDB [asp6,lys10]n/ofq(1-13)nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-aib-r-k-s-a-r-k-l-a-n-q-conh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD etbut-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftrkrksarklanq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkrrnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarklark NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ly-2940094 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 nociceptin receptor OPRL1 Clinical trial target unknown 7.07 TTD , DGIDB 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgcrkscrk NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(1-phenylethyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkyanq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD btrx-246040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 nociceptin receptor OPRL1 Clinical trial target unknown 7.07 TTD , DGIDB va-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ac-ryyrik-ggg-k-(nh2)-yrfb-ggggg NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkrknq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarklade NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD cyclo-[asp6,lys10]n/ofq(1-13)nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD [d-asp7,lys10]n/ofq(1-13)nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-a-r-k-s-a-r-k-l-mea-n-q-cooh NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD h-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-cyclopropylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkwrnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-a-r-k-s-mea-r-k-l-a-n-q-conh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD jtc-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 nociceptin receptor OPRL1 Clinical trial target antagonist 10.61 TTD , DGIDB sch-221510 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD ac-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target agonist NA TTD , DGIDB cyclo[dasp7,lys10]n/ofq(1-13)nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgcrksarkc NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarklrnq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkranq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD nox 2137a/b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD t-buac-ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarkcarkc NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD cfggftcarksark NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD banyu compound-24 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD f-g-g-f-t-g-aib-r-k-s-aib-r-k-l-a-n-q-conh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD [nphe(1)]-nociceptin (1-13)-nh(2) NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD jtc-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 nociceptin receptor OPRL1 Clinical trial target unknown 10.61 TTD , DGIDB ufp-112 NA NA investigative nociceptin receptor OPRL1 Clinical trial target agonist 7.07 TTD , DGIDB 1-benzhydryl-4-p-tolylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkrkrk NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(3-phenylpropyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkaanq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 3-(1-benzylpiperidin-4-yl)-5-chloro-1h-indole NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD epicept np-1 small molecule Pain[MeSHID:D010146] investigational nociceptin receptor OPRL1 NA unknown NA drugbank 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD nd1251 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] discontinued in phase 1 nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkkknq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD cfggftgarkcark NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD fggftgarksarkvanq NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD bz--ryyrik-nh2 NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol NA NA investigative nociceptin receptor OPRL1 Clinical trial target unknown NA TTD tyr-d-ala-gly-phe-met-pro-leu-trp-nh-bzl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 3,6-bis(dmt-tic-nh-methyl)-2(1h)-pyrazinone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-methoxy-4-phenylpiperidine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD phenazocine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dm3a6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-asp-nh-bzl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD nktr-181 NA Low Back Pain[MeSHID:D017116],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437] phase 3 opioid receptor mu OPRM1 Successful target unknown 0.51 TTD , DGIDB ac-d-pro-l-phe-d-trp-l-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-imidph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-asp-nh-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-3,5dmp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD n-(17-methylmorphinan-3-yl)-n'-phenylurea NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD bremazocine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-ch2-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD c[l-phe-d-pro-l-mtyr-d-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD naltrexone small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Alcohol consumption[MeSHID:D000428],emotional dependency[MeSHID:D003858],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disease[MeSHID:D004194] approved,investigational,vet_approved mu-type opioid receptor OPRM1 NA antagonist 1.35 drugbank , DGIDB h-dmt-tic-nh-ch2-indn NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-(r)-spiro-aba-gly-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-ch[(ch2)4-nh-ac]-bid NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD c[l-phe-d-pro-l-phe-l-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD naltriben NA NA investigative opioid receptor mu OPRM1 Successful target antagonist 0.13 TTD , DGIDB tyr-pro-d-phe-d-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD frakefamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor mu OPRM1 Successful target agonist 0.51 TTD , DGIDB methylnaltrexone small molecule Constipation[MeSHID:D003248] approved mu-type opioid receptor OPRM1 NA antagonist 0.51 drugbank , DGIDB 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-ch[(ch2)4-nh-z]-bid NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mu-type opioid receptor OPRM1 NA agonist 0.43 drugbank , DGIDB 6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-tert-butylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD buprenorphine NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Pain[MeSHID:D010146] approved opioid receptor mu OPRM1 Successful target unknown 0.62 TTD , DGIDB [tyr-pro-phe-nh-ch2-]2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ac-ryyrik-ggg-k-(nh2)-yrfb-ggggg NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD levacetylmethadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Opiate Addiction[MeSHID:D009293] approved,investigational mu-type opioid receptor OPRM1 NA agonist NA drugbank c[l-ala-d-pro-l-phe-d-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD met-enkephalin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor mu OPRM1 Successful target unknown 0.51 TTD , DGIDB morphiceptin NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mr-1526 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-(s)ch(ch2-cooh)-bid(n1-me) NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD c[l-phe-d-pro-l-tyr-d-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-phe-och3 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-d-trp-c[cys-tyr-d-trp-arg-thr-pen]-thr-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mu-type opioid receptor OPRM1 NA agonist NA drugbank morphine glucuronide small molecule Pain[MeSHID:D010146] investigational mu-type opioid receptor OPRM1 NA unknown NA drugbank h-dmt-tic-nh-(d)-ch[(ch2)4-nh-z]-bid NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD bis-((-)-n-propargylmorphinan-3-yl) sebacoylate NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-l-(nme)phe-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ac-ryyrik-k-(nh2)-yafgyps NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-imp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD (h-dmt-tic-glu-nh-(ch(2))(5)-co-dap(6dmn)-nh(2) NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-aba-ser-gly-phe-leu-thr-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD levorphanol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Cerebrovascular accident[MeSHID:D020521],Expiration, function[MeSHID:D045853] approved mu-type opioid receptor OPRM1 NA agonist 1.28 drugbank , DGIDB tyr-pro-hfe-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-trp-d-2-nal-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ac-ryyrik-k-(nh2)-yrfb NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD damgo NA NA investigative opioid receptor mu OPRM1 Successful target unknown 1.28 TTD , DGIDB naldemedine tosylate NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target antagonist 0.51 TTD , DGIDB ly-25582 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical opioid receptor mu OPRM1 Successful target unknown NA TTD 3-(2-methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD sb-0304 NA NA investigative opioid receptor mu OPRM1 Successful target unknown 0.51 TTD , DGIDB tyr-pro-phe-ala-bn NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD alks33 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD 3,6-bis(dmt-tic-nh-ethyl)-2(1h)-pyrazinone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dcp-c[d-cys-gly-phe(pno2)-d-cys]nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-l-phe-d-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD alvimopan small molecule Intestines, Small[MeSHID:D007421],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved,investigational mu-type opioid receptor OPRM1 NA antagonist 1.71 drugbank , DGIDB sn-23 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-d-ala-bn NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1,10-bis-(dmt-tic-amino)decane NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ac-yggfl-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD eluxadoline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mu-type opioid receptor OPRM1 NA agonist 1.03 drugbank , DGIDB alvimopan NA Intestines, Small[MeSHID:D007421],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved opioid receptor mu OPRM1 Successful target unknown 1.71 TTD , DGIDB m3ibu6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-c[d-allylgly-gly-phe-l-allylgly]nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-trp-d-ala-bn NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD spiroindanyloxymorphone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dimepheptanol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-indl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD beta-endorphin NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-433 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcp-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-(2s,3s)-beta-mecha-phe-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 2-benzylaminomethyl-3-hydroxymorphinan NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-pro-dap(6dmn)-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-glu-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD [3h]u69593 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved mu-type opioid receptor OPRM1 NA agonist 0.46 drugbank , DGIDB trefentanil hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-tic-cha-phe-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-nle-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-phe-n(ch3)2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-dmt-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1,4-bis-(dmt-tic-amino)butane NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD quadazocine NA NA investigative opioid receptor mu OPRM1 Successful target antagonist 0.17 TTD , DGIDB butorphan NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-gly-phe-nh-nh-phe-asp-nmenle-d-trp-boc NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD naloxonazine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD remifentanil NA Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target unknown 0.92 TTD , DGIDB hydromorphone small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Addictive Behavior[MeSHID:D016739],Drug Overdose[MeSHID:D062787],Coughing[MeSHID:D003371],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit mu-type opioid receptor OPRM1 NA agonist 0.72 drugbank , DGIDB 1-benzhydryl-4-phenylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dynorphin b NA NA investigative opioid receptor mu OPRM1 Successful target agonist NA TTD , DGIDB c[l-tyr(ome)-d-pro-l-phe-d-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mm3b6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD gnti NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] preclinical opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-hfe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-(r or s)atc-asp-val-val-gly-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ethylmorphine NA Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-(4-((phenethylamino)methyl)phenoxy)benzamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 5-(4-((phenethylamino)methyl)phenoxy)picolinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD epicept np-1 small molecule Pain[MeSHID:D010146] investigational mu-type opioid receptor OPRM1 NA unknown NA drugbank mirfentanil hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-met-phe-his-leu-met-asp-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD vp004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] discontinued in phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD d-phgly-cys-tyr-d-trp-lys-thr-pen-thr-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-tic-phe-phe-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 3-methylthiofentanyl small molecule NA experimental,illicit mu-type opioid receptor OPRM1 NA agonist NA drugbank h-tyr-gly-gly-phe-met-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dslet NA NA investigative opioid receptor mu OPRM1 Successful target agonist NA TTD , DGIDB 2-hydroxymethyl-3-hydroxymorphinan NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-aba-gly-nh-ch2-bid NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-aba-gly-nh-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-trp-ac NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-aba-gly-nh-ch2-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD fentanyl NA Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350] approved opioid receptor mu OPRM1 Successful target unknown 0.22 TTD , DGIDB mcl-435 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-aba-gly-gly-phe-leu-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD opnt001 NA Disease[MeSHID:D004194],Eating[MeSHID:D004435],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD nalbuphine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Prurigo[MeSHID:D011536] approved mu-type opioid receptor OPRM1 NA antagonist,agonist 1.11 drugbank , DGIDB 6beta-naltrexol hcl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-147 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-o-tolylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-sar-phe-d-2-nal-nh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD [3h]diprenorphine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD aiko-150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD , DGIDB naldemedine small molecule Constipation[MeSHID:D003248] approved,investigational mu-type opioid receptor OPRM1 NA antagonist 0.51 drugbank , DGIDB levomethadyl acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] approved opioid receptor mu OPRM1 Successful target unknown NA TTD , DGIDB mcl-446 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD d-phe-cys-tyr-d-trp-arg-thr-pen-thr-nh2(ctap) NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD methadyl acetate small molecule Narcotic Dependence[MeSHID:D009294],Opiate Addiction[MeSHID:D009293],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,illicit mu-type opioid receptor OPRM1 NA agonist NA drugbank , DGIDB thebaine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD c[l-mtyr-d-pro-l-phe-d-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-(nme)ala-l-phe-d-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD td-1211 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 opioid receptor mu OPRM1 Successful target unknown 1.03 TTD , DGIDB 1-benzhydryl-4-p-tolylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-phe-glu-val-val-gly-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-183 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ethylketocyclazocine NA NA investigative opioid receptor mu OPRM1 Successful target agonist 0.17 TTD , DGIDB pholcodine small molecule Sputum[MeSHID:D013183],disease transmission[MeSHID:D018562],Respiratory Muscles[MeSHID:D012132],Structure of intercostal muscle[MeSHID:D007366],Movement[MeSHID:D009068],Coughing[MeSHID:D003371],Medulla Oblongata[MeSHID:D008526],Desiccation[MeSHID:D003890],Motor Neurons[MeSHID:D009046],Inspiration function[MeSHID:D001239] approved,illicit mu-type opioid receptor OPRM1 NA antagonist NA drugbank tyr-d-ala-gly-nmephe NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD methadone small molecule Addictive Behavior[MeSHID:D016739],Metabolic Detoxication, Drug[MeSHID:D008658],Opiate Addiction[MeSHID:D009293],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved mu-type opioid receptor OPRM1 NA agonist 0.18 drugbank , DGIDB ketocyclazocine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD alvimopan NA Intestines, Small[MeSHID:D007421],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] approved opioid receptor mu OPRM1 Successful target antagonist 1.71 TTD , DGIDB tyr-(r)-aba-gly-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-gly-nh-ch2-bid NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD nct-400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-phe-och2oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-ch[(ch2)4-nh2]-bid NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD endomorphin-1 NA NA investigative opioid receptor mu OPRM1 Successful target agonist 0.77 TTD , DGIDB alfentanil small molecule Pain, Postoperative[MeSHID:D010149],Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit mu-type opioid receptor OPRM1 NA agonist 4.62 drugbank , DGIDB [tyr-pro-phe-nh-]2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-d-trp-h NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-144 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dadle NA NA investigative opioid receptor mu OPRM1 Successful target agonist 0.26 TTD , DGIDB 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-bta NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD carfentanil small molecule NA illicit,investigational,vet_approved mu-type opioid receptor OPRM1 NA agonist NA drugbank krp-100 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD aiko-152 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-lys-nh-ch2-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-phe-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phg-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-(2r,3s)-beta-mecha-phe-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD oripavine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD kin-3031 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD krp-110 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD cyt-1010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD 1,6-bis-(n,n-dimethyl-dmt-tic-nh)hexane NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-dmp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tq-1017 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-d-val-bn NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD sn-28 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-phe-nhch3 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD cyprodime NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-phe-och2ch3 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 2-(2-methylquinolin-4-ylamino)-n-phenylacetamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD codeinone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD trans-h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational mu-type opioid receptor OPRM1 NA ligand NA drugbank tyr-d-ala-phe-thr(-d-glc)-tyr-pro-ser-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mu-type opioid receptor OPRM1 NA agonist NA drugbank h-dmt-tic-d-asp-nh-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 3,6-bis(dmt-tic-nh-propyl)-2(1h)-pyrazinone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD endomorphin-1 NA NA investigative opioid receptor mu OPRM1 Successful target unknown 0.77 TTD , DGIDB diamorphine small molecule Operative Surgical Procedures[MeSHID:D013514],Myocardial Infarction[MeSHID:D009203],Pain[MeSHID:D010146],Pulmonary Edema[MeSHID:D011654],Dyspnea[MeSHID:D004417] approved,illicit,investigational mu-type opioid receptor OPRM1 NA agonist NA drugbank cyclorphan NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD leucine-enkephalin NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD amisulpride small molecule Emotions[MeSHID:D004644],Disease[MeSHID:D004194],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Vomiting[MeSHID:D014839],Neoplasm Metastasis[MeSHID:D009362],Hostility[MeSHID:D006791],Mood Disorders[MeSHID:D019964],Affect (mental function)[MeSHID:D000339],Postoperative Nausea[MeSHID:D020250],Behavior[MeSHID:D001519],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Thinking, function[MeSHID:D013850],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational mu-type opioid receptor OPRM1 NA agonist NA drugbank hydromorphone NA Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Addictive Behavior[MeSHID:D016739],Drug Overdose[MeSHID:D062787],Coughing[MeSHID:D003371],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target unknown 0.72 TTD , DGIDB tyr-pro-trp-d-val-bn NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD c[l-phe-d-pro-l-phe-d-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 6-desoxonaltrexone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-gly-phe-met-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD alfentanil NA Pain, Postoperative[MeSHID:D010149],Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target unknown 4.62 TTD , DGIDB dynorphin a NA NA discontinued in phase 2 opioid receptor mu OPRM1 Successful target agonist NA TTD , DGIDB 3-(1-benzylpiperidin-4-yl)-5-chloro-1h-indole NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-phe-gly-d-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 6-(2-phenethylisoindolin-5-yloxy)nicotinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ctap NA NA investigative opioid receptor mu OPRM1 Successful target antagonist NA TTD , DGIDB naltrexone small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Alcohol consumption[MeSHID:D000428],emotional dependency[MeSHID:D003858],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],HIV Infections[MeSHID:D015658] approved,investigational,vet_approved mu-type opioid receptor OPRM1 NA antagonist 1.35 drugbank , DGIDB tyr-pro-l-phe-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-445 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD butorphanol small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,vet_approved mu-type opioid receptor OPRM1 NA antagonist 0.88 drugbank , DGIDB [tyr-pro-phe-phe-nh-ch2-]2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD grt-6005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] phase 3 opioid receptor mu OPRM1 Successful target unknown NA TTD dihydromorphine NA Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target agonist 0.68 TTD , DGIDB mc-cam NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-butylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-aic-asp-val-val-gly-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mm3a6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-cpa-gly-gly-phe-met-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD c6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-ethoxy-4-phenylpiperidine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-d-tca-c[cys-tyr-d-trp-arg-thr-pen]-thr-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-phe-gly-tyr-pro-thr(beta-d-glc)-gly-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 3,6-bis(dmt-tic-nh-butyl)-2(1h)-pyrazinone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD (+/-)-trans-u-50488 methanesulfonate NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD n-isobutylnoroxymorphone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD m3p6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dpi-3290 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-458 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-457 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-glu-nh-(ch2)5-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-139 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dc6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD endomorphins NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 3-methylfentanyl small molecule NA illicit mu-type opioid receptor OPRM1 NA agonist NA drugbank 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-trp-gly-bn NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-c[d-allylgly-gly-phe-d-allylgly]nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational mu-type opioid receptor OPRM1 NA unknown NA drugbank h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-trp-boc NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-gly-nh-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD c[l-phe-d-pro-l-tyr(ome)-d-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD damgo NA NA investigative opioid receptor mu OPRM1 Successful target agonist 1.28 TTD , DGIDB h-dmt-tic-(2r,3r)-beta-mecha-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD semorphone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-nh-3,5-bzl(cf3)2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD d-phe-cys-tyr--trp-lys-thr-pen-thr-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD sufentanil small molecule Vagina[MeSHID:D014621],Maintenance[MeSHID:D008283],Labor (Childbirth)[MeSHID:D007743],Environmental air flow[MeSHID:D014691],Health Care[MeSHID:D003695],Operative Surgical Procedures[MeSHID:D013514],Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mu-type opioid receptor OPRM1 NA agonist 0.88 drugbank , DGIDB codeine small molecule Solutions[MeSHID:D012996],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved,illicit mu-type opioid receptor OPRM1 NA agonist 0.58 drugbank , DGIDB tapentadol small molecule Acute onset pain[MeSHID:D059787],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Patient Discharge[MeSHID:D010351],Chronic pain[MeSHID:D059350] approved mu-type opioid receptor OPRM1 NA agonist 0.41 drugbank , DGIDB fluperamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD methylnaltrexone bromide NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] approved opioid receptor mu OPRM1 Successful target unknown NA TTD , DGIDB tapentadol hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved opioid receptor mu OPRM1 Successful target agonist 0.26 TTD , DGIDB h-tyr-d-ala-gly-phe-nh-nh-d-phe-d-asp-d-nle-trp-h NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-(nme)phe-asp-nle-trp-ac NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD cis-h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD trimebutine small molecule Irritable Bowel Syndrome[MeSHID:D043183],Operative Surgical Procedures[MeSHID:D013514],Paralytic Ileus[MeSHID:D007418],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mu-type opioid receptor OPRM1 NA agonist NA drugbank methadyl acetate NA Narcotic Dependence[MeSHID:D009294],Opiate Addiction[MeSHID:D009293],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target unknown NA TTD , DGIDB h-dmt-tic-d-asp-n(me)-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dihydroakuammine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-(s)-spiro-aba-gly-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD v1003 small molecule Pain[MeSHID:D010146] investigational mu-type opioid receptor OPRM1 NA unknown NA drugbank h-mcpa-ala-gly-phe-leu-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ypaa-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-434 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD beta-funaltrexamine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD herkinorin NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD [tyr-pro-phe-phe-nh-]2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-(spiro[chromene-2,4'-piperidine]-4-yl)phenol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-hfe-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD pentazocine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved mu-type opioid receptor OPRM1 NA antagonist 1.2 drugbank , DGIDB h-dmt-tic-nh-ch2-boa NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-gly-nh-bzl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-gly-n(me)-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-d-arg(no2)-phe-lys(z)-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-trp-d-nle-d-asp-d-phe-h NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-443 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD nalbuphine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Prurigo[MeSHID:D011536] approved mu-type opioid receptor OPRM1 NA antagonist 1.11 drugbank , DGIDB h-dmt-d-arg(no2)-phe-lys(z)-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD butorphanol small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,vet_approved mu-type opioid receptor OPRM1 NA antagonist,agonist 0.88 drugbank , DGIDB h-dmt-tic-(2r,3s)-beta-mecha-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD clocinnamox NA NA investigative opioid receptor mu OPRM1 Successful target unknown 1.03 TTD , DGIDB fentanyl small molecule Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350] approved,illicit,investigational,vet_approved mu-type opioid receptor OPRM1 NA agonist 0.22 drugbank , DGIDB h-dmt-tic-asp-n(me)-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD methylnaltrexone bromide NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] approved opioid receptor mu OPRM1 Successful target antagonist 0.51 TTD , DGIDB etorphine NA NA investigative opioid receptor mu OPRM1 Successful target agonist 1.2 TTD , DGIDB mcl-182 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-cpa-gly-gly-phe-met-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD morphine small molecule Disease Management[MeSHID:D019468],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194],Physical Examination[MeSHID:D010808],emotional dependency[MeSHID:D003858],Drug abuse[MeSHID:D019966],Patient Monitoring[MeSHID:D008991],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved,investigational mu-type opioid receptor OPRM1 NA agonist 0.2 drugbank , DGIDB norbinaltorphimine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-phe-oc(ch3)3 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-cyclohexylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-phe-nhnh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mr-1029 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD levallorphan small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Respiratory Depression[MeSHID:D012131],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mu-type opioid receptor OPRM1 NA partial agonist,antagonist 2.05 drugbank , DGIDB mcl-428 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-imp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-mmp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational mu-type opioid receptor OPRM1 NA antagonist NA drugbank bch-2687 NA Benign Hereditary Chorea[MeSHID:D002819],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-431 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-m-tolylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD n-(4-iodophenyl)-n'-(17-methylmorphinan-3-yl)urea NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 3-methylfentanyl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD opium small molecule Diarrhea[MeSHID:D003967],Vision[MeSHID:D014785],Chronic pain[MeSHID:D059350] approved,illicit mu-type opioid receptor OPRM1 NA agonist NA drugbank tyr-pro-phe-phg-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dm3b6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phg-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-c[d-allylgly-gly-phe-d-allylgly]-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-145 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ac-ryyrik-ggg-k-(nh2)-yafgyps-gg NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-apa-ala-gly-phe-leu-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-dmt-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD m3s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved mu-type opioid receptor OPRM1 NA binder NA drugbank elaeocarpenine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved mu-type opioid receptor OPRM1 NA binder NA drugbank tyr-d-nle-gly-d-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD cyclazocine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD naltrexone-6-alpha-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tianeptine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational mu-type opioid receptor OPRM1 NA agonist 1.54 drugbank , DGIDB nalmefene small molecule Disease Management[MeSHID:D019468],Respiratory Depression[MeSHID:D012131],Physical Examination[MeSHID:D010808],Alcohol consumption[MeSHID:D000428],Drug Overdose[MeSHID:D062787],Alcoholic Intoxication, Chronic[MeSHID:D000437],Drinking function[MeSHID:D004326],Metabolic Detoxication, Drug[MeSHID:D008658],Withdrawal Symptoms[MeSHID:D013375],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] approved,investigational,withdrawn mu-type opioid receptor OPRM1 NA antagonist 0.34 drugbank , DGIDB benzyl derivative of m6g NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dynorphin(1-8) NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ctop NA NA investigative opioid receptor mu OPRM1 Successful target antagonist NA TTD , DGIDB ypwa-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD adc-5510 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Movement Disorders[MeSHID:D009069] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD c[l-tyr-d-pro-l-phe-d-trp] NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mu-type opioid receptor OPRM1 NA agonist 0.46 drugbank , DGIDB nalbzoh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dhp-c[d-cys-gly-phe(pno2)-d-cys]nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD somatostatin NA Disease Management[MeSHID:D019468],Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],long-term care[MeSHID:D008134] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD hydrocodone small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Common Cold[MeSHID:D003139],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,illicit,investigational mu-type opioid receptor OPRM1 NA agonist 1.33 drugbank , DGIDB dimethylthiambutene NA Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD buprenorphine NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Pain[MeSHID:D010146] approved opioid receptor mu OPRM1 Successful target agonist 0.62 TTD , DGIDB salvinorin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebral Vasospasm[MeSHID:D020301] phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD dpdpe NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-(r)ch(ch2-cooh)-bid(n1-me) NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-451 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-pro-ala-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-phe-asp-val-val-thr[beta-d-glc]-gly-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD antanal 1 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD knt-5 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD gsk1521498 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1 opioid receptor mu OPRM1 Successful target antagonist 0.51 TTD , DGIDB ici-199441 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD oxycodone small molecule Pain[MeSHID:D010146],Patient Discharge[MeSHID:D010351],Back Pain[MeSHID:D001416],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational mu-type opioid receptor OPRM1 NA agonist 0.57 drugbank , DGIDB etonitazene NA NA investigative opioid receptor mu OPRM1 Successful target agonist 0.13 TTD , DGIDB diphenoxylate NA Disease Management[MeSHID:D019468],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target unknown 3.59 TTD , DGIDB tyr-pro-l-(nme)phe-d-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ethylmorphine small molecule Pain[MeSHID:D010146] experimental,illicit mu-type opioid receptor OPRM1 NA agonist NA drugbank carfentanil NA NA phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD 3-methylthiofentanyl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD hydromorphone NA Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Addictive Behavior[MeSHID:D016739],Drug Overdose[MeSHID:D062787],Coughing[MeSHID:D003371],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target agonist 0.72 TTD , DGIDB propoxyphene hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved opioid receptor mu OPRM1 Successful target agonist 0.51 TTD , DGIDB aiko-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-ch2-imid NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD kin-4044 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD fentanyl NA Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Chronic pain[MeSHID:D059350] approved opioid receptor mu OPRM1 Successful target agonist 0.22 TTD , DGIDB mr-2266 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD diphenoxylate small molecule Disease Management[MeSHID:D019468],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit mu-type opioid receptor OPRM1 NA agonist 3.59 drugbank , DGIDB dextropropoxyphene small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn mu-type opioid receptor OPRM1 NA agonist NA drugbank h-tyr-c[d-cys-gly-phe-d-cys]nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1,6-bis-(dmt-tic-amino)hexane NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD remifentanil small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mu-type opioid receptor OPRM1 NA agonist 0.92 drugbank , DGIDB h-tyr-c[d-orn-(d or l)atc-glu]-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD li-301 small molecule Premature Ejaculation[MeSHID:D061686] investigational mu-type opioid receptor OPRM1 NA unknown NA drugbank 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-(2s,3r)-beta-mecha-phe-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD oxycodone NA Pain[MeSHID:D010146],Patient Discharge[MeSHID:D010351],Back Pain[MeSHID:D001416],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target unknown 0.57 TTD , DGIDB mcl-449 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-(ch2)6-nh-tic-h NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD eluxadoline NA Irritable Bowel Syndrome[MeSHID:D043183],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target agonist 1.03 TTD , DGIDB tyr-pro-3,5dmp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-emp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-nle-gly-d-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD deltorphin NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-154 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-d-2-nal-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-432 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD loxicodegol small molecule Back Pain[MeSHID:D001416],Drug abuse[MeSHID:D019966],Chronic pain[MeSHID:D059350] investigational mu-type opioid receptor OPRM1 NA agonist NA drugbank h-dmt-tic-lys(z)-nh-ch2-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD endomorphin 2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD n-benzyl-17-(cyclobutylmethyl)morphinan-3-amine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 6-(allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-nle-gly-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-pro-phe-phe-nh-(ch2)5-(c=o)-dap(6dmn)-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dermorphin NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-phe-d-1-nal-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD buprenorphine small molecule Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Pain[MeSHID:D010146] approved,illicit,investigational,vet_approved mu-type opioid receptor OPRM1 NA partial agonist,agonist 0.62 drugbank , DGIDB tyr-d-ala-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD m3b6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dm6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-gly-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-(2r,3r)-beta-mecha-phe-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 14-o-phenylpropylnaltrexone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-153 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-benzylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD d-phe-cys-tyr-d-trp-lys-thr-pen-thr-nh2(ctp) NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-phe-d-phg-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tpm-1/morphine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD anileridine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved opioid receptor mu OPRM1 Successful target unknown 2.57 TTD , DGIDB antanal 2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-d-trp-nle-asp-phe-h NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational mu-type opioid receptor OPRM1 NA unknown NA drugbank 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD lofentanil NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-(s)-aba-gly-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD deltorphin-ii NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD kn-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD naloxone NA Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved opioid receptor mu OPRM1 Successful target antagonist 0.89 TTD , DGIDB h-mcpa-ser-gly-phe-leu-thr-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-glu-dap(6dmn)-nh(2) NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD (+/-)-nantenine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD morphine NA Disease Management[MeSHID:D019468],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194],Physical Examination[MeSHID:D010808],emotional dependency[MeSHID:D003858],Drug abuse[MeSHID:D019966],Patient Monitoring[MeSHID:D008991],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved opioid receptor mu OPRM1 Successful target agonist 0.2 TTD , DGIDB oxycodone NA Pain[MeSHID:D010146],Patient Discharge[MeSHID:D010351],Back Pain[MeSHID:D001416],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target agonist 0.57 TTD , DGIDB [dcp1]dyn a(1-11)-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-c[d-cys-gly-phe-l-cys]nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD metazocine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-dmp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-phe-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD morphinone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD morphine NA Disease Management[MeSHID:D019468],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194],Physical Examination[MeSHID:D010808],emotional dependency[MeSHID:D003858],Drug abuse[MeSHID:D019966],Patient Monitoring[MeSHID:D008991],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved opioid receptor mu OPRM1 Successful target unknown 0.2 TTD , DGIDB h-aba-ala-gly-phe-met-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD m6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ketobemidone small molecule Fracture[MeSHID:D050723],Malignant Neoplasms[MeSHID:D009369],Kidney Calculi[MeSHID:D007669],Nephrolithiasis[MeSHID:D053040],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational mu-type opioid receptor OPRM1 NA agonist NA drugbank m6g thiosaccharide analogue NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-450 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD (-)-eseroline NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD rti-5989-31 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD morphine-6-glucuronide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 3 opioid receptor mu OPRM1 Successful target unknown NA TTD pti-601 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-sar-phe-d-2-nal-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 6-(4-((benzylamino)methyl)phenoxy)nicotinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD falcarindiol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 3-desoxy-3-carboxamidonaltrexone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-149 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD naloxegol small molecule Constipation[MeSHID:D003248],Malignant Neoplasms[MeSHID:D009369],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mu-type opioid receptor OPRM1 NA antagonist NA drugbank 4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD yrfb NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-(2s,3s)-beta-mecha-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-nme-bzl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational mu-type opioid receptor OPRM1 NA unknown NA drugbank h-dmt-tic-lys(ac)-nh-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-aba-ala-gly-phe-leu-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-cyclopropylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD normorphine NA NA investigative opioid receptor mu OPRM1 Successful target agonist 0.17 TTD , DGIDB h-tyr-d-ala-tic-asp-val-val-gly-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD m3pr6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD oxymorphone semicarbazone hydrochloride NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD samidorphan small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Maintenance[MeSHID:D008283] approved,investigational mu-type opioid receptor OPRM1 NA antagonist 0.34 drugbank , DGIDB tyr-gly-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD sn-11 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-phe-thr[-d-glc(oac)4]-tyr-pro-ser-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD yawf-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD adl-5945 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-lys-nh-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-d-phe-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD nrp290 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD , DGIDB 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD anileridine hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved opioid receptor mu OPRM1 Successful target agonist 0.26 TTD , DGIDB h-2',6'-dimethyltyrosine-tic-phe-phe-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD (-)-cyclorphan NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD sl-3111 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-pro-gly-trp-nmenle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 17-methyl-4'-methyldihydromorphinone NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-(r)ch(ch2-cooh)-bid NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-d-phg-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD naloxegol NA Constipation[MeSHID:D003248],Malignant Neoplasms[MeSHID:D009369],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor mu OPRM1 Successful target unknown NA TTD yggwl-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-phe-gly-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD oxymorphone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,vet_approved mu-type opioid receptor OPRM1 NA agonist 1.03 drugbank , DGIDB anileridine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,illicit mu-type opioid receptor OPRM1 NA agonist 2.57 drugbank , DGIDB oliceridine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787],Thyroid Diseases[MeSHID:D013959] approved,investigational mu-type opioid receptor OPRM1 NA agonist 0.51 drugbank , DGIDB dimethylthiambutene small molecule Pain[MeSHID:D010146] experimental,illicit mu-type opioid receptor OPRM1 NA agonist NA drugbank mcl-447 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD htyr-gly-gly-phe-leu-arg-arg-lle-arg-pro-lysnh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 17-(cyclobutylmethyl)-n-phenylmorphinan-3-amine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD n-alpha-amidino-tyr(me)-d-pro-gly-trp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD transdur-sufentanil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-nme-3,5-bzl(cf3)2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-phe-asp-nle-d-trp-boc NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved mu-type opioid receptor OPRM1 NA binder NA drugbank oxymorphindole NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD nalfurafine hcl NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] approved opioid receptor mu OPRM1 Successful target unknown NA TTD [leu5]enkephalin NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD naloxone small molecule Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved,vet_approved mu-type opioid receptor OPRM1 NA antagonist 0.89 drugbank , DGIDB n-alpha-amidino-tyr(me)-pro-trp-p-cl-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-d-tic-c[cys-tyr-d-trp-arg-thr-pen]-thr-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD diprenorphine small molecule NA illicit,vet_approved mu-type opioid receptor OPRM1 NA antagonist 0.34 drugbank , DGIDB trv734 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-lys(ac)-nh-ch2-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-448 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dezocine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mu-type opioid receptor OPRM1 NA agonist 2.31 drugbank , DGIDB n-benzyl-17-(cyclopropylmethyl)morphinan-3-amine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-emp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-phe-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-429 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-hexylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-isopropylpiperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD knt-62 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD aminofentanyl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly phe-pro-leu-trp-o-3,5-bzl(cf3)2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ne-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ufp-512 NA NA investigative opioid receptor mu OPRM1 Successful target agonist 0.17 TTD , DGIDB n-alpha-amidino-tyr(me)-pro-trp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-2',6'-dimethyltyrosine-tic-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD butyrfentanyl small molecule Drug abuse[MeSHID:D019966] illicit mu-type opioid receptor OPRM1 NA agonist NA drugbank o-desmethyl tramadol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD hydrocodone NA Allergic rhinitis (disorder)[MeSHID:D065631],Common Cold[MeSHID:D003139],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved opioid receptor mu OPRM1 Successful target unknown 1.33 TTD , DGIDB deprotected cogener of m6g NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mr-2034 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 8-carboxamidocyclazocine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD levopropoxyphene napsylate anhydrous NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved opioid receptor mu OPRM1 Successful target unknown NA TTD naloxone NA Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved opioid receptor mu OPRM1 Successful target unknown 0.89 TTD , DGIDB mcl-117 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD hydrocodone NA Allergic rhinitis (disorder)[MeSHID:D065631],Common Cold[MeSHID:D003139],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved opioid receptor mu OPRM1 Successful target agonist 1.33 TTD , DGIDB tyr-pro-d-(nme)phe-d-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD knt-63 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-cdp-ala-gly-phe-leu-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD levallorphan small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Respiratory Depression[MeSHID:D012131],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mu-type opioid receptor OPRM1 NA partial agonist 2.05 drugbank , DGIDB buprenorphine small molecule Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Pain[MeSHID:D010146] approved,illicit,investigational,vet_approved mu-type opioid receptor OPRM1 NA partial agonist 0.62 drugbank , DGIDB adl-7445 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD pl017 NA NA investigative opioid receptor mu OPRM1 Successful target agonist NA TTD , DGIDB ac-l-phe-d-trp-l-phe-d-pro-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-tmp-phe-nh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD mcl-444 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-o-bzl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-tmp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-(2s,3r)-beta-mecha-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD zyklophin NA NA investigative opioid receptor mu OPRM1 Successful target antagonist 0.17 TTD , DGIDB etorphine small molecule NA illicit,vet_approved mu-type opioid receptor OPRM1 NA agonist 1.2 drugbank , DGIDB h-cdp-ser-gly-phe-leu-thr-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dmt-pro-phe-d-2-nal-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD dihydromorphine small molecule Pain[MeSHID:D010146] experimental,illicit mu-type opioid receptor OPRM1 NA agonist 0.68 drugbank , DGIDB h-tyr-d-ala-gly-phe-pro-leu-trp-nh-bzl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-cdp-gly-gly-phe-leu-oh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-phenyl-4-propoxypiperidine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD metenkefalin small molecule Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529] investigational mu-type opioid receptor OPRM1 NA agonist NA drugbank h-dmt-tic-nh-(ch2)6-nh-phe-h NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD nrt-300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-dmt-tic-nh-(ch2)6-nh-dmt-h NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD carboxyfentanyl NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-c[d-orn-aic-glu]-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD buprenorphine + naloxone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-nh-nh-d-trp-nle-asp-phe-bo NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD m3a6s NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ondansetron small molecule Malignant Neoplasms[MeSHID:D009369],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Postoperative Nausea[MeSHID:D020250],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Subacute Bacterial Endocarditis[MeSHID:D004698],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved mu-type opioid receptor OPRM1 NA unknown NA drugbank 17-methylmorphinan-3-yl 4-iodophenyl carbamate NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-d-ala-gly-d-trp-nle-asp-phe-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD h-tyr-pro-phe-phe-nh-ch2-ch2-nh tic dmt-h NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 6-(2-benzylisoindolin-5-yloxy)nicotinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 4-phenyl-1-(1-phenylethyl)piperidin-4-ol NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ufp-502 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD akuammine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD tyr-pro-mmp-phe-nh NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD 17-(cyclopropylmethyl)-n-phenylmorphinan-3-amine NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD nociceptin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Headache[MeSHID:D006261] phase 1 opioid receptor mu OPRM1 Successful target unknown NA TTD [d-ala2]met-enkephalinamide NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD diprenorphine NA NA investigative opioid receptor mu OPRM1 Successful target antagonist 0.34 TTD , DGIDB dezocine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mu-type opioid receptor OPRM1 NA agonist,partial agonist 2.31 drugbank , DGIDB h-dmt-tic-lys(z)-nh-ph NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD ygwfl-nh2 NA NA investigative opioid receptor mu OPRM1 Successful target unknown NA TTD rp4010 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 calcium-release activated calcium channel ORAI1 Clinical trial target unknown NA TTD , DGIDB chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha1-acid glycoprotein ORM1 NA binder NA drugbank progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved alpha-1-acid glycoprotein 1 ORM1 NA binder NA drugbank amsacrine small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational alpha-1-acid glycoprotein 1 ORM1 NA unknown NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational,withdrawn alpha1-acid glycoprotein ORM1 NA binder NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved,investigational,withdrawn alpha1-acid glycoprotein ORM1 NA binder NA drugbank lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-1-acid glycoprotein 1 ORM1 NA unknown NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha1-acid glycoprotein ORM1 NA binder NA drugbank progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved alpha-1-acid glycoprotein 1 ORM1 NA binder NA drugbank dipyridamole small molecule Heart Valves[MeSHID:D006351],Angina Pectoris[MeSHID:D000787],Postoperative Complications[MeSHID:D011183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved alpha-1-acid glycoprotein 1 ORM1 NA unknown NA drugbank lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved alpha-1-acid glycoprotein 2 ORM2 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational alpha-1-acid glycoprotein 2 ORM2 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental alpha-1-acid glycoprotein 2 ORM2 NA binder NA drugbank imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved alpha-1-acid glycoprotein 2 ORM2 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational alpha-1-acid glycoprotein 2 ORM2 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational alpha-1-acid glycoprotein 2 ORM2 NA binder NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved alpha1-acid glycoprotein ORM2 NA binder NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved alpha1-acid glycoprotein ORM2 NA binder NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational,withdrawn alpha1-acid glycoprotein ORM2 NA binder NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved,investigational,withdrawn alpha1-acid glycoprotein ORM2 NA binder NA drugbank disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved alpha-1-acid glycoprotein 2 ORM2 NA unknown NA drugbank adr58 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative oncostatin-m OSM Clinical trial target unknown NA TTD gsk2330811 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Crohn Disease[MeSHID:D003424] phase 2 oncostatin-m OSM Clinical trial target unknown NA TTD , DGIDB n-(phosphonoacetyl)-l-ornithine small molecule NA experimental ornithine carbamoyltransferase, mitochondrial OTC NA unknown NA drugbank dtx301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ornithine carbamoyltransferase deficiency[MeSHID:D020163] phase 1/2 ornithine transcarbamylase OTC Clinical trial target unknown NA TTD norvaline small molecule NA experimental ornithine carbamoyltransferase, mitochondrial OTC NA unknown NA drugbank ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical ornithine carbamoyltransferase, mitochondrial OTC NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical ornithine carbamoyltransferase, mitochondrial OTC NA unknown NA drugbank ethylmercurithiosalicylic acid small molecule NA experimental succinyl-coa:3-ketoacid coenzyme a transferase 1, mitochondrial OXCT1 NA unknown NA drugbank 5-(6-chloro-2-hexyl-1h-indol-1-yl)-5-oxo-valeric acid NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target antagonist NA TTD , DGIDB 5-oxo-ode NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target agonist NA TTD , DGIDB 5-oxo-15-hete NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target agonist 31.83 TTD , DGIDB 5-oxo-12-hete NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target antagonist NA TTD , DGIDB [3h]5-oxo-ete NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target agonist NA TTD , DGIDB 5-oxo-20-hete NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target agonist NA TTD , DGIDB 5-oxo-c20:3 NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target agonist NA TTD , DGIDB 5s-hete NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target agonist NA TTD , DGIDB gue1654 NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target allosteric modulator NA TTD , DGIDB 5s-hpete NA NA investigative oxoeicosanoid receptor 1 OXER1 Literature-reported target agonist NA TTD , DGIDB lte4 NA NA investigative oxoglutarate receptor OXGR1 Literature-reported target unknown NA TTD alpha-ketoglutaric acid NA NA investigative oxoglutarate receptor OXGR1 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase osr1 OXSR1 NA inhibitor NA drugbank pf-271836 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] investigative oxytocin receptor OXTR Successful target unknown NA TTD 1'-tosylspiro[indene-1,4'-piperidine] NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [lys8(alexa 488) ]pva NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [lys8(alexa 546) ]pva NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[lys8(5/6-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD desmopressin NA von Willebrand Disease, Type 1[MeSHID:D056725],Disease Management[MeSHID:D019468],Hemostatic function[MeSHID:D006487],Urination[MeSHID:D014554],Maintenance[MeSHID:D008283],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Polyuria[MeSHID:D011141],Nocturia[MeSHID:D053158],Hemophilia A[MeSHID:D006467],Polydipsia[MeSHID:D059606],Pituitary Diseases[MeSHID:D010900],Craniocerebral Trauma[MeSHID:D006259],Central Diabetes Insipidus[MeSHID:D020790],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved oxytocin receptor OXTR Successful target agonist 3.35 TTD , DGIDB [mpa1, d-tyr(et)2, d-tic7, d-tic9]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [mpa1, d-tyr(et)2, aib7, d-tic9]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [ho1][thr4,lys8(5/6c-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD l-365,209 NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB oxytocin biotech Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659],Breast Feeding[MeSHID:D001942],Lactation[MeSHID:D007774],Autism Spectrum Disorders[MeSHID:D000067877] approved,vet_approved oxytocin receptor OXTR Successful target agonist 3.35 TTD , drugbank , DGIDB [d-tic7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [35s]-non-peptide ot antagonist NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD l-366,948 NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB d(ch2)5[tyr(me)2]avp NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB d(ch2)5[tyr(me)2,thr4,orn8(5/6c-flu),tyr-nh29]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [pip7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD triazole derivative 5 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB atosiban small molecule Nulliparity[MeSHID:D010298],Uterine Contraction[MeSHID:D014590],Premature Birth[MeSHID:D047928],Cervical dilatation (function)[MeSHID:D007747],Heart Rate, Fetal[MeSHID:D006340],Birth[MeSHID:D036801],Gestational Age[MeSHID:D005865] approved,investigational,phase 4 oxytocin receptor OXTR Successful target antagonist 5.03 TTD , drugbank , DGIDB triazole derivative 4 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB [mpa1, d-tyr(et)2, d-tic7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [mpa1, d-tyr(et)2, l-tic7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[orn4]avp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[leu4]avp NA NA investigative oxytocin receptor OXTR Successful target agonist NA TTD , DGIDB d[leu4,dab8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD l-366,682 NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB [mpa1, d-tyr(et)2, pip7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD pmid28906174-compound-figure1g NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB [mpa1, d-tic2, aib7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [ho1][thr4,orn8(5/6c-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[leu4,orn8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD ls-192629 NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB relcovaptan small molecule NA investigational oxytocin receptor OXTR NA antagonist 1.91 drugbank , DGIDB [ho1][orn8(5/6c-rhm)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[val4]avp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD triazole derivative 6 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB d[leu4,lys8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [mpa1, l-tic7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [mpa1, d-tic7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[arg4,orn8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD oxytocin biotech Disease Management[MeSHID:D019468],Vagina[MeSHID:D014621],Postpartum Hemorrhage[MeSHID:D006473],Labor (Childbirth)[MeSHID:D007743],Uterine Contraction[MeSHID:D014590],Rupture[MeSHID:D012421],Gestational Diabetes[MeSHID:D016640],Uterine Inertia[MeSHID:D014593],Rh Sensitization[MeSHID:D012203],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Pre-Eclampsia[MeSHID:D011225],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved oxytocin receptor OXTR Successful target agonist 3.35 TTD , drugbank , DGIDB triazole derivative 7 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB d[cha4]avp NA NA investigative oxytocin receptor OXTR Successful target agonist NA TTD , DGIDB [ho1][orn8(5/6c-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD carbetocin small molecule Birth[MeSHID:D036801],Hemorrhage[MeSHID:D006470],Postpartum Hemorrhage[MeSHID:D006473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational oxytocin receptor OXTR Successful target agonist 10.05 TTD , drugbank , DGIDB d[cha4,orn8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [mpa1, d-tyr(et)2, gly(but)7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD fe-202767 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] phase 2 oxytocin receptor OXTR Successful target unknown 6.7 TTD , DGIDB l023103 NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB pf-3274167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arousal[MeSHID:D001143] discontinued in phase 1 oxytocin receptor OXTR Successful target unknown NA TTD pyrrolidine derivative 13 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB [aib7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD l-367,773 NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB [l-tic7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[cha4,dap8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD ssr149415 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Anxiety Disorders[MeSHID:D001008],Unipolar Depression[MeSHID:D003866] phase 2 oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB l-368899 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spontaneous abortion[MeSHID:D000022] discontinued in phase 1 oxytocin receptor OXTR Successful target unknown NA TTD pyrrolidine derivative 9 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB pyrrolidine derivative 10 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB l-372662 NA NA investigative oxytocin receptor OXTR Successful target antagonist 3.35 TTD , DGIDB pyrrolidine derivative 12 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB d[leu4,dap8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[arg4]avp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD ssr126768a NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB d[arg4,lys8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD barusiban NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 2 oxytocin receptor OXTR Successful target antagonist 6.7 TTD , DGIDB d[thr4,orn8(5/6c-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [mpa1, d-tyr(et)2, d-tic7, aib9]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD retosiban NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] phase 3 oxytocin receptor OXTR Successful target unknown 10.05 TTD , DGIDB d[arg4,dab8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD l-366,509 NA NA investigative oxytocin receptor OXTR Successful target antagonist NA TTD , DGIDB [mpa1, d-tyr(et)2, aib7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD pyrrolidine derivative 11 NA NA patented oxytocin receptor OXTR Successful target unknown NA TTD , DGIDB tt-235 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spontaneous abortion[MeSHID:D000022] discontinued in phase 1 oxytocin receptor OXTR Successful target unknown NA TTD [mpa1, d-tyr(et)2, gly(but)3, gly(but)7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [thr4,gly7]ot NA NA investigative oxytocin receptor OXTR Successful target agonist NA TTD , DGIDB argenine vasopressin NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[cha4,lys8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [phe3]ot NA NA investigative oxytocin receptor OXTR Successful target agonist NA TTD , DGIDB desmopressin NA von Willebrand Disease, Type 1[MeSHID:D056725],Disease Management[MeSHID:D019468],Hemostatic function[MeSHID:D006487],Urination[MeSHID:D014554],Maintenance[MeSHID:D008283],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Polyuria[MeSHID:D011141],Nocturia[MeSHID:D053158],Hemophilia A[MeSHID:D006467],Polydipsia[MeSHID:D059606],Pituitary Diseases[MeSHID:D010900],Craniocerebral Trauma[MeSHID:D006259],Central Diabetes Insipidus[MeSHID:D020790],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved oxytocin receptor OXTR Successful target unknown 3.35 TTD , DGIDB [ho1][lys8(5/6c-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[orn4,lys8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD desgly-nh2,d(ch2)5[d-tyr2,thr4,orn8(5/6c-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[orn8(5/6c-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD barusiban NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] phase 2 oxytocin receptor OXTR Successful target unknown 6.7 TTD , DGIDB d[thr4,lys8(5/6c-flu)]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD retosiban NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] phase 3 oxytocin receptor OXTR Successful target antagonist 10.05 TTD , DGIDB gsk-557296 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Ejaculation[MeSHID:D061686] phase 2 oxytocin receptor OXTR Successful target unknown 6.7 TTD , DGIDB d[orn4,orn8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD pmid16250654c37 NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD vasopressin small molecule Systemic arterial pressure[MeSHID:D062186],Shock[MeSHID:D012769],Body Fluids[MeSHID:D001826],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Insipidus[MeSHID:D003919],Bedwetting[MeSHID:D053206],Enuresis[MeSHID:D004775],Polyuria[MeSHID:D011141],Urinary Incontinence[MeSHID:D014549] approved oxytocin receptor OXTR NA agonist 0.2 drugbank , DGIDB d(ch2)5[tyr(me)2,thr4,orn8,tyr9-nh2]vt NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD d[cha4,dab8]vp NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD [gly(but)7]ot NA NA investigative oxytocin receptor OXTR Successful target unknown NA TTD tnp-atp NA NA investigative p2x purinoceptor 1 P2RX1 Literature-reported target antagonist 15.91 TTD , DGIDB ip5i NA NA investigative p2x purinoceptor 1 P2RX1 Literature-reported target antagonist NA TTD , DGIDB mrs 2219 NA NA investigative p2x purinoceptor 1 P2RX1 Literature-reported target allosteric modulator NA TTD , DGIDB l-betagamma-meatp NA NA investigative p2x purinoceptor 1 P2RX1 Literature-reported target unknown NA TTD bzatp NA NA investigative p2x purinoceptor 1 P2RX1 Literature-reported target agonist NA TTD , DGIDB nf449 NA NA investigative p2x purinoceptor 1 P2RX1 Literature-reported target antagonist NA TTD , DGIDB nf023 NA NA investigative p2x purinoceptor 1 P2RX1 Literature-reported target antagonist NA TTD , DGIDB bzatp NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target agonist NA TTD , DGIDB gefapixant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Overactive Bladder[MeSHID:D053201] phase 3 p2x purinoceptor 3 P2RX3 Clinical trial target antagonist 38.19 TTD , DGIDB bay-1817080 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 1 p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD [3h]a317491 NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD gefapixant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Overactive Bladder[MeSHID:D053201] phase 3 p2x purinoceptor 3 P2RX3 Clinical trial target unknown 38.19 TTD , DGIDB af-130 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 1 p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD , DGIDB bay-1902607 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] phase 2 p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD cyclic lvvypwt NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD bay 1817080 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Endometriosis[MeSHID:D004715] phase 1 p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD af353 NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target antagonist NA TTD , DGIDB mk-3901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD isoppads NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD lvvypwt NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD lvaypwt NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD bay 1902607 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] phase 1/2 p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD tnp-atp NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target antagonist 6.37 TTD , DGIDB lvvapwt NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD lavypwt NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD avvypwt NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target unknown NA TTD ro3 NA NA investigative p2x purinoceptor 3 P2RX3 Clinical trial target antagonist NA TTD , DGIDB eslicarbazepine acetate small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640] approved p2x purinoceptor 4 P2RX4 NA antagonist NA drugbank mrs-2160 NA NA investigative p2x purinoceptor 4 P2RX4 Clinical trial target unknown NA TTD eslicarbazepine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved p2x purinoceptor 4 P2RX4 NA unknown NA drugbank indole carboxamide derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB thiazole derivative 5 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB quinoline derivative 10 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB az-11657312 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD gsk1482160 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 p2x purinoceptor 7 P2RX7 Clinical trial target antagonist,allosteric modulator 17.36 TTD , DGIDB a804598 NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target antagonist NA TTD , DGIDB pmid27724045-compound-19 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB fused triazoloamino-phenyl analog 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB pmid27724045-compound-15 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB decavanadate NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target antagonist NA TTD , DGIDB triazolo-pyrazinone derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB azd9056 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 p2x purinoceptor 7 P2RX7 Clinical trial target unknown 11.57 TTD , DGIDB isothiazolidine derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB pmid27724045-compound-33 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB kn-62 NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD a-740003 NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD aminobenzoxazole analog 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB jnj-55308942 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anhedonia[MeSHID:D059445],Mood Disorders[MeSHID:D019964] phase 1 p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB stylissadine b NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD jnj-54175446 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 p2x purinoceptor 7 P2RX7 Clinical trial target unknown 5.79 TTD , DGIDB pmid27724045-compound-17 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB dihydroisoquinoline carboxamide analog 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB chelerythrine NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target allosteric modulator 0.41 TTD , DGIDB jnj-479655 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB stylissadine a NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD pmid27724045-compound-14 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB afc-5128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD isoppads NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD bicyclic heteroaryl amide derivative 2 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB pmid27724045-compound-29 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 12 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB a438079 NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target antagonist NA TTD , DGIDB isoindole 1,3-dione analog 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB piperazine derivative 6 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB pyridazinone derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB ce-224535 NA Arthralgia[MeSHID:D018771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 p2x purinoceptor 7 P2RX7 Clinical trial target antagonist 11.57 TTD , DGIDB tetrazole derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB fluorophenyl-substituted heterocyclic amide analog 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB bicyclic heteroaryl amide derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB piperidinone derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB imidazolidine derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB heterocyclic-fused piperazine derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB bicyclic heteroaryl amide derivative 3 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB quinoline derivative 12 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB azd9056 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 p2x purinoceptor 7 P2RX7 Clinical trial target antagonist 11.57 TTD , DGIDB thiazole-fused cycloalkyl carboxamide derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB sgm-1019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 1 p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB quinoline derivative 13 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB evt 401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB chlorobenzamide derivative 1 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB az11645373 NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target allosteric modulator NA TTD , DGIDB gsk1482160 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 p2x purinoceptor 7 P2RX7 Clinical trial target unknown 17.36 TTD , DGIDB az11657312 (salt free) NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target antagonist NA TTD , DGIDB quinoline derivative 11 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB triazole derivative 2 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB bil010t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB a839977 NA NA investigative p2x purinoceptor 7 P2RX7 Clinical trial target antagonist NA TTD , DGIDB benzamide derivative 13 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB chlorobenzamide derivative 2 NA NA patented p2x purinoceptor 7 P2RX7 Clinical trial target unknown NA TTD , DGIDB ce-224535 NA Arthralgia[MeSHID:D018771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 p2x purinoceptor 7 P2RX7 Clinical trial target unknown 11.57 TTD , DGIDB a2p5p NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB pmid18445527c67 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD bms compound 4c NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB 2,2'-pyridylisatogen tosylate NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target allosteric modulator NA TTD , DGIDB mrs2500 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB 2-cl-adp(alpha-bh3) NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD adenosine-3'-5'-bisphosphate NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB datpalphas NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD mrs-2179 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD adenosine diphosphate NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD mrs2279 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB mrs2950 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB 1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD n-(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD pmid18445527c11 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD ppads NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB mrs2298 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB 2',3'-ddatp NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target agonist NA TTD , DGIDB 2mesatp NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target agonist,antagonist NA TTD , DGIDB [35s]adpbetas NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD atpgammas NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD pmid23368907c16 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD mrs2496 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB glaxosmithkline compound 6i NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD mrs2365 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target agonist NA TTD , DGIDB glaxosmithkline compound 5h NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD 2-chloroadenosine-5-triphosphate NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB [32p]mrs2500 NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target antagonist NA TTD , DGIDB 2mesadp NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target agonist NA TTD , DGIDB pmid22873688c3a NA NA investigative p2y purinoceptor 1 P2RY1 Literature-reported target unknown NA TTD dioctanoylglycerol pyrophosphate NA NA investigative p2y purinoceptor 10 P2RY10 Literature-reported target antagonist NA TTD , DGIDB lpa NA NA investigative p2y purinoceptor 10 P2RY10 Literature-reported target agonist NA TTD , DGIDB 2mesatp NA NA investigative p2y purinoceptor 11 P2RY11 Discontinued target agonist NA TTD , DGIDB datp NA NA investigative p2y purinoceptor 11 P2RY11 Discontinued target agonist 10.61 TTD , DGIDB nf546 NA NA investigative p2y purinoceptor 11 P2RY11 Discontinued target agonist NA TTD , DGIDB ins 316 NA Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 p2y purinoceptor 11 P2RY11 Discontinued target unknown NA TTD atpgammas NA NA investigative p2y purinoceptor 11 P2RY11 Discontinued target unknown NA TTD atp small molecule NA investigational,nutraceutical p2y purinoceptor 11 P2RY11 NA agonist 1.25 drugbank , DGIDB nf157 NA NA investigative p2y purinoceptor 11 P2RY11 Discontinued target antagonist NA TTD , DGIDB bzatp NA NA investigative p2y purinoceptor 11 P2RY11 Discontinued target agonist NA TTD , DGIDB naadp NA NA investigative p2y purinoceptor 11 P2RY11 Discontinued target agonist NA TTD , DGIDB nf340 NA NA investigative p2y purinoceptor 11 P2RY11 Discontinued target antagonist NA TTD , DGIDB elinogrel small molecule Myocardial Infarction[MeSHID:D009203],Cardiovascular Diseases[MeSHID:D002318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 p2y purinoceptor 12 P2RY12 Successful target antagonist 10.61 TTD , drugbank , DGIDB arl66096 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target antagonist NA TTD , DGIDB 2mesadp NA NA investigative p2y purinoceptor 12 P2RY12 Successful target agonist NA TTD , DGIDB clopidogrel small molecule Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Peripheral Vascular Diseases[MeSHID:D016491],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved p2y purinoceptor 12 P2RY12 Successful target antagonist 2.12 TTD , drugbank , DGIDB pmid22984835c20o NA NA investigative p2y purinoceptor 12 P2RY12 Successful target unknown NA TTD ins49266 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target antagonist NA TTD , DGIDB psb-0702 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target unknown NA TTD prasugrel small molecule Acute Coronary Syndrome[MeSHID:D054058],Angina, Unstable[MeSHID:D000789],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Intracranial Hemorrhages[MeSHID:D020300],Transient Cerebral Ischemia[MeSHID:D002546],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved p2y purinoceptor 12 P2RY12 Successful target antagonist 3.09 TTD , drugbank , DGIDB prt-060096 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] investigative p2y purinoceptor 12 P2RY12 Successful target unknown NA TTD pcmps NA NA investigative p2y purinoceptor 12 P2RY12 Successful target unknown NA TTD elinogrel small molecule Myocardial Infarction[MeSHID:D009203],Cardiovascular Diseases[MeSHID:D002318],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 p2y purinoceptor 12 P2RY12 Successful target unknown 10.61 TTD , drugbank , DGIDB vicagrel small molecule NA investigational p2y purinoceptor 12 P2RY12 NA antagonist,inhibitor NA drugbank arl-67085 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 p2y purinoceptor 12 P2RY12 Successful target unknown NA TTD , DGIDB clopidogrel small molecule Acute Coronary Syndrome[MeSHID:D054058],Peripheral Arterial Diseases[MeSHID:D058729],Peripheral Vascular Diseases[MeSHID:D016491],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved p2y purinoceptor 12 P2RY12 Successful target antagonist 2.12 TTD , drugbank , DGIDB brilinta NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteries[MeSHID:D001158],Thrombosis[MeSHID:D013927],Myocardial Infarction[MeSHID:D009203] approved p2y purinoceptor 12 P2RY12 Successful target unknown 3.54 TTD , DGIDB adenosine diphosphate NA NA investigative p2y purinoceptor 12 P2RY12 Successful target unknown NA TTD cangrelor small molecule Myocardial Infarction[MeSHID:D009203],Thrombosis[MeSHID:D013927],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved p2y purinoceptor 12 P2RY12 Successful target inhibitor 10.61 TTD , drugbank , DGIDB r-138727 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target antagonist NA TTD , DGIDB bx 048 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target antagonist NA TTD , DGIDB [3h]psb-0413 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target antagonist NA TTD , DGIDB bx 667 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target antagonist NA TTD , DGIDB 2mesamp NA NA investigative p2y purinoceptor 12 P2RY12 Successful target antagonist NA TTD , DGIDB psb-0739 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target antagonist 3.54 TTD , DGIDB pmid23083103c4 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target unknown NA TTD ticagrelor small molecule Coronary Arteriosclerosis[MeSHID:D003324],Acute Coronary Syndrome[MeSHID:D054058],Cessation of life[MeSHID:D003643],Coronary heart disease[MeSHID:D003327],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203] approved p2y purinoceptor 12 P2RY12 NA inhibitor 3.54 drugbank , DGIDB pmid22984835c4 NA NA investigative p2y purinoceptor 12 P2RY12 Successful target unknown NA TTD regrelor small molecule Coronary Arteriosclerosis[MeSHID:D003324],Thrombosis[MeSHID:D013927],Coronary heart disease[MeSHID:D003327] investigational p2y purinoceptor 12 P2RY12 NA antagonist 7.07 drugbank , DGIDB treprostinil small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational p2y purinoceptor 12 P2RY12 NA agonist 2.21 drugbank , DGIDB ticagrelor small molecule Coronary Arteriosclerosis[MeSHID:D003324],Acute Coronary Syndrome[MeSHID:D054058],Cessation of life[MeSHID:D003643],Coronary heart disease[MeSHID:D003327],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203] approved p2y purinoceptor 12 P2RY12 NA inhibitor,antagonist 3.54 drugbank , DGIDB ins-50589 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 p2y purinoceptor 12 P2RY12 Successful target unknown 10.61 TTD , DGIDB ticlopidine small molecule Cerebrovascular accident[MeSHID:D020521],Thrombus[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved p2y purinoceptor 12 P2RY12 NA antagonist 2.45 drugbank , DGIDB cangrelor small molecule Myocardial Infarction[MeSHID:D009203],Thrombosis[MeSHID:D013927],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved p2y purinoceptor 12 P2RY12 Successful target inhibitor,antagonist 10.61 TTD , drugbank , DGIDB epoprostenol small molecule Pulmonary Hypertension[MeSHID:D006976],Scleroderma[MeSHID:D012594],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved p2y purinoceptor 12 P2RY12 NA agonist NA drugbank mrs2211 NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target antagonist NA TTD , DGIDB ppads NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target antagonist NA TTD , DGIDB atpgammas NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target unknown NA TTD [33p]2mesadp NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target agonist NA TTD , DGIDB 2mesamp NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target antagonist NA TTD , DGIDB 2mesatp NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target agonist NA TTD , DGIDB 2mesadp NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target agonist NA TTD , DGIDB mrs2603 NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target antagonist NA TTD , DGIDB adenosine diphosphate NA NA investigative p2y purinoceptor 13 P2RY13 Literature-reported target unknown NA TTD pptn NA NA investigative p2y purinoceptor 14 P2RY14 Literature-reported target antagonist NA TTD , DGIDB mrs2690 NA NA investigative p2y purinoceptor 14 P2RY14 Literature-reported target agonist NA TTD , DGIDB mrs2905 NA NA investigative p2y purinoceptor 14 P2RY14 Literature-reported target agonist NA TTD , DGIDB udp-glucose NA NA investigative p2y purinoceptor 14 P2RY14 Literature-reported target agonist 15.91 TTD , DGIDB mrs2802 NA NA investigative p2y purinoceptor 14 P2RY14 Literature-reported target agonist NA TTD , DGIDB alpha.beta-methylene-2-thio-udp NA NA investigative p2y purinoceptor 14 P2RY14 Literature-reported target unknown NA TTD 2-thio-udp NA NA investigative p2y purinoceptor 14 P2RY14 Literature-reported target agonist NA TTD , DGIDB udp-glucuronic acid NA NA investigative p2y purinoceptor 14 P2RY14 Literature-reported target agonist NA TTD , DGIDB acid blue 25 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target unknown NA TTD sb-416 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target unknown NA TTD denufosol small molecule Cystic Fibrosis[MeSHID:D003550] investigational p2y purinoceptor 2 P2RY2 NA agonist 31.83 drugbank , DGIDB mrs2698 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target agonist NA TTD , DGIDB ar-c126313 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target antagonist NA TTD , DGIDB psb1114 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target agonist NA TTD , DGIDB rb 2 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target unknown NA TTD mdt-006 NA Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative p2y purinoceptor 2 P2RY2 Clinical trial target unknown NA TTD 4-thio-utp NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target agonist 7.07 TTD , DGIDB diquafosol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Desiccation[MeSHID:D003890],Disorder of eye[MeSHID:D005128],Dry Eye Syndromes[MeSHID:D015352],Disease[MeSHID:D004194] phase 3 p2y purinoceptor 2 P2RY2 Clinical trial target unknown 10.61 TTD , DGIDB 5brutp NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target agonist NA TTD , DGIDB suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] investigational p2y purinoceptor 2 P2RY2 NA antagonist 1.12 drugbank , DGIDB 2-thioutp NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target agonist NA TTD , DGIDB psb-0963 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target unknown NA TTD suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational p2y purinoceptor 2 P2RY2 NA antagonist 1.12 drugbank , DGIDB ins-37217 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 p2y purinoceptor 2 P2RY2 Clinical trial target unknown 14.14 TTD , DGIDB utpgammas NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target unknown NA TTD psb-716 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target unknown NA TTD ar-c118925xx NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target antagonist NA TTD , DGIDB denufosol small molecule Cystic Fibrosis[MeSHID:D003550] investigational p2y purinoceptor 2 P2RY2 NA unknown 31.83 drugbank , DGIDB mrs2768 NA NA investigative p2y purinoceptor 2 P2RY2 Clinical trial target agonist NA TTD , DGIDB ins 316 small molecule Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 p2y purinoceptor 2 P2RY2 Clinical trial target unknown NA TTD , drugbank diquafosol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Desiccation[MeSHID:D003890],Disorder of eye[MeSHID:D005128],Dry Eye Syndromes[MeSHID:D015352],Disease[MeSHID:D004194] phase 3 p2y purinoceptor 2 P2RY2 Clinical trial target agonist 10.61 TTD , DGIDB n4-phenylethoxycytidine-5'-triphosphate NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target agonist NA TTD , DGIDB utpgammas NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target unknown NA TTD ctp NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target unknown NA TTD ppads NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target antagonist NA TTD , DGIDB ins 316 NA Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 p2y purinoceptor 4 P2RY4 Discontinued target unknown NA TTD mrs2927 NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target agonist NA TTD , DGIDB mrs4062 NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target agonist NA TTD , DGIDB (n)methanocarba-utp NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target agonist NA TTD , DGIDB 2-amino-uridine-5'-monophosphate NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target agonist NA TTD , DGIDB itp NA NA investigative p2y purinoceptor 4 P2RY4 Discontinued target agonist NA TTD , DGIDB 2mesatp NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target agonist NA TTD , DGIDB mrs2578 NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target antagonist NA TTD , DGIDB ins48823 NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target agonist NA TTD , DGIDB mrs2567 NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target antagonist NA TTD , DGIDB rb 2 NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target unknown NA TTD 3-phenacyl-udp NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target agonist NA TTD , DGIDB udp-beta-s NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target unknown NA TTD psb-0952 NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target unknown NA TTD mrs2693 NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target agonist NA TTD , DGIDB mrs2957 NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target agonist NA TTD , DGIDB mrs2782 NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target agonist NA TTD , DGIDB 5brutp NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target agonist NA TTD , DGIDB up3u NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target agonist NA TTD , DGIDB adenosine diphosphate NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target unknown NA TTD gc021109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 p2y purinoceptor 6 P2RY6 Clinical trial target unknown NA TTD , DGIDB ins 316 NA Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 p2y purinoceptor 6 P2RY6 Clinical trial target unknown NA TTD rp-5-ome-udpalphab NA NA investigative p2y purinoceptor 6 P2RY6 Clinical trial target unknown NA TTD ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical prolyl 3-hydroxylase 1 P3H1 NA cofactor NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical prolyl 3-hydroxylase 1 P3H1 NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical prolyl 3-hydroxylase 2 P3H2 NA unknown NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical prolyl 3-hydroxylase 2 P3H2 NA cofactor NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical prolyl 3-hydroxylase 3 P3H3 NA cofactor NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical prolyl 3-hydroxylase 3 P3H3 NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical prolyl 4-hydroxylase subunit alpha-1 P4HA1 NA unknown NA drugbank hydralazine small molecule treatment failure[MeSHID:D017211],Heart failure[MeSHID:D006333],Essential Hypertension[MeSHID:D000075222],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved prolyl 4-hydroxylase subunit alpha-1 P4HA1 NA inhibitor NA drugbank lufironil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver Cirrhosis[MeSHID:D008103] phase 2 prolyl 4-hydroxylasesubunit alpha-1 P4HA1 Clinical trial target unknown 21.22 TTD , DGIDB safironil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft Rejection[MeSHID:D006084] phase 1 prolyl 4-hydroxylasesubunit alpha-1 P4HA1 Clinical trial target unknown 21.22 TTD , DGIDB ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical prolyl 4-hydroxylase subunit alpha-1 P4HA1 NA cofactor NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical prolyl 4-hydroxylase subunit alpha-2 P4HA2 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational protein disulfide-isomerase P4HB NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental protein disulfide-isomerase P4HB NA binder NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein disulfide-isomerase P4HB NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational protein disulfide-isomerase P4HB NA ligand NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational protein disulfide-isomerase P4HB NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational protein disulfide-isomerase P4HB NA unknown NA drugbank ribostamycin small molecule NA approved,experimental protein disulfide-isomerase P4HB NA unknown NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical transmembrane prolyl 4-hydroxylase P4HTM NA cofactor NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical pyrroline-5-carboxylate reductase P5CR2 NA unknown NA drugbank atrc-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 polyadenylate-binding protein 1 PABPC1 Clinical trial target unknown NA TTD citrulline small molecule NA investigational,nutraceutical protein-arginine deiminase type-1 PADI1 NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical protein-arginine deiminase type-2 PADI2 NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical protein-arginine deiminase type-3 PADI3 NA unknown NA drugbank n-[(1s)-1-(aminocarbonyl)-4-(ethanimidoylamino)butyl]benzamide small molecule NA experimental protein-arginine deiminase type-4 PADI4 NA unknown NA drugbank azithromycin small molecule Uterine Cervicitis[MeSHID:D002575],Otitis Media[MeSHID:D010033],Sinusitis[MeSHID:D012852],Abscess[MeSHID:D000038],Maintenance[MeSHID:D008283],Tonsillitis[MeSHID:D014069],Operative Surgical Procedures[MeSHID:D013514],Chlamydial pneumonia[MeSHID:D061387],Lung[MeSHID:D008168],Pharyngitis[MeSHID:D010612],Muscle strain[MeSHID:D013180],Disease Exacerbation[MeSHID:D018450],Peptic Ulcer[MeSHID:D010437],Infection[MeSHID:D007239],Disease[MeSHID:D004194],Chancroids[MeSHID:D002602],Pneumonia[MeSHID:D011014],Urethritis[MeSHID:D014526],Reproduction[MeSHID:D012098],Staphylococcal Skin Infections[MeSHID:D013207],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Bronchitis[MeSHID:D001991] approved protein-arginine deiminase type-4 PADI4 NA inhibitor NA drugbank streptomycin small molecule Bacteremia[MeSHID:D016470],Endocardium[MeSHID:D004699],Meninges[MeSHID:D008578],Chancroids[MeSHID:D002602],Granuloma Inguinale[MeSHID:D006100],Pneumonia[MeSHID:D011014],Neoplasm Metastasis[MeSHID:D009362],Influenza[MeSHID:D007251],Muscle strain[MeSHID:D013180],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved protein-arginine deiminase type-4 PADI4 NA inhibitor NA drugbank tetracycline small molecule Lyme Disease[MeSHID:D008193],Bovine Anaplasmosis[MeSHID:D000712],Q Fever[MeSHID:D011778],Bacterial Infections[MeSHID:D001424],Pneumonia[MeSHID:D011014],Acne Vulgaris[MeSHID:D000152],Rocky Mountain Spotted Fever[MeSHID:D012373],Rickettsialpox[MeSHID:D000073605],Upper Respiratory Infections[MeSHID:D012141],Brill-Zinsser Disease[MeSHID:D014438],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved protein-arginine deiminase type-4 PADI4 NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical protein-arginine deiminase type-4 PADI4 NA unknown NA drugbank citrulline small molecule NA investigational,nutraceutical protein-arginine deiminase type-6 PADI6 NA product of NA drugbank 12-bromododecanoic acid small molecule NA experimental glycodelin PAEP NA unknown NA drugbank glycerin small molecule NA approved,investigational glycodelin PAEP NA unknown NA drugbank palmitic acid small molecule NA approved glycodelin PAEP NA unknown NA drugbank (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate small molecule NA experimental platelet-activating factor acetylhydrolase ib subunit gamma PAFAH1B3 NA unknown NA drugbank bh4 NA NA investigative phenylalanine hydroxylase PAH Successful target unknown NA TTD fenclonine NA NA investigative phenylalanine hydroxylase PAH Successful target inhibitor 2.65 TTD , DGIDB sapropterin small molecule Malnutrition[MeSHID:D044342] approved,investigational phenylalanine-4-hydroxylase PAH NA cofactor 84.87 drugbank , DGIDB pegvaliase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Phenylketonurias[MeSHID:D010661] approved phenylalanine hydroxylase PAH Successful target unknown 10.61 TTD , DGIDB l-erythro-7,8-dihydrobiopterin small molecule NA experimental phenylalanine-4-hydroxylase PAH NA unknown NA drugbank quinonoid 7,8-tetrahydrobiopterin small molecule NA experimental phenylalanine-4-hydroxylase PAH NA unknown NA drugbank norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved phenylalanine-4-hydroxylase PAH NA inhibitor NA drugbank alpha-methylphenylalanine NA NA investigative phenylalanine hydroxylase PAH Successful target unknown NA TTD sapropterin small molecule Malnutrition[MeSHID:D044342] approved,investigational phenylalanine-4-hydroxylase PAH NA cofactor,activator 84.87 drugbank , DGIDB phenylalanine hydroxylase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 2 phenylalanine hydroxylase PAH Successful target unknown NA TTD , DGIDB sapropterin hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperphenylalaninaemia[MeSHID:D010661] approved phenylalanine hydroxylase PAH Successful target unknown NA TTD , DGIDB beta-2-thienyl-l-alanine small molecule NA experimental phenylalanine-4-hydroxylase PAH NA unknown NA drugbank d-norleucine small molecule NA experimental phenylalanine-4-hydroxylase PAH NA unknown NA drugbank droxidopa small molecule AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Hypotension[MeSHID:D007022],Disease[MeSHID:D004194],Amyloid Neuropathies, Familial[MeSHID:D028227],Multiple System Atrophy[MeSHID:D019578],Neurogenesis[MeSHID:D055495],Parkinson Disease[MeSHID:D010300],Blood[MeSHID:D001769],Hematological Disease[MeSHID:D006402],Syncope[MeSHID:D013575],Shy-Drager Syndrome[MeSHID:D012791],Dizziness[MeSHID:D004244],Hypotension, Orthostatic[MeSHID:D007024],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational phenylalanine-4-hydroxylase PAH NA inhibitor NA drugbank altu-236 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hereditary Diseases[MeSHID:D030342] investigative phenylalanine hydroxylase PAH Successful target unknown NA TTD phenylalanine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Tardive Dyskinesia[MeSHID:D000071057],Vitiligo[MeSHID:D014820] approved,investigational,nutraceutical phenylalanine-4-hydroxylase PAH NA unknown NA drugbank hepastem NA Liver Failure[MeSHID:D017093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phenylalanine hydroxylase PAH Successful target unknown NA TTD , DGIDB bmn-168 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Phenylketonurias[MeSHID:D010661] investigative phenylalanine hydroxylase PAH Successful target unknown NA TTD aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical multifunctional protein ade2 PAICS NA substrate NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase pak 1 PAK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase pak 2 PAK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase pak 3 PAK3 NA inhibitor NA drugbank pf-3758309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pak-4 protein kinase PAK4 Clinical trial target inhibitor 1.68 TTD , DGIDB kpt-9274 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1 pak-4 protein kinase PAK4 Clinical trial target unknown 3.35 TTD , DGIDB pf-3758309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pak-4 protein kinase PAK4 Clinical trial target unknown 1.68 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase pak 4 PAK4 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase pak 5 PAK5 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase pak 6 PAK6 NA inhibitor NA drugbank n-alpha-acetyl-3,5-diiodotyrosylglycine small molecule NA experimental peptidyl-glycine alpha-amidating monooxygenase PAM NA unknown NA drugbank n-alpha-acetyl-3,5-diiodotyrosyl-d-threonine small molecule NA experimental peptidyl-glycine alpha-amidating monooxygenase PAM NA unknown NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical peptidyl-glycine alpha-amidating monooxygenase PAM NA cofactor NA drugbank probenecid small molecule Mental concentration[MeSHID:D001288],Serum[MeSHID:D044967],Neoplasm Metastasis[MeSHID:D009362],Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational pannexin-1 PANX1 NA antagonist NA drugbank cordycepin triphosphate small molecule NA experimental poly(a) polymerase alpha PAPOLA NA unknown NA drugbank 3-sulfino-l-alanine small molecule NA experimental poly(a) polymerase alpha PAPOLA NA unknown NA drugbank triphosphoric acid small molecule NA experimental poly(a) polymerase alpha PAPOLA NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational pappalysin-1 PAPPA NA unknown NA drugbank adenosine 5'-phosphosulfate small molecule NA experimental,investigational bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 PAPSS1 NA unknown NA drugbank adenosine-5'-diphosphate-2',3'-vanadate small molecule NA experimental bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 PAPSS1 NA unknown NA drugbank glycerin small molecule NA approved,investigational bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 PAPSS1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein dj-1 PARK7 NA unknown NA drugbank rucaparib small molecule Diploid Cell[MeSHID:D004171],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational poly [adp-ribose] polymerase 1 PARP1 NA antagonist,inhibitor 0.96 drugbank , DGIDB tricyclic indole compound 13 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 6-amino-benzo[de]isoquinoline-1,3-dione small molecule NA experimental poly [adp-ribose] polymerase 1 PARP1 NA unknown NA drugbank theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved poly [adp-ribose] polymerase 1 PARP1 NA unknown NA drugbank pmid27841036-compound-33 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 5-fluoro-1-[4-(4-phenyl-3,6-dihydropyridin-1(2h)-yl)butyl]quinazoline-2,4(1h,3h)-dione small molecule NA experimental poly [adp-ribose] polymerase 1 PARP1 NA unknown NA drugbank iniparib small molecule NA investigational poly [adp-ribose] polymerase 1 PARP1 NA unknown 7.96 drugbank , DGIDB ti3 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD olaparib small molecule Fallopian Tubes[MeSHID:D005187],Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Peritoneum[MeSHID:D010537],Recurrence (disease attribute)[MeSHID:D012008],Ovary[MeSHID:D010053],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471] approved poly [adp-ribose] polymerase 1 PARP1 NA inhibitor 2.16 drugbank , DGIDB 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivative 2 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 8-hydroxy-2-(4-nitro-phenyl)-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD bz5 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-aminobenzo[c][1,5]naphthyridin-6(5h)-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 5-aminoisoquinolin-1(2h)-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD benzo[c][1,5]naphthyridin-6(5h)-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational poly [adp-ribose] polymerase 1 PARP1 NA unknown NA drugbank bz6 NA Ataxia Telangiectasia[MeSHID:D001260],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD hydamtiq NA Brain Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-phenylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD pmid27841036-compound-37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 3-ethynylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 8-hydroxy-2-phenyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD carba-nicotinamide-adenine-dinucleotide small molecule NA experimental,investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , drugbank 3-(4-aminophenyl)quinoxaline-5-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-(3-chlorophenyl)-2h-indazole-7-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-phenyl isoquinolin-1(2h) derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 3-(4-methoxyphenyl)quinoxaline-5-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 4-benzylphthalazin-1(2h)-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 8-methoxy-2-methyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-methoxybenzamide small molecule NA experimental,investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , drugbank 2-(3-piperidin-1-yl-propyl)-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 5-methylpyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD ino-1002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 5-amino-3,4-dihydroisoquinolin-1(2h)-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-methylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-(4-amino-phenyl)-8-hydroxy-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD ti4 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD phthalazine ketone derivative 2 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB niraparib small molecule Fallopian Tubes[MeSHID:D005187],Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Peritoneum[MeSHID:D010537],Recurrence (disease attribute)[MeSHID:D012008],Ovary[MeSHID:D010053] approved,investigational poly [adp-ribose] polymerase 1 PARP1 NA antagonist 3.54 drugbank , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental poly [adp-ribose] polymerase 1 PARP1 NA component of NA drugbank nicaraven NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cerebrovascular Disorders[MeSHID:D002561] phase 3 poly [adp-ribose] polymerase 1 PARP1 Successful target unknown 5.3 TTD , DGIDB s-070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 8-methoxy-2-phenyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD pd-128763 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-benzyl-2h-indazole-7-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD quinazolinedione derivative 3 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 4-carboxamido-isoindolinone derivative 5 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 4-(4-morpholin-4-yl-butyl)-2h-phthalazin-1-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivative 4 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 2-phenyl-2h-benzo[d][1,2,3]triazole-4-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-morpholin-4-ylmethyl-5h-phenanthridin-6-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD (e)-n-(4-phenylthiazol-2-yl) cinnamamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD phthalazine derivative 3 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 8-methoxy-2-(4-nitro-phenyl)-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD dr2313 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-aminobenzamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-ethylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 4-carboxamido-isoindolinone derivative 4 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 8-nitro-6h,11h-indeno[1,2-c]isoquinolin-5-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD pj34 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] preclinical poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD dihydrodiazepinocarbazolone derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB thieno-phenanthridin-6-one NA Brain Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 9-fluoro-6h,11h-indeno[1,2-c]isoquinolin-5-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD pyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-(4-methoxyphenyl)quinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD cc-486 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190] phase 3 poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 2-(2-chlorophenyl)-2h-indazole-7-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-(4-azido-phenyl)-8-methoxy-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 2,8-dimethyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivative 5 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 2-phenyl-2h-indazole-7-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD quinazolinedione derivative 2 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 3-(4-cyanophenyl)quinoxaline-5-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD benzimidazole carboxamide derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB talazoparib small molecule Breast[MeSHID:D001940],Germ Line[MeSHID:D005854],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Arthritis, Psoriatic[MeSHID:D015535],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational poly [adp-ribose] polymerase 1 PARP1 NA inhibitor 1.45 drugbank , DGIDB ang-2864 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 4-carboxamido-isoindolinone derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB dihydropyrido phthalazinone derivative 2 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 8-fluoro-6h,11h-indeno[1,2-c]isoquinolin-5-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 4-methylpyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD ku-58684 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3-phenyl isoquinolin-1(2h) derivative 2 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB rucaparib small molecule Diploid Cell[MeSHID:D004171],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational poly [adp-ribose] polymerase 1 PARP1 NA antagonist 0.96 drugbank , DGIDB 2,3-dihydro-1h-benzo[de]isoquinolin-1-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD kr-33889 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-(4-methoxy-phenyl)-8-methyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-ethylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD bz3 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD cep-6800 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD quinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-(3'-methoxyphenyl) benzimidazole-4-carboxamide small molecule NA experimental,investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , drugbank 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bh)-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD ku-0058948 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved poly [adp-ribose] polymerase 1 PARP1 Successful target unknown 7.96 TTD , DGIDB quinazolinedione derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB iniparib small molecule NA investigational poly [adp-ribose] polymerase 1 PARP1 NA inhibitor 7.96 drugbank , DGIDB 2-{3-[4-(4-fluorophenyl)-3,6-dihydro-1(2h)-pyridinyl]propyl}-8-methyl-4(3h)-quinazolinone small molecule NA experimental poly [adp-ribose] polymerase 1 PARP1 NA unknown NA drugbank 2h-isoquinolin-1-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 4-amino-1,8-naphthalimide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD nicotinamide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved,investigational poly [adp-ribose] polymerase 1 PARP1 Successful target binder 3.54 TTD , drugbank , DGIDB 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD veliparib small molecule NA investigational poly [adp-ribose] polymerase 1 PARP1 NA inhibitor 3.71 drugbank , DGIDB a-620223 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , drugbank bpi-704001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD pyrrolo[3,4-e]indole-1,3(2h,6h)-dione NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 7-azaindole derivative 8 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 3-prop-1-ynylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD cph-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Persistent Hepatitis[MeSHID:D006521],Malignant Neoplasms[MeSHID:D009369] preclinical poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB stenoparib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD nms-03305293 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroleptic Malignant Syndrome[MeSHID:D009459],Malignant Neoplasms[MeSHID:D009369] phase 1 poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD ag-014376 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD amxi 5001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD dihydropyrido phthalazinone derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 2-(4-chlorophenyl)-5-quinoxalinecarboxamide small molecule NA experimental,investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , drugbank niraparib tosylate NA Fallopian Tube Carcinoma[MeSHID:D005185],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Peritoneum[MeSHID:D010537] approved poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational poly [adp-ribose] polymerase 1 PARP1 NA unknown NA drugbank me0328 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target inhibitor NA TTD , DGIDB ag140699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB eb-47 NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD [2(r,s)-2-sulfanylheptanoyl]-phe-ala NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 9-amino-6h,11h-indeno[1,2-c]isoquinolin-5-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD n-(4-phenylthiazol-2-yl)isonicotinamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 8-methyl-2-phenyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD tetra-hydro-quinoline derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 2-phenylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 8-amino-6h,11h-indeno[1,2-c]isoquinolin-5-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-(4-chlorophenyl)-2h-indazole-7-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-8-methyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 3,4-dihydro-5-methyl-isoquinolinone small molecule NA experimental poly [adp-ribose] polymerase 1 PARP1 NA unknown NA drugbank s-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 4-carboxamido-isoindolinone derivative 3 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivative 3 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 3-ethenylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational poly [adp-ribose] polymerase 1 PARP1 NA component of NA drugbank 2-(4-amino-phenyl)-8-methyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD ang-2684 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD phthalazine ketone derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD niraparib small molecule Fallopian Tubes[MeSHID:D005187],Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Peritoneum[MeSHID:D010537],Recurrence (disease attribute)[MeSHID:D012008],Ovary[MeSHID:D010053] approved,investigational poly [adp-ribose] polymerase 1 PARP1 NA antagonist,inhibitor 3.54 drugbank , DGIDB 3-hydroxy-benzamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD nu1025 small molecule NA experimental,terminated poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , drugbank 8-methyl-2-(4-nitro-phenyl)-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD phthalazine ketone derivative 3 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB veliparib small molecule NA investigational poly [adp-ribose] polymerase 1 PARP1 NA unknown 3.71 drugbank , DGIDB 4-carboxamido-isoindolinone derivative 2 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 4-(5-morpholin-4-yl-pentyl)-2h-phthalazin-1-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD 2-methylquinoline-8-carboxamide NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD tetra-cyclic pyridophthalazinone derivative 1 NA NA patented poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD , DGIDB 5-chloro-2-methyl-3h-quinazolin-4-one NA NA investigative poly [adp-ribose] polymerase 1 PARP1 Successful target unknown NA TTD n~2~,n~2~-dimethyl-n~1~-(6-oxo-5,6-dihydrophenanthridin-2-yl)glycinamide small molecule NA experimental poly [adp-ribose] polymerase 15 PARP15 NA unknown NA drugbank rucaparib small molecule Diploid Cell[MeSHID:D004171],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational poly [adp-ribose] polymerase 2 PARP2 NA antagonist,inhibitor 1.1 drugbank , DGIDB dihydrodiazepinocarbazolone derivative 1 NA NA patented poly [adp-ribose] polymerase 2 PARP2 Clinical trial target unknown NA TTD , DGIDB veliparib small molecule NA investigational poly [adp-ribose] polymerase 2 PARP2 NA inhibitor 6.37 drugbank , DGIDB talazoparib small molecule Breast[MeSHID:D001940],Germ Line[MeSHID:D005854],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Arthritis, Psoriatic[MeSHID:D015535],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational poly [adp-ribose] polymerase 2 PARP2 NA inhibitor 2.48 drugbank , DGIDB niraparib small molecule Fallopian Tubes[MeSHID:D005187],Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Peritoneum[MeSHID:D010537],Recurrence (disease attribute)[MeSHID:D012008],Ovary[MeSHID:D010053] approved,investigational poly [adp-ribose] polymerase 2 PARP2 NA antagonist,inhibitor 6.06 drugbank , DGIDB 3-phenyl isoquinolin-1(2h) derivative 1 NA NA patented poly [adp-ribose] polymerase 2 PARP2 Clinical trial target unknown NA TTD , DGIDB olaparib small molecule Fallopian Tubes[MeSHID:D005187],Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Peritoneum[MeSHID:D010537],Recurrence (disease attribute)[MeSHID:D012008],Ovary[MeSHID:D010053],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471] approved poly [adp-ribose] polymerase 2 PARP2 NA inhibitor 1.68 drugbank , DGIDB pmid27841036-compound-37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 poly [adp-ribose] polymerase 2 PARP2 Clinical trial target unknown NA TTD , DGIDB niraparib small molecule Fallopian Tubes[MeSHID:D005187],Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Peritoneum[MeSHID:D010537],Recurrence (disease attribute)[MeSHID:D012008],Ovary[MeSHID:D010053] approved,investigational poly [adp-ribose] polymerase 2 PARP2 NA antagonist 6.06 drugbank , DGIDB veliparib small molecule NA investigational poly [adp-ribose] polymerase 2 PARP2 NA unknown 6.37 drugbank , DGIDB tetra-cyclic pyridophthalazinone derivative 1 NA NA patented poly [adp-ribose] polymerase 2 PARP2 Clinical trial target unknown NA TTD , DGIDB stenoparib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 poly [adp-ribose] polymerase 2 PARP2 Clinical trial target unknown NA TTD amxi 5001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 poly [adp-ribose] polymerase 2 PARP2 Clinical trial target unknown NA TTD rucaparib small molecule Diploid Cell[MeSHID:D004171],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational poly [adp-ribose] polymerase 2 PARP2 NA antagonist 1.1 drugbank , DGIDB 2-methyl-3,5,7,8-tetrahydro-4h-thiopyrano[4,3-d]pyrimidin-4-one small molecule NA experimental poly [adp-ribose] polymerase 3 PARP3 NA unknown NA drugbank rucaparib small molecule Diploid Cell[MeSHID:D004171],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational poly [adp-ribose] polymerase 3 PARP3 NA antagonist 0.77 drugbank , DGIDB 3-phenyl isoquinolin-1(2h) derivative 1 NA NA patented poly [adp-ribose] polymerase 3 PARP3 Patented-recorded target unknown NA TTD , DGIDB olaparib small molecule Fallopian Tubes[MeSHID:D005187],Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Peritoneum[MeSHID:D010537],Recurrence (disease attribute)[MeSHID:D012008],Ovary[MeSHID:D010053],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471] approved poly [adp-ribose] polymerase 3 PARP3 NA inhibitor 0.94 drugbank , DGIDB rucaparib small molecule Diploid Cell[MeSHID:D004171],Diagnosis[MeSHID:D003933],Mutation[MeSHID:D009154],Germ Line[MeSHID:D005854],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational poly [adp-ribose] polymerase 3 PARP3 NA antagonist,inhibitor 0.77 drugbank , DGIDB n~2~,n~2~-dimethyl-n~1~-(6-oxo-5,6-dihydrophenanthridin-2-yl)glycinamide small molecule NA experimental poly [adp-ribose] polymerase 3 PARP3 NA unknown NA drugbank 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2h)-one small molecule NA experimental poly [adp-ribose] polymerase 3 PARP3 NA unknown NA drugbank me0328 NA NA investigative poly [adp-ribose] polymerase 3 PARP3 Patented-recorded target inhibitor NA TTD , DGIDB proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical probable proline--trna ligase, mitochondrial PARS2 NA unknown NA drugbank bms-986120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 prostate apoptosis response-4 PAWR Clinical trial target unknown NA TTD bms-986141 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 prostate apoptosis response-4 PAWR Clinical trial target unknown NA TTD pfi-3 NA NA investigative polybromo-1 PBRM1 Literature-reported target inhibitor NA TTD , DGIDB pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical pyruvate carboxylase, mitochondrial PC NA unknown NA drugbank biotin small molecule NA approved,investigational,nutraceutical pyruvate carboxylase, mitochondrial PC NA cofactor NA drugbank 5-(hexahydro-2-oxo-1h-thieno[3,4-d]imidazol-6-yl)pentanal small molecule NA experimental pyruvate carboxylase, mitochondrial PC NA unknown NA drugbank l-erythro-7,8-dihydrobiopterin small molecule NA experimental pterin-4-alpha-carbinolamine dehydratase PCBD1 NA unknown NA drugbank biotin small molecule NA approved,investigational,nutraceutical propionyl-coa carboxylase alpha chain, mitochondrial PCCA NA cofactor NA drugbank valine small molecule Emotions[MeSHID:D004644],Respiratory Diaphragm[MeSHID:D003964],Hepatic Encephalopathy[MeSHID:D006501],Phenylketonurias[MeSHID:D010661],Muscle[MeSHID:D009132] approved,nutraceutical propionyl-coa carboxylase beta chain, mitochondrial PCCB NA unknown NA drugbank biotin small molecule NA approved,investigational,nutraceutical propionyl-coa carboxylase beta chain, mitochondrial PCCB NA cofactor NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical protocadherin-19 PCDH19 NA unknown NA drugbank 1-(2-fluorobenzyl)-3-butyl-8-(n-acetyl-4-aminobenzyl)-xanthine small molecule NA experimental phosphoenolpyruvate carboxykinase, cytosolic [gtp] PCK1 NA unknown NA drugbank phosphoenolpyruvate small molecule NA experimental phosphoenolpyruvate carboxykinase, cytosolic [gtp] PCK1 NA unknown NA drugbank 1-allyl-3-butyl-8-(n-acetyl-4-aminobenzyl)-xanthine small molecule NA experimental phosphoenolpyruvate carboxykinase, cytosolic [gtp] PCK1 NA unknown NA drugbank 5'-guanylylmethylenebisphosphonate small molecule NA experimental phosphoenolpyruvate carboxykinase, cytosolic [gtp] PCK1 NA unknown NA drugbank s-adenosyl-l-homocysteine small molecule NA experimental protein-l-isoaspartate(d-aspartate) o-methyltransferase PCMT1 NA unknown NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved proliferating cell nuclear antigen PCNA NA downregulator NA drugbank atx-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 3 proliferating cell nuclear antigen PCNA Clinical trial target unknown 21.22 TTD , DGIDB chelase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinal Diseases[MeSHID:D012164] discontinued in phase 1 proliferating cell nuclear antigen PCNA Clinical trial target unknown NA TTD liothyronine small molecule Disease Management[MeSHID:D019468],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Thyroid carcinoma[MeSHID:D013964],Hyperthyroidism[MeSHID:D006980],Constipation[MeSHID:D003248],Desiccation[MeSHID:D003890],Pituitary Diseases[MeSHID:D010900],Pallor[MeSHID:D010167],Term Birth[MeSHID:D047929],Hypothyroidism[MeSHID:D007037],Thyroid Gland[MeSHID:D013961],Endemic goiter[MeSHID:D006043],Neoplasm Metastasis[MeSHID:D009362],Hypothalamic structure[MeSHID:D007031],Plasma[MeSHID:D010949],Subacute thyroiditis[MeSHID:D013968],Voice[MeSHID:D014831],Hair[MeSHID:D006197],Lethargy[MeSHID:D053609],Drowsiness[MeSHID:D012894],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,vet_approved proliferating cell nuclear antigen PCNA NA antagonist NA drugbank phenylacetyl-arg-val-arg-4-amidinobenzylamide NA NA investigative neuroendocrine convertase 1 PCSK1 Literature-reported target inhibitor NA TTD , DGIDB phenylacetyl-arg-val-arg-4-amidinobenzylamide NA NA investigative neuroendocrine convertase 2 PCSK2 Literature-reported target unknown NA TTD peptide 18 NA NA investigative neuroendocrine convertase 2 PCSK2 Literature-reported target unknown NA TTD furin inhibitor peptide NA NA investigative proprotein convertase subtilisin/kexin type 4 PCSK4 Literature-reported target inhibitor NA TTD , DGIDB peptide 18 NA NA investigative proprotein convertase subtilisin/kexin type 7 PCSK7 Literature-reported target unknown NA TTD furin inhibitor peptide NA NA investigative proprotein convertase subtilisin/kexin type 7 PCSK7 Literature-reported target inhibitor NA TTD , DGIDB aln-pcs NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical pcsk9 messenger rna PCSK9 Clinical trial target unknown NA TTD bococizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 3 proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target unknown 31.83 TTD , DGIDB inclisiran biotech Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Heterozygote[MeSHID:D006579],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational proprotein convertase subtilisin/kexin type 9 PCSK9 NA antisense oligonucleotide NA drugbank amg 145 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target unknown NA TTD , DGIDB bococizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 3 proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target inhibitor 31.83 TTD , DGIDB evolocumab biotech Homozygote[MeSHID:D006720],Atherosclerosis[MeSHID:D050197],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938] approved proprotein convertase subtilisin/kexin type 9 PCSK9 NA inhibitor 10.61 drugbank , DGIDB pf-04950615 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target unknown 31.83 TTD , DGIDB mpsk3169a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Metabolic Diseases[MeSHID:D008659] phase 2 pcsk9 messenger rna PCSK9 Clinical trial target unknown NA TTD alirocumab biotech Diet therapy[MeSHID:D004035],Angina, Unstable[MeSHID:D000789],Hyperlipidemia[MeSHID:D006949],Hospitalization[MeSHID:D006760],Cardiovascular Diseases[MeSHID:D002318],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Heterozygote[MeSHID:D006579],Hypercholesterolemia, Familial[MeSHID:D006938] approved proprotein convertase subtilisin/kexin type 9 PCSK9 NA inhibitor 26.52 drugbank , DGIDB 1d05 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] investigative proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target unknown NA TTD ly3015014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 2 proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target unknown 10.61 TTD , DGIDB spc5001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 1 proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target unknown NA TTD , DGIDB pcsk9 adnectin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target unknown NA TTD , DGIDB regn-727 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypercholesterolemia, Familial[MeSHID:D006938] approved proprotein convertase subtilisin/kexin type 9 PCSK9 Successful target unknown 26.52 TTD , DGIDB bms-pcsk9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Coronary Arteriosclerosis[MeSHID:D003324] preclinical pcsk9 messenger rna PCSK9 Clinical trial target unknown NA TTD palmitoyl-linoleoyl phosphatidylcholine small molecule NA experimental phosphatidylcholine transfer protein PCTP NA unknown NA drugbank l-dilinoleoyllecithin small molecule NA experimental phosphatidylcholine transfer protein PCTP NA unknown NA drugbank choline salicylate small molecule Exanthema[MeSHID:D005076],Teething syndrome[MeSHID:D014078],Oral Ulcer[MeSHID:D019226],Pain[MeSHID:D010146],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,nutraceutical choline-phosphate cytidylyltransferase a PCYT1A NA product of NA drugbank choline small molecule NA approved,nutraceutical choline-phosphate cytidylyltransferase a PCYT1A NA product of NA drugbank sphingosine NA NA phase 1 cholinephosphate cytidylyltransferase PCYT1B Clinical trial target unknown 10.61 TTD , DGIDB choline salicylate small molecule Exanthema[MeSHID:D005076],Teething syndrome[MeSHID:D014078],Oral Ulcer[MeSHID:D019226],Pain[MeSHID:D010146],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,nutraceutical choline-phosphate cytidylyltransferase b PCYT1B NA product of NA drugbank choline small molecule NA approved,nutraceutical choline-phosphate cytidylyltransferase b PCYT1B NA product of NA drugbank ct-2584 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 cholinephosphate cytidylyltransferase PCYT1B Clinical trial target unknown 31.83 TTD , DGIDB cholesterol NA NA investigative cholinephosphate cytidylyltransferase PCYT1B Clinical trial target unknown NA TTD pmid30107136-compound-example16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB aunp-12 NA NA preclinical programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB cemiplimab biotech Radiation[MeSHID:D011827],Cells[MeSHID:D002477],Carcinoma[MeSHID:D002277],Cessation of life[MeSHID:D003643],Operative Surgical Procedures[MeSHID:D013514],Squamous cell carcinoma[MeSHID:D002294],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational programmed cell death protein 1 PDCD1 Successful target inhibitor,antibody 9.09 TTD , drugbank , DGIDB pmid30247903-compound-general structure13 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD medi0680 biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 programmed cell death protein 1 PDCD1 Successful target inhibitor,antibody NA TTD , drugbank , DGIDB pmid30247903-compound-general structure25 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD prolgolimab biotech NA experimental programmed cell death protein 1 PDCD1 NA antibody NA drugbank adpt01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD apl-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD 1,2,4-oxadiazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB cbt-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Color Blindness, Blue[MeSHID:D003117] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB xmab20717 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],melanoma[MeSHID:D008545] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD nivolumab biotech melanoma[MeSHID:D008545],Renal Cell Carcinoma[MeSHID:D002292],Microsatellite Instability[MeSHID:D053842],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Squamous cell carcinoma[MeSHID:D002294],Mismatch Repair[MeSHID:D053843],Liver carcinoma[MeSHID:D006528],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Adenocarcinoma Of Esophagus[MeSHID:C562730],Carcinoma, Transitional Cell[MeSHID:D002295],Hodgkin Disease[MeSHID:D006689],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved programmed cell death protein 1 PDCD1 Successful target inhibitor,antibody 2.12 TTD , drugbank , DGIDB cyclic compound 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB pmid30247903-compound-general structure24 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD lzm009 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB tislelizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Liver carcinoma[MeSHID:D006528] investigational,approved programmed cell death protein 1 PDCD1 Successful target antagonist,inhibitor 9.09 TTD , drugbank , DGIDB xmab23104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD bi-754091 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB sym021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown 4.55 TTD , DGIDB nivolumab biotech melanoma[MeSHID:D008545],Renal Cell Carcinoma[MeSHID:D002292],Microsatellite Instability[MeSHID:D053842],Stomach[MeSHID:D013270],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Squamous cell carcinoma[MeSHID:D002294],Mismatch Repair[MeSHID:D053843],Liver carcinoma[MeSHID:D006528],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Adenocarcinoma Of Esophagus[MeSHID:C562730],Carcinoma, Transitional Cell[MeSHID:D002295],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant mesothelioma[MeSHID:C562839],Adenocarcinoma[MeSHID:D000230],Triple Negative Breast Neoplasms[MeSHID:D064726],Malignant neoplasm of ovary[MeSHID:D010051],Esophageal Neoplasms[MeSHID:D004938],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant neoplasm of prostate[MeSHID:D011471],Lymphoma, Follicular[MeSHID:D008224],Myeloid Leukemia, Chronic[MeSHID:D015464],Pancreatic carcinoma[MeSHID:C562463],Pleura[MeSHID:D010994],Glioblastoma[MeSHID:D005909],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of pancreas[MeSHID:D010190],Lymphoma[MeSHID:D008223],Recurrence (disease attribute)[MeSHID:D012008] approved programmed cell death protein 1 PDCD1 Successful target inhibitor,antibody 2.12 TTD , drugbank , DGIDB jnj 63723283 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant neoplasm of prostate[MeSHID:D011471],Ulcerative Colitis[MeSHID:D003093],Malignant Neoplasms[MeSHID:D009369] phase 2 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB dostarlimab biotech Mismatch Repair[MeSHID:D053843],Endometrial Carcinoma[MeSHID:D016889],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved,investigational programmed cell death protein 1 PDCD1 Successful target binder,antibody NA TTD , drugbank mgd013 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Liver carcinoma[MeSHID:D006528],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB pdr001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Squamous cell carcinoma of esophagus[MeSHID:C562729],Lymphoma[MeSHID:D008223],melanoma[MeSHID:D008545],Carcinoma, Neuroendocrine[MeSHID:D018278],Malignant Neoplasms[MeSHID:D009369] phase 3 programmed cell death protein 1 PDCD1 Successful target unknown 9.09 TTD , DGIDB tislelizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Liver carcinoma[MeSHID:D006528] investigational,approved programmed cell death protein 1 PDCD1 Successful target antagonist,inhibitor,antibody 9.09 TTD , drugbank , DGIDB pmid30247903-compound-general structure23 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD pmid30247903-compound-general structure16 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD mgd019 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD medi5752 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD incshr1210 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Squamous cell carcinoma of esophagus[MeSHID:C562729],Bronchioloalveolar Adenocarcinoma[MeSHID:D002282] phase 3 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB pmid30247903-compound-general structure22 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD tsr-042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown 4.55 TTD , DGIDB bgb-a317 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Squamous cell carcinoma[MeSHID:D002294],Liver carcinoma[MeSHID:D006528] phase 3 programmed cell death protein 1 PDCD1 Successful target unknown 9.09 TTD , DGIDB spartalizumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] investigational,phase 3 programmed cell death protein 1 PDCD1 Successful target inhibitor,antibody 9.09 TTD , drugbank , DGIDB cetrelimab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD ibi-308 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bronchioloalveolar Adenocarcinoma[MeSHID:D002282] phase 3 programmed cell death protein 1 PDCD1 Successful target unknown 4.55 TTD , DGIDB aunp-12 NA NA preclinical programmed cell death protein 1 PDCD1 Successful target inhibitor NA TTD , DGIDB syn125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cystadenocarcinoma, Serous[MeSHID:D018284],Uterus[MeSHID:D014599] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD 1,3,4-oxadiazole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB pmid30247903-compound-general structure20 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD mk-3475 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved programmed cell death protein 1 PDCD1 Successful target unknown 1.03 TTD , DGIDB toripalimab biotech NA investigational programmed cell death protein 1 PDCD1 NA inhibitor,antibody NA drugbank 609a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD sasanlimab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Muscle[MeSHID:D009132],Malignant neoplasm of muscle[MeSHID:D019042],Urinary Bladder[MeSHID:D001743] phase 3 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD mga012 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Merkel cell carcinoma[MeSHID:D015266],Malignant Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of penis[MeSHID:D010412] phase 3 programmed cell death protein 1 PDCD1 Successful target unknown 4.55 TTD , DGIDB pembrolizumab biotech Triple Negative Breast Neoplasms[MeSHID:D064726],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Carcinoma[MeSHID:D002277],Squamous Epithelial Cells[MeSHID:D004847],Urinary Bladder[MeSHID:D001743],Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of urinary bladder[MeSHID:D001749],Operative Surgical Procedures[MeSHID:D013514],Muscle[MeSHID:D009132],Disease Progression[MeSHID:D018450],Recurrence (disease attribute)[MeSHID:D012008],Merkel cell carcinoma[MeSHID:D015266],Malignant neoplasm of muscle[MeSHID:D019042],Stomach[MeSHID:D013270],Microsatellite Instability[MeSHID:D053842],Neoplasm Metastasis[MeSHID:D009362],Mismatch Repair[MeSHID:D053843],cervical cancer[MeSHID:D002583],Mutation[MeSHID:D009154],Carcinoma in Situ[MeSHID:D002278],B-Cell Lymphomas[MeSHID:D016393],Squamous cell carcinoma[MeSHID:D002294],Endometrial Carcinoma[MeSHID:D016889],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Liver carcinoma[MeSHID:D006528],Disease[MeSHID:D004194],Adenocarcinoma[MeSHID:D000230],Cancer of Head and Neck[MeSHID:D006258],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of stomach[MeSHID:D013274],Unmarried[MeSHID:D012847],Esophageal Neoplasms[MeSHID:D004938],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471],Small cell carcinoma of lung[MeSHID:D055752],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943] approved programmed cell death protein 1 PDCD1 Successful target inhibitor,antibody 1.03 TTD , drugbank , DGIDB jtx-4014 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD pmid30107136-compound-example15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB ro7121661 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Squamous cell carcinoma of esophagus[MeSHID:C562729] phase 2 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD rg6139 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD retifanlimab biotech NA investigational programmed cell death protein 1 PDCD1 NA inhibitor,antibody NA drugbank 1,2,4-oxadiazole derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB sintilimab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689] investigational,approved programmed cell death protein 1 PDCD1 Successful target inhibitor,antibody NA TTD , drugbank camrelizumab biotech Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational programmed cell death protein 1 PDCD1 NA inhibitor,antibody NA drugbank pmid30247903-compound-general structure17 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD ct-011 biotech Neoplasms[MeSHID:D009369] investigational programmed cell death protein 1 PDCD1 NA unknown 6.82 drugbank , DGIDB pf-06801591 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown 4.55 TTD , DGIDB si-b003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD rg6279 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD amg 404 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD cdx-527 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD pmid30247903-compound-general structure14 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD 1,3,4-oxadiazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB amp-224 biotech Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,phase 1 programmed cell death protein 1 PDCD1 Successful target inhibitor,antibody 4.55 TTD , drugbank , DGIDB cyclic compound 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB cyclic compound 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatitis[MeSHID:D006505],HIV Infections[MeSHID:D015658],Malignant Neoplasms[MeSHID:D009369],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141] patented programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB gsk2661380 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB ct-011 biotech Neoplasms[MeSHID:D009369] investigational programmed cell death protein 1 PDCD1 NA antibody 6.82 drugbank , DGIDB ibi318 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD pmid30247903-compound-general structure15 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD m7824 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 programmed cell death protein 1 PDCD1 Successful target unknown 1.52 TTD , DGIDB ak104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],cervical cancer[MeSHID:D002583] phase 2 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD cc-90006 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD , DGIDB agen2034 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],cervical cancer[MeSHID:D002583] phase 2 programmed cell death protein 1 PDCD1 Successful target unknown 4.55 TTD , DGIDB pmid30247903-compound-general structure21 NA NA investigative programmed cell death protein 1 PDCD1 Successful target unknown NA TTD bi 754091 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 1 PDCD1 Successful target unknown NA TTD mk-3475 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved programmed cell death protein 1 PDCD1 Successful target antibody 1.03 TTD , DGIDB rhigm12b7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 programmed cell death protein 2 PDCD2 Clinical trial target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational programmed cell death protein 6 PDCD6 NA unknown NA drugbank calcium citrate small molecule NA approved,investigational programmed cell death protein 6 PDCD6 NA agonist NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational programmed cell death protein 6 PDCD6 NA unknown NA drugbank calcium phosphate small molecule NA approved programmed cell death protein 6 PDCD6 NA agonist NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical programmed cell death protein 6 PDCD6 NA unknown NA drugbank calcium phosphate dihydrate small molecule NA approved programmed cell death protein 6 PDCD6 NA unknown NA drugbank 4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1h-imidazole small molecule NA experimental camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA unknown NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE10A NA inhibitor NA drugbank imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB triazolo-pyridine derivative 2 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB tak-063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 phosphodiesterase 10a PDE10A Clinical trial target unknown 25.46 TTD , DGIDB imidazo[5,1-c][1,2,4]benzotriazine derivative 4 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB triazolo-pyridine derivative 5 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB pq-10 small molecule NA experimental camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA unknown NA drugbank 1,2,4-triazole [4,3-a]quinoxaline derivative 1 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE10A NA inhibitor NA drugbank 6,7-dimethoxy-4-[(3r)-3-(2-naphthyloxy)pyrrolidin-1-yl]quinazoline small molecule NA experimental camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA unknown NA drugbank imidazo[5,1-c][1,2,4]benzotriazine derivative 2 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB oms824 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816] phase 2 phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB tofisopam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] experimental camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA inhibitor NA drugbank pf-02545920 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Huntington Disease[MeSHID:D006816] phase 2 phosphodiesterase 10a PDE10A Clinical trial target unknown 38.19 TTD , DGIDB lu af11167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD mardepodect small molecule NA investigational camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA inhibitor 38.19 drugbank , DGIDB pmid27321640-compound-59 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB rg7203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB 1,2,4-triazole [4,3-a]quinoxaline derivative 3 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB amg 579 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB pbf-999 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Huntington Disease[MeSHID:D006816] phase 1 phosphodiesterase 10a PDE10A Clinical trial target inhibitor 6.37 TTD , DGIDB triflusal small molecule Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Cerebrovascular accident[MeSHID:D020521] approved,investigational camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA antagonist NA drugbank tofisopam NA Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] phase 2 phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD pmid27321640-compound-58 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB 1,2,4-triazole [4,3-a]quinoxaline derivative 2 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB dipyridamole small molecule Heart Valves[MeSHID:D006351],Angina Pectoris[MeSHID:D000787],Postoperative Complications[MeSHID:D011183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA inhibitor 1.47 drugbank , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB 2-({4-[4-(pyridin-4-ylmethyl)-1h-pyrazol-3-yl]phenoxy}methyl)quinoline small molecule NA experimental camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA unknown NA drugbank imidazo[5,1-c][1,2,4]benzotriazine derivative 3 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB frm-6308 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1b phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB triazolo-pyridine derivative 6 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB 2-{[4-(4-pyridin-4-yl-1h-pyrazol-3-yl)phenoxy]methyl}quinoline small molecule NA experimental camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA unknown NA drugbank imidazo[5,1-c][1,2,4]benzotriazine derivative 1 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB triazolo-pyridine derivative 3 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB papaverine small molecule Vascular constriction (function)[MeSHID:D014661],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10a PDE10A NA inhibitor NA drugbank triazolo-pyridine derivative 4 NA NA patented phosphodiesterase 10a PDE10A Clinical trial target unknown NA TTD , DGIDB tadalafil small molecule Benign prostatic hypertrophy[MeSHID:D011470],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dual 3',5'-cyclic-amp and -gmp phosphodiesterase 11a PDE11A NA inhibitor 47.74 drugbank , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE11A NA inhibitor NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE11A NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE1A NA inhibitor NA drugbank nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1a PDE1A NA inhibitor NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE1A NA inhibitor NA drugbank bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1a PDE1A NA inhibitor NA drugbank felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1a PDE1A NA inhibitor NA drugbank us10092575, example 141 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB us9073936, 3 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB ac1mozol NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB ac1lddoq NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB ic-041 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD nicardipine small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1b PDE1B NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE1B NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved phosphodiesterase enzymes PDE1B NA inhibitor NA drugbank us10034861, example 1 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB sch51866 NA NA investigative phosphodiesterase 1b PDE1B Patented-recorded target inhibitor NA TTD , DGIDB s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1b PDE1B NA unknown NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE1B NA inhibitor NA drugbank us10034861, example 165 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB us10034861, example 164 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1b PDE1B NA inhibitor NA drugbank bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1b PDE1B NA inhibitor NA drugbank us10092575, example 101 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB us9073936, 1 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB us10092575, example 158 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB us9073936, 2 NA NA patented phosphodiesterase 1b PDE1B Patented-recorded target unknown NA TTD , DGIDB trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE1C NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE1C NA inhibitor NA drugbank cyclic gmp small molecule NA experimental cgmp-dependent 3',5'-cyclic phosphodiesterase PDE2A NA activator NA drugbank , DGIDB imidazo[5,1-c][1,2,4]benzotriazine derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB tofisopam NA Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] phase 2 phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE2A NA inhibitor NA drugbank imidazo[5,1-c][1,2,4]benzotriazine derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo triazine derivative 5 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c][1,2,4]benzotriazine derivative 4 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB triazolo-pyridine derivative 5 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazotriazinone derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pmid27321640-compound-74 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pmid27321640-compound-75 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB cp-461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 phosphodiesterase 2a PDE2A Clinical trial target unknown 12.73 TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB bay-60-7550 NA NA investigative phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB isobutylmethylxanthine NA NA investigative phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD imidazo triazine derivative 4 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo triazine derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB (2r,3s)-3-(6-amino-purin-9-yl)-nonan-2-ol NA NA investigative phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD pyrazolo[3,4-d]pyrimidine derivative 4 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB triazolo-pyridine derivative 4 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB doxofylline small molecule Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Muscle Spasticity[MeSHID:D009128],Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchial Diseases[MeSHID:D001982],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental phosphodiesterase 2a, cgmp-stimulated PDE2A NA inhibitor NA drugbank pmid27321640-compound-59 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pyrazolo[3,4-d]pyrimidine derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pmid27321640-compound-58 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB oxindole derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 3-isobutyl-1-methyl-7h-xanthine small molecule NA experimental cgmp-dependent 3',5'-cyclic phosphodiesterase PDE2A NA unknown NA drugbank 2-morpholin-4-yl-8-phenylethynyl-chromen-4-one NA NA investigative phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD pyrido[2,3-d]pyrimidine-2,4-diamine derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1,2,4-triazole [4,3-a]quinoxaline derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB nd7001 small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] investigational cgmp-dependent 3',5'-cyclic phosphodiesterase PDE2A NA unknown NA drugbank , DGIDB imidazo triazine derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB triazolo-pyridine derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pyrazolo[3,4-d]pyrimidine derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c][1,2,4]benzotriazine derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1,2,4-triazole [4,3-a]quinoxaline derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD nd7001 small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] investigational phosphodiesterase 2a, cgmp-stimulated PDE2A NA unknown NA drugbank , DGIDB triazolo-pyridine derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB tofisopam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] experimental cgmp-dependent 3',5'-cyclic phosphodiesterase PDE2A NA inhibitor NA drugbank pyrazolo[3,4-d]pyrimidine derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB benzodiazepine derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pmid27321640-compound-76 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo triazine derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD 1,2,4-triazole [4,3-a]quinoxaline derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB purin-6-one derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE2A NA inhibitor NA drugbank triazolo-phthalazine derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 1 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB cyclic guanosine monophosphate NA NA investigative phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD nd7001 NA Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 1 phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB triazolo-pyridine derivative 6 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB exisulind small molecule Disease[MeSHID:D004194],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Esophagus[MeSHID:D004947],Colonic Polyps[MeSHID:D003111],Barrett Esophagus[MeSHID:D001471],Esophageal Diseases[MeSHID:D004935],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cgmp-dependent 3',5'-cyclic phosphodiesterase PDE2A NA unknown NA drugbank ehna NA NA investigative phosphodiesterase 2a PDE2A Clinical trial target inhibitor 2.55 TTD , DGIDB imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 NA NA patented phosphodiesterase 2a PDE2A Clinical trial target unknown NA TTD , DGIDB 8-chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD 7-iodo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD 8-methyl-2-morpholino-7-phenyl-4h-chromen-4-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD kurarinol NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD anagrelide small molecule Thrombocytosis[MeSHID:D013922],Hemorrhage[MeSHID:D006470],Neoplasm Metastasis[MeSHID:D009362],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocythemia, Essential[MeSHID:D013920] approved cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 19.37 drugbank , DGIDB oxtriphylline small molecule Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 1.38 drugbank , DGIDB aminophylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 1.11 drugbank , DGIDB enoximone small molecule Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 4.15 drugbank , DGIDB 8-methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD aminophylline NA Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 3a PDE3A Successful target inhibitor 1.11 TTD , DGIDB cilostazol NA Pain[MeSHID:D010146],Intermittent Claudication[MeSHID:D007383],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 3a PDE3A Successful target unknown 2.13 TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE3A NA inhibitor NA drugbank 1,5-dihydro-imidazo[2,1-b]quinazolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD 1,3-dihydro-naphtho[2,3-d]imidazol-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD milrinone small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Electrocardiogram[MeSHID:D004562],Heart Ventricle[MeSHID:D006352],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 5.53 drugbank , DGIDB enoximone NA Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 3a PDE3A Successful target inhibitor 4.15 TTD , DGIDB vesnarinone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approved phosphodiesterase 3a PDE3A Successful target unknown 0.4 TTD , DGIDB 6-(2-imidazol-1-yl-vinyl)-1h-quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD ibudilast small molecule Asthma[MeSHID:D001249],Cerebrovascular Disorders[MeSHID:D002561],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Angiolymphoid hyperplasia[MeSHID:D005871],Opiate Addiction[MeSHID:D009293],Amyotrophic Lateral Sclerosis[MeSHID:D000690],emotional dependency[MeSHID:D003858] investigational cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 0.55 drugbank , DGIDB 2-morpholin-4-yl-8-phenylethynyl-chromen-4-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 0.69 drugbank , DGIDB 7-fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD amrinone small molecule Congestive heart failure[MeSHID:D006333] approved cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 1.08 drugbank , DGIDB cilostazol NA Pain[MeSHID:D010146],Intermittent Claudication[MeSHID:D007383],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 3a PDE3A Successful target inhibitor 2.13 TTD , DGIDB emd-53998 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] discontinued in phase 1 phosphodiesterase 3a PDE3A Successful target unknown NA TTD benzoylenurea NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD 2-morpholino-7-(2-phenylethynyl)-4h-chromen-4-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD sophoflavescenol NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD 7-methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD kuraidin NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD tofisopam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] experimental cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor NA drugbank 8-methyl-2-morpholino-7-phenoxy-4h-chromen-4-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD 1,3-dihydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD bemoradan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 phosphodiesterase 3a PDE3A Successful target unknown 2.77 TTD , DGIDB trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE3A NA inhibitor NA drugbank levosimendan small molecule Heart Diseases[MeSHID:D006331],Congestive heart failure[MeSHID:D006333],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976],Cardiac Output[MeSHID:D002302],Heart failure[MeSHID:D006333],Syndrome[MeSHID:D013577] approved,investigational cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor NA drugbank cilostazol small molecule Pain[MeSHID:D010146],Intermittent Claudication[MeSHID:D007383],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cgmp-inhibited 3',5'-cyclic phosphodiesterase a PDE3A NA inhibitor 2.13 drugbank , DGIDB 1,3,9,9a-tetrahydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD ci-930 NA NA discontinued in phase 2 phosphodiesterase 3a PDE3A Successful target unknown NA TTD 7-ethoxy-1,3-dihydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD enoximone NA Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 3a PDE3A Successful target unknown 4.15 TTD , DGIDB 5-methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD isobutylmethylxanthine NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD anagrelide NA Thrombocytosis[MeSHID:D013922],Hemorrhage[MeSHID:D006470],Neoplasm Metastasis[MeSHID:D009362],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocythemia, Essential[MeSHID:D013920] approved phosphodiesterase 3a PDE3A Successful target unknown 19.37 TTD , DGIDB 2-morpholino-7-phenyl-4h-chromen-4-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD 6-imidazol-1-yl-3,4-dihydro-1h-quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD aminophylline NA Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 3a PDE3A Successful target unknown 1.11 TTD , DGIDB 7-chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD tetrahydrobenximidazole NA NA investigative phosphodiesterase 3a PDE3A Successful target unknown NA TTD anagrelide NA Thrombocytosis[MeSHID:D013922],Hemorrhage[MeSHID:D006470],Neoplasm Metastasis[MeSHID:D009362],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocythemia, Essential[MeSHID:D013920] approved phosphodiesterase 3a PDE3A Successful target inhibitor 19.37 TTD , DGIDB trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE3B NA inhibitor NA drugbank 6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2h)-one small molecule NA experimental cgmp-inhibited 3',5'-cyclic phosphodiesterase b PDE3B NA unknown NA drugbank hg9a-9, nonanoyl-n-hydroxyethylglucamide small molecule NA experimental cgmp-inhibited 3',5'-cyclic phosphodiesterase b PDE3B NA unknown NA drugbank 3-isobutyl-1-methyl-7h-xanthine small molecule NA experimental cgmp-inhibited 3',5'-cyclic phosphodiesterase b PDE3B NA unknown NA drugbank us8741907-compound-3 NA NA patented phosphodiesterase 3b PDE3B Patented-recorded target unknown NA TTD , DGIDB amrinone small molecule Congestive heart failure[MeSHID:D006333] approved cgmp-inhibited 3',5'-cyclic phosphodiesterase b PDE3B NA inhibitor NA drugbank us9388139, 12 NA NA patented phosphodiesterase 3b PDE3B Patented-recorded target unknown NA TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE3B NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved phosphodiesterase enzymes PDE3B NA inhibitor NA drugbank apremilast small molecule Dental Plaque[MeSHID:D003773],Behcet Syndrome[MeSHID:D001528],Oral Ulcer[MeSHID:D019226],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational phosphodiesterase isozyme 4 PDE4 NA antagonist NA drugbank awd-12-281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD , DGIDB nis-62949 NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD sophoflavescenol NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD al-59640 NA Xerophthalmia[MeSHID:D014985],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD cc-1088 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 0.51 TTD , DGIDB dyphylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor 2.64 drugbank , DGIDB roflumilast small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Bronchial Spasm[MeSHID:D001986],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Dermatitis, Atopic[MeSHID:D003876],Asthma[MeSHID:D001249] approved camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor 2.05 drugbank , DGIDB tas-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD 6-azido-8-(3-iodo-phenyl)-quinoline NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD piclamilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 1.37 TTD , DGIDB ibudilast small molecule Asthma[MeSHID:D001249],Cerebrovascular Disorders[MeSHID:D002561],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Angiolymphoid hyperplasia[MeSHID:D005871],Opiate Addiction[MeSHID:D009293],Amyotrophic Lateral Sclerosis[MeSHID:D000690],emotional dependency[MeSHID:D003858] investigational camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor 1.03 drugbank , DGIDB enprofylline NA Disease Management[MeSHID:D019468],Anemia, Sickle Cell[MeSHID:D000755],Peripheral Vascular Diseases[MeSHID:D016491],Asthma[MeSHID:D001249],Cerebrovascular Insufficiency[MeSHID:D002561],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 4a PDE4A Successful target unknown 9.24 TTD , DGIDB benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD sotb07 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 phosphodiesterase 4a PDE4A Successful target unknown NA TTD , DGIDB ch-3697 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cyclic neutropenia[MeSHID:C536227],Asthma[MeSHID:D001249] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD nitraquazone NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD denbufylline NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 phosphodiesterase 4a PDE4A Successful target unknown 0.68 TTD , DGIDB sch-351591 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 phosphodiesterase 4a PDE4A Successful target unknown NA TTD chf-5480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Congestive heart failure[MeSHID:D006333] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD gpd-1116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD , DGIDB ci-1044 NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD oxtriphylline small molecule Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Bronchitis[MeSHID:D001991],Pulmonary Emphysema[MeSHID:D011656],Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] approved camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor 1.44 drugbank , DGIDB ox-914 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 0.68 TTD , DGIDB mk-0873 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 phosphodiesterase 4a PDE4A Successful target inhibitor 1.37 TTD , DGIDB ta-7906 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD , DGIDB gsk-356278 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816] phase 1 phosphodiesterase 4a PDE4A Successful target unknown 0.68 TTD , DGIDB (2,5-diphenyl-furan-3-yl)-phenyl-methanone NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD 2,5-bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD 8-(3-azido-phenyl)-6-pyridin-4-ylmethyl-quinoline NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD cilomilast NA Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Bronchitis[MeSHID:D001991] discontinued in phase 3 phosphodiesterase 4a PDE4A Successful target unknown NA TTD las-37779 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD ocid-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD iloprost small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inducer NA drugbank cd-160130 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE4A NA inhibitor NA drugbank ym-976 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 phosphodiesterase 4a PDE4A Successful target unknown NA TTD kurarinol NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD 1-methyl-3-propyl-3,7-dihydro-purine-2,6-dione NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD 2,5-bis-(3,4-dimethoxy-phenyl)-furan NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD oglemilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 2.05 TTD , DGIDB 8-(3-azido-phenyl)-6-iodo-quinoline NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD zl-n-91 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pneumonia[MeSHID:D011014] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD amrinone small molecule Congestive heart failure[MeSHID:D006333] approved camp-specific 3',5'-cyclic phosphodiesterase 4 (pde4) PDE4A NA inhibitor NA drugbank kuraidin NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD kw-4490 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD tofisopam small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] experimental camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor NA drugbank isobutylmethylxanthine NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD (s)-rolipram NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD kf-66490 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD daxalipram NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] discontinued in phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD tofimilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 0.68 TTD , DGIDB l-869298 NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD an-2898 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD , DGIDB theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor 0.68 drugbank , DGIDB propentofylline small molecule NA investigational camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA unknown NA drugbank benzyl-(2-phenyl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD revamilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4a PDE4A Successful target inhibitor 1.37 TTD , DGIDB (4r)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA unknown NA drugbank benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD v-11294a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD 6-imidazol-1-ylmethyl-8-phenyl-quinoline NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD crisaborole small molecule Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor 1.37 drugbank , DGIDB 8-(3-nitro-phenyl)-6-phenyl-[1,7]naphthyridine NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD d-4418 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410] discontinued in phase 1 phosphodiesterase 4a PDE4A Successful target unknown NA TTD rolipram NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown 0.68 TTD , DGIDB enprofylline small molecule Disease Management[MeSHID:D019468],Anemia, Sickle Cell[MeSHID:D000755],Peripheral Vascular Diseases[MeSHID:D016491],Asthma[MeSHID:D001249],Cerebrovascular Insufficiency[MeSHID:D002561],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor 9.24 drugbank , DGIDB ave-8112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 phosphodiesterase 4a PDE4A Successful target unknown NA TTD , DGIDB ci-1018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD ucb-101333-3 NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA unknown NA drugbank dyphylline NA Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 4a PDE4A Successful target inhibitor 2.64 TTD , DGIDB l-791943 NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD lirimilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 1.37 TTD , DGIDB ronomilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 phosphodiesterase 4a PDE4A Successful target unknown NA TTD , DGIDB dipyridamole small molecule Heart Valves[MeSHID:D006351],Angina Pectoris[MeSHID:D000787],Postoperative Complications[MeSHID:D011183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor 0.16 drugbank , DGIDB 8-(3-nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD rs-25344 NA NA investigative phosphodiesterase 4a PDE4A Successful target inhibitor NA TTD , DGIDB rs-14491 NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD ht-0712 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 0.68 TTD , DGIDB revamilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 1.37 TTD , DGIDB cdp840 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 phosphodiesterase 4a PDE4A Successful target inhibitor 0.51 TTD , DGIDB l-454560 NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD gsk256066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE4A NA inhibitor NA drugbank rolipram NA NA investigative phosphodiesterase 4a PDE4A Successful target inhibitor 0.68 TTD , DGIDB tofisopam NA Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] phase 2 phosphodiesterase 4a PDE4A Successful target unknown NA TTD mk-0873 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 phosphodiesterase 4a PDE4A Successful target unknown 1.37 TTD , DGIDB mem-1414 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 1 phosphodiesterase 4a PDE4A Successful target unknown NA TTD , DGIDB (r)-rolipram NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD dyphylline NA Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 4a PDE4A Successful target unknown 2.64 TTD , DGIDB 1-butyl-3-methyl-3,7-dihydro-purine-2,6-dione NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD asp-3258 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD drotaverine small molecule Cholecystitis[MeSHID:D002764],Smooth muscle (tissue)[MeSHID:D009130],Gall Bladder Diseases[MeSHID:D005705],Spasm[MeSHID:D013035],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA inhibitor NA drugbank piclamilast small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] experimental camp-specific 3',5'-cyclic phosphodiesterase 4a PDE4A NA unknown 1.37 drugbank , DGIDB 4-(2,5-diphenyl-furan-3-yl)-morpholine NA NA investigative phosphodiesterase 4a PDE4A Successful target unknown NA TTD denbufylline NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.64 TTD , DGIDB dyphylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 1.93 drugbank , DGIDB asp-3258 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD iloprost small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inducer NA drugbank cilomilast small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Bronchitis[MeSHID:D001991] investigational camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor NA drugbank d-4418 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410] discontinued in phase 1 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD 8-bromo-adenosine-5'-monophosphate NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD benzyl-(2-phenyl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD adenosine phosphate small molecule NA approved,investigational,nutraceutical camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA product of NA drugbank rs-25344 NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target inhibitor NA TTD , DGIDB (r)-rolipram NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 0.32 drugbank , DGIDB las-37779 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD rolipram NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target inhibitor 1.61 TTD , DGIDB kuraidin NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD rs-14491 NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE4B NA inhibitor 0.32 drugbank , DGIDB ym-976 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD sotb07 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD , DGIDB 1-ethyl-n-(phenylmethyl)-4-(tetrahydro-2h-pyran-4-ylamino)-1h-pyrazolo[3,4-b]pyridine-5-carboxamide small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown NA drugbank gpd-1116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD , DGIDB s,s-(2-hydroxyethyl)thiocysteine NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD (r)-rolipram small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor NA drugbank (s)-rolipram small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE4B NA inhibitor NA drugbank tas-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD oglemilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 1.93 TTD , DGIDB ibudilast small molecule Asthma[MeSHID:D001249],Cerebrovascular Disorders[MeSHID:D002561],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Angiolymphoid hyperplasia[MeSHID:D005871],Opiate Addiction[MeSHID:D009293],Amyotrophic Lateral Sclerosis[MeSHID:D000690],emotional dependency[MeSHID:D003858] investigational camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 0.58 drugbank , DGIDB 8-bromo-adenosine-5'-monophosphate small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown NA drugbank 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown NA drugbank benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD lirimilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.64 TTD , DGIDB gsk-356278 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816] phase 1 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.64 TTD , DGIDB cdp840 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 phosphodiesterase 4b PDE4B Clinical trial target inhibitor 0.48 TTD , DGIDB rolipram small molecule NA investigational camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 1.61 drugbank , DGIDB nitraquazone NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD ch-3697 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cyclic neutropenia[MeSHID:C536227],Asthma[MeSHID:D001249] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD roflumilast small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Bronchial Spasm[MeSHID:D001986],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Dermatitis, Atopic[MeSHID:D003876],Asthma[MeSHID:D001249] approved camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 1.93 drugbank , DGIDB rolipram small molecule NA investigational camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown 1.61 drugbank , DGIDB daxalipram NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] discontinued in phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD ci-1044 NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD cc-1088 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.48 TTD , DGIDB ucb-101333-3 NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD mem-1414 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 1 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD , DGIDB rolipram NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown 1.61 TTD , DGIDB crisaborole small molecule Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 1.29 drugbank , DGIDB kw-4490 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD (s)-rolipram NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD sch-351591 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD kf-66490 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown NA drugbank al-59640 NA Xerophthalmia[MeSHID:D014985],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD kurarinol NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 0.32 drugbank , DGIDB revamilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.64 TTD , DGIDB cd-160130 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD ocid-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD ox-914 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.64 TTD , DGIDB ave-8112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD , DGIDB tofimilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.64 TTD , DGIDB 3-(2-bromophenyl)-2-thioxo-(1h )-quinazolin-4-one NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD 1-(2-chlorophenyl)-3,5-dimethyl-1h-pyrazole-4-carboxylic acid ethyl ester small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown NA drugbank s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown NA drugbank filaminast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD piclamilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 1.93 TTD , DGIDB ta-7906 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD , DGIDB papaverine small molecule Vascular constriction (function)[MeSHID:D014661],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 0.77 drugbank , DGIDB awd-12-281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD , DGIDB mk-0873 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.64 TTD , DGIDB ronomilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD , DGIDB filaminast small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor NA drugbank ht-0712 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown 0.64 TTD , DGIDB l-869298 NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD isobutylmethylxanthine NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD amrinone small molecule Congestive heart failure[MeSHID:D006333] approved camp-specific 3',5'-cyclic phosphodiesterase 4 (pde4) PDE4B NA inhibitor 0.43 drugbank , DGIDB v-11294a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD enprofylline small molecule Disease Management[MeSHID:D019468],Anemia, Sickle Cell[MeSHID:D000755],Peripheral Vascular Diseases[MeSHID:D016491],Asthma[MeSHID:D001249],Cerebrovascular Insufficiency[MeSHID:D002561],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor 5.79 drugbank , DGIDB piclamilast small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown 1.93 drugbank , DGIDB chf-5480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Congestive heart failure[MeSHID:D006333] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD zl-n-91 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pneumonia[MeSHID:D011014] investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD theobromine small molecule Disease Management[MeSHID:D019468],Hypotension, Orthostatic[MeSHID:D007024],Fatigue[MeSHID:D005221],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA inhibitor NA drugbank daxalipram small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] experimental camp-specific 3',5'-cyclic phosphodiesterase 4b PDE4B NA unknown NA drugbank ci-1018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD an-2898 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD , DGIDB l-454560 NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD 8-(3-nitro-phenyl)-6-phenyl-[1,7]naphthyridine NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD sophoflavescenol NA NA investigative phosphodiesterase 4b PDE4B Clinical trial target unknown NA TTD piclamilast small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] experimental camp-specific 3',5'-cyclic phosphodiesterase 4c PDE4C NA unknown NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE4C NA inhibitor NA drugbank crisaborole small molecule Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4c PDE4C NA inhibitor 1.33 drugbank , DGIDB dyphylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved camp-specific 3',5'-cyclic phosphodiesterase 4c PDE4C NA inhibitor 3.98 drugbank , DGIDB iloprost small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4c PDE4C NA inducer NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE4C NA inhibitor NA drugbank roflumilast small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Bronchial Spasm[MeSHID:D001986],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Dermatitis, Atopic[MeSHID:D003876],Asthma[MeSHID:D001249] approved camp-specific 3',5'-cyclic phosphodiesterase 4c PDE4C NA inhibitor 1.99 drugbank , DGIDB ibudilast small molecule Asthma[MeSHID:D001249],Cerebrovascular Disorders[MeSHID:D002561],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Angiolymphoid hyperplasia[MeSHID:D005871],Opiate Addiction[MeSHID:D009293],Amyotrophic Lateral Sclerosis[MeSHID:D000690],emotional dependency[MeSHID:D003858] investigational camp-specific 3',5'-cyclic phosphodiesterase 4c PDE4C NA inhibitor 1.19 drugbank , DGIDB amrinone small molecule Congestive heart failure[MeSHID:D006333] approved camp-specific 3',5'-cyclic phosphodiesterase 4 (pde4) PDE4C NA inhibitor NA drugbank exisulind small molecule Disease[MeSHID:D004194],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Esophagus[MeSHID:D004947],Colonic Polyps[MeSHID:D003111],Barrett Esophagus[MeSHID:D001471],Esophageal Diseases[MeSHID:D004935],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational camp-specific 3',5'-cyclic phosphodiesterase 4c PDE4C NA unknown NA drugbank roflumilast small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Bronchitis, Chronic[MeSHID:D029481],Bronchial Spasm[MeSHID:D001986],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Dermatitis, Atopic[MeSHID:D003876],Asthma[MeSHID:D001249] approved camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA inhibitor 1.59 drugbank , DGIDB d-4418 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410] discontinued in phase 1 phosphodiesterase 4d PDE4D Successful target unknown NA TTD 1-(4-methoxyphenyl)-3,5-dimethyl-1h-pyrazole-4-carboxylic acid ethyl ester small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank sotb07 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 phosphodiesterase 4d PDE4D Successful target unknown NA TTD , DGIDB kw-4490 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD las-37779 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD crisaborole small molecule Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA inhibitor 0.71 drugbank , DGIDB ibudilast small molecule Asthma[MeSHID:D001249],Cerebrovascular Disorders[MeSHID:D002561],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Angiolymphoid hyperplasia[MeSHID:D005871],Opiate Addiction[MeSHID:D009293],Amyotrophic Lateral Sclerosis[MeSHID:D000690],emotional dependency[MeSHID:D003858] investigational camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA inhibitor NA drugbank exisulind small molecule Disease[MeSHID:D004194],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Esophagus[MeSHID:D004947],Colonic Polyps[MeSHID:D003111],Barrett Esophagus[MeSHID:D001471],Esophageal Diseases[MeSHID:D004935],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank isobutylmethylxanthine NA NA investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD awd-12-281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD , DGIDB ch-3697 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cyclic neutropenia[MeSHID:C536227],Asthma[MeSHID:D001249] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD cd-160130 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD chf-5480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424],Congestive heart failure[MeSHID:D006333] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD ci-1018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD piclamilast small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown 2.12 drugbank , DGIDB kf-66490 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD ocid-2987 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE4D NA inhibitor NA drugbank mk-0873 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 0.71 TTD , DGIDB rs-25344 NA NA investigative phosphodiesterase 4d PDE4D Successful target inhibitor NA TTD , DGIDB ym-976 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 phosphodiesterase 4d PDE4D Successful target unknown NA TTD 1-(4-aminophenyl)-3,5-dimethyl-1h-pyrazole-4-carboxylic acid ethyl ester small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank cdp840 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 phosphodiesterase 4d PDE4D Successful target inhibitor 0.53 TTD , DGIDB denbufylline NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 phosphodiesterase 4d PDE4D Successful target unknown 0.71 TTD , DGIDB 1-methyl-3-propyl-3,7-dihydro-purine-2,6-dione NA NA investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD zardaverine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Chronic Obstructive Airway Disease[MeSHID:D029424],Expiration, function[MeSHID:D045853] experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank sch-351591 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 phosphodiesterase 4d PDE4D Successful target unknown NA TTD zl-n-91 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pneumonia[MeSHID:D011014] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD dyphylline small molecule Bronchial Spasm[MeSHID:D001986],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA inhibitor 1.82 drugbank , DGIDB revamilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 0.71 TTD , DGIDB ta-7906 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD , DGIDB gpd-1116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD , DGIDB ronomilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 phosphodiesterase 4d PDE4D Successful target unknown NA TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved phosphodiesterase enzymes PDE4D NA inhibitor NA drugbank ucb-101333-3 NA NA investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE4D NA inhibitor NA drugbank rolipram small molecule NA investigational camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown 1.77 drugbank , DGIDB (r)-rolipram small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank iloprost small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA inducer NA drugbank cilomilast small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646],Bronchitis[MeSHID:D001991] investigational camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA inhibitor NA drugbank (4r)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank piclamilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 2.12 TTD , DGIDB 3,5-dimethyl-1h-pyrazole-4-carboxylic acid ethyl ester small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank l-454560 NA NA investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD v-11294a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD daxalipram NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] discontinued in phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD papaverine NA Vascular constriction (function)[MeSHID:D014661],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved phosphodiesterase 4d PDE4D Successful target unknown 0.14 TTD , DGIDB 1-butyl-3-methyl-3,7-dihydro-purine-2,6-dione NA NA investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD ave-8112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 phosphodiesterase 4d PDE4D Successful target unknown NA TTD , DGIDB 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank asp-3258 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD gsk-356278 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816] phase 1 phosphodiesterase 4d PDE4D Successful target unknown 0.71 TTD , DGIDB tofimilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 0.71 TTD , DGIDB bpn14770 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 4.24 TTD , DGIDB ox-914 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 0.71 TTD , DGIDB (s)-rolipram small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank l-869298 NA NA investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD adenosine phosphate small molecule NA approved,investigational,nutraceutical camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA product of NA drugbank tas-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD rolipram NA NA investigative phosphodiesterase 4d PDE4D Successful target inhibitor 1.77 TTD , DGIDB ht-0712 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 0.71 TTD , DGIDB 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank al-59640 NA Xerophthalmia[MeSHID:D014985],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative phosphodiesterase 4d PDE4D Successful target unknown NA TTD rolipram small molecule NA investigational camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA inhibitor 1.77 drugbank , DGIDB 3-isobutyl-1-methyl-7h-xanthine small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank 2-[3-(2-hydroxy-1,1-dihydroxymethyl-ethylamino)-propylamino]-2-hydroxymethyl-propane-1,3-diol small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank cc-1088 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 0.53 TTD , DGIDB mem-1414 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 1 phosphodiesterase 4d PDE4D Successful target unknown NA TTD , DGIDB oglemilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 1.41 TTD , DGIDB 3,5-dimethyl-1-phenyl-1h-pyrazole-4-carboxylic acid ethyl ester small molecule NA experimental camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank rolipram NA NA investigative phosphodiesterase 4d PDE4D Successful target unknown 1.77 TTD , DGIDB amrinone small molecule Congestive heart failure[MeSHID:D006333] approved camp-specific 3',5'-cyclic phosphodiesterase 4 (pde4) PDE4D NA inhibitor NA drugbank bpn14770 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase 4d PDE4D Successful target allosteric modulator 4.24 TTD , DGIDB an-2898 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 phosphodiesterase 4d PDE4D Successful target unknown NA TTD , DGIDB lirimilast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 phosphodiesterase 4d PDE4D Successful target unknown 0.71 TTD , DGIDB tetomilast small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigational camp-specific 3',5'-cyclic phosphodiesterase 4d PDE4D NA unknown NA drugbank rolipram NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown 0.44 TTD , DGIDB benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD kurarinol NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD uk-371800 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] phase 1 phosphodiesterase 5a PDE5A Successful target unknown 2.65 TTD , DGIDB papaverine NA Vascular constriction (function)[MeSHID:D014661],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Muscle Cramp[MeSHID:D009120] approved phosphodiesterase 5a PDE5A Successful target unknown 0.18 TTD , DGIDB sch51866 NA NA investigative phosphodiesterase 5a PDE5A Successful target inhibitor NA TTD , DGIDB avanafil NA Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 5a PDE5A Successful target inhibitor 10.61 TTD , DGIDB sildenafil small molecule Congenital Disorders[MeSHID:D009358],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Neoplasm Metastasis[MeSHID:D009362],Erectile dysfunction[MeSHID:D007172],Heart[MeSHID:D006321],Mental association[MeSHID:D001244],Lung[MeSHID:D008168],Connective Tissue Diseases[MeSHID:D003240],Hemodynamics[MeSHID:D006439],Heart Diseases[MeSHID:D006331],Pulmonary Hypertension[MeSHID:D006976],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA inhibitor 2.89 drugbank , DGIDB sophoflavescenol NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD dipyridamole small molecule Heart Valves[MeSHID:D006351],Angina Pectoris[MeSHID:D000787],Postoperative Complications[MeSHID:D011183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA inhibitor 0.46 drugbank , DGIDB 8-prenylquercetin NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD sophoraflavanone b NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD sch-57726 NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD guanosine-5'-monophosphate small molecule NA experimental cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA unknown NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE5A NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved phosphodiesterase enzymes PDE5A NA inhibitor NA drugbank icariin NA NA phase 3 phosphodiesterase 5a PDE5A Successful target unknown 2.65 TTD , DGIDB slx-2101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Raynaud Disease[MeSHID:D011928],Hypertensive disease[MeSHID:D006973],Erectile dysfunction[MeSHID:D007172] discontinued in phase 2 phosphodiesterase 5a PDE5A Successful target unknown NA TTD , DGIDB 7-(2-hydroxyethyl)-3-o-rhamnosylicariin NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD rwj-387273 NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD udenafil small molecule Hypertensive disease[MeSHID:D006973],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA inhibitor 23.87 drugbank , DGIDB trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE5A NA inhibitor NA drugbank 3-isobutyl-1-methyl-7h-xanthine small molecule NA experimental cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA unknown NA drugbank aom-0890 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stickler syndrome, type 1[MeSHID:C537492],Erectile dysfunction[MeSHID:D007172] investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD vardenafil NA Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 5a PDE5A Successful target unknown 17.24 TTD , DGIDB gamma-glutamyl[s-(2-iodobenzyl)cysteinyl]glycine small molecule NA experimental cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA unknown NA drugbank udenafil NA Hypertensive disease[MeSHID:D006973],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 5a PDE5A Successful target inhibitor 23.87 TTD , DGIDB avanafil NA Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 5a PDE5A Successful target unknown 10.61 TTD , DGIDB avanafil small molecule Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA inhibitor 10.61 drugbank , DGIDB tadalafil NA Benign prostatic hypertrophy[MeSHID:D011470],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 5a PDE5A Successful target inhibitor 7.96 TTD , DGIDB kuraidin NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA inhibitor NA drugbank isobutylmethylxanthine NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD vardenafil small molecule Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA inhibitor 17.24 drugbank , DGIDB dasantafil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] discontinued in phase 2 phosphodiesterase 5a PDE5A Successful target unknown NA TTD udenafil NA Hypertensive disease[MeSHID:D006973],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 5a PDE5A Successful target unknown 23.87 TTD , DGIDB exisulind NA Disease[MeSHID:D004194],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Esophagus[MeSHID:D004947],Colonic Polyps[MeSHID:D003111],Barrett Esophagus[MeSHID:D001471],Esophageal Diseases[MeSHID:D004935],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 phosphodiesterase 5a PDE5A Successful target unknown 0.88 TTD , DGIDB tpn-729 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD tadalafil small molecule Benign prostatic hypertrophy[MeSHID:D011470],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA inhibitor 7.96 drugbank , DGIDB dipyridamole NA Heart Valves[MeSHID:D006351],Angina Pectoris[MeSHID:D000787],Postoperative Complications[MeSHID:D011183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved phosphodiesterase 5a PDE5A Successful target inhibitor 0.46 TTD , DGIDB uk-369003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] discontinued in phase 1/2 phosphodiesterase 5a PDE5A Successful target unknown NA TTD osi-461 small molecule Malignant neoplasm of kidney[MeSHID:D007680],Crohn Disease[MeSHID:D003424],Malignant neoplasm of prostate[MeSHID:D011471],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Inflammatory Bowel Diseases[MeSHID:D015212] investigational cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA unknown 2.65 drugbank , DGIDB dipyridamole NA Heart Valves[MeSHID:D006351],Angina Pectoris[MeSHID:D000787],Postoperative Complications[MeSHID:D011183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved phosphodiesterase 5a PDE5A Successful target unknown 0.46 TTD , DGIDB guanosine-5'-monophosphate NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD exisulind small molecule Disease[MeSHID:D004194],Adenomatous Polyposis Coli[MeSHID:D011125],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Esophagus[MeSHID:D004947],Colonic Polyps[MeSHID:D003111],Barrett Esophagus[MeSHID:D001471],Esophageal Diseases[MeSHID:D004935],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA unknown 0.88 drugbank , DGIDB 5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)thiophene-2-sulfonamide small molecule NA experimental cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA unknown NA drugbank lorneic acid a NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown 5.3 TTD , DGIDB theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved cgmp-specific 3',5'-cyclic phosphodiesterase PDE5A NA inhibitor 0.33 drugbank , DGIDB t0156 NA NA investigative phosphodiesterase 5a PDE5A Successful target inhibitor NA TTD , DGIDB ckd-533 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD icariside ii NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD gamma-glutamyl[s-(2-iodobenzyl)cysteinyl]glycine NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD emr-62203 NA Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172] discontinued in phase 2 phosphodiesterase 5a PDE5A Successful target unknown NA TTD brl-61063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] discontinued in phase 2 phosphodiesterase 5a PDE5A Successful target unknown NA TTD cartazolate NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD 8-prenylapigenin NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD sinitrodil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 2 phosphodiesterase 5a PDE5A Successful target unknown NA TTD e-4021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] discontinued in phase 2 phosphodiesterase 5a PDE5A Successful target unknown NA TTD 3,7-bis(2-hydroxyethyl)icaritin NA NA investigative phosphodiesterase 5a PDE5A Successful target unknown NA TTD tadalafil NA Benign prostatic hypertrophy[MeSHID:D011470],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 5a PDE5A Successful target unknown 7.96 TTD , DGIDB vardenafil NA Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphodiesterase 5a PDE5A Successful target inhibitor 17.24 TTD , DGIDB pf-489791 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Raynaud Disease[MeSHID:D011928],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 phosphodiesterase 5a PDE5A Successful target unknown NA TTD , DGIDB rhucin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Angioedemas, Hereditary[MeSHID:D054179] approved phosphodiesterase 5a PDE5A Successful target unknown 1.33 TTD , DGIDB trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE6A NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE6A NA inhibitor NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE6B NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE6B NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE6C NA inhibitor NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE6C NA inhibitor NA drugbank 3-isobutyl-1-methyl-7h-xanthine small molecule NA experimental retinal rod rhodopsin-sensitive cgmp 3',5'-cyclic phosphodiesterase subunit gamma PDE6G NA unknown NA drugbank vardenafil small molecule Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinal rod rhodopsin-sensitive cgmp 3',5'-cyclic phosphodiesterase subunit gamma PDE6G NA allosteric modulator NA drugbank tadalafil small molecule Benign prostatic hypertrophy[MeSHID:D011470],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinal rod rhodopsin-sensitive cgmp 3',5'-cyclic phosphodiesterase subunit gamma PDE6G NA inhibitor NA drugbank sildenafil small molecule Congenital Disorders[MeSHID:D009358],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Neoplasm Metastasis[MeSHID:D009362],Erectile dysfunction[MeSHID:D007172],Heart[MeSHID:D006321],Mental association[MeSHID:D001244],Lung[MeSHID:D008168],Connective Tissue Diseases[MeSHID:D003240],Hemodynamics[MeSHID:D006439],Heart Diseases[MeSHID:D006331],Pulmonary Hypertension[MeSHID:D006976],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational retinal rod rhodopsin-sensitive cgmp 3',5'-cyclic phosphodiesterase subunit gamma PDE6G NA inhibitor NA drugbank sildenafil small molecule Congenital Disorders[MeSHID:D009358],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Neoplasm Metastasis[MeSHID:D009362],Erectile dysfunction[MeSHID:D007172],Heart[MeSHID:D006321],Mental association[MeSHID:D001244],Lung[MeSHID:D008168],Connective Tissue Diseases[MeSHID:D003240],Hemodynamics[MeSHID:D006439],Heart Diseases[MeSHID:D006331],Pulmonary Hypertension[MeSHID:D006976],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational retinal cone rhodopsin-sensitive cgmp 3',5'-cyclic phosphodiesterase subunit gamma PDE6H NA inhibitor NA drugbank vardenafil small molecule Erectile dysfunction[MeSHID:D007172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinal cone rhodopsin-sensitive cgmp 3',5'-cyclic phosphodiesterase subunit gamma PDE6H NA allosteric modulator NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE7A NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE7A NA inhibitor NA drugbank pf-3557156 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 1 phosphodiesterase 7a PDE7A Discontinued target unknown NA TTD 3-(2,6-difluorophenyl)-2-(methylthio)quinazolin-4(3h)-one small molecule NA experimental high affinity camp-specific 3',5'-cyclic phosphodiesterase 7a PDE7A NA unknown NA drugbank 3-isobutyl-1-methyl-7h-xanthine small molecule NA experimental high affinity camp-specific 3',5'-cyclic phosphodiesterase 7a PDE7A NA unknown NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE7B NA inhibitor NA drugbank brl50481 NA NA investigative phosphodiesterase 7b PDE7B Discontinued target inhibitor NA TTD , DGIDB sch51866 NA NA investigative phosphodiesterase 7b PDE7B Discontinued target inhibitor NA TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE7B NA inhibitor NA drugbank pf-3557156 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 1 phosphodiesterase 7b PDE7B Discontinued target unknown NA TTD us8846654, 11 NA NA patented phosphodiesterase 8 PDE8A Patented-recorded target unknown NA TTD 3-isobutyl-1-methyl-7h-xanthine small molecule NA experimental high affinity camp-specific and ibmx-insensitive 3',5'-cyclic phosphodiesterase 8a PDE8A NA unknown NA drugbank us8846654, 251 NA NA patented phosphodiesterase 8 PDE8A Patented-recorded target unknown NA TTD bc11-28 NA NA patented phosphodiesterase 8 PDE8A Patented-recorded target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE8A NA inhibitor NA drugbank pf-04957325 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Inflammation[MeSHID:D007249] investigative phosphodiesterase 8 PDE8A Patented-recorded target inhibitor NA TTD , DGIDB us9493447, 1001 NA NA patented phosphodiesterase 8 PDE8A Patented-recorded target unknown NA TTD us8846654, 294 NA NA patented phosphodiesterase 8 PDE8A Patented-recorded target unknown NA TTD ac1m1sp5 NA NA patented phosphodiesterase 8 PDE8A Patented-recorded target unknown NA TTD pf-4957325-00 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative phosphodiesterase 8 PDE8A Patented-recorded target unknown NA TTD trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE8A NA inhibitor NA drugbank trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE8B NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE8B NA inhibitor NA drugbank caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved cyclic nucleotide phosphodiesterase PDE9A NA inhibitor NA drugbank imr-687 NA Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase 9 PDE9A Clinical trial target unknown NA TTD trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental cyclic nucleotide phosphodiesterase PDE9A NA inhibitor NA drugbank sch51866 NA NA investigative phosphodiesterase 9 PDE9A Clinical trial target inhibitor NA TTD , DGIDB pf-4181366 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative phosphodiesterase 9 PDE9A Clinical trial target unknown NA TTD asp-4901 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase 9 PDE9A Clinical trial target unknown NA TTD e2027 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lewy Body Disease[MeSHID:D020961],Parkinson Disease[MeSHID:D010300] phase 2 phosphodiesterase 9 PDE9A Clinical trial target unknown NA TTD gamma-glutamyl[s-(2-iodobenzyl)cysteinyl]glycine small molecule NA experimental high affinity cgmp-specific 3',5'-cyclic phosphodiesterase 9a PDE9A NA unknown NA drugbank bi-409306 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 phosphodiesterase 9 PDE9A Clinical trial target unknown NA TTD 3-isobutyl-1-methyl-7h-xanthine small molecule NA experimental high affinity cgmp-specific 3',5'-cyclic phosphodiesterase 9a PDE9A NA unknown NA drugbank pf-4447943 NA Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 phosphodiesterase 9 PDE9A Clinical trial target unknown NA TTD 8-(2,4-dimethoxyphenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 2-(n-morpholino)-ethanesulfonic acid NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(2,3,4-trimethoxyphenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD metoprine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 polypeptide deformylase PDF Successful target unknown 3.03 TTD , DGIDB 6-phenylsulfanylmethyl-pteridine-2,4-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD ro 5-4864 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative polypeptide deformylase PDF Successful target unknown NA TTD sri-9662 NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD ly333531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 polypeptide deformylase PDF Successful target unknown NA TTD , DGIDB 5-phenylsulfanyl-2,4-quinazolinediamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD biopterin NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 5-formyl-6-hydrofolic acid NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(2,4,6-trimethoxyphenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 6-(2-phenylsulfanyl-ethyl)-pteridine-2,4-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 5-(2-fluorobenzyloxy)quinazoline-2,4-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD ddathf NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD cycloguanil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] investigative polypeptide deformylase PDF Successful target unknown NA TTD mcb-3837 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved polypeptide deformylase PDF Successful target unknown NA TTD , DGIDB furo[2,3d]pyrimidine antifolate NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 5-p-tolylsulfanyl-quinazoline-2,4-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD gnf-pf-607 NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 2'-monophosphoadenosine 5'-diphosphoribose NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD n*6*-benzyl-quinazoline-2,4,6-triamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD meprobamate NA Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved polypeptide deformylase PDF Successful target unknown 0.51 TTD , DGIDB sri-9439 NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(3,4,5-trimethoxyphenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 2'-monophosphoadenosine-5'-diphosphate NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 5-(4-methoxyphenoxy)-2,4-quinazolinediamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD premetrexed NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD , DGIDB 2-[(formyl-hydroxy-amino)-methyl]-heptanoic acid [1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-2-methyl-propyl]-amide small molecule NA experimental peptide deformylase, mitochondrial PDF NA unknown NA drugbank 2-sulfhydryl-ethanol NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-pyridin-4-yl-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD aminopterin NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market polypeptide deformylase PDF Successful target unknown NA TTD edatrexate NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 5-chloryl-2,4,6-quinazolinetriamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD trimetrexate NA Malignant Neoplasms[MeSHID:D009369],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Pneumonia[MeSHID:D011014],Malignant tumor of colon[MeSHID:D003110],Pneumocystis jiroveci pneumonia[MeSHID:D011020],Immunocompromised Host[MeSHID:D016867],Toxoplasmosis[MeSHID:D014123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved polypeptide deformylase PDF Successful target unknown 1.01 TTD , DGIDB 3-benzyl-2-mercapto-6-nitroquinazolin-4(3h)-one NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 5-phenethyl-quinazoline-2,4-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD ustekinumab NA Disease Management[MeSHID:D019468],Necrosis[MeSHID:D009336],Psoriasis[MeSHID:D011565],Crohn Disease[MeSHID:D003424],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Arthritis, Psoriatic[MeSHID:D015535],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Malaria[MeSHID:D008288] approved polypeptide deformylase PDF Successful target unknown 0.91 TTD , DGIDB 6-m-tolyl-pteridine-2,4,7-triamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(2,6-dichloro-phenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(3,5-dimethoxyphenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 5-((e)-styryl)-quinazoline-2,4-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD gnf-pf-173 NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD pralatrexate NA Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved polypeptide deformylase PDF Successful target unknown 3.03 TTD , DGIDB 3-phenylsulfanylmethyl-quinoxaline-5,7-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(3,4-dimethoxyphenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 7-methyl-7h-pyrrolo[3,2-f]quinazoline-1,3-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD chlorproguanil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved polypeptide deformylase PDF Successful target unknown 4.55 TTD , DGIDB bromo-wr99210 NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD tylophorinidine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 6-phenylaminomethyl-quinazoline-2,4-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD nb3322 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative polypeptide deformylase PDF Successful target unknown NA TTD pergularinine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 6,7-diphenyl-pteridine-2,4-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 2-allylthio-6-amino-3-benzyl-quinazolin-4(3h)-one NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD bb-3497 small molecule NA experimental peptide deformylase, mitochondrial PDF NA inhibitor NA drugbank proguanil NA Muscle strain[MeSHID:D013180],Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved polypeptide deformylase PDF Successful target unknown 2.27 TTD , DGIDB 3-benzyl-2-ethylthio-6-nitro-quinazolin-4(3h)-one NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(3,4-dichlorophenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 7h-pyrrolo[3,2-f]quinazoline-1,3-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-benzyl-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(2,4,5-trimethoxyphenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 2-allylthio-3-benzyl-6-nitro-quinazolin-4(3h)-one NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 4-(2,6-diamino-9h-purin-8-yl)-2,6-dimethoxyphenol NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD brodimoprim-4,6-dicarboxylate NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD nb3178 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative polypeptide deformylase PDF Successful target unknown NA TTD dihydrofolic acid NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD 8-(2,5-dimethoxyphenyl)-9h-purine-2,6-diamine NA NA investigative polypeptide deformylase PDF Successful target unknown NA TTD squalamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Macular Edema, Cystoid[MeSHID:D008269] phase 3 platelet-derived growth factor a PDGFA Clinical trial target unknown 7.96 TTD , DGIDB cr-002 NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 platelet-derived growth factor b PDGFB Clinical trial target unknown NA TTD , DGIDB pegpleranib small molecule Disease[MeSHID:D004194],Disorder of eye[MeSHID:D005128],Age related macular degeneration[MeSHID:D008268],Infection[MeSHID:D007239],Eye Infections[MeSHID:D015817] investigational platelet-derived growth factor subunit b PDGFB NA unknown NA drugbank pdgf-bb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] phase 3 platelet-derived growth factor b PDGFB Clinical trial target unknown NA TTD , DGIDB gam-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] phase 2 platelet-derived growth factor b PDGFB Clinical trial target unknown NA TTD , DGIDB e-10030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 2 platelet-derived growth factor b PDGFB Clinical trial target unknown 5.3 TTD , DGIDB tandutinib small molecule leukemia[MeSHID:D007938],Anaplasia[MeSHID:D000708],Mixed Oligodendroglioma-Astrocytoma[MeSHID:D009837],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mixed oligoastrocytoma[MeSHID:D001254] investigational platelet-derived growth factor d PDGFD NA unknown NA drugbank cr002 biotech Kidney Diseases[MeSHID:D007674] investigational platelet-derived growth factor d PDGFD NA unknown NA drugbank , DGIDB 3-(3,4-dichloro-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 4-(6,7-dimethoxy-quinolin-3-yl)-benzoic acid NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 5,7-dimethyl-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved platelet-derived growth factor receptor alpha PDGFRA NA antagonist,inhibitor 0.59 drugbank , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved platelet-derived growth factor receptor alpha PDGFRA NA antagonist,inhibitor 0.59 drugbank , DGIDB becaplermin biotech Diabetes Mellitus[MeSHID:D003920],Skin Ulcer[MeSHID:D012883],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA agonist 3.86 drugbank , DGIDB pmid22765894c8h NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD pd-0173956 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD (1h-indol-2-yl)(5-methoxy-1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD ripretinib small molecule Diagnosis[MeSHID:D003933],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Mastocytosis, Systemic[MeSHID:D034721] approved platelet-derived growth factor receptor alpha PDGFRA Successful target inhibitor NA TTD , drugbank sri-62-834 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD d-65476 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 5,7-dimethoxy-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved platelet-derived growth factor receptor alpha PDGFRA NA antagonist 0.59 drugbank , DGIDB pmid21561767c8h NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved platelet-derived growth factor receptor alpha PDGFRA NA inhibitor 0.14 drugbank , DGIDB 5-(6,7-dimethoxy-quinolin-3-yl)-1h-pyridin-2-one NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-(3-methoxy-phenyl)-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD avapritinib NA Gastrointestinal Stromal Tumors[MeSHID:D046152],Mutation[MeSHID:D009154],Leukemia, Mast-Cell[MeSHID:D007946],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mastocytosis, Systemic[MeSHID:D034721] approved platelet-derived growth factor receptor alpha PDGFRA Successful target unknown 1.93 TTD , DGIDB famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor alpha PDGFRA Successful target unknown 0.28 TTD , DGIDB erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA substrate NA drugbank su-11652 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD romiplostim NA Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved platelet-derived growth factor receptor alpha PDGFRA Successful target unknown 0.12 TTD , DGIDB (1h-indol-2-yl)(6-methoxy-1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA inhibitor NA drugbank jnj-10198409 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 1-phenyl-1h-benzoimidazole NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6-methoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD pyridine derivative 20 NA NA patented platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD , DGIDB pyridine derivative 22 NA NA patented platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved platelet-derived growth factor receptor alpha PDGFRA NA inhibitor 0.32 drugbank , DGIDB bis-(5-hydroxy-1h-indol-2-yl)-methanone NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 platelet-derived growth factor receptor alpha PDGFRA Successful target unknown 0.06 TTD , DGIDB 6,7-dimethoxy-3-phenylethynyl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD pd-0173952 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD ro-4396686 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD bms-536924 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD medi-575 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 platelet-derived growth factor receptor alpha PDGFRA Successful target antibody 2.89 TTD , DGIDB pyridine derivative 18 NA NA patented platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD , DGIDB rpr-101511 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 5,6,7-trimethoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD mp470 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD , DGIDB 5-methoxy-1-phenyl-1h-benzoimidazole NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD cp-868596 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Gastrointestinal Stromal Tumors[MeSHID:D046152],Malignant Glioma[MeSHID:D005910] phase 3 platelet-derived growth factor receptor alpha PDGFRA Successful target unknown 2.41 TTD , DGIDB pyridine derivative 19 NA NA patented platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD , DGIDB 3-cyclopentyl-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-benzyloxy-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-pyridin-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved platelet-derived growth factor receptor alpha PDGFRA NA inhibitor 0.12 drugbank , DGIDB lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA inhibitor 0.16 drugbank , DGIDB 3-(1h-indol-3-yl)-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 7-methoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 4-(6,7-dimethoxy-quinolin-3-yl)-phenol NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD xl-820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor alpha PDGFRA Successful target inhibitor 0.32 TTD , DGIDB 3-(4-fluoro-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD medi-575 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 platelet-derived growth factor receptor alpha PDGFRA Successful target unknown 2.89 TTD , DGIDB tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA inhibitor NA drugbank 6,7-dichloro-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-phenyl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-p-tolyl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor alpha PDGFRA Successful target inhibitor 0.28 TTD , DGIDB 5,11-dimethyl-6h-pyrido[4,3-b]carbazol-9-ol NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved platelet-derived growth factor receptor alpha PDGFRA NA antagonist 0.59 drugbank , DGIDB 3-(1h-indol-3-yl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-(4-nitro-phenyl)-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD (1h-indol-2-yl)(5-phenoxy-1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD olaratumab biotech Operative Surgical Procedures[MeSHID:D013514],Sarcoma[MeSHID:D012509],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor alpha PDGFRA Successful target antagonist 8.68 TTD , drugbank , DGIDB 5,7-dimethoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD di(1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD pd-0173958 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD (5-hydroxy-1h-indol-2-yl)(1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-(2-methoxy-phenyl)-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-difluoro-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD xl-820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor alpha PDGFRA Successful target unknown 0.32 TTD , DGIDB 6,7-dimethoxy-3-thiophen-2-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-(3-fluoro-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 7-chloro-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-(4-methoxy-phenyl)-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD pd-0166326 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD pd-0179483 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD cp-673451 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target inhibitor NA TTD , DGIDB amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational platelet-derived growth factor receptor alpha PDGFRA NA unknown 0.41 drugbank , DGIDB 7-fluoro-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD xl820 small molecule Neoplasms[MeSHID:D009369] investigational platelet-derived growth factor receptor alpha PDGFRA NA unknown NA drugbank , DGIDB olaratumab biotech Operative Surgical Procedures[MeSHID:D013514],Sarcoma[MeSHID:D012509],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor alpha PDGFRA Successful target antagonist,antibody 8.68 TTD , drugbank , DGIDB pmid28460551-compound-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471],Malignant tumor of colon[MeSHID:D003110],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of breast[MeSHID:D001943] patented platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD , DGIDB 4-(5-methoxy-benzoimidazol-1-yl)-phenylamine NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD (5-fluoro-1h-indol-2-yl)-(1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-(3,4-difluoro-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-(3,4-dimethoxy-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD sunitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA inhibitor 0.55 drugbank , DGIDB pp121 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target inhibitor NA TTD , DGIDB 4-(3,4-dimethoxy-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-cyclopent-1-enyl-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD hki-9924129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-pyridin-4-yl-quinoline-5,7-diol NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA inhibitor 0.25 drugbank , DGIDB 3-(2-cyclohexyl-ethyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 7-thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-pyridin-3-yl-quinoline-6,7-diol NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6-methoxy-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD midostaurin small molecule Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA antagonist,inhibitor 0.12 drugbank , DGIDB pd-0173955 NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD cep-2563 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational platelet-derived growth factor receptor alpha PDGFRA NA inhibitor 0.41 drugbank , DGIDB 3-pyridin-4-yl-quinolin-7-ol NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 4-benzoimidazol-1-yl-phenylamine NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 7-methoxy-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-cyclohexylethynyl-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD becaplermin biotech Diabetes Mellitus[MeSHID:D003920],Skin Ulcer[MeSHID:D012883],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational platelet-derived growth factor receptor alpha PDGFRA NA unknown 3.86 drugbank , DGIDB 5-fluoro-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 6,7-dimethoxy-3-((e)-styryl)-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved platelet-derived growth factor receptor alpha PDGFRA NA agonist NA drugbank pyridine derivative 21 NA NA patented platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD , DGIDB 1-phenyl-1h-benzoimidazol-5-ol NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD rpr-108514a NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD 3-((e)-styryl)-quinoline NA NA investigative platelet-derived growth factor receptor alpha PDGFRA Successful target unknown NA TTD famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor beta PDGFRB Successful target unknown 0.35 TTD , DGIDB polaprezinc small molecule Peptic Ulcer[MeSHID:D010437],Dyspepsia[MeSHID:D004415],Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcer[MeSHID:D014456] experimental platelet-derived growth factor receptor beta PDGFRB NA agonist NA drugbank imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved platelet-derived growth factor receptor beta PDGFRB NA antagonist,inhibitor 0.23 drugbank , DGIDB 5,7-dimethoxy-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA inhibitor NA drugbank 5,6,7-trimethoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pyridine derivative 18 NA NA patented platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD , DGIDB famitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor 0.35 TTD , DGIDB 3-cyclohexylethynyl-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD (1h-indol-2-yl)(5-phenoxy-1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 5,7-dimethoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD bms-536924 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-(3-ethoxy-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved platelet-derived growth factor receptor beta PDGFRB NA agonist NA drugbank cp-673451 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA inhibitor NA drugbank sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor beta PDGFRB Successful target antagonist 0.14 TTD , drugbank , DGIDB bis(5-aminobenzo[b]furan-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved platelet-derived growth factor receptor beta PDGFRB NA inhibitor 0.12 drugbank , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved platelet-derived growth factor receptor beta PDGFRB NA antagonist 0.23 drugbank , DGIDB pd-0173958 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-(1h-indol-3-yl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pmid22765894c8h NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-cyclopent-1-enyl-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD tak-593 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor 0.32 TTD , DGIDB (1h-indol-2-yl)(5-methoxy-1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-(6,7-dimethoxy-quinolin-3-yl)-benzoic acid NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 5-(6,7-dimethoxy-quinolin-3-yl)-1h-pyridin-2-one NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-(3-ethyl-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-phenyl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6-methoxy-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD cep-2563 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor 0.05 TTD , DGIDB (5-fluoro-1h-indol-2-yl)-(1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved platelet-derived growth factor receptor beta PDGFRB NA inhibitor 0.27 drugbank , DGIDB 4-(3,4-dimethoxy-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-(1h-indol-3-yl)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-cyclopentyl-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD (2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD xb-387 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD (1h-indol-2-yl)(6-methoxy-1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD bis(5-methoxybenzo[b]furan-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA substrate NA drugbank 6,7-dimethoxy-3-((e)-styryl)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD romiplostim NA Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved platelet-derived growth factor receptor beta PDGFRB Successful target unknown 0.1 TTD , DGIDB 6,7-dichloro-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD gtp-14564 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor 0.2 TTD , DGIDB xl999 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational platelet-derived growth factor receptor beta PDGFRB NA unknown NA drugbank , DGIDB benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-4-m-tolyloxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pd-0166326 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pdgf receptor tyrosine kinase inhibitor iii NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor NA TTD , DGIDB 7-fluoro-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA antagonist,inhibitor 0.12 drugbank , DGIDB 3-pyridin-4-yl-quinoline-5,7-diol NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-difluoro-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD e-3810 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 platelet-derived growth factor receptor beta PDGFRB Successful target unknown 0.05 TTD , DGIDB 1-phenyl-1h-benzoimidazole NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-pyridin-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pexidartinib small molecule Giant Cell Tumors[MeSHID:D005870],Operative Surgical Procedures[MeSHID:D013514],Testicular Germ Cell Tumor[MeSHID:C563236],Pigmented villonodular synovitis[MeSHID:D013586],Neurofibromatosis 1[MeSHID:D009456],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA inhibitor NA drugbank 3-(3-fluoro-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD snn-0031 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] phase 1/2 platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD , DGIDB 6,7-dimethoxy-4-(3-methoxy-phenoxy)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD rpr-108514a NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pd-0173956 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved platelet-derived growth factor receptor beta PDGFRB NA antagonist 0.23 drugbank , DGIDB 3-(2-cyclohexyl-ethyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD ki-20227 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor 0.2 TTD , DGIDB 2-(1h-indazol-3-yl)-1h-benzo[d]imidazole NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-pyridin-4-yl-quinolin-7-ol NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD sunitinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA inhibitor 0.28 drugbank , DGIDB bis(benzo[b]furan-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-phenylethynyl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 7-methoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pmid25656651-compound-21b NA NA patented platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD , DGIDB sri-62-834 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD hki-9924129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD tg-100435 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-((e)-styryl)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-(5-methoxy-benzoimidazol-1-yl)-phenylamine NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6-methoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-4-(4-methoxy-phenoxy)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD ripretinib small molecule Diagnosis[MeSHID:D003933],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Mastocytosis, Systemic[MeSHID:D034721] approved platelet-derived growth factor receptor beta PDGFRB NA inhibitor NA drugbank 6,7-dimethoxy-4-(3-nitro-phenoxy)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor 0.12 TTD , DGIDB cdp-860 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor 0.81 TTD , DGIDB 3-benzyloxy-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA inhibitor NA drugbank 4-(6,7-dimethoxy-quinolin-3-yl)-phenol NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-thiophen-2-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD su-11652 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD (5-hydroxy-1h-indol-2-yl)(1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-(3,5-dimethoxy-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-(3,4-dichloro-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD midostaurin small molecule Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA antagonist,inhibitor 0.06 drugbank , DGIDB ro-4396686 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-(4-nitro-phenyl)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-(4-dimethylamino-benzylidenyl)-2-indolinone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD rpr-101511 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA antagonist,inhibitor 0.12 drugbank , DGIDB 4-(3-fluoro-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-(2,3-dimethoxy-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pd-0179483 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD agl 2043 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor NA TTD , DGIDB regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved platelet-derived growth factor receptor beta PDGFRB NA inhibitor 0.12 drugbank , DGIDB 3-(6,7-dimethoxy-quinolin-4-yloxy)-phenol NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet-derived growth factor receptor beta PDGFRB Successful target antagonist,inhibitor 0.14 TTD , drugbank , DGIDB bis(6-hydroxybenzo[b]furan-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD xl-820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor beta PDGFRB Successful target unknown 0.27 TTD , DGIDB bis(5-hydroxybenzo[b]furan-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD di(1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-(3-methoxy-phenyl)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 7-chloro-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 7-methoxy-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 7-thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pd-0173952 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-(3-bromo-phenoxy)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD xl-820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 platelet-derived growth factor receptor beta PDGFRB Successful target inhibitor 0.27 TTD , DGIDB xl820 small molecule Neoplasms[MeSHID:D009369] investigational platelet-derived growth factor receptor beta PDGFRB NA unknown NA drugbank , DGIDB pd-0173955 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD ki-11502 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-p-tolyl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD tak-593 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 platelet-derived growth factor receptor beta PDGFRB Successful target unknown 0.32 TTD , DGIDB 3-(3,4-difluoro-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-(3,4-dimethoxy-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-(6,7-dimethoxy-quinolin-4-yloxy)-phenylamine NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-4-phenoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-pyridin-3-yl-quinoline-6,7-diol NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 5-methoxy-1-phenyl-1h-benzoimidazole NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-benzoimidazol-1-yl-phenylamine NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA antagonist 0.12 drugbank , DGIDB 3-benzimidazol-2-ylhydroquinolin-2-one NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD bis(5-acetoxybenzo[b]furan-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 4-(3-bromo-phenoxy)-6,7-dimethoxy-quinazoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-pyridin-4-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD mk-2461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 platelet-derived growth factor receptor beta PDGFRB Successful target unknown 0.12 TTD , DGIDB xl820 small molecule Neoplasms[MeSHID:D009369] investigational platelet-derived growth factor receptor beta PDGFRB NA inhibitor NA drugbank , DGIDB bis-(5-hydroxy-1h-indol-2-yl)-methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 3-(4-fluoro-phenyl)-6,7-dimethoxy-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 6,7-dimethoxy-3-(4-methoxy-phenyl)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD becaplermin biotech Diabetes Mellitus[MeSHID:D003920],Skin Ulcer[MeSHID:D012883],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational platelet-derived growth factor receptor beta PDGFRB Successful target agonist 2.01 TTD , drugbank , DGIDB 6,7-dimethoxy-4-(2-methoxy-phenoxy)-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 5,7-dimethyl-3-thiophen-3-yl-quinoline NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD jnj-10198409 NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pmid28460551-compound-2 NA NA patented platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved platelet-derived growth factor receptor beta PDGFRB NA antagonist,inhibitor 0.23 drugbank , DGIDB trapidil small molecule Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Acute Coronary Syndrome[MeSHID:D054058] experimental platelet-derived growth factor receptor beta PDGFRB NA antagonist NA drugbank (benzo[b]furan-2-yl)-(1h-indol-2-yl)methanone NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD 1-phenyl-1h-benzoimidazol-5-ol NA NA investigative platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD pmid25656651-compound-21a NA NA patented platelet-derived growth factor receptor beta PDGFRB Successful target unknown NA TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational platelet-derived growth factor receptor beta PDGFRB NA antagonist 0.12 drugbank , DGIDB becaplermin biotech Diabetes Mellitus[MeSHID:D003920],Skin Ulcer[MeSHID:D012883],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational platelet-derived growth factor receptor beta PDGFRB Successful target unknown 2.01 TTD , drugbank , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical pyruvate dehydrogenase e1 component subunit alpha, somatic form, mitochondrial PDHA1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical pyruvate dehydrogenase e1 component subunit alpha, testis-specific form, mitochondrial PDHA2 NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical pyruvate dehydrogenase e1 component subunit beta, mitochondrial PDHB NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical pyruvate dehydrogenase e1 component subunit beta, mitochondrial PDHB NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational protein disulfide-isomerase a3 PDIA3 NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental protein disulfide-isomerase a3 PDIA3 NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational protein disulfide-isomerase a3 PDIA3 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational protein disulfide-isomerase a3 PDIA3 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein disulfide-isomerase a3 PDIA3 NA unknown NA drugbank pmid25684022-compound-wo2008005457 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2009153313 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 29 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB indolinone derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 26 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 28 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 27 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB 4-[(3-chloro-4-{[(2r)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino}phenyl)sulfonyl]-n,n-dimethylbenzamide small molecule NA experimental [pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial PDK1 NA unknown NA drugbank heteroaryl-carboxamide derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2011137219 36(3-5) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic-carboxamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2011137219 35(1-11) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB dichloroacetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658],Pyruvate Dehydrogenase Complex Deficiency Disease[MeSHID:D015325],Disease[MeSHID:D004194] phase 4 pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD pmid25684022-compound-wo2012135799 43(1.5) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pyridinone carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB dibenzo [c,f]-[2,7]naphthyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB benzimidazole and imidazopyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2012135799 42(1.4) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2004087707 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2008079988 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB indazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB dichloroacetic acid small molecule NA approved,investigational [pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial PDK1 NA inhibitor 31.83 drugbank , DGIDB pmid25684022-compound-us20120277229 41(1.3) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pyrimidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pyrazolopyridines and imidazopyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2008107444 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2011137219 37(4-6) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB benzonaphthyridine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pyrido[4,3-d]pyrimidin-5(6h)-one derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2011137219 38(5-7) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pyrimidinone derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-us20120277229 44(1.4) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2006015124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thieno[3,2-c]pyridine-7-carboxamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB imidazo quinoline derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB bis-indolylmaleimide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-us20130053382 35(1-11) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-wo2010127754 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-us20130053382 37(4-6) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thieno[3,2-c]pyridine-7-carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-us20130053382 38(5-7) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB 1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heteroaryl-carboxamide derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-us20120277229 45(1.5) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 25 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB benzonaphthyridine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic-carboxamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pyrazole derivative 61 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-us20120277229 40(1.2) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-us20130053382 36(3-5) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-ep20041486488 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB thiazole carboxamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB pmid25684022-compound-us20120277229 39(1.1) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB heterocyclic derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362] patented pyruvate dehydrogenase kinase 1 PDK1 Clinical trial target unknown NA TTD , DGIDB 4-({(2r,5s)-2,5-dimethyl-4-[(2r)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazin-1-yl}carbonyl)benzonitrile small molecule NA experimental [pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial PDK2 NA unknown NA drugbank (2r)-n-{4-[ethyl(phenyl)sulfamoyl]-2-methylphenyl}-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide small molecule NA experimental [pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial PDK2 NA unknown NA drugbank n-(2-aminoethyl)-2-{3-chloro-4-[(4-isopropylbenzyl)oxy]phenyl} acetamide small molecule NA experimental [pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial PDK2 NA unknown NA drugbank radicicol small molecule NA experimental [pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial PDK3 NA unknown NA drugbank dihydrolipoic acid small molecule NA experimental [pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial PDK3 NA unknown NA drugbank 4-[4-(4-methoxyphenyl)-5-methyl-1h-pyrazol-3-yl]benzene-1,3-diol small molecule NA experimental [pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial PDK4 NA unknown NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical [pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial PDK4 NA unknown NA drugbank bx-795 NA NA investigative phosphoinositide dependent protein kinase-1 PDPK1 Clinical trial target inhibitor 0.44 TTD , DGIDB 5-hydroxy-3-[(1r)-1-(1h-pyrrol-2-yl)ethyl]-2h-indol-2-one small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank (z)-3-((1h-pyrrol-2-yl)methylene)indolin-2-one NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD ar-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 phosphoinositide dependent protein kinase-1 PDPK1 Clinical trial target unknown 2.65 TTD , DGIDB isis 29477 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD mir-375 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD 1-{2-oxo-3-[(1r)-1-(1h-pyrrol-2-yl)ethyl]-2h-indol-5-yl}urea small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank bisindolylmaleimide i small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank isis 29244 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29475 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD 2-(1h-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank 3-(1h-indol-3-yl)-4-(1-{2-[(2s)-1-methylpyrrolidinyl]ethyl}-1h-indol-3-yl)-1h-pyrrole-2,5-dione small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank nu-6102 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD gsk-2334470 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative phosphoinositide dependent protein kinase-1 PDPK1 Clinical trial target unknown NA TTD isis 29219 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD l-serine-o-phosphate NA NA investigative phosphoinositide dependent protein kinase-1 PDPK1 Clinical trial target unknown NA TTD isis 29256 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29236 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29257 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD pht-427 NA NA investigative phosphoinositide dependent protein kinase-1 PDPK1 Clinical trial target inhibitor NA TTD , DGIDB staurosporine small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank pf-5177624 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative phosphoinositide dependent protein kinase-1 PDPK1 Clinical trial target unknown NA TTD isis 29224 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD bx-912 NA NA investigative phosphoinositide dependent protein kinase-1 PDPK1 Clinical trial target inhibitor NA TTD , DGIDB 3-[1-(3-aminopropyl)-1h-indol-3-yl]-4-(1h-indol-3-yl)-1h-pyrrole-2,5-dione small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank isis 29232 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA inhibitor NA drugbank isis 29469 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD bx-517 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD su-6689 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD bx-201 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29234 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29470 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD inositol 1,3,4,5-tetrakisphosphate small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank isis 29233 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD bisindolylmaleimide viii small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank isis 29471 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD celecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA inhibitor 0.29 drugbank , DGIDB isis 29255 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29239 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29237 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD 7-hydroxystaurosporine small molecule NA experimental,investigational 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA inhibitor 0.61 drugbank , DGIDB dexfosfoserine small molecule NA experimental 3-phosphoinositide-dependent protein kinase 1 PDPK1 NA unknown NA drugbank isis 29246 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29223 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD isis 29243 NA NA investigative pdk-1 messenger rna PDPK1 Literature-reported target unknown NA TTD pmid20005102c1 NA NA investigative phosphoinositide dependent protein kinase-1 PDPK1 Clinical trial target unknown NA TTD (2r)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9h-purin-2-yl}amino)butan-1-ol small molecule NA experimental pyridoxal kinase PDXK NA unknown NA drugbank pyridoxal small molecule NA experimental,nutraceutical pyridoxal kinase PDXK NA unknown NA drugbank pyridoxine small molecule Vitamin B 6 Deficiency[MeSHID:D026681],Nausea[MeSHID:D009325],Pregnancy[MeSHID:D011247],Vomiting[MeSHID:D014839],Peripheral Neuropathy[MeSHID:D010523] approved,investigational,nutraceutical,vet_approved pyridoxal kinase PDXK NA ligand NA drugbank adenosine-5'-[beta, gamma-methylene]triphosphate small molecule NA experimental pyridoxal kinase PDXK NA unknown NA drugbank o6-(r)-roscovitine, r-2-(6-benzyloxy-9-isopropyl-9h-purin-2-ylamino)-butan-1-ol small molecule NA experimental pyridoxal kinase PDXK NA unknown NA drugbank l-betagamma-meatp NA NA investigative pyridoxal kinase PDXK Literature-reported target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical pyridoxal phosphate phosphatase PDXP NA cofactor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational phosphatidylethanolamine-binding protein 1 PEBP1 NA unknown NA drugbank adenine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical peroxisomal trans-2-enoyl-coa reductase PECR NA unknown NA drugbank calcium citrate small molecule NA approved,investigational peflin PEF1 NA ligand NA drugbank calcium phosphate small molecule NA approved peflin PEF1 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved peflin PEF1 NA unknown NA drugbank drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn platelet factor 4 PF4 NA unknown NA drugbank dociparstat sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 platelet factor 4 PF4 Clinical trial target unknown NA TTD heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational platelet factor 4 PF4 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical phosphoribosylformylglycinamidine synthase PFAS NA unknown NA drugbank adenosine 5'-[gamma-thio]triphosphate small molecule NA experimental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 PFKFB1 NA unknown NA drugbank guanosine-5'-triphosphate small molecule NA experimental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 PFKFB1 NA unknown NA drugbank fructose-6-phosphate small molecule NA experimental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 PFKFB1 NA unknown NA drugbank d-gluco-2,5-anhydro-1-deoxy-1-phosphonohexitol-6-phosphate small molecule NA experimental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 PFKFB1 NA unknown NA drugbank sn-glycerol 3-phosphate small molecule NA experimental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 PFKFB1 NA unknown NA drugbank 3po NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] investigative renal carcinoma antigen ny-ren-56 PFKFB3 Clinical trial target unknown NA TTD pfk-158 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 renal carcinoma antigen ny-ren-56 PFKFB3 Clinical trial target unknown NA TTD , DGIDB phosphoaminophosphonic acid-adenylate ester small molecule NA experimental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 PFKFB4 NA unknown NA drugbank fructose-6-phosphate small molecule NA experimental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 PFKFB4 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational profilin-1 PFN1 NA ligand NA drugbank 7-hydroxy-4-methyl-3-(2-hydroxy-ethyl)coumarin small molecule NA experimental profilin-1 PFN1 NA unknown NA drugbank triglyme small molecule NA experimental profilin-2 PFN2 NA unknown NA drugbank pentaglyme small molecule NA experimental profilin-2 PFN2 NA unknown NA drugbank sucralfate small molecule Maintenance[MeSHID:D008283],Gastritis[MeSHID:D005756],Ulcer[MeSHID:D014456],Dyspepsia[MeSHID:D004415],Gastroesophageal reflux disease[MeSHID:D005764],Duodenal Ulcer[MeSHID:D004381],Peptic Ulcer[MeSHID:D010437],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved pepsin a-5 PGA5 NA inhibitor 84.87 drugbank , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational phosphoglycerate mutase 1 PGAM1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational phosphoglycerate mutase 1 PGAM1 NA ligand NA drugbank benzene hexacarboxylic acid small molecule NA experimental phosphoglycerate mutase 2 PGAM2 NA unknown NA drugbank 3-phospho-d-glyceric acid small molecule NA experimental phosphoglycerate mutase 2 PGAM2 NA unknown NA drugbank nicotinamide 8-bromo-adenine dinucleotide phosphate small molecule NA experimental 6-phosphogluconate dehydrogenase, decarboxylating PGD NA unknown NA drugbank (2r)-2-methyl-4,5-dideoxy NA NA investigative phosphogluconate dehydrogenase PGD Successful target unknown NA TTD dacarbazine small molecule melanoma[MeSHID:D008545],Hodgkin Disease[MeSHID:D006689],Neoplasm Metastasis[MeSHID:D009362],Cutaneous Melanoma[MeSHID:C562393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 6-phosphogluconate dehydrogenase, decarboxylating PGD NA inhibitor NA drugbank 6-phospho-d-gluconic acid small molecule NA experimental 6-phosphogluconate dehydrogenase, decarboxylating PGD NA unknown NA drugbank pyrophosphate 2- NA NA investigative phosphogluconate dehydrogenase PGD Successful target unknown NA TTD gadopentetic acid small molecule Blood Vessel[MeSHID:D001808],Brain[MeSHID:D001921],Vertebral column[MeSHID:D013131],Body tissue[MeSHID:D014024],Heart[MeSHID:D006321] approved 6-phosphogluconate dehydrogenase, decarboxylating PGD NA inhibitor NA drugbank 6-phosphogluconic acid NA NA investigative phosphogluconate dehydrogenase PGD Successful target unknown NA TTD 4-phospho-d-erythronate NA NA investigative phosphogluconate dehydrogenase PGD Successful target unknown NA TTD 5-deoxy-5-phosphono-d-arabinonate NA NA investigative phosphogluconate dehydrogenase PGD Successful target unknown NA TTD ketotifen small molecule Asthma[MeSHID:D001249],Pruritus[MeSHID:D011537],Eye[MeSHID:D005123],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 6-phosphogluconate dehydrogenase, decarboxylating PGD NA inhibitor NA drugbank ghrp-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved phosphogluconate dehydrogenase PGD Successful target unknown NA TTD , DGIDB sflt-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 placenta growth factor PGF Successful target unknown NA TTD , DGIDB 2-methyl-2,4-pentanediol NA NA investigative placenta growth factor PGF Successful target unknown NA TTD aflibercept biotech Neoplasm Metastasis[MeSHID:D009362],Pathologic Neovascularization[MeSHID:D009389],Structure of central vein of the retina[MeSHID:D012169],Macular Edema, Cystoid[MeSHID:D008269],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved placenta growth factor PGF Successful target binder,inhibitor 12.73 TTD , drugbank , DGIDB tb-403 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 placenta growth factor PGF Successful target unknown 42.43 TTD , DGIDB aflibercept biotech Neoplasm Metastasis[MeSHID:D009362],Pathologic Neovascularization[MeSHID:D009389],Structure of central vein of the retina[MeSHID:D012169],Macular Edema, Cystoid[MeSHID:D008269],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved placenta growth factor PGF Successful target binder 12.73 TTD , drugbank , DGIDB ro-5323441 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 placenta growth factor PGF Successful target unknown 42.43 TTD , DGIDB r7334 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 placenta growth factor PGF Successful target unknown NA TTD , DGIDB l-269,289 NA NA investigative geranylgeranyl transferase i PGGT1B Clinical trial target unknown NA TTD a-313326 NA NA investigative geranylgeranyl transferase i PGGT1B Clinical trial target unknown NA TTD j-109,390 NA NA investigative geranylgeranyl transferase i PGGT1B Clinical trial target unknown NA TTD 2-[methyl-(5-geranyl-4-methyl-pent-3-enyl)-amino]-ethyl-diphosphate small molecule NA experimental geranylgeranyl transferase type-1 subunit beta PGGT1B NA unknown NA drugbank l-778123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 geranylgeranyl transferase i PGGT1B Clinical trial target unknown NA TTD pd-83176 NA NA investigative geranylgeranyl transferase i PGGT1B Clinical trial target unknown NA TTD geranylgeranyl diphosphate small molecule NA experimental geranylgeranyl transferase type-1 subunit beta PGGT1B NA unknown NA drugbank l-778123 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] experimental geranylgeranyl transferase type-1 subunit beta PGGT1B NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational phosphoglycerate kinase 1 PGK1 NA ligand NA drugbank adenosine-5'-[beta, gamma-methylene]triphosphate small molecule NA experimental phosphoglycerate kinase 1 PGK1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational phosphoglycerate kinase 1 PGK1 NA unknown NA drugbank 3-phospho-d-glyceric acid small molecule NA experimental phosphoglycerate kinase 1 PGK1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational n-acetylmuramoyl-l-alanine amidase PGLYRP2 NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental n-acetylmuramoyl-l-alanine amidase PGLYRP2 NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational n-acetylmuramoyl-l-alanine amidase PGLYRP2 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational n-acetylmuramoyl-l-alanine amidase PGLYRP2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational n-acetylmuramoyl-l-alanine amidase PGLYRP2 NA unknown NA drugbank 2-acetamido-2-deoxy-beta-d-glucopyranose(beta1-4)-2-acetamido-1,6-anhydro-3-o-[(r)-1-carboxyethyl]-2-deoxy-beta-d-glucopyranose-l-alanyl-gamma-d-glutamyl-meso-diaminopimelyl-d-alanine small molecule NA experimental peptidoglycan recognition protein 3 PGLYRP3 NA unknown NA drugbank alpha-d-glucose 1,6-bisphosphate small molecule NA experimental phosphoglucomutase-1 PGM1 NA unknown NA drugbank alpha-d-glucose-1-phosphate-6-vanadate small molecule NA experimental phosphoglucomutase-1 PGM1 NA unknown NA drugbank zk-112993 NA NA investigative progesterone receptor PGR Successful target unknown NA TTD norgestimate small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational progesterone receptor PGR Successful target agonist 2.05 TTD , drugbank , DGIDB lindane small molecule Lice Infestations[MeSHID:D010373],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Scabies[MeSHID:D012532] approved,withdrawn progesterone receptor PGR NA unknown NA drugbank norgestrel small molecule Pregnancy[MeSHID:D011247] approved progesterone receptor PGR NA binder,agonist 0.76 drugbank , DGIDB mifepristone small molecule Hyperglycemia[MeSHID:D006943],Operative Surgical Procedures[MeSHID:D013514],Impaired glucose tolerance[MeSHID:D018149],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Cushing Syndrome[MeSHID:D003480],Adrenal Gland Hyperfunction[MeSHID:D000308],ADULT SYNDROME[MeSHID:C538052],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational progesterone receptor PGR NA antagonist 0.57 drugbank , DGIDB tanaproget small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,investigative progesterone receptor PGR Successful target agonist 3.41 TTD , drugbank , DGIDB ulipristal small molecule Coitus[MeSHID:D003075],Uterine Fibroids[MeSHID:D007889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved progesterone receptor PGR Successful target modulator 5.68 TTD , drugbank , DGIDB progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved progesterone receptor PGR Successful target agonist 0.22 TTD , drugbank , DGIDB telapristone acetate small molecule Uterine Fibroids[MeSHID:D007889],Endometriosis[MeSHID:D004715] investigational progesterone receptor PGR NA modulator 1.14 drugbank , DGIDB fluticasone small molecule Disease Management[MeSHID:D019468],Rhinitis, Allergic, Perennial[MeSHID:D012221],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental progesterone receptor PGR NA agonist NA drugbank progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved progesterone receptor PGR Successful target agonist 0.22 TTD , drugbank , DGIDB mometasone furoate small molecule Pruritus[MeSHID:D011537],Hay fever[MeSHID:D006255],Asthma[MeSHID:D001249],Dermatitis[MeSHID:D003872],Nasal Polyps[MeSHID:D009298],Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666] approved,investigational,vet_approved progesterone receptor PGR NA unknown NA drugbank 6-(3-nitro-phenyl)-3h-benzothiazol-2-one NA NA investigative progesterone receptor PGR Successful target unknown NA TTD 1-benzyl-3-phenylquinazoline-2,4(1h,3h)-dione NA NA investigative progesterone receptor PGR Successful target unknown NA TTD enzacamene small molecule Sunscreening Agents[MeSHID:D013473] approved progesterone receptor PGR NA antagonist NA drugbank npc-01 NA Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 progesterone receptor PGR Successful target unknown NA TTD , DGIDB virexxa NA Endometrial Carcinoma[MeSHID:D016889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 progesterone receptor PGR Successful target unknown NA TTD , DGIDB megestrol acetate small molecule Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Anorexia[MeSHID:D000855],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Malignant neoplasm of prostate[MeSHID:D011471],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Cachexia[MeSHID:D002100],Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of breast[MeSHID:D001943],Weight decreased[MeSHID:D015431],Recurrence (disease attribute)[MeSHID:D012008] approved,investigational,vet_approved progesterone receptor PGR NA agonist NA drugbank , DGIDB 4-(2,4-diethyl-1h-pyrrol-3-yloxy)benzonitrile NA NA investigative progesterone receptor PGR Successful target unknown NA TTD dienogest small molecule Endometriosis[MeSHID:D004715] approved progesterone receptor PGR NA agonist 1.14 drugbank , DGIDB pf-02367982 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] investigative progesterone receptor PGR Successful target unknown NA TTD gestrinone small molecule Infertility[MeSHID:D007246],Unmarried[MeSHID:D012847],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved progesterone receptor PGR NA antagonist,agonist NA drugbank asoprisnil small molecule Uterine Fibroids[MeSHID:D007889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] investigational,discontinued in phase 3 progesterone receptor PGR Successful target modulator 4.55 TTD , drugbank , DGIDB fluticasone furoate small molecule Asthma[MeSHID:D001249],Disease Management[MeSHID:D019468],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221] approved progesterone receptor PGR NA agonist NA drugbank dydrogesterone small molecule Previous Abortion[MeSHID:D000028],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menstruation Disturbances[MeSHID:D008599] approved,investigational,withdrawn progesterone receptor PGR Successful target agonist 4.17 TTD , drugbank , DGIDB pf-2413873 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 1 progesterone receptor PGR Successful target unknown NA TTD , DGIDB levonorgestrel small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Patient Discharge[MeSHID:D010351],Coitus[MeSHID:D003075],Menorrhagia[MeSHID:D008595],Endometrial Hyperplasia[MeSHID:D004714],Off-Label Use[MeSHID:D056687],Unmarried[MeSHID:D012847],Osteoporosis[MeSHID:D010024],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational progesterone receptor PGR Successful target modulator 4.17 TTD , drugbank , DGIDB phthalic acid small molecule NA experimental progesterone receptor PGR NA unknown NA drugbank estradiol valerate/dienogest NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved progesterone receptor PGR Successful target unknown NA TTD , DGIDB gestodene small molecule NA investigational progesterone receptor PGR NA binder,activator 1.14 drugbank , DGIDB medroxyprogesterone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved progesterone receptor PGR Successful target unknown 0.41 TTD , DGIDB mometasone small molecule Asthma[MeSHID:D001249],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] experimental progesterone receptor PGR NA agonist NA drugbank telapristone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 2 progesterone receptor PGR Successful target unknown NA TTD , DGIDB norethisterone small molecule Atrophic[MeSHID:D001284],Endometriosis[MeSHID:D004715],Osteoporosis, Postmenopausal[MeSHID:D015663] approved progesterone receptor PGR NA agonist 1.52 drugbank , DGIDB way-255348 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative progesterone receptor PGR Successful target antagonist 1.14 TTD , DGIDB org-31710 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 progesterone receptor PGR Successful target unknown NA TTD 5,n-dihydroxythalidomide NA NA investigative progesterone receptor PGR Successful target unknown NA TTD gsk-325971a NA NA investigative progesterone receptor PGR Successful target unknown NA TTD 3,3-dimethyl-5-m-tolyl-2,3-dihydro-1h-inden-1-one NA NA investigative progesterone receptor PGR Successful target unknown NA TTD medroxyprogesterone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved progesterone receptor PGR Successful target agonist 0.41 TTD , DGIDB 2,2,4-trimethyl-6-phenyl-1,2-dihydro-quinoline NA NA investigative progesterone receptor PGR Successful target unknown NA TTD mifepristone small molecule Hyperglycemia[MeSHID:D006943],Operative Surgical Procedures[MeSHID:D013514],Impaired glucose tolerance[MeSHID:D018149],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Cushing Syndrome[MeSHID:D003480],Adrenal Gland Hyperfunction[MeSHID:D000308],ADULT SYNDROME[MeSHID:C538052],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary-dependent Cushing's disease[MeSHID:D047748] approved,investigational progesterone receptor PGR NA antagonist,agonist 0.57 drugbank , DGIDB gsk-008a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Female Genital Diseases[MeSHID:D005831] investigative progesterone receptor PGR Successful target unknown NA TTD zk-114043 NA NA investigative progesterone receptor PGR Successful target unknown NA TTD demegestone small molecule NA experimental progesterone receptor PGR NA agonist NA drugbank drospirenone small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Hirsutism[MeSHID:D006628],Menarche[MeSHID:D008572],Acne Vulgaris[MeSHID:D000152],Postmenopause[MeSHID:D017698],Menstruation[MeSHID:D008598],Atrophic[MeSHID:D001284],Osteoporosis[MeSHID:D010024],Dysmenorrhea[MeSHID:D004412],Premenstrual Dysphoric Disorder[MeSHID:D065446],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved progesterone receptor PGR NA agonist 2.84 drugbank , DGIDB segesterone acetate; ethinyl estradiol NA NA approved progesterone receptor PGR Successful target unknown NA TTD ethynodiol diacetate small molecule Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved progesterone receptor PGR Successful target agonist 1.52 TTD , drugbank , DGIDB ethynodiol diacetate small molecule Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved progesterone receptor PGR Successful target agonist NA TTD , drugbank , DGIDB mitotane small molecule Tumors of Adrenal Cortex[MeSHID:D000306],Cushing Syndrome[MeSHID:D003480],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adrenocortical carcinoma[MeSHID:D018268] approved progesterone receptor PGR NA unknown NA drugbank gtpl8662 NA NA investigative progesterone receptor PGR Successful target unknown NA TTD segesterone acetate small molecule Reproduction[MeSHID:D012098],Vagina[MeSHID:D014621],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational progesterone receptor PGR NA agonist,activator NA drugbank vilaprisan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 2 progesterone receptor PGR Successful target unknown 1.14 TTD , DGIDB hydroxyprogesterone caproate small molecule Pregnancy[MeSHID:D011247],Premature Birth[MeSHID:D047928] approved,investigational progesterone receptor PGR NA agonist 0.28 drugbank , DGIDB homosalate small molecule Malignant neoplasm of skin[MeSHID:D012878],Sunburn[MeSHID:D013471],Sunscreening Agents[MeSHID:D013473],Skin Aging[MeSHID:D015595] approved,investigational progesterone receptor PGR NA antagonist NA drugbank oxybenzone small molecule Sunscreening Agents[MeSHID:D013473] approved,investigational progesterone receptor PGR NA antagonist NA drugbank al-43 NA NA investigative progesterone receptor PGR Successful target unknown NA TTD darolutamide small molecule Diagnosis[MeSHID:D003933],Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational progesterone receptor PGR NA antagonist NA drugbank s-prant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Uterine Fibroids[MeSHID:D007889] phase 2 progesterone receptor PGR Successful target unknown NA TTD , DGIDB 3-phenyl-1-propylquinazoline-2,4(1h,3h)-dione NA NA investigative progesterone receptor PGR Successful target unknown NA TTD desogestrel small molecule Ovulation[MeSHID:D010060],Pregnancy[MeSHID:D011247],Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved progesterone receptor PGR Successful target agonist 2.84 TTD , drugbank , DGIDB [3h]methyltrienolone NA NA investigative progesterone receptor PGR Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved progesterone receptor PGR NA agonist NA drugbank norelgestromin small molecule Malignant neoplasm of breast[MeSHID:D001943],Pregnancy[MeSHID:D011247] approved,investigational progesterone receptor PGR NA agonist 2.65 drugbank , DGIDB mk-8342 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 progesterone receptor PGR Successful target unknown NA TTD , DGIDB danazol small molecule Breast Fibrocystic Disease[MeSHID:D005348],Angioedemas, Hereditary[MeSHID:D054179],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menorrhagia[MeSHID:D008595],Malignant neoplasm of breast[MeSHID:D001943] approved progesterone receptor PGR NA agonist 0.36 drugbank , DGIDB lgd-5552 NA NA investigative progesterone receptor PGR Successful target unknown NA TTD lecanindole d NA NA investigative progesterone receptor PGR Successful target unknown NA TTD 3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile NA NA investigative progesterone receptor PGR Successful target unknown NA TTD levonorgestrel small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Patient Discharge[MeSHID:D010351],Coitus[MeSHID:D003075],Menorrhagia[MeSHID:D008595],Endometrial Hyperplasia[MeSHID:D004714],Off-Label Use[MeSHID:D056687],Unmarried[MeSHID:D012847],Osteoporosis[MeSHID:D010024],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational progesterone receptor PGR Successful target modulator,agonist 4.17 TTD , drugbank , DGIDB 5-(2-oxoindolin-5-yl)-1h-pyrrole-2-carbonitrile NA NA investigative progesterone receptor PGR Successful target unknown NA TTD tosagestin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 progesterone receptor PGR Successful target unknown 1.14 TTD , DGIDB gsk-1564023a NA NA investigative progesterone receptor PGR Successful target unknown NA TTD zk-136798 NA NA investigative progesterone receptor PGR Successful target unknown NA TTD asoprisnil small molecule Uterine Fibroids[MeSHID:D007889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] investigational,discontinued in phase 3 progesterone receptor PGR Successful target antagonist 4.55 TTD , drugbank , DGIDB norgestrel small molecule Pregnancy[MeSHID:D011247] approved progesterone receptor PGR NA binder 0.76 drugbank , DGIDB org2058 NA NA investigative progesterone receptor PGR Successful target agonist NA TTD , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved progesterone receptor PGR NA agonist NA drugbank metribolone small molecule NA experimental progesterone receptor PGR NA unknown NA drugbank bay 86-5044 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 progesterone receptor PGR Successful target unknown NA TTD , DGIDB medrogestone small molecule Metrorrhagia[MeSHID:D008796],Menstruation[MeSHID:D008598],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568] approved,withdrawn progesterone receptor PGR NA ligand NA drugbank fluticasone propionate small molecule Disease Management[MeSHID:D019468],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666] approved progesterone receptor PGR NA agonist NA drugbank , DGIDB etonogestrel small molecule Breast Feeding[MeSHID:D001942],Insertion Mutation[MeSHID:D016254],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational progesterone receptor PGR Successful target agonist 2.27 TTD , drugbank , DGIDB nestorone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 3 progesterone receptor PGR Successful target unknown NA TTD onapristone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 progesterone receptor PGR Successful target unknown 1.14 TTD , DGIDB medroxyprogesterone acetate small molecule Atrophic[MeSHID:D001284],Vagina[MeSHID:D014621],Mental concentration[MeSHID:D001288],Osteoporosis, Postmenopausal[MeSHID:D015663],Renal Cell Carcinoma[MeSHID:D002292],Endometrium[MeSHID:D004717],Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Endometrial Hyperplasia[MeSHID:D004714],Pain[MeSHID:D010146],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Vulva[MeSHID:D014844] approved,investigational progesterone receptor PGR NA agonist 0.41 drugbank , DGIDB norethindrone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved progesterone receptor PGR Successful target unknown 1.52 TTD , DGIDB norethindrone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved progesterone receptor PGR Successful target agonist 1.52 TTD , DGIDB megestrol acetate small molecule Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Anorexia[MeSHID:D000855],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Malignant neoplasm of prostate[MeSHID:D011471],Diagnosis[MeSHID:D003933],Neoplasm Metastasis[MeSHID:D009362],Cachexia[MeSHID:D002100],Endometrial Carcinoma[MeSHID:D016889],Malignant neoplasm of breast[MeSHID:D001943],Weight decreased[MeSHID:D015431],Recurrence (disease attribute)[MeSHID:D012008] approved,investigational,vet_approved progesterone receptor PGR NA agonist 0.28 drugbank , DGIDB allylestrenol small molecule Premature Obstetric Labor[MeSHID:D007752],Benign Prostatic Hyperplasia[MeSHID:D011470],Spontaneous abortion[MeSHID:D000022] experimental progesterone receptor PGR NA agonist NA drugbank onapristone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 progesterone receptor PGR Successful target antagonist 1.14 TTD , DGIDB megestrol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved progesterone receptor PGR Successful target unknown 1.7 TTD , DGIDB 2-(4-amino-3'-chloro-biphenyl-3-yl)-propan-2-ol NA NA investigative progesterone receptor PGR Successful target unknown NA TTD nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sigma receptor PGRMC1 NA binder NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved membrane-associated progesterone receptor component 1 PGRMC1 NA binder NA drugbank sertraline small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Post-Traumatic Stress Disorder[MeSHID:D013313],Vasovagal syncope[MeSHID:D019462],Phobia, Social[MeSHID:D000072861],Cerebrovascular accident[MeSHID:D020521],Panic Disorder[MeSHID:D016584],Obsessive compulsive behavior[MeSHID:D003192],Premenstrual Dysphoric Disorder[MeSHID:D065446],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sigma receptor PGRMC1 NA inhibitor,binder NA drugbank rocaglamide small molecule NA experimental prohibitin PHB NA inhibitor NA drugbank didesmethylrocaglamide small molecule NA experimental prohibitin PHB NA inhibitor NA drugbank rocaglamide small molecule NA experimental prohibitin-2 PHB2 NA inhibitor NA drugbank capsaicin small molecule Solutions[MeSHID:D012996],Postherpetic neuralgia[MeSHID:D051474],Neuralgia[MeSHID:D009437],Pain[MeSHID:D010146],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prohibitin-2 PHB2 NA unknown NA drugbank didesmethylrocaglamide small molecule NA experimental prohibitin-2 PHB2 NA inhibitor NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical d-3-phosphoglycerate dehydrogenase PHGDH NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform PHKG1 NA inhibitor NA drugbank choline small molecule NA approved,nutraceutical phosphoethanolamine/phosphocholine phosphatase PHOSPHO1 NA product of NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phytanoyl-coa dioxygenase, peroxisomal PHYH NA antagonist NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational phytanoyl-coa dioxygenase, peroxisomal PHYH NA antagonist NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical phytanoyl-coa dioxygenase, peroxisomal PHYH NA cofactor NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational phytanoyl-coa dioxygenase, peroxisomal PHYH NA antagonist NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical 5-phosphohydroxy-l-lysine phospho-lyase PHYKPL NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical 5-phosphohydroxy-l-lysine phospho-lyase PHYKPL NA cofactor NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational phosphatidylinositol 4-kinase type 2-beta PI4K2B NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational phosphatidylinositol 4-kinase type 2-beta PI4K2B NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational phosphatidylinositol 4-kinase beta PI4KB NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational phosphatidylinositol 4-phosphate 3-kinase c2 domain-containing subunit beta PIK3C2B NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational phosphatidylinositol 4-phosphate 3-kinase c2 domain-containing subunit gamma PIK3C2G NA inhibitor NA drugbank n-(5-{4-chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide small molecule NA experimental phosphatidylinositol 3-kinase catalytic subunit type 3 PIK3C3 NA unknown NA drugbank pilaralisib small molecule NA investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PIK3CA NA inhibitor 0.17 drugbank , DGIDB etp-46321 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative pi3-kinase alpha PIK3CA Successful target unknown NA TTD buparlisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase alpha PIK3CA Successful target unknown 0.3 TTD , DGIDB pwt-33597 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase alpha PIK3CA Successful target unknown NA TTD , DGIDB alpelisib small molecule Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PIK3CA NA inhibitor 0.3 drugbank , DGIDB xl765 small molecule Malignant Neoplasms[MeSHID:D009369] investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PIK3CA NA inhibitor 0.14 drugbank , DGIDB hhcyh33 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 pi3-kinase alpha PIK3CA Successful target unknown NA TTD copanlisib small molecule Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008] approved,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PIK3CA NA inhibitor 0.23 drugbank , DGIDB atp small molecule NA investigational,nutraceutical phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PIK3CA NA unknown NA drugbank ly3023414 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 pi3-kinase alpha PIK3CA Successful target unknown 0.21 TTD , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PIK3CA NA inhibitor NA drugbank gdc-0032 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase alpha PIK3CA Successful target inhibitor 0.46 TTD , DGIDB wortmannin small molecule Expiration, function[MeSHID:D045853],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Hematologic Neoplasms[MeSHID:D019337] experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PIK3CA NA inhibitor 0.02 drugbank , DGIDB buparlisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase alpha PIK3CA Successful target inhibitor 0.3 TTD , DGIDB bay 80-6946 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224], Non-Hodgkin[MeSHID:D008228] approved pi3-kinase alpha PIK3CA Successful target unknown NA TTD , DGIDB pa-799 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase alpha PIK3CA Successful target inhibitor 0.17 TTD , DGIDB xl765 small molecule Malignant Neoplasms[MeSHID:D009369] investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform PIK3CA NA unknown NA drugbank , DGIDB mln1117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase alpha PIK3CA Successful target unknown 0.42 TTD , DGIDB alpelisib NA Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved pi3-kinase alpha PIK3CA Successful target unknown 0.3 TTD , DGIDB alpelisib NA Breast[MeSHID:D001940],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved pi3-kinase alpha PIK3CA Successful target inhibitor 0.3 TTD , DGIDB bly719 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase alpha PIK3CA Successful target unknown NA TTD , DGIDB gdc-0032 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase alpha PIK3CA Successful target unknown 0.46 TTD , DGIDB pqr309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Cells[MeSHID:D002477] phase 2 pi3-kinase beta PIK3CB Clinical trial target unknown 0.39 TTD , DGIDB buparlisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase beta PIK3CB Clinical trial target inhibitor 0.12 TTD , DGIDB isis 31996 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD buparlisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase beta PIK3CB Clinical trial target unknown 0.12 TTD , DGIDB pik-75 NA NA investigative pi3-kinase beta PIK3CB Clinical trial target inhibitor NA TTD , DGIDB gsk2636771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 pi3-kinase beta PIK3CB Clinical trial target unknown 0.18 TTD , DGIDB isis 31963 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32021 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32039 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD ly-292223 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD bay 1082439 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase beta PIK3CB Clinical trial target unknown NA TTD , DGIDB pi-3065 NA NA investigative pi3-kinase beta PIK3CB Clinical trial target inhibitor NA TTD , DGIDB gsk2636771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 pi3-kinase beta PIK3CB Clinical trial target inhibitor 0.18 TTD , DGIDB azd8186 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase beta PIK3CB Clinical trial target unknown 0.49 TTD , DGIDB isis 32020 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32003 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32010 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32008 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32015 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32028 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform PIK3CB NA inhibitor NA drugbank isis 32035 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32004 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32024 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD ethyl 1-[(1h-benzimidazol-2(3h)one-5-yl)sulfonyl]-1h-pyrrole-2-carboxylate NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32006 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD ku-0060648 NA NA investigative pi3-kinase beta PIK3CB Clinical trial target inhibitor 0.16 TTD , DGIDB pa-799 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase beta PIK3CB Clinical trial target inhibitor 0.16 TTD , DGIDB azd8186 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase beta PIK3CB Clinical trial target inhibitor 0.49 TTD , DGIDB isis 32002 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 32005 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD isis 31982 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD xl765 small molecule Malignant Neoplasms[MeSHID:D009369] investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform PIK3CB NA unknown NA drugbank isis 32000 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD pp121 NA NA investigative pi3-kinase beta PIK3CB Clinical trial target inhibitor NA TTD , DGIDB isis 32014 NA NA investigative pi3k p110 beta messenger rna PIK3CB Literature-reported target unknown NA TTD tgx-221 NA NA investigative pi3-kinase beta PIK3CB Clinical trial target inhibitor NA TTD , DGIDB idelalisib small molecule Chronic Lymphocytic Leukemia[MeSHID:D015451],Relapse[MeSHID:D012008],Neoplasm Metastasis[MeSHID:D009362],B-Cell Lymphomas[MeSHID:D016393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA inhibitor 0.86 drugbank , DGIDB amg 319 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Hematologic Neoplasms[MeSHID:D019337] phase 1 pi3-kinase delta PIK3CD Successful target unknown NA TTD , DGIDB rp6530 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 pi3-kinase delta PIK3CD Successful target unknown NA TTD , DGIDB ic87114 NA NA investigative pi3-kinase delta PIK3CD Successful target unknown NA TTD copanlisib small molecule Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008] approved,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA inhibitor 0.23 drugbank , DGIDB caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA inhibitor NA drugbank parsaclisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] phase 2 pi3-kinase delta PIK3CD Successful target inhibitor 1.03 TTD , DGIDB ipi-145 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Chronic Lymphocytic Leukemia[MeSHID:D015451],Arthritis[MeSHID:D001168] approved pi3-kinase delta PIK3CD Successful target unknown 1.23 TTD , DGIDB buparlisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase delta PIK3CD Successful target inhibitor 0.17 TTD , DGIDB me-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] phase 1 pi3-kinase delta PIK3CD Successful target inhibitor 2.05 TTD , DGIDB 2-((9h-purin-6-ylthio)methyl)-5-chloro-3-(2-methoxyphenyl)quinazolin-4(3h)-one small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA unknown NA drugbank etp-46321 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative pi3-kinase delta PIK3CD Successful target unknown NA TTD hmpl-689 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 pi3-kinase delta PIK3CD Successful target unknown NA TTD idelalisib NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Relapse[MeSHID:D012008],Neoplasm Metastasis[MeSHID:D009362],B-Cell Lymphomas[MeSHID:D016393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved pi3-kinase delta PIK3CD Successful target inhibitor 0.86 TTD , DGIDB tg100-115 small molecule Myocardial Infarction[MeSHID:D009203],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA inhibitor 0.51 drugbank , DGIDB me-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224] phase 1 pi3-kinase delta PIK3CD Successful target unknown 2.05 TTD , DGIDB incb50465 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Lymphoma, Follicular[MeSHID:D008224] phase 2 pi3-kinase delta PIK3CD Successful target unknown NA TTD , DGIDB umbralisib small molecule Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA inhibitor 0.51 drugbank , DGIDB bay 80-6946 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224], Non-Hodgkin[MeSHID:D008228] approved pi3-kinase delta PIK3CD Successful target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 28 NA NA patented pi3-kinase delta PIK3CD Successful target unknown NA TTD , DGIDB duvelisib small molecule Lymphocyte[MeSHID:D008214],Cells[MeSHID:D002477],Blood Cells[MeSHID:D001773],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Bone Marrow[MeSHID:D001853],Cardiac Arrest[MeSHID:D006323],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Term Birth[MeSHID:D047929],lymph nodes[MeSHID:D008198],Disease[MeSHID:D004194],Body tissue[MeSHID:D014024],Blood[MeSHID:D001769],Lymphoid leukemia[MeSHID:D007945],leukemia[MeSHID:D007938],Cancer Stem Cells[MeSHID:D014411],Growth[MeSHID:D006128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA inhibitor 1.23 drugbank , DGIDB umbralisib NA Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Non-Hodgkin[MeSHID:D008228],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved pi3-kinase delta PIK3CD Successful target inhibitor 0.51 TTD , DGIDB pa-799 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase delta PIK3CD Successful target inhibitor 0.17 TTD , DGIDB me-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Lymphoma, Follicular[MeSHID:D008224] phase 1 pi3-kinase delta PIK3CD Successful target unknown 2.05 TTD , DGIDB bgb-10188 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393] phase 1 pi3-kinase delta PIK3CD Successful target unknown NA TTD incb40093 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1/2 pi3-kinase delta PIK3CD Successful target unknown NA TTD , DGIDB me-401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Chronic Lymphocytic Leukemia[MeSHID:D015451],Lymphoma, Follicular[MeSHID:D008224] phase 1 pi3-kinase delta PIK3CD Successful target inhibitor 2.05 TTD , DGIDB ethyl 1-[(1h-benzimidazol-2(3h)one-5-yl)sulfonyl]-1h-pyrrole-2-carboxylate NA NA investigative pi3-kinase delta PIK3CD Successful target unknown NA TTD leniolisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859] phase 2 pi3-kinase delta PIK3CD Successful target inhibitor 0.51 TTD , DGIDB gs-9901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 pi3-kinase delta PIK3CD Successful target unknown 1.03 TTD , DGIDB gs-9820 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Lymphoma[MeSHID:D008223] phase 1 pi3-kinase delta PIK3CD Successful target unknown 0.62 TTD , DGIDB idelalisib NA Chronic Lymphocytic Leukemia[MeSHID:D015451],Relapse[MeSHID:D012008],Neoplasm Metastasis[MeSHID:D009362],B-Cell Lymphomas[MeSHID:D016393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved pi3-kinase delta PIK3CD Successful target unknown 0.86 TTD , DGIDB xl765 small molecule Malignant Neoplasms[MeSHID:D009369] investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA unknown NA drugbank , DGIDB xl-499 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical pi3-kinase delta PIK3CD Successful target unknown NA TTD , DGIDB ly-292223 NA NA investigative pi3-kinase delta PIK3CD Successful target unknown NA TTD buparlisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase delta PIK3CD Successful target unknown 0.17 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PIK3CD NA inhibitor NA drugbank ic980033 NA NA investigative pi3-kinase delta PIK3CD Successful target unknown NA TTD bay 80-6946 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224], Non-Hodgkin[MeSHID:D008228] approved pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB 5-quinoxalin-6-ylmethylene-thiazolidine-2,4-dione small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank cudc-907 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447] phase 1/2 pi3-kinase gamma PIK3CG Successful target unknown 0.07 TTD , DGIDB (5e)-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank pa-799 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase gamma PIK3CG Successful target inhibitor 0.11 TTD , DGIDB sf1126 NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Liver carcinoma[MeSHID:D006528] phase 2 pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB ly-292223 NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD zstk474 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB wortmannin small molecule Expiration, function[MeSHID:D045853],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Hematologic Neoplasms[MeSHID:D019337] experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA inhibitor 0.04 drugbank , DGIDB xl765 small molecule Malignant Neoplasms[MeSHID:D009369] investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank , DGIDB tgx-221 NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD vs-5584 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant mesothelioma[MeSHID:C562839],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target inhibitor 0.16 TTD , DGIDB myricetin NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD enzastaurin NA Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] phase 3 pi3-kinase gamma PIK3CG Successful target unknown 0.07 TTD , DGIDB p-7170 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB bgt226 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase gamma PIK3CG Successful target unknown 0.21 TTD , DGIDB pqr309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Cells[MeSHID:D002477] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.25 TTD , DGIDB pik-75 NA NA investigative pi3-kinase gamma PIK3CG Successful target inhibitor NA TTD , DGIDB staurosporine small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank ly294002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroblastoma[MeSHID:D009447] phase 1 pi3-kinase gamma PIK3CG Successful target unknown NA TTD tg100-115 NA Myocardial Infarction[MeSHID:D009203],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 pi3-kinase gamma PIK3CG Successful target unknown 0.48 TTD , DGIDB czc 24832 NA NA investigative pi3-kinase gamma PIK3CG Successful target inhibitor NA TTD , DGIDB 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD gdc-0084 NA Brain[MeSHID:D001921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.21 TTD , DGIDB azd8186 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target unknown 0.21 TTD , DGIDB ipi-145 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Chronic Lymphocytic Leukemia[MeSHID:D015451],Arthritis[MeSHID:D001168] approved pi3-kinase gamma PIK3CG Successful target unknown 0.76 TTD , DGIDB perifosine NA Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of brain[MeSHID:D001932],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target unknown 0.13 TTD , DGIDB gdc-0077 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 2 pi3-kinase gamma PIK3CG Successful target inhibitor 0.32 TTD , DGIDB azd8186 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target inhibitor 0.21 TTD , DGIDB gdc-0077 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.32 TTD , DGIDB ds-7423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target inhibitor 0.11 TTD , DGIDB zstk474 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target inhibitor NA TTD , DGIDB hm-5016699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD adyvia NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 pi3-kinase gamma PIK3CG Successful target unknown NA TTD pi-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] investigative pi3-kinase gamma PIK3CG Successful target inhibitor 0.06 TTD , DGIDB pf-4989216 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD pf-04691502 NA Endometrial Carcinoma[MeSHID:D016889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.11 TTD , DGIDB gsk2126458 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 pi3-kinase gamma PIK3CG Successful target inhibitor 0.13 TTD , DGIDB rigosertib NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 pi3-kinase gamma PIK3CG Successful target unknown 0.07 TTD , DGIDB pf-04691502 NA Endometrial Carcinoma[MeSHID:D016889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 pi3-kinase gamma PIK3CG Successful target inhibitor 0.11 TTD , DGIDB pa-799 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase gamma PIK3CG Successful target unknown 0.11 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA inhibitor NA drugbank gdc-0980/rg7422 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB pp121 NA NA investigative pi3-kinase gamma PIK3CG Successful target inhibitor NA TTD , DGIDB sf1126 NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Liver carcinoma[MeSHID:D006528] phase 2 pi3-kinase gamma PIK3CG Successful target inhibitor NA TTD , DGIDB cu-906 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD multiform pi3k inhibitors NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD gsk1059615 NA Endometrial Carcinoma[MeSHID:D016889],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Lymphoma[MeSHID:D008223] discontinued in phase 1 pi3-kinase gamma PIK3CG Successful target unknown NA TTD px-866 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.17 TTD , DGIDB 5-quinoxalin-6-ylmethylene-thiazolidine-2,4-dione NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD ethyl 1-[(1h-benzimidazol-2(3h)one-5-yl)sulfonyl]-1h-pyrrole-2-carboxylate NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD px-866 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target inhibitor 0.17 TTD , DGIDB bez235 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target inhibitor 0.07 TTD , DGIDB duvelisib small molecule Lymphocyte[MeSHID:D008214],Cells[MeSHID:D002477],Blood Cells[MeSHID:D001773],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451],Bone Marrow[MeSHID:D001853],Cardiac Arrest[MeSHID:D006323],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Term Birth[MeSHID:D047929],lymph nodes[MeSHID:D008198],Disease[MeSHID:D004194],Body tissue[MeSHID:D014024],Blood[MeSHID:D001769],Lymphoid leukemia[MeSHID:D007945],leukemia[MeSHID:D007938],Cancer Stem Cells[MeSHID:D014411],Growth[MeSHID:D006128],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA inhibitor 0.76 drugbank , DGIDB as-604850 NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD sar245409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.11 TTD , DGIDB quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank ku-0060648 NA NA investigative pi3-kinase gamma PIK3CG Successful target inhibitor 0.11 TTD , DGIDB p-6915 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD bag956 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD aezs-126 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acrodermatitis enteropathica[MeSHID:C538178],Malignant Neoplasms[MeSHID:D009369] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD pf-03772304 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD clr457 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB wx-037 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative pi3-kinase gamma PIK3CG Successful target inhibitor 0.08 TTD , DGIDB lor-220 NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD clr-1401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 pi3-kinase gamma PIK3CG Successful target unknown 0.64 TTD , DGIDB ka2237 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1 pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB tg100-115 NA Myocardial Infarction[MeSHID:D009203],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 pi3-kinase gamma PIK3CG Successful target inhibitor 0.48 TTD , DGIDB myricetin small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank ipi-549 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258],Adrenocortical carcinoma[MeSHID:D018268],Malignant neoplasm of breast[MeSHID:D001943],Mesothelioma[MeSHID:D008654] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.64 TTD , DGIDB n-(5-{4-chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank pf-05212384 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.09 TTD , DGIDB her2- and psa-targeted tgx-d1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD czc-19091 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD 1-methyl-3-naphthalen-2-yl-1h-pyrazolo[3,4-d]pyrimidin-4-amine small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank ds-7423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target unknown 0.11 TTD , DGIDB buparlisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase gamma PIK3CG Successful target inhibitor 0.08 TTD , DGIDB ly-294002 small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4h)-one small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank hs-173 NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD vs-5584 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant mesothelioma[MeSHID:C562839],Malignant Neoplasms[MeSHID:D009369] phase 1 pi3-kinase gamma PIK3CG Successful target unknown 0.16 TTD , DGIDB gdc-0032 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase gamma PIK3CG Successful target unknown 0.17 TTD , DGIDB buparlisib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 pi3-kinase gamma PIK3CG Successful target unknown 0.08 TTD , DGIDB pki-402 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD xl147 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target inhibitor 0.13 TTD , DGIDB clr-1404 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB xl147 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.13 TTD , DGIDB 2-((9h-purin-6-ylthio)methyl)-5-chloro-3-(2-methoxyphenyl)quinazolin-4(3h)-one small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank gdc0941 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of breast[MeSHID:D001943],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target unknown NA TTD , DGIDB tg100-115 small molecule Myocardial Infarction[MeSHID:D009203],Angioedema[MeSHID:D000799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA inhibitor 0.48 drugbank , DGIDB bez235 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 pi3-kinase gamma PIK3CG Successful target unknown 0.07 TTD , DGIDB gsk2126458 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 pi3-kinase gamma PIK3CG Successful target unknown 0.13 TTD , DGIDB pi-3065 NA NA investigative pi3-kinase gamma PIK3CG Successful target unknown NA TTD 3-[4-amino-1-(1-methylethyl)-1h-pyrazolo[3,4-d]pyrimidin-3-yl]phenol small molecule NA experimental phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG NA unknown NA drugbank wortmannin small molecule Expiration, function[MeSHID:D045853],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Hematologic Neoplasms[MeSHID:D019337] experimental phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 NA unknown NA drugbank sf1126 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Liver carcinoma[MeSHID:D006528] investigational phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 NA inhibitor NA drugbank , DGIDB enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 NA unknown NA drugbank sf1126 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Liver carcinoma[MeSHID:D006528] investigational phosphatidylinositol 3-kinase regulatory subunit beta PIK3R2 NA inhibitor NA drugbank , DGIDB sf1126 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Liver carcinoma[MeSHID:D006528] investigational phosphatidylinositol 3-kinase regulatory subunit gamma PIK3R3 NA inhibitor NA drugbank , DGIDB ym-201636 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical phosphatidylinositol-3-phosphate 5-kinase PIKFYVE Clinical trial target unknown NA TTD lam-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Cell Lymphomas[MeSHID:D016393],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 phosphatidylinositol-3-phosphate 5-kinase PIKFYVE Clinical trial target unknown NA TTD , DGIDB apilimod dimesylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 2 phosphatidylinositol-3-phosphate 5-kinase PIKFYVE Clinical trial target unknown NA TTD , DGIDB (4r)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank 3,4-dihydroxy-1-methylquinolin-2(1h)-one small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank n-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank tricetin small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank imidazole small molecule NA experimental,investigational serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank (2s)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank dexfosfoserine small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank ncgc00167772-01 NA NA investigative serine/threonine-protein kinase pim-1 PIM1 Clinical trial target unknown NA TTD imidazopyridazin 1 small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank bisindolylmaleimide i small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank leucettine l41 NA NA investigative serine/threonine-protein kinase pim-1 PIM1 Clinical trial target inhibitor NA TTD , DGIDB (4r)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank 2,3-diphenyl-1h-indole-7-carboxylic acid small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank benzothiazine derivative 1 NA NA patented serine/threonine-protein kinase pim-1 PIM1 Clinical trial target unknown NA TTD , DGIDB n-phenyl-1h-pyrrolo[2,3-b]pyridin-3-amine small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank 6-(5-bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank sel-24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 serine/threonine-protein kinase pim-1 PIM1 Clinical trial target unknown NA TTD , DGIDB 4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5h)-one small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank pmid21982499c14k NA NA investigative serine/threonine-protein kinase pim-1 PIM1 Clinical trial target unknown NA TTD smi-4a NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative serine/threonine-protein kinase pim-1 PIM1 Clinical trial target unknown NA TTD pmid22136433c20 NA NA investigative serine/threonine-protein kinase pim-1 PIM1 Clinical trial target unknown NA TTD cxr-1002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase pim-1 PIM1 Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase pim-1 PIM1 NA inhibitor NA drugbank 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank staurosporine small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank ly-294002 small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank (3e)-3-[(4-hydroxyphenyl)imino]-1h-indol-2(3h)-one small molecule NA experimental serine/threonine-protein kinase pim-1 PIM1 NA unknown NA drugbank azd1208 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase pim-2 PIM2 Clinical trial target inhibitor NA TTD , DGIDB azd1208 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 serine/threonine-protein kinase pim-2 PIM2 Clinical trial target unknown NA TTD , DGIDB lgh-447 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 serine/threonine-protein kinase pim-2 PIM2 Clinical trial target unknown 5.3 TTD , DGIDB iddbcp226234 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative serine/threonine-protein kinase pim-2 PIM2 Clinical trial target unknown NA TTD pmid21982499c14k NA NA investigative serine/threonine-protein kinase pim-2 PIM2 Clinical trial target unknown NA TTD lgh-447 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 serine/threonine-protein kinase pim-2 PIM2 Clinical trial target inhibitor 5.3 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase pim-3 PIM3 NA inhibitor NA drugbank ac-phe-thr(po3h2)-pip-nal-gln-nh2 NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD beta-(2-naphthyl)-alanine NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD (r)-3-(2-naphthamido)-4-m-tolylbutanoic acid NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD avastin+/-tarceva NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 3 rotamase pin1 PIN1 Clinical trial target unknown NA TTD , DGIDB 3,6,9,12,15,18-hexaoxaicosane NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD (r)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD (r,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD 3,6,9,12,15,18-hexaoxaicosane small molecule NA experimental peptidyl-prolyl cis-trans isomerase nima-interacting 1 PIN1 NA unknown NA drugbank ac-bth-thr(po3h2)-pip-nal-gln-nh2 NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD (r)-2-(2-naphthamido)-3-p-tolylpropanoic acid NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD ac-phe-d-thr(po3h2)-pip-nal-gln-nh2 NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD (r)-2-(2-naphthamido)-3-m-tolylpropanoic acid NA NA investigative rotamase pin1 PIN1 Clinical trial target unknown NA TTD beta-(2-naphthyl)-alanine small molecule NA experimental peptidyl-prolyl cis-trans isomerase nima-interacting 1 PIN1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational phosphatidylinositol 5-phosphate 4-kinase type-2 beta PIP4K2B NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational phosphatidylinositol 5-phosphate 4-kinase type-2 gamma PIP4K2C NA inhibitor NA drugbank isa-2011b NA NA investigative ptdins(4)p-5-kinase 1 alpha PIP5K1A Literature-reported target inhibitor NA TTD , DGIDB glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved peroxisomal sarcosine oxidase PIPOX NA product of NA drugbank phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical phosphatidylserine decarboxylase proenzyme PISD NA unknown NA drugbank 1,2-diacyl-sn-glycero-3-phosphoinositol small molecule NA experimental phosphatidylinositol transfer protein alpha isoform PITPNA NA unknown NA drugbank (z,z)-4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxo-9-octadecenyl)oxy]-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium-4-oxide small molecule NA experimental phosphatidylinositol transfer protein alpha isoform PITPNA NA unknown NA drugbank phenamil NA NA investigative polycystic kidney disease 2-like 1 PKD2L1 Literature-reported target blocker 5.3 TTD , DGIDB flufenamate NA NA investigative polycystic kidney disease 2-like 1 PKD2L1 Literature-reported target blocker NA TTD , DGIDB citric acid NA NA investigative polycystic kidney disease 2-like 1 PKD2L1 Literature-reported target activator NA TTD , DGIDB malic acid NA NA investigative polycystic kidney disease 2-like 1 PKD2L1 Literature-reported target activator NA TTD , DGIDB benzamil NA NA investigative polycystic kidney disease 2-like 1 PKD2L1 Literature-reported target blocker 2.65 TTD , DGIDB n-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (2s)-2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 4-(4-chlorophenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank h-89 small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 3,5-diiodotyrosine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 4-(4-chlorobenzyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)ethylamino)ethyl)amide small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank myristic acid small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 6-{4-[4-(4-chlorophenyl)piperidin-4-yl]phenyl}-9h-purine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 3-pyridin-4-yl-2,4-dihydro-indeno[1,2-.c.] pyrazole small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank n-methyl-1-[4-(9h-purin-6-yl)phenyl]methanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (1s)-2-(1h-indol-3-yl)-1-[({5-[(e)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank a-674563 small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 5-(2-methylpiperazine-1-sulfonyl)isoquinoline small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 5-benzyl-1,3-thiazol-2-amine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (2s)-1-(3h-indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (2r)-2-(4-chlorophenyl)-2-phenylethanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (1s)-1-(1h-indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphtyridin-5-yloxy)-ehylamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 2-[4-(3-methyl-1h-pyrazol-4-yl)phenyl]ethanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (s)-1-phenyl-1-[4-(9h-purin-6-yl)phenyl]methanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (2s)-1-(1h-indol-3-yl)-3-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}propan-2-amine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (s)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 1-[4-(4-chlorophenyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 3-pyridin-4-yl-1h-indazole small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank y-27632 small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank fasudil small molecule NA investigational camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 1-[4-(4-chlorobenzyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (2r)-2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank hydroxyfasudil small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank (4r,2s)-5'-(4-(4-chlorobenzyloxy)pyrrolidin-2-ylmethanesulfonyl)isoquinoline small molecule NA experimental camp-dependent protein kinase inhibitor alpha PKIA NA unknown NA drugbank 2-phosphoglycolic acid small molecule NA experimental pyruvate kinase pklr PKLR NA unknown NA drugbank beta-d-fructofuranose 1,6-bisphosphate small molecule NA experimental pyruvate kinase pklr PKLR NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical pyruvate kinase pklr PKLR NA unknown NA drugbank 2-phosphoglycolic acid small molecule NA experimental pyruvate kinase pkm PKM NA unknown NA drugbank l-phospholactate small molecule NA experimental pyruvate kinase pkm PKM NA unknown NA drugbank 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one small molecule NA experimental pyruvate kinase pkm PKM NA unknown NA drugbank tp-1454 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 pyruvate kinase m2 PKM Clinical trial target unknown NA TTD cap-232 NA Renal Cell Carcinoma[MeSHID:D002292],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2a pyruvate kinase m2 PKM Clinical trial target unknown NA TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational pyruvate kinase pkm PKM NA ligand NA drugbank 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine small molecule NA experimental pyruvate kinase pkm PKM NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational pyruvate kinase pkm PKM NA unknown NA drugbank 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine small molecule NA experimental pyruvate kinase pkm PKM NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical pyruvate kinase pkm PKM NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase PKMYT1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase n1 PKN1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase n2 PKN2 NA inhibitor NA drugbank atu-027 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein kinase n3 PKN3 Clinical trial target unknown 63.65 TTD , DGIDB agkistrodon piscivorus antivenin biotech Disease Management[MeSHID:D019468] approved,experimental group 10 secretory phospholipase a2 PLA2G10 NA antagonist NA drugbank varespladib methyl small molecule Coronary Arteriosclerosis[MeSHID:D003324],Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational group 10 secretory phospholipase a2 PLA2G10 NA inhibitor 10.61 drugbank , DGIDB crotalus adamanteus antivenin biotech NA approved,experimental group 10 secretory phospholipase a2 PLA2G10 NA antagonist NA drugbank mrx-4 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Retardation, X-Linked 1[MeSHID:C567906] phase 2 phospholipase a2 PLA2G1B Successful target unknown 1.45 TTD , DGIDB sc-106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 phospholipase a2 PLA2G1B Successful target unknown NA TTD bolinaquinone NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD 4'-hydroxy-6,3',5'-triprenylisoflavonone NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD alpha-d-mannose NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD phosphonic acid 2-dodecanoylamino-hexyl ester propyl ester small molecule NA experimental phospholipase a2 PLA2G1B NA unknown NA drugbank agn-190383 NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD darapladib NA Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 phospholipase a2 PLA2G1B Successful target unknown NA TTD hyrtiosulawesine NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD petrosaspongiolide p NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD p-anisic acid small molecule NA experimental,investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD , drugbank miltefosine NA Leishmaniasis, Visceral[MeSHID:D007898],Disease susceptibility[MeSHID:D004198],Amebiasis[MeSHID:D000562],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leishmaniasis[MeSHID:D007896] approved phospholipase a2 PLA2G1B Successful target unknown 0.58 TTD , DGIDB clocortolone NA Scalp Dermatoses[MeSHID:D012536],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rosacea[MeSHID:D012393] approved phospholipase a2 PLA2G1B Successful target unknown 0.96 TTD , DGIDB epc-k1 NA Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] discontinued in phase 2 phospholipase a2 PLA2G1B Successful target unknown NA TTD way-123641 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 phospholipase a2 PLA2G1B Successful target unknown NA TTD mepacrine NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD manoalide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] phase 2 phospholipase a2 PLA2G1B Successful target unknown 1.45 TTD , DGIDB cacospongionolide NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD 1-o-octyl-2-heptylphosphonyl-sn-glycero-3-phosphoethanolamine small molecule NA experimental phospholipase a2 PLA2G1B NA unknown NA drugbank sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phospholipase a2 PLA2G1B NA antagonist NA drugbank cacospongionolide b NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD rilapladib NA Atherosclerosis[MeSHID:D050197],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 phospholipase a2 PLA2G1B Successful target unknown 0.96 TTD , DGIDB 3,9-dihydroxy-2,10-diprenylpterocap-6a-ene NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD acetate ion NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phospholipase a2 PLA2G1B Successful target unknown NA TTD , drugbank , DGIDB allerb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] phase 2b phospholipase a2 PLA2G1B Successful target unknown NA TTD , DGIDB mrx-6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Contact Dermatitis[MeSHID:D003877],Mental Retardation, X-Linked 1[MeSHID:C567906] phase 2 phospholipase a2 PLA2G1B Successful target unknown NA TTD , DGIDB pf-05212372 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 phospholipase a2 PLA2G1B Successful target unknown NA TTD cacospongionolide e NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD pyruvaldehyde small molecule NA experimental phospholipase a2 PLA2G1B NA unknown NA drugbank abyssinone v NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD sb-435495 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 phospholipase a2 PLA2G1B Successful target unknown NA TTD heptanoic acid small molecule NA experimental,investigational,investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD , drugbank clobetasol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lichen Planus, Oral[MeSHID:D017676],Rosacea[MeSHID:D012393] approved phospholipase a2 PLA2G1B Successful target unknown 0.72 TTD , DGIDB 2-methyl-2,4-pentanediol NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD niflumic acid small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental phospholipase a2 PLA2G1B NA inhibitor NA drugbank , DGIDB ly178002 NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD lpc-ether small molecule NA experimental,investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD , drugbank azelastine small molecule Pruritus[MeSHID:D011537],Hay fever[MeSHID:D006255],Allergic Conjunctivitis[MeSHID:D003233],Rhinitis, Vasomotor[MeSHID:D012223],Hypersensitivity[MeSHID:D006967],Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phospholipase a2 PLA2G1B NA inhibitor NA drugbank ly256548 NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD cholic acid small molecule Disease[MeSHID:D004194],Peroxisomal Disorders[MeSHID:D018901],Steatorrhea[MeSHID:D045602],Zellweger Spectrum[MeSHID:D015211],Liver diseases[MeSHID:D008107],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved phospholipase a2 PLA2G1B Successful target unknown 2.89 TTD , drugbank , DGIDB n-tridecanoic acid small molecule NA experimental,investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD , drugbank ursolic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Syndrome X[MeSHID:D024821] phase 2 phospholipase a2 PLA2G1B Successful target unknown NA TTD wa-8242-a1 NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD hexane-1,6-diol small molecule NA experimental,investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD , drugbank bm-162115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD sb-203347 NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD 1-decyl-3-trifluoro ethyl-sn-glycero-2-phosphomethanol small molecule NA experimental phospholipase a2 PLA2G1B NA unknown NA drugbank folipastatin NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD bmy-30129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] discontinued in phase 2 phospholipase a2 PLA2G1B Successful target unknown NA TTD petrosaspongiolide m NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD helenaquinone NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD diflorasone NA Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rosacea[MeSHID:D012393] approved phospholipase a2 PLA2G1B Successful target unknown 0.96 TTD , DGIDB medical cannabis biotech NA experimental,investigational phospholipase a2 PLA2G1B NA inhibitor,inducer NA drugbank methylglyoxal NA NA investigative phospholipase a2 PLA2G1B Successful target unknown NA TTD 1-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}-4-(1,1,3,3-tetramethylbutyl)benzene small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank n-tridecanoic acid NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD 6-phenyl-4(r)-(7-phenyl-heptanoylamino)-hexanoic acid small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational phospholipase a2, membrane associated PLA2G2A NA inhibitor NA drugbank cacospongionolide b NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational phospholipase a2, membrane associated PLA2G2A NA inhibitor NA drugbank kh064 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] clinical trial group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD , DGIDB didodecanoylphloroglucinol NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD ochnaflavone NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] investigational phospholipase a2, membrane associated PLA2G2A NA inhibitor NA drugbank bolinaquinone NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD kh064 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] experimental phospholipase a2, membrane associated PLA2G2A NA inhibitor NA drugbank , DGIDB kh064 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank , DGIDB lauric acid NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational phospholipase a2, membrane associated PLA2G2A NA inhibitor NA drugbank ginkgo biloba biotech Memory[MeSHID:D008568],Cognition[MeSHID:D003071] approved,investigational,nutraceutical phospholipase a2, membrane associated PLA2G2A NA inhibitor NA drugbank (1-benzyl-5-methoxy-2-methyl-1h-indol-3-yl)acetic acid small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank 1,4-butanediol NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD 2-propanol, isopropanol NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD b-octylglucoside NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD 4-(1-benzyl-3-carbamoylmethyl-2-methyl-1h-indol-5-yloxy)-butyric acid small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank 2-(4-phenoxyphenoxy)ethanamine NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD luffariellolide NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD n-tridecanoic acid small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank varespladib methyl small molecule Coronary Arteriosclerosis[MeSHID:D003324],Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigational phospholipase a2, membrane associated PLA2G2A NA inhibitor 3.03 drugbank , DGIDB lauric acid small molecule NA approved,experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank cacospongionolide e NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD (2r)-2-acetamido-3-(octadecyloxy)propyl 2-(methylsulfanyl)ethyl hydrogen phosphate small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank elaidoylamide NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD [3-(1-benzyl-3-carbamoylmethyl-2-methyl-1h-indol-5-yloxy)-propyl-]-phosphonic acid small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank dysidine NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD kh064 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] clinical trial group iia phospholipase a2 PLA2G2A Clinical trial target inhibitor NA TTD , DGIDB elaidamide small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank 1,4-butanediol small molecule NA experimental phospholipase a2, membrane associated PLA2G2A NA unknown NA drugbank cacospongionolide NA NA investigative group iia phospholipase a2 PLA2G2A Clinical trial target unknown NA TTD lauric acid small molecule NA approved,experimental group iid secretory phospholipase a2 PLA2G2D NA unknown NA drugbank stearic acid small molecule NA approved,experimental group iid secretory phospholipase a2 PLA2G2D NA unknown NA drugbank (2e)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank 1,4-butanediol small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank (2-carbamoylmethyl-5-propyl-octahydro-indol-7-yl)acetic acid small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank (r)-atenolol small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank 9-hydroxy-8-methoxy-6-nitro-phenanthrol[3,4-d][1,3]dioxole-5-carboxylic acid small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank indolepropionic acid small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank indoleacetic acid small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank licofelone small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank glycerin small molecule NA approved,investigational group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank n-tridecanoic acid small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank p-anisic acid small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank 3-{3-[(dimethylamino)methyl]-1h-indol-7-yl}propan-1-ol small molecule NA experimental group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank aminosalicylic acid small molecule Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Lung[MeSHID:D008168] approved group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank nimesulide small molecule Degenerative polyarthritis[MeSHID:D010003],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Lymphoma, Non-Hodgkin[MeSHID:D008228],Expiration, function[MeSHID:D045853],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational,withdrawn group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank oxyphenbutazone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved,withdrawn group iie secretory phospholipase a2 PLA2G2E NA unknown NA drugbank 1,1,1,2,2-pentafluoro-9-phenyl-nonan-3-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD tert-butyl 2-(2-oxohexadecanamido)acetate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1-trifluoro-4-(4-hexyloxy-phenyl)-butan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1,2,2-pentafluoro-8-phenyl-octan-3-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD ethyl 2-(2-oxohexadecanamido)acetate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD (s)-methyl 4-(2-oxohexadecanamido)octanoate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD [6,4''']biflavone NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD (z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1-trifluoro-5-(4-octylphenoxy)pentan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD way-196025 NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1-trifluoro-7-phenylheptan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD fluticasone propionate small molecule Disease Management[MeSHID:D019468],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666] approved cytosolic phospholipase a2 PLA2G4A NA inhibitor NA drugbank , DGIDB n-(4-ethoxybutyl)-2-oxohexadecanamide NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD [6,3''']biflavone NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD allyl 4-(2-oxohexadecanamido)butanoate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD ethyl 4-(2-oxohexadecanamido)benzoate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1-trifluoro-6-(naphthalen-2-yl)hexan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD darapladib small molecule Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational cytosolic phospholipase a2 PLA2G4A NA unknown NA drugbank methyl arachidonyl fluorophosphonate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1-trifluoro-8-phenyl-octan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD [3,4''']biflavone NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 4-(4-decyloxy-phenyl)-1,1,1-trifluoro-butan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 4-(2-oxohexadecanamido)butanoic acid NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1,3-tetrafluoro-6-phenylhexan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD tert-butyl 5-(2-oxohexadecanamido)pentanoate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1-trifluoro-6-(4-hexyloxy-phenyl)-hexan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD fluticasone small molecule Disease Management[MeSHID:D019468],Rhinitis, Allergic, Perennial[MeSHID:D012221],Dermatologic disorders[MeSHID:D012871],Asthma[MeSHID:D001249],Common Cold[MeSHID:D003139],Nose[MeSHID:D009666],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental cytosolic phospholipase a2 PLA2G4A NA inhibitor NA drugbank tert-butyl 3-(2-oxohexadecanamido)propanoate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD arachidonyl trifluoromethylketone NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1-trifluoroheptadecan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD [4',4''']-biflavone NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD (s)-tert-butyl 4-(2-oxohexadecanamido)pentanoate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD methyl 2-(2-oxo-8-phenyloctanamido)acetate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD methyl 2-(2-oxohexadecanamido)acetate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1,1,1,3-tetrafluoro-7-phenylheptan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD tert-butyl 3-(2-oxo-8-phenyloctanamido)propanoate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD ax-048 NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved cytosolic phospholipase a2 PLA2G4A NA inhibitor NA drugbank 1,1,1,3-tetrafluoro-heptadecan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD ax-006 NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD (s)-ethyl 6-(2-oxohexadecanamido)decanoate NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD niflumic acid small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental cytosolic phospholipase a2 PLA2G4A NA unknown NA drugbank quinacrine small molecule Disease Management[MeSHID:D019468],Leishmaniasis, Cutaneous[MeSHID:D016773],Pleural Effusion, Malignant[MeSHID:D016066],Giardiasis[MeSHID:D005873] investigational cytosolic phospholipase a2 PLA2G4A NA inhibitor NA drugbank ecopladib NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD ar-c70484xx NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 1-imidazol-1-yl-3-(4-octylphenoxy)propan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD 6-(4-decyloxy-phenyl)-1,1,1-trifluoro-hexan-2-one NA NA investigative cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD zpl521 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 1/2 cytosolic phospholipase a2 PLA2G4A Clinical trial target unknown NA TTD , DGIDB quinacrine small molecule Disease Management[MeSHID:D019468],Leishmaniasis, Cutaneous[MeSHID:D016773],Pleural Effusion, Malignant[MeSHID:D016066],Giardiasis[MeSHID:D005873] investigational 85/88 kda calcium-independent phospholipase a2 PLA2G6 NA inhibitor NA drugbank gsk2647544 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD , DGIDB rpaf-ah NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Total Hypotrichosis, Mari type[MeSHID:C536973] discontinued in phase 3 platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD sb-381320 NA NA investigative platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD 4-fluorobenzaldehyde o-benzoyloxime NA NA investigative platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD indolizine derivative 1 NA NA patented platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD , DGIDB bicyclic pyrimidine derivative 2 NA NA patented platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD , DGIDB goxalapladib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD 3,4-difluorobenzaldehyde o-benzoyloxime NA NA investigative platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate small molecule NA experimental,investigative platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD , drugbank gsk568859 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD (e)-(thiophen-2-ylmethylidene)amino benzoate NA NA investigative platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD rilapladib small molecule Atherosclerosis[MeSHID:D050197],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target inhibitor 21.22 TTD , drugbank , DGIDB benzaldehyde o-benzoyloxime NA NA investigative platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown NA TTD rilapladib small molecule Atherosclerosis[MeSHID:D050197],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 platelet-activating factor acetylhydrolase PLA2G7 Clinical trial target unknown 21.22 TTD , drugbank , DGIDB 5-(dimethylamino)-2-naphthalenesulfonic acid small molecule NA experimental,investigative tissue-type plasminogen activator PLAT Successful target unknown NA TTD , drugbank iloprost small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tissue-type plasminogen activator PLAT NA unknown NA drugbank human c1-esterase inhibitor biotech Angioedemas, Hereditary[MeSHID:D054179] approved tissue-type plasminogen activator PLAT NA inhibitor NA drugbank 2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine NA NA investigative tissue-type plasminogen activator PLAT Successful target unknown NA TTD n-(5-benzyloxy-isoquinolin-1-yl)-guanidine NA NA investigative tissue-type plasminogen activator PLAT Successful target unknown NA TTD bms-344577 NA NA investigative tissue-type plasminogen activator PLAT Successful target unknown NA TTD conestat alfa biotech Angioedemas, Hereditary[MeSHID:D054179] approved,investigational tissue-type plasminogen activator PLAT NA inhibitor NA drugbank aminocaproic acid small molecule Postoperative Hemorrhage[MeSHID:D019106],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194] approved,investigational tissue-type plasminogen activator PLAT Successful target antagonist NA TTD , drugbank , DGIDB n-(4-chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine NA NA investigative tissue-type plasminogen activator PLAT Successful target unknown NA TTD dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tissue-type plasminogen activator PLAT NA modulator NA drugbank aminocaproic acid small molecule Postoperative Hemorrhage[MeSHID:D019106],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194] approved,investigational tissue-type plasminogen activator PLAT Successful target antagonist,inhibitor 3.54 TTD , drugbank , DGIDB n-(7-benzyloxy-isoquinolin-1-yl)-guanidine NA NA investigative tissue-type plasminogen activator PLAT Successful target unknown NA TTD 1-guanidino-n-phenyl-7-isoquinolinesulphonamide NA NA investigative tissue-type plasminogen activator PLAT Successful target unknown NA TTD n-(4-phenyl-pyridin-2-yl)-guanidine NA NA investigative tissue-type plasminogen activator PLAT Successful target unknown NA TTD atn-658 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 7-methoxy-8-[1-(methylsulfonyl)-1h-pyrazol-4-yl]naphthalene-2-carboximidamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank upamostat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 urokinase-type plasminogen activator PLAU Successful target inhibitor 7.34 TTD , DGIDB 4-chloro-1-guanidino-7-isoquinolinesulphonamide NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD wx-uk1 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1/2 urokinase-type plasminogen activator PLAU Successful target inhibitor NA TTD , DGIDB 6-fluoro-2-[2-hydroxy-3-(2-methyl-cyclohexyloxy)-phenyl]-1h-indole-5-carboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank 4-(2-aminoethoxy)-3,5-dichloro-n-[3-(1-methylethoxy)phenyl]benzamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank cra_10655 small molecule NA experimental,investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , drugbank pro-urokinase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , DGIDB 4-iodobenzo[b]thiophene 2-carboxamidine NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD amediplase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927],Myocardial Infarction[MeSHID:D009203] phase 3 urokinase-type plasminogen activator PLAU Successful target unknown 1.22 TTD , DGIDB uk-356202 NA Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertrophy[MeSHID:D006984] clinical trial urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , DGIDB thieno[2,3-b]pyridine-2-carboxamidine small molecule NA experimental,investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , drugbank pai-2 NA NA discontinued in phase 2 urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 2-(2-hydroxy-5-methoxy-phenyl)-1h-benzoimidazole-5-carboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank urokinase NA Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved urokinase-type plasminogen activator PLAU Successful target unknown 2.86 TTD , DGIDB htu-pa NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , DGIDB (4-guanidino-benzyl)-carbamic acid benzyl ester NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 4-(2-aminoethoxy)-n-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank 6-(n-phenylcarbamyl)-2-naphthalenecarboxamidine small molecule NA experimental,investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , drugbank fibrinolysin biotech Hematoma[MeSHID:D006406],Operative Surgical Procedures[MeSHID:D013514],Ulcer[MeSHID:D014456],Injury wounds[MeSHID:D014947],Burn injury[MeSHID:D002056],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational urokinase-type plasminogen activator PLAU NA unknown NA drugbank 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine small molecule NA experimental,investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , drugbank 4-(2-aminoethoxy)-n-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank [2,4,6-triisopropyl-phenylsulfonyl-l-[3-amidino-phenylalanine]]-piperazine-n'-beta-alanine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank pmid18163548c4 NA Coronary Arteriosclerosis[MeSHID:D003324],Reperfusion Injury[MeSHID:D015427],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Ischemia[MeSHID:D017202] clinical trial urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , DGIDB 6-chloro-2-(2-hydroxy-biphenyl-3-yl)-1h-indole-5-carboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank 4-iodobenzo[b]thiophene-2-carboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank upa-targeted oncolytic sendai virus NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD uk-356202 NA Myocardium[MeSHID:D009206],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertrophy[MeSHID:D006984] clinical trial urokinase-type plasminogen activator PLAU Successful target inhibitor NA TTD , DGIDB 2-amino-1h-benzimidazol-5-ol small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank 6-[(z)-amino(imino)methyl]-n-[4-(aminomethyl)phenyl]-4-(pyrimidin-2-ylamino)-2-naphthamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank (4-nitro-1h-pyrazol-1-yl)(phenyl)methanone NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 6-[n-(1-isopropyl-1,2,3,4-tetrahydro-7-isoquinolinyl)carbamyl]-2-naphthalenecarboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank saruplase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 urokinase-type plasminogen activator PLAU Successful target unknown 2.45 TTD , DGIDB 6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1h-benzoimidazole-5-carboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank n-(4-carbamimidoyl-3-choro-phenyl)-2-hydroxy-3-iodo-5-methyl-benzamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank 1-benzoyl-n-phenyl-1h-pyrazole-3-carboxamide NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD (4-nitro-1h-pyrazol-1-yl)(o-tolyl)methanone NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD trans-6-(2-phenylcyclopropyl)-naphthalene-2-carboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank atf-hi-8 NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 1-guanidino-n-phenyl-7-isoquinolinesulphonamide NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1h-1,3-benzodiazole-5-carboximidamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank recombinant human pro-urokinase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 2-(2-hydroxy-phenyl)-3h-benzoimidazole-5-carboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved urokinase-type plasminogen activator PLAU NA inhibitor NA drugbank 1-guanidino-7-isoquinolinesulphonamide NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD (4-bromo-1h-pyrazol-1-yl)(p-tolyl)methanone NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD (3,4-dichlorophenyl)(1h-pyrazol-1-yl)methanone NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD (3-nitro-1h-pyrazol-1-yl)(p-tolyl)methanone NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD wx-uk1 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1/2 urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , DGIDB 6-[n-(4-ethyl-1,2,3,4-tetrahydro-6-isoquinolinyl)carbamyl]-2-naphthalenecarboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank 4-methoxy-n'-(2-phenylacetyl)benzohydrazide NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD upamostat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 urokinase-type plasminogen activator PLAU Successful target unknown 7.34 TTD , DGIDB 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 6-[(z)-amino(imino)methyl]-n-[3-(cyclopentyloxy)phenyl]-2-naphthamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank 2-amino-5-hydroxy-benzimidazole NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD benzamidine small molecule NA experimental,investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , drugbank (2r)-1-(2,6-dimethylphenoxy)propan-2-amine small molecule NA experimental,investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , drugbank 8-(pyrimidin-2-ylamino)naphthalene-2-carboximidamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank pai-1 NA NA phase 4 urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , DGIDB 2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD fucose NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD b-623 NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD 6-[n-(4-(aminomethyl)phenyl)carbamyl]-2-naphthalenecarboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank 4-(2-aminoethoxy)-n-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank cra_8696 small molecule NA experimental,investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , drugbank 5-methylsulfanyl-thiophene-2-carboxamidine NA NA investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD n-(1-adamantyl)-n'-(4-guanidinobenzyl)urea small molecule NA experimental,investigative urokinase-type plasminogen activator PLAU Successful target unknown NA TTD , drugbank 6-[n-(1-isopropyl-3,4-dihydro-7-isoquinolinyl)carbamyl]-2-naphthalenecarboxamidine small molecule NA experimental urokinase-type plasminogen activator PLAU NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational urokinase plasminogen activator surface receptor PLAUR NA unknown NA drugbank tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved urokinase plasminogen activator surface receptor PLAUR NA unknown NA drugbank urokinase biotech Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved,investigational,withdrawn urokinase plasminogen activator surface receptor PLAUR NA inducer,modulator 24.75 drugbank , DGIDB ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved urokinase plasminogen activator surface receptor PLAUR Successful target unknown 2.12 TTD , DGIDB wx-uk1 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational urokinase plasminogen activator surface receptor PLAUR NA unknown NA drugbank alteplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Pulmonary Embolism[MeSHID:D011655],Acute Cerebrovascular Accidents[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved urokinase plasminogen activator surface receptor PLAUR NA unknown NA drugbank ruxolitinib NA Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved urokinase plasminogen activator surface receptor PLAUR Successful target unknown 2.12 TTD , DGIDB inositol 2,4,5-trisphosphate small molecule NA experimental 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 PLCD1 NA unknown NA drugbank 1d-myo-inositol 1,4,5-trisphosphate small molecule NA experimental 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 PLCD1 NA unknown NA drugbank quinacrine small molecule Disease Management[MeSHID:D019468],Leishmaniasis, Cutaneous[MeSHID:D016773],Pleural Effusion, Malignant[MeSHID:D016066],Giardiasis[MeSHID:D005873] investigational inactive phospholipase c-like protein 1 PLCL1 NA inhibitor NA drugbank carbocisteine small molecule Mucous body substance[MeSHID:D009093],Bodily secretions[MeSHID:D012634],Disease[MeSHID:D004194],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational pi-plc x domain-containing protein 3 PLCXD3 NA inhibitor NA drugbank lax-101 small molecule Huntington Disease[MeSHID:D006816],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigational phospholipase d1 PLD1 NA unknown NA drugbank us9127005, p2b NA NA patented phospholipase d1 PLD1 Patented-recorded target unknown NA TTD , DGIDB ml272 NA NA patented phospholipase d1 PLD1 Patented-recorded target unknown NA TTD , DGIDB choline salicylate small molecule Exanthema[MeSHID:D005076],Teething syndrome[MeSHID:D014078],Oral Ulcer[MeSHID:D019226],Pain[MeSHID:D010146],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,nutraceutical phospholipase d1 PLD1 NA product of NA drugbank us9127005, p0l NA NA patented phospholipase d1 PLD1 Patented-recorded target unknown NA TTD , DGIDB us9453017, 1 NA NA patented phospholipase d1 PLD1 Patented-recorded target unknown NA TTD , DGIDB 1-(pyridin-2-yl)piperazine NA NA investigative phospholipase d1 PLD1 Patented-recorded target unknown NA TTD 1-(pyridin-4-yl)piperazine NA NA investigative phospholipase d1 PLD1 Patented-recorded target unknown NA TTD halopemide NA NA investigative phospholipase d1 PLD1 Patented-recorded target unknown 10.61 TTD , DGIDB choline small molecule NA approved,nutraceutical phospholipase d1 PLD1 NA product of NA drugbank us9127005, p2c NA NA patented phospholipase d1 PLD1 Patented-recorded target unknown NA TTD , DGIDB us9453017, 2 NA NA patented phospholipase d1 PLD1 Patented-recorded target unknown NA TTD , DGIDB vu0364739 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] clinical trial phospholipase d2 PLD2 Clinical trial target unknown NA TTD , DGIDB choline salicylate small molecule Exanthema[MeSHID:D005076],Teething syndrome[MeSHID:D014078],Oral Ulcer[MeSHID:D019226],Pain[MeSHID:D010146],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,nutraceutical phospholipase d2 PLD2 NA product of NA drugbank choline small molecule NA approved,nutraceutical phospholipase d2 PLD2 NA product of NA drugbank pip2 NA NA investigative phospholipase d2 PLD2 Clinical trial target activator NA TTD , DGIDB vu0364739 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] clinical trial phospholipase d2 PLD2 Clinical trial target inhibitor NA TTD , DGIDB citric acid small molecule NA approved,nutraceutical,vet_approved pleckstrin homology domain-containing family a member 1 PLEKHA1 NA unknown NA drugbank inositol 1,3,4,5-tetrakisphosphate small molecule NA experimental pleckstrin homology domain-containing family a member 4 PLEKHA4 NA unknown NA drugbank streptokinase biotech Arteries[MeSHID:D001158],Thrombosis[MeSHID:D013927],Deep Vein Thrombosis[MeSHID:D020246],Dental Occlusion[MeSHID:D003766],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasminogen PLG Successful target activator 21.95 TTD , drugbank , DGIDB grassystatin a NA NA investigative plasminogen PLG Successful target unknown NA TTD gabexate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatitis[MeSHID:D010195] investigational plasminogen PLG NA inhibitor NA drugbank retinostat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 2 plasminogen PLG Successful target unknown NA TTD , DGIDB tranexamic acid small molecule Angioedemas, Hereditary[MeSHID:D054179],Hemophilia A[MeSHID:D006467],Menorrhagia[MeSHID:D008595],Hemorrhage[MeSHID:D006470],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen PLG Successful target inhibitor NA TTD , drugbank , DGIDB n-(4-chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine NA NA investigative plasminogen PLG Successful target unknown NA TTD tranexamic acid small molecule Angioedemas, Hereditary[MeSHID:D054179],Hemophilia A[MeSHID:D006467],Menorrhagia[MeSHID:D008595],Hemorrhage[MeSHID:D006470],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen PLG Successful target inhibitor 2.19 TTD , drugbank , DGIDB 1-(2-oxo-2-p-tolyl-ethyl)-1h-indole-2,3-dione NA NA investigative plasminogen PLG Successful target unknown NA TTD 2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine NA NA investigative plasminogen PLG Successful target unknown NA TTD streptokinase biotech Arteries[MeSHID:D001158],Thrombosis[MeSHID:D013927],Deep Vein Thrombosis[MeSHID:D020246],Dental Occlusion[MeSHID:D003766],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasminogen PLG Successful target activator 21.95 TTD , drugbank , DGIDB aminocaproic acid small molecule Postoperative Hemorrhage[MeSHID:D019106],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194] approved,investigational plasminogen PLG Successful target inhibitor 1.1 TTD , drugbank , DGIDB aprotinin biotech Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn plasminogen PLG NA inhibitor 2.19 drugbank , DGIDB urokinase biotech Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved,investigational,withdrawn plasminogen PLG NA activator 3.29 drugbank , DGIDB anistreplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Embolus[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] approved plasminogen PLG Successful target activator 7.68 TTD , drugbank , DGIDB ranolazine NA Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved plasminogen PLG Successful target unknown 0.31 TTD , DGIDB m5 NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative plasminogen PLG Successful target unknown NA TTD desmoteplase biotech Cerebral Ischemia[MeSHID:D002545],Cerebrovascular accident[MeSHID:D020521],Cerebral Infarction[MeSHID:D002544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 plasminogen PLG Successful target activator 8.78 TTD , drugbank , DGIDB tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen PLG Successful target activator 8.78 TTD , drugbank , DGIDB 1-guanidino-n-phenyl-7-isoquinolinesulphonamide NA NA investigative plasminogen PLG Successful target unknown NA TTD bicine small molecule NA experimental,investigative plasminogen PLG Successful target unknown NA TTD , drugbank tranexamic acid small molecule Angioedemas, Hereditary[MeSHID:D054179],Hemophilia A[MeSHID:D006467],Menorrhagia[MeSHID:D008595],Hemorrhage[MeSHID:D006470],Term Birth[MeSHID:D047929],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen PLG Successful target inhibitor NA TTD , drugbank , DGIDB melagatran NA NA phase 3 plasminogen PLG Successful target unknown 0.37 TTD , DGIDB 1-(3,3-dimethyl-2-oxo-butyl)-1h-indole-2,3-dione NA NA investigative plasminogen PLG Successful target unknown NA TTD reteplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Embolus[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasminogen PLG Successful target activator 8.78 TTD , drugbank , DGIDB desmoteplase biotech Cerebral Ischemia[MeSHID:D002545],Cerebrovascular accident[MeSHID:D020521],Cerebral Infarction[MeSHID:D002544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 plasminogen PLG Successful target unknown 8.78 TTD , drugbank , DGIDB alteplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Pulmonary Embolism[MeSHID:D011655],Acute Cerebrovascular Accidents[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen PLG Successful target activator 1.16 TTD , drugbank , DGIDB textilinin NA Disease[MeSHID:D004194],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative plasminogen PLG Successful target unknown NA TTD 1-guanidino-7-isoquinolinesulphonamide NA NA investigative plasminogen PLG Successful target unknown NA TTD plasminogen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 plasminogen PLG Successful target unknown NA TTD bis-triazole derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Otitis Media[MeSHID:D010033] clinical trial plasminogen PLG Successful target inhibitor NA TTD , DGIDB xp-21510 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Menorrhagia[MeSHID:D008595] investigative plasminogen PLG Successful target unknown NA TTD tranexamic acid small molecule Angioedemas, Hereditary[MeSHID:D054179],Hemophilia A[MeSHID:D006467],Menorrhagia[MeSHID:D008595],Hemorrhage[MeSHID:D006470],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen PLG Successful target inhibitor 2.19 TTD , drugbank , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasminogen PLG NA unknown NA drugbank aminocaproic acid small molecule Postoperative Hemorrhage[MeSHID:D019106],Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194] approved,investigational plasminogen PLG Successful target inhibitor NA TTD , drugbank , DGIDB plasminogen NA Hypoplasminogenemia[MeSHID:C580017],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 plasminogen PLG Successful target unknown NA TTD smtp-0 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative plasminogen PLG Successful target unknown NA TTD troplasminogen alfa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 2 plasminogen PLG Successful target unknown NA TTD , DGIDB bis-triazole derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Otitis Media[MeSHID:D010033] clinical trial plasminogen PLG Successful target unknown NA TTD , DGIDB galsulfase biotech Mucopolysaccharidosis VI[MeSHID:D009087],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] approved,investigational perilipin-3 PLIN3 NA unknown 47.74 drugbank , DGIDB idursulfase biotech Mucopolysaccharidosis II[MeSHID:D016532],Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved perilipin-3 PLIN3 NA unknown 111.39 drugbank , DGIDB tak-960 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 polo-like kinase 1 PLK1 Clinical trial target unknown 0.72 TTD , DGIDB 4-(4-methylpiperazin-1-yl)-n-[5-(2-thienylacetyl)-1,5-dihydropyrrolo[3,4-c]pyrazol-3-yl]benzamide small molecule NA experimental serine/threonine-protein kinase plk1 PLK1 NA unknown NA drugbank gsk461364 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1 polo-like kinase 1 PLK1 Clinical trial target inhibitor 0.9 TTD , DGIDB mk-1496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 polo-like kinase 1 PLK1 Clinical trial target unknown 0.72 TTD , DGIDB volasertib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 polo-like kinase 1 PLK1 Clinical trial target unknown 0.6 TTD , DGIDB dihydropyrido pyrazinone compound 3 NA NA patented polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD , DGIDB cyc-800 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD , DGIDB gw853606 NA NA investigative polo-like kinase 1 PLK1 Clinical trial target inhibitor NA TTD , DGIDB 1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1h-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea small molecule NA experimental serine/threonine-protein kinase plk1 PLK1 NA unknown NA drugbank tak-960 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 polo-like kinase 1 PLK1 Clinical trial target inhibitor 0.72 TTD , DGIDB chr-4125 NA CHROMATE RESISTANCE (disorder)[MeSHID:C566125],Zellweger Syndrome[MeSHID:D015211],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD dihydropyrido pyrazinone compound 2 NA NA patented polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD , DGIDB ro5203280 NA Nasopharyngeal carcinoma[MeSHID:C538339],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD tkm-plk1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 plk1 messenger rna PLK1 Clinical trial target unknown NA TTD , DGIDB 3-[3-(3-methyl-6-{[(1s)-1-phenylethyl]amino}-1h-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide small molecule NA experimental serine/threonine-protein kinase plk1 PLK1 NA unknown NA drugbank rigosertib NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 polo-like kinase 1 PLK1 Clinical trial target unknown 0.08 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase plk1 PLK1 NA inhibitor NA drugbank pmid19097784c2 NA NA investigative polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD mk-1496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 polo-like kinase 1 PLK1 Clinical trial target inhibitor 0.72 TTD , DGIDB pcm-075 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 polo-like kinase 1 PLK1 Clinical trial target unknown 0.18 TTD , DGIDB lc-445 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD mln-0905 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] investigative polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD cyc140 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD nms-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuroleptic Malignant Syndrome[MeSHID:D009459],Malignant Neoplasms[MeSHID:D009369] investigative polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD hmn-214 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471] discontinued in phase 1 polo-like kinase 1 PLK1 Clinical trial target inhibitor 0.18 TTD , DGIDB dap-81 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical polo-like kinase 1 PLK1 Clinical trial target unknown 0.36 TTD , DGIDB zk-thiazolidinone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD , DGIDB volasertib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 polo-like kinase 1 PLK1 Clinical trial target inhibitor 0.6 TTD , DGIDB gsk461364 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1 polo-like kinase 1 PLK1 Clinical trial target unknown 0.9 TTD , DGIDB wortmannin small molecule Expiration, function[MeSHID:D045853],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Hematologic Neoplasms[MeSHID:D019337] experimental serine/threonine-protein kinase plk1 PLK1 NA unknown 0.03 drugbank , DGIDB 3-[3-chloro-5-(5-{[(1s)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol small molecule NA experimental serine/threonine-protein kinase plk1 PLK1 NA unknown NA drugbank bi 2536 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 polo-like kinase 1 PLK1 Clinical trial target unknown NA TTD , DGIDB gsk579289a NA NA investigative polo-like kinase 1 PLK1 Clinical trial target inhibitor 0.18 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase plk2 PLK2 NA inhibitor NA drugbank us8598172, 1 NA NA patented polo-like kinase 2 PLK2 Patented-recorded target unknown NA TTD , DGIDB on-123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative polo-like kinase 2 PLK2 Patented-recorded target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase plk3 PLK3 NA inhibitor NA drugbank cfi-400945 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 polo-like kinase 4 PLK4 Literature-reported target inhibitor 1.1 TTD , DGIDB xmd8-92 NA NA investigative polo-like kinase 4 PLK4 Literature-reported target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase plk4 PLK4 NA inhibitor NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 PLOD1 NA cofactor NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2 NA cofactor NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 PLOD3 NA cofactor NA drugbank imcgp100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cutaneous Melanoma[MeSHID:C562393],melanoma[MeSHID:D008545] phase 2 melanocytes lineage-specific antigen gp100 PMEL Clinical trial target unknown 42.43 TTD , DGIDB multi-epitope tyrosinase/gp100 vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 melanocytes lineage-specific antigen gp100 PMEL Clinical trial target unknown NA TTD , DGIDB ae-08 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 melanocytes lineage-specific antigen gp100 PMEL Clinical trial target unknown NA TTD , DGIDB melanoma vaccine (alvac) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 2 melanocytes lineage-specific antigen gp100 PMEL Clinical trial target unknown NA TTD melanoma vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 melanocytes lineage-specific antigen gp100 PMEL Clinical trial target unknown NA TTD , DGIDB multi-epitope peptide melanoma vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 melanocytes lineage-specific antigen gp100 PMEL Clinical trial target unknown NA TTD , DGIDB gp100:209-217(210m) peptide vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 melanocytes lineage-specific antigen gp100 PMEL Clinical trial target unknown NA TTD , DGIDB arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational protein pml PML NA unknown NA drugbank , DGIDB oleic acid small molecule NA approved,investigational,vet_approved myelin p2 protein PMP2 NA unknown NA drugbank s-hydroxycysteine small molecule NA experimental myelin p2 protein PMP2 NA unknown NA drugbank palmitic acid small molecule NA approved myelin p2 protein PMP2 NA unknown NA drugbank dodecyldimethylamine n-oxide small molecule NA experimental myelin p2 protein PMP2 NA unknown NA drugbank adenosine 5'-[gamma-thio]triphosphate small molecule NA experimental mismatch repair endonuclease pms2 PMS2 NA unknown NA drugbank ms-1819 NA Exocrine pancreatic insufficiency[MeSHID:D010188],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 pancreatic triacylglycerol lipase PNLIP Successful target unknown 9.09 TTD , DGIDB (hydroxyethyloxy)tri(ethyloxy)octane small molecule NA experimental,investigative pancreatic triacylglycerol lipase PNLIP Successful target unknown NA TTD , drugbank b-octylglucoside NA NA investigative pancreatic triacylglycerol lipase PNLIP Successful target unknown NA TTD orlistat small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Overweight[MeSHID:D050177],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational pancreatic triacylglycerol lipase PNLIP Successful target inhibitor 18.19 TTD , drugbank , DGIDB daio-orengedokuto (dot) NA NA investigative pancreatic triacylglycerol lipase PNLIP Successful target unknown NA TTD methoxyundecylphosphinic acid small molecule NA experimental,investigative pancreatic triacylglycerol lipase PNLIP Successful target unknown NA TTD , drugbank dalbavancin NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved pancreatic triacylglycerol lipase PNLIP Successful target unknown 9.09 TTD , DGIDB pancrecarb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreas[MeSHID:D010179] nda filed pancreatic triacylglycerol lipase PNLIP Successful target unknown NA TTD , DGIDB b-nonylglucoside small molecule NA experimental,investigative pancreatic triacylglycerol lipase PNLIP Successful target unknown NA TTD , drugbank liprotamase NA Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 pancreatic triacylglycerol lipase PNLIP Successful target unknown 3.03 TTD , DGIDB cetilistat small molecule Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational pancreatic triacylglycerol lipase PNLIP NA unknown 9.09 drugbank , DGIDB capric dimethyl amine oxide small molecule NA experimental pancreatic lipase-related protein 2 PNLIPRP2 NA unknown NA drugbank [(3r)-7-nitro-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank 7-iodo-1,2,3,4-tetrahydro-isoquinoline small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank (1r)-2-amino-1-[3-(trifluoromethyl)phenyl]ethanol small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank (3r)-n-(4-chlorophenyl)-3-(hydroxymethyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank (1s,4r,9s)-5-(trifluoromethyl)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-9-amine small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank trans-(1s,2s)-2-amino-1,2,3,4-tetrahydronaphthalen-1-ol small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank 1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid amide small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank (3r)-3-(fluoromethyl)-n-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank s-adenosyl-l-homocysteine small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank 8,9-dichloro-2,3,4,5-tetrahydro-1h-benzo[c]azepine small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank cis-(1r,2s)-2-amino-1,2,3,4-tetrahydronaphthalen-1-ol small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank (3r)-3-(fluoromethyl)-7-(thiomorpholin-4-ylsulfonyl)-1,2,3,4-tetrahydroisoquinoline small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank n-(4-chlorophenyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline small molecule NA experimental phenylethanolamine n-methyltransferase PNMT NA unknown NA drugbank 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (dhdmbf30) NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD ci-972 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1 purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 8-iodo-guanine NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 9-(5,5-difluoro-5-phosphonopentyl)guanine small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank bcx-3408 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Diabetes, Autoimmune[MeSHID:D003922],Gout[MeSHID:D006073] phase 2 purine nucleoside phosphorylase PNP Clinical trial target unknown 25.46 TTD , DGIDB dadme-immg NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 8-aminoguanine NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 2-amino-7-[2-(2-hydroxy-1-hydroxymethyl-ethylamino)-ethyl]-1,7-dihydro-purin-6-one small molecule NA experimental purine nucleoside phosphorylase PNP NA unknown NA drugbank 8-aza-dadme-immh NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 2-hydroxymethyl-pyrrolidine-3,4-diol NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 9-deazainosine-2',3'-o-ethylidenephosphonate small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank peldesine small molecule NA investigational,phase 1 purine nucleoside phosphorylase PNP Clinical trial target unknown 38.19 TTD , drugbank , DGIDB guanosine small molecule NA experimental,investigational,phase 1 purine nucleoside phosphorylase PNP Clinical trial target unknown 38.19 TTD , drugbank , DGIDB guanosine-2',3'-o-methylidenephosphonate small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank (3r,4r)-3-hydroxy-4-(hydroxymethyl)-1-[(4-oxo-4,4a,5,7a-tetrahydro-3h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]pyrrolidinium small molecule NA experimental purine nucleoside phosphorylase PNP NA unknown NA drugbank 2'3'-dideoxyinosine NA NA phase 2 purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , DGIDB 2,6-diamino-(s)-9-[2-(phosphonomethoxy)propyl]purine small molecule NA experimental purine nucleoside phosphorylase PNP NA unknown NA drugbank 3-((2-pyrrolidine-1-yl)-ethyl)uracil NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD forodesine small molecule leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Lymph[MeSHID:D008196],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], T-Cell, Cutaneous[MeSHID:D016410],Burkitt Lymphoma[MeSHID:D002051] investigational,phase 1/2 purine nucleoside phosphorylase PNP Clinical trial target inhibitor 76.38 TTD , drugbank , DGIDB 3'-deoxyguanosine small molecule NA experimental purine nucleoside phosphorylase PNP NA unknown NA drugbank mt-immucillin-h NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD didanosine small molecule HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved purine nucleoside phosphorylase PNP NA substrate NA drugbank 8-amino-9-benzylguanine NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 5'-methylthio-immucillin-h NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 5'-deoxy-4'-hydroxy-5'-methylthio-dadme-immh NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD aza-c-nucleosides NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD guanosine-2',3'-o-ethylidenephosphonate small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank hypoxanthine small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank guanine small molecule NA experimental purine nucleoside phosphorylase PNP NA unknown NA drugbank 9-deazahypoxanthine NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD inosine small molecule Athletic Performance[MeSHID:D054874] experimental,investigational purine nucleoside phosphorylase PNP NA unknown NA drugbank 8-aminoguanosine NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD (+/-)-5'-deoxy-4'-fluoro-5'-methylthio-dadme-immh NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD immucillin-g small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank ribose-1-phosphate small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank forodesine small molecule leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Lymph[MeSHID:D008196],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], T-Cell, Cutaneous[MeSHID:D016410],Burkitt Lymphoma[MeSHID:D002051] investigational,phase 1/2 purine nucleoside phosphorylase PNP Clinical trial target unknown 76.38 TTD , drugbank , DGIDB (2s,3r,4s,5s)-3,4-dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-1h-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium small molecule NA experimental purine nucleoside phosphorylase PNP NA unknown NA drugbank 9-deazainosine small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational purine nucleoside phosphorylase PNP NA inducer NA drugbank 5'-phenylthio-immh NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 8-azaguanine small molecule NA experimental,investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD , drugbank 3-deoxyguanosine NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD 5'-methylthio-immh NA NA investigative purine nucleoside phosphorylase PNP Clinical trial target unknown NA TTD flavin mononucleotide small molecule NA approved,investigational pyridoxine-5'-phosphate oxidase PNPO NA unknown NA drugbank mercaptoethanol small molecule NA experimental pyridoxine-5'-phosphate oxidase PNPO NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical pyridoxine-5'-phosphate oxidase PNPO NA cofactor NA drugbank clofarabine small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphocyte[MeSHID:D008214],Relapse[MeSHID:D012008],Lymphoid leukemia[MeSHID:D007945],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna polymerase alpha catalytic subunit POLA1 NA inhibitor 12.12 drugbank , DGIDB cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational dna polymerase alpha catalytic subunit POLA1 NA inhibitor NA drugbank ho-221 NA Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 dna polymerase alpha catalytic p180 POLA1 Discontinued target unknown NA TTD fludarabine small molecule Chronic Lymphocytic Leukemia[MeSHID:D015451],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved dna polymerase alpha catalytic subunit POLA1 NA inhibitor 3.18 drugbank , DGIDB nelarabine small molecule Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218],T-Cell Lymphoma[MeSHID:D016399],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna polymerase alpha catalytic subunit POLA1 NA inhibitor 45.47 drugbank , DGIDB dacarbazine small molecule melanoma[MeSHID:D008545],Hodgkin Disease[MeSHID:D006689],Neoplasm Metastasis[MeSHID:D009362],Cutaneous Melanoma[MeSHID:C562393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna polymerase alpha subunit b POLA2 NA unknown 24.48 drugbank , DGIDB ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved dna polymerase beta POLB NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna polymerase beta POLB NA unknown NA drugbank cytarabine small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Blast Phase[MeSHID:D001752],Diagnosis[MeSHID:D003933],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna polymerase beta POLB NA inhibitor 0.04 drugbank , DGIDB ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved dna polymerase beta POLB NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved dna polymerase beta POLB NA unknown NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved dna polymerase beta POLB NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved dna polymerase beta POLB NA unknown NA drugbank datp small molecule NA experimental dna polymerase beta POLB NA unknown NA drugbank ff-10502 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 dna polymerase beta POLB Clinical trial target unknown NA TTD (1s)-1,2,3,4-tetrahydro-benzo[c]phenanthrene-2,3,4-triol small molecule NA experimental dna polymerase beta POLB NA unknown NA drugbank cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational dna polymerase epsilon catalytic subunit a POLE NA inhibitor NA drugbank cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational dna polymerase epsilon subunit 2 POLE2 NA inhibitor NA drugbank cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational dna polymerase epsilon subunit 3 POLE3 NA inhibitor NA drugbank cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational dna polymerase epsilon subunit 4 POLE4 NA inhibitor NA drugbank 1,2,3-trihydroxy-1,2,3,4-tetrahydrobenzo[a]pyrene small molecule NA experimental dna polymerase kappa POLK NA unknown NA drugbank 2'-deoxy-n-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate) small molecule NA experimental dna polymerase kappa POLK NA unknown NA drugbank 1-[2-deoxyribofuranosyl]-2,4-difluoro-5-methyl-benzene-5'monophosphate small molecule NA experimental dna polymerase kappa POLK NA unknown NA drugbank etorphine small molecule NA illicit,vet_approved pro-opiomelanocortin POMC NA unknown NA drugbank dihydromorphine small molecule Pain[MeSHID:D010146] experimental,illicit pro-opiomelanocortin POMC NA agonist NA drugbank loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved pro-opiomelanocortin POMC NA modulator NA drugbank loperamide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Diarrhea[MeSHID:D003967],Patient Discharge[MeSHID:D010351],Gastroenteritis[MeSHID:D005759],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved pro-opiomelanocortin POMC NA modulator NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serum paraoxonase/arylesterase 1 PON1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental serum paraoxonase/arylesterase 1 PON1 NA inducer NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational serum paraoxonase/arylesterase 1 PON1 NA inducer NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational serum paraoxonase/arylesterase 1 PON1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational serum paraoxonase/arylesterase 1 PON1 NA unknown NA drugbank cefazolin small molecule Operative Surgical Procedures[MeSHID:D013514],Stomach[MeSHID:D013270],Bacterial Infections[MeSHID:D001424],Blood[MeSHID:D001769],Skin Diseases, Bacterial[MeSHID:D017192],Heart Valves[MeSHID:D006351],Lung[MeSHID:D008168],Urinary tract[MeSHID:D014551],Bone Tissue[MeSHID:D001842],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serum paraoxonase/arylesterase 1 PON1 NA inhibitor NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental nadph--cytochrome p450 reductase POR NA unknown NA drugbank vtp-201227 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 cytochrome p450 reductase POR Discontinued target unknown NA TTD flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved nadph--cytochrome p450 reductase POR NA unknown NA drugbank flavin mononucleotide small molecule NA approved,investigational nadph--cytochrome p450 reductase POR NA unknown NA drugbank lgk974 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein-serine o-palmitoleoyltransferase porcupine PORCN Clinical trial target unknown 15.91 TTD , DGIDB etc-1922159 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein-serine o-palmitoleoyltransferase porcupine PORCN Clinical trial target unknown 31.83 TTD , DGIDB fenofibrate small molecule Hypertriglyceridemia[MeSHID:D015228],Dyslipidemias[MeSHID:D050171],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 0.47 TTD , drugbank , DGIDB ll-6531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD ragaglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] investigational,phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 1.93 TTD , drugbank , DGIDB ertiprotafib small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank zyh7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171],Lipid Metabolism Disorders[MeSHID:D052439] phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 0.96 TTD , DGIDB pirinixic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] preclinical peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank db-900 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD lauric acid small molecule NA approved,experimental peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank pmid25416646-compound-figure5-a NA NA patented peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank flavonoid derivative 8 NA NA patented peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB ave0897 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor alpha PPARA NA activator NA drugbank gsk-9578 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD soybean oil biotech Enteral Feeding[MeSHID:D004750],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor alpha PPARA NA activator NA drugbank ave-0847 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD pemafibrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439] approved peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD gw7647 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 0.2 TTD , DGIDB bm-17.0744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD isoflavone small molecule Blood[MeSHID:D001769],Bone Density[MeSHID:D015519] experimental peroxisome proliferator-activated receptor alpha PPARA NA agonist NA drugbank phthalic acid small molecule NA experimental peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank arachidonic acid small molecule NA experimental peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank drf 2519 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB ns-220 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 0.96 TTD , DGIDB gw-590735 small molecule NA investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank clinofibrate small molecule NA experimental peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank myristic acid small molecule NA experimental peroxisome proliferator-activated receptor alpha PPARA NA unknown 1.93 drugbank , DGIDB ragaglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] investigational,phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 1.93 TTD , drugbank , DGIDB naveglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 1.45 TTD , DGIDB fenoprofen small molecule Degenerative polyarthritis[MeSHID:D010003],Pain[MeSHID:D010146],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor alpha PPARA NA activator NA drugbank mc-3001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] preclinical peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB ad-5061 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB reglitazar small molecule Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] investigational,investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 0.48 TTD , drugbank , DGIDB sodelglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 0.32 TTD , DGIDB troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank (e)-12-nitrooctadec-12-enoic acid NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA agonist NA drugbank muraglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational,phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 0.48 TTD , drugbank , DGIDB fenofibric acid small molecule Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved peroxisome proliferator-activated receptor alpha PPARA NA agonist 1.61 drugbank , DGIDB romazarit NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] preclinical peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 1.93 TTD , DGIDB palmitic acid small molecule NA approved peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank clofibrate small molecule Hypercholesterolemia[MeSHID:D006937],Hyperlipoproteinemia Type III[MeSHID:D006952],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA agonist 0.71 drugbank , DGIDB gsk-677954 NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD myrrh small molecule Malignant Neoplasms[MeSHID:D009369],Aphthous Stomatitis[MeSHID:D013281],Menstruation[MeSHID:D008598],Gingivitis[MeSHID:D005891],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Ulcer[MeSHID:D014456],Coughing[MeSHID:D003371],Hemorrhoids[MeSHID:D006484],Leprosy[MeSHID:D007918],Furunculosis[MeSHID:D005667],Syphilis[MeSHID:D013587],Asthma[MeSHID:D001249],Dyspepsia[MeSHID:D004415],Inflammation[MeSHID:D007249],Pressure Ulcer[MeSHID:D003668],Tooth structure[MeSHID:D014070],Halitosis[MeSHID:D006209],Injury wounds[MeSHID:D014947],Pharyngeal structure[MeSHID:D010614],Common Cold[MeSHID:D003139],Lip structure[MeSHID:D008046] approved peroxisome proliferator-activated receptor alpha PPARA NA agonist NA drugbank cardarine small molecule Hyperlipidemia[MeSHID:D006949] investigational peroxisome proliferator-activated receptor alpha PPARA NA agonist NA drugbank e-3030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD ar-h049020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] discontinued in phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD ono-5129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB pmid25416646-compound-figure5-h NA NA patented peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB bezafibrate small molecule Diabetes Mellitus[MeSHID:D003920],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Neoplasm Metastasis[MeSHID:D009362],Atherosclerosis[MeSHID:D050197],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 5.79 TTD , drugbank , DGIDB stearic acid small molecule NA approved,experimental peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank tpst-1120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD lg-101280 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arteriosclerosis[MeSHID:D001161] discontinued in phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD deoxy-bigchap NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD l-165461 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD (9z,12e)-12-nitrooctadeca-9,12-dienoic acid NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD reglixane NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD zy h2 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD oxeglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 0.48 TTD , DGIDB flufenamic acid small molecule Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor alpha PPARA NA activator NA drugbank gft14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB gw-409544 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB krp-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA agonist NA drugbank doconexent small molecule NA approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA ligand NA drugbank caprylic acid small molecule NA investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank 8s-hete NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB mp-136 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] discontinued in phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD elafibranor small molecule Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank oleic acid small molecule NA approved,investigational,vet_approved peroxisome proliferator-activated receptor alpha PPARA NA unknown 0.12 drugbank , DGIDB ly-929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] discontinued in phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD cp-775146 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB ly-518674 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 3.86 TTD , DGIDB imiglitazar NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 1.45 TTD , DGIDB ly-465608 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB gft-505 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 0.48 TTD , DGIDB imiglitazar NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 1.45 TTD , DGIDB (e)-13-nitrooctadec-12-enoic acid NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD (e)-4-(3,5-dimethoxystyryl)phenol NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD eicosatetranoic acid NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD muraglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational,phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 0.48 TTD , drugbank , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank ciprofibrate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipoproteinemias[MeSHID:D006951] approved,investigational peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 1.29 TTD , drugbank , DGIDB n,n-bis(3-(d-gluconamido)propyl)deoxycholamide small molecule NA experimental peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank omega-3 fatty acids small molecule Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Recurrence (disease attribute)[MeSHID:D012008] approved,nutraceutical peroxisome proliferator-activated receptor alpha PPARA NA activator NA drugbank dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank rosiglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank indeglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 0.64 TTD , drugbank , DGIDB pristanic acid NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB cdt-fenofibrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB naveglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 1.45 TTD , DGIDB aleglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 1.93 TTD , drugbank , DGIDB bms-687453 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 1.93 TTD , DGIDB lobeglitazone NA Patient Monitoring[MeSHID:D008991],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 0.48 TTD , DGIDB fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical peroxisome proliferator-activated receptor alpha PPARA NA regulator NA drugbank gw-2331 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD n-oleoylethanolamide NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB drf 10945 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 1 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB ciprofibrate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipoproteinemias[MeSHID:D006951] approved,investigational peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 1.29 TTD , drugbank , DGIDB tzd18 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target agonist NA TTD , DGIDB pirinixic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] preclinical peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 0.77 TTD , DGIDB zyh-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB gemfibrozil small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Fasting[MeSHID:D005215],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Serum[MeSHID:D044967],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Weight decreased[MeSHID:D015431],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor alpha PPARA NA agonist 0.88 drugbank , DGIDB leukotriene b4 small molecule NA investigational peroxisome proliferator-activated receptor alpha PPARA NA activator NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA agonist NA drugbank ly-518674 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 3.86 TTD , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical peroxisome proliferator-activated receptor alpha PPARA NA activator NA drugbank krp-297 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Expiration, function[MeSHID:D045853],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD mc-3002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] preclinical peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB l-796449 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD tesaglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] investigational,phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target agonist 1.45 TTD , drugbank , DGIDB gw7647 NA NA investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 0.2 TTD , DGIDB tesaglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] investigational,phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown 1.45 TTD , drugbank , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor alpha PPARA NA agonist NA drugbank ave-8134 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] discontinued in phase 2 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD alpha-linolenic acid small molecule NA approved,investigational,nutraceutical peroxisome proliferator-activated receptor alpha PPARA NA unknown NA drugbank fibrates NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] investigative peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD cs-038 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor alpha PPARA Successful target unknown NA TTD , DGIDB heptyl-beta-d-glucopyranoside NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD gft-505 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Nonalcoholic Steatohepatitis[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown 0.24 TTD , DGIDB cardarine small molecule Hyperlipidemia[MeSHID:D006949] investigational peroxisome proliferator-activated receptor delta PPARD NA agonist NA drugbank indeglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,discontinued in phase 2 peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist 0.32 TTD , drugbank , DGIDB cer-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] phase 1 peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist 1.94 TTD , DGIDB l-796449 NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist 0.24 TTD , DGIDB sar351034 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] phase 1 peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD , DGIDB gsk-677954 NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD oleic acid small molecule NA approved,investigational,vet_approved peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank gw2433 NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist 0.49 TTD , DGIDB l-165461 NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD treprostinil small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor delta PPARD NA agonist NA drugbank elafibranor small molecule Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank clinofibrate small molecule NA experimental peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank {4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid small molecule NA experimental peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank l-165041 NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist 0.24 TTD , DGIDB cer-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] phase 1 peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown 1.94 TTD , DGIDB mbx-8025 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bile fluid[MeSHID:D001646],Obesity[MeSHID:D009765],Cholangitis[MeSHID:D002761],Hypercholesterolemia, Familial[MeSHID:D006938] phase 2/3 peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist 1.46 TTD , DGIDB rosiglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank gsk-3787 NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD savx-1 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical peroxisome proliferator-activated receptor delta PPARD NA regulator NA drugbank sodelglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist 0.16 TTD , DGIDB l-165041 NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown 0.24 TTD , DGIDB heptyl glucoside small molecule NA experimental peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank sulindac small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor delta PPARD NA negative modulator NA drugbank l-783483 NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist NA TTD , DGIDB fenofibric acid small molecule Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved peroxisome proliferator-activated receptor delta PPARD NA unknown 0.32 drugbank , DGIDB t3d-959 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown 0.73 TTD , DGIDB db-900 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD kd3010 small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown 1.46 TTD , drugbank , DGIDB kd3010 small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist 1.46 TTD , drugbank , DGIDB (2s)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid small molecule NA experimental peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank phthalic acid small molecule NA experimental peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank bezafibrate small molecule Diabetes Mellitus[MeSHID:D003920],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Neoplasm Metastasis[MeSHID:D009362],Atherosclerosis[MeSHID:D050197],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor delta PPARD NA agonist 0.49 drugbank , DGIDB mbx-8025 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bile fluid[MeSHID:D001646],Obesity[MeSHID:D009765],Cholangitis[MeSHID:D002761],Hypercholesterolemia, Familial[MeSHID:D006938] phase 2/3 peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown 1.46 TTD , DGIDB pmid25416646-compound-figure5-c NA NA patented peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD , DGIDB alpha-linolenic acid small molecule NA approved,investigational,nutraceutical peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank 2-({[3-(3,4-dihydroisoquinolin-2(1h)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid small molecule NA experimental peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank (11e)-octadec-11-enoic acid NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD kd-3020 NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Mucocutaneous Lymph Node Syndrome[MeSHID:D009080],Bulbo-Spinal Atrophy, X-Linked[MeSHID:D055534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD , DGIDB cis-vaccenic acid small molecule NA experimental peroxisome proliferator-activated receptor delta PPARD NA unknown NA drugbank glycerin small molecule NA approved,investigational peroxisome proliferator-activated receptor delta PPARD NA agonist NA drugbank gw0742x NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target agonist NA TTD , DGIDB icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical peroxisome proliferator-activated receptor delta PPARD NA agonist NA drugbank gsk-0660 NA NA investigative peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD gw-501516 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] discontinued in phase 4 peroxisome proliferator-activated receptor delta PPARD Clinical trial target unknown NA TTD elafibranor small molecule Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank mbx-2044 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target modulator 1.38 TTD , DGIDB sodelglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.15 TTD , DGIDB l-tryptophan-l-aspartic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor gamma PPARG NA activator NA drugbank glipizide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank chs-131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB (4s,5e,7z,10z,13z,16z,19z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank lobeglitazone small molecule Patient Monitoring[MeSHID:D008991],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,approved peroxisome proliferator-activated receptor gamma PPARG Successful target activator 0.46 TTD , drugbank , DGIDB ym-440 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] discontinued in phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD 1-(biphenyl-4-yl-methyl)-1h-imidazole derivative 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB (9z,12e)-12-nitrooctadeca-9,12-dienoic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD rosiglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist 0.39 drugbank , DGIDB clx-0921 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 1.38 TTD , drugbank , DGIDB rivoglitazone NA Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Vision[MeSHID:D014785] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.92 TTD , DGIDB mitiglinide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank chlorocyclinone b NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD triclosan small molecule Health Care[MeSHID:D003695],Operative Surgical Procedures[MeSHID:D013514],Hand[MeSHID:D006225],Hyperostosis, Diffuse Idiopathic Skeletal[MeSHID:D004057],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Trypanosomiasis[MeSHID:D014352],Malaria[MeSHID:D008288],Communicable Diseases[MeSHID:D003141] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank biaromatic compound 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB ragaglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] investigational,phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 1.15 TTD , drugbank , DGIDB 3-fluoro-n-[1-(4-fluorophenyl)-3-(2-thienyl)-1h-pyrazol-5-yl]benzenesulfonamide small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank ragaglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] investigational,phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 1.15 TTD , drugbank , DGIDB netoglitazone NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target modulator 1.38 TTD , DGIDB (e)-6-nitrooctadec-5-enoic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD ds-6930 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA activator NA drugbank telmisartan small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA partial agonist NA drugbank gsk-677954 NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD l-tryptophan-l-arginine NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD clinofibrate small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank isis 105990 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD curcumin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank gw7845 NA NA investigative peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.46 TTD , DGIDB dsp-8658 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB gw-409544 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank reglitazar small molecule Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist 0.23 drugbank , DGIDB oms405 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293],Nicotine Dependence[MeSHID:D014029] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.92 TTD , DGIDB mrl24 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB (e)-9-nitrohexadec-9-enoicacid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD 2-{5-[3-(7-propyl-3-trifluoromethylbenzo[d]isoxazol-6-yloxy)propoxy]indol-1-yl}ethanoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank netoglitazone NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 1.38 TTD , DGIDB omega-3 fatty acids small molecule Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Recurrence (disease attribute)[MeSHID:D012008] approved,nutraceutical peroxisome proliferator-activated receptor gamma PPARG NA ligand NA drugbank ono-5129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB fused ring compound 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB mbx-2044 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 1.38 TTD , DGIDB 2-[(2,4-dichlorobenzoyl)amino]-5-(pyrimidin-2-yloxy)benzoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank muraglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational,phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.23 TTD , drugbank , DGIDB reglixane NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD clofazimine small molecule Erythema Nodosum[MeSHID:D004893],Leprosy, Lepromatous[MeSHID:D015440],Leprosy[MeSHID:D007918],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Mycobacterium Infections[MeSHID:D009164] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA modulator NA drugbank l-tryptophan-l-leucine NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.27 TTD , drugbank , DGIDB a-substituted phenylpropionic acid derivative 2 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB mrl20 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target agonist NA TTD , DGIDB farglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.46 TTD , DGIDB repaglinide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank mc-3002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] preclinical peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational peroxisome proliferator-activated receptor gamma PPARG NA antagonist 0.02 drugbank , DGIDB rosiglitazone + simvastatin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB l-165461 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist 0.46 TTD , DGIDB medical cannabis biotech NA experimental,investigational peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank oxeglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.23 TTD , DGIDB glitazone NA NA phase 4 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.46 TTD , DGIDB gnf-pf-3037 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD bezafibrate small molecule Diabetes Mellitus[MeSHID:D003920],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Neoplasm Metastasis[MeSHID:D009362],Atherosclerosis[MeSHID:D050197],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank a-substituted phenylpropionic acid derivative 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB telmisartan small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA partial agonist NA drugbank naveglitazar small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational,phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.69 TTD , drugbank , DGIDB clx-0921 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 1.38 TTD , drugbank , DGIDB (9z,11e,13s)-13-hydroxyoctadeca-9,11-dienoic acid small molecule NA experimental,investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , drugbank ad-5061 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA activator,agonist 0.04 drugbank , DGIDB rosiglitazone xr NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB arhalofenate small molecule NA investigational peroxisome proliferator-activated receptor gamma PPARG NA modulator 0.69 drugbank , DGIDB (e)-12-nitrooctadec-12-enoic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD (5r,6e,8z,11z,14z,17z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank tirotundin NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist 0.46 TTD , DGIDB cs-038 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB oms405 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Opiate Addiction[MeSHID:D009293],Nicotine Dependence[MeSHID:D014029] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.92 TTD , DGIDB rivoglitazone NA Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Vision[MeSHID:D014785] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.92 TTD , DGIDB badge NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist,antagonist NA TTD , DGIDB ciglitazone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] experimental,preclinical peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.46 TTD , drugbank , DGIDB ciglitazone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] experimental,preclinical peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.46 TTD , drugbank , DGIDB sb-213068 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD (8r,9z,12z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank ged-0507-34-levo NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB [3h]gw2331 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD brl-48482 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank gw1929 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist 0.17 TTD , DGIDB l-796449 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist 0.23 TTD , DGIDB l-764406 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank phthalic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank tesaglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] investigational,phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.69 TTD , drugbank , DGIDB pmid25416646-compound-figure2-j NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB bardoxolone methyl NA Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Mixed Connective Tissue Disease[MeSHID:D008947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976],Idiopathic pulmonary arterial hypertension[MeSHID:D065627] phase 3 ppar-gamma messenger rna PPARG Literature-reported target antagonist 0.12 TTD , DGIDB imiglitazar NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.46 TTD , DGIDB (e)-9-nitrooctadec-9-enoic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD 9(s)-hode small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank tesaglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] investigational,phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.69 TTD , drugbank , DGIDB zyh-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB phenylpyridine derivative 3 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB ave-0847 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD gnf-pf-2893 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown 0.04 TTD , DGIDB sulfonamide derivative 18 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB pmid25416646-compound-figure5-h NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB (2s)-3-(1-{[2-(2-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-1h-indol-5-yl)-2-ethoxypropanoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank indeglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,discontinued in phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.31 TTD , drugbank , DGIDB cannabinoid quinone derivative 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor gamma PPARG NA agonist 0.1 drugbank , DGIDB fk-614 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.92 TTD , DGIDB (2s)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid small molecule NA experimental,investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , drugbank flavonoid derivative 8 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB gw0072 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB (5e,14e)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank gw1929 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown 0.17 TTD , DGIDB imiglitazar NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.46 TTD , DGIDB fenofibric acid small molecule Hypercholesterolemia[MeSHID:D006937],Dyslipidemias[MeSHID:D050171],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved peroxisome proliferator-activated receptor gamma PPARG NA unknown 0.46 drugbank , DGIDB pmid25416646-compound-figure2-n NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB 2-chloro-5-nitro-n-phenylbenzamide small molecule NA experimental,investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , drugbank ploglitazone NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD chlorocyclinone a NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD (e)-5-nitrooctadec-5-enoic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD pmid25416646-compound-figure5-c NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA activator,agonist 0.04 drugbank , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank (2s)-2-ethoxy-3-{4-[2-(10h-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank (e)-13-nitrooctadec-12-enoic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD englitazone sodium NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB balaglitazone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.92 TTD , DGIDB lg100754 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB phenylpropionic acid derivative 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB zy h2 NA NA investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD pmid25416646-compound-figure5-a NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB 9-hydroxyoctadecadienoic acid NA NA investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD db-900 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD spirolaxine derivative 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB 2-chloro-5-nitro-n-phenylbenzamide NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD pmid25416646-compound-figure2-k NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB netoglitazone NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 1.38 TTD , DGIDB capric acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA ligand NA drugbank oleic acid small molecule NA approved,investigational,vet_approved peroxisome proliferator-activated receptor gamma PPARG NA ligand NA drugbank t3d-959 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.69 TTD , DGIDB thiazolidinedione NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.46 TTD , DGIDB 2-{5-[3-(6-benzoyl-1-propylnaphthalen-2-yloxy)propoxy]indol-1-yl}ethanoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank difluoro(5-{2-[(5-octyl-1h-pyrrol-2-yl-kappan)methylidene]-2h-pyrrol-5-yl-kappan}pentanoato)boron small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank pat5a NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB mesalazine small molecule Crohn's disease of large bowel[MeSHID:D003424],ileum[MeSHID:D007082],Ulcerative Colitis[MeSHID:D003093],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor gamma PPARG NA agonist 0.16 drugbank , DGIDB pmid25416646-compound-figure5-e NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB isis 105989 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD 3-phenyl acrylic acid derivative 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB balsalazide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist 0.58 drugbank , DGIDB (e)-10-nitrohexadec-9-enoic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD l-783483 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB t0070907 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target antagonist NA TTD , DGIDB mrl20 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB tagitinin a NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB pioglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Obesity[MeSHID:D009765] approved,investigational peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.49 TTD , drugbank , DGIDB curcumin sulfate small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank mbx-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] phase 2/3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.69 TTD , DGIDB isis 105987 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD (8e,10s,12z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank ertiprotafib small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank amg-131 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational peroxisome proliferator-activated receptor gamma PPARG NA partial agonist 0.92 drugbank , DGIDB muraglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924] investigational,phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown 0.23 TTD , drugbank , DGIDB ly-465608 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB aleglitazar small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist 0.92 drugbank , DGIDB crystalline anhydrous toluene derivative 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB balaglitazone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target partial agonist 0.92 TTD , DGIDB l-tryptophan-l-glutamine NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD l-tryptophan-l-asparagine NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD darglitazone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Complications of Diabetes Mellitus[MeSHID:D048909],Expiration, function[MeSHID:D045853] experimental,terminated peroxisome proliferator-activated receptor gamma PPARG Successful target agonist NA TTD , drugbank cooh NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA activator NA drugbank flufenamic acid small molecule Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank rosiglitazone + metformin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Complications of Diabetes Mellitus[MeSHID:D048909] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB krp-297 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Expiration, function[MeSHID:D045853],Hyperlipidemia[MeSHID:D006949] discontinued in phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD (e)-10-nitrooctadec-9-enoic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational peroxisome proliferator-activated receptor gamma PPARG NA antagonist 0.02 drugbank , DGIDB alpha-linolenic acid small molecule NA approved,investigational,nutraceutical peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank nateglinide small molecule Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank thiazolidine dione crystalline derivative 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB naveglitazar small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigational,phase 2 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.69 TTD , drugbank , DGIDB isis 106008 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD fenoprofen small molecule Degenerative polyarthritis[MeSHID:D010003],Pain[MeSHID:D010146],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank pd-068235 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD 15-deoxy-delta(12, 14)-prostaglandin j(2) NA NA investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD isoflavone small molecule Blood[MeSHID:D001769],Bone Density[MeSHID:D015519] experimental peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank ly-929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] discontinued in phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD [125i]sb-236636 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB tzd18 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB l-tryptophan-l-2-aminoadipic acid NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD ntzdpa NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target agonist NA TTD , DGIDB mrl24 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target agonist NA TTD , DGIDB chlorocyclinone c NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD drf 2519 NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD chlorocyclinone d NA NA investigative ppar-gamma messenger rna PPARG Literature-reported target unknown NA TTD doconexent small molecule NA approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA ligand NA drugbank farglitazar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 3 peroxisome proliferator-activated receptor gamma PPARG Successful target agonist 0.46 TTD , DGIDB fused aromatic compound 1 NA NA patented peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , DGIDB (2s)-2-(4-ethylphenoxy)-3-phenylpropanoic acid small molecule NA experimental,investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , drugbank reglitazar NA Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] investigative ppar-gamma messenger rna PPARG Literature-reported target agonist 0.23 TTD , DGIDB e-3030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] discontinued in phase 1 peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD gw-2331 NA NA investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD (2s)-2-(4-chlorophenoxy)-3-phenylpropanoic acid small molecule NA experimental,investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , drugbank 3-(5-methoxy-1h-indol-3-yl)propanoic acid small molecule NA experimental,investigative peroxisome proliferator-activated receptor gamma PPARG Successful target unknown NA TTD , drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor gamma PPARG NA agonist NA drugbank (s)-3-(4-(2-carbazol-9-yl-ethoxy)-phenyl)-2-ethoxy-propionic acid small molecule NA experimental peroxisome proliferator-activated receptor gamma PPARG NA unknown NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational peroxisome proliferator-activated receptor gamma coactivator 1-beta PPARGC1B NA agonist NA drugbank amiodarone small molecule Disease[MeSHID:D004194],Supraventricular tachycardia[MeSHID:D013617],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxisome proliferator-activated receptor gamma coactivator 1-beta PPARGC1B NA agonist NA drugbank azathioprine NA Rheumatoid Arthritis[MeSHID:D001172],Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved amidophosphoribosyltransferase PPAT Successful target inhibitor 1.27 TTD , DGIDB mercaptopurine small molecule Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Crohn Disease[MeSHID:D003424] approved amidophosphoribosyltransferase PPAT Successful target inhibitor 1.33 TTD , drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational amidophosphoribosyltransferase PPAT NA unknown NA drugbank l-glutamine small molecule Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Short Bowel Syndrome[MeSHID:D012778] approved,investigational,nutraceutical amidophosphoribosyltransferase PPAT NA substrate NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational amidophosphoribosyltransferase PPAT NA unknown NA drugbank mycophenolic bis(sulfonamide) NA NA investigative amidophosphoribosyltransferase PPAT Successful target unknown NA TTD tiazofurin adenine dinucleotide NA NA investigative amidophosphoribosyltransferase PPAT Successful target unknown NA TTD azathioprine NA Rheumatoid Arthritis[MeSHID:D001172],Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved amidophosphoribosyltransferase PPAT Successful target unknown 1.27 TTD , DGIDB mercaptopurine small molecule Maintenance[MeSHID:D008283],Lymphoid leukemia[MeSHID:D007945],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Middle East Respiratory Syndrome[MeSHID:D018352] approved amidophosphoribosyltransferase PPAT Successful target inhibitor 1.33 TTD , drugbank , DGIDB 6-chloropurine riboside, 5'-monophosphate NA NA investigative amidophosphoribosyltransferase PPAT Successful target unknown NA TTD mycophenolic hydroxamic acid NA NA investigative amidophosphoribosyltransferase PPAT Successful target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational platelet basic protein PPBP NA unknown NA drugbank ethanesulfonic acid small molecule NA experimental platelet basic protein PPBP NA unknown NA drugbank pantothenoylaminoethenethiol small molecule NA experimental phosphopantothenoylcysteine decarboxylase PPCDC NA unknown NA drugbank flavin mononucleotide small molecule NA approved,investigational phosphopantothenoylcysteine decarboxylase PPCDC NA unknown NA drugbank (3r)-1-acetyl-3-methylpiperidine small molecule NA experimental peptidyl-prolyl cis-trans isomerase a PPIA NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational peptidyl-prolyl cis-trans isomerase a PPIA NA ligand NA drugbank 1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea NA NA investigative rotamase a PPIA Successful target unknown NA TTD cyclosporine small molecule Eczema[MeSHID:D004485],Graft-vs-Host Disease[MeSHID:D006086],Rupture[MeSHID:D012421],Keratoconjunctivitis, Vernal[MeSHID:D003233],Eye[MeSHID:D005123],Nephrotic Syndrome[MeSHID:D009404],Connective Tissue Diseases[MeSHID:D003240],Kidney[MeSHID:D007668],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Mental Suffering[MeSHID:D013315],Immune thrombocytopenic purpura[MeSHID:D016553],Psoriasis[MeSHID:D011565],Keratoconjunctivitis Sicca[MeSHID:D007638],Liver[MeSHID:D008099],Rheumatoid Arthritis[MeSHID:D001172],Segmental glomerulosclerosis[MeSHID:C538457],Dental Plaque[MeSHID:D003773],Membranous glomerulonephritis[MeSHID:D015433],Bulla[MeSHID:D001768],Tears body substance[MeSHID:D013666],Lipoid nephrosis[MeSHID:D009402],Ulcerative Colitis[MeSHID:D003093],Immunocompromised Host[MeSHID:D016867],Disease[MeSHID:D004194],Graft Rejection[MeSHID:D006084],Dry Eye Syndromes[MeSHID:D015352],Kidney Glomerulus[MeSHID:D007678],Dermatitis, Atopic[MeSHID:D003876],Laceration[MeSHID:D022125],Uveitis[MeSHID:D014605] approved,investigational,vet_approved peptidyl-prolyl cis-trans isomerase a PPIA NA inhibitor,binder,modulator 2.82 drugbank , DGIDB 4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide NA NA investigative rotamase a PPIA Successful target unknown NA TTD (3r)-1-acetyl-3-methylpiperidine NA NA investigative rotamase a PPIA Successful target unknown NA TTD sanglifehrin a small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental peptidyl-prolyl cis-trans isomerase a PPIA NA unknown NA drugbank ethyl oxo(piperidin-1-yl)acetate NA NA investigative rotamase a PPIA Successful target unknown NA TTD l-proline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved rotamase a PPIA Successful target unknown 31.83 TTD , DGIDB ethyl oxo(piperidin-1-yl)acetate small molecule NA experimental peptidyl-prolyl cis-trans isomerase a PPIA NA unknown NA drugbank cyclosporine small molecule Eczema[MeSHID:D004485],Graft-vs-Host Disease[MeSHID:D006086],Rupture[MeSHID:D012421],Keratoconjunctivitis, Vernal[MeSHID:D003233],Eye[MeSHID:D005123],Nephrotic Syndrome[MeSHID:D009404],Connective Tissue Diseases[MeSHID:D003240],Kidney[MeSHID:D007668],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Mental Suffering[MeSHID:D013315],Immune thrombocytopenic purpura[MeSHID:D016553],Psoriasis[MeSHID:D011565],Keratoconjunctivitis Sicca[MeSHID:D007638],Liver[MeSHID:D008099],Rheumatoid Arthritis[MeSHID:D001172],Segmental glomerulosclerosis[MeSHID:C538457],Dental Plaque[MeSHID:D003773],Membranous glomerulonephritis[MeSHID:D015433],Bulla[MeSHID:D001768],Tears body substance[MeSHID:D013666],Lipoid nephrosis[MeSHID:D009402],Ulcerative Colitis[MeSHID:D003093],Immunocompromised Host[MeSHID:D016867],Disease[MeSHID:D004194],Graft Rejection[MeSHID:D006084],Dry Eye Syndromes[MeSHID:D015352],Kidney Glomerulus[MeSHID:D007678],Dermatitis, Atopic[MeSHID:D003876],Laceration[MeSHID:D022125],Uveitis[MeSHID:D014605] approved,investigational,vet_approved peptidyl-prolyl cis-trans isomerase a PPIA NA inhibitor,binder 2.82 drugbank , DGIDB 3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide NA NA investigative rotamase a PPIA Successful target unknown NA TTD 7-amino-4-methyl-chromen-2-one NA NA investigative rotamase a PPIA Successful target unknown NA TTD proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical peptidyl-prolyl cis-trans isomerase a PPIA NA binder NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peptidyl-prolyl cis-trans isomerase a PPIA NA unknown NA drugbank 1,4-dithiothreitol small molecule NA experimental peptidyl-prolyl cis-trans isomerase b PPIB NA unknown NA drugbank 1,4-dithiothreitol NA NA investigative rotamase b PPIB Successful target unknown NA TTD proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical peptidyl-prolyl cis-trans isomerase b PPIB NA binder NA drugbank l-proline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved rotamase b PPIB Successful target unknown 127.3 TTD , DGIDB proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical peptidyl-prolyl cis-trans isomerase c PPIC NA unknown NA drugbank cyclosporine small molecule Eczema[MeSHID:D004485],Graft-vs-Host Disease[MeSHID:D006086],Rupture[MeSHID:D012421],Keratoconjunctivitis, Vernal[MeSHID:D003233],Eye[MeSHID:D005123],Nephrotic Syndrome[MeSHID:D009404],Connective Tissue Diseases[MeSHID:D003240],Kidney[MeSHID:D007668],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Mental Suffering[MeSHID:D013315],Immune thrombocytopenic purpura[MeSHID:D016553],Psoriasis[MeSHID:D011565],Keratoconjunctivitis Sicca[MeSHID:D007638],Liver[MeSHID:D008099],Rheumatoid Arthritis[MeSHID:D001172],Segmental glomerulosclerosis[MeSHID:C538457],Dental Plaque[MeSHID:D003773],Membranous glomerulonephritis[MeSHID:D015433],Bulla[MeSHID:D001768],Tears body substance[MeSHID:D013666],Lipoid nephrosis[MeSHID:D009402],Ulcerative Colitis[MeSHID:D003093],Immunocompromised Host[MeSHID:D016867],Disease[MeSHID:D004194],Graft Rejection[MeSHID:D006084],Dry Eye Syndromes[MeSHID:D015352],Kidney Glomerulus[MeSHID:D007678],Dermatitis, Atopic[MeSHID:D003876],Laceration[MeSHID:D022125],Uveitis[MeSHID:D014605] approved,investigational,vet_approved peptidyl-prolyl cis-trans isomerase f, mitochondrial PPIF NA binder NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical peptidyl-prolyl cis-trans isomerase f, mitochondrial PPIF NA unknown NA drugbank coumarin 120 small molecule NA experimental peptidyl-prolyl cis-trans isomerase f, mitochondrial PPIF NA unknown NA drugbank triglyme small molecule NA experimental peptidyl-prolyl cis-trans isomerase f, mitochondrial PPIF NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical peptidyl-prolyl cis-trans isomerase g PPIG NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical peptidyl-prolyl cis-trans isomerase h PPIH NA unknown NA drugbank vp-102 NA Molluscum Contagiosum[MeSHID:D008976],Warts[MeSHID:D014860],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 protein phosphatase 1a PPM1A Clinical trial target unknown NA TTD , DGIDB abl127 NA NA investigative protein phosphatase methylesterase 1 PPME1 Patented-recorded target inhibitor NA TTD , DGIDB aminolevulinic acid hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623] approved protoporphyrinogen oxidase PPOX Successful target unknown NA TTD , DGIDB cantharidic_acid NA NA investigative serine/threonine pp1-alpha PPP1CA Successful target unknown NA TTD 2,6,8-trimethyl-3-amino-9-benzyl-9-methoxynonanoic acid small molecule NA experimental serine/threonine-protein phosphatase pp1-alpha catalytic subunit PPP1CA NA unknown NA drugbank palasonin NA NA investigative serine/threonine pp1-alpha PPP1CA Successful target unknown NA TTD norcantharidin NA NA investigative serine/threonine pp1-alpha PPP1CA Successful target unknown NA TTD tautomycin NA NA investigative serine/threonine pp1-alpha PPP1CA Successful target unknown NA TTD microcystin-lr NA NA investigative serine/threonine pp1-alpha PPP1CA Successful target unknown NA TTD cantharidin NA Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Dermatologic disorders[MeSHID:D012871],Herpes zoster disease[MeSHID:D006562],Leishmaniasis, Cutaneous[MeSHID:D016773],Skin callus[MeSHID:D002145],Molluscum Contagiosum[MeSHID:D008976],Warts[MeSHID:D014860],Bone callus[MeSHID:D002146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serine/threonine pp1-alpha PPP1CA Successful target unknown 10.61 TTD , DGIDB 9,10-deepithio-9,10-didehydroacanthifolicin small molecule NA experimental serine/threonine-protein phosphatase pp1-gamma catalytic subunit PPP1CC NA unknown NA drugbank calyculin a small molecule NA experimental serine/threonine-protein phosphatase pp1-gamma catalytic subunit PPP1CC NA unknown NA drugbank motuporin small molecule NA experimental serine/threonine-protein phosphatase pp1-gamma catalytic subunit PPP1CC NA unknown NA drugbank 2,6,8-trimethyl-3-amino-9-benzyl-9-methoxynonanoic acid small molecule NA experimental serine/threonine-protein phosphatase 2a catalytic subunit alpha isoform PPP2CA NA unknown NA drugbank lb-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Astrocytoma[MeSHID:D001254] phase 2 serine/threonine pp2a-alpha PPP2CA Clinical trial target unknown 21.22 TTD , DGIDB vp-102 NA Molluscum Contagiosum[MeSHID:D008976],Warts[MeSHID:D014860],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 serine/threonine pp2a-alpha PPP2CA Clinical trial target unknown NA TTD , DGIDB vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved serine/threonine-protein phosphatase 2a catalytic subunit alpha isoform PPP2CA NA unknown NA drugbank (2s,3s,4e,6e,8s,9s)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid small molecule NA experimental serine/threonine-protein phosphatase 2a catalytic subunit alpha isoform PPP2CA NA unknown NA drugbank vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved serine/threonine-protein phosphatase 2a catalytic subunit beta isoform PPP2CB NA unknown NA drugbank 2,6,8-trimethyl-3-amino-9-benzyl-9-methoxynonanoic acid small molecule NA experimental serine/threonine-protein phosphatase 2a 65 kda regulatory subunit a alpha isoform PPP2R1A NA unknown NA drugbank (2s,3s,4e,6e,8s,9s)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid small molecule NA experimental serine/threonine-protein phosphatase 2a 65 kda regulatory subunit a alpha isoform PPP2R1A NA unknown NA drugbank 2,6,8-trimethyl-3-amino-9-benzyl-9-methoxynonanoic acid small molecule NA experimental serine/threonine-protein phosphatase 2a 55 kda regulatory subunit b alpha isoform PPP2R2A NA unknown NA drugbank norcantharidin NA NA investigative pp2a b subunit isoform r5-alpha PPP2R5A Literature-reported target unknown NA TTD (2s,3s,4e,6e,8s,9s)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid small molecule NA experimental serine/threonine-protein phosphatase 2a 56 kda regulatory subunit gamma isoform PPP2R5C NA unknown NA drugbank 2,6,8-trimethyl-3-amino-9-benzyl-9-methoxynonanoic acid small molecule NA experimental serine/threonine-protein phosphatase 2a 56 kda regulatory subunit gamma isoform PPP2R5C NA unknown NA drugbank tacrolimus NA Eczema[MeSHID:D004485],Transplanted tissue[MeSHID:D019737],Dermatitis, Atopic[MeSHID:D003876],Pancreas[MeSHID:D010179],Trachea[MeSHID:D014132],Heart[MeSHID:D006321],Limb structure[MeSHID:D005121],Lung[MeSHID:D008168],Cornea[MeSHID:D003315],Kidney[MeSHID:D007668],Intestines, Small[MeSHID:D007421],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved calcineurin PPP3CA Successful target unknown 0.47 TTD , DGIDB voclosporin NA Lupus Nephritis[MeSHID:D008181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Kidney Diseases[MeSHID:D007674] approved calcineurin PPP3CA Successful target unknown 6.37 TTD , DGIDB pimecrolimus NA Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcineurin PPP3CA Successful target unknown 5.3 TTD , DGIDB ciclosporin NA Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Graft-vs-Host Disease[MeSHID:D006086] approved calcineurin PPP3CA Successful target unknown NA TTD ciclosporin NA Xerophthalmia[MeSHID:D014985],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Brain Injuries[MeSHID:D001930] approved calcineurin PPP3CA Successful target unknown NA TTD myristic acid small molecule NA experimental serine/threonine-protein phosphatase 2b catalytic subunit alpha isoform PPP3CA NA unknown NA drugbank l-685,818 NA NA investigative calcineurin PPP3CA Successful target unknown NA TTD voclosporin small molecule Lupus Nephritis[MeSHID:D008181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Kidney Diseases[MeSHID:D007674] approved,investigational calcineurin subunit b type 1 PPP3R1 NA inhibitor NA drugbank myristic acid small molecule NA experimental calcineurin subunit b type 1 PPP3R1 NA unknown NA drugbank cyclosporine small molecule Eczema[MeSHID:D004485],Graft-vs-Host Disease[MeSHID:D006086],Rupture[MeSHID:D012421],Keratoconjunctivitis, Vernal[MeSHID:D003233],Eye[MeSHID:D005123],Nephrotic Syndrome[MeSHID:D009404],Connective Tissue Diseases[MeSHID:D003240],Kidney[MeSHID:D007668],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Mental Suffering[MeSHID:D013315],Immune thrombocytopenic purpura[MeSHID:D016553],Psoriasis[MeSHID:D011565],Keratoconjunctivitis Sicca[MeSHID:D007638],Liver[MeSHID:D008099],Rheumatoid Arthritis[MeSHID:D001172],Segmental glomerulosclerosis[MeSHID:C538457],Dental Plaque[MeSHID:D003773],Membranous glomerulonephritis[MeSHID:D015433],Bulla[MeSHID:D001768],Tears body substance[MeSHID:D013666],Lipoid nephrosis[MeSHID:D009402],Ulcerative Colitis[MeSHID:D003093],Immunocompromised Host[MeSHID:D016867],Disease[MeSHID:D004194],Graft Rejection[MeSHID:D006084],Dry Eye Syndromes[MeSHID:D015352],Kidney Glomerulus[MeSHID:D007678],Dermatitis, Atopic[MeSHID:D003876],Laceration[MeSHID:D022125],Uveitis[MeSHID:D014605] approved,investigational,vet_approved calcineurin subunit b type 2 PPP3R2 NA inhibitor 7.19 drugbank , DGIDB voclosporin small molecule Lupus Nephritis[MeSHID:D008181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Kidney Diseases[MeSHID:D007674] approved,investigational calcineurin subunit b type 2 PPP3R2 NA inhibitor NA drugbank atp small molecule NA investigational,nutraceutical serine/threonine-protein phosphatase 5 PPP5C NA unknown NA drugbank plitidepsin NA Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 palmitoyl-protein thioesterase 1 PPT1 Clinical trial target unknown 63.65 TTD , DGIDB palmitic acid small molecule NA approved palmitoyl-protein thioesterase 1 PPT1 NA unknown NA drugbank plitidepsin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Angioimmunoblastic Lymphadenopathy[MeSHID:D007119] phase 3 palmitoyl-protein thioesterase 1 PPT1 Clinical trial target unknown 63.65 TTD , DGIDB hexadecanesulfonyl fluoride small molecule NA experimental palmitoyl-protein thioesterase 1 PPT1 NA unknown NA drugbank pp-1420 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1/2 pancreatic hormone PPY Clinical trial target unknown NA TTD imc-f106c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 tumor expressed melanoma antigen PRAME Clinical trial target unknown NA TTD ima 203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1 tumor expressed melanoma antigen PRAME Clinical trial target unknown NA TTD piperidinyl pyrazole derivative 2 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl triazole derivative 4 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB cyclohexane carboxamide derivative 1 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl pyrazole derivative 4 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB cyclohexane carboxamide derivative 2 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl triazole derivative 1 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB benzodihydroisofuran derivative 2 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB benzodihydroisofuran derivative 4 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl triazole derivative 6 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB cyclopentane carboxamide derivative 2 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB imidazole derivative 9 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB benzodihydroisofuran derivative 1 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl triazole derivative 2 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB proline amide derivative 1 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB pmid24157366c35 NA NA investigative prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD pyrrolidine carboxamide derivative 2 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB benzodihydroisofuran derivative 3 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl triazole derivative 5 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl pyrazole derivative 3 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB cyclohexane carboxamide derivative 3 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB cyclopentane carboxamide derivative 1 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl triazole derivative 3 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB piperidinyl pyrazole derivative 1 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB imidazole derivative 8 NA NA patented prolylcarboxypeptidase PRCP Patented-recorded target unknown NA TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational peroxiredoxin-1 PRDX1 NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational peroxiredoxin-1 PRDX1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational peroxiredoxin-1 PRDX1 NA ligand NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational peroxiredoxin-1 PRDX1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental peroxiredoxin-1 PRDX1 NA binder NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxiredoxin-1 PRDX1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxiredoxin-2 PRDX2 NA unknown NA drugbank 3-sulfino-l-alanine small molecule NA experimental peroxiredoxin-2 PRDX2 NA unknown NA drugbank n-carbamoyl-alanine small molecule NA experimental peroxiredoxin-2 PRDX2 NA unknown NA drugbank diterpene triepoxide derivative 1 NA NA patented thioredoxin reductase PRDX5 Successful target unknown NA TTD , DGIDB diminazene small molecule NA experimental peroxiredoxin-5, mitochondrial PRDX5 NA unknown NA drugbank eptacog beta NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 1/2 thioredoxin reductase PRDX5 Successful target unknown NA TTD auranofin small molecule Arthritis[MeSHID:D001168],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxiredoxin-5, mitochondrial PRDX5 NA inhibitor NA drugbank motexafin gadolinium NA Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of brain[MeSHID:D001932],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved thioredoxin reductase PRDX5 Successful target unknown NA TTD , DGIDB 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental peroxiredoxin-6 PRDX6 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational peroxiredoxin-6 PRDX6 NA unknown NA drugbank ono-1603 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 prolyl endopeptidase PREP Clinical trial target unknown 21.22 TTD , DGIDB double oxidized cysteine NA NA investigative prolyl endopeptidase PREP Clinical trial target unknown NA TTD monothioglycerol small molecule NA experimental,investigative prolyl endopeptidase PREP Clinical trial target unknown NA TTD , drugbank 1-hydroxy-1-thio-glycerol small molecule NA experimental,investigative prolyl endopeptidase PREP Clinical trial target unknown NA TTD , drugbank z-321 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] discontinued in phase 1 prolyl endopeptidase PREP Clinical trial target unknown NA TTD (6s)-1-chloro-3-[(4-fluorobenzyl)oxy]-6-(pyrrolidin-1-ylcarbonyl)pyrrolo[1,2-a]pyrazin-4(6h)-one small molecule NA experimental prolyl endopeptidase PREP NA unknown NA drugbank 1-{3-oxo-3-[(2s)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]propyl}-3-phenylquinoxalin-2(1h)-one small molecule NA experimental prolyl endopeptidase PREP NA unknown NA drugbank s-oxy-l-cysteine small molecule NA experimental prolyl endopeptidase PREP NA unknown NA drugbank s-17092-1 NA Cognition Disorders[MeSHID:D003072],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 prolyl endopeptidase PREP Clinical trial target unknown NA TTD , DGIDB alv-003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Celiac Disease[MeSHID:D002446] phase 2 prolyl endopeptidase PREP Clinical trial target unknown 21.22 TTD , DGIDB jtp-4819 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 prolyl endopeptidase PREP Clinical trial target unknown NA TTD z-pro-prolinal small molecule NA experimental,investigative prolyl endopeptidase PREP Clinical trial target unknown NA TTD , drugbank 2-{3-[(2s)-4,4-difluoro-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]-3-oxopropyl}-isoindole-1,3(2h)-dione small molecule NA experimental prolyl endopeptidase PREP NA unknown NA drugbank ari-3531 NA NA investigative prolyl endopeptidase PREP Clinical trial target inhibitor NA TTD , DGIDB baicalein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 prolyl endopeptidase PREP Clinical trial target unknown NA TTD pmid21692504c8 NA NA investigative prolyl endopeptidase-like PREPL Literature-reported target unknown NA TTD sargramostim biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational bone marrow proteoglycan PRG2 NA unknown NA drugbank chymopapain biotech Operative Surgical Procedures[MeSHID:D013514],Digestion[MeSHID:D004063],Cell Nucleus[MeSHID:D002467],Hernia[MeSHID:D006547],Pain[MeSHID:D010146],Nerve Tissue[MeSHID:D009417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Diseases[MeSHID:D009140] approved,withdrawn bone marrow proteoglycan PRG2 NA degradation NA drugbank atp small molecule NA investigational,nutraceutical 5'-amp-activated protein kinase catalytic subunit alpha-1 PRKAA1 NA unknown NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase PRKAA1 NA activator NA drugbank phenformin small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn 5'-amp-activated protein kinase catalytic subunit alpha-1 PRKAA1 NA activator 4.08 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 5'-amp-activated protein kinase catalytic subunit alpha-1 PRKAA1 NA inhibitor NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase catalytic subunit alpha-1 PRKAA1 NA activator NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 5'-amp-activated protein kinase PRKAA1 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved 5'-amp-activated protein kinase PRKAA1 NA activator NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 5'-amp-activated protein kinase PRKAA2 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved 5'-amp-activated protein kinase PRKAA2 NA activator NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase PRKAA2 NA activator NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 5'-amp-activated protein kinase PRKAB1 NA inhibitor NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase subunit beta-1 PRKAB1 NA activator NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase PRKAB1 NA activator NA drugbank metformin small molecule Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 5'-amp-activated protein kinase subunit beta-1 PRKAB1 NA inducer,activator 4.69 drugbank , DGIDB metformin small molecule Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved 5'-amp-activated protein kinase subunit beta-1 PRKAB1 NA inducer,activator 4.69 drugbank , DGIDB acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved 5'-amp-activated protein kinase PRKAB1 NA activator NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved 5'-amp-activated protein kinase PRKAB2 NA activator NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase PRKAB2 NA activator NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 5'-amp-activated protein kinase PRKAB2 NA inhibitor NA drugbank (2s)-1-(3h-indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank (2s)-1-(6h-indol-3-yl)-3-{[5-(7h-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl]oxy}propan-2-amine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank h-89 small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA inhibitor 2.02 drugbank , DGIDB isis 102609 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD xhpnyyouzwownt-pyuwxlgesa-n NA NA patented prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102558 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD (1s)-2-(1h-indol-3-yl)-1-[({5-[(e)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank hydroxyfasudil small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102614 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102563 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102486 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD (4r,2s)-5'-(4-(4-chlorobenzyloxy)pyrrolidin-2-ylmethanesulfonyl)isoquinoline small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102619 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102633 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD balanol small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank balanol analog 2 small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank y-27632 small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank 4-(4-chlorophenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank (1s)-1-(1h-indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphtyridin-5-yloxy)-ehylamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank dexfosfoserine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102604 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD (2s)-2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank 1-[4-(4-chlorobenzyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102624 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD 4-(4-chlorobenzyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank nm-pp1 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102676 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102490 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102668 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD ro-4396686 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD phosphonothreonine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102458 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational camp-dependent protein kinase catalytic subunit alpha PRKACA NA inhibitor NA drugbank isis 102660 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD 6-{4-[4-(4-chlorophenyl)piperidin-4-yl]phenyl}-9h-purine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102450 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD 3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank (2r)-2-(4-chlorophenyl)-2-phenylethanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank myristic acid small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102629 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102466 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD isis 102664 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD a-674563 small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank 3-(1h-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1h-indol-3-yl}-1h-pyrrole-2,5-dione small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank (2s)-1-{[5-(1h-indazol-5-yl)-3-pyridinyl]oxy}-3-(7ah-indol-3-yl)-2-propanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank 2-[4-(3-methyl-1h-pyrazol-4-yl)phenyl]ethanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank balanol analog 1 small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank 3,5-diiodotyrosine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank (2s)-1-(1h-indol-3-yl)-3-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}propan-2-amine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank vfedeoubybldkn-aafjcebusa-n NA NA patented prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD (s)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank 5-(2-methylpiperazine-1-sulfonyl)isoquinoline small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102482 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD 1-[4-(4-chlorophenyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational camp-dependent protein kinase catalytic subunit alpha PRKACA NA inhibitor NA drugbank isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)ethylamino)ethyl)amide small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank n-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102478 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD pentanal small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank (s)-1-phenyl-1-[4-(9h-purin-6-yl)phenyl]methanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank agggwzcoulseer-pyuwxlgesa-n NA NA patented prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD h-89 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target inhibitor 2.02 TTD , DGIDB isis 102454 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD 5-benzyl-1,3-thiazol-2-amine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102584 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD (2r)-2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank 3-pyridin-4-yl-2,4-dihydro-indeno[1,2-.c.] pyrazole small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102599 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD n-methyl-1-[4-(9h-purin-6-yl)phenyl]methanamine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank fasudil small molecule NA investigational camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown 0.2 drugbank , DGIDB 3-pyridin-4-yl-1h-indazole small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank n-[(1s)-2-amino-1-(2,4-dichlorobenzyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide small molecule NA experimental camp-dependent protein kinase catalytic subunit alpha PRKACA NA unknown NA drugbank isis 102462 NA NA investigative prkaca messenger rna PRKACA Patented-recorded target unknown NA TTD phosphonothreonine small molecule NA experimental camp-dependent protein kinase catalytic subunit beta PRKACB NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational camp-dependent protein kinase catalytic subunit beta PRKACB NA inhibitor NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase PRKAG1 NA activator NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved 5'-amp-activated protein kinase PRKAG1 NA activator NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 5'-amp-activated protein kinase PRKAG1 NA inhibitor NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase PRKAG2 NA activator NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 5'-amp-activated protein kinase PRKAG2 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved 5'-amp-activated protein kinase PRKAG2 NA activator NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational 5'-amp-activated protein kinase PRKAG3 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved 5'-amp-activated protein kinase PRKAG3 NA activator NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical 5'-amp-activated protein kinase PRKAG3 NA activator NA drugbank cyclic guanosine monophosphate NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD [3h]camp NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adoc(betaasp)2alaarg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adcahxarg4nh(ch2)6nh2 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adoc(gaba)arg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adcahxarg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD 5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD sp-adenosine-3',5'-cyclic-monophosphorothioate NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD gem-231 biotech Neoplasms[MeSHID:D009369] investigational camp-dependent protein kinase type i-alpha regulatory subunit PRKAR1A NA unknown NA drugbank adoc(aoc)arg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adoc(dpr)2alaarg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adoc(aun)arg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adoc(ahx)arg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD (rp)-camps small molecule NA experimental camp-dependent protein kinase type i-alpha regulatory subunit PRKAR1A NA unknown NA drugbank adocglyarg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adcahxarg4lys(biotin)-peg-ome NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD cyclic gmp small molecule NA experimental camp-dependent protein kinase type i-alpha regulatory subunit PRKAR1A NA unknown NA drugbank adoc(beta-ala)2alaarg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adoc(beta-ala)arg6 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD ro-316233 NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD adcahxarg4lys-pegome NA NA investigative camp-dependent protein kinase a type i PRKAR1A Literature-reported target unknown NA TTD cyclic adenosine monophosphate small molecule NA experimental camp-dependent protein kinase type i-alpha regulatory subunit PRKAR1A NA unknown NA drugbank gem-231 biotech Neoplasms[MeSHID:D009369] investigational camp-dependent protein kinase type ii-alpha regulatory subunit PRKAR2A NA unknown NA drugbank cyclic adenosine monophosphate small molecule NA experimental camp-dependent protein kinase type ii-beta regulatory subunit PRKAR2B NA unknown NA drugbank 4-cycloheptyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD tannin NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD midostaurin small molecule Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved,investigational protein kinase c alpha type PRKCA NA antagonist,inhibitor 0.35 drugbank , DGIDB prostratin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative protein kinase c alpha PRKCA Successful target unknown NA TTD 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD sodium phenylbutyrate NA Spinal Muscular Atrophy[MeSHID:D009134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c alpha PRKCA Successful target unknown NA TTD , DGIDB diheptan-3-yl 5-(hydroxymethyl)isophthalate NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD ci-1040 NA NA investigative protein kinase c alpha PRKCA Successful target unknown 0.13 TTD , DGIDB 2,3,3-triphenyl-acrylonitrile NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical protein kinase c alpha type PRKCA NA unknown NA drugbank 3-(1h-indol-3-yl)-4-phenylamino-pyrrole-2,5-dione NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD go 6983 NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD ly-326449 NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD sotrastaurin acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 protein kinase c alpha PRKCA Successful target unknown NA TTD , DGIDB bryostatin 1 small molecule NA investigational protein kinase c alpha type PRKCA NA activator NA drugbank isis 3521 NA NA discontinued in phase 2 protein kinase c alpha PRKCA Successful target unknown NA TTD affinitak + gemcitabine NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative pkc-alpha messenger rna PRKCA Literature-reported target unknown NA TTD 4-cyclohexyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD kt-5720 NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD ro31-8220 NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD isis 9606 NA NA investigative pkc-alpha messenger rna PRKCA Literature-reported target unknown NA TTD calceolarioside b NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved protein kinase c alpha type PRKCA NA unknown NA drugbank 2-(4-hydroxy-phenyl)-3,3-diphenyl-acrylonitrile NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD ingenol mebutate small molecule Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved protein kinase c alpha type PRKCA NA ligand,activator NA drugbank , DGIDB benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCA NA inhibitor NA drugbank leucosceptoside a NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved protein kinase c alpha type PRKCA NA unknown NA drugbank dihexan-3-yl 5-(hydroxymethyl)isophthalate NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD (-)-cercosporamide NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational protein kinase c alpha type PRKCA NA inhibitor NA drugbank 3,3-bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD ingenol mebutate small molecule Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved protein kinase c alpha type PRKCA NA ligand NA drugbank , DGIDB kn-62 NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD d-alpha-tocopherol acetate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Skin Aging[MeSHID:D015595],Premenstrual syndrome[MeSHID:D011293],Fertility[MeSHID:D005298],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Asthma[MeSHID:D001249],Muscle Cramp[MeSHID:D009120],Cataract[MeSHID:D002386],Disorder of eye[MeSHID:D005128],Ultraviolet Rays[MeSHID:D014466] approved,nutraceutical,vet_approved protein kinase c alpha type PRKCA NA unknown NA drugbank isis 4189 NA NA investigative pkc-alpha messenger rna PRKCA Literature-reported target unknown NA TTD [2,2':5',2'']terthiophene-4-carbaldehyde NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD punicafolin NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCA NA inhibitor NA drugbank [2,2':5',2'']terthiophene-4,5''-dicarbaldehyde NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD forsythiaside NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD ro-316233 NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD 3,3-bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD calceolarioside a NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD pmid28460551-compound-3 NA NA patented protein kinase c alpha PRKCA Successful target unknown NA TTD , DGIDB aprinocarsen small molecule Malignant neoplasm of lung[MeSHID:D008175] investigational protein kinase c alpha type PRKCA NA unknown NA drugbank 4-cyclopentyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD affinitak + cisplatin NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative pkc-alpha messenger rna PRKCA Literature-reported target unknown NA TTD 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD ro-32-0557 NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD [2,2':5',2'']terthiophen-4-yl-methanol NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD perifosine small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Malignant neoplasm of brain[MeSHID:D001932],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational protein kinase c alpha type PRKCA NA unknown NA drugbank plantainoside d NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD staurosporinone NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD 3-(4-hydroxy-phenyl)-2,3-diphenyl-acrylonitrile NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD 1,2-dioctanoyl-sn-glycerol NA NA investigative protein kinase c alpha PRKCA Successful target unknown NA TTD punicafolin NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD [2,2':5',2'']terthiophene-4-carbaldehyde NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational protein kinase c beta type PRKCB NA unknown 2.83 drugbank , DGIDB ro-32-0557 NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD 2-(4-hydroxy-phenyl)-3,3-diphenyl-acrylonitrile NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD 4-cyclopentyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD cholecystokinin small molecule Exocrine pancreatic insufficiency[MeSHID:D010188],Diagnosis[MeSHID:D003933],Gall Bladder Diseases[MeSHID:D005705] approved,investigational protein kinase c beta type PRKCB NA agonist NA drugbank go 6983 NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD prostratin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD phosphorylcolamine small molecule NA experimental protein kinase c beta type PRKCB NA unknown NA drugbank k00248 NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved protein kinase c beta type PRKCB NA unknown NA drugbank benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCB NA inhibitor NA drugbank tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCB NA inhibitor NA drugbank enzastaurin NA Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] phase 3 protein kinase c beta PRKCB Clinical trial target inhibitor 2.83 TTD , DGIDB (-)-cercosporamide NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD enzastaurin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] investigational protein kinase c beta type PRKCB NA inhibitor 2.83 drugbank , DGIDB d-alpha-tocopherol acetate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Skin Aging[MeSHID:D015595],Premenstrual syndrome[MeSHID:D011293],Fertility[MeSHID:D005298],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Asthma[MeSHID:D001249],Muscle Cramp[MeSHID:D009120],Cataract[MeSHID:D002386],Disorder of eye[MeSHID:D005128],Ultraviolet Rays[MeSHID:D014466] approved,nutraceutical,vet_approved protein kinase c beta type PRKCB NA unknown NA drugbank sotrastaurin acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 protein kinase c beta PRKCB Clinical trial target unknown NA TTD , DGIDB ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational protein kinase c beta type PRKCB NA inhibitor NA drugbank 4-cyclohexyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved protein kinase c beta type PRKCB NA unknown NA drugbank tannin NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD 3,3-bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD [2,2':5',2'']terthiophen-4-yl-methanol NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD [2,2':5',2'']terthiophene-4,5''-dicarbaldehyde NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD ly333531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 protein kinase c beta PRKCB Clinical trial target unknown NA TTD , DGIDB ro-316233 NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD 3-(4-hydroxy-phenyl)-2,3-diphenyl-acrylonitrile NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD ms-553 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 protein kinase c beta PRKCB Clinical trial target unknown NA TTD 3-(1h-indol-3-yl)-4-phenylamino-pyrrole-2,5-dione NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD enzastaurin NA Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Glioblastoma[MeSHID:D005909] phase 3 protein kinase c beta PRKCB Clinical trial target unknown 2.83 TTD , DGIDB 3,3-bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD 4-cycloheptyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD ruboxistaurin hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 3 protein kinase c beta PRKCB Clinical trial target unknown NA TTD , DGIDB linetastine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] discontinued in phase 2 protein kinase c beta PRKCB Clinical trial target unknown NA TTD ly-326449 NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD 2,3,3-triphenyl-acrylonitrile NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD o-phosphoethanolamine NA NA investigative protein kinase c beta PRKCB Clinical trial target unknown NA TTD go 6983 NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD 13-acetylphorbol NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD 3,3-bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD prostratin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCD NA inhibitor NA drugbank ingenol mebutate small molecule Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved protein kinase c delta type PRKCD NA ligand NA drugbank , DGIDB 4-cyclohexyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD ly-326449 NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD 8-octyl-benzolactam-v9 NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD [2,2':5',2'']terthiophene-4,5''-dicarbaldehyde NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD [2,2':5',2'']terthiophene-4-carbaldehyde NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD kai-9803 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 1/2 protein kinase c delta PRKCD Clinical trial target unknown 5.62 TTD , DGIDB ro-32-0557 NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD isis 17252 NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD ingenol-3-bezoate NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD 2-(4-hydroxy-phenyl)-3,3-diphenyl-acrylonitrile NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD dihexan-3-yl 5-(hydroxymethyl)isophthalate NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD isis 10311 NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD 4-cycloheptyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD phorbol 12,13-butyrate NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD 3,3-bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD 3-(4-hydroxy-phenyl)-2,3-diphenyl-acrylonitrile NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD isis 10303 NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD [2,2':5',2'']terthiophen-4-yl-methanol NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD 13-acetylphorbol small molecule NA experimental protein kinase c delta type PRKCD NA unknown NA drugbank indolactum NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD isis 10310 NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCD NA inhibitor NA drugbank ly-326449 NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD thymeleatoxin NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD ro-316233 NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD prostratin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD 2,3,3-triphenyl-acrylonitrile NA NA investigative protein kinase c delta PRKCD Clinical trial target unknown NA TTD diheptan-3-yl 5-(hydroxymethyl)isophthalate NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD ingenol mebutate small molecule Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] approved protein kinase c delta type PRKCD NA ligand,activator NA drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational protein kinase c delta type PRKCD NA inhibitor NA drugbank bisindolylmaleimide-i NA NA investigative pkc-delta messenger rna PRKCD Literature-reported target unknown NA TTD 2-(4-hydroxy-phenyl)-3,3-diphenyl-acrylonitrile NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD prostratin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative pkc-epsilon messenger rna PRKCE Literature-reported target unknown NA TTD ly-326449 NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD [2,2':5',2'']terthiophen-4-yl-methanol NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD bryostatin-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 protein kinase c epsilon PRKCE Successful target unknown NA TTD , DGIDB benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCE NA inhibitor NA drugbank 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD 8-octyl-benzolactam-v9 NA NA investigative pkc-epsilon messenger rna PRKCE Literature-reported target unknown NA TTD 3,3-bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD 3,3-bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD [2,2':5',2'']terthiophene-4,5''-dicarbaldehyde NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD ro-316233 NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD bryostatin 1 small molecule NA investigational protein kinase c epsilon type PRKCE NA activator NA drugbank phorbol 12-myristate NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD 4-cyclohexyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD isis 7948 NA NA investigative pkc-epsilon messenger rna PRKCE Literature-reported target unknown NA TTD bisindolylmaleimide-i NA NA investigative pkc-epsilon messenger rna PRKCE Literature-reported target unknown NA TTD 3-(4-hydroxy-phenyl)-2,3-diphenyl-acrylonitrile NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD ro-316233 NA NA investigative pkc-epsilon messenger rna PRKCE Literature-reported target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCE NA inhibitor NA drugbank 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD 4-cycloheptyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD isis 7942 NA NA investigative pkc-epsilon messenger rna PRKCE Literature-reported target unknown NA TTD ro-32-0557 NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD meprobamate NA Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288],Reperfusion Injury[MeSHID:D015427] approved protein kinase c epsilon PRKCE Successful target unknown 0.47 TTD , DGIDB [2,2':5',2'']terthiophene-4-carbaldehyde NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD chelerythrine NA NA investigative pkc-epsilon messenger rna PRKCE Literature-reported target inhibitor 0.3 TTD , DGIDB 2,3,3-triphenyl-acrylonitrile NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational protein kinase c epsilon type PRKCE NA inhibitor NA drugbank kai-1455 small molecule Reperfusion Injury[MeSHID:D015427] investigational protein kinase c epsilon type PRKCE NA unknown NA drugbank , DGIDB 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c epsilon PRKCE Successful target unknown NA TTD go 6983 NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCG NA inhibitor NA drugbank bisindolylmaleimide-i NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD (-)-cercosporamide NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 3-(4-hydroxy-phenyl)-2,3-diphenyl-acrylonitrile NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD prostratin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative protein kinase c gamma PRKCG Successful target unknown NA TTD ly-326449 NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 3,3-bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD [2,2':5',2'']terthiophene-4,5''-dicarbaldehyde NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD monoctanoin component c NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD ro-32-0557 NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 8-octyl-benzolactam-v9 NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCG NA inhibitor NA drugbank 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 4-cycloheptyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD [2,2':5',2'']terthiophene-4-carbaldehyde NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 4-cyclohexyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 2-(4-hydroxy-phenyl)-3,3-diphenyl-acrylonitrile NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD [2,2':5',2'']terthiophen-4-yl-methanol NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD midostaurin NA Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved protein kinase c gamma PRKCG Successful target inhibitor 0.21 TTD , DGIDB ro-316233 NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 4-cyclopentyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational protein kinase c gamma type (prkcg) PRKCG NA inhibitor NA drugbank midostaurin NA Mastocytosis, Systemic[MeSHID:D034721],Leukemia, Mast-Cell[MeSHID:D007946],Hematologic Neoplasms[MeSHID:D019337], Myelocytic, Acute[MeSHID:D015470],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Myelomonocytic, Chronic[MeSHID:D015477],Colorectal Cancer[MeSHID:D015179] approved protein kinase c gamma PRKCG Successful target unknown 0.21 TTD , DGIDB 2,3,3-triphenyl-acrylonitrile NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD 3,3-bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c gamma PRKCG Successful target unknown NA TTD isis 6434 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6442 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD prostratin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6581 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6431 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6443 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6603 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6445 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6432 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6553 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD ly-326449 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD 8-octyl-benzolactam-v9 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD isis 6435 NA NA investigative pkc-eta messenger rna PRKCH Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational protein kinase c iota type PRKCI NA inhibitor NA drugbank benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCI NA inhibitor NA drugbank bisindolylmaleimide i small molecule NA experimental protein kinase c iota type PRKCI NA unknown NA drugbank tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCI NA inhibitor NA drugbank crt-0004592 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative protein kinase c iota PRKCI Literature-reported target unknown NA TTD 2-(4-hydroxy-phenyl)-3,3-diphenyl-acrylonitrile NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational protein kinase c theta type PRKCQ NA inhibitor NA drugbank prostratin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD 4-cycloheptyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD 4-(1h-indol-5-yloxy)-5-styrylnicotinonitrile NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD ro-316233 NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD isis 109351 NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD isis 109353 NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD 4-(3h-indol-4-ylamino)-5-styrylnicotinonitrile NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD phosphonothreonine NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD isis 109354 NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCQ NA inhibitor NA drugbank sotrastaurin acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 protein kinase c theta PRKCQ Clinical trial target unknown NA TTD , DGIDB 4-(1h-indol-5-ylamino)-5-styrylnicotinonitrile NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD 4-(1h-indol-6-ylamino)-5-styrylnicotinonitrile NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD ly-326449 NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD [2,2':5',2'']terthiophene-4,5''-dicarbaldehyde NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD 4-cyclohexyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD isis 109355 NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD 8-octyl-benzolactam-v9 NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD 3,3-bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD staurosporine small molecule NA experimental protein kinase c theta type PRKCQ NA unknown NA drugbank 3-(4-hydroxy-phenyl)-2,3-diphenyl-acrylonitrile NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCQ NA inhibitor NA drugbank 3,3-bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD 2,3,3-triphenyl-acrylonitrile NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD dexfosfoserine small molecule NA experimental protein kinase c theta type PRKCQ NA unknown NA drugbank ro-32-0557 NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD phosphonothreonine small molecule NA experimental protein kinase c theta type PRKCQ NA unknown NA drugbank 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD l-serine-o-phosphate NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD isis 109352 NA NA investigative pkc-theta messenger rna PRKCQ Literature-reported target unknown NA TTD [2,2':5',2'']terthiophen-4-yl-methanol NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD [2,2':5',2'']terthiophene-4-carbaldehyde NA NA investigative protein kinase c theta PRKCQ Clinical trial target unknown NA TTD 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD 4-cycloheptyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD isis 9008 NA NA investigative pkc-zeta messenger rna PRKCZ Literature-reported target unknown NA TTD ly-326449 NA NA investigative pkc-zeta messenger rna PRKCZ Literature-reported target unknown NA TTD bisindolylmaleimide-i NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD isis 9025 NA NA investigative pkc-zeta messenger rna PRKCZ Literature-reported target unknown NA TTD 3,3-bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD go 6983 NA NA investigative pkc-zeta messenger rna PRKCZ Literature-reported target unknown NA TTD isis 9007 NA NA investigative pkc-zeta messenger rna PRKCZ Literature-reported target unknown NA TTD ro-32-0557 NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCZ NA inhibitor NA drugbank y-9680 NA NA patented protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD , DGIDB [2,2':5',2'']terthiophene-4-carbaldehyde NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD 3,3-bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD ly-326449 NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD us8889696, 39 NA NA patented protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD , DGIDB benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein kinase c PRKCZ NA inhibitor NA drugbank g6976 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD [2,2':5',2'']terthiophene-4,5''-dicarbaldehyde NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD isis 9023 NA NA investigative pkc-zeta messenger rna PRKCZ Literature-reported target unknown NA TTD 2,3,3-triphenyl-acrylonitrile NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD 4-cyclohexyliden(4-hydroxyphenyl)methylphenol NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD 3-(4-hydroxy-phenyl)-2,3-diphenyl-acrylonitrile NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD us8889672, 252-036-001 NA NA patented protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD , DGIDB 2-(4-hydroxy-phenyl)-3,3-diphenyl-acrylonitrile NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD [2,2':5',2'']terthiophen-4-yl-methanol NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD isis 9022 NA NA investigative pkc-zeta messenger rna PRKCZ Literature-reported target unknown NA TTD ro-316233 NA NA investigative protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD methyl 2-amino-4-phenylthiophene-3-carboxylate NA NA patented protein kinase c zeta PRKCZ Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase d1 PRKD1 NA inhibitor NA drugbank bryostatin 1 small molecule NA investigational serine/threonine-protein kinase d1 PRKD1 NA activator NA drugbank 2-morpholino-6-(naphthalen-1-yl)-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(piperidin-1-yl)-4h-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(2-fluoro-phenyl)-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholino-6-(thiophen-2-yl)-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 7-propoxy-2-(morpholin-4-yl)-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-pyridin-3-yl-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-phenyl-2-thiomorpholin-4-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(furan-2-yl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-(3-hydroxyphenyl)-2-morpholino-4h-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholino-6-(naphthalen-2-yl)-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD ama37 NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 4-thiomorpholin-4-yl-benzo[g]chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholino-6-(thianthren-1-yl)-4h-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 1-morpholin-4-yl-benzo[f]chromen-3-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD azd7648 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 dna-dependent protein kinase catalytic PRKDC Clinical trial target inhibitor NA TTD , DGIDB 8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 7-phenylethoxy-2-morpholin-4-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-6-phenyl-4h-thiopyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-(4-hydroxyphenyl)-2-morpholino-4h-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholino-6-phenyl-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 4-piperidin-1-yl-chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-tert-butyl-2-morpholin-4-yl-4h-thiopyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 4-morpholin-4-yl-benzo[g]chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(4-amino-phenyl)-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-8-styrylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 3-(6-morpholino-4-oxo-4h-pyran-2-yl)benzonitrile NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(2-methoxyphenyl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 4-morpholin-4-yl-benzo[h]chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-6-phenyl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 3-(6-morpholino-4-oxo-4h-pyran-2-yl)benzaldehyde NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD ic86621 NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-benzo[h]chromene-4-thione NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholino-6-styryl-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(4-methoxyphenyl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD nu-7432 NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(benzofuran-2-yl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD m3814 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rectal Carcinoma[MeSHID:D012004],Malignant Neoplasms[MeSHID:D009369] phase 1/2 dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown 10.61 TTD , DGIDB 2-[1,4]oxazepan-4-yl-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved dna-dependent protein kinase catalytic subunit PRKDC NA inhibitor NA drugbank 2-morpholino-6-(thiophen-3-yl)-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-methoxy-2-morpholin-4-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-(4-fluorostyryl)-2-morpholino-4h-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD ethyl 1-[(1h-benzimidazol-2(3h)one-5-yl)sulfonyl]-1h-pyrrole-2-carboxylate NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(3-acetylphenyl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-methyl-2-morpholin-4-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 7-hydroxy-2-(morpholin-4-yl)chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 7-methoxy-4-morpholin-4-yl-chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD pik-75 NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target inhibitor NA TTD , DGIDB 6-methyl-4-morpholin-4-yl-chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD ku-55933 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD ku-0060648 NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target inhibitor 5.3 TTD , DGIDB 2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD sf1126 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Liver carcinoma[MeSHID:D006528] investigational dna-dependent protein kinase catalytic subunit PRKDC NA unknown NA drugbank , DGIDB 7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholino-4h-benzo[g]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-furan-2-yl-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD ku-0060648 NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown 5.3 TTD , DGIDB 3-morpholino-1h-benzo[f]chromen-1-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(1h-indol-5-yl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-(1h-indol-5-yl)-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(2-methyl-morpholin-4-yl)-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 4-morpholin-4-yl-chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(4-fluorophenyl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholinobenzo[h]quinolin-4(1h)-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-(4-chlorophenyl)-4-morpholino-2h-pyran-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(3-methoxyphenyl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-methyl-4-morpholin-4-yl-chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-isopropyl-2-morpholin-4-yl-4h-thiopyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD shrna molecule silencing dnapk radiosensitizer NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-thiomorpholino-4h-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(2-aminophenyl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD alpha-naphthoflavone NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 7-methoxy-2-morpholin-4-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-methoxy-4-morpholin-4-yl-chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholino-6-(quinolin-8-yl)-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-pyrrolidin-1-yl-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 4-(6-morpholino-4-oxo-4h-pyran-2-yl)benzonitrile NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD pp121 NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target inhibitor NA TTD , DGIDB ly-292223 NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-chloro-4-morpholin-4-yl-chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 4-morpholino-6-phenyl-2h-pyran-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholino-6-(naphthalen-1-yl)-4h-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD m9831 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD , DGIDB 2-(4-chlorophenyl)-6-morpholino-4h-pyran-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 8-phenyl-2-piperidin-1-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 2-(3-fluoro-phenyl)-benzo[h]chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 3-(6-morpholino-4-oxo-4h-pyran-2-yl)benzoic acid NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-(4-methoxyphenyl)-4-morpholino-2h-pyran-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-biphenyl-2-yl-2-morpholin-4-yl-chromen-4-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD 6-methoxy-4-morpholin-4-yl-chromen-2-one NA NA investigative dna-dependent protein kinase catalytic PRKDC Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational cgmp-dependent protein kinase 2 PRKG2 NA inhibitor NA drugbank ntx-488 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] discontinued in phase 2 prolactin PRL Discontinued target unknown NA TTD prolanta NA Fallopian Tube Carcinoma[MeSHID:D005185],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 prolactin receptor PRLR Clinical trial target unknown NA TTD , DGIDB lfa-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 prolactin receptor PRLR Clinical trial target unknown NA TTD , DGIDB endostatin NA Neoplasms[MeSHID:D009369],Diabetic Retinopathy[MeSHID:D003930],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 prolactin receptor PRLR Clinical trial target unknown 21.22 TTD , DGIDB lonapegsomatropin biotech treatment failure[MeSHID:D017211],Growth[MeSHID:D006128],Failure to Thrive[MeSHID:D005183],Bodily secretions[MeSHID:D012634] approved,investigational prolactin receptor PRLR NA ligand NA drugbank somatotropin biotech Hypothalamic Diseases[MeSHID:D007027],Bodily secretions[MeSHID:D012634],Prader-Willi Syndrome[MeSHID:D011218],treatment failure[MeSHID:D017211],Body Weight[MeSHID:D001835],Operative Surgical Procedures[MeSHID:D013514],Failure to Thrive[MeSHID:D005183],Short Bowel Syndrome[MeSHID:D012778],Cachexia[MeSHID:D002100],Traumatic injury[MeSHID:D014947],Dwarfism[MeSHID:D004392],Hypopituitarism[MeSHID:D007018],Chronic Kidney Diseases[MeSHID:D051436],Turner Syndrome[MeSHID:D014424],Birth[MeSHID:D036801],Growth[MeSHID:D006128],Gestational Age[MeSHID:D005865],Pituitary Diseases[MeSHID:D010900],Macrophage Activation Syndrome[MeSHID:D055501],Malnutrition[MeSHID:D044342] approved,investigational prolactin receptor PRLR NA ligand NA drugbank s-adenosyl-l-homocysteine small molecule NA experimental protein arginine n-methyltransferase 1 PRMT1 NA unknown NA drugbank s-adenosyl-l-homocysteine small molecule NA experimental protein arginine n-methyltransferase 3 PRMT3 NA unknown NA drugbank pf-06939999 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein arginine methyltransferase 5 PRMT5 Clinical trial target unknown NA TTD cmp5 NA NA investigative protein arginine methyltransferase 5 PRMT5 Clinical trial target unknown NA TTD gsk3326595 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant neoplasm of breast[MeSHID:D001943],Malignant Neoplasms[MeSHID:D009369] phase 2 protein arginine methyltransferase 5 PRMT5 Clinical trial target unknown NA TTD , DGIDB prt811 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910] phase 1 protein arginine methyltransferase 5 PRMT5 Clinical trial target unknown NA TTD prt543 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1 protein arginine methyltransferase 5 PRMT5 Clinical trial target unknown NA TTD jnj-64619178 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 protein arginine methyltransferase 5 PRMT5 Clinical trial target unknown NA TTD epz015666 NA NA investigative protein arginine methyltransferase 5 PRMT5 Clinical trial target inhibitor NA TTD , DGIDB ds-437 NA NA investigative protein arginine methyltransferase 5 PRMT5 Clinical trial target inhibitor NA TTD , DGIDB ds-437 NA NA investigative protein arginine methyltransferase 7 PRMT7 Literature-reported target inhibitor NA TTD , DGIDB tetracycline small molecule Lyme Disease[MeSHID:D008193],Bovine Anaplasmosis[MeSHID:D000712],Q Fever[MeSHID:D011778],Bacterial Infections[MeSHID:D001424],Pneumonia[MeSHID:D011014],Acne Vulgaris[MeSHID:D000152],Rocky Mountain Spotted Fever[MeSHID:D012373],Rickettsialpox[MeSHID:D000073605],Upper Respiratory Infections[MeSHID:D012141],Brill-Zinsser Disease[MeSHID:D014438],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved major prion protein PRNP NA inhibitor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alternative prion protein PRNP NA unknown NA drugbank cupric chloride small molecule Solutions[MeSHID:D012996],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vitamin k-dependent protein c PROC NA unknown NA drugbank pmid24418773c37 NA NA investigative vitamin k-dependent protein c PROC Successful target unknown NA TTD ancrod NA Hypertensive disease[MeSHID:D006973],Insertion Mutation[MeSHID:D016254],Deep Vein Thrombosis[MeSHID:D020246],Femoral Neck Fractures[MeSHID:D005265],Retinal Vein Occlusion[MeSHID:D012170],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematological Disease[MeSHID:D006402] phase 3 vitamin k-dependent protein c PROC Successful target unknown 7.96 TTD , DGIDB ged-apc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenomatous Polyposis Coli[MeSHID:D011125],Cardiovascular Diseases[MeSHID:D002318] discontinued in phase 1 vitamin k-dependent protein c PROC Successful target unknown NA TTD sodium tetradecyl sulfate small molecule Varicosity[MeSHID:D014648],Pathological Dilatation[MeSHID:D004108],Hemangioma[MeSHID:D006391],Spider Veins[MeSHID:D013684],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vitamin k-dependent protein c PROC Successful target inhibitor NA TTD , drugbank , DGIDB menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical vitamin k-dependent protein c PROC NA activator 1.14 drugbank , DGIDB kappadione small molecule Metabolism[MeSHID:D008660],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Hemorrhagic Disease of Newborn[MeSHID:D006475],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved vitamin k-dependent protein c PROC NA agonist NA drugbank protein s human biotech Malnutrition[MeSHID:D044342],Emergencies [Disease/Finding][MeSHID:D004630] approved vitamin k-dependent protein c PROC NA cofactor NA drugbank rpr-118071 NA NA investigative vitamin k-dependent protein c PROC Successful target unknown NA TTD rpr-120844 NA NA investigative vitamin k-dependent protein c PROC Successful target unknown NA TTD 3k3a-apc NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Adenomatous Polyposis Coli[MeSHID:D011125],Cerebrovascular accident[MeSHID:D020521] phase 2 vitamin k-dependent protein c PROC Successful target unknown NA TTD , DGIDB drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn endothelial protein c receptor PROCR NA unknown NA drugbank phosphatidylethanolamine small molecule NA experimental endothelial protein c receptor PROCR NA unknown NA drugbank tetradecyl hydrogen sulfate (ester) small molecule Varicosity[MeSHID:D014648],Pathological Dilatation[MeSHID:D004108],Esophageal Varices[MeSHID:D004932],Gastrointestinal Hemorrhage[MeSHID:D006471] approved endothelial protein c receptor PROCR NA antagonist NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical proline dehydrogenase 1, mitochondrial PRODH NA unknown NA drugbank triazine compound pc10 NA NA investigative prokineticin receptor 2 PROKR2 Literature-reported target antagonist NA TTD , DGIDB pkr-a NA NA investigative prokineticin receptor 2 PROKR2 Literature-reported target antagonist NA TTD , DGIDB ict-121 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],COPPER TOXICOSIS, IDIOPATHIC[MeSHID:C565846],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1 prominin-1 PROM1 Clinical trial target unknown NA TTD , DGIDB anti-cd133-car vector-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],T-Lymphocyte[MeSHID:D013601],Malignant neoplasm of liver[MeSHID:D008113],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of brain[MeSHID:D001932],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 prominin-1 PROM1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting cd133 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],T-Lymphocyte[MeSHID:D013601] preclinical prominin-1 PROM1 Clinical trial target unknown NA TTD , DGIDB menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical vitamin k-dependent protein s PROS1 NA activator 1.14 drugbank , DGIDB sodium tetradecyl sulfate small molecule Varicosity[MeSHID:D014648],Pathological Dilatation[MeSHID:D004108],Hemangioma[MeSHID:D006391],Spider Veins[MeSHID:D013684],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vitamin k-dependent protein s PROS1 NA inhibitor NA drugbank kappadione small molecule Metabolism[MeSHID:D008660],Jaundice, Obstructive[MeSHID:D041781],Celiac Disease[MeSHID:D002446],Crohn Disease[MeSHID:D003424],Neoplasm Metastasis[MeSHID:D009362],Hemorrhagic Disease of Newborn[MeSHID:D006475],Inherited Factor II deficiency[MeSHID:D007020],Biliary Fistula[MeSHID:D001658],Fibrocystic Disease of Pancreas[MeSHID:D003550],Intestines[MeSHID:D007422],Ulcerative Colitis[MeSHID:D003093] approved vitamin k-dependent protein s PROS1 NA agonist NA drugbank drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn vitamin k-dependent protein s PROS1 NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical proline synthase co-transcribed bacterial homolog protein PROSC NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical proline synthase co-transcribed bacterial homolog protein PROSC NA binder NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase prp4 homolog PRPF4B NA inhibitor NA drugbank benzamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD amylamine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank (s)-n-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank bis(5-amidino-2-benzimidazolyl)methanone small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank n-alpha-(2-naphthylsulfonyl)-n-(3-amidino-l-phenylalaninyl)-d-pipecolinic acid small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 4-piperidin-4-ylbutanal small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank benzamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank (2s,3r)-2-[[4-(tert-butylcarbamoyl)piperazine-1-carbonyl]amino]-6-(diaminomethylideneamino)-3-formylhexanoic acid small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD zk-806450 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_1144 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank nalpha-(2-naphthylsulfonylglycyl)-3-amidino-d,l-phenylalanine-isopropylester small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1h-benzoimidazole-5-carboxamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank gr-133686 NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD rwj-56423 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] experimental trypsin-1 PRSS1 NA inhibitor NA drugbank 2-o-(4'-amidinophenyl)-5-o-(3''-amidinophenyl)-1,4:3,6-dianhydro-d-sorbitol small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_9785 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank atf-hi-8 NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD n-alpha-(2-naphthylsulfonyl)-n(3-amidino-l-phenylalaninyl)-4-acetyl-piperazine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_9678 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_8696 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank (s)-n-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_11092 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 1-{[1-(2-amino-3-phenyl-propionyl)-pyrrolidine-2-carbonyl]-amino}-2-(3-cyano-phenyl)-ethaneboronic acid small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 4-phenylbutylamine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cvs-2139 NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD l-375378 NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 2,5-bis-o-{3-[amino(imino)methyl]phenyl}-1,4:3,6-dianhydro-d-glucitol small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank (s)-n-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_10972 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_10656 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank recaat, ppl therapeutics/bayer NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 2-(2-methylphenyl)-1h-indole-5-carboximidamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2,5-o,o-bis-{4',4''-amidinophenyl}-1,4:3,6-dianhydro-d-sorbitol small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_1801 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_16847 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 3-{5-[amino(iminio)methyl]-1h-indol-2-yl}-5-methoxy-1,1'-biphenyl-2-olate small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 4-(methylsulfonyl)benzenecarboximidamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank diminazene small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2-(3-methylphenyl)-1h-indole-5-carboximidamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 1-benzyl-1h-indole-5-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD thieno[2,3-b]pyridine-2-carboxamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank aminomethylcyclohexane small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 3-phenylpropylamine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank alpha-1 antitrypsin NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Blood Coagulation Disorders[MeSHID:D001778] phase 2 cationic trypsinogen PRSS1 Successful target unknown NA TTD , DGIDB jbp-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD cvs-2359 NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD monoisopropylphosphorylserine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_10991 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank ulinastatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] phase 3 cationic trypsinogen PRSS1 Successful target unknown 9.09 TTD , DGIDB 2-(2-iodo-phenyl)-benzo[d][1,3]oxazin-4-one NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 4-(5-nitro-indol-1-ylmethyl)-benzamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 8-furan-3-yl-6-styryl-naphthalene-2-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD [4-(6-chloro-naphthalene-2-sulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2h-[1,4']bipyridinyl-4-yl)-methanone small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank imino[2-(2-oxo-1,2-dihydro-3-pyridinyl)-1h-benzimidazol-5-yl]methanaminium small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 6-styryl-naphthalene-2-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 5-amino-2,4,6-tribromobenzene-1,3-dicarboxylic acid small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank tert-butyloxy carbonyl-d-phe-pro-arg-h NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD (s)-n-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank rpr128515 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2-naphthalenesulfonic acid small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank macrocyclic tripeptide motif NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD rwj-51084 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_17312 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 4-(3,4-diethoxy-benzylamino)-benzamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD rpr131247 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank benzo[b]thiophene-2-carboxamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank aeruginosin 98-b small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank (1r,2s)-2-phenylcyclopropanaminium small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra-9334 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2h-benzimidazol-2-amine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank [n-[n-(4-methoxy-2,3,6-trimethylphenylsulfonyl)-l-aspartyl]-d-(4-amidino-phenylalanyl)]-piperidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank [4-({[5-benzyloxy-1-(3-carbamimidoyl-benzyl)-1h-indole-2-carbonyl]-amino}-methyl)-phenyl]-trimethyl-ammonium small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank rwj-50353 NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 4-(4-benzyloxy-3-methoxy-benzylamino)-benzamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD n-cycloheptylglycyl-n-(4-carbamimidoylbenzyl)-l-prolinamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank phenethylamine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank n-cyclooctylglycyl-n-(4-carbamimidoylbenzyl)-l-prolinamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_10433 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank (s)-n-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 1,3-di-p-tolyl-[1,3]diazetidine-2,4-dione NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 6-chloro-2-(2-hydroxy-biphenyl-3-yl)-1h-indole-5-carboxamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_9076 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank grassystatin a NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD benzylamine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank bortezomib NA Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] approved cationic trypsinogen PRSS1 Successful target unknown 0.3 TTD , DGIDB 5-amidino-benzimidazole small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2-(2-hydroxy-phenyl)-3h-benzoimidazole-5-carboxamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank dermolastin NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] discontinued in phase 2 cationic trypsinogen PRSS1 Successful target unknown NA TTD , DGIDB n-alpha-(2-naphthylsulfonyl)-n(3-amidino-l-phenylalaninyl)isopipecolinic acid methyl ester small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank zinc;[amino-[2-[[5-[amino(azaniumylidene)methyl]benzimidazol-1-id-2-yl]methyl]benzimidazol-1-id-5-yl]methylidene]azanium small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Pancreatitis[MeSHID:D010195] investigational trypsin-1 PRSS1 NA inhibitor 1.65 drugbank , DGIDB melagatran NA NA phase 3 cationic trypsinogen PRSS1 Successful target unknown 1.52 TTD , DGIDB cra_23653 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2-propionyl-1h-indole-6-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD bis(5-amidino-benzimidazolyl)methanone zinc small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 1-(3-nitro-benzyl)-1h-indole-5-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 2-(2-methylphenyl)-1h-indole-6-carboximidamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cyclotheonamide a small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank rwj-56423 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 cationic trypsinogen PRSS1 Successful target unknown NA TTD cra_10655 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank [n-(benzyloxycarbonyl)amino](4-amidinophenyl)methane-phosphonate small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank +/-methyl 4-(aminoiminomethyl)-beta-[3- inh (aminoimino)phenyl]benzene pentanoate small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 1-(4-amidinophenyl)-3-(4-chlorophenyl)urea small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank cra_17693 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank bis(5-amidino-benzimidazolyl)methane small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank bis(5-amidino-2-benzimidazolyl)methane ketone hydrate small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank piperidine-1-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 4-indol-1-ylmethyl-benzamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD phosphorylisopropane small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank [(1-{2[(4-carbamimidoyl-phenylamino)-methyl]-1-methyl-1h-benzoimidazol-5-yl}-cyclopropyl)-pyridin-2-yl-methyleneaminooxy]-acetic acid ethyl ester small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank pop-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 1,4:3,6-dianhydro-2-o-(3-carbamimidoylphenyl)-5-o-(4-carbamimidoylphenyl)-d-glucitol small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank bis(5-amidino-2-benzimidazolyl)methane ketone small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 1-(2-amidinophenyl)-3-(phenoxyphenyl)urea small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank nafamostat small molecule Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Disease[MeSHID:D004194] investigational trypsin-1 PRSS1 NA inhibitor 1.65 drugbank , DGIDB cra_10762 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank (s)-n-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank pmid3514912c9 NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 4-iodobenzo[b]thiophene-2-carboxamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank hemi-babim small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank zk-806711 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank zk-805623 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 2-(2-hydroxy-5-methoxy-phenyl)-1h-benzoimidazole-5-carboxamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank aprotinin biotech Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn trypsin-1 PRSS1 NA unknown NA drugbank 4-{[1-methyl-5-(2-methyl-benzoimidazol-1-ylmethyl)-1h-benzoimidazol-2-ylmethyl]-amino}-benzamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 8-bromo-6-styryl-naphthalene-2-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1h-1,3-benzodiazole-5-carboximidamide small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank camostat small molecule Pancreatitis, Chronic[MeSHID:D050500],Hereditary pancreatitis[MeSHID:C537262],Lung Injury[MeSHID:D055370],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental trypsin-1 PRSS1 NA inhibitor 9.09 drugbank , DGIDB 1-(3-amino-benzyl)-1h-indole-5-carboxamidine NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD 4-fluorobenzylamine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 3,5-diiodotyrosine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank diethyl [(1r)-1,5-diaminopentyl]boronate small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank bis-benzamidine small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank 1,3-dibenzyl-[1,3]diazetidine-2,4-dione NA NA investigative cationic trypsinogen PRSS1 Successful target unknown NA TTD cra_1802 small molecule NA experimental trypsin-1 PRSS1 NA unknown NA drugbank o-benzylsulfonyl-serine small molecule NA experimental trypsin-2 PRSS2 NA unknown NA drugbank phosphorylisopropane small molecule NA experimental trypsin-2 PRSS2 NA unknown NA drugbank phenethylamine small molecule NA experimental trypsin-2 PRSS2 NA unknown NA drugbank benzylamine small molecule NA experimental trypsin-2 PRSS2 NA unknown NA drugbank benzamidine small molecule NA experimental trypsin-2 PRSS2 NA unknown NA drugbank 3-phenylpropylamine small molecule NA experimental trypsin-2 PRSS2 NA unknown NA drugbank monoisopropylphosphorylserine small molecule NA experimental trypsin-2 PRSS2 NA unknown NA drugbank [4-(1,3,2-dioxaborolan-2-yloxy)methyl]benzamidine small molecule NA experimental trypsin-3 PRSS3 NA unknown NA drugbank 1,3,2-dioxaborolan-2-ol small molecule NA experimental trypsin-3 PRSS3 NA unknown NA drugbank 4-(1,3,2-dioxaborolan-2-yloxy)butan-1-aminium small molecule NA experimental trypsin-3 PRSS3 NA unknown NA drugbank 4-hydroxybutan-1-aminium small molecule NA experimental trypsin-3 PRSS3 NA unknown NA drugbank benzamidine small molecule NA experimental trypsin-3 PRSS3 NA unknown NA drugbank diamino-n-[3-(1,3,2-dioxaborolan-2-yloxy)propyl]methaniminium small molecule NA experimental trypsin-3 PRSS3 NA unknown NA drugbank 4-(hydroxymethyl)benzamidine small molecule NA experimental trypsin-3 PRSS3 NA unknown NA drugbank guanidine-3-propanol small molecule NA experimental trypsin-3 PRSS3 NA unknown NA drugbank 1-[4-(hydroxymethyl)phenyl]guanidine small molecule NA experimental prostasin PRSS8 NA unknown NA drugbank elafin small molecule Disease[MeSHID:D004194] investigational myeloblastin PRTN3 NA unknown NA drugbank , DGIDB pmid22595175c4g NA NA investigative leukocyte proteinase-3 PRTN3 Clinical trial target unknown NA TTD combined pr1/wt1 vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Nephroblastoma[MeSHID:D009396] phase 2 leukocyte proteinase-3 PRTN3 Clinical trial target unknown NA TTD , DGIDB tiprelestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 2 leukocyte proteinase-3 PRTN3 Clinical trial target unknown 15.91 TTD , DGIDB di-stearoyl-3-sn-phosphatidylethanolamine small molecule NA experimental proactivator polypeptide PSAP NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical phosphoserine aminotransferase PSAT1 NA cofactor NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical phosphoserine aminotransferase PSAT1 NA unknown NA drugbank car-t cells targeting psca NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],T-Lymphocyte[MeSHID:D013601] phase 1 prostate stem cell antigen PSCA Clinical trial target unknown NA TTD , DGIDB mb-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 prostate stem cell antigen PSCA Clinical trial target unknown NA TTD gem3psca NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 prostate stem cell antigen PSCA Clinical trial target unknown NA TTD anti-psca mab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 prostate stem cell antigen PSCA Clinical trial target unknown NA TTD , DGIDB bpx-601 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Adenocarcinoma[MeSHID:D000230],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 prostate stem cell antigen PSCA Clinical trial target unknown NA TTD , DGIDB car-t cells targeting psca NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],T-Lymphocyte[MeSHID:D013601] phase 1 prostate stem cell antigen PSCA Clinical trial target unknown NA TTD , DGIDB 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6h)-one NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD r-flurbiprofen NA NA phase 2 presenilin 1 PSEN1 Clinical trial target unknown NA TTD , DGIDB (2s,3r)-2-(benzyloxy)-3-methoxycyclohexanone NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD drug 311440 NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD (5r,6s)-5,6-bis(benzyloxy)cyclohex-2-enone NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD 1-chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD drug 311952 NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD drug 311383 NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD (s)-flurbiprofen NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Periarthritis[MeSHID:D010489],Myalgia[MeSHID:D063806] preregistration presenilin 1 PSEN1 Clinical trial target unknown NA TTD drug 311951 NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD (5r,6s)-6-(benzyloxy)-5-methoxycyclohex-2-enone NA NA investigative presenilin 1 PSEN1 Clinical trial target unknown NA TTD drug 311440 NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD (5r,6s)-6-(benzyloxy)-5-methoxycyclohex-2-enone NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD drug 311951 NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD r-flurbiprofen NA NA phase 2 presenilin 2 PSEN2 Clinical trial target unknown NA TTD , DGIDB 1-chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD (s)-flurbiprofen NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Periarthritis[MeSHID:D010489],Myalgia[MeSHID:D063806] preregistration presenilin 2 PSEN2 Clinical trial target unknown NA TTD drug 311952 NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD (2s,3r)-2-(benzyloxy)-3-methoxycyclohexanone NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6h)-one NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD drug 311383 NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD (5r,6s)-5,6-bis(benzyloxy)cyclohex-2-enone NA NA investigative presenilin 2 PSEN2 Clinical trial target unknown NA TTD e-2012 small molecule NA investigational gamma-secretase subunit pen-2 PSENEN NA unknown NA drugbank alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational pregnancy-specific beta-1-glycoprotein 5 PSG5 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit alpha type-1 PSMA1 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit alpha type-2 PSMA2 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit alpha type-3 PSMA3 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational proteasome subunit alpha type-3 PSMA3 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit alpha type-4 PSMA4 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit alpha type-5 PSMA5 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit alpha type-6 PSMA6 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit alpha type-7 PSMA7 NA unknown NA drugbank acetylleucyl-leucyl-norleucinal small molecule NA experimental proteasome subunit alpha type-7 PSMA7 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit beta type-1 PSMB1 NA unknown NA drugbank bortezomib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] approved,investigational proteasome subunit beta type-1 PSMB1 NA inhibitor 0.71 drugbank , DGIDB carfilzomib small molecule Unmarried[MeSHID:D012847],Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved,investigational proteasome subunit beta type-1 PSMB1 NA inhibitor 1.12 drugbank , DGIDB carfilzomib small molecule Unmarried[MeSHID:D012847],Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved,investigational proteasome subunit beta type-10 PSMB10 NA inhibitor 1.12 drugbank , DGIDB peptide analog 23 NA NA patented proteasome beta-10 PSMB10 Patented-recorded target unknown NA TTD peptide analog 36 NA NA patented proteasome beta-10 PSMB10 Patented-recorded target unknown NA TTD peptide analog 38 NA NA patented proteasome beta-10 PSMB10 Patented-recorded target unknown NA TTD peptide analog 21 NA NA patented proteasome beta-10 PSMB10 Patented-recorded target unknown NA TTD peptide analog 37 NA NA patented proteasome beta-10 PSMB10 Patented-recorded target unknown NA TTD (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit beta type-2 PSMB2 NA unknown NA drugbank carfilzomib small molecule Unmarried[MeSHID:D012847],Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved,investigational proteasome subunit beta type-2 PSMB2 NA inhibitor 0.84 drugbank , DGIDB (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit beta type-3 PSMB3 NA unknown NA drugbank (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit beta type-4 PSMB4 NA unknown NA drugbank pmid29865878-compound-43 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid29865878-compound-46 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 23 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD carfilzomib small molecule Unmarried[MeSHID:D012847],Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved,investigational proteasome subunit beta type-5 PSMB5 NA inhibitor 0.81 drugbank , DGIDB peptide analog 37 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 33 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid29865878-compound-44 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 41 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 11 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD bortezomib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] approved,investigational proteasome subunit beta type-5 PSMB5 NA inhibitor 0.51 drugbank , DGIDB pmid29865878-compound-53 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 27 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 21 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 34 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 28 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 19 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 13 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 17 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 38 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid29865878-compound-49 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 31 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid24946214c3b NA NA investigative proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid29865878-compound-51 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid29865878-compound-8 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 39 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD peptide analog 25 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid29865878-compound-55 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid29865878-compound-48 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit beta type-5 PSMB5 NA unknown NA drugbank peptide analog 36 NA NA patented proteasome beta-5 PSMB5 Patented-recorded target unknown NA TTD pmid29865878-compound-51 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD pmid29865878-compound-49 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD pmid29865878-compound-53 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit beta type-6 PSMB6 NA unknown NA drugbank pmid29865878-compound-55 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD peptide analog 39 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD peptide analog 23 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD pmid29865878-compound-46 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD peptide analog 41 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD peptide analog 21 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD pmid29865878-compound-48 NA NA patented proteasome beta-1 PSMB6 Patented-recorded target unknown NA TTD peptide analog 38 NA NA patented proteasome beta-2 PSMB7 Patented-recorded target unknown NA TTD peptide analog 36 NA NA patented proteasome beta-2 PSMB7 Patented-recorded target unknown NA TTD peptide analog 21 NA NA patented proteasome beta-2 PSMB7 Patented-recorded target unknown NA TTD peptide analog 37 NA NA patented proteasome beta-2 PSMB7 Patented-recorded target unknown NA TTD peptide analog 23 NA NA patented proteasome beta-2 PSMB7 Patented-recorded target unknown NA TTD peptide analog 41 NA NA patented proteasome beta-2 PSMB7 Patented-recorded target unknown NA TTD (3ar,6r,6as)-6-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-6a-methyl-4-oxo-hexahydro-2h-furo[3,2-c]pyrrole-6-carbaldehyde small molecule NA experimental proteasome subunit beta type-7 PSMB7 NA unknown NA drugbank peptide analog 39 NA NA patented proteasome beta-2 PSMB7 Patented-recorded target unknown NA TTD pmid29865878-compound-55 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-46 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-61 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 17 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 27 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 33 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-8 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD carfilzomib small molecule Unmarried[MeSHID:D012847],Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved,investigational proteasome subunit beta type-8 PSMB8 NA inhibitor 0.7 drugbank , DGIDB pmid29865878-compound-58 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-64 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD dipeptide analog 1 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 19 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-53 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 34 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-49 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 25 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-44 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 28 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-63 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 13 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 23 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 41 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-57 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 31 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 11 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-48 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-62 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-51 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD peptide analog 21 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-59 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD pmid29865878-compound-43 NA NA patented proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD ht1042 NA NA investigative proteasome beta-8 PSMB8 Clinical trial target inhibitor NA TTD , DGIDB m3258 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 proteasome beta-8 PSMB8 Clinical trial target unknown NA TTD carfilzomib small molecule Unmarried[MeSHID:D012847],Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved,investigational proteasome subunit beta type-9 PSMB9 NA inhibitor 0.93 drugbank , DGIDB peptide analog 14 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD peptide analog 21 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD peptide analog 41 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD pmid29865878-compound-55 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD pmid29865878-compound-51 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD pmid29865878-compound-53 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD pmid29865878-compound-49 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD dipeptide analog 1 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD peptide analog 23 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD pmid29865878-compound-48 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD pmid29865878-compound-46 NA NA patented proteasome beta-9 PSMB9 Patented-recorded target unknown NA TTD phenethyl isothiocyanate small molecule NA investigational 26s protease regulatory subunit 6a PSMC3 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational proteasome activator complex subunit 1 PSME1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational phosphoserine phosphatase PSPH NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational phosphoserine phosphatase PSPH NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational phosphoserine phosphatase PSPH NA binder NA drugbank 3-phosphono-d-alanine small molecule NA experimental phosphoserine phosphatase PSPH NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental phosphoserine phosphatase PSPH NA binder NA drugbank 7alpha-nhme-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD dersalazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 platelet-activating factor receptor PTAFR Successful target unknown 2.45 TTD , DGIDB df-1111301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] discontinued in phase 1 platelet-activating factor receptor PTAFR Successful target unknown NA TTD de-081 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Conjunctivitis[MeSHID:D003231],Eye[MeSHID:D005123],Expiration, function[MeSHID:D045853] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD 7alpha-cl-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD 7alpha-nh2-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD tcv-309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD l-652731 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD ticlopidine NA Cerebrovascular accident[MeSHID:D020521],Thrombus[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved platelet-activating factor receptor PTAFR Successful target unknown 0.38 TTD , DGIDB 10-obn-epi-ginkgolide c NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD israpafant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 platelet-activating factor receptor PTAFR Successful target antagonist 4.9 TTD , DGIDB ym-264 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD , DGIDB cv-3988 NA NA investigative platelet-activating factor receptor PTAFR Successful target antagonist 2.45 TTD , DGIDB 10-obn-7alpha-f-gingkolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD fr-900452 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD 7-epi-ginkgolide c NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD lau-0901 NA Brain Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD agn-191743 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] discontinued in phase 1 platelet-activating factor receptor PTAFR Successful target unknown NA TTD israpafant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 platelet-activating factor receptor PTAFR Successful target unknown 4.9 TTD , DGIDB methylcarbamyl paf NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD 7alpha-nhet-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD ur-12510 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD enantio paf c-16 NA NA investigative platelet-activating factor receptor PTAFR Successful target agonist NA TTD , DGIDB 10-obn-ginkgolide c NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD rupatadine small molecule Urticaria[MeSHID:D014581],Nose[MeSHID:D009666],Rhinitis, Allergic, Perennial[MeSHID:D012221] approved,phase 4 platelet-activating factor receptor PTAFR Successful target antagonist 7.34 TTD , drugbank , DGIDB abt-299 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 1 platelet-activating factor receptor PTAFR Successful target antagonist 4.9 TTD , DGIDB 60p002 NA Dengue Fever[MeSHID:D003715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD 10-obn-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD etizolam small molecule Depressive disorder[MeSHID:D003866],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] experimental platelet-activating factor receptor PTAFR NA antagonist NA drugbank platelet activating factor small molecule NA experimental platelet-activating factor receptor PTAFR NA unknown NA drugbank veraguensin NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD 2-o-ethyl-paf c-16 NA NA investigative platelet-activating factor receptor PTAFR Successful target agonist NA TTD , DGIDB sdz-62-434 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 platelet-activating factor receptor PTAFR Successful target unknown NA TTD bn50727 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD e-6123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD 7alpha-oac-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD 2-o-methyl-paf c-18 NA NA investigative platelet-activating factor receptor PTAFR Successful target agonist NA TTD , DGIDB bb-823 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD foropafant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 3 platelet-activating factor receptor PTAFR Successful target antagonist 4.9 TTD , DGIDB ur-12519 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD sm-10661 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD paf NA NA investigative platelet-activating factor receptor PTAFR Successful target agonist NA TTD , DGIDB 7alpha-f-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD ur-10324 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD ur-11353 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD cmi-392 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD , DGIDB ro-24-4736 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD sri-63-675 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD bn 50730 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 3 platelet-activating factor receptor PTAFR Successful target unknown NA TTD minopafant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target antagonist 4.9 TTD , DGIDB 7alpha-ococh2ph-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD 7alpha-n3-ginkgolide b NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD rp-52770 NA NA investigative platelet-activating factor receptor PTAFR Successful target antagonist 4.9 TTD , DGIDB pegcntf NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 1 platelet-activating factor receptor PTAFR Successful target unknown NA TTD , DGIDB lexipafant NA Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Traumatic injury[MeSHID:D014947],Communicable Diseases[MeSHID:D003141],Nerve Tissue[MeSHID:D009417] phase 2 platelet-activating factor receptor PTAFR Successful target unknown 4.9 TTD , DGIDB ko-286011 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD a 137491 NA NA investigative platelet-activating factor receptor PTAFR Successful target unknown NA TTD uk-74505 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD dacopafant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 1 platelet-activating factor receptor PTAFR Successful target unknown NA TTD mk-287 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 2 platelet-activating factor receptor PTAFR Successful target unknown NA TTD phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical phosphatidylserine synthase 1 PTDSS1 NA unknown NA drugbank phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical phosphatidylserine synthase 2 PTDSS2 NA unknown NA drugbank phosphatidylethanolamine small molecule NA experimental phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase pten PTEN NA substrate NA drugbank ts-022 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD , DGIDB ah6809 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target antagonist NA TTD , DGIDB nedocromil small molecule Asthma[MeSHID:D001249] approved,investigational prostaglandin d2 receptor PTGDR NA unknown NA drugbank delta12-pgj2 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD ono-4053 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD , DGIDB pgf2alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD , DGIDB 192c86 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD , DGIDB bwa868c NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target antagonist NA TTD , DGIDB sq-27986 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB bw 245c NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB l-888,291 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB l-644,698 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB diastereomer 2 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD sar-389644 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD , DGIDB butaprost (free acid form) NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB laropiprant NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161] phase 4 prostaglandin d2 receptor PTGDR Clinical trial target unknown 3.5 TTD , DGIDB pgj2 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB pgd2 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB laropiprant+niacin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dyslipidemias[MeSHID:D050171] discontinued in phase 3 prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD mk-1029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 prostaglandin d2 receptor PTGDR Clinical trial target unknown 2.45 TTD , DGIDB rs 93520 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB 15-deoxy-delta12,14-pgj2 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD cloprostenol NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist 0.98 TTD , DGIDB u46619 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB ono-4127 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD setipiprant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 prostaglandin d2 receptor PTGDR Clinical trial target unknown 2.45 TTD , DGIDB s-5751 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis[MeSHID:D012220] discontinued in phase 2 prostaglandin d2 receptor PTGDR Clinical trial target antagonist NA TTD , DGIDB tth 03-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD laropiprant NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161] phase 4 prostaglandin d2 receptor PTGDR Clinical trial target antagonist 3.5 TTD , DGIDB qaw-039 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 prostaglandin d2 receptor PTGDR Clinical trial target unknown 2.45 TTD , DGIDB zk110841 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist NA TTD , DGIDB amg 853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD , DGIDB ono-ae3-237 NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target antagonist NA TTD , DGIDB carbacyclin NA NA investigative prostaglandin d2 receptor PTGDR Clinical trial target agonist 0.61 TTD , DGIDB s-555739 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] phase 2 prostaglandin d2 receptor PTGDR Clinical trial target unknown 9.79 TTD , DGIDB mk-1092 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 1 prostaglandin d2 receptor PTGDR Clinical trial target unknown NA TTD pgf2alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD , DGIDB cay 10471 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist NA TTD , DGIDB azd1981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist 10.61 TTD , DGIDB laropiprant NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161] phase 4 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 0.51 TTD , DGIDB adc-3680 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 7.07 TTD , DGIDB mk-7246 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 7.07 TTD , DGIDB am-211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 10.61 TTD , DGIDB 15-deoxy-delta12,14-pgd2 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD ramatroban small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis, Allergic, Perennial[MeSHID:D012221] investigational,phase 2/3 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 2.12 TTD , drugbank , DGIDB 2-(2-acetyl-4-bromophenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD arry-502 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 10.61 TTD , DGIDB 2-(4-bromo-2-cyclohexylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 15-deoxy-delta12,14-pgj2 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD bbi-5000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(2-formylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD zomepirac small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn prostaglandin d2 receptor 2 PTGDR2 NA unknown NA drugbank rg-7185 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD l-888607 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(2-allyl-4-chlorophenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD u46619 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target agonist NA TTD , DGIDB 3-(4-chloro-2-cyclohexylphenoxy)propanoic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(4-chloro-2-cycloheptylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD delta12-pgj2 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD amg 853 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD , DGIDB ap-761 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD , DGIDB ramatroban small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis, Allergic, Perennial[MeSHID:D012221] investigational,phase 2/3 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist 2.12 TTD , drugbank , DGIDB qav-680 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 10.61 TTD , DGIDB pgj2 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target agonist NA TTD , DGIDB 2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD pgd3 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(2-cyclohexyl-4-fluorophenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD pgd2 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target agonist NA TTD , DGIDB azd1981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 10.61 TTD , DGIDB fevipiprant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist 3.54 TTD , DGIDB am-461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 5.3 TTD , DGIDB iw-1221 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD mk-7246 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist 7.07 TTD , DGIDB l-888,291 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target agonist NA TTD , DGIDB alprostadil small molecule Patent ductus arteriosus[MeSHID:D004374],Maintenance[MeSHID:D008283],Congenital Heart Defects[MeSHID:D006330],Neurogenesis[MeSHID:D055495],Erectile dysfunction[MeSHID:D007172],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved,investigational prostaglandin d2 receptor 2 PTGDR2 NA agonist NA drugbank 2-(2-benzoyl-4-bromophenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD sulindac small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin d2 receptor 2 PTGDR2 NA antagonist NA drugbank 2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(2-cyclohexylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(4-bromo-2-formylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(4-bromo-2-tert-butylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(4-chloro-2-cyclohexylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(4-chloro-2-cyclopentylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 4-(4-chloro-2-cyclohexylphenoxy)butanoic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 13,14-dihydro-15-keto-pgd2 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target agonist NA TTD , DGIDB indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational prostaglandin d2 receptor 2 PTGDR2 NA agonist 0.37 drugbank , DGIDB adc-9971 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 15(s)-15-methyl-pgd2 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target agonist NA TTD , DGIDB oc-000459 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 14.14 TTD , DGIDB 13,14-dihydro-15-keto-pgf2alpha NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD arry-502 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist 10.61 TTD , DGIDB iloprost small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin d2 receptor 2 PTGDR2 NA agonist NA drugbank prostaglandin d2 small molecule NA investigational prostaglandin d2 receptor 2 PTGDR2 NA unknown NA drugbank azd5985 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(2-cyclohexyl-4-methylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD azd8075 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 15(r)-15-methyl-pgd2 NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target agonist NA TTD , DGIDB am-461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140],Respiration Disorders[MeSHID:D012120] phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist 5.3 TTD , DGIDB dinoprostone small molecule Disease Management[MeSHID:D019468],Cervical Ripening[MeSHID:D020070],Postpartum Hemorrhage[MeSHID:D006473],Cessation of life[MeSHID:D003643],Pregnancy[MeSHID:D011247],Missed abortion[MeSHID:D000030],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Gestational Age[MeSHID:D005865],Hydatidiform Mole[MeSHID:D006828],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin d2 receptor 2 PTGDR2 NA agonist NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin d2 receptor 2 PTGDR2 NA agonist 0.37 drugbank , DGIDB setipiprant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist 5.3 TTD , DGIDB am-156 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD 2-(2,4-diphenylthiazol-5-yl)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD dinoprost small molecule NA approved,investigational prostaglandin d2 receptor 2 PTGDR2 NA agonist NA drugbank 2-(4-cyano-2-cyclohexylphenoxy)acetic acid NA NA investigative prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown NA TTD setipiprant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target unknown 5.3 TTD , DGIDB am-211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 prostaglandin d2 receptor 2 PTGDR2 Clinical trial target antagonist 10.61 TTD , DGIDB vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved prostaglandin-h2 d-isomerase PTGDS NA ligand NA drugbank pgd2 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target agonist NA TTD , DGIDB alprostadil small molecule Patent ductus arteriosus[MeSHID:D004374],Maintenance[MeSHID:D008283],Congenital Heart Defects[MeSHID:D006330],Neurogenesis[MeSHID:D055495],Erectile dysfunction[MeSHID:D007172],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved,investigational prostaglandin e2 receptor ep1 subtype PTGER1 NA agonist 2.12 drugbank , DGIDB bimatoprost small molecule Eyelash[MeSHID:D005140],Glaucoma, Open-Angle[MeSHID:D005902],Hypotrichosis[MeSHID:D007039],Ocular Hypotension[MeSHID:D015814],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901],Alopecia[MeSHID:D000505] approved,investigational prostaglandin e2 receptor ep1 subtype PTGER1 NA agonist 3.54 drugbank , DGIDB sc-19220 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target antagonist 1.77 TTD , DGIDB u46619 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target agonist NA TTD , DGIDB butaprost NA NA patented prostaglandin e2 receptor ep1 PTGER1 Clinical trial target unknown 0.71 TTD , DGIDB ono-di-004 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target unknown NA TTD m&b 28767 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target unknown NA TTD misoprostol small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Spontaneous abortion[MeSHID:D000022],Postpartum Hemorrhage[MeSHID:D006473],Rheumatoid Arthritis[MeSHID:D001172],Off-Label Use[MeSHID:D056687],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep1 subtype PTGER1 NA agonist NA drugbank bupivacaine small molecule Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Decompression, external[MeSHID:D003664],Spatial Visualization[MeSHID:D065854],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational prostaglandin e2 receptor ep1 subtype PTGER1 NA unknown NA drugbank ono-8713 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target antagonist NA TTD , DGIDB as-013 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 3 prostaglandin e2 receptor ep1 PTGER1 Clinical trial target unknown 3.54 TTD , DGIDB zk110841 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target agonist NA TTD , DGIDB zm 325802 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target unknown NA TTD carboprost tromethamine small molecule Disease Management[MeSHID:D019468],Fetal Membranes, Premature Rupture[MeSHID:D005322],Disease[MeSHID:D004194],Postpartum Hemorrhage[MeSHID:D006473],Pregnancy[MeSHID:D011247],Uterine Inertia[MeSHID:D014593],Fetal Tissue[MeSHID:D005333],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Tissue membrane[MeSHID:D008566],Rupture, Spontaneous[MeSHID:D012422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep1 subtype PTGER1 NA agonist NA drugbank , DGIDB cicaprost NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target agonist 0.88 TTD , DGIDB carbacyclin NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target agonist 0.44 TTD , DGIDB pgf2alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial prostaglandin e2 receptor ep1 PTGER1 Clinical trial target unknown NA TTD , DGIDB iloprost small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin e2 receptor ep1 subtype PTGER1 NA agonist 1.96 drugbank , DGIDB cloprostenol NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target agonist 0.71 TTD , DGIDB sc-51322 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target antagonist NA TTD , DGIDB gw848687x NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target antagonist 3.54 TTD , DGIDB dinoprostone small molecule Disease Management[MeSHID:D019468],Cervical Ripening[MeSHID:D020070],Postpartum Hemorrhage[MeSHID:D006473],Cessation of life[MeSHID:D003643],Pregnancy[MeSHID:D011247],Missed abortion[MeSHID:D000030],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Gestational Age[MeSHID:D005865],Hydatidiform Mole[MeSHID:D006828],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep1 subtype PTGER1 NA agonist 2.72 drugbank , DGIDB mf266-1 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target antagonist NA TTD , DGIDB zd6416 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 prostaglandin e2 receptor ep1 PTGER1 Clinical trial target unknown NA TTD limaprost small molecule Emotions[MeSHID:D004644],Ability[MeSHID:D001076],Cold Temperature[MeSHID:D003080],Spinal Stenosis[MeSHID:D013130],Stenosis[MeSHID:D003251],Ulcer[MeSHID:D014456],Thromboangiitis Obliterans[MeSHID:D013919],Intermittent Claudication[MeSHID:D007383],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Gait[MeSHID:D005684],Pain[MeSHID:D010146],Hypesthesia[MeSHID:D006987],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational prostaglandin e2 receptor ep1 subtype PTGER1 NA agonist NA drugbank ah6809 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target antagonist NA TTD , DGIDB 17-phenyl-omega-trinor-pge2 NA NA investigative prostaglandin e2 receptor ep1 PTGER1 Clinical trial target unknown NA TTD dinoprostone small molecule Disease Management[MeSHID:D019468],Cervical Ripening[MeSHID:D020070],Postpartum Hemorrhage[MeSHID:D006473],Cessation of life[MeSHID:D003643],Pregnancy[MeSHID:D011247],Missed abortion[MeSHID:D000030],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Gestational Age[MeSHID:D005865],Hydatidiform Mole[MeSHID:D006828],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep2 subtype PTGER2 NA agonist 3.5 drugbank , DGIDB mycophenolate mofetil NA Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737],Pemphigus Vulgaris[MeSHID:D010392],Immune System Diseases[MeSHID:D007154] approved prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB pgd2 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target agonist NA TTD , DGIDB 3-(2-((e)-3-phenylprop-1-enyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD alprostadil small molecule Patent ductus arteriosus[MeSHID:D004374],Maintenance[MeSHID:D008283],Congenital Heart Defects[MeSHID:D006330],Neurogenesis[MeSHID:D055495],Erectile dysfunction[MeSHID:D007172],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved,investigational prostaglandin e2 receptor ep2 subtype PTGER2 NA agonist 2.42 drugbank , DGIDB ah13205 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target agonist NA TTD , DGIDB 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD 19(r)-oh-pge2 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target agonist NA TTD , DGIDB pmid25772215-compound-us02014179750m2 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB ono-ae1-329 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD pmid25772215-compound-us02014179750tg6-129 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB laropiprant NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161] phase 4 prostaglandin e2 receptor ep2 PTGER2 Successful target unknown 0.65 TTD , DGIDB butaprost NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown 0.91 TTD , DGIDB ono-ae-248 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD de-117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 3 prostaglandin e2 receptor ep2 PTGER2 Successful target unknown 4.55 TTD , DGIDB tg7-171 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target antagonist NA TTD , DGIDB pmid25772215-compound-us02014179750tg7-76 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB pmid25772215-compound-us02014179750tg7-112-2 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB m&b 28767 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD pf-00212062 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD dinoprostone NA Disease Management[MeSHID:D019468],Cervical Ripening[MeSHID:D020070],Postpartum Hemorrhage[MeSHID:D006473],Cessation of life[MeSHID:D003643],Pregnancy[MeSHID:D011247],Missed abortion[MeSHID:D000030],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Gestational Age[MeSHID:D005865],Hydatidiform Mole[MeSHID:D006828],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep2 PTGER2 Successful target agonist 3.5 TTD , DGIDB pmid25772215-compound-ep2149552diaminopyrimidines NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB pmid25772215-compound-us02014179750m3 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB ah6809 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target antagonist NA TTD , DGIDB pf-4418948 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] phase 1 prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB alprostadil NA Patent ductus arteriosus[MeSHID:D004374],Maintenance[MeSHID:D008283],Congenital Heart Defects[MeSHID:D006330],Neurogenesis[MeSHID:D055495],Erectile dysfunction[MeSHID:D007172],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved prostaglandin e2 receptor ep2 PTGER2 Successful target unknown 2.42 TTD , DGIDB pmid25772215-compound-us02014179750tg7-74 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB taprenepag NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 2 prostaglandin e2 receptor ep2 PTGER2 Successful target agonist 9.09 TTD , DGIDB dinoprostone NA Disease Management[MeSHID:D019468],Cervical Ripening[MeSHID:D020070],Postpartum Hemorrhage[MeSHID:D006473],Cessation of life[MeSHID:D003643],Pregnancy[MeSHID:D011247],Missed abortion[MeSHID:D000030],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Gestational Age[MeSHID:D005865],Hydatidiform Mole[MeSHID:D006828],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep2 PTGER2 Successful target unknown 3.5 TTD , DGIDB pmid20080612c1 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD pgf2alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB 16,16-dimethyl-pge2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stem cells[MeSHID:D013234] phase 2 prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB butaprost (free acid form) NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target agonist NA TTD , DGIDB r-65 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD pmid25772215-compound-us02014179750tg8-15 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB isocarbacyclin NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD cp-533536 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 prostaglandin e2 receptor ep2 PTGER2 Successful target unknown 2.27 TTD , DGIDB taprenepag NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 2 prostaglandin e2 receptor ep2 PTGER2 Successful target unknown 9.09 TTD , DGIDB mycophenolate mofetil NA Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB pmid25772215-compound-us02014179750tg7-170 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB pmid25772215-compound-ep20082149552c9 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB pmid25772215-compound-us02014179750tg6-10-1 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB iloprost NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep2 PTGER2 Successful target agonist 1.01 TTD , DGIDB tpst-1495 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD limaprost small molecule Emotions[MeSHID:D004644],Ability[MeSHID:D001076],Cold Temperature[MeSHID:D003080],Spinal Stenosis[MeSHID:D013130],Stenosis[MeSHID:D003251],Ulcer[MeSHID:D014456],Thromboangiitis Obliterans[MeSHID:D013919],Intermittent Claudication[MeSHID:D007383],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Gait[MeSHID:D005684],Pain[MeSHID:D010146],Hypesthesia[MeSHID:D006987],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational prostaglandin e2 receptor ep2 subtype PTGER2 NA agonist NA drugbank tg4-155 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target antagonist NA TTD , DGIDB 11-deoxy-pge1 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD u46619 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target agonist NA TTD , DGIDB alprostadil NA Patent ductus arteriosus[MeSHID:D004374],Maintenance[MeSHID:D008283],Congenital Heart Defects[MeSHID:D006330],Neurogenesis[MeSHID:D055495],Erectile dysfunction[MeSHID:D007172],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved prostaglandin e2 receptor ep2 PTGER2 Successful target agonist 2.42 TTD , DGIDB 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD carbacyclin NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target agonist 0.57 TTD , DGIDB cicaprost NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD 17-phenyl-omega-trinor-pge2 NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD pmid25772215-compound-wo2012177618m4 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB misoprostol small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Spontaneous abortion[MeSHID:D000022],Postpartum Hemorrhage[MeSHID:D006473],Rheumatoid Arthritis[MeSHID:D001172],Off-Label Use[MeSHID:D056687],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep2 subtype PTGER2 NA agonist NA drugbank iloprost NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep2 PTGER2 Successful target unknown 1.01 TTD , DGIDB 3-(2-cinnamylphenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD pmid25772215-compound-us02014179750m1 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB pmid25772215-compound-wo2012177618m5 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB pmid25772215-compound-wo2012177618m6 NA NA patented prostaglandin e2 receptor ep2 PTGER2 Successful target unknown NA TTD , DGIDB gemeprost small molecule Pathological Dilatation[MeSHID:D004108],Cervix Uteri[MeSHID:D002584],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cervical dilatation (function)[MeSHID:D007747] approved,withdrawn prostaglandin e2 receptor ep2 subtype PTGER2 NA agonist NA drugbank ono-ae1-329 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD 16,16-dimethyl-pge2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stem cells[MeSHID:D013234] phase 2 prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD , DGIDB i-bop NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD misoprostol small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Spontaneous abortion[MeSHID:D000022],Postpartum Hemorrhage[MeSHID:D006473],Rheumatoid Arthritis[MeSHID:D001172],Off-Label Use[MeSHID:D056687],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep3 subtype PTGER3 NA agonist 10.61 drugbank , DGIDB bimatoprost small molecule Eyelash[MeSHID:D005140],Glaucoma, Open-Angle[MeSHID:D005902],Hypotrichosis[MeSHID:D007039],Ocular Hypotension[MeSHID:D015814],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901],Alopecia[MeSHID:D000505] approved,investigational prostaglandin e2 receptor ep3 subtype PTGER3 NA agonist 5.3 drugbank , DGIDB sta2 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD ono-8713 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD ono-ae2-227 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD 3-(2-cinnamylphenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD ono-ae5-599 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD dinoprostone small molecule Disease Management[MeSHID:D019468],Cervical Ripening[MeSHID:D020070],Postpartum Hemorrhage[MeSHID:D006473],Cessation of life[MeSHID:D003643],Pregnancy[MeSHID:D011247],Missed abortion[MeSHID:D000030],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Gestational Age[MeSHID:D005865],Hydatidiform Mole[MeSHID:D006828],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep3 subtype PTGER3 NA agonist 3.06 drugbank , DGIDB cloprostenol NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target agonist 0.8 TTD , DGIDB ah6809 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target antagonist NA TTD , DGIDB ono-ap-324 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD sc46275 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD m&b 28767 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD butaprost (free acid form) NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target agonist NA TTD , DGIDB 3-(2-((e)-3-phenylprop-1-enyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD ono-ae-248 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target agonist NA TTD , DGIDB ono-ae3-240 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD pgf2alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD , DGIDB l-798,106 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target antagonist NA TTD , DGIDB dg041 NA Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD , DGIDB 11-deoxy-pge1 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD ono-ae3-208 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD molecule 21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD 17-phenyl-omega-trinor-pge2 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD gemeprost small molecule Pathological Dilatation[MeSHID:D004108],Cervix Uteri[MeSHID:D002584],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cervical dilatation (function)[MeSHID:D007747] approved,withdrawn prostaglandin e2 receptor ep3 subtype PTGER3 NA agonist NA drugbank ono-9054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 2 prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown 1.99 TTD , DGIDB isocarbacyclin NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD u46619 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target agonist NA TTD , DGIDB fr-181157 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD l-826266 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target antagonist NA TTD , DGIDB limaprost small molecule Emotions[MeSHID:D004644],Ability[MeSHID:D001076],Cold Temperature[MeSHID:D003080],Spinal Stenosis[MeSHID:D013130],Stenosis[MeSHID:D003251],Ulcer[MeSHID:D014456],Thromboangiitis Obliterans[MeSHID:D013919],Intermittent Claudication[MeSHID:D007383],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Gait[MeSHID:D005684],Pain[MeSHID:D010146],Hypesthesia[MeSHID:D006987],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational prostaglandin e2 receptor ep3 subtype PTGER3 NA agonist NA drugbank 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD pgd2 NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD gr-63799x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown NA TTD cicaprost NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target agonist 0.99 TTD , DGIDB butaprost NA NA patented prostaglandin e2 receptor ep3 PTGER3 Clinical trial target unknown 0.8 TTD , DGIDB fluprostenol NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target agonist 1.33 TTD , DGIDB castor oil biotech Hair[MeSHID:D006197],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical,vet_approved prostaglandin e2 receptor ep3 subtype PTGER3 NA agonist,activator NA drugbank carbacyclin NA NA investigative prostaglandin e2 receptor ep3 PTGER3 Clinical trial target agonist 0.5 TTD , DGIDB ono-ae1-329 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB cp734432 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB gw 627368 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target antagonist NA TTD , DGIDB cr-5790 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD pf-04475270 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD ono-ae3-240 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD dinoprostone small molecule Disease Management[MeSHID:D019468],Cervical Ripening[MeSHID:D020070],Postpartum Hemorrhage[MeSHID:D006473],Cessation of life[MeSHID:D003643],Pregnancy[MeSHID:D011247],Missed abortion[MeSHID:D000030],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Gestational Age[MeSHID:D005865],Hydatidiform Mole[MeSHID:D006828],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep4 subtype PTGER4 NA agonist 2.72 drugbank , DGIDB ono-4578 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD , DGIDB tpst-1495 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD ono-4232 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 1 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD , DGIDB ono-ae3-208 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target antagonist NA TTD , DGIDB pgd2 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB mk-2894 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target antagonist 3.54 TTD , DGIDB 11-deoxy-pge2 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD butaprost (free acid form) NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB kag-308 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD ono-4819 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fracture[MeSHID:D050723] discontinued in phase 2 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD limaprost small molecule Emotions[MeSHID:D004644],Ability[MeSHID:D001076],Cold Temperature[MeSHID:D003080],Spinal Stenosis[MeSHID:D013130],Stenosis[MeSHID:D003251],Ulcer[MeSHID:D014456],Thromboangiitis Obliterans[MeSHID:D013919],Intermittent Claudication[MeSHID:D007383],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Gait[MeSHID:D005684],Pain[MeSHID:D010146],Hypesthesia[MeSHID:D006987],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational prostaglandin e2 receptor ep4 subtype PTGER4 NA unknown NA drugbank u46619 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB 19(r)-oh-pge2 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD m&b 28767 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD rq-00000008 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD tcs 2510 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB 3-(2-cinnamylphenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD 3-(2-((e)-3-phenylprop-1-enyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD carbacyclin NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist 0.44 TTD , DGIDB rq-00000007 (oral) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD , DGIDB 16,16-dimethyl-pge2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stem cells[MeSHID:D013234] phase 2 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD , DGIDB ono-ae1-437 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD , DGIDB butaprost NA NA patented prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown 0.71 TTD , DGIDB e7046 NA Rectum[MeSHID:D012007],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD , DGIDB fr-181157 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD grapiprant small molecule Degenerative polyarthritis[MeSHID:D010003],Edema[MeSHID:D004487],Erythema[MeSHID:D004890],Inflammation[MeSHID:D007249],Intrinsic drive[MeSHID:D004328],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146] investigational,vet_approved prostaglandin e2 receptor ep4 subtype PTGER4 NA antagonist 10.61 drugbank , DGIDB castor oil biotech Hair[MeSHID:D006197],Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical,vet_approved prostaglandin e2 receptor ep4 subtype PTGER4 NA agonist NA drugbank bgc-20-1531 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 2 prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD , DGIDB 8-aza-11-deoxyprostaglandin e1 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD 1-oh-pge1 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD 11-deoxy-pge1 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB misoprostol small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Spontaneous abortion[MeSHID:D000022],Postpartum Hemorrhage[MeSHID:D006473],Rheumatoid Arthritis[MeSHID:D001172],Off-Label Use[MeSHID:D056687],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e2 receptor ep4 subtype PTGER4 NA agonist NA drugbank 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD l902688 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB er819762 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target antagonist NA TTD , DGIDB ah23848 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target antagonist NA TTD , DGIDB ono-ae2-227 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD 13,14-dihydro-pge1 NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist NA TTD , DGIDB pgf2alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial prostaglandin e2 receptor ep4 PTGER4 Clinical trial target unknown NA TTD , DGIDB cicaprost NA NA investigative prostaglandin e2 receptor ep4 PTGER4 Clinical trial target agonist 0.88 TTD , DGIDB imidazopyridine derivative 6 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzimidazole derivative 13 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB imidazopyridine derivative 7 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB pmid28627961-compound-22 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB pmid28627961-compound-33 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB pmid28627961-compound-41 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzimidazole derivative 11 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzimidazole derivative 16 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzamide derivative 16 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzimidazole derivative 14 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB pmid28627961-compound-32 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB phthalazinone derivative 1 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB betais-sulfonylamino derivative 1 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB pyrimidine derivative 2 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB carboxylic acid derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194] patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzimidazole derivative 15 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB polycyclic compound 1 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB piperidine carboxamide derivative 1 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB imidazole benzamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Knee[MeSHID:D007717] patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB pmid28627961-compound-44 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzamide derivative 15 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB methyl-piperidine compound 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194] patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB pmid28627961-compound-30 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB alpha-substituted pirinixic acid and pirinixic acid ester derivative 1 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB pmid28627961-compound-31 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB boswellia acid derivative 1 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB imidazopyridine derivative 5 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzimidazole derivative 12 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzimidazole derivative 17 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzamide derivative 18 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB benzamide derivative 14 NA NA patented prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB aad-2004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 prostaglandin e synthase PTGES Clinical trial target unknown NA TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin e synthase 3 PTGES3 NA unknown NA drugbank grn163l small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Lymph[MeSHID:D008196] investigational prostaglandin e synthase 3 PTGES3 NA unknown NA drugbank acetaminophen small molecule Disease Management[MeSHID:D019468],Asthma[MeSHID:D001249],Fever[MeSHID:D005334],Allergic Reaction[MeSHID:D006967],Pain[MeSHID:D010146],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin e synthase 3 PTGES3 NA inhibitor NA drugbank tafluprost small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Ocular Hypotension[MeSHID:D015814],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved prostaglandin f2-alpha receptor PTGFR Successful target agonist 14.98 TTD , drugbank , DGIDB cloprostenol NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target agonist 0.75 TTD , DGIDB pdc-41 NA Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Plasmacytoid Dendritic Cells[MeSHID:D003713] phase 1 prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD , DGIDB fluprostenol NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target agonist 1.25 TTD , DGIDB dinoprost tromethamine small molecule Incomplete spontaneous abortion[MeSHID:D000027],Congenital Abnormality[MeSHID:D000013],Pregnancy[MeSHID:D011247],Stillbirth[MeSHID:D050497],Fetal Death[MeSHID:D005313],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved prostaglandin f2-alpha receptor PTGFR NA agonist 3.74 drugbank , DGIDB bimatoprost small molecule Eyelash[MeSHID:D005140],Glaucoma, Open-Angle[MeSHID:D005902],Hypotrichosis[MeSHID:D007039],Ocular Hypotension[MeSHID:D015814],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901],Alopecia[MeSHID:D000505] approved,investigational prostaglandin f2-alpha receptor PTGFR NA agonist 14.98 drugbank , DGIDB 13,14-dihydro-16-m-chlorophenoxy-w-tetranor-pgf1alpha NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD ono-9054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 2 prostaglandin f2-alpha receptor PTGFR Successful target unknown 3.74 TTD , DGIDB [3h]pgf2alpha NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD butaprost NA NA patented prostaglandin f2-alpha receptor PTGFR Successful target unknown 0.75 TTD , DGIDB bol-303259-x NA Renal Cell Carcinoma[MeSHID:D002292],Glaucoma, Open-Angle[MeSHID:D005902],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin f2-alpha receptor PTGFR Successful target unknown 7.49 TTD , DGIDB latanoprostene bunod small molecule Glaucoma, Open-Angle[MeSHID:D005902],Solutions[MeSHID:D012996],Ocular Hypertension[MeSHID:D009798],Ocular Hypotension[MeSHID:D015814] approved,investigational prostaglandin f2-alpha receptor PTGFR NA agonist NA drugbank , DGIDB latanoprostene bunod small molecule Glaucoma, Open-Angle[MeSHID:D005902],Solutions[MeSHID:D012996],Ocular Hypertension[MeSHID:D009798],Ocular Hypotension[MeSHID:D015814] approved,investigational prostaglandin f2-alpha receptor PTGFR NA agonist 7.49 drugbank , DGIDB bimatoprost (free acid form) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial prostaglandin f2-alpha receptor PTGFR Successful target agonist NA TTD , DGIDB al-8810 NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD as604872 NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target antagonist NA TTD , DGIDB carbacyclin NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target agonist 0.47 TTD , DGIDB carboprost tromethamine NA Disease Management[MeSHID:D019468],Fetal Membranes, Premature Rupture[MeSHID:D005322],Disease[MeSHID:D004194],Postpartum Hemorrhage[MeSHID:D006473],Pregnancy[MeSHID:D011247],Uterine Inertia[MeSHID:D014593],Fetal Tissue[MeSHID:D005333],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Tissue membrane[MeSHID:D008566],Rupture, Spontaneous[MeSHID:D012422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin f2-alpha receptor PTGFR Successful target agonist 3.74 TTD , DGIDB ncx-125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] investigative prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD latanoprost small molecule Glaucoma, Open-Angle[MeSHID:D005902],Diagnosis[MeSHID:D003933],Ocular Hypotension[MeSHID:D015814],Angle Closure Glaucoma[MeSHID:D015812],Ocular Hypertension[MeSHID:D009798],Physiologic Intraocular Pressure[MeSHID:D007429],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Glaucoma[MeSHID:D005901],Eye[MeSHID:D005123],Disease[MeSHID:D004194] approved,investigational prostaglandin f2-alpha receptor PTGFR Successful target agonist 19.97 TTD , drugbank , DGIDB travoprost small molecule Glaucoma[MeSHID:D005901],Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Ocular Hypotension[MeSHID:D015814],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin f2-alpha receptor PTGFR Successful target agonist 48.67 TTD , drugbank , DGIDB u46619 NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target agonist NA TTD , DGIDB carboprost tromethamine NA Disease Management[MeSHID:D019468],Fetal Membranes, Premature Rupture[MeSHID:D005322],Disease[MeSHID:D004194],Postpartum Hemorrhage[MeSHID:D006473],Pregnancy[MeSHID:D011247],Uterine Inertia[MeSHID:D014593],Fetal Tissue[MeSHID:D005333],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Tissue membrane[MeSHID:D008566],Rupture, Spontaneous[MeSHID:D012422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD , DGIDB m&b 28767 NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD pgf2alpha-ie NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 3 prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD , DGIDB laropiprant NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161] phase 4 prostaglandin f2-alpha receptor PTGFR Successful target unknown 0.53 TTD , DGIDB ono-9054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 2 prostaglandin f2-alpha receptor PTGFR Successful target agonist 3.74 TTD , DGIDB pgf2alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD , DGIDB al12180 NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target agonist NA TTD , DGIDB i-bop NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD bimatoprost (free acid form) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD , DGIDB dinoprostone NA Disease Management[MeSHID:D019468],Cervical Ripening[MeSHID:D020070],Postpartum Hemorrhage[MeSHID:D006473],Cessation of life[MeSHID:D003643],Pregnancy[MeSHID:D011247],Missed abortion[MeSHID:D000030],Gestational Trophoblastic Neoplasms[MeSHID:D031901],Uterus[MeSHID:D014599],Menstruation[MeSHID:D008598],Gestational Age[MeSHID:D005865],Hydatidiform Mole[MeSHID:D006828],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin f2-alpha receptor PTGFR Successful target unknown 0.58 TTD , DGIDB pgd2 NA NA investigative prostaglandin f2-alpha receptor PTGFR Successful target agonist NA TTD , DGIDB pdc-31 NA Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Plasmacytoid Dendritic Cells[MeSHID:D003713] investigative prostaglandin f2-alpha receptor PTGFR Successful target unknown NA TTD dinoprost tromethamine small molecule Incomplete spontaneous abortion[MeSHID:D000027],Congenital Abnormality[MeSHID:D000013],Pregnancy[MeSHID:D011247],Stillbirth[MeSHID:D050497],Fetal Death[MeSHID:D005313],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved prostacyclin receptor PTGIR Successful target antagonist NA TTD , drugbank , DGIDB treprostinil small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Ability[MeSHID:D001076],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostacyclin receptor PTGIR Successful target agonist 3.28 TTD , drugbank , DGIDB ataprost NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 3 prostacyclin receptor PTGIR Successful target unknown NA TTD carbacyclin NA NA investigative prostacyclin receptor PTGIR Successful target agonist 0.47 TTD , DGIDB tei-9063 NA NA investigative prostacyclin receptor PTGIR Successful target agonist NA TTD , DGIDB esuberaprost NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] phase 3 prostacyclin receptor PTGIR Successful target agonist 11.23 TTD , DGIDB ym533 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Kidney Diseases[MeSHID:D051436],Kidney Failure, Chronic[MeSHID:D007676] discontinued in phase 3 prostacyclin receptor PTGIR Successful target unknown NA TTD selexipag small molecule Disease Progression[MeSHID:D018450],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Hospitalization[MeSHID:D006760],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostacyclin receptor PTGIR Successful target agonist 18.72 TTD , drugbank , DGIDB laropiprant NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161] phase 4 prostacyclin receptor PTGIR Successful target unknown 0.53 TTD , DGIDB beraprost small molecule Pulmonary Hypertension[MeSHID:D006976],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 4 prostacyclin receptor PTGIR Successful target unknown 3.74 TTD , drugbank , DGIDB bmy 45778 NA NA investigative prostacyclin receptor PTGIR Successful target agonist NA TTD , DGIDB beraprost small molecule Pulmonary Hypertension[MeSHID:D006976],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 4 prostacyclin receptor PTGIR Successful target agonist 3.74 TTD , drugbank , DGIDB clinprost NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in preregistration prostacyclin receptor PTGIR Successful target unknown NA TTD ep 157 NA NA investigative prostacyclin receptor PTGIR Successful target agonist NA TTD , DGIDB esuberaprost NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] phase 3 prostacyclin receptor PTGIR Successful target unknown 11.23 TTD , DGIDB fr-193262 NA NA investigative prostacyclin receptor PTGIR Successful target unknown NA TTD cicaprost NA NA investigative prostacyclin receptor PTGIR Successful target agonist 0.94 TTD , DGIDB butaprost (free acid form) NA NA investigative prostacyclin receptor PTGIR Successful target agonist NA TTD , DGIDB bay-73-1449 NA NA investigative prostacyclin receptor PTGIR Successful target antagonist NA TTD , DGIDB prostacyclin analog NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] investigative prostacyclin receptor PTGIR Successful target unknown NA TTD u46619 NA NA investigative prostacyclin receptor PTGIR Successful target agonist NA TTD , DGIDB iloprost small molecule Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostacyclin receptor PTGIR NA agonist 5.41 drugbank , DGIDB isocarbacyclin NA NA investigative prostacyclin receptor PTGIR Successful target unknown NA TTD misoprostol NA Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Spontaneous abortion[MeSHID:D000022],Postpartum Hemorrhage[MeSHID:D006473],Rheumatoid Arthritis[MeSHID:D001172],Off-Label Use[MeSHID:D056687],Duodenal Ulcer[MeSHID:D004381],Gastric ulcer[MeSHID:D013276],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostacyclin receptor PTGIR Successful target unknown 3.74 TTD , DGIDB op-2507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 prostacyclin receptor PTGIR Successful target unknown NA TTD ralinepag NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] phase 2 prostacyclin receptor PTGIR Successful target unknown 11.23 TTD , DGIDB epoprostenol small molecule Pulmonary Hypertension[MeSHID:D006976],Scleroderma[MeSHID:D012594],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostacyclin receptor PTGIR Successful target agonist 9.98 TTD , drugbank , DGIDB ro3244794 NA NA investigative prostacyclin receptor PTGIR Successful target antagonist NA TTD , DGIDB ro1138452 NA NA investigative prostacyclin receptor PTGIR Successful target antagonist NA TTD , DGIDB afp-07 NA NA investigative prostacyclin receptor PTGIR Successful target agonist NA TTD , DGIDB ralinepag NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976] phase 2 prostacyclin receptor PTGIR Successful target agonist 11.23 TTD , DGIDB fr-181157 NA NA investigative prostacyclin receptor PTGIR Successful target unknown NA TTD (5z)-7-{(1r,4s,5r,6r)-6-[(1e)-1-octen-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl}-5-heptenoic acid small molecule NA experimental prostacyclin synthase PTGIS NA unknown NA drugbank epoprostenol small molecule Pulmonary Hypertension[MeSHID:D006976],Scleroderma[MeSHID:D012594],Idiopathic pulmonary arterial hypertension[MeSHID:D065627],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostacyclin synthase PTGIS NA inducer NA drugbank phenylbutazone small molecule Back Pain[MeSHID:D001416],Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved,vet_approved prostacyclin synthase PTGIS NA inhibitor 37.13 drugbank , DGIDB nicotinamide adenine dinucleotide phosphate small molecule NA experimental prostaglandin reductase 1 PTGR1 NA unknown NA drugbank (5e,13e)-11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid small molecule NA experimental prostaglandin reductase 1 PTGR1 NA unknown NA drugbank p-coumaric acid small molecule NA experimental prostaglandin reductase 1 PTGR1 NA unknown NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin reductase 2 PTGR2 NA inhibitor NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational prostaglandin reductase 2 PTGR2 NA inhibitor NA drugbank (5e,13e)-11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid small molecule NA experimental prostaglandin reductase 2 PTGR2 NA unknown NA drugbank indoprofen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] withdrawn from market prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD (3-chloro-4-propoxy-phenyl)-acetic acid small molecule NA experimental,investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank 2-(3-phenyl-propyl)-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(2-methylpropanoyl)-1,3,5-benzenetriol NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD naproxen small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Juvenile arthritis[MeSHID:D001171],Gout[MeSHID:D006073],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] approved,vet_approved prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 0.56 TTD , drugbank , DGIDB resveratrol potassium4,-sulfate NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD alpha-d-mannose NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD nitroflurbiprofen NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD iodoindomethacin NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD (-)-3-o-acetylspectaline NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4,5-bis(4-methoxyphenyl)-3h-1,2-dithiol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD flurbiprofen small molecule Soft Tissue Injuries[MeSHID:D017695],Tendinitis[MeSHID:D052256],Rheumatoid Arthritis[MeSHID:D001172],long-term care[MeSHID:D008134],Inflammation[MeSHID:D007249],Miosis disorder[MeSHID:D015877],Bursitis[MeSHID:D002062],Eye[MeSHID:D005123],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Spondylitis[MeSHID:D013166],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor 1.61 drugbank , DGIDB acemetacin small molecule Degenerative polyarthritis[MeSHID:D010003],Edema[MeSHID:D004487],Vertebral column[MeSHID:D013131],Body tissue[MeSHID:D014024],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Operative Surgical Procedures[MeSHID:D013514],Low Back Pain[MeSHID:D017116],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Rheumatic Fever[MeSHID:D012213],Arthritis[MeSHID:D001168],Syndrome[MeSHID:D013577],Pain[MeSHID:D010146] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank triflusal small molecule Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Cerebrovascular accident[MeSHID:D020521] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank 3 beta-o-acetyloleanolic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-methyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4,5-bis(4-chlorophenyl)isothiazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD diflunisal small molecule Traumatic injury[MeSHID:D014947],Degenerative polyarthritis[MeSHID:D010003],Inflammation[MeSHID:D007249],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor 1.16 drugbank , DGIDB 4'-methoxy-5,3'-dipropyl-biphenyl-2ol NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD acetic acid 2-hex-2-ynylsulfanyl-phenyl ester NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD eicosapentaenoic acid/docosa-hexaenoic acid NA Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , DGIDB choline magnesium trisalicylate small molecule Disease[MeSHID:D004194],Fever[MeSHID:D005334],Inflammation[MeSHID:D007249],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank 2-bromoacetyl group small molecule NA experimental,investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank flufenamic acid small molecule Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank , DGIDB magnesium salicylate small molecule Myalgia[MeSHID:D063806] experimental prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank bufexamac small molecule Dermatologic disorders[MeSHID:D012871],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] approved,withdrawn prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.33 drugbank , DGIDB metamizole small molecule Fever[MeSHID:D005334],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,withdrawn,withdrawn from market prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank acetic acid 2-hexylsulfanyl-phenyl ester NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD fr122047 NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor NA TTD , DGIDB medical cannabis biotech NA experimental,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank 2,4'-dimethoxy-5,3'-di-(2-propenyl)-biphenyl NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD imrecoxib NA NA phase 4 prostaglandin g/h synthase 1 PTGS1 Successful target unknown 0.48 TTD , DGIDB trolamine salicylate small molecule Ligaments[MeSHID:D008022],Tendon structure[MeSHID:D013710],Low Back Pain[MeSHID:D017116],Musculoskeletal Pain[MeSHID:D059352],Contusions[MeSHID:D003288],Sprain[MeSHID:D013180],Back Pain[MeSHID:D001416],Pain[MeSHID:D010146],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank nepafenac small molecule Inflammation[MeSHID:D007249],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor 1.93 drugbank , DGIDB heme NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(1,1'-biphenyl-4-yl)propanoic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD meclofenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Menorrhagia[MeSHID:D008595],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthralgia[MeSHID:D018771] approved,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank , DGIDB acetic acid 2-heptylselanyl-phenyl ester NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(3'-ethylsulfanyl-biphenyl-4-yl)-propionic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(3'-vinyl-biphenyl-4-yl)-propionic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4-amino-n-(4-chlorophenyl)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD (r)-2-(4-isobutyl-phenyl)-n-phenyl-propionamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 1-(4-aminosulfonylphenyl)-2-(4-pyridyl)acetylene NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD fenbufen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved prostaglandin g/h synthase 1 PTGS1 Successful target unknown 0.48 TTD , DGIDB lumiracoxib small molecule Osteoarthritis, Knee[MeSHID:D020370],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank thermoprofen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 3 prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , DGIDB resveratrol potassium3-sulfate NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD salicyclic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Seborrheic dermatitis[MeSHID:D012628] approved prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , DGIDB icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank oxaprozin small molecule Arthralgia[MeSHID:D018771],Degenerative polyarthritis[MeSHID:D010003],Edema[MeSHID:D004487],Rheumatoid Arthritis[MeSHID:D001172],Inflammation[MeSHID:D007249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 2.25 drugbank , DGIDB 2-(3'-ethyl-biphenyl-4-yl)-propionic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(n-(2-fluorophenyl)pyrrol-2-yl) acetic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD meclofenamate sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 0.14 TTD , DGIDB sc-560 NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 0.24 TTD , DGIDB meclofenamate sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , DGIDB dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank iodosuprofen NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4-(4-chlorophenyl)-5-p-tolyl-3h-1,2-dithiol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD (s)-flurbiprofen NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Periarthritis[MeSHID:D010489],Myalgia[MeSHID:D063806] preregistration prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD etodolac small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 2.25 drugbank , DGIDB 2-phenyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD exo-230 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] phase 1/2 prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , DGIDB suprofen small molecule Vision[MeSHID:D014785],Operative Surgical Procedures[MeSHID:D013514],Eye[MeSHID:D005123],Miosis disorder[MeSHID:D015877],Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 4.82 TTD , drugbank , DGIDB 4-amino-n-p-tolylbenzenesulfonamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD beta-d-mannose NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.12 drugbank , DGIDB 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD (11h-dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-n-[(1r)-1-(hydroxymethyl)propyl]acetamide small molecule NA experimental prostaglandin g/h synthase 1 PTGS1 NA unknown NA drugbank 5-(4-chlorophenyl)-4-p-tolyl-1,2-selenazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD diclofenac small molecule Degenerative polyarthritis[MeSHID:D010003],Disease[MeSHID:D004194],Injuries, Surgical[MeSHID:D007431],Rheumatoid Arthritis[MeSHID:D001172],Stomach[MeSHID:D013270],Physical Examination[MeSHID:D010808],Ulcer[MeSHID:D014456],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Spondylitis[MeSHID:D013166],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.4 drugbank , DGIDB indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.33 drugbank , DGIDB 2-[4-(1h-indol-5-yl)-phenyl]-propionic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(2-methoxyphenyl)-1h-indene NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 5,3'-dipropyl-biphenyl-2,4'-diol NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(3'-allyl-biphenyl-4-yl)-propionic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD n-(3-phenylamino-4-pyridinyl)methanesulfonamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD acetic acid 2-heptylsulfanyl-phenyl ester NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD acetic acid 2-hept-3-ynylsulfanyl-phenyl ester NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.43 drugbank , DGIDB 1-(4-(methylsulfonyl)phenyl)-3-phenylurea NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2'-epi-guianin NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4,5-bis(4-methoxyphenyl)-3h-1,2-dithiole-3-thione NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD dihomo-gamma-linolenic acid small molecule NA investigational,nutraceutical prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank diethylcarbamazine small molecule Disease[MeSHID:D004194],Communicable Diseases[MeSHID:D003141],Eosinophilia, Tropical[MeSHID:D004802],Filarial Elephantiases[MeSHID:D004605],Infection[MeSHID:D007239],Loiasis[MeSHID:D008118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank salsalate small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Rheumatism[MeSHID:D012216],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 3.38 TTD , drugbank , DGIDB mefenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Fever[MeSHID:D005334],Inflammation[MeSHID:D007249],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.58 drugbank , DGIDB n-(3-phenoxy-4-pyridinyl)ethanesulfonamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD (11h-dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD phenyl salicylate small molecule Fever[MeSHID:D005334],Pain[MeSHID:D010146] approved prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank mefenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Fever[MeSHID:D005334],Inflammation[MeSHID:D007249],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank , DGIDB piroxicam small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 0.79 TTD , drugbank , DGIDB honokiol NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 5-(4-methoxyphenyl)-4-p-tolylisothiazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD n-(3-phenoxy-4-pyridinyl)propanesulfonamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4-(4-chlorophenyl)-5-p-tolylisothiazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD phenidone NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD resorcinol NA Seborrheic dermatitis[MeSHID:D012628],Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Acne Vulgaris[MeSHID:D000152] investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD tebufelone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD ketoprofen small molecule Degenerative polyarthritis[MeSHID:D010003],Ankylosing spondylitis[MeSHID:D013167],Dental Health Services[MeSHID:D003752],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Traumatic injury[MeSHID:D014947],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Pain[MeSHID:D059352],Migraine Disorders[MeSHID:D008881] approved,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 1.74 drugbank , DGIDB flurbiprofen methyl ester small molecule NA experimental prostaglandin g/h synthase 1 PTGS1 NA unknown NA drugbank epicatechin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Friedreich Ataxia[MeSHID:D005621] phase 1/2 prostaglandin g/h synthase 1 PTGS1 Successful target unknown 0.96 TTD , DGIDB antipyrine small molecule Ear structure[MeSHID:D004423],Solutions[MeSHID:D012996],Otitis Media[MeSHID:D010033],Liver[MeSHID:D008099] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank 2-furan-2-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4,5-bis(4-methoxyphenyl)-1,2-selenazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD oxametacin NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD mesalazine small molecule Crohn's disease of large bowel[MeSHID:D003424],ileum[MeSHID:D007082],Ulcerative Colitis[MeSHID:D003093],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 0.29 TTD , drugbank , DGIDB 5-ethyl-3,4-diphenyl-isoxazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-n-[(1s)-1-(hydroxymethyl)propyl]acetamide small molecule NA experimental prostaglandin g/h synthase 1 PTGS1 NA unknown NA drugbank r-ketoprofen NA NA discontinued in phase 2 prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD gamma-homolinolenic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gamma Rays[MeSHID:D005720],Malnutrition[MeSHID:D044342] approved prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , DGIDB (11h-dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD o-acetyl-l-serine small molecule NA experimental prostaglandin g/h synthase 1 PTGS1 NA unknown NA drugbank demethoxycurcumin NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD acetaminophen small molecule Disease Management[MeSHID:D019468],Asthma[MeSHID:D001249],Fever[MeSHID:D005334],Allergic Reaction[MeSHID:D006967],Pain[MeSHID:D010146],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.2 drugbank , DGIDB 1-(4-iodobenzoyl)-5-methoxy-2-methyl indole-3-acetic acid small molecule NA experimental prostaglandin g/h synthase 1 PTGS1 NA unknown NA drugbank tiaprofenic acid small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank p-(2'-iodo-5'-thenoyl)hydrotropic acid small molecule NA experimental,investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank nitroaspirin small molecule NA investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank balsalazide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] approved,investigational prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 1.69 TTD , drugbank , DGIDB 5-(2-1h-indenyl)-1,3-benzodioxole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 5-(4-chlorophenyl)-4-p-tolylisothiazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD menthyl salicylate small molecule Muscle[MeSHID:D009132],Fibromyalgia[MeSHID:D005356],Neuralgia[MeSHID:D009437],Low Back Pain[MeSHID:D017116],Rheumatism[MeSHID:D012216],Sprain[MeSHID:D013180],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095] approved prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank arachidonic acid small molecule NA experimental,investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank , DGIDB n-(1h-indazol-5-yl)acetamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD n-(3-(phenylthio)pyridin-4-yl)methanesulfonamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD prifelone NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-benzyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD talniflumate small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Cystic Fibrosis[MeSHID:D003550] experimental prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank bromfenac small molecule Inflammation[MeSHID:D007249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor 2.89 TTD , drugbank , DGIDB curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 prostaglandin g/h synthase 1 PTGS1 Successful target unknown 0.04 TTD , DGIDB droxicam small molecule Inflammation[MeSHID:D007249],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank primary alcohol metabolite of celecoxib NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD lornoxicam small molecule Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 5-(2-imidazol-1-yl-ethyl)-7,8-dihydro-quinoline NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 5-(4-chlorophenyl)-4-p-tolyl-3h-1,2-dithiol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD bendazac small molecule Pruritus[MeSHID:D011537],Eczema[MeSHID:D004485],Vision[MeSHID:D014785],Insect Bites[MeSHID:D007299],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Urticaria[MeSHID:D014581],Cataract[MeSHID:D002386],Inflammation[MeSHID:D007249],Burn injury[MeSHID:D002056],Dermatitis[MeSHID:D003872],Pain[MeSHID:D010146],Prescription procedure[MeSHID:D055656] approved,withdrawn prostaglandin g/h synthase 1 PTGS1 NA unknown NA drugbank sulindac small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.48 drugbank , DGIDB ketorolac small molecule Degenerative polyarthritis[MeSHID:D010003],Headache[MeSHID:D006261],Pain, Postoperative[MeSHID:D010149],Tissue Pain[MeSHID:D059226],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Menstruation Disturbances[MeSHID:D008599],emotional dependency[MeSHID:D003858],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 2.57 drugbank , DGIDB tenoxicam small molecule Back Pain[MeSHID:D001416],Degenerative polyarthritis[MeSHID:D010003],Pain[MeSHID:D010146],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 1.35 drugbank , DGIDB (z)-2'-des-methyl sulindac sulfide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4-(4-chlorophenyl)-5-p-tolyl-1,2-selenazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD niflumic acid small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental prostaglandin g/h synthase 1 PTGS1 NA unknown NA drugbank nabumetone small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.83 drugbank , DGIDB fenoprofen small molecule Degenerative polyarthritis[MeSHID:D010003],Pain[MeSHID:D010146],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 1.29 drugbank , DGIDB (+)-2-(4-biphenyl)propionic acid small molecule NA experimental prostaglandin g/h synthase 1 PTGS1 NA unknown NA drugbank tolmetin small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 1.93 drugbank , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank n-(3-phenoxypyridin-4-yl)methanesulfonamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank 5-phenyl-pentanoic acid benzyl-hydroxy-amide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD phenacetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn,withdrawn from market prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank 4-(5-(4-hydroxyphenyl)isothiazol-4-yl)phenol NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD crx-401 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD methylhonokiol NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD acetic acid salicyloyl-amino-ester small molecule NA experimental,investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank minoxidil small molecule Hypertensive disease[MeSHID:D006973],Androgenetic Alopecia[MeSHID:D000505],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inducer NA drugbank b-octylglucoside NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD phenazone NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4,5-bis(4-methoxyphenyl)isothiazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(2,3,4-trimethoxyphenyl)-1h-indene NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD beta-d-glucose small molecule NA experimental,investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank 2-(p-methylsulfonylbenzoyl)furan NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 5-(4-methoxyphenyl)-4-p-tolyl-1,2-selenazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 5-(4-chlorophenyl)-4-(4-methoxyphenyl)isothiazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 4,5-bis(4-chlorophenyl)-1,2-selenazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD phenylbutazone small molecule Back Pain[MeSHID:D001416],Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.4 drugbank , DGIDB tolfenamic acid small molecule Pain[MeSHID:D010146],Migraine Disorders[MeSHID:D008881] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank o-acetylserine NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD propacetamol small molecule Fever[MeSHID:D005334],Dysmenorrhea[MeSHID:D004412] experimental prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank 3-(4-methanesulfonyl-phenyl)-1-phenyl-propynone NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-(n-(2-ffuorophenyl)pyrrol-3-yl) acetic acid NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD trl-382 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD meloxicam small molecule Degenerative polyarthritis[MeSHID:D010003],Operative Surgical Procedures[MeSHID:D013514],Juvenile arthritis[MeSHID:D001171],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor 0.96 drugbank , DGIDB antrafenine small molecule Pain[MeSHID:D010146] approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank acetic acid 2-hept-2-ynylsulfanyl-phenyl ester NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD aceclofenac small molecule Degenerative polyarthritis[MeSHID:D010003],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Inflammation[MeSHID:D007249],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational,phase 3 prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor NA TTD , drugbank 4-(4-chlorophenyl)-5-(4-methoxyphenyl)isothiazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD salicylic acid small molecule Acne Vulgaris[MeSHID:D000152],Keratosis pilaris[MeSHID:C537412],Skin callus[MeSHID:D002145],Warts[MeSHID:D014860],Psoriasis[MeSHID:D011565],Bone callus[MeSHID:D002146] approved,investigational,vet_approved prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank , DGIDB 4-amino-n-(2-chlorophenyl)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD glycol salicylate small molecule Muscle[MeSHID:D009132],Musculoskeletal Pain[MeSHID:D059352] approved prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank carprofen small molecule Arthralgia[MeSHID:D018771],Operative Surgical Procedures[MeSHID:D013514],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved,withdrawn prostaglandin g/h synthase 1 PTGS1 NA inhibitor NA drugbank aminosalicylic acid NA Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Lung[MeSHID:D008168] approved prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , DGIDB hyperforin small molecule NA nutraceutical,investigative prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor NA TTD , drugbank acetic acid 2-pentylsulfanyl-phenyl ester NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 2-phenethyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD 5-methyl-3,4-diphenyl-isoxazole NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational,phase 3 prostaglandin g/h synthase 1 PTGS1 Successful target inhibitor NA TTD , drugbank dexketoprofen small molecule Term Birth[MeSHID:D047929],Toothache[MeSHID:D014098],Dysmenorrhea[MeSHID:D004412],Musculoskeletal Pain[MeSHID:D059352] approved,investigational prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank protoporphyrin ix containing co small molecule NA experimental,investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , drugbank carbamate derivative 2 NA NA patented prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD , DGIDB catechin NA NA investigative prostaglandin g/h synthase 1 PTGS1 Successful target unknown NA TTD loxoprofen small molecule Arthropathy[MeSHID:D007592],Inflammation[MeSHID:D007249],Pain[MeSHID:D010146] approved prostaglandin g/h synthase 1 PTGS1 NA antagonist NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational,withdrawn prostaglandin g/h synthase 2 PTGS2 NA antagonist 0.14 drugbank , DGIDB 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD rofecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Rheumatoid Arthritis[MeSHID:D001172],Aura[MeSHID:D004827],Dysmenorrhea[MeSHID:D004412],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 1.76 TTD , drugbank , DGIDB dihomo-gamma-linolenic acid small molecule NA investigational,nutraceutical prostaglandin g/h synthase 2 PTGS2 NA unknown NA drugbank dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor 1.08 drugbank , DGIDB meloxicam small molecule Degenerative polyarthritis[MeSHID:D010003],Operative Surgical Procedures[MeSHID:D013514],Juvenile arthritis[MeSHID:D001171],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 2.17 TTD , drugbank , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.03 drugbank , DGIDB gw-406381 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Degenerative polyarthritis[MeSHID:D010003] discontinued in phase 3 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-(3-phenyl-propyl)-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD ocophyllals a NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD bendazac small molecule Pruritus[MeSHID:D011537],Eczema[MeSHID:D004485],Vision[MeSHID:D014785],Insect Bites[MeSHID:D007299],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Urticaria[MeSHID:D014581],Cataract[MeSHID:D002386],Inflammation[MeSHID:D007249],Burn injury[MeSHID:D002056],Dermatitis[MeSHID:D003872],Pain[MeSHID:D010146],Prescription procedure[MeSHID:D055656] approved,withdrawn prostaglandin g/h synthase 2 PTGS2 NA unknown NA drugbank r-ketoprofen NA NA discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD heme NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD balsalazide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor 1.08 drugbank , DGIDB alpha-linolenic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD (z)-2'-des-methyl sulindac sulfide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 1-phenylsulfonamide-3-trifluoromethyl-5-parabromophenylpyrazole small molecule NA experimental prostaglandin g/h synthase 2 PTGS2 NA unknown NA drugbank 2-furan-2-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-(2,3,4-trimethoxyphenyl)-1h-indene NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD acetaminophen small molecule Disease Management[MeSHID:D019468],Asthma[MeSHID:D001249],Fever[MeSHID:D005334],Allergic Reaction[MeSHID:D006967],Pain[MeSHID:D010146],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.15 drugbank , DGIDB fenbufen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved prostaglandin g/h synthase 2 PTGS2 Successful target unknown 0.36 TTD , DGIDB 2,4-dimethoxy-2'-hydroxychalcone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD droxicam small molecule Inflammation[MeSHID:D007249],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank antrafenine small molecule Pain[MeSHID:D010146] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank 4-fluoro-n-(4-(methylsulfonyl)phenyl)aniline NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD darbufelone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2/3 prostaglandin g/h synthase 2 PTGS2 Successful target unknown 0.36 TTD , DGIDB eicosapentaenoic acid/docosa-hexaenoic acid NA Hypertriglyceridemia[MeSHID:D015228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , DGIDB talniflumate small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Disease[MeSHID:D004194],Rheumatoid Arthritis[MeSHID:D001172],Cystic Fibrosis[MeSHID:D003550] experimental prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank salicylic acid small molecule Acne Vulgaris[MeSHID:D000152],Keratosis pilaris[MeSHID:C537412],Skin callus[MeSHID:D002145],Warts[MeSHID:D014860],Psoriasis[MeSHID:D011565],Bone callus[MeSHID:D002146] approved,investigational,vet_approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank , DGIDB nimesulide small molecule Degenerative polyarthritis[MeSHID:D010003],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Lymphoma, Non-Hodgkin[MeSHID:D008228],Expiration, function[MeSHID:D045853],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational,withdrawn,terminated prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.22 TTD , drugbank , DGIDB sulindac small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.36 drugbank , DGIDB ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.32 TTD , drugbank , DGIDB valdecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 5.06 TTD , drugbank , DGIDB ocophyllals b NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD fluoro loxoprofen NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD diflunisal small molecule Traumatic injury[MeSHID:D014947],Degenerative polyarthritis[MeSHID:D010003],Inflammation[MeSHID:D007249],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 1.45 TTD , drugbank , DGIDB menthyl salicylate small molecule Muscle[MeSHID:D009132],Fibromyalgia[MeSHID:D005356],Neuralgia[MeSHID:D009437],Low Back Pain[MeSHID:D017116],Rheumatism[MeSHID:D012216],Sprain[MeSHID:D013180],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095] approved prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank ginseng biotech NA investigational,nutraceutical prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank flurbiprofen small molecule Soft Tissue Injuries[MeSHID:D017695],Tendinitis[MeSHID:D052256],Rheumatoid Arthritis[MeSHID:D001172],long-term care[MeSHID:D008134],Inflammation[MeSHID:D007249],Miosis disorder[MeSHID:D015877],Bursitis[MeSHID:D002062],Eye[MeSHID:D005123],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Spondylitis[MeSHID:D013166],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 1.57 TTD , drugbank , DGIDB 2,4'-dimethoxy-5,3'-di-(2-propenyl)-biphenyl NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD fenoprofen small molecule Degenerative polyarthritis[MeSHID:D010003],Pain[MeSHID:D010146],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.72 drugbank , DGIDB 3-benzyloxy-4-methoxy-2'-hydroxychalcone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD firocoxib small molecule Fever[MeSHID:D005334],Inflammation[MeSHID:D007249] experimental,vet_approved,investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , drugbank clematomandshurica saponin a NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD lenalidomide small molecule Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA negative modulator NA drugbank piroxicam small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.59 drugbank , DGIDB tebufelone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 3,4-dibenzyloxy-2'-hydroxychalcone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD l-748780 NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD (11h-dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD naproxen small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Juvenile arthritis[MeSHID:D001171],Gout[MeSHID:D006073],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715] approved,vet_approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.84 TTD , drugbank , DGIDB prifelone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD parecoxib small molecule Term Birth[MeSHID:D047929] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.72 drugbank , DGIDB propacetamol small molecule Fever[MeSHID:D005334],Dysmenorrhea[MeSHID:D004412] experimental prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank carprofen small molecule Arthralgia[MeSHID:D018771],Operative Surgical Procedures[MeSHID:D013514],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved,withdrawn prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 7.96 TTD , drugbank , DGIDB cg-100649 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] phase 3 prostaglandin g/h synthase 2 PTGS2 Successful target unknown 0.72 TTD , DGIDB 5-thia-8,11,14,17-eicosatetraenoic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD cr-4174 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD prostaglandin g2 small molecule NA experimental,investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , drugbank apricoxib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 2.17 TTD , DGIDB resveratrol potassium4,-sulfate NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD mefenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Fever[MeSHID:D005334],Inflammation[MeSHID:D007249],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor NA TTD , drugbank , DGIDB tolmetin small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 2.17 TTD , drugbank , DGIDB bryostatin 1 small molecule NA investigational prostaglandin g/h synthase 2 PTGS2 NA inducer NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved,investigational,withdrawn prostaglandin g/h synthase 2 PTGS2 NA antagonist 0.14 drugbank , DGIDB oxametacin NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-benzyloxy-2'-hydroxychalcone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank cimicoxib small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational,phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown 2.17 TTD , drugbank , DGIDB primary alcohol metabolite of celecoxib NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 5,3'-dipropyl-biphenyl-2,4'-diol NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD glycol salicylate small molecule Muscle[MeSHID:D009132],Musculoskeletal Pain[MeSHID:D059352] approved prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank 2-(n-(2-ffuorophenyl)pyrrol-3-yl) acetic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 1-(4-(methylsulfonyl)phenyl)-1h-pyrrole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-(4-methyl-benzylideneamino)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD meclofenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Menorrhagia[MeSHID:D008595],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthralgia[MeSHID:D018771] approved,vet_approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank , DGIDB oxaprozin small molecule Arthralgia[MeSHID:D018771],Degenerative polyarthritis[MeSHID:D010003],Edema[MeSHID:D004487],Rheumatoid Arthritis[MeSHID:D001172],Inflammation[MeSHID:D007249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 2.41 drugbank , DGIDB nectamazin c NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD morniflumate small molecule Nose[MeSHID:D009666],Disease[MeSHID:D004194],Ear structure[MeSHID:D004423],Gastrointestinal Diseases[MeSHID:D005767],Pharyngeal structure[MeSHID:D010614],Affect (mental function)[MeSHID:D000339],Upper Respiratory Infections[MeSHID:D012141],Bone Tissue[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Otitis Media[MeSHID:D010033] experimental prostaglandin g/h synthase 2 PTGS2 NA unknown NA drugbank s-2474 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD choline magnesium trisalicylate small molecule Disease[MeSHID:D004194],Fever[MeSHID:D005334],Inflammation[MeSHID:D007249],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.3 TTD , drugbank , DGIDB trolamine salicylate small molecule Ligaments[MeSHID:D008022],Tendon structure[MeSHID:D013710],Low Back Pain[MeSHID:D017116],Musculoskeletal Pain[MeSHID:D059352],Contusions[MeSHID:D003288],Sprain[MeSHID:D013180],Back Pain[MeSHID:D001416],Pain[MeSHID:D010146],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank sc-75416 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , DGIDB dup 697 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 1 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-(benzylideneamino)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD lumiracoxib small molecule Osteoarthritis, Knee[MeSHID:D020370],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 2.17 TTD , drugbank , DGIDB 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD clematomandshurica saponin b NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD lenalidomide small molecule Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA negative modulator NA drugbank n-(3-phenylamino-4-pyridinyl)methanesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank thioctic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD etodolac small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,vet_approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 3.13 TTD , drugbank , DGIDB pomalidomide small molecule Disease Progression[MeSHID:D018450],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank dipyrithione small molecule Scalp structure[MeSHID:D012535],Seborrheic dermatitis of scalp[MeSHID:D063807] approved prostaglandin g/h synthase 2 PTGS2 NA unknown NA drugbank oxindole 94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD ketorolac small molecule Degenerative polyarthritis[MeSHID:D010003],Headache[MeSHID:D006261],Pain, Postoperative[MeSHID:D010149],Tissue Pain[MeSHID:D059226],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Menstruation Disturbances[MeSHID:D008599],emotional dependency[MeSHID:D003858],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 2.17 drugbank , DGIDB curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 prostaglandin g/h synthase 2 PTGS2 Successful target unknown 0.03 TTD , DGIDB 4-(4-chlorophenyl)-5-p-tolyl-1,2-selenazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 5-(4-chlorophenyl)-4-p-tolyl-1,2-selenazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-(3-nitro-benzylideneamino)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-(p-methylsulfonylbenzoyl)furan NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD lm-4108 NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD n-(3-phenoxy-4-pyridinyl)ethanesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD phenidone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2,4'-dimethoxy-5,3'-dipropyl-biphenyl NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD nabumetone small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 1.03 TTD , drugbank , DGIDB apricoxib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown 2.17 TTD , DGIDB acemetacin small molecule Degenerative polyarthritis[MeSHID:D010003],Edema[MeSHID:D004487],Vertebral column[MeSHID:D013131],Body tissue[MeSHID:D014024],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Operative Surgical Procedures[MeSHID:D013514],Low Back Pain[MeSHID:D017116],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Rheumatic Fever[MeSHID:D012213],Arthritis[MeSHID:D001168],Syndrome[MeSHID:D013577],Pain[MeSHID:D010146] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank celecoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.17 TTD , drugbank , DGIDB resveratrol potassium3-sulfate NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD aceclofenac small molecule Degenerative polyarthritis[MeSHID:D010003],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Inflammation[MeSHID:D007249],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank n-(3-(phenylthio)pyridin-4-yl)methanesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2'-hydroxychalcone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD phenylbutazone small molecule Back Pain[MeSHID:D001416],Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved,vet_approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.54 TTD , drugbank , DGIDB sc-558 NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank tolfenamic acid small molecule Pain[MeSHID:D010146],Migraine Disorders[MeSHID:D008881] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank alclofenac small molecule Ankylosing spondylitis[MeSHID:D013167],Pain[MeSHID:D010146],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank tenosal NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD (s)-flurbiprofen NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Periarthritis[MeSHID:D010489],Myalgia[MeSHID:D063806] preregistration prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD magnesium salicylate small molecule Myalgia[MeSHID:D063806] experimental prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank 2,3-dimethoxy-2'-hydroxychalcone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-(4-methoxy-benzylideneamino)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD furan-3-yl(4-(methylsulfonyl)phenyl)methanone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD tilmacoxib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Colonic Polyps[MeSHID:D003111] discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD prinomide tromethamine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] discontinued in phase 3 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank 5-ethyl-3,4-diphenyl-isoxazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD nepafenac small molecule Inflammation[MeSHID:D007249],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor 1.45 drugbank , DGIDB methylhonokiol NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD (r)-2-(4-isobutyl-phenyl)-n-phenyl-propionamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD b-octylglucoside NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD ketoprofen small molecule Degenerative polyarthritis[MeSHID:D010003],Ankylosing spondylitis[MeSHID:D013167],Dental Health Services[MeSHID:D003752],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Traumatic injury[MeSHID:D014947],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Pain[MeSHID:D059352],Migraine Disorders[MeSHID:D008881] approved,vet_approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 1.59 TTD , drugbank , DGIDB flufenamic acid small molecule Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , drugbank , DGIDB (e)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4,5-bis(4-chlorophenyl)-1,2-selenazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4,5-bis(4-methoxyphenyl)-3h-1,2-dithiol-3-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD phenyl salicylate small molecule Fever[MeSHID:D005334],Pain[MeSHID:D010146] approved prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank mesalazine small molecule Crohn's disease of large bowel[MeSHID:D003424],ileum[MeSHID:D007082],Ulcerative Colitis[MeSHID:D003093],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.29 drugbank , DGIDB pmid29130358-compound-lonimacranthoidevi NA NA patented prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , DGIDB 2-methyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD pac-10649 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD suprofen small molecule Vision[MeSHID:D014785],Operative Surgical Procedures[MeSHID:D013514],Eye[MeSHID:D005123],Miosis disorder[MeSHID:D015877],Cardiac Arrest[MeSHID:D006323],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn prostaglandin g/h synthase 2 PTGS2 NA inhibitor 2.89 drugbank , DGIDB 6,7'-oxybis(2-phenyl-4h-chromen-4-one) NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 5-methyl-3,4-diphenyl-isoxazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-phenyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-amino-n-(4-chlorophenyl)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.21 drugbank , DGIDB (11h-dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD dfu NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD lornoxicam small molecule Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank 8alpha,19-dihydroxylabd-13 e-en-15-oic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1h-indole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD (e)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD c-myb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank (11h-dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD e-6087 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 1 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD (e)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2,6-dihydroxy-1,7-dimethoxyxanthone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4,5-bis(4-chlorophenyl)isothiazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 3 beta-o-acetyloleanolic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 5-(2-imidazol-1-yl-ethyl)-7,8-dihydro-quinoline NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD thermoprofen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 3 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , DGIDB 4-amino-n-(4-iodophenyl)benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 3-bromo-2'-hydroxy-4-methoxychalcone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank , DGIDB 4-phenyliminomethyl-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD licofelone small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational prostaglandin g/h synthase 2 PTGS2 NA unknown 0.72 drugbank , DGIDB gw-637185x NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD tiaprofenic acid small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor NA TTD , drugbank , DGIDB 2'-hydroxy-3,4,5-trimethoxychalcone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD microxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD indomethacin small molecule Disease Management[MeSHID:D019468],Acute onset pain[MeSHID:D059787],Patent ductus arteriosus[MeSHID:D004374],Degenerative polyarthritis[MeSHID:D010003],Tendinitis[MeSHID:D052256],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Arthritis, Gouty[MeSHID:D015210],Bursitis[MeSHID:D002062],Body Fluids[MeSHID:D001826],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.3 TTD , drugbank , DGIDB 2-phenethyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD (e)-2-(4-(methylsulfonyl)styryl)furan NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD nsc-27236 NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.03 drugbank , DGIDB salsalate small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Rheumatism[MeSHID:D012216],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 2.17 drugbank , DGIDB rwj-67657 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] phase 1 prostaglandin g/h synthase 2 PTGS2 Successful target unknown 0.24 TTD , DGIDB cx-9051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 1-(4-(methylsulfonyl)phenyl)-3-phenylurea NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD gsk-644784 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-(4-nitro-benzylideneamino)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-(4-methyl-phenyliminomethyl)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD ca102n NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD etoricoxib small molecule Degenerative polyarthritis[MeSHID:D010003],Acute onset pain[MeSHID:D059787],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Low Back Pain[MeSHID:D017116],Gout[MeSHID:D006073],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 9.4 TTD , drugbank , DGIDB indoprofen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] withdrawn from market prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 3-(4-methanesulfonyl-phenyl)-1-phenyl-propynone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD sc-57666 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD n-(1h-indazol-5-yl)acetamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 5-phenyl-pentanoic acid benzyl-hydroxy-amide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4,5-bis(4-methoxyphenyl)-1,2-selenazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD honokiol NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-(4-(methylsulfonyl)phenyl)pyridine NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD bufexamac small molecule Dermatologic disorders[MeSHID:D012871],Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] approved,withdrawn prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank rq-00317076 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD meclofenamate sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.1 TTD , DGIDB gr-253035 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD sb 239063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD aminosalicylic acid small molecule Tuberculosis[MeSHID:D014376],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Lung[MeSHID:D008168] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor NA TTD , drugbank , DGIDB wogonin NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD fk-3311 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , DGIDB 5-(4-methoxyphenyl)-4-p-tolyl-1,2-selenazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD carbamate derivative 2 NA NA patented prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , DGIDB 4-(4-fluoro-benzylideneamino)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD meclofenamate sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD , DGIDB (e)-3-(4-(methylsulfonyl)styryl)thiophene NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD pmi-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177] discontinued in phase 3 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 2-(n-(2-fluorophenyl)pyrrol-2-yl) acetic acid NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD (e)-2-(4-(methylsulfonyl)styryl)thiophene NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD silicon-modified indomethacin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 4-(3-hydroxy-benzylideneamino)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD l-761000 NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD antipyrine small molecule Ear structure[MeSHID:D004423],Solutions[MeSHID:D012996],Otitis Media[MeSHID:D010033],Liver[MeSHID:D008099] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA inhibitor NA drugbank nitroflurbiprofen NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD diclofenac small molecule Degenerative polyarthritis[MeSHID:D010003],Disease[MeSHID:D004194],Injuries, Surgical[MeSHID:D007431],Rheumatoid Arthritis[MeSHID:D001172],Stomach[MeSHID:D013270],Physical Examination[MeSHID:D010808],Ulcer[MeSHID:D014456],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Spondylitis[MeSHID:D013166],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 0.33 drugbank , DGIDB 4-(3-methoxy-benzylideneamino)-benzenesulfonamide NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD neolignan 9-nor-7,8-dehydro-isolicarin b NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD dexketoprofen small molecule Term Birth[MeSHID:D047929],Toothache[MeSHID:D014098],Dysmenorrhea[MeSHID:D004412],Musculoskeletal Pain[MeSHID:D059352] approved,investigational prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank 3,4-dihydroxyxanthone NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD mefenamic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Fever[MeSHID:D005334],Inflammation[MeSHID:D007249],Pain[MeSHID:D010146],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 0.51 TTD , drugbank , DGIDB crx-401 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD xgp-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD tenoxicam small molecule Back Pain[MeSHID:D001416],Degenerative polyarthritis[MeSHID:D010003],Pain[MeSHID:D010146],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor 1.3 TTD , drugbank , DGIDB bimetopyrole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD 1-(4-(methylsulfonyl)phenyl)-1h-indole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD loxoprofen small molecule Arthropathy[MeSHID:D007592],Inflammation[MeSHID:D007249],Pain[MeSHID:D010146] approved prostaglandin g/h synthase 2 PTGS2 NA antagonist NA drugbank bromfenac small molecule Inflammation[MeSHID:D007249],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved prostaglandin g/h synthase 2 PTGS2 NA inhibitor 1.81 drugbank , DGIDB imrecoxib NA NA phase 4 prostaglandin g/h synthase 2 PTGS2 Successful target unknown 0.36 TTD , DGIDB 2-benzyl-1,2-dihydro-indazol-3-one NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD niflumic acid small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,approved prostaglandin g/h synthase 2 PTGS2 Successful target inhibitor NA TTD , drugbank , DGIDB 4,5-bis(4-methoxyphenyl)isothiazole NA NA investigative prostaglandin g/h synthase 2 PTGS2 Successful target unknown NA TTD parathyroid hormone NA Osteoporosis[MeSHID:D010024] investigative parathyroid hormone PTH Successful target unknown NA TTD teriparatide NA Fracture[MeSHID:D050723],Osteoporosis[MeSHID:D010024],Bone Density[MeSHID:D015519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteogenesis Imperfecta[MeSHID:D010013],Disease[MeSHID:D004194] approved parathyroid hormone PTH Successful target unknown 1.25 TTD , DGIDB ostabolin-c NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 parathyroid hormone PTH Successful target unknown NA TTD , DGIDB kur-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bone Diseases[MeSHID:D001847] phase 2 parathyroid hormone PTH Successful target unknown NA TTD , DGIDB abx-pth biotech Parathyroid Diseases[MeSHID:D010279],Kidney Failure, Chronic[MeSHID:D007676],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational,terminated parathyroid hormone PTH Successful target unknown NA TTD , drugbank mg-1101 NA NA investigative parathyroid hormone PTH Successful target unknown NA TTD d-norleucine small molecule NA experimental parathyroid hormone PTH NA unknown NA drugbank teriparatide biotech Fracture[MeSHID:D050723],Osteoporosis[MeSHID:D010024],Bone Density[MeSHID:D015519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteogenesis Imperfecta[MeSHID:D010013],Disease[MeSHID:D004194] approved,investigational parathyroid hormone/parathyroid hormone-related peptide receptor PTH1R NA binder 14.14 drugbank , DGIDB parathyroid hormone biotech Osteoporosis[MeSHID:D010024] approved,investigational parathyroid hormone/parathyroid hormone-related peptide receptor PTH1R NA activator NA drugbank , DGIDB parathyroid hormone biotech Osteoporosis[MeSHID:D010024] approved,investigational parathyroid hormone/parathyroid hormone-related peptide receptor PTH1R NA activator,agonist 7.07 drugbank , DGIDB teriparatide biotech Fracture[MeSHID:D050723],Osteoporosis[MeSHID:D010024],Bone Density[MeSHID:D015519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteogenesis Imperfecta[MeSHID:D010013],Disease[MeSHID:D004194] approved,investigational parathyroid hormone/parathyroid hormone-related peptide receptor PTH1R NA binder,agonist 14.14 drugbank , DGIDB abaloparatide biotech Spinal Fractures[MeSHID:D016103],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational parathyroid hormone/parathyroid hormone-related peptide receptor PTH1R NA ligand,agonist 14.14 drugbank , DGIDB abaloparatide NA Spinal Fractures[MeSHID:D016103],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved parathyroid hormone 1 receptor PTH1R Successful target unknown 14.14 TTD , DGIDB abaloparatide NA Spinal Fractures[MeSHID:D016103],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved parathyroid hormone 1 receptor PTH1R Successful target agonist 14.14 TTD , DGIDB abaloparatide biotech Spinal Fractures[MeSHID:D016103],Osteoporosis, Postmenopausal[MeSHID:D015663],Bone structure of spine[MeSHID:D013131],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational parathyroid hormone/parathyroid hormone-related peptide receptor PTH1R NA ligand 14.14 drugbank , DGIDB pco371 NA Hypoparathyroidism[MeSHID:D007011],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 parathyroid hormone 1 receptor PTH1R Successful target unknown 7.07 TTD , DGIDB hemoparatide NA NA investigative parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD sdz-pts-893 NA NA investigative parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD semparatide NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD pth(7-34) liposomal cream NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alopecia[MeSHID:D000505] phase 1 parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD , DGIDB parathyroid hormone biotech Osteoporosis[MeSHID:D010024] approved,investigational parathyroid hormone 2 receptor PTH2R NA activator NA drugbank , DGIDB gsk768974 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD , DGIDB bb-pth 1-84 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD uni-ph (1-34) NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD , DGIDB pthr pepducins NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endocrine System Diseases[MeSHID:D004700] investigative parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD npsp-795 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD , DGIDB zp-2307 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative parathyroid hormone receptor PTH2R Clinical trial target unknown NA TTD ba-058 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 parathyroid hormone receptor PTH2R Clinical trial target unknown 21.22 TTD , DGIDB bi-853520 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target inhibitor 4.9 TTD , DGIDB vs-6063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Mesothelioma[MeSHID:D008654] phase 2 focal adhesion kinase 1 PTK2 Clinical trial target unknown 2.45 TTD , DGIDB in10018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target unknown NA TTD endostatin biotech Neoplasms[MeSHID:D009369],Diabetic Retinopathy[MeSHID:D003930],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational focal adhesion kinase 1 PTK2 NA unknown NA drugbank cep-37440 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target unknown 3.67 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational focal adhesion kinase 1 PTK2 NA inhibitor NA drugbank pmid23414845c30 NA NA investigative focal adhesion kinase 1 PTK2 Clinical trial target unknown NA TTD 1,2,4-triazolo[1,5a]pyridine derivative 1 NA NA patented focal adhesion kinase 1 PTK2 Clinical trial target unknown NA TTD , DGIDB gsk-2256098 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target unknown 2.45 TTD , DGIDB 7-pyridin-2-yl-n-(3,4,5-trimethoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-2-amine small molecule NA experimental focal adhesion kinase 1 PTK2 NA unknown NA drugbank pf-562271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target inhibitor 0.12 TTD , DGIDB bi-853520 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target unknown 4.9 TTD , DGIDB cep-37440 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target inhibitor 3.67 TTD , DGIDB gsk-2256098 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target inhibitor 2.45 TTD , DGIDB pf-228 NA NA investigative focal adhesion kinase 1 PTK2 Clinical trial target unknown NA TTD 2-({5-chloro-2-[(2-methoxy-4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl}amino)-n-methylbenzamide small molecule NA experimental focal adhesion kinase 1 PTK2 NA unknown NA drugbank bms-536924 NA NA investigative focal adhesion kinase 1 PTK2 Clinical trial target unknown NA TTD vs-4718 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target unknown 7.34 TTD , DGIDB vs-4718 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target inhibitor 7.34 TTD , DGIDB pf-562271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 focal adhesion kinase 1 PTK2 Clinical trial target unknown 0.12 TTD , DGIDB baricitinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein-tyrosine kinase 2-beta PTK2B NA inhibitor 0.42 drugbank , DGIDB baricitinib small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational protein-tyrosine kinase 2-beta PTK2B NA inhibitor 0.42 drugbank , DGIDB leflunomide small molecule Disease Management[MeSHID:D019468],Disease Progression[MeSHID:D018450],Physical Examination[MeSHID:D010808],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103],Arthritis[MeSHID:D001168] approved,investigational protein-tyrosine kinase 2-beta PTK2B NA antagonist NA drugbank aloisine NA NA investigative focal adhesion kinase 2 PTK2B Literature-reported target inhibitor 1.12 TTD , DGIDB genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational protein-tyrosine kinase 2-beta PTK2B NA unknown NA drugbank leflunomide small molecule Disease Management[MeSHID:D019468],Disease Progression[MeSHID:D018450],Physical Examination[MeSHID:D010808],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Multiple Sclerosis[MeSHID:D009103],Disease[MeSHID:D004194] approved,investigational protein-tyrosine kinase 2-beta PTK2B NA antagonist NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational protein-tyrosine kinase 2-beta PTK2B NA inhibitor NA drugbank 4-{[4-{[(1r,2r)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-n-methylbenzenesulfonamide small molecule NA experimental protein-tyrosine kinase 2-beta PTK2B NA unknown NA drugbank zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein-tyrosine kinase 6 PTK6 NA inhibitor NA drugbank vandetanib small molecule Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved protein-tyrosine kinase 6 PTK6 NA inhibitor 0.15 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational protein-tyrosine kinase 6 PTK6 NA inhibitor NA drugbank pmid21855335c19a NA NA investigative tyrosine-protein kinase brk PTK6 Clinical trial target unknown NA TTD isis-crp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Inflammation[MeSHID:D007249] phase 1 tyrosine-protein kinase brk PTK6 Clinical trial target unknown NA TTD , DGIDB tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein-tyrosine kinase 6 PTK6 NA unknown NA drugbank zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational protein-tyrosine kinase 6 PTK6 NA inhibitor NA drugbank pf-06647020 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 inactive tyrosine-protein kinase 7 PTK7 Clinical trial target unknown 63.65 TTD , DGIDB sodium orthovanadate NA NA investigative protein tyrosine phosphatase iva 3 PTP4A3 Literature-reported target unknown NA TTD abyssinin ii NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 1,2,5-thiadiazolidin-3-one-1,1-dioxide NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD (4s)-5-[[(2s)-1-[[(2s)-1-amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank n-(bromoacetyl)-beta-alanyl-n-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-l-serinamide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 4-phosphonooxy-phenyl-methyl-[4-phosphonooxy]benzen small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank methyl3beta-hydroxyolean-12-en-27-oate NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isis 107775 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 5-(3-hydroxyphenyl)isothiazol-3(2h)-one 1,1-dioxide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank ionis-ptp1brx NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 protein-tyrosine phosphatase 1b PTPN1 Clinical trial target unknown NA TTD , DGIDB 3-(carboxymethoxy)thieno[2,3-b]pyridine-2-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 3-(oxalyl-amino)-naphthalene-2-carboxylic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank [{2-bromo-4-[(2r)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank abyssinoflavanone vii NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD compound 5, 2-(naphthalen-1-yl-oxalyl-amino)-benzoicacid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 3alpha,24-dihydroxyolean-12-en-27-oic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD caulerpin NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD abyssinone-vi-4-o-methyl ether NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD burttinone NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD [(3r)-3-(methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank abyssinone-iv NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 4'-(2-butylbenzofuran-3-yl)biphenyl-4-ol NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD ttp-814 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1/2 protein-tyrosine phosphatase 1b PTPN1 Clinical trial target unknown NA TTD , DGIDB 1-iodyl-4-nitro-benzene NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD oleanonic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 1,2,5-thiadiazolidin-3-one-1,1-dioxide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 1-methyl-3-phenyl-1h-pyrazol-5-ylsulfamic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 3-iodyl-benzoic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isothiazolidinone analog small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank rk-682 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD usimine a NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD compound 19 small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank para-(benzoyl)-phenylalanine NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD folitenol NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isis 107773 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 1,2,3,4,6-penta-o-galloyl-d-glucopyranose NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank formylchromone NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD pnu177836 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isochroman mono-carboxylic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank sigmoidin b NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 1-methyl-3-phenyl-1h-pyrazol-5-ylsulfamic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD kr61639 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD ursolic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Syndrome X[MeSHID:D024821] phase 2 ptpn1 messenger rna PTPN1 Successful target unknown 0.44 TTD , DGIDB [(4-{4-[4-(difluoro-phosphono-methyl)-phenyl]-butyl}-phenyl)-difluoro-methyl]-phosphonic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 3beta-hydroxyolean-12-en-27-oic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD {[2-(1h-1,2,3-benzotriazol-1-yl)-2-(3,4-difluorophenyl)propane-1,3-diyl]bis[4,1-phenylene(difluoromethylene)]}bis(phosphonic acid) small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank licoagrochalcone a NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD trypan blue NA Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye Injuries[MeSHID:D005131],Operative Surgical Procedures[MeSHID:D013514] approved ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 5-(4-methoxybiphenyl-3-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank mulberrofuran c NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 5-[3-(benzylamino)phenyl]-4-bromo-3-(carboxymethoxy)thiophene-2-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank methyl 3beta-hydroxyolean-12-en-28-oate NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 6-(oxalyl-amino)-1h-indole-5-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank kuwanon j NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD kuwanon l NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD ohioensin c NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 7-(1,1-dioxo-1h-benzo[d]isothiazol-3-yloxymethyl)-2-(oxalyl-amino)-4,7-dihydro-5h-thieno[2,3-c]pyran-3-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank rotungenic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid [4-(thiazol-2-ylsulfamoyl)-phenyl]-amide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank mulberrofuran d NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD l-cysteic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank mulberrofuran w NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid dimethylamide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank p-benzoyl-l-phenylalanine small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 4-bromo-3-(carboxymethoxy)-5-[3-(cyclohexylamino)phenyl]thiophene-2-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank albafuran a NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD chromotropate NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD [(3s)-3-(methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 5-(3-{3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]propenyl}phenyl)-4-(hydroxymethyl)isoxazole-3-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank licoagrochacone a NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD erybreadin c NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD phelligridin i NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD usnic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 2-(oxalyl-amino)-4,7-dihydro-5h-thieno[2,3-c]pyran-3-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank isis 107772 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD trodusquemine NA Obesity[MeSHID:D009765],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 protein-tyrosine phosphatase 1b PTPN1 Clinical trial target inhibitor 3.98 TTD , DGIDB trodusquemine small molecule Obesity[MeSHID:D009765],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown 3.98 drugbank , DGIDB 2-(oxalyl-amino)-benzoic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 3-epi-masilinic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD acetate ion NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD oxalylaminobenzoic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD double oxidized cysteine NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 4-[[(2s)-1-[[6-[(1-amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank kuwanon v NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD abyssinin i NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 6-(difluoro-phosphono-methyl)-naphthalene-2-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 1,2-naphthoquinone NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3beta-hydroxyurs-12-en-27-oic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD trodusquemine small molecule Obesity[MeSHID:D009765],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA inhibitor 3.98 drugbank , DGIDB ertiprotafib small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Expiration, function[MeSHID:D045853] investigational tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank kq-791 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 protein-tyrosine phosphatase 1b PTPN1 Clinical trial target unknown NA TTD , DGIDB neorautenol NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD trodusquemine NA Obesity[MeSHID:D009765],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 protein-tyrosine phosphatase 1b PTPN1 Clinical trial target unknown 3.98 TTD , DGIDB isoxazolecarboxylic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 5-(4-chloro-5-phenyl-3-thienyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank spathodic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 4-carbamoyl-4-{[6-(difluoro-phosphono-methyl)-naphthalene-2-carbonyl]-amino}-butyric acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank erybreadin d NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD dysidine NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD ohioensin f NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD cysteinesulfonic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3-oxoolean-12-en-27-oic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid (4-sulfamoyl-phenyl)-amide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 2-[{4-[(2s)-2-{[(allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 2-{[4-(2-acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-yl]-oxalyl-amino}-benzoic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank [[4-(aminomethyl)phenyl]amino]oxo-acetic acid, small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank isis 107774 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD pomolic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD iodyl-benzene NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isis 113715 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 ptpn1 messenger rna PTPN1 Successful target unknown NA TTD , DGIDB n-acetyl-l-phenylalanyl-4-[difluoro(phosphono)methyl]-l-phenylalaninamide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank novo nordisk a/s compound NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD erysubin e NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 2-(oxalyl-amino)-4,7-dihydro-5h-thieno[2,3-c]thiopyran-3-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank cysteine sulfenic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD n-(3-carboxypropanoyl)-l-phenylalanyl-3-carboxy-o-(carboxymethyl)-n-pentyl-l-tyrosinamide small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 2-methyl-2,4-pentanediol NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD b-octylglucoside NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 2-(oxalyl-amino)-benzoic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD (3r)-methylcarbamoyl-7-sulfoamino-3,4-dihydro-1h-isoquinoline-2-carboxylic acid benzyl ester small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank maslinic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD novo nordisk a/s compound small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank abyssinoflavanone vi NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 6-(oxalyl-amino)-1h-indole-5-carboxylic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD sp7343-sp7964 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD ohioensin g NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD kuwanon r NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 1-iodyl-3-nitro-benzene NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD {4-[(2s)-2-({[(1s)-1-carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank {4-[(2s,4e)-2-(1,3-benzothiazol-2-yl)-2-(1h-1,2,3-benzotriazol-1-yl)-5-phenylpent-4-enyl]phenyl}(difluoro)methylphosphonic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank {[7-(difluoro-phosphono-methyl)-naphthalen-2-yl]-difluoro-methyl}-phosphonic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank [[4-(aminomethyl)phenyl]amino]oxo-acetic acid, NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD pnu177836 small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank sigmoidin a NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD oleanolic_acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown 1.77 TTD , DGIDB 3beta,6beta-dihydroxyolean-12-en-27-oic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD sanggenon c NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD uvaol NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 4-iodyl-benzoic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3-(oxalyl-amino)-naphthalene-2-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 5-deoxyabyssinin ii NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD (4-{(2s)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank isis 107791 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isis-ptp1brx NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 ptpn1 messenger rna PTPN1 Successful target unknown NA TTD hydrogen peroxide NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3beta-acetoxyolean-12-en-27-oic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD augustic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isothiazolidinone analog NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3-(4,5-bis-biphenyl-4-yl-1h-imidazol-2-yl)-phenol NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 4-bromo-3-(carboxymethoxy)-5-(4-hydroxyphenyl)thiophene-2-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 4'-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isis 107776 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 24-hydroxyursolic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 3,9-dihydroxy-4-prenyl-[6ar,11ar]pterocarpan NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isis 107792 NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 18alpha-glycyrrhetic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD ohioensin a NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 16-alphah,17-isovaleryloxy-ent-kauran-19-oic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD sigmoidin f NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 2-[(7-hydroxy-naphthalen-1-yl)-oxalyl-amino]-benzoic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank erythribyssin a NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD erybreadin b NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 4-bromo-3-(carboxymethoxy)-5-phenylthiophene-2-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank 18beta-glycyrrhetic acid NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD sanggenon g NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD isis 113715 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank , DGIDB 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione NA NA investigative ptpn1 messenger rna PTPN1 Successful target unknown NA TTD 5-(2-fluoro-5-{(1e)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid small molecule NA experimental tyrosine-protein phosphatase non-receptor type 1 PTPN1 NA unknown NA drugbank dodecane-trimethylamine NA NA investigative protein-tyrosine phosphatase shp-2 PTPN11 Clinical trial target unknown NA TTD tno155 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein-tyrosine phosphatase shp-2 PTPN11 Clinical trial target unknown NA TTD , DGIDB jab-3312 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 protein-tyrosine phosphatase shp-2 PTPN11 Clinical trial target unknown NA TTD sar442720 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein-tyrosine phosphatase shp-2 PTPN11 Clinical trial target unknown NA TTD dodecyltrimethylammonium small molecule NA experimental tyrosine-protein phosphatase non-receptor type 11 PTPN11 NA unknown NA drugbank rly-1971 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein-tyrosine phosphatase shp-2 PTPN11 Clinical trial target unknown NA TTD nsc-87877 NA NA patented protein-tyrosine phosphatase shp-2 PTPN11 Clinical trial target unknown NA TTD bbp-398 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein-tyrosine phosphatase shp-2 PTPN11 Clinical trial target unknown NA TTD jab-3068 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein-tyrosine phosphatase shp-2 PTPN11 Clinical trial target unknown NA TTD tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved tyrosine-protein phosphatase non-receptor type 12 PTPN12 NA inhibitor NA drugbank isis 18473 NA NA investigative fap-1 messenger rna PTPN13 Patented-recorded target unknown NA TTD us9217012, 10 NA NA patented fap-1 messenger rna PTPN13 Patented-recorded target unknown NA TTD abbv-cls-579 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein phosphatase non-receptor type 2 PTPN2 Clinical trial target unknown NA TTD alendronic acid small molecule Osteoporosis[MeSHID:D010024],Osteitis Deformans[MeSHID:D010001] approved tyrosine-protein phosphatase non-receptor type 4 PTPN4 NA inhibitor NA drugbank bdbm50054344 NA NA patented protein-tyrosine phosphatase shp-1 PTPN6 Patented-recorded target unknown NA TTD , DGIDB nsc-87877 NA NA patented protein-tyrosine phosphatase shp-1 PTPN6 Patented-recorded target unknown 5.3 TTD , DGIDB tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved tyrosine-protein phosphatase non-receptor type 6 PTPN6 NA inhibitor NA drugbank akb-9778 NA Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269],Peripheral Vascular Diseases[MeSHID:D016491] phase 2 protein tyrosine phosphatase beta PTPRB Clinical trial target unknown 15.91 TTD , DGIDB (4-{4-[(tert-butoxycarbonyl)amino]-2,2-bis(ethoxycarbonyl)butyl}phenyl)sulfamic acid small molecule NA experimental receptor-type tyrosine-protein phosphatase beta PTPRB NA unknown NA drugbank {4-[2,2-bis(5-methyl-1,2,4-oxadiazol-3-yl)-3-phenylpropyl]phenyl}sulfamic acid small molecule NA experimental receptor-type tyrosine-protein phosphatase beta PTPRB NA unknown NA drugbank razuprotafib small molecule NA investigational receptor-type tyrosine-protein phosphatase beta PTPRB NA inhibitor NA drugbank {4-[2-benzyl-3-methoxy-2-(methoxycarbonyl)-3-oxopropyl]phenyl}sulfamic acid small molecule NA experimental receptor-type tyrosine-protein phosphatase beta PTPRB NA unknown NA drugbank (4-ethylphenyl)sulfamic acid small molecule NA experimental receptor-type tyrosine-protein phosphatase beta PTPRB NA unknown NA drugbank iomab-b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 leukocyte common antigen PTPRC Clinical trial target unknown 5.3 TTD , DGIDB lm-cd45 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft Rejection[MeSHID:D006084] phase 1 leukocyte common antigen PTPRC Clinical trial target unknown NA TTD , DGIDB anti-cd45 mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 leukocyte common antigen PTPRC Clinical trial target unknown NA TTD , DGIDB 131i-labelled acd45 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 leukocyte common antigen PTPRC Clinical trial target unknown NA TTD [131i]-bc8 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 leukocyte common antigen PTPRC Clinical trial target unknown NA TTD , DGIDB iomab-act NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Burkitt Lymphoma[MeSHID:D002051] phase 1 leukocyte common antigen PTPRC Clinical trial target unknown NA TTD asp-brpmp-leu NA NA investigative leukocyte common antigen PTPRC Clinical trial target unknown NA TTD alendronic acid small molecule Osteoporosis[MeSHID:D010024],Osteitis Deformans[MeSHID:D010001] approved receptor-type tyrosine-protein phosphatase epsilon PTPRE NA inhibitor NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved receptor-type tyrosine-protein phosphatase epsilon PTPRE NA inhibitor NA drugbank alendronic acid small molecule Osteoporosis[MeSHID:D010024],Osteitis Deformans[MeSHID:D010001] approved receptor-type tyrosine-protein phosphatase s PTPRS NA inhibitor NA drugbank etidronic acid NA Osteogenesis[MeSHID:D010012],Strabismus[MeSHID:D013285],Spinal Cord Injuries[MeSHID:D013119],Osteitis Deformans[MeSHID:D010001],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein-tyrosine phosphatase sigma PTPRS Successful target unknown NA TTD , DGIDB etidronic acid small molecule Osteogenesis[MeSHID:D010012],Strabismus[MeSHID:D013285],Spinal Cord Injuries[MeSHID:D013119],Osteitis Deformans[MeSHID:D010001],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved receptor-type tyrosine-protein phosphatase s PTPRS NA inhibitor NA drugbank , DGIDB orthovanadate NA NA investigative protein-tyrosine phosphatase sigma PTPRS Successful target unknown NA TTD mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737],Pemphigus Vulgaris[MeSHID:D010392],Immune System Diseases[MeSHID:D007154] approved,investigational 6-pyruvoyl tetrahydrobiopterin synthase PTS NA inhibitor NA drugbank mycophenolate mofetil small molecule Lupus Nephritis[MeSHID:D008181],Hepatitis A[MeSHID:D006506],Neoplasm Metastasis[MeSHID:D009362],Dermatitis[MeSHID:D003872],Off-Label Use[MeSHID:D056687],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational 6-pyruvoyl tetrahydrobiopterin synthase PTS NA inhibitor NA drugbank biopterin small molecule NA experimental 6-pyruvoyl tetrahydrobiopterin synthase PTS NA unknown NA drugbank formic acid small molecule NA experimental,investigational parvalbumin alpha PVALB NA unknown NA drugbank myristic acid small molecule NA experimental poliovirus receptor PVR NA unknown NA drugbank sphingosine small molecule NA experimental poliovirus receptor PVR NA unknown NA drugbank com701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 transmembrane protein pvrig PVRIG Clinical trial target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical pyrroline-5-carboxylate reductase 1, mitochondrial PYCR1 NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical pyrroline-5-carboxylate reductase 1, mitochondrial PYCR1 NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical pyrroline-5-carboxylate reductase 2 PYCR2 NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical pyrroline-5-carboxylate reductase 2 PYCR2 NA unknown NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical pyrroline-5-carboxylate reductase 3 PYCRL NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glycogen phosphorylase, brain form PYGB NA cofactor NA drugbank alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational glycogen phosphorylase, brain form PYGB NA unknown NA drugbank ({[(3e)-2'-oxo-2',7'-dihydro-2,3'-biindol-3(7h)-ylidene]amino}oxy)acetic acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank ethyl 2beta-hydroxyolean-12-en-28-oate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD (2s)-n-[(3s)-1-(2-amino-2-oxoethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-2-chloro-2h-thieno[2,3-b]pyrrole-5-carboxamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank n-acetyl-n'-beta-d-glucopyranosyl urea small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank alpha-d-glucose-6-phosphate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD c-(1-hydrogyl-beta-d-glucopyranosyl) formamide NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 1-deoxy-1-methoxycarbamido-beta-d-glucopyranose NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD nojirimycine tetrazole NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD asiatic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD n-beta-d-glucopyranosylacetamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2-hydroxyiminours-12-en-28-oic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD beta-d-glucopyranose spirohydantoin NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 1-d-glucopyranosyl cytosine NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD n-[(5s,7r,8s,9s,10r)-8,9,10-trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2alpha-hydroxyurs-12-en-28-oic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glycogen phosphorylase, muscle form PYGM NA cofactor NA drugbank indirubin-5-sulphonate small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2alpha-hydroxyolean-12-en-28-oic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD beta-d-glucose small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 4-{3-chloro-4-[3-(2,4-dichloro-benzoyl)-ureido]-phenoxy}-butyric acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank flavopiridol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 2 myophosphorylase PYGM Discontinued target unknown NA TTD 2-hydroxyiminoolean-12-en-28-oic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 1-deoxy-1-acetylamino-beta-d-gluco-2-heptulopyranosonamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank (s)-2-chloro-n-(1-(2-(2-hydroxyethylamino)-2-oxoethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-6h-thieno[2,3-b]pyrrole-5-carboxamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank n-butyl 2beta-hydroxyolean-12-en-28-oate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 3,8,9,10-tetrahydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank alpha-d-glucopyranosyl-2-carboxylic acid amide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank oleanolic_acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD beta-d-glucose NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 2beta,3alpha-dihydroxyurs-12-en-28-oic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank (3s,5r,7r,8s,9s,10r)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank nojirimycine tetrazole small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank betulin NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 2-(beta-d-glucopyranosyl)-5-methyl-1,3,4-benzothiazole small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank (3r,4r,5r)-5-(hydroxymethyl)-1-(3-phenylpropyl)piperidine-3,4-diol small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 1-deoxy-1-methoxycarbamido-beta-d-glucopyranose small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2-oxoolean-12-en-28-oic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 2-isooleanolic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD inosinic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 1-n-acetyl-beta-d-glucosamine NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD (5r,7r,8s,9s,10r)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank n(6)-(pyridoxal phosphate)-l-lysine small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2-(beta-d-glucopyranosyl)-5-methyl-1,3,4-oxadiazole small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2-isoursolic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD c-(1-azido-alpha-d-glucopyranosyl) formamide NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD c-(1-hydrogyl-beta-d-glucopyranosyl) formamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 8,9,10-trihydroxy-7-hydroxymethyl-2-thioxo-6-oxa-1,3-diaza-spiro[4.5]decan-4-one small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank psn357 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 myophosphorylase PYGM Discontinued target unknown NA TTD , DGIDB alpha-d-glucose-1-phosphate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 7-{2,6-dichloro-4-[3-(2-chloro-benzoyl)-ureido]-phenoxy}-heptanoic acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank ursolic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Syndrome X[MeSHID:D024821] phase 2 glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD (5s,7r,8s,9s,10r)-3-amino-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank fluoro-phosphite ion NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 2-chloro-n-[(3r)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-6h-thieno[2,3-b]pyrrole-5-carboxamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank heptulose-2-phosphate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD heptulose-2-phosphate small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2-chloro-n-[(1r,2r)-1-hydroxy-2,3-dihydro-1h-inden-2-yl]-6h-thieno[2,3-b]pyrrole-5-carboxamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 4-{2,4-bis[(3-nitrobenzoyl)amino]phenoxy}phthalic acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank n'-pyridoxyl-lysine-5'-monophosphate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD jtt-651 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD gsk-1362885 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 myophosphorylase PYGM Discontinued target unknown NA TTD dexfosfoserine small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank oleanonic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 2-deoxy-glucose-6-phosphate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 2,3-dicarboxy-4-(2-chloro-phenyl)-1-ethyl-5-isopropoxycarbonyl-6-methyl-pyridinium small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2-deoxy-3,4-bis-o-[3-(4-hydroxyphenyl)propanoyl]-l-threo-pentaric acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank acurea NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD l-serine-o-phosphate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD alpha-d-glucopyranosyl-2-carboxylic acid amide NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 8,9,10-trihydroxy-7-hydroxymethyl-3-methyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank (3s,5r,7r,8s,9s,10r)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank beta-d-glucopyranose spirohydantoin small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank n-benzoyl-n'-beta-d-glucopyranosyl urea NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD alpha-d-glucose 6-phosphate small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2beta,3alpha-dihydroxyolean-12-en-28-oic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD cp-320626 small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank c-(1-azido-alpha-d-glucopyranosyl) formamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 3alpha-hydroxyurs-12-en-28-oic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD benzyl 2-hydroxyiminoolean-12-en-28-oate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD (3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl)-phosphoramidic acid dimethyl ester small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank alpha-d-glucose-1-phosphate small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 2-deoxy-glucose-6-phosphate small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank monofluorophosphate ion small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 4-{2-[(3-nitrobenzoyl)amino]phenoxy}phthalic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 2-(beta-d-glucopyranosyl)-5-methyl-1,2,3-benzimidazole small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank n-(benzoylcarbamoyl)-beta-d-glucopyranosylamine small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 5-{3-[3-(2,4-dichloro-benzoyl)-ureido]-2-methyl-phenoxy}-pentanoic acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 4-{4-[3-(2,4-dichloro-benzoyl)-ureido]-2,3-dimethyl-phenoxy}-butyric acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank indirubin-5-sulfonate NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 23-hydroxybetulinic acid NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 4-{2-[(3-nitrobenzoyl)amino]phenoxy}phthalic acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank n-acetyl-n'-beta-d-glucopyranosyl urea NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD inosinic acid small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank 1-d-glucopyranosyl uracil NA NA investigative glycogen phosphorylase muscle form PYGM Patented-recorded target unknown NA TTD 1-deoxy-1-methoxycarbamido-beta-d-gluco-2-heptulopyranosonamide small molecule NA experimental glycogen phosphorylase, muscle form PYGM NA unknown NA drugbank peptide yy 3-36 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 peptide tyrosine tyrosine pyy PYY Clinical trial target unknown NA TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational pregnancy zone protein PZP NA binder NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational pregnancy zone protein PZP NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental pregnancy zone protein PZP NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational pregnancy zone protein PZP NA unknown NA drugbank 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental dihydropteridine reductase QDPR NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical dihydropteridine reductase QDPR NA unknown NA drugbank pq-912 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 glutaminyl cyclase QPCT Clinical trial target unknown NA TTD , DGIDB pbd150 NA NA investigative glutaminyl cyclase QPCT Clinical trial target inhibitor NA TTD , DGIDB glutamine t-butyl ester small molecule NA experimental glutaminyl-peptide cyclotransferase QPCT NA unknown NA drugbank n-acetylhistamine small molecule NA experimental glutaminyl-peptide cyclotransferase QPCT NA unknown NA drugbank 1-benzylimidazole small molecule NA experimental glutaminyl-peptide cyclotransferase QPCT NA unknown NA drugbank niacin small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Coronary heart disease[MeSHID:D003327],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Atherosclerosis[MeSHID:D050197],Myocardial Infarction[MeSHID:D009203],Avitaminosis[MeSHID:D001361],Dyslipidemias[MeSHID:D050171] approved,investigational,nutraceutical nicotinate-nucleotide pyrophosphorylase [carboxylating] QPRT NA binder 28.29 drugbank , DGIDB guanosine-5'-diphosphate small molecule NA experimental ras-related protein rab-11a RAB11A NA unknown NA drugbank 5'-guanosine-diphosphate-monothiophosphate small molecule NA experimental ras-related protein rab-11a RAB11A NA unknown NA drugbank l-methionine (s)-s-oxide small molecule NA experimental ras-related protein rab-5a RAB5A NA unknown NA drugbank guanosine-5'-triphosphate small molecule NA experimental ras-related protein rab-5a RAB5A NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental ras-related protein rab-5a RAB5A NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental ras-related protein rab-7a RAB7A NA unknown NA drugbank phosphoaminophosphonic acid guanylate ester small molecule NA experimental ras-related protein rab-8b RAB8B NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental ras-related protein rab-8b RAB8B NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental,investigative ras-related protein rab-9a RAB9A Successful target unknown NA TTD , drugbank benzoic acid NA Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ras-related protein rab-9a RAB9A Successful target unknown NA TTD , DGIDB farnesyl diphosphate small molecule NA experimental geranylgeranyl transferase type-2 subunit alpha RABGGTA NA unknown NA drugbank geranylgeranyl diphosphate small molecule NA experimental geranylgeranyl transferase type-2 subunit alpha RABGGTA NA unknown NA drugbank n-formylmethionine small molecule NA experimental geranylgeranyl transferase type-2 subunit alpha RABGGTA NA unknown NA drugbank n-formylmethionine small molecule NA experimental geranylgeranyl transferase type-2 subunit beta RABGGTB NA unknown NA drugbank geranylgeranyl diphosphate small molecule NA experimental geranylgeranyl transferase type-2 subunit beta RABGGTB NA unknown NA drugbank farnesyl diphosphate small molecule NA experimental geranylgeranyl transferase type-2 subunit beta RABGGTB NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental ras-related c3 botulinum toxin substrate 1 RAC1 NA unknown NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadph oxidase RAC1 NA inhibitor NA drugbank azathioprine small molecule Rheumatoid Arthritis[MeSHID:D001172],Graft Rejection[MeSHID:D006084],Kidney[MeSHID:D007668],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Transplanted organ[MeSHID:D019737] approved ras-related c3 botulinum toxin substrate 1 RAC1 NA modulator NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nadph oxidase RAC2 NA inhibitor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational receptor of activated protein c kinase 1 RACK1 NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental dna repair protein rad51 homolog 1 RAD51 NA unknown NA drugbank amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational dna repair protein rad51 homolog 1 RAD51 NA unknown 9.09 drugbank , DGIDB gw-5074 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD isis 6729 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD isis 11061 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD xl281 small molecule Neoplasms[MeSHID:D009369] investigational raf proto-oncogene serine/threonine-protein kinase RAF1 NA unknown NA drugbank , DGIDB lerafaon biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational raf proto-oncogene serine/threonine-protein kinase RAF1 NA unknown NA drugbank xl281 small molecule Neoplasms[MeSHID:D009369] investigational raf proto-oncogene serine/threonine-protein kinase RAF1 NA inhibitor 1.63 drugbank , DGIDB dabrafenib small molecule melanoma[MeSHID:D008545],Disease[MeSHID:D004194],Anaplastic thyroid carcinoma[MeSHID:D065646],Mutation[MeSHID:D009154],Continuance of life[MeSHID:D013534],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational raf proto-oncogene serine/threonine-protein kinase RAF1 NA antagonist,inhibitor NA drugbank isis 9058 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD cholecystokinin small molecule Exocrine pancreatic insufficiency[MeSHID:D010188],Diagnosis[MeSHID:D003933],Gall Bladder Diseases[MeSHID:D005705] approved,investigational raf proto-oncogene serine/threonine-protein kinase RAF1 NA agonist NA drugbank zm-336372 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD debromohymenialdisine NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational raf proto-oncogene serine/threonine-protein kinase RAF1 NA inhibitor 0.47 drugbank , DGIDB isis 7853 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD isis 10707 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD semapimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Diabetes, Autoimmune[MeSHID:D003922] phase 2 proto-oncogene c-raf RAF1 Clinical trial target unknown 0.41 TTD , DGIDB lerafaon NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 raf messenger rna RAF1 Clinical trial target unknown NA TTD 6-benzylsulfanyl-9h-purine NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD l-790070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD ico-007 small molecule Disorder of eye[MeSHID:D005128],Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] investigational raf proto-oncogene serine/threonine-protein kinase RAF1 NA unknown NA drugbank , DGIDB rg7304 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 raf messenger rna RAF1 Clinical trial target unknown NA TTD lxh254 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 raf messenger rna RAF1 Clinical trial target inhibitor NA TTD , DGIDB belvarafenib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-raf RAF1 Clinical trial target unknown NA TTD isis 6717 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD mln2480 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 2 raf messenger rna RAF1 Clinical trial target unknown NA TTD spn-803 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Solitary Pulmonary Nodule[MeSHID:D003074],Parkinson Disease[MeSHID:D010300] phase 1 raf messenger rna RAF1 Clinical trial target unknown NA TTD isis 7855 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD isis 15770 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD isis 6720 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD 5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational raf proto-oncogene serine/threonine-protein kinase RAF1 NA inhibitor NA drugbank ico-007 NA Disorder of eye[MeSHID:D005128],Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 1 raf messenger rna RAF1 Clinical trial target unknown NA TTD , DGIDB bgb-3245 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 proto-oncogene c-raf RAF1 Clinical trial target unknown NA TTD regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved raf proto-oncogene serine/threonine-protein kinase RAF1 NA inhibitor 0.26 drugbank , DGIDB isis 7847 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD 6-[(e)-2-(4-fluoro-phenyl)-vinyl]-9h-purine NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD gdc-5573 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-raf RAF1 Clinical trial target unknown NA TTD , DGIDB isis 7849 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD isis 7848 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD plx-ori3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD isis 7851 NA NA investigative raf messenger rna RAF1 Clinical trial target unknown NA TTD guanosine-5'-diphosphate small molecule NA experimental ras-related protein ral-a RALA NA unknown NA drugbank pramlintide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved,investigational receptor activity-modifying protein 1 RAMP1 NA agonist 42.43 drugbank , DGIDB pramlintide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved,investigational receptor activity-modifying protein 2 RAMP2 NA agonist 50.92 drugbank , DGIDB pramlintide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] approved,investigational receptor activity-modifying protein 3 RAMP3 NA agonist 42.43 drugbank , DGIDB guanosine-5'-diphosphate small molecule NA experimental gtp-binding nuclear protein ran RAN NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational ran-specific gtpase-activating protein RANBP1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational ran-specific gtpase-activating protein RANBP1 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental ras-related protein rap-2a RAP2A NA unknown NA drugbank guanosine-5'-triphosphate small molecule NA experimental ras-related protein rap-2a RAP2A NA unknown NA drugbank am001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623] phase 2 rap guanine nucleotide exchange factor 3 RAPGEF3 Clinical trial target unknown NA TTD esi-09 NA NA investigative rap guanine nucleotide exchange factor 4 RAPGEF4 Literature-reported target inhibitor NA TTD , DGIDB hjc 0350 NA NA investigative rap guanine nucleotide exchange factor 4 RAPGEF4 Literature-reported target inhibitor NA TTD , DGIDB agn193109 NA NA investigative retinoic acid receptor alpha RARA Clinical trial target antagonist NA TTD , DGIDB tamibarotene small molecule leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] investigational,phase 3 retinoic acid receptor alpha RARA Clinical trial target agonist 4.62 TTD , drugbank , DGIDB agn193836 NA NA investigative retinoic acid receptor alpha RARA Clinical trial target agonist NA TTD , DGIDB pmid27336223-compound-5 NA NA patented retinoic acid receptor alpha RARA Clinical trial target unknown NA TTD , DGIDB ro-40-0655 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative retinoic acid receptor alpha RARA Clinical trial target unknown NA TTD alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational retinoic acid receptor alpha RARA NA agonist 2.74 drugbank , DGIDB tazarotene small molecule Acne Vulgaris[MeSHID:D000152],Sunlight[MeSHID:D013472],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor alpha RARA NA agonist 2.57 drugbank , DGIDB ro 41-5253 NA NA investigative retinoic acid receptor alpha RARA Clinical trial target antagonist NA TTD , DGIDB lgd-1550 small molecule Neoplasms[MeSHID:D009369] investigational retinoic acid receptor alpha RARA NA unknown NA drugbank , DGIDB isotretinoin small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor alpha RARA NA agonist 1.49 drugbank , DGIDB pmid27336223-compound-4 NA NA patented retinoic acid receptor alpha RARA Clinical trial target unknown NA TTD , DGIDB bms753 NA NA investigative retinoic acid receptor alpha RARA Clinical trial target agonist NA TTD , DGIDB bms614 NA NA investigative retinoic acid receptor alpha RARA Clinical trial target antagonist NA TTD , DGIDB isotretinoin small molecule Acne Vulgaris[MeSHID:D000152],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor alpha RARA NA unknown 1.49 drugbank , DGIDB acitretin small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor alpha RARA NA agonist 0.9 drugbank , DGIDB sy-1425 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 retinoic acid receptor alpha RARA Clinical trial target unknown NA TTD , DGIDB tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid receptor alpha RARA NA agonist 0.5 drugbank , DGIDB adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor alpha RARA NA unknown 3.23 drugbank , DGIDB isotretinoin small molecule Acne Vulgaris[MeSHID:D000152],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor alpha RARA NA agonist 1.49 drugbank , DGIDB ro 40-6055 NA NA investigative retinoic acid receptor alpha RARA Clinical trial target agonist NA TTD , DGIDB lg100268 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acquired Immunodeficiency Syndrome[MeSHID:D000163] discontinued in phase 1 retinoic acid receptor alpha RARA Clinical trial target unknown NA TTD adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor alpha RARA NA agonist 3.23 drugbank , DGIDB etretinate small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Keratosis[MeSHID:D007642] withdrawn retinoic acid receptor alpha RARA NA agonist 1.76 drugbank , DGIDB tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid receptor alpha RARA NA unknown 0.5 drugbank , DGIDB trifarotene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor alpha RARA NA agonist 1.37 drugbank , DGIDB cd666 NA NA investigative retinoic acid receptor alpha RARA Clinical trial target agonist NA TTD , DGIDB isotretinoin small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor alpha RARA NA unknown 1.49 drugbank , DGIDB irx-5183 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 retinoic acid receptor alpha RARA Clinical trial target unknown 4.11 TTD , DGIDB bms641 NA NA investigative retinoic acid receptor beta RARB Successful target agonist NA TTD , DGIDB pmid27336223-compound-8 NA NA patented retinoic acid receptor beta RARB Successful target unknown NA TTD , DGIDB alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational retinoic acid receptor beta RARB Successful target agonist 4.71 TTD , drugbank , DGIDB agn193109 NA NA investigative retinoic acid receptor beta RARB Successful target antagonist NA TTD , DGIDB adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor beta RARB NA agonist 6.67 drugbank , DGIDB pmid27336223-compound-7 NA NA patented retinoic acid receptor beta RARB Successful target unknown NA TTD , DGIDB pmid27336223-compound-10 NA NA patented retinoic acid receptor beta RARB Successful target unknown NA TTD , DGIDB tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid receptor beta RARB NA agonist 0.39 drugbank , DGIDB acitretin small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor beta RARB NA agonist 1.06 drugbank , DGIDB tamibarotene small molecule leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] investigational,phase 3 retinoic acid receptor beta RARB Successful target agonist 8.49 TTD , drugbank , DGIDB etretinate small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Keratosis[MeSHID:D007642] withdrawn retinoic acid receptor beta RARB NA agonist 1.82 drugbank , DGIDB ac261066 NA NA investigative retinoic acid receptor beta RARB Successful target agonist NA TTD , DGIDB trifarotene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor beta RARB NA agonist 2.83 drugbank , DGIDB lgd-1550 small molecule Neoplasms[MeSHID:D009369] investigational retinoic acid receptor beta RARB NA unknown NA drugbank , DGIDB tazarotene small molecule Acne Vulgaris[MeSHID:D000152],Sunlight[MeSHID:D013472],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor beta RARB NA agonist 4.24 drugbank , DGIDB cd666 NA NA investigative retinoic acid receptor beta RARB Successful target agonist NA TTD , DGIDB arotinoid acid small molecule NA experimental retinoic acid receptor beta RARB NA unknown NA drugbank ttnpb NA NA investigative retinoic acid receptor beta RARB Successful target agonist NA TTD , DGIDB ac55649 NA NA investigative retinoic acid receptor beta RARB Successful target agonist NA TTD , DGIDB tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid receptor gamma RARG Successful target agonist 1.36 TTD , drugbank , DGIDB lgd-1550 small molecule Neoplasms[MeSHID:D009369] investigational retinoic acid receptor gamma RARG NA unknown NA drugbank , DGIDB r667 small molecule Pulmonary Emphysema[MeSHID:D011656],Pathological accumulation of air in tissues[MeSHID:D004646] investigational retinoic acid receptor gamma RARG NA unknown NA drugbank , DGIDB pmid27336223-compound-13 NA NA patented retinoic acid receptor gamma RARG Successful target unknown NA TTD , DGIDB tazarotene small molecule Acne Vulgaris[MeSHID:D000152],Sunlight[MeSHID:D013472],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor gamma RARG Successful target agonist 4.68 TTD , drugbank , DGIDB 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid small molecule NA experimental retinoic acid receptor gamma RARG NA unknown NA drugbank isotretinoin small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor gamma RARG NA agonist 0.68 drugbank , DGIDB adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor gamma RARG NA agonist 5.88 drugbank , DGIDB acitretin small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor gamma RARG NA agonist 0.94 drugbank , DGIDB agn193109 NA NA investigative retinoic acid receptor gamma RARG Successful target antagonist NA TTD , DGIDB bms-181156 small molecule NA experimental retinoic acid receptor gamma RARG NA unknown NA drugbank pmid27336223-compound-14 NA NA patented retinoic acid receptor gamma RARG Successful target unknown NA TTD , DGIDB 3-fluoro-4-{[(2r)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid small molecule NA experimental retinoic acid receptor gamma RARG NA unknown NA drugbank alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational retinoic acid receptor gamma RARG Successful target agonist 3.74 TTD , drugbank , DGIDB pmid27336223-compound-9 NA NA patented retinoic acid receptor gamma RARG Successful target unknown NA TTD , DGIDB etretinate small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Keratosis[MeSHID:D007642] withdrawn retinoic acid receptor gamma RARG NA agonist 2.14 drugbank , DGIDB mm 11253 NA NA investigative retinoic acid receptor gamma RARG Successful target antagonist NA TTD , DGIDB sr11254 small molecule NA experimental,investigative retinoic acid receptor gamma RARG Successful target unknown NA TTD , drugbank isotretinoin small molecule Acne Vulgaris[MeSHID:D000152],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor gamma RARG NA agonist 0.68 drugbank , DGIDB dodecyl-alpha-d-maltoside small molecule NA experimental,investigative retinoic acid receptor gamma RARG Successful target unknown NA TTD , drugbank bms184394 small molecule NA experimental,investigative retinoic acid receptor gamma RARG Successful target unknown NA TTD , drugbank palovarotene NA Pathological accumulation of air in tissues[MeSHID:D004646],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Emphysema[MeSHID:D011656],Fibrodysplasia Ossificans Progressiva[MeSHID:D009221] phase 3 retinoic acid receptor gamma RARG Successful target unknown 11.23 TTD , DGIDB pmid27336223-compound-12 NA NA patented retinoic acid receptor gamma RARG Successful target unknown NA TTD , DGIDB pmid27336223-compound-15 NA NA patented retinoic acid receptor gamma RARG Successful target unknown NA TTD , DGIDB cd2665 NA NA investigative retinoic acid receptor gamma RARG Successful target antagonist NA TTD , DGIDB ahpn NA NA investigative retinoic acid receptor gamma RARG Successful target agonist NA TTD , DGIDB bms270394 NA NA investigative retinoic acid receptor gamma RARG Successful target agonist NA TTD , DGIDB cd564 small molecule NA experimental,investigative retinoic acid receptor gamma RARG Successful target unknown NA TTD , drugbank cd666 NA NA investigative retinoic acid receptor gamma RARG Successful target agonist NA TTD , DGIDB palovarotene NA Pathological accumulation of air in tissues[MeSHID:D004646],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Emphysema[MeSHID:D011656],Fibrodysplasia Ossificans Progressiva[MeSHID:D009221] phase 3 retinoic acid receptor gamma RARG Successful target agonist 11.23 TTD , DGIDB trifarotene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor gamma RARG Successful target agonist 3.74 TTD , drugbank , DGIDB pmid27336223-compound-11 NA NA patented retinoic acid receptor gamma RARG Successful target unknown NA TTD , DGIDB tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid receptor responder protein 1 RARRES1 NA agonist 5.79 drugbank , DGIDB acitretin small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinol-binding protein 1 RBP1 NA agonist NA drugbank lapachone small molecule NA investigational retinol-binding protein 3 RBP3 NA unknown NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinol-binding protein 4 RBP4 NA unknown NA drugbank dipyridamole small molecule Heart Valves[MeSHID:D006351],Angina Pectoris[MeSHID:D000787],Postoperative Complications[MeSHID:D011183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved calcipressin-1 RCAN1 NA unknown NA drugbank cid16197121 NA NA investigative ras converting caax endopeptidase 1 RCE1 Literature-reported target inhibitor NA TTD , DGIDB pmid17942791c3 NA NA investigative ras converting caax endopeptidase 1 RCE1 Literature-reported target unknown NA TTD myristic acid small molecule NA experimental recoverin RCVRN NA unknown NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved retinol dehydrogenase 11 RDH11 NA substrate NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved retinol dehydrogenase 12 RDH12 NA substrate NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved retinol dehydrogenase 13 RDH13 NA substrate NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved retinol dehydrogenase 14 RDH14 NA substrate NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical 11-cis retinol dehydrogenase RDH5 NA unknown NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved 11-cis retinol dehydrogenase RDH5 NA substrate NA drugbank vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved retinol dehydrogenase 8 RDH8 NA substrate NA drugbank 1d-myo-inositol 1,4,5-trisphosphate small molecule NA experimental radixin RDX NA unknown NA drugbank dexfosfoserine small molecule NA experimental lithostathine-1-alpha REG1A NA unknown NA drugbank n-acetyl-alpha-neuraminic acid small molecule NA experimental lithostathine-1-alpha REG1A NA unknown NA drugbank hip-2b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hip structure[MeSHID:D006615],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Bone structure of ischium[MeSHID:D007512], Insulin-Dependent[MeSHID:D003922] phase 1 regenerating human pro-islet peptide REG3A Clinical trial target unknown NA TTD , DGIDB alf-5755 NA Liver Failure[MeSHID:D017093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 regenerating human pro-islet peptide REG3A Clinical trial target unknown NA TTD , DGIDB sc-236 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Malignant Neoplasms[MeSHID:D009369],Expiration, function[MeSHID:D045853] experimental,investigational nuclear factor nf-kappa-b complex RELA NA inhibitor NA drugbank dimethyl fumarate small molecule Multiple Sclerosis[MeSHID:D009103],Relapse[MeSHID:D012008] approved,investigational transcription factor p65 RELA NA unknown NA drugbank glucosamine small molecule Arthralgia[MeSHID:D018771],Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational transcription factor p65 RELA NA inhibitor NA drugbank 1-methyl-2-oxy-5,5-dimethyl pyrrolidine NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD 3-phenyl-1,2-propandiol NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD n-{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydro-4h-1,4-benzothiazin-4-yl]ethyl}acetamide small molecule NA experimental renin REN NA unknown NA drugbank pro-his-pro-his-phe-phe-val-tyr NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD act-178882 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 angiotensinogenase renin REN Successful target unknown NA TTD , DGIDB 2-cyclopropylmethylenepropanal NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD 2-methyl-3-(2-aminothiazolo)propanal small molecule NA experimental renin REN NA unknown NA drugbank pro-his-pro-his-phe-phe-val-tyr-lys NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD 1-methyl-2-oxy-5,5-dimethyl pyrrolidine small molecule NA experimental renin REN NA unknown NA drugbank isoamyl alcohol small molecule NA experimental renin REN NA unknown NA drugbank spp-800 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigative angiotensinogenase renin REN Successful target unknown NA TTD aliskiren NA Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensinogenase renin REN Successful target unknown 43.76 TTD , DGIDB 6-(2,4-diamino-6-ethylpyrimidin-5-yl)-4-(3-methoxypropyl)-2,2-dimethyl-2h-1,4-benzoxazin-3(4h)-one small molecule NA experimental renin REN NA unknown NA drugbank n-methyl-n-(methylbenzyl)formamide NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD spp-600 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 angiotensinogenase renin REN Successful target unknown NA TTD , DGIDB (2s)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-2h-1,4-benzoxazin-3(4h)-one small molecule NA experimental renin REN NA unknown NA drugbank aliskiren NA Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensinogenase renin REN Successful target inhibitor 43.76 TTD , DGIDB 6-ethyl-5-[9-(3-methoxypropyl)-9h-carbazol-2-yl]pyrimidine-2,4-diamine small molecule NA experimental renin REN NA unknown NA drugbank n-{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-2,3-dihydro-4h-1,4-benzoxazin-4-yl]ethyl}acetamide small molecule NA experimental renin REN NA unknown NA drugbank zankiren NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensinogenase renin REN Successful target unknown NA TTD ro-66-1168 NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD 5-{4-[(3,5-difluorobenzyl)amino]phenyl}-6-ethylpyrimidine-2,4-diamine small molecule NA experimental renin REN NA unknown NA drugbank 2-methyl-3-(2-aminothiazolo)propanal NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD aliskiren small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational renin REN NA inhibitor 43.76 drugbank , DGIDB vtp-27999 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 1 angiotensinogenase renin REN Successful target unknown 23.87 TTD , DGIDB sr-43845 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 2 angiotensinogenase renin REN Successful target unknown NA TTD , DGIDB jt-2724 NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD n-methyl-n-(methylbenzyl)formamide small molecule NA experimental renin REN NA unknown NA drugbank card-024 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 angiotensinogenase renin REN Successful target unknown 3.98 TTD , DGIDB enalkiren small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] experimental renin REN NA inhibitor NA drugbank lisinopril small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational renin REN NA inhibitor NA drugbank spp-1148 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 angiotensinogenase renin REN Successful target unknown NA TTD pp2-pro-phe-n-mehis-lva-ile-amp-(o) NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD iva-his-pro-phe-his-sta-leu-phe-nh2 NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD 6-ethyl-5-[(2s)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine small molecule NA experimental renin REN NA unknown NA drugbank rs-8891 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 angiotensinogenase renin REN Successful target unknown NA TTD sul-pro-phe-n-mehis-lva-ile-amp-(o) NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD minoxidil small molecule Hypertensive disease[MeSHID:D006973],Androgenetic Alopecia[MeSHID:D000505],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational renin REN NA unknown NA drugbank (h-261)boc-his-pro-phe-his-leu(oh)-val-ile-his-oh NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD glu-trp-pro-arg-pro-gln-ile-pro-pro NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD sul-pro-phe-n-mehis-lva-ile-amp NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD lisinopril small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational renin REN NA inhibitor NA drugbank iva-his-pro-phe-his-ahppa-leu-phe-nh2 NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD cp-80794 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2 angiotensinogenase renin REN Successful target unknown 7.96 TTD , DGIDB pro-his-pro-phe-his-leu(ch2nh)val-ile-his-lys NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD dimethylformamide NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD 1-hydroxy-2-amino-3-cyclohexylpropane small molecule NA experimental renin REN NA unknown NA drugbank pro-his-pro-his-leu-phe-val-tyr NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD iva-his-pro-phe-his-achpa-leu-phe-nh2 NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD remikiren small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental renin REN NA inhibitor 71.61 drugbank , DGIDB n,n-dimethylformamide small molecule NA experimental renin REN NA unknown NA drugbank remikiren NA Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensinogenase renin REN Successful target unknown 71.61 TTD , DGIDB ro-65-7219 NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD 2-cyclopropylmethylenepropanal small molecule NA experimental renin REN NA unknown NA drugbank 1-hydroxy-3-methylbutane NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD spp-676 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 1 angiotensinogenase renin REN Successful target unknown NA TTD enalkiren NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] discontinued in phase 2 angiotensinogenase renin REN Successful target unknown NA TTD fk-906 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensinogenase renin REN Successful target unknown NA TTD pp1-pro-phe-n-mehis-lva-ile-amp-(o) NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD spp1148 small molecule Hypertensive disease[MeSHID:D006973] investigational renin REN NA unknown NA drugbank es-6864 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigative angiotensinogenase renin REN Successful target unknown NA TTD cp-305202 NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD 3-phenyl-1,2-propandiol small molecule NA experimental renin REN NA unknown NA drugbank 1-hydroxy-2-amino-3-cyclohexylpropane NA NA investigative angiotensinogenase renin REN Successful target unknown NA TTD tak-272 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 angiotensinogenase renin REN Successful target unknown 7.96 TTD , DGIDB n-acetylglucosamine small molecule Degenerative polyarthritis[MeSHID:D010003] approved,investigational,nutraceutical n-acylglucosamine 2-epimerase RENBP NA unknown NA drugbank romiplostim NA Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocytopenia[MeSHID:D013921] approved proto-oncogene c-ret RET Successful target unknown 0.12 TTD , DGIDB tamatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor 0.24 drugbank , DGIDB selpercatinib NA Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pyrrolo-pyridinone derivative 4 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pralsetinib NA Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ret RET Successful target inhibitor 1.43 TTD , DGIDB pyrrolo-pyridinone derivative 3 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB dihydropyridine compound 6 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB (z)-3-((1h-pyrrol-2-yl)methylene)indolin-2-one NA NA investigative proto-oncogene c-ret RET Successful target unknown NA TTD dihydropyridine compound 3 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pyrazolo[3,4-d]pyrimidine derivative 6 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB benzo(b)carbazol-11-one compound 2 NA NA patented ret y791f mutant RET Patented-recorded target unknown NA TTD , DGIDB ast-487 NA NA investigative proto-oncogene c-ret RET Successful target unknown 0.14 TTD , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Intestinal Cancer[MeSHID:D007414],Mastocytosis, Systemic[MeSHID:D034721] approved ret proto-oncogene RET NA inhibitor 0.04 drugbank , DGIDB sorafenib small molecule Renal Cell Carcinoma[MeSHID:D002292],Liver carcinoma[MeSHID:D006528],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor 0.15 drugbank , DGIDB quinazoline derivative 14 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB xl999 small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational ret proto-oncogene RET NA unknown NA drugbank tamatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial proto-oncogene c-ret RET Successful target unknown 0.01 TTD , DGIDB lenvatinib small molecule Thyroid Gland[MeSHID:D013961],Disease[MeSHID:D004194],Radioactivity[MeSHID:D011851],Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Cell Differentiation process[MeSHID:D002454],Liver carcinoma[MeSHID:D006528],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] approved,investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor 0.48 drugbank , DGIDB imatinib small molecule Aggressive Systemic Mastocytosis[MeSHID:D034721],Myelodysplastic-Myeloproliferative Diseases[MeSHID:D054437],Pdgfra-Associated Chronic Eosinophilic Leukemia[MeSHID:C580364],Dermatofibrosarcoma[MeSHID:D018223],Gastrointestinal Stromal Tumors[MeSHID:D046152],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA[MeSHID:C564650],Hypereosinophilic syndrome[MeSHID:D017681],Chromosomes[MeSHID:D002875],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved ret proto-oncogene RET NA inhibitor 0.04 drugbank , DGIDB pyrazolo[3,4-d]pyrimidine derivative 8 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB benzo(b)carbazol-11-one compound 2 NA NA patented ret s891a mutant RET Patented-recorded target unknown NA TTD , DGIDB selpercatinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved,investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor NA drugbank , DGIDB pyrrolo-pyridinone derivative 1 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pyridine derivative 19 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor 0.35 drugbank , DGIDB gw-559768x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative proto-oncogene c-ret RET Successful target unknown NA TTD pyrrolo-pyridinone derivative 2 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB 1-ter-butyl-3-p-tolyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine small molecule NA experimental proto-oncogene tyrosine-protein kinase receptor ret RET NA unknown NA drugbank cabozantinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Medulla Oblongata[MeSHID:D008526],Liver carcinoma[MeSHID:D006528],Adrenal Medulla[MeSHID:D000313],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA antagonist,inhibitor 1.36 drugbank , DGIDB dihydropyridine compound 2 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB vandetanib small molecule Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved proto-oncogene tyrosine-protein kinase receptor ret RET NA unknown 0.81 drugbank , DGIDB selpercatinib NA Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] approved proto-oncogene c-ret RET Successful target inhibitor NA TTD , DGIDB pmid21493067c1d NA NA investigative proto-oncogene c-ret RET Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor NA drugbank vandetanib small molecule Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor 0.81 drugbank , DGIDB pyrrolo-pyrimidine derivative 4 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pyrazolo[3,4-d]pyrimidine derivative 7 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pralsetinib small molecule Medullary carcinoma of thyroid[MeSHID:C536914],Thyroid carcinoma[MeSHID:D013964],Radioactivity[MeSHID:D011851],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor 1.43 drugbank , DGIDB quinazoline derivative 15 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB dihydropyridine compound 5 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pyrrolo-pyrimidine derivative 6 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB (z)-5-amino-3-(4-methoxybenzylidene)indolin-2-one NA NA investigative proto-oncogene c-ret RET Successful target unknown NA TTD benzo(b)carbazol-11-one compound 2 NA NA patented ret v804m mutant RET Patented-recorded target unknown NA TTD , DGIDB pyridine derivative 22 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB vandetanib NA Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved proto-oncogene c-ret RET Successful target inhibitor 0.81 TTD , DGIDB ponatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ret RET Successful target inhibitor 0.35 TTD , DGIDB pmid21561767c8h NA NA investigative proto-oncogene c-ret RET Successful target unknown NA TTD pyrrolo-pyrimidine derivative 2 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB vandetanib NA Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved proto-oncogene c-ret RET Successful target unknown 0.81 TTD , DGIDB benzo(b)carbazol-11-one compound 1 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB benzo(b)carbazol-11-one compound 2 NA NA patented ret m918t mutant RET Patented-recorded target unknown NA TTD , DGIDB tg-100435 NA NA investigative proto-oncogene c-ret RET Successful target unknown NA TTD tpx-0046 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 proto-oncogene c-ret RET Successful target unknown NA TTD amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA unknown 0.41 drugbank , DGIDB benzo(b)carbazol-11-one compound 2 NA NA patented ret v804l mutant RET Patented-recorded target unknown NA TTD , DGIDB regorafenib NA Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ret RET Successful target unknown 0.24 TTD , DGIDB amuvatinib small molecule Malignant Neoplasms[MeSHID:D009369],DNA Repair[MeSHID:D004260],Cells[MeSHID:D002477],Genetic Selection[MeSHID:D012641],Hepatic methionine adenosyltransferase deficiency[MeSHID:C564683] investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA inhibitor 0.41 drugbank , DGIDB ponatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ret RET Successful target unknown 0.35 TTD , DGIDB dihydropyridine compound 4 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB regorafenib NA Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ret RET Successful target inhibitor 0.24 TTD , DGIDB erdafitinib small molecule Diagnosis[MeSHID:D003933],Neoplasms[MeSHID:D009369],Carcinoma, Transitional Cell[MeSHID:D002295],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369] approved,investigational ret proto-oncogene RET NA substrate NA drugbank cep-32496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 proto-oncogene c-ret RET Successful target unknown 1.43 TTD , DGIDB cep-32496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 proto-oncogene c-ret RET Successful target inhibitor 1.43 TTD , DGIDB pyrrolo-pyrimidine derivative 3 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB dihydropyridine compound 1 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pyrrolo-pyrimidine derivative 5 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB itri-305 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid carcinoma[MeSHID:D013964] investigative proto-oncogene c-ret RET Successful target unknown NA TTD pyrazolo[3,4-d]pyrimidine derivative 5 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB bos172738 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-ret RET Successful target unknown NA TTD pyridine derivative 20 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB cabozantinib small molecule Renal Cell Carcinoma[MeSHID:D002292],Thyroid carcinoma[MeSHID:D013964],Medulla Oblongata[MeSHID:D008526],Liver carcinoma[MeSHID:D006528],Adrenal Medulla[MeSHID:D000313],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational proto-oncogene tyrosine-protein kinase receptor ret RET NA antagonist 1.36 drugbank , DGIDB carboxamide derivative 4 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB quinazoline derivative 16 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB tamatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial proto-oncogene c-ret RET Successful target inhibitor NA TTD , DGIDB mgcd516 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 proto-oncogene c-ret RET Successful target unknown 0.07 TTD , DGIDB benzo(b)carbazol-11-one compound 2 NA NA patented ret g691s mutant RET Patented-recorded target unknown NA TTD , DGIDB benzo(b)carbazol-11-one compound 2 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB (e)-3-(4-hydroxybenzylidene)indolin-2-one NA NA investigative proto-oncogene c-ret RET Successful target unknown NA TTD ast-487 NA NA investigative proto-oncogene c-ret RET Successful target inhibitor 0.14 TTD , DGIDB pyridine derivative 21 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB gsk3179106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 1 proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB pyridine derivative 18 NA NA patented proto-oncogene c-ret RET Successful target unknown NA TTD , DGIDB vitamin a small molecule Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved,nutraceutical,vet_approved all-trans-retinol 13,14-reductase RETSAT NA substrate NA drugbank riboflavin small molecule Riboflavin Deficiency[MeSHID:D012257],Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical,vet_approved riboflavin kinase RFK NA ligand NA drugbank flavin mononucleotide small molecule NA approved,investigational riboflavin kinase RFK NA unknown NA drugbank riboflavin small molecule Riboflavin Deficiency[MeSHID:D012257],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congenital Abnormality[MeSHID:D000013],Keratoconus[MeSHID:D007640],Ultraviolet Rays[MeSHID:D014466],Cornea[MeSHID:D003315] approved,investigational,nutraceutical,vet_approved riboflavin kinase RFK NA ligand NA drugbank procainamide NA Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved e3 ubiquitin-protein ligase cop1 RFWD2 Successful target unknown NA TTD tocainide NA Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Judgment[MeSHID:D007600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved e3 ubiquitin-protein ligase cop1 RFWD2 Successful target unknown NA TTD flecainide NA Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved e3 ubiquitin-protein ligase cop1 RFWD2 Successful target unknown NA TTD propafenone NA Cardiac Arrhythmia[MeSHID:D001145],Heart Diseases[MeSHID:D006331],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved e3 ubiquitin-protein ligase cop1 RFWD2 Successful target unknown NA TTD quinine NA Muscle Cramp[MeSHID:D009120],Malaria[MeSHID:D008288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved e3 ubiquitin-protein ligase cop1 RFWD2 Successful target unknown NA TTD elezanumab NA Spinal Cord Injuries[MeSHID:D013119],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 repulsive guidance molecule a RGMA Clinical trial target unknown 127.3 TTD , DGIDB elezanumab NA Spinal Cord Injuries[MeSHID:D013119],Multiple Sclerosis[MeSHID:D009103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 repulsive guidance molecule a RGMA Clinical trial target antibody 127.3 TTD , DGIDB calcium phosphate small molecule NA approved regucalcin RGN NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved regucalcin RGN NA unknown NA drugbank calcium citrate small molecule NA approved,investigational regucalcin RGN NA ligand NA drugbank rgs4 inhibitor 13 NA NA investigative regulator of g-protein signaling 4 RGS4 Literature-reported target inhibitor NA TTD , DGIDB ccg-50014 NA NA investigative regulator of g-protein signaling 4 RGS4 Literature-reported target inhibitor 0.22 TTD , DGIDB thiadiazolidinone (tdzd) deriv. 6 NA NA investigative regulator of g-protein signaling 4 RGS4 Literature-reported target unknown NA TTD [14c]methylamine NA NA investigative ammonium transporter rh type a RHAG Literature-reported target unknown NA TTD , DGIDB sulforaphane NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Dermatologic disorders[MeSHID:D012871] investigative inactive rhomboid protein 2 RHBDF2 Literature-reported target unknown NA TTD [14c]methylamine NA NA investigative ammonium transporter rh type c RHCG Literature-reported target unknown NA TTD roledumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2/3 blood group rh(d) polypeptide RHD Clinical trial target inhibitor 42.43 TTD , DGIDB rozrolimupab NA Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] discontinued in phase 2 blood group rh(d) polypeptide RHD Clinical trial target inhibitor 21.22 TTD , DGIDB roledumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2/3 blood group rh(d) polypeptide RHD Clinical trial target unknown 42.43 TTD , DGIDB rozrolimupab biotech Thrombocytopenia[MeSHID:D013921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] investigational rhesus blood group d antigen RHD NA inhibitor 21.22 drugbank , DGIDB human rho(d) immune globulin biotech Erythrocytes[MeSHID:D004912],Rh Isoimmunization[MeSHID:D012203],Immune thrombocytopenic purpura[MeSHID:D016553],Pregnancy[MeSHID:D011247] approved,investigational rhesus blood group d antigen RHD NA antibody NA drugbank guanosine-5'-triphosphate small molecule NA experimental gtp-binding protein rheb RHEB NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental gtp-binding protein rheb RHEB NA unknown NA drugbank b-nonylglucoside small molecule NA experimental,investigative rhodopsin RHO Literature-reported target unknown NA TTD , drugbank b-octylglucoside NA NA investigative rhodopsin RHO Literature-reported target unknown NA TTD palmitic acid small molecule NA approved rhodopsin RHO NA unknown NA drugbank nsc-88915 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative rhodopsin RHO Literature-reported target unknown NA TTD hexadecanoic acid NA NA investigative rhodopsin RHO Literature-reported target unknown NA TTD heptyl 1-thiohexopyranoside small molecule NA experimental,investigative rhodopsin RHO Literature-reported target unknown NA TTD , drugbank dodecyldimethylamine n-oxide small molecule NA experimental rhodopsin RHO NA unknown NA drugbank dexfosfoserine small molecule NA experimental rhodopsin RHO NA unknown NA drugbank 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine small molecule NA experimental rhodopsin RHO NA unknown NA drugbank l-serine-o-phosphate NA NA investigative rhodopsin RHO Literature-reported target unknown NA TTD hexadecanal small molecule NA experimental,investigative rhodopsin RHO Literature-reported target unknown NA TTD , drugbank lauryl dimethylamine-n-oxide NA NA investigative rhodopsin RHO Literature-reported target unknown NA TTD phosphonothreonine small molecule NA experimental,investigative rhodopsin RHO Literature-reported target unknown NA TTD , drugbank beta-d-mannose NA NA investigative rhodopsin RHO Literature-reported target unknown NA TTD alpha-d-mannose NA NA investigative rhodopsin RHO Literature-reported target unknown NA TTD n-acetylmethionine small molecule NA experimental,investigative rhodopsin RHO Literature-reported target unknown NA TTD , drugbank b-2-octylglucoside small molecule NA experimental,investigative rhodopsin RHO Literature-reported target unknown NA TTD , drugbank halothane small molecule Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved rhodopsin RHO NA other NA drugbank (hydroxyethyloxy)tri(ethyloxy)octane small molecule NA experimental,investigative rhodopsin RHO Literature-reported target unknown NA TTD , drugbank heptane-1,2,3-triol small molecule NA experimental,investigative rhodopsin RHO Literature-reported target unknown NA TTD , drugbank isis 25566 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD isis 25552 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD isis 25544 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD isis 25551 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD es-285 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 transforming protein rhoa RHOA Discontinued target unknown NA TTD isis 25564 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD isis 25547 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD isis 25554 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD isis 25567 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD isis 25563 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD isis 25565 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD guanosine-5'-diphosphate small molecule NA experimental transforming protein rhoa RHOA NA unknown NA drugbank isis 25549 NA NA investigative rhoa messenger rna RHOA Literature-reported target unknown NA TTD botulinum toxin type a biotech Neurogenic Thoracic Outlet Syndrome[MeSHID:D013901],Strabismus[MeSHID:D013285],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Facial Nerve Diseases[MeSHID:D005155],Overactive Bladder[MeSHID:D053201],Temporomandibular Joint Disorders[MeSHID:D013705],Hyperhidrosis disorder[MeSHID:D006945],Disease[MeSHID:D004194],Spasm[MeSHID:D013035],Postherpetic neuralgia[MeSHID:D051474],Neurogenesis[MeSHID:D055495],Neuralgia[MeSHID:D009437],Cervical Dystonia[MeSHID:D014103],Cerebrovascular accident[MeSHID:D020521],Diabetic Neuropathies[MeSHID:D003929],Spinal Cord Injuries[MeSHID:D013119],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blepharospasm[MeSHID:D001764] approved,investigational rho-related gtp-binding protein rhob RHOB NA inhibitor NA drugbank theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved protein ric-3 RIC3 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase rio1 RIOK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase rio2 RIOK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase rio3 RIOK3 NA inhibitor NA drugbank dnl747 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690] phase 1 receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD pmid24900635c21 NA NA investigative receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD ripa-56 NA Non-alcoholic Fatty Liver Disease[MeSHID:D065626],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative receptor-interacting protein 1 RIPK1 Clinical trial target inhibitor NA TTD , DGIDB gsk'963 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951] investigative receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD gsk3145095 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1/2 receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD tricyclic compound 9 NA NA patented receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational receptor-interacting serine/threonine-protein kinase 1 RIPK1 NA inhibitor NA drugbank pk68 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD dnl758 NA Lupus Erythematosus, Cutaneous[MeSHID:D008178],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD dnl104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD r552 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurological observations[MeSHID:D009461],Autoimmune Diseases[MeSHID:D001327] phase 1 receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD gne684 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD tricyclic compound 10 NA NA patented receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD , DGIDB gsk2982772 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Ulcerative Colitis[MeSHID:D003093],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] phase 2 receptor-interacting protein 1 RIPK1 Clinical trial target inhibitor NA TTD , DGIDB gsk2982772 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Ulcerative Colitis[MeSHID:D003093],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] phase 2 receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD , DGIDB tricyclic compound 8 NA NA patented receptor-interacting protein 1 RIPK1 Clinical trial target unknown NA TTD , DGIDB nm-pp1 NA NA investigative rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational receptor-interacting serine/threonine-protein kinase 2 RIPK2 NA inhibitor NA drugbank isis 104254 NA NA investigative rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD isis 104256 NA NA investigative rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD isis 104257 NA NA investigative rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD src kinase inhibitor i NA NA investigative rip2 messenger rna RIPK2 Clinical trial target inhibitor NA TTD , DGIDB isis 104253 NA NA investigative rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD isis 104255 NA NA investigative rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD isis 104258 NA NA investigative rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD isis 104211 NA NA investigative rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD isis-crp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Inflammation[MeSHID:D007249] phase 1 rip2 messenger rna RIPK2 Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational receptor-interacting serine/threonine-protein kinase 4 RIPK4 NA inhibitor NA drugbank 2'-deoxycytidine-2'-deoxyadenosine-3',5'-monophosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank deoxycytidylyl-3',5'-guanosine small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank cytidine 3'-monophosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank uridylyl-2'-5'-phospho-adenosine small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank 5'-deoxy-5'-piperidin-1-ylthymidine small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank arabinouridine 3'-phosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank 5-aminouracil small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved ribonuclease pancreatic RNASE1 NA unknown NA drugbank 1-(2,5-dideoxy-5-pyrrolidin-1-yl-beta-l-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1h,3h)-dione small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank 2'-cytidylic acid small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank 3'-phosphate-adenosine-5'-diphosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank uridylyl-2'-5'-phospho-guanosine small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank 2'-fluoro-2'-deoxyuridine 3'-monophosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical ribonuclease pancreatic RNASE1 NA unknown NA drugbank guanidine small molecule Lambert-Eaton Myasthenic Syndrome[MeSHID:D015624],Paresis[MeSHID:D010291],Muscle Weakness[MeSHID:D018908],Myasthenia Gravis[MeSHID:D009157] approved ribonuclease pancreatic RNASE1 NA unknown NA drugbank uridine-2',3'-vanadate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank 2'-monophosphoadenosine-5'-diphosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank n-formylmethionine small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank 2'-deoxyuridine 3'-monophosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank cysteine-s-acetamide small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank purine riboside-5'-monophosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank 3'-uridinemonophosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank tert-butanol small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank adenosine-2'-5'-diphosphate small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank adenylate-3'-phosphate-[[2'-deoxy-uridine-5'-phosphate]-3'-phosphate] small molecule NA experimental ribonuclease pancreatic RNASE1 NA unknown NA drugbank formic acid small molecule NA experimental,investigational ribonuclease pancreatic RNASE1 NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental non-secretory ribonuclease RNASE2 NA unknown NA drugbank adenosine-2'-5'-diphosphate small molecule NA experimental non-secretory ribonuclease RNASE2 NA unknown NA drugbank adenosine-2'-5'-diphosphate small molecule NA experimental eosinophil cationic protein RNASE3 NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved eosinophil cationic protein RNASE3 NA unknown NA drugbank pranlukast small molecule Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational eosinophil cationic protein RNASE3 NA unknown NA drugbank 2'-deoxyuridine 3'-monophosphate small molecule NA experimental ribonuclease 4 RNASE4 NA unknown NA drugbank guanosine-5'-triphosphate small molecule NA experimental rho-related gtp-binding protein rhoe RND3 NA unknown NA drugbank rnf43-721 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 ring finger protein 43 RNF43 Clinical trial target unknown NA TTD , DGIDB lys-thiol NA NA investigative arginyl aminopeptidase RNPEP Literature-reported target unknown NA TTD ama-237 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD sb-747651a NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD netarsudil small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Ocular Hypotension[MeSHID:D015814],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved rho-associated protein kinase 1 ROCK1 Successful target inhibitor 2.12 TTD , drugbank , DGIDB ripasudil small molecule Glaucoma[MeSHID:D005901],Diabetic Retinopathy[MeSHID:D003930],Ocular Hypertension[MeSHID:D009798],Macular Edema, Cystoid[MeSHID:D008269] experimental rho-associated protein kinase 1 ROCK1 NA inhibitor NA drugbank , DGIDB rki-1447 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target inhibitor NA TTD , DGIDB kt-5720 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD as-1892802 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD pmid28048944-compound-2 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB pmid28048944-compound-7 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB fasudil small molecule NA investigational,investigative rho-associated protein kinase 1 ROCK1 Successful target unknown 0.28 TTD , drugbank , DGIDB pmid28048944-compound-5 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB belumosudil small molecule Graft-vs-Host Disease[MeSHID:D006086] approved,investigational rho-associated protein kinase 1 ROCK1 NA inhibitor NA drugbank , DGIDB pmid28048944-compound-4 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB sr-3850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD ins-117548 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 1 rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB pmid20462760c22 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD sar-407899 NA Diabetic Nephropathy[MeSHID:D003928],Microvascular Angina[MeSHID:D017566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 rho-associated protein kinase 1 ROCK1 Successful target inhibitor 2.12 TTD , DGIDB gsk269962a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] clinical trial rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB ci-1040 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown 0.09 TTD , DGIDB (s)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine small molecule NA experimental rho-associated protein kinase 1 ROCK1 NA unknown NA drugbank gsk269962a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] clinical trial rho-associated protein kinase 1 ROCK1 Successful target inhibitor NA TTD , DGIDB ro31-8220 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD pmid28048944-compound-19 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB hydroxyfasudil small molecule NA experimental rho-associated protein kinase 1 ROCK1 NA inhibitor NA drugbank ats-907 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD fasudil small molecule NA investigational,investigative rho-associated protein kinase 1 ROCK1 Successful target inhibitor 0.28 TTD , drugbank , DGIDB pmid28048944-compound-20 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB y-27632 small molecule NA experimental rho-associated protein kinase 1 ROCK1 NA unknown NA drugbank pmid20684608c35 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD kn-62 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD pmid28048944-compound-6 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB bisindolylmaleimide-i NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD pmid28048944-compound-21 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB (4-fluoro-phenyl)-(9h-purin-6-yl)-amine NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD pmid28048944-compound-3 NA NA patented rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB h-1152 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD , DGIDB sar-407899 NA Diabetic Nephropathy[MeSHID:D003928],Microvascular Angina[MeSHID:D017566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 rho-associated protein kinase 1 ROCK1 Successful target unknown 2.12 TTD , DGIDB acid-activated omeprazole NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD trn-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD pmid19364658c33 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD ro-316233 NA NA investigative rho-associated protein kinase 1 ROCK1 Successful target unknown NA TTD gsk269962a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] clinical trial rho-associated protein kinase 2 ROCK2 Clinical trial target inhibitor NA TTD , DGIDB ama-237 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD belumosudil small molecule Graft-vs-Host Disease[MeSHID:D006086] approved,investigational rho-associated protein kinase 2 ROCK2 NA inhibitor NA drugbank , DGIDB pmid20471253c32 NA NA investigative rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD y-27632 small molecule NA experimental rho-associated protein kinase 2 ROCK2 NA unknown 1.82 drugbank , DGIDB ins-117548 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 1 rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB ats-907 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] investigative rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD pmid28048944-compound-4 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB trn-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD pmid28048944-compound-19 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB tricyclic compound 6 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB glycyl-h 1152 NA NA investigative rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD rki-1447 NA NA investigative rho-associated protein kinase 2 ROCK2 Clinical trial target inhibitor NA TTD , DGIDB kd025 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Systemic Scleroderma[MeSHID:D012595],Psoriasis[MeSHID:D011565],Scleroderma[MeSHID:D012594],Arthritis, Psoriatic[MeSHID:D015535],Rheumatoid Arthritis[MeSHID:D001172] phase 2 rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB pmid28048944-compound-7 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB tricyclic compound 7 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB pmid28048944-compound-2 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB pmid28048944-compound-3 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB tricyclic compound 4 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB tricyclic compound 5 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB pmid28048944-compound-5 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB netarsudil small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Ocular Hypotension[MeSHID:D015814],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved rho-associated protein kinase 2 ROCK2 NA inhibitor 0.91 drugbank , DGIDB pmid20462760c22 NA NA investigative rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD indazolyl-thiadiazolamine derivative 1 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB pmid20684608c35 NA NA investigative rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD sr-3850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD fasudil small molecule NA investigational rho-associated protein kinase 2 ROCK2 NA unknown 0.24 drugbank , DGIDB gsk269962a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] clinical trial rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB pmid28048944-compound-11 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB pmid28048944-compound-6 NA NA patented rho-associated protein kinase 2 ROCK2 Clinical trial target unknown NA TTD , DGIDB ripasudil small molecule Glaucoma[MeSHID:D005901],Diabetic Retinopathy[MeSHID:D003930],Ocular Hypertension[MeSHID:D009798],Macular Edema, Cystoid[MeSHID:D008269] experimental rho-associated protein kinase 2 ROCK2 NA inhibitor NA drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational rho-associated protein kinase 2 ROCK2 NA inhibitor NA drugbank fasudil small molecule NA investigational rho-associated protein kinase 2 ROCK2 NA inhibitor 0.24 drugbank , DGIDB vls-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 neurotrophic tyrosine kinase ror1 ROR1 Clinical trial target unknown NA TTD ror1 car-specific autologous t-lymphocytes NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],T-Lymphocyte[MeSHID:D013601],Chronic Lymphocytic Leukemia[MeSHID:D015451],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1 neurotrophic tyrosine kinase ror1 ROR1 Clinical trial target unknown NA TTD , DGIDB ror1r-car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] phase 1 neurotrophic tyrosine kinase ror1 ROR1 Clinical trial target unknown NA TTD , DGIDB nbe-002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 neurotrophic tyrosine kinase ror1 ROR1 Clinical trial target unknown NA TTD cirmtuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522] phase 2 neurotrophic tyrosine kinase ror1 ROR1 Clinical trial target unknown 63.65 TTD , DGIDB cct301-59 (targeting ror2) NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 neurotrophic tyrosine kinase ror2 ROR2 Clinical trial target unknown NA TTD , DGIDB cct301-38 (targeting ror2) NA Renal Cell Carcinoma[MeSHID:D002292],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 neurotrophic tyrosine kinase ror2 ROR2 Clinical trial target unknown NA TTD , DGIDB cholesterol sulfate small molecule NA experimental nuclear receptor ror-alpha RORA NA unknown NA drugbank cholesterol small molecule NA approved,investigational nuclear receptor ror-alpha RORA NA agonist 31.83 drugbank , DGIDB all-trans-4-oxo-retinoic acid NA NA investigative rar-related orphan receptor-beta RORB Patented-recorded target antagonist NA TTD , DGIDB melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved nuclear receptor ror-beta RORB NA agonist NA drugbank us9598431, 1 NA NA patented rar-related orphan receptor-beta RORB Patented-recorded target unknown NA TTD , DGIDB us9598431, 2 NA NA patented rar-related orphan receptor-beta RORB Patented-recorded target unknown NA TTD , DGIDB melatonin small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Cluster Headache[MeSHID:D003027],Malignant neoplasm of prostate[MeSHID:D011471],Cerebral Palsy[MeSHID:D002547],Autistic Disorder[MeSHID:D001321],Circadian Rhythm Disorders[MeSHID:D021081],Wakefulness[MeSHID:D014851],Developmental Disabilities[MeSHID:D002658],Jet Lag Syndrome[MeSHID:D020179],Sleep Disorders[MeSHID:D012893],Blind Vision[MeSHID:D001766],Delayed Sleep Phase Syndrome[MeSHID:D020178],Sunburn[MeSHID:D013471],Intellectual Disability[MeSHID:D008607],Thrombocytopenia[MeSHID:D013921],Anxiety Disorders[MeSHID:D001008],Tardive Dyskinesia[MeSHID:D000071057],Anxiety[MeSHID:D001007],Primary Insomnia[MeSHID:D007319],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical,vet_approved nuclear receptor ror-beta RORB NA agonist NA drugbank us9598431, 5 NA NA patented rar-related orphan receptor-beta RORB Patented-recorded target unknown NA TTD , DGIDB lyc-55716 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB sr1078 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of liver[MeSHID:D008113] preclinical nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD 25-hydroxycholesterol NA NA investigative nuclear receptor ror-gamma RORC Clinical trial target agonist 0.24 TTD , DGIDB esr0114 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 1/2 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB vtp-43742 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Autoimmune Diseases[MeSHID:D001327] phase 2 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB ml209 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327] preclinical nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD tak-828 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] phase 1 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB jte-451 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 1 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB sr1555 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] preclinical nuclear receptor ror-gamma RORC Clinical trial target agonist NA TTD , DGIDB sr2211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Autoimmune Diseases[MeSHID:D001327] preclinical nuclear receptor ror-gamma RORC Clinical trial target agonist NA TTD , DGIDB arn-6039 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB gsk2981278 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 2 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB gsk2981278 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 2 nuclear receptor ror-gamma RORC Clinical trial target agonist NA TTD , DGIDB jnj-3534 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB azd0284 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 1 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB nobiletin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atherosclerosis[MeSHID:D050197],Arteriosclerosis[MeSHID:D001161] preclinical nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD bbi-6000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB arn-6039 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Multiple Sclerosis[MeSHID:D009103] phase 1 nuclear receptor ror-gamma RORC Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational proto-oncogene tyrosine-protein kinase ros ROS1 NA inhibitor NA drugbank tpx-0005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 proto-oncogene c-ros ROS1 Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented proto-oncogene c-ros ROS1 Successful target unknown NA TTD , DGIDB crizotinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ros ROS1 Successful target inhibitor 2.93 TTD , DGIDB entrectinib NA Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved proto-oncogene c-ros ROS1 Successful target unknown 0.33 TTD , DGIDB pmid28270010-compound-figure21-b NA Brain[MeSHID:D001921],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented proto-oncogene c-ros ROS1 Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented proto-oncogene c-ros ROS1 Successful target unknown NA TTD , DGIDB lorlatinib NA Neoplasm Metastasis[MeSHID:D009362],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ros ROS1 Successful target unknown 2.82 TTD , DGIDB entrectinib small molecule Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved,investigational proto-oncogene tyrosine-protein kinase ros ROS1 NA inhibitor 0.33 drugbank , DGIDB carboxamide derivative 4 NA NA patented proto-oncogene c-ros ROS1 Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented proto-oncogene c-ros ROS1 Successful target unknown NA TTD , DGIDB crizotinib NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ros ROS1 Successful target unknown 2.93 TTD , DGIDB ab-106 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 proto-oncogene c-ros ROS1 Successful target unknown NA TTD ds-6051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-ros ROS1 Successful target unknown NA TTD , DGIDB pmid24432909c8e NA NA investigative proto-oncogene c-ros ROS1 Successful target unknown NA TTD lorlatinib NA Neoplasm Metastasis[MeSHID:D009362],Disease[MeSHID:D004194],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-ros ROS1 Successful target inhibitor 2.82 TTD , DGIDB voretigene neparvovec biotech Visual Impairment[MeSHID:D014786],Structure of retinal pigment epithelium[MeSHID:D055213],Cells[MeSHID:D002477],Vision[MeSHID:D014785],Leber Congenital Amaurosis[MeSHID:D057130],Retinal Cone[MeSHID:D017949],Mutation[MeSHID:D009154],Retinal Diseases[MeSHID:D012164],Retinal Degeneration[MeSHID:D012162],Retinal Dystrophies[MeSHID:D058499],LEBER CONGENITAL AMAUROSIS, TYPE II (disorder)[MeSHID:C536601],Light[MeSHID:D008027],Blind Vision[MeSHID:D001766],Electricity[MeSHID:D004560] approved retinoid isomerohydrolase RPE65 NA gene replacement NA drugbank tgaag76 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blind Vision[MeSHID:D001766] phase 1/2 retinal pigment epithelium protein RPE65 Clinical trial target unknown NA TTD , DGIDB aav2-hrpe65v2 NA Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 retinal pigment epithelium protein RPE65 Clinical trial target unknown 21.22 TTD , DGIDB leber's congenital amaurosis gene therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leber Congenital Amaurosis[MeSHID:D057130] phase 1/2 retinal pigment epithelium protein RPE65 Clinical trial target unknown NA TTD , DGIDB emixustat NA Diabetic Retinopathy[MeSHID:D003930],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 retinal pigment epithelium protein RPE65 Clinical trial target inhibitor 42.43 TTD , DGIDB emixustat NA Diabetic Retinopathy[MeSHID:D003930],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 retinal pigment epithelium protein RPE65 Clinical trial target unknown 42.43 TTD , DGIDB aav-rpe65 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leber Congenital Amaurosis[MeSHID:D057130] phase 1/2 retinal pigment epithelium protein RPE65 Clinical trial target unknown NA TTD biib-088 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinitis Pigmentosa[MeSHID:D012174] phase 2/3 x-linked retinitis pigmentosa gtpase regulator RPGR Clinical trial target unknown NA TTD aav-rpgr NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinitis Pigmentosa[MeSHID:D012174] phase 1/2 x-linked retinitis pigmentosa gtpase regulator RPGR Clinical trial target unknown NA TTD agtc-501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinitis Pigmentosa[MeSHID:D012174] phase 1/2 x-linked retinitis pigmentosa gtpase regulator RPGR Clinical trial target unknown NA TTD 4-phospho-l-threonic acid small molecule NA experimental ribose-5-phosphate isomerase RPIA NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 60s ribosomal protein l10 RPL10 NA ligand NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l10-like RPL10L NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l10-like RPL10L NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l10-like RPL10L NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l11 RPL11 NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l11 RPL11 NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l11 RPL11 NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l13a RPL13A NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l13a RPL13A NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l13a RPL13A NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 60s ribosomal protein l14 RPL14 NA ligand NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l15 RPL15 NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l15 RPL15 NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l15 RPL15 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 60s ribosomal protein l18 RPL18 NA ligand NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l19 RPL19 NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l19 RPL19 NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l19 RPL19 NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l23 RPL23 NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l23 RPL23 NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l23 RPL23 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 60s ribosomal protein l23a RPL23A NA ligand NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l23a RPL23A NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l23a RPL23A NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l23a RPL23A NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l26-like 1 RPL26L1 NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l26-like 1 RPL26L1 NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l26-like 1 RPL26L1 NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l3 RPL3 NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l3 RPL3 NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l3 RPL3 NA unknown NA drugbank omacetaxine mepesuccinate small molecule Leukemia, Myeloid, Chronic-Phase[MeSHID:D015466],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational 60s ribosomal protein l3 RPL3 NA antagonist NA drugbank xanthinol small molecule Metabolism[MeSHID:D008660],Brain[MeSHID:D001921],Diet therapy[MeSHID:D004035],Attention[MeSHID:D001288],Hyperlipidemia[MeSHID:D006949],Peripheral Vascular Diseases[MeSHID:D016491],Memory[MeSHID:D008568],Blood[MeSHID:D001769],Awareness[MeSHID:D001364] approved,withdrawn 60s ribosomal protein l3 RPL3 NA binder NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 60s ribosomal protein l35 RPL35 NA ligand NA drugbank puromycin aminonucleoside-5'-monophosphate small molecule NA experimental 60s ribosomal protein l37 RPL37 NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l37 RPL37 NA unknown NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l37 RPL37 NA unknown NA drugbank virginiamycin s1 small molecule NA experimental 60s ribosomal protein l37 RPL37 NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l37 RPL37 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 60s ribosomal protein l4 RPL4 NA ligand NA drugbank anisomycin small molecule NA experimental 60s ribosomal protein l8 RPL8 NA unknown NA drugbank puromycin small molecule NA experimental 60s ribosomal protein l8 RPL8 NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental 60s ribosomal protein l8 RPL8 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s13 RPS13 NA ligand NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s17 RPS17 NA ligand NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s18 RPS18 NA ligand NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s19 RPS19 NA ligand NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 40s ribosomal protein s2 RPS2 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s28 RPS28 NA ligand NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s5 RPS5 NA ligand NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s6 RPS6 NA ligand NA drugbank bi-d1870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] preclinical ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target unknown 4.55 TTD , DGIDB 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1 NA NA patented ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target unknown NA TTD , DGIDB purvalanol a small molecule NA experimental ribosomal protein s6 kinase alpha-1 RPS6KA1 NA unknown NA drugbank 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2 NA NA patented ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ribosomal protein s6 kinase alpha-1 RPS6KA1 NA inhibitor NA drugbank pyrrolo[2,3-d]pyrimidine derivative 1 NA NA patented ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 2 NA NA patented ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target unknown NA TTD , DGIDB gsk-1838705a NA NA investigative ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target inhibitor NA TTD , DGIDB heterocyclic derivative 26 NA NA patented ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target unknown NA TTD , DGIDB bi-d1870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] preclinical ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target inhibitor 4.55 TTD , DGIDB pmid19364658c33 NA NA investigative ribosomal protein s6 kinase alpha-1 RPS6KA1 Patented-recorded target unknown NA TTD bi-d1870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] preclinical ribosomal protein s6 kinase alpha-2 RPS6KA2 Literature-reported target inhibitor 31.83 TTD , DGIDB bi-d1870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] preclinical ribosomal protein s6 kinase alpha-2 RPS6KA2 Literature-reported target unknown 31.83 TTD , DGIDB pmid22564207c25b NA NA investigative ribosomal protein s6 kinase alpha-2 RPS6KA2 Literature-reported target unknown NA TTD pmid22564207c25b NA NA investigative ribosomal protein s6 kinase alpha-3 RPS6KA3 Patented-recorded target unknown NA TTD pmid22765894c8h NA NA investigative ribosomal protein s6 kinase alpha-3 RPS6KA3 Patented-recorded target unknown NA TTD bix 02565 NA NA investigative ribosomal protein s6 kinase alpha-3 RPS6KA3 Patented-recorded target inhibitor NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 35 NA NA patented ribosomal protein s6 kinase alpha-3 RPS6KA3 Patented-recorded target unknown NA TTD , DGIDB pmid27410995-compound-figure3j NA NA patented ribosomal protein s6 kinase alpha-3 RPS6KA3 Patented-recorded target unknown NA TTD , DGIDB bi-d1870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] preclinical ribosomal protein s6 kinase alpha-3 RPS6KA3 Patented-recorded target unknown 0.94 TTD , DGIDB indole-based analog 14 NA NA patented ribosomal protein s6 kinase alpha-3 RPS6KA3 Patented-recorded target unknown NA TTD , DGIDB bi-d1870 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] preclinical ribosomal protein s6 kinase alpha-3 RPS6KA3 Patented-recorded target inhibitor 0.94 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ribosomal protein s6 kinase alpha-3 RPS6KA3 NA inhibitor NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved ribosomal protein s6 kinase alpha-3 RPS6KA3 NA inhibitor NA drugbank flavin mononucleotide small molecule NA approved,investigational ribosomal protein s6 kinase alpha-4 RPS6KA4 NA unknown NA drugbank us9365572, 5 NA NA patented ribosomal protein s6 kinase alpha-5 RPS6KA5 Patented-recorded target unknown NA TTD , DGIDB pmid15955699c24 NA NA investigative ribosomal protein s6 kinase alpha-5 RPS6KA5 Patented-recorded target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ribosomal protein s6 kinase alpha-6 RPS6KA6 NA inhibitor NA drugbank pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1 NA NA patented ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD , DGIDB kt-5720 NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD ro31-8220 NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD pmid27410995-compound-figure3c NA NA patented ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD , DGIDB sb-415286 NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD ro-316233 NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD pf-4708671 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] clinical trial ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target inhibitor NA TTD , DGIDB ci-1040 NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown 0.09 TTD , DGIDB actb-1003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD m2698 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown 0.66 TTD , DGIDB 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD pmid20005102c1 NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD pf-4708671 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] clinical trial ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD , DGIDB 4-[(3,5-diamino-1h-pyrazol-4-yl)diazenyl]phenol NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD kn-62 NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD sb-747651a NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD staurosporinone NA NA investigative ribosomal protein s6 kinase beta-1 RPS6KB1 Clinical trial target unknown NA TTD pmd-026 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],ANOPHTHALMIA AND PULMONARY HYPOPLASIA[MeSHID:C537768],Neoplasm Metastasis[MeSHID:D009362],Pelizaeus-Merzbacher Disease[MeSHID:D020371],Triple Negative Breast Neoplasms[MeSHID:D064726],Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943] phase 1 ribosomal protein s6 kinase beta-2 RPS6KB2 Clinical trial target unknown NA TTD artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s8 RPS8 NA ligand NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational 40s ribosomal protein s9 RPS9 NA ligand NA drugbank tigapotide biotech Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigational 40s ribosomal protein sa RPSA NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 40s ribosomal protein sa RPSA NA unknown NA drugbank pmid25747044-compound-mirna NA NA patented laminin receptor 37/67kda RPSA Patented-recorded target unknown NA TTD , DGIDB radezolid small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pneumonia[MeSHID:D011014] investigational ribosome-binding protein 1 RRBP1 NA unknown NA drugbank gemcitabine small molecule Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Severe Acute Respiratory Syndrome[MeSHID:D045169],Middle East Respiratory Syndrome[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ribonucleoside-diphosphate reductase large subunit RRM1 NA inhibitor 1.07 drugbank , DGIDB fludarabine small molecule Chronic Lymphocytic Leukemia[MeSHID:D015451],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved ribonucleoside-diphosphate reductase large subunit RRM1 NA inhibitor 1.59 drugbank , DGIDB lor-2501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 rrm1 messenger rna RRM1 Discontinued target unknown NA TTD tezacitabine small molecule Malignant neoplasm of stomach[MeSHID:D013274],leukemia[MeSHID:D007938],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of lung[MeSHID:D008175] investigational ribonucleoside-diphosphate reductase large subunit RRM1 NA inhibitor 3.03 drugbank , DGIDB gallium maltolate small molecule Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant neoplasm of prostate[MeSHID:D011471],Osteitis Deformans[MeSHID:D010001],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigational ribonucleoside-diphosphate reductase large subunit RRM1 NA unknown NA drugbank clofarabine small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphocyte[MeSHID:D008214],Relapse[MeSHID:D012008],Lymphoid leukemia[MeSHID:D007945],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational ribonucleoside-diphosphate reductase large subunit RRM1 NA inhibitor 6.57 drugbank , DGIDB imexon small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of ovary[MeSHID:D010051],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] investigational ribonucleoside-diphosphate reductase large subunit RRM1 NA unknown NA drugbank cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational ribonucleoside-diphosphate reductase large subunit RRM1 NA inhibitor 2.12 drugbank , DGIDB gemcitabine small molecule Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved ribonucleoside-diphosphate reductase large subunit RRM1 NA inhibitor 1.07 drugbank , DGIDB hydroxyurea small molecule Disease Management[MeSHID:D019468],Epithelial ovarian cancer[MeSHID:C538090],melanoma[MeSHID:D008545],Anemia, Sickle Cell[MeSHID:D000755],Recurrence (disease attribute)[MeSHID:D012008],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ribonucleoside-diphosphate reductase large subunit RRM1 NA inhibitor 2.6 drugbank , DGIDB nkp-46 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown NA TTD , DGIDB calaa-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown NA TTD , DGIDB imexon small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of ovary[MeSHID:D010051],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] investigational ribonucleoside-diphosphate reductase subunit m2 RRM2 NA unknown NA drugbank gemcitabine NA Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved ribonucleoside-diphosphate reductase m2 RRM2 Successful target inhibitor 0.18 TTD , DGIDB gti 2040 small molecule Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943] investigational ribonucleoside-diphosphate reductase subunit m2 RRM2 NA unknown NA drugbank gemcitabine NA Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Severe Acute Respiratory Syndrome[MeSHID:D045169],Middle East Respiratory Syndrome[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ribonucleoside-diphosphate reductase m2 RRM2 Successful target inhibitor 0.18 TTD , DGIDB gallium maltolate NA Malignant neoplasm of urinary bladder[MeSHID:D001749],Lymphoma[MeSHID:D008223],Malignant neoplasm of prostate[MeSHID:D011471],Osteitis Deformans[MeSHID:D010001],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] discontinued in phase 2 ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown NA TTD hydroxyurea NA Disease Management[MeSHID:D019468],Epithelial ovarian cancer[MeSHID:C538090],melanoma[MeSHID:D008545],Anemia, Sickle Cell[MeSHID:D000755],Recurrence (disease attribute)[MeSHID:D012008],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown 1.05 TTD , DGIDB gemcitabine NA Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown 0.18 TTD , DGIDB co-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2 ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown 4.9 TTD , DGIDB hydroxyurea NA Disease Management[MeSHID:D019468],Epithelial ovarian cancer[MeSHID:C538090],melanoma[MeSHID:D008545],Anemia, Sickle Cell[MeSHID:D000755],Recurrence (disease attribute)[MeSHID:D012008],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ribonucleoside-diphosphate reductase m2 RRM2 Successful target inhibitor 1.05 TTD , DGIDB gemcitabine NA Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Severe Acute Respiratory Syndrome[MeSHID:D045169],Middle East Respiratory Syndrome[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown 0.18 TTD , DGIDB triapine NA Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] phase 2 ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown 4.9 TTD , DGIDB cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational ribonucleoside-diphosphate reductase subunit m2 RRM2 NA inhibitor 2.28 drugbank , DGIDB mdl 101,731 NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown NA TTD gallium nitrate small molecule Hypercalcemia[MeSHID:D006934],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational ribonucleoside-diphosphate reductase subunit m2 RRM2 NA inhibitor 6.53 drugbank , DGIDB motexafin gadolinium small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of brain[MeSHID:D001932],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigational ribonucleoside-diphosphate reductase subunit m2 RRM2 NA unknown NA drugbank , DGIDB ly-2334737 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ribonucleoside-diphosphate reductase m2 RRM2 Successful target unknown 4.9 TTD , DGIDB cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational ribonucleoside-diphosphate reductase subunit m2 b RRM2B NA inhibitor 3.3 drugbank , DGIDB anisomycin small molecule NA experimental probable ribosome biogenesis protein rlp24 RSL24D1 NA unknown NA drugbank (s)-3-phenyllactic acid small molecule NA experimental probable ribosome biogenesis protein rlp24 RSL24D1 NA unknown NA drugbank puromycin small molecule NA experimental probable ribosome biogenesis protein rlp24 RSL24D1 NA unknown NA drugbank nu-206 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Diseases[MeSHID:D005767] phase 1 roof plate-specific spondin-1 RSPO1 Clinical trial target unknown NA TTD , DGIDB rosmantuzumab NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 r-spondin-3 RSPO3 Clinical trial target unknown 63.65 TTD , DGIDB omp-131r10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 r-spondin-3 RSPO3 Clinical trial target unknown NA TTD sucrose small molecule NA approved,experimental,investigational trna-splicing ligase rtcb homolog RTCB NA unknown NA drugbank ati-355 NA Traumatic injury[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nerve Tissue[MeSHID:D009417] phase 1 reticulon-4 RTN4 Clinical trial target unknown 63.65 TTD , DGIDB quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational ruvb-like 2 RUVBL2 NA unknown NA drugbank ml290 NA NA investigative relaxin receptor 1 RXFP1 Clinical trial target allosteric modulator NA TTD , DGIDB rlx030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] approval submitted relaxin receptor 1 RXFP1 Clinical trial target unknown 4.55 TTD , DGIDB 135pam1 NA NA investigative relaxin-3 receptor 1 RXFP3 Literature-reported target allosteric modulator NA TTD , DGIDB bexarotene small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-alpha RXRA Successful target agonist 1.57 TTD , drugbank , DGIDB tributylstannanyl NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target unknown NA TTD phthalic acid small molecule NA experimental retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor rxr-alpha RXRA NA agonist 0.87 drugbank , DGIDB bezafibrate small molecule Diabetes Mellitus[MeSHID:D003920],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Neoplasm Metastasis[MeSHID:D009362],Atherosclerosis[MeSHID:D050197],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-alpha RXRA NA agonist NA drugbank methoprene acid NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target agonist NA TTD , DGIDB etodolac small molecule Disease Management[MeSHID:D019468],Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational,vet_approved retinoic acid receptor rxr-alpha RXRA NA other NA drugbank rosiglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank 3,20-pregnanedione small molecule NA experimental retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank (5beta)-pregnane-3,20-dione NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target unknown NA TTD alfacalcidol small molecule Disease Management[MeSHID:D019468],Adult Rickets[MeSHID:D010018],Hypocalcemia[MeSHID:D006996],Malabsorption Syndrome[MeSHID:D008286],Hypophosphatemic Rickets, X-Linked Dominant[MeSHID:D053098],Vitamin D-resistant rickets[MeSHID:D063730],Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],Rickets[MeSHID:D012279],Kidney Failure, Chronic[MeSHID:D007676] approved,nutraceutical retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank evt-101 small molecule Pain[MeSHID:D010146],Parkinson Disease[MeSHID:D010300],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank pa451 NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target antagonist NA TTD , DGIDB 2-chloro-5-nitro-n-phenylbenzamide small molecule NA experimental,investigative retinoic acid receptor rxr-alpha RXRA Successful target unknown NA TTD , drugbank oleic acid small molecule NA approved,investigational,vet_approved retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank acitretin small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor rxr-alpha RXRA NA agonist 0.16 drugbank , DGIDB alpha-linolenic acid small molecule NA approved,investigational,nutraceutical retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank arachidonic acid small molecule NA experimental retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank uvi3003 NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target unknown NA TTD cd3254 NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target unknown NA TTD lg100754 NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target antagonist NA TTD , DGIDB agn-34 NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target unknown NA TTD bexarotene small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-alpha RXRA Successful target agonist,activator 1.57 TTD , drugbank , DGIDB tributyltin small molecule NA experimental retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank doconexent small molecule NA approved,investigational retinoic acid receptor rxr-alpha RXRA NA activator 0.58 drugbank , DGIDB tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid receptor rxr-alpha RXRA NA unknown 0.05 drugbank , DGIDB 2-[(2,4-dichlorobenzoyl)amino]-5-(pyrimidin-2-yloxy)benzoic acid small molecule NA experimental retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank phytanic acid NA NA investigative retinoic acid receptor rxr-alpha RXRA Successful target unknown 1.74 TTD , DGIDB alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational retinoic acid receptor rxr-alpha RXRA Successful target agonist 1.45 TTD , drugbank , DGIDB etretinate small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Keratosis[MeSHID:D007642] withdrawn retinoic acid receptor rxr-alpha RXRA NA agonist 0.5 drugbank , DGIDB 1-benzyl-3-(4-methoxyphenylamino)-4-phenylpyrrole-2,5-dione small molecule NA experimental retinoic acid receptor rxr-alpha RXRA NA unknown NA drugbank bexarotene small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-beta RXRB NA agonist 11.32 drugbank , DGIDB alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational retinoic acid receptor rxr-beta RXRB Successful target agonist 7.86 TTD , drugbank , DGIDB rosiglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational retinoic acid receptor rxr-beta RXRB NA unknown NA drugbank lg100754 NA NA investigative retinoic acid receptor rxr-beta RXRB Successful target antagonist NA TTD , DGIDB doconexent small molecule NA approved,investigational retinoic acid receptor rxr-beta RXRB NA activator NA drugbank lg-100268 small molecule NA experimental retinoic acid receptor rxr-beta RXRB NA unknown NA drugbank n-(tert-butyl)-3,5-dimethyl-n'-[(5-methyl-2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]benzohydrazide small molecule NA experimental retinoic acid receptor rxr-beta RXRB NA unknown NA drugbank bezafibrate small molecule Diabetes Mellitus[MeSHID:D003920],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Neoplasm Metastasis[MeSHID:D009362],Atherosclerosis[MeSHID:D050197],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-beta RXRB NA agonist NA drugbank to-901317 small molecule NA experimental retinoic acid receptor rxr-beta RXRB NA unknown NA drugbank etretinate small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Keratosis[MeSHID:D007642] withdrawn retinoic acid receptor rxr-beta RXRB NA agonist 3.03 drugbank , DGIDB (2e,4e)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoic acid small molecule NA experimental retinoic acid receptor rxr-beta RXRB NA unknown NA drugbank agn-34 NA NA investigative retinoic acid receptor rxr-beta RXRB Successful target unknown NA TTD adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor rxr-beta RXRB NA agonist 8.08 drugbank , DGIDB acitretin small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor rxr-beta RXRB NA agonist 1.33 drugbank , DGIDB bexarotene small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-beta RXRB NA agonist,activator 11.32 drugbank , DGIDB phthalic acid small molecule NA experimental retinoic acid receptor rxr-beta RXRB NA unknown NA drugbank tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid receptor rxr-beta RXRB NA agonist 1.5 drugbank , DGIDB tazarotene small molecule Acne Vulgaris[MeSHID:D000152],Sunlight[MeSHID:D013472],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-beta RXRB NA agonist 4.42 drugbank , DGIDB rosiglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved,investigational retinoic acid receptor rxr-gamma RXRG NA unknown NA drugbank adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor rxr-gamma RXRG NA agonist 9.09 drugbank , DGIDB phthalic acid small molecule NA experimental retinoic acid receptor rxr-gamma RXRG NA unknown NA drugbank bexarotene small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-gamma RXRG NA agonist 11.14 drugbank , DGIDB irx4204 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943] phase 1 retinoic acid receptor rxr-gamma RXRG Successful target unknown NA TTD , DGIDB alitretinoin small molecule AIDS with Kaposi's sarcoma[MeSHID:C554498],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kaposi Sarcoma[MeSHID:D012514] approved,investigational retinoic acid receptor rxr-gamma RXRG Successful target agonist 8.84 TTD , drugbank , DGIDB bexarotene small molecule Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-gamma RXRG NA agonist,activator 11.14 drugbank , DGIDB nrx-4204 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 retinoic acid receptor rxr-gamma RXRG Successful target unknown NA TTD , DGIDB vitamin a NA Vitamin A Deficiency[MeSHID:D014802],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Night Blindness[MeSHID:D009755] approved retinoic acid receptor rxr-gamma RXRG Successful target unknown NA TTD , DGIDB bezafibrate small molecule Diabetes Mellitus[MeSHID:D003920],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Arteriosclerosis[MeSHID:D001161],Neoplasm Metastasis[MeSHID:D009362],Atherosclerosis[MeSHID:D050197],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational retinoic acid receptor rxr-gamma RXRG NA agonist NA drugbank 9cuab-30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 retinoic acid receptor rxr-gamma RXRG Successful target unknown NA TTD , DGIDB etretinate small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Keratosis[MeSHID:D007642] withdrawn retinoic acid receptor rxr-gamma RXRG NA agonist 4.55 drugbank , DGIDB agn-34 NA NA investigative retinoic acid receptor rxr-gamma RXRG Successful target unknown NA TTD tretinoin small molecule Skin Wrinkling[MeSHID:D015595],Palmoplantar Keratosis[MeSHID:D007645],Ichthyosis Vulgaris[MeSHID:D016112],Acne Vulgaris[MeSHID:D000152],Senility[MeSHID:D000375],Hyperkeratosis, Epidermolytic[MeSHID:D017488],Psoriasis[MeSHID:D011565],Keratosis Follicularis[MeSHID:D007644],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Dermatologic disorders[MeSHID:D012871],Keratoderma, Palmoplantar, Diffuse[MeSHID:D015776],Seborrheic keratosis[MeSHID:D017492],Hyperpigmentation[MeSHID:D017495],Warts[MeSHID:D014860],Congenital Nonbullous Ichthyosiform Erythroderma[MeSHID:D017490],Acute Promyelocytic Leukemia[MeSHID:D015473],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,nutraceutical retinoic acid receptor rxr-gamma RXRG NA agonist 1.69 drugbank , DGIDB doconexent small molecule NA approved,investigational retinoic acid receptor rxr-gamma RXRG NA activator NA drugbank lg100754 NA NA investigative retinoic acid receptor rxr-gamma RXRG Successful target unknown NA TTD acitretin small molecule Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved retinoic acid receptor rxr-gamma RXRG NA agonist 1.99 drugbank , DGIDB ruthenium red NA NA investigative ryanodine receptor 1 RYR1 Discontinued target blocker NA TTD , DGIDB (o10eq)-beta-alanyl-anhydro-ryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD n-methyl ryanodine-succinamidate NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD benzyloxycarbonyl-glycylryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD dantrolene small molecule Disease Management[MeSHID:D019468],Skeletal muscle structure[MeSHID:D018482],Malignant hyperpyrexia due to anesthesia[MeSHID:D008305],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fever[MeSHID:D005334] approved,investigational ryanodine receptor 1 RYR1 NA antagonist 5.75 drugbank , DGIDB arm036 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] discontinued in phase 2 ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD di-benzyloxycarbonyl-guanidino acetylryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD (o10eq)-guanidino acetylryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD cdp-1050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] discontinued in phase 1 ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD ryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target blocker,activator 1.33 TTD , DGIDB suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational ryanodine receptor 1 RYR1 NA agonist,activator 0.21 drugbank , DGIDB (o10eq)-beta-alanylryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD anhydroryanidine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved ryanodine receptor 1 RYR1 NA activator 0.8 drugbank , DGIDB tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved ryanodine receptor 1 RYR1 NA modulator NA drugbank (o10eq)-beta-guanidinopropionylryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] investigational ryanodine receptor 1 RYR1 NA agonist,activator 0.21 drugbank , DGIDB (o10eq)-benzyloxycarbonyl-beta-alanylryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD glycylryanodine NA NA investigative ryanodine receptor 1 RYR1 Discontinued target unknown NA TTD caffeine small molecule Respiratory Depression[MeSHID:D012131],Premature Birth[MeSHID:D047928],Drug Overdose[MeSHID:D062787],Apnea[MeSHID:D001049],Pain[MeSHID:D010146],Bronchopulmonary Dysplasia[MeSHID:D001997],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypotension, Orthostatic[MeSHID:D007024] approved ryanodine receptor 1 RYR1 NA unknown 0.8 drugbank , DGIDB flecainide small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn ryanodine receptor 2 RYR2 NA inhibitor NA drugbank tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved ryanodine receptor 2 RYR2 NA modulator NA drugbank olopatadine small molecule Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved protein s100-a1 S100A1 NA antagonist NA drugbank phenethyl isothiocyanate small molecule NA investigational protein s100-a10 S100A10 NA unknown NA drugbank phosphonothreonine small molecule NA experimental protein s100-a11 S100A11 NA unknown NA drugbank olopatadine small molecule Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved protein s100-a12 S100A12 NA antagonist NA drugbank atogepant NA Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2/3 calgranulin d S100A12 Clinical trial target unknown 12.73 TTD , DGIDB amlexanox small molecule Paste substance[MeSHID:D009824],Aphthous Stomatitis[MeSHID:D013281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] approved,investigational,withdrawn protein s100-a12 S100A12 NA antagonist NA drugbank olopatadine small molecule Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved protein s100-a13 S100A13 NA unknown NA drugbank calcium phosphate small molecule NA approved protein s100-a13 S100A13 NA ligand NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical protein s100-a13 S100A13 NA unknown NA drugbank calcium phosphate dihydrate small molecule NA approved protein s100-a13 S100A13 NA unknown NA drugbank calcium chloride small molecule Disease[MeSHID:D004194],Hyperkalemia[MeSHID:D006947],Hypocalcemia[MeSHID:D006996],Extracellular Fluid[MeSHID:D045604],Electrocardiogram[MeSHID:D004562],Plasma[MeSHID:D010949],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein s100-a13 S100A13 NA unknown NA drugbank amlexanox small molecule Paste substance[MeSHID:D009824],Aphthous Stomatitis[MeSHID:D013281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory tract structure[MeSHID:D012137],Inflammation[MeSHID:D007249] approved,investigational,withdrawn protein s100-a13 S100A13 NA antagonist NA drugbank calcium citrate small molecule NA approved,investigational protein s100-a13 S100A13 NA ligand NA drugbank calcium phosphate small molecule NA approved protein s100-a16 S100A16 NA ligand NA drugbank calcium citrate small molecule NA approved,investigational protein s100-a16 S100A16 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved protein s100-a16 S100A16 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental protein s100-a2 S100A2 NA inactivator,regulator NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational protein s100-a2 S100A2 NA inactivator,regulator NA drugbank olopatadine small molecule Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved protein s100-a2 S100A2 NA antagonist NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein s100-a2 S100A2 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational protein s100-a2 S100A2 NA unknown NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical protein s100-a2 S100A2 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational protein s100-a2 S100A2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein s100-a4 S100A4 NA unknown NA drugbank trifluoperazine small molecule Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational protein s100-a4 S100A4 NA inhibitor NA drugbank calcium citrate small molecule NA approved,investigational protein s100-a6 S100A6 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved protein s100-a6 S100A6 NA unknown NA drugbank calcium phosphate small molecule NA approved protein s100-a6 S100A6 NA ligand NA drugbank ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved protein s100-a7 S100A7 NA inducer NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational protein s100-a7 S100A7 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational protein s100-a7 S100A7 NA binder NA drugbank 8-anilinonaphthalene-1-sulfonic acid small molecule NA experimental protein s100-a7 S100A7 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental protein s100-a7 S100A7 NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational protein s100-a7 S100A7 NA unknown NA drugbank dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein s100-a7 S100A7 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein s100-a8 S100A8 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental protein s100-a8 S100A8 NA regulator NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational protein s100-a8 S100A8 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational protein s100-a8 S100A8 NA regulator NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical protein s100-a8 S100A8 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational protein s100-a8 S100A8 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational protein s100-a9 S100A9 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational protein s100-a9 S100A9 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental protein s100-a9 S100A9 NA regulator NA drugbank tasquinimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 calgranulin b S100A9 Clinical trial target unknown 31.83 TTD , DGIDB calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical protein s100-a9 S100A9 NA unknown NA drugbank paquinimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177] phase 2 calgranulin b S100A9 Clinical trial target unknown 31.83 TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational protein s100-a9 S100A9 NA regulator NA drugbank calcium phosphate dihydrate small molecule NA approved protein s100-b S100B NA unknown NA drugbank arundic acid small molecule Cerebral Ischemia[MeSHID:D002545],Cerebral Infarction[MeSHID:D002544] investigational protein s100-b S100B NA unknown NA drugbank 2-[(5-hex-1-yn-1-ylfuran-2-yl)carbonyl]-n-methylhydrazinecarbothioamide small molecule NA experimental protein s100-b S100B NA unknown NA drugbank calcium phosphate small molecule NA approved protein s100-b S100B NA ligand NA drugbank calcium citrate small molecule NA approved,investigational protein s100-b S100B NA ligand NA drugbank (z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide small molecule NA experimental protein s100-b S100B NA unknown NA drugbank n-formylmethionine small molecule NA experimental protein s100-b S100B NA unknown NA drugbank ono-2506 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Cerebrovascular accident[MeSHID:D020521],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Expiration, function[MeSHID:D045853] phase 2/3 s100 calcium-binding protein b S100B Clinical trial target unknown NA TTD , DGIDB olopatadine small molecule Hay fever[MeSHID:D006255],Nose[MeSHID:D009666],Pruritus[MeSHID:D011537],Allergic Conjunctivitis[MeSHID:D003233],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967],Eye[MeSHID:D005123] approved protein s100-b S100B NA unknown NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical protein s100-b S100B NA unknown NA drugbank n-formylmethionine small molecule NA experimental protein s100-g S100G NA unknown NA drugbank cromoglicic acid small molecule Disease Management[MeSHID:D019468],Conjunctivitis, Vernal[MeSHID:D003233],Asthma[MeSHID:D001249],Keratitis[MeSHID:D007634],Natural Springs[MeSHID:D060985] approved protein s100-p S100P NA antagonist NA drugbank 1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD cym5442 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist NA TTD , DGIDB ozanimod small molecule Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Multiple Sclerosis[MeSHID:D009103],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Crohn Disease[MeSHID:D003424] approved,investigational sphingosine 1-phosphate receptor 1 S1PR1 NA agonist 3.64 drugbank , DGIDB sar247799 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist NA TTD , DGIDB ozanimod NA Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Multiple Sclerosis[MeSHID:D009103],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Crohn Disease[MeSHID:D003424] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 3.64 TTD , DGIDB bms-520 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD asp-4058 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 1.52 TTD , DGIDB afd(r) NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist NA TTD , DGIDB gnf-pf-826 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD fingolimod NA Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist 7.58 TTD , DGIDB pf-4629991 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD krp 203-phosphate NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD [3-(4-nonyl-benzylamino)-propyl]-phosphonic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD gsk-2018682 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 3.03 TTD , DGIDB auy954 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist NA TTD , DGIDB cs-0777 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD , DGIDB krp-107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD ponesimod NA Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 3.03 TTD , DGIDB siponimod small molecule Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational sphingosine 1-phosphate receptor 1 S1PR1 NA agonist 3.64 drugbank , DGIDB 3-(n-alkylamino) propylphosphonic acid derivative NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD gsk-1842799c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD siponimod NA Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist 3.64 TTD , DGIDB krp-203 NA Lupus Erythematosus, Cutaneous[MeSHID:D008178],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 6.06 TTD , DGIDB ponesimod small molecule Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] approved,investigational sphingosine 1-phosphate receptor 1 S1PR1 NA agonist,modulator,regulator 3.03 drugbank , DGIDB fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational sphingosine 1-phosphate receptor 1 S1PR1 NA modulator,agonist 7.58 drugbank , DGIDB mt-1303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Multiple Sclerosis[MeSHID:D009103] phase 2 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 1.21 TTD , DGIDB fingolimod NA Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 7.58 TTD , DGIDB lpa NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist NA TTD , DGIDB fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sphingosine 1-phosphate receptor 1 S1PR1 NA modulator 7.58 drugbank , DGIDB ponesimod NA Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist 3.03 TTD , DGIDB 1-(4-nonylbenzyl)azetidine-3-carboxylic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD sew2871 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist NA TTD , DGIDB sphingosine-1-phosphate NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD , DGIDB 1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD apd-334 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Diabetes, Autoimmune[MeSHID:D003922],Pyoderma Gangrenosum[MeSHID:D017511] phase 3 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 2.02 TTD , DGIDB vpc23019 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target antagonist NA TTD , DGIDB nibr-0213 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target antagonist NA TTD , DGIDB fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational sphingosine 1-phosphate receptor 1 S1PR1 NA modulator 7.58 drugbank , DGIDB 3-amino-5-(4-octylphenyl)pentanoic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD (3-tetradecylamino-cyclohexyl)-phosphonic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sphingosine 1-phosphate receptor 1 S1PR1 NA modulator,agonist 7.58 drugbank , DGIDB (s)-fty720p NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 6.06 TTD , DGIDB nibr-785 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD 3-(tetradecylamino)propylphosphonic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD w146 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target antagonist NA TTD , DGIDB vpc03090-p NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target antagonist NA TTD , DGIDB ono-4641 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD , DGIDB vpc44116 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target antagonist NA TTD , DGIDB nox-s91 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD gnf-pf-78 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 0.3 TTD , DGIDB fingolimod NA Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist 7.58 TTD , DGIDB sar247799 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD , DGIDB fty720-phosphate NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD 4-amino-6-(4-octylphenyl)hexanoic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD (3-tetradecylamino-cyclopentyl)-phosphonic acid NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD fingolimod NA Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 7.58 TTD , DGIDB amg-247 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown NA TTD sonepcizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 3.03 TTD , DGIDB cym5181 NA NA investigative sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist NA TTD , DGIDB ozanimod NA Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Multiple Sclerosis[MeSHID:D009103],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Crohn Disease[MeSHID:D003424] approved sphingosine-1-phosphate receptor 1 S1PR1 Successful target agonist 3.64 TTD , DGIDB bms-986104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 sphingosine-1-phosphate receptor 1 S1PR1 Successful target unknown 3.03 TTD , DGIDB jte 013 NA NA patented sphingosine-1-phosphate receptor 2 S1PR2 Patented-recorded target unknown NA TTD , DGIDB us8975409, comparative compound b NA NA patented sphingosine-1-phosphate receptor 2 S1PR2 Patented-recorded target unknown NA TTD , DGIDB auy954 NA NA investigative sphingosine-1-phosphate receptor 2 S1PR2 Patented-recorded target unknown NA TTD unii-r228s06soh NA NA patented sphingosine-1-phosphate receptor 2 S1PR2 Patented-recorded target unknown NA TTD , DGIDB schembl15295829 NA NA patented sphingosine-1-phosphate receptor 2 S1PR2 Patented-recorded target unknown NA TTD , DGIDB us8975409, example 9(3) NA NA patented sphingosine-1-phosphate receptor 2 S1PR2 Patented-recorded target unknown NA TTD , DGIDB us8975409, example 13 NA NA patented sphingosine-1-phosphate receptor 2 S1PR2 Patented-recorded target unknown NA TTD , DGIDB fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sphingosine 1-phosphate receptor 3 S1PR3 NA modulator NA drugbank fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational sphingosine 1-phosphate receptor 3 S1PR3 NA modulator NA drugbank fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational sphingosine 1-phosphate receptor 4 S1PR4 NA modulator NA drugbank fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sphingosine 1-phosphate receptor 4 S1PR4 NA modulator NA drugbank auy954 NA NA investigative sphingosine-1-phosphate receptor 5 S1PR5 Clinical trial target agonist NA TTD , DGIDB afd(r) NA NA investigative sphingosine-1-phosphate receptor 5 S1PR5 Clinical trial target agonist NA TTD , DGIDB siponimod small molecule Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational sphingosine 1-phosphate receptor 5 S1PR5 NA modulator,agonist 7.96 drugbank , DGIDB fty720-phosphate NA NA investigative sphingosine-1-phosphate receptor 5 S1PR5 Clinical trial target unknown NA TTD ozanimod small molecule Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Multiple Sclerosis[MeSHID:D009103],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Crohn Disease[MeSHID:D003424] approved,investigational sphingosine 1-phosphate receptor 5 S1PR5 NA agonist 6.37 drugbank , DGIDB fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Multiple Sclerosis, Primary Progressive[MeSHID:D020528],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sphingosine 1-phosphate receptor 5 S1PR5 NA modulator,agonist 11.93 drugbank , DGIDB vpc03090-p NA NA investigative sphingosine-1-phosphate receptor 5 S1PR5 Clinical trial target agonist NA TTD , DGIDB fingolimod small molecule Disease[MeSHID:D004194],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Multiple Sclerosis[MeSHID:D009103],Neoplasm Metastasis[MeSHID:D009362],Syndrome[MeSHID:D013577],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational sphingosine 1-phosphate receptor 5 S1PR5 NA modulator,agonist 11.93 drugbank , DGIDB asp-4058 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 1 sphingosine-1-phosphate receptor 5 S1PR5 Clinical trial target unknown 3.98 TTD , DGIDB vpc44116 NA NA investigative sphingosine-1-phosphate receptor 5 S1PR5 Clinical trial target agonist NA TTD , DGIDB guanosine-5'-diphosphate small molecule NA experimental gtp-binding protein sar1b SAR1B NA unknown NA drugbank serine small molecule NA investigational,nutraceutical serine--trna ligase, cytoplasmic SARS NA unknown NA drugbank n-ethyl-n-[3-(propylamino)propyl]propane-1,3-diamine small molecule NA experimental diamine acetyltransferase 1 SAT1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase sbk1 SBK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational uncharacterized serine/threonine-protein kinase sbk3 SBK3 NA inhibitor NA drugbank phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical scavenger receptor class b member 1 SCARB1 NA unknown NA drugbank aramchol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 2/3 acyl-coa desaturase SCD Successful target unknown 12.73 TTD , DGIDB isis 147919 NA NA investigative acyl-coa desaturase SCD Successful target unknown NA TTD 2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide NA NA investigative acyl-coa desaturase SCD Successful target unknown NA TTD sterculic acid NA NA investigative acyl-coa desaturase SCD Successful target unknown NA TTD cvt-12012 NA Vertical talus, congenital[MeSHID:D005413],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] investigative acyl-coa desaturase SCD Successful target unknown NA TTD mf-152 NA NA investigative acyl-coa desaturase SCD Successful target unknown NA TTD isoxyl NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved acyl-coa desaturase SCD Successful target unknown NA TTD , DGIDB mk-8245 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 acyl-coa desaturase SCD Successful target unknown 4.24 TTD , DGIDB 4,4'-bis([h]methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl small molecule NA experimental uteroglobin SCGB1A1 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical selenocysteine lyase SCLY NA cofactor NA drugbank mercaptoethanol small molecule NA experimental polycomb protein scmh1 SCMH1 NA unknown NA drugbank batrachotoxin NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target activator NA TTD , DGIDB pd-32577 NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN10A NA inhibitor NA drugbank orphenadrine small molecule Acute onset pain[MeSHID:D059787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor NA drugbank tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN10A NA blocker 0.15 drugbank , DGIDB lacosamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved sodium channel protein type 10 subunit alpha SCN10A NA blocker 0.14 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN10A NA inhibitor NA drugbank dsp-2230 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target blocker 0.84 TTD , DGIDB lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor,blocker 0.31 drugbank , DGIDB amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN10A NA blocker NA drugbank cr-4892 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN10A NA blocker NA drugbank rilpivirine NA treatment failure[MeSHID:D017211],HIV Seropositivity[MeSHID:D006679],HIV Infections[MeSHID:D015658],Cells[MeSHID:D002477],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown 0.84 TTD , DGIDB proparacaine small molecule Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 2.51 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN10A NA inhibitor,blocker 0.02 drugbank , DGIDB proparacaine NA Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown 2.51 TTD , DGIDB pf-01247324 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD , DGIDB dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN10A NA antagonist NA drugbank levobupivacaine small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Pain, Postoperative[MeSHID:D010149],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 1.95 drugbank , DGIDB dsp-2230 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown 0.84 TTD , DGIDB sch-725737 NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD cinchocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525] approved,vet_approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor NA drugbank procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 1.47 drugbank , DGIDB ropivacaine NA Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown 1.01 TTD , DGIDB mepivacaine small molecule Cardiac Arrest[MeSHID:D006323],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 0.6 drugbank , DGIDB veratridine NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN10A NA inhibitor NA drugbank corus 1030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD sch-725739 NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN10A NA inhibitor NA drugbank a-803467 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD hexylcaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 2.09 drugbank , DGIDB 1-[5-(4-chlorophenyl)-2-furoyl]piperazine NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD vx-150 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN10A NA modulator NA drugbank vx-128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD , DGIDB bw-202w92 NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD tetracaine NA Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown 0.15 TTD , DGIDB tiapride NA Abnormal behavior[MeSHID:D000066553],Psychotic Disorders[MeSHID:D011618],Dyskinetic syndrome[MeSHID:D020820],Aggressive behavior[MeSHID:D000374],Substance Withdrawal Syndrome[MeSHID:D013375],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] approved voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown 0.42 TTD , DGIDB carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN10A NA inhibitor,blocker 0.02 drugbank , DGIDB lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 0.31 drugbank , DGIDB oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN10A NA inhibitor,blocker 0.04 drugbank , DGIDB dyclonine small molecule Reflex action[MeSHID:D012018],Vagina[MeSHID:D014621],Respiratory tract structure[MeSHID:D012137],Dental Health Services[MeSHID:D003752],Trachea[MeSHID:D014132],Pharyngeal structure[MeSHID:D010614],Esophagus[MeSHID:D004947],Larynx[MeSHID:D007830],Aphthous Stomatitis[MeSHID:D013281],Urinary tract[MeSHID:D014551],Gagging[MeSHID:D005683],Mucous Membrane[MeSHID:D009092],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 0.56 drugbank , DGIDB bupivacaine small molecule Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Decompression, external[MeSHID:D003664],Spatial Visualization[MeSHID:D065854],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,investigational sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 0.42 drugbank , DGIDB chloroprocaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 1.05 drugbank , DGIDB 5-(4-chlorophenyl)-n-(2-methylbenzyl)nicotinamide NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD n-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD conatumumab NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown 0.21 TTD , DGIDB sipatrigine NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD ropivacaine small molecule Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 1.01 drugbank , DGIDB tetracaine NA Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha nav1.8 SCN10A Successful target blocker 0.15 TTD , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN10A NA inhibitor NA drugbank cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN10A NA inhibitor 0.16 drugbank , DGIDB n-benzyl-5-(4-chlorophenyl)nicotinamide NA NA investigative voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown NA TTD benzocaine small molecule Traumatic injury[MeSHID:D014947],Pain[MeSHID:D010146],Disease[MeSHID:D004194],Hemorrhoids[MeSHID:D006484],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 2.93 drugbank , DGIDB fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN10A NA inhibitor NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN10A NA inhibitor,blocker 0.03 drugbank , DGIDB pf-01247324 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.8 SCN10A Successful target blocker NA TTD , DGIDB bupivacaine NA Diagnosis[MeSHID:D003933],Operative Surgical Procedures[MeSHID:D013514],Decompression, external[MeSHID:D003664],Spatial Visualization[MeSHID:D065854],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha nav1.8 SCN10A Successful target unknown 0.42 TTD , DGIDB pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN10A NA inhibitor NA drugbank oxybuprocaine small molecule Foreign Bodies[MeSHID:D005547],Eye[MeSHID:D005123],Pressure- physical agent[MeSHID:D011312],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 10 subunit alpha SCN10A NA inhibitor 1.4 drugbank , DGIDB propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN10A NA blocker NA drugbank hp-184 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.04 TTD , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN11A NA inhibitor NA drugbank amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN11A NA blocker NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN11A NA modulator NA drugbank eslicarbazepine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.21 TTD , DGIDB oxcarbazepine NA Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target blocker 0.11 TTD , DGIDB pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN11A NA blocker NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN11A NA inhibitor NA drugbank flecainide NA Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.15 TTD , DGIDB cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN11A NA inhibitor 0.2 drugbank , DGIDB brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN11A NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 11 subunit alpha SCN11A NA inhibitor 0.42 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 11 subunit alpha SCN11A NA inhibitor,blocker 0.42 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN11A NA inhibitor,blocker 0.02 drugbank , DGIDB iboctadekin + rituximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Follicular[MeSHID:D008224],Atrial Fibrillation[MeSHID:D001281], Non-Hodgkin[MeSHID:D008228] phase 1 voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown NA TTD , DGIDB dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN11A NA antagonist NA drugbank lidocaine NA Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target blocker 0.13 TTD , DGIDB pd-32577 NA NA investigative voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown NA TTD lidocaine NA Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.13 TTD , DGIDB oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN11A NA inhibitor 0.11 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN11A NA inhibitor 0.08 drugbank , DGIDB sb-221420-a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown NA TTD fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN11A NA inhibitor NA drugbank riluzole NA Amyotrophic Lateral Sclerosis[MeSHID:D000690],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target blocker 0.09 TTD , DGIDB eslicarbazepine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target blocker 0.21 TTD , DGIDB carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN11A NA inhibitor,blocker 0.02 drugbank , DGIDB tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN11A NA blocker 0.1 drugbank , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN11A NA inhibitor NA drugbank pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN11A NA inhibitor NA drugbank propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN11A NA blocker NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN11A NA inhibitor,blocker 0.11 drugbank , DGIDB lamotrigine NA Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.08 TTD , DGIDB lamotrigine NA Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target blocker 0.08 TTD , DGIDB lacosamide NA Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.18 TTD , DGIDB riluzole NA Amyotrophic Lateral Sclerosis[MeSHID:D000690],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.09 TTD , DGIDB oxcarbazepine NA Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.11 TTD , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN11A NA inhibitor,blocker 0.08 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN11A NA inhibitor NA drugbank tolperisone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target unknown 0.53 TTD , DGIDB lacosamide NA Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved voltage-gated sodium channel alpha nav1.9 SCN11A Successful target blocker 0.18 TTD , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel protein type 1 subunit alpha SCN1A NA inhibitor 0.18 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN1A NA inhibitor 0.19 drugbank , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN1A NA modulator NA drugbank phenazopyridine small molecule Insertion Mutation[MeSHID:D016254],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Traumatic injury[MeSHID:D014947],Urinary tract[MeSHID:D014551],Infection[MeSHID:D007239],Mucous Membrane[MeSHID:D009092],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved sodium channel protein type 1 subunit alpha SCN1A NA inhibitor NA drugbank brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN1A NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN1A NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN1A NA inhibitor 0.56 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN1A NA inhibitor 0.28 drugbank , DGIDB carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN1A NA inhibitor 0.37 drugbank , DGIDB tetrodotoxin small molecule Breakthrough Pain[MeSHID:D059390],Malignant Neoplasms[MeSHID:D009369],Opiate Addiction[MeSHID:D009293],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sodium channel protein type 1 subunit alpha SCN1A NA blocker 0.34 drugbank , DGIDB tetrodotoxin small molecule Breakthrough Pain[MeSHID:D059390],Malignant Neoplasms[MeSHID:D009369],Opiate Addiction[MeSHID:D009293],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sodium channel protein type 1 subunit alpha SCN1A NA unknown 0.34 drugbank , DGIDB permethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532],Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] approved,investigational sodium channel protein type 1 subunit alpha SCN1A NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN1A NA inhibitor,blocker 0.56 drugbank , DGIDB phenacemide small molecule Epilepsy[MeSHID:D004827],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 1 subunit alpha SCN1A NA inhibitor 0.72 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel protein type 1 subunit alpha SCN1A NA inhibitor,blocker 0.18 drugbank , DGIDB dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN1A NA antagonist NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN1A NA inhibitor,blocker 0.19 drugbank , DGIDB phenazopyridine small molecule Insertion Mutation[MeSHID:D016254],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Traumatic injury[MeSHID:D014947],Urinary tract[MeSHID:D014551],Infection[MeSHID:D007239],Mucous Membrane[MeSHID:D009092],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved sodium channel protein type 1 subunit alpha SCN1A NA inhibitor NA drugbank phenacemide small molecule Epilepsy[MeSHID:D004827],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 1 subunit alpha SCN1A NA inhibitor,blocker 0.72 drugbank , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN1A NA inhibitor NA drugbank pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN1A NA inhibitor NA drugbank tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN1A NA blocker 0.28 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN1A NA inhibitor NA drugbank pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN1A NA blocker NA drugbank cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN1A NA inhibitor NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN1A NA inhibitor NA drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 1 subunit alpha SCN1A NA inhibitor 0.49 drugbank , DGIDB nitrazepam small molecule Accidental Falls[MeSHID:D000058],Dyssomnias[MeSHID:D020920],Nocturia[MeSHID:D053158],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 1 subunit alpha SCN1A NA unknown 0.15 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN1A NA inhibitor,blocker 0.28 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 1 subunit alpha SCN1A NA inhibitor,blocker 0.49 drugbank , DGIDB propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN1A NA blocker NA drugbank amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN1A NA blocker NA drugbank carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN1A NA inhibitor,blocker 0.37 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN1A NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN1B NA inhibitor NA drugbank cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN1B NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel subunit beta-1 SCN1B NA inhibitor 22.14 drugbank , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN1B NA inhibitor NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN1B NA inhibitor NA drugbank dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN1B NA antagonist NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel subunit beta-1 SCN1B NA unknown NA drugbank brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN1B NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN1B NA inhibitor NA drugbank propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sodium channel protein type 2 subunit alpha SCN2A NA inhibitor 0.11 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN2A NA inhibitor NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN2A NA inhibitor NA drugbank tetrodotoxin small molecule Breakthrough Pain[MeSHID:D059390],Malignant Neoplasms[MeSHID:D009369],Opiate Addiction[MeSHID:D009293],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sodium channel protein type 2 subunit alpha SCN2A NA unknown 0.24 drugbank , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN2A NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 2 subunit alpha SCN2A NA inhibitor 0.42 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN2A NA inhibitor 0.33 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN2A NA inhibitor 0.1 drugbank , DGIDB tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN2A NA blocker 0.1 drugbank , DGIDB propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sodium channel protein type 2 subunit alpha SCN2A NA inhibitor 0.11 drugbank , DGIDB brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN2A NA inhibitor NA drugbank carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN2A NA inhibitor,blocker 0.11 drugbank , DGIDB fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN2A NA inhibitor NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel protein type 2 subunit alpha SCN2A NA inhibitor 0.19 drugbank , DGIDB tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 2 subunit alpha SCN2A NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN2A NA inhibitor,blocker 0.21 drugbank , DGIDB dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN2A NA antagonist NA drugbank propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN2A NA blocker NA drugbank pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN2A NA inhibitor NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN2A NA inhibitor,blocker 0.33 drugbank , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN2A NA modulator NA drugbank metergoline small molecule NA approved sodium channel protein type 2 subunit alpha SCN2A NA inhibitor NA drugbank phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel protein type 2 subunit alpha SCN2A NA inhibitor,blocker 0.19 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 2 subunit alpha SCN2A NA inhibitor,blocker 0.42 drugbank , DGIDB amylmetacresol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein type 2 subunit alpha SCN2A NA antagonist NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN2A NA inhibitor NA drugbank , DGIDB pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN2A NA blocker NA drugbank carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN2A NA inhibitor 0.11 drugbank , DGIDB cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN2A NA inhibitor NA drugbank amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN2A NA blocker NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN2A NA inhibitor 0.21 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN2A NA inhibitor,blocker 0.1 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel subunit beta-2 SCN2B NA inhibitor 22.14 drugbank , DGIDB cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN2B NA inhibitor NA drugbank dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN2B NA antagonist NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN2B NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN2B NA inhibitor NA drugbank brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN2B NA inhibitor NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN2B NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN2B NA inhibitor NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN3A NA inhibitor NA drugbank 5-hexyl-5-phenyl-imidazolidine-2,4-dione NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD aryl carboxamide derivative 2 NA NA patented voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD , DGIDB 4-biphenyl-4-yl-2-hexyl-1h-imidazole NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN3A NA inhibitor,blocker 0.05 drugbank , DGIDB cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN3A NA inhibitor NA drugbank lacosamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved sodium channel protein type 3 subunit alpha SCN3A NA blocker 0.18 drugbank , DGIDB pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN3A NA blocker NA drugbank rq-00203066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD 2-hexyl-4-(4-isobutyl-phenyl)-1h-imidazole NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD pyrimidine derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD , DGIDB lidoflazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown 0.27 TTD , DGIDB 5-heptyl-5-phenyl-imidazolidine-2,4-dione NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD 4-biphenyl-4-yl-2-cyclohexylmethyl-1h-imidazole NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN3A NA antagonist NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN3A NA inhibitor NA drugbank propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN3A NA blocker NA drugbank tetrodotoxin small molecule Breakthrough Pain[MeSHID:D059390],Malignant Neoplasms[MeSHID:D009369],Opiate Addiction[MeSHID:D009293],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sodium channel protein type 3 subunit alpha SCN3A NA blocker 0.35 drugbank , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN3A NA modulator NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN3A NA inhibitor NA drugbank bw-202w92 NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN3A NA inhibitor,blocker 0.04 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 3 subunit alpha SCN3A NA inhibitor,blocker 0.42 drugbank , DGIDB 5-nonyl-5-phenyl-imidazolidine-2,4-dione NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN3A NA inhibitor NA drugbank 5-ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN3A NA inhibitor NA drugbank 4-biphenyl-4-yl-2-(1-propyl-butyl)-1h-imidazole NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN3A NA inhibitor NA drugbank veratridine NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target activator 0.27 TTD , DGIDB l-741742 NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD batrachotoxin NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target activator NA TTD , DGIDB amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN3A NA blocker NA drugbank ccncsskwcrdhsrcc NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD 2-hydroxy-2-phenyl-nonanoic acid amide NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD tetrodotoxin small molecule Breakthrough Pain[MeSHID:D059390],Malignant Neoplasms[MeSHID:D009369],Opiate Addiction[MeSHID:D009293],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sodium channel protein type 3 subunit alpha SCN3A NA unknown 0.35 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel protein type 3 subunit alpha SCN3A NA blocker 0.08 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN3A NA inhibitor,blocker 0.02 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 3 subunit alpha SCN3A NA inhibitor 0.42 drugbank , DGIDB carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN3A NA inhibitor,blocker 0.02 drugbank , DGIDB sipatrigine NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD pyrrolo-pyridinone derivative 6 NA NA patented voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN3A NA inhibitor NA drugbank 4-biphenyl-4-yl-2-(1-pentyl-hexyl)-1h-imidazole NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD 2-(1-pentyl-hexyl)-4-phenyl-1h-imidazole NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN3A NA blocker 0.1 drugbank , DGIDB aryl carboxamide derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD , DGIDB pyrrolo-pyridinone derivative 5 NA NA patented voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD , DGIDB 4-biphenyl-4-yl-2-methyl-1h-imidazole NA NA investigative voltage-gated sodium channel alpha nav1.3 SCN3A Successful target unknown NA TTD ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN3B NA inhibitor NA drugbank cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN3B NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN3B NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN3B NA inhibitor NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN3B NA inhibitor NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel subunit beta-3 SCN3B NA inhibitor 22.14 drugbank , DGIDB brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN3B NA inhibitor NA drugbank dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN3B NA antagonist NA drugbank sipatrigine NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 4 subunit alpha SCN4A NA blocker 0.12 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN4A NA inhibitor,blocker 0.04 drugbank , DGIDB ccncaskwcrdhsrcc NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN4A NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN4A NA inhibitor,blocker 0.05 drugbank , DGIDB bw-202w92 NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD veratridine NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sodium channel protein type 4 subunit alpha SCN4A NA inhibitor 0.1 drugbank , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN4A NA inhibitor,blocker 0.14 drugbank , DGIDB carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN4A NA inhibitor,blocker 0.02 drugbank , DGIDB pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN4A NA blocker NA drugbank 3-(4-phenoxy-phenyl)-1h-pyrazole NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN4A NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN4A NA inhibitor NA drugbank v-102862 NA NA discontinued in phase 1 voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN4A NA blocker NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN4A NA inhibitor,blocker 0.02 drugbank , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN4A NA inhibitor NA drugbank ccncsskwcrdhsrcc NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD grayanotoxin iii NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN4A NA blocker NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN4A NA modulator NA drugbank 3-[4-(4-fluoro-phenoxy)-phenyl]-1h-pyrazole NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD ccncsskwcrahsrcc NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD parachlorophenol small molecule NA approved sodium channel protein type 4 subunit alpha SCN4A NA unknown NA drugbank tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN4A NA blocker 0.09 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 4 subunit alpha SCN4A NA inhibitor,blocker 0.39 drugbank , DGIDB xep-018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD batrachotoxin NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD znccncsskwcrdhsrcc NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN4A NA inhibitor NA drugbank flecainide small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn sodium channel protein type 4 subunit alpha SCN4A NA inhibitor NA drugbank ccncsakwcrdhsrcc NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD propofol small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sodium channel protein type 4 subunit alpha SCN4A NA inhibitor 0.1 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN4A NA inhibitor NA drugbank ccncsskwcrdharcc NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 4 subunit alpha SCN4A NA inhibitor 0.39 drugbank , DGIDB lanperisone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Diseases[MeSHID:D009140] phase 3 voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown 0.99 TTD , DGIDB ccacsskwcrdhsrcc NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD zrccncsskwcrdhsrcc NA NA investigative voltage-gated sodium channel alpha nav1.4 SCN4A Clinical trial target unknown NA TTD dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN4A NA antagonist NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN4A NA inhibitor NA drugbank cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN4B NA inhibitor NA drugbank dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN4B NA antagonist NA drugbank zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel subunit beta-4 SCN4B NA inhibitor 22.14 drugbank , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN4B NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN4B NA inhibitor NA drugbank brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN4B NA inhibitor NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN4B NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN4B NA inhibitor NA drugbank tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN5A NA blocker 0.07 drugbank , DGIDB aprindine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] experimental sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 1.07 drugbank , DGIDB flecainide small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 1.23 drugbank , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN5A NA inhibitor NA drugbank ethotoin small molecule Epilepsy, Temporal Lobe[MeSHID:D004833],Tonic-Clonic Epilepsy[MeSHID:D004830],Tonic - clonic seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor,blocker 0.57 drugbank , DGIDB veratridine NA NA investigative voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD mephenytoin NA Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target blocker 0.42 TTD , DGIDB cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN5A NA inhibitor 0.2 drugbank , DGIDB hexylcaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 2.15 drugbank , DGIDB lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor,blocker 0.49 drugbank , DGIDB benzonatate small molecule Coughing[MeSHID:D003371],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 5 subunit alpha SCN5A NA antagonist 3.58 drugbank , DGIDB n-butyl-n'-(4-methyl-benzoyl)-guanidine NA NA investigative voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.49 drugbank , DGIDB brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN5A NA inhibitor NA drugbank lomerizine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 0.24 TTD , DGIDB mephenytoin small molecule Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational,withdrawn sodium channel protein type 5 subunit alpha SCN5A NA inhibitor,blocker 0.42 drugbank , DGIDB n-(4-methyl-benzoyl)-n'-phenethyl-guanidine NA NA investigative voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD kc-12291 NA NA investigative voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD ethotoin small molecule Epilepsy, Temporal Lobe[MeSHID:D004833],Tonic-Clonic Epilepsy[MeSHID:D004830],Tonic - clonic seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.57 drugbank , DGIDB isavuconazole small molecule Zygomycosis[MeSHID:D020096],Mucormycosis[MeSHID:D009091],Aspergillosis[MeSHID:D001228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Candidemia[MeSHID:D058387],Systemic candidiasis[MeSHID:C536777],Invasive Candidiasis[MeSHID:D058365] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA inhibitor NA drugbank aconitine NA NA investigative voltage-gated sodium channel alpha nav1.5 SCN5A Successful target activator 0.72 TTD , DGIDB vernakalant small molecule Atrial Fibrillation[MeSHID:D001281],Operative Surgical Procedures[MeSHID:D013514],pathologic fistula[MeSHID:D005402],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA blocker NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN5A NA inhibitor NA drugbank ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN5A NA inhibitor,blocker 0.51 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN5A NA inhibitor,blocker 0.02 drugbank , DGIDB lubeluzole NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in preregistration voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD quinidine small molecule Preexcitation Syndrome[MeSHID:D011226],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Conduction disorder of the heart[MeSHID:D000075224] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.41 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.11 drugbank , DGIDB riluzole small molecule Amyotrophic Lateral Sclerosis[MeSHID:D000690],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA inhibitor,blocker 0.22 drugbank , DGIDB acecainide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 3 voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.28 drugbank , DGIDB aryl carboxamide derivative 3 NA NA patented voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD , DGIDB disopyramide NA Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 1.91 TTD , DGIDB procainamide small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 2.15 drugbank , DGIDB mexiletine small molecule Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Premature ventricular contractions[MeSHID:D018879],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 1.97 drugbank , DGIDB prilocaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.46 drugbank , DGIDB indecainide small molecule Cardiac Arrhythmia[MeSHID:D001145],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 6.44 drugbank , DGIDB aryl carboxamide derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD , DGIDB cinchocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525] approved,vet_approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor NA drugbank propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN5A NA blocker NA drugbank dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD , DGIDB disopyramide small molecule Cardiac Arrhythmia[MeSHID:D001145],Conduction disorder of the heart[MeSHID:D000075224],Preexcitation Syndrome[MeSHID:D011226],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 1.91 drugbank , DGIDB oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN5A NA inhibitor,blocker 0.21 drugbank , DGIDB pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN5A NA inhibitor NA drugbank moricizine small molecule heart rate[MeSHID:D006339],Cardiac Arrhythmia[MeSHID:D001145],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 2.5 drugbank , DGIDB carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN5A NA inhibitor,blocker 0.12 drugbank , DGIDB riluzole small molecule Amyotrophic Lateral Sclerosis[MeSHID:D000690],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.22 drugbank , DGIDB ethotoin NA Epilepsy, Temporal Lobe[MeSHID:D004833],Tonic-Clonic Epilepsy[MeSHID:D004830],Tonic - clonic seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target blocker 0.57 TTD , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN5A NA inhibitor NA drugbank benzonatate NA Coughing[MeSHID:D003371],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 3.58 TTD , DGIDB mephenytoin small molecule Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational,withdrawn sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.42 drugbank , DGIDB fosphenytoin NA Term Birth[MeSHID:D047929],Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 2.5 TTD , DGIDB indecainide NA Cardiac Arrhythmia[MeSHID:D001145],Tachycardia, Ventricular[MeSHID:D017180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 6.44 TTD , DGIDB pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN5A NA blocker NA drugbank aryl carboxamide derivative 2 NA NA patented voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD , DGIDB sipatrigine NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD quinidine barbiturate small molecule NA approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor NA drugbank tetrodotoxin NA Breakthrough Pain[MeSHID:D059390],Malignant Neoplasms[MeSHID:D009369],Opiate Addiction[MeSHID:D009293],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 0.16 TTD , DGIDB fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN5A NA inhibitor NA drugbank amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN5A NA blocker NA drugbank mexiletine NA Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Premature ventricular contractions[MeSHID:D018879],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 1.97 TTD , DGIDB prilocaine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target blocker 0.46 TTD , DGIDB hexylcaine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 2.15 TTD , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN5A NA inhibitor,blocker 0.03 drugbank , DGIDB tocainide small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Judgment[MeSHID:D007600],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 1.43 drugbank , DGIDB bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN5A NA modulator NA drugbank carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN5A NA inhibitor 0.12 drugbank , DGIDB ajmaline small molecule Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental sodium channel protein type 5 subunit alpha SCN5A NA inhibitor NA drugbank prilocaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor,blocker 0.46 drugbank , DGIDB mephenytoin NA Epilepsies, Partial[MeSHID:D004828],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 0.42 TTD , DGIDB propafenone small molecule Cardiac Arrhythmia[MeSHID:D001145],Heart Diseases[MeSHID:D006331],Heart Ventricle[MeSHID:D006352],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Recurrence (disease attribute)[MeSHID:D012008],Tachyarrhythmia[MeSHID:D013610],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 0.39 drugbank , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor,blocker 0.11 drugbank , DGIDB 1-[5-(4-chlorophenyl)-2-furoyl]piperazine NA NA investigative voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD encainide small molecule Disease Management[MeSHID:D019468],Cardiac Arrhythmia[MeSHID:D001145],Atrial Flutter[MeSHID:D001282],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 5.01 drugbank , DGIDB dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN5A NA antagonist NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium channel protein type 5 subunit alpha SCN5A NA inhibitor NA drugbank prilocaine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 0.46 TTD , DGIDB dyclonine NA Reflex action[MeSHID:D012018],Vagina[MeSHID:D014621],Respiratory tract structure[MeSHID:D012137],Dental Health Services[MeSHID:D003752],Trachea[MeSHID:D014132],Pharyngeal structure[MeSHID:D010614],Esophagus[MeSHID:D004947],Larynx[MeSHID:D007830],Aphthous Stomatitis[MeSHID:D013281],Urinary tract[MeSHID:D014551],Gagging[MeSHID:D005683],Mucous Membrane[MeSHID:D009092],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 0.08 TTD , DGIDB f-15845 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 1 voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD , DGIDB batrachotoxin NA NA investigative voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown NA TTD ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN5A NA inhibitor 0.51 drugbank , DGIDB ethotoin NA Epilepsy, Temporal Lobe[MeSHID:D004833],Tonic-Clonic Epilepsy[MeSHID:D004830],Tonic - clonic seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 0.57 TTD , DGIDB fosphenytoin small molecule Term Birth[MeSHID:D047929],Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA inhibitor 2.5 drugbank , DGIDB oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN5A NA inhibitor 0.21 drugbank , DGIDB moricizine NA heart rate[MeSHID:D006339],Cardiac Arrhythmia[MeSHID:D001145],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 2.5 TTD , DGIDB dibucaine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 1.07 TTD , DGIDB encainide NA Disease Management[MeSHID:D019468],Cardiac Arrhythmia[MeSHID:D001145],Atrial Flutter[MeSHID:D001282],Ventricular Fibrillation[MeSHID:D014693],Tachycardia, Ventricular[MeSHID:D017180],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market voltage-gated sodium channel alpha nav1.5 SCN5A Successful target unknown 5.01 TTD , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 5 subunit alpha SCN5A NA inhibitor,blocker 0.28 drugbank , DGIDB brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN7A NA inhibitor NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN7A NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN7A NA inhibitor,blocker 0.06 drugbank , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN7A NA inhibitor NA drugbank dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN7A NA antagonist NA drugbank cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN7A NA inhibitor NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN7A NA inhibitor,blocker 0.03 drugbank , DGIDB tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN7A NA blocker 0.11 drugbank , DGIDB propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN7A NA blocker NA drugbank amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN7A NA blocker NA drugbank pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN7A NA blocker NA drugbank pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN7A NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN7A NA modulator NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN7A NA inhibitor NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN7A NA inhibitor NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN7A NA inhibitor NA drugbank carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN7A NA inhibitor,blocker 0.02 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN7A NA inhibitor,blocker 0.04 drugbank , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN8A NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN8A NA modulator NA drugbank tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN8A NA blocker 0.1 drugbank , DGIDB veratridine NA NA investigative voltage-gated sodium channel alpha nav1.6 SCN8A Clinical trial target activator 0.27 TTD , DGIDB phenytoin small molecule Seizures[MeSHID:D012640],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved,vet_approved sodium channel protein type 8 subunit alpha SCN8A NA inhibitor,blocker 0.06 drugbank , DGIDB brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN8A NA inhibitor NA drugbank amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN8A NA blocker NA drugbank batrachotoxin NA NA investigative voltage-gated sodium channel alpha nav1.6 SCN8A Clinical trial target activator NA TTD , DGIDB cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN8A NA inhibitor NA drugbank valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN8A NA inhibitor NA drugbank oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN8A NA inhibitor,blocker 0.05 drugbank , DGIDB ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN8A NA inhibitor NA drugbank xen901 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 1 voltage-gated sodium channel alpha nav1.6 SCN8A Clinical trial target unknown NA TTD , DGIDB prax-330 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 1 voltage-gated sodium channel alpha nav1.6 SCN8A Clinical trial target unknown NA TTD , DGIDB fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN8A NA inhibitor NA drugbank promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN8A NA inhibitor NA drugbank propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN8A NA blocker NA drugbank tetrodotoxin small molecule Breakthrough Pain[MeSHID:D059390],Malignant Neoplasms[MeSHID:D009369],Opiate Addiction[MeSHID:D009293],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sodium channel protein type 8 subunit alpha SCN8A NA unknown 0.24 drugbank , DGIDB pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN8A NA inhibitor NA drugbank lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN8A NA inhibitor,blocker 0.04 drugbank , DGIDB 4,9-anhydro-tetrodotoxin NA NA investigative voltage-gated sodium channel alpha nav1.6 SCN8A Clinical trial target unknown NA TTD carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN8A NA inhibitor,blocker 0.02 drugbank , DGIDB topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN8A NA inhibitor,blocker 0.03 drugbank , DGIDB dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN8A NA antagonist NA drugbank pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN8A NA blocker NA drugbank xen-907 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD 4-(2'-(trifluoromethoxy)biphenyl-3-yl)oxazole NA NA investigative voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD rg7893 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown 1.87 TTD , DGIDB pramocaine small molecule Pruritus[MeSHID:D011537],Disease[MeSHID:D004194],Lip structure[MeSHID:D008046],Pain[MeSHID:D010146],Hemorrhoids[MeSHID:D006484] approved voltage-gated sodium channel alpha subunit SCN9A NA blocker NA drugbank cyclopropyl-spiro piperidine derivative 2 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB corus 1030 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD cyclopropyl-spiro piperidine derivative 3 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB cyclopropyl-spiro piperidine derivative 4 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB xen-402 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Degenerative polyarthritis[MeSHID:D010003],Vasodilation[MeSHID:D014664],Pain[MeSHID:D010146],Limb structure[MeSHID:D005121] phase 2 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown 0.94 TTD , DGIDB dwj-208 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB methylsulfonylbenzamide derivative 2 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN9A NA inhibitor NA drugbank topiramate small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Body Weight[MeSHID:D001835],Lennox-Gastaut syndrome[MeSHID:D065768],Mood Disorders[MeSHID:D019964],Off-Label Use[MeSHID:D056687],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Epilepsy[MeSHID:D004827] approved voltage-gated sodium channel alpha subunit SCN9A NA inhibitor,blocker 0.02 drugbank , DGIDB dichlorobenzyl alcohol small molecule Pharyngitis[MeSHID:D010612] approved sodium channel protein SCN9A NA antagonist NA drugbank v-102862 NA NA discontinued in phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD 4-(2'-(trifluoromethyl)biphenyl-3-yl)oxazole NA NA investigative voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD 4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole NA NA investigative voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium channel protein SCN9A NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sodium channel protein SCN9A NA inhibitor NA drugbank bioallethrin small molecule Parasitic Diseases[MeSHID:D010272],Scabies[MeSHID:D012532] approved,experimental voltage-gated sodium channel alpha subunit SCN9A NA modulator NA drugbank tetracaine small molecule Eye[MeSHID:D005123],Veins[MeSHID:D014680],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,vet_approved voltage-gated sodium channel alpha subunit SCN9A NA blocker 0.09 drugbank , DGIDB gdc0310 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB amylocaine small molecule NA approved,withdrawn voltage-gated sodium channel alpha subunit SCN9A NA blocker NA drugbank lacosamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Term Birth[MeSHID:D047929],Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] approved sodium channel protein type 9 subunit alpha SCN9A NA blocker 0.16 drugbank , DGIDB benzene sulfonamide derivative 12 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB n-me-aminopyrimidinone 9 NA NA investigative voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target inhibitor NA TTD , DGIDB propoxycaine small molecule Allergic Reaction[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved voltage-gated sodium channel alpha subunit SCN9A NA blocker NA drugbank dsp-3905 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB pyrimidine derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational voltage-gated sodium channel alpha subunit SCN9A NA inhibitor NA drugbank pf-05089771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown 1.87 TTD , DGIDB aryl carboxamide derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB pf-05241328 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown 0.94 TTD , DGIDB benzene sulfonamide derivative 9 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB pyrrolo-benzo-diazine derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB pf-05089771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 2 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target blocker 1.87 TTD , DGIDB tarizine derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB cc8464 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB pf-05186462 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB valproic acid small molecule Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Maintenance[MeSHID:D008283],Status Epilepticus[MeSHID:D013226],Absence Epilepsy[MeSHID:D004832],Seizures, Focal[MeSHID:D012640],Migraine Disorders[MeSHID:D008881],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein SCN9A NA inhibitor NA drugbank veratridine NA NA investigative voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target activator 0.23 TTD , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 9 subunit alpha SCN9A NA inhibitor 0.37 drugbank , DGIDB aryl carboxamide derivative 4 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB carbamazepine small molecule Bipolar Disorder[MeSHID:D001714],Restless Legs Syndrome[MeSHID:D012148],Epilepsy[MeSHID:D004827],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Substance Withdrawal Syndrome[MeSHID:D013375],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Adenocarcinoma[MeSHID:D000230],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] approved,investigational voltage-gated sodium channel alpha subunit SCN9A NA inhibitor,blocker 0.02 drugbank , DGIDB pyrrolo-pyridinone derivative 6 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB enzoxazolinone sulfonamide derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB sipatrigine NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD ranolazine small molecule Cardiac Arrhythmia[MeSHID:D001145],Acute Coronary Syndrome[MeSHID:D054058],Blood Platelets[MeSHID:D001792],Angina Pectoris[MeSHID:D000787],Heart[MeSHID:D006321],Tachycardia, Ventricular[MeSHID:D017180],Off-Label Use[MeSHID:D056687],Stable angina[MeSHID:D060050],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atrial Fibrillation[MeSHID:D001281] approved,investigational sodium channel protein SCN9A NA inhibitor 0.4 drugbank , DGIDB oxcarbazepine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein SCN9A NA inhibitor,blocker 0.05 drugbank , DGIDB lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 9 subunit alpha SCN9A NA inhibitor,blocker 0.35 drugbank , DGIDB cyclopropyl-spiro piperidine derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB biib095 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB dsp-2230 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target blocker 0.94 TTD , DGIDB dsp-2230 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown 0.94 TTD , DGIDB rg7893 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target blocker 1.87 TTD , DGIDB promethazine small molecule Nausea[MeSHID:D009325],Allergic Conjunctivitis[MeSHID:D003233],Vomiting[MeSHID:D014839],Rhinitis[MeSHID:D012220],Blood[MeSHID:D001769],Plasma[MeSHID:D010949],Coughing[MeSHID:D003371],Signs and Symptoms, Respiratory[MeSHID:D012818],Motion Sickness[MeSHID:D009041],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Nose[MeSHID:D009666],Pain[MeSHID:D010146],anaphylaxis[MeSHID:D000707],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational voltage-gated sodium channel alpha subunit SCN9A NA inhibitor NA drugbank pyrrolo-pyridinone derivative 5 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB aryl carboxamide derivative 2 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB pyrrolopyrimidine 48 NA NA investigative voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD batrachotoxin NA NA investigative voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target activator NA TTD , DGIDB benzene sulfonamide derivative 15 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB biib074 NA Radiculopathy[MeSHID:D011843],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Trigeminal Neuralgia[MeSHID:D014277],Bipolar Disorder[MeSHID:D001714] phase 2 voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown 1.87 TTD , DGIDB lidocaine small molecule Brachial plexus structure[MeSHID:D001917],Nerve Tissue[MeSHID:D009417],Peripheral Nerves[MeSHID:D010525],Dysmenorrhea[MeSHID:D004412],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium channel protein type 9 subunit alpha SCN9A NA inhibitor 0.35 drugbank , DGIDB zonisamide small molecule Epilepsy[MeSHID:D004827],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium channel protein type 9 subunit alpha SCN9A NA inhibitor,blocker 0.37 drugbank , DGIDB lamotrigine small molecule Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Mood (psychological function)[MeSHID:D000339],Epilepsy[MeSHID:D004827],Mental Depression[MeSHID:D003863],Unmarried[MeSHID:D012847],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational voltage-gated sodium channel alpha subunit SCN9A NA inhibitor,blocker 0.04 drugbank , DGIDB brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational sodium channel protein SCN9A NA inhibitor NA drugbank rufinamide small molecule Lennox-Gastaut syndrome[MeSHID:D065768],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved sodium channel protein type 9 subunit alpha SCN9A NA modulator,blocker 0.17 drugbank , DGIDB benzene sulfonamide derivative 11 NA NA patented voltage-gated sodium channel alpha nav1.7 SCN9A Clinical trial target unknown NA TTD , DGIDB triamterene small molecule Hypertensive disease[MeSHID:D006973],Hypokalemia[MeSHID:D007008],Maintenance[MeSHID:D008283],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Neoplasm Metastasis[MeSHID:D009362],Nephrotic Syndrome[MeSHID:D009404],Hyperaldosteronism[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit alpha SCNN1A NA inhibitor 8.84 drugbank , DGIDB amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit alpha SCNN1A NA inhibitor 9.09 drugbank , DGIDB triamterene small molecule Hypertensive disease[MeSHID:D006973],Hypokalemia[MeSHID:D007008],Maintenance[MeSHID:D008283],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Neoplasm Metastasis[MeSHID:D009362],Nephrotic Syndrome[MeSHID:D009404],Hyperaldosteronism[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit alpha SCNN1A NA inhibitor,blocker 8.84 drugbank , DGIDB triamterene small molecule Hypertensive disease[MeSHID:D006973],Hypokalemia[MeSHID:D007008],Maintenance[MeSHID:D008283],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Neoplasm Metastasis[MeSHID:D009362],Nephrotic Syndrome[MeSHID:D009404],Hyperaldosteronism[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit beta SCNN1B NA inhibitor,blocker 5.3 drugbank , DGIDB triamterene small molecule Hypertensive disease[MeSHID:D006973],Hypokalemia[MeSHID:D007008],Maintenance[MeSHID:D008283],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Neoplasm Metastasis[MeSHID:D009362],Nephrotic Syndrome[MeSHID:D009404],Hyperaldosteronism[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit beta SCNN1B NA inhibitor 5.3 drugbank , DGIDB amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit beta SCNN1B NA inhibitor 6.82 drugbank , DGIDB amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit delta SCNN1D NA inhibitor 15.91 drugbank , DGIDB triamterene small molecule Hypertensive disease[MeSHID:D006973],Hypokalemia[MeSHID:D007008],Maintenance[MeSHID:D008283],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Neoplasm Metastasis[MeSHID:D009362],Nephrotic Syndrome[MeSHID:D009404],Hyperaldosteronism[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit delta SCNN1D NA inhibitor 8.84 drugbank , DGIDB triamterene small molecule Hypertensive disease[MeSHID:D006973],Hypokalemia[MeSHID:D007008],Maintenance[MeSHID:D008283],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Neoplasm Metastasis[MeSHID:D009362],Nephrotic Syndrome[MeSHID:D009404],Hyperaldosteronism[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit gamma SCNN1G NA inhibitor 8.84 drugbank , DGIDB amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit gamma SCNN1G NA inhibitor 10.23 drugbank , DGIDB triamterene small molecule Hypertensive disease[MeSHID:D006973],Hypokalemia[MeSHID:D007008],Maintenance[MeSHID:D008283],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Neoplasm Metastasis[MeSHID:D009362],Nephrotic Syndrome[MeSHID:D009404],Hyperaldosteronism[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved amiloride-sensitive sodium channel subunit gamma SCNN1G NA inhibitor,blocker 8.84 drugbank , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational protein sco1 homolog, mitochondrial SCO1 NA unknown NA drugbank l-benzylsuccinic acid small molecule NA experimental retinoid-inducible serine carboxypeptidase SCPEP1 NA unknown NA drugbank secretin NA Gastrinoma[MeSHID:D015408],Exocrine pancreas[MeSHID:D046790],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved secretin receptor SCT Successful target unknown NA TTD secretin human biotech Exocrine pancreas[MeSHID:D046790],Gastrinoma[MeSHID:D015408],Bodily secretions[MeSHID:D012634],Diagnosis[MeSHID:D003933],Identification (Psychology)[MeSHID:D007062],pancreatic juice[MeSHID:D010189],Lesser duodenal papilla structure[MeSHID:D010183],Ampulla of Vater[MeSHID:D014670] approved secretin receptor SCTR NA ligand NA drugbank grn163l small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Lymph[MeSHID:D008196] investigational n-terminal kinase-like protein SCYL1 NA unknown NA drugbank cart-138 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1/2 syndecan-1 SDC1 Clinical trial target unknown NA TTD , DGIDB cd138 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1/2 syndecan-1 SDC1 Clinical trial target unknown NA TTD , DGIDB car-t cells targeting cd138 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] clinical trial syndecan-1 SDC1 Clinical trial target unknown NA TTD , DGIDB bt-062 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 syndecan-1 SDC1 Clinical trial target unknown 31.83 TTD , DGIDB car138 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Immune System Diseases[MeSHID:D007154] phase 1 syndecan-1 SDC1 Clinical trial target unknown NA TTD , DGIDB sargramostim biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational syndecan-2 SDC2 NA agonist NA drugbank malonate ion small molecule NA experimental stromal cell-derived factor 2 SDF2 NA unknown NA drugbank thenoyltrifluoroacetone small molecule NA experimental succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial SDHA NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial SDHA NA unknown NA drugbank ubidecarenone small molecule Gingival Diseases[MeSHID:D005882],Diabetes Mellitus[MeSHID:D003920],Periodontal Diseases[MeSHID:D010510],Hypertensive disease[MeSHID:D006973],Diet therapy[MeSHID:D004035],Congestive heart failure[MeSHID:D006333],Fibromyalgia[MeSHID:D005356],Heart[MeSHID:D006321],Parkinson Disease[MeSHID:D010300],Migraine Disorders[MeSHID:D008881] approved,investigational,nutraceutical succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial SDHA NA cofactor NA drugbank ubiquinone q1 small molecule NA experimental succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial SDHA NA unknown NA drugbank carboxin small molecule NA approved,experimental succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial SDHA NA unknown NA drugbank ubiquinone q1 small molecule NA experimental succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial SDHB NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial SDHB NA unknown NA drugbank ubiquinone q1 small molecule NA experimental succinate dehydrogenase cytochrome b560 subunit, mitochondrial SDHC NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental succinate dehydrogenase cytochrome b560 subunit, mitochondrial SDHC NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial SDHD NA unknown NA drugbank ubiquinone q1 small molecule NA experimental succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial SDHD NA unknown NA drugbank hexachlorophene small molecule Disease Outbreaks[MeSHID:D004196],Communicable Diseases[MeSHID:D003141],Infectious disease prevention / control[MeSHID:D017053],Infection[MeSHID:D007239],Surgical Scrubbing[MeSHID:D006235],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial SDHD NA inhibitor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical l-serine dehydratase/l-threonine deaminase SDS NA cofactor NA drugbank serine small molecule NA investigational,nutraceutical l-serine dehydratase/l-threonine deaminase SDS NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine dehydratase-like SDSL NA cofactor NA drugbank vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved sec14-like protein 2 SEC14L2 NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved sec14-like protein 2 SEC14L2 NA unknown NA drugbank d-alpha-tocopherol acetate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Skin Aging[MeSHID:D015595],Premenstrual syndrome[MeSHID:D011293],Fertility[MeSHID:D005298],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Asthma[MeSHID:D001249],Muscle Cramp[MeSHID:D009120],Cataract[MeSHID:D002386],Disorder of eye[MeSHID:D005128],Ultraviolet Rays[MeSHID:D014466] approved,nutraceutical,vet_approved sec14-like protein 2 SEC14L2 NA unknown NA drugbank d-alpha-tocopherol acetate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Skin Aging[MeSHID:D015595],Premenstrual syndrome[MeSHID:D011293],Fertility[MeSHID:D005298],Rheumatoid Arthritis[MeSHID:D001172],Cardiovascular Diseases[MeSHID:D002318],Asthma[MeSHID:D001249],Muscle Cramp[MeSHID:D009120],Cataract[MeSHID:D002386],Disorder of eye[MeSHID:D005128],Ultraviolet Rays[MeSHID:D014466] approved,nutraceutical,vet_approved sec14-like protein 3 SEC14L3 NA unknown NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved sec14-like protein 3 SEC14L3 NA unknown NA drugbank vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved sec14-like protein 3 SEC14L3 NA unknown NA drugbank vitamin e small molecule Diet therapy[MeSHID:D004035],Vitamin E Deficiency[MeSHID:D014811],Cholestasis[MeSHID:D002779],Cystic Fibrosis[MeSHID:D003550],Abetalipoproteinemia[MeSHID:D000012],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved,nutraceutical,vet_approved sec14-like protein 4 SEC14L4 NA unknown NA drugbank gmi-1070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 e-selectin SELE Clinical trial target unknown 10.61 TTD , DGIDB o-sialic acid NA NA investigative e-selectin SELE Clinical trial target unknown NA TTD bimosiamose NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Chronic Obstructive Airway Disease[MeSHID:D029424],Dermatitis, Atopic[MeSHID:D003876],Disease[MeSHID:D004194],Asthma[MeSHID:D001249] phase 2a e-selectin SELE Clinical trial target unknown 7.96 TTD , DGIDB fucose NA NA investigative e-selectin SELE Clinical trial target unknown NA TTD carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational e-selectin SELE NA inhibitor NA drugbank n-acetyl-alpha-neuraminic acid small molecule NA experimental e-selectin SELE NA unknown NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational e-selectin SELE NA inhibitor NA drugbank bimosiamose NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Chronic Obstructive Airway Disease[MeSHID:D029424],Dermatitis, Atopic[MeSHID:D003876],Disease[MeSHID:D004194],Asthma[MeSHID:D001249] phase 2a e-selectin SELE Clinical trial target inhibitor 7.96 TTD , DGIDB gmi-1359 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 1 e-selectin SELE Clinical trial target unknown NA TTD , DGIDB smart anti-e/p selectin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 e-selectin SELE Clinical trial target unknown NA TTD gmi-1271 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 e-selectin SELE Clinical trial target unknown 7.96 TTD , DGIDB cy-1503 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2/3 e-selectin SELE Clinical trial target unknown NA TTD , DGIDB endostatin biotech Neoplasms[MeSHID:D009369],Diabetic Retinopathy[MeSHID:D003930],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational e-selectin SELE NA unknown NA drugbank 1na NA NA investigative e-selectin SELE Clinical trial target unknown NA TTD efomycine m NA NA investigative e-selectin SELE Clinical trial target unknown NA TTD ld201t1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigative l-selectin SELL Clinical trial target unknown NA TTD 2,3,4-trihydroxybenzoic acid NA NA investigative l-selectin SELL Clinical trial target unknown NA TTD gmi-1070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 l-selectin SELL Clinical trial target unknown 28.29 TTD , DGIDB baicalein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 l-selectin SELL Clinical trial target unknown NA TTD dalteparin small molecule Acute Disease[MeSHID:D000208],Malignant Neoplasms[MeSHID:D009369],Blood coagulation[MeSHID:D001777],Kidney Failure, Acute[MeSHID:D058186],Acute Coronary Syndrome[MeSHID:D054058],Angina, Unstable[MeSHID:D000789],Deep Vein Thrombosis[MeSHID:D020246],Lung diseases[MeSHID:D008171],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655] approved p-selectin SELP NA inhibitor NA drugbank 2,3,4-trihydroxybenzoic acid NA NA investigative p-selectin SELP Successful target unknown NA TTD cy-1503 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] phase 2/3 p-selectin SELP Successful target unknown NA TTD , DGIDB gallicacid NA NA investigative p-selectin SELP Successful target unknown NA TTD baicalein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 p-selectin SELP Successful target unknown NA TTD cy-1787 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] discontinued in phase 1 p-selectin SELP Successful target unknown NA TTD nadroparin small molecule Blood coagulation[MeSHID:D001777],Angina, Unstable[MeSHID:D000789],Deep Vein Thrombosis[MeSHID:D020246],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923] approved,investigational p-selectin SELP NA inhibitor NA drugbank n-acetyl-alpha-neuraminic acid small molecule NA experimental p-selectin SELP NA unknown NA drugbank gmi-1070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 3 p-selectin SELP Successful target unknown 15.16 TTD , DGIDB 2-methyl-2,4-pentanediol NA NA investigative p-selectin SELP Successful target unknown NA TTD smart anti-e/p selectin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 p-selectin SELP Successful target unknown NA TTD psi-697 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Atherosclerosis[MeSHID:D050197],Thrombosis[MeSHID:D013927],Arteriosclerosis[MeSHID:D001161] phase 1 p-selectin SELP Successful target unknown 9.09 TTD , DGIDB o-sialic acid NA NA investigative p-selectin SELP Successful target unknown NA TTD selg1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 p-selectin SELP Successful target unknown 27.28 TTD , DGIDB heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational p-selectin SELP NA inhibitor NA drugbank crizanlizumab biotech Anemia, Sickle Cell[MeSHID:D000755],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational p-selectin SELP Successful target inhibitor,antibody 27.28 TTD , drugbank , DGIDB efomycine m NA NA investigative p-selectin SELP Successful target unknown NA TTD cdp-850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 p-selectin SELP Successful target unknown NA TTD rpsgl-ig NA Delayed Graft Function[MeSHID:D051799],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 p-selectin SELP Successful target unknown NA TTD , DGIDB 1na NA NA investigative p-selectin SELP Successful target unknown NA TTD fucose NA NA investigative p-selectin SELP Successful target unknown NA TTD neihulizumab biotech Arthritis, Psoriatic[MeSHID:D015535],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 p-selectin glycoprotein ligand 1 SELPLG Clinical trial target agonist 31.83 TTD , drugbank , DGIDB ro-4905417 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] phase 2 p-selectin glycoprotein ligand 1 SELPLG Clinical trial target unknown 15.91 TTD , DGIDB abgn-168 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] phase 2 p-selectin glycoprotein ligand 1 SELPLG Clinical trial target unknown NA TTD , DGIDB pepinemab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1/2 semaphorin-4d SEMA4D Clinical trial target antibody 63.65 TTD , DGIDB vx-15 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Huntington Disease[MeSHID:D006816],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] phase 2 semaphorin-4d SEMA4D Clinical trial target unknown 63.65 TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational semenogelin-1 SEMG1 NA cofactor NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental semenogelin-1 SEMG1 NA cofactor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational semenogelin-1 SEMG1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational semenogelin-1 SEMG1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational semenogelin-2 SEMG2 NA cofactor NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental semenogelin-2 SEMG2 NA cofactor NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational selenoprotein p SEPP1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational selenoprotein p SEPP1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational selenoprotein p SEPP1 NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental selenoprotein p SEPP1 NA binder NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical o-phosphoseryl-trna(sec) selenium transferase SEPSECS NA cofactor NA drugbank aro-aat NA alpha-1-Antitrypsin Deficiency, Autosomal Recessive[MeSHID:C566273],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],alpha 1-Antitrypsin Deficiency[MeSHID:D019896],Alopecia[MeSHID:D000505] phase 2 serpina1 messenger rna SERPINA1 Clinical trial target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-1-antitrypsin SERPINA1 NA unknown NA drugbank igmesine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Chronic Obstructive Airway Disease[MeSHID:D029424],Cystic Fibrosis[MeSHID:D003550],Major Depressive Disorder[MeSHID:D003865] phase 2 alpha-1-antitrypsin SERPINA1 Successful target unknown 15.91 TTD , DGIDB mercaptoethanol small molecule NA experimental alpha-1-antitrypsin SERPINA1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational alpha-1-antitrypsin SERPINA1 NA ligand NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental alpha-1-antitrypsin SERPINA1 NA ligand NA drugbank agtc-0106 NA alpha-1-Antitrypsin Deficiency, Autosomal Recessive[MeSHID:C566273],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],alpha 1-Antitrypsin Deficiency[MeSHID:D019896] phase 2 alpha-1-antitrypsin SERPINA1 Successful target unknown NA TTD , DGIDB recombinant alpha 1-antitrypsin biotech Eczema[MeSHID:D004485],alpha-1-Antitrypsin Deficiency, Autosomal Recessive[MeSHID:C566273],alpha 1-Antitrypsin Deficiency[MeSHID:D019896],Dermatitis, Atopic[MeSHID:D003876],Chronic Obstructive Airway Disease[MeSHID:D029424] investigational alpha-1-antitrypsin SERPINA1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational alpha-1-antitrypsin SERPINA1 NA unknown NA drugbank glassia NA Pathological accumulation of air in tissues[MeSHID:D004646],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Emphysema[MeSHID:D011656] approved alpha-1-antitrypsin SERPINA1 Successful target unknown 31.83 TTD , DGIDB 2-sulfhydryl-ethanol NA NA investigative alpha-1-antitrypsin SERPINA1 Successful target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational alpha-1-antitrypsin SERPINA1 NA unknown NA drugbank 2-[3,4-dihydroxy-2-hydroxymethyl-5-(2-hydroxy-nonyl)-tetrahydro-furan-2-yloxy]-6-hydroxymethyl-tetra hydro-pyran-3,4,5-triol small molecule NA experimental alpha-1-antitrypsin SERPINA1 NA unknown NA drugbank zemaira NA Pathological accumulation of air in tissues[MeSHID:D004646],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Emphysema[MeSHID:D011656] approved alpha-1-antitrypsin SERPINA1 Successful target unknown NA TTD ppl-100 small molecule HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational alpha-1-antitrypsin SERPINA1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational alpha-1-antichymotrypsin SERPINA3 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational alpha-1-antichymotrypsin SERPINA3 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational alpha-1-antichymotrypsin SERPINA3 NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental alpha-1-antichymotrypsin SERPINA3 NA binder NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational kallistatin SERPINA4 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational kallistatin SERPINA4 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational kallistatin SERPINA4 NA unknown NA drugbank drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn plasma serine protease inhibitor SERPINA5 NA unknown NA drugbank tifuvirtide small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163],HIV Infections[MeSHID:D015658],Infection[MeSHID:D007239] investigational plasma serine protease inhibitor SERPINA5 NA unknown NA drugbank urokinase biotech Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved,investigational,withdrawn plasma serine protease inhibitor SERPINA5 NA substrate NA drugbank ppl-100 small molecule HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational plasma serine protease inhibitor SERPINA5 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational corticosteroid-binding globulin SERPINA6 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental corticosteroid-binding globulin SERPINA6 NA modulator NA drugbank i-vation NA Diabetic Retinopathy[MeSHID:D003930],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 corticosteroid-binding globulin SERPINA6 Successful target unknown NA TTD , DGIDB paramethasone NA Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269],Inflammation[MeSHID:D007249] approved corticosteroid-binding globulin SERPINA6 Successful target unknown 10.61 TTD , DGIDB ciclesonide NA Rhinitis, Allergic, Perennial[MeSHID:D012221],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Diseases, Obstructive[MeSHID:D008173],Asthma[MeSHID:D001249] approved corticosteroid-binding globulin SERPINA6 Successful target unknown 7.07 TTD , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational corticosteroid-binding globulin SERPINA6 NA modulator NA drugbank ciclesonide NA Rhinitis, Allergic, Perennial[MeSHID:D012221],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved corticosteroid-binding globulin SERPINA6 Successful target unknown 7.07 TTD , DGIDB alclometasone NA Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved corticosteroid-binding globulin SERPINA6 Successful target unknown 7.07 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational corticosteroid-binding globulin SERPINA6 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational corticosteroid-binding globulin SERPINA6 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thyroxine-binding globulin SERPINA7 NA unknown NA drugbank urokinase biotech Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved,investigational,withdrawn plasminogen activator inhibitor 2 SERPINB2 NA substrate,inducer 63.65 drugbank , DGIDB tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen activator inhibitor 2 SERPINB2 NA unknown NA drugbank lanoteplase biotech Myocardial Infarction[MeSHID:D009203] investigational plasminogen activator inhibitor 2 SERPINB2 NA unknown NA drugbank d-serine small molecule NA approved,experimental serpin b3 SERPINB3 NA unknown NA drugbank dexfosfoserine small molecule NA experimental serpin b3 SERPINB3 NA unknown NA drugbank s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental serpin b5 SERPINB5 NA unknown NA drugbank drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn serpin b6 SERPINB6 NA unknown NA drugbank raloxifene small molecule Osteopenia[MeSHID:D001851],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serpin b9 SERPINB9 NA unknown NA drugbank o-desulfated heparin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB protamine sulfate biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Kidney[MeSHID:D007668] approved antithrombin-iii SERPINC1 NA unknown NA drugbank antithrombin iii human biotech Thromboembolism[MeSHID:D013923],Hereditary Antithrombin Deficiency[MeSHID:D020152] approved antithrombin-iii SERPINC1 NA agonist NA drugbank dalteparin small molecule Acute Disease[MeSHID:D000208],Malignant Neoplasms[MeSHID:D009369],Blood coagulation[MeSHID:D001777],Kidney Failure, Acute[MeSHID:D058186],Acute Coronary Syndrome[MeSHID:D054058],Angina, Unstable[MeSHID:D000789],Deep Vein Thrombosis[MeSHID:D020246],Lung diseases[MeSHID:D008171],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655] approved antithrombin-iii SERPINC1 NA potentiator,activator 2.55 drugbank , DGIDB ardeparin small molecule Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Pulmonary Embolism[MeSHID:D011655],Knee[MeSHID:D007717],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556] approved,investigational,withdrawn antithrombin-iii SERPINC1 Successful target potentiator NA TTD , drugbank , DGIDB pnu-87663 NA NA investigative antithrombin-iii SERPINC1 Successful target unknown NA TTD fitusiran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 3 serpinc1 messenger rna SERPINC1 Clinical trial target unknown NA TTD n-formylmethionine small molecule NA experimental,investigative antithrombin-iii SERPINC1 Successful target unknown NA TTD , drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational antithrombin-iii SERPINC1 NA unknown NA drugbank opk-0018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB fondaparinux small molecule Hip Fractures[MeSHID:D006620],Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Thrombosis[MeSHID:D013927],Cessation of life[MeSHID:D003643],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Myocardium[MeSHID:D009206],Knee[MeSHID:D007717],Myocardial Infarction[MeSHID:D009203] approved,investigational antithrombin-iii SERPINC1 NA potentiator 17.82 drugbank , DGIDB kw-3357 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] phase 3 antithrombin-iii SERPINC1 Successful target unknown 2.55 TTD , DGIDB danaparoid small molecule Deep Vein Thrombosis[MeSHID:D020246],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Veins[MeSHID:D014680] approved,withdrawn antithrombin-iii SERPINC1 NA positive allosteric modulator,activator 2.55 drugbank , DGIDB heparin sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Deep Vein Thrombosis[MeSHID:D020246],Blood Coagulation Disorders[MeSHID:D001778] approved antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB tinzaparin small molecule Venous Thrombosis[MeSHID:D020246],Pulmonary Embolism[MeSHID:D011655],Venous Thromboembolism[MeSHID:D054556] approved antithrombin-iii SERPINC1 NA potentiator 6.37 drugbank , DGIDB heparin calcium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved antithrombin-iii SERPINC1 Successful target activator 2.55 TTD , DGIDB enoxaparin small molecule Hospitalization[MeSHID:D006760],ambulatory care services[MeSHID:D000553],Deep Vein Thrombosis[MeSHID:D020246],Patient Care Management[MeSHID:D010346],Angina, Unstable[MeSHID:D000789],Operative Surgical Procedures[MeSHID:D013514],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655] approved antithrombin-iii SERPINC1 NA potentiator,activator 5.94 drugbank , DGIDB fondaparinux small molecule Hip Fractures[MeSHID:D006620],Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Thrombosis[MeSHID:D013927],Cessation of life[MeSHID:D003643],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Myocardium[MeSHID:D009206],Knee[MeSHID:D007717],Myocardial Infarction[MeSHID:D009203] approved,investigational antithrombin-iii SERPINC1 NA potentiator,activator 17.82 drugbank , DGIDB heparin pentasaccharide NA NA investigative antithrombin-iii SERPINC1 Successful target unknown NA TTD lhd-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative antithrombin-iii SERPINC1 Successful target unknown NA TTD m118 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] phase 2 antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB heparin sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Deep Vein Thrombosis[MeSHID:D020246],Blood Coagulation Disorders[MeSHID:D001778] approved antithrombin-iii SERPINC1 Successful target activator 2.55 TTD , DGIDB mer-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB nadroparin small molecule Blood coagulation[MeSHID:D001777],Angina, Unstable[MeSHID:D000789],Deep Vein Thrombosis[MeSHID:D020246],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923] approved,investigational antithrombin-iii SERPINC1 NA potentiator NA drugbank heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational antithrombin-iii SERPINC1 NA potentiator,activator 0.97 drugbank , DGIDB heparin calcium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB heparin small molecule Arteries[MeSHID:D001158],Blood coagulation[MeSHID:D001777],Acute Coronary Syndrome[MeSHID:D054058],Maintenance[MeSHID:D008283],Angina, Unstable[MeSHID:D000789],Venous Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Blood[MeSHID:D001769],Physical Dialysis[MeSHID:D003956],Atrial Fibrillation[MeSHID:D001281],Myocardial Infarction[MeSHID:D009203],Embolism[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational antithrombin-iii SERPINC1 NA potentiator 0.97 drugbank , DGIDB pmx-60056 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] phase 2 antithrombin-iii SERPINC1 Successful target unknown 5.09 TTD , DGIDB tinzaparin small molecule Venous Thrombosis[MeSHID:D020246],Pulmonary Embolism[MeSHID:D011655],Venous Thromboembolism[MeSHID:D054556] approved antithrombin-iii SERPINC1 NA potentiator,activator 6.37 drugbank , DGIDB unfractionated heparin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 3 antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB deligoparin sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] discontinued in phase 3 antithrombin-iii SERPINC1 Successful target unknown NA TTD enoxaparin small molecule Hospitalization[MeSHID:D006760],ambulatory care services[MeSHID:D000553],Deep Vein Thrombosis[MeSHID:D020246],Patient Care Management[MeSHID:D010346],Angina, Unstable[MeSHID:D000789],Operative Surgical Procedures[MeSHID:D013514],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655] approved antithrombin-iii SERPINC1 NA potentiator 5.94 drugbank , DGIDB alpha-d-mannose NA NA investigative antithrombin-iii SERPINC1 Successful target unknown NA TTD ro-14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Venous Thrombosis[MeSHID:D020246] phase 1 antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB sulodexide biotech Disease[MeSHID:D004194],Veins[MeSHID:D014680],Thrombosis[MeSHID:D013927],Peripheral Arterial Diseases[MeSHID:D058729],Peripheral Vascular Diseases[MeSHID:D016491],Myocardium[MeSHID:D009206],Diabetic Nephropathy[MeSHID:D003928],Vascular Diseases[MeSHID:D014652],Intermittent Claudication[MeSHID:D007383],Diabetic Neuropathies[MeSHID:D003929],Arterial Occlusive Diseases[MeSHID:D001157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tinnitus[MeSHID:D014012] approved,investigational antithrombin-iii SERPINC1 Successful target potentiator 7.64 TTD , drugbank , DGIDB heparin low molecular weight NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 3 antithrombin-iii SERPINC1 Successful target unknown NA TTD , DGIDB bemiparin small molecule Blood coagulation[MeSHID:D001777],Veins[MeSHID:D014680],Thrombus[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Thromboembolism[MeSHID:D013923],Recurrence (disease attribute)[MeSHID:D012008] approved,investigational antithrombin-iii SERPINC1 NA antagonist NA drugbank org-36764 NA NA investigative antithrombin-iii SERPINC1 Successful target unknown NA TTD sr-123781a small molecule Cardiovascular Diseases[MeSHID:D002318],Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Venous Thrombosis[MeSHID:D020246] investigational antithrombin-iii SERPINC1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational heparin cofactor 2 SERPIND1 NA unknown NA drugbank bemiparin small molecule Blood coagulation[MeSHID:D001777],Veins[MeSHID:D014680],Thrombus[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556],Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Thromboembolism[MeSHID:D013923],Recurrence (disease attribute)[MeSHID:D012008] approved,investigational heparin cofactor 2 SERPIND1 NA antagonist NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational heparin cofactor 2 SERPIND1 NA unknown NA drugbank sulodexide biotech Disease[MeSHID:D004194],Veins[MeSHID:D014680],Thrombosis[MeSHID:D013927],Peripheral Arterial Diseases[MeSHID:D058729],Peripheral Vascular Diseases[MeSHID:D016491],Myocardium[MeSHID:D009206],Diabetic Nephropathy[MeSHID:D003928],Vascular Diseases[MeSHID:D014652],Intermittent Claudication[MeSHID:D007383],Diabetic Neuropathies[MeSHID:D003929],Arterial Occlusive Diseases[MeSHID:D001157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tinnitus[MeSHID:D014012] approved,investigational heparin cofactor 2 SERPIND1 NA agonist 95.48 drugbank , DGIDB zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational heparin cofactor 2 SERPIND1 NA agonist NA drugbank ardeparin small molecule Deep Vein Thrombosis[MeSHID:D020246],Operative Surgical Procedures[MeSHID:D013514],Pulmonary Embolism[MeSHID:D011655],Knee[MeSHID:D007717],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927],Venous Thromboembolism[MeSHID:D054556] approved,investigational,withdrawn heparin cofactor 2 SERPIND1 NA agonist NA drugbank , DGIDB alpha-d-mannose NA NA investigative heparin cofactor ii SERPIND1 Literature-reported target unknown NA TTD zinc sulfate, unspecified form small molecule NA approved,experimental heparin cofactor 2 SERPIND1 NA agonist NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational heparin cofactor 2 SERPIND1 NA unknown NA drugbank sideroxylonal a NA NA investigative endothelial plasminogen activator inhibitor SERPINE1 Clinical trial target unknown NA TTD troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn plasminogen activator inhibitor 1 SERPINE1 NA antagonist NA drugbank anistreplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Embolus[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Coronary Syndrome[MeSHID:D054058] approved plasminogen activator inhibitor 1 SERPINE1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasminogen activator inhibitor 1 SERPINE1 NA unknown NA drugbank fibrinolysin biotech Hematoma[MeSHID:D006406],Operative Surgical Procedures[MeSHID:D013514],Ulcer[MeSHID:D014456],Injury wounds[MeSHID:D014947],Burn injury[MeSHID:D002056],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational plasminogen activator inhibitor 1 SERPINE1 NA unknown NA drugbank thr-18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 endothelial plasminogen activator inhibitor SERPINE1 Clinical trial target unknown NA TTD , DGIDB reteplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Embolus[MeSHID:D004617],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasminogen activator inhibitor 1 SERPINE1 NA unknown NA drugbank urokinase biotech Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved,investigational,withdrawn plasminogen activator inhibitor 1 SERPINE1 NA substrate,inducer 3.18 drugbank , DGIDB diaplasinin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 endothelial plasminogen activator inhibitor SERPINE1 Clinical trial target unknown 3.18 TTD , DGIDB sideroxylonal c NA NA investigative endothelial plasminogen activator inhibitor SERPINE1 Clinical trial target unknown NA TTD alteplase biotech Myocardial Infarction[MeSHID:D009203],Disease Management[MeSHID:D019468],Pulmonary Embolism[MeSHID:D011655],Acute Cerebrovascular Accidents[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen activator inhibitor 1 SERPINE1 NA unknown NA drugbank tenecteplase biotech Myocardial Infarction[MeSHID:D009203],Embolus[MeSHID:D004617],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved plasminogen activator inhibitor 1 SERPINE1 NA unknown NA drugbank drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn plasminogen activator inhibitor 1 SERPINE1 NA unknown NA drugbank sideroxylonal b NA NA investigative endothelial plasminogen activator inhibitor SERPINE1 Clinical trial target unknown NA TTD ar-ho29953xx NA NA investigative endothelial plasminogen activator inhibitor SERPINE1 Clinical trial target unknown NA TTD copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational pigment epithelium-derived factor SERPINF1 NA unknown NA drugbank adpedr NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Age related macular degeneration[MeSHID:D008268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 pigment epithelium-derived factor SERPINF1 Clinical trial target unknown NA TTD , DGIDB pedf gene therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 pigment epithelium-derived factor SERPINF1 Clinical trial target unknown NA TTD , DGIDB ocriplasmin biotech Tissue Adhesions[MeSHID:D000267],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved alpha-2-antiplasmin SERPINF2 NA ligand NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-2-antiplasmin SERPINF2 NA unknown NA drugbank ppl-100 small molecule HIV Infections[MeSHID:D015658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational plasma protease c1 inhibitor SERPING1 NA unknown NA drugbank rhucin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Erectile dysfunction[MeSHID:D007172],Angioedemas, Hereditary[MeSHID:D054179] approved c1 esterase inhibitor SERPING1 Successful target unknown 15.91 TTD , DGIDB cinryze NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angioedemas, Hereditary[MeSHID:D054179] approved c1 esterase inhibitor SERPING1 Successful target unknown 15.91 TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational plasma protease c1 inhibitor SERPING1 NA unknown NA drugbank bms-986263 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] phase 2 serpinh1 messenger rna SERPINH1 Clinical trial target unknown NA TTD s-adenosyl-l-homocysteine small molecule NA experimental histone-lysine n-methyltransferase setd7 SETD7 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational splicing factor 1 SF1 NA ligand NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational splicing factor 3a subunit 2 SF3A2 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational splicing factor 3a subunit 3 SF3A3 NA unknown NA drugbank h3b-8800 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Myeloid Leukemia, Chronic[MeSHID:D015464] investigational splicing factor 3b subunit 1 SF3B1 NA inhibitor NA drugbank , DGIDB h3b-8800 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],MYELODYSPLASTIC SYNDROME[MeSHID:D009190], Myelomonocytic, Chronic[MeSHID:D015477] investigational splicing factor 3b subunit 1 SF3B1 NA inhibitor NA drugbank , DGIDB quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational splicing factor 3b subunit 3 SF3B3 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational splicing factor, proline- and glutamine-rich SFPQ NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational splicing factor, proline- and glutamine-rich SFPQ NA ligand NA drugbank cyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved secreted frizzled-related protein 4 SFRP4 NA inhibitor NA drugbank perindopril small molecule Coronary Artery Disease[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Coronary heart disease[MeSHID:D003327],Congestive heart failure[MeSHID:D006333],Essential Hypertension[MeSHID:D000075222],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved secreted frizzled-related protein 4 SFRP4 NA inhibitor NA drugbank 2-(n-morpholino)ethanesulfonic acid small molecule NA experimental pulmonary surfactant-associated protein a1 SFTPA1 NA unknown NA drugbank beta-d-glucose small molecule NA experimental pulmonary surfactant-associated protein d SFTPD NA unknown NA drugbank srp-9004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Dystrophies, Limb-Girdle[MeSHID:D049288] phase 1/2 sarcoglycan alpha SGCA Clinical trial target unknown NA TTD raav1.tmck.human-alpha-sarcoglycan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 sarcoglycan alpha SGCA Clinical trial target unknown NA TTD , DGIDB srp-9003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Muscular Dystrophies, Limb-Girdle[MeSHID:D049288] phase 1/2 beta-sarcoglycan SGCB Clinical trial target unknown NA TTD [4-(5-naphthalen-2-yl-1h-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid small molecule NA experimental serine/threonine-protein kinase sgk1 SGK1 NA unknown NA drugbank kn-62 NA NA investigative serine/threonine-protein kinase sgk1 SGK1 Clinical trial target unknown NA TTD ci-1040 NA NA investigative serine/threonine-protein kinase sgk1 SGK1 Clinical trial target unknown 0.92 TTD , DGIDB bisindolylmaleimide-i NA NA investigative serine/threonine-protein kinase sgk1 SGK1 Clinical trial target unknown NA TTD cgp-57380 NA NA investigative serine/threonine-protein kinase sgk1 SGK1 Clinical trial target unknown NA TTD gsk-650394 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] investigative serine/threonine-protein kinase sgk1 SGK1 Clinical trial target unknown NA TTD flavin mononucleotide small molecule NA approved,investigational serine/threonine-protein kinase sgk1 SGK1 NA unknown NA drugbank 4,5,6,7-tetrabromo-1h-benzo[d][1,2,3]triazole NA NA investigative serine/threonine-protein kinase sgk1 SGK1 Clinical trial target unknown NA TTD ro-316233 NA NA investigative serine/threonine-protein kinase sgk1 SGK1 Clinical trial target unknown NA TTD 4-(5-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid small molecule NA experimental serine/threonine-protein kinase sgk1 SGK1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase sgk3 SGK3 NA inhibitor NA drugbank lx2931 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871],Acantholysis[MeSHID:D000051],Rheumatoid Arthritis[MeSHID:D001172] phase 2 sphingosine-1-phosphate lyase 1 SGPL1 Clinical trial target inhibitor 127.3 TTD , DGIDB lx2931 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871],Acantholysis[MeSHID:D000051],Rheumatoid Arthritis[MeSHID:D001172] phase 2 sphingosine-1-phosphate lyase 1 SGPL1 Clinical trial target unknown 127.3 TTD , DGIDB pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical sphingosine-1-phosphate lyase 1 SGPL1 NA cofactor NA drugbank pmid24809814c31 NA NA investigative sphingosine-1-phosphate lyase 1 SGPL1 Clinical trial target unknown NA TTD abo-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] phase 1/2 n-sulphoglucosamine sulphohydrolase SGSH Clinical trial target unknown NA TTD sobi003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidosis III[MeSHID:D009084] phase 1/2 n-sulphoglucosamine sulphohydrolase SGSH Clinical trial target unknown NA TTD hgt-1410 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidosis III[MeSHID:D009084] phase 2 n-sulphoglucosamine sulphohydrolase SGSH Clinical trial target unknown 63.65 TTD , DGIDB lys-saf302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] phase 2/3 n-sulphoglucosamine sulphohydrolase SGSH Clinical trial target unknown NA TTD pazopanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Sarcoma[MeSHID:D012509] approved sh2b adapter protein 3 SH2B3 NA inhibitor NA drugbank phenolphthalein small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn sex hormone-binding globulin SHBG NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank 4'-hydroxyflavanone small molecule NA experimental sex hormone-binding globulin SHBG NA unknown NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sex hormone-binding globulin SHBG NA binder NA drugbank tamoxifen small molecule Breast[MeSHID:D001940],Radiation[MeSHID:D011827],Noninfiltrating Intraductal Carcinoma[MeSHID:D002285],Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sex hormone-binding globulin SHBG NA inducer NA drugbank masoprocol small molecule Precancerous Conditions[MeSHID:D011230],Growth[MeSHID:D006128],Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank toremifene small molecule Prostatic Intraepithelial Neoplasias[MeSHID:D019048],Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of breast[MeSHID:D001943],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank toremifene small molecule Prostatic Intraepithelial Neoplasias[MeSHID:D019048],Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved sex hormone-binding globulin SHBG NA binder NA drugbank progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved sex hormone-binding globulin SHBG NA binder,potentiator NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental sex hormone-binding globulin SHBG NA modulator NA drugbank naringenin small molecule NA experimental sex hormone-binding globulin SHBG NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational sex hormone-binding globulin SHBG NA modulator NA drugbank levonorgestrel small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Patient Discharge[MeSHID:D010351],Coitus[MeSHID:D003075],Menorrhagia[MeSHID:D008595],Endometrial Hyperplasia[MeSHID:D004714],Off-Label Use[MeSHID:D056687],Unmarried[MeSHID:D012847],Osteoporosis[MeSHID:D010024],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sex hormone-binding globulin SHBG NA inhibitor,binder NA drugbank hesperetin small molecule Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental sex hormone-binding globulin SHBG NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank equol small molecule NA investigational sex hormone-binding globulin SHBG NA unknown NA drugbank dienestrol small molecule Vulvar Lichen Sclerosus[MeSHID:D007724],Atrophic Vaginitis[MeSHID:D059268],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank diethylstilbestrol small molecule Malignant neoplasm of prostate[MeSHID:D011471],Spontaneous abortion[MeSHID:D000022],Premature Birth[MeSHID:D047928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gonorrhea[MeSHID:D006069],Vaginitis[MeSHID:D014627] approved,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank dioxybenzone small molecule Sunscreening Agents[MeSHID:D013473] approved sex hormone-binding globulin SHBG NA binder NA drugbank clomifene small molecule Anovulation[MeSHID:D000858],Polycystic Ovary Syndrome[MeSHID:D011085],Female infertility[MeSHID:D007247],Ovulation[MeSHID:D010060],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sex hormone-binding globulin SHBG NA unknown NA drugbank estriol small molecule Fetal Tissue[MeSHID:D005333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342],Multiple Sclerosis[MeSHID:D009103] approved,investigational,vet_approved sex hormone-binding globulin SHBG NA unknown NA drugbank progesterone small molecule Blastocyst Implantation, natural[MeSHID:D010064],Vagina[MeSHID:D014621],Attention[MeSHID:D001288],Fibroid Tumor[MeSHID:D007889],Pregnancy[MeSHID:D011247],Neoplasm Metastasis[MeSHID:D009362],Amenorrhea[MeSHID:D000568],Female infertility[MeSHID:D007247],Endometrial Hyperplasia[MeSHID:D004714],Uterine Cancer[MeSHID:D014594],Endocrine System Diseases[MeSHID:D004700],Uterine hemorrhage[MeSHID:D014592],Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Obstetric Labor[MeSHID:D007752] approved,vet_approved sex hormone-binding globulin SHBG NA binder,potentiator NA drugbank estrone small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sex hormone-binding globulin SHBG NA unknown NA drugbank zeranol small molecule NA experimental,vet_approved sex hormone-binding globulin SHBG NA unknown NA drugbank norethynodrel small molecule NA approved sex hormone-binding globulin SHBG NA unknown NA drugbank genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sex hormone-binding globulin SHBG NA unknown NA drugbank estriol tripropionate small molecule NA experimental sex hormone-binding globulin SHBG NA unknown NA drugbank afimoxifene small molecule Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] investigational sex hormone-binding globulin SHBG NA unknown NA drugbank gestrinone small molecule Infertility[MeSHID:D007246],Unmarried[MeSHID:D012847],Endometriosis[MeSHID:D004715],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved sex hormone-binding globulin SHBG NA antagonist NA drugbank 5-hydroxymethyl-5,6-dihydrofolic acid small molecule NA experimental serine hydroxymethyltransferase, cytosolic SHMT1 NA unknown NA drugbank triglu-5-formyl-tetrahydrofolate small molecule NA experimental serine hydroxymethyltransferase, cytosolic SHMT1 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine hydroxymethyltransferase, cytosolic SHMT1 NA cofactor NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical serine hydroxymethyltransferase, cytosolic SHMT1 NA cofactor NA drugbank mimosine small molecule NA experimental serine hydroxymethyltransferase, cytosolic SHMT1 NA inhibitor NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved serine hydroxymethyltransferase, cytosolic SHMT1 NA product of NA drugbank n-pyridoxyl-glycine-5-monophosphate small molecule NA experimental serine hydroxymethyltransferase, cytosolic SHMT1 NA unknown NA drugbank glycine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical,vet_approved serine hydroxymethyltransferase, mitochondrial SHMT2 NA product of NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine hydroxymethyltransferase, mitochondrial SHMT2 NA cofactor NA drugbank tetrahydrofolic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] nutraceutical serine hydroxymethyltransferase, mitochondrial SHMT2 NA cofactor NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational serine hydroxymethyltransferase, mitochondrial SHMT2 NA ligand NA drugbank acarbose small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Cardiovascular Diseases[MeSHID:D002318] approved,investigational sucrase-isomaltase, intestinal SI NA inhibitor 12.73 drugbank , DGIDB scopolamine small molecule Nausea[MeSHID:D009325],Motion Sickness[MeSHID:D009041],Postoperative Nausea and Vomiting[MeSHID:D020250],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Addictive Behavior[MeSHID:D016739],Disease[MeSHID:D004194] approved,investigational sucrase-isomaltase, intestinal SI NA inhibitor NA drugbank beta-d-glucose small molecule NA experimental sialoadhesin SIGLEC1 NA unknown NA drugbank n-acetyl-alpha-neuraminic acid small molecule NA experimental sialoadhesin SIGLEC1 NA unknown NA drugbank nc318 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 sialic acid-binding immunoglobulin-like lectin 15 SIGLEC15 Clinical trial target unknown NA TTD n-acetyl-alpha-d-glucosamine small molecule NA experimental sialic acid-binding ig-like lectin 7 SIGLEC7 NA unknown NA drugbank fenfluramine small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Obesity[MeSHID:D009765] approved,illicit,investigational,withdrawn sigma non-opioid intracellular receptor 1 SIGMAR1 NA antagonist NA drugbank panamesine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 2 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD phenylpropylamine derivative 4 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB (rs)-ppcc NA NA investigative opioid receptor sigma 1 SIGMAR1 Successful target agonist NA TTD , DGIDB sertraline small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Post-Traumatic Stress Disorder[MeSHID:D013313],Vasovagal syncope[MeSHID:D019462],Phobia, Social[MeSHID:D000072861],Cerebrovascular accident[MeSHID:D020521],Panic Disorder[MeSHID:D016584],Obsessive compulsive behavior[MeSHID:D003192],Premenstrual Dysphoric Disorder[MeSHID:D065446],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sigma receptor SIGMAR1 NA inhibitor,binder NA drugbank piperidine derivative 5 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB benzamide derivative 9 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB kb-5492 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Peptic Ulcer[MeSHID:D010437] discontinued in phase 2 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD naltrexone small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Alcohol consumption[MeSHID:D000428],emotional dependency[MeSHID:D003858],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],HIV Infections[MeSHID:D015658] approved,investigational,vet_approved hcg20471, isoform cra_c SIGMAR1 NA antagonist 2.89 drugbank , DGIDB piperidine derivative 6 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB (+)-sk&f10047 NA NA investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD pentazocine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sigma non-opioid intracellular receptor 1 SIGMAR1 NA agonist NA drugbank pmid30185082-compound-57 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB igmesine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Chronic Obstructive Airway Disease[MeSHID:D029424],Cystic Fibrosis[MeSHID:D003550],Major Depressive Disorder[MeSHID:D003865] phase 2 opioid receptor sigma 1 SIGMAR1 Successful target unknown 2.89 TTD , DGIDB bd-1047 NA NA investigative opioid receptor sigma 1 SIGMAR1 Successful target antagonist NA TTD , DGIDB dextromethorphan polistirex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved opioid receptor sigma 1 SIGMAR1 Successful target agonist 2.89 TTD , DGIDB isoindoline derivative 2 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB isoindoline derivative 4 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB naltrexone small molecule Disease Management[MeSHID:D019468],Maintenance[MeSHID:D008283],Alcohol consumption[MeSHID:D000428],emotional dependency[MeSHID:D003858],Metabolic Detoxication, Drug[MeSHID:D008658],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Alcoholic Intoxication, Chronic[MeSHID:D000437],Disease[MeSHID:D004194] approved,investigational,vet_approved hcg20471, isoform cra_c SIGMAR1 NA antagonist 2.89 drugbank , DGIDB pentoxyverine small molecule Sinusitis[MeSHID:D012852],Influenza[MeSHID:D007251],Coughing[MeSHID:D003371],Bronchitis[MeSHID:D001991],Common Cold[MeSHID:D003139] approved,investigational sigma non-opioid intracellular receptor 1 SIGMAR1 NA agonist NA drugbank cns-1169 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD ssr-125329a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] phase 1 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sigma receptor SIGMAR1 NA binder NA drugbank adx n05 NA Hypersomnia[MeSHID:D006970],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 3 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB isoindoline derivative 3 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB bms-181100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 3 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD piperazine derivative 7 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB captodiame small molecule Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007] experimental sigma non-opioid intracellular receptor 1 SIGMAR1 NA agonist NA drugbank dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hcg20471, isoform cra_c SIGMAR1 NA agonist 9.09 drugbank , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved sigma non-opioid intracellular receptor 1 SIGMAR1 NA unknown 0.24 drugbank , DGIDB phencyclidine small molecule NA illicit sigma non-opioid intracellular receptor 1 SIGMAR1 NA unknown NA drugbank 2-(1h-indol-3-yl)-n,n-dimethylethanamine NA NA investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD dextromethorphan NA Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor sigma 1 SIGMAR1 Successful target unknown 9.09 TTD , DGIDB phenylpropylamine derivative 5 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB dimemorfan NA NA investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD 1,3-ditolylguanidine NA NA investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD hydrocodone small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Common Cold[MeSHID:D003139],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] approved,illicit,investigational sigma non-opioid intracellular receptor 1 SIGMAR1 NA ligand NA drugbank benzamide derivative 8 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB aryl alkanolamine derivative 2 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB pmid30185082-compound-64 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sigma non-opioid intracellular receptor 1 SIGMAR1 NA unknown 0.24 drugbank , DGIDB arylacenamide small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471] investigational hcg20471, isoform cra_c SIGMAR1 NA unknown NA drugbank 1,2,4-triazole derivative 3 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sigma non-opioid intracellular receptor 1 SIGMAR1 NA agonist 9.09 drugbank , DGIDB benzamide derivative 11 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB benzamide derivative 7 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB anavex 2-73 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cognition Disorders[MeSHID:D003072],Rett Syndrome[MeSHID:D015518],Parkinson Disease[MeSHID:D010300],West Syndrome[MeSHID:D013036] phase 1 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB phenylpropylamine derivative 3 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB dextromethorphan polistirex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB mc-116 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD sa-5845 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 1 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB pimavanserin small molecule Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Psychotic Disorders[MeSHID:D011618],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sigma non-opioid intracellular receptor 1 SIGMAR1 NA binder NA drugbank amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sigma non-opioid intracellular receptor 1 SIGMAR1 NA agonist NA drugbank 1,2,4-triazole derivative 4 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB cm-2395 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sigma non-opioid intracellular receptor 1 SIGMAR1 NA agonist NA drugbank mc-113 NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD cm-156 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD remoxipride small molecule Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn sigma non-opioid intracellular receptor 1 SIGMAR1 NA antagonist NA drugbank avp-786 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Pain[MeSHID:D010146],Disease[MeSHID:D004194] phase 3 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB dup-734 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD dextromethorphan NA Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved opioid receptor sigma 1 SIGMAR1 Successful target agonist 9.09 TTD , DGIDB noscapine small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Multiple Myeloma[MeSHID:D009101],Lymphoma, Non-Hodgkin[MeSHID:D008228] approved,investigational sigma non-opioid intracellular receptor 1 SIGMAR1 NA unknown NA drugbank ssr-125047 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Cataract[MeSHID:D002386] phase 1 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB anavex 1-41 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB pmid28051882-compound-xiv NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB cutamesine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] preclinical opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB [3h]pentazocine NA NA investigative opioid receptor sigma 1 SIGMAR1 Successful target agonist NA TTD , DGIDB c-10068 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] investigative opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD piperidine derivative 4 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB prasterone small molecule Osteopenia[MeSHID:D001851],Schizophrenia[MeSHID:D012559],Lupus Erythematosus, Discoid[MeSHID:D008179],Lupus Vulgaris[MeSHID:D008177],Exanthema[MeSHID:D005076],Prescription of drug (procedure)[MeSHID:D011307],Ability[MeSHID:D001076],Disease[MeSHID:D004194], Systemic[MeSHID:D008180],Pregnancy[MeSHID:D011247],Anorexia Nervosa[MeSHID:D000856],Symptom Flare Up[MeSHID:D000067251],Bone Density[MeSHID:D015519],Oral Ulcer[MeSHID:D019226],Skeletal bone[MeSHID:D001842],Penile Erection[MeSHID:D010410],Osteoporosis[MeSHID:D010024],Eating[MeSHID:D004435],Myalgia[MeSHID:D063806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational,nutraceutical sigma non-opioid intracellular receptor 1 SIGMAR1 NA agonist NA drugbank isoindoline derivative 1 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB isoindoline derivative 5 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB benzamide derivative 10 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB dimethyltryptamine small molecule NA experimental,illicit sigma non-opioid intracellular receptor 1 SIGMAR1 NA unknown NA drugbank gevotroline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD aryl alkanolamine derivative 1 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB phenylpropylamine derivative 1 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB pyrazole derivative 86 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB oxycodex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD anavex 1007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471] preclinical opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB opc-14523 NA Bulimia[MeSHID:D002032],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive-Compulsive Personality[MeSHID:D003193],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] phase 2 opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB phenylpropylamine derivative 2 NA NA patented opioid receptor sigma 1 SIGMAR1 Successful target unknown NA TTD , DGIDB dabrafenib small molecule melanoma[MeSHID:D008545],Disease[MeSHID:D004194],Anaplastic thyroid carcinoma[MeSHID:D065646],Mutation[MeSHID:D009154],Continuance of life[MeSHID:D013534],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serine/threonine-protein kinase sik1 SIK1 NA antagonist,inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase sik1 SIK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase sik2 SIK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase sik3 SIK3 NA inhibitor NA drugbank hg-9-91-01 NA NA investigative sik family kinase 3 SIK3 Literature-reported target inhibitor NA TTD , DGIDB bi 765063 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 inhibitory receptor shps-1 SIRPA Clinical trial target unknown NA TTD fsi-189 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 inhibitory receptor shps-1 SIRPA Clinical trial target unknown NA TTD cc-95251 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 inhibitory receptor shps-1 SIRPA Clinical trial target unknown NA TTD resveratrol NA Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 3 nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown 0.31 TTD , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational nad-dependent protein deacetylase sirtuin-1 SIRT1 NA unknown 0.31 drugbank , DGIDB srt2379 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD , DGIDB pmid25435179-compound-wo2012106509tenovin-6 NA NA patented nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD , DGIDB pmid25435179-compound-wo2012106509cay10602 NA NA patented nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD , DGIDB mb-12066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown 0.09 TTD , DGIDB sen-196 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816] phase 2 nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD , DGIDB cambinol small molecule NA experimental nad-dependent protein deacetylase sirtuin-1 SIRT1 NA inhibitor 0.82 drugbank , DGIDB yk-3237 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD selisistat small molecule NA experimental nad-dependent protein deacetylase sirtuin-1 SIRT1 NA inhibitor NA drugbank , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational nad-dependent protein deacetylase sirtuin-1 SIRT1 NA unknown 0.31 drugbank , DGIDB 2h-chromeno[2,3-d]pyrimidine-2,4(3h)-dione NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD para-sirtinol NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown 4.9 TTD , DGIDB resveratrol NA Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] phase 3 nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown 0.31 TTD , DGIDB (s)-sirtinol NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD meta-sirtinol NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown 4.9 TTD , DGIDB 2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD srt1720 NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target activator NA TTD , DGIDB srt3025 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD , DGIDB cambinol NA NA patented nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown 0.82 TTD , DGIDB gsk2245840 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD , DGIDB gsk184072 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110],Hematologic Neoplasms[MeSHID:D019337] discontinued in phase 2 nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD pmid25435179-compound-wo2012106509salermide NA NA patented nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD , DGIDB splitomicin NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target inhibitor 0.49 TTD , DGIDB ro31-8220 NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD ro-316233 NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD (r)-sirtinol NA NA investigative nad-dependent deacetylase sirtuin-1 SIRT1 Clinical trial target unknown NA TTD bdbm50363773 NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB agk2 NA NA investigative nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target inhibitor NA TTD , DGIDB bdbm50363782 NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB zinc915379 NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB ac1lfgwu NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB us9359293, ta NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB indus-815c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Retinal Diseases[MeSHID:D012164] investigative nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD bdbm50363780 NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB us9359293, tm NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB ac1lojyq NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB cambinol small molecule NA experimental nad-dependent protein deacetylase sirtuin-2 SIRT2 NA inhibitor NA drugbank us9359293, tb NA NA patented nad-dependent deacetylase sirtuin-2 SIRT2 Patented-recorded target unknown NA TTD , DGIDB adenosine-5-diphosphoribose small molecule NA experimental nad-dependent protein deacetylase sirtuin-3, mitochondrial SIRT3 NA unknown NA drugbank adenosine-5-diphosphoribose small molecule NA experimental nad-dependent protein deacylase sirtuin-5, mitochondrial SIRT5 NA unknown NA drugbank cambinol small molecule NA experimental nad-dependent protein deacylase sirtuin-5, mitochondrial SIRT5 NA inhibitor NA drugbank 2'-o-acetyl adenosine-5-diphosphoribose small molecule NA experimental nad-dependent protein deacylase sirtuin-5, mitochondrial SIRT5 NA unknown NA drugbank suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational nad-dependent protein deacylase sirtuin-5, mitochondrial SIRT5 NA inhibitor 1.12 drugbank , DGIDB suramin small molecule Disease[MeSHID:D004194],African Trypanosomiasis[MeSHID:D014353],Onchocerciasis[MeSHID:D009855],Helminthiasis[MeSHID:D006373],Trematode Infections[MeSHID:D014201],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] investigational nad-dependent protein deacylase sirtuin-5, mitochondrial SIRT5 NA inhibitor 1.12 drugbank , DGIDB nicotinamide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatologic disorders[MeSHID:D012871] approved,investigational nad-dependent protein deacylase sirtuin-5, mitochondrial SIRT5 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational apoptosis regulatory protein siva SIVA1 NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational apoptosis regulatory protein siva SIVA1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational apoptosis regulatory protein siva SIVA1 NA binder NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental apoptosis regulatory protein siva SIVA1 NA binder NA drugbank (2s)-2-(1h-indol-3-yl)hexanoic acid small molecule NA experimental s-phase kinase-associated protein 1 SKP1 NA unknown NA drugbank indoleacetic acid small molecule NA experimental s-phase kinase-associated protein 1 SKP1 NA unknown NA drugbank (2s)-8-[(tert-butoxycarbonyl)amino]-2-(1h-indol-3-yl)octanoic acid small molecule NA experimental s-phase kinase-associated protein 1 SKP1 NA unknown NA drugbank (2s)-2-(1h-indol-3-yl)pentanoic acid small molecule NA experimental s-phase kinase-associated protein 1 SKP1 NA unknown NA drugbank 1-naphthaleneacetic acid small molecule NA experimental s-phase kinase-associated protein 1 SKP1 NA unknown NA drugbank pvx-410 NA Triple Negative Breast Neoplasms[MeSHID:D064726],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant Neoplasms[MeSHID:D009369] phase 2 slam family member 7 slamf7 SLAMF7 Successful target unknown NA TTD elotuzumab biotech Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved slam family member 7 SLAMF7 NA modulator,inhibitor 318.26 drugbank , DGIDB ucartcs1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 slam family member 7 slamf7 SLAMF7 Successful target unknown NA TTD cs1-car t therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 slam family member 7 slamf7 SLAMF7 Successful target unknown NA TTD mb-104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 slam family member 7 slamf7 SLAMF7 Successful target unknown NA TTD elotuzumab NA Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved slam family member 7 slamf7 SLAMF7 Successful target inhibitor 318.26 TTD , DGIDB abbv-838 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 slam family member 7 slamf7 SLAMF7 Successful target unknown NA TTD elotuzumab NA Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved slam family member 7 slamf7 SLAMF7 Successful target unknown 318.26 TTD , DGIDB bcma-cs1 ccar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 slam family member 7 slamf7 SLAMF7 Successful target unknown NA TTD elotuzumab biotech Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved slam family member 7 SLAMF7 NA modulator 318.26 drugbank , DGIDB elotuzumab biotech Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved slam family member 7 SLAMF7 NA modulator,antibody 318.26 drugbank , DGIDB elotuzumab NA Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved slam family member 7 slamf7 SLAMF7 Successful target antibody 318.26 TTD , DGIDB lum001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary sclerosing cholangitis[MeSHID:D015209],Congenital Abnormality[MeSHID:D000013],Primary biliary cirrhosis[MeSHID:D008105],Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Cholangitis[MeSHID:D002761],Progressive intrahepatic cholestasis (disorder)[MeSHID:C535933] phase 2 sodium/bile acid cotransporter SLC10A1 Successful target unknown NA TTD , DGIDB bulevirtide biotech Hepatitis D Infection[MeSHID:D003699],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium/bile acid cotransporter SLC10A1 Successful target inhibitor NA TTD , drugbank maralixibat small molecule Pruritus[MeSHID:D011537],Cholestasis[MeSHID:D002779],Alagille Syndrome[MeSHID:D016738],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Progressive intrahepatic cholestasis (disorder)[MeSHID:C535933] approved,investigational,phase 3 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target inhibitor NA TTD , drugbank a-3309 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 3 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target unknown 38.19 TTD , DGIDB gsk2330672 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537] phase 2 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target unknown 12.73 TTD , DGIDB 1614235 + 2330672 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target unknown NA TTD , DGIDB lum001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary sclerosing cholangitis[MeSHID:D015209],Congenital Abnormality[MeSHID:D000013],Primary biliary cirrhosis[MeSHID:D008105],Liver[MeSHID:D008099],Bile fluid[MeSHID:D001646],Cholangitis[MeSHID:D002761],Progressive intrahepatic cholestasis (disorder)[MeSHID:C535933] phase 2 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target unknown NA TTD , DGIDB 264w94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target inhibitor NA TTD , DGIDB 264w94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target unknown NA TTD , DGIDB azd-7806 NA NA investigative ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target unknown NA TTD odevixibat small molecule Pruritus[MeSHID:D011537],Progressive intrahepatic cholestasis (disorder)[MeSHID:C535933],Alagille Syndrome[MeSHID:D016738],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,phase 3 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target inhibitor NA TTD , drugbank s-8921 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target unknown 12.73 TTD , DGIDB volixibat small molecule Disease[MeSHID:D004194] experimental,investigational ileal sodium/bile acid cotransporter SLC10A2 NA inhibitor NA drugbank taurocholic acid NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 ileal sodium/bile acid cotransporter SLC10A2 Clinical trial target unknown NA TTD , DGIDB ferric maltol small molecule Malnutrition[MeSHID:D044342],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Onychomycosis[MeSHID:D014009],Iron deficiency anemia[MeSHID:D018798] approved natural resistance-associated macrophage protein 2 SLC11A2 NA substrate NA drugbank ethacrynate sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved solute carrier family 12 member 1 SLC12A1 Successful target unknown NA TTD , DGIDB ethacrynic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved solute carrier family 12 member 1 SLC12A1 Successful target unknown NA TTD , DGIDB piretanide small molecule NA approved,investigative solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 1.52 TTD , drugbank , DGIDB chlorthalidone small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Renal Insufficiency[MeSHID:D051437],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Nephrotic Syndrome[MeSHID:D009404],Chronic Kidney Diseases[MeSHID:D051436],Kidney Failure, Chronic[MeSHID:D007676],Glomerulonephritis[MeSHID:D005921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 3.18 TTD , drugbank , DGIDB potassium chloride small molecule Hypokalemia[MeSHID:D007008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier family 12 member 1 SLC12A1 Successful target binder NA TTD , drugbank , DGIDB chlormerodrin small molecule Diagnosis[MeSHID:D003933],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier family 12 member 1 SLC12A1 NA inducer 13.64 drugbank , DGIDB cl-301 NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative solute carrier family 12 member 1 SLC12A1 Successful target unknown NA TTD ethacrynate sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 4.55 TTD , DGIDB quinethazone small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 1 SLC12A1 NA inhibitor NA drugbank furosemide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Nephrotic Syndrome[MeSHID:D009404],Diuresis[MeSHID:D004231],Pulmonary Edema[MeSHID:D011654],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 3.85 TTD , drugbank , DGIDB torasemide small molecule Kidney Failure[MeSHID:D051437],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Congestive heart failure[MeSHID:D006333],Kidney[MeSHID:D007668],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 2.89 TTD , drugbank , DGIDB hydroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 9.09 TTD , drugbank , DGIDB bumetanide small molecule Nephrotic Syndrome[MeSHID:D009404],Congestive heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 3.25 TTD , drugbank , DGIDB calyculin-a NA NA investigative solute carrier family 12 member 1 SLC12A1 Successful target unknown NA TTD ethacrynic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 0.38 TTD , DGIDB trichlormethiazide NA Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 1 SLC12A1 Successful target unknown 5.3 TTD , DGIDB etacrynic acid small molecule Hypertensive disease[MeSHID:D006973],Kidney Failure[MeSHID:D051437],Liver Failure[MeSHID:D017093],Edema[MeSHID:D004487],Congestive heart failure[MeSHID:D006333] approved,investigational solute carrier family 12 member 1 SLC12A1 NA inhibitor NA drugbank methyclothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn,approved solute carrier family 12 member 1 SLC12A1 Successful target inhibitor 9.09 TTD , drugbank , DGIDB bendroflumethiazide NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 1 SLC12A1 Successful target unknown 2.27 TTD , DGIDB aldosterone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved solute carrier family 12 member 1 SLC12A1 Successful target unknown 0.91 TTD , DGIDB bumetanide small molecule Nephrotic Syndrome[MeSHID:D009404],Congestive heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 2 SLC12A2 NA inhibitor 12.12 drugbank , DGIDB potassium chloride small molecule Hypokalemia[MeSHID:D007008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier family 12 member 2 SLC12A2 NA unknown NA drugbank torasemide small molecule Kidney Failure[MeSHID:D051437],Disease[MeSHID:D004194],Edema[MeSHID:D004487],Congestive heart failure[MeSHID:D006333],Kidney[MeSHID:D007668],Liver diseases[MeSHID:D008107],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 2 SLC12A2 NA inhibitor NA drugbank quinethazone small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 2 SLC12A2 NA inhibitor NA drugbank quinethazone small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 3 SLC12A3 NA inhibitor 24.75 drugbank , DGIDB chlorothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved solute carrier family 12 member 3 SLC12A3 NA inhibitor 5.3 drugbank , DGIDB metolazone small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Edema[MeSHID:D004487] approved solute carrier family 12 member 3 SLC12A3 Successful target inhibitor 7.07 TTD , drugbank , DGIDB hydrochlorothiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Nephrotic Syndrome[MeSHID:D009404],Chronic Kidney Diseases[MeSHID:D051436],Kidney Failure, Chronic[MeSHID:D007676],Glomerulonephritis[MeSHID:D005921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved solute carrier family 12 member 3 SLC12A3 NA inhibitor 1.08 drugbank , DGIDB bendroflumethiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 3 SLC12A3 Successful target inhibitor 12.38 TTD , drugbank , DGIDB benzthiazide small molecule Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 3 SLC12A3 NA inhibitor 6.19 drugbank , DGIDB polythiazide small molecule Systemic arterial pressure[MeSHID:D062186],Edema[MeSHID:D004487],Blood Pressure[MeSHID:D001794],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved solute carrier family 12 member 3 SLC12A3 Successful target inhibitor 28.29 TTD , drugbank , DGIDB indapamide small molecule Hypertensive disease[MeSHID:D006973],Systemic arterial pressure[MeSHID:D062186],Retention (Psychology)[MeSHID:D012153],Blood Pressure[MeSHID:D001794],Congestive heart failure[MeSHID:D006333],Body Fluids[MeSHID:D001826],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 3 SLC12A3 NA inhibitor 3.54 drugbank , DGIDB trichlormethiazide small molecule Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved solute carrier family 12 member 3 SLC12A3 NA inhibitor 2.95 drugbank , DGIDB potassium chloride small molecule Hypokalemia[MeSHID:D007008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier family 12 member 4 SLC12A4 NA unknown NA drugbank dioa NA NA investigative solute carrier family 12 member 4 SLC12A4 Literature-reported target inhibitor NA TTD , DGIDB bumetanide small molecule Nephrotic Syndrome[MeSHID:D009404],Congestive heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 4 SLC12A4 NA inhibitor 18.19 drugbank , DGIDB potassium chloride small molecule Hypokalemia[MeSHID:D007008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier family 12 member 5 SLC12A5 NA unknown NA drugbank bumetanide small molecule Nephrotic Syndrome[MeSHID:D009404],Congestive heart failure[MeSHID:D006333],Edema[MeSHID:D004487],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 12 member 5 SLC12A5 NA inhibitor 13.64 drugbank , DGIDB potassium chloride small molecule Hypokalemia[MeSHID:D007008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier family 12 member 6 SLC12A6 NA unknown NA drugbank potassium chloride small molecule Hypokalemia[MeSHID:D007008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier family 12 member 7 SLC12A7 NA unknown NA drugbank dioa NA NA investigative solute carrier family 12 member 7 SLC12A7 Literature-reported target inhibitor NA TTD , DGIDB cefotaxime small molecule Gonorrhea[MeSHID:D006069],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Pyelonephritis[MeSHID:D011704],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 15 member 1 SLC15A1 NA unknown NA drugbank dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 15 member 1 SLC15A1 NA unknown NA drugbank ceftriaxone small molecule Body tissue[MeSHID:D014024],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Hemolysis (disorder)[MeSHID:D006461],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 15 member 1 SLC15A1 NA unknown NA drugbank phenoxymethylpenicillin small molecule Bacteremia[MeSHID:D016470],Bacterial Endocarditis[MeSHID:D004697],Operative Surgical Procedures[MeSHID:D013514],Scarlet Fever[MeSHID:D012541],Skin Diseases, Infectious[MeSHID:D012874],Heart[MeSHID:D006321],Pharyngitis[MeSHID:D010612],Hypersensitivity[MeSHID:D006967],Infection[MeSHID:D007239],Congenital Disorders[MeSHID:D009358],Necrotizing Ulcerative Gingivitis[MeSHID:D005892],Body tissue[MeSHID:D014024],Respiratory tract structure[MeSHID:D012137],Erysipelas[MeSHID:D004886],Heart valve disease[MeSHID:D006349],Heart Diseases[MeSHID:D006331],Upper Respiratory Infections[MeSHID:D012141] approved,vet_approved solute carrier family 15 member 1 SLC15A1 NA unknown NA drugbank ampicillin small molecule Meningitis[MeSHID:D008581],Urinary tract infection[MeSHID:D014552],Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved solute carrier family 15 member 1 SLC15A1 NA unknown NA drugbank benzoic acid small molecule Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 15 member 1 SLC15A1 NA unknown NA drugbank oxacillin small molecule Staphylococcal Infections[MeSHID:D013203],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 15 member 1 SLC15A1 NA unknown NA drugbank benzylpenicillin small molecule Endocarditis[MeSHID:D004696],Sepsis[MeSHID:D018805],Meningitis[MeSHID:D008581],Pneumonia[MeSHID:D011014],Infection[MeSHID:D007239],Pericarditis[MeSHID:D010493] approved,vet_approved solute carrier family 15 member 1 SLC15A1 NA substrate,inhibitor NA drugbank ampicillin small molecule Meningitis[MeSHID:D008581],Urinary tract infection[MeSHID:D014552],Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved solute carrier family 15 member 2 SLC15A2 NA unknown NA drugbank lys[z(no2)]-lys[z(no2)] NA NA investigative solute carrier family 15 member 2 SLC15A2 Literature-reported target inhibitor NA TTD , DGIDB benzylpenicillin small molecule Endocarditis[MeSHID:D004696],Sepsis[MeSHID:D018805],Meningitis[MeSHID:D008581],Pneumonia[MeSHID:D011014],Infection[MeSHID:D007239],Pericarditis[MeSHID:D010493] approved,vet_approved solute carrier family 15 member 2 SLC15A2 NA inhibitor NA drugbank cefotaxime small molecule Gonorrhea[MeSHID:D006069],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Pyelonephritis[MeSHID:D011704],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 15 member 2 SLC15A2 NA unknown NA drugbank [3h]glysar NA NA investigative solute carrier family 15 member 2 SLC15A2 Literature-reported target unknown NA TTD , DGIDB [11c]glysar NA NA investigative solute carrier family 15 member 2 SLC15A2 Literature-reported target unknown NA TTD , DGIDB oxacillin small molecule Staphylococcal Infections[MeSHID:D013203],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 15 member 2 SLC15A2 NA unknown NA drugbank lys[z(no2)]-pro NA NA investigative solute carrier family 15 member 2 SLC15A2 Literature-reported target inhibitor NA TTD , DGIDB [14c]glysar NA NA investigative solute carrier family 15 member 2 SLC15A2 Literature-reported target unknown NA TTD , DGIDB [14c]histidine NA NA investigative solute carrier family 15 member 3 SLC15A3 Literature-reported target unknown NA TTD , DGIDB [3h]histidine NA NA investigative solute carrier family 15 member 3 SLC15A3 Literature-reported target unknown NA TTD , DGIDB [3h]histidine NA NA investigative solute carrier family 15 member 4 SLC15A4 Literature-reported target unknown NA TTD , DGIDB [14c]histidine NA NA investigative solute carrier family 15 member 4 SLC15A4 Literature-reported target unknown NA TTD , DGIDB pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical monocarboxylate transporter 1 SLC16A1 NA unknown NA drugbank mersalyl small molecule Hypertensive disease[MeSHID:D006973],Edema[MeSHID:D004487] experimental monocarboxylate transporter 1 SLC16A1 NA antagonist NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical monocarboxylate transporter 8 SLC16A2 NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical monocarboxylate transporter 4 SLC16A3 NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical monocarboxylate transporter 5 SLC16A4 NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical monocarboxylate transporter 6 SLC16A5 NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical monocarboxylate transporter 7 SLC16A6 NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical monocarboxylate transporter 2 SLC16A7 NA unknown NA drugbank pyruvic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical monocarboxylate transporter 3 SLC16A8 NA unknown NA drugbank reserpine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational chromaffin granule amine transporter SLC18A1 NA inhibitor 1.27 drugbank , DGIDB ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical chromaffin granule amine transporter SLC18A1 NA inhibitor NA drugbank mmda small molecule NA experimental,illicit chromaffin granule amine transporter SLC18A1 NA inhibitor NA drugbank metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit chromaffin granule amine transporter SLC18A1 NA inhibitor NA drugbank norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved chromaffin granule amine transporter SLC18A1 NA binder NA drugbank isometheptene small molecule Vascular constriction (function)[MeSHID:D014661],Tension Headache[MeSHID:D018781],Migraine Disorders[MeSHID:D008881] approved synaptic vesicular amine transporter SLC18A2 NA inhibitor NA drugbank serotonin small molecule NA investigational,nutraceutical synaptic vesicular amine transporter SLC18A2 NA unknown NA drugbank mmda small molecule NA experimental,illicit synaptic vesicular amine transporter SLC18A2 NA inhibitor NA drugbank deutetrabenazine NA Huntington Disease[MeSHID:D006816],Chorea[MeSHID:D002819],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tardive Dyskinesia[MeSHID:D000071057] approved synaptic vesicle amine transporter SLC18A2 Successful target unknown 3.18 TTD , DGIDB alkavervir NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved synaptic vesicle amine transporter SLC18A2 Successful target unknown 3.18 TTD , DGIDB mmda NA NA investigative synaptic vesicle amine transporter SLC18A2 Successful target unknown NA TTD mazindol small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational synaptic vesicular amine transporter SLC18A2 NA unknown NA drugbank dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved synaptic vesicular amine transporter SLC18A2 NA unknown NA drugbank tetrabenazine NA Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Hemiballismus[MeSHID:D020820],Gilles de la Tourette syndrome[MeSHID:D005879],Huntington Disease[MeSHID:D006816],Tic disorder[MeSHID:D013981],Tardive Dyskinesia[MeSHID:D000071057],Chorea, Senile[MeSHID:D002819],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved synaptic vesicle amine transporter SLC18A2 Successful target inhibitor 8.75 TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved synaptic vesicular amine transporter SLC18A2 NA unknown NA drugbank som3355 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Huntington Disease[MeSHID:D006816],Tardive Dyskinesia[MeSHID:D000071057] phase 2 synaptic vesicle amine transporter SLC18A2 Successful target unknown NA TTD , DGIDB amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational synaptic vesicular amine transporter SLC18A2 NA inhibitor 1.27 drugbank , DGIDB tetrabenazine small molecule Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Hemiballismus[MeSHID:D020820],Gilles de la Tourette syndrome[MeSHID:D005879],Huntington Disease[MeSHID:D006816],Tic disorder[MeSHID:D013981],Tardive Dyskinesia[MeSHID:D000071057],Chorea, Senile[MeSHID:D002819],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational synaptic vesicular amine transporter SLC18A2 NA inhibitor 8.75 drugbank , DGIDB rauwolfia serpentina root small molecule Hypertensive disease[MeSHID:D006973],Schizophrenia[MeSHID:D012559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tooth root structure[MeSHID:D014092] investigational synaptic vesicular amine transporter SLC18A2 NA inhibitor NA drugbank ingrezza NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tardive Dyskinesia[MeSHID:D000071057],Gilles de la Tourette syndrome[MeSHID:D005879] phase 4 synaptic vesicle amine transporter SLC18A2 Successful target unknown NA TTD av 133 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 synaptic vesicle amine transporter SLC18A2 Successful target unknown NA TTD , DGIDB nomifensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,withdrawn synaptic vesicular amine transporter SLC18A2 NA unknown NA drugbank ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical synaptic vesicular amine transporter SLC18A2 NA inhibitor NA drugbank deutetrabenazine NA Huntington Disease[MeSHID:D006816],Chorea[MeSHID:D002819],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tardive Dyskinesia[MeSHID:D000071057] approved synaptic vesicle amine transporter SLC18A2 Successful target inhibitor 3.18 TTD , DGIDB reserpine NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved synaptic vesicle amine transporter SLC18A2 Successful target inhibitor 1.78 TTD , DGIDB haloperidol small molecule Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disease[MeSHID:D004194],Attention[MeSHID:D001288],Gilles de la Tourette syndrome[MeSHID:D005879],Aggressive behavior[MeSHID:D000374],Behavioral tic[MeSHID:D020323],Hyperactive behavior[MeSHID:D006948],Tic disorder[MeSHID:D013981],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Immune Tolerance[MeSHID:D007108],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved synaptic vesicular amine transporter SLC18A2 NA unknown NA drugbank midomafetamine small molecule Anxiety Disorders[MeSHID:D001008],Malignant Neoplasms[MeSHID:D009369],Anxiety[MeSHID:D001007],Post-Traumatic Stress Disorder[MeSHID:D013313] experimental,illicit,investigational synaptic vesicular amine transporter SLC18A2 NA inhibitor NA drugbank methylenedioxymethamphetamine NA NA investigative synaptic vesicle amine transporter SLC18A2 Successful target unknown 1.91 TTD , DGIDB deutetrabenazine small molecule Huntington Disease[MeSHID:D006816],Chorea[MeSHID:D002819],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tardive Dyskinesia[MeSHID:D000071057] approved,investigational synaptic vesicular amine transporter SLC18A2 NA inhibitor 3.18 drugbank , DGIDB [11c]dtbz NA NA investigative synaptic vesicle amine transporter SLC18A2 Successful target inhibitor NA TTD , DGIDB propylhexedrine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] approved synaptic vesicular amine transporter SLC18A2 NA unknown NA drugbank benzphetamine small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit synaptic vesicular amine transporter SLC18A2 NA inducer NA drugbank metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit synaptic vesicular amine transporter SLC18A2 NA inhibitor NA drugbank tetrabenazine NA Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Hemiballismus[MeSHID:D020820],Gilles de la Tourette syndrome[MeSHID:D005879],Huntington Disease[MeSHID:D006816],Tic disorder[MeSHID:D013981],Tardive Dyskinesia[MeSHID:D000071057],Chorea, Senile[MeSHID:D002819],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved synaptic vesicle amine transporter SLC18A2 Successful target unknown 8.75 TTD , DGIDB reserpine NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved synaptic vesicle amine transporter SLC18A2 Successful target unknown 1.78 TTD , DGIDB valbenazine tosylate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Tardive Dyskinesia[MeSHID:D000071057] approved synaptic vesicle amine transporter SLC18A2 Successful target unknown NA TTD , DGIDB reserpine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational synaptic vesicular amine transporter SLC18A2 NA inhibitor 1.78 drugbank , DGIDB norepinephrine small molecule Hypotension[MeSHID:D007022],Neurogenesis[MeSHID:D055495],Continuance of life[MeSHID:D013534],Shock[MeSHID:D012769],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved synaptic vesicular amine transporter SLC18A2 NA binder NA drugbank alseroxylon NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved synaptic vesicle amine transporter SLC18A2 Successful target unknown 4.24 TTD , DGIDB nbi-98854 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Movement Disorders[MeSHID:D009069],Gilles de la Tourette syndrome[MeSHID:D005879] phase 3 synaptic vesicle amine transporter SLC18A2 Successful target unknown 6.37 TTD , DGIDB dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit synaptic vesicular amine transporter SLC18A2 NA inducer 2.12 drugbank , DGIDB histamine small molecule Gastric Acid[MeSHID:D005744],Diagnosis[MeSHID:D003933] approved,investigational synaptic vesicular amine transporter SLC18A2 NA unknown NA drugbank beta-methoxyamphetamine NA NA investigative synaptic vesicle amine transporter SLC18A2 Successful target unknown NA TTD deserpidine small molecule Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved synaptic vesicular amine transporter SLC18A2 NA inhibitor 5.57 drugbank , DGIDB 4-methoxyamphetamine small molecule NA experimental,illicit synaptic vesicular amine transporter SLC18A2 NA inhibitor NA drugbank [125i]7-azido-8-iodoketanserine NA NA investigative synaptic vesicle amine transporter SLC18A2 Successful target inhibitor NA TTD , DGIDB dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit synaptic vesicular amine transporter SLC18A2 NA inducer,inhibitor 2.12 drugbank , DGIDB lobeline NA Addictive Behavior[MeSHID:D016739],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Substance Use Disorders[MeSHID:D019966] phase 2 synaptic vesicle amine transporter SLC18A2 Successful target unknown 6.37 TTD , DGIDB [3h]vesamicol NA NA investigative vesicular acetylcholine transporter SLC18A3 Discontinued target unknown NA TTD , DGIDB [123i]iodobenzovesamicol NA NA investigative vesicular acetylcholine transporter SLC18A3 Discontinued target unknown NA TTD , DGIDB vesamicol NA NA investigative vesicular acetylcholine transporter SLC18A3 Discontinued target inhibitor 31.83 TTD , DGIDB aminobenzovesamicol NA NA investigative vesicular acetylcholine transporter SLC18A3 Discontinued target inhibitor NA TTD , DGIDB t-588 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690] discontinued in phase 2 vesicular acetylcholine transporter SLC18A3 Discontinued target unknown NA TTD methotrexate NA Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Proliferative vitreoretinopathy[MeSHID:D018630],leukemia[MeSHID:D007938],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369] approved solute carrier family 19 member 1 SLC19A1 Successful target inhibitor 0.11 TTD , DGIDB methotrexate NA Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved solute carrier family 19 member 1 SLC19A1 Successful target inhibitor 0.11 TTD , DGIDB methotrexate NA Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved solute carrier family 19 member 1 SLC19A1 Successful target unknown 0.11 TTD , DGIDB methotrexate NA Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Proliferative vitreoretinopathy[MeSHID:D018630],leukemia[MeSHID:D007938],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369] approved solute carrier family 19 member 1 SLC19A1 Successful target unknown 0.11 TTD , DGIDB folic acid NA Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 19 member 1 SLC19A1 Successful target unknown NA TTD , DGIDB folic acid NA Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Avitaminosis[MeSHID:D001361] approved solute carrier family 19 member 1 SLC19A1 Successful target unknown NA TTD , DGIDB [3h]thiamine NA NA investigative solute carrier family 19 member 2 SLC19A2 Literature-reported target unknown NA TTD , DGIDB [3h]thiamine NA NA investigative solute carrier family 19 member 3 SLC19A3 Literature-reported target unknown NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical excitatory amino acid transporter 3 SLC1A1 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical excitatory amino acid transporter 3 SLC1A1 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical excitatory amino acid transporter 2 SLC1A2 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical excitatory amino acid transporter 1 SLC1A3 NA unknown NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical neutral amino acid transporter a SLC1A4 NA unknown NA drugbank p-nitrophenyl glutamyl anilide NA NA investigative alanine/serine/cysteine transporter 2 SLC1A5 Literature-reported target unknown NA TTD asparagine small molecule NA approved,investigational,nutraceutical neutral amino acid transporter b(0) SLC1A5 NA unknown NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved neutral amino acid transporter b(0) SLC1A5 NA binder NA drugbank benzylserine NA NA investigative alanine/serine/cysteine transporter 2 SLC1A5 Literature-reported target inhibitor NA TTD , DGIDB [3h]etb-tboa NA NA investigative excitatory amino acid transporter 4 SLC1A6 Literature-reported target unknown NA TTD dl-tboa NA NA investigative excitatory amino acid transporter 4 SLC1A6 Literature-reported target inhibitor NA TTD , DGIDB glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical excitatory amino acid transporter 4 SLC1A6 NA unknown NA drugbank threo-3-methylglutamate NA NA investigative excitatory amino acid transporter 4 SLC1A6 Literature-reported target inhibitor NA TTD , DGIDB d-aspartic acid NA NA investigative excitatory amino acid transporter 4 SLC1A6 Literature-reported target unknown NA TTD glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical excitatory amino acid transporter 5 SLC1A7 NA unknown NA drugbank d-aspartic acid NA NA investigative excitatory amino acid transporter 5 SLC1A7 Literature-reported target unknown NA TTD dl-tboa NA NA investigative excitatory amino acid transporter 5 SLC1A7 Literature-reported target inhibitor NA TTD , DGIDB [3h]etb-tboa NA NA investigative excitatory amino acid transporter 5 SLC1A7 Literature-reported target unknown NA TTD lesinurad small molecule Serum[MeSHID:D044967],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 22 member 11 SLC22A11 NA inhibitor NA drugbank ceftriaxone small molecule Body tissue[MeSHID:D014024],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Hemolysis (disorder)[MeSHID:D006461],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 11 SLC22A11 NA unknown NA drugbank probenecid small molecule Mental concentration[MeSHID:D001288],Serum[MeSHID:D044967],Neoplasm Metastasis[MeSHID:D009362],Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 22 member 11 SLC22A11 NA inhibitor 13.92 drugbank , DGIDB cefotaxime small molecule Gonorrhea[MeSHID:D006069],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Pyelonephritis[MeSHID:D011704],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 11 SLC22A11 NA unknown NA drugbank benzoic acid derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB tihoacetate derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB cycloalkyl acid derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB pmid27414413-compound-figure6right NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB tetrazole acetic acid derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB sulfinpyrazone small molecule Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 12 SLC22A12 NA inhibitor 1.99 drugbank , DGIDB rdea3170 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] phase 2 urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB lesinurad small molecule Serum[MeSHID:D044967],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 22 member 12 SLC22A12 NA inhibitor 11.93 drugbank , DGIDB sulfonamide derivative 10 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB succinamide derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB benzofurans derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB urc102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] phase 2 urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB 2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB triazole propanedioic acid derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB ring-fused compound 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB fused heterocyclic compound 12 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB lesinurad NA Serum[MeSHID:D044967],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved urate anion exchanger 1 SLC22A12 Successful target inhibitor 11.93 TTD , DGIDB sulfonamide derivative 11 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB phenylthioacetate derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB rdea-684 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] phase 2 urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB cycloalkyl acid derivative 2 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB pmid27414413-compound-figure8right NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB lesinurad NA Serum[MeSHID:D044967],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved urate anion exchanger 1 SLC22A12 Successful target unknown 11.93 TTD , DGIDB morin NA NA investigative urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD 3-benzyloxyphenyloxoacetic acid derivative 1 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB benzene sulfonamide derivative 16 NA NA patented urate anion exchanger 1 SLC22A12 Successful target unknown NA TTD , DGIDB levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational solute carrier family 22 member 4 SLC22A4 NA unknown NA drugbank levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational solute carrier family 22 member 5 SLC22A5 NA unknown NA drugbank ceftriaxone small molecule Body tissue[MeSHID:D014024],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Hemolysis (disorder)[MeSHID:D006461],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 6 SLC22A6 NA unknown NA drugbank cefotaxime small molecule Gonorrhea[MeSHID:D006069],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Pyelonephritis[MeSHID:D011704],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 6 SLC22A6 NA unknown NA drugbank probenecid small molecule Mental concentration[MeSHID:D001288],Serum[MeSHID:D044967],Neoplasm Metastasis[MeSHID:D009362],Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 22 member 6 SLC22A6 NA inhibitor 6.96 drugbank , DGIDB cefotaxime small molecule Gonorrhea[MeSHID:D006069],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Pyelonephritis[MeSHID:D011704],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 7 SLC22A7 NA unknown NA drugbank probenecid small molecule Mental concentration[MeSHID:D001288],Serum[MeSHID:D044967],Neoplasm Metastasis[MeSHID:D009362],Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational solute carrier family 22 member 8 SLC22A8 Successful target inhibitor 7.34 TTD , drugbank , DGIDB cefotaxime small molecule Gonorrhea[MeSHID:D006069],Communicable Diseases[MeSHID:D003141],Operative Surgical Procedures[MeSHID:D013514],Pyelonephritis[MeSHID:D011704],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 8 SLC22A8 NA unknown 2.45 drugbank , DGIDB buproprion+zonisamide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 solute carrier family 22 member 8 SLC22A8 Successful target unknown NA TTD , DGIDB avatrombopag small molecule Liver[MeSHID:D008099],Chronic disease[MeSHID:D002908],Thrombocytopenia[MeSHID:D013921] approved,investigational solute carrier family 22 member 8 SLC22A8 NA inhibitor NA drugbank 3r14s-ochratoxin a NA NA investigative solute carrier family 22 member 8 SLC22A8 Successful target unknown NA TTD adipate NA NA investigative solute carrier family 22 member 8 SLC22A8 Successful target unknown NA TTD aminohippuric acid NA NA investigative solute carrier family 22 member 8 SLC22A8 Successful target unknown NA TTD heptanoate NA NA investigative solute carrier family 22 member 8 SLC22A8 Successful target unknown NA TTD benzylpenicillin small molecule Endocarditis[MeSHID:D004696],Sepsis[MeSHID:D018805],Meningitis[MeSHID:D008581],Pneumonia[MeSHID:D011014],Infection[MeSHID:D007239],Pericarditis[MeSHID:D010493] approved,vet_approved solute carrier family 22 member 8 SLC22A8 NA substrate,inhibitor 14.69 drugbank , DGIDB glutarate NA NA investigative solute carrier family 22 member 8 SLC22A8 Successful target unknown NA TTD gemfibrozil small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Fasting[MeSHID:D005215],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Serum[MeSHID:D044967],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Weight decreased[MeSHID:D015431],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 8 SLC22A8 NA inhibitor NA drugbank fluorescein NA Angioscopy[MeSHID:D017546],Diagnosis[MeSHID:D003933],gastric fundus[MeSHID:D005748],Iris (Eye)[MeSHID:D007498],Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 8 SLC22A8 Successful target unknown 0.7 TTD , DGIDB ceftriaxone small molecule Body tissue[MeSHID:D014024],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Hemolysis (disorder)[MeSHID:D006461],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 22 member 8 SLC22A8 NA unknown NA drugbank vitamin c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ascorbic Acid Deficiency[MeSHID:D001206],Urinary tract infection[MeSHID:D014552] approved solute carrier family 23 member 1 SLC23A1 Successful target unknown NA TTD , DGIDB phloretin NA NA investigative solute carrier family 23 member 1 SLC23A1 Successful target inhibitor 3.35 TTD , DGIDB ursodeoxycholic acid NA Biliary calculi[MeSHID:D042882],Cholecystolithiasis[MeSHID:D041761],Operative Surgical Procedures[MeSHID:D013514],Cholelithiasis[MeSHID:D002769],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Primary biliary cirrhosis[MeSHID:D008105] approved solute carrier family 23 member 2 SLC23A2 Successful target unknown NA TTD , DGIDB vitamin c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ascorbic Acid Deficiency[MeSHID:D001206],Urinary tract infection[MeSHID:D014552] approved solute carrier family 23 member 2 SLC23A2 Successful target unknown NA TTD , DGIDB 1,2,3-benzenetricarboxylic acid NA NA investigative mitochondrial citrate transporter SLC25A1 Literature-reported target inhibitor NA TTD , DGIDB aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical calcium-binding mitochondrial carrier protein aralar1 SLC25A12 NA unknown NA drugbank aspartic acid small molecule Acquired Immunodeficiency Syndrome[MeSHID:D000163] approved,nutraceutical calcium-binding mitochondrial carrier protein aralar2 SLC25A13 NA unknown NA drugbank ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical mitochondrial ornithine transporter 1 SLC25A15 NA unknown NA drugbank ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical mitochondrial ornithine transporter 2 SLC25A2 NA unknown NA drugbank levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational mitochondrial carnitine/acylcarnitine carrier protein SLC25A20 NA unknown NA drugbank levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational mitochondrial carnitine/acylcarnitine carrier protein cacl SLC25A29 NA unknown NA drugbank cardiolipin NA NA investigative adenine nucleotide translocator 1 SLC25A4 Successful target unknown NA TTD clodronic acid small molecule Disease Management[MeSHID:D019468],Lytic lesion[MeSHID:D010014],Neoplasm Metastasis[MeSHID:D009362],Malignant Bone Neoplasm[MeSHID:D001859],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390] approved,investigational,vet_approved adp/atp translocase 1 SLC25A4 NA inhibitor NA drugbank [3-(dodecanoylamino)propyl](hydroxy)dimethylammonium small molecule NA experimental adp/atp translocase 1 SLC25A4 NA unknown NA drugbank carboxyatractyloside small molecule NA experimental adp/atp translocase 1 SLC25A4 NA inhibitor NA drugbank , DGIDB tetrastearoyl cardiolipin small molecule NA experimental adp/atp translocase 1 SLC25A4 NA unknown NA drugbank carboxyatractyloside NA NA investigative adenine nucleotide translocator 1 SLC25A4 Successful target inhibitor NA TTD , DGIDB di-stearoyl-3-sn-phosphatidylcholine NA NA investigative adenine nucleotide translocator 1 SLC25A4 Successful target unknown NA TTD etidronic acid small molecule Osteogenesis[MeSHID:D010012],Strabismus[MeSHID:D013285],Spinal Cord Injuries[MeSHID:D013119],Osteitis Deformans[MeSHID:D010001],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adp/atp translocase 1 SLC25A4 NA inhibitor NA drugbank atp small molecule NA investigational,nutraceutical adp/atp translocase 1 SLC25A4 NA unknown NA drugbank di-stearoyl-3-sn-phosphatidylcholine small molecule NA experimental adp/atp translocase 1 SLC25A4 NA unknown NA drugbank clodronate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypercalcemia[MeSHID:D006934] approved adenine nucleotide translocator 1 SLC25A4 Successful target unknown 25.46 TTD , DGIDB bongkrek acid NA NA investigative adenine nucleotide translocator 1 SLC25A4 Successful target inhibitor NA TTD , DGIDB etidronic acid small molecule Osteogenesis[MeSHID:D010012],Strabismus[MeSHID:D013285],Spinal Cord Injuries[MeSHID:D013119],Osteitis Deformans[MeSHID:D010001],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adp/atp translocase 2 SLC25A5 NA inhibitor NA drugbank clodronic acid small molecule Disease Management[MeSHID:D019468],Lytic lesion[MeSHID:D010014],Neoplasm Metastasis[MeSHID:D009362],Malignant Bone Neoplasm[MeSHID:D001859],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390] approved,investigational,vet_approved adp/atp translocase 2 SLC25A5 NA inhibitor NA drugbank etidronic acid small molecule Osteogenesis[MeSHID:D010012],Strabismus[MeSHID:D013285],Spinal Cord Injuries[MeSHID:D013119],Osteitis Deformans[MeSHID:D010001],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved adp/atp translocase 3 SLC25A6 NA inhibitor NA drugbank clodronic acid small molecule Disease Management[MeSHID:D019468],Lytic lesion[MeSHID:D010014],Neoplasm Metastasis[MeSHID:D009362],Malignant Bone Neoplasm[MeSHID:D001859],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390] approved,investigational,vet_approved adp/atp translocase 3 SLC25A6 NA inhibitor NA drugbank pmid25815140c48 NA NA investigative solute carrier family 28 member 2 SLC28A2 Literature-reported target unknown NA TTD n6-cyclopentyladenosine NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target unknown NA TTD ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved equilibrative nucleoside transporter 1 SLC29A1 NA unknown 0.16 drugbank , DGIDB troglitazone small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved,investigational,withdrawn equilibrative nucleoside transporter 1 SLC29A1 NA inhibitor NA drugbank 9-benzyl-6-(4-nitro-benzylsulfanyl)-9h-purine NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target unknown NA TTD nbtgr NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational equilibrative nucleoside transporter 1 SLC29A1 NA inhibitor NA drugbank s6-nitrobenzyl mercaptopurine riboside NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target unknown NA TTD nitrobenzylthioinosine NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target unknown NA TTD lidoflazine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved solute carrier family 29 member 1 SLC29A1 Successful target unknown 1.14 TTD , DGIDB 6-(4-nitro-benzylsulfanyl)-9-phenethyl-9h-purine NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target unknown NA TTD [3h]nitrobenzylmercaptopurine ribonucleoside NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target unknown NA TTD , DGIDB dilazep NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target inhibitor 0.91 TTD , DGIDB kf24345 NA NA investigative solute carrier family 29 member 1 SLC29A1 Successful target inhibitor NA TTD , DGIDB ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved equilibrative nucleoside transporter 2 SLC29A2 NA unknown NA drugbank decynium 22 NA NA investigative solute carrier family 29 member 4 SLC29A4 Literature-reported target inhibitor NA TTD , DGIDB sertraline small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Post-Traumatic Stress Disorder[MeSHID:D013313],Vasovagal syncope[MeSHID:D019462],Phobia, Social[MeSHID:D000072861],Cerebrovascular accident[MeSHID:D020521],Panic Disorder[MeSHID:D016584],Obsessive compulsive behavior[MeSHID:D003192],Premenstrual Dysphoric Disorder[MeSHID:D065446],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved equilibrative nucleoside transporter 4 SLC29A4 NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 NA unknown NA drugbank carboxymethylcellulose small molecule Flatulence[MeSHID:D005414],Desiccation[MeSHID:D003890],Environmental Wind[MeSHID:D014919],Sunlight[MeSHID:D013472],Eye[MeSHID:D005123] approved,investigational solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 NA binder NA drugbank streptozocin small molecule Pancreatic Endocrine Carcinoma[MeSHID:D018273],Malignant neoplasm of pancreas[MeSHID:D010190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatic carcinoma[MeSHID:C562463] approved,investigational solute carrier family 2, facilitated glucose transporter member 2 SLC2A2 NA ligand NA drugbank ds-1150b NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 glucose transporter type 4 SLC2A4 Clinical trial target unknown NA TTD , DGIDB aa-193 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] discontinued in phase 2 glucose transporter type 9 SLC2A9 Discontinued target unknown NA TTD quinapril NA treatment failure[MeSHID:D017211],Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD gallopamil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Asthma[MeSHID:D001249] phase 2 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD enalapril NA Disease Management[MeSHID:D019468],Hospitalization[MeSHID:D006760],Heart failure[MeSHID:D006333],heart rate[MeSHID:D006339],Ventricular Dysfunction, Left[MeSHID:D018487],Hypertension, Renovascular[MeSHID:D006978],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD moexipril NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD [cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD rip NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD zabiciprilat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD gw-796406 NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD enalaprilat NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD 2-(acetylamino)-2-deoxy-a-d-glucopyranose NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD astragalin NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD fosinopril NA Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Congestive heart failure[MeSHID:D006333],Kidney[MeSHID:D007668],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD captopril NA Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD rescinnamine NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD trandolapril NA Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Congestive heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Kidney[MeSHID:D007668],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD butein NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD perindopril NA Coronary Artery Disease[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Coronary heart disease[MeSHID:D003327],Congestive heart failure[MeSHID:D006333],Essential Hypertension[MeSHID:D000075222],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD benazepril NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD hydrochlorothiazide NA Hypertensive disease[MeSHID:D006973],Disease Management[MeSHID:D019468],Edema[MeSHID:D004487],Liver Cirrhosis[MeSHID:D008103],Congestive heart failure[MeSHID:D006333],Nephrotic Syndrome[MeSHID:D009404],Chronic Kidney Diseases[MeSHID:D051436],Kidney Failure, Chronic[MeSHID:D007676],Glomerulonephritis[MeSHID:D005921],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD cilazapril NA Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD idrapril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD contigoside b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2/3 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD deserpidine NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD rxp-407 NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD kaempferol-3-o-(2''-o-galloyl)-glucoside NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD ramipril NA Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Cerebrovascular accident[MeSHID:D020521],Kidney[MeSHID:D007668],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD m-100240 NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD n-carboxymethyl-n-cyclopentyl-phthalamic acid NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD lisinopril NA Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD spirapril NA Hypertensive disease[MeSHID:D006973],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD moexiprilat NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD rb-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD fasidotrilat NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD delapril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD imidapril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD rjm-0035-k002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD brl-36378 NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD lisinopril-tryptophan NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD alacepril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD ceronapril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD metiapril NA Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD utibapril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] discontinued in phase 2 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD acetate ion NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD lisinopril NA Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD temocapril hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD captopril NA Congestive heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Hypertension, Renovascular[MeSHID:D006978],Ventricular Dysfunction, Left[MeSHID:D018487],Continuance of life[MeSHID:D013534],Myocardial Infarction[MeSHID:D009203],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD ly-292223 NA NA investigative angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD ramipril NA Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Congestive heart failure[MeSHID:D006333],Cerebrovascular accident[MeSHID:D020521],Kidney[MeSHID:D007668],Myocardial Infarction[MeSHID:D009203],Disease Progression[MeSHID:D018450],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD ilepatril NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Diabetic Nephropathy[MeSHID:D003928],Kidney Failure[MeSHID:D051437],Heart failure[MeSHID:D006333] discontinued in phase 2/3 angiotensin-converting enzyme SLC33A1 Successful target unknown NA TTD alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical proton-coupled amino acid transporter 1 SLC36A1 NA unknown NA drugbank indole-3-propionic acid NA NA investigative solute carrier family 36 member 1 SLC36A1 Literature-reported target inhibitor NA TTD , DGIDB 5-hydroxy-l-tryptophan NA NA investigative solute carrier family 36 member 1 SLC36A1 Literature-reported target inhibitor 3.54 TTD , DGIDB 5-hydroxy-l-tryptophan NA NA investigative solute carrier family 36 member 2 SLC36A2 Literature-reported target inhibitor 10.61 TTD , DGIDB asparagine small molecule NA approved,investigational,nutraceutical sodium-coupled neutral amino acid transporters SLC38A1 NA inhibitor NA drugbank asparagine small molecule NA approved,investigational,nutraceutical sodium-coupled neutral amino acid transporters SLC38A2 NA inhibitor NA drugbank histidine small molecule Serum[MeSHID:D044967],Uremia[MeSHID:D014511],Anemia[MeSHID:D000740],Rheumatoid Arthritis[MeSHID:D001172] investigational,nutraceutical sodium-coupled neutral amino acid transporter 3 SLC38A3 NA unknown NA drugbank asparagine small molecule NA approved,investigational,nutraceutical sodium-coupled neutral amino acid transporters SLC38A3 NA inhibitor NA drugbank asparagine small molecule NA approved,investigational,nutraceutical sodium-coupled neutral amino acid transporters SLC38A4 NA inhibitor NA drugbank [14c]histidine NA NA investigative solute carrier family 38 member 5 SLC38A5 Literature-reported target unknown NA TTD , DGIDB [3h]histidine NA NA investigative solute carrier family 38 member 5 SLC38A5 Literature-reported target unknown NA TTD , DGIDB sgn-liv1a NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Small cell carcinoma of lung[MeSHID:D055752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 solute carrier family 39 member 6 SLC39A6 Clinical trial target unknown NA TTD sgn liv1a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 solute carrier family 39 member 6 SLC39A6 Clinical trial target unknown NA TTD , DGIDB ign523 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 lymphocyte activation antigen 4f2 SLC3A2 Clinical trial target unknown NA TTD , DGIDB ign523 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 lymphocyte activation antigen 4f2 SLC3A2 Clinical trial target antibody NA TTD , DGIDB ly2928057 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2 solute carrier family 40 member 1 SLC40A1 Clinical trial target antibody NA TTD , DGIDB ferroportin mab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 1 solute carrier family 40 member 1 SLC40A1 Clinical trial target unknown NA TTD , DGIDB m012 NA Thalassemia[MeSHID:D013789],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Polycythemia Vera[MeSHID:D011087] phase 1 solute carrier family 40 member 1 SLC40A1 Clinical trial target unknown NA TTD ly2928057 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anemia[MeSHID:D000740] phase 2 solute carrier family 40 member 1 SLC40A1 Clinical trial target unknown NA TTD , DGIDB asg-5me NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 choline transporter-like protein 4 SLC44A4 Clinical trial target unknown 63.65 TTD , DGIDB methotrexate NA Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved proton-coupled folate transporter SLC46A1 Successful target unknown 0.44 TTD , DGIDB methotrexate NA Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Proliferative vitreoretinopathy[MeSHID:D018630],leukemia[MeSHID:D007938],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369] approved proton-coupled folate transporter SLC46A1 Successful target unknown 0.44 TTD , DGIDB [3h]folinic acid NA NA investigative proton-coupled folate transporter SLC46A1 Successful target unknown NA TTD , DGIDB [3h]n5-methylfolate NA NA investigative proton-coupled folate transporter SLC46A1 Successful target unknown NA TTD , DGIDB folic acid NA Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proton-coupled folate transporter SLC46A1 Successful target unknown NA TTD , DGIDB folic acid NA Folic Acid Deficiency[MeSHID:D005494],Anemia[MeSHID:D000740],Anemia, Megaloblastic[MeSHID:D000749],Pregnancy[MeSHID:D011247],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Avitaminosis[MeSHID:D001361] approved proton-coupled folate transporter SLC46A1 Successful target unknown NA TTD , DGIDB premetrexed NA NA investigative proton-coupled folate transporter SLC46A1 Successful target unknown NA TTD , DGIDB metformin NA Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved solute carrier family 47 member 1 SLC47A1 Successful target unknown 3.77 TTD , DGIDB [14c]tea NA NA investigative solute carrier family 47 member 1 SLC47A1 Successful target unknown NA TTD , DGIDB metformin NA Diagnosis[MeSHID:D003933],Patient Discharge[MeSHID:D010351],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier family 47 member 1 SLC47A1 Successful target unknown 3.77 TTD , DGIDB [14c]tea NA NA investigative multidrug and toxin extrusion protein 2 SLC47A2 Literature-reported target unknown NA TTD , DGIDB gamma-hydroxybutyric acid small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Athletic Performance[MeSHID:D054874],Narcolepsy[MeSHID:D009290],Alcoholic Intoxication, Chronic[MeSHID:D000437],Mental Depression[MeSHID:D003863],Sleeplessness[MeSHID:D007319] approved,illicit,investigational gamma-hydroxybutyrate (ghb) receptor SLC52A2 NA agonist NA drugbank 10-methoxy-n(1)-methylburnamine-17-o-veratrate NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD qcpac NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD alstiphyllanine f NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD 1614235 + 2330672 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD , DGIDB alstiphyllanine d NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD lx-4211 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318], Insulin-Dependent[MeSHID:D003922] phase 3 sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown 4.9 TTD , DGIDB qspac NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD lx2761 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD sophoraflavanone g NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD acerogenin b NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD kuraidin NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD burnamine-17-o-3',4',5'-trimethoxybenzoate NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD alstiphyllanine e NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD acerogenin a NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD t-1095 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD sergliflozin NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target inhibitor 2.45 TTD , DGIDB lik-066 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown 3.26 TTD , DGIDB o-spiroketal glucoside NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD gsk1614235 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown 4.9 TTD , DGIDB qneqcpqvsac NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD phlorizin NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD kurarinone NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD kushenol n NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD qcp NA NA investigative sodium/glucose cotransporter 1 SLC5A1 Clinical trial target unknown NA TTD empagli ozin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD burnamine-17-o-3',4',5'-trimethoxybenzoate NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD formononetin NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD maackiain NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD dapagliflozin propanediol; saxagliptin hydrochloride NA NA approved sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD dapagliflozin small molecule Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/glucose cotransporter 2 SLC5A2 Successful target antagonist,inhibitor 4.24 TTD , drugbank , DGIDB kuraidin NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD kurarinone NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD ro-4998452 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD remogliflozin etabonate NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 2 sodium/glucose cotransporter 2 SLC5A2 Successful target inhibitor 4.24 TTD , DGIDB o-spiroketal glucoside NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD ts-033 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] discontinued in phase 2 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD ave-2268 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 2 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD sophoraflavanone g NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD asp1941 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] phase 3 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD sergliflozin a NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD canagliflozin small molecule Diabetic Ketoacidosis[MeSHID:D016883],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Cessation of life[MeSHID:D003643],Hospitalization[MeSHID:D006760],Serum[MeSHID:D044967],Diet therapy[MeSHID:D004035],Diagnosis[MeSHID:D003933],Heart failure[MeSHID:D006333],Diabetic Nephropathy[MeSHID:D003928],Cause of Death[MeSHID:D002423], Non-Insulin-Dependent[MeSHID:D003924],Cerebrovascular accident[MeSHID:D020521],Myocardial Infarction[MeSHID:D009203],Albuminuria[MeSHID:D000419],Kidney Failure, Chronic[MeSHID:D007676],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/glucose cotransporter 2 SLC5A2 Successful target inhibitor 4.24 TTD , drugbank , DGIDB empagliflozin small molecule Disease Management[MeSHID:D019468],Diabetes Mellitus[MeSHID:D003920],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922],Diet therapy[MeSHID:D004035],Hospitalization[MeSHID:D006760],Cessation of life[MeSHID:D003643],Heart failure[MeSHID:D006333],Cardiovascular Diseases[MeSHID:D002318], Non-Insulin-Dependent[MeSHID:D003924],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/glucose cotransporter 2 SLC5A2 Successful target inhibitor 5.66 TTD , drugbank , DGIDB dapagliflozin small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/glucose cotransporter 2 SLC5A2 Successful target antagonist,inhibitor 4.24 TTD , drugbank , DGIDB bi-44847 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD acerogenin c NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD egt-0001474 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD sergliflozin NA NA investigative sodium/glucose cotransporter 2 SLC5A2 Successful target inhibitor 2.12 TTD , DGIDB pf-04971729 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD ym-543 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD lik-066 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD 10-methoxy-n(1)-methylburnamine-17-o-veratrate NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD alstiphyllanine e NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD alstiphyllanine f NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD bexagliflozin NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 slc5a2 messenger rna SLC5A2 Clinical trial target inhibitor 4.24 TTD , DGIDB alstiphyllanine d NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD isis-sglt2 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD ertugliflozin small molecule Diet therapy[MeSHID:D004035],Sedentary lifestyle[MeSHID:D057185],Liver[MeSHID:D008099],Reproductive History[MeSHID:D017584],Blood[MeSHID:D001769],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Insulin Resistance[MeSHID:D007333],Aging[MeSHID:D000375],Obesity[MeSHID:D009765],Kidney[MeSHID:D007668],Eye[MeSHID:D005123],Malnutrition[MeSHID:D044342],Muscle[MeSHID:D009132] approved,investigational sodium/glucose cotransporter 2 SLC5A2 NA antagonist,inhibitor 4.24 drugbank , DGIDB acerogenin b NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD kushenol n NA NA investigative slc5a2 messenger rna SLC5A2 Clinical trial target unknown NA TTD lx-4211 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318], Insulin-Dependent[MeSHID:D003922] phase 3 sodium/glucose cotransporter 2 SLC5A2 Successful target unknown NA TTD remogliflozin etabonate NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174], Insulin-Dependent[MeSHID:D003922] phase 2 sodium/glucose cotransporter 2 SLC5A4 Clinical trial target unknown NA TTD , DGIDB ponalrestat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Gout[MeSHID:D006073] discontinued in phase 3 sodium/glucose cotransporter 2 SLC5A4 Clinical trial target unknown NA TTD saxadapa fdc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909],Familial dilated cardiomyopathy[MeSHID:C536231] phase 3 sodium/glucose cotransporter 2 SLC5A4 Clinical trial target unknown NA TTD , DGIDB remogli ozin-etabonate NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 sodium/glucose cotransporter 2 SLC5A4 Clinical trial target unknown NA TTD , DGIDB rg7201 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 sodium/glucose cotransporter 2 SLC5A4 Clinical trial target unknown NA TTD , DGIDB ad5cmv-nis NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 sodium/iodide cotransporter SLC5A5 Clinical trial target unknown NA TTD , DGIDB iodine small molecule Pain[MeSHID:D010146],Breast Diseases[MeSHID:D001941] approved,investigational sodium/iodide cotransporter SLC5A5 NA substrate NA drugbank potassium perchlorate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperthyroidism[MeSHID:D006980] approved,investigational sodium/iodide cotransporter SLC5A5 NA inhibitor NA drugbank gabapentin enacarbil NA Postherpetic neuralgia[MeSHID:D051474],Restless Legs Syndrome[MeSHID:D012148],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 2 sodium-dependent multivitamin transporter SLC5A6 Successful target unknown NA TTD , DGIDB lipoic acid small molecule NA approved,investigational,nutraceutical sodium-dependent multivitamin transporter SLC5A6 NA unknown NA drugbank [3h]hemicholinium-3 NA NA investigative high affinity choline transporter 1 SLC5A7 Literature-reported target unknown NA TTD , DGIDB guvacine small molecule NA experimental sodium- and chloride-dependent gaba transporter 1 SLC6A1 NA inhibitor NA drugbank (r/s) ef-1500 NA NA investigative gaba transporter gat-1 SLC6A1 Successful target inhibitor NA TTD , DGIDB gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 gaba transporter gat-1 SLC6A1 Successful target unknown NA TTD , DGIDB metadoxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved gaba transporter gat-1 SLC6A1 Successful target unknown NA TTD , DGIDB tiagabine NA Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827] approved gaba transporter gat-1 SLC6A1 Successful target inhibitor 63.65 TTD , DGIDB nipecotic acid NA NA investigative gaba transporter gat-1 SLC6A1 Successful target unknown NA TTD (r)-nipecotic acid NA NA investigative gaba transporter gat-1 SLC6A1 Successful target unknown NA TTD (r)-ef-1520 NA NA investigative gaba transporter gat-1 SLC6A1 Successful target inhibitor NA TTD , DGIDB (s)-piperidine-3-carboxylic acid NA NA investigative gaba transporter gat-1 SLC6A1 Successful target unknown NA TTD (s)-ef-1520 NA NA investigative gaba transporter gat-1 SLC6A1 Successful target inhibitor NA TTD , DGIDB skf89976a NA NA investigative gaba transporter gat-1 SLC6A1 Successful target inhibitor NA TTD , DGIDB ci-966 NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 gaba transporter gat-1 SLC6A1 Successful target inhibitor 12.73 TTD , DGIDB tiagabine small molecule Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827] approved,investigational sodium- and chloride-dependent gaba transporter 1 SLC6A1 NA inhibitor 63.65 drugbank , DGIDB lu32-176b NA NA investigative gaba transporter gat-1 SLC6A1 Successful target unknown NA TTD 4-hydroxy-piperidine-3-carboxylic acid NA NA investigative gaba transporter gat-1 SLC6A1 Successful target unknown NA TTD 2,4-diamino-butyric acid(gaba) NA NA investigative gaba transporter gat-1 SLC6A1 Successful target unknown NA TTD ci-966 NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 gaba transporter gat-1 SLC6A1 Successful target unknown 12.73 TTD , DGIDB tiagabine NA Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Epilepsy[MeSHID:D004827] approved gaba transporter gat-1 SLC6A1 Successful target unknown 63.65 TTD , DGIDB guvacine small molecule NA experimental sodium- and chloride-dependent gaba transporter 3 SLC6A11 NA inhibitor NA drugbank nipecotic acid NA NA investigative gaba transporter-3 SLC6A11 Clinical trial target unknown NA TTD 4-hydroxy-piperidine-3-carboxylic acid NA NA investigative gaba transporter-3 SLC6A11 Clinical trial target unknown NA TTD gsk683699 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 2 gaba transporter-3 SLC6A11 Clinical trial target unknown NA TTD , DGIDB 2,4-diamino-butyric acid(gaba) NA NA investigative gaba transporter-3 SLC6A11 Clinical trial target unknown NA TTD beta-alanine NA NA investigative gaba transporter-3 SLC6A11 Clinical trial target unknown NA TTD guvacine small molecule NA experimental sodium- and chloride-dependent betaine transporter SLC6A12 NA inhibitor NA drugbank (r)-ef-1520 NA NA investigative na(+)/cl(-) betaine/gaba transporter SLC6A12 Literature-reported target inhibitor NA TTD , DGIDB nnc052090 NA NA investigative na(+)/cl(-) betaine/gaba transporter SLC6A12 Literature-reported target unknown NA TTD lu32-176b NA NA investigative na(+)/cl(-) betaine/gaba transporter SLC6A12 Literature-reported target unknown NA TTD (r/s) ef-1500 NA NA investigative na(+)/cl(-) betaine/gaba transporter SLC6A12 Literature-reported target inhibitor NA TTD , DGIDB (s)-ef-1520 NA NA investigative na(+)/cl(-) betaine/gaba transporter SLC6A12 Literature-reported target inhibitor NA TTD , DGIDB guvacine small molecule NA experimental sodium- and chloride-dependent gaba transporter 2 SLC6A13 NA inhibitor NA drugbank proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical sodium- and chloride-dependent neutral and basic amino acid transporter b(0+) SLC6A14 NA unknown NA drugbank 2-(tert-butylamino)-1-p-tolylpropan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD gsk-1360707 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(tert-butylamino)-1-m-tolylpropan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD protriptyline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 1.3 drugbank , DGIDB 2-aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD benzatropine small molecule Bradykinesia[MeSHID:D018476],Dystonia[MeSHID:D004421],Disease[MeSHID:D004194],Dyskinetic syndrome[MeSHID:D020820],Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Akathisia[MeSHID:D011595],Movement[MeSHID:D009068],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Term Birth[MeSHID:D047929] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank 3alpha-(bis-chloro-phenylmethoxy)tropane NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD n,n-dimethyl(2-phenoxyphenyl)methanamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD suronacrine maleate NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 norepinephrine transporter SLC6A2 Successful target unknown NA TTD tesofensine small molecule Obesity[MeSHID:D009765],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational sodium-dependent noradrenaline transporter SLC6A2 NA unknown 0.87 drugbank , DGIDB venlafaxine small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Phobia, Social[MeSHID:D000072861],Obsessive compulsive behavior[MeSHID:D003192],Off-Label Use[MeSHID:D056687],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Agoraphobia[MeSHID:D000379],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 1.13 drugbank , DGIDB cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank dov-216303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD hypericum NA NA phase 4 norepinephrine transporter SLC6A2 Successful target unknown NA TTD netarsudil NA Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Ocular Hypotension[MeSHID:D015814],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-(4-fluorobenzyloxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.36 drugbank , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.97 drugbank , DGIDB 1-(3,4-dichloro-phenyl)-3-diethylamino-indan-5-ol NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD nomifensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,withdrawn sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.87 drugbank , DGIDB 8-methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.49 drugbank , DGIDB 4-(2-(benzyloxy)-6-fluorophenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(2,3-dihydro-1h-indol-5-yl)-1-methyl-ethylamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD sibutramine small molecule Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 3.03 drugbank , DGIDB 2-(n-pyrrolidinyl)-3'-methoxypropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-aminomethyl-5-(phenyl)tetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(aminomethyl)-5-(1'-naphthyl)tetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 3-(3'-furyl)-aniline NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD duloxetine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Low Back Pain[MeSHID:D017116],Urinary Stress Incontinence[MeSHID:D014550],Anxiety Disorders[MeSHID:D001008],Osteoarthritis, Knee[MeSHID:D020370],Peripheral Neuropathy[MeSHID:D010523],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 1.17 drugbank , DGIDB 1-(2-(2-fluorobenzyloxy)phenyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-(3-chlorophenoxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD atomoxetine NA Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target unknown 4.42 TTD , DGIDB mazindol NA Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target inhibitor 2.27 TTD , DGIDB trodusquemine small molecule Obesity[MeSHID:D009765],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational sodium-dependent noradrenaline transporter SLC6A2 NA unknown NA drugbank 2-(n-pyrrolidinyl)-3'-bromopropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD atomoxetine NA Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target inhibitor 4.42 TTD , DGIDB mazindol small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 2.27 drugbank , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank 4-(2-(3-fluorophenoxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD maprotiline NA Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target unknown 0.87 TTD , DGIDB 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 3-p-tolyl-8-aza-bicyclo[3.2.1]octane NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-(4-fluorophenoxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD maprotiline small molecule Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.87 drugbank , DGIDB 2-(n-pyrrolidinyl)-3'-nitropropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD amitriptyline NA Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target unknown 0.39 TTD , DGIDB spn-812 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Solitary Pulmonary Nodule[MeSHID:D003074],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD levomilnacipran NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved norepinephrine transporter SLC6A2 Successful target unknown 0.87 TTD , DGIDB spn-812 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Solitary Pulmonary Nodule[MeSHID:D003074],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 4 norepinephrine transporter SLC6A2 Successful target unknown NA TTD amoxapine NA Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target inhibitor 0.52 TTD , DGIDB 2-(n-tert-butylamino)propiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD bicifadine NA Low Back Pain[MeSHID:D017116],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437] phase 3 norepinephrine transporter SLC6A2 Successful target unknown NA TTD sibutramine NA Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target unknown 3.03 TTD , DGIDB levomilnacipran NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved norepinephrine transporter SLC6A2 Successful target inhibitor 0.87 TTD , DGIDB 4-(3-fluoro-2-phenoxyphenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD s33005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD trimipramine NA Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target unknown 1.14 TTD , DGIDB r-sibutramine metabolite NA Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] discontinued in phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD methylphenidate small molecule Narcolepsy[MeSHID:D009290],Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Traumatic Brain Injury[MeSHID:D000070642] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.49 drugbank , DGIDB 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-phenoxy-3-(piperidin-4-yl)pyridine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD spiroglumide NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach Diseases[MeSHID:D013272] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD levomilnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.87 drugbank , DGIDB (s)-norduloxetine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD [3-(3,4-dichloro-phenyl)-indan-1-yl]-methyl-amine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD orphenadrine small molecule Acute onset pain[MeSHID:D059787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank 7-(piperidin-4-ylmethoxy)-2-naphthonitrile NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n-tert-butylamino)-3'-chloroheptanophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD phenmetrazine NA Anorexia[MeSHID:D000855],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target unknown 3.9 TTD , DGIDB 2-(n-cyclopentylamino)-3'-chloropropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-fluoro-6-phenoxyphenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD nsd-644 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],N-Acetylneuraminic acid storage disease[MeSHID:C535525] discontinued in phase 1 norepinephrine transporter SLC6A2 Successful target unknown NA TTD , DGIDB 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD amfepramone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Obesity[MeSHID:D009765] approved norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD radafaxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD amineptine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] illicit,withdrawn sodium-dependent noradrenaline transporter SLC6A2 NA unknown NA drugbank d-254c NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD venlafaxine NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Phobia, Social[MeSHID:D000072861],Obsessive compulsive behavior[MeSHID:D003192],Off-Label Use[MeSHID:D056687],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Agoraphobia[MeSHID:D000379],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target unknown 1.13 TTD , DGIDB pdc-1421 NA Plasmacytoid Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n-tert-butylamino)-3'-chloropentanophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD pf-526014 NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD sertraline small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Post-Traumatic Stress Disorder[MeSHID:D013313],Vasovagal syncope[MeSHID:D019462],Phobia, Social[MeSHID:D000072861],Cerebrovascular accident[MeSHID:D020521],Panic Disorder[MeSHID:D016584],Obsessive compulsive behavior[MeSHID:D003192],Premenstrual Dysphoric Disorder[MeSHID:D065446],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor,downregulator NA drugbank ephedrine small molecule Asthma[MeSHID:D001249],Nose[MeSHID:D009666],Hypotension[MeSHID:D007022],Bronchial Diseases[MeSHID:D001982],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inverse agonist NA drugbank bicifadine small molecule Low Back Pain[MeSHID:D017116],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437] investigational sodium-dependent noradrenaline transporter SLC6A2 NA unknown NA drugbank netarsudil small molecule Glaucoma, Open-Angle[MeSHID:D005902],Ocular Hypertension[MeSHID:D009798],Ocular Hypotension[MeSHID:D015814],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glaucoma[MeSHID:D005901] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank crx-119 small molecule Gingival Diseases[MeSHID:D005882],Rheumatoid Arthritis[MeSHID:D001172],Periodontal Diseases[MeSHID:D010510] investigational sodium-dependent noradrenaline transporter SLC6A2 NA unknown NA drugbank 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD amoxapine NA Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target unknown 0.52 TTD , DGIDB pti-601 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD diethylpropion small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929] approved,illicit sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 3.25 drugbank , DGIDB imipramine NA Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target inhibitor 0.8 TTD , DGIDB pf-3409409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.39 drugbank , DGIDB 3-(1h-indol-1-yl)-n-methyl-3-phenylpropan-1-amine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD reboxetine NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target inhibitor 9.09 TTD , DGIDB pf-18298 NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(3-fluorophenoxy)phenyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD rti-219 NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD amiflamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (r)-n-isopropyl-n-(pyrrolidin-3-yl)-2-naphthamide NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(2'-aminoethyl)-5-benzyltetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-phenoxyphenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD dasotraline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289],Eating[MeSHID:D004435],Disease[MeSHID:D004194],Mood Disorders[MeSHID:D019964] approved norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(1h-indol-3-yl)-n,n-dimethylcyclohex-3-enamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical sodium-dependent noradrenaline transporter SLC6A2 NA negative modulator NA drugbank phentermine NA Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Epidemic[MeSHID:D058872],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Rubella[MeSHID:D012409],Overweight[MeSHID:D050177],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target unknown 2.27 TTD , DGIDB 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-(benzyloxy)-3-fluorophenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD clomipramine small molecule Premature Ejaculation[MeSHID:D061686],Premenstrual syndrome[MeSHID:D011293],Stuttering[MeSHID:D013342],Narcolepsy[MeSHID:D009290],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Trichotillomania[MeSHID:D014256],Obsessive-Compulsive Disorder[MeSHID:D009771],Pain[MeSHID:D010146],Mental Depression[MeSHID:D003863],Chronic pain[MeSHID:D059350],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autistic Disorder[MeSHID:D001321],Tension Headache[MeSHID:D018781],Neuralgia[MeSHID:D009437],Cataplexy[MeSHID:D002385],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Personality[MeSHID:D003193],Pain Disorder[MeSHID:D013001],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.5 drugbank , DGIDB 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (s)-n-isobutyl-n-(pyrrolidin-3-yl)-2-naphthamide NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD para-chloroamphetamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD rg-7166 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 1 norepinephrine transporter SLC6A2 Successful target unknown NA TTD acetaminophen NA Disease Management[MeSHID:D019468],Asthma[MeSHID:D001249],Fever[MeSHID:D005334],Allergic Reaction[MeSHID:D006967],Pain[MeSHID:D010146],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target unknown NA TTD escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank methylenedioxymethamphetamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n-cyclopentylamino)-3'-methoxypropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD [3h]win35428 NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD way-256805 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD methylenedioxyamphetamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (r)-n-isobutyl-n-(pyrrolidin-3-yl)-2-naphthamide NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD desvenlafaxine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 1.95 drugbank , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 1.14 drugbank , DGIDB polygalatenoside b NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD r-norduloxetine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (s)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-((2-iodophenoxy)(phenyl)methyl)morpholine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD n-desalkylquetiapine NA NA investigative norepinephrine transporter SLC6A2 Successful target inhibitor NA TTD , DGIDB d-257a NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 6-(piperidin-4-ylmethoxy)-2-naphthonitrile NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 4.42 drugbank , DGIDB ginkgo biloba biotech Memory[MeSHID:D008568],Cognition[MeSHID:D003071] approved,investigational,nutraceutical sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank dasotraline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289],Eating[MeSHID:D004435],Disease[MeSHID:D004194],Mood Disorders[MeSHID:D019964] investigational sodium-dependent noradrenaline transporter SLC6A2 NA unknown NA drugbank spd-473 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Symphysis Pubis Dysfunction[MeSHID:D059388],Mood Disorders[MeSHID:D019964] discontinued in phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD zotepine small molecule Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,investigational,withdrawn sodium-dependent noradrenaline transporter SLC6A2 NA antagonist,inhibitor 0.09 drugbank , DGIDB 2-(tert-butylamino)-3',4'-dichlorobutyrophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD tapentadol small molecule Acute onset pain[MeSHID:D059787],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Patient Discharge[MeSHID:D010351],Chronic pain[MeSHID:D059350] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.78 drugbank , DGIDB chlorpheniramine small molecule Hay fever[MeSHID:D006255],Rhinitis[MeSHID:D012220],Asthma[MeSHID:D001249],Urticaria[MeSHID:D014581],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank phentermine small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Epidemic[MeSHID:D058872],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Rubella[MeSHID:D012409],Overweight[MeSHID:D050177],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 2.27 drugbank , DGIDB 4-(3'-furyl)-aniline NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(aminomethyl)-5-phenethyltetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD mdl-28618 NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n,n-diethylamino)-3'-chloropropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD tq-1017 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 1.06 drugbank , DGIDB 4-(2-(phenoxymethyl)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD d-257c NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine (enantiomeric mix) NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD venlafaxine NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Phobia, Social[MeSHID:D000072861],Obsessive compulsive behavior[MeSHID:D003192],Off-Label Use[MeSHID:D056687],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Agoraphobia[MeSHID:D000379],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target inhibitor 1.13 TTD , DGIDB (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD milnacipran NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target inhibitor 1.3 TTD , DGIDB amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.52 drugbank , DGIDB loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA binder NA drugbank dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit sodium-dependent noradrenaline transporter SLC6A2 NA negative modulator 1.08 drugbank , DGIDB mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank d-166a NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD solriamfetol small molecule Sleep Apnea, Obstructive[MeSHID:D020181],Narcolepsy[MeSHID:D009290],Apnea[MeSHID:D001049],Airway Obstruction[MeSHID:D000402],Drowsiness[MeSHID:D012894],Hypersomnia[MeSHID:D006970],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 1.3 drugbank , DGIDB bl-1021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Burkitt Lymphoma[MeSHID:D002051] phase 1 norepinephrine transporter SLC6A2 Successful target unknown NA TTD protriptyline NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target unknown 1.3 TTD , DGIDB maprotiline NA Involutional Depression[MeSHID:D003865],Mental Suffering[MeSHID:D013315],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target inhibitor 0.87 TTD , DGIDB (r)-1-((s)-morpholin-2-yl)-1,2-diphenylethanol NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD ns-2389 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD bupropion+naltrexone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 3 norepinephrine transporter SLC6A2 Successful target unknown NA TTD [3h]nisoxetine NA NA investigative norepinephrine transporter SLC6A2 Successful target inhibitor NA TTD , DGIDB dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank d-211a NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD trans-3-(o-tolyloxy)-2,3-dihydro-1h-inden-1-amine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1s,2r-milnacipran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank (r)-duloxetine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD desipramine NA Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved norepinephrine transporter SLC6A2 Successful target unknown 1.06 TTD , DGIDB 4-((naphthalen-2-yloxy)methyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 1.3 drugbank , DGIDB viloxazine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved,investigational,withdrawn sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank 2-(n-cyclopentylamino)-3'-bromopropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.23 drugbank , DGIDB mct-125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fatigue[MeSHID:D005221] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine (enantiomeric mix) NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD amitifadine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Alcoholic Intoxication, Chronic[MeSHID:D000437],Mood Disorders[MeSHID:D019964] investigational sodium-dependent noradrenaline transporter SLC6A2 NA unknown NA drugbank 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2,3-dihydro-1h-indol-5-ylmethyl)-propylamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n-pyrrolidinyl)-3'-fluoropropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD cis-3-phenoxy-2,3-dihydro-1h-inden-1-amine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(benzyloxy)phenyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD napitane mesilate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank norzotepine NA NA investigative norepinephrine transporter SLC6A2 Successful target inhibitor NA TTD , DGIDB 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD d-211b NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD pyrovalerone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (2s,3s)-2-(m-tolyl)-3,5,5-trimethylmorpholin-2-ol NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD protriptyline NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target inhibitor 1.3 TTD , DGIDB 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD mmda NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD mmda small molecule NA experimental,illicit sodium-dependent noradrenaline transporter SLC6A2 NA negative modulator NA drugbank (s)-3-(naphthalen-2-ylmethoxy)pyrrolidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD win-35066-2 NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank 2-(n-cyclopropylamino)-3-chloropropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n-tert-butylamino)-3'-chlorooctanophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-aminomethyl-5-(p-bromophenyl)tetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.8 drugbank , DGIDB cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.37 drugbank , DGIDB bupropion small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Diet therapy[MeSHID:D004035],Weight Gain[MeSHID:D015430],Body Weight[MeSHID:D001835],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Seasonal Affective Disorder[MeSHID:D016574],Cessation of smoking[MeSHID:D016540],Mood (psychological function)[MeSHID:D000339],Obesity[MeSHID:D009765],Off-Label Use[MeSHID:D056687],Overweight[MeSHID:D050177],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.69 drugbank , DGIDB vortioxetine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA blocker NA drugbank n-benzyl-n-isobutylpiperidin-4-amine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD milnacipran NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target unknown 1.3 TTD , DGIDB nisoxetine NA NA investigative norepinephrine transporter SLC6A2 Successful target inhibitor 1.3 TTD , DGIDB 2-(aminomethyl)-5-(2'-naphthyl)tetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(tert-butylamino)-3',4'-dichloropentanophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD serdexmethylphenidate small molecule Attention deficit hyperactivity disorder[MeSHID:D001289] approved sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor NA drugbank cocaine NA Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target unknown 0.37 TTD , DGIDB 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD n-(2-oxazolemethyl)milnacipran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-(benzyloxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.51 drugbank , DGIDB 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (r)-norfluoxetine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD amitriptyline NA Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target inhibitor 0.39 TTD , DGIDB 1-(2-(4-fluorophenoxy)phenyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD bupropion NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Diet therapy[MeSHID:D004035],Weight Gain[MeSHID:D015430],Body Weight[MeSHID:D001835],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Seasonal Affective Disorder[MeSHID:D016574],Cessation of smoking[MeSHID:D016540],Mood (psychological function)[MeSHID:D000339],Obesity[MeSHID:D009765],Off-Label Use[MeSHID:D056687],Overweight[MeSHID:D050177],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved norepinephrine transporter SLC6A2 Successful target unknown 0.69 TTD , DGIDB {2-[3-(phenylsulfonyl)-1h-indol-4-yl]ethyl}amine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD reboxetine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 9.09 drugbank , DGIDB biphenyl-2-ylmethyl-(s)-pyrrolidin-3-yl-amine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-phenoxyphenyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD imipramine NA Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target unknown 0.8 TTD , DGIDB desvenalfaxine succinate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved norepinephrine transporter SLC6A2 Successful target unknown NA TTD ddp-225 small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Diarrhea[MeSHID:D003967],Gastrointestinal Diseases[MeSHID:D005767],Irritable Bowel Syndrome[MeSHID:D043183],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vomiting[MeSHID:D014839] investigational sodium-dependent noradrenaline transporter SLC6A2 NA unknown NA drugbank kf-a5 NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD esreboxetine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] discontinued in phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD roclatan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] phase 3 norepinephrine transporter SLC6A2 Successful target unknown NA TTD debrisoquine small molecule Hypertensive disease[MeSHID:D006973],Renal hypertension[MeSHID:D006977] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inducer NA drugbank 2-(n-cyclopentylamino)-3'-fluoropropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD guanadrel small molecule Hypertensive disease[MeSHID:D006973] approved sodium-dependent noradrenaline transporter SLC6A2 NA partial agonist NA drugbank phendimetrazine small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent noradrenaline transporter SLC6A2 NA negative modulator NA drugbank xen-2174 NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD ns 2359 NA Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970],Mood Disorders[MeSHID:D019964] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD desipramine NA Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved norepinephrine transporter SLC6A2 Successful target inhibitor 1.06 TTD , DGIDB 2pyrrolidin-1-yl-1-phenylpentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD amitifadine NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Alcoholic Intoxication, Chronic[MeSHID:D000437],Mood Disorders[MeSHID:D019964] phase 3 norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine (enantiomeric mix) NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(1-phenyl-2-o-tolylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD duloxetine NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Low Back Pain[MeSHID:D017116],Urinary Stress Incontinence[MeSHID:D014550],Anxiety Disorders[MeSHID:D001008],Osteoarthritis, Knee[MeSHID:D020370],Peripheral Neuropathy[MeSHID:D010523],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target unknown 1.17 TTD , DGIDB 18f-lmi-1195 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational sodium-dependent noradrenaline transporter SLC6A2 NA agonist,substrate NA drugbank s-34324 NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-(2-fluorobenzyloxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (r)-3-(naphthalen-2-ylmethoxy)pyrrolidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD bupropion NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Diet therapy[MeSHID:D004035],Weight Gain[MeSHID:D015430],Body Weight[MeSHID:D001835],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Seasonal Affective Disorder[MeSHID:D016574],Cessation of smoking[MeSHID:D016540],Mood (psychological function)[MeSHID:D000339],Obesity[MeSHID:D009765],Off-Label Use[MeSHID:D056687],Overweight[MeSHID:D050177],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved norepinephrine transporter SLC6A2 Successful target inhibitor 0.69 TTD , DGIDB nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 0.94 drugbank , DGIDB 2-(n-pyrrolidinyl)-3'-methylpropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD manifaxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(phenoxymethyl)phenyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD phenmetrazine small molecule Anorexia[MeSHID:D000855],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 3.9 drugbank , DGIDB dexmethylphenidate small molecule Behavior[MeSHID:D001519],Attention deficit hyperactivity disorder[MeSHID:D001289],Educational Status[MeSHID:D004522] approved,investigational sodium-dependent noradrenaline transporter SLC6A2 NA inhibitor 7.14 drugbank , DGIDB metaiodobenzylguanidine i-131 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Pheochromocytoma[MeSHID:D010673],Neuroblastoma[MeSHID:D009447],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD td-9855 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Hypotension, Orthostatic[MeSHID:D007024] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(1,2-diphenylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit sodium-dependent noradrenaline transporter SLC6A2 NA negative modulator NA drugbank iobenguane i-123 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n-tert-butylamino)-3',4'-dichloropropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (r)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (r)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(3,4-dichloro-phenyl)-3-methylamino-indan-5-ol NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n-cyclopentylamino)-3'-methylpropiophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD difluorobenztropine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-amino-1-(4-methylthiophenyl)propane NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD xen-2174 small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational sodium-dependent noradrenaline transporter SLC6A2 NA unknown NA drugbank (s)-norfluoxetine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD ((3r,4r)-4-(o-tolyloxy)chroman-3-yl)methanamine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 2-(n-tert-butylamino)-3'-chlorohexanophenone NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD trimipramine NA Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target inhibitor 1.14 TTD , DGIDB guanethidine small molecule Hypertensive disease[MeSHID:D006973],Renal hypertension[MeSHID:D006977],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent noradrenaline transporter SLC6A2 NA inducer 6.5 drugbank , DGIDB midomafetamine small molecule Anxiety Disorders[MeSHID:D001008],Malignant Neoplasms[MeSHID:D009369],Anxiety[MeSHID:D001007],Post-Traumatic Stress Disorder[MeSHID:D013313] experimental,illicit,investigational sodium-dependent noradrenaline transporter SLC6A2 NA negative modulator NA drugbank 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(1,4-diphenylbutan-2-yl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD tapentadol hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute onset pain[MeSHID:D059787] approved norepinephrine transporter SLC6A2 Successful target unknown NA TTD bli-1005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD sibutramine NA Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved norepinephrine transporter SLC6A2 Successful target inhibitor 3.03 TTD , DGIDB duloxetine NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Low Back Pain[MeSHID:D017116],Urinary Stress Incontinence[MeSHID:D014550],Anxiety Disorders[MeSHID:D001008],Osteoarthritis, Knee[MeSHID:D020370],Peripheral Neuropathy[MeSHID:D010523],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved norepinephrine transporter SLC6A2 Successful target inhibitor 1.17 TTD , DGIDB 2-aminomethyl-5-(p-chlorophenyl)tetrahydrofuran NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD (2s,3s)-2-phenyl-3,5,5-trimethylmorpholin-2-ol NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative norepinephrine transporter SLC6A2 Successful target unknown NA TTD pf-18298 NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-aminomethyl-5-(phenyl)tetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(5-phenylpentyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine (enantiomeric mix) NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD [3h]win35428 NA NA investigative dopamine transporter SLC6A3 Successful target inhibitor NA TTD , DGIDB 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD sertraline small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Post-Traumatic Stress Disorder[MeSHID:D013313],Vasovagal syncope[MeSHID:D019462],Phobia, Social[MeSHID:D000072861],Cerebrovascular accident[MeSHID:D020521],Panic Disorder[MeSHID:D016584],Obsessive compulsive behavior[MeSHID:D003192],Premenstrual Dysphoric Disorder[MeSHID:D065446],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor,binder 0.3 drugbank , DGIDB benzatropine small molecule Bradykinesia[MeSHID:D018476],Dystonia[MeSHID:D004421],Disease[MeSHID:D004194],Dyskinetic syndrome[MeSHID:D020820],Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Akathisia[MeSHID:D011595],Movement[MeSHID:D009068],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Term Birth[MeSHID:D047929] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank coclaurine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-phenyl-3-aza-bicyclo[3.1.0]hexane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-phenylpiperidine hydrochloride NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD benzyl-(2-phenyl-quinazolin-4-yl)-amine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD amineptine NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] withdrawn from market dopamine transporter SLC6A3 Successful target unknown NA TTD ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical sodium-dependent dopamine transporter SLC6A3 NA negative modulator NA drugbank (+/-)-threo-n-methyl-30-methylmethylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(4-phenylbutyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(1-benzo[b]thiophen-2-yl-cycloheptyl)-azepane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank 2-(tert-butylamino)-1-m-tolylpropan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(3-phenylpropyl)ritalinol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(4-methylpyridine)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(2-methylthiopene)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD bip-tyr-thr-pro-ala-thr(obzl)-gly NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD pseudococaine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-methylphenidate amide NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(1h-indol-3-yl)-n,n-dimethylcyclohex-3-enamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(4-methoxybenzyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD tesofensine small molecule Obesity[MeSHID:D009765],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational sodium-dependent dopamine transporter SLC6A3 NA unknown NA drugbank (+/-)-threo-n-(3-methylpyridine)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-[(diphenylmethyl)amino]-2-phenylquinazoline NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD manifaxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 dopamine transporter SLC6A3 Successful target unknown NA TTD d-257a NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-benzylmethylphenidate amide NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(2-methylpyridine)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD bip-tyr-thr-pro-lys-thr NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD bip-tyr(3bzl)-thr-pro-lys-thr NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD bupropion+naltrexone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 3 dopamine transporter SLC6A3 Successful target unknown NA TTD , DGIDB 1-(3,4-dichloro-phenyl)-3-methylamino-indan-5-ol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-amino-1-(4-methylthiophenyl)propane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD bip-tyr-thr-pro-thr(obzl)-gly NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD mmda small molecule NA experimental,illicit sodium-dependent dopamine transporter SLC6A3 NA negative modulator NA drugbank 6-(piperidin-4-ylmethoxy)-2-naphthonitrile NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 10r-hydroxylobelane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD vanoxerine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970] discontinued in phase 1 dopamine transporter SLC6A3 Successful target inhibitor 0.11 TTD , DGIDB 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD d-257c NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD d-254c NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD nsd-644 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],N-Acetylneuraminic acid storage disease[MeSHID:C535525] discontinued in phase 1 dopamine transporter SLC6A3 Successful target unknown NA TTD , DGIDB obaberine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-3-fluororitalinol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD homoaromoline NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD diethylpropion small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929] approved,illicit sodium-dependent dopamine transporter SLC6A3 NA inhibitor 2.12 drugbank , DGIDB 4-(2-phenoxyphenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (s)-3-(naphthalen-2-ylmethoxy)pyrrolidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-tert-butylamino)propiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD rg-7166 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 1 dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-propargylmethylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(2-phenylethyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD modafinil NA Narcolepsy[MeSHID:D009290],Wakefulness[MeSHID:D014851],Hypersomnia[MeSHID:D006970],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714],Brain Injuries[MeSHID:D001930] approved dopamine transporter SLC6A3 Successful target inhibitor 0.85 TTD , DGIDB 2-aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD phentermine small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Epidemic[MeSHID:D058872],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Rubella[MeSHID:D012409],Overweight[MeSHID:D050177],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent dopamine transporter SLC6A3 NA inhibitor 1.06 drugbank , DGIDB dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit sodium-dependent dopamine transporter SLC6A3 NA negative modulator 1.24 drugbank , DGIDB 2-(2,3-dihydro-1h-indol-5-yl)-1-methyl-ethylamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD chloroprocaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank (rs/sr)-2-[1-(4-chlorophenyl)hexyl]piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-3',5'-dimethylmethylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD mazindol small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA inhibitor 2.65 drugbank , DGIDB dasotraline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289],Eating[MeSHID:D004435],Disease[MeSHID:D004194],Mood Disorders[MeSHID:D019964] investigational sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.71 drugbank , DGIDB 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD venlafaxine small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Phobia, Social[MeSHID:D000072861],Obsessive compulsive behavior[MeSHID:D003192],Off-Label Use[MeSHID:D056687],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Agoraphobia[MeSHID:D000379],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank threo-3,4-dichlororitalinol hydrochloride NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD nisoxetine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD pmid25037917c58 NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(6-phenylhexyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD n,ndimethyl milnacipran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(1-benzo[b]thiophen-2-yl-cyclohexyl)-azepane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-cyclopentylamino)-3'-chloropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD sibutramine small molecule Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn sodium-dependent dopamine transporter SLC6A3 NA inhibitor 1.41 drugbank , DGIDB 4-(2-fluoro-6-phenoxyphenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA binder NA drugbank (r)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-tert-butylamino)-3'-chlorooctanophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit sodium-dependent dopamine transporter SLC6A3 NA negative modulator NA drugbank erythro-3,4-dichloromethylphenidate hydrochloride NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(2-phenoxyphenyl)piperazine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-allylmethylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD dov-216303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(tert-butylamino)-1-p-tolylpropan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(tert-butylamino)-3',4'-dichlorobutyrophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(4-fluorophenoxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-benzyl-3',4'-dichlororitalinol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 3-phenyl-2-nortropene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (rs/sr)-2-[1-(4-chlorophenyl)ethyl]piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD desvenlafaxine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.35 drugbank , DGIDB (+/-)-threo-n-benzyl-3'-chloromethylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-pyrrolidinyl)-3'-bromopropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(1,4-diphenylbutan-2-yl)piperazine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD cis-3-phenoxy-2,3-dihydro-1h-inden-1-amine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD r-226161 NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(2,3-dihydro-1h-indol-5-ylmethyl)-propylamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD midomafetamine small molecule Anxiety Disorders[MeSHID:D001008],Malignant Neoplasms[MeSHID:D009369],Anxiety[MeSHID:D001007],Post-Traumatic Stress Disorder[MeSHID:D013313] experimental,illicit,investigational sodium-dependent dopamine transporter SLC6A3 NA negative modulator NA drugbank (+/-)-threo-n-(4-chlorobenzyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD phenmetrazine small molecule Anorexia[MeSHID:D000855],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent dopamine transporter SLC6A3 NA inhibitor 3.71 drugbank , DGIDB procaine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank 4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 3-p-tolyl-8-aza-bicyclo[3.2.1]octane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (r)-3-(naphthalen-2-ylmethoxy)pyrrolidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 10s-hydroxylobelane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(tert-butylamino)-3'-fluoropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-cyclopentylamino)-3'-bromopropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD cocaine NA Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine transporter SLC6A3 Successful target unknown 0.51 TTD , DGIDB 2-aminomethyl-5-(p-bromophenyl)tetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD anolobine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent dopamine transporter SLC6A3 NA binder NA drugbank gsk-1360707 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 dopamine transporter SLC6A3 Successful target unknown NA TTD , DGIDB 1s,2r-milnacipran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2pyrrolidin-1-yl-1-phenylpentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD d-166a NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD secocularidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD serdexmethylphenidate small molecule Attention deficit hyperactivity disorder[MeSHID:D001289] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank altropane NA Attention deficit hyperactivity disorder[MeSHID:D001289],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine transporter SLC6A3 Successful target unknown 3.18 TTD , DGIDB norboldine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA modulator NA drugbank (+/-)-threo-n-(2-chlorobenzyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(3-chlorobenzyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(2-phenylethyl)ritalinol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD aminobenztropine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD dasotraline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289],Eating[MeSHID:D004435],Disease[MeSHID:D004194],Mood Disorders[MeSHID:D019964] investigational sodium-dependent dopamine transporter SLC6A3 NA unknown 0.71 drugbank , DGIDB 4-(2-(3-fluorophenoxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(4-nitrobenzyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-tert-butylamino)-4'-chloropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(3-methylthiopene)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-tert-butylamino)-3'-chloropentanophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD chlorpheniramine small molecule Hay fever[MeSHID:D006255],Rhinitis[MeSHID:D012220],Asthma[MeSHID:D001249],Urticaria[MeSHID:D014581],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD d-211a NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-benzo[b]thiophen-2-yl-cycloheptylamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD dexmethylphenidate hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] approved dopamine transporter SLC6A3 Successful target inhibitor 0.53 TTD , DGIDB radafaxine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(benzyloxy)-3-fluorophenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD o-methyldauricine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD armodafinil small molecule Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Schizoaffective Disorder[MeSHID:D011618],Sleep Apnea, Obstructive[MeSHID:D020181],Sleep Disorders[MeSHID:D012893],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA antagonist,inhibitor 1.59 drugbank , DGIDB 2-(tert-butylamino)-3',4'-dichloropentanophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n,n-diethylamino)-3'-chloropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD anonaine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (2s,3s)-2-(m-tolyl)-3,5,5-trimethylmorpholin-2-ol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(phenoxymethyl)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.51 drugbank , DGIDB [3h]gbr12935 NA NA investigative dopamine transporter SLC6A3 Successful target inhibitor NA TTD , DGIDB 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD spiroglumide NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach Diseases[MeSHID:D013272] phase 2 dopamine transporter SLC6A3 Successful target unknown 0.53 TTD , DGIDB threo-1-aza-5-phenyl[4.4.0]decane hydrochloride NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (rs/sr)-2-[1-(4-chlorophenyl)butyl]piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-methoxyamphetamine small molecule NA experimental,illicit sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank vanoxerine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970] investigational sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.11 drugbank , DGIDB altropane small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational sodium-dependent dopamine transporter SLC6A3 NA unknown 3.18 drugbank , DGIDB (r)-n-isobutyl-n-(pyrrolidin-3-yl)-2-naphthamide NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 3-(4-trifluoromethylphenyl)-2-nortropene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-benzo[b]thiophen-2-yl-cyclohexylamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (s)-norfluoxetine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-phenoxy-3-(piperidin-4-yl)pyridine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD dexmethylphenidate small molecule Behavior[MeSHID:D001519],Attention deficit hyperactivity disorder[MeSHID:D001289],Educational Status[MeSHID:D004522] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA inhibitor 7.43 drugbank , DGIDB ns 2359 NA Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970],Mood Disorders[MeSHID:D019964] phase 2 dopamine transporter SLC6A3 Successful target unknown NA TTD , DGIDB (r)-norfluoxetine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD methylphenidate NA Narcolepsy[MeSHID:D009290],Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Traumatic Brain Injury[MeSHID:D000070642] approved dopamine transporter SLC6A3 Successful target unknown 0.47 TTD , DGIDB trans-3-(o-tolyloxy)-2,3-dihydro-1h-inden-1-amine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (rs/sr)-2-[1-(3,4-dichlorophenyl)butyl]piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD [3-(3,4-dichloro-phenyl)-indan-1-yl]-methyl-amine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD isopiline NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD ioflupane i-123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved dopamine transporter SLC6A3 Successful target unknown NA TTD , DGIDB modafinil small molecule Narcolepsy[MeSHID:D009290],Wakefulness[MeSHID:D014851],Hypersomnia[MeSHID:D006970],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714],Brain Injuries[MeSHID:D001930] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.85 drugbank , DGIDB win-35066-2 NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD solriamfetol small molecule Sleep Apnea, Obstructive[MeSHID:D020181],Narcolepsy[MeSHID:D009290],Apnea[MeSHID:D001049],Airway Obstruction[MeSHID:D000402],Drowsiness[MeSHID:D012894],Hypersomnia[MeSHID:D006970],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.71 drugbank , DGIDB (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-benzylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD methylphenidate NA Narcolepsy[MeSHID:D009290],Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Traumatic Brain Injury[MeSHID:D000070642] approved dopamine transporter SLC6A3 Successful target inhibitor 0.47 TTD , DGIDB 2-(n-pyrrolidinyl)-3'-methoxypropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (rs/sr)-2-[1-(4-chlorophenyl)pentyl]piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-3',4'-dichloromethylphenidate amide NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 3-alpha-phenylmethoxy-3-beta-phenyl-nortropane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-((2-iodophenoxy)(phenyl)methyl)morpholine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD o-2442 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970] investigative dopamine transporter SLC6A3 Successful target unknown NA TTD pf-3409409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] investigative dopamine transporter SLC6A3 Successful target unknown NA TTD indatraline NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 8-methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank methylenedioxyamphetamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.27 drugbank , DGIDB kp106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] discontinued in phase 1 dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-pyrrolidinyl)-3'-fluoropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(3-chlorophenoxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD trodusquemine small molecule Obesity[MeSHID:D009765],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] investigational sodium-dependent dopamine transporter SLC6A3 NA unknown NA drugbank 2-(tert-butylamino)-3',5'-difluoropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 3alpha-(bis-chloro-phenylmethoxy)tropane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved sodium-dependent dopamine transporter SLC6A3 NA binder NA drugbank 3-(4-chlorophenyl)-2-nortropene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD methylenedioxymethamphetamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown 0.85 TTD , DGIDB fencamfamin small molecule Lethargy[MeSHID:D053609],Convalescence[MeSHID:D003289],Fatigue[MeSHID:D005221],Attention[MeSHID:D001288] experimental,illicit,withdrawn sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank r-norduloxetine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.19 drugbank , DGIDB n-benzylmethylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD biphenyl-2-ylmethyl-(s)-pyrrolidin-3-yl-amine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD bip-tyr-thr-pro-lys-thr(obzl)-gly NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(2-fluorobenzyloxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(1-benzo[b]thiophen-2-yl-cyclopentyl)-azepane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD mmda NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank (+/-)-threo-4'-ethylmethylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD bupropion small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Diet therapy[MeSHID:D004035],Weight Gain[MeSHID:D015430],Body Weight[MeSHID:D001835],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Seasonal Affective Disorder[MeSHID:D016574],Cessation of smoking[MeSHID:D016540],Mood (psychological function)[MeSHID:D000339],Obesity[MeSHID:D009765],Off-Label Use[MeSHID:D056687],Overweight[MeSHID:D050177],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.87 drugbank , DGIDB pyrovalerone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(3-phenylpropyl)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(4-fluorobenzyloxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-pyrrolidinyl)-3'-nitropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (rs/sr)-2-[1-(4-chlorophenyl)propyl]piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(3-methylfuran)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-tert-butylamino)-3'-chlorohexanophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD norstephalagine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 8r-hydroxylobelane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-aminomethyl-5-(p-chlorophenyl)tetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-pyrrolidinyl)-3'-methylpropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 3-(3,4-dichlorophenyl)-2-nortropene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(2'-aminoethyl)-5-benzyltetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(2-methylfuran)methylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(aminomethyl)-5-(2'-naphthyl)tetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD threo-ritalinol hydrochloride NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 8r-hydroxylobel-9-ene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD min-117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 dopamine transporter SLC6A3 Successful target unknown NA TTD , DGIDB bip-tyr-thr-ala-pro-phe NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD benzphetamine small molecule Disease Management[MeSHID:D019468],Low-Calorie Diet[MeSHID:D031204],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD rti-219 NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-isopropylamino)-3'-chloropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-cyclopentylamino)-3'-methylpropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD duloxetine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Low Back Pain[MeSHID:D017116],Urinary Stress Incontinence[MeSHID:D014550],Anxiety Disorders[MeSHID:D001008],Osteoarthritis, Knee[MeSHID:D020370],Peripheral Neuropathy[MeSHID:D010523],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank (2r,3s)-2-[(3-iodophenoxy)phenylmethyl]morpholine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (2r,3s)-2-[(2-iodophenoxy)phenylmethyl]morpholine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD win-35065 NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD diphenylpyraline small molecule Dermatologic disorders[MeSHID:D012871],Hay fever[MeSHID:D006255],Hypersensitivity[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (1-phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD nomifensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,withdrawn sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.71 drugbank , DGIDB 3-(4-fluorophenyl)-2-nortropene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (r)-duloxetine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-benzo[b]thiophen-2-yl-cyclopentylamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-tert-butylamino)-3',4'-dichloropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD dasotraline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289],Eating[MeSHID:D004435],Disease[MeSHID:D004194],Mood Disorders[MeSHID:D019964] approved dopamine transporter SLC6A3 Successful target unknown 0.71 TTD , DGIDB 10r-hydroxylobel-7-ene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-3',4'-dichlororitalinol methyl ether NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(aminomethyl)-5-(1'-naphthyl)tetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD bip-tyr-ala-pro-lys-thr(obzl)-gly NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD difluorobenztropine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (2s,3s)-iodoreboxetine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (2s,3s)-2-phenyl-3,5,5-trimethylmorpholin-2-ol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD cocaine.hcl NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD amitifadine NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Alcoholic Intoxication, Chronic[MeSHID:D000437],Mood Disorders[MeSHID:D019964] phase 3 dopamine transporter SLC6A3 Successful target unknown 1.06 TTD , DGIDB (2r,3r)-iodoreboxetine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD rti-336 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970] phase 1 dopamine transporter SLC6A3 Successful target unknown 1.06 TTD , DGIDB beta-methoxyamphetamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved sodium-dependent dopamine transporter SLC6A3 NA inducer NA drugbank 2-(n-cyclopentylamino)-3'-fluoropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD threo-n-ethylritalinol hydrochloride NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD methylphenidate small molecule Narcolepsy[MeSHID:D009290],Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Traumatic Brain Injury[MeSHID:D000070642] approved,investigational sodium-dependent dopamine transporter SLC6A3 NA inhibitor 0.47 drugbank , DGIDB d-211b NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD para-chloroamphetamine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD [n-[2-[(3'-n'-propyl-3''alpha-(bis(4-fluororphenyl)methoxy)tropane-2''beta-carboxylic acid methyl ester)(2-mercaptoethyl)amino]acetyl]-2-aminoethanethiolato]rhenium(v) oxide (diastereomeric mix) NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(benzyloxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD gb-12819 NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent dopamine transporter SLC6A3 NA inhibitor NA drugbank isotetrandrine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(2-(4-fluorophenoxy)phenyl)piperazine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-cyclopentylamino)-3'-methoxypropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 10s-hydroxylobel-7-ene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-cyclopropylamino)-3-chloropropiophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 8s-hydroxylobelane NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 7-(piperidin-4-ylmethoxy)-2-naphthonitrile NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(2-(phenoxymethyl)phenyl)piperazine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-phenyl-1-(piperidin-2-yl)propan-2-one NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-benzylpiperidine hydrochloride NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD ns-2389 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 dopamine transporter SLC6A3 Successful target unknown NA TTD antioquine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD pf-526014 NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD dasotraline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289],Eating[MeSHID:D004435],Disease[MeSHID:D004194],Mood Disorders[MeSHID:D019964] approved dopamine transporter SLC6A3 Successful target inhibitor 0.71 TTD , DGIDB 8s-hydroxylobel-9-ene NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(3,4-dichloro-phenyl)-3-diethylamino-indan-5-ol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD modafinil NA Narcolepsy[MeSHID:D009290],Wakefulness[MeSHID:D014851],Hypersomnia[MeSHID:D006970],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bipolar Disorder[MeSHID:D001714],Brain Injuries[MeSHID:D001930] approved dopamine transporter SLC6A3 Successful target unknown 0.85 TTD , DGIDB (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-3',5'-dichloromethylphenidate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD threo-ritalinol methyl ether hydrochloride NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD methyl 2-(naphthalen-2-yl)benzoate NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(n-tert-butylamino)-3'-chloroheptanophenone NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-(benzyloxy)-6-fluorophenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD (+/-)-threo-n-(4-phenylbutyl)ritalinol NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD spd-473 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Symphysis Pubis Dysfunction[MeSHID:D059388],Mood Disorders[MeSHID:D019964] discontinued in phase 2 dopamine transporter SLC6A3 Successful target unknown NA TTD (2r,3s)-2-[(4-iodophenoxy)phenylmethyl]morpholine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational sodium-dependent dopamine transporter SLC6A3 NA negative modulator 0.78 drugbank , DGIDB dexmethylphenidate hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] approved dopamine transporter SLC6A3 Successful target unknown NA TTD , DGIDB dimethylgrisabine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 2-(aminomethyl)-5-phenethyltetrahydrofuran NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD phenmetrazine NA Anorexia[MeSHID:D000855],Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dopamine transporter SLC6A3 Successful target unknown 3.71 TTD , DGIDB 4-(3-fluoro-2-phenoxyphenyl)piperidine NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD 1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine (enantiomeric mix) NA NA investigative dopamine transporter SLC6A3 Successful target unknown NA TTD nav5001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dopamine transporter SLC6A3 Successful target unknown 1.06 TTD , DGIDB clomipramine small molecule Premature Ejaculation[MeSHID:D061686],Premenstrual syndrome[MeSHID:D011293],Stuttering[MeSHID:D013342],Narcolepsy[MeSHID:D009290],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Trichotillomania[MeSHID:D014256],Obsessive-Compulsive Disorder[MeSHID:D009771],Pain[MeSHID:D010146],Mental Depression[MeSHID:D003863],Chronic pain[MeSHID:D059350],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autistic Disorder[MeSHID:D001321],Tension Headache[MeSHID:D018781],Neuralgia[MeSHID:D009437],Cataplexy[MeSHID:D002385],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Personality[MeSHID:D003193],Pain Disorder[MeSHID:D013001],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 1 drugbank , DGIDB para-chloroamphetamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD [3h]win35428 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.43 drugbank , DGIDB nortriptyline NA Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target unknown 0.81 TTD , DGIDB 1-(1,3-diphenylpropyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD loxapine small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Psychotic Disorders[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA binder NA drugbank norzotepine NA NA investigative serotonin transporter SLC6A4 Successful target inhibitor NA TTD , DGIDB n,n-dimethyl(2-phenoxyphenyl)methanamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD zotepine small molecule Emotions[MeSHID:D004644],Schizophrenia[MeSHID:D012559],Hallucinations[MeSHID:D006212],Movement Disorders[MeSHID:D009069],Diagnosis[MeSHID:D003933],Delusions[MeSHID:D003702],Affect (mental function)[MeSHID:D000339],Choice Behavior[MeSHID:D002755],Mental Suffering[MeSHID:D013315],Thinking, function[MeSHID:D013850],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved,investigational,withdrawn sodium-dependent serotonin transporter SLC6A4 NA antagonist,inhibitor 0.07 drugbank , DGIDB tapentadol small molecule Acute onset pain[MeSHID:D059787],Neuralgia[MeSHID:D009437],Peripheral Neuropathy[MeSHID:D010523],Patient Discharge[MeSHID:D010351],Chronic pain[MeSHID:D059350] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank sertraline NA Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Post-Traumatic Stress Disorder[MeSHID:D013313],Vasovagal syncope[MeSHID:D019462],Phobia, Social[MeSHID:D000072861],Cerebrovascular accident[MeSHID:D020521],Panic Disorder[MeSHID:D016584],Obsessive compulsive behavior[MeSHID:D003192],Premenstrual Dysphoric Disorder[MeSHID:D065446],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 0.67 TTD , DGIDB 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluoxetine NA Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 0.43 TTD , DGIDB nortriptyline small molecule Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.81 drugbank , DGIDB 1-benzylpiperidine hydrochloride NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (r)-n-isopropyl-n-(pyrrolidin-3-yl)-2-naphthamide NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 3-(1h-indol-3-yl)-n,n-dimethylpropan-1-amine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine (enantiomeric mix) NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-aminomethyl-5-(p-chlorophenyl)tetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-benzyl-6-nitro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (r)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD quipazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-(benzyloxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD sertraline NA Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Post-Traumatic Stress Disorder[MeSHID:D013313],Vasovagal syncope[MeSHID:D019462],Phobia, Social[MeSHID:D000072861],Cerebrovascular accident[MeSHID:D020521],Panic Disorder[MeSHID:D016584],Obsessive compulsive behavior[MeSHID:D003192],Premenstrual Dysphoric Disorder[MeSHID:D065446],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 0.67 TTD , DGIDB sibutramine NA Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 2.52 TTD , DGIDB sep-228432 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] phase 1 serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-aminomethyl-5-(phenyl)tetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD brasofensine NA Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-(benzyloxy)-3-fluorophenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluoxetine small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.43 drugbank , DGIDB bicifadine NA Low Back Pain[MeSHID:D017116],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437] phase 3 serotonin transporter SLC6A4 Successful target unknown NA TTD 4-bromo-6-nitro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (r)-norfluoxetine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD vortioxetine NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved serotonin transporter SLC6A4 Successful target inhibitor 0.36 TTD , DGIDB 3-(3-aminocyclopentyl)-1h-indole-5-carbonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(3,4-dichloro-phenyl)-3-diethylamino-indan-5-ol NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD pf-18298 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD trans-3-(o-tolyloxy)-2,3-dihydro-1h-inden-1-amine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD min-117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.54 drugbank , DGIDB 6-nitro-4-phenyl-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-phenyl-3-aza-bicyclo[3.1.0]hexane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD nomifensine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,withdrawn sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank tefludazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD doxepin small molecule Emotions[MeSHID:D004644],Disease Management[MeSHID:D019468],Involutional Depression[MeSHID:D003865],Eczema[MeSHID:D004485],Maintenance[MeSHID:D008283],Ability[MeSHID:D001076],Physical Examination[MeSHID:D010808],Phobic anxiety disorder[MeSHID:D010698],Post-Traumatic Stress Disorder[MeSHID:D013313],Sleep Disorders[MeSHID:D012893],Affect (mental function)[MeSHID:D000339],Panic[MeSHID:D010200],Nociceptors[MeSHID:D009619],Anxiety Disorders[MeSHID:D001008],Lichen Simplex Chronicus[MeSHID:D009450],Obsessive-Compulsive Disorder[MeSHID:D009771],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Pruritus[MeSHID:D011537],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Neuralgia[MeSHID:D009437],Alcoholic Intoxication, Chronic[MeSHID:D000437],Obsessive compulsive behavior[MeSHID:D003192],Dermatitis, Atopic[MeSHID:D003876],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.3 drugbank , DGIDB 6-(piperidin-4-ylmethoxy)-2-naphthonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-hydroxyamino-1-(4-methylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD sibutramine small molecule Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn sodium-dependent serotonin transporter SLC6A4 NA inhibitor 2.52 drugbank , DGIDB (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(benzyloxy)phenyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD citalopram NA Depressive disorder[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Mental Depression[MeSHID:D003863],Alcohol abuse[MeSHID:D000437],Cerebrovascular accident[MeSHID:D020521],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 0.51 TTD , DGIDB dexfenfluramine small molecule Disease Management[MeSHID:D019468],Diet therapy[MeSHID:D004035],Maintenance[MeSHID:D008283],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational,withdrawn sodium-dependent serotonin transporter SLC6A4 NA inhibitor 7.55 drugbank , DGIDB n-(piperidin-4-yl)-n-propyl-2-naphthamide NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD da-8031 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature Ejaculation[MeSHID:D061686] phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-propargylamino-1-(4-methylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-(4-fluorobenzyloxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD biphenyl-2-ylmethyl-(s)-pyrrolidin-3-yl-amine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD desvenlafaxine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 1.62 drugbank , DGIDB spd-473 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Symphysis Pubis Dysfunction[MeSHID:D059388],Mood Disorders[MeSHID:D019964] discontinued in phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD levomilnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.72 drugbank , DGIDB acetaminophen NA Disease Management[MeSHID:D019468],Asthma[MeSHID:D001249],Fever[MeSHID:D005334],Allergic Reaction[MeSHID:D006967],Pain[MeSHID:D010146],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown NA TTD 3-phenyl-2-nortropene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD vortioxetine small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.36 drugbank , DGIDB 3-alpha-phenylmethoxy-3-beta-phenyl-nortropane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 8s-hydroxylobel-9-ene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD phentermine small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Epidemic[MeSHID:D058872],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Rubella[MeSHID:D012409],Overweight[MeSHID:D050177],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent serotonin transporter SLC6A4 NA inhibitor 1.89 drugbank , DGIDB 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD aripiprazole small molecule Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Unipolar Depression[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autism Spectrum Disorders[MeSHID:D000067877],Pervasive Development Disorder[MeSHID:D002659],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Porphyria, Erythropoietic[MeSHID:D017092] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA modulator NA drugbank rg-7166 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 1 serotonin transporter SLC6A4 Successful target unknown NA TTD 3-(3,4-dichlorophenyl)-2-nortropene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-allyl-6-nitro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD pmid29334795-compound-61 NA NA patented serotonin transporter SLC6A4 Successful target unknown NA TTD dexmethylphenidate small molecule Behavior[MeSHID:D001519],Attention deficit hyperactivity disorder[MeSHID:D001289],Educational Status[MeSHID:D004522] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank 1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD piperidine derivative 1 NA NA patented serotonin transporter SLC6A4 Successful target unknown NA TTD atomoxetine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA binder,inhibitor 0.86 drugbank , DGIDB r-norduloxetine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD tianeptine NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown NA TTD citalopram small molecule Depressive disorder[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Mental Depression[MeSHID:D003863],Alcohol abuse[MeSHID:D000437],Cerebrovascular accident[MeSHID:D020521],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.51 drugbank , DGIDB d-254c NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(phenoxymethyl)phenyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD mmda NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD nortriptyline NA Irritable Bowel Syndrome[MeSHID:D043183],Depressive Symptoms[MeSHID:D003863],Pain[MeSHID:D010146],Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target inhibitor 0.81 TTD , DGIDB cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank 2-n-methylamino-1-(4-methylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD mazindol small molecule Hypertensive disease[MeSHID:D006973],Diabetes Mellitus[MeSHID:D003920],Hyperlipidemia[MeSHID:D006949],Low-Calorie Diet[MeSHID:D031204],Body Weight[MeSHID:D001835],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD citalopram derivative 1 NA NA patented serotonin transporter SLC6A4 Successful target unknown NA TTD pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.13 drugbank , DGIDB 8r-hydroxylobel-9-ene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-(3-chlorophenoxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n,n-dimethylamino-1-(4-methylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 6-nitro-2-piperazin-1-yl-4-vinyl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(tert-butylamino)-3',4'-dichloropentanophenone NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD tesofensine small molecule Obesity[MeSHID:D009765],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigational sodium-dependent serotonin transporter SLC6A4 NA unknown 0.72 drugbank , DGIDB trimipramine small molecule Depressive disorder[MeSHID:D003866],Dyssomnias[MeSHID:D020920],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.67 drugbank , DGIDB 2-n-methylamino-1-(4-methylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(3-fluoro-2-phenoxyphenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD zimelidine NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] withdrawn from market serotonin transporter SLC6A4 Successful target unknown NA TTD venlafaxine small molecule Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Phobia, Social[MeSHID:D000072861],Obsessive compulsive behavior[MeSHID:D003192],Off-Label Use[MeSHID:D056687],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Agoraphobia[MeSHID:D000379],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.93 drugbank , DGIDB 4-chloro-6-nitro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluvoxamine NA Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Mental Depression[MeSHID:D003863],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved serotonin transporter SLC6A4 Successful target unknown 1.08 TTD , DGIDB 4-(2-(3-fluorophenoxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD zimelidine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank fluvoxamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Mental Depression[MeSHID:D003863],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 1.08 drugbank , DGIDB 3-(4-fluorophenyl)-2-nortropene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-propargylamino-1-(4-methylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD [3-(3,4-dichloro-phenyl)-indan-1-yl]-methyl-amine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD escitalopram NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 0.72 TTD , DGIDB methylenedioxyamphetamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (r)-duloxetine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-methyl-4-p-tolyl-piperidine-4-carbonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD litoxetine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 3 serotonin transporter SLC6A4 Successful target unknown NA TTD paroxetine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.47 drugbank , DGIDB (s)-n-isobutyl-n-(pyrrolidin-3-yl)-2-naphthamide NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD gsk-1360707 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(n-cyclopropylamino)-3-chloropropiophenone NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluoxetine NA Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 0.43 TTD , DGIDB 1-(1,2-diphenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD dov-216303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] discontinued in phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD levomilnacipran NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved serotonin transporter SLC6A4 Successful target unknown 0.72 TTD , DGIDB 6-iodo-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD venlafaxine NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Phobia, Social[MeSHID:D000072861],Obsessive compulsive behavior[MeSHID:D003192],Off-Label Use[MeSHID:D056687],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Agoraphobia[MeSHID:D000379],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target unknown 0.93 TTD , DGIDB fluvoxamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Mental Depression[MeSHID:D003863],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 1.08 drugbank , DGIDB cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD nsd-644 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],N-Acetylneuraminic acid storage disease[MeSHID:C535525] discontinued in phase 1 serotonin transporter SLC6A4 Successful target unknown NA TTD , DGIDB amineptine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] illicit,withdrawn sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank 3-(4-chlorophenyl)-2-nortropene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD citalopram NA Depressive disorder[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Mental Depression[MeSHID:D003863],Alcohol abuse[MeSHID:D000437],Cerebrovascular accident[MeSHID:D020521],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 0.51 TTD , DGIDB bgc-20-1259 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(2'-aminoethyl)-5-benzyltetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD bl-1021 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Burkitt Lymphoma[MeSHID:D002051] phase 1 serotonin transporter SLC6A4 Successful target unknown NA TTD 6,8-dinitro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD imipramine small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Stress Disorders, Traumatic, Acute[MeSHID:D040701],Enuresis[MeSHID:D004775],Post-Traumatic Stress Disorder[MeSHID:D013313],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Depressive Symptoms[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Attention deficit hyperactivity disorder[MeSHID:D001289],Postherpetic neuralgia[MeSHID:D051474],Bedwetting[MeSHID:D053206],Bulimia Nervosa[MeSHID:D052018],Neoplasm Metastasis[MeSHID:D009362],Diabetic Neuralgia[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.83 drugbank , DGIDB 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 10r-hydroxylobelane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD ns-2389 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] discontinued in phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(aminomethyl)-5-(1'-naphthyl)tetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 10r-hydroxylobel-7-ene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD threo-3,4-dichlororitalinol hydrochloride NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD lumateperone small molecule Schizophrenia[MeSHID:D012559] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.65 drugbank , DGIDB (r)-n-isobutyl-n-(pyrrolidin-3-yl)-2-naphthamide NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(aminomethyl)-5-phenethyltetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD benzatropine small molecule Bradykinesia[MeSHID:D018476],Dystonia[MeSHID:D004421],Disease[MeSHID:D004194],Dyskinetic syndrome[MeSHID:D020820],Extrapyramidal Disorders[MeSHID:D001480],Parkinsonian Disorders[MeSHID:D020734],Akathisia[MeSHID:D011595],Movement[MeSHID:D009068],Tremor[MeSHID:D014202],Parkinson Disease[MeSHID:D010300],Dystonia Disorders[MeSHID:D020821],Term Birth[MeSHID:D047929] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank duloxetine NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Low Back Pain[MeSHID:D017116],Urinary Stress Incontinence[MeSHID:D014550],Anxiety Disorders[MeSHID:D001008],Osteoarthritis, Knee[MeSHID:D020370],Peripheral Neuropathy[MeSHID:D010523],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target inhibitor 0.92 TTD , DGIDB vilazodone small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.62 drugbank , DGIDB 10s-hydroxylobel-7-ene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD dasotraline small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289],Eating[MeSHID:D004435],Disease[MeSHID:D004194],Mood Disorders[MeSHID:D019964] investigational sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank 6-chloro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD bicifadine small molecule Low Back Pain[MeSHID:D017116],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437] investigational sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank 2-n-hydroxyamino-1-(4-ethylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(1h-indol-3-yl)-n,n-dimethylcyclohex-3-enamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(tert-butylamino)-3',4'-dichlorobutyrophenone NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD r-sibutramine metabolite NA Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] discontinued in phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(3-fluorophenoxy)phenyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD duloxetine small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Low Back Pain[MeSHID:D017116],Urinary Stress Incontinence[MeSHID:D014550],Anxiety Disorders[MeSHID:D001008],Osteoarthritis, Knee[MeSHID:D020370],Peripheral Neuropathy[MeSHID:D010523],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.92 drugbank , DGIDB methylenedioxymethamphetamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD clomipramine NA Premature Ejaculation[MeSHID:D061686],Premenstrual syndrome[MeSHID:D011293],Stuttering[MeSHID:D013342],Narcolepsy[MeSHID:D009290],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Trichotillomania[MeSHID:D014256],Obsessive-Compulsive Disorder[MeSHID:D009771],Pain[MeSHID:D010146],Mental Depression[MeSHID:D003863],Chronic pain[MeSHID:D059350],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autistic Disorder[MeSHID:D001321],Tension Headache[MeSHID:D018781],Neuralgia[MeSHID:D009437],Cataplexy[MeSHID:D002385],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Personality[MeSHID:D003193],Pain Disorder[MeSHID:D013001],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 1 TTD , DGIDB rti-219 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD amoxapine small molecule Depressive disorder[MeSHID:D003866],Reactive depression[MeSHID:D000275],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.36 drugbank , DGIDB 1-(3,4-dichloro-phenyl)-3-methylamino-indan-5-ol NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(n-cyclopentylamino)-3'-methoxypropiophenone NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (+/-)-nantenine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD escitalopram NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 0.72 TTD , DGIDB threo-1-aza-5-phenyl[4.4.0]decane hydrochloride NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD desvenlafaxine NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 1.62 TTD , DGIDB 6-bromo-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD dasotraline NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289],Eating[MeSHID:D004435],Disease[MeSHID:D004194],Mood Disorders[MeSHID:D019964] approved serotonin transporter SLC6A4 Successful target unknown NA TTD win-35065 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD d-257a NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-((naphthalen-2-yloxy)methyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD ((3r,4r)-4-(o-tolyloxy)chroman-3-yl)methanamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-methylamino-1-(4-ethylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD opc-14523 small molecule Bulimia[MeSHID:D002032],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive-Compulsive Personality[MeSHID:D003193],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964],Arousal[MeSHID:D001143] investigational sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank , DGIDB beta-methoxyamphetamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD dextromethorphan polistirex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371],Desiccation[MeSHID:D003890] approved serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-ethylamino-1-(4-methylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD amitifadine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Alcoholic Intoxication, Chronic[MeSHID:D000437],Mood Disorders[MeSHID:D019964] investigational sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank 3-p-tolyl-8-aza-bicyclo[3.2.1]octane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluvoxamine NA Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Mental Depression[MeSHID:D003863],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 1.08 TTD , DGIDB 1-(2-(2-fluorobenzyloxy)phenyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine (enantiomeric mix) NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD n-(2-oxazolemethyl)milnacipran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD protriptyline small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 1.39 drugbank , DGIDB cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(naphthalen-2-yl)ethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(1,4-diphenylbutan-2-yl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD duloxetine NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Unipolar Depression[MeSHID:D003866],Fibromyalgia[MeSHID:D005356],Low Back Pain[MeSHID:D017116],Urinary Stress Incontinence[MeSHID:D014550],Anxiety Disorders[MeSHID:D001008],Osteoarthritis, Knee[MeSHID:D020370],Peripheral Neuropathy[MeSHID:D010523],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target unknown 0.92 TTD , DGIDB 2-n-ethylamino-1-(4-ethylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD amitriptyline NA Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target unknown 0.59 TTD , DGIDB 4-(2-(phenoxymethyl)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD cocaine NA Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 0.36 TTD , DGIDB (2r,3s)-2-[(2-iodophenoxy)phenylmethyl]morpholine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (2r,3s)-2-[(4-iodophenoxy)phenylmethyl]morpholine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.36 drugbank , DGIDB 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (s)-norduloxetine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 3-(1h-indol-1-yl)-n-methyl-3-phenylpropan-1-amine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD clr-3001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD lu-aa34893 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD pf-3409409 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] investigative serotonin transporter SLC6A4 Successful target unknown NA TTD jnj-28583867 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD amitriptyline small molecule Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.59 drugbank , DGIDB 4-(2-(benzyloxy)-6-fluorophenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluoxetine NA Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 0.43 TTD , DGIDB 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD venlafaxine NA Disease Management[MeSHID:D019468],Disease[MeSHID:D004194],Neoplasm Metastasis[MeSHID:D009362],Phobia, Social[MeSHID:D000072861],Obsessive compulsive behavior[MeSHID:D003192],Off-Label Use[MeSHID:D056687],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Agoraphobia[MeSHID:D000379],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target inhibitor 0.93 TTD , DGIDB trazodone NA Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target unknown 0.31 TTD , DGIDB s-34324 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-fluoro-6-phenoxyphenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD minaprine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.9 drugbank , DGIDB 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-(n-propyl)amino-1-(4-methylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 3-(4-trifluoromethylphenyl)-2-nortropene NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD r-226161 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD amfepramone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Obesity[MeSHID:D009765] approved serotonin transporter SLC6A4 Successful target unknown NA TTD oxycodex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD cx-1001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-naphthalen-2-ylmethyl-4,5-dihydro-1h-imidazole NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD kf-a5 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-hydroxyamino-1-(4-methylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-phenoxyphenyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-phenoxy-3-(piperidin-4-yl)pyridine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD nisoxetine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD serotonin small molecule NA investigational,nutraceutical sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank luvox NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved serotonin transporter SLC6A4 Successful target unknown NA TTD cocaine small molecule Laryngeal Mucosa[MeSHID:D007820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.36 drugbank , DGIDB 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 8r-hydroxylobelane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluvoxamine NA Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Mental Depression[MeSHID:D003863],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 1.08 TTD , DGIDB escitalopram small molecule Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Maintenance[MeSHID:D008283],Obsessive compulsive behavior[MeSHID:D003192],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.72 drugbank , DGIDB butriptyline small molecule NA approved,withdrawn sodium-dependent serotonin transporter SLC6A4 NA antagonist,inhibitor NA drugbank 4-furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluvoxamine NA Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Bulimia Nervosa[MeSHID:D052018],Mental Depression[MeSHID:D003863],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Disorder[MeSHID:D009771],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved serotonin transporter SLC6A4 Successful target inhibitor 1.08 TTD , DGIDB 7-(piperidin-4-ylmethoxy)-2-naphthonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD win-35066-2 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD iti-007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sleeplessness[MeSHID:D007319],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 3 serotonin transporter SLC6A4 Successful target unknown 0.65 TTD , DGIDB 2-(aminomethyl)-5-(2'-naphthyl)tetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit sodium-dependent serotonin transporter SLC6A4 NA negative modulator NA drugbank trazodone small molecule Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Fibromyalgia[MeSHID:D005356],Alcoholic Intoxication, Chronic[MeSHID:D000437],Off-Label Use[MeSHID:D056687],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Eating[MeSHID:D004435],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.31 drugbank , DGIDB s33005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] investigative serotonin transporter SLC6A4 Successful target unknown NA TTD chlorpheniramine small molecule Hay fever[MeSHID:D006255],Rhinitis[MeSHID:D012220],Asthma[MeSHID:D001249],Urticaria[MeSHID:D014581],Common Cold[MeSHID:D003139],Allergic Reaction[MeSHID:D006967],Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank 2-n-hydroxyamino-1-(4-ethylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-(n-tert-butylamino)-3',4'-dichloropropiophenone NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank nefazodone small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865] approved,withdrawn sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.78 drugbank , DGIDB d-211b NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-((dimethylamino)methyl)phenoxy)benzonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (r)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD sertraline small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Fibromyalgia[MeSHID:D005356],Mental Depression[MeSHID:D003863],Post-Traumatic Stress Disorder[MeSHID:D013313],Vasovagal syncope[MeSHID:D019462],Phobia, Social[MeSHID:D000072861],Cerebrovascular accident[MeSHID:D020521],Panic Disorder[MeSHID:D016584],Obsessive compulsive behavior[MeSHID:D003192],Premenstrual Dysphoric Disorder[MeSHID:D065446],Anxiety Disorders[MeSHID:D001008],Obsessive-Compulsive Disorder[MeSHID:D009771],Diabetic Neuropathies[MeSHID:D003929],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor,binder,downregulator 0.67 drugbank , DGIDB dexfenfluramine NA Disease Management[MeSHID:D019468],Diet therapy[MeSHID:D004035],Maintenance[MeSHID:D008283],Obesity[MeSHID:D009765],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] withdrawn from market serotonin transporter SLC6A4 Successful target unknown 7.55 TTD , DGIDB 1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine (enantiomeric mix) NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD paroxetine NA Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 0.47 TTD , DGIDB 8s-hydroxylobelane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 3alpha-(bis-chloro-phenylmethoxy)tropane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (2s,3s)-iodoreboxetine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fenfluramine small molecule Infantile Severe Myoclonic Epilepsy[MeSHID:D004831],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577],Obesity[MeSHID:D009765] approved,illicit,investigational,withdrawn sodium-dependent serotonin transporter SLC6A4 NA substrate,inhibitor NA drugbank 2-amino-1-(4-ethylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-ethylamino-1-(4-ethylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD d-211a NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD verapamil small molecule Hypertensive disease[MeSHID:D006973],Tachyarrhythmia[MeSHID:D013610],Atrial Flutter[MeSHID:D001282],Angina, Unstable[MeSHID:D000789],Cluster Headache[MeSHID:D003027],Supraventricular tachycardia[MeSHID:D013617],Stable angina[MeSHID:D060050],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Off-Label Use[MeSHID:D056687],Angina Pectoris, Variant[MeSHID:D000788],pathologic fistula[MeSHID:D005402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank (s)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD milnacipran small molecule Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Child Behavior[MeSHID:D002652],Unipolar Depression[MeSHID:D003866],Abnormal behavior[MeSHID:D000066553],Fibromyalgia[MeSHID:D005356],Feeling suicidal (finding)[MeSHID:D059020],Thinking, function[MeSHID:D013850],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor 1.08 drugbank , DGIDB 4-(2-phenoxyphenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD bupropion NA Major Depressive Disorder[MeSHID:D003865],Disease Management[MeSHID:D019468],Bipolar Disorder[MeSHID:D001714],Unipolar Depression[MeSHID:D003866],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Diet therapy[MeSHID:D004035],Weight Gain[MeSHID:D015430],Body Weight[MeSHID:D001835],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Seasonal Affective Disorder[MeSHID:D016574],Cessation of smoking[MeSHID:D016540],Mood (psychological function)[MeSHID:D000339],Obesity[MeSHID:D009765],Off-Label Use[MeSHID:D056687],Overweight[MeSHID:D050177],Dyslipidemias[MeSHID:D050171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],emotional dependency[MeSHID:D003858],Smoking[MeSHID:D012907],Tobacco smoking behavior[MeSHID:D000073869] approved serotonin transporter SLC6A4 Successful target unknown 0.13 TTD , DGIDB mdl-28618 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD desvenlafaxine NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 1.62 TTD , DGIDB dosulepin small molecule Depressive Symptoms[MeSHID:D003863] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor 0.4 drugbank , DGIDB 1-methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD cocaine.hcl NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-amino-1-(4-ethylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD levomilnacipran NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved serotonin transporter SLC6A4 Successful target inhibitor 0.72 TTD , DGIDB dextromethorphan small molecule Coughing[MeSHID:D003371],Affect (mental function)[MeSHID:D000339],Signs and Symptoms, Respiratory[MeSHID:D012818],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank mmda small molecule NA experimental,illicit sodium-dependent serotonin transporter SLC6A4 NA negative modulator NA drugbank 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD avp-786 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Pain[MeSHID:D010146],Disease[MeSHID:D004194] phase 3 serotonin transporter SLC6A4 Successful target unknown NA TTD 10s-hydroxylobelane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD ns 2359 NA Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cocaine Dependence[MeSHID:D019970],Mood Disorders[MeSHID:D019964] phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD mianserin small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank 2-n-(isopropyl)amino-1-(4-methylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD pf-526014 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD ephedra sinica root biotech Asthma[MeSHID:D001249],Wheezing[MeSHID:D012135],Dyspnea[MeSHID:D004417] nutraceutical sodium-dependent serotonin transporter SLC6A4 NA negative modulator NA drugbank erythro-3,4-dichloromethylphenidate hydrochloride NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(1-phenyl-2-o-tolylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-methoxyamphetamine small molecule NA experimental,illicit sodium-dependent serotonin transporter SLC6A4 NA inhibitor NA drugbank n-benzyl-n-isobutylpiperidin-4-amine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-methoxyamino-1-(4-methylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-(2-fluorobenzyloxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD td-9855 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Hypotension, Orthostatic[MeSHID:D007024] phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-cyclopropylamino-1-(4-methylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD n-cyclobutyl-n-(piperidin-4-yl)-2-naphthamide NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-iodo-6-nitro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD d-257c NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD ad-337 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325],Myalgia[MeSHID:D063806],Fibromyalgia[MeSHID:D005356] phase 1 serotonin transporter SLC6A4 Successful target unknown NA TTD n*1*-(6-nitro-quinolin-2-yl)-ethane-1,2-diamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD paroxetine NA Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Premature Ejaculation[MeSHID:D061686],Post-Traumatic Stress Disorder[MeSHID:D013313],Irritable Bowel Syndrome[MeSHID:D043183],Phobia, Social[MeSHID:D000072861],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 0.47 TTD , DGIDB 3-bromo-6-nitro-2-piperazin-1-yl-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD clomipramine NA Premature Ejaculation[MeSHID:D061686],Premenstrual syndrome[MeSHID:D011293],Stuttering[MeSHID:D013342],Narcolepsy[MeSHID:D009290],Panic Disorder[MeSHID:D016584],Off-Label Use[MeSHID:D056687],Trichotillomania[MeSHID:D014256],Obsessive-Compulsive Disorder[MeSHID:D009771],Pain[MeSHID:D010146],Mental Depression[MeSHID:D003863],Chronic pain[MeSHID:D059350],Schizophrenia[MeSHID:D012559],Depressive disorder[MeSHID:D003866],Gilles de la Tourette syndrome[MeSHID:D005879],Autistic Disorder[MeSHID:D001321],Tension Headache[MeSHID:D018781],Neuralgia[MeSHID:D009437],Cataplexy[MeSHID:D002385],Obsessive compulsive behavior[MeSHID:D003192],Obsessive-Compulsive Personality[MeSHID:D003193],Pain Disorder[MeSHID:D013001],Diabetic Neuropathies[MeSHID:D003929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 1 TTD , DGIDB 1-(2-(4-fluorophenoxy)phenyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD amitifadine NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765],Alcoholic Intoxication, Chronic[MeSHID:D000437],Mood Disorders[MeSHID:D019964] phase 3 serotonin transporter SLC6A4 Successful target unknown NA TTD 2-amino-1-(4-methylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD meperidine small molecule Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium-dependent serotonin transporter SLC6A4 NA binder NA drugbank amitriptyline NA Urinary Incontinence[MeSHID:D014549],Disease Management[MeSHID:D019468],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disease[MeSHID:D004194],Bedwetting[MeSHID:D053206],Fibromyalgia[MeSHID:D005356],Tension Headache[MeSHID:D018781],Enuresis[MeSHID:D004775],Irritable Bowel Syndrome[MeSHID:D043183],Sleep Disorders[MeSHID:D012893],Spina Bifida[MeSHID:D016135],Diabetic Neuropathies[MeSHID:D003929],Sleeplessness[MeSHID:D007319],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved serotonin transporter SLC6A4 Successful target inhibitor 0.59 TTD , DGIDB midomafetamine small molecule Anxiety Disorders[MeSHID:D001008],Malignant Neoplasms[MeSHID:D009369],Anxiety[MeSHID:D001007],Post-Traumatic Stress Disorder[MeSHID:D013313] experimental,illicit,investigational sodium-dependent serotonin transporter SLC6A4 NA negative modulator NA drugbank kf-a6 NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (s)-3-(naphthalen-2-ylmethoxy)pyrrolidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD vilazodone NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 0.62 TTD , DGIDB o-desmethyl tramadol NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational sodium-dependent serotonin transporter SLC6A4 NA binder NA drugbank chlorphentermine hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown NA TTD sibutramine NA Obesity[MeSHID:D009765],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target inhibitor 2.52 TTD , DGIDB 2-(3-methyl-piperazin-1-yl)-6-nitro-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-aminomethyl-5-(p-bromophenyl)tetrahydrofuran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD pyrovalerone NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD difluorobenztropine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD fluoxetine NA Major Depressive Disorder[MeSHID:D003865],Bipolar Disorder[MeSHID:D001714],Depressive disorder[MeSHID:D003866],Maintenance[MeSHID:D008283],Bulimia Nervosa[MeSHID:D052018],Obsessive-Compulsive Disorder[MeSHID:D009771],Obsessive compulsive behavior[MeSHID:D003192],Panic Disorder[MeSHID:D016584],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Mental Depression[MeSHID:D003863],Agoraphobia[MeSHID:D000379],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotonin transporter SLC6A4 Successful target unknown 0.43 TTD , DGIDB 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (2r,3s)-2-[(3-iodophenoxy)phenylmethyl]morpholine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD crx-119 small molecule Gingival Diseases[MeSHID:D005882],Rheumatoid Arthritis[MeSHID:D001172],Periodontal Diseases[MeSHID:D010510] investigational sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank nisoxetine small molecule NA experimental sodium-dependent serotonin transporter SLC6A4 NA unknown NA drugbank ym-992 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] discontinued in phase 2 serotonin transporter SLC6A4 Successful target unknown NA TTD d-166a NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD lorpiprazole small molecule Disease[MeSHID:D004194],Thinking, function[MeSHID:D013850],Hallucinations[MeSHID:D006212],Delusions[MeSHID:D003702],Hand[MeSHID:D006225],Anxiety Disorders[MeSHID:D001008],Eye[MeSHID:D005123],Anxiety[MeSHID:D001007],Paranoia[MeSHID:D010259] approved sodium-dependent serotonin transporter SLC6A4 NA antagonist NA drugbank 2-n-allylamino-1-(4-methylthiophenyl)propan NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (r)-3-(naphthalen-2-ylmethoxy)pyrrolidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD vortioxetine NA Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] approved serotonin transporter SLC6A4 Successful target unknown 0.36 TTD , DGIDB 8-methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-n-ethylamino-1-(4-methylthiophenyl)propane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-[1,4]diazepan-1-yl-6-nitro-quinoline NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 4-(2-(4-fluorophenoxy)phenyl)piperidine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1-(4-benzylsulfanyl-phenyl)-propylamine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (2r,3r)-iodoreboxetine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 2-amino-1-(4-methylthiophenyl)butane NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD (s)-norfluoxetine NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD 1s,2r-milnacipran NA NA investigative serotonin transporter SLC6A4 Successful target unknown NA TTD pmid25037917c58 NA NA investigative sodium-dependent proline transporter SLC6A7 Literature-reported target unknown NA TTD proline small molecule Tendon structure[MeSHID:D013710],Myocardium[MeSHID:D009206],Maintenance[MeSHID:D008283] nutraceutical sodium-dependent proline transporter SLC6A7 NA unknown NA drugbank lp-403812 NA NA investigative sodium-dependent proline transporter SLC6A7 Literature-reported target inhibitor NA TTD , DGIDB phosphocreatine small molecule Disease[MeSHID:D004194],Cardiovascular Diseases[MeSHID:D002318],Skeletal muscle structure[MeSHID:D018482],Cerebrovascular accident[MeSHID:D020521],Muscle Strength[MeSHID:D053580],Cerebrovascular Disorders[MeSHID:D002561] nutraceutical sodium- and chloride-dependent creatine transporter 1 SLC6A8 NA unknown NA drugbank creatine small molecule NA approved,investigational,nutraceutical sodium- and chloride-dependent creatine transporter 1 SLC6A8 NA unknown NA drugbank rgx-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] phase 1 solute carrier family 6 member 8 SLC6A8 Clinical trial target unknown NA TTD pmid29338548-compound-18 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-25 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB ssr-103800 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB bi 425809 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD pmid29338548-compound-44 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB [35s]acppb NA NA investigative glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB organon-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB [3h](r)-npts NA NA investigative glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB org-25935 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown 10.61 TTD , DGIDB ly2365109 NA NA investigative glycine transporter glyt-1 SLC6A9 Clinical trial target inhibitor NA TTD , DGIDB ssr-504734 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-24 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-31 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pf-3463275 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown 21.22 TTD , DGIDB ssr-103800 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical glycine transporter glyt-1 SLC6A9 Clinical trial target inhibitor NA TTD , DGIDB pmid29338548-compound-15 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-38 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB r1678 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-28 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-49 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB [3h]sb-733993 NA NA investigative glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB [3h]gsk931145 NA NA investigative glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB amg 747 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 2 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB gsk931145 NA NA investigative glycine transporter glyt-1 SLC6A9 Clinical trial target inhibitor NA TTD , DGIDB jnj-17305600 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB as-1522489-00 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD alx-5407 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown 3.54 TTD , DGIDB pmid29338548-compound-39 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-29 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-41 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB organon-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB organon NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical glycine transporter glyt-1 SLC6A9 Clinical trial target unknown 10.61 TTD , DGIDB pmid29338548-compound-17 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-30 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-16 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB [3h]nfps NA NA investigative glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-45 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB org-24461 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] preclinical glycine transporter glyt-1 SLC6A9 Clinical trial target unknown 10.61 TTD , DGIDB glyt1 pet radiotracers NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB ro-4840700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] investigative glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD pmid29338548-compound-22 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-36 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-40 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-47 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB gsk1018921 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] discontinued in phase 1 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD pmid29338548-compound-33 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-37 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-46 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-19 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-27 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-20 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB mk-2637 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-26 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-23 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-34 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-48 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB pmid29338548-compound-14 NA NA patented glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB dcccyb NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 1 glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB [3h]n-methyl-ssr504734 NA NA investigative glycine transporter glyt-1 SLC6A9 Clinical trial target unknown NA TTD , DGIDB ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical high affinity cationic amino acid transporter 1 SLC7A1 NA unknown NA drugbank lysine small molecule Virus Physiological Phenomena[MeSHID:D018406],Herpes Simplex Infections[MeSHID:D006561] approved,nutraceutical high affinity cationic amino acid transporter 1 SLC7A1 NA unknown NA drugbank arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical high affinity cationic amino acid transporter 1 SLC7A1 NA unknown NA drugbank acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational cystine/glutamate transporter SLC7A11 NA activator NA drugbank riluzole small molecule Amyotrophic Lateral Sclerosis[MeSHID:D000690],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cystine/glutamate transporter SLC7A11 NA inducer 8.3 drugbank , DGIDB sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cystine/glutamate transporter SLC7A11 NA inhibitor NA drugbank cystine small molecule Degenerative polyarthritis[MeSHID:D010003],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194] approved,nutraceutical cystine/glutamate transporter SLC7A11 NA unknown NA drugbank sxc-2023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Trichotillomania[MeSHID:D014256] phase 2 cystine/glutamate transporter SLC7A11 Clinical trial target unknown NA TTD thimerosal small molecule NA approved cystine/glutamate transporter SLC7A11 NA antagonist NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical cystine/glutamate transporter SLC7A11 NA unknown NA drugbank lysine small molecule Virus Physiological Phenomena[MeSHID:D018406],Herpes Simplex Infections[MeSHID:D006561] approved,nutraceutical low affinity cationic amino acid transporter 2 SLC7A2 NA unknown NA drugbank ornithine small molecule Athletic Performance[MeSHID:D054874],Wound Healing[MeSHID:D014945] approved,nutraceutical low affinity cationic amino acid transporter 2 SLC7A2 NA unknown NA drugbank lysine small molecule Virus Physiological Phenomena[MeSHID:D018406],Herpes Simplex Infections[MeSHID:D006561] approved,nutraceutical cationic amino acid transporter 3 SLC7A3 NA unknown NA drugbank fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved cationic amino acid transporter 3 SLC7A3 NA binder NA drugbank arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical cationic amino acid transporter 3 SLC7A3 NA unknown NA drugbank arginine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational,nutraceutical cationic amino acid transporter 4 SLC7A4 NA unknown NA drugbank lysine small molecule Virus Physiological Phenomena[MeSHID:D018406],Herpes Simplex Infections[MeSHID:D006561] approved,nutraceutical cationic amino acid transporter 4 SLC7A4 NA unknown NA drugbank (+/-)-2-amino-1,2,3,4-tetrahydro-2-naphthoic acid NA NA investigative large neutral amino acids transporter 1 SLC7A5 Literature-reported target unknown NA TTD bch NA NA investigative large neutral amino acids transporter 1 SLC7A5 Literature-reported target unknown NA TTD (+/-)-2-aminoindane-2-carboxylic acid NA NA investigative large neutral amino acids transporter 1 SLC7A5 Literature-reported target unknown NA TTD fluciclovine (18f) small molecule Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Malignant neoplasm of prostate[MeSHID:D011471],Blood[MeSHID:D001769],Growth[MeSHID:D006128],Recurrence (disease attribute)[MeSHID:D012008] approved y+l amino acid transporter 1 SLC7A7 NA binder NA drugbank phenylalanine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Tardive Dyskinesia[MeSHID:D000071057],Vitiligo[MeSHID:D014820] approved,investigational,nutraceutical large neutral amino acids transporter small subunit 2 SLC7A8 NA unknown NA drugbank alanine small molecule Protein Biosynthesis[MeSHID:D014176] nutraceutical large neutral amino acids transporter small subunit 2 SLC7A8 NA unknown NA drugbank caldaret small molecule Myocardial Infarction[MeSHID:D009203],Heart Diseases[MeSHID:D006331] investigational sodium/calcium exchanger 1 SLC8A1 NA unknown NA drugbank dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/calcium exchanger 1 SLC8A1 NA inhibitor NA drugbank icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical sodium/calcium exchanger 1 SLC8A1 NA inhibitor NA drugbank alpha-linolenic acid small molecule NA approved,investigational,nutraceutical sodium/calcium exchanger 1 SLC8A1 NA unknown NA drugbank n-(4-chloro-3-methanesulfonyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-[2-(1h-benzoimidazol-2-yl)-benzoyl]-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-[4-(1h-benzoimidazol-2-yl)-benzoyl]-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD biib-513 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-(3-methanesulfonyl-4-methyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-[5-(2-ethyl-phenyl)-furan-2-carbonyl]-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-(4-bromo-3-methanesulfonyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD zoniporide hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 3 sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD , DGIDB eniporide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] discontinued in phase 2 sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-(3-methanesulfonyl-4-methoxy-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-(5-o-tolyl-furan-2-carbonyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-(5-m-tolyl-furan-2-carbonyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-[5-(2-nitro-phenyl)-furan-2-carbonyl]-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-(4-cyano-3-methanesulfonyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD n-(5-phenyl-furan-2-carbonyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD 5'-(n-ethyl-n-isopropyl)amiloride NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD amiloride small molecule Hypertensive disease[MeSHID:D006973],Congestive heart failure[MeSHID:D006333],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sodium/hydrogen exchanger 1 SLC9A1 NA inhibitor NA drugbank cariporide small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] investigational,discontinued in phase 2 sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown 63.65 TTD , drugbank , DGIDB homoserine lactone small molecule NA experimental,investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD , drugbank n-(5-methanesulfonyl-2-methyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 1 SLC9A1 Clinical trial target unknown NA TTD ave-0657 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cheyne-Stokes Respiration[MeSHID:D002639] phase 2 sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD , DGIDB n-(3-methanesulfonyl-4-methyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD n-(4-bromo-3-methanesulfonyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD n-(4-chloro-3-methanesulfonyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD n-(4-cyano-3-methanesulfonyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD azd1772//rdx5791 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Kidney Diseases[MeSHID:D051436] phase 2 sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD , DGIDB eniporide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] discontinued in phase 2 sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD cariporide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 2 sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD n-(5-methanesulfonyl-2-methyl-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD tenapanor small molecule Physical Dialysis[MeSHID:D003956],Irritable Bowel Syndrome[MeSHID:D043183],Constipation[MeSHID:D003248],Chronic Kidney Diseases[MeSHID:D051436],Hyperphosphatemia (disorder)[MeSHID:D054559],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney Diseases[MeSHID:D007674] approved,investigational sodium/hydrogen exchanger 3 SLC9A3 Successful target inhibitor NA TTD , drugbank n-(3-methanesulfonyl-4-methoxy-benzoyl)-guanidine NA NA investigative sodium/hydrogen exchanger 3 SLC9A3 Successful target unknown NA TTD naringin NA NA investigative sodium-independent organic anion transporter SLCO1A2 Literature-reported target inhibitor 2.27 TTD , DGIDB [3h]estrone-3-sulphate NA NA investigative sodium-independent organic anion transporter SLCO1A2 Literature-reported target unknown NA TTD , DGIDB clarithromycin small molecule Endocarditis[MeSHID:D004696],Bacteremia[MeSHID:D016470],Tonsillitis[MeSHID:D014069],Skin Diseases, Infectious[MeSHID:D012874],Hemolysis (disorder)[MeSHID:D006461],Pharyngitis[MeSHID:D010612],Infection[MeSHID:D007239],Encephalitis[MeSHID:D004660],Legionnaires' Disease[MeSHID:D007877],Pneumonia[MeSHID:D011014],Respiratory Tract Infections[MeSHID:D012141],Duodenal Ulcer[MeSHID:D004381],Cryptosporidiosis[MeSHID:D003457],Maxillary Sinusitis[MeSHID:D015523],Pertussis[MeSHID:D014917],Bartonella Infections[MeSHID:D001474],Otitis Media[MeSHID:D010033],HIV Infections[MeSHID:D015658],Immediate hypersensitivity[MeSHID:D006969],Communicable Diseases[MeSHID:D003141],Lyme Disease[MeSHID:D008193],Bronchitis, Chronic[MeSHID:D029481],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier organic anion transporter family member 1b1 SLCO1B1 NA unknown NA drugbank gemfibrozil small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Fasting[MeSHID:D005215],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Serum[MeSHID:D044967],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Weight decreased[MeSHID:D015431],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier organic anion transporter family member 1b1 SLCO1B1 NA inhibitor 0.5 drugbank , DGIDB [3h]estrone-3-sulphate NA NA investigative liver organic anion transporter 1 SLCO1B1 Literature-reported target unknown NA TTD , DGIDB clarithromycin small molecule Endocarditis[MeSHID:D004696],Bacteremia[MeSHID:D016470],Tonsillitis[MeSHID:D014069],Skin Diseases, Infectious[MeSHID:D012874],Hemolysis (disorder)[MeSHID:D006461],Pharyngitis[MeSHID:D010612],Infection[MeSHID:D007239],Encephalitis[MeSHID:D004660],Legionnaires' Disease[MeSHID:D007877],Pneumonia[MeSHID:D011014],Respiratory Tract Infections[MeSHID:D012141],Duodenal Ulcer[MeSHID:D004381],Cryptosporidiosis[MeSHID:D003457],Maxillary Sinusitis[MeSHID:D015523],Pertussis[MeSHID:D014917],Bartonella Infections[MeSHID:D001474],Otitis Media[MeSHID:D010033],HIV Infections[MeSHID:D015658],Immediate hypersensitivity[MeSHID:D006969],Communicable Diseases[MeSHID:D003141],Lyme Disease[MeSHID:D008193],Bronchitis, Chronic[MeSHID:D029481],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier organic anion transporter family member 1b1 SLCO1B1 NA unknown NA drugbank [3h]estradiol-17beta-glucuronide NA NA investigative liver organic anion transporter 1 SLCO1B1 Literature-reported target unknown NA TTD telaprevir small molecule Genotype[MeSHID:D005838],Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier organic anion transporter family member 1b1 SLCO1B1 NA inhibitor NA drugbank ginsenoside rb1 small molecule NA nutraceutical solute carrier organic anion transporter family member 1b3 SLCO1B3 NA inhibitor NA drugbank [3h]estradiol-17beta-glucuronide NA NA investigative liver organic anion transporter 2 SLCO1B3 Literature-reported target unknown NA TTD ginsenoside rg1 small molecule NA nutraceutical solute carrier organic anion transporter family member 1b3 SLCO1B3 NA unknown NA drugbank clarithromycin small molecule Endocarditis[MeSHID:D004696],Bacteremia[MeSHID:D016470],Tonsillitis[MeSHID:D014069],Skin Diseases, Infectious[MeSHID:D012874],Hemolysis (disorder)[MeSHID:D006461],Pharyngitis[MeSHID:D010612],Infection[MeSHID:D007239],Encephalitis[MeSHID:D004660],Legionnaires' Disease[MeSHID:D007877],Pneumonia[MeSHID:D011014],Respiratory Tract Infections[MeSHID:D012141],Duodenal Ulcer[MeSHID:D004381],Cryptosporidiosis[MeSHID:D003457],Maxillary Sinusitis[MeSHID:D015523],Pertussis[MeSHID:D014917],Bartonella Infections[MeSHID:D001474],Otitis Media[MeSHID:D010033],HIV Infections[MeSHID:D015658],Immediate hypersensitivity[MeSHID:D006969],Communicable Diseases[MeSHID:D003141],Lyme Disease[MeSHID:D008193],Bronchitis, Chronic[MeSHID:D029481],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier organic anion transporter family member 1b3 SLCO1B3 NA unknown NA drugbank gemfibrozil small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Fasting[MeSHID:D005215],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Serum[MeSHID:D044967],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Weight decreased[MeSHID:D015431],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier organic anion transporter family member 1b3 SLCO1B3 NA inhibitor 0.44 drugbank , DGIDB clarithromycin small molecule Endocarditis[MeSHID:D004696],Bacteremia[MeSHID:D016470],Tonsillitis[MeSHID:D014069],Skin Diseases, Infectious[MeSHID:D012874],Hemolysis (disorder)[MeSHID:D006461],Pharyngitis[MeSHID:D010612],Infection[MeSHID:D007239],Encephalitis[MeSHID:D004660],Legionnaires' Disease[MeSHID:D007877],Pneumonia[MeSHID:D011014],Respiratory Tract Infections[MeSHID:D012141],Duodenal Ulcer[MeSHID:D004381],Cryptosporidiosis[MeSHID:D003457],Maxillary Sinusitis[MeSHID:D015523],Pertussis[MeSHID:D014917],Bartonella Infections[MeSHID:D001474],Otitis Media[MeSHID:D010033],HIV Infections[MeSHID:D015658],Immediate hypersensitivity[MeSHID:D006969],Communicable Diseases[MeSHID:D003141],Lyme Disease[MeSHID:D008193],Bronchitis, Chronic[MeSHID:D029481],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier organic anion transporter family member 1b3 SLCO1B3 NA unknown NA drugbank [3h]estrone-3-sulphate NA NA investigative organic anion transporter f SLCO1C1 Literature-reported target unknown NA TTD , DGIDB bromsulphthalein NA NA investigative prostaglandin transporter SLCO2A1 Patented-recorded target unknown NA TTD bromocresol green NA NA investigative prostaglandin transporter SLCO2A1 Patented-recorded target unknown NA TTD pmid26099857-compound-wo2011037610formula(i) NA NA patented prostaglandin transporter SLCO2A1 Patented-recorded target unknown NA TTD , DGIDB gemfibrozil small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertriglyceridemia[MeSHID:D015228],Fasting[MeSHID:D005215],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Hyperlipidemia[MeSHID:D006949],Serum[MeSHID:D044967],Coronary heart disease[MeSHID:D003327],Heart[MeSHID:D006321],Heart Diseases[MeSHID:D006331],Weight decreased[MeSHID:D015431],Pancreatitis[MeSHID:D010195],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved solute carrier organic anion transporter family member 2b1 SLCO2B1 NA inhibitor 0.46 drugbank , DGIDB telaprevir small molecule Genotype[MeSHID:D005838],Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239],Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn solute carrier organic anion transporter family member 2b1 SLCO2B1 NA inhibitor NA drugbank [3h]estrone-3-sulphate NA NA investigative organic anion transporter b SLCO2B1 Literature-reported target unknown NA TTD , DGIDB [3h]estrone-3-sulphate NA NA investigative organic anion transporter d SLCO3A1 Literature-reported target unknown NA TTD , DGIDB [3h]estrone-3-sulphate NA NA investigative organic anion transporter e SLCO4A1 Literature-reported target unknown NA TTD , DGIDB digoxin NA Disease[MeSHID:D004194],Myocardial Contraction[MeSHID:D009200],Maintenance[MeSHID:D008283],treatment failure[MeSHID:D017211],Diagnosis[MeSHID:D003933],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Heart Ventricle[MeSHID:D006352],Atrial Fibrillation[MeSHID:D001281],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] approved organic anion transporter m1 SLCO4C1 Successful target unknown 1.87 TTD , DGIDB asg-15me NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] phase 1 slit and ntrk-like family member 6 SLITRK6 Clinical trial target unknown NA TTD , DGIDB 2-[4-[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile small molecule NA experimental ste20-like serine/threonine-protein kinase SLK NA unknown NA drugbank k-00546 small molecule NA experimental ste20-like serine/threonine-protein kinase SLK NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ste20-like serine/threonine-protein kinase SLK NA inhibitor NA drugbank dexfosfoserine small molecule NA experimental mothers against decapentaplegic homolog 2 SMAD2 NA unknown NA drugbank fluorescein NA Angioscopy[MeSHID:D017546],Diagnosis[MeSHID:D003933],gastric fundus[MeSHID:D005748],Iris (Eye)[MeSHID:D007498],Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mothers against decapentaplegic homolog 3 SMAD3 Successful target unknown 0.04 TTD , DGIDB ellagic acid NA Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigative mothers against decapentaplegic homolog 3 SMAD3 Successful target unknown 0.01 TTD , DGIDB sis-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney[MeSHID:D007668],Fibrosis[MeSHID:D005355] preclinical mothers against decapentaplegic homolog 3 SMAD3 Successful target unknown NA TTD gnf-pf-2272 NA NA investigative mothers against decapentaplegic homolog 3 SMAD3 Successful target unknown 0.01 TTD , DGIDB isis 28466 NA NA investigative smad7 messenger rna SMAD7 Clinical trial target unknown NA TTD ged-0301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] phase 3 smad7 messenger rna SMAD7 Clinical trial target unknown 31.83 TTD , DGIDB isis 28472 NA NA investigative smad7 messenger rna SMAD7 Clinical trial target unknown NA TTD ged-0301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093],Crohn Disease[MeSHID:D003424] phase 3 mothers against decapentaplegic homolog 7 SMAD7 Clinical trial target unknown 31.83 TTD , DGIDB isis 28465 NA NA investigative smad7 messenger rna SMAD7 Clinical trial target unknown NA TTD isis 28477 NA NA investigative smad7 messenger rna SMAD7 Clinical trial target unknown NA TTD 4-deoxy-alpha-d-glucose small molecule NA experimental swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a member 5 SMARCA5 NA unknown NA drugbank beta-d-glucose small molecule NA experimental swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a member 5 SMARCA5 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily e member 1 SMARCE1 NA unknown NA drugbank grn163l small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Lymph[MeSHID:D008196] investigational telomerase-binding protein est1a SMG6 NA unknown NA drugbank lmi070 NA Spinal Muscular Atrophy[MeSHID:D009134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 survival motor neuron protein SMN1 Successful target unknown 0.49 TTD , DGIDB zolgensma NA Spinal Muscular Atrophy[MeSHID:D009134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved survival motor neuron protein SMN1 Successful target unknown NA TTD rg7800 NA Spinal Muscular Atrophy[MeSHID:D009134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 survival motor neuron protein SMN1 Successful target unknown NA TTD , DGIDB nusinersen biotech Spinal Muscular Atrophy[MeSHID:D009134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational survival motor neuron protein SMN2 NA antisense oligonucleotide 1 drugbank , DGIDB bms-833923 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1b smoothened homolog SMO Successful target unknown 9.79 TTD , DGIDB pmid25726713-compound-27 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pyrimidine derivative 22 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB tak-441 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 smoothened homolog SMO Successful target unknown 19.59 TTD , DGIDB isoflavone derivative 5 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB isoflavone derivative 1 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-25 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-60 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-19 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-22 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-11 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB isoflavone derivative 3 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-31 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-14 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB bicyclic hexapeptide derivative 2 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-13 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-36 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB isoflavone derivative 4 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-16 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-47 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-30 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-33 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-18 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB fluocinonide small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] approved,investigational smoothened homolog SMO NA agonist NA drugbank sonidegib small molecule Operative Surgical Procedures[MeSHID:D013514],Basal cell carcinoma[MeSHID:D002280] approved,investigational smoothened homolog SMO NA antagonist 11.75 drugbank , DGIDB pmid25726713-compound-37 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-17 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-29 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-20 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-61 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-15 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-63 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB vismodegib small molecule Radiation[MeSHID:D011827],Basal cell carcinoma[MeSHID:D002280],Carcinoma[MeSHID:D002277],Operative Surgical Procedures[MeSHID:D013514],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Medulloblastoma[MeSHID:D008527],Neuroectodermal Tumor, Primitive[MeSHID:D018242] approved,investigational smoothened homolog SMO Successful target antagonist,inhibitor 29.38 TTD , drugbank , DGIDB pmid25726713-compound-44 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-34 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB 1-benzyl-4-(4-phenylpiperazin-1-yl)phthalazine NA NA investigative smoothened homolog SMO Successful target unknown NA TTD pmid25726713-compound-28 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pyrimidine derivative 19 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB tak-441 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 smoothened homolog SMO Successful target antagonist 19.59 TTD , DGIDB cyclic sulfonamide derivative 1 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-26 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB isoflavone derivative 2 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-17 NA NA patented smoothened d473h mutant SMO Patented-recorded target unknown NA TTD , DGIDB pmid25726713-compound-46 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB smoi2-17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative smoothened homolog SMO Successful target unknown NA TTD pmid25726713-compound-10 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-49 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-62 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB imidazo bicyclic iminium derivative 9 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-23 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pyrimidine derivative 20 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB imidazo bicyclic iminium derivative 8 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB cyclic sulfonamide derivative 2 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB lde225 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Medulloblastoma[MeSHID:D008527],Malignant neoplasm of skin[MeSHID:D012878] phase 2 smoothened homolog SMO Successful target unknown 11.75 TTD , DGIDB pmid25726713-compound-50 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB ly2940680 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 smoothened homolog SMO Successful target inhibitor NA TTD , DGIDB lde225 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Medulloblastoma[MeSHID:D008527],Malignant neoplasm of skin[MeSHID:D012878] phase 2 smoothened homolog SMO Successful target inhibitor 11.75 TTD , DGIDB isoflavone derivative 6 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-58 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pf-04449913 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Leukemia, Myelomonocytic, Chronic[MeSHID:D015477] approved smoothened homolog SMO Successful target unknown 9.79 TTD , DGIDB pmid25726713-compound-12 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB leq-506 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 smoothened homolog SMO Successful target unknown 9.79 TTD , DGIDB imidazo bicyclic iminium derivative 4 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB cyclopamine NA NA investigative smoothened homolog SMO Successful target unknown NA TTD imidazo bicyclic iminium derivative 7 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-57 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-59 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-35 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-51 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-45 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB glasdegib small molecule Erythrocytes[MeSHID:D004912],Hematologic Neoplasms[MeSHID:D019337],Leukemia, Myelocytic, Acute[MeSHID:D015470],Blood Platelets[MeSHID:D001792],Diagnosis[MeSHID:D003933],myeloblast[MeSHID:D042381],leukemia[MeSHID:D007938],Intention - mental process[MeSHID:D033182],Bone Marrow[MeSHID:D001853] approved,investigational smoothened homolog SMO NA inhibitor,antagonist 9.79 drugbank , DGIDB vismodegib small molecule Radiation[MeSHID:D011827],Basal cell carcinoma[MeSHID:D002280],Carcinoma[MeSHID:D002277],Operative Surgical Procedures[MeSHID:D013514],Electromagnetic Radiation[MeSHID:D060733],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Medulloblastoma[MeSHID:D008527],Neuroectodermal Tumor, Primitive[MeSHID:D018242] approved,investigational smoothened homolog SMO Successful target antagonist 29.38 TTD , drugbank , DGIDB bms-833923 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1b smoothened homolog SMO Successful target antagonist 9.79 TTD , DGIDB sonidegib small molecule Operative Surgical Procedures[MeSHID:D013514],Basal cell carcinoma[MeSHID:D002280] approved,investigational smoothened homolog SMO NA antagonist,inhibitor 11.75 drugbank , DGIDB imidazo bicyclic iminium derivative 6 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-64 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-38 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB isoflavone derivative 7 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-42 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB ly2940680 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-43 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-39 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB halcinonide small molecule Dermatologic disorders[MeSHID:D012871],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn smoothened homolog SMO NA agonist,activator NA drugbank pyrimidine derivative 21 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB imidazo bicyclic iminium derivative 5 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB imidazo bicyclic iminium derivative 3 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB isoflavone derivative 9 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB cyclic sulfonamide derivative 4 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-56 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-24 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB cyclic sulfonamide derivative 3 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB isoflavone derivative 8 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-48 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB bicyclic hexapeptide derivative 1 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB azd8542 NA NA investigative smoothened homolog SMO Successful target antagonist NA TTD , DGIDB pmid25726713-compound-21 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB pmid25726713-compound-32 NA NA patented smoothened homolog SMO Successful target unknown NA TTD , DGIDB spermine small molecule NA experimental,nutraceutical spermine oxidase SMOX NA ligand NA drugbank mdl72527 small molecule NA experimental spermine oxidase SMOX NA inhibitor NA drugbank amlodipine small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypertensive disease[MeSHID:D006973],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Heart failure[MeSHID:D006333],Stable angina[MeSHID:D060050],Angina Pectoris, Variant[MeSHID:D000788],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sphingomyelin phosphodiesterase SMPD1 NA inhibitor NA drugbank medical cannabis biotech NA experimental,investigational sphingomyelin phosphodiesterase SMPD1 NA inducer NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved sphingomyelin phosphodiesterase SMPD1 NA inhibitor NA drugbank desipramine small molecule Peripheral Neuropathy[MeSHID:D010523],Disease Management[MeSHID:D019468],Depressive Syndrome[MeSHID:D003866],Attention deficit hyperactivity disorder[MeSHID:D001289],Neoplasm Metastasis[MeSHID:D009362],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863] approved,investigational sphingomyelin phosphodiesterase SMPD1 NA inhibitor NA drugbank chlorpromazine small molecule Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Operative Surgical Procedures[MeSHID:D013514],Psychomotor Agitation[MeSHID:D011595],Mood (psychological function)[MeSHID:D000339],Impulsive Behavior[MeSHID:D007175],Drug Tolerance[MeSHID:D004361],Frustration[MeSHID:D005639],Conduct Disorder[MeSHID:D019955],Hiccup[MeSHID:D006606],Term Birth[MeSHID:D047929],Bipolar Disorder[MeSHID:D001714],Schizophrenia[MeSHID:D012559],Acute intermittent porphyria[MeSHID:D017118],Attention[MeSHID:D001288],Nausea[MeSHID:D009325],MAJOR AFFECTIVE DISORDER 2[MeSHID:C564108],Vomiting[MeSHID:D014839],Hyperactive behavior[MeSHID:D006948],Immune Tolerance[MeSHID:D007108],Behavior[MeSHID:D001519],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved sphingomyelin phosphodiesterase SMPD1 NA inhibitor NA drugbank phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical sphingomyelin phosphodiesterase 3 SMPD3 NA unknown NA drugbank phosphatidyl serine small molecule Cognition Disorders[MeSHID:D003072],Memory impairment[MeSHID:D008569] investigational,nutraceutical sphingomyelin phosphodiesterase 4 SMPD4 NA unknown NA drugbank nd1251 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] discontinued in phase 1 sphingomyelin phosphodiesterase 4 SMPD4 Discontinued target unknown NA TTD spermine small molecule NA experimental,nutraceutical spermine synthase SMS NA ligand NA drugbank lly-507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical set and mynd domain-containing protein 2 SMYD2 Preclinical target inhibitor NA TTD , DGIDB epz032597 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical set and mynd domain-containing protein 2 SMYD2 Preclinical target unknown NA TTD a-893 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] preclinical set and mynd domain-containing protein 2 SMYD2 Preclinical target unknown NA TTD az505 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical set and mynd domain-containing protein 2 SMYD2 Preclinical target inhibitor NA TTD , DGIDB bay 598 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical set and mynd domain-containing protein 2 SMYD2 Preclinical target unknown NA TTD epz033294 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical set and mynd domain-containing protein 2 SMYD2 Preclinical target unknown NA TTD gsk2807 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone-lysine n-methyltransferase smyd3 SMYD3 Preclinical target unknown NA TTD epz031686 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone-lysine n-methyltransferase smyd3 SMYD3 Preclinical target unknown NA TTD epz0330456 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant tumor of colon[MeSHID:D003110] preclinical histone-lysine n-methyltransferase smyd3 SMYD3 Preclinical target unknown NA TTD epz028862 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical histone-lysine n-methyltransferase smyd3 SMYD3 Preclinical target unknown NA TTD botulinum toxin type a biotech Neurogenic Thoracic Outlet Syndrome[MeSHID:D013901],Strabismus[MeSHID:D013285],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Trigeminal Neuralgia[MeSHID:D014277],Pain[MeSHID:D010146],Facial Nerve Diseases[MeSHID:D005155],Overactive Bladder[MeSHID:D053201],Temporomandibular Joint Disorders[MeSHID:D013705],Hyperhidrosis disorder[MeSHID:D006945],Disease[MeSHID:D004194],Spasm[MeSHID:D013035],Postherpetic neuralgia[MeSHID:D051474],Neurogenesis[MeSHID:D055495],Neuralgia[MeSHID:D009437],Cervical Dystonia[MeSHID:D014103],Cerebrovascular accident[MeSHID:D020521],Diabetic Neuropathies[MeSHID:D003929],Spinal Cord Injuries[MeSHID:D013119],Migraine Disorders[MeSHID:D008881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blepharospasm[MeSHID:D001764] approved,investigational synaptosomal-associated protein 25 SNAP25 Successful target inhibitor NA TTD , drugbank , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational alpha-synuclein SNCA NA unknown NA drugbank prx002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 synuclein alpha SNCA Clinical trial target unknown NA TTD npt200-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Multiple System Atrophy[MeSHID:D019578],Shy-Drager Syndrome[MeSHID:D012791] phase 1 synuclein alpha SNCA Clinical trial target unknown NA TTD biib054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 synuclein alpha SNCA Clinical trial target inhibitor 4.11 TTD , DGIDB resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational alpha-synuclein SNCA NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alpha-synuclein SNCA NA unknown NA drugbank posiphen r-phenserine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 synuclein alpha SNCA Clinical trial target unknown NA TTD , DGIDB rg7935 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 synuclein alpha SNCA Clinical trial target unknown 4.11 TTD , DGIDB medi1341 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1 synuclein alpha SNCA Clinical trial target unknown NA TTD , DGIDB biib054 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 2 synuclein alpha SNCA Clinical trial target unknown 4.11 TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational snf-related serine/threonine-protein kinase SNRK NA inhibitor NA drugbank malonic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] experimental u1 small nuclear ribonucleoprotein a SNRPA NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational small nuclear ribonucleoprotein sm d2 SNRPD2 NA ligand NA drugbank (s)-3-phenyllactic acid small molecule NA experimental nhp2-like protein 1 SNU13 NA unknown NA drugbank anisomycin small molecule NA experimental nhp2-like protein 1 SNU13 NA unknown NA drugbank s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental sorting nexin-3 SNX3 NA unknown NA drugbank ezetimibe small molecule Homozygote[MeSHID:D006720],Hyperlipidemia, Familial Combined[MeSHID:D006950],Hyperlipidemia[MeSHID:D006949],Sitosterolemia[MeSHID:C537345],Hypercholesterolemia, Familial[MeSHID:D006938],Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved sterol o-acyltransferase 1 SOAT1 NA inhibitor NA drugbank hesperetin small molecule Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental sterol o-acyltransferase 1 SOAT1 NA inhibitor NA drugbank isis 140158 NA NA investigative soat2 messenger rna SOAT2 Literature-reported target unknown NA TTD isis 140161 NA NA investigative soat2 messenger rna SOAT2 Literature-reported target unknown NA TTD pyripyropene a NA NA investigative soat2 messenger rna SOAT2 Literature-reported target unknown NA TTD isis 140153 NA NA investigative soat2 messenger rna SOAT2 Literature-reported target unknown NA TTD isis 140157 NA NA investigative soat2 messenger rna SOAT2 Literature-reported target unknown NA TTD isis 140148 NA NA investigative soat2 messenger rna SOAT2 Literature-reported target unknown NA TTD hesperetin small molecule Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental sterol o-acyltransferase 2 SOAT2 NA inhibitor NA drugbank oleic acid anilide NA NA investigative soat2 messenger rna SOAT2 Literature-reported target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational superoxide dismutase [cu-zn] SOD1 NA cofactor NA drugbank tempol NA Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD methoxyestradiol NA NA phase 2 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational superoxide dismutase [cu-zn] SOD1 NA unknown NA drugbank pc-sod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Diseases, Interstitial[MeSHID:D017563],Pyruvate Carboxylase Deficiency Disease[MeSHID:D015324] phase 2 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD aeol-10150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103] preclinical superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD isis-sod1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Motor Neuron Disease[MeSHID:D016472] phase 1 sod1 messenger rna SOD1 Clinical trial target unknown NA TTD isis 150464 NA NA investigative sod1 messenger rna SOD1 Clinical trial target unknown NA TTD midismase NA Cerebral Infarction[MeSHID:D002544],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD isoprenaline small molecule Shock, Cardiogenic[MeSHID:D012770],Bronchial Spasm[MeSHID:D001986],Congestive heart failure[MeSHID:D006333],Heart Block[MeSHID:D006327],Tachycardia, Ventricular[MeSHID:D017180],Hypovolemic Shock[MeSHID:D012769],Body Fluids[MeSHID:D001826],Hypovolemic[MeSHID:D020896],Cardiac Arrest[MeSHID:D006323],Septic Shock[MeSHID:D012772] approved,investigational superoxide dismutase [cu-zn] SOD1 NA stabilization NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational superoxide dismutase [cu-zn] SOD1 NA inhibitor NA drugbank vlts-582 NA NA investigative superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD superoxide dismutase NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] phase 2 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD 5-fluorouridine small molecule NA experimental superoxide dismutase [cu-zn] SOD1 NA unknown NA drugbank isis 150450 NA NA investigative sod1 messenger rna SOD1 Clinical trial target unknown NA TTD benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved superoxide dismutases SOD1 NA inhibitor NA drugbank isis 150453 NA NA investigative sod1 messenger rna SOD1 Clinical trial target unknown NA TTD atn-224 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD tdi-0107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] investigative superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational superoxide dismutase [cu-zn] SOD1 NA inhibitor NA drugbank isis 150451 NA NA investigative sod1 messenger rna SOD1 Clinical trial target unknown NA TTD coprexa NA nervous system disorder[MeSHID:D009422],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD isis 150463 NA NA investigative sod1 messenger rna SOD1 Clinical trial target unknown NA TTD euk-189 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Burn injury[MeSHID:D002056] phase 1 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD acetate ion NA NA investigative superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD tdi-0079 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] investigative superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD s-oxy-l-cysteine small molecule NA experimental superoxide dismutase [cu-zn] SOD1 NA unknown NA drugbank apn-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] phase 1/2 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD ec-sod NA NA investigative superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD isis 150454 NA NA investigative sod1 messenger rna SOD1 Clinical trial target unknown NA TTD tdi-0060 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] investigative superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD dopamine small molecule Sepsis[MeSHID:D018805],Kidney Failure[MeSHID:D051437],Heart Decompensation[MeSHID:D006333],Traumatic injury[MeSHID:D014947],Hemodynamics[MeSHID:D006439],Shock[MeSHID:D012769],Myocardial Infarction[MeSHID:D009203],Hypotension[MeSHID:D007022],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved superoxide dismutase [cu-zn] SOD1 NA unknown NA drugbank biib067 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690] phase 3 superoxide dismutase cu-zn SOD1 Clinical trial target unknown NA TTD isis 150452 NA NA investigative sod1 messenger rna SOD1 Clinical trial target unknown NA TTD arimoclomol small molecule Amyotrophic Lateral Sclerosis[MeSHID:D000690],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Cerebral Ischemia[MeSHID:D002545],Inclusion Body Myositis (disorder)[MeSHID:D018979],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational superoxide dismutase [cu-zn] SOD1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational superoxide dismutase [cu-zn] SOD1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental superoxide dismutase [cu-zn] SOD1 NA cofactor NA drugbank medical cannabis biotech NA experimental,investigational superoxide dismutase [cu-zn] SOD1 NA inhibitor NA drugbank benzylsulfonic acid small molecule NA experimental superoxide dismutase [mn], mitochondrial SOD2 NA unknown NA drugbank 3-fluoro-l-tyrosine small molecule NA experimental superoxide dismutase [mn], mitochondrial SOD2 NA unknown NA drugbank imisopasem manganese NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 superoxide dismutase mn SOD2 Clinical trial target unknown NA TTD benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved superoxide dismutases SOD2 NA inhibitor NA drugbank benzoyl peroxide small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved superoxide dismutases SOD3 NA inhibitor NA drugbank nicotinamide-adenine-dinucleotide NA NA investigative sorbitoldehydrogenase SORD Literature-reported target unknown NA TTD nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical sorbitol dehydrogenase SORD NA unknown NA drugbank cp-166572, 2-hydroxymethyl-4-(4-n,n-dimethylaminosulfonyl-1-piperazino)-pyrimidine small molecule NA experimental sorbitol dehydrogenase SORD NA unknown NA drugbank cp-470,711 NA NA investigative sorbitoldehydrogenase SORD Literature-reported target unknown NA TTD ly2541546 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 sclerostin SOST Successful target unknown NA TTD , DGIDB amg 167 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 sclerostin SOST Successful target unknown NA TTD , DGIDB romosozumab biotech Fracture[MeSHID:D050723],Osteoporosis[MeSHID:D010024],Postmenopause[MeSHID:D017698],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoporosis, Postmenopausal[MeSHID:D015663] approved,investigational sclerostin SOST Successful target inhibitor 63.65 TTD , drugbank , DGIDB bps-804 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],POPLITEAL PTERYGIUM SYNDROME, LETHAL TYPE[MeSHID:C564874],Metabolic Bone Disorder[MeSHID:D001851] phase 2 sclerostin SOST Successful target unknown 21.22 TTD , DGIDB terameprocol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 transcription factor sp1 SP1 Clinical trial target unknown 31.83 TTD , DGIDB calcium citrate small molecule NA approved,investigational sparc SPARC NA ligand NA drugbank calcium phosphate small molecule NA approved sparc SPARC NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved sparc SPARC NA unknown NA drugbank pmid27539678-compound-16 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB pmid27539678-compound-14 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB vpc-94075 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Premature ventricular contractions[MeSHID:D018879],Vascular Diseases[MeSHID:D014652] investigative sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD pmid27539678-compound-10 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB pmid27539678-compound-6 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB methylbenzenesulfonamide derivative 1 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB gsk618334 NA Nasopharyngeal carcinoma[MeSHID:C538339],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Drug abuse[MeSHID:D019966] phase 1 sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB phenoxodiol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB pmid27539678-compound-17 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB pf-543 NA NA investigative sphingosine kinase 1 SPHK1 Clinical trial target inhibitor NA TTD , DGIDB pmid27539678-compound-12 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB pmid27539678-compound-9 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB pmid27539678-compound-7 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB pmid27539678-compound-11 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB sk1-i NA NA investigative sphingosine kinase 1 SPHK1 Clinical trial target inhibitor NA TTD , DGIDB pmid27539678-compound-13 NA NA patented sphingosine kinase 1 SPHK1 Clinical trial target unknown NA TTD , DGIDB (s)-2-amino-6-hydroxy-n-(4-octylphenyl)hexanamide NA NA investigative sphingosine kinase 2 SPHK2 Clinical trial target unknown NA TTD (r)-2-amino-3-(4-octylphenylamino)propan-1-ol NA NA investigative sphingosine kinase 2 SPHK2 Clinical trial target unknown NA TTD opaganib small molecule NA investigational sphingosine kinase 2 SPHK2 NA inhibitor 31.83 drugbank , DGIDB dimethylspingosine NA NA investigative sphingosine kinase 2 SPHK2 Clinical trial target unknown 21.22 TTD , DGIDB rome NA NA investigative sphingosine kinase 2 SPHK2 Clinical trial target inhibitor NA TTD , DGIDB (s)-2-amino-4-hydroxy-n-(4-octylphenyl)butanamide NA NA investigative sphingosine kinase 2 SPHK2 Clinical trial target unknown NA TTD abc294640 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Liver carcinoma[MeSHID:D006528],Cholangiocarcinoma[MeSHID:D018281],Neoplasms[MeSHID:D009369] phase 3 sphingosine kinase 2 SPHK2 Clinical trial target unknown NA TTD , DGIDB (r)-2-amino-4-hydroxy-n-(4-octylphenyl)butanamide NA NA investigative sphingosine kinase 2 SPHK2 Clinical trial target unknown NA TTD leucine - reduced carbonyl small molecule NA experimental serine protease inhibitor kazal-type 6 SPINK6 NA unknown NA drugbank latrunculin b small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798],Glaucoma[MeSHID:D005901] experimental protein spire homolog 2 SPIRE2 NA unknown NA drugbank biopterin small molecule NA experimental sepiapterin reductase SPR NA unknown NA drugbank oxaloacetate ion small molecule NA experimental sepiapterin reductase SPR NA unknown NA drugbank nicotinamide adenine dinucleotide phosphate small molecule NA experimental sepiapterin reductase SPR NA unknown NA drugbank n-acetylserotonin small molecule NA experimental sepiapterin reductase SPR NA unknown NA drugbank 1d-myo-inositol 1,4,5-trisphosphate small molecule NA experimental spectrin beta chain, non-erythrocytic 1 SPTBN1 NA unknown NA drugbank abt-413 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 spectrin non-erythroid beta chain 1 SPTBN1 Clinical trial target unknown NA TTD , DGIDB calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical spectrin beta chain, non-erythrocytic 1 SPTBN1 NA agonist NA drugbank serine small molecule NA investigational,nutraceutical serine palmitoyltransferase 1 SPTLC1 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine palmitoyltransferase 1 SPTLC1 NA cofactor NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine palmitoyltransferase 2 SPTLC2 NA cofactor NA drugbank serine small molecule NA investigational,nutraceutical serine palmitoyltransferase 2 SPTLC2 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine palmitoyltransferase 3 SPTLC3 NA cofactor NA drugbank geraniin NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD terbinafine small molecule Skin Diseases, Infectious[MeSHID:D012874],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Nail plate[MeSHID:D009262],Mycoses[MeSHID:D009181],Onychomycosis[MeSHID:D014009],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved squalene monooxygenase SQLE NA inhibitor NA drugbank epigallocatechin gallate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis, Liver[MeSHID:D008103] phase 3 squalene monooxygenase SQLE Successful target unknown NA TTD , DGIDB trisnorsqualene difluoromethylidene NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD n-dodecylgallate NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD ethylgallate NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD thiocarbamate NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational,investigative squalene monooxygenase SQLE Successful target inhibitor NA TTD , drugbank octyl_gallate NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD theasinensin a NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD green tea NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD naftifine small molecule Tinea Pedis[MeSHID:D014008],Tinea[MeSHID:D014005],Dermatomycoses[MeSHID:D003881],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved squalene monooxygenase SQLE Successful target inhibitor 148.52 TTD , drugbank , DGIDB tolnaftate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pruritus[MeSHID:D011537],Tinea[MeSHID:D014005] approved squalene monooxygenase SQLE Successful target unknown 7.07 TTD , DGIDB trisnorsqualene cyclopropylamine NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD tellurium NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD chebulinic acid NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD mallotusinic acid NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD sanguiin h-6 NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD mallotinic acid NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD furosin NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD corilagin NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD procyanidin b-2 3,3'-di-o-gallate NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD pedunculagin NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD trisnorsqualene alcohol NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD 1,2,3,4,6-penta-o-galloyl-beta-d-glucose NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD butenafine small molecule Tinea Pedis[MeSHID:D014008],Pruritus[MeSHID:D011537],Tinea Versicolor[MeSHID:D014010],Foot[MeSHID:D005528],Tinea[MeSHID:D014005],Infection[MeSHID:D007239],Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved squalene monooxygenase SQLE NA inhibitor NA drugbank eugeniin NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD allylamines NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD 1(beta)-o-galloylpedunculagin NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD 1,2,6-tri-o-galloyl-beta-d-glucose NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD n-cetylgallate NA NA investigative squalene monooxygenase SQLE Successful target unknown NA TTD dpi59 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru83876 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bosutinib small molecule Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved proto-oncogene tyrosine-protein kinase src SRC NA inhibitor 0.39 drugbank , DGIDB sks-927 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD tg-100435 NA NA investigative proto-oncogene c-src SRC Successful target unknown 2.12 TTD , DGIDB saracatinib NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 2 proto-oncogene c-src SRC Successful target inhibitor 0.65 TTD , DGIDB pd-0173955 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD phosphonotyrosine NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD y-c[d-pen-(2r,3r)-2-me-(2')nal-gsfc]kr-nh2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD kx2-361 NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 proto-oncogene c-src SRC Successful target unknown 2.12 TTD , DGIDB ru84687 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bas-00387347 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD y-c[d-pen-d-(2')nal-gsfc]kr-nh2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru79073 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ac-cys-ile-tyr-lys-phe(4-cn)-tyr NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru90395 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru82197 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru79072 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD su 6656 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved proto-oncogene c-src SRC Successful target inhibitor 0.31 TTD , DGIDB y-c[d-pen-(2s,3r)-2-me-(2')nal-gsfc]kr-nh2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD phenylphosphate small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank malonic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank aromatic bicyclic compound 4 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB ru78191 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank pd-0166326 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bas-09534324 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD y-c[d-pen-(3,5-dii)tyr-gsfc]kr-nh2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ac-cys-ile-phe(4-no2)-lys-phe(4-no2)-tyr NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD xl228 small molecule leukemia[MeSHID:D007938],Lymph[MeSHID:D008196] investigational proto-oncogene tyrosine-protein kinase src SRC NA inhibitor 0.27 drugbank , DGIDB pd-0179483 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD phosphonotyrosine small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru82197 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pd-0173956 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD tirbanibulin small molecule Scalp structure[MeSHID:D012535],Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational proto-oncogene tyrosine-protein kinase src SRC NA inhibitor NA drugbank ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational proto-oncogene tyrosine-protein kinase src SRC NA inhibitor 0.16 drugbank , DGIDB pmid28460551-compound-6 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB sun-k0706 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Chronic Lymphocytic Leukemia[MeSHID:D015451],Sunlight[MeSHID:D013472] phase 1 proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB phenylphosphate NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD tpx-0046 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 proto-oncogene c-src SRC Successful target unknown NA TTD n-(4-(phenylamino)quinazolin-6-yl)acrylamide NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD deuterated 3-cyanoquinoline derivative 1 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB kx-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623] phase 3 proto-oncogene c-src SRC Successful target unknown NA TTD n-phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD cysteine sulfenic acid NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru85053 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pd-0173952 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD wh-4-023 NA NA investigative proto-oncogene c-src SRC Successful target inhibitor NA TTD , DGIDB ru78300 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD aromatic bicyclic compound 3 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB aromatic bicyclic compound 5 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB y-c[d-pen-(2')nal-gsfc]kr-nh2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ac-cys-ile-tyr-lys-phe(4-no2)-phe(4-no2) NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ac-cys-ile-phe(4-no2)-lys-tyr-tyr NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD cyclo[ac-cys-ile-tyr-lys-tyr-tyr] NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD 4-chloro-5,7-diphenyl-7h-pyrrolo[2,3-d]pyrimidine NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD 3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bosutinib NA Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved proto-oncogene c-src SRC Successful target unknown 0.39 TTD , DGIDB ru90395 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD 2-(4-carcoxy-5-isopropylthiazolyl)benzopiperidine NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD y-c[d-pen-(3-i)tyr-gsfc]kr-nh2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru85493 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved proto-oncogene c-src SRC Successful target unknown 0.31 TTD , DGIDB pasbn NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD aromatic bicyclic compound 2 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB 7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD 4-[(4-methyl-1-piperazinyl)methyl]-n-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ac-cys-ile-cyclo[phe-lys]-tyr-tyr NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bosutinib NA Blast Phase[MeSHID:D001752],Philadelphia Chromosome[MeSHID:D010677],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved proto-oncogene c-src SRC Successful target inhibitor 0.39 TTD , DGIDB (2e)-n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru82209 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru85053 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank iso24 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank citric acid small molecule NA approved,nutraceutical,vet_approved proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru78191 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru79256 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved proto-oncogene c-src SRC Successful target inhibitor 0.31 TTD , DGIDB saracatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Osteosarcoma[MeSHID:D012516],Hematologic Neoplasms[MeSHID:D019337] phase 2 proto-oncogene c-src SRC Successful target unknown 0.65 TTD , DGIDB nm-pp1 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ac-cys-ile-phe(4-no2)-lys-tyr-phe(4-no2) NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational proto-oncogene tyrosine-protein kinase src SRC NA multitarget 0.31 drugbank , DGIDB cyclo[ac-cys-ile-tyr-lys-tyr-phe] NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pyridine derivative 18 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB pd-0173958 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ski-758 NA Ischemia[MeSHID:D007511],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved proto-oncogene c-src SRC Successful target unknown 0.35 TTD , DGIDB [4-({4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank kx2-361 NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 proto-oncogene c-src SRC Successful target inhibitor 2.12 TTD , DGIDB saracatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Osteosarcoma[MeSHID:D012516],Hematologic Neoplasms[MeSHID:D019337] phase 2 proto-oncogene c-src SRC Successful target inhibitor 0.65 TTD , DGIDB pd-174265 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru82209 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD dasatinib NA Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved proto-oncogene c-src SRC Successful target unknown 0.31 TTD , DGIDB y-c[d-pen-(2r,3s)-2-me-(2')nal-gsfc]kr-nh2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ac-cys-ile-tyr-lys-phe(4-n3)-tyr NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru78783 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bas-01047341 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bas-00387275 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ap-24163 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD isis-crp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318],Inflammation[MeSHID:D007249] phase 1 proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB xl228 small molecule leukemia[MeSHID:D007938],Lymph[MeSHID:D008196] investigational proto-oncogene tyrosine-protein kinase src SRC NA unknown 0.27 drugbank , DGIDB oxalic acid NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pp-121 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank iso24 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational proto-oncogene tyrosine-protein kinase src SRC NA inhibitor NA drugbank cgp-62464 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pmid22765894c8h NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational proto-oncogene tyrosine-protein kinase src SRC NA multitarget,inhibitor 0.31 drugbank , DGIDB bas-450225 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru79256 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD 5,7-diphenyl-7h-pyrrolo[2,3-d]pyrimidin-4-ol NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pas219 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank y-c[d-pen-(2s,3s)-2-me-(2')nal-gsfc]kr-nh2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD saracatinib NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] phase 2 proto-oncogene c-src SRC Successful target unknown 0.65 TTD , DGIDB a-770041 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bas-00387328 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru78783 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank 3-[4-amino-1-(1-methylethyl)-1h-pyrazolo[3,4-d]pyrimidin-3-yl]phenol small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank bas-00672722 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD 1-[1-(3-aminophenyl)-3-tert-butyl-1h-pyrazol-5-yl]-3-phenylurea small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank n-(4-phenylamino-quinazolin-6-yl)-acrylamide small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank cgp-191 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ap-24226 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bas-01047655 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD purvalanol a small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank 1-(1-methylethyl)-3-quinolin-6-yl-1h-pyrazolo[3,4-d]pyrimidin-4-amine small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank 1-[1-(3-aminophenyl)-3-tert-butyl-1h-pyrazol-5-yl]-3-naphthalen-1-ylurea small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru78299 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru78262 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD sbb007833 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru78300 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ng-25 NA NA investigative proto-oncogene c-src SRC Successful target inhibitor NA TTD , DGIDB nintedanib small molecule Adenocarcinoma[MeSHID:D000230],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Systemic Scleroderma[MeSHID:D012595],Lung[MeSHID:D008168],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Hamman-Rich syndrome[MeSHID:D011658],Recurrence (disease attribute)[MeSHID:D012008],Pneumonia, Interstitial[MeSHID:D017563],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] approved proto-oncogene tyrosine-protein kinase src SRC NA inhibitor 0.15 drugbank , DGIDB ac-cys-ile-tyr-lys-phe(4-no2)-tyr-phe NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational proto-oncogene tyrosine-protein kinase src SRC NA multitarget 0.31 drugbank , DGIDB ac-cys-ile-tyr-lys-phe(4-cl)-tyr NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD n6-benzyl adenosine-5'-diphosphate NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bms-279700 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD al3818 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometrial Carcinoma[MeSHID:D016889],Alveolar Soft Part Sarcoma[MeSHID:D018234],leiomyosarcoma[MeSHID:D007890],Fallopian Tube Carcinoma[MeSHID:D005185],cervical cancer[MeSHID:D002583],Malignant Neoplasms[MeSHID:D009369],synovial sarcoma[MeSHID:D013584],Malignant neoplasm of ovary[MeSHID:D010051] phase 3 proto-oncogene c-src SRC Successful target unknown 0.21 TTD , DGIDB ru79072 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank 2-(4-carcoxy-5-isopropylthiazolyl)benzopiperidine small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank 1-tert-butyl-3-(4-chloro-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank ru83876 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank oxalic acid small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank hki-9924129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative proto-oncogene c-src SRC Successful target unknown NA TTD cyclo[ac-cys-ile-phe]-lys-tyr-tyr NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ac-cys-ile-tyr-lys-tyr-phe(4-no2) NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD cp-868596 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Gastrointestinal Stromal Tumors[MeSHID:D046152],Malignant Glioma[MeSHID:D005910] phase 3 proto-oncogene c-src SRC Successful target unknown 0.13 TTD , DGIDB aromatic bicyclic compound 1 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB bas-01373578 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD 2-[4-[(z)-2-acetamido-3-oxo-3-[[(3s)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank glu-pro-gln-f2pmp-glu-glu-ile-pro-ile-tyr-leu NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru78262 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank aromatic bicyclic compound 6 NA NA patented proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB ru82129 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD k00244 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pd-168393 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank bas-4844343 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pas219 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pasbn small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational proto-oncogene tyrosine-protein kinase src SRC NA multitarget,inhibitor 0.31 drugbank , DGIDB glu-pro-gln-ptyr-glu-glu-ile-pro-ile-tyr-leu NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD tpx-0022 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 proto-oncogene c-src SRC Successful target unknown NA TTD pmid15546730c2 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru85493 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD n6-benzyl adenosine-5'-diphosphate small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank cgp 77675 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD masitinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stomach[MeSHID:D013270],Malignant neoplasm of pancreas[MeSHID:D010190],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Gastrointestinal Stromal Tumors[MeSHID:D046152],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369],Multiple Sclerosis[MeSHID:D009103],Malignant neoplasm of ovary[MeSHID:D010051] phase 3 proto-oncogene c-src SRC Successful target unknown 0.15 TTD , DGIDB ac-cys-ile-tyr-lys-phe(4-i)-tyr NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD pp121 NA NA investigative proto-oncogene c-src SRC Successful target inhibitor NA TTD , DGIDB herbimycin a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB pd173074 NA Nasopharyngeal carcinoma[MeSHID:C538339],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative proto-oncogene c-src SRC Successful target unknown NA TTD , DGIDB ru79073 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank paratoulene phosphate small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank jnj-10198409 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru81843 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD a-420983 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD bas-0338872 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru78299 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank bas-0338868 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD dpi59 NA NA investigative proto-oncogene c-src SRC Successful target unknown NA TTD ru84687 small molecule NA experimental proto-oncogene tyrosine-protein kinase src SRC NA unknown NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved 3-oxo-5-alpha-steroid 4-dehydrogenase SRD5A1 NA antagonist NA drugbank 1-methyl-5-phenyl-piperidin-2-one NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD 4,4'-dihydroxyoctafluoroazobenzene NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD gp515 NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD ly-266111 NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown 12.73 TTD , DGIDB dutasteride small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Urinary Retention[MeSHID:D016055],Prostate[MeSHID:D011467],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 NA inhibitor 38.19 drugbank , DGIDB 4-methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD as-601811 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD 5-(4-chloro-phenyl)-1-methyl-piperidin-2-one NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-oxo-5-alpha-steroid 4-dehydrogenase SRD5A1 NA antagonist NA drugbank (e)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD levonorgestrel small molecule Endometriosis[MeSHID:D004715],Pregnancy[MeSHID:D011247],Patient Discharge[MeSHID:D010351],Coitus[MeSHID:D003075],Menorrhagia[MeSHID:D008595],Endometrial Hyperplasia[MeSHID:D004714],Off-Label Use[MeSHID:D056687],Unmarried[MeSHID:D012847],Osteoporosis[MeSHID:D010024],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 NA inhibitor 16.97 drugbank , DGIDB 4-[4-(benzhydryloxy)benzoyl]benzoic acid NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD finasteride small molecule Operative Surgical Procedures[MeSHID:D013514],Urinary Retention[MeSHID:D016055],Androgenetic Alopecia[MeSHID:D000505],Prostate[MeSHID:D011467],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 NA inhibitor 6.85 drugbank , DGIDB 1-methyl-5-(4-phenylazo-phenyl)-piperidin-2-one NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD norgestrel small molecule Pregnancy[MeSHID:D011247] approved 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 NA inhibitor NA drugbank (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD 4-[4-benzyloxy)benzoyl]benzoic acid NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD fr-146687 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD , DGIDB 1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD 2,3,5,6-tetrafluoro-4-pentafluorophenylazo-phenol NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD 3,4,5,6-tetrahydrobenzo[c]quinolizin-3-(4ah)-one NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD 5-(4-chloro-phenyl)-1-methyl-piperidine-2-thione NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD mk-386 NA Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD 4-(4-phenoxybenzoyl)benzoic acid NA NA investigative steroid 5-alpha-reductase 1 SRD5A1 Clinical trial target unknown NA TTD finasteride NA Operative Surgical Procedures[MeSHID:D013514],Urinary Retention[MeSHID:D016055],Androgenetic Alopecia[MeSHID:D000505],Prostate[MeSHID:D011467],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown 26.93 TTD , DGIDB gp515 NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD 4-(4-phenoxybenzoyl)benzoic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-oxo-5-alpha-steroid 4-dehydrogenase SRD5A2 NA antagonist NA drugbank (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD (e)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD finasteride NA Operative Surgical Procedures[MeSHID:D013514],Urinary Retention[MeSHID:D016055],Androgenetic Alopecia[MeSHID:D000505],Prostate[MeSHID:D011467],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved steroid 5-alpha-reductase 2 SRD5A2 Successful target inhibitor 26.93 TTD , DGIDB 3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD 4,4'-dihydroxyoctafluoroazobenzene NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD 2,3,5,6-tetrafluoro-4-pentafluorophenylazo-phenol NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD 4-[3-(benzyloxy)benzoyl]benzoic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD 4-[4-(benzylamino)benzoyl]benzoic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD finasteride small molecule Operative Surgical Procedures[MeSHID:D013514],Urinary Retention[MeSHID:D016055],Androgenetic Alopecia[MeSHID:D000505],Prostate[MeSHID:D011467],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-oxo-5-alpha-steroid 4-dehydrogenase 2 SRD5A2 NA inhibitor 26.93 drugbank , DGIDB dutasteride small molecule Benign Prostatic Hyperplasia[MeSHID:D011470],Urinary Retention[MeSHID:D016055],Prostate[MeSHID:D011467],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational 3-oxo-5-alpha-steroid 4-dehydrogenase 2 SRD5A2 NA inhibitor 95.48 drugbank , DGIDB spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved 3-oxo-5-alpha-steroid 4-dehydrogenase SRD5A2 NA antagonist NA drugbank 4-[4-(benzoylamino)benzoyl]benzoic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD 4-(4-phenoxybenzoyl)phenylacetic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD 4-[4-benzyloxy)benzoyl]benzoic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD azelaic acid small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-oxo-5-alpha-steroid 4-dehydrogenase 2 SRD5A2 NA inhibitor NA drugbank 4-[4-(benzhydryloxy)benzoyl]benzoic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid NA NA investigative steroid 5-alpha-reductase 2 SRD5A2 Successful target unknown NA TTD spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved 3-oxo-5-alpha-steroid 4-dehydrogenase SRD5A3 NA antagonist NA drugbank spironolactone small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Acne Vulgaris[MeSHID:D000152],Nephrotic Syndrome[MeSHID:D009404],Mental association[MeSHID:D001244],Off-Label Use[MeSHID:D056687],Term Birth[MeSHID:D047929],Hypertensive disease[MeSHID:D006973],Congenital adrenal hyperplasia[MeSHID:D000312],Disease[MeSHID:D004194],Edema[MeSHID:D004487],treatment failure[MeSHID:D017211],Adrenal Cortical Adenoma[MeSHID:D018246],Hirsutism[MeSHID:D006628],Androgenetic Alopecia[MeSHID:D000505],Hair[MeSHID:D006197],Body Fluids[MeSHID:D001826],Acne, Adult[MeSHID:C565791],Growth[MeSHID:D006128],Conn Syndrome[MeSHID:D006929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved 3-oxo-5-alpha-steroid 4-dehydrogenase SRD5A3 NA antagonist NA drugbank omega-3 fatty acids small molecule Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Recurrence (disease attribute)[MeSHID:D012008] approved,nutraceutical sterol regulatory element-binding protein 1 SREBF1 NA inhibitor NA drugbank doconexent small molecule NA approved,investigational sterol regulatory element-binding protein 1 SREBF1 NA inhibitor NA drugbank omega-3-acid ethyl esters small molecule Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,investigational sterol regulatory element-binding protein 1 SREBF1 NA inhibitor NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical sterol regulatory element-binding protein 1 SREBF1 NA regulator NA drugbank calcium phosphate small molecule NA approved sorcin SRI NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved sorcin SRI NA unknown NA drugbank calcium citrate small molecule NA approved,investigational sorcin SRI NA ligand NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase srms SRMS NA inhibitor NA drugbank pmid21802293c66 NA NA investigative tyrosine-protein kinase srms SRMS Literature-reported target unknown NA TTD artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational signal recognition particle 14 kda protein SRP14 NA ligand NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental srsf protein kinase 2 SRPK2 NA unknown NA drugbank purvalanol small molecule NA experimental srsf protein kinase 2 SRPK2 NA unknown NA drugbank adenine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical srsf protein kinase 2 SRPK2 NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical serine racemase SRR NA cofactor NA drugbank serine small molecule NA investigational,nutraceutical serine racemase SRR NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serine/arginine-rich splicing factor 1 SRSF1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational serine/arginine-rich splicing factor 4 SRSF4 NA ligand NA drugbank cbl0102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1/2 facilitates chromatin transcription complex SSRP1 Clinical trial target unknown NA TTD , DGIDB cbl0137 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] phase 1 facilitates chromatin transcription complex SSRP1 Clinical trial target unknown NA TTD , DGIDB cysteamine NA Nephropathic cystinosis[MeSHID:D003554],Cornea[MeSHID:D003315],Fanconi Syndrome[MeSHID:D005198],Cystinuria[MeSHID:D003555],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin SST Successful target unknown 18.19 TTD , DGIDB des-aa1,2,4,13-[d-trp8]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa5-[d-trp8]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target agonist NA TTD , DGIDB des-aa1,2,5-[d-nal8,(nalphame)iamp9,tyr11]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-nal8,iamp9,(nalphame)phe11]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD srif-28 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target agonist 2.65 TTD , DGIDB des-aa1,2,5-[(nalphame)d-nal8,iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-nal8,(nalphame)iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD pasireotide small molecule Pituitary Gland[MeSHID:D010902],Pituitary-dependent Cushing's disease[MeSHID:D047748],Pituitary Diseases[MeSHID:D010900],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 1 SSTR1 Successful target unknown 6.63 TTD , drugbank , DGIDB l-817,818 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target agonist NA TTD , DGIDB 99mtc-mip-1407 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD l-797,591 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target agonist NA TTD , DGIDB srif-14 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target agonist 2.12 TTD , DGIDB cytotoxin peptide conjugate NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[(nalphame)cys3,d-trp8,iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-nal8,iamp9,(nalphame)cys14]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[iamp9,tyr11]-srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD somatostatin small molecule Disease Management[MeSHID:D019468],Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],long-term care[MeSHID:D008134] approved,investigational,investigative somatostatin receptor type 1 SSTR1 Successful target agonist NA TTD , drugbank des-aa1,2,5-[d-trp8,iamp9,(nalphame)cys14]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,4,5,13-[tyr2,d-trp8]-srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD sra880 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target antagonist NA TTD , DGIDB des-aa1,2,5-[d-trp8,iamp9,m-i-tyr11]cbm-srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5,12,13-[d-trp8,iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-trp8,iamp9]srif ch-275 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-trp8,iamp9,(nalphame)ser13]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-nal8,iamp9,(nalphame)thr12]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD pasireotide small molecule Pituitary Gland[MeSHID:D010902],Pituitary-dependent Cushing's disease[MeSHID:D047748],Pituitary Diseases[MeSHID:D010900],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 1 SSTR1 Successful target agonist 6.63 TTD , drugbank , DGIDB des-aa1,2,5-[d-nal8,iamp9,(nalphame)ser13]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target agonist NA TTD , DGIDB des-aa1,5-[tyr2,d-trp8,iamp9]cbm-srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-trp8,iamp9,tyr11]cbm-srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD cgp 23996 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target agonist NA TTD , DGIDB des-aa1,2,4,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-trp8,(nalphame)iamp9,tyr11]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-trp8,(nalphame)iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-nal8,iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,4,5,13-[d-trp8]-srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,4,5-[d-trp8]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD odt-8 NA NA phase 3 somatostatin receptor type 1 SSTR1 Successful target unknown 1.06 TTD , DGIDB edotreotide gallium ga-68 small molecule Diagnosis[MeSHID:D003933],Radioactivity[MeSHID:D011851],Neuroendocrine Tumors[MeSHID:D018358] approved somatostatin receptor type 1 SSTR1 NA ligand NA drugbank des-aa1,2,5-[d-trp8,iamp9,(nalphame)thr12]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,5-[tyr2,d-trp8,iamp9]srif ch-288 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,5-[tyr2,d-trp8,(nalphame)iamp9]cbm-srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[(nalphame)cys3,d-nal8,iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD des-aa1,2,5-[d-trp8,tyr11]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD srif-28 NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown 2.65 TTD , DGIDB des-aa1,2,5-[(nalphame)lys4,d-nal8,iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD lutetium lu 177 dotatate small molecule Neuroendocrine Tumors[MeSHID:D018358],Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650],Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational somatostatin receptor type 1 SSTR1 Successful target agonist NA TTD , drugbank , DGIDB des-aa1,5-[tyr2,d-trp8,(nalphame)iamp9]srif NA NA investigative somatostatin receptor type 1 SSTR1 Successful target unknown NA TTD ala11-srif-14-amide NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD des-aa1,2,4,5,11,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD octreotide NA Flushing[MeSHID:D005483],Neoplasms[MeSHID:D009369],Diarrhea[MeSHID:D003967],Carcinoid Tumor[MeSHID:D002276],Vipoma[MeSHID:D003969],Acromegaly[MeSHID:D000172],Patient Discharge[MeSHID:D010351],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 2 SSTR2 Successful target unknown 2.72 TTD , DGIDB des-aa1,2,4,5-[d-trp8]srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD ala7-srif-14-amide NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD des-aa5-[d-trp8]srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD des-aa1,2,4,5,6,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD pen-221 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] phase 1/2 somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD , DGIDB cytotoxin peptide conjugate NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD odt-8 NA NA phase 3 somatostatin receptor type 2 SSTR2 Successful target unknown 0.75 TTD , DGIDB copper oxodotreotide cu-64 small molecule Neuroendocrine Tumors[MeSHID:D018358] approved somatostatin receptor type 2 SSTR2 NA binder NA drugbank des-aa1,2,4,5,13-[d-trp8]-srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD ga-68-dotatoc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD re-188-p-2045 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] phase 1/2 somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD , DGIDB h-d-phe-c[cys-ala-d-trp-lys-thr-cys]-thr-nh2 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD dotatate gallium ga-68 small molecule Malignant Neoplasms[MeSHID:D009369],Neuroendocrine Cells[MeSHID:D055099],Neuroendocrine Tumors[MeSHID:D018358] approved,investigational somatostatin receptor type 2 SSTR2 NA binder NA drugbank l-779,976 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target agonist NA TTD , DGIDB somatostatin small molecule Disease Management[MeSHID:D019468],Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],long-term care[MeSHID:D008134] approved,investigational,investigative somatostatin receptor type 2 SSTR2 Successful target agonist NA TTD , drugbank vapreotide small molecule Diarrhea[MeSHID:D003967],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Hemorrhage[MeSHID:D006470],Liver diseases[MeSHID:D008107] experimental,investigational somatostatin receptor type 2 SSTR2 NA inducer 3.74 drugbank , DGIDB cgp 23996 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target agonist NA TTD , DGIDB d-phe-c[cys-tyr-d-trp-lys-val-cys]-asp-nh2 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD h-d-phe-cys-tyr-d-trp-lys-val-cys-thr-nh2 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD srif-14 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target agonist 1.5 TTD , DGIDB lanreotide acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acromegaly[MeSHID:D000172] approved somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD , DGIDB tbr-760 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pituitary Adenoma[MeSHID:D010911] phase 2 somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD pasireotide small molecule Pituitary Gland[MeSHID:D010902],Pituitary-dependent Cushing's disease[MeSHID:D047748],Pituitary Diseases[MeSHID:D010900],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 2 SSTR2 Successful target unknown 4.68 TTD , drugbank , DGIDB pyz11-d-trp8-srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD copper dotatate cu-64 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD vapreotide small molecule Diarrhea[MeSHID:D003967],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Hemorrhage[MeSHID:D006470],Liver diseases[MeSHID:D008107] experimental,investigational somatostatin receptor type 2 SSTR2 NA inducer,agonist 3.74 drugbank , DGIDB octreotide NA Flushing[MeSHID:D005483],Neoplasms[MeSHID:D009369],Diarrhea[MeSHID:D003967],Carcinoid Tumor[MeSHID:D002276],Vipoma[MeSHID:D003969],Acromegaly[MeSHID:D000172],Patient Discharge[MeSHID:D010351],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 2 SSTR2 Successful target agonist 2.72 TTD , DGIDB pyz6-d-trp8-srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD 98mtc-cim-ant NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD 99mtc-mip-1407 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD srif-28 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target agonist 1.87 TTD , DGIDB des-aa1,2,4,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD des-aa1,2,4,13-[d-trp8]srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD edotreotide gallium ga-68 small molecule Diagnosis[MeSHID:D003933],Radioactivity[MeSHID:D011851],Neuroendocrine Tumors[MeSHID:D018358] approved somatostatin receptor type 2 SSTR2 NA ligand NA drugbank l-054852 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acromegaly[MeSHID:D000172] investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD pasireotide small molecule Pituitary Gland[MeSHID:D010902],Pituitary-dependent Cushing's disease[MeSHID:D047748],Pituitary Diseases[MeSHID:D010900],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 2 SSTR2 Successful target agonist 4.68 TTD , drugbank , DGIDB lanreotide small molecule Neuroendocrine Tumors[MeSHID:D018358],Acromegaly[MeSHID:D000172] approved somatostatin receptor type 2 SSTR2 NA agonist 1.5 drugbank , DGIDB h-c[cys-phe-dtrp-lys-thr-cys]-oh NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD lutetium lu 177 dotatate small molecule Neuroendocrine Tumors[MeSHID:D018358],Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650],Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational somatostatin receptor type 2 SSTR2 NA agonist NA drugbank l-054,522 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target agonist NA TTD , DGIDB des-aa1,2,5-[d-trp8,tyr11]srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD lanreotide acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acromegaly[MeSHID:D000172] approved somatostatin receptor type 2 SSTR2 Successful target agonist 1.87 TTD , DGIDB ala6-srif-14-amide NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD h-dphe-c[cys-phe-dtrp-lys-thr-cys]-thr-nh2 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD srif-28 NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown 1.87 TTD , DGIDB des-aa1,2,5,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 2 SSTR2 Successful target unknown NA TTD des-aa5-[d-trp8]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target agonist NA TTD , DGIDB edotreotide gallium ga-68 small molecule Diagnosis[MeSHID:D003933],Radioactivity[MeSHID:D011851],Neuroendocrine Tumors[MeSHID:D018358] approved somatostatin receptor type 3 SSTR3 NA ligand NA drugbank des-aa1,2,5-[d-trp8,(nalphame)iamp9]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD srif-28 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target agonist 0.88 TTD , DGIDB pasireotide small molecule Pituitary Gland[MeSHID:D010902],Pituitary-dependent Cushing's disease[MeSHID:D047748],Pituitary Diseases[MeSHID:D010900],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 3 SSTR3 Successful target unknown 6.63 TTD , drugbank , DGIDB cytotoxin peptide conjugate NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD somatostatin small molecule Disease Management[MeSHID:D019468],Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],long-term care[MeSHID:D008134] approved,investigational,investigative somatostatin receptor type 3 SSTR3 Successful target agonist 4.24 TTD , drugbank , DGIDB des-aa1,2,5-[d-trp8,iamp9,m-i-tyr11]cbm-srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,2,4,5,13-[d-trp8]-srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,4,5,13-[tyr2,d-trp8]-srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD pasireotide small molecule Pituitary Gland[MeSHID:D010902],Pituitary-dependent Cushing's disease[MeSHID:D047748],Pituitary Diseases[MeSHID:D010900],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 3 SSTR3 Successful target agonist 6.63 TTD , drugbank , DGIDB lutetium lu 177 dotatate small molecule Neuroendocrine Tumors[MeSHID:D018358],Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650],Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational somatostatin receptor type 3 SSTR3 NA agonist NA drugbank l-796,778 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target agonist NA TTD , DGIDB bn-81,644 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target agonist NA TTD , DGIDB des-aa1,2,4,5,10,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,2,4,13-[d-trp8]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,2,4,5-[d-trp8]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,2,4,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,2,5,12,13-[d-trp8,iamp9]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD srif-14 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target agonist 4.24 TTD , DGIDB cgp 23996 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target agonist NA TTD , DGIDB des-aa1,5-[tyr2,d-trp8,iamp9]cbm-srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD bn-81,674 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target agonist NA TTD , DGIDB nvp acq090 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD h-dphe-c[cys-phe-dtrp-lys-thr-cys]-thr-nh2 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,2,5,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD h-d-phe-c[cys-ala-d-trp-lys-thr-cys]-thr-nh2 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,2,5-[d-trp8,iamp9]srif ch-275 NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD odt-8 NA NA phase 3 somatostatin receptor type 3 SSTR3 Successful target unknown 3.18 TTD , DGIDB 99mtc-mip-1407 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,2,5-[d-trp8,tyr11]srif NA NA investigative somatostatin receptor type 3 SSTR3 Successful target unknown NA TTD des-aa1,5-[tyr2,d-trp8,(nalphame)iamp9]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,5-[d-trp8,(nalphame)iamp9]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa5-[d-trp8]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target agonist NA TTD , DGIDB lutetium lu 177 dotatate small molecule Neuroendocrine Tumors[MeSHID:D018358],Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650],Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational somatostatin receptor type 4 SSTR4 NA agonist NA drugbank pyz6-d-trp8-srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,5-[tyr2,d-trp8,(nalphame)iamp9]cbm-srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,4,5,6,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD d-trp8-srif-14 NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD pyz11-d-trp8-srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,5-[d-nal8,iamp9,(nalphame)thr12]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD cntx-0290 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 1 somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD , DGIDB des-aa1,2,5-[iamp9,tyr11]-srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD somatostatin small molecule Disease Management[MeSHID:D019468],Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],long-term care[MeSHID:D008134] approved,investigational,investigative somatostatin receptor type 4 SSTR4 Clinical trial target agonist NA TTD , drugbank des-aa1,2,5-[d-trp8,tyr11]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD odt-8 NA NA phase 3 somatostatin receptor type 4 SSTR4 Clinical trial target unknown 1.82 TTD , DGIDB pyz7-d-trp8-srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD srif-28 NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target agonist 1.52 TTD , DGIDB des-aa1,2,5,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,5,12,13-[d-trp8,iamp9]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD ala6-srif-14-amide NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD l-803,087 NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target agonist NA TTD , DGIDB beta3-tetrapeptide NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD cgp 23996 NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target agonist NA TTD , DGIDB srif-14 NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target agonist 3.64 TTD , DGIDB cytotoxin peptide conjugate NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,4,5,10,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD 99mtc-mip-1407 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,4,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD 177lu-dotatate NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 somatostatin receptor type 4 SSTR4 Clinical trial target unknown 9.09 TTD , DGIDB nnc269100 NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target agonist NA TTD , DGIDB ala11-srif-14-amide NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,4,13-[d-trp8]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,4,5-[d-trp8]srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD des-aa1,2,4,5,13-[d-trp8]-srif NA NA investigative somatostatin receptor type 4 SSTR4 Clinical trial target unknown NA TTD pasireotide small molecule Pituitary Gland[MeSHID:D010902],Pituitary-dependent Cushing's disease[MeSHID:D047748],Pituitary Diseases[MeSHID:D010900],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 5 SSTR5 Successful target agonist 5.68 TTD , drugbank , DGIDB des-aa1,2,4,5,13-[d-trp8]-srif NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD ptr-3046 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD l-817,818 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target agonist NA TTD , DGIDB edotreotide gallium ga-68 small molecule Diagnosis[MeSHID:D003933],Radioactivity[MeSHID:D011851],Neuroendocrine Tumors[MeSHID:D018358] approved somatostatin receptor type 5 SSTR5 NA ligand NA drugbank pasireotide small molecule Pituitary Gland[MeSHID:D010902],Pituitary-dependent Cushing's disease[MeSHID:D047748],Pituitary Diseases[MeSHID:D010900],Operative Surgical Procedures[MeSHID:D013514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved somatostatin receptor type 5 SSTR5 Successful target unknown 5.68 TTD , drugbank , DGIDB cytotoxin peptide conjugate NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD odt-8 NA NA phase 3 somatostatin receptor type 5 SSTR5 Successful target unknown 0.91 TTD , DGIDB des-aa1,2,5,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD srif-14 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target agonist 1.82 TTD , DGIDB h-d-phe-cys-tyr-d-trp-lys-val-cys-thr-nh2 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD lutetium lu 177 dotatate small molecule Neuroendocrine Tumors[MeSHID:D018358],Gastro-enteropancreatic neuroendocrine tumor[MeSHID:C535650],Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational somatostatin receptor type 5 SSTR5 NA agonist NA drugbank des-aa1,2,5-[d-trp8,tyr11]srif NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD lanreotide small molecule Neuroendocrine Tumors[MeSHID:D018358],Acromegaly[MeSHID:D000172] approved somatostatin receptor type 5 SSTR5 NA agonist 5.46 drugbank , DGIDB h-d-phe-c[cys-ala-d-trp-lys-thr-cys]-thr-nh2 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD des-aa1,2,4,12,13-[d-trp8]srif NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD des-aa5-[d-trp8]srif NA NA investigative somatostatin receptor type 5 SSTR5 Successful target agonist NA TTD , DGIDB srif-28 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target agonist 0.76 TTD , DGIDB somatostatin small molecule Disease Management[MeSHID:D019468],Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],long-term care[MeSHID:D008134] approved,investigational,investigative somatostatin receptor type 5 SSTR5 Successful target agonist NA TTD , drugbank vapreotide small molecule Diarrhea[MeSHID:D003967],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Hemorrhage[MeSHID:D006470],Liver diseases[MeSHID:D008107] experimental,investigational somatostatin receptor type 5 SSTR5 NA agonist 4.55 drugbank , DGIDB h-dphe-c[cys-phe-dtrp-lys-thr-cys]-thr-nh2 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD des-aa1,2,4,5-[d-trp8]srif NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD d-phe-c[cys-tyr-d-trp-lys-val-cys]-asp-nh2 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD cgp 23996 NA NA investigative somatostatin receptor type 5 SSTR5 Successful target agonist NA TTD , DGIDB des-aa1,2,4,13-[d-trp8]srif NA NA investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD 99mtc-mip-1407 NA Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative somatostatin receptor type 5 SSTR5 Successful target unknown NA TTD pmid25489658c4d NA NA investigative suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD us8569313, inhibitor 14 NA NA patented suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD , DGIDB us8569313, inhibitor 15 NA NA patented suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD , DGIDB us8569313, inhibitor 18 NA NA patented suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD , DGIDB 3-tapap NA NA investigative suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD camostat small molecule Pancreatitis, Chronic[MeSHID:D050500],Hereditary pancreatitis[MeSHID:C537262],Lung Injury[MeSHID:D055370],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental suppressor of tumorigenicity 14 protein ST14 NA inhibitor NA drugbank pmid23849879c3 NA NA investigative suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD inhibitor 1 [colombo et al., 2012] NA NA investigative suppressor of tumorigenicity 14 protein ST14 Patented-recorded target inhibitor NA TTD , DGIDB 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine NA NA investigative suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD urokinase biotech Arteries[MeSHID:D001158],Transplanted tissue[MeSHID:D019737],Thrombus[MeSHID:D013927],Coronary artery[MeSHID:D003331],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myocardial Infarction[MeSHID:D009203] approved,investigational,withdrawn suppressor of tumorigenicity 14 protein ST14 NA substrate NA drugbank us8569313, inhibitor 19 NA NA patented suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD , DGIDB benzamidine small molecule NA experimental,investigative suppressor of tumorigenicity 14 protein ST14 Patented-recorded target unknown NA TTD , drugbank carbocisteine small molecule Mucous body substance[MeSHID:D009093],Bodily secretions[MeSHID:D012634],Disease[MeSHID:D004194],Prescription procedure[MeSHID:D055656],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved,investigational lactosylceramide alpha-2,3-sialyltransferase ST3GAL5 NA inducer NA drugbank 99mtc-14 f7 mab biotech Malignant neoplasm of breast[MeSHID:D001943] investigational lactosylceramide alpha-2,3-sialyltransferase ST3GAL5 NA unknown NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved stabilin-2 STAB2 NA binder NA drugbank platinum iv complexe 1 NA NA patented signal transducer and activator of transcription 1 STAT1 Patented-recorded target unknown NA TTD , DGIDB pmid26394986-compound-10 NA NA patented signal transducer and activator of transcription 1 STAT1 Patented-recorded target unknown NA TTD , DGIDB avt-02 ue NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Skin Diseases, Infectious[MeSHID:D012874] discontinued in phase 2 signal transducer and activator of transcription 1 STAT1 Patented-recorded target unknown NA TTD , DGIDB peptide analog 8 NA NA patented signal transducer and activator of transcription 1 STAT1 Patented-recorded target unknown NA TTD , DGIDB oxazole derivative 1 NA NA patented signal transducer and activator of transcription 1 STAT1 Patented-recorded target unknown NA TTD , DGIDB peptidomimetic analog 5 NA NA patented signal transducer and activator of transcription 1 STAT1 Patented-recorded target unknown NA TTD , DGIDB flavonoid derivative 4 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB gnf-pf-1399 NA NA investigative signal transducer and activator of transcription 3 STAT3 Successful target unknown 0.4 TTD , DGIDB flavonoid derivative 3 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB isis 113209 NA NA investigative stat3 messenger rna STAT3 Clinical trial target unknown NA TTD pmid26394986-compound-11 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB napabucasin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770],Liver carcinoma[MeSHID:D006528],Pancreatic carcinoma[MeSHID:C562463],Hematologic Neoplasms[MeSHID:D019337],Malignant Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Recurrence (disease attribute)[MeSHID:D012008],Respiratory Tract Infections[MeSHID:D012141],Glioblastoma[MeSHID:D005909] phase 3 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD peptidomimetic analog 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-42 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-21 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pyrazole derivative 62 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB tak-114 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcerative Colitis[MeSHID:D003093] phase 1 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB peptidomimetic analog 2 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB c188-9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 stat3 messenger rna STAT3 Clinical trial target unknown NA TTD pmid26394986-compound-12 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB peptidomimetic analog 5 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB isis 113176 NA NA investigative stat3 messenger rna STAT3 Clinical trial target unknown NA TTD pmid26394986-compound-10 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-54 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB isis 17148 NA NA investigative stat3 messenger rna STAT3 Clinical trial target unknown NA TTD pyrazole derivative 65 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB quinoline carboxamide derivative 2 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB flavonoid derivative 2 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB atiprimod NA Rheumatoid Arthritis[MeSHID:D001172],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 signal transducer and activator of transcription 3 STAT3 Successful target unknown 2.77 TTD , DGIDB oxazole derivative 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB salicylic acid derivative 6 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB isis 113210 NA NA investigative stat3 messenger rna STAT3 Clinical trial target unknown NA TTD gold-complexed thiosaccharide derivative 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB salicylic acid derivative 3 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB peptidomimetic analog 3 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB platinum iv complexe 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB curcumin analog 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB nt219 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD pmid26394986-compound-53 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB peptidomimetic analog 4 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-43 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-figure17 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB flavonoid derivative 5 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-52 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB opb-51602 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-44 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB salicylic acid derivative 7 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-22 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pyrazole derivative 63 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB curcumin analog 2 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB isis 17152 NA NA investigative stat3 messenger rna STAT3 Clinical trial target unknown NA TTD quinoline carboxamide derivative 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-50 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB isis-stat3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 stat3 messenger rna STAT3 Clinical trial target unknown NA TTD pmid26394986-compound-figure16 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB tri-substituted purine derivative 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-13 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pyrazole derivative 66 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pmid26394986-compound-51 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB imx-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB salicylic acid derivative 5 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB wp1220 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410] phase 1 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD salicylic acid derivative 4 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB gold-complexed thiosaccharide derivative 2 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB dsp-0337 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD quinoline carboxamide derivative 3 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB opb-31121 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1/2 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB golotimod NA Parasitic Diseases[MeSHID:D010272],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141],Hepatitis[MeSHID:D006505],Tuberculosis[MeSHID:D014376],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Immune System Diseases[MeSHID:D007154] phase 2 signal transducer and activator of transcription 3 STAT3 Successful target unknown 2.77 TTD , DGIDB opb-111077 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Liver carcinoma[MeSHID:D006528],Hematologic Neoplasms[MeSHID:D019337] investigational,phase 1 signal transducer and activator of transcription 3 STAT3 Successful target inhibitor NA TTD , drugbank pmid26394986-compound-20 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB salicylic acid derivative 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB peptide analog 7 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB acitretin NA Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved signal transducer and activator of transcription 3 STAT3 Successful target unknown 0.17 TTD , DGIDB flavonoid derivative 1 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB glg-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1/2 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB salicylic acid derivative 2 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB pyrazole derivative 64 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB enmd-1198 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational signal transducer and activator of transcription 3 STAT3 NA unknown NA drugbank wp-1066 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of brain[MeSHID:D001932],Malignant Neoplasms[MeSHID:D009369],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 1/2 signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB isis 113187 NA NA investigative stat3 messenger rna STAT3 Clinical trial target unknown NA TTD gold-complexed thiosaccharide derivative 3 NA NA patented signal transducer and activator of transcription 3 STAT3 Successful target unknown NA TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational signal transducer and activator of transcription 5b STAT5B NA inhibitor 1.18 drugbank , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational signal transducer and activator of transcription 5b STAT5B NA inhibitor 1.18 drugbank , DGIDB amg 509 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 metalloreductase steap1 STEAP1 Clinical trial target unknown NA TTD rg7450 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 metalloreductase steap1 STEAP1 Clinical trial target unknown 127.3 TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational stress-induced-phosphoprotein 1 STIP1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 10 STK10 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 16 STK16 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 17a STK17A NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 17b STK17B NA inhibitor NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational serine/threonine-protein kinase 17b STK17B NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 24 STK24 NA inhibitor NA drugbank 2-[4-[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile small molecule NA experimental serine/threonine-protein kinase mst4 STK26 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase mst4 STK26 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 3 STK3 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 32a STK32A NA inhibitor NA drugbank pmid24793884c74 NA NA investigative yet another novel kinase 2 STK32B Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 33 STK33 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 35 STK35 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 36 STK36 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 38 STK38 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase 38-like STK38L NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational ste20/sps1-related proline-alanine-rich protein kinase STK39 NA inhibitor NA drugbank tat-120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary Arteriosclerosis[MeSHID:D003324],Myocardial Ischemia[MeSHID:D017202] investigative mst-1 protein kinase STK4 Literature-reported target unknown NA TTD pbi-shrna stmn1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] phase 1 stmn1 messenger rna STMN1 Clinical trial target unknown NA TTD lomustine small molecule Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Brain Neoplasms[MeSHID:D001932],Hodgkin Disease[MeSHID:D006689],Relapse[MeSHID:D012008],Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational stathmin-4 STMN4 NA antagonist NA drugbank 2-mercapto-n-[1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]acetamide small molecule NA experimental stathmin-4 STMN4 NA unknown NA drugbank 2-adamantan-2-ylidenemethyl-benzooxazol-6-ol NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 4-(2-hydroxy-benzoyl)-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 3-(4-hydroxy-benzoyl)-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 2-(4-cyclohexylthiosemicarbazono)methyl-phenol NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 4-(3-methoxy-benzoyl)-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 3-(3-methoxy-benzoyl)-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 2-nonyl-4-oxo-4h-chromen-6-yl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 3-(3-hydroxy-benzoyl)-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD benzomate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 2',4'-dicyanobiphenyl-4-yl sulfamate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid hexyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid nonyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid cyclohexyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid cycloheptyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid cyclopentyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD emate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 3-(4-methoxy-benzoyl)-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 4-benzoyl-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD estradiol 17-o-sulfamate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 2-methylsulfanylestradiol 3,17-o,o-bis-sulfamate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD b-octylglucoside NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD pgl-2001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715],Paraganglioma[MeSHID:D010235] phase 2 steryl-sulfatase STS Successful target unknown NA TTD , DGIDB coumate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 steryl-sulfatase STS Successful target unknown NA TTD , DGIDB 2-ethylestradiol 3,17-o,o-bis-sulfamate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD stx 64 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 steryl-sulfatase STS Successful target unknown NA TTD , DGIDB 3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid propyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid cyclooctyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD irosustat small molecule NA investigational steryl-sulfatase STS NA inhibitor 14.14 drugbank , DGIDB 2-amino-3-oxo-4-sulfo-butyric acid small molecule NA experimental,investigative steryl-sulfatase STS Successful target unknown NA TTD , drugbank 3-(4-cyclohexylthiosemicarbazono)methyl-phenol NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 4-(2-methoxy-benzoyl)-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-(4-cyclohexylthiosemicarbazono)methyl-phenol NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD sulfamic acid 3-benzoyl-phenyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD tranilast NA Eczema[MeSHID:D004485],Allergic rhinitis (disorder)[MeSHID:D065631],Keloid[MeSHID:D007627],Asthma[MeSHID:D001249],Cicatrix, Hypertrophic[MeSHID:D017439],Dermatitis, Atopic[MeSHID:D003876],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eye[MeSHID:D005123],Vision[MeSHID:D014785],Allergic Reaction[MeSHID:D006967] approved steryl-sulfatase STS Successful target unknown 0.71 TTD , DGIDB 4-sulfamoyloxy-benzoic acid heptyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid butyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD nortropinyl-arylsulfonylurea 3 NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD pgl-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometriosis[MeSHID:D004715],Paraganglioma[MeSHID:D010235] phase 2 steryl-sulfatase STS Successful target unknown NA TTD , DGIDB mhl cyclohexylthiosemicarbazone NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD stx-140 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 steryl-sulfatase STS Successful target unknown NA TTD , DGIDB 4-sulfamoyloxy-benzoic acid octyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD estradiol 3,17-o,o-bis-sulfamate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-sulfamoyloxy-benzoic acid pentyl ester NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 3-(4-hexylthiosemicarbazono)methyl-benzoic acid NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD 4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate NA NA investigative steryl-sulfatase STS Successful target unknown NA TTD phenethyl isothiocyanate small molecule NA investigational succinyl-coa ligase [gdp-forming] subunit beta, mitochondrial SUCLG2 NA unknown NA drugbank pmid21571530c7e NA NA investigative succinate receptor SUCNR1 Literature-reported target unknown NA TTD succinic acid small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical succinate receptor 1 SUCNR1 NA agonist NA drugbank , DGIDB pmid21571530c5g NA NA investigative succinate receptor SUCNR1 Literature-reported target unknown NA TTD disufenton NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 extracellular sulfatase sulf-2 SULF2 Clinical trial target unknown NA TTD p-nitrophenol small molecule NA experimental sulfotransferase 1a1 SULT1A1 NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental sulfotransferase 1a1 SULT1A1 NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental sulfotransferase family cytosolic 1b member 1 SULT1B1 NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental estrogen sulfotransferase SULT1E1 NA unknown NA drugbank 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol small molecule NA experimental estrogen sulfotransferase SULT1E1 NA unknown NA drugbank cyclizine small molecule Vertigo[MeSHID:D014717],Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Dizziness[MeSHID:D004244],Motion Sickness[MeSHID:D009041],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved estrogen sulfotransferase SULT1E1 NA inhibitor NA drugbank 3'-phospho-5'-adenylyl sulfate small molecule NA experimental estrogen sulfotransferase SULT1E1 NA unknown NA drugbank aetiocholanolone small molecule NA experimental bile salt sulfotransferase SULT2A1 NA unknown NA drugbank mercuric iodide small molecule NA experimental bile salt sulfotransferase SULT2A1 NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental bile salt sulfotransferase SULT2A1 NA unknown NA drugbank adenosine 3',5'-diphosphate small molecule NA experimental sulfotransferase family cytosolic 2b member 1 SULT2B1 NA unknown NA drugbank pregnenolone small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,experimental sulfotransferase family cytosolic 2b member 1 SULT2B1 NA unknown NA drugbank n-cyclohexyltaurine small molecule NA experimental sulfotransferase family cytosolic 2b member 1 SULT2B1 NA unknown NA drugbank {[2-amino-4-oxo-6,7-di(sulfanyl-κs)-3,5,5a,8,9a,10-hexahydro-4h-pyrano[3,2-g]pteridin-8-yl]methyl dihydrogenato(2-) phosphate}(dioxo)sulfanylmolybdenum small molecule NA experimental sulfite oxidase, mitochondrial SUOX NA unknown NA drugbank chaetocin NA NA investigative lysine n-methyltransferase 1a SUV39H1 Literature-reported target inhibitor 31.83 TTD , DGIDB seletracetam small molecule Epilepsy[MeSHID:D004827],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 synaptic vesicle glycoprotein 2a SV2A Successful target modulator 47.74 TTD , drugbank , DGIDB brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational synaptic vesicle glycoprotein 2a SV2A Successful target modulator 15.91 TTD , drugbank , DGIDB padsevonil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 2/3 synaptic vesicle glycoprotein 2a SV2A Successful target unknown NA TTD brivaracetam small molecule Seizures[MeSHID:D012640],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Epilepsy[MeSHID:D004827] approved,investigational synaptic vesicle glycoprotein 2a SV2A Successful target unknown 15.91 TTD , drugbank , DGIDB levetiracetam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Epilepsy[MeSHID:D004827],Myoclonic Epilepsy, Juvenile[MeSHID:D020190],Idiopathic generalized epilepsy[MeSHID:C562694],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved synaptic vesicle glycoprotein 2a SV2A Successful target agonist,modulator 22.73 TTD , drugbank , DGIDB levetiracetam small molecule Epilepsies, Myoclonic[MeSHID:D004831],Epilepsy[MeSHID:D004827],Myoclonic Epilepsy, Juvenile[MeSHID:D020190],Idiopathic generalized epilepsy[MeSHID:C562694],Seizures, Focal[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibromyalgia[MeSHID:D005356] approved synaptic vesicle glycoprotein 2a SV2A Successful target agonist 22.73 TTD , drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase syk SYK Successful target inhibitor 6.37 TTD , drugbank , DGIDB pmid23312943c21 NA NA investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD pyrimidopyridazinone derivative 2 NA NA patented tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB r-343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 tyrosine-protein kinase syk SYK Successful target inhibitor 2.12 TTD , DGIDB ski-o-703 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB staurosporine small molecule NA experimental tyrosine-protein kinase syk SYK NA unknown NA drugbank vrt-750018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD tamatinib small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,investigational,clinical trial tyrosine-protein kinase syk SYK Successful target unknown 0.1 TTD , drugbank , DGIDB tamatinib small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,investigational,clinical trial tyrosine-protein kinase syk SYK Successful target unknown NA TTD , drugbank , DGIDB n-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indole-5-carboxamide small molecule NA experimental tyrosine-protein kinase syk SYK NA unknown NA drugbank hm43239 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 tyrosine-protein kinase syk SYK Successful target unknown NA TTD k00592a NA NA investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD gs-9876 NA Lupus Erythematosus, Cutaneous[MeSHID:D008178],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB hmpl-523 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 1 tyrosine-protein kinase syk SYK Successful target inhibitor 1.06 TTD , DGIDB cerdulatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],B-Cell Lymphomas[MeSHID:D016393],Vitiligo[MeSHID:D014820] phase 2 tyrosine-protein kinase syk SYK Successful target unknown 0.71 TTD , DGIDB asn002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Eczema[MeSHID:D004485],Lymphoma[MeSHID:D008223] phase 2 syk messenger rna SYK Clinical trial target unknown NA TTD prt-062607 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 tyrosine-protein kinase syk SYK Successful target unknown 2.83 TTD , DGIDB ellagic acid small molecule Fetal Growth Retardation[MeSHID:D005317],Obesity[MeSHID:D009765],Brain Injuries[MeSHID:D001930],Sunlight[MeSHID:D013472],Lentigo[MeSHID:D007911],Lymphoma, Follicular[MeSHID:D008224] investigational,investigative tyrosine-protein kinase syk SYK Successful target inhibitor NA TTD , drugbank pmid17600705c23 NA NA investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD gsk2646264 NA Lupus Erythematosus, Cutaneous[MeSHID:D008178],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urticaria[MeSHID:D014581] phase 1 tyrosine-protein kinase syk SYK Successful target inhibitor NA TTD , DGIDB sbb007833 NA NA investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD 2-{[(1r,2s)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide small molecule NA experimental tyrosine-protein kinase syk SYK NA unknown NA drugbank pyrimidopyridazinone derivative 1 NA NA patented tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB tak-659 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Hematologic Neoplasms[MeSHID:D019337] phase 2 tyrosine-protein kinase syk SYK Successful target unknown 2.12 TTD , DGIDB gs-9973 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Leukemia, Myelocytic, Acute[MeSHID:D015470],Hematologic Neoplasms[MeSHID:D019337] phase 2 tyrosine-protein kinase syk SYK Successful target unknown 6.37 TTD , DGIDB n-benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide NA NA investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD pyrrolo-pyrazine derivative 4 NA NA patented tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB dnx-2000 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD gsk2646264 NA Lupus Erythematosus, Cutaneous[MeSHID:D008178],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urticaria[MeSHID:D014581] phase 1 tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB tak-659 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Hematologic Neoplasms[MeSHID:D019337] phase 2 tyrosine-protein kinase syk SYK Successful target inhibitor 2.12 TTD , DGIDB cg-103065 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD prt6207 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB pf-3526299 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1 tyrosine-protein kinase syk SYK Successful target unknown NA TTD pyrrolo-pyrazine derivative 3 NA NA patented tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB tamatinib small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,investigational,clinical trial tyrosine-protein kinase syk SYK Successful target inhibitor 0.1 TTD , drugbank , DGIDB 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-n-[(1s)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide small molecule NA experimental tyrosine-protein kinase syk SYK NA unknown NA drugbank fostamatinib disodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] phase 3 tyrosine-protein kinase syk SYK Successful target unknown NA TTD , DGIDB tamatinib small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,investigational,clinical trial tyrosine-protein kinase syk SYK Successful target inhibitor NA TTD , drugbank , DGIDB cerdulatinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Eczema[MeSHID:D004485],Dermatitis, Atopic[MeSHID:D003876],B-Cell Lymphomas[MeSHID:D016393],Vitiligo[MeSHID:D014820] phase 2 tyrosine-protein kinase syk SYK Successful target inhibitor 0.71 TTD , DGIDB prt-060318 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] investigative tyrosine-protein kinase syk SYK Successful target unknown NA TTD adenosine 5'-[gamma-thio]triphosphate small molecule NA experimental synapsin-1 SYN1 NA unknown NA drugbank botulinum toxin type b biotech Neck Pain[MeSHID:D019547],Cervical Dystonia[MeSHID:D014103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational synaptotagmin-2 SYT2 NA unknown NA drugbank , DGIDB gi-6301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Chordoma[MeSHID:D002817] phase 2 t-box transcription factor t T Clinical trial target unknown NA TTD sep-363856 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] investigational trace amine-associated receptor 1 TAAR1 NA agonist NA drugbank , DGIDB lisdexamfetamine small molecule Binge eating disorder[MeSHID:D056912],Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational trace amine-associated receptor 1 TAAR1 NA agonist 2.12 drugbank , DGIDB rg-7351 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 1 trace amine-associated receptor-1 TAAR1 Successful target unknown NA TTD , DGIDB amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational trace amine-associated receptor 1 TAAR1 NA agonist 0.99 drugbank , DGIDB spd-465 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Symphysis Pubis Dysfunction[MeSHID:D059388],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 3 trace amine-associated receptor-1 TAAR1 Successful target unknown NA TTD , DGIDB tyramine NA NA investigative trace amine-associated receptor-1 TAAR1 Successful target agonist 1.41 TTD , DGIDB hydroxyamphetamine hydrobromide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Horner Syndrome[MeSHID:D006732] approved trace amine-associated receptor-1 TAAR1 Successful target unknown NA TTD , DGIDB lisdexamfetamine NA Binge eating disorder[MeSHID:D056912],Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289],Weight decreased[MeSHID:D015431],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved trace amine-associated receptor-1 TAAR1 Successful target unknown 2.12 TTD , DGIDB ro5166017 NA NA investigative trace amine-associated receptor-1 TAAR1 Successful target agonist NA TTD , DGIDB sep-363856 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 3 trace amine-associated receptor-1 TAAR1 Successful target unknown NA TTD , DGIDB amphetamine NA Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved trace amine-associated receptor-1 TAAR1 Successful target unknown 0.99 TTD , DGIDB hydroxyamphetamine hydrobromide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Horner Syndrome[MeSHID:D006732] approved trace amine-associated receptor-1 TAAR1 Successful target unknown 0.24 TTD , DGIDB 3-iodothyronamine NA NA investigative trace amine-associated receptor-1 TAAR1 Successful target unknown NA TTD dextroamphetamine NA Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved trace amine-associated receptor-1 TAAR1 Successful target unknown 2.48 TTD , DGIDB epptb NA NA investigative trace amine-associated receptor-1 TAAR1 Successful target antagonist NA TTD , DGIDB sep-363856 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Major Depressive Disorder[MeSHID:D003865],Schizophrenia[MeSHID:D012559] phase 3 trace amine-associated receptor-1 TAAR1 Successful target agonist NA TTD , DGIDB tyramine NA NA investigative trace amine-associated receptor-1 TAAR1 Successful target unknown 1.41 TTD , DGIDB dextroamphetamine small molecule Attention deficit hyperactivity disorder[MeSHID:D001289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Narcolepsy[MeSHID:D009290] approved,illicit trace amine-associated receptor 1 TAAR1 NA agonist 2.48 drugbank , DGIDB r(-)amphetamine NA NA investigative trace amine-associated receptor-1 TAAR1 Successful target agonist NA TTD , DGIDB nt0202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Attention deficit hyperactivity disorder[MeSHID:D001289] phase 3 trace amine-associated receptor-1 TAAR1 Successful target unknown NA TTD , DGIDB propylhexedrine small molecule Allergic rhinitis (disorder)[MeSHID:D065631],Nose[MeSHID:D009666],Common Cold[MeSHID:D003139],Hypersensitivity[MeSHID:D006967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] approved trace amine-associated receptor 1 TAAR1 NA agonist NA drugbank metamfetamine small molecule Obesity[MeSHID:D009765],Attention deficit hyperactivity disorder[MeSHID:D001289] approved,illicit trace amine-associated receptor 1 TAAR1 NA agonist NA drugbank isoamylamine NA NA investigative trace amine receptor 3 TAAR3P Literature-reported target unknown NA TTD trimethylamine NA NA investigative trace amine receptor 5 TAAR5 Literature-reported target unknown NA TTD dimethylethylamine NA NA investigative trace amine receptor 5 TAAR5 Literature-reported target unknown NA TTD manganese small molecule Plasma[MeSHID:D010949],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved,nutraceutical tgf-beta-activated kinase 1 and map3k7-binding protein 1 TAB1 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tachykinin-3 TAC3 NA unknown NA drugbank homspera NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] investigative substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB h-phe-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD septide NA NA investigative substance-p receptor TACR1 Successful target agonist NA TTD , DGIDB gsk 679769 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Unipolar Depression[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008],Major Depressive Disorder[MeSHID:D003865],Nausea[MeSHID:D009325] discontinued in phase 2 substance-p receptor TACR1 Successful target unknown NA TTD gw 597599 NA Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Gastrointestinal Diseases[MeSHID:D005767],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Mood Disorders[MeSHID:D019964],Unipolar Depression[MeSHID:D003866] phase 2 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB sdz-nkt-343 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 1 substance-p receptor TACR1 Successful target unknown NA TTD arg-pro-lys-pro-ala-gln-phe-phe-gly-leu-met-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD casopitant small molecule Urinary Incontinence[MeSHID:D014549],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] investigational neurokinin 1 receptor TACR1 NA unknown 3.54 drugbank , DGIDB rolapitant NA Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved substance-p receptor TACR1 Successful target antagonist 5.3 TTD , DGIDB netupitant NA Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 substance-p receptor TACR1 Successful target unknown 2.65 TTD , DGIDB tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neurokinin 1 receptor TACR1 NA inhibitor NA drugbank mdl-28163 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD [125i]l703,606 NA NA investigative substance-p receptor TACR1 Successful target antagonist NA TTD , DGIDB substance p NA NA investigative substance-p receptor TACR1 Successful target agonist NA TTD , DGIDB (d)-phe-(d)-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD ta-5538 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] discontinued in phase 2 substance-p receptor TACR1 Successful target unknown NA TTD aprepitant NA Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved substance-p receptor TACR1 Successful target antagonist 7.07 TTD , DGIDB 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD spantide ii NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD 7-methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide (structural mix) NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD aprepitant small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved,investigational neurokinin 1 receptor TACR1 NA antagonist 7.07 drugbank , DGIDB win-66306 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD rolapitant NA Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved substance-p receptor TACR1 Successful target unknown 5.3 TTD , DGIDB win-68577 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD sch 206272 NA NA investigative substance-p receptor TACR1 Successful target antagonist NA TTD , DGIDB h-tyr-d-ala-gly-phe-pro-leu-trp-nh-3,5-bzl(cf3)2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD nkp 608 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mood Disorders[MeSHID:D019964] phase 2 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB orvepitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] phase 2 substance-p receptor TACR1 Successful target unknown 0.88 TTD , DGIDB (d)-phe-(l)-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD l-759274 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Mood Disorders[MeSHID:D019964],Depressive disorder[MeSHID:D003866] discontinued in phase 3 substance-p receptor TACR1 Successful target unknown NA TTD cs-003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 substance-p receptor TACR1 Successful target unknown NA TTD rolapitant small molecule Nausea[MeSHID:D009325],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neurokinin 1 receptor TACR1 NA antagonist 5.3 drugbank , DGIDB sch-900978 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] phase 2 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB gw 597599 small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Gastrointestinal Diseases[MeSHID:D005767],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Mood Disorders[MeSHID:D019964],Unipolar Depression[MeSHID:D003866] investigational neurokinin 1 receptor TACR1 NA unknown NA drugbank , DGIDB ssr240600 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] phase 2 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB nolpitantium besilate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 substance-p receptor TACR1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-o-bzl NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD spantide NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD 3-benzyloxy-2-phenyl-piperidine NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD aprepitant NA Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved substance-p receptor TACR1 Successful target unknown 7.07 TTD , DGIDB netupitant small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational neurokinin 1 receptor TACR1 NA antagonist 2.65 drugbank , DGIDB h-tyr-pro-phe-phe-oh NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD h-tyr(ome)-phe(2-me)-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD h-tyr-d-ala-gly phe-pro-leu-trp-o-3,5-bzl(cf3)2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD dnk-333 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 substance-p receptor TACR1 Successful target unknown NA TTD vapreotide small molecule Diarrhea[MeSHID:D003967],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Hemorrhage[MeSHID:D006470],Liver diseases[MeSHID:D008107] experimental,investigational neurokinin 1 receptor TACR1 NA antagonist 1.33 drugbank , DGIDB kassinin NA NA investigative substance-p receptor TACR1 Successful target agonist 0.88 TTD , DGIDB s-41744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative substance-p receptor TACR1 Successful target unknown NA TTD casopitant small molecule Urinary Incontinence[MeSHID:D014549],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] investigational neurokinin 1 receptor TACR1 NA antagonist 3.54 drugbank , DGIDB cp-122721 NA Asthma[MeSHID:D001249],Irritable Bowel Syndrome[MeSHID:D043183],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] phase 2 substance-p receptor TACR1 Successful target unknown 1.77 TTD , DGIDB lanepitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 substance-p receptor TACR1 Successful target antagonist 3.54 TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved neurokinin 1 receptor TACR1 NA antagonist NA drugbank [18f]spa-rq NA NA investigative substance-p receptor TACR1 Successful target antagonist NA TTD , DGIDB fosnetupitant small molecule Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839] approved neurokinin 1 receptor TACR1 NA antagonist NA drugbank ave-5883 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1/2 substance-p receptor TACR1 Successful target unknown NA TTD h-tyr-d-ala-gly-phe-pro-leu-trp-nh-bzl NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD ac-phe-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD tka-731 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB vestipitant small molecule NA investigational neurokinin 1 receptor TACR1 NA unknown 8.84 drugbank , DGIDB serlopitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Prurigo[MeSHID:D011536] phase 3 substance-p receptor TACR1 Successful target unknown 1.77 TTD , DGIDB ketamine small molecule Disease Management[MeSHID:D019468],Depressive disorder[MeSHID:D003866],Relaxation[MeSHID:D012063],Operative Surgical Procedures[MeSHID:D013514],Diagnosis[MeSHID:D003933],Visceral Pain[MeSHID:D059265],Skeletal muscle structure[MeSHID:D018482],Stupor[MeSHID:D053608],Mental Depression[MeSHID:D003863],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,vet_approved neurokinin 1 receptor TACR1 NA antagonist NA drugbank h-pro-phe-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD cgp-49823 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 substance-p receptor TACR1 Successful target unknown NA TTD neurokinin a NA NA investigative substance-p receptor TACR1 Successful target agonist NA TTD , DGIDB casopitant NA Urinary Incontinence[MeSHID:D014549],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] withdrawn from market substance-p receptor TACR1 Successful target antagonist 3.54 TTD , DGIDB vofopitant small molecule NA investigational neurokinin 1 receptor TACR1 NA antagonist 2.65 drugbank , DGIDB selegiline NA Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Parkinson Disease[MeSHID:D010300],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Nausea[MeSHID:D009325],Unipolar Depression[MeSHID:D003866] approved substance-p receptor TACR1 Successful target unknown 0.2 TTD , DGIDB h-tyr-d-ala-gly-phe-pro-leu-trp-nme-3,5-bzl(cf3)2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD figopitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] phase 1 substance-p receptor TACR1 Successful target unknown 0.88 TTD , DGIDB tak-637 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] discontinued in phase 2 substance-p receptor TACR1 Successful target antagonist 1.77 TTD , DGIDB cp-99,994 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD bl-1832 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Burkitt Lymphoma[MeSHID:D002051] discontinued in phase 3 substance-p receptor TACR1 Successful target unknown NA TTD cp-122721 small molecule Asthma[MeSHID:D001249],Irritable Bowel Syndrome[MeSHID:D043183],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigational neurokinin 1 receptor TACR1 NA unknown 1.77 drugbank , DGIDB fk-224 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 substance-p receptor TACR1 Successful target unknown NA TTD r-226161 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD av608 small molecule Urinary Incontinence[MeSHID:D014549],Irritable Bowel Syndrome[MeSHID:D043183],Anxiety Disorders[MeSHID:D001008] investigational neurokinin 1 receptor TACR1 NA unknown NA drugbank , DGIDB h-ala-pro-phe-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD slv-323 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cell motility[MeSHID:D002465],Stomach Diseases[MeSHID:D013272],Nausea[MeSHID:D009325] discontinued in phase 1 substance-p receptor TACR1 Successful target unknown NA TTD h-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD physalaemin NA NA investigative substance-p receptor TACR1 Successful target agonist 1.77 TTD , DGIDB dapitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 substance-p receptor TACR1 Successful target unknown 1.77 TTD , DGIDB ezlopitant NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Vomiting[MeSHID:D014839] discontinued in phase 2 substance-p receptor TACR1 Successful target antagonist 0.88 TTD , DGIDB t2328 NA NA investigative substance-p receptor TACR1 Successful target antagonist NA TTD , DGIDB endomorphin 2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD l-736281 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD 2-phenyl-3-(1-phenyl-ethoxy)-piperidine NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD zd-6021 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD palonosetron + fosnetupitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] approved substance-p receptor TACR1 Successful target unknown NA TTD (l)-phe-(d)-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD cj-12255 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 1 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB vofopitant hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vomiting[MeSHID:D014839] phase 2 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB vofopitant small molecule NA investigational neurokinin 1 receptor TACR1 NA unknown 2.65 drugbank , DGIDB tyr-d-ala-gly-phe-met-pro-leu-trp-nh-bzl NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD h-tyr-pro-phe-ala-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD lanepitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 substance-p receptor TACR1 Successful target unknown 3.54 TTD , DGIDB serlopitant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Prurigo[MeSHID:D011536] phase 3 substance-p receptor TACR1 Successful target antagonist 1.77 TTD , DGIDB pro-lys-pro-gln-gln-phe-phe-gly-leu-met-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD h-tyr-pro-ala-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD arg-pro-lys-pro-ala-ser-phe-phe-gly-leu-met-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD fr139317 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Anxiety Disorders[MeSHID:D001008] phase 2 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB l-708568 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD sp-sap NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] investigative substance-p receptor TACR1 Successful target unknown NA TTD befetupitant NA NA investigative substance-p receptor TACR1 Successful target antagonist 1.77 TTD , DGIDB eu-c-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Injuries[MeSHID:D001930] investigative substance-p receptor TACR1 Successful target unknown NA TTD ly-2590443 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] phase 2 substance-p receptor TACR1 Successful target unknown 0.88 TTD , DGIDB h-tyr-d-ala-gly-phe-pro-leu-trp-nme-bzl NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD gsk1144814 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 1 substance-p receptor TACR1 Successful target unknown NA TTD , DGIDB arg-pro-lys-pro-gln-ser-phe-phe-gly-leu-met-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD eledoisin NA NA investigative substance-p receptor TACR1 Successful target agonist 0.88 TTD , DGIDB 7-methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (s)-[(s)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide (enantiomeric mix) NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD fk-888 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881] discontinued in phase 2 substance-p receptor TACR1 Successful target antagonist 0.88 TTD , DGIDB [sar9,met(o2)11]-sp NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD h-tyr-ala-phe-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD win-64745 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD 3,6-diphenyl-1-oxa-7-aza-spiro[4.5]decane NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD cp-100263 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vomiting[MeSHID:D014839] investigative substance-p receptor TACR1 Successful target unknown NA TTD ly-686017 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Alcoholic Intoxication, Chronic[MeSHID:D000437],Eczema[MeSHID:D004485] phase 3 substance-p receptor TACR1 Successful target unknown 2.65 TTD , DGIDB 7-methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (s)-[(r)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide (enantiomeric mix) NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD vestipitant small molecule NA investigational neurokinin 1 receptor TACR1 NA antagonist 8.84 drugbank , DGIDB casopitant NA Urinary Incontinence[MeSHID:D014549],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nausea[MeSHID:D009325] withdrawn from market substance-p receptor TACR1 Successful target unknown 3.54 TTD , DGIDB h-arg-pro-lys-pro-gln-gln-phe-oh NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD netupitant NA Nausea[MeSHID:D009325],Malignant Neoplasms[MeSHID:D009369],Vomiting[MeSHID:D014839],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 substance-p receptor TACR1 Successful target antagonist 2.65 TTD , DGIDB r673 small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Anxiety[MeSHID:D001007] investigational neurokinin 1 receptor TACR1 NA unknown NA drugbank r116031 NA NA investigative substance-p receptor TACR1 Successful target antagonist NA TTD , DGIDB sr 140333 small molecule Asthma[MeSHID:D001249],Inflammatory Bowel Diseases[MeSHID:D015212] investigational neurokinin 1 receptor TACR1 NA unknown NA drugbank h-leu-phe-nh2 NA NA investigative substance-p receptor TACR1 Successful target unknown NA TTD l-703,606 NA NA investigative substance-p receptor TACR1 Successful target antagonist NA TTD , DGIDB slv-332 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] preclinical substance-k receptor TACR2 Clinical trial target unknown NA TTD , DGIDB saredutant small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 substance-k receptor TACR2 Clinical trial target antagonist 12.12 TTD , drugbank , DGIDB zm 253270 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB ym44781 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB rambazole NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Asthma[MeSHID:D001249] phase 2 substance-k receptor TACR2 Clinical trial target unknown 2.27 TTD , DGIDB ym44778 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB ym49598 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB ibodutant NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 substance-k receptor TACR2 Clinical trial target antagonist 27.28 TTD , DGIDB zd-6021 NA NA investigative substance-k receptor TACR2 Clinical trial target unknown NA TTD nepadutant NA Ileus[MeSHID:D045823],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infantile Colic[MeSHID:D003085] phase 1/2 substance-k receptor TACR2 Clinical trial target antagonist 18.19 TTD , DGIDB ibodutant NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 substance-k receptor TACR2 Clinical trial target unknown 27.28 TTD , DGIDB cs-003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 substance-k receptor TACR2 Clinical trial target unknown NA TTD neurokinin a NA NA investigative substance-k receptor TACR2 Clinical trial target agonist NA TTD , DGIDB gr100679 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB zm-274773 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB pmx-53 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 substance-k receptor TACR2 Clinical trial target unknown NA TTD , DGIDB a-987306 NA NA investigative substance-k receptor TACR2 Clinical trial target unknown NA TTD uk-224671 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 1 substance-k receptor TACR2 Clinical trial target unknown NA TTD gr94800 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB fk-224 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 substance-k receptor TACR2 Clinical trial target unknown NA TTD nepadutant NA Ileus[MeSHID:D045823],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infantile Colic[MeSHID:D003085] phase 1/2 substance-k receptor TACR2 Clinical trial target unknown 18.19 TTD , DGIDB r396 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB hoo-phe-orn-pro-hle-pff-phe-nh2 NA NA investigative substance-k receptor TACR2 Clinical trial target unknown NA TTD dnk-333 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 substance-k receptor TACR2 Clinical trial target unknown NA TTD saredutant small molecule Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 substance-k receptor TACR2 Clinical trial target unknown 12.12 TTD , drugbank , DGIDB sr 144190 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Depressive disorder[MeSHID:D003866],Mental Depression[MeSHID:D003863],Anxiety Disorders[MeSHID:D001008],Urinary Incontinence[MeSHID:D014549],Chronic pain[MeSHID:D059350] discontinued in phase 1 substance-k receptor TACR2 Clinical trial target unknown NA TTD sch 206272 NA NA investigative substance-k receptor TACR2 Clinical trial target antagonist NA TTD , DGIDB way-207024 NA NA investigative substance-k receptor TACR2 Clinical trial target unknown NA TTD ave-5883 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 1/2 substance-k receptor TACR2 Clinical trial target unknown NA TTD 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one NA NA investigative substance-k receptor TACR2 Clinical trial target unknown NA TTD sch 206272 NA NA investigative neuromedin-k receptor TACR3 Clinical trial target antagonist NA TTD , DGIDB gr138676 NA NA investigative neuromedin-k receptor TACR3 Clinical trial target antagonist NA TTD , DGIDB neurokinin b NA NA investigative neuromedin-k receptor TACR3 Clinical trial target agonist NA TTD , DGIDB r-820 NA NA investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD pd-161182 NA NA investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD senktide NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 2 neuromedin-k receptor TACR3 Clinical trial target agonist 5.79 TTD , DGIDB n',2-diphenylquinoline-4-carbohydrazide 8m NA NA investigative neuromedin-k receptor TACR3 Clinical trial target antagonist NA TTD , DGIDB 3-methoxy-n',2-diphenylquinoline-4-carbohydrazide NA NA investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD talnetant small molecule Chronic Obstructive Airway Disease[MeSHID:D029424],Irritable Bowel Syndrome[MeSHID:D043183],Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 neuromedin-k receptor TACR3 Clinical trial target antagonist 20.25 TTD , drugbank , DGIDB pd 154740 NA NA investigative neuromedin-k receptor TACR3 Clinical trial target antagonist NA TTD , DGIDB gsk1144814 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Alcoholic Intoxication, Chronic[MeSHID:D000437] phase 1 neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD , DGIDB azd2624 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Multiple Sclerosis[MeSHID:D009103] phase 2 neuromedin-k receptor TACR3 Clinical trial target antagonist 17.36 TTD , DGIDB senktide NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] phase 2 neuromedin-k receptor TACR3 Clinical trial target unknown 5.79 TTD , DGIDB n-phenethyl-2-phenylquinoline-4-carboxamide NA NA investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD pd-157672 NA NA investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD n',2-diphenylquinoline-4-carbohydrazide NA NA investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD pd-160946 NA NA investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD osanetant small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Schizophrenia[MeSHID:D012559],Visceral Pain[MeSHID:D059265],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cessation of life[MeSHID:D003643],Schizoaffective Disorder[MeSHID:D011618],Expiration, function[MeSHID:D045853] investigational,discontinued in phase 2b neuromedin-k receptor TACR3 Clinical trial target antagonist 3.86 TTD , drugbank , DGIDB azd2624 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Multiple Sclerosis[MeSHID:D009103] phase 2 neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD , DGIDB cs-003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] discontinued in phase 2 neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD kassinin NA NA investigative neuromedin-k receptor TACR3 Clinical trial target agonist 2.89 TTD , DGIDB gsk-172981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD sb222200 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559],Schizoaffective Disorder[MeSHID:D011618] preclinical neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD , DGIDB eledoisin NA NA investigative neuromedin-k receptor TACR3 Clinical trial target agonist 2.89 TTD , DGIDB neurokinin a NA NA investigative neuromedin-k receptor TACR3 Clinical trial target agonist NA TTD , DGIDB ssr-146977 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] discontinued in phase 1 neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD 2-phenyl-n-(1-phenylethyl)quinoline-4-carboxamide NA NA investigative neuromedin-k receptor TACR3 Clinical trial target unknown NA TTD pavinetant small molecule NA investigational neuromedin-k receptor TACR3 NA antagonist 17.36 drugbank , DGIDB sacituzumab govitecan biotech Triple Negative Breast Neoplasms[MeSHID:D064726],Urothelium[MeSHID:D019459],Neoplasm Metastasis[MeSHID:D009362],Cessation of life[MeSHID:D003643] approved,investigational tumor-associated calcium signal transducer 2 TACSTD2 NA antibody NA drugbank , DGIDB skb264 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 tumor associated calcium signal transducer 2 TACSTD2 Clinical trial target unknown NA TTD artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational transgelin TAGLN NA ligand NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational transgelin-2 TAGLN2 NA ligand NA drugbank pmid20873740c18 NA NA investigative tao kinase 1 TAOK1 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase tao1 TAOK1 NA inhibitor NA drugbank dexfosfoserine small molecule NA experimental serine/threonine-protein kinase tao2 TAOK2 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase tao2 TAOK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase tao3 TAOK3 NA inhibitor NA drugbank lmt-x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 3 tar dna binding protein 43 TARDBP Clinical trial target unknown NA TTD , DGIDB threonine small molecule Metabolism[MeSHID:D008660],Dental Enamel[MeSHID:D003743],Liver[MeSHID:D008099],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Lipid Metabolism[MeSHID:D050356],Digestion[MeSHID:D004063],Intestines[MeSHID:D007422] approved,nutraceutical threonine--trna ligase, cytoplasmic TARS NA unknown NA drugbank threonine small molecule Metabolism[MeSHID:D008660],Dental Enamel[MeSHID:D003743],Liver[MeSHID:D008099],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Lipid Metabolism[MeSHID:D050356],Digestion[MeSHID:D004063],Intestines[MeSHID:D007422] approved,nutraceutical threonine--trna ligase, mitochondrial TARS2 NA unknown NA drugbank sucrose small molecule NA approved,experimental,investigational taste receptor type 1 member 2 TAS1R2 NA unknown NA drugbank aspartame small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,nutraceutical taste receptor type 1 member 2 TAS1R2 NA agonist NA drugbank aspartame small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,nutraceutical taste receptor type 1 member 3 TAS1R3 NA unknown NA drugbank probenecid small molecule Mental concentration[MeSHID:D001288],Serum[MeSHID:D044967],Neoplasm Metastasis[MeSHID:D009362],Arthritis, Gouty[MeSHID:D015210],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational taste receptor type 2 member 16 TAS2R16 NA unknown NA drugbank glutamic acid small molecule Craving[MeSHID:D066249],Schizophrenia[MeSHID:D012559],Brain[MeSHID:D001921],Fatigue[MeSHID:D005221],Ulcer[MeSHID:D014456],Lifting[MeSHID:D017770],Alcoholic Intoxication, Chronic[MeSHID:D000437],Respiratory Diaphragm[MeSHID:D003964],Wound Healing[MeSHID:D014945] approved,nutraceutical tyrosine aminotransferase TAT NA unknown NA drugbank tyrosine small molecule Narcolepsy[MeSHID:D009290],Fatigue[MeSHID:D005221] approved,investigational,nutraceutical tyrosine aminotransferase TAT NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical tyrosine aminotransferase TAT NA cofactor NA drugbank phenylalanine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Tardive Dyskinesia[MeSHID:D000071057],Vitiligo[MeSHID:D014820] approved,investigational,nutraceutical tyrosine aminotransferase TAT NA unknown NA drugbank pyrimidinyl compound 1 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB pyrimidinyl compound 2 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB aminopyrimidine derivative 7 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB pyrimidinyl compound 7 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB aminopyrimidine derivative 9 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB aminopyrimidine derivative 10 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB pyrimidinyl compound 6 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB pyrimidinyl compound 5 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB pmid26293650-compound-34 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB pmid23099093c17d NA NA investigative nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD aminopyrimidine derivative 6 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase tbk1 TBK1 NA inhibitor NA drugbank pmid26293650-compound-35 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB aminopyrimidine derivative 8 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB pyrimidinyl compound 4 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB mrt67307 NA NA investigative nf-kappa-b-activating kinase TBK1 Patented-recorded target inhibitor NA TTD , DGIDB pyrimidinyl compound 3 NA NA patented nf-kappa-b-activating kinase TBK1 Patented-recorded target unknown NA TTD , DGIDB ono-8809 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] investigative thromboxane a2 receptor TBXA2R Successful target unknown NA TTD terutroban sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 3 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD laropiprant NA Coronary Arteriosclerosis[MeSHID:D003324],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161] phase 4 thromboxane a2 receptor TBXA2R Successful target unknown 0.43 TTD , DGIDB kw-3635 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 thromboxane a2 receptor TBXA2R Successful target antagonist NA TTD , DGIDB g-619 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB ridogrel small molecule Myocardial Infarction[MeSHID:D009203],Mental Suffering[MeSHID:D013315],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,approved thromboxane a2 receptor TBXA2R Successful target antagonist 21.22 TTD , drugbank , DGIDB i-bop NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB 10,10-difluoro txa2 NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB m&b 28767 NA NA investigative thromboxane a2 receptor TBXA2R Successful target unknown NA TTD kp-496 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB u46619 NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB sta2 NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB carbocyclic thromboxane a2 NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB cgs-22652 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 1 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD sq-30741 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD i-sap NA NA investigative thromboxane a2 receptor TBXA2R Successful target antagonist NA TTD , DGIDB ah23848 NA NA investigative thromboxane a2 receptor TBXA2R Successful target antagonist NA TTD , DGIDB domitroban NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in preregistration thromboxane a2 receptor TBXA2R Successful target antagonist 3.03 TTD , DGIDB kt2-962 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 1 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD pgf2alpha NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] clinical trial thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB cloprostenol NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist 0.61 TTD , DGIDB [125i]sq-29548 NA NA investigative thromboxane a2 receptor TBXA2R Successful target antagonist NA TTD , DGIDB seratrodast small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] experimental,discontinued in phase 3 thromboxane a2 receptor TBXA2R Successful target antagonist NA TTD , drugbank [125i]pta-oh NA NA investigative thromboxane a2 receptor TBXA2R Successful target antagonist NA TTD , DGIDB ramatroban NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis, Allergic, Perennial[MeSHID:D012221] phase 2/3 thromboxane a2 receptor TBXA2R Successful target unknown 1.21 TTD , DGIDB dt-tx-30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 1 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB alprostadil NA Patent ductus arteriosus[MeSHID:D004374],Maintenance[MeSHID:D008283],Congenital Heart Defects[MeSHID:D006330],Neurogenesis[MeSHID:D055495],Erectile dysfunction[MeSHID:D007172],Continuance of life[MeSHID:D013534],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Foot[MeSHID:D017719] approved thromboxane a2 receptor TBXA2R Successful target unknown 0.2 TTD , DGIDB tak-128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] phase 2 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB ep 171 NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB sq-29548 NA NA investigative thromboxane a2 receptor TBXA2R Successful target antagonist 3.03 TTD , DGIDB pgh2 NA NA investigative thromboxane a2 receptor TBXA2R Successful target unknown NA TTD [125i]sap NA NA investigative thromboxane a2 receptor TBXA2R Successful target antagonist NA TTD , DGIDB u-44069 NA NA investigative thromboxane a2 receptor TBXA2R Successful target unknown NA TTD fluprostenol NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist 1.01 TTD , DGIDB agn192093 NA NA investigative thromboxane a2 receptor TBXA2R Successful target unknown NA TTD z-335 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD ono-3708 NA NA investigative thromboxane a2 receptor TBXA2R Successful target antagonist 3.03 TTD , DGIDB sq 26655 NA NA investigative thromboxane a2 receptor TBXA2R Successful target unknown NA TTD ym-57158 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB ifetroban sodium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 2 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB bm-573 NA NA investigative thromboxane a2 receptor TBXA2R Successful target unknown NA TTD s 18204 NA NA investigative thromboxane a2 receptor TBXA2R Successful target unknown NA TTD [125i]bop NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB carbacyclin NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist 0.38 TTD , DGIDB morniflumate small molecule Nose[MeSHID:D009666],Disease[MeSHID:D004194],Ear structure[MeSHID:D004423],Gastrointestinal Diseases[MeSHID:D005767],Pharyngeal structure[MeSHID:D010614],Affect (mental function)[MeSHID:D000339],Upper Respiratory Infections[MeSHID:D012141],Bone Tissue[MeSHID:D001842],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Otitis Media[MeSHID:D010033] experimental thromboxane a2 receptor TBXA2R NA unknown NA drugbank bibv 308 NA Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB agn 191976 NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB linotroban NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD daltroban NA NA discontinued in phase 3 thromboxane a2 receptor TBXA2R Successful target antagonist 3.03 TTD , DGIDB fk-070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 2 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD , DGIDB ici-192605 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in phase 2 thromboxane a2 receptor TBXA2R Successful target unknown NA TTD ramatroban NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rhinitis, Allergic, Perennial[MeSHID:D012221] phase 2/3 thromboxane a2 receptor TBXA2R Successful target antagonist 1.21 TTD , DGIDB butaprost (free acid form) NA NA investigative thromboxane a2 receptor TBXA2R Successful target agonist NA TTD , DGIDB nm-702 small molecule Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] investigational,phase 3 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD , drugbank , DGIDB cv-6504.hcl NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD sulfasalazine small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Neoplasm Metastasis[MeSHID:D009362],Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thromboxane-a synthase TBXAS1 NA antagonist NA drugbank nv-52 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] phase 1 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD , DGIDB 5-imidazol-1-yl-5,6,7,8-tetrahydro-quinoline NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD fk-070 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] phase 2 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD , DGIDB ono-1581 NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD 6-imidazol-1-yl-isoquinoline NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD 2-(8-imidazol-1-yl-octyl)-isoindole-1,3-dione NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD 4-methyl-pyridine NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD 2-(6-imidazol-1-yl-hexyl)-isoindole-1,3-dione NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD imitrodast NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD 2-(10-imidazol-1-yl-decyl)-isoindole-1,3-dione NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD satigrel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] discontinued in preregistration thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD pyridine NA NA phase 4 thromboxane-a synthase TBXAS1 Clinical trial target unknown 21.22 TTD , DGIDB ev-077 NA Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epidermodysplasia Verruciformis[MeSHID:D004819] phase 2 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD , DGIDB 5-(2-imidazol-1-yl-ethyl)-7,8-dihydro-quinoline NA NA investigative thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD dazoxiben small molecule NA experimental,terminated thromboxane-a synthase TBXAS1 Clinical trial target inhibitor NA TTD , drugbank e-6700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD , DGIDB g-619 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD , DGIDB ridogrel small molecule Myocardial Infarction[MeSHID:D009203],Mental Suffering[MeSHID:D013315],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental thromboxane-a synthase TBXAS1 NA inhibitor NA drugbank rolafagrel NA Nephritis[MeSHID:D009393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD milacainide tartrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiac Arrhythmia[MeSHID:D001145] discontinued in phase 2 thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD ono-1301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] preclinical thromboxane-a synthase TBXAS1 Clinical trial target unknown NA TTD , DGIDB tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved v-atpase subunits TCIRG1 NA inhibitor NA drugbank hydroxocobalamin small molecule Kidney Diseases[MeSHID:D007674],Pancreatic carcinoma[MeSHID:C562463],Diet, Macrobiotic[MeSHID:D015623],Malignant neoplasm of pancreas[MeSHID:D010190],Biliary Tract Diseases[MeSHID:D001660],Diarrhea[MeSHID:D003967],Cestode Infections[MeSHID:D002590],Malabsorption Syndrome[MeSHID:D008286],Poisoning[MeSHID:D011041],Alcoholic Intoxication, Chronic[MeSHID:D000437],Hyperthyroidism[MeSHID:D006980],Vegan diet[MeSHID:D000067269],Anemia, Pernicious[MeSHID:D000752],ileum[MeSHID:D007082],Vitamin B 12 Deficiency[MeSHID:D014806],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lung Injury[MeSHID:D055370] approved transcobalamin-1 TCN1 NA other NA drugbank biib 015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 teratocarcinoma-derived growth factor 1 TDGF1 Clinical trial target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 6 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 4 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB hti-1090 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD 4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD pmid29473428-compound-76 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB 680c91 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD 2,3-diamino-benzo[b]thiophene derivative 3 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 1 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB indazole derivative 3 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB lm10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical tryptophan 2,3-dioxygenase TDO2 Clinical trial target inhibitor NA TTD , DGIDB pmid27172114-compound-30 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 8 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB epl-1410 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD 2,3-diamino-benzo[b]thiophene derivative 5 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB 2,3-diamino-benzo[b]thiophene derivative 2 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB dn1406131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD 2,3-diamino-benzo[b]thiophene derivative 7 NA NA patented tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD , DGIDB rg70099 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical tryptophan 2,3-dioxygenase TDO2 Clinical trial target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase tec TEC NA inhibitor NA drugbank pyrazolo[4,3-c]pyridine derivative 2 NA NA patented tyrosine-protein kinase tec TEC Patented-recorded target unknown NA TTD , DGIDB pmid24915291c31 NA NA investigative tyrosine-protein kinase tec TEC Patented-recorded target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase tec TEC NA inhibitor NA drugbank pmid24915291c38 NA NA investigative tyrosine-protein kinase tec TEC Patented-recorded target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase tec TEC NA inhibitor NA drugbank altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 angiopoietin 1 receptor TEK Clinical trial target inhibitor 1.33 TTD , DGIDB tivozanib small molecule Renal Cell Carcinoma[MeSHID:D002292],Disease Progression[MeSHID:D018450],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational angiopoietin-1 receptor TEK NA unknown NA drugbank n-{4-methyl-3-[(3-pyrimidin-4-ylpyridin-2-yl)amino]phenyl}-3-(trifluoromethyl)benzamide small molecule NA experimental angiopoietin-1 receptor TEK NA unknown NA drugbank 3-(4-methoxyphenyl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD dcc-2036 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Myeloid Leukemia, Chronic[MeSHID:D015464],Malignant neoplasm of breast[MeSHID:D001943] phase 1/2 angiopoietin 1 receptor TEK Clinical trial target unknown 0.71 TTD , DGIDB cep-11981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 angiopoietin 1 receptor TEK Clinical trial target unknown 0.59 TTD , DGIDB a-420983 NA NA investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD 3,4-diphenyl-1h-pyrrole-2,5-dione NA NA investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD regorafenib small molecule Liver carcinoma[MeSHID:D006528],Gastrointestinal Stromal Tumors[MeSHID:D046152],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved angiopoietin-1 receptor TEK NA inhibitor 0.51 drugbank , DGIDB (4-phenoxy-phenyl)-quinazolin-4-yl-amine NA NA investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD ap-101 NA Ischemia[MeSHID:D007511],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD akb-9778 NA Peripheral Arterial Diseases[MeSHID:D058729],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269],Peripheral Vascular Diseases[MeSHID:D016491] phase 2 angiopoietin 1 receptor TEK Clinical trial target unknown 1.77 TTD , DGIDB 3,4-di-(4-methoxyphenyl)-1h-pyrrole-2,5-dione NA NA investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD ampicillin small molecule Meningitis[MeSHID:D008581],Urinary tract infection[MeSHID:D014552],Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved angiopoietin-1 receptor TEK NA unknown 0.64 drugbank , DGIDB 3-(indole-3-yl)-4-phenyl-1h-pyrrole-2,5-dione NA NA investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD ponatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational angiopoietin-1 receptor TEK NA inhibitor NA drugbank ripretinib small molecule Diagnosis[MeSHID:D003933],Gastrointestinal Stromal Tumors[MeSHID:D046152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Mastocytosis, Systemic[MeSHID:D034721] approved angiopoietin-1 receptor TEK NA inhibitor NA drugbank vandetanib small molecule Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved angiopoietin-1 receptor TEK NA inhibitor 0.07 drugbank , DGIDB cep-11981 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 angiopoietin 1 receptor TEK Clinical trial target inhibitor 0.59 TTD , DGIDB altiratinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 angiopoietin 1 receptor TEK Clinical trial target unknown 1.33 TTD , DGIDB pmid21561767c8h NA NA investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD arry-614 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] discontinued in phase 1 angiopoietin 1 receptor TEK Clinical trial target unknown 0.71 TTD , DGIDB abtaa NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] investigative angiopoietin 1 receptor TEK Clinical trial target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational angiopoietin-1 receptor TEK NA inhibitor NA drugbank 2-heptyl-1(3)h-anthra[1,2-d]imidazole-6,11-dione NA NA investigative tert messenger rna TERT Successful target unknown NA TTD nsc-745886 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD nsc-745799 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[2-(isobutylamino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD nsc-745885 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD grnvac1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB vx-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB nsc-745888 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD kml-001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB dendritic cell vaccine NA Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Antigen-Presenting Cells[MeSHID:D000938] phase 2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB tertomotide biotech NA investigational telomerase reverse transcriptase TERT NA unknown NA drugbank tmpyp4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD dendritic cell vaccine NA Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Antigen-Presenting Cells[MeSHID:D000938],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB telob-vax NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB 2-methyl-1(3)h-anthrasimidazole-6,11-dione NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 7,8,3',4'-tetrahydroxyflavone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD imetelstat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Primary Myelofibrosis[MeSHID:D055728],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocythemia, Essential[MeSHID:D013920],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943] phase 2/3 telomerase reverse transcriptase TERT Clinical trial target inhibitor 8.68 TTD , DGIDB nsc-745795 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD cantide + cisplatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] investigative tert messenger rna TERT Successful target unknown NA TTD zidovudine small molecule Infection[MeSHID:D007239],Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved telomerase reverse transcriptase TERT NA inhibitor NA drugbank 2,3,7-trichloro-5-nitroquinoxaline (tnqx) NA NA investigative telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD 2,7-bis(benzoamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis(acetamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis(cyclohexanecarbonamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[3-(propylamino)propionamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown 5.79 TTD , DGIDB grn163 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB 2,7-bis(cyclopropanecarbonamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[3-(butylamino)propionamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD epithalon NA Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Vision[MeSHID:D014785] phase 1/2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB 1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one NA NA investigative tert messenger rna TERT Successful target unknown NA TTD nsc-745794 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[2-(butylamino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD nsc-745887 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,3-dimethylnaphtho[2,3-f]quinoxaline-7,12-dione NA NA investigative tert messenger rna TERT Successful target unknown NA TTD dendritic cell vaccine NA Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Antigen-Presenting Cells[MeSHID:D000938],Glioblastoma[MeSHID:D005909] phase 2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB 2,7-bis(chloroacetamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis(cyclopentanecarbonamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD gv1001 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 3 telomerase reverse transcriptase TERT Clinical trial target unknown 8.68 TTD , DGIDB nsc-745884 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD obp-301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of liver[MeSHID:D008113] phase 1/2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB 2-butyl-1(3)h-anthra[1,2-d]imidazole-6,11-dione NA NA investigative tert messenger rna TERT Successful target unknown NA TTD telomestatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] investigative telomerase reverse transcriptase TERT Clinical trial target unknown 5.79 TTD , DGIDB 2,7-bis[2-(piperidino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-dinitroantraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[3-(piperazino)propionamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown 5.79 TTD , DGIDB nsc-745798 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD nsc-745797 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[2-(dimethylamino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis(propionamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[2-(ethylamino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD lividomycin a NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis(phenylacetamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-diaminoanthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis(3-chloropropionamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD berberine NA NA phase 4 telomerase reverse transcriptase TERT Clinical trial target unknown 0.72 TTD , DGIDB 2,7-bis[2-(piperazino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[3-(piperidino)propionamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown 5.79 TTD , DGIDB aurasperone a NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[3-(pyrrolidino)propionamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown 5.79 TTD , DGIDB 2,7-bis[2-(propylamino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD doxorubicin NA Epithelial ovarian cancer[MeSHID:C538090],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Bronchogenic Carcinoma[MeSHID:D002283],Carcinoma[MeSHID:D002277],Urinary Bladder[MeSHID:D001743],Nephroblastoma[MeSHID:D009396],lymph nodes[MeSHID:D008198],Leukemia, Myelocytic, Acute[MeSHID:D015470],Thyroid carcinoma[MeSHID:D013964],Body tissue[MeSHID:D014024],Regression - mental defense mechanism[MeSHID:D012043],Lymphoma[MeSHID:D008223],Stomach[MeSHID:D013270],Osteosarcoma[MeSHID:D012516],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Neuroblastoma[MeSHID:D009447],Carcinoma, Transitional Cell[MeSHID:D002295],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved tert messenger rna TERT Successful target unknown NA TTD ppa NA NA investigative telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD fluorouracil NA Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Biliary tract structure[MeSHID:D001659],Cells[MeSHID:D002477],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Colon structure (body structure)[MeSHID:D003106],Pancreas[MeSHID:D010179],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Carcinoid Tumor[MeSHID:D002276],Rectum[MeSHID:D012007],Kidney[MeSHID:D007668],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] approved tert messenger rna TERT Successful target unknown NA TTD cb-10-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB 2,7-bis[2-(isopropylamino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD dendritic cell vaccine NA Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Antigen-Presenting Cells[MeSHID:D000938],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB 2,7-bis(4-chlorobutyramido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD nsc-745883 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD hoe-33258 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis[2-(pyrrolidino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD dc/i540/klh vaccine NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 telomerase reverse transcriptase TERT Clinical trial target unknown NA TTD , DGIDB 2,7-bis[3-(ethylamino)propionamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown 5.79 TTD , DGIDB imetelstat NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Primary Myelofibrosis[MeSHID:D055728],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Thrombocythemia, Essential[MeSHID:D013920],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant neoplasm of breast[MeSHID:D001943] phase 2/3 telomerase reverse transcriptase TERT Clinical trial target unknown 8.68 TTD , DGIDB 2,7-bis[2-(diethylamino)acetamido]anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis(butyramido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD 2,7-bis(phenylpropionamido)anthraquinone NA NA investigative tert messenger rna TERT Successful target unknown NA TTD nsc-745796 NA NA investigative tert messenger rna TERT Successful target unknown NA TTD grn163l small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Lymph[MeSHID:D008196] investigational telomerase reverse transcriptase TERT NA unknown NA drugbank pmid22902653c31 NA NA investigative testis-specific kinase 1 TESK1 Literature-reported target unknown NA TTD pmid22902653c30 NA NA investigative testis-specific kinase 1 TESK1 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity testis-specific protein kinase 1 TESK1 NA inhibitor NA drugbank pmid22902653c35 NA NA investigative testis-specific kinase 1 TESK1 Literature-reported target unknown NA TTD pmid22902653c31 NA NA investigative testis-specific kinase 2 TESK2 Literature-reported target unknown NA TTD pmid22902653c30 NA NA investigative testis-specific kinase 2 TESK2 Literature-reported target unknown NA TTD pmid22902653c35 NA NA investigative testis-specific kinase 2 TESK2 Literature-reported target unknown NA TTD silver small molecule Acne Vulgaris[MeSHID:D000152],Disease Management[MeSHID:D019468],Dental Health Services[MeSHID:D003752],Dental caries[MeSHID:D003731] approved,investigational metallothionein TESMIN NA binder NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved serotransferrin TF NA unknown NA drugbank cisplatin small molecule ovarian neoplasm[MeSHID:D010051],Testicular Neoplasms[MeSHID:D013736],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Osteosarcoma[MeSHID:D012516] approved serotransferrin TF NA unknown NA drugbank manganese small molecule Plasma[MeSHID:D010949],Solutions[MeSHID:D012996],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283] approved,nutraceutical serotransferrin TF NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved serotransferrin TF NA unknown NA drugbank aluminium phosphate small molecule NA approved,investigational serotransferrin TF NA unknown NA drugbank aluminum acetate small molecule NA approved,investigational serotransferrin TF NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational serotransferrin TF NA ligand NA drugbank isoflurophate small molecule Glaucoma[MeSHID:D005901],Esotropia[MeSHID:D004948],Disorder of eye[MeSHID:D005128],Eye[MeSHID:D005123],Visual Accommodation[MeSHID:D000065],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ocular Hypertension[MeSHID:D009798] approved,investigational,withdrawn serotransferrin TF NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational serotransferrin TF NA unknown NA drugbank calaa-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 transferrin TF Clinical trial target unknown NA TTD , DGIDB ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved serotransferrin TF NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational serotransferrin TF NA unknown NA drugbank dichlorvos small molecule NA vet_approved serotransferrin TF NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental serotransferrin TF NA ligand NA drugbank ep-2167 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical transferrin TF Clinical trial target unknown NA TTD , DGIDB aluminium small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperhidrosis disorder[MeSHID:D006945] approved,investigational serotransferrin TF NA unknown NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved serotransferrin TF NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational serotransferrin TF NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved serotransferrin TF NA unknown NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved serotransferrin TF NA unknown NA drugbank raloxifene small molecule Osteopenia[MeSHID:D001851],Malignant neoplasm of breast[MeSHID:D001943],Osteoporosis[MeSHID:D010024],Osteoporosis, Postmenopausal[MeSHID:D015663],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational trefoil factor 1 TFF1 NA unknown NA drugbank afimoxifene small molecule Gynecomastia[MeSHID:D006177],Mastodynia[MeSHID:D059373],Breast Diseases[MeSHID:D001941],Keloid[MeSHID:D007627],Menstrual cycle[MeSHID:D008597],Breast Fibrocystic Disease[MeSHID:D005348],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ductal Carcinoma[MeSHID:D044584],Malignant neoplasm of breast[MeSHID:D001943] investigational trefoil factor 1 TFF1 NA unknown NA drugbank ag-013 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Oral Mucositis[MeSHID:D013280] phase 2/3 trefoil factor-1 TFF1 Clinical trial target unknown NA TTD , DGIDB pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational trefoil factor 2 TFF2 NA unknown NA drugbank coagulation factor viia recombinant human biotech Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved tissue factor pathway inhibitor TFPI NA unknown NA drugbank tifacogin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] phase 3 tissue factor pathway inhibitor TFPI Clinical trial target unknown 6.37 TTD , DGIDB bax-499 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia B[MeSHID:D002836] phase 1 tissue factor pathway inhibitor TFPI Clinical trial target unknown 6.37 TTD , DGIDB nn-7415 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174]VAJO NEUROHEPATOPATHY[MeSHID:C538344],Hemophilia B[MeSHID:D002836] phase 1 tissue factor pathway inhibitor TFPI Clinical trial target unknown NA TTD , DGIDB dalteparin small molecule Acute Disease[MeSHID:D000208],Malignant Neoplasms[MeSHID:D009369],Blood coagulation[MeSHID:D001777],Kidney Failure, Acute[MeSHID:D058186],Acute Coronary Syndrome[MeSHID:D054058],Angina, Unstable[MeSHID:D000789],Deep Vein Thrombosis[MeSHID:D020246],Lung diseases[MeSHID:D008171],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655] approved tissue factor pathway inhibitor TFPI NA inhibitor NA drugbank pf-06741086 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemophilia A[MeSHID:D006467] phase 3 tissue factor pathway inhibitor TFPI Clinical trial target unknown NA TTD andexanet alfa biotech Hemorrhage[MeSHID:D006470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194] approved,investigational tissue factor pathway inhibitor TFPI NA inhibitor NA drugbank ferric derisomaltose small molecule Iron deficiency anemia[MeSHID:D018798],Chronic Kidney Diseases[MeSHID:D051436] approved transferrin receptor TFR2 NA binder NA drugbank ferrous sulfate anhydrous small molecule Iron deficiency anemia[MeSHID:D018798] approved transferrin receptor TFR2 NA substrate NA drugbank ferrous succinate small molecule Iron deficiency anemia[MeSHID:D018798] approved transferrin receptor protein 1 TFRC NA unknown NA drugbank ferrous glycine sulfate small molecule Iron deficiency anemia[MeSHID:D018798] approved transferrin receptor protein 1 TFRC NA unknown NA drugbank ferrous sulfate anhydrous small molecule Iron deficiency anemia[MeSHID:D018798] approved transferrin receptor TFRC NA substrate NA drugbank ferrous gluconate small molecule Iron deficiency anemia[MeSHID:D018798] approved transferrin receptor protein 1 TFRC NA unknown NA drugbank ferrous ascorbate small molecule Iron deficiency anemia[MeSHID:D018798] approved transferrin receptor protein 1 TFRC NA unknown NA drugbank ferric cation small molecule Physical Dialysis[MeSHID:D003956],Serum[MeSHID:D044967],Chronic Kidney Diseases[MeSHID:D051436] approved transferrin receptor protein 1 TFRC NA agonist NA drugbank iron small molecule Iron deficiency anemia[MeSHID:D018798],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transferrin receptor protein 1 TFRC NA unknown NA drugbank ferric derisomaltose small molecule Iron deficiency anemia[MeSHID:D018798],Chronic Kidney Diseases[MeSHID:D051436] approved transferrin receptor TFRC NA binder NA drugbank ferrous fumarate small molecule Iron deficiency anemia[MeSHID:D018798] approved transferrin receptor protein 1 TFRC NA unknown NA drugbank tetraferric tricitrate decahydrate small molecule Physical Dialysis[MeSHID:D003956],Iron deficiency anemia[MeSHID:D018798],Serum[MeSHID:D044967],Chronic Kidney Diseases[MeSHID:D051436] approved transferrin receptor protein 1 TFRC NA ligand NA drugbank ly3016859 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Kidney Diseases[MeSHID:D051436] phase 1/2 transforming growth factor alpha TGFA Clinical trial target unknown NA TTD , DGIDB ly2157299 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Arteriosclerosis[MeSHID:D001161],Liver carcinoma[MeSHID:D006528],Pancreatic carcinoma[MeSHID:C562463],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 2/3 transforming growth factor beta 1 TGFB1 Successful target unknown NA TTD , DGIDB foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved transforming growth factor beta-1 TGFB1 NA agonist NA drugbank hyaluronidase (ovine) biotech Pharmacy Distribution[MeSHID:D010594],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational transforming growth factor beta-1 TGFB1 NA inhibitor NA drugbank disitertide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 2 transforming growth factor beta 1 TGFB1 Successful target unknown 3.44 TTD , DGIDB abbv-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 transforming growth factor beta 1 TGFB1 Successful target unknown NA TTD foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved transforming growth factor beta-1 TGFB1 NA agonist NA drugbank pirfenidone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Idiopathic Pulmonary Fibrosis[MeSHID:D054990],Hamman-Rich syndrome[MeSHID:D011658] approved transforming growth factor beta 1 TGFB1 Successful target unknown 0.74 TTD , DGIDB terazosin small molecule Hypertensive disease[MeSHID:D006973],Benign Prostatic Hyperplasia[MeSHID:D011470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transforming growth factor beta-1 TGFB1 NA inducer NA drugbank tg-c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] phase 3 transforming growth factor beta 1 TGFB1 Successful target unknown NA TTD , DGIDB srk-181 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 transforming growth factor beta 1 TGFB1 Successful target unknown NA TTD hyaluronidase (human recombinant) biotech NA approved,investigational transforming growth factor beta-1 TGFB1 NA inhibitor NA drugbank mannose phosphate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 transforming growth factor beta 1 TGFB1 Successful target unknown NA TTD art-144 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative transforming growth factor beta 1 TGFB1 Successful target unknown NA TTD hyaluronidase biotech NA approved transforming growth factor beta-1 TGFB1 NA inhibitor NA drugbank ranagengliotucel-t NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 tgf beta-2 messenger rna TGFB2 Clinical trial target unknown NA TTD belagenpumatucel-l NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Small cell carcinoma of lung[MeSHID:D055752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 tgf beta-2 messenger rna TGFB2 Clinical trial target unknown 15.91 TTD , DGIDB lerdelimumab NA NA investigative transforming growth factor beta 2 TGFB2 Clinical trial target inhibitor 31.83 TTD , DGIDB ap12009 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 transforming growth factor beta 2 TGFB2 Clinical trial target unknown NA TTD , DGIDB trabedersen biotech Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of brain[MeSHID:D001932] investigational transforming growth factor beta-2 TGFB2 NA unknown 15.91 drugbank , DGIDB ot-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Occupational therapy regime[MeSHID:D009788],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Merkel cell carcinoma[MeSHID:D015266],Coronavirus Infections[MeSHID:D018352],Glioblastoma[MeSHID:D005909] phase 2/3 tgf beta-2 messenger rna TGFB2 Clinical trial target unknown NA TTD lerdelimumab NA NA investigative transforming growth factor beta 2 TGFB2 Clinical trial target unknown 31.83 TTD , DGIDB avotermin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sarcoidosis[MeSHID:D012507] phase 3 transforming growth factor beta 3 TGFB3 Clinical trial target unknown 31.83 TTD , DGIDB 1,4-dioxane small molecule NA experimental transforming growth factor beta-3 TGFB3 NA unknown NA drugbank pmid23639540c13r NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD ly2157299 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Arteriosclerosis[MeSHID:D001161],Liver carcinoma[MeSHID:D006528],Pancreatic carcinoma[MeSHID:C562463],Glioma[MeSHID:D005910],Malignant Neoplasms[MeSHID:D009369],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 2/3 tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD , DGIDB 4-pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD ptl-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD pf-06952229 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD ace-435 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cachexia[MeSHID:D002100] investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD ly3200882 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD , DGIDB 5''-quinolin-4-yl-[2,4'']bithiazolyl-2''-ylamine NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD tew-7197 NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Myeloproliferative disease[MeSHID:D009196],Malignant Neoplasms[MeSHID:D009369] phase 2 tgf-beta receptor type i TGFBR1 Clinical trial target unknown 6.06 TTD , DGIDB sd-208 NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target inhibitor NA TTD , DGIDB n-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1h-imidazol-2-yl]acetamide small molecule NA experimental tgf-beta receptor type-1 TGFBR1 NA unknown NA drugbank ly2109761 NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tgf-beta receptor type-1 TGFBR1 NA inhibitor NA drugbank p-2745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia, Chronic[MeSHID:D015464] phase 1 tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD , DGIDB pmid23639540c13d NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD hts-466284 NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target inhibitor 6.82 TTD , DGIDB 4-(3-pyridin-2-yl-1h-pyrazol-4-yl)quinoline small molecule NA experimental tgf-beta receptor type-1 TGFBR1 NA unknown NA drugbank sb-431542 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Fibrosis[MeSHID:D011658] preclinical tgf-beta receptor type i TGFBR1 Clinical trial target inhibitor 1.01 TTD , DGIDB 2-phenyl-n-(pyridin-4-yl)quinazolin-4-amine NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD 4-pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD wilvent NA Lung diseases[MeSHID:D008171],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD sb-525334 NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD sb-505124 NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD naphthyridine inhibitor small molecule NA experimental tgf-beta receptor type-1 TGFBR1 NA unknown NA drugbank 4-pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD in-1166 NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD gw-788388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD metelimumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595],Scleroderma[MeSHID:D012594] phase 1/2 tgf-beta receptor type i TGFBR1 Clinical trial target unknown 4.55 TTD , DGIDB in-1130 NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD 3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole small molecule NA experimental tgf-beta receptor type-1 TGFBR1 NA unknown NA drugbank tp-0184 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD ldn-214117 NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target inhibitor NA TTD , DGIDB pmid16539403c15b NA NA investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD tgf-beta shield NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD 2-(6-methylpyridin-2-yl)-n-pyridin-4-ylquinazolin-4-amine small molecule NA experimental tgf-beta receptor type-1 TGFBR1 NA unknown NA drugbank drp-049 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355] investigative tgf-beta receptor type i TGFBR1 Clinical trial target unknown NA TTD n-1h-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine small molecule NA experimental tgf-beta receptor type-1 TGFBR1 NA unknown NA drugbank foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved tgf-beta receptor type-2 TGFBR2 NA agonist NA drugbank pmid16539403c15b NA NA investigative tgf-beta receptor type ii TGFBR2 Clinical trial target unknown NA TTD tgf-br2 mab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tgf-beta receptor type ii TGFBR2 Clinical trial target unknown NA TTD , DGIDB pmid23639540c13a NA NA investigative tgf-beta receptor type ii TGFBR2 Clinical trial target unknown NA TTD ly2109761 NA NA investigative tgf-beta receptor type ii TGFBR2 Clinical trial target inhibitor NA TTD , DGIDB foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved tgf-beta receptor type-2 TGFBR2 NA agonist NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tgf-beta receptor type-2 TGFBR2 NA inhibitor NA drugbank pmid23639540c13d NA NA investigative tgf-beta receptor type ii TGFBR2 Clinical trial target unknown NA TTD pyrazolodiazepine derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB ntu281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney[MeSHID:D007668],Fibrosis[MeSHID:D005355] preclinical tissue transglutaminase TGM2 Preclinical target unknown NA TTD pmid26560530-compound-27 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB isothiocyanate derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB guanosine-5'-diphosphate small molecule NA experimental protein-glutamine gamma-glutamyltransferase 2 TGM2 NA unknown NA drugbank pmid26560530-compound-3 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-48 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-8 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB guanosine-5'-diphosphate NA NA investigative tissue transglutaminase TGM2 Preclinical target unknown NA TTD benzotriazole derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB azachalcone derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-4 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-23 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB dipeptide analog 3 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB acyl piperidine derivative 3 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-16 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-7 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-18 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB 3-acylidene-2-oxoindole derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB dipeptide analog 2 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB peptide analog 54 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-33 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-25 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB dihydroisoxazole derivative 2 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-15 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-32 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB dihydroisoxazole derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-50 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-13 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB peptide analog 52 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-6 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-24 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-34 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB chloroacetyl ester derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-54 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB dipeptide analog 4 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-17 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-46 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-14 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-26 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-11 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB acyl piperidine derivative 2 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-35 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-49 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB sulfonamide derivative 9 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-12 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-5 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB triazole derivative 1 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB 3-acylidene-2-oxoindole derivative 2 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-47 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB hexylresorcinol small molecule Malignant Neoplasms[MeSHID:D009369],Skin Diseases, Infectious[MeSHID:D012874],Burn injury[MeSHID:D002056],Aging[MeSHID:D000375],Pharyngitis[MeSHID:D010612],Pain[MeSHID:D010146] approved protein-glutamine gamma-glutamyltransferase 2 TGM2 NA inhibitor NA drugbank pmid26560530-compound-2 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB peptide analog 53 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB pmid26560530-compound-31 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB chalcone derivative 5 NA NA patented tissue transglutaminase TGM2 Preclinical target unknown NA TTD , DGIDB guanosine-5'-monophosphate small molecule NA experimental protein-glutamine gamma-glutamyltransferase e TGM3 NA unknown NA drugbank 5'-guanosine-diphosphate-monothiophosphate small molecule NA experimental protein-glutamine gamma-glutamyltransferase e TGM3 NA unknown NA drugbank b-2-octylglucoside small molecule NA experimental protein-glutamine gamma-glutamyltransferase e TGM3 NA unknown NA drugbank guanosine-5'-diphosphate small molecule NA experimental protein-glutamine gamma-glutamyltransferase e TGM3 NA unknown NA drugbank 3-chlorotyrosine NA NA investigative tyrosine 3-monooxygenase TH Successful target inhibitor NA TTD , DGIDB metyrosine small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Pheochromocytoma[MeSHID:D010673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine 3-monooxygenase TH Successful target binder,inhibitor 4.55 TTD , drugbank , DGIDB meta-tyrosine NA NA investigative tyrosine 3-monooxygenase TH Successful target unknown NA TTD tyrosine small molecule Narcolepsy[MeSHID:D009290],Fatigue[MeSHID:D005221] approved,investigational,nutraceutical tyrosine 3-monooxygenase TH NA binder NA drugbank metyrosine small molecule Disease Management[MeSHID:D019468],Operative Surgical Procedures[MeSHID:D013514],Pheochromocytoma[MeSHID:D010673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine 3-monooxygenase TH Successful target binder 4.55 TTD , drugbank , DGIDB phenylalanine small molecule Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866],Tardive Dyskinesia[MeSHID:D000071057],Vitiligo[MeSHID:D014820] approved,investigational,nutraceutical tyrosine 3-monooxygenase TH NA binder NA drugbank 3-tyrosine small molecule NA experimental tyrosine 3-monooxygenase TH NA unknown NA drugbank 7,8-dihydrobiopterin NA NA investigative tyrosine 3-monooxygenase TH Successful target unknown NA TTD l1-79 NA Autism Spectrum Disorders[MeSHID:D000067877],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pervasive Development Disorder[MeSHID:D002659] phase 2 tyrosine 3-monooxygenase TH Successful target unknown NA TTD 3-iodotyrosine NA NA investigative tyrosine 3-monooxygenase TH Successful target inhibitor NA TTD , DGIDB tetrahydrobiopterin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved tyrosine 3-monooxygenase TH Successful target unknown 3.41 TTD , DGIDB oxb-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 tyrosine 3-monooxygenase TH Successful target unknown NA TTD prosavin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 1/2 tyrosine 3-monooxygenase TH Successful target unknown NA TTD , DGIDB l-tyrosine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved tyrosine 3-monooxygenase TH Successful target unknown 31.83 TTD , DGIDB alpha-propyldopacetamide NA NA investigative tyrosine 3-monooxygenase TH Successful target unknown NA TTD sapropterin small molecule Malnutrition[MeSHID:D044342] approved,investigational tyrosine 3-monooxygenase TH NA cofactor NA drugbank l-erythro-7,8-dihydrobiopterin small molecule NA experimental tyrosine 3-monooxygenase TH NA unknown NA drugbank l-phenylalanine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved tyrosine 3-monooxygenase TH Successful target unknown 7.96 TTD , DGIDB dexibuprofen small molecule Ankylosing spondylitis[MeSHID:D013167],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thrombomodulin THBD NA modulator NA drugbank drotrecogin alfa biotech Severe Sepsis[MeSHID:D018805],Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn thrombomodulin THBD NA unknown NA drugbank ibuprofen small molecule Diuretic Effect[MeSHID:D004232],Cystic Fibrosis[MeSHID:D003550],Pregnancy, Prolonged[MeSHID:D011273],Pain[MeSHID:D010146],Platelet aggregation[MeSHID:D010974],Psychological inhibition[MeSHID:D007266],Pain, Postoperative[MeSHID:D010149],Body tissue[MeSHID:D014024],Rheumatoid Arthritis[MeSHID:D001172],Tension Headache[MeSHID:D018781],Fever[MeSHID:D005334],Malignant neoplasm of breast[MeSHID:D001943],Hypotension, Orthostatic[MeSHID:D007024],Migraine Disorders[MeSHID:D008881],Degenerative polyarthritis[MeSHID:D010003],Patent ductus arteriosus[MeSHID:D004374],Dental Health Services[MeSHID:D003752],Heart failure[MeSHID:D006333],Lung[MeSHID:D008168],Inflammation[MeSHID:D007249],Parkinson Disease[MeSHID:D010300],Descending aorta[MeSHID:D001013],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Chronic pain[MeSHID:D059350],Blood Vessel[MeSHID:D001808],Disease[MeSHID:D004194],Headache[MeSHID:D006261],Labor (Childbirth)[MeSHID:D007743],Pulmonary artery structure[MeSHID:D011651],Hypernatremia[MeSHID:D006955],Rheumatism[MeSHID:D012216],Toothache[MeSHID:D014098],Birth[MeSHID:D036801],Spondylitis[MeSHID:D013166],neutrophil[MeSHID:D009504],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thrombomodulin THBD NA inducer NA drugbank thrombomodulin NA Disseminated Intravascular Coagulation[MeSHID:D004211],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 thrombomodulin THBD Discontinued target unknown NA TTD cvx-045 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cervix Uteri[MeSHID:D002584] phase 2 thrombospondin-1 THBS1 Clinical trial target unknown NA TTD , DGIDB abt-510 NA Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 thrombospondin-1 THBS1 Clinical trial target unknown 1.99 TTD , DGIDB cvx-045 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cervix Uteri[MeSHID:D002584] phase 2 thrombospondin-1 THBS1 Clinical trial target antibody NA TTD , DGIDB bvi-007 NA Cerebrovascular accident[MeSHID:D020521],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombus[MeSHID:D013927],Myocardial Infarction[MeSHID:D009203] phase 1 thrombopoietin THPO Clinical trial target unknown NA TTD , DGIDB 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD tiratricol NA Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial thyroid hormone receptor alpha THRA Successful target agonist 2.55 TTD , DGIDB detrothyronine NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD levothyroxine small molecule Disease Management[MeSHID:D019468],Hypothyroidism[MeSHID:D007037],Thyroid Gland[MeSHID:D013961],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Hypothalamic structure[MeSHID:D007031],Cell Differentiation process[MeSHID:D002454],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyroid hormone receptor alpha THRA Successful target agonist 6.37 TTD , drugbank , DGIDB nrp409 small molecule Hypothyroidism[MeSHID:D007037],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] investigational thyroid hormone receptor alpha THRA NA unknown NA drugbank 4-hexylphenyl propiolate NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD thyroid, porcine biotech Thyroid Gland[MeSHID:D013961] approved thyroid hormone receptor alpha THRA NA substrate NA drugbank 3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD kb-141 small molecule NA experimental thyroid hormone receptor alpha THRA NA agonist NA drugbank , DGIDB dronedarone small molecule Disease Management[MeSHID:D019468],Atrial Fibrillation[MeSHID:D001281],pathologic fistula[MeSHID:D005402],Hospitalization[MeSHID:D006760],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyroid hormone receptor alpha THRA NA inhibitor NA drugbank (e)-1-(4-heptylphenyl)but-2-en-1-one NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD liotrix small molecule Disease Management[MeSHID:D019468],Hypothyroidism[MeSHID:D007037],Hashimoto Disease[MeSHID:D050031],Thyroid Gland[MeSHID:D013961],Bodily secretions[MeSHID:D012634],Thyroid carcinoma[MeSHID:D013964],Thyrotoxicosis[MeSHID:D013971],Neoplasm Metastasis[MeSHID:D009362],Hyperthyroidism[MeSHID:D006980],Goiter[MeSHID:D006042] approved thyroid hormone receptor alpha THRA NA agonist NA drugbank 4-(4-hexylphenyl)-4-oxobut-2-enoic acid NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD 1-(4-hexylphenyl)-3-morpholinopropan-1-one NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD rt3 NA NA investigative thyroid hormone receptor alpha THRA Successful target agonist NA TTD , DGIDB bct303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypothyroidism[MeSHID:D007037] phase 2 thyroid hormone receptor alpha THRA Successful target unknown NA TTD , DGIDB dextrothyroxine sodium NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyroid hormone receptor alpha THRA Successful target agonist 3.18 TTD , DGIDB 3-(3,5-dibromo-4-hexyloxy-phenyl)-propionic acid NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD dextrothyroxine small molecule Hypercholesterolemia[MeSHID:D006937] approved,investigational thyroid hormone receptor alpha THRA NA agonist 16.97 drugbank , DGIDB 3-bromo-1-(4-hexylphenyl)propan-1-one NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD tiratricol NA Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] clinical trial thyroid hormone receptor alpha THRA Successful target unknown 2.55 TTD , DGIDB eprotirome small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765],Hyperlipidemia[MeSHID:D006949],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] investigational thyroid hormone receptor alpha THRA NA unknown NA drugbank dextrothyroxine sodium NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyroid hormone receptor alpha THRA Successful target unknown NA TTD , DGIDB (z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD liothyronine small molecule Disease Management[MeSHID:D019468],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Thyroid carcinoma[MeSHID:D013964],Hyperthyroidism[MeSHID:D006980],Constipation[MeSHID:D003248],Desiccation[MeSHID:D003890],Pituitary Diseases[MeSHID:D010900],Pallor[MeSHID:D010167],Term Birth[MeSHID:D047929],Hypothyroidism[MeSHID:D007037],Thyroid Gland[MeSHID:D013961],Endemic goiter[MeSHID:D006043],Neoplasm Metastasis[MeSHID:D009362],Hypothalamic structure[MeSHID:D007031],Plasma[MeSHID:D010949],Subacute thyroiditis[MeSHID:D013968],Voice[MeSHID:D014831],Hair[MeSHID:D006197],Lethargy[MeSHID:D053609],Drowsiness[MeSHID:D012894],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,vet_approved thyroid hormone receptor alpha THRA Successful target agonist 7.96 TTD , drugbank , DGIDB (3,5-dibromo-4-hexyloxy-phenyl)-acetic acid NA NA investigative thyroid hormone receptor alpha THRA Successful target unknown NA TTD bct303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypothyroidism[MeSHID:D007037] phase 2 thyroid hormone receptor beta THRB Successful target unknown NA TTD , DGIDB 2-[4-(4-hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-2h-[1,2,4]triazine-3,5-dione small molecule NA experimental thyroid hormone receptor beta THRB NA unknown NA drugbank 1-(4-heptylphenyl)prop-2-en-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD cacodylate ion NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD [3,5-dibromo-4-(4-hydroxy-3-phenethylcarbamoyl-phenoxy)-phenyl]-acetic acid small molecule NA experimental thyroid hormone receptor beta THRB NA unknown NA drugbank levothyroxine small molecule Disease Management[MeSHID:D019468],Hypothyroidism[MeSHID:D007037],Thyroid Gland[MeSHID:D013961],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Thyroid carcinoma[MeSHID:D013964],Neoplasm Metastasis[MeSHID:D009362],Hypothalamic structure[MeSHID:D007031],Cell Differentiation process[MeSHID:D002454],Pituitary Diseases[MeSHID:D010900],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyroid hormone receptor beta THRB NA agonist 0.58 drugbank , DGIDB 3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD axitirome NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 1 thyroid hormone receptor beta THRB Successful target unknown 1.3 TTD , DGIDB 4-(4-hexylphenyl)-4-oxobut-2-enoic acid NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD 1-(4-hexylphenyl)-3-morpholinopropan-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD 4-hexylphenyl propiolate NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD (3,5-dibromo-4-butoxy-phenyl)-acetic acid NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD mb07811 small molecule Hyperlipidemia[MeSHID:D006949] investigational thyroid hormone receptor beta THRB NA unknown 2.6 drugbank , DGIDB 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD 4-(3-(dimethylamino)propanoyl)-n-hexylbenzamide NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD vk-2809 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 thyroid hormone receptor beta THRB Successful target unknown NA TTD , DGIDB zyt-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lipid Metabolism Disorders[MeSHID:D052439] phase 1 thyroid hormone receptor beta THRB Successful target unknown NA TTD , DGIDB eprotirome small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765],Hyperlipidemia[MeSHID:D006949],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] investigational thyroid hormone receptor beta THRB NA unknown 1.95 drugbank , DGIDB 1-(4-hexylphenyl)-3-(propylamino)propan-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD 3-bromo-1-(4-hexylphenyl)propan-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD (4-hexylphenyl)(oxiran-2-yl)methanone NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD (e)-1-(4-heptylphenyl)but-2-en-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD mgl-3196 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Hypercholesterolemia, Familial[MeSHID:D006938] phase 2 thyroid hormone receptor beta THRB Successful target unknown 1.95 TTD , DGIDB gc-24 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperthyroidism[MeSHID:D006980] experimental,investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD , drugbank 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD mb-07811 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] phase 2 thyroid hormone receptor beta THRB Successful target unknown 2.6 TTD , DGIDB eprotirome small molecule Metabolic Diseases[MeSHID:D008659],Obesity[MeSHID:D009765],Hyperlipidemia[MeSHID:D006949],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiovascular Diseases[MeSHID:D002318] investigational thyroid hormone receptor beta THRB NA agonist 1.95 drugbank , DGIDB (3,5-dibromo-4-hexyloxy-phenyl)-acetic acid NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD liotrix small molecule Disease Management[MeSHID:D019468],Hypothyroidism[MeSHID:D007037],Hashimoto Disease[MeSHID:D050031],Thyroid Gland[MeSHID:D013961],Bodily secretions[MeSHID:D012634],Thyroid carcinoma[MeSHID:D013964],Thyrotoxicosis[MeSHID:D013971],Neoplasm Metastasis[MeSHID:D009362],Hyperthyroidism[MeSHID:D006980],Goiter[MeSHID:D006042] approved thyroid hormone receptor beta THRB NA agonist NA drugbank (3,5-dibromo-4-pentyloxy-phenyl)-acetic acid NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD sobetirome small molecule NA investigational thyroid hormone receptor beta THRB NA unknown 0.97 drugbank , DGIDB 1-(4-(hexyloxy)phenyl)-3-morpholinopropan-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD detrothyronine NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD 1-(4-octylphenyl)prop-2-en-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD dextrothyroxine sodium NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyroid hormone receptor beta THRB Successful target unknown NA TTD , DGIDB kb-141 small molecule NA experimental thyroid hormone receptor beta THRB NA agonist NA drugbank , DGIDB liothyronine small molecule Disease Management[MeSHID:D019468],Pituitary Gland[MeSHID:D010902],Operative Surgical Procedures[MeSHID:D013514],Thyroid carcinoma[MeSHID:D013964],Hyperthyroidism[MeSHID:D006980],Constipation[MeSHID:D003248],Desiccation[MeSHID:D003890],Pituitary Diseases[MeSHID:D010900],Pallor[MeSHID:D010167],Term Birth[MeSHID:D047929],Hypothyroidism[MeSHID:D007037],Thyroid Gland[MeSHID:D013961],Endemic goiter[MeSHID:D006043],Neoplasm Metastasis[MeSHID:D009362],Hypothalamic structure[MeSHID:D007031],Plasma[MeSHID:D010949],Subacute thyroiditis[MeSHID:D013968],Voice[MeSHID:D014831],Hair[MeSHID:D006197],Lethargy[MeSHID:D053609],Drowsiness[MeSHID:D012894],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,vet_approved thyroid hormone receptor beta THRB NA agonist 0.89 drugbank , DGIDB rt3 NA NA investigative thyroid hormone receptor beta THRB Successful target agonist NA TTD , DGIDB mgl-3196 NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949],Hypercholesterolemia, Familial[MeSHID:D006938] phase 2 thyroid hormone receptor beta THRB Successful target agonist 1.95 TTD , DGIDB 1-(4-hexylphenyl)prop-2-en-1-one small molecule NA experimental,investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD , drugbank mb07811 small molecule Hyperlipidemia[MeSHID:D006949] investigational thyroid hormone receptor beta THRB NA agonist 2.6 drugbank , DGIDB 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD dextrothyroxine small molecule Hypercholesterolemia[MeSHID:D006937] approved,investigational thyroid hormone receptor beta THRB NA agonist 1.95 drugbank , DGIDB sobetirome small molecule NA investigational thyroid hormone receptor beta THRB NA agonist 0.97 drugbank , DGIDB tiratricol small molecule Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,clinical trial thyroid hormone receptor beta THRB Successful target agonist 0.52 TTD , drugbank , DGIDB tiratricol small molecule Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,clinical trial thyroid hormone receptor beta THRB Successful target unknown 0.52 TTD , drugbank , DGIDB 3-(3,5-dibromo-4-hexyloxy-phenyl)-propionic acid NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD 2-hexylphenyl acrylate NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD thyroid, porcine biotech Thyroid Gland[MeSHID:D013961] approved thyroid hormone receptor beta THRB NA substrate NA drugbank dextrothyroxine sodium NA Hypercholesterolemia[MeSHID:D006937],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyroid hormone receptor beta THRB Successful target agonist 0.32 TTD , DGIDB (z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid NA NA investigative thyroid hormone receptor beta THRB Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase receptor tie-1 TIE1 NA inhibitor NA drugbank sea-tgt NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 v-set and immunoglobulin domain-containing protein 9 TIGIT Clinical trial target unknown NA TTD m6223 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 v-set and immunoglobulin domain-containing protein 9 TIGIT Clinical trial target unknown NA TTD ab154 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 v-set and immunoglobulin domain-containing protein 9 TIGIT Clinical trial target unknown NA TTD ociperlimab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],cervical cancer[MeSHID:D002583] phase 3 v-set and immunoglobulin domain-containing protein 9 TIGIT Clinical trial target unknown NA TTD asp8374 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 v-set and immunoglobulin domain-containing protein 9 TIGIT Clinical trial target unknown 63.65 TTD , DGIDB com902 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 v-set and immunoglobulin domain-containing protein 9 TIGIT Clinical trial target unknown NA TTD pimagedine small molecule Diabetic Nephropathy[MeSHID:D003928] investigational metalloproteinase inhibitor 3 TIMP3 NA unknown NA drugbank rbn-2397 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 protein mono-adp-ribosyltransferase tiparp TIPARP Clinical trial target unknown NA TTD 6-hydroxypropylthymine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD deoxythymidine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 9-(4-hydroxybutyl)-n2-phenylguanine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD ad-oc-hsvtk/valacyclovir NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 thymidine kinase 1 TK1 Successful target unknown NA TTD , DGIDB 9-hydroxypropyladenine, s-isomer NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD (south)-methanocarba-thymidine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 3-(2-propyn-1-yl)thymidine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD sitimagene ceradenovec NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 3 thymidine kinase 1 TK1 Successful target unknown NA TTD itdu NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 1-[7-(triphenylmethoxy)heptyl]thymine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy NA Adenovirus Infections[MeSHID:D000257],Suicide[MeSHID:D013405],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 thymidine kinase 1 TK1 Successful target unknown NA TTD , DGIDB rp101 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 2/3 thymidine kinase 1 TK1 Successful target unknown NA TTD 5-propyl-2'-deoxyuridine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 2'-deoxyuridine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD thymidine-5'-phosphate NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD bvdu-mp NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 9-hydroxypropyladenine, r-isomer NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 5-iodo-2'-deoxyuridine-5'-monophosphate NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD dithioerythritol small molecule NA experimental thymidine kinase, cytosolic TK1 NA unknown NA drugbank 3'-(1,2,3-triazol-1-yl)-3'-deoxy-beta-d-thymidine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD penciclovir NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Herpes Labialis[MeSHID:D006560],Disease[MeSHID:D004194],Recurrence (disease attribute)[MeSHID:D012008],Coronavirus Infections[MeSHID:D018352] approved thymidine kinase 1 TK1 Successful target unknown 10.61 TTD , DGIDB rilapladib NA Atherosclerosis[MeSHID:D050197],Cardiovascular Diseases[MeSHID:D002318],Arteriosclerosis[MeSHID:D001161],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 thymidine kinase 1 TK1 Successful target unknown 3.54 TTD , DGIDB l-5-iodo-2'-deoxyuridine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD n2-(3-trifluoromethylphenyl)guanine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD hqk-1004 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 thymidine kinase 1 TK1 Successful target unknown 10.61 TTD , DGIDB fv-100 NA Chickenpox[MeSHID:D002644],Herpes zoster disease[MeSHID:D006562],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 thymidine kinase 1 TK1 Successful target unknown 10.61 TTD , DGIDB tk-dli NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Graft-vs-Host Disease[MeSHID:D006086] preregistration thymidine kinase 1 TK1 Successful target unknown NA TTD , DGIDB 2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD edoxudine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 1-[6-(triphenylmethoxy)hexyl]thymine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD l-5-(bromovinyl)deoxyuridine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD penciclovir NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved thymidine kinase 1 TK1 Successful target unknown 10.61 TTD , DGIDB 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 2'-deoxythymidine triphosphate NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 5-bromothienyldeoxyuridine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 1-[(z)-4-(triphenylmethoxy)-2-butenyl]thymine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD deoxycytidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] approved thymidine kinase 1 TK1 Successful target unknown 2.65 TTD , DGIDB p1-(5'-adenosyl)p5-(5'-thymidyl)pentaphosphate NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD radiosensitizer gene therapy NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 3 thymidine kinase 1 TK1 Successful target unknown NA TTD , DGIDB thymidine 5'-triphosphate small molecule NA experimental thymidine kinase, cytosolic TK1 NA unknown NA drugbank 1-[5-(triphenylmethoxy)pentyl]thymine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 6-(dihydroxy-isobutyl)-thymine NA NA investigative thymidine kinase 1 TK1 Successful target unknown NA TTD 2'-deoxycytidine small molecule NA experimental,investigational thymidine kinase 2, mitochondrial TK2 NA unknown NA drugbank brivudine small molecule NA approved,investigational thymidine kinase 2, mitochondrial TK2 NA substrate NA drugbank thymidine small molecule NA experimental,investigational thymidine kinase 2, mitochondrial TK2 NA unknown NA drugbank thymidine 5'-triphosphate small molecule NA experimental thymidine kinase 2, mitochondrial TK2 NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational transketolase TKT NA unknown NA drugbank 1-methoxy-2-[2-(2-methoxy-ethoxy]-ethane NA NA investigative transketolase TKT Literature-reported target unknown NA TTD pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical alanine-glyoxylate aminotransferase homolog TLH6 NA cofactor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase tousled-like 1 TLK1 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase tousled-like 2 TLK2 NA inhibitor NA drugbank methyl n-{[(1r)-1-({1-[(benzyloxy)carbonyl]-l-prolyl-6-ammonio-l-norleucyl}amino)-2-phenylethyl](hydroxy)phosphoryl}-l-alanyl-l-prolinate small molecule NA experimental tolloid-like protein 2 TLL2 NA unknown NA drugbank f-50040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] discontinued in phase 1 toll-like receptor 2 TLR2 Clinical trial target unknown NA TTD lyme disease vaccine (recombinant ospa) biotech Lyme Disease[MeSHID:D008193] approved,withdrawn toll-like receptor 2 TLR2 NA unknown NA drugbank s-(dimethylarsenic)cysteine small molecule NA experimental,investigative toll-like receptor 2 TLR2 Clinical trial target unknown NA TTD , drugbank mcs-18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 2 toll-like receptor 2 TLR2 Clinical trial target unknown NA TTD , DGIDB cadi-05 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 toll-like receptor 2 TLR2 Clinical trial target unknown NA TTD , DGIDB malp-2s NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1/2 toll-like receptor 2 TLR2 Clinical trial target unknown NA TTD , DGIDB lipoteichoic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 toll-like receptor 2 TLR2 Clinical trial target unknown NA TTD , DGIDB opn-305 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 toll-like receptor 2 TLR2 Clinical trial target unknown 31.83 TTD , DGIDB tuberculin purified protein derivative biotech Communicable Diseases[MeSHID:D003141],Diagnosis[MeSHID:D003933],Infection[MeSHID:D007239] approved toll-like receptor 2 TLR2 NA ligand NA drugbank om-174 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 2 TLR2 Clinical trial target unknown NA TTD , DGIDB cblb-612 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Radiation Syndrome[MeSHID:D011832] investigative toll-like receptor 2 TLR2 Clinical trial target unknown NA TTD adapalene small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved toll-like receptor 2 TLR2 NA antagonist NA drugbank golotimod small molecule Parasitic Diseases[MeSHID:D010272],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141],Hepatitis[MeSHID:D006505],Tuberculosis[MeSHID:D014376],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Immune System Diseases[MeSHID:D007154] investigational toll-like receptor 2 TLR2 NA unknown NA drugbank rintatolimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 3 toll-like receptor 3 TLR3 Clinical trial target unknown 31.83 TTD , DGIDB poly-iclc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Malignant Neoplasms[MeSHID:D009369],Glioblastoma[MeSHID:D005909] phase 2 toll-like receptor 3 TLR3 Clinical trial target unknown 15.91 TTD , DGIDB rintatolimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 3 toll-like receptor 3 TLR3 Clinical trial target agonist 31.83 TTD , DGIDB poly ic-poly arginine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Keratosis[MeSHID:D007642] investigative toll-like receptor 3 TLR3 Clinical trial target unknown NA TTD anti-tlr3 mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative toll-like receptor 3 TLR3 Clinical trial target unknown NA TTD poly-icr NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623],Keratosis[MeSHID:D007642] investigative toll-like receptor 3 TLR3 Clinical trial target unknown NA TTD bcg65-e7 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Anus Neoplasms[MeSHID:D001005] discontinued in phase 3 toll-like receptor 3 TLR3 Clinical trial target unknown NA TTD rintatolimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Chronic Fatigue Syndrome[MeSHID:D015673],Disease[MeSHID:D004194] phase 3 toll-like receptor 3 TLR3 Clinical trial target unknown 31.83 TTD , DGIDB rintatolimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Chronic Fatigue Syndrome[MeSHID:D015673],Disease[MeSHID:D004194] phase 3 toll-like receptor 3 TLR3 Clinical trial target agonist 31.83 TTD , DGIDB polyic NA NA investigative toll-like receptor 3 TLR3 Clinical trial target unknown NA TTD myristic acid small molecule NA experimental,investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , drugbank cadi-05 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB fibronectin extra domain a NA NA investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD mpl-containing pollinex allergy desensitization vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Allergic Reaction[MeSHID:D006967] preregistration toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB ni-0101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 1 toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB cs-4771 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 1 toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD resatorvid NA Sepsis[MeSHID:D018805],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 toll-like receptor 4 TLR4 Clinical trial target antagonist 17.36 TTD , DGIDB (r)-3-hydroxytetradecanoic acid small molecule NA experimental toll-like receptor 4 TLR4 NA unknown NA drugbank crx-526 NA NA investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD lauric acid small molecule NA approved,experimental,investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , drugbank e5531 small molecule Sepsis[MeSHID:D018805] investigational toll-like receptor 4 TLR4 NA unknown NA drugbank 6-(2-aminophenoxy)benzo[d]isothiazol-3-amine NA NA investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD mpl-containing pollinex allergy desensitization vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] preregistration toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB mifamurtide small molecule Operative Surgical Procedures[MeSHID:D013514],Osteosarcoma[MeSHID:D012516],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,experimental toll-like receptor 4 TLR4 NA ligand NA drugbank gsk1795091 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB eritoran small molecule Sepsis[MeSHID:D018805],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 3 toll-like receptor 4 TLR4 Clinical trial target unknown 23.15 TTD , drugbank , DGIDB 3-hydroxy-myristic acid NA NA investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD trimixdc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD om-294-dp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD cyclobenzaprine small molecule Spinal Cord Diseases[MeSHID:D013118],Spasm[MeSHID:D013035],Fibromyalgia[MeSHID:D005356],Cerebral Palsy[MeSHID:D002547],Muscle Spasticity[MeSHID:D009128],Sleep Disorders[MeSHID:D012893],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved toll-like receptor 4 TLR4 NA inhibitor NA drugbank crx-675 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB om-197-mp-ac NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD papain small molecule NA approved toll-like receptor 4 TLR4 NA activator NA drugbank naloxone small molecule Pruritus[MeSHID:D011537],Depressive disorder[MeSHID:D003866],Opiate Addiction[MeSHID:D009293],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Off-Label Use[MeSHID:D056687],Mental Depression[MeSHID:D003863],Pain[MeSHID:D010146],Septic Shock[MeSHID:D012772],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Depression[MeSHID:D012131] approved,vet_approved toll-like receptor 4 TLR4 NA inhibitor NA drugbank om-174 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB golotimod small molecule Parasitic Diseases[MeSHID:D010272],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141],Hepatitis[MeSHID:D006505],Tuberculosis[MeSHID:D014376],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Immune System Diseases[MeSHID:D007154] investigational toll-like receptor 4 TLR4 NA unknown NA drugbank resatorvid NA Sepsis[MeSHID:D018805],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 toll-like receptor 4 TLR4 Clinical trial target unknown 17.36 TTD , DGIDB g100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228] phase 2 toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB mpl-containing pollinex allergy desensitization vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787],Allergic Reaction[MeSHID:D006967] preregistration toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD , DGIDB as04 NA NA investigative toll-like receptor 4 TLR4 Clinical trial target unknown NA TTD entolimod NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Radiation Syndrome[MeSHID:D011832] phase 1 toll-like receptor 5 TLR5 Clinical trial target agonist 63.65 TTD , DGIDB cblb-502 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Radiation Syndrome[MeSHID:D054508] phase 2 toll-like receptor 5 TLR5 Clinical trial target unknown 63.65 TTD , DGIDB entolimod NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Radiation Syndrome[MeSHID:D011832] phase 1 toll-like receptor 5 TLR5 Clinical trial target unknown 63.65 TTD , DGIDB malp-2s NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463] phase 1/2 toll-like receptor 6 TLR6 Clinical trial target unknown NA TTD , DGIDB pf-4878691 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 toll-like receptor 7 TLR7 Successful target unknown 5.3 TTD , DGIDB gsk2245035 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 toll-like receptor 7 TLR7 Successful target agonist 10.61 TTD , DGIDB cv8102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Squamous cell carcinoma[MeSHID:D002294],melanoma[MeSHID:D008545] phase 1 toll-like receptor 7 TLR7 Successful target unknown NA TTD loxoribine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] phase 2 toll-like receptor 7 TLR7 Successful target agonist 10.61 TTD , DGIDB nktr-262 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 1/2 toll-like receptor 7 TLR7 Successful target unknown NA TTD , DGIDB hydroxychloroquine small molecule Rheumatoid Arthritis[MeSHID:D001172],Lupus Erythematosus, Discoid[MeSHID:D008179],Malaria[MeSHID:D008288], Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved toll-like receptor 7 TLR7 Successful target antagonist 2.89 TTD , drugbank , DGIDB rg7854 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 toll-like receptor 7 TLR7 Successful target unknown NA TTD resiquimod small molecule Genital Herpes[MeSHID:D006558],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Actinic keratosis[MeSHID:D055623],Herpes Simplex Infections[MeSHID:D006561] investigational,phase 2 toll-like receptor 7 TLR7 Successful target agonist 10.61 TTD , drugbank , DGIDB lhc165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 7 TLR7 Successful target unknown NA TTD imiquimod small molecule Condylomata Acuminata[MeSHID:D003218],Scalp structure[MeSHID:D012535],Actinic keratosis[MeSHID:D055623],Immunocompetence[MeSHID:D007121],Reproduction[MeSHID:D012098],Warts[MeSHID:D014860],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of skin[MeSHID:D012878] approved,investigational toll-like receptor 7 TLR7 Successful target agonist 22.99 TTD , drugbank , DGIDB gsk2245035 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 toll-like receptor 7 TLR7 Successful target unknown 10.61 TTD , DGIDB azd-8848 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 toll-like receptor 7 TLR7 Successful target unknown 10.61 TTD , DGIDB medi9197 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 7 TLR7 Successful target unknown 2.65 TTD , DGIDB rg6115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] phase 1 toll-like receptor 7 TLR7 Successful target unknown NA TTD bnt411 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] phase 1/2 toll-like receptor 7 TLR7 Successful target unknown NA TTD afimetoran small molecule NA investigational toll-like receptor 7 TLR7 NA antagonist NA drugbank ana-975 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] discontinued in phase 1 toll-like receptor 7 TLR7 Successful target unknown NA TTD im0-8400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] discontinued in phase 1/2 toll-like receptor 7 TLR7 Successful target unknown NA TTD , DGIDB gs-9620 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 2 toll-like receptor 7 TLR7 Successful target unknown 5.3 TTD , DGIDB cpg 52364 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 toll-like receptor 7 TLR7 Successful target unknown NA TTD , DGIDB loxoribine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] phase 2 toll-like receptor 7 TLR7 Successful target unknown 10.61 TTD , DGIDB rg-7795 small molecule Neoplasms[MeSHID:D009369] investigational toll-like receptor 7 TLR7 NA unknown NA drugbank tmx-30x NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative toll-like receptor 7 TLR7 Successful target unknown NA TTD tmx-202 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] investigative toll-like receptor 7 TLR7 Successful target unknown NA TTD dsp-0509 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 toll-like receptor 7 TLR7 Successful target unknown NA TTD , DGIDB dv-1179 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Autoimmune Diseases[MeSHID:D001327] phase 1 toll-like receptor 7 TLR7 Successful target unknown NA TTD , DGIDB imo-3100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Diabetes, Autoimmune[MeSHID:D003922] phase 2 toll-like receptor 7 TLR7 Successful target unknown NA TTD , DGIDB isatoribine small molecule Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,phase 2 toll-like receptor 7 TLR7 Successful target unknown 10.61 TTD , drugbank , DGIDB hydroxychloroquine small molecule Rheumatoid Arthritis[MeSHID:D001172],Lupus Erythematosus, Discoid[MeSHID:D008179],Malaria[MeSHID:D008288], Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved toll-like receptor 7 TLR7 Successful target antagonist 2.89 TTD , drugbank , DGIDB tmx-201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative toll-like receptor 7 TLR7 Successful target unknown NA TTD ana773 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2a toll-like receptor 7 TLR7 Successful target unknown NA TTD , DGIDB resiquimod small molecule Genital Herpes[MeSHID:D006558],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Actinic keratosis[MeSHID:D055623],Herpes Simplex Infections[MeSHID:D006561] investigational,phase 2 toll-like receptor 7 TLR7 Successful target unknown 10.61 TTD , drugbank , DGIDB golotimod small molecule Parasitic Diseases[MeSHID:D010272],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141],Hepatitis[MeSHID:D006505],Tuberculosis[MeSHID:D014376],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Immune System Diseases[MeSHID:D007154] investigational toll-like receptor 7 TLR7 NA unknown NA drugbank ana971 small molecule Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational toll-like receptor 7 TLR7 NA unknown NA drugbank resiquimod small molecule Genital Herpes[MeSHID:D006558],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Actinic keratosis[MeSHID:D055623],Herpes Simplex Infections[MeSHID:D006561] investigational,phase 2 toll-like receptor 8 TLR8 Clinical trial target unknown 25.46 TTD , drugbank , DGIDB nktr-262 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 1/2 toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD , DGIDB selgantolimod NA Hepatitis B[MeSHID:D006509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 toll-like receptor 8 TLR8 Clinical trial target agonist 12.73 TTD , DGIDB vtx-1463 NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD , DGIDB vtx-744 NA NA investigative toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD afimetoran small molecule NA investigational toll-like receptor 8 TLR8 NA antagonist NA drugbank imiquimod small molecule Condylomata Acuminata[MeSHID:D003218],Scalp structure[MeSHID:D012535],Actinic keratosis[MeSHID:D055623],Immunocompetence[MeSHID:D007121],Reproduction[MeSHID:D012098],Warts[MeSHID:D014860],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of skin[MeSHID:D012878] approved,investigational toll-like receptor 8 TLR8 NA agonist NA drugbank im0-8400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] discontinued in phase 1/2 toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD , DGIDB cpg 52364 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD , DGIDB sbt6050 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD vtx-763 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD vtx-2337 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] discontinued in phase 2 toll-like receptor 8 TLR8 Clinical trial target unknown 38.19 TTD , DGIDB medi9197 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 8 TLR8 Clinical trial target unknown 6.37 TTD , DGIDB odn-1411 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD dn1508052 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD resiquimod small molecule Genital Herpes[MeSHID:D006558],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Actinic keratosis[MeSHID:D055623],Herpes Simplex Infections[MeSHID:D006561] investigational,phase 2 toll-like receptor 8 TLR8 Clinical trial target agonist 25.46 TTD , drugbank , DGIDB cv8102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Squamous cell carcinoma[MeSHID:D002294],melanoma[MeSHID:D008545] phase 1 toll-like receptor 8 TLR8 Clinical trial target unknown NA TTD cpg 10101 biotech Hepatitis[MeSHID:D006505],Virus Diseases[MeSHID:D014777],Hepatitis A[MeSHID:D006506] investigational toll-like receptor 9 TLR9 NA unknown NA drugbank , DGIDB cmp-001 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB ir-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] discontinued in phase 3 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD tilsotolimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD sar-21609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved,investigational,vet_approved toll-like receptor 9 TLR9 NA inhibitor 2.32 drugbank , DGIDB bl-7040 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212],Burkitt Lymphoma[MeSHID:D002051] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB litenimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown 3.98 TTD , DGIDB tolamba NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB hydroxychloroquine small molecule Rheumatoid Arthritis[MeSHID:D001172],Lupus Erythematosus, Discoid[MeSHID:D008179],Malaria[MeSHID:D008288], Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved toll-like receptor 9 TLR9 NA antagonist 1.45 drugbank , DGIDB ast-008 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB imo-2125 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 3 toll-like receptor 9 TLR9 Clinical trial target unknown 3.98 TTD , DGIDB chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Malaria[MeSHID:D008288],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved toll-like receptor 9 TLR9 NA inhibitor 2.32 drugbank , DGIDB zadaxin/lamivudine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB dv281 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB sd-101 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545],Dermatologic disorders[MeSHID:D012871],Cells[MeSHID:D002477],Squamous cell carcinoma[MeSHID:D002294] phase 3 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB hydroxychloroquine small molecule Rheumatoid Arthritis[MeSHID:D001172],Lupus Erythematosus, Discoid[MeSHID:D008179],Malaria[MeSHID:D008288], Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved toll-like receptor 9 TLR9 NA antagonist 1.45 drugbank , DGIDB imo-3100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Diabetes, Autoimmune[MeSHID:D003922] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB mgn-1703 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Membranous glomerulonephritis[MeSHID:D015433],Malignant Neoplasms[MeSHID:D009369] phase 3 toll-like receptor 9 TLR9 Clinical trial target unknown 3.98 TTD , DGIDB lefitolimod NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD mis-416 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239],Diabetes, Autoimmune[MeSHID:D003922] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB cadi-05 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB cpg 52364 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB im0-8400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diffuse Large B-Cell Lymphoma[MeSHID:D016403] discontinued in phase 1/2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB cpg-10101 NA Hepatitis C[MeSHID:D006526],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB cavrotolimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD jvrs-100 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB iss-1018 small molecule Hepatitis A[MeSHID:D006506],Lymphoma[MeSHID:D008223],Hepatitis[MeSHID:D006505],Colorectal Cancer[MeSHID:D015179],Hepatitis B[MeSHID:D006509],Lymphoma, Non-Hodgkin[MeSHID:D008228],B-Lymphocytes[MeSHID:D001402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational toll-like receptor 9 TLR9 NA unknown NA drugbank , DGIDB cyt003 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB golotimod small molecule Parasitic Diseases[MeSHID:D010272],Hepatitis A[MeSHID:D006506],Communicable Diseases[MeSHID:D003141],Hepatitis[MeSHID:D006505],Tuberculosis[MeSHID:D014376],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249],Immune System Diseases[MeSHID:D007154] investigational toll-like receptor 9 TLR9 NA unknown NA drugbank azd1419 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB cov08-0064 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] investigative toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD mgn-1706 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Membranous glomerulonephritis[MeSHID:D015433],Malignant Neoplasms[MeSHID:D009369] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB imo-2055 NA Renal Cell Carcinoma[MeSHID:D002292],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 toll-like receptor 9 TLR9 Clinical trial target unknown 3.98 TTD , DGIDB odn-2088 NA Spinal Cord Injuries[MeSHID:D013119],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD gnkg-168 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown 3.98 TTD , DGIDB n-8295 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB dv-1179 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Autoimmune Diseases[MeSHID:D001327] phase 1 toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB agatolimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] discontinued in phase 2 toll-like receptor 9 TLR9 Clinical trial target agonist 11.93 TTD , DGIDB imo-2134 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249],Allergic Reaction[MeSHID:D006967] preclinical toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD , DGIDB dims-9054 NA Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative toll-like receptor 9 TLR9 Clinical trial target unknown NA TTD adu- s100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 2 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD snx281 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD tak-676 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD gsk3745417 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD synb1891 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD c-176 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],AICARDI-GOUTIERES SYNDROME 1[MeSHID:C535607] investigative stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD adu-s100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258] phase 2 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD c-178 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],AICARDI-GOUTIERES SYNDROME 1[MeSHID:C535607] investigative stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD mk-2118 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD bms-986301 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD sb 11285 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Squamous cell carcinoma of the head and neck[MeSHID:C535575],melanoma[MeSHID:D008545] phase 1 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD imsa101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD e7766 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD mk-1454 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Cells[MeSHID:D002477] phase 2 stimulator of interferon genes protein TMEM173 Clinical trial target unknown NA TTD piperazinyl norbenzomorphane compound 3 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB n-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 3 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 7 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 1 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB n-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 1 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB piperidine derivative 5 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB isoindoline derivative 1 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-28 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB n-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 2 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid28051882-compound-figure9 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid28051882-compound-xiv NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB fused aryl carbocycle derivative 2 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB piperazinyl norbenzomorphane compound 1 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB bicyclo-heptan-2-amine derivative 1 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-63 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-55 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB min-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] phase 3 sigma intracellular receptor 2 TMEM97 Clinical trial target unknown 15.91 TTD , DGIDB pmid30185082-compound-54 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB anavex 1007 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of prostate[MeSHID:D011471] preclinical sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB 1,3-ditolylguanidine NA NA investigative sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD piperazinyl methyl quinazolinone derivative 1 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB piperazinyl methyl quinazolinone derivative 2 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB isoindoline derivative 5 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB piperazinyl norbenzomorphane compound 2 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB piperidine derivative 6 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB fused aryl carbocycle derivative 3 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-27 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 10 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-56 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB piperazinyl methyl quinazolinone derivative 3 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-14 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB fused aryl carbocycle derivative 8 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB sm 21 NA NA investigative sigma intracellular receptor 2 TMEM97 Clinical trial target antagonist NA TTD , DGIDB fused aryl carbocycle derivative 9 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 8 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 2 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB isoindoline derivative 3 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB fused aryl carbocycle derivative 1 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB bicyclo-heptan-2-amine derivative 4 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 4 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB bicyclo-heptan-2-amine derivative 3 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB aryl azepine derivative 2 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB fused aryl carbocycle derivative 4 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-53 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 9 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid28051882-compound-xi NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 3 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB bicyclo-heptan-2-amine derivative 2 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB isoindoline derivative 4 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB ct1812 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB aryl azepine derivative 1 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-64 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB benzamide derivative 11 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB piperazinyl norbenzomorphane compound 4 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB isoindoline derivative 2 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB piperazine derivative 7 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB pmid30185082-compound-57 NA NA patented sigma intracellular receptor 2 TMEM97 Clinical trial target unknown NA TTD , DGIDB ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical trimethyllysine dioxygenase, mitochondrial TMLHE NA cofactor NA drugbank bromhexine small molecule Disease[MeSHID:D004194],Viscosity[MeSHID:D014783],Influenza[MeSHID:D007251],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Mucous body substance[MeSHID:D009093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859] approved transmembrane protease serine 2 TMPRSS2 NA unknown NA drugbank camostat small molecule Pancreatitis, Chronic[MeSHID:D050500],Hereditary pancreatitis[MeSHID:C537262],Lung Injury[MeSHID:D055370],Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental transmembrane protease serine 2 TMPRSS2 NA inhibitor 21.22 drugbank , DGIDB pmid21741839c5 NA NA investigative transmembrane protease serine 2 TMPRSS2 Literature-reported target unknown NA TTD mm3122 small molecule NA experimental transmembrane protease serine 2 TMPRSS2 NA inhibitor NA drugbank inhibitor 1 [colombo et al., 2012] NA NA investigative transmembrane protease serine 6 TMPRSS6 Literature-reported target inhibitor NA TTD , DGIDB aln-tmp NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],beta Thalassemia[MeSHID:D017086] preclinical tmprss6 messenger rna TMPRSS6 Clinical trial target unknown NA TTD ionis-tmprss6-lrx NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],beta Thalassemia[MeSHID:D017086] phase 2 tmprss6 messenger rna TMPRSS6 Clinical trial target unknown NA TTD sln124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],beta Thalassemia[MeSHID:D017086] phase 1 tmprss6 messenger rna TMPRSS6 Clinical trial target unknown NA TTD f-16-il-2 fusion protein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tenascin TNC Clinical trial target unknown NA TTD , DGIDB 8h9 NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tenascin TNC Clinical trial target unknown 12.73 TTD , DGIDB f-16-131i NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1/2 tenascin TNC Clinical trial target unknown NA TTD , DGIDB avx-470 NA Ulcerative Colitis[MeSHID:D003093],Inflammatory Bowel Diseases[MeSHID:D015212],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB adalimumab biotech Arthritis, Psoriatic[MeSHID:D015535],Disease[MeSHID:D004194],Pyoderma Gangrenosum[MeSHID:D017511],Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Crohn Disease[MeSHID:D003424],Hidradenitis Suppurativa[MeSHID:D017497],Rheumatoid Arthritis[MeSHID:D001172],Dental Plaque[MeSHID:D003773],Ulcerative Colitis[MeSHID:D003093],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Panuveitis[MeSHID:D015864],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental tumor necrosis factor TNF Successful target antibody 1.43 TTD , drugbank , DGIDB y-39041 NA NA investigative tumor necrosis factor TNF Successful target unknown NA TTD pkf-242-484 NA NA investigative tumor necrosis factor TNF Successful target unknown NA TTD crx-191 NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 tumor necrosis factor TNF Successful target unknown NA TTD abp 501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] phase 3 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational tumor necrosis factor TNF Successful target antibody,inhibitor 1.28 TTD , drugbank , DGIDB etanercept biotech Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Dental Plaque[MeSHID:D003773],Senile Plaques[MeSHID:D058225],Polyarthritis[MeSHID:D001168],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sciatica[MeSHID:D012585],Pemphigus Vulgaris[MeSHID:D010392],Arthritis[MeSHID:D001168] approved,investigational tumor necrosis factor TNF Successful target antibody 1.28 TTD , drugbank , DGIDB foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved tumor necrosis factor TNF NA agonist NA drugbank segard NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] discontinued in phase 3 tumor necrosis factor TNF Successful target unknown NA TTD pn0621 biotech Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Psoriasis[MeSHID:D011565],Immune System Diseases[MeSHID:D007154] investigational tumor necrosis factor TNF NA unknown NA drugbank lenalidomide NA Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor TNF Successful target unknown 0.13 TTD , DGIDB pegsunercept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tumor necrosis factor TNF Successful target unknown 1.87 TTD , DGIDB pr-104 small molecule Neoplasms[MeSHID:D009369] investigational tumor necrosis factor TNF NA unknown NA drugbank dexanabinol small molecule Traumatic Brain Injury[MeSHID:D000070642],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tumor necrosis factor TNF NA unknown NA drugbank polaprezinc small molecule Peptic Ulcer[MeSHID:D010437],Dyspepsia[MeSHID:D004415],Helicobacter Infections[MeSHID:D016481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Ulcer[MeSHID:D014456] experimental tumor necrosis factor TNF NA inhibitor NA drugbank clenbuterol small molecule Asthma[MeSHID:D001249],Chronic disease[MeSHID:D002908],Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved tumor necrosis factor TNF NA unknown NA drugbank pentoxifylline NA Blood Vessel[MeSHID:D001808],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Intermittent Claudication[MeSHID:D007383],Arterial Occlusive Diseases[MeSHID:D001157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor TNF Successful target unknown 0.03 TTD , DGIDB thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational,withdrawn tumor necrosis factor TNF Successful target inhibitor 0.27 TTD , drugbank , DGIDB cyt-007-tnfqb NA Allergic rhinitis (disorder)[MeSHID:D065631],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1/2 tumor necrosis factor TNF Successful target unknown NA TTD afelimomab biotech Sepsis[MeSHID:D018805] investigational tumor necrosis factor TNF NA inhibitor 1.87 drugbank , DGIDB ethyl pyruvate small molecule Sepsis[MeSHID:D018805],Reperfusion Injury[MeSHID:D015427],Disease[MeSHID:D004194],Burn injury[MeSHID:D002056],Infection[MeSHID:D007239] investigational tumor necrosis factor TNF NA unknown NA drugbank certolizumab pegol biotech Disease Management[MeSHID:D019468],Cells[MeSHID:D002477],Maintenance[MeSHID:D008283],Inflammation[MeSHID:D007249],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Senile Plaques[MeSHID:D058225],Signal Transduction[MeSHID:D015398],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disease[MeSHID:D004194],Body tissue[MeSHID:D014024],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Spondylarthritis[MeSHID:D025241],Cell Death[MeSHID:D016923],Dental Plaque[MeSHID:D003773] approved tumor necrosis factor TNF NA neutralizer NA drugbank , DGIDB amrinone small molecule Congestive heart failure[MeSHID:D006333] approved tumor necrosis factor TNF NA inhibitor NA drugbank esba-105 NA Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB sd118 small molecule Neuralgia[MeSHID:D009437] investigational tumor necrosis factor TNF NA unknown NA drugbank baicalein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 tumor necrosis factor TNF Successful target unknown NA TTD binimetinib small molecule Mutation[MeSHID:D009154],melanoma[MeSHID:D008545] approved,investigational tumor necrosis factor TNF NA unknown NA drugbank inb03 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tumor necrosis factor TNF Successful target unknown NA TTD pmi-005 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB certolizumab pegol biotech Disease Management[MeSHID:D019468],Cells[MeSHID:D002477],Maintenance[MeSHID:D008283],Inflammation[MeSHID:D007249],Cell Differentiation process[MeSHID:D002454],Continuance of life[MeSHID:D013534],Senile Plaques[MeSHID:D058225],Signal Transduction[MeSHID:D015398],Arthritis, Psoriatic[MeSHID:D015535],Psoriasis[MeSHID:D011565],Disease[MeSHID:D004194],Body tissue[MeSHID:D014024],Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Spondylarthritis[MeSHID:D025241],Cell Death[MeSHID:D016923],Dental Plaque[MeSHID:D003773] approved tumor necrosis factor TNF NA neutralizer,inhibitor 0.94 drugbank , DGIDB vx-702 small molecule Coronary Arteriosclerosis[MeSHID:D003324],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] investigational tumor necrosis factor TNF NA unknown NA drugbank 2-propanol, isopropanol NA NA investigative tumor necrosis factor TNF Successful target unknown NA TTD ast-005 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB cyt-609 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB pf-06410293 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 3 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB als-00t2-0501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 1 tumor necrosis factor TNF Successful target unknown NA TTD foreskin fibroblast (neonatal) biotech Tendon structure[MeSHID:D013710],Joint Capsule[MeSHID:D017746],Injury wounds[MeSHID:D014947],Dermis[MeSHID:D020405],Bone Tissue[MeSHID:D001842],Foot[MeSHID:D005528],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved tumor necrosis factor TNF NA agonist NA drugbank bryostatin 1 small molecule NA investigational tumor necrosis factor TNF NA inducer NA drugbank chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Severe Acute Respiratory Syndrome[MeSHID:D045169],Malaria[MeSHID:D008288],Disease[MeSHID:D004194],Middle East Respiratory Syndrome[MeSHID:D018352] approved,investigational,vet_approved tumor necrosis factor TNF NA inhibitor NA drugbank pf-06438179 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 3 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB infliximab biotech Arthritis, Psoriatic[MeSHID:D015535],Rectovaginal Fistula[MeSHID:D012006],Maintenance[MeSHID:D008283],Crohn Disease[MeSHID:D003424],Physical Examination[MeSHID:D010808],Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Ulcerative Colitis[MeSHID:D003093],Disease Progression[MeSHID:D018450],Mucous Membrane[MeSHID:D009092],Senile Plaques[MeSHID:D058225],Arthritis[MeSHID:D001168],Cardiac Arrest[MeSHID:D006323],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],pathologic fistula[MeSHID:D005402],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] approved tumor necrosis factor TNF Successful target inhibitor 1.59 TTD , drugbank , DGIDB adalimumab biotech Arthritis, Psoriatic[MeSHID:D015535],Disease[MeSHID:D004194],Pyoderma Gangrenosum[MeSHID:D017511],Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Crohn Disease[MeSHID:D003424],Hidradenitis Suppurativa[MeSHID:D017497],Rheumatoid Arthritis[MeSHID:D001172],Dental Plaque[MeSHID:D003773],Ulcerative Colitis[MeSHID:D003093],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Panuveitis[MeSHID:D015864],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental tumor necrosis factor TNF Successful target antibody,inhibitor 1.43 TTD , drugbank , DGIDB abx-0401 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] preclinical tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB lenalidomide NA Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor TNF Successful target unknown 0.13 TTD , DGIDB adalimumab biotech Arthritis, Psoriatic[MeSHID:D015535],Disease[MeSHID:D004194],Pyoderma Gangrenosum[MeSHID:D017511],Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Crohn Disease[MeSHID:D003424],Hidradenitis Suppurativa[MeSHID:D017497],Rheumatoid Arthritis[MeSHID:D001172],Dental Plaque[MeSHID:D003773],Ulcerative Colitis[MeSHID:D003093],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Panuveitis[MeSHID:D015864],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental tumor necrosis factor TNF Successful target antibody 1.43 TTD , drugbank , DGIDB abbv-257 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 tumor necrosis factor TNF Successful target unknown 0.47 TTD , DGIDB dlx-105 NA Degenerative polyarthritis[MeSHID:D010003],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB cova322 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] phase 1/2a tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB golnerminogene pradenovac NA Esophageal Neoplasms[MeSHID:D004938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB glycyrrhizic acid small molecule Neoplasms[MeSHID:D009369],Premenstrual syndrome[MeSHID:D011293],Stomach Diseases[MeSHID:D013272],Ulcer[MeSHID:D014456],Virus Diseases[MeSHID:D014777],Peptic Ulcer[MeSHID:D010437] approved,experimental tumor necrosis factor TNF NA antagonist NA drugbank talmapimod small molecule Rheumatoid Arthritis[MeSHID:D001172],Pain[MeSHID:D010146] investigational tumor necrosis factor TNF NA unknown NA drugbank pf-05230905 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 1 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB ortataxel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart[MeSHID:D006321],Malignant Neoplasms[MeSHID:D009369],Graft Rejection[MeSHID:D006084] phase 2 tumor necrosis factor TNF Successful target unknown 0.23 TTD , DGIDB ik-862 NA NA investigative tumor necrosis factor TNF Successful target unknown NA TTD nafamostat NA Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Disease[MeSHID:D004194] approved tumor necrosis factor TNF Successful target unknown 0.09 TTD , DGIDB an0128 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485],Disease[MeSHID:D004194] phase 2 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB pkf-241-466 NA NA investigative tumor necrosis factor TNF Successful target unknown NA TTD golimumab biotech Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Unmarried[MeSHID:D012847],Arthritis, Psoriatic[MeSHID:D015535],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] approved tumor necrosis factor TNF Successful target antibody 4.68 TTD , drugbank , DGIDB cdp571 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424] discontinued in phase 3 tumor necrosis factor TNF Successful target unknown NA TTD atiprimod small molecule Rheumatoid Arthritis[MeSHID:D001172],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tumor necrosis factor TNF NA unknown NA drugbank epinephrine small molecule Structure of carotid sinus[MeSHID:D002346],Operative Surgical Procedures[MeSHID:D013514],Genetic Selection[MeSHID:D012641],Heart Block[MeSHID:D006327],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Angioedema[MeSHID:D000799],Mucous Membrane[MeSHID:D009092],Bronchi[MeSHID:D001980],Shock, Cardiogenic[MeSHID:D012770],Wheezing[MeSHID:D012135],Uterine Contraction[MeSHID:D014590],Rhinitis[MeSHID:D012220],Urticaria[MeSHID:D014581],Syncope[MeSHID:D013575],Dyspnea[MeSHID:D004417],anaphylaxis[MeSHID:D000707],Sinusitis[MeSHID:D012852],Relaxation[MeSHID:D012063],Insect Bites[MeSHID:D007299],Maintenance[MeSHID:D008283],Glaucoma, Open-Angle[MeSHID:D005902],Body Weight[MeSHID:D001835],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Asthma[MeSHID:D001249],Accidents[MeSHID:D000059],Hay fever[MeSHID:D006255],Mydriasis[MeSHID:D015878],myometrium[MeSHID:D009215],Fire - disasters[MeSHID:D005390],Hemorrhage[MeSHID:D006470],Serum Sickness[MeSHID:D012713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Allergic Reaction[MeSHID:D006967] approved,vet_approved tumor necrosis factor TNF NA antagonist,agonist NA drugbank rdp58 NA Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB abt-122 NA Arthritis, Psoriatic[MeSHID:D015535],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tumor necrosis factor TNF Successful target unknown 0.47 TTD , DGIDB ap-301-ih NA Inspiration function[MeSHID:D001239],Pneumonia[MeSHID:D011014],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB celastrol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Motor Neuron Disease[MeSHID:D016472] preclinical tumor necrosis factor TNF Successful target unknown 0.23 TTD , DGIDB pegsunercept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tumor necrosis factor TNF Successful target inhibitor 1.87 TTD , DGIDB thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved,investigational,withdrawn tumor necrosis factor TNF Successful target inhibitor 0.27 TTD , drugbank , DGIDB tnf alpha kinoid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] phase 2 tumor necrosis factor TNF Successful target unknown NA TTD , DGIDB nafamostat NA Blood Vessel[MeSHID:D001808],Blood coagulation[MeSHID:D001777],Cell Respiration[MeSHID:D019069],Hemorrhage[MeSHID:D006470],Tissue membrane[MeSHID:D008566],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805],Pancreatitis[MeSHID:D010195] approved tumor necrosis factor TNF Successful target unknown 0.09 TTD , DGIDB ysil6 small molecule Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tumor necrosis factor TNF NA unknown NA drugbank certolizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved tumor necrosis factor TNF Successful target unknown 0.94 TTD , DGIDB art621 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Rheumatoid Arthritis[MeSHID:D001172] phase 1/2 tumor necrosis factor TNF Successful target unknown 2.81 TTD , DGIDB adalimumab biotech Arthritis, Psoriatic[MeSHID:D015535],Disease[MeSHID:D004194],Pyoderma Gangrenosum[MeSHID:D017511],Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Crohn Disease[MeSHID:D003424],Hidradenitis Suppurativa[MeSHID:D017497],Rheumatoid Arthritis[MeSHID:D001172],Dental Plaque[MeSHID:D003773],Ulcerative Colitis[MeSHID:D003093],Juvenile arthritis[MeSHID:D001171],Senile Plaques[MeSHID:D058225],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Panuveitis[MeSHID:D015864],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental tumor necrosis factor TNF Successful target antibody,inhibitor 1.43 TTD , drugbank , DGIDB pranlukast small molecule Inspiration function[MeSHID:D001239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] investigational tumor necrosis factor TNF NA unknown NA drugbank chloroquine small molecule Amebic colitis[MeSHID:D004404],Rheumatism[MeSHID:D012216],Off-Label Use[MeSHID:D056687],Amebiasis[MeSHID:D000562],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] approved,investigational,vet_approved tumor necrosis factor TNF NA inhibitor NA drugbank pseudoephedrine small molecule Nose[MeSHID:D009666],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor TNF NA inhibitor NA drugbank camobucol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 tumor necrosis factor TNF Successful target unknown NA TTD oms-103hp small molecule Pain[MeSHID:D010146],Disease[MeSHID:D004194] investigational tumor necrosis factor TNF NA unknown NA drugbank onercept biotech Crohn Disease[MeSHID:D003424],Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational tumor necrosis factor TNF NA inhibitor 0.94 drugbank , DGIDB dom-0215 NA NA investigative tumor necrosis factor TNF Successful target unknown NA TTD plinabulin small molecule Neoplasms[MeSHID:D009369],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tumor necrosis factor TNF NA unknown NA drugbank pomalidomide small molecule Disease Progression[MeSHID:D018450],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Systemic Scleroderma[MeSHID:D012595] approved tumor necrosis factor TNF NA inhibitor NA drugbank enbrel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] approved tumor necrosis factor TNF Successful target unknown 0.94 TTD , DGIDB isis 104838 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crohn Disease[MeSHID:D003424],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 tnfa messenger rna TNF Discontinued target unknown NA TTD infliximab biotech Arthritis, Psoriatic[MeSHID:D015535],Rectovaginal Fistula[MeSHID:D012006],Maintenance[MeSHID:D008283],Crohn Disease[MeSHID:D003424],Physical Examination[MeSHID:D010808],Rheumatoid Arthritis[MeSHID:D001172],Ankylosing spondylitis[MeSHID:D013167],Ulcerative Colitis[MeSHID:D003093],Disease Progression[MeSHID:D018450],Mucous Membrane[MeSHID:D009092],Senile Plaques[MeSHID:D058225],Arthritis[MeSHID:D001168],Cardiac Arrest[MeSHID:D006323],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],pathologic fistula[MeSHID:D005402],Wound Healing[MeSHID:D014945],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor TNF Successful target inhibitor 1.59 TTD , drugbank , DGIDB andrographolide small molecule Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dysentery, Bacillary[MeSHID:D004405] investigational tumor necrosis factor TNF NA unknown NA drugbank golimumab biotech Ankylosing spondylitis[MeSHID:D013167],Rheumatoid Arthritis[MeSHID:D001172],Juvenile arthritis[MeSHID:D001171],Unmarried[MeSHID:D012847],Arthritis, Psoriatic[MeSHID:D015535],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] approved tumor necrosis factor TNF Successful target antibody,inhibitor 4.68 TTD , drugbank , DGIDB cyt007-tnfqb biotech Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational tumor necrosis factor TNF NA unknown NA drugbank , DGIDB ame-527 biotech Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Apparent mineralocorticoid excess[MeSHID:C537422] investigational,discontinued in phase 1/2 tumor necrosis factor TNF Successful target unknown NA TTD , drugbank , DGIDB dilmapimod small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Diagnosis[MeSHID:D003933],Traumatic injury[MeSHID:D014947],Inflammation[MeSHID:D007249],Arthritis[MeSHID:D001168],Pain[MeSHID:D010146],Nerve Tissue[MeSHID:D009417],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] investigational tumor necrosis factor TNF NA unknown NA drugbank cpl-7075 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180],Cystic Fibrosis[MeSHID:D003550],Diffuse Scleroderma[MeSHID:D045743],Systemic Scleroderma[MeSHID:D012595],Rheumatoid Arthritis[MeSHID:D001172] phase 3 tumor necrosis factor TNF Successful target unknown 0.31 TTD , DGIDB crx-139 small molecule Rheumatoid Arthritis[MeSHID:D001172] investigational tumor necrosis factor TNF NA unknown NA drugbank donepezil small molecule Disease Management[MeSHID:D019468],Lewy Body Disease[MeSHID:D020961],ALZHEIMER DISEASE 10[MeSHID:C566465],Dementia, Vascular[MeSHID:D015140],Parkinson Disease[MeSHID:D010300],Patient Discharge[MeSHID:D010351],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor-inducible gene 6 protein TNFAIP6 NA inhibitor NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved tumor necrosis factor-inducible gene 6 protein TNFAIP6 NA binder NA drugbank acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved tumor necrosis factor-inducible gene 6 protein TNFAIP6 NA inhibitor,downregulator NA drugbank mapatumumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 trail receptor 1 TNFRSF10A Clinical trial target agonist 79.56 TTD , DGIDB mapatumumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 trail receptor 1 TNFRSF10A Clinical trial target antibody 79.56 TTD , DGIDB rhapo2l/trail NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1/2 trail receptor 1 TNFRSF10A Clinical trial target unknown NA TTD mapatumumab NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 trail receptor 1 TNFRSF10A Clinical trial target unknown 79.56 TTD , DGIDB dr-5/dr-4 cross reactive mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cross Reactions[MeSHID:D003429],Malignant Neoplasms[MeSHID:D009369] investigative trail receptor 1 TNFRSF10A Clinical trial target unknown NA TTD conatumumab NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 trail receptor 2 TNFRSF10B Clinical trial target antibody 9.09 TTD , DGIDB rhapo2l/trail NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1/2 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD inbrx-109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD anti-dr5 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Cells[MeSHID:D002477] phase 1/2 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD , DGIDB bi 905711 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD conatumumab NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 trail receptor 2 TNFRSF10B Clinical trial target agonist 9.09 TTD , DGIDB dr-5/dr-4 cross reactive mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cross Reactions[MeSHID:D003429],Malignant Neoplasms[MeSHID:D009369] investigative trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD hgs-tr2j biotech Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational tumor necrosis factor receptor superfamily member 10b TNFRSF10B NA unknown NA drugbank , DGIDB lexatumumab biotech Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational tumor necrosis factor receptor superfamily member 10b TNFRSF10B NA unknown 54.56 drugbank , DGIDB lexatumumab biotech Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational tumor necrosis factor receptor superfamily member 10b TNFRSF10B NA antibody 54.56 drugbank , DGIDB hgs-tr2j NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD , DGIDB ds-8273 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD ad5-10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD igm-8444 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD lexatumumab NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 trail receptor 2 TNFRSF10B Clinical trial target unknown 54.56 TTD , DGIDB lby-135 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD lexatumumab NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 trail receptor 2 TNFRSF10B Clinical trial target antibody 54.56 TTD , DGIDB conatumumab NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 trail receptor 2 TNFRSF10B Clinical trial target unknown 9.09 TTD , DGIDB gen1029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 trail receptor 2 TNFRSF10B Clinical trial target unknown NA TTD enmd-1198 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational tumor necrosis factor receptor superfamily member 11a TNFRSF11A NA unknown NA drugbank enavatuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tnf superfamily receptor 12a TNFRSF12A Clinical trial target unknown 127.3 TTD , DGIDB enavatuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tnf superfamily receptor 12a TNFRSF12A Clinical trial target agonist 127.3 TTD , DGIDB auto2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 transmembrane activator and caml interactor TNFRSF13B Clinical trial target unknown NA TTD , DGIDB vay736 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sjogren's Syndrome[MeSHID:D012859],Pemphigus Vulgaris[MeSHID:D010392],Rheumatoid Arthritis[MeSHID:D001172] phase 2 b-cell-activating factor receptor TNFRSF13C Clinical trial target unknown NA TTD , DGIDB im21 cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB kite-585 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB anti-bcma-car-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938],Cells[MeSHID:D002477] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB bcma car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB bcma cart and hucart19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB autologous anti-bcma-car-expressing cd4+/cd8+ t-lymphocytes fcarh143 NA CD8-Positive T-Lymphocytes[MeSHID:D018414],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB lcar-b4822m car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB jcarh125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Multiple Myeloma[MeSHID:D009101],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Chronic Lymphocytic Leukemia[MeSHID:D015451], Follicular[MeSHID:D008224] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB lcar-b38m car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB cart-ddbcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD cart-19/bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB car-bcma t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] clinical trial b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB amg 701 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD bcma nanobody car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB phe885 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD regn5458 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD pbcar269a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD descartes-08 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB regn5459 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB bcma cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB car-t cells targeting bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB anti-bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB hpn217 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD jnj-68284528 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB medi2228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD belantamab mafodotin biotech Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor receptor superfamily member 17 TNFRSF17 NA binder NA drugbank bcma-cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] clinical trial b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB idecabtagene vicleucel biotech Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor receptor superfamily member 17 TNFRSF17 NA binder NA drugbank car-t cells targeting bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] clinical trial b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB anti-bcma car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB idecabtagene vicleucel NA Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-cell maturation protein TNFRSF17 Successful target unknown NA TTD cc-99712 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD bcma car-t NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB bcma-ucart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] clinical trial b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB anti-bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Cells[MeSHID:D002477] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB p-psma-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD cc-98633 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD ciltacabtagene autoleucel NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 3 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD bb21217 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB cd38 and bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB car-t cells targeting bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB c-car088 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB tnb-383b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD descartes-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD rg6296 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD anti-bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB ct053 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD bcma-cs1 ccar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD bcma-specific car-expressing t lymphocytes NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB bb2121 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 2 b-cell maturation protein TNFRSF17 Successful target unknown 31.83 TTD , DGIDB anti-bcma cart cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB car-t cells targeting bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB anti-cd19/bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB cart-bcma cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Cells[MeSHID:D002477] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB belantamab mafodotin NA Multiple Myeloma[MeSHID:D009101],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-cell maturation protein TNFRSF17 Successful target unknown NA TTD cc-93269 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD wvt078 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD car-t cells targeting bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] clinical trial b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB amg 420 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB auto2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB ctx120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD allo-715 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD cart-bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB car-t cells targeting bcma NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB p-bcma-101 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB p-bcma-all01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] preclinical b-cell maturation protein TNFRSF17 Successful target unknown NA TTD bcma-cd19 ccar NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 1 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD anti-bcma car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Cells[MeSHID:D002477] phase 1/2 b-cell maturation protein TNFRSF17 Successful target unknown NA TTD , DGIDB regn6569 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cells[MeSHID:D002477] phase 1 activation-inducible tnfr family receptor TNFRSF18 Clinical trial target unknown NA TTD mk-4166 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 activation-inducible tnfr family receptor TNFRSF18 Clinical trial target unknown NA TTD , DGIDB incagn01876 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 activation-inducible tnfr family receptor TNFRSF18 Clinical trial target unknown NA TTD trx518 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 activation-inducible tnfr family receptor TNFRSF18 Clinical trial target unknown NA TTD , DGIDB trx-518 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545] phase 1/2 activation-inducible tnfr family receptor TNFRSF18 Clinical trial target unknown 63.65 TTD , DGIDB amg 228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 activation-inducible tnfr family receptor TNFRSF18 Clinical trial target unknown NA TTD incagn1876 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 activation-inducible tnfr family receptor TNFRSF18 Clinical trial target unknown NA TTD , DGIDB asp1951 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 activation-inducible tnfr family receptor TNFRSF18 Clinical trial target unknown NA TTD drug 2862277 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute Lung Injury[MeSHID:D055371] phase 2 tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD nm-2014 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD gsk1995057 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Distress Syndrome, Adult[MeSHID:D012128] phase 1 tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD tasonermin biotech Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Fever[MeSHID:D005334],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tumor necrosis factor receptor superfamily member 1a TNFRSF1A NA agonist NA drugbank anti-tnf human mabs NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD 6-[3-(4-morpholinyl)propyl]-2-(3-nitrophenyl)-5-thioxo-5,6,-dihydro-7h-thienol[2',3':4,5]pyrrolo[1,2-c]imidazol-7-one small molecule NA experimental tumor necrosis factor receptor superfamily member 1a TNFRSF1A NA unknown NA drugbank tnfmab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD nm-9405 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD alf-421 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver Failure, Acute[MeSHID:D017114] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD vb-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Glioma[MeSHID:D005910],Recurrence (disease attribute)[MeSHID:D012008],Malignant neoplasm of ovary[MeSHID:D010051],Glioblastoma[MeSHID:D005909] phase 3 tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD tnfr1 nam NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis[MeSHID:D009103],Native American myopathy[MeSHID:C538343] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD tnfcept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD ads-0101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD avx-470 NA Ulcerative Colitis[MeSHID:D003093],Inflammatory Bowel Diseases[MeSHID:D015212],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD recombinant human tnf receptor NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis[MeSHID:D001168] investigative tumor necrosis factor receptor type i TNFRSF1A Clinical trial target unknown NA TTD tasonermin biotech Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Fever[MeSHID:D005334],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tumor necrosis factor receptor superfamily member 1b TNFRSF1B NA agonist NA drugbank ptx-35 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tumor necrosis factor receptor member 25 TNFRSF25 Clinical trial target unknown NA TTD anti-ox40 mab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 ox40l receptor TNFRSF4 Clinical trial target unknown NA TTD , DGIDB tremelimumab + medi0562 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ox40l receptor TNFRSF4 Clinical trial target unknown NA TTD , DGIDB pf-04518600 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 ox40l receptor TNFRSF4 Clinical trial target unknown 21.22 TTD , DGIDB medi0562 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ox40l receptor TNFRSF4 Clinical trial target unknown 21.22 TTD , DGIDB tak-252 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ox40l receptor TNFRSF4 Clinical trial target unknown NA TTD gbr 830 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 ox40l receptor TNFRSF4 Clinical trial target unknown NA TTD , DGIDB incagn01949 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 ox40l receptor TNFRSF4 Clinical trial target unknown NA TTD incagn1949 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 ox40l receptor TNFRSF4 Clinical trial target unknown NA TTD , DGIDB bgb-a445 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 ox40l receptor TNFRSF4 Clinical trial target unknown NA TTD vt-362 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetes, Autoimmune[MeSHID:D003922] investigative lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD brentuximab vedotin biotech Lymphoma[MeSHID:D008223],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tumor necrosis factor receptor superfamily member 8 TNFRSF8 NA binder,antibody NA drugbank , DGIDB cd30 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],T-Lymphocyte[MeSHID:D013601] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB h22xki-4 NA NA investigative lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD brentuximab vedotin biotech Lymphoma[MeSHID:D008223],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tumor necrosis factor receptor superfamily member 8 TNFRSF8 NA binder,inhibitor 0.71 drugbank , DGIDB 4scar19 and 4scar30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393] phase 1/2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB afm13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Mycosis Fungoides[MeSHID:D009182],Peripheral T-Cell Lymphoma[MeSHID:D016411],Hodgkin Disease[MeSHID:D006689] phase 2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB sgn-30 NA Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Lymphoma, Non-Hodgkin[MeSHID:D008228],Autoimmune Diseases[MeSHID:D001327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 lymphocyte activation antigen cd30 TNFRSF8 Successful target agonist 21.22 TTD , DGIDB anti-cd30-car-transduced t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB xmab-2513 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown 10.61 TTD , DGIDB xmab 2513 biotech Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228] investigational tumor necrosis factor receptor superfamily member 8 TNFRSF8 NA unknown NA drugbank anti-cd30 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],leukemia[MeSHID:D007938],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB car-t cells targeting cd30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 1/2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB brentuximab vedotin biotech Lymphoma[MeSHID:D008223],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tumor necrosis factor receptor superfamily member 8 TNFRSF8 NA binder NA drugbank , DGIDB car-t cells targeting cd30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 1/2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB anti-cd30-car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reticulosarcoma[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],Hodgkin Disease[MeSHID:D006689] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB cart30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689] phase 1/2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB afm13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Mycosis Fungoides[MeSHID:D009182],Peripheral T-Cell Lymphoma[MeSHID:D016411],Hodgkin Disease[MeSHID:D006689] phase 2 lymphocyte activation antigen cd30 TNFRSF8 Successful target antibody NA TTD , DGIDB sgn-30 NA Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Lymphoma, Non-Hodgkin[MeSHID:D008228],Autoimmune Diseases[MeSHID:D001327],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown 21.22 TTD , DGIDB brentuximab vedotin NA Lymphoma[MeSHID:D008223],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lymphocyte activation antigen cd30 TNFRSF8 Successful target inhibitor 0.71 TTD , DGIDB car-t cells targeting cd30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938] phase 2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB atlcar.cd30 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Lymphatic Diseases[MeSHID:D008206],Immunoproliferative Disorders[MeSHID:D007160],Immune System Diseases[MeSHID:D007154],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB brentuximab vedotin NA Lymphoma[MeSHID:D008223],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lymphocyte activation antigen cd30 TNFRSF8 Successful target antibody NA TTD , DGIDB car.cd30 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Lymphatic Diseases[MeSHID:D008206],Immunoproliferative Disorders[MeSHID:D007160],Immune System Diseases[MeSHID:D007154],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 1/2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB brentuximab vedotin NA Lymphoma[MeSHID:D008223],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB iratumumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown 31.83 TTD , DGIDB sgn-cd30c NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD car cd30 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],T-Lymphocyte[MeSHID:D013601] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB car-t cells targeting cd30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],T-Lymphocyte[MeSHID:D013601] phase 2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB anti-cd30 car t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Lymphocyte[MeSHID:D013601],Lymphoma[MeSHID:D008223] phase 1/2 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB atlcar.cd30.ccr4 cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223],Lymphatic Diseases[MeSHID:D008206],Immunoproliferative Disorders[MeSHID:D007160],Immune System Diseases[MeSHID:D007154],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB icar30 t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],T-Lymphocyte[MeSHID:D013601],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728] phase 1 lymphocyte activation antigen cd30 TNFRSF8 Successful target unknown NA TTD , DGIDB mcla-145 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD lvgn6051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD anti-cd137 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD , DGIDB mg7-cart NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD , DGIDB utomilumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target antibody 63.65 TTD , DGIDB gen1042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD inbrx-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD pf-05082566 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown 63.65 TTD , DGIDB urelumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],melanoma[MeSHID:D008545] phase 2 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target antibody 95.48 TTD , DGIDB rg7827 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD urelumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],melanoma[MeSHID:D008545] phase 2 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown 95.48 TTD , DGIDB urelumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],melanoma[MeSHID:D008545] investigational tumor necrosis factor receptor superfamily member 9 TNFRSF9 NA antibody 95.48 drugbank , DGIDB ctx-471 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD adg106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] phase 1/2 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD gen1046 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD cd28 and cd137 car-t cells NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],T-Lymphocyte[MeSHID:D013601] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD , DGIDB cd137 car-t cell NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],B-Cell Lymphomas[MeSHID:D016393],Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218] phase 1/2 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD , DGIDB rg6076 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD urelumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],melanoma[MeSHID:D008545] phase 2 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target agonist 95.48 TTD , DGIDB urelumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],melanoma[MeSHID:D008545] investigational tumor necrosis factor receptor superfamily member 9 TNFRSF9 NA unknown 95.48 drugbank , DGIDB amg 506 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD agen2373 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD urelumab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],B-Cell Lymphomas[MeSHID:D016393],melanoma[MeSHID:D008545] investigational tumor necrosis factor receptor superfamily member 9 TNFRSF9 NA agonist 95.48 drugbank , DGIDB hg-1051 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune System Diseases[MeSHID:D007154] investigative co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD nm21-1480 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 co-stimulatory molecule 4-1bb TNFRSF9 Clinical trial target unknown NA TTD ad5-trail NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 tnf related apoptosis inducing ligand TNFSF10 Clinical trial target unknown NA TTD , DGIDB abbv-621 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1 tnf related apoptosis inducing ligand TNFSF10 Clinical trial target unknown NA TTD da-3607 NA Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tnf related apoptosis inducing ligand TNFSF10 Clinical trial target unknown NA TTD , DGIDB denosumab NA Hip Fractures[MeSHID:D006620],Neoplasms[MeSHID:D009369],Bone structure of spine[MeSHID:D013131],Fracture[MeSHID:D050723],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Bone Density[MeSHID:D015519],Malignant neoplasm of breast[MeSHID:D001943],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoporosis, Postmenopausal[MeSHID:D015663],Rheumatoid Arthritis[MeSHID:D001172] approved osteoclast differentiation factor TNFSF11 Successful target unknown 71.61 TTD , DGIDB lenalidomide small molecule Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor ligand superfamily member 11 TNFSF11 NA inhibitor 3.41 drugbank , DGIDB thiocolchicoside small molecule Contracture[MeSHID:D003286],Pain[MeSHID:D010146],Collagen Diseases[MeSHID:D003095],Muscle Tonus[MeSHID:D009129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] experimental tumor necrosis factor ligand superfamily member 11 TNFSF11 NA antagonist NA drugbank amgn-0007 biotech Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Neoplasm Metastasis[MeSHID:D009362] investigational tumor necrosis factor ligand superfamily member 11 TNFSF11 NA unknown NA drugbank denosumab biotech Hip Fractures[MeSHID:D006620],Neoplasms[MeSHID:D009369],Bone structure of spine[MeSHID:D013131],Fracture[MeSHID:D050723],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Bone Density[MeSHID:D015519],Malignant neoplasm of breast[MeSHID:D001943],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoporosis, Postmenopausal[MeSHID:D015663],Rheumatoid Arthritis[MeSHID:D001172] approved tumor necrosis factor ligand superfamily member 11 TNFSF11 NA antibody,inhibitor 71.61 drugbank , DGIDB denosumab biotech Hip Fractures[MeSHID:D006620],Neoplasms[MeSHID:D009369],Bone structure of spine[MeSHID:D013131],Fracture[MeSHID:D050723],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Bone Density[MeSHID:D015519],Malignant neoplasm of breast[MeSHID:D001943],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoporosis, Postmenopausal[MeSHID:D015663],Rheumatoid Arthritis[MeSHID:D001172] approved tumor necrosis factor ligand superfamily member 11 TNFSF11 NA antibody 71.61 drugbank , DGIDB lenalidomide small molecule Congenital chromosomal disease[MeSHID:D025063],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Chromosome Aberrations[MeSHID:D002869],Deletion Mutation[MeSHID:D017384],Anemia[MeSHID:D000740],Multiple Myeloma[MeSHID:D009101],Lymphoma, Follicular[MeSHID:D008224],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor ligand superfamily member 11 TNFSF11 NA inhibitor 3.41 drugbank , DGIDB cep-37251 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Bone Tissue[MeSHID:D001842] phase 1 osteoclast differentiation factor TNFSF11 Successful target unknown NA TTD , DGIDB alx-0141 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 osteoclast differentiation factor TNFSF11 Successful target unknown NA TTD , DGIDB denosumab NA Hip Fractures[MeSHID:D006620],Neoplasms[MeSHID:D009369],Bone structure of spine[MeSHID:D013131],Fracture[MeSHID:D050723],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Bone Density[MeSHID:D015519],Malignant neoplasm of breast[MeSHID:D001943],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoporosis, Postmenopausal[MeSHID:D015663],Rheumatoid Arthritis[MeSHID:D001172] approved osteoclast differentiation factor TNFSF11 Successful target antibody 71.61 TTD , DGIDB denosumab NA Hip Fractures[MeSHID:D006620],Neoplasms[MeSHID:D009369],Bone structure of spine[MeSHID:D013131],Fracture[MeSHID:D050723],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Bone Density[MeSHID:D015519],Malignant neoplasm of breast[MeSHID:D001943],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoporosis, Postmenopausal[MeSHID:D015663],Rheumatoid Arthritis[MeSHID:D001172] approved osteoclast differentiation factor TNFSF11 Successful target inhibitor 71.61 TTD , DGIDB ro-5458640 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tnf-related weak inducer of apoptosis TNFSF12 Clinical trial target unknown 127.3 TTD , DGIDB biib 023 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 tnf-related weak inducer of apoptosis TNFSF12 Clinical trial target unknown NA TTD , DGIDB atacicept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179], Systemic[MeSHID:D008180],Lymphoma[MeSHID:D008223],Multiple Sclerosis[MeSHID:D009103],Lupus Vulgaris[MeSHID:D008177],Rheumatoid Arthritis[MeSHID:D001172] phase 3 a proliferation-inducing ligand TNFSF13 Clinical trial target inhibitor 95.48 TTD , DGIDB atacicept NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Discoid[MeSHID:D008179], Systemic[MeSHID:D008180],Lymphoma[MeSHID:D008223],Multiple Sclerosis[MeSHID:D009103],Lupus Vulgaris[MeSHID:D008177],Rheumatoid Arthritis[MeSHID:D001172] phase 3 a proliferation-inducing ligand TNFSF13 Clinical trial target unknown 95.48 TTD , DGIDB 1,4-diethylene dioxide NA NA investigative b-cell-activating factor TNFSF13B Successful target unknown NA TTD tabalumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 3 b-cell-activating factor TNFSF13B Successful target unknown 25.46 TTD , DGIDB lymphorad-131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] discontinued in phase 1 b-cell-activating factor TNFSF13B Successful target unknown NA TTD receptor-fc fusion proteins NA NA investigative b-cell-activating factor TNFSF13B Successful target unknown NA TTD belimumab NA Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-cell-activating factor TNFSF13B Successful target antibody 63.65 TTD , DGIDB belimumab NA Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-cell-activating factor TNFSF13B Successful target unknown 63.65 TTD , DGIDB blisibimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 3 b-cell-activating factor TNFSF13B Successful target unknown 38.19 TTD , DGIDB tabalumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] phase 3 b-cell-activating factor TNFSF13B Successful target inhibitor 25.46 TTD , DGIDB belimumab biotech Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor ligand superfamily member 13b TNFSF13B NA neutralizer 63.65 drugbank , DGIDB blisibimod NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 3 b-cell-activating factor TNFSF13B Successful target inhibitor 38.19 TTD , DGIDB belimumab biotech Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor ligand superfamily member 13b TNFSF13B NA neutralizer,antibody 63.65 drugbank , DGIDB 1,4-dioxane small molecule NA experimental tumor necrosis factor ligand superfamily member 13b TNFSF13B NA unknown NA drugbank belimumab biotech Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tumor necrosis factor ligand superfamily member 13b TNFSF13B NA neutralizer,inhibitor 63.65 drugbank , DGIDB br3-fc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immune thrombocytopenic purpura[MeSHID:D016553],Rheumatoid Arthritis[MeSHID:D001172] discontinued in phase 2 b-cell-activating factor TNFSF13B Successful target unknown NA TTD amg 570 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lupus Erythematosus, Systemic[MeSHID:D008180] phase 2 b-cell-activating factor TNFSF13B Successful target unknown NA TTD belimumab NA Lupus Erythematosus, Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved b-cell-activating factor TNFSF13B Successful target inhibitor 63.65 TTD , DGIDB rg7888 NA Carcinoma, Transitional Cell[MeSHID:D002295],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tax transcriptionally-activated glycoprotein 1 TNFSF4 Clinical trial target unknown NA TTD , DGIDB mrna-2752 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tax transcriptionally-activated glycoprotein 1 TNFSF4 Clinical trial target unknown NA TTD amg 386 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Asthma[MeSHID:D001249] phase 3 tax transcriptionally-activated glycoprotein 1 TNFSF4 Clinical trial target unknown NA TTD , DGIDB medi6383 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tax transcriptionally-activated glycoprotein 1 TNFSF4 Clinical trial target unknown 31.83 TTD , DGIDB mrna-2416 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051],Lymphoma[MeSHID:D008223] phase 1 tax transcriptionally-activated glycoprotein 1 TNFSF4 Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational traf2 and nck-interacting protein kinase TNIK NA inhibitor NA drugbank xmd8-92 NA NA investigative non-receptor tyrosine-protein kinase tnk1 TNK1 Literature-reported target inhibitor NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational non-receptor tyrosine-protein kinase tnk1 TNK1 NA inhibitor NA drugbank entrectinib small molecule Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Neuroblastoma[MeSHID:D009447],Colorectal Cancer[MeSHID:D015179],Mammary Analogue Secretory Carcinoma[MeSHID:D000069295] approved,investigational activated cdc42 kinase 1 TNK2 NA unknown 0.06 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational activated cdc42 kinase 1 TNK2 NA inhibitor NA drugbank us8481733, 95 NA NA patented activated cdc42 kinase 1 TNK2 Patented-recorded target unknown NA TTD , DGIDB bdbm50379214 NA NA patented activated cdc42 kinase 1 TNK2 Patented-recorded target unknown NA TTD , DGIDB debromohymenialdisine small molecule NA experimental activated cdc42 kinase 1 TNK2 NA unknown NA drugbank us8481733, 106 NA NA patented activated cdc42 kinase 1 TNK2 Patented-recorded target unknown NA TTD , DGIDB atp small molecule NA investigational,nutraceutical activated cdc42 kinase 1 TNK2 NA unknown NA drugbank pmid17280833c30 NA NA investigative activated cdc42 kinase 1 TNK2 Patented-recorded target unknown NA TTD us8481733, 118 NA NA patented activated cdc42 kinase 1 TNK2 Patented-recorded target unknown NA TTD , DGIDB pmid27841036-compound-37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 tankyrase-1 TNKS Clinical trial target unknown NA TTD , DGIDB stenoparib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 tankyrase-1 TNKS Clinical trial target unknown NA TTD pmid27841036-compound-37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 tankyrase-2 TNKS2 Clinical trial target unknown NA TTD , DGIDB stenoparib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 tankyrase-2 TNKS2 Clinical trial target unknown NA TTD levosimendan small molecule Heart Diseases[MeSHID:D006331],Congestive heart failure[MeSHID:D006333],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976],Cardiac Output[MeSHID:D002302],Heart failure[MeSHID:D006333],Syndrome[MeSHID:D013577] approved,investigational troponin c, slow skeletal and cardiac muscles TNNC1 NA potentiator 57.29 drugbank , DGIDB bepridil small molecule Hypertensive disease[MeSHID:D006973],Stable angina[MeSHID:D060050],Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn troponin c, slow skeletal and cardiac muscles TNNC1 NA other 6.94 drugbank , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational troponin c, slow skeletal and cardiac muscles TNNC1 NA other NA drugbank levosimendan NA Heart Diseases[MeSHID:D006331],Congestive heart failure[MeSHID:D006333],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pulmonary Hypertension[MeSHID:D006976],Cardiac Output[MeSHID:D002302],Heart failure[MeSHID:D006333],Syndrome[MeSHID:D013577] approved troponin c TNNC1 Successful target unknown 57.29 TTD , DGIDB trifluoperazine small molecule Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Schizophrenia[MeSHID:D012559] approved,investigational troponin c, slow skeletal and cardiac muscles TNNC1 NA unknown NA drugbank aluminium monostearate small molecule NA experimental troponin c, slow skeletal and cardiac muscles TNNC1 NA stimulator NA drugbank 5-[1-(3,4-dimethoxy-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-6-methyl-3,6-dihydro-[1,3,4]thiadiazin-2-one small molecule NA experimental troponin c, slow skeletal and cardiac muscles TNNC1 NA unknown NA drugbank n-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide small molecule NA experimental troponin c, slow skeletal and cardiac muscles TNNC1 NA unknown NA drugbank dihydroxyaluminium NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dermatitis[MeSHID:D003872] approved troponin c TNNC1 Successful target unknown NA TTD , DGIDB calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical troponin c, slow skeletal and cardiac muscles TNNC1 NA agonist NA drugbank ck-2017357 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Muscle Fatigue[MeSHID:D018763] phase 3 fast skeletal muscle troponin complex TNNC2 Clinical trial target unknown 21.22 TTD , DGIDB felodipine small molecule Essential Hypertension[MeSHID:D000075222],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973] approved,investigational troponin c, skeletal muscle TNNC2 NA other NA drugbank ck-2127107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Muscular Atrophy[MeSHID:D009133],Spinal Muscular Atrophy[MeSHID:D009134] phase 2 fast skeletal muscle troponin complex TNNC2 Clinical trial target unknown 31.83 TTD , DGIDB octylphenoxy polyethoxyethanol small molecule NA experimental troponin c, skeletal muscle TNNC2 NA unknown NA drugbank calcium small molecule Signal Transduction Pathways[MeSHID:D015398],Bone Tissue[MeSHID:D001842],Cells[MeSHID:D002477],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] nutraceutical troponin c, skeletal muscle TNNC2 NA agonist NA drugbank n-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide small molecule NA experimental troponin i, cardiac muscle TNNI3 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase tnni3k TNNI3K NA inhibitor NA drugbank becatecarin NA Malignant neoplasm of stomach[MeSHID:D013274],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Malignant neoplasm of liver[MeSHID:D008113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 3 dna topoisomerase i TOP1 Successful target inhibitor 0.22 TTD , DGIDB irinotecan small molecule Adenocarcinoma[MeSHID:D000230],Pancreas[MeSHID:D010179],Colorectal Cancer[MeSHID:D015179],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Disease Progression[MeSHID:D018450],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna topoisomerase 1 TOP1 NA inhibitor 0.28 drugbank , DGIDB lucanthone small molecule Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 1 TOP1 NA inhibitor NA drugbank peg-sn38 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB ds-6157 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gastrointestinal Stromal Tumors[MeSHID:D046152] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD lurtotecan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175] discontinued in phase 2 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB afeletecan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 1 dna topoisomerase i TOP1 Successful target unknown 1.34 TTD , DGIDB it-141 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown 0.27 TTD , DGIDB nsc-341622 NA NA investigative dna topoisomerase i TOP1 Successful target unknown 3.35 TTD , DGIDB elomotecan hydrochloride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB sacituzumab govitecan biotech Triple Negative Breast Neoplasms[MeSHID:D064726],Urothelium[MeSHID:D019459],Neoplasm Metastasis[MeSHID:D009362],Cessation of life[MeSHID:D003643] approved,investigational dna topoisomerase 1 TOP1 NA inhibitor NA drugbank tlc-388 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB lmp744 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD dts-108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD etirinotecan pegol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943] phase 3 dna topoisomerase i TOP1 Successful target inhibitor 1.34 TTD , DGIDB abi-011 NA Ankle brachial pressure index (observable entity)[MeSHID:D055109],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB nk-611 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD 3-(4-phenyl-2,4'-bipyridin-6-yl)phenol NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD irinotecan NA Adenocarcinoma[MeSHID:D000230],Pancreas[MeSHID:D010179],Colorectal Cancer[MeSHID:D015179],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Disease Progression[MeSHID:D018450],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase i TOP1 Successful target inhibitor 0.28 TTD , DGIDB mln-576 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB drf-1042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB de-310 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD edotecarin NA Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Esophageal Neoplasms[MeSHID:D004938],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dna topoisomerase i TOP1 Successful target unknown 2.01 TTD , DGIDB cositecan small molecule melanoma[MeSHID:D008545],Malignant neoplasm of brain[MeSHID:D001932],Malignant neoplasm of lung[MeSHID:D008175] investigational dna topoisomerase 1 TOP1 NA unknown NA drugbank diflomotecan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB 7-amino-4-hydroxy-2-naphthalenesulfonic acid NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD 2,3-dimethoxy-12h-[1,3]dioxolo[5,6]indeno[1,2-c]isoquinolin-6-ium small molecule NA experimental dna topoisomerase 1 TOP1 NA unknown NA drugbank s-16020-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] discontinued in phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD etirinotecan pegol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943] phase 3 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB camptothecin small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental dna topoisomerase 1 TOP1 NA unknown 1.01 drugbank , DGIDB 5-hydroxy-1h-indole-3-acetic acid NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD 4-(4,6-diphenylpyridin-2-yl)phenol NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD pegamotecan NA Esophageal Neoplasms[MeSHID:D004938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB 3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD tafluposide NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown 0.34 TTD , DGIDB homocamptothecins (hcpts) NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD kt6006 NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD ati-1150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD beta-lapachone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna topoisomerase i TOP1 Successful target unknown 0.05 TTD , DGIDB (5z,9z)-5,9-heptacosadienoic acid NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD camptothecin NA Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 dna topoisomerase i TOP1 Successful target unknown 1.01 TTD , DGIDB ser-203 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD atiratecan NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD belotecan hydrocholoride NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB hexylresorcinol small molecule Malignant Neoplasms[MeSHID:D009369],Skin Diseases, Infectious[MeSHID:D012874],Burn injury[MeSHID:D002056],Aging[MeSHID:D000375],Pharyngitis[MeSHID:D010612],Pain[MeSHID:D010146] approved dna topoisomerase 1 TOP1 NA inhibitor NA drugbank karenitecin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175] phase 3 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB trastuzumab deruxtecan biotech Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna topoisomerase 1 TOP1 NA inhibitor NA drugbank elsamitrucin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 1 TOP1 NA unknown NA drugbank crisnatol mesilate NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD edotecarin small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Esophageal Neoplasms[MeSHID:D004938],Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dna topoisomerase 1 TOP1 NA unknown 2.01 drugbank , DGIDB ds-7300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 dna topoisomerase i TOP1 Successful target unknown NA TTD gz402674 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB xmt-1001 NA Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB cho793076 NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD rubitecan NA Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of ovary[MeSHID:D010051],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] phase 3 dna topoisomerase i TOP1 Successful target unknown 1.01 TTD , DGIDB 10-hydroxycamptothecin NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD 3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD polyglutamate camptothecin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB 2,3-dimethoxybenzo[i]phenanthridines NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD dibenzo-p-dioxin-2-carboxylic acid NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD quinizarin NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD ckd602 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB 3-(6-phenyl-2,4'-bipyridin-4-yl)phenol NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD nogalamycin NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD topetecan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB pen-866 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB daniquidone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 dna topoisomerase i TOP1 Successful target unknown 0.22 TTD , DGIDB 4-hydroxysaprothoquinone NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD xr-5000 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB a35566-a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD cz-48 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB namitecan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB 9-aminocamptothecin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acquired Immunodeficiency Syndrome[MeSHID:D000163] phase 2 dna topoisomerase i TOP1 Successful target unknown 0.06 TTD , DGIDB gimatecan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 2 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB ar-67 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Glioblastoma[MeSHID:D005909] phase 2 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB le-sn38 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB eq-917 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB e-758 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD men-14295 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD topostatin NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD topotecan small molecule Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Malignant neoplasm of ovary[MeSHID:D010051],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Hypersensitivity[MeSHID:D006967],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna topoisomerase 1 TOP1 NA inhibitor 0.76 drugbank , DGIDB (s)-drf-1042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] clinical trial dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB idn-6384 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD intoplicine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB genz-644282 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB rosettacin NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD b-lactams NA Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB lmp400 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD 4-(6-phenyl-2,4'-bipyridin-4-yl)phenol NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD irinotecan NA Adenocarcinoma[MeSHID:D000230],Pancreas[MeSHID:D010179],Colorectal Cancer[MeSHID:D015179],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Disease Progression[MeSHID:D018450],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase i TOP1 Successful target unknown 0.28 TTD , DGIDB exatecan NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 dna topoisomerase i TOP1 Successful target unknown 0.67 TTD , DGIDB idn-5174 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD 7-ethyl-10-hydroxycamptothecin small molecule Colorectal Cancer[MeSHID:D015179] investigational dna topoisomerase 1 TOP1 NA unknown NA drugbank kt6528 NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD sodium stibogluconate small molecule Protozoan Infections[MeSHID:D011528],Neoplasms[MeSHID:D009369],Leishmaniasis[MeSHID:D007896],bite injury[MeSHID:D001733],Temperance[MeSHID:D013695],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna topoisomerase 1 TOP1 NA inhibitor NA drugbank xmt-1001 small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 1 TOP1 NA unknown NA drugbank , DGIDB topotecan NA Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Malignant neoplasm of ovary[MeSHID:D010051],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Hypersensitivity[MeSHID:D006967],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved dna topoisomerase i TOP1 Successful target unknown 0.76 TTD , DGIDB dfp 13318 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB 4-(5,11-dioxo-5h-indeno[1,2-c]isoquinolin-6(11h)-yl)butanoate small molecule NA experimental dna topoisomerase 1 TOP1 NA unknown NA drugbank (s)-drf-1042 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749] clinical trial dna topoisomerase i TOP1 Successful target inhibitor NA TTD , DGIDB th-1320 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative dna topoisomerase i TOP1 Successful target unknown NA TTD crlx101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Malignant neoplasm of ovary[MeSHID:D010051],Non-Small Cell Lung Carcinoma[MeSHID:D002289] phase 2 dna topoisomerase i TOP1 Successful target unknown NA TTD , DGIDB 3,3'-(4-phenylpyridine-2,6-diyl)diphenol NA NA investigative dna topoisomerase i TOP1 Successful target unknown NA TTD rubitecan small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],melanoma[MeSHID:D008545],Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of ovary[MeSHID:D010051],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigational dna topoisomerase 1 TOP1 NA unknown 1.01 drugbank , DGIDB topotecan small molecule Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Malignant neoplasm of ovary[MeSHID:D010051],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Hypersensitivity[MeSHID:D006967],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna topoisomerase i, mitochondrial TOP1MT NA inhibitor 2.83 drugbank , DGIDB irinotecan small molecule Adenocarcinoma[MeSHID:D000230],Pancreas[MeSHID:D010179],Colorectal Cancer[MeSHID:D015179],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Disease Progression[MeSHID:D018450],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna topoisomerase i, mitochondrial TOP1MT NA inhibitor 4.4 drugbank , DGIDB pk1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 dna topoisomerase ii alpha TOP2A Clinical trial target unknown NA TTD , DGIDB amonafide small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dna topoisomerase 2-alpha TOP2A NA unknown 2.78 drugbank , DGIDB rta 744 small molecule Malignant neoplasm of brain[MeSHID:D001932] investigational dna topoisomerase 2-alpha TOP2A NA unknown NA drugbank , DGIDB dactinomycin small molecule Inferior Colliculus[MeSHID:D007245],Nephroblastoma[MeSHID:D009396],Testis[MeSHID:D013737],Ewings sarcoma[MeSHID:D012512],Rhabdomyosarcoma[MeSHID:D012208],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna topoisomerase 2 TOP2A NA inhibitor NA drugbank sp1049c small molecule Esophagus[MeSHID:D004947],Carcinoma[MeSHID:D002277] investigational dna topoisomerase 2-alpha TOP2A NA unknown NA drugbank pefloxacin small molecule Urethritis[MeSHID:D014526],Gonorrhea[MeSHID:D006069],Gram-Negative Bacterial Infections[MeSHID:D016905],Urinary tract[MeSHID:D014551],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank banoxantrone small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] investigational dna topoisomerase 2-alpha TOP2A NA unknown NA drugbank epirubicin small molecule Neoplasms[MeSHID:D009369],Patient Participation[MeSHID:D010358],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved dna topoisomerase 2-alpha TOP2A NA inhibitor 0.16 drugbank , DGIDB moxifloxacin small molecule Secondary Infections[MeSHID:D060085],Sinusitis[MeSHID:D012852],Conjunctivitis[MeSHID:D003231],Bacterial conjunctivitis[MeSHID:D003234],Pneumonia[MeSHID:D011014],Lung[MeSHID:D008168],Bronchitis, Chronic[MeSHID:D029481],Infection[MeSHID:D007239],pathologic fistula[MeSHID:D005402],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank trovafloxacin small molecule Gonorrhea[MeSHID:D006069],Uterine Cervicitis[MeSHID:D002575],Urethra[MeSHID:D014521],Urethritis[MeSHID:D014526],Rectum[MeSHID:D012007],Muscle strain[MeSHID:D013180],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank idarubicin small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase 2-alpha TOP2A NA inhibitor 0.18 drugbank , DGIDB lucanthone small molecule Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank doxorubicin small molecule Epithelial ovarian cancer[MeSHID:C538090],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Bronchogenic Carcinoma[MeSHID:D002283],Carcinoma[MeSHID:D002277],Urinary Bladder[MeSHID:D001743],Nephroblastoma[MeSHID:D009396],lymph nodes[MeSHID:D008198],Leukemia, Myelocytic, Acute[MeSHID:D015470],Thyroid carcinoma[MeSHID:D013964],Body tissue[MeSHID:D014024],Regression - mental defense mechanism[MeSHID:D012043],Lymphoma[MeSHID:D008223],Stomach[MeSHID:D013270],Osteosarcoma[MeSHID:D012516],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Neuroblastoma[MeSHID:D009447],Carcinoma, Transitional Cell[MeSHID:D002295],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational dna topoisomerase 2-alpha TOP2A NA inhibitor 0.13 drugbank , DGIDB mitoxantrone small molecule Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Relapse[MeSHID:D012008],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna topoisomerase 2-alpha TOP2A NA inhibitor 0.23 drugbank , DGIDB dexrazoxane small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Cardiomyopathies[MeSHID:D009202],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140] approved,withdrawn dna topoisomerase 2-alpha TOP2A NA inhibitor 1.33 drugbank , DGIDB ciprofloxacin small molecule Solutions[MeSHID:D012996],Sinusitis[MeSHID:D012852],Otitis Media[MeSHID:D010033],Febrile Neutropenia[MeSHID:D064147],Bacterial conjunctivitis[MeSHID:D003234],Skin Diseases, Infectious[MeSHID:D012874],Eye[MeSHID:D005123],Ear structure[MeSHID:D004423],Intraabdominal Infections[MeSHID:D059413],Anthrax disease[MeSHID:D000881],Pyelonephritis[MeSHID:D011704],Corneal Ulcer[MeSHID:D003320],Urinary tract infection[MeSHID:D014552],Patient Discharge[MeSHID:D010351],Infection[MeSHID:D007239],Plague[MeSHID:D010930],Chronic Bacterial Prostatitis[MeSHID:D011472],Otitis Media with Effusion[MeSHID:D010034],Otitis Externa[MeSHID:D010032],Conjunctivitis[MeSHID:D003231],Pneumonia[MeSHID:D011014],Respiratory Tract Infections[MeSHID:D012141],Bone Tissue[MeSHID:D001842],Inspiration function[MeSHID:D001239],Bronchitis, Chronic[MeSHID:D029481] approved,investigational dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank annamycin small molecule leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] investigational dna topoisomerase 2-alpha TOP2A NA unknown NA drugbank nk314 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] investigative dna topoisomerase ii alpha TOP2A Clinical trial target unknown NA TTD etoposide small molecule Malignant Neoplasms[MeSHID:D009369],Myeloid Leukemia[MeSHID:D007951],Lymphoma[MeSHID:D008223],Small cell carcinoma of lung[MeSHID:D055752],Testicular Neoplasms[MeSHID:D013736],Glioblastoma[MeSHID:D005909],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase 2-alpha TOP2A NA inhibitor 0.89 drugbank , DGIDB 13-deoxydoxorubicin small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] investigational dna topoisomerase 2-alpha TOP2A NA unknown NA drugbank enoxacin small molecule Gonorrhea[MeSHID:D006069],Urethra[MeSHID:D014521],Muscle strain[MeSHID:D013180],Urinary tract infection[MeSHID:D014552],Cystitis[MeSHID:D003556],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank camsirubicin NA Sarcoma[MeSHID:D012509],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 dna topoisomerase ii alpha TOP2A Clinical trial target unknown NA TTD teniposide small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase 2-alpha TOP2A NA inhibitor 1.09 drugbank , DGIDB genistein small molecule Malignant neoplasm of prostate[MeSHID:D011471],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dna topoisomerase 2-alpha TOP2A NA unknown 0.06 drugbank , DGIDB podofilox small molecule Condylomata Acuminata[MeSHID:D003218],Warts[MeSHID:D014860],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reproduction[MeSHID:D012098] approved dna topoisomerase 2-alpha TOP2A NA inhibitor 0.28 drugbank , DGIDB daunorubicin small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Monocytes[MeSHID:D009000],Diagnosis[MeSHID:D003933],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Kaposi Sarcoma[MeSHID:D012514] approved dna topoisomerase 2-alpha TOP2A NA inhibitor 0.09 drugbank , DGIDB aldoxorubicin small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509],Small cell carcinoma of lung[MeSHID:D055752],Carcinoma, Pancreatic Ductal[MeSHID:D021441],Glioblastoma[MeSHID:D005909] investigational dna topoisomerase 2-alpha TOP2A NA inhibitor 1.19 drugbank , DGIDB valrubicin small molecule Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] approved dna topoisomerase 2-alpha TOP2A NA inhibitor 1.33 drugbank , DGIDB etoposide small molecule Malignant Neoplasms[MeSHID:D009369],Myeloid Leukemia[MeSHID:D007951],Lymphoma[MeSHID:D008223],Small cell carcinoma of lung[MeSHID:D055752],Testicular Neoplasms[MeSHID:D013736],Glioblastoma[MeSHID:D005909],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Malignant neoplasm of testis[MeSHID:D013736],Disease[MeSHID:D004194] approved dna topoisomerase 2-alpha TOP2A NA inhibitor 0.89 drugbank , DGIDB norfloxacin small molecule Urinary tract infection[MeSHID:D014552],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank sparfloxacin small molecule Muscle strain[MeSHID:D013180],Bronchitis, Chronic[MeSHID:D029481],Infection[MeSHID:D007239],Pneumonia[MeSHID:D011014],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank ofloxacin small molecule Gonorrhea[MeSHID:D006069],Respiratory tract structure[MeSHID:D012137],Body tissue[MeSHID:D014024],Urethra[MeSHID:D014521],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank becatecarin small molecule Malignant neoplasm of stomach[MeSHID:D013274],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Malignant neoplasm of liver[MeSHID:D008113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 2-alpha TOP2A NA unknown 0.53 drugbank , DGIDB fleroxacin small molecule Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank finafloxacin small molecule Muscle strain[MeSHID:D013180],Otitis Externa[MeSHID:D010032],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary tract infection[MeSHID:D014552] approved,investigational dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank amsacrine small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational dna topoisomerase 2-alpha TOP2A NA inhibitor 0.9 drugbank , DGIDB declopramide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dna topoisomerase 2-alpha TOP2A NA unknown NA drugbank lomefloxacin small molecule Respiratory tract structure[MeSHID:D012137],Bacterial Infections[MeSHID:D001424],Pneumonia[MeSHID:D011014],Cloaca Chamber[MeSHID:D002988],Respiratory Tract Infections[MeSHID:D012141],Urinary tract[MeSHID:D014551],Urinary tract infection[MeSHID:D014552],Bronchitis, Chronic[MeSHID:D029481],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna topoisomerase 2-alpha TOP2A NA inhibitor NA drugbank amrubicin small molecule Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] investigational dna topoisomerase 2-alpha TOP2A NA inhibitor 1.59 drugbank , DGIDB becatecarin small molecule Malignant neoplasm of stomach[MeSHID:D013274],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Malignant neoplasm of liver[MeSHID:D008113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 2-alpha TOP2A NA inhibitor 0.53 drugbank , DGIDB elsamitrucin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 2-alpha TOP2A NA unknown NA drugbank annamycin NA leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1/2 dna topoisomerase ii alpha TOP2A Clinical trial target unknown NA TTD zen-012 small molecule Neoplasms[MeSHID:D009369] investigational dna topoisomerase 2-alpha TOP2A NA unknown NA drugbank amp-pnp NA NA investigative dna topoisomerase ii beta TOP2B Successful target unknown NA TTD etoposide small molecule Malignant Neoplasms[MeSHID:D009369],Myeloid Leukemia[MeSHID:D007951],Lymphoma[MeSHID:D008223],Small cell carcinoma of lung[MeSHID:D055752],Testicular Neoplasms[MeSHID:D013736],Glioblastoma[MeSHID:D005909],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna topoisomerase 2-beta TOP2B NA inhibitor 0.23 drugbank , DGIDB declopramide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dna topoisomerase 2-beta TOP2B NA unknown NA drugbank xb-947 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase ii beta TOP2B Successful target unknown NA TTD , DGIDB etoposide small molecule Malignant Neoplasms[MeSHID:D009369],Myeloid Leukemia[MeSHID:D007951],Lymphoma[MeSHID:D008223],Small cell carcinoma of lung[MeSHID:D055752],Testicular Neoplasms[MeSHID:D013736],Glioblastoma[MeSHID:D005909],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Malignant neoplasm of testis[MeSHID:D013736],Disease[MeSHID:D004194] approved dna topoisomerase 2-beta TOP2B NA inhibitor 0.23 drugbank , DGIDB dexrazoxane NA Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Cardiomyopathies[MeSHID:D009202],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140] approved dna topoisomerase ii beta TOP2B Successful target unknown 1.52 TTD , DGIDB 3'-thio-thymidine-5'-phosphate small molecule NA experimental dna topoisomerase 2-beta TOP2B NA unknown NA drugbank daunorubicin small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Monocytes[MeSHID:D009000],Diagnosis[MeSHID:D003933],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Kaposi Sarcoma[MeSHID:D012514] approved dna topoisomerase 2-beta TOP2B NA inhibitor 0.07 drugbank , DGIDB dactinomycin small molecule Inferior Colliculus[MeSHID:D007245],Nephroblastoma[MeSHID:D009396],Testis[MeSHID:D013737],Ewings sarcoma[MeSHID:D012512],Rhabdomyosarcoma[MeSHID:D012208],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna topoisomerase 2 TOP2B NA inhibitor NA drugbank becatecarin small molecule Malignant neoplasm of stomach[MeSHID:D013274],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Malignant neoplasm of liver[MeSHID:D008113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 2-beta TOP2B NA inhibitor 1.01 drugbank , DGIDB phosphoaminophosphonic acid-adenylate ester small molecule NA experimental dna topoisomerase 2-beta TOP2B NA unknown NA drugbank becatecarin small molecule Malignant neoplasm of stomach[MeSHID:D013274],leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Malignant neoplasm of liver[MeSHID:D008113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna topoisomerase 2-beta TOP2B NA unknown 1.01 drugbank , DGIDB 3'-thio-thymidine-5'-phosphate NA NA investigative dna topoisomerase ii beta TOP2B Successful target unknown NA TTD xk-469 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dna topoisomerase ii beta TOP2B Successful target unknown NA TTD , DGIDB zen-012 small molecule Neoplasms[MeSHID:D009369] investigational dna topoisomerase 2-beta TOP2B NA unknown NA drugbank amonafide small molecule Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dna topoisomerase 2-beta TOP2B NA unknown 0.76 drugbank , DGIDB dexrazoxane small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Cardiomyopathies[MeSHID:D009202],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Respiratory Tract Diseases[MeSHID:D012140] approved,withdrawn dna topoisomerase 2-beta TOP2B NA unknown 1.52 drugbank , DGIDB technetium tc-99m ciprofloxacin small molecule Communicable Diseases[MeSHID:D003141],Parasitic Diseases[MeSHID:D010272],Infection[MeSHID:D007239] investigational dna topoisomerase 2-beta TOP2B NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational cellular tumor antigen p53 TP53 NA chaperone NA drugbank , DGIDB alt-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of urinary bladder[MeSHID:D001749],Leukemia, Myelocytic, Acute[MeSHID:D015470],Muscle[MeSHID:D009132],Malignant neoplasm of muscle[MeSHID:D019042],Urinary Bladder[MeSHID:D001743] phase 2 cellular tumor antigen p53 TP53 Clinical trial target unknown 0.17 TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational cellular tumor antigen p53 TP53 NA unknown NA drugbank ingn-225 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 2 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB dendritic cell vaccine NA Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Antigen-Presenting Cells[MeSHID:D000938],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB isa-p53-01 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB apg-115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Prolymphocytic Leukemia[MeSHID:D015463] phase 2 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB nu-8231 NA NA investigative cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD triethyl phosphate small molecule NA experimental cellular tumor antigen p53 TP53 NA unknown NA drugbank dendritic cell vaccine NA Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258],Antigen-Presenting Cells[MeSHID:D000938] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB opi-1002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Acute kidney injury[MeSHID:D058186] phase 2 p53 messenger rna TP53 Clinical trial target unknown NA TTD contusugene ladenovec NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of mouth[MeSHID:D009062],Liver[MeSHID:D008099] phase 3 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB sgt-53 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Malignant Neoplasms[MeSHID:D009369],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB acetylsalicylic acid small molecule Angina, Unstable[MeSHID:D000789],Ability[MeSHID:D001076],Operative Surgical Procedures[MeSHID:D013514],Phonophobia[MeSHID:D012001],Stable angina[MeSHID:D060050],Myocardial Infarction[MeSHID:D009203],Back Pain[MeSHID:D001416],Sprain[MeSHID:D013180],Pain[MeSHID:D010146],Hypersensitivity[MeSHID:D006967],Cardiac Arrest[MeSHID:D006323],Patient Discharge[MeSHID:D010351],Platelet aggregation[MeSHID:D010974],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Myositis[MeSHID:D009220],Insertion Mutation[MeSHID:D016254],Coronary heart disease[MeSHID:D003327],Fracture[MeSHID:D050723],Neuralgia[MeSHID:D009437],Fever[MeSHID:D005334],Cerebrovascular accident[MeSHID:D020521],Migraine Disorders[MeSHID:D008881],Cessation of life[MeSHID:D003643],Sound - physical agent[MeSHID:D013016],Diagnosis[MeSHID:D003933],Cerebral Infarction[MeSHID:D002544],Influenza[MeSHID:D007251],Inflammation[MeSHID:D007249],Bursitis[MeSHID:D002062],Photophobia[MeSHID:D020795],Arthritis[MeSHID:D001168],Dysmenorrhea[MeSHID:D004412],Synovitis[MeSHID:D013585],Coronary Arteriosclerosis[MeSHID:D003324],Headache[MeSHID:D006261],Thrombosis[MeSHID:D013927],Traumatic injury[MeSHID:D014947],Burn injury[MeSHID:D002056],Common Cold[MeSHID:D003139],Toothache[MeSHID:D014098],Thromboembolism[MeSHID:D013923],Platelet Adhesiveness[MeSHID:D010973] approved,vet_approved cellular tumor antigen p53 TP53 NA inducer NA drugbank cgm097 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown 0.08 TTD , DGIDB coti-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometrial Carcinoma[MeSHID:D016889],Fallopian Tube Carcinoma[MeSHID:D005185],cervical cancer[MeSHID:D002583],Malignant Neoplasms[MeSHID:D009369],Cancer of Head and Neck[MeSHID:D006258],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB 1-(9-ethyl-9h-carbazol-3-yl)-n-methylmethanamine small molecule NA experimental,investigative cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , drugbank apr-246 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Esophageal Neoplasms[MeSHID:D004938],Stomach[MeSHID:D013270],Malignant neoplasm of urinary bladder[MeSHID:D001749],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Adenocarcinoma[MeSHID:D000230],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 cellular tumor antigen p53 TP53 Clinical trial target unknown 1.18 TTD , DGIDB ad-p53 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD onyx-015 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cancer of Head and Neck[MeSHID:D006258] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown 0.17 TTD , DGIDB dendritic cell vaccine NA Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Antigen-Presenting Cells[MeSHID:D000938],Glioblastoma[MeSHID:D005909] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB sar-405838 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown 0.84 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational cellular tumor antigen p53 TP53 NA unknown NA drugbank qpi-1002 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Structure of renal artery[MeSHID:D012077],Arteries[MeSHID:D001158],Disease[MeSHID:D004194],Kidney Diseases[MeSHID:D007674] phase 3 cellular tumor antigen p53 TP53 Clinical trial target unknown 0.17 TTD , DGIDB nutlin-3 NA NA investigative cellular tumor antigen p53 TP53 Clinical trial target unknown 0.76 TTD , DGIDB zinc sulfate, unspecified form small molecule NA approved,experimental cellular tumor antigen p53 TP53 NA chaperone NA drugbank thymoquinone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Polycystic Ovary Syndrome[MeSHID:D011085] phase 2/3 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD cenersen NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 p53 messenger rna TP53 Clinical trial target unknown NA TTD ingn-234 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of mouth[MeSHID:D009062] discontinued in phase 2 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD hdm201 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],liposarcoma[MeSHID:D008080],Hematologic Neoplasms[MeSHID:D019337] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB azd 3355 small molecule Gastroesophageal reflux disease[MeSHID:D005764] investigational cellular tumor antigen p53 TP53 NA unknown NA drugbank ahl NA Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukoencephalitis, Acute Hemorrhagic[MeSHID:D004684] investigative p53 messenger rna TP53 Clinical trial target unknown NA TTD kevetrin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 2 cellular tumor antigen p53 TP53 Clinical trial target unknown 0.34 TTD , DGIDB pc14586 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 p53 y220c mutant TP53 Clinical trial target unknown NA TTD dendritic cell vaccine NA Dendritic Cells[MeSHID:D003713],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Antigen-Presenting Cells[MeSHID:D000938],Malignant neoplasm of prostate[MeSHID:D011471] phase 1 cellular tumor antigen p53 TP53 Clinical trial target unknown NA TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational tumor protein p73 TP73 NA cofactor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational tumor protein p73 TP73 NA chaperone NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental tumor protein p73 TP73 NA chaperone NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational tumor protein p73 TP73 NA unknown NA drugbank pf-06263507 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 oncotrophoblast glycoprotein 5t4 TPBG Clinical trial target unknown 15.91 TTD , DGIDB gen1044 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 oncotrophoblast glycoprotein 5t4 TPBG Clinical trial target unknown NA TTD trovax NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] phase 3 oncotrophoblast glycoprotein 5t4 TPBG Clinical trial target unknown 15.91 TTD , DGIDB naptumomab estafenatox NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2/3 oncotrophoblast glycoprotein 5t4 TPBG Clinical trial target antibody NA TTD , DGIDB naptumomab estafenatox NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2/3 oncotrophoblast glycoprotein 5t4 TPBG Clinical trial target unknown NA TTD , DGIDB naptumomab estafenatox NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2/3 oncotrophoblast glycoprotein 5t4 TPBG Clinical trial target unknown 15.91 TTD , DGIDB cv-9201 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 oncotrophoblast glycoprotein 5t4 TPBG Clinical trial target unknown NA TTD , DGIDB phosphatidyl (3,5) inositol biphosphate NA NA investigative two pore calcium channel protein 1 TPCN1 Literature-reported target unknown NA TTD phosphatidyl (3,5) inositol biphosphate NA NA investigative two pore calcium channel protein 2 TPCN2 Literature-reported target unknown NA TTD phenethyl isothiocyanate small molecule NA investigational tumor protein d54 TPD52L2 NA unknown NA drugbank kar5585 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 tryptophan 5-hydroxylase 1 TPH1 Clinical trial target unknown 5.3 TTD , DGIDB 6-fluorotryptophan NA NA investigative tryptophan 5-hydroxylase 1 TPH1 Clinical trial target inhibitor NA TTD , DGIDB lx1031 small molecule Gastrointestinal Diseases[MeSHID:D005767],Irritable Bowel Syndrome[MeSHID:D043183] investigational tryptophan 5-hydroxylase 1 TPH1 NA unknown NA drugbank , DGIDB alpha-propyldopacetamide NA NA investigative tryptophan 5-hydroxylase 1 TPH1 Clinical trial target unknown NA TTD telotristat ethyl small molecule Malignant Carcinoid Syndrome[MeSHID:D008303],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tryptophan 5-hydroxylase 1 TPH1 NA antagonist NA drugbank , DGIDB telotristat ethyl small molecule Malignant Carcinoid Syndrome[MeSHID:D008303],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tryptophan 5-hydroxylase 1 TPH1 NA antagonist,inhibitor 5.3 drugbank , DGIDB agn-2979 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psychotic Disorders[MeSHID:D011618] phase 2 tryptophan 5-hydroxylase 1 TPH1 Clinical trial target unknown NA TTD , DGIDB sapropterin small molecule Malnutrition[MeSHID:D044342] approved,investigational tryptophan 5-hydroxylase 1 TPH1 NA cofactor NA drugbank fenclonine NA NA investigative tryptophan 5-hydroxylase 1 TPH1 Clinical trial target inhibitor 1.33 TTD , DGIDB telotristat ethyl small molecule Malignant Carcinoid Syndrome[MeSHID:D008303],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tryptophan 5-hydroxylase 1 TPH1 NA antagonist,inhibitor NA drugbank , DGIDB telotristat ethyl small molecule Malignant Carcinoid Syndrome[MeSHID:D008303],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tryptophan 5-hydroxylase 2 TPH2 NA antagonist,inhibitor 3.98 drugbank , DGIDB 5-fluorotryptophan small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank tert-butanol small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank 3-phospho-d-glyceric acid small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental triosephosphate isomerase TPI1 NA binder NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational triosephosphate isomerase TPI1 NA unknown NA drugbank 1,4-dithiothreitol small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank 3-(butylsulphonyl)-propanoic acid small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational triosephosphate isomerase TPI1 NA binder NA drugbank 2-phosphoglycolic acid small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank [2(formyl-hydroxy-amino)-ethyl]-phosphonic acid small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank 3-(2-benzothiazolylthio)-1-propanesulfonic acid small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank dihydroxyacetone phosphate small molecule NA investigational triosephosphate isomerase TPI1 NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational triosephosphate isomerase TPI1 NA unknown NA drugbank n-hydroxy-4-phosphonobutanamide small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank phosphoglycolohydroxamic acid small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational triosephosphate isomerase TPI1 NA ligand NA drugbank 2-carboxyethylphosphonic acid small molecule NA experimental triosephosphate isomerase TPI1 NA unknown NA drugbank pyrithiamine pyrophosphate small molecule NA experimental thiamin pyrophosphokinase 1 TPK1 NA unknown NA drugbank thiamine small molecule Alcohol Amnestic Disorder[MeSHID:D000425],Delirium[MeSHID:D003693],Wernicke-Korsakoff Syndrome[MeSHID:D020915],Malnutrition[MeSHID:D044342],Neuritis[MeSHID:D009443] approved,investigational,nutraceutical,vet_approved thiamin pyrophosphokinase 1 TPK1 NA substrate NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational tropomyosin alpha-1 chain TPM1 NA ligand NA drugbank phenethyl isothiocyanate small molecule NA investigational tropomyosin alpha-1 chain TPM1 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational tropomyosin alpha-3 chain TPM3 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational tropomyosin alpha-4 chain TPM4 NA unknown NA drugbank olsalazine small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Ulcerative Colitis[MeSHID:D003093],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thiopurine s-methyltransferase TPMT NA inhibitor NA drugbank resorcinol small molecule Seborrheic dermatitis[MeSHID:D012628],Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Acne Vulgaris[MeSHID:D000152] approved thyroid peroxidase TPO NA unknown NA drugbank 2-mercaptobenzothiazole small molecule NA approved,experimental,vet_approved thyroid peroxidase TPO NA inhibitor NA drugbank propylthiouracil small molecule Graves Disease[MeSHID:D006111],Hyperthyroidism[MeSHID:D006980],Thyroid Gland[MeSHID:D013961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thyroid peroxidase TPO Successful target inhibitor 13.73 TTD , drugbank , DGIDB methimazole small molecule Radioactivity[MeSHID:D011851],Graves Disease[MeSHID:D006111],Carrying[MeSHID:D017770],Hyperthyroidism[MeSHID:D006980],Goiter[MeSHID:D006042],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyroid peroxidase TPO Successful target substrate,inhibitor 14.14 TTD , drugbank , DGIDB carbimazole small molecule Hyperthyroidism[MeSHID:D006980],Thyrotoxicosis[MeSHID:D013971],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thyroid peroxidase TPO Successful target inhibitor 38.9 TTD , drugbank , DGIDB tpo gene plasmid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] investigative thyroid peroxidase TPO Successful target unknown NA TTD triclosan small molecule Health Care[MeSHID:D003695],Operative Surgical Procedures[MeSHID:D013514],Hand[MeSHID:D006225],Hyperostosis, Diffuse Idiopathic Skeletal[MeSHID:D004057],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Trypanosomiasis[MeSHID:D014352],Malaria[MeSHID:D008288],Communicable Diseases[MeSHID:D003141] approved,investigational thyroid peroxidase TPO NA weak inhibitor NA drugbank dextrothyroxine small molecule Hypercholesterolemia[MeSHID:D006937] approved,investigational thyroid peroxidase TPO NA unknown NA drugbank cerliponase alfa NA Disease[MeSHID:D004194],Ataxia[MeSHID:D001259],Cessation of life[MeSHID:D003643],Cerebellar Ataxia[MeSHID:D002524],Rare Diseases[MeSHID:D035583],Lysosomes[MeSHID:D008247],Neuronal Ceroid-Lipofuscinoses[MeSHID:D009472],Blind Vision[MeSHID:D001766],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved tripeptidyl-peptidase i TPP1 Successful target unknown NA TTD , DGIDB peptide 4 NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD l-norvalyl-l-prolinamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD (2s)-aminobutyryl-l-proline (r)-sec-butylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD l-valyl-l-prolinamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD l-norleucyl-l-prolinamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD l-leucyl-l-prolinamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD (2s)-aminobutyryl-l-prolinamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD l-valyl-l-proline benzylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD (2s)-aminobutyryl-l-proline n-pentylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD (2s)-aminobutyryl-l-proline n-propylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD (2s)-aminobutyryl-(r)-pipecolinic acid amide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD (2s)-aminobutyryl-l-proline n-butylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD (2s)-aminobutyryl-l-proline-(2s)-methylbutylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD (2s)-aminobutyryl-l-proline isobutylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD ucl-2000; butabindide NA NA discontinued in phase 1 tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD alpha-methylalanyl-l-proline butylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD example 8 [wo1999033801a1] NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target inhibitor NA TTD , DGIDB l-isoleucyl-l-prolinamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD l-valyl-l-proline hexylamide NA NA investigative tripeptidyl-peptidase ii TPP2 Discontinued target unknown NA TTD amg-126737 NA NA investigative tryptase alpha/beta-1 TPSAB1 Successful target unknown NA TTD grassystatin a NA NA investigative tryptase alpha/beta-1 TPSAB1 Successful target unknown NA TTD apc-366 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] discontinued in phase 2 tryptase alpha/beta-1 TPSAB1 Successful target unknown NA TTD bms-262084 NA NA investigative tryptase alpha/beta-1 TPSAB1 Successful target unknown NA TTD lactoferrin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative tryptase alpha/beta-1 TPSAB1 Successful target unknown NA TTD , DGIDB mol 6131 NA NA investigative tryptase alpha/beta-1 TPSAB1 Successful target unknown NA TTD 1-[1'-(3-phenylacryloyl)spiro[1-benzofuran-3,4'-piperidin]-5-yl]methanamine small molecule NA experimental tryptase alpha/beta-1 TPSAB1 NA unknown NA drugbank apc-2059 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammatory Bowel Diseases[MeSHID:D015212] discontinued in phase 2 tryptase alpha/beta-1 TPSAB1 Successful target unknown NA TTD pentamidine NA Pneumonia[MeSHID:D011014],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved tryptase alpha/beta-1 TPSAB1 Successful target unknown 5.3 TTD , DGIDB lactoferrin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tryptase alpha/beta-1 TPSAB1 Successful target unknown NA TTD , DGIDB 1-(1'-{[3-(methylsulfanyl)-2-benzothiophen-1-yl]carbonyl}spiro[1-benzofuran-3,4'-piperidin]-5-yl)methanamine small molecule NA experimental tryptase alpha/beta-1 TPSAB1 NA unknown NA drugbank jnj-27390467 small molecule NA experimental tryptase beta-2 TPSB2 NA unknown NA drugbank 4-piperidin-4-ylbutanal small molecule NA experimental tryptase beta-2 TPSB2 NA unknown NA drugbank [4-(3-aminomethyl-phenyl)-piperidin-1-yl]-(5-phenethyl- pyridin-3-yl)-methanone small molecule NA experimental tryptase beta-2 TPSB2 NA unknown NA drugbank amido phenyl pyruvic acid small molecule NA experimental tryptase beta-2 TPSB2 NA unknown NA drugbank cer-227185 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] discontinued in phase 1/2 translationally-controlled tumor protein TPT1 Discontinued target unknown NA TTD calcium citrate small molecule NA approved,investigational translationally-controlled tumor protein TPT1 NA ligand NA drugbank calcium phosphate dihydrate small molecule NA approved translationally-controlled tumor protein TPT1 NA unknown NA drugbank calcium phosphate small molecule NA approved translationally-controlled tumor protein TPT1 NA ligand NA drugbank 3-indolebutyric acid small molecule NA experimental t-cell receptor alpha chain c region TRAC NA unknown NA drugbank s-palmitoyl-l-cysteine small molecule NA experimental trafficking protein particle complex subunit 1 TRAPPC1 NA unknown NA drugbank myristic acid small molecule NA experimental trafficking protein particle complex subunit 3 TRAPPC3 NA unknown NA drugbank palmitic acid small molecule NA approved trafficking protein particle complex subunit 3 TRAPPC3 NA unknown NA drugbank s-palmitoyl-l-cysteine small molecule NA experimental trafficking protein particle complex subunit 3 TRAPPC3 NA unknown NA drugbank s-palmitoyl-l-cysteine small molecule NA experimental trafficking protein particle complex subunit 4 TRAPPC4 NA unknown NA drugbank s-palmitoyl-l-cysteine small molecule NA experimental trafficking protein particle complex subunit 5 TRAPPC5 NA unknown NA drugbank s-palmitoyl-l-cysteine small molecule NA experimental trafficking protein particle complex subunit 6a TRAPPC6A NA unknown NA drugbank s-palmitoyl-l-cysteine small molecule NA experimental trafficking protein particle complex subunit 6b TRAPPC6B NA unknown NA drugbank 3-indolebutyric acid small molecule NA experimental t-cell receptor beta-1 chain c region TRBC1 NA unknown NA drugbank trbc1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728],Peripheral T-Cell Lymphoma[MeSHID:D016411],Angioimmunoblastic Lymphadenopathy[MeSHID:D007119] phase 1/2 t-cell receptor beta constant 1 TRBC1 Clinical trial target unknown NA TTD , DGIDB pentamidine small molecule Pneumonia[MeSHID:D011014],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational trna (cytosine(38)-c(5))-methyltransferase TRDMT1 NA other NA drugbank s-adenosyl-l-homocysteine small molecule NA experimental trna (cytosine(38)-c(5))-methyltransferase TRDMT1 NA unknown NA drugbank glycerin small molecule NA approved,investigational trna (cytosine(38)-c(5))-methyltransferase TRDMT1 NA unknown NA drugbank d-tartaric acid NA NA investigative triggering receptor expressed on monocytes 1 Trem1 Literature-reported target unknown NA TTD d-tartaric acid small molecule NA experimental triggering receptor expressed on myeloid cells 1 TREM1 NA unknown NA drugbank rx-77368 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 thyrotropin-releasing hormone TRH Clinical trial target unknown NA TTD kps-0373 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] phase 3 thyrotropin-releasing hormone TRH Clinical trial target unknown 15.91 TTD , DGIDB metrh NA NA investigative thyrotropin-releasing hormone receptor TRHR Successful target agonist NA TTD , DGIDB posatirelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] discontinued in phase 3 thyrotropin-releasing hormone receptor TRHR Successful target unknown NA TTD azetirelin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 3 thyrotropin-releasing hormone receptor TRHR Successful target unknown 12.73 TTD , DGIDB jtp-2942 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 thyrotropin-releasing hormone receptor TRHR Successful target unknown NA TTD mk-771 NA NA investigative thyrotropin-releasing hormone receptor TRHR Successful target unknown NA TTD protirelin small molecule CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thyrotropin releasing hormone receptor TRHR NA ligand 25.46 drugbank , DGIDB protirelin NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyrotropin-releasing hormone receptor TRHR Successful target unknown 25.46 TTD , DGIDB protirelin NA CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thyrotropin-releasing hormone receptor TRHR Successful target agonist 25.46 TTD , DGIDB corymbone b NA NA investigative thyrotropin-releasing hormone receptor TRHR Successful target unknown NA TTD protirelin small molecule CNS disorder[MeSHID:D002493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thyrotropin releasing hormone receptor TRHR NA ligand,agonist 25.46 drugbank , DGIDB montirelin tetrahydrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in preregistration thyrotropin-releasing hormone receptor TRHR Successful target unknown NA TTD c4x-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endocrine System Diseases[MeSHID:D004700] investigative thyrotropin-releasing hormone receptor TRHR Successful target unknown NA TTD etorphine small molecule NA illicit,vet_approved e3 ubiquitin-protein ligase trim13 TRIM13 NA agonist NA drugbank diprenorphine small molecule NA illicit,vet_approved e3 ubiquitin-protein ligase trim13 TRIM13 NA unknown NA drugbank dihydromorphine small molecule Pain[MeSHID:D010146] experimental,illicit e3 ubiquitin-protein ligase trim13 TRIM13 NA agonist NA drugbank pmid25974391c34 NA NA investigative tripartite motif-containing 24 TRIM24 Literature-reported target unknown NA TTD icilin NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD nppb NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB artepillin c NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB pf-4840154 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator 2.45 TTD , DGIDB menthol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pharyngeal structure[MeSHID:D010614] approved transformation-sensitive protein p120 TRPA1 Successful target unknown 6.53 TTD , DGIDB cinnamaldehyde NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD hx-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929] phase 1 transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD , DGIDB (s)-camphor small molecule Ache[MeSHID:D010146],Myalgia[MeSHID:D063806] experimental transient receptor potential cation channel subfamily a member 1 TRPA1 NA inhibitor NA drugbank gingerol NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD a-967079 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative transformation-sensitive protein p120 TRPA1 Successful target inhibitor NA TTD , DGIDB dibenzoxazepine NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved transient receptor potential cation channel subfamily a member 1 TRPA1 NA inducer NA drugbank amg-9090 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational transient receptor potential cation channel subfamily a member 1 TRPA1 NA unknown NA drugbank butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn transient receptor potential cation channel subfamily a member 1 TRPA1 NA inhibitor NA drugbank mtsea NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD resolvin d2 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD acrolein NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator 0.82 TTD , DGIDB 2-pentenal NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD amg-2504 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD 2-methyl-1-(pyridin-4-yl)pent-1-en-3-one oxime NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD methyl salicylate NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD prostaglandin a2 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD acetaldehyde NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator 0.41 TTD , DGIDB 4-oxo-nonenal NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD chlorobenzylidene malononitrile NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB [3h]resolvin d1 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD 1,6-hexamethylene diisocyanate NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB methylglyoxal NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator 2.45 TTD , DGIDB 3-methyl-4-phenylbut-3-en-2-one oxime NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD methyl p-hydroxybenzoate NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD morphanthridine NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator 2.45 TTD , DGIDB super cinnamaldehyde NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD tetrahydrocannabivarin small molecule NA investigational transient receptor potential cation channel subfamily a member 1 TRPA1 NA agonist NA drugbank cannabidivarin small molecule Fragile X Syndrome[MeSHID:D005600],Rett Syndrome[MeSHID:D015518] investigational transient receptor potential cation channel subfamily a member 1 TRPA1 NA agonist NA drugbank camphor small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved transient receptor potential cation channel subfamily a member 1 TRPA1 NA inhibitor NA drugbank chloropicrin NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator 2.45 TTD , DGIDB dibutyl phthalate NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB formaldehyde NA Operative Surgical Procedures[MeSHID:D013514],Warts[MeSHID:D014860],Desiccation[MeSHID:D003890] investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD crotylaldehyde NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD tcs 5861528 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target inhibitor NA TTD , DGIDB benzyl bromide NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB amg-5445 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD methyl isocyanate NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational transient receptor potential cation channel subfamily a member 1 TRPA1 NA agonist NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational transient receptor potential cation channel subfamily a member 1 TRPA1 NA unknown NA drugbank 2-methyl-1-(thiophen-3-yl)pent-1-en-3-one oxime NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD 1'-acetoxychavicol acetate NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB isovelleral NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator 0.15 TTD , DGIDB bromoacetone NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB amg-7160 NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD 2-methyl-1-(pyridin-3-yl)pent-1-en-3-one oxime NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD omega-chloroacetophenone NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB oleocanthal NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target activator NA TTD , DGIDB 2-methyl-1-(thiophen-2-yl)pent-1-en-3-one oxime NA NA investigative transformation-sensitive protein p120 TRPA1 Successful target unknown NA TTD oag NA NA investigative short transient receptor potential channel 2 TRPC2 Literature-reported target unknown NA TTD sag NA NA investigative short transient receptor potential channel 2 TRPC2 Literature-reported target unknown NA TTD 2-apb NA NA investigative short transient receptor potential channel 2 TRPC2 Literature-reported target unknown NA TTD 2-apb NA NA investigative short transient receptor potential channel 4 TRPC4 Clinical trial target blocker NA TTD , DGIDB bi 1358894 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] phase 2 short transient receptor potential channel 4 TRPC4 Clinical trial target unknown NA TTD ml204 NA NA investigative short transient receptor potential channel 4 TRPC4 Clinical trial target blocker NA TTD , DGIDB (-)-englerin a NA NA investigative short transient receptor potential channel 4 TRPC4 Clinical trial target activator NA TTD , DGIDB daidzein NA NA investigative short transient receptor potential channel 5 TRPC5 Clinical trial target activator 0.18 TTD , DGIDB kb-r7943 NA NA investigative short transient receptor potential channel 5 TRPC5 Clinical trial target blocker NA TTD , DGIDB bromoenol lactone NA NA investigative short transient receptor potential channel 5 TRPC5 Clinical trial target unknown NA TTD bi 1358894 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] phase 2 short transient receptor potential channel 5 TRPC5 Clinical trial target unknown NA TTD 2-apb NA NA investigative short transient receptor potential channel 5 TRPC5 Clinical trial target blocker NA TTD , DGIDB btp2 NA NA investigative short transient receptor potential channel 5 TRPC5 Clinical trial target blocker NA TTD , DGIDB ml204 NA NA investigative short transient receptor potential channel 5 TRPC5 Clinical trial target blocker NA TTD , DGIDB lysophosphatidylcholine NA NA investigative short transient receptor potential channel 5 TRPC5 Clinical trial target activator 1.41 TTD , DGIDB (-)-englerin a NA NA investigative short transient receptor potential channel 5 TRPC5 Clinical trial target activator NA TTD , DGIDB 2-apb NA NA investigative short transient receptor potential channel 7 TRPC7 Literature-reported target blocker NA TTD , DGIDB oag NA NA investigative short transient receptor potential channel 7 TRPC7 Literature-reported target unknown NA TTD gea 3162 NA NA investigative long transient receptor potential channel 2 TRPM2 Literature-reported target activator NA TTD , DGIDB 2-apb NA NA investigative long transient receptor potential channel 2 TRPM2 Literature-reported target blocker NA TTD , DGIDB acaa NA NA investigative long transient receptor potential channel 2 TRPM2 Literature-reported target blocker NA TTD , DGIDB naadp NA NA investigative long transient receptor potential channel 2 TRPM2 Literature-reported target activator NA TTD , DGIDB cadpr NA NA investigative long transient receptor potential channel 2 TRPM2 Literature-reported target activator NA TTD , DGIDB adp ribose NA NA investigative long transient receptor potential channel 2 TRPM2 Literature-reported target activator NA TTD , DGIDB oaadpr NA NA investigative long transient receptor potential channel 2 TRPM2 Literature-reported target activator NA TTD , DGIDB 2-apb NA NA investigative long transient receptor potential channel 3 TRPM3 Literature-reported target inhibitor NA TTD , DGIDB sphinganine NA NA investigative long transient receptor potential channel 3 TRPM3 Literature-reported target unknown NA TTD nn-dimethyl-d-erythrosphingosine NA NA investigative long transient receptor potential channel 3 TRPM3 Literature-reported target activator NA TTD , DGIDB epipregnanolone sulphate NA NA investigative long transient receptor potential channel 3 TRPM3 Literature-reported target activator NA TTD , DGIDB glyburide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035] approved transient receptor potential cation channel subfamily m member 4 TRPM4 NA inhibitor NA drugbank 9-phenanthrol NA NA investigative long transient receptor potential channel 4 TRPM4 Clinical trial target blocker NA TTD , DGIDB amp-pnp NA NA investigative long transient receptor potential channel 4 TRPM4 Clinical trial target inhibitor NA TTD , DGIDB pip2 NA NA investigative long transient receptor potential channel 4 TRPM4 Clinical trial target activator NA TTD , DGIDB btp2 NA NA investigative long transient receptor potential channel 4 TRPM4 Clinical trial target activator NA TTD , DGIDB decavanadate NA NA investigative long transient receptor potential channel 4 TRPM4 Clinical trial target activator NA TTD , DGIDB adenosine diphosphate NA NA investigative long transient receptor potential channel 4 TRPM4 Clinical trial target unknown NA TTD 1,4-dithiothreitol small molecule NA experimental transient receptor potential cation channel subfamily m member 7 TRPM7 NA unknown NA drugbank phosphoaminophosphonic acid-adenylate ester small molecule NA experimental transient receptor potential cation channel subfamily m member 7 TRPM7 NA unknown NA drugbank ws-3 NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD m8-b NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD 2-(5-fluoro-1h-indol-3-yl)ethanamine NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD isopulegol NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD ws-5 NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD d-3263 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 long transient receptor potential channel 8 TRPM8 Successful target unknown 23.87 TTD , DGIDB ws-12 NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD hydroxycitronellal NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD amtb NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target blocker NA TTD , DGIDB geraniol NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved transient receptor potential cation channel subfamily m member 8 TRPM8 NA inducer NA drugbank frescolat ml NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD d-3263 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 long transient receptor potential channel 8 TRPM8 Successful target agonist 23.87 TTD , DGIDB cps125 NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD ws-23 NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD 2-apb NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD medical cannabis biotech NA experimental,investigational transient receptor potential cation channel subfamily m member 8 TRPM8 NA unknown NA drugbank (s)-camphor small molecule Ache[MeSHID:D010146],Myalgia[MeSHID:D063806] experimental transient receptor potential cation channel subfamily m member 8 TRPM8 NA activator NA drugbank 5-benzyloxytryptamine NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target blocker 7.96 TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational transient receptor potential cation channel subfamily m member 8 TRPM8 NA blocker 3.18 drugbank , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational transient receptor potential cation channel subfamily m member 8 TRPM8 NA unknown NA drugbank 5-methoxytryptamine NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD linalool NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD perillaldehyde NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD 2-(7-(benzyloxy)-1h-indol-3-yl)ethanamine NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD eucalyptol NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD frescolat mga NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD rq-00203078 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD menthol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pharyngeal structure[MeSHID:D010614] approved long transient receptor potential channel 8 TRPM8 Successful target unknown 34.48 TTD , DGIDB icilin NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD nada NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target blocker NA TTD , DGIDB pmd38 NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD pbmc NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD thio-bctc NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD acaa NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target blocker NA TTD , DGIDB cooling agent 10 NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown NA TTD tetrahydrocannabivarin small molecule NA investigational transient receptor potential cation channel subfamily m member 8 TRPM8 NA antagonist NA drugbank pf-05105679 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 long transient receptor potential channel 8 TRPM8 Successful target blocker 15.91 TTD , DGIDB pf-05105679 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 long transient receptor potential channel 8 TRPM8 Successful target unknown 15.91 TTD , DGIDB 5-benzyloxytryptamine NA NA investigative long transient receptor potential channel 8 TRPM8 Successful target unknown 7.96 TTD , DGIDB camphor small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved transient receptor potential cation channel subfamily m member 8 TRPM8 NA activator NA drugbank pmid25666693-compound-26 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-71 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-(cyclohexylamino)-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-57 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 6'-iodononivamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-36 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB nada NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker NA TTD , DGIDB mr-1817 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 3.03 TTD , DGIDB pmid25666693-compound-59 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB asp-8370 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-156 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB mr-1817 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB [3h]a778317 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker NA TTD , DGIDB pmid25666693-compound-159 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB n-[2-(5-hydroxy-1h-indol-3-yl)ethyl]lauramide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD atc-120 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-140 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB sb452533 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker NA TTD , DGIDB pmid25666693-compound-150 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-149 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-146 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB n-[2-(5-hydroxy-1h-indol-3-yl)ethyl]undecanamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD acetaminophen small molecule Disease Management[MeSHID:D019468],Asthma[MeSHID:D001249],Fever[MeSHID:D005334],Allergic Reaction[MeSHID:D006967],Pain[MeSHID:D010146],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transient receptor potential cation channel subfamily v member 1 TRPV1 NA activator 0.19 drugbank , DGIDB ne-28345 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD amg-8563 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-143 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-133 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB (e)-octadec-9-enal NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-60 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-63 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB sb-705498 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Migraine Disorders[MeSHID:D008881],Rhinitis[MeSHID:D012220] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 1.52 TTD , DGIDB 4-heptyl-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-151 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB ppahv NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-153 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-(hexyl(methyl)amino)-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD amg-628 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB capsaicin small molecule Solutions[MeSHID:D012996],Postherpetic neuralgia[MeSHID:D051474],Neuralgia[MeSHID:D009437],Pain[MeSHID:D010146],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist 0.66 drugbank , DGIDB pmid25666693-compound-37 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB capsaicin NA Solutions[MeSHID:D012996],Postherpetic neuralgia[MeSHID:D051474],Neuralgia[MeSHID:D009437],Pain[MeSHID:D010146],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transient receptor potential cation channel v1 TRPV1 Successful target unknown 0.66 TTD , DGIDB pmid25666693-compound-157 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-155 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-141 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-35 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB sb-782443 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-147 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB n-[2-(5-hydroxy-1h-indol-3-yl)ethyl]linoleamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-161 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-29 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB sar-115740 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-64 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-135 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB (s)-1-(1h-indazol-4-yl)-3-(1-p-tolylethyl)urea NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD a-795614 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD nonivamide small molecule Flavoring[MeSHID:None] investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist NA drugbank pmid25666693-compound-32 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-119 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB amg 9810 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker NA TTD , DGIDB pmid25666693-compound-152 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB (5e,8e,11e,14e)-icosa-5,8,11,14-tetraenal NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-67 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-118 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB (e)-3-(4-tert-butyl-phenyl)-n-phenyl-acrylamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD resiniferatoxin small molecule Urinary Incontinence[MeSHID:D014549],Interstitial Cystitis[MeSHID:D018856],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA activator 3.03 drugbank , DGIDB pmid25666693-compound-137 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB amg-517 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] discontinued in phase 1 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 1.52 TTD , DGIDB 2-apb NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker NA TTD , DGIDB pmid25666693-compound-145 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB resiniferatoxin small molecule Urinary Incontinence[MeSHID:D014549],Interstitial Cystitis[MeSHID:D018856],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA unknown 3.03 drugbank , DGIDB pmid25666693-compound-114 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-107 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-122 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-27 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-decyl-n-(pyridin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD capsaicin NA Solutions[MeSHID:D012996],Postherpetic neuralgia[MeSHID:D051474],Neuralgia[MeSHID:D009437],Pain[MeSHID:D010146],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transient receptor potential cation channel v1 TRPV1 Successful target activator 0.66 TTD , DGIDB (r)-1-(1h-indazol-4-yl)-3-(1-p-tolylethyl)urea NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-142 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-108 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-53 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-(3-methylpyridin-2-yl)-n-p-tolylbenzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD 1,3-dibenzyl urea NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD n-(4-iodophenyl)-4-(trifluoromethoxy)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-33 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-160 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-41 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 5s-hpete NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-144 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-heptyl-n-(pyridin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD jnj-17203212 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coughing[MeSHID:D003371] investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-162 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-68 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB capsicum oleoresin biotech Arthritis[MeSHID:D001168],Sprain[MeSHID:D013180],Back Pain[MeSHID:D001416],Ache[MeSHID:D010146],Myalgia[MeSHID:D063806] approved transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist,activator NA drugbank pmid25666693-compound-20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB tramadol small molecule Disease Management[MeSHID:D019468],Pain[MeSHID:D010146],Off-Label Use[MeSHID:D056687],Premature Ejaculation[MeSHID:D061686],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist NA drugbank 4-butyl-n-(pyridin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-110 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 1-(4-bromo-benzyl)-3-quinazolin-8-yl-urea NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD sc-0030 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD ricinoleic acid small molecule NA experimental transient receptor potential cation channel subfamily v member 1 TRPV1 NA unknown NA drugbank phenylacetylrinvanil NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target activator NA TTD , DGIDB 12s-hpete NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD n-methyl-4-pentyl-n-(pyridin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-138 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 1-(isoquinolin-5-yl)-3-(4-morpholinobenzyl)urea NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-56 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-44 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-40 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB abt-116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD zucapsaicin small molecule Pain[MeSHID:D010146],Osteoarthritis, Knee[MeSHID:D020370] approved,investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist,activator 0.76 drugbank , DGIDB pmid25666693-compound-22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-54 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 1-(isoquinolin-5-yl)-3-(1-phenylpropyl)urea NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD lassbio-881 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD capsazepine NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown 0.22 TTD , DGIDB (s)-camphor small molecule Ache[MeSHID:D010146],Myalgia[MeSHID:D063806] experimental transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist,activator NA drugbank pmid25666693-compound-34 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-butyl-n-(7-hydroxynaphthalen-1-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-129 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-42 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-39 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-148 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-61 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB kjm429 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD 6-iodo-nordihydrocapsaicin NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker NA TTD , DGIDB grc-15300 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target unknown 1.52 TTD , DGIDB pmid25666693-compound-81 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB grc-6211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 1.52 TTD , DGIDB n-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD azd1386 NA Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Esophagus[MeSHID:D004947],Hypersensitivity[MeSHID:D006967] discontinued in phase 2 transient receptor potential cation channel v1 TRPV1 Successful target inhibitor 3.03 TTD , DGIDB pmid25666693-compound-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-90 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB resiniferatoxin NA Urinary Incontinence[MeSHID:D014549],Interstitial Cystitis[MeSHID:D018856],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB 4-octyl-n-(pyridin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 1-benzhydryl-3-(isoquinolin-5-yl)urea NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD diphenylboronic anhydride NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target activator NA TTD , DGIDB pmid25666693-compound-132 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB propacetamol small molecule Fever[MeSHID:D005334],Dysmenorrhea[MeSHID:D004412] experimental transient receptor potential cation channel subfamily v member 1 TRPV1 NA antagonist NA drugbank grc-6211 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target unknown 1.52 TTD , DGIDB pmid25666693-compound-5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB jnj-39439335 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Musculoskeletal Pain[MeSHID:D059352] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB xen-d0501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 3.03 TTD , DGIDB pmid25666693-compound-116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-58 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-72 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-75 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB bctc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker NA TTD , DGIDB pmid25666693-compound-80 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-121 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-120 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-154 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 5s-hete NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target activator NA TTD , DGIDB pmid25666693-compound-158 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB camphor small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist,activator 1.01 drugbank , DGIDB 4-(butyl(methyl)amino)-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD jts-653 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Overactive Bladder[MeSHID:D053201] discontinued in phase 2 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 1.52 TTD , DGIDB pmid25666693-compound-31 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pf-3864086 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-52 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-(methyl(octyl)amino)-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-51 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pyrrolidin-1-yl-thiourea NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-127 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-(methyl(nonyl)amino)-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-66 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pac-14028 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 3.03 TTD , DGIDB pmid25666693-compound-113 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-126 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-55 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-111 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB capsaicin small molecule Solutions[MeSHID:D012996],Postherpetic neuralgia[MeSHID:D051474],Neuralgia[MeSHID:D009437],Pain[MeSHID:D010146],Muscle[MeSHID:D009132],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist,activator 0.66 drugbank , DGIDB pmid25666693-compound-73 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-25 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-38 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB cntx-4975 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteoarthritis, Knee[MeSHID:D020370],Pain[MeSHID:D010146],Neuroma[MeSHID:D009463] phase 3 transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-94 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB ca-011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hippocampus Proper[MeSHID:D006624],Chronic pain[MeSHID:D059350] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB dwp-05195 NA Neuralgia[MeSHID:D009437],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB [125i]resiniferatoxin NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-28 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB cannabidivarin small molecule Fragile X Syndrome[MeSHID:D005600],Rett Syndrome[MeSHID:D015518] investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA agonist NA drugbank agatoxin 489 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD 4-nonyl-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD resiniferatoxin NA Urinary Incontinence[MeSHID:D014549],Interstitial Cystitis[MeSHID:D018856],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target activator 3.03 TTD , DGIDB pmid25666693-compound-105 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-83 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-97 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-butyl-n-phenylbenzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD icosapent small molecule Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Diabetic Nephropathy[MeSHID:D003928],Cystic Fibrosis[MeSHID:D003550],Disease Progression[MeSHID:D018450],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical transient receptor potential cation channel subfamily v member 1 TRPV1 NA inducer NA drugbank pmid25666693-compound-103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA unknown NA drugbank pmid25666693-compound-77 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-69 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-49 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-131 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-139 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-136 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 2-(4-pentylphenyl)-n-(pyridin-3-yl)acetamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-86 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-84 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA activator NA drugbank pmid25666693-compound-47 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB abt-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB pmid25666693-compound-62 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB n-(4-iodophenyl)-4-(trifluoromethyl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-104 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-tert-butyl-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD arvanil NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pac-14028 NA Dermatitis, Atopic[MeSHID:D003876],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Eczema[MeSHID:D004485] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB phe-377 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB pmid25666693-compound-98 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB capsazepine NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker 0.22 TTD , DGIDB xen-d0501 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Overactive Bladder[MeSHID:D053201] phase 2 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB a778317 NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target blocker NA TTD , DGIDB pmid25666693-compound-65 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-hexyl-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB a-993610 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD tivanisiran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Desiccation[MeSHID:D003890],Disorder of eye[MeSHID:D005128],Dry Eye Syndromes[MeSHID:D015352],Disease[MeSHID:D004194] phase 3 trpv1 messenger rna TRPV1 Clinical trial target unknown NA TTD pmid25666693-compound-74 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-87 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-134 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-butyl-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-130 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-99 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB a-425619 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] preclinical transient receptor potential cation channel v1 TRPV1 Successful target unknown 1.52 TTD , DGIDB pmid25666693-compound-101 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-70 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-79 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-95 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-85 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-89 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-96 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-93 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-45 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-92 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-50 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB alpha-linolenic acid small molecule NA approved,investigational,nutraceutical transient receptor potential cation channel subfamily v member 1 TRPV1 NA inhibitor NA drugbank pmid25666693-compound-91 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB nuvanil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] discontinued in phase 2 transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-46 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-88 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-82 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB pmid25666693-compound-8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 15s-hpete NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD da-5018 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Diabetic Neuropathies[MeSHID:D003929],Postherpetic neuralgia[MeSHID:D051474] discontinued in phase 2 transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-128 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB kmj-372 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146] investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD 4-butyl-n-(isoquinolin-5-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-48 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB azd1386 NA Gastroesophageal reflux disease[MeSHID:D005764],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Esophagus[MeSHID:D004947],Hypersensitivity[MeSHID:D006967] discontinued in phase 2 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 3.03 TTD , DGIDB pmid25666693-compound-43 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB abt-102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] phase 1 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 3.03 TTD , DGIDB pmid25666693-compound-19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-propyl-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-76 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB 4-octyl-n-(quinolin-3-yl)benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD ngd-8243 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] discontinued in phase 2 transient receptor potential cation channel v1 TRPV1 Successful target unknown 3.03 TTD , DGIDB ngd-8243 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] discontinued in phase 2 transient receptor potential cation channel v1 TRPV1 Successful target antagonist 3.03 TTD , DGIDB aspartame small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,nutraceutical transient receptor potential cation channel subfamily v member 1 TRPV1 NA inducer NA drugbank medical cannabis biotech NA experimental,investigational transient receptor potential cation channel subfamily v member 1 TRPV1 NA unknown NA drugbank 4-pyridin-2-yl-piperazine-1-carboxylic acid amide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD 4-pentyl-n-pyridin-3-yl benzamide NA NA investigative transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD pmid25666693-compound-78 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neuralgia[MeSHID:D009437],Degenerative polyarthritis[MeSHID:D010003],Malignant Neoplasms[MeSHID:D009369],Pain[MeSHID:D010146] patented transient receptor potential cation channel v1 TRPV1 Successful target unknown NA TTD , DGIDB cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational transient receptor potential cation channel subfamily v member 2 TRPV2 NA activator 19.1 drugbank , DGIDB medical cannabis biotech NA experimental,investigational transient receptor potential cation channel subfamily v member 2 TRPV2 NA unknown NA drugbank tetrahydrocannabivarin small molecule NA investigational transient receptor potential cation channel subfamily v member 2 TRPV2 NA agonist NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational transient receptor potential cation channel subfamily v member 2 TRPV2 NA unknown NA drugbank cannabidivarin small molecule Fragile X Syndrome[MeSHID:D005600],Rett Syndrome[MeSHID:D015518] investigational transient receptor potential cation channel subfamily v member 2 TRPV2 NA agonist NA drugbank cinnamaldehyde NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD diphenyltetrahydrofuran NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD edp-18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Major Depressive Disorder[MeSHID:D003865],Unipolar Depression[MeSHID:D003866] investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD levomenthol small molecule Cold Temperature[MeSHID:D003080],Coughing[MeSHID:D003371],Oral Ulcer[MeSHID:D019226],Pharyngitis[MeSHID:D010612],Common Cold[MeSHID:D003139],Upper Respiratory Infections[MeSHID:D012141],Pain[MeSHID:D010146],Inspiration function[MeSHID:D001239] approved transient receptor potential cation channel subfamily v member 3 TRPV3 NA inducer NA drugbank aspirin-triggered resolvin d1 NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target blocker NA TTD , DGIDB tetrahydrocannabivarin NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD 6-tert-butyl-m-cresol NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD medical cannabis biotech NA experimental,investigational transient receptor potential cation channel subfamily v member 3 TRPV3 NA unknown NA drugbank camphor small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic pain[MeSHID:D059350] approved transient receptor potential cation channel subfamily v member 3 TRPV3 NA agonist,activator NA drugbank dihydrocarveol NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD 2-apb NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD diphenylboronic anhydride NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD carveol NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD eugenol small molecule Dental caries[MeSHID:D003731],Toothache[MeSHID:D014098] approved transient receptor potential cation channel subfamily v member 3 TRPV3 NA unknown NA drugbank (s)-camphor small molecule Ache[MeSHID:D010146],Myalgia[MeSHID:D063806] experimental transient receptor potential cation channel subfamily v member 3 TRPV3 NA agonist,activator NA drugbank incensole acetate NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational transient receptor potential cation channel subfamily v member 3 TRPV3 NA activator NA drugbank carvacrol NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD citral NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD borneol NA NA investigative transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational transient receptor potential cation channel subfamily v member 3 TRPV3 NA unknown NA drugbank sar292833 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pain[MeSHID:D010146],Diabetes Mellitus, Insulin-Dependent[MeSHID:D003922] phase 2 transient receptor potential cation channel v3 TRPV3 Clinical trial target unknown NA TTD , DGIDB citric acid NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD bisandrographolide NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational transient receptor potential cation channel subfamily v member 4 TRPV4 NA activator NA drugbank 4alpha-pdd NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD capsazepine NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD rn1747 NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target activator NA TTD , DGIDB hc067047 NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target blocker NA TTD , DGIDB phorbol 12-myristate 13-acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 transient receptor potential cation channel v4 TRPV4 Clinical trial target activator NA TTD , DGIDB 5,6-epoxyeicosatrienoic acid NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD gsk2798745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 transient receptor potential cation channel v4 TRPV4 Clinical trial target antagonist 63.65 TTD , DGIDB rn1734 NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target blocker NA TTD , DGIDB nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational transient receptor potential cation channel subfamily v member 4 TRPV4 NA unknown NA drugbank pyrrolidin-1-yl-thiourea NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD butamben small molecule Pruritus[MeSHID:D011537],Pain[MeSHID:D010146],Mucous Membrane[MeSHID:D009092],Disease[MeSHID:D004194] approved,withdrawn transient receptor potential cation channel subfamily v member 4 TRPV4 NA inhibitor NA drugbank 4-pyridin-2-yl-piperazine-1-carboxylic acid amide NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD gsk2798745 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] phase 2 transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown 63.65 TTD , DGIDB 4alpha-pdh NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD gsk2193874 NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target blocker NA TTD , DGIDB sc-0030 NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD gsk1016790a NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target activator NA TTD , DGIDB medical cannabis biotech NA experimental,investigational transient receptor potential cation channel subfamily v member 4 TRPV4 NA unknown NA drugbank 5'-iodoresiniferatoxin NA NA investigative transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD phorbol 12-myristate 13-acetate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 transient receptor potential cation channel v4 TRPV4 Clinical trial target unknown NA TTD , DGIDB 2-apb NA NA investigative transient receptor potential cation channel v6 TRPV6 Clinical trial target activator NA TTD , DGIDB sor-c13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 transient receptor potential cation channel v6 TRPV6 Clinical trial target unknown 63.65 TTD , DGIDB fgi-101-1a6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 1 tumor susceptibility gene protein 101 TSG101 Clinical trial target unknown 4.9 TTD , DGIDB thyrotropin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypothyroidism[MeSHID:D007037] approved thyrotropin receptor TSHR Successful target unknown 0.28 TTD , DGIDB recombinant tsh superagonists NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thyroid carcinoma[MeSHID:D013964] investigative thyrotropin receptor TSHR Successful target unknown NA TTD thyrotropin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypothyroidism[MeSHID:D007037] approved thyrotropin receptor TSHR Successful target agonist 0.28 TTD , DGIDB thyrotropin alfa biotech Thyroid carcinoma[MeSHID:D013964],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved thyrotropin receptor TSHR Successful target agonist 1.4 TTD , drugbank , DGIDB thyrotropin alfa biotech Thyroid carcinoma[MeSHID:D013964],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved thyrotropin receptor TSHR Successful target agonist NA TTD , drugbank , DGIDB tezepelumab biotech Asthma[MeSHID:D001249],Status Asthmaticus[MeSHID:D013224],Maintenance[MeSHID:D008283],Bronchial Spasm[MeSHID:D001986],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,phase 3 thymic stromal lymphopoietin TSLP Clinical trial target binder,antibody NA TTD , drugbank medi9929 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 2 thymic stromal lymphopoietin TSLP Clinical trial target unknown NA TTD , DGIDB iodophenyl-n-methyl-n-fluoroalkyl-3-isoquinoline carboxamide derivative 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB bidentate pyrazolopyrimidine acetamide analog 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27599163-compound-75 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB isoquinoline carboxamide derivative 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB fgin-1-27 NA NA investigative translocator protein TSPO Successful target unknown NA TTD pmid27599163-compound-52 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pyrazolopyrimidine acetamide analog 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quinoline carboxamide derivative 6 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB 11c-pbr-28 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Diseases[MeSHID:D001927] phase 2 translocator protein TSPO Successful target unknown NA TTD , DGIDB triazolam NA Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.19 TTD , DGIDB eszopiclone NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.62 TTD , DGIDB (r)pk-11195 NA NA investigative translocator protein TSPO Successful target unknown NA TTD indole-based analog 10 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB bidentate pyrazolopyrimidine acetamide analog 3 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-65 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB 6-thia-10b-aza-benzo[e]azulen-4-one NA NA investigative translocator protein TSPO Successful target unknown NA TTD quinoline carboxamide derivative 8 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB bidentate pyrazolopyrimidine acetamide analog 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27599163-compound-77 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-60 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB aryl oxyanilide derivative 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 12 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-64 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 6 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB chlormezanone small molecule Anxiety Disorders[MeSHID:D001008],Disease Management[MeSHID:D019468],Anxiety[MeSHID:D001007],Spasm[MeSHID:D013035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn translocator protein TSPO Successful target agonist 11.23 TTD , drugbank , DGIDB quinazoline derivative 4 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tln-4601 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 translocator protein TSPO Successful target unknown 3.74 TTD , DGIDB midazolam NA Status Epilepticus[MeSHID:D013226],Stereotyped Behavior[MeSHID:D013239],Amnesia[MeSHID:D000647],Stereotypic Movement Disorder[MeSHID:D019956],Epilepsy[MeSHID:D004827],Stereotyping[MeSHID:D013240],Nose[MeSHID:D009666],Seizures[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Irritable Mood[MeSHID:D007508] approved translocator protein TSPO Successful target unknown 0.05 TTD , DGIDB tricyclic indole compound 5 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quinoline carboxamide derivative 5 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB u-89854 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative translocator protein TSPO Successful target unknown NA TTD adinazolam NA Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Status Epilepticus[MeSHID:D013226],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.11 TTD , DGIDB pmid27607364-compound-62 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pk 11195 NA NA investigative translocator protein TSPO Successful target unknown NA TTD quinoline carboxamide derivative 7 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazopyridine acetamide analog 5 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzoxazepine analog 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB clorazepate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved translocator protein TSPO Successful target unknown 0.37 TTD , DGIDB fludiazepam NA Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.11 TTD , DGIDB dextofisopam NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 translocator protein TSPO Successful target unknown 1.87 TTD , DGIDB tricyclic indole compound 10 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 14 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB bidentate pyrazolopyrimidine acetamide analog 4 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imepitoin NA Convulsions[MeSHID:D012640],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 translocator protein TSPO Successful target unknown NA TTD quinazoline derivative 6 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine acetamide derivative 4 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzothiazepine analog 4 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzimidazolone acetamide derivative 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27599163-compound-79 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB bay-85-8102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain Diseases[MeSHID:D001927] phase 1 translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-10 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine acetamide derivative 5 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27599163-compound-76 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quinoline carboxamide derivative 4 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 9 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quinazoline derivative 5 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quinazoline derivative 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 11 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB aryl oxyanilide derivative 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB indole-based analog 5 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB emapunil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 translocator protein TSPO Successful target unknown NA TTD quinoline carboxamide derivative 9 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzothiazepine analog 9 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB halazepam NA Anxiety Disorders[MeSHID:D001008],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.09 TTD , DGIDB tricyclic indole compound 7 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quinazoline derivative 3 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pyrazolopyrimidine acetamide analog 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzodiazepine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative translocator protein TSPO Successful target unknown NA TTD imidazopyridine acetamide analog 3 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-63 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazopyridine acetamide analog 6 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB 18f-fedaa-1106 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-61 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazopyridine derivative 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB indole-based analog 9 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB 11c-pbr-170 NA NA investigative translocator protein TSPO Successful target unknown NA TTD benzothiazepine analog 3 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB estazolam NA Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Early Awakening[MeSHID:D007319],Term Birth[MeSHID:D047929],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.08 TTD , DGIDB clotiazepam NA Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.11 TTD , DGIDB lirequinil NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 2 translocator protein TSPO Successful target unknown NA TTD lorazepam NA Spasm[MeSHID:D013035],Status Epilepticus[MeSHID:D013226],Nausea[MeSHID:D009325],Amnesia[MeSHID:D000647],Vomiting[MeSHID:D014839],Delirium[MeSHID:D003693],Anxiety[MeSHID:D001007],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Substance Withdrawal Syndrome[MeSHID:D013375],Alcohol Withdrawal Delirium[MeSHID:D000430],Catatonia[MeSHID:D002389],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.57 TTD , DGIDB pmid27607364-compound-162 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 4 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-141 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazopyridine acetamide analog 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB 2-(2-phenyl-1h-indol-3-yl)-n,n-dipropyl-acetamide NA NA investigative translocator protein TSPO Successful target unknown NA TTD n,n-dimethyl-2-(2-phenyl-1h-indol-3-yl)-acetamide NA NA investigative translocator protein TSPO Successful target unknown NA TTD tricyclic indole compound 3 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB zopiclone small molecule Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO NA agonist 1.87 drugbank , DGIDB benzodiazepine derivative 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quinoline carboxamide derivative 10 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27599163-compound-78 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tricyclic indole compound 8 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB flumazenil NA Disease Management[MeSHID:D019468],Diagnosis[MeSHID:D003933],Drug Overdose[MeSHID:D062787],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.1 TTD , DGIDB benzimidazolone acetamide derivative 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazopyridine acetamide analog 7 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB prazepam NA Anxiety Disorders[MeSHID:D001008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.09 TTD , DGIDB n-hexyl-2-(2-phenyl-1h-indol-3-yl)-acetamide NA NA investigative translocator protein TSPO Successful target unknown NA TTD n,n-dihexyl-2-(2-phenyl-1h-indol-3-yl)-acetamide NA NA investigative translocator protein TSPO Successful target unknown NA TTD aryl oxyanilide derivative 3 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB alprazolam NA Depressive disorder[MeSHID:D003866],Premenstrual syndrome[MeSHID:D011293],Panic Disorder[MeSHID:D016584],Anxiety Disorders[MeSHID:D001008],Mental Depression[MeSHID:D003863],Patient Discharge[MeSHID:D010351],Agoraphobia[MeSHID:D000379],Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Epilepsy[MeSHID:D004827] approved translocator protein TSPO Successful target unknown 0.12 TTD , DGIDB s-8510 NA Cognition Disorders[MeSHID:D003072],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 2 translocator protein TSPO Successful target unknown NA TTD imidazopyridine acetamide analog 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB cinolazepam NA Disease Management[MeSHID:D019468],Anxiety Disorders[MeSHID:D001008],Depressive Symptoms[MeSHID:D003863],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] approved translocator protein TSPO Successful target unknown 0.11 TTD , DGIDB imidazopyridine derivative 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-4 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB phenylpurine acetamide analog 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine acetamide derivative 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB ssr-180575 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] phase 2 translocator protein TSPO Successful target unknown NA TTD , DGIDB alpidem NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] approved translocator protein TSPO Successful target unknown 1.87 TTD , DGIDB ro 5-4864 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gram-Positive Bacterial Infections[MeSHID:D016908] investigative translocator protein TSPO Successful target unknown NA TTD benzothiazepine analog 6 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27599163-compound-82 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quinazoline derivative 7 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzothiazepine analog 8 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB quazepam NA Sleeplessness[MeSHID:D007319],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.09 TTD , DGIDB imidazo[1,2-b]pyridazine acetamide derivative 3 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazopyridine acetamide analog 4 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB diazepam NA Paraplegia[MeSHID:D010264],Diploid Cell[MeSHID:D004171],Aggressive behavior[MeSHID:D000374],Tetanus[MeSHID:D013742],Stiff-Person Syndrome[MeSHID:D016750],Cerebral Palsy[MeSHID:D002547],Myoclonus[MeSHID:D009207],Operative Surgical Procedures[MeSHID:D013514],Nose[MeSHID:D009666],Sleeplessness[MeSHID:D007319],Myositis[MeSHID:D009220],Spasm[MeSHID:D013035],Stereotyped Behavior[MeSHID:D013239],Compassion Fatigue[MeSHID:D000068376],Stereotypic Movement Disorder[MeSHID:D019956],Tremor[MeSHID:D014202],Alcohol Withdrawal Delirium[MeSHID:D000430],Seizures[MeSHID:D012640],Disease Management[MeSHID:D019468],Irritable Mood[MeSHID:D007508],Neurotic Disorders[MeSHID:D009497],Dental Health Services[MeSHID:D003752],Fear (Mental Process)[MeSHID:D005239],Mental association[MeSHID:D001244],Muscle Spasticity[MeSHID:D009128],Epilepsy[MeSHID:D004827],Anxiety Disorders[MeSHID:D001008],Term Birth[MeSHID:D047929],Stress Fractures[MeSHID:D015775],Reflex action[MeSHID:D012018],Disease[MeSHID:D004194],Stress Disorders, Traumatic[MeSHID:D040921],Muscle Cramp[MeSHID:D009120],Athetosis[MeSHID:D001264],Stereotyping[MeSHID:D013240],Motor Neuron Disease, Upper[MeSHID:D016472],Anxiety[MeSHID:D001007],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.25 TTD , DGIDB phenylpurine acetamide analog 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27599163-compound-81 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB ono-2952 NA Irritable Bowel Syndrome[MeSHID:D043183],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 translocator protein TSPO Successful target unknown 1.87 TTD , DGIDB 5-phenyl-6-thia-10b-aza-benzo[e]azulene NA NA investigative translocator protein TSPO Successful target unknown NA TTD benzothiazepine analog 7 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB pmid27607364-compound-59 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzothiazepine analog 5 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB flurazepam NA Behaviorial Habits[MeSHID:D006184],Sleep[MeSHID:D012890],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.09 TTD , DGIDB tro-40303 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lateral Sclerosis[MeSHID:D016472] discontinued in phase 2 translocator protein TSPO Successful target unknown NA TTD imidazo[1,2-b]pyridazine acetamide derivative 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB tgsc01aa(4) NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] investigative translocator protein TSPO Successful target unknown NA TTD 5-phenyl-6-thia-10b-aza-benzo[e]azulen-4-one NA NA investigative translocator protein TSPO Successful target unknown NA TTD ro-16-6028 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Anxiety Disorders[MeSHID:D001008] discontinued in phase 3 translocator protein TSPO Successful target unknown NA TTD n,n-diethyl-2-(2-phenyl-1h-indol-3-yl)-acetamide NA NA investigative translocator protein TSPO Successful target unknown NA TTD iodophenyl-n-methyl-n-fluoroalkyl-3-isoquinoline carboxamide derivative 3 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB 4-methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene NA NA investigative translocator protein TSPO Successful target unknown NA TTD flunitrazepam NA Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 1.87 TTD , DGIDB imidazo[1,2-b]pyridazine acetamide derivative 6 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzothiazepine analog 1 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB chlordiazepoxide NA Disease Management[MeSHID:D019468],Alcoholic Intoxication, Chronic[MeSHID:D000437],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.09 TTD , DGIDB temazepam NA Disease Management[MeSHID:D019468],Accidental Falls[MeSHID:D000058],Sleeplessness[MeSHID:D007319],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.51 TTD , DGIDB iodophenyl-n-methyl-n-fluoroalkyl-3-isoquinoline carboxamide derivative 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB benzothiazepine analog 2 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB imidazo[1,2-b]pyridazine acetamide derivative 7 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB oxazepam NA Disease Management[MeSHID:D019468],Alcohol consumption[MeSHID:D000428],Anxiety Disorders[MeSHID:D001008],Withdrawal Symptoms[MeSHID:D013375],Anxiety[MeSHID:D001007],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved translocator protein TSPO Successful target unknown 0.07 TTD , DGIDB pmid27607364-compound-58 NA NA patented translocator protein TSPO Successful target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational testis-specific serine/threonine-protein kinase 1 TSSK1B NA inhibitor NA drugbank pmid24900538c2c NA NA investigative testis-specific serine kinase 2 TSSK2 Literature-reported target unknown NA TTD s-mercaptocysteine small molecule NA experimental thiosulfate sulfurtransferase TST NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical gdp-l-fucose synthase TSTA3 NA unknown NA drugbank 2,6-dihydroanthra/1,9-cd/pyrazol-6-one NA NA investigative dual specificity protein kinase ttk TTK Clinical trial target unknown NA TTD tricyclic isoxazoloquinazoline derivative 2 NA NA patented dual specificity protein kinase ttk TTK Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational dual specificity protein kinase ttk TTK NA inhibitor NA drugbank tricyclic isoxazoloquinazoline derivative 4 NA NA patented dual specificity protein kinase ttk TTK Clinical trial target unknown NA TTD , DGIDB tricyclic isoxazoloquinazoline derivative 3 NA NA patented dual specificity protein kinase ttk TTK Clinical trial target unknown NA TTD , DGIDB gne-7915 NA NA investigative dual specificity protein kinase ttk TTK Clinical trial target inhibitor NA TTD , DGIDB bay1161909 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dual specificity protein kinase ttk TTK Clinical trial target unknown NA TTD , DGIDB bos172722 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,phase 1 dual specificity protein kinase ttk TTK Clinical trial target inhibitor NA TTD , drugbank , DGIDB pyrazolanthrone small molecule NA experimental dual specificity protein kinase ttk TTK NA unknown NA drugbank cfi-402257 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 dual specificity protein kinase ttk TTK Clinical trial target unknown NA TTD theophylline small molecule Lung diseases[MeSHID:D008171],Pathological accumulation of air in tissues[MeSHID:D004646],Asthma[MeSHID:D001249],Lung[MeSHID:D008168],Pulmonary Emphysema[MeSHID:D011656],Bronchitis, Chronic[MeSHID:D029481],Chronic disease[MeSHID:D002908],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] approved tubulin monoglycylase ttll3 TTLL3 NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental transthyretin TTR NA inducer NA drugbank vutrisiran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiomyopathies[MeSHID:D009202] phase 3 transthyretin messenger rna TTR Successful target unknown NA TTD patisiran NA Amyloidosis, Hereditary[MeSHID:None],Complication Aspects[MeSHID:None],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686],Cardiomyopathies[MeSHID:D009202] approved transthyretin messenger rna TTR Successful target unknown 14.14 TTD , DGIDB tafamidis small molecule Cardiomyopathies[MeSHID:D009202] approved,investigational transthyretin TTR NA chaperone 35.36 drugbank , DGIDB inotersen NA AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Polyneuropathy, Familial[MeSHID:D011115],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved transthyretin TTR Successful target unknown 21.22 TTD , DGIDB aln-ttr01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686],Cardiomyopathies[MeSHID:D009202] phase 1 transthyretin messenger rna TTR Successful target unknown NA TTD zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational transthyretin TTR NA inducer NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational transthyretin TTR NA unknown NA drugbank isis-ttr NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686] phase 3 transthyretin messenger rna TTR Successful target unknown NA TTD zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational transthyretin TTR NA unknown NA drugbank aln-ttrsc NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cardiomyopathies[MeSHID:D009202] phase 3 transthyretin TTR Successful target unknown NA TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational transthyretin TTR NA unknown NA drugbank revusiran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686] phase 3 transthyretin messenger rna TTR Successful target unknown NA TTD (1r,2r,3s,4r,6s)-3,4,6-trihydroxy-5-{[(s)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)] small molecule NA experimental tubby protein homolog TUB NA unknown NA drugbank vinblastine small molecule Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Neuroblastoma[MeSHID:D009447],Malignant neoplasm of testis[MeSHID:D013736],Histiocytosis[MeSHID:D015614],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tubulin alpha-1a chain TUBA1A NA binder 0.4 drugbank , DGIDB phenethyl isothiocyanate small molecule NA investigational tubulin alpha-1a chain TUBA1A NA unknown NA drugbank albendazole small molecule Polycystic liver disease[MeSHID:C536330],Cysticercosis[MeSHID:D003551],Lung[MeSHID:D008168],Neurocysticercosis[MeSHID:D020019],Peritoneum[MeSHID:D010537],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Helminthiasis[MeSHID:D006373] approved,vet_approved tubulin alpha-1a chain TUBA1A NA inhibitor NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational tubulin alpha-1a chain TUBA1A NA ligand NA drugbank patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin alpha-1a chain TUBA1A NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin alpha-1a chain TUBA1A NA unknown NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin alpha-1a chain TUBA1A NA unknown NA drugbank mebendazole small molecule Coinfection[MeSHID:D060085],Nematode infections[MeSHID:D009349],Hookworm Infections[MeSHID:D006725],Infection by Trichuris trichiura[MeSHID:D014257],Enterobiasis[MeSHID:D017229],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Helminthiasis[MeSHID:D006373] approved,vet_approved tubulin alpha-1a chain TUBA1A NA inhibitor 2.12 drugbank , DGIDB 2-mercapto-n-[1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]acetamide small molecule NA experimental tubulin alpha-1a chain TUBA1A NA unknown NA drugbank colchiceine small molecule NA approved,experimental tubulin alpha-1a chain TUBA1A NA binder NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin alpha-1b chain TUBA1B NA unknown NA drugbank 2-mercapto-n-[1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]acetamide small molecule NA experimental tubulin alpha-1b chain TUBA1B NA unknown NA drugbank patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin alpha-1b chain TUBA1B NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin alpha-1b chain TUBA1B NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin alpha-1c chain TUBA1C NA unknown NA drugbank patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin alpha-1c chain TUBA1C NA unknown NA drugbank 2-mercapto-n-[1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]acetamide small molecule NA experimental tubulin alpha-1c chain TUBA1C NA unknown NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin alpha-1c chain TUBA1C NA unknown NA drugbank patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin alpha-3c/d chain TUBA3C NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational tubulin alpha-3c/d chain TUBA3C NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin alpha-3c/d chain TUBA3C NA unknown NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin alpha-3c/d chain TUBA3C NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tubulin alpha-3c/d chain TUBA3C NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin alpha-3e chain TUBA3E NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin alpha-4a chain TUBA4A NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational tubulin alpha-4a chain TUBA4A NA unknown NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin alpha-4a chain TUBA4A NA unknown NA drugbank cabazitaxel small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved tubulin alpha-4a chain TUBA4A NA binder,inhibitor 0.18 drugbank , DGIDB vincristine small molecule Nephroblastoma[MeSHID:D009396],Philadelphia Chromosome[MeSHID:D010677],Rhabdomyosarcoma[MeSHID:D012208],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Neuroblastoma[MeSHID:D009447],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tubulin alpha-4a chain TUBA4A NA inhibitor 0.21 drugbank , DGIDB cabazitaxel small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved tubulin alpha-4a chain TUBA4A NA binder 0.18 drugbank , DGIDB patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin alpha-4a chain TUBA4A NA unknown NA drugbank podofilox small molecule Condylomata Acuminata[MeSHID:D003218],Warts[MeSHID:D014860],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reproduction[MeSHID:D012098] approved tubulin alpha-4a chain TUBA4A NA inhibitor 0.67 drugbank , DGIDB cyt997 small molecule Neoplasms[MeSHID:D009369] investigational putative tubulin-like protein alpha-4b TUBA4B NA unknown NA drugbank patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin alpha-8 chain TUBA8 NA unknown NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin alpha-8 chain TUBA8 NA unknown NA drugbank vinflunine small molecule Carcinoma, Transitional Cell[MeSHID:D002295],Transitional Epithelial Cells[MeSHID:D004847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational tubulin beta chain TUBB NA inhibitor 0.34 drugbank , DGIDB ca4p small molecule Carcinoma, Neuroendocrine[MeSHID:D018278],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] investigational tubulin beta chain TUBB NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta chain TUBB NA unknown NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin beta chain TUBB NA unknown NA drugbank colchiceine small molecule NA approved,experimental tubulin beta chain TUBB NA binder NA drugbank zen-012 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta chain TUBB NA unknown NA drugbank colchicine small molecule Familial Mediterranean Fever[MeSHID:D010505],Behcet Syndrome[MeSHID:D001528],Pain Disorder[MeSHID:D013001],Postpericardiotomy Syndrome[MeSHID:D011185],Gout[MeSHID:D006073],Pain[MeSHID:D010146],Pericarditis[MeSHID:D010493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved tubulin beta chain TUBB NA inhibitor,binder 0.42 drugbank , DGIDB vinblastine small molecule Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Neuroblastoma[MeSHID:D009447],Malignant neoplasm of testis[MeSHID:D013736],Histiocytosis[MeSHID:D015614],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tubulin beta chain TUBB NA binder 0.36 drugbank , DGIDB colchicine small molecule Familial Mediterranean Fever[MeSHID:D010505],Behcet Syndrome[MeSHID:D001528],Pain Disorder[MeSHID:D013001],Postpericardiotomy Syndrome[MeSHID:D011185],Gout[MeSHID:D006073],Pain[MeSHID:D010146],Pericarditis[MeSHID:D010493],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Arthritis, Gouty[MeSHID:D015210] approved tubulin beta chain TUBB NA inhibitor,binder 0.42 drugbank , DGIDB podofilox small molecule Condylomata Acuminata[MeSHID:D003218],Warts[MeSHID:D014860],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Reproduction[MeSHID:D012098] approved tubulin beta chain TUBB NA inhibitor 0.26 drugbank , DGIDB vinblastine small molecule Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Neuroblastoma[MeSHID:D009447],Malignant neoplasm of testis[MeSHID:D013736],Histiocytosis[MeSHID:D015614],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tubulin beta chain TUBB NA binder,inhibitor 0.36 drugbank , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational tubulin beta chain TUBB NA ligand NA drugbank vinorelbine small molecule Squamous Epithelial Cells[MeSHID:D004847],Cancer of Head and Neck[MeSHID:D006258],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Fibromatosis, Aggressive[MeSHID:D018222],Unmarried[MeSHID:D012847],Hodgkin Disease[MeSHID:D006689],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational tubulin beta chain TUBB NA antagonist,inhibitor NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tubulin beta chain TUBB NA unknown NA drugbank vincristine small molecule Nephroblastoma[MeSHID:D009396],Philadelphia Chromosome[MeSHID:D010677],Rhabdomyosarcoma[MeSHID:D012208],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Neuroblastoma[MeSHID:D009447],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tubulin beta chain TUBB NA inhibitor 0.21 drugbank , DGIDB milataxel small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational tubulin beta chain TUBB NA unknown NA drugbank depatuxizumab mafodotin biotech NA investigational tubulin beta chain TUBB NA nucleotide exchange blocker NA drugbank patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin beta chain TUBB NA unknown NA drugbank tirbanibulin small molecule Scalp structure[MeSHID:D012535],Actinic keratosis[MeSHID:D055623],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471] approved,investigational tubulin beta chain TUBB NA inhibitor NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-1 chain TUBB1 NA unknown NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin beta-1 chain TUBB1 NA unknown NA drugbank , DGIDB docetaxel small molecule Cancer of Head and Neck[MeSHID:D006258],Stomach[MeSHID:D013270],Malignant neoplasm of prostate[MeSHID:D011471],Neoplasm Metastasis[MeSHID:D009362],Malignant neoplasm of breast[MeSHID:D001943],Prostate[MeSHID:D011467],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational tubulin beta-1 chain TUBB1 NA unknown 0.09 drugbank , DGIDB cabazitaxel small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved tubulin beta-1 chain TUBB1 NA binder 0.22 drugbank , DGIDB irofulven/taxotere NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tubulin beta-1 chain TUBB1 Clinical trial target unknown NA TTD , DGIDB ai-850 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 tubulin beta-1 chain TUBB1 Clinical trial target unknown NA TTD , DGIDB zen-012 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-1 chain TUBB1 NA unknown NA drugbank milataxel small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational tubulin beta-1 chain TUBB1 NA unknown 0.82 drugbank , DGIDB patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin beta-1 chain TUBB1 NA unknown NA drugbank paclitaxel small molecule Breast[MeSHID:D001940],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Ovary[MeSHID:D010053] approved,vet_approved tubulin beta-1 chain TUBB1 NA inhibitor 0.25 drugbank , DGIDB phenethyl isothiocyanate small molecule NA investigational tubulin beta-1 chain TUBB1 NA unknown NA drugbank vindesine small molecule leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Hodgkin Disease[MeSHID:D006689],Polycythemia Vera[MeSHID:D011087],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational tubulin beta-1 chain TUBB1 NA inhibitor 2.14 drugbank , DGIDB cabazitaxel small molecule Prostatic Cancer, Castration-Resistant[MeSHID:D064129],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] approved tubulin beta-1 chain TUBB1 NA binder,inhibitor 0.22 drugbank , DGIDB angiostatin/paclitaxel/carboplatin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] investigative tubulin beta-1 chain TUBB1 Clinical trial target unknown NA TTD eribulin small molecule Breast[MeSHID:D001940],Malignant neoplasm of breast[MeSHID:D001943],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tubulin beta-1 chain TUBB1 NA unknown NA drugbank pi-88/taxotere NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tubulin beta-1 chain TUBB1 Clinical trial target unknown NA TTD , DGIDB 3-bromo-4,4',5-trimethoxy-(z)-stilbene NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD 3,4',5-trimethoxy-(z)-stilbene NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD phenethyl isothiocyanate small molecule NA investigational tubulin beta-2a chain TUBB2A NA unknown NA drugbank 3,4,4',5-tetramethoxy-(z)-stilbene NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD 6-ile-ustiloxin NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD dolastatin-10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 tubulin beta-2 chain TUBB2A Successful target unknown NA TTD 2,3'-diamino-3,4,4',5-tetramethoxy-(z)-stillbene NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD ustiloxin d NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD 2'-amino-3,4,4',5-tetramethoxy-(z)-stillbene NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD n-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD ustiloxin f NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD 2-amino-3,4',5-trimethoxy-(z)-stillbene NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-2a chain TUBB2A NA unknown NA drugbank ustiloxin a NA NA investigative tubulin beta-2 chain TUBB2A Successful target unknown NA TTD vinblastine NA Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Neuroblastoma[MeSHID:D009447],Malignant neoplasm of testis[MeSHID:D013736],Histiocytosis[MeSHID:D015614],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tubulin beta-2 chain TUBB2A Successful target unknown 0.25 TTD , DGIDB cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-2b chain TUBB2B NA unknown NA drugbank 2-mercapto-n-[1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]acetamide small molecule NA experimental tubulin beta-2b chain TUBB2B NA unknown NA drugbank zen-012 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-3 chain TUBB3 NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-3 chain TUBB3 NA unknown NA drugbank ixabepilone small molecule Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Renal Cell Carcinoma[MeSHID:D002292],Cancer of Head and Neck[MeSHID:D006258],Lymphoma[MeSHID:D008223],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tubulin beta-3 chain TUBB3 NA inhibitor 0.36 drugbank , DGIDB patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin beta-3 chain TUBB3 NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational tubulin beta-3 chain TUBB3 NA unknown NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin beta-3 chain TUBB3 NA unknown NA drugbank zen-012 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-4a chain TUBB4A NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational tubulin beta-4a chain TUBB4A NA ligand NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin beta-4a chain TUBB4A NA unknown NA drugbank patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin beta-4a chain TUBB4A NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-4a chain TUBB4A NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-4b chain TUBB4B NA unknown NA drugbank mebendazole small molecule Coinfection[MeSHID:D060085],Nematode infections[MeSHID:D009349],Hookworm Infections[MeSHID:D006725],Infection by Trichuris trichiura[MeSHID:D014257],Enterobiasis[MeSHID:D017229],Unmarried[MeSHID:D012847],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Helminthiasis[MeSHID:D006373] approved,vet_approved tubulin beta-4b chain TUBB4B NA inhibitor 2.07 drugbank , DGIDB albendazole small molecule Polycystic liver disease[MeSHID:C536330],Cysticercosis[MeSHID:D003551],Lung[MeSHID:D008168],Neurocysticercosis[MeSHID:D020019],Peritoneum[MeSHID:D010537],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Helminthiasis[MeSHID:D006373] approved,vet_approved tubulin beta-4b chain TUBB4B NA inhibitor NA drugbank epothilone d small molecule Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational tubulin beta-4b chain TUBB4B NA unknown NA drugbank oxibendazole small molecule Communicable Diseases[MeSHID:D003141],Parasitic Diseases[MeSHID:D010272],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational,vet_approved tubulin beta-4b chain TUBB4B NA unknown NA drugbank patupilone small molecule Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of brain[MeSHID:D001932] experimental,investigational tubulin beta-4b chain TUBB4B NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational tubulin beta-4b chain TUBB4B NA unknown NA drugbank cyt997 small molecule Neoplasms[MeSHID:D009369] investigational tubulin beta-6 chain TUBB6 NA unknown NA drugbank artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational tubulin beta-6 chain TUBB6 NA ligand NA drugbank vinblastine small molecule Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Neuroblastoma[MeSHID:D009447],Malignant neoplasm of testis[MeSHID:D013736],Histiocytosis[MeSHID:D015614],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tubulin delta chain TUBD1 NA binder NA drugbank vinblastine small molecule Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Neuroblastoma[MeSHID:D009447],Malignant neoplasm of testis[MeSHID:D013736],Histiocytosis[MeSHID:D015614],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tubulin epsilon chain TUBE1 NA binder NA drugbank vinblastine small molecule Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Malignant neoplasm of breast[MeSHID:D001943],Kaposi Sarcoma[MeSHID:D012514],Neuroblastoma[MeSHID:D009447],Malignant neoplasm of testis[MeSHID:D013736],Histiocytosis[MeSHID:D015614],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved tubulin gamma-1 chain TUBG1 NA binder NA drugbank guanosine-5'-diphosphate small molecule NA experimental elongation factor tu, mitochondrial TUFM NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational elongation factor tu, mitochondrial TUFM NA unknown NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational elongation factor tu, mitochondrial TUFM NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental elongation factor tu, mitochondrial TUFM NA cofactor NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational elongation factor tu, mitochondrial TUFM NA cofactor NA drugbank fus-1 tumor suppressor gene therapy NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 tumor suppressor candidate 2 TUSC2 Clinical trial target unknown NA TTD cnvn-202 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 tumor suppressor candidate 2 TUSC2 Clinical trial target unknown NA TTD , DGIDB quaratusugene ozeplasmid NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 tumor suppressor candidate 2 TUSC2 Clinical trial target unknown NA TTD zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosine-protein kinase txk TXK NA inhibitor NA drugbank zanubrutinib small molecule Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse[MeSHID:D020522],Waldenstrom Macroglobulinemia[MeSHID:D008258],Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451],B-Cell Lymphomas[MeSHID:D016393] approved,investigational tyrosine-protein kinase txk TXK NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase txk TXK NA inhibitor NA drugbank phenethyl isothiocyanate small molecule NA investigational thioredoxin TXN NA unknown NA drugbank px-12 NA Malignant neoplasm of stomach[MeSHID:D013274],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] phase 2 thioredoxin TXN Clinical trial target unknown 31.83 TTD , DGIDB px-12 NA Malignant neoplasm of stomach[MeSHID:D013274],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 2 thioredoxin TXN Clinical trial target unknown 31.83 TTD , DGIDB cacodylate ion NA NA investigative thioredoxin TXN Clinical trial target unknown NA TTD acetate ion NA NA investigative thioredoxin TXN Clinical trial target unknown NA TTD pmid27977313-compound-44 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB motexafin gadolinium small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of brain[MeSHID:D001932],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigational thioredoxin reductase 1, cytoplasmic TXNRD1 NA unknown NA drugbank , DGIDB pmid27977313-compound-27 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB triazole gold complexe 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-19 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-46 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB px-12 small molecule Malignant neoplasm of stomach[MeSHID:D013274],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational thioredoxin reductase 1, cytoplasmic TXNRD1 NA unknown NA drugbank pmid27977313-compound-45 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB 5,8-dihydroxy-1,4-naphthoquinone NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malaria[MeSHID:D008288] investigative cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD fotemustine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown 31.83 TTD , DGIDB palmarumycin derivative 3 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-47 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB acyl oxymethyl acrylamide ester derivative 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB 4-aryl quinol derivative 7 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB triazole gold complexe 3 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB 4-aryl quinol derivative 3 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB golden phosphorous acetyletic compound 3 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational thioredoxin reductase 1, cytoplasmic TXNRD1 NA inhibitor NA drugbank , DGIDB acyl oxymethyl acrylamide ester derivative 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB arsenic trioxide small molecule Acute Promyelocytic Leukemia[MeSHID:D015473],Chromosomal translocation[MeSHID:D014178],Gene Expression[MeSHID:D015870],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational thioredoxin reductase 1, cytoplasmic TXNRD1 NA inhibitor 10.61 drugbank , DGIDB 4-aryl quinol derivative 4 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-28 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-7 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB terpyridineplatinum(ii) complexe 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-6 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB palmarumycin derivative 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-30 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB bis(2,4-dinitrophenyl)sulfane NA NA investigative cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD disulfide compound 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB terpyridineplatinum(ii) complexe 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB spermidine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] experimental thioredoxin reductase 1, cytoplasmic TXNRD1 NA unknown 14.14 drugbank , DGIDB pmid27977313-compound-42 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB triazole gold complexe 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB spermidine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Rheumatoid Arthritis[MeSHID:D001172] phase 3 cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown 14.14 TTD , DGIDB bis-sulfonamide derivative 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB 4,6-dinitrobenzo[c][1,2,5]thiadiazole NA NA investigative cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD bis-sulfonamide derivative 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-5 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB metal complex derivative 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB binuclear gold(i) compound 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB golden phosphorous acetyletic compound 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB metal complex derivative 3 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB metal complex derivative 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-32 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-48 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB px-12 small molecule Malignant neoplasm of stomach[MeSHID:D013274],Neoplasms[MeSHID:D009369],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352] investigational thioredoxin reductase 1, cytoplasmic TXNRD1 NA unknown NA drugbank pmid27977313-compound-18 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB 4-aryl quinol derivative 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB benzisoselenazolone difluorocytidine derivative 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-figure4b NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB flavin-adenine dinucleotide NA NA investigative cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD pmid27977313-compound-8 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB palmarumycin derivative 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-17 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-figure6c NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-43 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB terpyridineplatinum(ii) complexe 4 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB binuclear gold(i) compound 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB disulfide compound 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB 3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide NA NA investigative cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD 4-aryl quinol derivative 5 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-31 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB golden phosphorous acetyletic compound 2 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB terpyridineplatinum(ii) complexe 3 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB terpyridineplatinum(ii) complexe 5 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB 4-aryl quinol derivative 1 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB fotemustine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational thioredoxin reductase 1, cytoplasmic TXNRD1 NA unknown 31.83 drugbank , DGIDB flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved thioredoxin reductase 1, cytoplasmic TXNRD1 NA unknown NA drugbank pmid27977313-compound-39 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB pmid27977313-compound-29 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB nadph small molecule NA experimental thioredoxin reductase 1, cytoplasmic TXNRD1 NA unknown NA drugbank binuclear gold(i) compound 3 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB palmarumycin derivative 4 NA NA patented cytoplasmic thioredoxin reductase TXNRD1 Successful target unknown NA TTD , DGIDB motexafin gadolinium small molecule Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of brain[MeSHID:D001932],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] investigational thioredoxin reductase 2, mitochondrial TXNRD2 NA unknown NA drugbank , DGIDB pyrrolo[2,3-d]pyrimidine derivative 8 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB aminooxazole carboxamide derivative 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational non-receptor tyrosine-protein kinase tyk2 TYK2 NA unknown 0.91 drugbank , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational non-receptor tyrosine-protein kinase tyk2 TYK2 NA inhibitor 0.91 drugbank , DGIDB pf-06700841 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Asthma[MeSHID:D001249] phase 2 tyk2 tyrosine kinase TYK2 Clinical trial target unknown 1.03 TTD , DGIDB pf-06826647 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 2 tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pmid27774824-compound-figure9example2down NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB tricyclic pyrrolopyridine compound 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB aminotriazolopyridine derivative 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB ruxolitinib small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved non-receptor tyrosine-protein kinase tyk2 TYK2 NA inhibitor 0.21 drugbank , DGIDB pyrazolopyridine derivative 5 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational non-receptor tyrosine-protein kinase tyk2 TYK2 NA unknown 0.91 drugbank , DGIDB imidazo[4,5-c]pyridine derivative 2 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB imidazopyridine derivative 3 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB cmp-6 NA NA investigative tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD pmid27774824-compound-figure3example18 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB tricyclic compound 11 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB bms-986165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 3 tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB thiazolopyridine derivative 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 5 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pmid27774824-compound-figure11example1up NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB aminopyrimidine derivative 5 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pyrrole derivative 7 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 3 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 6 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB tricyclic heterocycle derivative 5 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB benzimidazole derivative 7 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pyrazolo[4,3-c]pyridine derivative 2 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB imidazo[4,5-c]pyridine derivative 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pmid27774824-compound-figure6example12 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pmid27774822-compound-figure9example15 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pf-06826647 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 1 tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB n-methylmethanesulfonamide derivative 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB tofacitinib small molecule Communicable Diseases[MeSHID:D003141],Ankylosing spondylitis[MeSHID:D013167],Graft Rejection[MeSHID:D006084],Rheumatoid Arthritis[MeSHID:D001172],Pneumonia[MeSHID:D011014],Ulcerative Colitis[MeSHID:D003093],Herpes zoster disease[MeSHID:D006562],Kidney[MeSHID:D007668],Urinary tract infection[MeSHID:D014552],Infection[MeSHID:D007239],Psoriasis[MeSHID:D011565],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational non-receptor tyrosine-protein kinase tyk2 TYK2 NA inhibitor 0.91 drugbank , DGIDB bis-aminopyrimidine derivative 4 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB aminopyridine derivative 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB tricyclic heterocycle derivative 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pyrazolopyridine derivative 3 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pmid27774822-compound-figure11example5 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB bms-986165 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565],Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773] phase 3 tyk2 tyrosine kinase TYK2 Clinical trial target allosteric modulator NA TTD , DGIDB pyrrolo[2,3-d]pyrimidine derivative 7 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pyrrolo-pyridone derivative 3 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational non-receptor tyrosine-protein kinase tyk2 TYK2 NA inhibitor NA drugbank pmid27774824-compound-figure9example2up NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 1 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB pmid27774822-compound-figure3compoundi-165 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB bis-aminopyrimidine derivative 2 NA NA patented tyk2 tyrosine kinase TYK2 Clinical trial target unknown NA TTD , DGIDB 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one small molecule NA experimental non-receptor tyrosine-protein kinase tyk2 TYK2 NA unknown NA drugbank ruxolitinib small molecule Eczema[MeSHID:D004485],Disease[MeSHID:D004194],Splenomegaly[MeSHID:D013163],Graft-vs-Host Disease[MeSHID:D006086],Immunocompetence[MeSHID:D007121],Primary Myelofibrosis[MeSHID:D055728],Polycythemia Vera[MeSHID:D011087],Thrombocythemia, Essential[MeSHID:D013920],Dermatitis, Atopic[MeSHID:D003876],Prescription procedure[MeSHID:D055656],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of pancreas[MeSHID:D010190],Pancreatic carcinoma[MeSHID:C562463],Vitiligo[MeSHID:D014820] approved non-receptor tyrosine-protein kinase tyk2 TYK2 NA inhibitor 0.21 drugbank , DGIDB 6-chloro-5-phenylpyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 1-benzyl-5'-o-tritylinosine NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 5-bromo-6-(cyclopropylamino)uracil hydrochloride NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD uridine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mental Depression[MeSHID:D003863],Depressive disorder[MeSHID:D003866] approved thymidine phosphorylase TYMP Successful target unknown 1.33 TTD , DGIDB 6-fluoro-5-phenylpyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 5-bromo-6-hydrazinouracil hydrochloride NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 5-benzyl-6-chloropyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 1-(cyclohexyl)methyl-5'-o-tritylinosine NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 1-(cyclopropyl)methyl-5'-o-tritylinosine NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 6-amino-5-bromouracil NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 1-allyl-5'-o-tritylinosine NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 6-chloro-5-heptylpyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 6-bromo-5-phenylpyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 6-amino-5-chlorouracil hydrochloride NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD tipiracil small molecule Colorectal Cancer[MeSHID:D015179] approved,investigational thymidine phosphorylase TYMP NA inhibitor NA drugbank thymine NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 1-propyl-5'-o-tritylinosine NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 5-butyl-6-chloropyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 6-chloro-5-pentylpyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 5-chloro-6-hydrazinouracil hydrochloride NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 6-chloro-5-hexylpyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 2'-aminoimidazolylmethyluracils NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 6-chloro-5-propylpyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD 6-chloro-5-(2-thienyl)pyrimidine-2,4(1h,3h)-dione NA NA investigative thymidine phosphorylase TYMP Successful target unknown NA TTD n-[2-chloro-5-(trifluoromethyl)phenyl]imidodicarbonimidic diamide small molecule NA experimental thymidylate synthase TYMS NA unknown NA drugbank deoxyuridine monophosphate small molecule NA experimental thymidylate synthase TYMS NA unknown 8.6 drugbank , DGIDB 10-propargyl-5,8-dideazafolic acid small molecule NA experimental thymidylate synthase TYMS NA unknown NA drugbank 2,4-diamino-5-phenyl-6-ethylpyrimidine small molecule NA experimental thymidylate synthase TYMS NA unknown NA drugbank pemetrexed small molecule Malignant mesothelioma[MeSHID:C562839],Disease[MeSHID:D004194],Pleura[MeSHID:D010994],Operative Surgical Procedures[MeSHID:D013514],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thymidylate synthase TYMS NA inhibitor 2.46 drugbank , DGIDB fluorouracil NA Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Biliary tract structure[MeSHID:D001659],Cells[MeSHID:D002477],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Colon structure (body structure)[MeSHID:D003106],Pancreas[MeSHID:D010179],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Carcinoid Tumor[MeSHID:D002276],Rectum[MeSHID:D012007],Kidney[MeSHID:D007668],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] approved thymidylate synthase messenger rna TYMS Successful target inhibitor 0.23 TTD , DGIDB capecitabine small molecule Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant tumor of colon[MeSHID:D003110],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thymidylate synthase TYMS NA inhibitor 0.48 drugbank , DGIDB osi-7904l small molecule Malignant neoplasm of stomach[MeSHID:D013274] investigational thymidylate synthase TYMS NA unknown 1.72 drugbank , DGIDB methotrexate small molecule Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved thymidylate synthase TYMS NA inhibitor 0.05 drugbank , DGIDB nuc-3373 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 thymidylate synthase TYMS Clinical trial target unknown NA TTD floxuridine small molecule Disease Management[MeSHID:D019468],Malignant neoplasm of liver[MeSHID:D008113],Adenocarcinoma[MeSHID:D000230],Liver[MeSHID:D008099],Operative Surgical Procedures[MeSHID:D013514],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved thymidylate synthase TYMS NA unknown 1.11 drugbank , DGIDB ici-198583 NA NA investigative thymidylate synthase TYMS Clinical trial target unknown NA TTD plevitrexed (r)-isomer NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Isomerism[MeSHID:D007536],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 thymidylate synthase TYMS Clinical trial target unknown NA TTD , DGIDB n-(3,5-dimethoxyphenyl)imidodicarbonimidic diamide small molecule NA experimental thymidylate synthase TYMS NA unknown NA drugbank thymidine monophosphate small molecule NA experimental thymidylate synthase TYMS NA unknown 6.88 drugbank , DGIDB fluorouracil NA Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Biliary tract structure[MeSHID:D001659],Cells[MeSHID:D002477],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Colon structure (body structure)[MeSHID:D003106],Pancreas[MeSHID:D010179],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Carcinoid Tumor[MeSHID:D002276],Rectum[MeSHID:D012007],Kidney[MeSHID:D007668],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] approved thymidylate synthase messenger rna TYMS Successful target unknown 0.23 TTD , DGIDB s,s-(2-hydroxyethyl)thiocysteine small molecule NA experimental thymidylate synthase TYMS NA unknown NA drugbank ts antisense + raltitrexed NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative thymidylate synthase messenger rna TYMS Successful target unknown NA TTD raltitrexed small molecule Rectum[MeSHID:D012007],Malignant tumor of colon[MeSHID:D003110],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thymidylate synthase TYMS NA inhibitor 3.93 drugbank , DGIDB tegafur small molecule Malignant neoplasm of stomach[MeSHID:D013274],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thymidylate synthase TYMS NA inhibitor 0.43 drugbank , DGIDB gemcitabine small molecule Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved thymidylate synthase TYMS NA inhibitor NA drugbank methotrexate small molecule Solutions[MeSHID:D012996],Neoplasms[MeSHID:D009369],Maintenance[MeSHID:D008283],Mycosis Fungoides[MeSHID:D009182],Operative Surgical Procedures[MeSHID:D013514],Rheumatoid Arthritis[MeSHID:D001172],Cancer of Head[MeSHID:D006258],Pregnancy[MeSHID:D011247],Malignant neoplasm of lung[MeSHID:D008175],Nevus[MeSHID:D009506],Choriocarcinoma[MeSHID:D002822],Osteosarcoma[MeSHID:D012516],Leukemia, Lymphocytic, Acute, L1[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Continuance of life[MeSHID:D013534],Hydatidiform Mole, Invasive[MeSHID:D002820],Juvenile arthritis[MeSHID:D001171],Lymphoma, Non-Hodgkin[MeSHID:D008228],Psoriasis[MeSHID:D011565],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Proliferative vitreoretinopathy[MeSHID:D018630],leukemia[MeSHID:D007938],Malignant neoplasm of prostate[MeSHID:D011471],Malignant Neoplasms[MeSHID:D009369] approved thymidylate synthase TYMS NA inhibitor 0.05 drugbank , DGIDB fluorouracil small molecule Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Biliary tract structure[MeSHID:D001659],Cells[MeSHID:D002477],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Colon structure (body structure)[MeSHID:D003106],Pancreas[MeSHID:D010179],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Carcinoid Tumor[MeSHID:D002276],Rectum[MeSHID:D012007],Kidney[MeSHID:D007668],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] approved thymidylate synthase TYMS NA inhibitor 0.23 drugbank , DGIDB thymectacin small molecule Colorectal Cancer[MeSHID:D015179] investigational thymidylate synthase TYMS NA unknown NA drugbank anx-510 small molecule Pancreatic carcinoma[MeSHID:C562463],Malignant neoplasm of pancreas[MeSHID:D010190],Malignant neoplasm of gallbladder[MeSHID:D005706],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational thymidylate synthase TYMS NA unknown NA drugbank 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine small molecule NA experimental thymidylate synthase TYMS NA unknown NA drugbank floxuridine small molecule Disease Management[MeSHID:D019468],Malignant neoplasm of liver[MeSHID:D008113],Adenocarcinoma[MeSHID:D000230],Liver[MeSHID:D008099],Operative Surgical Procedures[MeSHID:D013514],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved thymidylate synthase TYMS NA inhibitor 1.11 drugbank , DGIDB tegafur-uracil small molecule Diagnosis[MeSHID:D003933],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179] approved,investigational thymidylate synthase TYMS NA antagonist NA drugbank trifluridine small molecule Keratitis, Herpetic[MeSHID:D016849],Keratoconjunctivitis[MeSHID:D007637],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008],Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational thymidylate synthase TYMS NA inhibitor NA drugbank pralatrexate small molecule Peripheral T-Cell Lymphoma[MeSHID:D016411],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,investigational thymidylate synthase TYMS NA inhibitor NA drugbank gemcitabine small molecule Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Severe Acute Respiratory Syndrome[MeSHID:D045169],Middle East Respiratory Syndrome[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved thymidylate synthase TYMS NA inhibitor NA drugbank fluorouracil small molecule Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Biliary tract structure[MeSHID:D001659],Cells[MeSHID:D002477],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Colon structure (body structure)[MeSHID:D003106],Pancreas[MeSHID:D010179],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Carcinoid Tumor[MeSHID:D002276],Rectum[MeSHID:D012007],Kidney[MeSHID:D007668],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] approved thymidylate synthase TYMS NA unknown 0.23 drugbank , DGIDB resorcinol compound 34 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-(propan-2-ylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 3-(phenoxymethyl) benzylamine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 16 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-hydroxy-3-phenylurea NA NA investigative tyrosinase TYR Successful target unknown NA TTD monobenzone small molecule Pallor[MeSHID:D010167],Vitiligo[MeSHID:D014820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosinase TYR Successful target inhibitor 7.96 TTD , drugbank , DGIDB resorcinol compound 31 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB cyclohexyl carbamate derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 26 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB hexylresorcinol small molecule Malignant Neoplasms[MeSHID:D009369],Skin Diseases, Infectious[MeSHID:D012874],Burn injury[MeSHID:D002056],Aging[MeSHID:D000375],Pharyngitis[MeSHID:D010612],Pain[MeSHID:D010146] approved tyrosinase TYR NA inhibitor NA drugbank pmid26815044-compound-93 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB benzothiazoline derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-51 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 5-{8(z),11(z),14-pentadecatrienyl}resorcinol NA NA investigative tyrosinase TYR Successful target unknown NA TTD 2-(butylthiomethyl)-5-hydroxy-4h-pyran-4-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD p-coumaric acid derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 5-hydroxy-2-(pentylthiomethyl)-4h-pyran-4-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB benzothiazole analog 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB thiazoline derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-hydroxy-3-(4-nitrophenyl)urea NA NA investigative tyrosinase TYR Successful target unknown NA TTD pmid26815044-compound-52 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB kazinol s NA NA investigative tyrosinase TYR Successful target unknown NA TTD 2,2',4,4'-tetrahydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD 6-(3-hydroxy-phenyl)-naphthalen-2-ol NA NA investigative tyrosinase TYR Successful target unknown NA TTD benzoic acid linked peptide analog 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-125 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 4'-(4-nitrobenzensulfonamide)-4-hydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol NA NA investigative tyrosinase TYR Successful target unknown NA TTD benzimidazole derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 2,2',4,4',6'-pentahydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD benzothiazole analog 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB cyclohexyl carbamate derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB p-coumaric acid derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB p-coumaric acid derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB benzothiazole analog 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-(1,4-diacetylphenyl)dithiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD pmid26815044-compound-127 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB p-coumaric acid derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-123 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB benzoic acid linked peptide analog 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB crocusatin-k NA NA investigative tyrosinase TYR Successful target unknown NA TTD benzoic acid linked peptide analog 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 3-(phenoxymethyl) benzylamine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB s-2-(o-toluidino)-2-oxoethyl carbamothioate NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD thiazolidine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD sodium zinc dihydrolipoylhistidinate NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(butan-2-ylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol NA NA investigative tyrosinase TYR Successful target unknown NA TTD polyhydroxy benzamide derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 3-(2,4-dihydroxyphenyl)propionic acid NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(2,5-dimethyl-1h-pyrrol-1-yl)thiourea NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine NA NA investigative tyrosinase TYR Successful target unknown NA TTD 3,4-dihydroxybenzaldehyde-o-ethyloxime NA NA investigative tyrosinase TYR Successful target unknown NA TTD azelaic acid small molecule Acne Vulgaris[MeSHID:D000152],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosinase TYR NA inhibitor NA drugbank pmid26815044-compound-h NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB cyclohexyl carbamate derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB cyclohexyl carbamate derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB askendoside b NA NA investigative tyrosinase TYR Successful target unknown NA TTD daedalin a NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-hydroxy-3-(4-(trifluoromethyl)phenyl)urea NA NA investigative tyrosinase TYR Successful target unknown NA TTD 2-(cyclohexylthiomethyl)-5-hydroxy-4h-pyran-4-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5-hydroxy-2-(propylthiomethyl)-4h-pyran-4-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD benzimidazole derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 4'-(4-fluorobenzensulfonamide)-4-hydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD multi-epitope peptide melanoma vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 tyrosinase TYR Successful target unknown NA TTD , DGIDB nicotinyl hydroxamic acid derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB thiazolidine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical tyrosinase TYR NA unknown NA drugbank n-butylresorcinol NA NA investigative tyrosinase TYR Successful target unknown NA TTD 4'-amino-4-hydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD 4,4'-(ethane-1,2-diyl)dibenzene-1,3-diol NA NA investigative tyrosinase TYR Successful target unknown NA TTD dihydroxyfumaric acid derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 27 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-47 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB sri-224 NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(1-(4-fluorophenyl)ethylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol NA NA investigative tyrosinase TYR Successful target unknown NA TTD aromatic hydrazine carboxyimidoamide derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(but-2-enylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD pmid26815044-compound-48 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-i NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Oculocutaneous albinism type 1[MeSHID:C537728],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB tropolone NA NA investigative tyrosinase TYR Successful target unknown NA TTD 3-(phenoxymethyl) benzylamine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 3-(phenoxymethyl) benzylamine derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 3-(phenoxymethyl) benzylamine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 24 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 28 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 21 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB melanoma vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 3 tyrosinase TYR Successful target unknown NA TTD , DGIDB 4-hexyl resorcinol NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5-benzhydryl-1,3,4-thiadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD thiazolidine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB kojic acid-phenylalanine amide NA NA investigative tyrosinase TYR Successful target unknown NA TTD mkc-1106-mt NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 tyrosinase TYR Successful target unknown NA TTD , DGIDB 5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5-cyclohexyl-1,3,4-oxadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(3-methylbutylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(1-p-tolylethylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 2-hydroxyphenethyl 3,4,5-trihydroxybenzoate NA NA investigative tyrosinase TYR Successful target unknown NA TTD rosmarinic acid NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] investigative tyrosinase TYR Successful target unknown NA TTD 2-(heptylthiomethyl)-5-hydroxy-4h-pyran-4-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD resorcinol compound 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB cyclohexyl carbamate derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB thiazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB oxyresveratrol NA NA investigative tyrosinase TYR Successful target unknown NA TTD cyclohexyl carbamate derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-(1-(pyridin-3-yl)ethylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 3-hydroxyphenethyl 3,4,5-trihydroxybenzoate NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(3-phenylallylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD aromatic hydrazine carboxyimidoamide derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB hinokitiol NA NA investigative tyrosinase TYR Successful target unknown NA TTD 2-hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD pmid26815044-compound-64 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB multi-epitope tyrosinase/gp100 vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-121 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB aromatic hydrazine carboxyimidoamide derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 5-benzhydryl-1,3,4-oxadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD arbutin small molecule Dermatologic disorders[MeSHID:D012871],Epidermis[MeSHID:D004817],Senility[MeSHID:D000375],Hyperpigmentation[MeSHID:D017495],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911] approved tyrosinase TYR NA inhibitor NA drugbank 5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD cyclohexyl carbamate derivative 8 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB phenylthiourea NA NA investigative tyrosinase TYR Successful target unknown 15.91 TTD , DGIDB 5,5'-methylenebis(1,3,4-oxadiazole-2(3h)-thione) NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5,5'-methylenebis(1,3,4-thiadiazole-2(3h)-thione) NA NA investigative tyrosinase TYR Successful target unknown NA TTD resorcinol compound 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB benzoic acid linked peptide analog 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-49 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB kojic acid NA NA investigative tyrosinase TYR Successful target unknown 11.93 TTD , DGIDB 3hydroxy-1-methyl-1-phenylurea NA NA investigative tyrosinase TYR Successful target unknown NA TTD broussonin c NA NA investigative tyrosinase TYR Successful target unknown NA TTD pmid26815044-compound-114 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB cyclohexyl carbamate derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 2-(hexylthiomethyl)-5-hydroxy-4h-pyran-4-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD (+/-)-daedalin a NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(1-(pyrazin-2-yl)ethylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 2,2'-bi(1,3,4-thiadiazole)-5,5'(4h,4'h)-dithione NA NA investigative tyrosinase TYR Successful target unknown NA TTD 4'-(benzensulfonamide)-4-hydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD resorcinol compound 32 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 25 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-(1-(thiophen-2-yl)ethylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD polyhydroxy benzamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB aromatic hydrazine carboxyimidoamide derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB benzothiazole analog 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB polynoma-1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 2 tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB kazinol f NA NA investigative tyrosinase TYR Successful target unknown NA TTD beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB p-coumaric acid derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-118 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 33 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 3-(phenoxymethyl) benzylamine derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-(4-methylpent-3-en-2-ylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 2-(ethylthiomethyl)-5-hydroxy-4h-pyran-4-one NA NA investigative tyrosinase TYR Successful target unknown NA TTD polyhydroxy benzamide derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 2,2',4,4'-tetrahydroxy-6'-methoxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD n-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide NA NA investigative tyrosinase TYR Successful target unknown NA TTD mimosine small molecule NA experimental tyrosinase TYR NA inhibitor NA drugbank 5-phenyl-1,3,4-thiadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD 7,3',4'-trihydroxyisoflavone NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5-phenyl-1,3,4-oxadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD diamine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol NA NA investigative tyrosinase TYR Successful target unknown NA TTD pmid26815044-compound-30 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 7,8,4'-trihydroxyisoflavone NA NA investigative tyrosinase TYR Successful target unknown NA TTD 5-benzyl-1,3,4-oxadiazole-2(3h)-thione NA NA investigative tyrosinase TYR Successful target unknown NA TTD aromatic hydrazine carboxyimidoamide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-(4-bromophenyl)-3-hydroxyurea NA NA investigative tyrosinase TYR Successful target unknown NA TTD 2,4,3',5'-tetrahydroxybibenzyl NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(4-(benzyloxy)phenyl)-3-hydroxyurea NA NA investigative tyrosinase TYR Successful target unknown NA TTD n-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide NA NA investigative tyrosinase TYR Successful target unknown NA TTD 4-hydroxyphenethyl 3,4,5-trihydroxybenzoate NA NA investigative tyrosinase TYR Successful target unknown NA TTD beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB polyhydroxy benzamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-50 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB benzoic acid linked peptide analog 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 29 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1'-(4-methyl-benzyl)-[1,4']bipiperidinyl NA NA investigative tyrosinase TYR Successful target unknown NA TTD aromatic hydrazine carboxyimidoamide derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-117 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 4'-(4-aminobenzensulfonamide)-4-hydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD monoamine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-124 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB diamine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB monoamine derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-ethylidenethiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD pmid26815044-compound-116 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-cyclohexylidenethiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD thiazoline derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 14 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 11 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 12 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 4',4-dihydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD 1-(1-(4-bromophenyl)ethylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD polyhydroxy benzamide derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB n-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide NA NA investigative tyrosinase TYR Successful target unknown NA TTD monoamine derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB ethisterone NA NA investigative tyrosinase TYR Successful target unknown NA TTD resorcinol compound 23 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB monoamine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 18 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-cyclopentylidenethiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD hydroquinone small molecule Chloasma[MeSHID:D008548],Hyperpigmentation[MeSHID:D017495],Sunspots[MeSHID:D019445],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational tyrosinase TYR Successful target inhibitor 0.94 TTD , drugbank , DGIDB 1-propylidenethiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD benzoic acid linked peptide analog 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 19 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB p-coumaric acid derivative 3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-122 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 4'-(p-toluenesulfonamide)-4-hydroxychalcone NA NA investigative tyrosinase TYR Successful target unknown NA TTD resorcinol compound 20 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB resorcinol compound 17 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB kazinol c NA NA investigative tyrosinase TYR Successful target unknown NA TTD 4-adamantyl resorcinol NA NA investigative tyrosinase TYR Successful target unknown NA TTD monoamine derivative 2 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-31 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid26815044-compound-126 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-(1-phenylethylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD pmid26815044-compound-32 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB diamine derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 5-{8(z),11(z)-pentadecadienyl}resorcinol NA NA investigative tyrosinase TYR Successful target unknown NA TTD beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB pmid29130358-compound-figure11(3) NA NA patented tyrosinase TYR Successful target unknown NA TTD , DGIDB benzothiazole analog 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 1-(3-oxocyclohexylidene)thiosemicarbazide NA NA investigative tyrosinase TYR Successful target unknown NA TTD resorcinol compound 22 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chloasma[MeSHID:D008548],Lentigo[MeSHID:D007911],Senility[MeSHID:D000375],Albinism[MeSHID:D000417],Menkes Kinky Hair Syndrome[MeSHID:D007706] patented tyrosinase TYR Successful target unknown NA TTD , DGIDB 5-{8(z),-pentadecenyl}resorcinol NA NA investigative tyrosinase TYR Successful target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase receptor tyro3 TYRO3 NA inhibitor NA drugbank flanvotumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],melanoma[MeSHID:D008545] phase 1 melanoma antigen gp75 TYRP1 Clinical trial target unknown 127.3 TTD , DGIDB flx-787 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035],Amyotrophic Lateral Sclerosis[MeSHID:D000690],Multiple Sclerosis[MeSHID:D009103] phase 2 melanoma antigen gp75 TYRP1 Clinical trial target unknown NA TTD , DGIDB uridine-diphosphate-n-acetylgalactosamine small molecule NA experimental udp-n-acetylhexosamine pyrophosphorylase UAP1 NA unknown NA drugbank uridine-diphosphate-n-acetylglucosamine small molecule NA experimental udp-n-acetylhexosamine pyrophosphorylase UAP1 NA unknown NA drugbank hexatantalum dodecabromide small molecule NA experimental ubiquitin-like modifier-activating enzyme 1 UBA1 NA unknown NA drugbank quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational ubiquitin-like modifier-activating enzyme 1 UBA1 NA unknown NA drugbank (4s)-5-fluoro-l-leucine small molecule NA experimental polyubiquitin-b UBB NA unknown NA drugbank pmid25553724-compound-us20130237529 36 NA NA patented polyubiquitin-c UBC Patented-recorded target unknown NA TTD , DGIDB n-formylmethionine small molecule NA experimental polyubiquitin-c UBC NA unknown NA drugbank pmid25553724-compound-us20130237529 35 NA NA patented polyubiquitin-c UBC Patented-recorded target unknown NA TTD , DGIDB (r,r)-2,3-butanediol small molecule NA experimental ubiquitin-conjugating enzyme e2 d2 UBE2D2 NA unknown NA drugbank mk-2206 NA Rectum[MeSHID:D012007],Adenocarcinoma[MeSHID:D000230],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 2 e2 ubiquitin-conjugating enzyme t UBE2T Clinical trial target unknown 3.74 TTD , DGIDB pcl-016 small molecule Acne Vulgaris[MeSHID:D000152],Herpesviridae Infections[MeSHID:D006566],Sexually Transmitted Diseases[MeSHID:D012749],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational e3 ubiquitin-protein ligase ubr4 UBR4 NA unknown NA drugbank verpasep caltespen biotech Condylomata Acuminata[MeSHID:D003218],Parasitic Diseases[MeSHID:D010272],HIV Infections[MeSHID:D015658],Communicable Diseases[MeSHID:D003141],Virus Diseases[MeSHID:D014777],Anus[MeSHID:D001003],Warts[MeSHID:D014860],Infection[MeSHID:D007239],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cervical Intraepithelial Neoplasia[MeSHID:D018290] investigational e3 ubiquitin-protein ligase ubr4 UBR4 NA unknown NA drugbank nsc632839 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical ubiquitin thioesterase l1 UCHL1 Preclinical target unknown NA TTD ldn-91946 NA NA investigative ubiquitin thioesterase l1 UCHL1 Preclinical target inhibitor NA TTD , DGIDB ldn-57444 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical ubiquitin thioesterase l1 UCHL1 Preclinical target unknown NA TTD phenethyl isothiocyanate small molecule NA investigational ubiquitin carboxyl-terminal hydrolase isozyme l1 UCHL1 NA unknown NA drugbank pmid26077642-compound-figure3a NA NA patented ubiquitin c-terminal hydrolase uch37 UCHL5 Patented-recorded target unknown NA TTD , DGIDB cytidine small molecule NA experimental uridine-cytidine kinase 2 UCK2 NA unknown NA drugbank cytidine-5'-monophosphate small molecule NA experimental uridine-cytidine kinase 2 UCK2 NA unknown NA drugbank uridine 5'-triphosphate small molecule NA experimental,investigational uridine-cytidine kinase 2 UCK2 NA unknown NA drugbank cytidine-5'-triphosphate small molecule NA experimental uridine-cytidine kinase 2 UCK2 NA unknown NA drugbank uridine monophosphate small molecule NA experimental uridine-cytidine kinase-like 1 UCKL1 NA unknown NA drugbank guanosine-5'-triphosphate small molecule NA experimental uridine-cytidine kinase-like 1 UCKL1 NA unknown NA drugbank uracil small molecule NA experimental,investigational uridine-cytidine kinase-like 1 UCKL1 NA unknown NA drugbank 5-o-phosphono-alpha-d-ribofuranosyl diphosphate small molecule NA approved,experimental,investigational uridine-cytidine kinase-like 1 UCKL1 NA unknown NA drugbank nc-2100 NA NA investigative mitochondrial uncoupling protein 1 UCP1 Clinical trial target unknown NA TTD cl-316,243 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 mitochondrial uncoupling protein 1 UCP1 Clinical trial target unknown NA TTD , DGIDB nc-2100 NA NA investigative mitochondrial uncoupling protein 2 UCP2 Clinical trial target unknown NA TTD cl-316,243 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 mitochondrial uncoupling protein 2 UCP2 Clinical trial target unknown NA TTD , DGIDB cl-316,243 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] phase 2 mitochondrial uncoupling protein 3 UCP3 Clinical trial target unknown NA TTD , DGIDB miglustat small molecule Veins[MeSHID:D014680],Gaucher Disease[MeSHID:D005776],Neurologic Symptoms[MeSHID:D009461],Hypersensitivity[MeSHID:D006967],Niemann-Pick Disease, Type C[MeSHID:D052556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved ceramide glucosyltransferase UGCG Successful target inhibitor 119.35 TTD , drugbank , DGIDB eliglustat tartrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] approved ceramide glucosyltransferase UGCG Successful target inhibitor NA TTD , DGIDB n-butylgalactonojirimycin NA NA investigative ceramide glucosyltransferase UGCG Successful target unknown NA TTD eliglustat small molecule Gaucher Disease[MeSHID:D005776],long-term care[MeSHID:D008134] approved ceramide glucosyltransferase UGCG NA antagonist 15.91 drugbank , DGIDB eliglustat tartrate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] approved ceramide glucosyltransferase UGCG Successful target unknown NA TTD , DGIDB venglustat NA Gaucher Disease[MeSHID:D005776],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300],Fabry Disease[MeSHID:D000795] phase 2 ceramide glucosyltransferase UGCG Successful target unknown 15.91 TTD , DGIDB copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational udp-glucose 6-dehydrogenase UGDH NA unknown NA drugbank nadh small molecule Parkinson Disease[MeSHID:D010300],Cardiovascular Diseases[MeSHID:D002318],Chronic Fatigue Syndrome[MeSHID:D015673],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical udp-glucose 6-dehydrogenase UGDH NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational udp-glucuronosyltransferase 1-1 UGT1A1 NA inhibitor NA drugbank at-342 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Crigler Najjar syndrome, type 1[MeSHID:D003414] phase 1/2 udp-glucuronosyltransferase 1a1 UGT1A1 Clinical trial target unknown NA TTD phenolphthalein small molecule Constipation[MeSHID:D003248],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn udp-glucuronosyltransferase 1-9 UGT1A9 NA unknown NA drugbank niflumic acid small molecule Rheumatoid Arthritis[MeSHID:D001172],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental udp-glucuronosyltransferase 1-9 UGT1A9 NA unknown NA drugbank isolongifolol NA NA investigative udp-glucuronosyltransferase 2b7 ugt3 Literature-reported target unknown NA TTD autoantibody lkm-3 NA NA investigative udp-glucuronosyltransferase 2b7 ugt3 Literature-reported target unknown NA TTD quercetin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Obesity[MeSHID:D009765] experimental,investigational udp-glucuronosyltransferase 3a1 UGT3A1 NA unknown NA drugbank kaempherol small molecule NA experimental udp-glucuronosyltransferase 3a1 UGT3A1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase ulk1 ULK1 NA inhibitor NA drugbank pmid21967808cr-16 NA NA investigative serine/threonine-protein kinase ulk1 ULK1 Literature-reported target unknown NA TTD fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase ulk2 ULK2 NA inhibitor NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational serine/threonine-protein kinase ulk3 ULK3 NA inhibitor NA drugbank pyrazofurin NA NA investigative orotidine 5'-monophosphate decarboxylase UMPS Literature-reported target unknown NA TTD 6-hydroxyuridine-5'-phosphate NA NA investigative orotidine 5'-monophosphate decarboxylase UMPS Literature-reported target unknown NA TTD alpha-phosphoribosylpyrophosphoric acid NA NA investigative orotidine 5'-monophosphate decarboxylase UMPS Literature-reported target unknown NA TTD 5-fluoro-6-ethyluridine-5'-o-monophosphate NA NA investigative orotidine 5'-monophosphate decarboxylase UMPS Literature-reported target unknown NA TTD 6-hydroxyuridine-5'-phosphate small molecule NA experimental uridine 5'-monophosphate synthase UMPS NA unknown NA drugbank 5-fluoro-6-amino-ump NA NA investigative orotidine 5'-monophosphate decarboxylase UMPS Literature-reported target unknown NA TTD 5-fluoro-6-iodo-ump NA NA investigative orotidine 5'-monophosphate decarboxylase UMPS Literature-reported target unknown NA TTD 5-fluoro-6-azido-ump NA NA investigative orotidine 5'-monophosphate decarboxylase UMPS Literature-reported target unknown NA TTD 1-(2-deoxy-5-o-phosphono-beta-d-erythro-pentofuranosyl)-4-methyl-1h-indole small molecule NA experimental uracil-dna glycosylase UNG NA unknown NA drugbank 4-[(1e,7e)-8-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl]benzoic acid small molecule NA experimental uracil-dna glycosylase UNG NA unknown NA drugbank 3-[(1e,7e)-8-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl]benzoic acid small molecule NA experimental uracil-dna glycosylase UNG NA unknown NA drugbank 5-benzylacyclouridine small molecule NA experimental uridine phosphorylase 1 UPP1 NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b-c1 complex subunit 9 UQCR10 NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b-c1 complex subunit 10 UQCR11 NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b-c1 complex subunit 10 UQCR11 NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b-c1 complex subunit 10 UQCR11 NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b-c1 complex subunit 10 UQCR11 NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b-c1 complex subunit 10 UQCR11 NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b-c1 complex subunit 10 UQCR11 NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b-c1 complex subunit 10 UQCR11 NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b-c1 complex subunit 7 UQCRB NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank myxothiazol small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome b-c1 complex subunit rieske, mitochondrial UQCRFS1 NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b-c1 complex subunit 6, mitochondrial UQCRH NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b-c1 complex subunit 6, mitochondrial UQCRH NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome b-c1 complex subunit 6, mitochondrial UQCRH NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b-c1 complex subunit 6, mitochondrial UQCRH NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b-c1 complex subunit 6, mitochondrial UQCRH NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b-c1 complex subunit 6, mitochondrial UQCRH NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b-c1 complex subunit 6, mitochondrial UQCRH NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b-c1 complex subunit 6, mitochondrial UQCRH NA unknown NA drugbank ubiquinone q2 small molecule NA experimental cytochrome b-c1 complex subunit 8 UQCRQ NA unknown NA drugbank (s)-famoxadone small molecule NA experimental cytochrome b-c1 complex subunit 8 UQCRQ NA unknown NA drugbank azoxystrobin small molecule NA experimental cytochrome b-c1 complex subunit 8 UQCRQ NA unknown NA drugbank methyl (2z)-3-methoxy-2-{2-[(e)-2-phenylvinyl]phenyl}acrylate small molecule NA experimental cytochrome b-c1 complex subunit 8 UQCRQ NA unknown NA drugbank 2-hexyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol small molecule NA experimental cytochrome b-c1 complex subunit 8 UQCRQ NA unknown NA drugbank (5s)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione small molecule NA experimental cytochrome b-c1 complex subunit 8 UQCRQ NA unknown NA drugbank 2-nonyl-4-quinolinol 1-oxide small molecule NA experimental cytochrome b-c1 complex subunit 8 UQCRQ NA unknown NA drugbank 6-hydroxy-5-undecyl-4,7-benzothiazoledione small molecule NA experimental cytochrome b-c1 complex subunit 8 UQCRQ NA unknown NA drugbank coproporphyrin i small molecule NA experimental uroporphyrinogen decarboxylase UROD NA unknown NA drugbank coproporphyrinogen iii small molecule NA experimental uroporphyrinogen decarboxylase UROD NA unknown NA drugbank ml323 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical deubiquitinating enzyme 1 USP1 Literature-reported target inhibitor NA TTD , DGIDB spautin 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical ubiquitin carboxyl-terminal hydrolase 10 USP10 Preclinical target unknown NA TTD spautin 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical ubiquitin carboxyl-terminal hydrolase 13 USP13 Preclinical target unknown NA TTD phenethyl isothiocyanate small molecule NA investigational ubiquitin carboxyl-terminal hydrolase 14 USP14 NA unknown NA drugbank bap-15 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical ubiquitin carboxyl-terminal hydrolase 14 USP14 Preclinical target unknown NA TTD pmid26077642-compound-figure3a NA NA patented ubiquitin carboxyl-terminal hydrolase 14 USP14 Preclinical target unknown NA TTD , DGIDB tricyclic heterocycle derivative 4 NA NA patented ubiquitin carboxyl-terminal hydrolase 14 USP14 Preclinical target unknown NA TTD , DGIDB iu1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] preclinical ubiquitin carboxyl-terminal hydrolase 14 USP14 Preclinical target inhibitor NA TTD , DGIDB ml364 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical ubiquitin carboxyl-terminal hydrolase 2 USP2 Preclinical target unknown NA TTD gsk2643943a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical ubiquitin carboxyl-terminal hydrolase 20 USP20 Preclinical target unknown NA TTD nc043 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neurodegenerative Disorders[MeSHID:D019636] preclinical ubiquitin carboxyl-terminal hydrolase 30 USP30 Preclinical target unknown NA TTD adc-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical herpesvirus ubiquitin-specific protease USP7 Preclinical target unknown NA TTD hbx19818 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical herpesvirus ubiquitin-specific protease USP7 Preclinical target unknown NA TTD pmid26077642-compound-vif1 NA NA patented herpesvirus ubiquitin-specific protease USP7 Preclinical target unknown NA TTD , DGIDB p22077 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] preclinical herpesvirus ubiquitin-specific protease USP7 Preclinical target unknown NA TTD pmid26077642-compound-vif2 NA NA patented herpesvirus ubiquitin-specific protease USP7 Preclinical target unknown NA TTD , DGIDB p5091 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical herpesvirus ubiquitin-specific protease USP7 Preclinical target unknown NA TTD adc-03 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical herpesvirus ubiquitin-specific protease USP7 Preclinical target unknown NA TTD smt-c1100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 utrophin UTRN Clinical trial target unknown 63.65 TTD , DGIDB zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational utrophin UTRN NA unknown NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental utrophin UTRN NA cofactor NA drugbank zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational utrophin UTRN NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational utrophin UTRN NA cofactor NA drugbank sb-706375 NA NA investigative urotensin ii receptor UTS2R Clinical trial target antagonist 9.09 TTD , DGIDB gsk1440115 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 urotensin ii receptor UTS2R Clinical trial target unknown NA TTD , DGIDB ac-7954 NA NA investigative urotensin ii receptor UTS2R Clinical trial target agonist 9.09 TTD , DGIDB ici-199441 NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD ac-wky-nh2 NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD palosuran NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Kidney Failure[MeSHID:D051437] discontinued in phase 2 urotensin ii receptor UTS2R Clinical trial target antagonist 18.19 TTD , DGIDB fl104 NA NA investigative urotensin ii receptor UTS2R Clinical trial target agonist NA TTD , DGIDB agtad[cfwkyc]v NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD urotensin ii-related peptide NA NA investigative urotensin ii receptor UTS2R Clinical trial target agonist NA TTD , DGIDB sb-328872 NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD ac-[cfwkfc]-nh2 NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD sb-611812 NA NA investigative urotensin ii receptor UTS2R Clinical trial target antagonist 9.09 TTD , DGIDB s6716 NA NA investigative urotensin ii receptor UTS2R Clinical trial target antagonist NA TTD , DGIDB ac-sfwkys-nh2 NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD ac-fwky-nh2 NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD sar101099 NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1 urotensin ii receptor UTS2R Clinical trial target unknown NA TTD sb-436811 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Asthma[MeSHID:D001249] phase 1 urotensin ii receptor UTS2R Clinical trial target unknown 9.09 TTD , DGIDB ac-[cfwkyc]-nh2 NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD jnj-28318706 NA NA investigative urotensin ii receptor UTS2R Clinical trial target unknown NA TTD botulinum toxin type b biotech Neck Pain[MeSHID:D019547],Cervical Dystonia[MeSHID:D014103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational vesicle-associated membrane protein 1 VAMP1 NA binder NA drugbank , DGIDB botulinum toxin type b biotech Neck Pain[MeSHID:D019547],Cervical Dystonia[MeSHID:D014103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational vesicle-associated membrane protein 2 VAMP2 NA binder,inhibitor 31.83 drugbank , DGIDB botulinum toxin type b biotech Neck Pain[MeSHID:D019547],Cervical Dystonia[MeSHID:D014103],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Parkinson Disease[MeSHID:D010300] approved,investigational vesicle-associated membrane protein 2 VAMP2 NA binder NA drugbank , DGIDB valine small molecule Emotions[MeSHID:D004644],Respiratory Diaphragm[MeSHID:D003964],Hepatic Encephalopathy[MeSHID:D006501],Phenylketonurias[MeSHID:D010661],Muscle[MeSHID:D009132] approved,nutraceutical valine--trna ligase VARS NA unknown NA drugbank clove oil biotech Disease[MeSHID:D004194],Abdominal colic[MeSHID:D003085],Flatulence[MeSHID:D005414],Toothache[MeSHID:D014098] approved,nutraceutical vascular cell adhesion protein 1 VCAM1 NA antagonist NA drugbank succinobucol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Coronary heart disease[MeSHID:D003327],Arteriosclerosis[MeSHID:D001161],Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Atherosclerosis[MeSHID:D050197] investigational vascular cell adhesion protein 1 VCAM1 NA unknown NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational vascular cell adhesion protein 1 VCAM1 NA inhibitor NA drugbank ethanol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Ganglia[MeSHID:D005724],Trigeminal Neuralgia[MeSHID:D014277],Nerve Tissue[MeSHID:D009417],Chronic pain[MeSHID:D059350],Cystitis[MeSHID:D003556],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vascular cell adhesion protein 1 VCAM1 NA unknown NA drugbank carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational vascular cell adhesion protein 1 VCAM1 NA inhibitor NA drugbank hyaluronic acid small molecule Degenerative polyarthritis[MeSHID:D010003],Skin Wrinkling[MeSHID:D015595],Urinary Bladder[MeSHID:D001743],Conjunctivitis[MeSHID:D003231],Body part[MeSHID:D018594],Interstitial Cystitis[MeSHID:D018856],Knee[MeSHID:D007717],Dry Eye Syndromes[MeSHID:D015352],Off-Label Use[MeSHID:D056687],Pain[MeSHID:D010146],Wound Healing[MeSHID:D014945] approved,vet_approved versican core protein VCAN NA binder NA drugbank phenethyl isothiocyanate small molecule NA investigational transitional endoplasmic reticulum atpase VCP NA unknown NA drugbank cb-5339 NA MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 valosin-containing protein p97 VCP Clinical trial target unknown NA TTD cb-5083 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Malignant Neoplasms[MeSHID:D009369] phase 1 valosin-containing protein p97 VCP Clinical trial target unknown 42.43 TTD , DGIDB phosphoaminophosphonic acid-adenylate ester small molecule NA experimental transitional endoplasmic reticulum atpase VCP NA unknown NA drugbank nabiximols small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Neuralgia[MeSHID:D009437],Compliance behavior[MeSHID:D010349],Muscle Spasticity[MeSHID:D009128],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Spasm[MeSHID:D013035] investigational voltage-dependent anion-selective channel protein 1 VDAC1 NA unknown NA drugbank aluminium monostearate small molecule NA experimental voltage-dependent anion-selective channel protein 1 VDAC1 NA inhibitor NA drugbank medical cannabis biotech NA experimental,investigational voltage-dependent anion-selective channel protein 1 VDAC1 NA unknown NA drugbank vda-1102 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Actinic keratosis[MeSHID:D055623] phase 2 voltage-dependent anion-selective channel 1 VDAC1 Clinical trial target unknown NA TTD cannabidiol small molecule Malignant Neoplasms[MeSHID:D009369],Disease[MeSHID:D004194],Multiple Sclerosis[MeSHID:D009103],Muscle Spasticity[MeSHID:D009128],Compliance behavior[MeSHID:D010349],Pain[MeSHID:D010146],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],West Syndrome[MeSHID:D013036],Epilepsy[MeSHID:D004827],Syndrome[MeSHID:D013577],Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] approved,investigational voltage-dependent anion-selective channel protein 1 VDAC1 NA unknown NA drugbank aluminium monostearate small molecule NA experimental voltage-dependent anion-selective channel protein 2 VDAC2 NA inhibitor NA drugbank prlx 93936 small molecule Neoplasms[MeSHID:D009369] investigational voltage-dependent anion-selective channel protein 2 VDAC2 NA unknown NA drugbank prlx 93936 small molecule Neoplasms[MeSHID:D009369] investigational voltage-dependent anion-selective channel protein 3 VDAC3 NA unknown NA drugbank prlx93936 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 voltage-dependent anion-selective channel 3 VDAC3 Clinical trial target unknown NA TTD , DGIDB aluminium monostearate small molecule NA experimental voltage-dependent anion-selective channel protein 3 VDAC3 NA inhibitor NA drugbank eldecalcitol small molecule Osteoporosis[MeSHID:D010024] investigational vitamin d3 receptor VDR NA unknown NA drugbank ergocalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Metabolism[MeSHID:D008660],Hypoparathyroidism[MeSHID:D007011],Adult Rickets[MeSHID:D010018],Disease[MeSHID:D004194],Familial Hypophosphatemic Rickets[MeSHID:D053098],Biological Transport[MeSHID:D001692],Kidney[MeSHID:D007668],Rickets[MeSHID:D012279],Bone Tissue[MeSHID:D001842],Malnutrition[MeSHID:D044342],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical vitamin d3 receptor VDR Successful target agonist 0.45 TTD , drugbank , DGIDB ksp-bcs-1-alpha-chf2-1624f2-2 NA NA investigative vitamin d3 receptor VDR Successful target unknown NA TTD calcitriol-26,23-lactone NA NA investigative vitamin d3 receptor VDR Successful target agonist NA TTD , DGIDB pmid27454349-compound-94 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB paricalcitol small molecule Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],Hyperparathyroidism[MeSHID:D006961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vitamin d3 receptor VDR Successful target agonist 0.76 TTD , drugbank , DGIDB pmid27454349-compound-93 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB elocalcitol small molecule Urinary Incontinence[MeSHID:D014549],Infertility[MeSHID:D007246],Benign Prostatic Hyperplasia[MeSHID:D011470],Prostatic Diseases[MeSHID:D011469] investigational vitamin d3 receptor VDR NA unknown 0.42 drugbank , DGIDB cholecalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Hypoparathyroidism[MeSHID:D007011],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Familial Hypophosphatemic Rickets[MeSHID:D053098],Vitamin D-resistant rickets[MeSHID:D063730],Vitamin D Deficiency[MeSHID:D014808],Chronic Kidney Diseases[MeSHID:D051436],Rickets[MeSHID:D012279],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical vitamin d3 receptor VDR Successful target agonist 0.07 TTD , drugbank , DGIDB becocalcidiol small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565] investigational vitamin d3 receptor VDR NA agonist 0.28 drugbank , DGIDB falecalcitrol NA Hyperparathyroidism[MeSHID:D006961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB ctap-201 NA Hyperparathyroidism[MeSHID:D006961],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB vitamin d small molecule Familial hypophosphatemia[MeSHID:D007015],Hypoparathyroidism[MeSHID:D007011],Familial Hypophosphatemic Rickets[MeSHID:D053098],Vitamin D-resistant rickets[MeSHID:D063730],Rickets[MeSHID:D012279] approved,nutraceutical,vet_approved vitamin d3 receptor VDR NA unknown NA drugbank , DGIDB elocalcitol small molecule Urinary Incontinence[MeSHID:D014549],Infertility[MeSHID:D007246],Benign Prostatic Hyperplasia[MeSHID:D011470],Prostatic Diseases[MeSHID:D011469] investigational vitamin d3 receptor VDR NA agonist 0.42 drugbank , DGIDB seocalcitol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rickets[MeSHID:D012279] investigational,phase 3 vitamin d3 receptor VDR Successful target unknown 0.69 TTD , drugbank , DGIDB alfacalcidol small molecule Disease Management[MeSHID:D019468],Adult Rickets[MeSHID:D010018],Hypocalcemia[MeSHID:D006996],Malabsorption Syndrome[MeSHID:D008286],Hypophosphatemic Rickets, X-Linked Dominant[MeSHID:D053098],Vitamin D-resistant rickets[MeSHID:D063730],Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],Rickets[MeSHID:D012279],Kidney Failure, Chronic[MeSHID:D007676] approved,nutraceutical vitamin d3 receptor VDR NA agonist NA drugbank calcidiol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin D Deficiency[MeSHID:D014808] approved vitamin d3 receptor VDR Successful target unknown 0.21 TTD , DGIDB ksp-bcs-1-alpha-chf2-20-epi-22-oxabishomo-26-oh NA NA investigative vitamin d3 receptor VDR Successful target unknown NA TTD tisocalcitate NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 vitamin d3 receptor VDR Successful target unknown NA TTD calcitriol small molecule Familial hypophosphatemia[MeSHID:D007015],Disease Management[MeSHID:D019468],Hypoparathyroidism[MeSHID:D007011],Kidney Failure, Chronic[MeSHID:D007676],Hypocalcemia[MeSHID:D006996],Familial Hypophosphatemic Rickets[MeSHID:D053098],Physical Dialysis[MeSHID:D003956],Vitamin D-resistant rickets[MeSHID:D063730],Chronic Kidney Diseases[MeSHID:D051436],Vitamin D Deficiency[MeSHID:D014808],Renal Osteodystrophy[MeSHID:D012080],Rickets[MeSHID:D012279],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congenital alopecia X-linked[MeSHID:C535981] approved,nutraceutical vitamin d3 receptor VDR Successful target antagonist,agonist 0.47 TTD , drugbank , DGIDB inecalcitol small molecule Hyperparathyroidism[MeSHID:D006961],Malignant neoplasm of prostate[MeSHID:D011471],Psoriasis[MeSHID:D011565] investigational vitamin d3 receptor VDR NA unknown 0.55 drugbank , DGIDB s-06911 NA Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB doxercalciferol small molecule Physical Dialysis[MeSHID:D003956],Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin d3 receptor VDR Successful target suppressor 0.69 TTD , drugbank , DGIDB inecalcitol small molecule Hyperparathyroidism[MeSHID:D006961],Malignant neoplasm of prostate[MeSHID:D011471],Psoriasis[MeSHID:D011565] investigational vitamin d3 receptor VDR NA agonist 0.55 drugbank , DGIDB cholecalciferol small molecule Familial hypophosphatemia[MeSHID:D007015],Hypoparathyroidism[MeSHID:D007011],Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Familial Hypophosphatemic Rickets[MeSHID:D053098],Vitamin D-resistant rickets[MeSHID:D063730],Vitamin D Deficiency[MeSHID:D014808],Chronic Kidney Diseases[MeSHID:D051436],Rickets[MeSHID:D012279],Osteoporosis[MeSHID:D010024],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical vitamin d3 receptor VDR Successful target agonist 0.07 TTD , drugbank , DGIDB tei-9647 NA NA investigative vitamin d3 receptor VDR Successful target unknown NA TTD lg190178 NA NA investigative vitamin d3 receptor VDR Successful target agonist NA TTD , DGIDB inecalcitol oral NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of prostate[MeSHID:D011471] phase 2 vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB cta018 small molecule Disease[MeSHID:D004194],Psoriasis[MeSHID:D011565],Kidney Diseases[MeSHID:D007674] investigational vitamin d3 receptor VDR NA unknown NA drugbank curcumin small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational vitamin d3 receptor VDR NA unknown 0.01 drugbank , DGIDB calcifediol small molecule Familial hypophosphatemia[MeSHID:D007015],Disease Management[MeSHID:D019468],Hypoparathyroidism[MeSHID:D007011],Kidney Failure, Chronic[MeSHID:D007676],Hypocalcemia[MeSHID:D006996],Familial Hypophosphatemic Rickets[MeSHID:D053098],Physical Dialysis[MeSHID:D003956],Vitamin D-resistant rickets[MeSHID:D063730],Chronic Kidney Diseases[MeSHID:D051436],Vitamin D Deficiency[MeSHID:D014808],Renal Osteodystrophy[MeSHID:D012080],Rickets[MeSHID:D012279],Osteoporosis[MeSHID:D010024],Disease[MeSHID:D004194],Coronavirus Infections[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,nutraceutical vitamin d3 receptor VDR NA agonist 0.18 drugbank , DGIDB pmid27454349-compound-96 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB ro-23-7553 NA Prostatic Diseases[MeSHID:D011469],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1 vitamin d3 receptor VDR Successful target unknown 0.28 TTD , DGIDB atocalcitol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] discontinued in phase 2 vitamin d3 receptor VDR Successful target unknown NA TTD pmid27454349-compound-91 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB pmid27454349-compound-97 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB (1r,3r)-5-[(2e)-3-{(1s,3r)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol small molecule NA experimental vitamin d3 receptor VDR NA unknown NA drugbank mc-1301 NA NA investigative vitamin d3 receptor VDR Successful target unknown NA TTD calcipotriol small molecule Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin d3 receptor VDR Successful target antagonist,agonist 2.91 TTD , drugbank , DGIDB pmid27454349-compound-95 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB pmid27454349-compound-102 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB 3-keto-lithocholic acid NA NA investigative vitamin d3 receptor VDR Successful target agonist NA TTD , DGIDB curcumin sulfate small molecule NA experimental vitamin d3 receptor VDR NA unknown NA drugbank pmid27454349-compound-99 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB cholesterol small molecule NA approved,investigational vitamin d3 receptor VDR NA unknown NA drugbank seocalcitol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rickets[MeSHID:D012279] investigational,phase 3 vitamin d3 receptor VDR Successful target agonist 0.69 TTD , drugbank , DGIDB pmid27454349-compound-92 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB calcipotriol small molecule Senile Plaques[MeSHID:D058225],Dental Plaque[MeSHID:D003773],Psoriasis[MeSHID:D011565],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin d3 receptor VDR Successful target antagonist 2.91 TTD , drugbank , DGIDB gemini NA NA investigative vitamin d3 receptor VDR Successful target unknown NA TTD pmid27454349-compound-101 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB calcitriol small molecule Familial hypophosphatemia[MeSHID:D007015],Disease Management[MeSHID:D019468],Hypoparathyroidism[MeSHID:D007011],Kidney Failure, Chronic[MeSHID:D007676],Hypocalcemia[MeSHID:D006996],Familial Hypophosphatemic Rickets[MeSHID:D053098],Physical Dialysis[MeSHID:D003956],Vitamin D-resistant rickets[MeSHID:D063730],Chronic Kidney Diseases[MeSHID:D051436],Vitamin D Deficiency[MeSHID:D014808],Renal Osteodystrophy[MeSHID:D012080],Rickets[MeSHID:D012279],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congenital alopecia X-linked[MeSHID:C535981] approved,nutraceutical vitamin d3 receptor VDR Successful target antagonist 0.47 TTD , drugbank , DGIDB lexacalcitol small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental,discontinued in phase 2 vitamin d3 receptor VDR Successful target agonist 0.42 TTD , drugbank , DGIDB 2md NA NA investigative vitamin d3 receptor VDR Successful target agonist 0.28 TTD , DGIDB doxercalciferol small molecule Physical Dialysis[MeSHID:D003956],Hyperparathyroidism, Secondary[MeSHID:D006962],Chronic Kidney Diseases[MeSHID:D051436],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin d3 receptor VDR Successful target suppressor,agonist 0.69 TTD , drugbank , DGIDB dihydrotachysterol small molecule Hypoparathyroidism[MeSHID:D007011],Osteoporosis[MeSHID:D010024],Adult Rickets[MeSHID:D010018],Acidosis[MeSHID:D000138],De Toni-Debre-Fanconi Syndrome[MeSHID:D005198],Hypocalcemia[MeSHID:D006996],Fanconi Anemia[MeSHID:D005199],Neoplasm Metastasis[MeSHID:D009362],Renal Osteodystrophy[MeSHID:D012080],Rickets[MeSHID:D012279],Pseudohypoparathyroidism[MeSHID:D011547],Hypophosphatemia[MeSHID:D017674],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin d3 receptor VDR Successful target agonist 1.25 TTD , drugbank , DGIDB bxl-746 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Inflammation[MeSHID:D007249] discontinued in phase 1 vitamin d3 receptor VDR Successful target unknown NA TTD zk159222 NA NA investigative vitamin d3 receptor VDR Successful target antagonist NA TTD , DGIDB pmid27454349-compound-100 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB 1,3-cyclohexanediol, 4-methylene-5-[(2e)-[(1s,3as,7as)-octahydro-1-(5-hydroxy-5-methyl-1,3-hexadiynyl)-7a-methyl-4h-inden-4-ylidene]ethylidene]-, (1r,3s,5z) small molecule NA experimental vitamin d3 receptor VDR NA unknown NA drugbank ro-26-9228 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Urinary Incontinence[MeSHID:D014549] discontinued in phase 2 vitamin d3 receptor VDR Successful target unknown NA TTD pmid27454349-compound-98 NA NA patented vitamin d3 receptor VDR Successful target unknown NA TTD , DGIDB carbamide derivative 16 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB bevasiranib biotech Diabetic Retinopathy[MeSHID:D003930],Age related macular degeneration[MeSHID:D008268],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational,discontinued in phase 3 vascular endothelial growth factor a VEGFA Successful target unknown 3.35 TTD , drugbank , DGIDB pmid28621580-compound-wo2014079545c69 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB navicixizumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fallopian Tube Carcinoma[MeSHID:D005185],Malignant Neoplasms[MeSHID:D009369],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] phase 1 vascular endothelial growth factor a VEGFA Successful target unknown 0.84 TTD , DGIDB antibodie derivative 4 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational vascular endothelial growth factor a VEGFA Successful target unknown 1.08 TTD , drugbank , DGIDB quinoline and quinazoline derivative 6 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB quinoline and quinazoline derivative 10 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pmid28621580-compound-wo2013112959c68 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB quinoline and quinazoline derivative 5 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB oxetane 3,3-dicarboxamide compound 2 NA Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB oxetane 3,3-dicarboxamide compound 1 NA Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Congestive heart failure[MeSHID:D006333],Disease[MeSHID:D004194] approved,investigational vascular endothelial growth factor a VEGFA NA other NA drugbank bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational vascular endothelial growth factor a VEGFA Successful target antibody 1.08 TTD , drugbank , DGIDB quinoline and quinazoline derivative 2 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB ranibizumab biotech Age related macular degeneration[MeSHID:D008268],Retinal Vein Occlusion[MeSHID:D012170],Macular Edema, Cystoid[MeSHID:D008269],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hereditary hemorrhagic telangiectasia[MeSHID:D013683] approved vascular endothelial growth factor a VEGFA Successful target inhibitor 8.79 TTD , drugbank , DGIDB pyridine derivative 3 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB antibodie derivative 1 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB 1,6-naphyridine-4-ketone fused heterocyclic derivative 1 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyridine derivative 11 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carbamide derivative 17 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyridine derivative 2 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB mp0250 NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 vascular endothelial growth factor a VEGFA Successful target unknown 0.84 TTD , DGIDB ptc299 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Rheumatoid Arthritis[MeSHID:D001172] phase 2 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB antibodie derivative 8 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB avastin+/-tarceva NA Non-Small Cell Lung Carcinoma[MeSHID:D002289],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Nasopharyngeal carcinoma[MeSHID:C538339] phase 3 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational vascular endothelial growth factor a VEGFA Successful target inhibitor 1.08 TTD , drugbank , DGIDB pmid28621580-compound-wo2013036866c66 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carbamide derivative 20 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carbamide derivative 22 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB abi-011 NA Ankle brachial pressure index (observable entity)[MeSHID:D055109],Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma[MeSHID:D008223] phase 1 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB faricimab biotech Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] investigational,phase 3 vascular endothelial growth factor a VEGFA Successful target antagonist NA TTD , drugbank indoline derivative 12 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyrimidine derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355],Vascular Diseases[MeSHID:D014652] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyridine derivative 5 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB vandetanib small molecule Heart failure[MeSHID:D006333],Long QT Syndrome[MeSHID:D008133],Disease[MeSHID:D004194],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved vascular endothelial growth factor a VEGFA NA inhibitor NA drugbank quinoline and quinazoline derivative 4 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pmid28621580-compound-wo2015089220c70 NA Macular Degeneration, Age-Related, 2[MeSHID:C562479],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268],Retinal Diseases[MeSHID:D012164] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB ranibizumab biotech Age related macular degeneration[MeSHID:D008268],Retinal Vein Occlusion[MeSHID:D012170],Macular Edema, Cystoid[MeSHID:D008269],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hereditary hemorrhagic telangiectasia[MeSHID:D013683] approved vascular endothelial growth factor a VEGFA Successful target unknown 8.79 TTD , drugbank , DGIDB antibodie derivative 9 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Carotid Artery Diseases[MeSHID:D002340],Malignant Neoplasms[MeSHID:D009369],Corneal Neovascularization[MeSHID:D016510],Age related macular degeneration[MeSHID:D008268] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyridine derivative 7 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carvedilol small molecule Hypertensive disease[MeSHID:D006973],Ventricular Ejection Fraction[MeSHID:D013318],Heart failure[MeSHID:D006333],Ventricular Dysfunction, Left[MeSHID:D018487],Myocardial Infarction[MeSHID:D009203],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Congestive heart failure[MeSHID:D006333] approved,investigational vascular endothelial growth factor a VEGFA NA other NA drugbank aflibercept biotech Neoplasm Metastasis[MeSHID:D009362],Pathologic Neovascularization[MeSHID:D009389],Structure of central vein of the retina[MeSHID:D012169],Macular Edema, Cystoid[MeSHID:D008269],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vascular endothelial growth factor a VEGFA Successful target binder,inhibitor 2.35 TTD , drugbank , DGIDB indoline derivative 13 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB antibodie derivative 11 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB veglin small molecule Neoplasms[MeSHID:D009369],Renal Cell Carcinoma[MeSHID:D002292],Kaposi Sarcoma[MeSHID:D012514],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational vascular endothelial growth factor a VEGFA NA unknown NA drugbank , DGIDB carbamide derivative 21 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyridine derivative 10 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB quinoline and quinazoline derivative 8 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carbamide derivative 19 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB quinoline and quinazoline derivative 3 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB antibodie derivative 2 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB sflt-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 NA Adenocarcinoma[MeSHID:D000230],Stomach[MeSHID:D013270],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyridine derivative 8 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB indoline derivative 15 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB indoline derivative 21 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB antibodie derivative 7 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB indoline derivative 14 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyrimidine derivative 5 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355],Vascular Diseases[MeSHID:D014652] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyridine derivative 4 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyridine derivative 6 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB rg7221 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyrimidine derivative 11 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB chondroitin sulfate small molecule Catabolism[MeSHID:D008660],Bone Tissue[MeSHID:D001842],Degenerative polyarthritis[MeSHID:D010003],Cartilage[MeSHID:D002356],Sclerosis[MeSHID:D012598],Body tissue[MeSHID:D014024],Inflammation[MeSHID:D007249],Synovial Membrane[MeSHID:D013583],Disease Progression[MeSHID:D018450],Pain[MeSHID:D010146] approved,investigational,nutraceutical vascular endothelial growth factor a VEGFA NA unknown NA drugbank bevacizumab + erlotinib NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528],Colorectal Cancer[MeSHID:D015179],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Squamous cell carcinoma[MeSHID:D002294] phase 3 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyrimidine derivative 8 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational vascular endothelial growth factor a VEGFA Successful target inhibitor 1.08 TTD , drugbank , DGIDB indoline derivative 17 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational vascular endothelial growth factor a VEGFA Successful target antibody 1.08 TTD , drugbank , DGIDB carbamide derivative 14 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB bevacizumab biotech Epithelial ovarian cancer[MeSHID:C538090],Malignant Neoplasms[MeSHID:D009369],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Renal Cell Carcinoma[MeSHID:D002292],Acute Lung Injury[MeSHID:D055371],Neoplasm Metastasis[MeSHID:D009362],Fallopian Tube Carcinoma[MeSHID:D005185],Peritoneum[MeSHID:D010537],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Glioblastoma[MeSHID:D005909],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Brain[MeSHID:D001921],Malignant neoplasm of lung[MeSHID:D008175],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational vascular endothelial growth factor a VEGFA Successful target unknown 1.08 TTD , drugbank , DGIDB mp-0112 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Age related macular degeneration[MeSHID:D008268] phase 1 vascular endothelial growth factor a VEGFA Successful target unknown 0.56 TTD , DGIDB bevacizumab + trastuzumab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] phase 3 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB snn-0029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lateral Sclerosis[MeSHID:D016472] phase 1/2 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB aflibercept biotech Neoplasm Metastasis[MeSHID:D009362],Pathologic Neovascularization[MeSHID:D009389],Structure of central vein of the retina[MeSHID:D012169],Macular Edema, Cystoid[MeSHID:D008269],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vascular endothelial growth factor a VEGFA Successful target binder 2.35 TTD , drugbank , DGIDB indoline derivative 16 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB denibulin small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor a VEGFA NA unknown NA drugbank minocycline small molecule Acne Vulgaris[MeSHID:D000152],Infection[MeSHID:D007239],Chronic Periodontitis[MeSHID:D055113],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Bacterial Infections[MeSHID:D001424],Rosacea[MeSHID:D012393] approved,investigational vascular endothelial growth factor a VEGFA NA inhibitor NA drugbank bevacizumab + rituximab NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Lymphoma[MeSHID:D008223] phase 3 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB indoline derivative 20 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pidolic acid small molecule Hair Diseases[MeSHID:D006201],Memory[MeSHID:D008568],Prescription procedure[MeSHID:D055656],Cognition[MeSHID:D003071] approved,investigational vascular endothelial growth factor a VEGFA NA unknown NA drugbank sns-032 small molecule leukemia[MeSHID:D007938],Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],Multiple Myeloma[MeSHID:D009101],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor a VEGFA NA unknown NA drugbank pyridine derivative 9 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB quinoline and quinazoline derivative 9 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB abicipar pegol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carbamide derivative 15 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659],Hyperplasia[MeSHID:D006965],Cell Proliferation[MeSHID:D049109],Disease[MeSHID:D004194],Vascular Diseases[MeSHID:D014652] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB dalteparin small molecule Acute Disease[MeSHID:D000208],Malignant Neoplasms[MeSHID:D009369],Blood coagulation[MeSHID:D001777],Kidney Failure, Acute[MeSHID:D058186],Acute Coronary Syndrome[MeSHID:D054058],Angina, Unstable[MeSHID:D000789],Deep Vein Thrombosis[MeSHID:D020246],Lung diseases[MeSHID:D008171],Heart failure[MeSHID:D006333],Heart[MeSHID:D006321],Chronic Kidney Diseases[MeSHID:D051436],Myocardial Infarction[MeSHID:D009203],Pulmonary Embolism[MeSHID:D011655] approved vascular endothelial growth factor a VEGFA NA inhibitor NA drugbank brolucizumab biotech Age related macular degeneration[MeSHID:D008268],Pathologic Neovascularization[MeSHID:D009389],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] approved,investigational vascular endothelial growth factor a VEGFA Successful target inhibitor 1.68 TTD , drugbank , DGIDB quinoline and quinazoline derivative 7 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB indoline derivative 18 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB antibodie derivative 3 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carbamide derivative 18 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB indoline derivative 19 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB carbamide derivative 23 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB foreskin keratinocyte (neonatal) biotech Skin Ulcer[MeSHID:D012883],Tendon structure[MeSHID:D013710],Ulcer[MeSHID:D014456],Dermis[MeSHID:D020405],Leg Ulcer[MeSHID:D007871],Venous Insufficiency[MeSHID:D014689],Bone Tissue[MeSHID:D001842],Muscle[MeSHID:D009132],Diabetic Foot[MeSHID:D017719] approved vascular endothelial growth factor a VEGFA NA agonist NA drugbank abt-510 small molecule Lymphoma[MeSHID:D008223],Neoplasms[MeSHID:D009369],melanoma[MeSHID:D008545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational vascular endothelial growth factor a VEGFA NA unknown NA drugbank ro5520985 NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB at001/r84 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyrimidine derivative 10 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyrimidine derivative 6 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Fibrosis[MeSHID:D005355],Vascular Diseases[MeSHID:D014652] patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pyrimidine derivative 9 NA NA patented vascular endothelial growth factor a VEGFA Successful target unknown NA TTD , DGIDB pegaptanib biotech Age related macular degeneration[MeSHID:D008268],Pathologic Neovascularization[MeSHID:D009389],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vascular endothelial growth factor a VEGFA NA antagonist 3.35 drugbank , DGIDB gliclazide small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Complications of Diabetes Mellitus[MeSHID:D048909] approved vascular endothelial growth factor a VEGFA NA unknown NA drugbank aflibercept biotech Neoplasm Metastasis[MeSHID:D009362],Pathologic Neovascularization[MeSHID:D009389],Structure of central vein of the retina[MeSHID:D012169],Macular Edema, Cystoid[MeSHID:D008269],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vascular endothelial growth factor b VEGFB Successful target binder 15.91 TTD , drugbank , DGIDB vgx-100 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 vascular endothelial growth factor c VEGFC Clinical trial target unknown 10.61 TTD , DGIDB opt-302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 vascular endothelial growth factor c VEGFC Clinical trial target unknown NA TTD eg-016 NA Peripheral Vascular Diseases[MeSHID:D016491],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] discontinued in phase 1/2 vascular endothelial growth factor d VEGFD Clinical trial target unknown NA TTD eg-011 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] discontinued in phase 1/2 vascular endothelial growth factor d VEGFD Clinical trial target unknown NA TTD opt-302 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Macular Edema, Cystoid[MeSHID:D008269] phase 2 vascular endothelial growth factor d VEGFD Clinical trial target unknown NA TTD pyrrolidine carboxamide derivative 1 NA NA patented von hippel-lindau disease tumor suppressor VHL Patented-recorded target unknown NA TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational vimentin VIM NA ligand NA drugbank phenethyl isothiocyanate small molecule NA investigational vimentin VIM NA unknown NA drugbank vasoactive intestinal peptide NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 2 vasoactive intestinal polypeptide receptor 1 VIPR1 Clinical trial target unknown NA TTD , DGIDB helodermin NA NA investigative vasoactive intestinal polypeptide receptor 1 VIPR1 Clinical trial target agonist NA TTD , DGIDB pacap-27 NA NA investigative vasoactive intestinal polypeptide receptor 1 VIPR1 Clinical trial target agonist NA TTD , DGIDB pb1046 NA Idiopathic pulmonary arterial hypertension[MeSHID:D065627],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypertensive disease[MeSHID:D006973],Heart failure[MeSHID:D006333],Cardiomyopathies[MeSHID:D009202] phase 2 helodermin-preferring vip receptor VIPR2 Clinical trial target unknown NA TTD , DGIDB rg-7103 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Obstructive Airway Disease[MeSHID:D029424] phase 1 helodermin-preferring vip receptor VIPR2 Clinical trial target unknown NA TTD , DGIDB helodermin NA NA investigative helodermin-preferring vip receptor VIPR2 Clinical trial target agonist NA TTD , DGIDB pb-1120 NA NA investigative helodermin-preferring vip receptor VIPR2 Clinical trial target unknown NA TTD pacap-27 NA NA investigative helodermin-preferring vip receptor VIPR2 Clinical trial target agonist NA TTD , DGIDB phenindione NA Cerebral Embolism[MeSHID:D020766],Thrombosis[MeSHID:D013927],Atrial Fibrillation[MeSHID:D001281],Cardiomyopathies[MeSHID:D009202],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target inhibitor 26.04 TTD , DGIDB warfarin NA Venous Thromboembolism[MeSHID:D054556],Heart Valves[MeSHID:D006351],Cerebrovascular accident[MeSHID:D020521],Rheumatism[MeSHID:D012216],Atrial Fibrillation[MeSHID:D001281],Mitral Valve[MeSHID:D008943],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Collagen Diseases[MeSHID:D003095],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target inhibitor 26.68 TTD , DGIDB warfarin small molecule Venous Thromboembolism[MeSHID:D054556],Heart Valves[MeSHID:D006351],Cerebrovascular accident[MeSHID:D020521],Rheumatism[MeSHID:D012216],Atrial Fibrillation[MeSHID:D001281],Mitral Valve[MeSHID:D008943],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Collagen Diseases[MeSHID:D003095],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin k epoxide reductase complex subunit 1 VKORC1 NA inhibitor 26.68 drugbank , DGIDB phenprocoumon NA Venous Thrombosis[MeSHID:D020246],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target inhibitor 43.81 TTD , DGIDB dicumarol NA Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target inhibitor 7.44 TTD , DGIDB dicumarol NA Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target unknown 7.44 TTD , DGIDB phenprocoumon small molecule Venous Thrombosis[MeSHID:D020246],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved,investigational vitamin k epoxide reductase complex subunit 1 VKORC1 NA inhibitor 43.81 drugbank , DGIDB phenindione NA Cerebral Embolism[MeSHID:D020766],Thrombosis[MeSHID:D013927],Atrial Fibrillation[MeSHID:D001281],Cardiomyopathies[MeSHID:D009202],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target unknown 26.04 TTD , DGIDB phenindione small molecule Cerebral Embolism[MeSHID:D020766],Thrombosis[MeSHID:D013927],Atrial Fibrillation[MeSHID:D001281],Cardiomyopathies[MeSHID:D009202],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Blood Coagulation Disorders[MeSHID:D001778] approved,investigational vitamin k epoxide reductase complex subunit 1 VKORC1 NA inhibitor 26.04 drugbank , DGIDB dicoumarol small molecule Deep Vein Thrombosis[MeSHID:D020246],Blood coagulation[MeSHID:D001777] approved vitamin k epoxide reductase complex subunit 1 VKORC1 NA inhibitor NA drugbank menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical vitamin k epoxide reductase complex subunit 1 VKORC1 NA cofactor 1.24 drugbank , DGIDB warfarin NA Venous Thromboembolism[MeSHID:D054556],Heart Valves[MeSHID:D006351],Cerebrovascular accident[MeSHID:D020521],Rheumatism[MeSHID:D012216],Atrial Fibrillation[MeSHID:D001281],Mitral Valve[MeSHID:D008943],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Collagen Diseases[MeSHID:D003095],Transient Cerebral Ischemia[MeSHID:D002546],Recurrence (disease attribute)[MeSHID:D012008],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target unknown 26.68 TTD , DGIDB tecarfarin NA Cerebral Ischemia[MeSHID:D002545],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 3 vitamin k epoxide reductase complex 1 VKORC1 Successful target unknown 11.57 TTD , DGIDB acenocoumarol NA Cerebral Embolism[MeSHID:D020766],Deep Vein Thrombosis[MeSHID:D020246],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Infarction[MeSHID:D007238],Pulmonary Embolism[MeSHID:D011655],Transient Cerebral Ischemia[MeSHID:D002546],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target unknown 55.94 TTD , DGIDB phenprocoumon NA Venous Thrombosis[MeSHID:D020246],Cerebrovascular accident[MeSHID:D020521],Atrial Fibrillation[MeSHID:D001281],Thromboembolism[MeSHID:D013923],Pulmonary Embolism[MeSHID:D011655],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved vitamin k epoxide reductase complex 1 VKORC1 Successful target unknown 43.81 TTD , DGIDB acenocoumarol small molecule Cerebral Embolism[MeSHID:D020766],Deep Vein Thrombosis[MeSHID:D020246],Myocardial Infarction[MeSHID:D009203],Thromboembolism[MeSHID:D013923],Infarction[MeSHID:D007238],Pulmonary Embolism[MeSHID:D011655],Transient Cerebral Ischemia[MeSHID:D002546],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] approved,investigational vitamin k epoxide reductase complex subunit 1 VKORC1 NA inhibitor 55.94 drugbank , DGIDB menadione small molecule Bone Mineralization[MeSHID:D002113],Blood coagulation[MeSHID:D001777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Vitamin K Deficiency[MeSHID:D014813],Malignant neoplasm of prostate[MeSHID:D011471] approved,nutraceutical vitamin k epoxide reductase complex subunit 1-like protein 1 VKORC1L1 NA cofactor 6.82 drugbank , DGIDB lauric acid small molecule NA approved,experimental very low-density lipoprotein receptor VLDLR NA unknown NA drugbank amphetamine small molecule Depressive disorder[MeSHID:D003866],Disease[MeSHID:D004194],Attention deficit hyperactivity disorder[MeSHID:D001289],Reproductive History[MeSHID:D017584],Hand[MeSHID:D006225],Genetic Heterogeneity[MeSHID:D018740],Narcolepsy[MeSHID:D009290],Sleep Disorders[MeSHID:D012893],Obesity[MeSHID:D009765],Mental Depression[MeSHID:D003863],Neurodevelopmental Disorders[MeSHID:D065886],Sleep[MeSHID:D012890],Hypersomnia[MeSHID:D006970],Chronic disease[MeSHID:D002908],Chronic pain[MeSHID:D059350],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,illicit,investigational vesicular monoamine transporter 2 (vmat2) VMAT2 NA unknown NA drugbank valbenazine small molecule Tardive Dyskinesia[MeSHID:D000071057] approved,investigational vesicular monoamine transporter 2 (vmat2) VMAT2 NA antagonist NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational vesicular monoamine transporter 2 (vmat2) VMAT2 NA inhibitor NA drugbank ca-170 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hippocampus Proper[MeSHID:D006624],Lymphoma[MeSHID:D008223] phase 1 v-set immunoregulatory receptor VSIR Clinical trial target unknown NA TTD , DGIDB ci-8993 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 v-set immunoregulatory receptor VSIR Clinical trial target unknown NA TTD jnj-61610588 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 v-set immunoregulatory receptor VSIR Clinical trial target unknown 63.65 TTD , DGIDB zinc small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945] approved,investigational vitronectin VTN NA unknown NA drugbank zinc acetate small molecule Growth Disorders[MeSHID:D006130],Diarrhea[MeSHID:D003967],Ear structure[MeSHID:D004423],Common Cold[MeSHID:D003139],Respiratory Tract Infections[MeSHID:D012141],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Recurrence (disease attribute)[MeSHID:D012008],Wound Healing[MeSHID:D014945],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hepatolenticular Degeneration[MeSHID:D006527],HIV Infections[MeSHID:D015658] approved,investigational vitronectin VTN NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational vitronectin VTN NA unknown NA drugbank zinc chloride small molecule Serum[MeSHID:D044967],Syndrome[MeSHID:D013577],Malnutrition[MeSHID:D044342],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Common Cold[MeSHID:D003139] approved,investigational vitronectin VTN NA inducer NA drugbank zinc sulfate, unspecified form small molecule NA approved,experimental vitronectin VTN NA inducer NA drugbank abciximab biotech Angina, Unstable[MeSHID:D000789],Infantile Neuroaxonal Dystrophy[MeSHID:D019150],Heart[MeSHID:D006321],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Angina Pectoris[MeSHID:D000787] approved vitronectin VTN NA unknown NA drugbank alx-0081 NA Purpura, Thrombotic Thrombocytopenic[MeSHID:D011697],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombocytopenia[MeSHID:D013921] phase 3 von willebrand factor VWF Successful target unknown 13.64 TTD , DGIDB turoctocog alfa pegol biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved von willebrand factor VWF NA binder NA drugbank lonoctocog alfa biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational von willebrand factor VWF NA binder NA drugbank antihemophilic factor, human recombinant biotech Factor XIII Deficiency[MeSHID:D005177],von Willebrand Disease[MeSHID:D014842],Hemophilia A[MeSHID:D006467] approved,investigational von willebrand factor VWF NA binder NA drugbank antihemophilic factor (recombinant), pegylated biotech Disease Management[MeSHID:D019468],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],von Willebrand Disease[MeSHID:D014842] approved,investigational von willebrand factor VWF NA binder NA drugbank egaptivon pegol biotech Platelet aggregation[MeSHID:D010974],Acute Coronary Syndrome[MeSHID:D054058],Thrombosis[MeSHID:D013927],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational von willebrand factor VWF NA unknown NA drugbank moroctocog alfa biotech Operative Surgical Procedures[MeSHID:D013514],Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved von willebrand factor VWF NA binder NA drugbank recombinant von willebrand factor/recombinant factor viii complex NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],von Willebrand Disease[MeSHID:D014842] phase 3 von willebrand factor VWF Successful target unknown NA TTD , DGIDB simoctocog alfa biotech Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved von willebrand factor VWF NA binding NA drugbank efmoroctocog alfa biotech Hemorrhage[MeSHID:D006470],Hemophilia A[MeSHID:D006467] approved,investigational von willebrand factor VWF NA binding NA drugbank caplacizumab biotech Blood coagulation[MeSHID:D001777],Thrombotic thrombocytopenic purpura, acquired[MeSHID:C536901],Acute Coronary Syndrome[MeSHID:D054058],Thrombosis[MeSHID:D013927],Blood Platelets[MeSHID:D001792],Rare Diseases[MeSHID:D035583],Ischemia[MeSHID:D007511],Thrombocytopenia[MeSHID:D013921],Anemia, Hemolytic[MeSHID:D000743],Purpura, Thrombotic Thrombocytopenic[MeSHID:D011697],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational von willebrand factor VWF Successful target inhibitor 13.64 TTD , drugbank , DGIDB vonvendi NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],von Willebrand Disease[MeSHID:D014842] approved von willebrand factor VWF Successful target unknown NA TTD arc1779 NA Intracranial Embolism[MeSHID:D020766],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 von willebrand factor VWF Successful target unknown 4.55 TTD , DGIDB da-697b NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Thrombosis[MeSHID:D013927] phase 1 von willebrand factor VWF Successful target unknown NA TTD , DGIDB susoctocog alfa biotech Factor 8 deficiency, acquired[MeSHID:C536392],Hemorrhage[MeSHID:D006470] approved,investigational von willebrand factor VWF NA binding NA drugbank auryntricarboxylic acid (ata) NA NA investigative von willebrand factor VWF Successful target unknown NA TTD tryptophan small molecule Emotions[MeSHID:D004644],Depressive disorder[MeSHID:D003866],Body Weight[MeSHID:D001835],Respiratory Diaphragm[MeSHID:D003964],Pain Threshold[MeSHID:D017288],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890] approved,nutraceutical,withdrawn tryptophan--trna ligase, cytoplasmic WARS NA inhibitor NA drugbank tryptophanamide small molecule NA experimental tryptophan--trna ligase, cytoplasmic WARS NA unknown NA drugbank tryptophanyl-5'amp small molecule NA experimental tryptophan--trna ligase, cytoplasmic WARS NA unknown NA drugbank tryptophan small molecule Emotions[MeSHID:D004644],Depressive disorder[MeSHID:D003866],Body Weight[MeSHID:D001835],Respiratory Diaphragm[MeSHID:D003964],Pain Threshold[MeSHID:D017288],Mental Depression[MeSHID:D003863],Sleep[MeSHID:D012890] approved,nutraceutical,withdrawn tryptophan--trna ligase, mitochondrial WARS2 NA inhibitor NA drugbank hematopoietic stem cell gene therapy NA Hematopoietic stem cells[MeSHID:D006412],Wiskott-Aldrich Syndrome[MeSHID:D014923],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 wiskott-aldrich syndrome protein WAS Clinical trial target unknown NA TTD , DGIDB (s)-wiskostatin small molecule NA experimental wiskott-aldrich syndrome protein WAS NA unknown NA drugbank otl-103 NA Wiskott-Aldrich Syndrome[MeSHID:D014923],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 3 wiskott-aldrich syndrome protein WAS Clinical trial target unknown NA TTD wasp gene therapy NA Wiskott-Aldrich Syndrome[MeSHID:D014923],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 wiskott-aldrich syndrome protein WAS Clinical trial target unknown NA TTD , DGIDB n-[4-(2-chlorophenyl)-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-c]carbazol-9-yl]formamide small molecule NA experimental wee1-like protein kinase WEE1 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational wee1-like protein kinase WEE1 NA inhibitor NA drugbank 9-hydroxy-4-phenyl-6h-pyrrolo[3,4-c]carbazole-1,3-dione small molecule NA experimental wee1-like protein kinase WEE1 NA unknown NA drugbank 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione NA NA investigative wee1-like protein kinase WEE1 Clinical trial target unknown NA TTD mk-1775 small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] investigational,phase 2 wee1-like protein kinase WEE1 Clinical trial target inhibitor 1.98 TTD , drugbank , DGIDB 8-bromo-4-(2-chlorophenyl)-n-(2-hydroxyethyl)-6-methyl-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-e]indole-7-carboxamide small molecule NA experimental wee1-like protein kinase WEE1 NA unknown NA drugbank 9-hydroxy-6-(3-hydroxypropyl)-4-(2-methoxyphenyl)pyrrolo[3,4-c]carbazole-1,3(2h,6h)-dione small molecule NA experimental wee1-like protein kinase WEE1 NA unknown NA drugbank 3-(9-hydroxy-1,3-dioxo-4-phenyl-2,3-dihydropyrrolo[3,4-c]carbazol-6(1h)-yl)propanoic acid small molecule NA experimental wee1-like protein kinase WEE1 NA unknown NA drugbank zn-c3 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Cystadenocarcinoma, Serous[MeSHID:D018284],Uterus[MeSHID:D014599] phase 2 wee1-like protein kinase WEE1 Clinical trial target unknown NA TTD 4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2h,6h)-dione small molecule NA experimental wee1-like protein kinase WEE1 NA unknown NA drugbank nsc 19630 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, T-Cell[MeSHID:D015458] investigative werner syndrome atp-dependent helicase WRN Literature-reported target unknown NA TTD wt-4869 NA leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 1/2 wilms tumor protein WT1 Clinical trial target unknown NA TTD , DGIDB fpi-01 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 2 wilms tumor protein WT1 Clinical trial target unknown NA TTD , DGIDB gsk-2130579a NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] phase 1 wilms tumor protein WT1 Clinical trial target unknown NA TTD , DGIDB combined pr1/wt1 vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Myeloid Leukemia[MeSHID:D007951],Nephroblastoma[MeSHID:D009396] phase 2 wilms tumor protein WT1 Clinical trial target unknown NA TTD , DGIDB wt1-targeted autologous dendritic cell vaccine NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Antigen-Presenting Cells[MeSHID:D000938],Leukemia, Myelocytic, Acute[MeSHID:D015470],Nephroblastoma[MeSHID:D009396],Dendritic Cells[MeSHID:D003713] phase 2 wilms tumor protein WT1 Clinical trial target unknown NA TTD , DGIDB inno-305 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Malignant neoplasm of lung[MeSHID:D008175] phase 1 wilms tumor protein WT1 Clinical trial target unknown NA TTD , DGIDB wt1 peptide vaccine NA leukemia[MeSHID:D007938],Nephroblastoma[MeSHID:D009396],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 wilms tumor protein WT1 Clinical trial target unknown NA TTD , DGIDB isis 103616 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103601 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103624 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103582 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103631 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103615 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103629 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103621 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103613 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103622 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103612 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103635 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103619 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103620 NA NA investigative wwp1 messenger rna WWP1 Literature-reported target unknown NA TTD isis 103771 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103736 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103752 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103819 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103803 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103701 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103671 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103747 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103708 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103669 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD isis 103806 NA NA investigative wwp2 messenger rna WWP2 Literature-reported target unknown NA TTD pmid27841045-compound-143 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB chrysoeriol NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD pmid27841045-compound-136 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 6 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB baicalein NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Orthomyxoviridae Infections[MeSHID:D009976] phase 2 xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD scutellarein NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD febuxostat small molecule Disease Management[MeSHID:D019468],Gout[MeSHID:D006073],Hyperuricemia[MeSHID:D033461],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved xanthine dehydrogenase/oxidase XDH Successful target inhibitor 2.27 TTD , drugbank , DGIDB 2-chloro-6(methylamino)purine NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD azaindole derivative 7 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB 1,2,3,4,6-penta-o-galloyl-beta-d-glucose NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD pmid27841045-compound-135 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB bof-4272 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] discontinued in phase 2 xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD azaindole derivative 6 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB azole benzene derivative 3 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fosdenopterin NA Combined molybdoflavoprotein enzyme deficiency[MeSHID:C535811],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD allopurinol small molecule Disease Management[MeSHID:D019468],Malignant Neoplasms[MeSHID:D009369],Kidney Diseases[MeSHID:D007674],Calculi[MeSHID:D002137],Serum[MeSHID:D044967],Lymphoma[MeSHID:D008223],Neoplasm Metastasis[MeSHID:D009362],leukemia[MeSHID:D007938],Gout[MeSHID:D006073],Recurrence (disease attribute)[MeSHID:D012008],Lithiasis[MeSHID:D020347],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] approved xanthine dehydrogenase/oxidase XDH Successful target inhibitor 1.99 TTD , drugbank , DGIDB levocarnitine small molecule Propionic acidemia[MeSHID:D056693],Multiple Acyl Coenzyme A Dehydrogenase Deficiency[MeSHID:D054069],Stomach[MeSHID:D013270],Inborn Errors of Metabolism[MeSHID:D008661],Neoplasm Metastasis[MeSHID:D009362],Renal carnitine transport defect[MeSHID:C536778],Hyperlipoproteinemias[MeSHID:D006951],pancreatic juice[MeSHID:D010189],Malonic aciduria[MeSHID:C535702],Kidney Failure, Chronic[MeSHID:D007676],Malnutrition[MeSHID:D044342] approved,investigational xanthine dehydrogenase/oxidase XDH NA unknown NA drugbank nc-2500 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperuricemia[MeSHID:D033461] investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD azaindole derivative 4 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB eniluracil small molecule Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hyperlipidemia[MeSHID:D006949] investigational xanthine dehydrogenase/oxidase XDH NA inhibitor NA drugbank azole benzene derivative 4 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB azaindole derivative 3 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB oxypurinol small molecule Congestive heart failure[MeSHID:D006333],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Heart failure[MeSHID:D006333] investigational,phase 2/3 xanthine dehydrogenase/oxidase XDH Successful target unknown 12.12 TTD , drugbank , DGIDB flavin-adenine dinucleotide NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD pmid27841045-compound-132 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB topiroxostat small molecule Gout[MeSHID:D006073],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,phase 2 xanthine dehydrogenase/oxidase XDH Successful target unknown 6.06 TTD , drugbank , DGIDB amentoflavone NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD y-700 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] discontinued in phase 2 xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD pmid27841045-compound-134 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB azaindole derivative 5 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB azole benzene derivative 2 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB 3,4'-(1h-1,2,4-triazole-3,5-diyl)dipyridine NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD 3,5-bis(2-methylpyridin-4-yl)-1h-1,2,4-triazole NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD aom-0763 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Stickler syndrome, type 1[MeSHID:C537492],Gout[MeSHID:D006073] investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD fused heterocyclic compound 7 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB acacetin NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD 1-(3-cyano-phenyl)-1h-pyrazole-4-carboxylic acid NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD azole benzene derivative 1 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB pmid27841045-compound-130 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 2 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB pmid27841045-compound-144 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB pmid27841045-compound-156 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 5 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 9 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB pmid27841045-compound-145 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fukugetin NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD persicarin NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD 3,5-di(pyridin-4-yl)-1h-1,2,4-triazole NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD tmx-049 NA Diabetic Nephropathy[MeSHID:D003928],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] phase 2 xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD curcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 3 xanthine dehydrogenase/oxidase XDH Successful target unknown 0.04 TTD , DGIDB pmid27841045-compound-155 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 11 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB 3-o-methylquercetin NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD wogonin NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD pmid27841045-compound-157 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 4 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 1 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB robinetin NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD niraxostat small molecule NA experimental xanthine dehydrogenase/oxidase XDH NA unknown NA drugbank dioxothiomolybdenum(vi) ion NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD liquirtigenin NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD fused heterocyclic compound 3 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB dihydrokaempferol NA NA investigative xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD pmid27841045-compound-131 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB pmid27841045-compound-137 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB dioxo(sulfanyl)molybdenum small molecule NA experimental xanthine dehydrogenase/oxidase XDH NA unknown NA drugbank flavin adenine dinucleotide small molecule Disorder of eye[MeSHID:D005128],Blepharitis[MeSHID:D001762],Riboflavin Deficiency[MeSHID:D012257],Keratitis[MeSHID:D007634] approved xanthine dehydrogenase/oxidase XDH NA unknown NA drugbank pmid27841045-compound-133 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB pmid27841045-compound-129 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB lc-350189 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Gout[MeSHID:D006073] phase 1 xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 10 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB fused heterocyclic compound 8 NA NA patented xanthine dehydrogenase/oxidase XDH Successful target unknown NA TTD , DGIDB phenoxodiol NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] phase 1/2 x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-38 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB hgs-1029 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Hematologic Neoplasms[MeSHID:D019337] phase 1 x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB bv-6 NA NA investigative xiap messenger rna XIAP Clinical trial target inhibitor NA TTD , DGIDB pmid25980951-compound-27 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB n-methylalanyl-3-methylvalyl-4-phenoxy-n-(1,2,3,4-tetrahydronaphthalen-1-yl)prolinamide small molecule NA experimental e3 ubiquitin-protein ligase xiap XIAP NA unknown NA drugbank 1-[3,3-dimethyl-2-(2-methylamino-propionylamino)-butyryl]-pyrrolidine-2-carboxylic acid(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide small molecule NA experimental e3 ubiquitin-protein ligase xiap XIAP NA unknown NA drugbank pmid25980951-compound-7 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-10 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB apg-1387 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Nasopharyngeal carcinoma[MeSHID:C538339],Hematologic Neoplasms[MeSHID:D019337] phase 1 x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB gdc-0152 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Obesity[MeSHID:D009765] phase 1 x-linked inhibitor of apoptosis protein XIAP Clinical trial target antagonist 1.52 TTD , DGIDB pmid25980951-compound-19 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB arpfaqk-fam NA NA investigative xiap messenger rna XIAP Clinical trial target unknown NA TTD aeg35156 NA leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1/2 xiap messenger rna XIAP Clinical trial target unknown NA TTD gdc-0152 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Obesity[MeSHID:D009765] phase 1 x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown 1.52 TTD , DGIDB pmid25980951-compound-37 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB at-406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 3 x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown 3.03 TTD , DGIDB pmid25980951-compound-36 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-5 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-11 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-6 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-44 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-43 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB azd5582 NA NA investigative xiap messenger rna XIAP Clinical trial target antagonist NA TTD , DGIDB at-406 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],Lymphoma[MeSHID:D008223],Malignant Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477] phase 3 x-linked inhibitor of apoptosis protein XIAP Clinical trial target antagonist 3.03 TTD , DGIDB pmid25980951-compound-42 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-31 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB sm-337 NA NA investigative xiap messenger rna XIAP Clinical trial target antagonist 1.01 TTD , DGIDB pmid25980951-compound-33 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB birinapant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 2 x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown 3.03 TTD , DGIDB pmid25980951-compound-22 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-29 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB aeg35156 small molecule leukemia[MeSHID:D007938],Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational e3 ubiquitin-protein ligase xiap XIAP NA unknown NA drugbank pmid25980951-compound-21 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-12 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-14 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB sm-131 NA NA investigative xiap messenger rna XIAP Clinical trial target unknown NA TTD sm-122 NA NA investigative xiap messenger rna XIAP Clinical trial target inhibitor 3.03 TTD , DGIDB pmid25980951-compound-30 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-32 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-26 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-28 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-39 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-1 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-4 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-20 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-3 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB dequalinium small molecule Bacterial Vaginosis[MeSHID:D016585],Trichomonas Infections[MeSHID:D014245],Vaginitis[MeSHID:D014627],Vaginal Discharge[MeSHID:D019522],Infection[MeSHID:D007239],Vulva[MeSHID:D014844],Candidiasis of vagina[MeSHID:D002181],Bone Marrow Diseases[MeSHID:D001855],Spinal Cord Diseases[MeSHID:D013118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational e3 ubiquitin-protein ligase xiap XIAP NA antagonist,inhibitor NA drugbank pmid25980951-compound-40 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB sm-122 NA NA investigative xiap messenger rna XIAP Clinical trial target unknown 3.03 TTD , DGIDB pmid25980951-compound-41 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-45 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB astx660 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 2 xiap messenger rna XIAP Clinical trial target unknown NA TTD birinapant NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Lymphoma[MeSHID:D008223] phase 2 x-linked inhibitor of apoptosis protein XIAP Clinical trial target antagonist 3.03 TTD , DGIDB avpiaqksek-fam NA NA investigative xiap messenger rna XIAP Clinical trial target unknown NA TTD pmid25980951-compound-13 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB pmid25980951-compound-15 NA NA patented x-linked inhibitor of apoptosis protein XIAP Clinical trial target unknown NA TTD , DGIDB selinexor small molecule Multiple Myeloma[MeSHID:D009101],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470],liposarcoma[MeSHID:D008080],Carcinoma, Neuroendocrine[MeSHID:D018278],Diffuse Large B-Cell Lymphoma[MeSHID:D016403],Malignant Neoplasms[MeSHID:D009369],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] approved,investigational,phase 3 exportin-1 XPO1 Clinical trial target inhibitor 36.37 TTD , drugbank , DGIDB selinexor oral NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Recurrence (disease attribute)[MeSHID:D012008],Glioblastoma[MeSHID:D005909] phase 2 exportin-1 XPO1 Clinical trial target unknown NA TTD , DGIDB eltanexor oral NA Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Malignant neoplasm of prostate[MeSHID:D011471] phase 1/2 exportin-1 XPO1 Clinical trial target unknown NA TTD , DGIDB octahydrocurcumin NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative exportin-1 XPO1 Clinical trial target unknown NA TTD s109 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigative exportin-1 XPO1 Clinical trial target unknown NA TTD selinexor small molecule Multiple Myeloma[MeSHID:D009101],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352] approved,investigational,phase 3 exportin-1 XPO1 Clinical trial target inhibitor 36.37 TTD , drugbank , DGIDB kos-1815 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] preclinical exportin-1 XPO1 Clinical trial target unknown NA TTD , DGIDB sl-801 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 exportin-1 XPO1 Clinical trial target unknown 9.09 TTD , DGIDB s-(dimethylarsenic)cysteine small molecule NA experimental dna repair protein xrcc4 XRCC4 NA unknown NA drugbank p-benzoyl-l-phenylalanine small molecule NA experimental tyrosine--trna ligase, cytoplasmic YARS NA unknown NA drugbank n6-isopentenyl-adenosine-5'-monophosphate small molecule NA experimental tyrosine--trna ligase, cytoplasmic YARS NA unknown NA drugbank 4-(2,2,2-trifluoroethyl)-l-phenylalanine small molecule NA experimental tyrosine--trna ligase, cytoplasmic YARS NA unknown NA drugbank tyrosine small molecule Narcolepsy[MeSHID:D009290],Fatigue[MeSHID:D005221] approved,investigational,nutraceutical tyrosine--trna ligase, cytoplasmic YARS NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Giant Cell Arteritis[MeSHID:D013700],Systemic Scleroderma[MeSHID:D012595],Colorectal Cancer[MeSHID:D015179],Rheumatoid Arthritis[MeSHID:D001172] investigational tyrosine--trna ligase, cytoplasmic YARS NA inhibitor NA drugbank tyrosinal small molecule NA experimental tyrosine--trna ligase, cytoplasmic YARS NA unknown NA drugbank resveratrol small molecule Herpesviridae Infections[MeSHID:D006566],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352] investigational tyrosine--trna ligase, cytoplasmic YARS NA inhibitor NA drugbank beta-(2-naphthyl)-alanine small molecule NA experimental tyrosine--trna ligase, cytoplasmic YARS NA unknown NA drugbank tyrosine small molecule Narcolepsy[MeSHID:D009290],Fatigue[MeSHID:D005221] approved,investigational,nutraceutical tyrosine--trna ligase, mitochondrial YARS2 NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase yes YES1 NA inhibitor 0.03 drugbank , DGIDB tg-100435 NA NA investigative yes tyrosine kinase YES1 Clinical trial target unknown NA TTD jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 yes tyrosine kinase YES1 Clinical trial target unknown 0.07 TTD , DGIDB dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational tyrosine-protein kinase yes YES1 NA inhibitor 0.03 drugbank , DGIDB fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase yes YES1 NA inhibitor NA drugbank jnj-26483327 NA Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] phase 1 yes tyrosine kinase YES1 Clinical trial target inhibitor 0.07 TTD , DGIDB phenethyl isothiocyanate small molecule NA investigational 14-3-3 protein beta/alpha YWHAB NA unknown NA drugbank copper small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational 14-3-3 protein beta/alpha YWHAB NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational 14-3-3 protein epsilon YWHAE NA unknown NA drugbank fusicoccin small molecule NA experimental 14-3-3 protein epsilon YWHAE NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational 14-3-3 protein eta YWHAH NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational 14-3-3 protein theta YWHAQ NA unknown NA drugbank phenethyl isothiocyanate small molecule NA investigational 14-3-3 protein zeta/delta YWHAZ NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational mitogen-activated protein kinase kinase kinase mlt ZAK NA inhibitor NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational mitogen-activated protein kinase kinase kinase mlt ZAK NA unknown NA drugbank dasatinib small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymph[MeSHID:D008196],Philadelphia Chromosome[MeSHID:D010677],Blast Phase[MeSHID:D001752],Severe Acute Respiratory Syndrome[MeSHID:D045169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Middle East Respiratory Syndrome[MeSHID:D018352],Myeloid Leukemia, Chronic[MeSHID:D015464] approved,investigational mitogen-activated protein kinase kinase kinase mlt ZAK NA unknown NA drugbank us8546370, 11 NA NA patented tyrosine-protein kinase zap-70 ZAP70 Patented-recorded target unknown NA TTD , DGIDB staurosporine small molecule NA experimental tyrosine-protein kinase zap-70 ZAP70 NA unknown NA drugbank fostamatinib small molecule Immune thrombocytopenic purpura[MeSHID:D016553],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Rheumatoid Arthritis[MeSHID:D001172] approved,investigational tyrosine-protein kinase zap-70 ZAP70 NA inhibitor NA drugbank us8546370, 17 NA NA patented tyrosine-protein kinase zap-70 ZAP70 Patented-recorded target unknown NA TTD , DGIDB aloisine NA NA investigative tyrosine-protein kinase zap-70 ZAP70 Patented-recorded target inhibitor 10.61 TTD , DGIDB us8546370, 102 NA NA patented tyrosine-protein kinase zap-70 ZAP70 Patented-recorded target unknown NA TTD , DGIDB k00592a NA NA investigative tyrosine-protein kinase zap-70 ZAP70 Patented-recorded target unknown NA TTD 3-cyclohexyl-l-alanine small molecule NA experimental zinc finger y-chromosomal protein ZFY NA unknown NA drugbank pcl-016 small molecule Acne Vulgaris[MeSHID:D000152],Herpesviridae Infections[MeSHID:D006566],Sexually Transmitted Diseases[MeSHID:D012749],Herpes Labialis[MeSHID:D006560],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational zinc finger y-chromosomal protein ZFY NA unknown NA drugbank tricyclic heterocycle derivative 3 NA NA patented zinc finger-containing ubiquitin peptidase 1 ZUP1 Patented-recorded target unknown NA TTD , DGIDB azepan-4-one derivative 1 NA NA patented zinc finger-containing ubiquitin peptidase 1 ZUP1 Patented-recorded target unknown NA TTD , DGIDB pmid26077642-compound-figure3h NA NA patented zinc finger-containing ubiquitin peptidase 1 ZUP1 Patented-recorded target unknown NA TTD , DGIDB pmid26077642-compound-figure3g NA NA patented zinc finger-containing ubiquitin peptidase 1 ZUP1 Patented-recorded target unknown NA TTD , DGIDB azepan-4-one derivative 2 NA NA patented zinc finger-containing ubiquitin peptidase 1 ZUP1 Patented-recorded target unknown NA TTD , DGIDB artenimol small molecule Communicable Diseases[MeSHID:D003141],Infection[MeSHID:D007239] approved,experimental,investigational zyxin ZYX NA ligand NA drugbank aluminum zirconium octachlorohydrex gly small molecule Hyperhidrosis disorder[MeSHID:D006945],Sweating[MeSHID:D013546],Sweat[MeSHID:D013542] approved sweat ducts NA NA antagonist NA drugbank bendazac small molecule Pruritus[MeSHID:D011537],Eczema[MeSHID:D004485],Vision[MeSHID:D014785],Insect Bites[MeSHID:D007299],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Erythema[MeSHID:D004890],Urticaria[MeSHID:D014581],Cataract[MeSHID:D002386],Inflammation[MeSHID:D007249],Burn injury[MeSHID:D002056],Dermatitis[MeSHID:D003872],Pain[MeSHID:D010146],Prescription procedure[MeSHID:D055656] approved,withdrawn free radicals NA NA blocker NA drugbank cp403700, (s)-1-{2-[(5-chloro-1h-indole-2-carbonyl)-amino]-3-phenyl-propionyl}-azetidine-3-carboxylate small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved hydroxylapatite NA NA antagonist,binder NA drugbank glucarpidase biotech Plasma[MeSHID:D010949],Kidney Failure[MeSHID:D051437],Attention[MeSHID:D001288],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational methotrexate NA NA metabolizer NA drugbank adenosine 5'-methylenediphosphate small molecule NA experimental dna NA NA unknown NA drugbank hyaluronidase (ovine) biotech Pharmacy Distribution[MeSHID:D010594],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hyaluronan NA NA other NA drugbank etidronic acid small molecule Osteogenesis[MeSHID:D010012],Strabismus[MeSHID:D013285],Spinal Cord Injuries[MeSHID:D013119],Osteitis Deformans[MeSHID:D010001],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved hydroxylapatite NA NA antagonist NA drugbank colesevelam small molecule Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved bile acids NA NA binder NA drugbank cocarboxylase small molecule NA approved,experimental rna NA NA binder NA drugbank cisplatin small molecule ovarian neoplasm[MeSHID:D010051],Testicular Neoplasms[MeSHID:D013736],Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Osteosarcoma[MeSHID:D012516] approved dna NA NA cross-linking/alkylation NA drugbank formaldehyde small molecule Operative Surgical Procedures[MeSHID:D013514],Warts[MeSHID:D014860],Desiccation[MeSHID:D003890] approved,vet_approved hematopoietic stem cells NA NA unknown NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical dna NA NA component of NA drugbank dacarbazine small molecule melanoma[MeSHID:D008545],Hodgkin Disease[MeSHID:D006689],Neoplasm Metastasis[MeSHID:D009362],Cutaneous Melanoma[MeSHID:C562393],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA cross-linking/alkylation NA drugbank viltolarsen biotech Muscular Dystrophy, Duchenne[MeSHID:D020388],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dmd gene (exon 53 viltolarsen target site) NA NA binder NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational,withdrawn dna NA NA intercalation NA drugbank thalidomide small molecule Erythema Nodosum[MeSHID:D004893],Recurrence (disease attribute)[MeSHID:D012008],Erythema[MeSHID:D004890],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Myeloma[MeSHID:D009101] approved,investigational,withdrawn dna NA NA intercalation NA drugbank gentian violet cation small molecule Mycoses[MeSHID:D009181],disease transmission[MeSHID:D018562],Blood[MeSHID:D001769],Candidiasis[MeSHID:D002177],Oral candidiasis[MeSHID:D002180] approved dna NA NA intercalation NA drugbank alglucosidase alfa biotech Glycogen storage disease type II[MeSHID:D006009],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glycogen NA NA cleavage NA drugbank altretamine small molecule Unmarried[MeSHID:D012847],Malignant neoplasm of ovary[MeSHID:D010051],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA unknown NA drugbank calaspargase pegol biotech Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],B-Lymphocytes[MeSHID:D001402],Serum[MeSHID:D044967],Maintenance[MeSHID:D008283],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved l-asparagine NA NA degradation NA drugbank azacitidine small molecule Refractory anemias[MeSHID:D000753],Leukemia, Myelocytic, Acute[MeSHID:D015470],Refractory anaemia with excess blasts[MeSHID:D000754],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukopenia[MeSHID:D007970], Myelomonocytic, Chronic[MeSHID:D015477],Thrombocytopenia[MeSHID:D013921],Sideroblastic anemia[MeSHID:D000756],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA other NA drugbank satraplatin small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of prostate[MeSHID:D011471],Malignant neoplasm of lung[MeSHID:D008175] investigational dna NA NA unknown NA drugbank sodium fluoride small molecule Maintenance[MeSHID:D008283],Mental concentration[MeSHID:D001288],Oral health[MeSHID:D009909],Drinking Water[MeSHID:D060766],Dental caries[MeSHID:D003731] approved hydroxyapatite NA NA unknown NA drugbank penicillamine small molecule Hepatolenticular Degeneration[MeSHID:D006527],Rheumatoid Arthritis[MeSHID:D001172],Cystinuria[MeSHID:D003555],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved copper NA NA chelator NA drugbank lurbinectedin small molecule Disease Progression[MeSHID:D018450],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Endometrial Carcinoma[MeSHID:D016889],leukemia[MeSHID:D007938],Malignant Neoplasms[MeSHID:D009369],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational dna NA NA adduct NA drugbank beta-d-glucose small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank cyclophosphamide small molecule Disease[MeSHID:D004194],Adenocarcinoma[MeSHID:D000230],Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Neuroblastoma[MeSHID:D009447],Nephrotic Syndrome, Minimal Change[MeSHID:D009402],Multiple Myeloma[MeSHID:D009101],Retinoblastoma[MeSHID:D012175],Ovary[MeSHID:D010053],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna NA NA cross-linking/alkylation NA drugbank trabectedin small molecule Malignant neoplasm of stomach[MeSHID:D013274],Neoplasms[MeSHID:D009369],Sarcoma[MeSHID:D012509],Malignant neoplasm of ovary[MeSHID:D010051],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna NA NA binder NA drugbank cytarabine small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Blast Phase[MeSHID:D001752],Diagnosis[MeSHID:D003933],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA cross-linking/alkylation NA drugbank taribavirin small molecule Hepatitis[MeSHID:D006505],Hepatitis A[MeSHID:D006506] investigational dna NA NA unknown NA drugbank propiolactone small molecule Milk (body substance)[MeSHID:D008892],Tissue Grafts[MeSHID:D019737],Disinfectants[MeSHID:D004202],Plasma[MeSHID:D010949],Drinking Water[MeSHID:D060766],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,withdrawn dna NA NA adduct NA drugbank sodium zirconium cyclosilicate small molecule Hyperkalemia[MeSHID:D006947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational potassium NA NA binder NA drugbank uracil mustard small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] approved dna NA NA intercalation NA drugbank bleomycin small molecule Malignant Neoplasms[MeSHID:D009369],Patient Care Management[MeSHID:D010346],Lymphoma[MeSHID:D008223],Trachea[MeSHID:D014132],Squamous cell carcinoma[MeSHID:D002294],Lung[MeSHID:D008168],Bronchi[MeSHID:D001980],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hodgkin Disease[MeSHID:D006689] approved,investigational dna NA NA cleavage NA drugbank asparaginase escherichia coli biotech Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational l-asparagine NA NA unknown NA drugbank oxamniquine small molecule Schistosomiasis[MeSHID:D012552],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA unknown NA drugbank thiotepa small molecule Neoplasms[MeSHID:D009369],Conditioning (Psychology)[MeSHID:D003213],Hematological Disease[MeSHID:D006402],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943] approved,investigational dna NA NA cross-linking/alkylation NA drugbank trioxsalen small molecule Pigmentation[MeSHID:D010858],Ultraviolet Rays[MeSHID:D014466],Vitiligo[MeSHID:D014820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA cross-linking/alkylation NA drugbank tirapazamine small molecule Cancer of Head and Neck[MeSHID:D006258],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] investigational dna NA NA unknown NA drugbank carmustine small molecule Multiple Myeloma[MeSHID:D009101],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],Brain Neoplasms[MeSHID:D001932] approved,investigational rna NA NA unknown NA drugbank octreotide small molecule Flushing[MeSHID:D005483],Neoplasms[MeSHID:D009369],Diarrhea[MeSHID:D003967],Carcinoid Tumor[MeSHID:D002276],Vipoma[MeSHID:D003969],Acromegaly[MeSHID:D000172],Patient Discharge[MeSHID:D010351],long-term care[MeSHID:D008134],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational somatostatin receptor NA NA agonist NA drugbank clofarabine small molecule Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Lymphocyte[MeSHID:D008214],Relapse[MeSHID:D012008],Lymphoid leukemia[MeSHID:D007945],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA unknown NA drugbank pancrelipase amylase biotech NA approved dietary starch NA NA cleavage NA drugbank pentamidine small molecule Pneumonia[MeSHID:D011014],Mycoses[MeSHID:D009181],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],HIV Infections[MeSHID:D015658] approved,investigational dna NA NA intercalation NA drugbank pentoxifylline small molecule Blood Vessel[MeSHID:D001808],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Intermittent Claudication[MeSHID:D007383],Arterial Occlusive Diseases[MeSHID:D001157],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational phosphodiesterase enzymes NA NA inhibitor NA drugbank guanidine small molecule Lambert-Eaton Myasthenic Syndrome[MeSHID:D015624],Paresis[MeSHID:D010291],Muscle Weakness[MeSHID:D018908],Myasthenia Gravis[MeSHID:D009157] approved dna NA NA unknown NA drugbank edetate calcium disodium anhydrous small molecule Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855] approved manganese cation NA NA chelator NA drugbank sodium cellulose phosphate small molecule NA approved calcium ions NA NA binder NA drugbank quinacrine small molecule Disease Management[MeSHID:D019468],Leishmaniasis, Cutaneous[MeSHID:D016773],Pleural Effusion, Malignant[MeSHID:D016066],Giardiasis[MeSHID:D005873] investigational dna NA NA intercalation NA drugbank edetic acid small molecule Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855] approved,vet_approved lead NA NA chelator NA drugbank edetate disodium anhydrous small molecule Hypercalcemia[MeSHID:D006934],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352] approved,vet_approved lead NA NA chelator NA drugbank plicamycin small molecule Hypercalcemia[MeSHID:D006934],Malignant Neoplasms[MeSHID:D009369],Hypercalciuria[MeSHID:D053565],Malignant neoplasm of testis[MeSHID:D013736],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175],Malignant neoplasm of ovary[MeSHID:D010051] approved,investigational,withdrawn dna NA NA antagonist NA drugbank galsulfase biotech Mucopolysaccharidosis VI[MeSHID:D009087],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mucopolysaccharidoses[MeSHID:D009083] approved,investigational dermatan sulfate NA NA unknown NA drugbank entecavir small molecule Serum[MeSHID:D044967],Virus Replication[MeSHID:D014779],Disease[MeSHID:D004194],Hepatitis B, Chronic[MeSHID:D019694],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA other NA drugbank dimercaprol small molecule Mercury Poisoning[MeSHID:D008630],Lead Poisoning[MeSHID:D007855],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cadmium NA NA chelator NA drugbank dimercaprol small molecule Mercury Poisoning[MeSHID:D008630],Lead Poisoning[MeSHID:D007855],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mercury NA NA chelator NA drugbank uric acid small molecule Acute Cerebrovascular Accidents[MeSHID:D020521] investigational glycogen phosphorylase, liver form NA NA unknown NA drugbank dimercaptosuccinic acid small molecule NA approved,experimental mercury NA NA chelator NA drugbank aloe vera leaf biotech Eczema[MeSHID:D004485],Dermatologic disorders[MeSHID:D012871],Neoplasm Metastasis[MeSHID:D009362],Acne Vulgaris[MeSHID:D000152],Radiodermatitis[MeSHID:D011855],Burn injury[MeSHID:D002056],Sunburn[MeSHID:D013471],Dermatitis[MeSHID:D003872],Dermatitis, Atopic[MeSHID:D003876],Hypersensitivity[MeSHID:D006967] experimental free radicals NA NA chelator NA drugbank patiromer small molecule Hyperkalemia[MeSHID:D006947] approved,investigational potassium NA NA binder NA drugbank pancrelipase biotech Pancreas[MeSHID:D010179],Hereditary pancreatitis[MeSHID:C537262],Pancreatic Diseases[MeSHID:D010182],Pancreatitis, Chronic[MeSHID:D050500],Steatorrhea[MeSHID:D045602],Cystic Fibrosis[MeSHID:D003550],Weight decreased[MeSHID:D015431],Exocrine pancreatic insufficiency[MeSHID:D010188],Malnutrition[MeSHID:D044342] approved,investigational dietary protein NA NA cleavage NA drugbank beta carotene small molecule Color[MeSHID:D003116],Photosensitivity Disorders[MeSHID:D010787],Erythropoietic Protoporphyria[MeSHID:D046351] approved,nutraceutical free radicals NA NA binder NA drugbank alpha-tocopherol acetate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved free radicals NA NA binder NA drugbank alpha-tocopherol succinate small molecule Diabetes Mellitus[MeSHID:D003920],Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Vision[MeSHID:D014785],Disease[MeSHID:D004194],Vitamin E Deficiency[MeSHID:D014811],Cardiovascular Diseases[MeSHID:D002318],Lipid Metabolism Disorders[MeSHID:D052439],Premature Birth[MeSHID:D047928],Rare Diseases[MeSHID:D035583],Malabsorption Syndrome[MeSHID:D008286],Inflammation[MeSHID:D007249],Abetalipoproteinemia[MeSHID:D000012],Eye[MeSHID:D005123],Chronic disease[MeSHID:D002908] approved,nutraceutical,vet_approved lung epithelial cells NA NA unknown NA drugbank carboplatin small molecule Epithelial ovarian cancer[MeSHID:C538090],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved dna NA NA cross-linking/alkylation NA drugbank 4-o-demethylpenclomedine small molecule Neoplasms[MeSHID:D009369] investigational dna NA NA unknown NA drugbank brilliant blue g small molecule Tissue membrane[MeSHID:D008566] approved internal limiting membrane (ilm) NA NA binder NA drugbank nalidixic acid small molecule Urinary tract infection[MeSHID:D014552],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA other NA drugbank agalsidase beta biotech Fabry Disease[MeSHID:D000795],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational globotriaosylceramide NA NA metabolizer,ligand NA drugbank epirubicin small molecule Neoplasms[MeSHID:D009369],Patient Participation[MeSHID:D010358],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved dna NA NA intercalation NA drugbank trifluridine small molecule Keratitis, Herpetic[MeSHID:D016849],Keratoconjunctivitis[MeSHID:D007637],Neoplasm Metastasis[MeSHID:D009362],Recurrence (disease attribute)[MeSHID:D012008],Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA unknown NA drugbank fluorouracil small molecule Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Biliary tract structure[MeSHID:D001659],Cells[MeSHID:D002477],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Colon structure (body structure)[MeSHID:D003106],Pancreas[MeSHID:D010179],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Carcinoid Tumor[MeSHID:D002276],Rectum[MeSHID:D012007],Kidney[MeSHID:D007668],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] approved rna NA NA incorporation into and destabilization NA drugbank calcium acetate small molecule Hyperphosphatemia (disorder)[MeSHID:D054559],Blood[MeSHID:D001769],Kidney Diseases[MeSHID:D007674],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypophosphatasia[MeSHID:D007014] approved,investigational phosphate NA NA binder NA drugbank capecitabine small molecule Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant tumor of colon[MeSHID:D003110],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA incorporation into and destabilization NA drugbank lanthanum carbonate small molecule Serum[MeSHID:D044967],Kidney Failure, Chronic[MeSHID:D007676],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hypophosphatasia[MeSHID:D007014] approved phosphate NA NA binder NA drugbank ranpirnase biotech Malignant Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of lung[MeSHID:D008175] investigational dna NA NA unknown NA drugbank naxitamab biotech Disease[MeSHID:D004194],Neuroblastoma[MeSHID:D009447],Bone Marrow[MeSHID:D001853],Bone Tissue[MeSHID:D001842],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Osteosarcoma[MeSHID:D012516] approved gd2 disialoganglioside NA NA binder,antibody NA drugbank fish oil biotech Myocardial Infarction[MeSHID:D009203],Hypertriglyceridemia[MeSHID:D015228],Diet therapy[MeSHID:D004035] approved,nutraceutical free radicals NA NA unknown NA drugbank laronidase biotech Mucopolysaccharidoses[MeSHID:D009083],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved iduronic acid NA NA unknown NA drugbank dexfosfoserine small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank adenine small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,nutraceutical dna NA NA unknown NA drugbank pyridoxal phosphate small molecule Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational,nutraceutical glycogen phosphorylase, liver form NA NA cofactor NA drugbank mipomersen small molecule Homozygote[MeSHID:D006720],Diet therapy[MeSHID:D004035],Hypercholesterolemia, Familial[MeSHID:D006938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational mrna of apob-100 NA NA binder NA drugbank rasburicase biotech Plasma[MeSHID:D010949],Hyperuricemia[MeSHID:D033461],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational uric acid NA NA metabolizer NA drugbank procarbazine small molecule Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA cross-linking/alkylation NA drugbank beta-d-glucose small molecule NA experimental dna NA NA unknown NA drugbank oxaliplatin small molecule Neoplasms[MeSHID:D009369],Carcinoma[MeSHID:D002277],Colon structure (body structure)[MeSHID:D003106],Malignant tumor of colon[MeSHID:D003110],Rectum[MeSHID:D012007],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA cross-linking/alkylation NA drugbank niclosamide small molecule Intestines[MeSHID:D007422],Cestode Infections[MeSHID:D002590],Large Intestine[MeSHID:D007420],Schistosomiasis[MeSHID:D012552],Trematode Infections[MeSHID:D014201],Diphyllobothriasis[MeSHID:D004169],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved dna NA NA antagonist NA drugbank indium in-111 satumomab pendetide biotech Diagnosis[MeSHID:D003933],Malignant Neoplasms[MeSHID:D009369] experimental,withdrawn tumor-associated glycoprotein 72 (tag-72) NA NA unknown NA drugbank digoxin immune fab (ovine) biotech Drug Overdose[MeSHID:D062787] approved digoxin NA NA unknown NA drugbank cladribine small molecule Disease[MeSHID:D004194],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410],Chronic Lymphocytic Leukemia[MeSHID:D015451],Leukopenia[MeSHID:D007970],Thrombocytopenia[MeSHID:D013921],Hairy Cell Leukemia[MeSHID:D007943],Anemia[MeSHID:D000740], Non-Hodgkin[MeSHID:D008228],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Multiple Sclerosis[MeSHID:D009103] approved,investigational dna NA NA unknown NA drugbank pipobroman small molecule Polycythemia Vera[MeSHID:D011087],Myeloid Leukemia, Chronic[MeSHID:D015464],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA cross-linking/alkylation NA drugbank succimer small molecule Arsenic Poisoning[MeSHID:D020261],Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved cadmium NA NA chelator NA drugbank succimer small molecule Arsenic Poisoning[MeSHID:D020261],Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved mercury NA NA chelator NA drugbank clodronic acid small molecule Disease Management[MeSHID:D019468],Lytic lesion[MeSHID:D010014],Neoplasm Metastasis[MeSHID:D009362],Malignant Bone Neoplasm[MeSHID:D001859],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390] approved,investigational,vet_approved hydroxylapatite NA NA antagonist NA drugbank acetylcysteine small molecule Disease Management[MeSHID:D019468],Drug Overdose[MeSHID:D062787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver diseases[MeSHID:D008107] approved,investigational napqi (n-acetyl-p-benzoquinone imine) NA NA reducer NA drugbank pancrelipase lipase biotech NA approved dietary fat NA NA cleavage NA drugbank adenosine phosphate small molecule NA approved,investigational,nutraceutical glycogen phosphorylase, liver form NA NA activator NA drugbank deferasirox small molecule Hemosiderosis[MeSHID:D006486],Iron Overload[MeSHID:D019190] approved,investigational iron NA NA chelator NA drugbank deferiprone small molecule Thalassemia[MeSHID:D013789],Iron Overload[MeSHID:D019190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved iron NA NA chelator NA drugbank daunorubicin small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Monocytes[MeSHID:D009000],Diagnosis[MeSHID:D003933],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369],Kaposi Sarcoma[MeSHID:D012514] approved dna NA NA intercalation NA drugbank technetium tc-99m pyrophosphate small molecule Diagnosis[MeSHID:D003933],Blood[MeSHID:D001769],Osteogenesis[MeSHID:D010012],Hemorrhage[MeSHID:D006470],Myocardial Infarction[MeSHID:D009203] approved amorphous calcium phosphate NA NA ligand NA drugbank dornase alfa biotech Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA unknown NA drugbank pentaerythritol tetranitrate small molecule Angina Pectoris[MeSHID:D000787],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved free radicals NA NA antagonist NA drugbank cinoxacin small molecule Urinary tract infection[MeSHID:D014552],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,withdrawn dna NA NA intercalation NA drugbank capecitabine small molecule Breast[MeSHID:D001940],Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Malignant tumor of colon[MeSHID:D003110],Malignant neoplasm of stomach[MeSHID:D013274],Malignant neoplasm of breast[MeSHID:D001943],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational rna NA NA incorporation into and destabilization NA drugbank alglucerase biotech Gaucher Disease[MeSHID:D005776],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malnutrition[MeSHID:D044342] approved,investigational glucocerebroside NA NA unknown NA drugbank edetate disodium anhydrous small molecule Hypercalcemia[MeSHID:D006934],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352] approved,vet_approved iron NA NA chelator NA drugbank idoxuridine small molecule Keratoconjunctivitis[MeSHID:D007637],Keratitis[MeSHID:D007634],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Herpes Simplex Infections[MeSHID:D006561] approved,investigational dna NA NA other NA drugbank furazolidone small molecule Enteritis[MeSHID:D004751],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] experimental,vet_approved dna NA NA cross-linking/alkylation NA drugbank casimersen biotech Muscular Dystrophy, Duchenne[MeSHID:D020388],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dmd gene (exon 45 casimersen target site) NA NA binder NA drugbank tallimustine small molecule Neoplasms[MeSHID:D009369],Ability[MeSHID:D001076],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] experimental dna NA NA binder NA drugbank patisiran biotech Amyloidosis, Hereditary[MeSHID:None],Complication Aspects[MeSHID:None],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Amyloidosis[MeSHID:D000686],Cardiomyopathies[MeSHID:D009202] approved,investigational transthyretin mrna NA NA suppressor NA drugbank risperidone small molecule Disease Management[MeSHID:D019468],Schizophrenia[MeSHID:D012559],Irritable Mood[MeSHID:D007508],Bipolar Disorder[MeSHID:D001714],Disease[MeSHID:D004194],Aggressive behavior[MeSHID:D000374],Autistic Disorder[MeSHID:D001321],Off-Label Use[MeSHID:D056687],Depressive Disorder, Treatment-Resistant[MeSHID:D061218],Term Birth[MeSHID:D047929],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational d(2l) dopamine receptor NA NA antagonist NA drugbank dactinomycin small molecule Inferior Colliculus[MeSHID:D007245],Nephroblastoma[MeSHID:D009396],Testis[MeSHID:D013737],Ewings sarcoma[MeSHID:D012512],Rhabdomyosarcoma[MeSHID:D012208],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna NA NA adduct NA drugbank cp-526423 small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank hydroxychloroquine small molecule Rheumatoid Arthritis[MeSHID:D001172],Lupus Erythematosus, Discoid[MeSHID:D008179],Malaria[MeSHID:D008288], Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved dna NA NA cross-linking/alkylation NA drugbank valrubicin small molecule Malignant neoplasm of urinary bladder[MeSHID:D001749],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Psoriasis[MeSHID:D011565] approved dna NA NA intercalation NA drugbank dinutuximab biotech Cells[MeSHID:D002477],Disease[MeSHID:D004194],Vision[MeSHID:D014785],Neuroblastoma[MeSHID:D009447],Mental Suffering[MeSHID:D013315],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] approved,investigational gd2 disialoganglioside NA NA inhibitor NA drugbank 4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank taliglucerase alfa biotech Gaucher Disease[MeSHID:D005776],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Metabolic Diseases[MeSHID:D008659] approved,investigational glucocerebroside NA NA unknown NA drugbank nitroxoline small molecule NA experimental magnesium cation NA NA chelator NA drugbank nitroxoline small molecule NA experimental manganese cation NA NA chelator NA drugbank lamivudine small molecule HIV Infections[MeSHID:D015658],Hepatitis B, Chronic[MeSHID:D019694],Communicable Diseases[MeSHID:D003141],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Infection[MeSHID:D007239] approved,investigational dna NA NA binder NA drugbank telbivudine small molecule Serum[MeSHID:D044967],Virus Replication[MeSHID:D014779],Disease[MeSHID:D004194],Hepatitis B, Chronic[MeSHID:D019694],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA unknown NA drugbank elapegademase biotech Severe Combined Immunodeficiency[MeSHID:D016511],Disease[MeSHID:D004194],Severe combined immunodeficiency due to adenosine deaminase deficiency[MeSHID:C531816],Leukocytes[MeSHID:D007962],Hereditary Diseases[MeSHID:D030342],Mental Suffering[MeSHID:D013315],Malnutrition[MeSHID:D044342],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Immunologic Deficiency Syndromes[MeSHID:D007153] approved adenosine NA NA metabolizer NA drugbank 2-(3,4-dihydroxyphenyl)acetic acid small molecule NA experimental dna NA NA unknown NA drugbank alvocidib small molecule Malignant neoplasm of liver[MeSHID:D008113],Lymphoma[MeSHID:D008223],Malignant neoplasm of lung[MeSHID:D008175],leukemia[MeSHID:D007938],Lymph[MeSHID:D008196],Esophageal Neoplasms[MeSHID:D004938] experimental,investigational glycogen phosphorylase, liver form NA NA unknown NA drugbank avapritinib small molecule Gastrointestinal Stromal Tumors[MeSHID:D046152],Mutation[MeSHID:D009154],Leukemia, Mast-Cell[MeSHID:D007946],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Mastocytosis, Systemic[MeSHID:D034721] approved,investigational platelet derived growth factor receptor alpha NA NA inhibitor NA drugbank spermine small molecule NA experimental,nutraceutical dna NA NA binder NA drugbank amsacrine small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198] approved,investigational dna NA NA intercalation NA drugbank idarubicin small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA intercalation NA drugbank fluorouracil small molecule Disease Management[MeSHID:D019468],Breast[MeSHID:D001940],Biliary tract structure[MeSHID:D001659],Cells[MeSHID:D002477],Basal cell carcinoma[MeSHID:D002280],Actinic keratosis[MeSHID:D055623],Colon structure (body structure)[MeSHID:D003106],Pancreas[MeSHID:D010179],Malignant Neoplasms[MeSHID:D009369],Stomach[MeSHID:D013270],Carcinoid Tumor[MeSHID:D002276],Rectum[MeSHID:D012007],Kidney[MeSHID:D007668],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Neoplasms[MeSHID:D009369] approved dna NA NA incorporation into and destabilization NA drugbank streptozocin small molecule Pancreatic Endocrine Carcinoma[MeSHID:D018273],Malignant neoplasm of pancreas[MeSHID:D010190],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Pancreatic carcinoma[MeSHID:C562463] approved,investigational dna NA NA cross-linking/alkylation NA drugbank technetium tc-99m pyrophosphate small molecule Diagnosis[MeSHID:D003933],Blood[MeSHID:D001769],Osteogenesis[MeSHID:D010012],Hemorrhage[MeSHID:D006470],Myocardial Infarction[MeSHID:D009203] approved hydroxyapatite NA NA ligand NA drugbank mechlorethamine small molecule Bronchogenic Carcinoma[MeSHID:D002283],Carcinoma[MeSHID:D002277],Mycosis Fungoides[MeSHID:D009182],Lymphoma[MeSHID:D008223],Myelocytes[MeSHID:D042381],Chronic Lymphocytic Leukemia[MeSHID:D015451],Polycythemia Vera[MeSHID:D011087],Lymphoma, Diffuse[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],T-Cell Lymphoma[MeSHID:D016399] approved,investigational dna NA NA intercalation NA drugbank dornase alfa biotech Cystic Fibrosis[MeSHID:D003550],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved dna NA NA unknown NA drugbank hydroxystilbamidine small molecule Blastomycosis[MeSHID:D001759],Mycoses[MeSHID:D009181] approved dna NA NA unknown NA drugbank gemcitabine small molecule Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved dna NA NA cross-linking/alkylation NA drugbank tioguanine small molecule Leukemia, Myelocytic, Acute[MeSHID:D015470] approved dna NA NA intercalation NA drugbank potassium iodide small molecule Radiation[MeSHID:D011827],Thyroid Gland[MeSHID:D013961],Radioactivity[MeSHID:D011851],Thyrotoxicosis[MeSHID:D013971],Hyperthyroidism[MeSHID:D006980],Electromagnetic Radiation[MeSHID:D060733],Emergencies [Disease/Finding][MeSHID:D004630],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved tyrosine NA NA binder NA drugbank amrubicin small molecule Malignant neoplasm of lung[MeSHID:D008175],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Small cell carcinoma of lung[MeSHID:D055752] investigational dna NA NA unknown NA drugbank bronopol small molecule Milk (body substance)[MeSHID:D008892],Heat (physical force)[MeSHID:D006358],Dental Pulp[MeSHID:D003782],Oil Fields[MeSHID:D061329],Pigmentation[MeSHID:D010858],Body Fluids[MeSHID:D001826],Drinking Water[MeSHID:D060766] approved thiol groups NA NA oxidizer NA drugbank tegafur-uracil small molecule Diagnosis[MeSHID:D003933],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179] approved,investigational rna NA NA unknown NA drugbank tegafur-uracil small molecule Diagnosis[MeSHID:D003933],Malignant Neoplasms[MeSHID:D009369],Neoplasm Metastasis[MeSHID:D009362],Colorectal Cancer[MeSHID:D015179] approved,investigational dna NA NA unknown NA drugbank givosiran biotech Porphobilinogen synthase deficiency[MeSHID:C562618],Acute intermittent porphyria[MeSHID:D017118],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational alas1 mrna NA NA cleavage NA drugbank inotersen biotech AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED[MeSHID:C567782],Polyneuropathy, Familial[MeSHID:D011115],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational transthyretin mrna NA NA inhibitor NA drugbank zoledronic acid small molecule Multiple Myeloma[MeSHID:D009101],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Bone neoplasms[MeSHID:D001859],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Postmenopause[MeSHID:D017698],Bone Tissue[MeSHID:D001842],Osteoporosis[MeSHID:D010024] approved hydroxylapatite NA NA antagonist,binder NA drugbank flucytosine small molecule Endocarditis[MeSHID:D004696],Sepsis[MeSHID:D018805],Lung[MeSHID:D008168],Muscle strain[MeSHID:D013180],Urinary tract infection[MeSHID:D014552],Meningitis[MeSHID:D008581],Infection[MeSHID:D007239],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA cross-linking/alkylation NA drugbank cholestyramine small molecule Pruritus[MeSHID:D011537],Hypercholesterolemia[MeSHID:D006937],Diet therapy[MeSHID:D004035],Serum[MeSHID:D044967],Cholestasis[MeSHID:D002779],Diarrhea[MeSHID:D003967],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational bile acids NA NA binder NA drugbank psn357 small molecule Diabetes Mellitus, Non-Insulin-Dependent[MeSHID:D003924],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational glycogen phosphorylase, liver form NA NA unknown NA drugbank silver sulfadiazine small molecule Burn injury[MeSHID:D002056],Neoplasm Metastasis[MeSHID:D009362],Wound Infection[MeSHID:D014946],Bacterial Infections[MeSHID:D001424],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved dna NA NA binder NA drugbank eteplirsen biotech Muscular Dystrophy, Duchenne[MeSHID:D020388],Skeletal muscle structure[MeSHID:D018482],Mutation[MeSHID:D009154],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dmd-001 gene (exon 51 target site) NA NA binding NA drugbank idursulfase biotech Mucopolysaccharidosis II[MeSHID:D016532],Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved heparan sulfate NA NA unknown NA drugbank fludarabine small molecule Chronic Lymphocytic Leukemia[MeSHID:D015451],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Hematologic Neoplasms[MeSHID:D019337] approved dna NA NA incorporation into and destabilization NA drugbank decitabine small molecule Refractory anemias[MeSHID:D000753],Refractory anaemia with excess blasts[MeSHID:D000754],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukemia, Myelomonocytic, Chronic[MeSHID:D015477],Sideroblastic anemia[MeSHID:D000756],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA unknown NA drugbank topotecan small molecule Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Malignant neoplasm of ovary[MeSHID:D010051],Neoplasm Metastasis[MeSHID:D009362],Small cell carcinoma of lung[MeSHID:D055752],Hypersensitivity[MeSHID:D006967],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna NA NA intercalation NA drugbank ganciclovir small molecule Disease[MeSHID:D004194],Maintenance[MeSHID:D008283],Cytomegalovirus Infections[MeSHID:D003586],Acquired Immunodeficiency Syndrome[MeSHID:D000163],Pneumonia[MeSHID:D011014],Cytomegalovirus Retinitis[MeSHID:D017726],Immunocompromised Host[MeSHID:D016867],Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA incorporation into and destabilization NA drugbank edetate calcium disodium anhydrous small molecule Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855] approved lead NA NA chelator NA drugbank stanozolol small molecule Pathogenicity[MeSHID:D014774],Cardiac Arrest[MeSHID:D006323],Angioedemas, Hereditary[MeSHID:D054179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,vet_approved glucocorticoid binding proteins NA NA binder NA drugbank tilactase biotech Diet therapy[MeSHID:D004035],Diarrhea[MeSHID:D003967],Lactose Intolerance[MeSHID:D007787],Large Intestine[MeSHID:D007420],Lanugo[MeSHID:D006197],Body Fluids[MeSHID:D001826] approved,experimental lactose NA NA cleavage NA drugbank pegaspargase biotech Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved,investigational l-asparagine NA NA unknown NA drugbank ifosfamide small molecule Inferior Colliculus[MeSHID:D007245],Sarcoma[MeSHID:D012509],Malignant neoplasm of urinary bladder[MeSHID:D001749],Testis[MeSHID:D013737],Operative Surgical Procedures[MeSHID:D013514],Malignant neoplasm of ovary[MeSHID:D010051],Osteosarcoma[MeSHID:D012516],Small cell carcinoma of lung[MeSHID:D055752],Germ Cell Cancer[MeSHID:D009373],Lymphoma, Non-Hodgkin[MeSHID:D008228],Recurrence (disease attribute)[MeSHID:D012008],cervical cancer[MeSHID:D002583],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] approved dna NA NA unknown NA drugbank edetic acid small molecule Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855] approved,vet_approved manganese cation NA NA chelator NA drugbank alendronic acid small molecule Osteoporosis[MeSHID:D010024],Osteitis Deformans[MeSHID:D010001] approved hydroxylapatite NA NA antagonist NA drugbank succimer small molecule Arsenic Poisoning[MeSHID:D020261],Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved lead NA NA chelator NA drugbank albumin human biotech Solutions[MeSHID:D012996],Ascites[MeSHID:D001201],Respiratory Distress Syndrome, Adult[MeSHID:D012128],Hypoalbuminemia[MeSHID:D034141],Nephrosis[MeSHID:D009401],Nephrotic Syndrome[MeSHID:D009404],Burn injury[MeSHID:D002056],Hypovolemia[MeSHID:D020896],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved nitric oxide NA NA binder NA drugbank azacitidine small molecule Refractory anemias[MeSHID:D000753],Leukemia, Myelocytic, Acute[MeSHID:D015470],Refractory anaemia with excess blasts[MeSHID:D000754],MYELODYSPLASTIC SYNDROME[MeSHID:D009190],Leukopenia[MeSHID:D007970], Myelomonocytic, Chronic[MeSHID:D015477],Thrombocytopenia[MeSHID:D013921],Sideroblastic anemia[MeSHID:D000756],Neutropenia[MeSHID:D009503],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational rna NA NA other NA drugbank pegademase biotech Severe combined immunodeficiency due to adenosine deaminase deficiency[MeSHID:C531816] approved adenosine NA NA metabolizer NA drugbank edetate disodium anhydrous small molecule Hypercalcemia[MeSHID:D006934],Cardiac Arrhythmia[MeSHID:D001145],Heart Ventricle[MeSHID:D006352] approved,vet_approved manganese cation NA NA chelator NA drugbank busulfan small molecule Precancerous Conditions[MeSHID:D011230],Myeloid Leukemia[MeSHID:D007951],Myelocytes[MeSHID:D042381],Leukemia, Myelocytic, Acute[MeSHID:D015470],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Syndrome[MeSHID:D013577] approved,investigational dna NA NA cross-linking/alkylation NA drugbank proflavine small molecule Injury wounds[MeSHID:D014947],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Sepsis[MeSHID:D018805] approved dna NA NA intercalation NA drugbank melphalan flufenamide small molecule Multiple Myeloma[MeSHID:D009101],Continuance of life[MeSHID:D013534],Relapse[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of ovary[MeSHID:D010051] approved,withdrawn dna NA NA cross-linking/alkylation NA drugbank 13-deoxydoxorubicin small molecule Neoplasms[MeSHID:D009369],Malignant neoplasm of breast[MeSHID:D001943] investigational dna NA NA unknown NA drugbank ibandronate small molecule Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hydroxylapatite NA NA antagonist NA drugbank 5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank 9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide small molecule NA experimental dna NA NA intercalation NA drugbank n-beta-d-glucopyranosylacetamide small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank sevelamer small molecule Serum[MeSHID:D044967],Chronic Kidney Diseases[MeSHID:D051436] approved phosphate NA NA binder NA drugbank sulisobenzone small molecule Malignant neoplasm of skin[MeSHID:D012878],Skin Aging[MeSHID:D015595],Actinic keratosis[MeSHID:D055623],Premature Birth[MeSHID:D047928],Sunburn[MeSHID:D013471],Sunscreening Agents[MeSHID:D013473],Premature aging syndrome[MeSHID:D019588] experimental skin epithelial cells NA NA protector NA drugbank mitoxantrone small molecule Multiple Sclerosis, Relapsing-Remitting[MeSHID:D020529],Relapse[MeSHID:D012008],Neoplasm Metastasis[MeSHID:D009362],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, Non-Hodgkin[MeSHID:D008228],Malignant Neoplasms[MeSHID:D009369] approved,investigational dna NA NA intercalation NA drugbank ap5346 small molecule Malignant Neoplasms[MeSHID:D009369] investigational dna NA NA unknown NA drugbank tocopherol small molecule Malignant Neoplasms[MeSHID:D009369],Infant, Very Low Birth Weight[MeSHID:D019102],Disease[MeSHID:D004194],Macular Degeneration, Age-Related, 2[MeSHID:C562479],Vitamin E Deficiency[MeSHID:D014811],Arteriosclerosis[MeSHID:D001161],Cardiovascular Diseases[MeSHID:D002318],Premature Birth[MeSHID:D047928],Malabsorption Syndrome[MeSHID:D008286],Atherosclerosis[MeSHID:D050197],Age related macular degeneration[MeSHID:D008268],Abetalipoproteinemia[MeSHID:D000012],Malnutrition[MeSHID:D044342] approved,investigational free radicals NA NA binder NA drugbank imiglucerase biotech Gaucher Disease[MeSHID:D005776],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved glucocerebroside NA NA unknown NA drugbank talimogene laherparepvec biotech Brain[MeSHID:D001921],melanoma[MeSHID:D008545],Disease[MeSHID:D004194],Operative Surgical Procedures[MeSHID:D013514],Lung[MeSHID:D008168],Bone Tissue[MeSHID:D001842],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,experimental,investigational heparan sulfate NA NA unknown NA drugbank lucanthone small molecule Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna NA NA intercalation NA drugbank valganciclovir small molecule Cytomegalovirus Infections[MeSHID:D003586],Virus Diseases[MeSHID:D014777],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA adduct NA drugbank sinapultide small molecule Respiratory Distress Syndrome, Newborn[MeSHID:D012127] approved lung epithelial cells NA NA agonist NA drugbank chlorambucil small molecule Lymphoma[MeSHID:D008223],Waldenstrom Macroglobulinemia[MeSHID:D008258],Lymphoid leukemia[MeSHID:D007945],Lymphatic vessel[MeSHID:D042601],Nephrotic Syndrome, Minimal Change[MeSHID:D009402],Lymphoma, Follicular[MeSHID:D008224], Diffuse[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Chronic Lymphocytic Leukemia[MeSHID:D015451] approved dna NA NA cross-linking/alkylation NA drugbank declopramide small molecule Inflammatory Bowel Diseases[MeSHID:D015212],Colorectal Cancer[MeSHID:D015179],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] investigational dna NA NA unknown NA drugbank dimercaprol small molecule Mercury Poisoning[MeSHID:D008630],Lead Poisoning[MeSHID:D007855],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved arsenic NA NA chelator NA drugbank pamidronic acid small molecule Lytic lesion[MeSHID:D010014],Breast[MeSHID:D001940],Neoplasm Metastasis[MeSHID:D009362],Osteitis Deformans[MeSHID:D010001],Malignant Bone Neoplasm[MeSHID:D001859],Malignant neoplasm of breast[MeSHID:D001943],Humoral hypercalcemia of malignancy (disorder)[MeSHID:C562390],Bone Tissue[MeSHID:D001842],Multiple Myeloma[MeSHID:D009101] approved hydroxylapatite NA NA antagonist NA drugbank nedaplatin small molecule Cancer of Head and Neck[MeSHID:D006258],Malignant Neoplasms[MeSHID:D009369],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Small cell carcinoma of lung[MeSHID:D055752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA ligand NA drugbank nedaplatin small molecule Cancer of Head and Neck[MeSHID:D006258],Malignant Neoplasms[MeSHID:D009369],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Small cell carcinoma of lung[MeSHID:D055752],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational glutathione NA NA ligand NA drugbank melphalan small molecule Amyloidosis[MeSHID:D000686],Epithelial ovarian cancer[MeSHID:C538090],melanoma[MeSHID:D008545],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Malignant neoplasm of breast[MeSHID:D001943],Multiple Myeloma[MeSHID:D009101],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Malignant neoplasm of ovary[MeSHID:D010051],Disease[MeSHID:D004194] approved dna NA NA cross-linking/alkylation NA drugbank lomustine small molecule Operative Surgical Procedures[MeSHID:D013514],Neoplasm Metastasis[MeSHID:D009362],Brain Neoplasms[MeSHID:D001932],Hodgkin Disease[MeSHID:D006689],Relapse[MeSHID:D012008],Malignant neoplasm of brain[MeSHID:D001932],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA cross-linking/alkylation NA drugbank risedronic acid small molecule Osteitis Deformans[MeSHID:D010001] approved,investigational hydroxylapatite NA NA antagonist NA drugbank 5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank pancrelipase biotech Pancreas[MeSHID:D010179],Hereditary pancreatitis[MeSHID:C537262],Pancreatic Diseases[MeSHID:D010182],Pancreatitis, Chronic[MeSHID:D050500],Steatorrhea[MeSHID:D045602],Cystic Fibrosis[MeSHID:D003550],Weight decreased[MeSHID:D015431],Exocrine pancreatic insufficiency[MeSHID:D010188],Malnutrition[MeSHID:D044342] approved,investigational dietary fat NA NA cleavage NA drugbank pancrelipase biotech Pancreas[MeSHID:D010179],Hereditary pancreatitis[MeSHID:C537262],Pancreatic Diseases[MeSHID:D010182],Pancreatitis, Chronic[MeSHID:D050500],Steatorrhea[MeSHID:D045602],Cystic Fibrosis[MeSHID:D003550],Weight decreased[MeSHID:D015431],Exocrine pancreatic insufficiency[MeSHID:D010188],Malnutrition[MeSHID:D044342] approved,investigational dietary starch NA NA cleavage NA drugbank doxorubicin small molecule Epithelial ovarian cancer[MeSHID:C538090],Neoplasms[MeSHID:D009369],Cells[MeSHID:D002477],Bronchogenic Carcinoma[MeSHID:D002283],Carcinoma[MeSHID:D002277],Urinary Bladder[MeSHID:D001743],Nephroblastoma[MeSHID:D009396],lymph nodes[MeSHID:D008198],Leukemia, Myelocytic, Acute[MeSHID:D015470],Thyroid carcinoma[MeSHID:D013964],Body tissue[MeSHID:D014024],Regression - mental defense mechanism[MeSHID:D012043],Lymphoma[MeSHID:D008223],Stomach[MeSHID:D013270],Osteosarcoma[MeSHID:D012516],Precursor Cell Lymphoblastic Leukemia Lymphoma[MeSHID:D054198],Malignant neoplasm of breast[MeSHID:D001943],Neuroblastoma[MeSHID:D009447],Carcinoma, Transitional Cell[MeSHID:D002295],Hodgkin Disease[MeSHID:D006689],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Liver carcinoma[MeSHID:D006528] approved,investigational dna NA NA intercalation NA drugbank pancrelipase protease biotech NA approved dietary protein NA NA cleavage NA drugbank elsamitrucin small molecule Lymphoma[MeSHID:D008223],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna NA NA unknown NA drugbank temozolomide small molecule Anaplastic astrocytoma[MeSHID:D001254],Maintenance[MeSHID:D008283],Diagnosis[MeSHID:D003933],Disease Progression[MeSHID:D018450],Glioblastoma[MeSHID:D005909],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Astrocytoma[MeSHID:D001254] approved,investigational dna NA NA cross-linking/alkylation NA drugbank amrinone small molecule Congestive heart failure[MeSHID:D006333] approved camp-specific 3',5'-cyclic phosphodiesterase 3 NA NA inhibitor NA drugbank nelarabine small molecule Precursor T-Cell Lymphoblastic Leukemia-Lymphoma[MeSHID:D054218],T-Cell Lymphoma[MeSHID:D016399],Disease[MeSHID:D004194],Relapse[MeSHID:D012008],leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational dna NA NA incorporation into and destabilization NA drugbank tolevamer small molecule NA approved,investigational potassium NA NA binder NA drugbank cysteamine small molecule Nephropathic cystinosis[MeSHID:D003554],Cornea[MeSHID:D003315],Fanconi Syndrome[MeSHID:D005198],Cystinuria[MeSHID:D003555],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational cystine NA NA cleavage NA drugbank troxacitabine small molecule leukemia[MeSHID:D007938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant Neoplasms[MeSHID:D009369] investigational dna NA NA unknown NA drugbank edetic acid small molecule Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855] approved,vet_approved iron NA NA chelator NA drugbank pentetic acid small molecule Renal Elimination[MeSHID:D065667],Renal Plasma Flow, Effective[MeSHID:D017596],Kidney Glomerulus[MeSHID:D007678] approved transuranium elements NA NA chelator NA drugbank dimercaptosuccinic acid small molecule NA approved,experimental arsenic NA NA chelator NA drugbank ave-2865 small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank tinidazole small molecule Liver Abscess, Amebic[MeSHID:D008101],Amebic colitis[MeSHID:D004404],Giardiasis[MeSHID:D005873],Senility[MeSHID:D000375],Trichomonas Infections[MeSHID:D014245] approved,investigational dna NA NA binder NA drugbank methoxyamine small molecule Neoplasms[MeSHID:D009369] investigational dna NA NA unknown NA drugbank ascorbic acid small molecule Scurvy[MeSHID:D012614],Ascorbic Acid Deficiency[MeSHID:D001206],Urine[MeSHID:D014556],Injury wounds[MeSHID:D014947],Bone Tissue[MeSHID:D001842],Wound Healing[MeSHID:D014945] approved,nutraceutical dna NA NA cleavage NA drugbank fluorescein small molecule Angioscopy[MeSHID:D017546],Diagnosis[MeSHID:D003933],gastric fundus[MeSHID:D005748],Iris (Eye)[MeSHID:D007498],Disease[MeSHID:D004194],Vision[MeSHID:D014785],Eye[MeSHID:D005123],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA other NA drugbank tiludronic acid small molecule Serum[MeSHID:D044967],Osteitis Deformans[MeSHID:D010001],Osteoporosis[MeSHID:D010024],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational,vet_approved adenosine triphosphate (atp) NA NA inhibitor NA drugbank n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea small molecule NA experimental glycogen phosphorylase, liver form NA NA unknown NA drugbank mitomycin small molecule Solutions[MeSHID:D012996],Cancer of Lip[MeSHID:D008048],Malignant Neoplasms[MeSHID:D009369],Breast[MeSHID:D001940],Urinary Bladder[MeSHID:D001743],Glaucoma[MeSHID:D005901],Operative Surgical Procedures[MeSHID:D013514],Urothelium[MeSHID:D019459],Digestion[MeSHID:D004063],Pharyngeal structure[MeSHID:D010614],Peritoneum[MeSHID:D010537],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of breast[MeSHID:D001943],Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] approved dna NA NA cross-linking/alkylation NA drugbank carmustine small molecule Multiple Myeloma[MeSHID:D009101],Lymphoma, Non-Hodgkin[MeSHID:D008228],Hodgkin Disease[MeSHID:D006689],Brain Neoplasms[MeSHID:D001932] approved,investigational dna NA NA unknown NA drugbank pegloticase biotech Gout[MeSHID:D006073],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational uric acid NA NA metabolizer NA drugbank agalsidase alfa biotech Fabry Disease[MeSHID:D000795],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved globotriaosylceramide NA NA metabolizer,ligand NA drugbank gallium nitrate small molecule Hypercalcemia[MeSHID:D006934],Lymphoma, Non-Hodgkin[MeSHID:D008228],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved,investigational hydroxylapatite NA NA modulator NA drugbank colestipol small molecule Coronary Arteriosclerosis[MeSHID:D003324],Hypercholesterolemia[MeSHID:D006937],Hypertriglyceridemia[MeSHID:D015228],Disease[MeSHID:D004194],Coronary heart disease[MeSHID:D003327],Serum[MeSHID:D044967],Counseling[MeSHID:D003376],Atherosclerosis[MeSHID:D050197],Carrying[MeSHID:D017770],Intention - mental process[MeSHID:D033182],Hypercholesterolemia, Familial[MeSHID:D006938],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved bile acids NA NA binder NA drugbank methoxsalen small molecule Psoriasis[MeSHID:D011565],Vitiligo[MeSHID:D014820],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Lymphoma, T-Cell, Cutaneous[MeSHID:D016410] approved dna NA NA intercalation NA drugbank melphalan small molecule Amyloidosis[MeSHID:D000686],Epithelial ovarian cancer[MeSHID:C538090],melanoma[MeSHID:D008545],Operative Surgical Procedures[MeSHID:D013514],Limb structure[MeSHID:D005121],Malignant neoplasm of breast[MeSHID:D001943],Multiple Myeloma[MeSHID:D009101],Recurrence (disease attribute)[MeSHID:D012008],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Intrahepatic Cholangiocarcinoma[MeSHID:D018281] approved dna NA NA cross-linking/alkylation NA drugbank deferoxamine small molecule Anemia[MeSHID:D000740],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational aluminum NA NA chelator NA drugbank idursulfase biotech Mucopolysaccharidosis II[MeSHID:D016532],Infertility[MeSHID:D007246],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dermatan sulfate NA NA unknown NA drugbank hydroxychloroquine small molecule Rheumatoid Arthritis[MeSHID:D001172],Lupus Erythematosus, Discoid[MeSHID:D008179],Malaria[MeSHID:D008288], Systemic[MeSHID:D008180],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA cross-linking/alkylation NA drugbank picoplatin small molecule Neoplasms[MeSHID:D009369],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Malignant neoplasm of prostate[MeSHID:D011471],Small cell carcinoma of lung[MeSHID:D055752],Colorectal Cancer[MeSHID:D015179],Malignant neoplasm of ovary[MeSHID:D010051] investigational dna NA NA unknown NA drugbank gemcitabine small molecule Pancreas[MeSHID:D010179],Adenocarcinoma[MeSHID:D000230],Urinary Bladder[MeSHID:D001743],Malignant neoplasm of ovary[MeSHID:D010051],Malignant neoplasm of breast[MeSHID:D001943],Non-Small Cell Lung Carcinoma[MeSHID:D002289],Carcinoma, Transitional Cell[MeSHID:D002295],Relapse[MeSHID:D012008],Severe Acute Respiratory Syndrome[MeSHID:D045169],Middle East Respiratory Syndrome[MeSHID:D018352],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved dna NA NA cross-linking/alkylation NA drugbank edetate calcium disodium anhydrous small molecule Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855] approved iron NA NA chelator NA drugbank succimer small molecule Arsenic Poisoning[MeSHID:D020261],Blood[MeSHID:D001769],Lead Poisoning[MeSHID:D007855],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved arsenic NA NA chelator NA drugbank annamycin small molecule leukemia[MeSHID:D007938],Malignant neoplasm of breast[MeSHID:D001943],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Leukemia, Myelocytic, Acute[MeSHID:D015470] investigational dna NA NA unknown NA drugbank deferoxamine small molecule Anemia[MeSHID:D000740],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174],Coronavirus Infections[MeSHID:D018352],Disease[MeSHID:D004194] approved,investigational iron NA NA chelator NA drugbank ethanolamine oleate small molecule Esophageal Varices[MeSHID:D004932],Hemorrhage[MeSHID:D006470],Disease[MeSHID:D004194],Disruptive, Impulse Control, and Conduct Disorders[MeSHID:D007174] approved calcium ions NA NA chelator NA drugbank